<SEC-DOCUMENT>0001213900-14-000604.txt : 20140131
<SEC-HEADER>0001213900-14-000604.hdr.sgml : 20140131
<ACCEPTANCE-DATETIME>20140131172945
ACCESSION NUMBER:		0001213900-14-000604
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20140131
DATE AS OF CHANGE:		20140131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-193714
		FILM NUMBER:		14565833

	BUSINESS ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>fs12014_actinium.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<html>
<head>
    <title>fs12014_actinium.htm</title>
    <!--Licensed to: Edgar Agents LLC-->
    <!--Document Created using EDGARizerAgent 5.4.5.1-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 7%; FONT-SIZE: 10pt; MARGIN-RIGHT: 7%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="filing_1"><!--EFPlaceholder--></a><a name="doc_1_1"><!--EFPlaceholder--></a><a name="gmnh1doc_1_1"><!--EFPlaceholder--></a>As filed with the Securities and Exchange Commission on&#160;January 31, 2014</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registration No. __________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>

<div>&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM S-1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;REGISTRATION STATEMENT UNDER THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES ACT OF 1933</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>

<div>&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="26%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2834</font></div>
</td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="26%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">88-0378336</font></div>
</td>
</tr><tr>
<td valign="middle" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of incorporation or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">organization)</font></div>
</td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Primary Standard</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Industrial Classification</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Code Number)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">501 Fifth Avenue, 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font> Floor</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New York, NY 10017</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(646) 459-4201</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address, including zip code, and telephone number,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">including area code, of registrant&#8217;s principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Action Stock Transfer Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2469 E. Fort Union Blvd., Suite 214</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Salt Lake City, UT 84121</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(801) 274-1088</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;(Name, address, including zip code, and telephone number,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">including area code, of agent for service)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Copies to:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="27%">&#160;</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Thomas Slusarczyk, Esq.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Hiscock &amp; Barclay LLP</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">One Park Place</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">300 South State Street</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Syracuse, New York 13202</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Tel No.: (315) 235-2299</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fax No.: (315) 624-7359</font></div>
</td>
<td align="left" valign="top" width="28%">&#160;</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Approximate date of commencement of proposed sale to the public:</font> As soon as practicable after this Registration Statement becomes effective.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> &#160;&#160;x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> &#160;&#160;o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> &#160;&#160;o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> &#160;&#160;o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b2 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer</font></div>
</td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">&#168;</font></div>
</td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer</font></div>
</td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">&#168;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer</font></div>
</td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">&#168;</font></div>
</td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company</font></div>
</td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">x</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Do not check if a smaller reporting company)</font></div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CALCULATION OF REGISTRATION FEE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title of Each Class Of Securities to be <br>
Registered</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount to</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">be</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registered</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(1)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Proposed</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Maximum</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offering</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Price</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">per share</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(2)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Proposed</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Maximum</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Aggregate <br>
Offering</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Price</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registration</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fee</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.001 par value per share</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,106,120</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.45</font></div>
</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,028,354</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">776.45</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.001 par value per share, issuable upon exercise of the common stock warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">276,529</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.45</font></div>
</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507,083</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">194.11</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,382,649</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">970.56</font></font></div>
</div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This registration statement includes an indeterminate number of additional shares of common stock issuable for no additional consideration pursuant to any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration, which results in an increase in the number of outstanding shares of our common stock. In the event of a stock split, stock dividend or similar transaction involving our common stock, in order to prevent dilution, the number of shares registered shall be automatically increased to cover the additional shares in accordance with Rule 416(a) under the Securities Act of 1933, as amended.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="92%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, using the average of the high and low prices as reported on the OTC Bulletin Board on January 24, 2014 which was $5.45 per share.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the commission, acting pursuant to said Section 8(a), may determine.</font></div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; COLOR: #ff0000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; COLOR: #ff0000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRELIMINARY PROSPECTUS</font></div>
</td>
<td valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; COLOR: #ff0000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUBJECT TO COMPLETION</font></div>
</td>
<td valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; COLOR: #ff0000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DATED&#160;January 31, 2014</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1,382,649 Shares of Common Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This prospectus covers the sale by the selling stockholders of up to (i) 1,106,120 shares of common stock, par value $0.001 per share, held by the selling stockholders, and (ii) 276,529 shares of our common stock issuable upon exercise of common stock warrants held by the selling stockholders named in this prospectus at an exercise price of $9.00 per share. The shares being sold by the selling stockholders were issued to them in private placement transactions which were exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Our common stock and warrants are more fully described in &#8220;Description of Securities.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We also have a resale registration statement that was declared effective by the Securities and Exchange Commission on November 8, 2013. The November 2013 prospectus covers the sale by the selling stockholders of up to (i) 16,162,319 shares of common stock, par value $0.001 per share, held by the selling stockholders, (ii) 1,559,438 shares of our common stock issuable upon exercise of Series B warrants held by the selling stockholders at an exercise price of $2.48 per share, (iii) 2,673,652 shares of our common stock issuable upon exercise of the 2011 stock offering warrants held by the selling stockholders at an exercise price of $0.78 per share, (iv) 3,755,562 shares of our common stock issuable upon exercise of consulting firm warrants held by the selling stockholders at an exercise price of $0.01 per share, (v) 1,120,499 shares of our common stock issuable upon exercise of placement agent warrants held by the selling stockholders at an exercise price of $0.78 per share, (vi) 464,027 shares of our common stock issuable upon exercise of placement agent warrants held by the selling stockholders at an exercise price of $2.48 per share.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are not selling any common stock under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders. <font style="DISPLAY: inline">These shares will be offered for sale by the selling shareholders in accordance with the &#8220;Plan of Distribution.&#8221; We will not receive any proceeds from sales of shares of our common stock or warrants by the selling stockholders. However, to the extent the warrants are exercised for cash, if at all, we will receive the exercise price of the warrants. We will pay the expenses incurred in connection with the offering described in this prospectus, with the exception of brokerage expenses, fees, discounts and commissions, which will be paid by selling stockholders.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our common stock is presently traded on the OTCQB under the symbol ATNM. On&#160;January 30, 2014, the last sale price of our shares as reported by the OTCQB was $5.70 per share. The prices at which the selling stockholders may sell the shares of common stock that are part of this offering may be market prices prevailing at the time of sale, at negotiated prices, at fixed prices, or at varying prices determined at the time of sale. See &#8220;Plan of Distribution.&#8221; &#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">An investment in our common stock may be considered speculative and involves a high degree of risk, including the risk of a substantial loss of your investment. See &#8220;Risk Factors&#8221; beginning on page 6 to read about the risks you should consider before buying shares of our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The date of this prospectus is&#160; __________,&#160;2014</font></div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="toc">TABLE OF CONTENTS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a001v1">PROSPECTUS SUMMARY</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a002v1">RISK FACTORS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a003v1">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a004v1">DIVIDEND POLICY</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a005v1">USE OF PROCEEDS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a006v1">DILUTION</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a007v1">PENNY STOCK CONSIDERATIONS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a008v1">SELLING STOCKHOLDERS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a009v1">DESCRIPTION OF BUSINESS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a010v1"><!--efplaceholder--><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MARKET PRICE OF AND DIVIDENDS ON OUR COMMON STOCK AND RELATED STOCKHOLDER</font><!--efplaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> MATTERS</font></font></a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a011v1"><!--efplaceholder--><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF</font><!--efplaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> OPERATIONS</font></font></font></a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a012v1">CHANGES IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">39</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a013v1">DIRECTORS AND EXECUTIVE OFFICERS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a014v1">EXECUTIVE COMPENSATION</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a015v1">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a016v1">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a017v1">DESCRIPTION OF SECURITIES</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a018v1">PLAN OF DISTRIBUTION</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a019v1">SHARES ELIGIBLE FOR FUTURE SALE</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a020v1">LEGAL MATTERS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a021v1">EXPERTS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a022v1">WHERE YOU CAN FIND MORE INFORMATION</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION OF&#160; SECURITIES ACT LIABILITIES</font></div>
</td>
<td align="left" valign="bottom" width="4%"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="transparent" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a023v1">INDEX TO FINANCIAL STATEMENTS</a></font></font></div>
</td>
<td align="right" valign="bottom" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-1</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Please read this prospectus carefully. It describes our business, our financial condition and results of operations. We have prepared this prospectus so that you will have the information necessary to make an informed investment decision.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">You should rely only on information contained in this prospectus. We have not authorized any other person to provide you with different information. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any state where the offer or sale is not permitted. The information in this prospectus is complete and accurate as of the date on the front cover, but the information may have changed since that date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a001v1">PROSPECTUS SUMMARY</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in the common stock. You should carefully read the entire prospectus, including &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the consolidated financial statements, before making an investment decision. Our actual results may differ significantly from the results discussed in these forward-looking statements as a result of certain factors, including those described in &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; All references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; mean Actinium Pharmaceuticals, Inc. and its subsidiary Actinium Corporation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Business Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are a biopharmaceutical company focused on the $54 billion market for cancer drugs. Our most advanced products are Actimab&#8482;-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab&#8482;-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Based on the successful Iomab-B End of Phase 2 (EOP-2) meeting and subsequent discussions with the U. S. Food and Drug Administration (FDA), the Company established an agreement on the path to a Biologics License Applications (BLA) submission which included a single pivotal Phase 3 clinical study design.&#160;&#160;The key clinical study design primary and secondary endpoints and study size were confirmed.&#160;&#160;Iomab-B is to be used in preparing patients for HSCT.&#160;&#160;The trial population in this two arm randomized controlled multicenter trial will be refractory AML patients over the age of 55.&#160;&#160;The trial size was set at 150 patients (75 patients per arm).&#160;&#160;The Company is developing its cancer drugs using its expertise in radioimmunotherapy. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC), whose indirect subsidiary, Actinium Holdings Ltd., is a significant stockholder of the Company.&#160;The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213. The final drug construct is designed to specifically target and kill cancer cells while minimizing side effects. The Company intends to develop a number of products for different types of cancer and derive revenue from partnering relationships with large pharmaceutical companies and/or direct sales of its products in specialty markets in the United States.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Since our inception on June 13, 2000, we have not generated any revenues, and as of September 30, 2013, we have incurred net losses of $60.6 million. As of December 31, 2012 and September 30, 2013 our cash balance was $5.7 million, and $4.0 million, respectively, and we need up to $25 million in cash to finance research and development and to cover our ongoing working capital needs through the first quarter of 2016. In December 2013 and January 2014, the Company closed on total gross proceeds of approximately $6.6 million from the private placement of common stock and warrants to new and existing accredited investors.&#160;&#160;If we do not raise any additional funding, we will be able to continue our operations through 2014 and into the first quarter of 2015<font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;As we have raised 25% of the needed funds,&#160;we will be able to conduct our planned operations through 2014 and into the first quarter of 2015. If we raise 50% of the needed funds, we will be able to conduct our planned development programs through the second half of 2015. If we raise 75% or more of the needed funds, we will be able to accelerate our planned development programs through 2015 and into the second quarter of 2016.&#160;&#160;Our first product is not expected to be commercialized until at least 2017. In the second quarter of 2013 we issued shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013.&#160;&#160;The warrants were exercised at $1.65 per share, resulting in gross proceeds of approximately $3.5 million for the Company.&#160;&#160;As the remainder of the outstanding warrants are exercisable on a cashless basis there can be no assurance that we will be able to realize any proceeds from their exercise.</font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Corporate Information</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our principal executive offices are located at 501 Fifth Avenue,&#160;3<font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font></font> Floor, New York, NY 10017 and our telephone number is (646) 459-4201. Our website address is <font style="FONT-STYLE: italic; DISPLAY: inline">www.actiniumpharmaceuticals.com</font>. The information contained therein or connected thereto shall not be deemed to be incorporated into this prospectus or the registration statement of which it forms a part. The information on our website is not part of this prospectus.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3.3pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THE OFFERING</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="17%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common stock offered by selling stockholders</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,382,649 shares of our common stock including: up to (i) 1,106,120 shares of common stock, par value $0.001 per share, held by the selling stockholders, and (ii) 276,529 shares of our common stock issuable upon exercise of common stock warrants held by the selling stockholders at an exercise price of $9.00 per share.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="17%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common stock outstanding before the offering</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,903,150 shares of common stock (1)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="17%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common stock outstanding after the offering</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,179,682 shares of common stock (2)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="17%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use of proceeds</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We will not receive any proceeds from the sale of the common stock by the selling stockholders. However, we may receive up to approximately $2.5 million in the aggregate upon the exercise of the common stock warrants if the holders exercise them for cash. The registration of common stock pursuant to this prospectus does not necessarily mean that any of those shares will ultimately be offered or sold by the selling stockholders. We intend to use the proceeds, if any, received from any cash exercise of the warrants for working capital and general corporate purposes.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="17%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Trading Symbol</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ATNM</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="17%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risk Factors</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The common stock offered hereby involves a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See &#8220;Risk Factors&#8221;.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td valign="top" width="77%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based upon the total number of issued and outstanding shares as of&#160;January 22, 2014</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td valign="top" width="77%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based upon the total number of issued and outstanding shares as of&#160;January 22, 2014, and including 276,529 shares of our common stock issuable upon exercise of common stock warrants held by the selling stockholders at an exercise price of $9.00 per share.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a002v1">RISK FACTORS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this Registration Statement, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could suffer. In that case, the trading price of our shares of common stock could decline and you may lose all or part of your investment. See &#8220;Cautionary Note Regarding Forward Looking Statements&#8221; above for a discussion of forward-looking statements and the significance of such statements in the context of this Registration Statement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Business</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have generated no revenue from commercial sales to date and our future profitability is uncertain.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have a limited operating history and our business is subject to all of the risks inherent in the establishment of a new business enterprise. Our likelihood of success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with this development and expansion. Since we began our business, we have focused on research, development and clinical trials of product candidates, and have incurred losses since inception. As of December 31, 2012 and September 30, 2013, we had a deficit accumulated during development stage of approximately $55.7 million and $60.6 million, respectively. If we continue to incur operating losses and fail to become a profitable company, we may be unable to continue our operations. We expect to continue to operate at a net loss as we continue our research and development efforts, continue to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that the products under development by us will be approved for sale in the U.S. or elsewhere. Furthermore, there can be no assurance that if such products are approved they will be successfully commercialized, and the extent of our future losses and the timing of our profitability are highly uncertain.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">We do not currently have sufficient capital for the development and commercialization of our lead product and we will need to continue to seek capital from time to time to continue development of our lead drug candidates and to acquire and develop other product candidates. Our first product is not expected to be commercialized until at least 2017 and we do not expect that the partnering revenues it will generate will be sufficient to fund our ongoing operations. Our cash balance as of September 30, 2013 was $4.0 million. In December 2013 and January 2014,</font> the Company closed on total gross proceeds of approximately $6.6 million from the private placement of common stock and warrants to new and existing accredited investors. <font style="DISPLAY: inline">We expect that we will need approximately $7 million over the next 12 months to finance research and development and to cover our ongoing working capital needs.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our business or operations may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If we cannot raise adequate funds to satisfy our capital requirements, we will have to delay, scale-back or eliminate our research and development activities, clinical studies or future operations.&#160;&#160;We may also be required to obtain funds through arrangements with collaborators, which arrangements may require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights to future product candidates or certain major geographic markets.&#160;&#160;We may further have to license our technology to others.&#160;&#160;This could result in sharing revenues which we might otherwise have retained for ourselves.&#160;&#160;Any of these actions may harm our business, financial condition and results of operations.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The amount of capital we may need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative, licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization of our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have limited access to the capital markets and even if we can raise additional funding, we may be required to do so on terms that are dilutive to you.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have limited access to the capital markets to raise capital.&#160;&#160;The capital markets have been unpredictable in the recent past for radio-immunotherapy and other oncology companies and unprofitable companies such as ours.&#160;&#160;In addition, it is generally difficult for development stage companies to raise capital under current market conditions.&#160;&#160;The amount of capital that a company such as ours is able to raise often depends on variables that are beyond our control.&#160;&#160;As a result, we may not be able to secure financing on terms attractive to us, or at all.&#160;&#160;If we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs.&#160;&#160;If adequate funds are not available on acceptable terms, or at all, our business, including our technology licenses, results of operations, financial condition and our continued viability will be materially adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to obtain or maintain necessary U.S. Food and Drug Administration clearances for our radio-immunotherapy products, or if such clearances are delayed, we will be unable to commercially distribute and market our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our products are subject to rigorous regulation by the U.S. Food and Drug Administration (FDA) and numerous other federal, state and foreign governmental authorities.&#160;&#160;The process of seeking regulatory clearance or approval to market a radio-immunotherapy product is expensive and time-consuming and, notwithstanding the effort and expense incurred, clearance or approval is never guaranteed.&#160;&#160;If we are not successful in obtaining timely clearance or approval of API products from the FDA, we may never be able to generate significant revenue and may be forced to cease operations.&#160;&#160;In particular, the FDA permits commercial distribution of a new radio-immunotherapy product only after the product has received approval of a Biologics License Application (&#8220;BLA&#8221;) filed with the FDA pursuant to 21 C.F.R. &#167; 314, seeking permission to market the product in interstate commerce in the United States.&#160;&#160;The BLA process is costly, lengthy and uncertain.&#160;&#160;Any BLA application filed by the Company will have to be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and efficacy of the product for its intended use.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obtaining clearances or approvals from the FDA and from the regulatory agencies in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other resources.&#160;&#160;The FDA and other agencies could ask us to supplement our submissions, collect non-clinical data, conduct additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications.&#160;&#160;In addition, even if we obtain a BLA approval or pre-market approvals in other countries, the approval could be revoked or other restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness.&#160;&#160;We cannot predict with certainty how, or when, the FDA will act.&#160;&#160;If we are unable to obtain the necessary regulatory approvals, our financial condition and cash flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited.&#160;&#160;Additionally, even if cleared or approved, the Company&#8217;s products may not be approved for the specific indications that are most necessary or desirable for successful commercialization or profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our radio-immunotherapy product candidates are in the early stages of development; and we have not demonstrated that any of our products actually cure cancer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Only two product candidates of the Company are currently in clinical development. &#160;&#160;There is an ongoing physician sponsored Phase 1 AML trial at MSKCC with a single dose of Actimab&#8482;-A.&#160;&#160;The Company has also commenced a Phase 1/2 multi-center AML trial with fractionated doses of Actimab&#8482;-A under its own federal Investigational New Drug Application (IND).&#160;&#160;Additionally, there are a number of physician IND trials that have been conducted or are currently ongoing at FHCRC with single doses of Iomab&#8482;-B.&#160;&#160;Neither the Company nor any relevant collaborative partner(s) has yet undertaken any clinical assessment or investigation of Company radio-immunotherapy product candidates for other indications, including colon cancer or prostate cancer.&#160;&#160;Significant further investment may be required to acquire antibody rights and to undertake necessary research and continued development.&#160;&#160;Further laboratory and specific clinical testing will be required prior to regulatory approval of any product candidates.&#160;&#160;Adverse or inconclusive results from pre-clinical testing or clinical trials of product candidates may substantially delay, or halt entirely, any further development of one or more of our products.&#160;&#160;The projected timetables for continued development of the technologies and related product candidates by us may otherwise be subject to delay or suspension.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Modifications to our product candidates may require federal New Drug Application (NDA) approvals.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The NDA application is the vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United States&#160;&#160;Once a particular Company product candidate receives FDA approval or clearance, expanded uses or uses in new indications of our products may require additional human clinical trials and new regulatory approvals or clearances, including additional IND and NDA submissions and premarket approvals before we can begin clinical development, and/or prior to marketing and sales.&#160; If the FDA requires new clearances or approvals for a particular use or indication, we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results.&#160;&#160;If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conducting clinical trials and obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals could adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">There is no guarantee that the FDA will grant BLA approval of our future product candidates and failure to obtain necessary clearances or approvals for our future product candidates would adversely affect our ability to grow our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have recently commenced a multi-center Phase 1/2 clinical trial for our lead drug candidate, Actimab&#8482;-A, in AML and in the future expect to submit an BLA to the FDA for approval of this product.&#160;&#160;This drug candidate is also the subject of an ongoing human safety trial being conducted under a physician IND at MSKCC in New York City.&#160;&#160;We are in the early stages of evaluating other drug candidates consisting of conjugates of Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer.&#160;&#160;In June 2012, the Company acquired rights to Iomab&#8482;, a Phase 2 clinical stage monoclonal antibody with safety and efficacy data in more than 250 patients in need of HSCT.&#160;&#160;Product candidates utilizing this antibody would also require FDA approval of a BLA.&#160;&#160;The FDA may not approve or clear these products for the indications that are necessary or desirable for successful commercialization.&#160;&#160;Indeed, the FDA may refuse our requests for BLA market approval of new products, new intended uses or indications to existing or future product candidates.&#160;&#160;Failure to receive approval for our new products would have an adverse effect on our ability to expand our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Clinical trials necessary to support BLA approval of our future product candidates will be time consuming and expensive.&#160;&#160;Delays or failures in our clinical trials will prevent us from commercializing our product candidates and will adversely affect our business, operating results and prospects and could cause us to cease operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Initiating and completing clinical trials necessary to support BLA approval of Actimab&#8482;-A and other product candidates, will be time-consuming and expensive and the outcome uncertain.&#160;&#160;Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product candidate we advance into clinical trials may not have favorable results in later clinical trials.&#160;&#160;We have worked with the FDA to develop a clinical trial designed to support initial safety and efficacy of Actimab&#8482;-A and on October 6, 2008, and January 5, 2009, we submitted IND amendments to the FDA for the conduct of a multi-center Phase 1/2 clinical trial for treatment of AML.&#160;&#160;The trial is now underway with the purpose of examining the use of Actimab&#8482;-A in AML patients who are not eligible for approved forms of treatment with curative intent.&#160;&#160;The trial is not designed to support final BLA approval of the product candidate and one or more additional trials will have to be conducted in the future before we file a BLA.&#160;&#160;In addition, there can be no assurance that the data generated during the trial will meet our chosen safety and effectiveness endpoints or otherwise produce results that will eventually support the filing or approval of a BLA.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The issued patents, which are licensed by the Company for the HuM-195 antibody, our acute myeloid leukemia targeting antibody, will begin to expire before we have commercialized Actimab&#8482;-A.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The humanized antibody which we use in the conjugated Actimab&#8482;-A product candidate is covered by the claims of issued patents that we license from Facet Biotech Corporation, a wholly-owned subsidiary of Abbott Laboratories (&#8220;Facet&#8221;).&#160;&#160;Some of those patents expired in 2013.&#160;&#160;After these patents expire, others may be eventually able to use an antibody with the same sequence in alpha particle drug products based on alpha particle emitters other than actinium 225 and bismuth 213.&#160;&#160;Any process that would enable such a competition as described above is likely to require several years of development before achieving our product candidate&#8217;s current status and may be subject to significant regulatory hurdles, but is nevertheless a possibility that can affect the Company&#8217;s business in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additionally, because we expect that certain of these patents will expire prior to commercialization of Actimab&#8482;-A, the Company expects that in order to attract a commercialization partner for that product candidate, it will may need to reach an agreement with Facet to reduce the milestone payments and royalties currently required to be paid under our license agreement for HuM-195.&#160;&#160;There can be no assurance that the parties will be able to agree on an amendment to the terms of the license.&#160;&#160;Failure to reach such an agreement could materially adversely affect the Company&#8217;s ability to find a commercialization partner for Actimab&#8482;-A which may materially harm our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The BC8 antibody utilized in Iomab&#8482;-B is not patent protected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The antibody we use in the conjugated Iomab&#8482; product candidate is not covered by the claims of any issued or pending patents.&#160;&#160;Accordingly, others may be eventually able to use an antibody with the same sequence in alpha particle drug products based on alpha particle emitters.&#160;&#160;Any process that would enable such a competition as described above is likely to require several years of development before achieving our product candidate&#8217;s current status and may be subject to significant regulatory hurdles, but is nevertheless a possibility that could negatively impact the Company&#8217;s business in the future.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may be unable to obtain a sufficient supply of Ac-225 medical grade isotope in order to continue clinical trials and to allow for the manufacture of commercial quantities of Actimab&#8482;-A</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There are limited quantities of Ac-225 available today.&#160;&#160;The existing supplier of Ac-225 to the Company is Oak Ridge National Laboratory (ORNL).&#160;&#160;It manufactures Ac-225 by eluting it from its supply of Thorium-229.&#160;&#160;Although this has proven to be a very reliable source of production for a number of years, it is limited by the quantity of Thorium-229 at ORNL.&#160;&#160;We believe that the current approximate maximum of Ac-225 production from this source is sufficient for approximately 1,000 - 2,000 patient treatments per year.&#160;&#160;Since our needs are significantly below that amount at this time, and will continue to be below that for as long as we do not have a commercial product with a potential of selling more than 2,000 patient doses per year, we believe that this supply will be sufficient for completion of clinical trials and early commercialization.&#160;&#160;To secure supplies beyond this amount, the Company has developed what it believes to be a scalable cost-effective process for manufacturing Ac-225 in a cyclotron at an estimated cost in excess of $5 million.&#160;&#160;This work has been conducted at Technical University Munich (TUM) in Germany.&#160;&#160;The Company is now in possession of detailed descriptions of all the developed manufacturing procedures and has rights to all relevant patent applications and other intellectual property.&#160;&#160;However, we do not currently have access to a commercial cyclotron capable of producing medical grade Ac-225.&#160;&#160;Although beam time on such cyclotrons is commercially available, the Company does not currently have a relationship with any entity that owns or controls a suitable cyclotron.&#160;&#160;It has identified possible sources and estimates that it could secure the necessary beam time when needed at a cost of approximately $2 million per year.&#160;&#160;The Company&#8217;s contract for supply of this isotope from ORNL extends through the end of 2014, is renewable for future years.&#160;&#160;However, there can be no assurance that ORNL will decide to renew the contract or that the U.S.&#160;&#160;Department of Energy will not change its policies that allow for the sale of isotope to the Company.&#160;&#160;Failure to acquire sufficient quantities of medical grade Ac-225 would make it impossible to effectively complete clinical trials and to commercialize Actimab&#8482;-A and would materially harm our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability of appropriate clinical trial investigators; support staff; and proximity of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance.&#160;&#160;For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our product candidates or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts.&#160;&#160;Patients may also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive product candidates.&#160;&#160;In addition, patients participating in refractory AML clinical trials are seriously and often terminally ill and therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events related or unrelated to the investigational products, or death.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials.&#160;&#160;They may also require additional data on certain categories of patients, should it emerge during the conduct of our clinical trials that certain categories of patients are likely to be affected in different and/or additional manner than most of the patients.&#160;&#160;In addition to FDA requirements, our clinical trial requires the approval of the institutional review board, or IRB, at each site selected for participation in our current Actimab&#8482;-A clinical trial.&#160;&#160;We have submitted our clinical trial to the IRBs at participating sites for approval and we have thus far obtained approval from five IRBs.&#160;&#160;The Company&#8217;s clinical trial protocols have not been rejected by any IRB.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Additional delays to the completion of clinical studies may result from modifications being made to the protocol during the clinical trial, if such modifications are warranted and/or required by the occurrences in the given trial</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each such modification has to be submitted to the FDA.&#160;&#160;This could result in the delay or halt of a clinical trial while the modification is evaluated.&#160;&#160;In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or all of the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial.&#160;&#160;This might require the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying clearance or approval of a product candidate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">There can be no assurance that the data generated using modified protocols will be acceptable to FDA.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There can be no assurance that the data generated using modified protocols will be acceptable to FDA or that if future modifications during the trial are necessary, that any such modifications will be acceptable to FDA.&#160;&#160;If the FDA believes that its prior approval is required for a particular modification, it can delay or halt a clinical trial while it evaluates additional information regarding the change.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Serious injury or death resulting from a failure of one of our drug candidates during current or future clinical trials could also result in the FDA delaying our clinical trials or denying or delaying clearance or approval of a product.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The ongoing Phase 1 clinical trial for Actimab&#8482;-A conducted at MSKCC was designed to establish the maximum tolerated dose of the product.&#160;&#160;As the Company expected, patients receiving highest dose of the drug administered in the trial so far had prolonged bone marrow suppression which could lead to fatal infections and other severe consequences.&#160;&#160;Consequently, the dose levels of our drug in that trial were reduced as we continue our work on establishing maximum tolerated dose.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Even though an adverse event may not be the result of the failure of our drug candidate, FDA or an IRB could delay or halt a clinical trial for an indefinite period of time while an adverse event is reviewed, and likely would do so in the event of multiple such events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Any delay or termination of our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product candidates or result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects.&#160;&#160;Lengthy delays in the completion of our Actimab&#8482;-A clinical trials would adversely affect our business and prospects and could cause us to cease operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize our product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We do not have the ability to independently conduct our pre-clinical and clinical trials for our product candidates and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials.&#160;&#160;If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results and prospects may be adversely affected.&#160;&#160;Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The future results of our current or future clinical trials may not support our product candidate claims or may result in the discovery of unexpected adverse side effects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign authorities will agree with our conclusions regarding them.&#160;&#160;Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies.&#160;&#160;The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses.&#160;&#160;If FDA concludes that the clinical trials for Actimab&#8482;-A, or any other product candidate for which we might seek clearance, have failed to demonstrate safety and effectiveness, we would not receive FDA clearance to market that product candidate in the United States for the indications sought.&#160;&#160;In addition, such an outcome could cause us to abandon the product candidate and might delay development of others.&#160;&#160;Any delay or termination of our clinical trials will delay the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product candidates and generate revenues.&#160;&#160;It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of a product candidate&#8217;s profile.&#160;&#160;In addition, our clinical trials for Actimab&#8482;-A involve a relatively small patient population.&#160;&#160;Because of the small sample size, their results may not be indicative of future results.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actimab&#8482;-A and future product candidates may never achieve market acceptance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actimab&#8482;-A and future product candidates that we may develop may never gain market acceptance among physicians, patients and the medical community.&#160;&#160;The degree of market acceptance of any of product will depend on a number of factors, including the actual and perceived effectiveness and reliability of the product; the results of any long&#8722;term clinical trials relating to use of the product; the availability, relative cost and perceived advantages and disadvantages of alternative technologies; the degree to which treatments using the product are approved for reimbursement by public and private insurers; the strength of our marketing and distribution infrastructure; and the level of education and awareness among physicians and hospitals concerning the product.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Failure of Actimab&#8482;-A or any of our other product candidates to significantly penetrate current or new markets would negatively impact our business financial condition and results of operations<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">To be commercially successful, physicians must be persuaded that using our product candidates for treatment of AML and other cancers are effective alternatives to existing therapies and treatments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We believe that oncologists and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating specific cancers.&#160;&#160;Patient studies or clinical experience may indicate that treatment with our product candidates does not provide patients with sufficient benefits in extension of life or quality of life.&#160;&#160;We believe that recommendations and support for the use of each product candidate from influential physicians will be essential for widespread market acceptance.&#160;&#160;Our product candidates are still in the development stage and it is premature to attempt to gain support from physicians at this time.&#160;&#160;We can provide no assurance that such support will ever be obtained.&#160;&#160;If our product candidates do not receive such support from these physicians and from long-term data, physicians may not use or continue to use, and hospitals may not purchase or continue to purchase, them.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Even if our product candidates are approved by regulatory authorities, if we or our suppliers fail to comply with ongoing FDA regulation or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Any product candidate for which we obtain FDA clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product candidate, will be subject to continued regulatory review, oversight and periodic inspections by the FDA.&#160;&#160;In particular, we and our suppliers are required to comply with FDA&#8217;s Quality System Regulations, or QSR, and International Standards Organization, or ISO, regulations for the manufacture of products and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product candidate for which we obtain clearance or approval.&#160;&#160;Additionally, because our product candidates include radio-active isotopes, they will be subject to additional regulation and oversight from the United States Nuclear Regulatory Commission (NRC) and similar bodies in other jurisdictions.&#160;&#160;Regulatory bodies, such as the FDA, enforce these regulations through periodic inspections.&#160;&#160;The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or safety issues, could result in, among other things, enforcement actions by the FDA and/or other regulatory bodies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If any of these actions were to occur, it would harm our reputation and cause our future product sales and profitability to suffer and may prevent us from generating revenue.&#160;&#160;Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our product candidates on a timely basis and in the required quantities, if at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Even if regulatory clearance or approval of a product candidate is granted, such clearance or approval may be subject to limitations on the intended uses for which a product may be marketed and reduce the potential to successfully commercialize that product and generate revenue from that product.&#160;&#160;If the FDA determines that the product promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we or our commercialization partners cease or modify our training or promotional materials or subject us to regulatory enforcement actions.&#160;&#160;It is also possible that other federal, state or foreign enforcement authorities might take action if they consider such training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with adverse event and pharmacovigilance reporting requirements, including the reporting of adverse events which occur in connection with, and whether or not directly related to, our products.&#160;&#160;Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to recall, replace or refund the cost of any product we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our revenue stream will depend upon third party reimbursement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The commercial success of our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage and reimbursement is available for patients that use our products.&#160;&#160;However, the availability of insurance coverage and reimbursement for newly approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products are approved by the FDA as safe and efficacious.&#160;&#160;Patients using existing approved therapies are generally reimbursed all or part of the product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as a result, they may not cover or provide adequate payment for these products.&#160;&#160;Submission of applications for reimbursement approval generally does not occur prior to the filing of an NDA for that product and may not be granted until many months after NDA approval.&#160;&#160;In order to obtain reimbursement arrangements for these products, we or our commercialization partners may have to agree to a net sales price lower than the net sales price we might charge in other sales channels.&#160;&#160;The continuing efforts of government and third-party payors to contain or reduce the costs of healthcare may limit our revenue.&#160;&#160;Initial dependence on the commercial success of our products may make our revenues particularly susceptible to any cost containment or reduction efforts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Business as a &#8220;Going Concern&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In expressing an opinion on our 2012 financial statements, our auditor has expressed its opinion as to our business being a &#8220;going concern&#8221;. Such an opinion indicates that the business lacks sufficient liquidity to remain operating as a business entity for the next 12 months. Our ability to continue operations is dependent on the successful execution of our plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. We may need to issue additional equity and incur additional liabilities with related parties to sustain our existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are dependent on third parties for manufacturing and marketing of our proposed proprietary products.&#160;&#160;If we are not able to secure favorable arrangements with such third parties, our business and financial condition would be harmed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We will not manufacture any of our proposed proprietary products for commercial sale nor do we have the resources necessary to do so.&#160;&#160;In addition, we currently do not have the capability to market drug products ourselves.&#160;&#160;We intend to contract with specialized manufacturing companies to manufacture our proposed proprietary products and partner with larger pharmaceutical companies for their commercialization.&#160;&#160;In connection with our efforts to commercialize our proposed proprietary products, we will seek to secure favorable arrangements with third parties to distribute, promote, market and sell them.&#160;&#160;If we are not able to secure favorable commercial terms or arrangements with third parties for distribution, marketing, promotion and sales of our proposed proprietary products, we may have to retain promotional and marketing rights and seek to develop the commercial resources necessary to promote or co-promote or co-market certain or all of our proprietary product candidates to the appropriate channels of distribution in order to reach the specific medical market that we are targeting.&#160;&#160;We may not be able to enter into any partnering arrangements on this or any other basis.&#160;&#160;If we are not able to secure favorable partnering arrangements, or are unable to develop the appropriate resources necessary for the commercialization of our proposed proprietary products, our business and financial condition could be harmed.&#160;&#160;In addition, we will have to hire additional employees or consultants, since our current employees have limited experience in these areas.&#160;&#160;Sufficient employees with relevant skills may not be available to us.&#160;&#160;Any increase in the number of our employees would increase our expense level, and could have an adverse effect on our financial position.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition, we, or our potential commercial partners, may not successfully introduce our proposed proprietary products or they may not achieve acceptance by patients, health care providers and insurance companies.&#160;&#160;Further, it is possible that we may not be able to secure arrangements to manufacture, market, distribute, promote and sell our proposed proprietary products at favorable commercial terms that would permit us to make a profit.&#160;&#160;To the extent that corporate partners conduct clinical trials, we may not be able to control the design and conduct of these clinical trials.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may have conflicts with our partners that could delay or prevent the development or commercialization of our product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We may have conflicts with our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration.&#160;&#160;If any conflicts arise with any of our partners, such partner may act in a manner that is adverse to our best interests.&#160;&#160;Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the partner to cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Upon commercialization of our product candidates, we may be dependent on third parties to market, distribute and sell them.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our ability to receive revenues may be dependent upon the sales and marketing efforts of any future co-marketing partners and third-party distributors.&#160;&#160;At this time, we have not entered into an agreement with any commercialization partner and only plan to do so after the successful completion of Phase II clinical trials and prior to commercialization.&#160;&#160;If we fail to reach an agreement with any commercialization partner, or if upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our product candidates will face significant competition in the markets for them, and if they are unable to compete successfully, our business will suffer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our product candidates face, and will continue to face, intense competition from large pharmaceutical companies, as well as academic and research institutions.&#160;&#160;We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii) emerging competition and (iv) new product introductions.&#160;&#160;Our competitors have existing products and technologies that will compete with our product candidates and technologies and may develop and commercialize additional products and technologies that will compete with our product candidates and technologies.&#160;&#160;Because several competing companies and institutions have greater financial resources than us, they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development, or R&amp;D, and (iii) carry on broader R&amp;D initiatives.&#160;&#160;Our competitors also have greater development capabilities than we do and have substantially greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products.&#160;&#160;They also have greater name recognition and better access to customers than us.&#160;&#160;Our chief competitors include companies such as Algeta ASA, Bayer Schering Pharma AG, GlaxoSmithKline Plc and&#160;Spectrum Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Adverse events involving our products may lead the FDA to delay or deny clearance for our product candidates or result in product recalls that could harm our reputation, business and financial results.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Once a product candidate receives FDA clearance or approval, the agency has the authority to require the recall of commercialized products in the event of adverse side effects, material deficiencies or defects in design or manufacture.&#160;&#160;The authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious injury or death.&#160;&#160;Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found.&#160;&#160;A government-mandated or voluntary recall by us or one of our distributors could occur as a result of adverse side effects, impurities or other product contamination, manufacturing errors, design or labeling defects or other deficiencies and issues.&#160;&#160;Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations.&#160;&#160;The FDA requires that certain classifications of recalls be reported to FDA within 10 working days after the recall is initiated.&#160;&#160;Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA.&#160;&#160;We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA.&#160;&#160;If the FDA disagrees with our determinations, they could require us to report those actions as recalls.&#160;&#160;A future recall announcement could harm our reputation with customers and negatively affect our sales.&#160;&#160;In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business depends upon securing and protecting critical intellectual property.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our commercial success will depend in part on our obtaining and maintaining patent, trade secret, copyright and trademark protection of our technologies in the United States and other jurisdictions, as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.&#160;&#160;We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable intellectual property protection, such as patents or trade secrets law, cover them.&#160;&#160;In particular, we place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes.&#160;&#160;Furthermore, the degree of future protection of our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage.&#160;&#160;Moreover, the degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages of development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether the commercial versions of these product candidates will incorporate proprietary technologies.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our patent position is highly uncertain and involves complex legal and factual questions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accordingly, we cannot predict the breadth of claims that may be allowed or enforced under our patents or in third-party patents.&#160;&#160;For example, we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and, we may not develop additional proprietary technologies that are patentable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As a result, our owned and licensed patents may not be valid and we may not be able to obtain and enforce patents and to maintain trade secret protection for the full commercial extent of our technology.&#160;&#160;The extent to which we are unable to do so could materially harm our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We or our licensors have applied for and will continue to apply for patents for certain products.&#160;&#160;Such applications may not result in the issuance of any patents, and any patents now held or that may be issued may not provide us with adequate protection from competition.&#160;&#160;Furthermore, it is possible that patents issued or licensed to us may be challenged successfully.&#160;&#160;In that event, if we have a preferred competitive position because of such patents, such preferred position would be lost.&#160;&#160;If we are unable to secure or to continue to maintain a preferred position, we could become subject to competition from the sale of generic products.&#160;&#160;Failure to receive, inability to protect, or expiration of our patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we license from third parties, or subsequent related filings, would adversely affect our business and operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Patents issued or licensed to us may be infringed by the products or processes of others.&#160;&#160;The cost of enforcing our patent rights against infringers, if such enforcement is required, could be significant, and the Company does not currently have the financial resources to fund such litigation.&#160;&#160;Further, such litigation can go on for years and the time demands could interfere with our normal operations.&#160;&#160;There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry.&#160;&#160;We may become a party to patent litigation and other proceedings.&#160;&#160;The cost to us of any patent litigation, even if resolved in our favor, could be substantial.&#160;&#160;Some of our competitors may be able to sustain the costs of such litigation more effectively than we can because of their substantially greater financial resources.&#160;&#160;Litigation may also absorb significant management time.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unpatented trade secrets, improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success.&#160;&#160;Although we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means, these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access to, the same or similar information.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certain of our patent rights are licensed to us by third parties.&#160;&#160;If we fail to comply with the terms of these license agreements, our rights to those patents may be terminated, and we will be unable to conduct our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we are found to be infringing on patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the development or sale of our products, and/or pay damages.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our manufacturing processes and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others, or the trade secrets of those persons and entities.&#160;&#160;As the pharmaceutical industry expands and more patents are issued, the risk increases that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others.&#160;&#160;These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the affected product or process.&#160;&#160;If any of these actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process.&#160;&#160;Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain.&#160;&#160;If we become involved in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our ability to protect and enforce our patents does not guaranty that we will secure the right to commercialize our patents.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A patent is a limited monopoly right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention.&#160;&#160;This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or using its invention.&#160;&#160;While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention where other permissions may be required for commercialization to occur.&#160;&#160;For example, a drug cannot be marketed without the appropriate authorization from the FDA, regardless of the existence of a patent covering the product.&#160;&#160;Further, the invention, even if patented itself, cannot be commercialized if it infringes the valid patent rights of another party.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We rely on confidentiality agreements to protect our trade secrets.&#160;&#160;If these agreements are breached by our employees or other parties, our trade secrets may become known to our competitors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We rely on trade secrets that we seek to protect through confidentiality agreements with our employees and other parties.&#160;&#160;If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us.&#160;&#160;We may not have any remedies against our competitors and any remedies that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure.&#160;&#160;In addition, we may have to expend resources to protect our interests from possible infringement by others.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may undertake international operations, which will subject us to risks inherent with operations outside of the United States.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Although we do not have any foreign operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant opportunities.&#160;&#160;However, even with the cooperating of a commercialization partner, conducting drug development in foreign countries involves inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If we were to experience any of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition may suffer and cause us to reduce or discontinue our international development and registration efforts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not be successful in hiring and retaining key employees.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our future operations and successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon to manage our business, in particular, Dr. Dragan Cicic, our Chief Operating Officer and Chief Medical Officer.&#160;&#160;If any member of our current senior management terminates his or her employment with us, such a departure may have a material adverse effect on our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our future success also depends on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical and regulatory personnel.&#160;&#160;There can be no assurance that such professionals will be available in the market, or that we will be able to retain existing professionals or meet or continue to meet their compensation requirements.&#160;&#160;Furthermore, the cost base in relation to such compensation, which may include equity compensation, may increase significantly, which could have a material adverse effect on us.&#160;&#160;Failure to establish and maintain an effective management team and work force could adversely affect our ability to operate, grow and manage our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We do not yet know what the consequences may be on our business of the Patient Protection and Affordable Care Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In March 2010, President Obama signed the Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;), which makes changes that are expected to significantly impact the pharmaceutical industries. One of the principal aims of the PPACA as currently enacted is to expand health insurance coverage to approximately 32 million Americans who are currently uninsured. The consequences of this significant coverage expansion on the sales of our products, once they are developed, are unknown and speculative at this point.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The PPACA contains a number of provisions designed to generate the revenues necessary to fund the coverage expansions among other things. This includes new fees or taxes on certain health-related industries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The PPACA provisions on comparative clinical effectiveness research extend the initiatives of the American Recovery and Reinvestment Act of 2009, also known as the stimulus package, which included $1.1 billion in funding to study the comparative effectiveness of health care treatments and strategies. This stimulus funding was designated for, among other things, conducting, supporting or synthesizing research that compares and evaluates the risks and benefits, clinical outcomes, effectiveness and appropriateness of products. The PPACA appropriates additional funding to comparative clinical effectiveness research. Although Congress has indicated that this funding is intended to improve the quality of health care, it remains unclear how the research will impact current Medicare coverage and reimbursement or how new information will influence other third-party payor policies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. Most recently, on August 2, 2011, the President Obama signed into law the Budget Control Act of 2011, which, among other things, creates the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, which threatened to trigger the legislation&#8217;s automatic reduction to several government programs, including aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, starting in 2013. Congress passed and President Obama signed, however, the American Taxpayer Relief Act of 2012 which delays these required cuts for one year. We expect that the PPACA, as well as other federal or state health care reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and our ability to successfully commercialize our products or could limit or eliminate our spending on certain development projects. The taxes imposed by the PPACA and the expansion in the government&#8217;s role in the U.S. healthcare industry may result in decreased profits to us, lower reimbursement by payors for our products, and/or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Managing our growth as we expand operations may strain our resources.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We expect to need to grow rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our drug candidates, which will place a significant strain on our financial, managerial and operational resources.&#160;&#160;In order to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities.&#160;&#160;Moreover, we will need to increase staffing and to train, motivate and manage our employees.&#160;&#160;All of these activities will increase our expenses and may require us to raise additional capital sooner than expected.&#160;&#160;Failure to manage growth effectively could materially harm our business, financial condition or results of operations.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may expand our business through the acquisition of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217; ownership interests in our company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our business strategy includes expanding our products and capabilities, and we may seek acquisitions of drug candidates, antibodies or technologies to do so.&#160;&#160;Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key employees of the acquired companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We can make no assurances that any acquisition will result in short-term or long-term benefits to us.&#160;&#160;We may incorrectly judge the value or worth of an acquired product, company or business.&#160;&#160;In addition, our future success would depend in part on our ability to manage the rapid growth associated with some of these acquisitions.&#160;&#160;We cannot assure that we will be able to make the combination of our business with that of acquired products, businesses or companies work or be successful.&#160;&#160;Furthermore, the development or expansion of our business or any acquired products, business or companies may require a substantial capital investment by us.&#160;&#160;We may not have these necessary funds or they might not be available to us on acceptable terms or at all.&#160;&#160;We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute each current stockholder&#8217;s ownership interest in the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Ownership of Our Common Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we became public by means of a &#8220;reverse merger,&#8221; we may not be able to attract the attention of major brokerage firms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional risks may exist since we became public through a &#8220;reverse merger.&#8221; Securities analysts of major brokerage firms may not provide coverage of us since there is little incentive to brokerage firms to recommend the purchase of our common stock. We cannot assure you that brokerage firms will want to conduct any secondary offerings on behalf of our company in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we were formerly an SEC-reporting shell company, we are subject to SEC rules on seasoning requirements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company, since it was formerly an SEC-reporting shell company, is also subject to SEC rules which require such companies to trade in the over-the-counter markets (or some other national exchanges) for one full fiscal year and to file all periodic reports with the SEC before seeking to &#8220;uplist&#8221; to a national securities exchange like NASDAQ or NYSE MKT. The Company can only bypass the one year over-the-counter trading requirement if it can complete a firm commitment underwritten public offering with gross proceeds of at least $40 million. As a result, our stockholders may find it more difficult to dispose of shares or obtain accurate quotations as to the market value of our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The sale of securities by us in any equity or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We believe we need up to $25 million in cash to finance research and development and to cover our ongoing working capital needs through 2016, and we have not completed efforts to establish a stable recurring source of revenues sufficient to cover our operating costs for the next twelve months, We have financed our operations primarily through sales of stock and the issuance of convertible promissory notes.&#160;&#160;It is likely that during the next twelve months we will seek to raise capital through the sales of stock and/or issuance of convertible promissory notes in order to expand our level of operations to continue our research and development efforts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Any sale of common stock by us in a future private placement offering could result in dilution to the existing stockholders as a direct result of our issuance of additional shares of our capital stock.&#160;&#160;In addition, our business strategy may include expansion through internal growth, by acquiring subscribers email lists, or by establishing strategic relationships with targeted customers and vendor.&#160;&#160;In order to do so, or to finance the cost of our other activities, we may issue additional equity securities that could dilute our stockholders&#8217; stock ownership.&#160;&#160;We may also assume additional debt and incur impairment losses related to goodwill and other tangible assets if we acquire another company and this could negatively impact our earnings and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The filing of our Registration Statement on Form S-1 on March 15, 2013 could have potentially affected our exemption from registration with the SEC for the share exchange that commenced on December 28, 2012, in connection with our exchange of common stock with the shareholders of Actinium Corporation (fka, Actinium Pharmaceuticals, Inc.).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, we completed a share exchange, that was approved by 78% of our shareholders (100% of those voting approved the share exchange),&#160;with Cactus Ventures, Inc. (&#8220;Cactus&#8221;), whereby Cactus acquired 21% of the issued and outstanding capital stock of Actinium Corporation from the shareholders of Actinium Corporation (the &#8220;Actinium Shareholders&#8221;) in exchange for the issuance of 4,309,015 shares of Common Stock of the Company to the Actinium Shareholders (the &#8220;Share Exchange&#8221;).&#160;&#160; We continued the physical process of exchanging shares with the Actinium Shareholders with closings on March 11, 2013 (with a total of 55.5% shares of Actinium Corporation exchanged) and August 22, 2013 (with a total of 93.7% shares of Actinium Corporation exchanged).&#160; On September 25, 2013 all of the remaining Actinium Shareholders shares were exchanged for our common stock pursuant to a merger under Delaware law whereby we merged into our self Actinium Corporation (our subsidiary that was 93.7% owned by us). Under Section 5 of the Securities Act of 1933, unless there is a valid exemption from registration of the securities sold in an offering. All issuers must register non-exempt securities with the SEC. The securities in the Share Exchange were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) of the Securities Act and Rule 506 of Regulation D &#160;(&#8220;Regulation D&#8221;) promulgated under the Securities Act.&#160;&#160;On March 15, 2013, we filed a Registration Statement on Form S-1 (the &#8220;Registration Statement&#8221;) with SEC to register shares of certain selling shareholders who had purchased shares of the Company in various private placements (the &#8220;2013 offering&#8221;).&#160; If the 2013 Offering were deemed integrated with the Share Exchange we may not be able to rely upon the exemptions from registration pursuant to Section 4(2) of the Securities Act and/or Regulation D, since the filing of the&#160;Registration Statement may be deemed general solicitation, which is prohibited for reliance on an exemption from registration under Regulation D.&#160; As a result, investors in the Share Exchange may potentially be entitled to bring suit against the Company for offering a non-exempt security without registering it, and such investor may be able to obtain rescission with interest, or damages if the investor sold the securities for less that he or she purchased them.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Future sales of our common stock in the public market could lower the price of our common stock and impair our ability to raise funds in future securities offerings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the then prevailing market price of our common stock and could make it more difficult for us to raise funds in the future through a public offering of our securities. We believe we need up to $25 million in cash to finance research and development and to cover our ongoing working capital needs through 2016, and we have not completed efforts to establish a stable recurring source of revenues sufficient to cover our operating costs for the next twelve months, We have financed our operations primarily through sales of stock and the issuance of convertible promissory notes. It is likely that during the next twelve months we will to continue to finance our operations through sales of stock and/or issuance of convertible promissory notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Common Stock is quoted on the OTCQB which may have an unfavorable impact on our stock price and liquidity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our common stock is quoted on the OTCQB, which is a significantly more limited trading market than the New York Stock Exchange or The NASDAQ Stock Market.&#160;&#160;The quotation of the Company&#8217;s shares on the OTCQB may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">There is limited liquidity on the OTCQB which may result in stock price volatility and inaccurate quote information.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">When fewer shares of a security are being traded on the OTCQB, volatility of prices may increase and price movement may outpace the ability to deliver accurate quote information.&#160;&#160;Due to lower trading volumes in shares of our common stock, there may be a lower likelihood of one&#8217;s orders for shares of our common stock being executed, and current prices may differ significantly from the price one was quoted at the time of one&#8217;s order entry.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our common stock is extremely thinly traded, so you may be unable to sell at or near asking prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate your shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Currently, the Company&#8217;s common stock is quoted in the OTCQB and future trading volume may be limited by the fact that many major institutional investment funds, including mutual funds, as well as individual investors follow a policy of not investing in OTCQB stocks and certain major brokerage firms restrict their brokers from recommending OTCQB stocks because they are considered speculative, volatile and thinly traded.&#160;&#160;The OTCQB market is an inter-dealer market much less regulated than the major exchanges and our common stock is subject to abuses, volatility and shorting.&#160;&#160;Thus, there is currently no broadly followed and established trading market for the Company&#8217;s common stock.&#160;&#160;An established trading market may never develop or be maintained. Active trading markets generally result in lower price volatility and more efficient execution of buy and sell orders. Absence of an active trading market reduces the liquidity of the shares traded there.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Common Stock is subject to price volatility unrelated to our operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The trading volume of our common stock has been and may continue to be extremely limited and sporadic.&#160;&#160;As a result of such trading activity, the quoted price for the Company&#8217;s common stock on the OTCQB may not necessarily be a reliable indicator of its fair market value.&#160;&#160;Further, if we cease to be quoted, holders would find it more difficult to dispose of our common stock or to obtain accurate quotations as to the market value of the Company&#8217;s common stock and as a result, the market value of our common stock likely would decline.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We expect the market price of our Common Stock to fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting the Company&#8217;s competitors or the Company itself. In addition, the OTCQB is subject to extreme price and volume fluctuations in general.&#160;&#160;This volatility has had a significant effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are subject to the provisions of Section 15(g) and Rule 15g-9 of the Exchange Act, commonly referred to as the &#8220;penny stock rule.&#8221;&#160;&#160;Section 15(g) sets forth certain requirements for transactions in penny stock, and Rule 15g-9(d) incorporates the definition of &#8220;penny stock&#8221; that is found in Rule 3a51-1 of the Exchange Act.&#160;&#160;The SEC generally defines a penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. We will be subject to the SEC&#8217;s penny stock rules.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Since our Common Stock is deemed to be penny stock, trading in the shares of our common stock is subject to additional sales practice requirements on broker-dealers who sell penny stock to persons other than established customers and accredited investors.&#160;&#160;&#8221;Accredited investors&#8221; are persons with assets in excess of $1,000,000 (excluding the value of such person&#8217;s primary residence) or annual income exceeding $200,000 or $300,000 together with their spouse. For transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of such security and must have the purchaser&#8217;s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, unless exempt the rules require the delivery, prior to the first transaction of a risk disclosure document, prepared by the SEC, relating to the penny stock market.&#160;&#160;A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities.&#160;&#160;Finally, monthly statements must be sent disclosing recent price information for the penny stocks held in an account and information to the limited market in penny stocks. Consequently, these rules may restrict the ability of broker-dealer to trade and/or maintain a market in our common stock and may affect the ability of the Company&#8217;s stockholders to sell their shares of common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There can be no assurance that our shares of common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock was exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock if the SEC finds that such a restriction would be in the public interest.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we do not intend to pay dividends, stockholders will benefit from an investment in our Common Stock only if it appreciates in value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have never declared or paid any cash dividends on our Preferred Stock or Common Stock.&#160;&#160;For the foreseeable future, it is expected that earnings, if any, generated from our operations will be used to finance the growth of our business, and that no dividends will be paid to holders of the Company&#8217;s Preferred Stock or Common Stock.&#160;&#160;As a result, the success of an investment in our Preferred Stock or Common Stock will depend upon any future appreciation in its value.&#160;&#160;There is no guarantee that our Preferred Stock or Common Stock will appreciate in value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Certain provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in the stockholders&#8217; interest.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our Certificate of Incorporation and Bylaws and certain provisions of Delaware State law could have the effect of making it more difficult or more expensive for a third party to acquire, or from discouraging a third party from attempting to acquire, control of the Company, even when these attempts may be in the best interests of our stockholders.&#160;&#160;For example, we are governed by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own, 15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing a change in our control.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compliance with the reporting requirements of federal securities laws can be expensive.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are subject to the information and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act.&#160;The costs of preparing and filing annual and quarterly reports and other information with the SEC and furnishing audited reports to stockholders are substantial.&#160;In addition, we will incur substantial expenses in connection with the preparation of registration statements and related documents with respect to the registration of resale of the Common Stock.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Applicable regulatory requirements, including those contained in and issued under the Sarbanes-Oxley Act, may make it difficult for us to retain or attract qualified officers and directors, which could adversely affect the management of its business and its ability to obtain or retain listing of our Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We may be unable to attract and retain those qualified officers, directors and members of board committees required to provide for effective management because of the rules and regulations that govern publicly held companies, including, but not limited to, certifications required by principal executive officers. The enactment of the Sarbanes-Oxley Act has resulted in the issuance of a series of related rules and regulations and the strengthening of existing rules and regulations by the SEC, as well as the adoption of new and more stringent rules by the stock exchanges. The perceived increased personal risk associated with these changes may deter qualified individuals from accepting roles as directors and executive officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Further, some of these changes heighten the requirements for board or committee membership, particularly with respect to an individual&#8217;s independence from the corporation and level of experience in finance and accounting matters. We may have difficulty attracting and retaining directors with the requisite qualifications. If we are unable to attract and retain qualified officers and directors, the management of our business and our ability to obtain or retain listing of our shares of Common Stock on any stock exchange (assuming we elect to seek and are successful in obtaining such listing) could be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or detect fraud.&#160;&#160;Investors could lose confidence in our financial reporting and this may decrease the trading price of our Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We must maintain effective internal controls to provide reliable financial reports and detect fraud. We have been assessing our internal controls to identify areas that need improvement. Failure to maintain an effective system of internal controls could harm our operating results and cause investors to lose confidence in our reported financial information.&#160;Any such loss of confidence would have a negative effect on the trading price of our Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">At December 31, 2012, management concluded that our disclosure controls and procedures and our internal control over financial reporting were not effective due to several material weaknesses.&#160;&#160;In addition, at September 30, 2013, management concluded that our disclosure controls and procedures were not effective due to several material weaknesses.&#160;&#160;To address these weaknesses, management is seeking a full time Chief Financial Officer who is familiar with the public company reporting rules. The Company in December 2012 also established an Audit Committee to address these issues. In September 2013, we hired a VP of Finance who has served in a variety of core finance and business development functions over the span of 12 years at three NASDAQ listed biopharmaceutical companies&#160;who is being tasked with remediating such weaknesses.&#160;&#160;&#160;We expect to&#160;remediate such weaknesses by the end of the fiscal year 2013.&#160;&#160;In May 2013, we also engaged an outside third party financial reporting consulting firm to assist with our public company&#160;reporting requirements.&#160;&#160;In November 2013, Richard Steinhart joined the Company&#8217;s Board of Directors and became the chairman of the Audit Committee. Mr. Steinhart is a CPA and was employed by MELA Sciences, Inc, as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary from April 2006 through December 30, 2013. We expect to incur costs of $0.2 million in connection with our remediation plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The price of our common stock may become volatile, which could lead to losses by investors and costly securities litigation.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The trading price of our Common Stock may be highly volatile and could fluctuate in response to factors such as:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">actual or anticipated variations in our operating results;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">announcements of developments by us or our competitors;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the timing of IND and/or NDA approval, the completion and/or results of our clinical trials;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">regulatory actions regarding our products;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></div>
</td>
</tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">adoption of new accounting standards affecting the our industry;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">additions or departures of key personnel;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">introduction of new products by us or our competitors;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">sales of the our Common Stock or other securities in the open market; and</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">other events or factors, many of which are beyond our control.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The stock market is subject to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful, could result in substantial costs and diversion of our management&#8217;s attention and Company resources, which could harm our business and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a003v1">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This prospectus contains forward looking statements that involve risks and uncertainties, principally in the sections entitled &#8220;Description of Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; All statements other than statements of historical fact contained in this prospectus, including statements regarding future events, our future financial performance, business strategy and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Risk Factors&#8221; or elsewhere in this prospectus, which may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assumes no obligation to update any such forward-looking statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this prospectus. Before you invest in our securities, you should be aware that the occurrence of the events described in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this prospectus could negatively affect our business, operating results, financial condition and stock price. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this prospectus to conform our statements to actual results or changed expectations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;<!--efplaceholder--><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a004v1">DIVIDEND POLICY</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We plan to retain any earnings for the foreseeable future for our operations. We have never paid any dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will depend on our financial condition, operating results, capital requirements and such other factors as our Board of Directors deems relevant. In addition, our credit facility restricts our ability to pay dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<!--efplaceholder--><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a005v1">USE OF PROCEEDS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We will not receive any proceeds from the sale of the common stock by the selling stockholders. However, we may receive up to approximately $14.8 million in the aggregate upon the exercise of the warrants if the holders exercise them for cash. However, as these warrants also include a cashless exercise feature there can be no assurance that we will receive any capital from the exercise of such warrants. The registration of common stock pursuant to this prospectus does not necessarily mean that any of those shares will ultimately be offered or sold by the selling stockholders.&#160;&#160;We intend to use the proceeds received from any cash exercise of the warrants for working capital and general corporate purposes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a006v1">DILUTION</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are not selling any of the shares of our common stock in this offering. All of the shares sold in this offering will be held by the selling stockholders at the time of the sale, so that no dilution will result from the sale of the shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a007v1">PENNY STOCK CONSIDERATIONS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our common stock will be a penny stock, therefore, trading in our securities is subject to penny stock considerations. Broker-dealer practices in connection with transactions in &#8220;penny stocks&#8221; are regulated by certain penny stock rules adopted by the SEC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system). Penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&#8217;s account. The broker-dealer must also make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s written agreement to the transaction. These requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our securities, which could severely limit their market price and liquidity of our securities. These requirements may restrict the ability of broker-dealers to sell our common stock and may affect your ability to resell our common stock.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a008v1">SELLING STOCKHOLDERS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The common shares being offered for resale by the selling stockholders consist of 1,382,649 shares of our common stock that are issued and outstanding, including up to (i) 1105,120 shares of common stock, par value $0.001 per share, held by the selling stockholders, and (ii) 276,529 shares of our common stock issuable upon exercise of common stock warrants held by the selling stockholders at an exercise price of $9.00 per share. These holders include investors in private placement offerings of the Company that closed (A) on December 27, 2013 for the sale of units consisting of an aggregate of (i) 554,310 shares of common stock, and (ii) common stock warrants to purchase up to 138,577 shares of common stock, and (B) on January 10, 2014 for the sale of units consisting of an aggregate of (i) 551,810 shares of common stock, and (ii) common stock warrants to purchase up to 137,952 shares of common stock.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We also have a resale registration statement that was declared effective by the Securities and Exchange Commission on November 8, 2013. The November 2013 prospectus covers the sale by the selling stockholders of up to (i) 16,162,319 shares of common stock, par value $0.001 per share, held by the selling stockholders, (ii) 1,559,438 shares of our common stock issuable upon exercise of Series B warrants held by the selling stockholders at an exercise price of $2.48 per share, (iii) 2,673,652 shares of our common stock issuable upon exercise of the 2011 stock offering warrants held by the selling stockholders at an exercise price of $0.78 per share, (iv) 3,755,562 shares of our common stock issuable upon exercise of consulting firm warrants held by the selling stockholders at an exercise price of $0.01 per share, (v) 1,120,499 shares of our common stock issuable upon exercise of placement agent warrants held by the selling stockholders at an exercise price of $0.78 per share, (vi) 464,027 shares of our common stock issuable upon exercise of placement agent warrants held by the selling stockholders at an exercise price of $2.48 per share.&#160;&#160;The selling stockholders listed in the November 2013 prospectus are not included in this prospectus.</font></div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table sets forth certain information regarding the selling stockholders and the shares offered by them in this prospectus. Each selling stockholder&#8217;s percentage of ownership is based upon 24,903,150 shares of common stock outstanding as of&#160;January 22, 2014 and all securities which the person has the right to acquire within 60 days through the exercise of any option or warrant or through the conversion of a convertible security.</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name of</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares Beneficially</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Owned</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percentage (%) Beneficially</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Owned</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares Beneficially Owned</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percentage Beneficially Owned</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Selling</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">prior</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">prior</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="4" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares to</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">after</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">After</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="26%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholder</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">to Offering</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">to Offering</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="4" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offer (1)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offering</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offering</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adam Biedrzycki</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Alan Greenhalgh &amp; Angela Greenhalgh (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">312,491</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">312,491</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Alberto Sadde &amp; Leonella Olivieri de Sadde (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Andreas Wawrla</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">636,053</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.55</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">416,659</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">219,394</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Andrew Bellamy</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">88,743</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,334</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55,409</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Andrew Ferrett</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Andrew Kelly</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,501</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,501</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">)</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anthony Athanas, Jr.</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anthony D&#8217;Amato &amp; Marianne D&#8217;Amato (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Benoit Dumont</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,228</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,228</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cesar Fernandez Cardenas</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,875</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,875</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Charles Moore</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,125</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,125</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Christopher Charles Hugh Phillips</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Christopher G. Davison</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Daniel Huber</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Danny Sergeant</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,166</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,166</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Scott</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(17</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dean Beaver</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(18</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Thomas J. Rutherford</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(19</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Eamon Judge</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,041</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,041</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(20</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Eduardo Guemez Sarre</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(21</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Enguerrand de Ponteves</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41,766</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,603</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(22</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,163</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fran Rooney</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Frank R. Deis &amp; Donna R. Deis (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,959</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,959</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(24</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Garfield W. Hardeman TOD</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(25</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gary Mossman</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(26</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Georges Zanellato</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gerhard Plaschka</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">97,235</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(28</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47,235</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gregory Alexander</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,166</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,166</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(29</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Graham M. Bones</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,541</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,541</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(30</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gurpreet Ahluwalia</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(31</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gustavo Almeida De Almedia</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,041</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,041</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(32</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">James N. White</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,603</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,603</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(33</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">James W. Anthony &amp; Delisa Anthony (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,834</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,834</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(34</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jared Sullivan &amp; Shannan Sullivan (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,294</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,041</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(35</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,253</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan Backvall</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,291</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,291</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(36</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jeffrey C. Boggs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,709</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,709</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(37</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jodi Bennett Cabler</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,084</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,084</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(38</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Lawrence Solomon Revocable Living Trust, Lawrence Solomon Trustee</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(39</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Luis Rafael Nunes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.062</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,062</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(40</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Malcolm C.S. Leslie &amp; Hilary Jane Leslie (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(41</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Matura Family Trust UA 05-26-1998</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46,799</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,959</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(42</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,840</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Michael C. Fox Revocable Trust DTD 05/05/05</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,834</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,834</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(43</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Michael J. Maher</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(44</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nicholas Osorio &amp; Paulina Veytia (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,709</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,709</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(45</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">P. Casey Fallon</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,291</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,291</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(46</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Palisade Productions LLC</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paul Knowlson</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(48</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paul T. Fallon</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(49</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pedro B. Torres</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,166</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,166</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pieter M. Duplessis</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(51</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard Burgess</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,911</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(52</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,702</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard P. Maves</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,791</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,791</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(53</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Simon C. Guscott</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,769</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%">&#160;</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,416</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(54</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51,353</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Solvay Bank as Custodian for Paul T, Fallon IRA</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%">&#160;</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(55</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sten Anders Fellman</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%">&#160;</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(56</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sterne Agee &amp; Leach Inc. C/F Karen Hale SEP IRA</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(57</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sterne Agee &amp; Leach Inc. C/F W. Garner McNett IRA</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(58</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sterne Agee &amp; Leach Inc. C/F Ralph Wallis Kettell II SEP IRA</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(59</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Steven W. Poe and Judith L. Poe (JTWROS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,202</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,084</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(60</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,118</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tim D. Lea</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12.500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(61</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tim Wells</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(62</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Timothy Fallon</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,209</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(63</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">William Bellinger</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(64</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TOTAL</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,382,649</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* Indicated less than 1%.&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify">
<table cellpadding="0" cellspacing="0" width="100%" style="TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: justify;">
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 25,000 shares of common stock and (ii) 6,250 shares of common stock issuable upon the exercise of the common stock warrants (Adam Biedrzycki).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 249,993 shares of common stock and (ii) 62,498 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;Alan Greenhalgh and Angela Greenhalgh may be deemed to be the beneficial owner of the shares of our common stock held by&#160;the Alan Greenhalgh &amp; Angela Greenhalgh (JTWROS) (Alan Greenhalgh &amp; Angela Greenhalgh (JTWROS).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 4,167 shares of common stock and (ii) 1,042 shares of common stock issuable upon the exercise of the common stock warrants.&#160;&#160; Alberto Sadde and Leonella Olivieri de Sadde may be deemed to be the beneficial owner of the shares of our common stock held by&#160;the Alberto Sadde &amp; Leonella Olivieri de Sadde (JTWROS). &#160;(Alberto Sadde &amp; Leonella Olivieri de Sadde (JTWROS)).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 333,327 shares of common stock and (ii) 83,332 shares of common stock issuable upon exercise of the common stock warrants. &#160;(Andreas Wawrla).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 26,667 shares of common stock and (ii) 6,667 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(Andrew Bellamy).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 4,167 shares of common stock and (ii) 1,042 shares of common stock issuable upon exercise of the common stock warrants (Andrew Ferrett).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 2,000 shares of common stock and (ii) 501 shares of common stock issuable upon the exercise of the common stock warrants (Andrew Kelly).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 20,000 shares of common stock and (ii) 5,000 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(Anthony Athanas, Jr.).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 9,000 shares of common stock, (and ii) 2,250 shares of common stock issuable upon exercise of the common stock warrants.&#160; Anthony D&#8217;Amato and Marianne D&#8217;Amato may be deemed to be the beneficial owner of the shares of our common stock held by&#160;the Anthony D&#8217;Amato &amp; Marianne D&#8217;Amato (JTWROS).&#160;&#160;(Anthony D&#8217;Amato &amp; Marianne D&#8217;Amato (JTWROS).</font></div>
</div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 983 shares of common stock and (ii) 245 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(Benoit Dumont).</font></div>
</div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 5,500 shares of common stock and (ii) 1,375 shares of common stock issuable upon the exercise of the common stock warrants.&#160;&#160;(Cesar Fernandez Cardenas).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 2,500 shares of common stock and (ii) 625 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(Charles Moore).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 4,000 shares of common stock and (ii) 1,000 shares of common stock issuable upon exercise of the common stock warrants (Christopher Charles Hugh Phillips).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 8,000 shares of common stock and (ii) 2,000 shares of common stock issuable upon the exercise of the common stock warrants (Christopher G. Davison).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 5,000 shares of common stock and (ii) 1,000 shares of common stock issuable upon exercise of the common stock warrants (Daniel Huber).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 3,333 shares of common stock and (ii) 833 shares of common stock issuable upon the exercise of the common stock warrants.&#160; (Danny Sergeant).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 5,000 shares of common stock and (ii) 1,250 shares of common stock issuable upon exercise of the common stock warrants. (David Scott).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 38,000 shares of common stock and (ii) 9,500 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(Dean Beaver).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon exercise of the common stock warrants (Dr. Thomas J. Rutherford).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 833 shares of common stock and (ii) 208 shares of common stock issuable upon exercise of the common stock warrants.&#160; (Eamon Judge).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon exercise of the common stock warrants (Eduardo Guemez Sarre).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 14,083 shares of common stock, and (ii) 3,520 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(Enguerrand de Ponteves).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 25,000 shares of common stock and (ii) 6,250 shares of common stock issuable upon exercise of the common stock warrants. (Fran Rooney).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 1,567 shares of common stock and (ii) 392 shares of common stock issuable upon exercise of common stock warrants. Frank R. Deis and Donna R. Deis may be deemed to be the beneficial owner of the shares of our common stock held by&#160;the Frank R. Deis &amp; Donna R. Deis (JTWROS).&#160;&#160;(Frank R. Deis &amp; Donna R. Deis (JTWROS)).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon exercise of the common stock warrants (Garfield W. Hardeman TOD).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 12,000 shares of common stock and (ii) 3,000 shares of common stock issuable upon exercise of the common stock warrants (Gary Mossman).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(Georges Zanellato).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 40,000 shares of common stock and (ii) 10,000 shares of common stock issuable upon exercise of the common stock warrants (Gerhard Plaschka).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 7,333 shares of common stock and (ii) 1,833 shares of common stock issuable upon exercise of the common stock warrants (Gregory Alexander).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 2,833 shares of common stock and (ii) 708 shares of common stock issuable upon exercise of the common stock warrants (Graham M. Bones).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon the exercise of the common stock warrants (Gurpreet Ahluwalia).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 833 shares of common stock and (ii) 208 shares of common stock issuable upon exercise of the common stock warrants (Gustavo Almeida De Almedia).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 2,083 shares of common stock and (ii) 520 shares of common stock issuable upon exercise of the common stock warrants (James N. White).</font></div>
</td>
</tr><tr>
<td valign="top" width="4%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34</font></div>
</td>
<td valign="top" width="96%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 16,667 shares of common stock and (ii) 4,167 shares of common stock issuable upon the exercise of the common stock warrants.&#160;&#160;James W. Anthony and Delisa Anthony may be deemed to be the beneficial owner of the shares of our common stock held by the James W. Anthony &amp; Delisa Anthony (JTWROS).&#160; (James W. Anthony &amp; Delisa Anthony (JTWROS)).</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<div>
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 833 shares of common stock and (ii) 208 shares of common stock issuable upon exercise of the common stock warrants. Jared Sullivan &amp; Shannan Sullivan may be deemed to be the beneficial owner of the shares of our common stock held by the Jared Sullivan &amp; Shannan Sullivan</font> (JTWROS)<font style="DISPLAY: inline">.&#160;&#160;(Jared Sullivan &amp; Shannan Sullivan (JTWROS)).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 1,833 shares of common stock and (ii) 458 shares of common stock issuable upon exercise of the common stock warrants. (Jan Backvall).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 6,167 shares of common stock and (ii) 1,542 shares of common stock issuable upon the exercise of the common stock warrants (Jeffrey C. Boggs).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 1,667 shares of common stock and (ii) 417 shares of common stock issuable upon the exercise of the common stock warrants. (Jodi Bennett Cabler).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">39</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 5,000 shares of common stock and (ii) 1,250 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;</font>Lawrence Solomon<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by the</font> Lawrence Solomon Revocable Living Trust, Lawrence Solomon Trustee<font style="DISPLAY: inline">.&#160;&#160;(</font>Lawrence Solomon Revocable Living Trust, Lawrence Solomon Trustee<font style="DISPLAY: inline">).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 7,250 shares of common stock and (ii) 1,812 shares of common stock issuable upon the exercise of the common stock warrants (Luis Rafael Nunes).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 25,000 shares of common stock and (ii) 6,250 shares of common stock issuable upon exercise of the common stock warrants. </font>Malcolm C.S. Leslie and Hilary Jane Leslie<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by the</font> Malcolm C.S. Leslie &amp; Hilary Jane Leslie (JTWROS).<font style="DISPLAY: inline"> (</font>Malcolm C.S. Leslie &amp; Hilary Jane Leslie (JTWROS)<font style="DISPLAY: inline">).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 7,167 shares of common stock and (ii) 1,792 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;</font>Margaret I. Matura and Gary D. Matura<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by the Matura Family Trust UA 05-26-1998</font>.<font style="DISPLAY: inline">&#160;&#160;(Matura Family Trust UA 05-26-1998).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 16,667 shares of common stock and (ii) 4,167 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(</font>Michael C. Fox Revocable Trust DTD 05/05/05<font style="DISPLAY: inline">).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 1,200 shares of common stock and (ii) 300 shares of common stock issuable upon exercise of the common stock warrants (Michael J. Maher).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 2,167 shares of common stock and (ii) 542 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;</font>Nicholas Osorio &amp; Paulina Veytia<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by the </font>Nicholas Osorio &amp; Paulina Veytia (JTWROS). <font style="DISPLAY: inline">(</font>Nicholas Osorio &amp; Paulina Veytia (JTWROS)<font style="DISPLAY: inline">).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 5,833 shares of common stock and (ii) 1,458 shares of common stock issuable upon exercise of the common stock warrants (P. Casey Fallon).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 5,000 shares of common stock and (ii) 1,250 shares of common stock issuable upon the exercise of the common stock warrants.&#160;&#160;</font>Ralph Kettell<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by Palisade Productions LLC</font>.<font style="DISPLAY: inline">&#160;&#160;(Palisade Productions LLC).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 4,000 shares of common stock and (ii) 1,000 shares of common stock issuable upon the exercise of the common stock warrants (Paul Knowlson).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 4,167 shares of common stock and (ii) 1.042 shares of common stock issuable upon exercise of the common stock warrants.&#160; (Paul T. Fallon).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 3,333 shares of common stock and (ii) 833 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;(Pedro B. Torres).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 2,000 shares of common stock and (ii) 500 shares of common stock issuable upon exercise of the common stock warrants. (Pieter M. Duplessis).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 8,167 shares of common stock and (ii) 2,042 shares of common stock issuable upon the exercise of the common stock warrants (Richard Burgess).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 6,233 shares of common stock and (ii) 1,558 shares of common stock issuable upon the exercise of the common stock warrants (Richard P. Maves).</font></div>
</div>
</td>
</tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 8,333 shares of common stock and (ii) 2,083 shares of common stock issuable upon the exercise of the common stock warrants (Simon C. Guscott).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;</font>Paul T. Pallon<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by</font> Solvay Bank as Custodian for Paul T, Fallon IRA.<font style="DISPLAY: inline">&#160;&#160;(</font>Solvay Bank as Custodian for Paul T, Fallon IRA<font style="DISPLAY: inline">).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon exercise of the common stock (Sten Anders Fellman).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 3,400 shares of common stock and (ii) 850 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;</font>Karen Hale<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by</font> Sterne Agee &amp; Leach Inc. C/F Karen Hale SEP IRA.<font style="DISPLAY: inline">&#160;&#160;(</font>Sterne Agee &amp; Leach Inc. C/F Karen Hale SEP IRA<font style="DISPLAY: inline">).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon the exercise of the common stock warrants.&#160;&#160;</font>Garner McNett<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by</font> Sterne Agee &amp; Leach Inc. C/F W. Garner McNett IRA.<font style="DISPLAY: inline"> (</font>Sterne Agee &amp; Leach Inc. C/F W. Garner McNett IRA<font style="DISPLAY: inline">).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Includes (i) 5,000 shares of common stock and (ii) 1,250 shares of common stock issuable upon the exercise of the common stock warrants.&#160;&#160;</font>Ralph Wallis Kettell<font style="DISPLAY: inline"> may be deemed to be the beneficial owner of the shares of the common stock held by</font> Sterne Agee &amp; Leach Inc. C/F Ralph Wallis Kettell II SEP IRA.<font style="DISPLAY: inline">&#160;&#160;(</font>Sterne Agee &amp; Leach Inc. C/F Ralph Wallis Kettell II SEP IRA<font style="DISPLAY: inline">).</font></font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 1,667 shares of common stock and (ii) 417 shares of common stock issuable upon the exercise of the common stock warrants.&#160;&#160;Steven W. Poe and Judith L. Poe may be deemed to be the beneficial owner of the shares of our common stock held by Steven W. Poe and Judith L. Poe (JTWROS).&#160; (Steven W. Poe and Judith L. Poe (JTWROS)).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 10,000 shares of common stock and (ii) 2,500 shares of common stock issuable upon the exercise of the common stock warrants.&#160;&#160;(Tim D. Lea).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 5,000 shares of common stock and (ii) 1,250 shares of common stock issuable upon exercise of the common stock warrants.&#160;&#160;&#160;(Tim Wells).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">63</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 4,167 shares of common stock and (ii) 1,042 shares of common stock issuable upon exercise of the common stock warrants (Timothy Fallon).</font></div>
</td>
</tr><tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">64</font></div>
</td>
<td valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes (i) 5,000 shares of common stock and (ii) 1,250 shares of common stock issuable upon exercise of the common stock warrants&#160;(William Bellinger).</font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Except as disclosed in the table above, to our knowledge, none of the selling stockholders or beneficial owners:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">has had a material relationship with us other than as a stockholder at any time within the past three years;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">has ever been one of our officers or directors or an officer or director of our affiliates; or</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td align="left" valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">are broker-dealers or affiliated with broker-dealers.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">With respect to those selling stockholders noted above who are or were affiliated with registered broker-dealers, each has represented to us that the shares being registered for resale were purchased in the ordinary course of business and, at the time of purchase, such selling stockholder had no agreements or understandings, directly or indirectly, with any person to distribute the shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><!--EFPlaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a009v1">DESCRIPTION OF BUSINESS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Business Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are a biopharmaceutical company focused on the $54 billion market for cancer drugs. Our most advanced products are Actimab&#8482;-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab&#8482;-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. The Company is currently designing a trial which the Company intends to submit for registration approval in HSCT in the settings of refractory and relapsed acute myeloid leukemia in older patients. The Company is developing its cancer drugs using its expertise in radioimmunotherapy. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC), whose indirect subsidiary, Actinium Holdings Ltd., is a significant stockholder of the Company. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213. The final drug construct is designed to specifically target and kill cancer cells while minimizing side effects. The Company intends to develop a number of products for different types of cancer and derive revenue from partnering relationships with large pharmaceutical companies and/or direct sales of its products in specialty markets in the U.S.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Corporate History and Background</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We were formed as a Nevada corporation on October 6, 1997, originally under the name Zurich U.S.A., Inc. On July 10, 2006, we changed our name to Cactus Ventures, Inc. and began pursuing our business of marketing sunglasses. The Company encountered numerous problems with various vendors and ceased its operations. The Company shifted its efforts to seeking a business combination opportunity with a business entity, and negotiated a merger of a target company into the Company.&#160;&#160;Upon ceasing its operations, the Company was considered a &#8220;blank check&#8221; or &#8220;Shell&#8221; company as such term is defined under the Securities Act. &#160;Upon completing the Share Exchange (as defined below), the Company ceased being considered a &#8220;blank check&#8221; or &#8220;Shell&#8221; company and is now a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On April 11, 2013, the change of domicile from the State of Nevada to the State of Delaware and the change of Cactus Ventures, Inc.&#8217;s name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. became effective in accordance with Articles of Merger filed with the State of Nevada and a Certificate of Merger filed with the State of Delaware.&#160;&#160;In connection with the name change we also changed (i) the name of our subsidiary Actinium Pharmaceuticals, Inc. to Actinium Corporation, (ii) our par value to $0.001 per share, and (iii) the number of authorized shares of preferred stock to 10 million shares.&#160;Effective April 18, 2013 our new trading symbol became ATNM. On September 25, 2013, we merged into our self our subsidiary, Actinium Corporation.&#160;&#160;In January 2014 we increased our authorized shares of common stock to 200 million shares and authorized shares of preferred stock to 50 million shares.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Acquisition of Actinium</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;) completed a share exchange with Cactus, whereby Cactus acquired 21% of the issued and outstanding capital stock of Actinium Corporation from the shareholders of Actinium Corporation (the &#8220;Actinium Shareholders&#8221;) in exchange for the issuance of 4,309,015 shares of Common Stock of the Company to the Actinium Shareholders (the &#8220;Share Exchange&#8221;).&#160;As part of the Share Exchange, Actinium Corporation paid $250,000 to the shareholders of Cactus before the consummation of the Share Exchange.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Share Exchange was treated as a recapitalization effected through a share exchange, with Actinium Corporation as the accounting acquirer and the Company the accounting acquiree.&#160;&#160;Unless the context suggests otherwise, when we refer in this Registration Statement to business and financial information for periods prior to the consummation of the Share Exchange, we are referring to the business and financial information of Actinium Corporation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effective following the expiration of the ten day period following the mailing of the information statement required by Rule 14f-1 under the Exchange Act, Diane S. Button resigned from her position as member of the Board of Directors of the Company. Effective upon the closing of the Share Exchange, Diane S. Button resigned as an officer of the Company. Also effective upon the closing of the Share Exchange, Jack V. Talley was appointed to our Board of Directors. Effective as of the expiration of the ten day period following the mailing of the information statement required by Rule 14f-1 under the Exchange Act Dr. Rosemary Mazanet, David Nicholson, Sandesh Seth and Sergio Traversa were appointed to our Board of Directors. In addition, our Board of Directors appointed Jack V. Talley to serve as our President and Chief Executive Officer, Dragan Cicic to serve as our Chief Operating Officer and Chief Medical Officer, and Enza Guagenti to serve as our Chief Financial Officer, effective immediately upon the closing of the Share Exchange. On February 28, 2013, Mr. Talley resigned as the President and Chief Executive Officer, and Director of the Company and Actinium. On March 1, 2013, the Board of Directors of the Company unanimously approved the appointment of Dr. Sergio Traversa as the Company&#8217;s interim President and Chief Executive Officer. Dr. Traversa is also currently a member of the Board of the Company. On September 16, 2013 Dr. Kaushik J. Dave was appointed by the Board of Directors as President, Chief Executive Officer and Director of the Company and at that time Dr. Traversa reverted back his role to as being a Director and interim Chief Financial Officer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 9, 2013, Ms. Guagenti resigned as the Chief Financial Officer of the Company and Actinium.&#160;&#160;On March 11, 2013, the Board of Directors of the Company unanimously approved the appointment of Sergio Traversa as the Company&#8217;s interim Chief Financial Officer. The Board is actively looking for a candidate to fill the Chief Financial Officer position of the Company. On March 13, 2013, the Board approved the appointment of Brio Financial Group as the Company&#8217;s interim Controller, responsible for the Company&#8217;s treasury and accounting functions.&#160;&#160;On September 16, 2013 Corey Sohmer was hired as the Company&#8217;s Vice President of Finance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As a result of the Share Exchange, the Company assumed the business and operations of Actinium Corporation.&#160;On April 11, 2013, the change of domicile from the State of Nevada to the State of Delaware and the change of Cactus Ventures, Inc.&#8217;s name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. became effective in accordance with Articles of Merger filed with the State of Nevada and a Certificate of Merger filed with the State of Delaware.&#160;&#160;&#160;Effective April 18, 2013 the Company&#8217;s new trading symbol is ATNM.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As the Company is a &#8220;reporting company&#8221; under the Exchange Act of 1934, it is required to file periodic filings with the SEC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 11, 2013, Actinium Corporation&#160;continued its Share Exchange with the Company, whereby the Company acquired an additional 36% of the issued and outstanding capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance of 7,344,390 shares of Common Stock of the Company to the Actinium Shareholders.&#160;&#160;On August 22, 2013, Actinium Corporation&#160;continued its Share Exchange with the Company, whereby the Company acquired an additional 38.2% of the issued and outstanding capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance of 8,009,550 shares of Common Stock of the Company to the Actinium Shareholders.&#160;&#160;On September 25, 2013 in accordance with a Certificate of Ownership Merging Actinium Corporation into the Company, the Company merged into itself Actinium Corporation, and Actinium Corporation ceased to exist. As a result of the merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Corporate History of Actinium</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Corporation was incorporated in 2000 in the state of Delaware. Until the Share Exchange, Actinium Corporation was a clinical-stage, privately held biopharmaceutical company with:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Two clinical-stage products, Iomab&#8482;-B and Actimab&#8482;-A, in development for blood borne cancers;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preclinical data in additional cancer indications;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A proprietary technology platform for novel radioimmunotherapy cancer treatments; and</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A proprietary process for manufacturing of the alpha particle emitting radioactive isotope actinium 225 (Ac-225).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Iomab&#8482;-B has completed a Phase 1/2 design trial as a preparatory regimen in conjunction with fludarabine and reduced intensity radiation conditioning in patients who are ineligible for&#160;standard myeloablative conditioning for hematopoietic stem cell transplantation (HSCT) and the Company expects it to enter a regulatory approval trial in 2014, subject to input from the FDA concerning the design and conduct of a pivotal trial. This trial was conducted in 68 human subjects at the Fred Hutchinson Cancer Research Center (FHCC) in Seattle, WA, USA.&#160; Currently, the IND for this drug is held by the licensor, FHCC.&#160; The Company intends to file its own separate IND for the purpose of conducting a Phase 3 trial in 2014. Actimab&#8482;-A is currently in a Phase 1/2 trial in newly diagnosed elderly acute myeloid leukemia (AML). In addition, using its patented Alpha Particle Immunotherapy Technology (APIT) platform and via its collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC), the Company has preclinical data on potential drug candidates in several other cancer indications and expects to further develop these into clinical stage drug candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Corporation has one wholly owned subsidiary, MedActinium, Inc., a Delaware corporation, which is party to certain isotope related licenses and contracts on which the Company relies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Upon Actinium Corporation&#8217;s formation in 2000, it acquired Pharmactinium, Inc. and MedActinium, Inc., and through Pharmactinium, Inc. acquired certain rights to the APIT platform. Core technology patents were in-licensed from N.V. Organon which also provided seed funding. Pharmactinium, Inc. was party to a research and development agreement with MSKCC beginning in 1996. In 2002, this agreement and relationship was significantly expanded and now includes research and development, preclinical development, clinical trials and commercial technology licenses. In 2007, Pharmactinium, Inc. was merged with and into the Company. In 2007, the Company also acquired its sister company, Actinium Pharmaceuticals, Limited (Bermuda) (the &#8220;Bermuda Company&#8221;), by a merger of the Bermuda Company into the Company and thereby also acquired certain patent licenses relating to APIT previously licensed by the Bermuda Company to the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In 2000, the Company also began what has become a long term relationship with General Atlantic Investments Limited (GAIL), an entity which provided most of the Company&#8217;s investment capital since 2000, totaling $50.7 million. In 2010, the parent of GAIL contributed and transferred its ownership of GAIL (now renamed Actinium Holdings, Limited), whose only asset at that time was the shares of API, to an indirect subsidiary of MSKCC. In January 2012, the Company closed on $6,685,418 in net funding through the sale of&#160;the Company&#8217;s&#160;stock and a Senior Convertible Note financing. On December 19, 2012, Actinium completed a private offering of units, consisting of common stock, Series A warrants and Series B warrants.&#160;&#160;The price per unit was $1.65 for aggregate net proceeds of $4.5 million.&#160;&#160;The Series A Warrants had a 120 day term from January 28, 2013 and were exercisable for an aggregate of up to 3,118,968 shares of the Company&#8217;s common stock at an initial per share exercise price of $1.65, subject to adjustment.&#160;&#160;The Series A Warrants expired on May 28, 2013.&#160;&#160;The Series B Warrants have a five year term from January 28, 2013 and are exercisable for an aggregate of up to 1,59,484 shares of the Company&#8217;s common stock at an initial per share exercise price of $2.48, subject to adjustment.&#160;&#160;In the second quarter of 2013, we issued shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013.&#160;&#160;The warrants were exercised at $1.65 per share, resulting in gross proceeds of $3.5 million for the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 25, 2013 in accordance with a Certificate of Ownership Merging Actinium Corporation into the Company, the Company merged into itself Actinium Corporation, and Actinium Corporation ceased to exist. As a result of the merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our executive office is located at 501 Fifth Avenue, 3rd Floor, New York, NY 10017 and our telephone number is (212) 300-2131. Our website address is http://www.actiniumpharmaceuticals.com. Except as set forth below, the information on our website is not part of this Registration Statement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary of Scientific and Business Achievements:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company&#8217;s scientific and business achievements to date include:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In-licensing a Phase 2 clinical stage monoclonal antibody, BC8, with safety and efficacy data in more than 250 patients in need of Hematopoietic Stem Cell Transplantation (HSCT), currently in 7 active Phase 1 and Phase 2 clinical trials;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Commencing a Company sponsored multi-center Phase 1/2 clinical trial for Actimab&#8482;-A in elderly AML;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Developing and organizing manufacturing of Actinium&#8217;s lead drug candidate Actimab&#8482;-A&#160;&#160;which was accepted by the FDA for multi-center human use;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Supporting three physician sponsored clinical trials, including a Phase 1 and a Phase 1/2 trial with the alpha emitting radioactive isotope bismuth 213 (Bi-213) based AML drug and a Phase I clinical trial with the alpha emitting radioactive isotope actinium 225 (Ac-225) based AML drug;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In-licensing the AML targeting monoclonal antibody known as HuM195 or Lintuzumab;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Establishing clinical and preclinical development relationships with world-class institutions such as MSKCC, FHCRC and University of Texas MD Anderson Cancer Center (the MD Anderson Cancer Center relationship includes clinical trials only), as well as leading clinical experts in the fields of AML and HSCT;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Securing rights to an intellectual property estate that covers key aspects of the Company&#8217;s proprietary technology platform;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Supporting a number of pipeline projects, including preclinical experiments in metastatic prostate cancer, metastatic colon cancer, antiangiogenesis and breast cancer models;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maintaining contractual relationship with ORNL of the Department of Energy (DOE) which gives API access to most of the current world supply of Ac-225; and</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Successfully developing commercial production methods for actinium 225.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Business Strategy</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We intend to potentially develop its most advanced clinical stage drug candidates through approval in the case of Iomab&#8482;-B and up to and including a Phase 2 proof of concept human clinical trial (a trial designed to provide data on the drug&#8217;s efficacy) in the case of Actimab&#8482;-A. If these efforts are successful, we may elect to commercialize Iomab&#8482;-B on its own or with a partner in the United States and/or outside of the United States to out-license the rights to develop and commercialize the product to a strategic partner. In the case of Actimab&#8482;-A, we will most likely seek to enter into strategic partnerships whereby the strategic partner(s) co-fund(s) further human clinical trials of the drug that are needed to obtain regulatory approvals for commercial sale within and outside of the United States. In parallel, the Company intends to identify and begin initial human trials with additional actinium-225 drug candidates in other cancer indications. We intend to retain marketing rights for its products in the United States whenever possible and outlicense marketing rights to its partners for the rest of the world.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Opportunity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are competing in the marketplace for cancer treatments estimated at over $54 billion in 2011 sales per IMS Health and projected to exceed $76 billion per year by 2015, according to the Global Academy for Medical Education. While surgery, radiation and chemotherapy remain staple treatments for cancer, their use is limited by the fact that they often cause substantial damage to normal cells. On the other hand, targeted monoclonal antibody therapies exert most or all of their effect directly on cancer cells, but often lack sufficient killing power to eradicate all cancer cells with just the antibody. A new approach for treating cancer is to combine the precision of antibody-based targeting agents with the killing power of radiation or chemotherapy by attaching powerful killing agents to precise molecular carriers called monoclonal antibodies (mAb). The Company uses monoclonal antibodies labeled with radioisotopes to deliver potent doses of radiation directly to cancer cells while sparing healthy tissues. The radioisotopes we use are the alpha emitter Ac-225 and the beta emitter I-131. I-131 is among the best known and well characterized radioisotopes. It is used very successfully in treatment of papillary and follicular thyroid cancer as well as other thyroid conditions. It is also attached to a monoclonal antibody in treatment of Non-Hodgkin&#8217;s Lymphoma (NHL). It is also used experimentally with different carriers in other cancers. Ac-225 has many unique properties and the Company is a leader in developing this alpha emitter for clinical applications using its proprietary APIT technology.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our most advanced products are Actimab&#8482;-A, Ac-225 labeled mAb for treatment of newly diagnosed AML, a cancer of the blood, in patients ineligible for currently approved therapies, and Iomab&#8482;-B, I-131 labeled mAb for preparation of relapsed and refractory AML patients for HSCT. Iomab&#8482;-B offers a potentially curative treatment for these patients most of whom do not survive beyond a year after being diagnosed with this condition. Iomab&#8482;-B has also demonstrated efficacy in HSCT preparation for other blood cancer indications, including Myelodysplastic Syndrome (MDS), acute lymphoblastic leukemia (ALL), Hodgkin&#8217;s Lymphoma, and Non-Hodgkin&#8217;s Lymphoma (NHL). These are all follow-on indications for which Iomab&#8482;-B can be developed and it is the Companies intention to explore these opportunities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There are currently no FDA approved treatments for either Actimab&#8482;-A or Iomab&#8482;-B targeted patients.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other potential product opportunities in which a significant amount of preclinical work is being undertaken include metastatic colorectal cancer, metastatic prostate cancer and antiangiogenesis which reduces the blood supply to solid tumors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We believe that our biggest market opportunity lies in the applicability of our APIT platform technology to a wide variety of cancers. A broad range of solid and blood borne cancers can be potentially targeted by monoclonal (mAbs) to enable treatment with its APIT technology. The APIT technology could potentially be applied to mAbs that are already FDA approved to create more efficacious and/or safer drugs (&#8220;biobetters&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Clinical Trials</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company has completed a Phase 1 and Phase 1/2 physician trial in AML at MSKCC using Bismab&#174;-A, The Company&#8217;s first generation AML drug that consists of bismuth-213 attached to the antibody Lintuzumab&#8482;. The Phase II arm of the Bismab&#174;-A drug study has shown signs of the drug&#8217;s efficacy and safety, including reduction in peripheral blast counts and complete responses in some patients. Bi-213 is a daughter, i.e., product of the degradation of Ac-225, with cancer cell killing properties similar to Ac-225 but is less potent.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company has commenced its first company sponsored Phase 1/2 multi-center trial with fractionated (two) doses of Actimab&#8482;-A, Actinium&#8217;s lead product for treatment of elderly AML that consists of an AML specific monoclonal antibody (HuM195, also known as Lintuzumab&#8482;) and the actinium 225 radioactive isotope attached to it. The Company intends to conduct these trials at world-class cancer institutions such as MSKCC, Johns Hopkins Medicine, University of Pennsylvania Health System, Fred Hutchinson Cancer Center and MD Anderson Cancer Center.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company also continues to sponsor a Phase 1 AML trial at MSKCC with a single-dose administration of Actimab&#8482;-A. Initial data shows elimination of leukemia cells from blood in 67% of all evaluable patients who received a full dose and in 83% of those treated at dose levels above 0.5 microcuries (&#181;Ci/kg), and eradication of leukemia cells in both blood and bone marrow in 20% of all evaluable patients and 25% of those treated at dose levels above 0.5 &#181;Ci/kg. Dose levels in that trial have been reduced as we continue our work on establishing a maximum tolerated dose.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This Phase I trial builds on the experience with Company&#8217;s first generation drug Bismab&#174;-A that contains the same antibody used in Actimab&#8482;-A but labeled with bismuth 213, a less potent alpha emitting daughter of actinium 225 used in Actimab&#8482;-A. Bismab&#174;-A trials and the Phase I Actimab&#8482;-A trial were focused on relapsed, refractory and other difficult to treat acute myeloid leukemia patients. The new multicenter Phase 1/2 trial is focused on newly diagnosed AML patients who have historically had better outcomes. In addition, the new trial includes low doses of chemotherapy with the goal of further improving patient outcomes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company&#8217;s current operations are primarily focused on furthering the development of its lead clinical drug candidates Actimab&#8482;-A and Iomab&#8482;-B. In the case of Actimab&#8482;-A, key ongoing activities include progressing a multi-center Phase 1/2 trial, support for an ongoing Phase 1 clinical trial at MSKCC in New York, managing isotope and other materials supply chain, and managing the manufacturing of the finished drug candidate product. The Company has secured access to much of the currently available world reserves of Ac-225 and Bi-213 through a renewable contractual arrangement with the United States Department of Energy (DOE). The Company projects that these quantities are sufficient to support early stages of commercialization of alpha isotopes based products. The Company has also developed its own proprietary process for industrial scale Ac-225 production in a cyclotron in quantities adequate to support full product commercialization.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operations related to Iomab&#8482;-B include planning for a registration trial which will include development of commercial scale manufacturing to be suitable for an approval trial and preparation of appropriate regulatory submissions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the fiscal years ended December 31, 2012 and December 31, 2011, we spent approximately&#160;$3.4 million $0.3 million, respectively, on research and development activities.&#160; The first nine months of 2013, the Company incurred $2.4 million on research and development. These expenditures consisted of materials maintenance and purchases, supply chain development and implementation, drug candidate manufacturing expenditures, clinical trials costs and intellectual property portfolio related expenses.&#160; Since we have no customers, none of the costs of such research and development activities were borne by our customers.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">In the second quarter of 2013 we issued shares of common stock pursuant to the exercise of Series A Warrants originally issued in connection with a private placement that closed in January 2013.&#160;&#160;The warrants were exercised at $1.65 per share, resulting in gross proceeds of $3.5 million for the Company.&#160;&#160;In December 2013 and January 2014,</font> the Company closed on total gross proceeds of approximately $6.6 million from the private placement of common stock and warrants to new and existing accredited investors.&#160;&#160;<font style="DISPLAY: inline">As of the end of the third quarter 2013 and the additional finances through this latest offering, we believe that we have sufficient cash to continue our operations for the balance of 2014 and into the first quarter of 2015.&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We estimate that we will need approximately up to $25 million cash for the period of 2014 to 2016, i.e. until we receive our first product approval.&#160;&#160;We intend to fund these expenses from a combination of equity and/or debt funding raises and payments obtained from licensing partners.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Failure to raise additional equity or debt funding in the amounts necessary to complete our programs and/or failure to out license our programs on the projected terms may result in a slowing down of our projected development plan or our inability to complete one or more of the planned programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our business plan has not been impacted by our accountants&#8217; going concern opinion.&#160; Due to our receipt of gross proceeds of $6.6 million in December 2013 and January 2013 from the latest offering, we believe that we have sufficient funds to fund our operations through the first quarter of 2015 and will seek to raise additional funds through equity and/or debt offerings to fund our operations in 2015 to 2016.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary of Material Agreements Related to Our Business</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Abbott Biotherapeutics Corp.</font> We entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, we made a license fee payment of $3.0 million.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We agreed to make milestone payments totaling $7.8 million for the achievement of the following agreed to and contracted milestones:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="83%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="83%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) when Company initiates a Phase 1 Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) when Company initiates a Phase 2 Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3) when Company initiates a Phase 3 Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4) Biological License Application filing with U.S. FDA</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5) First commercial sale</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6) after the first $10,000,000 in net sales</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under the agreement, we agreed to pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of up to 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of December 31, 2012, we met our first milestone and upon reaching the milestone we paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Memorial Sloan Kettering Cancer Center (MSKCC)</font>.&#160;&#160;In February 2002, we entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and an annual research funding of $50,000 for as long as the agreement is in force.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="83%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="83%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval for each licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under the agreement, we agreed to pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.&#160;&#160;We expect to file the NDA for regulatory approval in 2016.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Oak Ridge National Laboratory (ORNL)</font> &#8211; We have contracted to purchase radioactive material to be used for research and development through December 2012. We contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d.&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Aptiv Solutions.</font>&#160;&#160;Aptiv Solutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab&#8482;-A) used in our clinical trials, Phase 1 and Phase 2. The total project is estimated to cost $1,859,333 and requires a 12.5% down payment of the total estimated project cost. &#160;The down payment totaling $239,000 was paid in 2007 and 2012. &#160;The agreement was amended to provide for additional services on August 6, 2012, October 22, 2012 and May 16, 2013. &#160;The total project is now estimated at $2,173,955.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">e.&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Fred Hutchinson Cancer Research Center (FHCRC)</font>.&#160;&#160;On June 15, 2012, we entered into a license and sponsored research agreement with FHCRC. We will build upon previous and ongoing clinical trials, with BC8 (licensed antibody) and eventually develop a clinical trial with Actinium 225. &#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and we intend to start preparation for a pivotal trial leading to an FDA approval. &#160;We have been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. &#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA. &#160;Under the terms of the sponsored research agreement, we will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter. &#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year. &#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug. &#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">MSKCC</font>.&#160;&#160;On March 27, 2012, we entered into a clinical trial agreement with Memorial Sloan Kettering Cancer Center. &#160;The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623. &#160;The amount due of $79,623 was paid on July 10, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">g.&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">FHCRC</font>.&#160;&#160;On July 19, 2012, we entered into a clinical trial agreement with FHCRC. &#160;We will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, we are required to pay a start-up fee of $19,749. &#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">h.&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The University of Texas M.D. Anderson Cancer Center</font>.&#160;&#160;On August 28, 2012, we entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center. &#160;The total estimated cost of conducting the clinical trial is $481,204, which includes a non- refundable institutional fee of $14,500. &#160;The estimated cost is based on treating 24 patients through 2013. &#160;Upon execution of the agreement, we were required to make a payment of $33,946. &#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">i.&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Johns Hopkins University</font>.&#160;&#160;On September 26, 2012, we entered into a clinical trial agreement with Johns Hopkins University. &#160;The Phase 1/2 clinical trial will be conducted with Actinium 225. &#160;The clinical trial will be conducted under the protocols established by us and pursuant to an Investigational New Drug Exemption (IND 10807) held by us. &#160;We will pay $38,501 per patient, who has completed the clinical trial. We are required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. &#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">j.&#160;&#160;</font></div>
</td>
<td valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">University of Pennsylvania</font>.&#160;&#160;&#160;On November 21, 2012, we entered into a clinical trial agreement with the University of Pennsylvania. &#160;The Phase 1/2 clinical trial will be conducted with Actinium 225. &#160;The clinical trial will be conducted under the protocols established by us and pursuant to an Investigational New Drug Exemption (IND 10807) held by us. &#160;We will pay $31,771 per patient, who has completed the clinical trial. We will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intellectual Property Portfolio</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company has a patent portfolio with 8 issued patents and 60 pending patents in various jurisdictions as follows:&#160;&#160;United States: 17 and international: 51.&#160;&#160;Most of the patents are in-licensed from third parties and some are held by the Company.&#160;&#160;These patents cover key areas of the Company&#8217;s activity, including use of the actinium 225 and other alpha emitting isotopes attached (labeled) to cancer specific carriers like monoclonal antibodies, methods for manufacturing key components of the Company&#8217;s drug candidates including actinium 225 alpha emitting radioisotope and carrier antibodies, methods for manufacturing finished drug candidates for use in cancer treatment, and methods for mitigating potential toxicities of the Company&#8217;s drug candidates.&#160;&#160;These patents are classified in families of related patents per the table below: &#160;&#160;</font></div>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ffffff">
<td align="left" valign="top" width="19%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Area</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="19%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Claims</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expiration</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Status</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Licensor</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Platform technology</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Metastases larger than 1 mm</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2020</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Allowed</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MSKCC</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Platform technology</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Use of the DOTA chelator for drug manufacturing</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2021</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issued</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MSKCC</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug preparation methods</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium 225 labeling method</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2029</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pending</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Owned</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug preparation methods</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bismuth 213 labeling method</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2017/2020</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issued</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MSKCC</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Isotope production methods</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium 225 manufacturing in a cyclotron</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2023/2025</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pending/Allowed</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Owned</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Monoclonal antibody composition and production</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacturing of leukemia targeting antibody</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2015</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issued</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Abbott Laboratories</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Methods of treatment</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Protection from actinium 225 toxicity</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2023</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pending</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MSKCC</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Key Strengths</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company believes that the key elements for its market success include:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Clinical results to date imply lower development risk for its lead drug candidates:</font> The Company&#8217;s lead drug candidates have been tested in over 300 patients and demonstrated favorable safety and efficacy profiles. Iomab&#8482;-B has been administered to more than 250 patients in a number of Phase I and Phase II trials and has shown a clear survival benefit in the indication for which it is being developed.&#160;&#160;Bismab&#174;-A and Actimab&#8482;-A, drugs based on the APIT platform have so far been tested in over 60 patients in 3 clinical trials. In each trial they exhibited few side effects and have shown indications of efficacy. The current proof-of-concept Actimab&#8482;-A Phase 1/2 clinical trial is directed at a patient population that is generally easier to treat (newly diagnosed vs. relapsed/refractory in previous trials), and employs a more potent treatment regimen (low dose chemotherapy plus two doses of Actimab&#8482;-A plus low dose chemotherapy vs. a single dose of Actimab&#8482;-A in the physician sponsored trial).</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Additional product opportunities from the APIT platform:</font> The Company&#8217;s Alpha Particle Immunotherapy technology has the potential for broad applicability for the treatment of many cancer types, which allows the Company to add new product candidates to its pipeline based on well-defined patent protected methods.</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Collaboration with MSKCC:</font> The Company&#8217;s collaboration with MSKCC includes licensing, research and clinical trial arrangements involving MSKCC labs and clinicians and included&#160;financial support with respect to certain pre-2012 R&amp;D-related expenses.</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Scientific backing of leading experts:</font> The Company&#8217;s clinical advisory board and collaborators include some of the best recognized clinicians and scientists working at some of the highest regarded medical institutions in the U.S. and the world, including MSKCC, Johns Hopkins University, University of Pennsylvania, FHCC and MD Anderson Cancer Center. This is expected to be beneficial to the Company both in clinical development and market acceptance assuming its drug candidates are approved.</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Isotope supply secured for clinical trials:</font>&#160;The Company has a contractual relationship with ORNL of the Department of Energy (DOE)) that provides the Company access to the largest known supply reserves of actinium 225. Iodine 131 is readily available from a number of qualified pharmaceutical supply vendors.</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Proprietary alpha emitting isotope manufacturing technology fully developed:</font> The Company has developed its own proprietary technology for commercial scale manufacturing of actinium 225. This is expected to ensure commercial supply of Ac-225 for Actimab&#8482;-A, Actimab&#8482;-B and other actinium-linked products should they be approved.</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">cGMP Actimab&#8482;-A manufacturing developed:</font> The Company has developed at a contractor&#8217;s site full cGMP (current good manufacturing practices) manufacturing&#160;&#160;processes for its drug candidate Actimab&#8482;-A.</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Substantial IP portfolio:</font>&#160;The Company has an intellectual property portfolio in excess of 60 patents and patent applications, both in the U.S. and other countries, which cover clinical applications of the APIT technology and methods of manufacturing actinium 225 thus giving the Company control over both the applications of its technology and a supply chain of its key ingredients, actinium 225 and bismuth 213 alpha emitting isotopes.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Competition Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">To the Company&#8217;s knowledge, there are no other commercial entities that have significant programs in place for developing Ac-225- or Bi-213-based drugs. In the wider field of medical oncology, the Company faces competition from: developers of other alpha emitter based drug candidates, other radioimmunotherapy based technologies, technologies for labeling antibodies with toxic drugs (antibody-drug conjugates), and for each disease indication from all drugs available and/or in development.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For Company&#8217;s lead indication, acute myeloid leukemia, there are a number of companies developing drugs for AML induction in the elderly. These drugs are most often small molecules. Until recently, our leukemia targeting monoclonal antibody HuM195 was under development as a native i.e. unconjugated mAb by Seattle Genetics, Inc., but its development has been discontinued due to lack of efficacy of the native mAb in that company&#8217;s pivotal trial in AML. To our knowledge, there are no clinical trials that have shown significant efficacy in this indication.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In the field of hematopoietic stem cell transplantation, pharmaceuticals currently used for bone marrow ablation/conditioning are generic drugs and to our knowledge there are no significant industry efforts to enter this area, especially not in older patients.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Government Regulation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Governmental authorities in the United States and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of radioimmunotherapy pharmaceutical products such as those being developed by the Company. In the United States, the U.S. Food and Drug Administration (FDA) regulates such products under the Federal Food, Drug and Cosmetic Act (FDCA) and implements regulations. Failure to comply with applicable FDA requirements, both before and after approval, may subject us to administrative and judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">United States FDA Regulation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our research, development and clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation in the United States and other countries. Most notably, all of our products sold in the United States are subject to the FDA as implemented and enforced by the FDA. Certain of our product candidates in the United States require FDA pre-marketing approval of a Biologics License Application (BLA) pursuant to 21 C.F.R. &#167; 314. Foreign countries may require similar or more onerous approvals to manufacture or market these products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Failure by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA, the Nuclear Regulatory Commission or other regulatory authorities, which may result in sanctions, including but not limited to, untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties; customer notifications or repair, replacement, refunds, recall, detention or seizure of our products; operating restrictions or partial suspension or total shutdown of production; refusing or delaying our requests for BLA premarket approval of new products or modified products; withdrawing BLA approvals that have already been granted; and refusal to grant export.<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Properties</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company does not own any property. The Company has office space at 501 Fifth Avenue, 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font> Floor, New York, NY 10017. The space is month to month and pays approximately $7,500 per month.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of January 22, 2013, we have 6 full-time employees. None of these employees are covered by a collective bargaining agreement, and we believe our relationship with our employees is good. We also engage consultants on an as-needed basis to supplement existing staff. &#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Legal Proceedings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a010v1">MARKET PRICE OF AND DIVIDENDS ON OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Information</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our Common Stock is listed on OTCQB, under the symbol &#8220;ATNM&#8221;.&#160; Our Common Stock ceased trading on the OTCBB on May 29, 2013.&#160;&#160;The last quoted price for our Common Stock was $5.70 for a trade on January 30, 2014, as reported on www.otcbb.com.&#160;&#160;However, as there is currently little to no market for our Common Stock, we believe that this last reported price does not accurately reflect the value of the Common Stock or the Company, and it may not be possible to sell Common Stock at this price. &#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table shows, for the periods indicated, the high and low bid prices per share of our common stock as reported by the OTCQB quotation service. These bid prices represent prices quoted by broker-dealers on the OTCQB quotation service. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions, and may not represent actual transactions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fiscal 2014</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fiscal 2013</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fiscal 2012</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">High</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Low</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">High</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Low</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">High</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Low</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">First Quarter (through January 30, 2014))</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.95</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.45</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.50</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.50</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Second Quarter (April 1 - June 30)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.00</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.10</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Third Quarter (July 1 - September 30)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.40</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.37</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fourth Quarter (October 1 - December 31)</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.45</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.70</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Holders</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of&#160;January 22, 2014 there were 24,903,150 shares of common stock issued and outstanding, which were held by 349 holders of record.&#160;&#160;There are no shares of preferred stock outstanding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Of the 24,903,150 shares of common stock issued and outstanding, 6,245,627 of such shares are restricted shares under the Securities Act.&#160;&#160;None of these restricted shares are eligible for resale absent registration or an exemption from registration under the Securities Act.&#160;&#160;As of the date hereof, until the provisions of Rule 144 are complied with, the exemption from registration provided by Rule 144 under the Securities Act is not available for these shares pursuant to Rule 144(i).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registration Rights</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certain shareholders are entitled to certain registration rights, including piggy-back registration rights, with respect to the shares of common stock purchased in the offerings conducted by the Company in 2013 and 2014.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following shares are subject to registration rights:<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,106,120 shares of common stock, par value $0.001 per share, held by the selling stockholders issued pursuant to the private placement that closed on December 27, 2013 and January 10, 2014;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">276,529 shares of our common stock issuable upon exercise of common stock warrants held by the selling stockholders at an exercise price of $9.00 per share issued pursuant to private placements that closed on December 27, 2013 and January 10, 2014; and</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">138,265 shares of our common stock issuable upon exercise of placement agent warrants held by the selling stockholders at an exercise price of $9.00 per share issued pursuant to private placements that closed on December 27, 2013 and January 10, 2014.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition:</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certain Investors have registration rights pursuant to the following agreement:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Second Amended and Restated Investor Rights Agreement,<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>dated as of October 5, 2011 (the &#8220;Agreement&#8221;), by and among Actinium Pharmaceuticals, Inc., a Delaware corporation<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">, </font>Actinium Holdings Limited (formerly named General Atlantic Investments Limited&#8221;), a Bermuda corporation<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">, </font>and the persons identified on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> thereto (collectively, the &#8220;Holders&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the terms of the Agreement the Holders have the following registration rights:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)&#160;&#160;Piggyback Rights.&#160; - If at any time or from time to time, the Company shall determine to register any of its equity securities for its own account in a direct public offering or an underwritten public offering, the Company will: (i) prior to the filing of such registration give to the Holders written notice thereof; and (ii)include in such registration (and any related qualification under blue sky laws or other compliance), and underwriting, all the Registrable Securities (as defined in the Agreement) specified in a written request or requests made within thirty (30) days after receipt of such written notice from the Company by any Holder.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)&#160;&#160;Demand Registration - If at any time after the earlier of (i) the third anniversary of the October 5, 2011, or (ii) three (3) months after the Company&#8217;s Common Stock becomes publicly traded (whether through a Qualified Initial Public Offering, a Pubco Transaction (each as defined in the Agreement) or otherwise, (the &#8220;Start Date&#8221;)) , whichever is earlier, Holders of at least thirty-five percent (35%) of the Registrable Securities&#160;&#160;(as defined in the Agreement) then outstanding request in writing that the Company file a registration statement under the Securities Act covering the registration of at least 20% of the then outstanding Registrable Securities (as defined in the Agreement), or a lesser percentage if the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed $10,000,000.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dividends</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have never declared or paid a cash dividend. Any future decisions regarding dividends are made by our Board of Directors. We currently intend to retain and use any future earnings for the development and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Our Board of Directors has complete discretion on whether to pay dividends. Even if our Board of Directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the Board of Directors may deem relevant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Authorized for Issuance Under Equity Compensation Plans</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In December 2013 the Company&#8217;s shareholders approved the Company&#8217;s 2013 Stock Plan. The expiration date of the plan is September 9, 2023 and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 5,750,000 shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In December 2013 the Company&#8217;s shareholders approved the Company&#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September 9, 2023 and the total number of shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 1,000,000 shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><!--EFPlaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a011v1">MANAGEMENT&#8217;S DISCUSSION&#160;AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The information and financial data discussed below is derived from the unaudited consolidated financial statements of the Company for its quarterly period ended&#160;September 30, 2013 and of Actinium Corporation for the quarterly period ended September&#160;30, 2012, and audited consolidated financial statements of Actinium Corporation&#160;&#160;for its fiscal years ended December 31, 2012 and 2011.&#160;&#160;&#160;The consolidated financial statements of the Company and Actinium Corporation were prepared and presented in accordance with generally accepted accounting principles in the United States. The information and financial data discussed below is only a summary and should be read in conjunction with the historical financial statements and related notes contained elsewhere in the&#160;Registration Statement of which this prospectus is a part. The financial statements contained elsewhere in the Registration Statement of which this prospectus is a part fully represent the Company&#8217;s&#8217; financial condition and results of operations; however, they are not indicative of the Company&#8217;s future performance. See &#8220;Cautionary Note Regarding Forward Looking Statements&#8221; above for a discussion of forward-looking statements and the significance of such statements in the context of this Registration Statement.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled &#8220;Risk Factors&#8221; and elsewhere herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that is in the market for a merger with an appropriate operating company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &#160;Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As a result of the Share Exchange, the Company is now a holding company operating through Actinium, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We develop drugs for treatment of cancer with intent to cure or significantly improve survival of the affected patients. As of now none of our drugs have been approved for sale in the United States or elsewhere. We have no commercial operations in sales or marketing of our products. All our product candidates are under development. In order to market and sell our products we must conduct clinical trials on patients and obtain regulatory approvals from appropriate regulatory agencies like the Food and Drug Administration (FDA) in the United States and similar agencies elsewhere in the world.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our products under development are monoclonal antibodies labeled with radioisotopes. We have one program with an antibody labeled with a beta emitter and several programs based on a proprietary patent protected platform technology called alpha particle immunotherapy or APIT. Our APIT technology is based on attaching actinium 225 (Ac-225) or bismuth 213 (Bi-213) alpha emitting radioisotopes to monoclonal antibodies. Alpha emitting radioisotopes are unstable chemical elements that decay by releasing alpha particles. Alpha particles can kill any cell in whose immediate proximity they are released. Monoclonal antibodies are genetically engineered proteins that target specifically certain cells, and can target cancer cells. It is crucial for the success of our drug candidates to contain monoclonal antibodies that can successfully seek cancer cells and can kill them with the attached isotope while not harming nearby normal cells. We do not have technology and operational capabilities to develop and manufacture such monoclonal antibodies and we therefore rely on collaboration with third parties to gain access to such monoclonal antibodies. We have secured rights to two monoclonal antibodies, HuM195 (Lintuzumab), in 2003 through a collaborative licensing agreement with Abbott Laboratories and BC8 in 2012 with the Fred Hutchinson Cancer Research Center. We expect to negotiate collaborative agreements with other potential partners that would provide us with access to additional monoclonal antibodies. Establishing and maintaining such collaborative agreements is a key to our success as a company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under our own sponsorship as well as activity at FHCRC, we have four product candidates in active clinical trials: Actimab&#8482;-A (HuM195-Ac-225), Iomab&#8482;-B (BC8-I-131), BC8-Y-90 and BC8-SA. At this time, the Company is actively pursuing development of Actimab&#8482;-A and Iomab&#8482;-B while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center.&#160;&#160;Actimab&#8482;-A is a combination of the monoclonal antibody we have in-licensed, Lintuzumab (HuM195), and the alpha emitting isotope actinium 225. Actimab&#8482;-A has shown promising results throughout preclinical development and an ongoing clinical trial started in 2006 in treating acute myeloid leukemia (AML) in the elderly. We have expanded the number of patients and number of clinical centers by commencing a new AML clinical trial which we have launched in 2012. This trial targets newly diagnosed AML patients over the age of 60. In order to conduct the trial we are engaged in funding, monitoring and quality assurance and control of the Lintuzumab antibody; procurement of actinium 225 isotope; funding, monitoring and quality assurance and control of the drug candidate Actimab&#8482;-A manufacturing and organizing and monitoring clinical trials. We estimate that the direct costs to completion of both parts of the ongoing Phase 1/2 trial will be approximately US $7.5 million.&#160;&#160;&#160;Assuming a successful trial we intend to explore out-licensing the Actimab&#8482;-A product and potentially receiving payments for co-developing the product with a partner.&#160;&#160;Iomab&#8482;-B is a combination of the in-licensed monoclonal antibody BC8 and the beta emitting radioisotope iodine 131. This construct has been extensively tested in Phase I and Phase II clinical trials in approximately 250 patients with different blood cancer indications who were in need of a hematopoietic stem cell transplantation (HSCT). Iomab&#8482;-B is used to condition the bone marrow of these patients by destroying blood cancer cells in their bone marrow and elsewhere thus allowing for a subsequent transplant containing healthy donor bone marrow stem cells. We have decided to develop this drug candidate by initially focusing on the patients over 55 with active acute myeloid leukemia in relapse and/or refractory to existing treatments. Our intention is to request the FDA to allow us to enter into a pivotal trial with Iomab&#8482;-B. We estimate the direct costs of such a trial to completion anticipated in 2016 will be approximately US $15 million, and up to approximately $25 million for both trials.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have primarily management position employees and consultants who direct, organize and monitor the activities described above through contractors. Much of the<font style="FONT-STYLE: italic; DISPLAY: inline"> in vivo</font> laboratory and clinical work contracted for by the Company has been conducted at Memorial Sloan-Kettering Cancer Center in New York. The Company has also made clinical trial arrangements with other well known cancer centers.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our Actimab&#8482;-A drug candidate and its components are contract manufactured and maintained under our supervision by specialized contract manufacturers and suppliers in the U.S., including IsoTex Diagnostics, Oak Ridge National Laboratory, Pacific GMP, Fischer Bioservices, BioReliance and others.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are a development stage company and have never generated revenue. Currently we do not have a stable recurring source of revenues sufficient to cover our operating costs. As of December 31, 2012, we had an accumulated deficit of $55.7 million. We incurred net losses of $8.3 million and $3.4 million in the years ending December 31, 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Opportunities, Challenges and Risks</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The market for drugs for cancer treatment is a large market in need of novel products, in which successful products can command multibillion dollars in annual sales. A number of large pharmaceutical and biotechnology company regularly acquire products in development, with preference given to products in Phase II or later clinical trials. These deals are typically structured to include an upfront payment that ranges from several million dollars to tens of million dollars or more and additional milestone payments tied to regulatory submissions and approvals and sales milestones. Our goal is to develop our product candidates through Phase II clinical trials and enter into partnership agreements with one or more large pharmaceutical and/or biotechnology companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We believe our future success will be heavily dependent upon our ability to successfully conduct clinical trials and preclinical development of our drug candidates. This will in turn depend on our ability to continue our collaboration with Memorial Sloan-Kettering Cancer Center and our Clinical Advisory Board members plan to continue and expand other research and clinical trial collaborations. In addition, we will have to maintain sufficient supply of actinium 225 and successfully maintain and if and when needed replenish or obtain our reserves of monoclonal antibodies. We will have to maintain and improve manufacturing procedures we have developed for production of our drug candidates from the components that include the iodine 131 and actinium 225 isotopes, monoclonal antibodies and other materials. It is possible that despite our best efforts our clinical trials results may not meet regulatory requirements for approval. If our efforts are successful, we will be able to partner our development stage products on commercially favorable terms only if they enjoy appropriate patent coverage and/or considerable know-how and other protection that ensures market exclusivity. For that reason we intend to continue our efforts to maintain existing and generate new intellectual property. Intellectual property is a key factor in the success of our business as well as market exclusivity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">To achieve the goals discussed above we intend to continue to invest in research and development at high and constantly increasing rates thus incurring further losses until one or more of our products are sufficiently developed to partner them to large pharmaceutical and biotechnology companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Since our inception on June 13, 2000, we have not generated any revenues, and that as of December 31, 2012, we have incurred net losses of $55.7 million.&#160;&#160;As of December 31, 2012 and September 30, 2013 our cash balance was $5.6 million and $4.0 million, respectively.&#160;&#160;In December 2013 and January 2014,</font> the Company closed on total gross proceeds of approximately $6.6 million from the private placement of common stock and warrants to new and existing accredited investors.<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> We need approximately $25 million in cash to finance research and development and to cover our ongoing working capital needs through 2016. If we do not raise any additional funding, we will be able to continue our operations through&#160;the first quarter of 2015. As we have raised 25% of the needed funds,&#160;we will be able to conduct our planned operations into the first quarter of 2015. If we raise 50% of the needed funds, we will be able to conduct our planned development programs through the second half of 2015. If we raise 75% or more of the needed funds, we will be able to accelerate our planned development programs through 2015 and into the second quarter of 2016.&#160;&#160;Our first product is not expected to be commercialized until at least 2017. In the second quarter of 2013 we issued shares of common stock pursuant to the exercise of Series A Warrants originally issued in connection with a private placement that closed in January 2013.&#160;&#160;The warrants were exercised at $1.65 per share, resulting in gross proceeds of $3,457,087 for the Company. We believe that we have enough cash on hand to fund our business through the first quarter of 2015.&#160;&#160;In order to fund our business beyond the first quarter of 2015 we will likely need to raise money through private offerings of debt and/or equity.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine Months Ended September 30, 2013 Compared to the Nine Months Ended September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table sets forth, for the periods indicated, data derived from our statements of operations:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the nine months ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;September 30,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development, net of reimbursements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,373,200</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,723,459</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,730,233</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,520,221</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">429</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,107,555</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,244,109</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other (income) expense:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,508</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">952,241</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Gain) loss on change in fair value of derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(216,112</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">287,604</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other (income) expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(213,604</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,239,845</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,893,951</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,483,954</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenues</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We recorded&#160;no&#160;commercial revenues for the nine months ended September 30, 2013 and&#160;2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development expenses decreased by $350,259 to $2,373,200 for the nine months ended September 30, 2013 compared to $2,723,459 for the nine months ended September 30, 2012. The decrease is primarily attributable to the Company conserving capital during the three months ended September 30, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General and Administrative Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Overall, total general and administrative expenses increased by $1,210,012 to $2,730,233 for the nine months ended September 30, 2013 compared to $1,520,221 for the nine months ended September, 2012. The increase was largely attributable to increases in professional fees and&#160;financing related fees&#160;incurred by the Company as discussed below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other&#160;Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other&#160;expense decreased by $1,453,449 for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012. The decrease is primarily attributable a decrease in interest expense&#160;related to the amortization of the convertible debt discount and deferred financing costs related to the convertible debt&#160;and an&#160;&#160;increase in the gain on the change in fair value of the derivative liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss decreased by $590,003 to $4,893,951&#160;for the nine months ended September 30, 2013 compared $5,483,954 for the nine months ended September 30, 2012. The decrease was primarily due to a decrease in interest expense associated with the amortization of debt discount to interest expense, a decrease in research and development and a gain from change in fair value of the derivative liability efforts and offset by an increase in professional fees and payroll related expense.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have financed our operations primarily through sales of the Company&#8217;s stock and the issuance of convertible promissory notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following tables sets forth selected cash flow information for the periods indicated:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the nine months ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,947,969</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,795,480</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,030</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,812</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash provided by financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,327,393</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">660,163</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net&#160;change in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,628,606</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,137,129)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities was $4,947,969 for the nine months ended September 30, 2013 compared to $3,795,480 used in operations for the same period in 2012. Cash used in operations increased due to the increase in spending related to preparations and eventual launch and conduct of a multicenter trial and an increase in spending related to professional fees combined with an increase in payroll-related expenses.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities was $3,327,393 for the nine months ended September 30, 2013 compared to net cash provided by financing activities of $660,163 for the same period in 2012. During the nine months ended September 30, 2013, the Company received proceeds from the exercise of warrants as more discussed below. During the nine months ended September 30, 2012, the Company received net proceeds of $660,163 from sale of its stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have experienced cumulative losses of $60,637,414 from inception (June 13, 2000) through&#160;September 30, 2013, and have stockholders&#8217; equity of $604,328 at September 30, 2013. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31, 2012 Compared to Year Ended December 31, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table sets forth, for the periods indicated, data derived from our statements of operations:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="59%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the Years ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;December 31,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="59%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Decrease)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="59%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="59%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development, net of reimbursements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,440,485</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">323,788</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,116,697</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,506,232</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,959,246</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,546,986</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="59%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">581</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">633</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(52</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,947,298</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,283,667</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,633,631</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="59%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other (income) expense:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,099,327</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">175,094</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">924,233</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="59%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on change in fair value of derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(685,420</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,966</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(671,454)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other (income) expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">413,907</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">161,128</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">252,779</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="59%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="59%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,361,205</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,444,795</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,916,410</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We recorded no commercial revenues for the year ended December 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and Development Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development expenses increased by $3,116,697 to $3,440,485 for the year ended December 31, 2012 compared to $323,788 for the year ended December 31, 2011. The increase is attributable to the costs incurred on initiation of the multi-center clinical trial for Actimab&#8482;-A. The Company also made its first milestone payment of $750,000 to Abbott Biotherapeutics Corp. upon reaching the milestone. The increase also reflected an agreement the Company made with MSKCC as of April 2010, in which MSKCC agreed to pay or reimburse the Company for certain costs and expenses related to the Company&#8217;s drug development and clinical study program. This agreement expired on October 5, 2011. No reimbursement was due for the year ended December 31, 2012 and $237,834 was due for the year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and Administrative Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Overall, total general and administrative expenses increased by $1,546,986 to $4,506,232 for the year ended December 31, 2012 compared to $2,959,246 for the year ended December 31, 2011. The increase was largely attributable to increases in professional fees and the stock-based compensation incurred by the Company as discussed below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In connection with the Company&#8217;s stock offering, in January 2012, we issued warrants to purchase 400,013 shares of common stock to the transaction manager for consulting services related to assisting the Company in preparing to become a publicly traded company. The fair value of $144,463, or $0.36 per share, was a noncash charge to general and administrative expenses for the year ended December 31, 2012. In February 2012, the Company granted options to purchase 2,125,000 shares of common stock to its employees and consultants with a fair value of $531,913. In July 2012, the Company granted options to purchase 90,000 shares of common stock to its consultants with a fair value of $23,770. In August 2012, the Company granted options to purchase 2,875,000 shares of common stock to its employees and consultants with a fair value of $724,784. During the fourth quarter, the Company granted options to purchase 1,085,000 shares of common stock to its employees and consultants with a fair value of $239,310.&#160;&#160;For the year ended December 31, 2012, the Company recorded amortization of stock-based compensation of $266,172 as a noncash charge to general and administrative expenses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The increase can also be attributed to additional professional fees of $549,383 related to the year-end audit, the quarterly review, legal fees, and management fees associated with the Company going public. In addition to the professional fees incurred, we increased our personnel. As such, payroll-related expenses for the year ended December 31, 2012 increased compared to the same period in 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense increased by $924,233 for the year ended December 31, 2012 compared to the year ended December 31, 2011. The increase in interest expense is directly attributable to interest accrued on the convertible debt, amortization of the convertible debt discount and deferred financing costs related to the convertible debt.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net Loss</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss increased by $4,916,410 to $8,361,205 for the year ended December 31, 2012 compared to $3,444,795 for to the year ended December 31, 2011. The increase was primarily due to additional costs incurred by the Company in research and development expenses, non-cash stock-based compensation costs and professional fees as discussed above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have financed our operations primarily through sales of the Company&#8217;s stock and the issuance of Convertible Promissory Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We did not have any cash or cash equivalents held in financial institutions located outside of the United States as of December 31, 2012 and 2011. We do not anticipate this practice will change in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following tables sets forth selected cash flow information for the periods indicated:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the years ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash provided by (used in) operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,212,710</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(517,592</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash provided by (used in) investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,359</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash provided by (used in) financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,129,940</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,025,255</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase (decrease) in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(85,129)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,507,663</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities was $5,212,710 for the year ended December 31, 2012 compared to $517,592 used in operations for the same period in 2011. Cash used in operations increased due to the increase in spending related to preparations and eventual launch and conduct of a multicenter trial and an increase in spending related to professional fees combined with an increase in payroll-related expenses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities was $5,129,940 for the year ended December 31, 2012 compared to $6,025,255 for the same period in 2011. In January 2012, we sold 968,759 shares of our stock at $0.78 per share. In 2012, we also sold 3,118,988 shares of our common stock at $1.65 per share. We raised funds through sale of the Company&#8217;s stock to finance the expansion of our research and development efforts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have experienced cumulative losses of approximately $55,743,463 from inception (June 13, 2000) through December 31, 2012, and have stockholders&#8217; equity of $1,145,635 at December 31, 2012. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Debt and Equity Offerings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During 2011, the Company raised $6,184,967 by selling 7,891,141 shares of the Company&#8217;s stock and warrants to purchase 19,972,785 shares of the Company&#8217;s stock through an offering (&#8220;Stock Offering&#8221;).&#160;&#160;A net amount of $5,379,367 was received by the Company in 2011. The Company paid Laidlaw &amp; Company (UK) Ltd. (&#8220;Laidlaw &amp; Co.&#8221;), the placement agent, total cash fees of $742,196, which consisted of placement agent commission of $618,497 and expense reimbursement of $123,699. In addition, the Company paid Laidlaw &amp; Co.&#8217;s outside counsel, McCormick &amp; O&#8217;Brien LLP, $60,904 for its services as the placement agent&#8217;s legal counsel and Signature Bank $2,500 for the bank escrow fee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 27, 2011, the Company completed a private offering of 8% Senior Subordinated Unsecured Convertible Promissory Notes (&#8220;Convertible Notes&#8221;) in the amount of $900,000 and received net proceeds of $750,000. The convertible notes were issued at 83.33% of the principal amount resulting in an original issue discount of $150,000. The Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount, accrued semi-annually and to be paid at maturity. On December&#160;19, 2012, in connection with the Share Exchange, the Convertible Notes were converted into 1,252,550 share of common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During 2012, the Company raised $759,300 by selling 968,759 shares and warrants to purchase 242,190 shares of the Company&#8217;s common stock under the Company&#8217;s Stock Offering.&#160;&#160;A net amount of $660,164 was received by the Company in 2012. The Company paid Laidlaw &amp; Co. total cash fees of $91,116, which consisted of placement agent commission of $75,930 and expense reimbursement of $15,186. In addition, the Company paid Laidlaw &amp; Co.&#8217;s outside counsel, McCormick &amp; O&#8217;Brien PLLC, $8,020 for its services as the placement agent&#8217;s legal counsel.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In 2012, the Company raised $5,151,450 through an offering of 3,118,988 shares of its common stock and &#8220;A Warrants&#8221; to purchase 3,118,988 shares of the Company&#8217;s common stock, exercisable at a price of $1.65 per share for a period of 120 days from the day of the final closing of the offering, and &#8220;B Warrants&#8221; to purchase 1,559,505 shares of the Company&#8217;s common stock, exercisable at a price of $2.48 per share for a period of 5 years from the date of the final closing of the offering. (&#8220;2012 Common Stock Offering&#8221;)&#160;&#160;A net amount of $4,469,776 was received by the Company. Pursuant to the 2012 Common Stock Offering agreement, the Company paid Laidlaw &amp; Co. total cash fees of $618,174, which consisted of placement agent commission of $515,145 and expense reimbursement of $103,029. The Company also issued the placement agent warrants to purchase an aggregate of 467,845 shares of the Company&#8217;s common stock, with an exercise price of $0.78 per share and a term of 5 years. These placement agent warrants were valued at $499,707 and recorded as derivative liabilities.&#160;&#160;In addition, the Company paid the Laidlaw &amp; Co.&#8217;s outside counsel, Richardson &amp; Patel, LLP, $60,000 for its services as the Laidlaw &amp; Co.&#8217;s legal counsel and Signature Bank $3,500 for the bank escrow fee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium intends to increase funds available to continue our research and development efforts, which include material supply, manufacturing, clinical development and pre-clinical trials and working capital.&#160;&#160;In 2014 we expect cash needs of up to $7,000,000 to finance research and development, which include material supply, manufacturing, clinical trials and pre-clinical trials and to cover our ongoing working capital needs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In the second quarter of 2013 we issued shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013.&#160;&#160;The warrants were exercised at $1.65 per share, resulting in gross proceeds of $3,457,087 for the Company.&#160;In December 2013 and January 2014,</font> the Company closed on total gross proceeds of approximately $6.6 million from the private placement of common stock and warrants to new and existing accredited investors.&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The proceeds from these exercised warrants and the offering will be used for the Company&#8217;s clinical and preclinical programs and for general working capital.&#160;&#160;This capital will allow us to continue to develop our drug candidates for treatment of the most difficult forms of cancer, including Acute Myeloid Leukemia, where the Company has&#160;made significant advances and already helped a number of patients. The Company intends to advance its programs and add new programs by the end of 2013. Shareholders exercised 2,095,204 (67.2%) of the 3,118,988 originally issued A-warrants. The A-warrants expired on May 28, 2013.&#160;&#160;With exercise of the A-warrants we believe that we have the needed capital for 2013.&#160;&#160;We do not expect proceeds from the exercise of the outstanding B- warrants, Stock Offering warrants, consulting firm warrants, and placement agent warrants since these warrants contain cash-less exercise provisions. To meet our capital needs beyond 2013 we intend to conduct offerings of either stock and/or debt and also engage in licensing activities.&#160;&#160;We are currently sponsoring conduct of two clinical trials with Actimab-A (Phase I Physician trial at MSKCC and Phase 1/2 multicenter trial) and preparing for a Phase III trial with Iomab-B. If we do not raise any additional funding, we will be able to continue our operations through&#160;the first quarter of 2015. If we do not raise any additional funding, we will be able to continue our operations through 2014 and into the first quarter of 2015</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;As we have raised 25% of the needed funds,&#160;we will be able to conduct our planned operations through 2014 and into the first quarter of 2015. If we raise 50% of the needed funds, we will be able to conduct our planned development programs through the second half of 2015. If we raise 75% or more of the needed funds, we will be able to accelerate our planned development programs through 2015 and into the second quarter of 2016.&#160;&#160; There can be no assurance that we will be successful in obtaining additional capital through offerings of our securities in the future. Our first product is not expected to be commercialized until at least 2017</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In the event we do not meet our cash needs of $25.0 million through 2016, it may be necessary for us to delay the timing of various product development efforts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Seasonality</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We do not have a seasonal business cycle. Our revenues and operating results are generally derived evenly throughout the calendar year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States. To prepare these financial statements, we must make estimates and assumptions that affect the reported amounts of assets and liabilities. These estimates also affect our expenses. Judgments must also be made about the disclosure of contingent liabilities. Actual results could be significantly different from these estimates. We believe that the following discussion addresses the accounting policies that are necessary to understand and evaluate our reported financial results.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Derivatives</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All derivatives are recorded at fair value and recorded on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value of Financial Instruments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity&#8217;s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Costs</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Share-Based Payments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There were various accounting standards and interpretations issued during 2012 and 2011, none of which are expected to have a material impact on the Company&#8217;s financial position, operations or cash flows.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsequent Event</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In December 2013 and January 2014, the Company also raised approximately $6,636,720 through an offering of 1,106,120 shares of its common stock and five year common stock warrants to purchase 276,529 shares of the Company&#8217;s common stock, exercisable at a price of $9.00 per share.&#160;&#160;A net amount of $5,756,813 was received by the Company. Pursuant to the 2012 Common Stock Offering agreement, the Company paid Laidlaw &amp; Co. total cash fees of $796,406, which consisted of placement agent commission of $663,672 and expense reimbursement of $132,734. The Company also issued the placement agent warrants to purchase an aggregate of 138,265 shares of the Company&#8217;s common stock, with an exercise price of $9.00 per share and a term of 5 years. In addition, the Company paid the Laidlaw &amp; Co.&#8217;s outside counsel, </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sichenzia Ross Friedman Ference LLP</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">, $50,000 for its services as the Laidlaw &amp; Co.&#8217;s legal counsel and Signature Bank $3,500 for the bank escrow fee.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a012v1">CHANGES IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(a)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, we dismissed R.R. Hawkins and Associates International, A PC, (&#8220;Hawkins&#8221;), as our independent registered public accounting firm. The dismissal was approved by the audit committee (&#8220;Audit Committee&#8221;) of our board of directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the fiscal years ended December 31, 2011 and 2010, Hawkins&#8217; reports on our financial statements did not contain an adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the fiscal years ended December 31, 2011 and 2010 and the subsequent periods through December 28, 2012, (i) there were no disagreements between us and Hawkins on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Hawkins, would have caused Hawkins to make reference to the subject matter of the disagreements in connection with its reports on the Registrant&#8217;s financial statements, and (ii) there were no reportable events as that term is described in Item 304(a)(1)(v) of Regulation S-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, we provided Hawkins with a copy of the disclosures it is making in response to Item 4.01 on Form 8-K, and requested that Hawkins furnish it with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements. A copy of the letter, dated December 28, 2012, was filed as Exhibit 16 to the Current Report on Form 8-K filed on January 2, 2013.&#160;&#160;A revised letter is attached to this Form S-1as Exhibit 16.1 that corrects the name of the registrant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(b)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, we engaged GBH CPAs, PC as our new independent registered public accounting firm beginning with our fiscal year ended December 31, 2012. The change in our independent registered public accounting firm was approved by the Audit Committee. During the two most recent fiscal years and through December 28, 2012, neither the Company nor anyone on its behalf consulted with GBH CPAs, PC regarding any of the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(i) The application of accounting principles to a specific transaction, either completed or proposed;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(ii) The type of audit opinion that might be rendered on the Company&#8217;s financial statements, and none of the following was provided to the Company:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(a) a written report; or (b) oral advice that GBH CPAs, PC concluded was an important factor considered by the Company in reaching a decision as to an accounting, auditing or financial reporting issue; or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(iii) Any matter that was subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K, or a reportable event, as described in Item 304(a)(1)(v) of Regulation S-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">39</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a013v1">DIRECTORS AND EXECUTIVE OFFICERS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Directors And Executive Officers</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The names, positions and ages of our directors and executive officers as of the date of this Memorandum, are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Age</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="57%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Position</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sandesh Seth, MS, MBA</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman of the Board</font></div>
</td>
</tr><tr>
<td valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="57%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave, PhD, MBA</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President, Chief Executive Officer and Director</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="57%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa, MBA</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interim Chief Financial Officer and Director</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="57%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dragan Cicic, MD</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Operating Officer and Chief Medical Officer</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="57%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Nicholson, PhD</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="57%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard I. Steinhart</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All directors hold office until the next annual meeting of stockholders and the election and qualification of their successors. Officers are elected annually by the board of directors and serve at the discretion of the board.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the Company&#8217;s charter, Mr. Traversa and Mr. Seth were appointed as directors of the Company by the former Series E preferred stock holders of Actinium Corporation. During 2011, Actinium Corporation raised $6.2 million through an offering of 23,697,119 shares (pre-Actinium Share Exchange) of the 2011 Series E preferred shares and 5,924,285 warrants (pre-Actinium share exchange). In January 2012, the Actinium Corporation raised $0.8 million through its final offering of the 2011 Series E preferred shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There are no other&#160;arrangements or understanding between any of our directors and any other persons pursuant to which they were selected as a director.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Background of Executive Officers and Directors</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The principal occupations for the past five years (and, in some instances, for prior years) of each of our directors and executive officers are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sandesh Seth, MS, MBA, Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mr. Sandesh Seth has been our Director since March 2012 and our Chairman of the Board since October 2013.&#160;&#160;Mr. Seth is the Head of Healthcare Investment Banking at Laidlaw &amp; Company (UK) Ltd. and has over 20 years of experience which includes prior investment banking at Cowen &amp; Co., equity research at Bear Stearns and Commonwealth Associates and in the pharmaceutical industry at Pfizer, Warner-Lambert, and SmithKline Beecham in strategic planning, business development and R&amp;D project management respectively. Mr. Seth&#8217;s financial services experience includes 100+ completed transactions in which $5 billion+ in capital was raised. Transactions included venture investments, private placements, IPOs, FOs, PIPEs, Convertible and High-Yield Debt. Mr. Seth was also involved with various strategic initiatives such as mergers and acquisitions, leveraged and management buy-outs, and licensing and joint ventures, including the $100 billion merger of Pfizer and Warner-Lambert and the $20 billion merger of Pharmacia &amp; Upjohn with Monsanto. Mr. Seth has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified (R.A.C.) by the Regulatory Affairs Professionals Society which signifies proficiency with United States FDA regulations. He also holds the following Securities Industry Licenses: Series 7, 79 and 63.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">That Mr. Seth has served in various business executive-level positions over the course of his career, has significant investment banking experience, has developed significant management and leadership skills and is well accustomed to interfacing with investors, analysts, auditors, C-level executives, and outside advisors, led us to conclude that Mr. Seth should serve as a director.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kaushik J. Dave, PhD, MBA, President, Chief Executive Officer and Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Kaushik J. Dave has been our President, Chief Executive Officer and Director since September 2013. From March 2008 to September 2013, Dr. Dave was the Executive Vice President of Product Development for Antares Pharmaceuticals Inc. (Antares). As part of the core management team at Antares, he was instrumental in setting strategy, vision, product portfolio development and business development. Dr. Dave led the clinical and regulatory approval of Anturol&#8482; and was also a key contributor to the change in company vision to combination products using Antares&#8217; medical device technology which resulted in a robust pipeline that included development and New Drug Application submission for Otrexup, which was approved on October 14, 2013. From January 2001 to June 2006, Dr. Dave was Vice President Product Development at Palatin Technologies Inc. where he obtained approval of NeutroSpecTM (a radiopharmaceutical monoclonal antibody product). From January 1997 to December 2000, Dr. Dave was employed at Schering-Plough Inc. and Merck &amp; Co. Inc., responsible for steering the development of several pharmaceutical product development programs. Dr. Dave received his pharmacy degree from the University of Bath, UK and a Ph.D. in Pharmaceutical Chemistry from the University of Kansas. Dr. Dave also received an MBA from the Wharton School of the University of Pennsylvania.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As President and Chief Executive Officer of the Company, Dr. Dave is the most senior executive of the Company and as such provides our Board of Directors with the greatest insight into the Company&#8217;s business and the challenges and material risks it faces. Dr. Dave has more than 23 years of healthcare industry experience and is especially qualified to understand the risks and leadership challenges facing a growing pharmaceutical company from a senior management and financial expertise perspective led us to conclude that Dr. Dave should serve as President, Chief Executive Officer and Director of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sergio Traversa, Interim Chief Financial Officer and Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Traversa has been a Director of the Company since August, 2012.&#160;&#160;Dr. Traversa is also the Chief Executive Officer of Relmada Therapeutics Inc.&#160;&#160;Previously, he was the co-founder and CEO of Medeor Inc. a spinoff pharmaceutical company from Cornell University.&#160;&#160;Dr. Traversa has over 25 years of experience in the healthcare sector in the United States and Europe, ranging from management positions in the pharmaceutical industry to investing and strategic advisory roles. He has held financial analyst, portfolio management and strategic advisory positions at large UNITED STATES investment firms specializing in healthcare, including Mehta and Isaly and Mehta partners, ING Barings, Merlin BioMed and Rx Capital. Dr. Traversa was a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. In Europe, he held the position of Area Manager for Southern Europe (Italy, Spain, Greece and Portugal) of Therakos Inc., a cancer and immunology division of Johnson &amp; Johnson. Prior to Therakos, Dr. Traversa was at Eli Lilly, where he served as Marketing Manager of the Hospital Business Unit. He was also a member of the CNS team at Eli Lilly, where he participated in the launch of Prozac and the early development of Zyprexa and Cymbalta. Dr. Traversa started his career as a sales representative at Farmitalia Carlo Erba, the largest pharmaceutical company in Italy later sold to Pharmacia and now part of Pfizer. Dr. Traversa holds a Laurea degree in Pharmacy from the University of Turin (Italy) and an MBA in Finance and International Business from the New York University Leonard Stern School of Business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Interim Chief Financial Officer of the Company, Mr. Traversa is a senior executive of the Company and as such provides our Board of Directors with great insight into the Company&#8217;s business and the challenges and material risks it faces. That Dr. Traversa serves in such executive officer positions with the Company and has more than 25 years of healthcare and financial industry experience in the United States and Europe and is especially qualified to understand the risks and leadership challenges facing a growing pharmaceutical company from a senior management and financial expertise perspective led us to conclude that Mr. Traversa should serve as a director.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Traversa devotes a minimum of 40 hours per week to the Company. Relmada Therapeutics, Inc., of which Dr. Traversa also serves as Chief Executive Officer, is not related to the Company and specializes in pain management, which is not related to our business. We do not believe that Dr. Traversa&#8217;s employment by Relmada Therapeutics, Inc. creates a material risk of conflicts of interest.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dragan Cicic, MD, MBA, Chief Operating Officer and Chief Medical Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dragan Cicic is the Chief Operating Officer and Chief Medical Officer of the Company. He joined the Company in 2005 and previously held the position of the CEO and prior to that of the Medical Director at Actinium. Dr. Cicic joined Actinium from the position of Project Director of QED Technologies Inc., a life sciences strategic consulting and transactional group focused on emerging biotech, pharmaceuticals and medical devices companies. Dr. Cicic prepared business and strategic plans on behalf of those clients and assisted them in raising funding. He also represented corporate and private investors in identifying acquisition and/or investment targets and negotiating, structuring and consummating deals. Prior to joining QED Technologies, Dr. Cicic was an investment banker with SG Cowen Securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Cicic graduated as a Medical Doctor from the School of Medicine at The Belgrade University, and received his MBA from Wharton School at The University of Pennsylvania. He was also a Nieman Fellow at Harvard University.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">C. David Nicholson, BS, PhD, Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C. David Nicholson is a Director of the Company and joined the Executive Committee of Bayer CropScience on March 5, 2012 as Head of Research &amp; Development responsible for the integration of the company&#8217;s R&amp;D activities into one global organization. Dr. Nicholson graduated in pharmacology, earning his B.Sc. from the University of Manchester (1975) and his Ph.D. from the University of Wales (1980). Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for the British company Beecham-W&#252;lfing in Gronau, Germany. The main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular drugs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">From 1988-2007, Dr, Nicholson held various positions of increasing seniority in the UK, the Netherlands and the USA with Organon a Business Unit of Akzo Nobel. Ultimately he became Executive Vice President, Research &amp; Development, and member of the Organon Executive Management Committee. He implemented change programs, leading to maximizing effectiveness in research &amp; development, ensuring customer focus and the establishment of a competitive pipeline of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough, Kenilworth, New Jersey as Senior Vice President, responsible for Global Project Management and Drug Safety. From 2009 to December 2011, he was Vice President Licensing and Knowledge Management at Merck in Rahway, New Jersey, reporting to the President of Merck R&amp;D. As an integration team member, David Nicholson played a role in the strategic mergers of Organon BioSciences, the human and animal health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck in 2009. Dr. Nicholson is presently on the Board of Directors of multiple biotechnology companies, including Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">That Dr. Nicholson brings over 25 years of pharmaceutical experience to our Board, Having served in various pharmaceutical research and development executive-level positions over the course of his career, and that Dr. Nicholson has developed significant management and leadership skills relating to the pharmaceutical industry. and is well accustomed to interfacing with investors, analysts, auditors, outside advisors and governmental officials, led us to conclude that Dr. Nicholson should serve as a director.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Richard I. Steinhart, Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard I. Steinhart has served as our Director and Chairman of the Audit Committee since November 2013.&#160;&#160;Mr. Steinhart is also a member of our Compensation Committee.&#160;&#160;Through December 2013, Mr. Steinhart was employed by MELA Sciences, Inc, as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary since April 2006 and in April 2012, Mr.&#160;Steinhart received a promotion to Sr. Vice President, Finance. From May 1992 until joining the Company Mr.&#160;Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr.&#160;Steinhart&#8217;s other experience includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Until December 2011, Mr.&#160;Steinhart served on the Board of Manhattan Pharmaceuticals, Inc., a biopharmaceutical company and was Chairman of its Audit Committee. Mr.&#160;Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds B.B.A. and M.B.A degrees from Pace University and is a Certified Public Accountant (inactive).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">That Mr.&#160;Steinhart brings over 20 years of financial experience to our Board, having served in various financial executive-level positions over the course of his career, and that Mr.&#160;Steinhart is a certified public accountant led us to conclude that Mr. Steinhart should serve as a director and chair the audit committee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Corporate Governance</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The business and affairs of the Company are managed under the direction of the Board of Directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Term of Office</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our directors are divided into three classes, designated Class I, Class II and Class III.&#160;&#160;Class I shall consists of two independent directors, Class II shall consist of two directors, and Class III shall consist of the chief executive officer.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The term of each director is set forth below or until their successors are duly elected:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Director</font></div>
</td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Class</font></div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Term (from 2013 Annual Meeting)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik Dave</font></div>
</td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Class III</font></div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36 months</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Nicholson</font></div>
</td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Class I</font></div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12 months</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sandesh Seth</font></div>
</td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Class II</font></div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30 months</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa</font></div>
</td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Class II</font></div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30 months</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard Steinhart</font></div>
</td>
<td valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Class I</font></div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12 months</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notwithstanding the foregoing, each director shall serve until his successor is duly elected and qualified, or until his or her retirement, death, resignation or removal. In order to implement a staggered board of directors, Class I shall serve a 12 month term from the date of the 2013 Annual Shareholders Meeting (December 2013); Class II shall serve a 30 month term from the date of the 2013 Annual Shareholders Meeting; and Class III shall serve a 36 month term from the date the date of the 2013 Annual Shareholders Meeting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Director Independence</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We use the definition of &#8220;independence&#8221; of The NASDAQ Stock Market to make this determination.&#160;&#160;We are not listed on NASDAQ, so although we use its definition of &#8220;independence&#8221;, its &#8220;independence&#8221; rules are inapplicable to us.&#160;&#160;NASDAQ Listing Rule 5605(a)(2) provides that an &#8220;independent director&#8221; is a person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the Company&#8217;s Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.&#160;&#160;The NASDAQ listing rules provide that a director cannot be considered independent if:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the director is, or at any time during the past three years was, an employee of the company;</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the director or a family member of the director accepted any compensation from the company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among other things, compensation for board or board committee service);</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a family member of the director is, or at any time during the past three years was, an executive officer of the company;</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to which the company made, or from which the company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient&#8217;s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);</font></div>
</td>
</tr></table>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three years, any of the executive officers of the company served on the compensation committee of such other entity; or</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the director or a family member of the director is a current partner of the company&#8217;s outside auditor, or at any time during the past three years was a partner or employee of the company&#8217;s outside auditor, and who worked on the company&#8217;s audit.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our Common Stock is not currently quoted or listed on any national exchange or interdealer quotation system with a requirement that a majority of our board of directors be independent and, therefore, the Company is not subject to any director independence requirements. Under the following three NASDAQ director independence rules a director is not considered independent: (a) NASDAQ Rule 5605(a)(2)(A), a director is not considered to be independent if he or she also is an executive officer or employee of the corporation, (b) NASDAQ Rule 5605(a)(2)(B), a director is not consider independent if he or she accepted any compensation from the company in excess of $120,000 during any period of twelve consecutive months within the three years preceding the determination of independence, and (c) NASDAQ Rule 5605(a)(2)(D), a director is not considered to be independent if he or she is a partner in, or a controlling shareholder or an executive officer of, any organization to which the company made, or from which the company received, payments for property or services in the current or any of the past three fiscal years that exceed 5% of the recipient&#8217;s consolidated gross revenues for that year, or $200,000. Under such definitions, David Nicholson and Sergio Traversa are the only independent directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Committees of the Board of Directors</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, our board of directors formed two standing committees: audit and&#160;compensation. Actions taken by our committees are reported to the full board. Each of our committees has a charter and each charter is posted on our website.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Audit Committee</font></div>
</td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation&#160;Committee</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard I. Steinhart*</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. David Nicholson*</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Sergio Traversa</font></div>
</td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sandesh Seth</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. David Nicholson</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard I. Steinhart</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">*</font> Indicates committee chair</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Audit Committee</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our audit committee, which currently consists of three directors, provides assistance to our board in fulfilling its legal and fiduciary obligations with respect to matters involving the accounting, financial reporting, internal control and compliance functions of the company. Our audit committee employs an independent registered public accounting firm to audit the financial statements of the company and perform other assigned duties. Further, our audit committee provides general oversight with respect to the accounting principles employed in financial reporting and the adequacy of our internal controls. In discharging its responsibilities, our audit committee may rely on the reports, findings and representations of the company&#8217;s auditors, legal counsel, and responsible officers. Our board has determined that all members of the audit committee are financially literate within the meaning of SEC rules and under the current listing standards of the Nasdaq Capital Market.&#160;&#160;Richard I. Steinhart was determined as a chairman of the audit committee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation Committee</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our compensation committee, which currently consists of three directors, establishes executive compensation policies consistent with the company&#8217;s objectives and stockholder interests. Our compensation committee also reviews the performance of our executive officers and establishes, adjusts and awards compensation, including incentive-based compensation, as more fully discussed below. In addition, our compensation committee generally is responsible for:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">establishing and periodically reviewing our compensation philosophy and the adequacy of compensation plans and programs for our directors, executive officers and other employees;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">overseeing our compensation plans, including the establishment of performance goals under the company&#8217;s incentive compensation arrangements and the review of performance against those goals in determining incentive award payouts;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">overseeing our executive employment contracts, special retirement benefits, severance, change in control arrangements and/or similar plans;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">acting as administrator of any company stock option plans; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">overseeing the outside consultant, if any, engaged by the compensation committee.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our compensation committee periodically reviews the compensation paid to our non-employee directors and the principles upon which their compensation is determined. The compensation committee also periodically reports to the board on how our non-employee director compensation practices compare with those of other similarly situated public corporations and, if the compensation committee deems it appropriate, recommends changes to our director compensation practices to our board for approval.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outside consulting firms retained by our compensation committee and management also will, if requested, provide assistance to the compensation committee in making its compensation-related decisions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Family Relationships</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There are no family relationships among any of our officers or directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Involvement in Certain Legal Proceedings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">To our knowledge, none of our current directors or executive officers has, during the past ten years:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</font></div>
</td>
</tr><tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="86%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Except as set forth in our discussion below in &#8220;Certain Relationships and Related Transactions,&#8221; none of our directors or executive officers has been involved in any transactions with us or any of our directors, executive officers, affiliates or associates which are required to be disclosed pursuant to the rules and regulations of the SEC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Code of Ethics</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company has adopted a code of ethics, a copy of which is attached as Exhibit 14.1 to the Form 8-K filed on January 2, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><!--EFPlaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a014v1">EXECUTIVE COMPENSATION</a></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary Compensation Table</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table provides information regarding the compensation earned during the fiscal years ended December 31, 2013, December 31, 2012 and December 31, 2011 by our Chief Executive Officer and the two next most highly compensated executive officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Name/Position</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Year</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Salary</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bonus</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Awards</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All Other</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Compensation</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave, President and CEO (3)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112,134</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58,412</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112,134</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jack Talley, former CEO, resigned on February 28, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">367,692</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">250,000</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">--</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">--</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58,412</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">367,692</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">308,412</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dragan Cicic, COO</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">220,450</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">190,658</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">190,658</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">75,000</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-58,426</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,717</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">295,450</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">249,084</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">250,375</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Enza Guagenti, former CFO, resigned on March 9, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41,486</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">90,000</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,394</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,394</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41,486</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">93,394</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Diane&#160;Button, CEO, CFO (1)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)&#160;&#160;&#160;Ms. Diane Button resigned as the Company&#8217;s CEO and CFO on December 28, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)&#160;&#160;&#160;Dr. Cicic&#8217;s options awards were determined by taking into consideration the following factors: (i) Dr Cicic&#8217;s responsibilities at the Company; (ii) his performance historically and as an incentive for future efforts; (iii) compensation data taken from peer group companies (newly public biotech firms); and (iv) the level of his past awards.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3)&#160;&#160;&#160;Dr. Kaushik J. Dave became the Company&#8217;s President and CEO on September 16, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As an &#8220;emerging growth company&#8221; we will not be required to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees, as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Director Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Historical non-management Directors of the Company do not receive any cash compensation. Commencing October 1, 2012, non-management Directors of Actinium Corporation (and now the Company) began to receive a quarterly cash retainer of $7,500 per calendar quarter for their service on the Board of Directors. They also receive reimbursement for out-of-pocket expenses and certain directors have received stock option grants for shares of Company Common Stock as described below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table sets forth the compensation of our directors for the 2013 fiscal year:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name(1)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fees&#160;Earned&#160;or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Paid in Cash</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock&#160;Awards</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option&#160;Awards</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">All Other</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Nicholson</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-00</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sandesh Seth</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard Steinhart</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,950</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,000</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employment Agreements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effective September 16, 2013, the Company and Dr. Kaushik J. Dave entered into an agreement (the &#8220;Employment Agreement&#8221;), to employ Dr. Dave as the Company&#8217;s Chief Executive Officer. Dr. Dave shall have such responsibilities, duties and authority as are assigned to him by the Board, or its designee. These responsibilities shall include implementation of the overall direction of the Company as set by the Board, including, planning, corporate policies, research and development, staffing, finance and operations. Dr. Dave shall perform such other duties and shall have authority consistent with his position as may be from time to time specified by the Board and subject to the discretion of the Board. Dr. Dave reports directly to the Board. Dr. Dave also agreed to devote his best efforts and substantially all of his business time to advance the interests of the Company and to discharge adequately his duties under the Employment Agreement. Dr. Dave may hold up to two board seats on for-profit and not-for-profit boards that do not represent a conflict with the Company and subject to Board approval after review of the time commitment involved.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the Employment Agreement, Dr. Dave is entitled to the following compensation and benefits:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></div>
</td>
<td align="left" colspan="2" valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A base salary at an annual rate of $350,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Upon the six month anniversary of the start date, the Board will review Dr. Dave&#8217;s base salary with the help of an independent compensation consultant to adjust the base salary to be competitively aligned to a range between the 25th (twenty-fifth) and 75th (seventy-fifth) percentile of the relevant market data of CEO positions of similarly situated publicly traded Biotech companies. The Board shall review the amount of the base salary and performance bonus, and shall determine the appropriate adjustments to each component of Dr. Dave&#8217;s compensation within 60 days of the start of each calendar year.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="74%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition, for the duration that the Company maintains its primary office in New York City, the Company will reimburse Dr. Dave for up to $500 per month in travel expenses plus the dollar amount of the difference between Dr. Dave&#8217;s New York State and New Jersey State taxes based on income from the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Dave shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to which the Board shall award bonuses to Dr. Dave, based upon the achievement of written individual and corporate objectives such as the Board shall determine.&#160;&#160;Upon the attainment of such performance objectives, Dr. Dave shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary.&#160;&#160;Within thirty (30) days after the start date, the Board shall establish written individual and corporate performance objectives for the balance of 2013 and the amount of the performance pro-rata bonus payable upon the attainment of each objective.&#160;&#160;At least thirty (30) days before each subsequent calendar year, the Board shall establish written individual and corporate performance objectives for such calendar year and the amount of the performance bonus payable upon the attainment of such objectives.&#160;&#160;Within sixty (60) days after the end of each calendar year, the Board shall determine the amount of any performance bonus payable thereunder.&#160;&#160;Any such performance bonus shall be due and payable within ninety (90) days after the end of the calendar year to which it relates.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Board has agreed to grant to Dr. Dave an option to purchase common shares of the Company and restricted stock (the &#8220;Grant&#8221;).&#160;&#160;The Grant will consist of (A) an option grant to purchase 675,000 common shares of the Company; (B) 125,000 shares of restricted and (C) 100,000 shares of restricted stock as a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work.&#160;&#160;An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock Options.&#160;&#160;Such options will have an exercise price equal to the prior day closing price of the Company&#8217;s common stock which is equal to fair market value as determined by the Board on the date of the grant (the &#8220;Grant date&#8221;).&#160;&#160;The Grant Date shall occur no later than 90 days from the start date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted Stock Grant (excluding the sign-on bonus).&#160;&#160;One third (33.33%) of the restricted stock shall be granted upon the next closing of a financing of the Company of at least $5 million, and shall vest per the vesting schedule below.&#160;&#160;The remaining two thirds (66.66%) of the restricted stock shall be granted upon the treatment of the first patient in 2014 for the Iomab&#8482;-B trial and subject to the vesting schedule below.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="7%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">&#160;</td>
<td valign="top" width="88%" style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vesting Schedule. Twenty-eight percent (28%) of the initial options or restricted stock granted shall vest twelve months after the date of grant and two percent (2%) of the remainder shall vest each month thereafter until fully vested. Such additional options or restricted stock will have an exercise price per share which is equal to fair market value as determined by the Board on the date of the grant. Two percent (2%) of such additional options or stock shall vest each month thereafter until fully vested. The term of all options granted under this Agreement will be for 10 years from the date of grant, subject to Dr. Dave&#8217;s continuing service with the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Dave is also eligible to participate in the Company&#8217;s benefit plans that are generally provided for executive employees.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The employment agreement also contains a non-solicitation provision that provides that during the term of employment and for a period of 24 months following the cessation of employment with the company you Dr. Dave shall not directly or indirectly solicit, induce, recruit or encourage any of the Company&#8217;s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing, either for himself or any other person or entity</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On July 23, 2012, Actinium Corporation entered into an employment agreement with Jack Talley, as our, Chief Executive Officer. The initial term of employment was for a period of three (3) years, provided that Mr. Talley&#8217;s employment with the company will be on an &#8220;at will&#8221; basis. Actinium Corporation agreed to pay a base salary of $250,000 per annum. The board will review Mr. Talley&#8217;s base salary with help of an independent compensation consultant to adjust his base salary to be competitively aligned to a range between the 25th and 75th percentile of the relevant market data of CEO positions of similarly situated publicly traded biotech companies. Mr. Talley was also entitled to participate in an executive bonus program, which shall be established by the board pursuant to which the board shall award bonuses to Mr. Tally, based on achievement of written individual and corporate objectives such as the board shall determine. Upon the attainment of such performance objectives, in addition to base salary, Mr. Talley was entitled to a cash bonus in an amount to be determined by the Board up to fifty percent (50%) of his base salary. Actinium Corporation also agreed to grant to Mr. Talley an option grant to purchase common shares of the Company equal to three percent (3.0%) of the Company&#8217;s issued and outstanding equity (common and preferred shares) on a fully diluted basis. Such options had an exercise price of $0.261 cents per share which is equal to fair market value as determined by the board on the date of the grant. Twenty-eight percent (28%) of the initial options granted shall vest twelve months after the date of grant and two percent (2%) of the remainder shall vest each month thereafter until fully vested. Additional options were to be granted upon the final closing of the Company&#8217;s next financing so that total options granted would equal three percent (3%) of fully diluted shares on that date. Such additional options will have an exercise price per share which is equal to fair market value as determined by the Board on the date of the grant. Two percent (2%) of such additional options shall vest each month thereafter until fully vested. The term of all options granted under this Agreement will be for 10 years from the date of grant, subject to your continuing service with the Company. On February 28, 2013, Mr. Talley resigned as Chief Executive Officer and Director of the Company and Actinium Corporation as per the terms of the Severance Agreement (as described below).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On January 2, 2006, Actinium Corporation entered into an employment agreement with Dragan Cicic, as our, Chief Operating Officer and Chief Medical Officer. The term of the employment agreement is one year; provided that the term shall be automatically extended for successive one year periods thereafter, unless, no later than 60 days prior to the expiration of any successive one-year renewal term, either party thereto provides the other party written notice of its desire not to extend the term.&#160;&#160;Actinium agreed to pay a base salary of $144,758 per annum during the term with an annual percentage increase of not less than an amount equal to the aggregate preceding 12 months annual percentage increase of the U.S. Department of Labor Consumer Price Index for All Urban Consumers (CPI-U) for the New York area.&#160;&#160;Mr. Cicic is also entitled to participate in any incentive compensation or bonus program which is instituted or maintained for company executives generally during the term of the agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On July 21, 2012, Actinium entered into an employment agreement with Enza Guagenti, as our Chief Financial Officer. Ms. Guagenti&#8217;s employment with the Company is on an &#8220;at will&#8221; basis, meaning that either Ms. Guagenti or the Company may terminate your employment at any time for any reason or no reason, without further obligation or liability, except that upon termination of Ms. Guagenti&#8217;s employment by the Company other than for cause Ms. Guagenti will be entitled to severance equal to 3 months base salary. In the event that a) the Company hires a CFO other than yourself, and 2) within two years thereafter Ms. Guagenti&#8217;s base salary is reduced below $115,000 per year, Ms. Guagenti may then within thirty days after the base salary reduction resign her position with the Company and collect the severance. Actinium Corporation agreed to pay an initial base salary of $90,000. Ms. Guagenti&#8217;s annual base salary will be increased to one hundred fifteen thousand dollars ($115,000) on the six month anniversary of the start date. Thereafter, before the beginning of each calendar year during the term of her employment, beginning in January 2014, the board shall review the amount of Ms. Guagenti&#8217;s base salary and performance bonus, and shall determine the appropriate adjustments to each component of her compensation for the following calendar year. The Company also agreed to grant to Ms. Guagenti an option grant to purchase 75,000 common shares of the Company. Such options will have an exercise price of $0.261 cents per share which is equal to fair market value as determined by the board on the date of the grant. Two percent (2%) of the options granted shall vest each month after the date of grant until fully vested. The term of all options granted under this Agreement will be for 10 years from the date of initial grant, subject to Ms. Guagenti&#8217;s continuing service with the Company. On March 9, 2013, Ms. Guagenti resigned as Chief Financial Officer of the Company and Actinium Corporation. Purusant to the terms of the employment agreement, Ms. Guagenti did not receive any severance payments upon resignation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Severance Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On February 28, 2013, the Company entered into a Separation and Settlement Agreement with Mr. Talley (the &#8220;Separation Agreement&#8221;). The Separation Agreement, among other things, provides for a cash payment in two (2) equal installments the aggregate amount of two hundred fifty thousand dollars ($250,000), with the first payment of $125,000 occurring on March 8, 2013 and the second payment of $125,000 occurring on September 1, 2013.&#160;&#160;The Company will also pay Mr. Talley (i) a discretionary performance bonus of $60,000 for the period of August 15, 2012 to December 31, 2012 and (ii) COBRA continuation coverage under the Company&#8217;s group health plan for six months.&#160;&#160;As part of the settlement Mr. Talley agreed to resign as a director from the Company and Actinium Corporation. The Separation Agreement also includes, subject to limited exceptions,&#160;mutual releases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Agreement with Dr. Mazanet</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On May 31, 2013, Dr. Rosemary Mazanet resigned as a director of the Company and Actinium Corporation, a subsidiary of the Company, to pursue other opportunities.&#160;&#160;Dr. Mazanet&#8217;s decision to resign from the board of directors of the Company was not based upon any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices as contemplated by Item 5.02(a) of Form 8-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On May 31, 2013, the Company and Actinium Corporation also entered into an agreement with Dr. Mazanet (the &#8220;Agreement&#8221;) which, among other things, provides for a cash payment to Dr. Mazanet of $25,000 in full satisfaction for all amounts owed under the Consulting Agreement.&#160;&#160;The parties also agreed that Dr. Mazanet is entitled to a total of 83,250 vested Company options (the Options&#8221;) which will be exercisable until the ten year anniversary of the grants, respectively.&#160;&#160;Dr. Mazanet agreed not to sell or otherwise transfer any shares of Company common stock underlying the Options or other securities of the Company owned by Dr. Mazanet until (i) the date that is the earlier of twelve (12) months from December 28, 2012; or (ii) six (6) months following the effective date of the Registration Statement filed by the Company with the Securities and Exchange Commission on March 15, 2013.&#160;&#160;Dr. Mazanet also resigned as a director from the Company and Actinium Corporation. The Agreement also includes, subject to limited exceptions,&#160;mutual releases, mutual non-disparagement clauses, and a non-solicitation provision.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<!--efplaceholder--><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a015v1">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table shows the beneficial ownership of our Common Stock as of January 22, 2014 held by (i) each person known to us to be the beneficial owner of more than five percent (5%) of any class of our shares; (ii) each director; (iii) each executive officer; and (iv) all directors and executive officers as a group.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beneficial ownership is determined in accordance with the rules of the SEC, and generally includes voting power and/or investment power with respect to the securities held.&#160;&#160;Shares of Common Stock subject to options and warrants currently exercisable or which may become exercisable within 60 days of January 22, 2014, are deemed outstanding and beneficially owned by the person holding such options or warrants for purposes of computing the number of shares and percentage beneficially owned by such person, but are not deemed outstanding for purposes of computing the percentage beneficially owned by any other person.&#160;&#160;Except as indicated in the footnotes to this table, the persons or entities named have sole voting and investment power with respect to all shares of our Common Stock shown as beneficially owned by them.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The percentages below are based on fully diluted shares of our Common Stock equivalents as of January 22, 2014.&#160;&#160; Unless otherwise indicated, the principal address of each of the persons below is c/o Actinium Pharmaceuticals, Inc., 501 Fifth Avenue, New York, NY 10017.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="71%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Executive Officers and Directors</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of<br>
Shares of<br>
Common Stock<br>
and Preferred<br>
Stock<br>
Beneficially<br>
Owned</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percentage of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ownership(a)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik Dave, PhD</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dragan Cicic, MD</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">258,413</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.04</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. David Nicholson</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,942</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.23</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sandesh Seth</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">183,345</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.74</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard I. Steinhart</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dr. Sergio Traversa</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,781</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.09</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">All Directors and Officers as a Group (4 persons)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">521,481</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.1</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" colspan="8" valign="bottom" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">All other 5% holders</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Holdings Ltd. (5)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c/o Sterling Management Limited</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">P.O. Box HM 1029</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Hamilton HM CX</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,702,387</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22.9</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;(a)&#160;&#160;</font></div>
</td>
<td valign="top" width="79%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on 24,903,150 shares of Common Stock outstanding as of January 22, 2014, and includes 400,000 shares of common stock of the Company that remained outstanding after the closing of the Share Exchange.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) Options granted to purchase an aggregate of 333,000 shares of Common Stock of the Company at an exercise price of $0.784 per share, options to purchase an aggregate of 99,900 shares of Common Stock of the Company at an exercise price of $1.50 per share, and options to purchase an aggregate of 81,784 shares of Common Stock of the Company at an exercise price of $1.35 per share. All shares are subject to vesting. 258,413 shares of Common Stock will have vested within 60 days of January 22, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) Options to purchase an aggregate of 49,950 shares of Common Stock of the Company at an exercise price of $0.784 per share and options to purchase an aggregate of 49,950 shares of Common Stock of the Company at an exercise price of $1.50 per share.&#160;&#160;All shares are subject to vesting. 57,942shares of Common Stock will have vested within 60 days of January 22, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3) Warrants to purchase an aggregate of 64,747 shares of Common Stock of the Company at an exercise price of $0.784 per share, exercisable on a cashless basis and warrants to purchase an aggregate of 99,617 of Common Stock of the Company at an exercise price of $0.784 per share, exercisable on a cashless basis issued to Amrosan, LLC, a partnership in which the majority member interest is owned by the family of Mr. Seth. Excludes warrants to purchase an aggregate of 375,556 shares of Common Stock of the Company at par value per share, exercisable on a cashless basis issued to Amrosan, LLC as the warrants are not exercisable upon less than 90 days notice. The holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver. The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transferred until the earlier of twelve months from December 28, 2012, the closing date of the going Share Exchange; or for six months after the Registration Statement of which this prospectus is a part is declared effective. Excludes 353,023 warrants issued to Carnegie Hill Asset Partners and irrevocable trust linked to Mr. Seth&#8217;s family and 721,068 warrants issued to Bioche Asset Management, LLC, a partnership in which the majority member interest is owned by the family of Mr. Seth whose terms are the same as those issued to Amrosan LLC. Also excludes warrants held by the Placement Agent or its affiliates in connection with the offering of common stock and Series A and Series B warrants that closed on December 19, 2012 (the &#8220;2012 Offering&#8221;), the Bridge Notes Financing, the Series E financing and by designees of Jamess Capital Group, LLC in connection with the Share Exchange. Also includes options to purchase an aggregate of 49,950 shares of Common Stock of the Company at an exercise price of $1.50 per share. All shares are subject to vesting.&#160;&#160;18,981 shares of Common Stock will have vested within 60 days of January 22, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4) Options to purchase an aggregate of 49,950 shares of Common Stock of the Company at an exercise price of $1.50 per share and options to purchase an aggregate of 20,000 shares of Common Stock of the Company at an exercise price of $3.60 per share.&#160;&#160;21,781 shares of Common Stock will have vested within 60 days of January 22, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5) Actinium Holdings Ltd., a Bermuda corporation (&#8220;AHL&#8221;), has entered the Share Exchange and a related Lock-up Agreement and is the record holder of the number of shares of Common Stock of the Company listed opposite its name.&#160;&#160;Michael Sheffrey&#160;has sole voting and investment power over the securities beneficially owned by Actinium Holdings Ltd.&#160;&#160;&#160;AHL is wholly owned by AHLB Holdings, LLC (&#8220;AHLB&#8221;), which in turn, is wholly owned by MSKCC.&#160;&#160; AHL, AHLB and MSKCC may be deemed to share investment and voting power and beneficial ownership of such shares.&#160;Investment power with respect to such shares is limited by AHL&#8217;s agreement not to transfer its shares of Common Stock, subject to exceptions for certain related-party transfers, transfers to trusts and other private transfers, until, in general, the earlier of (i) December 28, 2013 (the first anniversary of the closing of the Share Exchange); or (ii) six (6) months following the effective date of the Registration Statement of which this prospectus is a part.&#160;&#160;&#160;AHL is entitled to certain demand and &#8220;piggyback&#8221; registration rights with respect to its shares of Common Stock.&#160;&#160;The shares to be registered by AHL will, however, in certain circumstances, be subject to &#8220;cutback&#8221; (or reduction of the number of shares includible in an underwritten registration) prior to the &#8220;cutback&#8221; of the shares being registered on behalf of investors in certain recent private placements of the Company.<a name="ref_id0e5b"><!--EFPlaceholder--></a>&#160;&#160;&#160;&#160;</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a016v1">CERTAIN RELATIONSHIPS&#160;AND RELATED TRANSACTIONS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Transactions with Related Persons</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On January 18, 2001, Actinium Corporation entered into a Clinical Trial Agreement with MSKCC and Sloan-Kettering Institute of Cancer Research (SKI), an entity related to MSKCC. Through an indirect subsidiary, Actinium Holdings Ltd. (AHL), MSKCC has been a principal stockholder of the Company since April 2010. The agreement provided for the conduct by SKI/MSKCC of Phase 1/2 clinical trials of the use of 213Bi-Hu195and cytarabine for the treatment of acute myeloid leukemia and for Actinium Corporation&#8217;s partial sponsorship of the study in exchange for access to data resulting from the study. Actinium Corporation was obligated to pay SKI (a) $10,000 for each completed case report on a completed subject, and (b) $2,500 for each case report on an incomplete subject. The trial enrolled 31 patients, was completed in 2007 and all the money due to MSKCC and SKI were paid in full.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On February 11, 2002, Actinium Corporation entered into a License, Development and Commercialization Agreement with SKI (the &#8220;License Agreement&#8221;).&#160;&#160;The agreement was amended in August 2006.&#160;&#160;Pursuant to the agreement, Actinium Corporation licenses certain intellectual property from SKI, including critical patents with respect to Actinium Corporation&#8217;s core technology, and also supports ongoing research and clinical development of Actinium Corporation related drug candidates.&#160;&#160;Certain amounts due under this agreement were deferred and then forgiven under the forbearance-related arrangements described below.&#160;&#160;On June 19, 2011, Actinium Corporation nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments. Since January 1, 2011, the Company has paid $100,000 for 2012 under this Agreement and as of December 31, 2012, the Company agreed to pay an additional $150,000 for research to be conducted in 2013 under this agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On February 25, 2006, Actinium Corporation entered into a Clinical Trial Agreement with MSKCC and SKI.&#160;&#160; The agreement provides for the conduct by SKI/MSKCC of a Phase I clinical trials of the use of Actinium 225-HuM195 for the treatment of advanced myeloid malignancy and for Actinium Corporation&#8217;s partial sponsorship of the study in exchange for access to data resulting from the study.&#160;&#160;Actinium Corporation is obligated to pay SKI (a) $10,000 for each completed case report on a completed subject, and (b) $2,500 for each case report on an incomplete subject. As of December 21, 2012, 18 subjects had been enrolled in this study, and the parties intend to attempt to enroll and additional 3 subjects. The maximum compensation for which Actinium Corporation is responsible for under the agreement is $328,000. Since the inception of the trial in 2006, Actinium Corporation has paid $180,000 and since January 1, 2011, Actinium Corporation has paid $70,000 under the agreement.&#160;&#160;As of December 31, 2012, no monies were due under this agreement.&#160;&#160;The trial is ongoing and further fees are likely to be accrued as patients are enrolled.&#160;&#160;In January and February 2012, two additional patients were treated in this trial.&#160;&#160;We anticipate enrollment of one more additional patient under this agreement in 2013 and closing the trial after that.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In April 2010, SKI agreed, on behalf of itself and its related or affiliated entities, including MSKCC, to forbear from collecting or otherwise enforcing Actinium Corporation&#8217;s then outstanding obligations to those entities and similar obligations arising during a defined forbearance period.&#160;&#160;The initial outstanding obligations consisted of approximately $260,000 due under Actinium Corporation&#8217;s license and clinical trials agreements with those entities. In June 2011, SKI agreed to forgive all current and future obligations subject to the forbearance in order to facilitate Actinium Corporation&#8217;s financing efforts.&#160;&#160;The forbearance period terminated on October 30, 2011, when the Company satisfied a financing condition to the termination of the forbearance period by raising in excess of $3,000.000 in new equity financing.&#160;&#160;The total amount forgiven was approximately $360,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MSKCC agreed, subject to certain conditions, to utilize donated funds for certain clinical and preclinical programs and activities related to Actinium Corporation&#8217;s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by Actinium Corporation. The following is a summary of activities related to the MSKCC arrangements at December 31, 2011 and 2010:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="71%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Qualified R&amp;D costs incurred by Actinium Corporation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">655,786</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash received from MSKCC</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">237,834</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">966,341</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of December 31, 2011 and 2010, the Company had reimbursement receivables for costs incurred of $237,834 and $279,401 from MSKCC, respectively.&#160;&#160;These amounts have since been paid.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">From&#160;July through October 2011, AHL agreed, in connection with Actinium Corporation&#8217;s Stock offering, to waive its rights to anti-dilution adjustments in respect of its outstanding stock and its preemptive rights to purchase the Company&#8217;s stock from the Stock Offering.&#160;&#160;AHL also agreed to the restructuring of its registration rights in favor of the private placement purchasers, the amendment of the stockholders agreement of Actinium Corporation (to permit, among other transactions, the share exchange) and the relinquishment of its rights to Board representation, although one director originally nominated by AHL continued to serve.&#160;&#160;Actinium agreed (i) not to reduce the indemnification, advancement of expenses and similar rights of present and former directors and officers of Actinium Corporation, (ii) until April 30, 2016 to maintain directors&#8217; and officers&#8217; liability insurance at least in the same manner and to the same extent as then in effect, and (iii) following any merger, asset transfer and certain other transactions to provide for the parity of such directors and officers in respect of indemnification, advancement of expenses and D&amp;O liability insurance with such rights applicable to the non-continuing directors following such transactions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 27, 2012, Actinium Corporation entered into an additional clinical trial agreement with Memorial Sloan-Kettering Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&#160;&#160;Actinium Corporation will pay $31,185 for each patient that has completed the clinical trial.&#160;&#160;Upon execution of the agreement, Actinium Corporation was required to pay a start-up fee of $79,623, which was paid on July 10, 2012. The total number of patients anticipated to be enrolled at MSKCC in this trial is 15.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 4, 2013, the Company entered into a letter agreement with Sloan-Kettering Institute for Cancer Research (SKI) to set forth the amount that the Company owes SKI for the period of 2011 to 2014.&#160;&#160;The total amount that the Company owes SKI for the period of 2011 to 2014 is $815,100 plus all relevant licensed intellectual property related pass through costs to be determined.&#160;&#160;The amount owed does not include amounts the Company may owe for patent expenses under the License Agreement (as defined above).&#160;&#160;During the period to 2011 to 2013, the Company paid SKI a total of $321,500, reducing the total amount owed for the period of 2011 to 2014 to $493,600.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">AHL has agreed not to transfer its shares of Common Stock, subject to exceptions for certain related-party transfers, transfers to trusts and other private transfers, until, in general, the earlier of (i) December 28, 2013 (the first anniversary of the closing date of the Share Exchange); or (ii) six (6) months following the effective date of the Registration Statement of which this prospectus is a part.&#160;&#160;&#160;AHL will be entitled to certain demand and &#8220;piggyback&#8221; registration rights with respect to the shares of Common Stock that it may acquire.&#160;&#160;The shares to be registered by AHL will, however, in certain circumstances, be subject to &#8220;cutback&#8221; (or reduction of the number of shares includible in an underwritten registration) prior to the &#8220;cutback&#8221; of the shares being registered on behalf of investors in certain recent private placements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On January 1, 2012, Actinium Corporation entered into a Consulting Services Agreement with Dr. Rosemary Mazanet, a former director of Cactus.&#160;&#160;Pursuant to the agreement, Dr. Mazanet provided, among other things, consulting services in the areas of implementation of the Actimab&#8482;-A trial including all aspects of study initiation until first patient in at each clinical site.&#160;&#160;Dr. Mazanet received compensation of $100,000 per year.&#160;&#160;Since January 1, 2011, Dr. Mazanet has received options to purchase 225,000 shares of common stock of Actinium. Dr. Mazanet resigned as a director of the Company on May 31, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 7, 2012, Actinium Corporation entered into an engagement agreement with Laidlaw &amp; Company (UK) Ltd. (the &#8220;Placement Agent&#8221;) for the 2012 Offering, of which Mr. Seth, a director of the Company, is Head of Healthcare Investment Banking. Pursuant to the agreement, the Placement Agent was engaged as the exclusive agent for the 2012 Offering. None of the Company&#8217;s current officers or directors had a prior relationship or affiliation with the Company prior to the closing of the Share Exchange. In consideration for its services, the Placement Agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the Placement Agent. The Placement Agent or its designees have also received warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of Common Stock issued as part of the Units sold in the 2012 Offering and the shares of Common Stock issuable upon exercise of the B Warrants included in such Units. The Placement Agent will also receive 5% solicitation fee for any Warrants exercised as a result of being called for redemption by the Company. Upon the final closing of the 2012 Offering the Placement Agent was engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000. This financial advisory services terminated in March 2013.&#160;&#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the Placement Agent, the Placement Agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the Placement Agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement. For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the Placement Agent. The Placement Agent also was engaged by Actinium Corporation as placement agent for its Stock Offering and notes financing in 2011 and, as a part of the fee for that engagement, designees of the Placement Agent also hold warrants to purchase 1,245,226 shares of the Company&#8217;s Common Stock.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On May 9, 2011, Actinium Corporation entered into a transaction management agreement with Jamess Capital Group, LLC. (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Sandesh Seth, a Director of the Company.&#160; Mr. Seth is a Managing Partner of the consulting firm some of whose member interests are held by entities owned by officers and employees of the Placement Agent.&#160; None of the Company&#8217;s current officers or directors had a prior relationship or affiliation with the Company prior to the closing of the Share Exchange.&#160; Pursuant to the agreement, the management firm was engaged to provide consulting services to Actinium Corporation related to the consummation of a going public transaction for Actinium.&#160; The management firm received a monthly fee of $12,500 which is terminable by the Company three months after the effective date of the going public transaction and designees of Jamess, including entities affiliated with Mr. Seth, were issued warrants to purchase common stock equal to 10% of the fully-diluted capital stock of the Company as of the effective date of the going public transaction. The fully diluted shares for this calculation included all issued and outstanding shares as well as those reserved under the Employee Stock Option Plan.&#160; Jamess Capital Group does not retain&#160;beneficial ownership of the warrants as they were&#160;issued to designess of the members in amounts which do not qualify either Jamess or the warrant holders for inclusion in the beneficial ownership table.&#160; The warrants contain&#160;a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver.&#160; The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transferred until the earlier of twelve months from December 28, 2012, the closing date of the Share Exchange; or for six months after the Registration Statement of which this prospectus is a party declared effective.&#160;The consulting firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.&#160;&#160;The transaction management agreement was terminated on March 31, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In 2010, Actinium Corporation entered into an agreement with Guagenti &amp; Associates LLC (&#8220;G&amp;A&#8221;).&#160;&#160;G&amp;A is affiliated with Enza Guagenti, the former Chief Financial Officer of the Company.&#160;&#160;Pursuant to the agreement, API leases storage space in Newark, NJ from G&amp;A.&#160;&#160;The rent is $300 per month.&#160;&#160;The agreement is on a month-to-month basis and requires a 45-day notice by either party to cancel. Since January 1, 2011, the Company has paid $7,200 pursuant to this agreement.&#160;&#160;&#160;Ms. Guagenti resigned as our Chief Financial Officer on March 9, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 9, 2013, the Company entered into an engagement agreement with Laidlaw &amp; Company (UK) Ltd. (the &#8220;Placement Agent&#8221;) for the December 2013 Offering, of which Mr. Seth, a director of the Company, is Head of Healthcare Investment Banking. Pursuant to the agreement, the Placement Agent was engaged as the exclusive agent for the December 2013 Offering.&#160;&#160;In consideration for its services, the Placement Agent received (a) a cash fee equal to 10% of the gross proceeds raised in the December 2013 Offering, and (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the December 2013 Offering,. The Placement Agent or its designees have also received warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of Common Stock issued as part of the Units sold in the December 2013 Offering and the shares of Common Stock issuable upon exercise of the common stock warrants included in such Units. The Placement Agent will also receive the same fee and expense schedule for any cash exercise of Warrants within 6 months of the final closing of the December 2013 Offering and a 5% solicitation fee for any Warrants exercised as a result of being called for redemption by the Company. Upon the final closing of the December 2013 Offering the Placement Agent has been engaged by the Company to provide certain financial advisory services to the Company for a period of 6 months<font style="DISPLAY: inline; FONT-SIZE: 10pt">, unless extended by mutual consent between the Company and the Placement Agent</font> for a monthly fee of $25,000. The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the Placement Agent, the Placement Agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the Placement Agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the December 9, 2013 engagement agreement.</font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Non-Competition Agreements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our executive officers have signed non-competition agreements, which provide that all inventions become the immediate property of the Company and require invention assignments. The agreements provide that the executive officers will hold proprietary information in the strictest confidence and not use the confidential information for any purpose not expressly authorized by us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a017v1">DESCRIPTION OF&#160;SECURITIES</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Authorized Capital Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Introduction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In the discussion that follows, we have summarized selected provisions of our certificate of incorporation, bylaws and Delaware law relating to our capital stock. This summary is not complete. This discussion is subject to the relevant provisions of Delaware law and is qualified in its entirety by reference to our articles of incorporation and our bylaws. You should read the provisions of our certificate of incorporation and our bylaws as currently in effect for provisions that may be important to you.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Authorized Capital Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The total authorized shares of capital stock of the Company currently consists of 200,000,000 shares of common stock, par value $0.001 per share, and 50,000,000 shares of preferred stock, par value $0.001 per share.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Holders of our common stock are entitled to receive notice of and to attend all meetings of our stockholders, and to one vote for each share on all matters submitted to a stockholder vote.&#160;&#160;Holders of common stock do not have cumulative voting rights.&#160;&#160;Therefore, holders of a majority of the shares of common stock voting for the election of directors can elect all of the directors.&#160;&#160;Holders of our common stock representing a majority of the voting power of our capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of our stockholders.&#160;&#160;A vote by the holders of a majority of our outstanding shares is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to our articles of incorporation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In the event of liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock.&#160;&#160;Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of January 22, 2014 there were 24,903,150 shares of Common Stock issued and outstanding, which were held by 349 holders of record.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dividends</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Holders of common stock are entitled to share in all dividends that the board of directors, in its discretion, declares from legally available funds.&#160;&#160;We have not paid any cash dividends on our Common Stock and do not plan to pay any such dividends in the foreseeable future. We currently intend to use all available funds to develop our business. We can give no assurances that we will ever have excess funds available to pay dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Preferred Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are authorized to issue up to 50,000,000 shares of preferred stock, par value $0.001 per share, in one or more series as may be determined by our Board of Directors, who may establish, from time to time, the number of shares to be included in each series, may fix the designation, powers, preferences and rights of the shares of each such series and any qualifications, limitations or restrictions thereof. Any preferred stock so issued by the Board may rank senior to the common stock with respect to the payment of dividends or amounts upon liquidation, dissolution or winding up of us, or both. Moreover, while providing desirable flexibility in connection with possible acquisitions and other corporate purposes, under certain circumstances, the issuance of preferred stock or the existence of the unissued preferred stock might tend to discourage or render more difficult a merger or other change of control. We currently do not have any preferred stock outstanding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Common Stock Warrants have a five year term from each closing that occurred on December 27, 2013 and January 10, 2014, and are exercisable for an aggregate of up to 276,529 shares of the Company&#8217;s common stock at an initial per share exercise price of $9.00, subject to adjustment as set forth below.&#160; The Company may also call this warrant for redemption upon written notice to all warrant holders at any time the closing price of the common stock exceeds $15.00 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective registration statement covering the resale of the shares underlying the warrants.&#160;&#160;In the 60 business days following the date the redemption notice is deemed given in accordance with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying the then applicable exercise price per share for every share exercised.&#160;&#160;Any shares not exercised on the last day of the exercise period will be redeemed by the Company at $0.001 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The exercise prices of the Common Stock Warrants are subject to adjustment upon certain events. If the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series A &amp; Series B Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Series A Warrants had a 120 day term from January 28, 2013 and were exercisable for an aggregate of up to 3,118,968 shares of the Company&#8217;s common stock at an initial per share exercise price of $1.65, subject to adjustment as set forth below (anti-dilution).&#160;&#160;The Company also had a right of first refusal on the holder&#8217;s sale of the warrant shares.&#160;&#160;The Series A Warrants either expired on May 28, 2013 or were exercise prior to expiration.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Series B Warrants have a five year term from January 28, 2013 and are exercisable for an aggregate of up to 1,59,484 shares of the Company&#8217;s common stock at an initial per share exercise price of $2.48, subject to adjustment as set forth below.&#160;&#160;These warrants have a cashless exercise provision.&#160;&#160;The Company also has a right of first refusal on the holder&#8217;s sale of the warrant shares.&#160;&#160;The Company may also call this warrant for redemption upon written notice to all warrant holders at any time the closing price of the common stock exceeds $1.50 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective registration statement covering the resale of the shares underlying the warrants.&#160;&#160;In the 60 business days following the date the redemption notice is deemed given in accordance with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying the then applicable exercise price per share for every share exercised.&#160;&#160;Any shares not exercised on the last day of the exercise period will be redeemed by the Company at $0.001 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The exercise prices of the Series A Warrants and Series B Warrants are subject to adjustment upon certain events. If the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant issue date, as applicable, the Company shall issue any shares of common stock for no consideration or a consideration per share less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional adjustment determined by multiplying such warrant exercise price by the following fraction:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td nowrap valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) + N(1)</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</td>
<td valign="top" width="92%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="8%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) + N(2)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Where:</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) = the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of such additional shares of common stock or common stock Equivalents;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(1) = the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable, in effect immediately prior to such issuance; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(2) = the number of such additional shares of common stock so issued or deemed to be issued.</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock Offering Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Stock Offering Warrants have a term ending on January 31, 2019 and are exercisable for an aggregate of up to 2,700,971 shares of the Company&#8217;s common stock at an initial per share exercise price of $0.78, subject to adjustment as set forth below (anti-dilution).&#160;&#160;The Company also has a right of first refusal on the holder&#8217;s sale of the warrant shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">These warrants have a cashless exercise provision.&#160;&#160;The Company also has a right of first refusal on the holder&#8217;s sale of the warrant shares.&#160;&#160;&#160;The exercise prices of the Stock Offering Warrants are subject to adjustment upon certain events. If the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant issue date, as applicable, the Company shall issue any shares of common stock for no consideration or a consideration per share less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional adjustment determined by multiplying such warrant exercise price by the following fraction:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) + N(1)</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</td>
<td valign="top" width="92%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="8%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) + N(2)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Where:</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) = the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of such additional shares of common stock or common stock Equivalents;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(1) = the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable, in effect immediately prior to such issuance; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(2) = the number of such additional shares of common stock so issued or deemed to be issued.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consulting Firm Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Consulting Firm Warrants have a term ending on December 17, 2019 and are exercisable for an aggregate of up to 3,755,562 shares of the Company&#8217;s common stock.&#160;&#160;These warrants may not be exercised by the Holder upon less than 90 days prior written notice of such exercise and provided further that that the Holder may elect, in its sole discretion, to waive the Prior Notice Requirement, in whole or in part, upon 65 days prior written notice of such waiver.&#160;&#160;&#160;&#160;These warrants have a cashless exercise provision and were issued at an initial per share exercise price of $0.001, subject to adjustment as if the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.&#160;&#160;The warrants are also subject to piggy-back registration rights.&#160;&#160;The holder has also agreed that following the consummation of the pubco transaction (which occurred on December 28, 2012), the holder will not sell or otherwise transfer any shares of common stock of the Company owned by holder, as a result of the exercise of the warrant until the date that is the earlier of&#160;&#160;(i) twelve (12) months from the closing date of the pubco transaction; or (ii) six (6) months following the effective date of the Registration Statement of which this prospectus is a part.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Placement Agent Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company issued three types of warrants to the Placement Agent, Placement Agent Stock Offering Warrants, Placement Agent Common Stock Warrants, and Placement Agent December 2013 Offering Warrants.<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Placement Agent Stock Offering Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Placement Agent Stock Offering Warrants have a term ending on January 31, 2019 and are exercisable for an aggregate of up to 1,245,210 shares of the Company&#8217;s common stock at an initial per share exercise price of $0.78, subject to adjustment as set forth below (anti dilution).&#160;&#160;These warrants have a cashless exercise provision.&#160;&#160; The exercise prices of the warrants are subject to adjustment upon certain events. If the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant issue date, as applicable, the Company shall issue any shares of common stock for no consideration or a consideration per share less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional adjustment determined by multiplying such warrant exercise price by the following fraction:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) + N(1)</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</td>
<td valign="top" width="92%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="8%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) + N(2)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Where:</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) = the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of such additional shares of common stock or common stock Equivalents;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(1) = the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable, in effect immediately prior to such issuance; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(2) = the number of such additional shares of common stock so issued or deemed to be issued.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Placement Agent Common Stock Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Placement Agent Common Stock Warrants have a five year term from January 28, 2013 and are exercisable for an aggregate of up to 467,845 shares of the Company&#8217;s common stock at an initial per share exercise price of $2.48, subject to adjustment as set forth below.&#160;&#160;These warrants have a cashless exercise provision.&#160;&#160; The Company may also call this warrant for redemption upon written notice to all warrant holders at any time the closing price of the common stock exceeds $1.50 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective registration statement covering the resale of the shares underlying the warrants.&#160;&#160;In the 60 business days following the date the redemption notice is deemed given in accordance with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying the then applicable exercise price per share for every share exercised.&#160;&#160;Any shares not exercised on the last day of the exercise period will be redeemed by the Company at $0.001 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The exercise prices of the warrants are subject to adjustment upon certain events. If the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant issue date, as applicable, the Company shall issue any shares of common stock for no consideration or a consideration per share less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional adjustment determined by multiplying such warrant exercise price by the following fraction:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) + N(1)</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</td>
<td valign="top" width="93%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="8%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) + N(2)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Where:</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(0) = the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of such additional shares of common stock or common stock Equivalents;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(1) = the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable, in effect immediately prior to such issuance; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 153pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N(2) = the number of such additional shares of common stock so issued or deemed to be issued.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;Placement Agent December 2013 Offering Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Placement Agent December 2013 Offering Warrants have a five year term from January 10, 2014 and are exercisable for an aggregate of up to 138,265 shares of the Company&#8217;s common stock at an initial per share exercise price of $9.00, subject to adjustment as set forth below.&#160;&#160;These warrants have a cashless exercise provision.&#160;&#160; The Company may also call this warrant for redemption upon written notice to all warrant holders at any time the closing price of the common stock exceeds $15.00 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective registration statement covering the resale of the shares underlying the warrants.&#160;&#160;In the 60 business days following the date the redemption notice is deemed given in accordance with the agreement, investors may choose to exercise this warrant or a portion of the warrant by paying the then applicable exercise price per share for every share exercised.&#160;&#160;Any shares not exercised on the last day of the exercise period will be redeemed by the Company at $0.001 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The exercise prices of the warrants are subject to adjustment upon certain events. If the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Anti-takeover Effects of Our Articles of Incorporation and By-laws</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our certificate of incorporation and bylaws include provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us. These provisions encourage persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">No Cumulative Voting Rights.</font>&#160;&#160;According to our Bylaws and Articles of Incorporation, neither the holders of our common stock nor the holders of our preferred stock have cumulative voting rights in the election of our directors. The combination of the present ownership by a few stockholders of a significant portion of our issued and outstanding common stock and lack of cumulative voting makes it more difficult for other stockholders to replace our Board of Directors or for a third party to obtain control of our Company by replacing our Board of Directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Undesignated preferred stock.</font>&#160;&#160;We believe the availability of the preferred stock under our certificate of incorporation provides us with flexibility in addressing corporate issues that may arise. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could issue shares of preferred stock without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. Our board of directors will make any determination to issue shares based on its judgment as to our and our stockholders&#8217; best interests.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Staggered Board.</font> Pursuant to our Articles of Incorporation our directors are divided into three classes, designated Class I, Class II and Class III. Class I shall consists of two independent directors, Class II shall consist of two directors that were appointed as directors to Actinium Corporation by the holders of the former Series E preferred stock holders of Actinium Corporation, and Class III shall consist of the chief executive officer. Each director shall serve a term ending on the date of the third annual meeting of shareholders following the annual meeting at which the director was elected. Notwithstanding the foregoing, each director shall serve until his successor is duly elected and qualified, or until his or her retirement, death, resignation or removal. In order to implement a staggered board of directors, Class I shall serve a six month term from the date of incorporation; Class II shall serve an 18 month term from the date of incorporation; and Class II shall serve a 30 month term from the date of incorporation. Directors elected at each annual meeting commencing in 2013 shall be elected for a three year term as specified above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Anti-takeover Effects of Delaware Law</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are governed by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own, 15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing a change in our control.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Listing</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our common stock is listed on the OTCQB under the symbol &#8220;ATNM.&#8221; &#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Transfer Agent</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The transfer agent and registrar for our common stock is Action Stock Transfer Corporation. The transfer agent&#8217;s address is 2469 E. Fort Union Boulevard, Suite 214, Salt Lake City, UT 84121, and its telephone number is (801) 274-1088.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a018v1">PLAN OF DISTRIBUTION</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The common shares being offered for resale by the selling stockholders consist of 1,382,649 shares. We will pay any fees and expenses incurred by us incident to the registration of the securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We also have a resale registration statement that was declared effective by the Securities and Exchange Commission on November 8, 2013. The November 2013 prospectus covers the sale by the selling stockholders of up to (i) 16,162,319 shares of common stock, par value $0.001 per share, held by the selling stockholders, (ii) 1,559,438 shares of our common stock issuable upon exercise of Series B warrants held by the selling stockholders at an exercise price of $2.48 per share, (iii) 2,673,652 shares of our common stock issuable upon exercise of the 2011 stock offering warrants held by the selling stockholders at an exercise price of $0.78 per share, (iv) 3,755,562 shares of our common stock issuable upon exercise of consulting firm warrants held by the selling stockholders at an exercise price of $0.01 per share, (v) 1,120,499 shares of our common stock issuable upon exercise of placement agent warrants held by the selling stockholders at an exercise price of $0.78 per share, (vi) 464,027 shares of our common stock issuable upon exercise of placement agent warrants held by the selling stockholders at an exercise price of $2.48 per share.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each selling stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the OTCQB or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder may use any one or more of the following methods when selling securities:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">privately negotiated transactions;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities at a stipulated price per security;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a combination of any such methods of sale; or</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">any other method permitted pursuant to applicable law.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The selling stockholders may also sell securities under Rule 144 under the Securities Act, if available, rather than under this prospectus.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under applicable rules and regulations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of securities of the common stock by the selling stockholders or any other person. We will make copies of this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a019v1">SHARES ELIGIBLE FOR FUTURE SALE</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prior to this offering there has been a limited public market for our common stock, and a significant public market for our common stock may never develop or be sustained after this offering. We cannot predict the effect, if any, that market sales of shares or the availability of shares for sale will have on the market price prevailing from time to time. Only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. However, sales of our common stock in the public market after the restrictions lapse, or the perception that these sales may occur, could adversely affect the market price of our common stock and our ability to raise equity capital in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Upon completion of this offering, we expect to have 25,179,682&#160;shares of common stock outstanding. The&#160;1,382,649 shares of common stock being sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless the shares are purchased by "affiliates" of our company, as that term is defined in Rule&#160;144 of the Securities Act. All remaining shares were issued and sold by us in private transactions and are eligible for public sale only if registered under the Securities Act, or if they qualify for an exemption from registration, including, among others, the exemption provided by Rules&#160;144 promulgated by the SEC under the Securities Act.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Rule 144 is not available for resale of securities issued by any shell companies (other than business combination-related shell companies) or any issuer that has been at any time previously a shell company. The SEC has provided an exception to this prohibition, however, if the following conditions are met:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the issuer of the securities that was formerly a shell company has ceased to be a shell company;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the issuer of the securities has filed all Exchange Act reports and materials required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and</font></div>
</td>
</tr><tr>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#9679;</font></div>
</td>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As a result, none of our stockholders is currently able to sell shares of our common stock in reliance on Rule 144. Assuming we continue to meet the requirements set forth above, Rule 144 will become available to our stockholders one year from the date we filed the information required in SEC Form 10. Our stockholders may currently sell their shares of our common stock only pursuant to a registration statement that has been declared effective under the Securities Act or pursuant to another exemption from registration.</font></div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--><!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a020v1">LEGAL MATTERS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The validity of the shares of common stock offered by this prospectus and certain other legal matters as to Delaware law will be passed upon for us by Hiscock &amp; Barclay, LLP, Syracuse, New York. &#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a021v1">EXPERTS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our audited consolidated financial statements appearing in this prospectus and registration statement have been audited by GBH CPAs, PC, an independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a022v1">WHERE YOU&#160;CAN FIND MORE INFORMATION</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We filed with the SEC a registration statement under the Securities Act for the common stock in this offering. This prospectus does not contain all of the information in the registration statement and the exhibits and schedule that were filed with the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and the exhibits that were filed with the registration statement. Statements contained in this prospectus about the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and we refer you to the full text of the contract or other document filed as an exhibit to the registration statement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We file annual, quarterly, and current reports and other information with the SEC. Our filings with the SEC are available to the public on the SEC&#8217;s website at www.sec.gov. Those filings are also available to the public on our corporate website at&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">www.actiniumpharmaceuticals.com. The information we file with the SEC or contained on, or linked to through, our corporate website or any other website that we may maintain is not part of this prospectus or the registration statement of which this prospectus is a part. You may also read and copy, at the SEC&#8217;s prescribed rates, any document we file with the SEC, including the registration statement (and its exhibits) of which this prospectus is a part, at the SEC&#8217;s Public Reference Room located at 100 F Street, N.E., Washington, D.C. 20549. You can call the SEC at 1-800-SEC-0330 to obtain information on the operation of the Public Reference Room.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="a023v1">FINANCIAL STATEMENTS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For period ended September 30, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The accompanying financial statements have been prepared by the Company and are unaudited. &#160;In the opinion of management, all adjustments (which include&#160;all normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2013 and 2012 and for the periods then ended have been made. &#160;Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. &#160;It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s audited financial statements for the year ended December 31, 2012. &#160;The results of operations for the period ended September 30, 2013 are not necessarily indicative of the operating results for the full year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Balance Sheets</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Assets:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,990,063</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">167,143</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Current Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,043,063</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,785,812</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net of accumulated depreciation</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,918</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,010</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4,049,981</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,788,822</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities and Stockholders&#8217; Equity</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">312,001</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">897,044</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses - related party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">375,686</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,185</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Note payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">140,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,757,966</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Current Liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,445,653</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,643,187</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,445,653</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,643,187</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commitments and contingencies</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholders&#8217; Equity:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred stock, $0.001 par value; 10,000,000 authorized</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0 shares issued and outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.001 par value; 100,000,000 shares authorized;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,656,582 and 21,391,665 shares issued and outstanding, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,657</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,392</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,218,085</font></div>
</div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56,867,706</font></div>
</div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit accumulated during the development stage</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(60,637,414</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(55,743,463</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Stockholders&#8217; Equity</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">604,328</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,145,635</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Liabilities and Stockholders&#8217; Equity</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4,049,981</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,788,822</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">from June 13, 2000</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the nine months ended</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Inception) to</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Operating expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development, net of reimbursements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">778,232</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,677,301</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,373,200</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,723,459</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,793,719</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">830,730</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">722,037</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,730,233</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,520,221</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,235,208</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">429</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,262,462</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on disposition of equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">554,308</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,608,962</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,399,450</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,107,555</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,244,109</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,845,697</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loss from operations</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,608,962</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,399,450</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,107,555</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,244,109</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(59,845,697</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other income (expense):</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,299</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(318,623</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,508</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(952,241</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,967,215</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on extinguishment of liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">260,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value - derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">189,348</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(294,381</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">216,112</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(287,604</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">915,498</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total other income&#160;(expense)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">188,049</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(613,004</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">213,604</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,239,845</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(791,717</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(1,420,913</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(3,012,454</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(4,893,951</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(5,483,954</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(60,637,414</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net loss per common share&#160;&#160;- basic and diluted</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.06</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3.76</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.22</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6.84</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted average number of common shares outstanding - basic and diluted</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,601,895</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">801,799</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,401,711</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">801,799</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Cash Flows</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Nine</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Nine</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">from June 13, 2000</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Months Ended</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Months Ended</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Inception) to</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Operating Activities:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,893,951</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,483,954</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(60,637,414</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">284,371</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">312,500</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,336,407</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">429</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,262,462</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on disposition of equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">554,308</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of debt discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">678,116</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">900,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of deferred financing costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">219,725</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">292,692</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on extinguishment of liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(260,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value&#160;derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(216,112</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">287,604</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(915,498</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Increase) decrease in:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">114,143</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,386</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">87,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase (decrease) in:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(585,043</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">173,614</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">653,730</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued liabilities - related party</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">344,501</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,100</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">375,686</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash&#160;Used In Operating Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,947,969</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,795,480</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(49,350,627</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Investing Activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payment made for patent rights</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,000,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchase of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,030</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,812</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(823,689</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used In Investing Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,030</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,812</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,823,689</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Financing Activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Borrowings on convertible debt, net of offering costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">645,888</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments on note payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(140,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(140,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sales of common stock, net of offering costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">660,163</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,191,098</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from the exercise of warrants for cash</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,467,393</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,467,393</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided By Financing Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,327,393</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">660,163</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,164,379</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net change&#160;&#160;in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,628,606</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,137,129</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,990,063</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash at beginning of period</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,703,798</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash at end of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3,990,063</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2,566,669</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3,990,063</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental disclosures of cash flow information:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for interest</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">561</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,243</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" colspan="4" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental disclosure of non-cash investing and financing activities:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beneficial conversion feature discount</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">372,850</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued with debt</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">377,150</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued with stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">318,087</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,985,238</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued to the placement agent</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">159,044</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,170,282</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of notes payable and accrued interest to stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">981,729</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transfer from derivative liability classification to equity classification</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">600,880</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,832,204</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying notes to consolidated&#160;financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nature of Business &#8211;</font> Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that was in the market for a merger with an appropriate operating company.</font></font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Presentation - Unaudited Interim Financial Information &#8211;</font> The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Principles of Consolidation &#8211;</font> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reclassification &#8211;</font> Certain prior period amounts have been reclassified to conform to current period presentation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2013 and December 31, 2012, all of the Company&#8217;s cash was deposited in one bank.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Impairment of Long-Lived Assets &#8211;</font> Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity&#8217;s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liabilities:</font></div>
</td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;At September 30, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,757,966</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,757,966</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;At December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same.&#160;&#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the nine months ended September 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,441,942 shares of the Company&#8217;s common stock. For the nine months ended September 30, 2012, potentially issuable shares included stock options to purchase 1,968,829 shares; warrants in the amount of 5,861,044 shares; convertible notes payable in the amount of 1,152,692 shares; and convertible preferred stock in the amount of 13,831,762 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 2 &#8211; Going Concern</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $4,893,951 and net cash used in operations of $4,947,969, for the nine months ended September 30, 2013; and a deficit accumulated during the development stage of $60,637,414 at September 30, 2013. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The ability of the Company to continue its operations is dependent on the successful execution of management&#8217;s plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 3 &#8211; Property and Equipment</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment consisted of the following at September 30, 2013 and December 31, 2012:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="57%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Lives</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="57%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office equipment</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;5 years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">162,384</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">156,162</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and fixture</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;7 years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,100</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,292</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="57%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total property and equipment</font></div>
</td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">165,484</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">157,454</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated depreciation</font></div>
</td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(154,444</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(154,444</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="57%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on disposition of equipment</font></div>
</td>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,122</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="57%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="57%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font></div>
</td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,918</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,010</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation expense for the nine months ended September 30, 2013 and 2012 were $0 and&#160;$429 respectively.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 4 &#8211; Note Payable</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, the Company entered into a premium finance agreement to pay a $140,000 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and&#160;is required&#160;to pay $12,636 in monthly installment for nine months. As of September 30, 2013, the outstanding balance related to the premium finance agreement was $0.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 5 &#8211; Derivatives</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Activities for derivative warrant instruments during the nine months ended September 30, 2013 were as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair Value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,146,338</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification to paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,130,536</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(600,880</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(216,112</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, September 30, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,015,802</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,757,966</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at September 30, 2013 and December 31, 2012.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September 30,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Market value of common stock on measurement date (1)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.17</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.65</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjusted exercise price</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.48 - $0.81</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.50 - $2.475</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate (2)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.10% - 0.77</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.33</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant lives in years</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4 months/5 years</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0 days/4.22 years</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility (3)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">125% - 161</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">139</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected dividend yield (4)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Probability of stock offering in any period over 5 years (5)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25% - 40</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td valign="top" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The market value of common stock is based on an enterprise valuation.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td valign="top" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td valign="top" width="87%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4)</font></div>
</td>
<td valign="top" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5)</font></div>
</td>
<td valign="top" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 6 &#8211; Commitments and Contingencies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employment Contracts</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 16, 2013, the Company&#8217;s Board of Directors appointed Dr. Kaushik J. Dave as its new Chief Executive Officer (CEO)&#160;and Director. Material terms of the Employment Agreement are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">a</font></div>
</td>
<td align="left" valign="top" width="97%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A base salary at an annual rate of $350,000, which will be re-evaluated upon the&#160;six month anniversary of the start date and reimbursement of certain expenses.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="97%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">b</font></div>
</td>
<td valign="top" width="97%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The CEO shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to which the Board shall award bonuses to the CEO, based upon the achievement of written individual and corporate objectives such as the Board shall determine.&#160;&#160;Upon the attainment of such performance objectives, the CEO shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="97%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">c</font></div>
</td>
<td valign="top" width="97%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An option to purchase common shares of the Company and restricted stock (the &#8220;Grant&#8221;).&#160;&#160;The Grant will consist of (i) an option grant to purchase 675,000 common shares of the Company; (ii) 125,000 shares of restricted and (iii) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work.&#160;&#160;An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date.&#160;&#160;As of October 25, 2013, the option has not been granted by the Board.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">License and Research Agreements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a.&#160;&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="78%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4) Biological License Application filing with U.S. FDA</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5) First commercial sale</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6) after the first $10,000,000 in net sales</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&#160;&#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Memorial Sloan Kettering Cancer Center (MSKCC) &#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and annual research funding of $50,000 for as long as the agreement is in force.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="78%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval for each licensed product</font></div>
</div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company expects to file the NDA for regulatory approval in the 2016-2017 time frame.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oak Ridge National Laboratory (ORNL) &#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&#160;&#160;The Company is currently negotiating the 2013 agreement.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase I and Phase II.&#160;&#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&#160;&#160;The down payment totaling $239,000 was paid in 2007 and 2012.&#160;&#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&#160;&#160;The total project is now estimated at approximately $2.2 million.&#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;e.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&#160;&#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&#160;&#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&#160;&#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&#160;&#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&#160;&#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&#160;&#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&#160;&#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 27, 2012, the Company entered into a clinical trial agreement with MSKCC.&#160;The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623.&#160;&#160;The amount due of $79,623 was paid on July 10, 2012.</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="84%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">g.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&#160;&#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $19,749.&#160;&#160;During the clinical trial additional fees apply and will be invoiced when applicable.&#160;&#160;The amount due has not been invoiced but accrued by the Company as of September 30, 2013.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">h.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&#160;&#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&#160;&#160;The estimated cost is based on treating 24 patients through 2013.&#160;&#160;Upon execution of the agreement, the Company is required to make a payment of $33,946.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">i.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="84%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">j.&#160;&#160;</font></div>
</td>
<td valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&#160;New York, NY. The agreement terminated on May 31, 2013. On June 1, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&#160;New York, NY. This agreement terminates on December 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination. The Company paid a one month refundable deposit.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On&#160;February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO. Pursuant to the agreement, the Company paid the former CEO $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid the former CEO a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 7 &#8211; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Approval of the 2013 Stock Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Board approved the Company&#8217;s 2013 Stock Plan.&#160;&#160;The expiration date of the plan is September&#160;&#160;9, 2023&#160;and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 2,750,000 shares.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Approval of the Equity Incentive Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Board approved the Company&#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September&#160;&#160;9, 2023&#160;&#160;and the total number of shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 450,000 shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following is a summary of&#160;option activities:</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,330,134</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.96</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.91</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">685,800</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cancellation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(49,950</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, September 30, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,280,184</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.95</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.17</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,609,035</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30, 2013&#160;was $1,014,474.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following is a summary of warrant activities:</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,770,636</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.97</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.48</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 6,114,768</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,304,910</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.65</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants expired</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,023,784</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.65</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, September 30, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,441,942</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0. 77</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.09</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,611,403</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the three months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $95,971, and $72,100, respectively. During the nine months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $284,371 and $168,000, respectively.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 8 &#8211; Subsequent Events</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management has evaluated subsequent events and has concluded no events warrant disclosure.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: gainsboro" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="TEXT-ALIGN: left; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc"><!--EFPlaceholder--><font style="FONT-STYLE: italic; DISPLAY: inline">TABLE OF CONTENTS</font></a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of December 31, 2012 and 2011 and for the period</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">from June 13, 2000 (inception) to December 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">To the Board of Directors</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Newark, NJ</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have audited the accompanying consolidated balance sheets of Actinium Pharmaceuticals, Inc. (Formerly Cactus Ventures, Inc.) (a Development Stage Company) (the &#8220;Company&#8221;) as of December 31, 2012 and 2011, and the related consolidated statements of operations, changes in stockholders&#8217; equity and cash flows for the years then ended and for the period from June 13, 2000 (Inception) to December 31, 2012. These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Actinium Pharmaceuticals, Inc. (Formerly Cactus Ventures, Inc.) as of December 31, 2012 and 2011 and the results of their operations and their cash flows for the years then ended and for the period from June 13, 2000 (Inception) to December 31, 2012, in conformity with accounting principles generally accepted in the United States of America.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has not generated any revenue since its inception, has a history of operating losses, and has an accumulated deficit since its inception. Those conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to those matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ GBH CPAs, PC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GBH CPAs, PC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">www.gbhcpas.com</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Houston, Texas</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 15, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Balance Sheets</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ASSETS</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current assets:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,703,798</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;R&amp;D reimbursement receivable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">237,834</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">167,143</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,384</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Deferred financing costs, net of accumulated amortization</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">252,248</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Total current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,785,812</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,199,264</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net of accumulated depreciation</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,010</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,233</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TOTAL ASSETS</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,788,822</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,200,497</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">897,044</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">644,511</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Accounts payable and accrued expenses &#8211; related party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,185</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Note payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">140,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Convertible notes payable, net&#160;of unamortized discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">124,363</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,439,613</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Total current liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,643,187</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,208,487</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Commitments and contingencies</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity:</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Preferred stock, $0.01 par value; 100,000,000 shares authorized;&#160;0 shares issued and outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Common stock, $0.01 par value, 100,000,000 shares authorized; 21,391,665 and 13,664,802 shares issued and outstanding, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">213,916</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">136,648</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Additional paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56,675,182</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,237,620</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Deficit accumulated during the development stage</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(55,743,463</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47,382,258</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Total stockholders&#8217; equity</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,145,635</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">992,010</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,788,822</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,200,497</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying summary of accounting policies and notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the Period</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the Years Ended</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">from June 13,</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2000 (Inception) to</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Research and development, net of reimbursements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,440,485</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">323,788</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,420,519</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,506,232</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,959,246</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,504,975</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Depreciation and amortization expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">581</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">633</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,262,462</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Loss on disposition of equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">550,186</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,947,298</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,283,667</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54,738,142</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss from operations</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,947,298</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,283,667</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(54,738,142</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other (income) expense:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,099,327</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">175,094</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,964,707</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Gain on extinguishment of liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(260,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on change in fair value of derivative&#160;liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(685,420</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,966</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(699,386</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Total other (income) expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">413,907</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">161,128</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,005,321</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,361,205</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,444,795</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(55,743,463</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss per common share - basic and diluted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7.58</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4.30</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average number of common shares outstanding - basic and diluted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,103,521</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">801,799</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying summary of accounting policies and notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statement of Changes in Stockholders&#8217; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period From June 13, 2000 (Inception)&#160;to December 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paid-in</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capital</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stage</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity (Deficit)</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of founder shares</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">999,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,990</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of&#160;stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">145,687</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,457</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,748,543</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(672,286</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(672,286</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2000</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,144,687</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,447</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,768,553</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(672,286</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,107,714</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">187,313</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,873</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,248,127</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,250,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,090,621</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,090,621</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2001</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,332,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,320</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,016,680</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,762,907</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,732,907</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">180,375</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,804</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,248,196</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,250,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,192,384</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,192,384</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2002</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,512,375</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,124</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,264,876</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,955,291</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,675,291</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">208,992</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,090</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,779,160</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,781,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,532,044</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,532,044</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2003</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,721,367</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,214</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,044,036</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,487,335</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,573,915</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">765,900</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,659</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,592,341</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,600,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,734,791</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,734,791</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2004</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,487,267</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,873</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,636,377</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(18,222,126</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">439,124</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">649,350</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,494</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,893,506</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,900,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">315,388</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">315,388</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,580,237</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,580,237</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2005</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,136,617</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,367</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,845,271</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(22,802,363</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,275</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying summary of accounting policies and notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statement of Changes in Stockholders&#8217; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period From June 13, 2000 (Inception)&#160;to December 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Continued)</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paid-in</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capital</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stage</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity (Deficit)</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2005</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,136,617</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,367</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,845,271</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(22,802,363</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,275</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">839,042</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,390</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,542,151</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,550,541</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">252,308</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">252,308</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,053,362</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,053,362</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2006</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,975,659</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">39,757</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,639,730</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(28,855,725</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,823,762</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">732,600</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,326</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,592,674</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,600,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock issued for services</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,402</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">664</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">398,146</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">398,810</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">255,061</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">255,061</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,617,581</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,617,581</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2007</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,774,661</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47,747</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,885,611</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(34,473,306</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,460,052</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">999,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,990</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,990,010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,000,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">269,618</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">269,618</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,570,905</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,570,905</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2008</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,773,661</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,737</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,145,239</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(40,044,211</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,158,765</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112,382</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112,382</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,425,986</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,425,986</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2009</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,773,661</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,737</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,257,621</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(43,470,197</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">845,161</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,166</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,166</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(467,266</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(467,266</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,773,661</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,737</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,278,787</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(43,937,463</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">399,061</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying summary of accounting policies and notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statement of Changes in Stockholders&#8217; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period From June 13, 2000 (Inception)&#160;to December 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Continued)</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paid-in</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217;</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capital</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stage</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity (Deficit)</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,773,661</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,737</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,278,787</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(43,937,463</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">399,061</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,891,141</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,911</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,300,456</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,379,367</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,935</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,935</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,153,442</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,153,442</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of derivative warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,887,850</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,887,850</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beneficial conversion feature discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">372,850</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">372,850</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,444,795</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,444,795</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,664,802</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">136,648</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,237,620</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47,382,258</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">992,010</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087,747</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,877</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,089,063</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,129,940</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of notes payable and accrued interest to stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,252,550</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,525</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">969,204</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">981,729</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares issued at the reverse merger</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,386,566</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,866</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23,866</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">266,172</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">266,172</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,957,754</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,957,754</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of derivative warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,052,089</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,052,089</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transfer&#160;from liability&#160;classification to equity classification</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,231,324</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,231,324</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,361,205</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,361,205</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balances, December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,391,665</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">213,916</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56,675,182</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(55,743,463</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,145,635</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying summary of accounting policies and notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Statements of Cash Flows</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the Year Ended December 31,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the Period</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">from June 13,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2000 (Inception) to</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,361,205</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,444,795</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(55,743,463</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Adjustments to reconcile net loss to net cash used in operating activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,223,926</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,173,377</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,052,036</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depreciation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">581</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">633</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,262,462</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Loss on disposition of equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">550,186</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of debt discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">775,637</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">124,363</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">900,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of deferred financing costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">252,248</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,444</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">292,692</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain on extinguishment of liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(260,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain on change in fair value of derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(685,420</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,966</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(699,386</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;R&amp;D reimbursement receivable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">234,088</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41,567</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,746</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(18,013</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,766</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23,397</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">334,263</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">556,019</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,238,773</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable and accrued expenses - related parties</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;31,185</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,185</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Net cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,212,710</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(517,592</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(44,402,658</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payment made for patent rights</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,000,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchases of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,359</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(815,659</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Net cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,359</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,815,659</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Borrowings on convertible debt, net of offering costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">645,888</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">645,888</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sales of stock, net of offering costs</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,129,940</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,379,367</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,191,098</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Net cash provided by financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,129,940</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,025,255</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,836,986</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase (decrease) in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(85,129</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,507,663</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash at beginning of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,703,798</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">196,135</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash at end of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,703,798</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SUPPLEMENTAL CASH FLOWS INFORMATION:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Income tax</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Interest</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">682</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" colspan="4" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NONCASH INVESTING AND FINANCING ACTIVITIES:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Beneficial conversion feature discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">372,850</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">372,850</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Fair value of warrants issued with debt</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">377,150</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">377,150</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Fair value of warrants issued with stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,393,338</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,591,900</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,985,238</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Fair value of warrants issued to the placement agent</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">658,753</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,484,529</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,170,282</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Conversion of notes payable and accrued interest to stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">981,729</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">981,729</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Transfer&#160;from liability&#160;classification to equity classification</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,231,324</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,231,324</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying summary of accounting policies and notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Nature of Business &#8211; Actinium Pharmaceuticals, Inc (Formerly</font> Cactus Ventures, Inc.) (the &#8220;Company&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that is in the market for a merger with an appropriate operating company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company agreed to acquire 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange was closed on December 28, 2012 when shareholders representing over 20% of the issued and outstanding shares of Actinium had finished the exchange process.&#160;&#160;On August 22, 2013, shareholders representing 38% of the issued and outstanding shares of Actinium completed the exchange.&#160;&#160;As a result of the Share Exchange, the former shareholders of Actinium became the controlling shareholders of the Company. At the closing, each Actinium shareholder shall receive 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Cactus common stock for each Actinium share exchanged. At the closing, all of the Actinium shareholders&#8217; options and warrants to purchase Actinium common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Cactus common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein Actinium is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Actinium, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &#160;Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; As a result of the Share Exchange, the Company is now a holding company operating through Actinium, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Principles of Consolidation &#8211;</font> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Reclassification &#8211;</font> Certain prior period amounts have been reclassified to conform to current period presentation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At December 31, 2012 and 2011, all of the Company&#8217;s cash was deposited in one bank.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Impairment of Long-Lived Assets &#8211;</font> Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity&#8217;s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of December 31, 2012 and 2011. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;At December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;At December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,439,613</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,439,613</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been anti dilutive. For the year ended December 31, 2012, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,596 shares of the Company&#8217;s common stock. For the year ended December 31, 2011, potentially issuable shares includes options and warrants&#160;to purchase 273,859 shares of the Company&#8217;s common stock and notes payable convertible to 3,448,276 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events from January 1, 2013 through March 15, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Note 2 &#8211; Going Concern</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $8,361,205 and net cash used in operations of $5,212,710, for the year ended December 31,&#160;2012; and an accumulated deficit of $55,743,463 at December 31, 2012. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The ability of the Company to continue its operations is dependent on the successful execution of management&#8217;s plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 3 &#8211; Related Party Transactions</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MSKCC:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI),&#160;an entity related to MSKCC.&#160;&#160;The agreement was amended in August 2006.&#160;&#160;Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect to the Company&#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates.&#160;&#160;Certain amounts due under this agreement were deferred and then forgiven under the forbearance-related arrangements described above.&#160;&#160;On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments. Since January 1, 2011, the Company has paid $100,000 under this agreement and as of December 31, 2012, the Company agreed to pay an additional $150,000 for research to be conducted in 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&#160;&#160;The Company will pay $31,185 for each patient that has completed the clinical trial.&#160;&#160;Upon execution of the agreement, the Company was required to pay a start-up fee of $79,623, which was paid on July 10, 2012.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; MSKCC agreed, subject to certain conditions, to utilize the donated funds for certain clinical and preclinical programs and activities related to the Company&#8217;s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by the Company. The following is a summary of activities related to the MSKCC arrangements for years ended December 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Qualified R&amp;D costs incurred by the Company</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">655,786</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reimbursements received from MSKCC</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">237,834</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">966,341</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In 2012 and 2011, the Company received total R&amp;D reimbursement payments of $237,834 and $299,200, respectively, from MSKCC.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; As of December 31, 2012 and 2011, the Company had a net receivable of $0 and $237,834, respectively, from MSKCC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dr. Rosemary Mazanet:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On January 1, 2012, the Company entered into a Consulting Services Agreement with Dr. Rosemary Mazanet, a director of Cactus.&#160;&#160;Pursuant to the agreement, Dr. Mazanet is to provide, among other things, consulting services in the areas of implementation of the Actimab&#8482;-A trial including all aspects of study initiation until first patient in at each clinical site.&#160;&#160;Dr. Mazanet receives compensation of $100,000 per year and may receive additional compensation in the form of options at determined by the board of the Company.&#160;&#160;Since January 1, 2011, Dr. Mazanet has also received options to purchase 99,900 shares of common stock of the Company. These options have exercise price ranging from $0.78 to $1.5 and have a life of 10 years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Jamess Capital Group, LLC:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On May 9, 2011, the Company entered into a transaction management agreement with Jamess Capital Group, LLC. (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Sandesh Seth, a Director of the Company&#160;(&#8220;Management Firm&#8221;).&#160; The Management Firm received a monthly fee of $12,500 which is terminable by the Company three months after the effective date of the going public transaction and designees of Jamess, including entities affiliated with Mr. Seth, were issued warrants to purchase common stock equal to 10% of the fully-diluted capital stock of the Company as of the effective date of the going public transaction. The fully diluted shares for this calculation included all issued and outstanding shares as well as those reserved under the Employee Stock Option Plan.&#160; The Management Firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Placement Agent:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On August 7, 2012, the Company entered into an engagement agreement with its placement agent for the 2012 Common Stock Offering,&#160;of which Mr. Seth, a director of the Company is Head of Healthcare Investment Banking.&#160;&#160;&#160;Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &#160;&#160;In consideration for its services, the placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&#160;&#160;The placement agent or its designees have also received warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.&#160;&#160;The placement agent will also receive the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company.&#160;&#160;Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent has been engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000.&#160;&#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.&#160;&#160;For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent.&#160;&#160;The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&#8217;s Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Guagenti &amp; Associates LLC:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In 2010, the Company entered into an agreement with Guagenti &amp; Associates LLC (&#8220;G&amp;A&#8221;).&#160;&#160;G&amp;A is affiliated with Enza Guagenti, the former Chief Financial Officer of Cactus.&#160;&#160;Pursuant to the agreement, the Company leases storage space in Newark, NJ from G&amp;A.&#160;&#160;The rent is $300 per month.&#160;&#160;Since January 1, 2011, the Company has paid $7,200 pursuant to this agreement.&#160;&#160;&#160;Ms. Guagenti resigned as the Company&#8217;s Chief Financial Officer on March 9, 2013.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 4 &#8211; Property and Equipment</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; Property and equipment consisted of the following at December 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Lives</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office equipment</font></div>
</td>
<td valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;5 years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">156,162</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">153,804</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and fixture</font></div>
</td>
<td valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;7 years</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,292</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,292</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total property, plant and equipment</font></div>
</td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">157,454</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">155,096</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated depreciation</font></div>
</td>
<td align="left" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(154,444</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(153,863</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment</font></div>
</td>
<td align="left" valign="bottom" width="10%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,010</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,233</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Depreciation expense for the years ended December 31, 2012 and 2011 were $581 and $633, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 5 &#8211; Note Payable and Convertible Notes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Note Payable</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 28, 2012, the Company entered into a premium finance agreement to pay $140,000 premium of its director and officer insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and has to pay $12,636 in monthly installment for nine months. As of December 31, 2012, outstanding balance related to the premium finance agreement was $140,000.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Notes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 27, 2011, the Company completed a private offering of 8% Senior Subordinated Unsecured Convertible Promissory Notes (&#8220;Convertible Notes&#8221;) in the amount of $900,000 and received net proceeds of $750,000. The convertible notes were issued at 83.33% of the principal amount resulting in an original issue discount of $150,000.&#160;The Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount, accrued semi-annually and to be paid at maturity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The principal amount of the Convertible Notes and accrued interest are automatically converted to common stock at the earlier of: (1) the effective date of a Qualified Public Offering, (2) a Public Company Transaction, defined as (i) a reverse merger or similar transaction between the Company and a corporation whose securities are publicly traded in the United States or other jurisdiction mutually agreed between the Company and Placement Agent, or (ii) the quotation of the Company&#8217;s securities for purchase and sale on a U.S. quotation service, or (iii) the filing with an applicable regulatory body which will result in the Company becoming an entity whose securities are traded on a public exchange in the U.S. or other mutually agreed upon jurisdiction, or (3) the acquisition or receipt by the Company of no less than $4,000,000 of gross proceeds in subsequent offerings of its common stock or equivalents following the issuance of the Company&#8217;s stock (See Note 9) and the Convertible Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In connection with the issuance of the Convertible Notes, warrants to purchase a total of 287,061 shares of common stock were issued to investors. The Placement Agent and the Management Firm (See Note 9) were issued warrants to purchase 143,532 shares and 126,829 shares of common stock, respectively. The warrants issued to the Placement Agent are exercisable at $0.78 per share and expire on January 31, 2019. &#160;The warrants issued to the Management Firm are exercisable at $0.01 per share and expire on January 31, 2019.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company analyzed the Convertible Notes and the Warrants for derivative accounting consideration under FASB ASC 470 and determined that the investor warrants and the placement agent warrants, with a grant date fair value of $565,729 (See Note 6), qualified for accounting treatment as a financial derivative (See Note 6) and the Convertible Notes were determined to also have a beneficial conversion feature discount of $372,850 resulting from the conversion price of $0.78 per share which is below the fair value of $1.11 per share on the date of the Convertible Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The total fees, including cash payments and the fair value of the warrants issued to the Placement Agent, incurred in connection with the financing were $292,692. These fees were amortized over the life (one year) of the Convertible Notes using the straight-line method as it approximates the effective interest method. &#160;The $150,000 original issue discount on the Convertible Notes was also amortized over the life of the Notes on a straight line basis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On October 23, 2012, the investors extended the note maturity date for 90 days. The maturity date of the notes has been extended to January 31, 2013, February 18, 2013 or March 27, 2013 for the 24 notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 19, 2012, the Convertible Notes and the accrued interests were automatically converted to common stock when the Company closed on an offering of its common stock in which the gross proceeds exceeded the $4,000,000 threshold.&#160;&#160;The Convertible Notes and accrued interest were converted into 1,252,550 shares of the Company&#8217;s common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the years ended December 31, 2012, the Company recorded amortization expense related to the deferred financing costs and the debt discount of $252,248 and $775,637, respectively.&#160;&#160;During the years ended December 31, 2011, the Company recorded amortization expense related to the deferred financing costs and the debt discount of $40,444 and $124,363, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; A summary of the 8% Senior Subordinated Unsecured Convertible Promissory Notes as of December 31, 2012 and 2011 are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principal amount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">900,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">900,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: original issuance discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(150,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(150,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: discount related to fair value of derivative warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(377,150</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(377,150</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: discount related to the beneficial conversion feature</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(372,850</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(372,850</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Add: amortization of discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">900,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">124,363</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: principal amount converted to stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(900,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Carrying value at December 31, 2012 and 2011, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">124,363</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 6 &#8211; Derivatives</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering&#160;(See Note 9), the Convertible Notes (See Note 5) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; Activities for derivative warrant instruments during the years ended December 31, 2012 and 2011 were as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair Value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued with Convertible Notes (See Note 5)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">287,061</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">377,150</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Placement agent warrants related to issuance of Convertible Notes (See Note 5)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">143,532</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">188,579</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued with Stock Offering (See Note 9)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,972,785</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,591,900</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Placement agent warrants related to issuance of stock (See Note 9)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">986,393</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,295,950</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,966</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,389,771</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,439,613</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued with Stock Offering (See Note 9)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">242,190</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">318,087</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Placement agent warrants related to Stock Offering (See Note 9)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">121,095</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">159,044</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued with 2012 Common Stock Offering-A (See Note 9)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,118,988</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,409,554</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued with 2012 Common Stock Offering-B (See Note 9)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,559,505</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,665,697</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Placement agent warrants related to 2012 Common Stock Offering (See Note 9)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">467,845</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">499,707</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transfer from liability classification to equity classification</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,753,056</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,231,324</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(685,420</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, December 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,146,338</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 19, 2012, as the result of the Share Exchange, it was determined that the floor for resetting the exercise price was met and the exercise price of the certain warrants was set to be $0.26 (before Exchange Ratio adjustment).&#160;Therefore, these warrants were considered indexed to the Company&#8217;s stock and qualified for the scope exception under FASB ASC 815-10 allowing for a transfer from liability classification to equity classification.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The fair values of the warrants issued in the Company&#8217;s stock and Convertible Notes Offering and the warrants issued to the Company&#8217;s placement agent were recognized as derivative warrant instruments at issuance and are measured at fair value at each reporting period. The Company determined the fair values of these warrants using a modified binomial valuation model.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date, the transfer date on December 19, 2012, and the date for the new grants in January and December 2012. (The market value of common stock, adjusted exercise price and offering price presented does not reflect the impact of the Share Exchange.)</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">January 31,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 19,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 27,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Market value of common stock on measurement date (1)</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.37</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.37</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.39</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.39</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.39</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjusted exercise price</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.24 - $0.26</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.23 - $0.26</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.41 - $0.83</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.22 - $0.26</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.41 - $0.83</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate (2)</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.35</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.24</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.10% - 0.77</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.94</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.10% - 0.77</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant lives in years</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7 years</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7 years</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4 months/5years</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6 years</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4 months/5years</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility (3)</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">156</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">157</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">125% - 161</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">161</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">125% - 161</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected dividend yield (4)</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Probability of stock offering in any period over 5 years (5)</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Range of percentage of existing shares offered (6)</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Offering price range (7)</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.18 - $0.55</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.13 - $0.56</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01 - $0.55</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.12 - $0.60</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01 - $0.55</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The market value of common stock is based on an enterprise valuation.</font></div>
</div>
</td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The risk-free interest rate was determined by management using the average of 5 and 7 year and the 3-month Treasury Bill as of the respective measurement date.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3)&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4)&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5)&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management has determined that the probability of a stock offering is 25% for each quarter of the next five years.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6)&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management estimates that the range of percentages of existing shares offered in each stock offering will be between 35% of the shares outstanding.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7)&#160;&#160;</font></div>
</td>
<td valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Represents the estimated offering price range in future offerings as determined by management.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 7 &#8211; Income Taxes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at December 31, 2012 and 2011 are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred tax assets:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Net operating losses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,609,036</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,089,314</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Share-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,497,556</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">741,420</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Other differences in tax basis</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">233,043</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,749</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total deferred tax assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,339,635</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,835,483</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: valuation allowance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,339,635</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,835,483</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="66%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred tax assets, net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; As of December 31, 2012, for U.S. federal income tax reporting purposes, the Company has approximately $43 million of unused net operating losses (&#8220;NOLs&#8221;) available for carry forward to future years. The benefit from the carry forward of such NOLs will begin expiring during the year ended December 31, 2020. Because United States tax laws limit the time during which NOL carry forwards may be applied against future taxable income, the Company may be unable to take full advantage of its NOL for federal income tax purposes should the Company generate taxable income. Further, the benefit from utilization of NOLs carry forwards could be subject to limitations due to material ownership changes that could occur in the Company as it continues to raise additional capital. Based on such limitations, the Company has significant NOLs for which realization of tax benefits is uncertain.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; The difference between the income tax provision and the amount that would result if the U.S. Federal statutory rate of 34% were applied to pre-tax income (loss) for the years ended December 31, 2012 and 2011 are as follows:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="14" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the years ended</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Federal income taxes at 34%</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,842,810</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-34.00</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,171,230</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-34.00</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share-based compensation costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">756,136</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.04</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">736,796</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21.39</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of derivatives</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">233,043</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.79</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,748</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.13</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of debt discounts</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">349,480</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.18</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56,033</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.63</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in valuation allowance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,504,151</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17.99</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">373,653</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.85</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provision for income tax</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 8 &#8211; Commitments and Contingencies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="78%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4) Biological License Application filing with U.S. FDA</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5) First commercial sale</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6) after the first $10,000,000 in net sales</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of December 31, 2012, the Company met its first milestone and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012. &#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MSKCC &#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and an annual research funding of $50,000 for as long as the agreement is in force.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="78%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval </font>for each licensed product</font></div>
</div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) upon the receipt of regulatory approval from the U.S. FDA for each </font>licensed product</font></div>
</div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company expects to file the NDA for regulatory approval in 2015.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="4%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oak Ridge National Laboratory (ORNL) &#8211; API has contracted to purchase radioactive material to be used for research and development through December 2012. API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end. &#160;The Company is currently negotiating the 2013 agreement.&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab&#8482;-A) used in the Company clinical trials, Phase I and Phase II. &#160;The total project is estimated to cost $1,859,333 and requires a 12.5% down payment of the total estimated project cost. &#160;The down payment totaling $239,000 was paid in 2007 and 2012. &#160;On August 6, 2012, the agreement was amended to provide for additional services. &#160;The total project is now estimated at $1,997,732. &#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">e.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody) and eventually develop a clinical trial with Actinium 225. &#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval. &#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. &#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA. &#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter. &#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year. &#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug. &#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 27, 2012, the Company entered into a clinical trial agreement with Memorial Sloan Kettering Cancer Center. &#160;The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623. &#160;The amount due of $79,623 was paid on July 10, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">g.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On May 9, 2011, Actinium entered into a transaction management agreement with Jamess Capital Group, LLC. (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Sandesh Seth, a Director of Cactus&#160;Ventures, Inc.&#160;by virtue of his position as a director of Actinium Pharmaceuticals.&#160; Mr. Seth is a Managing Partner of the consulting firm some of whose member interests are held by entities owned by officers and employees of the Placement Agent.&#160; None of Cactus&#8217; current officers or directors had a prior relationship or affiliation with Cactus prior to the closing of the Share Exchange.&#160; Pursuant to the agreement, the management firm was engaged to provide consulting services to Actinium related to the consummation of a going public transaction for Actinium.&#160; The management firm received a monthly fee of $12,500 which is terminable by the Company three months after the effective date of the going public transaction and designees of Jamess, including entities affiliated with Mr. Seth, were issued warrants to purchase common stock equal to 10% of the fully-diluted capital stock of the Company as of the effective date of the going public transaction. The fully diluted shares for this calculation included all issued and outstanding shares as well as those reserved under the Employee Stock Option Plan.&#160; Jamess Capital Group does not retain&#160;beneficial ownership of the warrants as they were&#160;issued to designees of the members in amounts which do not qualify either Jamess or the warrant holders for inclusion in the beneficial ownership table.&#160; The warrants contain&#160;a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver.&#160; The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transferred until the earlier of twelve months from the closing date of the Pubco Transaction; or for six months after the planned Registration Statement is declared effective.&#160;The consulting firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">h.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC. &#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $19,749. &#160;During the clinical trial additional fees apply and will be invoiced when applicable. &#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">i.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center. &#160;The total estimated cost of conducting the clinical trial is $481,204, which includes a non- refundable institutional fee of $14,500. &#160;The estimated cost is based on treating 24 patients through 2013. &#160;Upon execution of the agreement, the Company is required to make a payment of $33,946. &#160;&#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">j.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University. &#160;The Phase 1/2 clinical trial will be conducted with Actinium 225. &#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company. &#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. &#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">k.&#160;&#160;</font></div>
</td>
<td valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania. &#160;The Phase 1/2 clinical trial will be conducted with Actinium 225. &#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company. &#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue, 3rd Floor, New York, NY 10017. &#160;The agreement terminates January 31, 2013 unless a Notice of Termination is provided to the landlord 60 days prior to January 1, 2013. &#160;The agreement automatically renews on a month-to-month basis and requires a two month notice of termination. &#160;The Company paid a two month refundable deposit.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 9 &#8211; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; From inception to December 31, 2010, the Company raised $42,711,791 by issuing 5,707,259 shares of the Company&#8217;s stock and issued 66,402 shares, valued at $398,810, for services.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; During 2011, the Company raised $6,184,967 by selling 7,891,141 shares of the Company&#8217;s stock and warrants to purchase 19,972,785 shares of the Company&#8217;s stock through an offering (&#8220;Stock Offering&#8221;).&#160;&#160;A net amount of $5,379,367 was received by the Company in 2011. The Company paid Laidlaw &amp; Company (UK) Ltd. (&#8220;Laidlaw &amp; Co.&#8221;), the placement agent, total cash fees of $742,196, which consisted of placement agent commission of $618,497 and expense reimbursement of $123,699. The Company also issued Laidlaw &amp; Co. warrants to purchase an aggregate of 986,393 shares of the Company&#8217;s common stock, with an exercise price of $0.78 per share and a term of 7 years. These placement agent warrants were valued at their grant date fair value of $188,579.&#160;In addition, the Company paid Laidlaw &amp; Co.&#8217;s outside counsel, McCormick &amp; O&#8217;Brien PLLC, $60,904 for its services as the placement agent&#8217;s legal counsel and Signature Bank $2,500 for the bank escrow fee.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; During 2012, the Company raised $759,300 by selling 968,759 shares and warrants to purchase 242,190 shares of the Company&#8217;s common stock under the Company&#8217;s Stock Offering.&#160;&#160;A net amount of $660,164 was received by the Company in 2012. The Company paid Laidlaw &amp; Co. total cash fees of $91,116, which consisted of placement agent commission of $75,930 and expense reimbursement of $15,186. The Company also issued Laidlaw &amp; Co. warrants to purchase an aggregate of 121,095 shares of the Company&#8217;s common stock, with an exercise price of $0.78&#160;per share and a term of 7 years. These placement agent warrants were valued at their grant date fair value of $159,044. In addition, the Company paid Laidlaw &amp; Co.&#8217;s outside counsel, McCormick &amp; O&#8217;Brien PLLC, $8,020 for its services as the placement agent&#8217;s legal counsel.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; In 2012, the Company also raised $5,151,450 through an offering of 3,118,988 shares of its common stock and &#8220;A Warrants&#8221; to purchase 3,118,988 shares of the Company&#8217;s common stock, exercisable at a price of $1.65 per share for a period of 120 days from the day of the final closing of the offering, and &#8220;B Warrants&#8221; to purchase 1,559,505 shares of the Company&#8217;s common stock, exercisable at a price of $2.48 per share for a period of 5 years from the date of the final closing of the offering. (&#8220;2012 Common Stock Offering&#8221;)&#160;&#160;A net amount of $4,469,776 was received by the Company. Pursuant to the 2012 Common Stock Offering agreement, the Company paid Laidlaw &amp; Co. total cash fees of $618,174, which consisted of placement agent commission of $515,145 and expense reimbursement of $103,029. The Company also issued the placement agent warrants to purchase an aggregate of 467,845 shares of the Company&#8217;s common stock, with an exercise price of $0.78 per share and a term of 5 years. These placement agent warrants were valued at $499,707 and recorded as derivative liabilities.&#160;&#160;In addition, the Company paid the Laidlaw &amp; Co.&#8217;s outside counsel, Richardson &amp; Patel, LLP, $60,000 for its services as the Laidlaw &amp; Co.&#8217;s legal counsel and Signature Bank $3,500 for the bank escrow fee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; During 2012, the Company&#8217;s convertible notes, plus accrued interest, were converted to 1,252,550 shares of the Company&#8217;s common stock as a result of the 2012 Common Stock Offering.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; As a result of the Share Exchange described in Note 1, the Company issued 400,000 shares to the original shareholders of the Company and 1,986,566 shares to the former shareholders of Actinium.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160; Placement Agent &#8211;</font> In connection with the money raised in 2011, the Company issued Laidlaw &amp; Co. warrants to purchase an aggregate of 1,129,925 shares of common stock, with an exercise price of $0.78 per share.&#160;&#160;With the money raised in 2012, the Company issued Laidlaw &amp; Co. warrants to purchase an aggregate of 588,940 shares of common stock, with an exercise price of $0.78 per share.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160; Management Firm &#8211;</font> In 2011, the Company entered into a&#160;management agreement with Jamess Capital Group, LLC (formerly, AmerAsia Inc., &#8220;Jamess&#8221;) for Jamess to provide consulting services related to funding and Actinium becoming a publicly traded entity.&#160;In 2011, the Company incurred $96,744 in management fees. In addition, Actinium issued Jamess warrants to purchase an aggregate of 1,974,774 shares of common stock, with an exercise price of $0.01 per share. The warrants have a fair value of $2,153,442 (see Note 11) and included a cashless exercise provision.&#160;&#160;In 2012, the Company issued Jamess warrants to purchase 1,716,340 shares of common stock with an exercise price of $0.01 per share. The warrants have a fair value of $1,957,754 (see Note 11) and included a cashless exercise provision.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 10 &#8211; Stock Option Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has adopted a 2003 Stock Plan under which it may grant up to 757,575 options to purchase common stock. The 2003 Stock Plan was amended in 2008 to increase the number of shares that it may grant up to 978,154. Option awards are generally granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of the grant. However, since the Company is not publicly traded, the fair market value of the stock represents the Board of Directors&#8217; best estimate, based on the information available, on the date of the grant. The awards generally vest over a four or five year period at a rate of approximately 2% per month.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In 2011, the 2003 Stock Plan was amended to increase the number of shares by 3,217,880.&#160;&#160;Total shares reserved for issuance under the Plan will be increased to 6,155,280.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In accordance with the terms of the 2012 Common Stock Offering, the Company adopted a 2012 Employee Stock Option Plan (&#8220;2012 ESOP&#8221;) and reserved 15% of the total issued and outstanding shares as of the final closing of the 2012 Common Stock Offering.&#160;&#160;Total shares reserved for issuance under the 2012 ESOP was 9,455,776 shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2006, options to purchase 206,060 shares of common stock were granted to several employees at an exercise price of $1.35 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $1,051,281 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 4.29% (2) expected life of 5 years, (3) expected volatility of 156%, and (4) zero expected dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2007, options to purchase 113,220 shares of common stock were granted to several employees at an exercise price of $1.35 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $137,652 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 3.46% (2) expected life of 5 years, (3) expected volatility of 143%, and (4) zero expected dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2008, options to purchase 69,941 shares of common stock were granted to an employee at an exercise price of $0.90 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $44,159 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 3.46% (2) expected life of 5 years, (3) expected volatility of 139%, and (4) zero expected dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2009, 20,613 options to one employee were cancelled as the result of termination of the employment and 128,050 options to one employee were forfeited as the employee deceased during the year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the year of 2010, options to purchase 33,300 shares of common stock were granted to an employee at an exercise price of $0.90 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $24,996 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 2.16% (2) expected life of 5 years, (3) expected volatility of 171%, and (4) zero expected dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In February 2012, the Company re-priced 273,859 units of employee stock options to reflect the current per share fair market value of the Company&#8217;s common stock. The exercise prices of all of the current outstanding stock options were reduced to $1.28 per share. The Company recorded an incremental compensation cost of $34,879 as a result of the re-pricing of options.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2012, options to purchase 2,056,275 shares of common stock were issued to several employees and consultants at an exercise price ranging from $0.78 to $1.5 per share.&#160;&#160;These options have a term of 10 years and vest over a 4 year period. The fair value of $1,519,777 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.8% (2) expected life of 7 years, (3) expected volatility of 160.44% ~ 162.49%, and (4) zero expected dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; The following is a summary of stock option activities for the years ended December 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">273,859</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.29</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.51</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">273,859</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.29</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.51</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,056,275</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.96</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.89</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,330,134</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.96</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.91</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">685,800</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31, 2012 and 2011 were $1,998,435 and $14,528, respectively. During the years ended December 31, 2012 and 2011, the Company recorded option expense of $266,172 and $19,935, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 11 &#8211; Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; During the year ended December 31, 2011, warrants to purchase 1,974,774 shares of common stock were granted to the Management Firm at an exercise price of $0.01 per share. These warrants have a term of 7 years and vest immediately. Fair value of $2,153,442 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate ranging from 1.92% to 3.17%, (2) warrant life of 10 years, (3) expected volatility ranging from 64.77% to 70.72%, and (4) zero expected dividends. The management firm receives warrants equal to ten (10%) percent of the issued and outstanding capital stock of the Company on a fully-diluted basis on the effective date of the agreement.&#160;&#160;The warrants are subject to weighted average non-dilution provisions to be calculated on the basis of the post-money fully diluted capitalization of the Company upon closing of any transaction, financing or otherwise, up to and including the Public Company transaction, provided that such anti-dilution provisions shall not extend beyond the date of any exercise of the warrants by the management firm prior to the closing of the Public Company transaction. Since these warrants vest immediately, the Company recorded the entire fair value of $2,153,442 as stock-based compensation expense during the year on these warrants issued by the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; During the year ended December 31, 2011, the Company also issued the following warrants:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued with convertible notes (See Note 5)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">287,061</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued to investors with Stock Offering (See Note 9)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,972,766</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Placement agent warrants related to issuance of:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Convertible Notes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">143,532</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Stock Offering (See Note 6 and Note 9)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">986,383</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,389,742</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; During the year ended December 31, 2012, warrants to purchase an aggregate of 1,716,340 shares of common stock were granted to the Management Firm at an exercise price of $0.01 per share. These warrants have a term of 7 years and vest immediately. Fair value of $1,957,754 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 1.82%, (2) warrant life of 7 years, (3) expected volatility of 60.64%, and (4) zero expected dividends.&#160;&#160;Since these warrants vest immediately, the Company recorded the entire fair value of $1,957,754 as stock-based compensation expense during the year on these warrants issued by the Company.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; During the year ended December 31, 2012, the Company also issued the following warrants:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued to investors with Stock Offering (See Note 6)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">242,189</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued to investors with Common Stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,678,491</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Placement agent warrants related to issuance of:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Stock Offering (See Note 6 and Note 9)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">121,094</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;2012 Common Stock Offering</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">467,845</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants issued to investors with stock &#8211; accrued dividend</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">180,115</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,689,734</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; The following is a summary of warrant activities for the years ended December 31, 2011 and 2012:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,364,557</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.51</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.76</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,364,557</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.51</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.76</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,261,367</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,406,079</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.32</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.76</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="47%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,770,636</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.97</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.48</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,114,768</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 12 &#8211; Employee Defined Contribution Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; In 2004, the Company established an employee deferred contribution plan. The plan requires 12 consecutive months of service and a minimum of 500 hours of service for participation. The Plan provides for employer matching of 50% of the employee contribution and discretionary contributions. Employees can contribute up to the maximum allowable under the Internal Revenue Service Code Section 401(k). The amount contributed by the Company for the years ended December 31, 2012 and 2011 was $8,942 and $8,885, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 13 &#8211; Subsequent Events</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; In February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO, Jack Talley. Pursuant to the agreement, the Company will pay Mr. Talley in 2 equal installments the aggregate amount of $250,000 and a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012. The $60,000 bonus was included in the accounts payable and accrued liabilities on the Company&#8217;s balance sheet at December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-36</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1,382,649 Shares of Common Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(FORMERLY CACTUS VENTURES, INC.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PROSPECTUS</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS DOCUMENT OR THAT WE HAVE REFERRED YOU TO. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION THAT IS DIFFERENT. THIS PROSPECTUS IS NOT AN OFFER TO SELL COMMON STOCK AND IS NOT SOLICITING AN OFFER TO BUY COMMON STOCK IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Until _____________, all dealers that effect transactions in these securities whether or not participating in this offering may be required to deliver a prospectus. This is in addition to the dealer&#8217;s obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The date of this prospectus is __________, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II&#8212; INFORMATION NOT REQUIRED IN THE PROSPECTUS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 13. Other Expenses Of Issuance And Distribution.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Securities and Exchange Commission registration fee</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,400</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transfer Agent Fees</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounting fees and expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Legal fees and expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Blue Sky fees and expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">114,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All amounts are estimates other than the SEC&#8217;s registration fee. We are paying all expenses of the offering listed above. No portion of these expenses will be borne by the selling stockholders. The selling stockholders, however, will pay any other expenses incurred in selling their common stock, including any brokerage commissions or costs of sale.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 14. Indemnification of Directors and Officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Section 102(b)(7) of the Delaware General Corporation Law allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the directors breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides for this limitation of liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Section 145 of the General Corporation Law of the State of Delaware provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation&#8217;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his conduct was illegal. A Delaware corporation may indemnify any persons who are, or were, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation&#8217;s best interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or directors has actually and reasonably incurred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our bylaws provide that we will indemnify our directors and officers to the fullest extent authorized by the General Corporation Law of the State of Delaware.&#160;&#160;Expenses (including attorneys&#8217; fees) incurred by an officer or director of the Corporation in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company as authorized under Delaware law.&#160;&#160;Such expenses (including attorneys&#8217; fees) incurred by former directors and officers or other employees and agents of the Company or by persons serving at the request of the Company as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the Company deems appropriate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We maintain a general liability insurance policy that covers liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">II-1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Holdings Ltd. Indemnification</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to a letter Agreement dated, July 2011, between API and Actinium Holdings Ltd., API agreed to indemnify certain officers and directors of a predecessor company.&#160;&#160;Pursuant to the agreement, API will not, and will not permit any of its subsidiaries to, eliminate or otherwise reduce the right of any present or former director or officer of API, Actinium Pharmaceuticals Limited, a Bermuda corporation that merged into the Company (&#8220;APL&#8221;), and/or the present and former subsidiaries of API or APL (all such entities, collectively, the &#8220;Company Group&#8221;) who currently serves, or at any time prior to the date thereof served, in any such capacity (all such directors and officers, collectively &#8220;Company Group Managers&#8221;) to be indemnified against any costs or expenses (including reasonable attorneys&#8217; fees), judgments, fines, losses, claims, damages or liabilities of any nature whatsoever, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to matters existing or occurring on, prior to or after the date thereof, whether asserted or claimed prior to, on or after the date thereof, arising, in whole or in part, out of or pertaining to the fact that he or she is or was, or at any time in the future will have been, a Company Group Manager or is or was, or at any time in the future will have been, serving at the request of any entity in the Company Group (or at the request of any present or former affiliate (as such term is defined in Rule 405 under the Securities Act of 1933, as amended) of API for and on behalf of any entity in the Company Group as a director, officer, employee, fiduciary or agent of another corporation, partnership, joint venture, trust, other entity or otherwise, or to be advanced expenses, in any of the foregoing cases, to the fullest extent that such Company Group Manager would be entitled to be indemnified or advanced expenses under applicable law, API&#8217;s or any such subsidiaries&#8217; certificate or articles of incorporation or bylaws or equivalent documents or any applicable contract (collectively, the &#8220;Applicable Documents&#8221;), in each case, as in effect on the date thereof.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We maintain a general liability insurance policy that covers liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">At the present time, there is no pending litigation or proceeding involving a director, officer, employee, or other agent of ours in which indemnification would be required or permitted. We are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification.<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 15. Recent Sales of Unregistered Securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During 2011, Actinium Corporation raised $6,184,967 through an offering of 23,697,119 shares (pre-Actinium Share Exchange) of the 2011 Series E preferred shares and 5,924,285 warrants (pre-Actinium share exchange).&#160;&#160;A net amount of $5,379,367 was received by the Company in 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 27, 2011, Actinium Corporation completed a private offering of 8% Senior Subordinated Unsecured Convertible Promissory Notes (&#8220;Convertible Notes&#8221;) in the amount of $900,000 and received net proceeds of $750,000.&#160;&#160;The convertible notes were issued at 83.33% of the principal amount resulting in an original issue discount of $150,000.The Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount, accrued semi-annually and to be paid at maturity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In January 2012, the Actinium raised $759,300 through its final offering of the 2011 Series E preferred shares.&#160;&#160;A net amount of $660,163 was received by Actinium Corporation.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 19, 2012, Actinium Corporation completed a private offering of units.&#160;&#160;Upon taking into account the exchange ratio in the Share Exchange that closed on December 28, 2012 the units consisted of an aggregate of (i) 3,118,968 shares of its common stock, (ii) Series A warrants to purchase 3,118,969 shares of its common stock which have a 120 day term from December 19, 2012 and an initial per share exercise price of $1.65, subject to adjustment, (iii) Series B warrants to purchase up to 1,559,484 shares of common stock which have a 5 year term and an initial per share exercise price of $2.48, subject to adjustment.&#160;&#160;The price per unit was $1.65 for aggregate gross proceeds of $5,151,448.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 28, 2012, we entered into a Share Exchange Agreement with (i) Actinium Corporation and (ii) the former shareholders of Actinium Corporation pursuant to which we acquired 12,939,986 shares of capital stock of Actinium from the Actinium Corporation Shareholders in exchange for the issuance of 4,309,015 shares of common stock to the Actinium Corporation shareholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 11, 2013, we entered into a second Share Exchange Agreement with (i) Actinium Corporation and (ii) the former shareholders of Actinium Corporation pursuant to which we acquired 22,055,225 shares of capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance of 7,344,390 shares of common stock to the Actinium Corporation shareholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 22, 2013, we entered into a third Share Exchange Agreement with (i) Actinium Corporation and (ii) the former shareholders of Actinium Corporation pursuant to which we acquired 24,052,702 shares of capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance of 8,009,550 shares of common stock to the Actinium Corporation shareholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 25, 2013 in accordance with a Certificate of Ownership Merging Actinium Corporation into the Company, the Company merged into itself Actinium Corporation, and Actinium Corporation ceased to exist. As a result of the merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock. An aggregate of 1,325,840 shares of the Company&#8217;s common stock were exchanged for shares for 3,981,501 shares of Actinium Corporation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 27, 2013 and January 10, 2014, we completed a private offering of units.&#160;&#160;The units consisted of an aggregate of (i)1,106,120 shares of its common stock, and (ii) common stock warrants to purchase 276,529 shares of its common stock which have a five year term and an exercise price of $9.00&#160;&#160;The price per unit was $6.00 for aggregate gross proceeds of $6,636,720.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">II-2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The above securities were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) of the Securities Act and Rule 506 of Regulation D (&#8220;Regulation D&#8221;) promulgated under the Securities Act.&#160;&#160;The Company made this determination based on the representations of the investors which included, in pertinent part, that each such investor was an &#8220;accredited investor&#8221; within the meaning of Rule 501 of Regulation D (there were no non-accredited investors in any of the offerings) and upon such further representations from each investor that (i) such investor is acquiring the securities for its own account for investment and not for the account of any other person and not with a view to or for distribution, assignment or resale in connection with any distribution within the meaning of the Securities Act, (ii) such investor agrees not to sell or otherwise transfer the purchased securities or shares underlying such securities unless they are registered under the Securities Act and any applicable state securities laws, or an exemption or exemptions from such registration are available, (iii) such investor has knowledge and experience in financial and business matters such that such investor is capable of evaluating the merits and risks of an investment in us, (iv) such investor&#160;&#160;had access to all of the Company&#8217;s documents, records, and books pertaining to the investment and was provided the opportunity to ask questions and receive answers regarding the terms and conditions of the Offering and to obtain any additional information which the Company possessed or was able to acquire without unreasonable effort and expense, and (v) such investor has no need for the liquidity in its investment in us and could afford the complete loss of such investment. In addition, there was no general solicitation or advertising for securities issued in reliance upon Regulation D.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 16. Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See Exhibit Index following the signature page.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 17. Undertakings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The undersigned registrant hereby undertakes:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5) Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">II-3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<!--efplaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereonto duly authorized, in the City of New York, State of New York, on January 31, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="36%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Kaushik J. Dave</font></div>
</td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave</font></div>
</td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Duly Authorized Officer and Principal Executive Officer)</font></div>
</td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="36%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Sergio Traversa</font></div>
</td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa</font></div>
</td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" nowrap valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interim Chief Financial Officer (Duly<br>
Authorized Officer and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Financial and Accounting Officer)</font></div>
</td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">POWER OF ATTORNEY</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sergio Traversa and Sandesh Seth, and each of them, his true and lawful attorneys-in-fact and agents with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by the registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.</font></div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Signature</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Capacity</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Kaushik J. Dave</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President, Chief Executive Officer and Director</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">January 31, 2014</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Executive officer)</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Sergio Traversa</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interim Chief Financial Officer</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">January 31, 2014</font></div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Financial and Accounting Officer)</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ David Nicholson</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">January 31, 2014</font></div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Nicholson</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Richard I. Steinhart</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">January 31, 2014</font></div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Richard I. Steinhart</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Sandesh Seth</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">January 31, 2014</font></div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sandesh Seth</font></div>
</td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">II-4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT INDEX</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="75%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share Exchange Agreement, dated December 28, 2012, by and among Cactus Ventures, Inc., Actinium Pharmaceuticals, Inc., Diane S. Button, and the shareholders of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.2</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share Exchange Agreement, dated March 11, 2013, by and among Cactus Ventures, Inc., Actinium Pharmaceuticals, Inc, and the shareholders of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on March 11, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.3</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share Exchange Agreement, dated August 22, 2013, by and among&#160;Actinium Pharmaceuticals, Inc, Actinium Corporation, and the shareholders of Actinium Corporation&#160;&#160;(incorporated by reference to Exhibit 2.3 to Form S-1/A filed on August&#160;22, 2013).</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.1</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Articles of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed with the SEC on April 17, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.2</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fifth Restated Certificate of Incorporation of Actinium Corporation (fka, Actinium Pharmaceuticals, Inc.) (incorporated by reference to Exhibit 3.5 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.3</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bylaws of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Form filed with the SEC on April 17, 2007).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.4</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bylaws of Actinium Corporation (fka, Actinium Pharmaceuticals, Inc.) (incorporated by reference to Exhibit 3.7 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.5</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Amendment to Articles of Incorporation filed January 7, 2014.**</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.1</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of A Warrant, dated December 19, 2012 (incorporated by reference to Exhibit 4.1 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.2</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of B Warrant, dated December 19, 2012 (incorporated by reference to Exhibit 4.2 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.3</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Lock Up Agreement, dated December ____, 2012 (incorporated by reference to Exhibit 4.3 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.4</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Stock Offering Warrant, dated April 12, 2013.</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.5</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Placement Agent Warrant, dated December 19, 2012.</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.6</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Consulting Firm Warrant, dated December 17, 2012.</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.7</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Lock-up Agreement, dated August 22, 2013&#160;&#160;(incorporated by reference to Exhibit 4.7 to Form S-1/A filed on August&#160;22, 2013).</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.8</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Common Stock Warrant, dated December 27, 2013 and January 10, 2014.**</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.9</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Lock-Up Agreement, dated December 27, 2013.**</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.1</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Opinion of Hiscock &amp; Barclay, LLP *</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.1</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Registration Rights Agreement, by and among Actinium Pharmaceuticals, Inc., General Atlantic Investments Limited, and Certain Stockholders, dated June 30, 2000 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.2</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amendment No. 1 to June 30, 2000 Registration Rights Agreement, dated September 29, 2011 (incorporated by reference to Exhibit 10.2 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.3</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">First Amended and Restated Stockholders Agreement, by and among Actinium Pharmaceuticals, Inc., Actinium Holdings Limited, N.V. Organon, and the Stockholders Listed Therein, dated October 5, 2011(incorporated by reference to Exhibit 10.3 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.4</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Second Amended and Restated Investor Rights Agreement, by and among Actinium Pharmaceuticals, Inc., Actinium Holdings Limited, and the Investors Listed Therein, dated October 5, 2011 (incorporated by reference to Exhibit 3.5 to Form 8-K filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.5</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intentionally left blank.</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.6</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Subscription Agreement, dated December 19, 2012 (incorporated by reference to Exhibit 10.6 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.7</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Unit Purchase Agreement, dated December 19, 2012&#160;&#160;(incorporated by reference to Exhibit 10.7 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.8</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employment Agreement, dated January 2, 2006,&#160;&#160;between Actinium Pharmaceuticals, Inc. and Dragan Cicic (incorporated by reference to Exhibit 10.8 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.9</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License, Development and Commercialization Agreement between Sloan-Kettering Institute of Cancer Research, and Actinium Pharmaceuticals, Inc., dated February 11, 2002; as amended by the First Amendment dated August 7, 2006 (incorporated by reference to Exhibit 10.9 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.10</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Phase 1/2 Study on the safety and efficiency of 225ACAc-HuM195 in patients with advanced Myeloid malignancies with Millennix Oncology, Averion Project, dated December 6, 2006 (incorporated by reference to Exhibit 3.5 to Form 8-K filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.11</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product Development and Patent License Agreement, dated February 27, 2003, by and between Abbott Biotherapeutics and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.11 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.12</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical Trial Agreement, dated July 19, 2012, by and between Fred Hutchinson Cancer Center and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.12 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.13</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employment Letter between Jack V. Talley and Actinium Pharmaceuticals, Inc., effective August 15, 2012 (incorporated by reference to Exhibit 3.5 to Form 8-K filed on January&#160;4, 2013).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><a href="#toc">TABLE OF CONTENTS</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.14</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employment Letter between Enza Guagenti and Actinium Pharmaceuticals, Inc., effective August 15, 2012 (incorporated by reference to Exhibit 10.14 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.15</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical Trial Agreement, dated January 18, 2001, between Actinium Pharmaceuticals, Inc. and Memorial Sloan Kettering Cancer Center for the purpose of conducting a clinical trial entitled &#8220;Phase 1/2 trial of 213Bi-M195 and cytarabine for Acute Myeloid Leukemia.&#8221; (incorporated by reference to Exhibit 10.15 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.16</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical Trial Agreement with The Trustees of the University of Pennsylvania, dated November 8, 2012 (incorporated by reference to Exhibit 10.16 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.17</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical Trial Agreement, dated March 27, 2012, with Memorial Sloan-Kettering Cancer Center (incorporated by reference to Exhibit 10.17 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.18</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical Trial Agreement, dated September 22, 2012, with Johns Hopkins University, dated September 24, 2012 (incorporated by reference to Exhibit 10.18 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.19</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License Agreement, dated June 14, 2012, for BC8 antibody with Fred Hutchinson Cancer Research Center&#160;(incorporated by reference to Exhibit 10.19 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.20</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012 Unit Investor Rights Agreement, dated December 19, 2012, by and among Actinium Pharmaceuticals, Inc., the persons identified on Exhibit A attached thereto hereto, and the Placement Agent (incorporated by reference to Exhibit 10.20 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.21</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Project Agreement, dated September 30, 2011, between Actinium Pharmaceuticals, Inc. and Aptiv Solutions, Inc. (incorporated by reference to Exhibit 10.21 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.22</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proposal, dated March 30, 2007, with IsoTherapeutics Group, LLC (incorporated by reference to Exhibit 10.22 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.23</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical Trial Agreement with The University of Texas M.D. Anderson Cancer, dated March 1, 2012 (incorporated by reference to Exhibit 10.23 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.24</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amendment No. 1 to Research Agreement, dated November 7, 2012, between Actinium Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer&#160;(incorporated by reference to Exhibit 10.24 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.25</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Letter Agreement, dated June 19, 2011, between Actinium Pharmaceuticals, Inc. and Sloan-Kettering Institute for Cancer Research&#160;&#160;(incorporated by reference to Exhibit 10.25 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.26</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Letter Agreement, dated April 9, 2010, between Actinium Pharmaceuticals, Inc. and Sloan-Kettering Institute for Cancer Research (incorporated by reference to Exhibit 10.26 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.27</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Letter Agreement, dated July __, 2010, between Actinium Pharmaceuticals, Inc. and Actinium Holdings Limited (Waiver of Anti-Dilution Rights) (incorporated by reference to Exhibit 10.27 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.28</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical Trial Agreement, dated April 12, 2006, with Sloan-Kettering Institute for Cancer Research and Memorial Hospital for Cancer and Allied Diseases (incorporated by reference to Exhibit 10.28 to Form 8-K /A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.29</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Letter Agreement, dated __, 2011, between Actinium Pharmaceuticals, Inc. and Actinium Holdings Limited (Waiver of Registration Rights) (incorporated by reference to Exhibit 10.29 to Form 8-K/A filed on January&#160;4, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.30</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Agreement, dated November 29, 2012, by and between Oak Ridge National Laboratory and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.30 to Form S-1/A filed on August&#160;22, 2013).</font></div>
</div>
</td>
</tr><tr bgcolor="#ffffff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.31</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transaction Management Agreement, dated May 9, 2011, by and between Jamess Capital Group, LLC (fka, AmerAsia Capital Group LLC) and Actinium Corporation (fka, Actinium Pharmaceuticals Inc.) (incorporated by reference to Exhibit 10.31 to Form S-1 filed on September&#160;30, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.32</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employment Agreement, effective September 16, 2013, by and between Actinium Pharmaceuticals, Inc. and Kaushik J. Dave (incorporated by reference to Exhibit 10.32 to Form S-1/A filed on October&#160;28, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.33</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan.**</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.34</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Equity Incentive Plan.**</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.35</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Unit Purchase Agreement, dated December 27, 2013 and January 10, 2014.**</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.36</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Subscription Agreement, dated December 27, 2013 and January 10, 2014.**</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.37</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Registration Rights Agreement, dated December 27, 2013 and January 10, 2014.**</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.38</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Letter Agreement, dated September 4, 2013, between Actinium Pharmaceuticals, Inc. and Sloan-Kettering Institute for Cancer Research.**&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14.1</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Code of Ethics (incorporated by reference to Exhibit 14.1 to Form 8-K filed on January&#160;2, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16.1</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Letter from R.R. Hawkins (prior auditor) (incorporated by reference to Exhibit 16.1 to Form S-1/A filed on August&#160;22, 2013).</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21.1</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Form 10-K filed on March&#160;29, 2013).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23.1</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consent of GBH CPAs, PC **</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23.2</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consent of Hiscock &amp; Barclay, LLP (included in Exhibit 5.1).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interactive Data File for&#160;nine month period ended&#160;September 30, 2013 furnished XBRL and Interative Data&#160;File for the&#160;nine month period ended&#160;September 30, 2012, and the Interactive Data File for&#160;the year ended December 31, 2012 furnished in XBRL and Interactive Data File for the year ended December 31, 2011 furnished in XBLR. **</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="right" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;*&#160;&#160;&#160;&#160;&#160;To be filed by amendment</font></div>
</td>
</tr><tr bgcolor="white">
<td align="right" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">**&#160;&#160;&#160; Filed herewith.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>2
<FILENAME>fs12014ex3v_actinium.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION FILED JANUARY 7, 2014.**
<TEXT>
<html>
<head>
    <title>fs12014ex3v_actinium.htm</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">Exhibit 3.5</font></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><img src="img001_v1.jpg" alt=""></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>3
<FILENAME>fs12014ex4viii_actinium.htm
<DESCRIPTION>FORM OF COMMON STOCK WARRANT, DATED DECEMBER 27, 2013 AND JANUARY 10, 2014.**
<TEXT>
<html>
<head>
    <title>fs12014ex4viii_actinium.htm</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 4.8</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMON STOCK PURCHASE WARRANT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Warrant Shares: [_______]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initial Exercise Date: __________, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant</font>&#8221;) certifies that, for value received, _____________ (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Holder</font>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Initial Exercise Date</font>&#8221;) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Termination Date</font>&#8221;) but not thereafter, to subscribe for and purchase from Actinium Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</font>&#8221;), up to ______ shares (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant Shares</font>&#8221;) of Common Stock.&#160;&#160;The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Section 1</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Definitions</font>.&#160;&#160;&#160;&#160;For the purposes hereof, in addition to the terms defined elsewhere in this Warrant, (a) capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement and (b) the following terms shall have the following meanings:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Business Day</font>&#8221; means any day except any Saturday, any Sunday, any day which shall be a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock Equivalents</font>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offering</font>&#8221; shall bear such meaning as ascribed to it in the Subscription Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Person</font>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Purchase Agreement</font>&#8221; means the Unit Purchase Agreement, dated as of ___________, 2013 among the Company and the original Holder, as amended, modified or supplemented from time to time in accordance with its terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Act</font>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subscription Agreement</font>&#8221; means the Subscription Agreement, dated as of ___________, 2013 among the Company and the original Holder, as amended, modified or supplemented from time to time in accordance with its terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsidiary</font>&#8221; shall have the meaning set forth in the Purchase Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Trading Day</font>&#8221; means a day on which the New York Stock Exchange is open for business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Trading Market</font>&#8221; means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board, or the other OTC markets, including the OTCQX, OTCQB and OTC Pink markets.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Transaction Documents</font>&#8221; shall have the meaning set forth in the Purchase Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">VWAP</font>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a national securities exchange, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the trading market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. New York City time to 4:02 p.m. New York City time); (b)&#160; if the Common Stock is quoted on the OTC Bulletin Board, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board; (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported on the OTC markets, including the OTCQX, OTCQB and OTC Pink markets, or in the &#8220;Pink Sheets&#8221; published by Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported; or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Company, the fees and expenses of which shall be paid by the Company; provided that in each case where Bloomberg L.P. data is being relied upon, Holder shall provide to the Company a copy of such information for the Company&#8217;s records</font></font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Section 2</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exercise</font>.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal">a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exercise of Warrant</font>.&#160;&#160;Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed notice of exercise (&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notice of Exercise</font>&#8221;) form annexed hereto; and, within 3 Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received&#160;&#160;payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier&#8217;s check drawn on a United States bank.&#160;&#160;Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within 3 Trading Days of the date the final Notice of Exercise is delivered to the Company.&#160;&#160;Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.&#160;&#160;The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.&#160;&#160;In the event of any dispute or discrepancy, the records of the Company shall be controlling and determinative in the absence of manifest error.&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exercise Price</font>.&#160;&#160;The exercise price per share of the Common Stock under this Warrant shall be <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$9.00</font>, subject to adjustment hereunder (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise Price</font>&#8221;).</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exercise Limitations</font>.&#160;&#160;Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise, the Holder (together with the Holder&#8217;s affiliates, and any other person or entity acting as a group together with the Holder or any of the Holder&#8217;s affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of this Section, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. Holder is solely responsible for any schedules required to be filed in accordance therewith. The Company shall have no obligation to verify or confirm the accuracy of such filings.&#160; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its <font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">affiliates since the date as of which such number of outstanding shares of Common Stock was reported.&#160;&#160;The &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Beneficial Ownership Limitation</font>&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares issuable upon exercise of this Warrant.&#160;&#160;The Holder, upon not less than 61 days&#8217; prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2.3, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2.3 shall continue to apply.&#160;&#160;Any such increase or decrease will not be effective until the 61<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font> day after such notice is delivered to the Company.&#160;&#160;The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</font></font></font></font></div>

<div style="TEXT-INDENT: 72pt; MARGIN-LEFT: 36pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Mechanics of Exercise</font>.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Delivery of Certificates Upon Exercise</font>.&#160;&#160;Certificates for shares purchased hereunder shall be transmitted by the Company&#8217;s transfer agent (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Transfer Agent</font>&#8221;) to the Holder by crediting the account of the Holder&#8217;s prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission (&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DWAC</font>&#8221;) system if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the resale of the Warrant Shares by the Holder or (B) the shares are eligible for resale without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of certificates to the address specified by the Holder in the Notice of Exercise within 4 Trading Days from the delivery to the Company of the Notice of Exercise Form, surrender of this Warrant (if required) and payment of the aggregate Exercise Price as set forth above (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant Share Delivery Date</font>&#8221;).&#160;&#160;For the avoidance of doubt, in the absence of an effective registration statement permitting the resale of the Warrant Shares or the eligibility of the Warrant Shares for resale without volume or manner-of-sale limitations pursuant to Rule 144, the Warrant Shares issuable upon exercise of this Warrant may be issued as unregistered shares with a customary Rule 144 restrictive legend. This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company.&#160;&#160;The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 2(e)(vi) prior to the issuance of such shares, have been paid.&#160;&#160;If the Company is obligated to and fails for any reason to deliver to the Holder certificates evidencing the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise, $10 per Trading Day (increasing to $20 per Trading Day on the seventh Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such certificates are delivered.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Delivery of New Warrants Upon Exercise</font>.&#160;&#160;If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Rescission Rights</font>.&#160;&#160;If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iv.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise</font>.&#160;&#160;In addition to any other rights available to the Holder, if the Company fails for any reason to deliver to the Holder such certificate or certificates by the Warrant Share Delivery Date, and if after such Share Delivery Date the Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Buy-In</font>&#8221;), then the Company shall (A) pay in cash to the Holder (in addition to any other remedies available to or elected by the Holder) the amount by which (x) the Holder&#8217;s total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that the Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of the Holder, either reissue (if surrendered) this Warrant in a principal amount equal to the principal amount of the attempted conversion or deliver to the Holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements under this Warrant.&#160;&#160;For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of this Warrant with respect to which the actual sale price of the Warrant Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Company shall be required to pay the Holder $1,000.&#160;&#160;The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.&#160;&#160;Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of this Warrant as required pursuant to the terms hereof.</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">v.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No Fractional Shares or Scrip</font>.&#160;&#160;No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&#160;&#160;As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">vi.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Charges, Taxes and Expenses</font>.&#160;&#160;Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">however</font>, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the assignment form (&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assignment Form</font>&#8221;) attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.&#160;&#160;The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">vii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Closing of Books</font>.&#160;&#160;The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Section 3</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Certain Adjustments</font>.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Stock Dividends and Splits</font>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.&#160;&#160;Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Intentionally Omitted</font>.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Fundamental Transaction</font>. If, at any time while this Warrant is outstanding, (i) the Company effects any merger or consolidation of the Company with or into another Person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (each &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Fundamental Transaction</font>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Alternate Consideration</font>&#8221;) receivable as a result of such merger, consolidation or disposition of assets by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such event. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&#160;&#160;If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&#160;&#160;To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder&#8217;s right to exercise such warrant into Alternate Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 3(c) and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.&#160;&#160;For the avoidance of doubt, in connection with a Fundamental Transaction the Holder shall not be entitled to any antidilution rights if the exercise price of the new warrant or the price per warrant share received by the Holder upon exercise of the new warrant is below the Exercise Price.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Calculations</font>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">e)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Notice to Holder</font>.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Adjustment to Exercise Price</font>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Notice to Allow Exercise by Holder</font>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.&#160;&#160;The Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Section 4</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Transfer of Warrant</font>.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Transferability</font>.&#160;&#160;Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) herein and to the provisions of the Subscription Agreement and Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&#160;&#160;Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&#160;&#160;The Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">New Warrants</font>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.&#160;&#160;Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Warrant Register</font>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant Register</font>&#8221;), in the name of the record Holder hereof from time to time.&#160;&#160;The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Transfer Restrictions</font>. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">, at the </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">registration</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> statement under the Securities Act</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> and </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">comply with the provisions of the Subscription Agreement and Purchase Agreement.</font></font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Arial; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Section 5</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Call Provision</font>.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> Subject to the provisions of this Section&#160;5, if during the period commencing upon effectiveness of the registration statement to be filed in accordance with that certain registration rights agreement, dated on even date herewith, between the Company and the Holder (&#8220;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Redemption Period</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8221;), the closing price for the Company&#8217;s Common Stock as reported on the Trading Market for each of fifteen (15)&#160;consecutive Trading Days (each such period, a &#8220;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Measurement Period</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8221;, the fifteenth consecutive Trading Day of which shall not fall on a date later than the last day of the Redemption Period), exceeds </font>$15.00,<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock, then the Company may upon sixty (60) days prior written notice (the &#8220;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Redemption Notice</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8221;), call for redemption (&#8220;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Call</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8221;) of this Warrant solely with respect to Covered Shares (as defined below) at the then outstanding at a price of $0.001 per share; </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">provided</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> that such Redemption Notice is delivered to the Holder within five (5) business days after the end of the Measurement Period. This Warrant can only be called if a registration statement registering the shares underlying this Warrant is in effect at the time of the Call.&#160;&#160;If the conditions set forth herein for such Call are satisfied, then this Warrant (with respect to Covered Shares only) for which a Notice of Exercise shall not have been received by the Redemption Date (as defined below) will be </font></font><a name="page_0_4_6"><!--EFPlaceholder--></a><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">cancelled at 6:00 p.m. (New York City time) on the 60th day after the date the Redemption Notice is delivered to the Holder (such date, the &#8220;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Redemption Date</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8221;). In furtherance thereof, the Company covenants and agrees that it will honor all Notices of Exercise with respect to Warrant Shares subject to a Redemption Notice that are tendered prior to 6:00 p.m. (New York City time) on the Redemption Date. For the purposes hereof, &#8220;Covered Shares&#8221; means those Warrant Shares which, from the date of the delivery of the Redemption Notice through and including the Redemption Date, are covered by an effective registration statement under the Securities Act providing for the resale of such Warrant Shares and the prospectus of such registration statement is available for use by the Holder for the resale of such Warrant Shares. Notwithstanding anything to the contrary set forth in this Warrant, </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">this Warrant shall not be cancelled (and any Redemption Notice will be void) with respect to any Warrant Shares which are not Covered Shares.&#160;&#160;</font>Laidlaw and Co. (UK) Ltd. (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Placement Agent</font>&#8221;) shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of this Warrant if the Company elects to call the warrant in accordance with this Section 5.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Section 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Registration Rights</font>.&#160;&#160;The shares of Common Stock issuable upon exercise of this Warrant shall have the registration rights set forth in the Registration Rights Agreement attached as an exhibit to the Purchase Agreement.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Section 7</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Miscellaneous</font>.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No Rights as Shareholder Until Exercise</font>.&#160;&#160;This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder of the Company prior to the exercise hereof.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Loss, Theft, Destruction or Mutilation of Warrant</font>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Saturdays, Sundays, Holidays, etc</font>.&#160;&#160;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Authorized Shares</font>.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock one hundred (100%) of the number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. In case such amount of Common Stock is insufficient at any time, the Company shall call and hold a special meeting to increase the number of authorized shares of common stock. Management of the Company shall recommend to shareholders to vote in favor of increasing the number of authorized shares of common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160;&#160;The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&#160;&#160;The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its amended and restated certificate of incorporation, as amended or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.&#160;&#160;Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">e)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Jurisdiction</font>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">f)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Restrictions</font>.&#160;&#160;The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">g)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Nonwaiver and Expenses</font>.&#160;&#160;No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder&#8217;s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date.&#160;&#160;If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">h)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Notices</font>.&#160;&#160;Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Limitation of Liability</font>.&#160;&#160;No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">j)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Remedies</font>.&#160;&#160;The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&#160;&#160;The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">k)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Successors and Assigns</font>.&#160;&#160;Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.&#160;&#160;The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">l)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Amendment</font>.&#160;&#160;This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">m)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Severability</font>.&#160;&#160;Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">n)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Headings</font>.&#160;&#160;The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">********************</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">&#160;</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTICE OF EXERCISE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">TO:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;&#160;&#160;&#160;&#160;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;&#160;&#160;&#160;&#160;Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="20%">&#160;</td>
<td width="30%" style="BORDER-TOP: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="20%">&#160;</td>
<td width="30%" style="BORDER-TOP: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="20%">&#160;</td>
<td width="30%" style="BORDER-TOP: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="20%">&#160;</td>
<td width="30%" style="BORDER-TOP: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Accredited Investor</font>.&#160;&#160;The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[SIGNATURE OF HOLDER]</font></div>

<div>&#160;</div>

<div align="center">
<table align="center" bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td nowrap width="16%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name of Investing Entity:</font></font></div>
</td>
<td width="84%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
</tr></table>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Signature of Authorized Signatory of Investing Entity</font>:</font></font></font></div>
</td>
<td width="66%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td nowrap width="20%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name of Authorized Signatory:</font></font></div>
</td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td nowrap width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title of Authorized Signatory:</font></font></div>
</td>
<td width="81%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:</font></font></div>
</td>
<td width="96%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
</tr></table>
</div>
</div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSIGNMENT FORM</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(To assign the foregoing warrant, execute</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">this form and supply required information.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Do not use this form to exercise the warrant.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</font></div>

<div>&#160;</div>

<div align="center">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">whose address is</font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<table align="center" bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" width="64%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">&#160;</td>
<td width="36%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">.</font></td>
</tr><tr>
<td colspan="2" width="64%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="36%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="64%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="36%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="47%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:&#160;&#160;</font></td>
<td width="17%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">&#160;</td>
<td width="1%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">,&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td width="30%" style="PADDING-BOTTOM: 2px">&#160;</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Holder&#8217;s Signature:</font></font></td>
<td width="30%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="30%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Holder&#8217;s Address:</font></font></td>
<td width="30%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="30%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="30%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Signature Guaranteed:</font></font></div>
</td>
<td width="47%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="39%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE:&#160;&#160;The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company.&#160;&#160;Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>4
<FILENAME>fs12014ex4ix_actinium.htm
<DESCRIPTION>FORM OF LOCK-UP AGREEMENT, DATED DECEMBER 27, 2013.**
<TEXT>
<html>
<head>
    <title>fs12014ex4ix_actinium.htm</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 4.9</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FORM OF LOCK-UP AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">December __, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each Purchaser referenced below:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Re:</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unit Purchase Agreement, dated as of _________, 2013 (the &#8220;Purchase <font style="DISPLAY: inline; TEXT-DECORATION: underline">Agreement</font>&#8221;), between Actinium Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company</font>&#8221;) and the purchasers signatory thereto (each, a &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Purchaser</font>&#8221; and, collectively, the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Purchasers</font>&#8221;)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Ladies and Gentlemen:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Defined terms not otherwise defined in this letter agreement (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Letter Agreement</font>&#8221;) shall have the meanings set forth in the Purchase Agreement.&#160;&#160;Pursuant to Section 5.1(k) of the Purchase Agreement and in satisfaction of a condition of the Company&#8217;s obligations under the Purchase Agreement, the undersigned irrevocably agrees with the Company that, from the date hereof until the 6 month anniversary of the effective date of the registration statement to be filed in accordance with the terms of that certain registration rights agreement, dated on even date herewith, between the Company and the Purchasers (such period, the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Restriction Period</font>&#8221;), the undersigned will not offer, sell,&#160;&#160;contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate of the undersigned or any person in privity with the undersigned or any Affiliate of the undersigned), directly or indirectly, including the filing (or participation in the filing) of a registration statement with the Commission in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act with respect to, any shares of Common Stock or Common Stock Equivalents beneficially owned, held or hereafter acquired by the undersigned (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Securities</font>&#8221;).&#160;&#160;Beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act.&#160;&#160;In order to enforce this covenant, the Company shall impose irrevocable stop-transfer instructions preventing the Transfer Agent from effecting any actions in violation of this Letter Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 446pt"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned acknowledges that the execution, delivery and performance of this Letter Agreement is a material inducement to each Purchaser to complete the transactions contemplated by the Purchase Agreement and that each Purchaser (which shall be a third party beneficiary of this Letter Agreement) and the Company shall be entitled to specific performance of the undersigned&#8217;s obligations hereunder.&#160;&#160;The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform this Letter Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit from the closing of the transactions contemplated by the Purchase Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Letter Agreement may not be amended or otherwise modified in any respect without the written consent of each of the Company, each Purchaser and the undersigned.&#160;&#160;This Letter Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles of conflict of laws. The undersigned <font style="DISPLAY: inline">hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting in the Southern District of New York and the courts of the State of New York located in Manhattan, for the purposes of any suit, action or proceeding arising out of or relating to this Letter Agreement, and hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that (i) it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding is brought in an inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper.</font> The undersigned hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the Company at the address in effect for notices to it under the Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.&#160;&#160;The undersigned hereby waives any right to a trial by jury.&#160;&#160;Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.&#160;&#160;The undersigned agrees and understands that this Letter Agreement does not intend to create any relationship between the undersigned and each Purchaser and that each Purchaser is not entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended by virtue of this Letter Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By its signature below, the Transfer Agent hereby acknowledges and agrees that, reflecting this Letter Agreement, it has placed an irrevocable stop transfer instruction on all Securities beneficially owned by the undersigned until the end of the Restriction Period.&#160;&#160;This Letter Agreement shall be binding on successors and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into a similar agreement for the benefit of the Purchasers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*** SIGNATURE PAGE FOLLOWS***</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Letter Agreement may be executed in two or more counterparts, all of which when taken together may be considered one and the same agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="20%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td width="5%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Signature</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="20%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Print Name</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="20%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Position in Company</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Address for Notice:</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="20%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td width="75%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="20%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="20%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td width="75%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of shares of Common Stock</font></td>
<td width="75%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="20%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="75%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="3" width="25%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of shares of Common Stock underlying subject to warrants, options, debentures or other convertible securities</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By signing below, the Company agrees to enforce the restrictions on transfer set forth in this Letter Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="30%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td width="30%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="67%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="30%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="33%">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acknowledged and agreed to</font></div>

<div>as of the date set forth above:</div>
</td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="30%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Action Stock Transfer Corp.</font></font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="30%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td width="30%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="67%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td width="67%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.9pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.9pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.9pt">3

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>5
<FILENAME>fs12014ex10xxxiii_actinium.htm
<DESCRIPTION>ACTINIUM PHARMACEUTICALS, INC. AMENDED AND RESTATED 2013 STOCK PLAN.**
<TEXT>
<html>
<head>
    <title>fs12014ex10xxxiii_actinium.htm</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibit 10.33</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">ACTINIUM PHARMACEUTICALS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amended and Restated 2013 STOCK PLAN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Purposes of the Plan</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The purposes of this 2013<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company&#8217;s business.&#160;&#160;Options granted under the Plan may be Incentive Stock Options or Nonstatutory Stock Options, as determined by the Administrator at the time of grant of an option and subject to the applicable provisions of Section 422 of the Code and the regulations promulgated thereunder.&#160;&#160;Stock purchase rights may also be granted under the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Definitions</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;As used herein, the following definitions shall apply:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Administrator</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the Board or its Committee appointed pursuant to Section 4 of the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Affiliate</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means an entity other than a Subsidiary (as defined below) which, together with the Company, is under common control of a third person or entity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Applicable Laws</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the legal requirements relating to the administration of stock option and restricted stock purchase plans under applicable U.S. state corporate laws, U.S. federal laws and other applicable state laws, the Code and regulations thereunder, any Stock Exchange rules or regulations and the applicable laws of any other country or jurisdiction where Options or Stock Purchase Rights are granted under the Plan, as such laws, rules, regulations and requirements shall be in place from time to time.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Board</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the Board of Directors of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Change of Control</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font>&#160;&#160;means a sale of all or substantially all of the Company&#8217;s assets, or any merger, consolidation or other transaction of the Company with or into another corporation, entity or person, other than a transaction in which the holders of at least a majority of the shares of capital stock of the Company outstanding immediately prior to such transaction continue to hold (either by the voting securities remaining outstanding or by their being converted into voting securities of the surviving entity) a majority of the total voting power represented by the voting securities of the Company, or such surviving entity, outstanding immediately after such transaction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Code</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the Internal Revenue Code of 1986, as amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Committee</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means one or more committees or subcommittees of the Board appointed by the Board to administer the Plan in accordance with Section 4 below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Common Stock</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the Common Stock of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Company</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means Actinium Pharmaceuticals, Inc.., a Delaware corporation.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Consultant</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means any person, including an advisor, who is engaged by the Company or any Parent, Subsidiary or Affiliate to render services and is compensated for such services, and any director of the Company whether compensated for such services or not.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Continuous Service Status</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the absence of any interruption or termination of service as an Employee or Consultant.&#160;&#160;Continuous Service Status as an Employee or Consultant shall not be considered interrupted in the case of:&#160;&#160;(i)&#160;sick leave; (ii)&#160;military leave; (iii)&#160;any other leave of absence approved by the Administrator, provided that such leave is for a period of not more than ninety (90) days, unless reemployment upon the expiration of such leave is guaranteed by contract or statute, or unless provided otherwise pursuant to Company policy adopted from time to time; or (iv)&#160;in the case of transfers between locations of the Company or between the Company, its Parents, Subsidiaries, Affiliates or their respective successors.&#160;&#160;A change in status from an Employee to a Consultant or from a Consultant to an Employee will not constitute an interruption of Continuous Service.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Corporate Transaction</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a sale of all or substantially all of the Company&#8217;s assets, or a merger, consolidation or other capital reorganization or transaction of the Company with or into another corporation, entity or person, and includes a Change of Control.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Director</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221; </font>means a member of the Board.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Employee</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means any person employed by the Company or any Parent, Subsidiary or Affiliate, with the status of employment determined based upon such factors as are deemed appropriate by the Administrator in its discretion, subject to any requirements of the Code or the Applicable Laws.&#160;&#160;The payment by the Company of a director&#8217;s fee to a Director shall not be sufficient to constitute &#8220;employment&#8221; of such Director by the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exchange Act</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the Securities Exchange Act of 1934, as amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Fair Market Value</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means, as of any date, the fair market value of the Common Stock, as determined by the Administrator in good faith on such basis as it deems appropriate and applied consistently with respect to Participants.&#160;&#160;Whenever possible, the determination of Fair Market Value shall be based upon the closing price for the Shares as reported in the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Wall Street Journal</font> for the applicable date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Incentive Stock Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code, as designated in the applicable Option Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Listed Security</font>&#8221; means any security of the Company that is listed or approved for listing on a national securities exchange or designated or approved for designation as a national market system security on an interdealer quotation system by the National Association of Securities Dealers, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Named Executive</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221; </font>means any individual who, on the last day of the Company&#8217;s fiscal year, is the chief executive officer of the Company (or is acting in such capacity) or among the four most highly compensated officers of the Company (other than the chief executive officer).&#160;&#160;Such officer status shall be determined pursuant to the executive compensation disclosure rules under the Exchange Act.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-2-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Nonstatutory Stock Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means an Option not intended to qualify as an Incentive Stock Option, as designated in the applicable Option Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a stock option granted pursuant to the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Option Agreement</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a written document, the form(s) of which shall be approved from time to time by the Administrator, reflecting the terms of an Option granted under the Plan and includes any documents attached to or incorporated into such Option Agreement, including, but not limited to, a notice of stock option grant and a form of exercise notice.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Option Exchange Program</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a program approved by the Administrator whereby outstanding Options are exchanged for Options with a lower exercise price or are amended to decrease the exercise price as a result of a decline in the Fair Market Value of the Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Optioned Stock</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the Common Stock subject to an Option.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Optionee</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means an Employee, Director or Consultant who receives an Option.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Parent</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a &#8220;parent corporation,&#8221;, whether now or hereafter existing, as defined in Section&#160;424(e) of the Code, or any successor provision.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Participant</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means any holder of one or more Options or Stock Purchase Rights, or the Shares issuable or issued upon exercise of such awards, under the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Plan</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means this 2013 Stock Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Reporting Person</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means an officer, Director, or greater than ten percent stockholder of the Company within the meaning of Rule 16a-2 under the Exchange Act, who is required to file reports pursuant to Rule 16a-3 under the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Restricted Stock</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means Shares of Common Stock acquired pursuant to a grant of a Stock Purchase Right under Section&#160;11 below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Restricted Stock Purchase Agreement</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a written document, the form(s) of which shall be approved from time to time by the Administrator, reflecting the terms of a Stock Purchase Right granted under the Plan and includes any documents attached to such agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Rule 16b-3</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means Rule 16b-3 promulgated under the Exchange Act, as amended from time to time, or any successor provision.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-3-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Share</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a share of the Common Stock, as adjusted in accordance with Section 14 of the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Stock Exchange</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means any stock exchange or consolidated stock price reporting system on which prices for the Common Stock are quoted at any given time.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Stock Purchase Right</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means the right to purchase Common Stock pursuant to Section&#160;11 below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Subsidiary</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a &#8220;subsidiary corporation,&#8221; whether now or hereafter existing, as defined in Section&#160;424(f) of the Code, or any successor provision.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(kk)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8220;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Ten Percent Holder</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#8221;</font> means a person who owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Stock Subject to the Plan</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Subject to the provisions of Section 14 of the Plan, the maximum aggregate number of Shares that may be sold under the Plan is 5,750,000 Shares of Common Stock.&#160;&#160;The Shares may be authorized, but unissued, or reacquired Common Stock.&#160;&#160;If an award should expire or become unexercisable for any reason without having been exercised in full, or is surrendered pursuant to an Option Exchange Program, the unpurchased Shares that were subject thereto shall, unless the Plan shall have been terminated, become available for future grant under the Plan.&#160;&#160;In addition, any Shares of Common Stock which are retained by the Company upon exercise of an award in order to satisfy the exercise or purchase price for such award or any withholding taxes due with respect to such exercise or purchase shall be treated as not issued and shall continue to be available under the Plan.&#160;&#160;Shares issued under the Plan and later repurchased by the Company pursuant to any repurchase right which the Company may have shall not be available for future grant under the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Administration of the Plan</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">General</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The Plan shall be administered by the Board or a Committee, or a combination thereof, as determined by the Board.&#160;&#160;The Plan may be administered by different administrative bodies with respect to different classes of Participants and, if permitted by the Applicable Laws, the Board may authorize one or more officers to make awards under the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Committee Composition</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>If a Committee has been appointed pursuant to this Section 4, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board.&#160;&#160;From time to time the Board may increase the size of any Committee and appoint additional members thereof, remove members (with or without cause) and appoint new members in substitution therefor, fill vacancies (however caused) and remove all members of a Committee and thereafter directly administer the Plan, all to the extent permitted by the Applicable Laws and, in the case of a Committee administering the Plan in accordance with the requirements of Rule 16b-3 or Section 162(m) of the Code, to the extent permitted or required by such provisions.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-4-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Powers of the Administrator</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Subject to the provisions of the Plan and in the case of a Committee, the specific duties delegated by the Board to such Committee, the Administrator shall have the authority, in its discretion:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to determine the Fair Market Value of the Common Stock, in accordance with Section 2(p) of the Plan, provided that such determination shall be applied consistently with respect to Participants under the Plan;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to select the Employees, Directors and Consultants to whom Plan awards may from time to time be granted;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to determine whether and to what extent Plan awards are granted;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to determine the number of Shares of Common Stock to be covered by each award granted;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to approve the form(s) of agreement(s) used under the Plan;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to determine the terms and conditions, not inconsistent with the terms of the Plan, of any award granted hereunder, which terms and conditions include but are not limited to the exercise or purchase price, the time or times when awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, any pro-rata adjustment to vesting as a result of a Participant&#8217;s transitioning from full- to part-time services (or vice versa), and any restriction or limitation regarding any Option, Optioned Stock, Stock Purchase Right or Restricted Stock, based in each case on such factors as the Administrator, in its sole discretion, shall determine;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to determine whether and under what circumstances an Option may be settled in cash under Section 10(c) instead of Common Stock;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(viii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;to implement an Option Exchange Program on such terms and conditions as the Administrator in its discretion deems appropriate, provided that no amendment or adjustment to an Option that would materially and adversely affect the rights of any Optionee shall be made without the prior written consent of the Optionee;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ix)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to adjust the vesting of an Option held by an Employee, Director or Consultant as a result of a change in the terms or conditions under which such person is providing services to the Company;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to construe and interpret the terms of the Plan and awards granted under the Plan, which constructions, interpretations and decisions shall be final and binding on all Participants; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(xi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in order to fulfill the purposes of the Plan and without amending the Plan, to modify grants of Options or Stock Purchase Rights to Participants who are foreign nationals or employed outside of the United States in order to recognize differences in local law, tax policies or customs.</font></div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-5-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Eligibility</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Recipients of Grants</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Nonstatutory Stock Options and Stock Purchase Rights may be granted to Employees, Directors and Consultants.&#160;&#160;Incentive Stock Options may be granted only to Employees, provided that Employees of Affiliates shall not be eligible to receive Incentive Stock Options.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Type of Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Each Option shall be designated in the Option Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">ISO $100,000 Limitation</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">. </font>Notwithstanding any designation under Section 5(b), to the extent that the aggregate Fair Market Value of Shares with respect to which Options designated as Incentive Stock Options are exercisable for the first time by any Optionee during any calendar year (under all plans of the Company or any Parent or Subsidiary) exceeds $100,000, such excess Options shall be treated as Nonstatutory Stock Options.&#160;&#160;For purposes of this Section&#160;5(c), Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of the Shares subject to an Incentive Stock Option shall be determined as of the date of the grant of such Option.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">No Employment Rights</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>The Plan shall not confer upon any Participant any right with respect to continuation of an employment or consulting relationship with the Company, nor shall it interfere in any way with such Participant&#8217;s right or the Company&#8217;s right to terminate his or her employment or consulting relationship at any time or any reason.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Term of Plan</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The Plan shall become effective upon its adoption by the Board of Directors.&#160;&#160;It shall continue in effect for a term of ten (10) years unless sooner terminated under Section 16 of the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Term of Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The term of each Option shall be the term stated in the Option Agreement; provided that the term shall be no more than ten&#160;years from the date of grant thereof or such shorter term as may be provided in the Option Agreement and provided further that, in the case of an Incentive Stock Option granted to a person who at the time of such grant is a Ten Percent Holder, the term of the Option shall be five years from the date of grant thereof or such shorter term as may be provided in the Option Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">[Reserved.]</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Option Exercise Price and Consideration</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exercise Price</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The per Share exercise price for the Shares to be issued pursuant to exercise of an Option shall be such price as is determined by the Administrator and set forth in the Option Agreement, but shall be subject to the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of an Incentive Stock Option</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 144pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;granted to an Employee who at the time of grant is a Ten Percent Holder, the per Share exercise price shall be no less than 110% of the Fair Market Value per Share on the date of grant; or</font></div>

<div style="TEXT-INDENT: 144pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-6-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 144pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(B)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;granted to any other Employee, the per Share exercise price shall be no less than 100% of the Fair Market Value per Share on the date of grant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of a Nonstatutory Stock Option, the per share Exercise Price shall be such price as determined by the Administrator provided that for any Nonstatutory Stock Option granted on any date on which the Common Stock is a Listed Security to an eligible person who is, at the time of the grant of such Option, a Named Executive of the Company, the per share Exercise Price shall be no less than 100% of the Fair Market Value on the date of grant if such Option is intended to qualify as performance-based compensation under Section 162(m) of the Code.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing, Options may be granted with a per Share exercise price other than as required above pursuant to a Corporate Transaction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Permissible Consideration</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>The consideration to be paid for the Shares to be issued upon exercise of an Option, including the method of payment, shall be determined by the Administrator (and, in the case of an Incentive Stock Option, shall be determined at the time of grant) and may consist entirely of (1)&#160;cash; (2)&#160;check; (3)&#160;delivery of Optionee&#8217;s promissory note with such recourse, interest, security and redemption provisions as the Administrator determines to be appropriate (subject to applicable provisions of Delaware law); (4)&#160;cancellation of indebtedness; (5) other Shares that have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which the Option is exercised, provided that in the case of Shares acquired, directly or indirectly, from the Company, such Shares must have been owned by the Optionee for more than six months on the date of surrender (or such other period as may be required to avoid the Company&#8217;s incurring an adverse accounting charge); (6)&#160;delivery of a properly executed exercise notice together with such other documentation as the Administrator and a securities broker approved by the Company shall require to effect exercise of the Option and prompt delivery to the Company of the sale or loan proceeds required to pay the exercise price and any applicable withholding taxes; or (7) any combination of the foregoing methods of payment.&#160;&#160;In making its determination as to the type of consideration to accept, the Administrator shall consider if acceptance of such consideration may be reasonably expected to benefit the Company and the Administrator may, in its sole discretion, refuse to accept a particular form of consideration at the time of any Option exercise.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exercise of Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">General</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exercisability</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>Any Option granted hereunder shall be exercisable at such times and under such conditions as determined by the Administrator, consistent with the term of the Plan and reflected in the Option Agreement, including vesting requirements and/or performance criteria with respect to the Company and/or the Optionee.&#160;&#160;The Administrator shall have the discretion to determine whether and to what extent the vesting of Options shall be tolled during any unpaid leave of absence; provided however that in the absence of such determination, vesting of Options shall be tolled during any such leave (unless otherwise required by the Applicable Laws.&#160;&#160;In the event of military leave, vesting shall toll during any unpaid portion of such leave, provided that upon a Participant&#8217;s return from military leave he or she will be given vesting credit with respect to awards to the same extent as would have applied had the Participant continued to provide services to the Company throughout the leave on the same terms as he or she was providing services immediately prior to the leave.</font></div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-7-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Minimum Exercise Requirements</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>An Option may not be exercised for a fraction of a Share.&#160;&#160;The Administrator may require that an Option be exercised as to a minimum number of Shares, provided that such requirement shall not prevent an Optionee from exercising the full number of Shares as to which the Option is then exercisable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Procedures for and Results of Exercise</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>An Option shall be deemed exercised when written notice of such exercise has been given to the Company in accordance with the terms of the Option by the person entitled to exercise the Option and the Company has received full payment for the Shares with respect to which the Option is exercised.&#160;&#160;Full payment may, as authorized by the Administrator, consist of any consideration and method of payment allowable under Section&#160;9(b) of the Plan, provided that the Administrator may, in its sole discretion, refuse to accept any form of consideration at the time of any Option exercise.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exercise of an Option in any manner shall result in a decrease in the number of Shares that thereafter may be available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Rights as Stockholder</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Optioned Stock, notwithstanding the exercise of the Option.&#160;&#160;No adjustment will be made for a dividend or other right for which the record date is prior to the date the stock certificate is issued, except as provided in Section&#160;14 of the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Termination of Employment or Consulting Relationship</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Except as otherwise set forth in this Section 10(b), the Administrator shall establish and set forth in the applicable Option Agreement the terms and conditions upon which an Option shall remain exercisable, if at all, following termination of an Optionee&#8217;s Continuous Service Status, which provisions may be waived or modified by the Administrator at any time in the Administrator&#8217;s sole discretion.&#160;&#160;Unless otherwise provided in the Option Agreement, to the extent that the Optionee is not vested in the Optioned Stock on the date of termination of his or her Continuous Service Status, or if the Optionee (or other person entitled to exercise the Option) does not exercise the Option to the extent so entitled within the time specified in the Option Agreement or below (as applicable), the Option shall terminate and the Optioned Stock underlying the unexercised portion of the Option shall revert to the Plan.&#160;&#160;In no event may any Option be exercised after the expiration of the Option term as set forth in the Option Agreement (and subject to Section 7).</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-8-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following provisions (1) shall apply to the extent an Option Agreement does not specify the terms and conditions upon which an Option shall terminate upon termination of an Optionee&#8217;s Continuous Service Status, and (2) establish the minimum post-termination exercise periods that may be set forth in an Option Agreement:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Termination other than Upon Disability or Death</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>In the event of termination of an Optionee&#8217;s Continuous Service Status, such Optionee may exercise an Option for 30 days following such termination to the extent the Optionee was vested in the Optioned Stock as of the date of such termination.&#160;&#160;No termination shall be deemed to occur and this Section 10(b)(i) shall not apply if (A) the Optionee is a Consultant who becomes an Employee, or (B) the Optionee is an Employee who becomes a Consultant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Disability of Optionee</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>In the event of termination of an Optionee&#8217;s Continuous Service Status as a result of his or her disability (including a disability within the meaning of Section 22(e)(3) of the Code), such Optionee may exercise an Option at any time within twelve months following such termination to the extent the Optionee was vested in the Optioned Stock as of the date of such termination.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Death of Optionee</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;In the event of the death of an Optionee during the period of Continuous Service Status since the date of grant of the Option, or within thirty days following termination of Optionee&#8217;s Continuous Service, the Option may be exercised by Optionee&#8217;s estate or by a person who acquired the right to exercise the Option by bequest or inheritance at any time within twelve months following the date of death, but only to the extent the Optionee was vested in the Optioned Stock as of the date of death or, if earlier, the date the Optionee&#8217;s Continuous Service Status terminated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Buyout Provisions.</font>&#160;&#160;The Administrator may at any time offer to buy out for a payment in cash or Shares an Option previously granted under the Plan based on such terms and conditions as the Administrator shall establish and communicate to the Optionee at the time that such offer is made.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Stock Purchase Rights</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Rights to Purchase</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;When the Administrator determines that it will offer Stock Purchase Rights under the Plan, it shall advise the offeree in writing of the terms, conditions and restrictions related to the offer, including the number of Shares that such person shall be entitled to purchase, the price to be paid, and the time within which such person must accept such offer. The offer to purchase Shares subject to Stock Purchase Rights shall be accepted by execution of a Restricted Stock Purchase Agreement in the form determined by the Administrator.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Repurchase Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">General</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">. </font>Unless the Administrator determines otherwise, the Restricted Stock Purchase Agreement shall grant the Company a repurchase option exercisable upon the voluntary or involuntary termination of the purchaser&#8217;s employment with the Company for any reason (including death or disability).&#160;&#160;The purchase price for Shares repurchased pursuant to the Restricted Stock Purchase Agreement shall be the original purchase price paid by the purchaser and may be paid by cancellation of any indebtedness of the purchaser to the Company. The repurchase option shall lapse at such rate as the Administrator may determine.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Other Provisions</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The Restricted Stock Purchase Agreement shall contain such other terms, provisions and conditions not inconsistent with the Plan as may be determined by the Administrator in its sole discretion.&#160;&#160;In addition, the provisions of Restricted Stock Purchase Agreements need not be the same with respect to each purchaser.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-9-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Rights as a Stockholder</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Once the Stock Purchase Right is exercised, the purchaser shall have the rights equivalent to those of a stockholder, and shall be a stockholder when his or her purchase is entered upon the records of the duly authorized transfer agent of the Company.&#160;&#160;No adjustment will be made for a dividend or other right for which the record date is prior to the date the Stock Purchase Right is exercised, except as provided in Section 14 of the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Taxes</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As a condition of the exercise of an Option or Stock Purchase Right granted under the Plan, the Participant (or in the case of the Participant&#8217;s death, the person exercising the Option or Stock Purchase Right) shall make such arrangements as the Administrator may require for the satisfaction of any applicable federal, state, local or foreign withholding tax obligations that may arise in connection with the exercise of the Option or Stock Purchase Right and the issuance of Shares.&#160;&#160;The Company shall not be required to issue any Shares under the Plan until such obligations are satisfied.&#160;&#160;If the Administrator allows the withholding or surrender of Shares to satisfy a Participant&#8217;s tax withholding obligations under this Section 12 (whether pursuant to Section 12(c), (d) or (e), or otherwise), the Administrator shall not allow Shares to be withheld in an amount that exceeds the minimum statutory withholding rates for federal and state tax purposes, including payroll taxes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of an Employee and in the absence of any other arrangement, the Employee shall be deemed to have directed the Company to withhold or collect from his or her compensation an amount sufficient to satisfy such tax obligations from the next payroll payment otherwise payable after the date of an exercise of the Option or Stock Purchase Right.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Section 12(c) shall apply only after the date, if any, upon which the Common Stock becomes a Listed Security.&#160;&#160;In the case of Participant other than an Employee (or in the case of an Employee where the next payroll payment is not sufficient to satisfy such tax obligations, with respect to any remaining tax obligations), in the absence of any other arrangement and to the extent permitted under the Applicable Laws, the Participant shall be deemed to have elected to have the Company withhold from the Shares to be issued upon exercise of the Option or Stock Purchase Right that number of Shares having a Fair Market Value determined as of the applicable Tax Date (as defined below) equal to the amount required to be withheld.&#160;&#160;For purposes of this Section 12, the Fair Market Value of the Shares to be withheld shall be determined on the date that the amount of tax to be withheld is to be determined under the Applicable Laws (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Tax Date</font>&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If permitted by the Administrator, in its discretion, a Participant may satisfy his or her tax withholding obligations upon exercise of an Option or Stock Purchase Right by surrendering to the Company Shares that have a Fair Market Value determined as of the applicable Tax Date equal to the amount required to be withheld.&#160;&#160;In the case of shares previously acquired from the Company that are surrendered under this Section 12(d), such Shares must have been owned by the Participant for more than six (6) months on the date of surrender (or such other period of time as is required for the Company to avoid adverse accounting charges).</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-10-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any election or deemed election by a Participant to have Shares withheld to satisfy tax withholding obligations under Section 12(c) or (d) above shall be irrevocable as to the particular Shares as to which the election is made and shall be subject to the consent or disapproval of the Administrator.&#160;&#160;Any election by a Participant under Section 12(d) above must be made on or prior to the applicable Tax Date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event an election to have Shares withheld is made by a Participant and the Tax Date is deferred under Section 83 of the Code because no election is filed under Section 83(b) of the Code, the Participant shall receive the full number of Shares with respect to which the Option or Stock Purchase Right is exercised but such Participant shall be unconditionally obligated to tender back to the Company the proper number of Shares on the Tax Date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Non-Transferability of Options and Stock Purchase Rights</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">General.</font>&#160;&#160;Except as set forth in this Section 13, Options and Stock Purchase Rights may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will or by the laws of descent or distribution.&#160;&#160;The designation of a beneficiary by an Optionee will not constitute a transfer.&#160;&#160;An Option or Stock Purchase Right may be exercised, during the lifetime of the holder of an Option or Stock Purchase Right, only by such holder or a transferee permitted by this Section&#160;13.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Limited Transferability Rights</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>Notwithstanding anything else in this Section 13, prior to the date, if any, on which the Common Stock becomes a Listed Security, the Administrator may in its discretion grant Nonstatutory Stock Options that may be transferred by instrument to an inter vivos or testamentary trust in which the Options are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift to &#8220;Immediate Family&#8221; (as defined below), on such terms and conditions as the Administrator deems appropriate.&#160;&#160;Following the date, if any, on which the Common Stock becomes a Listed Security, the Administrator may in its discretion grant transferable Nonstatutory Stock Options pursuant to Option Agreements specifying the manner in which such Nonstatutory Stock Options are transferable.&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Immediate Family</font>&#8221; means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, and shall include adoptive relationships.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Adjustments Upon Changes in Capitalization, Merger or Certain Other Transactions</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Changes in Capitalization</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Subject to any required action by the stockholders of the Company, the number of Shares of Common Stock covered by each outstanding Option or Stock Purchase Right, the number of Shares set forth in Sections 3 and 8 above and the number of Shares of Common Stock that have been authorized for issuance under the Plan but as to which no Options or Stock Purchase Rights have yet been granted or that have been returned to the Plan upon cancellation or expiration of an Option or Stock Purchase Right, as well as the price per Share of Common Stock covered by each such outstanding Option or Stock Purchase Right, shall be proportionately adjusted for any increase or decrease in the number of issued Shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination, recapitalization or reclassification of the Common Stock, or any other increase or decrease in the number of issued Shares of Common Stock effected without receipt of consideration by the Company; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been &#8220;effected without receipt of consideration.&#8221;&#160;&#160;Such adjustment shall be made by the Administrator, whose determination in that respect shall be final, binding and conclusive.&#160;&#160;Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of Shares of Common Stock subject to an Option or Stock Purchase Right.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-11-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Dissolution or Liquidation</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;In the event of the dissolution or liquidation of the Company, each Option and Stock Purchase Right will terminate immediately prior to the consummation of such action, unless otherwise determined by the Administrator.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Corporate Transaction</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;In the event of a Corporate Transaction, each outstanding Option or Stock Purchase Right shall be assumed or an equivalent option or right shall be substituted by such successor corporation or a parent or subsidiary of such successor corporation (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Successor Corporation</font>&#8221;), unless the Successor Corporation does not agree to assume the award or to substitute an equivalent option or right, in which case such Option or Stock Purchase Right shall terminate upon the consummation of the transaction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For purposes of this Section 14(c), an Option or a Stock Purchase Right shall be considered assumed, without limitation, if, at the time of issuance of the stock or other consideration upon a Corporate Transaction or a Change of Control, as the case may be, each holder of an Option or Stock Purchase Right would be entitled to receive upon exercise of the award the same number and kind of shares of stock or the same amount of property, cash or securities as such holder would have been entitled to receive upon the occurrence of the transaction if the holder had been, immediately prior to such transaction, the holder of the number of Shares of Common Stock covered by the award at such time (after giving effect to any adjustments in the number of Shares covered by the Option or Stock Purchase Right as provided for in this Section 14); provided that if such consideration received in the transaction is not solely common stock of the Successor Corporation, the Administrator may, with the consent of the Successor Corporation, provide for the consideration to be received upon exercise of the award to be solely common stock of the Successor Corporation equal to the Fair Market Value of the per Share consideration received by holders of Common Stock in the transaction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Certain Distributions</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;In the event of any distribution to the Company&#8217;s stockholders of securities of any other entity or other assets (other than dividends payable in cash or stock of the Company) without receipt of consideration by the Company, the Administrator may, in its discretion, appropriately adjust the price per Share of Common Stock covered by each outstanding Option or Stock Purchase Right to reflect the effect of such distribution.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Time of Granting Options and Stock Purchase Rights</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The date of grant of an Option or Stock Purchase Right shall, for all purposes, be the date on which the Administrator makes the determination granting such Option or Stock Purchase Right, or such other date as is determined by the Administrator, provided that in the case of any Incentive Stock Option, the grant date shall be the later of the date on which the Administrator makes the determination granting such Incentive Stock Option or the date of commencement of the Optionee&#8217;s employment relationship with the Company.&#160;&#160;Notice of the determination shall be given to each Employee, Director or Consultant to whom an Option or Stock Purchase Right is so granted within a reasonable time after the date of such grant.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-12-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Amendment and Termination of the Plan</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Authority to Amend or Terminate</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The Board may at any time amend, alter, suspend or discontinue the Plan, but no amendment, alteration, suspension or discontinuation (other than an adjustment pursuant to Section 14 above) shall be made that would materially and adversely affect the rights of any Optionee or holder of Stock Purchase Rights under any outstanding grant, without his or her consent.&#160;&#160;In addition, to the extent necessary and desirable to comply with the Applicable Laws, the Company shall obtain stockholder approval of any Plan amendment in such a manner and to such a degree as required.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Effect of Amendment or Termination</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;No amendment or termination of the Plan shall materially and adversely affect Options or Stock Purchase Rights already granted, unless mutually agreed otherwise between the Optionee or holder of the Stock Purchase Rights and the Administrator, which agreement must be in writing and signed by the Optionee or holder and the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Conditions Upon Issuance of Shares</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Notwithstanding any other provision of the Plan or any agreement entered into by the Company pursuant to the Plan, the Company shall not be obligated, and shall have no liability for failure, to issue or deliver any Shares under the Plan unless such issuance or delivery would comply with the Applicable Laws, with such compliance determined by the Company in consultation with its legal counsel.&#160;&#160;As a condition to the exercise of an Option or Stock Purchase Right, the Company may require the person exercising the award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by law.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Reservation of Shares</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Agreements</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Options and Stock Purchase Rights shall be evidenced by Option Agreements and Restricted Stock Purchase Agreements, respectively, in such form(s) as the Administrator shall from time to time approve.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Stockholder Approval</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;If required by the Applicable Laws, continuance of the Plan shall be subject to approval by the stockholders of the Company within twelve (12) months before or after the date the Plan is adopted.&#160;&#160;Such stockholder approval shall be obtained in the manner and to the degree required under the Applicable Laws.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-13-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Information and Documents to Optionees and Purchasers</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Prior to the date, if any, upon which the Common Stock becomes a Listed Security and if required by the Applicable Laws, the Company shall provide financial statements at least annually to each Optionee and to each individual who acquired Shares pursuant to the Plan, during the period such Optionee or purchaser has one or more Options or Stock Purchase Rights outstanding, and in the case of an individual who acquired Shares pursuant to the Plan, during the period such individual owns such Shares.&#160;&#160;The Company shall not be required to provide such information if the issuance of Options or Stock Purchase Rights under the Plan is limited to key employees whose duties in connection with the Company assure their access to equivalent information.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">22.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Awards Granted to California Residents</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Prior to the date, if any, upon which the Common Stock becomes a Listed Security, Options or Stock Purchase Rights granted under the Plan to persons resident in California shall be subject to the provisions set forth in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Attachment A</font> hereto.&#160;&#160;To the extent the provisions of the Plan conflict with the provisions set forth on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Attachment&#160;A</font>, the provisions on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Attachment&#160;A</font> shall govern the terms of such Options.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-14-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Attachment A</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Provisions Applicable to Award Recipients</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Resident in California</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Until such time as any security of the Company becomes a Listed Security and if required by Applicable Laws, the following additional terms shall apply to Options and Stock Purchase Rights, and Shares issued upon exercise of such awards, granted under the 2002<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>Stock Plan (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Plan</font>&#8221;) to persons resident in California as of the grant date of any such award (each such person, a &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">California Recipient</font>&#8221;):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of an Option, whether an Incentive Stock Option or a Nonqualified Stock Option, that is granted to a California Recipient who, at the time of the grant of such Option, owns stock representing more than 10% of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price shall be no less than 110% of the Fair Market Value on the grant date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of a Nonqualified Stock Option that is granted to any other California Recipient, the per Share exercise price shall be no less than 85% of the Fair Market Value per Share on the grant date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the case of a Stock Purchase Right granted to a California Recipient, the purchase price applicable to stock purchased under such Stock Award shall not be less than 85% of the Fair Market Value of the Shares as of the Grant Date, or, in the case of a person owning stock representing more than 10% of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the price shall not be less than 100% of the Fair Market Value of the Shares as of the grant date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to an Option or Stock Purchase Right issued to any California Recipient who is not an Officer, Director or Consultant, such Option or Stock Purchase Right shall become exercisable, or any repurchase option in favor of the Company shall lapse, at the rate of at least 20% per year over five years from the grant date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following rules shall apply to an Option issued to any California Recipient or to stock issued to a California Recipient upon exercise of a Stock Purchase Right, in the event of termination of the California Recipient&#8217;s employment or services with the Company:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If such termination was for reasons other than death or disability, the California Recipient shall have at least 30 days after the Termination Date (but in no event later than the expiration of the term of such Option established by the Plan Administrator as of the grant date) to exercise such Option to the extent the California Recipient was vested in the Optioned Stock as of the Termination Date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If such termination was on account of the death or disability of the California Recipient, the holder of the Option may, but only within six months from the Termination Date (but in no event later than the expiration date of the term of such Option established by the Plan Administrator as of the grant date), exercise the Option to the extent the California Recipient was vested in the Optioned Stock as of the Termination Date. To the extent that the California Recipient was not vested in the Optioned Stock as of the Termination Date, or if the holder does not exercise such Option to the extent so entitled within six months from the Termination Date, the Option shall terminate and the Common Stock underlying the unexercised portion of the Option shall revert to the Plan.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall provide financial statements at least annually to each California Recipient during the period such person has one or more Options or Stock Awards outstanding, and in the case of an individual who acquired Shares pursuant to the Plan, during the period such individual owns such Shares.&#160;&#160;The Company shall not be required to provide such information if the issuance of awards under the Plan is limited to key employees whose duties in connection with the Company assure their access to equivalent information.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unless defined below or otherwise in this Attachment, Capitalized terms shall have the meanings set forth in the Plan.&#160;&#160;For purposes of this Attachment, &#8220;Officer&#8221; means a person who is an officer of the Company within the meaning of Section 16(a) of the Exchange Act and the rules and regulations promulgated thereunder.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-2-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exhibit D to Minutes of API Board of Directors Meeting of ________, 2013</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013 STOCK PLAN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">NOTICE OF STOCK OPTION GRANT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">You have been granted an option to purchase Common Stock of Actinium Pharmaceuticals, Inc. (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Company</font>&#8221;) as follows:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">Board Approval Date:</td>
<td><font color="red" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;BoardApprovalDate&#187;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 171pt">
<div>
<div>Date of Grant (Later of Board</div>
</div>
</td>
<td>&#160;</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">
<div>Approval Date or Commencement</div>
</td>
<td>&#160;</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">of Employment/Consulting):</td>
<td><font color="red" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;GrantDate&#187;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">Exercise Price per Share:</td>
<td>$<font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;ExercisePrice&#187;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">Total Number of Shares Granted:&#160;</td>
<td><font color="red" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;NoofShares&#187;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">Total Exercise Price:</td>
<td>$<font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;TotalExercisePrice&#187;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">Type of Option:</td>
<td><font color="red" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;NoSharesISO&#187;</font> Shares Incentive Stock Option</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">&#160;</td>
<td>
<div><font color="red" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;NoSharesNSO&#187;</font> Shares Nonstatutory Stock Option</div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">Expiration Date:</td>
<td><font color="red" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;Term&#187;</font>/<font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;ExpirationDate&#187;</font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">Vesting Commencement Date:&#160;</td>
<td><font color="red" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;VestingCommencementDate&#187;</font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Vesting/Exercise Schedule:</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">So long as your full time employment or consulting relationship with the Company continues, the Shares underlying this Option shall vest and become exercisable in accordance with the following schedule: ___________ of the Shares subject to the Option shall vest and become exercisable on the ________ month anniversary of the Vesting Commencement Date and _______ of the total number of Shares subject to the Option shall vest and become exercisable</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">each month thereafter.</font></font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Termination Period:</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Option may be exercised for ___ days after termination of employment or consulting relationship except as set out in Section&#160;5 of the Stock Option Agreement (but in no event later than the Expiration Date).&#160;&#160;Optionee is responsible for keeping track of these exercise periods following termination for any reason of his or her service relationship with the Company.&#160;&#160;The Company will not provide further notice of such periods.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36.349pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 171pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Transferability:</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Option may not be transferred.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-3-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By your signature and the signature of the Company&#8217;s representative below, you and the Company agree that this option is granted under and governed by the terms and conditions of the Actinium Pharmaceuticals, Inc. 2013 Stock Plan and the Stock Option Agreement, both of which are attached and made a part of this document.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, you agree and acknowledge that your rights to any Shares underlying the Option will be earned only as you provide services to the Company over time, that the grant of the Option is not as consideration for services you rendered to the Company prior to your Vesting Commencement Date, and that nothing in this Notice or the attached documents confers upon you any right to continue your employment or consulting relationship with the Company for any period of time, nor does it interfere in any way with your right or the Company&#8217;s right to terminate that relationship at any time, for any reason, with or without cause.</font></div>

<div align="left">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" width="47%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: normal"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></font></font></div>
</td>
</tr><tr>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" width="47%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="37%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td colspan="3" width="45%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="37%"><font color="red" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="4%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td width="43%" style="BORDER-BOTTOM: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;</font></font></td>
<td colspan="2" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-4-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013 STOCK PLAN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">STOCK OPTION AGREEMENT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Grant of Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Actinium Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Compan</font>y&#8221;), hereby grants to <font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font> (&#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Optionee</font>&#8221;), an option (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Option</font>&#8221;) to purchase the total number of shares of Common Stock (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Shares</font>&#8221;) set forth in the Notice of Stock Option Grant (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Notice</font>&#8221;), at the exercise price per Share set forth in the Notice (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exercise Price</font>&#8221;) subject to the terms, definitions and provisions of the Actinium Pharmaceuticals, Inc. 2013 Stock Plan (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Plan</font>&#8221;) adopted by the Company, which is incorporated in this Agreement by reference. Unless otherwise defined in this Agreement, the terms used in this Agreement shall have the meanings defined in the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Designation of Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>This Option is intended to be an Incentive Stock Option as defined in Section&#160;422 of the Code only to the extent so designated in the Notice, and to the extent it is not so designated or to the extent the Option does not qualify as an Incentive Stock Option, it is intended to be a Nonstatutory Stock Option.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding the above, if designated as an Incentive Stock Option, in the event that the Shares subject to this Option (and all other Incentive Stock Options granted to Optionee by the Company or any Parent or Subsidiary, including under other plans of the Company) that first become exercisable in any calendar year have an aggregate fair market value (determined for each Share as of the date of grant of the option covering such Share) in excess of $100,000, the Shares in excess of $100,000 shall be treated as subject to a Nonstatutory Stock Option, in accordance with Section 5(c) of the Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exercise of Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;This Option shall be exercisable during its term in accordance with the Vesting/Exercise Schedule set out in the Notice and with the provisions of Section&#160;10 of the Plan as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Right to Exercise</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Option may not be exercised for a fraction of a share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event of Optionee&#8217;s death, disability or other termination of employment, the exercisability of the Option is governed by Section&#160;5 below, subject to the limitations contained in this Section&#160;3.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In no event may this Option be exercised after the Expiration Date of the Option as set forth in the Notice.</font></div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Method of Exercise</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Option shall be exercisable by execution and delivery of the Exercise Notice and Restricted Stock Purchase Agreement attached hereto as <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exhibit A</font> (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exercise Agreement</font>&#8221;) or of any other form of written notice approved for such purpose by the Company which shall state Optionee&#8217;s election to exercise the Option, the number of Shares in respect of which the Option is being exercised, and such other representations and agreements as to the holder&#8217;s investment intent with respect to such Shares as may be required by the Company pursuant to the provisions of the Plan.&#160;&#160;Such written notice shall be signed by Optionee and shall be delivered to the Company by such means as are determined by the Plan Administrator in its discretion to constitute adequate delivery.&#160;&#160;The written notice shall be accompanied by payment of the Exercise Price.&#160;&#160;This Option shall be deemed to be exercised upon receipt by the Company of such written notice accompanied by the Exercise Price.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As a condition to the exercise of this Option and as further set forth in Section 12 of the Plan, Optionee agrees to make adequate provision for federal, state or other tax withholding obligations, if any, which arise upon the vesting or exercise of the Option, or disposition of Shares, whether by withholding, direct payment to the Company, or otherwise.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company is not obligated, and will have no liability for failure, to issue or deliver any Shares upon exercise of the Option unless such issuance or delivery would comply with the Applicable Laws, with such compliance determined by the Company in consultation with its legal counsel. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>This Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any applicable federal or state securities or other law or regulation, including any rule under Part&#160;221 of Title&#160;12 of the Code of Federal Regulations as promulgated by the Federal Reserve Board.&#160;&#160;As a condition to the exercise of this Option, the Company may require Optionee to make any representation and warranty to the Company as may be required by the Applicable Laws.&#160;&#160;Assuming such compliance, for income tax purposes the Shares shall be considered transferred to Optionee on the date on which the Option is exercised with respect to such Shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Voting Agreement.&#160;&#160;</font>Upon exercise of the Option, Optionee shall enter into a voting agreement providing that Otionee will grant a revocable proxy to management of the Company to vote the Otionee&#8217;s Option Shares for all purposes, in form and substance satisfactory to the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Method of Payment</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Payment of the Exercise Price shall be by any of the following, or a combination of the following, at the election of Optionee:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;cash or check;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;prior to the date, if any, upon which the Common Stock becomes a Listed Security, by surrender of other shares of Common Stock of the Company that have an aggregate Fair Market Value on the date of surrender equal to the Exercise Price of the Shares as to which the Option is being exercised.&#160;&#160;In the case of shares acquired directly or indirectly from the Company, such shares must have been owned by Optionee for more than six&#160;(6) months on the date of surrender (or such other period of time as is necessary to avoid the Company&#8217;s incurring adverse accounting charges); or</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-2-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;following the date, if any, upon which the Common Stock is a Listed Security, delivery of a properly executed exercise notice together with irrevocable instructions to a broker approved by the Company to deliver promptly to the Company the amount of sale or loan proceeds required to pay the exercise price.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Termination of Relationship</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Following the date of termination of Optionee&#8217;s Continuous Service Status for any reason (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Termination Date</font>&#8221;), Optionee may exercise the Option only as set forth in the Notice and this Section 5.&#160;&#160;To the extent that Optionee is not vested in the Optioned Stock as of the Termination Date, or if Optionee (or other person entitled to exercise the Option) does not exercise this Option within the Termination Period set forth in the Notice or the termination periods set forth below, the Option shall terminate in its entirety.&#160;&#160;In no event, may any Option be exercised after the Expiration Date of the Option as set forth in<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>the Notice.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Termination</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>In the event of termination of Optionee&#8217;s Continuous Service Status other than as a result of Optionee&#8217;s disability or death, Optionee may, to the extent Optionee is vested in the Optioned Stock as of the Termination Date, exercise this Option during the Termination Period set forth in the Notice.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Other Terminations</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>In connection with any termination other than a termination covered by Section 5(a), Optionee may exercise the Option only as described below:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Termination upon Disability of Optionee</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">. </font>In the event of termination of Optionee&#8217;s Continuous Service Status as a result of Optionee&#8217;s disability, Optionee may, to the extent Optionee was vested in the Optioned Stock as of such Termination Date, exercise this Option at any time within six months from the Termination Date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Death of Optionee</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;In<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>the event of the death of Optionee (A) during the term of this Option and while an Employee or Consultant of the Company and having been in Continuous Service Status since the date of grant of the Option, or (B) within thirty (30) days after Optionee&#8217;s Termination Date, to the extent Optionee was vested in the Optioned Stock as of the Termination Date, the Option may be exercised at any time within six months following the date of death by Optionee&#8217;s estate or by a person who acquired the right to exercise the Option by bequest or inheritance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Non-Transferability of Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Optionee only by him or her.&#160;&#160;The terms of this Option shall be binding upon the executors, administrators, heirs, successors and assigns of Optionee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Tax Consequences</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Below is a brief summary as of the date of this Option of certain of the federal tax consequences of exercise of this Option and disposition of the Shares under the laws in effect as of the Date of Grant.&#160;&#160;THIS SUMMARY IS INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE.&#160;&#160;OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-3-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Incentive Stock Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Tax Treatment upon Exercise and Sale of Shares</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>If this Option qualifies as an Incentive Stock Option, there will be no regular federal income tax liability upon the exercise of the Option, although the excess, if any, of the fair market value of the Shares on the date of exercise over the Exercise Price will be treated as an adjustment to the alternative minimum tax for federal tax purposes and may subject Optionee to the alternative minimum tax in the year of exercise.&#160;&#160;If Shares issued upon exercise of an Incentive Stock Option are held for at least one year after exercise and are disposed of at least two years after the Option grant date, any gain realized on disposition of the Shares will also be treated as long-term capital gain for federal income tax purposes.&#160;&#160;If Shares issued upon exercise of an Incentive Stock Option are disposed of within such one-year period or within two years after the Option grant date, any gain realized on such disposition will be treated as compensation income (taxable at ordinary income rates) to the extent of the difference between the Exercise Price and the lesser of (i)&#160;the fair market value of the Shares on the date of exercise, or (ii)&#160;the sale price of the Shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Notice of Disqualifying Dispositions</font>.&#160;&#160;With respect to any Shares issued upon exercise of an Incentive Stock Option, if Optionee sells or otherwise disposes of such Shares on or before the later of (i)&#160;the date two years after the Option grant date, or (ii)&#160;the date one year after the date of exercise, Optionee shall immediately notify the Company in writing of such disposition.&#160;&#160;Optionee acknowledges and agrees that he or she may be subject to income tax withholding by the Company on the compensation income recognized by Optionee from the early disposition by payment in cash or out of the current earnings paid to Optionee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Nonstatutory Stock Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;If this Option does not qualify as an Incentive Stock Option, there may be a regular federal (and state) income tax liability upon the exercise of the Option. Optionee will be treated as having received compensation income (taxable at ordinary income tax rates) equal to the excess, if any, of the fair market value of the Shares on the date of exercise over the Exercise Price.&#160;&#160;If Optionee is an Employee, the Company will be required to withhold from Optionee&#8217;s compensation or collect from Optionee and pay to the applicable taxing authorities an amount equal to a percentage of this compensation income at the time of exercise.&#160;&#160;If Shares issued upon exercise of a Nonstatutory Stock Option are held for at least one year, any gain realized on disposition of the Shares will be treated as long-term capital gain for federal income tax purposes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Lock-Up Agreement</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;In connection with the initial public offering of the Company&#8217;s securities and upon request of the Company or the underwriters managing any underwritten offering of the Company&#8217;s securities, Optionee hereby agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company however and whenever acquired (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed 180 days) from the effective date of such registration as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the public offering.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-4-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Effect of Agreement</font>.&#160;&#160;Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof (and has had an opportunity to consult counsel regarding the Option terms), and hereby accepts this Option and agrees to be bound by its contractual terms as set forth herein and in the Plan.&#160;&#160;Optionee hereby agrees to accept as binding, conclusive and final all decisions and interpretations of the Plan Administrator regarding any questions relating to the Option.&#160;&#160;In the event of a conflict between the terms and provisions of the Plan and the terms and provisions of the Notice and this Agreement, the Plan terms and provisions shall prevail.&#160;&#160;The Option, including the Plan, constitutes the entire agreement between Optionee and the Company on the subject matter hereof and supersedes all proposals, written or oral, and all other communications between the parties relating to such subject matter.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">[Signature Page Follows]</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-5-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one document.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="95%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" width="40%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="7%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="48%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="40%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="red" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font></font></td>
<td width="7%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" width="52%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ACTINIUM PHARMACEUTICALS, INC.</font></td>
</tr><tr>
<td colspan="2" width="40%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="7%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" width="52%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="40%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="7%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td colspan="3" width="50%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="40%">&#160;</td>
<td width="7%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="4%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td width="48%" style="BORDER-BOTTOM: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="4%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:</font></td>
<td width="36%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="7%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;</font></font></td>
<td colspan="2" width="49%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-6-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">EXHIBIT A</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013 STOCK PLAN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">EXERCISE NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Agreement (&#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Agreement</font>&#8221;) is made as of _______________, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Company</font>&#8221;), and <font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font> (&#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Purchaser</font>&#8221;).&#160;&#160;To the extent any capitalized terms used in this Agreement are not defined, they shall have the meaning ascribed to them in the Company&#8217;s 2013 Stock Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exercise of Option</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Subject to the terms and conditions hereof, Purchaser hereby elects to exercise his or her option to purchase <font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;NoofShares&#187;</font> shares of the Common Stock (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Shares</font>&#8221;) of the Company under and pursuant to the Company&#8217;s 2013 Stock Plan (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Plan</font>&#8221;) and the Stock Option Agreement granted <font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;GrantDate&#187;</font> (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Option Agreement</font>&#8221;).&#160;&#160;The purchase price for the Shares shall be $<font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;ExercisePrice&#187;</font> per Share for a total purchase price of $__________.&#160;&#160;The term &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Shares</font>&#8221; refers to the purchased Shares and all securities received in replacement of the Shares or as stock dividends or splits, all securities received in replacement of the Shares in a recapitalization, merger, reorganization, exchange or the like, and all new, substituted or additional securities or other properties to which Purchaser is entitled by reason of Purchaser&#8217;s ownership of the Shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Time and Place of Exercise</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">. </font>The purchase and sale of the Shares under this Agreement shall occur at the principal office of the Company simultaneously with the execution and delivery of this Agreement in accordance with the provisions of Section 3(b) of the Option Agreement.&#160;&#160;On such date, the Company will deliver to Purchaser a certificate representing the Shares to be purchased by Purchaser (which shall be issued in Purchaser&#8217;s name) against payment of the exercise price therefor by Purchaser by (a) check made payable to the Company, (b) cancellation of indebtedness of the Company to Purchaser, (c) delivery of shares of the Common Stock of the Company in accordance with Section 4 of the Option Agreement, or (d)&#160;by a combination of the foregoing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Limitations on Transfer</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;In addition to any other limitation on transfer created by applicable securities laws, Purchaser shall not assign, encumber or dispose of any interest in the Shares except in compliance with the provisions below and applicable securities laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Right of First Refusal</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>Before any Shares held by Purchaser or any transferee of Purchaser (either being sometimes referred to herein as the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Holder</font>&#8221;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions set forth in this Section 3(a) (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Right of First Refusal</font>&#8221;).</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Notice of Proposed Transfer</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The Holder of the Shares shall deliver to the Company a written notice (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Notice</font>&#8221;) stating:&#160;&#160;(i)&#160;the Holder&#8217;s bona fide intention to sell or otherwise transfer such Shares; (ii)&#160;the name of each proposed purchaser or other transferee (&#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Proposed Transferee</font>&#8221;); (iii)&#160;the number of Shares to be transferred to each Proposed Transferee; and (iv)&#160;the terms and conditions of each proposed sale or transfer.&#160;&#160;The Holder shall offer the Shares at the same price (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Offered Price</font>&#8221;) and upon the same terms (or terms as similar as reasonably possible) to the Company or its assignee(s).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exercise of Right of First Refusal</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection&#160;(iii) below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Purchase Price</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The purchase price (&#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Purchase Price</font>&#8221;) for the Shares purchased by the Company or its assignee(s) under this Section 3(a) shall be the Offered Price.&#160;&#160;If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Payment</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness, or by any combination thereof within 30 days after receipt of the Notice or in the manner and at the times set forth in the Notice.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Holder&#8217;s Right to Transfer</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section&#160;3(a), then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer is consummated within 60 days after the date of the Notice and provided further that any such sale or other transfer is effected in accordance with any applicable securities laws and the Proposed Transferee agrees in writing that the provisions of this Section&#160;3 shall continue to apply to the Shares in the hands of such Proposed Transferee.&#160;&#160;If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, or if the Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee, a new Notice shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exception for Certain Family Transfers</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Anything to the contrary contained in this Section&#160;3(a) notwithstanding, the transfer of any or all of the Shares during Purchaser&#8217;s lifetime or on Purchaser&#8217;s death by will or intestacy to Purchaser&#8217;s Immediate Family or a trust for the benefit of Purchaser&#8217;s Immediate Family shall be exempt from the provisions of this Section 3(a).&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Immediate Family</font>&#8221; as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister.&#160;&#160;In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance with the terms of this Section&#160;3.</font></div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-2-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Involuntary Transfer</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Company&#8217;s Right to Purchase upon Involuntary Transfer</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>In the event, at any time after the date of this Agreement, of any transfer by operation of law or other involuntary transfer (including death or divorce, but excluding a transfer to Immediate Family as set forth in Section 3(a)(vi) above) of all or a portion of the Shares by the record holder thereof, the Company shall have an option to purchase all of the Shares transferred at the greater of the purchase price paid by Purchaser pursuant to this Agreement or the Fair Market Value of the Shares on the date of transfer.&#160;&#160;Upon such a transfer, the person acquiring the Shares shall promptly notify the Secretary of the Company of such transfer.&#160;&#160;The right to purchase such Shares shall be provided to the Company for a period of thirty (30) days following receipt by the Company of written notice by the person acquiring the Shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Price for Involuntary Transfer</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>With respect to any stock to be transferred pursuant to Section&#160;3(b)(i), the price per Share shall be a price set by the Board of Directors of the Company that will reflect the current value of the stock in terms of present earnings and future prospects of the Company.&#160;&#160;The Company shall notify Purchaser or his or her executor of the price so determined within thirty (30) days after receipt by it of written notice of the transfer or proposed transfer of Shares.&#160;&#160;However, if the Purchaser does not agree with the valuation as determined by the Board of Directors of the Company, the Purchaser shall be entitled to have the valuation determined by an independent appraiser to be mutually agreed upon by the Company and the Purchaser and whose fees shall be borne equally by the Company and the Purchaser.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Assignment</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any shareholder or shareholders of the Company or other persons or organizations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Restrictions Binding on Transferees</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>All transferees of Shares or any interest therein will receive and hold such Shares or interest subject to the provisions of this Agreement.&#160;&#160;Any sale or transfer of the Company&#8217;s Shares shall be void unless the provisions of this Agreement are satisfied.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Termination of Rights</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The right of first refusal granted the Company by Section&#160;3(a) above and the option to repurchase the Shares in the event of an involuntary transfer granted the Company by Section 3(b) above shall terminate upon the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Securities Act</font>&#8221;).&#160;&#160;Upon termination of the right of first refusal described in Section 3(a) above, a new certificate or certificates representing the Shares not repurchased shall be issued, on request, without the legend referred to in Section 5(a)(ii) herein and delivered to Purchaser.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Investment and Taxation Representations</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>In connection with the purchase of the Shares, Purchaser represents to the Company the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchaser is aware of the Company&#8217;s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Shares.&#160;&#160;Purchaser is purchasing these securities for investment for his or her own account only and not with a view to, or for resale in connection with, any &#8220;distribution&#8221; thereof within the meaning of the Securities Act or under any applicable provision of state law.&#160;&#160;Purchaser does not have any present intention to transfer the Shares to any person or entity.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-3-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchaser understands that the Shares have not been registered under the Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Purchaser&#8217;s investment intent as expressed herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchaser further acknowledges and understands that the securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available.&#160;&#160;Purchaser further acknowledges and understands that the Company is under no obligation to register the securities.&#160;&#160;Purchaser understands that the certificate(s) evidencing the securities will be imprinted with a legend which prohibits the transfer of the securities unless they are registered or such registration is not required in the opinion of counsel for the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchaser is familiar with the provisions of Rules&#160;144 and 701, each promulgated under the Securities Act, which, in substance, permit limited public resale of &#8220;restricted securities&#8221; acquired, directly or indirectly, from the issuer of the securities (or from an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions.&#160;&#160;Purchaser understands that the Company provides no assurances as to whether he or she will be able to resell any or all of the Shares pursuant to Rule 144 or Rule 701, which rules require, among other things, that the Company be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, that resales of securities take place only after the holder of the Shares has held the Shares for certain specified time periods, and under certain circumstances, that resales of securities be limited in volume and take place only pursuant to brokered transactions.&#160;&#160;Notwithstanding this paragraph (d), Purchaser acknowledges and agrees to the restrictions set forth in paragraph (e) below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchaser further understands that in the event all of the applicable requirements of Rule&#160;144 or 701 are not satisfied, registration under the Securities Act, compliance with Regulation&#160;A, or some other registration exemption will be required; and that, notwithstanding the fact that Rules&#160;144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rule&#160;144 or 701 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchaser understands that Purchaser may suffer adverse tax consequences as a result of Purchaser&#8217;s purchase or disposition of the Shares.&#160;&#160;Purchaser represents that Purchaser has consulted any tax consultants Purchaser deems advisable in connection with the purchase or disposition of the Shares and that Purchaser is not relying on the Company for any tax advice.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-4-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Restrictive Legends and Stop-Transfer Orders</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Legends</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>The certificate or certificates representing the Shares shall bear the following legends (as well as any legends required by applicable state and federal corporate and securities laws):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.&#160;&#160;NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Stop-Transfer Notices</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Purchaser agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Refusal to Transfer</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The Company shall not be required (i)&#160;to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii)&#160;to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">No Employment Rights</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a parent or subsidiary of the Company, to terminate Purchaser&#8217;s employment or consulting relationship, for any reason, with or without cause.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Lock-Up Agreement</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;In connection with the initial public offering of the Company&#8217;s securities and upon request of the Company or the underwriters managing any underwritten offering of the Company&#8217;s securities, Purchaser agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company however or whenever acquired (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed 180 days) from the effective date of such registration as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the public offering.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-5-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Miscellaneous</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Governing Law</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>Delaware, without giving effect to principles of conflicts of law.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Entire Agreement; Enforcement of Rights</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter herein and merges all prior discussions between them.&#160;&#160;No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement.&#160;&#160;The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Severability</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;If one or more provisions of this Agreement are held to be<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font>unenforceable under applicable law, the parties agree to renegotiate such provision in good faith.&#160;&#160;In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i)&#160;such provision shall be excluded from this Agreement, (ii)&#160;the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii)&#160;the balance of the Agreement shall be enforceable in accordance with its terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Construction</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of or against any one of the parties hereto.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Notices</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient when delivered personally or sent by telegram or fax or forty-eight (48) hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party to be notified at such party&#8217;s address as set forth below or as subsequently modified by written notice.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Counterparts</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Successors and Assigns</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font>&#160;&#160;The rights and benefits of this Agreement shall inure to the benefit of, and be enforceable by the Company&#8217;s successors and assigns.&#160;&#160;The rights and obligations of Purchaser under this Agreement may only be assigned with the prior written consent of the Company.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-6-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">California Corporate Securities Law</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE.&#160;&#160;THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">[Signature Page Follows]</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-7-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The parties have executed this Exercise Notice and Restricted Stock Purchase Agreement as of the date first set forth above.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="left">
<div align="left">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%">&#160;</td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="41%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%">&#160;</td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="5" width="47%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMPANY:</font></font></div>
</td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="5" width="47%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="5" width="47%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></font></div>
</td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="5" width="47%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td colspan="4" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="3%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="3%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td colspan="2" width="2%" style="BORDER-BOTTOM: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">&#160;</td>
</tr><tr>
<td width="50%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="3%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="4%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td colspan="3" width="43%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
</tr></table>
</div>

<div align="left">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="47%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="47%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURCHASER:</font></font></div>
</td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="47%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="47%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="red" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="red" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font></font></div>
</td>
</tr><tr>
<td width="50%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="47%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Signature)</font></font></div>
</td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div align="left">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="3%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="6%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Address:</font></td>
<td width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="7%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%">&#160;</td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="40%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, ______________________, spouse of <font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font>, have read and hereby approve the foregoing Agreement.&#160;&#160;In consideration of the Company&#8217;s granting my spouse the right to purchase the Shares as set forth in the Agreement, I hereby agree to be irrevocably bound by the Agreement and further agree that any community property or other such interest shall hereby by similarly bound by the Agreement.&#160;&#160;I hereby appoint my spouse as my attorney-in-fact with respect to any amendment or exercise of any rights under the Agreement.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="57%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%" style="BORDER-TOP: black 2px solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Spouse of <font color="red" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font></font></font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-8-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">RECEIPT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned hereby acknowledges receipt of Certificate No.&#160;_____ for __________ shares of Common Stock of Actinium Pharmaceuticals, Inc.</font></font></div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="4%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:&#160;</font></td>
<td width="15%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="41%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="4%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="15%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="41%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="35%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font color="red" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="red" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font></font></div>
</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-9-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">RECEIPT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc. (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Company</font>&#8221;) hereby acknowledges receipt of (check as applicable):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 85.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_________</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A check in the amount of $____________</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 85.5pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_________</font></font></div>
</div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The cancellation of indebtedness in the amount of $____________</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 85.5pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_________</font></font></div>
</div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certificate No. _____ representing __________ shares of the Company&#8217;s Common Stock with a fair market value of $___________</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">given by <font color="red" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#171;Optionee&#187;</font> as consideration for Certificate No. _____ for _________ shares of Common Stock of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated:&#160;&#160;______________</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" width="50%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></font></div>
</td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="46%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></font></font></div>
</td>
<td colspan="3" width="48%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="46%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="4%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></font></font></div>
</td>
<td width="46%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="4%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="46%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(print)</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="46%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="3%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></font></font></div>
</td>
<td colspan="2" width="3%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">-10-<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>6
<FILENAME>fs12014ex10xxxiv_actinium.htm
<DESCRIPTION>ACTINIUM PHARMACEUTICALS, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN.**
<TEXT>
<html>
<head>
    <title>fs12014ex10xxxiv_actinium.htm</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 10.34</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.&#160;&#160;AMENDED AND RESTATED 2013</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EQUITY INCENTIVE PLAN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Purpose; Eligibility</font>.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.1&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">General Purpose</font>. The name of this plan is the Actinium Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Plan</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font>). The purposes of the Plan are to (a) enable Actinium Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;), and any Affiliate to attract and retain the types of Employees, Consultants and Directors who will contribute to the Company&#8217;s long range success; (b) provide incentives that align the interests of Employees, Consultants and Directors with those of the shareholders of the Company; and (c) promote the success of the Company<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s business.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.2&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Eligible Award Recipients</font>. The persons eligible to receive Awards are the Employees, Consultants and Directors of the Company and its Affiliates and such other individuals designated by the Committee who are reasonably expected to become Employees, Consultants and Directors after the receipt of Awards.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.3&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Available Awards</font>. Awards that may be granted under the Plan include: (a) Restricted Awards, (b) Performance Share Awards, and (c) Performance Compensation Awards.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Definitions</font>.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Affiliate</font>&#8221;&#160;means a corporation or other entity that, directly or through one or more intermediaries, controls, is controlled by or is under common control with, the Company.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Applicable Laws</font>&#8221;&#160;means the requirements related to or implicated by the administration of the Plan under applicable state corporate law, United States federal and state securities laws, the Code, any stock exchange or quotation system on which the shares of Common Stock are listed or quoted, and the applicable laws of any foreign country or jurisdiction where Awards are granted under the Plan.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Award</font>&#8221;&#160;means any right granted under the Plan, including a Restricted Award, a Performance Share Award or a Performance Compensation Award.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Award Agreement</font>&#8221;&#160;means a written agreement, contract, certificate or other instrument or document evidencing the terms and conditions of an individual Award granted under the Plan which may, in the discretion of the Company, be transmitted electronically to any Participant. Each Award Agreement shall be subject to the terms and conditions of the Plan.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Beneficial Owner</font>&#8221;&#160;has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the Exchange Act, except that in calculating the beneficial ownership of any particular &#8220;person&#8221; (as that term is used in Section 13(d)(3) of the Exchange Act), such &#8220;person&#8221; shall be deemed to have beneficial ownership of all securities that such &#8220;person&#8221; has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only after the passage of time. The terms &#8220;Beneficially Owns&#8221; and &#8220;Beneficially Owned&#8221; have a corresponding meaning.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Board</font>&#8221;&#160;means the Board of Directors of the Company, as constituted at any time.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Cause</font>&#8221;&#160;means:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;With respect to any Employee or Consultant: (a) If the Employee or Consultant is a party to an employment or service agreement with the Company or its Affiliates and such agreement provides for a definition of Cause, the definition contained therein; or (b) If no such agreement exists, or if such agreement does not define Cause: (i) the commission of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude or the commission of any other act involving willful malfeasance or material fiduciary breach with respect to the Company or an Affiliate; (ii) conduct that results in or is reasonably likely to result in harm to the reputation or business of the Company or any of its Affiliates; (iii) gross negligence or willful misconduct with respect to the Company or an Affiliate; or (iv) material violation of state or federal securities laws.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;With respect to any Director, a determination by a majority of the disinterested Board members that the Director has engaged in any of the following: (a) malfeasance in office; (b) gross misconduct or neglect; (c) false or fraudulent misrepresentation inducing the director&#8217;s appointment; (d) wilful conversion of corporate funds; or (e) repeated failure to participate in Board meetings on a regular basis despite having received proper notice of the meetings in advance.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to whether a Participant has been discharged for Cause.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Change in Control</font>&#8221;&#160;(a) The direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of the Company and its subsidiaries, taken as a whole, to any Person that is not a subsidiary of the Company; (b) The Incumbent Directors cease for any reason to constitute at least a majority of the Board; (c) The date which is 10 business days prior to the consummation of a complete liquidation or dissolution of the Company; (d) The acquisition by any Person of Beneficial Ownership of 50% or more (on a fully diluted basis) of either (i) the then outstanding shares of Common Stock of the Company, taking into account as outstanding for this purpose such Common Stock issuable upon the exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Common Stock (the &#8220;Outstanding Company Common Stock&#8221;) or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the &#8220;Outstanding Company Voting Securities&#8221;); provided, however, that for purposes of this Plan, the following acquisitions shall not constitute a Change in Control: (A) any acquisition by the Company or any Affiliate, (B) any acquisition by any employee benefit plan sponsored or maintained by the Company or any subsidiary, (C) any acquisition which complies with clauses, (i), (ii) and (iii) of subsection (e) of this definition or (D) in respect of an Award held by a particular Participant, any acquisition by the Participant or any group of persons including the Participant (or any entity controlled by the Participant or any group of persons including the Participant); or (e) The consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company that requires the approval of the Company&#8217;s shareholders, whether for such transaction or the issuance of securities in the transaction (a &#8220;Business Combination&#8221;), unless immediately following such Business Combination: (i) more than 50% of the total voting power of (A) the entity resulting from such Business Combination (the &#8220;Surviving Company&#8221;), or (B) if applicable, the ultimate parent entity that directly or indirectly has beneficial ownership of sufficient voting securities eligible to elect a majority of the members of the board of directors (or the analogous governing body) of the Surviving Company (the &#8220;Parent Company&#8221;), is represented by the Outstanding Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which the Outstanding Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of the Outstanding Company Voting Securities among the holders thereof immediately prior to the Business Combination; (ii) no Person (other than any employee benefit plan sponsored or maintained by the Surviving Company or the Parent Company) is or becomes the Beneficial Owner, directly or indirectly, of 50% or more of the total voting power of the outstanding voting securities eligible to elect members of the board of directors of the Parent Company (or the analogous governing body) (or, if there is no Parent Company, the Surviving Company); and (iii) at least a majority of the members of the board of directors (or the analogous governing body) of the Parent Company (or, if there is no Parent Company, the Surviving Company) following the consummation of the Business Combination were Board members at the time of the Board&#8217;s approval of the execution of the initial agreement providing for such Business Combination.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Code</font>&#8221;&#160;means the Internal Revenue Code of 1986, as it may be amended from time to time. Any reference to a section of the Code shall be deemed to include a reference to any regulations promulgated thereunder.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Committee</font>&#8221;&#160;means a committee of one or more members of the Board appointed by the Board to administer the Plan in accordance with <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.3</font> and <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.4</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock</font>&#8221;&#160;means the common stock, $0.001 par value per share, of the Company, or such other securities of the Company as may be designated by the Committee from time to time in substitution thereof.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;&#160;means Actinium Pharmaceuticals, Inc. a Delaware corporation, and any successor thereto.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Consultant</font>&#8221;&#160;means any individual who is engaged by the Company or any Affiliate to render consulting or advisory services.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Continuous Service</font>&#8221;&#160;means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Consultant or Director, is not interrupted or terminated. The Participant&#8217;s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, <font style="FONT-STYLE: italic; DISPLAY: inline">provided that</font> there is no interruption or termination of the Participant&#8217;s Continuous Service; <font style="FONT-STYLE: italic; DISPLAY: inline">provided further that</font> if any Award is subject to Section 409A of the Code, this sentence shall only be given effect to the extent consistent with Section 409A of the Code. For example, a change in status from an Employee of the Company to a Director of an Affiliate will not constitute an interruption of Continuous Service. The Committee or its delegate, in its sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal or family leave of absence.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Covered Employee</font>&#8221;&#160;has the same meaning as set forth in Section 162(m)(3) of the Code, as interpreted by <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Internal Revenue Service (www.practicallaw.com/0-382-3556)</font> Notice 2007-49.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Director</font>&#8221;&#160;means a member of the Board.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Effective Date</font>&#8221;&#160;shall mean the date as of which this Plan is adopted by the Board.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Employee</font>&#8221;&#160;means any person, including an Officer or Director, employed by the Company or an Affiliate. Mere service as a Director or payment of a director&#8217;s fee by the Company or an Affiliate shall not be sufficient to constitute &#8220;employment&#8221; by the Company or an Affiliate.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exchange Act</font>&#8221;&#160;means the Securities Exchange Act of 1934, as amended.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Fair Market Value</font>&#8221;&#160;means, as of any date, the value of the Common Stock as determined below. If the Common Stock is listed on any established stock exchange or a national market system, including without limitation, the OTCBB, the New York Stock Exchange or the NASDAQ Stock Market, the Fair Market Value shall be the closing price of a share of Common Stock (or if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination, as reported in the <font style="FONT-STYLE: italic; DISPLAY: inline">Wall Street Journal</font> or such other source as the Committee deems reliable. In the absence of an established market for the Common Stock, the Fair Market Value shall be determined in good faith by the Committee and such determination shall be conclusive and binding on all persons.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Grant Date</font>&#8221;&#160;means the date on which the Committee adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant that specifies the key terms and conditions of the Award or, if a later date is set forth in such resolution, then such date as is set forth in such resolution.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Incumbent Directors</font>&#8221;&#160;means individuals who, on the Effective Date, constitute the Board, <font style="FONT-STYLE: italic; DISPLAY: inline">provided that</font> any individual becoming a Director subsequent to the Effective Date whose election or nomination for election to the Board was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for Director without objection to such nomination) shall be an Incumbent Director. No individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to Directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be an Incumbent Director.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Negative Discretion</font>&#8221;&#160;means the discretion authorized by the Plan to be applied by the Committee to eliminate or reduce the size of a Performance Compensation Award in accordance with Section 7.4(d)(iv) of the Plan; <font style="FONT-STYLE: italic; DISPLAY: inline">provided</font>, <font style="FONT-STYLE: italic; DISPLAY: inline">that</font>, the exercise of such discretion would not cause the Performance Compensation Award to fail to qualify as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Non-Employee Director</font>&#8221;&#160;means a Director who is a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Officer</font>&#8221;&#160;means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Outside Director</font>&#8221;&#160;means a Director who is an &#8220;outside director&#8221; within the meaning of Section 162(m) of the Code and Treasury Regulations Section 1.162-27(e)(3) or any successor to such statute and regulation.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Participant</font>&#8221;&#160;means an eligible person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance Compensation Award</font>&#8221;&#160;means any Award designated by the Committee as a Performance Compensation Award pursuant to Section 7.4 of the Plan.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance Criteria</font>&#8221;&#160;means the criterion or criteria that the Committee shall select for purposes of establishing the Performance Goal(s) for a Performance Period with respect to any Performance Compensation Award under the Plan. The Performance Criteria that will be used to establish the Performance Goal(s) shall be based on the attainment of specific levels of performance of the Company (or Affiliate, division, business unit or operational unit of the Company) and shall be limited to the following:&#160;(a) net earnings or net income (before or after taxes); (b) basic or diluted earnings per share (before or after taxes); (c) net revenue or net revenue growth; (d) gross revenue; (e) gross profit or gross profit growth; (f) net operating profit (before or after taxes); (g) return on assets, capital, invested capital, equity, or sales; (h) cash flow (including, but not limited to, operating cash flow, free cash flow, and cash flow return on capital); (i) earnings before or after taxes, interest, depreciation and/or amortization; (j) gross or operating margins; (k) improvements in capital structure; (l) budget and expense management; (m) productivity ratios; (n) economic value added or other value added measurements; (o) share price (including, but not limited to, growth measures and total shareholder return); (p) expense targets; (q) margins; (r) operating efficiency; (s) working capital targets; (t) enterprise value; (u) safety record; and (v) completion of acquisitions or business expansion.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;Any one or more of the Performance Criteria may be used on an absolute or relative basis to measure the performance of the Company and/or an Affiliate as a whole or any division, business unit or operational unit of the Company and/or an Affiliate or any combination thereof, as the Committee may deem appropriate, or as compared to the performance of a group of comparable companies, or published or special index that the Committee, in its sole discretion, deems appropriate, or the Committee may select Performance Criterion (o) above as compared to various stock market indices. The Committee also has the authority to provide for accelerated vesting of any Award based on the achievement of Performance Goals pursuant to the Performance Criteria specified in this paragraph. To the extent required under Section 162(m) of the Code, the Committee shall, within the first 90 days of a Performance Period (or, if longer or shorter, within the maximum period allowed under Section 162(m) of the Code), define in an objective fashion the manner of calculating the Performance Criteria it selects to use for such Performance Period. In the event that applicable tax and/or securities laws change to permit the Committee discretion to alter the governing Performance Criteria without obtaining shareholder approval of such changes, the Committee shall have sole discretion to make such changes without obtaining shareholder approval.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance Formula</font>&#8221;&#160;means, for a Performance Period, the one or more objective formulas applied against the relevant Performance Goal to determine, with regard to the Performance Compensation Award of a particular Participant, whether all, some portion but less than all, or none of the Performance Compensation Award has been earned for the Performance Period.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance Goals</font>&#8221;&#160;means, for a Performance Period, the one or more goals established by the Committee for the Performance Period based upon the Performance Criteria. The Committee is authorized at any time during the first 90 days of a Performance Period (or, if longer or shorter, within the maximum period allowed under Section 162(m) of the Code), or at any time thereafter (but only to the extent the exercise of such authority after such period would not cause the Performance Compensation Awards granted to any Participant for the Performance Period to fail to qualify as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code), in its sole and absolute discretion, to adjust or modify the calculation of a Performance Goal for such Performance Period to the extent permitted under Section 162(m) of the Code in order to prevent the dilution or enlargement of the rights of Participants based on the following events: &#160;(a) asset write-downs; (b) litigation or claim judgments or settlements; (c) the effect of changes in tax laws, accounting principles, or other laws or regulatory rules affecting reported results; (d) any reorganization and restructuring programs; (e) extraordinary nonrecurring items as described in Accounting Principles Board Opinion No. 30 (or any successor or pronouncement thereto) and/or in management&#8217;s discussion and analysis of financial condition and results of operations appearing in the Company&#8217;s annual report to shareholders for the applicable year; (f) acquisitions or divestitures; (g) any other specific unusual or nonrecurring events, or objectively determinable category thereof; (h) foreign exchange gains and losses; and (i) a change in the Company&#8217;s fiscal year.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance Period</font>&#8221;&#160;means the one or more periods of time not less than one fiscal quarter in duration, as the Committee may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a Performance Compensation Award.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance Share Award</font>&#8221;&#160;means any Award granted pursuant to <font style="DISPLAY: inline; FONT-WEIGHT: bold">Section 7.3 </font>hereof.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance Share</font>&#8221;&#160;means the grant of a right to receive a number of actual shares of Common Stock or share units based upon the performance of the Company during a Performance Period, as determined by the Committee.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Plan</font>&#8221;&#160;means this Actinium Pharmaceuticals, Inc. 2013 Equity Incentive Plan, as amended and/or amended and restated from time to time.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Restricted Award</font>&#8221;&#160;means any Award granted pursuant to <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.2(a)</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Restricted Period</font>&#8221;&#160;has the meaning set forth in <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.2(a)</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Rule 16b-3</font>&#8221;&#160;means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Securities Act</font>&#8221;&#160;means the Securities Act of 1933, as amended.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></font></div>
</div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Administration</font>.</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; &#160;&#160; 3.1&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Authority of Committee</font>. The Plan shall be administered by the Committee or, in the Board&#8217;s sole discretion, by the Board. Subject to the terms of the Plan, the Committee&#8217;s charter and Applicable Laws, and in addition to other express powers and authorization conferred by the Plan, the Committee shall have the authority:</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;to construe and interpret the Plan and apply its provisions;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160; &#160;to promulgate, amend, and rescind rules and regulations relating to the administration of the Plan;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160; to delegate its authority to one or more Officers of the Company with respect to Awards that do not involve Covered Employees or &#8220;insiders&#8221; within the meaning of Section 16 of the Exchange Act;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;to determine when Awards are to be granted under the Plan and the applicable Grant Date;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160; &#160;from time to time to select, subject to the limitations set forth in this Plan, those Participants to whom Awards shall be granted;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)&#160;&#160;&#160; &#160;to determine the number of shares of Common Stock to be made subject to each Award;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;&#160;&#160;&#160;to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium of payment and vesting provisions, and to specify the provisions of the Award Agreement relating to such grant;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160; &#160;&#160;to determine the target number of Performance Shares to be granted pursuant to a Performance Share Award, the performance measures that will be used to establish the performance goals, the performance period(s) and the number of Performance Shares earned by a Participant;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(j)&#160;&#160; &#160;&#160;&#160;to designate an Award (including a cash bonus) as a Performance Compensation Award and to select the Performance Criteria that will be used to establish the Performance Goals;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(k)&#160;&#160;&#160;&#160;&#160;to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding Award; <font style="FONT-STYLE: italic; DISPLAY: inline">provided, however</font>, that if any such amendment impairs a Participant&#8217;s rights or increases a Participant&#8217;s obligations under his or her Award or creates or increases a Participant&#8217;s federal income tax liability with respect to an Award, such amendment shall also be subject to the Participant&#8217;s consent;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(l)&#160;&#160;&#160; &#160;&#160;to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Company&#8217;s employment policies;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(m)&#160;&#160;&#160;&#160;to make decisions with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers anti-dilution adjustments;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(n)&#160;&#160;&#160;&#160;&#160;to interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any instrument or agreement relating to, or Award granted under, the Plan; and</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(o)&#160;&#160;&#160;&#160;&#160;to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the administration of the Plan.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; The Committee also may modify the purchase price or the exercise price of any outstanding Award, <font style="FONT-STYLE: italic; DISPLAY: inline">provided that</font> if the modification effects a repricing, shareholder approval shall be required before the repricing is effective.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; 3.2&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Committee Decisions Final</font>. All decisions made by the Committee pursuant to the provisions of the Plan shall be final and binding on the Company and the Participants, unless such decisions are determined by a court having jurisdiction to be arbitrary and capricious.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; 3.3&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delegation</font>. The Committee, or if no Committee has been appointed, the Board, may delegate administration of the Plan to a committee or committees of one or more members of the Board, and the term &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Committee</font>&#8221; shall apply to any person or persons to whom such authority has been delegated. The Committee shall have the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board or the Committee shall thereafter be to the committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan. The members of the Committee shall be appointed by and serve at the pleasure of the Board. From time to time, the Board may increase or decrease the size of the Committee, add additional members to, remove members (with or without cause) from, appoint new members in substitution therefor, and fill vacancies, however caused, in the Committee. The Committee shall act pursuant to a vote of the majority of its members or, in the case of a Committee comprised of only two members, the unanimous consent of its members, whether present or not, or by the written consent of the majority of its members and minutes shall be kept of all of its meetings and copies thereof shall be provided to the Board. Subject to the limitations prescribed by the Plan and the Board, the Committee may establish and follow such rules and regulations for the conduct of its business as it may determine to be advisable.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; 3.4&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Committee Composition</font>. Except as otherwise determined by the Board, the Committee shall consist solely of two or more Non-Employee Directors who are also Outside Directors. The Board shall have discretion to determine whether or not it intends to comply with the exemption requirements of Rule 16b-3 and/or Section 162(m) of the Code. However, if the Board intends to satisfy such exemption requirements, with respect to Awards to any Covered Employee and with respect to any insider subject to Section 16 of the Exchange Act, the Committee shall be a compensation committee of the Board that at all times consists solely of two or more Non-Employee Directors who are also Outside Directors. Within the scope of such authority, the Board or the Committee may (a) delegate to a committee of one or more members of the Board who are not Outside Directors the authority to grant Awards to eligible persons who are either (i) not then Covered Employees and are not expected to be Covered Employees at the time of recognition of income resulting from such Award or (ii) not persons with respect to whom the Company wishes to comply with Section 162(m) of the Code or (b) delegate to a committee of one or more members of the Board who are not Non-Employee Directors the authority to grant Awards to eligible persons who are not then subject to Section 16 of the Exchange Act. Nothing herein shall create an inference that an Award is not validly granted under the Plan in the event Awards are granted under the Plan by a compensation committee of the Board that does not at all times consist solely of two or more Non-Employee Directors who are also Outside Directors.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; 3.5&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnification</font>. In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed by Applicable Laws, the Committee shall be indemnified by the Company against the reasonable expenses, including attorney&#8217;s fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Committee may be party by reason of any action taken or failure to act under or in connection with the Plan or any Award granted under the Plan, and against all amounts paid by the Committee in settlement thereof (<font style="FONT-STYLE: italic; DISPLAY: inline">provided, however</font>, that the settlement has been approved by the Company, which approval shall not be unreasonably withheld) or paid by the Committee in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Committee did not act in good faith and in a manner which such person reasonably believed to be in the best interests of the Company, or in the case of a criminal proceeding, had no reason to believe that the conduct complained of was unlawful; <font style="FONT-STYLE: italic; DISPLAY: inline">provided, however</font>, that within 60 days after institution of any such action, suit or proceeding, such Committee shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Shares Subject to the Plan</font>.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; 4.1&#160;&#160;&#160;&#160;Subject to adjustment in accordance with <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">11</font>, a total of 1,000,000 shares of Common Stock shall be available for the grant of Awards under the Plan. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;4.2&#160;&#160;&#160;&#160;Shares of Common Stock available for distribution under the Plan may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares reacquired by the Company in any manner.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; 4.3&#160;&#160; &#160;Any shares of Common Stock subject to an Award that is canceled, forfeited or expires prior to exercise or realization, either in full or in part, shall again become available for issuance under the Plan. Notwithstanding anything to the contrary contained herein: shares subject to an Award under the Plan shall not again be made available for issuance or delivery under the Plan if such shares are delivered or withheld by the Company to satisfy any tax withholding obligation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Eligibility</font>.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; 5.1&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Eligibility for Specific Awards</font>. Awards may be granted to Employees, Consultants and Directors and those individuals whom the Committee determines are reasonably expected to become Employees, Consultants and Directors following the Grant Date.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Intentionally left blank</font>.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Provisions of Awards</font>.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;7.1&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Intentionally left blank</font>. &#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;7.2&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Restricted Awards</font>. &#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">General</font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A Restricted Award is an Award of actual shares of Common Stock (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Restricted Stock</font>&#8221;) or hypothetical Common Stock units (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Restricted Stock Units</font>&#8221;) having a value equal to the Fair Market Value of an identical number of shares of Common Stock, which may, but need not, provide that such Restricted Award may not be sold, assigned, transferred or otherwise disposed of, pledged or hypothecated as collateral for a loan or as security for the performance of any obligation or for any other purpose for such period (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Restricted Period</font>&#8221;) as the Committee shall determine. Each Restricted Award granted under the Plan shall be evidenced by an Award Agreement. Each Restricted Award so granted shall be subject to the conditions set forth in this Section 7.2, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Restricted Stock and Restricted Stock Units</font></font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; (i)</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each Participant granted Restricted Stock shall execute and deliver to the Company an Award Agreement with respect to the Restricted Stock setting forth the restrictions and other terms and conditions applicable to such Restricted Stock. If the Committee determines that the Restricted Stock shall be held by the Company or in escrow rather than delivered to the Participant pending the release of the applicable restrictions, the Committee may require the Participant to additionally execute and deliver to the Company (A) an escrow agreement satisfactory to the Committee, if applicable and (B) the appropriate blank stock power with respect to the Restricted Stock covered by such agreement. If a Participant fails to execute an agreement evidencing an Award of Restricted Stock and, if applicable, an escrow agreement and stock power, the Award shall be null and void. Subject to the restrictions set forth in the Award, the Participant generally shall have the rights and privileges of a shareholder as to such Restricted Stock, including the right to vote such Restricted Stock and the right to receive dividends; <font style="FONT-STYLE: italic; DISPLAY: inline">provided that</font>, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld by the Company for the Participant&#8217;s account, and interest may be credited on the amount of the cash dividends withheld at a rate and subject to such terms as determined by the Committee. The cash dividends or stock dividends so withheld by the Committee and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the Participant in cash or, at the discretion of the Committee, in shares of Common Stock having a Fair Market Value equal to the amount of such dividends, if applicable, upon the release of restrictions on such share and, if such share is forfeited, the Participant shall have no right to such dividends.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; (ii)</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The terms and conditions of a grant of Restricted Stock Units shall be reflected in an Award Agreement. No shares of Common Stock shall be issued at the time a Restricted Stock Unit is granted, and the Company will not be required to set aside a fund for the payment of any such Award. A Participant shall have no voting rights with respect to any Restricted Stock Units granted hereunder. At the discretion of the Committee, each Restricted Stock Unit (representing one share of Common Stock) may be credited with cash and stock dividends paid by the Company in respect of one share of Common Stock (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Dividend Equivalents</font>&#8221;). Dividend Equivalents shall be withheld by the Company for the Participant&#8217;s account, and interest may be credited on the amount of cash Dividend Equivalents withheld at a rate and subject to such terms as determined by the Committee. Dividend Equivalents credited to a Participant&#8217;s account and attributable to any particular Restricted Stock Unit (and earnings thereon, if applicable) shall be distributed in cash or, at the discretion of the Committee, in shares of Common Stock having a Fair Market Value equal to the amount of such Dividend Equivalents and earnings, if applicable, to the Participant upon settlement of such Restricted Stock Unit and, if such Restricted Stock Unit is forfeited, the Participant shall have no right to such Dividend Equivalents.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Restrictions</font></font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; (i)</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted Stock awarded to a Participant shall be subject to the following restrictions until the expiration of the Restricted Period, and to such other terms and conditions as may be set forth in the applicable Award Agreement: (A) if an escrow arrangement is used, the Participant shall not be entitled to delivery of the stock certificate; (B) the shares shall be subject to the restrictions on transferability set forth in the Award Agreement; (C) the shares shall be subject to forfeiture to the extent provided in the applicable Award Agreement; and (D) to the extent such shares are forfeited, the stock certificates shall be returned to the Company, and all rights of the Participant to such shares and as a shareholder with respect to such shares shall terminate without further obligation on the part of the Company.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; (ii)</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted Stock Units awarded to any Participant shall be subject to (A) forfeiture until the expiration of the Restricted Period, and satisfaction of any applicable Performance Goals during such period, to the extent provided in the applicable Award Agreement, and to the extent such Restricted Stock Units are forfeited, all rights of the Participant to such Restricted Stock Units shall terminate without further obligation on the part of the Company and (B) such other terms and conditions as may be set forth in the applicable Award Agreement.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; (iii)</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Committee shall have the authority to remove any or all of the restrictions on the Restricted Stock and Restricted Stock Units whenever it may determine that, by reason of changes in Applicable Laws or other changes in circumstances arising after the date the Restricted Stock or Restricted Stock Units are granted, such action is appropriate.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-WEIGHT: bold">Restricted Period</font></font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With respect to Restricted Awards, the Restricted Period shall commence on the Grant Date and end at the time or times set forth on a schedule established by the Committee in the applicable Award Agreement.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No Restricted Award may be granted or settled for a fraction of a share of Common Stock. The Committee may, but shall not be required to, provide for an acceleration of vesting in the terms of any Award Agreement upon the occurrence of a specified event.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Delivery of Restricted Stock and Settlement of Restricted Stock Units</font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Upon the expiration of the Restricted Period with respect to any shares of Restricted Stock, the restrictions set forth in <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.2(c) </font>and the applicable Award Agreement shall be of no further force or effect with respect to such shares, except as set forth in the applicable Award Agreement. If an escrow arrangement is used, upon such expiration, the Company shall deliver to the Participant, or his or her beneficiary, without charge, the stock certificate evidencing the shares of Restricted Stock which have not then been forfeited and with respect to which the Restricted Period has expired (to the nearest full share) and any cash dividends or stock dividends credited to the Participant&#8217;s account with respect to such Restricted Stock and the interest thereon, if any. Upon the expiration of the Restricted Period with respect to any outstanding Restricted Stock Units, the Company shall deliver to the Participant, or his or her beneficiary, without charge, one share of Common Stock for each such outstanding Restricted Stock Unit (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Vested Unit</font>&#8221;) and cash equal to any Dividend Equivalents credited with respect to each such Vested Unit in accordance with <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.2(b)(ii) </font>hereof and the interest thereon or, at the discretion of the Committee, in shares of Common Stock having a Fair Market Value equal to such Dividend Equivalents and the interest thereon, if any; <font style="FONT-STYLE: italic; DISPLAY: inline">provided, however</font>, that, if explicitly provided in the applicable Award Agreement, the Committee may, in its sole discretion, elect to pay cash or part cash and part Common Stock in lieu of delivering only shares of Common Stock for Vested Units. If a cash payment is made in lieu of delivering shares of Common Stock, the amount of such payment shall be equal to the Fair Market Value of the Common Stock as of the date on which the Restricted Period lapsed with respect to each Vested Unit.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Stock Restrictions</font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each certificate representing Restricted Stock awarded under the Plan shall bear a legend in such form as the Company deems appropriate.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; 7.3&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Performance Share Awards</font>. &#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Grant of Performance Share Awards</font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each Performance Share Award granted under the Plan shall be evidenced by an Award Agreement. Each Performance Share Award so granted shall be subject to the conditions set forth in this Section 7.3, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. The Committee shall have the discretion to determine: (i) the number of shares of Common Stock or stock-denominated units subject to a Performance Share Award granted to any Participant; (ii) the performance period applicable to any Award; (iii) the conditions that must be satisfied for a Participant to earn an Award; and (iv) the other terms, conditions and restrictions of the Award.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Earning Performance Share Awards</font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The number of Performance Shares earned by a Participant will depend on the extent to which the performance goals established by the Committee are attained within the applicable Performance Period, as determined by the Committee. No payout shall be made with respect to any Performance Share Award except upon written certification by the Committee that the minimum threshold performance goal(s) have been achieved.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; 7.4&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Performance Compensation Awards</font>. &#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">General</font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Committee shall have the authority, at the time of grant of any Award described in this Plan, to designate such Award as a Performance Compensation Award in order to qualify such Award as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code. In addition, the Committee shall have the authority to make an Award of a cash bonus to any Participant and designate such Award as a Performance Compensation Award in order to qualify such Award as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Eligibility</font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Committee will, in its sole discretion, designate within the first 90 days of a Performance Period (or, if longer or shorter, within the maximum period allowed under Section 162(m) of the Code) which Participants will be eligible to receive Performance Compensation Awards in respect of such Performance Period. However, designation of a Participant eligible to receive an Award hereunder for a Performance Period shall not in any manner entitle the Participant to receive payment in respect of any Performance Compensation Award for such Performance Period. The determination as to whether or not such Participant becomes entitled to payment in respect of any Performance Compensation Award shall be decided solely in accordance with the provisions of this Section 7.4. Moreover, designation of a Participant eligible to receive an Award hereunder for a particular Performance Period shall not require designation of such Participant eligible to receive an Award hereunder in any subsequent Performance Period and designation of one person as a Participant eligible to receive an Award hereunder shall not require designation of any other person as a Participant eligible to receive an Award hereunder in such period or in any other period.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Discretion of Committee with Respect to Performance Compensation Awards</font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With regard to a particular Performance Period, the Committee shall have full discretion to select the length of such Performance Period (provided any such Performance Period shall be not less than one fiscal quarter in duration), the type(s) of Performance Compensation Awards to be issued, the Performance Criteria that will be used to establish the Performance Goal(s), the kind(s) and/or level(s) of the Performance Goal(s) that is (are) to apply to the Company and the Performance Formula. Within the first 90 days of a Performance Period (or, if longer or shorter, within the maximum period allowed under Section 162(m) of the Code), the Committee shall, with regard to the Performance Compensation Awards to be issued for such Performance Period, exercise its discretion with respect to each of the matters enumerated in the immediately preceding sentence of this Section 7.4(c) and record the same in writing.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Payment of Performance Compensation Awards</font></font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td width="9%" style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td width="91%">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; (i)&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Condition to Receipt of Payment</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unless otherwise provided in the applicable Award Agreement, a Participant must be employed by the Company on the last day of a Performance Period to be eligible for payment in respect of a Performance Compensation Award for such Performance Period.</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td width="9%" style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td width="91%">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; (ii)&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Limitation</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A Participant shall be eligible to receive payment in respect of a Performance Compensation Award only to the extent that: (A) the Performance Goals for such period are achieved; and (B) the Performance Formula as applied against such Performance Goals determines that all or some portion of such Participant&#8217;s Performance Compensation Award has been earned for the Performance Period.</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td width="9%" style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td width="91%">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; (iii)&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Certification</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following the completion of a Performance Period, the Committee shall review and certify in writing whether, and to what extent, the Performance Goals for the Performance Period have been achieved and, if so, calculate and certify in writing the amount of the Performance Compensation Awards earned for the period based upon the Performance Formula. The Committee shall then determine the actual size of each Participant&#8217;s Performance Compensation Award for the Performance Period and, in so doing, may apply Negative Discretion in accordance with Section 7.4(d)(iv) hereof, if and when it deems appropriate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td width="9%" style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td width="91%">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; (iv)&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Use of Discretion</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In determining the actual size of an individual Performance Compensation Award for a Performance Period, the Committee may reduce or eliminate the amount of the Performance Compensation Award earned under the Performance Formula in the Performance Period through the use of Negative Discretion if, in its sole judgment, such reduction or elimination is appropriate. The Committee shall not have the discretion to (A) grant or provide payment in respect of Performance Compensation Awards for a Performance Period if the Performance Goals for such Performance Period have not been attained or (B) increase a Performance Compensation Award above the maximum amount payable under Section 7.4(d)(vi) of the Plan.</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td width="9%" style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td width="91%">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; (v)&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Timing of Award Payments</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Performance Compensation Awards granted for a Performance Period shall be paid to Participants as soon as administratively practicable following completion of the certifications required by this Section 7.4 but in no event later than 2 1/2 months following the end of the fiscal year during which the Performance Period is completed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td width="9%" style="WIDTH: 89.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td width="91%">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; (vi)&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Maximum Award Payable</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding any provision contained in this Plan to the contrary, the maximum Performance Compensation Award payable to any one Participant under the Plan for a Performance Period is 1,000,000 shares of Common Stock or, in the event such Performance Compensation Award is paid in cash, the equivalent cash value thereof on the first or last day of the Performance Period to which such Award relates, as determined by the Committee. The maximum amount that can be paid in any calendar year to any Participant pursuant to a cash bonus Award described in the last sentence of <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.4(a) </font>shall be $150,000. Furthermore, any Performance Compensation Award that has been deferred shall not (between the date as of which the Award is deferred and the payment date) increase (A) with respect to a Performance Compensation Award that is payable in cash, by a measuring factor for each fiscal year greater than a reasonable rate of interest set by the Committee or (B) with respect to a Performance Compensation Award that is payable in shares of Common Stock, by an amount greater than the appreciation of a share of Common Stock from the date such Award is deferred to the payment date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Securities Law Compliance</font>. Each Award Agreement shall provide that no shares of Common Stock shall be purchased or sold thereunder unless and until (a) any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel and (b) if required to do so by the Company, the Participant has executed and delivered to the Company a letter of investment intent in such form and containing such provisions as the Committee may require. The Company shall use reasonable efforts to seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; <font style="FONT-STYLE: italic; DISPLAY: inline">provided, however</font>, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Awards unless and until such authority is obtained.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Use of Proceeds from Stock</font>. Proceeds from the sale of Common Stock pursuant to Awards, or upon exercise thereof, shall constitute general funds of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Miscellaneous</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;10.1&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Acceleration of Exercisability and Vesting</font>. The Committee shall have the power to accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 10.2&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Shareholder Rights</font>. Except as provided in the Plan or an Award Agreement, no Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until such Participant has satisfied all requirements for exercise of the Award pursuant to its terms and no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for which the record date is prior to the date such Common Stock certificate is issued, except as provided in <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">11 </font>hereof.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;10.3&#160; &#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Employment or Other Service Rights</font>. Nothing in the Plan or any instrument executed or Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or shall affect the right of the Company or an Affiliate to terminate (a) the employment of an Employee with or without notice and with or without Cause or (b) the service of a Director pursuant to the By-laws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;10.4&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer; Approved Leave of Absence</font>. For purposes of the Plan, no termination of employment by an Employee shall be deemed to result from either (a) a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another, or (b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the Employee&#8217;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise so provides in writing, in either case, except to the extent inconsistent with Section 409A of the Code if the applicable Award is subject thereto.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 10.5&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Withholding Obligations</font>. To the extent provided by the terms of an Award Agreement and subject to the discretion of the Committee, the Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under an Award by any of the following means (in addition to the Company&#8217;s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the exercise or acquisition of Common Stock under the Award, <font style="FONT-STYLE: italic; DISPLAY: inline">provided, however</font>, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law; or (c) delivering to the Company previously owned and unencumbered shares of Common Stock of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Adjustments Upon Changes in Stock</font>. In the event of changes in the outstanding Common Stock or in the capital structure of the Company by reason of any stock or extraordinary cash dividend, stock split, reverse stock split, an extraordinary corporate transaction such as any recapitalization, reorganization, merger, consolidation, combination, exchange, or other relevant change in capitalization occurring after the Grant Date of any Award, Awards granted under the Plan and any Award Agreements, the maximum number of shares of Common Stock subject to all Awards stated in <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">4 </font>and the maximum number of shares of Common Stock with respect to which any one person may be granted Awards during any period stated in <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">4 </font>and Section 7.4(d)(vi) will be equitably adjusted or substituted, as to the number, price or kind of a share of Common Stock or other consideration subject to such Awards to the extent necessary to preserve the economic intent of such Award. Any adjustments made under this Section 11 shall be made in a manner which does not adversely affect the exemption provided pursuant to Rule 16b-3 under the Exchange Act. Further, with respect to Awards intended to qualify as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code, any adjustments or substitutions will not cause the Company to be denied a tax deduction on account of Section 162(m) of the Code. The Company shall give each Participant notice of an adjustment hereunder and, upon notice, such adjustment shall be conclusive and binding for all purposes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Effect of Change in Control</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 12.1&#160;&#160; &#160;Unless otherwise provided in an Award Agreement, notwithstanding any provision of the Plan to the contrary:</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160; With respect to Performance Compensation Awards, in the event of a Change in Control, all incomplete Performance Periods in respect of such Award in effect on the date the Change in Control occurs shall end on the date of such change and the Committee shall (i) determine the extent to which Performance Goals with respect to each such Performance Period have been met based upon such audited or unaudited financial information then available as it deems relevant and (ii) cause to be paid to the applicable Participant partial or full Awards with respect to Performance Goals for each such Performance Period based upon the Committee&#8217;s determination of the degree of attainment of Performance Goals or, if not determinable, assuming that the applicable &#8220;target&#8221; levels of performance have been attained, or on such other basis determined by the Committee.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To the extent practicable, any actions taken by the Committee under the immediately preceding clauses (a) shall occur in a manner and at a time which allows affected Participants the ability to participate in the Change in Control with respect to the shares of Common Stock subject to their Awards.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;12.2&#160;&#160; &#160;In addition, in the event of a Change in Control, the Committee may in its discretion and upon at least 10 days&#8217; advance notice to the affected persons, cancel any outstanding Awards and pay to the holders thereof, in cash or stock, or any combination thereof, the value of such Awards based upon the price per share of Common Stock received or to be received by other shareholders of the Company in the event.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;12.3&#160;&#160; &#160;The obligations of the Company under the Plan shall be binding upon any successor corporation or organization resulting from the merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to all or substantially all of the assets and business of the Company and its Affiliates, taken as a whole.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13.&#160;&#160; &#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment of the Plan and Awards</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;13.1&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment of Plan</font>. The Board at any time, and from time to time, may amend or terminate the Plan. However, except as provided in <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">11 </font>relating to adjustments upon changes in Common Stock and <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.3</font>, no amendment shall be effective unless approved by the shareholders of the Company to the extent shareholder approval is necessary to satisfy any Applicable Laws. At the time of such amendment, the Board shall determine, upon advice from counsel, whether such amendment will be contingent on shareholder approval.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;13.2&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Shareholder Approval</font>. The Board may, in its sole discretion, submit any other amendment to the Plan for shareholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Section 162(m) of the Code and the regulations thereunder regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to certain executive officers.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;13.3&#160; &#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Intentionally left blank</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 13.4&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Impairment of Rights</font>. Rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;13.5&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment of Awards</font>. The Committee at any time, and from time to time, may amend the terms of any one or more Awards; <font style="FONT-STYLE: italic; DISPLAY: inline">provided, however</font>, that the Committee may not affect any amendment which would otherwise constitute an impairment of the rights under any Award unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14.&#160;&#160;&#160;&#160;&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">General Provisions</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.1&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Forfeiture Events</font>. The Committee may specify in an Award Agreement that the Participant&#8217;s rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain events, in addition to applicable vesting conditions of an Award. Such events may include, without limitation, breach of non-competition, non-solicitation, confidentiality, or other restrictive covenants that are contained in the Award Agreement or otherwise applicable to the Participant, a termination of the Participant&#8217;s Continuous Service for Cause, or other conduct by the Participant that is detrimental to the business or reputation of the Company and/or its Affiliates.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.2&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Compensation Arrangements</font>. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.3&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Sub-plans</font>. The Committee may from time to time establish sub-plans under the Plan for purposes of satisfying blue sky, securities, tax or other laws of various jurisdictions in which the Company intends to grant Awards. Any sub-plans shall contain such limitations and other terms and conditions as the Committee determines are necessary or desirable. All sub-plans shall be deemed a part of the Plan, but each sub-plan shall apply only to the Participants in the jurisdiction for which the sub-plan was designed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.4&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Deferral of Awards</font>. The Committee may establish one or more programs under the Plan to permit selected Participants the opportunity to elect to defer receipt of consideration upon exercise of an Award, satisfaction of performance criteria, or other event that absent the election would entitle the Participant to payment or receipt of shares of Common Stock or other consideration under an Award. The Committee may establish the election procedures, the timing of such elections, the mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts, shares or other consideration so deferred, and such other terms, conditions, rules and procedures that the Committee deems advisable for the administration of any such deferral program.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.5&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Unfunded Plan</font>. The Plan shall be unfunded. Neither the Company, the Board nor the Committee shall be required to establish any special or separate fund or to segregate any assets to assure the performance of its obligations under the Plan.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.6&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Recapitalizations</font>. Each Award Agreement shall contain provisions required to reflect the provisions of <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">11</font>.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.7&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery</font>. Upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable period of time.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.8&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">No Fractional Shares</font>. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Committee shall determine whether cash, additional Awards or other securities or property shall be issued or paid in lieu of fractional shares of Common Stock or whether any fractional shares should be rounded, forfeited or otherwise eliminated.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.9&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Provisions</font>. The Award Agreements authorized under the Plan may contain such other provisions not inconsistent with this Plan, including, without limitation, restrictions upon the exercise of the Awards, as the Committee may deem advisable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.10&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 409A</font>. The Plan is intended to comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the &#8220;short-term deferral period&#8221; as defined in Section 409A of the Code shall not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately following the Participant&#8217;s termination of Continuous Service shall instead be paid on the first payroll date after the six-month anniversary of the Participant&#8217;s separation from service (or the Participant&#8217;s death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Participant under Section 409A of the Code and neither the Company nor the Committee will have any liability to any Participant for such tax or penalty.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.11&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 16</font>. It is the intent of the Company that the Plan satisfy, and be interpreted in a manner that satisfies, the applicable requirements of Rule 16b-3 as promulgated under Section 16 of the Exchange Act so that Participants will be entitled to the benefit of Rule 16b-3, or any other rule promulgated under Section 16 of the Exchange Act, and will not be subject to short-swing liability under Section 16 of the Exchange Act. Accordingly, if the operation of any provision of the Plan would conflict with the intent expressed in this Section 14.11, such provision to the extent possible shall be interpreted and/or deemed amended so as to avoid such conflict.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; &#160;14.12&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 162(m)</font>. To the extent the Committee issues any Award that is intended to be exempt from the deduction limitation of Section 162(m) of the Code, the Committee may, without shareholder or grantee approval, amend the Plan or the relevant Award Agreement retroactively or prospectively to the extent it determines necessary in order to comply with any subsequent clarification of Section 162(m) of the Code required to preserve the Company&#8217;s federal income tax deduction for compensation paid pursuant to any such Award.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.13&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Beneficiary Designation</font>. Each Participant under the Plan may from time to time name any beneficiary or beneficiaries by whom any right under the Plan is to be exercised in case of such Participant&#8217;s death. Each designation will revoke all prior designations by the same Participant, shall be in a form reasonably prescribed by the Committee and shall be effective only when filed by the Participant in writing with the Company during the Participant&#8217;s lifetime.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.14&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Expenses</font>. The costs of administering the Plan shall be paid by the Company.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.15&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Severability</font>. If any of the provisions of the Plan or any Award Agreement is held to be invalid, illegal or unenforceable, whether in whole or in part, such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining provisions shall not be affected thereby.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;14.16 &#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Plan Headings</font>. The headings in the Plan are for purposes of convenience only and are not intended to define or limit the construction of the provisions hereof.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160; 14.17&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Non-Uniform Treatment</font>. The Committee&#8217;s determinations under the Plan need not be uniform and may be made by it selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing, the Committee shall be entitled to make non-uniform and selective determinations, amendments and adjustments, and to enter into non-uniform and selective Award Agreements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Effective Date of Plan</font>. The Plan shall become effective as of the Effective Date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Termination or Suspension of the Plan</font>. The Plan shall terminate automatically on September 9, 2023. No Award shall be granted pursuant to the Plan after such date, but Awards theretofore granted may extend beyond that date. The Board may suspend or terminate the Plan at any earlier date pursuant to <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1 </font>hereof. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. Unless the Company determines to submit <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.4 </font>of the Plan and the definition of &#8220;Performance Goal&#8221; and &#8220;Performance Criteria&#8221; to the Company&#8217;s shareholders at the first shareholder meeting that occurs in the fifth year following the year in which the Plan was last approved by shareholders (or any earlier meeting designated by the Board), in accordance with the requirements of Section 162(m) of the Code, and such shareholder approval is obtained, then no further Performance Compensation Awards shall be made to Covered Employees under <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Section </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.4 </font>after the date of such annual meeting, but the Plan may continue in effect for Awards to Participants not in accordance with Section 162(m) of the Code.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Choice of Law</font>. The law of the State of Delaware shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such state&#8217;s conflict of law rules.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As adopted by the Board of Directors of Actinium Pharmaceuticals, Inc. on September 9, 2013.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">16<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>7
<FILENAME>fs12014ex10xxxv_actinium.htm
<DESCRIPTION>FORM OF UNIT PURCHASE AGREEMENT, DATED DECEMBER 27, 2013 AND JANUARY 10, 2014.**
<TEXT>
<html>
<head>
    <title>fs12014ex10xxxv_actinium.htm</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 10.35</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNIT PURCHASE AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">UNIT PURCHASE AGREEMENT (this &#8220;Agreement&#8221;) made as of the date set forth on the signature page hereof between Actinium Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), and the subscriber(s) identified on Exhibit A annexed hereto (the &#8220;Subscriber&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">W I T N E S S E T H:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">WHEREAS, the Company is conducting a private offering (the &#8220;Offering&#8221;) consisting of up to a maximum of 50 units (the &#8220;Units&#8221;), each Unit consisting of (a) twenty thousand (20,000) shares of the Company&#8217;s common stock par value $0.001 per share (the &#8220;Common Stock&#8221;) at a purchase price of $6.00 per share and (b) a five-year warrant (collectively, the &#8220;Warrants&#8221; and together with the Units and Common Stock, the &#8220;Securities&#8221;) to purchase five thousand (5,000) shares of Common Stock of the Company at an exercise price equal to $9.00 per share, subject to equitable adjustment thereunder (the &#8220;Exercise Price&#8221;) at a negotiated price of $120,000 per Unit (the &#8220;Unit Purchase Price&#8221;);</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">WHEREAS, the Company has retained Laidlaw &amp; Company (UK) Ltd. to act as its placement agent in connection with the sale of the Units pursuant to this Agreement (the &#8220;Placement Agent&#8221;);</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">WHEREAS, the Offering is on a &#8220;reasonable efforts, all-or-none&#8221; basis to attain the minimum offering amount of $2,000,000 purchase price for the Units (the &#8220;Minimum Offering&#8221;), and on a &#8220;reasonable efforts&#8221; basis as to the remaining Units to be sold up to the maximum offering amount of $6,000,000 purchase price for the Units (subject to the right of the Company to increase the maximum offering amount to $8,000,000 to cover over-allotments)<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font> (the &#8220;Maximum Offering&#8221;), to a limited number of &#8220;accredited investors&#8221; (as that term is defined by Rule 501(a) of Regulation D (&#8220;Regulation D&#8221;) promulgated by the Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;);</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">WHEREAS, the Company and each Subscriber is executing and delivering this agreement in reliance upon the exemption from securities registration afforded by Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated by the SEC under the Securities Act;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">WHEREAS the subscription for the Securities will be made in accordance with and subject to the terms and conditions of this Subscription Agreement and the Company&#8217;s Confidential Private Placement Memorandum dated December 11, 2013, together with all amendments thereof and supplements and exhibits thereto and as such may be amended from time to time (the &#8220;Memorandum&#8221;); and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">WHEREAS, the Subscriber desires to purchase such number of Units as set forth on the signature page hereof on the terms and conditions hereinafter set forth.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: left; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOW, THEREFORE, in consideration of the premises and the mutual representations and covenants hereinafter set forth, the parties hereto do hereby agree as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 42px">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I.</font></font></div>
</td>
<td width="939">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">SUBSCRIPTION FOR SECURITIES</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms and conditions hereinafter set forth and as set forth in the Memorandum, the Subscriber hereby subscribes for and agrees to purchase from the Company, and the Company subject to its rights to accept or reject this subscription, agrees to sell to the Subscriber, such number of Units for the aggregate purchase price as is set forth on the signature page hereof.&#160;&#160;The purchase price is payable by wire transfer, to be held in escrow until the conditions to closing are achieved, to Signature Bank, the escrow agent (the &#8220;Escrow Agent&#8221;) as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; Bank: Signature Bank</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; ABA Number: 026013576</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; Account #: 1502171417</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 108pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; Account Name: Signature Bank, as Escrow Agent for Actinium Pharmaceuticals, Inc., Account No. 1502171417</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 108pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; Swift Code: SIGNUS33</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Subscriber understands acknowledges and agrees that, except as otherwise set forth herein or otherwise required by law, that once irrevocable, the Subscriber is not entitled to cancel, terminate or revoke this Agreement or any agreements of the Subscriber hereunder and that this Agreement and such other agreements shall survive the death or disability of the Subscriber and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives and permitted assigns. If the Subscriber is more than one person, the obligations of the Subscriber hereunder shall be joint and several and the agreements, representations, warranties and acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and his/her heirs, executors, administrators, successors, legal representatives and permitted assigns.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">II.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">REPRESENTATIONS BY SUBSCRIBER</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each Subscriber hereby severally, and not jointly, represents and warrants to the Company that each such Subscriber&#8217;s representations in the Subscription Agreement, in the form attached as Exhibit A to the Memorandum, entered into in connection with this Agreement are true and correct as of the date hereof.</font></div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 42px">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">III.</font></font></div>
</td>
<td width="939">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">REPRESENTATIONS BY AND COVENANTS OF THE COMPANY</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company hereby represents and warrants to the Subscriber that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Organization, Good Standing and Qualification</font>.&#160;&#160;The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has full corporate power and authority to own and use its properties and its assets and conduct its business as currently conducted.&#160;&#160;Each of the Company&#8217;s subsidiaries identified on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.1</font> hereto (the &#8220;Subsidiaries&#8221;) is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation with the requisite corporate power and authority to own and use its properties and assets and to conduct its business as currently conducted. Neither the Company, nor any of its Subsidiaries is in violation of any of the provisions of their respective articles of incorporation, by-laws or other organizational or charter documents, including, but not limited to the Charter Documents (as defined below). Each of the Company and its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not result in a direct and/or indirect (i)&#160;material adverse effect on the legality, validity or enforceability of any of the Securities and/or this Agreement, (ii)&#160;material adverse effect on the results of operations, assets, business, condition (financial and other) or prospects of the Company and its Subsidiaries, taken as a whole, or (iii) material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under the Transaction Documents (any of (i), (ii) or (iii), a &#8220;Material Adverse Effect&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Capitalization and Voting Rights</font>.&#160;&#160;The authorized, issued and outstanding capital stock of the Company is as set forth in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.2</font> hereto and all issued and outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable.&#160;&#160;Except as set forth in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.2</font> hereto, (i) there are no outstanding securities of the Company or any of its Subsidiaries which contain any preemptive, redemption or similar provisions, nor is any holder of securities of the Company or any Subsidiary entitled to preemptive or similar rights arising out of any agreement or understanding with the Company or any Subsidiary by virtue of any of the Transaction Documents, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (ii) neither the Company nor any Subsidiary has any stock appreciation rights or <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>phantom stock<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font> plans or agreements or any similar plan or agreement; and (iii) except as set forth in Schedule 3.2 there are no outstanding options, warrants, agreements, convertible securities, preemptive rights or other rights to subscribe for or to purchase or acquire, any shares of capital stock of the Company or any Subsidiary or contracts, commitments, understandings, or arrangements by which the Company or any Subsidiary is or may become bound to issue any shares of capital stock of the Company or any Subsidiary, or secur&#173;ities or rights convertible or exchangeable into shares of capital stock of the Company or any Subsidiary.&#160;&#160;Except as set forth in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.2</font> and as otherwise required by law, there are no restrictions upon the voting or transfer of any of the shares of capital stock of the Company pursuant to the Company&#8217;s Charter Documents (as defined below) or other governing documents or any agreement or other instruments to which the Company is a party or by which the Company is bound.&#160;&#160;All of the issued and outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable and the shares of capital stock of the Subsidiaries are owned by the Company, free and clear of any mortgages, pledges, liens, claims, charges, encumbrances or other restrictions (collectively, &#8220;Encumbrances&#8221;). All of such outstanding capital stock has been issued in compliance with applicable federal and state securities laws.&#160;&#160;The issuance and sale of the Securities and, upon issuance, the Shares, as contemplated hereby will not obligate the Company to issue shares of Common Stock or other securities to any other person (other than the Subscriber) and except as set forth in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.2</font> will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security.&#160;&#160;The Company does not have outstanding stockholder purchase rights or &#8220;poison pill&#8221; or any similar arrangement in effect giving any person the right to purchase any equity interest in the Company upon the occurrence of certain events.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Authorization; Enforceability</font>. The Company has all corporate right, power and authority to enter into, execute and deliver this Agreement and each other agreement, document, instrument and certificate to be executed by the Company in connection with the consummation of the transactions contemplated hereby, including, but not limited to Transaction Documents and to perform fully its obligations hereunder and thereunder.&#160;&#160;All corporate action on the part of the Company, its directors and stockholders necessary for the (a) authorization execution, delivery and performance of this Agreement and the Transaction Documents by the Company; and (b) authorization, sale, issuance and delivery of the Securities and upon issuance, the Shares contemplated hereby and the performance of the Company&#8217;s obligations under this Agreement and the Transaction Documents has been taken.&#160;&#160;This Agreement and the Transaction Documents have been duly executed and delivered by the Company and each constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies, and to limitations of public policy.&#160;&#160;The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Encumbrances other than restrictions on transfer provided for in the Transaction Documents.&#160;&#160;The Shares, when issued and paid for in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Encumbrances imposed by the Company other than restrictions on transfer provided for in the Transaction Documents.&#160;&#160;The Company has reserved a sufficient number of Warrant Shares for issuance upon the exercise of the Warrants, free and clear of all Encumbrances, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws.&#160;&#160;Except as set forth on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.3 </font>hereto, the issuance and sale of the Securities contemplated hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any person other than the Subscribers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No Conflict; Governmental Consents</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;The execution and delivery by the Company of this Agreement and the Transaction Documents, the issuance and sale of the Securities (including, when issued, the Shares) and the consummation of the other transactions contemplated hereby or thereby do not and will not (i) result in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court or governmental authority to or by which the Company is bound including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect, (ii) conflict with or violate any provision of the Company&#8217;s Articles of Incorporation (the &#8220;Articles&#8221;), as amended or the Bylaws, (and collectively with the Articles, the &#8220;Charter Documents&#8221;) of the Company, and (iii) conflict with, or result in a material breach or violation of, any of the terms or provisions of, or constitute (with or without due notice or lapse of time or both) a default or give to others any rights of termination, amendment, acceleration or cancellation (with&#160;&#160;or without due notice, lapse of time or both) under any agreement, credit facility, lease, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which the Company or any Subsidiary is a party or by which any of them is bound or to which any of their respective properties or assets is subject, nor result in the creation or imposition of any Encumbrances upon any of the properties or assets of the Company or any Subsidiary.</font></div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;No approval by the holders of Common Stock, or other equity securities of the Company is required to be obtained by the Company in connection with the authorization, execution, delivery and performance of this Agreement and the other Transaction Documents or in connection with the authorization, issue and sale of the Securities and, upon issuance, the Shares, except as has been previously obtained.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;No consent, approval, authorization or other order of any governmental authority or any other person is required to be obtained by the Company in connection with the authorization, execution, delivery and performance of this Agreement and the other Transaction Documents or in connection with the authorization, issue and sale of the Securities and, upon issuance, the Shares, except such post-sale filings as may be required to be made with the SEC, FINRA and with any state or foreign blue sky or securities regulatory authority, all of which shall be made when required.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Consents of Third Parties</font>. No vote, approval or consent of any holder of capital stock of the Company or any other third parties is required or necessary to be obtained by the Company in connection with the authorization, execution, deliver and performance of this Agreement and the other Transaction Documents or in connection with the authorization, issue and sale of the Securities and, upon issuance, the Shares, except as previously obtained, each of which is in full force and effect.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Shell Company Status; SEC Reports; Financial Statements</font>.&#160;&#160;Except as set forth on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.6</font>, the Company has never been an issuer subject to Rule 144(i) under the Securities Act. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &#8220;SEC Reports&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.&#160;&#160;As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.&#160;&#160;Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;GAAP&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Licenses</font>.&#160;&#160;Except as otherwise set forth in the SEC Reports, the Company and its Subsidiaries have sufficient licenses, permits and other governmental authorizations currently required for the conduct of their respective businesses or ownership of properties and is in all material respects in compliance therewith.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Litigation</font>.&#160;&#160;Except as set forth in the SEC Reports, the Company knows of no pending or threatened legal or governmental proceedings against the Company or any Subsidiary which could materially adversely affect the business, property, financial condition or operations of the Company and its Subsidiaries, taken as a whole, or which materially and adversely questions the validity of this Agreement or the other Transaction Documents or the right of the Company to enter into this Agreement and the other Transaction Documents, or to perform its obligations hereunder and thereunder. Neither the Company nor any Subsidiary is a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality which could materially adversely affect the business, property, financial condition or operations of the Company and its Subsidiaries taken as a whole. Except as set forth in the SEC Reports, there is no action, suit, proceeding or investigation by the Company or any Subsidiary currently pending in any court or before any arbitrator or that the Company or any Subsidiary intends to initiate.&#160;&#160;Neither the Company nor any Subsidiary, nor any director or officer thereof, is nor since the Form 10-K has been the subject of any action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.&#160;&#160;There has not been, and to the Company&#8217;s knowledge, there is not pending or contemplated, any investigation by the SEC involving the Company or any current or former director or officer of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Compliance</font>.&#160;&#160;Except as set forth in the SEC Reports or on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.9</font>, neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.10&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Regulatory Permits</font>.&#160;&#160;The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as currently conducted, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&#8220;Material Permits&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.11&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">FDA</font>. As to each of the Company&#8217;s product candidates subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;FDCA&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product candidate, a &#8220;Pharmaceutical Product&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and other federal or state laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect. There is no pending, completed or, to the Company&#8217;s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i)&#160;contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii)&#160;withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)&#160;imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv)&#160;enjoins production at any facility of the Company or any of its Subsidiaries, (v)&#160;enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi)&#160;otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have or reasonably be expected to have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.12&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Investment Company</font>.&#160;&#160;The Company is not an &#8220;investment company&#8221; within the meaning of such term under the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.13&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Brokers</font>.&#160;&#160;Except for the fees payable to the Placement Agent as set forth on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.13</font>, neither the Company nor any of the Company<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s officers, directors, employees or stockholders has employed or engaged any broker or finder in connection with the transactions contemplated by this Agreement and no fee or other compensation is or will be due and owing to any broker, finder, underwriter, placement agent or similar person in connection with the transactions contemplated by this Agreement.&#160;&#160;The Company is not party to any agreement, arrangement or understanding whereby any person has an exclusive right to raise funds and/or place or purchase any debt or equity securities for or on behalf of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.14&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Intellectual Property; Employees</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes necessary for its business as now conducted and as presently proposed to be conducted, without any known infringement of the rights of others as described in the SEC Reports&#160;&#160;and which the failure to so have could have a Material Adverse Effect (collectively, the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Intellectual Property Rights</font>&#8221;).&#160;&#160;Except as disclosed on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.14</font> or the SEC Reports, there are no material outstanding options, licenses or agreements of any kind relating to the Intellectual Property Rights, nor is the Company bound by or a party to any material options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes of any other person or entity other than such licenses or agreements arising from the purchase of &#8220;off the shelf&#8221; or standard products.&#160;&#160;The Company has not received any written communications alleging that the Company has violated or, by conducting its business as presently proposed to be conducted, would violate any Intellectual Property Rights of any other person or entity.&#160;&#160;The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;Except as disclosed in the SEC Reports, the Company is not aware that any of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with their duties to the Company or that would conflict with the Company&#8217;s business as presently conducted.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the execution nor delivery of this Agreement, nor the carrying on of the Company&#8217;s business by the employees of the Company, nor the conduct of the Company&#8217;s business as presently conducted, will, to the Company&#8217;s knowledge, conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any employee is now obligated.</font></div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;To the Company&#8217;s knowledge, no employee of the Company, nor any consultant with whom the Company has contracted, is in violation of any term of any employment contract, proprietary information agreement or any other agreement relating to the right of any such individual to be employed by, or to contract with, the Company because of the nature of the business conducted by the Company; and to the Company&#8217;s knowledge the continued employment by the Company of its present employees, and the performance of the Company&#8217;s contracts with its independent contractors, will not result in any such violation.&#160;&#160;The Company has not received any written notice alleging that any such violation has occurred.&#160;&#160;Except as described in SEC Reports, no employee of the Company has been granted the right to continued employment by the Company or to any compensation following termination of employment with the Company except for any of the same which would not have a Material Adverse Effect on the business of the Company.&#160;&#160;The Company is not aware that any officer, key employee or group of employees intends to terminate his, her or their employment with the Company, nor does the Company have a present intention to terminate the employment of any officer, key employee or group of employees.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.15&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Title to Properties and Assets; Liens, Etc</font>.&#160;&#160;Except as described in the SEC Reports, the Company has good and marketable title to its properties and assets, including the properties and assets reflected in the most recent balance sheet included in the Company&#8217;s financial statements, and good title to its leasehold estates, in each case subject to no Encumbrances, other than (a) those resulting from taxes which have not yet become delinquent; and (b) Encumbrances which do not materially detract from the value of the property subject thereto or materially impair the operations of the Company; and (c) those that have otherwise arisen in the ordinary course of business, none of which are material.&#160;&#160;Except as set forth in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.15</font>, the Company is in compliance with all material terms of each lease to which it is a party or is otherwise bound.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.16&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Obligations to Related Parties</font>.&#160;&#160;Except as described in the SEC Reports and in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.16</font>, there are no obligations of the Company to officers, directors, stockholders, or employees of the Company other than (a) for payment of salary or other compensation for services rendered, (b) reimbursement for reasonable expenses incurred on behalf of the Company and (c) for other standard employee benefits made generally available to all employees (including stock option agreements outstanding under any stock option plan approved by the Board of Directors of the Company).&#160;&#160;Except as disclosed in the SEC Reports, none of the officers or directors of the Company and, to the Company&#8217;s knowledge, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than as holders of stock options and/or warrants, and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the Company&#8217;s knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.17&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Material Changes</font>.&#160;&#160;Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans and (vi) the Company has not increased any salary paid to any officer, director or employee. The Company does not have pending before the Commission any request for confidential treatment of information.&#160;&#160;Except for the issuance of the Securities contemplated by this Agreement or as set forth on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.17</font>, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, properties, operations, assets or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 trading day prior to the date that this representation is made.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.18&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Sarbanes-Oxley; Internal Accounting Controls</font>.&#160;&#160;Except as described in the SEC Reports the Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.&#160;&#160;Except as described in the SEC Reports the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the SEC Reports the Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms.&#160;&#160;The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Evaluation Date</font>&#8221;).&#160;&#160;The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date.&#160;&#160;Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.19&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No General Solicitation</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.</font> None of the Company, its Subsidiaries, any of their affiliates, and any person acting on their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation&#160;D under the Securities Act) in connection with the offer or sale of the Securities.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.20&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No Integrated Offering</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">.&#160;&#160;</font>Assuming the accuracy of the Subscriber representations and warranties set forth in Article I hereunder, none of the Company, its Subsidiaries, any of their affiliates, and any person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of any of the Securities under the Securities Act or that is likely to cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable stockholder approval provisions, including without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated. Except as disclosed in the SEC Reports, none of the Company, its Subsidiaries, their affiliates and any person acting on their behalf, have taken any action or steps referred to in the preceding sentence that would require registration of any of the Securities under the Securities Act or cause the offering of the Securities to be integrated with other offerings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.21&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Application of Takeover Protections</font>.&#160;&#160;The Company has taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company&#8217;s Charter Documents or the laws of its state of incorporation that is or could become applicable to the Subscriber as a result of the Subscriber and the Company fulfilling their obligations or exercising their rights under this Agreement, including, without limitation, the Company&#8217;s issuance of the Securities and the Subscriber&#8217; ownership of the Securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.22&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Taxes</font>. Each of the Company and its Subsidiaries has filed all U.S. federal, state, local and foreign tax returns which are required to be filed by each of them and all such returns are true and correct in all material respects, except for such failures to file which could not reasonably be expected to have a Material Adverse Effect.&#160;&#160;The Company and each Subsidiary has paid all taxes pursuant to such returns or pursuant to any assessments received by any of them or by which any of them are obligated to withhold from amounts owing to any employee, creditor or third party. The Company and each Subsidiary has properly accrued all taxes required to be accrued and/or paid, except where the failure to accrue would not have a Material Adverse Effect.&#160;&#160;To the knowledge of the Company, the tax returns of the Company and its Subsidiaries are not currently being audited by any state, local or federal authorities.&#160;&#160;Neither the Company nor any Subsidiary has waived any statute of limitations with respect to taxes or agreed to any extension of time with respect to any tax assessment or deficiency.&#160;&#160;The Company has set aside on its books adequate provision for the payment of any unpaid taxes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.23&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Registration Rights</font>.&#160;&#160;Except as set forth on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 3.23</font>, no person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.24&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Listing and Maintenance Requirements</font>.&#160;&#160;The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating terminating such registration.&#160;&#160;The Company has not, in the 12 months preceding the date hereof, received notice from any trading market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such trading market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.25&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Disclosure</font>.&#160;&#160;Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the Memorandum, the Warrant, the Registration Rights Agreement and all other exhibits, annexes and appendices thereto (collectively referred to as the &#8220;Offering Materials&#8221;), the Company confirms that neither it nor any other person acting on its behalf has provided the Subscriber or its agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Subscriber will rely on the foregoing representation in effecting transactions in securities of the Company. All disclosure furnished by or on behalf of the Company to the Subscriber regarding the Company, its business and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole together the SEC Reports do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements, in light of the circumstances under which they were made and when made, not misleading.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.26&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Private Placement</font>. Assuming the accuracy of the Subscribers&#8217; representations and warranties set forth in Section 1, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Subscriber as contemplated hereby.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.27&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Intentionally Omitted</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.28&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">OFAC</font>. Neither the Company nor, to the Company&#8217;s knowledge, any director, officer, agent, employee, affiliate or person acting on its behalf, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;OFAC&#8221;); and the Company will not directly or indirectly use the proceeds of the sale of the Units, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or entity, towards any sales or operations in Cuba, Iran, Syria, Sudan, Myanmar or any other country sanctioned by OFAC or for the purpose of financing the activities of any person currently subject to any U.S. sanctions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.29&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Regulation M Compliance</font>.&#160; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&#8217;s placement agent in connection with the placement of the Securities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.30&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Foreign Corrupt Practices</font>.&#160;&#160;Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has: (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is&#160;&#160;in violation of law or (iv) violated in any material respect any provision of FCPA</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.31&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Investment Company</font>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended.&#160;&#160;The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.32&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Bad Actor Disqualification</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No Disqualification Events</font>. With respect to Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act (<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Regulation D Securities<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font>), none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering, any beneficial owner of 20% or more of the Company&#8217;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Issuer Covered Person<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font> and, together, <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Issuer Covered Persons<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font>) is subject to any of the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Bad Actor<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font> disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Disqualification Event<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font>), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Placement Agent and the Subscriber a copy of any disclosures provided thereunder.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Other Covered Persons</font>. The Company is not aware of any person that (i) has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of the Securities and (ii) who is subject to a Disqualification Event.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 108pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Notice of Disqualification Events</font>. The Company will notify the Placement Agent in writing of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Issuer Covered Person, prior to any Closing of this Offering.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 42px">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IV.</font></font></div>
</td>
<td width="939">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">TERMS OF SUBSCRIPTION</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Securities will be offered for sale until the earlier of (i) the date upon which subscriptions for the Maximum Offering offered hereunder have been accepted, (ii) January 31, 2014 (subject to the right of the Company and the Placement Agent to extend the offering until February 28, 2014 without further notice to investors), or (iii) the date upon which the Company and the Placement Agent elect to terminate the Offering (the &#8220;Termination Date&#8221;).&#160;&#160;The Offering is being conducted on a &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">reasonable efforts, all or none</font>&#8221; basis with respect to the Minimum Offering and thereafter on a &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">reasonable efforts</font>&#8221; basis for up to the Maximum Offering.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company may hold an initial closing (&#8220;Initial Closing&#8221;) at any time after the receipt of accepted subscriptions for the Minimum Offering.&#160;&#160;After the Initial Closing, subsequent closings with respect to additional Securities may take place at any time prior to the Termination Date as determined by the Company, with respect to subscriptions accepted prior to the Termination Date (each such closing, together with the Initial Closing, being referred to as a &#8220;Closing&#8221;).&#160;&#160;The last Closing of the Offering, occurring on or prior to the Termination Date, shall be referred to as the &#8220;Final Closing&#8221;.&#160;&#160;Any subscription documents or funds received after the Final Closing will be returned, without interest or deduction.&#160;&#160;In the event that the any Closing does not occur prior to the Termination Date, all amounts paid by the Subscriber shall be returned to the Subscriber, without interest or deduction.&#160;&#160;The Subscriber may revoke its subscription and obtain a return of the subscription amount paid to the Escrow Account at any time before the date of the Initial Closing by providing written notice to the Placement Agent, the Company and the Escrow Agent as provided in Section 6.1 below. Upon receipt of a revocation notice from the Subscriber prior to the date of the Initial Closing, all amounts paid by the Subscriber shall be returned to the Subscriber, without interest or deduction.&#160;&#160;The Subscriber may not revoke this subscription or obtain a return of the subscription amount paid to the Escrow Agent on or after the date of the Initial Closing.&#160;&#160;Any subscription received after the Initial Closing but prior to the Termination Date shall be irrevocable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;The minimum purchase that may be made by any prospective investor shall be $120,000.&#160;&#160;Subscriptions for investment below the minimum investment may be accepted at the discretion of the Placement Agent and the Company.&#160;&#160;The Company and the Placement Agent reserve the right to reject any subscription made hereby, in whole or in part, in their sole discretion.&#160;&#160;The Company&#8217;s agreement with each Subscriber is a separate agreement and the sale of the Securities to each Subscriber is a separate sale.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;All funds shall be deposited in the account identified in Section 1.1 hereof.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certificates representing the Securities purchased by the Subscriber pursuant to this Agreement will be prepared for delivery to the Subscriber as soon as practicable following the Closing (but in no event later than five (5) days after a Closing) at which such purchase takes place. The Subscriber hereby authorizes and directs the Company to deliver the certificates representing the Securities purchased by the Subscriber pursuant to this Agreement directly to the Subscriber&#8217;s residential or business or brokerage house address indicated on the signature page hereto.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company&#8217;s agreement with each Subscriber is a separate agreement and the sale of Securities to each Subscriber is a separate sale.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">V.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">CONDITIONS TO OBLIGATIONS OF THE SUBSCRIBER</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Subscriber&#8217;s obligation to purchase the Securities at the Closing at which such purchase is to be consummated is subject to the fulfillment on or prior to such Closing of the following conditions, which conditions may be waived at the option of each Subscriber to the extent permitted by law:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Representations and Warranties; Covenants</font>.&#160;&#160;The representations and warranties made by the Company in Section 3 hereof qualified as to materiality shall be true and correct as of the Initial Closing and on each Closing Date, except (i) to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date, and, (ii) the representations and warranties made by the Company in Section 3 hereof not qualified as to materiality shall be true and correct in all material respects at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date; <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">provided however</font>, that notwithstanding the foregoing, the Company shall only be required to update the Disclosure Schedules by the delivery to the Subscribers by the Company of an amended Disclosure Schedule with respect to any information that is of a material nature as of such proposed Closing Date.&#160;&#160;All covenants, agreements and conditions contained in this Agreement to be performed by the Company on or prior to the date of such Closing shall have been performed or complied with in all material respects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No Legal Order Pending</font>.&#160;&#160;There shall not then be in effect any legal or other order enjoining or restraining the transactions contemplated by this Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No Law Prohibiting or Restricting Such Sale</font>.&#160;&#160;There shall not be in effect any law, rule or regulation prohibiting or restricting such sale or requiring any consent or approval of any person, which shall not have been obtained, to issue the Securities (except as otherwise provided in this Agreement).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Required Consents</font>.&#160;&#160;The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary or appropriate for consummation of the purchase and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect.</font></div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Adverse Changes</font>.&#160;&#160;Since the date of execution of this Agreement, no event or series of events shall have occurred that reasonably could have or result in a Material Adverse Effect.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">No Suspensions of Trading in Common Stock; Listing</font>.&#160;&#160;Trading in the Common Stock shall not have been suspended by the SEC or any trading market (except for any suspensions of trading of not more than one trading day solely to permit dissemination of material information regarding the Company) at any time since the date of execution of this Agreement, and the Common Stock shall have been at all times since such date listed for trading on a trading market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Blue Sky</font>.&#160;&#160;The Company shall have completed qualification for the Securities and the Shares under applicable Blue Sky laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Legal Opinion</font>.&#160;&#160;The Company&#8217;s corporate counsel shall have delivered a legal opinion addressed to the Subscribers in a form reasonably acceptable to the Placement Agent.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Proceedings and Litigation</font>.&#160;&#160;No action, suit or proceeding shall have been commenced by any Person against any party hereto seeking to restrain or delay the purchase and sale of the Units or the other transactions contemplated by this Agreement or any of the other Offering Documents.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Disclosure Schedules</font>.&#160;&#160;The Company shall have delivered a copy of its Disclosure Schedules (or amended Disclosure Schedules) qualifying any of the representations and warranties contained in Section 3 which original Disclosure Schedules will speak only as Initial Closing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Lock-Up Agreement</font>.&#160;&#160;The directors, officers, and the Placement Agent shall execute a lock-up agreement, substantially in the form of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exhibit B</font> attached hereto. The Company shall use its reasonable best efforts to have the 5% or greater shareholders enter into lock-up agreements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">VI.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">COVENANTS OF THE COMPANY</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Transfer Restrictions.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Securities may only be disposed of in compliance with state and federal securities laws.&#160;&#160;In connection with any transfer of Securities other than pursuant to an effective registration statement or Rule 144 promulgated under the Securities Act, to the Company or to an affiliate of a Subscriber or in connection with, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act.&#160;&#160;As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement, and shall have the rights of a Subscriber under this Agreement.</font></div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Subscriber agrees to the imprinting, so long as is required by this Section 5.1, of a legend on any of the Securities, including the Shares, in the following form:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[NEITHER] THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.&#160;&#160;THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [EXERCISE] [CONVERSION] OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certificates evidencing the Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, or (ii) following any sale of such Shares pursuant to Rule 144, or (iii) if such Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC). The Company shall cause its counsel, at the Company&#8217;s expense, to issue a legal opinion to the Company&#8217;s transfer agent promptly (but in no event later than the requisite share delivery date set forth in the Warrants) if required by the Company&#8217;s transfer to effect the removal of the legend hereunder.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Listing of Securities</font>.&#160;&#160;The Company agrees, (i) if the Company applies to have the Common Stock traded on any other trading market, it will include in such application the shares of Common Stock and Shares, and will take such other action as is necessary or desirable to cause the shares of Common Stock and Shares to be listed on such other trading market as promptly as possible, and (ii) it will take all action reasonably necessary to continue the listing and trading of its Common Stock on a trading market and will comply in all material respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the trading market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Reservation of Shares</font>.&#160;&#160;The Company shall at all times while the Warrants are outstanding maintain a reserve from its duly authorized shares of Common Stock of a number of shares of Common Stock sufficient to allow for the issuance of the Warrant Shares.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Replacement of Securities</font>.&#160;&#160;If any certificate or instrument evidencing any Securities or the Shares is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested.&#160;&#160;The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement securities.&#160;&#160;If a replacement certificate or instrument evidencing any securities is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Furnishing of Information</font>.&#160;&#160;Until the time that no Subscriber owns Securities, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.&#160;&#160;&#160;&#160;As long as Subscriber owns Securities, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to Subscriber and make publicly available in accordance with Rule 144(c) such information as is required for the Subscribers to sell the Securities under Rule 144.&#160;&#160;The Company further covenants that it will take such further action as any holder of Securities may reasonably request, to the extent required from time to time to enable such person to sell such Securities without registration under the Securities Act within the requirements of the exemption provided by Rule 144.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Securities Laws; Publicity</font>.&#160;&#160;The Company shall, by 8:30 a.m. (New York City time) on the second trading day immediately following a Closing hereunder, issue a Current Report on Form 8-K disclosing the material terms of the transactions contemplated hereby and including the Transaction Documents as exhibits thereto to the extent required by law.&#160;&#160;The Company shall not publicly disclose the name of Subscriber, or include the name of any Subscriber in any filing with the SEC or any regulatory agency or trading market, without the prior written consent of Subscriber, except: (a) as required by federal securities law in connection with the filing of final Transaction Documents (including signature pages thereto) with the SEC and (b) to the extent such disclosure is required by law, in which case the Company shall provide the Subscriber with prior notice of such disclosure permitted under this clause (b).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Form D; Blue Sky Filings</font>.&#160;&#160;The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D promulgated under the Securities Act and to provide a copy thereof, promptly upon request of the Subscriber. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Subscriber at the Closing under applicable securities or &#8220;Blue Sky&#8221; laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Subscriber.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Equal Treatment of Subscribers</font>.&#160;&#160;No consideration (including any modification of any Transaction Document) shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 90pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Indemnification.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company agrees to indemnify and hold harmless the Subscriber, its affiliates and their respective officers, directors, employees, agents and controlling persons (collectively, the &#8220;Indemnified Parties&#8221;) from and against , any and all loss, liability, damage or deficiency suffered or incurred by any Indemnified Party by reason of any misrepresentation or breach of warranty by the Company or,<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">after any applicable notice and/or cure periods, </font>nonfulfillment of any covenant or agreement to be performed or complied with by the Company under this Agreement, the Transaction Documents; and will promptly reimburse the Indemnified Parties for all expenses (including reasonable fees and expenses of legal counsel) as incurred in connection with the investigation of, preparation for or defense of any pending or threatened claim related to or arising in any manner out of any of the foregoing, or any action or proceeding arising therefrom (collectively, &#8220;Proceedings&#8221;), whether or not such Indemnified Party is a formal party to any such Proceeding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;If for any reason (other than a final non-appealable judgment finding any Indemnified Party liable for losses, claims, damages, liabilities or expenses for its gross negligence or willful misconduct) the foregoing indemnity is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless, then the Company shall contribute to the amount paid or payable by an Indemnified Party as a result of such loss, claim, damage, liability or expense in such proportion as is appropriate to reflect not only the relative benefits received by the Company on the one hand and the Advisor on the other, but also the relative fault by the Company and the Indemnified Party, as well as any relevant equitable considerations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; 6.10&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Non-Public Information</font>.&#160;&#160;Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company covenants and agrees that neither it, nor any other person acting on its behalf, will provide Subscriber or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto Subscriber shall have executed a written agreement regarding the confidentiality and use of such information.&#160;&#160;The Company understands and confirms that Subscriber shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160; 6.11&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Use of Proceeds</font>.&#160;&#160;Except as set forth on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 6.11</font> attached hereto, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall not use such proceeds for: (a) the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices), (b) the redemption of any Common Stock or Common Stock equivalents or (c) the settlement of any outstanding litigation.</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 6.12&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">DTC Eligibility</font>.&#160;&#160;Within sixty (60) days of the Final Closing, the Company&#8217;s will take all necessary steps to have its common stock eligible for deposit with the Depositary Trust Company.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 42px">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">VII.</font></font></div>
</td>
<td width="939">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">MISCELLANEOUS</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile or by electronic communication at or prior to 5:30 p.m. (New York City time) on a day in which the New York Stock Exchange is open for trading (a &#8220;Trading Day&#8221;), (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or electronic communication on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.&#160;&#160;The address for such notices and communications shall be addressed as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">if to the Company, to it at:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">501 Fifth Avenue, 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">New York, New York 10017</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Attn:&#160;&#160;Kaushik J. Dave, CEO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With a copy to (which shall not constitute notice):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Thomas Slusarczyk, Esq.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Hiscock &amp; Barclay LLP</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">One Park Place</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">300 South State Street</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Syracuse, New York 13202</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel No.: (315) 235-2299</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fax No.: (315) 624-7359</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">if to the Subscriber, to the Subscriber&#8217;s address indicated on the signature page of this Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With a copy to (which shall not constitute notice):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sichenzia Ross Friedman Ference LLP</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">61 Broadway, 32<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">New York, NY 10006</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Attn:&#160;&#160;Richard A. Friedman, Esq.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">if to the Escrow Agent, to it at:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Signature Bank</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">261 Madison Ave.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">New York, NY 10016</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Attn: Cliff Broder, Group Director and Senior Vice President</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fax: <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">646-822-1359</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise provided herein, this Agreement shall not be changed, modified or amended except by a writing signed by the Company and the parties to be charged, and this Agreement may not be discharged except by performance in accordance with its terms or by a writing signed by the party to be charged.&#160;&#160;No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement shall be binding upon and inure to the benefit of the parties hereto and to their respective heirs, legal representatives, successors and assigns.&#160;&#160;The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Subscriber (other than by merger).&#160;&#160;Subscriber may assign any or all of its rights under this Agreement to any person to whom Subscriber assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Transaction Documents and the Offering Materials, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon the execution and delivery of this Agreement by the Subscriber and the Company, this Agreement shall become a binding obligation of the Subscriber with respect to the purchase of Securities as herein provided, subject, however, to the right hereby reserved by the Company to enter into the same agreements with other Subscriber and to reject any subscription, in whole or in part, provided the Company returns to Subscriber any funds paid by Subscriber with respect to such rejected subscription or portion thereof, without interest or deduction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.&#160;&#160;Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.&#160;&#160;Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;In order to discourage frivolous claims the parties agree that unless a claimant in any proceeding arising out of this Agreement succeeds in establishing his claim and recovering a judgment against another party (regardless of whether such claimant succeeds against one of the other parties to the action), then the other party shall be entitled to recover from such claimant all of its/their reasonable legal costs and expenses relating to such proceeding and/or incurred in preparation therefor.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;The holding of any provision of this Agreement to be invalid or unenforceable by a court of competent jurisdiction shall not affect any other provision of this Agreement, which shall remain in full force and effect.&#160;&#160;If any provision of this Agreement shall be declared by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced in whole or in part, such provision shall be interpreted so as to remain enforceable to the maximum extent permissible consistent with applicable law and the remaining conditions and provisions or portions thereof shall nevertheless remain in full force and effect and enforceable to the extent they are valid, legal and enforceable, and no provisions shall be deemed dependent upon any other covenant or provision unless so expressed herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;It is agreed that a waiver by either party of a breach of any provision of this Agreement shall not operate, or be construed, as a waiver of any subsequent breach by that same party.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.10&#160;&#160;&#160;&#160;&#160;The Company agrees to execute and deliver all such further documents, agreements and instruments and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.11&#160;&#160;&#160;&#160;&#160;This Agreement may be executed in two or more counterparts each of which shall be deemed an original, but all of which shall together constitute one and the same instrument.&#160;&#160;In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.12&#160;&#160;&#160;&#160;&#160;Nothing in this Agreement shall create or be deemed to create any rights in any person or entity not a party to this Agreement.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.13&#160;&#160;&#160;&#160;&#160;In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Subscriber and the Company will be entitled to specific performance under this Agreement.&#160;&#160;The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.14&#160;&#160;&#160;&#160;&#160;The Company further understands and acknowledges that (i) Subscriber may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Shares deliverable with respect to Securities are being determined, and (ii) such hedging activities (if any) could reduce the value of the existing stockholders&#8217; equity interests in the Company at and after the time that the hedging activities are being conducted.&#160; The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</font></div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IN WITNESS WHEREOF, the parties hereto have executed this Unit Purchase Agreement as of the date set forth in the first paragraph hereof.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="3" valign="top" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMPANY:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;</font></font></div>
</td>
<td align="left" valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="25%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="48%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="3" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></font></div>
</td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" colspan="3" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></font></div>
</td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" colspan="3" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Address:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">email:</font></font></div>
</td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="3" valign="top" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="4" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUBSCRIBERS:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Subscribers set forth on <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exhibit A</font> to the Agreement have executed a Subscription Agreement with the Company which provides, among other things, that by executing the Subscription Agreement each Subscriber is deemed to have executed this UNIT PURCHASE AGREEMENT in all respects and is bound to purchase the Units set forth in such Subscription Agreement and <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exhibit A</font> to the Agreement.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">EXHIBIT A</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SCHEDULE OF SUBSCRIBERS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="TEXT-DECORATION: underline">Name of</font> <br>
<font style="TEXT-DECORATION: underline">Subscriber</font></font></font></div>
</td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></font></div>
</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="TEXT-DECORATION: underline">Shares of</font> <br>
<font style="TEXT-DECORATION: underline">Common</font> <br>
<font style="TEXT-DECORATION: underline">Stock</font></font></font></div>
</td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="TEXT-DECORATION: underline">Warrant</font> <br>
<font style="TEXT-DECORATION: underline">Shares</font></font></font></div>
</td>
<td valign="bottom" width="21%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Purchase</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price</font></font></div>
</td>
</tr><tr>
<td valign="top" width="13%" style="BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%" style="BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="21%" style="BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="13%" style="BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%" style="BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="21%" style="BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">EXHIBIT B</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form of Lock-Up Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>8
<FILENAME>fs12014ex10xxxvi_actinium.htm
<DESCRIPTION>FORM OF SUBSCRIPTION AGREEMENT, DATED DECEMBER 27, 2013 AND JANUARY 10, 2014.**
<TEXT>
<html>
<head>
    <title>fs12014ex10xxxvi_actinium.htm</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 10.36</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">To subscribe for Units</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">in the private offering of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Date and Fill</font> in the number of units (the &#8220;Units&#8221;) (each Unit consisting of (a) twenty thousand (20,000) shares of the Company&#8217;s common stock par value $0.001 per share (the &#8220;Common Stock&#8221;) at a purchase price of $6.00 per share and (b) a five-year warrant (collectively, the &#8220;Warrants&#8221; and together with the Units and Common Stock, the &#8220;Securities&#8221;) to purchase five thousand (5,000) shares of Common Stock of the Company at an exercise price equal to $9.00 per share, subject to equitable adjustment thereunder (the &#8220;Exercise Price&#8221;) at a negotiated price of $120,000 per Unit being subscribed for and <font style="DISPLAY: inline; FONT-WEIGHT: bold">Complete and Sign</font> the Signature Page included in the Subscription Agreement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial </font>the Accredited Investor Certification attached to this Subscription Agreement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Complete and Sign</font> the Signature Page attached to this Subscription Agreement.&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTICE: Please note that by executing the attached Subscription Agreement, you will deemed to have executed the Unit Purchase Agreement (Exhibit B to the Memorandum, as defined below), the Registration Rights Agreement (Exhibit D to the Memorandum) and agreed to the terms of the Warrant (Exhibit C to the Memorandum) and all exhibits, supplements and schedules thereto, as such may be amended from time to time (collectively the &#8220;Transaction Documents&#8221;), each of which are attached to the Memorandum, and will be treated for all purposes as if you did review, approve and execute, if required, each such Transaction Document even though you may not have physically signed the signature pages to such documents</font>.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Complete and Return</font> the attached Purchaser Questionnaire and, if applicable, Wire Transfer Authorization attached to this Subscription Agreement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Return</font> all forms to your Account Executive and then send all signed original documents with a check (if applicable) to:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Laidlaw &amp; Co. (UK) Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;546 Fifth Avenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font id="TAB1" style="MARGIN-LEFT: 58.5pt"></font>5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font id="TAB1" style="MARGIN-LEFT: 58.5pt"></font>New York, NY 10036</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Please make your subscription payment payable to the order of &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Signature Bank, as Escrow Agent for Actinium Pharmaceuticals, Inc.&#8221; Account No. 1502171417.&#8221;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">For wiring funds directly to the escrow account,</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">use the following instructions:</font></font></div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Signature Bank</font></font></div>
</td>
<td width="80%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="10%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">261 Madison Avenue</font></font></div>
</td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="10%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New York, NY 10016</font></font></div>
</td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Acct. Name:</font></font></div>
</td>
<td width="80%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Signature Bank as Escrow Agent for</font></font></td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></font></div>
</td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ABA Number:</font></font></td>
<td width="80%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">026013576</font></font></div>
</td>
</tr><tr>
<td width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SWIFT Code:</font></font></td>
<td width="80%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNUS33</font></font></div>
</td>
</tr><tr>
<td width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">A/C Number:</font></font></td>
<td width="80%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1502171417</font></font></div>
</td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FBO:</font></font></div>
</td>
<td width="80%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Purchaser Name</font></font></td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Social Security Number</font></font></font></div>
</td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Address</font></font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ALL SUBSCRIPTION DOCUMENTS MUST BE FILLED IN AND SIGNED EXACTLY AS SET FORTH WITHIN.</font></div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ii</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUBSCRIPTION AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">501 Fifth Avenue, 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">New York, New York 10017</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Attn:&#160;&#160;Kaushik J. Dave, CEO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Ladies and Gentlemen:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subscription.</font><font style="DISPLAY: inline">&#160;&#160;The undersigned (the &#8220;Purchaser&#8221;) will purchase the </font>number of units (collectively, the &#8220;Units&#8221;) of securities of <font style="DISPLAY: inline">Actinium Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), set forth on the signature page to this Subscription Agreement, at a purchase price of $120,000 per Unit</font>, with each Unit consisting of&#160;&#160;(a) twenty thousand (20,000) shares of the Company&#8217;s common stock par value $0.001 per share (the &#8220;Common Stock&#8221;) at a purchase price of $6.00 per share and (b) a five-year warrant (collectively, the &#8220;Warrants&#8221; and together with the Units and Common Stock, the &#8220;Securities&#8221;) to purchase five thousand (5,000) shares of Common Stock of the Company at an exercise price equal to $9.00 per share, subject to equitable adjustment thereunder (the &#8220;Exercise Price&#8221;).<font style="DISPLAY: inline">&#160;&#160;The Units are being offered </font>(the &#8220;Offering&#8221;) <font style="DISPLAY: inline">by the Company pursuant to the offering terms set forth in the Company&#8217;s Confidential Private Placement Memorandum, dated December 11, 2013, as may be amended and/or supplemented, from time to time (collectively, the &#8220;Memorandum&#8221;).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">The Units are being offered on a &#8220;reasonable efforts, all or none&#8221; basis with respect to the minimum of $2,000,000 </font>purchase price for the Units<font style="DISPLAY: inline"> (the &#8220;Minimum Offering&#8221;) and thereafter on a &#8220;reasonable efforts&#8221; basis up to the maximum of $6,000,000 </font>purchase price for the Units (subject to the right of the Company to increase the maximum offering amount to $8,000,000 to cover over-allotments)<font style="DISPLAY: inline"> (the &#8220;Maximum Offering&#8221;). </font>The Units will be offered for sale until the earlier of (i)&#160;&#160;the date upon which subscriptions for the Maximum Offering offered hereunder have been accepted, (ii) January 31, 2014 (subject to the right of the Company and the Placement Agent to extend the offering until February 28, 2014 without further notice to investors), or (iii) the date upon which the Company and the Placement Agent elect to terminate the Offering (the &#8220;Termination Date&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company may hold an initial closing (&#8220;Initial Closing&#8221;) at any time after the receipt of accepted subscriptions for the Minimum Offering.&#160;&#160;After the Initial Closing, subsequent closings with respect to additional Securities may take place at any time prior to the Termination Date as determined by the Company, with respect to subscriptions accepted prior to the Termination Date (each such closing, together with the Initial Closing, being referred to as a &#8220;Closing&#8221;).&#160;&#160;The last Closing of the Offering, occurring on or prior to the Termination Date, shall be referred to as the &#8220;Final Closing&#8221;.&#160;&#160;Any subscription documents or funds received after the Final Closing will be returned, without interest or deduction.&#160;&#160;In the event that the any Closing does not occur prior to the Termination Date, all amounts paid by the Purchaser shall be returned to the Purchaser, without interest or deduction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subscriptions for investment below the minimum investment may be accepted at the discretion of the Placement Agent and the Company.&#160;&#160;<font style="DISPLAY: inline">The Company reserves the right (but is not obligated) to have its employees, agents, officers, directors and affiliates purchase Units in the Offering and all such purchases will be counted towards the Minimum Offering and the Maximum Offering.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The terms of the Offering are more completely described in the Memorandum and such terms are incorporated herein in their entirety.&#160;&#160;Certain capitalized terms used, but not otherwise defined herein, will have the respective meanings provided in the Memorandum.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Payment.</font><font style="DISPLAY: inline">&#160;&#160;The Purchaser encloses herewith a check payable to, or will immediately make a wire transfer payment to, &#8220;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Signature Bank, as Escrow Agent for Actinium Pharmaceuticals, Inc.</font><font style="DISPLAY: inline">,&#8221; in the full amount of the purchase price of the Units being subscribed for.&#160;&#160;Together with the check for, or wire transfer of, the full purchase price, the Purchaser is delivering a completed and executed Signature Page to this Subscription Agreement along with a completed and executed Accredited Investor Certification, which are annexed hereto.&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">By executing this Subscription Agreement, </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">you will be deemed to have executed the Unit Purchase Agreement (Exhibit B to the Memorandum) and the Registration Rights Agreement (Exhibit D to the Memorandum) as well as agreed to the terms of the Warrant (Exhibit C to the Memorandum) and all exhibits, supplements and schedules thereto, as such may be amended from time to time (collectively the &#8220;Transaction Documents&#8221;), each of which are attached to the Memorandum, and will be treated for all purposes as if you did review, approve and execute, if required, each such Transaction Document even though you may not have physically signed the signature pages to such documents.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Deposit of Funds.</font>&#160;&#160;All payments made as provided in Section 2 hereof will be deposited by the Purchaser as soon as practicable with Signature Bank, as escrow agent (the &#8220;Escrow Agent&#8221;), or such other escrow agent appointed by Laidlaw and the Company, in a non-interest bearing escrow account (the &#8220;Escrow Account&#8221;).&#160;&#160;In the event that the Company does not effect a Closing during the Offering Period, the Escrow Agent will refund all subscription funds, without deduction and/or interest accrued thereon, and will return the subscription documents to each Purchaser.&#160;&#160;If the Company or Laidlaw rejects a subscription, either in whole or in part (at the sole discretion of the Company or Laidlaw), the rejected subscription funds or the rejected portion thereof will be returned promptly to such Purchaser without interest, penalty, expense or deduction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Acceptance of Subscription.</font><font style="DISPLAY: inline">&#160;&#160;The Purchaser understands and agrees that the Company or Laidlaw, each in its sole discretion, reserves the right to accept this or any other subscription for the Units, in whole or in part, notwithstanding prior receipt by the Purchaser of notice of acceptance of this or any other subscription.&#160;&#160;The Company will have no obligation hereunder until the Company executes and delivers to the Purchaser an executed copy of the Purchase Agreement.&#160;&#160;If Purchaser&#8217;s subscription is rejected in whole (at the sole discretion of the Company or Laidlaw), the Offering is terminated or the Minimum Offering is not subscribed for and accepted prior to the Termination Date, all funds received from the Purchaser will be returned without interest, penalty, expense or deduction, and this Subscription Agreement will thereafter be of no further force or effect.&#160;&#160;If Purchaser&#8217;s subscription is rejected in part (at the sole discretion of the Company or Laidlaw) and the Company accepts the portion not so rejected, the funds for the rejected portion of such subscription will be returned without interest, penalty, expense or deduction, and this Subscription Agreement will continue in full force and effect to the extent such subscription was accepted. </font>The Purchaser may revoke its subscription and obtain a return of the subscription amount paid to the Escrow Account at any time before the date of the Initial Closing.&#160;&#160;The Purchaser may not revoke this subscription or obtain a return of the subscription amount paid to the Escrow Agent on or after the date of the Initial Closing.&#160;&#160;Any subscription received after the Initial Closing but prior to the Termination Date shall be irrevocable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Representations and Warranties of the Purchaser.</font>&#160;&#160;The Purchaser hereby acknowledges, represents, warrants, and agrees as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Units, the Common Stock, the Warrants or the shares of Common Stock of the Company issuable upon exercise of the Warrants (collectively referred to hereafter as the &#8220;Securities&#8221;) are registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or any state securities laws.&#160;&#160;The Purchaser understands that the offering and sale of the Securities is intended to be exempt from registration under the Securities Act, by virtue of Section 4(2) thereof and the provisions of Regulation D promulgated thereunder, based, in part, upon the representations, warranties and agreements of the Purchaser contained in this Subscription Agreement and the&#160;&#160;Purchase Agreement;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser and the Purchaser&#8217;s attorney, accountant, purchaser representative and/or tax advisor, if any (collectively, &#8220;Advisors&#8221;), have received and have carefully reviewed the Memorandum, this Subscription Agreement, and each of the Transaction Documents and all other documents requested by the Purchaser or its Advisors, if any, and understand the information contained therein, prior to the execution of this Subscription Agreement;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Securities and Exchange Commission (the &#8220;Commission&#8221;) nor any state securities commission has approved or disapproved of the Securities or passed upon or endorsed the merits of the Offering or confirmed the accuracy or determined the adequacy of the Memorandum.&#160;&#160;The Memorandum has not been reviewed by any Federal, state or other regulatory authority.&#160;&#160;Any representation to the contrary may be a criminal offense;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All documents, records, and books pertaining to the investment in the Securities including, but not limited to, all information regarding the Company and the Securities, have been made available for inspection and reviewed by the Purchaser and its Advisors, if any;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser and its Advisors, if any, have had a reasonable opportunity to ask questions of and receive answers from the Company&#8217;s officers and any other persons authorized by the Company to answer such questions, concerning, among other related matters, the Offering, the Securities, the Transaction Documents and the business, financial condition, results of operations and prospects of the Company and all such questions have been answered by the Company to the full satisfaction of the Purchaser and its Advisors, if any;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or other information (oral or written) other than as stated in the Memorandum;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser is unaware of, is in no way relying on, and did not become aware of the offering of the Securities through or as a result of, any form of general solicitation or general advertising including, without limitation, any article, notice, advertisement or other communication published in any newspaper, magazine or similar media or broadcast over television, radio or over the Internet, in connection with the offering and sale of the Securities and is not subscribing for the Securities and did not become aware of the Offering through or as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by, a person not previously known to the Purchaser in connection with investments in securities generally;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser has taken no action which would give rise to any claim by any person for brokerage commissions, finders&#8217; fees or the like relating to this Subscription Agreement or the transactions contemplated hereby (other than fees to be paid by the Company to Laidlaw, as described in the Memorandum);</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser, either alone or together with its Advisors, if any, has such knowledge and experience in financial, tax, and business matters, and, in particular, investments in securities, so as to enable it to utilize the information made available to it in connection with the Offering to evaluate the merits and risks of an investment in the Securities and the Company and to make an informed investment decision with respect thereto;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser is not relying on the Company, Laidlaw or any of their respective employees or agents with respect to the legal, tax, economic and related considerations of an investment in any of the Securities and the Purchaser has relied on the advice of, or has consulted with, only its own Advisors;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser is acquiring the Securities solely for such Purchaser&#8217;s own account for investment and not with a view to resale or distribution thereof, in whole or in part.&#160;&#160;The Purchaser has no agreement or arrangement, formal or informal, with any person to sell or transfer all or any part of any of the Securities and the Purchaser has no plans to enter into any such agreement or arrangement;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser understands and agrees that purchase of the Securities is a high risk investment and the Purchaser is able to afford an investment in a speculative venture having the risks and objectives of the Company.&#160;&#160;The Purchaser must bear the substantial economic risks of the investment in the Securities indefinitely because none of the Securities may be sold, hypothecated or otherwise disposed of unless subsequently registered under the Securities Act and applicable state securities laws or an exemption from such registration is available.&#160;&#160;Legends will be placed on the certificates representing the Common Stock, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants to the effect that such securities have not been registered under the Securities Act or applicable state securities laws and appropriate notations thereof will be made in the Company&#8217;s books;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser has adequate means of providing for such Purchaser&#8217;s current financial needs and foreseeable contingencies and has no need for liquidity from its investment in the Securities for an indefinite period of time;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser is aware that an investment in the Securities involves a number of very significant risks and has carefully read and considered the Company<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s periodic filings with the United States Securities and Exchange Commission (the &#8220;Commission&#8221;), and the matters set forth in the Memorandum and, in particular, the matters under the caption &#8220;Risk Factors&#8221; therein and understands any of such risk may materially adversely affect the Company&#8217;s operations and future prospects;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(o)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be <font style="DISPLAY: inline">an &#8220;accredited investor&#8221; within the meaning of Regulation D, Rule 501(a), promulgated by the Commission under the Securities Act and has truthfully and accurately completed the Purchaser Questionnaire attached to this Subscription Agreement and will submit to the Company such further assurances of such status as may be reasonably requested by the Company;</font></font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser: (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof; (ii) if a corporation, partnership, or limited liability company, or association, joint stock company, trust, unincorporated organization or other entity, represents that such entity was not formed for the specific purpose of acquiring the Securities, such entity is duly organized, validly existing and in good standing under the laws of the state of its organization, the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of state law or its charter or other organizational documents, such entity has full power and authority to execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the Securities, the execution and delivery of this Subscription Agreement has been duly authorized by all necessary action, this Subscription Agreement has been duly executed and delivered on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this Subscription Agreement in a representative or fiduciary capacity, represents that it has full power and authority to execute and deliver this Subscription Agreement in such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability company or partnership, or other entity for whom the Purchaser is executing this Subscription Agreement, and such individual, partnership, ward, trust, estate, corporation, or limited liability company or partnership, or other entity has full right and power to perform pursuant to this Subscription Agreement and make an investment in the Company, and represents that this Subscription Agreement constitutes a legal, valid and binding obligation of such entity.&#160;&#160;The execution and delivery of this Subscription Agreement will not violate or be in conflict with any order, judgment, injunction, agreement or controlling document to which the Purchaser is a party or by which it is bound;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(q)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaer hereby acknowledges receipt and careful review of this Agreement, the Memorandum, the Warrant, the Registration Rights Agreement and all other exhibits, annexes and appendices thereto (collectively referred to as the &#8220;Offering Materials&#8221;), and has had access to the Company&#8217;s Annual Report on Form 10-K and the exhibits thereto for the fiscal year ended December 31, 2012 (the &#8220;Form 10-K&#8221;), the Company&#8217;s Quarterly Report on Form 10-Q and the exhibits thereto for the quarterly periods ended March 31, June 30 and September 30, 2013 (collectively, the &#8220;Form 10-Q&#8221;) and all subsequent periodic and current reports filed with the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) as publicly filed with and available at the website of the SEC which can be accessed at www.sec.gov, and hereby represents that the Purchaser has been furnished by the Company during the course of the Offering with all information regarding the Company, the terms and conditions of the Offering and any additional information that the Purchaser has requested or desired to know, has been afforded the opportunity to ask questions of and receive answers from duly authorized officers or other representatives of the Company concerning the Company and <font style="DISPLAY: inline">has been provided any such additional information by the Company in writing to the full satisfaction of the Purchaser, if any;</font></font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser represents to the Company that any information which the undersigned has heretofore furnished or is furnishing herewith to the Company is complete and accurate and may be relied upon by the Company in determining the availability of an exemption from registration under Federal and state securities laws in connection with the offering of securities as described in the Memorandum;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser has significant prior investment experience, including investment in non-listed and unregistered securities.&#160;&#160;The Purchaser has a sufficient net worth to sustain a loss of its entire investment in the Company in the event such a loss should occur.&#160;&#160;The Purchaser&#8217;s overall commitment to investments which are not readily marketable is not excessive in view of the Purchaser&#8217;s net worth and financial circumstances and the purchase of the Securities will not cause such commitment to become excessive.&#160;&#160;This investment is a suitable one for the Purchaser;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser is satisfied that it has received adequate information with respect to all matters which it or its Advisors, if any, consider material to its decision to make this investment;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser acknowledges that any and all estimates or forward-looking statements or projections included in the Memorandum were prepared by the Company in good faith, but that the attainment of any such projections, estimates or forward-looking statements cannot be guaranteed, will not be updated by the Company and should not be relied upon;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No oral or written representations have been made, or oral or written information furnished, to the Purchaser or its Advisors, if any, in connection with the offering of the Securities which are in any way inconsistent with the information contained in the Memorandum;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Within five (5) days after receipt of a request from the Company, the Purchaser will provide such information and deliver such documents as may reasonably be necessary to comply with any and all laws and ordinances to which the Company is subject;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF CERTAIN STATES AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS.&#160;&#160;THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.&#160;&#160;THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE COMMISSION, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE MEMORANDUM.&#160;&#160;ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In making an investment decision, investors must rely on their own examination of Company and the terms of the Offering, including the merits and risks involved.&#160;&#160;Investors should be aware that they will be required to bear the financial risks of this investment for an indefinite period of time;</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">(For ERISA plans only)</font>&#160;&#160;&#160;&#160;The fiduciary of the ERISA plan (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Plan</font>&#8221;) represents that such fiduciary has been informed of and understands the Company&#8217;s investment objectives, policies and strategies, and that the decision to invest &#8220;plan assets&#8221; (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require diversification of plan assets and impose other fiduciary responsibilities.&#160;&#160;The Purchaser or Plan fiduciary (a) is responsible for the decision to invest in the Company; (b) is independent of the Company and any of its affiliates; (c) is qualified to make such investment decision; and (d) in making such decision, the Purchaser or Plan fiduciary has not relied on any advice or recommendation of the Company or any of its affiliates; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser has read in its entirety the Memorandum and all exhibits and annexes thereto, including, but not limited to, all information relating to the Company,&#160;&#160;and the Securities, and understands fully to its full satisfaction all information included in the Memorandum including, but not limited to, the Section entitled &#8220;Risk Factors&#8221; as well as any other information in the Offering Materials;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(bb)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser represents that (i) the Purchaser was contacted regarding the sale of the Securities by the Company or the Placement Agent (or another person whom the Purchaser believed to be an authorized agent or representative thereof) with whom the Purchaser had a prior substantial pre-existing relationship and (ii) it did not learn of the offering of the Securities by means of any form of general solicitation or general advertising, and in connection therewith, the Purchaser did not (A) receive or review any advertisement, article, notice or other communication published in a newspaper or magazine or similar media or broadcast over television or radio, whether closed circuit, or generally available; or (B) attend any seminar meeting or industry investor conference whose attendees were invited by any general solicitation or general advertising;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser consents to the placement of a legend on any certificate or other document evidencing the Securities and, when issued, the shares of Common Stock issuable upon exercise of the Warrants (the &#8220;Warrant Shares&#8221;), that such securities have not been registered under the Securities Act or any state securities or &#8220;blue sky&#8221; laws and setting forth or referring to the restrictions on transferability and sale thereof contained in this Agreement.&#160;&#160;The Purchaser is aware that the Company will make a notation in its appropriate records with respect to the restrictions on the transferability of such Securities. The legend to be placed on each certificate shall be in form substantially similar to the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 36pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;) OR ANY STATE SECURITIES OR &#8220;BLUE SKY LAWS,&#8221; AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser acknowledges that if he or she is a Registered Representative of a Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) member firm, he or she must give such firm the notice required by the FINRA&#8217;s Rules of Fair Practice, receipt of which must be acknowledged by such firm prior to an investment in the Securities.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To effectuate the terms and provisions hereof, the Purchaser hereby appoint the Placement Agent as its attorney-in-fact (and the Placement Agent hereby accepts such appointment) for the purpose of carrying out the provisions of the Escrow Agreement by and between the Company, the Placement Agent and Signature Bank (the &#8220;Escrow Agreement&#8221;) including, without limitation, taking any action on behalf of, or at the instruction of, the Purchaser and executing any release notices required under the Escrow Agreement and taking any action and executing any instrument that the Placement Agent may deem necessary or advisable (and lawful) to accomplish the purposes hereof.&#160;&#160;All acts done under the foregoing authorization are hereby ratified and approved and neither the Placement Agent nor any designee nor agent thereof shall be liable for any acts of commission or omission, for any error of judgment, for any mistake of fact or law except for acts of gross negligence or willful misconduct.&#160;&#160;This power of attorney, being coupled with an interest, is irrevocable while the Escrow Agreement remains in effect.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser agrees not to issue any public statement with respect to the Offering, Purchaser&#8217;s investment or proposed investment in the Company or the terms of any agreement or covenant between them and the Company without the Company&#8217;s prior written consent, except such disclosures as may be required under applicable law.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser understands, acknowledges and agrees with the Company that this subscription may be rejected, in whole or in part, by the Company, in the sole and absolute discretion of the Company, at any time before any Closing notwithstanding prior receipt by the Purchaser of notice of acceptance of the Purchaser&#8217;s subscription.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser acknowledges that the information contained in the Offering Materials or otherwise made available to the Purchaser is confidential and non-public and agrees that all such information shall be kept in confidence by the Purchaser and neither used by the Purchaser for the Purchaser&#8217;s personal benefit (other than in connection with this subscription) nor disclosed to any third party for any reason, notwithstanding that a Purchaser&#8217;s subscription may not be accepted by the Company; provided, however, that (a) the Purchaser may disclose such information to its affiliates and advisors who may have a need for such information in connection with providing advice to the Purchaser with respect to its investment in the Company so long as such affiliates and advisors have an obligation of confidentiality, and (b) this obligation shall not apply to any such information that (i) is part of the public knowledge or literature and readily accessible at the date hereof, (ii) becomes part of the public knowledge or literature and readily accessible by publication (except as a result of a breach of this provision) or (iii) is received from third parties without an obligation of confidentiality (except third parties who disclose such information in violation of any confidentiality agreements or obligations, including, without limitation, any subscription or other similar agreement entered into with the Company).</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchaser understands that Rule 144 promulgated under the Act (&#8220;Rule 144&#8221;) requires, among other conditions, a minimum holding period of six-months prior to the resale of securities acquired in a non-public offering without having to satisfy the registration requirements under the Act. The Purchaser understands and hereby acknowledges that the Company is under no obligation to register the Securities under the Act or any state securities or &#8220;blue sky&#8221; laws or to assist the Purchaser in obtaining an exemption from various registration requirements, other than as set forth herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Representations and Warranties of the Company.</font><font style="DISPLAY: inline">&#160;</font>The representations and warranties contained in Article 3 of the Purchase Agreement to be entered into by the Company and the Purchasers shall be incorporated herein by reference and shall be deemed to be made under this Subscription Agreement.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Indemnification.</font>&#160;&#160;The Purchaser agrees to indemnify and hold harmless the Company, Laidlaw and each of their respective officers, directors,&#160;&#160;managers, employees, agents, attorneys, control persons and affiliates from and against all losses, liabilities, claims, damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating, preparing or defending against any litigation commenced or threatened) based upon or arising out of any actual or alleged false acknowledgment, representation or warranty, or misrepresentation or omission to state a material fact, or breach by the Purchaser of any covenant or agreement made by the Purchaser herein or in any other document delivered in connection with this Subscription Agreement or any other Transaction Document.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Binding Effect.</font>&#160;&#160;This Subscription Agreement will survive the death or disability of the Purchaser and will be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives, and permitted assigns.&#160;&#160;If the Purchaser is more than one person, the obligations of the Purchaser hereunder will be joint and several and the agreements, representations, warranties and acknowledgments herein will be deemed to be made by and be binding upon each such person and such person&#8217;s heirs, executors, administrators, successors, legal representatives and permitted assigns.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Modification.</font>&#160;&#160;This Subscription Agreement will not be modified or waived except by an instrument in writing signed by the party against whom any such modification or waiver is sought.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Notices.</font>&#160;&#160;Any notice or other communication required or permitted to be given hereunder will be in writing and will be mailed by certified mail, return receipt requested, or delivered by reputable overnight courier such as FedEx against receipt to the party to whom it is to be given (a) if to the Company, at the address set forth in the Purchase Agreement or (b) if to the Purchaser, at the address set forth on the signature page hereof (or, in either case, to such other address as the party will have furnished in writing in accordance with the provisions of this <font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 10</font>).&#160;&#160;Any notice or other communication given by certified mail will be deemed given at the time of certification thereof, except for a notice changing a party&#8217;s address which will be deemed given at the time of receipt thereof.&#160;&#160;Any notice or other communication given by overnight courier will be deemed given at the time of delivery.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Assignability.</font>&#160;&#160;This Subscription Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser and the transfer or assignment of any of the Securities will be made only in accordance with all applicable laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Applicable Law. </font><font style="DISPLAY: inline">This Subscription Agreement will be governed by and construed under the laws of the State of New York as applied to agreements among New York residents entered into and to be performed entirely within New York.&#160;&#160;The parties hereto (1) agree that any legal suit, action or proceeding arising out of or relating to this </font>Subscription<font style="DISPLAY: inline; COLOR: #0000ff">&#160;</font><font style="DISPLAY: inline">Agreement will be instituted exclusively in New York State Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (2) waive any objection which the parties may have now or hereafter to the venue of any such suit, action or proceeding, and (3) irrevocably consent to the jurisdiction of the New York State Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding.&#160;&#160;Each of the parties hereto further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New York State Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agrees that service of process upon it mailed by certified mail to its address will be deemed in every respect effective service of process upon it, in any such suit, action or proceeding.&#160;&#160;THE PARTIES HERETO AGREE, TO THE EXTENT PERMITTED BY APPLICABLE LAW, TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS SUBSCRIPTION AGREEMENT OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Blue Sky Qualification.</font>&#160;&#160;The purchase of Securities pursuant to this Subscription Agreement is expressly conditioned upon the exemption from qualification of the offer and sale of the Securities from applicable federal and state securities laws.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Use of Pronouns.</font>&#160;&#160;All pronouns and any variations thereof used herein will be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the person or persons referred to may require.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Confidentiality.</font>&#160;&#160;The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company not otherwise properly in the public domain, was received in confidence.&#160;&#160;The Purchaser agrees not to divulge, communicate or disclose, except as may be required by law or for the performance of this Subscription Agreement, or use to the detriment of the Company or for the benefit of any other person or persons, or misuse in any way, any confidential information of the Company, including any trade or business secrets of the Company and any business materials that are treated by the Company as confidential or proprietary, including, without limitation, confidential information obtained by or given to the Company about or belonging to third parties.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Miscellaneous.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Subscription Agreement, together with the other Transaction Documents, constitute the entire agreement between the Purchaser and the Company with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings, if any, relating to the subject matter hereof.&#160;&#160;The terms and provisions of this Subscription Agreement may be waived, or consent for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions.</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of the Purchaser&#8217;s and the Company&#8217;s representations and warranties made in this Subscription Agreement will survive the execution and delivery hereof and delivery of the Securities.</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of the parties hereto will pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the transactions contemplated hereby are consummated.</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Subscription Agreement may be executed in one or more counterparts each of which will be deemed an original, but all of which will together constitute one and the same instrument.</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each provision of this Subscription Agreement will be considered separable and, if for any reason any provision or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality will not impair the operation of or affect the remaining portions of this Subscription Agreement.</font></div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Paragraph titles are for descriptive purposes only and will not control or alter the meaning of this Subscription Agreement as set forth in the text.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">17.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Signature Page.</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">It is hereby agreed by the parties hereto that the execution by the Purchaser of this Subscription Agreement, in the place set forth hereinbelow, will be deemed and constitute the agreement by the Purchaser to be bound by all of the terms and conditions hereof as well as by the Unit Purchase Agreement and each of the other Transaction Documents, and will be deemed and constitute the execution by the Purchaser of all such Transaction Documents without requiring the Purchaser&#8217;s separate signature on any of such Transaction Documents.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">[Remainder of page intentionally left blank.]</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ANTI-MONEY LAUNDERING REQUIREMENTS</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The USA PATRIOT Act</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">What is money <br>
laundering?</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">How big is the problem <br>
and why is it important?</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The USA PATRIOT Act is designed to detect, deter, and punish terrorists in the United States and abroad.&#160;&#160;The Act imposes new anti-money laundering requirements on brokerage firms and financial institutions.&#160;&#160;Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money laundering programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">To help you understand theses efforts, we want to provide you with some information about money laundering and our steps to implement the USA PATRIOT Act.</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Money laundering is the process of disguising illegally obtained money so that the funds appear to come from legitimate sources or activities.&#160;&#160;Money laundering occurs in connection with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The use of the U.S. financial system by criminals to facilitate terrorism or other crimes could well taint our financial markets.&#160;&#160;According to the U.S. State Department, one recent estimate puts the amount of worldwide money laundering activity at $1 trillion a year.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="3" valign="top" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">What are we required to do to eliminate money laundering?</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under new rules required by the USA PATRIOT Act, our anti-money laundering program must designate a special compliance officer, set up employee training, conduct independent audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance with the new laws.</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As part of our required program, we may ask you to provide various identification documents or other information.&#160;&#160;Until you provide the information or documents we need, we may not be able to effect any transactions for you.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SIGNATURE PAGE TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SUBSCRIPTION AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Purchaser hereby elects to purchase a total of ______Unit(s) at a purchase price of $120,000 per Unit (NOTE: to be completed by the Purchaser).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date (NOTE: To be completed by the Purchaser): __________________, 201_</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="8" width="100%" style="TEXT-ALIGN: center; BORDER-TOP: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If the Purchaser is an INDIVIDUAL, and if purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY:</font></font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Print Name(s)</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Social Security Number(s)</font></font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Signature(s) of Purchaser(s)</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Signature</font></font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Address</font></font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="8" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST:</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Name of Partnership,&#160;<br>
Corporation, Limited&#160;<br>
Liability Company or Trust</font></font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="top" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Federal Taxpayer&#160;<br>
Identification Number</font></font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">By:</font></font></td>
<td width="41%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name:</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">State of Organization</font></font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title:</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%">&#160;</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%">&#160;</td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Address</font></font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="8" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AGREED AND ACCEPTED:</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="8" width="100%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
</td>
</tr><tr>
<td width="5%">&#160;</td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;By:</font></td>
<td colspan="2" width="44%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%" style="TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="44%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" width="44%" style="TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACCREDITED INVESTOR CERTIFICATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For Individual Investors Only</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(All individual investors must <font style="FONT-STYLE: italic; DISPLAY: inline">INITIAL</font> where appropriate.&#160;&#160;Where there are joint investors both parties must <font style="FONT-STYLE: italic; DISPLAY: inline">INITIAL</font>):</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 144pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>&#160;</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I certify that<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>I have a &#8220;net worth&#8221; of at least $1 million either individually or through aggregating my individual holdings and those in which I have a joint, community property or other similar shared ownership interest with my spouse.&#160;&#160;For purposes of calculating net worth under this paragraph, (i) the primary residence shall not be included as an asset, (ii) to the extent that the indebtedness that is secured by the primary residence is in excess of the fair market value of the primary residence, the excess amount shall be included as a liability, and (iii) if the amount of outstanding indebtedness that is secured by the primary residence exceeds the amount outstanding 60 days prior to the execution of this Subscription Agreement, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I certify that<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>I have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For Non-Individual Investors</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(all Non-Individual Investors must <font style="FONT-STYLE: italic; DISPLAY: inline">INITIAL</font> where appropriate):</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet either of the criteria for Individual Investors, above.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at least $5 million and was not formed for the purpose of investing in Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA &#167;3(21)) that is a bank, savings and loan association, insurance company or registered investment adviser.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of the Subscription Agreement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet either of the criteria for Individual Investors, above.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is a broker-dealer registered pursuant to &#167;15 of the Securities Exchange Act of 1934.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is an organization described in &#167;501(c)(3) of the Internal Revenue Code with total assets exceeding $5,000,000 and not formed for the specific purpose of investing in Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing in Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial _______</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned certifies that it is an insurance company as defined in &#167;2(a)(13) of the Securities Act of 1933, as amended, or a registered investment company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Purchaser Questionnaire</font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(<font style="FONT-STYLE: italic; DISPLAY: inline">Must be completed by Purchaser)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section A - Individual Purchaser Information</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Purchaser Name(s): </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Individual executing Profile or Trustee: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Social Security Numbers / Federal I.D. Number: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">_______________________________________________________________________________________________________________________</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Birth: _____________________&#160;&#160;Marital Status: _____________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Joint Party Date of Birth:_____________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investment Experience (Years): _______________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Annual Income: _____________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Liquid Net Worth:_________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net Worth: ____________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 216pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investment Objectives <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">(circle one or more):</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Long Term Capital Appreciation, Short Term Trading, Businessman&#8217;s Risk, Income, Safety of Principal, Tax Exempt Income or other</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Home Street Address: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Home City, State &amp; Zip Code: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Home Phone: ________________________ Home Fax: _____________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Home Email: _______________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Employer: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Employer Street Address: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Employer City, State &amp; Zip Code: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Bus. Phone: __________________________ Bus. Fax: _______________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Bus. Email: ________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Type of Business: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">LAIDLAW Account Executive / Outside Broker/Dealer: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Please check if you are a FINRA member or affiliate of a FINRA member firm: ________</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="center">
<div align="center">
<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Purchaser Questionnaire</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(<font style="FONT-STYLE: italic; DISPLAY: inline">Must be completed by Purchaser)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section B &#8211; Entity Purchaser Information</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Purchaser Name(s): </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Authorized Individual executing Profile or Trustee: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Social Security Numbers / Federal I.D. Number: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investment Experience (Years): ___________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Annual Income: _______________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net Worth: ________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Was the Entity formed for the specific purpose of purchasing the Common Stock and Warrants?</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Yes&#160;&#160;[&#160;&#160;] No</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Principal Purpose (Trust)_________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Type of Business: ________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 216pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investment Objectives <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">(circle one or more):</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Long Term Capital Appreciation, Short Term Trading, Businessman&#8217;s Risk, Income, Safety of Principal, Tax Exempt Income or other</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Street Address: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">City, State &amp; Zip Code: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">_______________________________________________________________________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Phone: ________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fax: ________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Email: __________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Laidlaw Account Executive / Outside Broker/Dealer:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____________________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Please check if you are a FINRA member or affiliate of a FINRA member firm: _______</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -2.15pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section C &#8211; Form of Payment &#8211; Check or Wire Transfer</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -2.15pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____ Check payable to &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURE BANK, AS ESCROW AGENT FOR</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">____ Wire funds from my outside account according to the &#8220;To subscribe for Units of Common Stock</font> and<font style="DISPLAY: inline">&#160;</font>Warrants to Purchase Shares of Common Stock<font style="DISPLAY: inline"> in the private offering of ACTINIUM PHARMACEUTICALS, INC.&#8221;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____ Wire funds from my LAIDLAW Account &#8211; See following page</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">____ The funds for this investment are rolled over, tax deferred from&#160;&#160;____________________ within the Allowed 60-day window</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -2.15pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section D &#8211; Purchaser Instructions for Payments of any Dividends</font></font></div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="90%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"><font style="FONT-FAMILY: wingdings; FONT-SIZE: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 18pt">o</font></font></td>
<td width="90%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Please make any dividend and any other payment checks pursuant to the Units to &#8220;</font>Sterne Agee &amp; Leach Inc. c/f [<font style="DISPLAY: inline; FONT-WEIGHT: bold">Insert Client Name]</font><font style="DISPLAY: inline">&#8221; and deliver such checks to Laidlaw so that they may deposit them into my Laidlaw brokerage account</font></font></font></div>
</td>
</tr><tr>
<td width="10%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="90%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"><font style="FONT-FAMILY: wingdings; FONT-SIZE: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 18pt">o</font></font></td>
<td width="90%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Please make out any dividend and any other payment checks pursuant to the Units in the registered name of the Purchaser set forth in the signature page to the Subscription Agreement for the Units and mail such checks to me at the address specified in such signature page</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section E &#8211; Securities Delivery Instructions (check one)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____&#160;&#160;Please deliver my securities to Laidlaw for deposit into my brokerage account.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____&#160;&#160;Please deliver my securities to the address listed in the above Purchaser Questionnaire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____&#160;&#160;Please deliver my securities to the below address:</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">_________________</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">_________________</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">_________________</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">_________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Purchaser Signature(s): _______________________________________Date:_______________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Wire Transfer Authorization</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">TO:&#160;&#160;&#160;&#160;&#160;OPERATIONS MANAGER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LAIDLAW &amp; CO. (UK) LTD.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">RE:&#160;&#160;&#160;&#160;&#160;Client Wire Transfer Authorization</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">DATE:________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This memorandum authorizes the transfer of the following listed funds from my LAIDLAW Brokerage Account as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">LAIDLAW Brokerage Account #&#160;&#160;______________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Wire Amount&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$______________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE BANK</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 36pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">261 Madison Avenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 36pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New York, NY 10016</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 36pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 36pt" align="justify">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ABA Number: 026013576</font></div>

<div align="justify">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For Credit to Signature Bank, as Escrow Agent for</font></div>

<div align="justify">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div align="justify">
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Account No.:</font> 1502171417</font></div>
</div>
</div>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">REFERENCE</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PURCHASER<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>S LEGAL NAME </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160; ______________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TAX ID NUMBER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">______________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PURCHASER<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>S ADDRESS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">______________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FBO:&#160;&#160;________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Signature:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Signature:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________________________</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (Joint Signature)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div style="TEXT-ALIGN: center">20

<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>9
<FILENAME>fs12014ex10xxxvii_actinium.htm
<DESCRIPTION>FORM OF REGISTRATION RIGHTS AGREEMENT, DATED DECEMBER 27, 2013 AND JANUARY 10, 2014.**
<TEXT>
<html>
<head>
    <title>fs12014ex10xxxvii_actinium.htm</title>
    <!--Licensed to: Edgar Efile Solutions Pvt Ltd.-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 10.37</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REGISTRATION RIGHTS AGREEMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THIS </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REGISTRATION </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RIGHTS </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AGREEMENT </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>(the&#160;&#160;&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Agreement</font>&#8221;),&#160;&#160;dated&#160;&#160;as of&#160;______________,&#160;&#160;2013,&#160;&#160;is&#160;&#160;made&#160;&#160;by&#160;&#160;and&#160;&#160;between&#160;&#160;Actinium Pharmaceuticals,&#160;&#160;Inc.,&#160;&#160;a Delaware corporation (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</font>&#8221;) and the undersigned investor (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investor</font>&#8221;).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">R E C I T A L S</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WHEREAS</font>, in connection with that certain Subscription Agreement of even date herewith by and between the Company and the Investor (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subscription Agreement</font>&#8221;) and Unit Purchase Agreement of even date herewith by and between the Company and the Investor (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Purchase Agreement</font>&#8221;), the Investor purchased from the Company, certain units (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Units</font>&#8221;), each Unit consisting of (a) twenty thousand (20,000) shares of the Company&#8217;s common stock par value $0.001 per share (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font>&#8221;) at a purchase price of $6.00 per share and (b) a five-year warrant (collectively, the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrants</font>&#8221; and together with the Units and Common Stock, the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities</font>&#8221;) to purchase five thousand (5,000) shares of Common Stock of the Company at an exercise price equal to $9.00 per share, subject to equitable adjustment thereunder (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise Price</font>&#8221;).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WHEREAS</font>, to induce the Investor to purchase the Units, the Company has agreed to grant the Investor certain rights with respect to registration of Registrable Securities under the Securities Act pursuant to the terms of this Agreement.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">AGREEMENT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOW,</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THEREFORE</font>, the Company and the Investor hereby covenant and agree as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Recitals</font>.&#160;&#160;&#160;The recitals set forth above are true and correct and are incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Certain</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Definitions</font>. As used in this Agreement, the following terms shall have the following respective meanings:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Agreement</font>&#8221; shall have the meaning set forth in the Preamble hereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Automatic&#160;&#160;&#160;Registration&#160;&#160;&#160;Statement</font>&#8221;&#160;&#160;&#160;shall&#160;&#160;&#160;have&#160;&#160;&#160;the&#160;&#160;&#160;meaning&#160;&#160;&#160;set&#160;&#160;&#160;forth&#160;&#160;&#160;in </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section 3(a) </font>of this Agreement.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Closing</font>&#8221; shall mean the closing of the sale of the Units in which the Investor </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Purchased the Units.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Closing Date</font>&#8221; means the date on which the Closing occurred.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commission</font>&#8221; shall mean the Securities and Exchange Commission, or any other federal agency at the time administering the Securities Act.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</font>&#8221; shall have the meaning set forth in the Preamble hereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Effectiveness</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8221;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">shall</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">mean</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">that</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">date</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">which</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">is</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> one hundred fifty days (150) days following the Filing Date or </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">one</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">hundred</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">eighty</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(180)</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">days following the Filing Date (in the case of a full SEC review).</font></font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Effectiveness</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Period</font>&#8221; shall have the meaning set forth in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: line-through">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3(a)</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>of this Agreement.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exchange Act</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8221; shall mean the Securities Exchange Act of 1934, as amended.</font></font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Filing</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date</font>&#8221; shall mean with respect to the Automatic Registration Statement required hereunder, that date which is forty-five (45) days following the Final Closing Date and, with respect to any additional Registration Statements which may be required herein, the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Final</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Closing</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date</font>&#8221; means closing date of the Offering after which the Company ceases to offer for sale the Units.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investor</font>&#8221; shall have the meaning set forth in the Preamble hereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Legal Counsel</font>&#8221; means Sichenzia Ross Friedman Ference LLP or such other counsel as thereafter designated by a majority of the Investors.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offering</font>&#8221; shall have the meaning set forth in the Subscription Agreement.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Piggyback</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registration</font>&#8221; shall have the meaning set forth in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4(a)</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>of this Agreement.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prospectus</font>&#8221; means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Purchase Agreement</font>&#8221; shall have the meaning set forth in the Preamble hereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Purchase Price</font>&#8221; shall have the meaning set forth in the Purchase Agreement.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Register</font>,&#8221; &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">registered</font>&#8221; and &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">registration</font>&#8221; each shall refer to a registration of the Registrable Securities effected by preparing and filing a Registration Statement or statements or similar documents in compliance with the Securities Act and the declaration or ordering of effectiveness of such Registration Statement or document by the Commission.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registrable Securities</font>&#8221; shall mean (a) all Shares, (b) all Warrant Shares then issuable upon exercise of the Warrant delivered to Investor in connection with the Offering (assuming on such date the Warrants are exercised in full without regard to any exercise limitations therein), (c) all shares of Common Stock issuable upon exercise of the warrants to be issued to Laidlaw and its agents in connection with the Offering (assuming on such date such warrants are exercised in full without regard to any exercise limitations therein), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution,&#160;&#160;recapitalization or similar event with respect to the foregoing provided, however, that any such Registrable Securities shall cease to be Registrable Securities (i) when subject to an effective Registration Statement under the Securities Act as provided for hereunder, (ii) upon any sale pursuant to a Registration Statement or Rule 144 under the Securities Act or (iii) at such time such securities become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Investors.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registration Statement</font>&#8221; means any registration statement required to be filed hereunder pursuant to Sections 3 or 4 and any additional registration statements contemplated herein, including (in each case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Rule 415</font>&#8221; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Rule 424</font>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SEC Guidance</font>&#8221; means (i) any publicly-available written or oral guidance, comments, requirements or requests of the Commission staff and (ii) the Securities Act.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Act</font>&#8221; shall mean the Securities Act of 1933, as amended.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</font>&#8221; shall have the meaning set forth in the Preamble hereof.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 63pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt"><br>
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subscription</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Agreement</font>&#8221; shall have the meaning set forth in the first Recital hereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant</font>&#8221; shall have the meaning set forth in the Preamble hereof.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrant Shares</font>&#8221; shall mean the shares of Common Stock to be issued upon exercise of the Warrants.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Capitalized terms used but not defined herein shall have the meanings set forth in the Subscription Agreement.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Automatic Registration</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On or prior to the Filing Date, the Company shall prepare and file with the Commission a registration statement (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Automatic</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Registration</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Statement</font>&#8221;) covering the resale of all of the Registrable Securities for an offering to be made on a continuous basis pursuant to Rule 415. The Automatic Registration Statement required hereunder shall be on Form S-1 or Form S-3, as applicable, and shall contain substantially the &#8220;Plan of Distribution&#8221; attached hereto as <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Annex A</font>.&#160; Subject to the terms of this Agreement, the Company shall use its reasonable best efforts to cause the Automatic Registration Statement to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event not later than the Effectiveness Date, and shall use its reasonable best efforts to keep the Automatic Registration Statement continuously effective under the Securities Act until the earlier of (a) one year from the date the Registration Statement is declared effective by the Commission or (b) until Rule 144 of the Securities Act is available to Investors with respect to all of the Registrable Securities (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Effectiveness Period</font>&#8221;). In the event the amount of Registrable Securities which may be included in the Registration Statement is limited due to SEC Guidance (provided that, the Company shall use diligent efforts to advocate with the Commission Staff for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, the SEC&#8217;s interpretive responses regarding Delayed or Continuous Offering and Sale of Securities No. 612.09) the Company shall use its reasonable best efforts to register such maximum portion of the Registrable Securities as permitted by SEC Guidance.&#160;&#160;In the event that there is a limitation by the Commission on the number of Registrable Securities that may be included for registration at one time, the Company shall promptly so advise the Investor and use its best efforts to file an additional Automatic Registration Statement covering such ineligible Registrable Securities, on a pro-rata basis, within 30 days of the date such securities become eligible and cause such Automatic Registration Statement to be declared effective by the Commission as soon as reasonably practicable.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall immediately notify the Investors via facsimile or by e-mail of the effectiveness of a Registration Statement on the second trading day after the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement.&#160;&#160;The Company shall, by 9:30 a.m. New York City time on the second trading day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424.&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to this Agreement, if any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Investor as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will first be reduced by Registrable Securities represented by the shares of Common Stock purchased by the Subscribers pursuant to the Subscription Agreement and second by Registrable Securities represented by Warrant Shares (applied, in the case that some Warrant Shares may be registered, to the Investors on a pro rata basis based on the total number of unregistered Warrant Shares held by such Investors). In the event of a cutback hereunder, the Company shall give the Investor at least 5 trading days prior written notice along with the calculations as to such Investor&#8217;s allotment.</font></font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At any time after the Automatic Registration Statement has become effective, the Company may, upon giving prompt written notice of such action to the Investor, suspend the use of any such Automatic Registration Statement if, in the good faith judgment of the Company, the use of the Automatic Registration Statement covering the Registrable&#160;Securities would be detrimental to the Company or its stockholders at such time and the Company concludes, as a result, that it is in the best interests of the Company or its stockholders to suspend the use of such Automatic Registration Statement at such time. The Company shall have the right to suspend such Automatic Registration Statement for a period of not more than thirty (30) consecutive days from the date the Company notifies the Investor of such suspension, with such suspension not to exceed an aggregate of sixty (60) days (whether or not consecutive) during any 12-month period. In the case of the suspension of any effective Automatic Registration Statement, the Investor, immediately upon receipt of notice thereof from the Company, will discontinue any sales of Registrable Securities pursuant to such Registration Statement until advised in writing by the Company that the use of such Automatic Registration Statement may be resumed.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If: (i) the Automatic Registration Statement is not filed on or prior to its Filing Date (if the Company files the Automatic Registration Statement without affording the Investors the opportunity to review and comment on the same as required by Section 5(a) herein, the Company shall be deemed to have not satisfied this clause (i), (ii) a Registration Statement registering for resale all of the Registrable Securities is not declared effective by the Commission by the Effectiveness Date (unless the reason for such non-registration of all or any portion of the Registrable Securities is as a result of SEC Guidance under Rule 415 or similar rule which limits the number of Registrable Securities which may be included in a registration statement with respect to the Investors), or (iii) after the effective date of a Registration Statement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Investors are otherwise not permitted to utilize the prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach being referred to as an &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Event</font>&#8221;, and for purposes of clause (i) and (iv), the date on which such Event occurs, and for purpose of clause (iii) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred to as &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Event Date</font>&#8221;), then, in addition to any other rights the Investors may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Investor an amount in cash, as partial liquidated damages and not as a penalty, equal to 1.0% of the aggregate purchase price paid by such Investor pursuant to the Subscription Agreement and Purchase Agreement. The parties agree that the maximum aggregate liquidated damages payable to an Investor under this Agreement shall be 6% of the aggregate Purchase Price paid by such Investor pursuant to the Purchase Agreement.&#160;&#160;If the Company fails to pay any partial liquidated damages pursuant to this Section in full within twenty days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Investor, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event. Notwithstanding the foregoing, no payments shall be owed with respect to any period during which all of the holder&#8217;s Registrable Shares may be sold by such holder under Rule 144 without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Legal Counsel</font>.&#160;&#160;Subject to the terms and conditions of this Agreement, Investors shall have the right to select Legal Counsel to review and oversee, solely on its behalf, any Registration Statement pursuant to this Agreement. The Company shall also reimburse Legal Counsel for its fees and disbursements in connection with registration, filing or qualification pursuant to this Agreement which amount shall be limited to $10,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Piggyback Registrations</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to any Registrable Securities not otherwise included in the Automatic Registration Statement or any other Registration Statement as a result of any limitation imposed by the Commission under Rule 415 (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Excluded Registrable Securities</font>&#8221;), whenever the Company proposes to register (including, for this purpose, a registration effected by the Company for other shareholders) any of its securities under the Securities Act (other than pursuant to (i) an Automatic Registration pursuant to <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section 3 </font>hereof or (ii) registration pursuant to a registration statement on Form S-4 or S-8 or any successor forms thereto), and the registration form to be used may be used for the registration of Registrable Securities (a &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Piggyback Registration</font>&#8221;), the Company will give written notice to the holder of Excluded Securities of its intention to effect such a registration and will, subject to the provisions of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsection 4(b) </font>hereof, include in such registration all Excluded Registrable Securities with respect to which the Company has received a written request for inclusion therein within twenty (20) days after the receipt of the Company&#8217;s notice.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a Piggyback Registration is an underwritten secondary registration on behalf of holders of the Company&#8217;s securities, and the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the number which can be sold in such offering without adversely affecting the marketability of the offering, the Company will include in such registration a pro rata share of Excluded Registrable Securities requested to be included in such Registration Statement as calculated by dividing the number of Excluded Registrable Securities requested to be included in such Registration Statement by the number of the Company&#8217;s securities requested to be included in such Registration Statement by all selling security holders. In such event, the holder of Excluded Registrable Securities shall continue to have registration rights under this Agreement with respect to any Excluded Registrable Securities not so included in such Registration Statement.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing, if, at any time after giving a notice of Piggyback Registration and prior to the effective date of the Registration Statement filed in connection with such registration, the Company shall determine for any reason not to register or to delay registration of such securities, the Company may, at its election, give written notice of such determination to each record holder of Excluded Registrable Securities and, following such notice, (i) in the case of a determination not to register, shall be relieved of its obligation to register any Excluded Registrable Securities in connection with such registration, and (ii) in the case of determination to delay registering, shall be permitted to delay registering any Excluded Registrable Securities for the same period as the delay in registering such other securities.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Registration</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Procedures</font>.&#160;&#160;If and whenever the&#160;&#160;Company&#160;&#160;is&#160;&#160;required to affect the registration of any Registrable Securities under the terms herein, the Company will:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not less than five (5) trading days prior to the filing of each Registration Statement and not less than one (1) trading day prior to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference), the Company shall (i) furnish to each seller of Registrable Securities copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such sellers, and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each seller of Registrable Securities, to conduct a reasonable investigation within the meaning of the Securities Act. Notwithstanding the above, the Company shall not be obligated to provide each seller of Registrable Securities advance copies of any universal shelf registration statement registering securities in addition to those required hereunder, or any Prospectus prepared thereto.&#160;&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;prepare&#160;&#160;and&#160;&#160;file&#160;&#160;with&#160;&#160;the&#160;&#160;Commission&#160;&#160;the&#160;&#160;Registration&#160;&#160;Statement&#160;&#160;with respect to such securities and use its best efforts to cause such Registration Statement to become effective in an expeditious manner;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible to each seller of Registrable Securities true and complete copies of all correspondence from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information contained therein which would constitute material non-public information regarding the Company), and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Securities and Exchange Act of 1934, as amended, with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by each seller of Registrable Securities thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notify the Investors of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one trading day prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than one Trading day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a &#8220;review&#8221; of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus, provided that, any and all of such information shall remain confidential to each Investor until such information otherwise becomes public, unless disclosure by a Investor is required by law; <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">further</font>, that notwithstanding each Investor&#8217;s agreement to keep such information confidential, each such Investor makes no acknowledgement that any such information is material, non-public information.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Use its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Investors of not less than the number of such Registrable Securities.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Furnish to Legal Counsel, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; provided, that any such item which is available on the EDGAR system need not be furnished in physical form;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;use&#160;&#160;its&#160;&#160;commercially&#160;&#160;reasonable&#160;&#160;efforts&#160;&#160;(i)&#160;&#160;to&#160;&#160;register&#160;&#160;or&#160;&#160;qualify&#160;&#160;the Registrable Securities covered by such Registration Statement under the state securities or &#8220;blue sky&#8221; laws of such jurisdictions as the sellers of Registrable Securities or, in the case of an underwritten public offering, the managing underwriter, reasonably shall request, (ii) to prepare and file in those jurisdictions such amendments (including post-effective amendments) and supplements, and take such other actions, as may be necessary to maintain such registration and qualification in effect at all times for the period of distribution contemplated thereby and (iii) to take such further action as may be necessary or advisable to enable the disposition of the Registrable Securities in such jurisdictions, provided, that the Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;use its commercially reasonable efforts to list the Registrable Securities covered by such Registration Statement with any securities exchange on which the common stock of the Company is then listed;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall cooperate with any broker-dealer through which a Investor proposes to resell its Registrable Securities in effecting a filing with the FINRA Corporate Financing Department pursuant to NASD Rule 5110, as requested by any such Investor, and the Company shall pay the filing fee required by such filing within two (2) Business Days of request therefor;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;immediately&#160;&#160;&#160;notify&#160;&#160;&#160;each&#160;&#160;&#160;seller&#160;&#160;&#160;of&#160;&#160;&#160;Registrable&#160;&#160;&#160;Securities&#160;&#160;&#160;and&#160;&#160;&#160;each underwriter under such Registration Statement, at any time when a Prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event of which the Company has knowledge as a result of which the Prospectus contained in such Registration Statement, as then in effect, includes any untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing and promptly amend or supplement such Registration Statement to correct any such untrue statement or omission;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Company notifies the Investors in accordance with any provision above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Investors shall suspend use of such Prospectus.&#160;&#160;The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.</font></font></font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if the offering is an underwritten offering, at the request of any seller of Registrable Securities, furnish to such seller on the date that Registrable Securities are delivered to the underwriters for sale pursuant to such registration: (i) a copy of an opinion, dated such date, of counsel representing the Company for the purposes of such registration, addressed to the underwriters, stating that such Registration Statement has become effective under the Securities Act and that (A) to the knowledge of such counsel, no stop order suspending the effectiveness thereof has been issued and no proceedings for that purpose have been instituted or are pending or contemplated under the Securities Act, (B) the Registration Statement, the related Prospectus and each amendment or supplement thereof comply as to form in all material respects with the requirements of the Securities Act (except that such counsel need not express any opinion as to financial statements or other financial or statistical information contained therein) and (C) to such other effects as reasonably may be requested by counsel for the underwriters; and (ii) a copy of a letter dated such date from the independent public accountants retained by the Company, addressed to the underwriters, stating that they are independent registered public accountants&#160;&#160;within&#160;&#160;the&#160;&#160;meaning&#160;&#160;of&#160;&#160;the&#160;&#160;Securities&#160;&#160;Act&#160;&#160;and&#160;&#160;that,&#160;&#160;in&#160;&#160;the&#160;&#160;opinion&#160;&#160;of&#160;&#160;such accountants, the financial statements of the Company included in the Registration Statement or the Prospectus, or any amendment or supplement thereof, comply as to form in all material respects with the applicable accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including information as to the period ending no more than five business days prior to the date of such letter) with respect to such registration as such underwriters reasonably may request;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;take all actions reasonably necessary to facilitate the timely preparation and delivery of certificates (not bearing any legend restricting the sale or transfer of such securities) representing the Registrable Securities to be sold pursuant to the Registration Statement and to enable such certificates to be in such denominations and registered in such names as each seller of Registrable Securities or any underwriters may reasonably request; and</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;take all other reasonable actions necessary to expedite and facilitate the registration of the Registrable Securities pursuant to the Registration Statement.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Obligations of </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Investor</font>.&#160;&#160;The Investor&#160;&#160;shall&#160;&#160;furnish&#160;&#160;to&#160;&#160;the&#160;&#160;Company&#160;&#160;such information regarding such Investor, the number of Registrable Securities owned and proposed to be sold by it, the intended method of disposition of such securities and any other information as shall be required to effect the registration of the Registrable Securities, and cooperate with the Company in preparing the Registration Statement and in complying with the requirements of the Securities Act.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Expenses</font>.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All expenses incurred by the Company in complying with <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sections</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">, </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4 and 5 </font>including, without limitation, all registration and filing fees (including the fees of the Commission and any other regulatory body with which the Company is required to file), printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or &#8220;blue sky&#8221; laws, if not previously paid by the Company in connection with an Issuer Filing, with respect to any filing that may be required to be made by any broker through which a Investor intends to make sales of Registrable Securities with FINRA pursuant to NASD Rule 5110, so long as the broker is receiving no more than a customary brokerage commission in connection with such sale and fees of transfer agents and registrars are called &#8220;Registration Expenses.&#8221; All underwriting discounts and selling commissions applicable to the sale of Registrable Securities are called &#8220;Selling Expenses.&#8221;</font></div>

<div style="TEXT-INDENT: 81pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will pay all Registration Expenses in connection with any Registration Statement filed hereunder, and the Selling Expenses in connection with each such Registration Statement shall be borne by the participating sellers in proportion to the number of Registrable Securities sold by each or as they may otherwise agree.&#160;&#160;In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder.&#160;&#160;In no event shall the Company be responsible for any broker or similar commissions of any Investor or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Investors</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, at the request of any Investor, the Company shall employ its counsel at the Company&#8217;s expense to prepare any and all legal opinions necessary for the prompt removal of restrictive legends from certificates representing Registrable Securities as, when and to the extent such legends may be removed in compliance with the Securities Act and/or Rule 144.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Indemnification and Contribution</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Indemnification by the Company</font>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Investor, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each Person who controls any such Investor (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&#8217; fees) and expenses (collectively, &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Losses</font>&#8221;), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding such Investor furnished in writing to the Company by such Investor expressly for use therein, or to the extent that such information relates to such Investor or such Investor&#8217;s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Investor expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Investor has approved Annex A hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(c)(iii)-(vi), the use by such Investor of an outdated or defective Prospectus after the Company has notified such Investor in writing that the Prospectus is outdated or defective and prior to the receipt by such Investor of the Advice contemplated in Section 6(d).&#160;&#160;The Company shall notify the Investors promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware.</font></font></div>

<div style="TEXT-INDENT: 72pt; MARGIN-LEFT: 36pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Indemnification by Investors</font>. Each Investor shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: (x) such Investor&#8217;s failure to comply with the prospectus delivery requirements of the Securities Act or (y) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Investor to the Company specifically for inclusion in such Registration Statement or such Prospectus or (ii) to the extent that such information relates to such Investor&#8217;s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Investor expressly for use in a Registration Statement (it being understood that the Investor has approved Annex A hereto for this purpose), such Prospectus or in any amendment or supplement thereto or (ii) in the case of an occurrence of an event of the type specified in Section 3(c)(iii)-(vi), the use by such Investor of an outdated or defective Prospectus after the Company has notified such Investor in writing that the Prospectus is outdated or defective and prior to the receipt by such Investor of the Advice contemplated in Section 6(d). In no event shall the liability of any selling Investor hereunder be greater in amount than the dollar amount of the net proceeds received by such Investor upon the sale of the Registrable Securities giving rise to such indemnification obligation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Conduct of Indemnification Proceedings</font>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Indemnified Party</font>&#8221;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#8220;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Indemnifying Party</font>&#8221;) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof; provided, that, the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have prejudiced the Indemnifying Party.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless:&#160;&#160;(1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party).&#160;&#160;The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed.&#160;&#160;No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading days of written notice thereof to the Indemnifying Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is judicially determined not to be entitled to indemnification hereunder.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Contribution</font>. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission.&#160;&#160;The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&#8217; or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph.&#160;&#160;Notwithstanding the provisions of this Section 5(d), no Investor shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Investor from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Investor has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Changes</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">in</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Capital</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Stock</font>. If, and as often as, there is any change in the capital stock of the Company by way of a stock split, stock dividend, combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby shall continue as so changed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Representations</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">and</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Warranties</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">of</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">the</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Company</font>. The Company represents and warrants to the Investor as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The&#160;&#160;execution,&#160;&#160;delivery&#160;&#160;and&#160;&#160;performance&#160;&#160;of&#160;&#160;this&#160;&#160;Agreement&#160;&#160;by&#160;&#160;the Company have been duly authorized by all requisite corporate action and will not violate any provision of law, any order of any court or other agency of government, the Certificate of Incorporation or Bylaws of the Company or any provision of any indenture, agreement or other instrument to which it or any or its properties or assets is bound, conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default under any such indenture, agreement or other instrument or result in the creation or imposition of any lien, charge or encumbrance of any nature whatsoever upon any of the properties or assets of the Company or its subsidiaries.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms, subject to any applicable bankruptcy, insolvency or other laws affecting the rights of creditors generally and to general equitable principles and the availability of specific performance.</font></div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Rule 144 Requirements</font>. The Company agrees to:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;make and keep current public information about the Company available, as those terms are understood and defined in Rule 144 under the Securities Act;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;use its best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;furnish to any holder of Registrable Securities upon request (i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents of the Company as such holder may reasonably request to avail itself of any similar rule or regulation of the Commission allowing it to sell any such securities without registration.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Termination</font>. All of the Company&#8217;s obligations to register Registrable Shares under <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sections 3, 4, </font>and <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5 </font>hereof shall terminate upon the date on which the Investor holds no Registrable Securities or all of the Registrable Securities are eligible for resale without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Company&#8217;s transfer agent and the Investor.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Miscellaneous</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as set forth on <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Schedule 13(a</font>) annexed hereto, neither the Company nor any of its security holders (other than the Investors in such capacity pursuant hereto) may include other securities of the Company in any Registration Statements other than the Registrable Securities during the Effectiveness Period.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto (including without limitation transferees of any Registrable Securities), whether so expressed or not.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All notices, requests, consents and other communications hereunder shall be in writing and shall be delivered in person, mailed by certified mail, return receipt requested, postage prepaid, addressed or sent by a nationally recognized overnight courier service: (i) if to the Company, at 501 Fifth Avenue, 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font> Floor, New York, New York 10017, Attn:, Chief Executive Officer; and (ii) if to any holder of Registrable Securities, to such holder at such address as may have been furnished to the Company or its counsel in writing by such holder; or, in any case, at such other address or addresses as shall have been furnished, in writing to the Company or its counsel (in the case of a holder of Registrable Securities) or to the holders of Registrable Securities (in the case of the Company) in accordance with the provisions of this paragraph.&#160;&#160;Any notice or other communication or deliveries hereunder shall be deemed given and effective upon actual receipt by the party to whom such notice is required to be given.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement shall be governed by and construed under the laws of the State of New York, without giving effect to principles of conflicts of laws. The Company and Investor (i) agree that any legal suit, action or proceeding arising out of or relating to this Agreement shall be instituted exclusively in in New York State Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (ii) waive any objection which the Company or Investor may have now or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consent to the jurisdiction of any such federal or state court in any such suit, action or proceeding. The Company and Investor further agree to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding and agree that service of process upon the Company or Investor mailed by certified mail, return receipt requested, postage prepaid, to, in the case of the Company, the Company&#8217;s address, and in the case of the Investor, to the Investor&#8217;s address as set forth on the Company&#8217;s books and records, shall be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding. THE PARTIES HERETO AGREE TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event of a breach by the Company or by the Investor, of any of their obligations under this Agreement, the Investor or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company and the Investor agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement and the provisions herein, including the provisions of this sentence, may not be terminated, amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Investors of 51% or more of the then outstanding Registrable Securities (including, for this purpose any Registrable Securities issuable upon exercise or conversion of any Security).&#160;&#160;If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Investor shall be reduced pro rata among all Investors and each Investor shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Investor or some Investors and that does not directly or indirectly affect the rights of other Investors may be given by such Investor or Investors of all of the Registrable Securities to which such waiver or consent relates; <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">however</font>, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section 13(e).</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof. No waiver shall be effective unless and until it is in writing and signed by the party granting the waiver.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement may be executed in two or more counterparts (including by facsimile or .pdf transmission) each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.</font></div>

<div style="TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 3.7pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The obligations of each Investor hereunder are several and not joint with the obligations of any other Investor hereunder, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert with respect to such obligations or the transactions contemplated by this Agreement. Each Investor shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, such illegality, invalidity or unenforceability shall attach only to such provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be carried out as if any such illegal, invalid or unenforceable provision were not contained herein.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement constitutes the entire agreement among the Company and the Investor relative to the subject matter hereof and supersedes in its entirety any and all prior agreements, understandings and discussions with respect thereto.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The headings of the sections of this Agreement are for convenience and shall not by themselves determine the interpretation of this Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[Signature Page Follows]</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 176.85pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[SIGNATURE PAGE OF HOLDERS FOLLOWS]</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[SIGNATURE PAGE OF HOLDERS TO ACTINIUM RRA]</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="11%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name of Holder:</font></td>
<td width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="64%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="29%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Signature of Authorized Signatory of Holder</font>:</font></td>
<td width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="46%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="20%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name of Authorized Signatory:</font></td>
<td width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="55%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="19%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title of Authorized Signatory:</font></td>
<td width="26%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="55%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Annex A</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Plan of Distribution</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each Selling Stockholder (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Selling Stockholders</font>&#8221;) of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the [principal Trading Market] or any other stock exchange, market or trading facility on which the securities are traded or in private transactions.&#160;&#160;These sales may be at fixed or negotiated prices.&#160;&#160;A Selling Stockholder may use any one or more of the following methods when selling securities:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">privately negotiated transactions;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a combination of any such methods of sale; or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left" valign="top" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">any other method permitted pursuant to applicable law.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Selling Stockholders may also sell securities under Rule 144 under the Securities Act of 1933, as amended (the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Act</font>&#8221;), if available, rather than under this prospectus.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Page22"><!--EFPlaceholder--></a><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales.&#160;&#160;Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.</font></font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume.&#160;&#160;The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities.&#160;&#160;The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales.&#160;&#160;In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.&#160;&#160;Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. In no event shall any broker-dealer receive fees, commissions and markups which, in the aggregate, would exceed eight percent (8%).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities.&#160;&#160;The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because Selling Stockholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder.&#160;&#160;In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. The Selling Stockholders have advised us that there is no underwriter or coordinating broker acting in connection with the proposed sale of the resale securities by the Selling Stockholders.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Page23"><!--EFPlaceholder--></a><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect.&#160;&#160;The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</font></font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution.&#160;&#160;In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of securities of the common stock by the Selling Stockholders or any other person.&#160;&#160;We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div>
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REGISTRATION RIGHTS AGREEMENT</font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Arial; FONT-SIZE: 10pt; TEXT-DECORATION: underline">EXHIBIT A</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name of<br>
Purchaser</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common <br>
Stock</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant <br>
Shares</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Purchase</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price Amount</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;$</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>10
<FILENAME>fs12014ex10xxxviii_actinium.htm
<DESCRIPTION>LETTER AGREEMENT, DATED SEPTEMBER 4, 2013, BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH.**
<TEXT>
<html>
<head>
    <title>fs12014ex10xxxviii_actinium.htm</title>
    <!--Licensed to: Edgar Agents-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">Exhibit 10.38</font></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><img src="img002_v1.jpg" alt=""></div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><img src="img003_v1.jpg" alt=""></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>fs12014ex23i_actinium.htm
<DESCRIPTION>ACCOUNTANTS CONSENT
<TEXT>
<html>
<head>
    <title>fs12014ex23i_actinium.htm</title>
    <!--Licensed to: Edgar Agents LLC-->
    <!--Document Created using EDGARizerAgent 5.4.5.1-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 7%; FONT-SIZE: 10pt; MARGIN-RIGHT: 7%">
<div>
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block">Exhibit 23.1<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We hereby consent to the inclusion in this Registration Statement on Form S-1 of our report dated March 15, 2013 relating to the consolidated financial statements of Actinium Pharmaceuticals, Inc. as of December 31, 2012 and 2011, for the years ended December 31, 2012 and 2011 and for the period from June 13, 2000 (inception) to December 31, 2012. We also consent to the reference to our firm under the heading <font style="FONT-STYLE: italic; DISPLAY: inline">"Experts" </font>appearing therein.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/ GBH CPAs, PC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GBH CPAs, PC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">www.gbhcpas.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Houston, Texas</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">January 31, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>fil-20130930.xml
<DESCRIPTION>XBRL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 7.0.3.3 [01/31/2014 09:02:27 PM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:fil="http://cactusventuresinc.com/20130930"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:net="http://www.xbrl.org/2009/role/net"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:us-types="http://fasb.org/us-types/2013-01-31"
 xmlns:utr="http://www.xbrl.org/2009/utr"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="fil-20130930.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_As_Of__31-Dec-2000">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2000-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2000_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2000-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2000_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2000-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2000_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2000-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2000">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2000-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2000-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2000-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2000-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2001">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2001-01-01
</xbrli:startDate>
<xbrli:endDate>
2001-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2001_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2001-01-01
</xbrli:startDate>
<xbrli:endDate>
2001-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2001_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2001-01-01
</xbrli:startDate>
<xbrli:endDate>
2001-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2001_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2001-01-01
</xbrli:startDate>
<xbrli:endDate>
2001-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2001">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2001-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2001_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2001-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2001_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2001-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2001_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2001-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Feb-2002_28-Feb-2002_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2002-02-01
</xbrli:startDate>
<xbrli:endDate>
2002-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2002">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2002-01-01
</xbrli:startDate>
<xbrli:endDate>
2002-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2002_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2002-01-01
</xbrli:startDate>
<xbrli:endDate>
2002-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2002_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2002-01-01
</xbrli:startDate>
<xbrli:endDate>
2002-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2002_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2002-01-01
</xbrli:startDate>
<xbrli:endDate>
2002-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2002">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2002-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2002_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2002-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2002_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2002-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2002_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2002-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2003">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2003-01-01
</xbrli:startDate>
<xbrli:endDate>
2003-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2003_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2003-01-01
</xbrli:startDate>
<xbrli:endDate>
2003-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2003_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2003-01-01
</xbrli:startDate>
<xbrli:endDate>
2003-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2003_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2003-01-01
</xbrli:startDate>
<xbrli:endDate>
2003-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2003">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2003-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2003_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2003-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2003_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2003-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2003_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2003-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2004">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2004-01-01
</xbrli:startDate>
<xbrli:endDate>
2004-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2004-01-01
</xbrli:startDate>
<xbrli:endDate>
2004-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2004-01-01
</xbrli:startDate>
<xbrli:endDate>
2004-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2004-01-01
</xbrli:startDate>
<xbrli:endDate>
2004-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2004">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2004-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2004_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2004-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2004_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2004-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2004_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2004-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2005">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-01-01
</xbrli:startDate>
<xbrli:endDate>
2005-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-01-01
</xbrli:startDate>
<xbrli:endDate>
2005-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-01-01
</xbrli:startDate>
<xbrli:endDate>
2005-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-01-01
</xbrli:startDate>
<xbrli:endDate>
2005-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2005">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2005-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2005-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2005-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2005_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2005-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2006">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2006_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2006_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2006">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2006-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2006-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2006-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2006_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2006-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2007">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2007-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2007-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2007-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2007_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2007-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2008">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2008-01-01
</xbrli:startDate>
<xbrli:endDate>
2008-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2008-01-01
</xbrli:startDate>
<xbrli:endDate>
2008-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2008-01-01
</xbrli:startDate>
<xbrli:endDate>
2008-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2008-01-01
</xbrli:startDate>
<xbrli:endDate>
2008-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2008-01-01
</xbrli:startDate>
<xbrli:endDate>
2008-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2008_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2008-01-01
</xbrli:startDate>
<xbrli:endDate>
2008-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2008_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2008-01-01
</xbrli:startDate>
<xbrli:endDate>
2008-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2008">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2008-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2008-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2008-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2008_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2008-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2009">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-01-01
</xbrli:startDate>
<xbrli:endDate>
2009-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-01-01
</xbrli:startDate>
<xbrli:endDate>
2009-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-01-01
</xbrli:startDate>
<xbrli:endDate>
2009-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-01-01
</xbrli:startDate>
<xbrli:endDate>
2009-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2009_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-01-01
</xbrli:startDate>
<xbrli:endDate>
2009-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2009">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2009_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Apr-2010_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Apr-2010_30-Apr-2010_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-04-01
</xbrli:startDate>
<xbrli:endDate>
2010-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Apr-2010_30-Apr-2010_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-04-01
</xbrli:startDate>
<xbrli:endDate>
2010-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2010_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2010_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2010_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2010_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_10-Apr-2011_09-May-2011_RelatedPartyTransactionsByRelatedPartyAxis_JamessCapitalGroupMember_AgreementAxis_TransactionManagementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:JamessCapitalGroupMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:TransactionManagementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-10
</xbrli:startDate>
<xbrli:endDate>
2011-05-09
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-05-20
</xbrli:startDate>
<xbrli:endDate>
2011-06-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__27-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_RangeAxis_MaximumMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_RangeAxis_MinimumMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fil:LaidlawAndCoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_SubsidiarySaleOfStockAxis_ManagementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fil:LaidlawAndCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fil:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_ManagementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">fil:SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2011_31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-12-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jan-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jan-2012_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jan-2012_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2012_31-Jan-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2012_31-Jan-2012_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2012_31-Jan-2012_RelatedPartyTransactionsByRelatedPartyAxis_RosemaryMazanetMember_AgreementAxis_ConsultingServicesAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:RosemaryMazanetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ConsultingServicesAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Feb-2012_29-Feb-2012_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-02-01
</xbrli:startDate>
<xbrli:endDate>
2012-02-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Feb-2012_29-Feb-2012_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-02-01
</xbrli:startDate>
<xbrli:endDate>
2012-02-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-06-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-06-14
</xbrli:startDate>
<xbrli:endDate>
2012-06-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28-Jul-2012_01-Aug-2012_AgreementAxis_RentalAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:RentalAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-28
</xbrli:startDate>
<xbrli:endDate>
2012-08-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05-Aug-2012_06-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-05
</xbrli:startDate>
<xbrli:endDate>
2012-08-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_08-Jul-2012_07-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:LaidlawAndCompanyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:EngagementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-08
</xbrli:startDate>
<xbrli:endDate>
2012-08-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-08-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-01
</xbrli:startDate>
<xbrli:endDate>
2012-08-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Aug-2012_31-Aug-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-01
</xbrli:startDate>
<xbrli:endDate>
2012-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-26
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-09-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_FinancialInstrumentAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_FinancialInstrumentAxis_WarrantOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fil:WarrantOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Oct-2012_23-Oct-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-10-01
</xbrli:startDate>
<xbrli:endDate>
2012-10-23
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-11-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__19-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__19-Dec-2012_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__19-Dec-2012_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2012_19-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2012_19-Dec-2012_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2012_19-Dec-2012_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2012_19-Dec-2012_StatementClassOfStockAxis_SeriesEPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__21-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__27-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__27-Dec-2012_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__27-Dec-2012_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2012_27-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fil:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2012_28-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fil:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:SloanKetteringInstituteOfCancerResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseDevelopmentAndCommercializationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fil:LaidlawAndCoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fil:LaidlawAndCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fil:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_ManagementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_RosemaryMazanetMember_AgreementAxis_ConsultingServicesAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:RosemaryMazanetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ConsultingServicesAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:LaidlawAndCompanyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:EngagementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_ManagementFirmMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:ManagementFirmMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseSecondClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseThirdClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:BiologicalLicenseApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:FirstCommercialSaleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:AfterFirstNetSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseFirstClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThreeStockPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThreeStockPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThreeStockPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:NewDrugApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:ReceiptOfRegulatoryApprovalFromUSFdaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:AfterFirstNetSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseFirstClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_GuagentiAndAssociatesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:GuagentiAndAssociatesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandTwelveEmployeeStockOptionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandTwelveEmployeeStockOptionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_FinancialInstrumentAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_FinancialInstrumentAxis_WarrantsBMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fil:WarrantsBMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">fil:SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThreeStockPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_PlanNameAxis_TwoThousandTwelveEmployeeStockOptionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandTwelveEmployeeStockOptionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jan-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Jan-2013_31-Jan-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Feb-2013_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_SeparationAndSettlementAgreementMember_TitleOfIndividualAxis_FormerChiefExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Feb-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_27-Feb-2013_28-Feb-2013_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_SeparationAndSettlementAgreementMember_TitleOfIndividualAxis_FormerChiefExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-02-27
</xbrli:startDate>
<xbrli:endDate>
2013-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Feb-2013_28-Feb-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-02-01
</xbrli:startDate>
<xbrli:endDate>
2013-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Mar-2013_31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-03-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-May-2013_31-May-2013_TitleOfIndividualAxis_FormerDirectorAndConsultantsMember_FinancialInstrumentAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:FormerDirectorAndConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-05-01
</xbrli:startDate>
<xbrli:endDate>
2013-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_10-Aug-2013_12-Aug-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-08-10
</xbrli:startDate>
<xbrli:endDate>
2013-08-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fil:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20-Sep-2013_25-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-20
</xbrli:startDate>
<xbrli:endDate>
2013-09-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20-Sep-2013_25-Sep-2013_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fil:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-20
</xbrli:startDate>
<xbrli:endDate>
2013-09-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__30-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AgreementAxis_RentalAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:RentalAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_FinancialInstrumentAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_FinancialInstrumentAxis_WarrantOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fil:WarrantOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseSecondClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseThirdClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:BiologicalLicenseApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:FirstCommercialSaleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:AfterFirstNetSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseFirstClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:NewDrugApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:ReceiptOfRegulatoryApprovalFromUSFdaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:AfterFirstNetSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fil:OptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_FinancialInstrumentAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenStockPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenEquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenStockPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenEquityIncentivePlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_TitleOfIndividualAxis_ChiefExecutiveOfficerAndDirectorMember_AgreementAxis_EmploymentContractsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:ChiefExecutiveOfficerAndDirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2000_30-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-14
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw65c444c555cT{h>5;III4==1IF7=18I=E1=4FE1J456J;74=4J4 -->
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Note"><xbrli:measure>fil:Note</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME__30-Sep-2013">Actinium Pharmaceuticals, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME__30-Sep-2013">0001388320</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_9ME__30-Sep-2013">false</dei:AmendmentFlag>
<dei:DocumentType contextRef="Context_9ME__30-Sep-2013">S-1</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME__30-Sep-2013">2013-09-30</dei:DocumentPeriodEndDate>
<dei:EntityFilerCategory contextRef="Context_9ME__30-Sep-2013">Smaller Reporting Company</dei:EntityFilerCategory>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2010" unitRef="USD" decimals="0">196135</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">5703798</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5618669</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">3990063</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__30-Sep-2012" unitRef="USD" decimals="0">2566669</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">237834</us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">5384</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">167143</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">53000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:DeferredFinanceCostsCurrentNet contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">252248</us-gaap:DeferredFinanceCostsCurrentNet>
<us-gaap:DeferredFinanceCostsCurrentNet contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredFinanceCostsCurrentNet contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsCurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">6199264</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5785812</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">4043063</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">1233</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">3010</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">6918</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">6200497</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5788822</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">4049981</us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">644511</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">897044</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">312001</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">31185</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">375686</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">140000</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">124363</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of__31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">124363</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of__31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">4439613</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">3574958</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">2757966</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">5208487</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">4643187</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">3445653</us-gaap:LiabilitiesCurrent>
<us-gaap:Liabilities contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">4643187</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">3445653</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">136648</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">21392</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">23657</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">48237620</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">56867706</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">61218085</us-gaap:AdditionalPaidInCapital>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">47382258</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">55743463</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">60637414</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2000" unitRef="USD" decimals="0">1107714</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2000_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">11447</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2000_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1768553</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2000_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-672286</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2001" unitRef="USD" decimals="0">-1732907</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2001_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">13320</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2001_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4016680</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2001_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-5762907</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2002" unitRef="USD" decimals="0">-1675291</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2002_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">15124</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2002_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7264876</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2002_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-8955291</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2003" unitRef="USD" decimals="0">1573915</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2003_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">17214</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2003_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">14044036</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2003_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-12487335</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2004" unitRef="USD" decimals="0">439124</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2004_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">24873</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2004_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">18636377</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2004_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-18222126</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2005" unitRef="USD" decimals="0">74275</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">31367</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22845271</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2005_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-22802363</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2006" unitRef="USD" decimals="0">1823762</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">39757</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">30639730</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2006_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-28855725</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2007" unitRef="USD" decimals="0">3460052</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">47747</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">37885611</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2007_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-34473306</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2008" unitRef="USD" decimals="0">4158765</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">57737</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">44145239</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2008_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-40044211</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2009" unitRef="USD" decimals="0">845161</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">57737</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">44257621</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2009_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-43470197</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2010" unitRef="USD" decimals="0">399061</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">57737</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">44278787</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2010_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-43937463</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">992010</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">136648</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">48237620</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-47382258</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">1145635</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">213916</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">56675182</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-55743463</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">604328</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">6200497</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5788822</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">4049981</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Dec-2011" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Dec-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of__30-Sep-2013" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of__31-Dec-2011" unitRef="shares" decimals="INF">100000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">100000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of__31-Dec-2011" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of__31-Dec-2011" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Dec-2011" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Dec-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__30-Sep-2013" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of__31-Dec-2011" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of__31-Dec-2011" unitRef="shares" decimals="INF">13664802</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">21391665</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">23656582</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of__31-Dec-2011" unitRef="shares" decimals="INF">13664802</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">21391665</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">23656582</us-gaap:CommonStockSharesOutstanding>
<us-gaap:SalesRevenueNet contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_3ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_3ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">323788</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">1677301</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">2723459</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">3440485</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">26420519</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">778232</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">2373200</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">28793719</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">2959246</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">722037</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">1520221</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">4506232</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">24504975</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">830730</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">2730233</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">27235208</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationAndAmortization contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">633</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">112</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">429</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">581</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">3262462</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_3ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationAndAmortization contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationAndAmortization contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3262462</us-gaap:DepreciationAndAmortization>
<us-gaap:OperatingExpenses contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">3283667</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">2399450</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">4244109</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">7947298</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">54738142</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">1608962</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">5107555</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">59845697</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-3283667</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">-2399450</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-4244109</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-7947298</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">-54738142</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">-1608962</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-5107555</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-59845697</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-175094</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">318623</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">952241</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-1099327</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">-1964707</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">1299</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">2508</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">1967215</us-gaap:InterestExpense>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">260000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">260000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-13966</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">-294381</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-287604</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-685420</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">-699386</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">189348</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">216112</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">915498</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">161128</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">-613004</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-1239845</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">413907</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">1005321</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">188049</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">213604</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-791717</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_14-Jun-2000_31-Dec-2000" unitRef="USD" decimals="0">-672286</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-672286</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2001" unitRef="USD" decimals="0">-5090621</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2001_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-5090621</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2002" unitRef="USD" decimals="0">-3192384</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2002_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-3192384</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2003" unitRef="USD" decimals="0">-3532044</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2003_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-3532044</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2004" unitRef="USD" decimals="0">-5734791</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-5734791</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2005" unitRef="USD" decimals="0">-4580237</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-4580237</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2006" unitRef="USD" decimals="0">-6053362</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-6053362</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2007" unitRef="USD" decimals="0">-5617581</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-5617581</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2008" unitRef="USD" decimals="0">-5570905</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-5570905</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2009" unitRef="USD" decimals="0">-3425986</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-3425986</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2010" unitRef="USD" decimals="0">-467266</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-467266</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-3444795</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-3444795</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">-3012454</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-5483954</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-8361205</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-8361205</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">-55743463</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">-1420913</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-4893951</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-60637414</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE__31-Dec-2011" unitRef="USD_per_Share" decimals="2">-4.30</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME__30-Sep-2012" unitRef="USD_per_Share" decimals="2">-3.76</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME__30-Sep-2012" unitRef="USD_per_Share" decimals="2">-6.84</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE__31-Dec-2012" unitRef="USD_per_Share" decimals="2">-7.58</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME__30-Sep-2013" unitRef="USD_per_Share" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME__30-Sep-2013" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="INF">801799</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME__30-Sep-2012" unitRef="shares" decimals="INF">801799</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME__30-Sep-2012" unitRef="shares" decimals="INF">801799</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="INF">1103521</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME__30-Sep-2013" unitRef="shares" decimals="INF">23601895</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME__30-Sep-2013" unitRef="shares" decimals="INF">22401711</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2000_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1144687</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2001_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1332000</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2002_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1512375</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2003_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1721367</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2004_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2487267</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3136617</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3975659</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">4774661</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">5773661</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">5773661</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">5773661</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">13664802</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">21391665</us-gaap:SharesOutstanding>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_14-Jun-2000_31-Dec-2000" unitRef="USD" decimals="0">30000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">9990</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">20010</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">999000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2000" unitRef="USD" decimals="0">1750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">1457</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1748543</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2001" unitRef="USD" decimals="0">2250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2001_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">1873</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2001_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2248127</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2001_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2002" unitRef="USD" decimals="0">3250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2002_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">1804</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2002_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3248196</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2002_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2003" unitRef="USD" decimals="0">6781250</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2003_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">2090</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2003_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6779160</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2003_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2004" unitRef="USD" decimals="0">4600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">7659</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4592341</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2005" unitRef="USD" decimals="0">3900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">6494</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3893506</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2006" unitRef="USD" decimals="0">7550541</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">8390</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7542151</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2007" unitRef="USD" decimals="0">6600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">7326</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6592674</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2008" unitRef="USD" decimals="0">6000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">9990</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5990010</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">5379367</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">78911</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5300456</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">5129940</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">40877</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5089063</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">23017827</us-gaap:ProceedsFromIssuanceOfCommonStock>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_Custom_14-Jun-2000_31-Dec-2000_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">145687</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2001_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">187313</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2002_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">180375</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2003_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">208992</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2004_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">765900</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">649350</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">839042</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">732600</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">999000</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">7891141</fil:ProceedsFromIssuanceOfCommonStockShares>
<fil:ProceedsFromIssuanceOfCommonStockShares contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">4087747</fil:ProceedsFromIssuanceOfCommonStockShares>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE__31-Dec-2007" unitRef="USD" decimals="0">398810</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">664</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">398146</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE__31-Dec-2007_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">398810</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_Custom_14-Jun-2000_31-Dec-2010" unitRef="USD" decimals="0">398810</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">66402</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE__31-Dec-2007_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">66402</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_14-Jun-2000_31-Dec-2010" unitRef="shares" decimals="0">66402</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<fil:ConversionOfNotesPayableAndAccruedInterestToStockValue contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">981729</fil:ConversionOfNotesPayableAndAccruedInterestToStockValue>
<fil:ConversionOfNotesPayableAndAccruedInterestToStockValue contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">12525</fil:ConversionOfNotesPayableAndAccruedInterestToStockValue>
<fil:ConversionOfNotesPayableAndAccruedInterestToStockValue contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">969204</fil:ConversionOfNotesPayableAndAccruedInterestToStockValue>
<fil:ConversionOfNotesPayableAndAccruedInterestToStockValue contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<fil:ConversionOfNotesPayableAndAccruedInterestToStockShares contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">1252550</fil:ConversionOfNotesPayableAndAccruedInterestToStockShares>
<fil:SharesIssuedAtReverseMergerValue contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<fil:SharesIssuedAtReverseMergerValue contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">23866</fil:SharesIssuedAtReverseMergerValue>
<fil:SharesIssuedAtReverseMergerValue contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-23866</fil:SharesIssuedAtReverseMergerValue>
<fil:SharesIssuedAtReverseMergerValue contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<fil:SharesIssuedAtReverseMergerShares contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">2386566</fil:SharesIssuedAtReverseMergerShares>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2005" unitRef="USD" decimals="0">315388</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">315388</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2005_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2006" unitRef="USD" decimals="0">252308</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">252308</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2006_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2007" unitRef="USD" decimals="0">255061</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">255061</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2007_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2008" unitRef="USD" decimals="0">269618</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">269618</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2008_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2009" unitRef="USD" decimals="0">112382</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">112382</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2009_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2010" unitRef="USD" decimals="0">21166</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">21166</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2010_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">19935</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">19935</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">266172</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">266172</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">2153442</fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense>
<fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2153442</fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense>
<fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">1957754</fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense>
<fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1957754</fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense>
<fil:AdjustmentsToAdditionalPaidInCapitalWarrantExpense contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-3887850</fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants>
<fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-3887850</fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants>
<fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-4052089</fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants>
<fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-4052089</fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants>
<fil:AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">4231324</fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4231324</fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_FYE__31-Dec-2012_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">4231324</fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">4832204</fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">372850</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">372850</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_FYE__31-Dec-2011_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">2173377</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">312500</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2012_FinancialInstrumentAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">168000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2012_FinancialInstrumentAxis_WarrantOneMember" unitRef="USD" decimals="0">168000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">2223926</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">6052036</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">284371</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2013_FinancialInstrumentAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">284371</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2013_FinancialInstrumentAxis_WarrantOneMember" unitRef="USD" decimals="0">284371</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">6336407</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">633</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">429</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">581</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">3262462</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3262462</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">124363</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">678116</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">775637</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">900000</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">900000</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">40444</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">219725</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">252248</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">292692</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">292692</us-gaap:AmortizationOfFinancingCosts>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">13966</fil:GainOnChangeInFairValueOfDerivatives>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-287604</fil:GainOnChangeInFairValueOfDerivatives>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">685420</fil:GainOnChangeInFairValueOfDerivatives>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">699386</fil:GainOnChangeInFairValueOfDerivatives>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">216112</fil:GainOnChangeInFairValueOfDerivatives>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">915498</fil:GainOnChangeInFairValueOfDerivatives>
<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-41567</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-234088</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">3746</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-4766</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-14386</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">18013</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">23397</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-114143</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-87000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">556019</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">173614</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">334263</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">1238773</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-585043</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">653730</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">2100</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">31185</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">31185</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">344501</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">375686</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-517592</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-3795480</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-5212710</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">-44402658</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-4947969</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-49350627</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">3000000</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3000000</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">1812</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">2359</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">815659</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">8030</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">823689</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-1812</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-2359</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">-3815659</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-8030</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-3823689</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">645888</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">645888</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">645888</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">140000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">140000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2000" unitRef="USD" decimals="0">1750000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2001" unitRef="USD" decimals="0">2250000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2006" unitRef="USD" decimals="0">7533741</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2007" unitRef="USD" decimals="0">6600000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2008" unitRef="USD" decimals="0">6000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">5379367</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">660163</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">5129940</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">53191098</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">53191098</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">3467393</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3467393</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">6025255</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">660163</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">5129940</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">53836986</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">3327393</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">57164379</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">5507663</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-3137129</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-85129</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">5618669</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-1628606</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3990063</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">682</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">561</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">1243</us-gaap:InterestPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">372850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">372850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">372850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">377150</fil:FairValueOfWarrantsIssuedWithDebt>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">377150</fil:FairValueOfWarrantsIssuedWithDebt>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">377150</fil:FairValueOfWarrantsIssuedWithDebt>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">2591900</fil:FairValueOfWarrantsIssuedWithStock>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">318087</fil:FairValueOfWarrantsIssuedWithStock>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">3393338</fil:FairValueOfWarrantsIssuedWithStock>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">5985238</fil:FairValueOfWarrantsIssuedWithStock>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">5985238</fil:FairValueOfWarrantsIssuedWithStock>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">1484529</fil:FairValueOfWarrantsIssuedToPlacementAgent>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">159044</fil:FairValueOfWarrantsIssuedToPlacementAgent>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">658753</fil:FairValueOfWarrantsIssuedToPlacementAgent>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">2170282</fil:FairValueOfWarrantsIssuedToPlacementAgent>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">2170282</fil:FairValueOfWarrantsIssuedToPlacementAgent>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">981729</fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">981729</fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">981729</fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 1 &amp;#8211; Description of Business and Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Nature of Business &amp;#8211; Actinium Pharmaceuticals, Inc (Formerly&lt;/font&gt; Cactus Ventures, Inc.) (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Cactus&amp;#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that is in the market for a merger with an appropriate operating company.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company agreed to acquire 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;Actinium&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange was closed on December 28, 2012 when shareholders representing over 20% of the issued and outstanding shares of Actinium had finished the exchange process.&amp;#160;&amp;#160;On August 22, 2013, shareholders representing 38% of the issued and outstanding shares of Actinium completed the exchange.&amp;#160;&amp;#160;As a result of the Share Exchange, the former shareholders of Actinium became the controlling shareholders of the Company. At the closing, each Actinium shareholder shall receive 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Cactus common stock for each Actinium share exchanged. At the closing, all of the Actinium shareholders&amp;#8217; options and warrants to purchase Actinium common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Cactus common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein Actinium is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Actinium, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;Actinium&amp;#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &amp;#160;Actinium&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; As a result of the Share Exchange, the Company is now a holding company operating through Actinium, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Development Stage Company &amp;#8211;&lt;/font&gt; The Company is considered a development stage company and has had no commercial revenue to date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Principles of Consolidation &amp;#8211;&lt;/font&gt; The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div
 align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/font&gt; The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Reclassification &amp;#8211;&lt;/font&gt; Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Cash and Cash Equivalents &amp;#8211;&lt;/font&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At December 31, 2012 and 2011, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Property and Equipment &amp;#8211;&lt;/font&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Impairment of Long-Lived Assets &amp;#8211;&lt;/font&gt; Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Derivatives &amp;#8211;&lt;/font&gt; All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/font&gt; Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit
 risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity&amp;#8217;s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of December 31, 2012 and 2011. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,439,613&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%"
 valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,439,613&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Income Taxes &amp;#8211;&lt;/font&gt; The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Research and Development Costs &amp;#8211;&lt;/font&gt; Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Share-Based Payments &amp;#8211;&lt;/font&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Earnings (Loss) Per Common Share &amp;#8211;&lt;/font&gt; The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&amp;#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &amp;#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been anti dilutive. For the year ended December 31, 2012, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,596 shares of the Company&amp;#8217;s common stock. For the year ended December 31, 2011, potentially issuable shares includes options and warrants&amp;#160;to purchase 273,859 shares of the Company&amp;#8217;s common stock and notes payable convertible to 3,448,276 shares of the Company&amp;#8217;s common stock have been excluded from the calculation.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Recent Accounting Pronouncements &amp;#8211;&lt;/font&gt; The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times
 new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Subsequent Events &amp;#8211;&lt;/font&gt; The Company&amp;#8217;s management reviewed all material events from January 1, 2013 through March 15, 2013.&lt;/font&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 1 &amp;#8211; Description of Business and Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Nature of Business &amp;#8211;&lt;/font&gt; Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Actinium&amp;#8221;, &amp;#8220;Cactus&amp;#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that was in the market for a merger with an appropriate operating company.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&amp;#160;&amp;#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;API&amp;#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&amp;#160;&amp;#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&amp;#160;&amp;#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;
 font-weight: bold;"&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211;&lt;/font&gt; The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Development Stage Company &amp;#8211;&lt;/font&gt; The Company is considered a development stage company and has had no commercial revenue to date.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Principles of Consolidation &amp;#8211;&lt;/font&gt; The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/font&gt; The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Reclassification &amp;#8211;&lt;/font&gt; Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/font&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2013 and December 31, 2012, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Property and Equipment &amp;#8211;&lt;/font&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Impairment of Long-Lived Assets &amp;#8211;&lt;/font&gt; Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such
 asset and its carrying value.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Derivatives &amp;#8211;&lt;/font&gt; All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/font&gt; Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity&amp;#8217;s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;
 padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At September 30, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Income Taxes &amp;#8211;&lt;/font&gt; The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Research and Development Costs &amp;#8211;&lt;/font&gt; Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Share-Based Payments &amp;#8211;&lt;/font&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/font&gt; The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same.&amp;#160;&amp;#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the nine months ended September 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to
 purchase 9,441,942 shares of the Company&amp;#8217;s common stock. For the nine months ended September 30, 2012, potentially issuable shares included stock options to purchase 1,968,829 shares; warrants in the amount of 5,861,044 shares; convertible notes payable in the amount of 1,152,692 shares; and convertible preferred stock in the amount of 13,831,762 shares of the Company&amp;#8217;s common stock have been excluded from the calculation.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Recent Accounting Pronouncements &amp;#8211;&lt;/font&gt; The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Subsequent Events &amp;#8211;&lt;/font&gt; The Company&amp;#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<fil:GoingConcernTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;font style="display: inline; font-weight: bold;"&gt;Note 2 &amp;#8211; Going Concern&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $8,361,205 and net cash used in operations of $5,212,710, for the year ended December 31,&amp;#160;2012; and an accumulated deficit of $55,743,463 at December 31, 2012. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; The ability of the Company to continue its operations is dependent on the successful execution of management&amp;#8217;s plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&amp;#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;/div&gt;</fil:GoingConcernTextBlock>
<fil:GoingConcernTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 2 &amp;#8211; Going Concern&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $4,893,951 and net cash used in operations of $4,947,969, for the nine months ended September 30, 2013; and a deficit accumulated during the development stage of $60,637,414 at September 30, 2013. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The ability of the Company to continue its operations is dependent on the successful execution of management&amp;#8217;s plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&amp;#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;/div&gt;</fil:GoingConcernTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 3 &amp;#8211; Related Party Transactions&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;"&gt;MSKCC:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI),&amp;#160;an entity related to MSKCC.&amp;#160;&amp;#160;The agreement was amended in August 2006.&amp;#160;&amp;#160;Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect to the Company&amp;#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates.&amp;#160;&amp;#160;Certain amounts due under this agreement were deferred and then forgiven under the forbearance-related arrangements described above.&amp;#160;&amp;#160;On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments. Since January 1, 2011, the Company has paid $100,000 under this agreement and as of December 31, 2012, the Company agreed to pay an additional $150,000 for research to be conducted in 2013.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&amp;#160;&amp;#160;The Company will pay $31,185 for each patient that has completed the clinical trial.&amp;#160;&amp;#160;Upon execution of the agreement, the Company was required to pay a start-up fee of $79,623, which was paid on July 10, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; MSKCC agreed, subject to certain conditions, to utilize the donated funds for certain clinical and preclinical programs and activities related to the Company&amp;#8217;s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by the Company. The following is a summary of activities related to the MSKCC arrangements for years ended December 31, 2012 and 2011:&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%"
 valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Qualified R&amp;amp;D costs incurred by the Company&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;655,786&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Reimbursements received from MSKCC&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;237,834&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;966,341&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; In 2012 and 2011, the Company received total R&amp;amp;D reimbursement payments of $237,834 and $299,200, respectively, from MSKCC.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; As of December 31, 2012 and 2011, the Company had a net receivable of $0 and $237,834, respectively, from MSKCC.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;"&gt;Dr. Rosemary Mazanet:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On January 1, 2012, the Company entered into a Consulting Services Agreement with Dr. Rosemary Mazanet, a director of Cactus.&amp;#160;&amp;#160;Pursuant to the agreement, Dr. Mazanet is to provide, among other things, consulting services in the areas of implementation of the Actimab&amp;#8482;-A trial including all aspects of study initiation until first patient in at each clinical site.&amp;#160;&amp;#160;Dr. Mazanet receives compensation of $100,000 per year and may receive additional compensation in the form of options at determined by the board of the Company.&amp;#160;&amp;#160;Since January 1, 2011, Dr. Mazanet has also received options to purchase 99,900 shares of common stock of the Company. These options have exercise price ranging from $0.78 to $1.5 and have a life of 10 years.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;font style="font-style: italic; font-weight: bold; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div
 align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;"&gt;Jamess Capital Group, LLC:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On May 9, 2011, the Company entered into a transaction management agreement with Jamess Capital Group, LLC. (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Sandesh Seth, a Director of the Company&amp;#160;(&amp;#8220;Management Firm&amp;#8221;).&amp;#160; The Management Firm received a monthly fee of $12,500 which is terminable by the Company three months after the effective date of the going public transaction and designees of Jamess, including entities affiliated with Mr. Seth, were issued warrants to purchase common stock equal to 10% of the fully-diluted capital stock of the Company as of the effective date of the going public transaction. The fully diluted shares for this calculation included all issued and outstanding shares as well as those reserved under the Employee Stock Option Plan.&amp;#160; The Management Firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;"&gt;Placement Agent:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On August 7, 2012, the Company entered into an engagement agreement with its placement agent for the 2012 Common Stock Offering,&amp;#160;of which Mr. Seth, a director of the Company is Head of Healthcare Investment Banking.&amp;#160;&amp;#160;&amp;#160;Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &amp;#160;&amp;#160;In consideration for its services, the placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&amp;#160;&amp;#160;The placement agent or its designees have also received warrants to purchase shares of the Company&amp;#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.&amp;#160;&amp;#160;The placement agent will also receive the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company.&amp;#160;&amp;#160;Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent has been engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000.&amp;#160;&amp;#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&amp;#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.&amp;#160;&amp;#160;For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent.&amp;#160;&amp;#160;The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&amp;#8217;s Common Stock.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;"&gt;Guagenti &amp;amp; Associates LLC:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;In 2010, the Company entered into an agreement with Guagenti &amp;amp; Associates LLC (&amp;#8220;G&amp;amp;A&amp;#8221;).&amp;#160;&amp;#160;G&amp;amp;A is affiliated with Enza Guagenti, the former Chief Financial Officer of Cactus.&amp;#160;&amp;#160;Pursuant to the agreement, the Company leases storage space in Newark, NJ from G&amp;amp;A.&amp;#160;&amp;#160;The rent is $300 per month.&amp;#160;&amp;#160;Since January 1, 2011, the Company has paid $7,200 pursuant to this agreement.&amp;#160;&amp;#160;&amp;#160;Ms. Guagenti resigned as the Company&amp;#8217;s Chief Financial Officer on March 9, 2013.&lt;/font&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 4 &amp;#8211; Property and Equipment&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; Property and equipment consisted of the following at December 31, 2012 and 2011:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;Lives&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Office equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="10%" valign="bottom"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;156,162&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;153,804&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Furniture and fixture&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;7 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,292&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,292&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total property, plant and equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;157,454&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;155,096&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(153,863&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="56%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,233&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Depreciation expense for the years ended December 31, 2012 and 2011 were $581 and $633, respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 3 &amp;#8211; Property and Equipment&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Property and equipment consisted of the following at September 30, 2013 and December 31, 2012:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="57%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;Lives&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Office equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="9%" valign="bottom"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;162,384&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;156,162&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Furniture and fixture&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="9%" valign="bottom"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;7 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,100&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,292&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;165,484&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;157,454&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Loss on disposition of equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4,122&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt;
 display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="57%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="57%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;6,918&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Depreciation expense for the nine months ended September 30, 2013 and 2012 were $0 and&amp;#160;$429 respectively.&lt;/font&gt;&amp;#160;&lt;/div&gt;
&lt;div  style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 5 &amp;#8211; Note Payable and Convertible Notes&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Note Payable&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On December 28, 2012, the Company entered into a premium finance agreement to pay $140,000 premium of its director and officer insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and has to pay $12,636 in monthly installment for nine months. As of December 31, 2012, outstanding balance related to the premium finance agreement was $140,000.&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Convertible Notes&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On December 27, 2011, the Company completed a private offering of 8% Senior Subordinated Unsecured Convertible Promissory Notes (&amp;#8220;Convertible Notes&amp;#8221;) in the amount of $900,000 and received net proceeds of $750,000. The convertible notes were issued at 83.33% of the principal amount resulting in an original issue discount of $150,000.&amp;#160;The Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount, accrued semi-annually and to be paid at maturity.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; The principal amount of the Convertible Notes and accrued interest are automatically converted to common stock at the earlier of: (1) the effective date of a Qualified Public Offering, (2) a Public Company Transaction, defined as (i) a reverse merger or similar transaction between the Company and a corporation whose securities are publicly traded in the United States or other jurisdiction mutually agreed between the Company and Placement Agent, or (ii) the quotation of the Company&amp;#8217;s securities for purchase and sale on a U.S. quotation service, or (iii) the filing with an applicable regulatory body which will result in the Company becoming an entity whose securities are traded on a public exchange in the U.S. or other mutually agreed upon jurisdiction, or (3) the acquisition or receipt by the Company of no less than $4,000,000 of gross proceeds in subsequent offerings of its common stock or equivalents following the issuance of the Company&amp;#8217;s stock (See Note 9) and the Convertible Notes.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; In connection with the issuance of the Convertible Notes, warrants to purchase a total of 287,061 shares of common stock were issued to investors. The Placement Agent and the Management Firm (See Note 9) were issued warrants to purchase 143,532 shares and 126,829 shares of common stock, respectively. The warrants issued to the Placement Agent are exercisable at $0.78 per share and expire on January 31, 2019. &amp;#160;The warrants issued to the Management Firm are exercisable at $0.01 per share and expire on January 31, 2019.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; The Company analyzed the Convertible Notes and the Warrants for derivative accounting consideration under FASB ASC 470 and determined that the investor warrants and the placement agent warrants, with a grant date fair value of $565,729 (See Note 6), qualified for accounting treatment as a financial derivative (See Note 6) and the Convertible Notes were determined to also have a beneficial conversion feature discount of $372,850 resulting from the conversion price of $0.78 per share which is below the fair value of $1.11 per share on the date of the Convertible Notes.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; The total fees, including cash payments and the fair value of the warrants issued to the Placement Agent, incurred in connection with the financing were $292,692. These fees were amortized over the life (one year) of the Convertible Notes using the straight-line method as it approximates the effective interest method. &amp;#160;The $150,000 original issue discount on the Convertible Notes was also amortized over the life of the Notes on a straight line basis.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;On October 23, 2012, the
 investors extended the note maturity date for 90 days. The maturity date of the notes has been extended to January 31, 2013, February 18, 2013 or March 27, 2013 for the 24 notes.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On December 19, 2012, the Convertible Notes and the accrued interests were automatically converted to common stock when the Company closed on an offering of its common stock in which the gross proceeds exceeded the $4,000,000 threshold.&amp;#160;&amp;#160;The Convertible Notes and accrued interest were converted into 1,252,550 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; During the years ended December 31, 2012, the Company recorded amortization expense related to the deferred financing costs and the debt discount of $252,248 and $775,637, respectively.&amp;#160;&amp;#160;During the years ended December 31, 2011, the Company recorded amortization expense related to the deferred financing costs and the debt discount of $40,444 and $124,363, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; A summary of the 8% Senior Subordinated Unsecured Convertible Promissory Notes as of December 31, 2012 and 2011 are as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Principal amount&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: original issuance
 discount&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(150,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(150,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: discount related to fair value of derivative warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(377,150&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(377,150&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: discount related to the beneficial conversion feature&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(372,850&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(372,850&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Add: amortization of discount&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;124,363&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: principal amount converted to stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(900,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Carrying value at December 31, 2012 and 2011, respectively&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;124,363&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 4 &amp;#8211; Note Payable&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On December 28, 2012, the Company entered into a premium finance agreement to pay a $140,000 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and&amp;#160;is required&amp;#160;to pay $12,636 in monthly installment for nine months. As of September 30, 2013, the outstanding balance related to the premium finance agreement was $0.&lt;/font&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 6 &amp;#8211; Derivatives&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&amp;#8217;s common stock at prices below such warrants&amp;#8217; respective exercise prices and these provisions could result in modification of the warrants&amp;#8217; exercise price based on a variable that is not an input to the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221; option as defined under FASB ASC Topic No. 815 &amp;#8211; 40. The warrants granted in connection with the issuance of the Company&amp;#8217;s Stock Offering and 2012 Common Stock Offering&amp;#160;(See Note 9), the Convertible Notes (See Note 5) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &amp;#8220;Lower Price&amp;#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; Activities for derivative warrant instruments during the years ended December 31, 2012 and 2011 were as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display:
 inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with Convertible Notes (See Note 5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;287,061&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;377,150&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Placement agent warrants related to issuance of Convertible Notes (See Note 5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;143,532&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;188,579&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,972,785&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,591,900&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Placement agent warrants related to issuance of stock (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;986,393&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,295,950&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(13,966&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,389,771&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,439,613&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;242,190&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;318,087&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Placement agent warrants related to Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;121,095&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;159,044&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with 2012 Common Stock Offering-A (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,118,988&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,409,554&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with 2012 Common Stock Offering-B (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,559,505&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,665,697&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Placement agent warrants related to 2012 Common Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;467,845&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;499,707&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Transfer from liability classification to equity classification&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3,753,056&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4,231,324&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(685,420&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline;
 font-family: times new roman; font-size: 10pt;"&gt;5,146,338&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On December 19, 2012, as the result of the Share Exchange, it was determined that the floor for resetting the exercise price was met and the exercise price of the certain warrants was set to be $0.26 (before Exchange Ratio adjustment).&amp;#160;Therefore, these warrants were considered indexed to the Company&amp;#8217;s stock and qualified for the scope exception under FASB ASC 815-10 allowing for a transfer from liability classification to equity classification.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; The fair values of the warrants issued in the Company&amp;#8217;s stock and Convertible Notes Offering and the warrants issued to the Company&amp;#8217;s placement agent were recognized as derivative warrant instruments at issuance and are measured at fair value at each reporting period. The Company determined the fair values of these warrants using a modified binomial valuation model.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date, the transfer date on December 19, 2012, and the date for the new grants in January and December 2012. (The market value of common stock, adjusted exercise price and offering price presented does not reflect the impact of the Share Exchange.)&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;January 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 19,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 27,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="28%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display:
 inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Market value of common stock on measurement date (1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.37&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.37&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Adjusted exercise price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.24 - $0.26&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.23 - $0.26&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.41 - $0.83&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.22 - $0.26&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.41 - $0.83&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%"
 valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Risk free interest rate (2)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.10% - 0.77&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.94&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.10% - 0.77&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrant lives in years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" nowrap="nowrap" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4 months/5years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;6 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" nowrap="nowrap" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4 months/5years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"
 width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected volatility (3)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;156&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;157&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;125% - 161&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;161&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;125% - 161&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Range of percentage of existing shares offered (6)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%"
 valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Offering price range (7)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.18 - $0.55&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.13 - $0.56&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.01 - $0.55&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.12 - $0.60&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.01 - $0.55&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0"
 cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="80%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The market value of common stock is based on an enterprise valuation.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="80%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The risk-free interest rate was determined by management using the average of 5 and 7 year and the 3-month Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="80%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="80%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="80%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management has determined that the probability of a stock offering is 25% for each quarter of the next five years.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(6)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="80%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management estimates that the range of percentages of existing shares offered in each stock offering will be between 35% of the shares outstanding.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(7)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="80%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Represents the estimated offering price range in future offerings as determined by management.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 5 &amp;#8211; Derivatives&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&amp;#8217;s common stock at prices below such warrants&amp;#8217; respective exercise prices and these provisions could result in modification of the warrants&amp;#8217; exercise price based on a variable that is not an input to the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221; option as defined under FASB ASC Topic No. 815 &amp;#8211; 40. The warrants granted in connection with the issuance of the Company&amp;#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &amp;#8220;Lower Price&amp;#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;Activities for derivative warrant instruments during the nine months ended September 30, 2013 were as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5,146,338&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Reclassification to paid-in capital&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3,130,536&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(600,880&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(216,112&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display:
 inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, September 30, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,015,802&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at September 30, 2013 and December 31, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%"
 valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Market value of common stock on measurement date (1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.17&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Adjusted exercise price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.48 - $0.81&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.50 - $2.475&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Risk free interest rate (2)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.10% - 0.77&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.33&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrant lives in years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4 months/5 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0 days/4.22 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family:
 times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected volatility (3)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;125% - 161&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;139&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25% - 40&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The market value of common stock is based on an enterprise valuation.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="87%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The risk-free interest rate was
 determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="87%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top" style="text-align: justify;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="87%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="87%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 7 &amp;#8211; Income Taxes&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&amp;#8217;s deferred tax assets and liabilities at December 31, 2012 and 2011 are as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net operating losses&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;13,609,036&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;13,089,314&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Share-based compensation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,497,556&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent:
 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;741,420&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Other differences in tax basis&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;233,043&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,749&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;15,339,635&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;13,835,483&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(15,339,635&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block;
 margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(13,835,483&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Deferred tax assets, net&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; As of December 31, 2012, for U.S. federal income tax reporting purposes, the Company has approximately $43 million of unused net operating losses (&amp;#8220;NOLs&amp;#8221;) available for carry forward to future years. The benefit from the carry forward of such NOLs will begin expiring during the year ended December 31, 2020. Because United States tax laws limit the time during which NOL carry forwards may be applied against future taxable income, the Company may be unable to take full advantage of its NOL for federal income tax purposes should the Company generate taxable income. Further, the benefit from utilization of NOLs carry forwards could be subject to limitations due to material ownership changes that could occur in the Company as it continues to raise additional capital. Based on such limitations, the Company has significant NOLs for which realization of tax benefits is uncertain.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; The difference between the income tax provision and the amount that would result if the U.S. Federal statutory rate of 34% were applied to pre-tax income (loss) for the years ended December 31, 2012 and 2011 are as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="46%" valign="bottom" style="border-bottom: black 2px solid;" colspan="14"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;For the years ended&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="22%" valign="bottom" style="border-bottom: black 2px solid;" colspan="6"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="22%" valign="bottom" style="border-bottom: black 2px solid;" colspan="6"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Federal income taxes at 34%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2,842,810&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-34.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1,171,230&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-34.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Share-based compensation costs&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;756,136&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;9.04&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;736,796&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;21.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value of derivatives&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;233,043&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2.79&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,748&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.13&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Amortization of debt discounts&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times
 new roman; font-size: 10pt;"&gt;349,480&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4.18&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;56,033&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.63&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,504,151&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;17.99&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;373,653&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;10.85&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Provision for income tax&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 8 &amp;#8211; Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" style="text-align: right;"&gt;
&lt;div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;a.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Abbott Biotherapeutics Corp &amp;#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5) First commercial sale&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(6) after the first $10,000,000 in net sales&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;As of December 31, 2012, the Company met its first milestone and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012. &amp;#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" style="text-align: right;"&gt;
&lt;div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;b.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;MSKCC &amp;#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and an annual research funding of $50,000 for as long as the agreement is in force.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;for each licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company expects to file the NDA for regulatory approval in 2015.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" style="text-align: right;"&gt;
&lt;div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;c.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Oak Ridge National Laboratory (ORNL) &amp;#8211; API has contracted to purchase radioactive material to be used for research and development through December 2012. API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end. &amp;#160;The Company is currently negotiating the 2013 agreement.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="4%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;d.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab&amp;#8482;-A) used in the Company clinical trials, Phase I and Phase II. &amp;#160;The total project is estimated to cost $1,859,333 and requires a 12.5% down payment of the total estimated project cost. &amp;#160;The down payment totaling $239,000 was paid in 2007 and 2012. &amp;#160;On August 6, 2012, the agreement was
 amended to provide for additional services. &amp;#160;The total project is now estimated at $1,997,732. &amp;#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="4%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;e.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody) and eventually develop a clinical trial with Actinium 225. &amp;#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval. &amp;#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. &amp;#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA. &amp;#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter. &amp;#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year. &amp;#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug. &amp;#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="4%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;f.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On March 27, 2012, the Company entered into a clinical trial agreement with Memorial Sloan Kettering Cancer Center. &amp;#160;The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623. &amp;#160;The amount due of $79,623 was paid on July 10, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="4%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;g.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On May 9, 2011, Actinium entered into a transaction management agreement with Jamess Capital Group, LLC. (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Sandesh Seth, a Director of Cactus&amp;#160;Ventures, Inc.&amp;#160;by virtue of his position as a director of Actinium Pharmaceuticals.&amp;#160; Mr. Seth is a Managing Partner of the consulting firm some of whose member interests are held by entities owned by officers and employees of the Placement Agent.&amp;#160; None of Cactus&amp;#8217; current officers or directors had a prior relationship or affiliation with Cactus prior to the closing of the Share Exchange.&amp;#160; Pursuant to the agreement, the management firm was engaged to provide consulting services to Actinium related to the consummation of a going public transaction for Actinium.&amp;#160; The management firm received a monthly fee of $12,500 which is terminable by the Company three months after the effective date of the going public transaction and designees of Jamess, including entities affiliated with Mr. Seth, were issued warrants to purchase common stock equal to 10% of the fully-diluted capital stock of the Company as of the effective date of the going public transaction. The fully diluted shares for this calculation included all issued and outstanding shares as well as those reserved under the Employee Stock Option Plan.&amp;#160; Jamess Capital Group does not retain&amp;#160;beneficial ownership of the warrants as they were&amp;#160;issued to designees of the members in amounts which do not qualify either Jamess or the warrant holders for inclusion in the beneficial ownership table.&amp;#160; The warrants contain&amp;#160;a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver.&amp;#160; The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transferred until the earlier of twelve months from the closing date of the Pubco Transaction; or for six months after the planned Registration Statement is declared effective.&amp;#160;The consulting firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="4%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;h.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC. &amp;#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $19,749. &amp;#160;During the clinical trial additional fees apply and will be invoiced when applicable. &amp;#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="4%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;i.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center. &amp;#160;The total estimated cost of conducting the clinical trial is $481,204, which includes a non- refundable institutional fee of $14,500. &amp;#160;The estimated cost is based on treating 24 patients through 2013. &amp;#160;Upon execution of the agreement, the Company is required to make a payment of $33,946. &amp;#160;&amp;#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="4%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;j.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University. &amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225. &amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company. &amp;#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. &amp;#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&lt;br /&gt; &lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="4%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;k.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="79%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania. &amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225. &amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company. &amp;#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue, 3rd Floor, New York, NY 10017. &amp;#160;The agreement terminates January 31, 2013 unless a Notice of Termination is provided to the landlord 60 days prior to January 1, 2013. &amp;#160;The agreement automatically renews on a month-to-month basis and requires a two month notice of termination. &amp;#160;The Company paid a two month refundable deposit.&lt;/font&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 6 &amp;#8211; Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Employment Contracts&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On September 16, 2013, the Company&amp;#8217;s Board of Directors appointed Dr. Kaushik J. Dave as its new Chief Executive Officer (CEO)&amp;#160;and Director. Material terms of the Employment Agreement are as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;a&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;A base salary at an annual rate of $350,000, which will be re-evaluated upon the&amp;#160;six month anniversary of the start date and reimbursement of certain expenses.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;b&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The CEO shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to which the Board shall award bonuses to the CEO, based upon the achievement of written individual and corporate objectives such as the Board shall determine.&amp;#160;&amp;#160;Upon the attainment of such performance objectives, the CEO shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;c&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;An option to purchase common shares of the Company and restricted stock (the &amp;#8220;Grant&amp;#8221;).&amp;#160;&amp;#160;The Grant will consist of (i) an option grant to purchase 675,000 common shares of the Company; (ii) 125,000 shares of restricted and (iii) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work.&amp;#160;&amp;#160;An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date.&amp;#160;&amp;#160;As of October 25, 2013, the option has not been granted by the Board.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;License and Research Agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;a.&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Abbott Biotherapeutics Corp &amp;#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display:
 block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5) First commercial sale&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline;
 font-family: times new roman; font-size: 10pt;"&gt;(6) after the first $10,000,000 in net sales&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&amp;#160;&amp;#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;b.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top" style="text-align: justify;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Memorial Sloan Kettering Cancer Center (MSKCC) &amp;#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and annual research funding of $50,000 for as long as the agreement is in force.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval for each licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="78%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company expects to file the NDA for regulatory approval in the 2016-2017 time frame.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;c.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Oak Ridge National Laboratory (ORNL) &amp;#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&amp;#160;&amp;#160;The Company is currently negotiating the 2013 agreement.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;d.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase I and Phase II.&amp;#160;&amp;#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&amp;#160;&amp;#160;The down payment totaling $239,000 was paid in 2007 and 2012.&amp;#160;&amp;#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&amp;#160;&amp;#160;The total project is now estimated at approximately $2.2 million.&amp;#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;e.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&amp;#160;&amp;#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&amp;#160;&amp;#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&amp;#160;&amp;#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&amp;#160;&amp;#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&amp;#160;&amp;#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&amp;#160;&amp;#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&amp;#160;&amp;#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;f.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On March 27, 2012, the Company entered into a clinical trial agreement with MSKCC.&amp;#160;The Company will pay $31,185 for each patient that has
 completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623.&amp;#160;&amp;#160;The amount due of $79,623 was paid on July 10, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;g.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&amp;#160;&amp;#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $19,749.&amp;#160;&amp;#160;During the clinical trial additional fees apply and will be invoiced when applicable.&amp;#160;&amp;#160;The amount due has not been invoiced but accrued by the Company as of September 30, 2013.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;h.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&amp;#160;&amp;#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&amp;#160;&amp;#160;The estimated cost is based on treating 24 patients through 2013.&amp;#160;&amp;#160;Upon execution of the agreement, the Company is required to make a payment of $33,946.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;i.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&amp;#160;&amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="6%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="84%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="right" width="6%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;j.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="84%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&amp;#160;&amp;#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&amp;#160;New York, NY. The agreement terminated on May 31, 2013. On June 1, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&amp;#160;New York, NY. This agreement terminates on December 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination. The Company paid a one month refundable deposit.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On&amp;#160;February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO. Pursuant to the agreement, the Company paid the former CEO $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid the former CEO a
 performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;div  style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; font-weight: bold; display: inline;"&gt;Note 9 &amp;#8211; Equity&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; From inception to December 31, 2010, the Company raised $42,711,791 by issuing 5,707,259 shares of the Company&amp;#8217;s stock and issued 66,402 shares, valued at $398,810, for services.&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; During 2011, the Company raised $6,184,967 by selling 7,891,141 shares of the Company&amp;#8217;s stock and warrants to purchase 19,972,785 shares of the Company&amp;#8217;s stock through an offering (&amp;#8220;Stock Offering&amp;#8221;).&amp;#160;&amp;#160;A net amount of $5,379,367 was received by the Company in 2011. The Company paid Laidlaw &amp;amp; Company (UK) Ltd. (&amp;#8220;Laidlaw &amp;amp; Co.&amp;#8221;), the placement agent, total cash fees of $742,196, which consisted of placement agent commission of $618,497 and expense reimbursement of $123,699. The Company also issued Laidlaw &amp;amp; Co. warrants to purchase an aggregate of 986,393 shares of the Company&amp;#8217;s common stock, with an exercise price of $0.78 per share and a term of 7 years. These placement agent warrants were valued at their grant date fair value of $188,579.&amp;#160;In addition, the Company paid Laidlaw &amp;amp; Co.&amp;#8217;s outside counsel, McCormick &amp;amp; O&amp;#8217;Brien PLLC, $60,904 for its services as the placement agent&amp;#8217;s legal counsel and Signature Bank $2,500 for the bank escrow fee.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; During 2012, the Company raised $759,300 by selling 968,759 shares and warrants to purchase 242,190 shares of the Company&amp;#8217;s common stock under the Company&amp;#8217;s Stock Offering.&amp;#160;&amp;#160;A net amount of $660,164 was received by the Company in 2012. The Company paid Laidlaw &amp;amp; Co. total cash fees of $91,116, which consisted of placement agent commission of $75,930 and expense reimbursement of $15,186. The Company also issued Laidlaw &amp;amp; Co. warrants to purchase an aggregate of 121,095 shares of the Company&amp;#8217;s common stock, with an exercise price of $0.78&amp;#160;per share and a term of 7 years. These placement agent warrants were valued at their grant date fair value of $159,044. In addition, the Company paid Laidlaw &amp;amp; Co.&amp;#8217;s outside counsel, McCormick &amp;amp; O&amp;#8217;Brien PLLC, $8,020 for its services as the placement agent&amp;#8217;s legal counsel.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; In 2012, the Company also raised $5,151,450 through an offering of 3,118,988 shares of its common stock and &amp;#8220;A Warrants&amp;#8221; to purchase 3,118,988 shares of the Company&amp;#8217;s common stock, exercisable at a price of $1.65 per share for a period of 120 days from the day of the final closing of the offering, and &amp;#8220;B Warrants&amp;#8221; to purchase 1,559,505 shares of the Company&amp;#8217;s common stock, exercisable at a price of $2.48 per share for a period of 5 years from the date of the final closing of the offering. (&amp;#8220;2012 Common Stock Offering&amp;#8221;)&amp;#160;&amp;#160;A net amount of $4,469,776 was received by the Company. Pursuant to the 2012 Common Stock Offering agreement, the Company paid Laidlaw &amp;amp; Co. total cash fees of $618,174, which consisted of placement agent commission of $515,145 and expense reimbursement of $103,029. The Company also issued the placement agent warrants to purchase an aggregate of 467,845 shares of the Company&amp;#8217;s common stock, with an exercise price of $0.78 per share and a term of 5 years. These placement agent warrants were valued at $499,707 and recorded as derivative liabilities.&amp;#160;&amp;#160;In addition, the Company paid the Laidlaw &amp;amp; Co.&amp;#8217;s outside counsel, Richardson &amp;amp; Patel, LLP, $60,000 for its services as the Laidlaw &amp;amp; Co.&amp;#8217;s legal counsel and Signature Bank $3,500 for the bank escrow fee.&lt;/font&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; During 2012, the Company&amp;#8217;s convertible notes, plus accrued interest, were converted to 1,252,550 shares of the Company&amp;#8217;s common stock as a result of the 2012 Common Stock Offering.&lt;/font&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; As a result of the Share Exchange described in Note 1, the Company issued 400,000 shares to the original shareholders of the Company and 1,986,566 shares to the former shareholders of Actinium.&lt;/font&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; Placement Agent &amp;#8211;&lt;/font&gt; In connection with the money raised in 2011, the Company issued Laidlaw &amp;amp; Co. warrants to purchase an aggregate of 1,129,925 shares of common stock, with an exercise price of $0.78 per share.&amp;#160;&amp;#160;With the money raised in 2012, the Company issued Laidlaw &amp;amp; Co. warrants to purchase an aggregate of 588,940 shares of common stock, with an exercise price of $0.78 per share.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display:
 block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; Management Firm &amp;#8211;&lt;/font&gt; In 2011, the Company entered into a&amp;#160;management agreement with Jamess Capital Group, LLC (formerly, AmerAsia Inc., &amp;#8220;Jamess&amp;#8221;) for Jamess to provide consulting services related to funding and Actinium becoming a publicly traded entity.&amp;#160;In 2011, the Company incurred $96,744 in management fees. In addition, Actinium issued Jamess warrants to purchase an aggregate of 1,974,774 shares of common stock, with an exercise price of $0.01 per share. The warrants have a fair value of $2,153,442 (see Note 11) and included a cashless exercise provision.&amp;#160;&amp;#160;In 2012, the Company issued Jamess warrants to purchase 1,716,340 shares of common stock with an exercise price of $0.01 per share. The warrants have a fair value of $1,957,754 (see Note 11) and included a cashless exercise provision.&lt;/font&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Note 7 &amp;#8211; Equity&lt;/font&gt;&lt;/div&gt;
&lt;div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Approval of the 2013 Stock Plan&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;The Board approved the Company&amp;#8217;s 2013 Stock Plan.&amp;#160;&amp;#160;The expiration date of the plan is September&amp;#160;&amp;#160;9, 2023&amp;#160;and the total number of underlying shares of the Company&amp;#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 2,750,000 shares.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Approval of the Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;The Board approved the Company&amp;#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September&amp;#160;&amp;#160;9, 2023&amp;#160;&amp;#160;and the total number of shares of the Company&amp;#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 450,000 shares.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;The following is a summary of&amp;#160;option activities:&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family:
 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px;
 border-bottom-style: solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="3"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="52%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;2,330,134&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0.96&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;8.91&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;685,800&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="52%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td
 width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="52%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Cancellation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(49,950&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="52%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="52%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, September 30, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;2,280,184&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0.95&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;8.17&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,609,035&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30, 2013&amp;#160;was $1,014,474.&lt;/font&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;The following is a summary of warrant activities:&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal;
 font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div align="right"&gt;
&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"
 colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="2"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="2"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="bottom" colspan="2"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="52%"
 valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;12,770,636&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0.97&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;4.48&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160; 6,114,768&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="52%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Warrants exercised&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(2,304,910&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="52%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Warrants expired&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(1,023,784&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font
 style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" width="52%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, September 30, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;9,441,942&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0. 77&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;5.09&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;9,611,403&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;During the three months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $95,971, and $72,100, respectively. During the nine months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $284,371 and $168,000, respectively.&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 10 &amp;#8211; Stock Option Plan&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; The Company has adopted a 2003 Stock Plan under which it may grant up to 757,575 options to purchase common stock. The 2003 Stock Plan was amended in 2008 to increase the number of shares that it may grant up to 978,154. Option awards are generally granted with an exercise price equal to the market price of the Company&amp;#8217;s stock at the date of the grant. However, since the Company is not publicly traded, the fair market value of the stock represents the Board of Directors&amp;#8217; best estimate, based on the information available, on the date of the grant. The awards generally vest over a four or five year period at a rate of approximately 2% per month.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; In 2011, the 2003 Stock Plan was amended to increase the number of shares by 3,217,880.&amp;#160;&amp;#160;Total shares reserved for issuance under the Plan will be increased to 6,155,280.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; In accordance with the terms of the 2012 Common Stock Offering, the Company adopted a 2012 Employee Stock Option Plan (&amp;#8220;2012 ESOP&amp;#8221;) and reserved 15% of the total issued and outstanding shares as of the final closing of the 2012 Common Stock Offering.&amp;#160;&amp;#160;Total shares reserved for issuance under the 2012 ESOP was 9,455,776 shares.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; During 2006, options to purchase 206,060 shares of common stock were granted to several employees at an exercise price of $1.35 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $1,051,281 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 4.29% (2) expected life of 5 years, (3) expected volatility of 156%, and (4) zero expected dividends.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; During 2007, options to purchase 113,220 shares of common stock were granted to several employees at an exercise price of $1.35 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $137,652 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 3.46% (2) expected life of 5 years, (3) expected volatility of 143%, and (4) zero expected dividends.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; During 2008, options to purchase 69,941 shares of common stock were granted to an employee at an exercise price of $0.90 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $44,159 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 3.46% (2) expected life of 5 years, (3) expected volatility of 139%, and (4) zero expected dividends.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; During 2009, 20,613 options to one employee were cancelled as the result of termination of the employment and 128,050 options to one employee were forfeited as the employee deceased during the year.&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; During the year of 2010, options to purchase 33,300 shares of common stock were granted to an employee at an exercise price of $0.90 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $24,996 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 2.16% (2) expected life of 5 years, (3) expected volatility of 171%, and (4) zero expected dividends.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; In February 2012, the Company re-priced 273,859 units of employee stock options to reflect the current per share fair market value of the Company&amp;#8217;s common stock. The exercise prices of all of the current outstanding stock options were reduced to $1.28 per share. The Company recorded an incremental compensation cost of $34,879 as a result of the re-pricing of
 options.&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; During 2012, options to purchase 2,056,275 shares of common stock were issued to several employees and consultants at an exercise price ranging from $0.78 to $1.5 per share.&amp;#160;&amp;#160;These options have a term of 10 years and vest over a 4 year period. The fair value of $1,519,777 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.8% (2) expected life of 7 years, (3) expected volatility of 160.44% &amp;#126; 162.49%, and (4) zero expected dividends.&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; The following is a summary of stock option activities for the years ended December 31, 2012 and 2011:&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 95%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times
 new roman; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;273,859&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.29&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5.51&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;273,859&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.29&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5.51&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,056,275&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.96&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;8.89&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="47%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,330,134&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.96&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;8.91&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;685,800&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160; All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31, 2012 and 2011 were $1,998,435 and $14,528, respectively. During the years ended December 31, 2012 and 2011, the Company recorded option expense of $266,172 and $19,935, respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<fil:WarrantsTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; font-weight: bold; display: inline;"&gt;Note 11 &amp;#8211; Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; During the year ended December 31, 2011, warrants to purchase 1,974,774 shares of common stock were granted to the Management Firm at an exercise price of $0.01 per share. These warrants have a term of 7 years and vest immediately. Fair value of $2,153,442 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate ranging from 1.92% to 3.17%, (2) warrant life of 10 years, (3) expected volatility ranging from 64.77% to 70.72%, and (4) zero expected dividends. The management firm receives warrants equal to ten (10%) percent of the issued and outstanding capital stock of the Company on a fully-diluted basis on the effective date of the agreement.&amp;#160;&amp;#160;The warrants are subject to weighted average non-dilution provisions to be calculated on the basis of the post-money fully diluted capitalization of the Company upon closing of any transaction, financing or otherwise, up to and including the Public Company transaction, provided that such anti-dilution provisions shall not extend beyond the date of any exercise of the warrants by the management firm prior to the closing of the Public Company transaction. Since these warrants vest immediately, the Company recorded the entire fair value of $2,153,442 as stock-based compensation expense during the year on these warrants issued by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; During the year ended December 31, 2011, the Company also issued the following warrants:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued with convertible notes (See Note 5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;287,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued to investors with Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1,972,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Placement agent warrants related to issuance of:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Convertible Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;143,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock Offering (See Note 6 and Note 9)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"
 style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;986,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3,389,742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; During the year ended December 31, 2012, warrants to purchase an aggregate of 1,716,340 shares of common stock were granted to the Management Firm at an exercise price of $0.01 per share. These warrants have a term of 7 years and vest immediately. Fair value of $1,957,754 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 1.82%, (2) warrant life of 7 years, (3) expected volatility of 60.64%, and (4) zero expected dividends.&amp;#160;&amp;#160;Since these warrants vest immediately, the Company recorded the entire fair value of $1,957,754 as stock-based compensation expense during the year on these warrants issued by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; During the year ended December 31, 2012, the Company also issued the following warrants:&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued to investors with Stock Offering (See Note 6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;242,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued to investors with Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;4,678,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Placement agent warrants related to issuance of:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%"
 valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock Offering (See Note 6 and Note 9)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;121,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2012 Common Stock Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;467,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued to investors with stock &amp;#8211; accrued dividend&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;180,115&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;5,689,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160; The following is a summary of warrant activities for the years ended December 31, 2011 and 2012:&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size:
 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: center;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Number of&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"
 valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Outstanding, December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt;
 text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;5,364,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;6.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Outstanding, December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;5,364,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display:
 inline;"&gt;0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;6.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3,261,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;7,406,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size:
 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;12,770,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;0. 97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;4.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;6,114,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</fil:WarrantsTextBlock>
<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&lt;/font&gt;&lt;/font&gt;
&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 12 &amp;#8211; Employee Defined Contribution Plan&lt;/font&gt;&lt;/div&gt;
&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&lt;/font&gt;&lt;/font&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&lt;/font&gt;&lt;/font&gt;
&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; In 2004, the Company established an employee deferred contribution plan. The plan requires 12 consecutive months of service and a minimum of 500 hours of service for participation. The Plan provides for employer matching of 50% of the employee contribution and discretionary contributions. Employees can contribute up to the maximum allowable under the Internal Revenue Service Code Section 401(k). The amount contributed by the Company for the years ended December 31, 2012 and 2011 was $8,942 and $8,885, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; font-weight: bold; display: inline;"&gt;Note 13 &amp;#8211; Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; In February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO, Jack Talley. Pursuant to the agreement, the Company will pay Mr. Talley in 2 equal installments the aggregate amount of $250,000 and a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012. The $60,000 bonus was included in the accounts payable and accrued liabilities on the Company&amp;#8217;s balance sheet at December 31, 2012.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 8 &amp;#8211; Subsequent Events&lt;/font&gt;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management has evaluated subsequent events and has concluded no events warrant disclosure.&lt;/font&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BusinessCombinationsPolicy contextRef="Context_FYE__31-Dec-2012">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Nature of Business &amp;#8211; Actinium Pharmaceuticals, Inc (Formerly&lt;/font&gt; Cactus Ventures, Inc.) (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Cactus&amp;#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that is in the market for a merger with an appropriate operating company.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company agreed to acquire 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;Actinium&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange was closed on December 28, 2012 when shareholders representing over 20% of the issued and outstanding shares of Actinium had finished the exchange process.&amp;#160;&amp;#160;On August 22, 2013, shareholders representing 38% of the issued and outstanding shares of Actinium completed the exchange.&amp;#160;&amp;#160;As a result of the Share Exchange, the former shareholders of Actinium became the controlling shareholders of the Company. At the closing, each Actinium shareholder shall receive 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Cactus common stock for each Actinium share exchanged. At the closing, all of the Actinium shareholders&amp;#8217; options and warrants to purchase Actinium common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Cactus common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein Actinium is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="letter-spacing: 9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Actinium, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;Actinium&amp;#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &amp;#160;Actinium&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="letter-spacing: 9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; As a result of the Share Exchange, the Company is now a holding company operating through Actinium, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
<us-gaap:BusinessCombinationsPolicy contextRef="Context_9ME__30-Sep-2013">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Nature of Business &amp;#8211;&lt;/font&gt; Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Actinium&amp;#8221;, &amp;#8220;Cactus&amp;#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that&amp;#160;was in the market for a merger with an appropriate operating company.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="letter-spacing: 9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&amp;#160;&amp;#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="letter-spacing: 9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;API&amp;#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="letter-spacing: 9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="letter-spacing: 9pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&amp;#160;&amp;#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Basis of Presentation - Unaudited Interim Financial Information &amp;#8211;&lt;/font&gt; The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&amp;#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.&lt;/font&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<fil:DevelopmentStageCompanyPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;p&gt;&lt;strong&gt;&lt;font size="2"&gt;Development Stage Company &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company is considered a development stage company and has had no commercial revenue to date.&lt;/p&gt;</fil:DevelopmentStageCompanyPolicyTextBlock>
<fil:DevelopmentStageCompanyPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Development Stage Company &amp;#8211;&lt;/font&gt; The Company is considered a development stage company and has had no commercial revenue to date.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</fil:DevelopmentStageCompanyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Principles of Consolidation &amp;#8211;&lt;/font&gt;&amp;#160;The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Principles of Consolidation &amp;#8211;&lt;/font&gt; The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_FYE__31-Dec-2012">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/font&gt; The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:UseOfEstimates contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/font&gt; The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Reclassification &amp;#8211;&lt;/font&gt;&amp;#160;Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Reclassification &amp;#8211;&lt;/font&gt; Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/font&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At December 31, 2012 and 2011, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/font&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At June 30, 2013 and December 31, 2012, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Property and Equipment &amp;#8211;&lt;/font&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Property and Equipment &amp;#8211;&lt;/font&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Impairment of Long-Lived Assets &amp;#8211;&lt;/font&gt; Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Impairment of Long-Lived Assets &amp;#8211;&lt;/font&gt; Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Derivatives &amp;#8211;&lt;/font&gt; All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Derivatives &amp;#8211;&lt;/font&gt; All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_FYE__31-Dec-2012">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/font&gt; Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 36pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 36pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 36pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of December 31, 2012 and 2011. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman;
 display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;At December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%"
 valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;4,439,613&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;4,439,613&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME__30-Sep-2013">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Fair Value of Financial Instruments &amp;#8211;&lt;/font&gt; Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 45pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of June 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td
 align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;At June 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;2,957,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;2,957,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font
 style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Income Taxes &amp;#8211;&lt;/font&gt; The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Income Taxes &amp;#8211;&lt;/font&gt; The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_FYE__31-Dec-2012">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Research and Development Costs &amp;#8211;&lt;/font&gt; Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME__30-Sep-2013">&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Research and Development Costs &amp;#8211;&lt;/font&gt; Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Share-Based Payments &amp;#8211;&lt;/font&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Share-Based Payments &amp;#8211;&lt;/font&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt; Earnings (Loss) Per Common Share &amp;#8211;&lt;/font&gt; The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&amp;#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &amp;#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been anti dilutive. For the year ended December 31, 2012, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,596 shares of the Company&amp;#8217;s common stock. For the year ended December 31, 2011, potentially issuable shares includes options and warrants&amp;#160;to purchase 273,859 shares of the Company&amp;#8217;s common stock and notes payable convertible to 3,448,276 shares of the Company&amp;#8217;s common stock have been excluded from the calculation.&lt;/font&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;&amp;#160; Earnings (Loss) Per Common Share &amp;#8211;&lt;/font&gt; The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&amp;#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &amp;#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the six months ended June 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,535,694 shares of the Company&amp;#8217;s common stock. For the six months ended June 30, 2012, potentially issuable shares includes options and warrants&amp;#160;to purchase 6,842,528 shares of the Company&amp;#8217;s common stock and notes payable convertible to 815,275 shares of the Company&amp;#8217;s common stock have been excluded from the calculation.&lt;/font&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Recent Accounting Pronouncements &amp;#8211;&lt;/font&gt;&amp;#160;The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.&lt;/font&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Recent Accounting Pronouncements &amp;#8211;&lt;/font&gt; The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.&lt;/font&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;p&gt;&lt;strong&gt;&lt;font size="2"&gt;Subsequent Events &amp;#8211;&lt;/font&gt;&lt;/strong&gt;&amp;#160;The Company&amp;#8217;s management reviewed all material events from January 1, 2013 through March 15, 2013.&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Subsequent Events &amp;#8211;&lt;/font&gt; The Company&amp;#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/font&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display:
 block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,439,613&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,439,613&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At September 30, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;
&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Qualified R&amp;amp;D costs incurred by the Company&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;655,786&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Reimbursements received from MSKCC&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;237,834&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;966,341&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;Lives&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Office equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="10%" valign="bottom"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;156,162&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;153,804&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Furniture and fixture&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;7 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,292&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,292&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total property, plant and equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;157,454&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;155,096&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(153,863&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="56%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new
 roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="56%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,233&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="57%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;Lives&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Office equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="9%" valign="bottom"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;162,384&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;156,162&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Furniture and fixture&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="9%" valign="bottom"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;7 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,100&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,292&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left"
 width="57%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;165,484&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;157,454&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="57%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Loss on disposition of equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4,122&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="57%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="57%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;6,918&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfDebtTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Principal amount&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: original issuance discount&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(150,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(150,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: discount related to fair value of derivative warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%"
 valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(377,150&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(377,150&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: discount related to the beneficial conversion feature&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(372,850&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(372,850&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Add: amortization of discount&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;124,363&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: principal amount converted to stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(900,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Carrying value at December 31, 2012 and 2011, respectively&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;124,363&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
<us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with Convertible Notes (See Note 5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;287,061&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;377,150&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Placement agent warrants related to issuance of Convertible Notes (See Note 5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;143,532&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;188,579&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,972,785&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,591,900&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Placement agent warrants related to issuance of stock (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;986,393&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,295,950&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(13,966&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,389,771&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,439,613&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;242,190&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;318,087&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Placement agent warrants related to Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;121,095&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;159,044&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with 2012 Common Stock Offering-A (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,118,988&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,409,554&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants issued with 2012 Common Stock Offering-B (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,559,505&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,665,697&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Placement agent warrants related to 2012 Common Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;467,845&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;499,707&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Transfer from liability classification to equity classification&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3,753,056&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4,231,324&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt;
 display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(685,420&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5,146,338&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
<us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5,146,338&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Reclassification to paid-in capital&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3,130,536&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(600,880&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(216,112&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, September 30, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,015,802&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right"
 style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
<fil:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;January 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 19,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 27,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="28%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Market value of common stock on measurement date (1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.37&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.37&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Adjusted exercise price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.24 - $0.26&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.23 - $0.26&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.41 - $0.83&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.22 - $0.26&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.41 - $0.83&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Risk free interest rate (2)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.10% - 0.77&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.94&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new
 roman; font-size: 10pt;"&gt;0.10% - 0.77&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrant lives in years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" nowrap="nowrap" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4 months/5years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;6 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" nowrap="nowrap" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4 months/5years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected volatility (3)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;156&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;157&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;125% - 161&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;161&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%"
 valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;125% - 161&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Range of percentage of existing shares offered (6)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="28%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Offering price range (7)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="3%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.18 - $0.55&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent:
 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.13 - $0.56&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.01 - $0.55&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.12 - $0.60&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.01 - $0.55&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="80%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The market value of common stock is based on an enterprise valuation.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="80%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The risk-free interest rate was determined by management using the average of 5 and 7 year and the 3-month Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="80%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="80%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times
 new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="80%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management has determined that the probability of a stock offering is 25% for each quarter of the next five years.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(6)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="80%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management estimates that the range of percentages of existing shares offered in each stock offering will be between 35% of the shares outstanding.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="right" width="3%" valign="top"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(7)&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="80%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Represents the estimated offering price range in future offerings as determined by management.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</fil:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock>
<fil:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Market value of common stock on measurement date (1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.17&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Adjusted exercise price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.48 - $0.81&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.50 - $2.475&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Risk free interest rate (2)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.10% - 0.77&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.33&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrant lives in years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4 months/5 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0 days/4.22 years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected volatility (3)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;125% - 161&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;139&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%"
 valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25% - 40&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The market value of common stock is based on an enterprise valuation.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="87%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="87%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top" style="text-align: justify;"&gt;
&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="87%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="87%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="3%" valign="top"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td width="87%" valign="top"&gt;
&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</fil:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net operating losses&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;13,609,036&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;13,089,314&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Share-based compensation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,497,556&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;741,420&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Other differences in tax basis&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right"
 width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;233,043&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,749&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;15,339,635&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;13,835,483&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(15,339,635&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(13,835,483&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="66%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left"
 width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Deferred tax assets, net&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="46%" valign="bottom" style="border-bottom: black 2px solid;" colspan="14"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;For the years ended&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="22%" valign="bottom" style="border-bottom: black 2px solid;" colspan="6"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="22%" valign="bottom" style="border-bottom: black 2px solid;" colspan="6"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Federal income taxes at 34%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2,842,810&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-34.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1,171,230&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block;
 margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-34.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Share-based compensation costs&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;756,136&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;9.04&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;736,796&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;21.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value of derivatives&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;233,043&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2.79&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4,748&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline;
 font-family: times new roman; font-size: 10pt;"&gt;0.13&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Amortization of debt discounts&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;349,480&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4.18&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;56,033&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.63&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,504,151&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;17.99&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;373,653&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;10.85&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Provision for income tax&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<fil:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;for each licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;</fil:MilestonePaymentsMilestoneMethodTableTextBlock>
<fil:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember">&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;(5) First commercial sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;(6) after the first $10,000,000 in net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt;
 font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="display: block; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;</fil:MilestonePaymentsMilestoneMethodTableTextBlock>
<fil:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">&lt;div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval&amp;#160;&lt;/font&gt;for each licensed product&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each&amp;#160;&lt;/font&gt;licensed product&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</fil:MilestonePaymentsMilestoneMethodTableTextBlock>
<fil:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember">&lt;div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font
 style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(5) First commercial sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(6) after the first $10,000,000 in net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</fil:MilestonePaymentsMilestoneMethodTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="left"&gt;
&lt;table style="width: 95%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display:
 inline; font-family: times new roman; font-size: 10pt;"&gt;273,859&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.29&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5.51&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times
 new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;273,859&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.29&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5.51&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,056,275&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.96&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;8.89&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td
 align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="47%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="47%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,330,134&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.96&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;8.91&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;685,800&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember">&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Number of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="11%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="11%" valign="bottom" colspan="3"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;2,330,134&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;0.96&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;8.91&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;685,800&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left"
 width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Cancellation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;(49,950&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size:
 10pt; display: inline;"&gt;Outstanding, September 30, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;2,280,184&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;0.95&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;8.17&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;1,609,035&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember">&lt;div align="left"&gt;
&lt;table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;
&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display:
 inline; font-family: times new roman; font-size: 10pt;"&gt;12,770,636&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.97&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4.48&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; 6,114,768&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants exercised&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2,304,910&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrants expired&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1,023,784&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td align="left" width="42%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, September 30, 2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;9,441,942&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0. 77&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5.09&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;
&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" width="9%" valign="bottom"&gt;
&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;9,611,403&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<fil:ScheduleOfWarrantsIssuedTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div style="text-align: justify; margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;During the year ended December 31, 2011, the Company also issued the following warrants:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued with convertible notes (See Note 5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;287,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued to investors with Stock Offering (See Note 9)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1,972,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Placement agent warrants related to issuance of:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Convertible Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;143,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock Offering (See Note 6 and Note 9)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;986,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td
 align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3,389,742&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160; During the year ended December 31, 2012, the Company also issued the following warrants:&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued to investors with Stock Offering (See Note 6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;242,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued to investors with Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;4,678,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Placement agent warrants related to issuance of:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock Offering (See Note 6 and Note 9)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;121,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2012 Common Stock Offering&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;467,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Warrants issued to investors with stock &amp;#8211; accrued dividend&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt;
 text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;180,115&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;5,689,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;</fil:ScheduleOfWarrantsIssuedTableTextBlock>
<fil:SummaryOfWarrantActivitiesTableTextBlock contextRef="Context_FYE__31-Dec-2012">&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: center;" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Number of&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left"
 valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Outstanding, December 31, 2010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td
 align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;-&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;5,364,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;6.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left"
 width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Outstanding, December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;5,364,557&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;6.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3,261,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;7,406,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;1.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;3.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%"
 valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;12,770,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;0. 97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;4.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;6,114,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-size: 10pt; font-family: times new roman; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;</fil:SummaryOfWarrantActivitiesTableTextBlock>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">4439613</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2011_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2011_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2011_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">4439613</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">3574958</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">3574958</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">2757966</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2757966</us-gaap:DerivativeLiabilities>
<fil:PercentageOfOwnershipInterestToBeAcquired contextRef="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">1.00</fil:PercentageOfOwnershipInterestToBeAcquired>
<fil:PercentageOfOwnershipInterestToBeAcquired contextRef="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="3">0.937</fil:PercentageOfOwnershipInterestToBeAcquired>
<fil:CommonStockIssuableInConsiderationForEquityInterestAcquisition contextRef="Context_Custom_01-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">0.99</fil:CommonStockIssuableInConsiderationForEquityInterestAcquisition>
<fil:CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage contextRef="Context_Custom_01-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember">Approximately 99% of the issued and outstanding common stock immediately after the closing of the Share Exchange, par value $0.01 per share, of the Company. The Share Exchange was closed on December 28, 2012.</fil:CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_FYE__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">Seven years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_FYE__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">Five years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">Seven years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">Five years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_01-Dec-2012_28-Dec-2012" unitRef="shares" decimals="3">0.333</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_20-Sep-2013_25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="3">0.333</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE__31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">273859</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE__31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember" unitRef="shares" decimals="0">3448276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">1968829</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember" unitRef="shares" decimals="0">1152692</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">5861044</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="0">13831762</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE__31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">2330134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE__31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">12770596</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">9441942</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember" unitRef="shares" decimals="0">2280184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<fil:PercentageOfSharesExchangedInShareExchangeProgramme contextRef="Context_9ME__30-Sep-2013_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="pure" decimals="2">0.38</fil:PercentageOfSharesExchangedInShareExchangeProgramme>
<fil:BusinessAcquisitionNumberOfSharesExchanged contextRef="Context_Custom_20-Sep-2013_25-Sep-2013" unitRef="shares" decimals="0">1322055</fil:BusinessAcquisitionNumberOfSharesExchanged>
<fil:BusinessAcquisitionNumberOfSharesExchanged contextRef="Context_Custom_20-Sep-2013_25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="0">3970137</fil:BusinessAcquisitionNumberOfSharesExchanged>
<fil:QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">655786</fil:QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty>
<fil:QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<fil:ReimbursementsReceivedFromRelatedParty contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">966341</fil:ReimbursementsReceivedFromRelatedParty>
<fil:ReimbursementsReceivedFromRelatedParty contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">237834</fil:ReimbursementsReceivedFromRelatedParty>
<fil:NumberOfPatients contextRef="Context_Custom_01-Jan-2012_31-Jan-2012_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="Note" decimals="INF">2</fil:NumberOfPatients>
<fil:NumberOfPatients contextRef="Context_Custom_01-Feb-2012_29-Feb-2012_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="Note" decimals="INF">2</fil:NumberOfPatients>
<fil:NumberOfPatients contextRef="Context_Custom_01-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="Note" decimals="INF">24</fil:NumberOfPatients>
<fil:AmountPaidUnderAgreementInYearTwoThousandEleven contextRef="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</fil:AmountPaidUnderAgreementInYearTwoThousandEleven>
<fil:AmountPaidUnderAgreementInYearTwoThousandTwelve contextRef="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">200000</fil:AmountPaidUnderAgreementInYearTwoThousandTwelve>
<fil:AmountPaidUnderAgreementInYearTwoThousandThirteen contextRef="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">250000</fil:AmountPaidUnderAgreementInYearTwoThousandThirteen>
<fil:MaintenanceFeesAndResearchPayments contextRef="Context_Custom_20-May-2011_19-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">50000</fil:MaintenanceFeesAndResearchPayments>
<fil:AmountPaidUnderAgreement contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">100000</fil:AmountPaidUnderAgreement>
<fil:AdditionalAmountDueUnderAgreement contextRef="Context_As_Of__21-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">150000</fil:AdditionalAmountDueUnderAgreement>
<fil:DescriptionOfConditionForTerminationOfForbearancePeriod contextRef="Context_Custom_01-Apr-2010_30-Apr-2010_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">The forbearance period terminated on October 30, 2011, when the Company satisfied a financing condition to the termination of the forbearance period by raising in excess of $3,000.000 in new equity financing.</fil:DescriptionOfConditionForTerminationOfForbearancePeriod>
<fil:TerminationDateOfForbearanceAgreement contextRef="Context_Custom_01-Apr-2010_30-Apr-2010_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember">2011-10-30</fil:TerminationDateOfForbearanceAgreement>
<fil:TerminationDateOfForbearanceAgreement contextRef="Context_Custom_01-Apr-2010_30-Apr-2010_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">2011-10-30</fil:TerminationDateOfForbearanceAgreement>
<fil:MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod contextRef="Context_As_Of__30-Apr-2010_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="3">3000.000</fil:MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod>
<fil:ForgivenAmountOfObligations contextRef="Context_Custom_01-Apr-2010_30-Apr-2010_RelatedPartyTransactionsByRelatedPartyAxis_SloanKetteringInstituteOfCancerResearchMember_AgreementAxis_LicenseDevelopmentAndCommercializationAgreementMember" unitRef="USD" decimals="0">360000</fil:ForgivenAmountOfObligations>
<fil:ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty contextRef="Context_FYE__31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">299200</fil:ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty>
<fil:ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">237834</fil:ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty>
<us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="Context_As_Of__31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">237834</us-gaap:AccountsReceivableRelatedPartiesCurrent>
<us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="Context_As_Of__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember" unitRef="USD" decimals="0">0</us-gaap:AccountsReceivableRelatedPartiesCurrent>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31185</fil:AmountPaidToEachPatient>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31366</fil:AmountPaidToEachPatient>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">481204</fil:AmountPaidToEachPatient>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">38501</fil:AmountPaidToEachPatient>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31771</fil:AmountPaidToEachPatient>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">79623</fil:StartUpFeeForClinicalTrial>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">19749</fil:StartUpFeeForClinicalTrial>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">33946</fil:StartUpFeeForClinicalTrial>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">22847</fil:StartUpFeeForClinicalTrial>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</fil:StartUpFeeForClinicalTrial>
<fil:StartUpDueCostPaidDate contextRef="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2012-07-10</fil:StartUpDueCostPaidDate>
<fil:StartUpDueCostPaidDate contextRef="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2013-09-30</fil:StartUpDueCostPaidDate>
<fil:StartUpDueCostPaidDate contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2013-09-30</fil:StartUpDueCostPaidDate>
<us-gaap:OfficersCompensation contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_RosemaryMazanetMember_AgreementAxis_ConsultingServicesAgreementMember" unitRef="USD" decimals="0">100000</us-gaap:OfficersCompensation>
<us-gaap:OfficersCompensation contextRef="Context_9ME__30-Sep-2013_TitleOfIndividualAxis_ChiefExecutiveOfficerAndDirectorMember_AgreementAxis_EmploymentContractsMember" unitRef="USD" decimals="0">350000</us-gaap:OfficersCompensation>
<fil:OptionExercisePriceRange contextRef="Context_Custom_01-Jan-2012_31-Jan-2012_RelatedPartyTransactionsByRelatedPartyAxis_RosemaryMazanetMember_AgreementAxis_ConsultingServicesAgreementMember">0.78 to 1.5</fil:OptionExercisePriceRange>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE__31-Dec-2011">P7Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01-Jan-2012_31-Jan-2012">P7Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01-Jan-2012_31-Jan-2012_RelatedPartyTransactionsByRelatedPartyAxis_RosemaryMazanetMember_AgreementAxis_ConsultingServicesAgreementMember">P10Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01-Dec-2012_19-Dec-2012_RangeAxis_MaximumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01-Dec-2012_19-Dec-2012_RangeAxis_MinimumMember">P4M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01-Dec-2012_27-Dec-2012">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE__31-Dec-2012_RangeAxis_MaximumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE__31-Dec-2012_RangeAxis_MinimumMember">P4M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME__30-Sep-2013_RangeAxis_MaximumMember">P4Y2M19D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME__30-Sep-2013_RangeAxis_MinimumMember">P0D</us-gaap:FairValueAssumptionsExpectedTerm>
<fil:OptionsReceivedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_RosemaryMazanetMember_AgreementAxis_ConsultingServicesAgreementMember" unitRef="shares" decimals="0">99900</fil:OptionsReceivedToPurchaseCommonStock>
<fil:DescriptionOfReceivablesOfPlacementAgentForServices contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember">Placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.</fil:DescriptionOfReceivablesOfPlacementAgentForServices>
<fil:DescriptionOfWarrantsReceivablesByPlacement contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember">The placement agent or its designees have also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.</fil:DescriptionOfWarrantsReceivablesByPlacement>
<fil:PeriodOfExerciseOfWarrants contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember">Within 6 months of the final closing of the 2012 common stock Offering.</fil:PeriodOfExerciseOfWarrants>
<fil:PercentageOfSolicitationFee contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember" unitRef="pure" decimals="2">0.05</fil:PercentageOfSolicitationFee>
<fil:PeriodicFeeForFinancialAdvisoryServices contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember" unitRef="USD" decimals="0">25000</fil:PeriodicFeeForFinancialAdvisoryServices>
<fil:DescriptionOfAdditionalReceivableByPlacementAgent contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember">The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.</fil:DescriptionOfAdditionalReceivableByPlacementAgent>
<fil:CommonStockPurchaseByHoldingOfWarrant contextRef="Context_Custom_08-Jul-2012_07-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaidlawAndCompanyMember_AgreementAxis_EngagementAgreementMember" unitRef="shares" decimals="0">1251015</fil:CommonStockPurchaseByHoldingOfWarrant>
<fil:PeriodicFeeReceivedByManagementFirm contextRef="Context_Custom_10-Apr-2011_09-May-2011_RelatedPartyTransactionsByRelatedPartyAxis_JamessCapitalGroupMember_AgreementAxis_TransactionManagementAgreementMember" unitRef="USD" decimals="0">12500</fil:PeriodicFeeReceivedByManagementFirm>
<fil:PercentageOfFullyDilutedCapitalStockEqualToCommonStock contextRef="Context_Custom_10-Apr-2011_09-May-2011_RelatedPartyTransactionsByRelatedPartyAxis_JamessCapitalGroupMember_AgreementAxis_TransactionManagementAgreementMember" unitRef="pure" decimals="2">0.10</fil:PercentageOfFullyDilutedCapitalStockEqualToCommonStock>
<fil:MaximumAmountOfOutOfPocketExpenses contextRef="Context_Custom_10-Apr-2011_09-May-2011_RelatedPartyTransactionsByRelatedPartyAxis_JamessCapitalGroupMember_AgreementAxis_TransactionManagementAgreementMember" unitRef="USD" decimals="0">5000</fil:MaximumAmountOfOutOfPocketExpenses>
<fil:PeriodicAmountOfRent contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_GuagentiAndAssociatesMember" unitRef="USD" decimals="0">300</fil:PeriodicAmountOfRent>
<fil:AmountPaidToPursuantLeaseAgreement contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_GuagentiAndAssociatesMember" unitRef="USD" decimals="0">7200</fil:AmountPaidToPursuantLeaseAgreement>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">155096</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">153804</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="USD" decimals="0">1292</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">157454</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">156162</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="USD" decimals="0">1292</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">165484</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">162384</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="USD" decimals="0">3100</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">153863</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">154444</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">154444</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<fil:LossOnDispositionOfPropertyAndEquipment contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">4122</fil:LossOnDispositionOfPropertyAndEquipment>
<us-gaap:Depreciation contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">633</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">429</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">581</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">0</us-gaap:Depreciation>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of__27-Dec-2011" unitRef="USD" decimals="0">900000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of__31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">900000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of__31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">900000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="USD" decimals="0">292691</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of__27-Dec-2011" unitRef="USD" decimals="0">-150000</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of__31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">150000</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of__31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">150000</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="USD" decimals="0">150000</us-gaap:DebtInstrumentUnamortizedDiscount>
<fil:DiscountRelatedToFairValueOfDerivativeWarrants contextRef="Context_As_Of__31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">377150</fil:DiscountRelatedToFairValueOfDerivativeWarrants>
<fil:DiscountRelatedToFairValueOfDerivativeWarrants contextRef="Context_As_Of__31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">377150</fil:DiscountRelatedToFairValueOfDerivativeWarrants>
<fil:DebtInstrumentDiscountRelatedToBeneficialConversionFeature contextRef="Context_As_Of__31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">372850</fil:DebtInstrumentDiscountRelatedToBeneficialConversionFeature>
<fil:DebtInstrumentDiscountRelatedToBeneficialConversionFeature contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">372850</fil:DebtInstrumentDiscountRelatedToBeneficialConversionFeature>
<fil:DebtInstrumentDiscountRelatedToBeneficialConversionFeature contextRef="Context_As_Of__31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">372850</fil:DebtInstrumentDiscountRelatedToBeneficialConversionFeature>
<fil:DebtInstrumentAmortizationOfDiscount contextRef="Context_As_Of__31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">124363</fil:DebtInstrumentAmortizationOfDiscount>
<fil:DebtInstrumentAmortizationOfDiscount contextRef="Context_As_Of__31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">900000</fil:DebtInstrumentAmortizationOfDiscount>
<fil:DebtInstrumentPrincipalAmountConvertedToCommonStock contextRef="Context_As_Of__31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" xsi:nil="true"/>
<fil:DebtInstrumentPrincipalAmountConvertedToCommonStock contextRef="Context_As_Of__31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">-900000</fil:DebtInstrumentPrincipalAmountConvertedToCommonStock>
<fil:CommonStockPurchaseDueToIssuanceOfWarrants contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="shares" decimals="0">143532</fil:CommonStockPurchaseDueToIssuanceOfWarrants>
<fil:CommonStockPurchaseDueToIssuanceOfWarrants contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_ManagementFirmMember" unitRef="shares" decimals="0">126829</fil:CommonStockPurchaseDueToIssuanceOfWarrants>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD_per_Share" decimals="2">0.78</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">0.78</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_ManagementMember" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_Custom_01-Dec-2012_19-Dec-2012_StatementClassOfStockAxis_SeriesEPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.26</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD_per_Share" decimals="2">0.78</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">0.78</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_ManagementMember" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">0.78</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_ManagementFirmMember" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_FinancialInstrumentAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.65</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_FinancialInstrumentAxis_WarrantsBMember" unitRef="USD_per_Share" decimals="2">2.48</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">0.78</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember">2019-01-31</invest:InvestmentWarrantsExpirationDate>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_ManagementFirmMember">2019-01-31</invest:InvestmentWarrantsExpirationDate>
<fil:AmortizationPeriodOfNote contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember">One year</fil:AmortizationPeriodOfNote>
<fil:PremiumFinanceAgreementPrincipalAmount contextRef="Context_As_Of__28-Dec-2012" unitRef="USD" decimals="0">140000</fil:PremiumFinanceAgreementPrincipalAmount>
<fil:PremiumFinanceAgreementPrincipalAmount contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">0</fil:PremiumFinanceAgreementPrincipalAmount>
<fil:PaymentUnderPremiumFinanceAgreement contextRef="Context_Custom_01-Jan-2013_31-Jan-2013" unitRef="USD" decimals="0">28000</fil:PaymentUnderPremiumFinanceAgreement>
<fil:PeriodicPaymentUnderPremiumFinanceAgreement contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">12636</fil:PeriodicPaymentUnderPremiumFinanceAgreement>
<fil:DurationOfPeriodicPaymentsForPremiumFinanceAgreement contextRef="Context_FYE__31-Dec-2012">P9M</fil:DurationOfPeriodicPaymentsForPremiumFinanceAgreement>
<fil:PremiumFinanceAgreementOutstandingAmount contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">140000</fil:PremiumFinanceAgreementOutstandingAmount>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of__27-Dec-2011" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<fil:ProceedsFromConvertibleNotes contextRef="Context_As_Of__27-Dec-2011" unitRef="USD" decimals="0">750000</fil:ProceedsFromConvertibleNotes>
<fil:PercentageOfPrincipleAmountInWhichConvertibleNoteIssued contextRef="Context_As_Of__27-Dec-2011" unitRef="pure" decimals="4">0.8333</fil:PercentageOfPrincipleAmountInWhichConvertibleNoteIssued>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_Custom_01-Dec-2011_31-Dec-2011">One year</us-gaap:DebtInstrumentMaturityDateDescription>
<fil:GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">4000000</fil:GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents>
<fil:DerivativeWarrantsIssuedWithConvertibleNotes contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">287061</fil:DerivativeWarrantsIssuedWithConvertibleNotes>
<fil:InvestmentWarrantGrantDateFairValue contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">565729</fil:InvestmentWarrantGrantDateFairValue>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of__31-Dec-2012" unitRef="USD_per_Share" decimals="2">0.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<fil:DebtInstrumentFairValuePerShare contextRef="Context_FYE__31-Dec-2012" unitRef="USD_per_Share" decimals="2">1.11</fil:DebtInstrumentFairValuePerShare>
<fil:ExtendedMaturityPeriodOfConvertibleNotes contextRef="Context_Custom_01-Oct-2012_23-Oct-2012">P90D</fil:ExtendedMaturityPeriodOfConvertibleNotes>
<fil:DescriptionOfExtendedMaturityDate contextRef="Context_Custom_01-Oct-2012_23-Oct-2012">Company was seeking approval to extend the note maturity date for 90 days. The Company was able to obtain approvals from all note holders and the maturity date of the notes has been extended to January 31, 2013, February 18, 2013 or March 27, 2013 for the 24 notes.</fil:DescriptionOfExtendedMaturityDate>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_Custom_01-Dec-2012_19-Dec-2012" unitRef="USD" decimals="0">4000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">1252550</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<fil:InsurancePolicyDownPayment contextRef="Context_As_Of__31-Jan-2013" unitRef="USD" decimals="0">28000</fil:InsurancePolicyDownPayment>
<fil:InsurancePolicyInstallmentPayment contextRef="Context_As_Of__31-Jan-2013" unitRef="USD" decimals="0">12636</fil:InsurancePolicyInstallmentPayment>
<us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">103050</us-gaap:DebtInstrumentAnnualPrincipalPayment>
<fil:DerivativeWarrantsUnits contextRef="Context_As_Of__31-Dec-2010" unitRef="shares" xsi:nil="true"/>
<fil:DerivativeWarrantsUnits contextRef="Context_As_Of__31-Dec-2011" unitRef="shares" decimals="0">3389771</fil:DerivativeWarrantsUnits>
<fil:DerivativeWarrantsUnits contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="0">5146338</fil:DerivativeWarrantsUnits>
<fil:DerivativeWarrantsUnits contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="0">2015802</fil:DerivativeWarrantsUnits>
<fil:DerivativeWarrantUnitsReclassificationToPaidInCapital contextRef="Context_9ME__30-Sep-2013" unitRef="shares" decimals="0">-3130536</fil:DerivativeWarrantUnitsReclassificationToPaidInCapital>
<fil:DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">143532</fil:DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes>
<fil:DerivativeWarrantsIssuedWithStockOffering contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">1972785</fil:DerivativeWarrantsIssuedWithStockOffering>
<fil:DerivativeWarrantsIssuedWithStockOffering contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">242190</fil:DerivativeWarrantsIssuedWithStockOffering>
<fil:DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">986393</fil:DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock>
<fil:DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">121095</fil:DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock>
<fil:DerivativeWarrantsIssuedWithCommonStockOffering contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">3118988</fil:DerivativeWarrantsIssuedWithCommonStockOffering>
<fil:DerivativeWarrantsIssuedWithCommonStockOfferingOne contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">1559505</fil:DerivativeWarrantsIssuedWithCommonStockOfferingOne>
<fil:DerivativePlacementAgentWarrantsRelatedToStock contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">467845</fil:DerivativePlacementAgentWarrantsRelatedToStock>
<fil:TransferFromLiabilityClassificationToEquityClassification contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">-3753056</fil:TransferFromLiabilityClassificationToEquityClassification>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of__31-Dec-2010" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">4439613</us-gaap:DerivativeFairValueOfDerivativeNet>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">3574958</us-gaap:DerivativeFairValueOfDerivativeNet>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">2757966</us-gaap:DerivativeFairValueOfDerivativeNet>
<fil:DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-600880</fil:DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue>
<fil:FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">377150</fil:FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes>
<fil:FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">188579</fil:FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes>
<fil:FairValueOfDerivativeWarrantsIssuedWithStockOffering contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">2591900</fil:FairValueOfDerivativeWarrantsIssuedWithStockOffering>
<fil:FairValueOfDerivativeWarrantsIssuedWithStockOffering contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">318087</fil:FairValueOfDerivativeWarrantsIssuedWithStockOffering>
<fil:FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">1295950</fil:FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock>
<fil:FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">159044</fil:FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock>
<fil:FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">1409554</fil:FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering>
<fil:FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">1665697</fil:FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne>
<fil:FairValueOfDerivativePlacementAgentWarrantsRelatedToStock contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">499707</fil:FairValueOfDerivativePlacementAgentWarrantsRelatedToStock>
<fil:ChangeInFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-13966</fil:ChangeInFairValueOfDerivativeWarrants>
<fil:ChangeInFairValueOfDerivativeWarrants contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-685420</fil:ChangeInFairValueOfDerivativeWarrants>
<fil:ChangeInFairValueOfDerivativeWarrants contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-216112</fil:ChangeInFairValueOfDerivativeWarrants>
<fil:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__31-Dec-2011" unitRef="USD_per_Share" decimals="2">0.37</fil:MarketValueOfCommonStockOnMeasurementDate>
<fil:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__31-Jan-2012" unitRef="USD_per_Share" decimals="2">0.37</fil:MarketValueOfCommonStockOnMeasurementDate>
<fil:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__19-Dec-2012" unitRef="USD_per_Share" decimals="2">0.39</fil:MarketValueOfCommonStockOnMeasurementDate>
<fil:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__27-Dec-2012" unitRef="USD_per_Share" decimals="2">0.39</fil:MarketValueOfCommonStockOnMeasurementDate>
<fil:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__31-Dec-2012" unitRef="USD_per_Share" decimals="2" id="Item_1">1.17</fil:MarketValueOfCommonStockOnMeasurementDate>
<fil:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__30-Sep-2013" unitRef="USD_per_Share" decimals="2" id="Item_3">1.65</fil:MarketValueOfCommonStockOnMeasurementDate>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Dec-2011_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.26</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Dec-2011_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.24</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Jan-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.26</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Jan-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.23</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__19-Dec-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.83</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__19-Dec-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.41</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__27-Dec-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.26</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__27-Dec-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.22</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Dec-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.81</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Dec-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.48</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__30-Sep-2013_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="3">2.475</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__30-Sep-2013_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE__31-Dec-2011" unitRef="pure" decimals="4">0.0135</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01-Jan-2012_31-Jan-2012" unitRef="pure" decimals="4">0.0124</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01-Dec-2012_19-Dec-2012_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0077</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01-Dec-2012_19-Dec-2012_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0010</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01-Dec-2012_27-Dec-2012" unitRef="pure" decimals="4">0.0094</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE__31-Dec-2012_RangeAxis_MaximumMember" unitRef="pure" decimals="4" id="Item_4">0.0077</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE__31-Dec-2012_RangeAxis_MinimumMember" unitRef="pure" decimals="4" id="Item_6">0.0010</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME__30-Sep-2013" unitRef="pure" decimals="4" id="Item_7">0.0033</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2011" unitRef="pure" decimals="2">1.56</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01-Jan-2012_31-Jan-2012" unitRef="pure" decimals="2">1.57</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01-Dec-2012_19-Dec-2012_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.61</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01-Dec-2012_19-Dec-2012_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.25</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01-Dec-2012_27-Dec-2012" unitRef="pure" decimals="2">1.61</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2012_RangeAxis_MaximumMember" unitRef="pure" decimals="2" id="Item_8">1.61</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2012_RangeAxis_MinimumMember" unitRef="pure" decimals="2" id="Item_10">1.25</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME__30-Sep-2013" unitRef="pure" decimals="2" id="Item_11">1.39</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2011" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01-Jan-2012_31-Jan-2012" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01-Dec-2012_19-Dec-2012" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01-Dec-2012_27-Dec-2012" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2012" unitRef="pure" xsi:nil="true" id="Item_12"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME__30-Sep-2013" unitRef="pure" xsi:nil="true" id="Item_14"/>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_FYE__31-Dec-2011" unitRef="pure" decimals="2">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_Custom_01-Jan-2012_31-Jan-2012" unitRef="pure" decimals="2">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_Custom_01-Dec-2012_19-Dec-2012" unitRef="pure" decimals="2">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_Custom_01-Dec-2012_27-Dec-2012" unitRef="pure" decimals="2">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_FYE__31-Dec-2012" unitRef="pure" decimals="2" id="Item_15">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_9ME__30-Sep-2013_RangeAxis_MaximumMember" unitRef="pure" decimals="2" id="Item_17">0.40</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_9ME__30-Sep-2013_RangeAxis_MinimumMember" unitRef="pure" decimals="2" id="Item_18">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<fil:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of__31-Dec-2011" unitRef="pure" decimals="2">0.35</fil:RangeOfPercentageOfExistingSharesOffered>
<fil:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of__31-Jan-2012" unitRef="pure" decimals="2">0.35</fil:RangeOfPercentageOfExistingSharesOffered>
<fil:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of__19-Dec-2012" unitRef="pure" decimals="2">0.35</fil:RangeOfPercentageOfExistingSharesOffered>
<fil:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of__27-Dec-2012" unitRef="pure" decimals="2">0.35</fil:RangeOfPercentageOfExistingSharesOffered>
<fil:RangeOfPercentageOfExistingSharesOffered contextRef="Context_As_Of__31-Dec-2012" unitRef="pure" decimals="2">0.35</fil:RangeOfPercentageOfExistingSharesOffered>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__31-Dec-2011_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.55</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__31-Dec-2011_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.18</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__31-Jan-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.56</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__31-Jan-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.13</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__19-Dec-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.55</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__19-Dec-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.01</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__27-Dec-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.60</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__27-Dec-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.12</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__31-Dec-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.55</fil:FairValueAssumptionOfferingPrice>
<fil:FairValueAssumptionOfferingPrice contextRef="Context_As_Of__31-Dec-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.01</fil:FairValueAssumptionOfferingPrice>
<fil:DescriptionOfRiskFreeInterestRateDetermination contextRef="Context_FYE__31-Dec-2012">Risk-free interest rate was determined by management using the average of 5 and 7 year and the 3-month Treasury Bill as of the respective measurement date.</fil:DescriptionOfRiskFreeInterestRateDetermination>
<fil:DescriptionOfProbabilityOfStockOffering contextRef="Context_FYE__31-Dec-2012">Probability of a stock offering is 25% for each quarter of the next five years.</fil:DescriptionOfProbabilityOfStockOffering>
<fil:DescriptionOfProbabilityOfStockOffering contextRef="Context_9ME__30-Sep-2013">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</fil:DescriptionOfProbabilityOfStockOffering>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">13089314</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">13609036</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">741420</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">1497556</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">4749</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">233043</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
<us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">13835483</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
<us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">15339635</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">13835483</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">15339635</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">-1171230</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">-2842810</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE__31-Dec-2011" unitRef="pure" decimals="4">-0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE__31-Dec-2012" unitRef="pure" decimals="4">-0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">736796</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">756136</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_FYE__31-Dec-2011" unitRef="pure" decimals="4">0.2139</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_FYE__31-Dec-2012" unitRef="pure" decimals="4">0.0904</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">4748</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">233043</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE__31-Dec-2011" unitRef="pure" decimals="4">0.0013</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE__31-Dec-2012" unitRef="pure" decimals="4">0.0279</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">56033</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">349480</us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization contextRef="Context_FYE__31-Dec-2011" unitRef="pure" decimals="4">0.0163</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization contextRef="Context_FYE__31-Dec-2012" unitRef="pure" decimals="4">0.0418</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization>
<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">373653</us-gaap:IncomeTaxReconciliationOtherAdjustments>
<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">1504151</us-gaap:IncomeTaxReconciliationOtherAdjustments>
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Context_FYE__31-Dec-2011" unitRef="pure" decimals="4">0.1085</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Context_FYE__31-Dec-2012" unitRef="pure" decimals="4">0.1799</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_FYE__31-Dec-2011" unitRef="pure" xsi:nil="true"/>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_FYE__31-Dec-2012" unitRef="pure" xsi:nil="true"/>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="-6">43000000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_FYE__31-Dec-2012">2020-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember" unitRef="USD" decimals="0">1750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember" unitRef="USD" decimals="0">1750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">7750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember" unitRef="USD" decimals="0">1750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember" unitRef="USD" decimals="0">1750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">7750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:PerformanceObjectiveDescription contextRef="Context_9ME__30-Sep-2013_TitleOfIndividualAxis_ChiefExecutiveOfficerAndDirectorMember_AgreementAxis_EmploymentContractsMember">Upon the attainment of such performance objectives, the CEO shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary.</fil:PerformanceObjectiveDescription>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenStockPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="0">2750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenEquityIncentivePlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="0">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">675000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_RestrictedStockMember" unitRef="shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<fil:OptionGrantedToPurchaseSharesAsSignOnBonus contextRef="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_RestrictedStockMember" unitRef="shares" decimals="INF">100000</fil:OptionGrantedToPurchaseSharesAsSignOnBonus>
<fil:OptionGrantedToPurchaseSharesAsSignOnBonusDescription contextRef="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_RestrictedStockMember">(C) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work. An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date</fil:OptionGrantedToPurchaseSharesAsSignOnBonusDescription>
<fil:PaymentOfLicenseFee contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">3000000</fil:PaymentOfLicenseFee>
<fil:PaymentOfLicenseFee contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">3000000</fil:PaymentOfLicenseFee>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_Custom_01-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="-6">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_Custom_14-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="-6">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<fil:MilestonePaymentDate contextRef="Context_Custom_28-Jul-2012_01-Aug-2012_AgreementAxis_RentalAgreementMember">2013-01-31</fil:MilestonePaymentDate>
<fil:MilestonePaymentDate contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">2012-07-24</fil:MilestonePaymentDate>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_Custom_01-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">Royalty payments of 2% of net sales will be due to FHCRC.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember">Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember">We agrees to pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">Royalty payments of 2% of net sales will be due to FHCRC.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">We agreed to pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of up to 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:RoyaltyOfNetSalesPercentage contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="pure" decimals="2">0.12</fil:RoyaltyOfNetSalesPercentage>
<fil:FirstCommercialSalePeriod contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">P12Y6M</fil:FirstCommercialSalePeriod>
<us-gaap:TechnologyServicesCosts contextRef="Context_Custom_01-Feb-2002_28-Feb-2002_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember" unitRef="USD" decimals="0">50000</us-gaap:TechnologyServicesCosts>
<us-gaap:MaintenanceCosts contextRef="Context_Custom_01-Feb-2002_28-Feb-2002_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember" unitRef="USD" decimals="0">50000</us-gaap:MaintenanceCosts>
<fil:ResearchAndDevelopmentArrangement contextRef="Context_Custom_01-Feb-2002_28-Feb-2002_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember" unitRef="USD" decimals="0">50000</fil:ResearchAndDevelopmentArrangement>
<fil:PurchaseOfRadioactiveMaterial contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">233100</fil:PurchaseOfRadioactiveMaterial>
<fil:PurchaseOfRadioactiveMaterial contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">233100</fil:PurchaseOfRadioactiveMaterial>
<fil:ProjectEstimatedCost contextRef="Context_Custom_05-Aug-2012_06-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">2200000</fil:ProjectEstimatedCost>
<fil:ProjectEstimatedCost contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">1859333</fil:ProjectEstimatedCost>
<fil:ProjectEstimatedCost contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="-5">1900000</fil:ProjectEstimatedCost>
<fil:DownPaymentOfProjectEstimatedCostPercentage contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="pure" decimals="3">0.125</fil:DownPaymentOfProjectEstimatedCostPercentage>
<fil:DownPaymentOfProjectEstimatedCostPercentage contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="pure" decimals="3">0.125</fil:DownPaymentOfProjectEstimatedCostPercentage>
<fil:DownPaymentForProject contextRef="Context_FYE__31-Dec-2007_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</fil:DownPaymentForProject>
<fil:DownPaymentForProject contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</fil:DownPaymentForProject>
<fil:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MaximumMember" unitRef="USD" decimals="-5">23500000</fil:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<fil:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_RangeAxis_MinimumMember" unitRef="USD" decimals="-5">13200000</fil:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<fil:FundToRelatedPartyUnderAgreementForFirstTwoYear contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">150000</fil:FundToRelatedPartyUnderAgreementForFirstTwoYear>
<fil:FundToRelatedPartyUnderAgreementAfterYearTwo contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">250000</fil:FundToRelatedPartyUnderAgreementAfterYearTwo>
<us-gaap:RoyaltyExpense contextRef="Context_Custom_10-Aug-2013_12-Aug-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">37500</us-gaap:RoyaltyExpense>
<fil:NonRefundableInstitutionalFee contextRef="Context_Custom_01-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">14500</fil:NonRefundableInstitutionalFee>
<fil:PharmacyFee contextRef="Context_Custom_01-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">2025</fil:PharmacyFee>
<fil:AmendmentProcessingFee contextRef="Context_Custom_01-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">500</fil:AmendmentProcessingFee>
<fil:WarrantExercisableNoticePeriodDescription contextRef="Context_Custom_10-Apr-2011_09-May-2011_RelatedPartyTransactionsByRelatedPartyAxis_JamessCapitalGroupMember_AgreementAxis_TransactionManagementAgreementMember">The warrants contain a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver.</fil:WarrantExercisableNoticePeriodDescription>
<fil:DescriptionOfSharesAvailabilityByExerciseOfWarrant contextRef="Context_Custom_10-Apr-2011_09-May-2011_RelatedPartyTransactionsByRelatedPartyAxis_JamessCapitalGroupMember_AgreementAxis_TransactionManagementAgreementMember">The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transfered until the earlier of twelve months from the closing date of the Pubco Transaction; or for six months after the planned Registration Statement is declared effective.</fil:DescriptionOfSharesAvailabilityByExerciseOfWarrant>
<fil:AgreementConsideration contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">The Company paid Mr. Talley $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid Mr.Talley a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.</fil:AgreementConsideration>
<fil:AmountPayableInInstallmentsUnderAgreement contextRef="Context_As_Of__28-Feb-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">250000</fil:AmountPayableInInstallmentsUnderAgreement>
<fil:NumberOfInstallments contextRef="Context_Custom_01-Feb-2013_28-Feb-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="Note" decimals="INF">2</fil:NumberOfInstallments>
<fil:PerformanceBonusPayableUnderAgreementForService contextRef="Context_As_Of__28-Feb-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">60000</fil:PerformanceBonusPayableUnderAgreementForService>
<fil:AgreementRenewalDescription contextRef="Context_9ME__30-Sep-2013_AgreementAxis_RentalAgreementMember">The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</fil:AgreementRenewalDescription>
<fil:PaymentOfFirstInstallmentForServicesByCompany contextRef="Context_Custom_01-Mar-2013_31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">125000</fil:PaymentOfFirstInstallmentForServicesByCompany>
<fil:PaymentOfFinalInstallmentForServicesByCompany contextRef="Context_Custom_01-Mar-2013_31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">125000</fil:PaymentOfFinalInstallmentForServicesByCompany>
<fil:PaymentOfPerformanceBonusForServicesByCompany contextRef="Context_Custom_01-Mar-2013_31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">60000</fil:PaymentOfPerformanceBonusForServicesByCompany>
<us-gaap:LeaseExpirationDate1 contextRef="Context_Custom_28-Jul-2012_01-Aug-2012_AgreementAxis_RentalAgreementMember">2013-01-31</us-gaap:LeaseExpirationDate1>
<us-gaap:LeaseExpirationDate1 contextRef="Context_Custom_01-Aug-2012_31-Aug-2012">2013-01-31</us-gaap:LeaseExpirationDate1>
<fil:NoticePeriodForTerminationOfAgreement contextRef="Context_Custom_01-Aug-2012_31-Aug-2012">60 days prior to January 1, 2013</fil:NoticePeriodForTerminationOfAgreement>
<fil:NoticePeriodForTerminationOfAgreement contextRef="Context_9ME__30-Sep-2013_AgreementAxis_RentalAgreementMember">The agreement terminated May 31, 2013.</fil:NoticePeriodForTerminationOfAgreement>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">273859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">273859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">5364557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2330134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">12770636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2280184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">9441942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_FYE__31-Dec-2009_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">128050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">-49950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="0">-2304910</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_FYE__31-Dec-2009_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">20613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="0">-1023784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember">P5Y6M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember">P5Y6M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember">P6Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">P8Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember">P4Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember">P8Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">3261367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">685800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">6114768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">1609035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">9691302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<fil:WarrantsIssuedToPurchaseCommonStockOffering contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">19972785</fil:WarrantsIssuedToPurchaseCommonStockOffering>
<fil:WarrantsIssuedToPurchaseCommonStockOffering contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">242190</fil:WarrantsIssuedToPurchaseCommonStockOffering>
<fil:IncreaseOfferingOfCommonStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2010_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">42711791</fil:IncreaseOfferingOfCommonStock>
<fil:IncreaseOfferingOfCommonStock contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">6184967</fil:IncreaseOfferingOfCommonStock>
<fil:IncreaseOfferingOfCommonStock contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">5151450</fil:IncreaseOfferingOfCommonStock>
<fil:IncreaseOfferingOfCommonStock contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">759300</fil:IncreaseOfferingOfCommonStock>
<fil:CommonStockSharesIssuedInStockOffering contextRef="Context_Custom_14-Jun-2000_31-Dec-2010_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">5707259</fil:CommonStockSharesIssuedInStockOffering>
<fil:CommonStockSharesIssuedInStockOffering contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">7891141</fil:CommonStockSharesIssuedInStockOffering>
<fil:CommonStockSharesIssuedInStockOffering contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">3118988</fil:CommonStockSharesIssuedInStockOffering>
<fil:CommonStockSharesIssuedInStockOffering contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">968759</fil:CommonStockSharesIssuedInStockOffering>
<fil:ProceedsFromIssuanceOfStockUnderStockOfferingNet contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">5379367</fil:ProceedsFromIssuanceOfStockUnderStockOfferingNet>
<fil:ProceedsFromIssuanceOfStockUnderStockOfferingNet contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">4469776</fil:ProceedsFromIssuanceOfStockUnderStockOfferingNet>
<fil:ProceedsFromIssuanceOfStockUnderStockOfferingNet contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">660164</fil:ProceedsFromIssuanceOfStockUnderStockOfferingNet>
<fil:PlacementAgentCashFees contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">742196</fil:PlacementAgentCashFees>
<fil:PlacementAgentCashFees contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">91116</fil:PlacementAgentCashFees>
<fil:PlacementAgentCashFees contextRef="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">618174</fil:PlacementAgentCashFees>
<fil:PlacementAgentCommission contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">618497</fil:PlacementAgentCommission>
<fil:PlacementAgentCommission contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">75930</fil:PlacementAgentCommission>
<fil:PlacementAgentCommission contextRef="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">515145</fil:PlacementAgentCommission>
<fil:PlacementAgentExpenseReimbursement contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">123699</fil:PlacementAgentExpenseReimbursement>
<fil:PlacementAgentExpenseReimbursement contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">15186</fil:PlacementAgentExpenseReimbursement>
<fil:PlacementAgentExpenseReimbursement contextRef="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">103029</fil:PlacementAgentExpenseReimbursement>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="shares" decimals="0">986393</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="0">1129925</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_ManagementMember" unitRef="shares" decimals="0">1974774</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="shares" decimals="0">121095</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="shares" decimals="0">588940</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_ManagementMember" unitRef="shares" decimals="0">1716340</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_FinancialInstrumentAxis_WarrantMember" unitRef="shares" decimals="0">3118988</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_FinancialInstrumentAxis_WarrantsBMember" unitRef="shares" decimals="0">1559505</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsIssuedToPurchaseCommonStock contextRef="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="shares" decimals="0">467845</fil:WarrantsIssuedToPurchaseCommonStock>
<fil:WarrantsExpirationTerm contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember">P7Y</fil:WarrantsExpirationTerm>
<fil:WarrantsExpirationTerm contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember">P7Y</fil:WarrantsExpirationTerm>
<fil:WarrantsExpirationTerm contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_FinancialInstrumentAxis_WarrantMember">P120D</fil:WarrantsExpirationTerm>
<fil:WarrantsExpirationTerm contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_FinancialInstrumentAxis_WarrantsBMember">P5Y</fil:WarrantsExpirationTerm>
<fil:WarrantsExpirationTerm contextRef="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember">P5Y</fil:WarrantsExpirationTerm>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">188579</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_ManagementMember" unitRef="USD" decimals="0">2153442</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">159044</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_SubsidiarySaleOfStockAxis_ManagementMember" unitRef="USD" decimals="0">1957754</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">499707</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<fil:PlacementAgentServicesFees contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">60904</fil:PlacementAgentServicesFees>
<fil:PlacementAgentServicesFees contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">8020</fil:PlacementAgentServicesFees>
<fil:PlacementAgentServicesFees contextRef="Context_Custom_14-Jun-2000_31-Dec-2012_StatementClassOfStockAxis_CommonStockMember" unitRef="USD" decimals="0">60000</fil:PlacementAgentServicesFees>
<fil:BankEscrowFee contextRef="Context_FYE__31-Dec-2011_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">2500</fil:BankEscrowFee>
<fil:BankEscrowFee contextRef="Context_FYE__31-Dec-2012_StatementClassOfStockAxis_CommonStockMember_TypeOfArrangementAxis_LaidlawAndCoMember" unitRef="USD" decimals="0">3500</fil:BankEscrowFee>
<fil:AccruedManagementFees contextRef="Context_FYE__31-Dec-2011_SubsidiarySaleOfStockAxis_ManagementMember" unitRef="USD" decimals="0">96744</fil:AccruedManagementFees>
<fil:CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">400000</fil:CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement>
<fil:CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">1986566</fil:CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement>
<fil:UnrecognizedShareBasedCompensationExpense contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">14528</fil:UnrecognizedShareBasedCompensationExpense>
<fil:UnrecognizedShareBasedCompensationExpense contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">1998435</fil:UnrecognizedShareBasedCompensationExpense>
<fil:UnrecognizedShareBasedCompensationExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">1014474</fil:UnrecognizedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">19935</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">2153442</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">72100</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">240400</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">266172</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">1957754</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">95971</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">188400</us-gaap:AllocatedShareBasedCompensationExpense>
<fil:AmountPaidForCancellationOfSharesByCompany contextRef="Context_Custom_01-May-2013_31-May-2013_TitleOfIndividualAxis_FormerDirectorAndConsultantsMember_FinancialInstrumentAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">25000</fil:AmountPaidForCancellationOfSharesByCompany>
<fil:SharesPurchasedAfterCancelationOfOptions contextRef="Context_Custom_01-May-2013_31-May-2013_TitleOfIndividualAxis_FormerDirectorAndConsultantsMember_FinancialInstrumentAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">49950</fil:SharesPurchasedAfterCancelationOfOptions>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01-May-2013_31-May-2013_TitleOfIndividualAxis_FormerDirectorAndConsultantsMember_FinancialInstrumentAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME__30-Sep-2013_FinancialInstrumentAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">3463641</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenStockPlanMember">2023-09-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenEquityIncentivePlanMember">2023-09-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="0">5364557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2056275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="0">7406079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<fil:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember">P6Y9M4D</fil:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm>
<fil:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">P8Y10M21D</fil:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm>
<fil:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember">P3Y9M4D</fil:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember" unitRef="shares" decimals="0">757575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<fil:MaximumGrantedOptionToPurchaseCommonStockAfterAmendment contextRef="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember" unitRef="shares" decimals="0">978154</fil:MaximumGrantedOptionToPurchaseCommonStockAfterAmendment>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2006_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2006_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2007_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2007_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2008_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2008_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2010_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2010_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember_RangeAxis_MinimumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember_RangeAxis_MaximumMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<fil:ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting contextRef="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember" unitRef="pure" decimals="2">0.02</fil:ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="2">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
<fil:PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering contextRef="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandTwelveEmployeeStockOptionPlanMember" unitRef="pure" decimals="2">0.15</fil:PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of__31-Dec-2012_PlanNameAxis_TwoThousandTwelveEmployeeStockOptionPlanMember" unitRef="shares" decimals="0">9455776</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease contextRef="Context_FYE__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember" unitRef="shares" decimals="0">3217880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
<fil:ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance contextRef="Context_As_Of__31-Dec-2012_PlanNameAxis_TwoThousandThreeStockPlanMember" unitRef="shares" decimals="0">6155280</fil:ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance>
<fil:StockOptionGrantedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">206060</fil:StockOptionGrantedToPurchaseCommonStock>
<fil:StockOptionGrantedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">113220</fil:StockOptionGrantedToPurchaseCommonStock>
<fil:StockOptionGrantedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">69941</fil:StockOptionGrantedToPurchaseCommonStock>
<fil:StockOptionGrantedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">33300</fil:StockOptionGrantedToPurchaseCommonStock>
<fil:StockOptionGrantedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="0">1974774</fil:StockOptionGrantedToPurchaseCommonStock>
<fil:StockOptionGrantedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">2056275</fil:StockOptionGrantedToPurchaseCommonStock>
<fil:StockOptionGrantedToPurchaseCommonStock contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="0">1716340</fil:StockOptionGrantedToPurchaseCommonStock>
<fil:StockOptionGrantedToPurchaseCommonStockExercisePrice contextRef="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.35</fil:StockOptionGrantedToPurchaseCommonStockExercisePrice>
<fil:StockOptionGrantedToPurchaseCommonStockExercisePrice contextRef="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.35</fil:StockOptionGrantedToPurchaseCommonStockExercisePrice>
<fil:StockOptionGrantedToPurchaseCommonStockExercisePrice contextRef="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.90</fil:StockOptionGrantedToPurchaseCommonStockExercisePrice>
<fil:StockOptionGrantedToPurchaseCommonStockExercisePrice contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.90</fil:StockOptionGrantedToPurchaseCommonStockExercisePrice>
<fil:StockOptionGrantedToPurchaseCommonStockExercisePrice contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.01</fil:StockOptionGrantedToPurchaseCommonStockExercisePrice>
<fil:StockOptionGrantedToPurchaseCommonStockExercisePrice contextRef="Context_FYE__31-Dec-2012_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.78</fil:StockOptionGrantedToPurchaseCommonStockExercisePrice>
<fil:StockOptionGrantedToPurchaseCommonStockExercisePrice contextRef="Context_FYE__31-Dec-2012_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="1">1.5</fil:StockOptionGrantedToPurchaseCommonStockExercisePrice>
<fil:StockOptionGrantedToPurchaseCommonStockExercisePrice contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.01</fil:StockOptionGrantedToPurchaseCommonStockExercisePrice>
<fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife contextRef="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember">P10Y</fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife>
<fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife contextRef="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember">P10Y</fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife>
<fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife contextRef="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember">P10Y</fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife>
<fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember">P10Y</fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife>
<fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember">P7Y</fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife>
<fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">P10Y</fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife>
<fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember">P7Y</fil:StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">1051281</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">137652</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">44159</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">24996</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">1519777</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_FYE__31-Dec-2011_RangeAxis_MaximumMember_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="4">0.0317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_FYE__31-Dec-2011_RangeAxis_MinimumMember_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="4">0.0192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="3">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="4">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2011_RangeAxis_MaximumMember_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="4">0.7072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2011_RangeAxis_MinimumMember_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="4">0.6477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2012_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">1.6044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2012_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">1.6149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="4">0.6064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2006_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2007_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2008_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2010_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2011_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<fil:EmployeeStockOptionUnitsReprised contextRef="Context_Custom_01-Feb-2012_29-Feb-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">273859</fil:EmployeeStockOptionUnitsReprised>
<fil:OutstandingStockOptionExercisePriceAfterRepricingOfStockOption contextRef="Context_Custom_01-Feb-2012_29-Feb-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.28</fil:OutstandingStockOptionExercisePriceAfterRepricingOfStockOption>
<fil:ShareBasedCompensationCostAfterRepricingOfStockOptions contextRef="Context_Custom_01-Feb-2012_29-Feb-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">34879</fil:ShareBasedCompensationCostAfterRepricingOfStockOptions>
<fil:WarrantsIssuedWithConvertibleNotes contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">287061</fil:WarrantsIssuedWithConvertibleNotes>
<fil:WarrantsIssuedWithConvertibleNotes contextRef="Context_FYE__31-Dec-2012" unitRef="shares" xsi:nil="true"/>
<fil:WarrantsIssuedToInvestorsWithStockOffering contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">1972766</fil:WarrantsIssuedToInvestorsWithStockOffering>
<fil:WarrantsIssuedToInvestorsWithStockOffering contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">242189</fil:WarrantsIssuedToInvestorsWithStockOffering>
<fil:WarrantsIssuedToInvestorsWithCommonStock contextRef="Context_FYE__31-Dec-2011" unitRef="shares" xsi:nil="true"/>
<fil:WarrantsIssuedToInvestorsWithCommonStock contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">4678491</fil:WarrantsIssuedToInvestorsWithCommonStock>
<fil:PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">143532</fil:PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes>
<fil:PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes contextRef="Context_FYE__31-Dec-2012" unitRef="shares" xsi:nil="true"/>
<fil:PlacementAgentWarrantsRelatedToIssuanceOfStockOffering contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">986383</fil:PlacementAgentWarrantsRelatedToIssuanceOfStockOffering>
<fil:PlacementAgentWarrantsRelatedToIssuanceOfStockOffering contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">121094</fil:PlacementAgentWarrantsRelatedToIssuanceOfStockOffering>
<fil:PlacementAgentWarrantsRelatedToIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2011" unitRef="shares" xsi:nil="true"/>
<fil:PlacementAgentWarrantsRelatedToIssuanceOfCommonStock contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">467845</fil:PlacementAgentWarrantsRelatedToIssuanceOfCommonStock>
<fil:WarrantIssuedToInvestorsWithStockAccruedDividend contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">180115</fil:WarrantIssuedToInvestorsWithStockAccruedDividend>
<fil:WarrantsIssued contextRef="Context_FYE__31-Dec-2011" unitRef="shares" decimals="0">3389742</fil:WarrantsIssued>
<fil:WarrantsIssued contextRef="Context_FYE__31-Dec-2012" unitRef="shares" decimals="0">5689734</fil:WarrantsIssued>
<us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="Context_FYE__31-Dec-2012">The plan requires 12 consecutive months of service and a minimum of 500 hours of service for participation.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="Context_FYE__31-Dec-2012" unitRef="pure" decimals="2">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="Context_FYE__31-Dec-2011" unitRef="USD" decimals="0">8885</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="Context_FYE__31-Dec-2012" unitRef="USD" decimals="0">8942</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
<fil:NumberOfInstallmentsInWhichConsiderationIsPayable contextRef="Context_Custom_27-Feb-2013_28-Feb-2013_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_SeparationAndSettlementAgreementMember_TitleOfIndividualAxis_FormerChiefExecutiveOfficerMember" unitRef="Note" decimals="INF">2</fil:NumberOfInstallmentsInWhichConsiderationIsPayable>
<fil:ConsiderationPayableUnderAgreement contextRef="Context_As_Of__28-Feb-2013_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_SeparationAndSettlementAgreementMember_TitleOfIndividualAxis_FormerChiefExecutiveOfficerMember" unitRef="USD" decimals="0">250000</fil:ConsiderationPayableUnderAgreement>
<fil:AmountOfPerformanceBonus contextRef="Context_Custom_27-Feb-2013_28-Feb-2013_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_SeparationAndSettlementAgreementMember_TitleOfIndividualAxis_FormerChiefExecutiveOfficerMember" unitRef="USD" decimals="0">60000</fil:AmountOfPerformanceBonus>
<fil:PeriodOfService contextRef="Context_Custom_27-Feb-2013_28-Feb-2013_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_SeparationAndSettlementAgreementMember_TitleOfIndividualAxis_FormerChiefExecutiveOfficerMember">August 15, 2012 to December 31, 2012</fil:PeriodOfService>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_FYE__31-Dec-2011" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_FYE__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_Custom_14-Jun-2000_31-Dec-2012" unitRef="USD" decimals="0">-550186</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-4122</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_Custom_14-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-554308</us-gaap:GainLossOnDispositionOfAssets1>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Item_1" xlink:label="lab_Item_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_1" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_3" xlink:label="lab_Item_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_3" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_4" xlink:label="lab_Item_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_4" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_6" xlink:label="lab_Item_6"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_6" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_7" xlink:label="lab_Item_7"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_7" xlink:to="Footnote_5" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_8" xlink:label="lab_Item_8"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_8" xlink:to="Footnote_9" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_10" xlink:label="lab_Item_10"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_10" xlink:to="Footnote_9" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_11" xlink:label="lab_Item_11"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_11" xlink:to="Footnote_9" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_12" xlink:label="lab_Item_12"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_12" xlink:to="Footnote_13" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_14" xlink:label="lab_Item_14"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_14" xlink:to="Footnote_13" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_15" xlink:label="lab_Item_15"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_15" xlink:to="Footnote_16" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_17" xlink:label="lab_Item_17"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_17" xlink:to="Footnote_16" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_18" xlink:label="lab_Item_18"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_18" xlink:to="Footnote_16" order="1.0"/>
<link:footnote xlink:type="resource" xlink:label="Footnote_2" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The market value of common stock is based on an enterprise valuation</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_5" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_9" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_13" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_16" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>fil-20130930.xsd
<DESCRIPTION>XBRL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://cactusventuresinc.com/20130930" elementFormDefault="qualified"
xmlns:fil="http://cactusventuresinc.com/20130930"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:us-types="http://fasb.org/us-types/2013-01-31"
>
<annotation><appinfo>
<link:roleType roleURI="http://cactusventuresinc.com/role/DocumentAndEntityInformation1" id="DocumentAndEntityInformation1">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/ConsolidatedBalanceSheetsparenthetical" id="ConsolidatedBalanceSheetsparenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>004 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Consolidatedstatementofchangesinstockholdersequitydeficit" id="Consolidatedstatementofchangesinstockholdersequitydeficit">
<link:definition>005 - Statement - Consolidated Statement of Changes in Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
<link:definition>006 - Statement - Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<link:definition>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Notes11" id="Notes11">
<link:definition>008 - Disclosure - Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/RelatedPartyTransaction" id="RelatedPartyTransaction">
<link:definition>009 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>010 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotes" id="NotePayableAndConvertibleNotes">
<link:definition>011 - Disclosure - Note Payable and Convertible Notes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Derivatives" id="Derivatives">
<link:definition>012 - Disclosure - Derivatives</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>013 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>014 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Equity" id="Equity">
<link:definition>015 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/StockOptionPlan" id="StockOptionPlan">
<link:definition>016 - Disclosure - Stock Option Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Warrants" id="Warrants">
<link:definition>017 - Disclosure - Warrants</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/EmployeeDefinedContributionPlan" id="EmployeeDefinedContributionPlan">
<link:definition>018 - Disclosure - Employee Defined Contribution Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Notes13" id="Notes13">
<link:definition>019 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<link:definition>020 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<link:definition>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/RelatedPartyTransactiontables" id="RelatedPartyTransactiontables">
<link:definition>022 - Disclosure - Related Party Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentTables" id="PropertyandEquipmentTables">
<link:definition>023 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesTables" id="NotePayableAndConvertibleNotesTables">
<link:definition>024 - Disclosure - Note Payable and Convertible Notes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DerivativesTables" id="DerivativesTables">
<link:definition>025 - Disclosure - Derivatives (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>026 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>027 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/StockOptionPlanTables" id="StockOptionPlanTables">
<link:definition>028 - Disclosure - Stock Option Plan (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/EquityTables" id="EquityTables">
<link:definition>029 - Disclosure - Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/WarrantsTables" id="WarrantsTables">
<link:definition>030 - Disclosure - Warrants (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<link:definition>031 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1">
<link:definition>032 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/GoingconcernDetails" id="GoingconcernDetails">
<link:definition>033 - Disclosure - Going concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/RelatedPartyTransactiondetails" id="RelatedPartyTransactiondetails">
<link:definition>034 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Relatedpartytransactiondetailstextual" id="Relatedpartytransactiondetailstextual">
<link:definition>035 - Disclosure - Related Party Transactions (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentDetails" id="PropertyandEquipmentDetails">
<link:definition>036 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Propertyandequipmentdetailstesxtual" id="Propertyandequipmentdetailstesxtual">
<link:definition>037 - Disclosure - Property and Equipment (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetails" id="NotePayableAndConvertibleNotesDetails">
<link:definition>038 - Disclosure - Note Payable and Convertible Notes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetailsTextual" id="NotePayableAndConvertibleNotesDetailsTextual">
<link:definition>039 - Disclosure - Note Payable and Convertible Notes (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DerivativesDetails" id="DerivativesDetails">
<link:definition>040 - Disclosure - Derivatives (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DerivativesDetails1" id="DerivativesDetails1">
<link:definition>041 - Disclosure - Derivatives (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DerivativesDetailsTextual" id="DerivativesDetailsTextual">
<link:definition>042 - Disclosure - Derivatives (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>043 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
<link:definition>044 - Disclosure - Income Taxes (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/IncometaxesdetailsTextual" id="IncometaxesdetailsTextual">
<link:definition>045 - Disclosure - Income Taxes (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
<link:definition>046 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
<link:definition>047 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1" id="CommitmentsAndContingenciesDetailsTextual1">
<link:definition>048 - Disclosure - Commitments and Contingencies (Details Textual 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Equitydetails" id="Equitydetails">
<link:definition>049 - Disclosure - Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Equitydetailstextual" id="Equitydetailstextual">
<link:definition>050 - Disclosure - Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/StockOptionPlanDetails" id="StockOptionPlanDetails">
<link:definition>051 - Disclosure - Stock Option Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/StockOptionPlanDetailsTextual" id="StockOptionPlanDetailsTextual">
<link:definition>052 - Disclosure - Stock Option Plan (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/WarrantsDetails" id="WarrantsDetails">
<link:definition>053 - Disclosure - Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/WarrantsDetails1" id="WarrantsDetails1">
<link:definition>054 - Disclosure - Warrants (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/WarrantsDetailsTextual" id="WarrantsDetailsTextual">
<link:definition>055 - Disclosure - Warrants (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/EmployeeDefinedContributionPlanDetails" id="EmployeeDefinedContributionPlanDetails">
<link:definition>056 - Disclosure - Employee Defined Contribution Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/SubsequenteventsDetails" id="SubsequenteventsDetails">
<link:definition>057 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="fil-20130930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="fil-20130930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="fil-20130930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="fil-20130930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
<import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="fil_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeriesCTwoPreferredStockMember" id="fil_SeriesCTwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeriesCThreePreferredStockMember" id="fil_SeriesCThreePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeriesCFourPreferredStockMember" id="fil_SeriesCFourPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssuanceOfCommonStockShares" id="fil_ProceedsFromIssuanceOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionOfNotesPayableAndAccruedInterestToStockValue" id="fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionOfNotesPayableAndAccruedInterestToStockShares" id="fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SharesIssuedAtReverseMergerValue" id="fil_SharesIssuedAtReverseMergerValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SharesIssuedAtReverseMergerShares" id="fil_SharesIssuedAtReverseMergerShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdjustmentsToAdditionalPaidInCapitalWarrantExpense" id="fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" id="fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfTransferFromLiabilityClassificationToEquityClassification" id="fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RetireOfDerivativeLiability" id="fil_RetireOfDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="GainOnChangeInFairValueOfDerivatives" id="fil_GainOnChangeInFairValueOfDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CashPaidForAbstract" id="fil_CashPaidForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfWarrantsIssuedWithDebt" id="fil_FairValueOfWarrantsIssuedWithDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfWarrantsIssuedWithStock" id="fil_FairValueOfWarrantsIssuedWithStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfWarrantsIssuedToPlacementAgent" id="fil_FairValueOfWarrantsIssuedToPlacementAgent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionOfNotesPayableAndAccruedInterestToCommonStock" id="fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoingConcernAbstract" id="fil_GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoingConcernTextBlock" id="fil_GoingConcernTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsAbstract" id="fil_WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsTextBlock" id="fil_WarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DevelopmentStageCompanyPolicyTextBlock" id="fil_DevelopmentStageCompanyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" id="fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentsMilestoneMethodTable" id="fil_MilestonePaymentsMilestoneMethodTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AbbottBiotherapeuticsCorpMember" id="fil_AbbottBiotherapeuticsCorpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MemorialSloanKetteringCancerCenterMember" id="fil_MemorialSloanKetteringCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentsMilestoneMethodLineItems" id="fil_MilestonePaymentsMilestoneMethodLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentsMilestoneMethodTableTextBlock" id="fil_MilestonePaymentsMilestoneMethodTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfWarrantsIssuedTableTextBlock" id="fil_ScheduleOfWarrantsIssuedTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfWarrantActivitiesTableTextBlock" id="fil_SummaryOfWarrantActivitiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" id="fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" id="fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ActiniumMember" id="fil_ActiniumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionsAndWarrantsMember" id="fil_OptionsAndWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" id="fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" id="fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfOwnershipInterestToBeAcquired" id="fil_PercentageOfOwnershipInterestToBeAcquired" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockIssuableInConsiderationForEquityInterestAcquisition" id="fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" id="fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfSharesExchangedInShareExchangeProgramme" id="fil_PercentageOfSharesExchangedInShareExchangeProgramme" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessAcquisitionNumberOfSharesExchanged" id="fil_BusinessAcquisitionNumberOfSharesExchanged" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoingConcernTextualAbstract" id="fil_GoingConcernTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" id="fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ReimbursementsReceivedFromRelatedParty" id="fil_ReimbursementsReceivedFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SloanKetteringInstituteOfCancerResearchMember" id="fil_SloanKetteringInstituteOfCancerResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" id="fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RosemaryMazanetMember" id="fil_RosemaryMazanetMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LaidlawAndCompanyMember" id="fil_LaidlawAndCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="JamessCapitalGroupMember" id="fil_JamessCapitalGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GuagentiAndAssociatesMember" id="fil_GuagentiAndAssociatesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" id="fil_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" id="fil_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ClinicalTrialAgreementMember" id="fil_ClinicalTrialAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LicenseDevelopmentAndCommercializationAgreementMember" id="fil_LicenseDevelopmentAndCommercializationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsultingServicesAgreementMember" id="fil_ConsultingServicesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EngagementAgreementMember" id="fil_EngagementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TransactionManagementAgreementMember" id="fil_TransactionManagementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsTextualAbstract" id="fil_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NumberOfPatients" id="fil_NumberOfPatients" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidUnderAgreementInYearTwoThousandEleven" id="fil_AmountPaidUnderAgreementInYearTwoThousandEleven" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidUnderAgreementInYearTwoThousandTwelve" id="fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidUnderAgreementInYearTwoThousandThirteen" id="fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="MaintenanceFeesAndResearchPayments" id="fil_MaintenanceFeesAndResearchPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidUnderAgreement" id="fil_AmountPaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdditionalAmountDueUnderAgreement" id="fil_AdditionalAmountDueUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfConditionForTerminationOfForbearancePeriod" id="fil_DescriptionOfConditionForTerminationOfForbearancePeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TerminationDateOfForbearanceAgreement" id="fil_TerminationDateOfForbearanceAgreement" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" id="fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NewEquityFinanceRaisedByCompany" id="fil_NewEquityFinanceRaisedByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ForgivenAmountOfObligations" id="fil_ForgivenAmountOfObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" id="fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidToEachPatient" id="fil_AmountPaidToEachPatient" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StartUpFeeForClinicalTrial" id="fil_StartUpFeeForClinicalTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StartUpDueCostPaidDate" id="fil_StartUpDueCostPaidDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfSharesTransferTerm" id="fil_DescriptionOfSharesTransferTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionExercisePriceRange" id="fil_OptionExercisePriceRange" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionsReceivedToPurchaseCommonStock" id="fil_OptionsReceivedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfReceivablesOfPlacementAgentForServices" id="fil_DescriptionOfReceivablesOfPlacementAgentForServices" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfWarrantsReceivablesByPlacement" id="fil_DescriptionOfWarrantsReceivablesByPlacement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodOfExerciseOfWarrants" id="fil_PeriodOfExerciseOfWarrants" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfSolicitationFee" id="fil_PercentageOfSolicitationFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodicFeeForFinancialAdvisoryServices" id="fil_PeriodicFeeForFinancialAdvisoryServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAdditionalReceivableByPlacementAgent" id="fil_DescriptionOfAdditionalReceivableByPlacementAgent" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockPurchaseByHoldingOfWarrant" id="fil_CommonStockPurchaseByHoldingOfWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodicFeeReceivedByManagementFirm" id="fil_PeriodicFeeReceivedByManagementFirm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfFullyDilutedCapitalStockEqualToCommonStock" id="fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MaximumAmountOfOutOfPocketExpenses" id="fil_MaximumAmountOfOutOfPocketExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodicAmountOfRent" id="fil_PeriodicAmountOfRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidToPursuantLeaseAgreement" id="fil_AmountPaidToPursuantLeaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="LossOnDispositionOfPropertyAndEquipment" id="fil_LossOnDispositionOfPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PropertyAndEquipmentTextualAbstract" id="fil_PropertyAndEquipmentTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" id="fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfConvertiblePromissoryNotesAbstract" id="fil_SummaryOfConvertiblePromissoryNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DiscountRelatedToFairValueOfDerivativeWarrants" id="fil_DiscountRelatedToFairValueOfDerivativeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentDiscountRelatedToBeneficialConversionFeature" id="fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentAmortizationOfDiscount" id="fil_DebtInstrumentAmortizationOfDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentPrincipalAmountConvertedToCommonStock" id="fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentMember" id="fil_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ManagementFirmMember" id="fil_ManagementFirmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotePayableAndConvertibleNotesTextualAbstract" id="fil_NotePayableAndConvertibleNotesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockPurchaseDueToIssuanceOfWarrants" id="fil_CommonStockPurchaseDueToIssuanceOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmortizationPeriodOfNote" id="fil_AmortizationPeriodOfNote" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumFinanceAgreementPrincipalAmount" id="fil_PremiumFinanceAgreementPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentUnderPremiumFinanceAgreement" id="fil_PaymentUnderPremiumFinanceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodicPaymentUnderPremiumFinanceAgreement" id="fil_PeriodicPaymentUnderPremiumFinanceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DurationOfPeriodicPaymentsForPremiumFinanceAgreement" id="fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumFinanceAgreementOutstandingAmount" id="fil_PremiumFinanceAgreementOutstandingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromConvertibleNotes" id="fil_ProceedsFromConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" id="fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" id="fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantsIssuedWithConvertibleNotes" id="fil_DerivativeWarrantsIssuedWithConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InvestmentWarrantGrantDateFairValue" id="fil_InvestmentWarrantGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentFairValuePerShare" id="fil_DebtInstrumentFairValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExtendedMaturityPeriodOfConvertibleNotes" id="fil_ExtendedMaturityPeriodOfConvertibleNotes" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfExtendedMaturityDate" id="fil_DescriptionOfExtendedMaturityDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InsurancePolicyDownPayment" id="fil_InsurancePolicyDownPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="InsurancePolicyInstallmentPayment" id="fil_InsurancePolicyInstallmentPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" id="fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantsUnits" id="fil_DerivativeWarrantsUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantUnitsReclassificationToPaidInCapital" id="fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" id="fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantsIssuedWithStockOffering" id="fil_DerivativeWarrantsIssuedWithStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" id="fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantsIssuedWithCommonStockOffering" id="fil_DerivativeWarrantsIssuedWithCommonStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantsIssuedWithCommonStockOfferingOne" id="fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativePlacementAgentWarrantsRelatedToStock" id="fil_DerivativePlacementAgentWarrantsRelatedToStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TransferFromLiabilityClassificationToEquityClassification" id="fil_TransferFromLiabilityClassificationToEquityClassification" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" id="fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" id="fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" id="fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativeWarrantsIssuedWithStockOffering" id="fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" id="fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" id="fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" id="fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" id="fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ChangeInFairValueOfDerivativeWarrants" id="fil_ChangeInFairValueOfDerivativeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" id="fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MarketValueOfCommonStockOnMeasurementDate" id="fil_MarketValueOfCommonStockOnMeasurementDate" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="RangeOfPercentageOfExistingSharesOffered" id="fil_RangeOfPercentageOfExistingSharesOffered" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionOfferingPrice" id="fil_FairValueAssumptionOfferingPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeTextualAbstract" id="fil_DerivativeTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfRiskFreeInterestRateDetermination" id="fil_DescriptionOfRiskFreeInterestRateDetermination" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfProbabilityOfStockOffering" id="fil_DescriptionOfProbabilityOfStockOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxesTextualAbstract" id="fil_IncomeTaxesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PhaseFirstClinicalTrialOfLicensedProductMember" id="fil_PhaseFirstClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PhaseSecondClinicalTrialOfLicensedProductMember" id="fil_PhaseSecondClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PhaseThirdClinicalTrialOfLicensedProductMember" id="fil_PhaseThirdClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BiologicalLicenseApplicationMember" id="fil_BiologicalLicenseApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FirstCommercialSaleMember" id="fil_FirstCommercialSaleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AfterFirstNetSalesMember" id="fil_AfterFirstNetSalesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NewDrugApplicationMember" id="fil_NewDrugApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ReceiptOfRegulatoryApprovalFromUSFdaMember" id="fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentAbstract" id="fil_MilestonePaymentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LongTermPurchaseCommitmentMilestonesPayment" id="fil_LongTermPurchaseCommitmentMilestonesPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTable" id="fil_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ChiefExecutiveOfficerAndDirectorMember" id="fil_ChiefExecutiveOfficerAndDirectorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesLineItems" id="fil_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTextualAbstract" id="fil_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PerformanceObjectiveDescription" id="fil_PerformanceObjectiveDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionGrantedToPurchaseSharesAsSignOnBonus" id="fil_OptionGrantedToPurchaseSharesAsSignOnBonus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionGrantedToPurchaseSharesAsSignOnBonusDescription" id="fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OakRidgeNationalLaboratoryMember" id="fil_OakRidgeNationalLaboratoryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AptivSolutionsMember" id="fil_AptivSolutionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FredHutchinsonCancerResearchCenterMember" id="fil_FredHutchinsonCancerResearchCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" id="fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="UniversityOfTexasMDAndersonCancerCenterMember" id="fil_UniversityOfTexasMDAndersonCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="JohnsHopkinsUniversityMember" id="fil_JohnsHopkinsUniversityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LaidlawAndCoMember" id="fil_LaidlawAndCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="UniversityOfPennsylvaniaMember" id="fil_UniversityOfPennsylvaniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProductDevelopmentAndPatentLicenseAgreementMember" id="fil_ProductDevelopmentAndPatentLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementMember" id="fil_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LicenseAndSponsoredResearchAgreementMember" id="fil_LicenseAndSponsoredResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentAgreementMember" id="fil_PlacementAgentAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RentalAgreementMember" id="fil_RentalAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SeparationAndSettlementAgreementMember" id="fil_SeparationAndSettlementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentOfLicenseFee" id="fil_PaymentOfLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentDate" id="fil_MilestonePaymentDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfRoyaltyPaymentToRelatedParty" id="fil_DescriptionOfRoyaltyPaymentToRelatedParty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RoyaltyOfNetSalesPercentage" id="fil_RoyaltyOfNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FirstCommercialSalePeriod" id="fil_FirstCommercialSalePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentArrangement" id="fil_ResearchAndDevelopmentArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PurchaseOfRadioactiveMaterial" id="fil_PurchaseOfRadioactiveMaterial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProjectEstimatedCost" id="fil_ProjectEstimatedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DownPaymentOfProjectEstimatedCostPercentage" id="fil_DownPaymentOfProjectEstimatedCostPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DownPaymentForProject" id="fil_DownPaymentForProject" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ClinicalTrialCostForApprovalForFoodAndDrugAdministration" id="fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FundToRelatedPartyUnderAgreementForFirstTwoYear" id="fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FundToRelatedPartyUnderAgreementAfterYearTwo" id="fil_FundToRelatedPartyUnderAgreementAfterYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NonRefundableInstitutionalFee" id="fil_NonRefundableInstitutionalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PharmacyFee" id="fil_PharmacyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmendmentProcessingFee" id="fil_AmendmentProcessingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantExercisableNoticePeriodDescription" id="fil_WarrantExercisableNoticePeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfSharesAvailabilityByExerciseOfWarrant" id="fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AgreementConsideration" id="fil_AgreementConsideration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPayableInInstallmentsUnderAgreement" id="fil_AmountPayableInInstallmentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NumberOfInstallments" id="fil_NumberOfInstallments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PerformanceBonusPayableUnderAgreementForService" id="fil_PerformanceBonusPayableUnderAgreementForService" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AgreementRenewalDescription" id="fil_AgreementRenewalDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentOfFirstInstallmentForServicesByCompany" id="fil_PaymentOfFirstInstallmentForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentOfFinalInstallmentForServicesByCompany" id="fil_PaymentOfFinalInstallmentForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentOfPerformanceBonusForServicesByCompany" id="fil_PaymentOfPerformanceBonusForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NoticePeriodForTerminationOfAgreement" id="fil_NoticePeriodForTerminationOfAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MccormickOBrienPllcMember" id="fil_MccormickOBrienPllcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandThirteenStockPlanMember" id="fil_TwoThousandThirteenStockPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandThirteenEquityIncentivePlanMember" id="fil_TwoThousandThirteenEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgencyAgreementMember" id="fil_PlacementAgencyAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="JamessCapitalGroupLlcMember" id="fil_JamessCapitalGroupLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantOneMember" id="fil_WarrantOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsBMember" id="fil_WarrantsBMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FormerDirectorAndConsultantsMember" id="fil_FormerDirectorAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeesDirectorsAndConsultantsMember" id="fil_EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EquityTextualAbstract" id="fil_EquityTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedToPurchaseCommonStockOffering" id="fil_WarrantsIssuedToPurchaseCommonStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseOfferingOfCommonStock" id="fil_IncreaseOfferingOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesIssuedInStockOffering" id="fil_CommonStockSharesIssuedInStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssuanceOfStockUnderStockOfferingNet" id="fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentCashFees" id="fil_PlacementAgentCashFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentCommission" id="fil_PlacementAgentCommission" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentExpenseReimbursement" id="fil_PlacementAgentExpenseReimbursement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedToPurchaseCommonStock" id="fil_WarrantsIssuedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsExpirationTerm" id="fil_WarrantsExpirationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentServicesFees" id="fil_PlacementAgentServicesFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="BankEscrowFee" id="fil_BankEscrowFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedManagementFees" id="fil_AccruedManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" id="fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" id="fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="UnrecognizedShareBasedCompensationExpense" id="fil_UnrecognizedShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountPaidForCancellationOfSharesByCompany" id="fil_AmountPaidForCancellationOfSharesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SharesPurchasedAfterCancelationOfOptions" id="fil_SharesPurchasedAfterCancelationOfOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" id="fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandThreeStockPlanMember" id="fil_TwoThousandThreeStockPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwelveEmployeeStockOptionPlanMember" id="fil_TwoThousandTwelveEmployeeStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeesAndConsultantsMember" id="fil_EmployeesAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsultantsMember" id="fil_ConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockOptionPlanTextualAbstract" id="fil_StockOptionPlanTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" id="fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" id="fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" id="fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" id="fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockOptionGrantedToPurchaseCommonStock" id="fil_StockOptionGrantedToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockOptionGrantedToPurchaseCommonStockExercisePrice" id="fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" id="fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeeStockOptionUnitsReprised" id="fil_EmployeeStockOptionUnitsReprised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" id="fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationCostAfterRepricingOfStockOptions" id="fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAbstract" id="fil_WarrantsIssuedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedWithConvertibleNotes" id="fil_WarrantsIssuedWithConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedToInvestorsWithStockOffering" id="fil_WarrantsIssuedToInvestorsWithStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedToInvestorsWithCommonStock" id="fil_WarrantsIssuedToInvestorsWithCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" id="fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" id="fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" id="fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantIssuedToInvestorsWithStockAccruedDividend" id="fil_WarrantIssuedToInvestorsWithStockAccruedDividend" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssued" id="fil_WarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantTextualAbstract" id="fil_WarrantTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeeDefinedContributionPlanTextualAbstract" id="fil_EmployeeDefinedContributionPlanTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FormerChiefExecutiveOfficerMember" id="fil_FormerChiefExecutiveOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubsequentEventsTextualAbstract" id="fil_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NumberOfInstallmentsInWhichConsiderationIsPayable" id="fil_NumberOfInstallmentsInWhichConsiderationIsPayable" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsiderationPayableUnderAgreement" id="fil_ConsiderationPayableUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountOfPerformanceBonus" id="fil_AmountOfPerformanceBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PeriodOfService" id="fil_PeriodOfService" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>fil-20130930_cal.xml
<DESCRIPTION>XBRL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedBalanceSheets" roleURI="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="40" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedStatementsOfOperations" roleURI="http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SalesRevenueNet" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationAndAmortization" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="50" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesRevenueNet" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StatementsOfCashFlows" roleURI="http://cactusventuresinc.com/role/StatementsOfCashFlows"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_fil_GainOnChangeInFairValueOfDerivatives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_fil_GainOnChangeInFairValueOfDerivatives" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="100" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="120" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyandEquipmentDetails" roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LossOnDispositionOfPropertyAndEquipment" xlink:label="loc_fil_LossOnDispositionOfPropertyAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_fil_LossOnDispositionOfPropertyAndEquipment" order="30" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayableAndConvertibleNotesDetails" roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DiscountRelatedToFairValueOfDerivativeWarrants" xlink:label="loc_fil_DiscountRelatedToFairValueOfDerivativeWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="loc_fil_DiscountRelatedToFairValueOfDerivativeWarrants" order="30" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="loc_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentAmortizationOfDiscount" xlink:label="loc_fil_DebtInstrumentAmortizationOfDiscount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="loc_fil_DebtInstrumentAmortizationOfDiscount" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" xlink:label="loc_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="loc_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" order="60" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#IncomeTaxesDetails" roleURI="http://cactusventuresinc.com/role/IncomeTaxesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#IncomeTaxesDetails1" roleURI="http://cactusventuresinc.com/role/IncomeTaxesDetails1"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncomeTaxesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncomeTaxesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="50" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#WarrantsDetails" roleURI="http://cactusventuresinc.com/role/WarrantsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/WarrantsDetails">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssued" xlink:label="loc_fil_WarrantsIssued" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedWithConvertibleNotes" xlink:label="loc_fil_WarrantsIssuedWithConvertibleNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fil_WarrantsIssued" xlink:to="loc_fil_WarrantsIssuedWithConvertibleNotes" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToInvestorsWithStockOffering" xlink:label="loc_fil_WarrantsIssuedToInvestorsWithStockOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fil_WarrantsIssued" xlink:to="loc_fil_WarrantsIssuedToInvestorsWithStockOffering" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToInvestorsWithCommonStock" xlink:label="loc_fil_WarrantsIssuedToInvestorsWithCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fil_WarrantsIssued" xlink:to="loc_fil_WarrantsIssuedToInvestorsWithCommonStock" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:label="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fil_WarrantsIssued" xlink:to="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" xlink:label="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fil_WarrantsIssued" xlink:to="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" xlink:label="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fil_WarrantsIssued" xlink:to="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantIssuedToInvestorsWithStockAccruedDividend" xlink:label="loc_fil_WarrantIssuedToInvestorsWithStockAccruedDividend" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fil_WarrantsIssued" xlink:to="loc_fil_WarrantIssuedToInvestorsWithStockAccruedDividend" order="70" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>fil-20130930_def.xml
<DESCRIPTION>XBRL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" >
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedBalanceSheets" roleURI="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedBalanceSheetsparenthetical" roleURI="http://cactusventuresinc.com/role/ConsolidatedBalanceSheetsparenthetical"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Consolidatedstatementofchangesinstockholdersequitydeficit" roleURI="http://cactusventuresinc.com/role/Consolidatedstatementofchangesinstockholdersequitydeficit"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StatementsOfCashFlows" roleURI="http://cactusventuresinc.com/role/StatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsandContingenciesTables" roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EquityTables" roleURI="http://cactusventuresinc.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Relatedpartytransactiondetailstextual" roleURI="http://cactusventuresinc.com/role/Relatedpartytransactiondetailstextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyandEquipmentDetails" roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayableAndConvertibleNotesDetails" roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayableAndConvertibleNotesDetailsTextual" roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetails1" roleURI="http://cactusventuresinc.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetailsTextual" roleURI="http://cactusventuresinc.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsandContingenciesDetails" roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingenciesDetailsTextual1" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Equitydetails" roleURI="http://cactusventuresinc.com/role/Equitydetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Equitydetailstextual" roleURI="http://cactusventuresinc.com/role/Equitydetailstextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StockOptionPlanDetails" roleURI="http://cactusventuresinc.com/role/StockOptionPlanDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StockOptionPlanDetailsTextual" roleURI="http://cactusventuresinc.com/role/StockOptionPlanDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#WarrantsDetails1" roleURI="http://cactusventuresinc.com/role/WarrantsDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#WarrantsDetailsTextual" roleURI="http://cactusventuresinc.com/role/WarrantsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#SubsequenteventsDetails" roleURI="http://cactusventuresinc.com/role/SubsequenteventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_fil_SeriesCTwoPreferredStockMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCTwoPreferredStockMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_fil_SeriesCThreePreferredStockMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCThreePreferredStockMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_fil_SeriesCFourPreferredStockMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCFourPreferredStockMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_AssetsCurrentAbstract_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_17" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_13" xlink:to="loc_us-gaap_AssetsCurrent_18" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_Assets_20" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_22" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_23" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_24" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_NotesPayableCurrent_25" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_26" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_27" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_LiabilitiesCurrent_28" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_22" xlink:to="loc_us-gaap_Liabilities_29" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommitmentsAndContingencies_30" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquityAbstract_31" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_PreferredStockValue_32" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_CommonStockValue_33" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_AdditionalPaidInCapital_34" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_35" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_31" xlink:to="loc_us-gaap_StockholdersEquity_36" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_37" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheetsparenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_fil_SeriesCTwoPreferredStockMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCTwoPreferredStockMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_fil_SeriesCThreePreferredStockMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCThreePreferredStockMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_fil_SeriesCFourPreferredStockMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCFourPreferredStockMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_13" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_14" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_15" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_17" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_18" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19" order="80" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Consolidatedstatementofchangesinstockholdersequitydeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_fil_SeriesCTwoPreferredStockMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_fil_SeriesCTwoPreferredStockMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_fil_SeriesCThreePreferredStockMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_fil_SeriesCThreePreferredStockMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_fil_SeriesCFourPreferredStockMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_fil_SeriesCFourPreferredStockMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_12" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_13" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_14" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_15" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_17" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_18" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_20" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProceedsFromIssuanceOfCommonStockShares" xlink:label="loc_fil_ProceedsFromIssuanceOfCommonStockShares_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_ProceedsFromIssuanceOfCommonStockShares_21" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_22" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" xlink:label="loc_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue_24" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" xlink:label="loc_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares_25" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesIssuedAtReverseMergerValue" xlink:label="loc_fil_SharesIssuedAtReverseMergerValue_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_SharesIssuedAtReverseMergerValue_26" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesIssuedAtReverseMergerShares" xlink:label="loc_fil_SharesIssuedAtReverseMergerShares_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_SharesIssuedAtReverseMergerShares_27" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_28" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" xlink:label="loc_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense_29" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" xlink:label="loc_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants_30" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_31" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RetireOfDerivativeLiability" xlink:label="loc_fil_RetireOfDerivativeLiability_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_RetireOfDerivativeLiability_32" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_33" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_34" order="190" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetIncomeLoss_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_5" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_7" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_10" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_fil_GainOnChangeInFairValueOfDerivatives_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_fil_GainOnChangeInFairValueOfDerivatives_11" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_15" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_20" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_24" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_25" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_26" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_27" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_29" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CashPaidForAbstract" xlink:label="loc_fil_CashPaidForAbstract_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_fil_CashPaidForAbstract_31" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CashPaidForAbstract_31" xlink:to="loc_us-gaap_InterestPaid_32" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CashPaidForAbstract_31" xlink:to="loc_us-gaap_IncomeTaxesPaid_33" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_35" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithDebt" xlink:label="loc_fil_FairValueOfWarrantsIssuedWithDebt_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_FairValueOfWarrantsIssuedWithDebt_36" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithStock" xlink:label="loc_fil_FairValueOfWarrantsIssuedWithStock_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_FairValueOfWarrantsIssuedWithStock_37" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="loc_fil_FairValueOfWarrantsIssuedToPlacementAgent_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_FairValueOfWarrantsIssuedToPlacementAgent_38" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock_39" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_40" order="50" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodLineItems" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodLineItems_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTable" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodLineItems_0" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodTableTextBlock_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodLineItems_0" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodTableTextBlock_6" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xlink:label="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_7" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ActiniumMember" xlink:label="loc_fil_ActiniumMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_fil_ActiniumMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_13" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_14" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsAndWarrantsMember" xlink:label="loc_fil_OptionsAndWarrantsMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_fil_OptionsAndWarrantsMember_15" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_CommonStockMember_16" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_17" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_17" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_18_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_17" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_18_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_18" xlink:to="loc_us-gaap_SubsequentEventMember_19" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfOwnershipInterestToBeAcquired" xlink:label="loc_fil_PercentageOfOwnershipInterestToBeAcquired_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_fil_PercentageOfOwnershipInterestToBeAcquired_21" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition_22" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" xlink:label="loc_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage_23" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_24" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_25" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_26" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfSharesExchangedInShareExchangeProgramme" xlink:label="loc_fil_PercentageOfSharesExchangedInShareExchangeProgramme_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_fil_PercentageOfSharesExchangedInShareExchangeProgramme_28" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BusinessAcquisitionNumberOfSharesExchanged" xlink:label="loc_fil_BusinessAcquisitionNumberOfSharesExchanged_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_20" xlink:to="loc_fil_BusinessAcquisitionNumberOfSharesExchanged_29" order="80" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Relatedpartytransactiondetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_fil_SloanKetteringInstituteOfCancerResearchMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_SloanKetteringInstituteOfCancerResearchMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RosemaryMazanetMember" xlink:label="loc_fil_RosemaryMazanetMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_RosemaryMazanetMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCompanyMember" xlink:label="loc_fil_LaidlawAndCompanyMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_LaidlawAndCompanyMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupMember" xlink:label="loc_fil_JamessCapitalGroupMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JamessCapitalGroupMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GuagentiAndAssociatesMember" xlink:label="loc_fil_GuagentiAndAssociatesMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_GuagentiAndAssociatesMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_fil_AgreementAxis_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_fil_AgreementAxis_11" xlink:to="loc_fil_AgreementDomain_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_12_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_fil_AgreementAxis_11" xlink:to="loc_fil_AgreementDomain_12_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialAgreementMember" xlink:label="loc_fil_ClinicalTrialAgreementMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_ClinicalTrialAgreementMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_fil_LicenseDevelopmentAndCommercializationAgreementMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_LicenseDevelopmentAndCommercializationAgreementMember_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultingServicesAgreementMember" xlink:label="loc_fil_ConsultingServicesAgreementMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_ConsultingServicesAgreementMember_15" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EngagementAgreementMember" xlink:label="loc_fil_EngagementAgreementMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_EngagementAgreementMember_16" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransactionManagementAgreementMember" xlink:label="loc_fil_TransactionManagementAgreementMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_TransactionManagementAgreementMember_17" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_fil_RelatedPartyTransactionsTextualAbstract_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_fil_RelatedPartyTransactionsTextualAbstract_18" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfPatients" xlink:label="loc_fil_NumberOfPatients_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_NumberOfPatients_19" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_fil_AmountPaidUnderAgreementInYearTwoThousandEleven_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_AmountPaidUnderAgreementInYearTwoThousandEleven_20" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve_21" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen_22" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaintenanceFeesAndResearchPayments" xlink:label="loc_fil_MaintenanceFeesAndResearchPayments_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_MaintenanceFeesAndResearchPayments_23" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreement" xlink:label="loc_fil_AmountPaidUnderAgreement_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_AmountPaidUnderAgreement_24" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdditionalAmountDueUnderAgreement" xlink:label="loc_fil_AdditionalAmountDueUnderAgreement_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_AdditionalAmountDueUnderAgreement_25" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_fil_DescriptionOfConditionForTerminationOfForbearancePeriod_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_DescriptionOfConditionForTerminationOfForbearancePeriod_26" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TerminationDateOfForbearanceAgreement" xlink:label="loc_fil_TerminationDateOfForbearanceAgreement_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_TerminationDateOfForbearanceAgreement_27" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_28" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewEquityFinanceRaisedByCompany" xlink:label="loc_fil_NewEquityFinanceRaisedByCompany_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_NewEquityFinanceRaisedByCompany_29" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ForgivenAmountOfObligations" xlink:label="loc_fil_ForgivenAmountOfObligations_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_ForgivenAmountOfObligations_30" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" xlink:label="loc_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty_31" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_32" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToEachPatient" xlink:label="loc_fil_AmountPaidToEachPatient_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_AmountPaidToEachPatient_33" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpFeeForClinicalTrial" xlink:label="loc_fil_StartUpFeeForClinicalTrial_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_StartUpFeeForClinicalTrial_34" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpDueCostPaidDate" xlink:label="loc_fil_StartUpDueCostPaidDate_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_StartUpDueCostPaidDate_35" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesTransferTerm" xlink:label="loc_fil_DescriptionOfSharesTransferTerm_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_DescriptionOfSharesTransferTerm_36" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_us-gaap_OfficersCompensation_37" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionExercisePriceRange" xlink:label="loc_fil_OptionExercisePriceRange_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_OptionExercisePriceRange_38" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_39" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_fil_OptionsReceivedToPurchaseCommonStock_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_OptionsReceivedToPurchaseCommonStock_40" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_fil_DescriptionOfReceivablesOfPlacementAgentForServices_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_DescriptionOfReceivablesOfPlacementAgentForServices_41" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_fil_DescriptionOfWarrantsReceivablesByPlacement_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_DescriptionOfWarrantsReceivablesByPlacement_42" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodOfExerciseOfWarrants" xlink:label="loc_fil_PeriodOfExerciseOfWarrants_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_PeriodOfExerciseOfWarrants_43" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfSolicitationFee" xlink:label="loc_fil_PercentageOfSolicitationFee_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_PercentageOfSolicitationFee_44" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_fil_PeriodicFeeForFinancialAdvisoryServices_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_PeriodicFeeForFinancialAdvisoryServices_45" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_fil_DescriptionOfAdditionalReceivableByPlacementAgent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_DescriptionOfAdditionalReceivableByPlacementAgent_46" order="270" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_fil_CommonStockPurchaseByHoldingOfWarrant_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_CommonStockPurchaseByHoldingOfWarrant_47" order="280" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_fil_PeriodicFeeReceivedByManagementFirm_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_PeriodicFeeReceivedByManagementFirm_48" order="290" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_49" order="300" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_fil_MaximumAmountOfOutOfPocketExpenses_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_MaximumAmountOfOutOfPocketExpenses_50" order="310" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicAmountOfRent" xlink:label="loc_fil_PeriodicAmountOfRent_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_PeriodicAmountOfRent_51" order="320" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_fil_AmountPaidToPursuantLeaseAgreement_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_18" xlink:to="loc_fil_AmountPaidToPursuantLeaseAgreement_52" order="330" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LossOnDispositionOfPropertyAndEquipment" xlink:label="loc_fil_LossOnDispositionOfPropertyAndEquipment_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_fil_LossOnDispositionOfPropertyAndEquipment_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" xlink:label="loc_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3" xlink:to="loc_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfConvertiblePromissoryNotesAbstract" xlink:label="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DiscountRelatedToFairValueOfDerivativeWarrants" xlink:label="loc_fil_DiscountRelatedToFairValueOfDerivativeWarrants_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" xlink:to="loc_fil_DiscountRelatedToFairValueOfDerivativeWarrants_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" xlink:to="loc_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentAmortizationOfDiscount" xlink:label="loc_fil_DebtInstrumentAmortizationOfDiscount_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" xlink:to="loc_fil_DebtInstrumentAmortizationOfDiscount_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" xlink:label="loc_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" xlink:to="loc_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_5" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_12" order="60" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentMember" xlink:label="loc_fil_PlacementAgentMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_PlacementAgentMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ManagementFirmMember" xlink:label="loc_fil_ManagementFirmMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_ManagementFirmMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_0" xlink:to="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_fil_CommonStockPurchaseDueToIssuanceOfWarrants_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_6" xlink:to="loc_fil_CommonStockPurchaseDueToIssuanceOfWarrants_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_6" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_6" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmortizationPeriodOfNote" xlink:label="loc_fil_AmortizationPeriodOfNote_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_6" xlink:to="loc_fil_AmortizationPeriodOfNote_12" order="50" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_fil_MarketValueOfCommonStockOnMeasurementDate_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_fil_MarketValueOfCommonStockOnMeasurementDate_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_13" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_fil_RangeOfPercentageOfExistingSharesOffered_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_fil_RangeOfPercentageOfExistingSharesOffered_14" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueAssumptionOfferingPrice" xlink:label="loc_fil_FairValueAssumptionOfferingPrice_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_fil_FairValueAssumptionOfferingPrice_15" order="80" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeTextualAbstract" xlink:label="loc_fil_DerivativeTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0" xlink:to="loc_fil_DerivativeTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DerivativeTextualAbstract_5" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_6" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseSecondClinicalTrialOfLicensedProductMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseThirdClinicalTrialOfLicensedProductMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BiologicalLicenseApplicationMember" xlink:label="loc_fil_BiologicalLicenseApplicationMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_BiologicalLicenseApplicationMember_11" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSaleMember" xlink:label="loc_fil_FirstCommercialSaleMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_FirstCommercialSaleMember_12" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_fil_AfterFirstNetSalesMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_AfterFirstNetSalesMember_13" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewDrugApplicationMember" xlink:label="loc_fil_NewDrugApplicationMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_NewDrugApplicationMember_14" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentAbstract" xlink:label="loc_fil_MilestonePaymentAbstract_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_fil_MilestonePaymentAbstract_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_MilestonePaymentAbstract_16" xlink:to="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_17" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_fil_CommitmentsAndContingenciesLineItems_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_fil_CommitmentsAndContingenciesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_fil_CommitmentsAndContingenciesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChiefExecutiveOfficerAndDirectorMember" xlink:label="loc_fil_ChiefExecutiveOfficerAndDirectorMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_fil_ChiefExecutiveOfficerAndDirectorMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_AgreementAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_fil_AgreementAxis_5" xlink:to="loc_fil_AgreementDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_fil_AgreementAxis_5" xlink:to="loc_fil_AgreementDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_6" xlink:to="loc_us-gaap_EmploymentContractsMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_RestrictedStockMember_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_us-gaap_OfficersCompensation_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceObjectiveDescription" xlink:label="loc_fil_PerformanceObjectiveDescription_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_PerformanceObjectiveDescription_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xlink:label="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonus_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonus_19" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xlink:label="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription_20" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_fil_CommitmentsAndContingenciesLineItems_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_fil_CommitmentsAndContingenciesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_fil_CommitmentsAndContingenciesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OakRidgeNationalLaboratoryMember" xlink:label="loc_fil_OakRidgeNationalLaboratoryMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_OakRidgeNationalLaboratoryMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AptivSolutionsMember" xlink:label="loc_fil_AptivSolutionsMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AptivSolutionsMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_fil_FredHutchinsonCancerResearchCenterMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_fil_UniversityOfTexasMDAndersonCancerCenterMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JohnsHopkinsUniversityMember" xlink:label="loc_fil_JohnsHopkinsUniversityMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JohnsHopkinsUniversityMember_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCoMember" xlink:label="loc_fil_LaidlawAndCoMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_LaidlawAndCoMember_12" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfPennsylvaniaMember" xlink:label="loc_fil_UniversityOfPennsylvaniaMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_UniversityOfPennsylvaniaMember_13" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupMember" xlink:label="loc_fil_JamessCapitalGroupMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JamessCapitalGroupMember_14" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_15" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_fil_AfterFirstNetSalesMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_fil_AfterFirstNetSalesMember_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_AgreementAxis_20" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_fil_AgreementAxis_20" xlink:to="loc_fil_AgreementDomain_21" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_21_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_fil_AgreementAxis_20" xlink:to="loc_fil_AgreementDomain_21_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_fil_ProductDevelopmentAndPatentLicenseAgreementMember_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_ProductDevelopmentAndPatentLicenseAgreementMember_22" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAgreementMember" xlink:label="loc_fil_LicenseAgreementMember_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_LicenseAgreementMember_23" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_fil_LicenseAndSponsoredResearchAgreementMember_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_LicenseAndSponsoredResearchAgreementMember_24" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialAgreementMember" xlink:label="loc_fil_ClinicalTrialAgreementMember_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_ClinicalTrialAgreementMember_25" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentAgreementMember" xlink:label="loc_fil_PlacementAgentAgreementMember_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_PlacementAgentAgreementMember_26" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransactionManagementAgreementMember" xlink:label="loc_fil_TransactionManagementAgreementMember_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_TransactionManagementAgreementMember_27" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RentalAgreementMember" xlink:label="loc_fil_RentalAgreementMember_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_RentalAgreementMember_28" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeparationAndSettlementAgreementMember" xlink:label="loc_fil_SeparationAndSettlementAgreementMember_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_SeparationAndSettlementAgreementMember_29" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_30" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31" xlink:to="loc_us-gaap_EmployeeStockOptionMember_32" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33" xlink:to="loc_us-gaap_EquityComponentDomain_34" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_34_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33" xlink:to="loc_us-gaap_EquityComponentDomain_34_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_34" xlink:to="loc_us-gaap_CommonStockMember_35" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_34" xlink:to="loc_us-gaap_RestrictedStockMember_36" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_37" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_37" xlink:to="loc_us-gaap_RangeMember_38" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_38_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_37" xlink:to="loc_us-gaap_RangeMember_38_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_38" xlink:to="loc_us-gaap_MaximumMember_39" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_38" xlink:to="loc_us-gaap_MinimumMember_40" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfLicenseFee" xlink:label="loc_fil_PaymentOfLicenseFee_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PaymentOfLicenseFee_42" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_43" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_44" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentDate" xlink:label="loc_fil_MilestonePaymentDate_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_MilestonePaymentDate_45" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_fil_DescriptionOfRoyaltyPaymentToRelatedParty_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_DescriptionOfRoyaltyPaymentToRelatedParty_46" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RoyaltyOfNetSalesPercentage" xlink:label="loc_fil_RoyaltyOfNetSalesPercentage_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_RoyaltyOfNetSalesPercentage_47" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSalePeriod" xlink:label="loc_fil_FirstCommercialSalePeriod_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_FirstCommercialSalePeriod_48" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_TechnologyServicesCosts_49" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_MaintenanceCosts_50" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentArrangement" xlink:label="loc_fil_ResearchAndDevelopmentArrangement_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_ResearchAndDevelopmentArrangement_51" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PurchaseOfRadioactiveMaterial" xlink:label="loc_fil_PurchaseOfRadioactiveMaterial_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PurchaseOfRadioactiveMaterial_52" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProjectEstimatedCost" xlink:label="loc_fil_ProjectEstimatedCost_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_ProjectEstimatedCost_53" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_fil_DownPaymentOfProjectEstimatedCostPercentage_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_DownPaymentOfProjectEstimatedCostPercentage_54" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentForProject" xlink:label="loc_fil_DownPaymentForProject_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_DownPaymentForProject_55" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_56" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear_57" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_fil_FundToRelatedPartyUnderAgreementAfterYearTwo_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_FundToRelatedPartyUnderAgreementAfterYearTwo_58" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_RoyaltyExpense_59" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfPatients" xlink:label="loc_fil_NumberOfPatients_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_NumberOfPatients_60" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToEachPatient" xlink:label="loc_fil_AmountPaidToEachPatient_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_AmountPaidToEachPatient_61" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpFeeForClinicalTrial" xlink:label="loc_fil_StartUpFeeForClinicalTrial_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_StartUpFeeForClinicalTrial_62" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpDueCostPaidDate" xlink:label="loc_fil_StartUpDueCostPaidDate_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_StartUpDueCostPaidDate_63" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NonRefundableInstitutionalFee" xlink:label="loc_fil_NonRefundableInstitutionalFee_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_NonRefundableInstitutionalFee_64" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PharmacyFee" xlink:label="loc_fil_PharmacyFee_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PharmacyFee_65" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmendmentProcessingFee" xlink:label="loc_fil_AmendmentProcessingFee_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_AmendmentProcessingFee_66" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_fil_PeriodicFeeReceivedByManagementFirm_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PeriodicFeeReceivedByManagementFirm_67" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_68" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantExercisableNoticePeriodDescription" xlink:label="loc_fil_WarrantExercisableNoticePeriodDescription_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_WarrantExercisableNoticePeriodDescription_69" order="270" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant_70" order="280" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_fil_MaximumAmountOfOutOfPocketExpenses_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_MaximumAmountOfOutOfPocketExpenses_71" order="290" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementConsideration" xlink:label="loc_fil_AgreementConsideration_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_AgreementConsideration_72" order="300" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPayableInInstallmentsUnderAgreement" xlink:label="loc_fil_AmountPayableInInstallmentsUnderAgreement_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_AmountPayableInInstallmentsUnderAgreement_73" order="310" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallments" xlink:label="loc_fil_NumberOfInstallments_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_NumberOfInstallments_74" order="320" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_fil_PerformanceBonusPayableUnderAgreementForService_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PerformanceBonusPayableUnderAgreementForService_75" order="330" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementRenewalDescription" xlink:label="loc_fil_AgreementRenewalDescription_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_AgreementRenewalDescription_76" order="340" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFirstInstallmentForServicesByCompany" xlink:label="loc_fil_PaymentOfFirstInstallmentForServicesByCompany_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PaymentOfFirstInstallmentForServicesByCompany_77" order="350" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_fil_PaymentOfFinalInstallmentForServicesByCompany_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PaymentOfFinalInstallmentForServicesByCompany_78" order="360" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_fil_PaymentOfPerformanceBonusForServicesByCompany_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_PaymentOfPerformanceBonusForServicesByCompany_79" order="370" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_us-gaap_LeaseExpirationDate1_80" order="380" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NoticePeriodForTerminationOfAgreement" xlink:label="loc_fil_NoticePeriodForTerminationOfAgreement_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_41" xlink:to="loc_fil_NoticePeriodForTerminationOfAgreement_81" order="390" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Equitydetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_12" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_13" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15" order="80" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Equitydetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_fil_SeriesCTwoPreferredStockMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCTwoPreferredStockMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_fil_SeriesCThreePreferredStockMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCThreePreferredStockMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_fil_SeriesCFourPreferredStockMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCFourPreferredStockMember_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_12" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAMember" xlink:label="loc_us-gaap_SeriesAMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAMember_13" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBMember" xlink:label="loc_us-gaap_SeriesBMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBMember_14" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCoMember" xlink:label="loc_fil_LaidlawAndCoMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" xlink:to="loc_fil_LaidlawAndCoMember_17" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MccormickOBrienPllcMember" xlink:label="loc_fil_MccormickOBrienPllcMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" xlink:to="loc_fil_MccormickOBrienPllcMember_18" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_19" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_19" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_19" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentMember" xlink:label="loc_fil_PlacementAgentMember_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" xlink:to="loc_fil_PlacementAgentMember_21" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ManagementMember" xlink:label="loc_us-gaap_ManagementMember_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" xlink:to="loc_us-gaap_ManagementMember_22" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_PlanNameAxis_23" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_23" xlink:to="loc_us-gaap_PlanNameDomain_24" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_24_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_23" xlink:to="loc_us-gaap_PlanNameDomain_24_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenStockPlanMember" xlink:label="loc_fil_TwoThousandThirteenStockPlanMember_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_24" xlink:to="loc_fil_TwoThousandThirteenStockPlanMember_25" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_fil_TwoThousandThirteenEquityIncentivePlanMember_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_24" xlink:to="loc_fil_TwoThousandThirteenEquityIncentivePlanMember_26" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_27" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgencyAgreementMember" xlink:label="loc_fil_PlacementAgencyAgreementMember_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_fil_PlacementAgencyAgreementMember_29" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupLlcMember" xlink:label="loc_fil_JamessCapitalGroupLlcMember_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_fil_JamessCapitalGroupLlcMember_30" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantOneMember" xlink:label="loc_fil_WarrantOneMember_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_fil_WarrantOneMember_31" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_us-gaap_WarrantMember_32" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsBMember" xlink:label="loc_fil_WarrantsBMember_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_fil_WarrantsBMember_33" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_us-gaap_EmployeeStockOptionMember_34" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_35" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_35" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_35" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FormerDirectorAndConsultantsMember" xlink:label="loc_fil_FormerDirectorAndConsultantsMember_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36" xlink:to="loc_fil_FormerDirectorAndConsultantsMember_37" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_fil_EmployeesDirectorsAndConsultantsMember_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36" xlink:to="loc_fil_EmployeesDirectorsAndConsultantsMember_38" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EquityTextualAbstract" xlink:label="loc_fil_EquityTextualAbstract_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_fil_EquityTextualAbstract_39" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_40" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_41" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToPurchaseCommonStockOffering" xlink:label="loc_fil_WarrantsIssuedToPurchaseCommonStockOffering_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_WarrantsIssuedToPurchaseCommonStockOffering_42" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_IncreaseOfferingOfCommonStock" xlink:label="loc_fil_IncreaseOfferingOfCommonStock_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_IncreaseOfferingOfCommonStock_43" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedInStockOffering" xlink:label="loc_fil_CommonStockSharesIssuedInStockOffering_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_CommonStockSharesIssuedInStockOffering_44" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xlink:label="loc_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet_45" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentCashFees" xlink:label="loc_fil_PlacementAgentCashFees_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_PlacementAgentCashFees_46" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentCommission" xlink:label="loc_fil_PlacementAgentCommission_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_PlacementAgentCommission_47" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentExpenseReimbursement" xlink:label="loc_fil_PlacementAgentExpenseReimbursement_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_PlacementAgentExpenseReimbursement_48" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_fil_WarrantsIssuedToPurchaseCommonStock_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_WarrantsIssuedToPurchaseCommonStock_49" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_50" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsExpirationTerm" xlink:label="loc_fil_WarrantsExpirationTerm_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_WarrantsExpirationTerm_51" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_52" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentServicesFees" xlink:label="loc_fil_PlacementAgentServicesFees_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_PlacementAgentServicesFees_53" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BankEscrowFee" xlink:label="loc_fil_BankEscrowFee_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_BankEscrowFee_54" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_55" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AccruedManagementFees" xlink:label="loc_fil_AccruedManagementFees_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_AccruedManagementFees_56" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" xlink:label="loc_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement_57" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" xlink:label="loc_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement_58" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_fil_UnrecognizedShareBasedCompensationExpense_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_UnrecognizedShareBasedCompensationExpense_59" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_60" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidForCancellationOfSharesByCompany" xlink:label="loc_fil_AmountPaidForCancellationOfSharesByCompany_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_AmountPaidForCancellationOfSharesByCompany_61" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesPurchasedAfterCancelationOfOptions" xlink:label="loc_fil_SharesPurchasedAfterCancelationOfOptions_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_fil_SharesPurchasedAfterCancelationOfOptions_62" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_63" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_64" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_65" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_66" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_39" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_67" order="270" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StockOptionPlanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_12" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_13" order="70" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StockOptionPlanDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThreeStockPlanMember" xlink:label="loc_fil_TwoThousandThreeStockPlanMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_fil_TwoThousandThreeStockPlanMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandTwelveEmployeeStockOptionPlanMember" xlink:label="loc_fil_TwoThousandTwelveEmployeeStockOptionPlanMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_fil_TwoThousandTwelveEmployeeStockOptionPlanMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_13" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_13" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesAndConsultantsMember" xlink:label="loc_fil_EmployeesAndConsultantsMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14" xlink:to="loc_fil_EmployeesAndConsultantsMember_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultantsMember" xlink:label="loc_fil_ConsultantsMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14" xlink:to="loc_fil_ConsultantsMember_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionPlanTextualAbstract" xlink:label="loc_fil_StockOptionPlanTextualAbstract_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_fil_StockOptionPlanTextualAbstract_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" xlink:label="loc_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_20" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" xlink:label="loc_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting_21" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_22" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" xlink:label="loc_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering_23" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_24" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_25" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" xlink:label="loc_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance_26" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStock" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStock_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStock_27" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice_28" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife_29" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_30" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_31" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_32" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_33" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_34" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_35" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeeStockOptionUnitsReprised" xlink:label="loc_fil_EmployeeStockOptionUnitsReprised_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_EmployeeStockOptionUnitsReprised_37" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" xlink:label="loc_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption_38" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" xlink:label="loc_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions_39" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_fil_UnrecognizedShareBasedCompensationExpense_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_fil_UnrecognizedShareBasedCompensationExpense_40" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_StockOptionPlanTextualAbstract_17" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_41" order="230" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/WarrantsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_12" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_13" order="70" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/WarrantsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_WarrantMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantTextualAbstract" xlink:label="loc_fil_WarrantTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_fil_WarrantTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStock" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStock_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStock_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_16" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_17" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_18" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_WarrantTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_19" order="90" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/SubsequenteventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeparationAndSettlementAgreementMember" xlink:label="loc_fil_SeparationAndSettlementAgreementMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_fil_SeparationAndSettlementAgreementMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FormerChiefExecutiveOfficerMember" xlink:label="loc_fil_FormerChiefExecutiveOfficerMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_fil_FormerChiefExecutiveOfficerMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SubsequentEventsTextualAbstract" xlink:label="loc_fil_SubsequentEventsTextualAbstract_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_fil_SubsequentEventsTextualAbstract_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallmentsInWhichConsiderationIsPayable" xlink:label="loc_fil_NumberOfInstallmentsInWhichConsiderationIsPayable_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SubsequentEventsTextualAbstract_11" xlink:to="loc_fil_NumberOfInstallmentsInWhichConsiderationIsPayable_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsiderationPayableUnderAgreement" xlink:label="loc_fil_ConsiderationPayableUnderAgreement_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SubsequentEventsTextualAbstract_11" xlink:to="loc_fil_ConsiderationPayableUnderAgreement_13" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountOfPerformanceBonus" xlink:label="loc_fil_AmountOfPerformanceBonus_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SubsequentEventsTextualAbstract_11" xlink:to="loc_fil_AmountOfPerformanceBonus_14" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodOfService" xlink:label="loc_fil_PeriodOfService_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SubsequentEventsTextualAbstract_11" xlink:to="loc_fil_PeriodOfService_15" order="30" use="optional"  />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>fil-20130930_lab.xml
<DESCRIPTION>XBRL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DocumentAndEntityInformationAbstract" xlink:label="loc_K567K28545K5_fil_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DocumentAndEntityInformationAbstract" xlink:to="lab_M789M40767M7_fil_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_62JJJ544JG849J4F45GF_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_EntityRegistrantName" xlink:to="lab_84LLL766LI061L6H67IH_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_K567K28545K5_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_EntityCentralIndexKey" xlink:to="lab_M789M40767M7_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_62JJJ544JG849J4F45GF_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_AmendmentFlag" xlink:to="lab_84LLL766LI061L6H67IH_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_K567K28545K5_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_DocumentType" xlink:to="lab_M789M40767M7_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_62JJJ544JG849J4F45GF_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_DocumentPeriodEndDate" xlink:to="lab_84LLL766LI061L6H67IH_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_K567K28545K5_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_EntityFilerCategory" xlink:to="lab_M789M40767M7_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Balance Sheets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_K567K28545K5_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StatementTable" xlink:to="lab_M789M40767M7_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class Of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementClassOfStockAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_K567K28545K5_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class Of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ClassOfStockDomain" xlink:to="lab_M789M40767M7_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_K567K28545K5_us-gaap_SeriesBPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_M789M40767M7_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C-1 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SeriesCPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_K567K28545K5_fil_SeriesCTwoPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_SeriesCTwoPreferredStockMember" xml:lang="en-US">Series C Two Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_SeriesCTwoPreferredStockMember" xml:lang="en-US">Series C-2 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_SeriesCTwoPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C two preferred stock or outstanding series C two preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_SeriesCTwoPreferredStockMember" xlink:to="lab_M789M40767M7_fil_SeriesCTwoPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_SeriesCThreePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_SeriesCThreePreferredStockMember" xml:lang="en-US">Series C Three Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_SeriesCThreePreferredStockMember" xml:lang="en-US">Series C-3 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_SeriesCThreePreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C three preferred stock or outstanding series C three preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_SeriesCThreePreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_SeriesCThreePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_K567K28545K5_fil_SeriesCFourPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_SeriesCFourPreferredStockMember" xml:lang="en-US">Series C Four Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_SeriesCFourPreferredStockMember" xml:lang="en-US">Series C-4 Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_SeriesCFourPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series C four preferred stock or outstanding series C four preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_SeriesCFourPreferredStockMember" xlink:to="lab_M789M40767M7_fil_SeriesCFourPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesDPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SeriesDPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_K567K28545K5_us-gaap_SeriesEPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SeriesEPreferredStockMember" xlink:to="lab_M789M40767M7_us-gaap_SeriesEPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_K567K28545K5_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AssetsAbstract" xlink:to="lab_M789M40767M7_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AssetsCurrentAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">R&amp;D reimbursement receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_K567K28545K5_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_M789M40767M7_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DeferredFinanceCostsCurrentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredFinanceCostsCurrentNet" xml:lang="en-US">Deferred Finance Costs, Current, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredFinanceCostsCurrentNet" xml:lang="en-US">Deferred financing costs, net of accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DeferredFinanceCostsCurrentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_K567K28545K5_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AssetsCurrent" xlink:to="lab_M789M40767M7_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net of accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_K567K28545K5_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_Assets" xlink:to="lab_M789M40767M7_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_K567K28545K5_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_M789M40767M7_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_K567K28545K5_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_M789M40767M7_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayableCurrent" xml:lang="en-US">Note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NotesPayableCurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_K567K28545K5_us-gaap_ConvertibleNotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible notes payable, net of unamortized discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Carrying value at December 31, 2012 and 2011, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_M789M40767M7_us-gaap_ConvertibleNotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_K567K28545K5_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LiabilitiesCurrent" xlink:to="lab_M789M40767M7_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_Liabilities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_K567K28545K5_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommitmentsAndContingencies" xlink:to="lab_M789M40767M7_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StockholdersEquityAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_K567K28545K5_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, 100,000,000 Shares .01 Par Authorized, 0 Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, 100,000,000 shares $.01 par authorized, 0 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PreferredStockValue" xlink:to="lab_M789M40767M7_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, 100,000,000 shares, $.01 par authorized, 11,155,008 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockValue" xml:lang="en-US">Common stock value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockValue" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_K567K28545K5_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Paid in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AdditionalPaidInCapital" xlink:to="lab_M789M40767M7_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Deficit accumulated during the development stage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_K567K28545K5_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholder's Deficiency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StockholdersEquity" xlink:to="lab_M789M40767M7_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_K567K28545K5_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_M789M40767M7_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_K567K28545K5_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PreferredStockSharesIssued" xlink:to="lab_M789M40767M7_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">No. of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_K567K28545K5_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_M789M40767M7_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_K567K28545K5_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock shares issued in exchange of equity securities of company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommonStockSharesIssued" xlink:to="lab_M789M40767M7_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_K567K28545K5_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Statements Of Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncomeStatementAbstract" xlink:to="lab_M789M40767M7_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SalesRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SalesRevenueNet" xml:lang="en-US">Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SalesRevenueNet" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_K567K28545K5_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_OperatingExpensesAbstract" xlink:to="lab_M789M40767M7_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development, net of reimbursements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_K567K28545K5_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_M789M40767M7_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DepreciationAndAmortization" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DepreciationAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_K567K28545K5_us-gaap_GainLossOnDispositionOfAssets1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_M789M40767M7_us-gaap_GainLossOnDispositionOfAssets1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingExpenses" xml:lang="en-US">Total expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OperatingExpenses" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_K567K28545K5_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Net loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_OperatingIncomeLoss" xlink:to="lab_M789M40767M7_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_K567K28545K5_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_InterestExpense" xlink:to="lab_M789M40767M7_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gains (Losses) On Extinguishment Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_K567K28545K5_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) On Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Loss on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Change in fair value - derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain/loss on change in fair value of the derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_M789M40767M7_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Net Other income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_K567K28545K5_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NetIncomeLoss" xlink:to="lab_M789M40767M7_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Loss Per Common Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_K567K28545K5_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common shares outstanding - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_M789M40767M7_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Changes In Stockholders' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_K567K28545K5_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_M789M40767M7_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_EquityComponentDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_K567K28545K5_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RetainedEarningsMember" xlink:to="lab_M789M40767M7_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommonStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_K567K28545K5_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_M789M40767M7_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xml:lang="en-US">Accumulated Deficit During Development Stage [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xml:lang="en-US">Deficit Accumulated During the Development Stage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_K567K28545K5_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SharesOutstanding" xlink:to="lab_M789M40767M7_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of founder shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of founder shares, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Sales of common stock, net of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of - stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProceedsFromIssuanceOfCommonStockShares" xlink:label="loc_K567K28545K5_fil_ProceedsFromIssuanceOfCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_ProceedsFromIssuanceOfCommonStockShares" xml:lang="en-US">Proceeds From Issuance Of Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_ProceedsFromIssuanceOfCommonStockShares" xml:lang="en-US">Proceeds from issuance of - stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_ProceedsFromIssuanceOfCommonStockShares" xml:lang="en-US">Proceeds from issuance of common stock shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_ProceedsFromIssuanceOfCommonStockShares" xlink:to="lab_M789M40767M7_fil_ProceedsFromIssuanceOfCommonStockShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Common stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Common stock issued for services, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" xml:lang="en-US">Conversion Of Notes Payable and Accrued Interest To Stock Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" xml:lang="en-US">Conversion of notes payable and accrued interest to stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" xml:lang="en-US">Conversion of notes payable and accrued interest to stock, Value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" xlink:to="lab_84LLL766LI061L6H67IH_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" xlink:label="loc_K567K28545K5_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" xml:lang="en-US">Conversion Of Notes Payable and Accrued Interest To Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" xml:lang="en-US">Conversion of notes payable and accrued interest to stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" xml:lang="en-US">Conversion of notes payable and accrued interest to stock, shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" xlink:to="lab_M789M40767M7_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesIssuedAtReverseMergerValue" xlink:label="loc_62JJJ544JG849J4F45GF_fil_SharesIssuedAtReverseMergerValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_SharesIssuedAtReverseMergerValue" xml:lang="en-US">Shares Issued At Reverse Merger Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_SharesIssuedAtReverseMergerValue" xml:lang="en-US">Shares issued at the reverse merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_SharesIssuedAtReverseMergerValue" xml:lang="en-US">Shares issued at the reverse merger value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_SharesIssuedAtReverseMergerValue" xlink:to="lab_84LLL766LI061L6H67IH_fil_SharesIssuedAtReverseMergerValue"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesIssuedAtReverseMergerShares" xlink:label="loc_K567K28545K5_fil_SharesIssuedAtReverseMergerShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_SharesIssuedAtReverseMergerShares" xml:lang="en-US">Shares Issued At Reverse Merger Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_SharesIssuedAtReverseMergerShares" xml:lang="en-US">Shares issued at the reverse merger, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_SharesIssuedAtReverseMergerShares" xml:lang="en-US">Shares issued at the reverse merger shares.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:label="lab_M789M40767M7_fil_SharesIssuedAtReverseMergerShares" xml:lang="en-US">Reverse merger transaction, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_SharesIssuedAtReverseMergerShares" xlink:to="lab_M789M40767M7_fil_SharesIssuedAtReverseMergerShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Option expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" xlink:label="loc_K567K28545K5_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" xml:lang="en-US">Adjustments To Additional Paid In Capital Warrant Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" xml:lang="en-US">Warrant expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" xml:lang="en-US">Adjustments to additional paid in capital warrant expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" xlink:to="lab_M789M40767M7_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" xml:lang="en-US">Adjustments To Additional Paid In Capital Fair Value Of Derivative Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" xml:lang="en-US">Fair value of derivative warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" xml:lang="en-US">Adjustments to additional paid in capital fair value of derivative warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" xlink:to="lab_84LLL766LI061L6H67IH_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_K567K28545K5_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair Value Of Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair value of Transfer from liability classification to equity classification.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_M789M40767M7_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RetireOfDerivativeLiability" xlink:label="loc_62JJJ544JG849J4F45GF_fil_RetireOfDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_RetireOfDerivativeLiability" xml:lang="en-US">Retire Of Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_RetireOfDerivativeLiability" xml:lang="en-US">Retire of derivative liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_RetireOfDerivativeLiability" xml:lang="en-US">Retire of derivative liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_RetireOfDerivativeLiability" xlink:to="lab_84LLL766LI061L6H67IH_fil_RetireOfDerivativeLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_K567K28545K5_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xml:lang="en-US">Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xml:lang="en-US">Beneficial conversion feature discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_M789M40767M7_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_K567K28545K5_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Employee Benefits and Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_M789M40767M7_us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DepreciationDepletionAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_K567K28545K5_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization Of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Add: amortization of discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_M789M40767M7_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization Of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_K567K28545K5_fil_GainOnChangeInFairValueOfDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain On Change In Fair Value Of Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_fil_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Change in fair value derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_GainOnChangeInFairValueOfDerivatives" xlink:to="lab_M789M40767M7_fil_GainOnChangeInFairValueOfDerivatives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">(Increase) decrease in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_K567K28545K5_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xml:lang="en-US">Increase (Decrease) In Accounts Receivable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xml:lang="en-US">R&amp;D reimbursement receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xml:lang="en-US">R&amp;D reimbursable receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (decrease) in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_K567K28545K5_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Increase (Decrease) In Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Accounts payable and accrued liabilities - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_M789M40767M7_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PaymentsToAcquireIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments To Acquire Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payment made for patent rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payment made for patent rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_K567K28545K5_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_M789M40767M7_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Proceeds From Debt, Net Of Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Borrowings on convertible debt, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_K567K28545K5_us-gaap_RepaymentsOfNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_M789M40767M7_us-gaap_RepaymentsOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds From Issuance Of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Sales of common stock, net of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from issuance of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_K567K28545K5_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from the exercise of warrants for cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_M789M40767M7_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">INCREASE IN CASH AND CASH EQUIVALENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CashPaidForAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_CashPaidForAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_CashPaidForAbstract" xml:lang="en-US">Cash Paid For [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_CashPaidForAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_CashPaidForAbstract" xml:lang="en-US">Cash paid for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_CashPaidForAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_CashPaidForAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_K567K28545K5_us-gaap_InterestPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_InterestPaid" xlink:to="lab_M789M40767M7_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxesPaid" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithDebt" xlink:label="loc_K567K28545K5_fil_FairValueOfWarrantsIssuedWithDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair Value Of Warrants Issued With Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair value of warrants issued with debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair value of warrants issued with debt.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueOfWarrantsIssuedWithDebt" xlink:to="lab_M789M40767M7_fil_FairValueOfWarrantsIssuedWithDebt"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_FairValueOfWarrantsIssuedWithStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair Value Of Warrants Issued With Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair value of warrants issued with stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair value of warrants issued with stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_FairValueOfWarrantsIssuedWithStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_FairValueOfWarrantsIssuedWithStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="loc_K567K28545K5_fil_FairValueOfWarrantsIssuedToPlacementAgent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair Value Of Warrants Issued To Placement Agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair value of warrants issued to the placement agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair value of warrants issued to the placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueOfWarrantsIssuedToPlacementAgent" xlink:to="lab_M789M40767M7_fil_FairValueOfWarrantsIssuedToPlacementAgent"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion Of Notes Payable and Accrued Interest To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion of notes payable and accrued interest to stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion of notes payable and accrued interest to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_K567K28545K5_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_M789M40767M7_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernAbstract" xlink:label="loc_K567K28545K5_fil_GoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_GoingConcernAbstract" xlink:to="lab_M789M40767M7_fil_GoingConcernAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_GoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_GoingConcernTextBlock" xml:lang="en-US">Going Concern [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_GoingConcernTextBlock" xml:lang="en-US">Going Concern</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_GoingConcernTextBlock" xml:lang="en-US">Going Concern assumption.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_GoingConcernTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_fil_GoingConcernTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_K567K28545K5_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Note Payable and Convertible Notes [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Note Payable and Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivatives [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Former CEO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_K567K28545K5_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EquityAbstract" xlink:to="lab_M789M40767M7_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_K567K28545K5_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_M789M40767M7_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock Option Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsAbstract" xlink:label="loc_K567K28545K5_fil_WarrantsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_WarrantsAbstract" xml:lang="en-US">Warrants [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_WarrantsAbstract" xml:lang="en-US">Warrants [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_WarrantsAbstract" xlink:to="lab_M789M40767M7_fil_WarrantsAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_WarrantsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsTextBlock" xml:lang="en-US">Warrants [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsTextBlock" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_WarrantsTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_fil_WarrantsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_K567K28545K5_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Employee Defined Contribution Plan [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_M789M40767M7_us-gaap_CompensationAndRetirementDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Employee Defined Contribution Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventsAbstract" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_K567K28545K5_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Nature of Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_M789M40767M7_us-gaap_BusinessCombinationsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_K567K28545K5_fil_DevelopmentStageCompanyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DevelopmentStageCompanyPolicyTextBlock" xlink:to="lab_M789M40767M7_fil_DevelopmentStageCompanyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_K567K28545K5_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_UseOfEstimates" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_UseOfEstimates" xlink:to="lab_M789M40767M7_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_M789M40767M7_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_K567K28545K5_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_M789M40767M7_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_K567K28545K5_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_M789M40767M7_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Share-Based Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_K567K28545K5_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings (Loss) Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_M789M40767M7_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured On Recurring and Nonrecurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Summary of set forth assets and liabilities measured at fair value on a recurring and non-recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule Of Related Party Transactions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Summary of activities related to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule Of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Summary of senior subordinated unsecured convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfDebtTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule Of Derivative Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_K567K28545K5_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair Value Of Derivative Warrants On Basis Of Valuation Model [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair value of derivative warrants on basis of valuation model.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:to="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Components of deferred tax assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule Of Components Of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of difference between the income tax provision and the U.S. Federal statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTable" xlink:label="loc_62JJJ544JG849J4F45GF_fil_MilestonePaymentsMilestoneMethodTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentsMilestoneMethodTable" xml:lang="en-US">Milestone Payments Milestone Method [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentsMilestoneMethodTable" xml:lang="en-US">Milestone Payments Milestone Method [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentsMilestoneMethodTable" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_MilestonePaymentsMilestoneMethodTable" xlink:to="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentsMilestoneMethodTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_K567K28545K5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_M789M40767M7_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_K567K28545K5_fil_AbbottBiotherapeuticsCorpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott biotherapeutics corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AbbottBiotherapeuticsCorpMember" xlink:to="lab_M789M40767M7_fil_AbbottBiotherapeuticsCorpMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_MemorialSloanKetteringCancerCenterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">MSKCC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial sloan kettering cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_MemorialSloanKetteringCancerCenterMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_MemorialSloanKetteringCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodLineItems" xlink:label="loc_K567K28545K5_fil_MilestonePaymentsMilestoneMethodLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_MilestonePaymentsMilestoneMethodLineItems" xml:lang="en-US">Milestone Payments Milestone Method [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_MilestonePaymentsMilestoneMethodLineItems" xml:lang="en-US">Milestone Payments Milestone Method [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_MilestonePaymentsMilestoneMethodLineItems" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_MilestonePaymentsMilestoneMethodLineItems" xlink:to="lab_M789M40767M7_fil_MilestonePaymentsMilestoneMethodLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_MilestonePaymentsMilestoneMethodTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone Payments Milestone Method [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Summary of milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentsMilestoneMethodTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_K567K28545K5_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AwardTypeAxis" xlink:to="lab_M789M40767M7_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_K567K28545K5_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EmployeeStockOptionMember" xlink:to="lab_M789M40767M7_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WarrantMember" xml:lang="en-US">A Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_WarrantMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ScheduleOfWarrantsIssuedTableTextBlock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ScheduleOfWarrantsIssuedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ScheduleOfWarrantsIssuedTableTextBlock" xml:lang="en-US">Schedule Of Warrants Issued [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ScheduleOfWarrantsIssuedTableTextBlock" xml:lang="en-US">Summary of warrant issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ScheduleOfWarrantsIssuedTableTextBlock" xml:lang="en-US">Tabular disclosure of warrant issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ScheduleOfWarrantsIssuedTableTextBlock" xlink:to="lab_84LLL766LI061L6H67IH_fil_ScheduleOfWarrantsIssuedTableTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfWarrantActivitiesTableTextBlock" xlink:label="loc_K567K28545K5_fil_SummaryOfWarrantActivitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_SummaryOfWarrantActivitiesTableTextBlock" xml:lang="en-US">Summary Of Warrant Activities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_SummaryOfWarrantActivitiesTableTextBlock" xml:lang="en-US">Summary of warrant activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_SummaryOfWarrantActivitiesTableTextBlock" xml:lang="en-US">Summary of warrant activities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_SummaryOfWarrantActivitiesTableTextBlock" xlink:to="lab_M789M40767M7_fil_SummaryOfWarrantActivitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_K567K28545K5_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_M789M40767M7_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_K567K28545K5_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_M789M40767M7_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_K567K28545K5_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_M789M40767M7_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured On Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xlink:label="loc_K567K28545K5_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xml:lang="en-US">Summary Of Assets and Liabilities Measured At Fair Value On Recurring and Non Recurring Basis [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xml:lang="en-US">Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xlink:to="lab_M789M40767M7_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLiabilities" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_K567K28545K5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description of business and summary of significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_M789M40767M7_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_62JJJ544JG849J4F45GF_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_dei_LegalEntityAxis" xlink:to="lab_84LLL766LI061L6H67IH_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_K567K28545K5_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_dei_EntityDomain" xlink:to="lab_M789M40767M7_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ActiniumMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ActiniumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ActiniumMember" xml:lang="en-US">Actinium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ActiniumMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_ActiniumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_K567K28545K5_us-gaap_MachineryAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_M789M40767M7_us-gaap_MachineryAndEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FurnitureAndFixturesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_K567K28545K5_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_M789M40767M7_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_K567K28545K5_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_M789M40767M7_us-gaap_ConvertiblePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ConvertibleNotesPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ConvertibleNotesPayableMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsAndWarrantsMember" xlink:label="loc_K567K28545K5_fil_OptionsAndWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_OptionsAndWarrantsMember" xml:lang="en-US">Options And Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_OptionsAndWarrantsMember" xml:lang="en-US">Options And Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_OptionsAndWarrantsMember" xml:lang="en-US">Options and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_OptionsAndWarrantsMember" xlink:to="lab_M789M40767M7_fil_OptionsAndWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SubsequentEventMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_K567K28545K5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description of business and summary of significant accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_M789M40767M7_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfOwnershipInterestToBeAcquired" xlink:label="loc_K567K28545K5_fil_PercentageOfOwnershipInterestToBeAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PercentageOfOwnershipInterestToBeAcquired" xml:lang="en-US">Percentage Of Ownership Interest To Be Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PercentageOfOwnershipInterestToBeAcquired" xml:lang="en-US">Percentage of ownership interest to be acquired by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PercentageOfOwnershipInterestToBeAcquired" xml:lang="en-US">Percentage of ownership interest to be acquired by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PercentageOfOwnershipInterestToBeAcquired" xlink:to="lab_M789M40767M7_fil_PercentageOfOwnershipInterestToBeAcquired"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_62JJJ544JG849J4F45GF_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock Issuable In Consideration For Equity Interest Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:to="lab_84LLL766LI061L6H67IH_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" xlink:label="loc_K567K28545K5_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" xml:lang="en-US">Common Stock Shares Issued In Exchange Of Equity Securities In Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" xml:lang="en-US">Common stock shares issued in exchange of equity securities in percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" xml:lang="en-US">Common stock shares issued in exchange of equity securities in percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" xlink:to="lab_M789M40767M7_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_K567K28545K5_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Shares received by each API shareholder of Actinium common stock for each API share exchanged</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_M789M40767M7_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially issuable shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfSharesExchangedInShareExchangeProgramme" xlink:label="loc_K567K28545K5_fil_PercentageOfSharesExchangedInShareExchangeProgramme" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PercentageOfSharesExchangedInShareExchangeProgramme" xml:lang="en-US">Percentage Of Shares Exchanged In Share Exchange Programme</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PercentageOfSharesExchangedInShareExchangeProgramme" xml:lang="en-US">Percentage Of Shares Exchanged In Share Exchange Programme</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PercentageOfSharesExchangedInShareExchangeProgramme" xml:lang="en-US">Percentage of shares exchanged in share exchange programme.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PercentageOfSharesExchangedInShareExchangeProgramme" xlink:to="lab_M789M40767M7_fil_PercentageOfSharesExchangedInShareExchangeProgramme"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BusinessAcquisitionNumberOfSharesExchanged" xlink:label="loc_62JJJ544JG849J4F45GF_fil_BusinessAcquisitionNumberOfSharesExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_BusinessAcquisitionNumberOfSharesExchanged" xml:lang="en-US">Business Acquisition Number Of Shares Exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_BusinessAcquisitionNumberOfSharesExchanged" xml:lang="en-US">Business acquisition number of shares exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_BusinessAcquisitionNumberOfSharesExchanged" xml:lang="en-US">Business acquisition number of shares exchanged.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_BusinessAcquisitionNumberOfSharesExchanged" xlink:to="lab_84LLL766LI061L6H67IH_fil_BusinessAcquisitionNumberOfSharesExchanged"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernTextualAbstract" xlink:label="loc_K567K28545K5_fil_GoingConcernTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_GoingConcernTextualAbstract" xlink:to="lab_M789M40767M7_fil_GoingConcernTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xml:lang="en-US">Related Party Transaction, Due From (To) Related Party, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xml:lang="en-US">Summary of activities related to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" xlink:label="loc_K567K28545K5_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" xml:lang="en-US">Qualified Research and Development Costs Incurred By Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" xml:lang="en-US">Qualified R&amp;D costs incurred by the Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" xml:lang="en-US">Qualified research and development costs incurred by related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" xlink:to="lab_M789M40767M7_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReimbursementsReceivedFromRelatedParty" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ReimbursementsReceivedFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ReimbursementsReceivedFromRelatedParty" xml:lang="en-US">Reimbursements Received From Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ReimbursementsReceivedFromRelatedParty" xml:lang="en-US">Reimbursements received from MSKCC</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ReimbursementsReceivedFromRelatedParty" xml:lang="en-US">Reimbursements received from related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ReimbursementsReceivedFromRelatedParty" xlink:to="lab_84LLL766LI061L6H67IH_fil_ReimbursementsReceivedFromRelatedParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule Of Related Party Transactions, By Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_SloanKetteringInstituteOfCancerResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Sloan Kettering Institute Of Cancer Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">SKI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_SloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Sloan kettering institute of cancer research.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_SloanKetteringInstituteOfCancerResearchMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_SloanKetteringInstituteOfCancerResearchMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_K567K28545K5_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center Sloan Kettering Institute Of Cancer Research [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">MSKCC and SKI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xml:lang="en-US">Memorial sloan kettering cancer center sloan kettering institute of cancer research.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:to="lab_M789M40767M7_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RosemaryMazanetMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_RosemaryMazanetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_RosemaryMazanetMember" xml:lang="en-US">Rosemary Mazanet [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_RosemaryMazanetMember" xml:lang="en-US">Dr. Rosemary Mazanet [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_RosemaryMazanetMember" xml:lang="en-US">Rosemary mazanet.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_RosemaryMazanetMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_RosemaryMazanetMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCompanyMember" xlink:label="loc_K567K28545K5_fil_LaidlawAndCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_LaidlawAndCompanyMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_LaidlawAndCompanyMember" xlink:to="lab_M789M40767M7_fil_LaidlawAndCompanyMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_JamessCapitalGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_JamessCapitalGroupMember" xml:lang="en-US">Jamess capital group.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_JamessCapitalGroupMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_JamessCapitalGroupMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GuagentiAndAssociatesMember" xlink:label="loc_K567K28545K5_fil_GuagentiAndAssociatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti and Associates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti &amp; Associates LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_GuagentiAndAssociatesMember" xml:lang="en-US">Guagenti and associates.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_GuagentiAndAssociatesMember" xlink:to="lab_M789M40767M7_fil_GuagentiAndAssociatesMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementAxis" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AgreementAxis" xlink:to="lab_84LLL766LI061L6H67IH_fil_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_K567K28545K5_fil_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AgreementDomain" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AgreementDomain" xlink:to="lab_M789M40767M7_fil_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ClinicalTrialAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical trial agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ClinicalTrialAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_ClinicalTrialAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_K567K28545K5_fil_LicenseDevelopmentAndCommercializationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License Development and Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License, Development and Commercialization Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_LicenseDevelopmentAndCommercializationAgreementMember" xml:lang="en-US">License development and commercialization agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_LicenseDevelopmentAndCommercializationAgreementMember" xlink:to="lab_M789M40767M7_fil_LicenseDevelopmentAndCommercializationAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultingServicesAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ConsultingServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConsultingServicesAgreementMember" xml:lang="en-US">Consulting services agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ConsultingServicesAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_ConsultingServicesAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EngagementAgreementMember" xlink:label="loc_K567K28545K5_fil_EngagementAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_EngagementAgreementMember" xml:lang="en-US">Engagement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_EngagementAgreementMember" xml:lang="en-US">Engagement agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_EngagementAgreementMember" xlink:to="lab_M789M40767M7_fil_EngagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransactionManagementAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_TransactionManagementAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_TransactionManagementAgreementMember" xml:lang="en-US">Transaction Management Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_TransactionManagementAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_TransactionManagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_K567K28545K5_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_M789M40767M7_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_RelatedPartyTransactionsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfPatients" xlink:label="loc_K567K28545K5_fil_NumberOfPatients" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_NumberOfPatients" xml:lang="en-US">Number Of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_NumberOfPatients" xml:lang="en-US">Number of Patients enrolled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_NumberOfPatients" xml:lang="en-US">Number of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_NumberOfPatients" xml:lang="en-US">Number of patients.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_NumberOfPatients" xlink:to="lab_M789M40767M7_fil_NumberOfPatients"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AmountPaidUnderAgreementInYearTwoThousandEleven" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Eleven</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount paid under agreement in 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreementInYearTwoThousandEleven" xml:lang="en-US">Amount paid under agreement in year two thousand eleven.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:to="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreementInYearTwoThousandEleven"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_K567K28545K5_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Twelve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount paid under agreement in 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" xml:lang="en-US">Amount paid under agreement in year two thousand twelve.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:to="lab_M789M40767M7_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount Paid Under Agreement In Year Two Thousand Thirteen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount paid under agreement in 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" xml:lang="en-US">Amount paid under agreement in year two thousand thirteen.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:to="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaintenanceFeesAndResearchPayments" xlink:label="loc_K567K28545K5_fil_MaintenanceFeesAndResearchPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance Fees and Research Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance fees and research payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_MaintenanceFeesAndResearchPayments" xml:lang="en-US">Maintenance fees and research payments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_MaintenanceFeesAndResearchPayments" xlink:to="lab_M789M40767M7_fil_MaintenanceFeesAndResearchPayments"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AmountPaidUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreement" xml:lang="en-US">Amount Paid Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreement" xml:lang="en-US">Amount paid under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreement" xml:lang="en-US">Amount paid under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AmountPaidUnderAgreement" xlink:to="lab_84LLL766LI061L6H67IH_fil_AmountPaidUnderAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdditionalAmountDueUnderAgreement" xlink:label="loc_K567K28545K5_fil_AdditionalAmountDueUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional Amount Due Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional amount due under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AdditionalAmountDueUnderAgreement" xml:lang="en-US">Additional amount due under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AdditionalAmountDueUnderAgreement" xlink:to="lab_M789M40767M7_fil_AdditionalAmountDueUnderAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfConditionForTerminationOfForbearancePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Description Of Condition For Termination Of Forbearance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Condition for termination of forbearance period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfConditionForTerminationOfForbearancePeriod" xml:lang="en-US">Description of condition for termination of forbearance period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:to="lab_84LLL766LI061L6H67IH_fil_DescriptionOfConditionForTerminationOfForbearancePeriod"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TerminationDateOfForbearanceAgreement" xlink:label="loc_K567K28545K5_fil_TerminationDateOfForbearanceAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination Date Of Forbearance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination date of forbearance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_TerminationDateOfForbearanceAgreement" xml:lang="en-US">Termination date of forbearance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_TerminationDateOfForbearanceAgreement" xlink:to="lab_M789M40767M7_fil_TerminationDateOfForbearanceAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_62JJJ544JG849J4F45GF_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum New Equity Financing Needed Under Condition For Termination Forbearance Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum new equity financing needed under condition for termination forbearance period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xml:lang="en-US">Minimum new Equity Financing needed under condition for termination Forbearance period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:to="lab_84LLL766LI061L6H67IH_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewEquityFinanceRaisedByCompany" xlink:label="loc_K567K28545K5_fil_NewEquityFinanceRaisedByCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New Equity Finance Raised By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New equity finance raised by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_NewEquityFinanceRaisedByCompany" xml:lang="en-US">New equity finance raised by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_NewEquityFinanceRaisedByCompany" xlink:to="lab_M789M40767M7_fil_NewEquityFinanceRaisedByCompany"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ForgivenAmountOfObligations" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ForgivenAmountOfObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven Amount Of Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven amount of obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ForgivenAmountOfObligations" xml:lang="en-US">Forgiven amount of obligations.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ForgivenAmountOfObligations" xlink:to="lab_84LLL766LI061L6H67IH_fil_ForgivenAmountOfObligations"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" xlink:label="loc_K567K28545K5_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" xml:lang="en-US">Research and Development Prepayments Amount Received By Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" xml:lang="en-US">Research and development reimbursement payments received from MSKCC</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" xml:lang="en-US">Research and development prepayments amount received by related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" xlink:to="lab_M789M40767M7_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsReceivableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsReceivableRelatedPartiesCurrent" xml:lang="en-US">Accounts Receivable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AccountsReceivableRelatedPartiesCurrent" xml:lang="en-US">Net receivable from MSKCC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToEachPatient" xlink:label="loc_K567K28545K5_fil_AmountPaidToEachPatient" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AmountPaidToEachPatient" xml:lang="en-US">Amount Paid To Each Patient</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AmountPaidToEachPatient" xml:lang="en-US">Amount paid to each patient after Completing clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AmountPaidToEachPatient" xml:lang="en-US">Amount to be paid for each Patient that has completed the clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AmountPaidToEachPatient" xlink:to="lab_M789M40767M7_fil_AmountPaidToEachPatient"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpFeeForClinicalTrial" xlink:label="loc_62JJJ544JG849J4F45GF_fil_StartUpFeeForClinicalTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_StartUpFeeForClinicalTrial" xml:lang="en-US">Start Up Fee For Clinical Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_StartUpFeeForClinicalTrial" xlink:to="lab_84LLL766LI061L6H67IH_fil_StartUpFeeForClinicalTrial"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpDueCostPaidDate" xlink:label="loc_K567K28545K5_fil_StartUpDueCostPaidDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_StartUpDueCostPaidDate" xml:lang="en-US">Start Up Due Cost Paid Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_StartUpDueCostPaidDate" xml:lang="en-US">Due date of start-up fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_StartUpDueCostPaidDate" xlink:to="lab_M789M40767M7_fil_StartUpDueCostPaidDate"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesTransferTerm" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfSharesTransferTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description Of Shares Transfer Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description of shares transfer term transfer by AHLB on behalf of AHL</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfSharesTransferTerm" xml:lang="en-US">Description of shares transfer term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfSharesTransferTerm" xlink:to="lab_84LLL766LI061L6H67IH_fil_DescriptionOfSharesTransferTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_K567K28545K5_us-gaap_OfficersCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_OfficersCompensation" xml:lang="en-US">Base salary at annual rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_OfficersCompensation" xlink:to="lab_M789M40767M7_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionExercisePriceRange" xlink:label="loc_62JJJ544JG849J4F45GF_fil_OptionExercisePriceRange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionExercisePriceRange" xml:lang="en-US">Option Exercise Price Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionExercisePriceRange" xml:lang="en-US">Option Exercise Price Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionExercisePriceRange" xml:lang="en-US">Option exercise price range.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_OptionExercisePriceRange" xlink:to="lab_84LLL766LI061L6H67IH_fil_OptionExercisePriceRange"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_K567K28545K5_us-gaap_FairValueAssumptionsExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Term of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Warrant lives in years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_OptionsReceivedToPurchaseCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options Received To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options received to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionsReceivedToPurchaseCommonStock" xml:lang="en-US">Options received to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_OptionsReceivedToPurchaseCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_OptionsReceivedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_K567K28545K5_fil_DescriptionOfReceivablesOfPlacementAgentForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description Of Receivables Of Placement Agent For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description of receivables of placement agent for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DescriptionOfReceivablesOfPlacementAgentForServices" xml:lang="en-US">Description of receivables of placement agent for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:to="lab_M789M40767M7_fil_DescriptionOfReceivablesOfPlacementAgentForServices"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfWarrantsReceivablesByPlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description Of Warrants Receivables By Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description of warrants receivables by placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfWarrantsReceivablesByPlacement" xml:lang="en-US">Description of warrants receivables by placement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfWarrantsReceivablesByPlacement" xlink:to="lab_84LLL766LI061L6H67IH_fil_DescriptionOfWarrantsReceivablesByPlacement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodOfExerciseOfWarrants" xlink:label="loc_K567K28545K5_fil_PeriodOfExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period Of Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period of exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PeriodOfExerciseOfWarrants" xml:lang="en-US">Period of exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PeriodOfExerciseOfWarrants" xlink:to="lab_M789M40767M7_fil_PeriodOfExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfSolicitationFee" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PercentageOfSolicitationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PercentageOfSolicitationFee" xml:lang="en-US">Percentage Of Solicitation Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PercentageOfSolicitationFee" xml:lang="en-US">Percentage of solicitation fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PercentageOfSolicitationFee" xml:lang="en-US">Percentage of solicitation fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PercentageOfSolicitationFee" xlink:to="lab_84LLL766LI061L6H67IH_fil_PercentageOfSolicitationFee"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_K567K28545K5_fil_PeriodicFeeForFinancialAdvisoryServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Periodic Fee For Financial Advisory Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Monthly fee for financial advisory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PeriodicFeeForFinancialAdvisoryServices" xml:lang="en-US">Periodic fee for financial advisory services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PeriodicFeeForFinancialAdvisoryServices" xlink:to="lab_M789M40767M7_fil_PeriodicFeeForFinancialAdvisoryServices"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfAdditionalReceivableByPlacementAgent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description Of Additional Receivable By Placement Agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description of additional receivable by placement agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfAdditionalReceivableByPlacementAgent" xml:lang="en-US">Description of additional receivable by placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:to="lab_84LLL766LI061L6H67IH_fil_DescriptionOfAdditionalReceivableByPlacementAgent"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_K567K28545K5_fil_CommonStockPurchaseByHoldingOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Common Stock Purchase By Holding Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Warrant held by placement agent to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_CommonStockPurchaseByHoldingOfWarrant" xml:lang="en-US">Common stock purchase by holding of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_CommonStockPurchaseByHoldingOfWarrant" xlink:to="lab_M789M40767M7_fil_CommonStockPurchaseByHoldingOfWarrant"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PeriodicFeeReceivedByManagementFirm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic Fee Received By Management Firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Monthly fee received by management firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic fee received by management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PeriodicFeeReceivedByManagementFirm" xlink:to="lab_84LLL766LI061L6H67IH_fil_PeriodicFeeReceivedByManagementFirm"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_K567K28545K5_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage Of Fully Diluted Capital Stock Equal To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:to="lab_M789M40767M7_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_62JJJ544JG849J4F45GF_fil_MaximumAmountOfOutOfPocketExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum Amount Of Out Of Pocket Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_MaximumAmountOfOutOfPocketExpenses" xlink:to="lab_84LLL766LI061L6H67IH_fil_MaximumAmountOfOutOfPocketExpenses"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicAmountOfRent" xlink:label="loc_K567K28545K5_fil_PeriodicAmountOfRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PeriodicAmountOfRent" xml:lang="en-US">Periodic Amount Of Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PeriodicAmountOfRent" xml:lang="en-US">Operating lease monthly amount of rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PeriodicAmountOfRent" xml:lang="en-US">Periodic amount of rent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PeriodicAmountOfRent" xlink:to="lab_M789M40767M7_fil_PeriodicAmountOfRent"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AmountPaidToPursuantLeaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount Paid To Pursuant Lease Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount paid to pursuant lease agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidToPursuantLeaseAgreement" xml:lang="en-US">Amount paid to pursuant lease agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AmountPaidToPursuantLeaseAgreement" xlink:to="lab_84LLL766LI061L6H67IH_fil_AmountPaidToPursuantLeaseAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OfficeEquipmentMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OfficeEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Property, Plant and Equipment, Net, By Type [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_M789M40767M7_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Equipment and parts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_K567K28545K5_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">(Less) Accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">(Less) Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_M789M40767M7_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LossOnDispositionOfPropertyAndEquipment" xlink:label="loc_62JJJ544JG849J4F45GF_fil_LossOnDispositionOfPropertyAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_LossOnDispositionOfPropertyAndEquipment" xml:lang="en-US">Loss On Disposition Of Property And Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_LossOnDispositionOfPropertyAndEquipment" xml:lang="en-US">Loss on disposition of property and equipment.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_LossOnDispositionOfPropertyAndEquipment" xml:lang="en-US">Loss on disposition of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_LossOnDispositionOfPropertyAndEquipment" xlink:to="lab_84LLL766LI061L6H67IH_fil_LossOnDispositionOfPropertyAndEquipment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PropertyAndEquipmentTextualAbstract" xlink:label="loc_K567K28545K5_fil_PropertyAndEquipmentTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PropertyAndEquipmentTextualAbstract" xlink:to="lab_M789M40767M7_fil_PropertyAndEquipmentTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_Depreciation" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xml:lang="en-US">Schedule Of Trading Securities and Other Trading Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xml:lang="en-US">Schedule of Trading Securities and Other Trading Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xml:lang="en-US">Major Types Of Debt and Equity Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_K567K28545K5_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xml:lang="en-US">Major Types Of Debt and Equity Securities [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="lab_M789M40767M7_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" xml:lang="en-US">Senior Subordinated Unsecured Convertible Promissory Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" xml:lang="en-US">8% Senior Subordinated Unsecured Convertible Promissory Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" xml:lang="en-US">Senior subordinated unsecured convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_K567K28545K5_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xml:lang="en-US">Schedule Of Trading Securities and Other Trading Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xml:lang="en-US">Schedule of Trading Securities and Other Trading Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_M789M40767M7_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfConvertiblePromissoryNotesAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_SummaryOfConvertiblePromissoryNotesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_SummaryOfConvertiblePromissoryNotesAbstract" xml:lang="en-US">Summary Of Convertible Promissory Notes [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_SummaryOfConvertiblePromissoryNotesAbstract" xml:lang="en-US">Summary of senior subordinated unsecured convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_SummaryOfConvertiblePromissoryNotesAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_SummaryOfConvertiblePromissoryNotesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_K567K28545K5_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible promissory note amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_M789M40767M7_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentUnamortizedDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Amount of original issue discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Less: original issuance discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DiscountRelatedToFairValueOfDerivativeWarrants" xlink:label="loc_K567K28545K5_fil_DiscountRelatedToFairValueOfDerivativeWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DiscountRelatedToFairValueOfDerivativeWarrants" xml:lang="en-US">Discount Related To Fair Value Of Derivative Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DiscountRelatedToFairValueOfDerivativeWarrants" xml:lang="en-US">Discount Related To Fair Value Of Derivative Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DiscountRelatedToFairValueOfDerivativeWarrants" xml:lang="en-US">Discount related to fair value of derivative warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_fil_DiscountRelatedToFairValueOfDerivativeWarrants" xml:lang="en-US">Less: discount related to fair value of derivative warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DiscountRelatedToFairValueOfDerivativeWarrants" xlink:to="lab_M789M40767M7_fil_DiscountRelatedToFairValueOfDerivativeWarrants"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt Instrument Discount Related To Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt Instrument Discount Related To Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Debt instrument discount related to the beneficial conversion feature.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xml:lang="en-US">Less: discount related to the beneficial conversion feature</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:to="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentAmortizationOfDiscount" xlink:label="loc_K567K28545K5_fil_DebtInstrumentAmortizationOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DebtInstrumentAmortizationOfDiscount" xml:lang="en-US">Debt Instrument Amortization Of Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DebtInstrumentAmortizationOfDiscount" xml:lang="en-US">Add: amortization of discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DebtInstrumentAmortizationOfDiscount" xml:lang="en-US">Debt instrument amortization of discount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DebtInstrumentAmortizationOfDiscount" xlink:to="lab_M789M40767M7_fil_DebtInstrumentAmortizationOfDiscount"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" xml:lang="en-US">Debt Instrument Principal Amount Converted To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" xml:lang="en-US">Less: principal amount converted to stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" xml:lang="en-US">Debt instrument principal amount converted to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentMember" xlink:label="loc_K567K28545K5_fil_PlacementAgentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PlacementAgentMember" xml:lang="en-US">Placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PlacementAgentMember" xlink:to="lab_M789M40767M7_fil_PlacementAgentMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ManagementFirmMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ManagementFirmMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ManagementFirmMember" xml:lang="en-US">Management Firm [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ManagementFirmMember" xml:lang="en-US">Management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ManagementFirmMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_ManagementFirmMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_K567K28545K5_fil_NotePayableAndConvertibleNotesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_NotePayableAndConvertibleNotesTextualAbstract" xml:lang="en-US">Note Payable and Convertible Notes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_NotePayableAndConvertibleNotesTextualAbstract" xml:lang="en-US">Note Payable and Convertible Notes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_NotePayableAndConvertibleNotesTextualAbstract" xlink:to="lab_M789M40767M7_fil_NotePayableAndConvertibleNotesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_62JJJ544JG849J4F45GF_fil_CommonStockPurchaseDueToIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common Stock Purchase Due To Issuance Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common stock shares purchasable through warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockPurchaseDueToIssuanceOfWarrants" xml:lang="en-US">Common stock shares purchase due to issuance of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:to="lab_84LLL766LI061L6H67IH_fil_CommonStockPurchaseDueToIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_K567K28545K5_invest_InvestmentWarrantsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Investment Warrants, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Exercise price of warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_invest_InvestmentWarrantsExercisePrice" xlink:to="lab_M789M40767M7_invest_InvestmentWarrantsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_62JJJ544JG849J4F45GF_invest_InvestmentWarrantsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Warrants expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_invest_InvestmentWarrantsExpirationDate" xlink:to="lab_84LLL766LI061L6H67IH_invest_InvestmentWarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmortizationPeriodOfNote" xlink:label="loc_K567K28545K5_fil_AmortizationPeriodOfNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AmortizationPeriodOfNote" xml:lang="en-US">Amortization Period Of Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AmortizationPeriodOfNote" xml:lang="en-US">Amortization period of note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AmortizationPeriodOfNote" xml:lang="en-US">Amortization period of note.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AmortizationPeriodOfNote" xlink:to="lab_M789M40767M7_fil_AmortizationPeriodOfNote"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PremiumFinanceAgreementPrincipalAmount" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PremiumFinanceAgreementPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium Finance Agreement Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium finance agreement principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PremiumFinanceAgreementPrincipalAmount" xml:lang="en-US">Premium finance agreement principal amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PremiumFinanceAgreementPrincipalAmount" xlink:to="lab_84LLL766LI061L6H67IH_fil_PremiumFinanceAgreementPrincipalAmount"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentUnderPremiumFinanceAgreement" xlink:label="loc_K567K28545K5_fil_PaymentUnderPremiumFinanceAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment Under Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment under premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Payment under premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PaymentUnderPremiumFinanceAgreement" xlink:to="lab_M789M40767M7_fil_PaymentUnderPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PeriodicPaymentUnderPremiumFinanceAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Periodic Payment Under Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Monthly amount payable under premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodicPaymentUnderPremiumFinanceAgreement" xml:lang="en-US">Periodic amount payable under premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:to="lab_84LLL766LI061L6H67IH_fil_PeriodicPaymentUnderPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:label="loc_K567K28545K5_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration Of Periodic Payments For Premium Finance Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration of periodic payments for premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xml:lang="en-US">Duration of periodic payments for premium finance agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:to="lab_M789M40767M7_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PremiumFinanceAgreementOutstandingAmount" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PremiumFinanceAgreementOutstandingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium Finance Agreement Outstanding Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium finance agreement outstanding amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PremiumFinanceAgreementOutstandingAmount" xml:lang="en-US">Premium finance agreement outstanding amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PremiumFinanceAgreementOutstandingAmount" xlink:to="lab_84LLL766LI061L6H67IH_fil_PremiumFinanceAgreementOutstandingAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_K567K28545K5_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Promissory note interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_M789M40767M7_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProceedsFromConvertibleNotes" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ProceedsFromConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProceedsFromConvertibleNotes" xml:lang="en-US">Proceeds From Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProceedsFromConvertibleNotes" xml:lang="en-US">Net proceeds of promissory note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProceedsFromConvertibleNotes" xml:lang="en-US">Proceeds from senior subordinated unsecured convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ProceedsFromConvertibleNotes" xlink:to="lab_84LLL766LI061L6H67IH_fil_ProceedsFromConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:label="loc_K567K28545K5_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage Of Principle Amount In Which Convertible Note Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage of principle amount in which convertible note issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xml:lang="en-US">Percentage of principle amount in which convertible note issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:to="lab_M789M40767M7_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentMaturityDateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Convertible note maturity term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentMaturityDateDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:label="loc_K567K28545K5_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross Proceeds In Subsequent Offerings Of Common Stock Or Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross proceeds in subsequent offerings of common stock or equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xml:lang="en-US">Gross proceeds in subsequent offerings of common stock or equivalents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:to="lab_M789M40767M7_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DerivativeWarrantsIssuedWithConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Derivative Warrants Issued With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Common stock issued to investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Warrants issued with Convertible Notes (See Note 5), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Derivative warrants Issued With Convertible Notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:to="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InvestmentWarrantGrantDateFairValue" xlink:label="loc_K567K28545K5_fil_InvestmentWarrantGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment Warrant Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment warrant grant date fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_InvestmentWarrantGrantDateFairValue" xml:lang="en-US">Investment warrant grant date fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_InvestmentWarrantGrantDateFairValue" xlink:to="lab_M789M40767M7_fil_InvestmentWarrantGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentFairValuePerShare" xlink:label="loc_K567K28545K5_fil_DebtInstrumentFairValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DebtInstrumentFairValuePerShare" xml:lang="en-US">Debt Instrument Fair Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DebtInstrumentFairValuePerShare" xml:lang="en-US">Convertible note fair value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DebtInstrumentFairValuePerShare" xml:lang="en-US">Debt instrument fair value per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DebtInstrumentFairValuePerShare" xlink:to="lab_M789M40767M7_fil_DebtInstrumentFairValuePerShare"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ExtendedMaturityPeriodOfConvertibleNotes" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ExtendedMaturityPeriodOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended Maturity Period Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended maturity Period of convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ExtendedMaturityPeriodOfConvertibleNotes" xml:lang="en-US">Extended maturity Period of convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ExtendedMaturityPeriodOfConvertibleNotes" xlink:to="lab_84LLL766LI061L6H67IH_fil_ExtendedMaturityPeriodOfConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfExtendedMaturityDate" xlink:label="loc_K567K28545K5_fil_DescriptionOfExtendedMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description Of Extended Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description of extended maturity date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DescriptionOfExtendedMaturityDate" xml:lang="en-US">Description of extended maturity date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DescriptionOfExtendedMaturityDate" xlink:to="lab_M789M40767M7_fil_DescriptionOfExtendedMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Convertible notes and the accrued interest converted into common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_K567K28545K5_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Common stock issued by conversion of note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_M789M40767M7_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InsurancePolicyDownPayment" xlink:label="loc_62JJJ544JG849J4F45GF_fil_InsurancePolicyDownPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_InsurancePolicyDownPayment" xml:lang="en-US">Insurance Policy Down Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_InsurancePolicyDownPayment" xml:lang="en-US">Down payment under insurance policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_InsurancePolicyDownPayment" xml:lang="en-US">Amount of down payment of insurance policy.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_InsurancePolicyDownPayment" xlink:to="lab_84LLL766LI061L6H67IH_fil_InsurancePolicyDownPayment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InsurancePolicyInstallmentPayment" xlink:label="loc_K567K28545K5_fil_InsurancePolicyInstallmentPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_InsurancePolicyInstallmentPayment" xml:lang="en-US">Insurance Policy Installment Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_InsurancePolicyInstallmentPayment" xml:lang="en-US">Premium monthly installment for nine months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_InsurancePolicyInstallmentPayment" xml:lang="en-US">Amount of monthly installment payment of insurance policy.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_InsurancePolicyInstallmentPayment" xlink:to="lab_M789M40767M7_fil_InsurancePolicyInstallmentPayment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentAnnualPrincipalPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Principal payment of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_K567K28545K5_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule Of Derivative Warrant Instruments Activity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:to="lab_M789M40767M7_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsUnits" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DerivativeWarrantsUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsUnits" xml:lang="en-US">Total warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsUnits" xml:lang="en-US">Beginning balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsUnits" xml:lang="en-US">Balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsUnits" xml:lang="en-US">Derivative warrants units.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DerivativeWarrantsUnits" xlink:to="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsUnits"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xlink:label="loc_K567K28545K5_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xml:lang="en-US">Derivative Warrant Units Reclassification To Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xml:lang="en-US">Reclassification to paid in capital, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xml:lang="en-US">Reclassification to paid in capital.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xlink:to="lab_M789M40767M7_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Derivative Placement Agent Warrants Related To Issuance Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Placement agent warrants related to issuance of Convertible Notes (See Note 5), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Derivative placement Agent warrants related to issuance of convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:to="lab_84LLL766LI061L6H67IH_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithStockOffering" xlink:label="loc_K567K28545K5_fil_DerivativeWarrantsIssuedWithStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Derivative Warrants Issued With Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Warrants issued with Stock Offering (See Note 9), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Derivative warrants issued with Stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DerivativeWarrantsIssuedWithStockOffering" xlink:to="lab_M789M40767M7_fil_DerivativeWarrantsIssuedWithStockOffering"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Derivative Placement Agent Warrants Related To Issuance Of Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Placement agent warrants related to issuance of Stock Offering (See Note 9), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Derivative Placement Agent warrants related to issuance of stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithCommonStockOffering" xlink:label="loc_K567K28545K5_fil_DerivativeWarrantsIssuedWithCommonStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Derivative Warrants Issued With Common Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Warrants issued with 2012 Common Stock Offering - A (See Note 9), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Derivative warrants issued with Common Stock Offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DerivativeWarrantsIssuedWithCommonStockOffering" xlink:to="lab_M789M40767M7_fil_DerivativeWarrantsIssuedWithCommonStockOffering"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Derivative Warrants Issued With Common Stock Offering One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Warrants issued with 2012 Common Stock Offering - B (See Note 9), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Derivative warrants issued with Common Stock Offering one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:to="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativePlacementAgentWarrantsRelatedToStock" xlink:label="loc_K567K28545K5_fil_DerivativePlacementAgentWarrantsRelatedToStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Derivative Placement Agent Warrants Related To Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Placement agent warrants related to 2012 Common Stock Offering (See Note 9), Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Derivative placement agent warrants related to stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DerivativePlacementAgentWarrantsRelatedToStock" xlink:to="lab_M789M40767M7_fil_DerivativePlacementAgentWarrantsRelatedToStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_62JJJ544JG849J4F45GF_fil_TransferFromLiabilityClassificationToEquityClassification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_TransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_TransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_84LLL766LI061L6H67IH_fil_TransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_K567K28545K5_us-gaap_DerivativeFairValueOfDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Beginning balance, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Balance, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_M789M40767M7_us-gaap_DerivativeFairValueOfDerivativeNet"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xml:lang="en-US">Derivative Warrant Units Reclassification To Paid In Capital Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xml:lang="en-US">Reclassification to paid in capital, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xml:lang="en-US">Reclassification to paid in capital, fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xlink:to="lab_84LLL766LI061L6H67IH_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_K567K28545K5_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Fair Value Of Derivative Warrants Issued With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Warrants issued with Convertible Notes (See Note 5), Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Fair value of derivative warrants issued with convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" xlink:to="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:label="loc_62JJJ544JG849J4F45GF_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Fair Value Of Derivative Placement Agent Warrants Related To Issuance Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Placement agent warrants related to issuance of Convertible Notes (See Note 5), Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Fair value of derivative placement agent warrants related to issuance of convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:to="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xlink:label="loc_K567K28545K5_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Fair Value Of Derivative Warrants Issued With Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Warrants issued with Stock Offering (See Note 9), Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xml:lang="en-US">Fair value of derivative warrants issued with stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xlink:to="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Fair Value Of Derivative Placement Agent Warrants Related To Issuance Of Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Placement agent warrants related to issuance of Stock Offering (See Note 9), Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xml:lang="en-US">Fair value of derivative placement agent warrants related to issuance of Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xlink:label="loc_K567K28545K5_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Fair Value Of Derivative Warrants Issued With Common Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Warrants issued with 2012 Common Stock Offering - A (See Note 9), Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xml:lang="en-US">Fair value of derivative warrants issued with Common Stock Offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xlink:to="lab_M789M40767M7_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:label="loc_62JJJ544JG849J4F45GF_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Fair Value Of Derivative Warrants Issued With Common Stock Offering One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Warrants issued with 2012 Common Stock Offering - B (See Note 9), Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xml:lang="en-US">Fair value of derivative warrants issued with Common Stock Offering one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:to="lab_84LLL766LI061L6H67IH_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xlink:label="loc_K567K28545K5_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Fair Value Of Derivative Placement Agent Warrants Related To Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Placement agent warrants related to 2012 Common Stock Offering (See Note 9), Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xml:lang="en-US">Fair value of derivative placement agent warrants related to stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xlink:to="lab_M789M40767M7_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ChangeInFairValueOfDerivativeWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change In Fair Value Of Derivative Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value of derivative warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ChangeInFairValueOfDerivativeWarrants" xlink:to="lab_84LLL766LI061L6H67IH_fil_ChangeInFairValueOfDerivativeWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_K567K28545K5_us-gaap_DerivativeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeTable" xlink:to="lab_M789M40767M7_us-gaap_DerivativeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RangeAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_K567K28545K5_us-gaap_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RangeMember" xlink:to="lab_M789M40767M7_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_MaximumMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_K567K28545K5_us-gaap_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_MinimumMember" xlink:to="lab_M789M40767M7_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_K567K28545K5_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary Of Fair Value Of Derivative Warrants On Basis Of Valuation Model [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="lab_M789M40767M7_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_62JJJ544JG849J4F45GF_fil_MarketValueOfCommonStockOnMeasurementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market Value Of Common Stock On Measurement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date (1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_MarketValueOfCommonStockOnMeasurementDate" xlink:to="lab_84LLL766LI061L6H67IH_fil_MarketValueOfCommonStockOnMeasurementDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_K567K28545K5_us-gaap_FairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Adjusted exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueAssumptionsExercisePrice" xlink:to="lab_M789M40767M7_us-gaap_FairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate (2)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_K567K28545K5_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility (3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_M789M40767M7_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield (4)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_K567K28545K5_us-gaap_FairValueInputsProbabilityOfDefault" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Fair Value Inputs, Probability Of Default</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Probability of stock offering in any period over 5 years (5)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FairValueInputsProbabilityOfDefault" xlink:to="lab_M789M40767M7_us-gaap_FairValueInputsProbabilityOfDefault"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_62JJJ544JG849J4F45GF_fil_RangeOfPercentageOfExistingSharesOffered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range Of Percentage Of Existing Shares Offered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered (6)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_RangeOfPercentageOfExistingSharesOffered" xml:lang="en-US">Range of percentage of existing shares offered.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_RangeOfPercentageOfExistingSharesOffered" xlink:to="lab_84LLL766LI061L6H67IH_fil_RangeOfPercentageOfExistingSharesOffered"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueAssumptionOfferingPrice" xlink:label="loc_K567K28545K5_fil_FairValueAssumptionOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FairValueAssumptionOfferingPrice" xml:lang="en-US">Fair Value Assumption Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FairValueAssumptionOfferingPrice" xml:lang="en-US">Offering price range (7)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FairValueAssumptionOfferingPrice" xml:lang="en-US">Fair value assumption offering price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FairValueAssumptionOfferingPrice" xlink:to="lab_M789M40767M7_fil_FairValueAssumptionOfferingPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xml:lang="en-US">Derivative Instruments, Gain (Loss) By Hedging Relationship, By Income Statement Location, By Derivative Instrument Risk [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_K567K28545K5_us-gaap_DerivativeInstrumentsGainLossLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DerivativeInstrumentsGainLossLineItems" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DerivativeInstrumentsGainLossLineItems" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_M789M40767M7_us-gaap_DerivativeInstrumentsGainLossLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DerivativeTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeTextualAbstract" xml:lang="en-US">Derivative Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DerivativeTextualAbstract" xml:lang="en-US">Derivative (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DerivativeTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_DerivativeTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfRiskFreeInterestRateDetermination" xlink:label="loc_K567K28545K5_fil_DescriptionOfRiskFreeInterestRateDetermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description Of Risk Free Interest Rate Determination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description of risk free interest rate determination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DescriptionOfRiskFreeInterestRateDetermination" xml:lang="en-US">Description of risk free interest rate determination.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DescriptionOfRiskFreeInterestRateDetermination" xlink:to="lab_M789M40767M7_fil_DescriptionOfRiskFreeInterestRateDetermination"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfProbabilityOfStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description Of Probability Of Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description of probability of stock offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description of probability of stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DescriptionOfProbabilityOfStockOffering" xlink:to="lab_84LLL766LI061L6H67IH_fil_DescriptionOfProbabilityOfStockOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_K567K28545K5_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components Of Deferred Tax Assets and Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of deferred tax assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_M789M40767M7_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components Of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_K567K28545K5_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_M789M40767M7_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_K567K28545K5_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xml:lang="en-US">Other differences in tax basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_M789M40767M7_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xml:lang="en-US">Total deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_K567K28545K5_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_M789M40767M7_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net Of Valuation Allowance, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DeferredTaxAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_K567K28545K5_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Schedule of difference between the income tax provision and the U.S. Federal statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_M789M40767M7_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income Tax Reconciliation, Income Tax Expense (Benefit), At Federal Statutory Income Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Federal income taxes at 34%</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, At Federal Statutory Income Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">U.S. Federal statutory rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Federal income taxes at 34%, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">U.S. Federal statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Income Tax Reconciliation, Nondeductible Expense, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Share-based compensation costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Share-based compensation costs, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Income Tax Reconciliation, Change In Deferred Tax Assets Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in fair value of derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Deferred Tax Assets Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in fair value of derivatives, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xml:lang="en-US">Income Tax Reconciliation, Nondeductible Expense, Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xml:lang="en-US">Amortization of debt discounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xlink:label="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xml:lang="en-US">Amortization of debt discounts, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xlink:to="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Income Tax Reconciliation, Other Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Change in valuation allowance, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Provision for income tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Provision for income tax, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_M789M40767M7_us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_IncomeTaxesTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_IncomeTaxesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_IncomeTaxesTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_IncomeTaxesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_K567K28545K5_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating losses ("NOLs")</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_OperatingLossCarryforwards" xlink:to="lab_M789M40767M7_us-gaap_OperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_OperatingLossCarryforwardsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Expiration dates of operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_K567K28545K5_us-gaap_LongTermPurchaseCommitmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-Term Purchase Commitment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-term Purchase Commitment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category Of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_K567K28545K5_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-Term Purchase Commitment, Category Of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_M789M40767M7_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PhaseFirstClinicalTrialOfLicensedProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase First Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase I Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase first clinical trial of a licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_PhaseFirstClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_K567K28545K5_fil_PhaseSecondClinicalTrialOfLicensedProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Second Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase II Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase second clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:to="lab_M789M40767M7_fil_PhaseSecondClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PhaseThirdClinicalTrialOfLicensedProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Third Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_PhaseThirdClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BiologicalLicenseApplicationMember" xlink:label="loc_K567K28545K5_fil_BiologicalLicenseApplicationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application filing with U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological license application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_BiologicalLicenseApplicationMember" xlink:to="lab_M789M40767M7_fil_BiologicalLicenseApplicationMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSaleMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_FirstCommercialSaleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_FirstCommercialSaleMember" xml:lang="en-US">First commercial sale.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_FirstCommercialSaleMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_FirstCommercialSaleMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_K567K28545K5_fil_AfterFirstNetSalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AfterFirstNetSalesMember" xml:lang="en-US">After first net sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AfterFirstNetSalesMember" xlink:to="lab_M789M40767M7_fil_AfterFirstNetSalesMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewDrugApplicationMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_NewDrugApplicationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_NewDrugApplicationMember" xml:lang="en-US">New drug application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_NewDrugApplicationMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_NewDrugApplicationMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_K567K28545K5_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt Of Regulatory Approval From U S Fda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of Regulatory Approval From U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of regulatory approval from U.S. FDA.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:to="lab_M789M40767M7_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LongTermPurchaseCommitmentLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentAbstract" xlink:label="loc_K567K28545K5_fil_MilestonePaymentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_MilestonePaymentAbstract" xml:lang="en-US">Milestone Payment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_MilestonePaymentAbstract" xml:lang="en-US">Summary of milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_MilestonePaymentAbstract" xlink:to="lab_M789M40767M7_fil_MilestonePaymentAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_62JJJ544JG849J4F45GF_fil_LongTermPurchaseCommitmentMilestonesPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long Term Purchase Commitment Milestones Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Milestones payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long term purchase commitment milestones payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:to="lab_84LLL766LI061L6H67IH_fil_LongTermPurchaseCommitmentMilestonesPayment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_K567K28545K5_fil_CommitmentsAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_CommitmentsAndContingenciesTable" xlink:to="lab_M789M40767M7_fil_CommitmentsAndContingenciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_TitleOfIndividualAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_K567K28545K5_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_M789M40767M7_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChiefExecutiveOfficerAndDirectorMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ChiefExecutiveOfficerAndDirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ChiefExecutiveOfficerAndDirectorMember" xml:lang="en-US">Chief Executive Officer And Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ChiefExecutiveOfficerAndDirectorMember" xml:lang="en-US">Highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ChiefExecutiveOfficerAndDirectorMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_ChiefExecutiveOfficerAndDirectorMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_K567K28545K5_us-gaap_EmploymentContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_EmploymentContractsMember" xml:lang="en-US">Employment Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_EmploymentContractsMember" xlink:to="lab_M789M40767M7_us-gaap_EmploymentContractsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RestrictedStockMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_K567K28545K5_fil_CommitmentsAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_CommitmentsAndContingenciesLineItems" xlink:to="lab_M789M40767M7_fil_CommitmentsAndContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_CommitmentsAndContingenciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceObjectiveDescription" xlink:label="loc_K567K28545K5_fil_PerformanceObjectiveDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PerformanceObjectiveDescription" xml:lang="en-US">Performance Objective Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PerformanceObjectiveDescription" xml:lang="en-US">Description regarding remuneration of CEO and director upon the attainment of performance objective.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PerformanceObjectiveDescription" xlink:to="lab_M789M40767M7_fil_PerformanceObjectiveDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Common stock available for grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Options granted to purchase shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xlink:label="loc_K567K28545K5_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xml:lang="en-US">Option Granted To Purchase Shares As Sign On Bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xml:lang="en-US">Option granted as sign on bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xml:lang="en-US">Option granted to purchase shares as sign on bonus.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xlink:to="lab_M789M40767M7_fil_OptionGrantedToPurchaseSharesAsSignOnBonus"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xlink:label="loc_62JJJ544JG849J4F45GF_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xml:lang="en-US">Option Granted To Purchase Shares As Sign On Bonus Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xml:lang="en-US">Option granted as sign on bonus, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xml:lang="en-US">Option granted to purchase shares as sign on bonus description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xlink:to="lab_84LLL766LI061L6H67IH_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OakRidgeNationalLaboratoryMember" xlink:label="loc_K567K28545K5_fil_OakRidgeNationalLaboratoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak ridge national laboratory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_OakRidgeNationalLaboratoryMember" xlink:to="lab_M789M40767M7_fil_OakRidgeNationalLaboratoryMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AptivSolutionsMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AptivSolutionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AptivSolutionsMember" xml:lang="en-US">Aptiv solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AptivSolutionsMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_AptivSolutionsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_K567K28545K5_fil_FredHutchinsonCancerResearchCenterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred hutchinson cancer research center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FredHutchinsonCancerResearchCenterMember" xlink:to="lab_M789M40767M7_fil_FredHutchinsonCancerResearchCenterMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and Ii Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I/II Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and II clinical trial for actimab in elderly acute myeloid leukemia.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_K567K28545K5_fil_UniversityOfTexasMDAndersonCancerCenterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University Of Texas M D Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of Texas M.D. Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of texas M.D. anderson cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_UniversityOfTexasMDAndersonCancerCenterMember" xlink:to="lab_M789M40767M7_fil_UniversityOfTexasMDAndersonCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JohnsHopkinsUniversityMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_JohnsHopkinsUniversityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns hopkins university.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_JohnsHopkinsUniversityMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_JohnsHopkinsUniversityMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCoMember" xlink:label="loc_K567K28545K5_fil_LaidlawAndCoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_LaidlawAndCoMember" xml:lang="en-US">Laidlaw &amp; Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_LaidlawAndCoMember" xlink:to="lab_M789M40767M7_fil_LaidlawAndCoMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfPennsylvaniaMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_UniversityOfPennsylvaniaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_UniversityOfPennsylvaniaMember" xml:lang="en-US">University Of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of pennsylvania.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_UniversityOfPennsylvaniaMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_UniversityOfPennsylvaniaMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_K567K28545K5_us-gaap_ChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Former CEO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_M789M40767M7_us-gaap_ChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ProductDevelopmentAndPatentLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product Development and Patent License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product development and patent license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_ProductDevelopmentAndPatentLicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAgreementMember" xlink:label="loc_K567K28545K5_fil_LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_LicenseAgreementMember" xml:lang="en-US">License agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_LicenseAgreementMember" xml:lang="en-US">License agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_LicenseAgreementMember" xlink:to="lab_M789M40767M7_fil_LicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_LicenseAndSponsoredResearchAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and Sponsored Research Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">license and sponsored research agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and sponsored research agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_LicenseAndSponsoredResearchAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_LicenseAndSponsoredResearchAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentAgreementMember" xlink:label="loc_K567K28545K5_fil_PlacementAgentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PlacementAgentAgreementMember" xml:lang="en-US">Placement agent agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PlacementAgentAgreementMember" xlink:to="lab_M789M40767M7_fil_PlacementAgentAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RentalAgreementMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_RentalAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_RentalAgreementMember" xml:lang="en-US">Rental agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_RentalAgreementMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_RentalAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeparationAndSettlementAgreementMember" xlink:label="loc_K567K28545K5_fil_SeparationAndSettlementAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_SeparationAndSettlementAgreementMember" xlink:to="lab_M789M40767M7_fil_SeparationAndSettlementAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfLicenseFee" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PaymentOfLicenseFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PaymentOfLicenseFee" xml:lang="en-US">Payment Of License Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PaymentOfLicenseFee" xml:lang="en-US">License fee payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PaymentOfLicenseFee" xml:lang="en-US">License fee payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PaymentOfLicenseFee" xlink:to="lab_84LLL766LI061L6H67IH_fil_PaymentOfLicenseFee"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_K567K28545K5_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Net sales in milestones payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_M789M40767M7_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentDate" xlink:label="loc_62JJJ544JG849J4F45GF_fil_MilestonePaymentDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentDate" xml:lang="en-US">Milestone Payment Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentDate" xml:lang="en-US">Milestone payment date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentDate" xml:lang="en-US">Milestone payment date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_MilestonePaymentDate" xlink:to="lab_84LLL766LI061L6H67IH_fil_MilestonePaymentDate"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_K567K28545K5_fil_DescriptionOfRoyaltyPaymentToRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description Of Royalty Payment To Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment to related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="lab_M789M40767M7_fil_DescriptionOfRoyaltyPaymentToRelatedParty"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RoyaltyOfNetSalesPercentage" xlink:label="loc_62JJJ544JG849J4F45GF_fil_RoyaltyOfNetSalesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty Of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of net sales percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_RoyaltyOfNetSalesPercentage" xlink:to="lab_84LLL766LI061L6H67IH_fil_RoyaltyOfNetSalesPercentage"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSalePeriod" xlink:label="loc_K567K28545K5_fil_FirstCommercialSalePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FirstCommercialSalePeriod" xml:lang="en-US">First Commercial Sale Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FirstCommercialSalePeriod" xlink:to="lab_M789M40767M7_fil_FirstCommercialSalePeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_TechnologyServicesCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology Services Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology access fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_TechnologyServicesCosts" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_TechnologyServicesCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_K567K28545K5_us-gaap_MaintenanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_MaintenanceCosts" xml:lang="en-US">Maintenance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_MaintenanceCosts" xml:lang="en-US">Annual maintenance fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_MaintenanceCosts" xlink:to="lab_M789M40767M7_us-gaap_MaintenanceCosts"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentArrangement" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ResearchAndDevelopmentArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and Development Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ResearchAndDevelopmentArrangement" xml:lang="en-US">Annual research funding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and development arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ResearchAndDevelopmentArrangement" xlink:to="lab_84LLL766LI061L6H67IH_fil_ResearchAndDevelopmentArrangement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PurchaseOfRadioactiveMaterial" xlink:label="loc_K567K28545K5_fil_PurchaseOfRadioactiveMaterial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase Of Radioactive Material</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material used for research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PurchaseOfRadioactiveMaterial" xlink:to="lab_M789M40767M7_fil_PurchaseOfRadioactiveMaterial"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProjectEstimatedCost" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ProjectEstimatedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProjectEstimatedCost" xml:lang="en-US">Project Estimated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost for clinical trials of drug Ac-225-HuM195</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ProjectEstimatedCost" xlink:to="lab_84LLL766LI061L6H67IH_fil_ProjectEstimatedCost"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_K567K28545K5_fil_DownPaymentOfProjectEstimatedCostPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down Payment Of Project Estimated Cost Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down payment of project estimated cost percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Percentage of total estimated project cost required for down payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DownPaymentOfProjectEstimatedCostPercentage" xlink:to="lab_M789M40767M7_fil_DownPaymentOfProjectEstimatedCostPercentage"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentForProject" xlink:label="loc_62JJJ544JG849J4F45GF_fil_DownPaymentForProject" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_DownPaymentForProject" xml:lang="en-US">Down Payment For Project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_DownPaymentForProject" xml:lang="en-US">Down payment for project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_DownPaymentForProject" xml:lang="en-US">Down payment for project.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_DownPaymentForProject" xlink:to="lab_84LLL766LI061L6H67IH_fil_DownPaymentForProject"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_K567K28545K5_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical Trial Cost For Approval For Food and Drug Administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:to="lab_M789M40767M7_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_62JJJ544JG849J4F45GF_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund To Related Party Under Agreement For First Two Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund to related party under agreement for first two Year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:to="lab_84LLL766LI061L6H67IH_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_K567K28545K5_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund To Related Party Under Agreement After Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund to related party under agreement after year two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:to="lab_M789M40767M7_fil_FundToRelatedPartyUnderAgreementAfterYearTwo"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_RoyaltyExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty payment for the commercial use of drugs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_RoyaltyExpense" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_RoyaltyExpense"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NonRefundableInstitutionalFee" xlink:label="loc_K567K28545K5_fil_NonRefundableInstitutionalFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_NonRefundableInstitutionalFee" xml:lang="en-US">Non Refundable Institutional Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_NonRefundableInstitutionalFee" xml:lang="en-US">Non - refundable institutional fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_NonRefundableInstitutionalFee" xml:lang="en-US">Non refundable institutional fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_NonRefundableInstitutionalFee" xlink:to="lab_M789M40767M7_fil_NonRefundableInstitutionalFee"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PharmacyFee" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PharmacyFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PharmacyFee" xml:lang="en-US">Pharmacy Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PharmacyFee" xml:lang="en-US">Annual pharmacy fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PharmacyFee" xml:lang="en-US">Pharmacy fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PharmacyFee" xlink:to="lab_84LLL766LI061L6H67IH_fil_PharmacyFee"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmendmentProcessingFee" xlink:label="loc_K567K28545K5_fil_AmendmentProcessingFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AmendmentProcessingFee" xml:lang="en-US">Amendment Processing Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AmendmentProcessingFee" xlink:to="lab_M789M40767M7_fil_AmendmentProcessingFee"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantExercisableNoticePeriodDescription" xlink:label="loc_62JJJ544JG849J4F45GF_fil_WarrantExercisableNoticePeriodDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant Exercisable Notice Period Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_WarrantExercisableNoticePeriodDescription" xlink:to="lab_84LLL766LI061L6H67IH_fil_WarrantExercisableNoticePeriodDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_K567K28545K5_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description Of Shares Availability By Exercise Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of period of shares availability by exercise of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of shares availability by exercise of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:to="lab_M789M40767M7_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementConsideration" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AgreementConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementConsideration" xml:lang="en-US">Agreement Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementConsideration" xml:lang="en-US">Consideration pursuant to agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementConsideration" xml:lang="en-US">Consideration under agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AgreementConsideration" xlink:to="lab_84LLL766LI061L6H67IH_fil_AgreementConsideration"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPayableInInstallmentsUnderAgreement" xlink:label="loc_K567K28545K5_fil_AmountPayableInInstallmentsUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AmountPayableInInstallmentsUnderAgreement" xml:lang="en-US">Amount Payable In Installments Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_AmountPayableInInstallmentsUnderAgreement" xml:lang="en-US">Amount payable in installments under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AmountPayableInInstallmentsUnderAgreement" xml:lang="en-US">Amount payable in installments under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AmountPayableInInstallmentsUnderAgreement" xlink:to="lab_M789M40767M7_fil_AmountPayableInInstallmentsUnderAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallments" xlink:label="loc_62JJJ544JG849J4F45GF_fil_NumberOfInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_NumberOfInstallments" xml:lang="en-US">Number Of Installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_NumberOfInstallments" xml:lang="en-US">Number of installments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_NumberOfInstallments" xlink:to="lab_84LLL766LI061L6H67IH_fil_NumberOfInstallments"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_K567K28545K5_fil_PerformanceBonusPayableUnderAgreementForService" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance Bonus Payable Under Agreement For Service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance bonus payable under agreement for service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance bonus payable under agreement for service.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PerformanceBonusPayableUnderAgreementForService" xlink:to="lab_M789M40767M7_fil_PerformanceBonusPayableUnderAgreementForService"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementRenewalDescription" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AgreementRenewalDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementRenewalDescription" xml:lang="en-US">Agreement Renewal Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementRenewalDescription" xml:lang="en-US">Rental agreement renewal description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AgreementRenewalDescription" xml:lang="en-US">Description regarding renewal of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AgreementRenewalDescription" xlink:to="lab_84LLL766LI061L6H67IH_fil_AgreementRenewalDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFirstInstallmentForServicesByCompany" xlink:label="loc_K567K28545K5_fil_PaymentOfFirstInstallmentForServicesByCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PaymentOfFirstInstallmentForServicesByCompany" xml:lang="en-US">Payment Of First Installment For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_PaymentOfFirstInstallmentForServicesByCompany" xml:lang="en-US">Payment of first installment for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PaymentOfFirstInstallmentForServicesByCompany" xml:lang="en-US">Payment of first installment for services by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PaymentOfFirstInstallmentForServicesByCompany" xlink:to="lab_M789M40767M7_fil_PaymentOfFirstInstallmentForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PaymentOfFinalInstallmentForServicesByCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Payment Of Final Installment For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Payment Of Performance Bonus For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PaymentOfFinalInstallmentForServicesByCompany" xlink:to="lab_84LLL766LI061L6H67IH_fil_PaymentOfFinalInstallmentForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_K567K28545K5_fil_PaymentOfPerformanceBonusForServicesByCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment Of Performance Bonus For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of Performance bonus for Services by Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PaymentOfPerformanceBonusForServicesByCompany" xlink:to="lab_M789M40767M7_fil_PaymentOfPerformanceBonusForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Rent agreement termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_LeaseExpirationDate1" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_LeaseExpirationDate1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NoticePeriodForTerminationOfAgreement" xlink:label="loc_K567K28545K5_fil_NoticePeriodForTerminationOfAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period For Termination Of Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice period for termination of agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period for termination of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_NoticePeriodForTerminationOfAgreement" xlink:to="lab_M789M40767M7_fil_NoticePeriodForTerminationOfAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of warrants activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Cancellation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Stock option forfeitures during period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_M789M40767M7_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Warrants expired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Stock option cancelled during period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAMember" xlink:label="loc_K567K28545K5_us-gaap_SeriesAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SeriesAMember" xml:lang="en-US">Series [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SeriesAMember" xlink:to="lab_M789M40767M7_us-gaap_SeriesAMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SeriesBMember" xml:lang="en-US">Series B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SeriesBMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SeriesBMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_K567K28545K5_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type Of Arrangement and Non-Arrangement Transactions [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_TypeOfArrangementAxis" xlink:to="lab_M789M40767M7_us-gaap_TypeOfArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-Arrangement Transactions [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MccormickOBrienPllcMember" xlink:label="loc_K567K28545K5_fil_MccormickOBrienPllcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_MccormickOBrienPllcMember" xml:lang="en-US">Mccormick O Brien Pllc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_MccormickOBrienPllcMember" xml:lang="en-US">McCormick &amp; O'Brien PLLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_MccormickOBrienPllcMember" xml:lang="en-US">McCormick O Brien PLLC.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_MccormickOBrienPllcMember" xlink:to="lab_M789M40767M7_fil_MccormickOBrienPllcMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale Of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_K567K28545K5_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale Of Stock, Name Of Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_M789M40767M7_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ManagementMember" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ManagementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ManagementMember" xml:lang="en-US">Management [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ManagementMember" xml:lang="en-US">Management Firm [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ManagementMember" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ManagementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_K567K28545K5_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_PlanNameAxis" xlink:to="lab_M789M40767M7_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_PlanNameDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenStockPlanMember" xlink:label="loc_K567K28545K5_fil_TwoThousandThirteenStockPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_TwoThousandThirteenStockPlanMember" xml:lang="en-US">Two Thousand Thirteen Stock Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_TwoThousandThirteenStockPlanMember" xml:lang="en-US">2013 Stock Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_TwoThousandThirteenStockPlanMember" xml:lang="en-US">Two thousand thirteen stock plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_TwoThousandThirteenStockPlanMember" xlink:to="lab_M789M40767M7_fil_TwoThousandThirteenStockPlanMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_TwoThousandThirteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_TwoThousandThirteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Thirteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_TwoThousandThirteenEquityIncentivePlanMember" xml:lang="en-US">2013 Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_TwoThousandThirteenEquityIncentivePlanMember" xml:lang="en-US">Two thousand thirteen equity incentive plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_TwoThousandThirteenEquityIncentivePlanMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_TwoThousandThirteenEquityIncentivePlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_K567K28545K5_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_FinancialInstrumentAxis" xlink:to="lab_M789M40767M7_us-gaap_FinancialInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Types Of Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Types of Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgencyAgreementMember" xlink:label="loc_K567K28545K5_fil_PlacementAgencyAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PlacementAgencyAgreementMember" xml:lang="en-US">Placement Agency Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgencyAgreementMember" xml:lang="en-US">Placement Agency Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PlacementAgencyAgreementMember" xml:lang="en-US">Placement agency agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PlacementAgencyAgreementMember" xlink:to="lab_M789M40767M7_fil_PlacementAgencyAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupLlcMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_JamessCapitalGroupLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_JamessCapitalGroupLlcMember" xml:lang="en-US">Jamess Capital Group Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_JamessCapitalGroupLlcMember" xml:lang="en-US">Jamess Capital Group, LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_JamessCapitalGroupLlcMember" xml:lang="en-US">Jamess capital group LLC.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_JamessCapitalGroupLlcMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_JamessCapitalGroupLlcMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantOneMember" xlink:label="loc_K567K28545K5_fil_WarrantOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_WarrantOneMember" xml:lang="en-US">Warrants One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_WarrantOneMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_WarrantOneMember" xml:lang="en-US">Warrant one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_WarrantOneMember" xlink:to="lab_M789M40767M7_fil_WarrantOneMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsBMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_WarrantsBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsBMember" xml:lang="en-US">Warrants B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsBMember" xml:lang="en-US">B Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsBMember" xml:lang="en-US">Warrant B.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_WarrantsBMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_WarrantsBMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FormerDirectorAndConsultantsMember" xlink:label="loc_K567K28545K5_fil_FormerDirectorAndConsultantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_FormerDirectorAndConsultantsMember" xml:lang="en-US">Former Director And Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_FormerDirectorAndConsultantsMember" xml:lang="en-US">Former director and consultants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_FormerDirectorAndConsultantsMember" xlink:to="lab_M789M40767M7_fil_FormerDirectorAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_EmployeesDirectorsAndConsultantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_EmployeesDirectorsAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_K567K28545K5_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class Of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ClassOfStockLineItems" xlink:to="lab_M789M40767M7_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EquityTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_EquityTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_EquityTextualAbstract" xml:lang="en-US">Equity (Textual) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_EquityTextualAbstract" xml:lang="en-US">Equity (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_EquityTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_EquityTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToPurchaseCommonStockOffering" xlink:label="loc_K567K28545K5_fil_WarrantsIssuedToPurchaseCommonStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_WarrantsIssuedToPurchaseCommonStockOffering" xml:lang="en-US">Warrants Issued To Purchase Common Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_WarrantsIssuedToPurchaseCommonStockOffering" xml:lang="en-US">Warrants issued to purchase common stock offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_WarrantsIssuedToPurchaseCommonStockOffering" xml:lang="en-US">Warrants Issued To Purchase Common Stock Offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_WarrantsIssuedToPurchaseCommonStockOffering" xlink:to="lab_M789M40767M7_fil_WarrantsIssuedToPurchaseCommonStockOffering"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_IncreaseOfferingOfCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_IncreaseOfferingOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_IncreaseOfferingOfCommonStock" xml:lang="en-US">Increase Offering Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_IncreaseOfferingOfCommonStock" xml:lang="en-US">Raised offering of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_IncreaseOfferingOfCommonStock" xml:lang="en-US">Increase offering of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_IncreaseOfferingOfCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_IncreaseOfferingOfCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedInStockOffering" xlink:label="loc_K567K28545K5_fil_CommonStockSharesIssuedInStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedInStockOffering" xml:lang="en-US">Common Stock Shares Issued In Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedInStockOffering" xml:lang="en-US">Common stock issued in stock offering, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedInStockOffering" xml:lang="en-US">Common stock shares issued in stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_CommonStockSharesIssuedInStockOffering" xlink:to="lab_M789M40767M7_fil_CommonStockSharesIssuedInStockOffering"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xml:lang="en-US">Proceeds From Issuance Of Stock Under Stock Offering Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xml:lang="en-US">Sale of common stock, net offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xml:lang="en-US">Proceeds from issuance of stock under stock offering, net.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xlink:to="lab_84LLL766LI061L6H67IH_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentCashFees" xlink:label="loc_K567K28545K5_fil_PlacementAgentCashFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PlacementAgentCashFees" xml:lang="en-US">Placement Agent Cash Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgentCashFees" xml:lang="en-US">Placement agent cash fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PlacementAgentCashFees" xml:lang="en-US">Placement agent cash fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PlacementAgentCashFees" xlink:to="lab_M789M40767M7_fil_PlacementAgentCashFees"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentCommission" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PlacementAgentCommission" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PlacementAgentCommission" xml:lang="en-US">Placement Agent Commission</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PlacementAgentCommission" xml:lang="en-US">Placement agent commission</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PlacementAgentCommission" xml:lang="en-US">Placement agent commission.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PlacementAgentCommission" xlink:to="lab_84LLL766LI061L6H67IH_fil_PlacementAgentCommission"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentExpenseReimbursement" xlink:label="loc_K567K28545K5_fil_PlacementAgentExpenseReimbursement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PlacementAgentExpenseReimbursement" xml:lang="en-US">Placement Agent Expense Reimbursement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgentExpenseReimbursement" xml:lang="en-US">Placement agent expense reimbursement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PlacementAgentExpenseReimbursement" xml:lang="en-US">Placement agent expense reimbursement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PlacementAgentExpenseReimbursement" xlink:to="lab_M789M40767M7_fil_PlacementAgentExpenseReimbursement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_WarrantsIssuedToPurchaseCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants Issued To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants issued to purchase common stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedToPurchaseCommonStock" xml:lang="en-US">Warrants Issued To Purchase Aggregate Shares Of Common Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_WarrantsIssuedToPurchaseCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsExpirationTerm" xlink:label="loc_K567K28545K5_fil_WarrantsExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_WarrantsExpirationTerm" xml:lang="en-US">Warrants Expiration Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_WarrantsExpirationTerm" xml:lang="en-US">Warrants expiration term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_WarrantsExpirationTerm" xml:lang="en-US">Warrants Expiration Term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_WarrantsExpirationTerm" xlink:to="lab_M789M40767M7_fil_WarrantsExpirationTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments To Additional Paid In Capital, Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Warrants issued to purchase common stock, fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentServicesFees" xlink:label="loc_K567K28545K5_fil_PlacementAgentServicesFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PlacementAgentServicesFees" xml:lang="en-US">Placement Agent Services Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgentServicesFees" xml:lang="en-US">Placement agent services fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PlacementAgentServicesFees" xml:lang="en-US">Placement agent services fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PlacementAgentServicesFees" xlink:to="lab_M789M40767M7_fil_PlacementAgentServicesFees"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BankEscrowFee" xlink:label="loc_62JJJ544JG849J4F45GF_fil_BankEscrowFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_BankEscrowFee" xml:lang="en-US">Bank Escrow Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_BankEscrowFee" xml:lang="en-US">Bank escrow fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_BankEscrowFee" xml:lang="en-US">Bank escrow fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_BankEscrowFee" xlink:to="lab_84LLL766LI061L6H67IH_fil_BankEscrowFee"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AccruedManagementFees" xlink:label="loc_K567K28545K5_fil_AccruedManagementFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AccruedManagementFees" xml:lang="en-US">Accrued Management Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AccruedManagementFees" xml:lang="en-US">Accrued management fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AccruedManagementFees" xml:lang="en-US">Accrued management fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AccruedManagementFees" xlink:to="lab_M789M40767M7_fil_AccruedManagementFees"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" xml:lang="en-US">Common Stock Shares Issued To Original Shareholder Under Share Exchange Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" xml:lang="en-US">Common stock issued to former shareholder under share exchange agreement, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" xml:lang="en-US">Common stock shares issued to original shareholder under share exchange agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" xlink:to="lab_84LLL766LI061L6H67IH_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" xlink:label="loc_K567K28545K5_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" xml:lang="en-US">Common Stock Shares Issued To Former Shareholder Under Share Exchange Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" xml:lang="en-US">Common stock issued to former shareholders under share exchange agreement, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" xml:lang="en-US">Common stock shares issued to former shareholder under share exchange agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" xlink:to="lab_M789M40767M7_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_62JJJ544JG849J4F45GF_fil_UnrecognizedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_UnrecognizedShareBasedCompensationExpense" xml:lang="en-US">Unrecognized Share Based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_UnrecognizedShareBasedCompensationExpense" xml:lang="en-US">Unrecognized share based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_UnrecognizedShareBasedCompensationExpense" xml:lang="en-US">Unrecognized share based compensation expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_UnrecognizedShareBasedCompensationExpense" xlink:to="lab_84LLL766LI061L6H67IH_fil_UnrecognizedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_K567K28545K5_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recorded option expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Fair value of warrants recorded as stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recorded option expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_M789M40767M7_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidForCancellationOfSharesByCompany" xlink:label="loc_62JJJ544JG849J4F45GF_fil_AmountPaidForCancellationOfSharesByCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidForCancellationOfSharesByCompany" xml:lang="en-US">Amount Paid For Cancellation Of Shares By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_AmountPaidForCancellationOfSharesByCompany" xml:lang="en-US">Amount paid for cancellation of shares by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_AmountPaidForCancellationOfSharesByCompany" xlink:to="lab_84LLL766LI061L6H67IH_fil_AmountPaidForCancellationOfSharesByCompany"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesPurchasedAfterCancelationOfOptions" xlink:label="loc_K567K28545K5_fil_SharesPurchasedAfterCancelationOfOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_SharesPurchasedAfterCancelationOfOptions" xml:lang="en-US">Shares Purchased After Cancelation Of Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_SharesPurchasedAfterCancelationOfOptions" xml:lang="en-US">Shares purchased after cancelation of options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_SharesPurchasedAfterCancelationOfOptions" xlink:to="lab_M789M40767M7_fil_SharesPurchasedAfterCancelationOfOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_K567K28545K5_us-gaap_ProceedsFromWarrantExercises" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_M789M40767M7_us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Units, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Granted Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xlink:to="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Grant Date Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThreeStockPlanMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_TwoThousandThreeStockPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_TwoThousandThreeStockPlanMember" xml:lang="en-US">Two Thousand Three Stock Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_TwoThousandThreeStockPlanMember" xml:lang="en-US">2003 Stock Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_TwoThousandThreeStockPlanMember" xml:lang="en-US">Two thousand three stock plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_TwoThousandThreeStockPlanMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_TwoThousandThreeStockPlanMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandTwelveEmployeeStockOptionPlanMember" xlink:label="loc_K567K28545K5_fil_TwoThousandTwelveEmployeeStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_TwoThousandTwelveEmployeeStockOptionPlanMember" xml:lang="en-US">Two Thousand Twelve Employee Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_TwoThousandTwelveEmployeeStockOptionPlanMember" xml:lang="en-US">2012 Employee Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_TwoThousandTwelveEmployeeStockOptionPlanMember" xml:lang="en-US">Two thousand twelve employee stock option plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_TwoThousandTwelveEmployeeStockOptionPlanMember" xlink:to="lab_M789M40767M7_fil_TwoThousandTwelveEmployeeStockOptionPlanMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesAndConsultantsMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_EmployeesAndConsultantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_EmployeesAndConsultantsMember" xml:lang="en-US">Employees and Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_EmployeesAndConsultantsMember" xml:lang="en-US">Employees and Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_EmployeesAndConsultantsMember" xml:lang="en-US">Employees and consultants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_EmployeesAndConsultantsMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_EmployeesAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultantsMember" xlink:label="loc_K567K28545K5_fil_ConsultantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_ConsultantsMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_ConsultantsMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_ConsultantsMember" xml:lang="en-US">Consultants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_ConsultantsMember" xlink:to="lab_M789M40767M7_fil_ConsultantsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionPlanTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_StockOptionPlanTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionPlanTextualAbstract" xml:lang="en-US">Stock Option Plan Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionPlanTextualAbstract" xml:lang="en-US">Stock Option Plan (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_StockOptionPlanTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_StockOptionPlanTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Maximum granted option to purchase common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" xlink:label="loc_62JJJ544JG849J4F45GF_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" xml:lang="en-US">Maximum Granted Option To Purchase Common Stock After Amendment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" xml:lang="en-US">Maximum granted option after amendment in 2008</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" xml:lang="en-US">Maximum granted option to purchase common stock after amendment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" xlink:to="lab_84LLL766LI061L6H67IH_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share based payment award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" xml:lang="en-US">Share Based Compensation Arrangement By Share Base Payment Award Periodic Percentage Of Award Vesting</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" xml:lang="en-US">Share based payment award monthly vesting percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" xml:lang="en-US">Share based compensation arrangement by share base payment award periodic percentage of award vesting.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" xlink:to="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Outstanding Stock Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xml:lang="en-US">Warrants percentage of total issued and outstanding shares of capital stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xml:lang="en-US">Percentage of total issued and outstanding shares of Series E Preferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" xml:lang="en-US">Percentage Of Aggregate Issued and Outstanding Common Shares Reserved Under Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" xml:lang="en-US">Percentage of aggregate issued and outstanding common shares reserved under offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" xml:lang="en-US">Percentage of aggregate issued and outstanding common shares reserved under offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" xlink:to="lab_84LLL766LI061L6H67IH_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_K567K28545K5_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Stock reserved for future issuance under ESOP</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_M789M40767M7_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Other Share Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xml:lang="en-US">Increment in number of shares under plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" xlink:label="loc_K567K28545K5_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" xml:lang="en-US">Share Based Compensation Share Based Arrangement Award Shares Reserved For Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" xml:lang="en-US">Total shares reserved for issuance under plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" xml:lang="en-US">Share based compensation share based arrangement award shares reserved for issuance.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" xlink:to="lab_M789M40767M7_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_StockOptionGrantedToPurchaseCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStock" xml:lang="en-US">Stock Option Granted To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStock" xml:lang="en-US">Warrant granted to Management Firm to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStock" xml:lang="en-US">Stock option granted to employees to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStock" xml:lang="en-US">Stock option granted to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_StockOptionGrantedToPurchaseCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xlink:label="loc_K567K28545K5_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xml:lang="en-US">Stock Option Granted To Purchase Common Stock Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xml:lang="en-US">Warrants granted to Management Firm to purchase common stock, exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xml:lang="en-US">Stock option granted to purchase common stock, exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xml:lang="en-US">Stock option granted to purchase common stock exercise price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xlink:to="lab_M789M40767M7_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xlink:label="loc_62JJJ544JG849J4F45GF_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xml:lang="en-US">Stock Option Granted To Purchase Common Stock Weighted Average Contractual Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xml:lang="en-US">Warrants granted to purchase common stock, term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xml:lang="en-US">Stock option granted to purchase common stock, term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xml:lang="en-US">Stock option granted to purchase common stock weighted average contractual life.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xlink:to="lab_84LLL766LI061L6H67IH_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_K567K28545K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair value of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair value of stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Discount For Postvesting Restrictions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xml:lang="en-US">Discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_K567K28545K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_M789M40767M7_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_M789M40767M7_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeeStockOptionUnitsReprised" xlink:label="loc_62JJJ544JG849J4F45GF_fil_EmployeeStockOptionUnitsReprised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_EmployeeStockOptionUnitsReprised" xml:lang="en-US">Employee Stock Option Units Reprised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_EmployeeStockOptionUnitsReprised" xml:lang="en-US">Employee stock option units repriced</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_EmployeeStockOptionUnitsReprised" xml:lang="en-US">Employee stock option units reprised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_EmployeeStockOptionUnitsReprised" xlink:to="lab_84LLL766LI061L6H67IH_fil_EmployeeStockOptionUnitsReprised"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" xlink:label="loc_K567K28545K5_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" xml:lang="en-US">Outstanding Stock Option Exercise Price After Repricing Of Stock Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" xml:lang="en-US">Outstanding stock option exercise price after repricing of stock option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" xml:lang="en-US">Outstanding stock option exercise price after repricing of stock option.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" xlink:to="lab_M789M40767M7_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" xml:lang="en-US">Share Based Compensation Cost After Repricing Of Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" xml:lang="en-US">Share based compensation cost after repricing of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" xml:lang="en-US">Share based compensation cost after repricing of stock options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" xlink:to="lab_84LLL766LI061L6H67IH_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedAbstract" xlink:label="loc_K567K28545K5_fil_WarrantsIssuedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_WarrantsIssuedAbstract" xml:lang="en-US">Warrants Issued [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_WarrantsIssuedAbstract" xml:lang="en-US">Summary of warrant issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_WarrantsIssuedAbstract" xlink:to="lab_M789M40767M7_fil_WarrantsIssuedAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedWithConvertibleNotes" xlink:label="loc_62JJJ544JG849J4F45GF_fil_WarrantsIssuedWithConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Warrants Issued With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Warrants issued with convertible notes (See Note 5)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedWithConvertibleNotes" xml:lang="en-US">Warrants issued with convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_WarrantsIssuedWithConvertibleNotes" xlink:to="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToInvestorsWithStockOffering" xlink:label="loc_K567K28545K5_fil_WarrantsIssuedToInvestorsWithStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_WarrantsIssuedToInvestorsWithStockOffering" xml:lang="en-US">Warrants Issued To Investors With Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_WarrantsIssuedToInvestorsWithStockOffering" xml:lang="en-US">Warrants issued to investors with Stock Offering (See Note 6 and Note 9)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_WarrantsIssuedToInvestorsWithStockOffering" xml:lang="en-US">Warrants issued to investors with Stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_WarrantsIssuedToInvestorsWithStockOffering" xlink:to="lab_M789M40767M7_fil_WarrantsIssuedToInvestorsWithStockOffering"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToInvestorsWithCommonStock" xlink:label="loc_62JJJ544JG849J4F45GF_fil_WarrantsIssuedToInvestorsWithCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedToInvestorsWithCommonStock" xml:lang="en-US">Warrants Issued To Investors With Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedToInvestorsWithCommonStock" xml:lang="en-US">Warrants issued to investors with Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedToInvestorsWithCommonStock" xml:lang="en-US">Warrants issued to investors with common Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_WarrantsIssuedToInvestorsWithCommonStock" xlink:to="lab_84LLL766LI061L6H67IH_fil_WarrantsIssuedToInvestorsWithCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:label="loc_K567K28545K5_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Placement Agent Warrants Related To Issuance Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Placement agent warrants related to issuance of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xml:lang="en-US">Placement agent warrants related to issuance of convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:to="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" xml:lang="en-US">Placement Agent Warrants Related To Issuance Of Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" xml:lang="en-US">Placement agent warrants related to issuance of Stock Offering (See Note 6 and Note 9)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" xml:lang="en-US">Placement agent warrants related to issuance of stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" xlink:to="lab_84LLL766LI061L6H67IH_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" xlink:label="loc_K567K28545K5_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" xml:lang="en-US">Placement Agent Warrants Related To Issuance Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" xml:lang="en-US">Placement agent warrants related to issuance of 2012 Common Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" xml:lang="en-US">Placement agent warrants related to issuance of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" xlink:to="lab_M789M40767M7_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantIssuedToInvestorsWithStockAccruedDividend" xlink:label="loc_62JJJ544JG849J4F45GF_fil_WarrantIssuedToInvestorsWithStockAccruedDividend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantIssuedToInvestorsWithStockAccruedDividend" xml:lang="en-US">Warrant Issued To Investors With Stock Accrued Dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantIssuedToInvestorsWithStockAccruedDividend" xml:lang="en-US">Warrant issued to investors with stock - accrued dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantIssuedToInvestorsWithStockAccruedDividend" xml:lang="en-US">Warrant issued to investors with stock accrued dividend.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_WarrantIssuedToInvestorsWithStockAccruedDividend" xlink:to="lab_84LLL766LI061L6H67IH_fil_WarrantIssuedToInvestorsWithStockAccruedDividend"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssued" xlink:label="loc_K567K28545K5_fil_WarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_WarrantsIssued" xml:lang="en-US">Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_WarrantsIssued" xml:lang="en-US">Total warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M789M40767M7_fil_WarrantsIssued" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_WarrantsIssued" xml:lang="en-US">Warrants issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_WarrantsIssued" xlink:to="lab_M789M40767M7_fil_WarrantsIssued"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_WarrantTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantTextualAbstract" xml:lang="en-US">Warrant Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_WarrantTextualAbstract" xml:lang="en-US">Warrant (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_WarrantTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_WarrantTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeeDefinedContributionPlanTextualAbstract" xlink:label="loc_K567K28545K5_fil_EmployeeDefinedContributionPlanTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_EmployeeDefinedContributionPlanTextualAbstract" xml:lang="en-US">Employee Defined Contribution Plan Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_EmployeeDefinedContributionPlanTextualAbstract" xml:lang="en-US">Employee Defined Contribution Plan (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_EmployeeDefinedContributionPlanTextualAbstract" xlink:to="lab_M789M40767M7_fil_EmployeeDefinedContributionPlanTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xml:lang="en-US">Description Of Defined Contribution Pension and Other Postretirement Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xml:lang="en-US">Description of employee deferred contribution plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_K567K28545K5_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Percentage of employer matching contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_M789M40767M7_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_62JJJ544JG849J4F45GF_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Contribution of the company in employee deferred contribution plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_84LLL766LI061L6H67IH_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventTable" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FormerChiefExecutiveOfficerMember" xlink:label="loc_62JJJ544JG849J4F45GF_fil_FormerChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_FormerChiefExecutiveOfficerMember" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_FormerChiefExecutiveOfficerMember" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_FormerChiefExecutiveOfficerMember" xml:lang="en-US">former chief executive officer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_FormerChiefExecutiveOfficerMember" xlink:to="lab_84LLL766LI061L6H67IH_fil_FormerChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_K567K28545K5_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_us-gaap_SubsequentEventLineItems" xlink:to="lab_M789M40767M7_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SubsequentEventsTextualAbstract" xlink:label="loc_62JJJ544JG849J4F45GF_fil_SubsequentEventsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent events textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_SubsequentEventsTextualAbstract" xlink:to="lab_84LLL766LI061L6H67IH_fil_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallmentsInWhichConsiderationIsPayable" xlink:label="loc_K567K28545K5_fil_NumberOfInstallmentsInWhichConsiderationIsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_NumberOfInstallmentsInWhichConsiderationIsPayable" xml:lang="en-US">Number Of Installments In Which Consideration Is Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_NumberOfInstallmentsInWhichConsiderationIsPayable" xml:lang="en-US">Number of installments in which consideration is payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_NumberOfInstallmentsInWhichConsiderationIsPayable" xml:lang="en-US">Number of installments in which consideration is payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_NumberOfInstallmentsInWhichConsiderationIsPayable" xlink:to="lab_M789M40767M7_fil_NumberOfInstallmentsInWhichConsiderationIsPayable"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsiderationPayableUnderAgreement" xlink:label="loc_62JJJ544JG849J4F45GF_fil_ConsiderationPayableUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConsiderationPayableUnderAgreement" xml:lang="en-US">Consideration Payable Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConsiderationPayableUnderAgreement" xml:lang="en-US">Consideration payable under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_ConsiderationPayableUnderAgreement" xml:lang="en-US">Consideration payable under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_ConsiderationPayableUnderAgreement" xlink:to="lab_84LLL766LI061L6H67IH_fil_ConsiderationPayableUnderAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountOfPerformanceBonus" xlink:label="loc_K567K28545K5_fil_AmountOfPerformanceBonus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M789M40767M7_fil_AmountOfPerformanceBonus" xml:lang="en-US">Amount Of Performance Bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M789M40767M7_fil_AmountOfPerformanceBonus" xml:lang="en-US">Performance bonus included in accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M789M40767M7_fil_AmountOfPerformanceBonus" xml:lang="en-US">Amount of performance bonus.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K567K28545K5_fil_AmountOfPerformanceBonus" xlink:to="lab_M789M40767M7_fil_AmountOfPerformanceBonus"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodOfService" xlink:label="loc_62JJJ544JG849J4F45GF_fil_PeriodOfService" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodOfService" xml:lang="en-US">Period Of Service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodOfService" xml:lang="en-US">Period of service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_84LLL766LI061L6H67IH_fil_PeriodOfService" xml:lang="en-US">Period of service.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_62JJJ544JG849J4F45GF_fil_PeriodOfService" xlink:to="lab_84LLL766LI061L6H67IH_fil_PeriodOfService"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>fil-20130930_pre.xml
<DESCRIPTION>XBRL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DocumentAndEntityInformation1" roleURI="http://cactusventuresinc.com/role/DocumentAndEntityInformation1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedBalanceSheets" roleURI="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedBalanceSheetsparenthetical" roleURI="http://cactusventuresinc.com/role/ConsolidatedBalanceSheetsparenthetical"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedStatementsOfOperations" roleURI="http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Consolidatedstatementofchangesinstockholdersequitydeficit" roleURI="http://cactusventuresinc.com/role/Consolidatedstatementofchangesinstockholdersequitydeficit"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StatementsOfCashFlows" roleURI="http://cactusventuresinc.com/role/StatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Notes11" roleURI="http://cactusventuresinc.com/role/Notes11"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#RelatedPartyTransaction" roleURI="http://cactusventuresinc.com/role/RelatedPartyTransaction"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyAndEquipment" roleURI="http://cactusventuresinc.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayableAndConvertibleNotes" roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotes"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Derivatives" roleURI="http://cactusventuresinc.com/role/Derivatives"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#IncomeTaxes" roleURI="http://cactusventuresinc.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingencies" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Equity" roleURI="http://cactusventuresinc.com/role/Equity"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StockOptionPlan" roleURI="http://cactusventuresinc.com/role/StockOptionPlan"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Warrants" roleURI="http://cactusventuresinc.com/role/Warrants"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EmployeeDefinedContributionPlan" roleURI="http://cactusventuresinc.com/role/EmployeeDefinedContributionPlan"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Notes13" roleURI="http://cactusventuresinc.com/role/Notes13"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#RelatedPartyTransactiontables" roleURI="http://cactusventuresinc.com/role/RelatedPartyTransactiontables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyandEquipmentTables" roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayableAndConvertibleNotesTables" roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesTables" roleURI="http://cactusventuresinc.com/role/DerivativesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#IncomeTaxesTables" roleURI="http://cactusventuresinc.com/role/IncomeTaxesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsandContingenciesTables" roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StockOptionPlanTables" roleURI="http://cactusventuresinc.com/role/StockOptionPlanTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EquityTables" roleURI="http://cactusventuresinc.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#WarrantsTables" roleURI="http://cactusventuresinc.com/role/WarrantsTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#GoingconcernDetails" roleURI="http://cactusventuresinc.com/role/GoingconcernDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#RelatedPartyTransactiondetails" roleURI="http://cactusventuresinc.com/role/RelatedPartyTransactiondetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Relatedpartytransactiondetailstextual" roleURI="http://cactusventuresinc.com/role/Relatedpartytransactiondetailstextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyandEquipmentDetails" roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Propertyandequipmentdetailstesxtual" roleURI="http://cactusventuresinc.com/role/Propertyandequipmentdetailstesxtual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayableAndConvertibleNotesDetails" roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayableAndConvertibleNotesDetailsTextual" roleURI="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetails" roleURI="http://cactusventuresinc.com/role/DerivativesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetails1" roleURI="http://cactusventuresinc.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetailsTextual" roleURI="http://cactusventuresinc.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#IncomeTaxesDetails" roleURI="http://cactusventuresinc.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#IncomeTaxesDetails1" roleURI="http://cactusventuresinc.com/role/IncomeTaxesDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#IncometaxesdetailsTextual" roleURI="http://cactusventuresinc.com/role/IncometaxesdetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsandContingenciesDetails" roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingenciesDetailsTextual1" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Equitydetails" roleURI="http://cactusventuresinc.com/role/Equitydetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Equitydetailstextual" roleURI="http://cactusventuresinc.com/role/Equitydetailstextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StockOptionPlanDetails" roleURI="http://cactusventuresinc.com/role/StockOptionPlanDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StockOptionPlanDetailsTextual" roleURI="http://cactusventuresinc.com/role/StockOptionPlanDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#WarrantsDetails" roleURI="http://cactusventuresinc.com/role/WarrantsDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#WarrantsDetails1" roleURI="http://cactusventuresinc.com/role/WarrantsDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#WarrantsDetailsTextual" roleURI="http://cactusventuresinc.com/role/WarrantsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EmployeeDefinedContributionPlanDetails" roleURI="http://cactusventuresinc.com/role/EmployeeDefinedContributionPlanDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#SubsequenteventsDetails" roleURI="http://cactusventuresinc.com/role/SubsequenteventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DocumentAndEntityInformation1">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DocumentAndEntityInformationAbstract" xlink:label="loc_fil_DocumentAndEntityInformationAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_4" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_5" order="40" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_6" order="50" use="optional" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_fil_SeriesCTwoPreferredStockMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCTwoPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_fil_SeriesCThreePreferredStockMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCThreePreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_fil_SeriesCFourPreferredStockMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCFourPreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_AssetsAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AssetsCurrent_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_23" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_23" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_23" xlink:to="loc_us-gaap_NotesPayableCurrent_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_23" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_23" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_23" xlink:to="loc_us-gaap_LiabilitiesCurrent_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_23" xlink:to="loc_us-gaap_Liabilities_30" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22" xlink:to="loc_us-gaap_CommitmentsAndContingencies_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquityAbstract_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_PreferredStockValue_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_CommonStockValue_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_AdditionalPaidInCapital_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_36" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_StockholdersEquity_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_38" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedBalanceSheetsparenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_fil_SeriesCTwoPreferredStockMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCTwoPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_fil_SeriesCThreePreferredStockMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCThreePreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_fil_SeriesCFourPreferredStockMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCFourPreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesIssued_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesIssued_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_DepreciationAndAmortization_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_OperatingExpenses_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_InterestExpense_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Consolidatedstatementofchangesinstockholdersequitydeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_fil_SeriesCTwoPreferredStockMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_fil_SeriesCTwoPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_fil_SeriesCThreePreferredStockMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_fil_SeriesCThreePreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_fil_SeriesCFourPreferredStockMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_fil_SeriesCFourPreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockholdersEquity_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_SharesOutstanding_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProceedsFromIssuanceOfCommonStockShares" xlink:label="loc_fil_ProceedsFromIssuanceOfCommonStockShares_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_ProceedsFromIssuanceOfCommonStockShares_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToStockValue" xlink:label="loc_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToStockShares" xlink:label="loc_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesIssuedAtReverseMergerValue" xlink:label="loc_fil_SharesIssuedAtReverseMergerValue_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_SharesIssuedAtReverseMergerValue_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesIssuedAtReverseMergerShares" xlink:label="loc_fil_SharesIssuedAtReverseMergerShares_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_SharesIssuedAtReverseMergerShares_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense" xlink:label="loc_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants" xlink:label="loc_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants_31" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RetireOfDerivativeLiability" xlink:label="loc_fil_RetireOfDerivativeLiability_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_fil_RetireOfDerivativeLiability_33" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_34" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_NetIncomeLoss_35" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockholdersEquity_36" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_SharesOutstanding_37" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetIncomeLoss_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_fil_GainOnChangeInFairValueOfDerivatives_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_fil_GainOnChangeInFairValueOfDerivatives_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CashPaidForAbstract" xlink:label="loc_fil_CashPaidForAbstract_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_fil_CashPaidForAbstract_33" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CashPaidForAbstract_33" xlink:to="loc_us-gaap_InterestPaid_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CashPaidForAbstract_33" xlink:to="loc_us-gaap_IncomeTaxesPaid_35" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_37" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithDebt" xlink:label="loc_fil_FairValueOfWarrantsIssuedWithDebt_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" xlink:to="loc_fil_FairValueOfWarrantsIssuedWithDebt_38" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithStock" xlink:label="loc_fil_FairValueOfWarrantsIssuedWithStock_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" xlink:to="loc_fil_FairValueOfWarrantsIssuedWithStock_39" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="loc_fil_FairValueOfWarrantsIssuedToPlacementAgent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" xlink:to="loc_fil_FairValueOfWarrantsIssuedToPlacementAgent_40" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" xlink:to="loc_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock_41" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" xlink:to="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_42" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Notes11">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernAbstract" xlink:label="loc_fil_GoingConcernAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernTextBlock" xlink:label="loc_fil_GoingConcernTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernAbstract_0" xlink:to="loc_fil_GoingConcernTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/RelatedPartyTransaction">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Derivatives">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StockOptionPlan">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Warrants">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsAbstract" xlink:label="loc_fil_WarrantsAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsTextBlock" xlink:label="loc_fil_WarrantsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsAbstract_0" xlink:to="loc_fil_WarrantsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EmployeeDefinedContributionPlan">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Notes13">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_fil_DevelopmentStageCompanyPolicyTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_fil_DevelopmentStageCompanyPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/RelatedPartyTransactiontables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyandEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTable" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodLineItems" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodTable_1" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodTableTextBlock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodLineItems_6" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodTableTextBlock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StockOptionPlanTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/WarrantsTables">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsAbstract" xlink:label="loc_fil_WarrantsAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ScheduleOfWarrantsIssuedTableTextBlock" xlink:label="loc_fil_ScheduleOfWarrantsIssuedTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsAbstract_0" xlink:to="loc_fil_ScheduleOfWarrantsIssuedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfWarrantActivitiesTableTextBlock" xlink:label="loc_fil_SummaryOfWarrantActivitiesTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsAbstract_0" xlink:to="loc_fil_SummaryOfWarrantActivitiesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xlink:label="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_8" xlink:to="loc_us-gaap_DerivativeLiabilities_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ActiniumMember" xlink:label="loc_fil_ActiniumMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_fil_ActiniumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsAndWarrantsMember" xlink:label="loc_fil_OptionsAndWarrantsMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_fil_OptionsAndWarrantsMember_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_CommonStockMember_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_17" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_18" xlink:to="loc_us-gaap_SubsequentEventMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_20" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfOwnershipInterestToBeAcquired" xlink:label="loc_fil_PercentageOfOwnershipInterestToBeAcquired_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_fil_PercentageOfOwnershipInterestToBeAcquired_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage" xlink:label="loc_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfSharesExchangedInShareExchangeProgramme" xlink:label="loc_fil_PercentageOfSharesExchangedInShareExchangeProgramme_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_fil_PercentageOfSharesExchangedInShareExchangeProgramme_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BusinessAcquisitionNumberOfSharesExchanged" xlink:label="loc_fil_BusinessAcquisitionNumberOfSharesExchanged_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_21" xlink:to="loc_fil_BusinessAcquisitionNumberOfSharesExchanged_30" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/GoingconcernDetails">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernAbstract" xlink:label="loc_fil_GoingConcernAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernTextualAbstract" xlink:label="loc_fil_GoingConcernTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernAbstract_0" xlink:to="loc_fil_GoingConcernTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/RelatedPartyTransactiondetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty" xlink:label="loc_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_1" xlink:to="loc_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReimbursementsReceivedFromRelatedParty" xlink:label="loc_fil_ReimbursementsReceivedFromRelatedParty_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract_1" xlink:to="loc_fil_ReimbursementsReceivedFromRelatedParty_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Relatedpartytransactiondetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_fil_SloanKetteringInstituteOfCancerResearchMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_SloanKetteringInstituteOfCancerResearchMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterSloanKetteringInstituteOfCancerResearchMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RosemaryMazanetMember" xlink:label="loc_fil_RosemaryMazanetMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_RosemaryMazanetMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCompanyMember" xlink:label="loc_fil_LaidlawAndCompanyMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_LaidlawAndCompanyMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupMember" xlink:label="loc_fil_JamessCapitalGroupMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JamessCapitalGroupMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GuagentiAndAssociatesMember" xlink:label="loc_fil_GuagentiAndAssociatesMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_GuagentiAndAssociatesMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_fil_AgreementAxis_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementAxis_11" xlink:to="loc_fil_AgreementDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialAgreementMember" xlink:label="loc_fil_ClinicalTrialAgreementMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_ClinicalTrialAgreementMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseDevelopmentAndCommercializationAgreementMember" xlink:label="loc_fil_LicenseDevelopmentAndCommercializationAgreementMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_LicenseDevelopmentAndCommercializationAgreementMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultingServicesAgreementMember" xlink:label="loc_fil_ConsultingServicesAgreementMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_ConsultingServicesAgreementMember_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EngagementAgreementMember" xlink:label="loc_fil_EngagementAgreementMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_EngagementAgreementMember_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransactionManagementAgreementMember" xlink:label="loc_fil_TransactionManagementAgreementMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_12" xlink:to="loc_fil_TransactionManagementAgreementMember_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_fil_RelatedPartyTransactionsTextualAbstract_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_fil_RelatedPartyTransactionsTextualAbstract_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfPatients" xlink:label="loc_fil_NumberOfPatients_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_NumberOfPatients_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandEleven" xlink:label="loc_fil_AmountPaidUnderAgreementInYearTwoThousandEleven_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_AmountPaidUnderAgreementInYearTwoThousandEleven_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandTwelve" xlink:label="loc_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreementInYearTwoThousandThirteen" xlink:label="loc_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaintenanceFeesAndResearchPayments" xlink:label="loc_fil_MaintenanceFeesAndResearchPayments_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_MaintenanceFeesAndResearchPayments_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidUnderAgreement" xlink:label="loc_fil_AmountPaidUnderAgreement_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_AmountPaidUnderAgreement_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AdditionalAmountDueUnderAgreement" xlink:label="loc_fil_AdditionalAmountDueUnderAgreement_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_AdditionalAmountDueUnderAgreement_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfConditionForTerminationOfForbearancePeriod" xlink:label="loc_fil_DescriptionOfConditionForTerminationOfForbearancePeriod_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_DescriptionOfConditionForTerminationOfForbearancePeriod_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TerminationDateOfForbearanceAgreement" xlink:label="loc_fil_TerminationDateOfForbearanceAgreement_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_TerminationDateOfForbearanceAgreement_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod" xlink:label="loc_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewEquityFinanceRaisedByCompany" xlink:label="loc_fil_NewEquityFinanceRaisedByCompany_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_NewEquityFinanceRaisedByCompany_30" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ForgivenAmountOfObligations" xlink:label="loc_fil_ForgivenAmountOfObligations_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_ForgivenAmountOfObligations_31" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty" xlink:label="loc_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_33" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToEachPatient" xlink:label="loc_fil_AmountPaidToEachPatient_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_AmountPaidToEachPatient_34" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpFeeForClinicalTrial" xlink:label="loc_fil_StartUpFeeForClinicalTrial_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_StartUpFeeForClinicalTrial_35" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpDueCostPaidDate" xlink:label="loc_fil_StartUpDueCostPaidDate_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_StartUpDueCostPaidDate_36" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesTransferTerm" xlink:label="loc_fil_DescriptionOfSharesTransferTerm_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_DescriptionOfSharesTransferTerm_37" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_us-gaap_OfficersCompensation_38" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionExercisePriceRange" xlink:label="loc_fil_OptionExercisePriceRange_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_OptionExercisePriceRange_39" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_40" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsReceivedToPurchaseCommonStock" xlink:label="loc_fil_OptionsReceivedToPurchaseCommonStock_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_OptionsReceivedToPurchaseCommonStock_41" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfReceivablesOfPlacementAgentForServices" xlink:label="loc_fil_DescriptionOfReceivablesOfPlacementAgentForServices_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_DescriptionOfReceivablesOfPlacementAgentForServices_42" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfWarrantsReceivablesByPlacement" xlink:label="loc_fil_DescriptionOfWarrantsReceivablesByPlacement_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_DescriptionOfWarrantsReceivablesByPlacement_43" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodOfExerciseOfWarrants" xlink:label="loc_fil_PeriodOfExerciseOfWarrants_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_PeriodOfExerciseOfWarrants_44" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfSolicitationFee" xlink:label="loc_fil_PercentageOfSolicitationFee_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_PercentageOfSolicitationFee_45" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeForFinancialAdvisoryServices" xlink:label="loc_fil_PeriodicFeeForFinancialAdvisoryServices_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_PeriodicFeeForFinancialAdvisoryServices_46" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfAdditionalReceivableByPlacementAgent" xlink:label="loc_fil_DescriptionOfAdditionalReceivableByPlacementAgent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_DescriptionOfAdditionalReceivableByPlacementAgent_47" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockPurchaseByHoldingOfWarrant" xlink:label="loc_fil_CommonStockPurchaseByHoldingOfWarrant_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_CommonStockPurchaseByHoldingOfWarrant_48" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_fil_PeriodicFeeReceivedByManagementFirm_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_PeriodicFeeReceivedByManagementFirm_49" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_50" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_fil_MaximumAmountOfOutOfPocketExpenses_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_MaximumAmountOfOutOfPocketExpenses_51" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicAmountOfRent" xlink:label="loc_fil_PeriodicAmountOfRent_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_PeriodicAmountOfRent_52" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToPursuantLeaseAgreement" xlink:label="loc_fil_AmountPaidToPursuantLeaseAgreement_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_RelatedPartyTransactionsTextualAbstract_19" xlink:to="loc_fil_AmountPaidToPursuantLeaseAgreement_53" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LossOnDispositionOfPropertyAndEquipment" xlink:label="loc_fil_LossOnDispositionOfPropertyAndEquipment_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_fil_LossOnDispositionOfPropertyAndEquipment_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Propertyandequipmentdetailstesxtual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PropertyAndEquipmentTextualAbstract" xlink:label="loc_fil_PropertyAndEquipmentTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_fil_PropertyAndEquipmentTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_PropertyAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember" xlink:label="loc_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3" xlink:to="loc_fil_SeniorSubordinatedUnsecuredConvertiblePromissoryNotesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfConvertiblePromissoryNotesAbstract" xlink:label="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_5" xlink:to="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DiscountRelatedToFairValueOfDerivativeWarrants" xlink:label="loc_fil_DiscountRelatedToFairValueOfDerivativeWarrants_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" xlink:to="loc_fil_DiscountRelatedToFairValueOfDerivativeWarrants_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" xlink:to="loc_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentAmortizationOfDiscount" xlink:label="loc_fil_DebtInstrumentAmortizationOfDiscount_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" xlink:to="loc_fil_DebtInstrumentAmortizationOfDiscount_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentPrincipalAmountConvertedToCommonStock" xlink:label="loc_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" xlink:to="loc_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfConvertiblePromissoryNotesAbstract_6" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentMember" xlink:label="loc_fil_PlacementAgentMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_PlacementAgentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ManagementFirmMember" xlink:label="loc_fil_ManagementFirmMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_ManagementFirmMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NotePayableAndConvertibleNotesTextualAbstract" xlink:label="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_6" xlink:to="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockPurchaseDueToIssuanceOfWarrants" xlink:label="loc_fil_CommonStockPurchaseDueToIssuanceOfWarrants_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_7" xlink:to="loc_fil_CommonStockPurchaseDueToIssuanceOfWarrants_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_7" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_7" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmortizationPeriodOfNote" xlink:label="loc_fil_AmortizationPeriodOfNote_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableAndConvertibleNotesTextualAbstract_7" xlink:to="loc_fil_AmortizationPeriodOfNote_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PremiumFinanceAgreementPrincipalAmount" xlink:label="loc_fil_PremiumFinanceAgreementPrincipalAmount_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_PremiumFinanceAgreementPrincipalAmount_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentUnderPremiumFinanceAgreement" xlink:label="loc_fil_PaymentUnderPremiumFinanceAgreement_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_PaymentUnderPremiumFinanceAgreement_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicPaymentUnderPremiumFinanceAgreement" xlink:label="loc_fil_PeriodicPaymentUnderPremiumFinanceAgreement_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_PeriodicPaymentUnderPremiumFinanceAgreement_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement" xlink:label="loc_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PremiumFinanceAgreementOutstandingAmount" xlink:label="loc_fil_PremiumFinanceAgreementOutstandingAmount_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_PremiumFinanceAgreementOutstandingAmount_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProceedsFromConvertibleNotes" xlink:label="loc_fil_ProceedsFromConvertibleNotes_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_ProceedsFromConvertibleNotes_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued" xlink:label="loc_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_22" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents" xlink:label="loc_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_fil_DerivativeWarrantsIssuedWithConvertibleNotes_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_DerivativeWarrantsIssuedWithConvertibleNotes_24" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InvestmentWarrantGrantDateFairValue" xlink:label="loc_fil_InvestmentWarrantGrantDateFairValue_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_InvestmentWarrantGrantDateFairValue_25" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature" xlink:label="loc_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature_26" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_27" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DebtInstrumentFairValuePerShare" xlink:label="loc_fil_DebtInstrumentFairValuePerShare_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_DebtInstrumentFairValuePerShare_28" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ExtendedMaturityPeriodOfConvertibleNotes" xlink:label="loc_fil_ExtendedMaturityPeriodOfConvertibleNotes_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_ExtendedMaturityPeriodOfConvertibleNotes_29" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfExtendedMaturityDate" xlink:label="loc_fil_DescriptionOfExtendedMaturityDate_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_DescriptionOfExtendedMaturityDate_30" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_31" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_32" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_33" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_34" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InsurancePolicyDownPayment" xlink:label="loc_fil_InsurancePolicyDownPayment_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_InsurancePolicyDownPayment_35" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InsurancePolicyInstallmentPayment" xlink:label="loc_fil_InsurancePolicyInstallmentPayment_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_InsurancePolicyInstallmentPayment_36" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_NotesPayableCurrent_37" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_38" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsUnits" xlink:label="loc_fil_DerivativeWarrantsUnits_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantsUnits_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_fil_DerivativeWarrantsIssuedWithConvertibleNotes_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantsIssuedWithConvertibleNotes_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xlink:label="loc_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:label="loc_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithStockOffering" xlink:label="loc_fil_DerivativeWarrantsIssuedWithStockOffering_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantsIssuedWithStockOffering_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:label="loc_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithCommonStockOffering" xlink:label="loc_fil_DerivativeWarrantsIssuedWithCommonStockOffering_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantsIssuedWithCommonStockOffering_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:label="loc_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativePlacementAgentWarrantsRelatedToStock" xlink:label="loc_fil_DerivativePlacementAgentWarrantsRelatedToStock_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativePlacementAgentWarrantsRelatedToStock_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_fil_TransferFromLiabilityClassificationToEquityClassification_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_TransferFromLiabilityClassificationToEquityClassification_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsUnits" xlink:label="loc_fil_DerivativeWarrantsUnits_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantsUnits_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_13" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xlink:label="loc_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue_14" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes" xlink:label="loc_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes_15" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:label="loc_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes_16" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering" xlink:label="loc_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering_17" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock" xlink:label="loc_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock_18" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering" xlink:label="loc_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering_19" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne" xlink:label="loc_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne_20" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock" xlink:label="loc_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock_21" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_22" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_fil_ChangeInFairValueOfDerivativeWarrants_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_ChangeInFairValueOfDerivativeWarrants_23" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_24" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_DerivativeLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_6" xlink:to="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_fil_MarketValueOfCommonStockOnMeasurementDate_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_fil_MarketValueOfCommonStockOnMeasurementDate_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_fil_RangeOfPercentageOfExistingSharesOffered_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_fil_RangeOfPercentageOfExistingSharesOffered_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueAssumptionOfferingPrice" xlink:label="loc_fil_FairValueAssumptionOfferingPrice_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_fil_FairValueAssumptionOfferingPrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeTextualAbstract" xlink:label="loc_fil_DerivativeTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5" xlink:to="loc_fil_DerivativeTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DerivativeTextualAbstract_6" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfRiskFreeInterestRateDetermination" xlink:label="loc_fil_DescriptionOfRiskFreeInterestRateDetermination_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_fil_DescriptionOfRiskFreeInterestRateDetermination_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_fil_DescriptionOfProbabilityOfStockOffering_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_fil_DescriptionOfProbabilityOfStockOffering_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RangeOfPercentageOfExistingSharesOffered" xlink:label="loc_fil_RangeOfPercentageOfExistingSharesOffered_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_fil_RangeOfPercentageOfExistingSharesOffered_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncomeTaxesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_13" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/IncometaxesdetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_IncomeTaxesTextualAbstract" xlink:label="loc_fil_IncomeTaxesTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_fil_IncomeTaxesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseSecondClinicalTrialOfLicensedProductMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseThirdClinicalTrialOfLicensedProductMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BiologicalLicenseApplicationMember" xlink:label="loc_fil_BiologicalLicenseApplicationMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_BiologicalLicenseApplicationMember_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSaleMember" xlink:label="loc_fil_FirstCommercialSaleMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_FirstCommercialSaleMember_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_fil_AfterFirstNetSalesMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_AfterFirstNetSalesMember_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewDrugApplicationMember" xlink:label="loc_fil_NewDrugApplicationMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_NewDrugApplicationMember_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentAbstract" xlink:label="loc_fil_MilestonePaymentAbstract_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" xlink:to="loc_fil_MilestonePaymentAbstract_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_MilestonePaymentAbstract_17" xlink:to="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_fil_CommitmentsAndContingenciesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_fil_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChiefExecutiveOfficerAndDirectorMember" xlink:label="loc_fil_ChiefExecutiveOfficerAndDirectorMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_fil_ChiefExecutiveOfficerAndDirectorMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_AgreementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementAxis_5" xlink:to="loc_fil_AgreementDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_6" xlink:to="loc_us-gaap_EmploymentContractsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_RestrictedStockMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_fil_CommitmentsAndContingenciesLineItems_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_CommitmentsAndContingenciesLineItems_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_15" xlink:to="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_us-gaap_OfficersCompensation_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceObjectiveDescription" xlink:label="loc_fil_PerformanceObjectiveDescription_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_PerformanceObjectiveDescription_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xlink:label="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonus_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonus_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xlink:label="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_fil_CommitmentsAndContingenciesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_fil_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OakRidgeNationalLaboratoryMember" xlink:label="loc_fil_OakRidgeNationalLaboratoryMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_OakRidgeNationalLaboratoryMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AptivSolutionsMember" xlink:label="loc_fil_AptivSolutionsMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AptivSolutionsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_fil_FredHutchinsonCancerResearchCenterMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_fil_UniversityOfTexasMDAndersonCancerCenterMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JohnsHopkinsUniversityMember" xlink:label="loc_fil_JohnsHopkinsUniversityMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JohnsHopkinsUniversityMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCoMember" xlink:label="loc_fil_LaidlawAndCoMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_LaidlawAndCoMember_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfPennsylvaniaMember" xlink:label="loc_fil_UniversityOfPennsylvaniaMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_UniversityOfPennsylvaniaMember_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupMember" xlink:label="loc_fil_JamessCapitalGroupMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JamessCapitalGroupMember_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_fil_AfterFirstNetSalesMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_fil_AfterFirstNetSalesMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_AgreementAxis_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementAxis_20" xlink:to="loc_fil_AgreementDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_fil_ProductDevelopmentAndPatentLicenseAgreementMember_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_ProductDevelopmentAndPatentLicenseAgreementMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAgreementMember" xlink:label="loc_fil_LicenseAgreementMember_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_LicenseAgreementMember_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_fil_LicenseAndSponsoredResearchAgreementMember_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_LicenseAndSponsoredResearchAgreementMember_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialAgreementMember" xlink:label="loc_fil_ClinicalTrialAgreementMember_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_ClinicalTrialAgreementMember_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentAgreementMember" xlink:label="loc_fil_PlacementAgentAgreementMember_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_PlacementAgentAgreementMember_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransactionManagementAgreementMember" xlink:label="loc_fil_TransactionManagementAgreementMember_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_TransactionManagementAgreementMember_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RentalAgreementMember" xlink:label="loc_fil_RentalAgreementMember_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_RentalAgreementMember_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeparationAndSettlementAgreementMember" xlink:label="loc_fil_SeparationAndSettlementAgreementMember_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_SeparationAndSettlementAgreementMember_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31" xlink:to="loc_us-gaap_EmployeeStockOptionMember_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33" xlink:to="loc_us-gaap_EquityComponentDomain_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_34" xlink:to="loc_us-gaap_CommonStockMember_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_34" xlink:to="loc_us-gaap_RestrictedStockMember_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_37" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_37" xlink:to="loc_us-gaap_RangeMember_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_38" xlink:to="loc_us-gaap_MaximumMember_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_38" xlink:to="loc_us-gaap_MinimumMember_40" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_fil_CommitmentsAndContingenciesLineItems_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_CommitmentsAndContingenciesLineItems_41" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_41" xlink:to="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfLicenseFee" xlink:label="loc_fil_PaymentOfLicenseFee_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PaymentOfLicenseFee_43" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_44" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_45" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentDate" xlink:label="loc_fil_MilestonePaymentDate_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_MilestonePaymentDate_46" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_fil_DescriptionOfRoyaltyPaymentToRelatedParty_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_DescriptionOfRoyaltyPaymentToRelatedParty_47" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RoyaltyOfNetSalesPercentage" xlink:label="loc_fil_RoyaltyOfNetSalesPercentage_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_RoyaltyOfNetSalesPercentage_48" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSalePeriod" xlink:label="loc_fil_FirstCommercialSalePeriod_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_FirstCommercialSalePeriod_49" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_TechnologyServicesCosts_50" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_MaintenanceCosts_51" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentArrangement" xlink:label="loc_fil_ResearchAndDevelopmentArrangement_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_ResearchAndDevelopmentArrangement_52" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PurchaseOfRadioactiveMaterial" xlink:label="loc_fil_PurchaseOfRadioactiveMaterial_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PurchaseOfRadioactiveMaterial_53" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProjectEstimatedCost" xlink:label="loc_fil_ProjectEstimatedCost_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_ProjectEstimatedCost_54" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_fil_DownPaymentOfProjectEstimatedCostPercentage_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_DownPaymentOfProjectEstimatedCostPercentage_55" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentForProject" xlink:label="loc_fil_DownPaymentForProject_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_DownPaymentForProject_56" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_57" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear_58" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_fil_FundToRelatedPartyUnderAgreementAfterYearTwo_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_FundToRelatedPartyUnderAgreementAfterYearTwo_59" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_RoyaltyExpense_60" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfPatients" xlink:label="loc_fil_NumberOfPatients_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_NumberOfPatients_61" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToEachPatient" xlink:label="loc_fil_AmountPaidToEachPatient_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_AmountPaidToEachPatient_62" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpFeeForClinicalTrial" xlink:label="loc_fil_StartUpFeeForClinicalTrial_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_StartUpFeeForClinicalTrial_63" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpDueCostPaidDate" xlink:label="loc_fil_StartUpDueCostPaidDate_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_StartUpDueCostPaidDate_64" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NonRefundableInstitutionalFee" xlink:label="loc_fil_NonRefundableInstitutionalFee_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_NonRefundableInstitutionalFee_65" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PharmacyFee" xlink:label="loc_fil_PharmacyFee_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PharmacyFee_66" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmendmentProcessingFee" xlink:label="loc_fil_AmendmentProcessingFee_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_AmendmentProcessingFee_67" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_fil_PeriodicFeeReceivedByManagementFirm_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PeriodicFeeReceivedByManagementFirm_68" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_69" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantExercisableNoticePeriodDescription" xlink:label="loc_fil_WarrantExercisableNoticePeriodDescription_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_WarrantExercisableNoticePeriodDescription_70" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant_71" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_fil_MaximumAmountOfOutOfPocketExpenses_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_MaximumAmountOfOutOfPocketExpenses_72" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementConsideration" xlink:label="loc_fil_AgreementConsideration_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_AgreementConsideration_73" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPayableInInstallmentsUnderAgreement" xlink:label="loc_fil_AmountPayableInInstallmentsUnderAgreement_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_AmountPayableInInstallmentsUnderAgreement_74" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallments" xlink:label="loc_fil_NumberOfInstallments_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_NumberOfInstallments_75" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_fil_PerformanceBonusPayableUnderAgreementForService_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PerformanceBonusPayableUnderAgreementForService_76" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementRenewalDescription" xlink:label="loc_fil_AgreementRenewalDescription_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_AgreementRenewalDescription_77" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFirstInstallmentForServicesByCompany" xlink:label="loc_fil_PaymentOfFirstInstallmentForServicesByCompany_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PaymentOfFirstInstallmentForServicesByCompany_78" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_fil_PaymentOfFinalInstallmentForServicesByCompany_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PaymentOfFinalInstallmentForServicesByCompany_79" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_fil_PaymentOfPerformanceBonusForServicesByCompany_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_PaymentOfPerformanceBonusForServicesByCompany_80" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_us-gaap_LeaseExpirationDate1_81" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NoticePeriodForTerminationOfAgreement" xlink:label="loc_fil_NoticePeriodForTerminationOfAgreement_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_42" xlink:to="loc_fil_NoticePeriodForTerminationOfAgreement_82" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Equitydetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Equitydetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCTwoPreferredStockMember" xlink:label="loc_fil_SeriesCTwoPreferredStockMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCTwoPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCThreePreferredStockMember" xlink:label="loc_fil_SeriesCThreePreferredStockMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCThreePreferredStockMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeriesCFourPreferredStockMember" xlink:label="loc_fil_SeriesCFourPreferredStockMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_fil_SeriesCFourPreferredStockMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAMember" xlink:label="loc_us-gaap_SeriesAMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAMember_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBMember" xlink:label="loc_us-gaap_SeriesBMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBMember_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCoMember" xlink:label="loc_fil_LaidlawAndCoMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" xlink:to="loc_fil_LaidlawAndCoMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MccormickOBrienPllcMember" xlink:label="loc_fil_MccormickOBrienPllcMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" xlink:to="loc_fil_MccormickOBrienPllcMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_19" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentMember" xlink:label="loc_fil_PlacementAgentMember_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" xlink:to="loc_fil_PlacementAgentMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ManagementMember" xlink:label="loc_us-gaap_ManagementMember_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" xlink:to="loc_us-gaap_ManagementMember_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_PlanNameAxis_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_23" xlink:to="loc_us-gaap_PlanNameDomain_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenStockPlanMember" xlink:label="loc_fil_TwoThousandThirteenStockPlanMember_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_24" xlink:to="loc_fil_TwoThousandThirteenStockPlanMember_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_fil_TwoThousandThirteenEquityIncentivePlanMember_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_24" xlink:to="loc_fil_TwoThousandThirteenEquityIncentivePlanMember_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgencyAgreementMember" xlink:label="loc_fil_PlacementAgencyAgreementMember_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_fil_PlacementAgencyAgreementMember_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupLlcMember" xlink:label="loc_fil_JamessCapitalGroupLlcMember_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_fil_JamessCapitalGroupLlcMember_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantOneMember" xlink:label="loc_fil_WarrantOneMember_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_fil_WarrantOneMember_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_us-gaap_WarrantMember_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsBMember" xlink:label="loc_fil_WarrantsBMember_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_fil_WarrantsBMember_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_28" xlink:to="loc_us-gaap_EmployeeStockOptionMember_34" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_35" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_35" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FormerDirectorAndConsultantsMember" xlink:label="loc_fil_FormerDirectorAndConsultantsMember_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36" xlink:to="loc_fil_FormerDirectorAndConsultantsMember_37" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_fil_EmployeesDirectorsAndConsultantsMember_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_36" xlink:to="loc_fil_EmployeesDirectorsAndConsultantsMember_38" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_39" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EquityTextualAbstract" xlink:label="loc_fil_EquityTextualAbstract_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39" xlink:to="loc_fil_EquityTextualAbstract_40" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_41" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_42" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToPurchaseCommonStockOffering" xlink:label="loc_fil_WarrantsIssuedToPurchaseCommonStockOffering_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_WarrantsIssuedToPurchaseCommonStockOffering_43" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_IncreaseOfferingOfCommonStock" xlink:label="loc_fil_IncreaseOfferingOfCommonStock_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_IncreaseOfferingOfCommonStock_44" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedInStockOffering" xlink:label="loc_fil_CommonStockSharesIssuedInStockOffering_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_CommonStockSharesIssuedInStockOffering_45" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet" xlink:label="loc_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet_46" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentCashFees" xlink:label="loc_fil_PlacementAgentCashFees_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_PlacementAgentCashFees_47" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentCommission" xlink:label="loc_fil_PlacementAgentCommission_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_PlacementAgentCommission_48" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentExpenseReimbursement" xlink:label="loc_fil_PlacementAgentExpenseReimbursement_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_PlacementAgentExpenseReimbursement_49" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToPurchaseCommonStock" xlink:label="loc_fil_WarrantsIssuedToPurchaseCommonStock_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_WarrantsIssuedToPurchaseCommonStock_50" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_51" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsExpirationTerm" xlink:label="loc_fil_WarrantsExpirationTerm_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_WarrantsExpirationTerm_52" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_53" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentServicesFees" xlink:label="loc_fil_PlacementAgentServicesFees_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_PlacementAgentServicesFees_54" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BankEscrowFee" xlink:label="loc_fil_BankEscrowFee_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_BankEscrowFee_55" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_56" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AccruedManagementFees" xlink:label="loc_fil_AccruedManagementFees_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_AccruedManagementFees_57" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement" xlink:label="loc_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement_58" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement" xlink:label="loc_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement_59" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_fil_UnrecognizedShareBasedCompensationExpense_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_UnrecognizedShareBasedCompensationExpense_60" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_61" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidForCancellationOfSharesByCompany" xlink:label="loc_fil_AmountPaidForCancellationOfSharesByCompany_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_AmountPaidForCancellationOfSharesByCompany_62" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesPurchasedAfterCancelationOfOptions" xlink:label="loc_fil_SharesPurchasedAfterCancelationOfOptions_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_fil_SharesPurchasedAfterCancelationOfOptions_63" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_64" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_65" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_66" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_40" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_68" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StockOptionPlanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StockOptionPlanDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThreeStockPlanMember" xlink:label="loc_fil_TwoThousandThreeStockPlanMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_fil_TwoThousandThreeStockPlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandTwelveEmployeeStockOptionPlanMember" xlink:label="loc_fil_TwoThousandTwelveEmployeeStockOptionPlanMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_fil_TwoThousandTwelveEmployeeStockOptionPlanMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_13" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesAndConsultantsMember" xlink:label="loc_fil_EmployeesAndConsultantsMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14" xlink:to="loc_fil_EmployeesAndConsultantsMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultantsMember" xlink:label="loc_fil_ConsultantsMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_14" xlink:to="loc_fil_ConsultantsMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionPlanTextualAbstract" xlink:label="loc_fil_StockOptionPlanTextualAbstract_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_fil_StockOptionPlanTextualAbstract_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment" xlink:label="loc_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting" xlink:label="loc_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering" xlink:label="loc_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance" xlink:label="loc_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStock" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStock_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStock_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice_29" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_31" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_33" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_36" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_37" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeeStockOptionUnitsReprised" xlink:label="loc_fil_EmployeeStockOptionUnitsReprised_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_EmployeeStockOptionUnitsReprised_38" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption" xlink:label="loc_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption_39" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationCostAfterRepricingOfStockOptions" xlink:label="loc_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions_40" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_fil_UnrecognizedShareBasedCompensationExpense_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_fil_UnrecognizedShareBasedCompensationExpense_41" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_StockOptionPlanTextualAbstract_18" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_42" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/WarrantsDetails">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsAbstract" xlink:label="loc_fil_WarrantsAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedAbstract" xlink:label="loc_fil_WarrantsIssuedAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsAbstract_0" xlink:to="loc_fil_WarrantsIssuedAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedWithConvertibleNotes" xlink:label="loc_fil_WarrantsIssuedWithConvertibleNotes_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsIssuedAbstract_1" xlink:to="loc_fil_WarrantsIssuedWithConvertibleNotes_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToInvestorsWithStockOffering" xlink:label="loc_fil_WarrantsIssuedToInvestorsWithStockOffering_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsIssuedAbstract_1" xlink:to="loc_fil_WarrantsIssuedToInvestorsWithStockOffering_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssuedToInvestorsWithCommonStock" xlink:label="loc_fil_WarrantsIssuedToInvestorsWithCommonStock_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsIssuedAbstract_1" xlink:to="loc_fil_WarrantsIssuedToInvestorsWithCommonStock_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes" xlink:label="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsIssuedAbstract_1" xlink:to="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering" xlink:label="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsIssuedAbstract_1" xlink:to="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock" xlink:label="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsIssuedAbstract_1" xlink:to="loc_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantIssuedToInvestorsWithStockAccruedDividend" xlink:label="loc_fil_WarrantIssuedToInvestorsWithStockAccruedDividend_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsIssuedAbstract_1" xlink:to="loc_fil_WarrantIssuedToInvestorsWithStockAccruedDividend_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsIssued" xlink:label="loc_fil_WarrantsIssued_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsIssuedAbstract_1" xlink:to="loc_fil_WarrantsIssued_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/WarrantsDetails1">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsAbstract" xlink:label="loc_fil_WarrantsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/WarrantsDetailsTextual">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantsAbstract" xlink:label="loc_fil_WarrantsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_WarrantMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantTextualAbstract" xlink:label="loc_fil_WarrantTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_fil_WarrantTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStock" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStock_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStock_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockExercisePrice" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife" xlink:label="loc_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_WarrantTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EmployeeDefinedContributionPlanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeeDefinedContributionPlanTextualAbstract" xlink:label="loc_fil_EmployeeDefinedContributionPlanTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" xlink:to="loc_fil_EmployeeDefinedContributionPlanTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="loc_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EmployeeDefinedContributionPlanTextualAbstract_1" xlink:to="loc_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EmployeeDefinedContributionPlanTextualAbstract_1" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EmployeeDefinedContributionPlanTextualAbstract_1" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/SubsequenteventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeparationAndSettlementAgreementMember" xlink:label="loc_fil_SeparationAndSettlementAgreementMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_fil_SeparationAndSettlementAgreementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FormerChiefExecutiveOfficerMember" xlink:label="loc_fil_FormerChiefExecutiveOfficerMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_fil_FormerChiefExecutiveOfficerMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SubsequentEventsTextualAbstract" xlink:label="loc_fil_SubsequentEventsTextualAbstract_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_11" xlink:to="loc_fil_SubsequentEventsTextualAbstract_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallmentsInWhichConsiderationIsPayable" xlink:label="loc_fil_NumberOfInstallmentsInWhichConsiderationIsPayable_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SubsequentEventsTextualAbstract_12" xlink:to="loc_fil_NumberOfInstallmentsInWhichConsiderationIsPayable_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsiderationPayableUnderAgreement" xlink:label="loc_fil_ConsiderationPayableUnderAgreement_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SubsequentEventsTextualAbstract_12" xlink:to="loc_fil_ConsiderationPayableUnderAgreement_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountOfPerformanceBonus" xlink:label="loc_fil_AmountOfPerformanceBonus_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SubsequentEventsTextualAbstract_12" xlink:to="loc_fil_AmountOfPerformanceBonus_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodOfService" xlink:label="loc_fil_PeriodOfService_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SubsequentEventsTextualAbstract_12" xlink:to="loc_fil_PeriodOfService_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img001_v1.jpg
<TEXT>
begin 644 img001_v1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@#I0*\`P$1``(1`0,1`?_$`(8``0`"`P$!`0``````
M```````$!0(#!@$'"`$!`````````````````````!```00!`P(%`P($`P4&
M!0('`@$#!`4`$1(&(1,Q02(4!U$R%6$C<4(S%H%2))&A8A<(L7)#4S24P=0E
M51B"8S71X7.$)C81`0````````````````````#_V@`,`P$``A$#$0`_`/U3
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?(>+DYS;Y5YJQRAIPHG%G8\
M.EI7E5&1;?;-2F$VBHAF\@Z@1:Z"O3`J?E:*Y0\W^-HM7'E7';6Y4*DWR-V7
MLC]]MHW'B03%MS3:AET3PUP-?RE`.OH^!-18[YNR.50)5K4-.JYM<E-FZ]%$
M7"01;(M=K9*@]?I@67PLD#E`\T[Z/-4B7(-Q.+R7'0=@+&!-[;K2&0@+KJ*J
MMH2@NB]/+`C_``YQ:F<IN2VYQ2_(5U]=L1'4=<ZL#N91A40NC:#T0/)4U3K@
M?.6)<V;_`--G#YDMZ3,E.<H`7OWW.X\+DM\2;(B,=VX?3ZUTP.Y^:ZZ,'Q$Q
M8I3GQ^>MU&=*"+I:M&Y(]N?]-4;T=:%%5!]/77KXX%Y1*WS3YCY?`Y!^Y7\2
M;B1::E,B%K_4MD;LPFD+:9+]@DJ=!\-%P.FY%52>-_'DRCH;&8D^2$EJLGR7
M'9<AAQ_>X);]KCI"TI;1Z*J)I@0>"V5)\C?%E1/OXZR'8K:A:17"<$@FQ0)A
M[N@"BNOB:"7AJB^*)@<1\<<8J6O@"1R:(<ANVF45DW*D-R'E5Q4<<-MPO5KW
M&NTB`2*BBFJ8'7?#]3%L*;C]_)A38-M$JX0E*<?<5N>$B"TJNN(A&VYH6NW=
MZA7JNFN!%N/<<H^<W.(7^CO&*RE&U@UHJ8!(?==1@G7U%?7VM2017HFNNFO7
M`^?\GG6D?X^^6J()$A:[BME%_MQXG3[D873;7L-N[D/:UNT'5>B+@?9OCNMC
MJR5HE?-II`-#7NU<B2KS6C2":/(V)NLH9;ON!>J>/7P#D_F?Y*F\5Y!QF5"E
M*W"K[(&^11"$T%V)+;V]S>B*.UA"W+K_`#*.!)^:)-O2!5_(-#*E$E$['<MH
MC3Q+#D53QD+Y$PGI,Q0T(3_E3KY8%?#O)-K\^<=G,3Y8TUOQQ^9$KC)UMA4%
M\A:>)@E%$,VCW>H=4Z)@5OPJ_,M)ME&L8]B[$@VUD_'Y"[+=5H/9RVA9AI^X
M:[=BEN%WHJ?;KUT"1S!;KXYY3+OY5C8V/QCR+O,7[3CSSCM5)>4A!V.0KWFF
M5,MO[?V_QV8$VZKF9GS72\;]Y-"F?XJ\11FI<D-"!]&VW^XCB$KJ"JIO7U?K
M@4W&I',^=_"+RMV$T>3T,V8U26K#QL'-.`A]A72!-KHG]AH70B355UP('(OD
M*;R^I^,N0PGI<%'^05]9;"T;L5IYYT-\QE6T4>XV#C>W5>GBB:]<"SL5M)/S
MER>E:&790Y3-2!,LS9#85[,I%"5)$`/T.(@H0[4Z*J*OG@7'R/6<OH;=KG/$
M)%A/2C88"YH">4XMA"1"%XVT744DMH&I*B:KT_Q#"Z.EMOA&UYK2/SF%*JM)
ME8JRY(DT3A&8DH]TOW&E;01770?`>F!V/Q16--\+I+;O2'9EI50')I//NO(3
MJ,(2N(CI'M(U-=VWQP.,LJ!H?F^HXTT]-6D>X[)?E,^^EHO>21VQ?4N[N5SK
MHA>6!(X`]/Y5S[Y%B\C<?5*F2W65</OF(QX;H*7<;%M1T<=V"?=^Y/)<"T_Z
M?.0W-U\>I^5<>E/5DZ77,64@MYRV(SFC;REUW=%[:KKU4<#Z5@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,"@N>"\;M[$+.0PY'LPT%9\)]Z&^8"FB-NN1S;)P-%TVGK
M^F!KL/COB$]RL=?@Z/THN!4OM.O-.1NZFADT0&*H2_YO'`TR_C'@\R(S%EUO
M?;CS?R;9&_(5SWNB#[@G>YW"<1!1$)2Z>6!8P^(<>A<@F\@AQ$CVMDT+,]YH
MS$7D!4VDXVB[%<333?INT\\"+Q[@'%>/0;.!413CPK=TWYS'?>-"<=!&W#%3
M,B%3%/4HKX]<"H>^%?CQWC\'CR07FJBMF%80(K,J2VC4@R4MPJ+B+HA*JBBK
MT\L"^Y7POC7+(#4#D$-)T5AU'V6U<<;VNBBB)HK9`NY$)=,"-<?'O%K6W;NG
MH[L:X;;1DK&%(?AR'&4_\)UQ@VR<#IX'K@6;-!6,SH<UH#!^#&.%'T=<V=@U
M`E$@4MIKJT.A$BK^O7`J:;XWXG3-WK=9'=C#R1QUZVVR'U5QU]3[C@:FO;)>
MXO4-/+Z)@>5/QKQ*JX9)X9#CNCQZ4#S3D0Y#QJC<A%1P0<(U,$755]*^*X#C
MWQQQJ@6O]A[P@J0-JM:D3)+[;`."H$(`XX0Z;>B:HNGEI@6%[Q&CNY$:7,:-
MNPAZ^TL(SCD>4TA="$7FE`]A?S"J[5^F!`D?&G"G^*S.+'7(E-8DKD]D7'1<
M?=(D-777D+NFXI"BJ1$JKI@=%$C-18K,5K7M,`+3>Y5(MH(@IJJ]571,"JLN
M'T-G16=%/9.35VQ.E,CN.N%JKZ[CV$I;@3=ZA053:OAI@:(G!./1HXQ4%]^&
ME<E.<61(>>:.(BEH)@X1(1:&H[U]6G373`\3@/&4Y<SRU&'$NX\=8;+J/.]L
M(ZB@]H6=W:$>FO0?'K@06?B;@T=-D>&\S&64DYZ&$N6D=Z4AHYWGFN[L<+>*
M+ZD7PP+IOBM(E7/J76%E5MDX^[+B2C.0V2R24W11'5+:"D2KM3HGE@0;CX[X
ME<6\:XG1'%LHD983$EF1(8)(Q;MS2]EP-1+>NNN!.B\3X[$B5D*'"")$IC[E
M;'CJ3+;1;2%5VMJ*%JCA:[M==<"+9?'_``ZR2N276-D%3)*;7-MD;0,R2/NJ
M\(-$`[U-5+54\U^N!@_\=\0?N9UT<,QM;)M&)TMJ3):-UI$04`NVX/I1!3HF
M!8UG'*>L=5V"PK)+'9B:=QPA[,=%1H=A$0^E"7KIJOFN!K=XGQUSCSW'%@-A
M1R`<:=@-ZMMJ#Q*;@H@**HA$2ZHF!,JJN!4UL6LKVNQ!AM"Q%912)`;!-HBB
MDJKHB)IXX$-_BG'W^21^3.Q$*\BL%%CS=Y[@9-54@04+9HJDOE@>3N)T$Z>[
M8/1B&<^T,=^2PZ['-QH%51!PF3;WH.\MN[735=,";55-945S%;5Q6X<"*.R/
M&9%`;`?'1!3]5UP)6`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!1\SM'(-*K<=X6)]
MBZW`@.$#KJ"])+8A[&44U[8[C7P30>I"G5`^+%SFXLO^G+EL&QDO,\NXFV=7
M:N*9C([C+@HT^I:[]7`\]?N0L"1\5`=AS$*=&WJ!EOBL1RVA(\YNLG;!H$]V
MRJ'H'M]NW>B;MQ+@;^)\-I?^?'*:<F#"MJH%7*JF!==T9<%1+>*[R7<1!ZE+
MQ\\"@N[V[XI&^;+RD<?6?'GPHT,T5QWVH/@).NMH>\40>^I:(GIT3RTP/L'%
M.`<:CUE//BNRW979;>?G'*?5R:KL=0(I:;R%W<A[M%Z(7VZ8'+_]-TF)#^)T
MF2Y9=HK*;ODR7"7722K#::N$6FJ"(H.OC^JX'*<<I_SOROSNMG5CLBJ&W3NW
M02B9*N08A/@K0B8F*F\V*[OM\E\<"TY-8VO'ODIVSNH4FPXS;V$1NMY3427.
M[7.`K;0P9+`D3?8)X5WIMT+>OB6B(%_\ZW5NS)X5QZ*X]'K.37;$"XD1S5IQ
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M)9.QSKAVZ01BF1J9;OM/1-FNJ*J^`8TCT[DGPWROY$O)3CG,816;D&0TZ\P5
M:L-%[+#;8D*!L4=^BHNN[U:X&JQYSR"7R+XUM[5FQDM6'&I-C<5%>\37N398
M5Q'>T)L@NOWBGZHG7`^A_%'(I3/Q.SR&UMAF-V#KKU:9&[*6.U(=[<6&XYHK
MCALDJ`2Z>/\`#7`@_#_(97)Z&\X5R6PE/\BX_.-N=.0G(K\J*<A7XTAOHVX#
M;@>C3_+_`!P-?Q3".SY?SH9<Z:XW1WY,UK:RWR`&%84594",A)M=Z]%3QZIU
M1,#CRY'R:!\=<?A0+>1&<Y'S&133[60^ZZ\W$&:\T(-O.D:M?MLB&J?]JZX'
M96"S:#YHH.)T:22X[?5$Q;>`DATPCHTJ[)3>\B)HMV@:BJ:Z_7`JJD^0<)YM
M$X+R2;9W7%^12&9/%;>0^92F9+1";T.2\"B2CIUT5=%3RZKH'W3`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`@S*2LF6<"SD-*<ZL[OLG4,Q0.^.QSTB2"6X4T]
M2+^F!0S/BW@4R1=.2*W>[R%`6[1'Y`I)0%]'<$7$31-.FB8$P>`\1&52RPKQ
M"5QUKV].^#CHFRSM0>WN0T4PVCX'JF!*B\4H(O(YG)&(NRZL&@CS)>]Q5<:;
MTV"H*2@FW3IH.!&@<"XE!<NG(]>*KR)56Z1UQUX9*DA"O<%TC'[35.B>'3`P
MX[P#C7'A;"M;?1J.)MPFGI,A\(S3B(A-QQ=,T:'TI]O_`&8$2O\`BO@]="8K
MX<`VJV-+&Q9@>XD$PDH"$Q=4"<5%5#!"T7TZ]=-<#";\3<(EC<@45]IOD+J/
MW;;,J0V,HT)2_<1'/!=VBBFB:=/#`W-?&/#V;0Y[,9UONR$FOPAD/>S<E`HJ
M#YQE-6E<!0%17;T5$7Q3`M^1<:H^1UJUMU$&7$4P=$24A('&UW`XV8*)@8KX
M$*HN!#K>"\<@/V$L&''["U:2/8V,AUQV2ZR(J(M]TBW`(HO1`T3S\>N!MXCP
M^CXE2MTM&VXQ6,D9,1W'3=1ON$ID@DXI$B;B5=-<#"SX5067(X/))+3GYFM:
M<8@R@><#MMNH0N(@"2`NY"ZZI]/I@>UG"^/5_'XW'VV"?JXC@/1VI+AOD+C;
MR/MEW'%(]0=3</7I@:;+@'&YW(6^1HT[#O0#LN6,)UR.Z\ST_:>5M41P.B:(
M2+IITTP-T_A7'9L"!#=CD*5;B/UD@'#21'=35.XV]JKFY=R[M57=_-K@1S^.
M^(G5W%<<'<U?HJ73RN.>XE;DT7NO[NXO3HB;M$3HB(F!&#XLX8VYQ]YF*XS+
MXPRD:FF-ONB^VP@[>T;F[5P-.FT]4\<"RXGPSC_%(LR+2,%'8G2G)\D3<<=4
MI#R"AGN<4BZ[4\\"%-^,^&S3FH]!TBV;Z2[2`#AA%EOHB(CC[(J@']J:IX$O
MW(N!NL>`<5L.15'(GXA):T8$U6NM.N-`VV0J*AV@(6U%4+P4<"/4_&/#ZB6<
MBLC.Q!.;^32*T^\,89:B0$X#&[MCN$U111-OZ=$P)\?A?'(_+)7+&(JMWTU@
M8LN4+CFCC0:;1)O=LZ;$ZZ:],#*BX?QZAFV<VIB^U?N'O<V2H;A"Z^JJJN;3
M(D$EW==NF!&3X]X=_;SO'EK0.H>>.448S</1]PU=)T#(E,#[BJ2$)(J+U3`W
M1>%\>CSY-G[<GK67&2#(LGG'#DK'%.C8NJNX!\_1IUZ^/7`FA0U`PX$-8PN1
MZPFS@"\JNDT;(J#9B;BD6X154W*NN!/P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.7^4
M+^UX_P#'G(+JI%"LH,)UV+N121#1--VU$77;KNT_3K@?(N8&WQ'X>XES'CED
M^]R,GX#@6+KCKKEB4_\`<D,OH2JA@YJ1;5^W3TZ+@3':F1=_+7-ZM^O<LH;C
ME$$D5E.-I#;D,&+\B.`'N%P=$5%#33Q7`^TV4UBEI7))-OO,0VQ3:PV<E[:F
M@ZH`ZF>GBO\`MP/BE%\H<HI/C#G$-Q2G\MX8<A8KTILV3DPWG5)B<3+VT]@"
M1+]%04Z]<#L_C3AG%Y'%>/<E[K\NZFM,V<B[=>/W,A^0WN<!P_3N:U<(4:TV
M)Y)KUP.<?X71+\TM\51);=,7$MR,!)D='1L%1'E<4U+NIHFAZZX&[C5;&Y!\
MJ?+=/9./G`-JJ80FWW0[".QB(NUJ2=L]PB6HIITP(_%)=WQCG=+\7\F5ZVCM
M..6/$N0$I(;D5IA_>Q+7<.YQG5$\T5--43I@<MR]UYKXS^9I45]]'8_(=D9\
M7G%[:`<4E%KU*H;2=/=IIXZ8'VXH41\Z929)_MU<A&Q`U1%0A8'3H8ZJ2?:J
M^'U3`^4<.LIE&]R_XJMG9KP'!=MZ.6KSA2&:^4P1.H[(W;Q)EW0!TZJJX'T7
MX10G?B'C!O$3KDBO;<?<<(C(R--24B)55=<#Y/\`!-+S6T<JKR%(=8KX-U;-
M\@=DS'7?=QU%&V618(G!7MEKU+;IXIK@4Z65D?PARYQR1)60SS%8T>04IP76
M&_=LBB,&IJ?024=HJGBJX'U_YNN;RAX0*\8=>9L*XX\P&6&GWB>8BNAK'U;!
MS:CG\RDOVHNO37`YGY$YHU?POBCD5,;IQ;>[C*[%CNHA&!@JN137<`$HF&TA
M)=-4P(OQ[[CFE!SVO2>[&KY-L$&!027GTEU0`:`1D0F3K9N$BF`(:@A#IX;D
MP*BSY-R9_P"`^74-S,EARSA3B0YUDV3K).[)`>W,7QT1SN,%ZM2W>"JG77`^
MB?*-E>,_&XU?')K\/D#M:LV*^RVZ\2MP`;=<;WM[E$GN@"NO75<#F^3?)$[E
MU#\;MUDIRMI^;3$BWLN.2M/MJT*=R(VZBZMJZX)AJB[E1.F!V7+.#5%5Q;DD
MRO>E1XWX.4PE8,AQ8J&TVK@21%54A?38B;T+JGZ]<"O^(JB-+XE16T^([!L'
M:9B"W(*4IE-:?C-/..DWKIO0A5!5?4FB^2X$#X`KF;CX8I?R"G,<&:])[A.F
MKBN1YI;%,U(E71`1%3P5.FF!5\ZH81_//":81=6KL(=H]8QD>>072)'#4C5#
M1>AN+M_R^7@F![>(UQ7YH;*`+\E8?#)4F'$<><=1V3"7MMD0;DU<)H=JD6JE
M_'`N_AZG9Y/\>1.4V%A*=Y!R(TG3[-I]1-LVG]4CLH/H:9'LH"MHG5-47`B_
M,_R%+XOR/CEK&==6LHIPIR2(+4A!.-/:)I'$<0>R:,?<J:]"4<#9S-UN5\\_
M&PM/$Y!E1+.2H-N$C3JM,(;)D@KM/:O4=<"R^4Y?)"F5L[BK,7D)T1/NW'%5
M>5M]]LP0$=:VK_4:U5$$A5%W>&NF!T_QW>UEUPVIL*_W`1Y#)*VS-7_4@K3A
M-N-N:]55LQ4-?TP.+EN/!_U.PXPNN)&D<4<=>C[R[1.#,4$-0UV[MJ::Z8%1
M`C7'Q[R>OXK/"5=</Y9/9>J9;[Q]ZOL4<%TXKAHHJK.UO>VFG5=477U8%KP8
M2YA\A<UE\D<<=>XW8_C*BH4S!B/%[>\)/:%10G)&NN\D7HGIP/I=)!CUE;&J
MVI;LSVK2"V[)<1U\FT705,^BETZ;E\?XX$_`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`\(1(5$
MD0A)-"%>J*B^2X'.57QSPNJ=BN0:T6D@NO2(#*FZ;,=V0JJX;#)D3;:KJNFT
M4TU7335<"9`XAQROY!8<AB0T:N;01"?,WN*3HMHB`A"1*/I041-$P)EC3UUB
M<,YC2N%`?&7%5#,-KP(HB2[%'=T)>A:I^F!7IPCC']S2>3+"W74R.D.3()QP
MA..B(G;)I2[6WI_EP,:?@G%*::Y+K("1C,MPLB;BQVR7Q5F.1*RRJ_\`[8)@
M;#X;QT^6!RPHJK?MQ_9A,[KJ:1U55[?;0^WIJ6OV^/7`AN_&W#795[+.`2R.
M2@#=VXC[XJ^+2:-^!ILVIT10TP+TZV"XY$==9%UZ"JK$><3>XVI`K9*)EJ6I
M`2HJZ]<"GB?'W$(H7C;=>),\D,W;MIUQUT)!N(J$I"X1(.J%IZ=/]R8&RDX-
MQBEKG:^NB$$9YI8Y]QYYXT9V[>T+CIFX`(G@(DB)Y8&T.(\>"M6O2(BLK"_&
M*\1F4A8>BIV5DJ2OJ/7_`#X&RBXS345$U15;)1ZI@";8C]UTU`"U51$S(C1.
MO3KT\L#3Q+AO'.(U:U?'XJPJ]7">['<==1#/3<J*Z1JFNGUP*9WX<^.7:&30
M.5.M/+F?D9$/W$E`*4O_`(FJ.;D_@BZ?I@=#"X[5PGI#[`.(_*89BONFZZ9J
MU'0A:'4R73;W"ZIU55U7`YD/A3XW"OKZYNL<;A53YRZUD)DP48D.*BDZVJ/(
MJ%JFO^WZK@3B^,.$K>2[UN"<>UGJT4Z3'D2&.^K!";:NBVX(&J$"+JJ=?/Q7
M`GW7">+W5985EA``X5LX+UFTVI,^X,4$4)TFE`BZ-BG5?),#;#XK2P[0[2.V
MZ,XXC4`W5?>)%CL:]L=A&H:CJOJTW=5ZX%-!^)/CN#02./L4S94\E]);L1UQ
MUX4D(B)W05PR)L^GB"I@6D;AG'X]5,JQ9=<BSVB8EJ](?>=-HAV*"O.F;J#M
M54T0L#13?'W%::3`D0(K@N5<<H=:CDB0\$=@]$(&@=,Q'5!1-=-=.F!G0<#X
MIQ]]YVFA>R%]PGCC-NN^W1PU12,(ZDK0$NGB(I@;Y_$..S^1UW))41'+JJ!Q
MN!+WN"K8/(J&FT20"U1?YD7`]+B7'RY2'*BBZWP15@C,WN=(ZEO5O9N[>F[K
M]NN!#B_'?#XED_81H'9>DO)*?9;=>&,3XJBH[[9#[&_5-==G5>OC@37^*<=D
M5$^G?@@[6V9O.3XQJ1"Z<@M[JDJKKZB7Z]/+`CL<#X@P50358T+E"VK%.[ZE
M<C-DFU0;-54M%1-%U7`)P3B8N@\U7`S)`70&2R3C3VV0>]W]T"$UWDFJZK@:
MF^"4;'(ZFZALA#*GAO0(K#`;![3Y"6U=%V[14==-OBNNN!-7B?'%Y"7(UKVO
MSI->W6QT7O=G33M[M?M_3`EMU-<W#CPQ8%8T10*.V7J0":74%12U7453HN!7
M6O">,VEJU;2XBI8LH@^Z8=>CF8(J*@/*P;?=%%3H+FJ)@3VZ6I;MBMVXC0V9
M1QAE+041Q8X&K@M:_P"5#)5TP)N`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!@#[#CCC0.";C6B.@)(I#N35-R)X:X
M!F0P^*DRX+HB2@2@2$B$GBBZ>:8&>`P&!JE2XL2.<B4\#$=M-7'7"0`%/U)=
M$P,F'V)##;\=P7F'10VG6R0@(235"$DZ*BI@9X#`8#`8&(N-F1")(1`NTT14
M5171%T7Z=%P,L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#F
M[IL%YMQIQ9"`8M6`C&Z;G$)MI5-.NN@;4U_[V!T0.MFI(!H2@NTT147:6FNB
MZ>"Z+@98#`^9\EX]91OD"5S/C"$Y=5T&.U:4^B-M64(R=500]/\`U`*"$T:_
M38NB+K@5;OR0,3@H7O&R8CH]'MKTX+T;8\XTU,V"KB"3;;:;G='B4E/7PU77
M`L;SG7+H=U<*Q(KTJZJ;3--,JRX3K[%J8-$'=[HB)#O4A(177Z8%?"^4.63)
MLGC[9P$MXD^WA#-).RT_^.[':00=/:AK[G]P4)5VBI#@=O9\CMH5%1'(&.S9
MW$B+!D/LDKT2.[(!5(Q)=BF*D&QO7Q(AUP./NK#D-I8T=582VX[]=RT8PRQ:
M[;,UMJ"Y-:404R5";UV$F[13'_#`["ZL94"SK>/4[D6J%^)*>8=>:U9UCB(M
ML-`)-CKJYW"1%UV"NB>:!06OR!>LQ[^;#*(ZG')4!@H2":E-"6TP9JV6[4%<
M61M8Z+J0Z+KKT"`',N?H$>0Y85NQ_D;G'5:]FX@H(276^\A^XU4E;!!0-/N\
M_+`DU/,^92;H>*RI,(;,I%JP%RVPO:<2"$<V4&.KRKO_`-7^XF[^1=/'5`A\
M1^0^;\BM`1PZ^#50J=JSLI78><%QY9,MA19(G`463&*C@GM)=/#QP-+7.^5S
MN.MOQ[=EM]RUI`8EI'9W%#LR:WHXPCCFQ"[A;-20]J)KUUP+:#S2Q_N>52@L
M`')G()5=^18;5-H,5K<L`>12T.3ZD;UW:;1\/)`KO^8G,)JLPH4B"Q*"'>N2
M)GMG'VW7J:4VP!L-HZ"['4-=R:KU\/#`[_B-P_=4E9;..@GOZ^)**(([2;-]
MON$2JJJNA:Z(BITT\\"[P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P(LJJK)<N),DQ6GI<%3*%(,!)QE7$VFK9*FH[AZ+IXX&<6!!B*^L6.VPLE
MTGY*MB@JXZ2(A.'HGJ)4%.JX&_`8&H(D4)3DL6@&2\`-NO(B(9`VI*`D7BJ"
MIEI_'`@6'%>,V*-)/J8<M&$<1E'F&W$%'EU<1$(5Z&O4OK@9GQSCYBHG71B$
MB8,D5H-%*+I[=5Z?^%HFS_+Y8&B;PSB,Z*]$FTL*3%D22G/LNQVC`Y1)H3Y"
M0JBN*G12\<"PD5T"1#6$_&:=AJ@C[<@%6]!5%%-JIIZ51-/I@:I=)3S'XK\N
M"P^]!=61#<<;$B9>+Q<;54])+]4ZX'EO1TUS'"-;0F9S#;@/-M2`%P1<;7<)
M(A(NBHJ8&9U%6=@-B45M9PMHPDA13?VT-'!'7Z"::I]%\,"@Y#\=TMK#@PH[
M3$"'%MFKB3'".!!(=;)2-#'440G%+53\=>OC@6Q\7XV<6/$.LC%'B.*_%:5H
M-&W2UW.!TZ$NY=53JNN!O9I*=F0LEF"PW(*.$-70;`26,VJJ#.J)_3%270?!
M-<"`SP3A3$)^"Q0U[4.4+828X161;<%DE)M#%!T+82JHZ^&!*7C/'524BUL;
M2:^,J7^T"=V0&FUX^G4TVIZO'`VO4E.^^V^]!8<>9:=8:<)L5(6G].ZV*Z=!
M<VIN3SP$"DIZXA*!!8B$##4059;%M4CL:]II-J)Z&]R[1\$UP)N`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/%,$
M-`4D0R15$=>JHFFJHGZ:I@>X&LY$=MYMDW0%Y[=V6R)$(]J:EM1>JZ)XZ8&3
MKK3+1NO&+;38J3CAJ@B(HFJJJKT1$P/0,3%#!4(21%$D75%1?!47`]P-<F5&
MBQSD2G08CM)N=>=)``13S(BT1$P(K-]1O05GLV,5R"A("RP>;)I#54%![B+M
MUW*B::X$[`8#`8#`8&+SS3+1O/&+3+8J;CAJ@B(BFJD2KT1$3`]$A(4(50A)
M-1).J*BX&N7,B0V"D2WVX[`:(3SI"`)N71-2)43JJZ8&W`UR)$>.R3TAT&60
M^]QPD$4U73JJZ)@9B0D*$*H0DFHDG5%1?-,#W`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8'RSEEN2V,?Y`:=D,5'$YSD*0N\5BR8#FD>>\C8KN56
MGE315_\`)73QP+^%RN5<7\V+"L&825DM&E@O"*G,B.0Q?"0RNNY44SU`AU%1
M%45-?`.4X9RSDDJFX,_+LF)TNZC6CTJ8Y';(FW&6=[:`C:CH@+]R)U+],"$'
MR%S3^U2LY\R'+&?Q!Z\;86*@@W*8-L%UU(M[9B]U$O!4^F!=67R'=P.17<-V
M7&9B0[>AC5[9-BIG$LD;%X1T+4E(R+:7EI@95O)N8RYS$=RW:#W%M=5*H,8-
M1&$CQQWFT77U`C2":%JA?HN!/G7*<A^"9MO.-B04[CS[\DP1.RKBQ24E$2UT
M1#3P7PP.)O>%RX7QYR*_E%`CM6=54L1*V$VOM4<C."82W=R!O>)QW1-J)H*(
MFJKUP+QOGO)%8O*-VZC!R*JLI<6!(..+:3`CUXS4`T)5:9T5Q$(]5]*?5<"V
MA\PY';6#I1)\-F%#X]#N'09:]PCLB8,KH+JFFC0JP))TU7ZX'.6/R-SB+1.V
M(V$-2C<9K^3."49-2<<0A?C+^XFUMX@U0ON'RUP+2Y^1[^#RK;"<;LJ[O6,0
MZUMH6S%^#6I-%H3(E=<<5Q%15$=NBHB)KUP,Q^2I:<7@\A&UAR8]V52)-IM;
M&J&P56WW''51=PB?I#N@*[DT)<#1;<\Y13P()3;FM>=*LO7'Y;`BL<Y-=L6*
M>XE'U(A:.@/3=KIX8%<'R#?]OD5T<P)T!GC%-8L5\AE!B]Z:CO>/HNJH6WU)
MN_3RP.UK>7G9<ALXC<^+6M<=G+#FUCJ`;C\<XH/-/BJ$)-[E/T:(J;177K]H
M<!S#E,R\XKS"LM76956-%#MJUX@;9(R?DO()BVAF0`A--H"'ZO-?'3`^A%R^
MR8YL%/8L%#K'"D>RG``O1WQ9CMND+SR&A1G6U[B[3#:0IT7`?+1Q7_BGD[FH
M.QCJI!H?0@(>TI(2+X*GFBX'.<QYS=T,V:%5(A-4M''HY0QFV4)7&+&:<-QI
M3W[0%`!"!1'_`'8'2<:Y<MO+?><LXT48DFPC3J9X1&2TD1Q&P)3WHJ(@#W"5
M15%0T\-.H=>!@8"8$A`2(0D*ZHJ+U145,#W`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8$4ZJK."Y7G#8*`[N1V(K8*R2.$I'N;5-J[B557IU7`]"KK&
MY+<IN(R$EEOL-/BV"&#2?^&)(FJ!_P`*=,#!JFJ&E;5J#';5E7%946@'8KRZ
MNJ.B=.XO4M/'SP"TE,K"1U@1NP+*Q1:[0;$CEIJR@Z:=M=J:CX8`Z:H<E)+.
M#'.4@@"2":!7-K1;VQWJF[0"ZC]%P-B5U>CX/I%:[[9&;;NP=XDZFCA"6FJ*
M?\WUP/?80?9%!]LU[(@5LHNP>TH%T45#3;M77PTP#T""]$]F]&:<AZ"/MC`2
M;T#1138J;=!T33`U+34ZN&XL&.KCCON#-6@W$]L[?=5=.I[/3N\=.F`B4U/#
M;5N)!CQFU:%A0::`$5D-VUO043T#O+0?#JN`*EIB;)LH$=6S8&*8*T"HL<-=
MK*II_337H/A@$IJ<9GO4@QTF;^Y[E&@[N_9V]V_3=NV>G77PZ8&(4-&W%D1`
MKHH19:D4J.++:-NJ:JI*X")M/<JZKK@>%Q^A./%C%6Q2C0?_`$3"L-J#/11_
M:';H'I73TX&QRGJ7(QQ7(4<XSC21S8)H%;)E-=&U%4T4$U7T^&`&HJ1F^_&%
M'&<K:,K+1H$=[8^`=S3=M37PUTP([?%N,-M*TW40@:)OL$V,=I!5K?W.VJ(.
MFW?ZMOAKUP-TNFKI#$MOV[(G-`PD.*TV>_>';530D5#]"(BH6NJ=/#`PC4-4
MS1LT91VWZQE@(WMG@$P)L!04$@5-BIT\--,#UZ@H7P?!ZMBNA*!MJ2)LMDCC
M;*ZM`XBCZA;_`)47P\L#-*2F23(E)`CI*EMHS+?[0=QUI$T0'#TW&.G31>F!
M*:::::!IH!;:;%!;;%$$1$4T1$1.B(B8&6`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&!"=NZ9JS:JG9\<+-\5<9@DZ"/F`^)"TJ[U1/T3`FX#`8%9,
MY3QF#)*+-MH<:2`J9,//M@:"B:JNTB1?!,"5$M*V:9A#ELR3;!MTQ:<$U$'A
MW-$J"JZ(8IJ*^:>&!)P&`P-4>7%DHXL=X'D:<)EU6R0MK@+H0%IX$*^*8&+5
MA`=F/PFI+3DR,(%(C"8JZV+FNQ3!%W"A:+IJG7`WX&A^P@1Y,:*_)::E3%(8
MC!F(FZK8[S1L574MH]5T\$P-^`P&!'A6,"<#CD*2U*!EPV'29,7$%UI=KC9*
M*KH0ET)/%,"1@,!@,!@,#7)E1HL=V3*=!B,P*N//ND@``"FI$1%HB(B>*K@9
MMN`X`N-DA@:(0&*ZHJ+U145,#0=A`;G-0#DM#.?`W68I&*.FVVJ(9B"KN414
MDU5$Z:X$C`8$<[&O":W!.2T,UU")J,IBCA("(I*(ZZKHB]<#)V;#9D,QW7VV
MY$E22.R9B)N*";BV"JZEM3JNF`AS84Z,$J$^W*C.:]M]DQ<`MJJ*Z$*JBZ*B
MI@;L!@>&8`*D9((IXDJZ)_OP/<!@,#4$N*<EV*#P%)8$#>80D4P%S781#XHA
M;"TU\=,`Q*BR.YV'@>[)JT[VR0MC@Z:@6G@2:]47`VX#`Q-UH%`3,1)Q=K:*
MJ(I%HJZ)KXKHF!X^^Q':)Y]P6F034W#)!%$_55Z)@9X#`8#`Q[K7=[.\>[MW
M]O5-VW7373QTUP,L!@,#6LJ,@$:NAL`MAEN31"\-J_K^F!C#FPYT5J7"?;DQ
M7Q0V7V20VS%?!1(55%3`W8#`U#,B%(2.+[92%;[R,H0J:MJNF_;KKMUZ:^&!
MZY(CMNM-..@#KRJC+9$B$:BFY4%%ZKHB:],#Q9<4901%>!)3@$Z#"DG<)L%$
M2-!\5$5,45?U3`S-UIM01PQ!7"V`A*B;BT5=$U\5T3`RP&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P.#Y:SPZRY74UQ.5S5]&G19S\@W&6YH=A4
M)EL/_%(WN@;?-M2_34.WCRXLE#*.\#R-F33BMDAH+@+H0%HJZ$*^*8&W`8'$
M<VC5K7).$AVF`.1=O.*&T$5POQDO<6G\R^&JX'+<FM)G'^7\HMZVP;KX]:''
M4EPU;9[;[+K[S"M&9HJM)L/HHZ+@=)Q_E%[><M(8EA6A6PG9\2VIB>[DT5C/
MJTP\#7:;-I5VZGO(A5"11\E4*WDW/9D'Y"@U,2Y;0%LX$"=5.#'!!:EQW7%(
M5+5]PR+MZ$*B(^'5=<"LK+OF$R'Q6XF<I5V-:\@<@NQXK,9EE6FEFB#:.()F
MJ&K+:*A+KK^N!,KN;V+K4B%.Y!'K^]974*-=]I@&A=AN`D9M=^YK=M(E5"ZD
M@KYX&FWY'*I^:6<YDF7ISU-1I(D"J,LHV[8.L/RC0A<(&VP-2WDBH(^.J8&Z
M7RSE=73L/_EXUW7#*EG(LZPX\F:S!:5M6W#9V"W*%C>J249$3TVJ/774+OY!
M7O7W!T8EI"=?LY`L2E$",=]9*^P7?3N7RU1?X+@<8[\MW+O%:>X"T98D^VA2
M9S:`QV'67+/V3[YF>XB0FVU7:R@[-=Q%IM3`ZO\`NB]9Y+=<6=?DO6L92N*I
MQN.TK;E8C0J+#A;$3K)WL^G]Q4ZZ^>![\67UY<]R7,Y#`N83T&(^+$4A)YB4
MZAD_O06F2;;55V@VYJ8[>JX'(TUUR"AOIAU,D9$*7RNSB2^-"PV3J@;)2"E=
MY"5P=A-[_#11+3373`F5WR/R:;2A?+>4S57-9KUEBT^,AZK=D2`"29_M`(-@
M!J"(]N47$]2J.N!NF<@YRDJJKO[N@-C-AW4QN?#:C25<:A$R48B(T!I2`7#%
MS8""NU?!?`.C+F)'\7T-_,MPK)%LQ6*]9M,@\`NRU:[FT2U;!%4B3<?I#Q77
M33`X:%\A<ZN2XA$"[8JW+.1?P[%^.U&E]TJE25DVW"16M5`.JB.U?'3P3`\A
M_+/*8=(W=R;2+9#-XY!MECFTVTU$D/3&H;SJDQW'.R/<(SW;M-J^'@@7CE_S
M5R940(_+*]R/:W3\1JPB"Q+<&&5<Y*9:,MC;/?$FM140T)%'5/J'-3^?7/(.
M$3JZQY!'A$'&ITN5+!I@5G/M29$)QK1T3:`11D4,6_5N<333`ZBLY+>2+6)%
MCW4.M9JWZZ.-2\XT93H;\-LR,6T;5_N$;A"VHGMU#JG1<"MXQ>%=?(?";B7;
M-2YMA56RN0!;9:6*>]@E8%$1'_0B;21Q5ZBI=/#`O>7<_FU'-*N'%GMG%=MH
M=7/KW2C-((S&5+>&NZ29(1@O3:/EUZX%MP;F,JZN+&'-4@?9CQY$<&^TY">8
M<)T4E1'PT,A/:@FV[Z@)//77`XCC]W91.8<J=]UW&)W,6ZPG'4:)(3:5@KW6
MR)%5"<VBRFY=J?355U"5"NYECRKB;5XZ3DZNY!<U\"?M:8]XPQ#<VO;$Z$BH
M6TNVB>H==$3`PX'R4F>-P:.%8,5#:P+.?7351HFGG&[%\-@H7IV,#L(T3Q0T
MT5-%P,K/Y`YNE$W8JXL&5>4<>WI8#4<3-N3#3O647]T%4NXP0D"FFJ==,"UY
M5\AV+%17W]:ZZG%[5HWW9C3326$)A%:[<L8LC^M&5$-7/3O1'!5/#`NN9ONR
M.4<+J57?6SYDA^8"HBBXL.(;[`EJG@CJ(?\`$<#EZSF?,?[B5^3<1Y<`>32J
M!RD;C`T81D$E:?5S4W"-I4$B\!4-?/`\XCS3EEA!XP[;7K"IS)J2^Q)C0P9"
M&L9A5]LV3A.B9D2[]SFOV$B)HO0)-?S_`)0,+CMW-,7*NU"54O1D``([1ETP
MB2&'"V>B7V2T$M$]0X&FWYER.IN[BO=L8JFV[QV`]8ML`JPSL%<"0^^/3[R%
M.WO7:.]%\-=0@<>Y1+KIUM2PI['?N.170!<.FV`-OL1V766%VMN-=PD+S'J(
M$NFN!VDKD5G%^.(5K+LV%LW4A-.6%>RCK+[S\AMG_3@^K8HCRGM$C]([MW@F
M!QU)S'G]V_15#5Y%A2Y<R]C3Y/MFI;NE7(%&!3MD#*%VS1#7;HOBFBJF!(I^
M1\GCQN.E*M!M'Y?)+>&^$AM@7S:CC-1IIG1$V=6!ZIU1"T^W`TWE[+N_B#D5
MS8742QB6''3>=JFVVM8DLA<0T%47?L$E$-'-50Q5=?+`Z&/R7DEARGVL*;"@
M0ZNS"!-KY;H=V5'*,CB&TVC7<0W-Z&U^YM417_`'R5R?D=58.1ZNSCUS`45E
M;$X]'1\D=KC84?$OL,7E0O2J_3`CR^>V[-C9,#*93V]U1PV6B0-PQ;((RO)Y
M*NJO'M+_`/E@5H\G^07+JN;.YC-P;F\N*5AIN,RILLQVWSBOB1&O<<;*-U]*
MBJ%ZNN!2TUUR*^FU'(F[6/67SG$'7Y-D<87FC6-.%7$5M-$$"4-305U'7T_5
M`Z/C/.^5<CFPT25!J'6/QCLZMDGM==8F16GWE1DVNYN(W2!HA<1-1T5%75,#
M`N0?(+7&0O5M&[-NP>>_TL%F*P]%A,)(19$47R-)+@H+1N-DOD2"N!]$H+^H
MNJZ/+K9K<QMUAE_<"INV2&T<;(P3J&\5U1%P/E?(K"PM*^,-E:^W]ESQF(R3
M(LLH;+4@>TV2$)[E;U1=?%53K@=9\DW[O'JIF'32PK+!]B>_":`&`;)8L<GB
M4C>$FP$25#+TJI=?U5`BM<HY(Y95D5^2XU&Y33QSIYL5EIU&+(14Y/H(5U'M
M."ZG<+30"1,"FB_)ML_SK\5"L&Y=7(&Z;[CX-,HR]5;!%!`?W-HDJ[W7"VGU
MVB*)U"&YRR,S?#R-R>#$MWA,!Y;)H!?:19$Y14P:10#^H?15+:GGT1<#'\M<
MWW):2.W>@,BLY!=58VXM,&X+80E-H%%!1CO*)=-0ZHFNW`V.\KOV%A<@=[<R
M[A\8OB:<1I6P?]M816VY'91==IM@CI"'BGV^6!8W$^TG\*Y5:V5S7V5='2-8
M\?.O))!Q38$71[CC0L;][P(0Z==JJBX'TJ"$@94XG9J2@)T5:C[0%8R=L=6E
M(.I:KZ_5UZ_3`F8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`ANTU
M0[,&:[!CN3142&230*ZBC]JH:INZ>77`DM,,M;NTV+>\E,]J(.XB\273Q5?K
M@9X#`U/18KSC3CS(..,%N9,Q0E`EZ:BJIZ5_A@8.UM<\KQ.Q67"D((R%)L25
MQ`^U#U3U;?+7`]"!!;E.3&X[02WD079`@*.&B>"$:)N5$T\\#!VIJG97NW83
M#DKT_ODT"N>CJ/J5-?3ITP,VZ^`TR##<9H&&R[C;0@*`)H6[<@HFB+NZZ_7`
MT.45(Y'2,Y7QCCHZDA&29;4$>3JCFU4TW_\`%XX$DXD1Q35QELU<#M.*0HNY
MOKZ"U3J/5>F!I9IZAAIAEF%'::BZ^U;!H!%K<FA=M$30==>NF!N>BQ7G&G'F
M0<<87<R9BA*!*FFHJJ=%_A@:%I:96D:]A'[2`3:-]H-J`9;B#33[2)-53ZX$
MO8.Y3T3>J:*6G71/+7_'`T0ZZOA(ZD**S&1\U=>1EL6][A>)EM1-Q+YJN!Z%
M?`"6<P(S0RW$T.0@"CA)TZ*>FY?!,#`*JK;;D--PV`;E:K*`6P075)-"[B(G
MJU\]<#%NFIVFV6VH,<&X[9,L`+0(+;9)H0`B)Z15/%$P-A5U></V)Q6BA:(/
MM5;%6MJ+JB;--NB+^F!C^*J_2OLV/21&/[8="<30R3IXDG15\\#QJHJ6DT:A
M1VT[:LZ"T"?M$NI-]$^U5754\,#)FKK&6FFF8;#;3!]QAL&P$0-=4W`B)H*]
M5ZI@:W**D=8;8=KXQL-*2M-$RVH`IKJ6T531-5\=,#,JFK*8U-*&P4U@=C$E
M6P5T`7IM`]-PI^B+@>-T]2U+68U"CA,)2(I(M`CJJ7W+O1-W77K@9.UE:Z^L
MAV(RX^NW5TFQ(U[:[@]2IKZ5ZI],#.-"AQ04(K#;`*NJBT`@FJKKX"B?7`UK
M55B@^"PV%"46^2/;#1PM==333U+K]<#W\;7:QU]JSK$_]*O;']K7_P`OIZ?\
M,#`J:G*.$8H,<HS:J3;"M`H"2^*B.FB*NN!+4`4A)112'7:JIU37QTP-#];7
M2$:21%9>1C^BCC8EL\/MU1=OAY8&NRJ8-BD=9+>YR(\,B*Z*[3;=#P("3PU1
M5%?JBJB],"FXKP6NH9%M*+M3)MM/D3W)91VVW122J?LJ8ZD0@G1%5?#`MW**
MD=KAK7*^,=<&FR$3+:LCHNJ:-Z;4ZK],"6L=A0`%;!0;45;%1305'[5%/+3R
MP-$NIJYC,IB7#8D,S11N8VZV)B\")H@N(J+O1$^N!&_MCC7X\ZW\3#_'N%O<
MA^W:[)$J:;E;V[573STP)<RNKYT,H4R,U)AFB"<9X!-M4%45$4"11Z*B:8&A
MOC]"U*9E-5T9N3&)PX[X,MB;9/H@ND)(FJ*XB(A:>/G@'./T+CPON5T8GADI
M-%U6@4DE(*`CZ+IKW-B(.[QTP-9\8XV<:;&*JB+'LEW6#/8;V2"7S>';H:]/
MYL#:%%2!.9GA7QAG1VO;QY2-`CH,Z(G;$]-R#HG@BX&-AQZALG"=L*Z-,<-@
MHIF^T#A*P:H1M*I(OH)415'PP/&^.<?;<;<"MBBXTTVPT:,M[A:875H$735!
M;5=13R\L#QGC7'6'6'6:N*V[&>=DQC!EL2;?D(J/.@J)Z3<U7<J=5\\`'&..
M-L16&ZN*#,%2*&V+((+*FJD?;1$].Y5U73QP-[U14O3F9[T)AR=&!6X\HV@)
MUL"^X0-4W"B_1%P(P<6XTW7M5S=5$"`PXKS,066T:!PE55(`1-HJNY==/JN!
MOB4M7#GRI\6.#,J8#+4EP$TWA&0A:143IZ4-43],#8596ENW1&5W.*\6K8KJ
MZNB*:]/NZ)U\<!+K*Z8XP[+BLR'(Q$<8W6Q-6R,5`E!21=JJ)**Z>6!N".PV
M#;;;8`#*:,B(HB`B)M]*)X=.G3`C_B*GW"R?9,>Y5257NT&]5<3::[M-?4G1
M?K@9?C*W9V_:,]OM>WV=L-.S_P"7II]G_#X8'@556`(V$-@00T=0!;!$1Q$V
MH>B)]VWIK@;O:QNXV[V0[C0J#1[4W")::B*^2+HG3`B.4%*Y"]BL)D87=!Y8
MP`(-JXV:."1`*(BZ&*+U^F!-!IH",@`1)Q=SBBB(I%HB:KIXKHB)@98#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`UO2([&
MSO.@UW#1MO>2#N,OM$=?%5\DP-F!I>FQ&9,>,ZZ(2)2DD=I5T(U`=Q;4\]!Z
MX&FUN*VJCA(L'T89<=:CMDJ*NYU\T;:!$%%55,R1$P)F!4V?*^.UDQ8<^>TQ
M+1KW"L%JIHSJH]Q41%].J*FN!E)Y1Q^,W'-V<UME->XCH"J:FSZ4[HB"$NSU
MIZO#`S?Y%1,/5[+L]@7+8E&L'>B^X5!W+VM-=WIZ]/+`CV?,N*U?O/R-I'BI
M7*TDXG30495]$5I'%\!4]4TUP,F>7<9>A/SFK)@XT5U(\DT+56WBTVMD/W(:
M[TT'37K@1F.?\-D*^C%LPZ49'2D""J1![<=[R*B)KN;'J0^*8$O^ZN.=JK=_
M(L*U=*(U)H:*DE2'>*-*GW:CUZ>6!:X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`^=?($.QY8<ZHIF6WI-``2XL@WC:[-P'[T3T*
MVHN((HFOJT]?A]`BQ.1V7+N4<;;AW,JG@RZ1^QGUL864<62U(99)IPWFG#'8
MIN"NW37;TP.?J>0\PJ*;B<"'-F3K%V)R'WD>4GNS<F0FR)AEUQ4W[P=T00WI
MKU3`O;ZS;L>)1;5JV>LX;ECQYTP-A`2.03F%>7T`)HI?<8%]GZ8$_C'*;:WY
MF["DW`,/5LFR8E<>&"Z+AQQ>5(<AQXR5!%&Q%0<1-KFY4\?`,[/W[WR[[>OG
MA!D?@0W$XQWD)/>$JB.I-CNVHOFO\,!Q^0E)SGFKMZBQQD%&EULTP463KF(B
M(331)KJK#@.D8)U]6[3U8'%T$:911^$W%@T<2A_N"ZD1U>#LI"@V0R2A=X2Z
MMB6Y/N^W<B+I@6/.K!JQXGS6T@.I)KY,^KC0Y(MD8$3+D87#;VIZQ`R^_P"W
M5%ZZ)@=#P+MQ.;\IBW"D7+99,2'I0L*Q%DU[0;(AQONU[8EL=0C(M^O7;MP-
M="Z`<.YXX2J@!979*NBZZ>I=41$U7I],"FI7Y33?Q1(E6(/PW![;+8QU:4#6
MJ=:1#+<7\Z[.J)U7`^OX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`YZPX17SI<B2Y8VS1R"W*VQ92V6P733]ML'$$$_1$P-*?'U6
MCZ/+97"DA"6U;2:J*@Z^E?W?M77JF!XU\>UC?A9W)=-%0K6:NOCU7]WQZX&T
M>"UJ.(Y^1MU5&^WM6TFJGGZM.[]W7QP,/[`J]=?R-OKM0-?RDW71/U[N!L+@
MU8N]/?VJ(8H.B6<U--/,?W>B_K@8IP.L155+&WZJBZ?E)NG1=?\`S<#(^"U9
M(XBSK7]PD)?_`*G-Z)_E3]WP7S3`V#PNL$A))=GZ5Z#^2FZ:=.FG=\.F!FYP
M^L-GM>YL1355W#834+KKY]WRUZ8'K?$JP$;_`-18&K8("*=A-55TT]1?N]2Z
M>.!FSQ>N:>5Y'YQ$I(6TY\PA1477[5=TT_1<"WP&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!'_`",#N@TCX*XX9M`"*BJI
MMBI&.B>8HG7`KZOE_';5N*[72_<LS2,8SP-NJV9-[MZ;]NU-NPM=5\L#V)R[
MC<PP&-/;<%PR::=]2-&X!J"@#JHC9%N14T$NN!(8OJF0[8LLO]QVI)`L`03U
M:)6T=05Z=5[9(7IU\<"N?Y_Q)AB,^[/T:EQ3G1R1IXMT5O:IO:("J@#W!U5?
MJF!ML.:<8KX@394Y$A.1TF#+`''6?;KU1WN-B8(/ZZX&)\XXNV[&:=F*V[,D
M##C-N,O@1ON#O!M$($ZD**J?HB_1<"7`Y)23[:PJ(DI';*K[?Y"-M-":[J*K
M>[<B)ZT%533QP+$S$`(R70115)?T3K@<\GR%Q%71:]Z2.&T,@06/(1>R9(`N
M:*W]BDNF[PP+:KMX-HPZ_",C;9?>C.*0&VJ.QW%:<30T%>A"NB^"^*=,"9@,
M!@,!@,!@55_R:HH8XO6+CB;D,P:89=D.D#:(KA(TR)FH@BHI+ITP)<VU@0JM
MZTE/(U`CLE)>?5%T%H!WD2IIKT'KX8$AMP'&Q<!=0-$(5\.BIJF!E@/'`8$-
M^W@,6D6K<<TG30==CM;27<#&WN+NTVIIW!\5P)F`P&!7<?Y%3\AK!LZB1[F$
M9N-"[M(/6R:MN#M-!+TF*IX8&VXN:RFKW+"SD#%A-*`N/GKM%7#1L-=$7Q(D
M3`WR)3$<0)XE%'#%H-$4M3-=HIT1?/`VX%1:<NX[5G(";-$#B-H],$!-U66U
M120WNV)]M%055-VFNF!:,/LR&&WV#%UEX4<:<!=1(234214\45,#/`8#`8&E
MF;'>D2([9*KT511X5$D1%,=PZ$J(A=/HN!NP-<F2S&CNR'E46614W"1%)4$4
MU5=!157_``P-B*BIJG@N`P&!%_*UWY5*GOC^15CW21OY^PA]ON?PW],"5@:9
MDV-#8[\D^VUN`-VBKZG#0`3045>I$B8&[`8$.LN*ZT"0<%Y'ABR'8CZHA#M>
M8+:X'J1/M+I@3,#3,F1X<=9$@E%H2$55$4EU,D`4T%%7J1)@;L!@,"._/C,2
MXT1Q21Z7O["(!D*]L=Q;B1%$>G^94U\L"1@5-7RWCEK9S*J!.;>L8'_JXJ;A
M,4W*&Y$)!W#N33<.J:X&,/E_'IB6"Q92O?BRV3=K3OI+54VCZ/6JJ.B(&NN!
M90Y;,N,W(9W;'1$T$Q4#'<*%M,"1"`M%ZB2:I@0XG(J>7+E1&9"=Z&BD\AB0
M"H)]QMF:"+@"OI(@541>B]<".WS+CKD:<^,I=*YP69;2MN"Z)N+M:1&U%#+N
MKIVU%%0]?3K@3JJWK[6)[J"[W6D,VC1442!QLE%QLP)$(3`DT4537`B1.7<<
MENS6V9P:U[?>DF>K8=E$U5X#-!%QH=%13!5%%145=<#W^ZZ!*Z38'+1N-#02
MD*:$)BA_TUV*F]>[JG;T3U:IIK@3*RTA6<5)4-SN-;B;+5"`A,"43`P)$(2$
MDT5%3`PL[FOK%AI,-6_?20AQE02)%>=15`2447;KM\5Z8$W`8#`8&#[P,LN/
M'KL:%3+:*F6@IJN@BBDJ_HB8$&YOZRFJBM;$S9A`K0FXC9FHJ\8MAJ`HI)ZC
M37IT\\"QP&`P&`P&`P&`P&`P&`P&`P*ESBO'"EC-.`TLEN7^1!W1=1E]KL*\
MG7H2M^E?KYX'!_%U/>R/BPFQDO07Y#5JQ$@DP+0M./2G^TZJ.CW25-45-Q:*
MBZX%?RB6W9_$43A-9!)KE<N'"@,4C8J)P7V]FKSJCT9:CJVKB.*NBZ)MU54P
M.@K^0P..<QY;'N.ZP[/>CSZU>TX0RF@@-,FC)"A(3@N1R10^[P7P7`I;FLY:
M],XY`I9#E1R!KBLX`>-E'6VY!'"463<(2:$E5HNOCTUTTP)MC)K9?P'8,TT&
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M<-J3%>;"*75M&$<4=RL@T*^G12(U7H&R?97T`;AS\C<[8?\`;DV&KA2'#WR#
MVS@VB.AHK&JN-(FU%Z[47`OZB=R>1:QD*1+&_.WDL6\-Q'4A_B!)WM.L#_2;
M'M*R3;J>HCU%5\40.6E<XY</&D%)-LW:1N+26YCR0WUTNFGF0#:2LJ!/=334
M?2J+@67(&[!94Z`Y*M)-'7W/'YJ/F4DW19=]<@NXB=Q6T)!(A3T@ODF!W7-Y
M4L)-,RXLAKCDIQX;>=#-UMYI4;UC:FRJ.BV9ZH1#Y[471%P.5XO_`'#.Y-P>
MPY`$@;!N#>!O)#!"85]@8AR`%5;%UV..\A+1=R>&J:(&OY3KY;E]R!6QFFDO
MAT]F(TSWRCNR&U<4F]H(3?<V&FB>)=--=,"E;N>7U35G$@OSRK6HE!(ELF$F
M:_&8=$F[)(:_MFJ@"-J0@NX=5(4UP.WAMVCGQ1<MPI\RZE'$L4JY,IAV-)-"
M!Q6&T%Q4=7:JH`&7J)-%_7`Y_CLN\:I(%.Z4V&K7&(#_`!Q\$>+=.!DQD"_N
M3JZ!JVG:<U11\OH&N1.>JKODK$UVQ2PL+2L3_3')%A&G8#"N.[A%Y6X_>9=!
M>UZM?3J.NY`G_'5G>SX7#';_`-S^89&WBS5DMFV:FRZC8=S<B:[FQ145?N\<
M"RO)7)8_R5`5D';&C?-B.Y'8=D,.PW#;>4GS!$]O(CF.F_54("1-/I@<?Q>Y
M<ATE?2VTBRJJERMD.19HE*1\;5J<8FQW#]6X0[:LM$NTT4DT4<"_X_=7,F\K
MX?+)%E#O`;KY%?&BM.A'D"<81E][M(3!HCQ'W4/3MZ)M\E4-7Q-93GK.8$YM
M^)%DS;-ZE8;[G9,5F.NOK*1138_^Z!`A>E0T4.N[`K_DY!:LN>`KLE'9=)4+
M&9%77!5?>OM.&TTB$&HKV]51.FO7Q7`ER;RWKIEA`9M9[S$3E53#B..H3IFS
M(;8.8R;G;559];BZ^`^"+TTP.@X%8<BD<AM5M6W)#$A#.%9`K[+/;9D&V,=Z
M"^G^GD@A:*3?I<%$+Q\0A\,NJ[C]UR.DY`91;FQNI$N*3HND,V/*V^U5@E$A
M+8T*-*V)*HJ"],#1RM^]&?;A7SID.^A/Q0XK6-JC<22SVVG##M)^V\!F+H.F
M?5L4Z;4ZJ'-6MO8L1IO(9?*[6#$+ECE-(3N`W'8@I(($[;9LKM5$T]?T\\"?
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M:@3C4EM>A+L7I@0OD7FEI7<YA1X#TN.W!DU`314758=8GRB:=[;(#M<'8G[C
MI$NPMHBFJE@1V^074F]@4;D^P.4DWD4:RC@+B",3:\4#NNB"(![>TK*H2$J+
MKUP*AF0\5%QN3"L[%J?`X/,FI+9=-UPY#2QB5N0CB&9;7A7:.FJ]1\$P.EE\
MJNK(I:U\N0UR&.[5OU-:UHK$J!)1@G7$`A%'17<^CA>+>WQ33`KF;SD#/'.1
MWK]Y.[T?D_XV.T>WM-0AMV@1!#M(6A,&HJ2_R^"^>!,F<HF2.8724%G+<?IF
MI;$.HD&O;L;8V#>%H`(=48C`'I4=J$2^*[>H10Y1;,<?2Q+DC\^N=LH;-Z]&
MBNLNUL4D=%\B]PKCC>KH@#O_`)8ZJB)XX'1?$01W>-7S<>0_*8.[M4;E.D:/
M&!O*0EO)!)5VEZ2_A@<YQN=<AQNCJGK&=&%>.^YK;%%>-QVS`C1UESN)N<)H
M1!1:)/4BEX^0=CR:YY%$^/:^?(0H-\Z[4#-:83N;''ID<938Z(?IV$:+^F!S
MEE:\U2RY`VW.(4`9(T]HT+Y1&%;F,;8\^*@;A<!'-$>:+0V54M/3@45[S'F]
M>Q&?EM6-5'D4]U&1II7+$2N!(3ADP^T#CA`0[E9(T3TIHOA@6D#D%_/O*:+8
MW5E5R9*54NLBI`=5)C"1T*<#A(B-@I.*?=1T4)M$14\4P.NY?,MH_+*5J-,D
MQ($NOM@DN--*^T#S3;3C#I"@EZP]:@BKZO#K@9?&LOD3U?+:OFC*:RXTOY$7
M#.+,$X[9(_'!U`<8W?\`B,JF@GKIXX&F->\+O[>=-4WUD0H$B*9+'F,[8;A@
M3Y(9LM>HC`>@DJ^G5//`YV'2V#%>TW12Y-QPR)8U$RK$W7'7VV67?]2V#KFY
MQZ.T@MN!U5?N!.B=`Z:JD.UDBY*;*2.G(;-5X\9(9BJ.0F1#5$30$)QLUT+3
M5?U7`X:RH^36'$ZNBJFY#%M4\:FQ+-I44A*4:112,3JJ(D3JM&J+N\/4BX&5
M[66]Q\AM\JKHLDN/5;E*DYA`-OW*L'*)QT0%.XX4-9#:J"IY+],#K*6>VRQ?
MN*XE:7)KA]GC\@FR5'7?9-M"ZHZ=-3C.*F[3<B?JF!R?)*.\N.-TT.DK%]]3
M44IB9$D,H(*ZBQA&+L/:)=XHI**>&B(O@O4+>W=:MKMSD42N??J(14QRU[;H
M.&3#[[A?LJ@DOLQ?%PD37Z>*8%YPAN=';YA9O"Z,*;;RI5>*-$KJLM1VF",6
M_N+<ZP>Q-/4FFGBF!QKI<FF5<*+;M2D?<NZ9U+2&Y*1A]AUQ=SK;3NK\)U!'
M]]K[0Z:+U7`B<CN[6OX6<.',N5O(,:U.LE[+!\3=C6"BR)$@J3SO;04'NJH[
M.O5%P+>V=Y`_'YQ90)MJCK$B&$)&5?/LPGXL,Y;D6*6P3,?W51!]2+N050L#
M1,C<A7C[<JANYUT3DF?,C5TH9]:CK&P`]NQ(7>^V;+G5CO*HEJ2::(BH'T'F
M;5R="U,JP>.;7OQYI06G"!R0TR:*_'U$A0E-I204+HI:8'&N0>45G$.8P9+U
MDLFG9LGJ*U%^09R`F-F[%$"4S<-R-JC7Z$G3QP(G,X:.4?(W]DPY\^MIW$)/
M<&!@CPB1`'J;1U"3U:#NTZKTP.OX9,FA8\OBN.S)4:!9K[!N4!;D;.*TX3;#
MA]7&^\IH*Z]/!.F!4_&5A8S+RQD$EDW4S:Z!*BL6/N"5N03DD)0;G_!P=H(X
M(:#K]J:=5"EIW+J59/6<&PN9,^)R6VCRXB...1%KH[KVK(M.JC")IVQ:+[M_
M1%T140*2'/Y6[3W#@'=0V9:4#@LE[[W+,ERP5F>T+YH)N.(P*(\K0B"?RIIU
MP/N5;7L5T!B#'5PF8X(`$\X;SBHGF;CBD9K]5)=<"3@,!@,!@,!@,!@,!@:)
M\V-`@R)THMD:*T;[YHBDHMMBI$NT44ET1/!$P-C+K3S0/-+N;=%#`O#4535/
M'^.!G@,"JD\E@,7+-3VI#S[I"#CK+)N,LD8$8(\8IH&]&UT5>GAKIJFH:DYC
M1KR(>/B;Q6!"JB0L/$QJF_4.^@*TA)VBU12\M/'`DUG(:FS=<:AO*3C>[03`
MV]XMGVR-O>@]P$/T[AU3`U2^5T46X:J'I"^_=)L-@MN&($^A*R+K@BH-JYVR
MV(:IK@8L<OX^_;I4M2MTPW'66UV.=HWF!WNM`]M[9&V/4A0M4Z_1=`D5=_46
MDBPC09"//U4A8D]O:8*T\@"YM7>@ZZ@:*BIT7ZX%A@,!@5CG(JUODC/'2[B6
M4B(Y.:3MGVE99<!L_P!W39N0G1].NN!9X#`8#`8#`8#`8#`8#`8#`8#`8#`:
M)KKYX%5R'C=?>LPVYAO-^QELSHQL.*T2/,*J@JZ?</7J*],"U445-%3I],!@
M,!M3333HOC@-$TTTZ?3`8#1/'SP&`P&`VCJBZ)JGA@,!@,!@,!@,!@,!@,!@
M,#%QIIS;W`0]A(0[D1="3P5-?-,#+`8&I^)%?-DWVA<*.?=84DUV'HH[AU\]
M"7K@;<!@,!@,!@,!@,!@,!@0:JEKJI)(P6R:"7(=F/@IF8]Y\U<=(4-2V[C)
M25!Z:X$[`8#`8#`8#`8#`8#`8'#6=-R)SE\RO21,<X]?-1Y!/MNN`D%R$:=]
MD#145L98;-$#KKO7I@?/PO[>5<\@6"%NU7S^/7)OQYS,QQ0L8[Q(VWO(=FX&
MS5&Q8VILVIZBT7`LN17W((,:W:A/6JORF*!^C;A1Y3H@".($GP!0;0MBHZ"^
M6FJ:KI@6W#_S+WR)8I<VUG^2B2IBA5>V=:@E7N$J13[JDY'<!`V*&S:XA:H6
MOJP-O/IEZ4^\@L.SXUDD)A[AY0%>0'I&Y>X#@A^T:BZ(=Q'.G:+I_-@6?"VX
MR\\YH\C<@9G=@)(=-7TCFJPP1491S1M=A-KJHIT^O73`J3K4K/DU'.,RWQ.\
M(UY-2O-O;`:T=3\C&=<11:5'A$5$?0>[7QP/:=F<V_Q>WDQ7P3BM780[UWMD
M;RN`#`=D&VQWO*:M=T=@*)(B*G54P%S3S);U_';;<$^26E-/K'G&S%%!@8Q/
M`6B*0*T$$R+>B:;D3Q7`U<=K[./_`&_QP@>.QJ;VRL)\MUDQ!8CCDQP7@-1[
M9=[W;8)HNO4O\JX'4<422G+^:=UMP&3FPSCD8$`&/X]@")LE1$--X$BZ+XI@
M?.[F3(/Y'OH<>TNSMX=I4.4D%DIAQ`:D(PLY"0?]-VE:4]R.+Z4\$UTP,77.
M2+2\GL)D^[9YE65-DS*98CO,PS=)TBB/1U1#!S1!1&%:Z[47?UP/H5E7R:7X
M^?8IY\QN7L1UJPD@]8OHZ^ZAF;S9;G2#4UWH*:B&NU$T3`^=^SL7Y#,*UC38
M<QBHY$)K$?FNMJZLB.XR462HBZ+9]@B9:UU1!TZ]-0DUE[RF;<<8D[;49!NU
MJV"J$EQMZ#(@(+SR@`BQ';65]R&BN;A55V#I@0()V[?`Z>UL+.^?KY<B7%Y+
M((9CTT6P]PS"VQQ1'1;$S'<3:>I=NY23`^P\;5(M97U1OS)KS$)DUGS6C%QT
M=-J*\:B`][IJ8?<GFF!<8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`:)KKYX#`8#`8%97\<JJ^WLK>,#B3K=6EG.&\ZX)=@5!O:V
M9$`;173T(F!9X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`B-6T%VT?JVW-\V*TV_(;05T`'E)&]Q:;=2[9:)KKTP
M,YEC"A+'24ZC7NGACQU+70G315$-?!%+;TU_A@2,!@,!@1["P@UT%^?/?"-"
MB@3LB0ZJ"``":D1*ODF!50N85\J1&96+-C>^<5N$Y(C.M@ZJ-D[JA:>A%`%5
M.YM7_'`O<!@,!@,"GM>4U]?:,U7:D2[)^.Y,&+&;5PDCLD(&X2]!^XT1$UW*
MO@BX$Z):0)1-@T\G?=8"4,<]0>1ESH)DT6ABFO3JGCTP)6!7/7\!GD$6A<1Q
M)TR,],878O:5N.;8.)W/#<BO#Z?I@6.!3\GY1!XY7.V,Z/*>B1V79$AR*R3W
M;;91",BV^'1>G^/TP(,7Y`J)"4Q%%FQPO7TC5YOL*VA$<=R4!*JKT$FV2_QZ
M+I@=-@,!@,!@,!@8M.M.MBZT8N-FB$!BJ**HO@J*GC@98#`8$"9>5\.UKJM\
MB&7:=Y(:(*J)+'#N&BDG0?3U37QP)^`P&!4U7)Z^UFO1X+;[K#/<1+!&U]J9
ML.JR\V#O@I@X*HJ>?EJB+@9WO(8-*E>LP722RFLU["M`IH+TA50%<7IM#5.I
M8%G@,!@,"#;7$.K8!R0I$Z\I-Q(S:(KK[HMF[VFA540C(&BT37`C2>4U,6+7
MNR%=9?M$T@P#:-);A]M7"!&--Z$`IZM4T'STP)-5<P[-'T8%UMV*:-R6'VS:
M<;,@0T14-$UU$D74=4P)V`P&`P&!02^;T4>QDUZ*_)D0GHT>=[9AQX([DO3M
M(Z0(J#T)"+_*BHJZ:X%Z#K1J:`8DK9;'$%451+1%T73P7147`RP*VNOX5A:6
MM:P+@R*=UIF4ICM%2>9%\%!=?4FPT_QP++`K.1<BK>/UPV%CW$BJ^Q&(V@)U
M1.2Z++:J(ZEIO<371,"P=>1K9J)%O)`38*EHI>:Z>"?5<"!R2_A<>I)=S.%P
MXD(4-Y&1WGM4D'H.J>&N!98%9-Y%70[>KJGE-9-N3X1"`%)O?&;[C@F:=!7:
MBZ(OCHN!9X%7R'DM50167[`SW27@C0XS($Z^^^YKM;:;!%(BT157Z(BJNB(N
M!L@74>;-DPD9D,28@MFX+[1-BHNHJBK9KZ#T451=JKHN!88#`8#`T+,953%I
M>^XTX#3S;2B1-D>U?6FOIT$T)?/;UP-^`P(MK/&NK)=@31OC$9<?)EK17#1L
M%/:&Y13<NFB:K@;(4H)<-B4"*(2&P=$2TU1#%"1%TU3SP(4WD$.)<Q*AQMTI
M4V/(DQB$4V$D50WM[E5/6O=113Z:X$*;S:LB<(+F!,O%6C$&<K*('>1HD0NJ
M;MNHHOJ]6!?B2$*$G5"35/X+@>X#`8#`8#`8#`8#`8#`8#`X"PGI%7G##$"3
M8V:/Q7G(<=5:D/1)$=AD38(/4J!VW4Z==15/UP.0=J;R/\;V]#&BRX4\^21T
MX_WV2Z-E.CO@XR&YU4:;`3)>O1$77SP/MV`P&`P.;^1Z"QY!PJTJ:TQ";(`%
M90UV@:M."ZK1KY"X@;%_1<#R9<6]OQV8U4094"Z?B/#']ZTK(QY*M%VT,]40
MM'-$W-*2>>NF!PMW&YE*J8K\&'9QF?QM8S-AJ;JOI-9L(_<1-"WELCH]W'!Z
M&/BI=,#0_1W<"[,H];8_C:SEL1RF!@72%J"]$%)Q@*+N5@GB<WZZIJO1,#15
M<<G/N4`6%7;DQKR%J:DCW*J@E*]Q![RH?4%TU:_73PP)E57<SE4XLVK=D$J9
MQVOCTSZ*\+T2T9$TDK(T51!Q7NVYW3^X>FO14P-DJKO7.3>_<AV;\N'RR-[:
M3H]VTK'83;3QMIN1OL=T3[FB?K@7_P`CTM?8V$9XHMQ$M8D1\Z[D=()DZR2]
M%C$(*N]'.A;#'8NG54P.2?A_)#KY6SU6^WRR;Q%MA9C```#,8DF\]&4A4P;=
M=!4V]=-R]%^@6+\&ZAR9-Q3U]LG''9M<_*I$[@/[1:>"8K,8U0]NXV"<`?O(
M2)-?,(W+&^4N6?&9G'J&P;A5]58'/KGMXO.Q9#L?2$$D3,F91`RIBF[R0-4U
MP/JE3/:DM-MMQ9,8!CL.BDELFU1'471M5)57N!M]:>73ZX%=\A#*/@G(68<9
MV9+?KI3,>*P*DXXXZT38"*)]2+`XGD=/97'%OC6)*IY)@$V"=Y`;%Q%C-)`=
M:=1TD]:`VZX(KUZI^F!SDFDY1*JZ>!=L\C*E.))C!$J@:5]F0Q/<6.3Q2!)Q
MM%CJUVG$)-J!U7K@=_\`*C=L=+`A0*Z78]]UQMYV-N<-I5BNBT;C0.,(YN<(
M4]:[!7U%X)@?.?=<@EU=;6W(W*6H45:%B3<9Z0<"5'EJ3KSAL&A"X\TV7BB*
M0[5U5%7`Z">\W*YV#$IRY<B,7HR@L8L>4<-QDH"-!#5^,JMBVU(^]"1-"%=W
M557`K:7CEO7\&H[*;5VLB04AYOE<91-^P<8$Y"1E]N\K@O--JZ/04W;=I>(Z
M8'G(@F0X,.!(2^]K^(8VOO@_*DP$:EJXXX^]7D/;=.+J)JOJT0415]>!>1PM
MYOR/%EQZZ:S4//S(DR2`&3$B&Y7M+%>*1O75LC'T(">DO'U:ZAS3=9;P^-U-
M%)KN0P^,RJR+'KXM.R*S8MG%>>5_N$8JY'5W<)`\I(*BBZZ8'T/Y!KY<VZX=
M%5J8]3NSWFK=N,KNQ6SANBW[GLJG[7<TUW>G7`^>$/)2XJ]$C55TXW8\;LZB
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M)PXL3@S[3$.3`E%/L');<AE]IPC<DN&VX@2$%5W-*"IMZ?XZX',$/(K"HA-W
MS$FR;>NJE!N(\67#DO-"1(?NH>BK&<CH/[CK>@+JFBHJ8'/W!<E>X3)@MP;T
MI->MT=&\RU,(Q[$Y"A!L0@U(61$VW'E7T=`W%TP.NE-7\E[FEM7MV[]I&<AN
MU,!PY++91'H4;W21F75&.3A:/(B:+M/Z+@0K&)=O<>;3BTN\[=B_*>6+<,O,
MA)(V602(+H]J5`7<*JPXJ;$-#5=15-0[WF)7/X:F>;8?2($N,7((D<E<?&(0
M$+B;F_4:-N$!'V_4HHNF!R*\8M"F\1.2S+GPX/))DFODN&^9QJUR.\C'>(E0
MM%<4$'N:JB:)X:X'2<P=F4W,J3E"PI-A4M19=;/&(TK[D7W)LNA)[+:$ZX*K
M'[9[$71%U^N!GR6TFSVJ"?$BS'./.3"&Z:1I^/(]N<=Q&GE:5&WT:!Y14TTU
M\]-$P.6_M7E#C42#-=M7H;"7[D`1D/(0M&0I7)(?:<$B,04NTAJ2Z>/J3`HX
MG]_)Q(R?:NE>>X9#DON#[E)'YJ.\2*(_SB\HZ;A0?4*>KIXAU5I!G?D+*PKF
M;H9+%W5E'%#DBRK;RLC,)IHU5LV=AGW4V[>FJ:*F!HH6.63+&L>(;"-R"!=3
M&>1&]W6X;]8:ODT0"1*R8*'9[1-HI"2:+IZL"9P"HOJR]JA,;,:]VF?&P6Q>
M>D*LUJ6`MJ1&9B)*WO4?J.!#YA7RXG)9_(.)-6E9RLGXL1^.,;NUUR`H![G4
MVF"=MG<WW][9#IHNO3`R8KN25UW9E#B26XKO*1G6VP3U>K'XH`+C)KZ"$'Q0
MG0#U[15-/)0UA%Y'"1J#=UEG:\5D.6`P1C&X[-B_ZC?#61ZQ>7]O=VRW+V_3
MNT\4#%8O)XGR/9S'ZN9+XK,F0`<%A'0DC(2$VV$LB`D1^.V0D#H)]I:'UTP.
MVYC$MT<JK>J!Z4_6R='ZUIS8DF/*%6'$+4A#5M3%U%)>FU<#Y_?\=YJW\83J
M1]N7.FU]I$9K)+*D[*D1&;)J5[M5'>0DC7I777[/UP+`(E_`?8C0HUFW!8Y:
M1M`(O*V-<<15(B1%52CK(-5Z_P`WTP(5FQ<3^!\CC/T%H'*SK5B6A")+'FR-
M^WN1=IJCBKZB;(4U`5T731$P.RX5`EP.0<IC]F2S5%)C/UW?WJ!*[%!9!-D:
MKKJ]NW_\6!QG]HH_+X]3.T<INM2VY"_8DV#HM"V^D@63<<U0OW^\*CHNBX$.
MBI.7SEX_7\I6Z!EJOJW*V9$8;WQYD5TO<),<,7";<+0-R^!MZHO774.]YQ$L
MH]]QKDL>.[.@TKLH;"%&!77^W,9[(R&FT5-Y,E]R(BEL(M$5<#SF+]K:55<_
M5QI)0H]G&.YADTZR^_`'7NB#:H+A(AD!$.GK$5'KK@<HO'+>5853#\.P3C+M
MY/:"&)/-"%2_7D(C(`3`P:]ZBJ"&G1%33:FB8$6JHG#Y"(<<]ZW;U%_-COSY
M#DB0RW7+%,^T1NF0&VK[S:B"JI;M5\L!)XWR0Z%X*QB='F%Q>8Q?"BN"]*MP
M$4B;7%43)Q'.\2&'B*BB]%1,#9S>CGP8<"/0TT\GVQB3F9C+;LIQ'RG-O2T(
MW'-S)H`*1>E5)%VCX:8$LJ6T:LK5R)626)#O+ZZ<_):;<%'X)`PJFIZZN`VF
MY'!\`75-.F!N9XI<OVM0\K<MNR:L+0.16&YP!?@/MO*VT)[AW`1&PC6SJ&U=
M-NBX&CXKXS95-M1S'H4Z,<SC:-71RS>/=8,OM:=[N&:(YM4]J^8X%SRFNY?[
MB\LX+;=E#2!-:B5[K*M3&Y/ME0$CO-D@OM2"$!5#3<*^"^6!3E"L8$J1%&@L
MIM?+9X^DA\%/UD/<;D.O-JXF\FQ%I'P3[D^[7K@9\$#DT%GAT6SI[`7*Z';Q
MI9NBCBMJTZVD92<W*/[S;:]M/_A@3+:NNE^`W:^#6NK<'2BRU6]M4>%XFT'9
MV]55#%5_VX%;-K9\)SD%,7&I\^EEV;!1!CZ;`1^L13>;$S%"%)8*A[O2)%NP
M+2FH+\8/$)4BN>><DU#='RF))>1'FVNRAH^9;]"('`("V^HNY^F!MHZ*2'+#
MC63=DLFOG2)]?9,B#4`H3H$U'ADXFBF+31(*M*FN]-WAUP/H6`P&`P&`P&`P
M&`P&`P,%;9[J.J(]Y!44/1-VW754U\=-<#%XHH?O/*`]D5+NGHFP=/4NY?!/
MK@5T#D<69R&THP9=!^K:BON/F@HTZ,Q'5#M*BJJ[>P2%JB8%M@:GWU:5M$:-
MWN&@+VT1=B+KZRU5/2FF!DR^P^VCC#@NMKJB&!(2:HJBO5/HJ*F!Y(D1XS)/
MR'099!-3=<)!$4\.I+HB8&S5,"+)F/,S(<<(KKP2B,7)`;>VP@-J:$YJJ+H2
MIM3:B]5P).\--=R::Z:Z^:>6![@-?+SP(K<UPI\F*<9QIF.VTX,PMO:<5Q3W
M`&B[M6]B;M43[DTP-DJ6S&BG)<U)MM-R[$4R7]!0=555P.8@_)5/)J2F/1)<
M*<-@E05/)`1E^^)!(&41"4%W-FCB$A;=G77`E/<]I!C,N1A>FR71DG[&.&Z0
M*02V2MP$HZ*T?H5-=5+1$UP)5ARZB@\8_N9U_?4DRW(9=;12)T7]O9%L?$B<
M4Q04^JX&F)S6J?8]3;S$\97X]RK,4]R,KM]WMZ"2@J=K]Q#0MNWKK@1B^0J9
M8<:1'8DR7GV'93T%IM%DL,QS1J03S2DBHK3B["$=2UU0473`M)W(H$>A2[80
MI\5UMMV(,7:9R$?T[2-:J*+OWIIUP*J+\@U[T1M7(4J/:'-.L_#NBVDCW;;7
M?,!5#[1!VDWHXA[53SP#WR+0A$BRVP?=9?BN6$C:""<:(RNUUZ0!J)"@'Z51
M$4NB].BX$R?PSAUK,.UF5D:3)D-@+TE13]YL.K:.Z:(X(Z^G=KI@5E7"X:US
MNQC0ZA(ULTRQ:/3D1!8=*83K.]M$+;W/VB0BVHJZ^*X'7[AW;=4W(FJCYZ+Y
MX%#<<+X?:VC=K9P&7I[8HQWU(@4V]=1:=02$70U75`<14_3`O4)M"1I%1"1-
M4!--=OAKI],#U2%"055-RZJB>:HGC_VX&+,AA\2)EP71$B`E`D)$,%T(5T\Q
M7HJ8&2$))J*HJ:JG3ZIT7`]U3737K],#P2$M=JHNBZ+IY+],#W`8%1%Y-#D\
MHG\<%EX9E?&CRW73%$:-N21B';775516BUZ8%O@,"#=7,*GA#+F$J-F\Q&;$
M=-Q.R719:%-51/4;B)@5MAS!FOX^%M*KIHOFI-A5`TARR='<J@(H6U?2"DB[
MM%'K@'^;U+-5'L7&90]]@I90E9(933#2HCSCK):$*-*7J3JO^5%P+"9?U$2G
M2Y>DBM:0M&W)#4Q,7R$6E';KKO4QT_C@03YI4`PV2B][QR6M<%<@)[CW:-J\
MK6F[8G[2;]REMV]=<`7-J(*BOMC)T8=E):A,EVC)0D/.]@6WD!"[>CW[9*O1
M"\\"^P&`P/"+:*EHJZ)KHG5<"!Q^\A7U)"N8*&D.>T+[".CL/8::IN'KHN!8
M8#`8#`8#`8#`8#`8#`8#`8%?34%/2M2&JN,,5N7(=F2!%27>^^6YQQ=RKU)<
M"PP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!\JY#0\CF?(L&P&E<6.S8.L
M/36B!6W*Z16*RANDX>_09!*BM@*(GW:$OJP*2/Q7DDZD"!8<<F@ZSPTJ:6;S
MD<FW94<P(60V.&9J>TMI*FU<"SY)QFSE/\C.JHY#`A"H"X_VQ!E0<B/ODX+.
MTQ[9,MO;23IYIU3`MH]%?R;M#DPWHUM%OG9?YA"'LO52J?:;W`NJI[<Q9[:H
MBH:;NNFJA3\9^/I]/1</=8KI3-U^6:D<C>]R1N=MMN4*D^I.KW&_W41!37Q3
MITP,X'$;JEXQ2.U$&,QRZELYALPI#B-#*BRY+J/@)`>BB3+HN(2H6BCX:X'4
M?(?&%E_%UM10H*3'#BZ-P@3<AF)HXJ`+A$OW)J**6!2V/'^53K&:B0Q&UB7$
M*307"@+38U(FRX]'4FUW?MAWFR$D]6J+_`+KG=/:V-[Q\XC,MR(P%F,\XCZ,
M;0?@FTVG4Q3N$Z0]LM%VKUZ8'#)P/F46M]HT3S[^J/P;;VX(CZ)#)A8MS!5W
M:Z1A^TKK.U==#UZ*JA:6$#F35L`C02"66[Q^=)=A/-%'8*(\@SF][Q@9J@:)
MT34AZZX%QQ.BM$Y-[N\A31MZ]Z:(VZ.LI"E1I!ZM+L`NX2]O8G;,?00KHOU#
M1R/C=]*O^5.0%E5Z6+-*D*S:`)`=^*^\KJDP9_N-")-HZ&B;AUTZX%WP]+JD
MX$T$^D%BQ@]\4J*PD,#07S[:L=UQ4%'!T-!)STZZ:],"B=K[>6%7>PJ"5#E0
M;Q+.V@S":[[XNPSB/.1^VZZB]L7!V"9)T'3Z8&BIXO=T-J=^Y#>EMS4NA.&S
MM<D-%9SVY,?TZ[=NQK0]"]*K]-=`2>-VD/A=!Q-*^1/F<6:JK%9&@E$EE`=#
MO1VG"+=W402(!(4_EZX&USCEP7)V^8N0'$;_`#`3!A"@G*&(E2<#>HHJ:$3A
MH1!XH*?7I@5]%PWD-!R!WDYU[DUZV@64<JMI6U5AV79N3V`>-3$>H/J#A#JB
M*.!>2*B>E%0T'L'W9W%QJIRO,H@0WUBJC3S3#A:JI`"$2`2"J^GKXX$2)QWD
M(\W7FI0C",[+E(Y6DHK*&,4!B.VZB(6W>;L-/1KT$]==4TP(%;Q+E<"#9OE6
M^ZD\CII++L5XP-(\UZ7)DML.]43M:3U0E15V[-.N!U/(.+V/]BUM'7S'F)L`
M8;34P6PE)K'0059+)DWWF31%1P4ZJBZHFN!\ME\2Y"]'F(]QF3'LZ_BK$>M"
M$AE$:GLSWR%(N\E7NB!@XWZM6QU37`Z1^OOGN>K-'C\Z-%E2+"+-F1T%2<C/
MQ!".ZXZX[JJ;@U$$%!;71--VY<"D@<(LHO$>*')JK,ZMZ`4;DM7$;!;(K$VF
MHK,IT'T+7MMMD.\210U0DZ>`=M55'(X?.H+RLO3*H6_;NG8@#DF*HQ$T>8G`
MNKH.DFQQHT^_4DP(?.(%P?/*RQCTLN0$*96:3HPHYK&(GQ?]2FG;0"<3N`(^
MH?46[0=H77Q[7RJKCEVPY5NQ9*6MK(]LB(VKZ/27'FC:<31"0VS%$/\`P\L"
MF^'J^QA6=RIU4NHK9D6ND1H<B.C+02.VX,E!-3-UQS5![A.>HE3<OW8'-\=I
M9,[D'O:R)/.\K>5VBN6LE74BA5B^[W8S;Q*HFTXJH(MIJJ.?04UP*F)0<EGT
ME[[^@LH@6+/'W'(#$=]A1?8G$$T6S%]YYXACHB$\1(ICIY;<#[%?<+CN\%D\
M;H"6K)MI5J7&S-.Q);/O,GNUW*B/(BDFO5.F!P//Z/D]I1U;[M-*8O9T:<]8
M#`<*4VU-*$,=EH@U%M.YXBZNO;45TZENP*6VHN9SN/3G"K+$KG^W.,D;NTQ=
M.7!E$],:$A12-Y!)=11>NNF!;28]^ZX[.G4-M(X\[R.3)EU8M[GSB288-,O+
M'WEO9!Y"(F]-R*J'_*J*'5\HX_/C_$BTM"W8O&TS%;2.K^EB<49#926>\I?U
M%C[P^[]$P.<Y=Q`5A2E9J)4^CD75)-A5:,$XL?V[H).>%E=#%LF1T(53JNOU
MP.M^5:VJF<,?AS(,V0TVB/1':T361%>83<TZTK8N&)C_`"Z`7T5-%P*:K#F<
M"5#N+N%(M'SIYL!T6P%#-V/*)R(KS0(0@<J/IO7[1/HNFN!(<XY;P?CVEX[&
M8<DV7'4J)3P-BH,OI$DMN.LM.%H)+M:+I_#ZX$,>/WP\X3F202""[;:K%0"2
M1[-:SVGNC:U5=_>1$VH.[9HJITTP)$GCUY_9X"45Y9<WDL>V*%T-R.PY;-R%
M$]I$/[;2;BT71.N!:_,9(/Q].-2?%!D0%58I.`\J+.80D;5I1/<HJJ(B8'*S
MJ2^JE?<JX\[^R7[$7':MA@I<SMG$V&?MI:$YVO=HA$*>K^9$TUU"RX=Q8HO+
MV&Y"W,V!7TL`H$VU,T!9`NR-441V!WP:=$30AUP+2^J>0_WQ"N*]L)L!DX[,
MV')!P"9!>YOE0Y`N(BZ"6CC*@N[IYX'`<7HKVAIJHXM+:..O<9L&[:,7N&W"
ME)(95IK<JJC9B'=[2(FNWH/BF!N@\2MK%YFNF5]FE)_<XR66B61%:2MDU:FZ
M*M([N!E)7382^DET\UP.@X?1VC'-%6S9M&9E8_+:CN,@V-4]7N#I$0GB3N.=
MMH0'9N4A<157IUP/J.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&!$?J*J181K*1#9>L(8F$26;8DZT+NF]&S5-P[MJ
M:Z8$O`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$.MIJNL64M?&"-[U\Y<K
MMIHCC[O4W"3_`#%YK@3,!@,!@,!@,!@,!@,!@1+6IK;:`[7V48)<)[;W8[J;
M@+82&.J?H0HN!+P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!3VO)XD%FQ)MIR4]6(RLEEM$33W"Z
M"B$:B.HCZR37PT^N!MM^1U=5`6PDN;H+;P,29#6ABRIFC>YS1>@B9(AK_+XK
MTUP+/`8#`8&B=+&'"D2S$C&.T;I`.FY4`5)435435=/-<#G.._(M1=6$:N6/
M(@3)M8W=1&Y*-Z.072$$<WMFX(J)&*$)*B]<#I$G0E5I$D-*KZDC";Q]:C]V
MSKZM//3`I(G,X,ZVF1(0@]"JWSB6\]7FP&,^#0NH)`2H2BJ'MW)_-K],"[69
M#1IMU7VT:>449<4QVFI]105UT77RTP-?Y:JVN%[QC:TH"ZO=#02<1"!"Z]%(
M511^N!!Y%R>#1MQE>3O/2I,:*W';($<_U3XL(YM(D50`CU+37I@.0\B_%'#C
M,1"G6-@9MPH@N-,[R:!7"U-TA1/2GEJOZ8&Z-R"`;\.')7V-G.;<=8K7R!'U
M%E41Q=!(D7;N3P7`L!=:(C$3$B;5$<%%15%535$5/+HN!33>5Q(][253;121
MNUE(U-:("9;*(WW"$NNJJ75$T3R77`N6G6W6Q<:,7&R343%45%3]%3`@W5I(
MK8JR&:]^P0!,W`CDR)"("I*O[QMHNNFB(F!1-?((.55':+526H=_(AL0B<-C
M<@3@5QMTA!P]$%$3<GCUP.J%]@FA=%P2:/10<14450O#1?!=<`\\RPT3SS@M
M-`FXW#5!$43S55Z)@>H\T0@2&*BYIVR14T+5-4VKY],`KK2&+:F*.&BJ`*J:
MJ@Z:JB>>FN!X<A@-Z&X`]H=[FI(FT5U]1?1.B]<#$YD0$:(WVQ1\D!A5(40R
M+P0-5]2K^F!Z4F,+X1R=!)#B*0,J2(9"GBJ#XJB8$6!>TT^O;LH<UE^`\1`U
M*`Q5LB`U;)!+71=#%4P)I$(Z;E1-5T37S7`\%ULMNTQ7>FX-%1=R?5/KXX!Q
MUMM$5PQ!")!%25$U(ET1$U\U7`K;J^:JGJMHV''ELYB0@)O:@MJK3CRN.*2I
MZ1%E?#KK@6/N&-@.=P>VYIVSW)H6[[=J^>OE@9;AW(.J;E151//1/'_MP,>^
MSWD8[@]]14T:U3?L1=%+;XZ:KXX%/6<G_)VCL>%#-^N8<?CNV@.-*V,B,H(3
M:@A;^JD2(NGB*ZZ=-0D7_((E+"&6\T]($I,:(K<84<,3EO`R!$FJ:"A.(I+]
M,"P)]@10B<%!(M@JJHB*6NFU/UUP,\!JFFNO3ZX#`J^0<@ATL)J0\BNNRGVX
MD&.*HA/27UVM-H1:"FY?->B)@5$SGX5U51R+2HF1+.^E)`B5'[)O#(47#07#
M1Q&D':TI;MWA@7''.1UO(*WWT%200=<CR6'4076)#!J#K+HHI;3`DT5-<">_
M(8CL.OO&@-,BKCIKX"(IJJK_`()@5/'.2I>(ZZU!?CPE;CR($YS8K4IF2UW!
M)I1)5U#P,23I^N!=8#5/#Z^&!4V7(X\"]IZ=QEPW;DI`LOBB=IM8S7>43777
M<0_:FGDN!#N.:Q*ZRE5S4&78R8$5N;/;ABV9M,/&8-D@&8&XJJT?I;15Z?P1
M0O&9L1YYQAIX#D-"!O,(2=P!<U4%,/N'=M735,#=JFFNO3ZX%,UR9ESF$GC/
MMW!>C0&;%92J/;('G7&D`4UW:BK6J_QP+G7`KN1WC%#06%W(9=D1ZV.Y*>:8
M05<)MH5,]B&0"J[4UZK@25F;H[;S#1/H9`B@"BA"AJB*2[E%/0BZDGC],#5<
MV\:IJI]D^A.-5T9V6\RTB$ZK;0$:H(JJ:JJ"J)^N!)C/A(CM/AJ@.@)BB^.A
M)JFN!5V?*JZ!+K8RH<C\E.6M%UA0,&9",F]H]J2*/I:5.B*NN!;=UK8)[QV'
MIL+5-%W>&B_K@9$2"BJ2HB)U55\,#%76T054TT-40%U3JJ]4T^N`[C>_M[DW
MZ:[-4UT_A@>>XC['#[H;&E5'2W)H*BFI;E\M//`P2;#5@9"/MJP::@]O'82?
M5"UT7`Q?L($=N0X_)::;B`KDHC,11H$'<I'JOI3;UU7`Q8GB^\VC+1N1'F$?
M;G"H*RJ$J;13U;]5%=WVZ:>>!(!UIP5)LQ,151)15%1%'HJ+IYI@>B0F*$*H
M0KU0DZHJ8$&9<Q(DR!%-",K!UQAIP-J@)M-DZ2&JJFG1M4Z(O7`G*8H2"JIN
M5%5!UZJB>/\`VX'./\YA,R%9*#+U"U;I7"06]$>>`#;=^_56E1Q.J=4\TP+*
MPOH<"S@5\@3$K!'E;?\`2C0=@4)4<)533=N]/3`L%=;0T;4Q0R^T%5-5_@G^
M&!X$A@P`P<$@<Z-DA(J$O_"OGX8'H.MN*2`8DH%M/:J+H2==%T\%ZX&6`P&`
MP&`P&`P&`P&`P/GTB@LG`YO7-1E<FV$QBQA/.;0&0TC+""V)HNFYLHQ-IN7I
MT5>BX$"QXC8A5<WFUU:-:O)HS<.#2J0;?=DALK.<%I7&FW'%>#=MUZ-H1+JO
M0/ID9MQJ,TVX:N.``B;B^)$B:*7^.!LP&`P(5XU(=I+!J,TKTAR,\++**(J9
MDVJ"**2H*:KTZKI@?-K#XQ#_`)3E$:I$F\K=IH5>_'D254R6-VR*.+YF8M-]
MP570%0?]V!*F_'YES&(^%294#@0WHC<.0W#;K),5\GW-S(;5-'3-#U:UW$FT
MDV]<"N9X;S",_?SV*QQE7>3.VGM(TIAMVQKG(:14!'%78BBXO=[;VB=--45=
M<"5`^+:R18P&K+C#"UK-+(81)CP34:D.RT>;9U+4E(!W+N%-H:[073`H*/XB
MLJ;AO$H[E"U+E167XO):Z*\PPZZY(#LC+[Y>ETF6]PZ;D7:?1=4TP+.WX1R5
MNP6,''F;EIJRJ)])<.R&N["C03CB[&-QXD?W`+#AB0(2'O7=UUU#N.=T,*\B
MPH4^B_-0E>4W'&W19DPS%LE;D,&1-DA;O3J!H2:Z]4UP.-8X'S,XE$Y+U>M(
M]7<5;5B\XV]+KUGF!0GW725>ZXRRUVW#;554EZ:HJK@;[3A_)K"&W*@5H5IQ
M8$1B;1DXV+=@Y#DM/(QWFU-.RK3;K0D:=4/JFFN!&Y#P_E<Y>.GQND9XO[5Z
MRF/LME%(&S<806FI+;?ITEEJ+BLJ6U//5<#O.)2+%(,6$_QQ>/QF(;2MQQ>C
MN,M'N(%C`C!?^&(BJ%M1%1?JBX%G=(^M1-2.R4E]6'$:C@HB1DH*@BBFHBFJ
M_5=,#A2XQ>/<%X'5NUY++IY-2MI&(VOVPA-['B54/:8H0]-JJJIY8'(+\=<G
M1IIJ3QZ3(I&I=XRM'!L&86R/92D=COL;'`;(!9W-J!$)#KTZ=,#Z#R[CDZ3Q
M2FI(5<DZ,U(AM36GS;?=9BM"J$X*R51MUP%04U/7S+0E1$4/E-U7VM-QBIXM
M>,!M.LGQ)T9R7">DQXASE6,]'!U^&VI@V([2#7[438.F!)DV=#8<P;UA+_;S
M4^G?BZ)'2:T]&8;`(_MWY#,AH$-P$-MM@NFY=?4N@=47!9[-:]:UE`<.X*YD
M2;.&,EH9-A!)YY6Q&2IF"('?%T&S5!W#M7377`Y+ET"MJGJSC\6`,=':F<EI
M4V$Z&Z]$C3Y2'WF$DR6&^_O`MI-D0CX>0X'4N4/)9O-::XAT)M4T&PC/QGP>
MB)W(3E:497GE<+W/<:(T%6T].U-4WDNN!ST'XJY(SQ^EJK:B?LJN'%GUTJIB
MSV6-7I$E74G;E(!-M]LM-%_<;T%1377`^C\ZXH[9U7&8;5>L]*RUKWWA[R:M
M,1U_=<57B'O)L]*HO5477`Y:-Q?FT&-6E'IC=)EGD-:<9)$<.RS8RQ?ANCJX
M@H`@V@[1ZCX:8%4]\:<E>XF_#=HR.P3B-=61A60QN&TANN+N%Q'!03;W`:.)
M]-$7`MIW`K1J^=6)1FO'6;>MG)":>8'O--UKT:0J`;B:Z.FVC@&J;T1?NU74
M-$OX_NHE/%K%I)%AQ]_\E'2BA3@8*&U.DHXP)$X0-JT+:;=07<UX#N37`ZOA
MO#1A\LOKN?6=J63L=BIFNNH^?M&X+#!B!;B)$)QDMVY$4NBK^@5\OB=^5Y*)
MJ(A6SENS8P^3JK8=NN`VU=AF0JKJJC/<9$-NPD)"5?'`N?C?C\VEA7@2H#<%
MR9=6,R.(=O5R/(?5QDR5I2_E+31>J?3`X*VX7RYFG=B?CG+.)82:PC?/:MG'
M&-:"^Y'>=;<;%]EAKN*V\@[]%1-%\@\M^(WX0+RI:XV])A3+6W6J)E6-&&Y<
M-OM$VV\YV@!V1W-QJFHZJHHF[`DQ^%\JL&N2(5>[$N)-#6-U5C(<1%:L0A.,
MR!!X3,A-.X@DX(Z>/JP-CG%[LZ!]RCI+&EFS9@D]&G.Q9C1N!&)C61$0S;*,
MXNC9JV0GX.>6N!U]U7<A7@=:R$`"FPDA.6-)"<U!YIA1[\5EUU1U'1.F[[D3
M:OW8'&V''+L6&9#5-(<J9?*X-I"INT!G"A,M`,APFU)1:0W1(]@KX%X:JJ8'
M2_*-59R[3@S]?"D2F:N^:ES5C"BJU'&.ZTIEJJ>G<Z.J)Y:X&'(.%US7(^,1
M8%,;M0]+LGKM6]29_P!6R9D4K<>I]R00KU1?#RTP*'BG&^0QH%[^:J[-SD\2
M)8L':+(;=BV"2B5QKL"A`1J6@[1<!.WIMUZX&J%PF9)A<=K;>LMOP)5-?&8K
MH3C41N!/BJ1/./H!@Z!$NBHZV7AJ/FF!'M>"NR:7E$IWCLV1;3^3`39;OWCK
MAEQR(VE[J:,JRT7I14_A@6T[A$MOFS$`8UHUQMAR'(H`JBB,U\0F"WOA(W)W
MQU<'>NQ?6A;<#5Q&AY"'(N,OVG'GVK:J<LVKR]$FDCR"D"JB\/[RNN"ZNU14
M@79U'`M/DSC4V?+*UI:V8QRV$P(4%[7N-AO<-2UC3$,A18R%H1H8JFFNU=WB
M$:5QKF`<JY!9A#W.S6J-XI496A%]N"Y_KX3:N$+@]T==J%TT\2P($ZAY=%L6
MKF+6/SN'.39+SO#6A:8DBW)AMQD+M$8M$GN$<<4%--$/=XII@.0\&Y0SRF%+
MIJ6/,XI&K:V%/H91MN./ML2C<5MEYQS5#B[A<3>6T]-NN!W'/J2PM>/M2:EE
M%OJI]FQJ&C4!19#*Z]DR+44%T%)LE\M=4ZHF!Q@?'G)6.,\OJ783$A7&+%>-
MDP:(IO7#"E)#]Q1[8-/$K8;E^S`W/<*N1GSO:4W8B_F*"UCJ+S6CBQNT,YQ!
MWIL<$`421>A^*:JJX$ESCEX[07\&31.2+]8%K%CWBO,"$U9BJK8Z"\C@[O1]
MXHC>W05T\0O.%4,JFMK!H*]858["K485%;42D,M&V_J@F1;D'MHI*G73Q7`H
M$X1:!+9;_&[XW]X/7#ZJ3&U8CT9T>ZNA(I)W7=-JIN_33`UP:/D,/C<>@L^.
M/V=-).;%]C'>B@<,#FO.1G4(W000&*X`@K9;FU'1$P.GYO33Y2T+L>$MM`KI
MG<LJE3;_`'V2CNLB2H^0MN*TX8N;37KITZZ8%!9<'<5YVN6F)_CDBD"NK(C;
MR$D"2CKBJJBX>HZBXUHZ"DH[.FB:8'.\OX+%B\<YU=<CK(\FV8IV5B7Y;5)Y
MYJN1ITVE(E)DN^'0>GDOBN!/=XQ:;Y/(:NEE1:U^362;+C6K8.3BCHX,M[MB
M>S=M=;514OW5:Z]%ZAK>^,6)=M3#9\<&91_FY\N/7&K9,P(,F&@H+C>\0VG*
M#N(V(D@[OTP-+/#.3/W%PLFE<:6YJ[RL5=8ZPVR=>`XA&>XGW>\"?U'-51?3
MM$4P+2;Q?E2BP]4P#C2V>.0(I$CC;*FY&E@Z[!0D)=I.,BX&_P"U-WC@>N<,
MDVKK<V)2+7U4V]@6,JHE=MLT"*T33[SC(D32;R%OT"J[M-R^.!?\5HYD'A%K
M4N09,363:#$B,NMMNI'?D.FS[9Q"V-?MN)V]53;@4=3PFS-JK;MX(VT9F].:
MY(D`VS(=96`3#<J:SJ#9O"ZNPMJ>M$0]-=<"C#AG.UXO`JQJGH\F*PRW'=1^
M,9MBW;*_V#=)TU$&XH-J/:ZDO12]*)@=DYQ^Z*RG/C#<1MWD<2<!(ZT*E%:C
M,M&[XKZ4(%U!?4J)T\<";S?BRWTZK5R`S-B1FIXN][:2"3\;M-H@%INW*O\`
MA@<O&X[RIR90*54_%?@C3+-?$HB@21D()&]PG''?VT(D0&UT5"5=24E3`M7N
M`6S-5R:JK#CQH4I9,GCH`@BC,B:U^\)IVU5M$=W[3!==KA)IT3`ON(5+;/O+
MEVI<IK6W[)6<(W@>'N1V^T)CVB-OJ/\`,G4D1-WA@=%@,!@,!@,!@,!@,!@,
M"&Y=4S4PH3D^.$P1)PHQ.@CJ``H1$H*N[015%5?I@:;#DO'JZ([,G64:/&98
M26XZ;H(B1R7:COC]BJNB%X8$"#S2KD7]G3ON-17(+\:/&-UX$62<J,,@4;`M
MJZZ%IHFNNF!<A8UYRSAA):*6T.]R.ABK@C]2'75$P(XW<%]UD(,F-*0W!!Y1
M?#4$-HG05$'=N(D'5!Z:CU\L#12\NXQ=@T55:1I??1TF0;<'>8L.*TZ0@NA*
M(FFBKII@2)=_1Q*M;:3/CM5:**+.)P>PF\T;']S7;U-4'Q\<#<=G6A+:AG*9
M&6^.]F.K@HX8IYB"KJJ?PP$F9V)+#2]I`<1PG2-Q`(1;'7<(*GK373=U33`C
MER/CP,'(.SB"PV1`XZK[:")`".$)*I:(J-KN7].OA@;TMJI3)M)C"F#HQR'N
M!JCS@H8-JFOWD*HJ#XJF`8MJM^6<-B8P[+;0B<C@X!."@%L)5!%W)M/TK^O3
M`UC:M).EQWB9:;C"TJ.*\"DJN(2JAM^(:(&J*OW?X8'D^]JX5$_>.2`.LCQR
MEE):5#`FA#?N!1U0D5/#3`YRO^0CFTU5/"O!'KZ5[2F:;ELR&G41HGE=.0QO
M;$$%ISH.Y>FFFJZ8%M'Y?6.\<FWI(;;%;[D9S):(8.PB('V]24154)M41==%
MP*I/D462EP[*M.'>1PAN,U:/-N$\-BZK#"@::>#HD+G3TZ>:=<"8SS9@W&X1
M12"Z<FNP/QRF*JCC+/N#/N)JG;[*B6[3^9!\<#='YG5GQ%[DTA"CQHC3QSV"
MT)QEV,I`^PNG13!P"#IXKX8$)>>JR+[$ZK>AV@'";C0C,%1\K!5%E`=Z#JA`
M:&B_;M7QZ8&EKY';>FLU+-6^M\Y,E0G*\R$$;]FT+YO$[U3M&#C?;+3KO3HG
M70.BH+EFYJ(UBT"L]X51V.:HIM.@2@ZT>G3<VX)`6GFF!SG(>3<69Y+1M6L2
M"_!DLRGX=_(<CJ$9Z*H*0(KB>G<A_<)>*:8%](;XM^8BR)(P?S+@[83SB,^Z
M(/4NC1+^XJ?=]OZX&TN1\?'NZV<1.PVCK_[[?H;(E`3+U=!4T445?/I@1+6)
MPJR=@O6S-;,==(/QCDH6'2(B15#L*YKJJIN4=N!<FXVTVIN$+;8)J1$J(*(G
MU5<",%O4N!(-N;',(I=N40N@J-'HB[7%1?2O7P7`Q<O:1N,U*<L(P1GT%67R
M>;0#0E01425=%U541-,"6KK0N"VIBCAHJ@"JFY4'QT3]-<".-K5E(;C#,862
M\*FTRC@*9@BZ*0CKJJ:X$6DY!%M83LI!6,C4B7'('2'7_1OFP9ZHJIM50U_1
M%ZX$YR=";)@')#8%)72.A&**XNFN@:KZNGTP.?YGS=KC9P8K<,["SLM_LH8&
MC?<[1M@:(9(7J3OBJ#IX;E\$7`QM.=QJ]UP'(;I%!AM3[EM"!7(;+Q*([Q%2
M$B]!JJ(7@*K@6/(>2PZ6/$(A61+LI`0ZR(V0H3[[B*2"A$J"@H`$9$O@*+_#
M`KRYU%<:9;@Q')5L[[O_`.E(0`ZBU[@MR44E50U$G`VIKZMR*G3`W_WK5N%Q
MLH@'*B\F<)N'*#:@AMC.2M7$)4+J+*CT3Q\<#H,#3[V&KP,]]OO.(1-M[QW$
M@+H2HFNJ[5\<"IA<M@2.3V7'W!2/)@A%<9<-QO22,L'#3M"B[O1V21>GZ^&!
M8Q9SCJS%?9]LS&=5L'2<;)'`$4)7/0J[$U54T+1>F!5N<SJV.4'0RB&,OLV)
ML>:ZZV+3R2'B8%L-2W;]P)_'5-,"]<=:;1%<,00EVBI*B:JODFOG@:V9D-XD
M%E]MPB'>*`8DJCKIN31?#7IK@:V+:JD-*ZQ,8=:%Q62<!T"%'4716U5%TW(O
MEXX&4N:U'B29']1(H$;@"J;O0._;^BJF!!XUR6OY!10;>*2-A-BLS.P1@KC0
M/MHX*.;55$5$+`L8LR)+9%^(^W(8+[76B0P7^!"JI@:(UFV;(%*V1'G7'&VV
M3=;)2[;B@BBHJJ+N1$73Q371>N!O]Y$WN!WV][6G='<.H[O#<FO37`%+B`#C
MA/-BVRNUTU)$0%Z="77HO7SP*WDW)ZV@X[-O)!"['AQG90M@8(3R-`I[6U)4
M15)$Z8%@]+1N.V]HFCA-IH1"&B.$B:ZDJ)T1==//RP,TE1E=1E'@5Y==&T)-
MWIZ%T\>GG@>N/,MJ*..""FJ"*$J)JJ^")K]<#6D^"KCK22&E=8T5YO>.X$7P
MW)KJ.OZX&(34=EHRR@N,["(WQ<%=IB2#LV(N[_-U\M,#-)D-6B>1]M6A54)S
M>.U%'[D5==.FG7`W(J*B*BZHO@N!@DAA2$$<#>2D(CN355#[D1/T\\")+N:^
M%WW)DAF/$CLB^])==`1$2)112U75$Z=%7HN!4+R*AM;JUXQ9,QR;CI%$&Y1-
MF$OW0&Z*"T::%IV2Z=?#7`O)MA75L59$Z2S#BAH*O/F+3::]$3<2HB8&T9,8
MDU%T%3=LU0D7UK_+_'],"LY%R>OI*2TMG$64%0TKTR/'("=$1'<J:$0HB[>N
MBK@3X-E7V#1NP9+4IMLR:<-DQ<07`^X"4570A\T\L"JE\QJF.65_&1)'I\YN
M0Z?;<;56$C"!Z.ANWIO1U-OIP+3\G6]J0[[MGMQ-?=GW!T:T'<O<77T^E=>O
ME@8#8B4O:/:6%[=)"2T=%?%?,/\`*H^I#UTP-GY&OVJ7N6MJ::KO'1-R;AUZ
M^:=4P(Y<CX\,.-.*TB#"FFC<.4K[2-/&6J"+1[MIDNBZ(*X'C][!%R;&C.M2
M)]>C2RHG<$"#O]6MRET'>B*HZ^.!**P@#,2"4EI)JM]Y(RF*.JVBZ;]FN[;K
MYZ8&$>VJI#[S$>:P\_'$3D--N@1M@::@1BBJHH2)T5?'`VQ9D26VKL5YM]M"
M(%-HD,4,%VD*J*KU%4T5,#;@,!@,!@,!@,!@,!@,#YE.XKSB7\B,6C\:.Y41
MI\AQA\7Q!1C2*Q8@KV$:0B<1U?61FJZ:;>F!1C\;\WE4+<!^#%C/,<6_`(7N
M4<4Y$=T#;+5`3]MU&^FOVZ]<"QY7\?7MP?+)(5,<IEJ_32ZM\W6T=%8*LJ\T
MIZ:AVU:)1T70M?+`M(G#N1GV(4AEJ.%5:S;"/9@ZCKDUB4#Z`#O1LP<)9*=W
M5%'T=->F@1N+<%NJOC?QY`6L8BR>/R$<N1:=`D]$*1%[J&@CW%,WD/33HFN!
M$?I)]5QWBM5$*)5\UK))LTS&Y7T=B*9,OKH*;D:[!H\0KZ1(115\,#LN:<>E
M3>&N5=5':>?9.(\Q%)&VFW/:R6WR#[5`-Z-JFNWHN!12>+<KFS7(4IAE8RW<
M>YC72NB3K3#3@/+&[:")(8[%8%47;VRU5==44+'EW';:UY74OM0F9-.U6VL*
MQ5UY6E59P-(VVB"BFB$K.A$G@B^&!R]E\7\G>K/;QYCJRXC[KW'K%UUHI47=
M%1A6IJDVK<V.ZH[%WHI]O3754Z!(=XCSO\I-<*'">;EV=%:.R6I"M)K`98;E
MM@T31::'&]&J]1+Q14P)/`.&7=7<-)>T\=TJ?WX5?)$G.O.NM3'T/I%,=&B<
M'^IZM$5.GBN!NMN"SK?D][*DQ%BQ);M25?8Q)?9E"Y!%]2EH@@0[VR>0$$]4
M,?'Z8'05#?):CA49E^$Q8W<1I&UAQ";BLN:'M3:I(C8?M^I4TTUZ)@4]?P>5
M7/1[.NCMQ3"W?M#JE4=@,RHWMWFFE']L#4D[RZ=%+=U]2K@:0X??%Q*?Q:8P
M#R\B&U?L;)ET1:BOSG#=;;1LD[AC^YMW#]/#K@1K3AG);JSD<CD1F(MO"2L&
MKAJXA`Y^/D+*?4G!1=HODXH`B^&U"7QTP)<7B-V-]_=[T</RWOY+OX\##583
ML4(K0$XOH[H^W`]4Z=5'KXX'KG!Y\SALWB,QM6ANFYDV;9,N(K<>;*E>Y[(M
MZBX8(;BZ+X*@Z+XX&%MQ/DUK.>NW&VVIT:55.PX"NHK3@UKCINEO1%V=WW1H
M.O\`E'7Q7`AU_$>7P+I.7K$;DVTFPL'9-2CXCLA2F6FHXB\2;.X'LVE+R]1:
M:Z)@=#$XHXWP%RDE-G[N8#KTX(<A6323+>*0^K,A$!1VNN$HEHG\$P.);^-.
M6OO5[-HQ'L(T%F]1)+Y-(\Z<\1;AD^C8["D*`EWGD'Q7SZX$*#\><]C0Z!IZ
MJC//T[=!M="4`;OQ:C[A'242)P_N1M?MVKX(6NH6<'X^O87&:QV/11&[:#<2
MITVO!]ME9,5]V63`)*;'[F/>"8;DZ$'ITZ+@2'?CNY9N:B?2P1K$A+`[T4Y?
MNX1L!)<?D-.M/B9=YGN$;+S:(N\OHF!T?-9DB;\5<H>GPU@O_B;(78KA@YM4
M&'41=X^E4735,#CX_"+-UAF[I..5[3$B-2QW:>2K"C(C0WTDG(W-;VN\`D@M
M*2KX:Z^"8&SBGQI;#:<?/D=-%DQJMR[<-R4\W/<$I\QN3$+<X"$1"@EJ7BB_
MQP.QYWQ>VM7*FSHW6V+NJ?-&'7B,6_;RP5B3NV>I2$"[@)_G%,#EKK@-Z%[$
M2JIHRU59.IW:YV/("(ZD6O$T=1\MAFZ0JZ>T.@J)?YM<#4_P;F#EE760P65]
MK-Y`DF(<D0%R/<=6'O0*CZ-J"8KZO--<#*DX=R>%"IJBUH@L:A^)41Y,9F>K
M;=9(JE(E>#781B9(!IV^NY-"U3K@=3\F4OYJC&M*B=ND)P'F3CR&HKT9]IP%
M!UMXR$FSVJ6AAU333SP.=<X+S#\?8,S#"RL.24<:GMIW<$.R^SW6R?5%1-Z*
MW*5?0*>H/#U=`Z+D5+<OS:2="BBXO&IPNLM$8*4N.[$.,\H:[4;<;[RJ.Y>N
MW]<"CJ>'7=/>L\M]F<J?)*V6=5M.M(K83WFWXZ"1DC9*'MA`U0O$]>HC@2H_
M$+:IC?'M>PT4X*&2:V,@%`!;`H,AC?H9(JIW'A30=5TP.R@6$Z186$617.Q&
M(AMI%F&;9-R@,-RFV@$I#L+450T1?/SP/F]M\:\J+D(3*@X\1BNL'7*F0CG;
M=&#;M$EFVJ"V75J07?912ZET71$3`<CX7=+>74FNI=^A<>;HY0&PABW7R"<D
M*A&0FTC8EII_-Y:ZX&MOC7*ZN]F64;C_`+V!_<,Z4_6"]''W46PB-LI,;WN`
MWO:(#$FW--1)5\<"%S/@-U-6V&OXPWV0XU$@4+#3D;2/-"4;JMLF:AV^SJ!(
M>FGIZ>&F!V7R;QB?R"+QB.Q"&<U"OH$VP;<($$8K*.(Z9">B.="TV^>N!Q-+
MPSEM/%KTKN+,A-B2>1[!<<C`R+,SN.0@)0+=V72(`4!TVZ:JB:8&J)PBP"HY
MG_=+(T59:-5<RF=?<B:1[&'&T51;CKVP('F@T$4]0Z(FN!]2I*N6UQY]YU@6
M;NV;*78@)*HI+>:05!#)-=K>T6QU3[4P/E4?XCOW>+Q&ZZJ9X];1J,ZVU`'0
M!+*2+C!"#AL*6YLA9<T=/U#O\--4P/JW%*V.RQ+F_A/P<FR,')D-7&W-3;:%
MI%T9(VA]((GI\?%>N!\[A_'G)1@T[46`M;85LB83)..L/0%C%:G*;C/LBIF.
MYE!)MUKU"70NG3`D/\'Y>TYR"3&B@[#G1WG6:Q]6')02QEC(%F-+T#<P^@J6
MUY?VR5$3HF`D<3YM)MY5^5<0Q"N&[1>/^Z:%R1'6L"(HGINC]YIX=^PRV%_G
MU1%P/.0?'UI^)M:6MHP?J[*A.%31C>:-*V8/N'2`U=+[7C>;03;W;5%$Z"B+
M@=/\A4-M=<4K&8D!)-A$L*N<<170!12-);<>VN%H"J((7\<"DJ."6T>ZC62U
M;,=UCE-A9.O;FNX<"7'>;`Q(-574W1W`JHO3`O.4\4MK#E$"UK30"C+$]TS+
M[;L%]EB4KI)VU$G&I+*$ILNAIUZ%T3`Y:T^/[&UX=<07>--L\D""Y5PYA2P-
MB4T;C1J0JBZ@)JTAKO;11+73QU4)W)?C^Z;GVTOB,./5G)HFH<18SB1-)3<Q
M7W&U)H=1[C9;>XF!E.X=8VU6+E35O\3LYLEZ7+5UR-,!7EC(P0S(RF\R\S($
M-A;"W>!=%5<#NZ5^S*.+%A"2(\PTPA&T8FP9DTBN(SUW[6SU'UBFOC@<';<!
MY(W?/650+"K`LOR5&;AB"BEFVK%LRN@+I]RO@2KU-=%Z)@:^5<(O95IR2-60
MM\2RX[#A1)CKC7;.3#D/%VG1+4]Y`Z.TU3;^N!'Y?Q*ZLY]Q.CT#A/)(X](@
M*AQ6W52!*1V4+#J.>@FVS)-5TUZHBJFF!T/R;0WMLQ"<IF72FQ0D*VX)L&P2
MN`(^VEQ)"BT\Q(343+7<&FH^*X'/RN+\R"[%ABE!R(_R*OO7YS<AAIAIEF(P
MPZV+:KW2,39)=$'333KXZ!ML..<EF<)NJ)SCH#;C52JUJT;=80)CCY:HK0[U
M(0<T[CG=VJ)=$0O'`Z;BE).K.7<G=]BD.HF^Q.`3:M(TXXVPK;Y(V"ZB6HBB
MJ0IJB)@<C,X=S2=)BQTK&X3\=JZBR;QM]G1T[-K:S,`4U=4MPCW!,445\-R)
M@6$#@;KE$VZM9-I>1O%%;F36+%9+@+"9,&9`JZ;C;[8*:CVW!3<*^I.F!3VW
M';^NC2+&^CQ@!.(K43YD1QF+'*6CZ=ID1<]*"8N:#O'8/5-41<#-OCKG)8CL
MA./FDR?;TUC8RI!0"CNMUYM-.]DHK\D?VVV2]"EKZE3KUP,G?CN]:HKJIATD
M3VEB[R$H(*;6^,L]L5B*WJNQL''$)2V>H5V^";L"ZN.*W;U=*[%8VY+?*DD$
MBFSO,X#S9/"1%J*F`!Z275%\L"0SQ*X>G,C.;%Q^'>2+./;D:$2P7E<)(Z?S
MZ['O;J"^G8FNO@F!R]-\4V,.-4,/U0M`S03*FS=KY0L/DX[,9?81HDVIZ19(
MD/R5=/K@=SQ!OD%0RS57"^]*0_*<8LMK+3JM(HFU[IMK:)/$*EO,$T735>JX
M'5X#`8#`8#`8#`8#`8#`JW>5<99M6:EVUB!:2#)IB"KS?>)P!0R!&]=VY!77
M3Z8&43D_&YK[L>':PY+[*HCS;3[1D"DJHB$@DNBJHK@5=CR\BN8%11I%G2+&
M#*L&'CD(+2A&)H!0=B.*2.&]IN3PT7QP+0^2\>:1[OV<1I8W;22AOMCVU>35
MO?JJ:;_Y=?'RP)(6E8XRT^$MDV)&G8=%P%!S45--A(NA:B*ET\L"+$Y%QJ:I
MN1+.%)5ELG'#:?:<V-"J;R51)=!1?%?#`EM6->]O[,IESMGVW-C@EM/;OVKH
MO0MB[M/IUP,QF1":9>%]LFI&WL.(0J+FY-1V+KH6J>&F!L(A%-25$3PU7IX]
M,"K=Y3Q]JZB4IS6ULYH2'(\<=2U&(HH_N(441V*::[E3`\G<MXW"8;??L&5;
M=>C1P5LNZO<FD@1T5&]RHCBEZ57IIUP)I65<!D!2F1,2("%7!14(`1PT5-?$
M07<OT3K@4-9S/WW/+3C`,-E'@U\.Q9GMN;T-)9N#L(431/Z2$.A+JBX%^-C7
MEOVRF5[3J1W-'!7:\6FC1=>AKN3T^/7`I+CF4,./VEE0/1+>15:=]@)`(`JB
MB1H9CNVJC:J2)Y^&!=E8UXN"V4ID7#=[``K@HJO;=_;1-?OV]=OCI@8,V]4]
M(<C,S&')#(HXZR+@J8@JZ(2BBZ[=>FN!);=:=15;,3024"451="%="%=/-%3
M1<"#,OZ6+)*"[8Q&;#MDZ,5Y]L'-HBI;E!5W;40555T\,#Q+ZJ9ALOSI\1A3
M::=,^^':T>Z"0&6W<!ET`M/5@5E+SBLL;VXIG38B3*N:,)IDY#:O/[F`?0Q9
M7:8_>J(G77153`FU?+>/6=45M$FME7"\]'*2:]L$<CNDRXBJ>FB(8*FOG_C@
M6^!"_.4J.*VMA&[@@;I!WF]R-M%L<-4U^T#3:2^2],#)^XJ8[<EQ^:PT$)12
M61N`B-*:(HHYJOI4D)--?'`J)W+FF+ZEA,=AZMMHLV4MBCJ;02&C1(J:(HJ!
M(ZNI;NFF!`O^91=(%(VS!F6UU"<F,PY,@?9.L-*VCH=_8>_>CW[?[>BZ:KHF
M!>UMQ6I50G'7H<07FF^TTR^V;*(>@`++B("&*KZ1T'K@2W+.N:5T7)30FR!N
M.AO'<(-HBF2CKKH.Y-?XX$.LY+5VB1'ZZ2Q)@3(GOFI`NHA*T2BC9]I40MA:
MKZO)4TP)/YFHVR#]]'VQ31J47=#1IPM$0'%U])+JG1<#9^1K_;N2?=,^W94Q
M=>[@[`5M=IH1:Z)M)-"U\,#:Z^RRT3SS@ML@FXG#5!%$^JJO3`BE=TH-,.G/
MC"U*36,XKS:"ZFJ#^VNNA=3%.GU3`@VG)%@<EIJ98W<;MPEDDON(/:**V+FB
M@J>I#0EZZ]-,"0S>Q6833MP_$KI),]]YA9(&`!N0=R.$C6X=21-VU$U7`V.W
M$0X\DX,B-*>BFC3K??$1!Q51-CA)OV%ZO!4UP/!Y#1%[S2>PB5[R1IQ$X(HT
M\H"YVS551$+:X*Z?K@8.<DI!G)7#-8*P.&5@U'4T3=%$D#O;NH[-RHF[`D-6
M<7M1?</,L/RQ%6V>Z);B)-=K:]-_Z*B=<#$[NF":,`Y\89QGVPBJ\VCJGM0]
MJ!KNUVKNTT\,"0W+BNO.LM/`;S.G>;$D4@W:Z;D1=4UT7QP/&IL-YYUAE]MQ
MYG3O-`8D0:JJ)N%%U3[5\<#*/*C26^['=!YO<0[VR0QW"NTDU37JBIHN!1CS
M.M/F@\5;%7)*UYV1R@(2:`6W@9[9Z+J)+W$)-?+`D3+_`(D:P6I<Z$ZDV0K=
M>+CC9BY)817-&]55-X;-?JB_K@6"V5<AO@LIG?%1"E#W!U:14U17$U]/^.!I
M*^HQC>Z*QBI&4MB/J\V@;E/MZ;M=-=_I_CTP,9-W!!B0<:1'?<BNA'?!7P!`
M=,A'8X7JV'ZN@KU7P\\#?^4K/>#!]VQ[T]VR+W`[J[$12T#7=Z4)%7I@9!80
M#<>;"2T3D=$*0"&*JV*ZZ*::^E%VKXX%9Q[E$.\EW+,1!)JHF#"]P#@N`ZJQ
MF9"D*CX:=_;I]4P+([&O`I`'*:$H@H<L5,45H215$G$U]"*B*J*N!36O-($1
M_CPQ$"PC<AFK"8EL/`38Z,NO=Q%3=W$_94?3@;.8\N@<8XQ:7[XK*9JF2?>C
MLD/<41+:J)JOUP+@)4<PWH8HF@D2*J(H[TU'=]-<"GM>60ZOD<"HF(##$Z)*
MF>_==!MMOVAL`H*A:?=[E%UU\L"Z1YE55$,55!0E35.@KX+_``P(EG>T]6Y"
M;L);<4[)](D$7"T[KY"1HV/ZJ(+@1..<D&V9<&2R,&P;?DLE`)T7'-L9\F>Z
MFFFHEMUZ)T\,"U9E1GR<%EX'29+8Z($A*!::[2T\%T7SP.-L?DM:^#;6,BDE
M?CJ6<L":\+C"FO5M!=;;4TW@7>'IKN_3`[(Y,9MUMDW0!UW5&FR)$(E1-5VH
MO5<#6EE7+)=BI*962P*./L=P>X`+X$8ZZBBZ>*X$2=R*JC5LF<$N.Z#'<%$[
M[8B3S::JUOU5$+RTP-U7:M3J6):FB1V949N40F2:-BXVCFA%X>E%\<"';\MH
M:RNB6#\QI8L^2S"B2!-":-Y\^V";QW)IN\5P*ZZY==TU?2'+I4>L;:4$!Z,Q
M*#M,ON(2BO=,14P78O5!U_3`W5W-&W;*;3V<,JJWA1AG*P\ZV3+L8R5M'6GQ
M7;M1P=I;D%4Z:IU3`NEL:IR65>4I@Y:IH4-7`5S[=W5O7=]JZ^'A@1H<_C4.
MJ1V%(A1ZEDB;$V3:".!(2[A115`1=VNJ?7`\C\HX_(MY%.Q.:<L(D9J;(9$O
MMCO[NVYN^W1=BKT7P_BF!N6^HTAK.6QBI"12%97>;[2$**1)OUVZHB*J]<#8
MQ:U<B2L6/,8>E"`NDPVX!.(V2(HFHHNNU=R:+^N!F5A`"6$(I+0S'$4FXRF*
M.DB)JJB&NY43^&!0T7*IEU>3&H+,5RD@NOPY$H9*')22P0C_`$0$A1LEWCZC
M0D4?#1<".?R11E;U<>,\P[5SF[$Y%H3J`TP5:ZVRX!*J;>KCNG54\/UP.E*R
MKA>99*4RCTA-T=M7!0G!^H)KJ2?PP)&`P&`P&`P&`P&`P/DM1QI;NZY.VW#B
M`Y&Y8S..R-!*2"1&HCPH`J&J$2"0"6[HBK_#`FQ/CRZ9X]!%84!+.+=2[.1"
M!UQMEUF6\^6U)#3;;@NMMR?2JCIJFB]%U0)X\">CSX$>J@1*JE8I;"L06'"4
MF'9[C3O[8;10@$FE5?4BJJX%2GQC82>/PX\JFJV;6/,J2F&W(>>:E1JQ]'%3
M5UK<VFBEVV^J)KIKI@6Q<"E-<P<FI`AV%9)F,3PD2)#[3L(HS(,@VS&`2:-!
M[6H+N'3<OC@<^_\`$%X[31H$-8548TTZ`8LZFR,F3/9F`BAVP[C)=E1<\.B^
M"X'0V_$[ZS_#6CD&)'L(LMQ^VJHTIUIB2CL=8W=60#0&3K:(.S<.FWTJOA@2
M&^!O0K6JF49#3QX!,MR*]EPG8DB*#*MJ!,F&@.-+T:<!473[OI@3[6LF\GX0
M]!O*Q8TR4**_7,2U$@<9>0VU:EMH*HNK8F):)^N!SS/!>:0I0/-SHEF\S%N(
M<:;/']U!F]ER&L@&FQ![:;&U[P4D7=JO5,"LB_'G-&FG93C,)9Q?VZ\302"0
M#>II*G(%%1D!;;-M4[>T>GAMP,G_`(LNWSOX3L>&[[Y;1ZLY"<A\GVULA<1&
M3BD)M(J=U6S,5]32(FF[`Z+B_&N0Q>:S+^PC1(T>7408'98><=,'X;KQ$@Z@
MV"M*+R:*OJZ8$PN(30Y9-L8SS`4\]H)+\(P4B*T93M-R.OI0>T@[D1-5(17`
MY&N^/.:MT]U&F-P')-C10:L=KYBT<F(<CN$HML-BTTXDCTH`^GPT\\"SLN&\
MK.Z`XC,,H`7[-Y[AV08NHW[1(SK:-BR2;@ZD*[O5^F!5TGQ;81>'3:2QJ(,R
MQ8C.UD:T]V^VY-A//BX:FHBI1G#0=ZH*D*.=4Z8'9\0@<IJ8;-?:F-B"O2B2
MP(P&0#&_6*CZ``"\Z0:]QP=.O^;JN!'>XBZ7(N2VZPXCKUE`8BU[SFG<W--O
M"8.%VU4`)74\%+IKTP/F5W5P*\H5#9MQIJ1ZJD@7%"$QIIZ2]6&K["1QDL"K
M[:*O7M&BEKHJ)@=B?Q_<E:R[!B/$;.;R:%=*\ID+R0X[#;9H2(VJ=WTD*#X:
M+]V!IN/CODTN'&*%V(%Q`*P*+*9>4HKWNY).DU-BN-DVZR^"H1IIO$TZ+_-@
M=_\`_5)L6PBOMK7FN]F),9<%Q2`@T%\4T10(27[5^GBN!\B9X[R!N7QWA]NW
M#"U;XY>UC$ME]2.2*C%:"0YJVAM]W[S^[0M?'`MO[*Y\=F]-&'7L,2'J5Z3'
M=D$\^05K9HX`.]K:+J'L47-OAKX+HN!/XUP"_A1N-LSFHR_C(]RS,VOFZB+9
M/(XT@[VT5U-J:&I:?XX$GCG"^0UTSAZRFHAQ*"A>JY:`X2FLEQ(Z)L1005;T
MC>*Z+U\,"HX_P/E]%'@,?CZ^U!VHAU4N/(>7L178+[KHNB)-?N-FCVNB(BH0
MIY=4"R+A?)7^8>_?B0&ZU`N6G'&GCW.C9=GLD3':0=Z#'0754UU\NG3`HY_Q
M9RB97PJU&X3)-<0&A=L%-3TF-N,F@;4$3-@^QZO#HOA@75[P6=:S+&S<JHY^
M^2F:?JR='8]^.F+(=?-=NS<('L!/%4'R\,"!:?'O)7:RZ&"U[2V=M;&93S6'
MV]J!-[:(,EAP":=8=T7O-DBKZ>B;EZ!UO**KD3P<<D0A:G'4S0D6D-51D9#?
MMW625I"U!"!QP7`$E1/3XX%#6\"EQN3\?EN5,5*N(=U(<90FR&&[8O-/,]L%
M%-5_;+<H>!$NG3`N^44UK-Y;QV='AC)KX#5BDU2<`>LB.C;0;"^Y#75%7R\\
M#AX?QWR7^VX$*93,.2(_#IE$XR;K)C[QPVNRUN7^14:W;M-$P-?_`"UY8Q*O
MI$>N9TL8G&%9;%YH-[]3)%V8)K_FVHNA?S8'0/\`$^1-V-KMJ8DR%+OELFC)
MP$=1IZN&-WF5)/V7F7P15+154==O7`I^+\`Y7!D1RLZB.\TWP\>/."LD'5*1
M&=,D`D(4%6Y`FBZ^6G7`E_V+RE_C<FFF10<*TJJ^+&><<;<2KF0F$:WZ;D4]
MCO[S9MKKN\D\<#QW@G(%Y'8VS-1'"4]R.KF,SE-E'3@1&&F9+NY$WB1]L_1Y
M[OXX'3\$XU=TS\@YCQ%!DQXZLQ9!C(DQGQ-U7F?=(*&\PF]%:WJJCJJ>&!ST
MGAO)3NIDUVJ9>CR:ZY@R8\64D07UF2VY#!`H#O`W&T(2<5=R'U\.N!T?'N/\
MDB\4M:N1+%N;(60E9.)`.2(/-(C3DP@06W7P-5W$*>I$3JJZK@?.3^._D.?'
MCM!6LT\B+QAFF]T$L5[DF+)9>5M%:U-&9(M$"DJ[D1<#LH'%IQK6694?L9JV
MJR[&._+"<ZB%#.(,E'G%(1(-17:WU5$^N!SCOQM=EQ"SI5I"=M&*PJN):/6*
MO#-%YX#>)&7%VM"ZK?<)#\%Z#TP)_._C2396%J5/3118E\6G5<54[#0!-?>1
MYH5;1/,M5[G\J_Q7`67".0OP;EEBG8;=D,T#C9@ZTBRI$"0+THC3IH8HFT37
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M)[>XN_J)*J>'50Z=NA61SD)$%^,<)V*P'+ZW>VZX$J(@G7D0(1;2)"+<NG5`
M'3`E<QXY(L.54-F50U<UT&-81Y$9PF4('):,(VXB/:"0[6C$NNO7P7`H@X.Y
M#?XY5TEHQ%LX$)NOY!![@NO.4RDI#IO]>K3@[&W%'JA%_@'5<SX_)M'^-NQ8
MS3XU5NS,D`XHCM81AYDB#<BIJ"NB6GZ=.N!R-A\?WL^3%DL0_P`;*?=Y`$J8
M#C2OQPM1(6'A(%12T7:2HBZHO\,#HOC?C+M5$?F6-5^-OI0,1[!WWKLX9"10
MV`X"N$6P/46T5]6GC@<7R?XTL;ASD\EKC(,\AL;$7J2\6:`@RC+;(L2W!%5)
M%!QG?L[9:^&!TMSQ'D=@W>5KB;BLY,&9$NT<$%CJPC(.@`#M<`F_;D8$/CO\
M4P*&PX'S&;>VLDZN.C3L3D$1EQ'F19>&Q[90_P!L11S<7;_>5PM=RJJ=-,"P
ML.$7,5VO<K::/(BN<??J)$$7&F4B2G0!>\@K^V:.;>VXH^K1$\4Z8%U+XYR$
MOCRBK6!$;6J2K=DPD,=C_L3:-Z/W231$-&U1"_\`A@5=EPBZ??<FLQOVYW(J
MNU.L-UM0C,1`:%\]%78CADVI*(*J+T7QUP+WY`KKR:O'BJH"SO8V\>;,1'6V
ME!AD30E3N*FXO7T3`H.7\/Y-R!KD]B[7Q_<R:DJ>BK>\F\Q-WNN.R'?2`[C$
M-@HJ[4%5UU+3`RG<0Y'->YM.BP&JZTMFX:T\Q7T%TB9C`+K9/,+W&?6*AN'^
M/7`U1^-<EAA$O:_CR,S7)4AZZXZ_9=_W*R6`923[EQ#;1QOMZ(/1%!2_FP-E
MYP2^=LIWX:,Q!BR*JH8C=MQ&VQ<JICCYPST#>C3K3B-H8BO1%U3RP)EKQ"5:
M646>]6[HSMI$DR:M\V%:9&*R^V<G0=XF;BN@*IXJ@CX8$JDXE9U?-9-E%,FZ
M>6D@I4-\FGA%YQ6E;.&YM[[0$@+W&578BHFU,".[PJS?MK9IY!2/-MX=S"MV
MR'O->W%E#CD*Z$G2.K:$/B#BZ^>H7'!ZJPK&;EJ;%2-W[>=+C*+@N"XQ)>5T
M'$V]1W;NHEU1=?+`YN/PZ_*XJ2DU\<8->-]'(1-LVE&<^!Q'E:(>N]O<ACXH
MNOBBX%?Q?@?)H)08]M41)[+[=5(?DN2B184FK;!K9VP3:\*=ON,J")ZNA]-%
MP/K&`P&`P&`P&`P&`P.:KN1V%I;6\>J@M)#J'UAR),AS83\L6P<(6Q!#T`4<
M%%,_/P3I@;1YC60EJX-^^S6WM@TV1UZ&KHMNFB(H*Z([4'?J($6W<OAUP,9G
MR+P.%/2!,OX$>8KI,=AR0V)=X"$";75>AH1HFWQP-L3G7$9=6_:1K1AV%%=<
MCON(J[@>:UWM*WIOWII]NW54\,#P^><+!B`^5W#1NTT_'+W@U?U-&OVQUU+1
MPD%?HO1<#1+^2>$QJFVM5M678E(BK9=E5<-O0U;3T"FY=S@J`JB:*O3`G_W3
M0B,MP[".+<-&O<BIHCC1/!W&Q<!?4)&"HHCIJN!'#GO"RKX]@EU$2'+5T8[I
M.B.\V$4G@1%5"WMHB[QTU'SP+>OGPK&#'GP7@DPI;8/1I#:[@<;<1"`Q5/%%
M1=<#?@,!@,!@,!@,!@,#$F6B<!P@$G&]>V:HBJ.O1=%\M<#+`8#`Q5IHG!=4
M!5P$5!-43<B+XZ+@98#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8&`,L@9F`")N+JX2(B*2IT354\<#/`Q1IM'%<0$1PD05/1-RHG@FN!E@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#DJ_C]_Q^WLUI@BRJ>Y
MEG/-I\W&78LEX4[Y(J"ZCS;ABA;?2HJJ]53P"'=<!L)<[DRLR&WHG*F8S4A)
M"*JQ"B@K>K:)_4$AZB/3:>JZJB]`YGY%I9M3P#F<J<#:E:7$:=7`PI$OJ<AM
M-@\2AZ-38]:IJB(N!?O\*OCY"'+F>P-H$X97XHC7M%'2"4-0[PCT>_<(]^U4
M\!\$UP-G'N!6-9RB);G[;L[;=V6V"DJA(M)3$@1:38B*`#'ZJJHJJNN!R%A\
M3?(5M"NX\^37C)M:1BM6P!U\G#EP9:OMO$';`&VWD-?2']/_`(L#J[+@_(Y-
M[9VT<X8./3*B;%;>W&)+7B0O@?H79N0OVS1%5%ZZ8&YC@4]J^AV8&R+?YR7=
MS&NNH=^N*"#;>@Z$JDJ&2KIY^.!=<2K^05=?"K+`(:QHD06^]&(]RO"9)H@$
M`"@=K:O3P+5---,#H,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#GJ[F$.9.N!+;'KZF8W6>
MY->KTPA`C$$3R17@!/-2U^F!LE\RJ&(\.4"F]&E6`U3C@BHJS(,U:1'0/:2:
M.H@+_'7PP+W`8#`8'/\`/K^?Q[B%E=P6V79,!KNBU(4D;)$5$5"4>J>/C@4U
M'\DLK.N(=\[#9:K)42&Q:Q'".-)>G!O;8!%0B%X?2A"A%]R?73`Z)GEW&7C;
M`+%GN.N-L@V2[2[KS*R&VU$M%$U9%3VKUTP-5CSCBE<!'-L6V1%(QKJA*NR8
MXC+!H@HJJ!N$@[O!%\=,#%CGG$GS5L+$$=22<$FS%P#22T*F3*B0HJ'L%21/
M-.J:I@13^3>$_C7K"/9!+8:AOV(C'0C-V/%35XF4T3N;-?4@^'G@;'.<4C$B
M2Y+GQHL&'7LV$H'MX2&6WR7:XX*IM1M4Z?\`>UP+*=R.E@N]J7)1IS34!43U
M/1LWE1O1/6J-M$2H.JI_BF!B/*./%0#R)+!G\&;2/C8[D[*M$NB'N^F!7ASW
MC)/R5*Q%EF'#6=*;?8?9,&>Z32.J3@AZ5)LD0=-5\4Z8%?R3Y&KX34=RMDL.
M*S;P:VY!\'$-@)BI_*NQ1<42%1U1?'PP+./S[BTF751HLM7SN?=>S)MLU%%@
MIK(%U=/VB#P5#T77IXX%M76U?9"X4)WN@THH1H)(*H8"X!`JHB&)`:*A#JF!
MLGOG'@R'PV[VFC,>XJH&HBJIN5-5T^N!PW&ODR;R#C8RFX05O((<F''NJF7N
M+M#+<`4=9(%3N-N`YO:/P7P\=<#JV^4T#EDU6A,%9;YO-,!M)!-R/_6`#5-A
M$'74477HOT7`E3+:##>99?-4<?<!H!`#/0G55`W[$+8)**HA%HG3`I:WY%XK
M8P!G1Y)JRX_+CLAVG%=<6`XK<@P;%"-0!1UW:?3ZX$U[E_&VDCD4]H@DHP33
MC:JX.V6XC4<B($)!%YPMH*6FY?#P7`JJ7F4J=66/=%A+AF7:18,8>XC9I7O.
M-`3BIO4$+M)N+Z]$P,N*?(=-<<;C64N0U&F)6Q;*RC#O5&ADM[]05417!W(0
MHHZ]4T\>F!JY#ST8K-0Y3BU+]Y=1:B>V_O9<821JIZ@2(0N".BHA)U1<"18<
MQ8;Y/2UL.5$=A31G'.=4U4A&$"(JMFB]O]MSTNHJZCT\,#?*^0>&1!F%*MF&
M$@.LL2D<5143DHJQ]$5-21[1>V0ZH7E@6@W-:M>Q8*^@1)/;[#AH0*:O*B-H
M@DB%J2JFB::X%#9?(=&$6J.OD))_-6!5,9]MLW$8DHVZ1=YM$0T[9-:$);53
MST\<"P<Y$W6G45MRXVEY:BX++<9MTF3=8;[CJHJH2@">2FOGI@4OQ_\`*?'N
M5<8A6CDIB)/<B!*G0E-4[6IJT2HIH*D*.HHZIY],#HZ_DE%8PY<R#.:D1H+C
MC,UP"_HN,IJX#B>(D*=51<#G*KE?,+NDC\DIJV)(J9QMNP(#KIM2W(3BH/?)
MSU-":C^Z+>GV^G<A8'1AR6@.<<$9[*R@WH3>Y$ZM(JN"A+Z5)M$]:(NH^>!5
M+\G?'Z`)_GHFUQM7FO7U<:1M'5-M/$QV$A:CKTP)A\XXB$*+.*WC)"FMB_'D
M=Q.V3)KM%U2\!!2Z;BT37`VR>7<8C278LBTC-R&-5?;)P45M!`7/7_E]#@JF
MOCK@:_[RXXI5PA,1Q;62<*&@"9*LAL",VS1$U;41;77=II@:XO+Z5*A;*791
M#C*[($)$8B-M0CO$V2^:_MZ(CB^`K^F!E+YQP^&FZ1<Q!1$CDJHZ)>F6JC'+
MTJOI=45VKX+@6-E;5U:T+LY\6`-=H:ZJI*B:KM%$4ET1%5=$Z)UP.7C_`"74
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MM?#3`@ASSAIUZ6*6\882R0A=XS0$]RXB$#2[M%0R$D44\T5,"1!Y9QN>Y`;A
MV+#[EHVZ]7B!:J\W'5!>4/\`^V1(A?3`W3>0T<&I<N)DYF/5LKH[-<)!:']S
MM=27I]_IP*Y?D/A`TPW17<1*PGEC#)5Q$17T'=VM/N[FWKMTUTZX%HMW4)(8
MCK,:1Z2V;T<%)$WMMHBF0Z^.U"15_3K@1G.7<6:"6;UM$:&`8-3%<>`.T;J:
MMB>Y4T5Q/L_S>6N!A!YGQ2>D=8=K&>]TTX_'VN)ZVV%T=5/^Y_,GBG^&!7%\
MI?'_`+.REM7<:0S4QTF3DCDKI!'+HCB""*I"J]-1U3`LIO*Z*!WW9]A&C160
MCF1FYH8^Z(A:4Q5/2)J.@+Y]?I@29=]31`DG)F-M)#$3E(2^H!(5,54?'J(*
MJ?PP/#Y#1-TB7IV$<:56AD)8JX*1^T6BB?<UV[5U\=<"%"Y=2V%@V$&SA/15
MC/2#!'/W]K3HM]T171.RB[D4_#733`@W_/JN%%9?@RHKZ!-AQ[$77%!6(\MX
M&U=4=-4T1P5'=HB_7`D#\B\,-RJ!JS;=_-/NQ:XFT,T-YCHXVJHGH(5Z:%I@
M2Y7+:.+R:/QM]_MV<F&[8-BJ+L1ADD`B(_!/'S^BX&^JY#2VSC[==+"0Y&V*
M^`ZH0HXBJ!:$B>DT1=J^"X&J9RSCD/W7N9[3:0FG7Y9*JJ+;;"B+I$2(J)VU
M--WTP*[EG,VJ<(BQ'([YI8P(EFVX:H3,><>Q'=!\%T]0[NBHBX%A`Y=QF?4K
M;PK)B16#W-\H"U`.SU<W_P"79IZM?#`WO<@I6)S<%Z8TW*=$R;;(M-R-CW#1
M"^W403<J:Z[>OA@5H<XX[,%A:FSB3#D=[L`#FY7NRQWR1K;T+:A@1>6BX$;A
M_P`AT%[513=LX*6WL6)UC$8>%49%\177U+KM$BVJODO1>N!>UMW4V49V1!E`
M^U',FI"BO5MQO[@,5T(23Z*F!7!SSB2TD>[*R;:K9+/N6WW-P:,[D%7"14U$
M4)=%(NF!:3[>L@0??RY`-1%V(+VNJ$KBH@(.W524E5--/'`JW.?\*;9:>*ZB
M(V_%2>R7<1=T531OO(B==B&NBKY>>!?HJ*B*BZHO5%3`8#`8#`8#`8#`8#`^
M>_V%8$SR2O8((KLB\8Y'4S3%7&%>$F74;=!"$UT>C+OT5.A(J8%GR[C5U>U]
M-#<)M#:MX<^<XTNUMMF&YW]HH6A'N)L0_B6O@F!U^`P&`P.=^0^+R.4\.L:"
M.\TP[.%L$=?!7&T070,D(1457415/'_;@8\JXJ[:U=?#KB8@G!L85AIL7MJD
M1X72`4#;HIH.W7RP*\^!/GRBUFF<-ZKM]73-QC6PCO+&2*0QY&O0"`=VJ]17
M5$Z+T"G/XOO"X65`KU5[]IR#V;=N(K+C[4"6$D?<@V0ZD:,BB[2TU55_3`LW
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M_;7U0Q)4H:'^9A7#]B!3'$EK%04+]N4VR;9;&@$=-P]/'7`L*[X\OX]O%L'9
M</\`:G74IYO8XX*MVR(3:(*J.JMN"FY%Z*.!<\3X=+XQ'&)6R&FZMPV2*JT=
M)B*B-DD@8:FX1`+CJB0@OI'KHG7`Z.PCE)@28P*@D^T;8DNNB*8JB*NG7SP.
M'D_%RSPXI9/S"@\EX^W"9F2HAF34R/&,''8KR%L5QHC;WBI)J)=?K@;87!+E
MN?6Q)$EA:&CLGK:N<;[B2W7'TD(C#PZ"V(->[+U"J[T1.@]=0E<CX=9VO+:^
MXBR`KOQZ1U&<PZZ,EUL'U.1$?93]EUAUOHFY=P%ZDP*BEX#RBAEL3ZLX)/QY
M%LVD9\W^VY!LYWO6E[FTB!UD_N3:2$G3<G3`]XW\>\IXO80QJ)T%^JD1HC%V
M,MIQ7T>B*7[T50+;H8ELV'IMTW:JNJ*$"F^..:4-Q:7E4[!*7>2IWY>O>?D>
MW=COO./Q'@/M$3;['=4"%!V$*_YNN!J:^*.8=BO4;&'$EUM!65L9UONN)[ZM
MG#+W%T:4F7!:$?JFJ],"SM_CWD4]U;;?#&U?OJZX>AD;JQP9KFQ9%L74;0R-
M1'=JH(FO3PZJ$2'\6\F;B,<??G1"XW$2T88E`CB3CCVC3@H+@J/:WLD\O7<N
M_1%71<#"1\9<JE<;KH#PTL:=6VM7,1R`TY'%^/5O=S5TMI%W#'P'11%=>JZX
M'<\MHI=K&@.07`"=5S6;"*+JJC3A-;A)IQ10E1#;<)$)$71=%T733`YP^#\B
M"?7V#3D0WEY`=Y9-$;C8`T<0X8M,;0)#,0-"4E0=Q(OUP+CE''[F;?TEO6''
MW5@36GFI*F**,MH1$A4!+51-M-1735%\>F!Q(?%/+CI:NO>>J^[7<=;JD(A<
M>9*;'ELR65-DP1"8+VHH?7=U71,#Z!QVFD-4C\2U@5T)R81K*B50DD=4,4`E
M4R%HC(D3J6U/IY:J%=P^AY1QRJA<<;6&]45BBQ"G&;BR%@MKHVVXR@`'=$-`
MWHYHNF[;Y8%5`X#R)AFNK9$B*]!H;"585,XE<*2YWFWT8!\-$!";*4N\MQ;T
M%%T157`K8%-R7CCGQO3%&BR["OC3X\IP7'1C[@CBB$#O:)14_':0)YHB],"5
M`^*[2K.9&AS&GH-S2_B+(WMR.1W1)\Q>C#M,2;599ZMDJ::(NJ]<"8[P?DD=
MCE0UDB,V]:-0&ZIUU254]FP#)][]LD!2V>DA0MOCXI@0J'X[Y16V46>1PE)F
M_?MG&?<27M8\R"D1Y.\Z"N$Z!*I#NZ%]1P-_%^"<FX^Y5S0.+(DLI8QI\(#<
M".K-A/68#S1$!%W&_`QT1"^J;4P*Z9\2735!9TE:[#=:>I:ZL@RY*N@?>@2'
M'B1X&Q)$:<[OB*ZIIX>>!UW.>*/<DJHS""#,V,:OQIC;SK$B+)[9`#T9YM%7
M45)45"'0AZ*F!SI\#YGW;J2[(A6,NP2A1HWB-H2*I)'))D(-&C:N.:DWMUT5
M?+3`A/?'7.YE[*L[!RL-_P!E<P(<MAZ0T:-V)H<;5CM]H.WIH9#J1+ZE5?#`
MZ3B_$+NMNZF?.>8<;@<=8IWE;-TW#E`X!N&BN"FK?HZ*J[EUZI@1;GA%_-G7
MDEIR-I/M*:?"%QQS^E6&P;K;F@+M4NR2AIJFJ]=,"%Q[A/-DYNS>WY5YPV8M
MC`=;9=?<-YN9)!]HD:)L&FT06]I!JOUZJN!F_P#&5K_9L>F.3&M)=7.;>K1F
MH2,.0HSAI&BR%%#)%;8<5$,!Z&B%I@=!&XY81."R*>KCU]3:/,2.TRP"NP6Y
M#ZD6I"8HK@J1>M2#U=5T\L#FH_QWR<"<$CAHP5Y5W`BK[[SB-PH[#+S2F;:;
MB18^K:^:?Y<#RUXO.]DS4K8-UW*Y%O.M*69$9<D=J/(?+W`J9@B!NC/D)+JG
MJT5-=,"S^60;@_'+D:,"$K<FL9BM.;R$E&?'VB9(AEIZ?46B_7`\>X-<.\BC
M7NZ,+RW864N+O<5L8[5>Y`#MKL]3RH:&6J(GEKTU4-2_'<Z2[R*MGMP'ZBU6
M:[7VA(3EBP=B"BZV0$&Q0!7#051S[-!TP/'>%\FE4M=[F)31[N%85LE\X:.-
MM2&:XD5-Q]I"%=NO;#:J!X:X$5_@W)V#:?08KK$:WN;AP!<<5T@G1Y#3#8#V
MM%/_`%/JU7RZ:ZX&AOAW(N3\)CI(;AU<EWC?XR(`&;RJY)!DU[Y=MI1!M6!1
M!%%ZD7^(="'#YUC=W\F^9BG6WE7#KW8S)FX2$RKZO:]QL$TUD^A?TUT3`KIG
M`N1K0\>$GH%W>4S_`'IJV0$W'FJL8XFXU`7E!P6R%4+86JIY:]`Z+D%',?X1
M.I*>+"CRI$,XT>,:*$-M71VDFC8:[!W+IH.!S?-N-V,@Y-G,:C)6!QN;520;
M]P^ZKTPF271IEI3)D.SXCZNNNWI@557$Y9R"K(8Z5TB4U85<]RQ&6\_%=&$;
M:FQH45DP<VL:]!7U%U5/#`MZO@?(H?(&K<G(B]J[LIR,";J)[.Q9%O779_6`
M@U4=-JZ_=@6'+^&6UW<K(B3`B1)5//IY3WJ[[*RU;-MYD=%`]":T(24>GG@6
M%-16@W07=HK+4L*\*XH\0S)DE%U7"=]0AIKTVCIZ>J:K@<].^,YDM[E*1Y*5
M<;D<69&D1V7''XSSTD=K<TXYH/:?`?2YL/0T^F!%_L'FTN7.M+!RM;G/2:69
M'C1C?)I2J#(W&S<,$).YN])(*Z>:+IU"7;_%OOXLPP>*';3[%VU;L8CQQW8,
MAR.W'0F5`-'QVLCW`<1$<\\"TJ^/\GK)-K$;.'+J)3DB;$D/FZDM),I%(VC1
M`4$;[A%M-"U0/3M7QP-,'A=NU5\,AR'V#.@BK&LW!W>M2@K%56/1_G77KMZ8
M%38_$AV7%:VDDOQVSI8#4."Z+:F#SC+D=\2D"NG[2G%%":Z^*KNUTP.OXW4S
M8E?(]Y&A0)TP^X\-:A*&[MBVADZ8MDZ>@)ZE%.FB>6!S<+@W*F(@QW;",ZLB
MB_!RR43(6S8[B,2FQ+J>\7?W6U(>O@JX%O8<;N8_&Z.HHI#6M2Y#!Y92D'>C
M1@V$*&V)$V:Z"6HIY;>B+@<=6_$7(XU.$-V=#5]./VE`2MH\C6Z;)5UAY$55
M700Z&*^"^"X'U"LCNQJV)'>45=99;;<4-=NX!1%VZ]=-4P).`P&`P&`P&`P&
M`P*?^\.-I:.U931;F,HZIBX)@'^G`''D%PD1LE;!T2-$+HB]<")'Y6P[=R06
M0V-.S71IH.DTX!*LAUT4)'"5!,2%M-HB.NO\4P**)\CN2+&\BOOM5S,.V@5E
M8_)B2=QK,::<[;C2D!(1$9`!KM'PU3ZA<Q^>5$TG`8<<ADQ;K2DLV.Z(O2`5
M=PL*FB*A(*[#7I_M3`E#SKBA-.O?D`%AII]_OF)BVXU$_P#4.,F0H+HMZ>I6
M]<#&%SSBDXI0Q9R.N1`C.O-HVZAJ$U-8Q-B0(KB.^`[->O3QP(8\V;GV_&DI
M7&I=1<G.:DO*)BX!0VRZ"A*"B0N@H&)#K_#`L)_**F#R!*R591XY-P'+!^*Z
M)HYV1>!E'^[JC8@A%M453555/\0V2.6T,?1'GS!Q3[:LJR]W$T<%I2)M`WH&
M]P4WZ;>OC@80^9\;F&P$>6I%(DR(+>YMT/\`4PT(GVBWB.T@1LE]7CITUP-M
M9RBAL[&36P98O38C;;[S2"2?LNJ0MN@1(@F!*V2(0*J=,#4/,N-E9K6A,W2_
M<E"1!;<4%D@RKYLHZ@]M3%M-5'=^GCTP*_B?(YMY'<Y`<@(M('O([D)YE6R!
MR)+<;1_OD2)L5H/4FW37P5.J8&RQ^1..0G:UO61*2TFL0([D9AQP$<E-$\R9
M$B)^T0"J[QU3_?@3/[SXRCY,N3@9VMO/"Z\)M-&W&_KFVZ:"VXC?B6TET3KX
M8%/<_(,;LQEHG6WWPLZN'8L2&7@(6+-P!$A0NTJ$H.(0KU3R5,#IHEQ72X3L
MYEW_`$;).";YB38_LJJ&2*:#J";5]2>E4ZHNF!33OD?A=>S,>G60Q6X,9N=(
M5UMX%]J\:-@\"*&K@*:H*J&NB^.F!OM.;4E=Q*3RHN^_51FU=/M,GWE%#V+M
M:<1L_'Z^77`W%R[CXNBV<K8I.,L*1-N"(/210FFG"4=K;A(0^@E1>J?5,!R+
MEU#QX6BMGR91X'G1VM.NZ-1A0WG"5L2VBV"ZJI:8$!WY,X2U8I7E8ZR5D1XA
M;6GB`79@;XR$X@;$%U-$$M=->FNN!81.6\>F`AQI:.HLURKT0'-R3&E+>T0J
M.X5'8JZJFFG7714P,+/F%'6W<2ED&Z4^7V]HLL.N@VCQJVRKQMB0M(X8D(J:
MHBJBX&J#SWB,VR>K8UDT<QEE)*M]40F"=[".MGIM,.[Z-17QP-L/F/'9;XQF
MY2C*(Y+?MW&W&W$.%M60BB0IIL1P5_77IK@0A^2>%.S8M>Q:`<Z='9E16@:>
M-58E`1LNEM#00(05=25-//3`CU?R3QUT8<=^<DMY^H*[*PC1G@B%$!5$G$U[
MA!KM51`E55TP.DA6];.[7M'Q>[T=N6WMUZL/:]MSJG@6BZ8$-WEW&V91QG9[
M8&V#[AF6J-(,7K(U=T[>YI.ICNU'SP(DSY#X9"C3Y,RT;C-5@M.3E=0P)MN0
M2"RZHJ.Y6S5>AHFW]<#VO^0>(6*QDB6".+*F.5K(JVZ"^\9!739-#`5`M@[D
MWZ:^6N!NG<UXM`8.1.L6HK#;QL../;FT$VC5HU+<B:`AIMW_`&Z^>!27OS)P
M"F*8W(G.OR8+I,28T6-(?<%ULP`P]`;=45X/YNNO37`T<F^1QJY#3L2;#D0V
MKF%6VK)-/(_&:E,J2HNA>ITB4"#T_;TT5<"<?/(\V=Q8Z%]B747DN7&DR#%P
M3#VL9YXD%%V*!BXPHFACT^FN!=57***UDG%@2T=?%H)*-J)`IQW%40>;WH/<
M:)15$,-1_7`B2.;<;@R'$FW$78=@%5':;15,)A-(?MG%%3_<7J2=!Z:)@:H_
MR-Q*3-J(L664C\VS)D0GVVG%:0(:HC_=-11&E!5T5#T5%Z+I@65-R:DNE<2M
ME(^32`9"HF!*VYJK;@H:"I-GHNTQ]*^2X$2=SGC$%R8$F60I`!TY;@,O.-MI
M'$3>13`"'<V!H1#KKIY8%A'O*B2ZZU'EMNNL-LO.-@NI(W(159+3Q5'-%VZ>
M.!R5U\IU=;R*HCJ;14,V'9R9L]$<)UERM5I#;[0(I[A[A;Q4=R:?HN!V164%
M(`3T=0HC@`;3H:DABYILV(.JDI[DVHGC@54+G'')LF,Q'?,O=1GYH/$RZVT#
M,5Q&75=-P11LA-=-IZ+T7`\A<^X?-8FOQ[1I6Z]!*6IH;:B+BJC9H+@B1@XJ
M*@$**A+]JK@1?[^JGIU24)YEZGL&YQR)Q$3:L%!$2,2$Q3:HZEO$]"'3]%P+
MU+BL6K"U*0#=<;8O))=U;'8:(HJN_:J:Z^>!RO(_ECC%7QI;N&_[YM)\>L-M
ML'%-I^0Z(+WFMO=#:!;]%'4NFGW)@7"\B2G@U0<ED-?D;24D&.4)EY6W7CWF
MUM#]PPU:;W'N70>O73K@5O$^?P[%UVOMY$:-<I-LX[$9I30#9K9)M*2$?3>C
M8B9)KKXKII@7]9R*DM),J+`F-R),)124R*Z&&_782BNB[3VKM+P+R7`IH')>
M0W,.XG4L*.4>(Y(BU`R7"%9C\4E;(U,-R-M$Z)`*Z*O3=^F!;/<DJ(DN-`GR
MFX]A(V"C.JJ*.&G0.YH@HI+T%"T4O+`J2^5/CH9X0%Y!#24Z1`V/<])&+BM*
M"']BGO!1VZZ_I@6+',>,2*=;EBP:<K41U5?'<NGM]>\BCIO16]J[TTU33K@1
MG_D/A#%LU4.W,8;)]H)#,;=J1,N`IBZFB:;-HJN[P3`2/D#BS,6/*&4K[,B9
M'@"K+9F0O2Q0V5,=-P@8$A(6FFBZX$QJ^AC[]Q^6PXU&DE';;C[C>$P:%PF3
M!-Q$[]Q;03[=.F!'D\\X?'CM/NVK.Q^*LYE`W&9QA)`)T6P0C41(D0NG3SP+
M-Y^4]'C/UBL/MO&T9.F:[%C$J*9MJ"%N+9]GDOUP(O')'('XLE;QAEF0$M]N
M,L?>@.1A-49<47/4)*/W)]>J=%P+7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8'S69\7\@G\E=LYUPR4<UM64<%DUE^TLF$;:;%PC4&_;$([4`414U5
M>I+@9S.!_(%G7FU9WU>4KV,=AMYJ"?JF09*28\D][JCM(P'N-H'UT5.F!L=^
M/>42SM)<RSA^[M+*HL2::CNHTTE6K2N-HI.J1]SL]%733`DS."WQO+V9L18Z
M<B:O`!QIQ"5A`_<9(A+^HA]0/3R35,#&!\:O,442D?F"[%I?=#22-%[JA)8>
M8'W'3J302%345]7BJ:X$0?COE;#$8X5I%8FQJ>KJ278]VW?8/&X^A*)@X#;P
MGM]*[DP)/%_CFSIRX_W9D0FZ:9;2G&H\=6@(;(W#;%D5(^UVN[I_#I@3.0<`
M?M.8%R%N8R+3M,[22(,F/WVS;=DMOD1)O!%0A`@45^NN!1M_#CS,5B-'M392
M$ZX]22=SIRJKN$)$S%D$:&ZPHCL5I[TJGZ>G`FN_&UT=TIA:L!0K:2[-V$L<
MB?=&PBFP^TKW<%!VFZ:@0CX+UUTZA?<*X[;T5>W7SI424Q"9;B07(\98[BL,
MHJ`3R[S13TZ*@HB>?GH@5U=P*?"E)&&P;<H@MG;IECMD$D'7C-XF.Z)H)-]]
MQ3U4==/2NJ=<"SXSQF;2\8=IBF-OO*Y,<9E(SM$?=O./IN:(SW;"=5/'JF!R
M]9\2S*D(BUMDVPC%JQ:_C]CI062!IYB0,1HG2)D74?WH"%M$DT\,#>?Q4<FE
MC<?ESP6HK1G!6$#/^H$9K#C#:F1$H[F`D.)T30^BKIIU"1<<!N^3\,;X]RNQ
MC2C]U%=EN16'&6WH\1P#4-J.H8&]V_42'Z=>B=,"RK>(3TX7.XI<V"SHSS,F
M!&F".V0D%X2;:1U5U$GFVRVJ:)H6FNGC@4O(?C6XNJ)UF39LE=-UZU<*4C*A
M'[:OQWR<=:W&JF911U1"V_1,#J.94#W(.+6%.T^,>1+:T9?(5(1<`D,%4445
MTW"FNBZ_3`H!^/K))$]M9K/XZXL8MQ8@@.*\$N,K!&#)&9IVG2BIHBIJ">&O
MD&SY$X5R#D^QF#:,1ZXX4R)+KI;)O,..2006I"B#C>XF53TB6J=57Q3`K!^-
M>1?B[1E;"*,V:M&L<Q!WMBM.K).;_5N7NDT6FG@BIK@3^+TT&5S>[Y-"&QA1
MW22/(@RFCCQWYK.K)S6A)44]S(`WN4=JHFJ8$SD?!BN.20KH)`0I,+M"U-81
MUN6C"$1/QR(7$;=;=]*:.`NWU*G54T"BK?BV[C\5>X^_8PD.&3:T5K'AHW)3
MV\@)+"S$W;7?4R`N(.F].J]>N!:6O%>96*4]@=C!:O(#DD9.C#Q1%8EM=DD;
M!7!<W`@B2;BZKKX(N!KXEP:_X\\T7O8TL6N/PJ;=VW&2617F^K;NB$:(V0R-
M"3QU3`@<7X==<,CUUG/DM36JJE6MLV8C#[KKH1W3>8.,V*J2F7<5#%47_AP+
MOXUXZQ4T7>`)(>\(BBM3@1N3'A;S.-$,15=J,BXJ"GBFO7K@0VN!\@_&7?''
M;5C^VK$9OLR&.OO62GD3BB9;T:,&G'"5/3J2:(7GJ&F]^/[N^JWG+!Z$-^Y%
MBP>^R)I&)IB4W*=)05-_[A-Z"*JJ#Y>*X&^7P"UDQ>5`,YF)+N+%JSJ)K+2D
M41Z.RPVT9B:Z&2%&15TZ+JJ8&KDWQQ+L;Z#9L)53P"($&:-Y!&:YHVXIC(9<
MU!4<_<+<*^E>GAI@3&N'7#--R6(W(C+*M[)VPA&8F3;8FK2@#J(J%JG:\1P(
M$_X_Y!,O;.V69$;)ZSK+.`P@.K__``YI6B:>+5/ZB+JA"G3Z+@8R/C&?*.*X
M_.;$G["PL+A&D(?_`.(03@JW%UUV[!-"W%XDBKIUZ!:\`X?,X[&5B<S5$ZPT
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MJ="KK.'-BQ0<5@G;'M;5`CT)1#M>I234M?+`M/[-;+X[B<3E1X\QMB'%AOL*
MX\TR:,("$H."I/`OHU`M=473`HY?QE=NTK50-X[(;_$V-2[/FD3TP5ENBZPY
MW$V]SM[$;-#^X4\NNH>6WQ[R2Y!FXFR(3'*H,:&U$)E'2AN.PI83=747::`Z
MXT@Z)JH(J]2P-G,/C^^Y<%$=A(CU[U=[J3(&&;WIF&@K%5LE04=!LA_<1P=#
M_P`OT"XY%Q[D'(^%C7S'X]?R`3CRA>C[WHJ28<@'V^C@@9-FK2;A5-41=.OC
M@5%]P"YMDG6+1185Q,L:J;VE)QQGMU+HN"!GM%5,_4FJ!HG3Z:X'4\BIY5@[
M4/1>RKE;/;ED+Z+M5O8;3FU1150T!U2']4Z],#BI7QA>3H3$23*CLMK:W4V2
M3).*7MKAJ2T@MJHC^XW[O7Z>G]<#J."T-K45+,:UC5K<R/'9B))K1,>ZVP*H
MA'O$5'QU0-51-5Z]<#3QWCM[QN6Y75_MI/&WY+TM"?<=&9'*2X;SH"FUQMT>
MZ?HZAHBZ==.H1)W`9T@;2N&8"5-O:,V[SI(JR&C9-AU6`1?00F<9-"54VHJI
MHO1<"EYC`L:>HIH[OMWI#W+6I,)!1W8HR)#CX(^0@:BHJ>BD@Z)HF!?U?#K:
M';-7JOQOR9^^"7'`32.K<YYMY%%?N)QOL`.Y4]2:^'3`AU7QW:TCLL:F;'1M
MV@:J8KS[2FXW+8<D.B\H*I`31%+U5O\`1$\,"+4?'O)JX[&6W*@C+GS*RQ-H
M?<*"NQ&1;E";A*IDCBAN`M.GFF!8,<%MV[=;=9;*RF;J1:1640^V4>1$2(3+
MB_=O0?4A=41>FFF!##XUM(\]9,65%%M^'<MRFU!Q/]7<O-OJ3>BZ"VV3(IX:
MKU7Q7`ZSBU785-)7U4HV7!@0XL4'&D)%(V6D;<54+^55%%'`M\!@,!@,!@,!
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MQ11K>1FFHCVU?'IKUUP-/)N8.,)%;JR)N0%S6U\\7V'!3M37`W"!&@BJ]MQ/
M4.NB]/'`N(W*Z*381X#$I#?E^Y2*J(NQPH1HW($"\%)LUT5,"JY?>7=9>\7B
M0G6QBW-FL28KC6]1:&*Z_H"H0Z$1LHFJZ^.!76O,)E/S*'26MK'CQ2J#GN/)
M'7<ZZQ)`'-@[CT16R^U-5U\,##DO.;?C?*:M9B#(XD[!-VYFML$APW%=`&))
M+O5>R6Y4<T%=GW+H.!/F\KFN<?Y3:U[[)?@?>"R/;(A(XT4'A0E51U3<JZ[>
MBHJ:+TP-'(>37U;1<<G-2&$<M;&NCRB<:7:C$O\`K(.A="T^U?\`;@3ZSE13
M^>V5)&?9?KX5;%E*@)^X#[[SP*BKKU%0:%4Z8%/S/GEG!;Y:M438?VQ7LN.$
M8H:E+E:F*::_:VR*+IYJ7Z=0DV'R1$.LN9M8T^$KC)MNW%=.9.*:Q#U5715T
M4]*M";@$GBHZ*GE@=N)(0H2+JBIJBX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8'SJ^`[!GD5?9<:GSTM@.*W(&)&418$-&@)5E?N[
M'=7`+0?N3P5-<")2N<CA'$6S@V]JH4X5<Q]84=N0\Z+BKWU=]VJCJ)>H41=5
MZZ^6!51ZGD"0*^#/@W<J-!I9E"ZK$2,Q(<;?)KLOMG[PA!UL(XIU3J77I@61
MR>43H$&%=UUU-D0Y\2>,UN%"8;48+J."!-I+(M[NSUDG35>B(G3`D\5F7-))
MD1UH[=^F1UYRL9<B1?<L>Z<[SPG(]V:N!W#7;Z$+3HN[1,#SFDR[M;+C4Z#2
MW#8T=C[Y]A(T8^\':<84-QRV=NHNJJ+U_A@;@LK=[G\:_P#[>N&(ZUWXXVG(
MT14%3>1Y7"<&8JHB;=JH@+@8M6W(W[T)D_CEM*@.UAP9$)R-`!"<)[<3BK[T
MD02!-J@J+Y+KXX$3C_%7:W@]YQFGI+6'%NUG%']XL(BBI*#LHVJ>[4C$/Y-2
MUVX'O)6>7R..T,!BIFC/H9<&4]*"/$=;?]HFA"TU[X5%#U\5)=$P+4&N41^<
MS.4'527:]^N8@-US8Q/<"K+IN[^Y[O:6I/%JFWPTP*7D%%:RI7+V$H;-MCED
M2,JRF?8NJR_%;5I4(%E#NU%`5.O7JG3`RY/3<IFUMVQ^'F/V_+&(U5,D-^R"
M+&AM;@=-!*49;MDAXAU7J2B/EK@?46&@99;:;3:#8H`#]$%-$3`SP&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&!SLZ^O(*.3YM;[>HA>^.<Z+X.'[>.WW&'Q!$U7N;210U0A7ZI@4,[Y
M!L8=IQEUV)(=B753+G/5<*.4F0CK2Q2;05'KZ&Y!H6O15\.NB8%VQS*`]=4C
M,=Y)%?R2([)JWA%=-T<0<)%7Q3>V[KZDZ*.GGI@57R)9<IJ)%*_6VO9CVEU!
MK78ZQV30&).HN$)'J6_<FJ+X)_E\\"Y=Y"Q01QBW$TK&6VO<DOLM`)-L//$#
M3KS0+Z13[%(4ZJBKHF!#E?)O'XDF0U)C6++466,!V84&0L;OF\+`HCJ"HJBD
MX/J3II@2(?R#0RI[,)`DMN/SWZH3<8(6TF1FU=-I3ZIU;`B%?!=/'7`Z7`XK
MD$CD\3E=%`8N2")=RI0&VD=A5::9B&^`@1"2JN]OJI>6`<YB_2\EEUUPZ[+@
MB-4TS(:C:(T_/-V/O>,5TV.O-BB:#Z5+Z8%I"YW03>1K013)^5H\J/M[7&=T
M8D!\"(")0("73UHFOEKHN!7<_P"6/U\(X]2\8V,:75I+<;%MP&FID]EE6W-^
MNU76R+31-=.O3`W2N?U4`9[A#/L29LRJQBQ89N.A(&,+_:$11-PJ/5'%Z:EI
MKI@>#\I\-]\W$.639$,E7'2%=C3D(=TAI[356S!$+H2:*HJB*JX$J3S9EE40
M*JP=)9T6"7[.P428J;)"$9"*M"B^K1=R+Z537`R3G5#[MEA5=1J4;[,*9LW,
M2'HR*KC3)BJ[CT$]J:>K:6GA@0J;Y1XO;0&9T?W+34T"=JFY+*LNSFVP%QPH
MC1JAN[4<3P35?+7`Z"UNJZK;`ICP@;RD$5C5$<><$%<[;0JJ;S41704ZK@<C
M&^1HT3EEQ66KCB1!FU\.`2,KHP<Z,!MA()$]"..JJ"I_S=%TZ8$CD'/X21[:
MJKWG(/(V*F9:Q!E,[!1N(X3"N%W=!V]U$^Y4U%4).F!)J+VX>YU*JY#@'7+3
M0;".V@Z&#SKS[;NI>:%VQZ>6!6UO/A@7MG`O'9+C3]T5?62PBE[1A%895IAU
M\!VBI&1:*2KU735/#`N:3Y%X=>7'XBILFILOLG(3L*C@;&G$;-%,=4$D4D])
M:+IU\,"NYAS21#E5\6I5S>-Y75MD]V>XQLEDG<:4U5-I(#@KN3P543SP)E=S
M>J*3'C.OOR#L+.96QW"C$T#,B+O)8[I>">EHMA+]^!O_`+KK2LS7W;@Q&(#D
MPVE8788"^K7=%WQ54[:H@)]R$BX%+5?(X+><B"X0ZVO@O5\:L8EMBR\X],94
M]J>I=5</H.JIIHNNF!G9_*5,_P`>ER:%QV38_C9LY@&V%=[*0U-I2>'44Z/M
MJ"#N]6BZ=.N!9.\H2+PBLNK!\F')C4#NR&6%>1'9:MC]@_:)&YMU7HFN!DS\
MA\:>O_P8%)]V,LZ]QTHSPQQEML]_LJ^0HWN-KU#HO7_9@1*?Y-J+&CK[(H<Q
MA^P22X%9VN[*!J&Z33SK@-J6@"0I_BJ"FJKI@6%YS6KK>(?W3'`[*O,&'(Z1
M4U)T9+@-MJ*%I_YB*NN!3P.=N1^:W5';$Z<=)L2-5O-QC[3/N8@.HV^\"*"*
M3A*@J2^*HF!:1_D'CC[3CH&^V"$;<=9##D7W+K:&KC4?W*,]PP[);D3`T+\I
M\#2MC62VS20Y(QS0UU0@"6X3+)FVNCB"3P*WKMZ+X].N!=7-_!J1!9`O.FX+
MCB-1VC><[;([G#V`BEH.J)T\U1$ZK@<\7.6V.16?><5VC8JZR;#1ADW'C=GR
M'V1VB**9;]C:(FG3SP+.!SCCTX4%AX_=JDI?8$V:2=8+@LR1[6FJJVX8BNFO
MCTU3`R7G'&D28[[L5B0"=;F3A]4=IYAP638-P=41[N.(*-KZE\DP,8/.N,30
MD*S,1'8SK\<XY"O=)R*T+[HM@B*3NC3@GZ->BX%\V8N`)@NHFB$*^'1>J>.!
MQUAS8"Y)QUFNE`=/.=LVK!U6RVJ4!E578ZNB(@."2+IKNZZ>&!:P>=<1GF`P
M[1E]7!BD"@JJBI/0UC)NTTU<1HM$\>G7RP-<_F5!`L76YMBD5(M85I)B.L."
M0QE<0$?(E'IM45'M_=U\,!.Y_P`6@O2V94EULX+\:+*_TLDD!Z:B+'#46U1=
M^J)JG1%5$715P,I'.N,QZ]R>_(-J.R,DWD-AX#`82HDE2;($-.WKJO3KY:X&
MJ+S[C[]A:17'5C,U?LD.<_H$=U;`=S'9-5T)%U1/XX&]GF?'9G<8@3P=F;I;
M(,H!D?=A(G?10T1?1N'^.J:+U3`I8?/9#'Q)!YE-;"5.?KHTA8[7[8.2I*``
M-#]^Q"><0?/3`MH['.69,$Y,V#(B&V[^4`6'&S;<4-6ECEW"0@$_22&FJIUU
M\L"JXS\C5SG%*6??2@9L)T*)*EJ#9HT"S#[+9*J;D`3>]`HJZ_X:K@=`7*J(
M9#K12A1M@#-V5XQQ[3J,N"3R:MH8.%M(%7<GTP)@3/<5YR6$-M=I[4>;("0@
MU3J!;5TU3_%/!=,"KX#=3[SA=+<V"LE-L(C4E_VXJ#2$Z.[:(D3BIMUTZE@:
M&>0S['F5E0PD!B)31F#G2C3<X<F7J;3;8ZHB`#8;C)?'<B)IHN!D5K;5<J(W
M<OM/-#!G2I[T9@Q'_2N-*!H*FZ:?M.+J*:ZEX8&==SKCD]DB;?5J0#H1BA/I
MVY'?<C^Z;90"7J9L+O$47_>BX%HQ;09$A8[!JZZ&WO"*+JUO;[@=U%ZAN'PU
MP*2RY!;Q_D.FH&D82LL*^=+>,A4G^]%-@`05W(B#H_JOI7PP+#B5E-LN/1)L
MTVW)3O<[CC+9-`6QP@11`B,AZ#X*6!LL>15\"<S">%XG7>WJ3;1FVVC[J,MJ
MX:)M'<XNGCKY^'7`K(OR-Q.3<_B6I+B2/<2(7=<8>:8]U$%7'V$><`&U,0%2
MZ+U3JF!"H>=!R#E[4:L)[\(M<[*!QV(;3<@N^V#3\>0>B.-J"EIM3KJBZ^&!
M/@WMO:<HNZN,+4:!2+&9*20JZ;TA]GON"@[@0!;;<;^NNN!$/DM[7<IA5]P4
M48#M7.G2EC@Z1B<)]H1,25551-I_50V*J$G0EP)L#GW')L8GFW7&W1DNPO9/
M`K4E9#+?=)H63T,C5OUH*)N5/+`LX=Y63);L.,\CDF.C:R64^]GO!W&T=#[F
MU(.J;D3`K)-W:-\_@T@*S^,DU<J::*!*]WH[[+::'NV[%%_PVZZIXX'.U?-^
M22ZKA<MQR&+U[8/Q+(!:<V]MH7ST9U<11(?;H*JJ$BZZ],#Z)@48WLB5RU^C
MB((-5L9B58/D.[<LHG1:9'J.U=&5-2Z^28$>?:6U?>U#$J2T422-@<L6VE'T
M,H+C"IJ1GN`/26W7<O71,"1"YOQB8HHU.$2-UA@!=$VU5R6S[B.*(:#ZG6O4
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MR>V%0U71->J%@95W!H]?;<<]L@_BN,U[\:'W%57U??[3>]530?Z39[NGB73`
MF\OXHG(VZ@?=E#*IM(MJ!"`N(X4557M$BJFB%N\4\,#R9QB6O*&^05EC[)UU
MIJ+:QC9%YN2PP9N-;54@)IP%=-$)%5-"ZBO14"'8\$<EU5C""S)IV;:MV[,A
M6D-&2:=:=%K8I(A#JQ^GC@:F?CPFI<>0-F2]B^?Y`0*R/J60PXQV$5"Z((O:
M[O'`ZN$U):B,MRG_`',@`07I"`C>\D3J6Q%5!U^F!76?'@L+ZFMG)!!^&-]Q
MF.(CM,WV2852)>NB":]$\\"MO^$.V\R6_P#DBCM2G*QWLBR!*!5<KW0Z$JZK
MW"Z+KX8$GCG%Y5%(DM1[$G*5QU^1&K39!%9<DND\8B\.BJTA&NP=NJ?YE3I@
M57(/C9RTM+68Q<.PF;A*XY,=&6W=LBKD"\RZV1>&Y`0"%47ZX'L/X^L&9STE
MVX1X7K_\\H>V0%0?;)'&-N%SR$17?IUTZIUP,X_Q\\'YVN>MW9'&+SW)E4N-
M`3C#LW<K_:DDI+V]QD8@H>DO/3I@6,;C=JE*S7S[@ILF.\RZQ-5AMM=L=P3`
M3`=4)50="+IKXHB8%='^.&&I<<%G.+25TIRPJ:M!VJQ*>1S>IO(6KK:*^:@!
M#Z57Q71-`AG\5,R>#T_#K&<$RMKH:Q'G2C"+Y&#>QB3'<0]8[S*IJA)NUP+_
M`)3P^MY)2)2V0A(KR11?;?;%U33MJ`F)KH0.`J[A,5UUP.7G?$3TF,[%2]>5
MAR;3S-S[2O/:4X`.TG5<12)\FA(CTZ=>BZZX&+?P^Z+DU7+E)"3*^RK%<=AM
M*^K=FZ+JF\^A"3QM[-/5T+Z)UU#J*OB\B)R,[M^:D@RK(M8C(M=M$6.;CA.Z
M[R^\G?M\OJN!&'A+B64XUL"6JL)[=I(@JVF_OM``H".[M.TI,@>FS=JGW=<#
M+AO#YO&FUA)9I*J&`1FNBK'!MT`1=4[\A"(GR$?2):#T^[<O7`K+'XSE/W3L
MJ%=%$JI%K$O)%8L<'=9D4@4]CQ$B@#R-"I#IT+JBZ+MP-S_QN,KCUE4R;`@>
MFVCMM&L(K?9>CN./H\.S4SU,4U#?YHOA@9\@^-X=RZZV4LX<!:O\7'9C#L=:
M47VWVWA>W+JH$R.@J.!4R?B:UG2IMI8\A1VZ?D09D1]J&+<9E^`VZTF^.3KG
M=!UI\@,5-/T5,"99?&]I)E+,C7J1)4RM.HN4&&"L2&2,S;-MI#'LFTKIH*ZE
MZ5Z]>N!;VO#W)G"&>,L3NRY':B-LSG&1=]4)QMP2)K<"+N[/714_3`@!\?R5
ME'+?L&GGW+X+Y46,J-HC<88HLB/=UW(`;D<5?NZ[<#RF^.G:9ZMDP;-?=UWO
MF-SK*$#L.?)]T31@AC^XV:#M<1?+J/7`FVW`X$G@[G$ZUXJYA`!(DE$[I-.-
MNH^+BBJCO_<'54U37`AN\`G.V=E-.V%4LK2MLC;6,B[`KA;3L(O<_P#$5E%W
MZ:C]%P-=E\=3IE?6H%PC5O4SY=A%F%%%Y@O>$[O9=C.&6X.V^H^EP5U35-/#
M`E,<%E,\@;N!L6R5V*U%LV3AM$CA1U-6G8ZZ_P"G5.ZJ*.A(J:>::X$[D/&[
M&PM:NVJ[4ZR=7=UMQ%;1]F1'D(/<:<;4F^J$`F!(714\%3I@5=OP&QER9<R/
M<F$J3#KXCA.M:]U:^0X\7>5HF=0D(\0."&W]%\L"MG?$Q3HCT23+8-LK.;9Q
M)(,N-2H93"0T6.\VZBH3:J:=4VDBIJGIZA[=?#T2U?MI/Y`H$VU%P9$B&V@B
M\0NLO0WI#!$3+CL8F-NY!3>*]<"38?',NYIF8%_*AS'FC==:D18I03CND"`T
M]%-IU76W!T527?ZM=.B8'6US5HT]):EN`]%'M^R<$5%S;L1#%SJ6J[TU0NGC
MIITU4.$@?$DYKV]=-N1F<>KUGA7QB8V2DC63)M.,./@X(KV^XNPT#73QP+6N
MX!(#AK7&+AV#:QFT;8>,H7:23&9'0$=$7-!>U1%[@>"IJ@ZX%9=_'CD"G,HQ
M.W;,6B=HF:Z4'?==;>?`A-QQ#:4T:`$143U$B=%W8&/'>,65K4RP?[5<<F?`
ML'IC<6<P^\<)QLE$QGN$[HH1P`2W=$U]/U#9?_%MO8Q[F+'O0:B7KD\ID9^(
MK[0C.;9;$@#O`A.,HQZ5+4?4J[47`\L/B-V8Q,:2V%HGFZER,\L87>U-J.@/
M*V9J#C;@HB*V7Z^K`LBX5?!)K[2).@1K>($J+(%N$00W8DQP'#!&A>WBX!,@
M2'OZKKJFB]`W-?'40OC-K@DV8<AAN$$+WXM@V>YK16G1!-10@(1)/'PP+JLB
M\C;9)NTG1I1H"`VZQ'-C<6U$(W!)UU.I==!TP.%E_#]D[1P*<+A@X\*'!C(3
M\0C5'*Z0K[;K2(\B-JYKM->I=.BHF!>%\<QDM9]FV\P#ELPZQ;15C(466IO(
M;;DAA3V$8M(K1$B(1ZZJO1$P+OCO'&J2G.I9D..Q4<?**+G7L,NF1-L!JJKL
M:$MHZKX)@0>.\>O./U_'::)*C/U-9%6)8D;1MON=MM$9<9VF0"NX?6)>.NJ+
M@)'$I;'*I/)*6<$258QVHUI&D,]]AY(V_L.IL-DP<!'2%5W*BCHFG3`V\@XY
M:6CK3T:S2N?;@RX?N&F=SH.2Q;VO-*1Z"K9-(NBH6OU3QP*:)\7PR&Y9N"AV
M,*\ELS)D1(BLB),QQ9U;)'2,7-X":.:ZIU\UUP+/^PX"W57=+(="TJV6XZ3F
MR47Y3(@HFU,554'@-=I]1U$DZ+UP-T[BIR>;5G*!EH"UT&5!]FK>Y#24;1[^
MXA(J;593IHN!A4T_):F-3PFID65&9<D?ER6.3)&V[O<;5A$<-&U`R$51=VY/
MI@0^8\&FW]@U+8L&HR-#&1I'HQ2":*/)201,KWFQ!7MH@:[=VB=%P,9/QTTZ
M;.R9L;&YDW4@>VI*XLJ.]&)I%4_3H#ZZ%IY)T\<#WB_"+>HFU3\RW&<W45[U
M4PG8[1NL&XR;1NJAJ/<;%A!7:&BZJO3`F#Q6?"Y+97E38=H;=MOWU=(;[K"R
M60%H)(*)-F)=H$`AUT+1/!>N!&Y%PJUMK(I\:[.LD#5RJZ(\PRA.LO3'6G2D
M(9'U0>P(B&GAKZL"F8^(FRBV4&>[!DUUG:#:/QFH:QE$D8!I%:<;=W-.@XVC
M@N#U\4+777`MFOCT$Y'6WKTU7+"K0&V[!`V2Y,=(ZLG'F.`J`\).*CR*H:B7
M1,"U?X\^[S*)R))2(U%@/P$A=O5560ZTZKG=W>78%-NWZ]<"EKOCN3#@<8A+
M:(0<=G/SS(65!9"O(\@M_P!54`1]RNOW:Z)X8'81@D`VHONH\>XE0Q'8FU25
M1'34OM'1-?/QP*&PXM-_N<>1T]@D*6[&2'8QGFE?CR6FU(V24$-H@<:)PM"$
MNJ*J*GAH&5QQFQLG(+_Y4XLJ&Q,:62PT@DKDMKM"Z*$1(/:7U(BZZKI@44/X
MPE&Y/2]L(MQ%M'(CLZ,<%&T(HL=6-S9=XR;)507$,?4))T7K@6,/X[KV+6IM
M7'E<LZAEJ.W9(A#,?9;:)M6I3V]>\!$>_0T\?UZX$U_BTAWGD3E/O=&8E<_7
M#7]O759#S;I.]W=T7]D4TVX&JVX6S9<FAWQN-,RX!-K$E-LH,L6QU[K"O[O4
MR]KH0$/AKIHNBH'/C\56S=?"B1N0K'*)`=@*XU&V;N[,"7O1`=%1U1OM&B+J
MHJJH0K@2FOC6<!116V!6(W(7>1("1E%2[RF2Q]4=TT0G27?I].GG@=1QRH>J
M*H83TGW;B/2'E>VJ']=\WMNBD:^GN;?'`L\!@,!@,!@,!@,"AD\UI8R/O/=Y
M*Z*LD9-F+:G';.$*D^)D.I#MVDFJCHJBJ:ZZ:A`?^2Z6,S)=F1)L96(;5DVT
M3*$X]%=(0WM"!&JJV1BABNA)],#%/E'C`/N19??@V#=A^*2%*;1IPY*L]]I`
M52[:H\UHK:[_`%:Z?=TP)#G.N/Q;F5%GS'82LL5YFU*:[;0+8.N-L?N::[S,
M-A(2Z#HGAUP)[/)6W;Z/4#"D(3\5V8LDD!&@%IU&MI>K=N)5U'1%Z8$:UYQ3
MUDJ2T^#SD>`306DUH1)F(3R(0=_U;T])B2J(J@BNJZ)@0Z.XLKCF%]&1R7%A
M4,EF,C2A'6-([D472T/0WMR*\)+U'^7]<#.K^08$Q55^'(AM+<2:-M]Q`[:O
M1R4!,BW>D7G!V-^:EHGG@>QODGB\FG9M67738DFXRPTC:JZ;S<KV7:04_G)_
MTBFO7JO@BX%M3\AAVDF?$;;>CS*UU&9<9\-I)N3<V8JBD)`X/J%47^.B],#G
M6/DFH:5&D&PL9DN=9Q(D,([:/=VL4N\P.B@.B("]LC+U>:X$7E_R0R/#)UEQ
MPW3F!`:GLR$9WMM`\X0#W=^@[MS1BH]5'3JF!.D?+'#V>0?@T==>DB](BO/-
M-[FFWXK/?<;-==WVZIN05'<FU51<"/%^9.&O0W9S_NX,)(;-E&D2XY-C)B/N
M"R+K*:D2HCC@"NY!7U(OVKK@>-?,G$Y+,4H#4R?(FR)<*+$CL[G#DP6?<.MB
M2D+9:MKJ!(>TO)<"JYI\MLEP&9:\2&6_.*K"S;DLQVW4AMO_`-(I0.F*(I;3
MU%$)40254Z=0ZESY!H&[H*@E=5]R0Y"!P10A64TWW2:047N_;_/LV:]-VN!4
MROF"A&GE646%.?;:ISO8FK*-I)C-D@.=M3(?4VICO$M-$)/'`ZB?R&'`@0I,
MH'!=L#:8B1!%">-]T5-&D1%TW((DI==$1%55T3`X_A7-Y\UMO\R[*:?F<ALJ
MV!'<8:%Q&XXO.`Q)V(HCL!HE0A7KM3JNJZA8M?+7$7JMBS9<=6'.%%JW'$!C
MWBH!FZ,?O&WJK*-KW-VFBZ)U54P)T/Y`HY\>ODUK<J?'GK&W.1V"+VXS1562
MD`NA@/30O2NW7U:)UP(-#\FP+5AQ/9/A8%-L(4.N'83KZ5CA`ZXVJD(;?2G5
M51$54'`D%\E\<*5#C11E37)C/NA*-'-P&V1>6.Z;I]!#LN)HXFNX?I@6/%^5
MPN1Q"EPH\EF-M:<CO2&T`'V7VT<;=9(5(2%4+14^X2U0D1<")>VUJ[R:!QFL
M>&&<J))G3)ZBCCC33)MM`C`EJVIDX]U4T5$1/!?(*GD-IRRAD\:C/VK,@+.^
M9@N/>V$#.(Y&=<[9HBJ*.*XU]X:=%\$P)KWRAQN,5HDYN7"2I8"4^4AE0WQS
M>6.CH)KJ@]T53UH/3U?;UP)3O.ZYN4Q#2',<GO;36&TT)NBP3ZL))T0]#9W)
MN4FU+0>JIUP,.76EQ#N>+1:^2$=BSLBC3Q)I'"-H8KTC0%54V*JL;==%Z+@>
M\+N;6SE<D&>X)-U]N]!A`@("BPVTT:;E12W*JN+UZ=,"BXWSV99\QE\?GS1J
MKJ(]*1:"5&(._"`R&/*B/J2=W<*`9:*J=53:FFN!(X5\AA*J$9NC=>M8[$Z0
M[(9C&(2&H$PXSA,MAN(C']O<(IXEZ=<#R9\C1K&!#E4,CLFQ?Q*:XCR&D)P"
M=<$'6%1"T$]'15"15TP+3@]U8SH5V[:R1=6!;V$5MY1%H1CQWE1L5TZ>@.FY
M?'Q7`W1>>T+_`'-PR8VWV_963'=91_WAJ$=&"(4%PC)--J+JGFB8&C_F5QG8
MRB^Z24].<JT@^U?60,MIDI"M&V@JHZM#O%?`A5%1=,#77?*/$[)80UYR9+DP
M6W.T$=WN,B](**)/MJ*&VG>`A+5/3M55T3K@>PN?T))-VSUL'0L9<%J*RSM?
M0X2)[AIMI5WO(SXD8IYX%K2<D8MK"ZAM1W65I9:0G77$1`<-6&WU4/T1'DP,
M&>7TCUC'A`X:^\)P(4K8OMWW&457&VG4])$*"73SVKIKI@4GQ[R*WY%4+RF2
M<EF)(!X`I3C@.TF'W$%QDT_</>VB#ZET54U3;X8&\/D^@_&QYTB-.B)(K'[H
M8ST8D?2'&4$=(@!3]2=T5VIJJHN!)_Y@\>4&B'W!K("(<418-5>*<!.,MM+I
MM(^VV1F.OI'JO3`LJGDE3:4Y6S#JMPVE=&1WQ)DV2CDHO`\!HA`0**ZHN!Q4
M_P"1W&.07;SDEZ%QNMHF+$7789D?<?D.`CP-Z(ZX"@VG3IIY_H'2+\A<:&[F
MTYNO-OUC0/V4EQAUN)'!QON@KLDQ%H=P^";O'I@('R!QR>DL(AO.RX,DH<F"
MC)^X1X`[JH@:>I.WZT4=4TP-3'R%5.W1UY1Y+,<*N/;^^>:)L.W)<-L&B`T0
MP=U#["377IITP/9GR/QR"UNG)*BNI.CUJQG(SO=[\S3L+L%"]!ZZ(:>G5%3Q
M3`GU/+:6U=5F&;A/`YV)#1-&)L/*RC_:D"J:M'VR1=#T^GCTP+.7+:B1R?=W
M*`J*:`)&2J9((H@BBKU5<#F7_E'B#;$9YE]^;[M9HQVX<=Z09'6KI*#:V)>H
M-%Z>?E@5'-/EBMA\/FV?'G'),U*Z/9171BNO--M3"VQR?TV[-^B]"744]2II
M@7W,>5/U$NCJH`-N6_()J1(HO:]L&F@5^4\6U4U[;(%M'5-25,"OY;8\PXYQ
MZPL4L8TL6G88PU.*HNBCTL&GD<47.V?[;F@*@#IYZX%X]RVF8NV*:03K,N3W
M_;DXT8-&L9L'74%U40%T!Q%UUTZ+YHN!C+YA41HS4A4=>&2XK4,60[A2-K2O
M[V$%5[@JTBDBCXIX8$/Y%M[>KXB]84\@(TQ'X;8.NM=U$"1*:8/T*H==KJZ8
M%;+O^2M\@Y?!&2V$>IJ8DZK56154==&1W%<7=ZT4HR=/3XK_`!P+BGY*#/`J
M[D5]);:0Z^/,G2=$:;0W6A)=$55TU(M$37`I.0?(S=3R.A;=;E#66$*T>?BA
M$==DJ]"5A1]`"1H@@;BZIT7IU\,"Z:Y_QAY^"VS()P+'V_MI"-FC*K,;5R,*
MN*B)N=$5T1/#STP*%GE_(OR4-E]YA&#Y/*IW-C:ZE%&*Z^R*ZJNCB$"(I)T5
M,#J[GDL"J,&G&WI4@A[A1HC:OO`SKM5XFQ]7;0NFJ(O_`&X$5[G%"S;#6F3V
MY90UY2T9-8PRS#N"P3R)M0R141/+<J#KN73`JX/R[P>7(5I)+\<$:FOI)E19
M$=E1K249:"XZ`(1-(FXA3KI@6P\LK)$B"VP;PA,E%&CO>W,F7T&,LE"!Y$[?
M;-OU`YKH2IM3K@1[#GM5&K(]E&C2K&-*D18K!16T+>4QWM`2*2@F@K]VO5.G
MUP+NQLF(+8D8FZXXNUJ.RF]TU3JNT=4UT3JN!R=WS!VP2@@T:RX_]QG(:2S:
M817(11VC)>ZV^)"A"Z""8&FNF[Z8$WD?*#KUD4H&\W:I3R;(+46$..VL9$%2
M,554W*1:H&!7\8^3JJ700G+$W4M_95CTIKLDWWGK)A7&TCH6@GO5ISP7IM77
M`Z2MY-5SZ-;H%<9B`CG>!\%;=;-DE!QLP7KO$Q4=$\?+7`HKWF,M&JV17-2H
MR-W#,&QBOQ#[KK3C)&HM(J+JGJ`MX=.BIJG70)#//J*2[5/C)>C19\>?(1M^
M.36@P"$7R>)Q$5I6EU]/BO\`A@5MO\J5Z4,^94L/NRXKD!L6S:Z&U92089D-
M*A;7`5"4DT+Q3:6BX'6T4:?'K&FITUR?(U,O<O-@R[L,E(`<!O0-P"J"JHB:
MZ:X$_`8#`8#`8#`8#`8'+KP..2V41R>^5%:%)<?J?1L1R8)B_H[HI["5Q30%
M^TNJ=.F!HE?'@3*T8TNVDOS6J_\`&,61"WWA!7`<)U=!VJX:LAN73KIX8&B=
M\80["VMI4^<<NMNWQ=L:A]EIQ@VPC#'%O4DWBH*V+@&*H0EK]<#;%^,ZYB;*
M>.8_,CRX%?5O1)HMR0.-7JYZ'.Z);^^CJ]Q=/'JG7`G4?!X%%*@'6/NMQ(,:
M1#&*XO=16GWT?!$,O4*,EJ((G\O3R3`RD\*K9,VZ=><-R%R!MMNTKRT5LR;;
M1G>)(B&*DT(B2:Z+IY==0E4G'DJ[&ZFI()Y;F4,PFU%!1I08;CH(JGBFUD5Z
M^>!4_P#+R,=+<U+T]XF;2Q=M8[X"`/1'W'TDBK1(BHO;>'<*DG\<#"7\84+L
M>T"*](A2+*9'L@DM$*K&E12`VR9$A44%7&]Y@NJ$I%]<"_JJEV&_(E2912YD
MM&A><44;#1D=HH`)KMU52)>OBN!S]?\`'CL&VA6+5N]K#E6LSL=IO8X5N:N$
M)^>UD^H::+]5P*J3\/N'0K2Q>12XL1Z`E?,%&6#1W;(.0+R"8KL-.Z0=/$?U
M1,"Q#@LZL_-N1+.1-K+,I<Q[CS@LH#DB2RJ.MB_M[C;;CB[]J+T)?'3I@4/%
M/BZ1,^/Z:-=RGXMJU1Q:YEI&VQ6";9MR47;ZA-QMUEM-2Z+LZIU7`Z*5P&?.
ML..V=A>O2K'CSTJ0V^K#`(Z4IDF-%`$$11L"Z:>*^.!1A\*N,\?<IHW(Y3;<
MNK"FL7288-7H[!.=@D%4V@XV#Q!N3Q335->N!T]5Q"RJ[J3-BW;OXZ8Z4J35
MFPR0+)<;07'!=5.Z(D8[]B+IKKITP*=OXDAI3QJEVS>./'HY?'U)&VQ,FIA-
MD3NO5$,>R.G33QP+OEG#O[AJ:^*EB_7SZN4Q.@V,9`W!(CHHHI-FA`0$)D)`
MO31<"LK/C=Z&41UVY<DR(MQ*O.X3#0(3LMAQDFMHZ:`/?(D\_#K@1XGQ,W!H
M./0(-S(CVG&"?_%VR-M$2-RMR.LN,&A-F"@2"GFFU%3`N&N(6+-TEBS?2A;?
M;CC:15;849+D9$%'4)`0FE<1-'$#HJ>")@5\?XT")90;"#9N,/ULVPEQ1)H7
M!5JT)3?CN;EW$*.*A"J$BIIYX$FJX"E;:,6#%@7<;KY4)U.T*[WYDE);LG4E
M+1>[JNQ=4P*NG^.;;C-B_/X_/:;6TG0W+2`+`L0DC,`8R.RRBGVW7E/>1#XE
MHFB)JN!?\FX@5M95ES!L'*NZJ.Z,62`"ZVXT^@HZQ(:+3N-EL%=$(514U14P
M-=YQ"3=#0.3+#;*I;)FT<-MI-CQM-FV30@1$K8%W%_F)4P*"O^*+.#,>EM\F
M>><?A_CW?<Q([W<96<4LN_N_JD;;ALDJ_P"92\<#8'Q!6)#KZ\GP2OJWRDUH
M-M*V_",I)/[8<D7.ZT&PD:V*JCM1.F!T?)>.3+:PHID6:$1:6;[T@-GO(\A,
MFP3>N]O9^V\>A=>NBZ=-%!Q;C<ND?NG'YHS!MI[EB*(UVE:5T1!6M4(D,1%L
M=%T1?'7`@2>&6<Z\J["RLF935++D3:]?:B$E">;<:!HWD/3MM@\2*@@BEH.J
M]%U"E+XEGE"9BI?DPJ0K2!(DQH_9=4;.6$S>TJ.*@*V;>TM==XJO@O7`V4OQ
M1)K$F:6[;JSKR/?/"D,6@$H[8#V&P!S014FA5%\D^J]<#H./\1.NK;J!.E#-
M:N9LR6?;;5G8$WJ37WN:[=5T+I_#`JX7QW9AQ^!43[TIA4K\1ZEDC'!DFT@G
MJTCZ`2]U3;_;<5-NH^"(JX$@^!O'91+-9PC+"U6YGHC2JV\^D%:]L&T5S5L!
M:5%\2553`HF/A=M%JSD6+92JI_W$&PCQ1C28^LLY9ML&!KZ'>YVW!<0T5/)%
M5<#>_P#$0R*FQK94YJ2$JSGVL%\XZB]"=FN(\V4=T'1,#8<U5"1="1="3`ZK
MC_'':BQNY*S/<L7$IN8C1-H)MN#&:C'J:+H:&C`E]J:=<"HX_P#'BU;,&MD3
M1F4M-+<FTL;L]IY@B4^TV;@GM,&1=,1]":IIKX=0M>&\:>X_QF/1R)0S1C=T
M0?%M655MQPC%"'>?J1#TU1>OZ8%:GQ_WZ^ACV$_N2>/O:QY,9I&>[$[:LK%>
M$R>W`XUM1W1?4J:Z)@8U_P`<QZVAJJZ',+OTDPIE=(=#4114<;".0B0JK3;#
MO:%-VNT4^F!-A\*B#QJVI9CO?_.G,=LG`%0%3GJ7<[8J1J(BA:)ZE\,#FWOB
MSD,]JQ2WY"S)D3Z!./\`N&X/:+TN$8R3_>+4OW%W`.T5_3`LYOQR[8CRIN?9
M(;?)6HC8=N.(K&.(R@(2(9."XBN)OT)/TZX&+O!.0N-P9R745GD=<^XY'FLU
MXA%5EYI&G63C=Y2+>@H6[NZH2)IZ?2H;+KX[<MYLF1*LR7W==$A/DC(H?N($
ME9<>2*HJ!_5)=[>W1>G5,#"T^/)-K)9LI<\&[=)M9,?<:9565;JS-P&0`SU'
M>3SB[M>FOATP-DC@<ESEB\G;F-,637?2.\RRK9.,N1U::CRT$T&0#+I*Z*EH
MNNB=/,+>^IK6UXXD!F?[.P7VY.2NWO`U:,#=;<:$PU;>02`A0_!?'`Y?C7Q5
M,HY%>Z%LTZ$%^WD]D8G9%2MR0T$4%U4`653PTZ_I@0Q^'+-NH>J8_(!:B6%1
M%I[05AH:G[(";:?8574[1$!Z&A;T^FF!UW,.)+R&##[,TJ^WJY+<VKLVP0^U
M(;117<TJHAMN`9`8*O5%^NBX&KDO&+KD'%Y=1*L6&94EQAP)+<8E;;1AX'D3
MMD[N+56_\_G@5A_'EP7)_P`W^=0T9ERY<-EV+W";29$2,K2N*[Z@;41($043
M1-%U\<#2_P#$%*]4I4JK;=:\\LJ5";;(6FI*MH*/UR[]\(A--Z;"5-57IUP+
MWE_%IM]QA*6/8K%>1V(X4UYI'R/VCS;VA@A-)JXK754TP(DOA5B_:<JL&[06
MW.0P8]?%!6-Z1`8!X5/JY^ZI%(4M/2F!/9XR;?"XO&R=8D>WB,0W')$='F'1
M9$0+>P1:*+@@J:;NFN!35WQDQ7#6,PYBMQ*V':06XY";FUNS=;=$6S-PB06%
M:V@*Z^GITTP.>+X3N=U.W_<H.PJ<JAV/&D0>\@N4XJ`=DE?_`&4>0E(]O7<O
MCM].!T\3X_>9F!)<L1/;?/7Y@D=$U5V.4<6$53+;L$]=_BOZ8$JZXE9R.41N
M1TUH-=,2*M?/!Z/[D'HW=1X=B=QKMN`6[0NJ>KJ*Z)@>#P6,+TX!EN)7R[%B
MY"+HBDW-9>!\]IEN_:=<:$E#:BHN[0NO0*R/\:365JR6W`RKW;F0XA11('7K
M@G"%5$G%T%GO$FU==_GI@2J/XZ9HP9:J9(PX;<\)ZUP-JL5M$C*PXU&;)S5D
M3(E<\51%\L".Q\5U\9V1-BR48LISM?+GFVT@1GIE?(5\I2QA)!%Q_=M/:7DF
M!T-WQY+&QJ+-E[V\ZH?-QDU'>)M/`K3[1#J/WBNJ$BZH2)Y:HH5<;A4V)+HW
MXUD`I7R9DRT$HPZS'IR$KA"HF/9T-PE3[OU^N!+Y%Q1RTF.3(TQ(;SM;,K'-
M6D=0AE(*MG]P*G:,==/YM=.F!0!\5.L@UV+=4=@1JEJJ,XXJC3]0#H`ZZB&/
M=%U'RW!J.GDOG@=78496G''J>SDDX<IA6I$M@49+<J?>V/K0=%ZBBZ_KK@07
M..7LN+4C96K,F77SPFOOA%5H76VQ,1:`$=+MKZT524B_AHO0*5CXO=WP69=I
M[F!$;N&#:1CM.FU<.(>G<%S02:\-4'U?I@2I7">1S>%%Q^POVY-@#L5R+9^R
M0!%(4AN0WW&!=]9%V40U0Q3Z(F!V0(:`*&J*>B;E1-$5?/1.N![@,!@,!@,!
M@,!@,#D/^9-8[;G608C\Q[?*C,$"((G*B(2FT2EIL0U!1!PO0J]-?#4,>._)
MU1<UK]H<9^NKF.PT4F9L$5F.JH.1$02)>XPYH#G33<NB*NBZ![&^28<NN*1!
MJI\R:VDE7JYEI.ZGLU1'%$C5MMQ#W#VE$EWZ]//0-1_*E0-A,@)!E^X@SJNO
MD`0M@HG<-@XR2[S'1`WZ.)XHODN`C<_&;$C2'X\NL!WD#E(PH(R\CRLNN-H;
MFJJK;3I-JFOW(OZ=<"=6<]A3:_W[D.1#98D3(UFDCMH418*D)FZ@F6J&HCLV
M:JNY%\,"5Q?ET+D!V#;$=]ARM>1ETG05&G$(=X.,NIZ7!45ZZ=17HJ8$&#\A
M1)DEIL*Z6U&GM.NT<UU&P:G*R"N$VVF_>V1`*F".".X45?+`XFAY1RJ[8XTC
MXV3']X0I<R4<=Z*A0DCDV;+L9?4FA"^B$"ZKT3TZ[L#H>,_(,1*&(RP%K>68
MA)D2X[[;"6+;#,QV.X;S;2MM*HN-D``WJ1(G1%ZX%XYSJL2R2%'C2I8C,6ND
M/QV]XLRDC^Y[;J:H0HH*B;M-NY=%7`SX7R_^Z:]R>%3.JXR'MC+/!L"?!4_J
M`+9N:)KJGJT7`\^1[:PI^`<CMZYWL3ZZME2XKNT3076&2<!5$T(534>J*F!7
M\4NY+]1'M7YUA/7V#4B7&<AHVA.N@)?L$C+&JZ[NB*O1<#77?*]+8@+,"')E
MVCCUBPS7L=MQ3*K5$>)'D/L["4P02W=5)$^N@5COR*_4\QM1L&9KM0Y%I'@:
M4&T2O6P>=CGWTU0D]6U33U*FGTP.TO+T:XXT1B.Y-LIRFD2&RH"2BVB*XZ1.
M*@``;DU)?-43Q7`XSC'.W?P=++N7+`K$>/R;F9&%ME0>%DVQ=$ET!>^TI(B"
M.T?4O^`3IGRW51:1BR=K9@R'V`G#5*C92UAGMT?$&S-"UW=`W;ET7ITP)Y\^
M:<?E#7UDJ=$C+(86>""+'NHK*O&R:DN]L>FSN$.W?Z<"#4?*`3:.#,.HE'9R
M:H+I^MB['B"*9(*$)[A`R/U*V&NXD%>B+@3:[Y%KK3D;--50)LYDV&)3]LTV
M"0F6I;*OQU,R,257!'P$5TU37`FR>55SUS,X[#?UM8[*E)[:@KD;>TKC;A-E
MU45Z:%HHZ]%P.9X9\ARBX=!.RAS9UJS55DMQX`;4IBSE1GNM[201VNHJN;MN
MU/5II@$^0V+FTX;(J)CT>+96=A73X*@T8F<.,^I@;B;M-CK*$!-EH28%GQ'D
M;L'XW&^Y'-<?]D$QZ=.=;V&K3$AU-Z@*"G1L$\$TTZX'D[Y/K(4))#L"4X9M
MRI,9J.@/)(C0Q;,WF#`E`T,74[2:ZFNJ)@8?\U:PY,]F-36TENL8&5.D!&$&
MVVSBI+;3]UQLE,FRTV::H71=,"SG<[IHT:M>;%V4MRC'XD64%?<%(%301+=M
M38V/<-5Z(/G@91.;U4CA3G+R9E1ZUF,]+>8?9)N2(1]W<16BT]7[:Z==%\NF
M!#N/DR@J?R2RH\T@JE@>Z-F.KOHLE46#!`52(4(5$^G1?K@1H?RG76%C6P(%
M=*.1,LY-3,:>0&G(CD-CON&Z.XM4VJ&B(NNA:_I@:8',)=CR/C*P);I5%M^9
M&1'D,MMN;X+H@"=$W#VR0Q3KZDZKUP,>0_(;G&^:6,>Q;E2J2/5Q)JI$CBXD
M97)$AIYYUS45V[6PZ:JOCHGC@6Q\UIH=O;1I<QT3BR8L-MAX6FF^_*8[K3;#
MB[-RN_\`&7W=,"VGW\"NIQMK)5@QU1I#%]0$@-XA``-=RMBN\T15W;4^NF!3
M._)%&U!D2G(\L3BP'[5V*K0H[[6,\3+ICJ6PNH;AT+0AT4577`L'.6P$D1&V
MX\E]J2ZC#DIIO<U',F>^G?774$V>):*B+T54P(_]^T+;1/3._!91D)+;TEI6
MVC:=?]NV0N]6]3-1T$B0M"151$P($3Y6XO+CJ<5'WY8NR62KFT;*3NA&V#Z@
M/<V.(*/`7[9%J*ZIK@2G?D;C;+\P7S<:B5Y2@GV)("QV#A[>X#Q"2DV1;_VT
M(?7_`"X&F?\`*''*YJ0MBU+B28QQ`*$;"E((9[G:CN-MMJ:F!N>GIU0DT5$7
MI@2^0\H:@<0<NWQEUHKVAT*.+LADGGA:'>SN4?$NOJT1.N!/K^10+":]%B"X
M[V'7H[SXBBM@['44,#5%5074M!W(FNBZ>6H<YS7G3L'="IP><EQK&KB3Y8-@
M<=A)LIH2;-3)%W$R?\@KMW#X:X%Q'YG3RG(L=LG6I$Z9,K6$-OJDF`CJO(75
M4TT8)17P7`H_CWG;D^CXY'NW3=N+:#)E^_5H&6'5B.H#B*B*B`YM-#V:>&OT
MP.@+F%.U10+F4KD./9$RW$9D#VWB<D+HVVH$O0E\>J]$ZKTP.?9^3*FQM*AZ
M!*5NH-+4;171$4;.L$.XADJ%Z0W*NX"VKXZJF!=L<ZHGI4B(*NI)86,@-$VJ
M*\DULG(Y-==%0T;-/5IHHKKY:A"C_)5(],K8[C$F'^0@3+(UF-]A8[,`Q;>1
MX"75"0C\NFB:ZZ:8&0?)G&S.0RWWSELN1&F8B-IW7UGBI1E93=HJ&@$J[E3;
MM7=II@>?'O*)]Y0V%E9`XT4>RL(X,.-=MYMF*^38`;8*?K01ZZ:ZX&#/REQQ
M0?68S-KSCR844F9,<D<4K)=(I(+?<T$UZ:EIM7[M,"3'YW5S6-(;$PY9R94%
M(J,_O`[#51>,D54!`%=NBJ77<GUP-/#N5F[\:5')K]]$=>KV94Y[8@JIF"*N
MC8)]Q$NB"*>/1,#8W\C\:6>-<\3T:P]^S5N176B0PDR8Y261+;N':XT"JA"J
MIY+I@:I'R;Q^-3K;/L3&XK:REE(3"H;#<)_L/N.CKT0277:FI*/5!T1=`C2N
M;'!NN2,V#_;K*U:E(;C+*N.(5@2MJ)>.J$:"FJZ;=<"/;<TDLV_(QDRGZNMX
MNY!(WF6&WTDC,:U5M4+>70R'J.W3SZ8%J[\F<2#D;%"DE7);\AV%W&T0VPE,
MM]TV'-%WB6Q%Z[=NO3=NZ8$&FYW)N>;5\.&R\U13:9VR9<D-""O?OM`RZT:&
M1;2`U780BJ(J*OC@=5;6\2KBB_)W*KC@,,,@B*XZ\Z6T&P153557]=$3JO1,
M"@E_)=!%<CQR8FNS9$F1!]DS')QX)49CW)M&(JO4FO4"HJB2>"Z8%O8<C@P;
M*LKG6WBE6R/K%$0U1/;M=T^XJJFWT]$_7`YF3\R\48B,R48GO"Y5MWA@U'W$
MU`<-6U><]6G[:IZQ%57Z(N!9O\\A`=P!PIS#-0[%9*8K(DV^4SM]OV^A*1I^
M\.Y=$TP-G&[NQG<HY77220HU5*C-PDVBA(#T-IXD515=WK)=->N!S_"OD@Y<
M,X]TCYS7)5P,.6#`BPZ%=*<%&6E%?4X+(HNFGJT7KT7`NJ7G=7.&NBQ_<SID
MN'!GDHM"!C&L=_9?<#<F@HK2]S;KMZ8%I9<DBP+:'5G&E/R9HJXV3#)&T#8&
M(....KH`(WW!4M5UT7HBX%#*^5N/(PX5:T_;2$CMS8\>(@$KT5U\6!>`E+8B
M:N(6TE0MO73`WV?R'453E@LEN:\Y#E08+D-ID7#&1/$29$-J^K=W!0E4M$7`
MEGSRB;6,#RFW(DF#"1?VS?;E&T3R176VS,@=V!X+TUT37K@5$3Y>X_(CMR%K
M[..P[6N7+;C\9&T6&P8B^2(IZ[FMXJ0>.B^G7`OY7,:&-(88.1J;\EF%H*:[
M'Y+:.,":+H2=P231=//`H_\`FSQXJUR>S$G$V-?/LF@-CLDX%6XC4II$<(='
M`-4^[1%\E7`ZVLG)/KHLY&7(Z2F@>1AY!1P$,4+::"I)N37KHN!)P&`P&`P&
M`P&`P&!R\?A4F$_:)5W4F#`L5??;@MML$,>7*%>X\T9`IZ;R[J`JZ;]5\%TP
M(<CXP@.N6QMV,J,EJ4:42,]L.S91%11GM:#HCKBB*N(J*):=4P-\K@DV2M7,
M/D5@W=UHNM'9M)'!9#+Y"3C3S';5G;^V*BJ#J*IKKXX$*Z^)*FTNI%J-I/@G
M+D5\R4S&-E!<D5?_`*=PU<:<-5TZ$FNBZ)],"?\`\NZ]&F&&YLAJ-&N5O6&`
M[6T7B,W39Z@J]HG'2+_-^N!->X94O'?*Z<@VN1`(3H_=5&@46494V133MF0B
MBD7CJB8$GCE195=>,:PMY%R^*"/NI(,MEH*:)T9`$U7^95\5P(-3P>MKV:Z,
MCAOPZ975IVG$3='[H&U]Z=3V-.$V.O\`*O75>N!IX_\`'\*CC<>CQITET..L
M/Q8JO=I5=9D;?2ZH@/V=L=JCI^NN!`B?%K$!^OD5UU.BRHA2PDR11A7),>;)
M*8XPYJWM':^6H&([A153SUP+-CA9Q>0R[6%;RXL2<2R)-4':5@IG:1GW&Y05
MS[!3<"EM4D1?XA+X_P`:_"5=96QY\AV/7"8JKB-;GT/73N[0'[5+5-FW]<#?
MR:AC<AX[944IUQF+:1G8<AQK;W$;>!0/;N0AUVDOBF!33.!.R^..4#]W,6"L
M48C*"$<5%&U!0(MK:;_Z:(0EZ21514ZX%:S\0U\>4Y/BW5C&M5FR)[%@TL=#
M96:`!)9`%95I67>T!;3!=%1%%4P+"Y^-X-J5P3UE,;*Z9@,R"#LZA^-<5UHP
MU;7UD1+NUU3Z(F!8\DXNMO*KY\6>]5VM81^UFL"V?[3VU'VG&W1(3!P03^!(
MA>6!3?\`+%L*V+#9NYNL2KFU`.NHPYW&YRHI.NBC8;C!0';MV^'7Q7`]<^.)
M(.44FOY!,K9]3#8KILB.VQMG1&-%V/-N`X(EN15$AZCN+3QP)M=P<J^\M9D>
MWE)46W==>I-&E9"5(_K/@ZHJ\F[379NVHNJX%;3_`!B]3M5*0KV0K]=#2JDO
MO--.>ZKVW"<99,=!$3:0MHN#UTUUUUP+?C/"X_'[:SEPY"^QFLPH\6N1M!",
MU`9[`")ZJ1ZC_FP(EW\?#:\@:O#L3:FPNZ=6Z+0*[&)Z.L<VT<Z;XY:]Q6B3
M[^N[RP*EGXFELU\:$'(7T;A5]=`BIV&]J'6/]\7C!2T/N_:X"^E>GTP-M'\4
M.5$RK?:OI,ANNM)UN;;S36KSE@!@8&3:!T'NDJ:)X_HF!?T7%I=5Q-:$K(I#
MVCZ!/)AI%3ON&XFK*[FR0=^FB^*8'/0OB-NI5F5Q^X=IK)IR22N1V&%B]B60
M&[&"(2*`-";>]M$+425>JHNF!TE1Q@Z[D5W;>].0U=)%5R&8"B-N1F484Q,=
M%7N"(ZHJ>73`I$^)ZF)Q^MJJ>=)KI%)*<FTUBG;><8)Q#'M$)CM<91IU6MA?
MR(B:]-<#H97'6YW&9=#9RWIC<^._&F2B40=(9"$)J.P4$=$/041.G3`Y*3\3
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M"(&A63(1@(YO*Z*"3:.--"A`&B:^&FJX$.-\9S1X^M'*Y),D1XB-#0N]MD7(
M:13!R,9EM+W#C9-HFX^A#T5.JJH2+KX]=OZ1FMO;(9[H-O`4M8K39`ZY_2DQ
MD%?V'V/Y#%?XX$>[^(Z*]>FN6I]TYL61!>D--`S(<9?42;1XQ31THY-H31$.
MNOC^H8W'QC+O:\@NKHGK36"C4]F.#2"$"0DD?VMQ>IUP=7%W)_PZ)@=%S+C?
M]R<;F4ONBA>Z[>DD`%P@5MP7$])]%U4-,"K8^/8X\Z;Y<[)3WK#3[">W;2.3
MX/JFT9A`NU]&$Z-:BBIKJJJN!"N_C*;-L;!Z#?NP8-I.AVDN`4=I\?=0E:5"
M:,E%0%SVS>Y.OA^N!MC_`!U-9Y%'LQNS6%#LY=K%KUC@JH<YIQMYLWE)2(=S
MY$'1-$Z>6!56/QJ#O'>.<,<6;)"KD)-_N!KLLB&TS[S+@H8G^^R^;6T!7TKJ
MJ],#J^8<2'D-3&AL37*J7`DLS:Z:P('VGHZKLU;--I@HJHJ*^2X$2RX*=P[6
M.7%@LGV<:?%F--LBTV^%BVC1;412)KMBF@Z$O1>N!K#A-\E%%KSY*\4ZO>8=
M@6"1F1VC'%0V.-)Z7.XV2B:ZI^FF!C>?'+5[.B2[6P-]1K9E19M"V(!*CSMG
M<T1%U:(2;115%7`Q?X%;RJ>NB2>0.+8TTQJ94V+4=L.VC+9,HVZVI$CJ&TX8
MFNY-==4TP+#C_$':NCLZUZR=DO6DF9+>F-@+!MG.(C+M(.[;L4O2JJJX%''^
M+),9I19NU[IC4(X9Q6C0BIS(Q+:I>+VJ;_IXIXX$B'\<S(-L=M$N5"8LV?*;
MWQ@-M&+)6S>C$.\5)$=9`Q/<B]-/!<"7"X`W'^/(W#7;%YY(C+;3-D@@#J$P
MXCK)[$]'H(!Z>:)UP*.IX+92;^]D6CCJSF[*LG0K<V@%I\H<,&U5M@2](ZDX
M)>K7U?3`SG?$!3(,J$]>.N1Y3%HPHN1F#1LK5]7E>;Z)HZVB]O<NNH_3`L+?
MXX<L3MS_`"I,E;K5JYM8$D#\4XCJ(FI=>Z7C]/+`SM_CLK)OE`'9JVO)5BJJ
MBR*^W2(@BB)J7KW(/773`DQ>$/Q9MBD>U=:IK1YV5)K!;;14=DBON$:D?U`!
MUPE<5/%"\"1.F!!C<$Y!6L,N5_('')==4.U-8LB.VXFJDV3#SZJ2*XX'902Z
MBA:Z],"XN.-R;NDKF9\D6;BO=C3FYD<5[0S8_521LEU)HE4A4%+51735%ZX$
M3^Q`_N*'>K-7W;$YZPE"C0HCQNP4@"'CJ(MM"FGBN!,Y'Q=VVL:>RC3B@3:=
MUTVS1L70<;D-*TZT8%IXZHJ$BZHJ8',UWQ&]7QVP8O7%?;X^O&^\4=M=6^\3
M@O[4)-#%#4=/!?'`M)'QZKCEX3=HZREVL%UQ1;%3;>@(V*&)$JZBX+(H0K^O
M7`MZ7C8UEU>VGN%>.[?9?)K8((TC,<&$%%3[M4;U55P*2!\90XGX_P#^HON)
M7R;68`J+:(;ELKF[?HFO[2/$@Z*FOG@2XGQ[3-0*&+(TD/<=8B,UL_8(206(
M@H6CH^I!>0$0P\%3`NI=4LBUBSE>46X[$B.['VHJ.#(5M>I>([>SY?7`HX'"
M9T6@<HRNG7H332,5JDRRAL@V0JSW"1/WE;V(.JZ:IX]>N!%MOC9+*:[+.T<:
M<DV=9:RA;:#:958`(M)N55$7";0E7Q3PP+>!QA^NOYEA!GJS73S*1+J^RV0E
M+,1!7D>Z.(BH"*H?7`H@^,'&Z^!$:N#`X---I1?[`;E2<31$_HA(B$'93:G^
MW`O(/&9\&]=GQ[=[\?)!KW%4XVV8=YEL6>XVYHAAN!L=P]4U37`IT^,&CJ6*
MV1:ONMA&MHTAWMMHX\MP2DXZ1==";W+IIT5>JI@=+50;*&H,ORAD1&HS+("C
M:-KW6]4,^A%T--O3RTP++`8#`8#`8#`8#`8'SOE/.9?YWCC54C[545Z5=962
M*TD<^PP^K[)B6YQ$%QK3=Z?4/BJ8%E$^4J2P>E!5QY%BPS!8L8\N.(JP\U(/
MMHB&2CVR%?42'IH/J\,#6Q\ARIM]25L*J<[,^590K1UPP0HKE:FA:;5430C7
MHJ+X>6!"^+N<3[&#65-PS*.PD1I<ABV?[&R4$24K!Z(T6X2%##[@'7RP.KY5
MR:/QRM;GR(DB8#LEB(+<40(T<DN(TVI;S;1!5PA'77SP*9SY.JF'H4>5!F,R
MI4U*UZ.C:.FQ)5D7E0^T1HK8]Q`)P544+STZX&IGY0H+&NA64$9#U7.GPH,6
M='[1(3LHM%!P%+N-]LT[;P&*$FO1-.N!*;^1:YV<S#9@3''9*V(1?2V.]RJ-
M0?'0W!4=Q?8I::_I@0J'Y6A70@,:FL&I,BNC6T",\C(G(CRG>PBCHZ0CVSTW
M[E3050O#`\KOD]NVM*6+605<8L9=E"ENFX"*T[6)H>S15$T(O/7PP)/&>=0;
M"J:]FS-F3O;R)KD20K'N0;;D/,H)D*BUZG62!O:O@G7ZX&;GR92H9(W%ENM"
MS6RN^(!M5BV>[##B(I[O2:+O14U31<"[M[^/72H<%&CDV%@CRPXK:@*FD<-[
MB[C41335$ZKXJF!3UWR%!LK.'7P:Z8ZY,C),`R%IL0:&0L9_?O<0D5@]-R(B
MZZ^G=@;KCG$2LY%^%<@R7>W!6SF3@[21V(HF39F:D8FJBHZ[1%5T\,"O'Y7H
MC;DN-P;!P8[L!IO;&(>\5FXC3*-JYVT51+[TU]*8&<?Y.@.3V8KU;,C-.3Y=
M4],<[*M-2H;9O*);7%,A-ILB$A%4\ET7I@9)\D1$CN2'*V5VGH#UK3(';<.?
M&C@)EV10O2XHF)"V>BJB_P#>1`LGN71EJH]C`BO3VI01S:%M6@T&4"F!.&Z8
M`"(.FOJ\51//`H:CF$F_Y3Q696R'6*.WI9\]VO=!O<3C3T4&U)4W*A!WB3H6
MBX'>8'#R>9.TEARB79%)GP:Z57QHD*,TT1@LT6Q%!75K>I.O)KN7HFG5?(+K
MBW+XE^EDW[9ZOG4\E8EC"DJVKC1]L707<T;C:B;;@DBH6!6VWR=25:$Y(CR#
M8<@/6=:ZRC9I-CQ10W^PF]%4P`D/:6FH]4P*GF'R'8?V'<3*NOG0+4:B79,$
M?MNY%9!HUCR744W`_<(-1;ZET75$TP-M'\J5:Q*6#([\ZR?2!#GNL@A*$N9'
M:=0B%-NH?NHID*:!YX'1\2Y:UR:&4Z-7RXD$D0HTB4C0H\BD8%L1MQPDVJWU
MW(GBF!2<;^3TNZ*/8,U#YSGQF/I6L.,FY[:')*-W4(B`54U'TCXJNJ>6N!:S
MN94;O!#Y7'E/%3'%26$N((D\C2Z*I")ZCN'S1?UP(4GY.JH\^3$.NL%2-:-T
MAOBR*@4QYE'FD!$/<H$A"F_1$15371.J!H<^5Z_MPFH]-92K6<4]MNK9;95T
M':LT"4!N*ZC*;27TKOT+RP(#/R?7G>QKC\@0\1G43,YIIQI!()#LX8P*6B*:
M$JO(!(O0=/XX%G&^4JN1V&F:Z:[-?GNU@1FP;)%?:C%+U%U3%LFS;;70Q+37
MHNF!A&^7>-E%"=/8E5E:[`<LF9LH`0#".8M26MH&;B.,..")(H]=?2I8&]WY
M.I@`]D27(<2P:JV08`#%UV0VKC)@XIBWL-$T55+TET+3`U4WR2%S9\=C0*Q\
M8]TU8.RG'E;$XA5QHR8&(F6NKR[=1U3`F\J^0*WC5I70K")*6/8/L1?R`"'8
M;>E.*TR"[B$W%(T]2-B6Q-%+1%3`L;OE-333($*8YMEV9&$!G415TFMJF(J:
MBBD@EN0?%=%TU7`J&N?.)+OFGJB7VZB>W`8<:$%1]3C!(5Q2,P%L4WZ*1J@^
M'75=,#4ORSQ1:9FV:]P]'=K'+HFVVT5UN`T2`;QCN3HBKX"JKT7`E3_D?CT&
MT2O=&27^JB0"E-LJ;(RYX(Y'9)17?N(2%57;HFY-5ZX$4OESA22I#`R'7`CL
MSI#DAMHC:VUFY)8[AU5"#:NFY$W?RZX$:R^:^$5D!B98NNPQDQQFQV7T:;><
MBF`F+[;9.(3@KNT1`U+5%3;@;+_GY>YK6J-MYY@[J)63;%&VRBZ.EHZWN,P-
M53<@[@%=#Z=>J8&GY'Y'>5O*>&U=?8'7P[J3,9L'&V&Y#B@Q$)\-B&#FB[@T
MZ)X8'G"OD(IE&#M@X=A(?L9-=3FTRC,F<$4%-7#851%D]K;A*A;$VHBZ)N1,
M"PE?*'&X],ENK<HX@-ON3-K2(47VCB,R`D;R$1<;<]*@BJ7151%3K@29'R#1
M1Y5JPX$G93("SI/:_91760>:$354W*XC@B*)XETP(W$>2VEKR[E4"6#K$:M*
M![.&^VT!MI(CJ9^MHCWH1)KU7I_V!*@<_I9SL,6&I*,V:O#4RS;1&911T(B%
MLMRJBD#9$.]!W(BJF!6?'W(K&TXRG,KN2_$B2X8R'83[;3<=@6][A.LJ"FZH
MJVJ(2F77;N1$UTP*Z3\ADW*Y'83'9M;20J>%.84F8YN-I(>D`LEM!5W<)"V!
M*CG@GDG7`O7/DFA9L[2`;4M6Z4&UL+)&=8HFZV#K;:.(NI&8NCH@CYX&V)\A
M4LN2["9CRULFGY,=(!,[73*&`&Z0*I(V0:/`B%OT55T\<"*7R5"9L[&-*@2H
M\2%#KY3<DQ1#><LGC89CHPNC@.*ZWL1"3Q\=$ZJ$FV^1*.K(FI#,LY8S@K?9
MLL*Z\KSS9.LJ@BJ_MN""[3\/KIHN@6\"_KY\A6(BJZXTI!,$=JK&=%!7M/CK
MN`U0M433KI@5O.KZTJ:R(W4@TMK:S6*V&Y(129:-]5W/."*B1(VV!%M14U71
M-4P(_+"Y'3\2NI\6X1946OD.QWI##6@2`%3!Q=B".P=--JBO\<"4?,:Z#,I:
MJ>9%/MR2/'?`41EQY(ZR"4%)14@407U"BHB]%T7`P;^0N-.US%DR^KM?+>9C
MPY8[.VZZ_NV@BJ2;"]'5'-JIJGUP,^4W<V/P&VO*]#A36*Q^;&&0U^XTX#!.
M"CC1?S"J:**X$EJ\BU_%HUO;R5!D8[+DF4\@MKN=04U-$01#U'U\$3`H;7G2
MU\YNT=9F%2C5SI;D1IEMTR]H^TG?0@(DVJT2D'KT(5Z=<">]\A4S-E5PG6)8
MA<NM1ZZ9VD5AUQZ.4D4%4+<J(V*[BV[47HJX%#7WG)$M.*QY%D3S<BYNH,WT
M-)[AF,$HH_<VBFPF^R/0=/UP.PE\FJXUVQ2;U=M'P%[VC:AW!8,E#O*)D*D`
MD*[MFY4\TP.>F?+W$H\.9.!)<N!$B+.]Y%85YIUD709/MD"KZA-Q-1+1=.O@
MF!95O.8,RS6M>KYU=*6([.:&<R+*.,LN(T:BN\O4BD*[2T7147`C_P#,SC:W
MD>E%)!S7I`0W4;;[@QY+C7>[3^PB4%$53<6FU%737`MKKDM?3$'O1=1HU:$G
MQ#5L%?>%AM")53JIGX#JJ)U7`U7_`"=*BTHJ_P!D[*.[E'%%QI11&>VP;ZF>
MY4U31O3I@:(?.JF44)H&9(29XSE9BN`(NH=::-OMD.[H>Y?3Y+]<#P.<53MH
M%8TS))PY7L'7P`2;9E>W21VW%$B5-HKHI:;4+HJX%7P7G:SJ3C[5T9K:VT!Z
M8DO8`,.+&-!=%-JIHX@DA;=OAJJ>"X%XUS"G<D1XZ*YWWY`PS;04(F)),D_V
MG]BEL)`'KY:JB8&MSD#CO-F^.1Q(4C0?R4][9J.UUU66&D)>B*2@X2^?IP(?
M&+&_LQY7#D3@23`M7X5=*%@41II8K#S6YO=H:MD^O55]7^[`J4Y+R.BXGR"S
MG2AM8U!*4H]BZV#9S(30ME(':UL`7&S5QH3TT51U5,#Z`)"8H0JA"2:B2=45
M%\TP/<!@,!@,!@,!@<8'Q;4C=)8?D9Y0QLCN6Z@G0*(,UX'`=-$4.YL/NJ6S
M?M0NJ>.![&^-&(U*]2M7=DE:BM)61R-HTAM,.HZVTWN;+N`FB!H]O]'I\,#9
M!^-J^%*B3&;&;[N'93+,'B-M5+\@NZ1'--FU6BZ:=-R:="P#7QS!@1(XT\V5
M#F0H$R!#D[P,A2:XCQ.%O;--XNBBBNW3]%P+FYX^Q<UD>#/><VLOQ91FTHBI
MN1'0?%%U1?21MIKI@0H_"F(G(95Q`L9L1J>??L*MLP6*](V"'>VF!&!*(HA;
M"1"T37`CM_'%#[PISY..SG)$26[)38T3KE>9G')U&Q$3/]Q4,]-2337P3`I>
M.4/.1Y#*>L%.)$.1)-P$6`Y&)J21%_IC;8"8A)Z%575354Z[L"<Y\1\8)*_M
MOS63K(4.NAN-OZ*+,"0,EE51145)7`3>JIZDZ*F!-K?CNG@3F9S<J6Y*CSIM
MBTXXX"_NV*(CXJB`B*'3TIXI]<#*J^/:2J<BNP7I3+L:/(B$X+NBNM2GB?7N
MZ)U5MUPB;5-%'5?K@)'QWQY]HV]9#>^/7Q-P.KN1NKD+)C*BDA>KN$NY5^[`
MM+2@B6%A76)..,SJLG2B/-JG@^';<`Q)"0A)-%T^J)@:X/%:J#:MV49#%YJ*
M<,`4D4-CCWN'"ZINWDYU5=?\,#3,X=5S>02KB6;CZ3*U:B17N**QBCDX3A+M
MV[MQ;U%?5IIY8$*%P$&(`07[JQFL,/Q'HR23:+MMP71=:93:V.J$H(AF6IE_
MFP,97QS5O2HSS<N2P#-NY>.LBK9`Z^\R3+C1[@5>T0&6HHOGXX%E5\1J:Y*I
M`5Q\J:,<*O-\D)0:<V(O@@IKM;$$7_+@5H?&M+'IZNIKY,N!&IYRV$%6G4(A
M(E<_95'1,2:$75$!5/2B#I]J8&-)\<0J<JU8UE,+\5"F5\-35E21J:ZVZJDJ
M-IJ3?9%`_P!^N!U;#9-,MMDX3I`*"KIZ;B5$TW%HB)JOZ)@<S/X%'G.6ROV4
MI6;:;!GN,?M[&G*\VC$6O1J@N>W#?KK^FFN!.I.)0*BTOK%EQQUSD,D)<MMS
M:H`0,!'VAHB+M46T7KKUP*I[XSJGZDJQZ;+<:"!+JX#RD'=C19J"C@MGLZJ(
M@("I:^E-.N!JO/B^#:Q18_*38A.5)4=BXPK/^KAD"A^Z)MD`F*D1"8(BIJJ>
M'3`D5GQW&J9K#M9;V$6&*1_=UXN-JS(<B,@PTXXJAO%5!H$<1LA0]/4GCJ%Q
MQ;CS'':&)3,/N2&HB&@/.H*&N\R/KL01_F^F!05?Q?`J`86ILI4:3';DQ69)
M(RZ:1)3W?]NN]M=PM.>ILBU).NJKK@64_@U7)X,O#6'7HE7[1N"#C:B3HLMH
M(Z;C0DU(1T5=,"(]\=0W9[TO\C*3O73%\3/[2BCT=D6$:3T;NV0MBJ]=VJ>.
M!4.?']I#Y742*V7(2&"WLB9.UC[F7K8FW`06R3U(+B$HKM731$7IK@3G?BBC
M-@&!ERFVVJQFKCJ"MH39,2!EC+1=G5_O@)JJ^G5/M\<"R8X<\KU3)L;B792J
MB4],:??%@%,WHQQD`A9;;%``'25$%/'QP*U?BJH>KXE=.F2)D&+72ZWLN"SJ
M?O7`=<?4D;14<$FAV[=$33PP)Q<)D28]<U:7DRQ.ML&;)IUT(P*2QP40:+M-
M`FQ27>J_=KYZ=,#&IX!&K)M;,:L)3S]<=@J$^H&KH63_`+AP#7:B^@T38J==
M/'7`T\G^.(]_9N3G;24P+IP7"CBC)@*USZR&NVK@$3:&Y_4VKZM,"TY/Q*NY
M*PD*U57JLFG&WH*B*H3A**M/@:IO;=9454"%>FN!5VWQZ[.LAFM7,B,+=C'M
M&XW;:<;[K,;VIB2$GK$P1"'=]IIN_3`Y&^X%=UE92T=:U+MHM<TY':F'&KI;
M;HR'M_8E1WCC;0:[8+W!547S%53`W/TW-7?D%V65=VB1R)[:9[6,]7N!&#U/
MFXKX2&72WFVB=LE'0=%ZX'5?\OR2LOJ9NU>"CNFY@-P.TTOMCL$)7R!U4WDG
M<<,Q%?#73JFF@:S^.G&GZJ567#T";75K=0\\++#HOQFM%`E;<$@!P215$AZ=
M5145-,#%/C;LRY"P[B1%K7[,+I(`MLGLF=Q'7MCC@FJ-NDFJAIT52T7KT"=R
MSA9WMQ0W#%B<";Q]Y]^(J-`\!E)95@MXEHO0"731?'`KHGQ=$B/C8,6<E;M;
M<KMZP=0"1QYQA8ILJT*`*-+'+8B)U3HNNN!`N?AMJP8-IFZ>C>X9GA-(F67E
M-^Q>[YR`0TV@8KZ/!=6]`UP+29\<-38_)V)-BYMY&L4T)ML`*,Y$9;;`@^X2
M3<R)Z*GZ>&!)X?PZQI+6[MK.X6WL+LHRO&D<8P-C%:5H!`!(_%%U7KXX'M7P
M2/7C`8;F&<&H=E/548FP_9*2)"";UU4NR#K@!X>DNNNF!LJ.$Q(O`6N&6#ZV
M$,8)5S[Z@+1.,D*M_:FX478O_P`<#FW?B.RET]O76')GI*V=4Q3-NI%9;1IF
M,X9MN;$54-S1Q1)>B+]/#0+AKX[%`Y%W;1]7KZ1&E-R6@;:<BN0VF@85OH0D
MHDP)^H?TP/9G"N02VJ^6?(R#D=:X\K%L$1E`5B0@B['*,JJ*BNP2UW:[D1?#
MI@8V?QT,^?*DN6CVV5"@QC0@`G/<U<@I,27W.B;A<-5,-NTL!+^/GY5A%LW;
M32>W9QK28X,<$!U(K!1PC@.Y2;#:9+JI$NJK@9R^!.O<BD\A8L!B6IQI$:'-
M8C-B\"/B*![@M=LD6%#5L7!Z8%CR;B;'(:)JNF2G6Y<8V9,2S9T!YF9']3<@
M!3T:H7515-JIJGA@:[3C=K;<1GT5C:B<J?%*,5@S'%O:IBH]Q&5,T5>NNF[3
M`IE^-K$N2!>'R!PG!F1IO96*PO5F-[9YD7"W&#+R>O8*^@M53`];^+HJ#/)U
M^.\]:$S^4!R&"QI@L[]2E1M_;<>/N)N=':6HC],"V?X6S_83_#XDUYIAR"Y7
M-37_`/4.@VX"MZKN5-VT2T37`EG0/.\79I),M'G`8:8>E$T.Q[MH*%W&5514
M'=NAAKHJ*J8'-P?BIF%6_BV+!&:TX5I`>C,QQ`4"T>5[]CU+V@8UVMAZDVX&
MB'\0^SF5KK%[(]M6R*^4,<V6#5TJ^(,-$-U4[FA@.[HJ:*JX%M#X&^R]2OO6
MIOOT\Z;8J?9;%'CG]U#`D3[1`9!H.G7PUP)]]PZNO)T:18+W0AN,R(@:;7&'
MF#4T<8>%1,.YT%Q.J$*;=.JX%27QNI<6MN*E<2%HY[#L:#'[;2'#:=554`<V
MZN(&NT-W@/3JO7`O;?C$&T>JGY!N`[4O=YHFUV]P5;4#9<_S-'Z2(?-1'Z8$
M&NX=(K>23+2!;R&:VQ?67-I5;9)A9!-HV1MFH]QM#TWFB+ZBZZIUU"-R_P".
MV.33_=/V<F*V4=J,3#2-DB=F2,H2!7!+9O,!%S3[Q1$\L"YN^/,VDNJF*^<:
M542O=1W6T%5)":-EQHMR+Z#!SKIYHF!3S?C:GE7'Y7W4IB0EDU:BC1H(BX#"
M1W64U%?V9`(G>#^9>N!-C<6EQ+]^PBV\AJLE.%(>I]K9->X($!3%Q4[@@7WD
M"+HI]?JBA&@_'M3&H:6F-]YYJD<WQWU40<<%4,2:<411%;,7-IBB>I,"3$XD
M<+DDRVAV3[,.Q<&3-J4%KL'(%H6NZ);>X.X0'>F[U*B?KJ&;U*ZQS`.0,(K@
M288UTQD=$5$!U767E55ZH'<,53Q]6N!A%XF[#&^]G:2([U[*6:KX@R11W5:;
M97M(8$*IL9'[T7`KYO#+27Q.5QFPMG[5JS569$UYN,R3,5=-S8`PVV):B.U.
MGBNOZ8'7B(@*"*((BF@BG1$1/),#W`8#`8#`8#`8'$_\R7/R7LUIW$;_`#3M
M![CO-Z>X&/[AEQ13KVW!Z+YBODN!LC_(;DW5FMJRDSH\1V78QE>$$9[+[D;M
M":"0F9N,.[/!-!U73`@R/EV+[2380*MV56185;8G)-P&B)FU,@:0&U0BW@H+
MN0M,"KY%R[D<O1UA"B_C.80ZJ*D1X@]TPJ@+C<I"%402[B^&OE_B'7UO,PL^
M(3[Z)&4'H/OFCBNET[\!QQHQWHG4%-KH6GAY8%+7_)=I+AUG9I"FV+L6NEW$
M:(9FD<+)"4%:)6]#VH"F2&H:)YZX&^Q^1[*'&D2_[>=<B,60U/<]RR*FZ<I(
MHN"*_P`GJ$O4J>:>74)%=S]V3+K(LFL6.[/LYM0ZHOBZ+3\%MUW>B[0W@X+"
MZ>"IJFJ8$;F[UD_R.'6"+JU?XR=-?]K,.&\KS!L]M44`\M=$_<3[EU143`V<
M>^0+6YBUYI1+$E6T,K*MBO2FU4X@-M%N<(!)`(G)`B(]>GJ73PP*RZ^8TB5T
MJPKJ5Z8Q"IDO92NNA'5ML7W&76"%4->Z'8/33TJJ::IXX'4<8Y/)N)$N/*@+
M!<9:CRHZHXCHNQI8D39:[0VFBMDA#IT\E7`XIKE7)[D>,VC8--2W+NUB1X`2
MG6F9#<:/,:`'U1KR-A"ZB7AJGTP+AGY5&;7QY%523;"4K3#\V%''>3(O/FP8
M]P44%-M63/0MJ$*=%ZX%[R?D4R%*A4]5$"==6@/'&9=>6,R+,=![SCCP@Z8Z
M=P1':"JJKY)JN!QU=\D6=#PSC4BT@NSU=BP4MY12$-\');B,)H""1.$)^HS<
MV"J>"J73`LFODR8V]81GZ[W,S\Q*JZ6+%5PC>;B-BXZX]Z"V;$U7IKKTZ8'1
M,<L8'C<.[LX4FK*43+2UTD120V_(=1@&B054=5<)-%U\.N!R'*?D#DS57)A1
M(#$/D<.XK*^1&<D[H[D>>Z"@X#_;0D%T5)O56]15"Z+HFH='86$GC(\:J(+)
M3$M+!81G,DN&;32L/RC)'21PW%!&=H(7EYX'+<)YU(K(HQ+M9$UF59WS;=L9
MJZ0_CY$AU&2!$4M$CL+LT^FFF!V_'>2O7,B8!54R`PPC1QI4IM6@D-O#NU!#
M030@5-#%1Z=.JX'/7C-U3<I<NZ^?,EUK$&?+N:V0]NC`0-"406A4?VU4@/H*
M^'5<#7Q*SN?[CK(LF>[+CW/'PM'VW=%5J4+K:$;?@@`8R--J=/2GZZA,XBMC
M>?&5>=E.F>]?CD4J7$-`E&H&6J`X"="7;IZ=,"3P#D,JS^/X5J][B;.;9="2
MV\V+$DWXQFV;9@JH`N;V]J]=->N!2ROF'VK4P'Z"5[^'/KZXH@N-+JY:""L+
MO)13TD>T]NJ(J=%5.N!+8^39$@XD1BD=*SDNV48HRR&A`'JIP0=3NKXB:%N$
MMO\`%,"#(^;:AFEF6RUTCL0JRKN'`4@0E8M7";$!\4[C:AU371?K@7Y<Q4N3
MM\;E0CBK/26W#E`^!FJQ0`B4@;U[6\'-S>I:].J)@0^'\CEQOB&JY#8*_92F
M:AN7)5-3?>(&=Q+^I%IUP.<N_D"R?Y%PZVIG$E54N/=&Y71939-30CL-N,O=
MS[=HZ+T+0A4M%'`Z7_F4TLKCR-U;Y5_(!B*U+WM[FCG-&\V)-(JEH*-HAEX(
MI)IK@80_D^._':<>JY$-^7/?JX$=XFS-V3$<>"0BHPKVP&_;JJFO3K@<U(^4
MK6/;C?G4V7XI*!)TVC<0&GHQ-3U9?=5LU%3)`U4?\PIKTUP.N/G^EBHLU;TF
ME"<W5NVS#C9H$ITA;T)G5#[8.N(!GKT7RTZX$&IY3.C'*JNU*M;:586Q0FS<
M;#2-#<354<)$`1!76V@3375>O35<"NX=\E/_`-ITP28TRYN?Q\29:=D1)Y!F
M.$`%HF@F6C;A$@KT0?U3`LI?RM$B+:OR:F5'JJF8M:_:/G'!E92.`">#AD#6
MCJ$KIHB"GC@7=GS*#6\,D\LDQW5A1(QRW6&E:<=5L.J[%$^T6J)JFAZ+@5$;
MY/:62]&FTLR$\S.@P3$RCGHEIL&*ZNQU4VJ1[21-5'3`PD_+_&V&WI/M+%VL
M89F/.63<0U81(*H)#N7:NKI:HUT]:HN!C:_)4UIZM;KZ*4XDNTA5S[DM$CAV
MIC!/$ZR1+ZU;4-A#_F_31<#<GR!7Q#5J/%L;)R5=2:@4_85&Y;39.]O4G&]K
M2H"[%ZZ>>F!KD?+-2S1%;+7R_P!BN>M9T,NT#S+,9Y6'@53,6R=!P23:A^7C
MU'4.KK[&3+>5"@/1HZL,O-R'2:T(W452:V@9$A-Z)N5>G7HJX'*44NWY=(OI
M*V$FJBUME(K*QF.@`:+%%&W'GT<$^YO=4B`5].W;TU7`]2YN*GF<V+.FN6$.
M-01YKS.UAD/<`^XTZ\&Y01M#$-Q(3FU,#<7RA2K#8?;;4'9%@_5M-R76HX%(
MC%H8@\1*V2F"*37J]7AT7`FU_.84_E$GC\>,X4B&9MRRW-H3)`"&)NM*2."T
MZ)IVG$14+KX8%783;H_D>SK&[%]J`''1EQXX(&QJ4<AUKO(NW<I;6TT0E5,"
M9QGDIQOB^JY)<NNRW!JF)M@^`;W#4F1<<-`;1/JJZ(GA@4LSG5M(N^,3*P#D
M0+!JVWU\1V-(9EI%;$V'0DHJ(`EXBJD/CM)-<"W?^2H"?V\]&ANR*_D"1B:D
M(;0&VDPQ;9562+>:(9HCBC]FJ>.N!1IRGD"MLNK,+T\R<JB':"(4-7#;1I?3
MKH/145.NJ>.!TO)N<QZ6^J:((A3+*WW&PUW66$5IHP!U0)X@1QP4=0D:'U**
M+],"&]\GUHRI7M*^98UT6+,D+/B-$8D[`)4=CHAHVF\MI=LMVTM-$7`G0N:$
M_<5E;(J)D%;9F2_$??5A05(W;7:7:<=VDX+NX47R1<#P.=Q5O"IRKIPO-O,Q
MGGT9[C0//-BZB;FU+411Q$,_M1<#9S3G%9Q*&W,L677&'"045I6D)2(Q!!$7
M#!3+4]=!UZ:K@3>0W,NJ;@%&@E/*9-9B."+@-=H'E5%>53^[;I]J=5P.9XUS
M9UE]*VS&5**5=657"GJ+>Q"C*X\TT>B-%U:;(1+9U4>J^>`J/DV+*<HH$"IM
MK%RY@?DH\HPBB@L"X+;G?-76Q$VU<'<@HOBFFN!LXU\D'-IZ&;>5KM45ZLI&
MW34.PTL=#<`7"4]PDXRTI#T\E_34+.\Y>D'B;-T$<@=G.1H\)AP@1>Y.?".P
M1**F.W5U#735=/+7I@5O.Y5G53^.RXUO+B,'/BQ9J*TTY!)A37NK*-6]S1.H
MJ-@:$B;]OZX$0>5W8>VN'7]\27R,Z9N"(;!"+WBA"J[DW*YWV^ZI:^"Z)TTP
M+[A_)';23>UDIP7)]#8'#?,`4$)LVPD,%IJJ:]IX1+3^9%P*B%\KPYIQT8I;
M!0G19TJ`1"PG>2M?[+X)^[H"KJA!O5$)%^N!FORM4N0W+2)#?D4D*+&FV\_1
M!6*U,:%\/VNI.*VR:..H/VC_`)EZ8$IGY%@NV:0_826VEM':599]KM^[!E)#
M6B"9&K;S:^DM.B_<B8'.1OD:YG)07S5;*%)E7;2GJ)IYDFS*&['$25XMB;D0
MBVZZ:Z^&!T]]S<HG$:WD53"*P&T=KABQS,6"[=B\TV)$I:HBH+OA]<#6OR)%
M.PE1H=;+G1XQ2F5F1Q16UDP14GVE4U`0]0JV)D6BFBITZ*H1O^8\TH4.2'&I
MHG/AR+",RX[%$NQ&%D]7%%TT$C1_TBFOV]=,"PXMSN%R&2+#,*3#5^OC6L7W
M*-HKD64I"!*@$>PD(%U%<#IL!@,!@,!@,!@,!@,!@4`\(HQD$^*/BX=DMR2H
M\>GNU:[.[37[>WTV>&!A#X#QV(Z#S(O]X6)44W2?=(G&IKJOO"YJ6A_NDI#K
M]NO31,#&1\><7?9G,+'-N/81HD)YAMPP`6("J486Q%4V=M27[<#U[@'''9'>
M,'O_`.*!=]I'W$;]\VB(+FU%ZCT1=GVZ]=,"QK^.5,"ME5K#2K#F.2'I#1F1
M[BEF3CW55U1"(UZ>6!6U_`:>NE5TJ%(F,/5T=N'J#Y;9$9G566I(Z;7$:W+M
M71"3PUTU3`W2>$4$J`Y!D-NN1G;`;8Q5US590/)(%=477:C@HNWPP,0X-1!+
M9EA[@7H]B_;M+WW51)4D";=7155-A`9)L^U-5T3`E3^,5DZW;M7U>26W%>@A
ML=,0[,A45Q-B+MW*HBN[QZ)@0DX%2M0Z>-#=E0BHVO;0)3+Q=](V@H3!N.;U
M-LNV&J%_E3Z8$2P^+N,S($V#OE,,3JMND=[3Y:I#;,C1!4T/UDKA;C755UP+
M:HXO"J[)ZP:D27GGHD6`HON;Q1J%O[:HFB>LE=)3)?'`K(WQQ319=>_'ES&F
MJN?*LXD07`1E'IB&CHJG;W*'[SFB;OYO'PT#17?%=#7E6E$FV+:U[9,.[9*C
M[QDGBD(W,013NB#CA[=--$)4\%5,"YO^)U=W*K9DDGV)U0\K\"7%=)EP%--K
M@*J="!P/28DG5/UP.?D_#G%'8BQ&G[&+'**Q#<%F8YJ8Q'5>C&X1[U(V3)=J
MJNFG145-,#?*^*^//N27AE3H\MZ?^5C2V7]'8DLF^TZ<8E$MJ/!JC@EN$M5Z
M8%Y-XO4SN.EQ^8+K]>;0M$INN*\NQ4(3[V[N;T)$+=KKK@5EK\=U%G!<CR)<
MP9+TN-/>L6W`&23T-45CU;-HB"BF@B*)_M74+BXH85J[7/2"<;>JY0S8CC1;
M51P0-I47HNHFVZ0DGT7`I8/QIQN*Q'9<61,2-+G3A62[NW.68.A)0Q%`!1)'
MST3;T\L"TXUQJ/00DB-3)<Y`1`;=G.]YP6@30&Q704VBGZ:KYJN!75'`FJVR
M6:MY<305QYXX4R7WHY$\.S0@4$(A`>@"I;4^FJ8%E3\8JZIT78XD;S;`PV'7
M50B;B@2D#`*B)Z!5?/KX:JNF!`JN"Q*F@B4=?9V+$6$^3[#J/"KNTB(E8(B!
M4)KUJB"J=.G7I@6+7&JIOCKG'P%Q*]UER.[^ZYWB%Y%[A$]KW%,U-54]==>N
M!S3/Q!Q\&W1=L+*2X\_72B?D2!<-'JI=8Y)N;VIY(2::+I]=<"TB_'])&M6+
M-IV2C\>7/FB"N(K9'9HGN`(=OV:HA"B+T7`HIWP?Q&;";@.RK$80P8U8ZPW)
MV(]'A/$]'1Y1#<:MJ:B*Z^'Z]<"W@_&U!"N_S##TM)(R9<QII7U5IMV>VC<A
M1#3KOVH7J5=%\-$Z8%G5<7AU?%HW&X<B2W$B1TBQY*.(DD0%-!5'$%/4B>>F
M!5+\7\42SC6+33C+\8K%P1:/:V3EL`!+,@TTU+M(J::(B^6!H@_$_'X,EA^+
M-LFD8&N161E$C3BU0B$<G!1/4J@"":>!)Y:]<"07QI0_@V:IM^6P46<]:0[%
MIU!ELRI+KCKIMN;=NA=\P45%4VKHN!LG?'M3-COMR)DXWY-6M,_,[Z=\HY&I
MD>]17]PE5?5I_!,#%KXYIF[*1+&3+6-+G,6DBN)Q%CK,C"`MNHFW>G5H3(4+
M0B1%7Z*&J3\9U3DAB8S8V$6QC3)<UF<R\/=1)Y(4F/H0$"LEL'1%'4=$5%UP
M-=7\5TE2_6/UT^PC.5T<(3A`^B%*BM.&XTS)79ZA;)TMJCM+3IK@6<+AD.%&
ME,QYDK6;8.6<MPS`E<<=T0VC'8@JRHIMV:?XX&C_`)=\>'A#W"V.]&I7A<`A
M9(1<$7GE>,07:HBBD:HB(/1.B:8&5GP*KL93\AV5*:)]^!*4&B;%!=K#1QA1
M56U+J2)OU5=?TP-$;XWIVH]O7O3)LNDN$?[M,^\A1F?=&IN^WT$7&TW%J*;]
M!_ETP-H\#8.JKX$RVL9QUDUFPBS9#K92$<CIM`"-&T0@VZ[MR:KJNJZX!G@%
M8VZTZ4R8Z;-N=Z"N.`O^I<;)I0^Q/VD$UT%/]N!S-QP7D$1VOJJ5V:=*(S$D
M3!=KWGE=L'U?<]PU-842:;--P=LM=5T45T14#NJ^MM6+`Y4JT*4RY%89*'V@
M;:%]I2[DAO15(>ZA(B@JJB:=,""QPJ)#N9UG5S95=^4=&19PV";5AYX0V*[M
M<`U;,Q04,@5-=J>?7`TWGQ[37,IZ3)D2P==BQH?[;@]`B24E-%ZQ-2+N)ZM^
MJ$G147`TR_C:GF1YT2;,FRH5@[(?DQ'W&W&E.4("2B)-KLV*&YO;U`E54P)S
M'":=JZAW)$\].KQ?"&XZ:&0-R!$2;WZ=P@'9J(D2Z*J_IH&,_A<69>SKHITM
MJ1.K5J"::,$:!E2(T,14"U=$G"42773733`D0.,M5_$XO'(4V2PU"BMPXTX2
M#W`BR*"!Z[=BDFU/$=%P*2'\5T4&RA6$!]Z(Y#*:\C+2-"P4BP9;9>=[2!L!
M?VMR"&@[E553K@1VOB"G:2O1FTL&@KPK&Q$#:1#2H-3C[U5M21"5?6(JB*O7
M37`LO^7M9X++D[1NEY`V*$"(D@EU[:^GU-;E5=%ZZ^>!9\CXO6<@C)%L4)R.
MAMN"";?2;3B.";9:;@/IIN%45$\.N!7M<"@LP+NJ:G2AIKMI]M:W<"MQBEH2
M/E&)1[@(6_5`W*(KX(FN!,D<2@2JZEAR'GU6C=CR(K[1]EPG(P;$WJ")Z3%5
M0Q31%3IX8'K?&&V.1OW<6;(CI,05GUXJ"QWW6Q0&WE0A4Q-`1!782;D0=?#`
MK.8?&]9RF4Z_-G2XXOUSM8ZU',!'MN/`\C@[@-1-":TZ>*=%UP+VUIPL(L=A
M9#L<HS[$AMYI1W[F#0]J[A)%0T3:73P7`I&OCV&V]"=2QED4&XD7C:$K:H3T
MH7!)H_1JK8B^0A_,B>?3`SXU\?5E`_7.QY<F0E7"D5T,)!`2"Q(?!]451`5)
M0[0@*K_*GUZX%=_8@1:B!Q%J.]/HTEG.6Q>>9`X?;E)*:9;!`0C1556QZ?;K
MN7ZAT7*Z#\Y1/5P.=A[>S(BNHG0'XKP2&55.NHHXT.J?3`\L./\`Y9X"LI#A
MUR@T3E,J-%'5YH^XAD>SNEH2#TW;?3X8&#?$H#=FDL''!C)(*=^/14[/O#3:
M3_ANUT55VZ[=R[M-W7`W4-"W5N64A3[LNUEG,E.Z:=5`6FP377T@TT(_[5\\
M"KA?'5+#&O%B1*0:QB?&BHI@OHLC1Q[=J'51(4V?33KK@80/C2A@Q?91W)'L
M7H4>OGQ2,=LIF(VK32O;1%=_;T`R%4W"B(6N!O#@-,,KW'>D*OY;\Z@*8;4E
M=GL(/0$7MH'\NOCYX$>J^-ZVOB0XHSYCC4!B=$C"1-(B,V!H9HNC?J)O:B`2
M_P".NN!.?X75O<5@\:5Z0,.N&(D20!BD@"@&!L'NV[5(2:'74=%^F!%3X]K`
M&\8;G36J^^[Y28`.BC+3LL2&0ZSZ%(2<WJ2HJJ.[U(FN!N+@E6OXI4DRQ.GK
MGJJ*XCJ*2LR&VVR-Q2%=SJ=D50OKK]<#;2\-K:B>Q-CO/F['K8]0`ND"BL>*
M1$V2H(#^YJ:ZKK_A@7V`P&`P&`P&`P&`P&`P/E$NUMF.9<AMI-:MB]3VL"MI
MVF)KC"@W81XX?N#M%HFU*1W#0MVB^'@BX%W:_)SE3!GV$^M$(=%(B0[]6WE<
M-M^6C*Z1D[8]X6TDMJJELUZZ)JF!&D_*UDU*B,#1"OO[R7QZ*92T361&0U;=
M)$:+1L^R6[^8?)"P+5CG$Z;\8R^7QH(1YK$*7)&$^YW&^[$[B**N`B*H$32Z
M+HBZ>28%'(Y7R6MM_P`X[#*1#<H8$NSA-OFK#3A23$UC[AT4T;<)>J#O04U7
MI@=3#Y7*L;)H*NN.55#+EU]C.4T:.._#(P(NT:?N-$;:AN`MVNGITP.;^4>7
MV84W):VC#;(J(<=ZPG]\F#964YZ!90!(B/M@1+U%/!-?'0+F7SMUF^6J&&VZ
M+CLJ.S)!]"$'(L096LA$'1I"U4=-RDG1=.O0*"E^4>4SJ6D?:XV=G8RX$&QM
M`@N(C0-3S(`1HG=NIH`JZJ$NB(FW=YX'9<@OY<&?6U<"*$BQM/<=A7G.TR"1
MFNX2F2(9]2411!'SU\L#CI7(;CD?(>,U4B,L&JMX=H%S6^X49`283K3)HCK*
M=1:+=L,#3=^F!Y\CWE]%&WXY"]%;'XM-LBL1D/-3VY$9%%D@<#[M5%-W5%_7
MR4),'Y*LV6_Q,^H(;Y$A#"9:?&0#X36'7`=(E1I4(/:N]P$1?!-JEK@=5QR=
M>W'&V7[FO.@MGA,)$07&WB:(244,'$115#1-PZIJFO7K@<9+A7M.DBO;F2_P
M=K>5\.$<B2Z](&(ZT)2NU(4W'1%QS41U+5.NFGIP-%O<6X<#Y.T,QT"I;UJ#
M7RFC,'?;)*BD($YN4CVB\32JJ^I$Z]=<"[^6G78-/6W33T^/^,LHCLB1!=46
MVHQ/"DAR4QO`7V4;U11T)4UU1/'`Z3DEO+JX;+L1AF1(?D-1P;?>[`_N+U5%
M07#,D1.@`*DN!P,SYKG,UHV35"#L$:4[R2ZLT140C/\`8E-`*-%N(/$-=N[P
M7;UP)\SY8EQ+EMEZC4*4K&#5K9%)!7%<LVP..01A`ET1710]Q)IY;NN!,K?D
MEV7^#4ZS:EP%HJH#X*39U1J"HF]&T(7=J^I53:NFOUP.;Y5S:XN>/K[-%KI5
M;<4#K[T*23C;L*?)971'4%I514-0,=-JIYJBX';<[YD/%8#$UUMH8SIJV[-E
MN.,Q&2T_;1YUMM]6T<+TH1#M^J^"*''UO,KFLYU?(<59U%-N*J"DM)9$$8YT
M".H>V:(50VU>=W%M(?NW:+@2I_S2U`6U]Q5*?L*V5:L]F0!";<.4D0VC<41;
M%Q2)%3:1#XIKJF!:3?D&ZBN##&@.9;M(P_.KX3CC_;C2GR:;('49$%<1MLG"
M$]@]-$)<"@IN?SN/64R%:1GWZ)V[M8S5L_*[KK7MF#F(`LF.]6D%LQ1=_1?+
M;I@6=WS&VE<8M!G5SE='F\>E6U?8P9/<,4!KU-*0""MO@CH$)`I"O71>G4*+
MF?*[V9QB+'J"<;_#3Z%FWLQE&PZKLDX[AM@V`JKH*W(#N(9#]WAZ5P.I'Y)D
MOORG(%))EUD=FR))NAM`DBL,FU:,W&T:1'B;)`(3+PZI@5I_+5O&C4A6E$S6
MRKY.Y!;?G#V3`E9[;0R4:[7N#!XR%HE378NBKK@=/ROE-A43:JMK*U+*RN#?
M".VX^D9H/;L$\JF:@XNB[=.@K@<]"^86"K(EE85+L1B?4C:PVVW$D.D2/-1S
M84`%/5W9+:`J:[DUU0=-,#QWY4N8_9@R>,26[V6]);@1-759?9B,@Z;XGV>\
M@KW1;35G7?\`\/7`VV7R!8E`NCDTLF)$KZ!FWE,]]&)X.2>]NCCIZ!)L&"7>
MCFNNG3`S?^39+-\Y41Z0W8\*761)LPY30[6K;T,.B'J(U$]-XKHNG7K@3H/R
M"DVZA5T>L=-N9.L(!2$<;U8_&IH;CS:^L4</H"?117^9,"_?LY,:B=LY,(@D
M,,&^Y!1QK<B@*EL[I$+7E]RDB8'+-?*#;BQV0JW7I3MRW1O-,N`H@;L7W8/H
M;B-;VU:Z]$P*IWY2?N^.3XM=6N-\@"OGR)L4)0@D08K[T-2&2B)J9.LD36@I
MKIXI@6%IR6U@_%-/.8DH-O:,5<)NP>4=&W[%66/<GN14505U3T5.JX%G,X[.
MK*V4]&O+`VFZZ0TZ$AU'C)U&_P!N2+A#N;<'1?M]*Z_;TP*>M^1UK:+B`6+1
M39%M%J0DR4=;[R.V"`TCQ,_=L[I)O-=$Z]-<"5#^6Z"1&M9:BHQJ=U&IR(I+
M(819!,$<B,0@\V`HG<4MJCM\%73`M7+T[?@<^WC*L178DLXSS#S;JZ-HX+;S
M3S2F"[D%#%?+7KUZ8'+<;D723/C9N3;2Y/OJ:7)LNXXBI)>[,8T-U-$UV$^6
MWZ=,"^^,'99<9E.S)DF>Z-G9M([)-7G$;C3GF&@3IX"VT/\`C@<U??)+EQ"H
M[#C3IE$+D=?!,V'!17VGD-'H\AMP1<9-M?Z@$**FB*BKK@74KY1!BB2T6J<W
MMG/;E1R>:38=8_V'@$AW*XI*BJ&T=-$U)1P.4Y9RSD\?D/.V(MD\S'J'>,.P
M6A44V#+D(,IL5VDNCP=%3`^C\OYE4\6AL2+$T:]X[[:(;B]MA9"@1MMNOJFQ
ME'%':AGH.JI@1&^<E(F-L5]5)G-MS`K[5QG1?:/FR+VJZ^AQL-Z"X0GZ5^N!
M!K?DJ1-JZFX.BD1JJUELPQ?<=94F2?(FD<<`%+T=Y$#5%Z[D7PP)MASQ(IFV
MQ4S+!SM.R&!AMD]W6FG$;311302/U*"%HBZ>.!9<@Y$M3`C20BJ^Y+=!EIIQ
MUJ,B&8J2(9/$/5=NU!%")2\O-`A#S9I_@+/+X,%V0$F(U+CP%(0=7O(.T"+U
M".F[JOA@<U_>MM3<QY`,Z/)F5?N:9DQ1YI6X!3P1DE!"4"(.ZH[MJ>>N!9N?
M(@M*VU7U,VPF3K2=5L,$XPVB2((F1HIF:"`$+)J'C@9,_(S[;*2+2G<@Q4N2
MIGWT?;=!CTHC<AY1T00-U4;\]%5-5P+N)RVF=D!$DR&H<^0XZ,&`^Z`2)#;3
MA`CK;1*)J)[%(=$\,"BC_(\&RK0FQHYG%.=`A*4=]KO-'+>%M4D-$HN-$T:H
M+C:IN5/#`FUW.79O+IG%UJ9#,V`:G)=,A[20C#6/*`OYT>/<V@#ZA42W::=0
MEO7L@^<Q^/L@HL-5YV4M[4?4IO(PPTB+JNBZ.$2I]!^N!S$SE4OC7)^7B^_-
MFQHU6%O7P)0(HFZA&#HQ'0'^EJ3(*!=1)57PP)D3E5P]0WL-X'8/+*:*,Y]E
M_M$VJ.@;C2@37=#M&3)AIJIBB=>NBX%K<\YB5O&*WD+4-Z;'LW(+4=AG8+G_
M`-1,&VE7N*"=%=37`K8/R<#TX(\NJ>B-):R:5^43K9-A(C1EE*8^"FTH`2;M
M-4)--//`RMOE&MK*=+1^!()AZHDWD+:32]YB(`NN-HN_H[VG!-$\-->NJ8$&
MP^6B;ANN0J=UV4$FG99CNN@".,W1BC9H0=S:0(I;A7S3QT7`U\2YO9A=7<*T
M%V5"_N:14PYBDW_I][`/,LJ*:$0:JJ(7BFY$\E7`ON3\\C<>M"C2XI.0F*J9
M<3)39:F#4,VP4`:T]9&KO^9,#1(Y_.8.4P7'9I2F9<>)&!%;%N0LILC`VW75
M:'02#:XGB/CU3`@K\IR`G'!=X[+;DMV4:H<$G6-$D2XR2`)%0NK8Z[2)/XIK
M@=!3<H*VXY+M6HA1Y,1R9'=B.F)(C\%UQDQ[@:HHJ;70OI@<5PSG-^U6\7*S
MAR;&?R&I&UL99R&&8\=EE6^^ZC1Z*.B2@7:'BB?77`Z.%\E09$.#8N0)#-99
MU\BT@2UV*ALQT[FTTU3MF;*BX*%TZJFNJ+@5\_Y;9@0)4^52RFHL5FNFN*KC
M*DD.S=)H'%02).XV0>MM%UT\%7`^@8#`8#`8#`8#`8#`8%$YPKC[AS7";>[M
MA+:GRG4D/H12(^SLET/HC?:%!'[=$\,!(X1QR1:RK)Z,INS^R4YA3)8[[D4A
M)AUQE5V*XWVQVEIY?HF!H7X]XNLQF63#A.Q[-RZCHK[J@$UX5`W!#=MT+<2[
M=--57`G1>+4<7CSG'68ZI4/-O,NQR,RU"2I*ZFY54O4KA>"]/+`B2.!T,B.<
M=U92@Y7M51JDEX26,P6X.J$GKU\3^Y?K@9U_":*NO9-U#1]F1+,WWXPR'O:E
M(<1!-_VZEVNZ8IHI;?\`?@:+_P".^+7T]V=/8=1^2PD2;[=]Z.,ED2W`$A&2
M#N=M==F[PU7`VQ>"<<BVB63+3R2!D2)@`LAXFA?F`H2#1I3V?N:JJ]/%55/'
M`A1?BWB$5^L?8:E-NU,?V44PF214HJ.]YMAU1<176VSZ@):HGAX8%W<<>K[9
MV"_([C<JM>]Q"DL&33@&HJ!)N'Q`P)1(5Z+_`+,"$QP;C\>RK+"*V['>J&WV
MH0`ZYVT"42&_O$E)#5PT0E(NNOG@.1\'H>0'(<GB\CDJ"[5R#8><:4XCQB9M
MKL5/,/'QT5?K@0K3XPXI:+(*8$DW9`0P5X9+S9@5<JE%=:("'MN-J9+N'3Q7
M7QP+YZFBO4SE0ZX^45UE8[CBON]]0)-"7O[NYN5/YMVN!55_`J2%6'7]V9*;
M(FC;>ERGI#K)1UU85DW"+M]LNH[?\=<#9-X/02^.O\?,'6X$EU9$A6G3!XWE
M>203BNHN_<3J;E77`D6G%Z^TFC(FNR'6-@MN5_>/V;B`2FG<8^PEU7K]=$1>
MF!LO>.55X$09X.*4&0,N(ZRZXPXVZ"*.X7&B`DU`R%>O5%7`H6OB7A;-8M8T
MQ("$M=(J%:]R\O\`HY3O><#<1*NN_P`"\=.F!L7XOXH2'W0D/$Y.A61$X^XJ
M^XK1`(Q)UZ(`MCZ4Z+YX&N/\2\(8L3GA%?WDLT@865(6.W^3';+1IG?VP1WJ
MJ[4\5U3`V._%W$W8Y,F,HMY0'#<.4^9DY5DIQ7"(R)5(5\?JB)KX8%U><?@W
M3*,3#>1G:XVXVTX0`ZV\.UQMP4])BJ?5-4\M,"J3XWXN#IN,MO,]R3!F$`/N
M;.[6-@U%5!551$$&0143[M.NN!7G\,\$..]'*/)5IZ&_7**S)*H,20\+Y,@B
MFJ"(N`BAI]N!=R^&4TJWA6[A20L(3*1N\U(=:[S`EO%N0($(NBAZEH2>*K]5
MP(B?&_&/<QY)`^X]&GR+1LG'W319,MI67]1)538;9*FS[4UZ8$F-P;CL>J<J
MFV7?8'#.N!DGW2[<1P=JLMJ1*HCIX==4^NB)@54GXCXB^0^J<RWMBI(88F/L
MM2"@H"1W'P`A%PQ1H$W+U7:FOA@6+G`J0G+$FW9D=FS;>;D1&93P1Q63_6=:
M90MC;AZKJ0IKJJKXK@;97":*771*N0#KE7#CA%;@*Z?9)MI05M3'7J8=I-"\
M?'ZX$RSX]765A76$CN)*JB=.&XVX3>BOM*R>Y!7U>@O/SZX%"W\4</&!&@&U
M(>AQ:]VI::=DNFGM7G1>)-5+7>CC8*)Z[DVIHO3`VN_&U$Y$C-^ZL/?0Y'NH
MMN4QYV<V9"@&@O.JYZ#;380:;53RUZX$JTX+26:3!DG*V6%<E3-$)#@]V.)*
MHJ9:[U<3>:;]=="77`U%\><?5^=(19`RK!V`_(?%XMV^K5%BZ?RH@[?4FGJ\
M\#FN,\9^28W+GYEC)%JO.>_+DFW,1UB0RZ"BVTS%.-W&=NC:%^_IJ.J:ZK@=
M8QQ-'>(.\<MILB>,@'VWIAN%W]KSA&*(XNI:M"2")+_E3`B?\N:=9C4QR;/=
MDM6$>U5PY"KODQ8WM14ATVH)M?>(HB+@:U^+N,#)&3'*5%?4I:2#9?(5?9G.
M$\_'>U1=S7=-3%/$5^U4U74+D.+4J<:9XV\PLFI9CMQ19?(G"[;0H(:N*N_<
M.U%0M=47KKK@1X?$F68[S,FRL+'NM.,(<I_4@;=':2#VQ;%5T3H1(I?K@51?
M%/&?;C':=F1V1_':@U()-2J2!8I*2HI:H+0B77JB?YNN!<'Q*J.V2XU>&U1@
M(BS1-1<5@'_<=HE1-%%3Z+KY=/K@;J_C-)749T<&,D>K<1]%C`JH*)*,W'=O
MTU)PO#P\L"+`X73PCI39*0I4$9V'7*X\1JC+P@!(>OWKM:'12Z],#?QSC$*@
MISJHC\AY@WI$@G9#JN/;Y;IO.+W$05^]Q53SP*B1\8\?D3&9SC\M)S<J#-=D
MBX(F^[6H:,][0-IZHZ2&NFXOKT3`TN_$_'G6'VBEST624[O.B^@&K5D][B0Q
MJ(IZ.]ZD_F\MVG3`V6'Q?13G[Z0[+FA(Y$,`)[S;H"0I6KN95GT+L55^[_=I
M@=%:4\>S:;9DF:QQ4N]'])-/@0*"MO`8DA#UW?75$ZX%+4?'E/2V83*F7.A1
MMC(/5;;ZE$=6.R,=HS!Q#/<+38"NTTW;4W:X&V+P*C9X:?$'B?F5#@.-$K[G
M[VUTU<]+C:-[=A%Z%'3;HF!G8<*KI,B#(C2IE8]!82(!PGU;[D5%149=0T<0
MA11Z%T-.NA)JN!MY-Q.#R#\>4B1)B/UDCW4.1$<1LQ-6S:+[A,5W-N$.NFJ:
MZBJ+UP-<'A55"X6WQ%EZ3^-:BK#;?)U5DB&BHA([I]X_RKITP($KXVJY16!O
MV$XW+-VN?DFIM:[ZI1)G3]KP,@0G/JOAI@2(O`*N/+BR@E25<B6DNY;0B;VK
M(F@X#HEHVG[:(\>U/']<"-=\);=I[NH@L#*B\ID.':C+=T;8&0T+;SC(H!$2
M_MHHCK]W75$P.F8K83#<<`:%5BMHRPX2(IB`CM1$)>OA@4R<%J%1TG''W)+[
MD-R1,4@1]Q:]SN1^X8B.[:7B2^I?K@;7^'5;MS"ND=D-V<$GMDD'5W.,R#0W
M(SNY"0F=P#M'^71-NF!G.I9:\GA7<,P14CN0;!HU5-S!$CC9MJB%ZVW$\%Z*
MA+YHF!B?#ZB3$>CVG<M"D13@OR)2BKIQS-34%)L6T3JOBB(O1/-,"/*X1#=@
MW#`R7REW;`PY<]X][PQA!6Q;;)$'38+AJ/GN)2557`L+/C5395<:L?`FXD-V
M,_&%@R:4#AN"ZQM(-%1!)M.F!"=X)Q]Q17MN"J63EPNCBJA27FR9=W(6J*!M
MN$*CX=>G7`RD<%XU)H!HGXY.0&X3]:SN,E<;B201MQH'-=R>A$%%UU1$P(\O
MXZX](%_:LB.^\,'20TZN]LZQ56*ZWN0P0PU\Q5%\TP-L/@E'"D/2(Q/MG)L_
MS,A%=4T.6K79550]V@J.GI'3JF!(O.'T=W()ZQ:)Q7(4FL?!"5!<BR]BNMDG
M\6Q5%314P(;'`XC<>&PY:V<D8,MB8R4B3W258R$C;1*0_P!/0O5_,6B*1*NN
MH>O?']$[-=F[Y`/O6C%TXHN=%DQV48!.J+HVH#U'`LJGCT&KKY4&,3BLRY$J
M4ZIDBDCDUXWW=%T3IO<7;^F!"H^$U-2U5"+K\QZFA.UL.3*,2/VSQ-D0&@"V
M!:=@!1=O@G\<#1&^/*-FJ2K)R0_$9C28,!'3%2BQ98B!LM$@HJH(@@@I[B1/
M/`B3OBVCG5TJODS)IL2ZZ%5NJCC:%VJ\U<9<14;_`*BD2[U\%\-,#LA141$5
M=53Q5?/_`&8#`8#`8#`8#`8#`8'RBPY1RF=9!W@9:*OYBE56A'>=;0XZ0C/6
M4NBH:+W$(A1/T_7`G.?*'(),<(U-2)/O&HTI^5%`E5DG8<LX1--N+L4>XZT2
M@9IIIXX'5\BY%(KEJ(D5@2LKN3[6*+Y;6FR%DY#A.*.JKM;9+1!\2T3]<#Y_
M7\]N^,\%EV$QIF=.CS+R1*8[[SAD,*<:=F.A"3I!L541P]!!!3=XI@6S_P`E
MW,2XOFGX3;L-F350:%AI#]RX[9-(XI/[E040-RKM3KZ=/%<#H&^66E?P>;R'
MDM8L&96MR7)4)DT<0QCD2`;1+IZ70%"'=HJ:]<#FN?\`-^2P:CD]8,-F-8-5
M8V%5+%TR:)APQ8?!U103!ULB7:H]"31>FBI@7O(9$KB'$&?P46.,UZ;"C`RZ
M;JQT=G2VF7%U];B#^XJII@4/&^4W5;>VS$AD9%(_R"QBC(<D&3[3@1!EM@VV
M2*G;)6W!TW=%T\L#H>$\QO>1FC\J@?JZN1"C3(4MXP+<;PZN,J(KKJ'14).B
MI],!/X_81N50;F#)F."ONSMA)\B8-GLJC#`L*7;%1=42`A#7H6J^KJ'-\4L+
M9N[X7*;D/OARJLER[YA]S>J/@VPZV_LT1`[9'V=`01T44TZ)@7G!`D3N"R8L
MYUZP)N79QOZ[BN.--3'@!OW!J!KZ$0-RE_C@>_%,Z47`8PS#E'.KCE1);<\V
MR?:<C/&'9)T%(#1M!01-2553J2ZZX'/Q_F&Z>:M2:IF7BB'2^S+OFTTZW=/*
MQKW";+>C+@Z;P11-.H],#;_S4Y,5A`I&Z:(5U*F6E;)<*4:1&GZUD9(."2-$
MX;;K)ZZ;4)"Z8&5-\Q2)W$WN2/50C&;I(5P,<'M7"<DNO-.M+J.@B),:B7FB
M^6!:O_(%BWSROXZE<V=?-ER8)S6W5<)HV(GN@(U$>V)'M,>TI;TTW>"X&CX_
MMIL#XEBV2QY%G*BMRC]LTIOON]N2ZFP-VIF6B:)YK@4KW-[.\L.*6W''8UB^
MZMRS[=EZ0Q&=]NT*B#P.`C@.(H)Z2#42\],"?8_-$*+5TUJ$5#:LV*V0]`WD
M4IH;-\6!4]@JVV+9']SBIW.J#X8$J%\A\@<.W>DU+8PXML[1UH1S-^2X^![0
M>=;46Q%I1T)=I*6F!26'*N9!=0[E:<8=O'X_;.R:B5*(8Z^TE1E%Q%;%S^H&
MJAJ*$F[0L#H'?E)ANID7"PU2OKG:YFS355='\DRRZA-"*+W.W[QK5.BKZM/!
M-0I>)<LLH=Y?4N\YT^RY581JU))GVH\=B"S+<35-ZH`J6@B/F6N!%X7SB_A<
M*AUD&L<MN2,QY$YR+W#<`A6RD,]E)#FBZ_MD@$7T3737`Z(_D+D#4J[-VC%:
MJCEI#E/,.F_)T<;C/`\D<6T51;9DD;HBJDFWTZ^.!=?W;W>"2>4UXL60MPY$
MV&$9PE:?%H3)L4-10A4T%$)%'45U3RP.9/Y6N4&6XE"TC$+\.X\XLM=29N7!
M`=H=G7>UN]0KT7R7`L)7RI&9K)MPW3SCIJT;'WDXA%L4<KG":06T5?W$?-LA
M$DZ)Y^>@1+WY'OVU@MPZ9ZN]U>5M8W(L@5L'XTP>ZZ38IJ2&""3:HJ="_P!P
M;F^>S6W@8A5"./S.0RJ0T?FEL`V&C>1]%5MQ4$P97]L4]*X$>3\QQHW''+1Z
MM5J6W#DR@AN/B(//1)A0SC1W=JJXXIAJF@?S!T]70.WF0"LF(1F](A.QWFI>
MV.XH*JA]S+NG0VR0E$A5/U\41<#RAIUJ*Y(/O9,]!<=<%^8YWGD%UPG$;WJF
MJBWNVCKUT1.N!88#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%"G!^-)8E8)&/W!SDM"3OO=M9B-
M=A'NUOV;NWT\-/\`'`BN?&O$#.*XD5UMV&[(=:=:DR`<7WCBO2&S,7$(VG7%
MWDV2J.OE@6E]QFFO8L>/8,J20W@DPG6S)IUA]K5`<:<!1("1%5.B^'1>F!3R
M?BSA$B/)CG`,6Y;<UF1MD/IN;LB[DH5U-443<1#T7H)=4TP-DGXTX;*AOQ7X
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MOK.*4-9.*=#C*W)4'&A,G'#0`==5]P6Q,B$$)PMRH*)Y>2)@(?%ZF%5K60T?
MC15><D+VI#XN*X\X3KA*ZA]SU&:JJ;M,#?"H:F%5%4QXZ#`-'!<952+?WE4G
M5,B52(C(U4B5=55<"AC_`!3P:..UJ"Z*(,($_P!7*7TUKG=ACU=7HR?4<#>Q
M\;\-8N6[EF`H6#4F7.;=1Y_:DBP'9*<V;]FKHHB+TT^F!$D_$7Q_(K8M8=<X
M$&)$_'LL,RI;*+%1SNHT:MNBK@H?J3?K@3P^/>(A:A:A"49S<PK%MQ'GT093
MC/8<=0-^Q%<;Z'TT+Q75>N!.J^,TU30LT-:R46KC@K;#+;KJ$`J2ET=W=S75
M===VN!X[Q6A<LH]E[5&YL8WW6G6B-O\`<E-HT\9""B)$0"B:DB_I@4SOQ1P1
MP([95YHS&;AM-LC)DBVHUI*43>".()JT1*J*2+^N!+F?'O$Y=-,J#B$$2;-.
MS=5MYX'1G&[WED-NH6\#1SU)M71/IITP/4X!QH2$T9=WI$E03-7W2(VIQBY(
M5Q2)=YN&"*IEZOUP-L7@_&8KBDQ$00<;C-/LDJFVZD+:D4W1-2W&RC8H)_=T
M3771-`A6'QEQ*=O,V7F9162W03&)#K;[<TFQ9-QMP2U%":!`4$].GE@:?^5'
M#4C5;#34EC\0CP176I<@759E'W)##KB'N<;=+J0DJ_II@6:<+HQ*P-I'VG+.
M8U92C!]U%]TR("!AJ2[4T9%%%/2J)III@23XQ3.4,JB<8W5TYMYN8VA$!.I)
MW=\B,%$MSBF2J2:=5P*U?COC1)+0@?49PP`D"K[BHJ5:H4735?3M5$4M/N\\
M#%KXVXF#]F91W78ULKY2ZYQ]XX>Z6BC)((ZEVP5[7U:)_#35<#"'\:<=CUC<
M!QZ?,!F2Q,CR)4Z2\^T[&3:UVG2/<"".HZ#XHJZZZX&]G@%`U*"2BR2=;M7;
MP-SY[4F/-$R?I1439L-?1X8'-6_QC,"=6A3&Z-?%1P5<&SDPWVUDR2DR'5$&
MWVGE4SU'H"IIIKIX!]`A0!BJX7>>><>V=PGC4NK8(&HCT$=VW4D%$37K@2<!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<#<5;-9\K<?N6F7Q&
MW:F0)TKW)DT3R-"[&;*.X>U$0675%6Q\?'QUP.^P&`P/G'-ZR+'YUPD&%=;"
MULI@V+8NO;7A_'ON()INTT0T143_`&8$19ES0?(%Y^(CL.U#+=`Q.;D.NJ\C
M3SC\;5C55'<*$A*IEZM-/'K@=1QSE5U=28\IJ`R5#*=GL)*;=17&2A2"8:)P
M2TW=_MFNT4U!>B^>@;'.36$?EDVDE!&;%Z.Q(X_O<5LY*[B"4!:[M59+8OI'
MP+`JD^1I3S$23'B"D:X=GQ:DS0R)MZ`TZ6LL$^T3*,?@NH]$7KKH%71<_P"=
M3:2`U&@0[CD0TD2ZG,`XL07O?$799:WJ7;+8V6XRU'=TZ:X%MSQRS'DW!W*]
MH"GG-F`#;SA`T.ZLD*JN;$7<@JB+HB==.FF!5P?ENQ!B(Y=UC4']ZRK+%QMU
M7F0M(&BM,MN(/V21W[%)-VY-FFN!U7)N26=%QZ+</PVR%MR-^:9$U)6&72$'
MC:70=_:(]>NGI15_3`X.XYT[ROB',J>1%:WQ&KD'Q;-UL@A1F5.#)3Q4ED;P
M(>HZIJJ>&!JE_(EK`XG<Q.2TL.?^)9HG66F7G.T\Q:/"R'<5P-4<9<;(M430
MNGA@=B-M<<A6R8*'%<XP3MC52M'C&6*Q4)E37;Z51QP#'8FA"FA:^*(%+\0<
MDO2KZ#CUI&81@N-0+&!+8=,S44063!Y'$3U]0+5.G54\M<"@YE<\LMI,T55H
MV*#FM-&J_;HXR0-DC2N>Z/<2$V2R4'TIYKT\-`Z!SY+Y7)C#7TU,U.Y.V%@;
MC"%MBNK63O8F@&X;9-H\?J$BW;?-%P.EYIRBSH./,6C<,B12%+%P&G):1&U:
M(R>)IA4=<`3$1+9X(N[P3`Y*;\N6<.?-D=B))I0IJJ=7FP3A=^9;25C!H\FH
M]@2\5V:Z=?TP+J/SJX*[E<5=;BIR*-(CM>Z1'!AJU*CNR6W$`BWJ8I'(5;0]
M?YM=/`.8G\ROZKGM8MJW$@7%O2)$:C*ZZ=>5@,]1)2DB.@B#:*J(2;M20.JX
M%M,NK^DYQ8NQV8CM=.L::)8&\X\CVZ6W[?6."(8#L786BKHO7SZX%C4<^MIL
MJGENQ(Z4/(IDB'5D!G[H$8:>=;>=14V*CPQB7:FBAJGCUT#C1N;Z7\42*6L"
M.VC?&I,^6_,><)Y0>)]MMMOM$VXA;6C575Z(NGCKJ@7W&>=<IF3*Z!4TZ3:.
M`[%JK:41:/`90VGCD(N_1`;[HHHJ&I>*+@1;#Y-^0H%&W>SZ:!!JI!O-^[!R
M3-&(K/<$3F]MME0:<<`45P=1;352UP+_`.0I4E^@XW-C*(R3NJAQI&WB[2J\
M^(J*N-_>VHN*G@J*GE@:F^=\EE>WHX\&,SS%QB;*<9<5XX*MU\I(IHV[HV2J
MZ1BH?Y>NOAU#EV?DJ*7,XW*R)]FKF<.;GK6./$@B^]8MM-H0+^T);CV=Q/+K
MX8$MFWY#`Y#R[\O$&:*VE"UV(LI]MIIF3L#OAN]2*)[=[8HB%IU\5P+FK^2K
MJ7>A%=J66ZX[BSHP-N0KD@G:]EQ\'4!0`$%P6"':I:HJIY8%EPKF-]>6#T>P
MK&HL?V,6P8E,.FX*>[4T]JXA`&CS/;]>B^?@F!57O-9$VPY/Q5UH:]Z/5S78
MS;CKC$QX0;1`E1S$5;)DMZIN`][9#U3Z`XOSCD+E.$.7#C?DV&*?LR792BR^
M-FFQ#(S!/W!4%50#=N541%\\#"E^3N37943,"@8!ZW8L'7CE2R:%DZR8,5X4
M$63,Q+=N!=$UUP)$+Y/L95>];-\=F.5'LAG,26@4UT[HMFVHHG[A"!*ZG:W:
MBBI]VFH7$7F3$OX^E<JV-2668DN23<1TB;<&,CFH@X0@0[D;\Q117Q\,#EP^
M59<:K;*MHQ.'#I:FX<[\U4-(U@1`K2*0&1NMBWT4E]7FJ+@=;S._MZ@J-NL;
MCN.6EFU`>]RIH@MN-.N*0[/YOVM.N!R?&N:2Z"OV6S)NU2R^0&L]QXG9`C`D
M/OIJV6Y=G:`A'UJO1.FB]`ZSC/)[.WLIS,BH?AU[;;#]=8."8"^#R+N;(#$5
M%QM43734514T7`K7/D5P*)[E05RN\59B2Y!2$<1):.Q'5;1OL*FU4>VKM+?T
M_F3`T7?R)>4R3(K]$,FX9;@R8D%B2B"ZS.E)$45=,-HFRZ7JZ:*G5%\=`A2?
MDWEL%;(++C3#*T`195ZXU/[H##DDXA.1_P!D"<<;!I34"0=4\%UP+-_Y$E,R
MXLA*X'N/S;4J5J<T_J\$@7"81QQG9_3*0"M^DE4?N5-/`(3/R-RB;0Q+6'11
M&2G2'(K$:7/VFAQED#)31IEPG"0XR"V+0DI;M5T1,#2_\DSK"#,EQJP7*=.*
MAR`V2?)B6IR4=VL"8BHCZ&2U/75%TTP)UCSVXA02GU],LZGK5AC:N$^2RQ:D
M-`ZZZTTC9]WL-O`1:DBEZM/#J$>N^4K*;9LM)3-A`6_D<<DO^ZWNMO,-$X+J
M-HWM("V:*F]%'`NN3<TD5K\Z!45;]O<0(T::<)M%%'&9#SC>T#1"1'-&#5$)
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M\-.H4]7\C/U=5#CV\`U=6!4N05:=61(D%8$D9!<!!Z&+HJI;2/IIUUZ8$E?D
M/DO<KZ].,F%M92)\:.$A_P!NRJ0FD="3J3:N=E[<B?9N%?)<";Q3G4ZYL*^'
M.K0@%957Y1A`?[Y"K;@-/M'H`CZ3>'82$NY/),#4]SV9$Y'?5TMAE68<BLA4
MX@1H;S]B"KH\6TA!$/Z)X)@6_'^4+9S+N!)B'#FT4E(\D55#!P#:%YIYHDT]
M)MGX*FJ+JF!3UWR%96\`K"HHI#L-ZL*RKWY&Y@''$T4(Y$HJB$X"[A(=4P-L
M'Y.J)M?13H\>0^UR)QX:]MIHC>`([9$ZKS:)J!`8*!#UT7_'`C!\D6B2(L>7
MQ]V$\54]<SVGW?W&6HKZ-/-@``7=-15"!-1UU37;@;;WFLB+Q&7=V-,ZE4D*
M')U9E"+AI+<V.MHH]LA-D"$U77U:Z"NN`L_E:AK9UM#E,O-O4J*4R.:(,@P)
M6Q9>C-+_`%VG%=TWB7I5-"3`Z&DN95D<_O5S\!F*^C45V0FU9#:M@:NB"HA"
MB$2AHOF.!Q5Y\LO185Z$2*R=C6P&Y\0M[CD9Q#DE&4>[L:$]JHBZMJJ==/+J
M'8\I<(*MI1,VS69!%%;4D74I;0JBJ/\`*J+HNO33QP*\>=M2)`I`K93\#9-5
M^T='V\5HH6J:&X[M31PA(4+RTZX%4/RS6L1I#EDQ[5(\UN"<L5,X8]^*DMIY
MQ[8)-LD*[.Z0;=W77:NN!=\>Y!86-_=0I(,A&@A!<B=D^XJI*85P]Y=$70TT
M'3Q3K@80^8D]RY..NQ-IN,RY#4@#4P0(;K+6AKM0=Y^X0MHDNU.A=<#I<!@,
M!@,!@,!@,!@,!@,"JB\8J8]L];;77YKI*8'(>=?%E23:?MP<(A90D^[MHFN!
M818K$5@6(X;&@UVCJJZ:JJKXZ^:X&W`8$"PH:BQG5\^;&%Z95.&]7OJI(3)N
M`K9J.BI]P+HNN!HD<4X_(D3I+L,2?LBC'.<0C$G"AKK'U5"3^FJ=$3`UP.&\
M;@7DJ[B0T;L9BJ3SFXU!"/3N$VVI*VV3FGK(!12\]<"PD5==)FQ)S\9MV9`[
MBPI!"BFUWAV.;"\MP]%P(,?B/'H\]^<U$1'Y!.N.(I&3:.2.CS@-JJ@!NIT,
MA1%7_;@5J?%O`T2M1*H-:EGVT$NX[N&/O[B,$6_<XT)HBH!ZBGDF!<7?'JJZ
M:9">V1%&<[L9YIQQEULU%0)0=:(#'<!*):+U153`K3XC&%ZJK8\:(SQNL(9;
M404<1])C+F]HT+=M44)=Q;M24NNN!?38<6=#?A2VA?B2FS9D,FFHFVX*B8DG
MT(5TP*MSAG%W($Z`M<TD6R8:BSP#4%>88;[3;9D*H2B+?I3KX8&FQ^/^'6(R
MAFUC;PS6XK4H5)P4<""2G&%4$D_I$NHX&Q>#\4]_-L!KFVYE@V;4QUM3#N(Z
MFUPE021$,DZ*:)N7ZX&ZLXIQZK?BOP(8L.P88UL0A(UV1!)"%E$4E3:BHGZX
M&N=PSC,Y]Q^3!$W'93$]U4-P4*5%1$9>41)$W!M3R\DU\$P(LCXYX5)1E'JM
MLUCOO2F3WN(0NRG.Z^NY"W*+CGJ(57:J^6!;6=)663<<);2DD4^['5LW&2`]
MA-ZB31`7V&J::X%<7`>&D*"52PH)!&J[>B[%A!JHLJ&NU1%5].J:IY8&<GA'
M%I4$H4F`+[)O-R2)PW#=[S/]-Q'B)74($Z"J%T3IX8&BS^.N$VD1R).J67H[
ML/\`&FWZD3VJ.(\C:;5331P4-"\=?/`UM_&_$@C-QBCOO-MOQ92*]*DNDKT'
M3VY$1N$2[-J+IX:^.!81N)<?C6/Y!F*@R$<=>;3<:MMNOB@NN-M*NP#-$ZD*
M(O4O\RZA12OASX[DPHD)RK48\..Y#;%M]]M2BNN*Z<=T@<$G6E<)2V&JIK@6
M-=\=\0K;E+BO@K$F]II@U:=>%MP6!0&E=:0^VX0"*(A$*K@8QOCKBT:ICU33
M+WM(ON$80I#YF@2RW/MJ9&I$#G@HEJGTP+"QXQ3V$:OBOM$,:K>9DPF6C)H`
M<C*BLKH"CJ@:=!7I@5Z?'G&D<5U`DH\LF5*5U)4A#UG;5DM[M^J,N*`JK:>G
M5$5$UP/9/QSPV5-.5(K0=4ZW\*L<E+V_L-V_LHRB]M$W)KKIJF!$3XHX6C+C
M9,27">=A///.3)3CAG6DI15(S<)5[:KKHO1?/`D,_'?&XH$4)IQF5^1?NFI!
M.NN*,^2!-N.KJ?J$A-15O7;ITP*[@_#.1TUJY,L9J)&[)LC`9F3IC)D1@0O;
M9ADC*B@DB`">?W+@6\W@/&)QS2EQS?2<$AMX#>=(1&8&R3VD4OVNZ":%LTP-
M#GQMQ(S$UCNBH,PX[>R0^&P:_7VQ!M-%$P0R'>/J5%5%Z+@;:;X]XM33HLVM
MC.,.00E-Q&N^\338SGN_(VMD2AZW$1?#IITP-D/@O'822QAM/,-2R[G8"0\C
M3)]SN[HS6_8QJYZU[:)JN!)C\5I6*&51`R2UTY)*3`(S(W5FD92"(U7=N<)P
ME5=?/`J#^+.&G#?AG'>*/(KHM0X/N7T7V<(E.."*AHJ*!*J[ON^JX%[;4-;;
M-1&YH&?L9#4R(8F8&#[.NPMPJBKT545%Z*BJBX%>QP7CK)1B1MXUBRI4UI''
MW3%79R&,C>)%H0&CA>A4VIKT3`D<8XG3\9@>PJD>&,FB-@^^](V`*:"VVKQ&
MH`*?:(]$P*]CXUX>S(L'1B&3-FC_`+J`;[Q0]92:/J$53[(*YJNY1%/%?K@2
M9O!N.3JE:J6RX]%48H:D\[W=L)Q'8Z=W=O\`08[O'KYX%3_83DSGMW=6A*Y3
MSHD".Q!%XNT\44G3-9+&U!+0C3;ZE3375,"\7A]`LOW/MEU]ZEGVMY=KWB!L
M[W;UV[O/P^[U?=UP(`_&W%&Z&!1QV'8T*L-TX),O."\W[A3[XH]N[FCB.F)=
M?!?X8'D+XTXK"9]O':?&+^)_`K'*0Z0+!0C(07<2JI#W202UU1%T3`DEP6@5
MQ20'1;<9CL2F$=)&Y`1%3LJ\FOK(4%!5?YAZ+JF`9X)QUAXGF6W6S*T*[+:\
MZB+-,%;(]-WVJ*Z;/M_3`]N."\>M;R->R&WV;:*VD<9<60_&,V$/N(T[V3#N
M!OZ[2U\5^N!C_8?'/>^\1IU'?R2W2BCSJ`LU6D9[B@A;51`'[5Z>>FN!Y&X!
MQJ.Y5&TRZB4JR2KVU><5L5F[N_N!2T/<CA(F[71/#`S_`+%XXB11!EQMN%`?
MJHK8O.((1).WN-HF[_\`;':OBFB:8$-SXOX>Y!D03CO*Q*KXU0\ON7T-8<(E
M)@$-#W(HJ2ZDBZKYX$.@X)+@<HFW4A5%V5*=?5^/83%`VU3:T+D)T29UV)H6
MA^/4=/!`Z6?QVJG6<>SD-E[V,P_%;<`S%%8E(/=;,47::*K8JFY.BIJF!42/
MC7BDD=LIE]\/9,UR"Y(>5$8C.=YA1T)-KC;GJ%Q/4GUP+!KB=4$NMF&4A^55
M*^41Y^0ZZ6LD=CN]3)=_I31-?#RP/*WA]+7384V,+WN($1ROCFX\XYI'=<%T
MQ+<2[E4P'U+UZ8&-KPKCUFM@4E@T=L_;K)>:<-MQ'(:[H[K9"J*#C:^!#@3*
M>C@U+!MQ][CKY(<N6\6]]]Q!0-[I_P`Q;11/T3HF!65/`>/54:3$A)(;AR#W
MC$60\33*=WO$VP!$J-MD?4@'HOAX=,#R9\?<:E,O-DV\VKDTK-EUI]ULX\PQ
M4">C$)?M*2$6J#T55553JN!-9XK4-6K-JB/'-8AG7@;C[KB*PXXCIH0F2H1$
M8HNY>N!61?C/BL?C4KC0A)<IY2""QW93[BMM`2$#3)D:DVV))JB(N!,L>"\7
MM`<;M(?OVW!D@K<DS<$1F;>^(;B]*'L1=$\%\-,"924$"FB%%BD^XV6W59+S
ML@]!!&Q'<Z1KH@BB:?\`QP*=OXRXD##S"L/FV]`6J(3DOEI$W]P6PU/T;"^Q
M1T5,"\L:6'8U[<"43RLMFRXA`ZXVXI1S%P%5P%$E]0(J]>OG@5@<!XP"6C:1
MW%B7"O'.@D\ZL8CDHJ/F#*EL;)S<JDH(FJJJ^.!N@\.HX4F5):%XGIW;]\3K
MSKB/HTQ[8$=$R423M^6GCU\<#96<5IZNUDV4$#8=E1X\5U@7"[&R**@TJ-:[
M4(07;N\=$1,"#7?'7%JZ^"]B-/A/:]SVM9,@F@2:YWI`BRIJV@F[Z]-OW=<#
MI<!@,!@,!@,!@,!@,!@,!@,!@,#YG)^1N8?W+>PH<&N=K:.T@UCQ..2!?)+$
M&MCB:`0ZMD^BDGFG@J>.!C<_)W)*KB4RVD1(!V%2EJ<^*V;Q=Y*MSMHL<-N\
M0<\3<+5&_P#BUP)Q\[>C3YTA^%&85^-2K!D;W")?RCILB,G0/2+3N[11^[7R
M5<#1.Y[S5J6_3QH%>[;Q[EFK<?=<>;C*Q+B^Z9?$!%T]R)Z3!2\NA=>@:)?-
M.0,<ACU$9B'#GO\`(6:VQ?$7'VWP*G2:1]5:(%14$4Z^"?QP+^CYC93KR11R
MVH\>TASY3<F.A$1+7M@AQY(IKJBN]YKQZ?<GE@8\PYM84]=?3J^,S*_MP&'Y
ML9TU;)QDT[CVPDZ"2-?8JHJ*73`T4C;EG\C<A6P%I]JH]@Y5ZBN]DGH[NXA7
M7IJ+A(7UP.;LY_(9117I$IN0XUSD(T`.H(Q&;`FB;/:I*O1"/3SUTZ>03*_Y
M7Y'<10CTM#[JZ]DLXFNX",*H3GHG;4C-L@1U(IJA^K9JFJ%@==S'DTCCM/%N
M'&FP@MRHP7!NJND>*^:-N.HH_P#E$8J2KTVZK@5LOF%](ENP*5B&4O\`'OVL
M0Y!&K3[(O*U'$"!43]Q$WF:*NQ"'TKNP.37Y7MI\;DE@,..[6P:&EMH]6^BK
MHY9HXXX#CHZ[]`%-/2G7_'`Z"9\@\BA\ALXCU=%6KK;6MK4<!TU?<"T1M!=T
M(1$5:)X55/5JFJ=/'`L:CF%U8\F:K1K@2`BV(3G]Q]R,<.0+,=#].S_4@JN"
MFJ+I]?,*GF?R)RBBF<B]K6PGH''(D.R><=?=1U^/(-T76P!&]H.CV"4-25%Z
M)Y]`L7>?O]ABRC10>JG+D*-T#(FWP,I20U>3H0D@O?R=/3UW>6!6Q/E"R"R@
MP+2&PP93K.LM#$G$1B1&_<@;=R*B^\85"%"5%55].N!/K^8\KEWDB.W4LN5E
M?/&LLI`NH!`?M&Y!R!WDFH(X\((&U2\]?+`L/CGD-_R/C$6\MXT6)^0`7XC$
M5PW=K1>".&2"BEYZCTP,>0<GN6+2964\6.]*@5R6;B2G%#O(1F`L-H/4=>T6
MKBZH/3TKK@5?$>?7W)>56$!F#&BU=6U`>DDXX922&RA>Z!`VIV]6S5!)%\NJ
M+@1^2_*4NCMKB%*A-QO80Y<NL&1W4&Q2+%*1K'DB*L[T)L@<9+UBB;T54Z8&
M+7RVZ4E@'*\6VYL:@<B_N+Z7KYUQO:9*@BJ,]O5--%+PZ8$;E4OE[',:&5$C
MP5O&X%X!"X\\D8F67(ILD2`)%N(5%=O\NY>J^8=)8\Y=C?&K7,F8!/F]`CSA
M@H2)M]R(%ZR_R-]S<:IUVHNF!2.<_P"9^RAFQ6U[ASKM*B',5]Y(S\<F3=&:
MWM`UVJH:;4)?!?5@9UOR5R&PE378E(+M/62+"!/FN.A&;!ZO;75Y7'2]+3CP
MJ&FQ5%-#5?%,"M?^5N0'$!AN-&8L`NJ:K>?<%\63"TV&XK`.H!FH(2B*_P`P
M^O1.B8$YGY2O95>_>0N/D_QYJ/9N',5UL%9=K5<$$/U$IB^3*CH(ZMKX[L"Y
MA\QMP^-'N8V4)A)`UQVS,".Z2BK7M_<-M$Z0_?\`RD2#IYI@4<GY,Y75,VXV
M]/#6=%C5\^N9CR7.V;%A(]KVWG";51<9<1=5$%0DZ],"78?(MW!@VDEVNCD?
M&7H[7(F6W37>+[0.D4,B$-W;%X2]:)NT44T7K@0YWRGR&N27<3:9H^+0[>13
M/.1G3<F"C+A-!+5M10-A.CL4-=4UW:Z8%@?R+;-,1GCJ6C_*4\BZJ@"3X^V;
M:<..^6PD0E1]-IAN'_M4-,KE?,FN0S*^QB01@1Z%^T?B,//=XG-Y`#8R-H;>
M@[5)!_5,#9&^0W?P,B35UG?&FJ8-C,C.255Q0E,J]VFS43(S!IO7<YIN54_5
M<#9(^2GXUTD&17@,;\^UQ_OB^I'K)A!+8?0.VGBKFPAUZ>.JX%W:\E?9N7:.
MMCMR;1NO*R0'G>R&Q'4:`%5!,O6J'ZD31-.OBF!Q=9R!_F'R!4-NAMX[-XS'
MO&8).F+K<AR6!`X7;7:I@H"*:+X:_73`D?(_(KT8G+JYHDC1:VOK94.5'<-N
M3W9,EP7$)15/3HPGA^OCY!.L_D^1"M)-,E0X_:C:%6Q&F2)T'&_8I/%\E$-P
M_MKM4=%T7STP+DN27P\!+D;E(4>X;@K-=H77%5P3`-YL=QL#53T1=OH\>G3`
M@%\B!(<J_P`4U'F,73K$:O=5XF]'W(KDUQ'D5O04!@!5$%5)5+31,")7\]O[
M#D554A!CQ7#<M6;5HW3/1RL-D![+G;%"!T9`N:[4^GDN!7TOR!(C<:IPJ*)L
M!D4DVV:BN335&U@N-B4?NFT9%O[W0U_V8%J[\EF;;#L&M[POG4@#3CA-N*EP
MJ;#1$;--C2+J2HO\I>&F!:<JY1;U5I2U=76-6$NY*2`$])6,VTL=E7M25&GB
M5"TTZ)K@5M1\BSKBH<E5U.I6$:`4R7`=?051X'W8Y1FR$#4U[D5W0]J)]O\`
MFZ!'O_E7\5#E35JS]M%BUUDIO.;-\&<XK;S@(`.^N+IN,?IUU3`FS?D"0$J3
M`KJLK.R]N]/K&(SB$W(BM:`)&]MV-$\]N%M/4BHFNO73`D\<Y7=W'(+.O=J&
MX4.K[`/O')WO]Z1%:D[.R+6ST][:J]SRP(,_Y"L8/,X5$]5@4*QEO0(TD']S
MJ.,0UE[C%!5L>Y]@`1H73<O3`L>#\T9Y2Q/=`09.$^D=Z$2F,N.X@(KC4MDQ
M'MF)ZHFU2$D]2+@4L'GW,;!T4AT,(@<>L8C?<GF&DBMD&RJDOMRT;<$-45$5
M47RTZX'EI\K.5T2CDN5@.#:NU+$@&Y(F3)VZJ/\`*"]&E1.I[=^OIP+>DYG.
MGV$NKDU[<:TA61PGXR/J7^E1KOMRQ4FPW(X!#Z43HJZ*O1<"GO;KDM1SRVD5
MD/\`*0&J:++FL/RRCM,HR](W>W%0=`G701?\B>E-Q=<"14?)<R]LC"BHI$ZI
M8F,0Y5AO!K:+T=N03R">FJ-=X4,-=WC_``P+*^Y=80.3Q:.%"8D=V"[8R'WI
M!,JVRP^TVYM`6G=Z['5).J=4TZ:ZX%/`^4ILJ*<\J"2Q62!@_B9;R]L9#ED\
M+3#?5%T]+@F1#JB>'CXA9KR^\8G,0YE6P).6X51O-22,=CD/W:/BBLB6J?8H
M+I]=V!HC<U&='8GK`TDL)<(#7N"$=]6\L<NB#H0N[==2'T?1<"N=^5;$F(;4
M.E67;SZE+V-7LN.NJL4@;V`1`RNUQQYP@3T[40=5)-43`U<LY7/LE@-0&%C1
MH/(ZF!:$XX3;R.FZP\;8""$+@(CP@6I(B]=-4TU#JN26WLKOC48XJO!8SG&!
M?%\VNRX,1YU%)L4T>$A;)-I+HBZ+XI@5_%><6=M.KHUA5MP$M*]VPBDW(60J
M=AX&C`_VFQ3<CHF*H7Z*F!2\SY!?2W.35T=D!&A>IGJ\V9#L=YUR0^!F+IIZ
M=BHBCIU14\<"S'Y"G.2I56S6@=Q&E2XH-(Z:M.I#88D*HDC:GN))0"B;/'7K
MI@7<[D4F+35TIR#V;&S<CQVZ^0Z`=MZ1U(''!WC^VB%KLUUTZ8%5R;G-AQ^I
M]Y,KV%E,@;TJ",G<XK`20CHXUHVNJ$CHFJDB(.NBX$*Y^68559VT&3#4':<5
M-Z*X?:DOMGVAC/10,4;=:<<=4#-'/VU3U>.!TE%;7,HK(;:N6$$)[;%DB2D$
MEE00]X"2(X*BJJ"HJ=535/T#G[/GUC'BH2Q&0&UJ9=E1O(X9+NC,H]VY`;1V
M^@Q+<*_4?)%4+;X^AHUQ:OFN,@U-L8T>1,)LW'!,U8`4-5<Z[E`4W?K]?'`Z
M3`8#`8#`8#`8#`8#`8#`IG>'\;<F/S%A",F5*8GR70(P5R3%%`9</82(6P43
MHO3ZX$"=\8<#G(ZDRH:>1]^3)=0C=]3DW_U/\WV.KU(/M5>NFO7`RJ^$0([L
MM9C;$B*]&BP(\-&U4&HL`W"CBI.$9&2=Q"U7P5,"QD<5H),B+(?B(X]#DI.C
MF1N:I)0.VCI>KUD@=$W:Z8&F1PWBSTIR5(A`<A^:S8DX9GJLQAM&FG1U+TDC
M8H&@]%3HN`H:.;&G3K:U<CO6\Y&V3=BM*TV,=A35EM-RF:JG<(B4B7JO31,#
M?-XQ0SIRSI407))`VVZ6I(+@,GW&A=!%0'$`^H[T73RP,XU#3P[F;<L,(U96
M0M-S7T(_W4814;U!5V:B/1%1-<"&?!>)G.*?^.;&44YNU-P",-9K3?:%]1`D
M%2V+HO3KYZX$)WXLX"X,,5J`%(!/E%4''@4?=.]]\54#%2`W?4H%J/Z8'16%
M?"L8$BOG,C(A2VR9DL&FHFVXBB0DGT5%TP*ZYX;QJY:8:GP1,([1QV4:-QA1
M8=%`<9U9)M>V0HB*'V]$Z=,#38<"X?8>Y]U5M%[R&%=*V*37<B-EN!HNVH>D
M%^WZ)T\,#!SX^X@Y*ERW(&^1-D1IDEPGGU4I$)46.YHIZ"K>B::8%3P[X]ET
M=FY82Y82);KTEZ3*:*2VLE9+AN?N1R>*.WMW]=@=535-N!*?X'%E\TL;^V5J
M3"E184:-#57002ANN.ZO"A]IY"<=110@Z:8%V'&J0+)RQ"*@RG7$><5"/MDZ
M@H*.JUKV^YHFF_;N_7`QD<5XY(D/R7ZYAQ^4_'ER'"!%4WX>GMW"^I-;4VX&
MLN&\:+D"\A6$/Y<A03DH;B(6@*VA$VA=M30%V[E'=ITUP$#B-'6PZJ%7-'$A
MTYD<%AMUW:*&)BH+J:[@_<7TEJB>6!ML^,45G/CV$V(+DV*!LLR$(P/M.Z=Q
MHE!1WMEM34"U'],#.!QREK[2=:0HHL3K(60G.@I)W$C!VV=1UVIL#TIHF!&+
MAG&2L#L#A(Y(-XY)(9N&UWW&58-U&2)6D(FE455!\,"KA_$GQU#8F,1Z5H6I
M[`198D;Q[V6BWM#J9DH]LM%!1T4=$TTT3`GL<$XHPW&;:@Z#$9DQF%5UY21J
M;I[A%)34B5S:FI$JKT3K@1.0\*CO\">XA2-L1XJL!&8C2B?<:1@312;W`:/#
MZ$40(2]"Z*GAI@5O#?C%NJCMC:R'9019;<ZLKUF2I3,-YIL@W`[(+NN*7<+5
M"]/T%.NH7$CXYX:_9V5DY7HLNW9<8L%1UU&W!>:[+A=I#[:&;?I4T'=IYX&E
MCXPX6S&?8&$9I(.$Z\ZY(?-U7:U!&*ZCA&IB8(")N%45?/`V#\<<1"RMK!N(
M;;MVRY'L6@>>%@Q?3:\2,(2-";B?<:#N7QU\<#._XJC_`,?SN)TO;C"Y6'65
MZ/*:MM@K"L-[B3<>@CIU\<#6G`JN5QX:JT)]\W0B^Z>]PZ3BE$,76P%Y=IJV
M+@ZHB^/GXX$F;PKCTJ\6[>;<26Z+3<IL77!8D(P2DSWV47MN*V2^E235,"HX
MS\>QH5A86%QMDRI=E-G1HR/.N11&21;#]N:`TCR-%L(D'ZKKJN!8#\=\6&H?
MJ`8<"O=C.0661=<3V\9Y$1QJ,2+N:$M$^U?)/HF!)E\,HI;S,AX'5E,P7:OW
M`NN"X<5X40@<5%]?5-R*75"ZI@8,<'XVR,9&XW_IXC=<2J2EWHC**C;,C75'
M1'<NF[_XK@1Y'QQQB1-.:\V^<@[1F\W*^[H,Z.UV6S$=V@BC?I44Z*F!:V''
M:J=8,63K2A8,-DP$MHE;=5APA(V2(=%)LB!%45\_#`C-<-H6>21^1,-&S91H
M*5;?;<(6O:":N"VK2+L7:2ZHNG3`T<CX!QOD*S5LFG=UA'9B2R8?=84VH[W?
M:U[9#U!Q5T+QT54\%P-%E\:\6L79;\H)"R9<MJQ]R$EYMYF4PRD<'6'`(2:7
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M<!N"IPS7<3+JH7[@J77U:KJJKKU7`FR^-4$N3'DR8#+C\6.]#CFHIZ(\A!%U
MI$3IM)`1-,"!,X#QB5'K&$C.10IVDC5Y0WGHQMQ]!%6-[1`1-DC8H0JO73`F
MU7&ZNJL+&=#$P>M"9.4)&1-ZQVD9;V`J[0T;%$]/CI@5,KXSXK*O?S;H2O?)
M*]\WMER!:"0K"QS,&D/MBKC2[3T3K@6E'QBJI2><B(ZY*D-LM2)DETWWW`CB
MHM";KBD1;$(M-?JN!"A\!HH;41N.<L/9N370+W+JD;EB1%()U5+]Q5(E4=WV
MKX8%0OPOP5>SN;F%V!AH&LV3]U<2+$<)$<T)QE$VB:]=O3`NZBCE_GYG(+5B
M.W:.,C7QUBN&Z/LVG3=#<K@-JAD3GJ1-4Z)U7`U\@^/^-7TUV9/;>[TB,D&:
MC,AYD)$43[B,O`V0B8;E+_`E3P5<#-K@G'6>1N<A8;>9G/=M7VVI#P1G#9;5
MIMPXXDC1&+:[451^GTP)SG'ZUSD+7("$UL68IP6RWEL1EQP7"3MZ[=5($ZX%
M4/QMQ`8D^%[0UA6`HV<97GNVR"'W$&,._P#TZ=W]S]K;ZNOTP-$?@4)YJ?`L
MFNY7K/CV%8^,J04L76&&FNX;J[3$]S*]1-=1)47SP)%;\<<5K&X3,!AYB-`6
M;V(PR'E:4;$M\@#`B5#%2ZBB_;Y8&;WQ_P`:=@5,+MOMA2@+->^U(?:D"P(H
M"LD^!BX;9"B(0D6BZ)],#39_&O%+&X6VD,OC(-V-)>:9DOM,.OPR$F'G60,0
M-P-@IN5-=$TP+FSHJVREUTN6!D_5/K*A*+A@@NJV;2J2"J(7H<)-"P(-3PCC
M]3(KY$%MUMRKC/0HBD^Z?[$AP77`/>1;_6"*BEKIY8'L[A5!-G39K[;J/6*1
M4F]M]UL7/9'W&=1`D1%1?%4\4Z+TP-5G\?<3LG%>D0R&0LS\C[AEYYEU)*M(
MP9B;9B0[V10#%%T)/'`LK:@J[6J6JFM*43T*"`9MF!-$A-&VX"H8&!"BB2+J
MBX%59_'7$K,4&;%<=5(RPB/W$@2-E7>]HX0FBFO<]6I:]<"=+XEQV9%?B2H0
M/QI/N.\TXI$B^\320B:KZ4<UZHGGU\<#;0<?@45>,""3Y,"NJ+)?>DN=!04_
M<>(R\!3IK@1`X3QX(\F.C!*Q(8>B("N'^RQ(31UIA==6A+37T_\`P3`M:Z!&
MKJ^-7Q148L-H&&!(E-4;;%!%%(E55Z)XK@2,!@,!@,!@,!@,!@,!@,#@G^<V
MX\VKZ^,["ETTNT?J'P9!U7F76(1RE4WB,0WH;:B38-DB)XDB],"TY#RBPI^4
MUD!U&4K+B-(9@N*!*Y^4:T<:9(E,`VNL[]H]%4A\<"FF\\OFQD3X@Q'H57<Q
MZ*QA."8/N$ZXRR;[1H9("H<C<+:BNX$^Y-<"!1<VYD_"AP&O;3;JT.\?C2GA
M[3(A6RBCL1Q#N)O,E45+0DT!"7]<#=\CG+FT/!9DMMABV+D%.YL:+W##;[A*
MC@BXFQ2!-2T)--?\<#<YS[D51H_R!((U57:K5WUE&%W:C;T=MR+)`=Y]D4?>
M%IX34MOCKI@7-YS";3<.;OIC++;DB0PV*N*0,QVILD6FG9!=51&@=$G=/-%T
MTP*OE"3?S?$W;0XKDB)R%T&7X^X=D8JV4:(ZA*NP]J(I==-$1<"K3Y%YG'F7
MD(8K%O(BMUEA7C'`67'(<XS&0$=DWMSY@W',VD(@(U7143IJ$L?DZ>U^%>D-
MH538;6W;D8KHM#*]T;!PI#).=V(]H@B"GN%7-1Z:8$&%\C_(]G4OW==0P_Q<
MR#[FC!^6TDAU]7@`6>V#A;B[9KJ*J"]Q-FJ:ZH'20N=G_P`NIO*W4"6<%N4Z
MXP+;D4Q6,1(3+[1]TVG6]NUU$W(A(NFJ:8%/?\ZYG4.VU:`P9D^*U4R8D[M.
MMQ=MI.6$K3C:/&XI"H$8D*Z*GBFJ=0ZB_N.0T7%4F%&2YM6U`9(06^VJB1?N
M.L1W'#)Q6PU)&NYN/31%UP.-:^4.66EA'@<:@Q+-6&84RPFNFD-LX\QXP519
M?<%YHA%HD5-#T<]*X$JSY%S5:YR?.9IY%<U>1ZWV1,2"/:EH$87T<,]O<342
M%-F@DFN[RP,JWGG/[2RL7X%%&*@B.6<4'GI+;3ON(!&VRBBI;T[CC2H:$";4
M5%U5/$.DX'R@K^H=?D&HSV)!QID-V,<-^,Z(H?8>:,W=3$21=XEM)%0AZ8$6
M_P"4W3-M:P*L([:TM<W9O%+0E]QW"=T:;VD.P4%@MSG70E3TX&'%N3\BY!=R
MU`8D:E@$R+K)`Z4LO=0&);:;]_;%061H7I77],""]SN^3GL:JCI"E4CUDY4O
M.,]PG&76Z\IFCKJD((]O#:K8@2(/5215TP)WQSS.=R1+(+!LH<^`;;<JJ>CG
M&D1G"W:H6XW!=;)1_;=!="37SP*%GFWR)*F5L>.M0V-M(N(3)&W(7M.5KCJ-
M.'M=T)"%G0Q]*HJZZ^6!H3Y;NWX7'[!EB(+<Y*?\G#'>\37Y:2K!$3JDT+0C
MMU:Z&1]=4%$UP+V%S*]>Y6YQ9Q8@VS%@Z\\V(&NE(C2&R\NAKHZXX8MZKTU0
MO3TP*+ETKE%?\HV=CQUN&Y)B\9:D/LS5=T>;9FNFK3:MJ*-F8[D0UU1%TU3`
MNX//.075VC5)5"5=`GC`NTE.--O`#K#3PO`G<0Q(.[HK9-+N\B33`F<EY/R2
M)RJ-4U3,)8;4$[2T>DDZKWMV71`FV`#0=YHJ[2(M$^BX'+P/E7F"5M?;6-3%
M&HY&Y7M44UI]O1EVQ<0-D@4<<WBT!;MZ;-Q)MVCJF!:4W/N2OW=?53&8;O<N
M)U-,DL"X"+[*'[A'0$C+8I&*BH*I8$!/D28]%K^1%61!DN<:M+5IPW'45LHC
MS&]E505_;<0A77374<!,^0/DN)(;IQIH%CR)(0W+L>(ZHLG#<>5D8X%(<9-'
M1T52=T4>GV]>@1>3W\SDDNGEMM1V*^GYC%KD!SN>[5U@]CA(J*@)J9>&BZAU
MUZI@6O-"OFOD^E=H0AN6`TED2-SW7&FB$9$7_P`H3)2ZKY=-<#"'\MRM*D[.
M$W%;Y+5Q9?'>VINJ[.>4&WHA]!U[9/`:*/BWN7^5<"^Y9>7\'DO#JVO)I&;:
M:^U:(39&JLLQ''EV*B^CU`G5?T_7`Y+BW*[;BG!VY$R`,JKC!>211HC22J0I
M3KC8J+B;45P-R::]-/'Z!VW#KOE%F<]+NH*N99-M8$A=@]\'!W$G;%QY45M>
MFY5T+Q1$P.:J_D?EKP09DRI@C76;EE$BJS)>)T)%=[@A-[5G1&G!B*GIU)%5
M/'PP)]9S'E4OV,!Z/7Q[NYA.6E:VCCQQPC-`PBMNFHMF;G<?ZJ`Z(/7^(:*G
MY&NK!Z`V=>Q$_-U!3:?>9N(4]EQ&WHQD">H4WB:$/50U73HN!HF\]F4)\EF2
MZ=%2ML8D:RE0E=D;6'H3;GO7&M!/8WN%#`-50>O73`VE\@*S.G3`CPY8+74K
MT2=&>/MO?E93D8=245_;!SU"J)JJ+]<#*T^0.0U;CM>_$A/6D2TK(<DT<<:8
M.);.]IIUI%1PD=$T)";5?!-VO5$P-4CY.LZ^K8FV\-J+'2=-@3K%M'78C)Q9
MJQ65=445QH'Q121Q141+TKXZX'5WO(3@VU13QVQ*;<E(%AUQ?VFTC,JZ2DB*
MA%KT1$3^/E@<0=M:<SF\0"0Q'BP'W;1J_J9'<<1UR`OMU5@AV(0BZF]LU\.B
M^/@%OR:UMEY4_P`9;[?X,N.3);XJCBO$ZAHP"=U"Z)M7^/C@1ZSG-[72%J+6
M"$EX(=.Y`**>A.E/4H[PF3R@WN;=:(DZIN%43QP.HIK2]6@?F\BAL54V,KZF
M*OB;"M-:J#Q&.NQ"#J2*J[>O5<#CX/R;R.2#C`5T0YC=C6PE,G'F&2:LF4<[
MC>\"</MJ7I543>/70?#`U6/+.2M0N4I>1H4]FHGU$;V3"NLB@R0C./DCJZD>
MTW]P:BGAHN!V(S[6Q5[LC$=J=TR+)-MUU'VR9U;'IL3U;Q)#'RZ*BK@<+\<<
MKY*O!Z"JIZO\G.B5E7(DR)$EL!)J41BYKO+NH0-M*0EM5"7I@==1\U=L>73J
M"3&6N>AB^H1I0F#\@&GD`)48O4R]',"U51+<!:(0]<#1*YU*:<ES&V&EJ8%J
MU32@<(@D]UUUIGNBFFW;O?':*IZA]6[JF!IX+$LYMO?V%ZXW*E5]S+8J7&U=
M'LQ3::3M:$6BIHB=---VJX%?!YI>>UJH-+50@G6]E=1=)$AY&&S@/OJKBJC9
MF7=)O54Z::].F!.XMSV[Y)#B/PX,5EQ*^!/L&'GB1$6:;B$#1H/@`,&J*0^I
M=$Z=5P)#G-K1MRNF+";*HLK1RH;$5/W($AN--OFFFFU7650A1-1%=R^"I@4E
M3\@\_L(U%-_$UC<3DKK\>`*29!.,&W'?>;)_1E$("6/ZMOAK@2Z'Y&O;D9%>
MU7Q6+ZNC27I[9O&44W(TMV&@L.(*.*#CD<UWJ'I33HJX&FK^3+ZUDSIT:%!B
M\;KJR':O29DAP'E&;#*2+>@-F`=LA1"+KT7HBKTP-KG-.4S#BC#&/#4.0M5<
MI7V7E[L0X0R=0%5$@)2<1$)?)/#RP)-5RMY;B330X34:PF6=B(N.$Z31!!;9
M4G5UT53/O`FT=$\?\O4*.9\P7Q.N-0*F.IQZ2PMY'>>/3O5,PHDB.*B&FUP@
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MNJ8%C4<RNY]6L>!$:L;^OC5C]BRI^W!SWZ(;G;4M4%1:0C37HJ^G`JWN03+C
MDG![-&P9A2;2UC,@AEWE;:B2`;[@HJ#ZE8(B147;Z4\=<#Z3@,!@,!@,!@,!
M@,!@,!@,"C7A'#RN2N5J8Q6ROA*68H(KB/@WVQ=1?Y3V>E53Q337P3`MI$*)
M))@I#(/%&<1Z.IBA;'4%10QU\"025-?UP*^-4<9*YF6$=B.=J9-I/<!1(][2
M:-$X*+HC@CT0E3=ITUTP(UAP'AMC#<A3JB/(BNRBGDT8JHI)/[W1Z^@CZ[MN
MFNJZ^*X$^SX]26D%J!/A-/Q(Y@Y':4=$:-K^F;6W10(/Y5'14P*JQX3%?@1:
M>";=?0(ZKEI`:913E)KOVJ\I;@4G$U<+0B)->J+UP+Z?!A3X3\*<PW)AR`)N
M1'>%#;,"30A(2Z*BX%#7\+X"L2)%@5\-R/3/N%%!I4/L2#31Q55%5=ZBNA;N
MNG3PP,8W`OCMB:01Z>`W-;98%0``[H-,N$;"HGW!M/782?P\L"U_MJA28DQ(
M+22$`0WHFFH@XKP;D3H6UTE-%5.A+KXX$.'P[A+3MB4.JA"Y-<3\DK38:DZ)
M=U-^GVFADA_77U>.!:LUM>S%<B-1FQBN[U=904V&KJJKBFG\RFJKNU\?/`JU
MX+P]8)P%J8_M'#:<)K9TW1]%85/-.UIZ$3H/E@6DRM@3609EL`^VT8N-(::[
M##[3%?$23R5.N!7'PGB+DJ!+.HBG)JT4:]XFA4F44MZ[%7_C]7\>OC@>M\.X
MNW`<KPK61A.R??.,(/I*5O1SO+U^_>*%K]>N!H_L[@TBWL)OXN$[:2FU9M#0
M`5PVWQ1"%Y$_\P!3[DZI@;SXC0K(KWQBB#E8^4N*0J2$CQ,K'4B+74OVB45W
M:]-/I@;;3B_'[26$RP@M2)+;11T>)%0E9<ZDT:HJ;VU7KL+5-?+`W0*.IKY<
MV9#C`S*LG!=G/#KO=,!V`IJNOVBFT?HG3`K9'`.&2;8K9^GCN6)OA*.00ZJK
M[8*V+BIKMW;%TUTZ^>!;5U57US`LPV4:;$1!.JD6P$T`=Q*I*@IT%->F!61^
M#<3CG&<:K6Q<ANRGHIJID33D[5))`2DJCW=?5I@0!^)_CD0CC^!C$D5MMAA3
M0C46V'>^T.I$J_MN=1U\/!.G3`MJRH=C6<VQG/LR9TM>W'=;8%@VX@*I-L*6
MXS<VJ2JI*OGT1,#7<\/XO;V$>RLX0/3(R(#;RF8;@$MXMNH!"+H(?JV.(HZ^
M6!B?!^)GR=.4%6M?GD!&UFIN0B045!4Q1=A$**J"1"I(G@N!->K*7\N%N\TU
M^3;8*($DE]:,&2&3::KX$0HJX%.W\<<!C5L^L&GC!6VI(LR&6O9(MZN)L!5V
MMZ.$IIV]/5U\<"KI?BKCT.ML*:SC1I5.[;G;545.X*LJ38BB$2EJ1[M^JZ^I
M"Z^>!9A\=<":BA"&L9"(S#=K&XR&:-A$D%O>:0-VB(X74O-?/`VV'`>%6358
M4ZN:D#3!VZYTC/<VUM05;5Q"0G&R1-"`U42\T7`\>X+P61<+<N5L8['O!+)]
M%T3W#2:!(4$79W13HCFF[3IKI@3;GC7';IZ.]91Q>?8!UJ.\)FVXC;X['F][
M9`2@:="'PP(1\8E/\FAS911$I:<=U'`:C[76GS:)EPR<553:+9*@"`CX]?!,
M"VM*.JM'(3D^.CSE?(&7"<U(2;>%%%"%145^TE14\%3QP*Z%P;A]?&A1V:]M
M&*]9/LQ>,WMGO=?<IJZ1JJ.[EW(NN!)X[QBAXY"*+3Q_;125"4%===1$$4$4
M172-1$13013HB>&!S_!OC>+15\@+)`DSGY,YY7F79/;1N<Z3A;6W#46SVGL(
MFT3737`Z$.+T8,5K(1E$:AI6*XT<<[C31-HT0([N[BH0(FNXEUT1?%$7`D.4
MM0X<!PX;).5:J5<:@.K"JVK2JTNGIU;)1Z>6!`/A7'#F29BQC&5+DC-?>!]\
M"5\&5CH:*)IM_978HIT5/%,#!G@7#V&R:9JVFV"@MU2L#N1KV;)$;;7;UV>@
MC)4+3=JOC@9N\(XN\`@]"1U1F,67<<<=)PI<5!1ATW%+>:MH`H*$JIT\,#%O
M@G$VRD$->"^[62LD2-PA/WCR2)"$)$J;3='?M\$77335<"=;T53;C'2>SW#B
M.^XAO`9M.M.H*AO:<;43!=IJ*Z+U1=/#`B-\+XRW)J)+4)&WJ%'1JE`W!1E)
M`[7O2A(AJXGW*>JKX^.!(L>.TME*63+8WR?;/0B<`S;)8\E$[C9=LAU1=J*F
MOVKU31<"K>^,^$/MNMOUO=!Z''KC1QY\O]-#-'(X"JN>E6C3<)IZD7KKK@6L
M3CE-%I#HVX^^K=;<:>8>-QY7`>U[B&;I&9[MRZ[BP*F/\8\'CFCC-:HN(_%E
M*YWY"F3T$4&.9$KBJ2MBB)U\?/7`EVW!N*VRV*SX".%;>V2Q(7'6E>]F6Z.I
M*V0+J"^:?IKX8&R/PWC4:ZG74>$C5E9`H37@-P1<U1!4E;0NVAJ@HBF@[E^N
M!!C_`!GP6.Y7.,U+8N5+(Q81[W5)(X%O!EQ5/]UL"]0BYN05ZI@6\2@J8DPI
MC+'^I(G2%QPS<5M9!(;R-;U+MBX0HI"&B*J8&ISBU"Y9NV;D5"E/DV;^I&K3
MCC"(C3ALZ]HC;T3:2CJFB?1,#92\=J*1)B5K"L)82G)TS5QQS?(>T[CG[A%H
MI:>73`@QN!\5C3XLYB&0284J5.BEWGU%N1/U]R8@I[/W-5U'31-5T1,#R-P#
MB$5V`Y'K@:*L!6H>TW$06U(C0#'=HX(D:D(GJ@K]NF!81>/4D1YYZ-#;9.0\
M<IW8FB*^ZBBX[M\$,T7U$G5?/`H++X]KS8XS7U8##I^/SEF>V%U\"V]IT!$'
M`+?][VY4(M%TT7I@6Y<.XPK#3"5S0-L,N16T;16U[#R[G6E4%12!PNI"O15Z
MKUP,'.$\5<?L7CKFB6VBMP;%M=W:=C,BHM-JUKVT0!-43047`T1_CWAT>'[1
MBM`&/=-3]$-W<LIA$0'U-3W*YH*(1*OJ3[M<"4QQ'CC!&;4(1<.8[8J[N-7$
ME2!4771-24AWBNU4%=-.FFF!B?"^*F0$=:R:A`<J40D546"\J*XP2*NA"2BF
MN[5?]JX$^14U\B-'C.M:LQ7&G8X(1#M..2$VNHJB^E13HOCYX%.7QWPHVGF7
M*IIQJ0Y+=D-FIF)E8&)RMR$2ZHZ38JH^'3I@7;5?":*.3;("45I6(Y:=0:+;
MJ`KXZ+VQ_P!F!#JN,4=3+E2JV*D5R8NY\`,^UJJZJH,J7:;W%U+8*:KU7K@3
M#KH!SVK`X[93F6C8:DJ*=P6G2$C!"\=I$V*JGZ8%7!X/Q2"T\S%KFP8?%UM6
M%4C:!N0FCP,@2J+(.?S"V@HN!K8X!P^,_`DLUK82*MI&(DC<YW!9%=PMF:EN
M<`2ZHCBJB+@(?`>'Q+<+B-6@%@V^]*8=W.*+3TD5!]QIM25MM71)=^P4W>*]
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MSFC1:H9,-]O=NU1/X8&ZU=;M.1\KIC:CPBBU$)]JY!.W*`W3E$VINH0EL8-A
M##Z+K]<")R*^Y$]\15ERQ).NMY0TYONJ**6LF5'!X505#3>CBHNFG3`J:^VN
MZ7E]V]&..E7-Y6Q7RHG:7N..2ZZ+N>[FJ;-BBBHFB[M5UP.GX/R+D=Y.*Q?.
M&7';&$U+KF6W0.4PZI*+C1]I2%P/^/5%0D5-,"K<^0K5>;M5,:5"=KICUE$;
M-0).P[61A=+<2F)NKW35'-H;!1-$+=@<PW\E?)CO&SND?JA"5QESD<9>PYL:
M<BN"CD=$5U2('`,?W"TT7P1?(.HK>=<JN^0F-8S#BUE?,9@64>:Z@O*C\<'N
M\WHF[=N>!&Q^TTUZHNF@5$7Y7Y/%I(MY;!")B=0R;-([`.`+,B)+9CHJN&:J
M3;@RQ(D711VKHJZX$`)O)>/<L^0;&'.@2[&3+XVG??!191F0GMB`Q:+421%]
M/5>FGUP+B/S?F[5E'>F2(;\!J\L*25#9C&V;P1HC\IIX7"=/8?["`HZ*B^.!
M[8\]YV7"G>50&J]B!*KZ^7"=<-7U:D2'FA?:)L-NYOMN%H2FBB2>"IX!MD<I
MYDM^Q4NS6&EB\I"M>>89T21!?K"L&VR$R+88;D%2%>NFN!=<VO;FKY3QM(LK
MMUAMV3]G"1H3*0,6+W0$3544%1?#3S\<#3QWEE[(Y15L3'69%3R2I6UKFVVE
M!^(;?:4VW20B`VR"0.TO'<BIII@0/EAV_E%&;HVY<AVB)NW*-"#7W$IAP2CQ
M734D%&S;1Q2%4\=BX%BO,+FYO*6-QQZ(-5=5#ELU+D-.FZ/:?CCMV"8#H;<C
M:J+HHEUZ^&!S-;SFX@5=#,N'(=M,>J[^P;G/-(R\CT`Q(6VR;4Q`"9+:>@Z^
MG_#`W?)TN[G\)DRW/8RX)RJ&91.Q"57-[T]I'$-7%V*/AVW$TW(JHJ)IU#I*
MOE_*;?D+0P*@`XZS,FP+&6Z^RKHE%4@!QL0=4T4G`42:-O5$]6N!1<IKB?\`
MEI?Q]-`MYSO'O]0S/<1L$%)J"V1)VWM>A&B=$_C@3N-54"QYSRV-9QP?9J$K
MX%5">5'6V8?M4=0P;)202<<,]3^Y=NGE@<QQEX[.;PJ19#[F%#O[V%2SI*]P
MG83;4D(BJ9HBJJHT@CKU+:A=<#9\XP:=>+\M=9ALK.-^B&6Z@BAN*LYL1`R_
M[BZ=?)?I@6_QG7UEA/YM$EPVHD<K)MJ1Q,Q[C,8F0320B&(@0S%1'DV`@_Q+
M=@:N*<3XS^-YC,_&1&Y,:UN&V)'9%%!MQM!(>B?9I_+X?I@<HD-Q*3X69D4S
M<1IFPA(R^KP/D2%`==7R0O68"XNOFB>>!]CO[9Z';T,5N*W(]](?#<?0FU:B
M.NH0$O0==NU57R7`H^(\PY'?O2HSC,>OLX#\5;*HEMN!)C,.B7<12`S;=WJ&
MK#H+L)/%$5,"9\E<:XK<\>=D\CKQM(]4#LJ-#<-P&R?V*(:HVJ:JNNU/'QP.
M)L(O(ZER/QJK@QIM9Q7CS-C^(ER7!&9)-TQ[:DHGO!@8Y;-_I0B'<GVJ@=KS
MEJUGT-8_`A.S61G0Y-G7-."#CL/75T$W:"YM51-0U3?MT\\#YZQ4W'*>%G;M
MV;E;0Q9EH56[.D.`3$$G6T8E@XPIJ91^T[V1(M%$DZ]$P/I,?F,,+M*Z23Q.
M2S92,XC*@PVDD'7&&B(]I]TVV"(DV]%5$Z8$#G7-[3CLV$L=AA^O65`8G_>X
M^(SY*QT5!':+:#]PD2EN7T[4\<"G_P"97)X]A'.;%@I5#<65/.1I75?TAQGI
M3+S6Y4'J#&AHJ>*]%P/>-V-A;_(?'KV2#+35QQ:1*::8)Q5%#E17`%S<NPE!
MMT4W"B+KN\M,#=9W5D4OY%L-6I*<=A)$@5KQ.(PJ>Q2:\;R`O_C*Z@=$UT#H
MO7`E1+`[6=85#L:-#;;HH,N)/;=)7&N[W%$3;73MHTXUN%=W5/X8&FSYY;M_
M"']Z1"8"U*J9F`3P[F5>,1U7:*CJA*OI37`IW;VQXIR^_G-Q6G(4^RHX]@/[
MB*X_/;",;D=%7:BCJ)$BZZHG^.!U'$^8\@Y'*@SXU2@<7G1W3]\;K2.M/MNJ
M(#L!QPC0Q^[414"3KKKT!8\UFQ^41:^,L.5!=LVJJ0+9&3S3CD1R2JN&GH!P
M>VG[>B^DD)5373`Y[_F/SQ^-`<9KZV*5E$M)`$^;[B-'5/*&F@HVKJ/@J$*>
MC;UUU\,#WBGRERWE9PY%/2,I#%FJ=LP=>!"1+)H7W2`E<`A1ELTV?M%W"U3T
MZ8&U/E.\BZ3[*!%_%N%=@TQ',^^BTG=7<3CB`WHZ,<DTV]%5%U\L"#9\BY#1
M7/(>1''CSIX4=6Y&;!QUJ*:/3'QV%KW="3?]XZZIY)X8%R7/>3QKB1&F182Q
M(-[%IY!LJ\KAM3V6C8<!"T03;-\4-%U0DUTT73`TM_)?*)/&9/*(W'^W2#4R
M;%MZ0\VB@_&121@A`B<(7$!?5VQ4%Z*BX&R9S'D[DJ56#V&)<>PI5;?8`S$H
M5DZB.-F)EKO%&G$4A5$T5%^N!T'+;FUKK3C#4,P&-8V91)X*&YPVTA2'Q1M=
M=!];":],")5\Y?L)/&Y;4<?PO*&"6*GC)8D`T4C]W12!6B;;)%5.HGHG7=T!
M\D/7[]2M-0NR(=C.:><;LHP&9,+'1#;3THO]5S:VNO\`*I>>!6Q^><FMJ+B,
MZGBQ(\F_<=B6+4]'T6)*88=)X4`-%+MO1C!4)4UZ=<#3#Y;R)*0)=D,2R+^Z
M?Q!;0..C;'Y!(8$V.KFXVG.OJ7JGZX%E$Y#8\CXO)LA:C)2S8UB*!N-)(=DB
M9;$AT424MA]SJFU=$Z^.!KIN674B+%KZNN]V_7C5M63S[K+8]N6RVXZZ/KW:
MM-%JB;50BZ)@;/F&#%<^/[V<3?\`K(D%XHL@547&UTUU`A5%1<"+\E0F8-=Q
M]BMCMH;_`""`B1E<)@'5)5$A,A0ETV#U3:OAX8&7)>(V%CQZ+"@Z\:N/R*/Q
MIM:\CHM.-":@Z?<]OW6W!%!-M17HNFGF@;N+VD;DDZ=%O(0Q>10HS<6[JEW$
MV.CSBMO-$2#O8?V;VRT\.B]47`Y>5':9^*/D*0WN%^$YR!B(Z)DAM--.N$V#
M9:ZB@***.GA@=77M(5CPPTB$V`0'E!WNJNS1AL1;)-=3U$E754733ZZ8&ZRG
MR9W/QX\\`K4M4STU\5UW.NOO)'%$(211$&T/7Z[OTP*3@EI;/5=%QNP$7:^T
MH$D0YS!&+[2,`PT0O*1;E(E?W`8H.FFGCUP)57R>?+^%G;Z:TW.FL54HI+<H
M?VY)1!<;-7!'3TO=K543ZX$R-S<AY1643S(P(\UL2ANN-J3,C_3(XK#+X%M"
M0V6NK1BFK:;DP.SP&`P&`P&`P&`P&`P&`P&!3O\`'>*O3W'7X48YSTAB:ZI(
M/<*1&':PZJ>.YL4T%<";!KJN'[EN%'98]R\<F6#0B.]Y[J;CB)XD>G55\<"N
MD\,X:_%:KWZ>"L5MEZ.Q%[+8@++W]9L`1$1!+S1,"T:B0&W&D;::%R,UVF-!
M'<VT6B;1\Q%>VG3]/TP(X<=H0=DNC7Q^Y,[B225L5WH\@HZBZIX.;$WI_-YX
M$J+!A1(;<**PVQ#9!&FHS8"#8`B:(`@B(*"B>6!#3C7'DK3J_P`;&6M--#A*
MT"LJB+N1%;5-NB+X)IHF!Y=<?A6M&[3DI16"$$8<CJ@&P;)";+C7DBMF`D/\
M,#R7QFFEC+.1%;6981EA3IS8"W(=94=J@KHIOV]>B:],"6Y65SL#\<[%:<@;
M!:]J8"36P=$$=BIIHFG3`BM\7XXVZZZ-9&[CTH)[I*T*JLML$`'^J?U!$41"
M\4P-M=14E8X\Y6U\:$Y))2D'':!I7"4E)5-01-?42KU\U7`A?V/P_P#(2;%:
M6&4^81'(E$R"N$1MJT:[E35%(%42T\?/`U#\?<)&,D5*6*D=()52-=M-OL3-
M'"CZ?Y%--VGUP-B\&X<MI'M5IH:V<1D8\:8K(=T&@1!`4/37TBF@_3RP/&>"
M<-99B,-TT1&(,9V%%:5H5`(TA45UG:NJ*!JFI(OC@:(_QOP*-7N5S%#";@NN
M-//1Q:%!<<C_`-$G/\ZM_P`N[PP)*<)XF,@)(U;`OMSBM0-!T5)S@[#D)I_.
M0IHJX$8OC;@10[&%^"AI$MG$=LF$:1`>,7.ZBFB?_N>K3PUP)A<.XN;SSQUC
M!.ORVK%TR'55EL"@-O\`7^<11!1?ITP)LVHK)LF'*EQ6WY->XKT)XQ12:<(5
M`B!?+42TP-=?0TU<\;\*&VP\XFTC%.J!KNV#K]H:]=H]/TP/8U'4QGY\AB,+
M;UH2'8.)KJZ0AVT4M5\@3;_#`K:C@'#J>3$DUE6U%>@-N,PB!3T9;=ZN`VBD
MJ")*FJHF!(_L[B_N8LG\:SWH2R2BEMZ-K-52DZ#X:.JOK33K@1&?CC@C%<Y6
MLT<1J`Z^$IR,#:""O-+N;+1---B]11.B>6!,B<1XQ#O)-]%K([%O,_\`530!
M!<<541%4M.FY4%-2\<"1^`IOSOY_V;?YGVWLO?Z?N^WW]SM;O\N_KI@:[3C'
M'[5Y'Y\%I]]![:O*FTU;Z_MD0Z$0>I?2O3`SL./4=C7-ULV"R]`95LF(Z@B`
MV3*HK1-H.FQ05$VJ.FF!&=X;Q9ZC.B=K&#J'"$W(9#J!&!HX)%YJ2&*%JJZZ
MI@2AH*8;I;P8;8VZL)$*:B:.DPA;D;(D^Y$+JFN!C7\=HZYF<S!A-L-63SLJ
M>`)T>>?31UP_JIZ=<"-_9G%O8U<!:UE8=(Z$BI95%48SK6O;)K5?2H[E1,"9
M84=18R8DJ=%"1(@$9PW#U56R=!6S4?\`O`2C_#`TL<6X\QVNS!:!6$81HD1=
MR)%W*P.[771ON%M3P35<";,@Q)K*,RVA>:$P=0#ZIO:-'`73_A(47`C6?'Z:
MT=:>GQ`?=:$FP-=47MN:*;9;53<!;4W`6HKIU3`V'35A)+16!TG;?=Z*J;]@
MH`ZZ+Y"*)TP)(QV`9%@6P%@$01:040$%/!$'PT3`KY/&Z65<1KA^/NL(G5AS
M>X@H6T@0B;0D`B$7"05(55-5TP(EYP/B%[)65;5;4J2J-(3R[A)?;DILJJ@H
MZJV1JHJOAKTP-W]G<8WB?XUE3"<5J!*FJI-,5$GT55Z&HDJ+@84_">*4TL)=
M96,Q9#0.-,N`BKVFWC0W&VD551L"(478.B?I@>EQ2`=Q:3W3-R-<Q`B6-:>A
M1W-B$/=4537>39]LNO443Z8![B%$O><CQ@C2GX(U92034_9AKM:ZKHJ#N7;K
MX:X$URDJ':?\*[#:<JNRD981`*M*R@[4#9IIIHF!`<X1Q1QTG3K6B<-^-*)5
MW=7X0H,9S373<T@IM7`VU/$>-4\Z5/JZYF'+F$9R7&DV[R</N&NGVHI'ZBT3
MJN!Y(X?QB1/2P>K6#F));G(_MT+W3([&W^G_`(@AZ=WCIT\,#&/POBT=6E9K
MF@[#<AIE.JH#<LMT@115T1'%^[`\B\)XE%>AOQJJ.R[`9;C1"`$38RPNK(=/
M%&UZAK]J^&!C%X-Q&+V$8JV0&*Y(=CAHJB!S$49"H*JJ?NHJ[OKJN!'8^-N"
MQXTF,S3,`Q,;98DMINT-J,6YAM>OVMK]J)T3`GR.*<=DONOO0&S>?DL373ZH
MI28HH+#JZ+]S8BB(OZ)@:TX7Q9&)T=*YI(]FCR3F$W(VY[@MSVH:[4[A=3T3
MKYX&QSBG'7'"=."VKII&0W.NY?9$IQM5UU_:)54<"=,KH,THY2F`>*(\,B*1
M)JK;HHHH8KY+M)4_@JI@1Z[C]/7.*<.,+74R;!%50;5PMSG9!546D,NI(")J
MOC@;QKH0V)V0M(DUQD(YO:KJK39$8CIKIT(R7P\\"NC<,XO%DQY,>N:;>BR7
MYL94W:-R9:*+[PCKM0W$(M5T\U^JX&;_`!+C;Z&CM>T2'-"S)-%1/>MZ;)'1
M>AIM1=?KUP$?B/&XSDPX\!IHI_>]V@:H)^Y7<\NU%T17%ZDJ>*X&+'#>+QYL
M6:S6LA+AL-Q([R(NX6&556VUZ^H05=1W:Z>6!-MZ>LN:U^LM(P2X$E$%^,XF
MH&B*A(BI_%,#V?45L]J.U-CB^$5YN1'0]5V/,KJVX*^.X?K@:G:"G>5M78PN
M*U("6V1*2J+[0[0-%5?$1Z8$U(["/E(1L4?,4;)U!3>H"JJ(J7CHBDNB?K@5
MO]J\=_$3*;V#7XNP)XYL33T.E))3>4T\^X1*I?7`VL\?IF7H#S440<JV2C5Y
M(I?M,D(B0#U\%0!3_#`2J9AZYA6PZ!+B-NQR/353CO[2)M5_[[8$G\/UP/(?
M'J2"A>RAM1E)M6$)H4%1:55+M@J?8"*NJ"/1,#)F@J&:(:$8H+4#&]G[14U!
M6%#MJ!?74>B_7`\9X]2,O,O-PVT=CD)L&J:J!BS[="'770NSZ-?';TP+#`8#
M`8#`8#`8#`8#`8#`8'`VO`^'N\]JI<>MCA=H^Y<3K!%7W2HR/;;3<JJ6PG7$
M]/VZ"J8$+C$>X@\JHZV;'5J;65DY;VQ$@5B2)OM]AW5-Q)W7.XX(GM4?7X^.
M!<<F..?/N"O@C9JX=B+3Z:*JME"4E0"3^4MHK_@F`*B6AOG+F-(.0JMS'9,8
ME\&9$@93IDJ:D:M;%!@?^-4\,"PX7S6)RJ'(D,QG891B9WM/*!+MDQFI;2ZM
MJ0_TGQU37HNN!T+3K3S8NM&+C1IN`P5"%47P5%3HN!E@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#6D:,DE97:#W*@C
M2O[4WJ"*I(&[QVZKKI@8E"AFPY'-D"8>%6W6U%%$P5%11)%\4T73`U_BJO;#
M'VC.VO5%@)VQT85`5M.UT]'H)1]/ETP)/;;4E+:FY4VJ6G54^FO^.!%K:BJK
M(OM*Z&S#B_\`D,-BV'AI]HHB>'3`WQHL:+';C16@8CLB@-,M"@``IX"(CHB(
MF!LP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&!K.3&!]N.;H#(>0B:94D0S$--RB/BJ#N373`V8#`8%?+Y#Q^$
MZZU,LXD9V.@D^V\^VV0":*H*:$2**%M737QP-\JSKHBL))DMLK)/MQ^X2"AF
MHJ:"*KXJHBJ_X8&%5=4]NP<BKFL3F&W":<=CN"Z(N!]PJHJNBI@3,#6DF.L@
MHR.@L@`1PV4)-Z`2J@DH^.BJ*HB_I@;,!@:F9<5]QYMEYMUR.7;D`!(1-FJ(
M6TT1?2NU471<#;@,!@1HEG73'Y3$60V\]"-&I;8$BDT9`C@B:)X*H&A)^BX$
M)GE_%7AEDW<0R&`*N35[[:=EM/YW-2](?\2],"Q;EQ7'$;;>`G5`74;0D4NV
M2J@GIX[5TZ+@;<!@>"8&.X"0A^J+JG3HN![@:WY,>.(D^Z#0F8M@ID@HIFN@
MBFOBI+T1,#9@,#4[+B-/,L.O-MOR-R,-$2";FQ-Q;!5=2VCU73`VHJ*FJ=47
MP7`Q<<;;;)QPD!L$4C,E1$1$35555\$3`B?G*7V3$[\A&]C*(0C2N\WVG"-=
M`$#UVDI+T1$7K@3<!@,"(_<U$>8S"?G1VIDDE"/&-T!=<(415$`5=Q*B$B]$
MP-C4^"Z(DU):<$W"9`A,50G0W(8)HO4AV%JGBFBX&_`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8'R,9]M(^8^.3;'C\ZN>*);L%)DO1391D28(.VC3Q^A$%")5%"U+Z>`?6(T
MF/*CMR8SH/QWA1QEYLD,#`DU$A)-45%3P5,#9@,#YXJNM\[Y<L"35!K&KG+)
MB>A$>@MN(I.*)!L;[2)IJB]=<#G^?/\`?'Y1-N<I,,<<A]A@2!6P4VI1B\*Z
M*HJGDJ+IY_3`MX%I=C?Q>.5MA#A)5M5KB/R3#NVL=QE`?+M`V(N*B-Z";2B@
ME^G3`@SN=39G![VU9Y`TS:.4MA*_"-BVDFO=93:!:I^XVK2)H:.HNI^&W3;@
M6)6O(S2TA\?M&K*?$H:Z;725!AQU]S>\AH9CKO21V>B^"*6J8'KGR0LY..V-
M=.")QWD[DAMJ=+;[)1BCQR4&]7100=<D`0Z.;DT%=NNJ8%E=\FO:7XZ9M9<J
M(_9H4=B9:QVS6$V+TD6')>Q5W=ML"4UZZ=/I@<BYR9VJM;Z%5\A9EV$ZS8+W
M:!#0D:6M[A";@B+`J*M[D(Q523THFJ[L"NA?)W+'ZI.0C+%R2O#8EFM<B(4=
M)1RC"3*[8IO+M-AN5!+PZ*GA@?4N,/VHU<^5(M&;]A7">K7X^Q25I6A+M&;(
M@V2]S=MVC]JHBZKUP.*E<HN)=8,N#R!)M1;T=A,EO`+#3E<ZRT)@XV2"A"**
M9-J+J*2*B+KT7`MF6E#X()Q)9J^YQK><].VCJE[#H2D@H*J*=$73`Y:QG]KB
M<VH*0Q+A/?'[TSODVRCQD+?;;57&T%"!`)$%-NGGXX%AR?G=W4P[K\1-A@M=
M0U,V*Z\V+@MG(DFT9.$A"I-*`_X>.N!/7F/((5E,@R+2*[%@<AC0)4U_L,.I
M$EP1D(`"I"V1H^X@I_-V]?%45<":S=<R:^&["YMWF?[E:KITA'(FP@`VQ<5C
M^F3@*:"([MJZ;M=,#`K=ZLEUW%ZZ0W55[5`4Z'/-`)'GP46@!%--AH&[N.=4
M(MP]=-V!RTKG_P`@2HLV?'LXU;-@5]/,;X^407'9#\U@79#'K-'O'4104W)^
MN!9W')^0U4LU2Q"4+W-(-:#$QMHT8A2Q!%!M003%=QEVR+5>G\5P)<3G5W/2
MML(T]ILIK]G$G4:MMN'%*&V_L<5?VW![;D8>XA^._HB=,"LB?(W)`CPG95M&
M,;"AIK75&&]6WY<UN-(0-"04!Q'-$)STMEZE7:FF!Y0<OD<DM^)2;%Z,4J-R
M*Z@CV7&S108ARA;15!5%2V***H]"\?/`Z'X\FR1&SJBE#"AU?(9T&K:<(#*3
M%!OO=@-Z[D[9NEIIU00^F!W,]GO09+.U#[C1AL)%5%W"J:*B*BX'RV`E>]\=
M_'=(3["V"2JA?9)M!Q3A*+\A.RNA"K:-JIHJ:IY]<#2'/^<1FX=N,B/;L29-
M[&=H6&$&0@5JR2CN`8$1:HL8&W-R:+O'P7Q"5=\]Y%$H9=M6VT.?'D\<>N8;
MK;.X8\E@@7ZCN9=1[:*'ZD4//K@='PGD-I,Y-RVAL9:3"HY,5(SZM`R?9EQ0
M>050%T)!/<B%HG^[`X^GM'83@33F,37I?-YE8TY(;9,V&''GM[3+FF]"+M!Y
M^"(FF!*X7;)&EPX$(HS<.7RKD+#X&(*:FV4IX=FB^DD<3^.W],#32?(_,'XC
M-@Y)A6#EG26EC"@-`D=D7ZN0VR.QQPR-1=%Q2-#+TZ>*)@=OPNXNK9ZSE2C!
MRH1QD:ASMHVZ8+'`W2<T)?!TB%/2/31>J+K@=/@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#Q0!5
M0E%%5-4153JFOC@!$1%!%$$13013HB(F![@,")*IZF8\#\N%'D/-_P!-UUH#
M(?X$2*J>&!L6!!7NZQFE[PH#WH'UB*:"A=.J(GAK@:W*BJ=?BON0F#?@Z^R=
M)H%-G<FB]HE34-4_RX`*BI;=ENMPF`=G])S@M`A/Z)M_=5$U/HNGJP,H=96P
MA08<1F,(@+8HRV+:(`]!%-J)T3R3`REU\"9$.'+C-2(CB;7([H";9)XZ*!(H
MK@;59:5KLJ`JRH[%;T3;MTTVZ>&FF!%"FJ&V`CA!CA';VJVR+0(`[$5!T%$T
M3:B],#8Q6UT=&A8BLM(P"ML(#8B@`2ZD(:)Z473JB8&R/'CQF19CM`RR'0&F
MQ013SZ"FB8&#,""QWNS'::]PNY_8`CW"TTU/1/4NGUP,PC1P82.#0"PB;4:0
M40$'Z;4Z:8!8L9?%D%]/;ZBGV?Y?X?I@>>UC;=O9#:HH"CM33:G@/\,"CY;P
MN%R.,RTX^40F'>^FQJ.\TX:@K?[S,AMUIW027;N3HO5,"QJ:&HJJW\=`B,L0
MRW*XRVVVV!DY_4)6VQ`-37J6@HF!["HJN)6Q:T&4=B0A1N,#_P"ZH"'V(BGJ
MOI31$P*Z)PV$QRNRY$ZY[EVP2.H1W6FE2.Y&;)H7&7-O<0B$R1>N!<.5U>Z1
MDY%9,G2`W")L54B;^PBU3JH^7TP/$JZQ'GWTB,H_*'MR7>V&]T.OI<+34DZ^
M"X&A>.\?5I&5K(BM(PL1&^PWM]NJ[E9TVZ=O5-=OA@;4IZA#:-(,=#9/NLDC
M0:@YMV;Q73H6Q-NJ>73`\8IZI@&@:B-"C+IR&?0BJ#SJDKC@JNJH1;RU7]<"
M9@0V*:GCS7)[$&.S.>U[TIMH!=/=HI;C1-RZZ==5P*[BO#JGCC#X1&P-]^1)
MD.3";;%XO=/E((",!%202/1-?)$P)S?'J!N/(C-UL4(TO_U3(L-H#O55_<%!
MT+JJKUP-\>MKH\AZ3'BLLR9"`,AYML1-Q&TV@ADB(I;4Z#KX8$<..\?#3961
M!TD>\31AM-)*?^/]O]3_`(_'`]3C]"BMDE;%0F73D,JC#>H/.?>X/IZ&7F2=
M5P(-GPRBEU+]?$C,UA.,.QV)41A@7&1?_J=M"`@T/^8530O/`<<XA643KLB,
M#82'VP9>]NRW&:(6B)07LM((;O7HI>.!>X#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`JG.5<=;Y&WQH[!E+YYA93==N_=5E%5%/3Z>E<"UP&`P*^QOZ:M/9-E`R2
M"AN:ZJC8+KH;BHB]L%V+ZCT3I@+'D%-71`ERY8-QW`)ULQU/>V([B,$!"4A0
M5U543`B)S?B:VT&I&S9.PLT=6`P"J?=]NI"\@$**.K:@J$FO3SP+O`8%7>\I
MX]0I'6XG-0_='VV.XJZDJ>*Z(BZ"/F2]$\UP)$2YJIGMO:2FY`S&5E1'&BW@
MZRBBBN`8ZB2?N#X+YX$S`8#`8#`CRK"%%5$DO@TJ@;GJ73T-)N,U^@BGBN!$
MJN4<;MW>U5VD6<[VT>V,/`X2M*NB.(@JNH:]-WA@6>`P-3DJ.W(:CF:(^^A*
MT'74D!$4O]FJ8&W`AV-Q5UI1!GR0CK.D!$B(:Z=Q]Q%4&Q_XEVK@;8-A"GQA
ME0G@D1R4A1QM=4W`2B0_Q$D5%3R7`WX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`X6JK8S?.Y=M1<D.8S,?<;Y!2.NA(99=CM=O<SHF^.X!(V)`I:$GEKI
M@=G`GPK"(U,A/A)BO)N:?;5"`DUTU%4\<#?@,#YUP>6S4<IYK#OY#<>VG6AS
MX??)!)ZK]NT+!-*6F\&MABJ#]JZZ^.!0\0!UJ^^.FI[CD6:<"]=:KG20'`CO
MO-.1T)K[AVLZ)M_ETT\L!0VLBHHN*E473T]+&]MVGFW^VXLH52<Z@%Z4(%%Y
MIOH*CU7KU7`GQOD'M<-/D<"V_)3>W7'=QGA,H]>;SXMS#,0'N,]D5-3:4M00
M==$\5#.&')UY#Q>M?Y8Y,K;`+.8+\!&D%]J.['<C-$^2.DYM%PQ(A5-P_P".
M!=\_81+*MG0.2,\?O83,AU@)B(<.7%38K[4D")O4$5!7<!(0^*8%%5<QM7TK
MT@(S6`[Q6;.9K!`4C-S([S;;;C:(*&K74E%/,/+7`H`YC;SN)R+.!S#02=H&
M61COP9;S;LIYIN;W=K9[-^]=$)?)?!.F!C9\SMXU=;TK=_,<G,6-U&II[IM-
MJ0P*YN2(N/--JCI-/.%L;0=21/5]N`>Y-.W<@Y*S;/M2BK>-6!-LGN:]J9;I
MCPLZ'^VC9FI*/A@34YE*M[1V#!Y/(CP)?*E@#+91I#&'(J.^RVT;K1(@E)%>
MV6G7ZKTP+[B]I:N\O"#-Y,/OXCLIF9QUQM3=<B`A#%=+H';+1L7.\B;7-RI]
M,"8Y(5SF'./=%H4.HAA$1>B#&<"29DBK_F=0D+_NI],#A_C1QN%(X/8WLH9`
MGQMB#P]QH"::*2;8K-C2'%W)WR[3:-[MHZ(6B;D7`K/_`,@HC$QMIV=8-2K%
MZN@7;Y1=M;42S,UF"#KXJ:.BVBBK9`H[A4D\\#I*WGBA81)[/(SE\9#E+M6L
MLB!YER+(JD>;`W1#70)FB`6OGMUP-$;Y"OW^.U3P7!*Y,J>2.NDK;8.J[7.[
M8KOJ!%$P'IMTZ^:8&QWE%M%K>-LWG,2K8-M3^];OW@8;<<LU[&U@-@"V2`)&
M7:(54]?'IT#+E/)$?MJP+>>0R(7*X#;%4XC;:I%[:@W*0!3NF#QEW-R]$7T]
M-%P.NKG&F>6<D966=?"&RKG4<`PVO2Y$4`.*HD);4-$:)=/42EKK@=O@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#!N.PV3AMMB!.KN=(11%(M--25/%=$
MP,\!@,#6[&C.FVXZT#ALKN:,A0E`OJ*KX+_#`]*.P3PO$V*O`BH#BBBDB+XH
MB^.!Z#30;M@".XE,MJ(FI+XJNGG@8A&C`+@@T`B\2F\B"B(9%T)2T\57SUP/
M6F666@::`6VFT06VP1!$43HB(B=$P*#G_+N-\3XQ,NN0*!0XH;QC%L(WG!5-
MC;0&J(1J6FGT\<"3&-KE'$F77FY-<W<PA,VQ<[4ID9#:+M1QI5VF.[Q%?'`K
M>.TW&J&[.O"P69?OQA-0?[*/I$$R1"V,-M"@D:+J9#J2IX],#J2::-0(@$E;
M7<"JB*HJJ*FJ?3HN`%IH511`45!V(J(B:"G@G\,#+1,#Q!%"4D1-RHB*7FJ)
MKI_VX$5VKA.63-DH:36&S9%T55-S3BHI`:>!#N%%37P7P\\#=)=!B,Z\:H`-
M`1D2^"(*:JN!\.H8#:_"7"TDNZ6'(+NMG2)KFG><E3+!)+CHZKU,AU__`$_I
M@?7J+C4>FF6\EF2\^MQ+]ZZT[LV-'V@906D`05!V-#XZX%QHGTP,'&&'-G<;
M$^V2&WN%%VFG@0Z^"]?'`=EGO=[8/>V[.YHF[;KKMU\=-<"/6U<*N9<:BAM[
MSIR'S)5(W'75W&9$O557_<FB)T3`EX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8'S3Y9^5;[@EUQMF'Q]R]K[HWX[P1E7W*/@@DT#(IJA*0[
MEVJG73Q3`U!RWY@Y6`AQOC0\3@.CJMOR)4.0B:HB]J`P2EO3553ND@KI@<9S
M;XCB3>9\(J[^XG<FN[*>[-G3)KFC#4.""OOMQX0?M--OF3;1=5TZ8'VKEW)J
M[BW&YMU-5$8AMZMM)KN==+TLL@B(JJ3CBB`HB>*X%-\;\4GUD!V[Y"@/<QO%
M23<R!U5&]>K41G=JHM,!H*"GBNI>>!V6`P&!'GV$"OC+*GR&XL82$%>>-`!"
M<)`!-Q*B:D1(B?K@2,#!]H7F'&B%#%P2`A)$450DT5%1?+`^(?'S\F=QWXLX
M^("KU7*GO6AKJJ,E2@[#-O0E1=RNR@TZ>'7`^Y8'Q^S^>K.*Z_=QN+/3/CF%
M+]I+Y6V^.JHA]LY#,;9W'&0/HI)T7R7`ZVI^6.,6OR),X+"1UVSA0@L')2(*
MQU`T;79NW;]Z"\*Z*.!4?+WRA/XA;</IZMMIZPY':M1G@>$BTB(8B\H[514)
M5<%$7KYX'TEPQ;`C)=!!%(E_1.N!\>_Z?/EVX^0I'+$LMJMUL]%K4`!!`B/[
MT:;)1^XA[7553SP)W_4SR^RXS\36+U82MS+)QNM!Y/N`)"%W"'SW=L2%-/!5
MUP.K^+:251_'7':J6XKLJ-!91\EUU[A#O).O7TJ6F!U.!R_,_D.CXKV8SS<B
MRN9:*4*DKFUD37A374T:'[6T5-%,M!3`XRYD?.<RM?O95O3\!JHP$^<1UK\D
M^VR*:J4E\MK2%_PMC_BN!V?QE><EO>$UMMR2($&UE"9&PV#C2;$-1;-6W?6"
MN`B%M7PUP.HP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!S7R%PL>6\?_'M
M2UK;*,^S.JK0`%PXLN,XCC;HB6B+X;23S15P.BC@Z##8/.=UX1%''=NW<2)U
M+:GAJO73`X.LL7++YMNV$%"C<?I8D?<NFHOSWC?+:FJ]";9#5=$\.OE@;+6(
M'*?DF%!=`SJ.'B%A(5#T:<M7Q_TS;C:CZECLKWD77H1#@=W@?%/^IWF4R%05
M7#*22K7(>5368S:-N;'`C]P44E45WBAN;0U3RW8'U?D%]!XYQV7<6)*D:O85
MQQ!ZD9"F@M@G\QF6@BGFJX'SGX*O><6-MSB-S`C"SB6;1A![O=9BM28XN@PT
M7T$-NO3QZ^.N!$_ZCZ:YY?`I.!T;P-6EF[(L=#UVJW7,J8H1)]J&\X`H2^>F
M!W7Q;S!GEO!:FWW[IA,BS9-DFTVYC/[<@2'55']P"TU\4ZX'5X'Y\KK^OX5\
MO<DY2[`DCP.YE)7+>"2K$B62B!RW>TBK^P^ZB(;VGWBJ8'VV[?ES>+6#W'W6
MI$R1#>6K=$]6C=)LNTJ.`OANTZHN!\('Y#X5"_Z9!HFY#97IUA4AT&JI-6R<
M167@5A%5W572(]=,#7_T><$6)7W7+[,B.[D/E5JR^*]^.,=4)T7-R[D(R4=1
M)$5$%/K@6?S5><=C_.OQFEC*$&ZUU]R<NFJ,E)VC$5U5](H;C:_X)K@??B%"
M115-47HJ?I@?ESX6O>)_%GR/SSCU_8MQ(,J8(UMH>Y(A*PKADP3NU`%T!?1"
M3PW(J?3`Z;Y1D6'S5`3C7Q^VQ)JZM\9LWDDM'&XA2&A)&HT0T%5=4E5>X0IM
M'I]<#M*CYPX\R^-3S./(XC?-Z`ZS8MJ,5P^B;H\L=S)B6[IZL"JYO_U`\4;C
MMUG$;J++MIB*BV0`[+C0@\-YML"9NNDO1II$ZKU+04ZAMX78RM94SB?$K"99
M3CVV?*.0*E;[AS554]A]R3VA55VM@R(CX)]<#HHGQ[-M)[%KSBR_-28ZBY%J
M&05FJCNB6Y#%A5(GS'1-IO*6GBB#@=O@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,`JHB:KT1/%<#Y_\4)76<CE7,83:=CD5L?M)/BKT:O:"$!IT^TG6
M72']%P)WQ8X],H["X?W=VWMK"2F\MY(TW)*,P/3HB`RP`Z8%]R?DM1QJDE7-
MJ\+,2,*KU5$)PU^QIM%^XS+TB*>*X'P_F]))B,\3Y]S".D*RF<GKI5TXV:Z0
M(`;TA1C4]$0&3(">T3[U)?I@=K%L7?D?FK1PO_\`A>)R^X4OH06=JTFC:-+H
MJ$Q$)5+<B^IS3_+@12F#PSYVG/3U]M0<X@L*W8/&@LC9UZ$/94BT05-A=437
MJN!9?'#J<KY+=?(+C8.0'5_$\4D*.BK7QC)7GQU75$D2%7KHFHB.![=?$K\6
MWE\BX!;EQ>\G$KE@SVTD5TLETZOQ25!$_/N!H75?'7`C?VC\S7X2*SE?)*V!
M1NEL>_`1WFILACS;5Y\R1A#3H2@BE]%P.]K.-TE;Q]CCT2&V--&CI$;ADF\%
M90=NTT+7=N3[MWCYX')1_ARHJ2D+Q*WL^+-R-Y%"KW@.&CAHGK&+);?;!=1_
MD0<#;Q/X>XO0W2<BDF_><H5I&7+NQ(7'E1/YA$1$`+RW(F[3IK@5-Q\:<ZK^
M6VM]P+D4>J:Y$HG<0)\;W#0/@`@,F,@J/[A(/J0NBZ_PT"UA_#O%BX]:5-Z3
MW()-ZH'=6LXM9,AQI%1DA(-J-=E%T;0--J8$-/BKE/;_`!Y?(-RM#N3_`$:#
M'25VD7^E[]`[^W;Z=WW?K@=A7<2XY`HHU$S7LG5Q$1&H[P"ZBDBZJX>]"W.$
M2J1&O5575>N!:M,M,MBTR`MMCT$`1!%/X(F!R'+;F;935XCQQ16X-!<L+,V0
MD1ZQK[A<=!ST&^Y_X37C_.OI3J%OQ+A]!Q2G:JJ6*$9@$17G!%$<><TT)UTD
M1-QEXJN!=8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Y-V-\K=T^U8T?:W+V]\*6
MI;=>F[25IKI@8^U^6O\`[E0_^RF?_-8#VORU_P#<J'_V4S_YK`>U^6O_`+E0
M_P#LIG_S6`]K\M?_`'*A_P#93/\`YK`X2/\`#_RO6W<BTH.<-5`S'CD2JU([
M\N&3CA*1;6I;[O;34E^U?^Q,"5R'E'S]22WA;K^/W%=%:[LJ9%,F7F^B[>XQ
M)EL(*EIKT/3]<"O:^6?E,VMY4$M"VHNT./37155\=CC<X@-/^)%T5/#`DNP_
MGKGM)*KIZ0.)5$M$$GR9=2Q>:U];?:;DO(P+B=%+N;]/),#IHL'GG':V!6,V
M?&JV`TC<*N8*)*;'5$VMM!NEIN)43P\5P/FM?S7Y*^-E<XI=QQ<$9<DZ>=&J
M9<T)P/N'*+MDS);%LA5Q4[:IZ4\5TZX'3T]5\M<T>J>5VDJGAPH1NO4]&Y'=
MD-*1:@U-?5F2J=]&U)!#>0AKK]W@'0W-=S:V:<X]<6'%I@3@7?5R8<DE=`>N
MO:*7JJ"J:ZHG3`V!#YYQVH:9&QXQ45$,1;:'V4F/':'701366(CUP(EG3<LY
MC3O5DZ?Q:[JW53O,>TDO!J*ZBNH3/22+X*BZX%K#J?D^%$9APY?'H\2.`ML,
M-0)8``"F@B(I*T1$3`W>U^6O_N5#_P"RF?\`S6`]K\M?_<J'_P!E,_\`FL"$
MS8_(+T]RN9Y#QARP9_K0PCR">#_O-I,W)_BF!-]K\M?_`'*A_P#93/\`YK`>
MU^6O_N5#_P"RF?\`S6!K$?E,FR<&VX\38*2&:0Y:B*@JH2*ON^FU4ZX&`)\L
M2(H2(5IQV0TZB&TX,68K9`75"$QE%JBIX:8&Y8WRYMZ6-!NTZ)[*9IK_`!]U
M@!C?+FU-UC0(6G5$A3%37^/NDP*7D-U\K5TJOK(\ZADVUJ\C4:(,28!"TG5^
M02^Y-!!EO4NOW*FU.JI@8\;XG\A<1HRC-7%&0"IR;&TEQ)7>D/%ZG9,EWW0H
MI%YJO1$Z>"8%X,?Y9(4(;.@4535%2%,5%1?_`/+P+2BN=U04BUMJV4\RI+)E
M05[<8!1=$UWNO*FGGJ6!;OR(\<$<?=!H%(00S)!3<9((CJOF1*B)^N!LP([%
MA7R'GV8\EIYZ*J#);;,2)HEZHCB(JJ*]//`R:FPWC[;3[;A^.T3$ET3]$7`W
M8#`8&+CS3:@CAB"N%L;0E1-Q:*NU-?%=$7`RP&!I*;#&2D8GVQDDFX6%,4-4
M^J#KK@)$R)')D9#[;)2#1I@7#$5<<5%5`#54W%HB]$P#,V&\\ZRR^VX\PJ(\
MV!B1`JHA(A(BZCT)%ZX&[`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'PWECY-?(O+ALV67>#=JK<
MY:+2ZS$:[#B-DXVB*I1-R)WMOJT_X=V!UG.>=.5#3)\<GQ#9B069WLQ%M678
MSTMF,VZCRD@=H`5Q4%OJJZ==.BA!3Y+L_P"[8U,EA"1T^23:QZ$XB([[)FO6
M0V6B+N%1<VJI+XHN!S/+.27ESQBKB7*HS=1^0\=-5%MEZ/LDR41N3$D-J3;S
M+JM$8_:8]1+IXAU5)S;D#MUQFJF2X\LY-Q?5<]]&FP<=;K!?[)(*'^V7[8J>
MT=%_37J$/X-Y1[MH..JXL$*J*IPZUQH4*6PY(<TFMNIJ*M(O[>P>HDB[O+`Z
M%V3!D?,D1Q@0<6'0S6Y<T-I"!+,CZ,N&GVD.TEVJOG@;OF1J)*^*N2(\@.QU
M@FZBKHHKLT,2U\--11<"JYD]51>>\4E4R--VHA,DV;S&B#^)"(>I2NUZB:]Q
MV>WTZDGIP*F+SOFMCQZ^G5LX'G:%(-BA`Q&><DQ76E>DL=IITT;50%2:12WI
MTW:X$[DG..2.2*F/364:$WR=B;.HY4Q&VD4&&F?;-:N"XB]Q'"?)"%#V^E/M
M7`^B4TIYZNC#+?CO60,,E/\`:EN;[I@BD0:^K82ZJ&OE@?*:/A\KD/(K\P"'
M"C5_+EG/6;::V)^V:9-&A(43MH1:`JJ7V:IMZZX$R9S;E$&+!>=NXDJ-<W4N
MG8FBTU&:BK'<E(VBN&3XJZX3(-^L=O3R)4U#<O+^;5+5*G(9D9QI&X:7%G5"
MW)9%]Z6;2H\RNCX,OM((BZV.@N:^6!'>YA;R8S5,MA&A%(+D+CTY&6>T]^,E
MFR,1&U-40U;/>XNNY4%5_P`V@47QGR[EKE!Q[C=*42*]`HJ>2GY$T$)(2U)'
M2:VH1F+8@C8[230_'RP+2L^0>9V%W(19[#4)RVOZ2/%".*DVE8RZ['D=PB52
M<16T0A5-J_3`Z*MY/,J?A./R:RN&W)3=.S,*TD-*X`NFP*IO;95"<_<+3HNJ
MK@<'P>ZYA(OTMK-QF-R:ZO7Z&=O1E\V*^/7%*BM-H!]L%:<+N&@Z[R5=<"PM
M?D&TY#P.UK+`HL9Q_A\VRD2=BZ2'1)^*X+(FJ@@AVA(TW*J;Q_C@=3S^T)OX
MWJ9<8]],_(JTN)C)*HMU9NMK)=W`J*H*'I)17[55<##Y7X_QEOX_Y%90XD5F
M8W4R6VWF1$![3NP_6(;1,=S8DBEX>6FJX&FPYCR:)(MX3ST">E9;T<?O.,$`
MK'LW&1<T%'"3>!.;FR5?]N!NX_S/EE].62R_61ZH';6),A$:^_8<AN$#&C?_
M`)@[1)T2T3:2*GZAK^+8NOP[!M))LR;"?3B3\]ME&G3!&B(1=/4B<42,EW+Y
MJO3`@?"T6V3X]XW)<8IHHE2C[.<V!+*%Y0'MDZ*HVBCV]5<T/JOZ8$F!\GW\
M?C<B1R$8$2^A6<.HLX39&C<3W#H-)+<(UZMOB:/->";%1%)5UP)$KEG-`FE4
M2I]152!AS;%JT+<[&,(LML`:-",$#8P:>X5"Z*2*.!G8?(EI&L9\<'H2-Q+V
MFKV]XDA'$LVXZN*FICZQ*0JB6FFB=4P(]-R6Z?"F<GNQ;$IW*[6`R3K*=R(S
M'2<+*-*A?U!2-IN5-=I*GZX'DCY3MH%9R`)449%UQ%N8]=,MMDVV;0]8#@JI
M%VP?:<1TBU+1`/I@=;Q"RY%.*:Y:K#*(78=K%BNHZYVG6D,^ZH*H*F_7MD/W
M#_M4.!C,4)?#]_R"UT9OE"P?M;$@W38MBT9]L14OW`..:-BR&O1$'3QU4--D
M_P`H?GW<BPF-I(C\)BSPB.LZE%L4]P7>%-^@F+K:KJ@Z^"?R]0DT]RYPZAB6
MLB#`E.,\49FRIT=D6)3Q1R;`0<<0W-60:<'S7JBK^F!TEERKD=9)AUZ.0;:1
M<2C9KI+'^G%L$AE(%'=[C@$X1CJ`H2;@Z^6!"I>8<[F<^@<;GM5T(4I&K>S!
ML7)!*XLHXQ@RZ+@`@D@H8JHKIX=<#Z-@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"&Y24SCLIYR!'-Z
M:"-3'":!2>;1-$!U534Q1/(L#1_:_&?;A&_$0O;M@33;/MVM@MF2$0(.W1!(
MA153ZI@;/[?H?R"V7XV+^154)9O8;[VHBH(O<V[N@KM\?#I@>C14@L-1QKXR
M,,.H^PTC+>P'1747`'3031?`DZX!FAHV7PD,UT5N0V;K@/`RV)B;_1TD)$U0
MG/YE\_/`]C4E+%-AR-`C,.10-N,;;+8*T#B[C%M11-J$7543QP-C%96QUD+'
MB,LK+,G)2MMB*NF2:$3FB)N)?-5P,GZ^!(AK"D1FGH:CL6,X`DTH::;=BHHZ
M:>6F!C$JZV&*C$B,QQ(4`D:;$$41\!7:B=$UZ8&JNH:.L0TK:Z+"1U$%Q([+
M;6Y$551"V(.O4E_VX&4^EI[&,W%L(,>9&:5%:8?:!T!5$VHHB:*B:(NF!L8K
M:^/*>EL1FFI4D6PD/@`B;@LHJ-H9(FI("$J#KX8&4>%#CF\<=AMDY!]V038"
M*N.:(.\U1$W%HB)JN!'*@HB@G7E715@.&KCD166U9(U+>IDWMVJ6[KKIXX!J
MBI6E;[4".WV@%IM`:`4%MLMP`B(B>D2744\E\,#%_CU!(86._61'8Y.G()DV
M&R!7G-=[BBHZ;RW+J7BNN!J/BG&#.`95$-3JB4JU>PW_`*=5\V?3Z/KZ?/K@
M21I:<'0>"!'%YMUQ]MQ&@0A=>31UQ%TU0S3[B\5\\#F+?A\"VGP^.%4ML</@
MZ6$M@0`(\F4KBJRQVQ30@`D)UU%1$5=GCUP.AB\9XY$/N1:J(P:.(^AML-BJ
M.BWVA<14'[D;].OCITP-4CA_$Y+$>._307(\4C.,R4=I0;)Q-#41V[4W?S?7
M`LVXL9N,,5MD`C`';%@11&T!$TVH*=-NG33`@Q.,\=AQ)$*+6168DK=[F.#(
M(VXAJJDACIH2=5Z+@;$HJ1!=!*^,@O\`:[P]EO0^QIV=R:=>WHFS7[?+`Q#C
MM`$]^P"MBC/DBH2)2,MHZX))H2&>FXM4\=?'`DM0(+4)(+4=IN$(=H8H@(M(
MWIIL0$3;MT\M,"$UQ7C#*(C-1";1!)M$".T*;#%1(>@^!"NBI],#9)X[026Y
M+<BMBNA,92-+0F6U[K")HC3G3U`B>`KTP(SW#.)/PX$)ZGAN0ZLM]?'-AL@8
M+335L531/'K]<#=)XQQN58K92:N(_8$`-E*=9;-Q1:+>VFXD5?275/I@:TXA
MQ9'A>&IBB\,Q;,7!:!"2:2*BR-437N*A+J7C@6!5\$BD$4=LBEB@2E4!7NBB
M**"YJGJ31531<"-1\>HJ&$D&E@,5T-%4D8C-BV&J^>@HF`?X[1/R#DO063>=
M-MUTU!/6XRNK1GY$0+X*N!J=XKQQZSDVCM<P=C-CK#ERB!%-V.J:=HU\P_3`
MQ:X?Q=H8P-U<<0AQ#KXP=M-H1'$1#CHGAVR1$U'PP-0\'X<-&E"--#2F$MXP
M$9#M(2=$)!T^[]?'`FQ*"DAS&YD6"PQ+9BC`:?;`1,8K9;P814\`$NJ#@3\!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,#E.7?*'#.)R1B6\MSWBM+).+%CORW0835.\X+`.*VWJ.FXM$P)4#Y`X
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MNT^NF!SE/SVLL^767%1ASHEG6-)(<*4PK3+K*N*T+K!JJ[P(D71=/+`Z'W$?
M<8]T-S::FFY-11/'7Z8!9,=$`E=!$<Z-KN30OX?7`]%]@B(1<$B#[T1451_C
M],`+[![-C@EOUV:$B[M/'3ZZ8'H.M&1"!B1`NAHBHJHOZZ>&!E@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?G[G;'+;;E-U*I^.<CJN3DI5
M=980_;'3SXC)KV3L1DJ0(WN)Q51!^Q4\==,#9RS@-6'R4[/N^`2>317Z:##A
MK7--%$*8RIHZ;G<=92-H"-MBGAMP.-YSQSG-]R+\Q(X?:1+*NG1FH,6%`BNQ
MVJZ,\"MDDWO&ZX[VA\&D$47I]<#M>3\)IE^5K^SM_CN;R5NT9@K4OQP9..KC
M8'WW'G77FD9-240T7R%%\\#AYWQ_\KW/(Y*6\"87(EG]QBY:KV";C-`\*LE$
ML2F-"VVVVB*@(S]4T5=<#]8:&C>B%J:)HA*GBNGBJ)@?F]K@W);1I6IW%[-O
MY-&P"5-YT\Z/M6&VY*&IP7`=U)OVX[&XXM_S:%YK@6?#N+\=O/EB\NKOXZLX
MOY64Q)J9MA$$6(YQFE-UYTNXNQQ][^70DZ#^N!]YF2%C0WY*-./JRV;B,,IN
M</8*KL`55-2+31$U\<#\]5\7Y!Y%\<S.'1N)3ZV\M;"1:VEG;(,:""G.6:`M
M$I.ND1;0;1$#TKUUT3`H>$<.^0(_*JJ_L:NU;LJMXIEY8)6,M2Y*"V:O,>Z*
M:X4M'B]"(+7FBIMT3`[NCY/S->5<XOXG#;H+.SALCQYJPC@Q'08$8E!IXD=7
M0G)#AJFGBFG5,#@>)\!OSY=*DR.-VH1;FFM&+-R36QX3"RWV=PMHC3KKBMJ0
M:`KI*N[33ZX"IX!\K#'BO6/'6Y4;C=<%OQRC[:HRS/>%&1AHAF*FK?62\.[4
MG$1-4P)?QU06_%^96-O(XE?3*B=4/L2V%JXT8WY#[[:F"--/%J&U"T[IJ6G^
M\,.+?&MP/QC/?I^+VE/\C5NYZ-834[2`$AX^\S5`KRB.D8BT3:/J5.NNBH'1
M?!W!N30.<K<N0)=16A#>8F([7-5B2W3(%!'@]W+<=(>IHYM3S37JN!^@L!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?(/EWG_`"NCY&W6Q[+^
MV*+V/N0Y"5:Y9-.S%<4/:NFFK<8`'0R,D\\"M?\`^HR#QZOCU]@<3D-U6QFB
MY',C3H,-KODWW'!B-O&V<E13R;'37IX]$#H[+YK>>9F2^'\8F\JK:Q@'[*?'
M=9CMMJXR,A&6Q<57'G1:,2,0'4=43QZ8'DOYDNV^1-<?A\*L)]E)K(]I&:9?
MCCM%]$U"3W%#VVP]P:GXJG1,"EL_^J'B\*1M2"CD>(0-W)%/@MOQW?3WFVHI
M.=Z3V5)4(FTT547:JX%@?R;\@R/DVVIZ7BQVM#518B&@RHC!$<PB<;E[W2UV
M$T"HC:=>FJZ=,#9:_/U/!^18W#`@C*]Q+8@K.9FQC477R0.K`$1^@E]2*J$G
MTP),KY?OTY9=\8K.$S[6?3$TINQI,5&"9=%3$S<,A%HR!$4&E]2_I@0VOG6:
M[3!*#BDE;AZ]/CL>B24RL@I#(*;QDNFT1;T]7BB)ZM=O7`^J.OM,QS??)&6F
MP5QTS5$$!%-255\-$3`^<1OFE795;,<XU/C\/MY;<"MY*Z30BZ[()0CN>TU]
MP++QZ;'%3P5%TTP.;_N;Y9YA\@V%;7QIU!0T<YNOD2(;]::(:"CKCTA)`.N.
M"39@H`UX)T7KX!]O\$ZKX>*X'P?C7R)\B7/,H$*7<M5-D<R0L_A$JM*,Y[*,
MCA(D2:_TDNF(`J[51$0MW1$P.@^,OD[GE^$RQO.-K#X\Y,G*S;E+B`W$CQ")
MI&76]R&9"XT2$YX==?MP,N"?/<3F%]94L"F+W<*&_-BHS-BR$D=@Q!&]S9;`
M(U--J[E']<"OX/\`-7)#XF_RSFM(M;Q@EE2V;Q)$90%GO*$:*,8%[QN*NC:$
MJ>HNOA@7'`?G:FY;RC^WO9A#DOL.2:]QJ=#GHZ#2IO%U(CCO8<020MI^/7KT
MP/IV`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!0\CYYPOC+S+'(+J'
M5O2!4V&Y3PM$8BNBJ*$J:IK@;97,>,1J6->'8LG43#;;BS655]MPGBV-H"M(
M>NI=/T\\"YP/E/+/C7CT:;.DV_+[N%5\LGBQ,IVG@]M)?EHC0L)M8-T`-L$!
M=#3TIU7`D3O^G_B;UG+DPI\^J@3S[DNJAK&1A7%!`(@-QEQYK<@IKL-/TTP-
M/(/C;BU;<*J<IN:*-RF6#+U/!?1&)4HFT;7U(RXZVKC;:"1(8^'BF!90/B%8
M?,"Y0/++MR2YVP=BFY&5DXS#A.M1B_8WJT*N$GW;M%\<"$O_`$_\62SD/L65
MC&K9,DI;E.R4=&$<</N&@NJR4D1(_5M1W]/#`MK+XIC2^2S[R+R&YJDM5:.R
M@0)`-,O&PVC0%N5LG0]`HF@&B?[5P*"-_P!/%1%6O;C<GO&X53.2QKH/=C$T
MV^AJ>Y=8^YQ=2^XU4OUP*VVK^-_$ME+Y5:<QN[.RL=9#E(X<=P[!QEKLAJVU
M'`M`':B%N$==-5P)7Q%Q5ZQYER+Y'MZ9^I?M716AA27&G1:CO,-=V2WVR,1<
MD=L=Z]%T33KJN!W'(^>_'$"0_0\@OJV-(>:()-?*D-`:M."J*)@2ZHA#]<"B
MJ_A:GB,Q6OSUM.@5J(7'X<F0VY'@.""@R\R"-IW"90OV^]O1/I@3.#?%Q<2L
MY4UKD]O:-S7'I$J'...;+DA_;O>7MLMEO]"(GJT_3`Z?DM$Q?\?L*20^]&8L
M6#C//QB0'1!Q-I;"5"1%TZ>&!S'&_BB'4V\.UGWMKR"35M.,U(V;S1A%%X$;
M<)M&FVM3)M-NXM5T_C@5"_`5,=))H'N2WQT#HN!'JO=MBPR+AJ>B;6D)U$(N
MG=4OUUP)W'OAR)4<C_//\BMK64L$ZPVICD?M>V-==@(RRTK>W1%38J=4P*JM
M^%^)V5!(I%Y1;75%%WP(T$I;2L0W8YHB(*,MAN=CF`[>[NT5.J>.!9?'7"^+
M5/(;-Z#>3;JXK$]C,24+38,=U!=VH+#$9LR]/W>K3PP/HN`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&!\6YASCBD/YL;2\8DOQJ6F./&;;@2)@N3IS
MS;BMMH#1IO1EL-"1=/5IKXX'#?F*KCA<6B3I5I36<.]?L;:H@C.&-#KI;SLX
M&'6X[9L.GZF6S%-=NJCTT7`Z;Y%KN2?\QVW*!RVE,<XICBU9#*E-PX$PE`'9
M1MHHHTC<0NX(^.]%TT5<"%>6_$.)\TXC5L<@OY'X"2Z'(Y#AVDALA!EQP>X*
M`XT\KL@Q0MNNU$TZ8%7\Q\DNKOFDB-26EJOLB""UQIAJT@O.N:*IO0Y,038/
MN;TT60FB;?\`+XATE_S;BT/Y;XR;=O<HU5A(AWK>E@Y%[K+2,QVB:!I6'5-U
MPR-P=>HZZX%;RBSN[6SY(U/E\CC<_BR7V^'4-6,EJ"#32I[20I@/MGVW2T-X
MWB\$441-.H44^UDRZOD/+!Y#>M7)7L2'1-1RGC"`D%A7Y'M2':;1;7BV]1V[
M4VHJZ8'ZHP/S9)LN472RGDG<AC_+3<Y4B4K(26:F"R$E!#N)L2([&[";B<,E
M(]W1/!,#?QY>`<M^:KN85K>"4M8K5(@'916G5:$WY8H:"`C'WH.T#44U1=/%
M,#]#3BEC"D%#`7)8MFL=LUT$G$%=B$ODBEXX'P7B5KPF=P>/Q2?Q>;;\UDJC
MEY7RZ]YMPK/>KQR)<Q0`$:[PIZ^XJ[-$T\L"MI[JSD.4]Y&M>1O<UC2FI7-&
M)+$MJLA0A0CG,%%(.QM`$4&4:W.$2(J>>!'XC845H?,[*7R7D8QZN1/M:>J-
MZ?&C)"C`FQ]R0ZWJO>\$;(O3KT'7K@5?')_+PH./S.&3N2WOR!#:61R"%9K+
M"O;C"P9K',7T1HE4]B,[%4S\>FO0.BH[L&)]-?UUWR6>['4S^0)=BS-"&U')
M@NXTD4FT$'T?4!:&,*J*(NJZ=<"NX%:LCQBXY,EKRBXN>//R9\#C2NSVV0C%
M(5I@'''&R*0CC>TSW*1".N@IHNH;/B*TMW_D"RA2+FQLZ^SI9;B]K\N">Y)P
M5V,.6*_U6P0T%P4#K@;_`(?F?'_&N.,2K"PY&W<-1G_SJ*W;>TC/R37<A-]M
M6N_J>B$**JFBE@;^(\VLH_QSRV-Q63;3KANR=?C++;F2Y46H<?;CC(8]T`]U
MP6!5U&MWW+U3RP*3E5RM?36<GA]SR691V-<Y#EV5C^0+N6Q/`L8HN\`?`P!'
M7'E;%`VZ#U7TX%Q*O1XC<<IK*OD7("A)40XYSY;,NS<:LY3I(LL$,1VBRR0]
MP0TZKT%233`O/^G%J[=LN02YTN=8Q`!EJ)9./6*PGU(W"/ML68H\#H(@[U%5
M'KIXX'W+`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'"<_Y5S6!R?CO'>)MUCD
MVZ;FO/':)(V-MPQ;+<*L?57=-/X?K@4M-\Y,-P9,.^K7Y'*JV9)A6-70M'.1
M$BF@+)%/2H,FJ^GN+NUU3KHN!*YS\@VKG":7E7"+")[:REQ(S;4R.XXKZS'P
M81K5##LFV1%OW"OAI@6OR%SB113*:HAA(8FW,R/&9L5@N3(8=QU!5IPP<:0#
M--=.JZ)JNF!KN/F'CE1R&XHI<"S]S20'+6:^,;]A8C0;U<;<4QWZKZ$Z?=JG
ME@5Y?/G$D@#+"LN751M'YD9J`9O1&"12!V4(DJ-B8)O%-=RCUTT5,"5=?-W#
MJJVA5AL6,QZTB#.IW(,-R2W-`T14",H:J9Z$FO1$3S5,#5.^=N'1&1?6):O-
M-M@[:&S!<-*Y#%#VSO\`RC$%W$'4D3JJ>&!&Y]\W4--46A4Y29;\-DD*YCP7
MIM9%D$"&T$EYM0'4MX]!)=-4UP.XXA-M9W%:>;;(VEI*A1WIJ,HJ-H\XV)&@
M(OEN7I@<K><CYO$^5N/4#;U>/'K893ZM`VZ4U6HC(DX1N$O:']YP!%!3545?
M#3`J/D?FWR;Q^P]Q7A5-QCF,PJ*A>1U^?;DYM[A`;1"D=`W+X@6B#J2HFF!]
M!>Y+$9Y-%X\4>44N7&<EC)!DRBB#9(*B;Z>D355Z)_\`TP/E-E\H\W7Y*D4_
M=6CXT-JQ4P9\FGD2&)#I".\?=]UD`)QS<`>A4\%UTP.LA<CYN7S`[QJ<]7_@
MPK7;)EF*V[[A&U?%AA7W'%45(E4]1!.FU.O7`^@+X8'YGY'\C<OY?QQJNNI%
M.-3;SI-?(@4LJ2U9HQ&)X')+J?O?Z1.UW'?3U;^FN!NXM_U!VS'Q[QNHK(83
M>:29C=:XS+-^0TQ'<<`694DP_<T<%]M!Z]>OTTP/T6]*")!.5-,6PCM*[)--
M=HH`[C5//1-,#Y70?(_/I]UQ6QDQX(\:YFY("LK`%Q9T>,VP<AB6Z[NV%O`$
M4Q0$0=R==<"\^.^1<VM.5<KK>1O0'&J1R+'8&M!T&Q=>9[[@D3RJ9J($WUZ)
MJJII@:N1<VDKR69[.447C'"V'+#E<YL4-7GD9(VZ\-47[6U[KNG5/0GFN!54
M?-OE-^^J8=E'JV_[JJYEA5P6A>4ZTXX-DPDQW<O=!SO")J(CH70?U#?Q*Y^4
MS^1RX[<VU98P*V`,N\.%"<8[+\G48T87#>/4B02<^U/2B=/5@6#W)^4W?)[5
M[BP))I^+-/QBCJ8-!:7!!I[;O$A;&HO3>2?^(NG\N!S3/RQS&@L.2AR-RMO(
M='7-R9#M2V\R,>SD.BU'JU-PG1<)Q3^[Q%.I(F!<T/)OE;^Y+/C-J-0_;E3A
M;P'F`?"+%>=>5E(DE=QF8^E5$QT541>F!*^/N?3W_CJ;R[F$R,C,:3-3W,5L
MFF5CQ'R8!0;-5/<X3:[1555=43`^>?\`.GY@_(_D/PC/XK\Y^,_!]@_>=GV7
MO.WWNYL]UL]/;V_U/3@?H?`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`^><H^/N<V'
M/`Y51\J8J4:@%6LQ7:Y)>QIUP'72W$\V*F1M"J+MZ>'7`Y"U_P"E^O?M/R$6
MV9DO2@3\JY=01LC<D*9..OLKW6$95TG"4@1%'7PP)MK\3<AAQ*"IK^8UM34<
M=>9G545ZL:WK+9`Q)XU&0R);C>,MH@B>'CYA,Y7Q3F%]9U4Y.>U,9FG?:EP&
MEKP<TEA&5AQPB]V.Y"5TR0?!-4\=,"=R_P".:3DG)*"\L[YML(T1(MS#!0!J
MT8!T7V@+U^EL9(;E'U(J:C]<#EN7_P#3]Q^PY;;6?YJLBMW#ON93%A!9ERF7
M#!!/V[SCS:`"Z(0B39:+@6D'X[O*OF<&^A<VK(T*'";JH5?^.914JP>1Q&A-
M'Q'>NW3N"'_Z<"ONO^F.NG\BM)[-A#&#;2G9KXRJQN7-:<?7<X+4DW1'9OU4
M4)HM-=.N!JOOA^9"II?!J_GL2FXU<R3=A43T)DY*J\ZCI1P-'FC-I2UZ""+I
MTUTP/L:6]9`*%6V%C&&T?$6VF5,&G'W$1$)6F5)2T\]$UT3`XEOXZYZOR0QS
M&1RN*XRPT[""O2L05]@Z^+ZL]WW'W^@4[FW_``P*.CX5<\9^00N.0_(%7,M;
M5Q$5B9#::G.Q]RH,6&;DDNTWN+P;;Z_QP/HD^6[36TRWN^11H7'GF6F(<*2+
M,<69"*2FZLEPDWJYJB(&G33`YJ-\<\ML[&M?Y9RT;VIJI06$"$S`:B=V0UK[
M=R2Z#A]SMZ[D0!%%+K@1^)\)Y?6_(,WD5GS&#9NS8[4>SKF:\8YDU&0^SM))
M#BM[2>527:NN!W-TZ_+H):U-HQ`D.-J$:T,0D,LFJZ(:@I`):+Y;L#YOQ_X1
MF5/QW:<;AVE:W;6<=88<DBU8,/\`M'!1'$=5M[>\9HI*AJYY^'3`B,?$L"/R
MRA!GD-2Q<P7(5E<PFX@!,GO0&R8:>0$D[F6^R7VB"IN]2ZK@?494VAN1L./A
M/9=E.1S:F1V'0-YIMT=BD0HI*'W=-R8'SZ'P>5Q9NMD7O+6Y5W'93CW"9+L%
M`:BG)%`%5C@9=]XQ:1#-2%-H^75<"+0<>YOQAOEL.KY;4WO)K9T[#\>3#<,H
MLN5VVCENHCT@^TVT&]&U#U:>/7`MJ>M^-7>"/_'=;RB%)?LXS\63):F1WIK\
MF4)=^0HH9*;IF2G_`+O#`D\<X^UQKD,&=R_D`7/+;5G\/3.C&]J"1F!60;3+
M`$[H1;%-UPBZZ"G31,"!'IYC/&[RHX=?0K/F-S8$[R"W%YM'(GN2V..HR!.D
M/MV11MEM5\D_7`F67%HDK@9<'X%REFA=JT!B9+CJ$N0TVB*KHNH+@&VXZ2[B
M-51?'ZX%5QOX[*9\=V7$8O*:^4TP\Q["73PFFFX<F(X+Z=X4>?[SBN-BKF\]
MVGCU77`L(7$+D%N4K^7PWOD*<4?\W9'$;>1N(T!"Q'"`+R*P&A;D537<6J]=
M>@:*CX3%?C5K@W*;!F^B5Y(=.X+#L,62;`A:5T69&Y[:1J7WIK_OP.9__&#_
M`/T#^VOSZ?D_S/YG\OV']-=FSM]KW6NO_'OUT_7K@?=\!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,#\Z_/1Q.0_)U%1U#5)97U;!DB["M7&BW.3C9;9:%DR$3>;
M%5?`"7P_BFH:_DGAOPKQXZ'BVZI8F2N0L3+493C`'%AN#[B0&U5$F8[HL"V(
MZZ>I/'7J$KDK?P.S\L4<20M!%K..5DIZ4"G'!OODZ`QHY"OH(@U<<0/%%77S
MP.)Y)S+@W,OD=SE:#0IQ]V)6L62W!1SG@V/<D2'(\8RVD\C:#'+;N5%4=J*N
MN@7=8'P"G(+=FU6!)IJ&CKZ^EASE!R8\X\CTIWM`*[S>W/"!(([A+HFF!]S^
M)Z^YKOC;CD*Z%QNS8@M#(:=)2<!=-1`U7KN`=!7^&!P/,[CXXE?./#F?=U06
MT1V4Y9RU<922C\=KL1(CAHJ&)JY(4A`EZ[?#`]Y'<_'$OY\XL#4NJ"UAC-.R
MEHXS[@YC8#$BPS-%0T<%7C5`+QT\.F!]$G2?<<]K8,;D@Q784-Z7.XT+;9G*
M9=)&FWS,O6`MN)TV^*X'Q[Y8<X/S6RK@XS<U%I,M)T2)9TT1B.[:2FPD`+IC
M-];\4666]==J)M1>O7`I+.WL+/Y5L9]C*JK&8WR!GCU=PN='"9*_'(X(//@!
MKHP"A^_W!!=W\RZ=,#]+V%A75-:_/G/MPZ^&VKC[[BH#;;8)JJJJ]$1$P/RE
M6W\)GY)KODW\($&OY#-L$@OLOQW?=5_M'0T*`R1/K()\=[SA=!4MJX'/U]7=
MIPZFXK+LH47B%]9U=C"%M]M2FO3B9"2P+9$/^GA."YW0\G-J=?'`_9XLM0:]
M&8;0MLQ6=D=@$T$1;'0`%$\D1--,#\Y\*_M6Y'A$Z,]&E<H9G2.4<YY`TJ(]
M#$&GE<9ENDB$T!FX+2-$J>D%TZ)K@=9\3VOQVY\D\]G44NJ8C@,5J*U"-D=\
M=EI9$J7^VNA@3TC0C\E'37`GPYEAR5FY^4!;)(E77S&^!PW!U7:+1*[8$VFN
MIRC!!;3_`,I$_P`V!ROQU1\0N+[@W]N)'LW*NNE6',+Z/M-7I5C'1I8TMW3<
M9NNNN&K9]104Z)@=#QBFX2G.+CE\2O@U'%.#,/5D"2PRTR!RA'?82E,!12%D
M$1@577KOP-C%A3.4ES\I<]<<JZVSAE!IHIJ0/PZE_H.U&]3&3,)4<+8NJ)L3
MIM7`^?QUHG^+\AYYQ)*JB*EHCKJ>KK#:D3(S,HQ$YEFY&W?N[`4FP]6WJJJI
M:X'3\<@_%<;E;MC5E6Q^!4U`E-:7*FT,*=*G/"O8>>70'S!L-3)25=SFB]<#
M#XRY.W6_#]Y;\#K8]K<RK.;(;HJ\FA2'WGB:C=\$5!$&V&0+HB;D_P`5P/?^
METZ^PE<TO(H2G'9<R,S)GS28-V0^TRI2'%)DC%%-YPBVBNU!4=JKUP/O.`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&!QW._D)>-3ZFG@5I6]]=]\H$)9#4-I6XH
MB3QN2'O2.B&FB(BJN!R[?S)S=^555\?@+B6MFS-D)#D634=6P@2$8=52<91%
M1=PD*^:+TU3K@:>+?)\'D_*JM0X8Q'*=`D6AW4E^-W6U@.E%?$/VU(]CX"`G
MO'450O#I@=%\?V<+G],O)+?B,:O20:C!=D*Q,<D,M^E'D/MBJ"JCZ=?%.J=%
M3`@?)4L>/SZGV/#JNQ8N)T>$]8R58`Q?E/(V@@SVU-T]JJYKN1-$7`T?+W).
M%<`H4E,\9@6=T\)N0JT8[0ZM,(A/ON$C9;&VA5-5\U5$3QP-7).6N5U@Z/'N
M(5UG?U%<%UR*41MQVXJ&!&C+;R-&X;[B`:AJ@^GJJ]<#9;_,]H[`.9Q2A2T:
MKJAB^O3E24C#&CR&5D!%'0'%.230J>W1!1--5ZX'ECR?=RWB/LN(5YPN5DU(
M:N9!,^\128*6X2,(&_<R`>HU/Q5-,!\I\VX]P^TKHU7QV';<JL9+#A;F@;]N
MU(D"P,I]X6S)%-XT$/-5U7R7`KN7_-!U?R;)XQ4Q:8)L=N)'=L;60]')QV5J
M8L"XRP^B""$/1PAZETP)7)?DK^W[&\MJ'BL694<=>:C<HN@,([YO/*"NM11%
MLE?)GN"KF\AZ]$ZX&_F7R!><<NW;=OAT<JQJ:Q4_D'WP8LYSD@A!/8M=LE=;
M%2\"--VBZ)TP/J,F-&E,''DM`^PXFCC+@H8$GT42U1<"M:@<4$V&FHT!#C[V
MXS8@SJWW-=X@B)Z=VJ[D3QP-W]N\?_8_^F1/]+_Z7]AO]KU;OV_3Z?5UZ>>!
M\NH/G*=?_(LCC%>U4M0X]B_!$Y,J0$M]N*NCKK`"P3!JNTM@]W7IUP-\GY&=
MK/D5OBA450D>WEE'FQHDH';-&B;-SWLR,#2-BRH)N+>YJ@E]>F!6-\DIKR1`
MB.\+BQ^!<QDO4L&T8<%B9(V(;B.FRR`$,9_VY:?N:J/54T73`N^/_+K/(.1I
M2<,C5SU-6&K,LWYB-2BC,%VW'(4%H'#)MO:HBIJ.[IHFG7`@<'^7DL+ZOBPJ
M2NA<=N1E216')`IL08S>\I%E&;;0&$/;MZGKJHHO7`IN(?)U=\F1Y-39552/
M&66W;*14LR)7Y`FHKJNM_P"E%AMIW>X(J8@X0KKUUUP.@X=\IR.:7T"IG4=?
M)H[F(Y/C>WE!/>B-M;":2R9[?;8-S?H*(2Z$BIY+@=_91JOCW'[6=65$=59C
M.ON0F`;CI(5ELB1LB0=OJZIJJ+IK@?+N/?*=K?1*VNA?'41ZJLP!YJ,S817V
MV>\P4MA93#;"I'[J!T5Q$]6!.XI\A7\FFOIU?\<QX$"L*4Q([-A$`'Y,(T;>
M:5$:#TBF_P!:ZITT3`E1/D>73?$LKGB<+:JH^UF7'J&)+(D]&?[:"^9`R`@6
MCGVJ*KTP+/@_R7R'D7)'J>?QD:YAEAUURRC6#-@P+S+HM+',F0$1<U)5V[M>
MGA@?0<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?$/F<K4;N7_<8<7<X<K#"5*<E
M,VR&3H??*,K`N/DYX;QZ)ILT7QP/D,]./HS4!SM994_]J:<=D-I-&XZ/N;S[
M(J3&]7/Y'7>VC.WU+@=?S`9RT'QREB:`:5$W^X%X^`&)<;0&.^I(A`HZAMW(
MVJBB[]FJHFH?I6K_`!_XR)^-[?X[LM^R[.G;[&Q.WLTZ;=FFF!\E^7G/D!.;
M<-2,Q4%3C<A^*64])%3E>R=VI+06B;#U[NTH*1;MOZX'R[_J%)S^_9Z5P<A6
M8J0%Y&0FB0DKT=9[(PD05)6UD>*JJ(CODN!VW-!M_P`Q\F#$<!..%'K5Y:X`
M(MPW'2"/<&(&]&G$./KJ3I!M53VB2HFH1N1B]O\`D08#C2<%(JPN1N1P5;8(
MB5\;5N*"FC9M%&VZFX0D**>T"5$U"]OW.=?\Z>&;6*C\4C-BE)N>E>J-HQW"
M/<UM&4C&O;$=45-VJHF!\TY@I?\`/",E8')%A_W)`7D9R23M^[5T_9(P(CIV
M4;U5E2+J.J:)XX'TGY)3F15$H.6E4-\/&UAE;/TXNN6;C*36_;`XT\K;;>J]
MON&+AD@_:*X%,Z,O2X2P<9_L%.;NG/.*"_D"F+-#8U*%"V#%23LW."1.J"#Z
M$U70-O$CYY_S@`?D1FJ_+*XJTKLIV3VDC["W)2M]OVRN^'=4S1[3Q33`_0&!
M\EJ__P`:?[N8_&_@_P"Z/>_Z?M;?<>\[G\O_`!]S_?@?59:2EBO)$(!E*!>W
M)Q%($<T7:I(BBJIKX]4P/BURG.3O>(KR1::.8S924`TR//QW+E8;VPIQ.*P;
M;0_N*HM(:J70E3QP,;9+D^=\>+G*U$>R%NP2"WQ]#??-Y:]SN%+.0K#@-(SK
MM%!)%/;J2)@5?#AF>TX'_<IZ0!I)H\.2E!5WG[#]QR4JE^W*]IN[;;>X-V[U
MZZ8'$\4!HN.\<2O>B-R!H[X>/'Q]KN61S%B)WW+('7&U;D(W]H`1(I^!HFW4
M.B^+T$K]@^.'QYKD*<9,8+-0+KD`D1YE7#NG=S;XODO00)M=/4NY5].!/Y\/
M*G)%@=TXQ&O5XK8)QEGC0%(CI'1QE9A*Z\4=U7%;V((B&B!JHJI],"S^$DHU
MY_).$5.#ZT$9`C\60CK$91\M#EO$HFLM5\!<;14#^95P._\`FQ;Y/BSDGX46
M5?6!(22KZN(J1NR7>5KMHJJ[L^Q%T37SP..^%G*[^P;0OC>/3_F?>A^091Z9
M^,[O:;ZMN&UW_P"AMU]&G<W8'+TSGR'_`/CC>C"CU.SMVR63KKTCW:!OD>^5
MP":VK(WZ[4(_MTU77`J_D=SY26BK%MF*D/CU*^L[@,O32KE9]\QV^\1-"^AJ
M&S?Z5T:W::E@?1?^G8K,J:048(37#=FE"U6DZZPCWNI/O%5R2+<C<I[=$(-N
*S;M5>N!]?P/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img003_v1.jpg
<TEXT>
begin 644 img003_v1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@#Q`*\`P$1``(1`0,1`?_$`+X``0`"`P$!`0``````
M```````$!0$#!@('"`$!`0$!`0$```````````````$"`P0%$``!!`$#`P,"
M!`($!PH'#`L"`0,$!0`1$@8A$P<Q(A1!46$R(Q5Q%H%",Q>14M+3))34H;'!
MT6)#)5655G)3D\,TQ(7P@I)C<X-$5'2$-28V1@AD165UX<*SY!$!`0$``0,#
M`@0%`@<!`````!$!`B$2`S%!!%%A@2(R$W&1H;$4T?'P4F(C,T,D!?_:``P#
M`0`"$0,1`#\`_5.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!4'S#B@2CB'<
MP@E-GVW&"D-"8G_BD*EJA?@N!;HJ+Z8'AUYMELG'"00!%(R5=$013555?PP-
M5?8P;*$Q.@/A*AR01V/(:)"`P)-1(23HJ+@2,`JZ8$6#:5T_NK"DM21CN$P^
M31B:`Z'YVRVJNA#]4^F!*P&`P(\VP@P6Q=FR&XS1F#0..F("KCA((`BDJ>XB
M71$^N!(1=<#0Y/A-S&83C[82Y`D;$<C%'#$--Y""KN5!U373`WX$.QN*FL%L
M[&8Q#!TD!HGW`:0B541!135-5ZX&R1808Q-!(D-,F^NUD7#$%,OL*$J;E_A@
M>G9D5EUIEUT`=?549;(A$C5.JH**NI:?A@>N^SW>UO'NZ;NWJF[;Z:Z>NF!D
M7FB<)L3%7`1%,$5-R(OIJGKUP/>`P-3DIALQ!PQ`S71L2)$4E^PZKUP,E(9%
MP6R,1</78"JB$6GKHB]5TP/7=#=MU]WKI]=/X8'D'VC,@$D(P70Q14547\43
MTP-F!A3%%TUZ_;`\]YM5T0D4O\5%15_P8&4<`E5$)%5/5$77`]8&%)$]<#6D
MIA6D>1P>RJ;D=W)LT^^[TTP-FY-$5.J+Z:8&!=$D1175%]%1=4P,[D]?I]\`
MA:X&<!@,!@$77`8&$)%UT^G1<!N3`:X&=<!@-<!K@,!@,!KUP&`UP&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P"^F!\KHV^*G=^3TY`,-
M:I;)GYJRNWV]G[<QNW;OMB(Y;AW,N55'%X$*98+$83BEG95ZRQ'NHL65M@&1
M.^XE^,0:B7X8'2\?Y'S*\MY2%=-,0(%'663D08S)JZ]-B.DYN-5U$-X(?3^'
MIE-<VG/N<%QU)4*V8@C`X=$Y"K+<5C8<I3-##[`T:-Z;1]/IIB#H[GEO.97(
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M]S;Q_P`BGSF9/[M76TAF&RV`?%$A9_20T7>>U/:6[^LG]&0=ERB\O7.6L\9J
MI[=2X55(M$F.M"]W#:=%H6D$_;L'=N<T]VFFFGKE/=R/'9LOF?->/6%H@#&G
M\6*3*J7&6W6%4Y;8N(/<12VN**$B^NB)C1TGE#C7';BKDQ'JZ//OK*,L&M)_
M:JQQ75?D"1?V0LJ7<(AT551$]=,8:X;F#0HQS]Q^0LJ92TU./'9Q*BN:H)&#
MS))K[G98]5'U7I@=WV4_OBK9#C0C+=XW(202(B$JC+8Z*OX*JZ9#W>^/,,->
M7>7&VV@$]751ND*:;BUDCJOXZ(F%:>?7-Y6<QXRL2<XW7K'M),VO;`2^0L2.
MCHCN7KUU5$^R]<)K7Q7F')9%OQL;!^/.K^5UCM@RD=KMK#=:%MS9NW%W&U![
M;J77<GXZ)3'ORGQ*BNZ]]DJX)O([)M(E5)-%4XBHN[Y('_S`L_VA$.FJH@]=
M43(KB^4]Q$YY9.&K]S0OT;7'YA+JZ`H#!MDT2>B2'G'-^W\VJHN7$=TRRV'F
MF0Z((#C_`!QM723ZD,TA37^"=,"%`J*ZB\N,@Q4!`9L*N3\:=%<U^4;;K3CZ
MS6U%%WAN3MFJEZEU^F!]&4PV*2JB"B:J2^FGWUR*^.5G(;!GR16\HDC+;I^5
M$]2[7FR".T#1*Y5N@2]-9&US7[[TRZB#8<4M;SE7.H=)%;9LDNJQZ/=JZC1P
MMD5EUTP044R4DW)M3H6[K@=KPAAEOR)Y!(`02657ZJB?XT$"+_"2ZKD56<A\
M@\SKK/DCL9F"Y3\8EP&Y#)B]\E^/-!M30#0]@N`KNJ=%U]-,J)#//+U[E@5)
MC$E5TTK5ALV6W.VT=>B*`J^I:.D2*J.B((@ET1=4PCD+/E$ZY\4V517Q8-?'
MB<1:LIL5&S5O_3&W4!F,.]-@MHR2[EW==$PNOIG*JJ;;^.G:R#.&NF2XC+3$
MIQ51M#79H!J*H6US\B[5UT7ID-?+[^7%7@7/:Z91.<<Y+'@1GI]:TYOAF(F0
M,RH+@:)M-4(2Z(J:>[*.V\?R*RYO["99LK$Y75`D`J1W_P"@PM55I6=%VO`^
MGN5[Z_EZ::8$CPJP#/"3$45/^E+0>JJ2Z#.=`4U)57H(HB?AD5JXGY!NK3ES
M%/,9CG$F1)<MB5$%U6@*))!A6A?-=DCVN(I&`HB%TZX&CEG.KV@YE=*9LO4=
M51,V`0=A"X;[TAQD5)W<J(FX!U]O0<J;J#R_G/.:SYE,2PH]LR[4/1YK`.DR
MY%L)R17&U`B4A<`Q5-=5U%=4T7(BV_G^Y#FD.CD1XKT";/?K"<C]XR:-J*L@
M2<>7]+>>TM64]PIIJN56[Q%+"-XHK)3Q$K49N69KJI%L:D/??JO0<:8@M>1.
M12(M>XY&C,,\FJ95A1/M$X9,N,,H^+<E%Z%JT:+N#3JBI@U.\5TH-<+@6Y(#
M-O;UT8YDQLG"1PD:U!UP7%5%<U-5(OK@<KXWAK$Y%.X]R!94/E.V0!SX[[I1
M;5I66$.0)DJZ/MIM-1T10W=.F746G&:F`_9\OXY)*QJH$:1%DK`<E.*)12;7
M5YJ2AFX+<@VR[@H:*FW\5R"(["LZ_P`.<Q,)<UN%I.D\=-UYU93,(016?U27
MN[2,2,$)==JHF-7'U*"XX57&)%U=5@%12UT4E!/7^G(:^*6=ER;B]=RQNR%V
M/RY^*R^S;,39$J$XQ+FA&-YAA]=(QL*YU%$]--%TRHFW=A8U7)Y7"X<R0%1,
MLJ)I7%>,G66IHO+*:%XE5Q.]\1/KT4UT]<*[3QK82W#Y+4O.F]'H[E^'!=<)
M7"2.33;XMJ9:D7:5Y035==-,"5S3E=U36%-7U%8U92[IU]AH7I"Q@`V6"?12
M5&W/:J`J+ID51IY9D)(>DG4/.<?BK.;EV3(O+V2KP)7#,B:!E6S<:)L=KF[7
M35.O2P4-CSCD5-R2UY'90!%MCC#$]JK:F.&V2%,T7=N!`!T`+15$51?OA'6S
MO([D6XL:E("'+8D5L2NU>VB^[9MFX.]=OZ:-]HMVF[5/3(M1YW)+5+?C`75,
MY#LWYM@PR#,U>QK'B.."[H`HCS;P![4<1%!>NF5$*G\PR94:/,L:0X<.;12+
MZ%V9"2'B"&H]YD@0`1"T<%075=?KIA5[Q#G4F^N958[`!E(\*)8)+8D(^T03
MD(FV_P`@*AH@+N^GHJ>N0<EY(Y9R7X_.:UM$C0Z2'6R84N*\82B<D.J2HNB#
M^;9M_-II]]<(OW/*!1Y%C7SJLXUM#L(]='C([W@=68RLAEQ3;`E%$;$E-$%=
M-/KA71<7Y#)O:8IKE>]72FW7F#B2$(-29)10P(A%2;<Z*);?3Z8'(<3\G7]S
M25>E0U)O[&-*G_#:D(VT,:,_V=5<,%]Q&J`*:=?551,H]5WE2?:6R%6592J<
MJ']Y;;1Q!F$\CYLDQL+0$(3:4/S::]=<)5=R3R+(N.(7OP2.OL:2?5-./PY*
M.MF,J0P7L>!`W(H&0&FG^'(5]$Y->.4U6LQN(4P^ZVUL$P:`$<)!5UUTUV@V
M'J1?[F%<=#\OK."L&NHI$V99.63`,MR&$;%ZK5$<3NFHHH'ZB6G]&5*0/-%:
M]&:G3:N57UDFJ?N(<MTFC5UN(H"^UVP)2$A)P4'=^;(J1/\`*O[6U.&WI),*
M=#:BRTB=UIQ78DM\8W=`Q7;JTX6A@O5/IKK@;[7RA%KK";`*LE2)$*UAU&UD
MFE[CE@TCK+@[B'V^[1=<%08OE*RG7-%7Q*-QLI\^?76S;[S2.17:\-QB*BNU
MS75"U1?R_C@=9R/DK=0[!ALQ7)]I9F;<""T0`I]H%<<(C<40$0%.JK^&!S\/
MRS42G(S0098N28T]X0-&P49-66V5"/4^CP>J?U53KK@K+/EOCKM%&NQ:>2!+
MAQIC3BJVGZDUY6&(R^[1'2-%U^B:+JN$I!\I5EDP#,"%*D6SDF1#_;6E:4T*
M((F\Z+JEV2;07`T-"ZJ2)ZX*D^*[BTM?'=/:6+KDN?(9<-XW$$725'31!+;M
M!"1$1/MA7+\1YM=2@CWD_P#<7Y]K(L8D/C3?Q59<&(^:(XV2DBM]AMO:9$?N
M)?KTPRZ"+Y:I)LJLB5]=93)-FT3R-M,)JP+,E(LA)&I)L)AU?>G^#7"XLN0<
MM?K.4<?H6J]V2EX4D2EMD""R,=O>JJ)$BKZI_1]\*Y;@?E1C]A@-\F.2,LXL
M^8=P^T#<9YN`^8O;5!4]S;>U?R(B_37".JXGS^DY-+FPH0N-2X`M./,N]LE5
MI]%5IP2:-T%0MJ]-=R?5$PKI<!@,!@,!@,!K@,"F/AG$')AS'*6"<MT^ZX^4
M=I3)S_'(E'52_%<"19\<X_:FPY9UL:<<9"2.4AD'5!'$VF@[T71"3UP$7CG'
MXA.E%K8S!/LC&>5MH!WL-IM!HM$Z@*=$'TP-"<.XFC)LI3PT9<CI#-M&&]JQ
MD7<C*IIIVT7KM],M'&77AP+2ZER77:XX,L@45=K@.?';;;%M&HTH7`0!$0]B
MJ"J/XXK,=_84U59P/V^RB-3H:[5)B0".@J@J**JA(NJHJ:Y&D4>)<8%04:J*
M*MR4G!HT":2D31'TT3^TT_K>N6D>Z[B_&ZVQEV=?5Q8EC.ZS);+(-NN]=?>8
MHBKUZY!0S_'L.SYX_P`BM6HTZ"=>S!9A.MJ1`;+Y/=Q55=JH2GIMT^B89B\?
MXGQF1=,WC]5%=N(XH#-@3(*^`IKH@N:;DTUZ?;%:>4XAQ<:UJL2KC)7,/I*9
MB(V/;!\3[B."/HA(?NU^^*/;/%^/,VSENS7,-V;RJ3DL01#4U':I_P#A*/12
M]=,"/7<&X?6V7[G`IHD:PWN.)*::$30GM.ZHJB=-^G73`DW7&J&[['[K!9F+
M&528)P=2#<FA;23KH2="3T7ZX&0XY1MVK5LW!9"R9C_#9E"*(81T77M#IZ!K
M],"#?^/^%\AF#-NZ:+82@;[(//AN)&]5+8B_;5<"3(XCQF0_!?>K(YNUH@$$
ME!/TA;5";$43IH"IJ*?1>J8$@J*I.Y"Z**VMJVRL8)BI^HC)+N)M%_Q57K@9
MCT51'MI-PS%;"SF-@U*EHGZCC;7Y!)?L.O3`Q94%-9R84J?#:DR*UU7X#K@Z
MDRXJ:*0+]-4P(]/Q+C=-(<D5=>S$==0A(FT7H)%O(0155`%37<HCHFN!$OO'
MG"^03OG7-0Q.EH"-(\\A*7;1=4'HJ=.N!)=X=QEZ;#F.5K*R(`MA$+140!9_
MLDVHNTNWK[-R+M^FF!(*@J5N2NOC#^Z$Q\0I6I;E8W;NWIKIMW=?3UP(4+A/
M':^+(CP80MI(9<CD3ANO*C;JJIMHKAD0@JKJHBJ)@;JSC%=!XPQQM!)VM9C?
M#4",M2:V[5121=W5.GK@>;#AO&[&FBTTR"+U9!)DXD92-$;*-IV5$D)"U#3I
MUP-U;QNGK9T^?"C(S,M#!RP?W&2O&V.P2+<JIJ@].F!FOXY45]G86<..C4ZU
M(#L'D(U5TFQV@I(2J/M'HFB8'.0?'K+G+^07=NVW(8L),*3`:%QW1%AL(VBO
M->ULE%Q-PZHN6LQ.9\:\,9L1LFJY`F`_(DMN(ZZB`[,%1D*`[]H]S55)$337
MKZXIVH\KQ-P*7#BPWZM%C1(BUS0"\^&L0EU[#B@8JX"+U1#5=%],':OY_'ZF
M?3+2RXZ.UB@#2QU(D]K6BA[D5"]JBBHNNN1I52O'7%)<"Q@RXKDEFV`&K$WG
MWS==;:55;;5U3WH`ZKH*+IEJ=K=+X+QN7<U]T]&/]VJV?CPI@/O`X+2KJH$H
MFF]%^N_7)4[4OCO&:CCM>5?4M$Q$)UR0K9...?J/&IN%JXI+[C)57#2LI?&G
M#Z2SCV=;#-F7$!YJ,2R'S%MJ26]QL0(U!`4NJ#IHB^F!*MN$<;MK0[.PB)(D
MNPSKG]QN(VY%<555MQM"0#T4ETU3IKTQ4B&?C7BSM9*KGV7Y#4M&$>?>DO'(
MVQ"WQT%]2[@HT74=%]>N*=KPUXNX@S:-V;<=X9;,PK%E?DR-@2C;[;C@@I[=
M7!_/T]WURU.U=T''JRAIVJBN;((+._MM.&3BIW"4R3<>JKJ1+D:S%3`\=<:@
M-$S&:=1CL/Q8S1/.$,9B2NKK<9%7])"_#T]$Z83<6M7Q^OK*-BCC`7[;&82*
MTVX9&2,H.U!4U7<OMZ>N$BC@^,:*&L@QD3G7G6CCQGW)3A.Q&G6P;,8Q]"!5
M%H?=U+IZY:1NE^/*67628#[\TEFJRLR:,IP);J1_[,3>!1+:/^*G3_#BD`\>
MTJ<>LZ%Q^=)AVXD$YV3+>>D$!"@;1=<4B$=J::)BK$F9Q59%A6/A-DLQZZ._
M&-AM]P4>!YM&T[@IT4@TW"?YD7TQ3,:XW`J,*R373._9MS(_PY+]@\<A\X_7
M1ON%HJ(BKKT^O7%5J'QSQ_\`;Y41WOONS'V)+\]YY2E]Z)M2,8NZ>U6=B;=$
M_P!]<5-&^"L0UJQK)<F*$.<Y8SG$>-3F./(7=^1]'>XI?UO33IBD6=KQN%9V
MM39ON/!)IGG'X?:/:"DZVK1]P=%W(H$J9%4@>+.,A9V,Q"EE&M"><F4ZR7/V
M\GI(J#SJ1ORH9H2Z_37KIKA(B,>'N."Q*CR9=C.:DUI4RI*E*[MAJ>\0#VIH
MK:_E)=5^^N$C)^'^.O1YX2IEE)DV/PR=G.RE^0V]7Z_&?9,1%&W`U]433\,M
M(GM^.:P5JG#G3WY-2^_*:E//HXZZ])9)APWB(%W?IFJ"@HB)]L4BJF^,6JZC
MCC1.R9%C3U$JHJ6GI`M(;4K:I=QT6]4<_3':7TTQ5FO/C7CO)*J4?R$GQ:I&
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MP3;,=?42'3#2AI_%3%7:1[`+F;).-(L9382$8)%.U1.]N(6Q5="'</\`Q8J;
MC0WX:I_VVLK)4^3)@UU7,I^T2-"3K,Y14S(A%-#!6QVJ/VQ3,;IOBINSK9T>
MWN),Z?*A,U[%FH,MN,M1WDD-J@".PC5T1(U+\VGHF*K7_=09S')LJ^E2I;]I
M`N'W7&HZ(3U<VC8`@@`((&@IJGT^F*FXW,>+_CVD>S9N'PEQ[>9<(2-,JBI/
M;1MZ/HJ*FW:GM+\R9#%URCBBW$NJLHLPJ^VIG3=@RT!'1VO`K;S3C2J.\'`_
M%%14147"JLO%M*[`KH[[SIOP+,[ER6*H!OR'B,GQ<04T[;J.*)`G]7I@C0YX
MDITX]9T\26_#*=9+;Q)C>U7(DD74>:1D211[;9IT!>G5?OEJ1Z<\>7CCM59G
MR9XN1UAO_P#211F>TXQ*$1<8^*.T!'],2%4+7<FO7TR55YPSC!<9XQ"HAEE-
M^$)B,IP!;(MYD?N`.G3=],#G(/BV771*<X5RJ6]'*G2(DUR.*M.,V3A./L.L
MB8ZCJ7M)"145$P)W'/'(T=]%M6;`GD:B2X\EDVA17GYTOYCS^]%]OZG1!1/3
M`G\CXM+M+R@N(DY(4BC=?-0)I'A>:DM=IP/S#M71$T+_`',#E@\-D=93U<NU
M1V'6PK2"]L8[9NC:+KO$MY;":Z:=%UP.GX;QR_IXYA=7`6[V@MLN-Q6X@HV'
M1",04M[A?UBU1/LB8'2X#`+@<'#\MU;UJW#>J[")$<L)-1^Z/`W\9)D7<JMJ
MHF1Z&C9;2VZ?3UPE04\Z\9^+/F)%E.1X<0+%E6>TZK\0WA8WB@'^F:$8KVST
M+;U1,L*D2.?PXUVU.M@M*=IFHFSGJZ0+/9[4>0#?<-`4S[RZCVT1=-"Z]<":
M7DZ!'^<Q9UTR!9Q`C.-5SB-F[("<YV8_95LB!5)WV$BJFU?7ID'GQU>W%K9<
MM&R5]OX-M\>-#D=I28;^*RXK8DUJ)#N-2%=5]<#<WY*JW+&*PD22E?82W:VO
MME0/C/3&-R$RGNWCN)LQ`B':2I@5GC.RY#R,9')9LF7'`WYT4:IU6"B*C,HV
MFB!`0G`-I&MI+N]RJN4Q#DWG,N+<@D'97"7M>%/.MK2*L=M@89QMJL(R3:(>
MQWW@@N*1+MUUP-_"^2\F6_JZFZG_`##Y!1)=MDC8`D:0)MBZRWL0=6ML@=N_
M4O;Z]<BIG$[_`)#9>,IEK(G(5NW^YBW.[0(B+%D/-M%VDT#H+:=,ONS>CH.$
M64^SX9164X^]-FU\63)<1$!"<=9$S5!31$U5?3(UKG:3RH4^`#KU-*;L9<^;
M!K:QLF3=?&"9BZ>Y7$`4!`]ZDJ)JJ(FN$=)3\C9Y)QM;.B/8ZZ+K302@459D
MM$K9MO@BZHK;@JA(B_T_7"OG]KS#FO$1Y8$RR#D+-571I,28<=N.3,^6Z3(1
MG!9T$@ZBY_C(/JO5%PBY@W_)HDOEG'9EBDNQJ*YFRK[0V6T+20V[J+C3:-ME
MVW6%V^GM7K]\&)<7EULOCJGL44)/(K:L"0S[=K7>6-WG'3$?RMAZK_0GUQ%J
MTXM?3I7CVKO9R+*FO5C,V0+0B!..$PCA(`JHBBDOHGI@4=1Y8C3>.5EF=3.*
M=80?W0ZR*`/.M1$5$5Y?>***ZZ"GYBZZ#A%S?<IE_P`A2^2<582X?*"LRI9'
M54?U#<'M30EZ==OK],%<OXQ\A2+^GEW3]VS:U[?Z911CI&GQI?=(18<9$E_M
M!V[$5-=?JN%US5?Y@YA-C14FDQ4_N?*YE$4Q1`P@QHS2$V"D2[#=<<3;N+I_
MN83697E?E\OPN[S%B>Q76E:[)BOJ,,I34J1&>5H5%$)>RTX@ZD77;]\&OHTS
MG,2I\;_SE8NM26(]<$U\H9;FG3)M%VLDOT-Q=HZX'#/>7+5CAST\I[#G*)$Z
MOKSJ?CN,A6G9&.S<+J"Z]M:)2WJNTE3ITP,!Y8Y`<T>,]YI+E>5.<=6R[2:?
M%;9^3W^SKL[B@NS_`!=>NF!V_BOF,KEG%!L9B`D^-*E0)G;3:!.Q'B:WB*JN
MF\40M->FN%>>4\@NJ[G/%JZ-($:NS&P*P8[*..$D-A'0[9:ZBJJNGHN!MXOY
M,XUR2;%BP$E@<Z*4Z$<F,XP#S+9HVYVR<1-R@1)N3\<"#Y0\@#QZ@N&ZPW2O
M8=><T":860W''54;.0G1!$R%43^"KZ)@33\BT$23#KYKQK+>*/&=>;#5D)<A
MI'&V")%]IN:IM333JFJIKE1#JO+-)+XZQ<2(DR(4DY(QX)-;I!A$,A<<$47J
M(H/N7Z+T]<@VEY<X7WD:8?DRD^(U8$]&B2'FABOM&\VZ3@`HH*BT7K]>F6%:
MW/,?#&V7GB*;VV8S$\U^%(ZPI">V6GL_L1_KG],1:VR_(%+5W%NMA:$4*'^W
M-)&"(XO9<L%(62[H;NZ+RZ>B>W(/3_/*R?$A/U\]RO4KIJIDM28;BNJ_JNZ*
M;9;5:5Q--KB]$P-]5Y,XC:3F(<22[ND_*1AYQAYIDC@DHR01TQ$-S>U55-?3
MKE*E4O.N.7,\($%UTI+L89\<39=`78AEM%\#(=J@1=$ZY!S?/?);U3'Y/`JV
MG&K:@KV+%9C[*G%5'W%%!^FOM`OKZ_PPRZ"-Y`XR_'EN#(<1V$^W$?CFRZV\
MK[PH30MM&(F?=%=044T5,+4^LY11VE*5U"D=VO;1WNF@EN`F%470-O3>A@HJ
MBCIKA5*QY5X3(K/W./*>>AJ*N"819.I-"V+IO"*MH1-`!IN-$T3T]<1*K^=^
M3(M95-G0R0DSC?KM#[+K\=&9\@`'>ZWH#9.-&I!N+\<L'1M\VXR;S3`S/U7K
M!VI;%6W4UFLBI&RJ[>BH(JNJ]%^^16AGR%P]YYYH)Z(K#!2]Q-NB#C`N=I7&
M3(4%T>Y[/TU7KI]TQ$H//^*N1%?"82&DE8*QNP^LD9(CO5LHVSO:H'O7V_EZ
M^F(K1P3ECEOP&)R6W=9:WMOOR7FQ)MD6V77!W[34B%-C>JZX'L/)?"5C'(.Q
M[#8/1HYH^T\T2.34W1O88"6CR?D+31<#-?Y)X382XL.)9(<F8\[%8;5IX/\`
M2&=5-DU,!1MS055`/153JF!L;\@\/<<D`-B&L9AV69*#B";$=51YUHE':Z+:
MI[E;UTP/<OGO#X;+S\JT:998BL3W7"W(*191[&7M=/RF73`@3?*/#X\4)#4H
MY0K8M5!@PRZ1A)>T44,=NY!V+N0M-"3\NN!9\DY=4\?&L6=W5_=9;<&*C31N
M+W'4544MJ+M1$3ZX@H^&^2(-I)DUEK*C1[D;&QAQ(K>].XU!=)$74M4W]L=Y
M#KZ==-,0J38^5>$PZ:;;#/\`DQX+3<AP6&W",VGG.TVXVFWWMD?M0QU'\<#J
M8\EJ1&;D,KJVZ*&"JBCJBIKZ$B*G].!RO#N?L\EN;VM".L9:QULH+A+JDJ&Z
MBB$H.B>PG6W!_H_'`Y^L\K71.07[.OBA7S[V1QUOXSQE(!YITV@>5LQ1#`E;
M]R"NHHNO7".FX)RBTY`Q;NSX[,9:VTE5C8L$9[TB'L5PMZ)IN^V!8)S+BJVK
MM2EI'_<64<5R-O3=^B.YU$^BD`]2%.J?7"L0^:<3F+"2+:QGELF')4#8XB]Y
MAG^T<;_QA#ZJGI@9'F7%2?A,#:1U>L1`H(;T_51U%5O;_P"&B>U/K],#=6\E
MH+.7(B5\]F5*B?\`I#+9(1`FY1U73Z;A5-?NF!#8YUQ9VWMZGYS82Z,6SLNX
MNP6T<'<FI%HG1/7^.!95%W47$9957,:FQQ)6S<9)"03'U$M/RDGV7`Y.)Y!L
M;&WM(E57-2V::Q&MGL+(V3115%"E(QL5.TF_4?=[D35,1'A?(]@LSD=>W5B]
M8U$QN!61&WE4YKSK(OI_4_1$0<3>2ZH.465ARVU@<FXU1/U[:G?-R2?>!]52
M.<1L7'!1%!.XB[M$7ID'13YT2!!?G3'18BQFR=D/&N@@`)N(E_@B85Q['E6A
M>MZX4D1VN/V54=HS</OBT**#S;7:(2T1%_51?S?A@=5)OJ2-)C19,^.S(F:?
M$9<=`2=U].VBK[M?II@;+"UK*V.LFPE-0XZ*@J\^8MAJOHFXE1,"M:YOQ-ZV
M?JF[6,4R-%"<\".AM&.[JH'NUTT41W?PZ_7`\R^=\.BC`-VXB=NSD?$A&#S9
MBX\B:D*$*JGM1.OVP+#]]I%D2(_[A&^1#'?+9[S>]D?\9P==03\5P/'\R<=V
MD7[I$V@X#)KWVM$=<Z@"^[\Q?1/5<"0=I6A-&"<MD9IBIA%5P4=4$]20%7<J
M?CI@1W>14#3$A]RQC(S%963)/N@J-LIKJX6B]!Z>N!B%R.AFQH4F-/8-JQ`7
M(*]P45T21%38*JBKZ^F!.>E1F$%7W0:0E5!4R0=51-5TU_!,#6U95SS@-LRF
MG''`[K8`X)*3?IO%$7J/XX!NQ@/`X;,EIP&E5'3`Q)`5.J[E1>FGXX35/1<Q
M@VLF[;T%ABEEI$.23H$VZA,MO(X)"NB#HZB=5P+"ZMPK:.;;"VLIN%&<E=II
M1U<%H%/025=O5$Z85BHNX=C4Q+$3%H)3+3ZMF0[F^\"."!Z+INT+")Z.-J6U
M"121$51UZZ+]<*]8#`+A-?*^(<,LK.18E;N.QZB+R2PL8U6[&5HWB,B1ESO$
M7N:_4(T1!3K]=,"2GB*W7BD[BSW*9$BH<9"+5-.1F=8K(.BZ*&0[5?(4;0!(
MM-!^FN:I%ORGQNUR6R218322*=3(J),=MM$(TDFVYWA<U]I`;0J*:*F2K$*=
MXMFVD5YZUO"=O1;AMU]JQ'!KXZU[_P`ADU94C0R)SJYJ6B^B(F"+KAO$K"AD
M7,N?9_N<JZE!,>)&`CBV8L@RJ"(D?14;3U7(*NO\9'$DQHZV2O<?@63EQ75I
M-)W&I+A&X@$^A>YIMUTC$=J+Z(JZ)@7/".*O\8X^52LU)A?(E20?5I&]%E/&
M^HJ*$6NTW%^OI@5%5P#D+<F9^]<A&T@60O#911@LQSD(Z"MB+CPD9;&Q+013
M`D\4X"]2V#,^78E92(->%/5D3:-(U#;)"]^BEO=-1#>?3\O1$RCWQ_A4RGX7
M*XVD\7C?^8H3.SL05FN&XOZ>]==A.KI[L5F+CBU*[2<<JZ9Q])*UD5F(DA`[
M>]&00$+;J6FJ#]\C3D(?BVSKY$>9"NA^;6V,^=5J[&0FQ8LR4Y,9\1<$G-27
M43115-$R]$CHJ+BSU'QR16U\I$L9#DF4=@ZTA"LN6X3INJRA"FU#/H&[TZ:Y
M%<[$\8WLBEM*7D5\U85UHR8NC%A#%=64X:'\MQQ7'E,Q44VHFB?T:8%G`X/8
MM!?S)T]N3?WT8(CLP65;9::9:)MH1:WD2]7",O=U5?HF"-7]UM'+XI54]RTW
M.G5-?^W1K!$<:T3MHVI(`G_6V"JINRTBXXMQ&)Q_AL+C+!J;,2(D4GDUU,MF
MTW-"4M-RZKIKTR#DZ+Q?R.CCU10+MA9\"L6C><<BDK3D(3WQSV(YJCS2JO77
M:6J]$P.HB<6D5/#8O'N/S/A/0&&F8<UT$>ZM*BJKC>H[D<T7<B*GKTP.4J?"
MU>[/N+'DR,2)%R32R&*WO0V=8\@WVWB(7.Z3NKFBKN]$TRIF1KXQX7<XSQNX
MI:NQ:W7,]V6[,DL%)5EHNC8--.N$'=;3T<+U7JJ+C53C\;<@J:V!1\/NF*WC
MD>$Y!EULR(DM72=4E.3W4-HNZ6]==?;^&1-5EAXILY$,>#LV+H\!6@_;3C$T
MWO;EMFBLR0=UW&XJIN(=-NB?C@9?\*2+"/:R;6T!R]G?M2L2F&5!ELJ94)@B
M;(R(E<+7N>[T71,*D)X><%!LTFM?S*E^7)%D]HOC*\3?96/LW[^WVNFN[77K
M@7O".$V'$ZV!61)C3L5'9<JY(F51R1)EFKNYI4/1L0,E314+4=,#?R/BMI9\
MJH+N-*9::I!F(<=QLB)U9C/:Z&))MVZ:^BZX%1Q7QO9TLWBTAZ>R^/'JV77/
M"#9BKRR7`-#'4EV[4:3HNN4:^:^.+^WG7SU/9QXD?DU:%;:-2V3>V*RAHT\P
MH&WHNUTD)"_CD&8'C>[@<I<L6)L`ZR:Y'E3FWX2.2PDL-`T?Q7B+0`=1I%]R
M*H_3!%8GB;DD>#5?&G5C\VE?G!$"=#-^,[!L'>\0/!OW(\!:*A!HG33ZX1<-
M>/[EMWD1),BJ-U31ZMA`95I&W6&W0)Q0!=J`JOZH(^FF5(@SO&%_)@38J3HH
M_*XNSQT"VN='V]VY]>OY%W>GKBD+'QA?2I<Z0$V*/RUH5$5%SV_LSG=<U5/_
M`!JK[?M]<-)#WCJ\<E27DEQD1[D\?D+::.:HPP``K*__`!B]OU],@AQ^`7=-
M"JI3ST>4W1R;NPDQVFW#)\+%'B!IL/J0]W147U^F5F*[P^X^EC%!L(<YMJN&
M$<V*4Y'(C3*[VXYMRP0`13)?:B[DT^R86KKFGCJ_NK'D3T"5$;B\@JXT`PD(
M[O;>B/&8DFSHH$+JZ_77(C7R+QIR"RM+6TC2H(RG9E=85C,EHWF%.#'..XW)
M#IJ+B.KM4>J>N".IJ:"QB\6>KW1A,6#[;^X(+2LQ`<>1=-H_G5$5>I+U7"QQ
MTKQ;R-NMXHL,ZJ9/HJQ:B?&LF7'H;S1(WJXV@Z&)B3*>OJBZ9:1YN?%_+3;M
M(%5*KAJ[6373G.\#C1LO0%90VV@:11[1C&'8FOM].N6I$@O'7*OWOVR(*TJ<
MA=OEW=[Y1!)9-MQI-$V"0*XNU=5U_#,JTCXYYW)X:[Q2PGUBQ:]EIFCF`RX3
MCJQG@=868!+M0=&D$Q;_`#>OX8(WQ>#<PBR*B[C1J6)<09,@Y=?$%YJ&ZS*9
M%DR[JB3BO#VT5"4?3V_C@7?&.+\DJO&Y\?.3&:O$9F!'E-(3D<'9!N.-$HN)
MJJ"KB:HJ8,<?&\7<T^6Y)?6`)2)-%+?5)$AXU.I<(G]QN![U<1?;Z)],IJX7
MQ_R)9"ENC(T?*G+TR%P]WQ#85K:GL_M>O\/QP=4>%XSY$[55-/8O1@9X]"GP
M(,UI2(Y(S(Y16B<!1'M[&RU--5U),'563O&?/K&IF1Y(US+SM!!I6`;>=).Y
M"E=TC,B;3VF'5-$Z>GXXZ'5;7?`N62+JXMH8Q"-^XI[6"PZZ8H85S(M/`X0@
MNQ5VZCIKC3'3\WH[FUBTKE:+!S*NTBV#C+QDVV8-(8N"AH)JBZ.:IT^F,-<G
M$\>\L9>K7%2(A1>265RZO<(D^/-:?!K1-B;C$GTW#]D]<M2*9SQ?Y!EPYWS!
M@_.F4@USCR2G20I3$M)`*@=H0:9,4T$03V?CD7'T_D#?)I?%'V(#3+5W*91I
M15Y4;:5S072%W9JJ@*KM]O5<BZYG^[^PH^6\>M^,H3D2)%<K+=F9+<)5@J@D
MR+6Y#]S;H[O5/KE1(\>\$_:!FR[BMAI;G:3YL26VJ/."U,>)P40R$5`D$MI:
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M"CLF+_D'()L9*];PHFRNW@X0+%:5LG7";50WN;M.B^@IA7+<JX9R&ZO`L8],
M-;R2).']NY7#D@VBUXNH6V4VBHX[JUJ*MD))KZ*F5$.;XZY>O)N4\KJ6DKN1
MC-;E<>D*\!LS8Z1FV78DIM%]K;A-:_<>BHO3"1>S(?,;3E/#+V71_"_:6[#]
MV;^4RX+1R6!;!&R1=3'</KIT3!71U\VPY)PUQY^"M=,GQGVEA.F+B`2H3:?J
M#[2$O5%^V1I\]KN#\I=BT[=A1`"U_$I=,8./1W42:?;$$'15Z.(UKN^FO7"(
MS?C_`)7W8L2THBMH%A6U##__`$C\<(,FM;031X0+<Z&].X)-:JJ],H[?R71V
M-K7UXP8\PY<62KT>=`..CL9SM&`N$S)5&GVRW;#!?HNN0<7-XISUM+)\N-PY
MTNQX[6Q#:;6.,0)<)YPGF19,QU7:XA-I^35-%73*-4+B/,&+-)[G'Y+[3?)V
M;80D/PC?.,]`^,X:["%H2;<T(A33_DZZ8$1KQYR?]IN(4_C\J5=1(%O&A7!3
MFG(TS]P$]G:84A+>XI#N1U-`TU1?3`VW?C:P?@W[<3C(H](XG"@P508XJMBT
MKBF(^[VN!O#WK]NBX%C$XC>+S0SMZ*;.:*P8MJZX"6TW'8`(P-JR\UKWM[2@
M0;!U$]W7ZX.JJH_'5W&I^/Q@X_\`$F'27L&U/1D41V4NZ*V^HE[T)4U'U1/P
MP5*@\<Y(+G%WXM!*C3(<.KBV$&:U%=@N!&<_4<0Q-3BOL%N<$Q7W]$5%P.U\
MC\?>N;7AJ)6K8Q85PDB>JB)`TPD9X-QH2IJ.\PU3K@<'4<'MJ\:"1#XR;4N)
M97_?'1MI?A2&I*1&C<$MPLN$XV@BGY?LFF#JKHG%^9=J8\QQR8S&>KZ0I=7L
MCQVG@@2R*9";`7%55[1(@]Q54T3J77&)U6#_`![D(.6-C#XW/CT1<A&P?IF`
MC!)>B.5H1T<:8-3:+MR$W$V7]'5,+CZ!4\<=B^+7Z2!%E1C<@2VH4*:Z#D@.
M^+G;;<,?8*^]/:G0?3Z9#7"TGC.':1'([E4[Q^ME<<:K;DY`HR3EHT39,OB*
MJNXX_;)>[]=41%7*.\\9,VLJG#D%XRVW=V+;;#Y-*A`K,35ML@7_`!75W.I_
MX60=IA3`:8'-\EYQ4<>N:*JFH2O7TE8L<QTVM+M51)S7T$CT!/Q7"(W(^<S*
MGDL*@BTSUG*G1)$UE6GF6TV15%'`T<5/=^H.WZ+^&"HM/Y2KKFPXW'K83SL7
MDL63+C2S4`[20R07FW6U7=N$BV].F6%=)+MI$:XBPU8!83S+STF:3S8*RK6W
M:G:+WDA;E]R=!TZY!,CSX4E7!C2&WR:5$<1LQ-154U3=M5=-4PKFK[R+3UJF
MW%(+&3&L8=98,-.")1SFF(B1ZZ_EWHJHF$KHBM*P8BS"F,C$1=%DJX"-:ZZ?
MGUV^O3UPM1N078U%!.N19*8U!CG*)EHA0C;;'>6Q25!UVIJG7";O16<?Y=/M
M5B.OTLBOKYL-)T>>XZPXUM5`)`<[9*H$HGKUZ=%ZX*OFK*N=8&0U*:<8)=!>
M$Q4%5/HA(NF%H-C`)009+2JXNC:(8KN54UT'KUZ=<)6QF1'?#>PX+H*JIO`D
M)-4Z*FJ?;"N+K/*E;8WXU+$&1VY$F=!@355OMO2:U-9#>Q"5QM$Z[2--%_P9
M4QYK/*;5E4ULR)32W)=K*=BQ*Q#8[^R.9-O22]^P66R!44E+[??(8ZARX0;Q
MBH%HC==CN2G7$5-K0`8@.[ZJID2Z?P7`@\5YO2<GD7#-6XKA4LTX$O5$1%<`
M4+</W!==$7\%PK/*>6-43E?%!A9MG;/%'KH0F#7<,&R=-2<<]HH@`O7[Z)A%
M8WY!E-!2+:44JL?NK(JMN,Z['<-HD;-P7'%:,QVEVU31%U^^%=<,A@C-L'!)
MP/S@BHJCKZ:I],"GK>4L3^2VE$VR2'5LQI"RMP$VZ,KN(FS:JJFU6EUUP+GO
ML_\`C!]=OJGK]OXX$&;:N,3HC`1B=B/(\LN>AMBU&1H-R=U")"]_HFU.GUPB
MMC<UJI5]"JXFK[$^`Y91[-L@6.3;3HM**+KKJJN(OIIA5U8V4&MANS9\@(T1
MA-SK[I(("GIU5<)JNJ>41;&[N*D&C:<J"CB3QJ.Q[Y3/>!6M%5>B=%UP8N.Z
MUOV;DWHFJCKUT^^F%4MERR'`Y-5<=<CR#F7`/N17FQ!61&,B$[W"4A)-$)/1
M%UUP)$"^9F75C4BP\#U8C)//F@(T?R!4@[:H2DO0>NJ)@5+OD*M2?)CLPILF
M+#FA6R[%AH38:E&H)L+WHYH"N"A&@;4^^!U/73\<#EZ[R%5V$N,W&B32@S)+
ML*):]I/BN/,*:&B$A*8CN:)$(@1%5.F!U&X-=$754]<$-P_?`:I@5L&]8?+M
MR6G(#YR'HT9B5M`W^QKJXT(D6X"%-PK]L#=56)3X?R7(K\%>XXWV)0H#GZ9J
M"%H*DFT]-P]?1<"9J/WP0U3"1G5,*JIO(H<._K:1T'5E6K<AR*X(ZM(D5!)Q
M#+7HNAIITP(EMS6NK;UFC./+DV<B,<QIF,PKJ*RT8@9;M4'VD8II^.46E1:,
M6E>S.8!UMM[71M]LFG14242$P+115%3():K]O7`K..<BK[^I"T@HZ,9QQUI!
M?!6S0F'":-%%?3W@N!::I@-4P,:HN!$MKBLJ*]ZQLI`QH4=$5UX]=$U71$1$
MU5555T1$ZJN!65W-:B;9,5G;EQ)TILWHK,R*]'[K;6F\@4Q0>FY.FNOX8%_K
MD#7`:IE$%VU9;M6*PFWE>?:<?!T6B5D1:445#=TVB2[^@JNJ]<";JF!#9MH[
MMK(K1!Y'HS3;QN$T8LD+JD@H#JIL,DV>X475/K@3%5,!JF`W)I@$4<#GK'R#
MQ&OLY57+G$$Z$`.RV18D'VVW==AF0-D*"NB]==,"Y@6,"PALS8,AN5#D"AL2
M&20P,5^HD.J+AE)147#3&HX2&Y/OA5?!O:J=8V%=%?1R95$V$]G:2*V3P=P$
MU5$1=P]>F&5AJF&F"4-%U7HG5<"DI.;\0NY,J+46T:9(A#NDM-&BD`:JF_KI
MJ&J?F3IA&^CY9QN]-UNHL&9ALB)N"VO78YJ@.(BZ;@+:NTDZ+]\*DW%U44T!
MRPM9;4*$UIW)#Q(`(JKHB:K]57T3`AAS+BCE$-\W:QG*8UVA.!P2;(E+;L14
MUU+=TV^N$;G^3<=8K&+1ZRC-UTE6QCRS=%&W"=7:V($JZ*I*NB(F!KN.6\6I
M9<:);VT2!*F=(S,AX&R/5=J;4)4_K=,$6WMPL8]OUP'L],!H&$97:F"-,R9#
MA1'IDMX6(L<"=??<7:``":D1*OHB)@9C2(LJ,U)C."['?`7670742`T0A)%^
MRHN%K;TP/)JV`*9*@@**I$O1$1/55P--?8P+&$S.@2&Y4*0*.,2&B0P,5]"$
MDZ*F$1[NAI+VO*MN(K<V"X0F<=U%4")LD(55/P5-<"<TTTTT#30H#;:((`*:
M((HFB(B)Z(B85[P&`77Z8'R;E?#.0<OB\JG.'+K)'LCTL0F&#(DKE21&>:-=
MQ#W9.J_F3IIAGK1ZJON4\KXA/N:>QKFPJ)L>Y-ISL=B5([2=M7&7-ZB?:/11
MZ>F!:N\8_:_(G#FJ:I<9X]3UUA&5UD4[#!2.UVQ55+>N[MEJNB]?7URJB^4*
M&VL>0,OPZIV<RG'KN$;K8BJ=Z4#2,,KN5/SJ"Z?3('COC$RFY6+K=0=;`>XW
M6L2'!`0`YS!'W!-!757!$D125/Z<"BY#Q*Y.XY1''CSTF/9\AIK%N2T#2M.Q
M&NQW]5WB6H$R:DFG^_A$:;Q?D<&0^;%!.=X_%Y%8OG50$C@X<67&!MF3':=7
MM&`.HY[.B^[7!';N4,J#X<ET<&OE"_\`M,B-#K'74DR1)ULQ;:-S5!(DW(BZ
M+HGIZ)@VJ*3P*<SXP;2IA2_WB1%J4M:J0^9$ZW7F!/Q@1TR`"<#>.@KM+TPL
M55QPN796#DN/QY\..6%]3R4IS9%M0&.TX,V43&Y$;$]P"2>I;==.N$C3R3QV
M12.4+7\9)$_=Z,J<V60%4C1D:&04=4)%$!`30M--<*[SQQ2OT]GRZ,-<5;6.
MV_?K&A;1I@F2C-"1LB/1$5P"UZ)URF./XI0<KA>3?WDJMZ+(ERK-.3$K(_`*
M)KK!>AFFJ]XT$$/9[BZ[TZ)A,JOX13\SX96Q.20JBPFK-D/Q.0<<=#=*!HI3
MKK$N$I*NP1`_>UNVEK]"R*[N?+OVZB_O84"6MK:.-P*F/V"5UA@4[0/&WT(1
M$W''BU^FF!54W%[OAGD&I*(+]K3VU:-9:/L1D;".<%46&^\HEU4T<<`E]?KA
M5MSZF*?S3@\G]K*<Q#FR3F2$91T&&RBF#:N$J>U%=(=/\.!R<.@NPD52!52V
M6VN<39ZHK2Z!$<:>0)"_9M5<3KA%-6\6Y8=%:BU57$?FL.NEPYDQY6&HDWNO
M"X?9>;VE(-X$7M$2_IZ_3*FX[?QO"`.:\BLH-#*HZB=!K!C!)C?%0G6$>%P4
M#7\PH0HO_N7#68IN8<#Y,EKR']BB:PC<B\JK'$5/=<0_:<-!7KI(1H2)?Q7[
MY$BPL.+V!77%"*N<<<DQ[I^[(04F0?L8Z+VGB_+U-=B:_;*DZN2J.'R9-)20
M9O')8MU_$)\-Z.Y&(!2QWMZ!HG0G#)M2!?KZIA<]7:<MIK>V\#C7NP'IENM9
M"5V"XWND$\SVB=38757$V%D-<UR'CLJ7-Y+<0:*:$@)G'G:(DCN-N`VRK22%
M9!/3MAO0_P#`N46?'Z6S/R$XY;PKA+>):S)3-DVVR%<[!>0D9$Y*#O-L6E$>
MPI:H::Z8,=)S6/.B<VXER1(K\FLKAGQK`HS9/N,_+:!&W5:;17"#<WH6T5TU
MR*W5=D\Q+Y#R8Z^:L"6Y#8AL#'/Y3HLCVB=&.J"X@;W/ZR(NU%733`Y'D-?-
MC<HE7/$HUI5<J=L6V9E;\=PZJV8%P`.0ZI"K#>C.J]U"$D5-.N$?58%D,TI8
M`R^Q\1\HY*^VK:.**(N]I5_.VN[H285\IK(,V!RJ#*X@S95I64]W^8^+S([J
MU[8%O[DYIQP>VR6]!-.V>AZ_ERI5'4U?*#H[-]F)=CRZ+`*-=1S8&,S+))0.
M/*U(1$^0ZXV)]DQ+H):+ICH=5\25K+_'[VCI[>#2MWW>FLNL24-$>@.L*01%
MW.`SW5!"]NW=[OQR%5_$..2+&RXI&O*^Q;C-!>F^T_\`)9$"_<1=AH\HJ(_D
M15!"7+"MM34O?S703[&LEN,1^1\@:;?<8?-6@E*I137HJBT6GM-?:F(55K'M
MPH:J-<LVR4#QWD9U8T1V4^S*>GDL1PVU0G418^O:<TT%5^F(5TM1'LHGD&M1
M0EVH[6&)1S6GFI<-0@H/?^0'^BOL.:?J!ZHZNJ8A4;R^]/6XF?#ASTF18,.1
M!F,,R9`FH34)T8R,_IM&`=72+W$*HB)IKB%1_@3TY"];`U/^6/-&PBN$DO8D
M!Z,".^Q?8C!%KN73:BXA3A(.N\QXA(EPIX<B8:MVN3R)#$E&TE&C:IJZ2=E1
M+:O:4%TV]$R*N^;*W_>G6N2)<^NBA1S&3L(++A;77I+*@"N"T\&Y1`B1/PRI
M59RN1*?A5UM2_NLE:^$3-ZV3<AEV?4*:,N$V"BFDLB%7&]$0]NOIN3!4L94"
M1S4HUBQ;HI/5TCB+\,)8,K#%H-X&:)VVT%S?\@7M%4=/PQ!SW'6)E:U2SXS5
MFC\M>3#.8960!$V).O1Q!MQ.VT2EHK1;4ZK]<:56Q9DYV-+C,.6;,24YQN0R
M+`6+:CNDDW._6<3>1[-.\2;47UV],0JX?GO4QOQI3\O]@A\GG,_#=6:?<B%`
M$P3O@+KO;!\B(=?;K]>B8A41^9*_:Z*OF7TZ152*MYJ/?0&9LXTN4D+N'4%%
MT7`#:C?=':O75$Q"N^\E0;0^.\>GBR_8!26E?96T9L$)]UB/KW3[0?G,")'-
M@_;IB%>N5\M9N.)6DCB'=GV<>*;K$B.R:&TBJ*.BV3@BJ/*UNV@GNU3JF"N-
MNWGE">7'+"P3BTB30E'>!R2IMRG9NR8#1GJ[M6-M)T5]HK]EURE99"=`N#>:
MF6*#7<T9@0FW'Y+C8UTED%?`A-21QI3,_<>NWZ*F0K3Q^)+FN<42=:6RC;.7
MT6V0I4H-T=AQTXPEU'M[=H["'0E]-53$*45]R!^LXX4RWFQ2>XK:_+ED+KB@
M^P\VVR^;2)J3H#N7TW+B%:W[RS_EA`^2C4B)/=W,I-F_!M!&$)?Z#.T[S!#N
MWB!ZCW=1ZXA4ZUY'R`9-ZY"=LFHR5/'I#T9Q7#D1H[SY)8&`HG1\8_\`:;>N
MO7UQ"M<^9-6VCPZBXGEQ63R&M9KY+4AXE5M^,\LU@7U4C)D3%M?<7M)51%P5
MVGC:;8EQ"V9:DNV$FML;2)7E+,S<(&'S2.#CCGN/IM3<OTR%<&S>VY4D:=`M
MYYV3]#9N\O8<==4HDYEA":-&RU^,Z,G5L!!$0A^BZ:Y85T_CB9/:Y=\!ZTF3
MV)G'*VS="8Z3VDMPC!TPW)H&X=NX1Z?73!7N/R2CJ/+O+G[*P:B,I658BKA:
M:D!/J8BG]8DWCT3KUQ"N*CSK2BK6$FR'N,<4Y#:7,R`ZZ,AA8PO$!00<5E0<
M81S5UX0+1-=$7[9$7T;D;A7+5/R'D]A#L6HU4[12([1QTL4)-9#GQU$Q<)US
MV.`?Y1T7IZY8M5C'++R6=T^_R1R#>5[-TEG0`+_<;%D7/B&*&JM,BV@MD#HI
M[]=.NN(5IF67(&ZV>2<HL^\/#(W(>CXHJ6`(2(0J@:H!:)O;3H7UR!/L;1;C
ME-M7W$B%R)1H9=97QU!!G..Q`$P)DA4G6R4B%=.@^OTRHN8G*K>9S"<Q(Y$-
M;9P)M@S)X^J.D9P`:+XY@VNC8H@B+J/I_!?MB+75^)UERO']=<W%Q(MG;>"Q
M*EN2R;5MM>TB."V@`""/KNUUZY%44?D?`K[D<JW@S(E@,&GF0*RI@&)R)$?1
M'))*+?4!7M"#0KI]5^J94JA\.6]92R9<BXGQY,.+0U[L2]5X5"%7*X:-5LE4
MT$763)?>NBFGKII@KZQRJ_XS3U3=Q<OQPC,F)PW'R;$2>)%1M&R-4'<2+T77
M\?3(5\MA)31YG%[*/80Y-:YR69.OW83@N0HTZ7$/X[?<%=F@:B.[71377U7*
MCP_L#PQ;2'5%N!)Y$LBH4]!'XKERVK1!K_5+W$.GT7$'6>5+/AQPYG')DRLA
MV=]'1F7(FNL-JS#ZHKY=Q4(E!%+M"GJ?]*X6KOEJ6SG`)$CB4TPG1HH2JQYO
M8??%D4<1M>X)HJ/`.W737KKD'&4/->1W/)2BQI,I*N^:C7O'B(`$VX$=-)L<
MM6_:KCNP1W:EM/75,HY\?(W+7^'VO(X_)H8R4J'Y3]6!-OR(<YIX43])60[(
M`BJV0ND6Y>J+B(NN0<FY75VI<?\`YICQ)35>%I7VEF3$<)9O/GO;5L&3%UMD
M!$=@*)^[77`Z3R3)E@_PAW]S=K67KIEN8K)BTVXAQGC1#[HKTW@FB+_OXQ=<
M78<[L94V5#6Z&;4VL+D3!-N_':'=!!4:[+(IWFT#J"JX7O\`S:)TRZF-M-Y%
MLH7C^=,;D+#M*6!5L#22.TK<:,\C0)9=P!(G6S;<4]4U$=-%35%R06+?(>8N
MVU/5,\IAO1K2UD1FY</L2W4C)7E($#<5MMI70<#45$?RJF[7"NM\?WUI=^/(
MUA/D@]9*$MEV6@"@F<9]UA'%`?9U1M"5$Z9!\WA<XYQ)XS&D0[EF"3/#_P!^
M)MN)'5"E,/$*Z(J;1;-!T443I]-,J)CG.+R%9\GMELR$7&>/)&CO(V;$(+,1
M%Z0(Z(2BTID75=-?S8'T#AUK=G?\AHK&5^Y,U+D8H=DH-@9A*:5Q674:004V
ME'U04U%4R*Z["F`P&J??`QJGWP&J??`:I]\!T^^$C.%,#1-GP8+/?FR&HK&J
M#W7C%L-Q+HB;B5$U5?3`C1.04,U]&(=E%DODBD+3+[;AJ@_F5!$E7I]<J58)
MI],A&.F%AJF`U3[X&@)\`YKD$)+1360%UV*ABKH-FJH)D&NY!)171<(/SX,=
MUAE^0TR[*)6XS;AB).&B;E$$5=271-=$P,Q)T&8TKT20W(:0B!7&C$QW@NTA
MU%5345Z*F%;^BX&.GWPC'M^^%:F)D-]UYIA]MUV,:-R``T(FS44)!-$7VKM5
M%T7Z8'BPM:RN:1ZPELPV2)`%Q]P6Q4E]$125$P)*;535%U3`:(GUP-4>7$E"
M11GVWQ;,FS)LA)!,%T(54570D^J8&W1,)#1$ZX5K63%^1\;O!\C;W$9W)OV:
MZ;MOKIK]<#;TP,(B)]<!HGWP"HF"&B??`:)]\)&-!^^"/(.,&1B#B$;2[7!0
MD5154UT)$].BX(]Z)]\$-$P1Y,V@44,T#>NT$5=-2^R?C@CUM3!#1/OA31-?
M7`*B>NN$AHGWPIM_%<#RIM"J[C1-J:EJOHGW7!%/R#BD"[=B2'9,R'+A;TCR
MH,@X[B"[IO`MJ[2$MJ="1?3"1.JJB'5PQBQ=^Q%(S<<,G''#-=2-PS52(B7U
M5<$3-J8(PJ"GJNFJ].N",Z"GJNFN",(@KZ+K_#!&=J85A=B>JZ8#8.B?9/1/
MIA(SL3!!`%/3I@C&P$7!!&P155$ZKU+\5_'!#MA]NN",*RTJZJ*:^NNB:X(R
M30&FA)N3[+U3I_'!&%:;4D)412'7:2^J:^NBX(PL=A5)5`5(DT-=$U5$^BX(
M+&CK_P`V/IM7VIZ?;T],$8^+&[HN]H>Z"*(.;4W"B_1%TU3!!8D97%=5L5=4
M=BN;4W*/^*JZ:Z?A@CT++(-HV`"+:)H@(B(.GVT3"M;,&&R2DRPVT2IHI``B
MNGVU1$P(\FBJI$&3!*.`1IB*,D&Q$-Z%Z[MJ)KKA(WG7P38;CN1VS8:1$;:,
M1(104T31%1=-$P1C]MKOC'%6,U\9S^TC[![9:_<--JX6/3L&$\RC#S#;C`Z;
M6C`2!-/30533IA(U2*6HD'W),)A]Q$04-UH#)$3T34D7HF")8@`AL%$0431$
M3T1/MA6L8T<"`A;$2`=C:HB(HBNGM3IT3HG3`BEQ^A+Y6ZNBK\[19NK+?ZRI
MZ=WV^_3_`)6*D>I5)42UC+*A,2%AJA1%=:`U:).B*WN1=J_PP1MG5M?/:%F=
M&:E,@8NBV\`N"A@NHFB$BIN%?1<*@KQ+BZNF\51#5YTS=<<6.TI$;H[7"5=N
MJJ8]"^^6C</':`'$<&NC"XC'Q$-&6T7X_P#XG73^S_Y/IBI&N+Q;C<0(K<2K
MB1VX1DY#!IEL$9,TT,VT$4VD2>JID(DQ*FLA0UA1(K4>&N[6,T`@W^HJJ?L%
M$3W*JZ_?!$0.(\6!M6PJ88MJPL101AM$^,2[E9TV_P!FI==OIEI'LN,<<4S<
M*LBJ;D9(3A*RVJE%3T8+5.K:?XOIDI&^KIZJJC)%K(K4.,BJ2,L`(#JOUT1,
M+$S`8&%UTP/C,_R7R"#R60[%L$LZ[N73(PB;8:;[E9&)YMJ."?Z21`XWL<,B
MT)?RCZ+A*FGSB=#JX$Q.619\2[>K&RE"TPBUPS-W==4@_30#)$!M'4]J^JKE
MA4A+_D4FXB<8;Y2SN.)830OV&&%[QQGQ!J.J$A,JK('N>V(F[3IMZY!1/>5.
M5KQZTLGI;$"2WQ:)<16B;#8,PWWFC(=_4@<1H505]-V$B99<WYFQ<V[X6C/[
M?4W5)""%V&M'6+,&$>`W?S>U7U(53KT^V4CI?&%C))F^_=+@IKW[_81(P2%:
M$A1IX@;;!!05_('0?PZ86N^R*C3JV!/%H)K`2`9<%YH'!0D%P-=IHB_5->F!
M\:XY+AT'BNYY-$@QCLZNZM_B22;%>PKUDY')TE'1=@-GN)-?1,K/L[SBEM>A
MR^XX[831MHL6)$GP[)&VVS%)*N"3#B-((+_9;P5$UVKU^^1IIYS9\H;Y/QBE
MI+)JM;NEG!)?<CC((?CQ^Z!`A$*:Z_3"/G\_RIS0>)C9-3V$M:^N?E2XS3#2
M,O+&GE$24ZX\7M9?%I>VVU[U)57T3"IG,>1<ZDTW/9<:_"#`HI`Q8C4:,WWB
M%]F.XBK((ETVJ^J:H/7"19W/*+6IY->Q$L(Z&S"I0B6"0VSE..39+S1-CL44
M<(^W^DA>P275>FN5%?%O[.\F\3.W[;DZMY?-@"YHUW.VQ$D(.]65)O?I^;9T
MR*\4'([#BM+'N>\VUQ(.27$7D(=I")H'YKH1Y`FG40!W031$]"_#"7H^K\:<
MMW:.._;$BSGT)X@04#8#A*3;:HG]8&U$27ZKAIP-SSSD-5R.XCV<QJLAMM37
M*9YUA'H#S<:.AHI/LDKH/LFA$XT2>X?RY4U0S>9\TE&Y6NV9PSAW=`T,I68X
M/N1[$4-QMYL"(`3<FJ)JA:="PF8NY?)N41)'*OVN.V^[!O&&'U@QV?FG$6O:
M><<!HR$9+X*2=%778G1.F%B)ND<LYAQLTM&9T&?QJ8\B.0P*,X9/,`1JP]J0
M[M4W"OIII@W'0>/N57UZL6#,5IB?2#(B\JC-M;1&6V:!'%I%7V`8)W1TUU'3
M&F)GD^;<16N-C66!UZR[V%%DD`":N-.$2J"[OIJ/7[Y#7&<8N[JBLS6.XRM3
M9<QM:^3!1G]0MXN.HZ+J%T)#:TV[=%1<J.B\=\PY;R"1!LI:1%H;>$<AML76
MN^R^!IHVV(*I&*`NCF_J))C5Q?<YN["N9JV*^2#$NQF#&`$:[\AU.V9J$=LB
M!O?[-2)PD$115^V17S&KY!ROD%W4W\)^%7WQ\6G'(??95UE?BV(AIM%P=J&K
M?5=RZ:KIE@N$\G<JLJ&SO:\8T):&JK[235OMD92EEQ_DN@CFX2;'9[6U1%U+
MU^V(+?\`GCD0\GF\<<[839_P9O'-6?=\![K,[H[O><;MFBZ:>H_?$2O?`^9<
MNY!/@V#\:./'+5F0;?O:%YEUD]&VP07#-WV(O=W"*B6"KKR!R"XI8M.M3V._
M8VT.N=62)&"-2242)$$A7<FFJ9%<G7\_YDQ+AK9.0I$0;V;02VV&'&W7?C,N
MO!(!5<-`7])!4-%_CEB5%>\E<_#B$OE#<2%^W/U`6E:;A`NQ]7@16-C3QFX'
M:<ZFNW:2>G7$*]W?,.<)9.4OSHT:3%OJB-\MB.6UR)8M*ZK)`9EU$AT4D7W)
M]L0J8WRZ=%Y7;4\2-"B3K&_:K0L1:70A2L&63KZ;D[CNT>V":I_N8A7AGGW-
MIMK`H6$@Q[`I5O739IM.&T3E:VVXT^RVC@^TT=3>"ET77KTQ"M-;Y/YE>UL1
MRDK8[EBW50+2;&,P!IQ9AFC@(XXZVK0"#)*AZ%UT1<0KQ?7UC?V5'-56&ZN!
MS!NM9C("K(0XPNMDZKN[1-Y:^W;^7ZY!]!YMR/\`EKB=E>(TCQ065<!I5VB1
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M,[7!Z[!)LGTU3KJGVQ"I51S_`)%9<FAUX061BOS;*)-:474?B-5Y:-NN%^1>
M_P!-O1$]R:*O7(N.DYKR0N.T)SVVA>D./QXD4'%46U>EO@PVKBIU0$)S4OPP
MCY[S'D%Y+LX=+-8C_O-+R.G.-)95QN.\U-1U6U(54C%1[9H8ZKK]/7*5ZE<D
MMKFVXNW;,-1;:GY8]63/B&:L.;*YYX3;W>[:8.`JB7HN(5ZIN>RZZCBM0:R)
M`^4]?/$9$\Y&[E=(/V(JKO[D@M2^R==$7TP5*NO*O(*NN@3WJ^,V3L2OES*W
M5YR2"SI`M&);106$:$NAN?F+HB=,%19?)[I^EO7[MB+9Q8?*XU9$CHCK';;2
M7';;+<):D0$XA_BNNO3$*NFO(ULX]!L0B,%QVPN':)M44_E-N@ZY';?-/R*!
MO-:**)J**BZ^N"M7"_)/(;F?Q\+.NBQH?(8LUZ.L=UPW&W8#J`2'O$1VN"6J
M:=4P/HRKHFN17Q;E7(.3SG9P238<2IYE5PJMM@G&?8J,FHO%[M4)'O=T7K_1
MEB5?->4;LF@K5K6BY&MA85Y-L=Y^-I7`+ANB@BCJH2.@B)IT55^V(5W'&[2P
MLZ&%86$`ZN<^VA2:]U4(V7$70A54]?35/PR#B9?D_D,6TL".F8*AJ;IFEG2Q
MDDLC24C*-/-L]O:J"4@4,5+7[985"L/,MK7G:(]5,/+#K9UDR++YD&L!\6B9
M-_M]HC(7$+]-5VK[5Q"I['+></\`+PJ;"%`CPG*:59%%:?=-PD1X&VM7>V&U
M=I=41.GW],%5E'Y+F,<<JV./\??FK&J8-A)@`Y(DNHW,4D;9:?4#WF@MD6YT
MDU_WD*Z>GY\]8\UF\<.,S$*)W%[+[AMS#:$15N0VT0(#K+BDJ:@:[=.N0JSY
MUR>1QGCQ6T>(DXQD1F%CJYVM4DO@SJA:$FJ=S7K@W7+%Y1OXTZ2Q.I&`8KKJ
M/36+[4I372=V_CNLBK8[].^/<0MNGTURPK>WY+N7+]RE;J679CS5B=>RW)4E
M[M<0HC4AP05H">$T)-I$H>A)B%6_#^<_S.U6/Q(R"Q+@+,GJIKNBO[T;2,0[
M>I;Q<0O33;Z=<AFI'+^7+1+`B1V/DV5HZXU":5'5#]%M77"/L@\YH@C]!7KE
MBZY*9Y?O68SAM\6="1&I2O9D:7(2,XVVR^;+K>PFR+=HVI-^FY/73$2MA^4[
M"+=<@*5#:*GKVJK]M%HC60Z]:ZHT)B@+ZDJ(NGY=/KKB*V.>5;]/B16N*OO6
MDR=(KX[1/+&9=)B.LD7FG)#;9$T:(HJJ@FTDR)7T1DW3C@;K?;=(44VM4+:2
MIU'<G1=%Z:X5\LHO)4N+5UL2KHY=@_8-6TQM)D\#,%KY9-N@;QHJJBJ7LT3H
MFB?3*FZD!Y?=*<<]Z"+7&!X_&O1<[FLM2E.$`M]O;MUWCL3W>O77$,UU5#R^
M3-O95!:5JUEM'C-3FVT=1]MV,\2M[P<$0]P."HF*I]M%5%R*V<QY4_QZ,P\U
M!^6+RN;W3>".RTC;:N>\RW+N/3:`B*ZK]DRXFIW&;Z/R#C]==Q@)N/91FI33
M;FF\1=%"02T^J:Y!R9^6%;MGXSM%*"KBW`T4JW[C*MMR'=B,GVT+N*V9.B*K
MI[=<*\UWEAZ=&1\>/R61DS3JZKN/,?Z5,:>=:=!-I$H`V+!.*9)IIZ:KA*R7
ME@NY&@M4,MZ[>GR:EZM%QE%:EQHWRD173(05MUK0A-/HO7*5L@^5@LX<?]II
MI,JW-B3(FU!&VT[&2$\L=]LS)=A'WD401.A>NJ)D*]P/+%-9V=?#K&#D!.B1
MYZN$;;+@1Y&_]0635#<%GMJCVS79EA42)YIX_(%]XHLA(7Q$FPI3:=P7P)T6
M6V^FG;><-P-@$O5%]?7(5+X-=7MAS#E\>T!Z,W#<KTC5[SC;HL=V+O/MDWTV
MDO7^.!W.%,`J:X%0G$>+#8K9)4PTL">62LOL-]Y7B'8KF_3=N45TUPD>6>&<
M28KY=<Q30FH$\E*=$".TC3Q*NJJX"#H7].6D'^&\4?KXM:[41#KX*ZPXBLAV
MV5_^+%$T'7ZZ>N0CU9<1XO:.-NV53$F.--+':)]AMQ19+U;'<BZ#^&"!\0XN
M:/(55$))#K3[Z*R&ANQT1&7"Z=2;1$VK],M(]!Q7C82RF#611EG(2:;Z,@AK
M)05!'E+37N;25-WKDI%KA6"%"147JB]%P*Z#QNA@0GX,*OCQX4E3*1%;:`6G
M%<_.I@B:%N^NOKEJ1[IZ&FIF"CU4)F"P2[B;8!`151-$UT^R=$R*HN5\':Y'
MR"@G2U8=KZ=91/PGFU-75DM=I%$M40=GKZ82+"=P;AL]&4FTD*0D=A8C`N1V
MR0(Z_P#-"BIT#\,*V!P_BX0YL)NKBC#LD1+".+0(V^B#L1'!TT+V].N!I?X'
MPQ]EYEZEAFU(:9CO`K(Z$U'75D%Z>C:]1^V*D>HW!N'Q3:<BT\-@V)"S62:9
M`%"2H[%>3:B>_;TU^V"*ZPX-W78]?7N1J_BYNE)MZIN,)'*>5P7=>ZI:`A&/
MZGM52^^#<=;ITTPJD/A'$SE2Y1U48WYR.)+,VT+N=X=CNX5U'5P>A+IU3UPD
M10\:\"",]&&AA(Q(%D'P[0^\8J[F-WU7MK^5<M5(E<&XE*[W?JV"60^,MXD'
M:12`#MB[N%47<C?MU^W3)0?XI4LJW*JH<:);PXAPZJ6K6J1P)-1!!%1_3W:*
M0HO7+1ZXI12:J$\5A(;FW,YSY%I.::1D'7M@MIM#4MHB`"(HI+D$VYHZBZB#
M#MHC<R,+@/"T\.X4<:)"`T_$23I@0FN%<4:5E6ZN.*QYA63.@?DF&FA2!^SB
MHOKA(4G#N,4TV785E3%@3YY*4Q^.V(DXJEJNJHB?F7JNGUPJ3=\;HKUAEBXA
M-3FH[HOL"\.[8Z**B$/V7153`K$\;<$%B.P%+%;9B=U([8!L$1D%O>#0=-0<
M+J0KT7[8HESN&<6GS6ITRM8>E,@+(.*.FK;9;@;(4T$Q`NHB2*B?3+1..IK3
MLF;-R.V5A&:-AB4HIW`;=45<`2^B$H#K_#(D0*GA7%*BUE6U95QX=A.55E2&
M@02-27<7X)N+J6GK]<+$VTI*JU&.EA'&2,1]N7&0]?8^U_9N#HJ>X=>F!!;X
M1Q5LVW`KFA)J<=JVJ;NDYU%0Y'K^<D5=<M2(3/B[Q^Q'L(S%)&:8M4TGM`BB
M+@J:.*.B+[14TW*@Z(JXI$F=P'B,\IA3*UMXI[D9V61*>IN0TTCEJA=%;3TT
MQ2/4C@O%)"3.[7MD4^0W,E&BFAE)8%!:>$D)"`P%$1"!4R4CVUPSC++L)YN"
M`NUR/I#<13W!\M-)!:[M2)W^L1:JN6D0"\6\!,:Q"IF52G#M5_4_TVD+>C:^
M[W@A]=IZIBD;GO'/#'KA;ARL;6Q62$Y7D)P4^4VFT7^V)('<TZ*6W5?KD(O9
MT&)/AO0IC02(D@":D,.(A`8&FA"2+ZHJ+A5'_=YQ!:J35'`[D*6C0R$<=>-P
MD875E$>(U='M*GLT+V_3+4C6GC7A2-=H:U$%9H62JCKR$LML.VCRGOW;E#VE
MU]WUUQ2,+XSX2L*5".O5R-,:2.Z#C[YJC(N]X6VB)Q2:%'?>B-JG7%(\%XMX
M,5A^X+7+\M)`3!<21(1$D`';[R"CB"AD'0RTU+^MKBD;6/&W"V&8K`5HJQ"A
MOUL9EQQUP!B2E17V5$S)"$]$UW:KBD1F?$W`V8DV(,!PF;&,W!F=R5*<(XS)
M*3;6\W2)!%5Z:+Z=/3%(F.>/N*&Y(<.*:G*FQ[20JOO>Z7$048=_/TVHV/1.
MBZ=4Q2.5X[X_Y+#Y`$V3VH:-RW)4B;#LIYC*0W"-06O=_P!':0]_NZKI],:K
MZ!<TU9=5K]99L#)@R1V/LEKHJ:ZHJ*BHJ*BHBHJ=47(*A[Q]QA^&49YEUPCD
M,S"F$^\LKY$;1&'>_N[FYM$T'KIEJ1M3@W&Q_;U&.2%62SL8QHX>Y9;@D)O.
MKKJX1(9(N_7UQ2.1Y%XSD-R*YJAA"_51?EN*RMG,@2&Y,UY'774>:1S>!+Z@
MOI],$6+/B6@FP1'D*OS[%V,W%G2$E2$[P,/*\PAJA`KA,$6@.$F[!%L[XYXJ
MZ$X"8=1NQFLV4H!D/()2XY"8.HF[05W-B1:?F5.N*1M8X'QMBS.P:9<$RDE/
M2-W36.,PQ43D@RJ[!=)"74D3U55]>N*1##QIQF+#@LPFWFSJHTR+6DLA[],)
M^O>U5"W*JJO0O4?IID6+ZAK"JZ2#6E(<EE$8!E9+Q*;CFP43<1$JDJK]UZX%
M-,\;\9ESY,UP9`NRYL:S>;"0Z+2RXB"C3J-H6U%]@[M$ZZ=<M2(\_P`5\2FM
M/BZDIMYZP<MPELRGF9#,MX=KALN@0FV)"FB@B[=/IDI'35M;$K*]F#$%1C1Q
MVMH1$9?=5(R52)57JJJNJX5Q%!P!QSD/(+"\;=2-*NALZZ(,A2CN(TPTVTZZ
MR.GO$VMVB_71?IEJ1[/PEPLHZQE.P2/\>5"!KYK^P(TTT-UD!5=!#<**F*1?
M2^$4\FTA6A.20FP8;E<#K;YAW([FFHO(G0]"%"37ZXI%0/B'B3:5O8<G1RK(
M@5PFQ,>:*1#:)2!B4H*/=`55?7KBD6L?@M0U?-71O2I,F*Y(=@M/N[VHQ2AV
MO=E--PB0]$%244^B)D(F\FXW7\CJEK+`G1C*ZR^JLGVRWQW!=;]W7IO!-4PN
MXJ9?C:AE.SW7'I:%96,6WD;7=$23"V=G9[?:'Z0ZC]=,M2*_^[:NHW&[FD^;
M-LJM9LBJK'9JMQU.<N]UCJ*B(&?74M=/OBD6W!>-?LT*9)>BM0[*ZEN65E'8
M)7&VWGM/TQ-4'=M1.JHB(JZK]<A&_EO#*SDS$493\F'*@/?)@6$%U6)+#NU0
M)0-$)-"$E$D5%14RU5;(\843Z2NY+G$LRI.C?,G]YE'<<)UP]YB1=TC,EW*O
M]&*D:9?B3C<M)HO29W;GPXD-\`?V>ZO_`/1I(J`H0OMZ="1=/PQ2)$/QQ!CR
M*B4[;6<Z93R')3<J6^#KCQNL]A1>U!$V(WT1`0?OZY".N5.BHBZ?CA7%5GBF
MGKCAFS83B*"Q81F5<)E?;:.=Y\BT:34D/J'V_'"1H#PYQQ(S$-V7,?A-TZ4,
MB.9M[7XK9$;1.*((2.-D:J)`HY:1>\?XBU537;"1.D6EDY':A_,E=M#&.RI$
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M+&TLYEN_;3K?XZRG'FV6A0HS?:%1%D11-1]<*Z7`8!?3`^4-\RNB\@2J&SN3
MH[1+(/V>KDL-)!L*I-NOQWU%2)\AW:^_5"Z;=,)5Y7^7^/2[5BO*#81&I$V5
M6-V,ED0B_,B;U-E7$,EU)&R45TT^FNN6*]+Y>H0CN2GX,YB,5>_;5SQM!I,B
M14U=)A$-5W(*H6QS:NU=<@\!YAX_VI92(<R&]'2"3+$H&VB?"S)0BF!*YL$2
M-%%>X0[=.N03)ODJ%%9%5JK!R6,4Y\V`#0=^-%:<5HG'14T1=2%=@@JJ2)JF
M4>J_R92V?(FJ.MB39I.,QI16#+.L0(\QDGF'2=4DT$D#;Z?FR")Y7O[2D@T<
MB#8_MC<NXBP9S_;;<TCR-V]4[@F@DFWHN7$W4#AWD*4'&[F\OI23*&+.[%#=
M"V+)SXY[`;)`38"KWB5M#3:)::],%36_,''W641B)+D6"2)$0ZQE&3?[D1M'
MG=B]WM.?IF)#L-5+7I]<%Q)D>5.,L7[5,YW4<<E!`61H"MA+<:[HL&._O(6W
MHJ]O:A=%77(J$YYHXTQ&GR)D.?%2!#:LB9<9'O'$?>[`.BT)D8^]4U`T$M.N
MF5*F/>3ZUMI3*HM>XR(NSXWQ?UXK+CQ,MNO-;]VUQ0(A0-Q;4UTP54<4\B.M
M7-A472RY)O<AF55=8=@!C-[`1UB,;@[/<H(6B[5_%=<*^C//-LL&\Z2-M-BI
MN&JZ((BFJJJ_@F!P?CGGEK?75W7VS01W![%I1MIHBG43!5&"/I^=";+?]MR)
MC1*8\M<;>)O9'FJQ(BRI\*2C&YN1&@KH^XVHDJ]%TT0T%5U33$2M/]\O&?VI
MFR6)/!J2V<B(TZP+#CT9MH'CD-"\8(3:"Z*:ZZJ71$7(J0]Y=X8V["09)/1I
MRPQ&8VB*TV5BB+%1S4A<3N(2>@KMU3=I@:6O,7&WI###,*R<.6[+C1-L0M'I
M,`B%Z.'7J?L)4_JZ)ZY1F5YDX;'IHMNIOG&D12GN`C:(ZQ&;<5IQQYLR%4V&
M)"HCJ71=$Z81M+RQQA+0J_MRU5N=&K7IB1R^,#\T`.-JZJI[74=%$5$^O7"K
M#A7,"Y,Q9O?M[T`:^?)@"C^W4UC&K9%[5+^LB],"#;<PDCR>Q@1!(XG&ZY+.
MV;:$2>?-Y'%8C-[]$'VLD9=?\5/O@<RQY=D#9P+.=%EMTDSC273M8S'1]YHO
MD(AO*0]=@M+KU7T]$UZ8'4V/E/B4"7'CNR",'RBB<H!16F5GZ?%[JJJ$G=U3
MT%=-4W:8%QRJ9=0Z1V330RGSP-K;%;5M#)M711U0[J@&X6U)4W*F!QG+^;<L
MI*J1.F0G:N"U<C%DVHM!,1BK(%(9@--J1*F[:!J:>U57HJ)@1+;F/(XG':.Q
MC\@KY$6UO&8+=TTTV;+E?($E%U4W[`=!15"ZZ?A@=#XYY1:WE=:2+!QF5"A3
M7&*V[8!669T4`$N^(*I)H)*0*0KM+;JF#$;@?.K/D-G?U\]D(;K/:GT/357:
MJ6"I'>)->I;VRW)]-43"5[@KY15EE9+\174K7"=3X^Q"GMOZM?\`.'M!UE-#
M#^IZH66%=%Q/D,;D?&:^\C"K;4]@7NT7JV:]#;7\0-%'^C(KCPYU8.\EMW'Y
M+M=445BW7K"*'W%FJZPVH`VXGZG>-Y]-B#TVIU3KJEB5;R?*_$HT=IQXI2/N
MR7H/P1BO'*&5':5XV39$5)"5M-P_XR>F0J\N^0L5/')MZZPZ]'A13F&RV"]T
M@`-ZB@+IUT^_IA7"M>6&XUX[(MN[&H3I(%H$=(SAO1RDO.-NN/$"+HV*(.I+
MHB>N$KK)G/N-P[AFI?D*C[SX0Q>055E)3H=QI@G/1'##J*85.Y)R>GXY7MS[
M9Y6(SC[483$#<7NOEL;'0$)>I+I@5,?R9Q:37+-8<>,AD.0B@JPZ$M)#(=QQ
MM8YH)HHM^[JGIA*\1_*/#IDV%!ARW)+]@PS*BJQ'?=!6)&]&W",041'5HD7<
MO1>B]<%0Z[R;0P^.ULRTL3GF]"&=*GQH;P`,<S4$DO-(AJPVJII[OLOV7!6K
MG_D9JKCM1Z9]'+'YU:S(-&#?CBU.D`.PW1_3`W&CW!JOV7ZIA7;V$^'70'YT
MUT6(D4"=?>-=!``34E7^"8'&\B\J54+BM[:U[;SL^G:%3@/QWFG0)]/T#<:(
M4/M'KKN].B]=<L2KRB6_&JD/SI#=B\9&[`_0*$?;44V-/`2EM+?JF[3TTZ9!
MR$OR!ROC4B\#E+,*8W7TY73#M:CK2`HN*TD5U'2/53+\CB::Z%TZ8TJXH>5<
MB.QMJ&V"*5S"KX]I&=80P8)N2C@]LA4C+5MUDDU1?<*HO3$*\5'*>0W'C:JY
M&R[7UTV9$"7.DS$<6(P.U2)=J$!*FJ:=333*J^X7;S[GB];:3V6H\N8RCKK;
M!]QKJJZ$V7^*8Z$GX+D%=#\D<?D/7+;B/1_V:>-8:N-.:O2"`"$610=QJ2N:
M(B=5]?3`NZ.^J[R"DZM>1Z/O-HET("!QLMIMN`:"0&))HHDFN!RW)^2\TI;B
M%)^'!=X[*L(M8D?<Y\\OE&C?R`)/TM!)=>WIKM15U^F,P18WDF<[:,R2CL_R
MY+O'>.QW$W=_OM(8)(557;L.0T3>W35.BZ_3"5=T'*9DSD/*JZ<VPQ'X^_';
M9?`B]S3\4)*FXI=$4=_TPK7PWF,GD-UR",<48T2L=C)`<U7N/,R8XOBZXB_E
MW;N@_;UP.LP.8\B\ELN-<8=N*]EE]]E^*RK4A30%&3(!A>H==1[N[`K'>8W,
M_G4GC5.49HJ@8CMA\IB0J/B^IJZ+3@Z"TH`&H*N[<JZ94J\NN8U51=T]')[G
MSKLW0A[6S,$[+:F2F0HJ)]$_I^V15!P7RE47%,R5O-B1;H6I<F9&;4@;!B(^
M;1N(1ZIH`BBE[M4UZX2IUCY5X;#JG+(9BR&6I$6*;;3;BNHY-5$850(4)`,5
MW(6FBIZ8*Z9^:+<!V8`$\(-$\+8(N\T$=R(*+]5PKB^#<\O.4P85I&9KWJR?
M'=<,XKSAN0I`(BC&E`0HN[JHDJ::*GIZ8%=Q3RO=61<2.RK8P,\N%](X0WC<
M>C''$C4G0,1U:5`TWIZ*J)]<)5]RWR'&X]R&AJ7(ZNM6D@69TM%T&(+^K<8S
M_P#EGTV)_3@KL,*YEOF$&++N%L["$$2#+;B,(P3AO`9LBXK;X:?VOJ2(&OLZ
MX%_"G1)T-B;#=&1%D@+K#P+J)@::B0K]E3`J9'.N)1W)C;]K';*`V3TO<>B`
MTVNUP]?11!5T)4_+]<L2MZ\JX^B2"6P8VQ&FI$DMZ:`U(35DU7[.)^7[XBM#
MW..)LU86KMK&"N<(@"0I]%)O7>.GYM0T7<FGM^N(E;"YAQ@6I#RVD7M109<E
M.=T=K82?[`R77H+G]5?KB%18GD'B4J5;QV[!H3HG$9LB-=@MFJ"NFI>NBF@_
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M1?%N2JR`%S<RPHKO``--24DUZHFNF#46_P#*<FFF<D1RC.17\6;CR+*6U(;0
MU8D@KF]MHA'<H"*[A4D_#7"5>\MYM7<;XC(Y,^TY)C--`ZS&93]9Y7-%``%?
MZRHNOX8*NJZ?&L*^-/BFCD:6T#[#@]4('!0A5/XHN%2,!@%P.#N_'MO<FD*R
MMFI-(-FW:,`<9?FL=IY'P89D=S01W#IOV;MNHX9G1SW"N(3[T))6SG9IHG([
M6P:K3C.,ON.&ZZ#1$Z9=6MKJN#M#KTZZ9:F8L5\263M(U4R[D'V:NMFU-&[\
M=4-MJ:VC'<D?J?J&VR*`FW:B^JXJQNE>,+)R1)>&?#>;E5U=62(4N'WX[K4`
MC5Q'!5ST>[BZ:=1T1=5PCQ6>*[6F;B%470MRDKG*F><ADG@*.3QO,*RBN;A*
M-W2!O<1(H]%Q5BYXAP%>-7<R5'EH[6O5]=718BAHXV-<V38F3FNA*>]=?:F1
M8D\YXK/Y"-,,.8W#6JLX]H2N-J[W%C:Z-IH0;=V[JO7&&XYR9XA>*'<U-?;_
M``J&PD-V=9#1E#*NL6W1?[C"J6U6#='<K1#IU71>N4CS<^,N27="%;<6U?.=
M<5TY!%7]IMIQ1$6'X?;<%QEUE44MV]=RKUZ:81*K?&U[6<@D28?(=*::X,J9
M&<BMG,66C0M&;<I5]HND".&FW77TTPL<XG@SD"PI##E_%)R35I5/O)")#<4)
M8ROD.'WE(W3VKO55]5Z:8Z)U=?<<)Y&[RH[ZCODJDL8S$2[86,C_`'!C*:MN
M1R(D[3B(Z0]4)/KID5#;\:V@/MG^Y,J(<F/DFBLGJH&V3?QU7?ZZ%^?_`',H
MZ7F5)97?'Y%3`E-PRF;6I+S@$>L=23N@*"0:*X&HZ_37(JBE^/&8'+:?DO&P
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MTV]+:D0K"RDV,,`;4'&TEFKA@X2D2'H2]-$3ID%=*X_)C\XN)"`95W+*YJ&Z
M^`[NQ+BBZ"*>GH+C+O1?3<.GU3`IJ[Q9R!B"+$BUBNNAQAWC(F##@CU+])]4
M5PORC^9/JN$;:_QA>UURU*AVL-(4EB`W:M/0D>>[T!@(_<B.D7Z7=;:%%0A+
M;ZIUPKZ6GI@4_(H-[(2(Y3RV8[D=Y3D,26R<9D-$V0*T>U14>I(2%U]/3`X9
MKQ)/88BC$DPHVG(@Y'*AM-&,0-@=OX\<$7VH?YC)?4M>F42_[NN0U]5=<?HK
M&.UQNS<WP8<@'%<@MOFBS([)@O\`9.(I[$Z;-WVR&)9>.@K^:4G(.-C%K(\%
MA^%:Q=KBK)C.[5;;%470>R8;AU_%,J9CK+FS*NK)$L&')+K0_HQFA4C<<7H`
M"B?XQ:=?1/7(JK\>\<D\<X554THT<EQ6E648_E[SIDZZ@_@AN*B8-<Y/\=7D
MIVYE-SHS,Q^\BWU,2"XH`Y%9;9[4E%_,)@VNJCZ:_AE9;&_'MPO*('(G9,9)
M7[J=G9L`A[-O[>L!MIDE1%51%=Q$2)K]L=%=ER*K*VX_9U0N=I;"(_%1W378
MKS9-[M/PW9%?.I/C#E4NLM8\F;!218\;CT"*V+W;%Y@G-75UZJ"BYZ>NN7HS
MU6,#Q_?0N6R)[;M8[3SY+5C)21%5V>S)!H&W`C/+[4;-6D5%)-P_3(TD>9''
M0XQ7DSM[Z754K*N(2@A),!=3V(J[=$ZKE2JFT\8\A?GER".]6GR`[)Z:[#F-
M./5YL.Q@B=E>B'O%MD2[FW\VO33"=5]QKB%Q4\A?LG7(1,.U,6O!J,V4<1?C
MO//$HM"FP&E61HB(NO3"N<J/%_*ZBI6#&F072GT;=':H[W=@*PKR-R&/:JE^
MG()";+3KIUR#S/\`%7*66YM533X14LR963T*:COR6W*Y&`-M.VFT@<&**HJ_
ME75,I==[S7CB\EXG94B/K$<G-*#4A$W=MP20VR4?JB&*:I]4R+CCN1>/N5<A
MKK^1+=@1[VXK8U2T#1.E&`([QO&Z9J"&I&3B[1V^U/JN5'T5SYGP3[8MK-[:
M[!)2[7=V]$4D3=MW?7373)H^=CP7F5O57U5R8ZL&;Z*ZW,FP5D.R"?5-K&B/
M((@TRGY03_A5<9AJYH>+WK=E:WUNY'.WFP(];'8CJ?8!N,)EN4R$2U=>>(E]
MOM31.N#&OCM!RCC_``:@X^$:!9/0F1B6HO.N`T32"J;FE5IS=UT]ICE/1<\&
MXT/&N,Q:43$TCJZ?Z:*+8J\Z;NQL5]`#?M%/LF0S7'S.!<K"WLK&&]#)1OV>
M0U;;AN#W?]$&&_'?]A(W^FB[#'=UTZ8-=9PWCTBI2WE2U;29=6#EC(9952::
M4VVVA;$E0=R[&D4BT34E7!BGMZSR#)Y2$YF-4G6PS1*PY#\GNLB:(+SY,BUV
MS>45(0]_1/XKEQ*@1/&UDU8Q8*NL_P`MP;Y[D;!;B^0KCN]P8Q`H[40)#I'O
MW=4T33&BR9X/*EVG-$LW59KN3.Q#CG#>,)(A'C-L&A%M1!4E:UZ*O1=,BXBT
MG".1\;M>4VE?-*SD6BQ/VQFRDF0+V60;<*0HMZH7M7;MUZ:9=U7T`==J:^OU
MR#E/)M!<<@XH]4U(,%+=D1'=TEPFFT&-);?+W"#BZJC6B=,#-'274;G?(+J2
MVR-=:QX+478Z1NH<07$/>"@(HBJ]T5"7TP'+*.ZE\GXM<5@,.A3/R5F,ON$T
MJM2HZL[@40<U(%Z[5TU^^!QD3QQS2/4\>892"W-J8U\VZ9FKC2/6F]8R[":T
M<!%).XA)_APD1%\;\\-BY?6-$25._8I+0.3WGR<D5+_<>!UTVO:CB?E44VIZ
M(.$?7W5G'7N=O8U.)E=G52`7E'IUT15%"^NF&GSNIX3=M\PA<G2JC4E@$5YO
MD2P9&K5J\;:"VBM(("B`Y[^X:;D].N!5<-\9<JXG$XY:U[$1+Z&P5;R.#W?T
M9<,WB=%UIW9[7FB+5-1]R:HOTPBUO/'5IR2DY2=FKD:XMB)*]EB5^B#<1/\`
MHY2Z:(0&F\NGYE7`[SC9W9T<%;UIMFX1D$G@R?<;[R)H9`6@^TEZITPKYW<\
M%OY%ER"3\$G!G7,>RK)4*<,68PC,!(W?;(AV(:&*HH'J)`2_PPE=_P`5BW$/
MC=;&NG&G;5F.V$UR.*`T3J)[E$4043^A$3"OF_&>"\HI4)J3QVOLI%.W-:JK
M1R:X2RVYI*O;^.XB@QN0OUM=4+3IZ]"1J/QQS*#QR?QJO98E0J^?#M**0[(5
MDI+;!@X<"00?J-HVHJ+)ZKH.U/IEJ1):XERVKF5U_5<9A*X96`6?'3GJ9:3T
M9_TA9;PF)NZL:.(B?E71-<58A<HX%SDV;^'65$%YN_IZV&BL2!C1XKL`W%-D
M&R'<H;7$V*G3IUTQ2)%]PKF[\V]>B5[;K97D+D$(/F_'^6+,9MAV)O;1#9,%
M!3$U7;JB8I'J+P[DU5-@6M=QQE6'X]DQ-I/G(ZXP]8.-N?**0^JBX3G;5'=O
MIKTUZY%QW'C2HLJ7@-%46;(L3X$-J/):`T<$3;3;T,>BI@?+OY&Y^]()QZC!
MM$K+^L)MJ3&",)3U0XRQV!TVMGM]RG[]RJI9<3=2;#QYROM#^WU+;?9H:1@X
MRNLMMR9-9-22_#/;K^=M%%#5-J^GIE*[CQ_7WC5]RNSLJA:=BXE19,-@G672
M5`AMLN*?94D0M[?7KDTQ0<_XKR:;>\K=KZOYD>\XS^VQ9(.-!ME-F^O;-#42
M]Z/#H2=.G7&&JFZX'RPIEA(JJKMM)#X^X$5MYJ.DMRL=,Y,;>"KL+:8[35-%
M4=-=,:8[_P`<U!UM5*-RJ<I7;&6[-<@OR?EO;W$%#<=-"-M#-4UV@NG].N17
M)>0.*VUO;S)U=12(7+(KC8<<Y7`>::%6E$%(9NK@D38%O0@,"U'\N7!"Y-X[
MY'><@Y58-QB:E(55*I7'S%8,YVO;)'8\B.)EJVX1:)W`Z?F3TRI72OQ.0\KN
M:A9\";QZOKXARW-RQ'=9[R*PK"]7Q46V2/0MO7=DB)/B6NOJ7C[W'+6(\S'I
M93T6EEODT2R:Y#58QZ-$6U1#V*BHGHF1IW&`P&!Y5P=VW5-R^B:]>GK@>4D-
M%NT,545VDFJ=%^R_C@95T$71537[:_?"41UM51$)%54U3JG5/NF16$>!=VTD
M7:NA:*BZ+]ERI4>;<5L$&3ER&V!D/!&84R1-[SB[0;'[DJX*DHZ!$HHJ*0_F
M1%35/XX**Z"$@*J(:IJ@ZIJJ)^&%%=;1%551$%-2553HGXX@RAHJ:IU14U1?
MII@85UM$U4D1-=-55/5?1,095P$)!540B]!5415T]=$P-,J5V8[[K;92'&0(
MTCMJG<)4%50$U5$U+T35<#S6SCF5T:6['<AN/M`XY$?V]UI2%%4'-BD.X==%
MT5<#>C@JNFJ:^J)JFJI]\(J9/)XK'*H''28=6181I$IJ2FWM"D4FQ,"]V[=^
ML*I[<%99Y-&<Y9*XU\=T9,6&S/602#VC;?<-I!%==VY";775,0JWW)IK],*J
M.0\GA4B0@>:=DRK)](L"(P@DXZZHD:HFY0%$$`4E4ETTP*B5Y,J(M;'G/P)X
M_(LQIOC*R*/!,<)``3%31-I$O0T54PE6+/,8,BPN(<>+)?2D!"ER@`58)S9O
M5AH]WO=!/S#]/O@J1Q?DT#DG'H5]!!UJ#/;[T=)`HVYVU5="(44M-=-?7"ME
M'?1+J#^X1!,81N$$5\T1$?`5T1UOK^0EUVJOJG7TP)4^?$KXCDR8\#$5E-SK
MSBH(BFNG55_%<#=NZZ?5?1,#3'L(4AR0##P.E%<[,E!5%[;B")["^R[31<"!
M+Y+$B\DKJ!QEU95FS(D1WD05908NS>)%KN0OU$TZ8%MKB#G[GF46MM1JVH,N
MRFHTW)DM0@%PF8[KO9%TT(@54WZ]`U71%73$$3D/DBDI+;]L<C2YCS+?>GG#
M:[H16E;-P3>]PK[A:)4045=$UQ!(E<^IHUY$J7F)8_-=&-&L?CG\(I#@=P&>
M]_CD/ITT^FNN6!'Y[3.\B&A-F7'DO=[X<E]@VXTA8W5\672Z$K:=5UTU3JFN
M1*Q0^0*"\G-PX?>`Y+)RJ]U]M6VY<=HT;-V.2JN\14D]=%T5%TT7(K?R#F%;
M1RHL5^/,ER9:^QJ#&=E*`[D'>[VT7MAN73<73+"O#G.*=KD3%"\W*:D2G"8C
M2C8<&*X^`*Z3(/*FU3V"J_;HO7`K(?E;CDVU9JX\2S*1)5\89G!?;9?6,!.'
MVGG!$"U$/:NO7$'455K"M:]BP@.H]$D#O:<3Z_145/5%%4T5%]%R"#_-E05W
M7T[9$\_9L29,5]M$-A0B&`.HIHOYD)U.F5%SA6=,@@V=Q!K8[KTD^K3+TCLC
MHKAMQQW.*`?UM$5/\.*,TUK%MZB%:Q-WQ9[#<EC>FTNVZ"&.Y.NBZ+E2IJKH
MF%5?&^15_(:H;.`C@QB<>9VO`K9H;#I,FBBO_+!<#')N25W'*:1;V*.?"C;.
MZK0*X2=PT;1=J?3<2:X%KUP&`P&!$M;.%5UTFQG.(S#B-D](=+T$`355Z:X$
M.IY-"L8LF1VGX(1'59?&<TL=47:)(2;^A"2&FA(O^[A*]U7(:ZTL+6!&4_DT
M[XQIHF"BB.&T+P[57\R*#B+JF%6F!X[S:/(RI)W%%30-4W;45$5=/MU3`P^^
MTPT3KQ"VV'4S)4%$3\57"5LU_#"JZAOZZ]A',KR,F&WWXI]P";)'8SI,NIM+
M1>A@N!8X#"4P4PKR;@`*D2H(BBJ1*NB(B>JJJX2LB2$FJ+JB]47"LZ8#3`82
MJZ!?5<^SL:V*[OFU)-A/:VDG;)X.XWU5$0MP]>F"HT[F-!"N&:A]\OG/.-LH
M(-N.`#CR*K0NN`)`VKFU=NY4URPJZ1=?ID5Y,T%-5Z)^/X],0J#57U5:NSFH
M#R/.5LDH<T=I#VWP$3(%W(FOM-.J=,)5AA3`8$*SN:VK!AR>\C`27VHK)*A+
MN>?+8V'M1?S%@3,)4%V\JVK>/3NR!"SE-.2(\5==YM-*B.&G3305)-<"?A5/
M<<NXY3/L1[2<U%>D*`M`>O\`SA]L%+1%VH1KM12T37IA*2^7\7AW+%)+M(L>
MWDHBQX#CH"\>OIH"KKU^GWP5O3D5)^\?LRS64M=N_P"%O3N[=-WY?X==/MUP
M5NCVU;)FR8+$EIV9#V++C@8DXUW-5#>*=1W:+IK@9A6==.5](4EJ0L9Q6)/:
M,3[;HHBJ![570D14Z85(U]VF$CUA3`8!<#X#2T#$GD3\BG@R_P"8('+Y[CM@
M"/`T-:&JOL*\J]O8ZA("`G7?HNG37";J-QGADN\>FU,JJFTL2VX_VD,XSC#4
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M-U$\W%O)7\RQVV5>EO5PR991ML:1N%UILG6G-B#U3+$=Y44_Q/$-C7Q6+`FG
M(<_X$6>*?,0'4<5IOM-HFSJ6C;>FHCHF1MP-CQ((%'Q87JBT<X_.JE&W:@Q_
MF2V[=QEAM'WV)".$)]ML@%Q$U`OMKK@7==6.,<H"!?4-K93A=K7N-W*ZN=AF
M,P`$$F4!"+1-N(9/CZ.Z^A82JOB-)8JEFY:P[H.1QZZRCWAFPVW#E&]N4"%Y
ML$<F*:HBL^Y2!-?3+%38_%^1-0N(2ZV*\)\@HF..<F%P2%R,@LB8RG!/JA`@
M.MK]U(<B1Y9X_8#S^5'>BVT>VA6"R./3([#7[?\`MXQT;8:<F*)$+`(BBXPI
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MD(R8".PD0D7=Z850<J()_#.*1ZZMDR(K_'Y(1)$=EZ2VR_\`$;%IE&6O:+ZD
MGL=<_)M+3JN!?<PBR[OP2V#L*1+G+`@//176362KC)LDZJM*G<4]!)=/5<)J
MBY!!FRY-^+,":W=/%7O<"E--/`++`MMH@(2)M8V.]Q7Q<TU%>NN6)45Z`Q`F
MWL1RBE*LGEI/OR`BR'8WQGX^K+KC32?Z4"N:H@:[1-44NB8ANI_C9JX69X_2
M=&FH[`A7<:4Y+8=`FU^0VC(N*:>W5L-!Z]=.F(N++R%%=D<CN&K>+,?AOTX#
MQ5Z&+Q]NP$G%<0%9_LY"GVE`BT]J>NFN16SB52Z/E9R9;1"*W#CE<,FP[1HT
M<X5<23M=1.VI;2'5$^F(*WRJ0Q^7Q;.A9EP^:1`)J(8QW'H]FTL<S",8HBMF
M.\E!354)O7773`ON139-MR'CX53TH+>GLF4LZHF36%V3;7Y#IFXV@%VP+1IP
M#_-T3*E9DOI>\_JIE3(F/Q(X3H%Y!D,&U'89[:CW&U=`"%TWA`4(27<&OTR$
M47'J"13W<"<LF5-XEP&MFL0Y11E1]\Y&U.RT(>]\8[#6U30?<6FFNBX(G\P_
M8.0S8=GQSY;7-09A2*F>R$ED7(CKHN;'2T1@VMA%W`/J/\<"QOI9VW.*!RDD
MR7)--8.1K:N=8,8@QS9-')"DX`^\?:+9@2ZZJGU7"K>&P_9>0YLUULPA4$0(
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M/HT#BIL?&+W!0`VKZ?AE1]+\5#$6!8OP)TR95R92.PQEQW8H,ZMBCC<=M]5>
M[>Y-5W=-RKID7'SBF8G0@9>K7+4;>%*OEY#7L./B@P%62ZT@-N?H@Z3A-DP0
MCJJKKU37+!!2?*>XAS2$VLIV+)KJ:3`C]N8X'<-S8_L.0BDX>Y![A)IJO71,
M1*O9UP__`'A*XV]81V_W6Q@S1-99D315Y]DMP(C#;"NB*L"**O\`6W:ZY$U5
MPI7)ZZFKWJV1:R9L[B+,JT`G)#SQ/,RV!?)I'5+9(2.3R#MT+I]TRBWMKJH;
MB0IE-.M1X1-L'4MI,AJ<\TR11$%D6Q56Y2,=[J:HNW?@=9)+DD+PR\M5+FV=
MPS`)8TUYI6ISH(2^]&UU)'>SU#7W*NFO7"XXGF0-2>*\V2FDRIG$G:J$]%0W
M)#NVQ)TT<!E357.K:-JX'HA?377(:[3RY7Q"\426FD=.)'*"_P"PW2/M!+9,
MR547N$B!JJZY4<?/=5B_O+JOERVD:Y/0A&5LY`M%'>C167E<#_G1)M20E/73
M3Z8@MN$65A/YNB3[:8S?PIEBW;TGQW^T<53/XI&X9JPC0-HVK1MBBJJZ??(N
M/'D)9\'R'93JH7UO7N*.I2H"O$AR6GS4Q`$7MJ8MZ$B*GKIA5!S16IW'+Y*6
M;-L.++65TR63CLAWLS@G-]S0E530BC[B>;]$TU5$PB=8\M;#GT(ZZPF-LLWL
M&&Z#[LDM\&1#7\C.G92,9J*B9[C(]5U3+!W'BU\$XK:N"I+I<W)^U-2ZSWC'
M:B^NHJBI]\A7R`^:6?[/<%`NIS0R^/)*8(GY#DH9C4\1,G#--@2$;/1QMH4%
M$Z=?7!71<CD3JMWF#D3D%FJ4;])+K4.6\X*.3"!).J?\XV8^K:Z@.JZ(F5%H
M%W</72$-A*;Y8SR98;M,KIJP50;NB*D?\G:^)H\CR#KO_K?3$%/#YI9*S15Y
M7<O]QC+R:/;`KCBN"K`/%$1XE3\X((DWKU^V1I76DNV?X;+C.W%A8?NO!&K2
M6V\^X9?+`VT(VT'10U$B0Q'U^N$CZER6XDQ/%+]GQ9YV6H0VBC2FR)YWL;A%
MYYM3W$9`UN(?X85R=K)O#;Y$]Q.YF65/51ZZZA.C)-Y2?;,SEP4=7<3@/Q@0
ME!5]I$GIA*DT-IS.9R*?#W3%CRD'E-1WC(=L-UDVV:YW5?:OR40B;]-O3"N<
MK^;7A<8F7<3DCLJ2,&*'(*T6GS?KWBDMA,E*CJDC+C+9N(C8)HJ)N1/;FF79
M^*GJIWF?.?VNQ.SB*[6$S*<>*2J@L/Z.DJJ8HNOU7,K'.VUDY4\EY].KYL@4
M2TIF;-]MTC6+"?::&4\(+JB=L=R(6GL_HRU&;:YN`G_M=;R*4E$YR6MA0+0'
MT<<)F9',Y<49!H?=%LMJB2ZJ*KIKTQ6G4^6HH0O'\!N18218A6-2,FP5]6G"
M:&8T#CC[H[4_+J1*O37KA(X]FU=@\CL;.ON7&FRYM"KW8H.A\=YB9%CMN=U%
M34R4?<):]%3ID%MXYY1<7/*6"E\B;2=OGLW7%U[IO-$TXJ-?IDB#'1I$30_1
MS7ZX,:/(UY=1^3<L88Y5(I_VFEAV5/!;5G:[,4WQ0%`P(W`<)L`4$]57+BD;
MEO(YW.2B2[YBEL8-A%:/C[I&IOPG8S9'VXZ#H>\S->]N]FWKHB+E*C4O(.1C
MP;B_(I'*9,IZ\O*^'(1SXZ-"RLUQIQH-H)U,-$/K]/ID1+KN7\B=?J;1FS=D
MW,JVG5]QQ8E#8TPPDA106D1'&R:%ELMZK[MW7U3`C<%O8]QSSAMH[>K9V-C1
MV+TV(9MZ1I!.1B<9!H4$F]BH0;2_Q?XY%7?.N1W`7?(X35RY1.4M.U9T@CV]
MLMY5=5Q31Q%[HB38-*`_XWW5,N)K'%$=L/+5G*FR'`EGQ^I?DUBD"M@;I/J;
M:MJ*EM`NJ=?5<:-OD23P67-_EV1,KH4IR9$LKR6\ZRV\R$9P'6]-51Q7G>T(
M!IZ#JOX+!S!$^KI1$5/YG<\A"\@_\ZD=-#%S3\W:_;TTU]-.F!W7&%:3RYS<
M1V(:Q*=2$=-R^Q_J2)UP,^,^S^\<[1M1U3D+NY!TZ+\2/ZZ85RO*N16='SGE
M\IFU=;48U&TRRZ39,QF)<@V9$D&E'71D54]?35?=TP.SX396I<@Y'2R9Q6M?
M5N12K[%S8KBI)95QQAPFQ`#)M4UUT_*2:X'98#`P?IA-5%%34E,4V-6(@E*D
MN3IC2NDZ7?D*BF:H9$H[OMZ8&.047'^3P'JBU;&;$1QLWXPN$*H;:H8(?;(2
M3T]%]<"SBC':C@U'0!991&P!O1!%`]J"B)Z;=--,#8!@:*H$A:*HKHJ+HJ>J
M=,*SIA(SHGVPI@:4E1OD+'1P/D('<5G<F]`5=-VW7737ZX99:DQG77&FW0-Y
MG3O-B2*0;DU'<B=4U3TUPTPW*BF\;`.`K[:(3C2$F\4+T4A]4UTZ82MW3"FB
M?;`:8&HI$<7A9)P4><15!M51")!]=J+U73`V:81G"O#[K331NNF+;0(I&9J@
MBB)ZJJKT1,(J*CB]#7VMA=PF?]/ME$Y<DG#=W(B)H@;R(0#Z[0T3ZX5==,!@
M>!=;)2$20E!=#%%151?7K]L#TA"NOX>N!$K*VO@`\W!:%EMYPGW&P_+W'.ID
M@^@[EZKI]>N!*$P/J.BZ?7U],`!MDI(*HJBNAHFBZ+^.!CN-[E'<FX4U(=4U
M1/NJ8&1(2].J+]4P,D0BG541/3KTP/!/,@'<(A%M.JFJH@I_3Z8'OHJ(O^#`
MSIA#"O#S+;S9M."A-F*B8K]47HJ=,`VT#;8M@*"V"((`B:(B)T1$3"1[PK5)
M8!Y@V34A!P5`E`E`M"33H0Z*B_PP-<")"@Q&8<-H&8L<$;99;1$$1'HB(B8&
M\S$!W&J"/IJJHB=?XX`S`$135!151-55$ZKT3UP`N`2>U4)$U1=-%ZIZI@`,
M#34%0A^Z=4P,JF$C*(GK]<**F$8541-57I^.%84Q33KIKT3""JB?[^%914+J
MF`T3!@@HGHFF#3;A(:8((B:KT_C@9T3"FB?;`QTUPD-,$-$3Z8(QM'_%3_!@
MAL#=OVIOTV[M.NGKIKA38WJOL35>J]$ZJN`[;6NNQ-=--=$]/M@901%$041$
M3HB)@>09:;':V`@.NNT41$U7^&$CTJ"BZZ=?OA7E&FDW:`*=SJ?1/=].OWP#
M3++0[6@%L=$3041$T3^&!CLLZFO;'4^AKHGN_C]\(P,6*+8-BR"-MKJV""B(
M*_\`)33IA7IQMIUM6W`0VRZ$!(BHJ?BBY*/"PX?75AM=20U]@]23T+T]<HR,
M>.+IO`T`O.(B&Z@HA$B>FI>JX%$UPZ*/,9O)7G?D.2XT:,$1QIL@9^*1D#@&
MJ;T)5=+7*+PH<0Y"238;*0(J`O*`J:"OJ*%IKHOVR(\?MM?V@9^*SV6RWMM]
ML=HEZ[D331%_'!&0KX`2SF!&:&6XB"Y)0!1PD3T0CTW*F%>6*FJ8?*0Q#8:D
M$I$3P-`)J1_F521-=2TZX&95=7RG&79,5E]R.6Y@W6Q,FR^X*2+M7^&!D(,$
M993!C-#+--IR4`4<(?LIZ;E3`COT%"_)64_6Q792DAJ^;#9.;ATT7<HZZIIA
M&_\`;H'S?G?&:^;L[?RM@]W9_B[]-VGX:XI'IJ!":E.RVX[02GT1'GQ`4<-!
M]$(T34M/QP$:O@Q7'G(L9I@Y!=R030""N'_C&HHFY?Q7"M;]35OR#DO0V'9+
MC*QG'S:`C)@EU5HB5-5!5_J^F!ZKZRNK8PQ:^*S#C"JJ+$=L6@15]5001$P)
M.`P,'Z8'R^5Q*GB<XAVG'8@1)E2$QVULD71R;)ELDC,-PUZOGO7NENUVZ"B>
MN$4/C=$9MO'DB&F^5=TE@]R1[^N\:$TYW'_\8PDN$**75-53*BUXC;O4'CZR
M*!&=-P^0VD1CXS#DGL(=@ZG=)IM")1;%%733UT3"K+P9+A.\:MF(J24;9N[+
M0Y;;K;A(<DC155U$52Z^[[+TR%1N<\\YC0W-U4PT8?F.P6K+BK':52?1@U2>
MP?O3<0`F]%Z:(N"MT?GMQ=V%/&J)K,:#R8Y;]/8&QW%2)!8;4D0%,4,W7C(D
MUTT`5RPJOK/)W*Y2HV^,9EUNDN)4A4!2!9U1+2-W6U4O[%S\VU?3[XA578\T
MDUURSR\F&2L97#:]T]4VM(],G@"$:I[NVV3VJ]?1,1'5>/8TZ+Y"YTW82&I<
MI?VDCE-,HPAHL4^I`A'U_'7(U5%S&?R&HY[R^ZH'(<=^NX]!FR_EM$XD@&'9
M)=G<!ALW"*IOZZ=.F$BQKN?<RM^0;ZR*P%-#L(\"QBR'&0<%MY@'2=WDXCO<
MW.IL#MZ$F!TWDB^OJ6F@/4A1QF2[.%!590$XV@2GD:)=`(%U'=KZX5RK?,_(
MBWLF"PW$F-<?DQ(5Z:]J.#R/-`X](#>\KK2_J?I`@DA:::_8RHCY#?6E[Q#F
M!OQ3&;5WLNKC-L>Z+LC@0-N.[]7?RIO30?=A5O*\KW\2-`DNC%[4[CD"T4B$
MA%F9-E-1MYJA?V`][<J>O3URPJSN.4<RJ),&A=E0Y]M;3WF(4V.V(*W';C?(
M076'70;[Q*BH*=SJ/7UR)KG>5\IYC><1Y'1SA@UUA7<;=FW3"HDL'G'^^TC;
M*B:"(B,=5(M2VD2#].I<U]*8<DL<`;<AN(Q)9JA*.Z0[T`QCHHDHKIKHOTPK
M@^,\OYM.IJFLCV$?]W#C;%_)FS&%))!/*H@SM%P=!107N.(NO5-$P.]HKQ>0
M\(AW6I5A6E>,G<2HJQU=:W;M5T3V:ZZX'R+Q-`/C_-UXER>OTY"K4A:_DL$S
M&/:1T99[O?Z[E>$5$]5]%7I^(8\<0;^R\.<KK:=]K]QF7MC$:=LGW4!6E>!L
MA)T=SNI-HH)HNNN`X==Q>"\?OJB50GQBY&<W%GR()2[5C1V*KK4EI21UQ$1L
M=!%>B$J:_7`M/!/)FD\(1U;F=RZ3]T[`OKM=?DMFX^O;0]%<Z&*JHHN6#Y[1
M<MN^,4=7>5BJY,E<%FV-B:^[N3`F?IR7D_K&!NKU7KIT],D'T/@$BO>;MN%W
M5=%>G)"@V#EH](,@MCL&U(/E.&/<WJX*IL]R:?E31-,"S_\`V?6)%71WO')L
M0H<ZDMY#4AD7E?BCWQ%]L8A$B*+0MF.@KU^_K@7_`)K9;>\4<H0Q0]L!TQ1?
MH0>X53[*BIT7`^?\GXE:0N(\XM"A-5''I=&RU'I&G4=$Y3/O*9L!$;:5441]
MO5=-5P.OC\YY5*OGX]77M.TU38MU=DKQ-M$(=D".0CI.HH[2=':':7<GURQ*
MKJ[R5S24LUJ/"CVDA:C]UKOB-N@VX:2NP;;*NFA2`05W`6@;U].BHN(5Z:\F
M\BL0C0*(6+&V?CSI>_XYL:?#>!D8ST9]YHVG=SJ=WW+M]4147$*^A1["S=XT
M%@D04M#B(^D#NB0?(5K=V>\GM5-_MW>GUR*^?0/*%[+;B00;!;R=,*&<4HSC
M#T(VHBR7&WX[SH;R54T;('-IC[DRQ*VKY"Y\]K`C4C*<@KX4>;:0"<;)LR>>
M<;4`=[H]H4!E2W^_15VKZ8A74>2='/'')55%3_HJ6:)KU0A8(D5%3ZHJ>J9%
M<]Q"GEM1(,Z-30ZJ=^S,I7V2OJX,B0\VA&W(:!&R5![8DI=5]=%RE<]R+E]E
MRSQ=<SI4>/'<@2($9VO0B5UNQ9F-=Y5-%7]$E45:)$U4?=B)5O;\PM'69T*X
MKH4UZHY-6045$=1I6I1L.,O"*DI(ZSWD^NBJFN(5!X9R"^HWV6!CQ7./VG*;
M6L515Q);;SDE]P'4U_34-6U%1]=.NOTR0K;XZY%=2[VB@PVHE92/5UI*DUC#
M;BCWV+3XY&)D6ONUW=?NOX:(KO>;7[M/QZ0_%$G+!]0BP&Q`G"60^NT%0`0B
M+9U-=$]$7+$KF?#-B^W5V7%)CTF1,XS+*.U(F@;<A^%(U>B/F+B"6JBI`O3U
M'(N:N.8<LGT%U4,F,<*>T21'*8]O0FIH-*[&!=%1%![:0_?71$]<%?/N1\WM
MN4^.TE.1&H\F(_5I8QMS@''M$M6VBC*JZJ(B(+NU370D^^6)5[8\MG2V4C7%
M;#DRJOED"K-0)X6D1U6G69+2?F[C??3H7M54R0K%QR:]Y#X_N[3X\4>.3ZJW
M[2BX8RV2C@X#6[^J:GL)20=-BI]<"W\?\CN9$Q*"S88!(U176$-^.1DJM2!-
MM0=WHFIB3.NH]%1<&)MUR>_6\F4O'HT5^=70F9[X37#;%T7W3`6VR'\GM9)5
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M2>R-%;-YX_L#8J1+_@3`^7^,N76,CF=E76LIUX>11AO*QAYMUM(RBJ,R((=T
M1U[8*T73[DN(E4O#HW*ID^&[3)8H[#Y/9!:V,B41PBJF9+S:QE;<=-3)$V(V
MB![=-=<*[CQ.KA1.3(X\\]V>0V<=I7W#=4&F7MK;8;U+:(IZ(F!0<EY).XYY
M`Y=;-([,:J^-1I[5:<AP&"=^0Z)J(^X`(A;1-VW`LY7DGD\2'R?N4;#MAQ^)
M%LPBLR3,7HDD3(DWJT*HZVC)]$31?OB)4Z1Y%=>GQ(53'9E):OM1JF4;I"TX
M7Q2F2#/:)+M:;VHFWJ1+ITTP54/\^8F3./.V=:3$N);V%?/[<ES9'D08CKIN
M`(H*2&W&QU%#1--?35,+5B?D6YB4?\PSZ<0HY4./*JWF'^ZZ3LMT&V8SK>Q%
M0B1T2W!N3U3U]25?<1Y!;VRV+=I5N5SL%]&FG51Q&9+9`AHZUW1;/HJJ)(H^
MJ85P//YEG4<GL9W(%LF^,2082LY'5/N;:@VQ1'4EQFR3V&:[E<4231=%T1,(
M[`.7VTZY?C4M8%A65\UFOLY*R$:=%7FP=-UD%11,&@=%5U)%+^KZ8'%\`\@S
M:>DJXMO'-VKDK=N,VAR">D:ULAYTD<;--=O:'0%WJO3*FZNH_EBQ^*;TNA?:
M22,+]F=7NMLOO6#J--1C<>:;VN!N0S4$(=OIKZ8BYJNXURVYJN07;%I&[CMC
MREBJ5H)1O-QD?KVW1-E7`15!2%5V:#IK@>Y/-7[>\XG-T<KVXU[;UTYD'B)M
MT(,60BD2(@(2*K2&**G3`O\`A?D25R2P8!*:1'K)T/Y\&Q5'5;V[D1&GE-IH
M1<(20QV$0JGUZ9#$KF7//Y?MZVL&,VX]9"2QW)4A(C3AB8#V&G"`P)]4/<($
MHZHGKEPU4.^5IC-K(:>H70I85RE%,MDDMD@.N]M&G49TW*VI/"A=?;K]<&/#
M'F2,3+DYRHE?M!17)<*<"$J&K;HLMM.[P;!LWR-%;T,DT]=,&:D<CY):A5C^
M^4\JN5JWK8S3D*:B"ZDAYM`<%T4$B`#+8ZVH^[K],8:Y>;RVYA\@Y)R2T8E.
MUW&KIB"@Q)RMM,PW8[(F;T=0VNMH4CNG_63Z?EQJ.LON6-';U4<H\I(PW[-=
M'EQI*--NNK%)XE=!$_49%54%#ZDFOTPN(U'Y?2>4!V92/P(%E'L7XLE7FWB(
MJHE1\.V'7J(JH+KU^V(JRXCY%_F&X:KTK3CC(K&+EB2CS;S:QY)*+8EMT(7-
M174>J?CD&.6<IN87+ZGCT2,"P[6%/?D3>\H.M?%`$3MCM7T[NOK@<UPGRJ</
MB-;_`#'&E(;7'VK8;-QP7CEH!`R[J*+N%Q7'0TW>NOTPE=GP[F)<A.P8=@.P
M9%<XV#BEN-ET70WB33J@WOT_*::=%P5TV%,!@<S`\9\"K[<;B%1Q&;0'#?"6
M(>]'7-4,TU5?<NY>N!8UG%N/U<V3.KX#,:7+U^0\V.A$A$IDB?XJ*9*2H.B:
M]?7*D;:>@J*9AV/5Q0B,O/'(=;;UT)YU=SAKJJ]27JN"-M?55]<VZW!CA';>
M><D.BVFB$\\6]PU_$B75<A&9%97R);$Q^,VY*C"XW'?(44P%Y$1P1)>J(:"F
MN"($OA_&I=;#K'JYE8->HE`9%%#L*"*(JT0*)!H*Z=%],M5HG\`X;/9A,S*:
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MW2<==)MK:(]MI7"/MCH`]`T],&M(>,>"!0RZ`:9E*><\DF5#U/8;Z*A=W7=J
MAZBB[D77"KFKHJJKAE#@1A9CGU<'4B4U44'4S)2(EVHB:JN$U0GXPXF#O'O@
MP&83'&I#LJN::%44#=0MPB2K[1(BW$GURF)]?P/B->LM8=3':2>T4>4.W<),
M&1&3*"2J@MD9D2@*(FJXJH!^)_'SE2[4N4C!P'C:<<;(G%+=''8QM<4NX/:'
MH"(6@IZ8HLXW"^,1($.!%KVV8L"2,Z,V&Y-)(ZZ.D6NXS]RZJ2KKD$R[HZR\
MJI%3:L)*KY8[),<B(1,===JJ*BNG3`US^.4\^A.AF1^_5.-#'<C&9^YH=-!4
MD7?]/O@5Q>/.'%?AR`JIDK@`%OY2J>I(V';!3'=L,A#VB1(JHGURU(AQ_$G`
M(Z(C-0(:,K&$D>?W"RKB/(V"]S44%P44=/R_33%(W3_%_!Y\5F-,JP?&.^Y)
M;=)QWO=Y_3O&3R&CA=S1-^XNOUQ5CH7:V$[6N5KC(_`<96.4<?:/94=FQ-NF
MB;>G3(.>E>,>%2ZYR!*KOD,NNM/DXZ\\3Z.1P[;)"^I]T5;#VCH71,M2,R_&
M/!IAUQOU+:E5-HQ"(2<!490MW;/:2=T-WN43U15ZXJQ8<NI9EUQ^551'([?S
M![+WRFW'6B9+HX!`TXP?N'IT/(.(3Q=RI&T:_<JPFPCG#:$H]@2-L.B@&#:+
M/79J(H.H]=,)"9XLY),<FN2)=,96#<=F;I"F@CH0U0H^X1FHFK:BFB^N6D;)
M7C7E<EV6Z]/IR<G2V+"47PIB;Y41!1AWI-Z*&P=$3ITQ2/<+QSRV%8G81YU.
M$DI#LP=8,LFPD/ZHZ\VT4U6P,]5W**?5<4C17^+>3US]?(A3:AE^K^0D%Q(<
MY5$93G=>$M9R[Q)SW;2U1%],5:M)W$_(4Z9`FRK>I.36.$]#)(4L!!PP5LB4
M1F()>PE3W(N*-M-PSDD;F1<FL)=>]*?82),<C,2F7'&6]5;#:4IQE-I+KJK>
MOKD'46U)66[33-E&"4RP^U*9!Q-4%Y@D-HT_$237*BOF<&XS,@3(#T)$C3YH
MV4P6S-M7)8&!HZI`J+KN:%?Z,4C6_P``XR^[(=<C&IRK!FW>)'G4UFQD%&G>
MA=-J`/M3IT],4B*WXMX6V]9.MP2#]V"0W+:%][M(DM-)"M-;^VTKNON4!15P
M1:5O$J:MLOW*(T82_AL5V\G#-/C1E56@VDJIJ*DO7UR&(_(>!<9O[&-8V48R
MF105D7FGG6%-E20U9=[1!W&E)-=AZI@UE."\=2U.S&.0NN2`FFPCAI'66V*"
M$A6479W$1$]VGTU]<M(T1/'7%XJ5R,QW$2K<F/0Q)YPD0[#=\G=JON0]Y=%]
M/IBD5SGAO@QP4@K&D)&2$M8H)+D)NB;^X#1JA^Y&R7]/7\OTQ2+!_P`<\8>D
MNR7&7E>>D0I;A_(=U5ZN%!C%^;^HB=?O]<4CR_XVXZ[\G:LME)DB3*EHS*>!
M'#FB(2$)$710,03V_3Z:8%^E5`&I2I%D4KT8^(D=/RHSL[>S^&WID5S;'BWB
MS,8XR#*)IRL*E+?*>-?@F6Y6D4B73371%]43IEJ1G^Z[BG[M&M1:D!*8:88=
M$)+PM2`B(@Q_E-B2`\K>U-%),"ZY#QZ'?53M9.)T(KQ`3O8<5HR[9(:"I#UT
M54ZI]<BHUWP^MN+2IM)3D@)M(X;L!UAU6MI.B@.;T3H:$/147IE1[XUQ2NXY
M%DQ:XGE:E27IKO?=)U>_(-3=)%+T0B55TR$9XWQ6NX\$X(!ODEC+=GR4?=5W
M]=]=SA#N_+N7Z856W?C?C]S/M9LTY2O7,!*N:C;Y`*Q1)300%$]B[B7W)UZK
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M"L29AI7V$JT;%YT74-^<!`^+BD"J0$+A=/QRD2N(^/*SB[I+!G3Y$4!)N#`E
MR%=CQ&B+<K<<-$T'IHFY55$Z)TR+C9R_@L/E&K4^=+;KW6>Q+KVB;[#P(:.(
M1"8&H&BIT,%0D3ZX1SG'>!39-U?R;GY3%>5^MI`KE-A8TA&VF48>+:A.]'&M
MVTB354153!$^+XAX^Q`L:IR;82:.>V\TU4/2=T:*CY;S^,B"A"J%U#<2[/ZN
MF4C<GC*,Y3C73;FSL#&7$FK.E/`;ZE!<1QAO\B`@(0^[0=5^JXI&BWXO+IHE
M\=3`=Y$]RR7K809#S++#*.LI')S511>V(`*$/4E^F!+C^-ZUFAXQ4MR'FF^,
M/,RXY-JB]UYEL@57%-"54+N$J_7!$!?&05557K4RI,F;0L6?[6PXXVVCSEDA
M*0N.('MT(O8J>GUUQ2('BZ@Y-5S01QJ?$K`C]J7'M&JT3)T=.WV7(*;S0?=J
M1]%U]-<@ZWD'#H]Q<UEO\Q^',K`DLMJSL47&98"+@&AB734!5%31>F%48^(*
M0H,*ODS)4B'#IG*%&U5L5-@S!Q'5(114=`FAVD.GIZ94CH>+<;ETD8VI5Q-N
MGS4465/(%,0!-!$4;%L?XKIJ2^JY!>84P"K@<4]Y6X^S,DQGXTYE&8\V4RZ;
M&U'VZY=)*M"I=SV_U=PHA?U=<)4-[S5QEEE]YR#:BW&BL6+BK$)/]!D>DKJ7
M]F&BH6ON^R+B+5K-\D\?ASBCN#(.(U(8AR[0&]T1B1*059;=/7<F[N!JJ#H*
MDFJIB)1CR30/.Q&Q"4AS+&74-"K/5)<$3-T2T5=$5&BVK]<0JF+S90/4\FQ@
M0+!Y0JY%O!;=8[*2F8I(#HMD1>H$2;M?IU37+"KB!Y"A2I<&`L&7^X26(LB6
MP`"?Q1F:HVKVA:[=07W"BHGUTR0K'*>92:WD4#CD>&^;UI"FR1L00"!A8HCH
MJB2]?<::]/\`#A:H>"^68<KBT`KI)AVS=*U;2GOBDB2@]H.G&`-5-4<)$T04
M]4TZ98E3I7EJ$#D9B+537Y9VS5--BJC0N1W'65D(1:&0EJVG1$7^.F2%=5R2
MZ"FI)-BH[S;%!89]%<?<5`9;_P#?.$B86N-I^:\@G>*K>TE.-Q>643,Z/9H`
M";83X"$JZ`O10/:))^"X*H*;R-RN4Q,98M&;84XRMVY9,QA'X,Y`$QC.;=6C
M1Q"54%?>B)UPR[WCW)5:\=UO)>02QU.N9GSY*`@"BNM"X2"`_B6@IZX:0GO*
MM!&1])T6?"D17HK,F)(8076PG'VX\@D0B'LD?M4D7VKT5$Q!.B\_I)$N7$`9
M'R(-DE3*!01-K_:[^]?=_9=KW;_MB%5;/F;A3GR/UG15IAN5'U$/])8>>2.V
M;.AJFA.F(^_:O5%],1*Z:/R&,Y1/7#S$F(S'!TWV)#)"^",:[_TQW*7Y?;MU
MW?3"USQ>6N--,27)+$Z,[$?A1WXKD8E>%;+_`-%+8"G[3]/NB^J82I$;R902
M87R&FI?REGG5)5$RHS%EMCW#;[2K]&_U%)2TVX5J\=<@N+WA#UE,D$4[Y-@T
MT\;(M$(L276FM[2=-1$$U3`Y[QUSBXOX''I,GD#$BSG1CEV%.$-`4FVD47$:
M-%]I"9!IJJZX%I;^38<_B%Q-XZ;[5C$K9\E'78_2(_"0A[<H#7V.;Q]H%ZIU
M],#PYY,KI/$K9SY<NKLJNLCSI4LX2D8MR6]1E,L'HCH;A+_!@:`\H-T_*>00
M[YY]VJB.UH19;,0B:C#,CH2E)<;14`2=7U+TU^V!)F^1@J[>='W2K<CO(M.,
M1J,+7PR?C`[IO545X2'WH7W73Z8$KR;R2YHF./N5\YFO:LK5B!-?DM(Z@,O@
M9*2:D""0J'UP,>-^8S^02N01'I4>UB4\MN/$NH@]MN0CC2.&!-[CT-E2VDJ+
MHN!-E>2N-17)K<@GVRKK&/4S-6239(E[>POXMGW!T-.G7`J+SR05?R^$T'R'
M:;XUF,N(S$-U]R17FTBFRHZDH"AEK].F(58GSVD_=8TO]WV5+M*MN,=8Z[#8
M5P$&0DCUW)O0>UIJNN(E5E]Y*4'ZA:X945$N6*ZWA2H3B/DU(C./-]H535=V
MT=%'7[+IA:ZZDY13W%&MU%=)N"/>1XI`JR;11R('A=`]%!0(%W:X%8UY(XT;
M<@R62RC`1W6T=CN@KX3"V1UCHJ?J=P^B(G7[IB%:_P"\_BPBR)E*&4],.M2#
M\9U9`2VVE>[)MB*J*DVFX/H2>BX@T,>5*&5/IV(K4ER);PY<])JM$(,MP3%M
MX715-XF)%H2:=,1*U67DFED\=N),*>]52*Z,Q*<?D0S<-IF6OZ#Z1RVJ8GHO
M\/K@J<7DOBS=PM.;S_RVYS56^Y\=U&0EOMHXT!N[=B=Q%]JZ]5PM6-+RRJN)
M;L>"CYBVAD,HFC&.XC;JLGVW53:2B8JBIB%:4YS0?OH4JFZ,IR0<)MU6C1@I
M3;7?-D753:IHWU^W]."HMMY"JJGDKE+.9D`#-:=J_/1LC9!H'$;T]J*2KK^'
MX?7$2J?D?DMMIJN>JW#85J\B5EW$D1C[X-26U<VHW^9"(5%15$7"UM+R*S96
M7%G:.2BUEE82X%HT^R;;S9QHSCJMF+FTFC`V_<BIZ8*O:+G7'+NQ.O@25*2C
M"2V1,"!'HQ$H(^PI)^HWN335/^'!7B5Y`XU&>G@XZ]VZT)!RY`L.FR/Q`0WP
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M>O8L#L$.'(B?N(NMMN.;8>J#WW$`54`0BT52_P"#!6WDW-:J@X^S>/`])AR'
M8S+/QVS,E66X+;9;435$]_U3_=Q%4E)Y(BKR.WIKJ0+3S=L-=4H#+HHHNQFG
MV@>/0A%PE,D3<J:_;$2NAB\SXY*N4IF9>LXT=5@5`Q![L+M>1EQ40'%;7\R"
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MX`_%W;>^VI"G<;W=-X:I@3J+EW'+YV6U430EN05!)0"ABH]T=S9>Y!U$T_*2
M=%Q"M'\[<<>LSJ(L]LK3<\PVTHGL*1'#>XTCFFPC!.I"A:HF$JC\?^5*+D-'
M".?816;PH'S["(VI"VV`JJ.$!.>HM_UM%7;]<0JW7R-PH84R:Y:-MQJ_M+--
MP7`5H9"Z,F0D*%L<_JEIHOWQ"K"9RBAANOLR)8B]'1HG6D$R/_2-R-(@BBJ1
M'L+01U7I@J34V]9;P&;"LD!*A/HJM/MKJ*Z+HJ?@J*FBHO5%P5+PI@,!@,!@
M,!HF`P&`5$7UP&`P&B8#`8#`8#`+Z8'R=_PU?NSGI17T8W'!M64?=@J<DV;4
M5%.\]WT4R8300Z(.U--,,Q.G^*+27#GQBMVA2=QMCCB$D8EVDRI:R/[7JA;U
M]GT^^6JW'XNG$MA!6S;6@NI,6?:Q%97O?(C(UO1AW?H+;RQP4D(54>NB]<4C
M4WXMNV[Z/,;NF4K(=W*O(T-8JJZIS6G`<:<=[NBH)/+M5!3IZXI&B/X=GA3U
M=6];MFU7TEC2..#'5"-+!1T>'5Q4'M[!]O77[XI$D_&5Y,L:*;8V<0Y%*D50
MGQH91Y8_'_M66W4=7]"0G0@-"TZZ8I%[RGA]C;<@JKB!/;AN5[$R(^TZRKPN
M-30!%VZ&WM(2:'[],A.KF`\07+53`A1[Y(S\'CKG'FY;+)">\W&W$D)^IJB:
M,H*CK]5T5,M2/,?Q'?QW79+%Q"8D%9P;:.VS`4&&G(D98KC>Q'M2$P+454M4
M7UUQ5CL.2\6=OIE2$PV'J6"\4F=7OM*?R'$!1977<@BC9%OT5%ZZ?;(.=<\7
M3XTOEHTTV)7T_*8:1UKDC$J,2>RK!2447!0E,"]PZ)Z)URCH0XQ8)P'^65DM
M+*_;?VU9J-DC:_H]CN=O=KZ==-V!$/@;DOQHUPJPF:DW!9@_N$8.VJ+'$4:>
M$"(^J$V):;LBH3WCB7<,W+G)Y;,NQMJP*CNQ&29;::;4W$=03,U5Q7CW^NB:
M(B94>J?Q9!@7)6;TMV4<BK"OL`/I\B2B$+DXU1?[8VW"#7[+BD5E3XOY-`H)
M%*]:UMA#;9"'!9D5@(+L42'<$[:>KQ*V.Q%';_C=5Q2+V@X//J."2N-,VCC+
M[X2@ARV=Y?"21N[;<?ND9[&-WLW%KD'*QO#G(6NXO[M`;[YT[SP,0G`3N4[R
MN;MRO$1*]K[B+KK@BT=\9WK5J_=5]JPS9C=OW$'N,&;/:E10BO1GA1P2+4&T
M5#%4T7Z9565'2V?#^$SHTATK>9WIDH5AQB4E*8\3J"+"&1%L)SZ%Z8'%\5L^
M4T%%1T8P[,XE0B`X\W1OB\^`(J[-3?(6T(M-RIUT3IC,9W4!^';*-V3$6Y:/
MDU:[$OQ6F>('IY@K836A1Y.WM;+8H==41/KUQN&:S:19LYFY!(%RT5KQ^+0(
MJTKY(!QU<4GU1'>HEWET'Z??$6MMA'ESG[QLH%T-7R1N"U:-)3O=\$@MBT2,
M'W=NCPC_`%A51_'$*Q8-37[2PL8D&Y8D2;N#=Q1<I)!@W\.,,567$1T5/>`Z
MHJ*FBXA5WS7D$V^2D*%4W,1VGL6;)>_327A=)@2%`_3<#:B[U^^,PW6OC5P=
M;R:YY+8U5Y(L;AN.P;,2FD,1VVXJ%L7:1NDXXN_J:KZ:)IC3%[?^-8/*)LZW
M-YV*U<U81G8)M[5"6WJ4688EU1Z.AJB)]/Z,BZW?R!8-S:5]B<V0557,KWU>
M;)7'WYB`I2"(21$U<;W$FG75>N6HI$\.6#M975TBT;%N%QY:$GV6B1SO"\T\
MU)!")4T$F!U!?7[XI%N?$.<V"4CU[<0I,NKLV9[B1HSC#),LM.-*`H3CA=QQ
M7=RDJZ)Z(F!.H.#O0^*7-!92!?"WDV3QN,(H;6K%TW-ON5?<'=TUR*I_[O\`
MFTOCL>MMKV(_+IW8;]#(9BFT/=@&A`Y+%7"4U<%-IH&B)ZIURU&]/'MRYR&'
MR&1+C#/_`'4+.R:;`^VK;,`X+3+*JNNJ"XI*1)U7Z8.J%7^,.2P3JGHUM':E
M0`N6''T9-51NV?\`D-N-(I?VC)BB>[HN*17AX@Y259>1GK*!W[JHB5KCK;+V
MO?BN$2R'#-PC<[@FNNO77\,="+>=XVNI3]@[\Z./S+ZONP'8YH+<$&A)I>OY
MC['1<$3^(<'M*;DMA<//1F&9[9I(@P$=!A]]7MXRC:-5!MU`]I;/S:ZKC=,5
MLGQYRM_F3%ZY8PWF(EO^XQ>\TZ4D8A1R8**);]@(&]5':G7^M@B;S'@_)K2^
M=MJ*T:K'9%,_4$XXV9N-D;PO-NM**BGJFTM?1.J=<$44?Q/R9AR5*:E5K,D[
M2MN8T=IM\6>[!8[+K3AD1&J.>J'ZZ^J8Z$68^,[)9T"8[*8)PK6;;7(B)@A+
M-B%#[4?3TV`J>X_54UP1*\=\&O.-`W&L':Q^-`CI#@2843X\MYH53:4IQ57W
M((HF@=%7JN"*^?XOMYU_=3DD1JZ-<1IT28L-7D66$IGM1RE1R7L]V/KKW!]Q
M>F"*U[Q5S>6R[\R?6HZY"IX(HR,A!1*B9\E252U5>ZG3TZ+CH1<S?'O(7YEB
M^$F(@2^1P+UH2[NHQX8,B31:)_:%V.B^G7'0>*;QUR&#+H7GI45P:JWM;-]!
M[FI-6/=[8!JGY@5_W:].F.@HI_B#FTGBS5!^XUYQDKID0V7$D=D)+\HWVY("
M.BFJ`>S0_P`OJF.B1T7\A\E<H>;P7WX?R^4"OQ3;[O;:(H+<0NYN3=HBM[DT
M^F%C`<-YE_,T:Y?.ODC616(=(RX3Z!%U$1F/[$'0W7411!=4T'I]5PC53>.>
M05]S7SR?B&W$L+N<X(JYN4;9=6134=-0_K_[F.@X:VIGN/)5\>L9%:DIJC*M
MGK(<G16YC+\DC[3#K+3O<T0=%'1"'=^."/I_(*:YY-X_C18C+59:'\"6W$D*
M:LMG%?:D=HB%$/;^EMUVZ_AA5/)\><G?=G/F["0Y7(Z^^$4)W:C4,&1<;74?
MSDK'M^G7`V\)\>77'[=`E!4R*J$[*<K;$(Y):$,HR/MNF7L';W%0C%=333HF
M*1'YQX]Y=9RN3C22(*PN5PF(TI)O=$X[L85`2;[8FA@8%Z+IHO7`]W/CRZG6
M%[(>BP9\2U&K0(KC\B.X"P`-#-MYH%)IP3-":,?MUQ2--9PCR74RX\N-8P+%
M^;!:K[IRR[SI`D9UTV'6B%$[Y"T]L+>@[U3=TP1F5X^YBMT]\=R`M4?(XW(D
M><-U)!"VV(.LJV(;$74-1+<NOV3`C1_&G)!8MX[D."M58@'<X]\R44(Y'R>Z
M<J.2AW(1[.J"WJF_K],4B0SXVY4\%)'L[!),>$U<1Y+[KQO2FX]DUVH[8ND`
MJ^3(HFXSVJN!%LO&G,;;CK,";\!N=4T<JC@/-..;))21::[SOZ>K0(VPB]M-
MWN7UZ9%=7QWC%O`YI<74E&4AV%?716A;,E-'8:.=S5%%$VKW?:NOTRICG2X)
MSA[FD&WD_!=BU]O+EM/*^\)_"EQR9%L(XM]H#;W>Y=54UZZY"(#/B'D,WB];
M06+T6$M'6SZ^'-C$3RO.S!0!=(2%O8V@CJ0:KJOUZ9:1TC/!["\L)T_E,>.S
M\ZE2BD1(CA.BX)&3CKRD0-Z=5_3334>N!32/&G+EXG2]V3%M>454P)LI)2N-
MQI:-L%$!M3;13`A845$M%]^JZ=<4CKN)5-S3LPX"5M=!KB;??FMPC-$:DN.(
M0@V)"G<14(E-PM%4OID,QT^%,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@%3`QI@-,(:84TP,Z8#3!&-$P1G`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#1,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#6U*C.D0M.@X0+H:"2$H
MK^.GI@;-<!JF!J:EQ77G66G@<>85$>;$D4@4DU3<B+J.J??`U?NM7_\`7&/[
M;XW]H']O_P"*]?S_`/)]<#:],B,&T#SS;1OGVV!,D%3/15V@BK[ET371,#;J
MGWP&J??`:I@-4P-;LJ,TXTVZ\#;CR[60(D%3)$UT%%]5T^V!LU3`:I]\!JF`
MU3[X#5,!JF`U3[X#5/O@:WI49C9WW@:[AHVWO)!W&7H(Z^JK]L#9JGWP&J??
M`PI"GJJ)_'\<#!NM!^<Q'_PE1/\`?P,*\RB(JF*(7Y554Z_PP/>J8#5,!JF`
MU3`:I@-4P/!O,MHBN&((JH**2HG5?1.N!E7&T+:I(A+Z)JFN`[K77WCT71>J
M>N!ZU3377I]\#RCC:FK:&BFB:J&J:HB_73`(XVJ:H2*GWU3`RA@O1"1?Z<#.
M`U3`8#5,#!&`Z;B1-RZ#JNFJ_9,#.J8#`P)@2:B2$GW1=?3`S@,!K@8W@BZ;
MDU5-437KI@-PZZ:IKZZ?A@9P,(0JFJ*BI]\#.`P&`P&`U1,#&X==-4U3UP,J
MJ(FJKTP"*BIJBZHOI@,!@,!@,!@,!@-4P&`P&`U3`8#`8#5,!@,!@,!@,!@,
M`OI@?$8MO:4%ORIRB&*S*LN:PZYXY#2F':DQ64)40";7<BEN3KA'T'@'(+>R
MI[7]Y=8<G4]E-KG)30*PTZ,4_:XH*1[/:J;O=A7`L^6^50X\MZ64:>P]5QI]
M?,1DH\='9<\80D&IDX<8>XA(9B)*B?9<)1BWO>.<RY3&63&?M[FTHJQJS^.C
M30+(BN%W761-=Q"(*@INZJHX5JIWYE:LAIUN%-??Y_\`&D.NQ4VZNLC^NR&Y
M>T\.FN[K]<TF-W'N0\A.GXG-MY$>X<G<EGQR=D115UH&5EH)1U0O8?Z&B*B>
MB[<R8FQ_(O,%JJ>Z5V&_$Y17SY<&.#!(4%V-&.4TADCGZP[0V.:[50O3[85<
M>/\`EW*K&]CU]Z[%D#84$*\86*R;/9-\E;<:7<;F]%Z$B]/K@5-AS#E-3R?E
MHE8MOQQLJFJJV7V41F(5B`+W34312$.XNJ?UETZI@KKN'WEY*M^04-R34B31
MO1Q:L6&U:!]J4SW0W-[C07`]"T73T7`^;,2>3V0\5E3;%J99_P`WV,>'*>CZ
M(RVTW,97V`:;D00U%-4^R_?"+6+Y(YU918=77-12Y#\6S?=?40!A]RMF+#`1
M!YYO8#BCO<5")13"[KM.0\CLHG#H=D#T:#8S"AM*A;I0(Y),1-N.+>G?<7<J
M-)Z$OKTP5R%5S[G=E+J:ILXD67*FW=?*D2(Y$2?MB(K#O;;=VH2Z^\=RI]EP
M(43R[RV+20;RT9A2(UC03[5N)';<;5J17FV'N<4SW-N=W4O:FW\<"RY'S_F7
M'/W&-(=AV#S<&!:0YC;)-@@2)H1'V'`1PM?S[FCU_CKI@2+KG_*8]Y8UD+X:
M_'Y#65$=QULR1&+",+IJ:`8ZF!%T7[8B57U?+N96/*..P)5@RTL>VNZZR%AC
M:U+2N:W-.*)&1-]"ZIJJ:]<0S72>/.77=Q96-?>[8EI$::<=J2CDR;6\S3N,
MO;S;DQS1$0'!ZZZZX6N*N)/(YS4DIDYN8]#Y["BU?=9T!@&R:VI[2U5-I_A_
M'KA-7!<_Y>L$X228:W$:SLJ\B9C&;DD8#:.@;,<G4`$]Z=TC<T1/3JJ8BI7C
M_E')^0<M"7+E@W6R..U=C^UMM>P'YJN]S:ZI:_F;^J+TZ?3$*\^8BL[AD>-5
M`S/D,L+;./06U<(9$<MU>T>GH#CX*1?@.$U!Y?<0^6<.X!=I!"44Z[@*["=0
M4T<4'0?8+<BHFUP5$D7[8-U5VO$;"GI:5JU89:9F<VARJZI:/OM08SQ*B,`:
MH/12%2413:BKHF4?2^57UA$N**BK3:8EWCLA$F/@KH--Q65=-!;0F]QET1$W
M>FJ_3(KD6O)G)6BKCL&XD>-(>LZ:4\+;BC^[P2)(RM*I]6I*-EH"^[=[=<#S
M"\J7TGCT*P5A@)KKD2GGQMFWX]P\^34@%4W4':R(?D4NJJ/NZX&RTYYSFG@Q
MW;J-'KF0D269EJC)2V&Q`P^(<IJ.Z11@=;,MY:D@$B?1<)70^0[*[C%Q?]HG
M!%"==1HTM5;[J.,N-N'M1=PZ(J@F%5-?Y!OI+U/;=N.=#<V\BE2$($,IA6S>
M;:>)S<J$JE'7>&U-$7UZ8'KR13W3U[6VU9!B\B"!%?;G<6E&@&ZR^8?Z3%(]
M01X-FWWIU1=$5%RIKC+RX:;<\>7G#ZU^>+55:)$BO>Z6#3(,B6H&OZKT?WZ!
MK[E^N15GRZ+Q$_"Z2^..#,@S+"!*<F*OZKTAZ>UWC>]%%Q5)1(=$T_+HF6C[
M+[430=-$Z:)D'QAJ,7'.6QW>0UX6-5979/4_,H)ZOLR9+I`$.>"^[MH2]H5%
M5#HB:(N5-55:[5!R2YX_?1EA\2M.33$6<FG8D36NT3$%\DT6."_F'Z.+[=4Z
MHL5WKL.*WYPKE!D15..2%113310F-`/ITZ"2I_#`T<]YURZFM[F-4LP"B5%(
M-V121>)QQ0><!QE-A"*;@:Z%_57Z+@:#\A<I8FVE;+_;VI+)53L)\0?).Q:$
MX*LHTA*<B0'978@[4/7Z:+B#76>4[M(]'9W4>/%HYDR?4VTE0,#9EQG7&XQ]
M3(0!_M;51=="T37KB#J+#D%W7\%6XE_$CVJM@:B_W`CMJ\Z@@)"FYPC0#1-B
M=2/HGKA-UQ,_DD_D#-,5C'%J93\UCUXF+9,J8`TIBXK1D9-J0NZ*.Y<%30\J
MW+93X\V/'B6S<B/#8J9#3S+K1S)GQF7R<)5;?C*!(?<;T]WMZ8,=;Q3D%K,M
MKRDMVV?G4KK")*C(0M/,2FNXT6PU,@--"$AW+]T]<*^=\-Y9><7KXQ.18SW&
M9MY=PU1M7%FMNMORY`FFJ]M0_04-NFJ>NOTPFZ[7@O*^5WDAIZRK&V*B?`:G
MP9@*(JAN*BK'(>XZKF@$)=Q-$^FF#-1FN<\HG<D>8JZH'Z6':'4SW35`-O8V
MBE([BNIT1PQ3M]O54ZHN#7,->5.;R^/,3G&:^*5M26MA!-H7G"8D5B^IH9(A
M@8KJB=-%^^$>[[DE_$CQ)HMPCY`G#YMFQ=*VYO`VE8,@1O?MVGO0O7\R?;IA
M7B?R:;0\F9Y'-`9L\>'MN/"RBM@Z\[/:!OH1%IU=Z]<"_;YWS1MUFIGU;,.V
MLK$8-/+?%6X[K7QSDNO$P+KCB=OLD"#W$W+HNJ=<%;?$H3FN*7;:HRW.;NK@
M=!0U81U)3FF@JN_9K]-==,*JN&<[YM;4]#7`<%_D5A5.W#\J0VZ#':!X6@;0
M`+=N(SZDBZ"B>BX'41><O3O'(\MC1F8[[D17_C3'NTRVZ);#%Q[3\HFB]43K
M]/7`]<"Y=8WYW4:P8!J143!C"\VVZP+S;C#;X.=E[5P.CNFBK^.!3+Y`Y6[Q
MF3RR'`@N47P9\N*!O.!(`XBEV1=Z*)=Y&RW(*(H+]\#0]Y#YPC3$-BGC2;V1
M7G<M18Y.O-K&50%EE27M*+IF2HI=1'3ZZX9JIY_RJXOJ&4+$1J)"J;:FC3P<
M</Y0R7'XSSH@K:[$1OOB"ZZH77#3=8\GN8?(YL>DC1(+\CED.LL7C5U[Y+3L
M$7A-4541LMJ(*[?MA%_Y:D6PU-)&A&T(3[J!$F@[OV.-.N]6UVJGL)4T)/JF
M$5M5R\J2$U^UUK`<2B7:T+@(X\4EMQQ]&%?!#W)VTDN;4;]4'JGVPJ_\?\IY
M-R)F3.LH,2%7`](BQE8><==)V+)<8-20@`4%4;11ZZX50R/*UW'NY$`X$5T%
M:M2C*RXZ0@Y6!W!!U]`5HB='\P-^YOT7"5I8\H<V>KY#C=%#>L#H6.1UL-J0
MZ7<:(MKS!JK::.)ZAM147TP.QXQRT>0OE(@(T[2K%BO,S0(E(WY`JX3:)IIH
MVVH*O775=,+B@B^2K1YV"!5[*)(Y%+X\\J.GT2.+A`^/L_K=KW"OI]\)JJJ_
M+W)9-="L)5-$9CVE?9RH*!*,R[]7JI`ZBM"B`X(]%354^J8,6$SRK9,-N&W4
M=_\`_+T2_:%HG'#3Y+O:<;(`!246D]ZJ**JHGI@UI<\L63M?`2HA1KBSGQY<
MUGX!OR8QQXC@MH@DVT3@N.$:#M,4V+^;"55>0>9W=WQ>R;@URP8]8[4I:$\^
M;,QF1)>CO$T`-IHO:;<1#W$F[73"YKN^<\LL>/)3!`KV[!^XL`K@!Q[L(!.M
MF8FJ[3U1.WURFZH*KR;>VALT\>H88Y4C\^/-B/2"^*U^W*VAF+H@I&+O?;V>
MWZ]?3!6BM\K7][,K8='0-..S(+LR4LJ7V4CG&F+#DM+M;-3V&*J*I^;\,)4"
MHYY,E0.$W7)(S:OSBLWTE0WW6VV1C1GG"4V-$1W5MM11"7HO7UR>RYJQE>6K
M.!7)/GTS8-3Z:1>4HA)U5QN*V+QQWU5M$;<[3@FBCN'U3Z85>\2YK97%S.JK
M*M"O?CQ(EA'5M_OH;$Q#1$/V!M,2;5%1-4_'`K[#R:_&DR)3=<+O'8-L%'/F
M]U4D!(,P:5T6=FA-`\Z(+[M?JB:9343@C-E<\LY#;V^X7JBWD08!,2GMG9!A
ML49-C0&B#0]^JIKOR(^DX4P&`P&`P&`P&!SG]WG#5D/2%K05Z1-;LWC4W%W3
M&?[-]?=^<?HN6I%E5\>IJL9@0(P,#8/N2YHHJJCK[W]H9(2KU+ZY"*.+XG\=
MQ4<1BBC"CL9R"XBH1(L9TMQM*A$OMU]$^GTRTCVSXL\?LU\RO;I6$B6'9^:"
M[R5Q8W]B1&1*>YO^J2+KBD;8OCCA,5EMF/5--MLS1LVQ%3Z30':+^N[531/J
MN*1[8\>\-CO-O,5;33C,XK1H@W)MFN(J$\B(6FY4)?PZKTQ2$;Q]P^,LM6*U
MMM)P/-2`13V;)*ZOBV.[:TCB_G[:)KBD2JSB7':R:S-@PQ9E1X85S+HD:J,1
MI=091%)4VBOID5JG<&XE/FV$V96,OR;5D(U@X:*O=;:_(A)KIJ.B:$G7HG7+
M4B;34%531RCUS/9!P^XZ1$3CCAJB)O<<<4C,M$1-27(JM9\>\.8FI-9K&PDC
M-*T$T4TTF&*B3R)NT0E0EUZ:=5RU(C3/%?C^;"8A2J5AZ-%?=E1P+?J#L@M[
MQ(6[=HX74QUT7ZIBD6]QQFBN:M*JRB!(KQ5L@8Z@@$RJ$V0*"BHJ"HFFBXI%
M=7^.>%5TQN9!JFH\EEQ]YIQM33:Y*%`?)$W::N"B(6*1MB\`X?&"$VS5LBW7
M1WH<)M=Q"W'D_P!NUM)511<_K:XI'EGQ[PYFKEU0UC90)S0QY3+BFYO9;UV-
M[C(B00U]J(OM^F*1JC>-.#QEU8JFFR^2Q.4D)S<LF*.UEXE4M5,$]%7%(V_W
M>\-W-G^V-*;4URS;)5-526^FUUW7=ZFG0D]%^V*1)H>(<<H7#<JH8QS-L65-
M2-PD:!5(6Q5PBV@*DJH*=,4S$=[Q_P`/>F2)KE8VLJ5*9L'W$4TW2H_]D]HA
M(FX=/MD5KD>-^$R%W/U33B_*>G*JJ>JR)(H#YJN[_G!1$(?1?MEJ1LJ.`</J
M)D.76UC4:17QEA0W`4]0C[B+M]25%1%,M-?37IBF+*+15D2QFV4=GMS;'M_-
M?0B57.TFUO7551-J+TTR+JG8\:\*8C,1F:T6X\69^YQFQ<=1`F*JJKX^_P#/
MU7*F+.[XS2W@Q1M(_P`@83X2XJ*9AL?;_(XFQ1]P_37(KU=<=J+IAEFQ8[R1
MW4?C."1-N-.BBHAMN`HF!:*J=%],#R'&*`($2`D)KX<%T)$1E1U0'FR4Q=37
MKOWJI;EZZY:D:9G#>,3:N=52JYEZOLWBDSHY)[7'S5")U=-%0]PHNJ8I$)/&
MO"QBL1!KT"-';<:%H77D0VWB0W`>]_ZJ&0HI;]<4BUNN.4UU$9B6<89$>.\W
M)8#4@V.LKJV8J"BJ*.14:)POC42T.TCPA;EFZ<E50C[:/N#M<>%I5[8N&/0B
M$=5RU(]V_%*2VE-3)C1_,9;)EJ2RZZPZC1JA$WO:(%VDJ)JF%:VN$\8:EU4M
MF$+3](V;-4K9&`L-N(B&(BA(*[M/=JG7%2*X_%?!":GL_MFUFTD),GLB\^+;
ML@3[B.J"&@H6_KTQ1:4G&HE596TUDS4[9\)#P*1J"$VVC:*B&1^XD3W*FFOV
MR*C,\`XJS8#.;B$C@2"F@RKSQ1TE&2D3Z1R-6D<W*J[MOKURHUN^..'/55M4
MO0.[7WCRR;5@W721YY515<55/42513\JIZ8J-]?P;C<"SAVD=EWY\",L&*\Y
M(?<4(Q+N5K0S)%35$7KD:QFWX3QJWE3I4^*3SUE!_;)I(ZZ*'$W*?:T$D1/<
M2]4Z_CEJ:BSO&W$)SCKLF(9//)$0GA??`T^`JK&4"$T4";W%[AZKJNN*162?
M'@,E'H*J)"8X8_(6PMV7E?>DG*1X7A%E"4@`#,$4EUZ==$ZXI'57U!5W]4_5
M6K2OPI&U7`0B`D("0P(3!1(2$Q145%Z+A%1&\:\/CEN9AF*K8-6ZZOOEK.9#
M8#R[C75=/77HOUQ5C`^,^'?&DQG89R6I+/QB20\\ZH,]WO=MI3)5;1'?>FW3
M1=-/3%(N*6@K:=IT(8%OD&CDE]TR=>=-!04)QPU(BT$41-5],E,Q7P.!<7@3
MCFQHJHX3STD&C<<<9;>E:]]QIHR4`)W<NY43ZK]UQ3<.+<!XKQ9U]RDB+&61
M[5%777!;#7=VV1<(A:#=UVAHF6D>"\=\27DKG)1AJ%L\J&\X#KHMFX([!>)E
M"[2N"/1#4=4R*U1_&7#F(\".$0U8K8\N'$:)YTA%B?K\@"127=OU^OI],M2#
M7C7B3;49KXSKC<2`_4LB[(><_P!#DZ=UHMYKNW;4ZKU33IBF`^-.']H678AR
M6DKBIR;D///(4(S1Q6SWDNY=R:[EZXJZT->*>&-TPU`QWU8;?;EM22E2"E-O
MLIM:,))&KH[!7:*(6FG3%1<\;XI2\<@O0JILVX[[[LMY'77'E)Y]=SA*3I&7
MN7KZY%5#/BWB4>)#CQ`E1?V\GOAOLRGA>;;DKJZP+FY51DNGL]$T33+4BUG\
M0H)W&3XR]&0:4V1CI%:56]K8:*&TA7<BBHHJ+KKKDJO''N&4G'Y4^57(_P#(
MLR;<G./ONOJXXT"-B:]TB]RBB:K]<"J;\2\*:*S[49X&K8)#<B.DE_L`DS7Y
M"L-;]C).Z^Y01,"1<^-.+6[=4DMN0#M.S\:%)CR7F'NPHB),FXT0$8&@)N0L
M#1:>*.&V4Q^4\R^U\I8Q2H\>2\RPZY"45CN.--D@D;:`B(OVP-T_QKQB<Y,=
M>&0+TZ>S:NNMR'6S&7';[39MD*HH:-IMT3Z9:D6E]QBKO&(;,_N*$"2S-C=M
MPFU1^.NK9*HKUVK]%R*A#P#C@VSUD+;J*_*"P=A]T_BE-;1-LGLZ[>YT1=?N
MB+ZX$_CW&ZWC\`H%=W!CD\])5'3)Q>Y(<5QQ=Q*JZ*9*NF$CG/[GN')(1\%F
M@HN3'66QEO(VW^XBJ2A;#=M$7-RKI]\M-RMS_$/V(&++C$3YMS7U[5/!CS99
MML+#!Q"VF2"Y[ATUW;=5P+7AG&8W'./LUK+;39[W9$E&!VMJ_(<5UW8B]=J$
M6@_AIDTQ5KXLXQ^]?NR.30>&P6V:CC*=&.W,,5%QP&47;^IN]R+@A#\6<8BL
MU;`E)<8J`FM16G'E(5"QU20)]$W:H2Z?;"Q'@>(>.0-3C3[09/PVJ]J4LUQ7
M6X\=Y'F0;5>@["'1.GIT77"1ZD^(N,/,1D"1/BSHTB1*2TBR2CRS<F*BR4-Q
MM!%1=VIJ*"B=.FF#,8MO$'%+)Z0:NSHC4QJ,U-BQ91MM/K"45CN.C[E)P-B)
MNUZIZZX5L\D<<MKM>,MUXGM@7,>;,D-.`VXTPTVX*F&_5"+4TZ:+KEQ-;4\9
MT(,PUCR)D:QA2'Y86[;J?+-V7_Z2KID)`:.]-14=.B:::)@B34^/^/U-O#LX
M'>:=A03KFF>YJT3+KW?<(Q5-2<)WW*6N0B'7^*^.06JIEMZ8[&IGI3T&.\\C
MC8C-;)IUE44>K6QPD$?IA6L/$W'$JW:QR3.>AK">JX8./(2Q(<G1'6HZ[-4U
M$4'<6XD%--<"XJ.&UE7<O6[#TAR6]"C5QHZXA!V8F[MJ@H*>[WKN7ZZX$)WQ
MO0N6LB:KLE(LR6W8RZI'!^&Y,9VJ#Y!MW;MP"2HA;55$54P+'C_%X=&]9NQ9
M#[RVTP["2+Y"2"\XB"7;VB.T=!1-/PP+G`8&"71,)KY=*\LO29M-(@QY$2N*
M\F4]C&?B.&^^D:.\0K'04W;NZSIM%%7Z+I@QT;OE/A[5)%N/D.N0I3+LE.VR
MX3K;$<E!]QYK;O;%HTVGN3HO3"O'D3E\VGX7^_4R"\RX3"G/%LI(1XCR^Z9V
M@T)P0%4+3^E>F!`K9OD:SXU&D0+6H7NI\AJ]-DG&G8W9`PU8;=$1/N*8F2'H
MB#T35<,J:U\H<A:X'QR[-D*>5;@KMC:.PY,ZOB`'1#<1D@,`>70@(ET$?7"K
M'F?.;NIFT5>Q-CP&9S;12N0RH,B16NNND(`R#K3@BP3G4A5PE3JB85T?/>8M
M\4H1F]I),Z7(9@5D5=41V5(+:VA**$J"/4BT_JHN!S;?-+68'':FHN8=C;7T
MB8,BV;CJD>,W`#?(;&.IH6X7"%M$,M>NJX16Q?*')[R&T-2W%AV$&HEVMN+H
M$\!O0Y)Q$BM^X-@N.,.%OZJB:8+[NMM_(T*N\=L<U2&]*BR8L:2W%83<?^EH
M&Q%7Z(BN(BKA5/7^3FH?+;ZOO''1A-S*^/6[8CB?'2?'$A&4X*$@;GBV(IJG
M7I@7,CR?QMF9)A[)1O,),1I48-`D.5P[I33!+HAFW_0B_15P-D7F4RS\>+RF
MLJWSENUY38=6Z*BXXYVNX#:>BJA+HB*GK],#G.)<UN;VDF6D"[K[2*U7N/.J
MW&)F3#L6T0ECR(Y.*6S3=T5$+IZKA'O@'->2\QKJ.9!DPUC@P#W)Y0-;@^0Z
MV+B0HPHYJ)MH?ZAEJB=/KZ!<<-Y%=V?)^7UL\V3BT4UF-`[3:MFH.QP?5754
MBW*G<V]$3TP8]!Y7X6=V--\EX993BJU<.-(%@9HZ:,$^H(V)GK[-5]WTPKRY
MY*X[,BV#4.4[$D-P)4Z+*>BNJ)LQ55MR0R"HBO"TYIJ*=5^G1=<"CYAY-_:>
M!N2:V:LV^:K8DU981#)E$DJ"-NOMIJ+*/:EM$BZ?P3`ZSEW,&>,Q*U]Z&_,6
MQG1J\!C@I*)R3V[RT^B?1/JO3`\N>0.-MVC=<XZX)N2DKTDJTY\9)I#N2,3^
MFQ'=%TVZ^O3UZ8%CR2X"GI95@0]PV0T89^KKYJ@,M)I]7'"$4_C@<C5\[NI_
MBFSY";343D]-&FA8PR%3::GUXGW&U'<BJ)*"*GN]%3":H:SR=R9[Y47Y$&P?
M_EG^8!F1&2V0Y"`A?&D@CK@DAZZA[A+1%Z?7!CMJ3DLT_'<+DU@"2);E8%A(
M:C-DB*1L]U0;#4RTZZ>JX5SW%_(K[=1&N.02WI(VD!NR"M8KW4>AM(**^X7;
MWD4=%(=AD.J]>J_0.C:\C<6?O&*2*^[*G26F)#78CON,]F6!&RZKP@K8@2`O
MN4M->F!OO>=<?HY2QI[CO<`&W9*LLNO"PV\YVFW'R;$D;$CZ(J_BOHF!'D^2
M>)Q[%R`[),7@60V+B-.*TX[$;5V0RVXB:&XV`JJBGV5$ZHN!61/,7&9]G3Q*
MYB;)CW'=)F>L20TPC;3"/]Q"<`=XJA)U'HGUP-\GR9QV736SL&<Y"?AUQ602
MI$1XD2*2$C<L&E02>:W#_5P/1>4.)PGTKYLQTYC"PFICX1)",@<\!6.XX:`0
M-@ZI(B*I:(JZ8$GR'RN1QNB;E1F3=E2ID6"T0-$\C:RGA;5P@'UVB2[4^I:)
M@1Z;FT")!5BXL_ES6;,:AU\(CL=?DR-#CM&U[MI*#@:DGMU7Z8'KC?DRCNV8
M1=J1">LI<R%`9D-&*N'!)Q'.NFU-1:4M%7\/7`R/E7A9E6BW*==.V;)Z"#<:
M09$V#Z1G")!!=B`ZNA;O3U7I@6%-S?C]O9'6PGU66+/RFA,"`7H^_M]YDB1$
M<;W]-1_#[X'I>94:6SU6KA]^,1-R'NV:QVW`9203;C^G;$D95#T5?3`K7/*O
M"V6GG)$PV$86-N%QEY#4)QJ$9T105(FW23023`W1?)'%9+,YT'W0_;8S4V6T
M]'?:<%A]21H^VX`D6Y6R31$UUP-43F=>Q)MUEV'R_CV20(T-B*Z+[;JL`[\9
M!]ROGHJGN%--O\,#+_E+AC%='L7)I?"?;[Y.HT[^BRCG95V0FW<R".HH*IHG
M5%^RX%C"YC1S;@ZF,XX[);)QM74:<["N,HBNMB_M[:F"&FJ:X'+<Y\F.UT3E
M<.J9-FUXW!8FE*E,&44D>)?:BIM1?:"]=WKZ:Z+@7C7DCBALO*$ATW8\H(!Q
M4COI(*0Z'=;`&5!'"0VT4Q)$T4>NN!KA>2Z"?>5%57B_*2YAO3HTP&G.R+;#
MB-$)DH^TD-="1=-OU]4P)MKSOC-5*L8L^43+]5"2RFCVG2V1%)1[R*(JABA(
MNNW73ZX&9'-^/,*HD^1N?H;&FVG#-Q9+9.M"V(BJF2M@I*B>B=5TP(3?E+@[
MKU>RS9(ZY:-#(A"VT\>YHG>QO)1!4!!<]I[M-O\`6TP+&FYEQZYFN0H$GN2F
MV1D]HP-M3CF2B+S>]!WMJ2:;AZ8&B7SSC465,CO2#W0$=66X++QM@L=E'W@5
MP14-X-$A*.NNF!XF^1N'067WI=B+3,:)'L'G%!S1(DL^VP[T%=1(^GX?7`CK
MY4X*,5Z2=DC;<>6W7O"XR^#@R7TW,@K9`A_J)U`M-"^F!N9\C<2D5;5C&EG(
M:>?<B-QVV'RDK(912=:^,@=Y";%-Q(H]$ZX'I?(O$59A/M3OD,SVD?8..TZ]
MHTKB,]QSMB2MBCI;%WZ:%T7T7`W?SSQC]U*K*:(2D[VTG!,&36*FZ0(/$B-&
M3*=3%"U'KKZ+@4M#S]+OG[U3!)'*<:ANP:,X[S#JN'(5I#$G4%#:,$U%1'^G
M`G#Y'X\EK?5\A7HO\O*P,V2\RX+1'(%%`6RV^]5W"@HG4E7VZX%M1\DJ;QEY
MRN=4UC.JQ*9<`V7F741%4'671!P"T5%]R>G7`Y7A'D^OLGBJ;F9'9ORL+"''
MCM@XVVX,)\VQ%#/<'<[8;E#?K]=-,#HZCF?';>>[`@2T<EMM)(1H@-ON,*6Q
M'FE,11UO=TWAJFN!'>\A\.9M952]9MA80=WS&%%S]+:VCJ[RV[$]A(J=>OTP
M/!^2.&-M"X[8HTI2_P!O1EQMT'DE]M749)H@1P25M-PZIU3TP,.^0^*N4L>T
MBV`.,SD?&"J-NF9''1>[N9$>ZB-*/ZFHIM^N!6\9\FU;G"Z2[Y%*9B2[&"U.
MDHT#BLM@ZNU'"5$/M-*2Z;C73\<"T_O&X9^XS*W]T:^;7]SYK6A_I*R@*:$6
MW;K^J.B:^[7IK@;1YYQ8XBRDG(@#)^"3/;=[Z2M-W96/M[V_;[M-OY>OI@1O
M'/*I/)>),WDOLB;KTIO<RA`UVV)#C0%HXJDFH-HJZX%.7EFG_FUR,,R/_+4:
MF=M94]6WA,%;D"TAH2IM-DA)50A1?3UTP.AL.?<0KUE)-M&8_P`$8QRU/<B-
MA,51CDJZ::.*FB82JM?)''OGN3"N804#-9\]S<#PR!1)*L*^JJB#V=4V::;M
MWX8%G%\@<0DQ)\MBT9-BL<!F<7O16W'=.T.U10B[FJ;-J+N^FN%Q,I>3T=XU
M(<J982TBN*S*$-R&TZ/JVX!()`:?XI)K@<L'-^4UW)HD#D=7$BU=I'F28CT5
M\W7XZ0@[II*$@$%W`OY@71"Z8&>)>0[&VLJR-8P6HC7(J]RUHMAD1HTT0(K4
MC5-.YL=`]1Z>J?35:E6/%N76=SQ&;<.0F69\5^?'2(+I*TI0GW&4_44=??V]
M==N-,U9<*OW>0\2J+UUD8[ME%:DFP*J0@K@[MJ$NFNF16^]Y+24333EK+"*C
MZD+(EN4C4!4RV@*$2[112+1.B83=:/YSXNDB'&_<F%>L!:.&(EN1Q)&O95"1
M%']33V:KU^F#-;+SE7'Z)&EMYS4-7D,FQ-555%I-7#T%"7:"+J1>B?7"MUGR
M"EK*M+6PG,QJU>WI,<-$:7NJ@M^_T]RDFF#=5X<]X>;<1P+:,34Y4&*ZAZ@:
MJXK*>[30=S@J`[M-5Z)A*].\[X@R<P'K6.VM>*G-W%HC8BXC)$I*FF@N$@*J
M>B]%P57\RYVS454I^M*/-G09<"-.B&:HK0SWVVA(MO5%4'-P_1<L*L^/\OI+
MZ59Q:QY7G*B4<*9J*CHZVB*6FJ=412TUR*N\!@%P/F<'QQR.);PG5FPSKZ_D
M,V\:!`=1XFIS;R$T2ZJ.\#D+HJ=-$PRK(_B'DL)NMD19=3(GQAGQ9C-A%.5%
M./-FG-`VQ51,76B<5/\`%+ZY5ZN\OJOD/\O,PJ.1&&6R(MNC)#:R^UVB;)O]
M)/TM55"%13IIIIIA.KC*WQMS"LXL515OU<=NRE++MJXQD?$`":;!8T;M$!(!
MDVINKTW*JZ(B+DZ'5T4BG\@R*IFK>E5"L2H[\:T(&'@1L7=1;^*&XA(0:7;M
M<]5Z_AE7JUVW#+R;6IQ47H8\-6%'AEN%U;`18VH2"NO97<()H6GM7[X.J/?<
M>Y7R&QD;SBQPH+.'9<6D$VXB&;31#(9DIJJD*HX0H8??T]N#JB1/&=Q`DL7\
M.5%_F@;.=:/"8N)")+%I&76$0?U-!%MLD/U4D7IUP=6EKQ+:5<%ANDLF1F/U
M<FHN),ELE0TEOE).2T@+T<!UUS:)=-"ZKTP1T7)^"_-\;'PZJ?&-VHD>+!>>
M12$?B*V3?<0>JHO:3=ID-4%EXYY18)R%QV;!&1>3:B;[0>0`_;>TKH]55?U%
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M0%-J)^7\'1,>;#Q)S(J:?4UUM`"/<U=?!M"D-.D3<FN:%E'8^Q4]CH`FHGZ+
MAK'<<VXY:7E/`:@2&&+*NGPK%HWQ,F".(ZCB@2`N_0M/IE35&WXWM$<D5CDR
M.?'G[H+_`*B?RP=%X91,"NJAL60&J%KJ@KMT^N-,=!RGC3U]/J&I*LG1PWUE
M3HCF_N.O`"I'VD*HB(V:[^OU1/MD-<ZYXWM8SG,XM/(B1J?E410:B&+I$Q-.
M.L=V0JZZ$C@Z*2)]43\<&+YKBLAG@!\<96.$\ZS]O<DB"BT3G8['<)!]ZI]<
M*]U?';&'X_C\<)YDYT>M2O22B%V5(6>TA[5]VGU5,#G*_P`?<GJVZF17S()S
MXU$WQ^P!\'>P;;*ZM/M;54D)%5=P+T+7U3`L>#<`?XO<O.MR6WJW]JKJN,&A
M(\BP$<U<-57;H?>7HGIET9M>+<N:YC(N^/6D2+$M6(\>U8F,&\8+%(MCT91,
M!W*#BBHGT]%R&J>%XQO84ZV99D53M1+.=(@R'8:_N3;LX7%5HY&JIVQ<=5=R
M)NV^W*F);7`>1,0^$?&GQ6YW%XKL*6X0.$VX#T48ZN,IT7<*@A(A=,*HHGB7
MEW8M/FV%>Y*M>/O4<F0(R"<<D&9$,IQPU52W;U4AT]O01Z8Z,K*;XSY!(B7S
M"3(@E;_LO954=5`_:NWW=R?7N*W[=/Z<=%=1SSCMER"HB1*]YEA^/80IQE(0
MU!0B/B\H)LZZELTUR*YFR\<\G>OIKT6=""IE7L#D&UT'2D;H@M`ZQT5`T7LH
MHE_0N7H/,'QURJ`W4E'F07'J2ZGV$3N"\@N1+'O[A<TZ]T/D=-.G3'1E[XGX
MSNJF54+/G1Y#$*KLJV6K`N-F:SY8R4-O75!VH.B]?7'03_'G!K[CJ-1[-VL?
MC5\;X5?)AQ%9EO-(J;"E.*JIN011%$.BK[EQT:1;KQK86_)9\\WV:Z)8-2(L
MUZ$3PO2XC\56`:DLK^B1M.%O%U/=HB#]\=&4!OQOS!R@:@RWZ49D636JW)AQ
M7(_>8KI`OJ;Y)J7<-&T1`'VBNJXZ#I>0\'_=>95%^W([+,5LX]M%T_\`2V1,
M7XP+_P#)2`W?P54P*2;X\Y6EI/NJN="9L_WU+FL!\738)HH*076)&W0D4@15
M0@]%QT:>;;QYRN9=,7!2:>=)EPA@7+,^&3K+:-O..MN0AU7J'>(=KGYNBK@6
M%+P>XA<[<OP<C0HCJOC,;ADZGSFR$1C%)CJB,@\SMZNAU+TR"-S+Q]R*XF<K
M^!)AMQ.2UD6$BOHZCC3T4W%1?8BBH$+R_CKE37BYX'RR3>6ME"EQ`:LIU=(=
MBN&^*.1X48V767#;1"3<9H:;?73:O1<=$:^&>.>3\?G<<?=DP'1JF+*%+!H7
MA16)LH939,HNNABH;20NF-7'0<NX*U?WM58$\C4=AJ1#MX^FJ3($D458Y?AW
M0`OX:I]<8;CES\57L7C%''A38D^]HYCDA"L@,HLEDFBB@RZ@>X5"-L$21/4?
MQPD6D#Q[9C;A(E.0F(3E%)J)3$!LF-CTJ1WB)@--J`*=-57<J]5QT&[QSPR_
MH$$+<:I5AQ@@Q95=')I]]IO31R01_E704]@=-=5QT7$&S\=W4[D=I/9>CUL:
MS:F1YI1G'E28S(B*PQ\F,2=I'F7-"[HKJHIMP:Y#FO$>55/#K>UN'H"HW15E
M,VS%[Q?JQ)PDAJIHGL-'.NB=/]W+T1:\YH[>'81^1ROB_N-QR&B:8BMD:L"S
M")S83CBBA*1JZ2JJ#[4VI],@N8_C_D<.[9Y1'>B%<K93)LRN(G!C$Q,CMQNV
M#J"I=P!C@6_9U7<FG7`@O>*[]IF`E<]%CV4=UZ8-TTZ^R_'?ESBER&A;1""1
M%(2V=IS3KUP#/B:W5+BH?_:TJ)7[B5?<"P16P+8]Q=AD7L383RZF*ZD*(FB8
M7%UQ'BW,8W*6;F_*O0&*9NH1N"3JJ1M/]SNZ&(H(DG]7Z85"Y#XZY'/O;^=#
ME16VI\JJM*Y7%<W)+J]B(R^(IIVC1O\`,BZIKZ=,#IN+<?G0[:[OK%&FI]X<
M<G(D<B<;:"*SV@_4(6U,RZJJ[4^B?3(.4B^-+QY0JK!R,%/$NYMXS-8,RE.+
M+5]6VMA"@M*"R5W%N773HG7`F>->#W_'G&F[:/3HE;%2OB6,!HTER6A4=I/*
M::->T$W`*JA%UP-=OXZNK-OG+2OQX_\`,4B'*JG?<YM*$VT@C)#0?81L)J@K
M^55P-+'!.3/K2RY$*HKY<:Z8M+)JO5W:;;$=QG7N&&YUPE=U3<B((IIKA)$2
MK\>\WIK1JV@K7R)'?N6WX;SKHM_%M98RVG`<%LE1QLAVF.WJGUPJ#7>*>85T
M2J:5FFM!6GCT]S'G]Y6@6*XZ0/,;1_4$A?7>V:)KHG7*G:NIWCB^ETO+H*/1
M8\BVM6;.H/W&U_HPL=MN2"(/M(HVA(*KT7\,B/#7">8,2ZKD,6%3Q+J'->?E
MUD<W1COM28Z1S,Y*@KBOCMU%5#1$]OXX:7'%>%V\7QW.XS;O,M3)RV(K(B$1
M"`SW77$45-`74>]_N8'+KXXYS8Q3CVRUL73BTGC3;L9UT][IJ':?4%;'8"HW
MU'553\<#S8^.>>V@W+TENN8?LXM)';CMONF(+52E?=W&K0Z[A7V],"V\B<#Y
M'R"UN)%>D86)_'CIV5>=("1]R4CRD2(!>Q!3^.N$4GD2GG5[E[<3BB1F+9^A
M;JWG9!M`Q(KW"<)QUU&C!E$7\A$BBOHJ=<N(Z?Q1/&1"N5&.VKSLTIDJ?&EA
M.CR9$D$4^V\#3`(K8@(J(CHB:=5ZXU<:8%)SR?=RY'(*RN:8L&7H3\MF:Z^X
MQ",2068S*L-")$2H3A$75?P1$R&G#>#7\*UHI-RL?M<5JG*FO)@E(I).DV*R
M"14'MIVF!3;JO55^FF!9\,H+RIXC95\QEI)[\NRDL-MN[P(9DAQYI%/:FB_J
M:%TP8CTC?)N)\"XM5)`9F6,98=?8,@Z6B-_D==9)`]RBB;M"VII]<&I'D"CY
M):2*C]J!EV&T<D;)LGEC/*+S*@VH/B)&@(2_J`&BDGUP1QW'?'W.*Y>,JVRU
M7V%9&@0[*8Q,[L:3&B*J.-2(IM^\A%=67`T457UT3J2.F\D<<Y3=R([54VP[
M7NP9\28)O+&=1V0T@LD3HB1DRBZ[VQ5-RZ:]$P-?(.*\BL?$4+C@1F"N&V*U
MI]@GOT=8;K)N_J*/7465T]N7%0.1<!N97,YLMNJ@6U'=-PD?&7(=96$Y#)?<
MC+:;7PZ[Q'5/?]<$5T_QUS.;%Y/!C"W7UUO#F"%>[*^2Q\YU]'6W8JJ'<C@Z
MB*3P*JCN7HG37&#W:<*YS:AR*2]7Q8TBY?H7F(R2]^P:QT3?0S[8IKH'MTR8
M1V?"J>ZJ;/DP3F6TA6%J[8U\D'=Q&#[;8J)M[4V*"M_==<*ZS`8#`PJI_3@<
M_3\TB6]JY#AP991`.0T-MVQ^(3T1SM/-[T+<BH>J#N%$+1=,#H-4UTP(\NQB
M176F'#3Y#Z.+'CHJ=QWM#O-`%?71,"OI.3Q+KB\?D4*.^465&64Q&44202:*
MJ!LUTWKIHB:X%A7S5F0(\LF'8I2&P=6,^B"ZVIBB['!15T(==%37`@AR:$?*
MG>-=IU)K4(;#NJ*=HFB=5G02UUW(0]4TP-<KEE=&Y5"XR;3ZV$^.[,8,016>
MTPHBXI'KT45,4TT^N!=*2)IK]?3`@OWU.PLA'IC+:Q3::DH1HG;<?T[0%]B/
M<FB?C@3=R:Z?7UT^N!E%U73[8%1=\MHZ2QJ*^P?[4J]DK#K@TUWNB"N:*OT3
M0=-?NJ)]<"WW(FFO15]-<!K^&`W(O]'K@-R>OT]=<!K^&`0D7JG7`T/3X;$B
M/&=>`'Y:D,5HE1"<4!4R0$^NT4U7`D*NF!4<7Y-!Y%3A:1&W6&#>?81N0B`:
M''>)D]4123\S:Z=<">S80WI3\1MT#DQ=BR615%)M'450W)]-R(JI@;MZ::HF
MOVT^N!6<7Y'#Y'21[B&VZU'D*X(MOH@N"K+I-$A(BDGY@7ZX&MWEM&SRICBS
MC^VZDQ')S,?3U8:-`)=?OJO1/LBX%QK@1;6P*OK9,T8C\THX*:1(HH;SFG]5
ML2444E_C@0J_D\*=R"?1`R\U-KH\:4\KHH@$W+0]FQ45=516R0OQP/=CR6NK
M[JKIY`N_+N#=;AD+:JWN8:5XT,_0?8*Z8$:5S&`QR)FB"'.E2G%!'9$:,;L9
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MD.17PYS@G""=VT:9ECV7A<=_*T8%U0]>FW`U<?Y'7WK$QZ&+@C"F2(#Z.CM7
MO13[;FG5?;KZ+@6J8#`PJ(J:*.J8'AXP!HC(%,6T4MJ)JO1->B8%#2<WK;F)
M6SHL66-?9Q')S<UUK8RTVVJ)M?-5]AEKJ*?9%P+]EYIYD'FB0VG!0VS%=442
M35%1?Q3`C.V8MVC=>L9]>XR;ZS$#6,&Q438;FOM-=VJ)]4UP*WCG,:^_<+X4
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M\JXLB(($(.Y(<`"<41UTUVBBDOK@6`$ABA)Z$B*G\%P/+K[+2AW#$%<)`#<J
M)N)?04U]5_#`]X#`K*#D57?1GY-:9&U&DOPGE,";5'HQJVZ.TT1>A)ZX%@CK
M2NJTA#W11"4-4W(*JJ(NGV73`]X!>F!75=_66<RRAPS(I%3(2+.$@(-KJMBZ
MB(I(FY-C@KJG3`G]QON(VJIO5%)!U35431%73[=<#U@,!@8+TP:^+TL"X=NZ
MONQI;7,&+R8?(I9@_P#'=J#5]13NK^B;1-*R+0BNHDGHBHN$QTWA6LC0>+2T
M;@N0'G+.P)QMUMQDE;68Z;!;7$1=JM$*HN$QRE$Y9#Y1JYH5MC";.QN8MFA,
M230A,=T<Y$HOTS`E%":04V-CHFNN%=1SFM97R9PNX?KWI4>.U8QW)++3CW:=
M<!LF-_;UVHNT_<O3"."XQ2V,"LI/CPK!E^=Q2V8MA4)":OMD/Q6S1>@.)[^V
MB:+IZ9H2J_CUW/>-]B--2[A\/K':8Y"R66AMF6G@+=JHMJ\.\45"_I3(+?QA
M&A_SZ,ZNJ)]=%<XXQ'F.38[[.LUJ2JN@1NIH3GNU(D_-ZZK@7?*)0P?+O'K)
MZ/)*!&J+%B1*9C/OM@X^]')H")H#ZDC19%<ISR7/Y)<-2)4"\8X]+B.PZAV%
M"5V0W.;D=7^T:;XQ.B@]ETD3HG737+,16\BXH`3.6+,H94N2EM1VBR$BF\KL
M9M(PRR$VDV.'J+BF`=?5=-,"TA5L][FTI;&-<,6#$Z1)@O,1$&([4FRH,LG*
MT54;!I4%6-=_<]$UZY1V?A6B;JN`U+KT>1'MID5DK5)9/*\K[0[/>+RJHZ)T
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M_N.3&G6$;;,GEVA(1M'4;UT7"K*/4M2HL)VNC7C==.Y%6./Q),9V`+(@V825
M;9;VF+:IM[QK[2+T^JXQ"AI'(W*N.NR*F8==5W]]%AD;#SBL1WT$HFBEJ2,J
M>NTU]J??&CO/)92PG\:=D1)$[C(3'/WR/%;<>/JR213<::U,VA>74D1%ZZ*N
M,77REVNMOY&CU`4-FR_\/D*UYE&D.$V\<LW([8LHHHV\8;2!]Q>@ZH/5<J+,
MX/(`'E,VOJYZ6%E&H9K[@1S%^1%::;&Q:;)Q!'OD@DBMJNY<@GQXGQW:>04"
MXE\*E6<M^;"?B&!-/NQP&,J0FQ[PQ1=0]$4=$<]VFFBX':>'H[U7XTK(TJ)(
MAG%67NBOMF+P@DITQU`M27V*BI]\:.-NZOE+D"-Y(8CN';QK8+)JG2(\EA\`
MO]".$NA?_55WZ=O\W^'(J-S2(S<<HY<U%;LCO#@5$CC0Q_E@+4PQ=V.$@JC;
M1(HCO[FGM1=?KEPQMLN,2W>,^2[%8EB=ZY)F,5:BLO4V7`8)/B-;M%$GFU5%
M!/O],:NNTXLQ+'R5>278[P1WZBI!J0XV8MF;2OJX*$2:*0]P=R>J9$2.9,R3
MYMP=UIAUQF--EG)=;;,P:$X#K0DX0HJ`BF:"FN%4\VJKY/D*-:<;B38/((]@
M+?(9)-2&8LF"C*B?=4T1A[H@(T0:DA)_'*CN*'D5?>0Y$F(#S8QI#T1]N0T;
M+@NL%M/V&B+HOJB_5,BN`>M&N7<A?#X%G&>"'.KJ3OP)$=EDGVE%V8Z^Z(@F
M_8(-HBZ[?IUZ4>>!UMD_R#BKQ0GX+7&N.'5V8NMJV/S'#CAV0541'-GQ2/<.
MHZ*/7KD%OP1M]G@=P#[#S3OSKHQ:-LP-1>F/N-J($B$J&!BHZ>N5$O@$Y:OQ
M[PZ)+B2ADO0X<$VD8<4F71C^[OIIJT(JVJ*1?73(J[YEN7B5T(-FZX<"2(-M
MBIF1$R2"(B.I*JJNG3`^>RZR5(\:^-8+D63OCRZ09[(-NBZT++.U[N(*(0(*
MIH2KE'/2H5I$@M0)L2S_`)2CVM[$)N/&=F.-`ZZ/[>YVBW.FT@$XC9CKM73$
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MZYJ+[BENV$TNFSU^B9-7&_ECA+SB7$NX5L_&D,0"XO(JT>V@^TZ12`5QKV-&
MI[%,G?:K?37UQBJ*35V[59R>ZCM6;LQGD3K,AH5DN&5*4EEQX8L<B$7!415?
M8FNW<B+],)KVR`QCITDC<S>%2WK-P-\:2VK4IWMK%#X[:?(".GZR,[TZ%^&W
M*8IHE+<O\1H*PX4[]3AEQ$?AFV^`_)16^P#@KHB.JHEMUZKA7U3Q_?TBUU3Q
M^*W(CRVZIB6+3\=]D5;Z-'M)X1]PN>H^J:I],FB!RALS\C,`\$@ZQSCM@$H0
M1Y6%/O,J"+L]G<V(>W^MD$GPY!"O\8<?:&,Y&>&$VLF,X)@ZCR#H:*#FA"NJ
M>F4?(W)5PY!MRB,V\5;'CMD)Q^U8*\-BU,;)I'I!(B.2=I%U;$1T7:FJ91U$
MKC$^3*Y=`IY,V.<2/57=.Z^]*[13F@<-X5<<+11>01!T-=.NJIKD1V7&.2,-
MLUUI<-R(4_FCXN0HABXZ#"(PBLL.$.YMHE;#7Z;B5<"3Y0B6R4<>ZIP??LJ"
M6S8MPHY$A2FFRTD1E$51#[C1%M1?ZR)D5RG&J;D[%E<P;?Y0U];\JXA24==5
M#6U97;%$D)2+X:HZ.GX@J9457&%GF7&'I82C>7@LQJ0Z^VZ3G?5QA5%PB3=W
M"V$NB^Y<*[_@3+J^):*.C1B^-(PTK)B0&CB1D%1(21"1=W31<@^3TT7DL+B=
M>]Q$K19K'&%8Y%&-9!*W*8)@&VV67E01DB`OH*`B=$_AA(^G^*SB/-6LRMFS
MI53*=:.,S-C.Q6V'$;VN@P,A5=5%5$4]?;NUV_7"N$YC)?DW,YBW:L"NHO)Z
MMRN;;;D''_:`D,J!MHTBLJ'YU<5?=N]?IA'MA+.VL+B#8R;0.2-)<M3JP(SX
M1I$5T'4B*LG=V.T@=OM*WH>[I]\)%:$MQ./\;KG95I4TS_'H[-7+APYCSC5N
MV6V0.T5$P>30$;[B;/S8(G<ACVJT_D:R2PN/W2M?;8K$;>E`@B]&C(X3++:[
M"7N(?Y45!773*=&.2QYD%WF)U\^VUJGZ293_`.D3'![SYA\L@35>ZA#^<.HI
M]DRD2[F3:O<EL(:3K)J,?,:YD>P[);1(3L`>\`$/1&5=UUT7:B_9<&XKG;.T
MCP8T&;/L8_&&+>[A.SB;G2S;V.#^W=TF2"2K:"1]L]RCKIKK@S$3FLJ<YQJ[
MJ>02[67+&CAKQETFI+*S%759#CK,?<"O*:"C@.:Z#I]UR:KZSY$M/A^/I\UO
MY>U&6>L!2;D(+C@"J[T$S`41?U"$=R#KIUR$?*HTE)#\);23+?@5',`5EP/G
MB#4257*3?;4U5TVU?+0255]>FB+A,?3_`"G9A!I*U3.2VS)LHS#KC#CC+8B6
MY?\`2C:1749Z>Y`T55T35$5<N#SX:M)MAP9@IS[TF9%DS(KKD@71=VM27$:0
MN][UT:VZ*NO3ZXU<Q\Q>M7&*J3#;>F1'95OR=R.;:R&F5=!U294DCHCKCWNU
M9'<@K[EZZ(F,->6;FW`;B\BO3'+VPXY0R4<$9)F30DK=FXVRFT>XV.Y=J:+K
MU'JN5F+)MYVRE4$2NY/9OT%Q=2&N]&25%1MDZ\R6.V\\KCQ`CR"NXU]I+M1<
MFKO%]#\ESK*FX0CD%R0C33\-FQEL[CDM0%?`)3PJ**2FC.NI(FJ=2^F,6/F<
M:VJ8LF[&',FE4V7)XK;$U7I(,FT56&U'Y*(KY,[PT#86I&@CNTPD5U9>7A1H
M%TU(F2N3KQ68Q!(ODD;LJ+.47$1E51#=!D=VA=55$5>O7)2/I_BF<U.2REP;
MQ^YJGB8*.+K,AL([FQ4=;%V43CID6B$X.N@+]M=,+F/H.%,!@-$TTTZ8!=$3
M`\`ZT9$(DBD'0Q1454UZ]4^F![T3`:)@,!HF!X1YE7";$A[@HA$"*FY$7T54
MP/>B8#1/M@:VGV'D56C%Q$54515%345T5.GU1<#9HF`T3`YR_P"&<:LIXVT_
MO1Y:-C&.3'ER(:N-;E4&W%9<;0T0C7:A??IZX%Q':KJZ"Q':%N-#8$6F0Z"`
MI^4137`E(@KUTP,Z)@>$>95TF4,5=1$(F]4W(B]$54]=.F![T3`\$ZR+@-D0
MHXYKVQ540BTZKHGUTP/>!X==::!3=)``4U(R5$1$_%5P/2;535-/O@9T3773
MK@-$P,$HBFJ]$^JX%97TM0U;3;V(BE+M6V0DO(Z1MF$=%1K:.J@FU#7J*?7`
MM-$P&B8#3`QHGVP-<>,Q';5MEL6P4B-1%-$4B7<2K^*JNJX&W1,!HF`TP&B8
M#`:)@-$P&B8#1,!HF`TP&F`T3`:)@-$P&F`T3`:)@,!HF`T3`:8&H8K"2BE(
MV/?,4;)W3W*"*JH.OVU7`VZ)@-$7`8%5R+C-7R"*U$LD=.,TZ+_;:>=80R%%
M3:YVB#>"H7N`NB_7`FE!BDXPX30J4;58_3H"J.WVIZ?EZ8$C1,!HGVP&F`T3
M`8#3KK]<!I@-$TT^F`P&B?;TP&B8#1/M@-$P&B8#1,!HF`T3[8#`:)]L!HGV
MP&B?;`:8#:/V3`;1^R8#:/V3`8#`+Z8-?(Y?E3E$>=.`&H<EA(5S)B.MMO=@
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M>D:BJ$;F[:O1"UZI@0X_->6QKF]B.S6'BE<F:H:?N,DC<43B!(WEM/WZ`BZ#
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M"'I^;JOKID1:P?(?,2O8H2@@?M+_`"29QTFV@>21HR#AM/[R)01?TM"'3KKE
M6I'#N><OO.05T=R,P,&6U-<LV4:=%VO.(_V6F3=W;#)[7773Z+ITR*KN8S^1
M5/D7D5M0#"[\#C$6;*&:CFCC<>3*-6Q5M1VD0@J;EUTZ=,J)S/D;D1VDBI<9
MCL3[6-`G<1`P/1UB5HD@7_=U.,6JGMT]NBY%Q(\C,69\XX*M44=NT[MF$=^4
M)&V*+!)5W""B1)T]-4RXB'1>0N6\B"'6P@AP+[X$V7,<=0WHQNPIA0D!E$("
MV..-J1%JNT53UP.1Y/S&]Y1QKE,A\T:IY'#&+)NI(->U(>-\27NZ^[WL]%T_
M+I@Q],X3R&\DWUS16PQR6M8@28CT83!.U,;/],]Y%N(":7W=-47TQJN?7R%S
M5NRD27&H!T<+DH\>?9`74E$V^33;;XDI;-P$^FX=.J:^F0097ECEL5JT=$(,
MP&Z>PM8+[;;PQN[7OBWVA<4D)]L@/J:"/N]-4P58Q[GR`]S2'!LYL'XC]'+L
M"@1X[G9)>ZV+:&1N;E)$/15]/7IUP:J./<_Y0]0U<+B]-$;DPZ:#9OUS:`U&
M4)3ACV6B=>:5EL`:+WZ'U5-<L3'64W-+E_GTBAM$;@-+WBKHSC+FLIAL04'H
M\M")ETDU+NMZ(0X5W>0,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@%P../Q'X_)XWEJ
MDWFLKT?D(*).14DB(HYM$'=RJHBFFO7`E.^-^&O-/-/UHO-R(#54\#CCIH4.
M.NYIK127\A=1)/=K]<"7QSA?'>.'+<J(JL/3U;*:\;SS[CI,CL`C-XS550>F
M!S]IXAXND"85'`9BVYM2PA/OG(<8:6<GZX]M'-!;<U741Z(JZIUP17\>\4+M
MDL7L=MJJD-`T=1&L;"6PX;;@.@\122%6U`F_:@)_%5PD=3<>/>'W%Q%N;*L"
M19Q!$&I*DX*D`%O`'4$A%T1+JB.(O7!&MKQKP=JWG6X4[/SK(71FDJF3;G?'
M:\JLJ7:0G!Z&2#JOUP1LXWX_XIQN4<NGA+'E.,#%-TGGGB[#9*0-ZNF>@BJ^
MU/IA27X]XC,>LGY%<)/6YM/3C1QP5)Z/IVG@VDG;<':FAAH73UP+2GI*ZHB+
M%@,]IHC)UPE(G'''#_,XXX:D9F7U(E5<"JB>/.(PWF'H\'8[%664<N\\JBM@
MNLI4U/\`YU>J_P"YIA(M:2DK:2JC5-6RD>OA@C<9A"(D`$]!124ET_IPJ-"X
MEQV"5>4.O986J%\*Y033LC*5%>0/_#5.N!$_N^XI^R.4?P5_:W97SSC]Y[K)
M5WO=S=OWZ]U-^FNFN!XD^.>'27I[SU>BG9R6)TW:ZZ(N28RH33NT304)"%%7
M1.JIUUPD>E\?\8!`)F)L>9GN6[#BNNEML'$5"D*BG[E77J*]/PP1RG"O&%U3
M6\.5(6/#&&1&^_`FSS28I"2*AQ'B^.T)$>]4'71?RZ85V-UP?C-S8I8V,)'I
M?92,X:..-HZPA]Q&7@`A%UO?UVFBI@1H?'KA_EBW%S\(HM:+K/'6XP&CS;4A
M!1TWS-=-ZH""@@FW3`LKWC%+>%%.QCJX]!,G8;[;CC+K1F*@2@XT0&FX5T5-
M>N!#E<#XI(8@,E7`T%8V;,'L&XP3;3J:.-H31`2@?]8571?K@>+'QUPVQ(EE
M5;9(4']J(0)QL5A(JJC"BV0CM35=/ME2)]?QJFK[.19Q(R-SI3+,:0_O,E-J
M,BHR*H1*GL15ZZ:Y#'.<9\=LQ+BXM;AIF3)E7#UI6J#KQ`V)M`T"FT6UONB@
M+[D%?7UPL;T\0^.D`@_96]A-/QMO<>T1B4NYYI$W]`)?ZJ=$^F$BVE<,XW)F
M0)KT)#EUC!18+V]Q";9,4$F]4)-R:(GYM>O7UP16O>*O'[S=8VY2LD-.WV:Y
M-SB*VSNW]I50M3;W==AZC@B8O`>*E+DRRA;GI:2$=W.O*(_+'9()H%/:T3H]
M"($1<*O(<5B)$9B1QV,1P%ID-570`1!%-2U5=$3ZX&W`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`XMSRC7#/9@#46QRI
M3<E^(V,4=7FHA(#I@A."NFI)MUT5=4TPE6W&.80.0N6+<5B1'.L>;8?22VC:
MJ3K`2!VCJJ_D=377KK@JPK;)R84P7(C\/XL@HX%($11Y!1%1YK:1:MEKT5=%
MPJ6ZXH-D:"IJ**NP=%)=$UT373K@5/$N55_***/=U[;S<&2IHQ\@$;,NV:@J
M[44NFX5P+*9.APHSDF6\#$=I$5QUPD$1U5$355_%<#+<Z&[)>C-O`<B/L5]H
M512#N(JAN3Z;D3I@;4(535%Z8&=4TUP*:IY;1VUU<4T&1W9U$;35DWIH@$^'
M<!$7Z]/7\<"YU3`*2)ZKI@8W#KIKUP,ZI@-R??`:I@:8\V)(-X&'@=.,?:?$
M"15!S:A;2T]%T)%TP-VJ8&$(5ZHNJ+Z*F!JF2AC1'I*B3B,MDXH!HI$@"I:#
MJJ)JNG3`B<=O(U[0U]U&;-J/8L-R6FW41'!%P4)$)$54UZ_?`W6EBU7UDNP<
M$G6X;+C[C;>BF0M@IJ@HJHFJHG3K@4U#SFNN;&%!CL/@<ZJ9NV''!%`^.^2`
M(*J$2]Q%7JFFGXX'2:I]\"H8Y)%>Y1+XZ+3HRX<5F:;Q"B-$V^9@*`6NJJBM
MKKJF02K"Q<BNPP;B/RAEOHR;C""0LHHD7==U(=`]NFJ:]53*)NJ8#5,`JHF`
MU_'`AP+!R4LI'(CT1(SY,`KZ"B/"*(J.M[2+V%KTUT7\,`U8.':O05B/@VTT
MVZ,XD'L.*9$BM@J+NWAMU+V_5,"6I(GJN!G5,#&X?37JF!@W``",B01%-Q$O
M1$1.JJN!XC2H\J.U)CN"ZP\*.-.@NHD))J)(J>J*F!L54^GK]L"@X_S!B]E$
M,.#+&`HD<:T<`/BOHVZK1H!"9&A(0^ABFJ=4P.@UP,;D^G5?HF!5\8Y'"Y%2
M,6\-MUJ/()T`;?%!<0F72:)"1%)/S-K]<#W8W;,6+,=C-.6,F#L1Z##VN2-S
MFBB.U5%-=I;NJ^F!8HO37`SN3[^GK@:9$R)&[7R'@:[S@LL[U1-[A_E`=?4E
M^V!NU3[X#5,!JF!IFR5C0GY(LN2%9;)Q&&40G7%%%78"*J(I%IHG7`1)"R(K
M+ZM&PKP"XK+J;7`W(B[#1%5$(==%ZX&[5/7`:IKI@-4UTP&N`U3`QN3377I]
M\"N2\9<E5[45EZ5&L`<<;L&!0XS8MHBIW'$7IW-?9HBZX%EJF`UP&J8$*VLU
MKHB2$BR)BJXVUV8H=QS]0T#?M51]H:[B7Z)@0K;EE76/0F75-\YT]NK%6$1Q
M&I+HJ8H[U38FU,"ZU^^!2W_+*JD9%Z21O(LJ-",(Z(X;;LPQ;:5Q-4VBJFFJ
M_;`F6MHM>VP:Q9$OOOM1]L5OND'=+;W7$U3:V'J1?1,":B_?`CV5C#K:^383
M7$9APVC?D.KZ"VV*D1?T(F!XI[>!;U42U@.H]!G-!(BNHBIN;<%"%=%].BX$
MS5,!JF`U3`:I@-4TUP,&8`!&9(("BJ1+T1$3JJJN!AIUMUL7&R0VS1"`Q75%
M%4U147[+@>M4P&J8#5,!@,!@,!@,!@,`OI@<%>]S^^#BYHRZ3+=99-NR!;,F
M@-XV%;$W$38*EVRTU7#/NXBZJ):<IO+EB)-2>SRVI6)(;"1I\56&&I)`(^TF
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M*E5M(<!SFT<[.5)8>C6MHIRW&9[:SQDD3<6.;B`D=0:5/9^HJ+H.U$55Q"H5
M?Q]ZJX)Q.>_`LR@S%<3EK8LOS92NBV;<0G8KRF:MMDJ_E'I[5T7`WS:2>,NN
MJK'^8W()U\$>-3VXPO2VGV7C-U'G=%2*\OZ>I'HFSHJ]%Q"MA<;=D6K,MR'8
MJ\YS:2R\ZJRQ_P"C'F50T]41(QEIJOY<0J(Y`LF*V'`L8=NG%6Y5Y!:9BQ')
M3K#CDI%A.=HT)S8C*DC+B:[5^V"MO)N.6>G)Y"1K:3/KZZ@<II#G?-]9;!*C
MK@]E>V3R#M[FS\<0KK.+V%3Q.VYA(FU<N-\R^`AE-1'2`VIK;(M.;T310[N[
M<J?E^N!U7D\W0X-9JW"?L"VMHL2*3@N$*NAN7]']0A%/<8CU(45/KD-?*J^F
MGRID.N>@V*UX\O5]$2+)A,?M\BO77:VBZ`PKW115=.O7U7!7JMA28T*O@W=1
M92N+LK>Q(<5&)#W9DE,)82FVB*YL6,JBR:]!^Z9=,?4?%S$F/XXXW'DL.Q7V
M*]AIV.^!-N`38(*B0EU1>GUR+KY53M6B7CTANHLH+<VIO(\Z.4622_(1Q#82
M1)/=\EPAW*!(FU-4$<L2NM\=Q)S/(^.*]#D,@SPV+%>-UEP!!\'@4FB(D1$-
M$1?:O7$*G>3!1+VI*WK)MKQ5V-+8DLP&W7R:FN;.PZ;3/O\`R;Q`_P"H2Z]/
M7(KF>21I<>7:&%/928@\?IX_9+OF[^G.)3%UYI5-XFFR0W@`E(AU3ZYJ)W(U
M!%MP=JV$BSP;A\U=>:UBOQ6AKWHAJA"UU06-Y>B]$7\<G:5IXWQ(7G>().@6
M"MRRO6+Q'EEHA,(Z9Q0?U7H&NU6T7^C$.["ACWK<?ADF1%ESYT>+`C2ZF<Q)
M%P$"2:)(C2TT0'61ZO`[T,$3':=SZ;Y0<<#B3JC!>L`61%1YB/W55&^^&YPP
M9_4<;!/<;8_F3ID77S'C_'I5C>4U5:1+%:ABWOQ,#:DQ&4C.@#L1-`)$!K=_
M9INZ>F6,W&ZWK[-85V.R2!AR6QD0HDJ)*DPI;)10%&GNTO<`#4B[+@]!/':O
M=C/*H5O*&Y)*RQBK*IN.[8C7R#)I]N:I/M`ZW^8VFE1#4?IZX[3N;;.*Y3N7
M,9J-,"E8Y1$D-UZ,27F9,<H2%(`1`7#)KNH1+M$AWHFJ:+B%=SXD:@L<2&/&
ME.2S;DOK)5T)#9-&XXK@L;)*"Z@M-F(CJGHF17)E66SW(C4XLEOE\?D@OM6"
M`[VCI"<34>]_9*S\74%;5?S_`$UZY8E4];#LY(4E$[66!.0V^2PI_>8>[&C^
M\HS9.%[#$Q4=B]4Q#N?3/%+49KQW0,QX;D#M0V6WX[S)L&+X-H+VH&B%_:(O
M7ZY%<+Q6NG':4:OQ);/(X[\]OF[[P/=I^*8.[=[BIVWA,^VK"!KM3TTZY47'
MB"76<?X?QJF?A2($ZU.6"`49T!1UEPS1'E)/TU)K10W>J9-7%IY6KUL/Y7BJ
MU)=CNW;`S4BJ\.D8FG1<[I,JBHVNJ(JJN5'+557*:\B+#G!;QYE=9=VH>CL*
M<-RI1A&VVG)A;OTA'5#;(MV_JFJ]<%<I9Q[0N"L0FZFQ&Q"MN7J^0,>2X024
ML''&@:9'8C3RCM-'3_J]!Q$JXL*Z0-9Y'>9K)K5G9'63HCS3#XNO`3$7=L(4
MU4D>`]XIU3KJF.T[DJ363$Y'-M6F+#Y37-(*Q7424HI`=89&0H#^7LE[]ZZ:
M8BUZXJ]&+F]>MA+DL28UC:"LEUF:W^X%)=)(C;AJ"1E1D179^H2+HFW&F:[#
MRS6QY,?C,M^"<UBNO(C\A&FC?-ME1<`CV-HI:;B'7IDS%<O40KMRYJB6/+9Y
MC%OY)74HA>1ARI,W53]1?T395A6A:'U$DZ(BZY8CM/):6/[56FRR[(JVK*.=
M\Q'0R=*`FY#T`/>8HXH$8IZBBY%?/_Y:=F6]3!=8L"XG(Y!-_;V1*6ULKW*Y
M4(7%%1,&"F:]M#5-$].F6)7U'FD4DX'=Q8H.*:5LAN,#2F3NY&21M`4?>I:Z
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MDD*\;:R#;=200&ZI>]=`WHB^N16GR!QJX?Y1'>K0D'%Y)`DT-L;9GLB*0]V-
M.VH2(BM[3%5315U'*E<[(C<E+QXW9V;$N/?-SJJN5ME7B,FJR:+1O[6U5=K_
M`.HX73\JIKD*@NTL9JTL("U\IA]WG4>7(-IJ0(E#<!"!P713;L5=VY17I]<%
M?0?$[4F/3V\$TD!'@W,]FO"3W548B.[F4`G?<0:%[5UPKYYR:K8CW7-8_P`*
M4U)G7]'*;=89D+OB[XRN.`Z"*/M,#UT75,)4HAG0$L8$;]P"'`YQ7I7MZRCT
MB.(P3Z(:[B-C>KBEJJBF4JZ\9N2@YK9M*CU@P\V^Y^\&,MAP%^5K\::P_P#H
MJZF[])UKU!/333(KHO(+LVQG5/%H';[M@Y\N:4EIUR,L6&J.*RXH;4_6/:.U
M2ZCNPFN!B3+BBX+S;ABO.Q9M`X3U3-BL2>T4&6X+W99)$(_TB<-DMBJ0IU3T
MRX5!5R%8"H0K2:#,[D=:BU,*18B4*O,.VZ.I"R0MNN"9$HCM37UUQ"K9J),9
M\@_M$B9:Q)M=/CK0"VQ(D-2*L&`'MG+(R:[:EO[_`'$WZ]>JZ8*Y_OW#_&.0
MRGI]RSRB-4SF;F"W&E,A\KN(K+B/J1"1H71E6/4%Z],0J3R>ND1`Y@Y`DVV^
MO@4]C6:2)II\YPE%YP$W+O(A0=X=4_Y.(5<1Y,V9S^6U93K*);Q+%]Z*PQ&?
M[#]2;&C:?(W=A&4!=2Z;T<3IUP5SE?`L'N-5["G9RI-[PZV2Q;DNRW5<E,J*
MQD47%T!Q%WH.FBJGWR85]9\<<AXZY34]%`)T);=5'EHP\T^'Z:HC9*A/"FNU
MSHJ:]/X98KF/-\U\76X;"36Y1U5@]`D,_))A)+:"K8@W%T4I/U!3)!$=>BY#
M5"P?(K(>7W=;(LW[J!65KU.RIR1;[DBO099-QR4&S<UW+MTZ'IZ+A';^(UBN
MLV<NOLIL^LDN-&TS,C/QFX[J-Z.@RDDC=55717.NU"]/KA7T+`8#`8#`8#`8
M#`\HH*JHA(JI^9$7TPD$4-RHA>Y/5-<*SHF$C*X5C1/O@8+:*:DNB)U557"1
ME$141475%ZHN%-/QP&B??`*B+]<#FJGQWQJKF!(B?*[3+A/1H+LN0[$9<)55
M3:CF9-BNJKITZ?33+4CI=,BBHGU7`QJ&[8I)N5-=NO73^&$@I`)"*DB$7Y45
M>JZ=>F%9Z:^N!K?BQGQ`7P%P0-'`0DU1#%=1+K]47`V*B8#1/O@-$^^`)1$5
M4E1!3JJK@$T5-475%],)&?Z<*QT^^`T3`:?C@C"J"$@J2(1>B:]5T]<!N#=M
MW)NTUVZ]=/X8&23TZZ??`QJ&NW<F[3737KI@9T_'`P9``J1D@BGJ2KHF!57_
M`!>HOFHXSNZ+D1Q7HDF,^[&>:-1454'&2`DU%=%371<)$JIIX%3%2-#$D#53
M,W#-UPS+U-QQQ2,R73U5<*F:)]\!HGWP/+KS++2N/."VV/YG#5!1/XJN!Z]O
MKKTP-*L1'9`/J@N/Q]P@?15#=^9$^RK@;E1%^N!A=J>JZ)A(RJ)]],*:(GUP
M&B??`YVIX!QVJD@]$23VV35R+#=E2'HS)DJKN98<,FP7W+IHG3Z8'0.FV#:F
MX:``IJ1DJ(B)^*K@>A451"%=45-45.J:8&>F!C3\<#.!C1/OA(=---<*(B??
M"1CVHNBEU+T15ZKI@C.W\5P0V_BN",$@HBJI:(G555>B8(*H:;E+V_?7I@C.
MB>NN%$_C@%T^^$AM3777!#:GW7!!$3"BI]=<#"H*)U71$_'"1G1/OA141?K@
M5]]0P+RM<KYJNBR9`8N,.&RZVXT2&VXVX"H0D)"BI@:*#C4&G$R;E2ITEU$1
MR;.?*0^H"JJ(;R]!35>B(F$BWV_BN"&W\5P0VZ?7!#:GIK@C&B??"M:0XPRR
MF;$^20(VKJ^NQ%UVI]DUZX2-VGUPK&GXX#3K@9P&!@ET3`^<#Y,NSY4-:$.+
M\1+.7726"5U);+,)A7UEDB(0J#J)[$T1/</N7"5JA>1N7S&:B0Q`@FURJ')D
M<=!"=W-OL-+(;9EKKH2.M)^8--I=-%]<L*UCY?FR:*#:PH;3HRV(,=QI$,B;
MMI[_`&>PJ;DU%C8:F/YO1/KD*]?S[Y&*;4TZ4L.+:V4B>P+LTW6FC;AMB\W(
M%MM73`7!+10)=47ZZ985IK/*7*#LXAV,&"%0_:V=,ZL<WB?1RN;==%Y-R(&T
MDCDBCZ_7!2/Y5Y4E2EO*HQ&LLHT5VF?)>T*2ISX,LQWE4S4TVO":N`*>BIIZ
M9"K'QLS8M<OYZ-BK"S5G0E=**A@T6L%M4)!<(U%5^O7*8HN27?(>.\[YI=TD
M2)*;@559-M&I+C@$XRU\E3%G8BBCB@/12Z=/3$*O8OD6Z>M[&D*-&&U)Z$[0
M-KW!2173=")\T5==S(BXCFWHBHGWQ"NGYK>R:/CS]A%6.+X$T`'+4D:'N.""
MKM;13<)$+VMCU)=$3UR&ZX2!Y,YI8R:VJB0X3=E,LK6K>D2P?9`5KFD>;>["
M$1CO%?<VI?TY855W?/[[F/C^QB18D-AXN-/6=R#W=<%5=[S(M1]J@2=8YEO+
M73VIIB%?4:B:U!X5!G&A$S&K6GB%.I*+<=#5$_'1,BN0+G_,(]'"NI,:M.'?
M-P4IE;<=16I-@\(`V_KKW`!MQ"(PVZK[=.J+E2M5CY%YC`L5H2B0'K=JXA5I
MRE5YN,Y'L6''F7A!%,P,.TJ&&Y?P7KB"&_Y5Y3'IXTJ;'A1.U-GU]I;*U(=K
MVY$)\6F4/MKW([;Z*2]P]4!4T7UQ!XE<]YQ72^1NM'!L`:Y#!J*^.Z+K0--3
M6V$%=X*6[17M573KU_AB%6%AY%Y=5Q.1-S(L!VPX^Y4`?8[W9<2R,1>TW+N3
M9N]B_P"')JMR>2.0G93)C-5WN,5TN?#L'D1!=:&O`E5]#5S0][@*/:[>NFBZ
MXQ*K^+V%U9^4:*WLQB@EGQ=Z5&"*CB;&W)3+@M.$9$AJ`FGN1$ZZ],*Z?F,[
MXW,.(,I!CR7)3L\&);V[N1W`ADXBM;5T]Z"HEK],(I.`>1.57<^@&YBPFHG(
MJN1/CC$[O<:=BN@!B:N+H0F+NJ:)TT^N%=#SSD=Q3C!;JUC]^5\A=CK;C[QJ
MPRK@@RPTH*>JI[R4D0!ZX10TGD'E?)H[3E)%@L2(T"LGV,68;B;_`-P13<!L
MQTV"VV):$0KJ73!6]OGU^M=-Y.+,,^,02LP?C;C2:*5W<%LA+50(G397<&U-
MHJBZKURPJKNO)?+Z.NDO2XT"7)?I"O:HF4>!H>R;0O1WO<2DFCXJ#@Z:]=4Q
M"M/,[_E]AQ_D7')(UB38U#)LK(Q!\VC9D=T([30D8DA(#1*9KJF[31,0K8SS
M^^JW**!&"+(KD6E@O-"#KCP#8-`*NOO(HMLDA$G;;T)23KTU3$*\U/E;E0A7
MV-U#@K53AN45J)WD?`Z975W:N*HJC@L*FFG1?KB%6<WG',*VGCV4MBOE,W/[
M>%-\57-P/SW$$@=`S1'`;$D5#0QW+TT3$*Z?AMMR*PK7UOX"09S$AQD$'04>
M9316GNVANJTIBO4%)=%_#$''6WE2YIY\^)8QXHG57,=FPV"Y[:.4"*$_J?3M
MD6TU_+JBXA6.1<EMTF5$U8<$;"16WLJKL"`S<C@P`G'44W:*CK6U7/\`<Q"N
M<#D'*X4YKDS"Q)5P/!HUG.<D`Z`/(#ZNJ*"!:H9"JINUZ+]/IB%?9%GOR:#Y
M\7:R^[$[[/<13$#-O>.Y$4=415ZY%?&JZ]Y:;G'N1B[$DW[G#9L]^0^VX+1"
M#\=[;L`M=RZ[==>GV^F6)75M>2>36KX%15(R&HS-7(L(YJ"*H632/N*+Q.-H
MWV6RU34"W+JG3$*NO,38.>+^2B2;D2"X2)^(Z$B_X4R*JW^>74?ED&J;",]7
M2+`*H^T#AFRIPUD`;K^HMHYN'JR@KH.BJ2:Y8E547S!:LG6-VK$9MWNV%=?"
MT)Z1K*,I?#;%2+H,M`78A=5Z:>N(5>P.:7X<RC4%T$>O)]L.R),O($POCHXZ
M423N5O>V[J*LFF[:F[7$,U<<IY#8P["EI:WLM6%X\\VU*DB3C30QF2>->V)`
MIDNF@CN3[_3(."L+BWY;8<0ASV8C;*VEI77=>ZR<B,\]!9=!2%%,-S9"BD*$
MGM5?KIE*ZKR!(M..\2KF.,NM0$;GUL`$<;)U$C.R`94!]PK^4O77TQ"N8X_=
MW-#R&V&.S%*HL.8%7RQ5'$?[DJ*R2.-Z+L%!-.J+KKKZIB%=#PCF_*.0SH4L
MZL0XW:,/O1Y7M`XYM.;6VRU<-7NX"*JJ(#M5-,@\>3ZJ]DV%/95<-B^:K!D'
M-XN^[VEE-.H`=YE5U!76=/:AII[O5%RJH*#E\@;#C[''I'8XTE/;2GH%HAB^
MW(@OB!-2'B(E#M&>S5==$15Z],1*U6/DCF<FIL6H[D:-,BN43K%@,=T6W&+6
M1VG`!MP]RB*C[7.FX?HF(5TT'F_*)_(B9A5H/TT.T<I[)U=&R;5IM-TD3)ST
M[I(*-;-5'KKB%7G+N1RJR32UL)&TGWLQ8<=Y]%)II`9<?,R$5%37:UH(ZIJJ
MY!P-SR*]Y"?&X$QN*T['Y0_3W,=0-V+)*-%><`A%2'5LAVEL+T+[Z985UG/N
M.4T?Q=:U;,=&(,*"XL-MI2%6";%5`VEUW"0+U'KTR*Y*-:60<@XSQ#E)I(O:
MBP23769)M2RKQB/Z2!1.G>:7:+P?XVA)T7+$JQA>0N?VE2[;4],P]"E5\F;5
MD^NQ!?CE^G'/:Z1NJ\`EU$1VEZ],0K-=Y;F6=L,"`U&(+2%"E<>?(347G73$
M9S1JA>Y8J&A%M]/KZ8A7=<GXY6<DH)M-9"JQ)C:MD0*HF"_U7`).J$*]47(K
MYWP6#97\R-6<D8:7^[R04+NM_EF3!:'LR4%/R@,8Q)17U<7_`)*82I\#R1R*
M0Q36RQHA4W)')<:N:%'._'=9;><85\MRBX)I&)'-HCL5?KEA7)6'.[<)?`>;
M<D8B1TEQYST4(*/F#34B$W_Z41:[0%TD4C1-!'$*^VU1SBKHY3W&'9A`*O.1
M4)&%)4U_3W*1;?MJN0KGN8\MG\>N*-'1CMT5FX]#E37M^YB4K1.1?14'8X0*
M*_773[X-UR;?D*XO^"V\F56Q%=K:JP_F*L?1U!":R1`$4D0MR";8$1:]=%33
M+"N>Y9<W5CQWF$%WXZ4U96T#M97M@0=ER0HN(B.;BZ(HZ:Z>FF(5V#GD;D,6
MSL**7&AK:MV\&J@26U<2/ML&%D"3@DN]2;`"1414W+IZ8A7N%Y%OTOXE#.AQ
MOF!='3V#[6\6S;*"4UA]A%5=JJ*()@2KHOUQ"H=#SGEEUR7C((46)!F_O86$
M4&S)3*LE#'`A-2]NHEKI]_OB%=1SWDMU1Q:G]HCQI$FSLH];I+(Q`/D(6AZM
MHJ^U1R%4L+G/,I5U\6/5LRHU=/9J[TFM0$#)H#?D-.N.#H#9.IM`@523ZX*C
M5ODWD<ZP9$(,5([S=JY*8=)UER#^VFK;:2G50@1'UT]VB:?3=E*KR\N<I:J[
M9[X$23*@MU$B*>V1&8>"U?6.2#W-QD+9I['-$0T^F(5!\E\CY79\/Y54R6J\
M'*!F)^[N,J^N]^0X+P?%U4"!&VMJ[C1=Q:IZ)@KZ?S*PL:[AUU85I-A/AP'Y
M$<WA4P0VFE--PHJ*OY<*XJ%S[F)U';B-P9=G4T<2ZM"?[K:24D@9BTSM5>V6
MQDE4RU3<J)IZXB/H-1:MW%%#M(P*+5A&;DLMN:HJ"\VAB)?_``NN17RGA'+^
M1D_21*J#%8J?Y=F60T+'=(RDLRU:1MMYQ=?<NFW=]U_#+$KN?'/,)/)ZZ5(D
MG&[\=T6G8[`O,O,&H(1M26)"(XVX!*J?8DZIC10<F\E<LJ;/DJQJN%(I^+%"
M>G.&\Z,AV++#>YVA0%!'&TU7JNB^GKD*\O>3>5-R+4UKX"0(UPG'ZYQ7GNXY
M+><:%EQT=FT&T%U5/KKJFB985[LO)?(Z@+0;"OBDYQV?":NY#1.(TM;/TVRV
M174D)K=^H!*OHJZXA6VQY$Y-Y#QA]^NCR8LFYF1J>6+K@N`VS#=T?%$]A]TF
MS%->FU47$*I++R-(M^$<A=M*Z&\Y7+#290NE)C262<DB)-R!)!)=OM)MQM=I
MXA5_(\C6[,A^<U"8/CD*Z&@E>X_F(X3@1UD"GY-@ON(FSU4?=K],0J#2^4.6
M2I59\RHBDQ;#;M0V(KSA/K)J#-$1=XB.UY&]$^J+B%='XZYE(Y1729,@HZ/Q
MW!:=C,B\T\P:MH1LR6'T0VW`)53[$G5,BNMP&!@O3`^65?!.8-\I<FO*4(')
MYS)$Z-:R3C/M$YO[7[:XWL'>&@$BGM^J82.QH^`<<I)@2H#;H]CNI!CN.FXS
M%206YX8S9*J-H:^NG\$Z9:1A[QWQ!ZBLJ,X`_MMK)<G36A(A4I+SB.DZ)BJ$
M!(8HHJ*],A'BM\<<9KI-5*CC)*33D^Y%?>DO.N$<H$;=-XG")75($1/=Z)Z9
M:1B/XWXO'.*;;;VL.P?MV4)YPD^7*$A>,D5?<A(X7M7IUR4B%#\/<"B0+"N:
MA.+`LA5MR*Y(?-MH%/N[8PD:]A$<1"3MZ:*B?;!%QQKA5)QQR:]7=\I%B39S
MI$E]V0XZ;((V!$3I%UVIIEJXTV_C_C5M:.V<UEPGY#3<>:V#S@,R6624VVWV
MA)`<$2)?5,5(C5=!<2>6O<@OH\%HX#;T&A^(IF[\5\Q,W'R-!03+MBB"/1.O
M7KD(N.1\;J>1595EHV3D53;=3MF33@.,FCC9@X"B0D)"BHJ+A=4]=XOXA76#
M5A#8?;ELR7YK3A2I!Z2)3:-/N:&9(JF"==<M2(K_`(;X"]!BPBAOBQ%CNP@5
MN7);,XKYJXXPZ8."3K>\E)!-51/IBD=;"KHL*OCU\<52)&:%AILU4_TP'8@J
MI*JE[4^N17+P_$?`8<*;!8KE^'.#MFP;SS@M`CG=08Z&:]A!<]Z=K;HNB_3+
M4B6/CKC")'4VGGGH\YNT22[(>-XY;([&W'7%+<YL#VH)=-/IBD1G?%?$'&GF
M>W*%B2<IR4T,N0@/?.-#D@Z*'H0.$*>U>GVQ5;9GC'A\N7(ENQ7!<E/Q9;P-
MOO-MJ_!T^.XC8F@"0[!]$ZZ)KBI"^\9<.OI\B?9Q7'7Y8,MRD!]YIMSXQ;V"
M-MLQ$C;7\I::ID(V-^-^'M\B?Y"$+2RE$KDG]1SL..J';5TH^[LJXH>W?MUR
MTCQQ_P`9\/H+%FPJXKC4F,TY&BJ<A]T&F'20R9;!PR`0W"F@HFB?3(JWM..U
M5I.KYTQLCDU1N.03$S#8;K:M&N@JB%J!*G7`@57`>+U3M4[!BDT=(P]%K55U
MPD:9D$A.CH1+NW*B?FUP)/(.(T/('(;MHP3KL`G"C.`XXT0HZ.QP5)L@50,>
MA"O1<"E#Q#X_#]NTK/\`\*:&/$7O/IJP!JX#3NA_K`)KJ(N:HF$B:QXXX;'O
MI-ZU7"EA,5PI&IN*R1O#L=<["EV4-P.A$@ZJF6D:@\8\-&LDUBPS<A2H_P`(
MVW'WC48J%O2.T1&I-M;OZH*B8I&V^\<\2OG67;.(;KK,8H/<!YYDCBFFA,.J
MT8*X"^NAZ]>N*1%D^)^"R'T?<@'O3XJH@2)`#O@(@QG-HN(G<;$4'?ZZ=,4B
M7$\><4B?`[,0D2K<E.P1)UTT`IV[Y.J$2H2.;RU0M?7%(AQO$GCZ-53:EJJ'
M]OL$$)#!N.N(@`?<`&E,R5H0/W"C>FBXI%]0<=J:"N&OK&B:CB2FJF9NN&9>
MI&XXIF9?B2XJM5EQ/CMF[->G0&GW;&)^WS7"3W.Q=5+M$O\`BZDJY$C$[B5#
M.F0IDJ,CCU<P]%B>XD`&9((VZ&Q%050@%$ZIEI%;'\8<,CQ2BMPS[)5Y4ZB3
M[Y+\$BWJQJ1JNW7T^J8I'1QH<>-#:AM#I'9;%EL%55]@#M1%5>J]/OD5SL+Q
MEPV"T#4:&8-MQ)%>V*OO$@Q91(3K*;C70544T^VG3+4C!>+^#E.KYRUR))K&
M&HL4T<=1%8C_`-BVZ*%M>1O3V]Q%TQ2+R[I:V[J9539M=^!-!6I+.XAW@OJ.
MX5$DU_!<BJ4_&G#3LTLR@K\P934\3[SR"DID.T+R`A[-RAT)=/=]<M2)[W#N
M-/N2''J]DSERV+"02CU.5&VHRZ7_`"@[8Z8I'G^3:#]Z_>"9,YO>^2*&ZZ30
MO]OM=X65+MB?;]NY!Q2-][QJIO&66K!LB6,ZDB*\T9LO,NBBHAM.MJ)@NBJB
MZ+U3ID(B#P7C0.U+K<8@.D-QVM477$V./HJ.F6A?J$YN7<IZZZK@B;?\>JK^
ML<K+1I7H;I`9`)$V2&T:.`0F"B0D)BBHJ+EI%:/CSBHJI)'<U6P"X55?>7_3
M6Q0`=ZG]!%$T],4CW1<`XG16LJTJH*1I<LC)S0W";%72W.*TT1*VUW"ZEL%-
M<A$JZXM47$B-*EBZ$R&+@194=YV.Z`O:=P4-H@70MB:ZY:1`=\;\-=:@M'7B
MH5S4B/''>YU:EI_I`.>[]5'?4M^NJ]?7%3>**UXEX(W&DQT@F3<R.Q$DJ<B0
M9DU$/N1_>3BDA-%^4D75,58FL>/.),\@_F!N#MM505-Y''=IF`=L73:W=LG$
M#IO4=WXXI%C>\=J;V*W&LF5<!AT)$=P")MUIYO\`(XVX"B8$GW1<BH2\$XSM
MK1^*O_1,DIT(NXYN&4>J&\9;M7#+>6JGKZY:D6=O40;>LD5D\%<A2P5N0V)$
M"D"^J;@4237\%R*UR:"JDO5[\A@77ZHU<KWCU4VC5M6B42]>H$J+]\M2*VB\
M>\1HK23:5$`8LR4IDXHFX38JZ6]SM-$2MM[RZEL%-<4B3"X?QJ"=><2O:96J
M60M>H)IV5F*JOJ/7_G%7KD%RJ:IIA533\6IZ>78S*]LFY%L_\JP,G#<[CVB#
MOT,B05VHB=/HF$B%%\?<6B2G9,>*3:N$^8,HZ[V6CEHJ2#8:W;&B<0EW*")Z
MK]\M(PSX]XHU%JHHQ%6/21WHE:V;CABVQ(;[3K:H1+O0F_;[M>F*1JI^`4]/
M:5\JN-YB-603KXT17GG![1N(:(2.&0J@;?9TU3[Z=,4B\MZ6KN(PQ;*,$J,#
MK;XM.)JB.LFCC9_Q$A1<AN(C_$./O0KB$401CWQ&=L(*0*^3C8M&I$*HJ*H`
MB=,4BKF^+>%S?D=^&:I+BQX,E!?>!'&8:HK"$@FB*0:?F]<M(DSO'W%9QV3D
MJ*3CMJY'?F.]UQ#[T1-([K9(6K9MHG0@TQ2/,CQYQ>1"9B.LNKV):6(24?=&
M2LO3:KQ/B2.*1#[5U7\O3TQ2/$'QIP^`M8L.&3'[.](D5^QYY-ARRW/HOO\`
M>)DB*HEJF*1:W7'*JZ&&-@V3J0)3<Z+M,V]LAG78?L4==-5Z+TR$5TKQ[Q5[
MDG\RK#TN?81NBXZ+3CC2:-..L"2-.&W_`%2(=4P1QW'/&%VS*1FT$&81J]^Y
M+&LY[\>:V^AHXW\!Y$99$^YJON7;_5^^6D7X>&^!BRZTL622/LQX[Q',E&9M
MPW.['12)Q5_3)$V_X,4B9R+QEP_D,M^5:173>EL!&FJS(?8&0TT6YM'Q:,!<
MV*OM4D54Q2.ADUL237/5T@.[#?9*.\T2JNYHQV$*KZ]17(KG/[KN'HQ&9%B0
M`QHJP%(94C>[#5=WQWSW[G6T^@FJZ?3+1U`1VFV$8;'MM""-@(>U!%$T1!T]
M-$R#E&O%7#66H334=]L:^-(A1E"3($OCRB4W6S)#W&F]=P[ORKZ9:D7-#Q>J
MHUDN0^ZY(F*VLJ5)=<?><[(;&T)QQ254`>B9%<N'CO\`<.:\CM+H.Y56*UQ1
M([<AQ`=^$VNJ26$015$<T5-577ZX2+L_'_%W(%M!=CFY&NY2SYXFZXJ_*]JH
MZV6NK1"K8J.S314RTC?'X70M5=C6N-'*9MQ(;1R29/.R$-OM+W'#5270/:GV
M^F*1A[A/'G0I&U8(&N/?_A33;A@+?Z*Q]%053=^D2C[L4BO+Q;Q-RNE0'PDR
M&IC+,5YUZ2\X]\>,YW6F1=(E-`$^OKBD2UX#QM;8[-6G.Z[(;FO1^Z?QSELH
M@MR#9UV*ZFU/=IZHB^N*1&9\9<49:@M"V_LKEFE$UD.ZBMEN^5[MVJ[]ZZ?;
MZ8I%I0<6JZ,I+D17G9$Q6_E2I+IOO.(R.QI",U5=`'HF15O@,`JZ8'-%Y%XH
M-D=><L@,$DJDDVG!C$L(=TH0?4>V1,C^=$7Z+]L)40_+'"VH,V;)D/16J]IF
M1)!^,^VY\>2:`R^+9!O)HR73<B:)]<%2(WDCB\F-*?:=?WQ)80'(IQW@DE)<
M%'&VP8(4<+>"[A5$TV]?3+"M#_E7AS-4W:%(>6,;;SSHBPZKK+49SM/N/M;=
M[8-N)M)23$*TS?,'!H;T]IR4\:58=V>\U&D.,M@K8/"2N@"AH3;@J/7KB%:K
M3R32RJJ<Y76+E;)KYD*+(=DPGC4?ENAVOT20"4'P+0'/1-=<0J<UY.XFY=_L
MP//?*^>=21K'>1@9H!O[!/*.Q"(>H=>N(5MK?(_&+&UC5D5UXY$U'C@&K+B-
M2`C'L>-IW;L40+HJJJ8BXI.>>2'ZQZ^I*Z*^U;5U$_<L6+C/<BHK:%M%>J:I
MJ&BJOUZ8B;J=2^3^/2:MY^4ZZS(@18DB:+K#C*FDP41HV!-$5P77-1';]>F0
MJYH>8TEY`ES(;A"->ZXQ8,O"H.QW6DW&#H==%050OQ3!5&OF#A80I$V2Y*B,
M1@BOKWXSHD<><XK4=\!1%(FW#337_#A7O^]WAJ1?D&<ILDG)5G%.)(&2$LP5
MQMLV-G<3N`FH=/=EB5!?\B#:6/#W^/R?^C+>SE5]I'?84'Q*/&=<5HQ<VFT;
M;C7N33$*VU7DBIB\<BSIDV1=/R2FN`42";;RL1'B!TRC#N(08Z`1+ZK]-5TQ
M"IZ^3N*'8Q8`F^83'(S#<T6'/C(]-!'8S1.*B:&X"HJ)I]>NF0JD\?>46+%F
M)4WKQ_OLN581V'TC&S&>*'(='M-N:=M74:;0E%"URPKQ5<TM9$WAJ,VJ6%==
M1[8YDE8?QW'#A:*T0M:D0;.HJ/\`6TR%>J+RS"!FOBR$F7`G2E=/W;$-6A<:
M!WMKI&%2(5Z+JGT_IP5V%7RVGM"K4@&;PVL-;&(X@+M^/[$0C7^JJ]Q-$7_@
MPJ':^0^.5=@Y#EF\@QW68\Z8#1%&C.R=.R#[J=`4MP_@FJ:Z:X%-2\AY)?<X
MN(K#[M=6<?FA$=BNQ1)N4TL8'"+O*2&#BFZB@J=-J>BZX%?=>49QO#\",_`8
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M,=K_`-O-I6Y7R6`[AAVCV^C?OUUTTQ%:Z_RGQ2RF5T2N.1,=LV&I<96([I@C
M#SA,H;AH.T$%P%$]WY5Q$K;R/E42EY"P,V<XW%"KFSW:\(W<1P(BMDX\CR=4
M)L2T[:?FU_#&8;K%AY.XI7LR7Y3KPM18<2P=(67"_P!'G.=IDTT3K[OS)],B
MH+GD*I:M#DRIDJ'!:JREN5<F$3)]):1T>[AZ$A*:[$;_`!0LL2K&=SNN;B@(
ML36["2LEN/"^,1246*GZKJM*NBMAN'W:Z+JFGKB*YOA_D3O5-'97ULHN2..I
M;SXR1D%H_P!4`)]'1ZH2*:`C2)]<@MI_E"%'>AQVJJ>Y)D6;54^PXRK1LF\R
MKXN+N70A5L>FU5_'33+$KU7\X@L)8*]*DV<E;>170X#<5&WQ<9;1PH[8HJ=P
M6PU+NDJ=,BO+_E[BC;$1UIN;+*;&DRF6(T5QQU!A&C<D'!T38XR2Z$)8%C#\
M@44ZPBPX`2)B26XSJR6&E)EH9K:NQU>+U#N`.J+II]\#I=>FN!PM3SN;,\B2
MZ&0P+5-)CN+03$_-(?@.=N>*KZ>U3'9^"*N$4\WF?)V)]HV,P-D/EE;4M)V0
M_P#09@1U<:7_`)6KZ^_URQ7=W_)H%*C(/MO2),A'"CQ(K:NOF+([W2$$TZ`F
MFO7ZHGJN0<JOD#M\I??-YQWCA442SBQ@C%\CNR99L)H.G<53]J;53HN!-D<]
MK9IU?Q)C]>977[1*C.1D<(I#;9&45U=51I"30D<%5P-;'F#BT@F`CQ[!XYB2
MOA"$-U5?=@FH2&6NG5P-JKI]OK@38?DOC<Y:]("2):6+#$L%99(NTS)=5ELW
MA_,"=P5$NGMTZX$WDO,JWCP@LQF2^1,OR2&,TKFQB**$\X:ZB(H**GUU7Z(N
M$5;ODWCLF:_505ENRABMREDL1''6FFI$8Y++Q%IMT(`737U+VX5CCW/ZN7%I
MX@NRK25+API#TX(VQ$&:BHRZ^V*KV>ZH*O35!^N6)46N\D541D6Y4F;:RYME
M8PX++4$@=[D)2(XR`'_BQ'03+3=ZY%2U\L<36LC632R7F)$)VS)MIDB=9B1S
M[;SKS?YAV'[53JNJ+HG3"+U_D]0QQX;]]PFZTVP>`B`D,D=5$:%&U3=N-21!
M'375<*J6?)7'R?&*\W*BSOGL5CL-]E1=:?E`IQU-$4D[;HBNTT54RQ*C'Y0K
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M;29L-T]B"L9Z`GZP.CKZHJ_3IIUUQ"HE7Y/IHT&,,J3-N)LYVR6)V(!@Z:5S
MRB\UV@UT5I-!15_-ZXA5C)\J<28K6+(77I$5^O\`WA589-PFH"*B*^Z">X41
M5TT]>B].F(5*Y7SB-0\5#D0PY$YATXP-,LCHYI*<%L")"TVHF]-<A6N9Y'X[
M"GI$DI(;`7F8DF<K)+%CR9""K3#[J=`,MXI]D54U5,%6EYR2!3!'^0#K\F8X
MK4.'&!77WC$5,D`.GY0%55571,*H5\M<25:T6/F2G;0'3C,1XCSKB+'>%A\'
M!$=6R9,_>A>GK@3^37B5UQ01UFN1?GRG6OCA&^0DGMQS=[7<U3L_DW(2:ZZ:
M82H_&O)W&.13(L6N^2A3HQS(+LB.XRV^TR:-N]LC1-Q-DJ;DP5*N^>T5//6%
M)20ZXWV?F.1F#>;C))/MLK(($78AEZ?X5Z=<L5J'R+QPKANLW/HK\AR%&F*R
M?Q79;**KD=M[3:KB;"33ZJBHFJX@@U_E[AL\$<9.4+)PY%@PZY%>`7689*,A
M&MPIO-I4]PIB#?7^5.'S6I3H/O,-18;%CODLN,H[%DKM:=9WHF]"/V=/ZW3(
M/;'DOC4AEU6?D.369)0G*L6268CXM]Y0[*?_`!7OUUTTP*[^]*KGR9<.`U+9
M8"E6X"W*,9`V!*8I^BNTR(%;+45TZIMRQ*D-^2^/0*F$[.ENS-(42786#$8T
M;9:E"G;D2!'=V!<ZEIUVIZ].N(5O?\H\38MG:MQR1WH\QBND/)'=5AN1*`3C
MB;R#L1'4,=I:Z=<A5M9<GK*VVK:F5W$F6RO#`00(A,H[:NF"FGM$MB*J(OKA
M5+(\C4,SCAV-=+=8&1`FS8\Q8KCO9""7:=<<9]JZ@Y_473=A*YODOE:9'H;H
M*M#^?1P:R<Y;O1_]&D!-,=R@WKJ.X-53KZ]/IEA7>\>Y54WI3FX*NB]7/?'E
ML2&C8<`U%#!=CB"NTP)"%?JF0JXPI@%P/FD?QQRO]JM^)R+>*G$9B3OAFTRX
MM@*3B,T:<,B[>UEQU511ZDB(BZ=<)$2]\9\NY!6R2L9=>U<?MK%1&<9[RLDV
MW+:DNO.:BA(1]A$$$14'KU7!$NX\=<JD7MK?UL^'&LBLX5I4BZ+KC2K&A?">
M9DHFU=KH*6A!U3+2-5WX[YC8V4&[*733;0XCD"UCSX9NPQ:-Y76RBCNW[FM5
M'WK[_KIBD;9OC2^?HN;UC<R(B\F)A(#BB8HR#49J,J.B*:=49U1`Z)KIBD+W
MQOR&RE<C>:E1`2Z=I7&4+N_II4F+CB'HG7N*/MT]/KBD>C\>7XNN/+*C$W_-
M2<E0!%Q3^.+2!V$33J[T]?3`Y7QA,>3D54#$:%+%OY;2--C8,RJQB4X;[J&T
M^*L-JK@@)#NU_P`7IE3-=GS7@-Y=75G.KID5EBUH'Z)\)`.*8$X9&#H*"Z:>
M_P!VOVR5=5EUXGNK8Y9G816'#JZJ)#/M&\(3*I]9"&XV:H)M&1;=OKID(ZOC
M''KB!12V)CL&-9S=ZZU,;X\9DE#8)`!*I&2+[E(U_#TRTCY+RG@'*>.<>EVT
MZ7`E29#%1`>5AJ23CLF+9@\DETR(S/>A$3G3IZ)T3(+[E_'[VMLJN[?=B'?7
M7)Z]U6FT=^(TU%B/,-@1Z=Q>A>XU%.I)TZ9:+^)XXN&9U/8'+BK+8O)5];B(
MN"!'*CG'[4?ZZ`))[C]=/QQ2*^M\9<VI6ZN;37$%JY@K8QY*2&'78KT2QE_+
M1-HFVX+C)Z::+H7UQ2/5WXQYC87C=@=S#EI%F5DV&],8<5YM8.U7V0%LQ;`'
MC13U%-W7:O1$R$3:7QM<1I4!F?-C/5-/:S+FO[0&,AUZ43I-@]NU$$:^06JA
MKNZ>F"/''O&M[5KQ179T5Q./#:H_M!Q.Z5DJJWLU7VH&ONU]<$1*+@]IPAJF
MN9D]A^'04K]=<-M1WG7'6D?^2)Q@!5+=_5451?PP1<>)^,LUE7,G,)(;A6$E
MQRGB2@5MR)7*9&S'0"1"`=[AN()=40D1?3"M%QXVLIDGD4-F>R/'N5/,RK-A
MP"60RXV+;;O8)%V*CH,A^;\JZKUP+[B_&[&IO.2SY,AEYF[FA,CMM"0DT(1V
MX^PU550NC2+JFF!SLKQK?.6LIYFQBI`>Y'%Y&VV;3G>3L@`NLD2'MZ]M-JZ?
MQP(DGQ3R(92V<"S@I:-VUE/9;EQ2D1#BV:@IL.MJ8EN`FT5#$DPD=5=\2FS_
M`!_-XP$QI)DR"Y"^83*`TA.BHD:,MJ*(*;N@HN".7L?%W*)=Y%L%MX1MPIU=
M.B=^,ZXZT,)D6W8S9(Z(@V9;G$T'75?=K@B3:>'(DV39/M6!QUDV;-I7;1_]
M#W;4GMM+KZ3/U-__`(7X9:1-G>/IDCG$/D$=Z)";A&UL?C-.-S#BMM*!0GB$
MT:=:(_<BD.H^B??"I]_Q6X>Y,SR*DEL,3/@N5<MF6V;C1L&XCK;@["%4-L]>
MGH2+IT]<@A<8\=O<>OZN5$E-G5UE(-*+!@7?(A=1Y7MZ%L]RC^7;_3@.0<#M
M9EM>OUL]F/#Y/";@V[+[1.&':`VD>CJ)"FY6G%%1+IJB+^&!63O%-I\BR;K[
M&.U73)]18,,NLN$ZVM4C(*VIH8H0F$9-/;JBKEJ1BQ\5W+L^9;0K*&%FMR];
M04DQ5?C=F1%"*[&D-J:*6HMH6\5147%(O:#AUG7<G2YDS([P+5-USC3+'8_5
M"0;Y&`B2B+?ZJB@Z:_=5P12<@A!R[G"1(O>;B0ZBXJ;22;+@(T[-^.#>Q7$$
M7-4$B1154T3!N(+WB3E,R#-;F74-9$FKK:L.U%<%L/VV3WT<75U5+N#T5/HN
M*D=+R7A%E:W\FU8D1.V_4+5+#EL$^T:E)%\U<3<*$!`*AIZ]=<+%-7^+KZI<
MK9=1<,LRH/SHR17VW9$4($X@-(S6YQ'?T":1052^Z::8I$=OPQ,*E@54BW#9
M#H"H_DLLJ+B/?):DM2013(?83`^U?7[XI%M-X7S>R@UKMI?1'KFMLH]@R;<,
MFXB`PV;1!VNZIJ3B.J2EO]=.FF*1K#QO<Q[([B+8L):,W4NVA(31]E6)S(L.
MQGD0MWY00D,?JGIBD8A^,)T.P8FMV#).+&MQFH3)(CDJX=!XG`T/VMMJV@H/
MJJ?7%(CU7BFSASN.2#GQ1<H(\.*EA&9<9ENL16NV[&,D<4'&7E3=H:+LZZ??
M%([1N)R7^7'8SDV.5\3;HMS@9(&!<)2[1]K>1>Q%35-W54R+CDI7BAIF)QQZ
MB.+77E%*:DNV"MN&CZ;%"4VJ(8KI(WKNZ_CE2/<SQO;2)EF^-@P(3^00+T!5
MHU4&X(LHK*Z&FI'V$T+Z:^F*JVYAQ6[L;6INZ"R:KK>J1]I/E,K(CO1Y2`CC
M9@)MDBHK0D*H7JF04]]XYY'829<MB]$)LBIC5GR#:(2-QB7\EPG.V8:-O(JM
MD(:*@KZY:D:(/BRTCOM$MA$%AKD8<B%AF,30B*1NP<<$WKIUZH7^'%(D4?C:
MUK7^-O'8,.E0R;:2XB-&/=_="<(13WKM[?<Z^NN*D5U?XAM8\3C\<K"(CU&V
MT+%JRPXW-;4)!//"T:.:$V^!;"!S5$ZKC=7,=!S[A%MR5Z*D:P98@C'F1I4*
M2R3[1%*;V-R!`3;17&>NW?JG5?KC-(C<6\?7%,-FK]BQ(<GU,"L;4&3!`<@L
M&SW2U,MR'W-=.F*16P/$UK'=XTIV$07>/1X4=JSCL.-3MD7H^RAHXHDS(3HH
M.(NW5=/P4B75^-;>%<5MB=DP:0;BTMG&A9--X6;9@+2+O716]_4OK]DQ2.)N
M.-3..N5M)*>8<-JOEQG);M;8O1Y83YA/G'$H#J$FU-$('%T775/KBD?2Y_'9
MO*/'\>MFH--8FW&?;1D=X1I,5P'F=`54U!#;'4%773IKKUR*J;/QO>V+SUT[
M8Q&N2G,KIC1@PX4,1K-_;:(%<1TD/O&I+O3Z?;+4>*_QGR"%/@6`W,9R=%NY
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MWE`&C%32X=1T$U4UT[2IU^_X8I'$V_'9O'_VB@DN1G2ATG[9(E2*ZR>8G-O/
MJ1M-G!<W=$!-S;FOKT]5RCZ9?<?M^5>.FZUU&J>W?:BO(VHJZRR_'<!Y`444
M"4-S>FFNNF9(JY/C2UD_N]:Y8,+0\@F,V5HSVC[X2`5HG@8)344;=)@53=J0
M]?7!%]RSB]A96%-<U4IN/;4;SKC`OB1,/-R&U:>:<V*A)J.BB2>BIE544'CN
M?5<EK;A9K#HLC9N6("T0JY)M'VWB5KW*@`WVA%$755R"XY7QFPM[CCEA$D,L
MC1S')CK;PD2NH<=QA!%15-O]KKJN$4/%/&]Q2R>)&_/COM<=@SH4A`;,5>*8
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MMNJ:9%='@,`JZ8%+8\MIX-C65[A$Z]:RC@1R9'N`,AIHGB!TD7V:`"^N$J;*
MM0CV$&$L:0X4XG!%]IM39:[0;]7C3HVA>@Z^J],*FZX%-&Y74R>3R^--H[^Z
M06&Y4A";)&T9>51;)'/RKN4531/M@7"KI],",EI7KHB2&M5>6,B;Q_MTU56O
M7\Z:>F$J3K^&%,"IL.54E?>55'+D(W9W7?\`V]CZN?&!#<_AHB],)5NJ_AA6
M-?PP&OX82&OX84U^FF`U_#`TE-BA+;B&X(RGA-QEE53>0-J*&2#ZJ@[QU7\<
M#?TP,*OX8#7ZZ8%'/YG30YM5%U.05M-<K6'6$0VPD,@9F+I:^W3M$G\>F$J\
MU_#"FN!C=^&!4Q^3PG^43.-BTZ,V%$8G..$*=HFI!F`[2UU545I=>F!8NSHC
M+T=AUT&WI1$$9LB1"<(14R04^N@BJX&BJLRGLO.'#D0E:?=81N2*`1HT2BCH
MHBE^F?J*_5,";N_#`UOR$98<>4")&@(U$>I+M371/QP*RCY-%NN,1.0PH[ZQ
MYL9);$8A1'U%1W(&W73>OIIK@3ZZ:4VOC2RCNQ"D-@X460B"\TIHB['!121"
M'714UP(O)+^+Q^@GW<MMQV-7,'(>;91"<4&TU+:BJ*>GXX$^.^+S#;PHJ"Z(
MFB+ZZ$FO7`\.SHK4AB.XZ(OR5)([2JB$>Q-Q;4^NT>JY*-VOX91C<FNF!G7"
MLHN$47)>855!63ILG=(*N!IV5%8VD\+;[G:`E%5'HI:_X%PE7BDB84UP&[\,
M#&]%ZHFN!76-]'BQ[`H[+EC,KFQ<>KHFTY"[T50$1(A3<2)JFJI@6`.;A1=%
M1537:OJF0>D-%RBIK>2Q)]];TK;+H2:;X_R'#04`TE-JX"MJBJJZ(/75$P+7
M>FNGU^V`4D^O3^.!I:GQ'9;\1MT#E1A`Y#*$BF".Z[%)/INVKI@;Q)"35.J?
M1<`1(*:JNB?=<#&]--?I]\#(FBJJ)ZIZI]L#"F**B+ZKT3\5P"GTZ)K^"?7`
MJ>,\GB<AX]'NX;+K;$CN[&'4%'45ETVB%41237<VOUP)E78.3:V-,=BNP7)`
M(10Y.U'FU7^H:"I#N3\%P)6_\,#3"L(4Z*$N$\$B,YKVWFB0@+:2BNBIZ]45
M,#$2RA3&W'(KP/MM.&RZ8$BH+C:[3%5^XKT7`DHNJ:X%!8<UIX<VMACOE'96
M!5(G'VF#,D&C>(75U3306UUTUZX%]O335>B8&<#"&B^G73HNGWP&Y/7T3[K@
M5$WDT.'R2LH'&G5E6S,E^,Z*)VD&(@*XA+KJBKW4TZ8*MD-,"',M#C2H+`0W
MY(372;-]E!5MA$!3[CRJ0J@KIM31%ZK@3-Z?7`RA)K@0VK)QRUDP%A/MA';:
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M1UVDB+IHN!?J6`W?A@557R2%8W5O4,M.A)I39;E$X*(!+(:[H*VJ*NY-JX%M
M@,#!>B?QZX'Y[KJ6N"T@U!,2HY)S>Q*<(_*#2.['D]E>]Z(+@F*;@+Z^NN&4
MZKL+)N%PT"F6#;3,CDL1UT4D..C'9"0D53$OSD`B':4^J]-,UN%=9X5D2/A6
M<5T.\,=R.@6K1R5CS-S">\6I7O9>'3]<$54W9E:UIR"KJ?,?(I5BX<>,=17L
MMO\`9=("<;=?,P$@`D(A1P=43[X*YFRN9MWS9')3UO5K,.OF<21B$\9'&%$5
MYM3U1IE3/=WA>3\BIEA5="I:.(]`637206MYQ.6P5&99(VS)^5\8DVZ[A+>U
M[AU]4UR)6G?:OU?(7)<FW9Y?$K;=JXALQ9#;1F>Y8SB2$50<1"V?'[/NT_#7
M"/M7`:F'6<7AI')\_EM-S)!RG'77%>>:%7%575(AU5/R_1?IAM\NYC!Y#R"!
M<<[K$:[M)-:?H6'&'TF;*APD(`35-$EJ;O\`4ZB0_P!!F]*U^2;]FUL1=^7*
MAQ;2DCG7/&S/!:V2Y((B?TCM&2.[!T(2VK[43T5<L'JQ@3)LOG-KQ\Y\R7$C
M5[G'S:=DJ#C+T01E%%$B1ITS;UT]?=^.1$1UQ6:`9]:Y</<0?MFG+=ARM=$6
M&OB."J-0ET?-D7^VKWJF[JFO7+5:I5(3H'%-^ZFQ(_$;%Z`Y+24P9OC*4X>Y
MMK:B&(_V0E[]NFJ95K,MKD$5F8M-^YN+.X[3SK@=)+SSSJ2T^<K8NKI\A8RJ
MA`*HNG33,ZE3ZRJKI\_C+3+UO(X]86E@Z3;[,F"R#!P-%:%H=IA'5[31'/4M
M=O3+"M'"`^+;\)N+F%.=.-26T5)#D>4\^)QY@FPV?M4MR1Q79N_-^.(N:^SP
MK@+KC06U(>Y)T97J\WA(/<8*K>\"1"'W>J+D5\5;BV9\?9>KFK)FY;X_:,<T
M;,9"&Y-^/HSJJ_G?67JK2M_U-?IIA-?6?'5+$K.)0/CH_P!R:RS*F+*-UQTI
M#C((XI=Y5(5U'J/31?I@Q\GI>/LB%!3K626!9YA9K8MBR^V*,&,M6B5Q$T[9
M`Z";D71==-<"*TEJ-#2P;5NW'C:A<P6UCPWY3[$A9I)$5P%1741(NG8<^B_7
M"U]=LF9K/C.6P:RGYC=,Z&YWW3#<2,J)N[7_`#JEZ[?ZV$?+IM&571\8;DQK
M=:&UJC6U=CL2)\D+9UAAL77V2WN`7;`A`D303^V!(OHUE#G6A.0+.P!OC]%$
M===!WNF03C)TGSC)JZK8&AOMM=2'5/KKA-U&H(#@\BHW[&LFR(E;R:U;CF4&
M0"-,S(B+&5MM4+ML*ZO3KM'ZZ93-3*B+(1Z*'(8,Y_BRV_(`E-&U)-!=>D(4
M%QQM$5PF5:[B-DB;4)4_#(M5Q\8NI456+^-927(_$I_Q$7Y*JCPS3.`#BMKH
M4H&-G1?=KEA5M"2T'F%9.*+)L3>CQTG#)BRVI$,AK-"?9D?V+L<B]KC)IN[J
MJJ=<A4'AE)*K*^E%N#81W9W$)S=L)-R>LH";[#9HO0'13N(VB:%IT3Z8*JSJ
MFY45R%/:L_WP>'5!5C#"RQ>;M$[S8&0"N@.HX(ZJ:>FNOURPKZ]SJOMYGBFY
M@=LI=N]4.M$VTFXG)"L:$@(GJI'Z9%?.)=7:1XUI8\8C6?\`+KS-.=M#V/F^
M^ZW(4IRQV'U0U+X^U'43\WIZY6:D5-#!#DG$['X%G,J'9=LC+LV*X!1TF--J
M`"R(H<>.K@GL[B)I_#3$&EOC?/:QV$U"C/NM\?GRJ.,\9$2RJVV52;ED2JNO
MPNXWJJIU5"R+4Y:>:QSHJJ4U;`Y"EP7>-38D=7(OPH\<&^T[*746PWH??$OS
M:]-5PKG':ZWD\0OE=C7H<I8JI$2V;2,;3+\HY`&#K3K:;I![T4FB;7H&NOVR
MQFOIGCZM6LYARZ+'8?8JW/VZ1%[J.]HW7(RI()LW-4)5(1WZ+Z^O7(TX_P`A
M4;G[[SXFJJ2[(MZBL2')CQW7$<[3YB^(N-HJ;TU#IZ_7+&:\7L"TK;#D35=!
ML%XTS=UTR9%CL.2%<C.0E^0;#3NJ/"DG:3HCKZ8A7TCQS!&'Q6.PW\WXRF\<
M8;,4;DBRXXI`*MH@JV":^P"ZB.B+D:?'^)5AE4U-M20[*58L1;X+[MN2&_DQ
M=7PC1P><]JN*\@=E0ZCH2Y8E8BU<Q\7XG[98M5\F;QJ4#3$.9%:00(@FJ'JY
M[0T1TB7<7JN(59<BXE%J(WDRMJ:*4V<FNA_L[D5AX^X`,""@V^.Y2/O#U'=N
M^J],0J>W7V+_`#]X[)FY;L&)P3*B7#C"L8Z[XPBC12R%=@C[T<9)453TTQ"K
MOPY%EPOW2,<4BB"$16+@V'X;LE=I[@E1WO\`Z2UT[KC?M/5/KD50<WII3O(N
M8VK$"8Y/BRN/.T[[+3Z^YHT1\V-B;3V@JHYIKHGKEB5Y6LGO\GN%L(UR-W&?
MMG6GV&$2')KY#+@QA64(KW`%M6Q%E%WHXFJ)]<0J"YQPZWC/$_DU]J5/8U9#
M?!&8=F2PM'([#3;KS+N\Q7:!@)"GM+K^.(5NE\?MX$WD:1JRP??DP^/NR'R!
M5E2H494"Q;)]M$`I!-CH8"NI?3$*ZSC=K$XW96\P8TN/Q.WL8,:E9&.Z@M2'
MVMC[O:)$)A@W=J:JB)OU^^-PS5WY1(TH86D%V>TME#^0#0.O"VWW-5=>89][
M[8?5OT7IKT3)AKYOQ'C,BQM^-P+FOL%@0EOVS&2U(CM"@SP>@]S:J`@[.K::
MZ=-$RPS5SXP@6)<B:?M8]O&Y'!:EL7KCK(-0)!.O;P<[VW_2=>BM;2U!-473
M&JG>5H\XKFOE0(;UG(CL*B51QGG(LA"D`JHS*9_]%E!LW"9>U1Z+TR8FJ0V+
MMF^_;?VVQ)]OG`6?R08=*.-=(:Z&CR>SMZZH0HO1?5,L*T\#XK)CS>/&S`FP
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M:2JA6U?;'QAB1>P?CQH;DIU@G)B+`<5@Q5SM_&W"TXB+MU3$2OKS$*X9\>_!
M@.R/W@*I68;TTQ62DA&%%I7S'V]S=IN7[Y%?+:>D@6/'[-'H'((\B;%AU\F*
M]&6,C5F!Z!(;4!U-QLU4G)"+LV)U5<L$H7KN/312N::;+?K[LOYX&*PZ:6`H
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M("CII+3#&\G%)J:^9$T`K^?8W_5ZKIEQ-5EX$F[Y#8OA7VX5-AR*A=;UCS&-
MT7XRA*<1!02%M?\`G-=/QQ#%E>4:0KCEM;%&=`J$@T3$*0$>1-CHL=QW<)!J
MJNLH.P9"`6NU>N04\IF7(J&8M_QZ6-4[2V+%-#ALRY$<;+OO?JB"HKS7>94"
M8[OY!U'7+A$V;&Y2L*&M/$G#.3A$=DF1!UHE=;D,J\P*EH(2"8%Q!]"Q!ZLJ
M_C<PJ"XJ>/6C5,WR*-)E-2HTG5M2B.LF3,0M7&P[O;1PD':I=?NN-Q*V`S/:
MFR%LX<U[BB<LL3MF";D'JP]&%(;O;T4W(POZZ[=11=%]$Q#-08_&YTJ;%BVC
M%B]4)5\@_;FW%E)MB+)`JYM_;I^HC>Y6Q/W::?7$6OJG"W;A[QO3J?<&Y6J9
M$OE"0N))1A!_5$]"1>XG77(9KYYQB!))VE?")-9E-5$UGGH26W]'Y';%`0]Z
M:.O+(WD!-Z^S\-,*[3PQ7C`\9<>86(<*0D1OY4=T":<%Y$VEO`T0D7IA'RU]
M;4[9]^/7VL4I,3DL6<U\>8;BNJFZ+WY.FCI&H[F=B(((J"*X*EK77]7#F#31
M+367QBF?LA!)"O//!*$9R`3G_P!*^(I)M1=V%=IXJ:KPY5S%^K@2851+<KW8
M"R([\<#$8B`?;1\17H:=4P/I>`P&`T333Z8#1,!HGVP&F`731=?3ZX'D2`M=
MJHNU=%_!?M@>M$^WIZ8&",012)4$4]27HF`T1?I@<W;<"J;*U=LRDSH<B2`-
MS@ARWH[<@&T401T`5$71%TU31=,M2+QI($*/'BMHVPPV@LQFM4%$0$T$`1?L
MB>F14CIZX&`<;/782%M70M%1=%3U1=/K@>M$P/#AMMBIFJ"/U)5T3_=P#K0/
M-&V::@XBB2=4U1>B^F$C$:.S&CMQV&Q:9:%`;;!-!$4Z(B)A7M?O]L(P#C9J
M2"2$HKM)$5%T7UT7"O6F$-,$8T1/I@9TZZ_7"FF$-$PIHF!A43`::X2&F"*Q
MKC];'OY?(!0TL)<=J+(,G"5M66%(@1`5=J:*9+K^.!8#(CE'^0C@*PH[T=0D
MV;?7=N]-,*P<A@&E=,Q%I$U5PE1!1/OJO3`V(B+UTPD8)1%.NB(GU^F16%<:
M0=55$'[KHB=<4>DT7T_HRC.`Z)@:T>95%5"%1'U5%31,E1ZU$QU!=47T)%_X
M4RJJJ.CIN+TK-;"7X]=&(U;[SJGHKSBF7O<77J9K]<)%MIKUP0T3[84TPD%T
M1%5?1/55PKRVZRZTCC1"XV2:B8*A(J?@J8&&WF'5,6S$B:7:X(JBJ)::Z$B>
MBZ+A(V:8(U*_'1X65,4>)%,6M4W**=%)!]=$U]<*/18[ZMJZV)JT2.-[DUVF
MGH2:_5-<#81"FFOU],#6<B.!;3,1)?1"5$5?\.!GO,H:-J2(:^@*J(O^#`V:
M)I^&!C:GVP*R_HZZW@_'L5<&,TX+Z$T^Y'(2;ZHO<:("T^Z:Z:>N$2:N-7Q:
MR-&K@;"`RT#<4&M%;1H4T!!T^FF%;E?BHZC"F".DFX6M4W*/W0?73`?(CJJI
MO%=OYNJ=/XX&4D1U4='!U+\G5.J?AA*RZ\RPV3CIBVT";C<)4$41/JJKT3"O
M0J)"A"J**IJBIZ*BX#;UU^N$C#A--@1N*@@**I$6B(B)UU55PK#3C3H"XV2&
M!(B@8JBHJ+U145/5,#WHF`T3`:8#1,!HF!@A145/O@4W'N)4M!WEKFW.X_M%
MY]]YQ]U0;4E;#N.D9;`WEM'71-<"ZP&B8#1,#6;S`."T1BCAZJ#:JFXM/543
MU73`V:)@-$P&B8#1,#63[`N`T1B+AZ]L%5$(MJ:KM3U73"5[Z+],#PX^RV0"
MX8@3A;&D)412+37047U71,*V=%P&`P&`7`^=M^1[=NTLJ69'C-6]=9;#:'NJ
M)5/QUE_+'7KN5L"#[;^F!2N>7.:AQV3?)Q]O]O<A19U:^Z1LMJLF2VTL=PMQ
MJ9=MY#0P1!^FF6)5F/D;DT6S6KL8D,I;/(HE(^Y')WMK'G14D@Z&_P!W<#7:
M2+T7\,BHI^5.42'G*JNK67KP9=NTV(BXZT354\#0>U#;)"=5T=5W:#U7K@KZ
M+0SY=A1PITV*4&7)8!R3"(A,F7"%%-M2%5%=I:IJF!\VC<PMZ^SGQ*>K@,2)
M_+GJB0X9O;7%*$D@91=5]^C:(0IT^V(5VOC_`))8<@XXDVQ9:9L&9,J%+&.I
M*RKD.0;!&WNU)!+M[D1?3`^<^3[3D,N/Y(K)3[+M-6U4%Z%&$"%P7'B,]W<W
M*FNYOKT^VGURQE<2?)G)8%G.HI<*,=JEA!A5QQ4<<;1N?&<DHK@&;:F;8QR3
MH0H2Z>F2+7:\,M+^RI4>OH*5]FVZZRZP*HHD(&J`ZB(3BAW`T+8I*H^F%?-?
M(KP-<YNI=Y&CVE'2\>:L(]<X#B."Y\LE0FW=Z"VXKC0ZFB?EZ??`O%Y[S6+L
M@V5:S'FV4Z)`I)KB=MEQ9+9N/$XPCSKFC'9+;[T[G333KA*YSB_)>14CUK1U
M\5J1=VG(+M]3::(V!&(+"EL9)YDOU">'_G/;U]<L*Z!GG_/'[4HA5U;7A"IX
M]O:!,D'N:-Q7FWF.\VI-)M-G5#7HB>N0KF^4\QMN1\`YE76;+3BP(E9+BRF6
M'HPN),<W>UM\B-1`FEV'TW)UTPM?<27057"5\;D>8>61H%K)^-!E+'I';F&X
MV#XQNXQ*%@V1>(O](#::*CH"**OIJF(5;O>1N3P9UG3SV816B3:J'5O-=U&$
M6W0M.^A+N+L]HU]JINZ>F"I_BH);4KF@2U:*0G(7NX;`D#9*L2,NY!(C5-?5
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M>0A0$`'4[2J"[U3`WM^1+TGX[?:C:'RM[CSOM-%^,#9F#B>[H[[4U^GX8%)'
MYIY(MJ[C%H<JOK8MO=C`^/'8>=<(&CE`?<)QQ$VE\<5T3K^.6)74<.YI<6?*
MK&EN.W!EQA=<;JS8=;=5H7MC3[,A2-J2R;>BD0:*)+HJ9%JRY]R2RXY!@6S*
M,_M3<Z.S>&\A:M0Y!HT3P$)"@]LS%2W:IMUP.:H?(%[>/V-0;,59E>[-*<!M
MN(!UO9WU[R#O54^5W!7\40NB:8B5R"7=O9<8GQ%2+%H'.`C/"CCLD++3KJ.C
MHVJFNB)LT35%Z?X<0JTM.87<7B%_664&NL&JRBK+&+'-MU62:?50-E]%/4U%
M6=1(=/X8BU<6OD+ED*ZM!;;@K45%W6U;C:@[\AUFQ!C4D+>@`;92-4]JHJ)]
M,0KZ7)C1I4=R/):%YAT5!UHTU$A7HJ*B_3`^`1Y<WCW`XG'KDEF<;O@CN<=G
M/(I?'E%)`RKG5_Q?4HY+]-1^B98R^AQ^:<KL.0R&:J"S^SP;5RHG$ZH"38@V
MG^D(2NB2KW2':WV_</HN(M4,/S!>-?M;=FU&20IV%7>`T!H+%NP1I!9%5-=$
ME(VNU%35>BZ]<0KZM7).^#'_`'!0*;V@^5VT5&^[M3?L15)4'=Z=<BODL_C4
MFIY=.X)7``\:YV+UBX6NAP^RH#9-A]QD`X';_P`0E+"+GD'+[FH7D,7CS4./
M!X3!BR7H+P$JR&S;-TFFC$P1H19;V@6TM2P.=Y_R'DEWQWEPR6XG[#33(;3+
M`-.+-<(RAR6EU4]B$"NJ*IMZ_33$*^E<,OW[VN<M2D-.19+[@Q(S;9-NQP;7
M8K,G<1+WQ(5WIHFB]/QP58\CLBK>/V-B#C#)Q(SKP.RS5N.)`"DBND**2!JG
M73KA7S%KR7S=7CKT",4M+FKKVY,F*['0H]E'5TC6.CI&)`0^W4NJ>J(N!/I^
M=\IM9$/CCAPF[EZ7;QI4]63*,;54X`?IQU<UW.]X-45Q=J(2]>F!=>%1V^*N
M."J"*C$T5`3045#+7:GVP.4<N^0<=Y'S*TJPAG5M\AKFK*(Z+G?=29%A,$3)
MB2")"KB$FHENZ^F!;1N?<DE+5V;11OV:YM95*U&1HUD1C:)YMF09J>A^^.JN
M!M31%]>F!Q]):<LF.\2O$F1GK][B]K).?)9(A7:\PX(JV!CKUZ?F31/I@?9>
M)7+EWQBIN76T:<LH<>6;0JJH)/-":BBK]$5<#YGY4NK4[K]WK`F.,<#=CS3&
M,T1LR''/_3VG3'I^E!/5/L18&_F[,:X\C<;>B5S-TW.H+,F6'3%MMP#*.K9*
M9(6G0^BZ:IKTRHT4/&[&DYKXXK;J0EA:P*6U;D3-2/4A)C8B&?N+MB>Q%+K_
M`(<@^C\SN7Z?C<FPCO,,/@K0-.24,@U==%O1`;]QFN[0`3\Q:)A7`U_D'G$Z
M=7U+21(\I^[LJ=^5)8/<C42)\EEWLMNZ(YUT(=VG\,%:(W/>1\HH6JE?AQK"
M126$^S<-HW&7DCR'(*---J8J(F0*9JI+M31/K@=QXP1/[M.+(B:)^TPNGV_T
M<,#YUR2`5%R*TN[>N8O^*3K1B0=Y&5$LZ>2V338MFB]3C@8)T!=115U1<"ML
MY<6!SOFD6WBJQPRRM8C'(+9G35K?!9)ME]--6H[QDO<='ZKHNFN[`[;E<"M#
MR#XT&*PTD9EVP".C8CL1L8*DV@:=-J:(HX1?^5FVW/&G*1<!#']KEJHDFJ+H
MR2IA7%M^1N1T3,RLF!%D.LQJ-:MQH":!M+0RC[7NXYH:-DUNW;AUUTZ985-?
MY7Y."PJJ/97QK&RFSXK<N2"N?H1XJ2&'398>)`/JHD&_KT7ID2HSG,N5WT"<
MZD.,?&GEMZR<+BM@XU\1MUL#'5TC,W#:7<TK::"J+KTZV%5W%^2>1J_CE)25
MX5TF1-XJW8\?`6G=6W834<>Q)_4]Z/"ZFTQVZ%DBUWW!N8N<L%+.$394OQ&$
M)=JHXD\]2D-*NO3L)M$ATU0L#/)K^X#D5=QNH>8B3K&),F!+E`KH?Z(K8BV(
M(0:J1/H1=>@HO]`<W9\^Y>D>]=@G7(_Q.MB3[)A!<=:F./-&^\$=W>"MM;&U
M%L]I>[U],"./DGEQV+TD4B!31K^OJ5C$R[\DX]BRP:$KG<V@XR4C_%5"_#$2
MO,WRIR*J6_\`W5IJ/-@-F4*J=9)I#`Y@QH\IJ6KBLOL;'!)W\J@71=,L*DN\
MO\F1IE;62F(,=Z?;_`:E/`AD45R(X^+Q,,2'$`P<:5-%/0T^V2%0^/\`,N:7
M?(>'@].CQ@?_`'IBVCM,$K<AVLD"QW!W.;@0QZBBZ[5^^%==Y7L[FL\=7UC3
MRDA6$6*3C,E0[BCIIKM34="T]%^F!S]SSGET!GD4B*Y#?#AC48[2*XRX#LWN
M,)(=5HD=5&$[9:-]#U-%UP/I+;AOQ4<:7MFZWN;4QUVJ0ZIN'5/3[8'PVEE\
MMLG^`VKTZ-(Y!(C\@[=A(CEM`!5$1%;!Q%/11Z)N'I_#J%U&\H\VN:R`M#7,
M.6W[-&N9<=Q01ITGW7&U:$W7F5:;3L$O<T/35/Z25]5.6H05EF*IL:[QMBJ$
MO0=RHBIZX5\VIN;>1[FJ6TB1(,>'8U96-3(DD"-M2`5"2.X@/D;@$TON<T'8
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M"3VGK[D^F"NLP&`P*DN,TR\A<Y"L45MG8G[>Y(7^M&0U<V*GI^9<)'.,>&>#
M,5TVM:CR1@S=J+'66^0LM@\,A&HZ$:]D.Z"$HAEI$^R\:\9L2L#D#([ME+C6
M#[[<AT'`E0P1MEUDA5%;40%$]OK@B"]X<X.[""+\:0UVI;\]F4U+D-R0?E:?
M(47Q/N(+NGN'71<@[&#"C083,**VC,:.`M,M#Z"`IHB=<*Y]/'?&DG_.1IY)
M'[I^]Z]]S3YO:[._;KIM[?MV^F6I%GQ[CE700785:!@P](>EF+CA.+W9)JXX
MNXU5>IDJZ9%5=WXXXO=3I\V?'=)^TB!!GHV^ZT#K#9;@0@`D'<.O0M-=,M2/
M%IXRXA:_N2SXAO':_&66:ONH6^$*C'<;)"16S;15T(-%Q2+NAHJZCK6JZO;(
M(S6JZN&;KAD2ZD;CCBD9D2^JDN14&9PCCLRXF6TN*LB580OVV8+CADTY$U5>
MT3*KV]-25==-<(JX_B3@\>D<I6X+BPG'6GT,Y,@WVW(ZZL*R^3BNM]K7V;23
M3+2/#WA[@3L#X9P7E'YAV0R$ER4DA+=%`<="0CG=%7!3W:%U^N2D3Q\=\3%R
M420$V3:\:>2PKCBM%"#7:UVU+:GYR]R>[JO7!$$/$/"`C38WQ'S:L8S$.<KD
MR29NLQ2W,H1$XI:A]_73IZ8(['M_I[%3<FFBHO75/3K@CB4\,>/DCE'_`&]U
M62BN0%!9<E4^(Z:.*PFKG1M"'VBGI],I%G/\<\3L/W'YD,GEM6XS<PE>=W+\
M+_T8@5"_3-K743#1=<A$WCG$Z3CH2QJF3:6>]\F8;CKKQ./;!!3(G2-=5$$U
MPN/%OPN@MK`9TYEQUY!9$VT>=%EQ([G>91UD21L]CGN3<F$U`=\8<,=D$^<`
MD=*:[8[P??#21(':\H[33:+J?G!/:7U3*1B)XMX-%".VS5CV8T)VL;9-QTVR
MAO$1&R8$2B8ZF6F[7;KTQ2++BW#^/<7B.1:6)\9IU45S<XX\:[4VB.]TC+:*
M=!'71/IDHU\GX+Q;DQQ7+J"DEZ$I+&>$W&G!1Q$0PWM$!*!Z>X571<&O$K@/
M%)4])SM>*/*#+3H`9MM.A%75@7F0)&W4:7\N\5TP-+GC7ACERMR=:A6*RQL4
M=[KR",L!V(^+:'L0U'U5$Z_7"MG]WW$OV2/2?`3]MB2OG1F>ZZBMR-Y.=P3W
M[T7>9+ZZ=5RU(WTW#./4\U9L"*K<C8;;9&ZZZC3;I]QP&A<(T;$S3<J#IUP1
M9V=9`M*^176#`284MLFI,=Q-1,"3117(J,/'J8'Y<AN(VV_/8"++=#VFXRT)
M"V"JFBZ"AEIE2*?^['A/998_;!1F/7E4-`CKR)\$]=6"T/W#[ETUZI],4C=*
M\><0EMRFY%<+@3(;-;*17'??$C+N9:70O05^OKBD;)/`^*R5EJ_!1Q9\F/.E
MJKCGODQ$%&'.A=%#MCII]L4B_(=P$*ZZ$BHNBZ+U_AD54-\2X^%$S0K"!RIC
M[%9BNJ3B"K1HX"H1JI:B:(J=<M2-'\B<3_F5>3?MK:79:;Y:*2;B$=@F0(O;
M(T'HA*.NGUR58DN\4XZZ;IG7LD;\QJQ>+:FI2V4%&WB^YB@#HOX8I%M@5DKC
ME/*NX=V_'WVE>#C4.3N-%;![3N"@HJ"N[:FNJ82(]KPSC=K8#83X0NRD;1AP
M]QBCK(EO%MX15!=`2ZH)HJ92/$C@O%I+-HR_`$V[I\)5F.]Q.\\UMV&NA=%'
MMC^73TQ2(<_QSQV3*64Q'^)(=LF;>4ZT;B*Y)8Z(:(A[14D]I+IU3(.@L:V'
M9ULBNL&1D0Y;9LR6#343;<11(5_BBX5S\3Q?P:(Z#S%4(NMNQI".*X\1*]"1
M4CN$JFJD3:$O5<M3<;'_`!QPQ]E&G*P5$9CMB)HXZ)I*?_MG$-#0T[GH0HNB
M_;%(N*.CJJ.J8JJJ,,2OBHHQXP:[0154E1-55?55R+B"[PKC+ET=R4$2GNN-
MO.GN/8;S";6G3:U[9.`G034=4RIK,7AG&XMJY:L00;FN.G(4D4E!'W!V..BV
MJ]L7#'H1(.JXI$6%XXX9![7Q*P&NPS)C,H)N:"S,7<^V.I=!-4]/I],5(NZJ
MLA5==&K8#2,0H;8LQF!550&P3011555Z)D7$5CC-+'A3X+45!BV;CSL]I2->
MZ<A-'E5555]Z>NF#4.MX'Q2MDULF#7BR]3L'$K#0W%[$=Q=3;!%)4VK^.4B;
M*XW2RKN%>2(J':UX.-0Y6XT)L'M.X*(BH.A:==4R'NV7E%57M6[5VT89<%_;
MW635415`D,5115"11(45%1=<*JX?CSAL*<U.BU;;,MB0<UIT2<U20XUV3=_-
MIN)OVE]\M2-3WC+@KT.'#<IVBCP%>6(.YQ%;222D\*$A;E!PB52%5T7[8%]5
MU=?55L:LKV!C08;8LQHXZ[0;!-!%-55=$3(JI>X%Q-Z>[.<KQ)Y]\94@=[G:
M=?%4477&4+M&2*B=5'*/?\C\64KDEKP)>0IMN=Q.$DE-NSWHI:?E]O33ID1I
M@^.^'0?VKXM<C?[(IE4IW7E2.KB;3[:$:Z(J=-/M@7%M50+:MDUEBRDB!,;)
MF2P2J@FV::$*Z*B]4PJJD<`X?(28,BK:>&?$:KY@N*1(Y%C_`-BVJ*2I[/5%
M]?QRH\UWC[A]=^VK"K`9*G<=>KC0W%)MQ\=CI[E)5-3#VJIZ],$99\?\.8O)
M5ZU4L!:S$-),A$70U<':X2AKLW&/0BVZJF*(J<*;H:IY.$Q8<&V[;;$5R=WW
MV`9`]W9T0^X+:(J[0!437%(MN,T+%'4-0&]BGN<>DN@"-HY(?-77G-J>FYPE
M73(K5R;AO&>3LL-7M>W.&*:N1E/<)-DJ:%M,%$DW)T)->OUPC3-X)Q.;(9D/
MUC2N,,#$!`W-B4=M=P,N`"B+C8KU02143!&7N"\5>.2;M<!%,FLV<E=SB;YD
M?;VGET+\P[!].G3*1X:\?</:26/[8VZW-;>8D-/$;P*U)/N/-B#A$("X?N)!
MTU7%(UUWC?A5<S!9A50,!6R?FPM#=4@D;.WW-RFJDNSVIN54TZ8H]L^.^&,E
M!)NK;$JV2].A%N<56Y$DMSQHJEU[A=2%>GX9%Q<6M57VM;)K+%@9,&8V3,E@
M]=IMFFA"NG7`I5\=<.5V.[^VCNC--1Q3N.[7&F"W-`^.[1Y`+J/<W81TB)IA
M<<W!\=</@2&9$2M%EZ,<IR.HN.Z-E.321L'=HB.?;Z?3"1&?\4>/WV*N.[3-
M&U3`K5>BDYJVTI;U:5=VIM[NNP]1_#"1UNU$1$1-$3HB?3"N5B>+>!P_GI%I
MVF!LR0I@@;@B7ZB.J(BA:`*N"A$(:(OURD;YOCOAT[]V275MNI>&T[:(I'HZ
MZPB(TYHA:`8;4T(-%Q2-L+@G%(7[5\6O!K]E5XJU4(U[92147B74O>KB+[E/
M77!%>QXG\?L"X+-.`"XP[$71Q[5([YHZ;0KO]H[Q0D0?3Z:9")\?@7%6#B.A
M"U>A2RL&'S==-SY3C?:)XS(U(R5OV^Y5Z91-3C=&+]F^D%E7KE`&U)1U^0(-
M]H4<1>BH@>W(J/QCA?&N+QW(]%!"$TZJ*X@D9JNU-!'<X1%M%.@CKHGTPB[P
MI@%P.5K.:UR6<R#86D9UX[8ZNO:89>!0=1@7TC.D6X2=0-Q;DT%4_'"5B3Y4
MX'';B&[:BGSC?;B`C3Y&X<5WL/B@""EJVYT+I^/IEAW8C0O(=1&B2WK6T:E;
M9\V/'&%%DJ8-0U17`<;07#(F!7]1Q$VY"H?D#R;'I66(]0^#UFLVN9D`;#SK
M0,SGP!1-T$1MIPFCW`AE_1A:LXW-H$9VY*PLFI01;)8$6-$COK(`Q8%U8Z@B
M&3SJ)N/<VFFW^&$J)_>MQV;*=A5CSBB50=PS;%'>.*#:*0(IZ"A>T@7<G3TV
M^N#N2&O)'&X-17/6EH#[CT.-+ES8[#WQP;DHB-R'=$/X[3I?E[BIA6Y[R;PM
MFY*G.>7S6Y;4!Y$9>5MN1(%#9!QW9VQ[B*FQ5+1<0JQY'RVFX^D?]P-U797<
M5AAAEQ]TA9'>Z:`V)+M;#J2_3`J)WEK@<,M';)21(\6:1M,/N`,6:NC#YF(*
M(MDOJ2KHGUP5#YWY%"J=AP:A]'+!;6O@SE5AQUD`ENBAM$Z*(V#JMEN%%+^C
MK@=1:<EJ*NRK*V:Z34JX=-BO3MF0FZV"N*"F**(KM153<O73`J;#R9Q&!&63
M(E.(PVKRON"PZ2--1W58=?=T'V,BXBCW%]J_3TP5A/)_#%N?V<9QE,^8%<2I
M'?5D)3H(XTV3VSM)W!7V>[0OI@28G/\`BTLH0LS%UL),J'&4FG`19$'<LALE
M(4V;$;+\WKITPE>Z+G/'+R><"!)(I0LC+;;<;-KO13)1&0RIH*.-*2:;A_X4
MPKQ*Y_QB-;I6.R3%WY`02D]IQ8H2W$10C'(0>V+I(2:"J_73UP52<:Y1R+D7
M+;9N.[\.IHY[D"1#?AN)WVQ9`NX,@E':YW#UVZ:;/IUUP*V;Y;.05;(KV7H<
M(>1E1622HSA&Z``ZBJR@]=RN-HFB(JX'1_WF\36H:M6Y#KK#J2%[`,.K(!(1
M;92N,[4<#LK^?5,"1&\@\8ES&HT224IMX6R28RV9QA1YE9#?<>1-@;FDW>[_
M`'\#90\ZXY=SS@09!+*%@9C3;@$WWHIDH#(:W)[VU)--4_X<`_SCC[-PW5$\
MXKQR4@J\#+AQPE*WW48-X44!-0Z]5_W<"&UY/XDXCA(^Z+0Q'K".\3#@A)BQ
MO[9R,2I^J@>JH/73KZ8&;'R=P^N9>?ERS!EB'%LC<1ETD^+.<[3#B;15>I]%
M3Z?7!4)CRS0.6<Z.Y'FQ85?`&PD3Y49U@$`G3:0=C@B?56ETZ=?I@KJ::YCV
ML<WF6GV5:<)EUJ2T3+@F*(J^TT35-"314Z+@0;/F='664FNEFZ$J+`<M#%&G
M"0HK*[7"`D30U!5344ZX%3?\]JUHTE0+(X*.-UTMNP6&Y);1B>^(-"H)MZO)
MJ/5?9KN7!5-?^49(.JD%EZ$U6\DB4MB;\<G.^R\B*YV4'7W*IIMTU731?KB%
M=&QY'XY(KV94=9+KTA]^(U7#'=^;WXNO?;6.J(:*VB:EKT]/NF`9\E<2?85]
MB6;K:5KMPJBTXO\`HD<^T\NFFN]MSVD'YD7Z8B5ZH>>0+KD<VFAQI"A$B1)H
MSR;467`F@3@;57T]J?7ZZ_;"O#_DOBK%K8UCS[P/U.J6+JQWD897MBX*$]M[
M>IBXFQ-?<OI@&/)/&)&]MIQXIP2_V\JU&B^5\GM*_L[?_P`BF_=KII@K0[Y6
MXB-4U:MNR7H+L=^8KC<9Y5;CQ#1M]UQ%%-H@:[5^OV],1*W.^3.*-64V`X^\
M)5H=V?(^.]\=H%920"D]MV?J-DFSK[EZ)B%:.'\LL;KEO)83HNLP*X*\H<:0
MPK#S:R6C-S=KU+5114^WIA6:SR76RVYI.PY<=R/9OU,6,K>YZ2\QJI=H47KH
M@$2Z^B)UP5<5W+:2PX\=_'>)*YD'CDD8&+C2QMR/`XTJ;T-M05%'377!5,OE
M;BP-DKZ3&'AD18A13BN=[N3P4XOZ8H2Z.(*Z?CT7!6ZO\E\;G.U;3:R6G;:5
M(@,`_'-I6Y<1%5UA[<GZ9H@JJ(OYOI@6?\UU`T<F\=<-BMBDZ+CSH*.O9<5H
ME`>JDA&F@:?F^F!7CY$HU9<4F9K4UN4D$:QR,8RG'R:[PBVVO0D5KW[D+1$]
M53!4-_RWQ-MF,X'S)#DIF4^W&8B/./#\$T"4#@(/L<:4O<)8B5`N.:V=MR&J
MI>.2G8<>SJ3MX]N$49`+J;0LH0N:(C>UQ5/T+JG5,+4?BGD)YZLXY.OK;LNR
M:.19V+"14%AQ&#!#?[Z:]OMZ_P!FGKNQ"K6R\I5\464:KI[D@["'7.1CCDT8
M?.]S;J;]$(5'7\JZZ]%TQ"KNGY?66]@]$A!((6%=!9:M*D<CCN(T\`N>F\#7
M1173\.F!&M?(/'JN<[%E&]VXSS,:=-!HCC1GI.G9!]Q/R;MX_@FY-=-<"HJ.
M0<CO.=7,)A]ROKN.S&H[D<XP&W*;<B@Z>KJKO`][B*"CTVIU1=<#%;SN5'O.
M30[/O31B6[5?41XK"$YM=@-RE!=-$T'4UWFJ8*FQO*G$Y+`OL./N-E5NW3:H
MR7OBL'VWMNOJXV70@]<0JXIN3UMP;:05<<;=AQYX/*"HWV9:*K2;O\=4'51^
MB8%+%\J\7D7#=6*3`<=FOU8R7(KH1DFQ]56.KRIMWEM78GUQ"H)^3Z>XA0)-
M5)G0(S]E#BA,<KS5N03[YM+'%74%$0C;4#-/R8A5A6>4N,6%I'KVOEM%*>EQ
M69+\9QJ.K\!3^0UW31$W"C9%]M$P5$N/)=0Y0VTB,_-K$C5ZV,>T6"3P%&4M
MB26`+VNHB]=I:+IUTTZX@V2O+/%8$UROEE,5R&[%C3YJ0WEC,G,`29-UU!V`
M#F].NOJN(-%;S\X=AR5FZ?5](ETE=3QV6P%TQ*$U*[2=10E%"-5(E],"PK_*
M'&+)8/[:LB<DYIM_5AE35AMUY8XD^B>X-'0(2Z+MTZ],0KKL!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@:9TR+"AO3);B-18P$Z^ZNN@@"*1$NGV1,#
MY%`H[6_EV-_QXH\D(W+`MZ\GS,(\M@:YN*:@Z`GZ*:Z*B*BJ.F$BUXGX]Y95
MW=#-L#@N-USUVY+5@W=52U?1]OMB8_U=-"U7+2(-GXPY2_"FM-M1/F/V]E9U
MUDS+D1I4(IFU6'&S`%0M-%[K:IM),$9M_&O/'4M(,:57R8-M8UUQ(E2%=:>&
M3$6/\AM`;$A4'/C;@75-NNFF02YO`.:M7<V_J7H(V+=V=I71Y).JP['?@!!>
M:?41W`>@;A(=<HF/\*YD[=%9./5YE-H7ZFP$$=:$'S<-UI6!1"U;U<VJI=>F
MOUR$5,7Q?RZ'2R:EE^"]'O*2%3VZNJYK'=AQ_BJ_'39^J)M%KL+;H7UP>S<_
MXOY$@V[45Z+VI=Q46$)73<W)'K&V`(7=!7WG\?IITZY3W=%Y"XOR2^=K0JWX
MWP&DDA90Y:N@#B/-;&CU9]Q=HM5[:J@EKU],AKC6?$7,5XS9U3TBO21-XY7T
M3)@3^P78)'JX6HZ["%SIIUUP)]IXWYNY*F1X4JO*IG7,._)9'>1]IY@FB>83
M8FTP)6?82JBIZ*F!U_D'B<GDW'2AP)20+>,\U-J;!4W?'E,&A`YI]4TU%4^R
MX'+7_BRS6X@S*(*J1%&N;J9L2ZCE)$6VC)P)#&W_`)S<Z6\2Z%]\#+_C;DBN
MSR:>A[)'(H%TPA*X.D>$VT!-D(AHAEV.B#[4U_#!B.SXMY3^Y167I4):*':V
MD\=G>24XS:M/`0KTV`;2R%TTU1?7IA(M_&W!N0<;0&;5*DPA1D@PY=?%5F5(
M:!4VN2C+\I;034`Z*O7"XC3/&]V^[:5/R8Y\:MK=N[<<+>DQDQ=;?=8!$380
MFXRFTU)%%%5-%Z81T'#N.V]//Y&_.-@V;BS.QB(RIJ0`;3;>QS<B)K^EK[<-
M.::\:\E:FMHDJ&4&/R<N1,KHZCRLNH:N-%_5WHKGMTZ=.N$0G/%'*69`64-Z
MI?L`FVCAQ;!AU^(Y$M'Q?T5$VF+K1"G5.A>F7$B=*\76DB]C2^]$ALMLA$E3
M(*.1GI,/XY,NQ7HP_P"CD.\MS9^H)T3!%EX]X3?\>$6K5RK>;A1@@P9$"(K$
MAYIO1!.49*ONVBGM#VZ]<BXQ#X7RJ!?6H1+.*G%;F6Y/EQS9-9S;C[:`^TT[
MN1O89#KN4=P]43!JNA^+;ERJK:BUGL.1**!-KJN2P!H\X$N.L47'T)=J*VTO
M5!_,77IZ916RO$O-)L%UJ59UR.E45]0VC;+Z"B5TM)`N$JFJKO%-%3Z+@=/?
M\,OIO(K&TAO0"C6=2W6R84]EQX%-EUQQ-4$A16S%XA+7K]L@T<4XYRWBY5]7
M&<8>IWYDEV5%57WDA15:3LLQGW2W;1=%5T-%_-HFB)E,6W+>%!?V--.^0L=R
ML><22B"A?)A2&U"1$/7^H[H&O\,BN>_NHEQN!S.,P)P*\].:D1I#XDH-1(\L
M'H\5$%=VUIIM&QRI'J7XXY"Y:S'F9L1*]_D$/D+0&VZKR+'`!=:(D+;U[2;%
M1/XX3<8C>..0P+<;R%-BE9,6UE/98=%Q&#B6B`CC)JGN%P%;$A-$T^FF%17?
M$]ZPVG[78Q0>EUUI76AR&7"'=:R%EF['$#338XJB@DOY?QQ4B\XCPJZH;M9C
MDN._#?JJ^!*;%LQ<^17@3:&V2DHHV:'KHJ:X7$:S\;3;)KFD=^<#37)WXTF$
MXVVI%'.(TT`=P27:XF]@55/MTR#G.6UU]25U*]9N5C-FEBLK]PA5TIN$RK4<
MFQWE%(GQ-WN?F+VK^7^-I&`X%R3DW%H\)@X5;5#"GUP0S:E&P:R516K!H'2!
MWN?F3];7U4D]<$7J>,;>54\E@V%BR#E\W`[$B,V2*R_`8;;0U%PEW"KC`EMU
M].F!<\1XUR6!R"XN[R9$D/VS$-HFH;3C8@403%2U<,]4/N:_AD,4_P#=Q?1[
M)RRAV$9)$6ZDW-4!M&@J$YLFY3$E4)==4-=A`G3IKKEJ1>5O$9L#C-O71IWQ
MK6W<F2W+!D-!9E355=[8$J]&]4TU]=,BN0KO$G)8]@W,<GUXZR:B7(;98?%2
M.K1Q#]YNF1*ZCFNXNNN6C'(N+/1JF7QYQV0Y>7MV_<4$^!&=(8+_`'0<!QYU
M4)MOM(JZJ2IN35$3`[;D7#8UKPM[C,=XX0*TV$62*(1-.,&+C3BHNF[0P153
MZY!3/\/YM-"LL[*WAO<CIYBRH2LQC:A*T;),/,F*FX[JX)J6_=[2TT33UHCQ
MO&5G'MVK09S*O.,VZS@[9H)2;<FRW-Z%T;:[(IHO5?7%&[CGCZXJ;*@E'-CO
M-TU"5&X(MF*N.*39(\*JOM']%/;_`+N!5!X=GNTU34S;)M6(-'-I9#K#9"9%
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M$_Y++6@#_#!CB>(<:M;E^Q20X#%1`Y;-M&V29=&0ZXR[O8T(U$>TIKOW(G5.
MF!<Q?&]LSPRAX^L]@GZ>T9LCDHT:`X#,LI7;$-^HJN[;KK@:H_BZP%NL8D3F
M'(\*VM+*0(M&*N,V@OCV07>NT@24ON^NGIBD>!\=<S<X19<4G<B8DPCKBJJH
MTB*V0M*B`+LI4<7N.`VB"FS:GUP*ECBMK>\AYI0&^VQ52':ANQ<-AW>Z#$1O
MN?&,E1OWJWMUZ[>OUP1:6_BRYEV%A:1;**U8.7"6]:C\59#`BL,83L>0V1IO
M0P#7<*BJ+Z9"-EEXSNI\BHD.SH;4JL5IQNQBQBBRF7!>5QYMA6C0.P\'Z?;<
MW)]>JY:1W=8W:@DG]Q>:?4I#A1.RVK>R.J_IMGJ1;C%/4NFOVR*F8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&"%"314U3[8&`;`$1`1!1.B(G1$3`]8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8!41<`B:8#`8#
M`8#`:)@$33`8#`8#`8#`8#`8#`*FN`T3`8#`8&-J:ZX&<!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#EG?)G#&;.37
M2)ZL28<AN%*)UE\&FI#R(3;9O$"-"IHJ;=2ZX%M4\BK+699PXAD4BHD)$G"8
M$&UU6Q=1!4D3<FPT75,"SU3`:I@,"#66S-@<P6VGF_A2#BN*^T;6XV]%4F]Z
M)O!=W0QZ+@2)DMJ)$?E.[E:C@3KB`BD6T$4ET%.JKHGHF!5TW+:NX_;R@A(-
MBSA#8Q9),."RK)J*"A.*FT7%WHNQ?=I@76J:Z?7`\*\TCHM*8HX2*0AJFY1'
M1%5$^R:I@>]4P&J8#`8#5,!@,!JF`P&J8#`UOR6(X=QYP6PW".XU1$W&2"*=
M?J1+HF`=D,,H"NN"WW#1L-RHFXR]!37U5?M@;->F!!M;F#5Q)$F2>J1H[LLV
M0]SI-,)N<4`]2TP-E591K2KAV4;=\:<RW)8WIM+MN@ACJGT70L"4JZ)@4,'F
M,&?='5Q(TIT6W'V#L1:UB"_&5$=9)Q%U$TW:)J.BZ+HN!?8#`T3I7Q(;\GM.
M/]ELG.RR.]T]B:[0'IJ2^B)@>HKZOQVGE;)KN@)]MQ-ICN37::?0D^N!MU3`
M:I@-<"KN^10Z=VM"4#I_NDQN!')H=R"ZZ)$*FNJ;1T!>N!::]/QP*JOY%"G7
M=K3M`Z$JG["RB,=`))(*;:MEJNY-!77`LGW4:9<=5%)&Q4U$>I+HFNB)]\#E
M1\D5+U-564*)+FN7,8YL&N8;%91,-(*N$H$8CJ.]/;NU55T37`ZIEU'6A<02
M%#%"0211)-4UT5%]%P*2WY?$KK(*UN)*L)O;:?D,PVT<)EAYWLBZ:*0ZCO1=
M4'5=$5=,"1R?E%-QFK6TN'TCPD=:95S15][[@M`FB?\`*+K^'7`U\DY97<?_
M`&_Y;4AXK.2,*(,9ONJKYBI"*]40=R"O5>F!6#Y.XT<6'(;^2?S+)*7L=DA=
M9GKK^B^!;5;7IKJO33`N+/D<2NMZBK?;<)ZY<=9BN`**V)L,D\7<77IJ(+IT
MP+77`:I]\"&[8FW:L0/B/FV^VXZLT1%6&U;440'"W;D(]WMZ?1<"8BHOI@0[
M6P<@1%D!$?FDA@'QXPB3BH9H"EH1"F@:[BZ^F!,1>F`U3KIUTP*EKD<1SD[_
M`!U&G1F,0VYZNDB(T33KA-H@EKKN0@77I@6VJ>FO5?3`J>.<DAWT.3*C-NL!
M%ER(+H/H(DCL5U6C_*I)HI#TZX%MJGWP&J??`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8!?3`^-,<6#F'+O(5*_9.1JIRTKG9T=IH=\@&(K2[
M!>/\H]QM$)137IZIA%=?7$JNMN6N@Z]&JBY-""[EM-/GVX:U@#O5(ZMN]OO@
M(F0%T_PY45/*KR="XVRQ$O[.=+:J9<VHLG!EQVW$"5JUV66]77WA#VH3Q:=O
MW*BZY5JWL.1\B_F&WDT4IVXFRXDPZM&')(.0WFX0F+,F"X@LFRJIJRZ.BJ:Z
M+KB)75^'9;4U;&7"NI=I`>;C*<:1&E,!&DH)(Z*'+-UQ7"Z=P17:*_QS+3EW
M)<V=R>-6N6=@D5WF-C%?!J3);UA_M^\6MXJBHTCW0=%Z+^5<K.:KH%ZY(I*6
M%R2=8I0+"N(\66)RQ<<L&)9-1FY#K.CQ$D7JWOZ%^*X7V(5GR*)QRB"C<F?/
M3@JD$$.ZGZ[+S`J3;))L20C7=V=-<(M)MUQ4JEAVBFW;U+86<5MTI;D\(C#B
MQW$(#,A^6H*HHI@!:*[M3<G7$6J/C$FS=D4%FKDN3R;^7;>#62'QF"CEC%E?
MH-N"?37M]?U?7ZJJIB%=MX=EI,DR9;%G/EB<..-C!EQ9+#<><*KW%(Y1N$KY
M:KO%OVZ(B_;"/4:OY#"YK/XH)RI%7*>'DE?/-]PNTV'M.`9D6_:LD041]-BD
MF1:YBJ<NIL&O*M?LEY%(J[1GFD5TY'LE#'+M$HFNUIQ)6B,JWIJ*].B9<PJN
MLN2V=GQ^<]7S+170X9#1QUL);1?N3,I!=4"5!U?3T+;U7\<;A7U/DT6-0>,K
M1(*V,ID(YOIVY#SDTN\2$:B\?<<%/<JKHFJ#KHF,Q*^;,7K\*)-;?E25I8_(
MXSBQ>U/;9=@/P$,FVC,7'>TCR*?7HJIUTURPJ=00&;B5PNN=N9UE%=_=ULWH
MLJ<`(8$#L=AYQ>V:=H501WZ:Z?9<FX(\-_E3[=S)BR;5KG,*+:-S:T8CHLND
M1D4<T?<)6#V@@_'[>BZ]%^N,P>HS;4R-6/54ZY.NG7]6C\8V)<$6/TW!E`FY
M5=5"T'O*J[-WIUQ"O=3#LX,VKD02L5F1^46=;$1YR6XT-:33ZLMF+BJ"L]WM
MJ)E_\+$6JIE;21PKD$P)=XU?I5"Q=04B28R#8C(!>Z+J*2N/:[D%65T5OUZ9
M85/Y/3QVW^1PC8G2J.#:\=L6A<^7(VB9#\QUM5W&73J:#KHOT1<D37:^5:^!
M)A\1F/0W7X4.\AN.J`/D;3!MN!N(&_U/S*"+JG3)%U14W[J[>5J_Z:US1B\?
M2\$^\C)5!&\HZ[OT.QV.UVM.J'^.[+"IWD2#'#G03W8;SCC_`!FTBQ9+;3SH
M_(U!0;7MH0HJ@I:;O7(.6CQ>1U-/V:%NR1]_B-7(F-)WW2)]F0`2!:%U=HO_
M`!=X[!T7+"OHWBUN*5=8R8,B>_6RY7=C-3HSD0&=0%'&X[3WZJ!N34MW3=KI
MB17!TT08#"D[!DM\:=Y3:I>`V$A%6.:NK"<,4_4)CN*.JCT]->F(RE4U'8S>
M2<9K[(K(J3_ILH8D[*:7X;<EDZU)!@0KJ@B6SN+N4?7$5"II\Q^[%6;1UJ_8
M6[:CJ^$UE+"4^;BP!<[@#%_105V^]4TTVY$J0TQ->IY+]0U8LHYQ:8UR2.ZD
MH75M1`$8V[O<LGN=W4F_5-/PRQ:@V4&T>@W=B35FMA"K^-OUJC\OVR11$D$V
MV/M(T'HZFG\<L1:29D=?(#K=E8R(WQK]'PFJU/`3C+'%H(*N-M_&5KODG57-
M/NFN9,ZNIYX#9<HK!O(\A_B;D&6TY\87C0)Y$WVU<&.BGJK2&C9?0OQTRQ:^
M<SZ7E+E-;NV[=H[>0>-UCL-QM92K\]M][:HBTNPY`M]ON::_C]<1'TORE'^9
M34+KC,AZ$Q<09$]8PNJX$=$-#-49_504W:%MQ%?/IM7:PH,2)*;MDX0]-M0@
MBW'>G2&&G4:2$3C2[GT;U1[M*J:CJ.NF(5BYH[-O^8)@-6S]M7Q^-E5S'!D)
M(-UD]KYDC'Z;CJ-EH[^;35=<1*LH3]BGDN)+:@6$5@K"XBV6Z/+<0VR94H[C
ML@OTB:,A160!-H)TUURP8X)3HECXS*;62`E0Z.8T^X['>'L.(;2M`X2H@@2J
M)[4+UR"]\@Q7I')9S%K'F/5DBE4./NPQ?)&[,7'%/16?R/*G:5LBZ:(O7UQ%
MK/$JF:'DD9EO$,K<>-5S<ZP[;B-'-`W$?%'?[-2T)-41<;AB?RZGE<POWZ!4
M1FK@07$E%)C.&R\_/`FD5H]S8D3#2$NJ*NBGB&N3&;R"TXAP>)81K!NXI[^/
M%LI(17-W;ABZU\SW@2=MT-A;E33KB(N.5\0C4$?C;5:$R>Z]RN+;6LLA*0\9
M*A"Z^ZK8H(B*;4Z(B(F7#?5:^4:YF79<3=G17Y-/'GO_`+FL<'3V-O0WFA4T
M8_4V$9H*Z?TY%UR4'C_*:&%QVYBMR')+DB91)`DNDKPUDZ090''-Y+^I%1!)
M=?=V]4^F-1VW-Z8(O`F*J'(D1@CG%::?:8<FI^D8JGRF17>XP>W1W1==%QBN
M'8"\4*60<"51]OCU\P^L5)!MLN*Z'QW6^\NJ*X@DXR#B[D1=N(E43K#4SC?(
M`C-SF;J16US3-0S&LX[A.0WFTDRFNZ#6XS4AW;-51$U)5RB]OZ.9"B\R@5$"
M<$+]VHY=:TT$DD(E-@I;C2]5)/:2N:=/77)!AJDELWS=NQ!G!/'F[B?(4).B
M5;[2HX2(7L2.9>JZ;=<16."K#'F54[/?E,RF'K)E)3\6<TMD[*?(XZO.D"15
M5IL"V:.%K_5Z819^3>/L3^833GU\V2S*X\L>I>AB^J?N+<@S;%#9T0'!W"0J
M:HGXX56M5'(RYA$C<C"W.V:*KD5EE`8!R,2,1FQDM'+5%[(*]W%>$M-Z+TUP
MCW%KY(SP6[K9;W$RO+]9['QWR3N271*%(-D$4S9V]Q!)!5$(D7\<1IEKA?+?
MV[CSQL2'SL(\[CUH#IDKK%9*<-R#*>U7J[&;`45?S>[1<K+H^!MW%'1%8\CA
M23LXO8H@%@"><=CPW58:E;!_JO*?=)?HF1<?2,BF`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&!A`1/I@-B?9.OK@-J=/P],!M377Z_?ZX&433`:
M8#3`:8#3I@8TP,Z8%-0\5KJ5Z:_'=DR)$]U77WYC[D@T355%L%<5=C8;EV@/
M1,"XTP,Z8#3`IN1\6@WR12?D2X<B$9.194%\X[H*8[334%T)"'U0D7"1*I:6
M%41/C15</<2N//ON$\\ZXJ(BFXX:J1$NB8,Q/PI@,!@,!@,!@,!@,`J(J*B^
MB^N!S=+P"AJ'P<BG+<98+=#AR);[\:.O7JRTX9"&FY43[?3"1TF%,#FV?'_'
M6;)V:'RMKSY2G(!2Y!0E?(MY._%4U:W*?N_+IKUP1TB8#`8#`8#`8#`8#`8#
M`8%4YQ>D<Y"'(7&%.V:9^.T^1N*(`JJJ[6E+MH7N5-VW=ITUP+5/3`BVM7`M
MJZ16V#*2(4H%;D,EJB$*^J:HJ*G]&!`HN(TU(X3L-'W'B#M]Z5(?E.(VBZ[!
M)\W%$?P3`N<#!B)@HDFHDFA(OHJ+@<[3>/N,4\II^"R\*1]5B1W9,AYAC=JB
M]AEUPVV_7IM'I],$='@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@>5<%$W+T%/5=>F!D20O3`S@,`JX'D3$M=JHJ)T5477JF!ZP&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*/G%=8V7$
MK6!6SDKK"5'-J+-)5$6W#Z#J0Z$*%^75.O7I@?+`MH4#CW,(D[C2U/(85*CT
M_CLAXW:N7'9WC\B,XVO47%51-41"]-W7*B]L?)')($FS&)`A+54;M.V\)$[W
MG&;,00D#3VB32GT5==4R*M0YY<E`E\C&/%<XQ"*S;D-H9C-']N5P1(==0)73
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M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"%<U$"XK9%;8-=Z%*'8^WN(%4==>A`
MHDG5/5%P*9[QYQV1&L6)8OS/W6-\"8_(D.N/+%ZKV0<4MP!J2Z[?7ZZX9C$K
MQSQ>4U8-OQW"&T^'\Y.\ZF_]OT^-Z%TV;4]/7ZXI&8_CGB4>\E734'_3)I.G
M(;)UTHZN/CL><2.I=E''1Z&2#JN%B)!\3<)@UZU\:&Z,3OL2`;*3(/841SNL
M`VI&2@VV?N0!]OX82)TSQ_Q>9R0.1OQ%6U'M[W`==!MU6?[)7F1)&W5;_JJ8
MKI@BIL^!&X*4,&)#3BEG*<L.0?*-YZ2<@GA>5&!+4-'"'W*I>WZ)E'0M<=;#
ME;O(4>-''80PBCH9]LD%Q7$,@4NWN'71%047JNN1I<8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&-R8&
M477`:X#7`QN3`;DP,ZI@8W)@-R:Z8&=4UTP,;DUTP,ZX&-R8&=<!JF!C<G]&
M!G7`:I@8W)@-R?C@9UP,:_QP&Y,#.N!C5/QP4W)@9UP,;DP,ZI@->NF!C7`;
MDP,ZI@8W)@%5,%-<#.N!C<F`4D3`;OP7_!@-W\<!KI]\#*KI@8W)@9U3`:X&
M-R8&475-<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@47.AY$?$K5KC;P,7SD<QK77%011Y>@IN+HBKZ(J_7`^/GSJ;(X7S
M<`*YXYRNEI>^[2SW2-6'6]RI,BR"U(Q<+HO73I^.74=M<\PLN.^"PY)'-95P
MS2,2FB?+>1OFP!$X>O4MJDIE^"9%<ER"WO\`B/$>`<IAV\NPL;.9`8N&7WB=
M;GA9-[G$1I5V`0$NK>Q$T3IE1>>1O)<OCW.^.JU+:'CL6:E;R-C=^IW;!K6.
MXH_XC.B*J_\`*R*\^2YW-:+E)<KX_)D3:^DBQW;OC*$I-R8;INBZ\R/7:\TC
M:*FB=4RIN]5KQ/R-PZ+QZLD2[DR"]?E2*IR2C[IN,G*(6QUVGM0=1%!5>F0?
M/ZSG\F%RCE7'+JPL(]=:\C?J(M^XZ1,U[2,B;;#3BE^BXX1J@%IH/KUTRS57
M'D:TL:3R'QVOB%:6%4M'-<=JHDMX2?<C**-NN&C@D2BAZD6JK_'"+#RS4S*#
MQ?=6T"_LRL*:"K,-])CJ*)_)W]QS82=QU!-`W'_53"IG(.-/0^`6=^Q<VPR6
MJ9Z8PS\Y]0"3\1%[B+NW+H0;D%5VZJJZ8'(<A*XA?_LYGRZ+=687,NHK'W'U
MEO$0R.Z'<>!5+45<1U4)$Z*FF!?6SDUGQKS"]BR+2JG!6RFX\*3+=-P'((JH
MS&E(S4"/<BKL+14TP*OQ=R*WL^>4U=&G3FX[''&)/)8=H\X:RGY`"K,B&+A&
MOJJ[S!43Z>N!"XHSR;D?BYR*UR&PA73W)I<2';I(=-UI&2<1D"U+W->Q!(<(
M]!Y7Y.''>76TF.Y&YMQ*G&):UI*91AE]\A"8VWKVR$V_U-43T33TP.KJPH:V
MCX7(M>1SVKZZ.(^W+5Y][]P?,0=<CD";FD`]VB#HFB>F0QN\\3;"'#X@4&6_
M$*1R2OBR%CNFUW&'B)'&SV*FX2T]%RX:YWEMQR;AO++GEPRI<_@YROVWD-5O
M-Q8`G'9()L5-541WNKO0?O\`X!6ODDSD]1%H[@(4_D7$6J)AN<W7RW!L(4@T
M5Q9^S<A/*3>G4O33`SY&[3/%^)<CIKBQD!?7%*R<M93S?<A.MHVH=L"$1[J#
MN/IJI*N2"SY9">HO)WC:I@SYO[=/F6I2H[DEXQ,49[[;9ZDN\&C_`"(6NB=,
M9AJ)9\="/YBH.*)8615<ZBG/R]9LE#.0CNB/JJ&FACK[=.B9<%EQ'Y;?G+E=
M.]-DR:^'2UW99>><($-P4%QQ`UVH9[?<J)@<WY(@/5W@]>3P;"P9M@BUS++P
MS)"=L?EHCBIH?4G$=5"(M5TTP+'S#4GQWCU`[3S+`4L>2UPOQQF/;E:?#8['
M`S<14!S8B[5+37[82/H/CV"TS5G*[<J$]9*DEZFF/N2"B*BJUM'N$9"A;-51
M%VZZZ85\LH@FVWD#FU')"SD1%O6X<>P8FO-C6M.13>W`(N(J:N"FGM4>O7(J
M=Q`YO-G?(UA?S9<6543Y-95--2'6$@,Q6U)MT`;(![A%[R(D77^&!S4?FW)+
MVB\0VUJ4UUVQD3V+:/#<-HY[49M=A*V!-H:GLW?Q],0?2?`%M/M^)S[)V>Y+
MK)-G*6FBR75>EPXHEM&-),M2WBJ:[55=$7UP*KQ8KG/'N57W(9$DIT:VE54*
M"V^ZR$"/'1$%&P;(41TM=Q&J:ZX1Z\O7]]Q;AD&MH;-QZXIV6+.4^^IJ_+BP
M7`$FU(474WUU4ON@EEA4OGO[ASBBXM.X?</U<^<#MA52V'%%LS"/W@8D(G0F
MR)-I:ITP.(MO+'(?[O\`FW+(,=^LY3";KJJTAN[E&!,0S:D.M`6H:;3$D5$^
MVNNF0?6:3@-5%ATTF).F)(8)N3)EE)>=6<IM*)I(WFHFA[MWIT7TP1\R\,MO
M6S2NVW[@(UMK826>0.S'5;_T26#3<,A5Q44%`EU$QT^V(.7Y3?2X-AS]D9%C
M'L$Y%%@<?N1ENMPZUQ\4/5\NXJ`RO75.VHKZ91]M\LE,8\/<B?600V,6K<=2
M9'(FB1]IO=W6R%4(?<FJ:+D5\^\77,F7Y(J:R&_+KH[''69%]764APUL7I#8
MJW*B-F;PKM_KF))]M,)FM/B!EVUG3?W0)ZLUMY9/,7[DU[MMC!DM"U"4%<45
M!1(M4,=%3TZX$B-87=+SN.SRV)-<BVMXA4G,ZZ4;D5T7GE2/7RV$+8`:?I::
M>O\`2N!JX'&>MN3\JA3TL/AP^23_`(]VDUX6X+<(6GVXZ#W/R$JEJA#MVZIE
M%UY<\D6''^54<^%*TI:&8R/)8HH>KK5@"@A:HFS;'%4-=5_,28*U^6K1(OE#
MAAJ$Z?4R*ZU>G5M<Z8E)!AA'&R0`<;0U#52'KKD')P>7\H/QUP>$MX[^W<PY
M`<5ZS!\G)46N)U5;@G)7WB\OY"+75/1%P/J/,.&UM-Q:]GU+\J&,>DFM##"2
M^K2FC:.-OIN-5%UM6_SIUZ]<I7S6KL[MZ/X1&1\QD9QI\R4LLC^:BQD=7O()
M[C]_N]^3V'Z/3"F`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&!!O*2ONZM^KL`)R')04=$#)LO82&*B8*)"J$*+JBX%!+\:\>
MFQ+./8'*FE;Q1@3)+[Y$^L054D8%Q-%$-255TZKKU7*S&R#XYX_%*$)%*F1Z
M^*Y`B1)<@WF`CN@C1AVR]I:MCMU+5=,C357>+^*07:LA;??8HR5RFAR7S>8B
M$J:(K($OJ`]`W:[4]-,J1(M/'G&[;CEAQVR;>E5EH\<B8#CQJX1FXCJZ.:[D
M1"1-$1>B=,BK"LXU7UTM93)OFZ45F$O>=-P5:C[NWJA*ON]ZZEZK]<$;J6DJ
MZ.N;K:MA(T%DC)E@=5$>X:N$@Z^B;B71/IC='R:N\<<3YI><D1QA\^'E.(Y#
M:R'=MC:CT?DZZZH#']F*"NBKK]L]?DXYXO'F?^SEUOTQQXWERWZ8G>/_`![1
M36$F.NS4E\:G65122FY;X&S"!]11K7=[M$]NJZ]$S'R<S-S<R7CFKX[O&NSE
M>.>,R^(O\3D-ONT\LB.6!2'5>=)QSNFKCREW"W'U7KGGKJLY?&ZV7QMSCK_=
M*L=C?"<%'"1Q6%'8HJXB[NH]-=<"LF>-^+3.%-\*D,NGQUIL&1B]]Q"[32H0
M`KB+O44T3ZX&M[QIQN1'G1Y93)C=A#6M?^1+><5(BJBDTWJ7L0M$W*/5?KB@
M/C/B(2J*6W&=;F\;9^-4RP><%T&--O:,T+]0-/ZIZY.Z$<;)G^'^$HE(P[-(
M:Z>MQ+;A+*F#&DJFI.2G`WH`Z*JD!+^.F>GQ_&\G++(Y\N>8^B1Z3C<^0_>-
M1V9)7$-N-(D)H82(B;B;$D_*0Z.E_0N>>;G3?7&\ZJF%XJX=$=K";C/''I'E
MDTT-V0ZXQ$=7ZLMD6@Z?1.J)],*M.4\-H.4-06KADW@KI(38B`Z;6R0U^1SV
M*.JC]-<#>UQJI!NU;)HGVKHR<L6GC)P#4VD9)$$E5!%0%$T3I@5KWCGBY[%:
M:?C$,1JN,HTEYI3B,"HMLGM-$(40E_'\<M(W7?`>*W576U4Z'_T?4.M/U\9E
MQQD6G(Z:,JG;(?R)Z:XHW6_#./V]U574]@W+*E(SK'D=<#M$XFAKM$D$MR=%
MW(N2C1<<8XN%ZUS6P`PLZ>*ZVW,[S@@W&T4G$5M"1M47JJZIEXYN[F9[FOF?
MCE7.;<XY%:7S)Q98Q8AU_P`4W(CR5LQ#-N/()H@[J*(B?OZHJKIGT?F_'X>/
MAP[?7KW;]WF\'EWGNU]2Y#PGC7(>/IQZTB=RF3MHD-LS9#1G16T_2(%T%431
M-<^:],:^1\#XUR2O@P+AAV3&K76Y$-$?>;(7FDVMN*;9B1$/T55P1)I.*U%-
M)F2H:/G*L%!9<B3(>DN$C2*@#N>,U$1W+T3I@C71\,X]1V=I9UL<FIMTXC]F
MZ3KKG=<'70E$R(45-=.B8$2V\<\3LYLV8_%<;?LVQ9M/C/O1QEM@FB#(%H@1
MSITU7KIT],#=,X#Q.7(I9#D%`/CO6E%DW&@C]$'V`V0C^4=.J>F6C=2<,XW1
MV=G9U,-(<JX<1ZQ[9GVW74U_4[:EL$EUZJ*)KD$1_P`=\5=M9EHW'<B3+)$2
MR*(^]'&3HFB*\#1")EITW::_CBD6,;C%+&<G&RPH?N+3<>4&\U!6F6U:;`14
MMH((*J>U$P1`I?'O$Z./6QJJ&46/4&\[7M"\\HM%(':[HA&NJ$B^B],$3W>,
M<?=.S)V`RY^]`#=J)BA#(%L%;%'!7VKH*Z8$&FX%QNG)CX33R-PT(8++LE]Y
MJ.A)M5&0<,A#HNB:>B>F!!A>).!PFA8BP76XPRDG?%25*5DI*$A]TFE=V$NX
M47JF6B4OC7A)-W;;E8+K?(R0[L'#<,9!)Z$2$2Z$GT4=-,E$MWAG'7N+?RJ[
M&(Z)6?C+$5UU=6?_`!:N;NXH_3\WITP(I>..&J_2R?V_25QX.U3R1<=1UAO3
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M:>E-SH_PY3DF0^\Z4=?5KN&:F(K]4%4UP1J'QKPP0HP&!H'&UUI!1U[2,O\`
MR/?U^WNUZ=,#IL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@<KY+NI=-PFTEPBVV#@#%@%]I$HT8:7^@G$7.WQ
M?'W<\S?3U8\FSBD,LUG"N$((IM@T4%5+3U/L-ZDOXD9)K_%<GDW?+Y+OOI^G
MBY7CW*Z#A'#Z>OO7R_F*:VLN1516SDS#D2S5]S1AI"/\[FFI:)GI\GAY^?R;
MO'/RYT^S'#EF<4W^\'FIMI)C<`LSA=5579$-J3M3ZI')Q2U7[*J+F/\`'X>G
M?QK7[F_1T/$N94_*(!R:\S!Z.XK,Z!('M2HSP^K;[2]0+_<7Z9Y_+X^7#?\`
MB-YRJ+<^4?'E++.':<B@19;?1R.3PJX*_8A'54_ISKX_B>7GESCL3>?'/5:4
M'*>.<AB%+H[*-91Q7:;D9P7$$OL6BZBO\<Y>3Q<N&SEDU<W-]%)Y`O+!AN!Q
M^F>[-]R%PHT1_1%^.R`[I,K3_P"*;_+_`,I4SK\?Q9N[SY?IX9?X_9GGNR9Z
MK2EXE1TU$M+!BBW"<`A?31%)XC':XXZ7J9GZD2^N<N?FY<N6<J9PR.>\&N&7
MBZE:+UBH_%3_`,&/(<:%/Z!!,]'S^,\V_A_9/'OY7=DJIZ9Y'16TO(Z6Y.:%
M9,;EE7/E$F=M=4;?!$4@5?35-?IF^7CY<?7/5GCRJSS#1@,`N!POE-TK"-4\
M/:)4=Y-,!B1IZI!C_P"D2R_I`-G_`+[/9\+IW>3VX9_7TQR\N^F?5$KHS4'S
ME-!@>VU8\=8<($Z)NBR5:'I^`'IF^6[R^)GV\F_UQ,Z<]Q]%SP.SF;?GM95<
MSIN*R8\CY=V#IQ)8@GQD)I%)6R-5_.J"JZ(F=>'AWEPWE]&=Y38Z;.31@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@8,P`5(R011-5)5T1$_IP/#,F,]N[+H.[>
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MKNZ]&<,QR'D?A[52!<[XK%&)R.G1)$D(P[!G0P761'>`=!-5;U4"5-47/1\?
MR]^_M\^N;_=CR9.N//C:Z8YKRJ^YDR)%61D:IZ)PDT_2`$?E&FOHINN(B_\`
M@IF_E^+EX>''Q[Z[^;?[)PY=W*OI2_;/GQV<)X0<#^[F"TB_J1Y$UE\?JC@3
M'4)%3Z+GM_\`T=_[V[[3/[.?A_2SY;Y7:U5/%IN/CW>3\C=6!4@BZ=O5-7I!
M+]!:#KK]],?"\&<^7=R_1QZZGEY;)GKKF^/<DH?&$4.(MU]E;#`$7^074*.4
MEMJ9+53_`%A#5S4DZ]$70=-<[^;Q\OD[^Y<X^V<=^S'"<.B^'SIP!S5([L^0
MZB:]EJMG$?3\.UGG_P`#R_\`3_-U_<QM'R?:R$5:_A-](1?[,WF68HE_Y9T2
M3^E,O^'F9^;GPS^O]F?W?LPYY"YNP*O2O']BD4>IDQ)B/NHGU5&1-"+^"+F?
M\?Q[LSR9?X:;Y-^CH.*\TH>4PBEU$CN(T:MRHS@JU(8<3U;>9/0P+^*9Q\_A
MY^+EV\\GT^[?'EFN<K32\\QVDI$WP^+5[=<V:+[?F32[[_3[BT+:+_'/1R_+
MX,SWY[?PQB9O/^#UR)3K_+G$IR:(S:1)]4\2_P",(C*:3^.K19OP7E\?GG_+
MRSE^'HG/IY,UWR+KGS\VNSPY'8=(%<`35LD-M21%VDGH2:^BY<Z$;,!@81=?
M1<@SE#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%)SAEM[AM\TXB$)5TM%1>J?V)8'R
M3CK$FKM/&4Y8,>HC6-7\`)L$NXY*DO01<9;EL[6?TQ[9.;M2]W3IKKEB5V7%
M>6\IO&#JW7HT3D50,QCD1*RJM-R150AF`;^C;J+WD]W44]<0KOH:/I&920X+
MKZ-BCKH)M$ST]Q".I:(J]437(K=@,"JY-R"%044VXF*JQX3:N*`_F,O0&P^Y
M&2H*?CF_%XN7DY9QX^NIRV8J>`\=G5T*1:W*HYR.[-)=J:=4;731J,'_`"&`
M7:GXZK]<Z_*\W'EN<>/Z>/I_K^+GX^/NZM/3/.ZM$U7_`(C_`&/[;MGVO_#V
MKM_W<9ZY?JF^CXU1M5MI_P#LQS8P*B.L5<P9X&OO;G,$;CO<^J%WAW=<^EY+
MQ^7F[]OY..?^-]9XO..?QJIG&FARX<=\D^RN-"2_[^>#R<9RW/NZ\?3&ZZ9F
M/U$YF&@K+=CNA'%Q=`5P@5`W?AN]<SPW,Y9?J<LZ.=\2\/D<0X!544O8LY@"
M.:3:ZBK[I*9Z+]=-=-?PST_,^1^[Y-Y,^+CVY'7*B+GDW'1P%AP;EM7>3K7@
M]O&@MVY]^SJK)DGXJR-J"LAGMDV;9DB)O3T7USUYY^'+,SR9NSTCEV;GHYJ?
MP#R?57\'F%?-C\HY/V9$26W-7XD5@']O;*(V.[:#:I[D5=Q??/1P^1XMX;X]
MSMXW/Q_BY]G+.5=[X_X>YQFE./+EE86TU]R=;6!)HKTI[3>J)]`%!013Z(F>
M/Y'ESR<NGIGH[<.,=/M3.$;-B:ZX[<6BBF(CY]SOA]O&MV.;\-8$N2Q-`L(&
M[MMV<33167%_+W`]6S7^&>SX_GSMWQ\_T[[^^?P<N?'WSU;O#O&KBFXP])O6
MR:OKN;(M+)LBWD!OE[&R+TU!M!3ID^;Y>//GG;^GCDP\6;UW5AY&XQ.NJ1MZ
MJ-&[VGD-V5.9?E60QK^F7_)=`E`OXY/B>;.'+>[]/+)J^7C<Z>J@A>2N>6X@
MQ3\!GL2T%$D/W#@08K9HGO02_5<<1"]-H=<US^-PX]=YY/MZG=L]$OM^=GE[
MRR.-P_\`]U[4V1_A=WM?[@YKCR^-F3>_=_!-[_LPCWGD2T5KC+@_XZ%.!5_H
M]V;_`/C^OD_EB;^Y]A;#S@.\'J:AD@2:"3$V2RO7U7WM'F=X_&]N7/\`'CG^
MIG[DZQT'!HW+XU"#'*W8[UJVX:([&(B0F=VK6\B$-30>A+IU]<\WFWAW?D]&
M_'FYZNASDV8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`T3X$2?#>A3&D>BR0)I]DORF
M!)H0K^"I@4L3@_&JL@D5%='C3XS!,5[Y"3B,(HZ(((J^T?35!TZ=,M2,4/&'
M6ZR:'(#CV-G<)_TR\RRK++J=OM(V+:D9;!;3:FXE7%(O8L6/$CM1HX(U'8`6
MF6A]!`$VB*?@B)D527%SRZ+.)JLXZ-E$04492SFXZJ2^H]L@)4T^^!!_F/R%
MU_\`R>WT_P#YHS_FLHH>0'SRYM*<9/%6OBUSQ3SAK9M*CKK:;65+]'31LCWZ
M??3.WB\G9FSUWHY\LNXO4Y#Y%_[H,_\`:K7^9SAF8ZG\Q>1]/_T/C_\`:S?^
M8RHQ_,'DA?\`]4(__:P?[/F8/GE]XLM;BZEV9\6?A!9$)VU9"OQ8A32!47=(
M92-[E73W:*FN>GC\GEF>V[]6-X/H#-YY%9:!EKAL4&FQ00`;9M$$431$1/C^
MB)G#U;;%Y!Y)U3_\HQM/K_TL'^SY)@)R#R5IUXC%1?\`^K#_`+/EF#"7_DE5
M73BL-43ITMD7K_JV(C`\@\DFFH\7@JG5%5+5%T5/X1L3%>TN_):K_P#HO!1/
MO^Z?_P#-C<P$N_)77_\`+,#_`+47_9LD#][\E^G\LP/^U%_V7*'[WY*Z(O&Z
M_7T__%"]?]5P,I<>2U7_`/1NO1/_`.IE_LN3<&5MO)7_`'<K_P#M,_\`9<08
M_=_)G_=RO_[3/_9<09_=O):IHO'*[_M,_P#9<#S^Z^3=?_T<KOX_N9_[+D[<
M'K]U\EK_`/J[7?\`:1_[+E@?NODO_N]6_P#:3G^RY.W!Y2U\G?\`=ZM_[2<_
MV7$'K]T\G?\`=^L3^-DY_LN482T\GZ?_`(!5HO\`_4G?]EP'[GY0_P"H:K_M
M%[_9<!^Y>4?I157_`&B]_LN`_<?*/_4E3_V@_P#[+@96P\I?2EJ/Z;!__9<#
MS\_RK_U-3_\`:$C_`&7`+.\K?2GIOZ9\G_9<#'SO+'_5%+_K\G_9<!\[RSK_
M`/A%(B?_`&^5_LN`^;Y9_P"J:/\`U^5_LN!CYOEO_JFC_P!?E?[+@$F^6OK4
MT:_PGRO]EP,_-\M(J?\`1-&J?72?*U_W8N`6=Y9^E12?Z_)_V7`?.\L?]44G
M^OR?]EP'SO+.G_X12:__`&^3_LN`6=Y8^E12?Z_)_P!EP,?.\L_]4TG^OR?]
MEPFGSO+/TJ:3_7Y7^RX.HDWRWKUJJ/\`UZ5_LN#JZ6J<M3@,E:M,LV"HOR&X
MQDXTBZKIL,Q;)>GW%,*EX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8'SP08Y)Y0O:FXU=@4$.$=?6$2HRX4Q'"=DN`
MBZ.*.Q&QW=!Z_5<J541.8RZN*U6<4KE1R1R.72*U</F3;+P,&^2M$UW3[(D'
MM%?HO3`N*[GO*IMOMBTORJF/+D5U@ZUH)`]%;7>Z!FY[A)\>V+>S=HJ+KB%5
M<;RY=#6R;63!C/06JEFS7L]T"9DR7NR$)\CW#O$NI%T737VY(5(N?(',Z:;(
MI9$.ODVP2*Q([XJ\U&<CV;YQUW"JN&#C3C:_54(?MEBI3?..6P[6=QRX8KPY
M"3,1ZC6/WECRA?/M/KH9(?\`HYIJ:)_5T7$2M/EX!6QX6JQ3G;K@FW(C1(!/
M!\-\U:]Q`*ZD"+H2Z:IC"J[@U]/@>.!M(<MA1LK<QA0YCC\@J]E]Y&_@[$_7
M>?95%3M)I[NB+M3"M@^6.0?M%9/EQ(]:P](F0YUE)9D%$"1$E_&!MQ6R4HR/
M"BDAN;A0O:N(FO?`;XF^8<AXW#-IEY;R=.DC(!Q.Y&4&DTB*BH)F)JBGZ[47
MTZX@T47+;]MFKJZ.NK()VLR_!W<CY--O0'B5'$%"0B[JZD::^OIDTQWW![][
MD/$JJ[?:%A^?'!YUD%50$UZ$@JO735.F!\]Y/9%Q?RC(Y<;YM4;8P:SD3:DO
M8;8EBYV9BIZ"K3P")%_BEFA(X&[/F>6;RSG$XAV%+"EQXIK[8S+DA\&@$?HI
M--B1_P#*5<BYJ3'X]36WE_EK%C$"2U^UU9")J7M(RD(1!HJ;25`'W#UZ8%GX
M@L)LFBLXK\IR?#JK>=7U5@Z2N&_$CN:-J3B_G4%4F]WUVXT=WD#(&4,@90P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&F`TP&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*6ZX?2VTZ/8OB['LXHJV
MQ81'3COHV2ZDVIMJFX%7KM+5,5(B1_'7%8[<(6H[FZ!/.V9=)YTG"FN"HF\X
M:DJN$0DJ+NZ9:1HE>.>/#:S[ZOC]B\F`X2&3KRQ5DFVK8R#C":-J>G12V[M,
M4CG.(^-+%A2BW+/:J#BN1)M9^Y2[&-*0P0/[*2(HR(Z:CI[OIBD=*/C7BR14
M8<"0^J/QI/R'I+[CZG"52C(KI&IJ#2JJB.NF*KTS1VTWF/[Q<-POC52.M\?5
MC>4C;)$4>-\C1!%=`VH(?QP+*YXO3W,RMF3P,WZE_P"5`4'#;0'MJCO5`5$+
MVJJ>[[Y*D5DSQIP^6_-?<B&V[8269TE67GF4^7'_`+.0"-F*`[TT4AT5?KEJ
MM+?B?A+3!QVHCS<5TG2D1AE2.TZC[B.N`X"N;3`C3=HO_#BD2D\>\464$P8I
M)*:L#MFGQ>=0AF.@C;ABJ%T$Q%$(/RK]L5(]0_'O%83T5^-%-MV$[,?C%WG5
MVN6&JRBZDNO<U_H^F*1YHN!4M'9QI=8CD=B'`_;8\7NNF"-=U7M20S)%425=
MJZ:]5ZXJIDCB''Y3UD[*BI)6W;::L6WB(VW08U[8JV2J";=?HF*-<KA'&Y5A
M/L7HQ+,LX:5TUT771WQ4UT;1!)$'3<NBCHJ8HBR?'/$'IC\]Z,XDB2PU%E.#
M)D-HXPPFUMLT%P44115Q18M<9H64J_CQ`8;IMRUC;*JVVUO!6RT`%0511)?5
M%^_KA*L$F1MHEW6]AKM`MR:*J?1/OZ9!M$A(4(5117JBIU1<*S@,#PX^RV0"
MX8@3B[6T)4127[#KZX'I3!%5%5$5.J]?IA*RBHJ:IU3"BJB(JJNB)ZJN!@#$
MQ0A5"%4U0D75%1?LN!G`\N.`VB*9(**J(FJHFJKZ)UP/6`P&!X5YM"05,4)>
MB)JFN$>\*8!5T15^V!X9>:>;1QHQ<;+\I@J$*_P5,#W@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@?+N5LNEY64&ZUZX1>.F_\`M[<GL`K@2T$2T,P#<J+M1<J5,M>3V/#PHJQJ
M$"UMDS\*O>E/F;C%H6A,QY1KK^D2*H]S75%33ZIB%2)7.N0_S$Y65U0L^/72
MXL.W-L211^0V+CKS;A*@(+*."NTNI=<1:@R_(O*6N(R^81ZV$]1_M\B?"3O&
MCPDRXB`VZ.FA=QO4E4=-BIIUQ"M?+N=\I9FV%;5#&BN0I]$T$EU'#[C-JZHN
M`HHJ;5%1TU3Z+]\1*\V?,9]#8<NGQZN,254^K2ZD(X\I.0GV`[LA!75!)@3_
M`"ITVHNO7$*F6OD6\&:,&G@-RY$Q9KU40BXZ+L:"C;:DJ`0]77W-HDBZ(/7K
MB%>?*<R;,\+V5A(CN5T]R&P^Y%1S]1AY7&U(.XVO7:JJFJ+B%:N0P&>+\VX?
M*HC=8*[F'6V58CKALO1_CF[WD:,B038)M%WBB=%T7!4#C',N2%'XU5T=36Q`
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M;`J[X[K;"R5>=W.`*._ID1-#N(>NG^'"K?C?,.16M9#C\?BUL7]NJZJ7,@R%
M=`%"<WO5M@A+](&FA7:1(6J],0J;Q_G7*;F_9*-5"?&79DV"Y*78VXPL0S:!
MQ35XNYW'&E3MHTBHBHNJZ+B%;^3\POVKJXK:((B.4-8W:3!FHXOR.XKFUEM0
M(.VFU@M7%0NJITR+5'3"G+O(C\NP;8D5#M)4V,&'(:,G6.\;SHJ![]`<0Q3<
M0CU1$3Z942_(E!51KGB;P1A5VRY*RL]PDW*ZA1'_`&&JZZA^F/L_+T],1'FV
MY#=T5M-XUPNH&3^U,M6#\9S38Y\YYQ2;!PWFNR`H!+NVDB+TT1,1:FQ^1\BN
M_F26!@)QYN7.JYD9U3^4*1P(.X)[E`B)T=.WL_*NN[$*X[B?.N447"*R)V83
MK+?#CN:M$%W<)P!;%6WRW>]'!=1?:@Z?CB%7:^3.507ID2S9@G)>8IGJPV!=
M!ILKA\HZB_O(E)&B#=N3;KZ=,0J)S.\M9L2;1W`,N3J+D%"K4V.)-MO,RY39
M-%VR(U!P4W":;M/K]<0JZC^0;UYVOM@;CG0S[QVA*&@FDMI1?.,W(4]RBJJZ
MW[PV=!7UZ8A42KYQY"NGV&*Z)$:?F1+!]QJ0R_I!D1'NS'8?-#$3[^OKT]%5
M-4Q#-7W`N:3.5-1)`-M-M,PD2Z:T5'&+/?L.-U)=O;[9[D7KU'[Y"J>IH:6T
M\E^0(UE#:D,*U4_G%-0[D=S>0$GN!5TU515%P.;XASCEZ4D3CU,JV4P7+A:B
MQDH+RR(5;)%B,A*X\QOWJYM)S<J[1UT7+"ND=\@<IB6:5EC%BQ9]Q5QY7'6@
MU>%9Y$C,J,XX)[749,P/4--6]5^F(5NJ.9<NM>0:1X+#W'F[&346"FK31!\=
M%#OB1/$9$;J?V/:_*NNJXA7.>/;_`)`/&JGC?'RBQ)42IE6BN2VS<!Q!GO,M
M,"(FWM'4%WGU4>G3$*V/^5.<SH$^XIHU<Q`KJ*#R!R),!XGC!]'B?CHX)@*+
MI'78>GVZ+KB%;[/R3SEI^QE0VJ_]NAW%97-1WVGT?-FT:845,T/02:*2B]!7
M733IB%;V_(G+_D'Q\PC.7RW$NL;G1VM&B;BQ`EB0L/OA^H2.H.G=^BKB%1;+
MR)Y+8:EMG&K($ZLX\=Y-8)#E(KT>0XTXR)M.H.UP&ONJ@J_7$*Z3A5SR"TYQ
MR-)4P5J68M6[#@=K16EEQR=+]3=U7=KKJG7IZ:9%=[@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#GK'A%5
M/O?WTWYD>S^-\)'HTEQE$8W]S8@BNWJ?77UPD19'C/BTFM>K93<B3#D15AN`
M](>-=A.J^3B$I;D=)SW*XB[NB=>B9:1D_&O&#O6+PAD_N#0,@Z22GT;D?&31
MDI3:$@/D'T(T7%(TQO%'"XPV33<5U8MHV^R_$.0^;#82EU?2.T1J#/<5=54$
M3%(\)XEX?\6:P82W#L$B?+E.3))OD<`MT9Q'5/<)@O\`6'%(MF>%433EP?:-
MS]^;!FT!UPW!<!ME6!30E7;^FNBZ>N*1#L_&G$K&MJJYV*;#%("-51Q7WHSS
M#:`C:@+K)`>TA30D5>N*187'$:2VXZ7'9C)?M!@#11VG#:U;;5%$=XJA^HI]
M<4C56\*HX%HEL(.R;06U8:FS'G9+K;2^H-*Z1(VB_7:B:_7%(T5/CWC53)KI
M,)IT':H90P5)]TT%)SG=D:H1*A;SZ]?3Z8I$:)XJX1%6R1NO56+8'FY<-QYY
MR,@R%U>1I@C5MKN+U+8B8I'J+XOXA&@1H3;#ZA$EMSV'SE2#D#(9%0;+ODXK
MF@@JCMUVZ=-,4B3%\?\`&8LMV2Q',%<<>?!CNN*RR])%1>=8:4MC1FA+JHI]
M5^ZXI'AC@=5$;X]&KR=B0^.&10F0>=74";4.T>I>\/=_7U].F*187?&*FY<C
M/S&R&7"(BAS&'#9D,J::'L=;421"3\R>BX5">\?<6>H9=$[%(Z^P<1Z?JZ[W
MGW142WNO[NZ9:@/J7TT],5(D.<.HW+23:FVX4Z9"2MD.J\[[HJ:KLV[MJ+J2
MKN1-?QQ2*PO%/!B<K72KM7*F.W$B+WGDUCLKJTT]H?ZP`O44<W:8I$N!X]XE
M`Y&_R*)`1JUDF3KQBXYVE=<30W494NT+A)T4T'5<4C==\)X[=31G3XRE*1E8
MKCC;KK*NQR7<K#W;(.XVI==I:ID(W0N*TL*[>NXS"MV+\=N&ZXAN;%CL+JTV
MC6[MB@ZKIH."/5WQBGNY%>_8M$ZY5R!F05%QQOMOBBB+F@$**J(2IURYIN(5
M_P"/N)7]I%M;6`+]A$'MM/H;C:DWNW=MU&R%'6]W78>J8I&M/&_#DOI-\->(
MV<M"^0Z+CJ`1F';)WM(7;1U07;O0=VGUQ2/"^,N&+#8A?`58T:O<IV6^\][8
M+RHKC.N_70MJ=?7\<4C;(\><1D)(1^`CJ2H;%<^AN.$BQHI;F`_-T5LO<))[
MM>NN*1[+@/%S@%!>B*\R<AF8Z;KKINN2(ZBK+CCREW#4-@Z:E],4CT'!^.L6
M;UK&BHW.>=*5JI.$RDHA4%D(PI=I'%3U)!U7%(X;CGC7EE*X,J*,"'90P<)E
MUJ;9.1I;QB2(C\1PNTRVIEN5`W*G]73%,QWW%*`Z>N<21V2LI[[DVT>C@K;3
MDI[3>0"NI;41$%-5UT3KD(BSO'7$9UA-L),(CE62`D\T?D`+XMIM`7`!P0(1
M3HB*FF6D>KOQYPR[@P8-C5,N1:S_`/#VV]S'833:HMJRK9"*HFBBBZ+]<4B>
M?&Z4WJQXX;2N4V[]K+;I\?>WVB[:)Z:A[<4B`'C[B#?(W>2-5C07;WN=EBII
MN/;L[G;0NWW-O3?MW?CBD1U\8\*^'"AC7=MBN%UN'VWGVS!N06]YM7`<$R;<
M+J0$2BOVQ2*QSQI"F<VGV5C%9.B<KH,&%#;=>;3_`$-QPU!U@-C1M?J#H);D
M]OIBD7<KQ_Q24<PWX*&4^6Q82U[KR;Y47:C#O0TT4-@Z(G3HF*1HL?&7";*/
M-8G5@/!82TL9*JXZAK+04!'A-#0FRV(@^Q4Z8I&TO'7#B!UO]M`6WX'[2Z`D
MX*+!W*2L:"2=%)555]5^^*1+K^'\?K[1;6'$%FP6,U")]"<55CL)HT!"I**[
M4Z(2IK^.07.%,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!D#*&`P&`P&`T3`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#7`8#`8#7`:Y*&4,`JZ8!%UP&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P*SDMXQ1TDNS>3<D</TV_J;IJ@--I^)F2#A*Y3@O/I)\(GSN6N-MW/'I
M,B#??'34>^R?Z?:$?5'0-O9]]<*L?[PF$)8SE18LVI2DAQJQQML7'S5E9"FT
MYW.R0"TBJ9;_`&KT7KB)5=9>9.,UT2/(E,3&E..W+FQG`!J1%9==5D2=9<,3
M(MXE[6T)=$U],L*VKY:I4MB@?MUAV@LEI7+!6@2,,TA%604]^[1W>B"6FB*J
M;M,BU757F2.YQ>#;6E:Y%FV)S"B5PNQT(F(3I`;B&XX(=$VCHJZJ2]$TZY8E
M0^>^4TD<)GR^*_,[S<2%,<LF@:!(@S7`5D'0?5"4C;5=PB*J*=<A7?<EY"M)
M"8D)#>FF^ZC(@RH`(ZB1J;SKI`VTVB!^8E]=$]5PKC_[[J=V!%FU]18V`2JM
M^Y1&483;'B/=F0A$;HCN;+[*N[^KK@J'Y)\E/?RC:'QA):R(L2'-?M8_9$8@
MS"`V4,7EW$IM+J0@*J@XB5W/*.2+11&'AA/32?=[2(V3;3;:()&KCSSQ`VV"
M(.FI+U543!7+GYHH2IV+2'"ES&CJW+R2T':%QF$R[V3)=YH)DAH6@@2ZZ:_;
M4J0]Y8KVK&;%=JIS<6LALV-G8+V.S'C2&7'@,M'%,E7LJ.T45=<".QYEI#;D
MH]$=8EM.Q68[).-$T\LU")K20)*T.U&R[B*OLT^O3$2L.>4FK6D(*>NFG;/Q
M9SAQ15MIR.$->R;R..+VS17"'M*.N[U]-<%3^,<GG,^*J.^EMOVLYVMANO""
MCW777@!",B)1`4U+<9+T1-5PM0"\R5?P`>"&12SL9-2C)2&`963%:[RH,HE1
MI>X*HC?^,JZ82NGN^4-5%3$F/1G#ESWH\6'`11%PI,K1`:4E7:.G7<NNB:+A
M:XSE'D.UDT_Q:^(]`MV+Z!2W$970%QH93S2ZM.HBHHOM.)M--%'7Z*F!;7=K
M=<.JN.0X8.VSEG:LP'G+"2AO-!)(G%'N;?U-B#L%5^GKK@4O%?($RNE.P;EJ
M2_"EW]M7LW#SP&+*QU<>;:4/SJV+31"A?14TRQ*Z+A_D=CD=FD1NN?88?B)/
MA35W&TXR1[4%Q=HHT[H0ELU7HOKD50<^YM9/.,1Z9M]F%`Y'65L^U9?%K5TY
M#7>8[6FXVMCJ`:Z_F7TZ+@2K7RS*BR;&"%1VYS,2RDP&W9+:D15J(JI(;!"[
M*.B2&'554?7;KE@TKYA<BP(/R:IV59?!AS;2/#(G2`9GY.R(MEW#444U!5'0
M?JJX@N?*-O=0.,Q2J14G)MC7PWC%U8[B,RI3;9H)[545,2V:IU'77Z9"N:B<
MM_E"9>00BVEI(9LJN"C$NP22(G9MZM#'-U$4&VR+:N[JOKB%7D;R38/74BC*
MI"/;1(_>E0GYC8O`2QE?10%!_69W_I*XVJZ%]-,%2N.<NOYWC"+RN36B_9NU
MZ3_VZ,[HCNH=S:!$/M54]$7_``X$!CR[#DROC18*O.2*N%:UFCR:2?FN"UV!
M]GM-HG!W>O147"5#N_(,J=2<A<=I93-33S2KWYT><##QOL3&FOTMB;Q%4<W*
MOV11^N%KQ/\`(W,FK"T8CP(9-1.20J..1/&A*S)%HE(DV+[R[O\`1K]=,L*L
MO[TG')CHQ*A^76@4]CYS7<VB_7`:N=U5;1L&C-HFQ/>JZZ:IUQ$J5PSR%*Y!
M9LP9=4M=\RIC7<$N\+RDQ)78HF@B.PP+3ZKJF0KS<>0W*SE46ED0!6+,G,5K
M;POH3^Z2T3@/*T`D@-;A4/>:$J]433+"N1X1Y+F4/%*C^88;[E6_'LW&+LI'
M?=<<KW'WC:=`DW)JRTNPMRZZ:+IB*Z"S\G7E7&F_,H4*>Q6)>1(S,C>+T(#$
M9([U;3:^PAH2CHJ%]%R"59^2T:D-L5\1)B37FH]5(0G2;>,HJS'C)&6W30&F
M]J>T5527Z:98E7/&>07ERS`EOTYUL63&<.4,DU%]F2#FQ&NTHHI`8HIH?3II
MTZY%=%@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@4/)>,E>RZM)#C154*1\J77NM(X,DA!4:0E54T1LRW
MIT7543";CF[#Q'%E6'(R8FI`J.1Q8[+]?%9%M6I4145F8V:+IW$5$U3;HNB:
MX'N5X[Y3,BPI4OE;A\FK9/R(%L,1D66P)HF'&5BHNTA=`U4U4M=VBIIIIE"3
MXSNEM6+6'RB1&GNQ0A7CY1V'5F`TX;@.`A)MCN"KI"*@FB#].FN*16<<X?9V
MMI>?N#CL6G9Y.5HS"=C*!R%C@R3!B^:]6E=;W?EZZ::Z8TQOC>(K.#"K@J^2
MO0K"G>F?MTSXS#@I"G.(Z[%>:/47?>B*A]%U3%(S?>'I5F%DS'Y'*BL7<:,Q
M=";++Y/O0T%&Y`D6WMD0BB&B)HOX9".FY?Q&1R"/5`W8N0GJR8W-0T;;>;=5
ML"#:ZR?L+\^X?\4D1?I@US--X:*MC]C][=D`E584[:G':14:L9'R"/VZ(I`7
M1.FBX(U3O"CCU=)KX?(9,*-90(<"W`&&7$?6`VC3+X[]>T:@*">G1?PRD=3R
MSA[]^%00V3D*14RAEB8MM/-NDC9-JCC+B=M?S;A73VEHJ9!\PN?'EU3O5M/'
M_<K&!`ANL19[=?`G@[\B23[C+S;AL]O;H'4O:?X:9:1W59X^D3F;:7R5_NR>
M35<6ON8+0@#;9,-F"DT8J2H2]XOJJ(OID&L_%MA(I`@V/*;&9/AO,/T]JHQV
MW89QM4;40`$;=4D-4<5Q%WIE(VR?&<QYZ%._F.<-TQ'D0YMDHL$LJ-*)#-HF
M5#M`@$**WL'V_CD$I[QVPYX\B\+2QD"S#9C,,V&C:O*D0Q-M3#;VS3]-$(53
M14]<"N/Q,I0[.&=Y(?C6\MZ981Y,>*\RXLAD&C'MJ"(FWMH0*GY5_#*1>67!
MH$WB]?0I(?8_:?BN5D\20I#+T+3LNZFA"9>WW(2:+JN0BNE>,V)48N[9/_N+
M]K%N9E@(-(3K\+9V`V**B+0HT*;4Z_CA5SRSBK?(HD)DY3T)^OFL6$65'V*8
MO,*NGM<$Q5"$E145,J:I1\6P/]&1V?(>;CW$F\5LT:T<=E@8.,GH/]GHZ7IU
M_'%(F<-X$/&5[;=Q86$%@.Q609C@&U%9UU[8;1`CTTVH3BDJ#T3!B!9>)Z^7
M:2I;5K.APYEA&N)%6RK7QRGQ3`T>U-LS3N=H=XH6B^OKD-:FO#U4$E'%M9YQ
MQ6RV0U)GMHW;HOR6U+M[R]RZB1%N3HFNB9:09\216'8+S%[:L28T5NOG/,NM
MMK.BLJJM-OH+:"B@A*(FV@EI]<4CH^3\69Y!6QX+LEZ&W&E1Y@''4-V^(X+K
M2+W!--N\$5>F"*FS\:0+"SFV3D^6V_.FU]@X+:M((NU::,(.H*NU=/<BKUQ2
M-\[@$2PY"Q<3ILB0D5\I4.&:M[&'386.?:<0.\+9"2JK>_;NZX(L>)<98XUQ
M^-21I3\N+#'MQSE*)&+2=`;U`03:`]$Z:_?(JJJ_%_$ZQZH=B1B$Z23,EP%4
MM=ISM>Z)?<1W(@)]-J?;"#_C>K>HKJF.7*2+>SCLI1H0;P=<=!TA:79[0W-I
MT77*1KL?&53,DV<CYLU@[.9%LC1EP!1J9#V(#[2*"Z$2-"A(NJ?@F*,L^,*A
MFPL)+,ZP;BV7?<>JQD?Z&,B4"@](!K3H9;E+37;N7=IKBD3*+@=936$&=&D2
M7':^J:I&1=,2%8S)H8$:(*:N:I^;!$.;XNI9=V[;E+G-.NV$:V6.V^@LI+BM
M]H30=JKH3:()"JZ?;3%(S!\6\9C-)&>1Z=`:&8W#@R30V8[=@I+)%M$057>A
MD**2JJ"NB+BD3:'@U=3N([WY%@Z$4:]AR<XCJM0Q7=V1T$=47IN(M2+1-5Z8
M(@EXJXPG%Z[CL59,&/4._(JYL5XFI;#R[M3!U-?5'"%45%14Z:8I%S5\9CUK
M\1QB7,,(D<X_9=?)P'5=-'"?>0M5-[</YU^BJF15S@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0KJVBU
M-5*L9.O9BMJX0BFI$J?E`43U(BT%$^^!\XX_YL8=\16/-KF*K-C2%(CVU6";
M#"6T[VP9T+51W;@]?35<&K&C_O8L*"NOBM8/R[!(TIVE^+HPU'>(3-H)&_N*
MX#1+[BZ*7TP.>G\A\JQ/(O'^&/WL,';N!+FO26X(DC+C&Y0;!"/WCT355ZX$
MYOEW.F/+-+PVPG1T8E4!6$]66!54F-:MFK9$O]FIIN1%3\,#DZOS/SIJLL*3
MDKL>OY+)B-V?%;9IH5CS(IF*$WVS]O>!%74=?][J'6S.7\N;\Q3N(A8BE4QQ
MXK9K_1VE=^0A=KJ2^HZ^[33\,(@<'Y_S._\`"]?RJ38`W<RK!IAUQMAI`1HI
MXQ2%`5%3\A:Z_?"L\E\E<IXSY9APYTMIS@\V6U5/[V@%V-+DQD>9)7DTU`B7
MZ_C@>^#^0N7WOE^?3RI38<<*K_=JJ$#("YV7'D995UU=3U,$[G3_`!DP-'D7
MG_*J;R>/'X]XE;4OT;UFTB1&Y+GRFC4`;%-I&:'IZ>OV7`@N>5>;P[WQN'(C
M2C:Y%$E/\A@?&0R$XJ:M[/:XZWW4)%(?I@=%XJYU<<BY;SEB99I+I**4RU5Z
ML@PHM.@;A$XNT#51VZ=<&)/C+RC,Y3R?DU'8QR@OPG6YE*V8H!NU4@$1E[U7
M555-W\"3`^;M>8N>I`N>Q=-S>3Q.3'3T?'BC,(DZ.VX`D"J`"2$@FJJ:%TTZ
MX'7^5?('-.(<JK+./*#^5(R0%Y'6DTV9@W-?=9)T'M-Z("MI]?7`S&\B<JL?
M-=/3Q9P!P^RC3'HT<&FU-Y(*DTKW>5%+8ZZ*[=O]5$^^!:6?E.7!\P57&7&M
MO&K%IZ`%@J)M*X;VN]D21=?:V2"O_*+\,#RWRGD/+?)]YQ2KL7*:FXLRPMA)
MCMM'*DRI*;T`2>%T0:`?70-57`J_*%[Y`XA44RIR$G"L>1QH`RPC,=W]OD@@
MJ)AVR%70,25"$>OVP,\KY-RFK\1\EY=4\@DR`!`?I'I<=@9#*-O_`!W6W`1H
M!(35-R;AW)]<#I'[#D;S'"VXUHXS*M8;ZRG"!H@<>6O5YLS';TV.^[0=/M@<
M@V_Y!=\KS>!AS":C3''PLF9JLPM_S2=1O<2=CJUK_4_W<#%SY+Y%QGR#SK]Q
MFN3*?C=#'L8E8(M"!27D`%U-`1S:KB_4NFN!TO&:GR!;\/K[]WE3S7(+-AF;
M\<6HZUK0O(CG8%KM*YM1M=N_?NUZ_A@:?*OE&?Q"[H?CM[Z5F:PG*I&H+V(T
MQ#98147W:[T5SV_0?QP5GG_).00?*7CVJK[%QBIO7)@649M&U!X6&>ZW[B$C
M'KZ[535,"=YBY#R:BJ*^?4QI<FK:EHO(DK$`IP0NV2[F1-%_YS;N7UT^WK@3
MO%O)Z_D?'W;.NNW+N"[)-(YR&Q:DQQ0!UC/B(A[P+5==.J+]<"G\K7U[6<N\
M?PZVP>AQ;FV6'9--;-'64!#05W"2IU3U'3`Y2Q\@\PXCRJSE\@L3E<`M9LNK
MB3=@(Y42VE5&NX8BBDVY]%+73_?"=6\JY)?<KXYP1FVD1&FN/L7=_;-JW\R4
M;R`@--N**B`[CW$0CK]$TP/IU!46U;)FI+M7K&`[VE@-24!76-HJCHDX`CO0
MET5%+K@76`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!S?,>,2^1+6PC>`:5J4,FUC+W1<D"T
MBDR`.-$"AM=VFO\`X*8'%1O!,9FUY?'68/\`)_+VA253(CBO-2`%-)(/F9>]
M3U)=4P.CXSQKR!4P*VFD7D-^KK!;9&6W%,9KS#*((-N;G":$E%$0C$>OV3`7
M/`9]AY.H^:A.:::IHK\3X*M$1.C(14,NYN3;IKT]JX&JQ\>V4GRE%YTU/:!(
ME:Y6!`)DE4A<525Q7$-.J$OIM],(B7'AZ#>\'I:"V?;.TH39>K[9IK;L<8-"
M_(1*NTQ3:0[OQP8FGXZDN>4W><'.!67JQ:@ZWM+KV5/N;^[O_-N_Y/I@5G%O
M$5A04T?BX7`/\2B3OGL1ECZ3"07_`)(,./=Q04$=1%54;U5.F%2N5^)8G+&N
M11+J0)P;Q^%(:%IK:ZP<)$%/>I$A;P':O1/5<(EU_CAR%Y-D<U:F@++U:W4C
M5BSM0&&B0@5'-_YM1_Q=-,*]R_'TE_RC#YVEB(?#@'6I7=G7<VX2F1*[O_-N
M]/;@.2>/7[CG_&^6A8)'7C@R`:A=G>CR2A07-SF\=OM3ITPBI:\263$KF4AB
M]0"YF\TY,'XW]BVVB@30+W454<:+8JK_`!PK87ANMA<[J>6\<?;HW*U@HDJ"
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MV/\`BI_AP:D6'C=;JLO:SD%HY.@W<<8J1V&6XH1A0R<(VA#=J9.%N4BU],*D
M\;X1/K7JYVUN#M_V>.46L%6&XZ`)"+:N'L4NXYVP0=>B>O3K@>6?'K+7DQ_G
MB3W5E/P!K"@;`[2,B2&BH7Y]V]-<"(]XIJY7,.0<AGR3F,\C@#66%6XV",_'
M`4$=I)[]W3UP-O'O']O1P8=/&Y-+.@@;!BPR:920C+:ZBP4I$W*"=!_*A:=-
MV!'N?$='>57((=RHSIE^9D5HY'9^1'!1$&VV2T71&1!-F$1'_#[SSO$I*\BF
M?.X<VXU6RB98,W$<#M*KZ$*H2]M$'II]_7*+%GQ[;M61VW\SS3MC>5XGE:81
ME05E&18*.(H"MB@[D]"W==<BH37C*;6V5=,I[.2Q(<N3MN0.MD##$M'&D;-M
MR.`Z*.T!$!3T74E55RHNN8\!C<FN>/6CTYZ*[QR6LZ(VT+:BXZJ(.CF]%73;
M]M,BO3G`:J90W=';$MC7WDB1(D-NB([%DKNVM[4_J+U$EZY409?BZN*726==
M-D5M]10QKHMJRC9D[%04%6I#;@DVX*[=WIJB^BX$]_AT^0$)7N0V/R(T]N>\
MZT;;0O"V*C\4FP%!1@M=5%.JKZKD5T^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&!#FV;451;0#?D'_9QVDW&OXKZ((_B73+
M!27<WE$=F)(9<9:?>F1V&Z\1[F]MQT4=WN+IU!G>7M3Z8@Z?,AE#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`:X')N\U=G\@&D
MXTP%B<1Y!O9Y*HQ8@)^9M#3^TD+]`'\O];3`ZS`8#`8%9)G29#Y0Z].H]'YJ
MHB@TO^**?UW/P]$^OVP),*!'AMEVT4G'%U>>-=SAEZ:D7_N3*(41&[*Q&Q35
M8T3>U#5?0C7VN.C^']0?Z?O@6Z)ID#`8#`T_-A]WL]]ONZZ=O>.[7[::ZX&[
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`IN46,V%%B!"4!?
MFS(\1''/0!=/]0D3ZD@(NW\<"X'1$Z+@1;.UKZN(4N>^,>./13+U55]!%$ZD
M2_1$ZX'%V4[D?+K5FKII#E-1L*AW<T4VS3%410C-:_V!.(NI+^<1^RKE@[.J
MJ*RI@MP*V,W$AM:]MEH4$4U755_%57JJKU7)1,P&J8#`K9CKTMXH,8U;$=%E
MR!]1%?\`FP7_`!R3Z_1,HFQH[$9D&611MH$T$4_]WKD'+\IY'$.:O'F9!(\H
MH=BL9%=?!DNHL@`:EW'O1.G0=5^V6)NM,OFL^G9;D/\`&943CK*M-'-5V.AL
M@9(V)E&0U/8*JFNBZHGTQ#-=FB].N115Z8%8MV,E"&J;^<:*HJZB[6!5.BZN
MZ*BZ?\G7`\C4S9*[K*89HO\`]'C:L-(GV547N%_27]&6B0W25#:"C<-D-I(X
MA(`[MXKJA*6FNNN*)N0,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@5/)J+]ZJRB"^L62VXU)ARQ1"5J0P:.-'M73<B$/5/JFJ94U`A#Y"(NU/
M*I9;1-%DQTD.&2Z?F1H]HC_!37"XKI%+$J)3!@\Y<\OG(K<.7.)#)H4_.\+:
M(C;336NJ[!37HFO7%'3T=/&J*\(;*J:ZJX^^?YW7C7<XZ:_4C+KDHG&8@*D2
MH(BFI$O1$1/JN!3&5E;-JY%D%7Q%1?CNB**ZXNBHAJAHNT->J)ZK^&41:NTY
M#-GM1>W'2-#!!LYP$IHY(1-%:9%$%$_QB55Z>F-P7-C+)AH`91#E/EVV`^FY
M4U4E_`4ZKB#,5AB!$T5SVBBF\\XJ(JDO4C)5R4<IR+E-O,(*CC@HU-L44(5@
M:(2"VB)W)0M_^+:1=$(OS%HB(N6%77%N*57'8'QXB*[*=_4G6+VA293RI[GG
MW/S$1?[GHG3)NB+R>"=Z]'HA)/A`\U*N-45=6FB1UIA/IJZX`[O^0B_?!JWL
MKB'7`"R"57GE48\<$W.NEZ[0!/5<GJ(C,*SL2[MJOQXR_P!G7-%KJ/\`\>:?
MF7_DC[?XY;!;,LM,MBTT"`V":``H@BB?9$3%'O`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8$"\NX%+6/V,XE&.RB:H"*9F1+M!L!3J1
MF2H(I]\"EX\VK4R1:6RH7()Z"AQ&M7?BQAZMQQT3II^8U^I?T91'N>4S';BN
MC5;[4>I!XW;:T<VD!-1TU*.RB^I&1"BFGI].N2"Z1B1:&IRA[=8FBLQ53W.Z
M=4-W[#]@_P`/VQZ"MN;299VW\MTY;4`=UY8"O6*T::BRW_\`'NIZ?X@^[[9,
M%_`@0JR"S"AM"Q$C@@--CZ"*?^[JN40&Y3+0R;R>ZC,01T8W]$!E%_-]]SA?
M\"9=%'>60268K\]@S"6X@TG'U50<ENZ;A.2/T`?S*B]!3J77IC,]C=6=771J
M-F1;6C@.6\[;\U\-5151-&X\<5U+8/H(IZKU7JN$BCO;WDUI9!0TZ_#G/(A2
MD%1(X<8T_MY)]4!PD_LFAZJO551$Q,]U11!KC/(ZSCO'!DV-S(C.R+$Y+[CC
M?;Z`,F8X9%M4G-=NU-Q::)TQ*779T]$$(BE27BFV;NO>FNHF[15U[;:)^1L?
MH*?TZY*+7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`K+WD=121B?L7T;%!(T!/<:B*:DJ"GT3[KTQ!QU%5W_,I<7DO(D>J:ME5.DX
MZV:B6U5]DJ:2:+W2'\H)T!/QRY,37:OTL-VK>KFMT5A\%;(HZ]LT0O70DZZK
M]\E,:%XIQQ9<&8M='636-JU7N*VBJP"Z=&_H/IZXJJ_D')I(V;/':0$?O90*
MXZXON:@QUZ?)?_BO1L/4E_!%Q@M:*CATT'XL;4E(B=D/GU<>>/J;KA?4B7_B
MRB-R*:RA1*TW>TLXC5X]=-L=@>X\JK]$TT'7\<8.>G7D:4$:[E-&]`1Q!XS4
M-HJ.SG]N@O$VJ>GJH:]!'WK@6G'Z*3#=D<@OG$D7LL$1S8JDS%9]1BQD5/RH
MOYB]3+JOT1(*,[*WO+EYBG($L65[3UB2=Z'6-JON%O707YAC^9$Z!]5Z:+<]
M!V-%0P*6'\>(A$3A*[)DNKO>?=+\SKIKU(E__LG3`GBRT+I.B`HX:(AFB)N5
M!]$5?5=-<@]X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8'+7_+=DF365)M+-B-=ZSGO]8D!K37<^J*FKBCJ0MZZ_5=$RBAXEQP;UT;
M>:CSU,I"]&*:FLFQ=1=1E/BNG;8'35EA$1/ZQ)Z8H^CHF0,#G.8<F?JQB5M6
MTDKD-N1,U<4OR"HIJY(>^S+(KN+[]!3JN7!(XGQB/00'&N\4RQEN+(L[)U$[
MLF07YC+_`!13T`$Z"/1,:+O(/EGDJ8W,N66X[B(,#;$D,HTKKDZ1((76ZUC0
M@_.C:$^O]4=->FN7!V'&^/S`>&YOE:=OW&NV@LHO8B,KU^/'1?I_C'ZDOX:)
MD$[DG&:KD4!N!9BX<0'FY"M-N&UO)I=1$U!151U]1^N,T38%?#KXC4.$PW&B
M,#M98:%``4^R"F*)&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.$\R2YT/
MB\21#DRHSG[K6M&L)PFWC:?E`TZTFU4UW@:I@UR\#F]W0V7->S'GV,.FCQIT
M*BM'%"?VEW?+?CF2.$<<4TVHJK[D5.F5EWD;E4^Q?W4D%JP@(4+69\A&Q5J4
M/==,-17=VFU`M-?=NTZ8'3Y&C`8#`8#`8#`8'+<[YC"H(K$4Y+<2PM$=;@OO
M:HT"MAN-Q51%U(47V@G4BZ(F7,%)QGB[MM&82='=B<:8)'(];)3238O]"6;8
MZZE[B346BZ_4OH*!]#1-$R#.`7TP.,H*F_+G5[;VL$&F25N-4S5>%Q5A`*+V
MFVD35M2=4C-57KT3Z8'9Y,%?R"?-KZ6;-@0SL9K#)G&@M:(;SB)[`15T1-5]
M5RX*+A_%)45T[F[[9W,G5Q(S75B&KB:N"TJ]2,R_M'5ZEZ=$R[ZCK<@8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`HN7\2B<HKF8$N5(BM,26)@'%(`
M-78QHXUJI@XFU#%%TTP*B5QB31/SN1UT:1RCDTIIN$@3I+3*)%[FY6P78+;8
M(I*9)MU+`D<:X'&I^*5='&?=@)"?&8[\(]B$YW%>-E55%W,JI;-/\5$P.LP&
M`P.4E>1ZJ-*>C'5W1FR9-D;55,<;)1734#%M1(5^BI@:O[SJKI_T/>KK_P#R
MF;_F\!_>;6KZ4M\O_LF8G^^&!E/)=>OI1WW_`&5*_P`G`?WE0_I07R_^RY'_
M``I@/[RHOTX]?K_[,?\`^'`TO\YK)+C+K_%;MYR.6^.;E69$V>FFX%+\JZ?5
M,#=_>.WK_P#HSR#^/[>?^5@%\CC].,\@7_V>7_"6!C^\=/\`NOR#_4%_R\#R
M7DE4].*<B+^$%/\`A<3`Q_>2[].(\B7_`.Y-I_OO8'M/(DA?3B7(/Z8K*?[[
M^!G^\&4J:IQ&^_IC,)_Y_`S_`#],^G$KW7_Y".G_`)_`S_/L]4Z<1O/_`"49
M/_6,!_/=FOIQ"[_^!%3_`-8P,_SS;::IP^Y_AMB)_P"L8&/YYN%].'7/^"&G
M_K&`_G:\_P"YMQ_A@_[3@/YVOOIPRW_^%!_VG`+S7D'TX7;+_P"_@)_ZS@8_
MG;D/_<NV_P#*0/\`:<!_.G)-.G"K;7[=VO3_`-:P,_SER9?3A5I_2]7I_P"L
MY1C^<>5?]R;/_6*__:<@PG+^7+_^I-@G\95?_M&!Z3EG,%__`%*G)_&77_Y_
M`?S7S%?_`-2YB?\`WR!_GL#/\T<R7TX;*_IFP?\`.X#^9^:_]S9'^O0O\O`?
MS/S;_N:__3/A_P"7@/YEYS].'._TV$-/^'`?S)SO3_\`0X_X?N,7`#R/G:JB
M%P\A151%7]QB]$^J^F!U8+JFN!G`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`:)@,!@,!@,#Y)RGF/(9'!^;
M<IK+!R"-3(=@4XMBV2)\%X6GGC0Q+<KKF].OH*)IE1;6]CR7B=YQMQ;1ZXI+
MV6%9+BRQ9[[+[S1&R\PZT#7M4F]IB2+ZZI@2H7DJ!=1*IF+'E1'>15T^7">7
M8A,K"5&W!+12T-"-%'35,@K."^3?_P`NU,6Y;D.3UXTU>K8ND&V6C8HD@0T5
M%[H$J;DT_K)A7>O7+$3CQW5B!0F6(JRY;3BIO:$6^X8DJ+IN'TZ?7`X3QASN
MYLEY%7WKS,FV@$-G$:C.`0K`FM]UAE"3IN9,2:)5^J8'NR\P"/'`LZZJ><D2
M^/2.10FGW``$&-L0VG5%2T).ZA=/7":J3\BWM-R"WM;"'+F5[=%564N`T\UV
MHB.N/C(=;0E3740$MHZJNF!U-GY,API,QP(+TFEJY;,"VM@,$&.\^@*B]I?>
M8!W@[BIZ:^BZ+A<4MSY(=G\>NY#M/9P*VKF)!=L(LEAITGV9X1B%I44BV]=R
MKIU'5/7+B:O+'R$]7\J8H952:=X9$DY0/MFC$"*.I3'P1-0;,O:":ZJN05L7
MS%">8>D'4RQ9.-&DUCHHJMR2FO(PQ'4R$`;>(S!=NJ^U==>F#$KQY9W<OE7-
M6;5'&2C38B,0C?\`D-LBY";-49/0?81*I::)A5?Q3]VYM1V?(';>9`DN39L>
MI9BNJVU#;AO$PUO:TVNF1-;W.YKZZ=$P**OY9R/G"<)C/-FQ$O*J?*L/B2W(
M1K*BN-L=P#;$C014E,$UT7=^&7$UIXQ/FOL\>Y%=%8G,F7[]5^C9N)'+8^^V
MTLB/M$#%M&-NB:;O5<:8[(/)KR5#O(I%,Z'&%A/3HMF#P.&2-F@-MN,Z"0&_
MKJWM4OQT7(NH3OEBU:$6UXU(.:[8QJV./<)F.ZLMLS`VWGV6E+83:BXFSIZZ
MKA,6E%=6D;G145@)-!:UB7#,4W.]\:0#J,RXX.]-[>I@0_9==.G3"NVP&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/G#_CN9*I>5\.-XXM->27I
M\2Q:$'%;&8XCDB.H&O0A=W$*^FTONF$7,?@3K]Q6VU_:NV[U,JG5QNTW'C-.
MD';5]6PW$;NU51%(M!U71,*J:+Q$53-KGAOI3\:H9L(U9#-IA`;9L50B$E$4
M,R!430E7KI@0V^`HX_Q7BCL&4_`X?VGPY&ZK33<AL6R#XH@V6\]Z[.Z*B@Z#
MA,=MRCCKE_6MUQREC1_D,O2A$`<1YMEQ'%9-#Z;#440OPPJOF<"AN\O@<EB2
M"@NQ(KT&1#8;;1J4P^2&HO+IN]I"BBJ>G].!0U_A:%'C-1)%U.EPX]5-HHT<
MQ8`6X4W;[=0;0E-O8FA*O7ZX$A[Q(U)@6<29=S)!6M1'I)$A08`T9C$9"X.T
M$'>O=)%Z:8$MWQ?7N29W^GR!K+9R/)MZQ$;[4B1&0$1S=MWM]Q&0[@BNA:?3
M`]/^-(;W%[7CYV,E6+>P<LWY*(TCH..R1E$`>W;M[@?5-=,#+'CA&KJRM/WB
M6X=Q(;=LFS!@NXPT.T(:'LW#'1-?:G7JO7K@0V/$%<%%(HI%U:3*U1;"L:>>
M;U@(PX+K*QU%L54FS`=I.;ET33TP+SBW#0H9UK8'92[*;<DPY,>EJU^>.TC(
MJ`M`V(ZBG5,"(YX\C`=D%;9S*J#<.D_8P8I-(V3KB:.FT1@9LJ[_`%]BIUZI
MHO7`D,\#JHUO2V,$W(3=!$=@0(#.SXZ,O("$A(0D:K^D.GN^F!"A>,*N)5UM
M<$^8XS5VI7<<S)I3*0;AND!JC:(K>]XNB)K^.!H@^(N/1(D^M*7/E4DQM]AF
MF?D*L6*W*7<XD<1$2'JOM4B79_5TP-L?QA!;8@MR+BUGNU\UB?'DRY`.N;HJ
M$+32JK>WMHAKKHFXOJ2X%C`X]*<YI,Y-/00((J5E6R*[M(_<[SKI_8G7-.B>
M@BGU7`Z/`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`:)@A@,!HF
MNNG5<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!JF`P&`U373`8#5,!@,!@,!@,!JF`147`8#`8#5,`BHJ:I@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@80?<JZKU^GT3`S@<EY.M.35/%SL^.NM)
M91WXXM17P$FI*OO@RC)DJHK>Y7/SHO3)[IJHK_(QV]E0RHCIQ(#C=D'(*QYI
M%D1Y<!L")ASIO$@4B]/S)HJ>N7523\Q\89ARY4N-/BK#&$Z[&=C_`*_9LG.U
M&=1L2)="+HJ+[D^J9*,L>7N/NSP@N0K&,[^X#4RC?C;`C2G416!>+<J(CR&.
MQ1U]>NF"ML+ROQN=:G6Q4?>=-F4_`)L0-):05VO@P@DI[T7\J&([OIE2]765
MLSYT"-,[+L?Y+0/)'?'MO-[Q0MC@?U2'714^^%2<#Y.YS2[_`)\G4-C<%0VB
M3VTH($EEM(%A6ZAO[3Y`JG(--_1#147H@X3%^?EWC(WI5`]UP]\MAAYM6C%V
M1!%3?90$/NBN@$@D8H)*FB+A:UU_EN#8P:^3#IK(G+="<J8SK;3+DEAMA)#C
MS>]Q!V`)(/N5%4O3)U&J/Y(HYLZHN?D6$*KE4\ZT%IYMH8QQHQM=QUY$4W4<
M!"38B=-"ZY4J[X]SAFVM%J9%?*J[`HH6$9B6C>KT0R0.X"M&XB*)*B&!:$.J
M=,#G>4ER>!S#C$`.0RVXO()\QN2TTW&$6F6HIO,MM*31DFU034E5=<$U/9YR
M_4V3_&9,.RNY]1';D6-HPPUM5EX'C;-0`A4C7L[-H#U+Z:8$=?,=:U$L7Y59
M*9*HDP8]HT)QW/CMV*HC3YF#BCM!5T<37</VP5-NO)U?62'HWQC>D!)=BQA5
MUED'RC,B]((#<)!1&^X(>[JI]$P5"B>8:^;*;;@T]C)C+7,VTB4C;8BS%>1W
MJ8$:.;P..0*(BJJOITP5)B^3EETD>VB5#KT>6Z+<9T9$=8RMDSWN\<D25MM!
MT[:B77?[<*Z/BG(X?)..P+V&)MQK!D7FFW-$,47HJ+HJIT5/I@?,>><CY#%Y
MGR>#7VMBU(BTD2;15\)GY`E/<<>;02;1L]PN*V"$AJB>J],N)K<SS_D/'^07
MLN\B2949B%0O6<=IP.S7G+%QN230F6I)W>JB/KIK@=-)\FA&Y,-$_6.MF^Y+
M9AF3K2..E#860IJSKN!IU!)&S)>OVTR&(%;Y<L+%BD=8XO,'^8Q,J877XP]U
M&XOR5(]"7MCT4=53\=,*F<4\IC?3Z=@ZA^!'O(TEZ!)=<:/5Z":!)9(`55':
MJ^T_0M,"-;MSK#RV-,5I/BUIT*S?CQ)!,BD@9:-(?M_Y"^GIE1.\=7ER_.Y)
MQZWE?/D<<GC&9LB$0-^.^P$AGNH""'=`3VDJ(FOKIUR*[;`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8%'S&DFW=(=?#>;8>)^,\CKPD8HD>0#ZIH*HNJ]O3`I
M[+QO&>YBG*JZ6Y6SG8DF-.!G\CKKS2-LR=NNWNLHFF[3JG3Z81R(>%.1K&=:
M=N(2.2(==%D.-Q'$(W*V:DL9!DKI$3CO7>J_5>G3$3JOK'QG:2Y5J\-BR`6-
M]`O`!6278,$6D5E5WIJKG83W?3*1MXKX]Y!QU^1'CW3+E.RDA:9@H8)(:)]2
M(1D/H6KS;*FNU$057ZKD([:L:G-5\9J>\,F<#0#*D`';%QU!1#,0U+:A+U1-
M>F&E?*YMPV))<BRKZNCR6B4'6'9;`&!)ZH0D:*B_QP/GW(%X[>H_76'.:9^D
M?L`L&Q,V%F1D:=%T6H[Z/[13<'Y]FY$54RLO->UQVOGV81?(%8E!-<E2H]81
M15<9?F;E<%9".;C91QQ30--?INTP.;Y;;<9JJ+AM(')XCK=''<CK<1XXS04Q
M9&.`&S%?&0UO;(O<);?HOTR"V@M\3O(%8=]R"J@Q6*JPI2K(Q,QM\.:H"#B#
MWG>P:-L`NS4M%]<HON.V/%*^U8M;GFE=:3X4']LA.B;+&C"F)F;B(XYN=<5L
M-RIH/3HG7(K;R2ZX3<<AX[;ARZOC)Q^0[)1C>VYWE>9)@A4MX[40#7T3UP(U
MA/X/*M.2S?YTBQQY%7,URBPXV+D?L"Z(O-N(6JE_I!?3*BII8?CN$%VS9<QK
M[")?5T>MF1`;8CM"D=LVA-M`4M/:YZ??K_"+F/4D/'[5/Q]BJYXU7W/'A,8]
MRI,R#?\`D(B2?DMN:BYWE3<OU1<IN+"'9<(BV\^W'F[9RI=4U5D\2M$X!LFZ
MX,G7313WOJNW;M]$PBE8K/'[$EN8US2+'FK8-63@QH[017'&HY1U7XGN;1PQ
M+>I_X^BZ=,*M.(7?'>+E75S/,VIG'H$-U@V'@;0B>)]7&C16P0D4`)1+Z+T^
MN03XO(_'['-YO*TY,!N3H+,`X2-KVQ".9N`:$@[]VKA955G(7?'-T[R-QSE"
ML_S''A1WQ!DB[0P#(P5O4%U4MZ[MV$0TB<`_>?W,.9R44;&3:ML)'0D1R8P4
M=T"(F5,QVG[-5]J=$P+*L>\?06>)MM<D><7B(.MQ26.?ZXO,JQ^J@M(G0%Z;
M=.N!'K6N`5S=&D;DTM#H6[!J*ZD4U(OW-5(S/1C3<V2ZAI]NNN/P$AV;Q<KR
M)>,\PG-V<>M&I-U(7<[K:&CA.F)1E_4(TUU3I^&7\!*J[+@%-%;9K;J<PZY/
M_<K.8L>0[(G.DBH8R3)A?:2:)H*#HB(B:)F5=*GDSAOI\UW_`%27_FL`ODSA
MJ+I\MY5_"',7_>9P']Y?#_\`ZT__`*E-7_S.7MT>D\D<27T?DK_"#._S.)J=
MV/2>1.+*NB.RE7_[!._S&3J=V,_WA<9]-\M5_"OG+_YC"L?WA\;TZ?.7^%=.
M_P`SE[1A?(?'?\2>O\*V?_F<=H?WA\?_`/%V*_\`LV?_`)G':SW,_P!X-"JZ
M(S9+_P"S9W^9QVG<?W@TGTC6:_PK)W^9R-,+Y`I]=/AVJZ^FE7._S6`7G]4B
M:I`ME_A5S?\`-8&/[P:S_JVX7_V7-_S>!C^\&N^E9<]?3_HN9_F\#IP+<*%U
M35-=%31>OW3`S@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,D#*&!%.IJW#)QR&P;A+J1DV"JJ_BJI@8_
M9ZG_`.I,?^2#_BP1E*FK3TAL)_\`-A_Q8(]#6UXKJ,9H5^Z-BG_!@A^W5_\`
M]6:_\F/_`!8(RD"$GI';3_W@_P#%@C/PXGT9;_\`@C_Q8(])%C)Z-!_\%/\`
MBP1E&&4]&Q_P)@.RU_B#_@3`SVV_\5/\"82,[!3T1,$9TPI@,!I@-/QP&F`T
MP&0-,H:8#3)`RAD@90TP&F`TP&`P&F`TP&F`TP&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&J8#`8#`8#`8#`8#7`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`XEOR&,7D_)8%X<2NIZ'X*#8&X2*96"*K8FA)M'14T]>N$J
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M=G7.6L><TRX3'8;)`5%+;JA:ZZHJ=/1>JX5/L^:U$#ADCERJ9U3$,IPZ@3;A
M@@[A'8:"0D71-"3`K(+ODER+7V3KE>JRC8.;4"RXBL1W53?VY*N>]UL2U74$
M0M.FF$JOX#Y,BW51!C6<G3D$AB6\2A&=!AQ(CYM.(T2HH&38H*D`DJX*DU_D
MSCT+C5986MK\T9$49;]BS%<:;1@CV?)=:]RL-[NGN_'+"M$?E=W><_L*:K?*
M'"HRB%([D,G6I3;[:N.?KJH]M5%4[2CZ]5ZX@K[7G-K&Y;R2HD<BKJ>/5A#.
MM23&5PW%F-JJ(?ZHJ2(XB)[1^N(NNI<YY40)CE19$Y^]Q&(SK\=EAU>]\DT:
M0HR::NCW>B[==O\`6R#+GD7BS=T-2Y)4'B<>8"00JD=7X[:NO,H[^7>`"JJG
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M(VL9)Q(,=)#3BBZ*D2]405V_73+"M]=Y'K;%9?PJRS?;A25AO.C$)`5X9"QG
M$`E5-W;)-QJGH/7(KK,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#Y+RG@O+[&SYJ[&@Q
MG(]Z5.M>KDA!U2M<0G>X.PMNY$]OKEB-EMP;F#MW9VL.+&/7D==<PF#D=ONL
M18J1GD,D`NV>ON3HNN!"@>-.411M(#U75RFQ"S.IO"D/+*(K$7-&U9,5!HD5
M[0W$7J*?EUP1T`\3Y"`<!5N+'$N.M&-H`O;40E@+%1&M`]_O7\.F$U4<?\>\
MKKXO%V9$>(14U#8UDO8^JHLB4K?:V?IIJ"]KW$OIKZ+AK'6\!J>2TE'0TEA'
MB_&KJEF-*DMND;GRV=`V`*@**TH)NW:ZZ_3((4WA#UCY-?O;.OA3*,JIJ"R+
M^CKJ/M2"?W]HP4=/?I^;7IE2-5GP*SM+;FO=-J/7<DJXU?#D-DI/-FRV\!*;
M>U$VZO?0OI@BE:\><DE4KC5O14?SC=C"XM:_)BO$$5#VR6YB!W&G0,D5L-%0
M>O7KA2R\7<OMH,:)9VC3[_\`+TNHE61J1.K)??;>:-1VBC@"C*":KHI>NF$C
MQ:^..=WTBUL+,JJ+82HM6D-ELGGXZRJJ2X^B/"0-ZLN]S143JG]&06]7PKD;
M-OQZU?BU,)R#)G2;&)7HX#>LJ*D<-A*&KIZIJ1&B=.B>F54/B?C[EW'7N/2D
M>@.E5UT^!8#J\NOR)/RFC9T'4NHH)(6GX9!U!4\WEO`':GE3`19=O#<CV+<5
M2V@KFHH3?<]R?0D0O3T7`T\=A>1XH1:^UD5KL6&@@=FQWDD2`;3045@Q[;1%
MI[E0R_!,)%)0>.N0UW\J=Z3$<7CZ6J2=BN_J_N*DK>S4>FW7W:_T9>A%3`\0
M\GK8].D>13RW6:T*FU;L(ARFMC+KCC3\7714-$=5"`O:N+A':\;XO:5G+^0V
M[SK!P;<(01FFT(70^&RK2[TT0/=KK[?3!BN=XKS"/ROD5S"_:GXUVW%;:8F=
M]5;^(!`)&@BHEN4]=.F%:;O@_+K.;`N$L8C=_1JPM-,[9H"H8[;$9()ZA('V
M@(K[>B^N$B-$\76C=I:,/2:\^.V;LN3JD36T:<G"?=:"4JZ=M#<(A+;NT]N0
M>G.!<]F\/>H;2\A//1$B#3O-1G`%2@O`\#LM%-5(C1I!)&]$3JN!K3QMRA9;
MUB5G"_<'.01[\-&'>R*-Q/B.LJF_<OM55$M?XY>B=4R9XTFS./\`(ZURP!B9
M:6QW-1/9!4.&_N;-DM"7J0$WU^Z+IBK&;KQS:%:5UA038D=6((U<YBPBI+;<
M8`U<%UM-P[7A(B7K[5UZIBD7O+>(!?5$2*$I8L^MD,3:R>@"7:E1OR&3?M$A
M)%42'IT7(1%:XM<S;^#>WTF,[)J&WAJHD1LQ8!Z0"`X^XKA$9%L]HIZ(BKZK
MEJZJ:CQI:0*;AU<5DRX7%IKDQQQ&21'Q,'@0$3?[%09"]>OIBH\.^-+YF:=M
M57342Y"TG6$5TXRNL?'L1;%V.\WW!4M.R)(:$G5,@DKX^OFN1C;Q;\-LUJ,%
MZ$B&VZ;SL5%%'HYZHC!&*[530D3Z=<M(WQ>-\IH>,S8E-.9<LY%H].9=-A5;
M%J5*[SC1B3GT$B3>B_T8*[8=-$TR*8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%?<S;6,RS^V01GR'71
M;(''NP#;:HJDX1[7%T'331!55UP.0IO(E];\?<NVZ:+%KT&<`R9$]!;;?A.&
MTG?56AV-N&VOO373ZIEB5[O_`"G5U]->G")B=>\?B,2["N%WV)WD$M!<054D
M02UUT^WWQ"NI_F*E;GL5CTUANSDBALPR<%'"U'=[17UZ9"I5=9U]E&25`D-R
MHRD0(\R2&"DV2@8ZITU$A5%PJ3@,"F+F/&$M7*E;./\`N36_N1>XF].V'<-/
MMN$/<H^J)UPE:ZGG'$;A]QBKN(DQUIA);@LNB6C"KIW-4Z;=?5?IA:J>,>08
MW(.9VU/7N1Y57!A19;$U@C4R.0;@$!HJ(.B=I%%4]47`#RR_N;JU@<7BQ"C4
MCR1)L^>XZ(.2]B.$RR#(DNC:$.\R7U71$73"161?*9U_(%KN8MQ*`/VUB:N]
MXB(7W9+L<F]RHB$'Z:$A:>B]<I72?S7%8O;:-+GP@A5L:,\;0D?RFE?4TW/)
M^38>U.WMZJNN15/R?R?41*^K=J9;+SEO8?MK3YMNN`PX(DKJNM"@N;@VZ;%V
MKU^V!CDG*^5T-9QOO-5IV-O/;KIQ[GAC-D\)D+K>NA:?I]1+[^N4K=%Y9:I(
MK!GSZ<&YTU]EDXQNNI+CLL*9)'_Q7@<$MZ$JIM3ID2IU=Y,X)9=Q85S'>!F*
M=@XXBD(?%;71QU#)$%1!?S:+T^N%97R3PD8Q27+0&F1D,Q"5T'&R1Z2&]@%`
MQ0OU1Z@NFBX&QKR%Q%ZJ"T9GH[$<=<CAL;=5U7F=5=;1G9W=P(*J2;>B8$%>
M?47[@$P;J%^Q+4E:D.QQ75:1U`22+OY.TGY=NF[=@1N1^0VQK(LN@=!QP+F!
M5V3,EIT'&QEN@!BK9]LQ/8Z)"JII@67,.4RJR934M8TV]=7TAQB'W]>RTVPV
MKK[[B#H1(`)T%%3553JF!6.<ULZ.^D4G(A:DFM<_:ULR$TX'>"*J(^R;*J\2
M&&X5115=47Z:8T<S"\C<LFKQYL9;;/\`-K)2(CB5DDEADVQW";5-=KP$1#[^
MF@ZK]LN1-=12>0($;CK4R[M&K*8KLP#<KH<D$5(1J+^V.O==06--#)>G^%,F
MF+.5Y$XE&*+W)OZ4M(RMR!!PF02;HD;NN(.UKO*OMWJF3%;N/\XXYR";)AU3
M[C[T-7!DJK#S8";3JLN!W'`$%(3'111=<"_P&4,!@,@90P&`R!E#(&4,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,#!+M%5T5=$UT3U7`^847%>1L^&+KCDJM4+>2%L$>&;C1(?S7WG&5
MWH2@FJ.IKJO3&]45%EPSF1UO,(+-3W%O::M:AN]]D425%CHPXP>J^NO7=^71
M,UN=$36^%WR\V?<G4B6%9,L8US$M3GFV,-QE@&R;.*)>]QI07MJ/M77KD@^D
M<?64M>JR:T*EWNO?Z&V8.#M[A;7-S:".KJ>]4_'KD:66`UPE?(9W#N>N\V8M
M/VQAV#"NY$U@FI0,-%#D1#80OCH'N?W'JX;BJ2_U5TRBN9\5<P=X_35*L,PG
MH_%Y]+*DHZ)"$J2XT;::!U-LNTNY4^^#77\+J.7KS2=?7E1'J6)-3#@`TQ)&
M0J.Q772+H("B`J.^W\,BO-=2<OXG?WBTU:S<TE[-.S`5DC%>BRGA$7@)#`A-
MHR!"0A75.O1<"OY3PKF5M-Y%)6-%<?M>,?L[)`[L#YA.NFH^X5)&T1U/=]=/
M1,J1&Y!XZY=92[.3'9C`9P:180//&@.RJEYQYQEU6T0Q;/N[4-/JFNF%2FN&
M<G5BAD-4L"LD-7PW%K#CRC<VMHP3)$3Y@BOO%NU7HB:=,@Z#R'QNUO2XZ,&*
MQ)9K;>/8S@DGL%661-%$443W$N_I].F$C7R#AKQV7$W**)'C0**P>FR(XZ,"
M@O1WFU[8B*IJKCVY?3!'+0?''-XE-0QV%@LV%50VE:3Q&KK8RYA`K!("MZ&'
MZ?OW)]?1<O0:8OC3FR63DUQF$`R+"BL71*8^^YK5ZI(0S-I-Q%ZCIHGTZ8Z*
ML"X+SF#:N7U05>=@Q=6,Z/"E.NBP]"L6FFU0W`!2;>`F4)-!5/IDZ#=>\*YO
M+FG/A2:Z-8%QY^L!X$(6PF.R1?38VH'HV@CM0E]VO73'05P>-N6]NR32N92=
M<U%PVVDF0ZHI![7R!<<<#<9EV/:7U5>NF.@[3F7&I-I-IKJJD,LW=!(-^(DA
M5[+K3[:M/L.*.I"A@O0D1=%1.BXJ*U[B]U:WDCD5L4-B:Q6R*VE@-.DXTW\K
M177GGE`%52VBF@AT3[JN%J/4\1OH9<"[TB`J<6C/1K)1=<U<5R.D<58U#T]N
MY=VGVQT160."\RIWHUG46-4MHU)M4?8E$\49R':2_E#[@1#%UHT3Z:%Z:XW<
M$A_@5O\`S6Y:#)I+")9C"*U.?'WR&9$,$;5R&.I`@F(IM$E]J]>N%=)P2K<H
M*R;$GS(KCDBRG3FU9<U1&YD@GQ$MVWW#OT7$1TG[A!_^L-?_``Q_X\*Q^Y5_
MUDM)_P#.!_QXB,+:U:?_`$QC_P`H'_'A6%N*I/6:PG\70_X\#S^^4WUGQD_^
M>;_X\1*PM]2)ZV$9/_GF_P#CPKS_`##0?]91?_+M_P"5@8_F7CO_`%K#_P!8
M:_RL0>5Y/QM%T6VAI_\`>&O\K$*\KROBZ:ZW$'IZ_P"DL_Y6(,+R_B:?_P`;
M@?ZTS_E8@PO,.)IZW4#_`%IG_*Q`_G'B/_7=?_K3/^5B#'\Y<1_Z\K_]:9_R
ML%6[9@X"&!(0$B*)(NJ*B]45%P,X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`:)@-$^V`P&!SD_@/'I\UZ
M9)6:KSY;S1N?,:#7T]K;;H@/]"82-']V7$_J$U?_`&C/_P`_EI&/[K^':Z]B
M4O\`&PG?Y[(1A?%O"E]8LA?XSYW^>RU6/[JN#_\`U)__`%Z=_GL4%\4\&7U@
MO+I]YLW_`#V*">*>")_]`=_IF3%_\]BI&/[J.!=-:TET]-9,I?\`SN*K*>*.
M`HNJ52=/N_(7_?<Q1G^ZK@/_`%0"_P`77O\`+Q1G^ZS@/_4[2_Q-U?\`_/)=
M&1\6\`3_`/@K'^%Q?]\L71E/%OC]/_X%%_I$E_X<70_NN\>KZT$-4_%O7_AQ
M=#^Z[QYKK_+\+7TZM(OKBZ/7]V'CW_N]`7^+`?\`%E[M!/&'CQ%U_ERN_P!7
M;_XL74C/]V/CO_NS6=/_`-U9_P`G)=(?W8^.]=?Y9J_]49_R<72,_P!VGCW7
M7^6JS7_[(S_DXND>D\<<`1=4XW6:_P#V1G_)RW1Z_N[X%_W<K/\`5&?\G%U7
MI/'_``9/3CU;_JC/^3BZD93@7"$]./UJ?_=&/\G%U7M.#\+3TH:[_5&/\G%T
M93A7#T]**N3_`.Z,?Y.+J1Z_DWB'_45?_JK/^1BZK/\`)W$D31*2OT^WQ6?\
MG%T9_E#B?I^RP-/_`+*S_DXNC/\`*?%OI30>GI_HS/\`DXNI,>DXMQE/_P"$
M0O\`5VO\G)=5G^6.-?\`5,+_`%=K_)Q0_EGCG_54/_5VO\G%&4XYQY/2KB?^
M0:_R<4CTG'Z%$T2MBHG_`,@W_DXJ1.$1$4$41!1-$1.B(B85G`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8%;R/D$#CU),NK#N?!@MJ])5H%<,6Q_,2`/5=/5=,"MK^?T4NRB5
MCH2H$VP!7*]J:P;"2!$=Y=HU381(/51UW:?3&]"KZ3+C18[DF2X+,=D5-UTU
M01$4ZJJJOHF!L%P21%'JBIJB_147`](NN`P&!R=EY'JH4^PC##F3&:AQIFUF
M1FP-N.X^@D`DBF+A:":$2B*H*+URQ*ZKN#NV:^[373ZZ??3(K7(F1HS+K\AP
M6F605QYPU1!$!154B5?1$TR49C2X\J,U)CFCL=X!<:<'J)`2:B2?Q1<HJ.,<
MOJ>2%9K6J9-5<PX#SACM$W6Q$B)OK[@]_1?K@>N3<D.E8:5BLF6\M\B1J%!`
M"<5`3<9*3A-@(I^)=5Z)@4/][%"_5U\ZNC3)QV$>3,^&V`@^S'A%LE&\+A#H
MK9^S:BJJET37+$JVD\WJ6GN.BR+TJ/R<]E=,9%%935@I`JXI*A)N`%TZ9%K7
M:<U_;K^'6OU,WX,R0W""X06_CI)=%2`-N_O**Z:;]FU%PE=-A3`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`X[S")GXOY.TTV;SSM<^TRTT!
M.&9F&T1$112555?I@<Q=/ERI.&55)&?=<JI\*SL;$F'&FHK4-I5-M#<$-77M
M>V@#KT5=<>Z/G,Z++M:FY8CUU@C%EQV:3L!YF8XY\V+.!T$D/.>UZ2C>[J(H
MFGM'5,,UU;K+DSF;#1!;PVT=K97$W(D)SM_%;:!'62?<3:P/<4^^+NFHKAKJ
M^L\6&H%BQ2L8D,!^X2EDI)1T5*0IZNFWWNJMD7Y%'VZ>F%76`P/C7.J]YKD-
MM=\79M*GFK)M--MLQW7JZZ!`#8,@=I,:)N4%<4A(--=<M2/+%-9O^2GOWB);
MI9MVJ2ZZ;$9:^"=>32!VG)BBI(T"*0FRJ]2ZHG77(G5R''.)MW'$ZU:*ME.S
MBJ;N+?.O`]V9+9@Z$-C<\O;=+Y"`36S7;HOIEC3ZY55,^=XL@U=&PE'*<B,,
M&S+CFSL1$$9`DV"@8J:(2;O7KKD%)Q.5?<-#EUCR.%_T>=LTL8*R,YJH&PPS
MW@$S7]`-$3IU31<%=?SCD%A3U@_MU?,FS9A*RV["C%+^/TZO.`*CJ@I^5/JO
M3"."AU\JHE0+NKH;-:Y:.;2MP9#6DQ)*2$D-/.MHI**2S(]27T7J6F4B>SQ6
MXIJ;Q=4G'=ENT<EI+-UD5,&4&"ZT1&2?U4<<0=<@M>5LSKGD-6-2Q91;2CL8
M[GRC$VZ]R*:I\I555[3R*RI`/3<A>FF"._UPIJF`U3`:I@-<!K@-<!@-<!K@
M-<!@-<!@,!K@-<!@,!@,!@-<!K@-<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@-,`J)@8T3`**+T7`S@,#
MGK#CW(Y,YU^/R>5!CFJ*W$:CPS$$1--$)QHS7[]5P(W\I\IUU7F,_P#A\>#_
M`)C`S_*7(U31>7V/V71F"G_F,"!0^-)E#5,U59RFT:@L;U9;(89J/<-3)$(F
M%7\Q+EHL/Y0O/KRZT_H"%_L^0>'N$VCPH+W*K0Q14)$((*HA"NJ+UC>J+E1E
M>%7"_P#ZWW"?ZE_LV13^2;77KRZY_ANA)_ZM@>DX58?UN5W2_P#SD1/]Z-@/
MY(F?]Z;K_P`K&_V?`?R1*TZ\GNE_^?8_S&`+@SZ__K-=^FFB2&D_\S@87@KB
MKJO)+O\`HE`G^\U@9_D1>NO(KM=?I\Q$_P!X$P'\ACKK^_W:_P#WXD_WAP,+
MP)M4T6^N_P#7W/\`@3`?R`Q];V\73_\`F+R?[VF!C^[Z+_UW>+_[3D_\!8!/
M'L/_`*ZO/^U)7^7@$\>0OK=7B_\`M27_`)>!Z_N^@_6WNU_]J2_\O`)X^KD7
M7]TN5_C:3/\`.8&4X!6?6QMU_C9S%_\`.8&?[OZGZS[5?XV<S_.8&4X!3:*G
MR[-=?O93/\[@$\?T?_C[%?XV,W_.Y:']WU!U_4GKKZ_](S?\[D&$\><=1--T
M[^FPF_Y[`S_=WQI5U5)NO_\`4)O^>P']WG%]-%;EK^*SYO\`GL#']W'$]/["
M2NOKK.G?Y[`+XWXB7K&D*GV6;-T__P!V!Y7QEPQ?6(^O_P!\F?Y[`?W9\+UU
M^$ZJ_C+EK_YW`?W9\+TT^"YU_P#WJ7_G<#I(\=F,PW'9':TT*`V.JKH(IHB:
MKJN!LP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`UP&`
MP&J:Z?7`:ZX#<B?7`:I@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,#Y;S>%R"PYM9UM$\\%B[0LNP226;#4>3\PP20H"
MJHNT?S(@KN1-JX&R\\GW-59RX;#,2P&,%@T*`2MDLBOA-RD$R)41"-3)"$15
M!33W:],L2O#GDCE8+\1&(??E/26ZBP>0HT9\8T1N1M,7G!(")QQ6_P`WH!$B
M+D-UTO*/V>QXFP_?$8MNM@ZD2)*-GO2#;]C+;K1-$Y[B]G73T+!4!;VRXSX]
MI"D2V[*P-R!6/V1GW6A=DO!'-YPQ5-Z-J2Z]4W*GTP*&;>V7(K6AI[/M`PEY
M95-HT"&C,T(L1P@,$WH0IH75-5VFGX85+\AW4F%><:KFFIT:##MZP!<::=)J
M2KW<!6U=35"%L4345755_A@?3DU^N`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&!%2KKDL2LTC-I8&VC!2]J=U6D7<C:GZ
M[=W73)!37W`N-6\:>+D)EB98":.V#337R$(P[1&AD)=5#VKKZIT7!N[[(E)X
MVX[#@O1;"+&L_D.-NO=V'&::4V45&R1AH!;0DW+[M-<N]3-UT%A14UBRVQ80
M6)C#2H334AH'0$D31%$3141=.G3)%KTE-4C6_M:0V$K=O;^$C8=G9Z[>WIMT
M_HRHP%)4!\;9"8'X:D414;#](C_,K?3V*7U5/7`DO1V'MG=;%SMDCC>Y$+:8
M^A)KZ*GWP-F`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
=P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img002_v1.jpg
<TEXT>
begin 644 img002_v1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@#F@*\`P$1``(1`0,1`?_$`*X``0`"`P$!`0``````
M```````$!0(#!@$'"`$!`0$!`0$```````````````$"`P0%$``!!`$#`@4#
M`@4#`@,$`!<"`0,$!0`1$@8A$S%!(A0'43(582-Q@4(S%E)B))$7H7(TL4-3
M)0C!T=)C<Y2"-296\%15X?&BDT1D=$5&$0$!`0`!`@,&!00#`0``````$0$"
M(1(Q00-1D=$3!!1A<8$B0K'!4F*A,J*R_]H`#`,!``(1`Q$`/P#]4X#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`A+=TZ3E@+.CI.1418O=#NZKX)LUW:KK@;(ME7
M2S=")*9D&RNUX6G!-0+Z$@JNU>GG@:["\I:YQMNPGQH;CJ:MA(=!HB1.FHH:
MIK@2^X';[BDB`B;M^J::::ZZX&N3-A16>_)D-L,*J)W7#$`U+P]1*B=<`LV&
MC[3"OMH^^*FRTICO,4\2$==21/TP/)%A`C&`29+3!N]&A<,04EUT]*$J:^.!
MBY9UK3KC3LMD'640GFR<%"`2\%)%75$7]<#%FXJ7U-&9T=U6A4W$!T"VBGBI
M:+T3`-W%0Z0"W.CF1KH`BZ"J2_IHO7`]&VJRTVS&%U7:FCH+U^GCD&:V$$2V
ME):0M=NU3'77PT\?'*,UE1A+83P(>NW:I)KK]--<#(G6Q)!(T0E\$5415P/.
MZWM4MX[$\2U31/YX`WV6PWN."`+_`%$J(G7]5P,T(535%147JBX&*.-KX$BZ
M^'5,#W>&JCN35.JIKUP/$=:4-Z&*@O@6J:?]<#U##_4G_7`;D^J?I@$7]4P/
M=<!@,!_#`=<!K@,!@,!@-4P&`P&`U3`8#`:I@,!JF`P&J8#`:I@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>%X8'P`7I
ME)REN5">K^5\,NN2H11'$0;:MLW)&TB;5/48M.!KUZ[/TRQ*M?BOD''Z6Y^5
M;"PF1XL:/R!YUUPC`5V`TB]$UU+KJB(GGB%:>&NU+W./E![FG:1]WLE&&>@H
MGX4F#4.TCG_N^OKV_P!7CUQ"XK^!/<AG_!E3Q*6<L+"_;F,Q%;V+,:J$4D!Y
M1<(5VZ$#:+]"3$*L>,7<'F7PE^#Y.`%/K9<6@Y!%=-!-'&I;;*%KKT(PT5%3
MSQ"G"$Y/Q7ER\0N83ET?&JZ;*XM9!L[\RO=-H`C;C44[K2CM74DZ::X*T_+-
MQ;6TWXZEI2K5W"7YC"KK<FTW.!')6U,F"=T`G-O@OCC,'D+DM%R+XFYY)G10
MB<X8KYD?EL9]!]R+[#)"&FO7L)I^UY)_'(5/^**J@F\8I(]]!K$?GU3,.G&*
MJ*])@N1`.4C^FTB]8+OUZ)_/+$:N#\9XQ9_+7R;`DU\5R/%>J?;M"V`]I1C;
MM6]J(H+N3^G!&$/AW$WOGZVH3JXBU0<5BB$-&P015)2HA"B)T)$T]2=<$5M)
M65TKY)^1&K"N@/\`'1M6?S,N20HY&9&O5P3;U3TZO"FXT+77)U(J/D>2VWS?
MY%G1Z=NZ93CU:I;E];`OZHLP`T4R5I-#7:J%TRQ:Z.Q;A+:?!XLV273?<=%+
M8E]4E&X.J&O55^]/!5U1?UQ"JWF-=8</.^Y?6LN3N*\@?G5O*ZE%4Q8<5YQE
MB<R.N@H):(XG_P":(9KHJII+3YTMZJ^9%^!2TL0^,5KJ(K!@X(I(?;:+T&:%
MZ-VGI3IDZCLOBRSXO:\<?F<;9D,53LZ5^S*Z*+J'M>%L=Q[6T-%01\/ITP8^
M3\-XG!Y1\7N4[KSD1R7RNP"/.CFHO,.-J\K1B7CH.P?3],L*GUTKD'(Z?EM+
M>O-T/-ZR%"I)ML[J+$@SDN+&=0DZ]N4.@EI]?Y8A5]\?0XUY;6E)RWC#=/R"
MI]E*E1(SG<K)(IW@CR603TIKZ]PK]$UZID1RGQ]2UDCX`NKYYLORC$6^9&4A
MEO5ON.;1)=>NSMCMU^W3IEA&_FU+7-?_`$-<?D(-E^7:H*UIB5O/<VA&V9D"
MZ]"(G%W%XKESQ6+;Y/X_54T3A#M<TL4;+E%6LP`,A;7>TH&FFNB"X@)N3P5<
M@[=SC%%<\ONTG,=X6/QSY`A$@DZVV^@HXB+U1!-%V_PR(^9?&=+`E_!UIR%_
MNK;,1;YE)'=<U)M#<V(6I>KM]L=B_P!.G3+".F^$(+!T5#;3H90)_P".C,PI
M922<_(H_'%YYPQUVD0D"KU]0]?KB+BM^2"EC\T0VHU<Y<(O&9,A:E'R:;<="
M1M%Q1140B$57P]7TQ%W4BKK&IGS(_P`-L''CX[Q^C:D4]:\\XHO')<_=?-5+
M<ZK>O;'<J[?XXC+A[.^O3^.;^`LR3(A47,V*RGG(\:/.1%D"A,=]"%304-0U
M5?#HOAD6OHWP_8NSN9<W*.Z]"JHDIF(UQJ:X3DF*^T'[LC0B-&VG_$4$E1=-
M<I6OC)N<Q^5^:QN0FX<;C+L:)3U*.&TT#;K:F4H@`AWFXO@1>">&!,^1W+3C
MWQ^]0<=M7OSDEN4_739!./O"#!K((.X.XE)=49#=]?TQXDB-=S'/DOXSXU84
MUF_3V-J^T3$V*9"4>6VRZ1MN(*^H$=:VF*^63"N5=^4.1L\3YC>NQW(G.N+U
M3%?;PRWDPW+600I*:;5>VHFV2.ZHGZ>&,*^D<4X1"_`T5@W:33L3&-.FV2R7
M36:1@AN`Z)$H*VYNZ"*)ITTRTK@?BD9%M+L&[`[,0K[VS<CWI37>RVW`E-BU
M"(5<5%`A-=4,=-/#+I7.<KY5:P+/G\=J?91[!+^'7\;LADNA"@.OMB:H^JFH
M`T6I:H0*B^&9'V'Y:DV<#XAOY;<HV;6'6DZ,R,1-$C[8HN\%%45$W85Q?QC>
MV%C\ALU<2;-:@1*".YR&NM'C,WY<@`)N3$!PG#V[57>8D@]4Z:Y8E:/AJ58W
M>JV4NW1Z!93WAN'9;BQG&8<P60A$!&0$B@?JW"B_15R%;J/D5]6<WAT_,OR4
M.786CJU'(8SY/U-DRX1DQ$-K56V%1M4041-=4RPS6KXSEVMU:6T2?8W*+!OK
M)(]HLH_:MQZ]YI0AF*DHFA":ZH0^'GE*O/D7Y/E<>YWQ\6I;`\=C31KN2L[T
M[J.V#>L<]OCL8]*D7^[)%1?E+DLBH^3J5B1/LV./.4UA,M(U:3F]5BZ;'4%O
MU:@A==,04,7G7/3X=\?54FUVRN:V;C/YYI6SD!6B6]L=XIVTDFV2"I:=%_7(
M.^YQ46O'^(<BMJN]G@U#I99,L/.J\02FA[K<D73W&A)L5"%55%U\,)7&P>8\
MFD6'Q`RLNQ8"Z;<6Y-Y00)JC#%]%544E^_KY=,%?=D\,*8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8!4UP(24M2,U)XPV!F
MHBBDI&@1U$7Q3?INZ_QRU(TGQ?C;AJ;E5#,U7<I%':55+77554?'7)2-D^@I
M;`VCGP(\LV?[)OM`XH>?I4D73+2-Q5T$I02UCM++:!6FI&P>X(+U4!/3<@K]
M,A$=>-T"HZGXV+H\8NO)V&_6X"[A,^GJ(5ZHJ^&6D35CLJZ+R@*N@BB#BHFY
M!+3<B+Y(NB:Y"(\VFJ9SS#\V$Q*?BKNC.O-`X39:HNH*2*HKJGBF,TB,[Q7C
M3KTA]RJAF_+11ENE':4GD5454<+;J:*J?U9:1[!XMQNODI+@54.)*$5`7V&&
MVS05\10A1%1%^F*1A"@<:BVTDX3$-FV>'N3"9%L9!BJ_<[M]:IN\RQ2(T5.&
M.S)-_$*O<F,HK4VU:)DG`04T4'7A5=NFG@2YGOQ>U7.4/Q7.]U,.'324(D<G
M2-(YHI$OI)X^J:JOANQWD6D6OX:1R;Z.S`(I#:M2[-OM%O:!$$@<=3HHBB::
M*NB9:D1H_'_C]F-!F1X-8W%@.*M9(`64;9==/KV33T@1'_I\5RTBV:H:9J"_
M!;ALC#EDX<F-L3MN$\NKBF*]%WJO7%(BWE%Q><<4KB-&<<:+MPG7M`<$B3[&
MCU$NJ>2+UQ2)M;35=9!&#6Q6H<,-=D=@$;!-RZEZ1T\?/)IF*^%PSB,$68\*
MKBQPBR%G,M-`@H$DD4>\B)X&J*J;LM(F3^/4=A[A)T%B2DL&VY*.MB:.`R2F
MT)Z_<@$2J/TQ2,:[C5'6M/MP8C;`RM/<J**I.:)M3>2JI+H/1.O3%(CQ>%<4
MB43]!%JX[-+)4UD5X!HR?<74]P^'J\_KBJ2>%<6E<?#CLBM8=HFQ$&ZTAU80
M0741V:^`KX8HWV?&:*TJ1J;&&U)K00-D9Q-1'M?VU%?$5#3HJ+JF2A`JZ2!7
M.LQ$;:B.*O?-#55(B3:JFZ1*2EITU4L5(B0.#\3@T#]!"KFF*27O[\%M21HT
M>_N?U?U^>GCEI&%1\?</IY4256UP1WH#9,P50G"%ELTT(6@,R$-4Z=$R54I[
MB_'3Y$SR-Z,'YQEE8S,Y2)#%E555;1-VW;JNOA@8W7$N.W4N/*GQD*?#$AC2
MVC-F0`.=#%'&B`]A>::Z9:D197QUPR311J!VK:2GB.B^Q";W-@+PKN1ST$*J
M6Y==57QQ2);'$N/,<C=Y&S#`+Q]A(TB:*DAN-#IM%Q$7:6FB:*J:XI&BTX)Q
MFRMQNGXQ-VR-=@IT9UV,Z;7_`,-PF2#>*>2%X8JQ*@\:I(,Q)L1KLNC&&$*B
M9[$8$E-!05+:B[B55+35?-<45U1\<\/IV6&*N(49B-,*Q99!]Y0&48J).;5-
M4ZH2]/#],B1:.<<HW9<Z8<1IQ^S8"+8$0H2/LM[D$'$7H2(ADF6D5U-P#C5,
ML=(#;S;$)26%%.0^XQ'W(J+VFC,A'1%T3IT\M,40HWQ/PB*RXQ'CR&XCTO\`
M(/QDF2NRY)WH?<<#N;2U)$547HN*1N=^+^$O-7K4B!WVN2FCETVZXX8O&/VG
MHI>@A\E#33%(FR^$T$SB?^*2&W7:-6!BDP3SJF3(^`$[N[BIHFGW9%11^->)
MA8T]FW'<;LJ*/[.NF`\Z+HQ]-J-.$A?N@B>"'KEJ1"J_B'B%8R$:&LYN$$M+
M`H2S9),')0T<[CC:GH6IBA*B]%7RQ2)L+XYXY#D1'&EDG'@/+*@P'9#CL9F0
M6[]T&S5?4F\MNJZ)KT3%,Q`B_#_$XC4N/'=L&XD^8MA.BI-?[3T@C0R)P=W5
M"(4W#KHN*1.M?C;C-MQN?QVQ!Z3763YR9:FZ2NDXX[WET=^X40TZ(G@G3PQ5
M>_\`;KCY7M3>.E)>L::(4"$XZ\1CV'$VF+@KT<4D\5+KBBM9^%N!,TCU(U%>
M"N*;^2B-H^YNARM=>Y#/7<SU\A73(+65P.NFU-A66$Z?.:LXRPI3K\A5<[!)
MH0!M01'=YD@ZK]<)$8?B[C(N\8<$I6[B`J%*G?+0!($;7N)_7Z$V]?+!'7(F
MB84P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P/D-.%,/SQSI'>RW'.A@+/740315<[I.*FFGHTW+],L2J
MCXTJ_BKDU_R\*@H;M3=MQVUH(6HLC$@&@=^2+:"(%(=ZH/BH>/BN*=4>1P?C
MLWC3@5$ZIXJQR:Y)^LA28K3D::Q`!6(K*LF0"2.*"O\`FOJ3+3=U]#^(VW)'
MQY&AV%1#K2:<EPY$.$V@PGD:?-HGF0_^&]IN_GF5<5\64H0.7\F^.B-J3QOB
M<]NVK(ZZ$:>^%7F6"14TVQW-23_=IB)FM''OE?F,YZ&Y*?#_`.;PN0R9$5&F
MT6K*I=4(VO\`4J+IM/N>)?3+"J:_N>5V_P`?<!Y1R&<S9%:7=))AUT:.VP8.
MBCRNH+BGH:N^GQT1%Q"OKOQKS!KD?#QO7YO=,G)"S0=$&5ADV9;HSB#T1613
M127Q^[SR+NN`K^66-;\P5MW8+(8X_P`[BE7QAD((M-/Q3(X/:5"75'V24M?J
M>$JUH^=<V_-<GI;(DD3N*2),U]6XZ`,FK**KD%L53P=<<\53_2N6%<PQ\L_(
MKG`XW(4FUI+92:88;@(V\;:SS5J6R\R"IM1L_L55W=%1<0JSB?*?+@;K@D38
MKFG-I'&9LGL@`G#;0B$U3=M;--OCB%5D/YGY[84?&6HKD#\Q>?FC"8[VV8QE
M6.J$=A5</8/<3J:ZZZ>&(5]NHN0UUJ+K+,F.[80^V%I%CNBZL=YQM#[9*G\>
MGUR*^#<CJ9_$0L;ZN8.;P_ELF97<FK$5'`BRSEN,QYK8KZ1!5T%Q/_V98E=E
M&Y[S6VY]=4-.,*/74\M:LVGU;%T-T/NL2A$C$W-7^FP1TV>>N2*Y[C/S-SVV
ML*6O?CLLNW#$JL[B1BT9OX3VCXKZ_P"P+"[_`/JFN7<'?_-?$!Y#P*:;+B,6
M],*V=5+\-C\5.[M+_8X@J))_]3(.<+G,YGXQ+Y2"(TMY=L0(T5LD4VHS+KXL
MCOV[544<=-TNOT3RPE1[#Y8YC&$X,<(;UC$Y:SQAR2\T8,OLR&D<%U!`_0X&
MOJ1%5,*H[;EEUQ3Y3L9%U)9"U?I*F)*L&&73KF'9-@;:R'6R-"`$;T352\<&
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M-O7?D>*2I\&)6O5UA*9>A;]HL>ZA(0LN(KI>I-%\>N3?!*^[84P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&!%*JKB=<=**RKKJ*+KBMCN,5Z*A+IJJ+^N6I,(U77Q5)
M8L9EA31$-6FP#<B>2[437(1C+IJJ8PW'EPH\B.RJ$RRZT!@"C]JB)(J)I^F%
M2P``!``4$13011-$1$^B8$9JL@,RG9;,9EJ4]_>?!L1</_S&B:E_/%,QK&BI
M@=DO!!CB[-11F.(T"$\B^*.+IZD7]<MU.W'A45,4:/%*!&*-$)#BLJT&QHQZ
MB38Z:"J>2IDI'K-)4LL2([,*.VQ+4BEM`T`@ZIIH2N"B:$I)XZXI&,B@I9#,
M9F1`C/,PE18;;C0$+.U-![:*F@:(G33+FFXDA"B@^[(!H!??04>=040C0-4%
M"7Q7;JNFN2DQ7!P_BK;!1PIX0QS>243*1VD!7T\'5%!TWIY%XY;JO3XCQ@X[
MD8ZF&49YY)3K*L-J!OIX.D.FBG_N\<5(Q=X9Q-V(U#<IH)Q&'5?8CE&:5L'5
M\7!#;HA+YJF2DQLK>-5E=;6=K&;0)MLK7O'!$1U1@5$$]*)_J5=5Z]?X85M9
MH*9F`Y7-0F`@.J1.Q4;'M$1EN-5#315(NJ_KBI&'^-4/YK\Y^/C?F%#M?D>T
M'N-G^GN:;M,M(V-T5.TXTZW#9!UEUV0R8MBBB\^BHZX*HG0CW+N7SR*DRXD>
M9&<BR6Q>CO"K;S)IJ)@2:*))YHJ8$)KC-`U2K1MU\<:905I:]&Q[&PNJCV_M
MTRU(B_X+Q'V<:&M3&6-#D>\C-DVBH$G77O(J]>YK_5XXIO%[8\(XI9R)DBQJ
MHLM^P9&+.<>;0U>8;)#!MS7[A$D143%3M>47#:2CLK*PKF`CO6BL>X%L4`=L
M9OMMIHGBNGB2]?\`IBK$IKC5&U5NU00FDK7R,WHBCN;(G#[AJJ+K]QKN_CD(
MQN.+4%TY"<M8+4PZYU)$$G4559=3P<#KT+]<"S<;%QLFSZB:*))X:HOCX851
MQN"<2BTCE''JV&JAQSOE#!%1ON[D/N)U]);TW:IUUZY:D'^"\4?K(]8[6,+!
MB$9QF411V$ZA(XJ$*H6KB&6_KZM5UUQ28\LN!\1LBC%-JH[WLVACQT4=J(P!
M"0,J(JB$V)`BH!:CJGABDQ[%X-Q>);R;>/`;;L)CR293J*>TWQ31'5;4NWW-
M/ZMNN*G;U7V1HP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&!3\MY55\5H)5]:]U*Z$B%)-D%<(1(D'=M3KIJN!
M$F\XK(D>K>-B6:VS3DB,PU')QT6FFNZ9.@.J@B#I_-43Q7`M:2WBW%1$M8HN
M#&FM"\T+[9-.H))JF]LO4*_HN!'Y3R:KXS02[VT(QKH(HY)<;!7"$-4'=M3J
MOCY8$"GYW76EC#@MP;!@K".4N(_(BDVR;0H*JO<U5$70T]):+@;.4<\X]QB=
M40K=UQEV]DI#KB%LC$GR5$024?MUW>*X&%GS_CM?RVNXDX\X[?V8$ZQ#9;)Q
M1:'75QTD]+8^E>I8%W8SV*^ODSY"&K$1HWW4;`C/:V*D6T!15)=$Z(F!1U'R
M!06UU%IHBO\`OI5:W<`VXR;:#$=+8"N;D382ETVKUP.EP&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P."^=*JRN/B^YJ*R.Y*
MGV*,1H[#2:J1&^'C_I%$ZD2^"9/--4/R53WE9\869,M/3.36S<2L1R"#CBQ6
MG'`;VL('K1MI-24OZBZK^FM1QO*X_)K'DI4GM+8&&;JJI:^2R$A&V*J,T+\A
M_N"J(123U$RU\$T5<:.U_P#H@EDV5!5<488D&S=V44;1^.RZZ,>`RXCCSCBM
MB>B:BB9"IE%,Y$Y%MH_"3<EOMS1<*QY.U)98)LV]O8C((MN$+*-CH6U!Z^>4
M<U\FU?+.50E")%;D\DH)M,#7::>"-[I9'>E.-&YH2LB*@A$B_P!*X*HYW^1Q
M>8\]Y=7094FUI*,(-3+6,Z*R9DES63(8$A]8,KT$4U](I@J!,@\C2NY:S`9N
M@"4[2\<KB<"4IZ.*#DZQ1%ZH3B[E4D\//`^G_%\!Y[FW-[J3&?8V2HU-6^X;
M,%]E7,H*$!']Z..&1:IC6L?3<S@90P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P*GD7)*^CCQW)2..O2WQBPHD<.X\\\:*2``ZH
MGVBI*JJB(B=<#*@Y!#O(KLB,V\PL=XXTAB2V3+K;K>FX2$O_`#)U3HOE@6>G
M3QP(UE,]E7R)B,/2ECMDZD:..]YS8FNQL=4W$O@B82ML9[OQVGE`VU<`35MQ
M-#'<FNTD\E3SPJGY)RVOH-GN8\N0A,O2"6(P3R-LQT17#<5-$%$W?Q7"5AQK
MF-=R`D2)'F,B<=J8PY*CFR#K#WV&V2ZHOZIXI@7^B?7"GI3S\,#W`:X#5,"C
MY3R^NXV$(YS,EW\A(&'%&*RKQ$^:*H!H/@I;5TP($'Y*XU.EUL2*3YOV<J3`
M$%9("8EPVU=>9DB>TFC0$U1%3K@=6BI@,!K@4W)^657&XL>59][M2I#<-CL-
M&\1/O+M;#:"*OJ+HF!C3\PI+6R?JF7'&+6,"//UTIIR.^C1+M1Q`<1-P:]-P
MZI@7>`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!Q7RG`HY]1"BW
M,><L<I8DS9UB.^XKWP`R;E"3(F8HB^E5T5.O7IA'SJ9.Y>=)`_.N3;/B[%I+
MBR+5FO<*3+B+'%(DF5#!!<(1>4P4Q'KH):8@GT]"2W[JR9-T0U7&HS]?-F>X
M!Q)(')1''&Q4&3?!HPU;+KX;DUQ$4%0\$CC7)7&Y,MJV<XNC#-2VW9-O/3&0
M+O30%YMK5YPS;1>WN+ZK@6]M'N9#EB"M3TY5W*IWADD1D=H8_981Q-R?MB@N
M=[W`N==%Z^6(KZISE2'A-^J"9N%72@!MH",B,F2$1$!1255)=$TRHX"YB.R_
MC?X[A;)H`<NICV#<=)#+PL(RH2!>[6TP%/`MWAA5--%V#\@U\>##LH[5=>QX
M3JDW,E=RO."K:$LA=6ACD>U$#U+NU(E3$1+6BYO"@<GHJYJ6?^,)-E<;F$9D
M<I;(.XRV!$O[A1@-UM$5?NV?3$55I$8ETT9RN>O4K9]]4C*8<C2H*,HFX):-
MBG[J(H_WCUV:^"ZY(B>XR_4\RLH];&FVL./&F,M@W[UBPA(Q!V@V#[BFQ(8=
M441HU]8N%KU77+F*R^.>4QN/V%M)L&Y[%)*B5!1_^%/[(/NH;+RZOH1DJ'M1
MUQ=NJ^K1,:8ZOYB1UQ.(-,J^#B<AAO&]'9)XFFVP<0G21`<%!%235233(:I;
M[@%96<CXI"4YL\+6XL)]Y.,C1QUQVO<:W..1Q;%IM?2""FU/++AK@[.7>.<+
M@,*S:C:PZ:4<&434]X]\>P,0;9;#;M?%H!4G757T::"NJY!>7\%R;3_(EXV[
M;^_8DM#3H!SF]K<AB,IJPPFU%U-"UT%=.OA@9\AJWH$WE[M>=GMJY]'*I$1V
M8X(N2";]X;:*I=S<.O<3JB?IB)KK/E.\ASJNL1AN025W)X#<K_C/]$C/(XZX
MB("J30BNN]/3EQ6<N5^=^2:KD4"+("DXO`GK/M29=;224H008S`D*&]L[:F6
MU--=$3K@SQU]$KIS$^!&G,(:,2F@>:1P";/:X*$FX"1"%=%ZHN14C`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%/RCE55QJO"?9]U(SCS4829:-Y
M>X^:-MHH@BKZC)!1?K@6Z%J*+IIKY+XX$*9%K;JLDP7T&57RP<CR!$O20KJ!
MCN%?XIT7`J:OBM5QMIZ>TY/L'8[)HVLJ0]->%H4W*TPCA%INVIT3JO3*B\KI
M@S8$>8+3K(R6P=1E\5;=!#%"VN`O4237JGED7$A5T3`Y%OY1XD5@["<>?CFS
M/_$NOO1WFV!FJB*+!/*/;0BW)MU71=4TP.M354^F`7PP(-=:A.D3F!CR&"@O
M=@C?:)L'5V">]@E_N!Z]-R>>N!IXYR*OY!`<FP.XC+4A^(8O!VS1V,Z33B;5
M_P!X+@3I<*-+`0D`C@`8N")=4W`NHJJ>>BX&34AETG0!P2-DD!T15%425$+0
MOHNTD7`K.0<JJ:$Z]NQ5T2M)(PH?:9<>W2#15$%[8EMU05\>G3`N-/UP-;#[
M+[:.LN"ZT6NTP5"%=%TZ*G\,#7/E##A/RR!QT8[9NDVR*N.$@"I*(`/4B73H
MB>.![`E#,A1Y8`XT,AL'1;>%6W!0Q0D$P+J))KU1?#`W*B?7`H+#F])"LGJQ
M$DS9L41<F-08[TKVXFFH]Y6A)`4DZH*^I4ZZ8"BYUQV]GC"K'S?<.$U9-N*V
M8`49YPVA)%)$Z[VR11\4\\"R9MF7;>35BR^+L5IIXWS:,6"1U21$;=5-IDFS
MU(GATP-=Y?P:6*$B7O+O.A'C,-"INNO.:[&VQ3Q)=%P*R1\@4$:OJ9LI)3`7
M3G8KV#BO]\GU15[)-(*D!^@NA)Y8%G2\@@6XR?:H\#D1Q&9#,AER.X!J`FFH
M.B*Z*)(J*G3`LL!@,"`5U$2?#A`CCI3FW76'VFR-A!9TW;WAU`57=Z45>OE@
M3]<!@<X[\@\5;?-LIB]AM_VKL_M.K#!_=M[12D'LH6[TKJ71>GC@;[CF-+4S
M`B2R=)\A!QP6&G'NTTXYV@>>[:%L;4^FY?U\D7`T5//J"UMFJR&DHGGV5DQW
MRBOC'<8T14="0H=I1+7T^K5<#H]<!JF`P&J8%?-O:R%:UU7(=4)MJKJ06]I*
MAJP'<<]2)M30.O5<#"7R.GB7D*C?D;+2Q!QV'&VFJN`SIW"0D3;Z-4UU7SP+
M(B$14B5$%$U4E71$1,`A(J(J*BHO5%3`AV]Q"JHPRIBFC).M,(K;9NKO>-&P
M]+:$6FXDU7P3Q7I@3=4P"KIU\O/`YQGY#X>_)9CLV0&LEY(T5Y`<[#SZKM1I
MI_;VG#UZ:"2X%G47U9<5@6E:][B"YW$!U!(=5:,FS])(A="!4\,#946T*VKH
M]E"-3AR@1QDR`FR45^H&@DG\TP(4SE]!#N&:=^3I/?<!D6Q!PQ%QT2-H'#$5
M!LC$%44-4UP-$[GO$8,N9$EV;34FO05G-JAJK*&FX5<T%4%%3JBK@6<"YKY\
MB7'BN]QV`X+,I-I"@F;8NBB*J(A:@:+J.J8$W`8#`AU-O7VU>W85[O>B.J:-
MN;2'56S4"Z$@KT(53PP,(MY5R[*=61I`N3ZWM>^CIKN:[XJ3>[5$3U"FJ:8$
M.WYIQ>GEI$LK)B-(VH9-$JJH`O@;FU%[8K_J/1,#=<<HHZ>$W.L98,Q7O[!C
MN<5Q$!7%4!;0R)$`5)51.B=?#`K#^3N"A-B0EN&/<3S;;A(*&0O&Z@J`-F@J
M!%H8JHHNJ:]<%=1K@-4P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M!P'S6ZC?#XZZ$1);59H("1JHM3FG#704)=!`5)5^F/--UQ#BN?Y*]9!*G..I
MS9N$VBNR28_'RHPH\(MZ]OM$2KZM-$5.BICV?JF[GM4$`F8/$*"MDORZFBWV
MT6YD!&FR"8M$>_XW<%L@<31M24"34=^,\,,UU5;6/2++ECUA96K\FII89PS>
M=?C[G7*YT'WE8!=G<4MJJ@_:7ZXY>&F:YRX6QDT=G-.;9A+@\/I)L)&G90[;
M$2<0W$`?N=14#<*HOCU3-+7TKX[!8?,^6UC3\EVO$*V9&22;KJ=V0P2R";-W
M7[B05(171%\DR:9KGN+\2C\JN^6M3ITANH8Y2E@5:#0MC)*.TP3)D\8[U;[K
M7@"]=OCDPM4BC/C45A?%)LGHY\FEPKDS67*1FH22X8*$42`NWN[>XF^NQ5\L
MTF<GEI(=@5%&XS:S+R,T,@X\!]N;`DR([LP>T<`QWJKS.FQMM_53;^B=<+5A
M8VLMB]N6[-Z<O%2Y4(V[@K(56HI5H$R"*/K&.LQ-#V=/+PUP.=AR?:\?@0GY
M4ZNXE(G7P+.]K.?,91S-T,W4:5I_562(FB75%+QZXSQ2IUX-HRSR*:=I;O65
M/'XX]7.&4AE2D$J!(<*,"JWN,%_=#JB:KJFN1:ZWA=KQGC/(^8#8&]#E6'(A
M995P))@:3&6ECJA*A-HCAH6A:_I],:9JX^5Y#34OA.]53;R.(Z>@D6T!:>$C
M+1%T%%--57IUQF&ZX7CZR?RU(^<ZQ>6QY!?5DEMY^4;90-LA60VDNT4W"WL/
MQZ]%Q"J"JFI&X=Q:LD3YM+3'628[DP(]A()J[%T1(%1HVW!=!O7M(NH;M>FN
M6%==$B394WG4N;;6I2ZBN8]H"O/QP1UZJT=<1@%V(:NIKH.NT_#KDA7/W4JU
MDTMM+6RLPEP>&U%A$[3\@42Q'N:GM%="<54%#%4777U)E*^C?'SCD?G')JP)
M,J1!]I5SFDE..O(C\EMWOJV3FNF[:"J(]$^B9-*K^'7U=PZWY54\H>6!/G7$
MFSA2W@/MS(L@15KLN"A(9MH';5O7<FGAD'/\[!F1=<BF0O>UA1>(#-@A'[L4
MTDA+?=9W(WIZMZHO;7_5U3-(V\FY#R%NTOWXLF8<5:WC\B<+(O.HW'=?<2>X
MPT"BN[L[=Z-KNTR1:TR8];*K>(N?DY5M7'RL3KY)A*C"W&<9/<VUN,G29;<Z
M"XXOGHBZ985UOS"\RR[PP"DE$4+^.ZL@40R::;9=0W%W"8HB;D15)-.N3$U7
M6]DY.HUA47(95GR6+9"=)9$*LL2)1;I`PW^TC;3C`LCM=Z(B(J?U8BUSECRF
M/+JJ+OV4^JHI\::,R<\W+>>8O.Z*JVYV#;,5;U+L#U!>FB+TQ"KV-:B?+!J^
M16-NU<-'5N\=5AMUKW<?L-^X4V@0F?W'NY[E'/L'3JF(M5%9>R9LJBHG9\UV
M8$KDL.UBJ4A"[:"^45IXNG5!V*UJNNGAB)6W@CD>7#^/Z6%92X\6;Q^PCSFF
MWGP49+8,#N3<OI<:-7-J^6BHF%KTK;FX<&ESY13&9?&U9HK)\>ZZ;PM3`2?8
M`V!(;FL9!423U)J>F2%=M\>*4SC-H5==N6T*2^_^)F&VZV#(FVG[3)ODXZZV
MVYKH1+^GEE''UMG6Q?@USATME5Y.U7O4[U!M)93L\T(-PMZ:F+IEW>XGIVKN
MUPC='K6XO)KR-93'2LH?#8+<YP'W1%7FQ?%U4VDB?1>GUU\\(KH5G=UO&>#-
M<>DR7);O%+!]N!O<<!R4S#9)G5LM4W`YN0$7^&2+6Z1RJM;X\%MQ^]L9=0_+
MKF^2/24D.A";5MQ'RW(@/`9N(VCZ`6@)U].7,6I?'TF6?)>.U1<IL)E8[`L9
MK4A@G(R2$8GL+&%5/>;@@V1AO)=7!3)N%2/FOD4JN=?CPI\J#/:I94Z&H.&U
M'5UET-";%H5-Y]-/L5=HAJJIB%55C?697-K:M7<SL0KSC[<5@7B2-V9[;"2@
M[>B(0$CA+HOAXXA3CER%GS?A\F=/D'R$;&[9N*QTW-D4Q8=!H$95-K:(V(H"
MI]R+KUP.NYG*8;^5N(MF^C)+6W75%VD.X(^BHODOI73^&!\QDS[E_@R`_<SY
M[EWPF58S&W7S(O<Q76MAMH""H+M,Q-$^Y$ZZY<PKI)?(GW>51ZR)R,ZUIMNK
M>XSN23)6?&<1%D(""8MR2,M6RWZJ"=>B8W!@S96S/"Y/(DY'8.R7.1MUR"Y(
M0F6X[=RK6P104^Y@MIKKU'3)`CS[:5<PM>2V`MS.66M*;(OCL]D+3I@V";>A
M"0!L/[AUZ+B"\JY').0?!EPQ`F.3KPF+6!"E$2$\XK+SS+*$:::N$V*)N\UZ
MX@N^*<GX'9<<I*V*]'<(`BMMTO3W,=Z/M5!<C_W&E9,-24A333":X;@-C)A2
M.*(S</%%NDY"W)A*X"L#[:2X\TXV&WTF*JOJUZHN745T3G%]-J*./+Y0E1)E
M4D69564CN&LN=[EP9";6]HR#06VP[*^.[HGTD7'?\"98+Y%YXXDHWG1DP.XR
MKBD**4%M2_;_`*=I:BGT\,H@PF+&=\J<UC5=FS%(!I5F,FT+RNLB!]UM=23;
MN#TZZ+IKD757;<DNDO;&O8O'XS`<QKJQM&R:U;B28(&Y'#4%1!WJJIYZX13V
M'-+1F@?KSY)(&=!=Y&S!DN/MLJZE:XGMU??05)UUM"T%H1]?B71,165IS7D$
MB%=W,?D;S?XRLX[8QX\<F4CJ[,7;)W)M)5;<\QUQ!UO'^4-V7+WXTOD3L2[A
MVTR(YQD=A"Y"`21@NUIN$.V@O=Y%\>GZ8'"S_D:Y'A,64G(WPN&*JRL&G''6
MF&G2C6#C+1D2`2R#VMH'9$4'3U$OA@?1^#3&I?R-S!\'0=[T.D=U;)%14..X
MNJ:>2ZZI@0^"6M33R.;,<EDL1+/\Q*ESBED(=V`Z@^T<'?\`>UV=`33IJBIX
MX1R7$JR<#WQ?$L9<FO<,[HX$-#1IT(2H;D1";-%+7LD(_HG3`WT$YZIX\LN%
M</*LGG15[BN.,N"33EB3;@(JAZ5<;7U:=>G3!,2F>?V)TMG>1K\G>3PV;5)?
M#5`'$9<BF0M+VA'O-(P`H2DNO<U_A@:2Y3R`XD9:SFL>;!L;BIBL2XA-RG6&
MYB.)(;<=-IMO]S:A`&W<'GTP/M%9$?B0(\9^4Y-?9;%MR6\@HXZ0IHIF@((Z
MEYZ)IA4G`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8!5TP(--=U=U"&=
M5R0EPR-QL7VUU%39-6W$_P#O3%4P)CC@@B*2HFJH*:KIJJKHB8$.MN(=BY-;
MC;]T"0421O`VT[H")+MW(F\=#3U#TP/)-U"C6T*K=[GNK!'2C;6S(-&!0CWF
MB;0Z%TW+U\L"?@,"JO\`E%)0-QG+:1[=N6\,:,6QQS>\?V-HC8GZBTZ?7`AQ
M>?\`$YCE:$2<,A;62]"A]L37_D1VR==:<]/[1B`*NAZ+@=#@,!@1IM?$FHT,
MD$<%AP7FQ77:C@?:2IX+M7JFOGUP).`P-3LEII"4R1-HD>W^I1#[E1/%=,#1
M3V\.WK8UE"4BB3&A>8(P-LE`DU34#02%?T5,"8JZ)K@5U!R"JOZQJTJGO<07
MB<%M[:0:JT:MGZ202Z$*IX8&M[DU$WR%GCKLE$N7VBDL0U`U(F@70G$+;MT1
M>B]<"UP&F`P&`P&`P&`P&F`P/-@[MVB;D31"TZZ?QP/=J?3`\VI_/`;!T5-$
MT7Q33IUP""B:=$Z=$P!`)::HBZ?5-?'QP/.V'T3ZKT3R\,`C8H6Y$35>JKHF
MN`)L"751153S5-<#Q&6T_H%.FG@GA],!VF]17:FH=`71.B+]/IBD>=EG;MV#
MM\=NB::_73%(>W8Z>@>BZIZ4Z+]<4C)ML&TT`4%/'1$1$_\`#%&L8<4'S?%D
M!?<31QU!1#)/HI)U7%!(<44':T`[==N@"FF[QTZ>>*'M(VC:=H-&EU:3:/I7
MZCTZ?RQ1D$=D#(P`1,_O(41%7^*IXXH#'8%Q71;$7"^XT1$5?XKXX&)0XRDI
M*T&Y20U)137<G@7\?UP,5KX*J*E':51)3%5`5T(DT(DZ>*IXXNCQ*^"@J"1V
MD$D05'MCHHC]J*FG@GEBZ1G[.+WE?1H$?(=BNH([U%/Z5+373],71J6KKB$1
M**RJ`A""*V"H@G]Z)TZ(7G]<71M:AQ63(VFFVS-$0R`1%504T%%5$ZZ>6+HU
MRJRNENM.RHK+[K*ZLN.M@9`NNNHJ2*J?RQ1F[!B//-ONLMN/M?VG2`2,-?\`
M22IJG\L#4E15BWVQB,(VA]U`1H$3N)_7II]WZ^.+HV-U\)J0[):CM-R7T1'W
MQ`4<-$\-YHFI:?K@:@HZ9MD6&X$8&1<[PM"RV@H[_P#$0433=_N\<";@,!@,
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MJ*;75524=1U0?/KA7/W/#6Z;D7&F95PZY9\CY%+GV$UA!BDAE5O,H+`HI]L4
M`1'752U7777$')V7.K1>#P]U]+2V8KKIR)(*03(.N0)AM,.*30]R3)$`%$;^
MW;J19>TJRL[ZUFU?/K^/RB>!4]?$?K&(T@1CBY+KFS,MB"JK^\J[4UZ+F=PK
M+D5E<U8\K=C<JL#_``T>FLH(.2!)/<3#VO(>@IN:,43]O[4UUT\,0S6V3SNQ
M9Y\/XNU=?-RQMH#E9*?)5<<9AD<5E(8HC;+?>;%&35=[FNO@N(;K'_-]G#RM
MZ7DLZ=,-BN3DS3Z..A6DY($9CQ((H<=Q$(A5L--HCN1.FN7,*GT_*CKI_'7Y
M?+$G<<FSK1E)R&Z,96EBBY'C]]Y2)\FW=R-GKK_3U5,1,JKX/<%877%[:VNI
M/O9O%IR,R#D$WWI#,U-4VKH*F+:;BZ?THJ^&094W-79M=31^2<GF4[LGC]?,
MII[!>N9.,R]WTVJ,AX2$`[*^1+TZZI<58P^:OC\GUC#5T\4:3=6%9/A2G^J(
MW'(F6DB"FQ@!<!.T:KO<\?#&F.@^%.04C?#J>G.8R-G,<LWXL/=^XXVU.>[A
M"GGMU37(J%\@63<7Y+0FY?MY3'$;<VS`T%P#[C)@HZ^!>A53^&$\G--<KY/5
M0#=CW<VS=F<3K;>6KBC(<9<.4#,J1'!!]*C',SVHGB*+EA7T3A?(^*@CRP>3
M.W%?8S@CUCLHU>!'S9WK&CR%35WH"FNJKM5=-?+!7=9%,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,#`V67%%3`34%U!21%5%^J:^&!CVXZO;E`>\B="T
M3<B>'CXX!(L5&^VC(=O7=LVIMW:ZZZ:>.N![[:/KN[0:Z[M=J:[OK_'`#&C`
MHJ+0"HZJ*H*)IKXZ8'B1(B"HHRV@KKJFU-.JZKY?7`%'CKNU:!=VF[44ZZ>&
MO\,(YR5\A<%"449^Q:-62V./=MPX[9_0I"`3(K]=3SI\KE[&=]3'2"C+R"YM
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MNGCITP(JTE:5C&GJR/N(8N#%T1$$.]HCA"B?U$B::_3`EG&C&:F;0$:IHI**
M*NGTU7`#&CB2$+0"J#L14%$7;_I_A@>!%C```+0"#:[FQ041!7ZBFG3QP-5G
M:5]7`DV%@^,:%$;5Z2^:^D&QZJ2Z>67CQW=F)NQN:>;>:!UM=S;@H0$GF))J
MBY)-FE:+6UKZJ`_8V+X18,4%=D2'%T``'Q(E^F7CG=TQ-V-[#[3[(/-$AM.B
MAMFG@0DFJ*G\4S/7-FM-F4,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#B/E2RN
M(53"2JE*P^[*T>C-2&8LJ0T+1D3<5V0)-(ZBHAZ%]R(J:YU]#..[M]C//P?+
MK7E-BP%_R.NY-,;F_P"-U$RO]RC`*:FXZ+BK&,%3RU)!\R7KX9]#CPR9QWAF
M_OW^SCW+/EG++[C5K[4.6O37JQRL=DI*]K&;5J?*T<$P0-9&YI>BAM1L4ZKK
MF/2]+CSV9P\;GNQ>?+<W.JX<Y%S"'R6YXTDR1-DQ'2OZ^0@@O<J$8(@BZB""
MNZ4/9_U*BZYRWTN/R\Y9YYVS_;V^YKNVZY8>><N3B,ZXC\OBON/Q:^3VV2&0
M]$DNRVVGT-#:;!D"%Q0[)ZDBCJB^.>G/0X?,S-X],[OUZ,9SY.DE77(J+FL>
M!8\BDV%>TXU'&2RL8U%UUAQ[M3X8`#B[]4,'6NFB:+YYY<X<=X;N9Y?W\E[M
MS>KGZ3F=U:NO4Q\@.7$O*^O<;?<>95\?>3_;R'1!E$6.A,ET:W+LU3547._/
MT>/'.[,\.6_TO]4X\]K>/-HK\RKCQ;<:J#(MGH+=,TK8Q8M/5[_<I)`A)%>D
M]E=!+U:$FU/')GI3KN=W[?'\=\)^1<0[GFES1U<5N#='".KAP9`U[CC++;+,
MF>38BZCJ&Y)/V^@*";4;VZJNN:]/T./+EUSSW_Y^*=^NF9Y6[;V]D)<N<KK)
MFPG5X\=:%LE.(#)^V-H=JN"1B@O]_51\O#.&>EV\<SMN=.K?=<<]1\ELX'$N
M*-U]^;B2.-VTI\C*.Z;<N+';<#UJ&Y%;(E])?SST\N&;SY7A)RX,Y9T]B4[R
MKED*CO>]R-V:\7$(U\P\\$5%8E.;D+MB+:!L+1.A(N<OD\-W)G\]S]&MY;UO
MLQ(N_D.UKROFSOQC/QIW'EK67"8%28F@S[I`%4U)L]YKKY>2YCCZ7&9T\N2W
MQ_-Y(Y'S)VV?-KE;S+:\P/CS47LQ";"*XUO\V]Q.#_0JKT^BXWT^$\/X7]3>
M6^3R#R3E\Z=44KG+'83)6%_6RK3MQ%=<"M5%8(E-O8+B(75433],UOI\,SEL
MZSC_`,^*9RWS4_Y_E,\DOBN%@7</ATR64MAIG62D6>2-.;'!(1;>1L37:B:H
MO1<Z\?3X>'EWY_1./+K^F+>;\C6_^15D@;[MM+/J(D^$91V(P!.C`X^"-DA/
M/*JGO[NX1'HB:Z+G#A]/Q[=S<_CN_P#*]V[N1Y%O>=/UD"S3E[R?DN3'1(S[
M>&K8,!+>;W#^WJIJ#:>>:WT^&<M_;X<;_P`8O#=F=6VJY3RV-,KY$KDKLQ@>
M33>/N,.M1T!R,RVZ:..=L!(G14$ZBJ=.FF.7I<=S<SC/VU./+>GZJF%\J<DB
MQI\ENZ_(M/48V3#KOMS<!PI@LN2AC-#JT`,&KG9(B71/5UUS7V_'EN=//^R9
MSZ>Y?WG,9D&-'C5G,&[.ML+-J.[<N$RVD-HXI.BP4QMMQE">=!-"4-11=/-,
MY^GZ6<N6[O'M[?+V]?8N\MS<0UYWR:##D!9\DC.&WQBPE,3HZMHR[-BRB;9=
M:-P`[AH&B%M3:2]43-\?0X;)F]>>>Z,[ZG3?;T_JBR^0W#3'-KD>0.I8-<;K
M)L..11S:WNQC<<,&3!=10]?T]77RS?'AQWLS,_EO]6N>_P#9T<?ELB7R.6,C
ME'XF156$6*W2$VT8RXCL=MS>C6G=,GC<+1P"T!!\/'//OI3CF9QN;F[NWPUK
MCM<F?-[.RIN2095TEC7S^)S;%DGSCBXKR$;>\&6DU8`FUZ-D1$FFJZ+KGI]/
MT>.;QV?S<[^W]/[NIA\FM8G,JF+(LG$HGDA0X@1"CN,`Z4+N%'FLJGN&S-?W
M`=%=NW1%TSS<O3X]FS.O7^ODZ=W[L2N4<U&7R!ROB\J9X]`"I;LZJR'L.,RW
M2?,'.KFY'0:%M$5L%15W?PS'#TIQNY>5Z_@N[OM1"YGR)V7)LF;-0D0N0L4R
M\<(&Q%V&\;;:.;53O(Z8.]\2W:(B:::(N=/E<<Z3^-[OQ9[NJMH[_G%E(XX!
M\J=!OD#MS&<4(\35L:YPU:)KT?W%%O1575-/Z<Z\O2X9G+]O_7M_],YSV9U_
MB^C_`!E=V%WP2FM+%U'ITEC60Z*(*&8&0*6T?2FNWRSQ?4>GV>IN8Z\>5RNH
MSDT8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8'.<MX@/)&F&7;%^$RR1$K;+<1T7"7312
M&4S(34?+;IXY?3];L]GO3EQJG?\`BYV0J%(Y-8O*C?917&*L_P!M%UV=8:^G
M7^GPST<?JYX<>/OY?%CY6/'OBQU\][_)K%YS8C6]QBK,NVBZH&I0U7:B^67/
MJYX<./OY?$WTLUN_[>6W=[J<RN4=V[.XB5Z%MUUVZ^TUTU\LS]QG^''_`-?%
M?E_BB_\`:=SMO-IR:Q[4@^X^'8K-'#3KN-/:>HOU7-;]7_KQ]_+XI\K&S_M=
M*]XDY>56:S43:DKM5W>VZ::=SVF_33]<?=S)V<9^?+XGR_Q1S^'FS9-E>1V(
MM."K9HTU7-%M(D-40PBB0^I-W1?'KFOO?],]_+XI\G\45?BGE_Y'>O.)!5W=
M1_LE7UZO[M-%+NJUIO\`_LFS7+GU?IS_`*9W?GJ?*ZI8?$*(T+:\ELG`$2;%
M76JYTMIDIDBFY%(EW&NY=5\<SQ^KG\./OY?%KY.>UO3XPF#*]V/++09>WM^Y
M1JM[NQ/Z-_M-VW],GW6>'9Q]_+XF>E^+`?BDQ`03DUB@@AH"(S6(B(Y]Z(GL
M_P"O^KZY?N_]./OY?$^2]7XK>(2%>46:B3:,JBLUBHK2+JC?6']B?Z?#)GU<
M_AQ]_+XGRASXK><-''.3V!N"(MB9QZHB0`74115A^`^29?N_]./OY?%?ELE^
M+Y.NJ\HL=>YW]?;U6O=_^)_Z/[_]WCF=^J_TSW\OB?+Q6V/PN]-L8,ESD\LV
M(:ODL=R'6GN.0B(9I_QA#<J"FJD!+G7C]=F9O[,Z_CR^+/REDY\8SW"(CY98
MDI-]A5*-5DJL_P#PM5A_9_M\,Y\?J\S^&>_E\6OEM:_%#Q&CA<EFDX@@*&42
MJ5=&_P"VFJP_`/Z?IE^]S_#/?R^*?*9)\734`&TY58(VVYWVP2+5H(N__$%/
M::(?^Y.N-^LS?'AGOY?$STL>M_%\UM14>4S]P.D^"^UJ]4>+[G$_XG0U\R\<
M?>9G\,]_+XGRF+'Q7)87='Y/-8+:0H342K#TN+J8^F)X$OBGGEWZW-\>&>_E
M\3Y3P?BN6,)8`\HFI7E]T)(E6C"ZKJJJW[39KKYZ8^]RWLR_GR^)OI_BR=^+
M93HM"]R><ZC`J$=#BU9(V))M46T6)Z45.FB8SZ[,\.&>_E\4^2]/XOF&JJ?*
M)I;FD8+=$JUU9%=4:ZQ/L3_3X9/O,_QSW\OBORV2?&EBDIN6G*Y_NV0[;,GV
MM7W0#PV"?M-R#^B8^[XR=F3\^7Q7L:1^)W!$A'D<L1,3`T2%4HBBXNIBO_#Z
MH2]53SR_>Y_CGOY?%/ELP^+902TF!R><,P01L9(Q*I'$!$VH._V>NFG3^&3[
MO).S)^?+XG8\/XLDFW%:/DTPFH*[H0%#J5%DD\VD6'Z/_O<9]7F>''.OX\OB
MO9K,OC.>5@-D7*IY6(CL&:L6J5]!\-O<]GNTZ_7'W>2=N3\^7Q3Y>^UJ:^*I
M#2L]GDTUKVZN+'V0ZH>VKW]U0TA^G?\`U:>.:^]\?V^/X\OBGRG5<7X_^!J`
MK4E',!LC('#:895$-==J!&;9;1$_\N>3U.>\MKIF+?,J8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#1,!HF2!HF(&B8@:)B!HF(&B8F!HF6!HF2!HF)@:)B!HF(&B8@9
M0P&`P&`P&`P&`P&`P&`T3"0T3"FB8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8!51,#`'FG$
M78:'M70MJHNBIY+I@9X#`*2(FJKHGUP&O37`\WCNVZ^K373STP/.X&_9KZDZ
MJ/GUP/=R8!"1?#K@>X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`K.3QDE<>LHJS"KO<17FO?BNBL;P4>ZB]/MUUPFOD=1='P1
M9X7G'F(/)*NB>=B3JTD]A:1(AMHKBCZ2;=`R!20^NA+ZLL%[+YI\D0FV&G8\
M#?.LJZ)`DNZ>MF<!]U2:8>>4>V8:@6[UIY>>(B+"YESJ=RJAI94R-&?CW%E7
M6I1V25F6$2&,EHP0CW!Z7="'5="_AA6SYYY*#/%;>D)R3%`ZQV2<EEB00F?V
MM,H\T!"'J%2<U5.FB>>"OI5/,9EU$*2RI*T\PV8*8D!:$**FHFB$G\TR:.'Y
M+PVK?YI3SZQMP.0MSVY]E;]QQ%;@MHJ''-==NQ[HV#6FGB7EKE'*\8ES$E\/
MOT4OSUYR"UB7/74RCI[E%8/_`&1_;M[$_IT_7&CL>"P&'YW/8#W<6*Y=F"AW
M#U0'(<<B02UW"BJ2^"XT8_&,=BNN^5TX5IU"QIC#[=<#J/148>9T:=85--JN
MJT1.!HFA?]<SJOH.4,!@19]K65S8NV$MF&T2[1<D."T*EXZ(IJB:X'L"SK;!
MGOP)3,MG73NL."X.OTW`JI@2<!@0;"^HZYP6["PC0W#3<`2'FVE)$\T0U37`
MDQI4:4R#\9X'V'$U!ULD,"3]"'5%P-NN!4N<NXHV1BY=00)M2%Q"DLHHJ*Z$
MBHI=-%\<"T;=;<;%QLD-LT0@,5U145-45%3R7`RU3`:I@-<!JF`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&!IFPHDZ&]#F-"_%D`33[)IJ)@::$))YHJ8%1`
MX-Q2#WNQ7@O?CK#<1XC?3VR^+`HZ1[6U\P3IEI'-W/Q)2-UE;6\9@QJ^*Q;Q
M+*>VIO"KC4;=Z`,5(T)-R;$U04R4CHEX%Q!6(+*UC:C6R2G0R53WA)<UWNJ>
M[>1'N7=N5=?/!%K:5=?:UTBML&!DP98$U)8/7:8%T45TT\<"!&XQ"8Y._?AJ
M,A^(W!)L5+:K;1J8J2*2BJIKHBZ)TP(#_P`8<&D73ET]6(Y9.OA*=?)Y_0GF
M]%`B;[G;7;HFB;=,M2+&+Q'CD6Y<N6((!8N*X:O:DJ";VG=,`5=@&YM3>0HB
MEYY%C#_#>.HQ;,C&(`O'.]9J#SP$XXHH.]#$T("T%$]"IX9:)5/0U=0T806B
M$G20GWG'#>><(4045QUTC</04T3<N06&`P&!P'S(TR[2T;3HB8GR&H1$-$)/
M_5BJ_=^F,37,\ZN(_&.?R;?C+3:RH/'Y\GD<9A$1E5`@]@<E`Z(:&IZ*OJV(
MOE@;V^7<M;;"+)OXSWY*;&;JG(11I,QQMR.XZ\WO0&XK0ZM[Q,T70-?%=,I6
MGA',^=<JLN-QEN&(C<BG*RLD;CM/*\Y'L%CD*%JB"CK::*H^'BF-PS71\O8B
MO?+/!A?;;<1(]NJH:"71&6D\_P".!Q,FXF4G).4IPF4S"I)%K1PD,&Q>B!83
M'E:GHR&J`B]I05Q!_K_77$.K[/3*ZS$;@3;$+&TB@*3'T$&C)2U43)D%5`W(
MG3(N.&MZ:G:^6^+PFH<<(WXBW4F.V&U4-R/NU'3KJI+KE13O<CY+!7F#C=\S
M64O')S53600A-.;4D-1NRB+N%=XD\H-HOIU7U=$PE:&/D/E4.HEW$V>AUO&>
M1E`O048[KRU;@-HCCA,)MWL..HI*WXHB_3$6MUQS/FPRPJV+2+73WJYR[B.S
MG&8[:BY))&F#WM'O;880>YMT/4O'$*E?Y!\AS'.5R8=O%5*F2U#@5:-LMB92
M&(SN@R75^]%=-&MXZ*JINP5477R1?CQOOUMS("RA0[25)A2XL6/*;=@O("#,
M,U5C8RJ]LD93<XJHJ:8A7UZBMF+*NCOB\TZ^3++D@&B0MA.MH>BHBJHZZ]-<
M@L<*8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%?;\?I+
MED&+:"Q/8;)'&VI`"X(FG@2(2+H2>2X2%?QZBK8KD6!`CQ8SVJOLM-``N*J:
M*IHB>K5/KA4)K@?"F:\*YJB@!`;?26$48[2-)(3P=0=NF_\`7%2-];Q+C%9*
M&56U42')`":!YAD&R1LSWF"**)Z2/U*GURTCVVXIQJWD-R;2LC39#(J#+S[8
MN&`E]PB1)JB+YZ9*1FYQGCSD!FO.MC+`C."]'B=H$:;<!=P&((FU"%>J+BJD
MM5E>S-D3FHS;<V4@)*DB*(XXC2*C:&2)J6U%737PP-;U'3O6C-J["9<LXX*V
MQ-(!5X`+Q$#5-R(OFB8&A[BO&GF)\=VLBN,6I;[-HF@49)=/4\BIZUZ>*Y:D
M(W%N-18TJ+&JHC$:;I[QEMEL`>T%!3N"B(A:"FG7)2,K3C7'K8HYVM9%GE$+
M?%*2RVZK1)YM[T7;_+"Q@]Q7C+[,YEZKBN-69B[8MDR"I(<'3:;J:>LDT315
MQ4C2[PCASS,9AZD@NLPT,8C;D=HA;1W^X@(HKIO_`*OKBD94O%*2FGS9M=$:
MBN3A9;=!EMMH$".*@V*(V(ZZ(OBNOT\,*N<!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@8N/,MZ=PQ#<NB;E1-5_G@:UFPT445]O4B1L4WCU-?`4Z^/Z8&[
M`8#`8#`8#`8#`CI805FE!22TLT1[A1D,>Z@?ZE#7=I^NF!L?D,,`AON`T"D@
MH1D@IN)=$35?-5\,#QZ5'8V=YP&NX:-M[R0=QEX".OB2^28&U%Z8&*NM":-D
M8H9?:"JFJ_P3`RP&`P&!X1".FY435=$U^J^6![@-<!@,!@,!@:Y$F/'!#?=!
MH2(0$G"044R70115TZJO@F!L1=<!@,!@,!@1V+&!(D/1V)+3K\=420RV8D;:
MKX;Q1=1UT\\"1@:O<L=]8Z.![A!WJSN3?LUTW;?'37SP-N!K20PKZQT<#OB*
M&K6Y-Z"JZ(2CXZ:^>!LP&`P,'GFF6B==,6V@34W#5!%$3S55Z)@9"2$*$BHJ
M+U14\,#W7`8#`Q<=;:;)QPD!L$4C,E1$1$\555P-;<R*XYV@>;)Q01U`$D4M
MA=!/1%^U?K@;L!@8-/LN[NV8GL)0/:J+M)/$5T\%P,\!@,!@,!@,!@-4UTUZ
M_3`*J(FJ]$3`:X#7`8#`8#`:X#7`8#`8#7`8#`8#`8#`8#`8#`8#`8')_)-#
M43N+W%A+BMR)D*JGC#=<3=VM["J2BB]$+4$]7C@?/Y]#71>)?&UI60X\>WF3
MJ,')*@NAJD9U4)Q!4=RHKBKKXK]<)4^-\A<VE-1*)@(Y\C<DW,8I@-@++JU#
MHMAL:>=;1%=[HJ:;U441=,JN^B6UL[PI+60TQ&MD@D^ZRV?N(X2`;52$3!4W
M@AIY+X9!\QD?)WR'7\?9M)OXU[\GQX;Z`+#+HI'<:<C"ZR[N<7>#@2M1)--"
MPE7')?D/EL*VNZ^M2$I0K2C@Q"?;<)$:M@1'.YL-%51,M1\.G3!46WYM\E5)
MWQ.O54EGBOXXYX!&?;.6,L!5X6E5XD:5-=07U=>FF6"R3GO(B?;N&ECN4O\`
MD!<=?JU;49`#W_:I(5U2_N=U$)6]FFQ?KUR%5(_*?*(K,J-8H#5ZY*AQ&ZYV
M.C*1TF/N-^Y:?-WLRHZB*(V>]/7T+QTPKZ#PJ=R*572`Y`TRW8Q9+K&K)@2F
MRFA-&Z#9."TX0$FX$)=,#D8WR!R-YV'=`4<J67?N\><JNT7N&D%\XP/]W=U<
MWM[R!1TV+]4ZAM^)J?W#MW;VA,SK*+>6K$:8K`@^"=]6ST<U)=I"`IM\D3`Y
MOELF^E)S1N7-&<Q7<BHVZN*\VB`QN=AO"B**ZZ:NJB]-5\<"TD<LO7'FZ^V"
M#8/UO,8=4DHHZBBLO-"\#K;:F?;>;[NU"U7*B\X/RZ\L>43ZF[,8LIIIU]FM
M5A10F4D*#<B+*$B;D,JWM0O`A/Q3(KSDS+)?,_"C)L2-*^W5"5$U3;[;3_IN
M7_K@:^:<SOTY$7'N+DPMBQ7O6!&Z36PW6G!!(Y]PV]H)KJZHZD**F6#D;7D7
M.7$Y"\U>>U1N]H8S++;8.BRS-&*KK+;B*B$&KZZEXE]4UQ$KI6>:\PG<ADC`
M2,E776KE-8-/DT"H@M(HR!_<[JNDZ2*+6W0@\]>N(JZ^+;;E-YQ6'>W\B*XM
MHPS(CL1&2:1I%%4-"(C/?N7JGAIX9!R_S!*N[22<6CCRWI'%0:N&EBCN`[$#
M1UB.ZNH]/;B>J?[Q7`M.0?(4^5`X_-X\O;KKR!)GA/1@I1(XRR#C,=6@T).X
M1J)+IY;4T54RP5Y\S^0VK!EN:,.*D3CK/(;>"D9Q7E<$W$?B-$KR[55`045=
M=%R#0'R+S6)1):36HCL6S"N6IE(<=.VY8/BT:D`/$),-H:;#,AU+TKE@DIRG
MY(*ZJ*!]V!#F3GK-IR238R35J,P#\9PVF7MC;G[FAAO77Q_3$%8Q\M<M@TT*
M\M`AR8]C02;1N(PV379D1'66M2<)PMS9]_>71-NGCYY!:2.6?(<)V!#>=@K^
M0MX4.+,<$''"BRXSKAD3,=U1%1<9_;+=ZA_ZY8E1:+E7+K;DO%&)-D#2>[OH
M5FVPR@M2RK'$:;<45)5#<'7:BJB+D5U_R5..%4U;HQX\@3N:UEP)+7>%!=E`
MWO!%5-K@*6HEY8$3A_*[F=RRPJ+EQ(TAL'GXM>K&@N1QD;&Y$:4)$#[?;($-
M%T(37JF!6<WY7><?YO.EA+)VIKN,2;3\3L'8;S,@0U(T]7FG7R37ZX%QQB]O
MTY8Y0VLEFR:?K&K>)/8;[6Q''%:-DD1211UT)LO'377737`U<JY9<5/,JV&X
M:0J.2<9D9O8]PTX^^Z0''D&);XQ$.WL&H[2)515RI7$W//\`GD_A-G?0Y+,"
M!-K)LB*^),%(B2(IZ"VR&XB<U;14=4Q10+PQ%?88C,S\.VV4K?+[*)[O8G4U
M'H>Q%T_ED'QOXW.U*KXO75\J/%O;6GE3WKQV()NN-QY(H,9?4F]%=?4S)5W:
M>&BKK@6M=SOG7)1$Z]Z'41_P#-Q(W1S?=1TW)++@LD3@AM58Z$!$B]/KE@HH
MUKRF*Q`Y#&G,/737!!M)4Z2PID^C3PR.T0@8]2ZBIZ]/%$Q$KZW<V4U_@LRR
MANK"F.5CDJ.\@H:M.*PK@JB%T7:OUPKY,%ORB"X/(HLMAZWC\#BV<J5)84UD
M=E\WNT2"8Z*8[A4]?UTQ!U\;F_*+/D3J5S,=*NNLH]=8QWC:!>R_';>)]"4T
M<[FYY$;!`T)$7SPE=)S:^L*=>/E#[:C8W$2OE"X*KJS(W(6U45-I(J)ID5Q<
M?GW,["PC5D1^"P<F7R&(LLF#=VC4F(QR$$<$55=WKZY8E5%_S>YY=\>6K"%&
MAJG$0N+$#;5Q'SF-O"H-H1)M`.PJ[NJ[E3Z=4*Z2LY?RB59^VJVXWXRIFQ:J
M>U()L"5IV*TXLA"5Q'-^]X>V"!H:(O77$*K(_.OD(N&U_(Y"QW(T\C)XH$,W
MWH;3".BKI,*[O>;(Q#N;.H#KX^.(5FQS/D0V?*)HW49Z&#5%^,$F3)@5L03<
ML8`7N.&XI*K8E]RJ**J(F(5E7<]YS9SZRF8<B19DFSN:N1+D1U,D2N;1QASM
M-NH"&J+ZQW:?P\,0J!)YU?\`+.$OPD6)%DO<4D6UFKC1.MO$:NQ^VT*F.P$5
MHB)=2TU%,F%:Y_+;/C\)Z7618"RX/$JB7%E/,DKQ"Y([),NF)BI-HGJ%$\%^
MN:*OY'..6P)%Y6R_;27ZVUKHB6$=@Q%J)8@+A.%'[AD9,[E3H77Q5.BY(5U7
M`[7D5G4R)-VR#3HS)#$,VV7&.]%9<4&I"@X1*G=%-R>'3(5\]J+N_P"/VE[,
M@C#.D?YDL"="5L_=&LWV[:NM.(:`A`1H6S8NY->J985KM/D/G\_AUK>PD8@5
MDBLL'X,O]E7XK\15[8@/>,G2(!+N;@'87EY8A5G?<YYO1&]4BL:?:3*9N=Q9
M?;DA2IC)(,J,8]WU%M,#314T35?+(K>7R=9SV*J13=ER%R66$2DDJ"*HBW#6
M1))4<=:`R5T5:`=R=17QPE:#Y[\C.K^+CUL(.20:Y+"=&5UHV'2]PXR@(XKP
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M%BV_$@!8UO)'..OR!)SLJ`@I"\S'4NZZXI:#VQ+7S\$P(U3\T\BO*?B+%9`A
ML<DY.W9&@2E<]JA5:D*MAH0GN>,4TU+TIKKK@JQ7Y2Y<]R]Z@A4;;SM.-9_D
M$8"4W1*Q%2?-EW<#?;C)YDB[_P!,%0XOS#R)RWCPG(4/M.\PD<6<,%=W=AII
M'0?'553N>.OEE'.CS;D[]%+L;\(UJV/.FJF(P!28W81MY&@(2:<'40T0D$M4
M5==VN1':TGR5RJ[*XM:VLAO\<K'[2&6]_L20?KD3LJZ3B]M`D%KY)L3157&+
MKB>7?)=SR3XXY]"E,A%DU-776,.=#[S.OO41S05,MR]LA5!<%=IIU3"8^ZT\
MEIR!';%P7'6V6N\B$A$*DVBIN\T54Z]<+4_"F`P&`P&`P&`P(UC70[*"_!FM
MH]$E-DU(9551#`TT(5T5%T5,)%<?#N.G!K(!0@6'3N-/UC.IZ,.,(J-$'77T
M(O37!$&=\8\$GP%@3*=EZ*LMRPV$IZI*>75QT30MPJ?]6BZ+A5Q+K`&C>K*]
MMM@/;%&BM:;6@104`30?`4_3`YKB'QE1U7$X]18PH\J4=<U66CB*XXV\VV.T
M@'NJJ@!+ZMJ:=<)$MGXNX&RT3;=.R(FY'><75S<3D/\`].9$I;B)OR55P1"8
M^.XLCFUUR"W9CS&)Q0CKV]7=S90VU'5T%5&S]2[AZ+HN6D7:<*XREP=P->TE
MDX?=-]-VA.[.WW5;U[?<V=-^W=IYY"(C/QGP=JOEUR4\<X4UL6)+#J&Z)-`2
MF#:=PBVB)+N1!TT7KA5Q24531U[==510B0FM5!EM%TU)=555554E7S55UP(C
M?#>--7!W+5>T%BXXKQ/)KIWE':KNS79W%'IOV[OUP)-+QVFI&GVJN*,5N2\<
MF0(*6AO.KJ;B[E7U$OC@0IW!.(SITN=+K&794XF#ENKNU<**J$R1:*B:@HIH
MOZ)@>EPCBQ2')!5S*O/30M'7%W:E-:':W(7K]XIT1<)&RFX?QNEDG)K(#<9\
MQ)M7!W*J`1JX0#N5=HJ:[E0=$UPKVWXAQRXGQ["R@MR)L4#:C224D<;!S[Q$
MA451"TZX$"3\9<"E0XL.31Q'H\)UQ^,!AN4''5U<+<J[EWK]VJ]?/+1(G<#X
MC/<G.3*J,\=D#3<]2#^Z,=45E"T7^C:FW3Z)BI!>!</_`#7YO\1%_+=OL^]1
MM$<[:!VT35/-`].OCIBJLZBGK:>N9K:R.$2!&';'C-)H`#KKH*?3KD&N'0U,
M,IQQHP-'9N*]8$.NKSBB@*1=?':B)_#`X;D?Q%#?_&QZ2)5M5,`'A;JIC#RM
MMN/F)D\RY'=:<%5VZ$*^E?T7+1TG%^"U-''C$0#)LV8Q0W)Q(:DK!.D[V!WD
MXJ-"1Z`)$NB>>0>P_C?@L*OGUT6BA,P+3_\`"$46A[;J:ZHA"ODBKJB)T1?#
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M*F&W$$T$2V:JNP-=@(I*JH(ZKM'P3RP,9G$^.S+8+:3`:=L`[>U\D775E5)I
M537:2@1*HJJ=/+"1#:^/.$LOV;[5+$!VX`V[,D;1.\#O]P23P]?]6GCEJK>%
M4P(-:W6Q&19@M-]EI@==HAIIM3KKD%0OQ]PY:R'5I5,C`KR(H+`;@[*N:[^V
M0DA"AZ^I-=%\\":QQ>A8GG/9@LMRW(PP3=$=-8K>NQG3[=@Z]$TP*^-\;\)B
MQRC,5##;!1'*\FQ0M%B.EN-C[OL(EUTRU(O&JZ(U!""VT(PP:1@6--11M!V(
M&B^6WIA5''^..$QXIQ6:A@([D-:UQI-VA0U)35A=2^S<JKIBC>/!.(#=1[Q*
MJ.EO%;!EB;L_<$&QV`FOFHCT%5ZID1.NZ&IO('L+6,$N+O!WM.:]#;7<!(J*
MBH0DFJ*BX5`A\"XC">:>B5<>.ZR4@VC;%142F(B2%31?_>(GJRU(CR?C+@<F
M)#B/TD4XT!@HD5I170(YZJ371>H:KKM7IBD2/\#XA^88NOQ,;\K&;%EF9L_<
M$&QV`FOFH#T%5ZHGABD"X'Q-:Z)7?C6AA0%<6&R"F*-][7NH.TD70]R[D\%Q
M2,)GQ[PR83JR:B,XKS#,5ST;=68RH3`)M5-.VJ)M5.J8I&<+@7$(,L)D.JCQ
MY+3KK[;K8J*BZ^"-.FFB^)@FA8I$>1\9\$DQ(D-^EC'&@-N,Q&MJH@-/*JN-
MIHO4"5=5%>FN0C=(^/\`ATALFWZIAQLXK5>0JBHBQ8YHXTST7[`-$5$^N6D5
M/-/CF-;1W3K&83<V5*8E60S6W7&I?MFR;:$R;,'&R#<BB8+Y:=4Q2+#@?$G>
M.5TAAUQO=*=[OM8RO%&9T%`VM>X-USKIJ2JJ:KY)D(F-\+XRW;G<-U[0V+KJ
M2''_`%:*^@[.]LUV=S;TW[=VGGEI$6/\<<'C2;*3'I8K3UN#C=B0M]'0>_NH
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M>?\`:GG>R0"!Q79*@A5R1]G8>N$VB($=?^5]@Z>64C"Q^(^;6(,A.8XG("-$
M2N8$HE@B)$%446%TD^H!5-4W:Z8I&4SXIYW-*04MGBCRRXC5?*4HUE^Y%845
M:9+24FHBH)BD3:O@WRG464JRJO\`%8LZ<#34R0,>R4G0CB@-"6Z02>@4T3%(
M77"/E:ZFP)]JG%9DRK<[U<\3-H"LN:HN\-DA$W=$ZXI&=OQ+Y?MYE?,LDXI)
ME53JOUSI-68JRX2:*8[7TZZ)IUP12K\0<V6+#BK6</\`;5YR'(;:!:HC93/_
M`%&G[^JHY_4*],4B97_&WR17OT[\2)Q-I[C[;C%,:#:JL=I[7N".KRZ[M>N[
M7(1KG_%O/["3/DS(/%'G[-]B7/-?RR*Z_$U1AQ='D_MHO1$P1X[\4\Y>)PG:
M[BA$]8+<.E_\U0EGJ*BK^J/:H2HNBHG1<$8'\0\P.JAU*5?%&X%>^Y+@`VML
M!L//+JX3;HO(X.[S1%TP1)D?&?/9%W%O':[B96L)MMEB2@V8_MLZ=H7!1S:Y
MLT].]%P1K<^*^<';_F5K.*_DO>I9H^)6H(DU$1.^("YL0ET]73KYY2/'?BWG
M;HR1.MXKLF6`V\@!.V$2G@NHOHB.:"NJZZ)TR$>%\6<\6;:S$K.*(]=BX-J*
M';"T]WQ4'25I#[:&0KHI(FN"(P_#O,@B3885'%O;V,5B#.%7[A>['C*BL@:]
MS7TZ)U\?+!'5_'O!^4TG++6ZMF:A@+2+&9>2L*81F[$51;,_<JJ?VRVJJ=>B
M8(^C84P&!\_^;^9W_#>#'>TA,)+:E1V%&2VKK:@^XC:]$(%U'=JG7`D7OR[Q
M#C4N567#\DIM9'CRK`VHKIMBS()&Q?4@0@$-ZZ+UZ82ITWY-XG#Y&SQ]U]PI
MKKL>,KK;1FPW(E@3D=EUT440-T`511?Y^."NBGS8T*!(FR3[<:*V;SY_Z0;%
M3)?Y(F%<)7\HYU+J8%M'JUEM7$"78QFV^V(1S[8G!C.J9(2JX/B2?UKIT'"9
MISGG?(*+AT&?`KC.]=:&=,KWQ%7&HD41>GJ:-J0H0M^@=%7U*F%;.=\PG0@X
MC*I[-B)6<@GA&?EO-@X'MWHSD@'1(R%!7]M$Z].N6)7/5_R/RVP@<??"1'%N
M7R=VA>FM,*K,Z&`N$$N.ADJAO[6WHI#XZ8A725S?RB\]$:FS(S;)A/;E/A%0
M"%4<_P"`]M5PT0E'1#;ZZIUU1<%7'#^7!=<66WEMI&?B'(CV;(ZDC;\)PFGT
M'S4=S:D/GHN0JK_[P<5"'(E2&9T9(R0G#9<C&KJLV1]N*\C8;BVF?3KZD\TP
M5*C_`"=Q]^&;P,3$EA/6J_%$PHS%EH'=V(TJ^':_<W:Z;>JX*B_'O)KJXX-*
MN)"',L&Y-F$=DFT8<,8TEUMAH@%-!+:`BOZX*X?@WRS<<F@F;-]&"\B1I;M_
MQV7#]O)B.ML&0>U15176VWD$2W[E5/%1\,%7W%OF>O'A5#8\B[CUQ.J?S-F$
M%@B"/$$]AR7!U]#:*NG355ZZ)@J^LOE[A=?:-P'7W74)R$R[,9;4X[1V0J<-
M'#3_`.,*:HJ(J)YZ85HF_,_#8=U*J)"3!D0;!BJF/>V-6&I$M-6-SJ>G:YY+
M@6?R3?SZ7@=]<53K8V%9#=E,*8HZ.]I-VTPU3HNFGCA*Y'@?R#=<YBU,>FM8
MJ2H#$63RZ6C0EJ[(:1SVD=E5Z=5T)Q>B::)JNNA5\7R_P]9$V,P;\@XC<TVB
M:;U&25:B++;C$J^LVMW7PUZZ:Z8%!4?-<B>UP76DDC(Y@KSAH(:@TPRVIJ0*
MI>K[@77_`$ZKA*O6?F;A3[<]UEQ\V8,.18@XC723$AN*U(=C=?6C9CHNNFOB
MFJ8*K+/Y=JYT:GDT\J571IMG61TERJYTVI35@*F+3*DH;=Z)HKG7:N"K*)\R
M\/D7;=.(S`D.6CM'WCCD+`SVAWJRKFNFI#U14PK*M^8N*65S7UD)F:]^6D28
MM;-%C_C/G"7;)4'%)/2VOBJIU\M<"#\O\OY'QV?PQFGDA';O;N/53M[0NKV7
MUZD&[[233`ES?F;B$&\DTTAN<C\*PCU4N0D8E8:DS$18^YQ%TVN:]%3^>![.
M^7J%N)?2(<*;/#CXS$DNL-"31.P-.\TA;M1)-W3>B:HBJ.NF$JGJ_E21+G43
MTM'XHSJ"1</T:1-SCQ-;2WLO]SH@IKM!?N147+"I/$OFFKM*CCTFR@2X4[DC
M,R17QQ:W`3<,">+:>Y?%I$TU\5R%9'\RULV=PMJFKY<V'R]7W6I/:T5MB.);
M_2I)ZD-$5?)!U7+%7G'/D[BG(;=:JM>,GR;>>ANF.UJ4U&>6.^<<M5W(VZFB
MZHGU35.N0<US+G/)FODN)Q.KD-U,%BL.YGV<F,C[1-,O"C@$JF.QOM(2;DZ[
M]/++$JZB_+_$WJZ;-4);(0JT;OLNL[77JX]=LED=?4/3P70D^G7(5;<4YO4<
MJ:>=JVI0QVA8<!^3'<8;=;DMHZ!LD:)O':O54\%PKD.%\HYA\@K:W579MTE!
M#FOU]5'2,W(<D+'7:3\@G%U$2+[0#1=//`LWOE"OXZW'K>4F1W,9N$EW(AM*
ML5AV>XK+!*I+KL<<%=-NY13QRP;+/YCXC6W,ZIE!,&16S(D">Z,<B9:=L$_X
MQ$XBZ;#\-?\`PR"3_P!U>)I>2*DC>!(IRF7;!6B]HCT!I'I37=37U-`7JU33
M7HBZX$#_`+W<)&BLKIQ93<6I;BR);9,_O)%GZ>VDH"*JJV>O\4\T3`ZCC_(H
MW((<I^(Q*B`P^<9%EL$P1J*(J.MBXGJ;)"11+SP/A_'?F;F\J!4OC81;6^EW
MSM4YQIM@!==@-.*!RAV+W&U;0=Q$6H8'UF7\I\2B\B<HGGG$?:>]H]*0-8X2
MNPLE(ZGKKW.R*ET'3RUUZ98(T3Y>XM*I`N0:EI#DN1F:W5I%68Y-548"/M(A
M(E45W(2HH?U:8@TROFS@\>K:LD<D/,%&=FR!:94CCQXSZ1GS>35-.T\NTA34
MOHBID$NW^5^,5ETE*;4V58'$8L&FHD5R1OC2749%U%!%](DOJUTT3`I^1?+U
M4]0<@7CKCJ6=?63["MFNQU*(_P#CR5MU6S5=IH+H[5UTU\4U3`N/CSY%@<H8
M;@FCK5[&@0IM@TZR3(D,QI#%UG=KJ!$A:8$>UY1R.5:<CC\=C^[7CC3#*Q!5
ML3DS9(BZ0";JH`]E@A5$7[B+KT3`@<OYCS*FKYDR1`>@5K-I':>LFFPF$S5N
M,[G)(,MJ1*0.^@]PKMUU1%1,"#>\]MJSBM3>M<AA3*N9=L1EN&&0-LJMY%4B
M(45=KP;51=//^GRP.ABVW)9?'KKDB3&V(#\4Y/'8HMMN$TRVRI@\\:*J&3JI
MNV?THNGC@5%7,^4K;C$*T@6$97+&D@RV5.*&B3W#%QT=-XZM.-$HK_H\4U7+
M$KIJ6_F)RRUXU8$+C\9AFQ@O(B"IQ9)&"@2)_4TZVHZ^8J/GD5HD?)_&H]E:
M0'@E@M*2A92ECFD9H^V#C8J]]NKJ.BC:>:Y8/(GREQF4V8LH^5@W.&L*K0!*
M3[HVE?$4025O16A4]V_31%ZX@CO?+O&`J`MACSW8G;DOO*,8A)EF$XC4DW-Z
M@B(VXNW1%555%T1=,0;I'RKQ2/:RJYSW7_!:;D39HQW"BLL/,%(;=<>1-J"0
M"J)_NZ8@YB;\BV!S.8N/2IM-5UE972XBNP6SDQBDFZAN"TJKW4)`'[E]/7PT
MQ!T[WRGQN/<'4.MS5?CSF*N5)]L:1VY,D!)C>[]J"YO1$5//$&]OY*XXY<1Z
MML9+ARY;]?$E`R1QW)45%5]M#'73M[2U4D1.BZ+TQ![R+F!U_)*OCK4)\WK:
M-+?">`B33/MA'Q15ZKN<%5_3$%!\??*L"=QBN/D$AQJS_#_EILYYA8\9YMI4
M&0XR6FU>V1)N1/JFF31U/&N;4O(9$V+#[K4RO[12HL@4!P0?%29<T1211-$7
M3KY:+IA*J*OY/KI35B[(@2XQ1+5RGB1U;W/2GV_)H47Q])*NJZ(*:JN6*\3Y
M3J7K*DAPH4M];>1+BR%[>PH;L$-SS<@"5"$Q73I].O7$$:Y^3H4OC5^5(3\.
MWATTBXKG)<=1%QEM#$'P$_$>X&FA(B_IB#HO\E8K^)PKFR[CBNL1E,6&U<<<
M>D(`B(-@GB3AZ?3^61*K%^5>+HU&)0F+(ERY-<W"",XX^DR&"N.L$+:$F[:.
MH]=%^N%8U/RUPZT>B@PY(9:F1GY<>5)CNL,*,/\`]2WW#1$[C&GK'RRP/^[/
M%`CRWY`S(@Q([<Y0?C.`;L-YQ&ADLBO4V]YHA>:>:8@DVGR9Q:KE3HTPY`.U
M\J)"DH$=US1VP'=&V]L2W"?AJGGTQ!7.?+5.X]3MPH$Z0=G9/U+S:QS;<C/Q
MFB=<%YLM"0M!143_`$]?+$3727_)ZZD]LW(!^1*F*8Q(41HGWW>V.]Q1;#R`
M>JJO3^:ID%5&^3^(RE9]J^Z^DBO>M6"!AU4.-&/8_IJ*?N-FNTF_N1?++"MH
M_(_%SA-30><*,_$C3F'$:/1QN:?;C`/3JZZ7VAXX@BN?)W&GZP7X+SSLIXY,
M<(;<=QV2T]$3]_NL"FX4954W:].J:>*8@J@YER!SX+3F(/-#>+2_D>ZK7[7>
M1ON+^TJIT7Z:X$]KY=X<W!==E2'VW(:Q&Y@G%?`A][H+#R"0(O9</HCB>G]<
M0KJHEO$EV$Z`SO5^N5L92J*H"$Z'<$1)>A+M5%73PR%<GR+Y`?JN?4M*+"%3
M2C]I;3R\&)DL%*`TBZ_U]H]W_F#ZX%=S?G'(:?ELRMC3ZZ#!C41W+93VU7>\
MT_VE94T=;T$D\T35/UP)/%^<WUURNFBNL!"KK3CH7;D-ULDDM/DZ#:M*:DB;
M4WZ]0URBWG_(517\LE4$QIY@(5=^5EV1@21@9W$/4]-/_=EU^O3QQ"K"@Y?3
MWC\F-#5YJ9$1LY$24RY'>%MY%5ISMN(*J!Z+H2?33QR%76%,!@?)?_HB2A6'
M$VN-//28KM@\W)"4Q7R[`12(X)[22*);5(M/N7PPFZ^>\UL:;DL[DDL9-C%_
MR"FB5&W\#:GVCBOH\3NO;35"]2(G\,)<6E)S&NIN:VEY72+$JR\&(Y:P7N/V
M;CH28C2,]R,:"(BC@I_7X987/:^D<%GR.8<`G0;6;(F2WAE0)DY^`[6*2/BN
MWML.H):`VZ@[O-4R1<7?QY^08XG7U5FP3%G4,MP)8JGI,HX(`NMEX$#@HA(J
M?73Q3!F-$O@S-MRF=:WS4:?"6,W$JHZB>]D-2*1O77:O=(AUT\A3+2.9K?BW
ME$6EXM4O64*1'XO:K.C*;3JJ4-`=;;C+J2]6P?44+Z"G3%(Z?F?$K*Z?XZ==
M(CQ6Z.S:LC!ULBWBT!M]L-BB@ZHXO7%(Z*9*;AQ'I+@F8,"KB@T"F9:>0BG5
M27RR$<KP7BUI7\,FQI#JP;BZ?GV#YAH2QGK!PW!0?+<T)#_-,I'(Q_A;DX,O
M(Y;5_=DQJMF0XW%>0G':N;[OO&9/$1F]UWJ7FOTQFD7,KXRY`E[*Y!`M(S-H
METMO7HXP9LHTY"&"['?%#$BW-CN0Q5-%Q2)4&CL.'?'%Q'GS3E2B.?+]U6Q7
M"=`ISQNIV8Z$X9DV3O1-?+`^63KVMM+N!>6E=9K<5L25&;L(G')[+THY,=8X
MG+U5=0!"4M@KU7S1.F,Q%1%;KH=-'@PPO$DN<=+B]G(<X].(#C=U7`?9#7TN
M"A$.A*J+X^6(KWD#4*SD--QSOVZR`M3^(B2..372CC5)HH[Q($7O>)%MW>6N
MF()%TY765E>S`;O64N+RNO`!>/3B[:5P[497U)NWZ)ZO+Z8A5Y>S_C>31\DA
M4/%KVHLN31W8\ZR2EG.ZH^:F9*"JFJ[E5>FG7$13PCAU-YQF^H6K^OMJ:O:J
M[DO\>FDS9L,"``CH(8[500^[JNNGTQ%J3QEZIHSN(@0KQZEL#G.0@+C3_OHZ
MV(D+@>[752`=VJ(@HJ^:Z8A7E5*9A1."-E&OG7N&#(CJ2<>F($F+):1D@TWZ
M@X@#]VNFOEB(T\?;@4_&+;C3<2\=KY429!JWUXP\DN.U-555'GT7<ZC>[HB;
M=?/RQ%6UE<0)O$^&T`P.1-KQ277RRD_@92I(_'#M04#<FS>GZKIB$5C#<-NV
M9GK&Y"0M\I<Y4K:<>E)KW&T;]LB[^FB:^O\`\,BH'#>57M'RN'+D_'\UZ''F
M33:D,P[%'XC$]TC-QB,>Z."FFW<@=<L'7_(W*8?+Y/''F:KD4'_'K-FU$3HI
M+W=-A?2VNA!M1>NN(.=N6XUC:7D](G(6DN+JMNT:7C\HNW^,3:C*KW$W=Q$3
MU=-,0;7TJY=W?6[U9R&-(OJ^=6S/8T,ID7TF*O:?DMJ9-F[''HA"B*7BN(D;
MJV8#-GQ^?.@\@>_"4;]"X+-!*;5T'A04=%5</:H((]%UUZY8ESVH,)LH5/Q"
M(PU?I.XB,UB-)+CDHFW8TYDF%0F^ZB]P!+5"W::^62+$BC6)41N"`W$Y$X]P
MSW;1F5!*V2F)J$)B@H>K9B)=%U5/TRJL/C>W@<*<..E;?SJIDWUK&O\`&W6Y
M;027.Z0.RM2(Q$E71$1/UR1+B3R&\I[_`)B]>2ZGD@U\FCDT$B`E'*[BMRCW
MDZCNO0D7P3;E@I!"$<*6S+B<A=E'QI.)P7PH)0@W%1=2>=!37>X6@]$5$33)
M"/H'&?E*LIN.U=.=!R1\ZV(S$5\::2"'V&T;W(/737;KIKB%QR?'>0N<4=M6
M.*P;Z/36DIR<,&;Q^6\41][^XK!@XVA`J]4`TZ?7$%9SEY[E<I]Q].2(R;$!
MN.T]QU]Q6GX3Z/&Z.PVQ_?5/5Z=4\$Z92/.1#&M[/D<X8G(F/S\^IG]M>/R2
M[/XCP#7N)N[GU\L03JVRCP7>40!@\D<XORAZ7*?KEH9'N&7IP*+R-R%/39JN
MY$V:_KDFBKV$Y\<3^&R8EV;DEB-#CV37&'63&/%<0P[VT]SKF@H.NY$3Z8FH
M^I-?,\`(X`O&>3$Z((._\.^@J2)IKIKX:XFK<?'HU+$CT$-AB-R2/R.IMW[B
MHO&>/R$5KW)(3T<VE<7>V6GANQF:;N+N!9%`Y7:WL6NNQ:N32;)CN\9<>=:L
M$8[2NQWG#)0:(M"4%U7R1?/+-2_BI2JZO\--C1ZV^@2WK*'<0FHW'Y2US$N(
M*B9^T=</I(WKO`204Z:8FGZIG+''.1UX0#8O(L1:Z5#?AL\8?;C>ZE.=SW+3
M3;@H.U$V^O<OGKJN3<TN>UT5/RJ+"YS&Y0]5\A?1FB9HW(HT,H%(F7.ZKR&I
MEM0B7[=/YXFESVJBGG'6<+O.%LM<@<H;!F:S6(YQV4LB,D]24D=<0]'!;4RV
MZ"/ZXT=-\4N,,<[[Z,7"'+IH52BS*B1"8%:QM4[I/N$0IW.N@Z>.1<=]25$J
MFYU?N]DCK>1JQ.:?'J+<IAE([S1_Z=X-@8KX+ZDPJXOJ^ZE##.HFMPGHSZ.O
M`\VKK3[6P@)DT0@5$520MR+T5,&N)_[1R@B",>9%BON\A9Y%*8:CDD1%9%![
M#+6]-J&@ZF2^)*JZ9:G5.@?'-Q4%>5M-9LL<5MF74B4SK)'[)]\%1PF'$-/V
MB,E+M::)Y:8J=73<1I)%%Q:III#P27JV*U$)]L5`31D$!"VJI::HGUR-8J*B
MHE2_D"VY0\T;$<(;5/7@XFTG!:=-Y][;X[2<)!#7QVZ^"I@0K+XR?LHW,(\B
MQ1I.326)<5UIKUQ7(K;0M*2$2B[ZF!)4Z?3+4CF^94_(*FCJ5M)<9R>ED$L[
M*%52%B1ECL&+:JU#-9($Z1]7-VG]/0<4FM4;X_Y'RCCK+`OPZVL;CV$%N,Y#
MDDR[[O0AL6X\EP70?W$XFKV[5%4D\<4B^'XIG2:[D4"QLVU"_KH$'O1F2;-I
MZ`RK:/(A&:$BEH6W^6*34:P^+^7V\7DA6MS!.PY!5Q:SN,1'`;;**X9]U4)T
MU+<CJ].G7%(E6'QE=2W+5S\E'`K&ZK;D/VC5`2O%D2;7U]5<]NFB^6N*DURO
M&SL?\V[D:&RZ\EM*DK62(5C&D1!E.JV_(1U2*#N[/7<*>O7ZDN59KZ1R3BME
M8\BHKJ!*99*J;FL/M/MDXCC4T&T7:HD&TA)E/'5.JY*KDP^%Y;U-45$ZS:*-
M`H)E%(<9:(3(I1M&#[>XE1-BL#Z5UUR:D=;PGCO(*EE\KR7!E2C0&P6NB)#!
M0;U];B;C4G#UZ]=J>28,Q0E\:7C4J5,B6;`2&;YR_I][1Z(LEM6Y,>3H7J$Q
M,D$@T5/'KEHR;^-+=FUKKJ/8L-V@6DRSL]6B)DDG1DBF#*;D45;;`=JEKJO5
M4Q2*B)\0<H;CS1DV\)Z3.HYE))E>W=[KSDEQ3"4Z:N:D7J]0^'^G1,5(["^X
MK=3N#L4,&P"+8,MQ0.1M/LNC'4%<:-`(7$;>$%$MI:Z+D6.>HOBVZK+6!+*;
M!]M#NYERD>/'-D4";%6.K()O)$V$2KK],I&EKX?LCJ*6JF63)1H#=TS--ILQ
M-QNY1Q$5K<2[2:[GGKKBD9V/Q7?W50ZQ<6<5;!BG.FKI,=DQ#0W&G"?>`B\2
M]N";!71.NB]<4CQSXSY=+GSK&?95YRY]A3V!-LL/`V'XE456QU<(E[FG15\,
M4C>GQKR%JS&RC3X:26^1R+UH7&G2#L28BQ#:+0D53$2W(2+I^F*1T'*.,V\N
M]IN0TTAANRJ!D,%'E(?8?CRQ!'!4F]2`A)H2%41?HN15('Q*(UE`S[_9-JY\
MJ;.D-AH,AJQ)PYT5`55V-N]Q$3KT04RU(B.?#CC7$9%-!GM),9LQL:=R2RCT
M=EF.\KD6&XUTWLM@9!I^NJ8I&YOX_P"7QI=9=09-1&N&&I<2?#9BN,UZQYA-
MFJM"!=SN`3`KN+[NJ+ITQ2+&+P"</Q(G!I$QOW:U95A3FP+M[E!01S8JZZ?I
MKBD4ESQN'!K["UYWLD?DJUCC@0ZME^0FS4R14T!7%-QTM1541`T3KYX(Z_@5
M#84W%8,6R?67<&V+MG+<T0W9)"B$I;>G1!0>GTR$<M<?$DBWXK;LS78Z<LLI
M1SF;5LGT:9D`ZA1#0%7_`-PV`"G3R_7*1;L<-N)/.(G([GV$AH*=*V3'$#-?
M<(^CZO-]Q-$'5-$1>N")CG&;4ODECDXNL?C6ZHZTF%W]_<;XO;TZ;-/3II@B
MGYM\;V/(KZPDMS&8]=;4BU$I5$UD-.MO$^RZTB>@AWGZD+R3]<4BUXYQN\#D
M3_)+YR,EDY`9K`9A*XK7;:<-XW"5Q!+<9GT'3TIYKD(ZS"F`P*KD/)(-&Q&.
M2#K[\Z0,2#$CBANO/FBD@"BJ(IZ0)54B1$1,&J5[Y,IV8L-]R%8"4RR2F1A6
M$1UN86F@.(1(B"OD:*H_KE2IK?-J]X[OL19;S-#N27)!L59<,`[AML&I)W#`
M?N3R7IXY-,VK#CM[#OZ.#=0VW6XE@R$B,+XH#G;<3<*D.JZ:IUR[BJZ]YFQ6
M6P54>OEVDY&FY4EF&($3,9UWL(ZJ&0;O7KZ1U+1%7(.A0Q5%T773ITPE:)UE
M!@1'9DUX(\5E-SKSBH("FNG55P57U')XEG<W-4TRZT_2/,LOFX@H#BR&1?`F
MU15U3:7GA5OW!W;?ZO%4\\!N%,`K@HNGGXZ>?3`@V]F]!CMNL0GYYF\TR3,?
M9O`730"=+>0IL;3U%YZ>&!-5P=VW7U)UT\],(J'N3Q6^51..*RZLF7$?FMR$
MV]I!CFVV8+UW;M717PP+=7!1415T4OM15ZKI],#G'^:@G)#I85=)L%BNLLVD
MIA6]D4I(*XTIB1"9#M34U%%VZI@:)OR14PK]BHDP;!MJ1+&N:MUCK[%9AIZ6
M>[KNU5?3NV[=>FN4;:SY#HK&Z"K9%\4D.R8\"<8BD>4]"722VR2$I:M]?N%$
M+1=NNF!/HN40+J3;1XK3[;M-+6%+%X-FKJ-B[J'5=PJ+B:+D'O&.3P.1UAV,
M%MYID)#\0VY`=MQ'(SI,N:CJO3<"Z8$V/:5\AZ4RQ(!QV$2-RQ$D56C44-!/
MZ+M)%P-YOM`R3Y$G:`5,C3JFU$U5>F!R=;\G4TJ?)A3H<ZE=8A.6;9V3*-"]
M"95$<>;42/[-4W"6A)JG3"IG'.=5MXX\PU%DQ9;<5J>U%D`(N/1)&[LO-H)$
MFA*"IM54)%Z*B8$J@Y;577&F.1,]R/7O`XY_R!0#`6C(#WHBEIHH+YX2L^*<
ME@<FH(EY7BZ$.8AJR+X['-`<)M=P]=-5#"K4G6Q34B1$_543`\5P$7JJ=/'K
M@>=T.NI(FB:KJJ)TP"/-JFJ$BHJ:ZHO33ZX#OM(0BI(A']B*J:K_``^N`5YM
M%T4D1>J]53P3Q_Z8HC0KBLG0`L(DEM^"8D020)%;4054)=WAHFU<"KB<TJIE
M_'JHVYYJ77?E8]@)"L<V>Z+*"*Z[MRJ2+X:8%ZKS2$(*:(9Z[05415T\=$7`
M])T!34R04^JJB8$:QLV84&9*T5XH;)ON,-JF]4`5/:B*J:*6G37"-%#?1;BC
MK+9M%9;M8S4N.RXJ(YM>;1Q!T1>JHA==,*G]YM>J$FBKHBZIX_3`\"0R:*H.
M":"NTE$D70OHOZX$>3<5D4HP2)3;13'>Q%0C%%<=T5=@?5=!7`SD6=?'E1XC
M\@&Y4O=[9DB1#<[:;CVCXKM3QR:-HOM%NVF);%VGHJ+H7T7Z+@>]T/\`4FBK
MIXIXKE#O-HA$IH@BNA%JFB?Q7`R0D5-47IXHN!5W_(ZVDI7;>4:G%;5L!1M4
M53<=<%IL!ZZ:D9HGZ8&J'R4$K/>W48Z0DD>U[,LVUW&3B-MJV;9$)BZJIL\_
MTR=1[Q[DT6Z=M&VF'(Y5<]ZN<1U1U,V0`U,$%5]*HZFF47`NMD9`)(I#]PHJ
M:IKUZI@%=;0T!21#5-4'5-51/-$P/$>;75$5%4?N1%35/XX'BOLH.I$B)JB:
MJJ)U7P3`]5UM#0%)$->J"JIJNGT3`=]OKZDZ)JO5/#ZX!7FT5-RHFY=!U5$U
M7]/K@.Z&NG@OT^NF!'A6];.8*1$D-O,"X;"N@2*/<;-0,=?JA"J82H'+>3Q>
M-43]S*8=D1XYM`X#.W?H\Z+2%ZB%-$4]5QA4N)9/.S9\=Z&]&9AD`M2W5;[3
MZ&&Y2:VDI:`OI7<B=<*VC9P"G%7B^!30:1\XR*BN(T1**&H_1231,#>CK:CN
M0D44\214TZ?K@5''>3QKV+/D1H[S7X^9)@.M.[4(G(I;24=I$FTOZ>N!GQ3D
ML7DG'H5W%:<88G-]P&'MJ."B$HZ$@J2>(_7`QY3RF%QVD<MY#3DB.TZRR8Q]
MI$BOO"RB]5%-!(TUP+?N#NVJJ;O'3ST^NF`0Q7`R145-4\,"LNKT:M8PI"E3
MG))$(MQ`$U%`%3(S4B`1'IIX^.!RP_+],=''NPJK/\9+%IR-))D!`Q>D!&3K
MW%VJANHNBZ+IU37";KK;>T<KXP/-0G[`C>:95F*@D8HZ:`3I;B!-C>NX_P!,
M*FHX*JJ>:>*8%.SRR`[RN3QD6)"3XD9N:ZZH(C'9>)0!4/=U52`DTT\L"XWI
MJB>:X$)+ZG5=$F-*JR5A)H:+K)3JK*?[T^F()R&BKHGCA*]UPJH9Y91O<ID\
M7;D;KJ)%;G/Q]/!ETU`5U^NJ=4_5/K@6J&GTP/=R?3`;DTP&[],`I(GCX)@-
MR?3"5J9F177GF6G1-V.J"^V*HI`1#N%"1/#45UP5NPI@,#C?E&OHK"DBQ+N)
M,=A.2@49]<CON8#H@1-R@)E"<':2;=41?'KTPFOFUH'*++B$"!92[&6VURF,
M%9R!F*;$YRO;%$68X`M^DFB,A[A`F[37-8CIN.W=K64UQPB]KG@GU,1YN#:P
MXCOLK!DFE(#!0%1&1U_<#S+PUS.XUBV^+.0Q&.,\3XQ*8E1[?\(R\H/QG6P3
MVZ"RZV1F*"C@%XBO73KEWQ3%!S:GM7^?<DET,)Q+DN+BW73D:,168CSOH;?5
M-B.]HDTZ_3(.=Y)5J_46TCC4"QBTDB%4C*ABU*:=6Q"P;5PFVU1'.X$5"1XQ
MZ+TU55RQ*[KY/XE"'X@M:2FKCD,,`#T6""&^YZ9(O&H(:D9%IN73QR*XR^J%
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M(28%MO55!4\$T7+",?C>&Z',^-RCHK"#/:HYD3D4Z3%=`3L5>8,U<D$FQU3(
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MCC0ZJNG@N!W7QW`DU=;=ZLO1Z9RQ?D4<)P21QN(38*H@T7K`2>[A`"IX+X8'
M)SQF\V#D3?X:V@VEI3S*RJ<G1"BQXK!BJ[3=->KDEW:I;?!$1/)=0N^'1K*;
MS$.0/P)%=$@<?CU1M26U;,Y7=5YX0#Q(6D%!W)T55Z:X$'B/&^62/CCCT*+V
MJV1"EOOSX-JP]HX(R77&A4`-HM$(A/QT7"1+^,["VXYQ+CU/R.$ZW/LY<MEC
MV\<T!G5UQX?<J1$H;^JBOAX857_)==0SOD*O9N*Y^SB.T-@/M([;KRD:/L]O
M4&OZD4EV$OVKYIB)7*77'N7P:"UK9M586=K;<7JHHOQ6U?$ID-QWNHZXBZ"X
M`F'55U+3IKEBKISA\62/.;&566$2=)LFQKY[,4WWDC.-1=YM,&NUYGNM%W@%
M.HZY&9J/!AWT0J.9,XX\C/L[VL<:K(SB-N%)=!R.\48UWQVY""9()]`5=.B+
MEC2EF4W(O\?IH_\`C]B%G7U%$;<L(YR'E.+)%9#0F1;8RLCKN$4WN:_1,07L
M'BSHWL.S_"RDEN<PL">?)AS5*N4PZ*J>O1(YJ0Z^6N6,UU/QE2]CXG"C>J#@
M2FX\F)*AR&$:1QW4Q4M%Z&):IH7GF6G!0N(O3./P(LCCLL$A\)DPO;G&-M$M
M`<;5!04T175,%,%_FF6"T2FNYW((8W<"Y-V0%/*IY\1ME`8*-';22T^^8JY&
M5'D,G!UT,5TZX@Z_GG'&;SF_$&YE>Y-J6TL4L"035D=[(=E'E%4313'IKYY(
M.3XM26_NIQ6=;;AR2##M(\Z6H,C!E#((B:4'&TWRE/T]L574.NNGG8FJ^!QV
MZ<2DK[JKN5;<JJ0*A^"VT/LY,!M/<-/.N"KD5>ZFXBZ(0].OAB(ZECB=Q!Y-
M>US=>4CC0..<BK-I[-\^2R3)1`)--FUU"=1?+<F0<&/'[QV!,8;H;)B--C<=
M,8K<-V.#;L2<ONQ1$)7%-ME?4X:[C1-?#3+%KH'N+N0[=M4X](>J:[F1RX\=
MN+W!&+)@=M7F07_W7N5U)1Z(O7(M=9\AU$I_F7$K&+6E*..-C'28#"/)&>D,
M#[9QQ?Z`1P==W@F!\['C%D]PBUWTEX%][&%"M8[K+8-/R69;9FY'2,(E)/3N
M%W]5]/15UZ8%CS;@<1N7RMJGH)*QVJ&&M)[=E]12<DI]TU85%_O#O!>GJ3_K
M@2+7C3C,_D;$"'.KX#LNKG5YA`=FPW)*174D%)C?<ZT1;1>V^I"T+Q3`ZBSA
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MG2+\<Y'`)#@KX=@UW;U3HJY4JK+C,J)Q9($:ED1["OL;H_9.UAR*Z<CSYDRR
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M[>>[C`N$:'[-E"=7MN%W20FB#H*:]4P+%VK*1PF^DU=5=LG->J4>KID46-'H
MTIM728C-"BJHMC^ZZGI+3STP+1^HMY%X\*P93?+&>2C+B6O;-62IR=1=._\`
MV^TD35LF577?_3KUP($SBG-Z64X5+!-YGB=P<NB!35?>0[?H\QJNJZ1.Z2]?
M]*8'U;CZ1:Q&>-,,OZ0(C3BS";)&'%,B0D%U>BN;A4B'RUP+668MQGG"1500
M)5014B71/(1U55_1,#XT-7:%_P#0Z5]45=,2Q!8;3L#LNC)3M6(&?H1$--&Q
M4M?IE3<:[6DG1!Y+!K:^<$)GE%-,K6FVY"AVE6,4MQI4UW-ZBXKFG377%-7/
M#HUA&^2;`DB/2H4E9SAV4F,]%DQ"5\22.ZX7[,IIS3]@A]0BFGAD,3W;`*OY
M<MK"5%FK`=IH<9N4S#DOM$\T^\X0"30&BJ@N"N#=<M<?E[OF'NK*%>0F)OL)
M/&7(L02-D62_>:=>5%]H9&FYU#T1073],N)NJU.,08E@PK_'9!)`YM*D2S;A
MO&GLY0/]AQM11>XWO,-5'7;YXI6`5-U(BWKDYJ[#E<6!<-3T;BJU%E=]#]L2
M20_OI_;[`@NX?X:X*^K\+A5W'N%1I+;,D-\5N;/!SOO2#?5D5=U!Q3<WJH_:
MGGY9%Q\^D5O):ESCGR(ZS[F6]/<<M84:*\4U(-MH)LN)J1*D-`:738GV+_,:
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M[PGJ.NJ?3!FOHV&C`8!53)1B!@?451?)51=>J>*91EID&KVL?W/NNV/N-G:[
MNGJV:[MNOTURHV:84T3`]1$TP&B8#1-.F!5EQVM7D2<AV'^4&*L%'.X>SL*?
M<4>WKL^_KKIKA%GHFF!@+K)&H"2*8HBD*+U1%\-4PM9[4^F![M3Z8!43`P)Y
MD"$2)!(UT`55$4E1-=$1?'`ST3_K@-$P"Z>>!K;>8=(T;,3)M=CB"J+M+37:
M6G@O7`V:)@-$P-$F9"B@A2GFV`(D`2=(012+H@HI*G5<`W,A.R'([;S9R&=.
MZR)"IAN\-PHNHZ_K@;_+`UFPP;@.DV).-:]HU1%4=R:+M7RUP*Q^GI%Y#%NW
MA1+AMAR'%=5PA5635''`%O=M+511?MUZ94BVVC],BO=$^F!K=?CLJ".N"VKI
M;6T)412+QVCKXK^F!X;\=HP`R$#=54;%51%)4354%%\>F`8?C2`[C!BZVJJB
M&"H0ZBNBIJG3HN!LVC],#!Y^.RB$\8MH1(`J:H.I$N@HFOFOE@9Z(OE@$1,#
MW1/I@>:)KX8#3],!HGBJ8&M'XZNJRABKPHA$VBIN05\%4?'1<#UMZ.Z;@-F)
MFVNUT45%455-="1/#I@9Z)],`@HGE@>Z)@8//,,-JX\8MMIIJ9J@BFJZ)U7`
MST3`*B+XX'FU/I@@B#KT3K@"%"%15$5%3147P5%P.>H_C_BE'*&36PE8-O7L
M-J\\XTRA=%[+3ADVUKK_`$"F7NTCH=J?3(1@KT<7D84Q1XD4Q:U3<HHNBD@^
M.B8&S1,#Q4'S3!&#;L=PC%LQ,FUVN"BHJBJIKH2)X8(V:)@-$P/-J?3`]T3Z
M8(:)@-$^F`T3`:)@>=/#!1=/%<#4$J(2MH#H+W%5&M"1=RC]R#UZZ>>F!N54
MP&B8&"N,HYV]R=S3=LU3=M\-=/'3`(ZR3BMH2*X*:J&OJ1%\%TP,M$3`Q;-I
MP54%0DUZJBZIJG1<(RT3Z84T3Z>&![HFNNG7`\U'7]<#FB^.^-K:OV.R2*RG
MEDRH0RY`PW7UTU<<C(?:(ET37TZ+YY:1TJ)YKXY`71.N!X!MDGH5"1%5.BZZ
M*GBG3`]T3`:)@>Z)@,!@,#G.8<EE53M/7P`;*SO)J0HAR$)66]K1O..&@J)%
MH#2Z"BIJOGD@^=_'M[R")%3C-6,)NYG6-_+-U]'2B@$2;L4&P0D-=YNIXEZ4
MU\<";&^6N66[+1T-(+TN+%C2K2$:HJ$3S[K+C;3ZFV(""1S,7"%47HF5*Z/C
MW-K2?S>PX_8`S!6-WBC0GFW@D/1P(4:DL/+JR^V:*N]!Z@NB+B%5?.?D+EE+
M;WK%;%A.0:*NAVCIR%=[KH/O.-N-"@Z"B[6E42_\,0K99?(UVR[96D6/'<H*
M:WCTTZ.2'[PU>5D#?;)%V)L.2.@**[D1>J=,0JU^,K7D-E464FZE-2G&[6?'
MCDTVK>UJ/)-H1ZD6J(@=,+7(2_ESE48;5P8\*2#-1/M8+C0/^WWP)`M=I'R5
M.^A`7J,!1$+HFJ89W6=M\E?(-:-X;K%48T;5;/=VC(17(\]=I,#J70P455'%
MZ>'IPMZ+9OGW+IUM*=K*YMRBAS9M=)==VBK90VRT?4^ZA%N>';VD;UVKJBY8
MFZIH7R_RF-5#:742$;4SCS-W"9B]T%!YU]N.C3IN*2*!$\);D1-J:^/CB%7'
M!&K1OY/YG^4..[-]G4*X[%;-ILM6WOZ3)Q=4\-=?#3(N%S\B7\<KJUA-1G*3
MCEFQ66$,Q-9;R.=I'GFS0MH*"R$V"HKN1%ZIJF%6W!;_`)A>3[=VQ]@W4P)T
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MN*AOD<JOK(\5B-R"5'L[&+%<DJ#81&W`E2&&S%QS4B$73#[1ZZ9(58I\A<LG
MVCK=%#CSX=6]7M63B$VVT\W,9!YV0TZXZ)``@ZBM^@MVBI@KH.=\BMZKV#%6
M\P$F8LC1IQLY$ASL,JX@L,BK:*F[3N&9H@C^JX5Q,21.YUR7BS]D$18%IQAV
M<]5R(ZR&1>==80U3<8]=53:OBB?]<)53PNQNH-10!5Q(\GE]Q`L)"6:L`CA,
MQ9/2.:N/M]S>ZXBJ6[41\L+7;5/+>8W4Q]MC\?6N4[E>U=09!*[N*6T#TA6W
MVRVH@(YM:714,D773`L/BRPO[#C3\NYG#-DG83VFG!:1K:#,IQH1T0BU3T=,
M#@(4KE-HO"YLN<Q+N3Y#<L1)CK"B++;;4MG10$_5HC::#J/T_7`L8WR;SVVK
MX,:GA1W;X8$B=+'1L6'SCS'(?;'OO,JVV:L*1&BDHZITQ$KN.5<KF5'&H4]I
MIL)UC(A0F4,NXRR[.=!O>9`J;@;WKX+ZNGUPK@>47'(IEU64DWVK]U0\G@!$
MLU:(&'6YD%YT")I"(A-M-4(1/KT7IK@2&;RUN[WB/YEIC\M3<EL:N1(C"0LN
MJS`?7NM(:D0H0D.X=>A(N!Y3<WN8W&*D*^'#K$E_FW7'8\8RC(_`DN"VR+(%
MN0I"ZF1:]5UTZKB)4FV^1^8U[$"0^W%22#=2=M5-LND3)63Z-.B\Z1HC&Q#_
M`&T]1$J*JIIEA6D+V^<AS';4XMLVWS5NMC-28_1ED9`-`36A=##5"%?)?XY%
M6,+Y"Y%("FN`2.=/?SIE8S"1LN_%-A'^RZ9[O7K[5>Z.B::]/#$*A47R'SZ7
M#B.'&AS9MKQP[J!#C`;:C):=;;5K<XYH:&CR**=.J::^>(E=CP?DYW="_.=D
M>X=C/O-/MK'.)(95I$567XYJ2@Z.O71=%Z*F%<Q7\YYE/8HY44H;C?+H4QZI
M9[9:PY++*OL"Z6_]T"%-KG0="_3`A57RS=V<BNCQ^P!758V,`C;+0+QIP0FQ
M#]?7L@6_;TZ(O7+$K>7R=R=MBPY$,!M[C%>MHU+;(F@>`JU#1M1T<)PC=-I=
MP*VFT51?+$*W\/\`RSGRI-EVCT>0_+XW`?1R*VK0:')?79U(]Z#X"7FF157.
MN[[CG)N;756,0J^-:U?Y2(Z!J^^$B.PR?9,201,=Z$FHKN7I@='4<PY%(Y#-
MXO,*.%Y"LD)4%M4$Z4P[K<@14U7<7]I5\$/`V\XY9R>'=QZ#C<8'K-Z"_8@3
MJ-J!]DQ;%K]QUC1%(_62*JBGE@JID?(O)F.00`((SD%^<Q7SHD8">2.3T)9)
M(4O<(D\)CT``)-FBJJ*N$JGYI=\BO?BB;<3'*]^JM:Z/.AQ`0Q?8?]VT0@J[
MB1P!$D0RZ*A8BUWW#[Z[F7/)*BX)AU^EE,@S(C`38DU)CA($5`R-=P;U'77K
M@KF7.><W:MGI!)`.CB<D&@?CBVZDDVG^V(/":FH(39/)J.WJFOAA*JIWRQRZ
M)%MGF_93$9I95Q!D`TX,97(LL6.VV2FAO-J!_?M'JG35,L*LG++Y03ETFO;L
MX+LP*!RPA0PC&,4GRDJ#0FI.[]=HH*EK_+(M='P7F,GE;+-@QL&O&&T,UM15
M'6[)57OL*NJZ=G;H0Z>*X*J)_P`@7\:=<,",=0KN15E2UJ!:E%G!'(]?5_<'
MOKHOAT\,"!`^1^6A9P7[%(CE3)M;FJ<CQVG$>0:T'W6GD,C)-52-M4=OGKKE
MB513.7VL6ZJ>=V'MI7>XM.GPHL<=G:%Z1$46C>4E0Q!'$W%Z?/(5T4[E_P`D
MP&H\9]F$+\RWA0(,UX1)'(\UHU,S9CO.[%;<;]*[_6F6%6GR;8\JJ>`L2(L]
MN-<))KF)<QEG<!=^2VR]VP,M10M_U5=.GZY%<P%Q>\>Y9RB9"]JL0^0U$6R;
M)LT<>][&CQS,"0M&U$C0TZ%KX8B5T'$^:\OO+F/+]DT/&)CTV*ID3(.L.1'#
M;;TT>-QTG.T6\%:';A:P^3>=<AXZZZM2Y'<]C`6Q>@JT;SSB"Z@+W2W-@PSM
M^T]5)2\!Z8'D[F_,%Y6=9`CM;6[2-`]DXPZX10GF$><G]X"$40-53;IITZ]5
M3"57L?(7-UC]^0D)0GW,BAK0CM%W`<8>>3O.*\ZVV6YMG00W)ZO/RQ"MCG.O
MDD^W2MUD=OE#4.3.-K<R;;PLR.RP*HL@$:[B>IS0S4-<L*TVGR3SF/(MG66:
M\(]3/J(IQ#1PS,+1MK>G>`MO[3CW0D%4)$Q"I"?(G*VYSG'G@COW*W+]8S,8
M:VM]IJ$$U"[+KHHKFCFS3N=?')"HEA\A_)+#<IER+6P9]=QYR[FLGOD)WH\A
MQHV1)IS:@N`UKXJH*OGB%2`YAS4[;EDN%K/CPHM0[7U+;*$XV,UM7'R;]8]X
MP#<2!_5HB=,J.WX5?)?<>8L?=LS5<-T">9;<835MPAV.,N^MMP=-#%?`LC6/
MF?#ISL&#PV/%KHLIQR7R-(RO"J.M.,'(,$9<UVMHYMV'JGA@27>>\NL:J$+4
MYNOMDO:N#907(3C,F.$HOW&70<-4(2)/0XV6AA@JQ#Y)Y0IS+@:X7>,5[]E'
MG+^VVXV-:![7`)72,S==:5.WVN@KKKTQ$K#B<BXF_*$&SMCBN.V/%DDL^U;(
M$`')8'VR(C/N;4-$0NFOTPJ)RR=R*H^1^26W'VX*R(7&XLR8,Y'-'6X[\@E;
M%6R%!(A%4WEKI],"QA?(W*KBX$Z:J1RGBRX<6P%Y6@(6Y4=I]QWND\!"3??%
M!#M+OT\>N6)53P.ZMHS;?%Z)8L69-L.134?DMFXT+46Q)L6Q;`F]5(W4U]7I
M%,0S4D/E;E#L:O?]K%8_-5<PJIHA-Q3NH#O:.)N0PW@]HJM:(A?],&ZZSX^Y
M?-Y5"&S1&D@+&CB8@)(X$_:JRVEU)4T:+0---477KD,==A7Q?D-Y.XSSCG][
M6,,/3(T6A%MN0I]K24^;+JZ`NJ*NJ+JGTP.^X7R"\L+'D%7<C'672S08!Z*)
M@VXT^P#[>HFIJA"CFU>O7`H7/D2^5]RU:9CEQYB]_P`?D1=#28B]X8ON4/=L
M_O$G[>W[.NNN!"J?D3FLJ'"<EMUK+MW:O4U3VT>)&W(KLA'GGT(AW(K<;T`*
MHN[Q7*51\3Y/R6HBRN/U45M^]FVU_+]#>YG2)*$=@-F\R2=PW4Z[EVIY+E2N
MTXSRSF]SRQ^O?AP8%?7QH+]BR1N.R1.;',R:;,%5E>VZ&F[P5,FXM0.7\ZO^
M.\SN#)YIZBJ^/A9#7]M1,Y#DDV14GMWI3<*:KMZ#Y9!?\=Y#R!>4S.-WHQG)
M#<)FRB380F#9-.F31MF!D:H0.!T77U"O@F!UN`P&!5<BXS3\AA-Q+-DG`8="
M1'=:<-EYIYO[7&G6U$P)-5ZHN!2M?%G#V(C$:+'D1EC27YD>4U+D#)!Z7TD*
M+^_N;7?ZAUT7^.*C*7\6\(E2*Z0=;VW*MD8T9&77615@"WBT\+9BCP(?JVN:
M]=?KEI$^NX50P+?\JRTZ4L5?)A7GW709642$_P!D#(A;[A"FJ"F*1KM^`\8M
MY%H_/BFZY<Q6H-BJ/.@CD=DE,`T$D0=")>HZ+UPL>%P'C!6Q6BQ2]P9L//!W
M7.RZ]&1!9>=9W=LW`1$T-4UZ)]$Q4B92\7IJ1R>=:P3*V4@Y<L5<,Q5UQ=34
M1,B$$)5550=$UR$<^GPU\>(V37XUSMDS(B[/=2=$CRBWNLBG<T%M2ZH*=$\L
MN:18S?CGB<T+`),0W!M68T:>G>=3N-0EU8'H73;]4\?/%-QXOQMPS\[)O$KM
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MZ9"+RMXW25EC.L8,9&)=DC*3#$C432.';:1`55`=@>E-J)TRK&N%Q'C4$H!0
MZUEA:OO_`([8.G9]VNK^S_[8OCA(AO\`QYQ-YQ]U8A@]*DNS'W6I#[9$\^VC
M3I*H&G0VQ05'P_3%(\/XWX.=K#M5IV$GP&VF8SH[A1&X_P#9$@%4`^W_`$;D
M73RR+$Z]XEQV^<B.6T(93D$C**:D8J'=':XFH$.HF/0A7HOG@1:O@'$:I^&_
M75Z1G:^*<"$0.._MQ7"WDT**:IHI=<I$61\6<!DTT*F?IVW*ZN,W8#2F[N9)
MQ55S8XA]Q$/7U)NT7%2)#_QUPE^WAW#E.PMC`!IJ*^B*.T&/[**`J@%V_P"C
M<B[?+(+&EXW24GN_Q448J3GSE2D!25"><7<9:$JH.Y5UT'1-<*@1?C[AT68U
M,CUH-2&)CMBR8F[H$I\5%UP1W;4WH2ZIIIU7I@1)7Q3\>RHL*+(I67&:XW7(
M:*3FH*^:N.CNW;E!PUU(%7:OTRTB^M*2IM:MVJL(K<BO>%`<C$F@;15%'333
M;M5$453P\L@K3X#Q,ZY*\X.]D9`34=)UY9'N6TV@][A3[W<$?2A;]=.GA@;A
MX;QH?QNV``K4/')KU0C16WW4(7'55"]9FAEN4]==<J.1Y+\6HZ[6M4<&"57!
M&1M@R7YL8VWI3J.N/-R(Q*XNXON`NGGBD647XEXD[`9;NX:6DY&6V9$IUQ]5
M-&7%=915)Q2+LD6C9&JDB>>*1;.<`X@X[(=*M#N2YC5E(5"<1"F,?VWM$+1"
M'37IX^>*1L8X5QB/.?G,P`"1)-UQU4(]G<?':\X#>[8!N)T(A1%7`CC\<\*&
M-'C#5-HQ%AE6QP0G$V1#,7":%=VNF\!7Z],4BVJ:.KJ6'&:]CL@\XKSY*1&;
MCI(B*9F:D9%H*)JJY%0ZKAO&:F84RN@-QWU5Q145)1#O%O=[0$JBWO+J6Q$U
MPC>QQCC[!L.,U[#9Q9#TR.0@B*$B3N[SHZ?U.;RW+^N*1#:X!PUJZEW;=1'2
MSG"8RW]JKW$<'8XI`J[-3'H2[=53QRU8\X]P'B''9)2J:L;AR"92*KHD9%V!
M)2%I-Y%H`JO1/+(-K_"^,/W!W#M>!V#A-..NJI;3<831DS;U[9&W_21#JF$1
MN.4-RU:S;KD!PW[5X?:13A-FV+<$'"<;`B<4B(U(M2\OI@Q)Y)PKBO)4C?G:
MUJ<4,E.*;FY#;4DT)!(5$MI:>H==%\\*C/\`QQPEZT_*.5+2SD?9E(ZBF*(_
M'%`:<$!)`0A%$'5$ZIT7"1I:^+>`-,V#+5)';9M%UG-CO031'$=VHB%Z![B;
ME$-$5<M%W`HJJ!.G3XD=&I=D39SGD4E5TF@[8*6JK]H)I@<UQOX_CPKJXMK9
MEB1)EV[MG7$!ND+8FT#0$;9Z-]T4!?4B=->BXI&T?B;XY%LVQHV4`V78Q#N=
MT[#Y]QQI/7T`BZ[4Z)Y8I$V\XNTX06U/&BCR>#&6+4S)G=)H`)4U!Q&R$B#_
M`,=<"9QFC&GJQCEVSE/..2I[S0=L')+YJX\X@)KHBDO3],")8?'_``VQM'+2
M;5M/3WG&'G'B4TW.Q516'%%"0=X:)H6FNG3PR*V,\'XHPY'=:KP$XDMZPCKN
M<7;*DHJ/.]2\30RUU^N*D1(7QCP*&\;T:E8`C:?CJ*[S!&)*ZO-"V1*`MFOB
M*)I@90/C3@U?!8@PZEMF+&E-SV0$G-1DLIHVYN4E)=B+H**NB>28JQ;WE%4W
MM6_5VT89<"2B(\P:JB+M)"%=15%14)$5%1<"M<^/^'NA)`ZT5&8_'E2?6[ZW
MH:(D<U]7BWL33^&6D95_`^(UU]*OX-6S'MYBD4B4&Y%(G/O-!UV"1Z>HA1%7
MSR(QY%P#B'(I*R;FL;F/E'*&9$1CNCFNY6S0"%"1"ZIKX+U3!KC7?BJU/D4B
M6S[.-'=D`ZQ91I-A'F-,MH`@VL=MQ([AB+:#O)>O]2+EI'9/_'W#I%+*I'ZM
MMVKFR#F2(QJ9(LEP^X3PDI;@/?UU%4ZX6(T[XMX!.@5\&53,N1JM36"FYP3#
MN+JXG<$D,D<7[T(EW>>N2I$F5\?\/E)-1ZM`AL'HTF8*&X*&[#T2.6@DB#V]
MJ:(FB=,M6-=G\;\)LVIS<^J;?&RE!/EJ1N(2RFP0`>$D)";-`3;J"ITP1L+X
M^X<3;C?XQM`=KUJ'!$G!0H)$I*RNA>"D2JJ^/ZXI&M_XWX6^^LARM1'U9CQN
M\#KP'VX:ZQ_4)HNYO3TE]WZY*1<5--65,/V=>PC#&\W"%%(B)QPE(S(R52(B
M)=5)5UP*EGX\X<RS$8;K11J"4HX@=QU4`IR$,E4U/_WB&6NOURI&!?''##KW
MJ]RN[L>0<=QU7'GS=4HG_I_WB-74[7].A=,$9L?'?"F+U^]:J61M)*$C[VIJ
M)J8=LB5I2[>\@]*EMU5//(1Y0?'/#./SQL*BM2++!DHS;O=>/8P9;U:!#,A$
M-R=!1-$\L*WW'".+W%A^0L82/2B92,Z:..`CK"%O1IX`(1=!"77::*F*1K?^
M/^'/\C;Y(Y6-K<MH"))0C%%5E-K1&V)(V9-IT%2%53RQ2-1_'/$%CM,A"-KL
MR7YK#S3[[;S;\I=T@@=$T<%'57UBB[5^F*D6(\7X\+%9'2O91FF<1VK;V]&'
M!`FT)OZ+M,D_G@C6O#^.?CPKPA"S#;F?D199(VD]UWE?5Q=BBJZN*I*G@N*L
M7.!S5G\=\2LYEC+FPR=?MA8"P+O/"CHQ30V$41-!3MDFJ:)BLQ9UW'ZFOL+&
MPB,J$NU,'9[BF9=PV@1L%T)50=`33THF*N8A?X-QG\R=ND14E.OC+<!''$8*
M4V.T)!,;NTKJ)_7MUPNM!_'7$3HOP90B_'I**>V/>=1UN4;BNJ\T\A=QL]Y*
MNHDGCE3$23\1\!D0&X3E:2-,RG9S3@2)`/#(D:(\8OBXCJ=W3UINT7SQ2+JI
MXM1U-A)GU\;V\B6TQ'?VF:@K445!D4;55`=@JJ=$R4C5;<+XU;6GY.PA)(E^
MT<KW%(C0'(KJJI-.MH2`X.JJJ;D73RPK90<4I:+>L!MSNN`#1/R'G9#O::U1
MMM''B,D`-5T'73"+C"F`P.7^2.52.,<5?LXS1.R5=8CL[6R=02D/"UO(1_T[
M]4^JZ)@0:+F\:+*;I+FR<FV+LLXK,XH1Q&NZ3?N&XKB_VT?%GJNFB?P7`PN?
MDRA<HKAV#8.U[L."LYFR=A.O->WW]M)+0*@H^"%]%_7PQ"JRQYU:1K+ED>1:
M!"@U;5,Y!G)$5]6UGJJ.;VT74D<(=$5?MU_3$9W5U&^3JIR7;QG(<QLZJQ&I
M;1&",I,DFA<T90=?(M>J^'7$7-:HGRSQ^9;U\.*V^<&?7R;,K(VR!EEN([VG
M1<W=1("0M^OA_/$6KCCO-:._E2X<%PQF0A:=?C/`K;G:D(I,NBB^('HNBX'(
M77RG**1I`CR(+-9R6+2V)/Q^XLEIT44T91-5154TTTZZ:?7"5T"?*'%BJF[$
M#?+N.R6/9=DDE"Y"U]R),EM(>UIZOY?7$6I\KG''8_#UY>LE7*!(XS/=-`3B
MJR6FA(`HI>?7ITP*R/\`*W%I#<OLI,*7$>CQU@%$>"2X4S7VY-M&(J3;B(JH
M?V]%UTP-]5\E<:M)M5#C&^C]PDKV:.,&`]R`2A):,E](N-J*ZCK^J8$&;\Q<
M0A"9/I.T9BI8/*,-XD"(KI,^X)1%41M"!=5U\.N!+;^3^+N-V!;Y#;E><=LF
M'6#:<>]YK[8F!<0=XO;5VK^G73"5%3YAXB;,<F/>27Y*2]D6/%<>>$Z]422T
M8AN03;W)Y^'5%PJ33?(]=<<FC4]?$D/19E6S;Q[/9HR3,@MK:=?4G@NNOGTP
M)7(N?45#(>8E^X=6(P,NP.,R3PQ8Y$HBZ^H_:*[27IJNB*NFB8%%,Y+?7'/G
M./T\MVOAPX<.P"<$9N0Q(1]QS>+A&O\`;)MO:"CHNY=?+`T?('R185P<KJJM
MAZ)845.%JU:.-@XPJF1H@H*KUZ-*G7S_`(8%U$^3>..1IRO$_'D5QQ6GV)#)
M,N.'-3_CJT)Z;A>5%VK^BZZ8A5KQOEM/R*L>L*YPE:C/.QI0&.UQIYA='&S%
M-R:I^BJBX'/N?,7$V8<R7(":PW"BLV!@Y&)'3B2'>RV\#:*I:*?D2(2?3`S+
MY:XX$QR(]'L&'(\UBOF$[$,18<E[4C$Z2KZ0>4TVE_UTP)H_(U"5JS`09"#)
MDO0(DY6O^*]+CHJN1P<U^_T$B:HB$J*B+K@1V_E7BYP8DX5DJQ.KI=M&_87<
ML>"J(^FU%UWCN^WSP*ZS^9J:-1V5E%KY[[L"-$FA%=91@GHTX^VR^WO)-6]W
M0O/],#H8/-8,RY*I9BRR?9(6I;O:%6H[Q,H^C3Q"9*!;"3KIMUZ:ZX%=RCFL
MR'=O<;AQ)`2W*B59,VPBV;+1,^D=1)>NA+UU'Z)YX%?Q?Y5@2*",5BU-*T:J
MX=@^B1"0I:2=K7<C`/W(KY;5Z)IX_;UP)#ORO`-^K8@UTR0[.MG:66WM;$XL
MAADGS0TWJ)>E$5-JJFGG@=7?V[-/3RK)Y-1CAJ()XF9*@M@GZF9(*8'$TW-.
M2S?C&\G32:B<PX^$Z/9`V(N-!+AB3@J(KT('`V$GZ+@4]7\B<JDQYS3$]FQ0
M.,)=K8ML"B0YW;0TC.;55LT<15)!^Y$3K@=[1\@[?`Z[D%W)%-:UF=82=J`*
M*;*.&J`.OUZ(F!72/E*@B1Y;D]B;#<A)&<D1GF-'48F.=IF1H)$BM;^A+KZ?
M-$P)S?/*5RPFUXH\LNOG-5LIO8GI=?:[P&G7^WV_4I?3`K`^7^'DKW[SB(##
M<N.JH"I(8=>&.#C2H2IHKABGKVKHJ+X8A70_GT7CTFX]E)!8S;SA0G0%M]58
MW:BB*6WU;?2N[14ZX%!$^4*]RCK[%^!,21+KAMY$%AL77&(A(G[IZ$FHZKZ4
M'U+HN@],"QY5?V;?!IEYQ9K\E+**,FM!L>YW1-$)#`-1WKL7<(Z]?#`X:9S^
MT/X\Y#R7C_)F;)J"TP<1QV,V$F,\A[9#,QC0-%T)%3TBJ?K@=?Q:XM.1RCMX
M5D!<8%I8L-`!LG9,ALE%V42Z?M"A)M%OQ\UT\,!\57MS>\,CVEQ(&1->?E-D
M8-BT*"Q)<9%$$?T;ZX%9\C\SG<>N:EN3/*CXY+;>23>I&&2VW,0@1AI]20A9
M;)%)=RIU7IJF!7<B^0K;C5MQ!;>UC%7V4*25@L=L%;DR6D:1CV[JJJ`+Q/>:
MZ)]<"?RFUYU0?'LFVD63/YM),<T1M@#999DR6VNPFNG<V`Y_<\U\L#K.2<E@
M<<KV)MBCI1G)#$0GF@WH!R#1H#<ZIM#>2(I>6!!B<\J)DZ3!8;D'*B62U$AK
MMIJ+Z,^X4ON_M]OKNP.5I^8VTVSX>U$M'I5=<Q;@I+LF,TP\;L,T1HE`?L5M
M54=$\?%<#I?C^[L+7X[JK:R>5Z>_$5R0^("BD8[D4D`40=>GA@4-=\MT4+CT
M)Z0=E;G^*&W>FA#$3*(KBMD\X`*(`H*FI"GE@=`?R%1C)M(NCZOU4>-+<%&T
M_?9F=&"C]?W-Q>G_`,W3`\9^0Z-VTC0.W(%F;)=@1+$VT2*[+8W=Q@7-VN[4
M"1-1T515$7`K*?Y#@M4$=]3GW<M\I[PM!%;"5V(<@FW2)D2$4%HM`'KN+IT5
M<%3)7RGQ6+/BQ'77$62Y%85U1$49>F@AL-O`1"Z)$))KZ/3KZM,"_P"07#5/
M42;!Q-ZLA^TTGBXZ:H#3:?J9D@X'&4?,^1S_`(SNILPFXO+J`)T:S1H1-H)L
M(2)"$5Z*VX.TD_1<"BH/D+E4YLF6;%NT![C:W#]@S'`?Q\Y&P,6#T_:,7-R[
M17U)MZX'><+N[.=\?T]Y/W39\NN9FOBR`@IN.M(XH-AJ(IXZ)UP./X7\@VKU
M7`NK,K&PDW<0I;7'V(L=39%DD5Q]DA,%[*(X((ADI$7A@=)&^4N.3;2OKJYN
M9/<LXS$Z.]&C$;0QI#BM(ZX>J;!`Q5#UZI@9\GYE*@<AB\;CPGU?L*^;,;LQ
M1LFF5C(*)J)+ZM"<15Z?3^04_"?E6NE<9@O7KC\><W2,V\R:^SVF7VU$1><9
M5/':X2(J:)XIITP.FXOS:HY&]/C0^XW-K#;";%=0-X(\.]HM6R<!1,?H7Z+@
M07?DRA9LS@/,S&CVS3CNFQM!_P#'#NDHRBKO7:GVJHHA>2K@5R_-'&?;N2$A
M6A-C7MVX(D,MQP#^Z0**OVM?UZZ+]$7`LK+Y-XY`4C/W#\..W'>L)S#6]B(W
M+3<R;ZZH2(0KN7:*[4ZKHF!M3Y#H%-0_?U2W2@)>UT280H8Z]?[9(2:'@5\#
MY:X]8/M,Q(T\UD)-&*9Q^VVZ]7;O<,`9DB=Q.VJIKT7ZX2O*+Y6KK.LIY)5T
MT)EM%&>,!IL77&HQN(TCI():J&XOZ45=.JII@S727W(H5(PPY)%QUV4\,:'%
M8%#>?>-%5`;%5%/M%5555$1$U7"J:#\F\?FRX$-IN4,NP.7';8-G83<F`.]^
M,]JN@.H/44\"3JBZ8&$7Y3XO*IXUPV;PUTJ([-&0;>B`#+R1U!SKZ3-U=H#Y
MKEB;KR)\I\;F,&D9)+M@,M8"U3;8G*]PC?>5-H$0**->M2WZ:?KTQ$K+XXY-
M86_!&+NT<)^0IS%=-&4:<4(\EUL4[(^!(#:(J?7(N:@1?FWA,F(4L5FMQ_Q[
MELPX]$=;21$9T[QL;D3N*WN]0IUQ"K"V^4.+51R@F'(18@P3=1M@S]-D:MQE
M':BZ[C%17Z+EA6Z#\@U4V<$-B)/[ZHWWP.*8+')X"<;"0):$V1`"JFJ:>'7K
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M5=&U:@PYDH7F38%P)3>J/,[D3<V1B2=/IA75X#`8'-?(?';7D/&3JZMQAF2<
MB,]W)6]6T&.^#ZI^WZM5[>F,\4URES\:<KM.5#;2)T)V(U9MS6.\+Y2&XBQB
MCNQ&U14;!/W"(21-27[LM2,A^/N>N<#L^(3;>`_$_&E54[H1W`-6UT`'9:J1
M>L&T0=K::*O7"O;SXRY!8_Y,K4R(VM]'J6&E,75[:UI;G%+3QW]=NGAYX'MC
M\=<P*?;N5UE#&#9W#%P<1YM_]T18!AZ,^39#JW^T)CIX^!=,"NK/AJ_8AQ*^
M390RAI`MZF;V6'`+VUF^LALV$4E$3`NBH7ITQ4CKN!\6OJ1AQ+EVN>D=MMAL
MZR)[1#!I%1''E52(G"^B>E/+#6*9_P"-N0%;3'VI\7\>_P`BB\B:;-ISO(K`
M`#K*DA;>O;3:NG\<,X@R/B7D(R/R4.?7E9MVME.;:FQ3D1#BVB@ILN-J0DA@
MK0J)BOZ8JQ:?)M;)B?#%Y7IH_*"N)I.PSL$W%T3]MAI%VCN7H*>6!#F_'W)[
M@'[=;.(Q9S1KF^R#3WM7(,(B=*._ZP=+OFZJEU3HB#UZX%),X/(A4\#A1ONE
M>.6SUO26E5#<98A-.R"-_N.$IM@G:=<#;NZHJ:(N*.GY+\9S[.3>)!F,1(5G
M0!0Q6";,E9V&2HZJH2;AVN*FU/\`KBF(5Y\3W-G,F30LHS$DVJHH*G&5YL)-
M5W$_=;,M'&G4?--O14^N*D3XO`>0!9T]E(F0$=KXU@S(CQ(A1F%.>+:#V@$U
MT!OM)KN52+KU3"XQX;\<W7'+*CE?D8[[==2MTD\.P:$ZC#I.M.,KO]'WZ$A(
MOZ8U4KD/!KJ5=6UA46#,=GD,`*VV9DM$[M1M#$'V-I"F]`>(5$NB]%R"3Q[A
M4FEY2[8L2&UJ?Q,*IBQ-A=X!@J:@9.:[2W(XJ:;<J*OFGQM;WEI?2H-BQ&8O
MZ8:B2T^P;I`;3CAMN@HF"::/%JBI],@TWGQ9:6D^UGC:,QY4L*IRO-8_=%F5
M4]Q4)P#+:XT[WB11Z=//+1U?':2U@4AQ;"6PY8/*9&]!CC%8;4DT'M-:G]NF
MNI$JJN!\Z7X2Y*Y"D,O7D,Y,JL;K),I(;G<=-F6DI)+IJ\I&X>BH>O\`+%'0
MWGQM;V3_`"!T;%AO\S/JIS(JR:]I*M6R4"]?K[BLIUZ:?KA6R#\;S8\B-#=G
MMN\=@6SEW"C=I?<H\X9NHR;JDHJV#KI$BH.Y4T3%%-&^';]J-%BG>1SCU]=:
MU4$4B$)=JSTVFZ7=7<;>B:Z(B+BHE6WQ)8V423'.T:;5^@AT@$C!+M>@O]\9
M"HI]1(NBAX_K@6#?Q];N\SA<GFSHJ2XBZNR(48XTB0RK/;6*^2.D#C*.+W!W
M"I)T37SPJ?R3AMG9<B8N(,]J-I62ZJ5'>9)W>$E1,3`A-O:H&":^.J9!S\GX
MFNS@1H\>\",_'H&*)'@8--RL2`>)Q='478Z+?;($7715ZY4>0/BB\A/C)9M8
M;3S5ZEY';:@JVP`G$]H\PC8N_P"E=077IYZXJNPY/QQZ^=K&'W&2IXTA)-C!
M>:5SW.P5[0Z[D04!Q4<ZHNJHF0<Y(^,9C-CR<Z29%KJGDM<D)ZN2,2HW)%LF
MO=ZB8HI*![2'3KHG7+47P<8F#P%.,>Y;23^-_&K,1M=BKV.QW>WNU\.NF[`P
M+A8ROCP.'6,CN#^/"N<F,#VU_;;0!=$54M%3:A::Y%0AX`_8?D'.2RFI\F=6
M?AE)AI6@2/J1$XHD1KW#,MWCHFG3*C71_&$.LMHUD[.>EO!5I73E<1$64^.H
M^]=5/%WMF8:_Z2TQ40ZCXVY#7T,BC=MX4^N!H(E>Q(KFU$HHF*JW-T/]Y>V/
M;11V_P"KJN*J_P",</\`PW$7./'*)YHTD"VJ;MK+<@B466D,C+MM">T-Q+T3
M(N*"L^-+RM8@''N&/?,U`T,YTHI=IV*TJK'<`$=U!UK<O5542U\,J.E#C3T+
MB,;CU)-*O*#'8C09J@CI`D?:B*0*HH6Y`T)-?/".5O/BJPN6^1OO6$:):<AB
M1X#K\6*0LBW&=5SNFVKNYUXE+3<I=$T3"K2)P.TJ^6N7M'9M08=@"%>TRQR.
M/)EIXRF_W![#A)T+1%W?U:KD,:^)<5Y7Q>/35#$]B95LOSGK,O;*V1!)<)YI
M`)7242!QQ4\%W)XZ85<W]-R"9+!VOG1PB%'<C2ZR=&63'>WJBH:H)M+J*:II
MU147".8A_$#$9.-1"E-2:>BAS8,J!(CJ22@L-.Z/]S:V`Z>@=JZ)TRF,"^+N
M3?X?/XG_`)&#]6X^TY4G)BDX_$CLOB\$<G.\BO"/;01(M%1,:KMN143%_P`<
MG4LY?VK".<=TP3[5,=$,$5?$2]0Y$U1\>^.XE+R!+MN6X_).`U#DHXB;7I+2
MKNG'HO\`><$MI+],J(-%\92ZI[C;BV8/+QX+,-.PH][\D:G_`*UV]O\`GK^F
M%7O$>,O\?XA#X^4I)3D-DV4E=OMH6Y25%V;B\-WUR#DX'Q!,ATY5HVX&*\=<
MXZCBQE1?W'2<]QIW/)#TV?\`CE%X]\>,/7/&[9R42/T<;VDIL`06Y@`@DRCB
M:KHC3X(Z*=>N!$KOC5Z*]#B'/1Z@K;5VZ@0^TJ/@^Z3CB-&]N5";!U\B3T:^
M"+X8$*)\7<@K0KI-1R`(EM!*>VY(*(CK+T6QE++)LF5<30VG%U`MW\4Q43F/
MCNXB<H=M8EXB09Y,/6D5Z(TZ\Y(8;%I7&7]4[7=%M-Z;5_VZ85><GXR=[(K&
MWW&BJ8<CW4VO=:[J25`51H57<B"C9KOZBNJHF15"7QF]&L^3/5$QBOJ^2P1B
MO5@1O0W(1LFO=(HF"*1`6A#M371.N5%U!XS.B\%9XU[MLY#->E<DWM*(+M:[
M*.*TA:_;UTW85NXO03:/A]=0+*"0_70VX;<OMJ`EV@1L#5O<7DB:INR#EZ7X
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M`)1LMG&#XRIJP753T_Y']SR1/L_\<#`OBJ<,:?7LVH#6WL"+`OFB84C(HK"1
ME>C%O1&U<9':2$A:>*95)'Q;;+;F[%N&F*A;R-R`(115-WO,-@V;2O=U$V$C
M2*/IU3]<B:SJ?BZP@_A!.S;="IGVDYU$8(5="T1U%;%>XNU6^^O7KK],"N3X
M=N"HZ.G>M8A#1M@U!L@AFU.C]IW<#D=\'M1(FTV&):B7CIY8'9<NXO(NDK),
M*4D*UII8SJ^08*ZTI[#:<;=;104@<;<(5T)%3QP*23\7!,K'6Y$\V;>1<#>/
M644.UL>1!:-MD5(E$"C"K2ZDJ]55<+C2[\/5R4O)*F+,.,S=R0E0=C8D$#M&
M#X-M-DNTF_<B3BCT1=RIEQ->K\?<J_\`E5D-S";Y#52''6W&8':@FR^SV76S
MC@ZA[B1-^_N?=^F!<<5X[-XQPMVKFRAGOL^\?*0RR32%[AUQ]41O<XNJ*XJ>
M.0<)P_XYM;_@%&%S+&.D?C\BLKF1CN-/,G/;%MTY".EJI-B""@HB>:_3`L97
MQ-RB<<M^;=PRDRQIQ+M0W``$IY"OH@ZO$2]S7S\,N$7EGP"PG\ZB\D]W'C)#
M=`@>CM&W-..C:BY#?<$T;>9,UW^L=1\L$4M-\2\DKCK1_/M`S3U]E65QQXI`
M\`6!"3;RFKI)W&E!/!-%TR",Q\-\E$'NY<04<E,U3<A6H;@J3E5)5_ND9/$9
MD]KZB)==<)%K,^,KERTE6<:SCM23Y`U?14-@S`1;B>S)EQ$<%250]2$BIU\L
M+%QSSAECR!:J;63&(=M3O..QUF1TEQ70>;[;K;K*D"]4ZHHEJBX5S?(_B7DM
MN';2[B('LXS38.PMS;$F/(]P3L9H'`;:%U=!+HI(B)URLQ8-?'O+&&;NJ:OV
M?\>M??.LPRB*K[;U@)[Q)Y'-%9!UPC%$'=Y:Y%67%^%651>1;%^:T^U'HX=*
M30-D!$<0R/O:J1)H6_[=.GUP.QPI@,!JF`U3`:I@-4^N`U3`:I@-4P-'OHGO
M?9(\'N^WWNQJF_M[MN_3Z;NF!6V7*(D#D-;1.,/G*M&9+\9P!16](@B1@2JJ
M*A*AIMZ8$RIL"L*V/-<BO07)`(:PY*(#S:K_`$F(J2(7\\#;$GP9C9N17P>;
M!PVC,"140VRV&.OU$DT7`K^6<CB\:X_-O)3+LB-`#N/-,().;=R(JHA**=-=
M5ZX'G*>3Q>.\=DWLIEU^+$`7'6F$%7-I$@ZHA$*=-W7K@7"&*BB^&J:Z+@4U
MERB+7W]/2/,ND_=^X2*^"#VA6,WW30U4D)%4?#1,"Y0D7SP/=4^N`P*VZN2K
M`84(,F>[(=1EMB(`D2+M4E(U,@$11!ZJJX''_P#>:I+CSG(`I;1:L`>-)"M-
M(*K'>1ET%5'5VDA:Z:^.BZ8@^@;Q0=5)-$\5P,D)%35%Z+X+@8HXVJJB$BJ/
M0NO@OZX#N-ZZ;DU5=$Z^?TP/>X&[;N3=IKMUZZ?73`;P^J?7Q\L"//LX$"(]
M,F2&X\6,.^0\X2((#XZDN!M;D,F@J)BN\=PIJFJBOGI@9J0HFJJB)^N!XKK2
M***8HI+H**J=5_3`]WA_J3IX]<"HY3R6+Q[CUA=NMG*:K6U=?8845<445-=-
MRBGZ]5P,.4\JC<>X\[>/,.26&29%QIE1W_ON@TB^I13TJXBK@7/<!"V*2;]-
M5'7KI]=,"IL^2QZ^_IZ=QDS.X]SVI`J/;;6*UW2WZKKZA\-$P+=##73<FOCI
MKY8!"%1W(NJ>2I@4E5S&EM.1W''XCJE8TB,+-!4Z:2!4AV+_`%;=-"^BX%*U
M\JT_O'&94&9$C-6I49SW!;)@9R*B`!*!D2":FB":CIJN!=\:Y4Q?':`S%>C?
MB9KE?(5]`3<\TB*:AL(M1T)-%7`N.^SW5:[@]U$W*WJF[;]=/'3`'(8`5(W`
M$4T124D1.OA_UP,MPIU54T3QP,2?8'12<$=R[1U5$U)?)/UP./Y7\E,T3UFW
M'JY%NM)%";<#%-D389=0U!4!T@W]&E(M/!,#JXDYB1'CNH2"LEH76VR5-VTA
M0O#]-<#&?:5T")(ES)+;$:('<E.F2(+8(FNI?3`W!)CFC>UP55U-S::IJ2::
MZHF!4V')X\+D=31DT;CUM[C8\"CL:6,TCJHXFN[U"OIZ8$R=82H\J"RU#.2W
M+=)M]\"`1CB+9'W#0E0B15%!T'5>N!+!YHUVB8D:(BJ**BKHO@N!6W/)*VK2
M0VXX+LYF&_/"`)"CSC,=-34454\U1-5P-G'[N-<TL&U916@FQF92,FJ;VQ?;
M1P1/3ST+`G-O,N@AMF)@7VD*HJ+Y=%3`IK_F5)16E+63W5"5?22B011-4WB"
MGJ:Z]!54047_`%*B8$7D'-@J+Z'2!62[";.C/S(Z1>SHK<511U/W'&_4G<'1
M//7`C5_R72V4KCC5>R_)8Y.T^]7RD$!`$BIJ\+PD2&)!X::+UP+/E/*V./+5
M]Z(_*2UFM5S*L;/0\_KL4]Y!Z?2O5-<"Y[[.NG<'7JNFJ:Z)X_\`3`]1YI4%
M4,50OMZIU_A@1+"Q5BNE2X;*V#T<#((K)@AN&":]L2)4!"7P]2X&YF6!M,$[
MHP\^"$C!D.Y%T15'HNBJ/GI@;4>:(R;0Q5P-%,$5-4U\-4P*.[Y8Q66D.H9B
M/6%K/:>D,1&%;%>S'VHX9$Z38]%<%$3755P)M3>1+&IBV6UR&W*3TLRQ1IT2
MU4=ABJKH6J>&N!$IN51K.YNJM&3CO4LEN*X3JAHZ3K`R!)O15738XGCUP+E'
MF5<)I'!5T412!%3<B+X*J8%,QRR$]RR3QP07NQH3<\I>X%:(77C9V)HNY"$F
MUUU3`RY9RB/QVF<M76#E-,O1V7&V5'<GN'@90EW*G05<15_3`MT>:[JL[Q[J
M)N[>J;MOAKIXZ8%?>7T:I&*+@D])G/#&A1&].XZZ2*2H.JHB(("ID2^")@3'
M9T-D'C>?;;&.'<?4B1.V")KN/5>B:>:X$6'R"GFOLQXLUEY^0PDMEL"12*.2
MH@N:?Z55>F!.%]@FU<%P2;'74T5%1-/'K^F!3O<GC-\IB\?)DU=E0GK!N8BA
MV-C#C;9!KKNW:NBOAI@7*FV)"*DB$6NU%7JNGCI@5%KR:)77=-4N-...W3KK
M++K>U0;)EDGU[FJH7J$%TT3`MS<;;'<9H(_4E1$Z_P`<!W&]R#N3<O5$UZKI
M@4G+^70^+P(\V7&D2FY,IF$V$40(^[)/8UJAD":*2Z:ZX&ZFY`Y82),>16RZ
MQR,@+I+%M!<1S=HK9MFX):;5U375,#&VY/%K;FFJG&G''+IUYEEX-JMME'95
M\NYJJ*FHBNFB8'MU?NU:[_Q\B7%&-)E/2F.WL;2,"&@%N(5W.]4#1-.G73`]
M@<C;L.*L<@A17GQDPAG1X([$?-'&NZ#2(I(.\D73J6FN!*@6T68:LH8A-;;:
M=DPE(5=9[PZB+@BJZ+T7_I@3<!@,#A?E9]!@T[#D1^1&DV(`^XV#[S+0]LU0
MI#$;]QX%+1!#5!WZ*2Z)A-?)5E6CO%Z:#:OV#;I4DF,+DF-9"<&6LTA;EI[=
MMT^X#0:(A*G04T+15P.ADT\Z9)YI:\>*?-G0J^O/C,CN2>TZCD-0D.1Q<)&G
M'#%53KKH6GGB)N]$1ULFJ=J?7A=.\4E6;:W<1VN<1612(38JW"7]XVT>V*^J
M:HI=4UZXBZCV_&Y90;%E`NIC4/ASAU;DD9(/K-26Z<7T-*@]X!4-HKZD'37+
M$Q*M(=W6RKE*J-9N5ST>@G738-OR''D5QSWY-@ZOK=5OM]T!751\LD+U;&.,
MQILJCC]JXE4+T:]>VRVI$<1!T6R9;[(;5;#?O[(.>KZ>6(NIWQG7R6^7\=LK
M6LE^_E\4AQSL'F'=4EQG7!=%]PD]!HWM^_QPF>+K>:1GW?D#BSB1WW8K4*W&
M2ZTV9`'=8;0$(Q305/:J#YKE77SNLK[IJOX0^<*9-GQ8$%B733(TH?"6N]Z/
M+'^S(:^YU'>AMHF6(CC1S*ZG8@OTUDW2,W-T%ZQ#@+((CD/&L!\620N\T+9=
M"!%VJJ8BYXLN7T-BM':55E47-N\M+!;XE(>9<DO`3:JL@7B838W(W;5/=XCT
MZZ+DT?5/E2#.M/C"\B0(SLB5(A(C,5L5[Q+J)*(CT7=HGAXXPU\XLJ.RC,VL
M_C4"S'B#\JJ>G5XLNF^_VT=6<XQ$E>LAU)GN"J>M17QQ#4QBBMV?\2&B9LT0
M'+UV$]9,*V4994,AC[P$42.UW2T;`NJ)B(4'#?S:0Z^/!FU+$JA?@\R]P#S*
MG8+VD8<0CT1U\'D<<[H*OI\^J9(KRDXQSF;:53US7FS'OX3=7R-G5=K'X9P2
M;D]/_P!-03']!4?IETS7V&JM!L`D*,9^,D9]R,HR&U:4U:717&T7[FR_I+SR
M*F.$@"IKKH*:KHFJZ)U\$ZX'Q6+4W!?_`$.UM5?C9@V3BSA"O5AP9*]Z<;@;
M6]-W4#0M4RLM%]1W%?;<@"LJK!SC8VM5-E0HK2NK(CK$<&43+;VX7E%_MDZ'
MGI]<1=U](^.ZY*WB#+#+4]MA#><BQ[+:,D6S-3$%`41&AZ^@/Z1TR#XG)I>1
MR:FU"/QVSA_D..OQSB-QGA09P3Q<`"=55=>>0%+]TO'^GIFHCH.1\,<8D<M>
MJZ26BQY-%,H2::=720AC[QZ.FOW[1_=)/YY(JT.AN7[TQ.NDAREKDJ36+Q&R
M[*TY.HNWW'V]OVNK*LJOW>7GDBJ6NJ+Y(M#6G1639U,/DD.<\3!]I?<H91@`
M]?W!---BIT\O'-1$6=P6P_QB9!A4$KN3N%QAFLFR:J]9QWA)!/?JA2!%"VZ]
M?_#)!U$.!-3Y&KK*MI9!0GC8"1%GP5CE":&(H))ARQ7:+?78Y&--=RJJ:8BK
M/Y7B5,GEO"&[:(Y.KS>L1DQ66W'E,/9$J(337J,=R(JIHN0?/;OBW*&>*1JQ
M:&P?E,U4DZJ0#12I#*?D">C0T(CV1W&F-BD?WE]J+Z<L1W4;CDP.=2:^/'__
M`!>Y"$;D4]EQ=CL>9$4!)E077I(-&S7KT43^N!PZ<=Y/+AVK<?CDZ"[9\<LH
MKL1&%!M)B2Q<;;-\R4Y#I!NVNG]VOIT\,D1=V_%YJT_*9-!436*FS8J4:K5:
M<%UZ<S*0Y3XQS]0Z-;4,E1-RHJ]?'+%6M/2V;GR&Z=I`MTL(MK)G0K9I&AKS
M@/`HM-N/[>Z0BV2!V%7[DU_7)%7GR13-S[[BK\ZL>LZ2*]."R:9:)[:DB(K;
M>]L/40D?1>FGURQ'*,\3Y-057$[&&&EZBR*)^$^[N,:RP>,XVXM2W'!$0+_R
MH2:X'U*1LXWQ0AK83LL:N)LAP6!4W75:#:V`HGBI*B9(KYXQQKE'&>1<4Y"'
M>MW)(O5_(FH\5!,6IR^Z*0XHDJEV9*>?])+ES$W4SA_"6;*SOY-[$FMM,\E?
MLZZ)(4FHSN@M]B2C?3N;2!53=TUZZ81=?&T6PC/<M]W#?B)*OI4J*KX*".L.
M`V@.!]1507&KCB+&JNCY^$]./S6FF;><,EYECN`]%D0#:!XI!'O,'#VIVPT`
M/IKC#4"-PF35\0X<KG'K!R"[#<9Y1!ALMNS4FG';99?=9D;]^P0,-4ZCJBXB
M/HUM32@^(IU.S&E/2?PKL:/$>/W$M3]NH-@;@Z;W-=$54\\*X&XX04-BDC?X
M_9/4$ZG5F5&JP:*1'M7>VKCSPR-RMFX`H/>%=04?'&"?:\9GI+^13:I9+LF9
MQZ+%@2NRCCDB0,9]MX&WM!5PU)P$)?/$,8P^/6KG,&1MJFU-WOULZELXR,A&
M8:8BMMFQ(=).ZUVW!<[C:+HYNQ#5<]Q>RL>"W=5+XE+3EL>KFQ)=HX@JS-=)
MWN@K*H:^X)TA0QW)Z/#5/#$%F5)/E\O3WE);)"D/5DWC\B*###,1N,V*.,2#
M+5R/L<$R,!^]"T\<L1AQ&GN@Y5Q1V?Q^6Q;UK]N'(+DFD[+QR056WD?W:N`X
MNFW_`$_;TR179<[K)<KD7#Y#$-Z4U$GRCEN-"I(TTY`?:U/JGI(S%,(Y#XNX
ME9TEMP]\Z=^$XM#+C7<@@T_?20T;+<@M>I(@GLU\$Q%7?-Z28?/`LV*EV8#_
M`!VQ@!,9:%Q6Y)$)MB9*J*.X=R#^JZ9%<:WPCD\.H%BEJ)$26_Q&O9G(V@M*
M_-C20)Z.9JJBKZL(0(I=-%T\,L1]&^-:MF-%LYD>OL:QJQDI(]G9HTT0N=M!
M-6X[*(#(JJ=?]2^K".<Y=Q/D/+H7*;$2?KI+"!'H8SD9%=(JXDE-/M$J[D[T
MGZ?THF!G)AWG*.7<-LIU;9U+94\]JU-K<P463(['[1."O356CT5/TPJPE\8;
MI>9<!ATE8\%'2M633CC0D;3"260%ON&JZJIFBZKUZ]5P+#Y/BSY/^+^SAOR_
M:WT*9)]NVKG;89W]PST\$3<F17$TG#946[J+(*!YF5_E=LY*D]G0TK9+;Z`I
MEKKV#4V_3X:^65E(9^/^5QJODE%7LI'CTP3BX3(W(.\K0%<VHOBVL;<;(E_N
M_3`TS>,RI=7R6124$JL@3.,'!?J"95DY%HFO:4&D5-QMCZ5=3[M4ZKIA4J+5
M3$Y)V;WBTVU&6%0_26+:(+<)8K((ZTZ[O$X_;>$G"T^_73KX85G\?<=M6>5-
MOW%;:,WE<[/&7:FK`5\IJ2Z1`:&"=U_<FS8!_P!O3(.@^2*.KMY5<S8UM@OM
MP=?@<AJ-_NX,@5%$$5;U/1P5_P!*BNFBI@<@=?S!UBG<YSQ^7RB++JI%>\Q'
M!M7F9)255IY]M#`6G'HVQ"<!?02+X81C9\0M%L[VR&CDK-;O:!^K>`5<<%B.
MW';DDTXJZD("#@F7]2?7*C4QQ7E+S]R`5]K'YC%;N$B7*DRU`D),1Q8Y(\*=
MUU=%;0&R7]M4U\L@@V7&+"PBWSE)Q2;6`_QJ"P$=UA&3<FPII.FV/J];NS3:
M7]7CKE%K?0+^T8YU*CT5BVU;RJ%ZO9<90771CDSWRV;EV[-B[M>N%6%%06A?
M(3CEO6VOY*):RYL2Y:[`5[D%\21H3>0>\2"T0M]A5^Y-<)YNCY<VXS\E<)L7
M]?QZ?D82&OVMRY+(JRJKY*8M&`_JNGGD5\W?XY?3N1/?_BU,C#)'D,.4W[="
M8/W+9+%-V49$X^CI"A"J^@-=HHFF428/'9,1(TV/PR2;KW#_`,>,=&$B.>^8
M4D=;<=!4-DG!Z"2+J2>&!%K:?DL,[!X>.V$BD2=43I=4,,(@R8S<9QE]MB*A
M:$K3O;,FS]1H/77"+>;Q"'83Z]IOBTR/0A272,P9+9FC;TA]IQD#'<2-F:B9
M-M:^GIX+E$"MH.0R9U0'(ZN[>-V#2E6RXH-(L9^(V/N6I+SB*Y&7O(I&2+ZQ
M73K@3:*HMQY?QIV?QZ8-]`N+,KR\["JPZS):>1EP9&OJ:)";01_HTTT3)JXZ
MCY9@RYITT8*=ZRCN)-%V0TRLI(YE'46]8ZJ+:JXJJ(N.:H'\5QAKCN.5'(AG
M\/FNU4V1.8BU,6UAV<0T5I8[9"<N+-0OVB:55[K1_P!SIC3':?-$65-X_4Q(
MT>1)-;FO?>&()*X###Z..N:CU':(^.0U47$&NMJ6TH8T:W<]Y,9?@VTXG%*-
M.<7T/-$[^XC,;M;R\NNWSPBK@U;]L]Q"-=T;H/1;2Q7DYF!+'?>*(XU[S=KH
M3,DB113R^W3IA47CU/>^SXBRY!E`[&J.0PWA=0A1KO."D-IPB71-0'0-?+-(
MAU'$937&G5KJN7#_`/Q.?K;V,ZC@'*M$:`8X`V2ZFXVHG^X/3141%R>8[+XW
MJ"@\WMI,FI<9>L*RH<9L%91!U9BJU(;-WQ1Q#1-P^.-5]1R*8#`+@<U<\'H+
M&S*X??EQ)+H`S*.),?BMOMMJNP'A:,!-$WJB:_73%2.@CQF(T=N,P"-LLB@-
MMBFB"(IHB(GZ85MT_7`?SP-:OL=]&.X/?4=Z-;DW[473=M\=,#,B$4U(D1/#
M55T\>B8&#K[#6BNN"VB^&XD'_P!N`.3&`1(W0$3^Q5)$1?X?7`V=/K@-4P&`
MU3`:I@,!@,!TP&J8&F5,B1&T=DOML-J0@AND("I&N@CJ2IU5>B)@;M<!@-4P
M&J8#5,!@-4P&N!3RJ[CUG?1)#Q`]<46YV.`NJCC'N@5M2)L23HX"*B;D_A@7
M&!SU##X3629$BE*&U(OI+KKKK3HF4J0WJKNU=Q;E#0M1'[>N!T*+@,!@:&9T
M1Y]YAE]MUZ,J#(;`D(FR)-PH:(NHJJ=4UP*J/4<4G<C<Y$PU'DWD,2KG)H$A
MN,H/J-E=%5`+U=>FO7`O$P&J8#7`CQ9\*43PQI#;Y1G%9D"V8FK;B(BJ!Z+Z
M2T5.BX"180HTB-'?D-M/RR((K1F@FZ0BI$+8KU)4%-5T\L"1JF`U3`CRK"%$
M-AN3(;9<E.=F,+AH*N.:*6P$5?46@JNB8$C5,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@1YU?#GQRC3&0?CFHJ33B(0JHKN%>OFBIJBX$A$T33`8#`
M8#`8#`8%9<<8X[<FTY;5L>>;"*+)2&Q<44+[D'<G373!JN_[;\`7_P#YZO7^
M,=O_`.IBI,>?]MOC_P#_`"=K_P#[G;_^IBK#_MK\?_\`Y.U__P!SM_\`U,4A
M_P!M?C__`/)VO_\`N=O_`.I@3*KAW%*B5[NKJ8L*3M4.\PT(%M7Q344\],4B
MYP&`P*#G-[(I>.2),-LGK-Y1C5C`"ID<E]=C>@)U+;KO5/HBX37$_$S8)77W
MQ]<#(DMU;RG%_(@H/R*VPW.-F8EUU%WN!JGT3*>3H_B6YFVO#(Y3G">E0I$N
MO)\UU)T84DXX.*OFI"":K]<AG@I>8?(-Y4<K2'"./(@L3:J'+C"R9D`V3R-&
M3[ZD`MN:$A-`"%JG4O'`K('R;S!F1$GV8PWJE^PNZ]R)&9<!]!JFY#K3J.$9
M)N-(JBH[?/77"XV<3FVMG\F<>N[%Z*\=KQ=Z4R,5M01H'9##G:5Q2/N(.]$0
MNG77">:3\R);7H?XQ3#+67%8_+$_"!#V2F2W5[3JZIH#CS9$7Z#A/-5\SNXG
M+>*?'%\W";DN3KV$KD)[041WM/"^P2DA::.`HKJGEEJQ"M.&3:6GH&;=F.V$
MSG$29`JF25YF#'?5=([9D(]%45-4$4'5>F*1WGR1R2YJ%A,5$AIJ3(:F/JRK
M/??<]JSO38A$VT#8DO[IF7AH@]5R%<M(^1N>3H,5ZHBM#->JJB?%B#&=E-RG
MK$M)($8$/9%@>J:JGU75,&:V6OR#S6M/E<XWH!UE!8,U49CL&V9.2PC;'W7B
M=V`#12%54TZ_5,*SE<S^0(LJ'QY_VJ6ME+DA!GB48G%CLQQ?`'&>YV1>,C\-
M_4$W(FN$UFSSSE[-S0MW?MZ^%-"*Q(D1&DFPCG.&8/1W)`'OCD2H/8514%U5
M%5<&+'FUW>5G/Z18\XAJVZFUGR:H6T+OG#1E43=KNU47-$Z=/YX+U.)<PY,_
M<\=:L7XMA!Y34N6C)16NT41QI&35O7>?<:(9&U"+KN3]=$*J^8<WYW76O+WJ
MZ3!_&\4;@2@A.QR)Z2,H%)QGN]Q$!5V^@D%>NB:836<?GG*)7-(=7'E1RK[6
M7:U[3R,(C<=R$QW&D`B-''G&S%1>].S7H*],&+3X]YCR#D+T:'-[;-A3!(C\
MM9!O:*3A<[;(-:JNT2`2=3QU%1^N%<;SJ3<RI/-H\J<DJ/#NN/,UL5]L>VPK
MCL=U%3:NOB:Z^:X2KQWY!Y1#?>II3[#LQ>1E2MVB-ML"C!01FAZ'#5ONJI=L
M=5T7^."NA;Y+?Q/C.;<7$JOCW,)J0CDQM2?B(XT9`!D+?52\-P"OW=-<*Y-K
MG_-O?E5>Y9!YOD4&I5^3':5Y8LV%[@M[;+FP7`-.G7]%P/*CG_-V7:R19RX\
M^,5I;4LF(Q&[1O+7-2'6Y`FAEM,_;H*@B;>N`D?(7,8M%"M4FQI@WO')]S'1
MM@42%)A1QD"G0OW&5[G;7?UW)X]=,(V<D^1^4Q/R_P"/F1>Y$JJ*>P)M(X(.
MV,M6'T+0D51(-%'Z85HNN1<Q*R2G?NT!RMY;6P#F1V&V>]%EQADHTX"J:>@R
MTZ+ZD\<#I>(\KO9?,9E1=/JT9-R7J^,++91I$=I\0!^++:)5/:!"+K;B;D)?
MI@4_+^5\AJ>0\F&L<B-.QG./!'?.,)FK=A**.Z#IH0DXB>(:_;Y8&<3G')_R
MJ<8E3V4GN<@?J0N_;@"(PS!"<@HSN)OO&I]L=?+KIK@4?$[N72T?&5:"-.1+
M'E!/B+`;W'(RS'T6,2*O:4R;T5!\47"+X.9WB<=C7"\GKWPMV*YR&RS'$WVG
MI;XMN-LB)Z&AH?;;[O@?4ETUPJKJN9\ILN0\=&78JV,>=R"++C,"RON4K=$9
M[FU2'>H%HNSIKU3`]C_)W,!XVG)7)%>Y7V$%AQII3;(X<J1+:84E!OU*PP#W
M[G<75"']<#H_CMEYGG//&Y$P9[Z2*U3DB`-J2+!'3<+?IU_7!BE8Y1R=R]&J
M@2XL#W_*;2K>>;B-J2LL05DMFJ:HA.H0=2+7=YX1>5?/;@?AEWE\IL)=K$B2
MC<0!4&W'(KKC/<44UVBO;WDB>&%Q6#RWE($W'D74-T+"=$;JGHG8D2W6WH[C
MCK?I0([?J;W@9Z_MZ^*Z8$&A^1N1W]77,N7,*DL7*9RS6:ZV#C$AYJ6Y&)%0
ME1.VV+*$X@+KZTT5$PFL85Q=5');6=!ELC7S>7Q(,R$K0KWAFPHPDXCBKN!1
M54(43]==<&.N^0;>?`Y!Q9J*3(I+=L!-760=,2:@.O-FV1=05"#KIXITP:Y7
MC7*?D2VC,Q1M([EI<<4;O*XTBMB#$U3$=FW7UMN;TUW>'E@Q(B_)-S<5E3:0
MWTAP+F7`IE><:%2C3#`SG$NY--PN",<$+T[]?'PPK)>6\B"96PIRL3G8')WJ
M@I?8#=)9"O<E`;?DT^*_MDH>:+X>&!%3Y'NV>'-\I&]@S`L8<<_QRM@"P'GY
M3;+CI&BJJ,QQ=VGW47UIKKIJF!VO![>W<9FQ[R?#E/!,)JM=8>;-PV5;%P0>
M[8MM]X4555`3[=%P.MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&!RO,.+W-Q.K)=;.B1'*MPWV5EQ7)2B\2;4<#9(CH
MF@JJ=47QPRI@X'S%.1?Y&[;U1W'MUB>\"M>;<[*ZZ!K[PQT$EW(BCXX%Q1?'
M-'3S:>9%W=RFA.P6#55WN)(-''3=5%VEN/4M-OW*JX:2+;X[X7;V+UE953,F
M;([/>>/?J2QBW,DJ(2)N!?`M-<)&R/P+B,=8I,UK0%#E/3HRHIKLDR45'G4U
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M5=,*AK\9\"6C;H2HH:T[3ON&X:M)L%[P[B+]V[3IKKX=,421X)Q`9T><-5'&
M5%%H(YB&B`D=-&=`1=O[2?9T]/EBB;8\=I;*9!G3X;4F96F3D!]P=39(TT)0
M7RU3%&BEXCQJD>=>J:YF&Z^BHX30Z>E24U$?](J2Z[1T37%35&Q\=07N<77(
M[5J--"?[)8+1`2FR4("'4]5V'ZBW#TZ+@Q-F?'O%_</VD"KA,7ZNN3(MBXPC
MBMS3!1[ZHBBJKJOJT5-<*F<4H)%1"=.=)";;SW?<VDUMI&`=>41!-K:*6T1`
M!$44E7IXX"?PGB=A.?GS:J-(F2NS[A]QM%(_;%N9W+Y]LDU'`\F\'XE.BSXL
MRIBR(UF\DFP:<:$A>?1$1'3U_K1$1-WCEJ1+7CU(M&M%[%C\.32QU@=L>SVE
M310V>&F15?$^/>$Q'P?C4D-EYMQI\'`9%"1V.*BTXB_Z@%=$7QR]R1)9XAQA
MDV#:K(X%&DG-CJ+:)LDN]''A^AGYKDJQ[!XAQBO62L*KC1UF"82=C8HA@XJJ
M8JGAM)5U44Z+@0X_QUP6/'*,Q106V'`;:<;%@$0@9/N-B73J@'ZAU\%RTB3+
MX;Q:7[E)-5%>2:\U)E]QH2[K[&G:=/7Q(-.BY"-E9Q7CU7*=EUU>Q$DO[NZZ
MTV@DN\MQ^'AN+JNGBO7`QF<0XS-DOR9=9'?D259*0ZXVA$:QEU84E7Q[:]0^
MF*,97"^*2V);$JIBOLSGQES`-H21V0.B"\6O]:(GW>.6CV)P_B\/VGM*J+'2
M`;CL)&FA!&G'D5'3#33131?4OGBD:`^/^$MPYD-JC@MQ+`T=G,!';$'C$MXD
M:(B:J)=4^BY!L:X/Q!DFC9IH;9,25G,J#`#LDJ.Q7AT3H:CTURU(]C<)XC&_
M(>WIH37Y;7\F@,-HDA"^Y'>GJ1=?/(K?3<8X_2"X-/7QZ]'D!'O;MBVI]M-H
M;E3QVIT37`\;XKQUN4,INNCC)"0Y,%Y&Q0TD/#L<>1?]9CT(O-,M$F#3U<"!
M^/A16H\'U?\`%;!!:T<55/T)T]2DNN05K/`N%L0$KV:."W!%]):10CMBWWQ^
MUW:B?<GURU(]<X)PUQB+'<I()L0G2?AM%';46G7"W&;:*GI4BZKIBD2#XMQU
MPS-RMC&;DD)SA*T*J4IM-`?7_P"R"G@7CD7$B?2U-@XPY.B,R7(V_P!N;H(:
MAW!V'M5?#<*Z+^F*-4+C=#!>COPZ^/'>B,>TC.-MB)-Q]=W:!4^T->NWPQ1Z
M]QZD>K'*MZ"PY7/$1.Q%;'M$1FKA$HZ::J:[M?KUQ1@'&./@S"9&OCHU7.=Z
M`';'1EWK^XW]"ZKZO'%&N-P_BL4IY1JB&RMKK^2V,-I[C=X]W1/7KKYXW1[!
MXEQB`S"8@U42*S6F;L!MID`1AQP5$S;1$])$)*BJF*+?`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8%+R/D;M,(F%9)L![3S[YQ^V@M-L#N)3)PP34OZ43J
MN$<ZU\J`Y$IYJT4YJ%=NP`@R7%8[:A8GL;(E`ST4>BD*]=%P8[0K&`$7W12&
MAB__`!U,4;ZKI]^NWQPK=W`0%-51`1-5+5----==<"N@<EH;"L&TASV':\R4
M!E(X*-J0DH*FY51/N3`S_P`@IORZT_NVOR:,>Z*)N3>C*KM0U3Z*N!7\DYC!
MIZEBS9!+%AZ;%@*L=P%02E/BPA*NJIZ"--4\<"^<=;:%3<)``452(E1$1$\U
M5<#0%E7FR#X26C9<UV.BX*B6WJNA:Z+II@>LV$)XQ;9?;<,P[H")B2DVO3>B
M(O4?UP/!LZXQ>,)3)!'7:^2.`J-E]#77TK_'`R6?#$B$GFT(%$3%3'5%/[45
M->BEY8$&9RKCL,H(R;&.VMF\L:!^X*HZZ**1""HO7:@KK],#==7M325KME:R
M0APF-.Z\XNB(I*@BGZJJKHB8%74<T@V%Y;U1",8JN0Q'9=-T%24LB.,@2:1%
M_P!)>&!;/7=0R4@79K`'%;)Z2!.@A-M@FI&8ZZB*)YK@95%O77%;'LJV0$J#
M*`76'VUU$A)-47`J;GG%/4\JI.-2=_O;SO>W-$_;!6@W"CA>2NZ$@?547`@<
MB^0'JCD+M)'II%D^S6E;F;#K(:L-N=LQ$7"%5<1?`?/ZX"F^2:VZO:BMKHKK
MT6ZJ5NHMBJB((PAB&P@7UH>IIY:8'4S9\*"PLB;(;C1QT0GGC%L$U^I$J)@8
M%:UHZ:RF4U:[Z:N`G[7_`,3Q^S_=X8'A6]8`=PI;*`C:/J:N`B=I5T1S77[-
M?ZO#`Q*[IQ88D%.CHQ)72,ZKK:`XOT`M="_E@:^1WL*@H9]W.W>SKF')+Z`F
MI;&Q4E1$^N!SR\_G,U,^RET3S;$.M6V9<:?9>:?:$=Q-@Z*[4<1/)>GT5<"5
M4\U<M)M9%BUCA+,B!-LG4=;48(O`)LMNK_4XXA=!'RZ^&!)XGRK_`"`[@?9G
M$_$6#U8:F8GW#805(QV^`KO3QZX$2ZYJ4;DB<=JXC=A:-QVYDE@I+<=18<=[
M?HW:[C1$(]JZ=$\>J8%XU>4SK!OM3XSC#1HVXZ#S:@)JNB"1(6B$NOA@;VI\
M)V'[UM]LXFU3]P)BK>T==2WHNW1-.JZX')QOE#CDNWK6HS[)TUC7R+%JZ)\`
M9%([S3*MDA::;E>1455P.H>MZMB0Q'>ELM/RO_3,FX`F[K_\,574OY8&Z1+C
M1F2>DN@PR.FYQPA`4U71-2543QP(HW](41V8$^,<-@E!^2+S:M`8KHHF:%M%
M47R7`\7D%$B,*MC%1)2`495?;_<%Q=H*WZO4A%T33Q7`A0>40AJ6["Y?AUJ/
M.N-`JRVG&2V.$([7EV"I$(ZJ*>"],"/SKFU?Q6@D6;I,O2FF^[&@./@RX^B$
M(EV]VJKIN\DP.C4T0$(NB::K^F!0W'.>-UW&[+D"3F)<&K;-Q]8[S;FI`.J-
M:H6U#+P1%P,J.^L9M7(GS8+;;;>IPUA/I,&0SVT/<"B@:%NU#:OFGTPFJ$/E
M%(1VS7):>12.U=?^70%=:DH]$W*WZ2:7074--J@OFOBN#%C5<V.6EO&E5QQ+
MBHCMRWJ[N@:FP^V3C1`YZ1ZJ!`6O@2?3KA6$GY`99^-FN;C!<<8<ALSEA(8H
MX@/(*Z;U]/I0NN!U@%J`EIXHBZ?QP*6!S?BLZ'+FQ[..4.!(.)*D*X(@#S2[
M2%2)4_JZ?K@6[$F/)CA(CN@ZPZB$VZV2$!"O@HDFJ*F!R?\`GD^/R6%5V=$_
M!K;1YZ/6VA/-GO<8;)Y>ZPGK:$P;(A5=?UTP,>,_(T6\GP8_LCB1[J._-HI)
MFA>X8C."!J0HB=LE$Q<$=5]*_7I@67&>7-7%;9S9$=:T*N;+@R$><`D3V9[2
M=4A]*"NFN!EPWEC/)H$V8S%=B!$G28/;?T0R6,>SN*/]._Q1%P)#]T3%V4)Y
M8[4%N&4MZ0<@!>!1<0>K*]>WM55[FNFO3`G5]G7V,9),"2U+CJJBCS!BX&H]
M%3<*JFJ>>!Q7_=,9/+9W'ZFH=LOQ3Z1K1QMYH'FBU:W&$8M#-L4?34M4\%TU
MTP(E'\TUEOR)JLBP3.*]:RJ4)`NB3X2(C:N$X]&TW-LF@KM+7^*)@7/'?D:O
MN;CE5<41ZO'B;C;<Y^2H(A=QLG5,4`BT%`'755P-?Q_S^UY:X^X[QR155@-H
MY%L'9,=]M_<O011@C5%V]5U\,"5)Y]&9^18?"%@O^ZF0G;`9Q*",=MHD'0>J
MDJ[ET\$P*FM^8*6;>Q80QS;K9\Z=5P;0C3:Y*K@WO(K>FH@6A(!:]=O@G3`R
MX=\M5G)+:OA!$.*S=1)$^DD$:'[AB*_V'-PHB=LO`T3KZ?UPGF[.?;U=<*'8
M3&(8%N42D.`TBH";BT4U3[1ZKA5)8<VA1KSC\-CM2:Z]"6ZEF#PJTV$1E'MR
M*FHD))Y[NF!<)>4Q)J,Z.2*Q[M%1T.L?_P",G7^W_N\,#976E;91EDU\IJ9'
M0E#NL&+@;A\1W"JIJGTP-2WU+^22J6?'2S)-4A=T._IIN_MZ[OMZ^'A@<A2_
M)DB?(X\RY6(S^;L+2N<5']_9*L[NA)Z4W]SL+]-/UP.UG64"`V+DV2U%;,D`
M#>,6Q4E\!125$UP([?(Z!R1&CMV44WY@(Y$:%]M3>`D54)L4+4T5$545,"GX
M_P`\KYU/)LK56*=N/82ZW]^0"`I1'R9W(9[$]>S73RP+S\U4;WV_>Q]\5M'Y
M(=T-6VB347#37TBJ=4)>F!K;Y'0NRRAM6,4Y8`KIQQ>;5Q`1$5244+71$5%U
MP(<WG/$8==-L7K>(L6N9&3--MYMQ6VC^PB$%)=#_`*?KY8%M%F19L5J5%<%Z
M.\*&TZ"H0D*^:*F$URG&><3+R/4OC!9CC/D6$>2V<H>ZVD!PVD)H%%%>WDWZ
MMOVHN73'1L7](^$@F;",Z,/_`-80/-DC/_VS1?3X>>16M>4<;2($Q;6&D1Q#
M)N0K[2-DC?\`<5"4M%V?U?3`V.W](T4879\8%F[5AH3S:=Y"TV]O5?7KKTTP
M,FKJI>EOPFIC+DR,FZ1&%P%<;'734P1=13^.!34?-8=QRRUI(:-/QJV-$DC8
M,/@\#BRB=%0VA]JAV?KYX'38#`8#`8#`8#`8%7R@'#XW:@TV;SKD-\&VFA4C
M(B;(1$13Q557"/F\JBM)7Q3P.K>JI1R(<ND2S@DVJ.--Q3'OJX*+T$=JZY<%
M`_QF]@J:?@K![C$3D%N3E5!:95SVTQL$C2(\=[<VXT)JXFU$Z;MR8'UWA54W
M6\0K:Q6'V68\=&AC37$D/@WUVMO&GI(D%41=.B>&!\HXMQVSKJSBX7'&)#]1
M5C:0K:M2,VX2RGW$5B6+(JO>;5I";0].F[Z82M,7A_):IHAD<<>MY3_%7H,?
M515!<&4^XW$>?0Q<$AC.-MIM+U:;47!FM47C_*?:WC845BC4RUX[/BB4=B.A
M-Q39]THL,GM;[?:745]6FFJJN!]7^38\V3PJQ9A5OY=\D:T@=54Q1X%(D!";
MWJ`HI;-R(6FB]%R+KY=6</MI%I6L6/'ICM>URQZR(I<>.@>SD5RAW";97MB*
MOZ;@0?XHO7*,*?@5W%B<?_$TKU5;"]R*.[/[0MJPQ*;?&#W"155&MQ-*`IT'
M3P3!K?,X7<V_'Y+5=QYZIDM\6?JK2*\+;23+#5I6!!4)1>4":=5'O]R=>JZ!
MKO..W]]:6DYSC$X(DZ7QAUMJ0#2.$W!=<]VIB+A;5`"T77KI@3`XC:0K2,\U
MQMURNK^92IK,9IIG1(,J&K2/,@1"*-=]=53IIXZ8'>_+E+.N?CRU@P(?OIA(
MRZS%1!4C5I\'"0-^B;M@KIDPUP=WQ2WG3>36K/'9`29%I02J<B;91X&8O9]Q
MVE0U[:MB!H6B_IURFM;_`!KE4KE@NKQU^,Q[R^9=)M(Z15:L(Y"P^3BFKSO>
M+0G%+H*]$'I@?2?C.-*A\!I(4RO<JY4.&S'D1'4;0D<9;0#+]M2'0B%53KUR
M*XCDW#N5WM+?<B925%Y"DQJ;1U)-QU)"JC_X(]Q=5$7?61>M/[BY43IO')O*
M/D&)/MZ>=$IY/'2A3%1[L;)#DA'3CN*PZADBAJG3TX%DUQ^3`^5*B1`K#9X]
M"H7JUM]I`%AIQ9#;C;6W=OTV-^*#I@3.=UMBY>\;M6X!6U56NRDL:]M`-S_D
M,=MI\6W%$3[9:HJ:ZZ%JF17(1?C7D,>NX\_$C@U+"18P)\5P@7V]':NN'V=4
MU$BC)L4`ZIKJGAE91?\`M]S&#PYMI8Q6$VFL(T6-$8=;:?E4=8Z?MQ1P_0CI
M=Q'5$M$511,#79</N6:^"_0<>GQ)ZE*=:A3BBSHKJ2I`.NL3VR/1CN$WW!-D
MO1]?+`^N\A*<E!,*)!"QF=@NW7.**-ODHZ*TJGH.A>'JZ9&GRN-PRW@0^4PN
M,5EC`XW84DEEKC\QP";"T>U$$A"KA]MO:J[_`%;/#;E1.X;4\SX2]4QX=;)L
MN-W##;EK!(VRDU,Y&P%TQ-QS5YETD74$55%4]/3I@=-\;5MK`=Y3^0A.0TG7
MLN;#5Q07N1WD!`--A%IKL7HO7(JDYIQ3D%MR?DA5D16%G<;&!"LR4!`I:/.&
MK2DB]P=P&@[M-,J*/DW#;NZC6$^%QPX+4J)417J4NP)//Q)XONNZ">S1AA%`
M2UU)/#"/L#%?"BUWLH<=J/%02%N,V`@V*%JJH@"FU-57KD:?%Z3@G(2KZ&-8
M\>(1K.-VM6\#JQC#W;IM=G:B&71U&RVDJ?QTRIK9$X1R4GJZ)<4,JRB2ZZF!
M'6YP,#`DUK:(X$A$/>J(XG<$FMVY>F$=C\X@!_%=^)MH\.QE>WT]7_);]/7S
M7PPKEKCA=_\`D+"^I:-V/!*S@2O\>9=9B/R`B1G6'GPVEV0-2=!1%2]6S5?+
M`L.+<#&)RVFE/\;6/5QJF0+?NG6IA1I3L])0"1D1%W--2U#417HBX%=QWB7(
MZINN>L>/'80$B6\!^J18Y&RY,GE(9>02-&U!YE=A*A:C_#7"57V?`><0^-V%
M([4%R"1/HZZ%!F@ZQ_Q7X.[NLD3Y@2#N)"`AUW*G7&KCZOS:IL[KA-O5USB1
MK*;"=9CD:Z(CAAIM(A\$7[55,AKYYR#BG(+:JY)-@4!UKUAQYJH;IE*.)/30
M<,D--IJUL9$MHF1)JG\,ICZHR1QJ=LFXA*ZTPA#"#8)J:!KVTZH"*J]/'3"Z
M^9S:'E7+:?DL6QX\_4VMS"VA/ER(KC0+'-'(L-H8YN%V]VXC,M.JJOT1#*\J
MJ:[E7')>23H!PWK"MCUL"O(FR=+V[;IN$6PB!-SSZB'J\$UZ:X7$&1QGD)_`
MC/&A@&M\-2Q"*!O;U[P((DF]2[>GIUUW85])85>PVI"HKM345TU1=/!=,@^2
MP.+\KK[!F65.4B'5<CLY[D0#87W46Q%SM2&!4A3='[OVGM7QTRS!VWQ]02Z7
MC[L:2VD=)$Z9,8@HJ$D9F3(-UMA-NH^@2ZH/1%\,@HW?\GM>6[[#B\EJ"TKT
M.!,.5#[+##PJ#LS8#ANDZX/I$=O0>GFN40>$\.Y'%LN),VD7VT7A5?*@#*0P
M(9CKVQEHVA$E)`[#6\MZ(NY=/+")=1PV_ET-]72'7*1R9?RK%AW8Q*1Z*X\C
MK8DVJD.T]/4*]<*LOC+C?(Z./>A=R_<G,MY<N,O;:;U:=/5'?VM>KOBHK]N0
M5?.>,6-ERF9+2H>L*Q_CSE<XL9]F.\3QS6G4!LS)%0A`5,55-NJ:>>47WQO!
MY%"I)+-Z/_(68\<9YP&&I+T<MNQV6,959[Y==RCX]%7KD'`\TX9R*W^0*VZI
MZ212\@A2MI\CC/,I%E0`>:Z2D0^X>YG>/;4-V[],K*+1_&W+V?DNLY040H-L
M,^P+DML+C/M)U<Z2^U;;9$E/N(.Q.H"J:*I*O3#2ZX]Q7DD7D7R?-GT/NH/(
MS9<JXC[[(A+%F.3),FHD:M]Q5_J3PP*FJXS8<&8N^9\8XO\`@Q.L;&1Q.1,;
M1AV6#VXW0-LW@'8UJ(Z:;U731,#HWZ/DLWYEX]RS\8;=-'I'8<MXG&MS<B02
M.[5;4D-4'[57;XY!RM#\/\C8M*>IE-=JHH[FWM?R2.`2/LSVU&,``B]SN(KB
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M#M6N=R0=HSFT;UA#LJNP8FI&C0ABMM@C3D45$]6E;56T`5$MW73+@J9'">8M
MDS,<HI,^*EE?#)J6)K,9Y8]K)%UB4)[^V2;!4#!2141<)%_,^-K-J?QQ:EAN
M)`>KAH^41^ZKJC`91'F$%T_4Z0$),[E\1-<&*M>+\P+F,>:?'U;A1;.W7_CN
M10C+&FQ#:9>0-W=<-Q=O=4_!>B)I@U5_]LN3CQ>'6QJ0(\I>%R:B6B%'$5L%
M=9<;;-1+U*O:)4/JG7QQI'VND-\JF&3\0H#RM#OA$H$32Z?:JMJ0:_\`E7(9
MCY+!X'R\H/'(Q0CA28SO)!?F=QI5C#9H\D5W4#55W*X*^GJGGEU69\7YC9<1
M[(\49J+JM9KF7E&4R)60USXN$PVZUKL9)$4@)S1=RZ*F02JWA$ER\XW8N<6.
M)$&9:3;./,DLS'6SEQ`:%QS4S'<Z8?:VJHGBO7"16TW"N8P(7%>U5/LVM?$B
M1+!MTXC]>ZPS--Q6GA(E<;<8!>XTZSYKIY8(TL_'7,'::SJSJ7&[V)$L(\'D
M3U@A1Y8S'>XH@T!;P60";7.X*;/+7"QVO!*RY#F5W<RN/E0P9]?6QX[!.1B7
MNQ.\C@J,<ST04<%!7S1,:/H&`P&!K?DQHXB3[H-"9"V"F2"BF2Z"*:JFJKY)
M@;->FN`P(KMK6-$\CLMEM8Z@+Z$X";"<^Q#U7TJ7].OCA*E(NJ847`)HO7`Q
M=<::;)UTA!L$4C,E1!$4ZJJJO@B8&,=^/)8;D1S%YAT4-IT%0A(235"$DZ*B
MX&S1/I@-$^F`VI],#S:/CHF`73Z8'NB?3`;4^F!&F3Z^$C2RWVXZ/N"PQW2$
M-[I_:`[E34B\D3`D:#XZ8#0?I@1Y=C7Q"8"7(;8*2XC,87"$5<=)-4`-5]1+
MIX)@2$1/I@>Z)@-$P/-$^F!&?L:YB7&AO/MMRYF[VK!$B&[VTW'L%>I;4ZKI
M@2M$^F`T3`:)@19UE60%CI-D-1UENC'C(Z2#W'C^UL-?$BTZ)@2M$^F`T3`:
M)],#Q-NOA@.B==,#WIXX$6QLJZLBE+L)#<2*"B)OND@`BF2"**J].I*B)@2L
M!HGTP(C=G6N6+M:W(;*PCM@\]%0D5P&W%5`,A\40E%=%_3`\MJFLMH3E?916
MYD)[3NQWA0@+:NY-17Z*FN!+$!041$Z)T1,#W1/I@1+*UK*N.,FPD-Q6"<;9
M%UU4$5<>-&VPU7S(R1$P)>B?3`:)@1(=I63)$N-$D-O/P'$9F-@J*33A"AH!
MIY*HDBX$I=$P(E=;5-F+IUTIF6#!JT\3)BX@.#]P$HJNA)YI@3-$^F`T3`B2
MK:MB38<&3(!J7/(PA,$NA.DV"N&@)Y[135<"7HF!#LK>KK&V3L)`1FY#S<9@
MG%T0WGEVMMI_N)>B8$OI],"(MI6):!5*^'Y%QA901OZU9$T!3_@A$B8$S1/I
M@.F!"EW%5#F0X<J0#,JQ,FX+)+H3IM@ID()YJ(HJX$W1,#Q=J==,#W1,#Q-J
M^6!"6TJ#M5IB?;*R1GW?LUT4^SOV(YM_T[^F!.T3`:)],!HF!&DUE=*D1I,F
M,T](A$KD1YP!(VC)-JDV2IJ*JG3I@2-H_3`>G37QP(4VZJ8,J%$ER08D63BL
M06C7177!!7%`/U0!5<";HGTP"*.NGG@:9DZ%#;%V8\##9F#0&X2"BN.D@`"*
MOF1*B(F!#N.1\?I59_+3V('N%46/<&+>]1ZJ@[O%?TPFM9\KXNVS"?.TBHS9
M'VZ]WN@HOG_I:)%T,OT3!BWT3Z84T3Z8#1/I@-$P/%1$\L#W1-/#`@6UY2U#
M0.V<QJ&#I;&E=)!W%IKH*>*KIUZ8&A.4<:(H(C91B6SU_&H+H+[C3Q[.B^O3
MSTRI6+O+>+-1IDIVTBA&KG>Q/>)T4!AWPV.EKH!?HN!:L/,OM`\R2&TX*$!I
MX$*IJBID5G@,!@<C\DS7(D&D,6(T@7;RM8<"4TCR"+TA`WM:JFUT%+42\L)K
MCJGGG.Y4^O23,B)$L[&ZJ`!F,HFT5>CQ1Y&XW"0E_9T(--%RE5E%SKY!<XY0
MUD":U,O)-$MTLV8C+8O'W=@LGO,$V#HJN&'J1%3!4;EZI)#Y%D/M-"\^QQ>0
MXC:HX".*XBJHG_5HO@7GC$UU"_('+I%_92(;4=::FLI-?/KW7&@>-N.PIBXU
MU5Y7G#Z@&W:0_P#7"U4\BY5S"7\??FH_)(@!9Q:V6PW#;%)#!/S6FWP%=Q(K
M*`[M4B]6Y%PFZM;'GO):^1;QEEL.K7<CJ:MDS:$2.+/&.KJ*B*B;_P!XE$D^
MF"HK'..13>1+5ORF;"EMF+MH2!D6FA.`J"`,*1=YS054'2,=JEKMZ8BYJSH;
M6QJ/_H?(-K7$`3J_CH28Q.#O#N,QMZ;AU35/3@JCM>=?(]6C\4[&#*D28]-.
MARABJ+<=+&8,1YAP$<523U;VR5=?'*5,NN8\WK8_)"&U8=F<+:AN26"C`V-E
MWP[SBJ*D1-(0EVV]A?>G77PR%>/\UYVW:3YP3XQU5=R2/3+4+&1'W8\L6$T[
MV]5[K2R-4T'KHNN"JW_N3SZ1QVRY+%EP&X*5UD^W#,F7'H\F&:]D0:%$<+01
M47D<+HJZI],1,U9LK\@.<WA0'^5)[F30R9\=`B,M1A><D,@T*M$KA'MW?=NU
MT^F&EY\=<MO^2JQ[HT:>J(Q0^2QU;0?_`)N+B`0"NB:"(@I^GR,<B>2BY!SC
MFE=8\YGM6#"U7%"8"/7E&'<?NXP$ANO[M1!DW-Z^GJB+E*B7L_D$RNB-W4V'
M/:8Y)1NU;[#K+CR-O.HJ]WLB+2*JZ[%'Q%>N(;K38_(/*7Y\N-$MD=@V$7D`
MQI+33#2-O5HZL^U15)XE#J!FZFA%U'IB+7D?FW,5@U]357,1N;%HJZR&79.,
M-A*-_7O=W42)6VQ#:2M^K<6JKA*]O.13;^SJITB>VS'K>:QJT*90;W`C&X!=
M(R_=WN*6]/+:J=,+7:\]M>3,<BXO44MFW6-W3TQB4^XP#Y)VHRN@K:&J)N0A
M\^F0KY_9_*/,FN(K.&U9_,5M?-E/-M,LBU)]G.*,,LR=U1&GA;5!;:]2EJNN
MB)EB5T<CFW*6N2SXCDUJ.U):F+QQW1AVL>)F*C@MOOBO>CO,GN)Q#])#X8A7
M0_&O(+&W@V4:T>DI<5\@69L26VP#L8C9`T$7(_[+P%N4P-/)=%\,%?.*$KBP
M_P`!WWCCEJ]:WP+8.@RZ\SM;?'8@Z(.N@HJ;DZ?33!5OQGF?.+R71!^8!H%I
M';.>PS&9,Y3L.<K!"*K_`&T>`=%V^"^&"L4YYR_\)66\>V&6M_264\HXLL__
M`"^3#CJ^V0(@[B`3_9,7-=2P,Y_R1R06K,Z^RC2'&>.5=DVVJ,:-R93ZMR#1
M=4U)0Z@!+INT3SQ"HMY+Y-80XIRK-78/^6U3/'I<AF.CPL]%-PQ;VH2]TB$=
MR)J@HNF"NYX)?7,NCN_R,C\I-I;*P@MOB`-&^$4M6]PMH@(:HNWHF#-Z..:^
M1+=.'CR6/R:/->G0HYOUJLM*M<\_+;9>?T#0T;C"ZHD+NNI#KKXX*G67)N;P
MYMS40)OY=($B"Y'D"L1B:\Q)9=<?BL*8C&-]OM(X.HIJ"Z>.BXA577\HO9EE
M:655R%9#[_':M^K:L.Q$:<=>?=;<+MD.UMPE#;_IWJFNHZ8A7=\0O)-SQ&:\
M<F6,^.[,BO\`NVV6Y49]E53M%V45DR:Z:&/0O'"N#X3R>]F\;X]5)R(XKKO'
M#MEM748=<=EB:"31*8J*BPB[C'[O4FJ],(N^=7$ZV^!2MY[01ITR'`DR&U3T
M`X;[)JNA?TZ]>OE@5UCS;E-/:SZ>7<M2:_\`+0XK?('D9BHPW,BNOG')P6W&
M4(3;`1)0\#37KUQ"NJ9Y)?UWQ;/O),B-=VU=%ENA(A:FR^K"GVUU$00E043?
ML3151=,@^=R^5/TW)+6VBWS=FY*IZ$'K9Q6!&.S*FO`\_P#M-J@@*'JFX%VZ
MIKEA5F5U?IR#B93.2!.:2;<"RL!YHFI(,Q1=CL/N=IL''D4E#T"GZ>K$*KT^
M1.9/\4.]B\E@[I3$$SB-DU(?B27IS3+HJTK+2-`@.DVH.*I;DZ+XXA4_EG(.
M<4;O*&FN4..KQJ%5S&5=CQ-7G)4AT'!>1`'T$(HF@[5^BY(5+MN3\EK$Y'`<
MN?>E4WE*VQ)?:C(?8L#85U@A$$#:F\MA:;D^N6+6N%R_EK=]$DN7)38KO);6
MD_%]N.+9,1V7G64W`*.=T391$7=X+U3SQ"JV!\E<I7CCG(%Y!!>CS8L5948#
M!]ZM??EML/ODV++7::8!PD4'5+U#KKIKB)75_'-A61.2<T%ZZ">+EI"99FO.
M,;G#=@LHVUJTC8$?1431.N2*^E:IT7`^&T%I9L/QZ^IM/Q[=MS6ZAS39!DS)
MOM//(B=P3020FQT73-1*[/A_*[R3\4O7CQ_D[B$S8B)H(H3[D%UYMM2%M$'<
M:-#J@HF9A5`G-16D8G1^;>]&T*K#LLM1E<8>DFJ.MH]H+;"/?;^ZFK>B^*Y8
M55P^56-D'"K"1("RM(%O?QP4"`B=6'$F`R"J"`A$0""*J"FOCB%27.<S?\,+
MD5=S$9LEV-62ID+ML*D-QV:TW*4E0=6F]CA-JVYU3;NU\<##DW)7;;\Q'.Q;
MFPJ_F-$Q7[2;T;;,HKI`ABB:IO(]%7$*AVG.K:7)L8L7D+CL2QKN1(.A,-/`
M_7+^S[=D15QG8B$'K)2/3=HG3$*W6O,+FJH@_%WRN`SPAVRCR"]N\:2V'611
MSN;?5]Z@HKT_G@J;8<QY14CR>.EY[LHS5),9>?\`;-N,MV#BA+!G06V^HCJT
MCG@J^."NT^.)MS-B6KT^Q]_%]\X%0I''-T(8B/;[I1^F\B4ONZZ::Y%?,:8G
MYDKCT4KY];%>773)/N&P[(8$&Y8"@(8*@J0(FFX5_1,HW,_(G*)E/207^11J
MI^1$LR:O);C<<)$N!-*,VA+VG6R46@1PVT0=^O3#+L/E67/+XOBRSL3B/E(J
MCF38A*P!"Y)9%U=7$51;5"5?5_/(JJF<POBDV4R'<E^0J;R+6QN/JC*A+@OD
MR".*FSN$;P.DZ+@+HFGT1<JJ.JY-*@T3<`.32/R,JXO0,77HZ'_Q77=B.2'1
M+LH*;3V;%(_!/3KE'0?'_(#O>8\9M94EM^=.X:+T@VU'0G2EM=Q4$?\`=KT3
MPS(U_(/.K"KY<ZU"N^RE?+IVI,!PF&60:FOH#J;30G)"N`6NY%$6]/'7$$"'
MR;E<JSJA_P`H>[5GR2VHC`&XFT8K`O$RK?[:_NAVA0277QZHN49\?YA?6S-7
M4V7(W*]LH5JX-V"1P.3)@3BCMB1$"M:MLCW#%!3=_#":@S_D_E#'&[6;96B5
M=D?$8UI!8)&F_P#G]U\#<9`Q52[B-MJH+KIKB";=<OY0Q.O+%KD1C&I;.A;9
M@",;LFU8A'20VX2AO42[Q*.A(J+B(ZGXE>,_\J9>M'ITIB_L&B9?<$S:;%W:
MWZ41"%%%.FO3Z87'`USC\B54Q3OI!3UYQ8L*;KC+K[`"S*$$`3%=JD")MW(J
M?1,#.;\AWZ\3CBO)#;MXS-\H/:QHZ/\`XJ23++S[Q`8D2(@HK+;?K5=5T1,:
M8ZCXWMRLN=WDR1<N2')5=428T#NMJRHOQ5-PV6T3=M%S7JBZ=>N#3Y2@S^:3
M)/%ZIE924\;W;SC<D&%8LW4W5Y&A=2[6PG-/U3!JKM>8IRBF^,KF,[&;LWKH
M6Y++QIL:F-0Y#3[9[%UZ.(J)I]4P-EIQ9>)M<18G367I5CS-+)]&Q1AAMR4R
M^I-1VR4E0!73S\>N!V?.;B:Q=<<IAGG4U]R[);E6;7;1Q'&6>XRP!NBX`*ZN
MJZJFJ[=$\<#BV.7\W:BT=A*L'9$&S=LN/"ZPTTB/31=,*RP'0%V]U&5$OZ-5
M1=-,#4WS_ES?#!N)\LHCT*1$X]=O/(#;+,MI\F[";O1H]!7TB)[=J:Z[>F$8
MV?,.5UU/'E.\B:LZZ,Y-<E2:=V.<P8H.-HR]H^V#<P8^I`ZC2(JZIIUQHZWY
M6DF-?QB0-F]617+R`,F0V8LHK3FY?W%<140=43HO\\*HV^9<A?FA8,V9).:Y
M*M+(XTJ-*"P5=[8GMV]WN=K_`)".(6FGZ9-,7OR/!.1=T$FJNX]/RJ$,MRI&
M<*.1)31(V,EAT=47JFU4(%W)EQ7SZRN+>W8X`]QV%#IKY9-XU&B$:%%[[;)@
MZL9Q$Z@Z6[M'IHFJ+IAE9\BY'Q.P^#.3P:MM*V;7L$U<5$HT67'EJZ/=]RI+
MJ9$>J]SJA>.17U^#;5<AYR%&E,NRHH-+(CMF)&V+H[FU,4744).H_7"IV`P&
M!!MZ.IN&66;.,,IJ.^W*8`]=!>97<VXFBIU%>J8$"/P3B,=R*XQ5LMG"DO3H
MBIN_;DR=4>='K]SFJ[L)$-[XL^.WH42"]Q^&Y$@NF_$9-O<C;CB[CVZ^1+XC
MX?IBD39O!^)3BG%+JV'ELT9&?N%='AC+JPAIKX-Z>GZ8I&7^%<2_R%.1_B8W
MYU`[?Y'MIWMJ)MZE]=O37QTZ8(C1_CC@4:)8Q(]#":BV_P#^$F0:%!>3=NT)
M/INZZ)YY:1[(^/.#29@S)%'#=E"+`BZ;2*2)%5%8\?-O1-J^.2DQZW\><&;G
M%/;HX8S2<>>60C0H>^0.UXD7RWHOJTQ2/+WB$>1P:PXK2@S71Y,%V#$'8JLL
MBZ"A]@JG0=W@F"-59\><5CT;=9)J8CHJD<Y:(WJ#C\441MS0M5]"IJ'^G+2+
M*?Q3C4^R9LYM9'D6#"(+4IQL2-$%=PIJOCM+J.O@OAD(HN-_'4"OY#=7MBS%
MF3["R.P@R$:5'&!)D&4%5)2U)$#[DT\5P1:KP/A2O6+WX.#W;85"S/V[>L@2
M5%47>GJ1535=?'!"XXK`D,,OU\:)&NJY@V*2P>CB_P"TW"@IL'45V]$]*$F%
M;N+T;U/6JS)D),L)#A2;":@"UWI#GWFC8ZH*=$$4UZ(B8&\./T+3\]\*^.+U
MKHED?;'61M':G>Z>O0>GJ\L)$.+P7AD2O;KHM)"9@-/C,;B@PV+8R`74'4%$
MTWCY%XIBD&^"\,:G%/;HX(S2=<?*2D=M'%=>':X>[374Q70OKEI&*\#X0K4%
MA:&`K56JE7-K&:5&%5=R]I-OIZ]>F*1LE<-XA)M%M9--">LU(#68;#9.[VO[
M9;U374?)<A$'EG"FN17-!,DDR<*G>?=?AO-=U'D?85G1%W(@;=VNNBX6)\GA
MG$I81PE4L)\(K*QHPN1VB1MDO%L$4>@+]$RU(];XAQ-IYUUNGA@X^"M/$C#:
M;P(=A"7IZH0IM7ZITQ2)E93U-7'6/6Q&H;"KN)MD$!%+3354%$U71-,A&AKC
M'&V7Q?:JXC;X.N2!=!EL21YU-KCB$B:[C3H2^*XI'L'C7'H#S;T&LBQ7F0)I
MEQED`(&S+<0"HHBH*EU5$\\4C*'QV@A/R'X=;&CO2]?=.-,@!.;NI;U1$W:^
M>N%4EW\=44JD>KJ>+#IG'4;#O-0V'`)MMU'>RZT0HCC1DGJ#5,5(C<4^,ZBF
M*0],C5\F0^;1H$6"U$C-DQN5LQ9%7/W$4U_<UU\DQ2.KAUM="1U(<9J,C[BO
M/]H!#>X7W&6U$U)?-5ZX(CQ^-\=C+,*/5Q&5L-??JVPV/?U\>[H/KU_W8(U_
MXGQ?V`UWXF)[$#[HQNPWVT<1--Z#IINTZ:Y:1D_Q?C3^WOU4-W:RD4=[#9:,
M(J*C2:C]B*FNWPR4B7"KX$&.,:%';C1PUVLM"@`FJZKZ1T3KA41>+<:6.U&6
MIA^W8<)YEGL-[`<-=3,1VZ(1:]5\\"=(B19,8XLAD'HS@['&'!0@(5_I45U1
M4P(B<>H?QI5GXZ,M:?0X2L@K)?Q;5-J_],M2);$2+'C!%89!J,V.QM@!00$4
M33:@IT1/TR+$&-QCC45MUJ-4PV&GP5IX&X[0"8*JJH&B"FX=5UT7%2-C=!1-
M,18[5=&"/!-'(3(LMH#)IX$T*)H"]?$<M(P_QOCFD@?Q4/28:.RT[#6CIBNH
MFYZ?62+X*N*1LD4E)()\I$",\4D0"23C0$K@MKJ`FI(NY!7PU\,4CQR@HG5=
M5RNC&KY`X^I,MKO-K^V1ZIZE#^E5\,4CT:*D$@(:^,)-O+);)&6T47R^YU%T
MZ&OF7CDI'C=%1,I*[5=&;2?K[[8RVG?U31>[HGKZ?ZLM(\C\=X_&;%N/61&6
MQ,'1!MAL41QK^V:(@IZ@_I7RR*L-$7`@MT-&T8FU71@,'%?`A9;11=)-%<14
M3H:IXEXY:D;XL&%$9[$5AN.RBJ2--"@#J2ZDN@HB=5\<4B*G'./)&>BI5Q$B
MR'.](81AM&W'$77>8[="+5-=5Q2-K=+3-&!MP(X&TX3S9"T"*+AIH1BJ)T(D
M\5\5R4C%NBHVVI++=?&!J:JE,;%EM!>4O%741-#U_P!V%CT:*D%OM#7QD:W`
M?;1EM!W-)HV6FFFH(GI7RRU(\"BI`?60%?&%\C-PG49;0U-Q-IDI(FNI)T)?
M/)2/!X_0BV+0UL5&A;5@01EM!1I5U5M$VZ;->NWPP16<IX9$NJ\HT9P*V01L
MF4EMAEU'!87T-/-NBHNM?[%_E@CSB'#(W'!E&CC;TN:H+)=8CLPVE1I%0$%A
ME$%/%>JZJOUPJV2DID?]PD",C_<5[O=H-_=5-%<W::[M//QP,2H*(XX1BKHI
M1FC[K3"LMJ`N:Z[Q';HA:^>!)E0XDM@X\ID)$=Q-KC+HH8$GT(2U1<#5^(J?
M=A,]DQ[MH4;;D]H.X()T01/3<B?IK@8'0T9DI'71B)7?<*1,MJO>TT[O5/OT
M_J\<#9'J:N,8'&AL,&T':;)ML`46U7=L%11-!UZZ8&,FFIY3ROR8,=]XA0"=
M=:`R417<@J1(JZ(O73`]"HJ@4%"$P*M.$\TJ-`FUPON,=$Z$OFOC@8G1TKC`
M,.5\8V&S5T&B9!0$UZJ:"J:(2_7`SDU-7*<!R3#8?<;%0`W6P,A$ON%%)%T1
M?-,4>%451(XA0F"1U1)U%:!=RM_8I=.NWR^F!M9A0V''G66&VG9!;GW``1)P
MD334U1-273ZX&O\`$U7>5_V;'?5SO*[VPW]Q$TW[M-=VG37QP-:T5(H@*U\9
M1;(S;166]!)Q-#(>G123[OK@;&*JLCNB\Q$9:>%M&!<!L1)&AZBVBHFNU/(?
M#`S:KX#3SS[49IMZ3I[AT0%"<T31-Y(FI?SP(P<=X^WMV5D0=A]T-K#::&O]
M::#T+]<"1+K:Z8K:S(K,E62WLJZV)J!?4=R+HO\`#!'LVO@3XZQYT9J5'545
M67@%P%5/!=I(J8&0Q8P-MM"T`M-:=H$%$$-OV[4\$T\M,#QR%#<9<8<8;-A[
M7O-$**![ONW"O1=?/7`BKQV@((S:UD56X?2('8;T:3771M-OH_E@2I<&%-85
MB9';DL*J$K3P"X&HKJ*[214U1>J8&O\`$U?OO?\`LV??[=GN^V'>VITV]S3=
MI_/`3JNLL&T;GQ&9;8]1!]L7$37Z(2+@>+452K'583"K$32*O:#5I/\`['T]
M'\L#6[Q^A=)XW:V*X<C_`-01LMDKG77UJH^KK]<#R'15D2QD6##`!*DMM,N&
M(B/[3.O;!-J)T3<N!88#`8'-\RY<[QS\.@5[T];:Q9KD1E6T[?=0EW+O(->@
M]$PFN:X5\D&<DZF].2[+>M[2#$LB8%N+I#<,P9(PVIO1D-?MT71>NN"KSC/R
M7QSD5N57`-Q)!1DG12-`V/QM^SN@H$>WU?TGM+14733`T/\`RIQ^/-MHS\><
MTU2N+'GSC808POZ-JVT+JDB*3O?'9_\`2PJHF_(_Y:30K22'8:AR(*BZB."T
M2DBQW'5#>*N@HJB"2$V6$3?^\O%R<DBPU*DBS$DSXQ,"VXLEF&NC_9$3W(0^
M*"X@J2>&N"K)[Y#K$:8=B1)<X9$:)+:6,`$FD\E%@3)300Z"I$1>D1355RE5
M8_,M"['B'$K[&9(FA/-J+'::,T*L<[<ILB5Q&]1+P5"T5/!<%3N/_(8WO)6:
MV#`>6LDU,>X8LR5L44)1$@"K>[>FFS1>GC^G7(8C/?*#4*XY'#LH#D:)1OPX
MD>2KC/\`R7YH";8"A&.W=O33=T1/%4P8U!\RTKH01B5EE-F3WY<5N%&::<-'
MX*(3PJ7<1LAVDA"8DHJF%&_F&M>DLQV:2V<*5+EUT4D991')L+=W&$57>FJ-
MDJ&N@=.JI@;87RU4SEJ@A5\Q^3:,E(]IHR#[(-R%BNH0&X/<)MU%WBWNT%-?
MIA,6_-+08!4*%(F1O>6T>*)0Q:)#)Q#5&G^[X,GM]2CZO#+@J^/_`"M5W5I7
M00K+"&%H4QF#+E`T+1OUY$+[?H<,^FQ50M-%^N#4'G_-KN)*Y!008[L4XO'9
M%NS=-FTJMN"I"&ULE5=!4/\`2O7],AC97?+%6Q5.K;L2XDF!!KY)E)%I%E#8
M:-,FWL,D13>115#VZ>*],+KH.)<RB<ECS7(S#K#]=(*++CN;%_<$4)%;=!2;
M<`D)-"%<(X3A_-KN6\U;SUGO6=E/LJZ!QX#C>V=&(\?K157]KV[;.A&I>I5\
M^F#%JG-W+SD?#7:R1(APYTBTA6U<X(B8OQ(Y:MO)ZO6TX'3:6B^/7"XB\$^1
M;%>%4K;[$KD/(7H,F?*1I6A<6/'DFSW"4U;%2)4V@*>.GEE%C*^9:%JOG6+4
M22_#B5#-\PZ/;'W,-XE`NTA$B[VB30Q+3K_'(B1=\RB.R*Q&UG,QBMZ^&U+A
MDSVWW)37>1MS<JJK.A(CFG77PP%5\JP9UC#BNU<R%'G2)\-B8]V5!9%;O5T-
MH&9Z$+1*)::+IIA6_C/R3#O[2%!CP)+0V5?^7A2C5I6RB=Q&T4T$MP&I*GIT
M7Q\?'`SN_D2-3\BBU$F`\C4J5%@MRU-H=SLQ=&R::(D<<;$M!<-/M7ZX$6-\
MIQ),^)'8K)+L>P<GM0)0DSH95:JDC>!&)`FHKLU\?/3`A1_F.._40K%::5%6
MU;5^JCRG&`*0PVTCCKJ*!.;$'<@HA=254TZ=<#-SYEIMT56(,MX'6X;DQO9M
MD1_?KHTBQU]9J.NYQ!^T>O7`-_+9.S(\9KCT\UF3YM3$<[D5!<FP=ZD'5S40
M(6B5#7IEB,7?F:M&HC36ZZ2Y+=C/S)%:A-]]IN*^49T1T4A=<[@$@"/W:9%2
M'/E:.%F<9:B8D%FPAUDBQ)60`'+!IMR.?;4NZJ*KPB2;=1P(4+Y;E!7E(M:P
M8TA^VG54!KW+(-$L(S%!)]Q1`7#[>@HOW%T3`ZKD_+!X]1L7,J$\Y&-Z,U+$
M"!"CA),6^ZYJNBBV1IOT7`K&?DRM<D6C!1G&W*>P=@SM3#TM,QEE%*Z+_;[8
M^'CKTRI5:?S#&"#*F+3S'&V&X3[/:V$+K4]Y&6]#+8".`1(IMZZZ+JFN(N);
MGR@C,T(;]1)24T_'BVD=H@?<BN2^K?1I#%P1%1)Q1+THO\<@N^0<G>KIC5=`
M@G9VS[#TMN&!@U^Q'44-5,^FI&X(BGFJ^28%-8?*#,)F7+*KD+`J4B_GG2)L
M7(92@%S:K6J]Q61<%7=J]/+7`QC_`":;MV%>=,^U"*W>HELE=944E--*Z!(T
M*[U!P4\?)<HK)'R5'NN,O6+<62S":FP6$<@S&@DB;TM&5:?%-#9("V]ULDZB
MO1<:,+[F]C-Y)QLJ\'HU&-](KY,\7Q$)'MHSZ/`;")N)M'6EVEKXCX>&0;#^
M:F$K)=FU2RWX;4-NPB.MKZ'67'Q90#-P6P;>_<$T#5=1\\N";.^4I,&2D.31
M2/R#/8*R@L&,AY@9+I-M;$9$P=78/<)-R:#]5P(5GS&SL^5\56O;?CTCMQ+@
MG,%\1"5[>,\AB;")JH=UI=BJO].NB=,@^@5$N=+@MOSH15\HE)#B$X#JB@DJ
M"N]OTKN%$+^>!,P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&!SO->+2>01:U(DP84NKL8]E'>-OO`I,;D4"#<'0A-?/`
MYUGXMFBL,7[)IUF/=3KB0VD=1[H3VW&R83]ST[4?+U?^&7HS%EP/A%WQEM(<
MN[2SK(C21JMA(K;#@,CIM[[HJJO&(H@HO3]>N%B/.^-'9T'E$1ZR5M;^>U9P
MWVFD0X;[`-(TOJ(A=T*.)=437JF%>_X'R"0S3%9W@2YU7:-VCKP1`9:<%MHF
MD8;:`_VT5#55+55UQT99<-X!:\;>6,=V4_C\='0K*PX[39M-NDJ['GQ]3PAN
M5`U1/UUP=4!OXB&'Q/\``5EHZSML@L`>?;1\%9:=WM0G6E(=\<`T!!W>6*-=
M'\1S*N?'DK==\8RVRMM>U!M/_G!"X?V'I^V8ZITZITP35CQ+XXE\=GU$IJV5
MX*^H:II3*L"/N`CF1LN(6Y5;5%<7<B:ZX7&GD'Q:_;6ES.9NG8!6;L&;&[3(
M$<:=7B@-/H1+H8J`Z$VJ?7K@S$R-P2V_,<?M[&\.?-I2EF\11VVA?68VC2B`
M@6C(@(IHB:_KA42M^,'X,BK>2V5S\;<S[K;[<1[A6".(3/WKM0.^6A>>$W%>
M7PV^]4P*F3<B]#@/G*:<6$V,EMYR64M78SZ'O8/U]M535%'RQJNPY9QEV^2H
MV2_:+56+%DG[:.]Q8Z%HVNI#M1=_CC!0TWQ@]6R.//+;$^M!+L9@HK`CWELU
M-3`M#7;V^ZNBIXXT2>6_'CM]:2K!FT.![ZH>I)C*,@ZALO$I(8J2HHD!$O\`
M'(*^?\2#/60LBW?$G:R!7,.,-`V;+U8[WV)8$JEZ^XNJBJ:>6!U?&Z>UK(1!
M9VSMS/<+<Y,=;;8'1$T009:T`!_]JX(Y>#\4E!A0$C7#H6M78S+*#8=D%1/R
M!$4AAQK=M-LNXOFBITZ],"9#^-8\.;2S69SGN*J7.L)!$V"^ZDV(D+QG_H1-
M_I0?X8$.G^*%IH]6M7<OQY];%D5YRU9;/OQ9+RR-AMJNU";<74"3^>N6BR;^
M,>--GQU0;-&N-L.Q(K*KJ+S+P()"_P#ZTW"A_P#FZY"-$?XPKHG'>/T4*8\U
M%X_/9L&G"07''B8,B$'"+R]6FJ==$P([/QJ=<S7R(T]^7*I9ME:Q65%IOOO6
M`.ZLD6F@"BO%M+_K@47Q=1<DK;1E"C2V(8L*U8)8P(,4]4U(`9?BDINZ.DJK
MJFWJJ^.5%]=?%B6=_+MQNI<7W4JOG+&`&#$7JU45M!-P"-&RV]0UTUU7(KEN
M*\<Y:/(S>]K-@NR'Y2V1385;V`9DD2N=B8R7?<)5VJ/IZZ>K*.K/XN0*7CT*
M!>3*^RXVV3$&W9%E739<%`<;=:,"9,201_I\41<@W_\`;EQN\&UA7]E$5YJ.
MS;1Q-LAF^UZ`XX9`I@XJ>DB;4=4Z91A#^,V8[]:]^2?<*LMYEVTA`TB&[.%P
M3:+0?L'OEMTZXI$./\2>S2"[6\AL8$Z(DIIZ8PC"%(CRY!229<`@(/0XXO;-
M$W#A(F2OC&-(.P(K.4/O[2#;ET;)0<KQ:%MI%(551+L#N4NN%:)/Q6+T*QKD
MN)'XJSERY<BN=9C/L_\`.53=#1P%5=KBJ8$JZBN$ZNF?XQ6R.*+QF0ANUQ0T
M@'O+<XK2-]O527^O1-=?KD550_C?CL66Y*1MQXWJENC?%PM4<C-ZZD?U<-"T
M(O%<M95K/Q6H\><HI/(K.;#0XWLUD$R11V8;PO--CH";^H"A&>I*B8N+U64G
M@0.<I<OXEM.@#,[2VM;',!CRC81!;,]14P7:B"6PDW)T7!U;>5<)"]G0+*/9
M2Z>UKT=;9G02;0R8?V]UDQ<%P"$E`53IT5-4QT,J'*^,ZQ]^;I,E#!M6XX7,
M%2`QEK%1``S,Q4T,P%!<45]2)BXDUDGQS"[R.^^D[ANSY`B?MZ>X-M6U;^W^
MV@E_']<7%FH;OQ-7OC+<DV<IZ;,]DC\W:P#IC7O^X9[FQM!<-3Z$X2;E3IBX
M36;?Q37-V[4QNSG!!8LG+ABHU:6,,I\3%_34%<[;G=)=F[1-5TQ<)K0W\00V
MZ&90I>VIU3X"S"C.NMF,-H71>[;.H>KJ""BN;E0>B8[L%K:<!9F<B&^CVMA7
M276FF+-B&X#;,P&"4F^\*B2BJ;E3<"BNU=,E-Q#A_%D");Q9S%I."%!L';6%
M4H32QVGY`F+R"JAW.V2NDNW=T5>F6DUU=1`>@06XKTMZ<X"DJRI*BKI;B4D0
ME!!'THNU.GAD,3<*8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#)`RA@,D#$#*&`P&`P&`P&`P&`P&`P&`P&`P&B82
M&%-$P&2!E#`8#`8#`9(&4,!DW`RA@,!@-,!I@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@>"8$FHDA)U35%UZHNBX'NJ?7`UA*C&^XP#H$^TB$ZTA(IBA?:I
M#XIKY8&+LR(RZTRZ^VV\^JHRV9")&J>*`BKJ7\L#=@%)!15)=$3JJKX(F!@R
M^R\T+S+@NM&FX'`5"$D7S14Z+@82YD2''*3+?;CQPTWO.D(`.JZ)J1*B)UP*
M]>7<53=K<P?0).&GN6=4`$W&2^KP%$U7"+-A]E]EM]DQ<:=%#;<%=1(23421
M4\45,*SP(ZV5<,X:]93*3R#N#$5P>\H)_4C>N[;^NF!B=I7A9-5AR6QL'FB?
M:B*2=TFFU03-!\5$5-$5?UP)6J?7`:I]<!JGUP&J8#`IV.9\0D3!A,7<!V81
MJV,<)+).*:+HH("%KN3Z8%QJGUP&J?7`BV=I7U<(YMA);B1&U%''WB0`%3)!
M'55^I$B)@2D7`:I]<!JGUP&J8#5,!JFFOE@-4P&J:>.!"CW%=)L9=:Q(!R=`
M1M9D<5U-I'D56U)/]R"NF!E:6]951%F64IN)%%4%77204W%T$4U\57R1.N!I
MIN14=T#IU4YF8C"H+Z-&BDV1)JB&/W"J_14P+'5,!JGUP&J?7`:I]<!JGUP(
M35Q7.VS]2#XE81FFY#T?KN%IU2$"U\-%4"P$ZZK8,N##E2`9E63A,P&BUU=<
M`%=(1T\T`%+`55Q76L994!\9$=''&5<%%1.XR:MN#ZD3[3%4P)NJ8$.;<5T*
M3#C2GD;>L'ECPP5%7N.H!.**:(NGI!5ZX$S5/K@-4P&!&KK&%8PVYD)]N3%=
MU[3[1(0%M51714^BHJ8$G5/K@-4P&J?7`:I@-4P&J?7`(J*FJ+JF!`M[RKIV
M&I%E(&,R\^U%:,D545Y\T!H.B+U(ETP)^N`0D5-475%\,"!:7M55E#&?(%A9
M\@(</<BKW)#NNQM-$7J6GG@2)<R/#B/2Y1HU&C@3CSI:Z"`IJ1+IY(F!4U/.
M>*6\F/&K;-F2]+;5^*(;D[K0HBJ;:JB(2(A(O3`FVE]55<B`Q.D"P[9OI$@@
M2$O=?(5)`31%T7:*KUP+#<GUP&J?7`:I@-4^N`U1<"#7W=582IT2'+:D2*UQ
M&9S39(1,N*.Y`/3P73KI@>U-U56S3SU;+:F-,/.1GG&20A%YI=#!53^H5\<"
M:JZ)@45)SCB5[/E5]/;1ITV%UDQV313$4+;NT\QW=-R=,#97<RXQ8QYDB%9Q
MWF("*<QU"T%L$U7N*I:>CT+H:>E=%ZX&@^>\0;I'+QRU8"K:/M.2251T<714
M;453?O5%U0=-=,"TI[BKN:YFRJY34V#(3<S)9)#`D1=%T5/HOC@3-4P&N`P&
M`P&`P&`P&`P&`P&!2\QY`5#QV98MM%(D@*-PHP(I&[)=)&V6Q%.I*1DG3"/D
MWPSR*WJ9/+^"6LA];2N)^XIY<UE6'GX\O<X;BL&O]+ZJNGZXBV^"EN^7?)UO
M\&-<MG7<:,U;#"92/"B['15V?V'%5TG%Z&VJ:HB)IX935CR;G]KQ#D/R%*;:
MB2)M9`HT"U2,(.DLL^TKLA07UML[E(1\O#")?,/SH<F^.BNIT2V=;Y'(*!-B
M@@$4189&T+PIZ4=7SV]%Z9!;_#_R#S'ELABSG^U_"63$HQCH;(OQ9,>2H"R#
M8$3QCV=.XKB(J%^BX5UWRQ%BROC3DS<D$<;&ME.(*ZIH0-$0KT^A)K@5'Q>$
MT_C+@!1K!N$T,"(LEDFP-90>V_L@I*B@N[0M1U7IA'=3H$*<P+$Q@)#*&#B-
MNBA#O;)"`M%Z>DDU3!KY'2U=0]PKY)?>B,&Y$MK\V'%`-6U2/MU%=/3Z25,"
M*SSGD_&:,V')S,MAOC]).B$;0,A#66^D-Q5)-=S8"F_4_!?TRPKZ+P2=>R`L
MF;:;&G>WDZ0GH[@..)'-L2$9"M`VWW$77[4^W37"JN3V1^=(1+L1Q>,R=%73
M=HDYG^?UQ$JMYIS^377[LNI<9G1(W'[>6C8MB:K*KWV071U/6H#O+>(KHNGU
MR*BVO,;2JB158Y3&MXUQ+@,!-_X[!0@DM.$2D\(N-(CYMHC6\.FOGTRQ$%WD
MG/W7V*TN1QFY`4UM-=E0&V)"&]!D`+"[W`0=VP]KNT=NNNFF(5+9Y]R0I_'Y
M\U\PJ;.)6JB01CO->^EL*X4:8V7[[7?(A[+@+M3P7$5O^..<W-HY&M[6\K2J
M)U=[F3$60VKT:4CHBNB"VUVFQW]LA=)5W(G7QR)7U9%1>J=4\EPKXK6_XG_V
MZY\/($8]A^<NT5"V[U<5U5:[7]7=WZ;-O7=IIE@T4?+^=(D&JE6D6MM*>+2^
M\B6#P-G)&2R!22)I67'G#)25L%`TT-.J8B5;M\SYA$=OZ9UXYESQ4IUC*<[3
M:)*KU8)VM;T$43]PCVELZ_ME]<%45_R"WM/COD3TN[@VM9(KH$R.#+S;S[+I
MR`[NXFFF0%HNFP2U)%1>N(5T4OE_(BFV-A'L%%RLY''I/\>V-J+L1XFF]W4>
M[W3%Y7@)"TT3PTUQ"JNJY5S?MU$]WD"34M)-W7R(/8CAV0@>Z5F4"B.[<VL<
M$/=Z5W)T^J%0H_*^=/U#;Z\F-')/#?\`)>X+$9%"4QM]((H*G:<W>M%U7Z*F
M(5;PN=\AMN1-,M6\*M=BOU6^MD.B*RHLV,VZZ3;"-DX9.&Z0MD!^E1Z^>(56
M1.5\OD0JYU^^=?2['D<(V@!AOMK7(^4=UH@'<C@]G15UT7Z8A7TKXS>1_P".
M^.O>[*<3E=%)Q\S%PE,F`4A4A1.HKT^OUR*X>;SBS#GC,.+=[X3UO+J9##BL
M-"WVX!.@#3*H3A$TZ**KI$B$JZ(*IE%+`^1.8UO'8]J_;+:2)_$CN":=;:V,
MR69#32O@#0BJ@@/J1HJK]N(E=?\`';D7_N)RT6+=;H2@TYA+,VG"45&1YM((
MZ==WAYY%;^8R68?RIQ&3<&+5'[6>W">=5$9"T-6NWO(O2)DPCB-JOZHF$K+E
M][6Q+"&M5)",[;V<2KOK:,H*3+?:>-D2<5";%PBT!%7JF[^&6*YV)?\`*YUY
M6T)W[K44K&ZKDLF18[TJ/"C-NLN[B!1[C1F0$0CHNWPQ$JB#GW,&^+1[4N0&
M[+L^)6-IJH1T;:EUYMBVZR.W^I"5'$)515^F%Q87W).65:<E>;Y+(=&EB4UL
MPV81M".:X3;[)Z-I^P2-ZH*=45?NR&IP<SOIO(K39R")!=KIME#D41N(4A8[
M+)K&=;CJWJ)>D7NZIJ*IJF6)4>#R>T"JXN%]R]V#'Y/5.V*W;B1F`;EA'8V1
MVSVH""F\W=I=25--=.F(5*N.:6$.PLV7>0.+$&IHGF9+33+9D],F&PXX".:(
MS[E$3U&JBWKKD$*DY#,M9W%QGSPFO5W,;&`R[W0=+LMP)7:$G!0.XJ"2)NV]
M<L*+S*Y=XK%9CWKI\IL+:VK*D=[+;:BS,<!9,GT]6XC`;NFFO1//$*]L.<R8
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ML7,W_(V8-G#9NVYO']ZG*8*(+BQB%DPVL]I`$NXNHGN_5,0J/:7W)X]?<N-\
MMF*<?B,3DK2[HVJ3-KB+I^WT9/8FH>:KXXA5RQS*WLN;%$7D$:KE0["$+%.X
M1$4ROD1VR56XZ#^[WB<)4=0O1IUZ8A5+7<BY))K:EYWD4N8MZQR6(\UO:%$]
M@CJQC9[8B2.AL3U(O5,0KZC\4/Q'_CKCKD:8LX%@1][ZN(\O<[0[P4D_TETT
M\LBOG'-N1I86=G$LK=8<VMY33185&3@-B</W$9P7U;)-SG=(S+?KTVZ>2Y8E
M1G^<3IUS(@Q;]Y^/:0^1LDT3X#(1Z%_8[<<!UC*WH0AZMQHFY4Q"M<;F$H*J
MEJ(O*F:=M>/0)=/9RGU<&1,4U&4&@HJ2%:V"'9UU]7UQ"I5WR4;*\@K:7!,6
ML#FD.$-"K@-@,4%1&7.P7K7N(7=[GZZ>60K[/>D`4-B1D@@,5Y2(ET1$1M=5
M5<*^0TEAR:I^$*_D<2P9F1XM)"2$T$9-\15(6Y+_`'!5PC[;!%KHG3;X94J+
M86BS8E.Y_E3-C4%RB'[.TC.]WV;;D1U";66\FPR4EU35/1NT^F(5MIK/E%AR
M*CX\YRN:,)Z;>,1[%I8Z/S8L'LE'<4B;(342,VU,4]2"N(5G6?($U)U!#?OR
M]\-UR")91E)LWEC10E%&1UI$W:@C;:@G12_77$*YPOD:[2IMBA<H-4<J*NQA
M2')+$B0#KU@C+QF.SMLJ;1(IL"I('AKKB%=]=EROBE[$B-6T^YK^21G*V`])
M5LRBVJDKC+JJVV"(!LJ77P39^N"OIT-@H\5E@W2?-IL0)YS3>:BB(IEIHFI>
M*Y%<7PEYD_D+Y`;;,24)=>IB*IJBK!#773^&!$^/KNFJZSF-A.F,1($?DMBC
M\EPQ%L-S@"FXE71-273`^A.*T3*J:BK1"NY5TVJ*IU_EI@?';6TXWRBQL7>,
MV<%9\*DLJGC4.&ZVK[[KK>YTT!OJ#3?9$6]?/5?IEAKEN0HW9T\1RE%7H-?P
MZ`W=MLIKM;&='<[!B.OK%EF1J"]437ZXB5VL;DW'*OE_,^2RY,9:-#JVJ]\C
M;1IZR&,:$++A+LW]LVP547IY^"X*Z;XK;IV^/R%K9L6<;\Z3+L3@FCD9N7)/
MO.,M$/I46T-!Z?Q\\BN.^4N:RJCD[XP[HXCU8E2Z<-UX&(_:E3%;=VLZ$4GN
M-ZH9%H+:(G75<"WX1R.8_P`]L:Z98'8#(&6_7OQI(2(1,-24':;*(CD5]A#%
MM4ZB?5==<L2OIN13`8#`8#`8#`8#`8#`X_Y`XOR6]*L*FF5T18#RR46QAE,T
M>'3M.-;76MA!UZ]?'".4D_&7R9*MEN)-WQYVV5DHRSRI25[LD*B3>_W.NU15
M4TQ^IN8Q3XN^1O\`'UXX5WQ[\"J;?QB4:^WTW;_[?N=$]?J_CC]3I[#_`+4_
M('<EN)=\>%9[`19O_P`@1>\PVB"#3FLGU`*(B(BY?U.GL:XWP]SB*U!9BW?'
MV&ZQU7Z\0X^"=EY=-7&_^3Z371.N+^),]B15_%OR-4SY4^KY)109LY5*;)C\
M>;;<>55U53(9**O7KDW\USIY)=CP7Y>LH;D*PYI52X;R;7HSU$!MF/T(5DZ*
MF.AJZX9P6PJX;,7D,FOMAKGA>HQB5X06X2H!`7;!#=ZKO7JBIIA'9JG33"JJ
M-Q3CD:'.A1ZZ.U$LR,[!@6T0'R=31PG4_J4T^[7QPD!XGQH=VE9&]44:\M6@
M5%B!]L=45.K:>0^&6D;Z:AIJ2"$"GA,5\%M5((T9L6FT4O%=HHB:KD5'LN)<
M9LYJ3K"LC2IJ!VDDNM"3B-HNNQ#7KMU7PRU-QE%XKQR(4<HE;&8*(T<>*K;0
M#VV7%W.-AHG03+J2>>*1I8X1Q"/5R*ABE@M5<LE.5!".TC+A+XD8(.TE_CBD
MQN#BG&FT91NKB@D>.4-A!9!$",Y][(Z)T`O,?!<4C!GB'%V)<>8S51&Y<4`;
MC/BRVAM@VFT!$D3H@HN@_3RQ2(MAP#B<N!:0DK(L=NZ1$M#9CLH3_5%U<517
M<OT5?!>J=<4B^98:99!EM-K;8H`#]!%-$3(JJC\,XC&EI,CTT%J6AJXD@(S0
MN;UZJ6Y!UW?KEK/;B3*H*.78Q[*5`COV,-%2)-<:`WFM?'MN*BD/\ER58DC"
MC`^Y(%L$?=$0==040R$-=HD7BJ)N73!%>QQ'BS$.3"8J8;4.8?=EQ@CM"VZY
MKKN<!!T)=?KEI&]:"E_(A9^PCK8MB@!,[0=U!%-$3?INZ(NB9"*7AO`JSC]:
MY&>"/,F/.RS?G)'%LW&Y<@WR:/53543N;?'JB9:1<#QR@%$0:Z*(BPL041EO
M1(Z^+*=/[?\`M\,4C)./T:28TM($9)4,.U#D=EON,MZ:;&STU$=/),4@SQ^C
M95E68$9M8Y.&QL9;3MD]_<(-$]*G_5IX^>*1(A5\&!%")!CMQ8K>O;89`6VQ
MU75=!%$1.JY%17.-T#DDY3E=%.4Z:.N/DPVKA."*B)D6W5205T1?IBIN-C-%
M3,JVK4&.VK32QVE!IL=K)+J38Z)T!?,?#+2%=1TU8*C708\(51!5([0-:BBJ
MJ(NQ$Z)JN16Z=7P;",<6=':E17$T<CO@+C9)_N$D5%PD:`H:0*U:L($8:PDV
ME!1EM&%15UT5O39_X9:KT:*G`8XA"CBD05"(B-`G:$DT(6^GI1?/3%2-:\;H
M%:!I:V+VFVR9;;[#>T6C74FQ3;H@DOBG@N+J=N,SH*4T<0X,<T>`&WD)EM=X
M-_VQ+5.J!_2B^&+IG'&94U24DY10F%E.-]AR0K0=PFO#MD>FY1_V^&18\>I:
M=Z(W#>A1W(;*HK,8V@)H%'[5$%3:FGEIBZ0D4M3)5Y9$-AY9`(T^KC0&KC8K
MJ('N1=PHO@BXNDP"EJ`(2"%'$P/NB0M`BHYIMWHJ)T+:FFOCBD8'QZB,1$ZZ
M*0BI*(DPVJ(IKJ:IJ/\`4OC]<4@G'Z-"0OQ\;<(@`KV6]4%M=P"GI\!7J*>6
M6D;$IZM#WC$80^ZK^]&@U[RIHKFNGWJG]7CD(!3U0%(,(;`G,_\`5DC0(KNO
MCW-$]?\`/"QFQ706'$=9CM-N""-(8`(DC8^`:HFNU/IBI&;\.*^ZTZ\R#CC"
MJ3)F(D0$J::BJIJ*_P`,*K.0\7A75=+C*2Q)4IKM)8,@WWP35%T0C$M1730A
M7HJ=,M2*KCGQY"K7WI=BXQ92W6T8W#"C16D;0T<T[3(Z$6Y-=Q*OZ:8I'3.0
M(3KS3[C#9O,:]AT@%3#7QV$J:C_+(1@557$ZZ\49DG7Q[;[BM@I.!_I-=-23
M]%P06HK50D6*RJ$"-%JV"ZMIX`O3[4^GAEI&7XR!WVY'MVO<-"K;+W;'>`+_
M`$B6FJ)^B9"/`K*\-G;C-`K2DK:BV*;5/[E'1.F[STQ2-L:)&BM"S&:!ED==
MK;8H`IJNJZ".B>.%:GJNN>D>Y>C,N2$1!1XVP(T%%W(FY4UT1>N$CP*JM;=5
MUN*R#JD3BN"V"%O--"+5$UW$GBN*02JK4;9;2*RC<8MT<.V&C9?4$T]*_P`,
M$9%6P#D>Y.,T4GTIWR;%7/2NH^I4UZ>6"-YM@X!-F*&!)H0DB*BHODJ+A6+4
M9AIKLM-@VUUT;$4$>OCT3IA(T+4UJPUA+%96&7W1NV':7KK]FFWQZ^&"-B0(
M:$T2,MH;*;62V#J`^&@KIZ4_A@C$:V"+Q/BPT+QEW#=0!0E-$V[E+355V]-<
M$:_PM3MV)#80-%3;VF]-%+<O33S+K_'!$#_&#/DOYF192'HS0(,&I5&TBL.*
M.PWAVBAD9"JIZB5$U73*1>:9%:6H<5EUQUID`==ZNN"(H1:?ZE1-5_G@19]!
M53J^37O1P2),Z2FP$11Q%74D+IUW>>!-%IL6A:041L404'3IHB:::8&ABKKH
MY]R/%99<TV[VVP`M/IJ*)@9LP8C"&C#+;2.DIN[`$=QEXD6B=57ZKA(UI4UB
M1PC>T8]LVJDVQVPV"J^*H.FB>."-S$:/'!&V&P:;3J@-B@CJOZ)A6#]=!D.J
MZ_':=<4>WO,!(MFNNW54UTU373`,5\&.ZX\Q';:=>7<\XV`B1K]35$12_GA(
MD84P&`P&`P&`P&`P&`P*KD-^U2QF7CC/RW)+X1F(\8$,R</5?4I*(`"(*J1&
M2(F!RA?-/&EB19,:#8S!EP9-BV$=A#5&83_MY*$N]!W-'X]=%3P5=4Q!(9^7
M^*FU,>=;EQ68L6/.CN2&D:25&F'VF'(^XNJ&YZ?5M_Z8@T,_,W'7_;LQH,Z5
M82),F"D&*VV^8RHC2/&VIMN*UH39;A-"VK]4Q!HOOE.NF</*9Q\)KUA-J9-E
M&&.TVKT1ME"#NO`Z2"FUY-FWJJJBZ(NF(,8/R]0P*NE:M7CD3'H=8=G*#M:-
M.V+8=HC;4A<+>1:KVP7:BZKB#&SY]+F\SXM"J!E,U$FTFP9<U0:]K+6+&>4P
M`E4G?0\UT71$+1?'!77W_*&*9Z%$2,]/L;$G!@P(VSNN(R&]TM7"`!$!\54O
M%43SP.;D?,M"D6/(A5UA8+(@R;'M1V1WMA!=1F4V[O,$!QDUT(?^FN!VM;8Q
MK*MB6,-=\6:RW(CDO35MT4,5T_@N!P?%_D&QLOD696R5:_`6<9Q[BS@*BD:U
M[JL3-RI_K4A<#_;@Q<I\D5/=9;*+)%7;H^/*JB.@RP%20BT+^V2)T+_PRP06
M?EVE>[9LP)CD>5"FV-?($6]C\>O7:\2>O45UTVH2==4R#9+^6^/1(ZR'F)`,
M_AX]Z#A(""L>4ZC(`JJ7I)#)-V[THG77`!\@V+W(^/UC=&\VS<#-)U]UQGT#
M#4$0@VF0N`:.(:$*]1\.N6"?SJ+<G"]]$Y"YQ^OKF7I-@ZPPR\ZX(#NTU?$P
M$1$27H.JKD$C@"WA<,J7;Z04JV?CB_*><`6SU=U,1(00110$D%=$\L"C^31Y
M1$JI5U4W[E8<!D?QM<TPT\,J81:`T_W!(S1TE%L1!15/'7+#7/<AYKR9A[D]
MPW*6.SPYVL8<JP$58D%)!IV;W55%-?1(VMJ))HHZ]=<1*S;YG?+8KR#WII5_
MY0O&UJ2$.Q[5"]OW]=.YWN_Z]V[3;Z=,0J9P7GR\@O(LJRDRH0W82G.,U2M"
M$1V)&-04R=T4G)!"/=TU1$%>B+HJYE707=Y.?YM5\8A&32)$>M[%QO1#-IEP
M666!(N@HZX:[E^@Z>>:''P_D7DME+XG;I7R6DG_FVW**,ZR8R/9]&24R4111
MV*FJDG7R\,@O)?S5QQFLA3V([\D)$%FS?CBH(^U'>-6T_;5=7'$("]`:KZ?X
M8'4\A<OC@PW:%MMYPI4<Y3;QJSNB*7[NTMIZ%MZZ:=?#I@<;:VG-(5SQ&+8R
M$AE87TN))",X+C<F$,=]^/KN!%;_`+0ZBG5.O5=<#H^76\>NLN-@^[*:&98D
MRAQC`&E48KSJC)0M5)K:VJZ#_4B8%>GR>TW7':2Z>7&JG8[4FLG&H*$GW#HL
MLM:(NK;AJ8D@E_2NODN$K2U\K@\L2,S22G;&7/DU81Q-M&^_'CK)0A>-0$VG
M`3H:>"ZZX6E?\N0+$Z5B'7N+,MV$D>T>=:9<!$D%&=!O>NCYLF!*8@O04U\T
MP)=)\G5MOR)JIBQ'2C2EE#$L0];9%#/8YW$1/VT-47MJJ^K3RP)'R1=3:_CY
M1:R6U"NK8O8U4I\A$&GG!(E>7=TT:`2+!JMH?DR/)^/:3D3K7>FV3D>N6*!"
M*?D3<]N;9&NHB*.B7J^F!J+Y:?-(C,3CDN5/ESIU6W%!Z.B>YK@4G?W"-!V+
ML)$+]/#!7B?,]*,Z0+T-X:M@)A?D6]740J\25Y'`$?0*J!"V6Y=RIY=,)6#?
MS&VJ()44I9!S8,)H&R%0/\CN1HT=-&QU$@VN!_3^J=<+6ZL^64DRHC<VE?@1
MGIDRLE2C>:,6)D%MQTPT!=Q@K;)*AIT\L%14^:XRU\B<E)+<CA'BS(AMJBBZ
MQ,D#'%%,D``>%7!)6]5]*^.!G/\`D^Y61$AQ:9&9H\A:H[-B0^!;`=8]R#C9
M`BB7<:5/_*OUP+&OXGRD7XJ3.0S'8X)8!)%3;W&W)/=%U(6Q_<8_I--.G31?
M'+$JP^/.0R[SC8/3MJV,.1*KIQ@F@D_"?-@C1/+N;-^GZY"O.1\V_"7D>K=@
M&Z,R#,F1)7<$0-V$*.'&T7JAD"[D7PTU^F%<9R?Y&?N>+4UI2-R(XOR*.6ZK
M3HBY_P`V:C9PC3IUVB6_RP+27SMFP8KEEPIE?*C\F;II3$>2`H#X@K@JX8IH
MZP8$*D&G_LP(7+^<VUEP&\GUL"5"KGJF7-J;YAX4)%C%H&\4T)HG4];>BKJ.
MNNBX'4<.Y?(MIL^HF0#@SJMF(\JFZ+J/,RVU)MS4?M+5LD(>NGU7&C.1S*<M
MW(KZRG=L8]?)CP[.2VZ`DT<D!<W`V2>L6@<$G/4G1>FN45T+Y/&3(K'5K#"F
MO7I$6EL>Z*]UZ.CA"+C6B*VCPL&K9:K^NFN9%*/S-82J)RPCT!1G)5#*OJ99
M$@"%T8B#W6W4;%5#;W!(?]2?3-03)_RO+I8E:[;U0BDEF"X^Z$D-3*:XC2K&
M:V[G$:4D)Q5VHFJ(BKB#6WSW\5;6D>+639\F5R-*A&W98$`O'"&0!M(?]IE1
M'[$\%U7,C+_O*TM=6/?BT9GV#LZ*L23*;9;257O(PY&;DD/;-UPEU:%=NY$7
M*.@^2.1VW'N(/VU7';?F-NQFQ;?+:(I(?!E2Z(NJIW/#`Y3_`#:VX]RSE+DN
M(_.K!L:AA_\`Y"*$))[#3?[($FIHCIHI(FG1=?TRP7]7\E-V7((]?&K'W*Z4
M_+BM6;:&0@Y#51(GAV((-N$!"!;UU5/#KB"-\C3+9R[XI2L(25US,D-6"M2"
MC.$+<1UP01P$WHB*._45\1TR#'C?/&^SQ^&<.0='<DY`IKI]]'GW7(XFH%)%
M!%15X&2(2U7]=-<#DN)\EFQ(?`+.QL93D;\??/6:N.D:.A$7>)N(J^L@1%VJ
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M^LRD?CRO<1(L!/WE8D.34)4$729`M64`NZ@MEIY:ZY8FZZCB')'^05*S9%>]
M6/MO.QW8[XDFI-%IW&B,6U-HTT("VID,UQ5-\A28SK%95TLF=+L[.[8`94\5
MV/5SBD?[AB6UH_Z$3[$Z85LK_F=^5"8FNT#D>-/II=S6*4ELB=]@@J^R:(/[
M?W^@M5U^B98-<OYEMXT:8\?%S_X=5'OR'WC?6O>0MZ]`71X%!=`\%_U)B"V=
M^406]&##JGYD`)C4"9,:1Q29-UD7E=4$;4.RVC@H9*XBIKX=,043/+[:\YOQ
M>P;C.Q*6SJ[>1!9&4O\`RF@1A67'FD%!;/0MP]2T0L081/E<*+A=%-;JW7*Q
MRLC3"*7.1V80O.HT3;>HD;YM(2$X9[1ZHFNJX@L8WR=;L2+L;""RJLWRT5*V
MRXX2F:,"[J]M:,D1`W&2B*_33$$5SEUU:\DX=/9KY4"6ZW=M/TKYN,-ONQ60
M[:ZF([@,DW-F0>"^&(.HXCSX.3-U+D6$K23H;LN>!.:G#<:=1CV[@[4U/NHX
M/E]BY!UF`P&`P&`P&`P&`P&`P.>YMQF=R"!$CPYPPCC3&9;@NM*^P^#2KJR^
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M!`>:=;0FRT7:*HJ$BHJ8-Q1Q/BE(9"L:S5$6MLH$C<P*JX_:OI(?D]"'31Q.
M@?3SQ2+^+QF=#X,QQJ'9*S+C5X5[-JC2*0JVTC2/(WN1-VB:Z;O'(;BGLOBZ
M`X''#IW&*:=QV0V^U+8C`I.B+2LN-&FX5V.B2[M57*;B+*^,)J6Q6#5TXL!J
MZ3D3-4+#6I24;4'&B?(M5`_Z>B;?UP.4X'Q^^=F-0WHK[<>3'EQ;8)M2D%R,
MS+0W'`8EHX3;A*^2?VPVEX],A'2U_P`36T-`<_R4GI#50S1LJ<)A6?;QWT='
M>TJKOW@BMN(J]45?#*1*I?BENGD4S\"T*.M3*G2/;ML`C"M6&U7(S+9*79;%
M6TV:*NG7ZXI'3\IX\'(*@ZMU\F(S[C2RMHH2N,MNBXXSU\$=0=BK]%R*UOQK
M_P#RN/(:E;:!(9MR81`"ZR5<16W`-/W$5!U0D7TZ:>>!6<IX;R"XMXT^#R,Z
MQF(VJ1XB0X\D0?+5%D(3NJ[]J[1^G\\M9W-19WQ<Q-E/$]:OE#LO9%?1E`%6
M:[7[>TXIIIV^YL%'4%/4B:=,58W_`/;6%^;]XLPUJ_R7YS\3L'9^15OMJZKG
MW;-?W-G^OKKY8I&''OC.-3V%:ZM@Y*@47N4H()MB/MDE]#0G4]3NP%4&]=-!
M^J]<*EW-',9YI4\IA`KZ-QG:NSCBJ(2QWS%UMT==->TZ'J3_`$DJ^6F05E'\
M6K4R*LV[EYZ/3NV+D&.;+6@A9ZJ39$.A%VR)50O/+4B-6_$#M6S5C5\DFP7H
M<(:V>\RVQK,BMNDZVA"0DC;@*X2"X'71<4CZ(`(`"">`HB)KU7I^JY%<YRSA
M[M_/I9S5B<!^CE',C;&P<$W#9-CUH?\`2@.%X94FH,GX]D3ID.99W3\Q^)8I
M8;5:;!HA2*<5(Z-IT$-CQJJIZE5?'%(@1_B!D:!_C\GD%E)JFP!JF:4F@.`C
M3@NLDVX((3CC1`*`3FN@IIBG58Q^`2UDTDRQOI=E.II;LWW#X,CWB=CE&0-C
M8@+8"!JOI3J75<4BL;^(&4K:VJ=N7WZZN=20#1L1]_>&84P76G-NYD]Q["4/
M$.F*1;<;X`M#9O.Q;F:Y3DZ](B43BM^VCNR24W-I(*.D&XE4`(M!UQ5Q:2N-
M-2^1QKB2^KS42,[&8KS`":$GB$C>U5%+?HV@_P`,5'"\H^/IM74VC=2Y-G1+
MFX:M)4*(W$(HBIZR*.P^B`Z).-M[@)?J2=?$1+X?PRYD?B)]G)?B#13'WZN.
MY&BQGG&I#':=22W'W-CJ1FH[5W=?5@FI\?XI@M.6D4[>>YQVS]R1<>4VTC-'
M-0D?5LD!'=NID0BI:"2ZXH\9^,'EAP&)_)+&R<K9T2=&D2NRI(,(E)IE4``%
M455]9Z;R^N*36QKXOA`32G8/NMMW$N[-H@:VF<ULVG&"T'^WL=+33K^N*345
MGXC%NA>HG.1V<FN_8"N:?)D_:,1GP?!H/VTW]6A'<YJ6U-$Q2)4[XOC2ILR<
M-K*8E2K>-=MN-BU^R_&82,@`A`J*!M)HN[7ZXI'73G7X\)UUAE9+[8*K3"*@
MJX2)Z1W%T35?/(KD.(<.O*-^M5;!>SLFR;N*""K$B;/?60I`BIO3M$2B);OM
M\LJ1?<DXI5<A_'+8"2K5S&Y\907:O<:0AVDOF!(2H0^>15*[\64:U+U9%??B
M,/7`WIDWL4N^,A)"-IN$D1O>*=/IEJ1D[\:0''C=6PDHIWH\CVHC6B2`;1M&
MOL_M;13]?UQ2*\?ARM"HLZ4+JS2EG,/QHE<KC:M0FY1;G4816]5\T#N*6U%T
M3%(Z*GX?'J[R=<-RWGGI\6)$=9<V=M!A"0@8[1$MQ=PMW73(1"E?'<-[E#U^
MQ:3X7O58.TK8SHA%EG&1!:-U%!31=HH);"'<B:+EI&JM^,JR`\PC4Z2=?`?D
M2ZBM/M*S$>E"8F3:H".$@]X]@F2H.O\`#01%B?$--'@5T`K"8]%K:B91-@:M
M(IQIVWN$:BV/K%`%!5-$Z>&*1%F?"M=+8=:>O[3_`)$6'%E&A1T)W\<YW(SA
M?L]%%?$1T%?--<4BS+XQKEMULUL9?<*X;OE:_9V>X;C>U0/[>[MJWXIKKKYY
M!#D_$-<_3OTQV\Y:R8[-=G122.8/>_>1]S5":7:39Z]HQT(=5ZY:1TO)^+0N
M0<;?H9#KL>.\+:"^RJ=ULF3%QLQ4T--1-M%]2+D523_BZOG-VJ2+2<3EN_7R
M93R$RAHY6;.TH?MZ)O5L=_3^&F6I$BE^.X51>2+&'93T@OONS`I%=3V+4E]5
M5UP`04/U*2EL4E%%75$Q2+*YXM%M;:ELW9+S+U&^Y)C-M*"`9NM$R2.H0DJI
ML,DZ*GCD565'QO55<F*3,N2Y7UTA^755CB@K$5Z0A(:MZ"AJ@]P]@D2[=5RI
M&BO^*J"''IHRR),F-2LSHS+#Y`0NM66O?%[0!5>BZ#IIIBD2N/\`Q]7T[L=P
MILJQ2!$.OK0F$!I'BN**DV.T04]4`1W'JNU$3%(PI?B_BE,]1/0F7!/CK4IF
MN(SW*@3%17-Z_P!6FGI^F*1@W\9U(6K5DDV6K[5P[?""DWL]R^Q[8@TV:]OM
M^":ZZ^>*1R/(_CFS@E5UU6W:3JJ+[U_W,1^O[Z29\CO."ZS-;[1-]2VD*:IJ
MJ+TQ2/H?'*^T_P`78@7[ON)Q,FU+/T(2B:J@BJM"`;A;5!)0%$5>J9%4$#XD
MJH;#;*6E@\C50]0MDZ;*J,-]47R:'U`@H@K^G77+4B1!^+:&,,]IY^1-C655
M&I94:0H;%C1`)MM4V`"H>TRU+7%(CI\25CE$=3,NK>:8N,NP;)^4BRXA124F
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MIHB>"8J1!?\`@SCKM<%>-I9,QTK&:=SMNMH3C$5U7F")5;7U@9+]NB+YHN*L
M3IGQ)22TLT*PL&RL9K-JVZT\(.19[((W[F.2!J)F@^I"U']-%Q2)+O!FX"UM
MM'D3;6VH`F.Q&Y#X;IC\MM!-'W"#1-VU$';M$?IBD;N!<:*K8LK.3""NL[^8
M5A/A-N(\+)$*"C?<1$0EZ*1;>FXBTR*ZK`8#`8#`8#`8#`8#`8&+CH-HBD2#
MKT3543_VX&M)<97`;1T.XXFYL-R;B'_4*>:82J?CG+H=S6R)QM+!"/.DUYC(
M,$_<BO$PJZHNWU$'3+"KE93"*2*8HH)J>I)Z4_7Z9"L1G1"=)H7FU=$4,FT,
M5)!7P)4UUT_7"HUA?T]=!DSYDQEF)#;[LIXC'0`5-44NO]7E]?+`EMRF'&!?
M`Q)DQWBXBIMVJFNNN!K.Q@@"F<AH00MBDK@HB&O@.JKX_I@9'-B@\##CS8/N
M:]MHC%#+3QVBO5?Y8!)T0MNUYM4-"4%0QZH/W*G7KIYX1K*VK$%266PB#]RJ
MZ&B=$7Z_14PJ+"NU,YJ3VFX+<:2;$<RD-&CS8`A]WTK^WXKJ!=4TUP)96M:,
M=N24ID8[NG:>5P$`M>OI)5T7^6!(1ULF^X)(0::[D5--$_7`C,VU8^9@S*9=
M-L$<<$'`)1`O`R1%705^N$K6U?4KP@;4^,X#CG9;(7FR0G=->V*HO4NOAXX5
MD]=5#"FC\V.RK6[NHXZV.W8*$6[54TVBJ*OZ8'K%Q5R'UCL2V'GQ;%XFFW0(
MT;--1-11==J^2^&!K;Y!2.,]]NPC&QO[7=%YM0[B)KLW(6F[3KIE@B2.:<6C
MOUC#EG&[EP9A6[70(7E;%2+82+HJ)MT_CT\<@WWG)J.B"*=M,:AI.D!$B]TD
M'>\Y]HIK_P!5^B8&];JH20[&6;'22P'=?8[H;VV]$7>8ZZB/7Q7`T+RGC8@9
ME:PQ!O=O-9#2(.W3=JN[IIN37^.!N&]IC)\!G1R.*".2A1YM5:`DU$G$1?2*
MIU15P-T.PA36$D0GVY3!*J(\R8N`JIT5-PJJ=%P.2G?*%$,VN:KW69L63:NT
M]A+1X0&*ZRPZ\1%KKN35E1\4P.B=Y-QUF-&DO6D1N-,36(^3[:-O)]6R4M"3
MKY8&-=RBBL;>PJ(4MMZPJU`9S`DBDVK@[D1?Y+U^F!"Y[S6#PWCC]W,9<DBT
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M$.6P^V[&;5P3>`D(45HE%Q%5/])"J+@0XW*^-RO;^VLXKWO&3E1.V\!=UAI=
M''6]%]0"OBJ>&6"DLOD6FJO?V%A.A?@HS,)R.]'>[L@BFDHAW&D300/TJV6O
MJ37Z8@5'R'62>0VM/82(D-R--9AU2*^.^6CT5N2*B):>K1S31/IB#IX-G7SO
M<)#D-R"B/%&E(V2%VW@1%)L]/`D0DU3(.8ON?LPK"Y@PV6GW*"`DVRD2'QC1
MVW'D58L<G211%7-JD1+T$=/KA*WTO-VI=W&I9S`19L^N:M*\VGA?9?:5!1\6
MW!1$563-/#H0JA)@K/FO*9]`=*$2&U,.YL6ZP>ZZK*-F\!F+BZ`YN%.VNJ:8
M5#HODRFE0)SMR35-*K+!ZJEM./(;92&!1PNRXB#W![9;OMU3KKX98E7L?E?&
MY#KS4>SC/.1XPS7Q;=`E"*X.X'UT7^V0]4+PR*BES[A0O`P5Y"1YQP&@;5\$
M7N.-HZ`]5Z*0+N37RRP;&N:\4>JBMF;6,]7"X3"R6W$,.Z'W-^G5=R>:>.(-
M4SY`X3#$"E7D%E'6FGVU)]OU,OEM:<3K]AJG0O#$2MU9S"BLN06=#$>4[&I[
M7O`VJB(KH[T1%\%T'37^.16ZXY3QZE-L+6P8A$[U!'C0>FJ#N77P'<NFY>F$
MKG;/G,YSF9\6H@B.SHD>/,EI+<<#>V^Z0DVRH(NABTVIZEJG@GZX*E<MY5<5
M-[Q^IK84>4=\[(8%V2\;2-''8)_54!MS5"$%3`B<=^5^,SJ)FPMGVJ>03\F*
M]&>=0T%R&\K#QBX*:$RAZ?N+HG5-<*LXGR%Q639W-<,P0>H>W^1-ST`/<!#3
M0EZ%HA)X>:Y8E9G\@\);BM2G;J(VP^KPM$;HBI%'35X4$M"W-I]PZ:IB%8-_
M(?%'KZMI(\X)$JVB%/@N->MHV!(1%4<3TKO4NFGT7(J/SGE=K0RZ"+`B1I)7
M<U8&^4\;(M&K)O":[`<W)^TJ+_+`W5?*G&D%OD;D"%(E2_95A1I*O-27%%/0
M!&+:HZA;A4-/+",Y?R-P6&R+TN]A,-GWMA./".[VQ]M[;K]W;/H6F"I4KF?%
MHK41Y^TC`S/$'(;JN"H.-N*B`:$FJ;"4D1"7IK@K6WSGB#EJ-0W<1"LR>.*D
M,715SOM)N-K;_K1/Z?'+%9L<TXO(]VK-G'<&`.^60FF@#N4-VOFBF*BBIKUZ
M8B5I<Y_PUNO;L7+>.,-TW&Q=4M-#9_NB0Z;A[?\`7N1-OGB+JTA7-9-F2X<6
M2V]*@$`360+4FB=!'`0T\MP*A)^F04=OS1J+R4J"(T#TF+`<M+1]T^VU&C#J
M+6Y41?4Z8KI]!12P:IJOY#MK'\6S%8JY$ZPIW;08K%@CA&ZV:"+;&@?N-%ZD
M[O@B],)U=7Q7DM=R7CL*\KE)8DT-X@::&!(JB;9IY$!HHK^J85C6<OXU9V+E
M;`L&9$UE#(V&RU71L^VXHKIH:`?I+:JZ+T7+$JXR*8#`8#`8#`8#`8#`8'#?
M+=&=S54L4:]RQ;;NZ]Z4RT.Y1C-NZOF6BCZ>WJBX'(_X7*8YT4)ZFL2@Q["%
M+XY8P"C-P8T.,RV",..DGN&A;47-6QZ.;OURLZK)?&N2=MH["CLYE(Y9\@]W
M7P@BE)'\A)WQ9*-2=P$!-*0[D]0;M<47D[X]MVK"D_&1#2'=5C=%RSW#J//-
M18Z(ZRZX[HG==[8G'5?/<GTPJH_QJ[_SAJ8/&),:&S/N6)2,-,DR[%EQ#!AX
MGC-7GD=+;Z>@!T%!Z9$U6?\`;2W;XJU`A\<-F3)X64.P!0;T<LV7VG&VW54O
M4[H!J"K_`-<+C[%81EF?'DR+&K7(QR*QYIFJ(`!P2-DA%I6Q500MR^&N%?+9
M7`I-?2\6%OC,Q^H=J'(E[55WM1EMV+[++92'AD*H&I"T0*XA;A\=<"[J^-V,
M+DJ0[/BKMLV;U9)I[LGFS&$W#8;;5I]Y2%W<P0&7H!4<W=?%<)515\4Y,R[0
M5SO'Y*,4KG)&I,E>SV3;L!=*-VO7N('-Z)X)HO3!C=2?%T-(_P`;QYO%@[,:
M*^/)6S;:)!D+"!D"D^I>XJF'3[L*VGPBT?Y,T4J@)ZN3F,FQ)7!:)KV3U=V>
M\HJ7V*\G453^6!3I2VU?"HZ@Z62])CL\@:*I;"+(1J%.E:,/>W<?91$023:0
MET3453KES$KZSP4*E?CZMBUS;HU\>)[00E`(._L(K)]T151W*0+KHJHOUPKY
M!P_B,N=PVBL:/C8"_&XW/C35?V--69R@06(Y*!H9BI"IZEMV^&J:XK*<YQ.:
MW"Y3+MHY4CQ+67'&Y\XH@(-E7Q]-@LQR4052;V*`HOH7Q7(M=*7"ILJZX?:6
M=*W*?,[&PY'Z6S;9?G1$`6U1Q=QH*H+2=%Z#JN%<Q!^,^4-\;I(,"I2JM4H;
MFNG2T)H5;>DF!16W7`)2(51M414UVZX$]G@UE.9@2W.*2(;Q755)LXTV7'E$
M3,$7`-P1$NTC8":(.GK-/%.F6B14</Y!7755+"@58$'DEQ("*)1Q1N'8-D+#
MP"I;1;0UW*(^I/ID2NR^3:>RL8=$_7P/R3M9<PYST5%;$R8;4A<V*ZHCJF]%
M\?#"N":X%R(BMXL^BD29K(7!U]TLUI8SXV8.H#8L:B?<)'!`A<38.W77PRT6
M3/QV3;_$]O&F6V85#-C6@H,?TS'H[#8B>B_N$2M$F[K_`!R"KK_CJYCU-3'?
MH741.+!5VHPWH[+ZS!E,&B(XI*)&`MD8D6HKX>>5*^C_`!W"OH-$ZQ=@"2?=
MOFRZC;3+SS)%J#LEMA5:%\NN_9T7QR*XN/PKD26L6.]3(L&-S"7<N2=["MN0
MY+3^QS9KNU`GA115-<)5-)X%S9>,'2MT(J#T2^CMFT]&!UOWDLGHC*N$I;(Y
MMJBJC::[D1%T3!7=\`IKZMY%<R+"M]O'LX]:\$GN-&J/,0PCO,F@KNW"8*N[
M[5^N%Q,N^/V%_P`L`9@O1:2OAFD9YLF2&1(F(K3Z$!BXJ=MCTHNW^LLHXMKB
M',RX=QSCDVK=?3C=_')E_P!RT)NU,0S[+RD)HJ.(T8BH]%U3(.CY5PI(D#C\
M/BU2/8A7\6VG-MF(*H-J2O.D;Q;G#+=]55<"Q^4Z*??<4_'088S7UFP7RCD0
M`BM,2VW75U<T'[`7IYX'&VG"N6,64VRKJGW$9KD+UDU5LRPB%*BR8#<576G!
M)$!QMP"+:>FJ*N7!&=^-;9B5&B)QL)G'YL&)%*N"U>:"N<BON/;75UW2&U[J
M%J/7<.B)IIBINI8<2YHS:UT9VF:E,5O(IEN=U[AH._&F-OHFH+JXC@]X0)-/
M`4TPFZZ'XMX_R"E<GL3([L6H[,8*Z/-<8D2V2#N=Q@9#'5V,WN3M*[Z^J^6-
M7%3R7AW+)'(>22H,)MZ++ETUK$4W0$)*UB@CT,Q7U"1[-1)4V^&175<*I9\6
MTY%<2HRUX7LMJ2S6J0$3?:CMLFXYVU(-[I!N7:J^7G@<_'XQRIJ]N:U^JB2:
MNPL)%I`Y(;HJ]%60SVE%&%'N=YK[0(5V[<)J@L?COEEEQ:/7G5LQ;"IX[.HD
M4'FE;G.2`;;:45U]+2*UW5[FBH2_SRI4KDGQ]R&8G*RA53.^S@TK-:J.-`JO
M07-SPZ_T;$TT7STZ95J)`X[+O;[DT.)7MCV>81I[MRIMH3`Q&8KS@B*+W.X6
MU6T\O4NJY-*RM:6764Z`;T:MYN/(YMKQ&.X\#AOA+DKN;V`NX@<9>)'$3[?%
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ME3QB0V7#N/I+C1.60J]:;E=:PZD@RI5%3WFHZ;/6`]M53_WBID5<<A^/N1S9
M'*"CP(YM6=S2SH0DZ`H4:N['>W)IZ5_9+:GZY:--IP/F87<ZYA0(\H6[Y^QC
MUQ2RB^YBRH+<4S1YM-6G0)M51"U147%&$KXQO/9746%4PH;4WBI4\*.R_N;:
ME./O.JTA.(I[![R>OS5/#%1UW$:/D-9RZ[ERXS25MK'KW`D"]N,'XL88[C*M
M[?J.Y#UR*B<IXOR)SDEQ-@QF;*!R"G&I=:?=1M8KC9.JAZ$B[VC1_P!2#UU3
M*C;Q'B5W3<M)Y]!>JVJ&NJ6IBN:N./P2<4R)M4U1"[O1=<A&WG?$YU[R3B;X
MPV9=55RI+UF+KFQ>V]%-@=@Z+N7<>OBF%4/R%P"^FL%3\9KH;5&Y2RZ\&6G4
M@JW(>7<&]0`C-GS[8JB;NI:Y<T0+#X\YO+:NT;CQ&W)BTMC%WRC[9R:MIH'(
MCO;`30#5I='17Z=,5%E5<)O0O>.7!TD.M]O83IUM&:EG*-%D0O:@X3SHHKKA
M%U71$1$T\<#5P?@_+Z"?Q5^1%CFW7P+&NLA"1_:&3,&2TXWZ/W/0&W;TT7&F
M+[Y,XW:7DCC1PZYFRCU5E[^=&D.``FT,=UI`1#$A)5)U%Z].F,56S>(6UOQY
M_C)4,2CHYLI%08SXD]$#J^<MK:.Q'ED:=M!^W[OTRIKG]G*(/*N`P[BKB2[N
M%!N6/;L.M@V^V`,"#X[TT`G$^\/+4O')IC6U\2<FK6(4)*^!?5\RJ:K;.)(E
MOQFHSC<AV0B@#:?OQQ]QMV+HOI3PUR$6Z<!Y,W+=<;BL;5Y@S>@2.H*K"!A&
MB7P5=_3H'T\\IBN7XTYH==8Q(0-P8(E'F5]-)EK(CI-C3/<DVR\`B^S%>#^@
ME7::ZHFB=5(D67`N42:MN1!IF*6\<=ER@D0+$C<CR7FVP19)O@02VGNW^\"C
MX(.G7%77T#CTZW<M;*!/@M-!""*C=DP7IE.&U^[J"B.Q6R'HFJ^E4R#C)E--
M@?+7)'S'<QRZB;CUCI:HVLN&C@''(]-!(@<0T^J:_3`I.&\!Y'P^;P^ZO/:L
MUG%N/2Z^V=!Y3)'7'NX*MCM3>BH*?KJNF!V7PG065+\?1&K)LV)4U^58'%<Z
M&R,Q\G@;)/(A`DW)Y+K@4W$>&\YA\TJ[>WBQ>U$9LXDEYF2NW9*?;>8*/%%L
M0:#1O11UW:ZJJKEJ1]5R*8#`8#`8#`8#`8#`8$>?/@P(CLR<^W&B,"IO2'B0
M``4\5(BT1,#2-Y2G`2Q";'*N5-WO4=#LZ*NG]S7;X_K@#O*4(K$LYT<8DDD"
M/(5UM&W"+P0#5=I*NGEA$HW6P`G#5``$4B,M$1$3JJJJ^&F%11NJ8J];(9L<
MJY$U6:CH=A$1=%_<UV>/3QP/7[FGC0VYTB9'9A/;4:E..@+1J?4=IJJ"N[RT
M7`F(J+X>'UP-:2(ZOK'0P]P(HXK.J;T!55$+;XZ*J::X&W1/I@-$P&B8$2QM
M:RM:;=L)+<5IYUN.T;I(*$\Z6UMM-?$B)=$3`I^74/!9[;,WE46"XW%)`8E3
MM@H"FJ>E'"4=-R_TZ]<"TDO4U74E[DV(%6P"-DIJ++#;:^E!U7:(IUT3`]I:
MVJK:N/"J6&X]<R.D9AE-&Q!?5Z?TZX2(J-<6Y,#$KMQ;5NNE$L=TA%U&93!*
M!J*JB[3!=4PJX73^>`T3`:)@-,!HF`T3`I[+EW%JR84*PM(L68+?>*.ZX(N(
MUX=S:JZ[?UP+*)*B3(K4N(Z#\60`N,/MJA`8&FHD))T5%3(-VB?3*&B?3`:)
M],#%UQMIHW#5!!M%(B^B)U5<"/66E?:UT>RKGADP98([&D!]I@2:B2?QP(Q<
MFX^,YF"4]A)DAXXK#'<'>;[0=QQH4UZF`=23RP(S7-N(NL1'VK:*;,\7SA&+
M@JCHQ/\`U"AIX]K3U?3`N6'V9#(/,F+K+HH;;@*A"0DFJ**IT5%3`ST3Z8#1
M/I@1+6TKZJ`]86#B,0XZ;GG=I$@HJHFN@H2^*_3`EIHJ:IYX$.MMJZR204)W
MNI%?<BR%VD.UYI=##U(FNFOBG3`F8#1,!HF!YI@5\IVDHX\F>Z#4-IYP2DN@
M"(3KSBHV&J"FYPS54%/%5\,"#_D?$7ZIOE#IM)$C=P&YS[2@ZV6_MN-B)BCH
MFICMVHFJKTP/8_.>)OT3]Z%BV-5&T]U(<0F^TI()(+@$B&)*ACT5->N!BYSW
MAX4\2X.S:2MG[O9R-"5'$!%4U$4'=M!!52731$ZKTPE6[MA`:A'/<?;"$#:O
ME)4D1M&D'=OW^&W;UUPJM9YIQ=ZID6[=@W^/B$@27B0@5LETVB0$B&A%O':F
MWU:IIKKE*]/F7&0J6[99P>P=<[#;B"2D3R*HJRC2(KG<115%#;N33PR)5A`F
MU]E$CV$-QN3&>!'8T@-"$A-.A"OZIA6NIM*ZR9>?@ZJVV^ZPZI-FTJNLDK9]
M#$57J/0O!?+"5.PJ%^8J_P`LM/[@/RB,>[]GK^YV-_;[FG^G?TP)`18H2#D@
MR`R'407'D%$,A'[4(M-51/+`V],!T^F$JOO+ZJHX*3[-[L15=:81S:1?N/N(
MTVF@H2^HR1-<*7M]4T-6]:V\A(E?'T5^22$H@A*@HI;45=-5TP--/RKC]S(D
M1JZ6+TJ)M65'42;=;1Q-0(FW$`]I>1::+A*M>GTPKW7],#SI@I_+!5<SR&I>
MOI-"VZJVD1AN5(84"3:R\1"!;U3:NJ@J=%PE;K>VKZ>ND65BYV(,0%=DO[2-
M``?N)4!"+1//IA5=3\WXU<RFXM=))U]YGW3`FP^RCC***=QLG0`3'UI]J^>(
ME7G3S3"ZTO1H:O!*<8`WV$+M/*"$X"*GJ05TW)K^F$5-5S7C]L%6Y`==>:N0
M?=@.HPZ@$,9='-Y**(VNO@AZ*OE@J\_E@HFGTPJON[ZKI(S,FQ<5IE^0S$;)
M`(_WI!HVT*[473<1(FJ],"QPE19TZ%#8<?E*@@P!OJFFXMK0[C4134BT3Z)@
MK&JLZ^XJHEG"+O09S+<B,X0JFYMP4,"VDB*G1?/"U,P*2YYA1U$YJ#+-TI+J
M-D3;#+KZM-O.=IMQWM"7;`G/3N+I@7>`P&`P&`P&`P&`P&`P.)^7*0;CC`1F
MY[<&Q8>]Y6(^*.,OR([3A]EQI?[@D&[IXIIJGA@<I7U;'+^&.P(JQ^*VT*R,
M[2N=;8G0'YS#`*6K;F@.LD)`XNW14+QZI@5L:5%M9-8=[!CU]8G"YSK$``0(
M8/\`>0)1L#IH*=H1(?/:6$3[RPLG?@*J"<]K/6)3)>@I)W0BNO,(^3HIZA0F
MM=VOEK@Q"L1$?D=Z$T*#QA>45G?;'I'25^*=+9I]NBOHRJIX;M//"HW&`BO\
MJB1K00/BH/<L_%`[HK&@RFD7;KZ=!:)_9_MW:=,)FOI'Q'(F+\7\:>LB)'OQ
M[2F;JZ+VT']LB4O_`+&B+UPK@$NY\/F]3\D28S\>FNI1TTF8XXS[?\7(5$K'
M4!'"(=7PWJJBG]SK@65AS'F4?D=B^ER'XRNY17TXUO891#BS@9WHX[U<W"KV
MH*FGAUUPE:N/<RYL]94CDR["1'MK&[JCB#'8;0?8]]8[H$**2F/835-=%U\,
M%1(7RM<G45$N7>QV"D\2EVM@ZC+;W;F,.,B+W9#0NG<+]OPZ85%M.46=C76U
M=9S!DC4<@XZY$)TXYO@W)>8<5'2CH+>J'KIIX>&JX'T;Y:@5MCPQVNL@$X$Z
M;`C20)=NK;TQH"T+5-%T7II@?(N:3;FT^,[CCMYO4^#(+-I+<U`9<D)#25S@
MDJIN18R]T_\`<J8'9WO/;*)SN/&B7(K""[@U4N$?MVF0:DQMY-B)(KSI[E0^
MZA"*:H*:]<")5\GY593Z*K;OEA)87'(8,M^.S%4R;@J:L;4("%#!!3KIU\\"
MIJ>;<A<=A<B>M')EFWQ"7+CUXDT+$N7%E&VJHT@ZJ1(VA&@+KTZ=.F!/_P`R
MY,5:S(K^81)D6?8TK+3\<V9;S"375;DBX2LM-B+GB`*.X=%\L#.3S.\:AO5+
MW(W?>Q;JUKV9"^U8<?:AL"\WWY!!VF^UW.J"VI'T33QP*A?D/F=A0R;=KDBQ
MS@\4K[Q66&XJME,5QT'MZD!+L/M>H45-%\-,L'7-\VE2[NT7_($B6]7--F)Q
M9!:+WL9(B.LH(*G>)7R+>CH%H*)I]<@W_%'*+:]DC+>Y!$M(TNN:D2*YESNO
MQ9F[]S<@M,]@.NSM'J6H]%\<#WD`VC_S"D:FFQ8=F?&74`I+??33WPZ:`A@O
M_MP()\HM4YT]1Q[B'2E4V$2/&I'2VK+@NL@1]J.C>KBNF9(!@?HV]4\<#1Q'
MF-K>$_+F\JC5X'"GI<UJ.`4JN?:<T!W8;0I'2.G0NXI"?1>N4=]R6X:J^`3;
M4+,D;C0%>"W;`)!JB-]'Q!-&S4ON3^G^60?+XG-N0R+%*EGD)"'^1UD,#!V-
M*>]G.@$ZXVKJ-[2U=3HHIT7HBK@2:CFME(&OI;GD#D6%[N]BK=D33;DARMD=
MJ+'<=V]M#5HB-=$3?M_CE@ZCX\G2&?@NKF5JH_*CTI'%5.N]UIHMO_4QR#B.
M/VS\&J^%F8TH0;NAD.6BJ+9$ZZ]")]QS>8D0GWB74A5/'1<L$;XZYE;SG_BU
M)4\'?R9W[$YOM1Q[B1R)&=$$!V+]=NF[SUQ$KO?@N1)+C-Q"-56%67MG!J]?
M!(K3ZJ`#_M`B(4_AD51\$YS)G<]@Q4O#F0+2+9J4:2XWWED0Y8"W_P`<!3VV
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M2:"8_P#L7`FW=S=U5AR0F>2SG&Z&UI#B-.N-D*A9$TDAIW0-3;43+:/]/E@?
M0_DJYGU/'F9,8S8C'.B,6<UK[X\)UX1?>1=%V[1Z*7]*+KY8'SCE,J3(KGHD
MBU?E4D'EE.W36BO^LVG39<?;[X_W4CN$6T^JI]?3@?0ODF#02.)%$N)SM<TK
MS/LK-LM'&);9;X[JF2$/WBFJGZ5\\#AZ"TJ;[AH0N5VH5#\:=&9A<DK'EAMS
MI#40'&G0-=PD8`NPQ7<.X>GTRP91;"SC6G&+OF#B%%2DMX137`[8./(^V31D
MVB:"Y*B,[D'3JNJ(GED1IDE*3X)C\3<<4N41Z:'.E5*(JR?8A(`C39IJNC0J
M"IX^656GD#GO^46G(J__`)'%V+CCCDR4UZF32(CG?<14Z$+/=9WKY:=?#%2/
M8)]GET7D\@NWQ,N56+S4PET83NUB1FY.Y?2C1R`<%#\-5UUZY!W?P[&E,\*$
MW@)MJ5.L)<%LQ4%2)(F.NL>E>HH39(2)]%PK@ZNWM;:XIJM_D,]N))L^31I3
MC+_;<-F*>L85<0=11L?L5-,TD?0OC&_>G_&M+;6DM7GO9[IDQWHJ]I2$C<7I
MUT'4LRKYS8V%C!GU'RV\VP$!^?VI,@73)\J6=I'9:5GMHB=DA!]4W+U4L"3R
M&^M&;WD=FQ?34:J;ZD:@Q0>7VR,3!820"@B:&!HX?1==--<#VMM[@+Z%*<O)
MSR.\QL*7VKCRJPL%6W5`-B"GVD(J!^7DN45E3SZR.%1`[<6#LN-07B78,H1R
M$E1"#M*0F*A[@$W*.[_V9$1W^2E,X_R6$[9E,AMRN.2H(*\]*00>D,J\HONB
MA'J0:EIZ47733"OI?SH8I\3<D12T4HR"'GJ2N#HB(GC_``P.4"RN*GD/*),I
M?>\QL*A?\-GMALB2X;+9.MQVVTU1)#;Q*IB1*I:IMZ940:^]D2^/3YU7R]76
M'RKA=8G-S8[#4I#7OQW91D;S!2438>S1`\>FN*B-+Y993&JV-*MY_&X\NN$J
M24\,F8Z=@W,=!\4=94`D+M!OM"ZBH;:ZZ8JQ,D<ME-\[8!+>8RBVDVOLV9!O
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MW>18YI^/8?DC^[L(2-1+7U*@IK@Q7\7M["%Q+AL:'82X[1U/(D>;%7`W.,*1
M,.&BHB]P5ZBJ_P`L@VQ;SD$&G>=CW\U94_A4:U=D3'''D;G"X+9F";2[1*):
M*@C_`+M.F4KJ.!\TX]&=O+65R-':AV3#8@P#DN35AJ\"-KO7:I"CS^NBKT3Z
MIC5Q>_,PDO"=^YQMMJPK77WVD53::;FM$X[T0M-@HI:Z=,BN,9L;*'9#%EVU
M@_\`'[MT\T-PZ\[W-BPA,&UE#H[[?W:D*'KIJB)KIE17L.S&[?C\V]DS'4_'
M\BBU,Q\GT60PV\"PE>0-$4S80E]::DB:KD2KGXA=FP[;CD%)DMZ).XE&E2(\
MDW#:"4RX#:=L23:T2`I"HCIKIUR[JXG_`")921Y#;0I\Z;6,A3#(XN["<=;1
MVP$W%=T[71UT5%E!:/5%%5Z=5R+K+B#$A[Y7ER[3NMVZ\<JBFMHXZC*2E-[O
M@@:]M=NY%VIX:Z^>5,?4LBF`P&`P&`P&`P&`P&!`NZ&GO()0+:&U-B%U[3H[
MM%T4=PKXB6BKU3K@0%X'PTH$*`=+#.'7&KD%DV1)&C)-",=47U%_4OGYX$ZS
MX_1VC3#-C7QY;48D*.#S8F(*B:>E%3ITPB*/$Z;\W.N'(S;DJPC-PI.X`VFP
MVJKL/IZ_'^K7IT3!C>WQ?CC=250%9&&K-=QPD:#M*6NNY1TTUU377QPKV3QK
MCTJN9K9%;&=KXRBL>(;0*TWMZ)L#3:G1?+`FO1(KT8XKK0'&,%;-DD104%31
M14?#33II@0W^.<?D5;=2_6QG:MG:C4$V@)@4#[-K:IM3;Y=.F!@7%^-EW-U7
M$7O/!)=U9!=[[2:-NETZF'])>*82,F>-\>9)@F:R*V45TWXRBR"*VZ[_`''`
MT3TD?]2IU7"M;'$.*,=SL4T%KNBX+NR.T.X7_P"ZBZ#U0_ZOK@>M<2XLT"MM
M4\(`+M;A&.TB+V/[6N@]>W_3]/+`G3($&:UV9D=N2RA":-O`)CN%=1+0D5-4
M7JBX&,NKK)C+C,N(S(9>5">:=;$Q-11$%2$D5%5-$TUP(Y\;X\Y)]TY5Q#DK
MV_WR8;4_V?[7J4=?1_3]/+`V-TE,V8&W`C`;9FXV0M`BB;J:.$*HG0C_`*E\
M\`U24K!,$S`C-%%0TC$#+8JTCGWHWHGIW>>GC@8M<?H6F59:K8K;*NI(5H6&
MQ%7DZHYM0=-_^[QP/3HJ,_OKXQ?N^X]3+:_O::=WJGW_`.[QP/!H*(6R;&MB
MBV8=HP1EM!5M%W;%33J.[KI@;1K*M)8RQB,I+;#M-R$;!'!;\-@GIN0?TP,H
MM;7PS>.)%9CG(+>^338@KA_ZC443<OZK@>K`@K+]XL=KW:#M21L'N;?IOTW:
M8`X$`Y03#C-%+;11;D*`JX(KXH)Z;D3`TOTU8X$M$C-`<X%;EN@`(;@JFGK+
M3U=/K@;(M="C5S5<TR(PF6A8;CJFH(V([4'1?+3I@8MU%2WM5N$P&S:H;6@3
M:H)H&FB=-J>'TPCTJNL-KM%#9)KN=Y&U;!1[GCOTTTW?KA6YMIEEI&6@%ML4
MT%L41!1/HB)TP*FBXI44L7V<-K6$#KCL1AQ!,8_=+<;;*JFX0W*JH.O3P3IA
M$UVIAJPK;#01G$$D9?:`$-HC313;U%40O/PRD:^/4-;0U#%37-=J)'14'55(
MR(E4C<,EZD9DJD2KXJN1<2VX,)L][<=L#W$6\0%%W']RZHGB6G7`]<B1'#4W
M&6S-14%(A1545\1U5/#],#%8$%==8S2ZB@+Z!^U/`?#P3`+"A]=8[:[E0E]`
M]2'P5>GBF##VD1"0NPWN0E-"V#JA+XKX>.!Z,2("@HLMBH:[%0433=XZ:)TU
MP:\&#"$-@QVT;TTV(`HFFNOAI]>N$9+%BJI:L@JEHI:BG7;X:]/+"MA`)"HD
MB**IHHKU14P-:18J-BTC(=H/L#:FU/X)II@9NLM.MDVZ`N-FFT@)$451?)47
M`U!`@MQVXP1VACLHB,LH`H`(/AM'31-/TP-AMLN)H8(:(J$B*B+U3JB]<#1^
M.B+8)8]O66C?8%U==1;4MRH*>6Y437ZY1(%EH6^V("+?5-B(B)U\>F0>$TRK
M?:)L5;TTV;44=/IIX8&2**=$3`P1EGR;%-/T3SP,T;;0=J"B#_ITZ8'G9:VH
M.P=J>`Z)I_TP'9:7^@?^B>6`[37^@>BZIT3Q^N`1IM%54!$55555$3JJ^.`1
MII$TV#IIIIHG@F!Z0@J:***GTTP/%%OIJ*=/#IX?PP/-C:HH[4T7Q33HN!EL
M'IT3IX?I@-H_1,!M'Z>.`VCKKHFN`VI],!M'Z8'NB:::=,#S:/TP"BGTP*Z_
MHHEW5/5LDW66GMJ]Z,XK+P$!(8$!CX*A"B_3ZX(KJWA=?$1PILJ7<27>VCDJ
M>X)FH-'O!O1H6@V(?JTV]5\=<HZ+HJ:+U^NN0-@::;4T\--.FF`VI],#W3`\
M417JJ(JIU3`=$Z:8'N`P&`P&`P&`P&`P&`P*;D_)X7'F(<F:T\<>7+8@]UD1
M)&G))HVV;NXAVAO5!54U\<#GI_R/"F5=RS6C)8LH3\^L4MK*DS)AQ2?5]=2(
M>UH@Z+U\4Z8B544GR>,S@[@V+=G$M(W'6K=^>++*./M&SHY)BBI*"D+FOI-!
M_AIA5_#Y_%UAQ8T.QM&Q2$Q.L&F@+LN3&A-I7P$A+7:8FXK8J(;NN$JF^/\`
MY"?=<CTUTDV1,GV=M$@6KK;0L.+"D.J+**"B6HLM]%[>U=/'7$6NCYISN)Q1
ME'I4*3)9%EV4^\UV@:;:8TW:N/&V*N+N]#8JI%UT\,"ND_+5%'LIT4X4Y8E;
M&8FSK-&VTC-,265>9)24T+4]NU$VZ[OTZY8+3B'.:[DSUA'CLNQY5638RFG%
M;<'1X=[9`ZR3C9ZHBHJ(6J+T7)$KF^6<[FO7%/%I`E-PFN1QJJPL@[/MW"T+
MOQE$E5U43H*D(Z;NFN%>1/DN/7DY%:AW-W.G7-G!C1E2,K@.PD[AM`N]H!90
M?[:DNOUQ"K!OY=XX5JD(A="*I2VUL$V&V+D`2.0C@`I.`*;"03)-"5-$\LL*
MC7_RC:0*(K&/QR6*F=?[0I)-`TZU8OBR*[Q,M'`W>IM>J:ID$5WGLOC_`"'E
MTBU]U+J8<NH:%E%:48`3F$1QPEU']H7%1375?K@=W6VXSY5BPVT8-P'TC=\E
M%0=/MB9[-%UT#?M77SP.3E?+<&'92H,NLDLN,Q9\U@")GNN-UFBN[FMVYKN#
MZF]_W)],L$-WYKAQH$R9.HK"*K%='N(;!JPIRH;[@-*;>QPA$FS<3<!*B]4R
M0J-RGY!L)E):Q6H\WCU[2V-3[A@S:(CBS9C8`:&TK@$#H;Q(==45-,"UB<V9
MCW5W!CL3IMH5PE?&@OO-=I7!A!)(F"\&F$:]1;M2W?QP5C<_*QTU='GV5!,A
MM$RC\MN2XPTXWJ_V%:;%27ON)_<T'^C1=>NF(*VL^0)]+>7[-I%FSJ=.1#7C
M:J;1-0DE-1^PWL4D=5ONNZ*J#Z=<08TWR&[3LVL::;UG8NWMLQ7,/.H*I'AJ
M)*/<VKH((2"":>*_SQ$KJK+FCP_',KF%?!<4VZYRP9@2T[#B*#:FH.H2>E1T
MZX56+\F2FJPI!5#LN37UL>TO&H[K>C#+XD2=O=IW3V-F>U/)/'7!73SQ<O:!
MHJNQ<A,SP:="?'0>[V'$0]6U-%02(5Z$J+I@?-X]SREB'"I%MY4F%;<E6KK+
MM[8DLZUJ.3[R]T!$5)763;;<VZJ/7Z+@;)O*.0I\;\A,+%\+'CMT58W8B@]Q
MYEJ:T([]45%567=AJB=537`LOF#FLBJI)L*ILFX%I&&/)D/[VT<!HY(`C8":
MZ[G1W==.@HOZ8'T4'`-L3;)#`T0@,5145%ZHJ*GUP/DW..:<D<+D,1MM8;=%
M<4C$1V*^J//C*>9)P'$5!31P7---=,"^_P"Z:"VY&=K"9O!L9%8E>KJN`IQV
M4D$[WFFW%V*T8K]GBNF(E7L/DTZ=PU.00ZF3[PHQ/MTTC]B0K@:ZLKN3HJJ/
MI54Z],*HR^5H)5%=:QXI/1;*+%=:T-5494UWM-12$0,MR*+BFJ)Z=OAB"'8?
M+<V%0%;.T+C*,+,]P$IY8XDD+0O^-O;[KRO`NYO]M$Z+N5,)5Q2<YLKGDLFJ
MB4Q?CX8QW)-F<AM$$)<9)#.C.F\E77:O7IXX5ARGY!DT%G.@G6*_V:EZVKW.
M]L]T48D%Z,(["47!0Q5/'77`YWDO-9]H[Q6=4`X,5RVKQ!69.P)*RX3KQQW4
MT1-C>H;M=?X:I@3%Y_%G%QNRL(4B$:3+2/*;9EKVF'JYE[O=P004D@J,DH:H
MFBZ+@J'SWEO)97`9M@-<_5L$%9.K)\:6*FX+\QI%8/;VR`^V7J3J.B^.(E=M
MQ7D\JXE7,*9"]A-II:17FA=1X#$V@?:<$T$/N!U-4TZ+]<*Y.;\@1Z"5R!U8
MAM[;L(#TJ;+-88$<)MX'2/8XD9HO2")IMWKJJIK@=E:\FCU'$WN16`;6HT5)
M3S+9"YU4478!IZ2U)=J%X8*Y>S^3K*G.7%M:@6[".$&4TTR_O;=BSY0Q%)#4
M!T<9</U#IHODN"M%I\E7G^31Z6NA,`C?(1I);K[I>MLH'O4-M!!=JJG1=?I^
MN!%N/DH+#C7+>_`3LTT9_P!W!"8Y%L![3JM[7!0`<:[@#W`<!514Z:X&OG'*
MK.PAC'JF%9@55W3P9<Y))MO*\X^P;@"`IZVT!X0/<2:JJ].F"N@I/D27;W[4
M6)4ONTLB1+BA:`#NUMR$9`IO*0"V@.FV0AM-5U\4ZXB5/Y%RNSBW*TE)!:G6
MK<$[-YN0ZK#?8!SMB`$(N?N.'JB:IHFG7"N..T>YYRRB9'<G&+"A*U;922_%
MDMNE(9'N?LHG[K6NT?5IU7!5YS&\OF.4Q..QT92IGT]E)DND;@R4..C8(H$*
M+IM[VOBFOUZ8'.<1^3IM+PZM&\@$0,<:BVL60#ZOO2-";CJ+J**;3-QT%312
MZ+UZX*[SAW([FW*P9M:EVN=A.`#3Y"Z+$@'`W;F>\#3GH743U'Q\,#GGOEH(
MMER!B9%;9;H6WW'89.$W.(6B$&G1:,!`V7U/TN`:H/\`5B%6$SF'*JYUF#8U
M,9NQLIC4.F-N2IQG>XR;SA.*H(X'9%HD+T^KIMP*H?E'D+\^)2PZ-ER^=E6%
M?*:<E*W';D5[+;Z$+G;(C:=;>%47;N3P5,#4S\OV,^O:=J*!^7:!#2;85:;S
M,%22Y%)ALVP(%/>PXJ$6@Z(GURPKL>4<G_"TT>:$97I4Z1&APXQDC>K\MP6P
M1PO5M05+4O'PZ9!PO-.9\DD4-K4=AJ#<5MM5P;`FWG.R[$GOM*!LN"*&G<`E
M`T5-4Z_I@77,#G<%^-YLGC@MMR8[C9B$EQY]IM9,@`<1O>I%M'N>@?!,"A;Y
M1><<Y=RR248)=?\`E:=B=OD'JS[Z.RR2Q6R$DT%QQ"5%4<%='4_(-K9\A"-$
MIG7J,YLNN<L`$T5ER&I`KKBDB-JV;@*";2W)TP5N^1.<67&&A<A16).V+)EF
M+KA]QSVPH2M-,LBXXJD.O[BIL'^K`I;3Y<GLR"&!6-/(V-4J1'WE:D2/R^B"
M4=!`T(6=WK73R+PTQ!E(^4K^,Y=NO4['XZILDIF76Y#CCSTQXF!8T:1KH'_(
M]:[M>G1,0KQ_Y.Y0TVU`/C[C5^^[*]LT;<A67H\00+OM@(*^B.*Z((A"FBZZ
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M;1(K;[-0K_>H(5\`,J;K@I*>1MT%;`=QBR*[_1ZE1/#$*UO_`"O*!BB>#\><
M6X0]MMW7_P`>;@OHT$<7T;_9>,%W:/(G7T^.(5N3Y2L_>2I@T[KW%X;D]F7/
M`31QG\<A[G34MK9"X;1`(BNY.FN!'XO97D[Y59E6C3489W&0E,1X[KC@()2T
M5$<0D$.X(GIN%.N!]/P&`P&`P&`P&`P&`P&!4\KX[%Y)QZ?22B)MF>RK7>#[
MVS^X'0_W-FB$/ZIE37/1OBZNB2K27'E.(_:585;BN(AHC@@39RU35-SKHJ.]
M?/;XXI$+_M1(6"L1;CTKQM.,;O;C]B+_`.H^_P"[3^GPQIB17?&UM67`RZ[D
M<B+`D!$2VK@8:5)#L-D&!<;=+4V.X#0H:#X_IA(]J_C)Z#(I'UM.ZM/9V%H@
M]@11Q;+N;VOO7:@=\M%Q5C=SKX[>Y3-8D!:'!`(<J`ZSV&I`J$M$176T=Z-N
MB@Z;]%Z*J8S3S18WQ.TL.ZB6-H[+9NZZ%7/JVT#!@L!M0;>;(5+0EW;M/#7%
M770\3H+JHC.#;W;UY*/:(ONM-1T$`141$;91!W+KJ1+XX2.<>^*'ORBNQ+QZ
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M.E:M%N:-S:CAEOT024M=-$RT0KWX_N7?C-^0:R[#DCE)#JXD-&F@.,`FTXZ`
M@F@J>\-2(E_I1,)'5SOC1NSBV13+.0=E;NP79,_MM`0M5SJ/1V`:TV"*%JI>
M:JJY%8V/Q7'ER["P8MY<&TE606\2;'1K?%?",,11`3$A-LVAT(31=<M1&NOB
M!NV%SO<@LA=DUWXR:^OMW''A1Y7T<W&VO;537U(VB(J:)Y8JIP_&D=;&2](L
MY,FOF36+276N(T@.3(PMB#A."`GM4F`-03IN3Z=,41Y'Q0R9%*B7<^OM4LI=
MG&LHW91QM9R"C[&PP-LVBV)T,575-<5(Z63QR/*XS(X_)>??C2HAPWY#A[GS
M%T%`S(]/O7<J^&0<]_VN91H1"XF`X_7!4VSJ(SK,BM;D;WH@;0<$3(4,$1=%
MRTCH+CCGO>.?@X,U^H91MMEM^'V^Z#3>B;![@F.BBFU>GAD54-_'FZN").N9
ML^1&DLS*V8\C`%$=C)M;[+;+;;6W150D45W(NBY49ROCJM?XC)XT$J0RU,?6
M7,G"H+(=D$^DEQPE(5'4W$\A\.B9!+Y7P/CO**Q^':Q&C=D"V!S4::]PB-FA
MH@N$)*B:C_TRB57U-A%O)TE99K5/-1VH5;Z.TP32*ADT@B*BA)IZ55?#RR*I
M;GXRK;2PLY9SYC(VK\&5)C-$WVT?KB$FG!W`1)N[8H2:Z=,M36JP^+*Z6[+D
MMV<^%8OV16T>?%<;!Z,^XP,<P;U!1)LVQ1"$T+7%(Z`F9M+QXPKV'[B7$956
M677A1^2XG7U/.:`A&OFO3"XYBL^,:N3Q*973H[E7)MIQ7#HPW_W8<LG$=;[#
MR)IJT2)X)MUUZ:+BIK.=\309S4=)=U:NR6XTJ%*FJ^"O269J"CHN*K>T/[8[
M>V@Z>&*1<<7X7&X]*F2(\R3*.<U%:>]R39(B0V>RV0[`#JH)ZL;IB;<\7J+B
MPJ9\YI3E4L@I4`T)1VN$VK:[M/$="UT^J)DIN*=GXSX_&@5$"&KT:+2V16T1
MMLA]3Y$X2HXI"6H?O$FB:=,M(PC_`!C3,^R0I,IX(4Z;8BVX;:B;EB)C(;<1
M`35O1X]$_7QQ2(C/Q!2-T,FB*RM'JYU&6X[;\KN^V8CO"^VRQN%404,$ZDBE
MHFFNF*1TM/QR+5VEO8LN.F_=/-R)8N$*@)M-"R/;1$1138VG3!BKD_'\-R19
M/LV,Z.=M*67-$#:)LE*.D56U;<;,";5L4Z$B]>NN0U9#Q.D3BB<5*/W*5(B0
M%CF2JJL(';T4O'73SRBF=^,:>55S(,^7-F.RV&(B6#KH^Y:9BN(\P+9B(HB@
MXF_54527[M<4C6/Q31(XLCWD]9I6+-N4U9&KONF6/;;D7;H@N->DAT_AICN(
M]E_%5'-;GC/ESI9SX;M:KSSPJZU$?<1TV@-`153<*:*>Y43HF.Y.UY/^)^/S
M)CTGW4^.,EZ)+EQF)';9=E0E#M/F&U?7HT.[31"TZIBK$VH^/::IOI%O"?F@
M$AUV3^+62:P&Y#ZJKKS<?[1(U55^B*JJB8I$J^X;7V]E'M._)@V,=ER)[N&X
MC;AQGE0G&7-PF)"I"BITU%>J*F16,'A%-`NH-K"5Z.5;`_%1(@'_`,=(NX2V
MJ"HJJ6X$]6NN6I&5_P`-K+JTA6;[LAB9!9D1FSC.]O<S+$4=;<31=R>@53]4
MR&JQ/BGBRQ8\1])$F)'J5H4CNNZ@4)2$]"VH*[T4!T-%UZ9:+?BO%(G'8AQV
M)<V<;BCODV$@Y3VT$T`-Y^`@G@B?SZY%5LCXTX_,F/OV92;-IYN6P$66]W&F
M6Y^GN`:T0302T31%)=O].F6I&ICXLH&JH8)RK&2ZR^U)B6,F6X]+CN1T4659
M=/7:@"2IIIHJ*N[7%566WQW*3DW&7:LI#4.&Y92;>U!\!E$_,8!M'"W(N]24
M=%T'1$1-,46,GXFXJZM<;'O(#E:RL47(4MY@WXY&KAM22%=71)PE)=>NJKUZ
MXJ.AON.5=Y3G4SVE6*2@0*V2MN-&R2&TXT8Z*!MD***ID532_C>CEUST*2]+
M<.3+CSY<U7])+ST115C>XB)Z0[8Z"B(G3*BYY'QZNY#12Z2R0RAS`0'>V:MN
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MNWJ)`B#M\-$Q2-DKXMXO)8L8[B2D9M(4>ME-C(<T6/%)2;05555"U)=Q>*ZK
MKBF86GQ=QBT=L79ONG'K)8ANNC)<;-MV`BI'=8(%$FG`U7U#XZ]<$;XWQW0Q
MY%=)$Y9R:QJ4RQ(=DN..'[Y$1\W2-25PRVIZE\-.F018OQ3QJ*S%:C.3F!AU
M_P"):)J8\!+&0U<!#(23<39$J@2]4RD7G'N,UU$,OVJNNOSGO<394@^XZ\[M
M$$(RT3P`$3HF#%+!^*N*P;EBTBI+;.)+>GPXB2GO:LOR1(7B;8W;!0]Y*J>&
MJY%8M_%'%PKV:T2F_C6A(#A+*<5ET2D+*5'15?5^Z2KKXZ=/#"1(C?&?%8UU
M,MFV7T.<;KK\)9#RPN](%0>>&-N[0N."JHI(F6D0Z[XCXM7(BQ';%M\(K<%F
M1[Z0KC4=EU'FFVR4O2C9)Z>GATQ2-SOQ9QAV+[,UE^S<5PIL9)+B-RB>>[[A
M2!UT(B<ZZIHOEX8I&UGXRXFU=S;88SN^P5PY4%9#RPC=?!6W7?:J7:[A@JHI
M;<4>\9^-N.<=L6K"`4PY+$7\?'63+>D"W$W]P60%PE1!!4]/TR*ZO`8#`8#`
M8#`8#`8#`8&MZ1'94$>=!M7"0&]Y(.XE\!'7Q5?I@:'+>I;;5QR:P#:*8J9.
M@B(K?4T557Q'S^F!$O.25]71O6O?8<;1DW8J$\VV#Y""F(-N$NU5)$Z::X&N
MCY56V-33S'WF8<JYBLRH\%QT.ZO>;1S:"+M4]N[R3!5BQ:5LA\H[$MEY\$4C
M9;<$C%$7:JJ**JIH73`HN0\\J:/DE#02D-9-\Z;3+HHG;941505U?+NFFP/J
MN!<3;RF@JHS9\>*:(A*+SH-KHO1%T)4\5P*FMYG"N7*AZD<CSJFS%\CEI(`7
M`[0HH[&5U)S<OW:?:G7`U\LYY74W%[BYKS8MGJ9M'),-I\$)$W(BH2COVKIJ
MO5/+`NTNJE)K5><QD+%X.XW#5P>\HZ:ZH&NY?^F![!N*JP5X:^:Q**.2"^C+
M@N*"KX(6U5TUT\\#FF^>6;7)X%39T#\"!;NO1ZNR)UHU-Q@"<T=8'UM(8`1`
MNJ_KI@=%9WM'5DT-E/8AD\NC*/N"WNT5$73<J?5,#`^2\=;G#7G:10G&ZC`Q
M2>;1U75'>C>S7=N4>NF!47W.H5=R.DHXY,2I-I,6'*:1Y$>CIV#?$^VB*J_9
MHNNFFN!GS;D=[003GUU*EM&BM%(G*L@6#1L%ZBR*B:NN*FN@^E/+75<D'O->
M5O\`'.(2.0,Q?<>W]N11WB[2H#SH-EN70M%!'-=/TRB>SRSC+U>]8LVT1Z#'
M<5E^2V\!M@X*Z*!$*JF[7RP56RN:MCR?CM9"1F777S$QX;!MU"0?:`)IM1$4
M2$M_CNP)S?->(.QI4INYAE&A*(S'D>#8TIKM#>NNB(2]$7SP5)/D=`!R0.PC
MB<)6DEBK@ZM*^J(UO37T]Q53;KXX%C@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@<9\JU5I/HH#M;#.?(K+:OL2BM*".FU&D";G;WJ(J6S7HJIEQ-<
M/7<,NI?(*Z5:<9<2$G*;6S>:D^V=$(LR&H-.$B&2+JZJ:BFO7`A57#^5UM56
M-SN,NVD,:JVJFZT2C$41^1,<=8=VNN"WVW6%$-PKJ.FFFF-'L#@?*%>KXES0
M39D61`I1CN,36&1@2*UH0<;D:%O01<'NB3.N[733&([KXSXHW3%?SYE.U7V4
MRWL7@EJ#*.N0WY'=:_<;4EV::+M5>GTQJXXSE$:%R:MY-9O7S=;;NO`M)7>[
MK2__``67<@&AJ1D'<=W&2=P?NR&I<2?QZ[YW"Y#R&/5L[N/A'>.5)KGD8L1D
M=Q0':ZXO1-5$T\LHH*86?QO!X9R8-;,I8EM`GS??0%[12(JL,OBK;RD0FYHJ
M:>KIU1,)1V9&G?'EK4E6T]9>!2-U`R6[*`1S7&B3:C)"YT9^X]7="U7PQ!,!
MVJ+F4MRR=AV$)ZS"YK;3\U&:9CZ,"WV761<1Q3;VJ`;4451>N!<_&%Y34CTV
M/+MH42F]O&"O;G3*]R<T8=SN1U?C'^\PTA)VB<]75<1<;XO/HUASB-)F1HB-
ML.G$JY)6M>333+JH)R$:!PG2>>VH*#MZ#T\UR*D?+?&.4WCDF/550S(TREEP
MDE-.LL/C)<)"!IUQWU(PNFNC?52\>F$5,G@O*'TMYGX$1G2[6@FQ]78_<[<`
M6$DEW$7HH]HT\=5UZ94NM\+B7-F+NHC/TP/L5?))=J[?)(93NQ9B/Z%VU_=[
M@(\($.G@*::^45<?+5UQV1%?XI:C$59L4G6)$F?'B>WD:JC#A";@/)M+U(8"
MOA@U)Y14R.5?$K]733&+R2_%8;"6CHJU*<C.-JXO<3</K5HOY^.%<U;<"Y6_
M:2>3U=0$0RGP9*<<&4,1Q]N+&=8=<)^.7;!Y5?U#U::`FOCE1O?^-[QYF@B0
M*X*:,U%O&I*-RE?6&Y:L[6EWFJFZ7<]1J'1%\,4B97\!LKMQ@>05;=7&8X^[
M036FG&W$E$ZH:&';UT::[2DWOT)%+PP,.-_'/+HUY3VES*9D&_$!GE(`I*#K
MM:>M8;0KYIJJN?5<BOHU1)LY$3N6,-(,GN.#[='1>38)J+9[Q1$]8(A:>6NF
M!-P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!X0B2:$FJ+XI@4
M_P#A?#O_`-15_7Q_XC'_`-9@>IPWB">%'7I_"*Q_]9BC).(<33PI8'_W*S_]
M;BI'J<3XLGA3P4T__MF?_K<4C+_%^-)X5,+_`.YVO_K<4>IQKCO_`.JH?_W.
MU_\`6Y:,@X]0`2$%;%$A5%$A8;145/!4].15@B:8#`8$=ZO@/GW'XS3KFFF\
MP$ET3RU5,#:TRTR"-M`+;:>`"B"B?P1,#/`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`+KIT\<`FNB:]%\\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@-4P"KI@,!JF
M`P&`P&J8#`:X#`8#5,!@,!@,!@,!K@,!JF`P&`P&`P&`U3`:I@-43QP&J8#5
M,!@,!JF`P&N`P&`P&`P&`P&`P&`P&`P&`P&`P&J8#5-=//`8!"1?!=<!@,!J
MGU\/'`(0KX*BZ=%P&X==-4U^F`P&N`U3`8#`:I@-4P&J8'FX=VW5-WCIYZ8'
MN`P&`P&`P&`P&`P&`P-<F0Q&C.R7S1MAD"<=<+P$`3<1+_!$P/G'Q5\FV7)[
MGE%1;Q%A659)&37Q#1$<*LE-B<8E\E73Q7_<F!7VGS]'+AMIR*GX[9/L0(\D
MEDR&VFXP2([R1U;-SN+KZR0O3KJFOGA-2&?E!J!R"<]?ORH,>!QIBYF59,L$
MR&YS:3H/-N&:N$J[$;\/UP8A<T^3KXX5$_619M#(7D=;63V);31"_%GMJY^V
M:=P"11TZ@6HKJF%=)1?,?%KKEB<=B(?<==EQX<HB;4'GJ]420*`)*X")KZ",
M40M%TP(GS.YS*%QJ7=<?Y#^&2K95UJ*W&;D.392D@M1R5S707%5`%`3527^6
M!UU+9W+GL(EG7&U*.O:DSI@*'MAE+M%R.*;M^Y%523IIIYX%#\K<AN*ZA2NX
M_(9C<DM.X-8Z^0B`)'!7G35"Z+Z10$_W$F!?</Y)%Y-Q:JOHO1FRC-OH'^@B
M3U@O_D/45P*#@]G:RN9<XBRYKLF)6SXS$!AS;M9!R(V\8CM%%74W%\57!CUW
MY2KUY"E-%@O2D*8Y6)*;5%1)C3>]1,$12%O=Z.XO1"_3`H*#Y;O9I<8?L:EF
M'!N*V?9SWT>0U;;AJ'V"B:Z")ZKYK@2B^;H05\N:M++<;8:AR65:(2%QJ=(&
M.";RV"+H$8J3>NNB^.$KOJ>=-FUC4J?!.LE'N[L)TP<)O:2HFIMJH+JB;NB^
M>%?.N'_(DNQ^2),-^8R_1W\=QWC3+9B1,E6N*R^)Z*JZR`)'A_VX%T/R@#MW
M&KX]6X\Q+LY5.Q)1UL2]Q";5QXC:+11;T`MJZZK]$U3`KX?S&[(J(5B[0NPP
MM7"9J1?D`J/$UW%D$79%TFQ;1GQ45W:I@>/_`#3'&+'=9HYCDGVC<V=7F)A)
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MB;%>950527[==$UPTM?EZ7-A\=KWX<IZ(Z5Q5LFXPXK:DT]+!IP"4?$2`U14
MP,U^2-LEQC\=T9Y$WQQPN\G_`+UL7`D)Z?\`>B*'_C@5,3YH-`BS;2E6#4RV
MK4FY(R$><1RG4U=%6D`?2X#:J"[O'HJ8'1\/YA97LF7'G4[M>C+3#\>2J.JP
MZ#XJJ@).M,KW&E30T1%3JFBX$=V5-#Y?C0TDO+!>H7WRB*:]GNMRV01Q`\-V
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MK%G\5!X7*T>)V%A)GDXXDTY0^DG4-$Z>I=41"3Q_1,#=5_*%A55`P[2M19#%
M93R*TFGB>*1^2-(C8N^A"$T>34MN[I^N!V7%;VYN(,S\E6N5<N+(<CMD0F@/
M`B(3<AH71`]J[M-"3Q1<#GW:+F<*DDG:VT>2PQ2S&)/MVWV72DH1.-R&S[B[
M5V:;_P#<GIT3`YSB-T5/PZLY3*KK'OLTT#;)>F$XQ82K$FV40A(W4%1=V%O5
M$5$+PRZ+FY^4.1U$UVE?J(K]\$ZNBM(W(,(SK%HK@M.H9-J8D!LD)BJ?JF09
M3ODWD$2U_&.5,8ID>96UTV(C[F\G;%M#)Z.O;];+*EIJHZKM+PTP-*\T=HCY
M!/9JFPB1.2M0KQ]9#IJ+$AI@4FHA(J#M[H(3::"B:KKE&^S^3;X7RAU%4$Z:
MZDZ5``$=<1Z'"=&.*_MHJB;[RKM+[4'1?/((T[Y8Y+'>LGDHV&8%.Y4^_:??
M-)2!:@&X!`0($<8-S1=2T73`G,_)'(I5\^W74#L^E9E3:\GVD,7`>A(8[R,O
MVE!QYM6T%/4FJ+^F!6-?+]H7%G+@F8>K4MJ+.<$)9)7(;*FY^0C;$D-JVXB-
MJJ)HNN[PP/HM-:+-HX5D^3">XC@^ZY'<[L=-P;B5MWIN#Z%],#YAPGFLYWY(
M[\N4\=3S..XY5Q7FW&@BO0"7LM"K@B*K(B%W5V_U)@7<7Y+NI?*H]5&KF"8>
MM9M4ZT;C@RF!A-]SW3@H)#VW43T^'W#ZNN!`J_E/EDVGJ9CU3%9?Y"^Y'J6F
M">DD'M4?60X\""TJIHR.P1+7KU\,#-[Y0YHXR$:)Q@OS\2$W/LZDU4B7N2'&
M1::,51&U,6"-"<\-414\<#VP^3^5,6,X6*F&<*#>1*0D-]P7C2>RR3;G02`5
M;.0F_P`=4\,#)KY-Y*:I3_CXY\C]_8055A'78RC7--NJ8@J@YZTD`.F[IU7"
M;J):_*O-HD6Q?6BBQ7:>FB75C#E/&3J=UUX)$<5;11W"C"J!?]4PJ?%8N^6\
MBY'76<P&JVDM*Z15>U[K+[>V.U*1",31#W(ZHDA(J?IA-8\GK_\`!JB'>P9#
MIK'NVRD-F9FA1+66++T=-Y&JB*NHX'T).FB8,?2\*^24O,;IB6Q34-5717K6
M\O8CQN.2%;%V$BNI(T34B5Q4]8II^F$=MP[D=ER3@\.[!AF/:3(YJC"J1,#(
M;(F]->A;%,/XZ87'$0OFBS<&J65#C-%.@2PDMBCBJS>QC(!@*JK_`.]5L]J?
M<NGZIEQ-18?(K_C?*N52AC1'8SMW3,6X;W=^^?$C,FL9/!-CA[O4O5/IXX%M
M3\MD,W$^CK(,.#:6?(K&*,@U=-DO:Q@D.2'`W"1.F*B.P21//RZA37-]RZIY
M797P0H`W,+B@2K:*KSKD=5BS7MX-$*(JD0BJ(I?;YZX,?0^6-3>0<`EA6S$J
MIEG#%8LMPE%&C>05$2(514W:[%5.O7IC#7RR9)AM\4YQ53J:1QCDL>A.0_5@
M\3T)P&$,0G07173[^A=!+73=UZXT='\:R:VZO6_RX.0>0T$-MFMHW2]+<-P!
MTF@0KMDJ_P"9_P!'V^.JK!;?$3(,_P"8`*%HWR6P:#<1%HV/;4!'<JZ".[HB
M8$=?D>];Y<-:L6/,A/R+*,T$5'%,3KX_?;%9!+VS=<VJ)MB/H7S5=<&J<OEG
MEJ4%I;L0H,EB%1,70N(,@`;DO$J%!=5?$VQ%5UZ+]13*BSLN;_(<67(J8U9#
MG7E?$;LI+$??V76I#S@,L"X\XTK9(#);W%0DUTZ8&UKY&Y"]9R)C-4+O&8,R
M9"L'444=9&$TI$^CBN_N*3@**-(WX:+KC5J#Q:QM[7Y+H;JP&,`VW&'I,=N*
MA_MMN26'!;<,B)'%$33U(B==>F31]7PI@,!@,!@,!@,!@,!@</\`+<I\>.!7
MMPK.8U8NBU+&JAI-<5@%0W&G`5QK:#PCL4M?!5RXFZ^:L?CH'/87+^/\-Y12
M%&BE"E5D:F;1B4T2J7[J]\=%1=-NB=-,$:X;8L?&-IP%WC/+GHMH<DRGI5M-
MN-K*=[RZ-]]4+::_7PP:T65>EM,E2+?C/+I@3J$./2VQJXS.X&W$=&0*B^NT
MT--4'33`VR?\AL./4U1:5G,)JT<^'/B2BJH;:Z0$5&FR%'^N[7UFJZK^F!.X
MC)L>+W$Z3`XYR\Z:7+?GM490(0MM/R557-'^[WB;U740U1/XX1NYW<\GY2_7
MN1J;F=$W7&KS;<&%!+>\J**.&3KI=1%504\O'QPN/H_`(]J=56RGW;*+&9A>
MT<JK9MKW1OMN=9;S@J9;W$3[4+3KD58.\48D<I<O9KR2P]H,.+!=:`FV41SN
M&X!+JNYQ=-WZ"GTPFY6CA/"PXK%GPV)IR84N8_-CQC``"-[DU<<::V?^[W+J
MB+X87%<'Q]:Q;/D$^NY$_"/D3XR)*#'8-6B%E&![)$BZ*@`G4M>N!E2_'"T]
MV[,@WD\:E]Y);](2MDR<K8@DZKJCWM#4=YANT4NN$0:[XAA0V:9@[:3)CTS,
MZ$#3@,HCL&>@H<9S:*+H.Q-#3U?KA'@?$9KQUVAD\GLYD,5C#7J_V2*,S$?!
M]MM-`3N+N:$5,]2VIIE7<=G=UCMG3S:YN6Y".8T;/NV4%7&T<3:I!O0AW:+T
MR*HKCX\KY\;C[;,IRO>XY(:E09$5MI#566E9V%N$DV&!*A"GCEJ1Q=/QWF;?
M,W;%J/-A27K%U^44AFM>@^V<=T/M2A3W:[F!1!'HJ+HB^E,J.G+XJA)QFJIX
M]O.BRZ-]R35W#"M!):)Y3WBJ;%:,"%TA42'JF164KXM8=GQ;"/?VT.<W'&'8
MR67PWSF1<)U$D*0%H2$X6TF]JBBZ)HF16:_&->KKCB6$I%<O6^1:?M:)(:!&
MQ:^S^WH*?[OURLH\GXF@'M?BW-A`LVI\RQCV44F@=!;`D*0QHK9-DT2BG0A7
M3ZX&ZP^*ZJ:%LVY83$;N*Z/5R=2`S1J,1&+B&8$2N$KA;E+7Q\,58NJ/BC%/
M;6UBS,D._F'&WY$5Q0[(O`T#).`B"A(IBT.O73Z9%4C_`,4U#EPY.;L9T>*Y
M:-7BUC1MI'2>TNJNIN`C1'/$Q0M%7KA$-GX5H0:]N=G8NQ!AV%<W&-QO8,:S
M-''0Z-H2J)IN$E77ZZY:1/'XP@A91K%NXLVI`1V(MEVGQ`9X1=>U[D1!/4FJ
MIJWM54Z9`A?%M1#MHTZ/83@C0K!ZUA5G<#VS4B4#@/H*;-^P^\2[=W15Z85;
M7_#X%Y.@R)TB0L>"XV]^/`T2,ZZRX+S)N#HJ[FS%%314^BY162?C&F?NW+59
MLUON6+%PL)MT4CI-C@C:.;=BEH8BB$F[3^&$UK9^)^-#'KHSKLF1&K3L3;8=
M,5%Q+5#22#N@IJ.CI;=--,4BSXEPJ)QIDVF;"?8ZB#31V+ZR":8:UV,M]!T$
M=?/JOFJZ9%2GN,PW.4L<D)YY)K$-R`#*$/95EUP7"U';NW;@'KNP-!\3B#+L
M+/NOO6\V.<0)AN;7&&2U5&HZB.C*;O5J@ZJNBKKHF!E#X]*7BC5'-LY3DGVH
MQG[5MS9*(MNA.B[IT/\`W:8%9$^,*5FJE5<J?96422TVR(3)*GV$9)'&R80!
M`0,31"W::ZHF!)<^/J9WCMM1NO27&KU7"MIBF/N7R=%&R530=J?MB@(@CHB)
MTP)EUQ*ON*R#7RWY`M5\B-*8<;-!<5V&2&TIKM75-PHJIIUP)/):.'?4$^EF
MZ^UL6'([I#]PHX*IN'7S%>J837/.<#:NVXTF_=>;MVJ^143'83RMM2([Z;3(
MAT_JTWHG]*_7*8V2OBWB\MEYB5[AYIZMC5!"KRBJ,0C[K!B0H)"Z#GJ0T7QR
M*NN.\<BT4)8S$B3,(R[CTN:\4B0X6B"BFX7CH(HB)X)@3;*"U85\F"\1@S*:
M-EPFUVF@N"HEM+R71<"I#A-`G#6^(.MG(I&HP0P;>-2<[3>G;_<30MP;4VEX
MIHF!`>^-*!\&BE/S),MJ7%G+.=?59!NP=?;B9HB:@&\O3IUU77QRFN8M^&<W
ME<OL9\17H7NWP*+:1;)6V6V0``'NP3:<W&FU=4$MI?IA'9IP:A*'R"&\#C\;
MDQN.6S3AJ2$3K(L%L_T)L`4Z?3(J-;_&O&+./4M$,B&=(U[>NE09#L5\&%`0
M)E7&E%2`Q!-R+@8R_C'BTENR:('VVK7V22VVWC$=*[3VR!U].W8FNGCYX#_M
MCQ=+B?:@DEMZR4W)4=N2\$97W05LY(L(7;%Y15?6B:^?C@>-_&=&TIO-S+`9
M[AMF[9)*/W)HRT3+;9GX&`@X7I)%ZKKX]<"R/A]*O%5XLT+D:G]M[)&F'";-
M&%':HHXB[NJ>*X&%UPJEN(]2Q,5]$I'VI5>;3I-&#S(J`$I#HJ^E531>BZX'
M%5/!^9L\F.8X1P=\\YDF=&M'W(SS9O*:@E<XWM%3#0513T3Q3*RZ5[XMXD]Q
MF)QTFY"08#ZRX#H2'0DL/D9&IM2!)'!75PO/P73(T\F_%/#9CD!QQA]MVO:6
M.#S,E]MQY@R[AM23$T)\#/4B0U7557ZX&][XWXP\Y*,VWM9MA'MWT%XQ3W<-
M`1DQ1%](BC8^E.G3`TV/Q9Q"P"0DAI\7I$\[5)3,AYI]J6Z"-&;+H$)-H0"@
MJ*=-,#;(^,^(OL36#C.(S85[=3*`7G40HC)$0AT+QU<+4ON75=5P+&MXG35U
MU,N8@.!-GMLMRE5UPFS]N"-MGVU79OV"@J6FJHF!HY-QYR\EUC,@P2IA26Y\
MEKJKCST8M\</]*`+FAE]=$3":V\7X\-)#EL#(<?25,?F:.FXZC:OEN5MM72,
MD!/'37Q5=-$Z8,1(GQWQB)/CSV&G1E1IDJP9/ONJB2)P[)!Z*6GK%?#P3RPJ
MSX]QZLX]3LU%6!-08^_L@9DXH[S4R]1J1+ZB5?'`B?X/Q?>II!;0RLDNB)-4
M59Z)M1]>OCI@1Y_QWQB>Y8.26G2.TE19TU4?='<_!V^W)-"].SMCT'HNG7`T
M6'Q?P^?&EL28SJ^\L%MC>!]YMYN:HH"O,N@0FTJBFW0%1-,#-SXSX>;;[:13
M!N17+3O`#SHHL,C4R#[ON(R55/[E55Z]<"VF\;J)M`M#*:5VK)D8Y,J9HJM@
MB(*;T5#U3:G777`JC^-^+O1;&/*;D3$M8Z0IKTF2\ZZ45%5>P+A$I`VJJNJ"
MJ:^>![.^-^*37J5]]AWW7'@5NHE!(>!YH%044>X)H1HJ`B>K7`L:+BU/1%/*
MM`VRLI)S9N]PW-\AS[W/6I:*6G73`H++XKXT2RI];'[%R;DJ5#><=?)AJ7,;
M)MUSLH:#M-2U,4\?XX35#QKXHD]IV#>,C&IWHA0I=9&LY\UF2)("(JI([?90
M-GIV=>NFNF#'77OQSQ"]EPYEI"[\J`WV&'D==;-6=456G5`Q[K:JFJB>J85Z
MU\=</:Y$[R)NO$;1]5-TT)SM$XH=M758W=GN;/3OVZZ8&''_`(UX=Q^P9L*F
M$3$J.RY&CJKSS@M,.DADTV!F0`&X45!1.F!T^`P&`P&`P&`P&`P&`P(%W?5-
M)#29:20BQE<;9%QQ41%<=-``4U\54BP*WCO,HES,MH:M>T?K+!RN`''`)9';
M:;>[K:)UVJ+J=,"?,Y'10H\V1)GQVV:YLG9Y*Z&K("FJJXB+J/\`/`DU]C#L
M(+,Z(Z+T60".-.BJ*BB2:HNJ8',R/DRB]_5,0#:GQ+"?)K9,YMX$;C.Q67'C
M4]?N3]DDUP.D=MZMF.U)>F,-1GU1&7S=`0-2\-A*NA:_I@2E7IK@06[^D>;>
M=:L(SC<<D!\P>;(6R5=$$U1=!55^N`;OJ1PFQ"PC$;SA,-"+S:J;H?<V*(O4
MA\Q3K@;$MZLIAPAF,+-:'>Y%1T.Z(IU4B#7<B=?I@8_FJC8)^^C[#:)\#[H:
M$R'W.(NO4!\R\,"!9\WXG6UTNQE6L5(L%0&48O`:@3JHC8D@JJH1Z^E//`G-
MWE.Y+:AA.CE+>'>S'%X%<,%3=N$==233KTP-/(>34G'XS,FWE!$8D/M163<5
M$W//$@@*:_\`5?HF!5\>YU`L[&SKI)QX<R'8NU\*.L@"<E"TRT]W6P7:2ZB]
MX(BZ8$R;S?BD*'83'K6+V:IHG[#8\!DT`:HJD(JJ_<FW^/3QP+.ML8=E!9G0
MW1>BR`0VG`5"11)-?%,#G.%_(%=R"&GN'(T*W[LP"JTD`X\C<.0<=7=J[#45
M[>NNW`MXG*N-3&9+\2TB/L0AWS'6WVR%H=%7<XJ+H(Z(O5>F!7</YDQR.??,
MQD9<B5$MN+'EQW4>!\3CMO[M430517=JCY:8%K.Y'0P)C,.=81HLI_3LL/.@
M!EN+8.@DJ+ZBZ)]5Z8!>14:6B5*SX_Y,D54@]T.\J"FY?1KNZ"N[^'7`CCS/
MB1-O.#<P5;C$#<@_<-;0-U=K:$N[IO5-!^N!ZSS'BKT1R8S;PW(C*-*[(%]M
M6P1]=K*D2+HG<7H/UP)'Y^F_*#4^]82S)%)(2N#W51$W+H/CT'KI],"C@<\@
MV/.TXY7N1Y<9*YV<]*9=WF#K4@&%:(1].B[UZZ^*8'1R;.!&E1HLB0VU)FD0
M0V3)$-TFQ4S0$7[E$4U73RP*F3S[A<6.$F1=PFF'6B?:<)\-":`^T1CUZB)^
ME5\EP*[G_P`@P.,T#\UEZ,_8]IM^'#<<5.ZV;H-[DV:KHN_TKYK@7;G)Z!FQ
M6L<GL#8")FL=31"T;'>?CYB'J5/'3K@94O)Z"\!URFL&+`&%!'BCN(X@]P4,
M-5'_`%"NJ8'+\I^4:VO"[CUBMOVG'W8(6#,C<VV(37@;54-/,`<W?3`Z!GFO
M%GJ]ZQ9LV'83#ZQ77FRW;7Q\6MHHI*?Z(F!95ME!LX+,Z`^$F'(%#8D-$A`8
MKYHJ8%)Q#DUA=6'(HLJ,TP-)8K7M&T9&KJ(RV]W"0A';T>1-$UP-MCSOBM>]
M,8DV#8R(++TB0PFXC0(X;W4%$3UD`KJ0CU3SP(%-\H\3MY[$&*^2/O5P6RJX
M)``1S7IO,D04)$157^&!+/Y%X2W%*6[<1FHX/)&(W25O1X@5T0421"U($W#T
MZIX8%["F19T-B;$<%Z+);%YAX>HF!HA"2?HJ+@<M_GS"?(X\1*.J,NQ3-FQU
M]!S6D%UV*G^X8[@.?SP+6;S+C,&P2OEV#+,M7`9[9JJ:.NCN;:4M-J&8]1%5
MU7`C-?(O"WG93+-LP\]"51E-MJ1D!([V%#0474^[Z=J==?+`S>Y]Q)FL:LSL
M6_8O(X0O(AEHC!;7E,1%2!&BZ&I(FWSTP-,KY)X/%FG!D7$=N2V\W&<%57:+
MKP(XT!&B;!W@J*.J]?+`VL_('$WZO\HQ.1V)WG(W[;;I.]YE%)QOLH/=W`*;
ME]/AU\,"-)^4N`QA$WKEA!-AB6A#N-/;R2467E4170")--R]$\],"93\RJ;:
M^N*2*+WNZ5QMJ61M&+:DX".>@U%!71"3SZ^73`\YCRVMX[7.NOOB$TV'W83*
MMNO*1,AN4B!E%/MCTW%T1-?'`J:'Y,H7:>C<MY;<:VM(4&5)9;!PF63GBG:0
MW$0Q:%PUVM]PDUP)59\F<:GQK"0)/M-U\YRM)#CO]QU]M5119;0%-Q=1+TBB
MJFFJ],")RGY.H(/$)%S636I#[D"5,K!1MU\26."ZJZ#2;VP%Q-AJ6W0NB]<#
MIZ&:].I*^<\@B]*BLO."/04)QM")$UUZ:K@<S??(*57.Z?COM>Y7SR6//LM?
M3'F/@1PF%3ZO(TY__#]<"?>?)/"Z&<[`MK-N++C@TZ^T0N%VVWU46W#41)!!
M5%=27HGG@:;;Y$XRT5I6Q[1EJX@,/FZCC3SC;!,Q^_O>V#]B`J'T+U)X8&JA
MY1:RN9_AGG(S\`J*':-26`,"-Y]TVW%3<2_MEL11335//`V\JY-9Q.1TO&ZE
M(X6%RW,?&3+$B:$(8"6Q``@4B,G!\^@ZKUP)W!.3IRCBE?=]GVSDD3%^.B[D
M!YEPF71$O,4<;+1?I@;>2'RGLM-<=&(DIPE[LB?W":;!$U_MM*)F1+T^Y$3Q
MP.)K?D?DUU&H8,*'$C<ALV+&5+[BF]%$*UWV^K.TFR()#JCL)5Z#UZX&H?EF
MTMZ\)M!#9_XE$G(+-B3N(E_<-OV;9"0[258[O[BHO@G3K@8V7R].1NYN:MJ,
M=#QP*QZ>P\A^ZD,6+8/FXT2$(AVVGDVZB6\D).F!]-F6$6'7OSY![(D9DY#S
MGT;`5,BT_04P.-K?D1P6N.A9170F<N5UZL988<<"-'%KNM(^0HNI[-JGX:*J
M^2:X&KX\^4(%S2P6[F6TU?.19$N4@M.,QU;BO&VZ39GJ"]M$3>*&JCYX'3T7
M+J*\?DQZ]XEDQ1;<>8=;<9<1I]%)IU`=$"5MQ$7:2=%P*GDG*.0ULRP9AT<J
M<S%B,28SK#7<%XS?1MX!7>.KC8+O1O3U)UUP*.SY]=L\MO:7\C55;-?&@OUQ
M6#3G<>=G[Q%HD%X/`P0?2BKU\,#I@Y[0M3F*N;(0+`G6X3Y@VZL49Q@A^V]Q
MM[:.+KZ14M?YX'-\C^7JGL17./S!<1FVB0K8WHS^P679)17A`B$$[HF&FB:K
M^G7$'01ODKB4JL&PB27'P)]V*D4&7?=(_''>\VL=11U";#U%J/1,08)\H\+/
MVI,S5?CRQBF$IIMPV`2>2A%[CJ#M!72141%_GI@8-_*O#'7Y+#$EYYZ*_P"S
M<`(TA=9/>['8!=FA.=S^E%\.OAA.YB_\L\+9CQWRD/E[IF3(99;BR''5""?;
MDHK8`1(31]"%<%2IGR1Q.*U%>*43T>4S'DB^PTZZVVQ,+9'=>(!7MBX71%+"
MI$?G/&W[P*0)*^]=-YE@E`D:=>C=7VFW5389M?U"B_7Z+@7^`P&`P&`P&`P&
M`P&`P.)^7Z:5:\11N+7K:/Q9\"8D,`!QPFX\MLW=@FJ"I=I"Z:]<N)KAGN)V
M:W,VW:X^^$W_`#"OG1)"LAWAKQ89;?("0ET;':8DB+U_7`IW>&\JFS)*)QB1
M$236<BKG64".,079)H[$7>ID\\CI#N[AJOJ71$3&H^T\'%P.)U3;L!RL<;BM
M`Y!>$`,"$4$MPMJ0IJJ:^.17S"#PVP6QJ:^5QL_80^66<^8ZK3"QG(DD)*QW
M>A:D"=\!T4?Y=,J*EGA7)6:JGCS^.V$ZG1BVK'ZJ&[&:>CI*L#>CN;72V(R<
M=4#4"10QH^VPH+T;C4>"+**ZQ#%@8QNDXFX&MJ-D\OJ+PT4_/QR#X.[P?F,R
MEM8Y<8D-+84-?"2)I$!D),.=W"9:;!Q5V`VO[9FJD2)JJ]<0=)?<#F?D.2R:
MSCFBNW-',J39!EM>U&5E93C75-FG;+=X*7ZY<$ZJX??K,K(,FM5NQJN0R;5_
MD?[>R3"?-YQ40T+N*;H.BT;:ITT^B)A=<_`X5S+\/45CO'G&_P`107U0ZZ3D
M?8Z_+0/;]L4-55MS9T5=-/-,AK;:_'7(UK)3%=1(VCG%ZB,3(*P".3X$M'G&
ME3=HKB-ZZ$O1?KE'51Z3D2_(C-Q"K7XD&3(!VTCS?;/14!(G:&3%<!5>9D#T
M:($U`DU7]<@O?D^IM;&EKUK(7Y"17VU?/.(A`!&U&D";B"KBB.NWZKA7(O<-
MY"Y.DS!IU22YS*+;@_O9WI`;9:;-S=NUT382;?%?IA%&/`^=S!DA(I4B')X[
M<U"BV]'&&U(DNHY'%AH%4D:/3H9>K554LJ/L_&CF+00/>PR@2@8;%V&1`9-J
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M4AEPI3-=,;>-1+04!E`;)0`O5J6FGU@SYUPGE4F=R9BCJF),"^B581W.^W'!
MDZ^0IFV3:IKZA+451-,HS#@/(G;RSC2ZUIR*_83;2KY$4US6,<QD@04AII^\
MUO4$+[=OZX$W@G'>81.1T<FVJ6($:JH#I7WF9`.HX\#S)`XV`IN[9BTI)NZI
MKUR-+[G-1=2K;B]K510FG2V!OR8Q.BRJLO1'HZD)DBIZ%=0E3S3*CB:3XZY;
M&BP0F0(ZN,4=[`=VO@0I(L9?>8$55$])!]Q>6$1Y7`?D%OCUA51Z^-+*XIZF
M*3KDH6UBR:UL6W&EU$MX'M4P(?/77"KJNX+R!CDTXIE5$F0EL)=O6W1RW5=:
M*6V2*RD5?0C@J?;1S7;L\M<(ZWXUHIE%P2DJ9T=N-808;4>6#1(8JXT.U50T
M1-VNFN35QR?+N%<KFS.8MPXC$B'?E4OQ77'T;5"@FVCS1@HKXBUJA:_IEPU$
MON!<O?N[6XAPX\C;=M6D*O<E''24Q^/&$ZBNM)N9=$DW`JZI]<(^@\-I_P`/
MQZ-!]FQ7J"FX4**1.--*Z:FHHX?J-=2]1:)JN!RM1`Y[2S>6/0J:-(.YLSGU
MKKDP0`1*.TP/>%`4NBL[E0?+IA5/!^-.1A*LH,N#`>CDY92*[D1R'R?0K)MU
M%!(NFQLQ)Y4(T710\M<(UN?'7-+""U$E-QH?N>*#0270DDYV9,9Q3:/1`%7`
M=Z;M%31-?'`DL\'Y3)&KF2:6MK[!FXKYED$>4[(5UF"#H*YW71U_][^VWIZ4
M\5QJX^J/D81R5D$,Q%5;:UVHJHGI'7RR&OET[XVY`7'ZJRBF*\W@V87+B.RC
M]G[AUQ?=@GI7T.,F3::#],J**SM&0YS:F+$>3'"ZAS'ZH+$&9I3HC#38D$1Q
ME7'/5HJ;#03VIX=<07TCXZY07%WX[*0_RL;DDB_AQW7#]O):=?<<%IXP%#`E
M;=7JB+H2)@1IGQIR$7X=A#IZ9WW,:5#MJ)QY\(K:2GT?[PNB*D\2JG[VX$W^
M6F%B1.^..1&S<L1VH2-S+2DF1!0R`$8JQCBZBCL+9_Z9=@]>B^."-%E\:\M_
M,S+F(S7RS2[E6$>NE.N`T_$F1&HQ[G`!5:>`FMR+H2:+IA&<WXNY`4*]C0V*
MV*U9\=9IXL>.IM,-2!>><-!':2HTG?Z+XJJ>'7%'5\7X_?5?*K^;*2.M9<>S
MD-$#A*\#S$5N,XV0J*#M_:W(6OGX8$;F'&.3O\E&ZH_:R$DU3]-,B3'#:1L7
M3[@/MF`.:JA=##1-4TZ],C3CK#XO^0'Z2#5(=>ZW!KZ=IC<^^VVW*K'0)Y=@
M-_N]Q`389_8FJ(G7-,I]A\;<N,9+D=*Y]V+R&3>5T>2X]V9+4YLP=9?VCJT0
M=U=A#N\/#(,I?QURR,S)2G8J&`N*5^HL(#?<88BN../.@[')`-7$UDDCB$@J
M2^K],#Z+QV'*K^/5D&5L*7#B,L/=M54%-IM`+:I(BZ*J>:9&G!7/Q?:7'%+9
M9+HM<PGRRL8T@)3ZQ&93+J%"-!T1-&6VP'[/K@5MG`Y%=<VY11HU!_(VO&*Z
M)9&3AJVP3KDL'#;39N<$4<54%=OE@=!'X%;QZ_F\$'&%:OXK<6J<(S4T1JM&
M"BR%V].K:%Z=<"9Q?B-W7<GBVLPHZQV>/PZ<Q:(U/W$9PC,D111-B[^GG@6?
M->//W4%IF+'B+.;-5BSY8J:PR(5!7F@1-2-!5=!W(B^?3`C<=J9G&)%+Q:HB
MMGQ>'7F+LLU/W`R`)-JKHG;+N[B(O/7],"7S2)RN96C$X][-"?)0G%,<>97L
M*GJ%HV!,A(O#=Y)X=<#G$X9RYMVGNF$JXUW61I=:D*/W@A)"D('903(5<W,F
MT)+Z4W=4Z>.!7M_$5G45PPJ"8QNET2<?M'Y*$*I^X;GNVA!"W%K(=]"JGBG7
MI@6-U\3UEJ[40"C16:>N;B-2Y*"I39;,!4)B*1:"(-(8"1+JJKX)IK@=CR*G
M&XX_9U)'VTL8C\7N?Z>\VH:_RW8'#UU/R.QB<*GL`S%M>*J[#MX4SN"*JL7V
MKJM$`EN\C;7[21?'`K6?B&]>I*.GG2HK;$&!=0)[T<G"/_YJ2JV3*$`Z]OIN
MW*F7-3<=3\?<5O*87G+EFH;EJTU'1VH8)I7A:U_=>(TUU+R!/2/7JNN-TS'9
MY%<;#X=-_P`_O;Z>$.14VD6%'88)"-X'(1&2&:$.S0E<\EZ:)A-Q4N?'5V;\
M^J*3&/C<^["_[RJY[QLT?"2Y'0=-BH3K?I<W(J"NFGA@8E\><C7B8UPR(:64
M?D!WT9?W>P8K.*8C+BZ;Q7UJ.Y$7!B+:?%G('IJ<@BOUKE^Y8R)TF!-:<<KS
M9DQFXJLHHZ.;P!@"[FWJNO33!N5'Y!\5\OL1;CLS*L8C+5>4-E67F6HLB%)[
M[R,,-+L0'O#<6I(B:>>*1:KP+EK?')\"+/B-2Y=\[<&*=X678K[_`'CBN$/[
M@;M=%(/_`*:X(B<=^,.1U4N(XY*KU8AA=MMM,@\":6[P/MIM)2T1H@VK^F*9
MC+CGQSSCC:P$J;6O1MVM@5UV,AEUW:=>)`#\/0AZDV:HHN=-41<*F\4^.K:B
MY$XX3M8_2MRI,V%(6*OY1%ED1DR;ZKLVB3B^M$W*G3"1]#PI@,!@,!@,!@,!
M@,!@%P-3,F,^KB,N`XK)]MU!)"4#1$51+3P+14Z+@;=$P&`T3Z8#1,!@-$P*
M^PY!1USZ1Y\^/$?)EV2+3SH`2L,(BNNHA*B[`1?4OE@;(-M63R(84EJ0H"VX
M7:)#]#P[VSZ?TF/45\%P)FB8#1,!@0KFZJJ:`=A:2`B0FU`7'W/M17"0`3IK
MXD2)@+*YJZQ8J3Y`Q_>R&X<3?K^Y(=70&QT3Q+3`7-Q64U9(M+-\8T"*'<D2
M#UV@.NFJZ(J^*X$L#$P0QZB2(J+^BX&6B8%-;<NX[43&(5A+1F3()L0!`,]O
M>/MM*XH"2-B9IM$CT15Z8%S@-$P(4&XKYTN=$C.*;]:X+,P5$AV&8"XB(I(B
M%Z21=1UP)NB8#1,#!UP&FB</[`12+1->B=5Z)@:*NRAVE=&L89$<64V+K!$!
M-DH$FJ:@:"0_P5,"5@,!HF!7K>UGYY*'N+^36*LY&=I:=A'$:4M^FW[R1--=
M<"PP&`T3`8%)<\OIJB8U"E=YR2Z@&3<=EQ]6VW'.T+KJ-B2@"N>G<O\`])<"
M[P&B8%>]?U#-W'I')`#:RV7)4>*OWFRR0B9I_!33`JK;Y$XE4V,NOL)1L/P&
MFY$XE8>)IEAY5%MUQT04!!5%4W*NB:=<#;(YUQQB=802><*360ALI8MLNN(D
M4]=C@$`JCF[:NB!JO3`M(+E78L1K:*+;HR6@=C2MB(:M.#N'153<FJ+X8$S3
M`8#`8$.79!&F0HBQWW5FF8"ZTVIM-;`4]7C3HVBZ:"J^*],"9@,#4U)8===9
M`Q)UA11T$5%(=R;AW(GAJG7`V],!@/Y8#`K+Z\JJ*&D^=JG<<;CL@T"F\Z\Z
M6UMIL1ZD1%X)@4\OY)X_#JY5C+9FL-P93,&6P<9Q'FWY&SM(H:=1+NCH0ZIU
M\<"S9Y17O7<NF8:D.RX+`/RS!I5:#N(J@VKGV]U4379XZ8'O%^3UG)J5BXK$
M=]E(4T:5YM6C7MFH%Z2Z_<*I@:^1\OIZ"OE39:DZ,(HX2F8Z(XZ'NG$::(@U
M31%4M?X8%WK@->F!S\[F,2/>)3L0I<^0V4=)QQ6Q<"*,M21DWM2$MJ]M==J+
MM3JN!)Y-R:#QVK2RFM.N1U?CQE1@4,D*4\+`*J*H^E#<35<#VIY+"L[2XK66
MG6Y%(^W'EJZ*")$ZR+XDVJ*NH[#3Z8%JBIIX=,"/83"AP9$H8[LDF&R<2,PB
M$ZXHIKL;%5%%(O!.N!G%D*_&:>5HV5=`35IQ$0P4DUVDB*OJ'P7`V[OTP/=<
M#S<FFOE@-WZ8'B&*Z_IXI@>[D\DP(\FQ@Q>U[EX&>^X+#&\D3>Z?00'7Q)=/
M#`WH8JJHGBGBGTP(EA8NQ7X;3<)Z4,I[LN.LH*BP.U2[KNY1]'IV]->JX$Q#
M%5T3QP/<!@,!@,!@,!@,!@,!@5W(;J/2TLRTD=6XC1.(&NBF?@#::^9FJ"GZ
MKA-?+/CMRVXOSTJVZCOQ$YI&_(J<HVBW7,=/^8#?;<<01-HA44_V8"FY?\@6
M(K-"<H1VH-L_;#V8YL,2(SA#"&,YXN`0)N7J6NFNJ:Z91%<YASL:WCD9WD49
MN=R&J.X:L7_;060=1EG;&!3:>`P`G"<).AJGFB)B(F0^<\NL.3#$2YK8A5\B
MN9DQ">`6Y3,IALWG&6B9*0YW3=7L$+B(FG5/'$$2AY)SZT<XR#O*2;'D27#3
MY!$BH3(USA=IQKTZ;U0="4M1_3SQ%J'#^2^86M?6MC=P:FR_"Q+(),MQMAF6
M\X\X#Q*VK3JN`B-(*@T0JBE_#&X9O1;%ROE[7(''RO%<A-\O:H$K>TPC?M9+
M`$J*>WN;VR/4%U\NNN3M*L/B6GA7G$(<ZSG.6UC&D6C/=D$TXXRKTAUDQ54#
M5-S::[2^OAIIE(L;.(Q0\^X)#J@[++T:?5O,AX+#CQQ>:W?_`&IP$T_\R_7(
M+3Y,L+JHXPM[62#92G?9FV+`")=^"T:++:]0DJ?M;B11Z],+KC8'-.8G*OXP
M%(D/5@2.15HJV/\`R*I^*2U\4D0!T(GQ+4?O]/CB(K;KF?)H5!(FTO('+5N9
MQAVY.3M9,HDR.36TP0`1!;>[ABK9HNFU=/!<0.<\L2UIOD&&EJS+KX<2D=B`
M#C9-ME(<U=VD'BA$">>6#+D?)AL;QK\C<^VF5G-(4)JB(V@!(K9CVG5;).X2
MN[NYOUT\O+)%KZ!\O[E^,.4;4]25LA4737P!?+`^?6G,.04)V;;%^=GQY?P[
MDBY?5M4K_>NF$D$>CAM%OM@!HJBNQ"UQ!]&^-IDR50OG(N6+X!EOC%GQB5P.
MSJBBUWE04>5O51[B)U_BBX3'!<LL9M1S/GEI52WG+&%15KPQ1-'!;0G9`..=
MG1=>RVO<%/K_`!RP:>1\DMX`V<:FY0_)I^[1.1;A767G&GITWL2(Z/**@0FQ
MH[M7J.OTZ8A6WE%S=UO()7'&N5&U-CA5I5R9$V&P6QQU5FG,!U`[AFWKM46U
M\MNBZY()-Q>\H!.;S8%I(>3B5Q#EC#!17N0`B,/2XJH@ZJ)"3A#Y[D\<L$7D
MO++ADJTIMZM!5\DCSI\*PEFXR++I*VD*/O%/2HL+W>V?W%JGEIB"+:\CY+'*
M]G.<DDD]2O\`'.TP"`RP:S1:&5O9(5-!>0R+8I>G$1]KLCV5LHT<5K:RXO=1
M=%'0%7<BK],C3X'_`)1R29Q?WQ<CFM2(O"8MS^TZ([IR.N(KKGIU7=L1"'P7
M+$K[PQ*??I6Y;*(Z^Y&%UM$^TC(-R)_!5R*^,\:Y$_=4LV3*YD]#E.58MVL1
M@7AD0;57A0#_`'546C[A*TC*)H:?PURQ*DM\[GM4S3W()LB%+8NFX7.1;,^W
M7@+!HWV5#<K<9\P;)7!7^I>J8@@W!L/32D5_(+!X(W$;65`ME<5F2ZK4T7&%
M[B")&`[=!_UBG777$2L[+G<G\U52?R[[$D)''UGMNNF+2L36T[_9CMCL)H]^
MKCKG@?I333$7N8\7N;UD>/S/\@FNR;6)R('UF.G(9%83BE$/LZ>+:)Y)N)/K
MB%1J[E]F]QZTLZF^*4^S4UPR8#<TIS[;JO(EE.!@%[B:,ETVZ+KX(F(5]*^+
M)0RZRPDQKLKRL=EJ<![MO"VT"MCN9:<D&XZZ(EJNJKT553RR;BURG,W9T3GO
M*YM(;[EY'XNR[#8;<=)>X+[Z%L:UV$8@NX0T7KHNG7*FJKD-T^W$LBXW?3G>
M..C2&,X9#SKC,U^>C<AIMTMQ^N-H3K?@*]=$UQJ/M-9`;JZYF&+[S[4<53OR
MG2>=5-575QP^I>/BN1<?&N32+)X4^5XK;#T>IM`<AF"NK**I:)84B.C6S3]W
M>X]IKUZ98JTG5C?+?D?DM=%M#B5]MQVO9?>8:$R=8<=D=P0-Q%$2[;J(O153
M=B)XK6BAPH_RW;U3**D5CC=;$;%=VFUIY]%#?YJ@&.NBZ]<+4;F<^36\YK!B
M.G*B-)`8.C8<?C2&4.2HC)BH'[,@-/2^V?@`ZZIA/-TORQ)DQ/C3DLJ,^Y&D
ML0'W&I#)*#@$(ZH0D/5%3(KYG='.9;LTI[>S>HWY/'U66DB09C->E[9HLN+J
M6U8RB3HIZ17Z>&6)4_D;,^!)Y!4LR;!NYK@@KP71Z2XKPH(J7JU47E)]3%_N
M:KLT\L".3,I^U"0[.LD==YK)KE$)$I`_'NL%W&T%%VHTIHFA^7DJ8A6R@G6+
M+W%V5E3TBPKKD,34ED.$L-EJ1[9'=^JN(/H[:GKKTTPBGC6UW$HB!7)$JK8G
M0%N;Z&$V0$F";3_K=B&2/-/"ZC?N@;+S1?TQ%KZ]\;,JSQ*.`SI5C'[CI1)4
MUHF'58)Q5;1`<57.V(KH"GZE'37(KYI9-.5O)^9$S'EMMR+RMD7!,#)W%3N,
M-)(<;(>BCW15#[:[D'=Y94=[\:!*!;\6'7G>-^_W<>*0KA$C),@KR-D[ZU91
M_=V_YZ=-,BN*^21C2.:\CA2)MBW)_P`>BOTD:$_)!5L5?D`T38,KM5Q2$$T+
MHJ:Z_I64&QL+9.9PBE!/:LHEQ61[8Q;F/(ZP]"V/DVK7_':B$XNFW0E4]554
MRCK.!T]U%OI/&YJOG6\3E.R*Z>XZ9K*:L!4XS;A*2D91P,Q+=_L7(KH?DR%1
MSN-A#NXTI^`_*9$I$%'._$<15)N6!-(IAVC%%W(G3SZ9%?,KJ1R1_@%[6S)L
MJ[A1+6J;IN0!%(9DEH9#+KRD`AHXL;:O[NS:7\LJ.PX5=S>-6CW#N0,NOGJ4
MRMY(S'<)F:T\2E_RS`5%N4.FA:KH714^F"IWPF+K?QO5L/-.,/M'*%QIYLVC
M%2E.FFHF@EU$D7)JN#YS4HS8_)8-0)7O;+\.]#=89?/N-(3*/$V8(0ZB8+JB
M=4TRIK.[;L*NPOHT2/8+Q1B_C/SV66'YBK&?KD[AMM'N)UE)FA."&NB^65'T
M[XZA+"X=!C"_-D-!W%CNV0=N3VB<(@0PT0@1!70$+U(.FN35Q\ZY'4SQY)\B
MS*2!(_(N1ZE6WF&W0=>9$E_(!&<Z"3BL]/2NNOAUQAJ->0]]5R)SCL66O%94
MFB<@Q>Q(Z3&YX',)EDQ[@BC0`KG33=KYZX1,O&YZ<HY,^[$E.<?._K'+H&V7
ME[T`:P6B(4$=SK021#N(&O1/IA6H:2^B5C?(:.'*F1*2^-WC]4:N`X]3S&PC
MOM;'-%[8NN$ZUO3TB/3IA"+Q;D$'BG+:JR9?=_QV%91*&6SW=\M+(/=(30BJ
MFI,J2,CHJ^&!46]3,?@WEDD.R*SA0>-O53B#+722V@H^3+:)IO$?2[T7SURB
MQFOPO^X#_P"6F2([<?D"2@LW&)XH4;VX-#`[K0+'[/?).I.:=.J:Y-7'T[Y*
M<=;X+<FU#D3W$CJB0XAFV\XBDB*@DWZ^B=50>JIJB8PU\@@5TN1;L5ZQ+#\;
M_E<64VC<27#B^Q?K%%Q0!578RKWW(2^/CXY4;Z6BM81\?D5,6;&LV[F]@L.N
MC)4&H';D^R;<[FHC'WJRH*73Z>>30;H;*PH$;I:Z?&M%XS/B<L9?!YHG['M`
MD=-SF@NO^X1PA<!5]*^.BIC%:KPK6VCWTB/76Z,2:OC@,E[>6R9OQYI>Z4$T
M$]P-KZNGA^G7*B39<=2-:RF@I93]-5\R@S&&4CO/B,9^$@/NLBJ$I@KZ^M1U
M1%ZY%=+\<,38_.+-$AO/PI#<EU;27%?ARV#*5N]I)4_V9/W*33H=4!-%R"]^
M18[[ESPQUEB0\D>Y0Y!,`X8@P45X")WMHJ(&XA3U85Q/Q=03:FWX7)2NG17Y
M59:,7;KS;Z)J$@#BC(5SH*Z;^VA>7AE1]MR*8#`8#`8#`8#`8#`8$2TJ*RUB
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M\9>1%>OF3\L6%BPQ+1`CM$J$Z@(G]3A"BD2_1$P+-QMMP";<%#`D5"`DU147
MQ147`Q%A@7%=%L1<44!31$0MHZJ(Z_1-5T3`C1:>HB@^$6#'8"2JK)%MH`1Q
M2\=Z"B;M=?/`Q"@HFV"CA7108(1`FA9;0%%M=0110=-!7P^F*,W*>I<D^Z<A
M1SE:"G?)H%<T!=0]2IKZ?+Z8$H@`Q42%"$DT(535%1?K@1V*VN8BE$8BLM12
MUW1P;$6UW>.H(FWK@;8\>/&9!B.T#+()H#38H(BGT04T1,#Q(<1'R?1AM'S3
M:;J"F]4^BEIJN!J"LJVV/;MPV0C[M_9%L$#?_JVHFFOZX(Y:[^-QMK:7+=M7
MA@V&SW=>3$5Y-`!&U%EYYHW6A(4ZH*_54T7`ZQF%#8;[;3(`)"@DB"GJ04VH
MA+Y]/K@9.1XSP(#K0&`JBB)"BHBIX*B+],`42*2DI,@JFJ*:J*+JJ>"KTZZ8
M&Q1$A451%%>BHOA@:TB1431&0TTVZ;4^WZ>'A@C8B"B(*)HB>")X)@8*Q'T+
M5H?6J$?I3JJ>"K^N!ZK+*H6K8KOZ'JB=4_7ZX!6F5\6Q7IM\$\/I_#!!&F?%
M`'P1/!/!.J8(BVE7%LJZ3`>WMLRFC9,V25MP4<1150,>HEUZ+BI%30\.;JY8
MS)%E-MY33:L1G9RLJK+1*BD(HRVRBJ6Q-2+5>F*1T0H*)H*(B)Y)A1$'77;H
MOUTP/-C8IT%$377HB>*X'JJGFG\L#STIT0?Y8'NT4ZHB8'J(GCI@>*@ZZZ=<
M"MY)0PN04$ZDFDXW#L&B8?)DD!Q`+QVDJ%I_TP)T=D6([;2*I(T*"A%U)=J:
M:KIYX&S4?I@.GTP'3PTP/>GC@.B8'B*GT\,#U%P*>/QN`UR:7R(''5GRXK4)
MX%/5GM,&1AM#3H6YPNNOG@6KS*.LFTJJ@F*BJBJBNA)IT5/!<"LXWQNLX[6I
M7UZ.JUN4W'I#KDAYPUZ*3CKJD9+HB)U7PP+75,!JFOA@$T\-,#W3`8&)&`]2
MZ)]5Z>.!ZBHJ:X'BF/A_X8'NY-?#Q\\#W1,#6#C1ZJ&A)JJ*J:+U3Q3I],#/
M4=?#`*0IX]$3SP.7:^.^-,V3DUL92"](*8Y`]W(6&4@RWJZL93[6[?ZO#37K
MI@=.AB7AUTP".`H;OZ=-=?+`]0A7]=>J8'@.-.:J!(6U5%514714\4Z8&2Z)
MUP,1-LM=JHNBZ+IUT7Z8'@N-DFHJA(FJ:IUZI@>J;:"IJJ(*>)*J:?\`7`R3
M1>J8#`8#`8#`8#`8#`8#`8'+?*5G957Q]?V5;(*).APW'X\@$$B$PZIT-"']
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M-W>AJH[13Q3KA-6Q?-O'_P`:$AN*\<Y7);1URN,`2>QV]X@>(T9<']P-FPEW
M:]//!5E5_*%7;6\.NK(DB3[IB-*<<56VC::F`IMN$PX0O*`[=#(17:O3$6K'
MF'+_`/'(S3WX]Z<+@O..&V;;330,!O+N.ND((1>`#XDN!SD_YGK8[#TMBGG2
MH$:N@W$F4'9$0A3]VAJ)FA*3>Q=P(FOTP(WR'SF;M;8I!E`Q6WE7"LK1@VP;
M0WWVN['(2]9CVWA0U%/%=/KC,'7\SY:'&($664%^P*7,8@-1XR@A]V26QM?6
MHIINT1>N2BA_[LQ`MHU8]62&WRD1H-BV)`ZY$E2@$Q`@;W=P0WCW#%=!URC7
M$^7JV35/68Q%2-WV8<->^T1.2GW3:1AT1U-AP-FXQ,>@KYX*TS/F(8W'RN?P
MDA&H_O/?=YUMAL%@Z;A9<<1.^3HKN:VCZD1?#"5(D_+#3-C.;2HE'65D:-,G
MV?<90`:FL$ZP@MJ6\S(Q[>U/-=?#`A<OY1R=$J"<JYM3)C\@KX_9:D-DU.8D
MB6H(XBB*BB]#$M-%3SP.OX;RA>1U;TLXA09425(@S(9F+G;?BN*V:(X'I,5T
MU14PKYY1<FN5Y.[;6[4K4^22./1P9G:Q@;(-&Q<B[4`D;V;MR:%N7^65%VOR
MS*=DL0H-`[*G2)%M$!OW+38(Y3D@N;C)/M<1=173(JMY9\EOW/Q_8N\>B2!E
M.\?6X??%]([D,'P/L[31"WN;FS71-.B>/5,"1(YVW12K*5[.;8RHM?2*XVDI
M.TZ,]TF!-IH_2!H?4U_JZ81:,_)KJH[$DU91KANY"B2*3XDSW76/=-.$^(]`
M)K_;KN].%67%>86/(H=?/8J"9A27IC$QPGVR[!1#)I"1$_N"ZX!(.WRZX$3Y
M#Y#/B3^,\>KW2C2>2V/MG90:;VHK#12)"@JZHAD(("+Y:Z^.!QMIS:QKJSG-
M]!D3>]P^[$I,22\+T=V-VVD>8:%!'8VK1[Q1=2$_/`^C<K2]L.'RBXR[LLWV
M6W8:D7;4Q4A,@0UU[9.-ZBA?TJNN#7`\2EV=K\?V+7%9,L[?1AB7364IUF1!
M--4?%N2X+IHKH=6SZCKU1<J9X,*6T>N9/%^,M2;6%'D#;O7`3)1.3@EP#;9]
MN4D=%(6W'MZ;5T)$'RPF)SG.K]?@/_*.[MNRA(TLI!3H\K_M5D(FFG_V3PTR
M>;6*ZWL[>HO9W#(MA)*ND6%$RW(<=-R0RS8]U)3:/$JN)W/:ZHNO3>NFG3&X
MFO8=K93N21N$OS)*U3=]913?%TP><BQ(3<IF.KXJCOH.1IKNW*@IJOCC,';_
M`!=<6-MPJ)(GO+)F,NRH9R2Z*[[20XP+BZ>9"VBJOURZ..J/D>SA4,&/340.
M=RML[50E6#A]O\?+5MUM73!QP]^[4%\O#HB9#'T1E\>2\6C28[S\%JXB-/`X
MT2"^V#X">@GHNTMI:;D\/+!KYB^=M51YE?7V,T^,VW(ZRIKY#\AQUX&G%1+!
M&)!JKO:,Q[8EN\=VU?#+FT;;BSM&?C_GL%F=);_QRS5BLE`\:/"PJ1Y`M$[J
MID@=X@]2Z[>BX'7?)CTMAKC#L:0\PJ\@K6G1:,@%QIUW88.(B^H53R7(KM$7
MRP/D')>62ITSY+D.J^5;PZN&)'A,/E%5QU^,LB2]W`U47-JH#9:>G37SQAK5
M"M7+F[E5\8IL"6YPZ#9P9R3G'$;+<I-:M*B`K@N)ZW/ZTZ*F5'<\$Y-+YA\:
MUEZ)I#G6D'<3HIZ6Y&BMD8HOD+@JJ9%<%\;P`*=:<9NW9U5RD6WF[`F)#Q1[
M!K5GN3([QJO[FOWZ:$&]4^BY482V+&GJ;*)52Y;?%;B_JZRL)U]UUQN.Z8MS
MR9>=(G$:=/4`7=]5'Q3`R*;,/DX<))YTJ!.3E%5.X6JQ4JOR"1%<UW[._P"6
MOAZ?#`Z+C7(;B+\8\CE(X<N5Q]ZYC5[YKO-QN`ZZ,?<J_<HB*#JOCI@<5<6]
MMQBI5NIFODMKQ1B?,DJX3A),.5'8.8BFJ[3,)1JNFB>E/I@3[YZ53W5EPZN?
M?:HI,_CS)(CID3+5@;H2FQ<55,>\D<=>O]2_7`[?XTD/A+Y52H9.5]+;%'K=
MRJ7;9<CM/]E"+5=&S=)$^B=,:8H&N86-9938]34Q`DV/*W*B2;CSVTR.&CPR
M2Z%H6@(A"/3Z8'8<&Y'8<AX\4J>TW%L&9,N#)2.JDUW8CQLJ;>_KM+9N1"R>
M"N)FTSO&KNZN.+.S#;J:2:Y==Y]V0$JQ44=B]'2(>ZV@F1J")HA(/Z94;>"H
M==RN@KXTAV3%O.,)8VQ&X1[Y8.-:2E557:;ON#153QT3Z9-,2^`U<"W^*HL>
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ML=W:'Y+JF:UE:4_#+Q[A%[5T+XP*^TGD]20K%9#@-5V@"32['`?:"00&0Z%J
M(E_+(JII&X<^1POBTFL2NJTE735O4B\Z_'<G5X[41'7"5QQM2,G0W+Y?[<"R
MKN27[/\`]#Y8VS;KCEE!AV#,25JI.$W&>=89>W>*DC0(N[]-<#G>4.N<?6RI
M:-YQJHGU5$[-4#+1HI5@,1YY"UU$GXZKO+7KX^.!*LU6+RJ3P^,JAQ=SDU4T
M[&%5[0MR8#DEV(FB]&S>9`E#P]6GG@=W\62)"P+V`2DL.IO)\&M4E5=L9LT(
M&T5?$6U-03]$T\L#FJ[F'(8LN-54\&LAOVO);BMDN*#RM[H[9O)(VH:*3AJW
MZTU37RTP.UX/>S>4<*BV$\1C3)(OQY7M5(11QETV")I2U(=5#<.OA@?.>04@
M<6@\UN^&-N5U?%HG8IJ)N*,BP$E(Y((:EJ<=O5"<3[B7_;@7_%Z^%!YE<\=@
M(OX*1Q^!+>C"1*`R#)YE31==4)YH$4E1?5IKXX&7`J:-=?"G'69D$+8FH`FS
M`DN$#3SHH0@CI>K5/_,B_7`O/B.0V?`*IH0?9<B]Z(\Q)-'7&W8[QMN-HXG0
MP`A40+_2B9!V.%,!@,!@,!@,!@,!@,"EYEQX^1\7M*(9'M?R4<XRR-B.;$<3
M12V*HZ]/UPFXYBT^*GK&392CMSCRIK-8D1]AD4.-*J2(VGTW$2&A$:[@5/#I
MA(RG?'/)I2UUE_E3@\G@J\!V10V#CN1Y&S>Q[1?2(BK0D*[M=W5===,$8V7Q
M9*G-7K9W1JMVU6M&ZXP!F"UA(6]="!"5U4Z]$1/+!&NV^(&;JVL9]G8(ASF)
M$;NPXX1I"@\8.,]]T247O:DVBLJ0:_77"YCJ.)T5U517!N+D[J8XHZR"9:C"
M(@FB(+32;=5\2+S7Z)A7/67Q6L][D3QV[K#UU-B64)]AH!<A28("#)`I*8NI
MHVFY"'KUP/9GQQ?R$K;`.526>3P.\!6XQHY-.,2=G<86(J=L03M"0^:%UU7`
MW3/C9R;=U5E+M"?&G=8?B$;#7O!-D%$T]X.T^V^J[G0VZ>2:)@B;S#@Y\BFU
MDH;)V`5=[@5`&VW@<&4WVR78ZA"+@:>@]%TZ_7`Y]OX8;2CL*EZ[D/!84T6B
M-Y661(&8:FH."B=-RHXJ+K@2+;XD6=+F$S>2HE?8S8MI,KVVV3`IL0FR[HF8
MJ0"YV!WBGGA,=+ROBZ<AC062E'$]C/C6(&V(DI'%<[@@N_7TJOC@U6G\?N!R
MF5=0+N=`AV+C<BTIV>TK#[[0(V+F\@5UO<("AH!)NTPJI>^'(DGW<B7<2BMY
M(QNW;1P8C/@]"=)UB22-AL=>13VJ1CU'IA(D67Q4=DVPLWD5B],")-@RII)'
M4WFYZ(CBH"M]ME1VH@JV*=.GG@C='^*ZQ(5Q"G3I,Z-=P(M;*`^VV0A";5IM
MULFQ%1/U;OXX5ZW\:N%%@-V/(+&TD0)\6P"5*5E2)86O:9V@V`(/JU(D3<2^
M*X%YQ?C#''VK!MF0Y(2QGR+%Q7=NHN2BWF([$'THOAKUP*)SXOC%"EL!;2VW
MW[G\^Q,$6.XQ+UU5`%6U`@5.FTQ7`QJOBBOK9T28W:37W(;UE(!9"LFI.6VG
M?4U1L==JIJ.!"+X5JDJVJZ-;V$1O\5^#G.-$QNE0Q4E;1U";(1-ON%H8(BZ+
MI@3Y_P`65LU9/=L)@K*C5T1U15K795/=Y@DU;^XC^_Z^6F$BHYKP6P:23*J0
MGSORUJW9V@PW(8OLDQ&[#78;ECV3#T#N$UU\TRB^X90\A8@0'+2;*:]DX^L>
M":1&U*.Z""VW+&(`LJ39:D/;TT\]<BMG.^*3;=RDMJW;^8X[/&?$;<7:#P$!
M,OL*7]/<:-=%\B1,"CY!\4C+K+^LKGG4;YI/:E<@=D."J,-#M[HL`(IZC!M&
MTU7IXZX'<65,S-K/QXO/1`!6U9>BGVW6U9)"#:6BI_3U14T5,#G:OXW"O@N-
MLW<\+20XPY*MVR9!YP8VY&F=G;)I&D$U11V=<"7*^/Z=YB&++LB'+@./NL6+
M#B>YWRT5)*D9B:%W=?5J/CHJ::)@B.?QY`)&ZQ''!XJ%452Y2=Q59-%)%%S3
M3<C@BB^O=JNOZ94;`^-Z)84QB2Y(E2YKL>0[9O.(LI'82(D4P(1$1[.WT^GZ
MZZZKBF8]_P"W5*,)EIIV0U-8F.V+=J+B>Z]V^BB\ZI**@N\"45';MTTT3HF1
M5W1TL"DJH]77-]F'%#8T"JI%U55(B)>I$1*I*J^*X'-0OBGC\-EIIJ3-(&84
MZM#>\*KV+%WO/Z^A-2W_`&KY8%RG%8@\4;XRS)E1X3408+<AEW9*%H!0$VNH
MG0MJ::HF!51?C*G9K9$!Z=8SV7NPK)3)9NE'**?<9.-T06R`T0M=/X],81)>
M^/:-_C$_CKA/^TM'#?L9".?\AYYPT,W#<T\2443HG1$T31,"PO.,P;N-!8FF
M]MKY3$Y@FSV%WXR[FR)=.J:^*8")22F>33K@ICQ1Y<=E@8!.$3(FTI*KHMKZ
M0)4+1=OCYX'/3_CAF5R#D3AJA4/,(;<>\C`:M/"\P"M"XV0IX.,KL-.BIHB_
M7`2?C6'`;?F\=4FKTJAN@BORGC-EN(WT!2!-=Q-_=]57SP1>T'$JNEXA$XM'
M%2KHD1(755$C#;M,E4?`CU55T\\"GC?%E$T$U'9=A(=F-.1@DN2G$?8CN]ON
M-,.#M(=_9'<7W+]<$2(OQIQMBOEP'"F38\L6@+WLQ^03:1RWM*RKA+VE`O4B
MCIUP-_\`@''OQGL>VZA^[_)>^[I^Z]ZO3W'>^[?M]/TV^G33`P:X+7Q9-,D`
MG(U?4C)$HB.N$$CW2+W$?`E47=Q*IJ1ZKK_%<#VN^.N*08TN,,0GX\R,D`VI
M+IO($(=VR,WO5=C0[UT%/_I)@&/CWC;=9,KW&G9`SS:<E2GWC<DDY'048-'E
M7>*LH`[-/#3^.!:T5#74D,HD$207'#??==,G'77G5U<=<,M5(B7SP*M/CWC?
MO5FJT\K_`.32[15?<V^]1KL[]NNFG;Z;?M_3`GT7&JRDA/PJ\7`8DOORG=[I
MN%WI)J;I(1*JIJ2JO3PP*BD^,.+TTUN7%]\\XTCJ-MRY\N4RBOHJ.%VGG#;U
M)%7KI@6%!PJ@H7'':U@P<-D(H&XX;JM1FE56V&E-2V-@I*J"F!#7XVXNO&AX
MWVY(U(/E*1H)<@#[A.*ZO[H&+FF\E+;NTUP-3/QO3PR@>P>EL^SGI8N.NS)3
M[KKB-]O89NN'N!1Z;2U3Z)K@BUO^)4U\<%RR:,GJUU7X;K+KC!B1@K9IN:(%
M43`E$A\%3`J(7Q1PF%#<AQH3H1G:]RH-M9,@O^$\X3ALHI&JHFXUT5.J8(]L
M?BCA%BZKDJ"XN]F/'?;"3(;!X(BBL?O"#@BX36U-I%JN!8\RXG$Y1QR5323)
MGN]MR-)#J;+[!HZRZFOBH.`B_K@5DSXRXW=I+E\C@A)M;:$U`N767I#;3S+)
M(:`(H8[1WCNZ=?UP-=O\:URQ[@J)$K[6_C-5UE9.&Z\7M&P[7H`B4>X#7I!?
MYK@7['%Z5KC3?&DC(5.U%&",955-6`!`05451?!/%,"D#XHX=[&9#?9DR@G*
MGN'GYDHWU;%SNBTCW<[@MH?7:A:*OCKBI&YKXQXDU"<AM-2FP>?;E./#/FI(
M5UH5$%[_`'NZ@H*JFW=M_3!$^9PKCDNMBUSD39&A.*]$)EQQEYIPD)",'FR%
MU"-#+<N[U:KKA49.!TK=I72F&48B5L!VM:@`IHR;#VFH.-[NV0HB>8ZZ^>!L
MA<!XI#KYM>U7B<2Q;%F8#QN/*;38[6VMSA&2`VG0!%=!\L#(."\8&I=J_9;H
MS[R2GC-UTWBD"J*+ROD2O=P=J;2W:IITP+*HIJZH@!!KF$8C`I$@(JDJFX2F
M9D1*I$1$JJJJNJK@54?@/%8\IF4U!VR(\U^S9<[KJJ,N4*@\[U/Q,5T5/#],
M"=5\9IJJG*FKX_MZTNZJL";BK^^2DYH:DIIN(U7QP*NE^,^$TKRO5U8C9JR<
M;1QU]\49<^\$!XW!1"\^F!/IN(T%-'D,5L3L!+$0D%W'#,@`=@!W#(C00'H*
M(N@^6!H3@?&`J(%.Q%./75A;X#+$B0RK2]?`VW!-4]2]%73`]<X94_DZ2;';
M2*-$CR0VF5($T?':0EH6U17Q75%55ZZX%_@,!@,!@,!@,!@,!@,#5(DQXX[W
MW0:#5$WF2"FJ]$35<)K65A"1'$1]I3:)`,=XIH9?:!=>BEY(N%Q2<0YG&Y)Q
MYBT!L8TMYMQTJTW@)UM&W3:3<J:>DB;^[33`G5E\T[60)-HK%;+GB*C$*2T[
M^X7_`+MMP507?XC@0N-\TAV\ZU@O`,*76V#U<VP;H$;_`&``U=;%-%T47$Z>
M6!>39T*"PLB;(;BL(J(KSQBV"*OAJ1*B836ERYJ6SC@Y.8`Y>GM!)T!5U%\.
MVBKZ]?TP8J.)<TBWH/@\+<*>S,F1!@*\#CIC">5DG11-I**[=?#IA5PS<U#Y
M2`9G1W3A_P#JQ!T"5KQ_N(B^CP7QP*&@Y_66UY=5XFP$:K>BL1IPR&W&Y1RV
ME=$0TT1"333;JJX&SD',VJV92L1`;G-VEHE2^ZVZ/_'<5LW%541"U).WHH],
M)GBNHMQ52I3T.-,9?EQ__41VW!-QO5=/6*+J/\\&/)MW307PCS9\>-(=V]IE
MUT`,MQ;!VB2HJZDNB?KA6E>3\<0I(K:14*&J)+17FT[2D6P>YJOIU+IU\\%4
MW).?0(%`5Q3.1K=MJ=%@OHR^*B!2)`,%J0;_`%!W-=N,2KMGD5"[9N53=C'.
MR:W=R&+H*ZFU$4M01=>B*BK],*UL<KXR^U*=8M8CK<'19A@\!(TA>"FJ+Z=?
M+7`P=YEQ-J%'G.7$,(<HB&-()X$`R!=I():Z>E>B_3`SY-R:FXW3/W-Q(2-7
MQD'N.JBKU,D$11$\5(E1,"DJ?D:JD<CLZ>=)AQ$9>BM5#BR!WS$EQT?':!;?
M5UTT'7`OV^0T9VQ5`SV"M!126$ACW41$U7TZZ]$75<#VUY!1U"-+:3F(2/+H
MTKYB&Y4TUTU_BF!&L.5T<:4Y6A/C+<(V9,P#<1#(@;5S;IU7[>NFFNG7`K>#
M\_I^2T$*:Y*BLV3D!FPL(#;PFL<'1UU+71=J+KU7`LF^8\6=@/3VK2.42.XC
M+SJ&GH<+3:"IX[BU31-.OE@5'"OD*#?5R/S'HT:2[*L6HK+3BDCS%<^3)/!N
M1%)-J(1?37`W,<V9D<KB0(QQWJ*73NV[5F#BKJC3S;?_`)-BB[NW:X%U4<@I
MKAMXZR6$I&#[;Z!KN`]$)$(51%35%U35.J8'*7WRE61O=A5FV\]56T*JN/<H
M;0-)+<`#("5$U4$<3],"Z+Y`X:-:U9?EF2AO.N,-.#N-2=915=!`%%/4$%5+
MIT3`]@<YXY8\@.B@RO<36XC,_<`DK1,2-5;(7--I:B.O1<"38<MXY72I46;/
M;8D0HBV$IHMVX(@EM5Y=$^Q%Z*J8&#_,^+L-&Z[8-B`-1WU5$(E5N7K[=11$
M525S8NT1U7`QB\XXG+&*4:R:=2:R_(BH.Y5-N(J(^J)IKJTJ^H5ZI],"K;YY
M'?Y-#CQY$8^.2Z5VY&QU)%VM/`.[<N@]O8YKX:X#A_/&^2<HOJZ(3;M96,P7
M8D@0=;<)98.$:."Z@^';11T3P7`TC\D5\'F5Q17DF/#9C.0&JLT1S<X4X"5!
M=7U"/K':*]$\O'`MUY[Q%+"17?D0]W%[_>!`<4=8@H<@1-!V&;0KJ0BJDGTP
M-K7,^,.PXLUNP;*+-C%.BO(A;3CAM17$73PU,41%ZJJ],"32\@I[IAUZMD=\
M&'28?%1-LVW0T4@<;<03`M%1>J>'7!4)[G/%FK;\04\4G]PF4;0'%%7FP[A,
MHX@]M74#KVT+=^F!R;7S)5/3*.P`^QQFTAV#[IOQW_=(Y!,$10`455%1(B70
M5P.KF<\XE$:BOOV`)'F-LO,OB)FVC4@D%EPS$5%L3(D05-43`A.?*W`&Y;L0
M[5$?8D>T?1&9"BV_WD8[9FC>P2[I(/5?/Z8%BWS/C;C[\=N7N?C3AJWVT;=W
M#,,.X+6FWS!=V[[=//`J:;Y"I1I($FRM&IKTU'7`D08TE&U:;D*QO5O:X;8B
M:B!$?3=@6P<SXV=X%(DO2P=-UID2;<1MQUA-SK;;JCVR,$ZD*%JG\EP*CFO-
MG.-<CX\S(<$*>Q&;[W1EUY_?'91QI&A:W$NO75$!<"5)^3.%1ZV)9E8HY7S6
M?=-266G70&/NV*\ZH`7:!"7:I'IHO\%PB0_SWBK%J-6[,5))D30$C3I,DZ+?
M>5D7D%6U<[?JV(6[],%:^-_(O$.22PBT\TI#KL5)S&YE]H78ZD@*;9N@`GM)
M40MJ]//"M_*>5UM'&VO/$,Y]IXX;+;+L@U[(;B<)MD2+MAJFXNB?KUP*#BOR
MA4/\.BVM[+%F>S3Q;FW%MEW8VS)1='!04/4=P%T155-.N!=R^>\6B6;%<_,V
M/R'FHP.=MQ64?D#O99-U!V";@]1%5P+&TOJNK=@-3G59.SDC#A^@B0WS$B$%
M445!U0%ZETP*-[Y1X:T+2^[=,Y#\N*PRU&D..F_7_P#J&A`&U7</_CY81'O/
MDJB#BJVE3+5]^972+"M5N.Z^J-L@J]YUH4W"`GH);M.O3"O:WY*HVJ>F<N9:
M-SIL:`4QP&R5AI^>`]H7#1%%ONFN@[EP+/CW.N.\AFRX=2\Z^[!)P))%'>:;
M$VG%:<!''`$"(3'JB+@<OS?Y0?@P>5,5+3D:QXPL$GY<E@CCF,IP-R#IIK^V
M73_P3`Z%GY%XP\Q*,'GD=B2QKW(AQW6Y!2##NM@#1B)%O;7>*^&G7"+7C_(*
MKD%2U:54A'X;ZF(GHHD)MDH&!B2(HD!BJ*BX51_&O([J_IY\RV)DGH]G.@M(
MPVK8]N&^3(JJ$1ZD6S5<#"#SB$P=I[N<Y8.C:NU\*#'ANC(`VF1=*.(=5>4!
MU-7>@Z+@92?E7AD>OCV!RW/9OL!*<>[+B=AAQQ61<D"0H38]Q%'JFO1?)-<)
MK)GY/XD[<C4`^^LI9Q5:NK&?&.DP0WHRKZAV]QCU'KUP-C'R/QEZ*_+%U](C
M2`K4DF'!;D=QU6`2.2IHX1.CMT3K_+KE%EQGE%1R.$[+K'2,8[SD64TX*@ZR
M^TNCC3@+X$G_`.[(8YSF_P`@3./\@IHK+`NU92&@Y'++_P#I69I$Q$).O];Z
M>KZ"GZX5<\BYSQ_CSKC5BZXAL12L)0LM&\K,0"0"?<0$54!"7RZ^/3IA$%?E
M+B*6;E>K\A'66`E2'2BOHRTPZR3X.NNJ"``D`+IJOCT\<%>L?*'%7O<-B\ZD
MQAQAKV!-[7S*4!.,;!5=JH8`2Z[NFBZZ8*B'\Q\)]M'?8=E2TDQ)$]L(T5YT
MNS$<[4G<@CZ2:/H2+@J3%^5.(2`EN)(>::BQ69XNO1W6A?C2#[;3K"F*=Q"<
M]'\<%:A^6^)$K;0K+<G.2WJ](#<<W7QEL,]\F2%O>.I->H5W:+]<%9U/R95V
M]Y35U;$E2(US`>L&I_;V-MBRZ+)-N"2H0D)JJ%JG3`[+"F`P&`P&`P&`P&`P
M&!0\ZXPQR?BEG2/(FLM@DCFJ)^V^/K9<37S!P17":X'C7#N8ERJ/;7D-IJ+=
MQH]ER.*"@8M6E:B-QFVU3[NX)(9+_J#**SAO"KFN>XE(<H78[H0+UF]<V-(:
ME*=[D=MY4+U[]/2G5$_3`T4'%>10:ZG@W'#'+N#*HX-<$<W&`6OE1'3)P7MS
MB;&S4A/N-:KZ=/I@Q._PZY&]?LAHG5F+S9NP"8(L]S\<D=&S=0U)"1K5%3;X
MK],:KL_E2HE6=3`"(Q,.5'E]^/*@@Q(5@T9<%#=C251M]HMZ@0^/JU3PPFN1
MA<>Y0W8MMWG#6+9NUA52`3#C`1:V1!']QHD,MX-@?[H=K=UZ8,:H7"^0!95<
MQJF<BS4Y1<2Y$]$91T(4QJ0#3Q$A[E`B=!=OCTZIB"K@_'G+7>+28KG'GV.0
MU\!F`[*D3VSCV+3$IM]QE@0+[)`MDJDZB**EM\UQ%3I?%>5S9E_=Q^+NPFW;
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MSC,.MN:?\:*"U,`3L@KG-ZLB^R*$RTJ>IO>NJ%XHB91KL."\E_&QY%)0.4ET
M93)`*W.:F-B[))O>S8A)4@?:D=O<XK>JCHFWKB([GY'H;B\X!:54!MMRT?9;
M5II21L#<;<!Q00BZ#NV*B*N17'7W#N76A<GF!3`U*M)=#)A@LAA2VUYM'(%3
M14TV=M43Z^643..<'OH7+R.RJ&I4:+93;*OY$<]XU1N:IEVQ@Z[1>1'.VI?;
MM_7`LODKCG(K27`E4$=T;**R\,>Q:D-`V).$"K'F1GT4'XSJ#Z]$4DTZ9!$K
M..\RA6]G`?IH$ZKD3Y-M$NS>3O-G*:5"9!D@4A=$E5L7-R)L_P"F4<ZU\5\N
M=X]45*QV(3K/%9%/+?1T5$9A/LNM@7;T(FS[);B'PW819-\0Y>AP>1,<<APK
MB'9,RIU5[\Y"S0;BN1>XLEU-HDTCVYD53P3KUPK73\(YS6NU%@E;&<DQ;*]=
M>A)*1!"/;N=QH^XH:+L5$0A1-?I@1H_Q?S%ZAKJE\&(CC?%9-+(D`\I@$LY#
M3K:(B()$V0L^I4^N!VWQ_1VL-)T^VI8=-93E9&0,22[,-[L`HH9NN(.@]=`%
M/!/'(.=N."\L>G7[;$6,_"L;ZKN8SIO[55J-V$?;-M0711]OZ>O77*C4]P;F
MP3YY1HT8X4Z\GSG0]QV72BRH@,M*CP@1M_N`JN`&BDFG7!U3OCCAO+>/V-:=
MA'C)'&@A54PVI!&K;\!QU4V"H)O%P74775-,ABYYMPB1>W-/81'09%A)$&Y$
MM=9%7,#]Y@53^K>V"BOEURX:Y^'\<\IK**E5N0S86]#:)*;;<-6PD0&&W(L=
M@G%$M'&XSB*)*GW_`,=<=#JUIP#EL.XB7L%B(Y*>F6TF77NR";:8&U:9`-C@
MMEOV+'0C1!3<I+I@5Y?%'+Y%!6U+AQ8SD?C#M,_(!TS%)??:=;3;L%29)&-#
M7QZ^"X'7\-I>5M<LN^07L2)"2UB0&`CQ9!R%%R(CJ'JI-M)M7N],:*KE/!.3
M64OE[D1N+MN_P_L"<=(5_P#E[J&]W-`+;T^W37^60UKC<*YPO.H-W,"$Y$@V
MD]\7$D.H2P9K"MMBW'%M&@,-?7UU->JKE,:?^T5J'&+ZG:FM$I2A/C`NH2ML
M1&9(SFXK^FA*!/[A+3^C;],+'7\'H["MAR7K&O@5T^<]WI#%:IN`JH"!O<><
M$"<-=OCMZ)HF1(YYCX^OA?6J=)@Z5J__`,AC6&\O=(BO+)6.K>W3<CJJ/<W_
M`&>6%0^/_'?+H'X()?LC"EAV\+>#KBDXDXQ)@]";Z?;ZTUZ>6N7HF5`K?B?E
M,`*IHX]/9L%5P:RV9GHZX+)P%)!>C(@Z."0E]A[?4B+KA731_C^9)XQRVCM"
M:$;Z?-F0W62(E;%]1-@SU$=#;,$+I],@QXU\=6-5R<+V7.&4;\)HK5I!VB_<
M`*M%-1--!1625M$^FGTR]$ZJ`/B_ES=)31&5AL7%9[HH]Y'DR&7HYR)A2$':
M(;9#!-EM-HTT4DPJWXS\>751R=UUYBHD4X395A"L%9(K0%EF3A,J1)VQT)PD
M[B+JH]-,@O>64%W+O^/WE1[=UZE.5W8LDS:%P);/:U%P!<T4%3711ZX'$E\.
M7<)Z"[!2GM$<B.1+=BWCF;(F[*<E]Z*([N@G((>V70DTZX(LZ[XVNZ[E$N4V
MU3RZI^6Y91Y<B.2V3+SH:$R!(G;0-_VFG41Z(F5.UOX;\?\`(:67Q1R6]%-N
MBII%7,[1.*1NO.-&!-(0IZ41GKKUZY%6?*>+<CD<EA7]$_%[H09-7-C3NX@*
MS(('$=;)M"5#`VTU14T)/-,#BO\`L_S5BA_%Q)E<IR^,L\=G/.H_M`XQ.*#K
M0BGJ$Q>5%W::>/7+T3JO(GQM?Q>5OS12HD5-A(CSY9R8Q.S8TEEIMLTBF2*"
MB?:114^H==,BNEYWQRUNHE6Y4N,-V%391[)D96]&7.RA"39*VA$FHN+HNGC@
M<U0?'')ZZYJK"5+AO>RM+>RD(TCH;@M`T``1=W4"7U:^7AEZ"NK?BOF=56Q6
MX,ZO.6Y42:2S%Y'E91MU]Z0R^PHINW"KZB8ET+Z],@D57Q9R.LL(CC;U1+B/
M1:YFV]Y$)YYMZN9%CNPB+IHX#:='/M+U)E'7\$XU8<?JYD2:ZT\<FRFSFR9W
M;4"6^3PB6_KN'?HN0<URSXVY%;2^6^QF1&H?)FJ]11\75=:>@D*+KM]*@0!T
M\]<HU\B^,.0V-S:7,27`"8[8P[*L9E,F_'7V\)8;K,H%TU%P251(.HY!W'&*
MJ75TK464D5)6IN.A!92/&$C)2VM-IUVIKIJO5?%<#CN/<1^2*.MF5D.95-MS
MK&5..:B2">:"9(5XQ!LDV$0H2B*JNF!IE_''+FK27>5%A"9MPNI%I6A(!TXY
M1Y<5N*ZQ($5$MVUI"0@\%P/;+XXY:_>LW03JF7+F0VH=W[^!W0%67#,'H0;O
M0HHZH[35471%7K@;#^..0$ZX23(NU>4M<B;14<U1AL$#LKY=Q=OBG3`JR^'+
MUQNR,)D&ND2'&)D>+&;==KSGQI"O)*=B/+L;[@^AP&NBZ[O'3!'T#B-/95=:
M3=C[))CSA.O!6L>VC`JHB(("NIET3J1+JN!RUG\4LWE9R;\\$:3<W9NI%F`K
MR`RT@($0535.K&F[I_5JN!R/-(ENS85D"[D13L!I4KK"6Y%LO;V(N.^ML7(>
MY5U[:*;9>9>GHJY<3<=7$X#97<3D+UQVZYCE=3#A.08Z$KD1R.TX"JBEZ53]
MW5!T\M%P1&=^,.6RJJ,4JQJ0O:V2U(@.L5R!$=1MHV326TI[C5T'5UVJFS^G
M(1/_`.W5X<V-,<G0A<;IK"K>;CQE8:[L]P7$-ML"]+;:MHFB^I?%5UP17S?A
M^TG08L1^T8;6-0Q*@'@94U25!D!):D;#)1(-[2;FU\4\\$64+@7)EF\?L+";
M7>[J9STR4U!B+&9<%V*49!!-Y%N]:D1&J_1.F",.+_&]Y13:"4-C&<6K:L(L
MT.R:(ZQ.E)*'M>OT&!"@KNU1<*^AX#`8#`8#`8#`8#`8#`*J>>!YZ5P*Y_D?
M'XULQ4/V##5I)_\`3PS<%'3712T$5777:BKI],"Q].`]/UP-,R9#AQ'IDMX&
M(L<"<?><5!``%-2(E7P1$P/8LJ++BLRXS@O1I`"ZP\"ZB8&FX2%?-%1=<#;Z
M<$1[*R@5E?(L9[XQH44"=D2'%T``%-2(E^B8&YMYIUH'6R0FW!0@)/!1)-45
M,#/IXX&B+809:.K%?!]&'38>5LD+8ZVNA@6G@0^:8&[5%\\"J$^-\GKI#)"S
M:5XO''DM.!O;[T<]"$A--%4#'!N)#=S4K;G2!(#\DRP,HXB:[Q8,E;$_#312
M%4P)V!"9NJEZU?J6I;1V<5L'I$0217&VW%5`(A\D)173`F+HF"(#%[5/W$JG
M:D"=E"::?E1D1=P-OZHV2JJ::%L7P7`GZC]<!J/UP/=4P(%U>5=+$"79/I&C
MN/-1Q<42).Z^:-MCZ47[C)$P)VJ>>"/-X(J#N35?!/KIXZ8&+[S;++CQKH#8
MJ9KHJZ(*:KT3K@1J:XK[FJB6M>[WH,UH7XSNBCN;--170D14_G@3-P_7`:C]
M?'`:I@>ZI@8@XV8[P)"%?`D75/\`JF!`O[ZNH:F1;6)DW!BBAON`!.*(J2#K
MM!%+Q7`F@^T:J@FBD.FX47JFJ:IJGETP,]1P1@X\TV@[B0=Z[015ZD6FNB?5
M>GA@0>/W];?5+-K7&1PGU,6R,";+5HR;-%`D0DT(%3K@62:8'BJFG3`YNK^0
M>.V;E2W$<>);LI80%)DQ12@$HOB>J>A445TU\<#I$7IUP/=<"-*GQXX.JJJX
MZTT3_MVTWND`>.P$ZEUZ)^N![7S1FP8\P6W&AD-BZ+3P*VZ*&B$@F"]1)->J
M+@2-4P/-PZZ>>!67W(85,PPX^+KSLIY(T2*P*&Z\\H$YL`544UV-D75431,#
M;77,696Q)Y(Y$;F(':9E@K#R$?1&S;/JAZ^6!IX[R2OOH;\N&+H-QI4B$Z+P
M=LD>BN*TYTU7IN%=%P+35,#W7`:I@-4P&N`U3QP/"<`!4B)!$452)>B(B=55
M<#"-)CR8[<F.X+K#PH;3H+J)"2:H2*GBBI@9KX:X%`',8SO(#J(L*7*%A[VL
MRP9`2C,/]E'^VZ6Y#3T$GJ0=-5TUP+]%1<#5+FQ(C/>DO`PUN$-[BH*;G"0`
M'5?,B5$3`K*/D\.XF6\5AMUMVEF+`E=T4%"<1H'MP:*6H[74ZX1<(0KY_KA<
M>[DTUUZ?7`\WCTZ^/A@0KFR=KZ]R6S$?L#;442)%05>/<2#J*&0)Z==R]?#"
M5-WCKHJ]=-=//!BGM.31JZ\IZAUETW;HWFH[P(/;`F&E>)'%54)-P"NW1%PK
MWD?)(](Q$W,N2I<]](D&&SL0W7B`G-J$XH`*;6R55)=,)NI=38E/KH\QR,]!
M-]M#.)*1`>:7S%Q!4DU3]%P9J9N'1%14T7JB_IA3<BKIK^O\L(YKEO.H7&>K
M]=86`-M%)EG7Q^^D=@5T5UW4AZ=%Z#J71>F%1[7Y.XY7JT>KLF,4-JSDRXX(
M3<:"^6UJ0]JHEM-=>@HJZ(JZ:)@6I\H@-\GB\<('??3(CLYAU`U8)IDP`T[F
MOW:N#TTP/8G)X,KD\_C@-O!.KH[$IXS#:T34DC$%;+7U=6B1>F!<8#`8#`8#
M`8#`8#`8#`Y+Y4N[:CX-9VM3("+/BHR33S@"X";GP`D(2Z=1)<N)KBKOE7.(
M-])X^SR&"W.J8\:8DFQ5F($T9+YJYN91ITB!ML4:3M$);NJXBJNQN)U';<UL
M`G"X9\CK8BR)2,"U"23$83W'<5H^V38DK8D2:)KU3QQ$U;0[SGLNYX_0_P"4
M11*<5HCTR$#$PB:B=EQE",FVFU=$7%!Q0';^FN#$`.:\RC<>8M9O(6W&+2]?
MI>\X$>(S";CR9`"XKZ-/(ANHR#>IBHIK]>N(:QL>6WTRK?H+?DL-DAHK*:MI
M![)MSC;=)D64<>;1LNRWIW>V*:DO31,0QU)O/%_]#ZV_!E.17@XPVZS)C$B&
M)-PD+TEUT^W3$77-_P"77?XJP9A\C6(7'^/P[.K=<2.Z,]TVS)WNEL_<`3;%
MG:WHJ*O5==,([OF]W:,?%%K>-+^-M&ZDIB(0@?9>1GN*"BXA"NA>GJF0UP-U
MS/E3$J_GLWY-1:23QY6(*-Q^T3=D+0R&W24=RB7<(AT5-,H^J<PY`E#QV7/#
M:4M$1F`R9(*.RWB[<=O5?]3A)_+"Z^;\("7POF,_B]@7LV^30EMJ]PWA>(K.
M."-V)BJ]$5S<#J)I]<1*J:2QNI<'XRO[OE4MY+J6I2=38CQA-(;^T$V`&Y3,
M430E7KX8A4UCGLK_`(T*[Y"5952K:^AN7B$RTK;D)Y!AQU=4>V'H(BZIZMNF
M(5HY%R:?4W,JW@V"6$YGB$,RLR:V*;2V:@[+5D471$;(G.B?RQ"N]^,K&3-B
M6AK?L<AKTDHL"1'(GNRV;8J3)R%04=5"]71-1UT7(K5#>8_[V632&/<7CL-2
M!%3=TF/^*>/@J8&GY9ORKEJ(@6KM8Y.]XK9"Z,5HR8CJ8J[(43--B]1;`55Q
M>G@BX'S5KD5A9-OWK?)'(%X[Q"KF17HW:UF3VG9"*VK9`7=0G?038?ZLL2ND
ML.5\F-^U?*Q>A<LK+&N8KN,[A1F3&?"/O3L::N(ZKKVKB+Z%'Q3;D5:,3^71
MN5W/%?<RY;D1];^OEDJ?N5YLJC<)3VZ+I,'9M\=GGE17?&W/62!R[N.7,/0?
M8M+<07N[_P`.<;J`JN&Z@I'U(^WVM-%TU3ZXA75?-!)_V_>=1U6@";6N%(!$
M7M@,]@B<ZHJ:"GJU7ID5QR\BNJ>U:-;^3,XK'Y-&BMV\HQ(#C2(+A2&''D%!
M<:;D[!$_(O3KTRQ*C\8N4L>4</L;&VE.@LWD<*.ZX\X`.*W*%(K9#H*$7:Z#
MJFJBF(KLOD*\2)R6FK;*>]4T$V--,YK+A,H<UM`[#!.CU'T$X8C_`%*GGIIA
M'S_CEW+_`,/K8#]K+JF6.*,2N/.L&32R)[9.H]JB)^ZX*BTG:775"7IB%7-=
MR2_F<S8AW%R[37T:1"<"F%E\PE0SB-D^(@A(PHDZ3F]S34%'$*O/B>YG2K&S
MAS9AVC@L,2&[1J2X_#?;<<=02[3J"461TT<:\-$14QN0JCN[>X9Y-=2PN)P!
M6\GIXD:*CI^W]O+;8&2TK:)M("WFO7[5ZIIB%;*^SN9]A`3W\Q.1NV\^#R*G
M5UU&@K]'MIBTB[6A;;%HFG0T4E7Q77$*Z'X<?8;^(*HFG)#CL:&0RD57''AD
M-BO<`4>U7<))T'PUQ%?+UY*],XKRJ/\`D)4J'+XS&F,L27),AQ)/>-MY3<=%
M![Z^A'0:1!0NB)TQ$7EK8N4]AS1V&_+9[ES7/VK@^[?5NJ>BL]Q]L&R%=G<1
M156E0D'73PQVE3*9N18\BXO6+R:TFU4QBTD!(9.3"1P67V#C!J9$Z8!^X(D9
M:F.J=4QN&.I^3V8H<CX+.EJ\$6/;F+KC1/((J[%=1O>C2^;FU.O\//&8.$X[
M(O*Z!2O4<B6=G81^3-C",W2CDZPZZ]#_`&"_;!>YIM+1%+7Q7$*[/XAFI8.3
M)T>WG3H[L>,,J#+CR61C3!1>[ZI9N'W2_P#>"'H31/KC<,45CR&6'R='&,_/
M95KD+<*:T[[EP2BNP5TT`$2,W%5W;L5=Q*6JZIDS%5=,MNU7\1_&,N+:-/<K
M6()-FB(^7N"8WZIH*&2CIKXY8E;UL+\:@I_%G;.2AT*.<ACF3YOA-"0RCBM"
M\J[)2LK(11#3P'],0J;8V5`]!A_AG+ERGM+![8Y)]\D9IU(2^GMZ)*,=Z>@-
MR#W=>O3':55<8.1(<A6EC[Y;:9P@V/>&,H'2EQG'!<1?]+B(B+UZJO5-5Q"M
MBR;J31F%@[9-W"\>JWN(.M+(0BG"QH^B[=$)_P!SM1P7?$/TUQ"MLX+EJYL[
M,W[#\A"Y34ML(V<HF!8?8CC-%MI/VR9)5<W=-J:>6(5WOR4Y):2B)T7BXXM@
M@\A]OW%)(Y,N(TI]KU]I)&S?I_/ID5PAU3A.\0:GMRI->SRF9^&<>]P;@52Q
MWD95TON0.XJ"!.==NW+$KKOF*MBR(O%Y<F*[*C5]]#=E=D'G";9(7`(U!G4E
M3<HIKITR*Y"EAS(EQ7V<%N:S-D<KNH[NY)*,^T?"0;?<:5.VC1.]HD-1\?/+
M$JQ^'&9QVBRICUL-N$+L<A@S(CC$;WB.(JN*ZZ1"\XI;MA-=-B]?+$5"^1F6
MY7,.5Q!D67Y0::!(X\Q!=E((V*N2`:,0:7MH2D(:[NFW55R)6J<Y9KSJ$X_%
ML`EMW;$6W,&I;HO1Y$#MN&CHZ,MQ"=700%%T)%)53+"I04=^SQWDW'Y2RWF^
M'Q+%NDGMO.F_+6?')V+JH%W"=C@6Q=?%51<"FNN-R$K[SVS-HKZ<3@V,=$<F
MDJW#?<%'!]760B(&H_\`5,15U'"UF\]0;A;=FP&=&F5,B+%+V[E?[<-[3DE?
M0VWN5Q'FRZZ^&JY!44/';`J_C:>SL#?M*SD$.Y"3[DMX*I+#;>1U=!Z_V]=%
MRQ*RK8TQBNX:Y75TITH<"MCR*&3%EQ]'1D(CTB)('1&GFR15=%WTD")Y8A7V
MFBY!"N6Y9Q0>;]C*=A/A(:)DD=95-RHA>(JA(HEYID5\G>I9,5WELF%4R4BN
M<GBO6HM-."Y)J>TQ[GL_U.AW!53$/%$),HUN<7=F7E=#6+/+ALF_?*%%3W+2
M-PG*Q1=W;5`VXYS%]`EI^G3(CL?E^E:D\+C-A7G8-5UC6R%C-MD^XC#$IONJ
M()J1Z-;M?/3"N+ETDL;^VNX];.;ECRZK=AO`U(%4@DQ':DF+::)V]@F+BZ:?
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M<(/'`XJ+Q.9'X_,M!J9KCO\`DSWYB*2/J^_2#--P0:9,EWM:$![13U"BI^F!
MM3B<E^[J&QK9:\5>Y)(?A0S!X!8@G6D#G<;Z*W'<E]1`T3^&BX'G!>-6-=;\
M)FA63HSP2;N)9.NB]J,)"<]DV\IJNC7V=I%_EE';?)-Y):C)1-5MI)8M&C&=
M-K89RD:C+Z7&Q4?!UQ%VC_I3K],@X[D-%;=KD05U%+"/R_CD.LJ8JMZK$>81
MYA&).U2%E!;D">JKIT+KK@=8M3.B?(O$Q%A]^+7T<R'(GHV2LHZ11MB&?@A'
MV27`EU\2:/RY<S2B/!"=IH+#<PFR1DW6I$@S`3\%41='`[/`8#`8#`8#`8#`
M8#`8$6RJZVSB'#L8S4R(YIW([X"XV6U=4W`2*BZ+UP;B/,XYQZ=*B2YE=%E2
MH"HL*0\RVX;*IX=HB15#^66CS_&..K[W6LBJEGULD5EM4DK_`/9]1_<_^^UR
M4(O&..1%AK%K(K"UXDW`5IAL%8`_O%E1%-B%Y[?'%&2<;X\D!VN2LBI72"(W
MX78;[!D:ZD1M[=A*2^*JF6C![C'&I$>-%?JX;T:%_P"C8..T3;/33]H5%4#I
M_IR":U!AM11B-,@$00[0QQ$4;0---J`B;=NGE@0_\9XWLBM_C(>R#_Z(.PUH
MQY_M)M]'_P![@39,6+*CG'DM@_'<3:XTX*&!)]"$D5%3`C+0T:BX*U\90=V*
MZ*LMZ%VO[>Y-O79_3KX>6!#Y-QLKR/'9"QD5W8<[J'&".:DJ)Z=4D-/#Z5ZH
MJ(BX-4A_&\QYT7I'++=YYM%1MPQKU($7QVDL5537],M2"?&;O;;:_P`HM^RR
M2&RRB0$;`A75%`/:[15/+3%(%\8[VR:<Y+;FP1]PV26$H*>NNY1]KINU\\4C
M;_VY=5SN+RBZ5S;L5SNQ=RA_IU]O]OZ8JQZS\=&PVC;/)[IEI/M;;>C`*?P$
M8Z)BC-KX^)N2,C_)+HW!(552D,KN05UV$J,HJBOTUR#J78[#R@KK8N=M=P;T
M0MI)YIKX+@:_QT'5HO;MZL?V%V#JWK_HZ>G^6$C,HL8GA?)L5?!%$'5%%-$7
MQ1"TU3"L^V&N[3U:::^>GTPD19U1`G1'HDAI%CR5_P"2"(B(XFNJH>B=47SP
M1*5IM6^VHHK>FFS1--/#33"L/:Q^TC*-BC*>#>U-J:>&@Z:82,NPUT]*+M75
M.B=%7S_CA0V6S1$,4)$75$)$7JG@O7"05AE4'4$78NH:HGI7ZI],$>]L-4+3
MU)T1?/3!'@LMAKL%!U75=$1-5^JX(][8?3Q\<4AV@UUT]2]%7SZ8(]041-$P
MKQ&Q3`=L<)'NQ/UPHHZX#:F$@B:844<!MZ:82&U,$-/U7!#3!#:F"&F"&W]<
M*;<)'NB85YM3]<)#3"JR/QRMC\@F7S?<_(3F&8LA5,E;5J.I$VB-_:BHKA=?
MUPD3Y$9N0PXPXI=MT";/:2BNTDT70AT5%_5,$0..\:J./5@5M6V;<8%4E5QP
MWG#(O$W'75,S)?J2XI%GM3]<*]TP/-J8(:82-;$6/'%19;1L2)3)!334B755
M7]5PK9I@-J8'NB8'FF`V_K@5[O'ZQV^8OC`_R<:.<1EU'#049=)#,>VB[%U(
M$754UZ8%@J82&F"&U/UPKW3`:8#3`:8#3`:8#3`:8#`8#`8#`8#`8#`8#`8#
M`YOY$Y3+XMQ&?>1(7OWHJ!I'WB"?N."WN)25.@[M51,#CX_R)84W+N3-6\:;
M(JVYM2P*(K!-5WY!@`T)4(5(5?--=F[377"+G_NO$[UB'X:>C<":54+Y(P@/
MST=!IN.S^YJJN=U"0E1!0==5PK;&^4(9SXM;*K),.R=M$II44U;)8[YQSE,F
M1"2B;3K3:J)!K^J8&AOY:AOQ(QQ:N2].DG9(D!2:`T;J'5:DFID6S[M-B:ZK
MKY=<)7.+\J2HW()O(&XEA,XX[QR#<_CMS`^V9=>=1Q]4(T3<K0BNP2)5P/I%
M_"F6U4VU!M':EIU1<?FQT#O=G:JJ+9.(0MJO3U**Z)A7S>IO.7S(W&./RK9X
MPNK*R%J_;$&93]7``S8--!V";WI]2#U%-4\<(VL\QY%-X-QRQ6<;,]ODC-/8
MNMB")*::L"AN;D5%V]P`0EVZ=<*M_E"784[E=<M7<^`W[V''%MII#KFVS?$7
MBG:`1;3`MHDI)H6GZX2OHB>&%,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,"EYGQEGD_&;"A>?.*$YM`]PVB$39"2&)()=%T(4Z
M+@<U/^*G)[=RDJ[>-Z[>K)$AY&&D47*I0(=J)Z?W%:3=]/+`E'\8Q':JU@NV
M+_=GVZWL26`@#D26ABXVK::*A"!!X%XIJBX&$SXR]T*3"N'V^0+9,VIVX--?
MW8[*Q@;1@D($;[)J.BZKJNNN!Q_(_CJRK&JFKB%:6=>R[82SL&8\"6Y[B>]O
M)MYA]&D05$CT,?KH2:82+Z'\:6-O5S7;Z><6?<4R4DIAAE@$:C@\X31H(;FQ
M=[;FTD%5!%^W"NJY%Q:3;\>:IFK:17B*-B_)8!DC>;`=I-F+@F&T_P"I-/T\
M,"O_`.WCAPX??O)DBWK912ZZU<!A#84FNR30-`V#7:5M511V_K@9N_'%7_CE
M30Q93\:/4S6;$'DV&Z\^R\LA2=4AT7N.JI'HB8$NZX@=S*D!/M'W*.4C/>I=
MC2-*K)(?]S;W=IJB;QW=<"VAU[T>=.DG,>D-RR`FHSFWML(`(*BUHB+H:^I=
M57K@3,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@:P?9-PVQ,2<:T[@(J*0[DU3<B>&J8&S`B'
M;5H36(!2F1G20-R-%5P4=<!O3>0!KJ2#JFJIX8'ME;5E7'2392V8492%OO2'
M!:#>:Z".XE1-57PP)6!#M[FIIX13K68Q`A@J(<B2X+3:*O@FXE1,#9`L(-A$
M:FP9#<J&^.]F0R8N-F*^8D*JBI@1+?DM!3*TEM81X*O[U91]P04T;1%-4U\A
MU37`A1_D'A4E]AB/=1'GI+C3,=MMT34S?0E:043_`%H!;5\%TP.@P"KHFN!X
M)(0H2=47P7`]P"^&!4V?*^/U?N?R$YJ,D-H'Y2FO1L'"V-[M$7J9=!'Q+R3`
MUU_,^,V,2',@6+,F)/=6-%?;+4"?3Q:5?Z3Z?:6BY8E6%I:0*JOD6%@\,>%%
M!79#Y:[0;'J1%HB]$\\BLJ^PB6,)B=#<1Z))!'6'4140@)-4)$)$7K@;C<$$
M125!151$55TZJNB)_/`"8DJH*Z[5T7]%^BX&6!X2Z)K@1*>YK;FO:L:R0$J"
M_N[,AM=1+82@6G\"%4P)F`UP&N`P&!BXX#8$X9((`BD1$NB(B=5557`]$M4U
M3P\L#U?#`KN/7]??U#%M7*90Y.[M$X*MEZ#4"U$NJ:$*X$X'FC,P$Q(VE1'!
M145154W(A)Y=%UP-%K91ZRME6,E#6-#9-]_MBIGL;%2+:*=271/#`]K;&-95
M\6PBJI1IC+<A@B315;=%#'5%\%T7`C0N1T\V[L*2/($[.K!ER='3[FQDH1-*
MO_F0%P++`AV-D,%8J+'?D>[D!&18[:N(VIHJ]QW3[&TV]2\L#10<BK[QF4["
M1Q!A2WX+Z.@H$CT8]CB(B^*:^"X!CD=8_?S*%HC6R@L-29#9`0CVGU(6U$U3
M:6JMEX>&!'J.7UEM;RZR(Q+WP]V^6Y&>;BGM+82,R#%&W-"_TJN6"SL;"-70
M'YTHE&/&!7'51%)=HIJN@BBJJ_1$R#FX7R=QB1"M)3WN:\Z;MK80YT=QB2"/
M]&%1HDW%W5Z!M\5Z8B5*_P`\HDX_:7AH^VQ2]Q+2,31+)8)D4,Q)H=5UV$A=
M.BIUPJ1=<NJ:>@;O9G=6O<[""33:F2>Z(0;513P34TU5?#`ND7`J:WD]58)O
M8<T:<DN1(CIZ",EUE"5SL:KJ8CL+K_M7RRP>\7Y)#Y'3MVL-IUIAQQYI&WQ0
M7$*.Z3)[D123[FU\\@M=<"CD\TH(TM^(])`7X\F/#<%3!-'Y2;F@ZDFFH]>O
M\M<L&?'N5P+V5;1HC+[3E-+*#,5\$`5>$4-4!44MR;3%=?UR"XU3P\\`A(NJ
M)XIXI@$77^6!3\MY;2\4HWKNY=5F`P38&2)J6YUQ&QT3^):K^F!;]P.VCFY-
MBIJA:IIHOGK@>J:(FJ]$^N!XCHJ2BBIN334=>J:_I@>(\V2:B2*FNFJ*B]4\
MNF`%T"TT5%W)JFBHNJ?5,`C[2J2(0JH+H:(J=%_7Z8$:;;UL%L'9DEMAMQT(
M[9&2(A/.D@`VG^Y2733`CWU^S3U$VR)AV;[%I7W(<7:;Y`GCL!2'7IU\<"F+
MY(JVWI7N(4N-#A.Q6Y$YYM`:1N<"$R\BZJJM[UV'TU%?%-.N$KK<*@)9R/S#
ML$H3@1&XXOI8J3?:(R-15I!W;]PHFY54=/UP)C;H.:[%0D%="5%1=%3R7`\*
M0T.NIBFU41=21-%7PUP*>UY5'KK^GJ'6"/\`+^Y1)2$"-LK%9[RHYJNOJ'PP
ME37;.0-I#B-0R>BRFW7')PFV@-*WMV"HJN\NYN7113IIUP5`Y/RZ)15S4[M+
M-;<G18#@L&&K92WA80BU7^DC35/'"KMI]IU-S1BX&JIN%45-4Z+U3"52<IYK
M2\:?J&;,B$KJ:%?%44U1''$70S7^D$7057ZJF%:>2\S6DMZFI;K'["9<^X]H
M+!-"FZ*WW3$E=(-/1X82JZM^5*BS?XXW!A27`Y(<IEDS0&UCNP=?<-R`(MPD
M&U4].N6%=KD4P&`P&`P&`P&`P&`P(UE8PZV#(G3'$:BQ6R>?<)=$$`3<J]?X
M82O@_"^27]#\R>XY$U+AU_R+'1QD9R-@#,^*BHRPUL(_3[=1!%+157*58Q+_
M`.0[>OY_/#D_MH?%IUO#C168K"NFVS&W,;GE^U6S7IZ>N0JBXER6RJU^.S8D
M!;D[Q.QFJ+S<=Q_O,,"ZC#;X`CHHI>DDW:KIUZX6HG+>16G(/@N9=V7(XUNS
M:-T\K\?L9!Z'+6:"20_;T_:0O2"&BDFB]<0=A2?(7*K7Y0LJU+*)$B55PM:[
M1R76VW'8*Q]6WV6T!7G'C<]:$A[-O33SP.^Y[94#->W7V-G`JK&S1V/42;(`
M=:1Y0T+0#(!5=A>&Y/\`Z6!Q?PH+L;A'&ZYZ>S5#73I\*/'C*'9N`8)P>\WW
M=QJA+J[^VOE_IP/H/,8T1>,W$ET`1T*V6TCY(FH@;2J0[E\$5137`^:2Q9=^
M-/BM]EX8\E^50L)-!`4Q%8Y)H*EJBZ*JZ(O@N5$,^<7S<>+2S>1!%C?D[RM7
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M&++G22DV\LH+HNLQ9W:`XK8.M^E7&^RTJJGB?7SP.XYQ),OBN^>F[677*223
MZ$NB"X<0M4Z_[ETR+KG)OR!!A?%T0*&>Q+Y%^&;.)%CFDAT>S'`GG%;;4B_:
M#5?XZ)XXA7'R[-J;4P9Q\L6THF^15#B2H[\@6XHN(2.BY*=+4]203VE_;)=.
MFN(/&.0K20[!G\N[&A.<KG1[Z9(D2#]M&)'"B*X8*CC`OD@)W-4U33RS25T'
M%';BRY?35LKEDR;&:IEGB[&7V[<PF;$@;,P-#,Q)G0277UIZLRKM_D2U?9IF
M:B"Z#=O?O#70$</9_<12>/70E38R)KJB+UTP/GE;/F\-C\[X;'./3O1X;M_Q
ME&R-UF.Q(!>\T*[$7]I\%+3;T0M?#+$J&_R9Y^BNI]9RET8Y3*-J+&9GA)D1
M@<?:;FD6F]1%Q2+Q7R5>F(5:SYEC"YLG&WN0RZ]R"_7K0$^,F2[.CEH4E%(2
M%IXC,C;/>BJ`Z+TTQ"ZHW.3W4BGY!,<Y!*B\C@UEN-K2M-2!-E]LE6,XAF1-
MM=O04:)L?W$+SQ"ZVW\RTAL<H>CWMFIUE93W$(5DN*GNGU(75TT]0&@CN:^W
MKX)B%6C=W.F<PLH\R\E0+B%,L/\`Y4TS(VO5?8+VYH:GV!;0=KB.B.Y#Z>>(
M.7FE:R>&R8QS[&?^7X*-E,;>>?=(IC#K:(0)_06PB0A'[D3JF(5V5=>-CS^K
M&OF.6E1)6.S'CM/2FY$/6(JH;C+FK<F*XGJ5Q>HGIU7$*Z3Y(LTAVO&FK%Q^
M/QF3(?&VDQU=!!>%K6&#KC.A@V;F[KKIN047$5\>*[DP."5[$.18Q9T*KDRH
M!E[M!4FK,]>TTV(D;^Q/W"=71`T]*ZKB)7064U:ZQY7(AK*CQY%_"E7+P-3'
ME2ID0P7O(V!`7;5]-#[:H2#KY)IB%8VDL6ZENOM[.SG\=DTMD5'/[4N.KTXG
M21MI4;4GBV,*B,=U5W#JO7$*^I<:M8]7\9U%E*$Q:A4\=U]O82.?M1AW`C>F
M[=JFFFGCD5\^AL7/%^0\7YG8BP0\A-Z%?%$!XW5&P5949Q[HOIBN"C6NG05P
MB/`-][D\@X=G/>O(W+I#!1?<2#8"HVH4D3;5>TC8MDJB7BAZ(GTRPK/C\28Q
MPS@MFDFR.RL+R$EFKSTHR5MLGVU1P#7T!M5-VJ(B]%7$'>?%^Y(_)$43'7D-
MF0[P(-1)U"0AW(FHKKT5.F(8UQW-GR[=ND#G:2A@CW$`]JDW)DF8B6FBD@F*
MZ)UZY%4O$2HZ*QL+KCA3F^##7.29T%QN48M30=W?\9AY.ZA*WO[@"FGV^>72
MOH3][7!0+>:F[7^W26*M-FXX32BACM:%%-25%Z#IKD'R*T?:Y+`MKF!%G2+;
MWE18S8QPI#`#`KI8N#$;5\&^ZZ(=QT]NNI=/IFD6LB++DT7RI<MLO>RO&C;J
M6U:-#>[-:,97`:TWKW'?2/IZZ:Y(58\[1YWX<9;98>=?-FK1&`:,G=0?8(OV
MT%3]*"NO3IA7=VXR7Z:<$)524Y'=2,2=%[A-KL7_`*Z9!\@@0:]Z@^'[$X#L
MF-7*C$LFF7'B8=6`XTO=%I"4=)0:$JIT7QRI553U%[$;I)E-%FQ;V<?)X[SQ
M@^`^M7W(/=0TV-@KR@3:DB)KB%=;\-PQ%^9-;&WCF[%CLV$*QB>R9"6TJ[U$
M235U[JN]P54533KKD5W\KBW'9CS[\NLBOO229.0ZXR!$X49=S"FJIJJM*NH:
M^'EEHX'B_(VN/S^<O3*^Q<<D73LF`RS!E&LD/;LMCV2%M07<;:CKKI_+$%8=
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MVN``(0BWO\41,0K7&HN5R/RXA%N(_-HD>W:&=VVF:^1[E36.22MNKVH[$:'=
MZ"3R1,08L<::FA62(=/=QX[][5E8PIT=(S;0QVW6WS!F.(>C:0BZZOI/IXZ+
MB#=5\3FP9-1(K:F5#FQ>3VC,9]67=K%6ZW(1CQ^V*IN-JG].N(N*IOBME(X/
M>"=->AR5*88%FRZRT#$F6$@#1QDF!`Y3JDA$+NJ[1\5R"SY#PWMV=T,7CTA^
MF:M..V;<48I.BYVU49[C0$GK/8HH[IU7SRYB;B]X[426ODR4X%4[(K)Q3%EN
MSX),/0M1!`!N4G[,J,]L1&VUU)O^&".J^56X;/QSR9":%7)D)UD``4WNR'@[
M+`II]Q*:B(X(L.)W)OH]2269#=E2L1&YKSS:BT\;K"$ILGJN]-R*B_KD5\Z^
M4^/V\^YY<L*KE2@G<88C1W&6S(793<PC1L"'^L1(2_AA-=3P&D6HYERL(M>Y
M!IY05S\7]L@9<>[!#((%7Q/7;O\`/7QRF*/GWQY;VG([9BK:1NMY57@5E-]*
MK%L*H]\1P17S?WH"_H*KD5H3C%E93^%S^0TI'(LI$V?R>*C:NL,./P.PVV\J
M=-J;1!$7*D4U?QGF!TO$6(<"7#M(E+?UXOO-DW[9QW:,(7#5?0BH";%Q%29U
M0%GQ1W\;PJPII3LFC:LF'&]AO>REB3NQMLRWBTVA*KW3=T\<@[?XTJ)%1.Y;
M$]@<"N*Z<?K&U;[;),NL-;B81.FU71/73SRI%+RWB=OS61RA77)-;'CQOQM4
MVY&$E<5O;)64P1+KZI`@B*G^A,BHTEODW)Y?QU.LJJSK)3(S1OC9163BO.Q.
MSN4Q7H!N_;IY98D6<_BK=+RW@$2BK'UIZIRQ64\V)."TLIA11QYPEW*3CI*I
M$NJ^>*1])R*8#`8#`8#`8#`8#`8%#S;C]C?T#U9`FLP'7R#N/2(K<YLFQ+4@
M)AU4!=WZ^&7!Q<OXKY]-]JL[F,*2L)46&KM#"-653316MQKLTT3PR]$O)NB_
M&?R#$22D3F\>*,PE<F(S100[QDFA$YU]:KYZY.A=:(GQ)S6&<9R)S*-'<A"0
M1#:H*T%:$U531M4TV(2JNNGCBX=6(?#O*@8?CIRV*D>4XCTID>/U:`ZXBZH9
MCMT(D^JY:1+#XPYR%A^2'FX#8[.TDT:2M1[MHFFSN;=VW]-<E(RL?C+F]FRC
M%GSCWS(KN%J335CP(2>:";9)KBD=+QCBMA6LH-W:_GWV'-]>^[$C1EBCLV*+
M(L"*#JGG_+&B_?CL2&38?;%UEQ-IMF*$)(ODHKJBY%:$J:M&&6$AL=B.2&PU
MVPV-FG@0#IH*I]4RU(Q<I*=R.<=R!&..Z?==9)D%`G/]9"J:*7ZY!,VCLVZ(
M@Z:;?+3Z85JCQ(D=IMEAAMEEK^VVV(B(_P#E%$T3QPD>N1(KK!QW&0-AS5'&
MB%%`D+JNX531=<*R:8989%IAL6F@30&P1!$4^B(G1,"K;XW6MVTNQ`/_`%Z!
M[V,2"3+CK7I!]05%T<V)M54\4TU\,M2%KQ>KLH[$1]O9`:?"2[#:00:>-M4(
M$=1$]0H:(6GFJ)KTQ2+5QIIP%!P!,"^X21%1?XHN16IF#"9-39CMMFOB0`(K
M_P!43%2,DBQD:[2,@C6N[MH*;=====--/'%5Z3#*H:*V*HY_<1130O+U?7"1
MZC;6]"V(A(FB%HFNGTPK(FP)44A15'J*JFNG\,"OO:2/<5<FO=<=CC)':LF,
M7;>#14)%`]%ZZIYII]<)$&AXBW5R')<J>_;3W&^S[N6+(D+6[=L$6&V@ZDFJ
MKIJN6D7VU-471-4\,A!0%=>B=?'IXX(\413^E/\`HF"";5\DPL>[?X82&U-=
M=$UTT_E@CQ"1>J=?U3KA35<)'N"/-?TP014_G@>JJ)A550<;A4BV*Q''7$M)
MCMA(1XD/1Y_;OV:(.T?2FB82+15TP1ZB]?UP,2>:%P6R,4</78"JB*6GCHGB
MNF%8OM,OLFR\FYMT5$Q7S%4T5.F$CUI&A!&F]$%O0$$=-!1$Z)HGATPK(S`$
M4C5!1/-51$_\<#SN!W$#5-ZIKMU373ZZ82".`IJ"*BFG4A14U37ZIA6>!$@U
M<*"4@HK2,^Z=5]X1UVJX7W%M\$4M-5T\5ZY4B42HB*J]$\UR*Q8?9?:%UDQ=
M:+J#@*A"J?HJ:I@%?;0D%23<NN@ZIKT\>F!XV\TXFK9(:::ZBJ*FB_PP5KEV
M$&(`'+?;C@X2-@3QB"$9>`HI*FJK],#83K8J*$2(IKH"*J>I?'I]<)&MVPA,
MGL=?;;/QV&8BO7]%7`VH\T3G:W)W$3<H:INT^NF%4W*./\=MF&#N_P!M(;BN
M1)0OG%<:,DVKL>;)LDW)T5->N5(WU<2DIHK$&(0,M/$I,";JF;QEU4M[A$;A
M+]=5P1.69$22,0G0228J8,*0[U%/$D#7<J?KD5NTPCW3"FF`P&B8$:970YCD
M=R2R+I17.]'WIJ@.(BHAHGAJB*NB^6!M9CL-$X;;8@;Q;W2%$12+334E\^B8
M&S3`8#1,!@,!I@,!HF`T3`:)@,!@,!@,!@,!@,!@,!@5/*^0-<=X[87CS#DE
MFN8*0ZPSM[A"'4MNY4373`Y"U^8(]6T/NZ:4U,1KW<BO5QHI(1"=5MMT`;5Q
M'"<T4D;1=VB98E37_DYI+1AF/5OR*I^T"D6U0VP$9I^(]DM'%`"])%_JZ:8B
MM<'Y8K9$>ID/0GHL>S<M&C<,@7L%4=Q75-$^Y#1DMNF(*YKYPJB@39KM:^RS
M':BR&GS-$C*U+=1H5>?V[&";W(3B+KM'KUQ!M7Y2L6;P`G5@1:1JB>NYD@9+
M;[@"T]LU#MZ@X"H/IVKZMR+B#.%\OM26W0_#R$G$[#9KF4+]F2Y.W*VVCYB`
M`;:`2NIUVI]<02OC&SNID;E"V'=*7&O)C+,5Y_O=H!!L@9!W339ZO3TZ:Y!R
M%?S_`)E8V'"[A8)'*LHEVKE-&E($9[VIM]HS(TVHH)N3715P+^3\U0?QT297
M5,J>;M?%M),)I#)]MF62B#;8M@X+CJ;"7344T3QZX%E\K75S`XY7E4IZK"SK
MX;Y*ZK!HS)D`)"A()**FGH5?%-<05]=S9F@BJPU"DR..0;5*:79R)92'F9+K
M@AH@N#O<8;>=1K<I;OTTP**-8V86$$5GRB`>>38:H3QJBQ^PZ2,EJOJ;%4Z"
MO1,#I6?E"9(;K)3%,IP.0!)3C[WN$0WGX[9NMM/!L_:]P#1*!(I:>!8@BQ?F
M:-)]EV8"*5C2E;0A5Y=2E`:-E7EZ.CB$7C_'IEB5A.YV]2\@O19J')%@EA2P
M)`%.7M$MBWL`VA,=C2-JNA(B>K[LD*EQOD^<XVQ%D5K42X=MY-(X#DA5AMNQ
M6%D;U?[8JJ.-[=J;-=5_3$*G1.;6MI\82N71((0YJ0I,J)#?=4PU80]JD8B*
MJ);-4T3PTPJE7Y0Y%7UP?DZIAV:]0)=URL/N*DQUM`[T81[.HN?N"J(.[QRQ
M*L`^3'I34`JV&U(6X>BQ*IPWB%LGWXI2W^XJ`JB+#8^6JJO3ID5><2Y([?P;
M%N9&]G95<MZMLHX&I@CK8B2&TYH"J!MN"0KHBIKI@KA>!<SO&>&U-95Q0M+.
M'4G:3"F2#`C922ZTVV![75)PU:+J71-.OCB)5D]\N.J_428T%LJFT*L$-SI+
M+0;14%'";`2%H6C)!_<5-_7;EA651\H7TRQ@-R*5EN%82[6OCJS))Q]9%7W5
M3T*V`[748)$]6J+B%7?Q]S5SE4.3(,8[3L<@!R(V;J2&'5'5QB4R\#9MFV73
M730O%,A7/\9Y]RR<S$A/MPGKFTLK=B&6KC;#4:K?-LMZ(BD1?8(Z>.NJ^&(K
M77?)/);.[AHS&BQX@55I(LH+SA":3JV6,5P1D*B`C>[[2)/!=5RQ*IN5<WL[
MSB=Y%ELMLOU4FADL2XBO@VZ$V4V7H5Q`(D':0[D])IU3(5=S.93:CD=O'K:J
M,LR7R&!5//./O(CB2H2.`^2:$@J&B#M%-%3]<+6QGY.NR@0VY,6)$L7)=K!F
M2C-U8(NU6[H)=#3O[?3N\-%\<)5V;G(^6?&8NLJE%=W$('&14CT8-U$)&R+0
M'/4GI)437KTPM<9P"NXI:4%C!MHLNF<@JV]?42OO)%5!5Y&WV3$MSC+O7J*I
MN4$U37*E97=;:U7P1.&4]+:=8=237@Z\Y[F/%.<)1V77-V\E!DD0D)5^BX5>
M?,--;S:]FQ"+'M*&F;>EV=.X])BOO("(N]A]@P'>VVAZ"::*JY!U%T,69PR:
MC*&,5^N<5I$4@-`5A5#JBH2*G\=<#@HI'9UGQ52SE)VKM(2O6#9$NC[D>N0V
M@<774O42G_$<#G:67)OX[%?<R77(=7Q^WD0))N$A*]&L'(C4I314U<999%1+
MRUU\\)7U7@-ER2TX_365EV%C3*F&^:Z&DE99AN>4T7T;%3:J:===<*^;\KY#
M(FUGRO<S&?>,<>VU,*N<<=:;[#;+;\@M62`Q)XG?N1==!1/#`Z2DNY,#Y1KZ
MIM22MY+0#9E$U(P9EQ2!LC!25=$<:<1"^JBB^.!3?($!FMYXMY=L_D^-3`%M
MV9')4F4SC2,CO3KT8(E$RV>I%+5=4RC8YRZ#:?+7&W"DR6U5;6"Q!5B2V(BC
M;8BX>YL14W#$B0M=!'3!5WQZMA4?RO,A,5IUS$VJ[D5UI[N,RU9?3O.O@OJ%
M\%=%$5==15>N2)5)S?D$X.6<AMI<-JQI.$L0'`J77"#N',U<?E"&A";C;>@M
M;^FJ%IUZY85!DRI"S+'D"D27['-HE;$7JCB0B5EE(W_VLX[IN*/AKZL17O%9
M,@9?"KD"5;R[O+F-=DGWN,#[E2;=_P!K"QVMB?TZ=/'$2OITRQN:GA\N?928
M*VD.,\\Y*5'&8*$&Y04DU<<0$33=HJK],BN"#Y'YQO>@H,7W35K4P@D2HSC.
M^/:,J9$K(O$0D!?;JNNG0A1<)4RIYSRNRGQN,.O0FK=R=;1'[)6#)AQFK5M$
MV1E=^]WW`ZHKBZ(A86M/%;R7QO\`^AV"YC-B<NKJ9+[0`GH[K2N;=!Z^E"\O
MI@5$5[\;<?&$,8T>9(M:BQE/6DH7')*2G(0//.(2.")=XB]:$*]/#3+$JOXK
M?.Q.-_$_)(,5FO.WE%23Z^'O%@XLA7E!$$R<+]IQI#%5)534O)<1'6_+-',=
MN*F\A1X]X=<@LS>,RNVJO1WGA7O1U<]+;NK:CN)-"3ITR-,)[E%-8^*[*G`T
MKUG@-<KVO=&.Y7OZ`6JJO3:B+_#`W?('!.'V5]5,%4QW[R]L6GI4]T=[X18"
M"^\HF6J@FC8-HB=/5A%DTTTW\XR71!!-[C32NJB=24)QHFO\EP-?RMQV5>U#
M4Z'(@26*AM^:=/9,!)AS-H=$<7<)-J*(2"8ZZ*N%<-RF2S/B\SL)#'LGH/%J
MN5QV,J()15<%UT>SI]II(``7;]$3+!G-<EDW=6[XHG+6.75,>*2]'1;((@BR
M/FC9,NNZCX+J2XB5]S;=;/=L,3VDHDHJBZ*GBBZ>:9%9X#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`J.6<?'D7'+&C.0<5NQ8.,<AM!(P$TT510M
M1UT^N5%):_';LRUB6T*]G5,]N(W7V#D1&=)<9M5(4,7`-`-"(MIAHJ:XI'.\
MD^/9]9;0)U1)GS:^3R.':R:4$:-F.2JON9&\A1[:OW*._P"[KIBF+*)\.P69
MT=QRWF/UL2182(U42,(R@6HFDEHB%M'"35TMJJ6J8IN)57\:SJZH*L:Y39OM
M-HVU!65[=Y&8S:Z]@@5I!>$A]!$YJ6WIJF*(\/X;HHJ1FPER?:MP9=;-AIVA
M9DQYSQ/N`HH'[0@X:[$;VZ)HGABF,Q^)Q*D2ME\CM9K\9YA^IL7W&E?A%%55
M95I!;$#5$)4-7!)23HN*J\XEQ`>.#8[;"38NVDLI\IZ5VD+O."(EM1H&Q05V
M)TTP*BH^*J^KD5CK-I-<&G&>W`:<5E1!NQ5%<#HVBKL5/0JKK]=<(T1?AVKA
MMU@P;FTA.5\)NL?=C/`VLR(R9&VW(_;5-1WDB&&TM%7KD5T/*.)1N108D)^2
M]$:A2X\UHHZBA*Y%-'&D+>)^G<B:_7+1`7XWJ5LY,GW$CV,R:W:R:C<"Q3G-
M*)(_U'N)J0"1`A;5)-=,#%KXUJFWFG4F2U)JZ=Y`**;>BRGA42!?1_:T)?3X
M_KD&RE^.::IE1'&'I#L2L<>>J:]XQ)B(<G5'.TB"AJFAD@;R7:BKIEH\8^,>
M(L.1'&H>TH5H[=Q_4OIF/H0F7_E]?0?#PQ4CRQ^-J:?:S+-V1+"1.EP)[R-N
M"(H[6?\`I]J*"Z#_`*D\\4CGN8?'L\$'\*W.F1YMG(MK)(\UB-)"0\T+0]KO
MMJR36@]1+JGBBXI'3\8H+5>).U/(WW)2RA>9('3;-T(KJ*(LFZR#(&0BJIN$
M4R*]@_']%&C4#3W>G.<:(CJI,MU77@(FU:]1:#N1`+1$TTZ)],M2-?\`VVXR
M''XM)%:<AQX,HI\!]AQ1?8E$X3JNMFJ%UU<)-%1445T5-,BK6DX]$IX;L:*K
MA%(=<D2I+I[WG7W?O=,M$3<NB>":(B:(FF$B@C_%''(L6$Q$>FQBA1GH(R&I
M"HZ[$D.*Z;#Q;5WCO)5'IN'R5,I&,SXBXG)DD\'NX@$L(TC19+C+*.5J"D4T
M`?Z@$$'^'Z]<4B2S\9\>:&&('*1(,J;-C_\`(+5'K$3&0JJB:Z+W2V_37IBD
M6/'N(UM&_)E1W'Y,V8#+<F9+=5YXVXPJ+(J2HGVH2_JOGK@BM'XPXVVJE'*5
M'>&>]9Q7VY!H<>1)U[_85=R`V[O+>&FU=<57LKXOXE(;C-G'=%J+%E0M@/N@
MCK$Y=T@7M"_<WGZ]2_JZXJ1'#XCXFD>4R?O7DG-PV91NS'S(QKS1R.JJI>(*
MB=4\L4B?(^/>.R+-VQ=!Y93L^/:F2/.(/NHC?:9)!UT1$#IM\%Q2.;Y1\;R>
MY$&CBD_#21,FR@2SE5\E)4TA(W`>;%Q"!="U!4_ABD=/5\7>/B;5)>ON325-
M7G.^X3@Z.=QL4D>ATE;T1$-=%73%(@-_%/&/Q[D-\IKY//-OOS"F/A)<)E25
MH2=;("V-]Q=H)T\_'%(F%\>\;/C<GCCK3[M7,<[LH793[CKA[A+4GC-7/$$Z
M;L5<2;3AU/:6#$V;[ATV6NPK*27P8=;W;MK[`DC;O7_4*XJ:Q3B4<K:XG//.
MJS<1FHCT0774;0&Q(5(1W;0(A/;J"#T_7%,'.$T!TD"E[!C"JT!*X@>=%YCM
MBH#VWD)'$]"J/W>'3%76N9\?\4EP(<!R`+<2"T<:.VR;C6D=U$1Q@E`A(FW-
MJ;Q)>OGBI%I'I*Z/9%8M-*$HH[<3H9=M&6B4@$6]=B:*2]437(.<E_&U9*M>
M0K)$7Z+E337YFM)3!5D,"C8N@;:BJ(XV(B:?[47ZX5*J.%-0^5.W[QB2L06Z
MFGC#JHQX3:H9;B+4B<</35?)!1/KEJ-EE\>\7LKE+:9&)R0I(;[7=<1AXQ$!
M`GF4+MFHHT.FJ>6*NXM9E)73)T6=)91R5"%X(KJJ2*V,@4%U$T5/N$43%2*Q
MG@M!&K)4",P6V5&.&3K[KS[B,GK^VCCAJX@ZEKHA)BD:P^/.+DW!25$26[!C
M,1!>=,U5UJ,J$TCZ;MKNPQW)OUT7%(GN<3X^Y<C='"`K(2%SOJJZ=P05L7%#
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M+2<<1UVIJ&15`"6^BB3Q$JKKM`BV"GF2K],$6?(>$<9Y"\P_;01D/Q]$;>0C
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M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`T3`8#`8#`8#`8#`8
M#`8#`8#3`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`TS)L.#%<E3'VXT5E-SK[I(`"GU(BT1,"J3G'#2<[8WD$G$W:@DAI5U$5,
MDT0O%!15TPE6D.=#FQ&9D1X'XL@!=8>;7<!@::B0JGBBIA6_5,!JF!YN3ZX$
M2TN:NJCA(L9(16#=;8!QQ=$5UXD!L/XD2Z)@3%5$P/-P_7`;A^N`W)@>ZI@>
M;AUTUZ_3`@W5[4TE>Y86DD8L-E0%QXD54%7#0`U045>I$B8$[<F`WAN0=4U7
MP3SZ8$:TM*ZJKY%C8R`BP8H*Y(D.+M``3Q4EP(UWR:BHZ\;&UEC&A&;;8OJA
M$*FZJ"VB;$+[U71,%0'/D+AC=4_:G:-C!BOC$E.;7-S3YJ@BVZWMW@1*2:;A
M3QP5T`N`0H2+T5->J*G_`+<#W</UP&X?K@-R:Z>>!#M[FLIX#EA8OI'B-;4-
MQ45?49(`"(BBD1$1(@BB:JN!3N_(W$6*R992)CC$6O<;9GH['D`XRX]IVT<:
M5ON)NW)HNW3$*L0Y+4'<%3`Z9V3<89CC"-.KL9-505,]NP5)17057=^F!EQ_
MD=/R"O2QJ7UD0U<<91U0-OUM&H&.C@@7I(53PP(U5RZHM;)R#"1]S8+AA*5A
MQ(SG9=5EQ&WU382@XFBIK_#I@7>J8$2SM85=#D2I)Z!&9<D.`"*;BMLCN-1!
M/46B?3`]J[*+95L2QBDI19K+<B.2HHJK;HH8JJ+X="\,"5JF`U3`\U3`AQ[,
M7Y\N&D=]M8?;U?<;467>Z.[]DUZ.;?`M/!<"81HB+YJB:Z)XX%;QKD$'D-)%
MN8*.)$F"I-"\"MN)M)05"!?!=17`WVUK"J:V393G.U#AM$\^>BJJ`":KHB=5
M_A@5"<UBMU3]A+K["(3#_MAA.1B*2\XJ(H=AMI7.XA(O117ZZZ:+@:(_R3QJ
M32MVL<I#G=EK7!`1AP9GO`UWQUCF@DABB*1:]$3KKI@29'.^/,TD"Z[SCD"Q
MD,PX[C;1FJ//N]D0<%$]&CGI+=X+B"9:<CKJRSJJV4KB2;AXX\+8V1@KC;1.
MDAFB;0]`*J:X$^1,BQA!9#H-(X8M-J:HFYPUT$$U\55?!,#;N3ZX'-<LY]4\
M8+6=&G/LMM]^9(AQC?:C,Z[>Z^0_:/BO35=$5=-,#RQ^0^.U\M&'77'6A;CO
M2I;0;V([4P^W'-\]4VHZ7AHB].JZ)UP+%>35P\H'C9(ZEB<,K`"4%[*L@X+1
M:.>"DA&G3!6*\JJ/\J#C".$5J<0YR@@Z@+(&+?J/R)5--!^G7`W\ANF*2EG6
MS[9NLP&')#C36U7"%H5,D!"445=$^N!(@6#$R'%E#Z4EM`\T!:;MIBA>"?1%
MZX&]'6E+:A)N\5'ST_A@KT'`--0)"1.FJ+KUP/.XWKIN37373STP(\RUK84.
M1-ER6V8D02.4\9(@MB*:KN7RP,+&R./5/3X<<[`VVE=9BL$`F]TU00)Q0!%7
M]53`D!*:40WJC;AHG[9*FY"5-=O1>J_PP/')38J0"2&\(J?914WJB?HJIXX%
M9Q7D\/D/'H-VR!1F9S/?%AY1[@#JJ>O:JIY?7`PYARR%QF@DW,ALI#<9!)8[
M1`CAB1B"J.]4UTWZX%Q[F.CR,*Z'?V[NUN3?M^NWQTP5X[+BM$`.O`V;BZ-B
M9(*DOT%%\<%>+,B(XC:OMHX2J(@I)N54354TUUU1,#%;*O2-[I9321?_`(ZF
M/;\=/OUVX&7O(FFJOMZ('<5=R?9_K\?M_7`Q.QKVU%#E-`I**"A&*:J?VZ:K
M_5Y8$1GDU`]*GQ6[".3]80C8!W!3LD8H2(>J].BI@6#3S+S8NLF+C9IN`P5"
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M.YM4P7<O3QTP.H=NZ9DFA=GQVRD(*L";H"KB.+H"AJOJW*NB:>."IJ*BX#`8
M#`8#`8#`8&F9"B3(Y,2V0?8)14FG$0A50)"'5%Z="1%P:^8\<BU;Y_)JN,L.
M^VMWG`U$%5LQK6/5^BHNN5ER-)S7D_&.(0D9L1G1UX?"LXL=QML1B&+S48W!
M[8J:M@TYO+=NZCK^F6%?2_CNQM;"/;-2KV+<Q$>'\=,A.C(=:;=:15!UX&F6
MB-"]0Z#T14W9"N`X/R"S?IN*TCO)9,9JV2V<FVZN1SD#*C/+VHB&XV0@JB1.
M*A)N7;IX8TK16\QMO?G?W=^[`?#BTIX%`0-APXTUUA)340D3>KC;8N[47S_T
MY(N:C3>7SK*AY#76%J,UJNM.-OPE<D1WW@"3)8-S>XP+8+ZT\$U0?#<N!]'^
M5K]ZM6HAL6SE6_/*5VT$V8X.=B.I_N2GA<[8@JH6T`(C7IX:X-U\[=YYRJPX
MZ[:,\G<8>B\,8O#"*D56RGMN&)D>YLUVFH:&'3]-,N8F:M97,^1U<RSB/7SS
M\1]N@E29K@L;Z]BS=<"6ZUL!$%M$`=N]"V:ZZXB[J2?+;NKN8S#UX;W'8G)F
M:\;9\FMKT637N/&P^]M0"[4C:(GT7R5=<0JKJN67EZ[7QFN52FH\AKDQ$]')
MA#,8$L4B%N)M538V7CIU3$*M/C>]=M>;4UG:6CI3K7B-=)",KNUEU]7'$?5M
MKPUZ(1:>"XTJI^2WXT>T^2V9%BZ#SM;3O0XKKVH('>)#-IHNF@$*>'FOZY#=
M6EERB356M]3RK^8<2/=U;,60;S;9",^,KQLO2D%.S'4P5=PIN3[4\<L2JW@?
M('+'EG#)MO=.R)"QKNNW]\T;>D1IS:,MD*H.\U8Z^I-21-5Q%KN_D-$Y#:PN
M$,M,S&I#1V%W#>=5H3AM_MM-JHBXOK>-"TT\!R*^>S^1O%\-OT%I+;'D'%;B
MNJIAJ7<0DCSV58>_I4Q)G15_@N6,U>_)/&6Z3B');R98>]L;^QJ'7W1;1EH6
MHLMD6@;;%37TMHJD2JJK@=A\E6LB#5U;S4AR-4R+*,S=3XY*)-0G-VI]P?4V
M!'L$C3P1?%,BUQ*V/)J]D+R),GV]!3WSD%EIMYQTYM7-:!I"5=?WO:RW?0ZJ
MKZ47KTS16MJ;\A0N(7P2)$QRWXF#L`Y2*\][I)+[;ZR@'5#>)B$>@^>[73,E
M0I=X\G'2F5?*ULJYR<X['BO.3Z]MUL8J]R+'L'"<?1P2_=!#51W^C],U"N]Y
M4M#;?&<,KWW\2!,"`:2?4DZ(\1MDR^:BBJAM.;2-=-/KTS*N`OKB[<X!S&NL
M[!B[:@N5C<#E,5A`.7ND`2MN@&X''8Z#ZE#TZ+UTZYJ,NPX1R/\``\@D<2Y'
MHMM-(I\#D`"O9M&7%])NDFHM/@*;5;5=NB>CITR+FIGPPZP[\?[2(D$9]HAZ
M[P)!*<^:+UVDFH$BHN0S7$<..-#XYQ.-,>F1^+3'K<+20+TIO;+&0?LP=<0D
M<;`@WJ.BHBEIKEA5EP]F^M>3\?B7EA9B#5,_+!M'GF$>6/9(,-R2@;4)PXVF
M]"^[SR:JP^16(K//H\U\'MS_`!JVBQC!'R;*0A-&+:HWJ&JAO7U)U_DF:QG=
M<M&=Y!44HM4CMB9/<1J9DIC]]XD<"0#<E6`-=`=2+N38&U>B>>2&;CZ-\:K$
MD5-F_!LIEA52Y!.0EDLO1A9$FT0VH_?57MB%JNI+T+73)%KYAQM_DCO&:VQX
MK86,Z[=X_8?FD>=?D`KK:HD-01Y>VC^_>C>S3<GC]<L+BP%IBRBUY5UC=N5%
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M]AML`[Q[D<=B<]%KKJ9*Y#(=AR(Y&_812!9+4=P4=5IDR%O7;T'^"X6CE/;1
M?C&(DB*^+\[DS-H$(6S)UF,];I)1#`451VM>LM?#"5V7.`?/DW""::=<;9MG
M''S:`C$`6"^VA.***@BIN"FJ_7!4?Y:K&Y==0278+DYFOO(,F0#39O&#*$0F
M:`&I*B;DUTQBUS%577#E[`)8TQGET3D#[EE,(748<IW"<44[G]DF5CJV``BZ
MB:>'CEW$KIODGD#(,EQQR%9NQ[%DOR$NOA/RT2,J[39$FA)$==34>OVIJOTR
M8F\L<CR>BM7@Y?!@U4G;S.!5MTH*TJ"PK3?8<:?5-195@='%W+X>&JY85V#\
M.:'RS4O`PZ<9J@E1BF=LE91XI#!`!.:::D+9+ID*IJ+CO/8'R552K-(4B+["
MP]]8QFY";C??9-$)3)11PMJ;4\$$5T\L+$;Y8KYLJVMVIU-+N:^;0.QJ'VK)
M2`9L%5Q74,1_MFX*M[7%\A5-?K#=54NCO9,6PC/U<Q.1/MU3W$K(6S1(HM1V
M1-M74Z,*R\CI.B2IN1?/-,U(@4=H]R6P6W@7B7$-ZT<6PAML-19$*4+B-(W)
M1.XZO;4!;94O2:(O1$UR-.E^'H5E`B6<65![49HXZ1+(HIU[LL4905[\4ET%
MUK:@&8H@FO5,BN)I.(7L1JEDU59*K[QZ7R-EZ:8&*MM2$?6"KRJJZ-;U:4/)
M%\//-)W83>'SK/C4IJJX_)@N+QB3!OH,AG8DJR'M+&04-=K[H&#I(\FNJ$GJ
MZZ9$=WS"`[9_#5I"K*M]J1)JC;AU:-=I]'5#0![0KZ2W=<-.*N^)V+\KD=FS
M1RCL!L./2*N0C9=U48%E)9L]>FU!-'-/']<J=V.AXW72FN5OMW'&9;MU#LI\
MQCDZ;4C'#D[NUHZ)[C5&E%KL*/14UZ>.17)5W'^3P:*M1[C]@\Y+XC8TSD5M
ML5)N63ZN-`^BDB`A"JJ)81CR/C7))%#:0IW&IEG-FU-,-"^#8.^U*(#?N8YJ
M1IV7$>$CZ?=KX],@Z2'Q^W>^0WSMJFT<D-VZV=5<LFP$(8A-"`M/.I^^G;'<
M"L=4+Q_7*1J^8Z._M)]@U`H),LRJ6E@V,4&W#)]F7W2C[G31&-J(A(H#N/7[
MNF$B'<<)F39MQ8)QUXI$GE=7.9<)L$=]DC4<91BJ%T#TN"XB+ZOUPK?#XM9U
MELKCG'G9'%H7(+-Q:AIILP6/+C-C'DLQM=AM@ZCB;435-VY$P(;'$N54XQ3_
M``4F<Q+I[NMCQ&59,HHRY?N(,=]3<$4`&?3KJNU?3@0K#X_N95-<$]QMYVQ_
MQ6FAUZD#1.)81-_<%LMW1QM5#U:^7C@7-MQ:Q.RY4ATM@S^2GUMC!MH+$1[8
MK<5H24V72U?0'VR[K2BNOCXX':\=D<BIOC5IY^E%+J)'=[5-``6T,T,NT@M[
MMC7<3:9!NT#54UZ87'*-\.Y3QJWXCR"&4JZD@KT.^C"RPV:1;#5]]TR104B:
ME;21%55\<)J=QS@4>TY-RR3R*LE>R?NFK"M9?=(8KZ-1V@!TF`/:2@XTJHC@
M_1=,&+GA%?:QN9\WERX+T:+938ST"0YMV/-M1&V"4="54]8+XHG3`XL_CZ6<
M]R4YQS>^YS8K!Q]6V=Q5AMJ).:[M>V7]0>?F.!73.$<H2LE5;7&G%BO/\C;A
M&PD7N,-S7$.(VV+I]MEAU.I$(J2:(/IURI5K&XU,6VXZTRTW&EW]0S5\WJW3
M`I`-0FA,'RV*:*7W,+JO5#3Z9%=GSNJLG)_&K*)`6RK:B8XY853:`I$V['-E
MMUL#40-6#+7;KX>'5,BN5C_'/(8T&JL:V(TQ81;><3->^0[8]+:F0/1E5-P_
MMBHNH"+HBIM3*B*/QKRVNX;,KX[*3'J68Q'H6!=%E^52Q)*2D9)[[1-S=MZZ
M(NQ-<N:1W7QY4%7TTQPJF14^_ENS#@2Y`RGU)P10R-0(VP4U'78!:?\`7)HX
MCC?%>2U-?Q>5,H')$>MDVZ6=.'MR=3W[Q%&D"*FC3FP%V+ZM40EP8D<,^-YT
M+E%(Y<T[3T&NJ93;+KG:>"*^_8^Z8CAN52_8:T$20=$\EP8^NHFF13`8#`8#
M`8#`8#`@LT5,Q[KL06&O?*JS=C0#WE)-%5W1/7JG^K%36+/'Z)@@)FOC-$TR
ML5M09`5%A>JLCHG1O_;X9:1MKJFKK(R1:V(S"C(JDC$=L6FT(NJKM!!35<A&
MASC?'78QQ7:R(<5UU9#C!,-JV3RKJKA"HZ*:K_5XX(WN5%4Z;9N0V#-ELF6B
M)L%4&C30FQ54Z"2)U%.F"-(<<X^VUV0K(@M:`/;%AI!T;75M-$'30%7T_3"I
M4NO@RT:25':D=DD<9[H">PT\"'<BZ+^J8&@:2E`5$8$81(.T0HRVB*&NNQ4V
M_;KUTQ4C8E76^M4BLZN@C3B]L/4VG1`+IU']/#%(\_%5:1!A^T9]F&BC&[8=
MI%1=4T#3;T7KX8I&25U>BZI&:U]2:[!_K^[R_J\\4C)N!";)LFV&P)H5!I1`
M44!7Q$=$Z(OT3%(.PX;I*3K+;A*.Q5,1)5'773JGAK@@4&$2$A,-DCFBGJ`K
MN4?#7IUT\L4CT8L5%$D:#424A7:G0E\23IXKBC/L,]SN;$[FFF_1-VGTUPK$
MHD9==6@77JOI3K_X8J1DK;:IM4444\$5-<I!6PV*"CJ&FBBOAI]-,A`6VQ%!
M%-!3HB)T1$Q2/>V."/%9;5-%%%3Z:=/^F*1EM'"L4:;1-$1$1/!$\,5(]V#I
MIIT3RR4@HBGCTRD>[17%((B)A7BH.NN`1!5-475%ZHJ8'AAN`AU5-R*FY/%-
M>FJ8Q%=QOCT#CU%#I8).E#@M]IA7CWN;=57U%TU\<"SVIA3;@>;4PAH.N!Z@
MIKK@-N"&G77"FB8&#;C+B*K9B:(JBJBJ*FJ=%3I],#$944I!11>!9("A&RA(
MKB"O@JCKJB8&U!1,#Q4377"=#1,#U-,53I@>*B+@AHB8'NU,`FF!YHF*/=!P
M&H_7`=,#3+E0X<9V5+?"/&8%3>?=)``!'JI$1:(B)@:'KRC922KT^.VD,`=E
M[G03M`[_`&R<U7TH?].OC@;I<^!"C^YF2&X\?41[SIB`:FJ"*;B5$U)51$P-
M_1//`]T3QP(_Y"O]_P#C_<M^_P"WW_:;Q[O:W;>YLUW;=W37`WZBG37`:C]<
M!JGUP,)$F/'8<D2'!:89`G'735!$0!-2(E7P1$3K@8Q)D27%9EQ'@?BR`%UA
MYM4(#`TU$A).BHJ8&[5/K@17+6M;L6JTY30V#[9O,Q5)$<)MM40S$?%1%235
M<"5N3ZX!%1?#`\U'PUP53-L<2K>1$8-Q(O(+L5(C1`"5*",*:KK]YHV.G\,"
MYU3ZX*;A^N![JF!#EW%7#F0X4J4VS+L2-N"R:Z$\38[S0$\]HIJN*)>X?K@-
MPZZ:X'N`P&!%M;`*ZLE6!@3K<1EQ]QMO13(6A4U0451371.G7`XF!\P0)@&H
MTEFRZY7M6M;'<::WS(SI"WN:VN$@[#<'?W-NT5W>&&:T,?+I3[&FB5M43B3K
M.95V1F^QI'<A,=\U`P,@<%15"W(OAKYX5K/YTX^,2;,"#*?B1H1649UGM.(_
M';=%HEZ'^T?J0D!S15'K^F"L[7Y:L&$<CQ:!\;2-;U]7*ARG605&K'0FGQ(#
M,5WBNB#KJA>.#-=1RGF$3CT6&<AM3EV#R1H<;<((3NPG"W.+J(B(`2J6#=<X
M/S%#*+62?P\T&KEM\*Y7$$%<L&"4/8:*O1QU156R7T$G77"5[??+9TTZTC/\
M>F/M4;$25<RF7&%!AB6BJIBBFA.=I17<@IX)KA<;S^6(!7_XR)`?F1_<O0?>
ML]420RTKJ[@T]+2JFSN*6F[].N"H%?\`-#4B#[Z512XD9VF.^@JKC3IO,-$(
MN!L;55`A5P5U7Q'K@;97R\VS6PWVZX)4V>,E^&Q&E"^P]&B("DZW(9!S7>3B
M`(J"+NZ+IE$NM^4V++D4"FC5QM.3(T:8;<QT8LL&I39.;@BN(A.HSMVN[2U%
M5\-,ABWNN7%6<C@TB0E?<GP9LUEY'$$46%V]6E145?7W4T+RPKCW_FZ2E:%A
M&XV](CI1Q^1R%]TR';BO$2.`B*FI.-[%T3^K],#5\B\ZL9M5)9HF7FXU=95,
M>;:MR%CF#LI]APFA;%%5P4:>%'-23[O/1<)NK1/EU'9<E(=,_*KF4L!;F@KB
M)W*T34N]N:1MMMTFB`#0RZ^*)K@S70<6Y)=7O'!N'JA*TY30R*Z,[(%SN-.L
MBXV3A-C^WJI;531=/'!KYO5\YYA/F\/OUB"_.LJ.UE/534LF8A]EQ@FS+<"H
MA"A**>DEZ^.#'1.?,J/QXS]-2R;/=!@V,R,T+A/`W8:JVVVC;;@$X("1%N(4
MT\%PJ;\S29C'"0DPI3\.0EC6@CT9TV7-CTQIIP54%1="`U14P+'Y/L8]7P*V
MEO1W)3$=L"<CLR#BND".@B[7@]8JGCT\?#!K!CF%Q+MI#575A)IZ^P_&6,LG
MT!YLA:1QU\6E'0FVE-!5-VY?),,XYIWYFMDH9G(&>.NO4XUSEG!DJ3C0*@."
M(LO&XV(H;@%O#8I)Y+AI,G?*=O7!>-V-0VR_3/P1=>:=<D1VXM@*D,A]0:1P
M49V*CFT%^NNF!B]\J7)HT%53#;RF8L29/9@&Y(`PF.$(I%>!OMEHVVKFKFU/
M+Q\".TY-R!FBX[.N'14TB,J8,Z+J;A>EMO0=5U,R0>F%<%\8<LL8L3D]-;2G
M+BRHR*S8>VF+DF),!7Q!L'$0OVWD<93RZ)@:G/F.\&EM+-JKARVX%/%NA5F2
M>W_EDJ)$<7MD@N@@JJ]?Y)@6%A\B\RBRSK6N/MSKB'':F3H<,WG@5N2\8,M-
M.JVV@N=MHB)31!UZ?K@9Q?DF_GV)G749/TJ/3HONRW@K3L(21''C5.WL<=;(
M-`U).B]<L9JJB_*_-Y,!E]NFK@<ET'^1QD*4\HBTTH]YES1I%WEO38J=/KD:
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MY53O(0GZB`402Z=<)K9:?)/.:TKDG8E:;=(%;->0._N=BV)*VK0:KH+K9`2[
MUZ+T]*8,69?(-XDP)PL1CH5ORXZZPF_W8'WO;#(W:J"_O>+>W[.NN%1(WR;R
M%V!2O'%BB]9-WB/(B.;1<J5-&5'U:[3[?K_\,(H;?Y,YX?%)[Y%"A3)/&XW(
M:^1%;<-6>ZX+;K1(X7J7U(HDFFGTP8^D<NY'.X[QH)BHU(L'7XD%LE$@8[TQ
M\(XN$FXB0!5S<J;OTUPKE['Y"Y132)[-B$1QBAL8#=Q/`'``JRQ307Q%3+MN
M,'_<15)-OJP(C7RY<-U]W(E1F2?XZ4V1.8$"`G(*`)5SP:F6WW".(2JOD)>&
MF!/_`,UYO&E1*RQCQ(\BXG1XM18%M4.TY'<??(V&WG>H]E1;_<3?K^BX$OX=
M:>;XS8MN=M'@N[835H5%O<DQSJ(*JJB?IK@<AP^5-9G01UAGR*ZN[Z(U>/1E
M5QEF,\ZXZ"?N:N;^T"`"DB(B?I@7%7SWG=Q<U--&"!$DN?DV[.0XTZXV3E3,
M;CD;"(8^AX'.F[[5^NF!T?-+WDT2_P".TU&Y%8*\.8T[(EM&[VECQE>`A$#;
MUZCHJ+@<-+^6^7M\=&S08?OH$?NV,%ELW!,F;$X+KQ.&0(TPX+2JSHI&JZ]-
M$Q!._P`VY-7VM^TY-&3[CD[5+7H8-@D5HX82$V[C$"5>HBA*FI+K^F(5[(YC
M\F=]NM<=KH,]NILYTAP6_=(KD"0`,_8Z@@KC9IW`U7:NNBX%EP7DE_><V?D2
MIJ#6O<?J+!JK0$V-NS1=)S:6NJ^H/%?+IY8&5US7E1<LLZVF&*+5$]`&6S+<
M::%YB4*&ZXID7<#02VM[15%)-%P%3R[D[W,)_&)TN*V[7I(EQ98LKMG1U%$;
M;;12T%V*9:2-%7R\-5T#F8GRESRNX_5\@MB@V4>XHIEF,2,R3"QI$,6S12-7
M'-[1HYZNB:+@6;_+_D.*D1DY<!1GVU=%ARU1I]PHTYMSN*;4=Q`%$-O5HMWJ
M3HOUQ"M$GG_.&./G)<<1P*NPM85Q:0XK;SH-07$%B24(G$5640M7^TJDG33Q
MP58UW.>56O)C_'OPDJ85HW7S([SC0$<8V1)'VTZO=QTG$)H?M4?^N!=\[Y-:
M\<M**8<@&N.3'7:^R56D,VY+S:K"=$M?!71[:CIXDF!QB\VYC8?'7(9D\8PV
M?'*R7'OH;\8'&3LVC4D'8JJ)-]@4+1-47>GTPB'ST6B:^3W%$$)SC549Z(B)
MJGN=.GZ:=,#MOF+;_P!KIB^A-#@*!.)J*+[QC0E_1,*H)W/.6U-]+XU-GL2%
M*SCQ8]X@-14;"5#=DI')#[C2.H;2"*KXH2:]<#KZOD5U%^/)-U:K&L+2OC2W
MG?8%O:>*+O44%11$W$@(A;>F[73`^86'+K*KO$Y6ME'M9KO$6Y3;J`VVTPDJ
MP8$R]":JTTCBEZ]=$%=?/":N+&ZY84FE;E<@9]HO)(K++\%UAPSB/17'.W+(
M&Q:U1P-0VIU%4UPC5&^0^9SH=A<1K*!&8:CW`N5CKC3DAA^`+JQ^VPC:.;A[
M.YWN&HJA:IY86IS=QSYR3Q6&7)0W<CKIE@\^$*.BM*W'8=;%I%W(J"3A=2\4
MP*ZGYSS.37P9,VU9D#>\5G6HL)&9%N/)AHVB$'CO$^XN\3U3Z:)@0Y_/.;-5
M-A.AW#,5BHXY2W(Q1BL*!NRD)'FR73TM'L\!T5/+`O\`_.^42N83FH\^#'C5
M5HD)^F?>!'GXJQQ-%:91I7R>=(]S9(YLT3PRH@<1O'[OG/!KN7;M3G[:GM'B
MA`+()%,BCD3(;41WT:;%0]5U%5QJXL/EOG5Q02IOXJU2._6US5@4(@8%OU25
M;4WW'MQ.(X(J`MM(BHO52\,AJY^-YKTCE/-@?MG)O:M!&+%<-LA;8*(PX"MH
M*(6S]S:GE_/!BD8Y[9_]QH,%NX&353+B?4R([@L,@"QXQ.`TRWU?(FW&]I.D
M6A*NB#X8U%QSN4U$^0.&R"<%E68UV[W"3?M0(@%NVIZB1--=$PKYQ;\ZY#/X
MSR"*O('29_#U-K%F`<9N0B2IG:?)4914:;,-%[9*1"GB67S3/!V#/,;^9S9R
MOBWL.,U66<:&M?*=;5Z9!=9`E>!D&=QFZ1JH&!H*;>J>.1<7WQ)-Y!;\;"\M
M[DK,IQO-ML(TRVVS[>2\UJ*M(BDIB(ZZ_3)JN#'EAVEYQ6\L+D0E!87:/5!(
MTHP?9QGP#]H41Y2``U)%+U:_PQ/ZL[JJG\VNK"IGQ7N1O>U$..SVI:/10?VS
M9O:D*?9':TV0H)=M2+9YEXIEWS-WKCL:[F5[/YV<)J_A10K[=*]VGD.HK\J$
MK*$#K;`L[B-W=W!=1S9HGAEG5K'US(&`P*GEC;KG%[AMIHWG3A21;9;15,R)
MHD011.JJJ]$PGD^?4_QA87'#*]+:S?C6BTT.NBI[86EB`T33SK;K)$O=5PV1
M!Q"T11333JN6IBRA_$KT:P:G?G73?:MG+<?^,P(:2(J19$?8B:;#!.B^(XI-
M8!\124XU8<9+DTUVD?86)6Q'&F52&P3B'MW(@D]M0=@*:^D<59J9;_%X6,VU
MG_EGH\RQF5D]IUMIM>P]5(B-[1+5#0_-"R)%QR[AR<A@P1"QD5MG5OC+K[2,
MC:NMO""MDJ@8J!B8&J$*IHN553<?&(W%;[&TNILO;'V1Y)HWW69O=[OOVR$4
M07A5$$$1-HCT1/'4BE_P*XMN8\DB6,N8W2SZ^JB2Y7::1+#VZ.]\4/\`H4MR
M">U/!5TR*Z!CXW;AWDZ?`NI\6MGNG*=HP)OVB2G`V$Z.H]Q$7[U;W;5+JJ9<
M(C0OBIB"Q5##NIK#]/4N4T22V+*'VW'`<[JZ@J;T[0I]-/+%(CI\-US0MR(%
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MJ&*FE@U#+ANQX$=N*TXZJ*9-M`@#N5$%%7:G7ID1R]1\44E5^/1B?/<"KBS(
M,$'7`)&X\Y14P3T(OHV#LU\-//+5:F?AWCL<JY8<^SAK!ALUKWMI2M>\B1M>
MTW*VBF_:A*FX=JZ+IK@QT'+N(5_**9*B<\_'C(\S(W131MS?'<1UO0E$M$0Q
M1<BJRT^-*RWCV#%K9V,T;&,,-Q7'@'MM(ZCI(T(`(BID([ETU5$TP,T^-:$>
M2N7[<B:T[(<;D3(#<@PA/R&A0`?>83TD>@IKY+IU3+4B`W\.<4;K;*K&18+6
M6+3C`P2EN$S%:>-#<"(!:HTA$GZZ)T31,4BS>X#6'8S;)J=.C3IQ1">?8?V+
MK!`FVD1-JCM47"WB2*A8J1`#X?X>V]`=C>\B+"92,8QI;K(R6$=)[MRA!11T
M>XX2]?JJ>'3%6.EN*"%;+!]R;H#7R6YC(,FH"KK/4.XB?<*+UVKD54<DX6S.
ML9'(8)&/(DK7JV*IO.-QB;=W$@O"WXIO+7=XIY9:CD>._&EM(B2JF\]Y$X_*
MB+%EU[EJ<]72U!1)HNTT3*#L^[=J6NFF*D=?=?'/&[BRB6<OW03HK*12?C27
MHZOQQ+<C,GM$'=#=UT+]?KD5A'^,^*QKB;:1PDLNSR<<?BA)>&(CSP*VX^$9
M"[0ND*_>@ZY:09^-.+LL1V&P?%N-5.4;*=]SI!=TW!KK]WI3U>/3(36#/Q7P
MYFSAV+3+[<B&S'C;0DO"T^$,4&/[EH20'U:1$VJ:+EI&^'\<<6B)7HRP[I5O
M3)$1#><)$<L=WN=VJ^I#[A=%\->F*)''^$4-`,(:[W`-U\<XD5MV2\Z`LN&)
M[=ID2+MV(@?Z4Z)TR*OUT7`I(/#Z.%^8]NVXB7SAO6>YUPNXXX';(AU7T:@B
M)Z=,J(2?&G#%8".Y`[T8*Q*1&'7'#!8`DA(THD2ZZ$*+N^[]<4BQXWQ6EXY"
M6'5-&VT1;W#==<?=)43:FYUXC-=HIHB:]$R*HD^'OCU`,/QQ]MQF3&4%D2-J
M,32WOLB/<T%LBZ[4Z)Y9:D6$WX]XG,&>,F&1C:,QHTY.\ZG<:A+K'%="Z;%^
MGCYXI&YO@W&&[@K<(FDPWTEFG<<[*RD#M^X5G=VN[LZ;]NN*1#9^+N#,S3FM
MUNV01230D=>T!9HJ,E&QW[01U"7<@HB:]?'%(V%\<<+6-[8JX2C_`(Y*;MDX
MZJ>P1=R,=2\$7KKX_KBJL9'&:*11+0R(HOU!-(R45TB-%`>J:D2J>J*FN[77
M7KKA-:H_#N.,U4RJ]HCT*Q14L`D$;Y2-PH"]YQU3,_0*#U7HF0B1_CM'W)KG
MLF5.Q9"-/U!%1YEH2`&S1>BB(F2:?K@BFC?%O`HU.Y3,5#05[CP25:0G-PNM
M?VC!Q2[@*W_3M)-/++1<4/&Z2@B'#IXHPXKCIR#:;551775U,UW*JZDOCD,0
M@X!Q`*Y*X*X!B#**P;%"<W!+,E(GVW-V\#)27515/%?KBJDQ>(\<BS8,V/`;
M:E5K3L>"Z.J*VT^J$Z*==%WDFI*O55Q4BJY?PYSD'(..3'":6!3O2G93)$X+
MKGN(Q,#VR;TT45/5>N#6V;\:<#G-M-RZ2*ZVS%2"V"BJ"D82W"UHBHBH)=4U
M\%ZY:-LOX\X3,&P"5317@M$:&P$PW(][<4%I2U_J!!30DZ],4C8QP3B$<&`8
MJH[0QHKL!A`#3;%?75UI-/Z37J7U7%(VP>'\9@38LZ'6L1Y<*,,&*^`(AMQ1
M74617_2GE],E4L.&\4L;F-=SJF+)MX:(D6<XT)/`B+J.AJFOI7JGTP-9<,XV
M+<16:V.+U:3[U8X0:]AZ3JKI@OBF]5]7UPBJX!\<U'&..1*]Z/&D6+<1(4V:
M#:[7F]54AVN*>T#5=2'P5<JK&!\?<'KXK<2#1PHT9J2,UMIID!$9(?8\FB?>
M/]*^7EBI'K_`.%2$5'J:*>KST@M6TZNR=.^1:>/=VIOU^[SR$2/\0XM^:;O?
MQ,1+EH$:;L>RWWQ`4VH*'IKT'HGZ=,*LI4.)+:%J2T#[8F#@BX*$B&V2$!(B
MZ]1)$5%P(TFAI9,29$D0F78MBJE/9,!4'U44%5=33UZB")U\DP([_$.+2$EH
M_5174GLMQ9J&T)=YAG^VTYJGJ`/)%\,";,K*Z97G72XS4B`X':<BN@)M$'^E
M1)%14P(3O$.+/5#E.[51':EY=SL(V0)HRZ>HA5%U+HG5>N!81($*'#;AQ&&X
M\1D4;:CM"(-B"=-H@*(B)^F!60>%<0KR=*#2P8Q/B;;RM1VAW@ZNK@%H/437
MQ3PQ4@SPWB+%8-2S30FZP'4D!!&.TC*/"NY'$;0=N]%3Q\<+&Q>)\767+FE4
MPUF3VU:G2>PUW'FU310=+;J8JGBBX2-O^/4.Z*7L(^Z$V3$->T&K+1CM)MOI
MZ!(>BHG3!&H.*<8`&@"IB"##)QF11AM$!AW^XT*;>@'KZA3HN*L%XCQ96G6O
MQ$/M/-!&>;[#>TV&EU;:)-NB@"IZ17HF*-J<<H$LFK3\=%_)LM]EF=V6^^#:
M)IL%S;O0=.FB+@:X?%>,0IQ3X=5#C3C(W"E-,-`ZIN?>6\10M2\_K@9V''./
MV3POV-;%F/@V3(NR&6W31L_N!",57:OFF!NBT]3$E.2XL-B/*>`&WGVFP`S!
MM-&Q(A1%413H*>6!I_QKCOO2G?C(GOB=1\I78;[JNB.T7-^W=N0>B%XX$A^M
MKGY#,E^,T[(CH0QWS`2-M#30T`E34=R>.GCA/%#:XGQ=EHV6:B$VTXVK#C8Q
MVA$FB7<39(@Z**EU4?#7!&\:*D26S,&OC),CM]F/)1EONMM::;`/;N$=/).F
M%;X5?!@QTC0F&XL<55199`6P15755011$ZK@:$H*(9ASDKHJ37%W.2D9;[I$
MJ;=5/;N5=O3QP-0<7XTVR;#=5#!AP.TXR,=I`)M"W[%';HH[NNGUQ4B0-/4C
M.&>D-A)P!V@EHT'=1O\`T(YIN0?TUPJ9@,!@>&8@"F2H(BFI$JZ(B)XJJX%:
MUR3C[T?W+-G$<C]Q&>\+[9!W%35`W(6F[3RQ$HYR2B&L&S2QB+7FNQJ8K[:,
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M([L-IZVB@5@+9PM71T=%Y=&B$D].CB]`U7U>6(=ST.9\7.T=JALXZV+"&KL;
M>FY.RFKJ?15;3[T1=1\\0[D-KY*X._#<F1KR$_';-MI76W4,>X\*FV'HU55(
M15>GDF(52<2^3'+BLH[*<]6PF+"'/F3&>\XKJ-PWE;1Z/JFTF4$=3(M--4TR
MPJ_K_D/A5B$MR%=1'VX+`2I;@N)M;8<34'5)=$45T\4_AXXAW*ODOR57Q:"9
M84#\>PF5\J''FQ'%,2:25(!E=XZ(8EM/<.OCB)W+T.9<:-J6Z%@T3<"6-=,5
M-RJU+(Q!&2337>I&*?SR+5UA7&\[^0FN*V%.P499+,V2V-F^BZ##B.FC`R#_
M`$[[H#_U^F&?-9\OY=7<?KGS??`)JQY#T-DA<<W+';4U(A:0B[8KIN+P37QP
MNN2O/E=*SXU8O%)C_)7ZB/:)!V.N,BKZ`GKV:J`$9*(*1)KE-6=E\BP::;9_
MD)`2F(\NM@-0X;+Q2&'IXII[A=%%1)2W"H^73QR(G,<SKV)MU[ZQ8./"EQXD
M>*PR][EMU]D3%EP%15<=<4MPHV/V_P`\L'I_)O#`CPY"V"*,\WVHC8M/$\;L
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MC[\RK.#%>BP?\@DT=@T\P1O/)'CO%JP@]4576=--%Z94=$Q\D\9>A0I,8WY`
MS6G'VV6F'">;;9>2.\3K6F\.V\6P^G1<1K&F!\EU\H[("KYK9P;5RF9!&5,I
M#[0=PE;05T0=$)=25.G\=,@U/_+_``YJ(U+`Y4AAVO\`RR*Q&=<VPQ<5HW2T
M3T]LD7>B^&$W4+Y!^1TK:IW\&Z3D]EZN1Z0#"O1VVYTAL1!PE5$$G&CW#].B
MKXIE1-#G]56RIS<^7(EJ=TM1#8;ADA-/K'!X8Z*.[N(J:DCBZ:ZZ>61<;6_E
M/C+M=&G-))/W+<MWV:,DDEL*XMDM76E5-O9)=JIXJOAKEBNBJ[F+:4T>VA(;
ML26R,F,FQ0,VS'<&@'M5%)/#7(/FT;Y;G2YG'+7V$QBIM*^TD/4[;`/RC.$X
MTC9@0+X(!%JFJ)KA-7<KY%I&;%NQ*S=_$%1I;C$2.FQQIUX`;?1XE0D/UH';
M\.NJJF$==36J6<19"1GXFAFV3,D$!Q%!=%7TJ0J*^(D*JBIA<<]PJ]M[+D?,
M(<Z0+T:GL6XD`!;0%%LXS3Z[R3[EW.Z:_I@QJG_*_&XMB]7@CLF2!RH[/:V*
M+LJ&T3SL8=3W(>T51"(4'5--=<L2H5-\L^]>J$F53L&+/HBOY<UPVU;8:#9N
M3H6Y11"U5=-?#IB+6S_O/Q9&WU)B6KS#L)OV[;8.N&-B:MQC'MF0Z$:;5%5W
M"OBF(9KM*V<LZOCS%CO1%?!#6-)%`>;U_I<%%+0D_CD5PM=\ASG_`)/*F=[/
M^.SVI$6F>%45P["M)%EH6G])"1('_P!K+">:WF?)5+&MEKO;R7D&R:I3E-`*
MMC/>:1X&EU)"TV$FI:::],*@QOERE?8<D)7S66$E%7QGI`-M-OS&WG&39;(G
M-/1V")2+1-N6,M#OS5QH*MJ>$:2X2LO29,1$`7F6H[RL.+M(D1Q>X*[4;5=R
M=4Q%K=)^7Z=J4\TW66#\>-/C5K\QML-B/36@=C*(D:.$+G=`>@^E5ZZ8A1?E
MRI2*JN07V;09<J"=4\;(.BY"!''E5S>K6W88*BH7521,0J+)^;:9N.[*9J;&
M1$CP(EK*?1MMM&HDLR;W&+C@GN:4"W"B:_37$*O>-\ML+;DO(ZIZN]M%I'VF
M&97<`^[W6`>0E%%U3<+B*G3^/7(CSD?/&:>7+BL5TFS<K(@V%JD;MIV(Q*2"
M7K(=YDC1D@#UT3^&!JH_D:+><A>J:NMER(T=&3>MT[214;E1DDL&FI]Q=XEI
MT'HOCA6WD7*+*!RJ@HHT'O,70RU?F=P0)E(S:%Z1+Q7UZY4<CP+Y4]OQ2J_R
M892N%3R;0KE_M*D@83B`_P"@"W(2;QTU%-V!V7$N;-\AF3X90'X,B"++A=S0
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M`[V':T"4T;(147$+3<A?3IA5I\O6%E6_'%Y8UDMR#/B,(['DLJB&)(X/^I"3
M1473PR)O@N+R^C\=H4G/BY*V+'89;145UY^0X+#0;ET34W#355_CE5SSOR9+
MCG/@RJ=&+BMD1VI33DH!B"S+$B9D^Y4==A=M0VHVI[^FGGB)4!OYD?F0:V15
M\>>EN6-9,M$;.2TRC8P'D9>;(B1?-=173K]$\BN[H+AFYI(%NP)`Q81FI30'
M]PB\"&B%IYINR:/FMS\F.Q/DZ`VEBRG&VY:\?GPM4[GO9`(X$I?]C;J#'_B2
MY6;U7_*?E`:.PL8C=84S\1[#WJ=X6G"_).*TS[<"1>YM+[^J?IKIB-5&E?*\
MJ))O._0N#744I*]Z:DALE=E.BRL=MMI!W_N+(1%7^G]<3$ZLB^4YHH,-RB?:
MN'9,B/&8-'T8>;C,B\<AISL]TF_6(?VON_3KCH=4*Q^9;")"E2UXQ(`:^JC7
M-@Q(>%A]IIYUQIUKM$*KW&U9)4\$+ZICH=4POE9]F7-KIE0K%HU+A1(+`NJ\
M+R6#1O,N&K;:D&T&3WB@EX=-<=%ZH[_RQ?B#;3?%G0GK7SK%Z/*D>W01KWA;
M-!W-J1"Z)H;9;4U\T3'1.JTXCS2WO^638_MF6J,:NML89;R61K8`X?K';M_]
MWIHB]-//7H5?<RM9M1Q&YMH`-NS*^%(E,`ZJH"DRV1^K1%7^G(KY<[S[DM+=
MV%[(B_D&0XU5VEC#243;+2$Z\+SD<"`D[A!UVZ(BZ::Y>B378C\C3'^1%!KZ
M9^;61[!*N;-:1Q2:=[8F3RIL[?:!3$2]>[STR=$NNY1=<-&`P*CET29,XM;1
M(49F9+?AOMQXDGHRZX;9"+;FBIZ25=%ZX37QR-\>\N?G.'+X^91)-EQ^<X,E
MZ$6@5R$$E.TTJ-CM'1!$=?3TUR]$ZK:#PWE=3<,6,>B;EUT.\N)`TPNL-ZQ[
M$01B2TA+VD5O:2*"Z*B$JY%=M\6TMI1\#JZBTC##FQ$=%R.!BZ(H3QF.T@Z:
M;23!CCJWX^O@Y/7S)=.R<"/R.YLW-QLGMBSXZ@R:!_J(UZCY::X,:H7QGREC
MAW$PB`U7<EIG)$&66\3%*N>Z8OB)AXJVV0.-IY$.#4GD/QS=G_E%+7P69%3R
M1F"U7SE<$%KO9M`QM(%3<J-HWW6U#^I?+QP=2UX1S-KDEK>U<2/))JXKK.%#
M??0$G-1J_P!D\AF@EVG!)>X!$BIK@RM-QP3E<J8Q8?X[72(L^!(K[/CS<YV(
MS&[\DG]_=:!$?1S?^^FU-5\,4GFQF\`YLT]+K8L&%+KW[ZMNV+$I"M.`S%["
M'&5L@,E5M&%%M=WVK]<$UWGR%67UEQPXU$##D])$9U&Y"B.K;3PFYVC(7!;=
MVC^V:BNTNN#7`5'`_D&FF!<1H$&5(CV=J_\`BGYSA`]&MA;7?[@VB)'6B:T7
M<*[D5?#"=5S%XIS:OO)!1X%-*JKAJO6:VXI@W7O0105&.QVR1YM$1%:34-"Z
MX7JUU_`^2L#554AJ.Y"H+>5<1+87?WY`/=\@9-M0U`R65M</<J:#YZZ(&BCX
M%S*CIN#OQ(\)^VXR$J/85Q/DVPZ$L=JNM/HT7K;T3Q#JBDF!&JOC?F,.#0-/
M-0E=JZZ]B24;?/:KEFYO80-6D]*:>KZ?K@RJOD_"K:HXJ#UJ$,(<3B<3C[[@
MO.(@S0E-$+JJ#6HLBH[NXOAXJ.FN7#:D5\2WY73\DKX+4*1:SI-=/D7#-@DR
M(ZL=YM.TKC4=D0<!F,GI$5\=57`OZ>OJ;OY1L;.FE*[4QT;/D$06U1I;J(2L
MQU0R0=3!I2[FW7[07&]#.KZ!3E;E6M+;-L-3]3[K<4B-I$WKLVD:"2^C37IX
MY%<7;_')\C:Y45^(D_<-K"KP8DO"V,-MM>P+HH@)N1\S<7TEU7],,XKUX1\B
MJW73G)-=)N%HG>/W".F\C)(J[FY;)HWNW*7]P%'K]>F%5DGXHYN'')U-#EUQ
MA<4<"JL#?5\>S(KFE:%QE1$M[;@KX%IM7`N+GX\Y/+FW\Z-(A"_83*2=`!PG
M=FZH4%<!Y4'44<5OTJ.N!E+^/.3'?65\Q+AC-*WAW%<R?=[1>W@>Q>9?Z:BA
M@1*!#NT7RPK9`^/+N-R:LORD15=&SL+6TCCW-NZ;$"(VVPNWKL%H5(B1-RZ]
M,&.?G?#W,Y7%X]!^3@%&"KDPC:<21VFY;TDW@D@([=_H-`T/[=-1UPD7%Q\;
M<EL6N3(LJ$#M^E-V^CVULJP@)W=TUT/;Z-/#SPK=1UL&Y^1[/D5;[AJMC`+4
M]AYAQEEZXC;V!?;1P1(U:CDH*0]%]/FF4=AQ*5R"32,O7[+3-FI.(Z+"&`*"
M.$C9;'-3!2;T515>BY!QS'QG="[!5^;&)J/R"QNGT`7$4F+!MYM&A5?ZP]PO
M5>G3"-;'Q9<OU,&HM;%AV-1UTVKII3+9B\8S&/:@[)%5VHK;/3:"Z$O7IX8$
M[_MHY.;XR5Q*9.140W*VW9CMDC$Z&8"B,&CA$6U'&@-=?HJ>"X&+?QC-C\,J
MJ!BS1Z5`LHE@_/D@I$ZW#?%QMO0214VM-`T*Z^"85C'^.+AFVCR$L8Y0XO(Y
M/(&F^R:.J$MIT#8(M^W42?70M/!/#"*^3\1W,BLB05L8@/19$R5'LFV76Y<5
MZ7-*5W(SH.(J:":@0%Z2Z*OTRTB>_P#'/(4ES"BW$<8,F\2Z6&[',A=`V4;=
MCR-K@[T0D$PTT35/4BXI$"K^'K2%4O5Y6[#F^AET#;B1B%$23(-X'E'N?T">
MU13QR*SL/B6Z=CSH4.\98@VJ5KU@VY%)TTEUHLAO9+NAM!X8X[A)%T7P7+B;
MBT?^.9SMQ[_\D`M_Y"WR%&>PNNUN(D3V^[?XJB;M^G\L#CN2\0LJ>1`A*\;@
M$5O).Q;JY,QHDM9*&<,AB/`\'I5==Q;2_BF7,1]6X@MC_C<!+&*W"F`R(.16
M05ML$'T@@MJ1[/0B>C<NWPUS,7'(4/Q98515.MR#[=-%LH405B[%5NP,2!35
M'.JMJ'71/5^F#7L3XLGQ(\`&;=HW(%"-!H_#%YIT1=!Q7'&R<T43$-A!]%7K
MA'2<$XFG%J4JP7T=;*0[(;:;$FV(XNKKV([9FX0-!_2.Y?%<+BI:X-R6%8<C
MEU=^U%7D4E)1J4+N''(6`CIVB[PHJ[6T74A\<&L*GXVF5MA-%B]>6@FF_(.K
M)AM74?D@HNK[I?6K9&2N;-/N\].F73$6%\2DW&JHLRX65'A4TCCTT$CBW[F$
M^@H"(J$7:,$!/4FNOZ9%;`^,[IVIC0++D[LXX4V#*BOE%9;T;KW4=`#$%1#<
M-11#<5?#RP=7<SV9#\%]F,_[:0ZV0-2-N_MD2:(>U537;XX'&S_BNN=HZ.%"
MD!7V5')CS&KAF,WWW'F$5#(TUZ]_<7<Z]=5RFN7?J.5KSR=.B0GPDE9#(8;D
MU[#L(@;;".CZ31=%0564+^E3'73KAETR_%C:<=;K&;B3'G1+5^ZK;5H&T<8?
MD.N.*.PD(##1\P5%\4R--DOXYLWI<&RC\HG1;IE@XEA8`W'+W;#CG=4%:(%;
M:4"7]M03T_KA"1\7,NNV!I:OC[^V@W"HH`2@=>+8@VA%JI(?8%25>OCA6B5\
M3(4Y^T@7LNNN2LY%G&G,MLEVDEMMM/1E;,2!QHA9!?4FNJ:X&RT^*6+!JY!Z
MXED5U5QZF0\:-FX@QS,^]N4>IFKI:^7T3I@7=)Q%*J_MK8)[KPW'8.1#,6T;
M%]AD6.Z)(F_U`VGIUTP(M]P1NRMI%G%LGZYZPA_C;4&1`QD1D4E#[T78X'<-
M!-/)?#"1OXQPF!QRQM)4%X^Q8I%`(:B*-L!"82.V+:HFY?0*:[E7"MM_Q4+:
MWI[4)KT*73&\K:LHV2.-R00'&S1P2Z+M3JG7%1S\;X=HPKZNNDS),N#65DVH
M5ASMIWF)Y"3A.*(HJ&/;':HZ85?<2XI(H&7`DW4^[<(1;:>GF!*VTWKM`4;%
ML=>OJ-44B\UP$CAE=*OK2UE.N/!;UP54N"6U&5C@3A=-$0]R]\T7U>>!2A\4
MQEXS.X],OK2="E--QF"D.MF<>.T:&+;?H1"7THBF:$6GGA(FQ/CR)#Y&_<1K
M6P:CRWTFRZ<'12$Y+04%7E!!WINVHI"A;57JJ86/)?QCQR0SREO5YG_+41+(
MVCVJ"]I&U5GIZ-VFXO\`4OC@B&S\35831FNVL]^1[V!9&IDSM*17-=EI=HMB
MB"0="%.GTTP1(;^+ZEN5&EM3YK<J+:RKAIX#!"[DY%&0ROH_M&B^'C^N!<\L
MXQ#Y-Q^9137GF(DX4;?..HBYM0D+02)#1-=/IA(J+'XVAVS+C-U;V%BT3/99
M`W&FD9)'`=%]OLMM_O`;0J)KKIBDQJD?%M9*-J7)LY[EPU+8FK;H;0OD49HV
M6P41;[2`C;IIH@>*J7CUPK"J^)**L1@6)\\QC1)T!E'70/1BQ=[KR:J&JJAH
MFU5_\<#I:6BCT]!"I(CKJQH$<(L=XU$G4!L=@*JZ(BDB)],&Y5++^-:.9P@^
M'R'Y1USJ[G)2F/NE)7_<;^[M^_N==VFN3?:9ODX[D7#.:/<JD2H(3R)6X[-;
M;M3HB-"C#2"CDIF0PXXA]Q2(NTFA?HNN:K.\78)\;TCU9>0;%Q^6/(W0E6BJ
M>S22#;8=R/L02:T5D2'1>BIF;K41W_BFGD5D6,_:VSEA"D+*BWBS"_(`:AVB
M1'M--A-^E0VZ+X^/7%U)C9-^*^.S(]@P[(F]NSK6JB6O?526.T9.(6\D(NX1
M.&I&JKKKENDQ[:_%O&K-R>_)=EC(GK"/W#3ZM.,.UPD$=Z.8(BMF*&6J^>N"
M-K?QK0BZV\4B:Z^,&56F\[()PW&II";YN$2*I.*0)H7EY)BZ3$29\6U@0I`5
M4Z;"ENU3-,#S<IQM$:C:HPZ7;1%5UI"70LN;$WC75/U4>73.54Y5E1Y$<HLI
M3Z$Z!AVS4M-.I(J^&1<R.7_[2\76!*A.O3GVIE8W2OF[)(W%AM&1@.Y>J$BF
MO7Z85+'XWXX'(4O6UE!*-6G),<)+HQGWF!0&WWV$5&S<$13U*G7SR=4F.J3*
MI@,!@,!@,!@,!@>&8@"F:H(BFJDJZ(B?QP/475-<"';6T"IA.3I[J,QFU$2-
M4554C)``11-54B(D%$3Q7";JI+GO&PX\=^\^;$`'#8(7F76W^\V2B3*,$*.*
MYN%404'K@J37<PX]84KUU'EBE=%0UENNH32L]L$,T=`T$@415%5%3!4.R^1^
M'5M?"L9M@+<*P9"5&>0'#'VYH*B\>P2[;?K3U'HF#-=%WVD:[RF*,[=_<U3;
MMTUW:^&FF%4(<]XR=2];C*5:QIP60E=MW8^X:[0&-Z=7]Q+H/;1=5\,1-T?Y
M]Q9FKC6:RU<CS'#9C`TVXX^;C2$KH(P`J[N:0"WHH^G1=<0S5H%K7R:D;..X
M,FO=8]RVZU^X+C*AOW"B:[M1\$PK5QRTJ[>B@VM5_P#@V>R$F+Z.WJVXFX54
M-$VKUP+$0$?!$35=5T33JN![@,!@4-ES*N@W05"1Y4R5JQ[I8C*O!&&49`R;
MZIU$2("ZHBZ(FJ],"^1<!@,!@5_(+J/1TDZXDMN.QJ]AR2^VR.]Q0:%2+8.J
M:KHGUP,'[T0X_P#F6(DB8"QQE-0XX(<AQ#%"0`!51%/1?#7`L6SWMB>U1W(B
M[2Z*FJ>"_K@>F8@*D2H@HBJI*NB(B=>JX%3Q7E5-RFE9N:9[OP'S=;;<TT7<
MRX31HJ>7J!?Y8$YZQB-2VX9NBDM\''6(^J;S!K3>HI_MWC_UP,*FQ<G5L:8]
M$=KW9`H2PY.T7FU7^DT%2'=_!<"'6\FB3[NZJ`:<:?I"8&0XYM0#22UW0(%1
M5Z(G1==,"T>?!J.;ZHI``J>@(I*J(FOI1-55?II@4G&^8QKN=/@>QEUTZN[1
M/QIK8@2M/H2M.`H$8J);"3QU14ZI@7Q&(_<J)KT37IUP,4>:7^L?';XIX_3^
M.!S+7.3_`"E35RJF1%G6T2;,!HC:+M^Q(!)LU`E3<?=%1TZ?7`L^+\BC7_&J
MZ_:;*-'L8X21:=5-P"XFNA*G35,"Q&5'(7"%T%1G5'50D5!5$U7=].GUP(4O
MDE'$2$3\Y@!LG48@%W!5'G%12T!47U=!7PP(MURJ-4WM/52&5V6Z2E]XIB+;
M/M&NZ6_=_J3`M7I\-E&NZ^VWWU06-YB.\E\$#5?4J_I@;''VFU!'#$%<7:"$
MJ(I%XZ)KXK@:';2N:;%QV4RVV1*V)DX`BIIXBBJOC^F!E^0A)+&&LAI)A#O&
M,ICW5!/ZD#7=I^NF(*=.90CYFSQAD0?-V$_,.4VZ!(V4=UMHF3!-50OW47K@
M1;[G)0N0AQVLA!96_MAFO1ED-QU1A7D:]&]"W.::GM73HGC@7C=[2NM./-SX
MQLLFC3KHO-J(.*NB`2HNB$NO@N(-B6=<L))WNF?9+U25W![6FNW[]=OCT\<#
M0O(J!.PJV47249-1E[S>CC@EM(`Z^HD+HJ)YY85L&ZJ2FNPAFL+,8%3>C=T.
MX`IHJD0:[D1-4UUR0:%Y3QQ(*SUM(GL1<[)2N^WVT<_T;]=-WZ8'I\EX\#K#
M1641')2-E$!7VT)U'5VMJVF[4D->@Z>.(52\I^0ZNJI9\^L=BVLFM<8;F0VY
M("3:/OBRI'M1Q4V[O-.NFF6)715MO5VC3CU;,9FLM.$RXY'<%T1<!=#!5!51
M"'S3(K"VO*>G8%^UFL063+8#DAP6A4M%+1%)4UZ(JX$29S+BD,@"5<0F"-&B
M!')#0JHOZ]I4U+P<T]*^>6:SW8J^<?($#C3#``<:1:/28C*5SCZ-/=J7(%CN
MB*(1+MW:HFG71>N1IT,RWK8<F+%E2FF)$TU;ALN&@F\8IN46Q7J2HG71,"`]
MRVA<KUDP[&&[W$D)%,GQ1HW(PD3HJ::]&]OK_P!*98E<Y(^1+%B0U'6'%D&Y
MQM^_1Z/((V2>84$5D#V=6BWHHN?^&15ZWR1UW@+7)=(\9YZM"P093JMQFS-A
M'41U[15%M%712T\,!_G7%XWMXUC;08]@X,='(Z/BNCDH45I!UT7:XOV*J=<L
M2O;3GO$ZP;!9=BT)UC+LB:T*J1@#"(KGI%%U4=R:HGAJF(4:Y[Q4XD"4=@TR
MW9`V<7NJHJJ.J@ANU3TZDNU-VFJ],0J1&Y?QN5;G3Q[!ARS;5P3C"6I;F=.Z
M*+IM4F]R;D1=4\\BXI:_Y`A6O.PX_6.QY<'\:[-=DM$2N"ZU(%G9X;%`MRZ$
MGFBXU-:G?DBLKN:VM#>R8E=&C#`_&ON.*)O.34<U$]WI'0FT05_7$*Z$N5\?
M"X"F.:V-FX6P(ZZHI&@=S8A:;-^SU;===/+$,UKY5RFKX_7D_-E-1WG&W5B`
M[N7>;8*?V@A'M3^I=.B9<-4]!\CT[W&*"TO)+%?,N8<>63(J:M@LA$1-3T78
M"F6T2-4UQ"I[/R)PIZX"F:MXQ6CC[D4(J'ZE?9UWM>&B&FGVJNJ^6(5L8YWQ
M)^<_!;LV%DQP==<%541V1UT?(#)$`T:7[]JKM\\0JOL>>U;\&._36,,2.QBP
M'5F@^(JKZH7:`4$2[KC:ZMJOIQ#N957RAQ.PKY,\'G&H\:8]`1'&7>XX['(A
M/MMB*F:?MDO1.B)UTQ#N1.;?)]'3\0E6]=.CR91U[MC5BJ./-.@`^DS[**H@
M1>G<2IURYB;JVY#?O5W#ORZR8L&0K;!>XEBX48#>(!]0M>O1=VB?KIDBL%^1
M>'#<?ABL@_))+2O-C:YZ91!O%HBV[1(A7TZKU\L0J+5_*7%K"L<L1*0RR,Q^
M`TT<=Y7GG8Q$A]IH04SZ-D2Z)T3QTQ"K@N54I<8<Y+&?]Y4MQSEH]'$G%)ML
M5(MHBFY23:J:::ZY%<6U\Q58V\:3/+V?'I=$Q<,DXP][@"=?5H^YM0OV@'15
M+;M3QUTRQEUDSG7&(5DS729B`^^;+0N;#5A'9*:L-F^@]H#=3[!(M5Z?5,1:
MOT77(I@,"GYC*?B<4N);#ZQGXT*2\S(';J!MM$0DF]%'HJ>>$U\=F\HY'%J.
M-MSN7^S9Y%5'9MW\QQN.R,_M,J$8"::4.V&I.=LNI]4URHV6O*>6!+O'&^4G
M^4JSI'*NH;!IMJ8Y-9;[S79,.^K;Q*6T==1\?+*,V>8S[+GK-1%Y*^PS:R[J
MK<0W6Q>9=8#6-VHJ"J,]HQT`B+<ZG54T7)1C9\KYL?QU;6+\^34VW&&FJ><\
MBB@OV0RVQ>D#O%4(58VD*_\`V14\L#*WN;VJLN0DWR><\SQ^]I6XC3SC1`;-
MEV/<M/;0%3;_`'#V)_3Y8&A.87TIZ\<=Y*4"Z@,W8SZ``=5UH&!=6&Z*'^VR
MC8@!"ZFJ'NTZKC!6\DL[-WC5Y`DW4V?'E<7J+I[>\N\'BDH,E6U;0=H$VB*8
M^&4?4N;W3L/@L2=32GCKCD01F6;1*X\%<X^`OR!-44ET;7J?DFI>61=<!RB9
MWZ.R9.UD3>-1.34R4=B4@R(A<=9.4TCZ+JZ#!J6TE5=OU].&==[\L1>/.<."
M/;SI%>`N(5=;,FN^/+::,F7#=+<FA:**J?1==//#6^+C(MAS._X(I?BHEG!B
M>[&?,CO+#:L%8C`,:0#9MNJX'5=R;M%,$T51R)&]ZV%SX8J*)Z<W2<CDT+!1
MZY026<MEME`&.H$`J2/]!(1]0[E3]<N+5G\D6[EKP&RXY&4F+V/$KI%_5Q0-
M7&H+[K?NA9730]&A<'TZ],)OBH7Y=A(E,3VICMIP;CW)*^5"G*":#%*&X#^A
M`(]QF*^Z'J1/2FJ?TX:8TJG6<LA<TL0-GB\FSY"Y&?(#T`9HL>W?4--1&1[9
MS8NG7<G^K&I'=?&=;/J?B>OBV39L2`B/NFPXBH;0/&X\VV0^**#9B*ID-?.*
M20^/%:2%<NSX,%.*1UX^Y&60TOY5M31X=&]%60.C6P#\4UZ>.7!ME7M^UR:H
M=L2L(]U#GTC=PB#*<`VY$81E=D&D1@(W<+U:[B4]?M1$QC.^*7Q%^Q@VG&+1
M^3:.F]9<@C68OG*>%8C2O.1Q5HM1T10#MKIJNO15QK6.]YE>,77Q)<W%&Z^H
MRZJ0]7N,BZU([G;+M[11$=$]Z::::ZY,77`\H@O0"K83LFY:HK.L5V+/C-RI
M\@+AXT(E54+>TXH;>UN38B[O#-,MES7W3-USF74QIAW:UE.K<@6S1UY`4DGB
MSHO9-_M+]HKT)>F0:F*MFT6B;B/7;G'[.\=20TXS*@"TPY7F#C8"BHZ#"O;=
M5-=-ZKMRC?%A62\HG,6*W#5O`?L%:5B.Y[216&P81D.7JHDV+:`B`/[G<3^>
M!55M?RV!3Q?P[%HMG/X<V<X7%D=QR:Q(:W-[WET;DJQW1!.B^'Z9!96JL/5K
M%A15%Y'XJ_8BY?078SKCFBQ";$FH+RJXK0/;%>VIZB]2;M,HK[VIF#0R*J?`
MN[:K?XX^SQDY##KL@)RF^I#(!E/VG%;5I&E/P!-J]=4P/H'+H\^3\*S(\>-)
M*Q.F`&HC0.#)1]&A000!]:&A^69:<7;4MB=G>6[$"Q*='NJ!ZK=$9/1I&XPS
M2:#[=NU'4=T3^.:9?2OD(Y\FG:I*]'`?NWPA.3&VC="/'/J^ZYL4=J=M%!-2
M3J29!P4NHOZ5>>\<9B/2Z^]K';.K>@1W&H[4\V29>BM;2<VFXH`X/J\57*-M
M7Q"KJ.5<0GM4SQ-R:B4U825$WG&YSPQSUD$9$;:JC;G\^GBN2Z*:FK9K-/20
M>2\?L;2O<I&(D5EC5'8=@S),G.ZJF!,$X/;47M>B#X_4++E$/D(\@Y#.CPI3
M]>5C3/RV(W;-R7$8AN-OBP+OH>[3Q`1"J>K3`[?@_L:7B"(V,P&&BD28\&:3
M13$;,R<1L6@41!.O[;7]*:)AK%+66SE/:<FY4VW82J.3$CR_QCVAS5EMJ:/)
M'9<)#%L&=GH5=-==N!T7/:$^3<,DM0T5)X@W/J5)-"&7'5'V-47334AVK^BK
M@<MQ7B7(6^7/3;6(+=38]KDC[**)]BW-HHQQ!Z>I`!4/=_J_CA-0.#\?Y!7G
MP)955*9&LKKIB=O$=62?>;-@"]2_>+:[=,(M(U#<K_\`0^%0.USOYC\$Y$_&
MJ@]WO]I0$--=-=VGGC5Q0R>&WT:5:#54IMUKC/'I4N"*`V$WV1N+/81-VA.J
MVH;MWWZ:*JXPUMD<0GI:1KF+0.G3#R-F?&I5;9%YA@X!1WWD9,D%L7)"H:AK
MY;M,:8ZKY)HSGWG%IS]0=U4U[\O\E$;`'EVR(RM-JK)J*.#O\?IXXPUP#OQW
MR.+#KJVRI9EO4OUIP6XD&4P"U[BS'9#;;AO=1!&G&P5UI=1V:=>F-,?2/D.I
MLGZJ@D0H;E@]36T&<]'942>)IE5%U6U<4$(D0]>JIKC#7`2N&\K*J?)ND?8L
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M;YT(W'DL>.6T&-&*(Q+&`$)]AXWC)P!TW@9FAD3?JW#FC6BYX'S&=+Y!'JV#
MB1+1J?O]ZZRXVDATFR;<AOM_\EL)7;T>;/H/BG7"=6P.,<F+V]JSQ7V$Z58L
MN6C13FI4P0:BN,)(8==U9;^\6]43?V]?/3"H_`_C;D$5^K"YJVXOL>//U+<U
M7&9),2O>DZRXWIZOL5"$M.F09.</YE-X([1R^+06+.%`B5;<YN2T936XTEIP
ME%5$>VR0MD9"XNNY?#S6CH8HWO&.1<BL6J5'X-Y:5P1&VGVFR[2QQCOO(VB+
MU;(-=O123KKTR,K'Y$J.0V$ND*IAM2F&G)(3S1UN/*;!YA0%6GC$U`"+H[L3
M>J>'GD:?/X_QGR\^*V$"141TGO<0B4+"K(:/67&<>_KT](*+@EK^F:3JLKKA
M?.W%N(D>MCSF;:QJK5FP=D@VXQ[/VZ.QC%1-24.P7;(>FA+_`#RCNOD/C4^]
MHVEJ2;:OJR4S84S[W]L9+!:[3TZ['`4@+]%PTYZE^-["HD<D!'`EUTEI]RC8
M)=#&58MZSU-5U01<>`5'Z;BP*Z#P'E34>G;<C,H43ATBAD:/HJ)-<1M`$>G4
M/VE]7Z^&$=2?';<_B->-DTTMN5'^-[2FG:[_`+7L?W-/MW>>F%<?:?&W*955
MR6.W&C^YM:2GKX9D\G21`W=[<6U=HHI(HKYZ>6!,F\"Y5)L[_P!F`5M;=1K-
MJ7&.1[B.Z],9V,2&6U#N1W"+J_H6U?HJY40C^/>7OR8[DZIK;&+9UT"#;1)4
MQ]!AN0-R(X';!!D-GNW[%050O/3(1E)^/.<3+]I^2D1J*U)MP26S(,-D2SCD
MRTXU%%M`%QM517-2W&6J[LI%MPKBW-(?(:69<Q($>-3TKE*1Q)!N$Z0NM$V\
M($T&T2%G[5+IKD5CR[@7(+6XY0W':B.5G*Z^)`<E/&J.1%C*XAGVMB]SH[N#
M0DT).N!KJOCFZ@<P<=?BUTZE6Q*VBVLAU]9S+ACHK21].RIHO07=R:#Y8%UR
M_C?)GN3Q+ZC&+*_^72JJ7"FN&R(A)('!?:,`=ZB3>ACIZD\\#BXGQ+RF*Q5-
M.Q*>S:*IA5-JS,<D]M@X&]!>9$!T?`D/56SV^I/'+@V4-'/Y%97U>VW%"L@\
MR*QDST<59"%%1IQ&P:0.A$2;=^_H.N-96,/XWY)^-J*:<$"1#XRLU:Z41N*L
MP9##K#+4AI`3MCM?_>5"+=IT\<BO(GQURX*J/"5]KVL2ZKK*%`D2G92QXL/0
MG60E&VCAH1)^T))Z4Z:X(C/_`!GS-H6'XRUDJ166]G-AQI3CXLR8EJ9.&CI`
M.YEYM23:H[D\?K@C.V^+^6!"LHM'^*:8O:(:>;&5'6&(CK:O$!Q1`3W-K[DD
M42T77U?5,&8Z_F7%[:[^/'>/QC8"R>9C-JXXIHPALFV9]412T78NG3+AJBF_
M'O(GIUI):=ABDWD=?>,H1.:HQ#!D7&S5!^]>SZ?+KA&NN^/>65<^'/C2(3SU
M3:6<J$R:N@+\.V-7'0=+:7;=;)4VJ*$G3]<BQTM#PYRNX;-HW7Q618%.>D.M
MBJ-@[8...FC8KUV`KNB?PPKDHGQCRS\4<:7*K_<+Q0N,(37?4>XBJC;R[DUV
M[5]2>.OA@;8?Q==Q+T9`E42J^6L%^>4R*3\MB3#8:8)8A*J!M-&14=Z:@O5-
M<#ZBB8#`8'CC8.`0&*$!)H0DFJ*B^2HN!I.O@FP#!QVB8;5%;:(!4!4?!1%4
MT33`IJSA\2%RFXY"3ON'[=8Y=IQMO1A8S793MFB;_4/CJN!8VE.U-@2H[#I0
M),D"09\801]IPAVHZ!$))O%/!51<#72<?B554U7(;DQ!53?DRE1QU]TUW&ZZ
M6B(I$2Z^'\.F!8+'85556PU+12]*==/#7^&`5IK4B4!5230ET3543R7`(VW_
M`*$\-O@GA],#+:.FFB:>&GZ8`0`101%$%/!$31$P!@!@0&*$!(HD*IJBHO14
M5%P/!$&P$!1!`4T$431$1/),!W$TU\OK@:&X$5N:[-$/^2\(MFZJJJ[`UT%$
M5=$35=>F!($D+PP!$@IJOAYK@>IHO7`8&`O,DZ3(F*N`B*;:*FY$7P54\4UP
M/7`0P(%\"31?+HO\,#4RU$@Q`:;0&(S`H("F@B(IT1.N!O3ZX&F1+BQMON'0
M90R0`5PA!%)?!$U5-5P-V`\$P-3<J.XZXT#@DZUIW6T)%(=W4=R)U37RUP-N
M!I*7&%\(ZN`DAP5,&5)$,A'Q)!\51->JX&[`8%7<\6X]=DT5O7L358U1E7AW
M;=WCI_'3`KD^->!)_P#Z&%]/[0X'O_;C@2=?P$'_`/D!_P#4P-,3@WQM,:5Z
M)2UDAK<0*XTTTX.X"43'445-1)-%3RP,EX3\;I.2"M-5I--M7ACJRSW5;%4%
M30--VU"5$UP-_P#V\X)X_P"/5VO_`/BM?_6X&^'PSB,-]'XE+!CO#]KK4=H2
M37QZH.N!=>"8$:-8P)3TAF-(;>=B.=F4VV8D33FU"V&B?:NU471<"3@,!HF`
MT3`8#1,!@,!@,!@-$P&`T3`:8#`8#`:8#`8#1,!@,!@,!@,!@,!I@,!@,!@8
M@VV&NP4'<NI:(B:K]5P,L!@,!@,!@,!@,!@,!@,#1/D'&A2)#;2ON,MFX#*$
M(*:B*J@H1J@IKIIJJZ8'S>K^7I4QQ^$Y7,?DS>KV*_LR#.*X=DCBBA/*V/\`
M9[![B!"$OZ5RS$ZK1WF7,NZ-0U0QUY,$:3.=AG,TCG'8=1EI6G4!5UD$OI0Q
M3;_5A$:R^3;*&%C8I5`M+12H\*]57]933CX-$Z30"*@8Q_<#N]7JZZ8&<+Y+
MG2),-E:YM/<<@F\><)'B5!6*VXX#R>GKO[6BIY:X@H&/E[EDNG"6M5$A'9TE
ME9U)]]Q_:_6KH8/#L#TDA(0[5_C@=7.M^2K\22;E'&&[M:8Y@N@IHVA^V[F]
M.FY"\_XX5Q_%+BWX_-CQ(E9%-N730^07L\IDE=6116G2;8,33OD`[ETT0E\<
M(L)?RMR6!5!82ZR(06E)*O:06G7-$2(T+Y1Y)*B^I6G$5##IKJFGG@1[7Y6Y
MM7,W#KE37J%1"@7#NC[RJ428JB;*>E/W@4"T+[?TR+CL^;\IF<=BU5F+315#
M\Z/%N'WB(5C1Y)=L7TTZ:"X0H6[R77+AKB9O/K/DO%N2U3T5AF3#CW`68`KJ
M$,1EA5A2&]5U_P"3W`,=?+73PPB#*Y?<M\"MJFYK(4UB'QB#:Q6.X_L=8<'M
MFS))-I;D5K7<&F!VL3D_(K"VDQZF/`_$T\R/7VC<HW`?476&W''6B1=@H"/"
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M:?7`H/D8Q'G<I^S::LJ6MXO,L2J7F>XCA,2`)4$E+T&2B.AH.J(F16-]\A\W
MHZR4X1P)[SU"E[7/MM.`TV3;K3;K#B(X6]LA?3MGJB^.J92N@YS+YA5?%=Y-
M=LF6[Z-&>>;G1&%$!'=J(BVX9^I&_3NU\>N#7(6-OR+CG(>874)^,90V>/.6
M2NL*I2^[O8-$VF/:]):H7JZIC!T5=S3E]GRQP8C<4:*';OU$YAYQH'1%H=!=
M!=_=5TST5&]FB@O\\*P^2;0:/FU3?A'1^16T-[(!O3J?9!AQ`U3KHJIUR"-8
M<WY74(['EV<.2DRI8M(-F,8D%EQV2U')CLMF7=[G>3V_5-2Z%TZY41:_G?.Y
MUA`IAEQXDEZ^L:9^2_&!QWLQH/NVC5MIWM(ZB^DD1=,(PA_)'+RJ./V<]X(]
M=(16;2SC1A?:&2$\XNLEG?W6&7@;T!P-4$U]71,-.VY9>VC/(J#CE?(2`=TD
MLBL2;1U1]HTABTV)^A3/?KU_I%<B.4X]S'G?(+NDK4FQ*]'8DUZQ<&-W>^=9
M9#$(V-7$V!(;ZIX[=>FN41(',^2#4PFH?8BI(?Y`A.PXP*I/P))A&;[":IH[
MXN'YEYINUPK9R+EG,*F.DN2<-B]:X?*M'C*.VJM36765($+<I=K]Q44-VFJ:
MX&T^:\GA2;:OG7+1&/X1Z%)"*VCFMH;@.1F@W("J7:]!N+Z=?5KA-5U1S+DM
MA>T$F59D?MG.1QGH3"L;)1UKK8QT<4$42<(%T]'\1TPA&^3.4?X\-Z=M7NQ+
M&+`4A`VW7*Y^7*!EYXFP`-K+(.Z*CJJN\>J^.4=%\;RX<3D_.&I%FU*-VYC-
M-2'"9`G7#@,[0T;V"1^E>B)JNF9U<?2<*8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`BVE;%LZR76RQ4HL
MUER/(%%455MT5`T14ZIT7`XI/A;BRQGF'Y=E()YB)'20Y++NMK7DI176B%!V
M.M;E023"1(F?$G')3$%"EV3<Z#W42V;FNA->"0J*\V^\G4P/:GI\M.FF%2W?
MC/C1SSDAWV6'UCE-KFW52+).&@HP;S:HJD0HV**J$F[1-VN"-2?%?&4N_P`P
M#DP'TL"MVHXR3&.W,<;5MQP&DZ?N(7J1<)"'\5<6BL5T<4D.,5<69!C-N/$2
M*Q8+K($_]6ODOEA(LX_#:IGB)<5[DERL..4,R<?,WU9,=BCW5]7V^G^&%C76
M\%HZ^<Q.81XWX]<%."/.DX"PVRW"!`O0EU_J7K@B"Q\5\3:@2(';D'#>BO5[
M3)R'22/$D*BNL1M5U;`M$3IY=/#"1MF_&7%IK<]N2T\86<*/63/WW4W1HBZM
M"FB]%1574DZKKA<7=G15EK3O4UDPDNNDM=B0PZJDAMZ::$OCY85$=X;QYQ;1
M?:"V5S&;A6!MD0$Y':`FP#453;M`U3I@5\CXRXE(8=8>C.FV_6M4SH^X>3=!
M97<#70O)?ZON_7`S<^->'N7K5Z<)5LVA:17>Z\@N+'%!9-YM#[;IMHGI(Q54
MP-E;\>\8K7*MR''<;*F.2Y7:OO'VRFJJR%T(EW;]R_=K^F!E?<!XO?3')MG#
M5Z2]#.N>,776NY%<55)LT;(4)-5737JFO3`UR_CGA\T)P3*\9(64:/"F@ZXZ
M:&Q$U5@=%+TJVJZB2>K7KK@6=#QRHH*T:ZI8[$854E13-PR(O$C<<4C(E^JK
M@52?&G#$K(]8E<B0XDHY\4$=>0FY+BDKC@N(>]-^\MR:Z+JN!E"^-^%P@!N)
M6`PVW&D0FP`W4%(\L^X^VB;M-'#ZK@:IWQ7P&>VPU+IVGFX\0*]L5)Q$6*UU
M;9/0DWB'].[73`L87#N.0K/\E&A"$S>XX+BDX2"X\*"X8`1*`$8HB$HIUP-[
M_&J1^Z2Z>B`Y9I'*$DDE)5]N:[B:4==JBJ]533`KF_CKA3=9)JQJ6?Q\MH6'
MXY*9"K(%O%I-251;0EU0!T3],"YF5<";6O5DQ@'X$AI6'HSB;@-HAVJ*Z^6F
M!3I\><+2+*BI41_;S6V&9;6A:.-Q5U8$^O7MKX8$@.%<4#D*\C&JC#>*&Q;%
M&T[RH@[>I>:[>F[QTP)DJAJ)=C'LI41IZ=%;<9CR#'4@;>31P$_VFB=4\\"N
M:X!PQJNEUK=/%2#.$0E1U#4#`"W`&BZZ")=1%.B+X8'L/@?#H4D),2FB1Y#3
MON&W6FA$A>5OM*XBI_4K?IU^F`:X#PUHHY-T\45BZHQHVB(**XKVFG@J=Q5/
MK_5U\<"QMJ.IMXX,6<1J6TV:.MBZ*%L<'P,5\1+KXI@8,<>I&)D>8Q`8:E1&
M%BQ7@;$2:8)456@5$](*J:Z)@<GRCXOBV4B&5<S5-0HO?5:V?7I*C]V0:.'(
M;V.,$#JJGJZJA9:BYJ>`\<A5$:ND0F)O8C.0U=>:%=6'C5QQE!7=M:4EZ!KI
MHB85.D<3XS)!X)%5$>&0#+3XN,@2&W'ZLB6J=4;_`*?ID'K/%.,L&TXS4PVS
M8?*6R0,-BH2#3:3HZ)T,DZ*2=<`QQ7C4<)P,5,-H+-56Q$&&Q20J^/>1!]?C
M_5@91>,<;B`V$6JAL`TX#S8M,-@@NM#M!Q-!3U"/1%\4P+/`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
38#`8#`8#`8#`8#`8#`8#`8'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEVCK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable and Convertible Notes (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="4">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">151 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 19, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 23, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 27, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotePayableAndConvertibleNotesTextualAbstract', window );"><strong>Note Payable and Convertible Notes (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible promissory note amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 900,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Amount of original issue discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(150,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PremiumFinanceAgreementPrincipalAmount', window );">Premium finance agreement principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">140,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentUnderPremiumFinanceAgreement', window );">Payment under premium finance agreement</a></td>
        <td class="nump">28,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PeriodicPaymentUnderPremiumFinanceAgreement', window );">Monthly amount payable under premium finance agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement', window );">Duration of periodic payments for premium finance agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">9 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PremiumFinanceAgreementOutstandingAmount', window );">Premium finance agreement outstanding amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Promissory note interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromConvertibleNotes', window );">Net proceeds of promissory note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued', window );">Percentage of principle amount in which convertible note issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">83.33%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Convertible note maturity term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">One year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents', window );">Gross proceeds in subsequent offerings of common stock or equivalents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsIssuedWithConvertibleNotes', window );">Common stock issued to investors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">287,061<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InvestmentWarrantGrantDateFairValue', window );">Investment warrant grant date fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">565,729<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature', window );">Beneficial conversion feature discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">372,850<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">372,850<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtInstrumentFairValuePerShare', window );">Convertible note fair value per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.11<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExtendedMaturityPeriodOfConvertibleNotes', window );">Extended maturity Period of convertible notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">90 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfExtendedMaturityDate', window );">Description of extended maturity date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Company was seeking approval to extend the note maturity date for 90 days. The Company was able to obtain approvals from all note holders and the maturity date of the notes has been extended to January 31, 2013, February 18, 2013 or March 27, 2013 for the 24 notes.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes and the accrued interest converted into common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">678,116<span></span></td>
        <td class="nump">775,637<span></span></td>
        <td class="nump">124,363<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">219,725<span></span></td>
        <td class="nump">252,248<span></span></td>
        <td class="nump">40,444<span></span></td>
        <td class="nump">292,692<span></span></td>
        <td class="nump">292,692<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InsurancePolicyDownPayment', window );">Down payment under insurance policy</a></td>
        <td class="nump">28,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InsurancePolicyInstallmentPayment', window );">Premium monthly installment for nine months</a></td>
        <td class="nump">12,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">140,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal payment of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">103,050<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">103,050<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Placement Agent [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotePayableAndConvertibleNotesTextualAbstract', window );"><strong>Note Payable and Convertible Notes (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockPurchaseDueToIssuanceOfWarrants', window );">Common stock shares purchasable through warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">143,532<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Exercise price of warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 31,
				 2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible promissory note amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">292,691<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">292,691<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Amount of original issue discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmortizationPeriodOfNote', window );">Amortization period of note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">One year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Management Firm [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotePayableAndConvertibleNotesTextualAbstract', window );"><strong>Note Payable and Convertible Notes (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockPurchaseDueToIssuanceOfWarrants', window );">Common stock shares purchasable through warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">126,829<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Exercise price of warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Warrants expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 31,
				 2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmortizationPeriodOfNote">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amortization period of note.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmortizationPeriodOfNote</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockPurchaseDueToIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares purchase due to issuance of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockPurchaseDueToIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt instrument discount related to the beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DebtInstrumentFairValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt instrument fair value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DebtInstrumentFairValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantsIssuedWithConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants Issued With Convertible Notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantsIssuedWithConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfExtendedMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of extended maturity date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfExtendedMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Duration of periodic payments for premium finance agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DurationOfPeriodicPaymentsForPremiumFinanceAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExtendedMaturityPeriodOfConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Extended maturity Period of convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExtendedMaturityPeriodOfConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross proceeds in subsequent offerings of common stock or equivalents.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GrossProceedsInSubsequentOfferingsOfCommonStockOrEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InsurancePolicyDownPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of down payment of insurance policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InsurancePolicyDownPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InsurancePolicyInstallmentPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of monthly installment payment of insurance policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InsurancePolicyInstallmentPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InvestmentWarrantGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investment warrant grant date fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InvestmentWarrantGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NotePayableAndConvertibleNotesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NotePayableAndConvertibleNotesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentUnderPremiumFinanceAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment under premium finance agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentUnderPremiumFinanceAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of principle amount in which convertible note issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfPrincipleAmountInWhichConvertibleNoteIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PeriodicPaymentUnderPremiumFinanceAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Periodic amount payable under premium finance agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PeriodicPaymentUnderPremiumFinanceAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PremiumFinanceAgreementOutstandingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Premium finance agreement outstanding amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PremiumFinanceAgreementOutstandingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PremiumFinanceAgreementPrincipalAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Premium finance agreement principal amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PremiumFinanceAgreementPrincipalAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProceedsFromConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from senior subordinated unsecured convertible promissory notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ProceedsFromConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 13<br><br> -Sentence Column A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentWarrantsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration date of warrants held.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 13<br><br> -Sentence Column A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentWarrantsExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the total principal payments made during the annual reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentAnnualPrincipalPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDateDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants (Details 1) (Warrant [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of warrants activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">12,770,636<span></span></td>
        <td class="nump">5,364,557<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Units, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,406,079<span></span></td>
        <td class="nump">5,364,557<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">9,441,942<span></span></td>
        <td class="nump">12,770,636<span></span></td>
        <td class="nump">5,364,557<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 0.97<span></span></td>
        <td class="nump">$ 0.51<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.32<span></span></td>
        <td class="nump">$ 0.51<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 0.77<span></span></td>
        <td class="nump">$ 0.97<span></span></td>
        <td class="nump">$ 0.51<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 9 months 4 days<span></span></td>
        <td class="text">6 years 9 months 4 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
        <td class="text">5 years 1 month 2 days<span></span></td>
        <td class="text">4 years 5 months 23 days<span></span></td>
        <td class="text">6 years 9 months 4 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">$ 6,114,768<span></span></td>
        <td class="nump">$ 3,261,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">$ 9,691,302<span></span></td>
        <td class="nump">$ 6,114,768<span></span></td>
        <td class="nump">$ 3,261,367<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYVMM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Aug. 31, 2012</div>
        </th>
        <th class="th">
          <div>Aug. 01, 2012

</div>
          <div>Rental Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Rental Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Phase I Clinical Trial of a licensed product [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Phase I Clinical Trial of a licensed product [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Phase I Clinical Trial of a licensed product [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2002

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]

</div>
          <div>License agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]

</div>
          <div>License agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]

</div>
          <div>License agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2012

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Oak Ridge National Laboratory [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Oak Ridge National Laboratory [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 06, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 12, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 19, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 28, 2012

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]

</div>
          <div>Note</div>
        </th>
        <th class="th">
          <div>Sep. 26, 2012

</div>
          <div>Johns Hopkins University [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 21, 2012

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>May 09, 2011

</div>
          <div>Jamess Capital Group LLC [Member]

</div>
          <div>Transaction management agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Former CEO [Member]

</div>
          <div>Separation and Settlement Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2013

</div>
          <div>Former CEO [Member]

</div>
          <div>Separation and Settlement Agreement [Member]

</div>
          <div>Note</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Former CEO [Member]

</div>
          <div>Separation and Settlement Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentOfLicenseFee', window );">License fee payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,000,000<span></span></td>
        <td class="nump">$ 3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,750,000<span></span></td>
        <td class="nump">7,750,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Net sales in milestones payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentDate', window );">Milestone payment date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 24,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">We agreed to pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of up to 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">We agrees to pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Royalty payments of 2% of net sales will be due to FHCRC.<span></span></td>
        <td class="text">Royalty payments of 2% of net sales will be due to FHCRC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RoyaltyOfNetSalesPercentage', window );">Royalty of Net Sales Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FirstCommercialSalePeriod', window );">First commercial sale period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TechnologyServicesCosts', window );">Technology access fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Annual maintenance fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ResearchAndDevelopmentArrangement', window );">Annual research funding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PurchaseOfRadioactiveMaterial', window );">Purchase of radioactive material used for research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">233,100<span></span></td>
        <td class="nump">233,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProjectEstimatedCost', window );">Project estimated cost for clinical trials of drug Ac-225-HuM195</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">1,900,000<span></span></td>
        <td class="nump">1,859,333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DownPaymentOfProjectEstimatedCostPercentage', window );">Down payment of project estimated cost percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.50%<span></span></td>
        <td class="nump">12.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DownPaymentForProject', window );">Down payment for project</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration', window );">Clinical trial cost for approval of food and drug administration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,500,000<span></span></td>
        <td class="nump">13,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear', window );">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FundToRelatedPartyUnderAgreementAfterYearTwo', window );">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payment for the commercial use of drugs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">37,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfPatients', window );">Number of Patients</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,366<span></span></td>
        <td class="nump">481,204<span></span></td>
        <td class="nump">38,501<span></span></td>
        <td class="nump">31,771<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,749<span></span></td>
        <td class="nump">33,946<span></span></td>
        <td class="nump">22,847<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StartUpDueCostPaidDate', window );">Start-up due cost paid date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 10,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NonRefundableInstitutionalFee', window );">Non - refundable institutional fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PharmacyFee', window );">Annual pharmacy fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,025<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmendmentProcessingFee', window );">Amendment processing fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PeriodicFeeReceivedByManagementFirm', window );">Monthly fee received by management firm</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock', window );">Percentage of fully diluted capital stock equal to common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantExercisableNoticePeriodDescription', window );">Warrant exercisable notice period description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The warrants contain a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant', window );">Description of period of shares availability by exercise of warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transfered until the earlier of twelve months from the closing date of the Pubco Transaction; or for six months after the planned Registration Statement is declared effective.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MaximumAmountOfOutOfPocketExpenses', window );">Maximum amount of out of pocket expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AgreementConsideration', window );">Consideration pursuant to agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The Company paid Mr. Talley $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid Mr.Talley a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPayableInInstallmentsUnderAgreement', window );">Amount payable in installments under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfInstallments', window );">Number Of Installments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PerformanceBonusPayableUnderAgreementForService', window );">Performance bonus payable under agreement for service</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">60,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AgreementRenewalDescription', window );">Rental agreement renewal description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentOfFirstInstallmentForServicesByCompany', window );">Payment of first installment for services by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">125,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentOfFinalInstallmentForServicesByCompany', window );">Outstanding payment of final installment for services by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">125,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentOfPerformanceBonusForServicesByCompany', window );">Payment of performance bonus for services by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Rent agreement termination date</a></td>
        <td class="text">Jan. 31,
				 2013<span></span></td>
        <td class="text">Jan. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NoticePeriodForTerminationOfAgreement', window );">Notice period for termination of agreement</a></td>
        <td class="text">60 days prior to January 1, 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement terminated May 31, 2013.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AgreementConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Consideration under agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AgreementConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AgreementRenewalDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description regarding renewal of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AgreementRenewalDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmendmentProcessingFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amendment processing fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmendmentProcessingFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPayableInInstallmentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount payable in installments under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPayableInInstallmentsUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical trial cost for approval of food and drug administration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommitmentsAndContingenciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfRoyaltyPaymentToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of royalty payment to related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfRoyaltyPaymentToRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of shares availability by exercise of warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DownPaymentForProject">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Down payment for project.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DownPaymentForProject</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DownPaymentOfProjectEstimatedCostPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of total estimated project cost required for down payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DownPaymentOfProjectEstimatedCostPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FirstCommercialSalePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>First commercial sale period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FirstCommercialSalePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FundToRelatedPartyUnderAgreementAfterYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement after year two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FundToRelatedPartyUnderAgreementAfterYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement for first two Year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FundToRelatedPartyUnderAgreementForFirstTwoYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MaximumAmountOfOutOfPocketExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum amount of out of pocket expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MaximumAmountOfOutOfPocketExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MilestonePaymentDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MilestonePaymentDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NonRefundableInstitutionalFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non refundable institutional fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NonRefundableInstitutionalFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NoticePeriodForTerminationOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notice Period for termination of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NoticePeriodForTerminationOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfInstallments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of installments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfInstallments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfPatients">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfPatients</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentOfFinalInstallmentForServicesByCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Outstanding payment of final installment for services by company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentOfFinalInstallmentForServicesByCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentOfFirstInstallmentForServicesByCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment of first installment for services by company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentOfFirstInstallmentForServicesByCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentOfLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License fee payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentOfLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentOfPerformanceBonusForServicesByCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment of Performance bonus for Services by Company</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentOfPerformanceBonusForServicesByCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of fully diluted capital stock equal to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PerformanceBonusPayableUnderAgreementForService">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Performance bonus payable under agreement for service.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PerformanceBonusPayableUnderAgreementForService</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PeriodicFeeReceivedByManagementFirm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Periodic fee received by management firm.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PeriodicFeeReceivedByManagementFirm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PharmacyFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Pharmacy fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PharmacyFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProjectEstimatedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Project estimated cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ProjectEstimatedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PurchaseOfRadioactiveMaterial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase of radioactive material.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PurchaseOfRadioactiveMaterial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ResearchAndDevelopmentArrangement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ResearchAndDevelopmentArrangement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RoyaltyOfNetSalesPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty of net sales percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RoyaltyOfNetSalesPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StartUpDueCostPaidDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up due cost paid date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StartUpDueCostPaidDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantExercisableNoticePeriodDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrant exercisable notice period description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantExercisableNoticePeriodDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaintenanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs incurred and are directly related to generating maintenance revenues. Also includes cost of maintenance on client contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MaintenanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TechnologyServicesCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs incurred in providing technology services. The services may include training, installation, engineering or consulting. Consulting services often include implementation support, software design or development, or the customization or modification of the licensed software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 605<br><br> -Section 25<br><br> -Paragraph 76<br><br> -URI http://asc.fasb.org/extlink&amp;oid=22169047&amp;loc=d3e132428-111767<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TechnologyServicesCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>24
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"0-LX-*`(``(`B```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VEUKVS`4!N#[P?Z#T>V(
M%7VX:TN<7NSC<BNL^P&:?1*;V)*1U"[Y]Y.=MI22I80%]M[$Q);.>6/(<Z.S
MN-GV7?9`/K3.EDSD<Y:1K5S=VG7)?MY]G5VR+$1C:],Y2R7;46`WR_?O%G>[
M@4*6=MM0LB;&X9KS4#74FY"[@6QZLG*^-S%]]6L^F&ICUL3E?'[!*V<CV3B+
M8PVV7'RFE;GO8O9EFV[ODWCJ`LL^[1>.O4IFAJ%K*Q-34OY@ZU==9H\=\K1S
M6A.:=@@?4@S&#W88G_R]P>.^[^G5^+:F[-;X^,WT*0;?=ORW\YM?SFWRXT4.
MI'2K55M1[:K[/KV!/`R>3!T:HMAW^73->]/:I]Q'^D^+`Y\NXLQ!QM\W%3XQ
MAP3)H4!R:)`<!4B."Y`<'T%R7(+DN`+)(>8H05!$%2BD"A13!0JJ`D55@<*J
M0'%5H,`J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4616*K`I%5H4B
MJT*15:'(JE!D52BR*A19%8JL"D56C2*K1I%5H\BJ4635*+)J%%DUBJP:15:-
M(JM&D;5`D;5`D;5`D;5`D;5`D;5`D;5`D;7X7[+&=+Y/?/K\]S_N5.:-`^80
M=QV%,Q\*[8N^U;DQGNH?T:=)B+,'>%G[6(XT)W#KW1#2Q(2GT]_"TTC$N'LV
MI$+D8TO/0Q&'A@N>.Z9IB],;OIINH'&>HZ;Z0&\^S8\L_P```/__`P!02P,$
M%``&``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N<F5L<R"B!`(HH``"
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````",DL].PS`,QN](O$/D^^IN2`BAI;M,2+LA5![`
M).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?
M5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61
M,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,
M0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@
M\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`
M"````"$`.F@U2&D"``#U(0``&@`(`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS(*($`2B@``$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````O)K-
M;MLP$(3O!?H.`N^UO+NDDQ21<PD*Y-JF#R#8]`]B2X;(M/7;EW`3Q0':Z<68
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M`EM.0'+8:P67BMW'L(V%362!1%8VD1426=A$%DAD91-9(9&-W<D&6]G8N]S@
M-O=L(GM(9,\FLH=$#NR<'&!.#A?-R;D\3\1B@"^1_719GS[A]F:O$%P@89-8
M((G9Y(/@8Y<&5D;8I1%8&V6;@D)34+8I*#0%8YN"05,P-G(,,L>S3<%#4_`7
M-87QX.;-&,:AE[,<#P]/`CNJ!QC5V<7!M6$']0"=G-W'L(V%362!1!8VD042
M6=D(5(A`H[<.[!UC[W*#V]RS$>@A`L-%@V#*QUWYNV)\;/ASC8ZUE)TF%*8)
MSX:PAQ`.[&`<8#!F%P?6AKV/X#82-H(%(EC9"%:(8&4C6"&"C=TZ!GO'7Q3!
M8R!_H_`X])K1X<-X8(>;`,.-L`U"H$$8FX$&(>C9!N&A001V3@\PI\\NVCMI
MTPYQ^2T/Y4V-\XQS/OP:=>IW+VO,?P,``/__`P!02P,$%``&``@````A`(:W
MAMY2!```H1````\```!X;"]W;W)K8F]O:RYX;6R4F$]OHT@0Q>\K[7=`W&=L
M_ME.%&>D))[=7++6VC,YHC:TXU:`9N@FMK_]%K`F#YJ@R<DIXWI=_?I7!>3F
MVRE-K#=>*"&SI>U\G=H6SR(9B^QE:?_8?O^RL"VE61:S1&9\:9^YLK_=_OG'
MS5$6KSLI7RT2R-32/FB=7T\F*CKPE*FO,N<97=G+(F6:PN)EHO*"LU@=.-=I
M,G&GT]DD92*S&X7KXG<TY'XO(OX@HS+EF6Y$"IXP3>6K@\B5?7NS%PG_V>S(
M8GG^Q%*J^Y385L*47L5"\WAI!Q3*(^]\493Y72D2NGKE33U[<MMN<EU8,=^S
M,M%;VMY%G?QR?=>=5;^LK/@I^%&])U6A=7H662R/U4_)VG,;>53`L;[T+&)]
MH.O3Z;3][F\N7@[Z\B7)3T"_=I#6J3^MK-[>Q9&03BI<95KH<_B8->X+24=8
MN?Y(.W-LJ[@6]$?Q&#M5X:AR3R;*1,2,+`KO6,*RB(>;*E6!A`L2[B<DPC4#
M%0]4:J\_+&2CJ9[JN%4H]^$_.0<5'U3\T5I:E4KD_L"(N]84\KTU)>BKM(GU
M\O=,'<+OA`XZ,H/\F@;<RP-742'RBM!JZ;M2B8PK59_4IL0JJ-7:,N;],OZ2
MU)(AG5#$BT[M5Y"UZ&?]6_4&'>::%43$MF"98E'=++#PC,AL%[[J2ZP+ZN4J
MNT;K5RGRZBPPO</4M)__)#6G]<]LE_!:@_9``T>+*GY"'03+,>!\X(5XHT9_
MHPGT?G0SY,@Q<'RD69;R<,M.W2SDQAG`+TV%;I"K=DT5:W*?!J/HRB`XCL'?
MBLS29RP607$&2)/1*P%>H[*F[L/4.9R18T#VS`HZVTZ;SA`GQ^!IE>:)/',>
M/O`]`=ELLA"[LEX=5T;`'(.P3;E3_%=)2(2KMZI)(76.8#D&6>.=052U#3I'
MQ&B0]N;6N!!A]2Z$C+D&8Q^W"R&T0QW$SC6P&^Z92B/I`#1'#EV#P_'6Z1B$
M)+H&B=`[`T4@E:Y!);;00#)RV=P*<?C=RY%."M%0I-4U:-WH7FL,5(*<N@:G
M33.::0MDU#48O3360"(RZ7V22<*G9=+K"!E,CL--`+5""X3;,Z!L[B!1<P>A
MMM=,)-BM'C)-0:_)1GJ#M*`,#Z&FX%,Z"/6B4Y`!Y@=--K`Q!-PS9N>X#A;D
M(>P4]'8VWJXXACRDG8)/"7780>@]@U[L>],7']&GH%?%0'*(;OC(+06_D;[E
M)UTR>A1OF?6160IZ(IWA,[`#),0WD!W*[FX!4?4-5`?S!_:`P]<W.!V?@1U'
M$53?`'5<"/GR$50*>JZ."R%?BXY!!JC_#]6!@T$N?8/+;EYH6KI`2P,#3?-V
M8)80()X4]#SX4**N!@A=X*$$!J'M#6*@`J0S,.CL9W;(#-!X"GK5&[D#%B(#
M@4'E^/,?4AET##"H-!X`!VXM"YQW0<WCI!X!]!H;L22B]^OJHWI!K<]Z<OGO
MPNU_````__\#`%!+`P04``8`"````"$`SY@T22('``#Z'@``&````'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;)29VX[B.!"&[U?:=T#<`['CQ`EJ>C4AY"#M
M2JO5'J[3$)IH@*`D/3WS]EN.";@J0)B^Z&Z2SV7[KW+9A5]^^W[8C[[E55V4
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M\C.NBLWOQ3$'M<%/R@-O9?E5H>E&/8+&LU[KJ/7`G]5HDV^SCWWS5_F9Y,7[
MK@%W.S`C-;'YYD>8UVM0%,Q,N:,LK<L]#`!^CPZ%"@U0)/O>_OTL-LUN,;;=
MJ2,MFP$^>LOK)BJ4R?%H_5$WY>$_#;&S*6V$GXU(&/WY/9]RSV&.^Q-6("3;
MH?A7*_+9H<STM%J5PJS)7E^J\G,$H0<#KT^9"F0V!\.=/'HR%\'NZ05"*2-?
ME)7%V!V/0(H:G/SMU;%?9M_`+^LS$MQ`!$:6':*\H,R&W8.K68:;K#JB:Q)U
M#ZY-'`>WB3ND:Y/H!_#[.GH7MTEO(/*"S$#+BZ#@:U/0VW'6Z:9@I5LWE$`_
M,(?"+]VTFBS[A.-A).PCQ,BJ3U`C41]AUQFW0XEO(&0HR0V$6$G[R'6T2%G[
M9Y15,*Q5TZ<^EBG0B#`0&I"#1#A(K`:):)"(!XEDD$@?$4AF$.3Y`%;P8@PN
MO"P=UR(R:\24F5\=K&-Z&`F'D=4P$@TC\3"2#"/I0P3)#;O(\W(K&$>U2S)B
MH!'H_^(1&M6#1#A(K`:):)"(!XEDD$@?$4AFV)M,F=4^9\-AXG%Z5HU(=)/0
M#33BM7N>E!ZW";`T`>9*:5O$8Z%)<%O:<$+$2VB%",EMX9!<%IF$+80E/+KK
M(0*Z\6BJ-@'N"FXYC/22(L23OBT-!,D-)QU3[L<R*YC(3$\/&M$R>[8%*F*)
MEB8@.;=LLLV$)L"A/;=)'RN38`ZW.">>BDQ".);;\W9L$MQW?"[(22)!!!@1
MOB2N2A$"[H:Q7)V%9%95"CF]#4>U:D3D)BDBT(B91'HYNT/488\Q$O5A]_::
MA:B!58<H`X*34(O,MXY''!&;;UWJR$2_U<%B<Q=\0(:7/B*0P'`D-@5^',<*
M)L(2UP8:>2CL,!)J1$]0L)ZRPQ:B820>1A)S'(YC,8\$>XH!8=^+8P:I^'F=
M6YH(37H.SHS6B+F6Y],@6"*$V[X/JQ%GE1`A#K.D0ZN)%4($%X)9-)81(GTA
MN7]=S_HHC1";>[;KD@26(,01TO:8H'&-&=\3CNM?[:#(9JJD,7+'X]!N:2+Y
MU7`[A^#,:,DG=S37A=29N2,Z8NZHCI@[LB/FCNZ(N2,\8NXICZ''TJN2YWGI
M=8$$Y_?+B<XEX1,PS9AYA:3TY3`2#B.K820:1N)A)!E&TH<(CG55_#PON"Z5
M4%%#EG3`--/%.O<)L,2`#:F1D_-&B!'N&,FQ75`K#/@.YX)LA!%"(//X-B?+
M,L:(="R?A$:""=\5TB)&4H1,F.]*SJY[&Q8;HO`GQ%8T3BR29.&`:<:,;KKG
M+9]@PB>8U1-,]`03/\$D9T8'$7<M^,'[3_J(P**K0LB(\.?J&_5%*!6?1%AP
M9O0@F>?;@B2?)2(FW!>P,^%YA`CAS.T=&%>(F'!/NA8)TP@CKN=`C8+[B3'"
M;-\EYX($$RXLF-ZA!2$^<X2Q6V/153UDB#ZPA>KJR4PKDNS?`3,K+.9Y4!W@
M&2X1,7&9;5&=0H1P9O>47"%BPF`;AI,"[BA"C``I:4Z($='ZE$1&@@G+<FQ:
M4J4(F4B?2>-K1JRV*HN>5UL744AMDH`#IAG9%N\3.$U9/B/,$C-0O'/AD,`,
M,2-@C?@.60$KS#C"`X;8B3`#9T`&13AV2XP9*/6%]`F38,9QI+"%2R:68LBU
M7%L*=AT1EE[52X;T3V87764A%UP[.)\9->-K%UA3BZS7)4.`/94$"#$`MSAD
M3:TPX$X],H8(`W"E0L(XQH"8$BF3\WMS?R)]I`\1K+6JF7Y>:UUI(:U)6`1P
MS::R_7F[@;0`V9PP2\1X%I/T8!,B`DXDP+!>L)L]W;(2(2N,6?`=!S$2(^26
MD>1,/-1=C^0VHG775X?Z4NR05^_Y,M_OZ]&Z_%#7@@(B\_+T<F7YA:LK&_(\
M8'.XPNH_#]D<[JGZSR,VA[LH>#Z[&(*;QU/VGO^15>_%L1[M\RT,P9I*V*<K
M?7>I/S3EJ;VZ>RL;N'-L_]W!'7,.EV;6%.!M63;=!]7!Y=;Z]7\```#__P,`
M4$L#!!0`!@`(````(0#W4,*\T`(```\(```9````>&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;)2576^;,!2&[R?M/R#?AR]#@"BD:E)UJ[1*T[2/:P=,L`(8
MV4[3_OL=XY0&DG7T)HG#P^OG'!NSO'FN*^N)"LEXDR+/=I%%FXSGK-FEZ-?/
M^UF,+*E(DY.*-S1%+U2BF]7G3\LC%WM94JHL2&ADBDJEVH7CR*RD-9$V;VD#
M5PHN:J)@*':.;`4E>7=373F^Z\Z=FK`&F82%F)+!BX)E](YGAYHVRH0(6A$%
M_K)DK7Q-J[,I<341^T,[RWC=0L2654R]=*'(JK/%PZ[A@FPKJ/O9"TCVFMT-
M+N)KE@DN>:%LB'.,Z&7-B9,XD+1:Y@PJT&VW!"U2=.LM-C%R5LNN/[\9/<JS
MWY8L^?&+8/DWUE!H-BR37H`MYWN-/N3Z+[C9N;C[OEN`[\+*:4$.E?K!CU\I
MVY4*5CN$@G1=B_SECLH,&@HQMA_JI(Q7(`"?5LWTSH"&D.?N^\AR5:;(C^TP
M<K$'N+6E4MTS'8FL["`5K_\8R#M%F1#_%(+!_G3=M_TX],+Y_U,<8]05>$<4
M62T%/UJP:6!.V1*]!;T%)%^O"$K1[*V&NUM`5L(J/*WBP%LZ3]"Z[,2L+QDO
M&B*;*TC<(PZ(]790\W0[#:<(BNCM<#R:>FV8X(P)^IF[&C?O$0,WF&BZFX9A
MU<_FC0-_.//:,%'75P_/W<3%\R&R&2)NG&#OS7]@!R5.M]/PV`X/IUX;)C9V
M01*%X5CNG(@"+_#=/F*@!EM^NIJ&QVIO)7=+MC:,4?,Q=H.1^^8<"*(@N>XU
M_XB7AH=>.!D_"H8YM2S$.)GCL)_:[+8!@F,<!O&;_*!KT4?L-#RV&V\WPQB[
MF7==;\B\ZZ=?=9,/$@V/_4:M61L&-E7_./NC$N#(US'_0$SWS)ENCKR6[.@C
M$3O62*NB!>2Z=@1[0Y@3W0P4;[LC;LL5G,3=SQ)>O!3./]<&N.!<O0[T.Z-_
ME:_^`@``__\#`%!+`P04``8`"````"$`+@K[A@L$```R#0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970T-"YX;6R4EUV/HS84AN\K]3\@[@,VF*\HR6I@=MJ5
M6JFJ=MMK`DZ"!G"$R63FW_<8$V([$S;-Q0P?KT^>\QY_G*R^O#>U]48[7K%V
M;6,'V19M"U96[7YM__C^LHAMB_=Y6^8U:^G:_J#<_K+Y]9?5F76O_$!I;T&$
MEJ_M0]\?EZ[+BP-M<NZP(VWAS8YU3=[#;;=W^;&C>3D,:FK70RATF[QJ;1EA
MV3T2@^UV54&?67%J:-O+(!VM\Q[X^:$Z\DNTIG@D7)-WKZ?CHF#-$4)LJ[KJ
M/X:@MM44RV_[EG7YMH:\WS')BTOLX>8F?%,5'>-LUSL0SI6@MSDG;N)"I,VJ
MK"`#8;O5T=W:?L++#`>VNUD-!OU3T3-7KBU^8.??NJK\HVHIN`UU$A78,O8J
MI-]*\0@&NS>C7X8*_-59)=WEI[K_FYU_I]7^T$.Y`\A()+8L/YXI+\!1".-X
M`T;!:@"`OU93B:D!CN3OP_]S5?:'M>V'3A`A'X/<VE+>OU0BI&T5)]ZSYE\I
MP@)J"N*-07R@']][CA<'.`A_'L651$."SWF?;U8=.ULP:^`[^3$7<Q`O(?(E
M,\DQY7HO5<`309Y$E+4=VA9DP:$^;YN8!"OW#3PM1DUZJPD,27:1B%H`WP0)
MJ:N0G]M^81%BP2*\$W"I?`"Q)S@<Z6S9)Y)XDF@HX)&*(OPB=V?"!4D,@IHK
M!"$F4WQ)*35$T1B*;$ZA,4(0E7'>+B%>VV#`Y(Z?)`:;U$1#81=>3+P8(UV2
M:1*,(^SY5XE&!VZI=,)!'U;D/*48I%/&)-014JF)?8F)'-\T<$:@$<(\5@GG
MR818)R/(,\BD)A[`HB#$OH&>:0(_C)*K0".+=++'O!.#=,*8&`L@E9K1N\1!
M,`>4#_FZ,%+*M`&P[6$_0<H'3PYH_.)`5':;>6>%6.<FR)_BRE4C-=)9S_<1
M,029*B`1N;.J$YWK,5_%()TO5N)+/JD9??6<2#,)X5M?M0'8\90JB,NOBVN"
MFK,8EM#CU@YJG9T@8[FDHTB:ZY.$Q-<5/627:8H@1/X].+&Q*W5_S%\LCP-U
M:XJ)N36-HM%AXN!(<RRZ=5@?@9W0\%@=H5LL3@DEB_G9B^69HM(39!QXZ2B2
M%N,`$1Q<5\[HL8PS5B'RP^">R>)\4/`>-%F>*BIF'!AU3K$4C2:CP61](68W
M$A1?D]5M_%_'$[X]GPBZ[HYRE8TBD$Z'F&=N6/,:G=`XHGY2Z$_.)K.*J>@6
M8;.8)YS52$+9HLH.KJ'=GF:TKKE5L)-H/STX8::G4VO\Y(E>R'B>BI9Y:'JG
M%]"Q'O,]_3/O]E7+K9KN("1R(L#J9,\K;WIV'/K&+>NA5QTN#_#;A$*OA1P0
M[QCK+S>BDSM??NUL_@,``/__`P!02P,$%``&``@````A`+EE2J"Y`@``$P<`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#4N>&ULC%5=;YLP%'V?M/]@^;U\
MA)#0**1JJ+I56J5IVL>S8PQ8Q1C93M/^^UW;"4U(U^4%,/?X<.ZYUY?ES8MH
MT3-3FLLNQW$08<0Z*DO>U3G^]?/^*L-(&]*5I)4=R_$KT_AF]?G3<B?5DVX8
M,P@8.IWCQIA^$8::-DP0'<B>=1"II!+$P%+5H>X5(Z7;)-IP$D6S4!#>8<^P
M4)=PR*KBE-U)NA6L,YY$L988T*\;WNL#FZ"7T`FBGK;]%96B!XH-;[EY=:08
M";IXJ#NIR*:%O%_B*:$';K<XHQ><*JEE90*@"[W0\YROP^L0F%;+DD,&UG:D
M6)7CVWA1S'"X6CI_?G.VTT?/2#=R]T7Q\AOO&)@-9;(%V$CY9*$/I7T%F\.S
MW?>N`-\5*EE%MJWY(7=?&:\;`]5.(2&;UZ)\O6.:@J%`$TQ2RT1E"P+@B@2W
MG0&&D!=WW_'2-#E.9D$ZCY(8X&C#M+GGEA(CNM5&BC\>%.^I/,ED3Y*`^GU\
M$DRR-$YG_V<)O2*7X!TQ9+54<H>@:>";NB>V!>,%,!\R\SJ&7/^5*N1H26XM
MB^."+#24YWF5I9-E^`R>TCUF[3$SC`9,FIY"B@/$U@+T#2(A]6.1[]M^T&+!
M8RW)Z8?6YYAX?@HIWH%D`^1$'=AVN3H+AO(?N9"ETX'7N;GVF.D19H0H/D*<
M:`.2R[59<(XA\:%"V;A$:X^9NQI/1[86/@C7@>!-^(DLZ/IC6;;K$CB5'Q?6
M;AK+FXVL\YC4RYO&UZ-XX>,7*(0^/5;XL3(+'BL;]=/:8[+$28N"Y,T95W08
M7Y;CO;AWS@\G?W8%4S4K6-MJ1.76#IX8:(>W?B:N82:Z"1(.`9A)/:G9(U$U
M[S1J605;HV`.KB@_U?S"R-Z=H(TT,(W<8P,_'P9'/0H`7$EI#@M[5H??V>HO
M````__\#`%!+`P04``8`"````"$`ML:B<V,$```(%```&0```'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6R4F%&/HD@0Q]\WN>]`>%^Q4=0QZF9T,G>;[":;
MS=WN,V*K9(`V-(XSW_ZJ*&3IEBEP'E2<7Q?_KG]W%?;BRUN:.*\RU['*EJX8
M#%U'9I':Q=EAZ?[W[_/GF>OH(LQV8:(RN73?I7:_K/[ZM+BH_$4?I2P<B)#I
MI7LLBM/<\W1TE&FH!^HD,_C/7N5I6,!E?O#T*9?AKAR4)IX_'$Z\-(PSER+,
M\SXQU'X?1_))1>=49@4%R642%J!?'^.3OD9+HS[ATC!_.9\^1RH]08AMG,3%
M>QG4==)H_O60J3S<)C#O-S$.HVOL\N(F?!I'N=)J7PP@G$=";^?\X#UX$&FU
MV,4P`TR[D\O]TGT4\XT_<;W5HDS0KUA>=..SHX_J\G<>[[[%F81L@T_HP%:I
M%T2_[O`K&.S=C'XN'?B1.SNY#\])\5-=_I'QX5B`W0',""<VW[T_21U!1B',
MP`\P4J02$`"O3AKCTH",A&_E^R7>%<>E.YH,@NEP)`!WME(7SS&&=)WHK`N5
M_B9(5*$HB%\%@?<JB`@&8S^8SNZ),JJBP/LURJ1W%(_F5:;I*2S"U2)7%P?6
M'BC7IQ!7LIA#Y&M^:#9UQCY*&&0*@SQBE*4[<1W(A0:77U>S8+;P7L&9J&+6
MQ,!KS0B3V-P205`C'@BN54,FFZK;W;R*0QC%H;NH=DU?-)7X]6U*8G-+B&F-
M&$H@9TTEF+_QA^OKJ@@'+5VX29V*6?!0QR>1Q(P;S-@D-AQA:(0@38U\MA"&
M5=ZX[T385A+#:>,(0QODJK\VA*V\389F5M;$3,M%.`V&\&<"&P8PE,%J;BKK
MYRP.LA5:RWQ-#)<]CC`T3DV-O+,(=SE+#*>-(PQMV$(;E877AK"=-\NX-3&S
MCYUE`$/9@ZFLG[,XR%9HE8TU,5SV.,+0**#5]4]?27=Y6T&</!8Q]6&Q[FVO
MH-)N5+R;G5M!9+`HMZZU!#8L8NK#$M[0U\]D087?U#DR"\BZ@M@\4IQVQ-2)
M5;RAD]\F@FH^7YTKJ/WFU-]8Q-0'8>[0A[2]2RP3UX*@RN?6&LTBICZK@:#/
M(]@['7ELZR16?UWC<R),ALTCAY@ZK7;2H8\Z0(?/7)NH?.804]]=K410%S#W
MR8W/!+'[F4-,?58[Z>ES6U_Y\TQ)3UJ"(-9G#C%U6LVEPV?J!QT^<TVC\IE#
M#'W^77VEI+OV<P5Q/K.(J<_J*_WJMM_67R96W:X@SF<6,75BA>]=MWWJ![S/
M%<3JZ]U7?+C7'?J0[O29(/*YM6R7-UVZK829/9AD4QVZ/.FLVCZ.LE7^^5U&
MN[F"V"Q2G';$U&EU%WXWXY$`Z.MPF6L9M)NK.'WTW=55X*#E-G]VU:X@^@$E
MVFVF..T(Y8\.9.BD(97Y06YDDF@G4F<\;!'P#%]_6Q\$/?KE44[]#SB'.84'
M^3W,#W&FG43N8>AP,(4$YG220Q>%.I7G&%M5P`E,^?$()VX2?NH/!P#OE2JN
M%WA65)_AK?X'``#__P,`4$L#!!0`!@`(````(0`LI!+A-P,``"`*```9````
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;)Q676^;0!!\K]3_@.X]!NS88,MV
ME#1*&ZF5JJH?SV<XS"G`H;MSG/S[[K(VG$GBT+Y8!F9G9V>7/9973V7A/0IM
MI*I6+!P%S!-5HE)9;5?LU\^[BYAYQO(JY86JQ(H]"\.NUA\_+/=*/YA<".L!
M0V56++>V7OB^27)1<C-2M:C@2:9TR2U<ZJUO:BUXV@25A3\.@IE?<EDQ8ECH
M(1PJRV0B;E6R*T5EB42+@EO0;W)9FR-;F0RA*[E^V-47B2IKH-C(0MKGAI1Y
M9;*XWU9*\TT!=3^%ESPY<C<7+^A+F6AE5&9'0.>3T)<US_VY#TSK92JA`K3=
MTR);L>MP<1->,G^];`SZ+<7>./\]DZO]9RW3K[(2X#;T"3NP4>H!H?<IWH)@
M_T7T7=.![]I+1<9WA?VA]E^$W.86VCV%BK"P1?I\*TP"C@+-:#Q%ID05(`!^
MO5+B:(`C_&G%QI!8IC9?L<EL-(V"20AP;R.,O9-(R;QD9ZPJ_Q`H;$015R/M
MEEN^7FJU]Z#?@#8UQ^D)%T",FB90&3&T*M\2">J0Y!I95FS&/`@WX.SC.I[%
M2_\1W$@.F!O"P&^+"5N$#VI:22##E?2Z/<?,",;,:!=*N:$;;IKQZVDFIVF.
ME9]/AT%-!]HBXMF\Y2<%A+ET"KUL$2>%`L0M=)@"#((>.>QQ%+3\I(`P`Q3`
MW+@*SM>.X%[M4=="RDR8N!F!630-@D[:2>DP*F[B8:5C4%]`UUP20)@!I4?_
MHP"#WC.?,`,4X%YW7KWSYB.X7WO??,*0^;`3WC1__B^)$=Q//.G-&V$.B2'M
M6UT/8;.X)6/;PS'</%][$];7T+U3U/@#R/4]CJ:MT)/I"W$7.=8/&[\FJB]C
MUF8XR*`UY\KHE)Z*Z.VY@2)HOYU__T,"#1&!R\IQXIU&T&H#]G;]1>/N#3\X
M0"":A@E.88<X-0#TN;G1@/G[PX!1_2Y$_2X0R#4@CKH#B63004VG82GT5GP2
M16&\1.WP$`YAA[5WVP^$ZW%SFK8/X'RN^59\XWHK*^,5(H/08!3!'M1TPM.%
M575SUFZ4A9.Y^9O#EYB`$RL8`3A3RAXO\!NB_;9;_P4``/__`P!02P,$%``&
M``@````A`)D"M%,`!0``LQ0``!D```!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&ULK%C;;JLX%'T?:?X!\7Y"@%QHE.2HA*LT(XU&<WFFQ$E0`4=`FYZ_GVW,
MYF)HG%/-2VD6:R]O+V\;V]OO'UFJO).B3&B^4_797%5('M-CDI]WZM]_>=\L
M52FK*#]&*<W)3OU!2O7[_M=?MC=:O)870BH%%/)RIUZJZKK1M#*^D"PJ9_1*
M<GASHD465?"S.&OEM2#1L0[*4LV8SU=:%B6YRA4VQ2,:]'1*8N+0^"TC><5%
M"I)&%>1?7I)KB6I9_(A<%A6O;]=O,<VN(/&2I$GUHQ95E2S>A.><%M%+"OW^
MT!=1C-KUCY%\EL0%+>FIFH&<QA,=]_E)>])`:;\])M`#9KM2D--.?=8WH6ZH
MVGY;&_1/0FYE[W^EO-";7R3'WY*<@-LP3FP$7BA]9=3PR"`(UD;17CT"?Q3*
MD9RBM[3ZD]X"DIPO%0SW$GK$.K8Y_G!(&8.C(#,SEDPIIBDD`'^5+&&E`8Y$
M'_7SEARKRTXU5[/E>F[J0%=>2%EY"9-4E?BMK&CV+R?IC107,1H1$[)OWALS
MPUKJR]5/J"P:%7BBBCZSELO%REH_G@LPZP[!\^L=6C4B\&Q$C)\V9=UHP//K
MB<`TK7L#SR\G\M1HP+/1T!\?'8W72UU^3E1%^VU!;PK,::B(\AJQ%4+?@#+6
M':^2MA(_*T2H0";RS%1V*M@,-5;"['G?6Z:^U=ZAXN.&8X\YJX7`.2"'%3@3
M=D3`1:!K2=#PD($:/@)=R'(YS"U`"L:$/4`#IUJ[8(K\#W8Q%687-F=S`!IM
M_5LO5\,<#V/.RC*&'&>*8PXY+C;>M26H>,C`]'P$NA!]/50-D((Q(0?Z7=*M
M-F;@*2PW?4^GESRL-$:&Q:WGE&4*^=N<`^M/Z^:B;;DNJX.4X4@9KI3A(0,]
M\1'X-+$`&1@2(C`5,G`1NMMWD4UDMMS>=Y,%[508JM8IRQ3JQ>:<>VY*&8Z4
MX4H9'C+0&A^!?O+"0`?(P:`0@2ZH"QGX"=Z)?NIK]O&56,KB1$N%Y<;F'$BE
MM=T0:O@@ISARBBNG>)QBP:--QM*%M<>7ZP2/Z(1W=0;VP[=$M'\%NZK[Y<R"
M1.^%KMB<T_>^*P"^.$@9CI3ACAF6*2R9'G*P-GT$>B-A=FMFG5R`'`P*$>B"
MNOX,'(4-C.BH*764!8F./@T74YMS++/^[L]GIE#M!\E[1_+>Y>_OC)B'##3%
MET@&8D#X><#`0W;<ZNV6[E<C(PO>+>:"=YQSIV\'*<.1,EPIPT-&ZR`"4V7%
M*Q$9&!(B,!4R<!'VF8^[R,BR#S[GW'-1RG"D#%?*\)"!EO@(3%G"740&AH0(
M3(4,7-1A\CYN8\T>5N/:$A87NR$MFIEL"&OGH7T_E5S='T=.<>44KZ6@+7Z+
M?-ITT%(P*&R1J:"AF6S#__#,UOGQP.0G<790L<?080PY8\@=0]X8\L=0,(;"
M`33L']N.]_KWU7,>W]4/-HSB9L&&>Y)ZRL*7J=M2&,)7X]"Q<+B<,>2.(6\,
M^6,H&$/L_J;)"UKD[O#[&'X@SDAQ)@>2IJ42TS=VUV+!/&A1O`=B%T'UM8GP
M!KJ-5T3"&[@[>JZOC@3<UC=POH5<!-S5-W"('>,^:WH"=XT-'-DF^,8&CF6L
MKVT#<&5TC<[D]Z@X)WFII.0$W9S/V$&AX)=._$=%K_75P`NMX+*H_O<"EX,$
M*GT^`_*)T@I_L`;:Z\;]?P```/__`P!02P,$%``&``@````A`/$E%FED"0``
ME2\``!D```!X;"]W;W)K<VAE971S+W-H965T-#$N>&ULK%K;;N,X$GT?8/_!
M\'O+NO@B&TD&K;N`76`PF-E]=FPE,=JV`LOI=/_]%,5[E2(ZC>V'5EP\52P>
M%LDJB7>__S@=)]^;2W=HS_?3P/.GD^:\:_>'\_/]].^_BB_Q=-)=M^?]]MB>
MF_OISZ:;_O[PK]_NWMO+M^ZE::X3L'#N[J<OU^OK9C;K=B_-:=MY[6MSAI:G
M]G+:7N'GY7G6O5Z:[;Y7.AUGH>\O9Z?MX3SE%C:76VRT3T^'79.UN[=3<[YR
M(Y?FN+V"_]W+X;63UDZ[6\R=MI=O;Z]?=NWI%4P\'HZ'Z\_>Z'1RVFWJYW-[
MV3X>8=P_@OEV)VWW/XCYTV%W:;OVZ>J!N1EWE(YY/5O/P-+#W?X`(V"T3R[-
MT_WT:["IHW`Z>[CK"?KOH7GOC+\GW4O[7EX.^W\?S@VP#?/$9N"Q;;\Q:+UG
M(E">$>VBGX$_+I-]\[1].U[_;-^KYO#\<H7I7L"(V,`V^Y]9T^V`43#CA0MF
M:=<>P0'X?W(ZL-``1K8_^N?[87]]N9]&2V^Q\J,`X)/'IKL6!V9R.MF]==?V
M]#\."H0I;B041B+PGK>'"VUD1'$N%.$I%>?>*O#7T0IZ'U&$UMYM>`ZX/:*X
M%(KP%(H++XP7P6+)QCNBN!**\!2*P=J+%XOY,G;X"DNM]Q6>G^MR+13A*13'
M:9WQN>U#)=M>MP]WE_9]`NL/9J][W;+5'&S`F(P1/EH5-1\%#40+,_*56;F?
M`G$0#QU$^O>'.%C<S;Y#=.X$)J&8Y3RP,:G$L&!DAC,LR*5`]X1L%!(A;912
MH%46R+=*0J1.;0AFP)2B"\+Y_T`7L\+HDMTE7`"=*OY6BR7BAF*6<6ACLB%,
M9&-RV;GN"UDI)$*Z5TJ!5@E6MM5*0J1.S07FD()8Z5B<PM:`.8U@LQO>IF3$
M,278D`S&E@&*A(1C8`-1K,Z5!WUXI4Y$YD3D3D0A$9*;4@H^=*R2"*E22\&0
MBL4F#/?S;#*E^RE,F6(J(NN78];]ZO:]:(VH'&_.4#,*G]QL#KPE6I\%;XYA
M&U8.Q@%:(*5M@T3H+39JTP8,4KMI<0Q^8(Z#%3M$'4'+]##-B,>$8\`/-5(<
MM!P11_U,K+VY;_V;YU_0BL\LA<`+`8*6?&Y!(B\B1@J!@(=R+,8<EQPTXGPE
M$2JPA5T^FL"+%J9S%NMPO)BLC^\/#(RH#M&@$XX9\3:EB%6(IB,;PJ#XS2D&
M62DD0O)22H&F&ZE4$B%5:BG0*JM0>V)Q":F*R65_[-\2P4P/TZJ[Z#?5A&/&
M:.4($<&PW-'&G:'VA5Z&?0\Y:L=[42':[5C5IT]OI.2@$3<KB5`$HWZ-(]HB
MEQ50.*>ZA5RFA\E%0T\XQO0:AW7JAF1N2.Z&%!R"=F6TGY5N.]4M=NI1.Q;]
MD,9B^MWY!%/"W*.(23A&A"TKFM`1Z&C/'.TY;S?G%BWY0B)D1)8.DY5HMU9"
MZ-M^UQ\;L7@-("G[/+&]%F)VB8[N1(`4M1&FU@7(7(!<`,;851!%K\MJ153J
M$16;359B&+O$^'$6\(+$S-#B$&V;B0"-##%U0S(W)'=#"@717/(AC'A7$:5:
M2?29IM>$S2<K.`P^V9'F7O8!+U,@NU99#:TC!&C$\]0-R=R0W`TI%$3SRH<P
MXEU%E&HET>/^B%=6>1B\.N*4UREFG$8X44\"#I*E1(SRU12UAVBWR!SMN=4>
M>O/5PLR0T:HI!'JNJO'2TO>]&&E41*-&&H;'=HS"))E<WIQV!4P1;:(!.FD3
M`1*;Z,I;F:/V_9#D]*G0&`F=S`W)W9!"0734\A'=[FPE;*!T`^5'M>K)'=BL
M\K@]L'F=8@4VSKP2]G85ILGD<S5'640Z`-)+KT]-,S<D'X#$V)]"@33M-WA8
M$;5:2=RLLB+$8/7V$.?5BTTP2@.2@(-$U-#*(14`<P8(N;1,0I#<;:50$$VM
MP[=*.@]3H`Z;V'@IUL]]K0QKD';/WDU8.8*HON'$XT6,S3.*T220I<^0$[V?
MJ1N2N2&Y@*C$3P^U[Z60[19G.($MW1U5"B+GJU:2H3':1+/:PR#:<03R2L4B
M>(FVJ23@('D$+JP3RO<1#2F"DP,165O:.S]:1;FP-K)("@61=)7(!8?'%3%0
MWVS`YIX5)[=SSTL9D_LX1.E%$G#0R/!3-R1S0W(WI%`0S;/3NXHHU4KBC.7P
MEXJX7LOUNEV`QGAU0S(W)'=#"@51O"K)$$7]9E,IB%2JE61(R8K3\%/E7(_&
M^1Q:U8D`R3V"?"Q#[?CTSW`[6@>YU1YX:)<H1+.1%UL*OH<SFXIHU$C#>'=J
MDP<+UESD-R<-(5/$/.*\6(!DTD#38`$8"=S,#<G=D$)!9("50O*A;Y4$6`<@
M?N]>*\/N./U4.1<.E',XSA(!,NF+C9GFZ<(`"!URF1N2#T!B_!JN4"#-,A_&
MJ(<54:N5Q,TJF/ZU`&:**(#Q@)*0@V20T!>/`F".CY#+;8Q`<K>50D$TM0[?
M*NF\'<`HX:R583?58`A3[<YZV;<YPC-R(A&@$8Y2-R1S0W(!45DOGO%"`BS2
M2-KK[JE2$#EAM9*XF68%S<VI5\C+'S/UBDC:*T#R2//1FY44M0?HBUV&V\F1
MYJSM"F'"/-:XTD=.542CQF[H0+*/-52@C=<-(:^Y(GX5B]U^2:@HI:*,BG(J
M*JBHI***BFI+9(\/U47]L0TA^\G+0R$MF,C'_42`(I@K73P;[]G$*<--`4K&
M>Z85I2BGHH**2BJJJ*BV1#8[J'+Y578&2AI\_B<A!R%V4-&9:I2D(J.BG(H*
M*BJIJ**BVA)9[+`MV]Q<&#M,]LG8Z<W8YR=YI9(($&)'+UH>.QJEV*&BG(H*
M*BJIJ**BVA+9[*!JXA=C)QKX:D1>&PL08@<ET:E&:7:X=6.QY1154%%)1145
MU9;(9F>H7/C\O@-W;W%.$.,S-A$@FYT(?4%--4JSPZU;[!!1015+*JJHB%T<
M9LYS\YP=?A&8W^X\-9?G)FV.QVZR:]_8)5_XXO-PI\3B!G*XVK#]'9Q&+;#?
M0DL\V+*&EO502^3#A>;^3C*V%K&KSOW%8-(2RDO0J`5N1W_M+T<C>1)LX%8H
M]3@/-G#UD\I+Z'I(GH<;N.@X@`\W<)D1Y#/5,5R*?MT^-__97IX/YVYR;)Z`
M3]]C=WLO_%HU_W%M7_L+M8_M%:Y#]W^^P/7W!HYRWP/P4]M>Y0_6@;I0__`/
M````__\#`%!+`P04``8`"````"$`X:W/)=D&``!](@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6R4FMN.HS@00-]7VG^(>.\$<R?J]&BX[DBSTFJU
MEV>:D`1-$B*@IV?^?LO827#!NM(O/1/ZN&P?%[C<Y/G3C]-Q\;UJN[HY;PRV
M-(U%=2Z;;7W>;XR__\J>`F/1]<5Y6QR;<[4Q?E:=\>GEUU^>WYOV6W>HJGX!
M$<[=QCCT_66]6G7EH3H5W;*Y5&?XS:YI3T4/']O]JKNT5;$=&IV.*\LTO=6I
MJ,^&B+!N'XG1['9U625-^7:JSKT(TE;'HH?Q=X?ZTEVCG<I'PIV*]MO;Y:EL
M3A<(\5H?Z_[G$-18G,KUE_VY:8O7(\S[!W.*\AI[^#`)?ZK+MNF:7;^$<"LQ
MT.F<PU6X@D@OS]L:9L"U+]IJMS$^LW5N><;JY7D0]$]=O7>C_R^Z0_.>M_7V
M:WVNP#:L$U^!UZ;YQM$O6WX)&J\FK;-A!?YH%]MJ5[P=^S^;]]^J>G_H8;E=
MF!&?V'K[,ZFZ$HQ"F*7E\DAE<X0!P,_%J>:I`4:*'\._[_6V/VP,VUNZOFDS
MP!>O5==G-0]I+,JWKF]._PJ(R5`BB"6#0`L9A%E+*W"9ZWT@BB>C^/<H_J-#
M68EI#9:2HB]>GMOF?0&I!P/O+@5/9+:&P%<]8C(W8?_G"T3Q()]YE(T!`P05
M'2SR]Q<_M)Y7WV%A2LE$4X:I1'PE^"KPL,GUPCVLZZIMTBMR;9.)"_#S-A37
M4]OD,XA_0U8@YF8'%FYL9SYIKA(XS"5<AQ*)"^.A("?QE'"#VTB$@RG"[H,=
MD'0&05&R&01%R:?(?;2*%%N5PE/&AOM2+X<W`FZT+!XSU:E&@G%&C*,2,4DD
M))&21$82N8Y07,%D'D\@#F\,6(=;ZOJAK1J(!!,,]YC+',^VT5+'8P)^&_H^
MNL\2DD@%`3]O(['NR3`D739%T&+E.D*1!(_%L:3'$HHWPK+0""+!C*>!B)@D
M$I)(!2&6Q`I\TT.^,S)$KB,45?"(':O2WW,<QHK0\S,2C!C\D\ULT[71XS(6
MB,9B0A(I260DD>L(11+L8V-)/)\<,*R7Q1MA6<A$)!B-B9@D$I)(!2&6A#FV
M:^-;CPR1ZPA%%2]ST?9//\MY(ZP*[2:18'2J2"(1A+RQ'(N%:,-(QP`+?<L/
M4'IG9">YCE!4A5-5=%;Q1E@5>F!'@M&I(HE$$#)G+&:&2$0Z!L+`L_'&DI%]
MY#I",<6@&OAX5@VML*L0;7\2TLFBD40B0I?-6!`&:%%2.DI&([D649WQHO3#
M=R(3I>RX9`A,=)=$$M(Z$W$T2"*CR!1SW=`U<8[1'64TDFL1U1DO69$S^I9D
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M,E:5X3*?Z<IGJ8Q$$CI**A&AC`6!ZZ/2,*.#Y%I$5<:+7:3L@7U2E,BJ,E19
M1DQ71TME))+(*#*%6&`&:&E2A;#<$(Y/DRPC^\FUHU6463-5/YUE0RN\6Z*E
MC22D>5+%-))(1*:0&YH.>MRE*F&%O,A5#R`9W4^N151E,T7_`\IFBO[)WU(M
MLJ*/:221B%3FP+'2G3@C.\KHCG(MHCJ#NPO?F0\XXZU0FC%<]%L"TJ89B20R
MBG3F>:X7XEN3[BBCD5R+J,YFJOX'G,U4_0Q5J9$E(*TS$DED%.',"4/?G"@C
M@V3T4'(MHBJ#&>$THS<`B[?":88JT4A"6F4BSAC!E6@BPTAG%OSMUIK<F],P
M",GH*+F*!+9EF?<HJK0/%?_\U2>299N31[^`Q"R?+.8QG(*QC#.6=1_?L*$F
M$I%1O,!U+/1@3U6$P1$"E8<9W4^N1515J/37GY/@#3E6%3`TR4A"XIQD^5`A
MX2G$$M&J$EUI3ENITM'L:2M3D-DS&W_KS^<T/USA2KS5%^^K3U6[K^+J>.P6
M9?/&W]C;<""\7;U]F^"SQ5_`HNL16\/;Y>GUA*WA#3)<7]T:P,O_2[&O?B_:
M?7WN%L=J!UV92Q_RL!5?'Q`?^N8RO#U_;7IX[3_\]P!?\ZC@O;6Y!'C7-/WU
M`^_@]L61E_\```#__P,`4$L#!!0`!@`(````(0#<K,X5+@T``-UQ```9````
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;)S=6U/;2!K&\?NMVN]`<3]@V8!M
M*F1J;)W/I]V]=L`DK@%,V<YDYMMOMR4;NJ7TWR07(8B?7OGPJ"WU*Z)/O__]
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MPM?7:EWGL,X;N='KN@=SJ.OI"_S#@K<J^H:"`SD4"9L%S=XD'VUT$&]%.@\E
M/IA#E>10Y6TE?<OI@1S6R0X+WM;I;"CO&KUNT26=,F77Z&6J+NF4J;OF79E+
MD<9C),4XI$2R?S`\)$]JF;S#2S,[+'CWTDR&:F3F?6:D&KMKK(E*G(:(9W8,
MY\WD2C5NG]$VY?69L5K'[QI+(T$/T1YQV"4WDZFZI:C'3+7]-.XQ$^WA)%VC
M/^*T2VZFVHN3]9B)9O*NT3=5=,G-]$9]YF77Z&6JADRN]F/<U>!FK$6K-M90
M<BX^*96<RZ'WZJ<?_H>\R[64O.L+YOH"6U_@-`O4W&JCJGN"\?J,ECC_!!.<
M8,(33-1CIMK[$Y]@DA-,>H+)^HPV/N0GF*+/:'M;>8*I^HRV]]==,QZ\[?U*
M@,5!VB\$6*ZE!%A?,-<7V/H"IUF@!EC;F=T3C'<PAP\/7U\0Z`O"PX)W8_YT
MH(XC48^9:/M7?())3C#I"2;K,5/M\>0GF*+/:/M[>8*INF8\T%[#^F#$6Z.$
M3@R02NC,1P=2BY.B=Y_0XX$V(LP:([9W_!37]M$Y"AN%@\)%X:'P400H0A01
MBAA%@B)%D:'(410H2A05BMHDE'B+4Z@/Q%OJNW-QR'&,KCCW5P>C66-,\49A
MHW`.0I[Z:3N8:_B9=_C9VS/0=CX?18`B1!&AB%$D*%(4&8H<18&B1%&AJ$U"
MB;28/?E`I*76(ZU%8M884Z11V"@<%"X*#X6/(D`1HH@:,=Z?M5P/Q!]UD(BQ
M0H(B19&AR%$4*$H4%8K:))1PRYGX]_-GYL,1J?5P:P=BL\:8PHW"1N&@<%%X
M*'P4`8H01=2(R3[<HH'133>62%"D*#(4.8H"18FB0E&;A))N,6/]@71+K:=;
M.RN;-<:4;A0V"@>%B\)#X:,(4(0HHD:TZ>X;N[%$@B)%D:'(410H2A05BMHD
ME'1;HM^AQ%O.P(W$0O,@OE]-S[DV'3-KD2GH3&PF#A.7B<?$9Q(P"9E$+6D2
MWQ=XKI$P29ED3'(F!9.22<6D-A(U^;(;<_IABR6YGGAMXF?6(F/BFSH&8G,5
MAXG+Q&/B,PF8A$PB)C&3I"7-?F/U'`>E7"1CDC,IF)1,*B:UD:B1EXV9]Y$_
M<;!O^CGJ%(LV9SZS&F3(]9R)S<1AXC+QF/A,`B8ADXA)S"1ADK:DW3MZ/E8R
M+I(S*9B43"HFM9&HT9<]'3WZ4S[.:5I!2O0M;>)@9C7(&'TD-E=QF+A,/"8^
MDX!)R"1B$O>0L?76C=M?(I/T(&W"+&62,<F9%$Q*)A63VDC4](ML=M)_PE&^
M7$T[YK&TF>V9U2!C^I'87,5AXC+Q6G+=7KPPN=+.SGVN$3`)F41,XI;\],$F
M7"-EDC')F11,2B85D]I(U-S+GI,^ZO/U)?+RTT[N]9Y2BXRY-[6\VFO[D#B\
M(9>)Q\1G$C`)F41,XI8TARJCSG1FPB52)AF3G$G!I&12,:F-1`V^[$R]#SY,
MYS2-+/4P1_L`G5FF;M<^S7,F-A.'B<O$8^(S"9B$3"(F<4O:P-]T9_`3+I(R
MR9CD3`HF)9.*26TD:N1EO^I]Y$^[EE!>X=X9Z_5^5(N,8[VI7=:.]4@<WI#+
MQ&/BMZ2)VW`TGHRTW3U0Q70JNDIJPS3DS41,8B8)DY1)QB1G4C`IF51,:B-1
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M3#PF/I.`2=B2=JK1$KU3]6@_XAHQDX1)RB1CDC,IF)1,*B:UD:B)%P<H'QGC
M)=?&^*'VQLV&#3(F'HG-51PF+A./B<\D8!(RB9C$3!(F*9.,2=Z2YE.K[^J'
M@HN43"HFM9&HD=<[LW!8T].1'6KMP-D0VZUS)C83AXG+Q&/B,PF8A$PB)C&3
MA$G*).LAXZ'6?\Q[D#:553`IF51,:B-14R^&XX\,])+K`[UV3#H;-NC]0#\>
M:J_%O!=I\YWV*<CI0=K&7"8>$Y])P"1D$C&)F21,4B99#QD/M5FZO`=I;T'!
MI&12,:F-1,U^7U>6KT:0_Q%/9Q_0IW!:]'X?T%Z1.1.;B</$9>(Q\9D$3$(F
M$9.82<(D99(QR5O2'.Q,IU/]A*7@&B63BDEM)&KR];:LG+RTKO$RM&%/?W;8
MF<OA_FQ;Q[!WV$P<)BX3CXG/)&`2,HF8Q$P2)BF3C$G.I&!2]I#Q4)LNJ7J0
M-I[61J+&OZ]%>TK\>WJTH\YI+G97YT,D-A.'B<O$8^(S"9B$3"(F,9.$2<HD
M8Y(S*9B4/60\TDXDJQ[4B;\I5&K\]3[M::VK84^_=J2=!<U:9!C9YTQL)@X3
MEXG'Q&<2,`F91$QB)@F3E$G&)&=2,"E[R'BDG5!6/:B3?M-%`&KZ95OT?>,6
MYGF:+JJ8F'S[?SWT:U1F0VRUSIG83!PF+A./B<\D8!(RB9C$3!(F*9.,2<ZD
M:,EDM+^T>W`QT&8U2JY1,:F-1$F\/*55$G_:>+]?39OK&6G/9=8BTWC/Q&;B
M,'&9>$Q\)@&3D$G$)&:2,$F99$QR)D5+FE/AH?R]+K5W5W*-BDEM)&KR]<9M
MDWP\SQWU='!'VJ37K$7&Z','EZLX3%PF'A.?2<`D9!(QB9DD3%(F&9.<2<&D
M["'CD39O6/4@_5#'2-3XRW;J^T.=$P?^I@NK'O+HLSRC!AG3C\3F*@X3EXG'
MQ&<2,`F91$QB)@F3E$G&)&=2M*1M^`ZOK8&E'2B47*5B4AN)FGV]G7MB]GO:
MNB-M,FHVXK8N$YN)P\1EXC'QF01,0B81DYA)PB1EDC')F11,2B952XY[D'[H
M5!MKJ,D78_*OC/IR->UP_TH[@)N-&F0<]9'87,5AXC+QF/A,`B8ADXA)S"1A
MDC+)F.1,"B8EDZHEQ]-E;>JS-I90@_]K_=Q13S]7OVG%K$7&X#=U#,3F*@X3
MEXG'Q&<2,`F91$QB)@F3E$G&)&=2,"F95"UIAOSNR7)M+*$&OZ^=*\^2S5.;
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M&UP(_+A>[P[?R`T<;\SX^?\```#__P,`4$L#!!0`!@`(````(0"EUM?E`00`
M`!4/```9````>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;)2776^C.!2&[U?:
M_X"X+V`^DRA)U8"Z,]*.M%KMSEP3<!)4P,AVFO;?SS$F!$,*I!=)B1]>WO-A
M;*^?/XI<>\>49:3<Z,BP=`V7"4FS\KC1___O]6FA:XS'91KGI,0;_1,S_7G[
MYQ_K"Z%O[(0QUT"A9!O]Q'FU,DV6G'`1,X-4N(21`Z%%S.&2'DU641RG]4U%
M;MJ6Y9M%G)6Z5%C1.1KD<,@2')'D7."22Q&*\YB#?W;**G95*Y(Y<D5,W\[5
M4T**"B3V69[QSUI4UXID]?U8$AKO<XC[`[EQ<M6N+P;R1990PLB!&R!G2J/#
MF)?FT@2E[3K-(`*1=HWBPT9_0:L(>;JY7=<)^IGA"^O\K[$3N?Q%L_3OK,20
M;:B3J,">D#>!?D_%3W"S.;C[M:[`/U1+\2$^Y_Q?<OF&L^.)0[D]B$@$MDH_
M(\P2R"C(&'9M(R$Y&(!/K<A$:T!&XH_Z^Y*E_+31'=_P`LM!@&M[S/AK)B1U
M+3DS3HI?$D+"5"MB-R+PW8@@SW!M+U@\HN(T*O!]5?$?5W$;%?B^JMB&O?"0
MYT]'9,KLU,F.8AYOUY1<-.A@B)]5L9@/:`7*URS+G+1Y_RKMD"HA\B)4-KJO
M:Y!1!KWRO@U<=VV^0WV3AME)!CY;!JE$."0\3T6B*R(Z!R)HPX`"=<.XWR17
MMP(6;D6EA?V=_*%KS5:?&PX)%*A(=`=9M(AB%OI@OED!0^]VTN9;?JLK_4L&
MRM>FMI?\<)*(Q@C%/3QFOGL!;W1(3>O,]GLUW4DFJ-L&^9Z[Z)M7`"]PO1X0
MJ8!G+6\)4JS#Q)]O7<"J=7AR+_&26=36GY#GPI]*A)-$U".<A>^T&HI[F%[S
MW0M8=3_(NT0:\RZR^STOQR&W;>UZP45CA&(]>,2Z@%7KMM^;;#O)2._^$MTF
M6CTAPNZP8R&K36@]''6'D>U\D6^QD^B\&L??*0)630?NK0OE-)7,2$+#22(:
M(Y24+Q]Q+^"IEXQDQMQ/$M$8H;A'L%^8G_R:[F>_WS(-U`T@</N-,P>*[D"W
MF:&&(=:KV3V$Y.HV_K9L(-GZR+>=P>M2)3P?H%[_]PAG87WE7RQJ\_W+);#K
MWW>7ZK-W2$+=,MP>+F?O-!*-(FH)Q,(V/P2Y#,)G^](;+K=H;*UL0IA$HE$5
M-01(U@,A"'IR,DBH6X7`[JUN(9H!17>@6SW5,,1*-[\2<EWL-M-PZR`.!!"K
MW#LXR.J]Z$-E'-G+P43HWJ^,2^?R="(WS`6F1QSB/&=:0L[BY(%@W6]_;4]%
M+W9]KFD'X%!2Q4?\(Z;'K&1:C@]PJV4$\&@JCS7R@I.JWH[O"8?C2/WO"8Z?
M&#:HE@'P@1!^O1#;W_9`N_T-``#__P,`4$L#!!0`!@`(````(0!^U5#)M`(`
M`.D&```9````>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)2576_:,!2&[R?M
M/UB^;[X@0"-"50C=*FW2-.WCVCA.8C6.(]N4]M_O."8I@6[M;B!V7C\^[SGV
MR?+F2=3HD2G-99/BT`LP8@V5.6_*%/_\<7>UP$@;TN2DE@U+\3/3^&;U\</R
M(-6#KA@S"`B-3G%E3)OXOJ85$T1[LF4-O"FD$L3`4)6^;A4C>;=(U'X4!#-?
M$-Y@1TC4>QBR*#AEF:1[P1KC((K5Q$#\NN*M[FF"O@<GB'K8MU=4BA80.UYS
M\]Q!,1(TN2\;J<BN!M]/X930GMT-+O""4R6U+(P'.-\%>NGYVK_V@;1:YAP<
MV+0CQ8H4WX;)=HK]U;++SR_.#OKD&>E*'CXIGG_A#8-D0YEL`792/ECI?6ZG
M8+%_L?JN*\`WA7)6D'UMOLO#9\;+RD"U8S!D?27Y<\8TA80"QHMB2Z*RA@#@
M%PEN3P8DA#QU_P>>FRK%DYD7SX-)"'*T8]K<<8O$B.ZUD>*W$X5'E(-$1PBL
M.$+"R(L6<1C/WJ;X+J+.8$8,62V5/"`X-+"G;HD]@F$"Y-Z9BV/P^C>KX-%"
M;BTEQ3.,P(6&\CRNYM/KI?\(.:5'S?I2$XX5FUYA$VBQ63_Q@HWC\9IM+['E
M`TN#+\C6J:_7*]6';\4V_'[CM9L`]N`G&N^[N53$B[$DNY2$\[%D^XKDA3+R
M,_D?/U8,9^PD_'D<C+=>.\WT1#,=*S9O*K(W%=M_*4;^()#WU\N*4PS)&\H3
M1F>I73O-O#N,9]XWI^^FT=E!S4[?QHNS0PIMQN[MN+/)9,B9<^-:B+MA@JF2
M;5A=:T3EWK:'"40SS`Z=ZS:R!^]L?ATF<!\NYS/H=-V\/RR`3M.2DGTEJN2-
M1C4K8*O`F\-U5JY7N8&1;7??=])`C^D>*_BD,+AI@0?B0DK3#^QU&CY2JS\`
M``#__P,`4$L#!!0`!@`(````(0"TL3UW^`,``+T0```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,X+GAM;)R8WV^K-A2`WR?M?T"\-\0DA"1*<G4)=+O2G31-
M^_%,P$E0`2/L-NU_OV,.)=C)M;/UH0WMY^/S^=C&[N;+>U4Z;[3E!:NW+IE,
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M7/X*&GLWK9^["OS>.CD]IJ^E^(-=?J7%Z2R@W`$82;%U_A%3GL&(0IB)WZ61
ML1(2@.].5<BI`2.2OG<_+T4NSEMWMI@$X71&`'<.E(OG0H9TG>R5"U;]@Q"1
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MB(:WHO9M1S921<-`RR!"9BQZS:#+<6\E8BN1F`C%4YYVM%>)W5,VLFVOR)@\
MK41L)1(3H7BN5$_S]BIAM8ZWVRLR)C\D<#)J6R.N2QN0F/I0[`B\_<=E-.MU
MM.ZG[Z\]9!+LD7[KT;9'5+0CB;$CU5(>&[3)^L"Y!P\;RLMRI6V1$4'(:(O(
ML-&&(*SN+G$?Q8`DQHY46WET^.^V>.!0;;6=-"((&6T1&53NO%;Z*`8D,7:D
MVLJ#Q,C6,H/QV*%::OMH1*RGEWV/H,+=-:H0Y-XKQ=B-Z@@#/G9\[)1`9"MM
MM:X"=>9%/62L*,;IRW5?%I%Q%/TMG!A[4G7EJ6)4T@=U\2RBEE8_+<A['(S)
M.%&M^OL[B.X2]PR>7N\7U]01VN(%%.]G37JBOZ7MJ:BY4](CG,ZGDQ!"M'C]
MQ`?!FNX>=F`"KHW=QS/\FX#")6TZ`?C(F/A\D!?<X1\/NW\!``#__P,`4$L#
M!!0`!@`(````(0"#0^H"?0L``'U8```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;)S<77/:O!('\/LS<[X#PWT#M@%#)LDS-;(LO\V<.7->K@EQ$J8!
M9X`V[;=_)$LF:.WH3]*+IB4_;VSO6I86XIN_?F]?!K^J_6%3[VZ'WM5X.*AV
MZ_IALWNZ'?[W/_S;?#@X'%>[A]5+O:MNAW^JP_"ONW_^X^:MWO\X/%?5<2`C
M[`ZWP^?C\?5Z-#JLGZOMZG!5OU8[^9W'>K]='>5_]T^CP^N^6CTT&VU?1OYX
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MACPCJ]_-U[?-P_'Y=AC,KJ;A./`D']Q7AR/?J)##P?KGX5AO_Z^19T+I(+X)
M(K^:()YW-9].)[-Y>'F4P$217]LH_I4_GWK3V2?V96*BR*]?/R"YT\U969R"
M>%_8%4]F4Y]<>?K:0PH_?7:]]O1Z7SHS(YWQIH#8ZKBZN]G7;P-Y5<J=.KRN
MU#7N7:O0;>GH1)^*Z:-:DD6DHGQ786Z'L^%`ELE!7@"_[L+IY&;T2Q;MVIBH
M:V83SS;+UJ@:58$9?2&F+_#VA?<?38(FK6B#BO:%]TVF4WM'TI:TVV3Z!?GW
MZ0BG,WN;O(>$-BE:TH8MSUX8R92<\B+3;>6E_U)N3[_2ZO2W82/]POG>AO00
MEWV&'!+K,^28XJ[QYO9A\R[Q;9%TQ90$$5WBD5U)>PB)DO40$B7O$K*W15?,
M)H%]1&77A-/W.%:RY75G)5M=A($<-]Q)5UM)=U:1(3UGD39R&#Q5+;DJEU`P
M*&(H.!0)%`**%(H,BAR*`HK2):S$R\18B7<G7.G;H:RK4S+#Z<*NND@;5\*A
M8%#$4'`H$B@$%"D4&10Y%`44I19A<^-;C-6?4UJL?,LIQ2?RK33)]^P]<'-_
MC+21/_]4$_0"AX)!$4/!H4B@$%"D4&10Y%`44)1:S)M\?_.F'R=<SHBLA%\V
MLJNM:.+)I";2QI5X*!@4,12\%6K.1XHS:;_W87$**%(H,BCR5O3L8Z&_IU/I
M3:Q,-E=8V6[<=Q#6Q1U^*==J*YKK]VF"OLBUT?OHS\]'E^;[2_U]1RTP*&(H
M.!0)%`**%(H,BAR*`HK2):RTJR8*74'AR9O:BJ:=S"`C;1QI74+!H(BAX%`D
M4`@MS&7FSP*RT$AAA`R*'(H"BM(EK+3+KL`7TJZVHFDG-^Q(&U?:H6!0Q%!P
M*!(H1%>$,[K4[AIR1C(H<B@**$J7L%*O6CI?R'VS&4T^N0XB@US9QX1A$F/"
M,4DP$89\?(=-<9`,DQR3`I/22>PJ4*V;\X'?O7CS=*?'6KW-2.<A,LB9?1W'
M01B.$F/",4DP$9BDF&28Y)@4F)2&S(-F:C^^&K^WC^SDJ^[.)Y*OFT%V\M]#
MZUF>:O'*FX,CLTM,&"8Q)AR3!!.!28I)ADF.28%):8@>J4+'JDXURJWL7[:L
M:S:C-P#:P#'(606N_E)32PQ'B3'AF"28"$Q23#),<DP*3$I#3D/`/`@"M2QL
M_[Q/3NP106;,J@EP.U"<U$)(UL^1IY&S%B!A.$K<0\*0=!QX#WH_%TW9)9@(
M3%),,DQR3`I,2B>Q"T`UA<YO"6I0F,@702'H7I)U:PAI`T"]F8MN#9`P'"7&
MA&.28"(,T6-MTW8YZYDVQ93B*!DF.28%)J63V&6@^D7G90#2K]M+=OII(\!S
M]:":D[7$A&$28\(Q23`1F*2&Z`KQY^%X1@:D#`?),2DP*9W$SKYJ&YUG_\*9
M@>XVV55`!M?(<[6D3!5`PG"4&!..28*),$2G>#J;ACZ9#:4X2(9)CDF!2>DD
M=A6H+M)Y%8`Q0#>=SK/O>9TQP-69,MF'A'F0Q)AP3!),A"$Z^T$H/^1#YC\I
M#I+!(#D.4F!2.HF=?-5'^D3R==OI//EA2%IDD>?J39GD0\)PE!@3CDF"B3!D
M8=;9(5D,ISA$!D+D.$2!2>DD5N)]VA9T7_4-IRL`V@XTR+4"P(1A$F/",4DP
M$8;HQ'M7GM>NJYJOY!:?XH`9)CDF!2:ED]B50%N#E\T"_)X684A;A`8Y*P*W
M"'NBA/0:C'L0F9-P3!),!"8I)ADF.28%)J63V(4@AW7K7J`*P5.%!,8&M1T=
M&\C<*/(U<E8")*PG2C@G-^*X!W4J`?ZH!$<1F*289)CDF!28E$YB5\+76H:^
M;O7)<WOZ?$\X)X-D9)"S$'0<QW*;X2@Q)AR3!!.!28I)ADF.28%)Z21V&<@D
M60,"&`<4M\<!SR=3I<C7R)E^2!B.$F/">XA/FEF),;H69[*</3+K$9:0L^%9
M0.Z"J24\?Q+,R'HILP3Y3%XS8\ZA*(QPG-G22>S4JP;=^;K@PDE!MS_HT65R
MI'XU`O0',6&8Q)CP'M(M`;V_N@1\;Q'Z9,4C3!0CIKX_(66?6F(RGDS('2FS
M@+_P9PM2B3D4A1'."G"=>[L"/M<:]'M:@W-R")%!YCSU?#;,`,<1,$QB3#@F
M"28"DQ23#),<DP*3TDGLY'^M,^CW=`;G9*R+#-)%X'4_7;4TP%D$L'48XR@<
MDP03@4F*289)CDF!2>DD=A&H]MOY/0#<_G6WSI[]D6$N\F%+;XD)PR3N(71@
MYQ>8I,>08Q*&F(+N^51NVA.$[DP&H^071"EZ#-G=TDGL`OA<<]#O:0[.R:TR
M,LAQ<2\Q89C$F'!#3.+&P9CV=!,<1&"28I)ADAOR\=X6.$CI)%;RU:>"/W'U
M-]R>_(=S,E6.#'(E'Q.&28P)QR3!1&"28I)ADF-28%(ZB9W^KW4%`]W-DPOX
M]Q9`]_?\8,MO:>(X*H5A$F/",4DP$9BDF&28Y)@4F)1.8I>!:I2=SP$N6P<&
MNK]FSP7(LC@RR)'C)28,DQ@3CDF"B3"DG0D$TX"L@%(<),,DQZ3`I'02NPIH
M/]`]$PSZ^H!D11P9Y,R^CN,@#$>),>&8))@(0SY\EQ"'R##),2DP*9W$SKT\
M_=8(`'*O.)T'T#<#`HT<B5UBPC"),>&8))@(0Z;-.\238+(@4Y\4Q\@PR3$I
M,"F=Q$Z^:A>=#_\@^;J[9`W[G5_Z#EPM*/WQ`$P8)C$F'),$$V&('O:;WAUY
MTR/%03(8),=!"DQ*)[&3_[D.8-#3`>S\!KA!SBM?QW$0AJ/$F'!,$DR$(?K7
MZ<EO5S?5G.(@&0R2XR`%)J63V,FG'4!PY?=T_A;DC=DH@%V[)28,DQ@3CDF"
MB>@AG8^BISV(]&0R3'),"DQ*)[$+X'/=OZ"G^[<@PV!DD./27F+",(DQX9@D
MF`A,4DPR3'),"DQ*)['33WM_%R[\=`\0K/\U<I8!)"R`),:$8Y)@(C!),<DP
MR3$I,"F=Q"J#">T"7E8&S69T%4#7_P:YR@`3ADF,"<<DP4088M;__FQ.W_M.
M<9`,DQR3`I/22>PJH,U`]V1@HOM[UC)@3M?_!CFS#_N$#$>),>&8))@(0]KU
M_YC<_5(<(L,DQZ3`I'02._>JE7?Y$E`^.12O_PURYE['<1"&H\28<$P23(0A
M'Z__<8P,DQR3`A/U=->//X"CDZ^?WJH?OKFM]D_5LGIY.0S6]4_U9-:);'.<
M7CT]-?9[\]!8\GKD7<NG8,I'/9+7N7<M'W79?5UXU_)QEO+UT6D#^?#7U]53
M5:[V3YO=8?!2/<I=&%^IY[3N]>-C]7^.]6OSB-#[^B@?^]K\\UD^YK>23^8<
M7TG\6-?']C_J!YP>''SW-P```/__`P!02P,$%``&``@````A`-^-YJ:R&0``
M*/<``!D```!X;"]W;W)K<VAE971S+W-H965T-#@N>&ULI-U;4]O8MH;A^UVU
M_P/%_0KX`-A4DE73EN63?#[[CB9.0G7`*:`[O?[]'K(D8PUIZ1UD]T5W1WD\
M),OZ!E.':3[^^Y_''V=_[YY?'O9/G\Y+'R[/SW9/]_LO#T_?/ITOYOZ_:N=G
M+Z]W3U_N?NR?=I_._[-[.?_WY__]GX^_]L]_OGS?[5[/I,+3RZ?S[Z^O/V\O
M+E[NO^\>[UX^['_NGN1OONZ?'^]>Y8_/WRY>?C[O[KX<7O3XXZ)\>7E]\7CW
M\'0>5;A]MM38?_WZ<+_S]O=_/>Z>7J,BS[L?=Z^R_2_?'WZ^)-4>[RWE'N^>
M__SKY[_N]X\_I<0?#S\>7O]S*'I^]GA_V_WVM'^^^^.'O.]_2M6[^Z3VX0^9
M\H\/]\_[E_W7UP]2[B+:T.Q[KE_4+Z32YX]?'N0=A+O]['GW]=.Y*]VZ?O7Z
M_.+SQ\,>6C[L?KV<_/_9R_?]K_;SPY?@X6DGNUL^J/`C^&.__S.DW2_A(GGQ
M1>;5_N$C&#^??=E]O?OKQ^MT_ZNS>_CV_54^[RMY2^$[N_WR'V_W<B^[5,I\
M*%^%E>[W/V0#Y-]GCP_AL2&[Y.Z?PW]_/7QY_?[IO'+]X>KFLE(2?O;'[N75
M?PA+GI_=__7RNG]<1:@4EXJ*E.,B\M^X2+EN?G$E?K'\-WGQS8=R[:IT=?V.
M3:@F[T-6_/]X([+_#[NC?+(UU0_5\M5-[5T[)-F<BNRXW]^<2K)CP_])RE3>
MOSF5XSY^>UL5^\=;.;Z;F[?-,!\E%]$1=SB`O;O7N\\?G_>_SJ0MR*YY^7D7
M-IG2;44J)X=N=*`=#^;_=BS+01Q6<6&93^?7YV=RF+Y(`O_^7+NI?[SX6T)S
M'YM&9.3?1W-=+:5-,\]<IHV779>JTDI$F+1P\_QLV:NK=-5VEJBJG:S01;I9
MHHKTLD(7Z6>)*A)$XG1OZR*#A"2[8)BMFMG[HZQ1:QYGA5[S)"')FJ?)@K?/
M756=986N.L^2ZZHZ,!99HU:TC$31CELE)-G\=;+@;?,S:]XD)GG15B]P<4)D
M^?'H5QOGXH`<?DY%J8KC<+(D/OBCSG](WO%@?RN<^6!='("30L?C/=ED%Q_?
MISLG6R@^PD\*Q4?TR9+"`_A"^LZQ^4A#336?_)^728\)==ACDBUN)`O>WGFM
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MXAE,*VNN2^HS\@VF;3`=@^D:3,]@^@83&,S`8(8YIJ8.X9'!C`UF8C#3K*GI
M[9D9S#S'U%7J%@:S-)B5P:SSC#KF-P:S-1CG+*AA07E1K:O-=GE9S:"<L-;J
M:A#C<M):JZL?M2XGKO5+]9/)Y>4U4RDGL/7+BNK?.8G-HIS(GJ)45Y53[=_H
MJN&K4EU5+VA&"]X&[YY>T$H6G`YIU=OU#::=9]2/XH[!=`VF9S#]/*-^Z@4&
M,S"889Y1A_'(8,8&,\F::]W#IHE)SEMF>L%<+UCH!4N]8*47K),%)T=.71TY
M&X/9&HQS%M2PH&,D"C;;'6/RAC)[V>5$)XMRLI-%.>')HISTW&3&C#GQJ5^J
M&+J<_&113H!.4:I[R37%W^A>X:M2W4LO:$8+3KJ77M#2"WR]H*T7=/2";K+@
M[;.NU=1QW#.8?F*2U`5ZP2!94+"F86*2*B.]8*P73/2"J5XPTPOF>L%"+UCJ
M!2N]8*T7;/2"K5[@7&9)(UERLD_*^@?W\4`X1>HC<EY2*=ES[GATO+WL6E\-
M<)DCQF4.&9<Y9MSQH#FN+.<0R:[L]!A))4BN@?U&@L)7R=G7R16^FCYE;T1&
M.N/Q*J!J!TT4'HH6"A]%&T4'11=%#T4?18!B@&*(8H1BC&*"8HIBAF*.8H%B
MB6*%8HUB@V*+PCDFG#K'L7.<.\?!<YP\Q]%SG#W'X7.</E<8OU3/E'N'J9Y9
M?`4JU)_.Y9KBL0_6+]5UH49DBGHE"@]%*Q(WAZMZE<O#/^G32Q]%&]?20=%%
MT4/11Q&@&*`8HABA&*.8H)BBF*&8HUB@6*)8H5BCV*#8HG".":?.-;D*Y\[%
MP2N(MXN35T0X>HZSYSA\CM/G"N.7ZI7A@U^G#UT4]\I0IWME[5I=)VU$IF!/
M-5%X*%J1J!UZY<W-5=@L5:]$T3X5I4,)5:.#HAN)@G?;0]$_74O>6PD(#`@,
M<2-&*,8H)BBF*&8HYB@6*)8H5BC6*#8HMBB<8\*1<YPYQZ%S<>H*CG;G\^;&
MN2NJ$@>OB'#R'$?/Q=G+7U&J4<ISA.]HE*%.-\KZI;KPVXA,_JH/#]TT47@H
M6BA\%&T4'13=2$0-NQ0-;E6W[3'IXWH"%`,40Q0C%&,4$Q13%#,4<Q0+%$L4
M*Q1K%)M(I(Z0](_T+0KG<#6.<^<X>(Z3YSAZCK/G.'R.T^?B^!4T&Q?'KX@4
MQB_5+4ORX,<[VN6!ZWZI'BQHQ*A@`YLQN8H>C"E5].,L'M=H,?'5:DHE=>6T
MS34Z3+I,>DSZ3`(F`R9#)B,F8R83)E,F,R9S)@LF2R8K)FLF&R9;)O)X<)C=
M3^<%.9/G@]DD82RJ8\BC,P12'BKF[3&$4AX\YCJ&6#I#+EUQ,-/=5)Y^2W73
MP]2(2[FO57RZ7@I?I]NJ>D*F$:."CZG)Q&/2RB'UDAH#^KE(W?9KYR#5@3M,
MNDQZ3/I,`B8#)D,FHQQ2+ZD'L,:Y2-TSG>0@M8>G3&9,YDP63)9,5DS63#9,
MMCFDK@<(TF2C:)ZF+JL,V72&<#I#.J7-9K=(?>329MD8PBEMENL8XBEMENL4
M!S3=9L,'R^T70TO1<^BI.T<E]219(T:GG[/:JTTF'I-63&J5P]CW\H/.O<\U
MVDPZ3+I,>DSZ3`(F`R9#)B,F8R83)E,F,R9S)@LF2R8K)FLF&R9;)M)1HS@6
M)$V&K6P,<91^RG620!9MCR&3SA!*Z:>\/8982C_E.L7!3/?3\*'Q=_33Z!ES
MV82W._%ZAD:C%*&"O=IDXC%IY9"ZGAKEYR#5W=M,.DRZ3'I,^DP")@,F0R8C
M)F,F$R93)C,F<R8+)DLF*R9K)ALF6R;24S%MTE/9&"(I/97KY(52Y4W&J%S'
M$$KIJ5S'$$OIJ5RG.)CIGBJ=[ST]->3J"D`I<V$U0H4]%8E70M)BXC-I,^DP
MZ3+I,>DS"9@,F`QC$MT=R7G<8<0UQDPF3*9,9DSF3!9,EDQ63-9,-DRV3*2?
M8D:DG[)I&HPACW+.S^LR)%+&J%S'D$EG"*7T4UY7<2S3_32<'/".,6HTER`]
M1LU<48V0;.=Q(*M^2C7#KV0JOL;N,6DQ\9FTF728=)GTF/29!$P&3(8Q*>BG
M^`F->343)E,F,R9S)@LF2R8K)FLF&R9;)M)/\4.2?LK&$$<9GW(=0R!E?,IU
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MF/A,VDPZ3+I,>DSZ3`(F`R9#)B,F8R83)E,F,R;SF,3=6;YW/3,E;I$B)?EB
MP0Q9IDGMJEZIJ&?#5KPM:R8;)ELFTEDQ:])9V1@"*2-6KF.(I(Q8N8XAE#)B
MY3J&6,J(E>L4!S/=6<,I&+_16:.9&^G.J@Z]1@FG=S29>$Q:3'PF;28=)ETF
M/29])@&3`9,ADQ&3,9,)DRF3&9,YDT5,3IZ^4P\"+E&L>#5K)ALF6R;25S%I
MTE?9&.(H?97K&`(I?97K&"(I?97K&$(I?97K%,<RU5?+X=2$T[Y:_.S_@:L[
M_V5U&ZH1HZ(K`$P\)BTF/I,VDPZ3+I,>DSZ3@,F`R9#)B,F8R83)E,F,R9S)
M@LDR)LG5B'`TF[X:L4*QYM5LF&R9R'>6\\0B0QKE.\NYCB&/\HWE7,>02/F^
M<JYCR*0SA-(94NF*8YGNI^'<@=-^:KNR6HZF'*3'J>J'?2-&A7T5IRYX7*7%
MQ&?29M)ATF728])G$C`9,!DR&3$9,YDPF3*9,9DS63!9,EDQ63/9,-DRD<Z*
M09)?!Q&9Y&=%WG?]2&L]1:5*WA449\BD]%;>(D,JI;=R'4,NI;=R'4,RI;<6
MU4GW5FF/F=Y:E0<-8,P:ODR/6?5W\94C5-A;D7A<I<7$9])FTF'29=)CTF<2
M,!DP&3(9,1DSF3"9,IDQF3-9,%DR63%9,]G$)&IXT7>;I0?'6Q3263%&TEG9
M-`W&D$?IJ[PN0R*EKW(=0R:EKW(=0RJEKQ;52??5<"[!;XQ9HRD(LIKC`ZGU
MLOXZJO!77!8_DMIDXC%I,?&9M)ETF'29])CTF01,!DR&3$9,QDPF3*9,9DSF
M3!9,EDQ63-9,-C&)!Y(Y\S"V**2O8M*DK[(QQ%'&JUS'$$CYY65<QQ!)^=5E
M7,<02KD6P'6*8YGNJS*:_)V^&KY,CU?U[*IRA`K'JT@\KM)BXC-I,^DPZ3+I
M,>DS"9@,F`R9C)B,F4R83)G,F,R9+)@LF:R8K&,2-<U*^`VWZ;'HAFMLF4A?
MQ1A)7V73-!A#'F6\RNLR)%+&JUS'D$D9KW(=0RIEO%I4)]U7P[D%I^-5./^/
MIB*DQZEZ=E7X2^!IG(K$XRHM)CZ3-I,.DRZ3'I,^DX#)@,F0R8C)F,F$R93)
MC,F<R8+)DLF*R9K)ALF6B714#))T5#9-@S$D4CIJLJ[/'__^K.]FRR`U^>NW
M\UQUQUN:*1M#(*69<AU#)*69%M5)-]-P8L%I,S7>L(KF(YPVU1O]12:-,DY:
M:#+QF+28^$S:3#I,NDQZ3/I,`B8#)D,F(R9C)I.8Q..U4JFF;F].N<:,R9S)
M@LF2R8K)FLF&R9:)M%1,FK14-H8XRLE_5"?Y("O7ZEZ*--134:V5RIG?"9G$
M,2Y2N\K\]MPDC<EJ;F[41",YZ^<W9$BCG/5SG>(\IAMJ.%O@M*'"Z#2:7)!N
MI)FS_:(9"-&W^I>1>$Q:3'PF;28=)ETF/29])@&3`9,ADQ&3,9-)3*)@W-2O
MR^IYYBG7F#&9,UDP63)9,5DSV3#9,I%&BC&21LJF:3!)'J,/LE2_J:J34FFD
MT9KB'EBI5W6K3=(8B7*Y5E4W8&1H>EJC=)UYH$WZ*+\?0QBECW*=XCBF^V@X
M?^`=?32:;G#:1^L5=4FH4<8Y"4TF'I,6$Y])FTF'29=)CTF?2<!DP&3(9,1D
MS&02D^37.F3FG4ZYQHS)G,F"R9+)BLF:R8;)EHGT44R:]%$VACC*@#2JDWR0
M5YD>F,3QOPM#&J63\O8:\B@G^5S'D$@YR2^JD^ZEX9R!=_32:(I!NI>JX7>C
MC/,0FDP\)BTF/I,VDPZ3+I,>DSZ3@,F`R9#)B,F8R83)E,F,R9S)@LF2R8K)
MFLF&R9:)=%/,FG13-H9`2C?E.DDDXY%K-7/O32Z:<A5#)&5LRG4,H92Q*=<I
MCF6JGU;"^0GV?GK@ZHY^1<_OCY'<!3L^3J4N,S>9>$Q:3'PF;28=)ETF/29]
M)@&3`9,ADQ&3,9,)DRF3&9,YDP63)9,5DS63#9,M$^<,IF$PAD`Z0R*=(9(N
MR61\IG]95I?/G2&1SA!)9\BD,X32%:<RW4[#*0#O:*?1C('T\%1=!&M4BJ85
M1)=,F7A,6DQ\)FTF'29=)CTF?28!DP&3(9,1DS&3"9,IDQF3.9,%DR63%9,U
MDPV3+1-IIY@U9\BC:QKJ&!(I[92WYRV3X4W_[`#6$$CIIKP>0R2EFW*=XE"F
MNZDTQE0WM=W1KX0O2P]2;RKJBG0C1H6#U*A.`?&X2HN)SZ3-I,.DRZ3'I,\D
M8#)@,F0R8C)F,F$R93)C,F>R8+)DLF*R9K)ALF4B716#)%V53=-@#(F4KLKK
M,F12QJE<)TEE?(&AG.W/AE!*7^4U%<<RW5?#R0&GHU1C7XWF%,BF',_K;ZKZ
MQE0%)QXTF7A,6DQ\)FTF'29=)CTF?28!DP&3(9,1DS&3"9,IDQF3.9,%DR63
M%9,UDPV3+1/IJY@UZ:ML#(&4DW^N8XBDG/QS'4,H9<0:U7G[1K'TG`DY^><5
M&4(I)_]%==)M-7SN7[?5&WE^M?BYJ4KXLO1PM5Y1%TP;,2H8BS:9>$Q:3'PF
M;28=)ETF/29])@&3`9,ADQ&3,9,)DRF3&9,YDP63)9,5DS63#9,M$VFK42`+
MLB9ME8TAD-)6N8XADM)6N8XAE-)6LW7J%7V!UA!,&;)F*ZFF)KVUR*1[:S@-
M0/=6>1P7FVLT?>!TS%JOJ&?/&I6B.0;Q%58D'E=I,?&9M)ETF'29])CTF01,
M!DR&3$9,QDPF3*9,9DSF3!9,EDQ63-9,-DRV3*2Y8I"DN;)I&HPAD7(M@-=E
MR*1<"^`Z>:FL5_1CKH9@2G/EM15',]U<PVD#NKF&=PUAX!K--CCMK3=5_7!5
M!:<D-)EX3%I,?"9M)ATF728])GTF`9,!DR&3$9,QDPF3*9,9DSF3!9,EDQ63
M-9,-DRT3Z:V8->FM;`R!E($KUS%$4@:N7,<02AFX1G6BZZQRE55=EY3K`;PB
M0RAES%I4)]U6PUD$NJV6+J5U0U^-9A^<]M5Z14^DJN`4A283CTF+B<^DS:3#
MI,NDQZ3/)&`R8#)D,F(R9C)A,F4R8S)GLF"R9+)BLF:R8;)E(GT5LR9]E8TA
MD-)7N8XADM)7N8XAE-)7N8XAEC)BY3IYP:R?W+A/-]=PRH!NKH8Q:S33(-5;
ML_>PBJ8CQ-<#D'@5)"TF/I,VDPZ3+I,>DSZ3@,F`R9#)B,F8R83)E,F,R9S)
M@LF2R8K)FLF&R9:)]%9,B?16-DV#,212K@?PN@R9E.L!7,>02AFV<ITDE_$#
MM>'@5X]^BW.9;JSA_(+3Q@J#U6@Z0KJA9BX"X)R%9@6)QZ3%Q&?29M)ATF72
M8])G$C`9,!DR&3$9,YDPF3*9,9DS63!9,EDQ63/9,-DRD8:*09*&RL802!FL
M<AU#)&6PRG4,H93!*M<QQ%(&JTF=P_=HJ2<+BB.9ZJ55/;O*]J#5X67JB8"J
MGF45([F#=GP:2]U?:S+QF+28^$S:3#I,NDQZ3/I,`B8#)D,F(R9C)A,F4R8S
M)G,F"R9+)BLF:R8;)ELFSAE,PV`,@72&1#I#))TAD\X02F=(I3/$TB6YC`:I
MX9>W9,:HA7LPW5?#:0:G8]2PKU[C#:MJ-#LA/5;5TZUB5-A7<9:#EU.E7E7]
MN96#%/&9M)ETF'29])CTF01,!DR&3$9,QDPF3*9,9DSF3!9,EDQ63-9,-DRV
M3*2S8I1<PV":!I.7214WZ:R\/89,2F?E.H942F?E.H9<NN)@IGNKM,=,;^4+
MJ]7P97K,JAX<:\2HL+=&=0J(QU5:3'PF;28=)ETF/29])@&3`9,ADQ&3,9,)
MDRF3&9,YDP63)9,5DS63#9,M$^FL&"3IK&R:!F-(I'167I<AD])9N8XAE=)9
MHSHG$[/T@-002VFL19N3;JSA1`(]:#4TUFC^@:SF>)Z?^?;$1K5HDD)TQXJ)
MQZ3%Q&?29M)ATF728])G$C`9,!DR&3$9,YDPF3*9,9DS63!9,EDQ63/9,-DR
MD<:*69/&RJ9I,(9$2F/E=1DR*8V5ZQA2*8TUJE/86'E5Q;E,-U89+/Y.8PU?
MID>LZFG<1C5"!</1)A./28N)SZ3-I,.DRZ3'I,\D8#)@,F0R8C)F,F$R93)C
M,F>R8+)DLF*R9K)ALF4BC16S)HV5C2&0<I65ZQ@B*5=9N8XAE'*5E>LDL;PY
M#^]*Y5U!-:12!JQ%:TKWU7"2P>F`M?A)@/#W5V?ZJ7YL-4;)]]=6+M4E@B8!
M+P;R+H[C8745I\7$9])FTF'29=)CTF<2,!DP&3(9,1DSF3"9,IDQF3-9,%DR
M63%9,]DPV3*17LH3A!H&D\2Q(&W22WE=ADA*+^4ZAE!*+^4ZAEC*'2NN4QS,
M=#<-YPV<=E/CLP#1=(/TZ;_^,JMJ=DY"_4I=SFCF(-4XO1Q2OU(/<[5RD*KC
M,VDSZ3#I,NDQZ3,)F`R8#)F,F(R93)A,F<R8S)DLF"R9K)BLF6R8;)E(=\WF
M345`1JIL#)&4[LIU#)&4[LIU#*&4[LIU#+&4[LIUBH,9==>+E^^[W:MW]WKW
M^>/C[OG;KKG[\>/E['[_UY.,#^LR5CXN/7O>??UT[EJE6^>7SB^R?].1O^GE
M_4VC?-NXRGN%O"!ON5>Z;>75"4JW@[SER]+M*F_YNG2[S5ON&K+BYN%O+HYO
M[^7SQY]WWW:#N^=O#T\O9S]V7V4'7'X(OX#F^>%;^-,F^L/K_N>G<[FM^,?^
M]77_>/C?[[N[+[OG$`C^NM^_)G^0G73Q:__\YV$G?_X_`0```/__`P!02P,$
M%``&``@````A`!Y-C&%B!@``%!\``!D```!X;"]W;W)K<VAE971S+W-H965T
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M=J,M]UOS,WO,G,"TGI\&@_ZMRK=N]+_1'9NW7]IJ]WMU+L%M&"<^`B]-\X6C
MO^WX);C9FMR=#2/P9VOLRGW^>NK_:MY^+:O#L8?A]B$B'MCC[GM2=@4X"C(K
MQ^=*17."#L!?HZYX:H`C^;?A\ZW:]<>MZ08K?VV[#'#CI>SZK.*2IE&\=GU3
M_R<@)J6$B"-%X%.*..S#(JX4@<^KB+?R''^]^4A7/*D"G;^J.!]7":0*?$H5
MYJR<C<_\0&^+)2P>1BS)^_SYJ6W>#)@&8&)WR?FD8H^@?!TJ8>QM\-X;.Q@T
M+O*9JVQ-N!^&I8.$^_H<^LZ3]162I)!,)!CX>V,8)N*IBN]C)+DB/&GXDU-Z
M(1M=L"#&6Z"0!^-`YW/Q&@^'>3S7QT3B`FC?.D_"BZ<$6Y/.SR`;C*13)`B(
M3#;'W'50T)"WRX/F\-8$]5N,H>_B_D6"@82^,1XF8BV1:(E42V0J`CD`75WN
M`(=AL1E%%SC4`<&H'-`2B99(M42F(I`#L.HL=X##-`?("$>"V0S3W'%=F[F$
MB!&Q=C=^B),DT0&I`"#&]_(L4Q$H?EB5EL?/81R_%Y+.1X(1\3]`LV_CZ&(!
M*#J?:(E42V3C;C!G8X^Z@>)??R1^#N/X??N^M@Q+;B0817BQEDBT1*HE,D'(
M/+0#=I^I*'Y>58YV./7"SV$<?TCWH$@P\KE@/-O0_$?$W`Q)$#$S0U(=D`E@
M?A10_"&.G^_P+I1T:A_X3=2'`*=Y))AP6`?L54B:XW$S6SED%B7JYE0TSX<W
MI&&F(I`!#*(=9\`R!X:[J`5D*XXD]*X'FO8$M4]-2C7MF6R?MPF;P.NBT33@
M)GBPAJK3@(EJ"M<$=#V0T+@3(5WQXSDH(`MG,@N1*C%=`F4ST'V28F-X.46,
MT<\/)HHP9$Q`2L)(0NMAA@0;?V.3@&-)C*USB$JR@$EGF'NX8KHH$>P(+ZX^
M[H@HR;`C]R59;!U,0&+M9($=VBZI\&.$S)F62$)E6KJ`R6:8NVG8$7C6V!'-
MI.$T7CD"AZR.$1/0.(C[PP>S8CV2Z)%4CV1*!!O!JZY1:FB,$#6:NI[F/PR`
M6THCM$BB5TGU2*9$L!&\^EINA*C5T-SPR7!'#!=TZ[4=N"1K8L3X;N#Y/MF2
M$HDH_$SU2*9$L!.\#%ONA"C:QD[X-HDR8N/*[L%Q;2]DDY53,(HP$RFC0%(]
MDBD1[`0OR98[(0HX[,1D:QV7@0_,=MSUI-ADJDIP6$D2/9+JD4R)8"=X;;;<
M"5')C9V8%MU,0&+G"#V/A1[9*&.$,&=N`B6(F9U`J404:9,I$>2$\T.UYW`7
MWD%"G\X2"=UJ3[(0Q*3=)W54(ML5<:9Z)%,BV(J9"E1?:#DS%6A`ETX)"2O8
M*J`UA6Q7A)KHD52/9$H$NP'I/IXBRUY*''X720P:;22A]]T0(DHWM$@JGZ)0
MR90(=N.'2DYGIN2D^V$DH>LT64^FB1"YMH>D/2'WTVF4RG:E#^(1\PCV`1B:
M%?JW-(??1;+"IUN)A,:="`.RIL2ST,01\3BL1!Z7SBB169LI$6P+*3L73A91
M-D(JWWY$#"?O:/SH!+P3^TK`F+<.2"@Q0EP'?FBB/\DG$AE;0J)-]4BF1+`A
MI/Q<:,A,&1K05S0X&.2&B)?6,`B9:].-%B&SGB4(F?4LE8C",WY(R?LRCPA#
MQ"&D.-*JR_90QN7IU!E%\\H/&!UX];Y=O1U^?G;XP0ZY'L.AZ'"":-T:X$SR
MDA_*/_+V4)T[XU3N0=)>K2%E6G&J*;[TS64X2'MI>CB-'/X]PNES">=3]@K@
M?=/TUR_P8.MVGOW\/P```/__`P!02P,$%``&``@````A`.5C4.97%0``=[(`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-3`N>&ULG-W9<MM(TH;A\S_BOP>%
MSD<BP%UA>P+<]WT_4\NTK6A+=$CJ=O?=3X)5D%@)&F_)<^"1JQ\F0`)?J@`6
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M]_N?SR<_7SQ_._QL/]U_'MP_[N7EE@,5'X(_#H<_8]K]'`_)@Z]3CVX=#\'D
MZ>+S_LOM7]]?9H>?G?W]UV\O<KR+\I3B9W;S^=_&_OE.7E(I<Q46XTIWA^^R
M`_+GQ<-]?&[(2W+[S_'_?]Y_?OGV\3)?NBJ6<_E`^,4?^^>7UGU<\O+B[J_G
ME\/#VJ#`EC)%0EM$SBI;)`BOPDHQ*);>4:6:[(IL+"E3?O>^!,G.!/FW,I6K
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MKO^6_GMG32UMB@67U!,2=]NX;B,9>*L;N`]I)B)Y2"L9>'M(L>@^IIV0Y#$=
M/=`U`_+GV_,IY]PJO;0IEES2/T/*+AD8<OK*J6<X3$2RMR,],-8#$STP-0/R
MY^OS*174=F;)@]Z,$O-$)'NRT`-+/;!*!MZ*ZJ.Q3DA2=:,'MGI@9P;DS]>G
M4]6')[+GY"G2QR<Z=TZJDR5*G931ZUF9['&4.@NCU]/PU:3.NBAUVD7VO"L=
MYPC'8)TYRTZ/W+7$^#7+TK"<+)^?R221C74<V60':\G`VXL:NN=J/2V*%9<T
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MAYEZF%G:5,MY=UMS#[,X9]0^+SW,*FW*5?7ZK-.F6E;'8N-AMAYFYV&BR`?5
M?)`]_T]/L]13BVPFLI'-23:RV<E&-D_9R&8L&]G<92.;11>]7>DXW4<N_9SN
M$U];Q5>GV?.R^%%.%](#=3W0T`--/=#2`VT]T-$#73W0TP-]/3`P`^8.5SQ[
M'>J!D1X8ZX&)'I@F`V_3TFI933=FB4GFLO-DX/1!ZF)SD9CD0<MD(.-!J\0D
M#UKK@8T>V.J!G1Z(HM1(+1DYW1?5:")[(KCGHOZ5:D^.4Y1J69$]8;*1/8E.
M4;6L?SO;$RL;V9,M&]D3,!O9D_)XRCG9D[LM3O:R,Q=K)W-ZH*X'&GJ@J0=:
M>J"M!SIZH*L'>GJ@KP<&9N`D<WI@I`?&>F"B!Z9Z8*8'YGI@H0>6>F"E!]9Z
M8*,'MGI@IP>B*#522XW8@_?V&D7VZ)V,V,-W,F*/W\F(/8`G(_8(GIZCY8KZ
M71_9HYJ-[)$^UG9.9+DS](X3.=;R2^;TQDA%W;>J&2,-YO7FB>J,=10-%$T4
M+11M%!T4710]%'T4`Q1#%",48Q03%%,4,Q1S%`L42Q0K%&L4&Q1;%#L44<2$
M4Q=Q["+.7<3!BSAY$4<OXNQ%'+XH,WU.(Y0W\)Q&Z#>;CA_U\5)NN[PVNR"G
M9H\U8[(:(HH&BB:*%HHVB@Z*KA&5X\V]4JF@7XT>5NBC&*`8HABA&*.8H)BB
MF*&8HUB@6*)8H5BCV*#8&O'+LV.'%:*("2<NJG,5SES$H8LX=1''+N+<139X
M&6TFRLR>TPSC54BG;]MF7][$6C=!=3%9,R9C[^HH&BB:*%HHVB@Z1I2/+2Y?
MK50"-07N$NCA-OHH!BB&*$8HQB@F**8H9BCF*!8HEBA6*-8H-BBV1OSZ_-EA
MB2ABPI&+.',1AR[BU$4<NXAS%]G@9321R$8OBV2&S^F"LDS(Z8)^4\+X46XW
MK%9T-S0F8R_K*!HHFBA:*-HH.BBZ*'HH^B@&*(8H1BC&*"8HIBAF*.8H%BB6
M*%8HUD:8"5U8"(.J^EVX.05!5>ZMEROJG;$M;F6'(HJ8U)AP["+.7<3!BSAY
M$4<OXNQ%'+XH,WU.0PSDW26G(V;/"X]<MT)]=6Q15B]DTF#29-*RQ)S-LD@Z
M*!35Z=SF*ATF728])GTF`R9#)B,F8R83)E,F,R9S)@LF2R8K)FM+S"E5+E;S
M.75&;1Q1"BJ%JE[7L^7M[)PJA;`<!.FWX2*N(TL6XXQ_O,S(HRQ99..12%G6
MR'623&;MCT<H93$D;\LCEE%V+MUN*6_).-W2;_X8Q`_375,M2JE9E/&JU)DT
MF#29M"PQIW@^""IR2>RNH6ESE0Z3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP63
M)9,5D[4EYI2JQA_L>5L#<URYOW%$N5(-`KW@?,O;V3E5Y,-5Y5!O2-9YFSQF
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M,EDQ63/9,-DRV3&1;FFR9CMW4`G*JG-+L\0XRN4X&X]`RN4XUTDB:6?F01#H
MY8A)(HTHQ[>$-?%(I'Q4D7<F.Y-NIY1?;._IE#'7U^#J:=3BKR*@3HFDP56:
M3%I,VDPZ3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP63)9,5DS63#9,MDQV3*13
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M,IDQF3-9,%DR63%9,]DPV3+9,9%.:;)6/7X"(G>5^I1^$D8#@JN2[DI)%`V0
M[QE4\QYY<\?=1$ZMH)8))8`DA+_<R22"OP1)`'\)DOC]$B3A2\#)=^:X_3!>
MS?^.?F@6_Y_VPVI%381K\7>*TK4VD@97:3)I,6DSZ3#I,NDQZ3,9,!DR&3$9
M,YDPF3*9,9DS63!9,EDQ63/9,-DRV3&1?I@.4CG5TLXELJJ7R\OTT:>61RZE
M0Z8KO<W'S/>JGDNFK(%*W:A,5THKCWS*E7>ZDMZG[(2Z?3->T7_:-SWO59H/
M`CC]4W_-5BW^+F7JGT@:7*7)I,6DS:3#I,NDQZ3/9,!DR&3$9,QDPF3*9,9D
MSF3!9,EDQ63-9,-DRV3'1/JG"9*YNBS(AX1RZIT#N?+&K$GK9),$TE[(5HOE
MLOZ6:&F<I[L3!L5\H:`^M2*+ADY-4*SF"KJ/)9&TFZI4BF4U1Y,K;]YCCTS*
MI7=6':=EQE_I[K3,[$OO(U=OA%?5BU&SZ/R%__$739U)@TF328M)FTF'29=)
MCTF?R8#)D,F(R9C)A,F4R8S)G,F"R9+)BLF:R8;)ELF.B7S#K_D8BVDJI9S\
M3TW6/-(8><0Q\LACY!%(^7[?TSVNY$*]PTD>DZ<DK50])8\X1AYYC+(#Z;;)
M>,'ZZ<P2VJ19W^[.*-5]UEJ8M0C>MDDD#:[29-)BTF;28=)ETF/29S)@,F0R
M8C)F,F$R93)C,F>R8+)DLF*R9K)ALF6R8R)M$H,D7X3.INYA/!(IC9*WE632
M],%\,=79DT0:$*:!1QZE3_*>9"?2[9/2\IP^Z7<%'L8/T]-*U?9K%F5.*TV=
M#-+@*DTF+29M)ATF728])GTF`R9#)B,F8R83)E,F,R9S)@LF2R8K)FM+3)KE
M7_D*B_K+!C9<9<MDQT3Z)09)^B6;NH?Q2*3T2]Z61R;E'X[@.AZIE*[)=;)S
MZ7;->&W[.V:79BF\[,+K&^M5_49_+?[7S>!^)9,&DR:3%I,VDPZ3+I,>DSZ3
M`9,ADQ&3,9,)DRF3&9,YDP63)9.5):85RM=?Z'MI:ZZQ8;)ELF,BO1*3)KV2
M3=W#>.11>B5ORR.1TBNYCD<FI5=RG>Q4NKU2)G=.KXQGF`59P`E7Y/'#]`Q3
M?X(G-"AC^EAGTF#29-*RQ&2@$-_843=*VERDPZ3+I,>DSV3`9,ADQ&3,9,)D
MRF3&9,YDP63)9,5DS63#9,MDQT2:)D9-FB8;CSS*G4NNXY%(N7/)=3Q"&7FD
M4IHF;RL[EV[3C!>XGTXP/9NF61?O3C356W&U^!^.IHDFD@97:3)I66*OH61U
M:[&D>GR;JW28=)GTF/29#)@,F8R8C)E,F$R9S)C,F2R8+)FLF*R9;)ALF>R8
M2-?$($G79%/W,!Z)E*DF;RO)I/2SUZM5=6=/III<QR.5TC6Y3G8NW:X9+V#7
M79/_1;70K'MWNZ9:T%JS*.-5J3-I6&+[72XH%/1G`II<I<6DS:3#I,NDQZ3/
M9,!DR&3$9,QDPF3*9,9DSF3!9,EDQ63-9,-DRV3'1+IFU@=1S,)'CSS*N^1<
M)TED1JZE:W(=CTQ*U^0Z'JF4KLEULG/I=LUX(?YIUX0+<[-NW^V6:F%4+33(
MWA`JIOZ1V+H#RF&@+Y8;#@@J%;FB=E<5-!T1%G(IT;(BX]BVF728=)GTF/29
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M`9,ADQ&3,9,)DZDEIFG*9U#T8IP9UY@S63!9,EDQ63/9,-DRV3&1IHDQDJ;)
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M])D,F`R9C)B,F4R83)G,F,PML6\4E>-WBM1;10NNLG2JR+^8G"JRXB)K)ALF
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M;C]]>-@_?=W7]]^_/U_<'?YZE`FC?*7FR?#%T_[+Q\M5<+,-+J]3X_(]>C?R
M)9QG_DLMO*D5SXS7PYOZN?%&>-,X-]X,;YKGQEOA3>O<>#N\:9\;[X0WG7/C
MW?"F>VX\DB=V;ER></W<\VT$-\USXZW@IG-N?!#<3,Z-SX*;Y;GQ7GC3.[<_
M_?"F?QR_?CN2GS[\N/VZ']X^?;U_?+[XOO\B1U6^55L^V_!T_S5>)6;^\G+X
M(4?[\N*/P\O+X>'XX[?][>?]4PP$?SD<7I*_R*&__GEX^O-XYGSZGP````#_
M_P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE
M;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`
MTDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B
M?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>
MG$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"
M'P'=B%76JM5F)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[
MGM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\
MTG7I@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:M
MD]$L@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4W
MEO#USG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:
MPA<HB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ
M0[Y<&M*\D/0%353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM
M9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV
M[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)
MZ9X*'>"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S
M*EAX.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?X
ME)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X
M*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`8
M1[TQD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L
M8C^04PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<
MB=_!G$TP,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\
MB_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?D
MIC2]MX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`
MIJ0#B1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC
M=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T0
M6+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ
M['B*U0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:
M'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P
M4P<2(=4.EJ$-#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/B
MJZ*S"R/:=O8U+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46
MYS3IBI=B!F?',4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\
M/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4
MYK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@R
ML6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N
M?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3A
MG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&
M80-1?<DV'D@72#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['S
MYLQEY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E
M33#!IRJ!H8<>F#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`/[[*WB7
M#```['<```T```!X;"]S='EL97,N>&UL[%W[;^/&$?Z]0/\'@M<6#5"?7I0E
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M["+*66_6`TDWU_[>,[UHIZV"O1_-]6%V2(N_>;>>ZY>Z%IN\#-8`XG?_W@?1
MU[^)_[SZPZM7_7]]]?4_OK/7__S^]\7OOO]*[Z5JB$SP0;W,U_U:L?!U++F7
M6'!SO0E\8H@!-"%;5Y_\X(MOXG<0#&`>_NSF>O>C]MERX<@`X:T"-PBU"+P,
M]K$CON79\2^6ENO<AP[^;&-YCOL<'Q[B`188R>\\!]R$!WNQAO/JN4<TJ4U3
MA,'9-,(CU"8/3++P8+U-U@\E-G&ZQLVZNO#'Z6)6U-LE35<Q+@H<=M&5^8KH
M"1_NY[II0@X9]/M(*W78B93-EGW0=S9EE^.S638R1^9$JF5<+!;]A@I'IDPJ
M&Q2:;R9OST:G?&55UB5I^%P]`#N<7!8=Z+HU_7MBXNL<<7+F`4VJQ[CH8)*Y
MQ,^Z7YX?[QS/WFD?["_:=X%G^4@N'=C8K\O'9?FB$3D7`J=1D458HWA)%<R)
M]4#%'KUQG0<_KJ]V^RV4\*O0V4;HS<Q:DG?EAC<+CQW$C>.Z63T\&F/%"$=N
MKJ$TC^S0-^&#EKR_>]Y"O>C#+`(A]N+?-?SZ(;2>!T-6-8DUV`6NLT84#TM6
MI295PO+RUES>,KT$F2B*"J&FN9R<0.CM8K:4CW0YF\D6.C3A)5GHFS&^)`LU
MX;^E-$Z3CF3(`IG)TR('9Y7]UY/9;#8=7$ZGTYDQ&A@&(_D^B6C'7]M/-DXT
MI=%41#`&!+/1='8Y!"!]8\I4G17!"`!,QN/I>#`;&O`_RV2G1R";T[&NVJL$
M@2*O$@2*O,HF-CT)F3_I*;#&H[BO$@2*O$H0*/+J1'(&GBCW*D&@R*L$@2*O
MLN4XB7T5UDX5]U6"0)%7"0)%7I56?"89>*;<JP2!(J\2!.?V:CJM6M[>FFQQ
MIEB92:N/$UU8Q+?7Q6:-,$^]#\(US)#3,S<#`^:(\;&;:]?>1#`C#9V'1_P;
M!5OX]SZ((C@E='.]=JR'P+=<>-M+6Z1_:UK"23,X/S;7HT=G]0F4<>LQ,3>Q
MBE-IR+*>@;,)8V+T)\9X>!E/V"2I]NRUL_>*UF6Z2^,2:$1NFPTG'/J9DB0<
M\G7!'GHA<9]@"^9JYFG!!A`3:4@(MI!A8[Y&+FHC:2%F(VD@:"-I(6HC=)VR
MSI4RN0[V<+[VT,&F.>WWXZ5(43WU`@GPDH@I!T':%/EL;%+":&.;MK9"?BGT
MC<407ZPZ+K&TH471SH8&)58VM!"UD8^;U+N<\&SI`M-S"9(#OKF?'P<#%,4-
M"1Z2X9/TA&=)XO,DPMFNTMI:Z<1F$-!QL#I@2Z$M,LA-AFL8_5>VZW[$\?CO
MFZP$@%6UF^NG#;G*`BY]P<L0\"(.?`M+U\G;>+B//P#)58V&E8TT:[MUGS_L
MO7L[--GU,$P%.XI+Y/FG!:M3\L]LC=^SV;J@'HOY-@PB>Q6QZW78688J/*,*
M/(-$D`B>+OKAHI)2$H$G83ZZZ(=UIU+]P(M2_1!<POIEQ@->F90$-;B`!G4=
M'ID(8'4A10!.4($`KZ1*.(#P5($`9FTI`@C0'`'`J8F*+OU@0+(9Q$"N$O2?
M2B7DF-1*3N4)K:Q*OZ"_QDJ32[^=:";Y%@(]IQD^U`#HI+(JQ:I*,<3MT--R
M"N!##04FC+IRAKQ!5<Y71@A)NH`A9P320!TC\J*2Y%S0F0.H9V0AL0XA08&I
M2#4$@*,$`G'$0-'X.Z`8%(W`-!H4#<$4`C<&G[%/4$]P(Z0B#(!'2:_(ZX0!
M-V*<D08"056&)-$P5)4B*095.3)WQ5!5BB005&5(Z@E5*9)B4)4CB2M4I4@"
M`1A1DB&I)U2E2(I!58[,73%2E2()!%49DGAB=.(4V:/+IO$B*ED_G5X>M7ZJ
M/6T:%U('59,F\'O:/)X]Q3-'\`6;2Y&I-.Y=L_#Z:%P[U1Z#T/D1)IFXAVT%
M!^Q0QSV/D;.B1[Z$UO;.?H*I:'S:Z6E3O=8+2-+UC<-@Y!%68LKUPQ*^KK51
M+IV?#EBZ$]%H.9O4-R[,'T0&O[C=&"&-(-#.!(-T^B6%)_8:U33A&IAJ##!(
M*L=`PJ5[#Z'Q@2=T6V8+Y"-9\P8L7`W#YRH3/(?)KT4V?0%P6G5=*%ZD<J%4
M><>XJ.("%^GJ`F.1K`VV"I1TV'U9A,'9W)[@,#\ZG`T>4,16;%M1<D3?(2YK
MPL/UY?@LQ\\(';M*I5T>)'FXB;OVOCP"S^#<SBP-]O(!NX&@\N+JB"`3I8V@
M;$%;!<RN/4,4-`9<L18:':[HJ,XC#7BZLM4QRYT8W4OSY1%XN`YQ8KJ8,]OD
MD7H\%1WT=.FW*H\<!;-KS^CH:ZZ6_S^JV=HME9!!EB<,BJ&#S,OY\Z@BMUNN
MX_#!ASIXE<M*]7,"#7</XR0OWA$I6/K6`ZN$TJ;4!Q5B\[)*;1W6L/#,HYCV
M7V;(^74Z@ER<-PKJP[]TY,+02\HT.I36![V@\?5P6O3&DX;H,7-S/$TMM<^T
MB1/JIX:I"N^H(Z8HQY##X:NO+=3CX]8UFNH(GD`%@R3O[C/`[5BE\=,]O/"K
M;E@_'[U"E7`1;D7%SI5.$HR02SJDJI\2Z06X/Q'2^43RXB.]`>Y/A'1N=/DE
M'19.]W?,)-*KP)][.2&=L'A.W65V5[4$4,BS?"UVDIFF;"QT@O'#?A<YFV=Z
M:4O[2TL(0+YT:6"+'_0KN:-XDZZ@=%*6I`=)X750G)Y^".R8W7B\\CW<;3V,
M1P?W'G_A51Q?4!38?&$%!;VJBLY7`7=^B<@`;.)+9Q$KCIH6'C4PGG[A3E)F
MX%DMQ`8_\AS%7_N^!B@V0M<%"65SIK\IEQ.5?.\N,M+^)%!K!%SMK`(!Z,S[
M6@&`$.W'=!O05.KXXO3AJ$B4"JF0]8^"I+IS'#-.GS*W9:5BFU77JK`Y+G"/
M@E`Y4!4P\!E5J"N]/$3%L,U.&<2W$*L[@3>$KE/:S8_EJDVLG-11-;3$]^\M
MT(*9;9.<Y,&W0L->>:E3&4J-]'`5E_`6AW(41X1WFI;SBB8]THB<L#>$BE",
M/D&(9<K9SA/8:T+NW,/?MR?;F:+A4PW@24S]WVH7VIL56I2-&!B#]WO'A=M_
MXI83W#6T@BERX"WB@\D^CSI9V0P.S::RH'1H*RLKI8>XDXS@@D3?5A:HC\OR
M$5A+9,%-C5K+@MU]B2S<YY?C,B!$V^*")HDLGONQ(/=&F1_9CM@<%YHL@HO*
MROV(-1^1!2:WE97[$1Q'98');67E?@2$1)8!2MK*ROT(7J"R(-S:RLK\:(#C
MB*RQ(/>7I7[D8Q6WKXG@HK)R/_*Q.A*,52HK]R,?JVAR6URY'T$JX<N`+]K*
MROW(YPE#,$]0&W,_\MR/!;D_S*A\Q`\%(SZ6DOL.WA&.<"(HPE$L)?<:'^4C
MP2B/I>3^XN/;$(SO6$KN*9!'+#+@"W&+,A^->'8-0787UCK-NGS`X#@C`@.>
M>+/:N_`LQ0"?Q,BV9^)B&S$(-^,+27JT5Y^T)=QM+Q/$]P<<1D4$W3YM7<NW
MHB!\UG!+9B:.=_I84-P?@R#CB)<PA(\B@/X$SZV$1V)JP$O,$!_#N"6PC9BL
M+_#TX/U9VHB!UC$:/O[P8J$V8J!U+(9/JE@_B8AYYV_WF8?X7(I#MXB(]X[_
MR5[SD<,S/`20(I(^V/LHM++XX[O44)"8#WB/QDP&GR+B!SNE-Y1,ZL\/<$O&
ME$0L\TG?P:F'"/"_["-"([8B0G`N)R+DSHG@3KII)^9$("PA$0%LD\Y$'&04
M01E_LT(?>PO7=0]BM,*B?-,Y5/_KI_Q^G8SW")_LRN[DF<T'@*BUO;'V;G27
M?3G7\_=_9O>HAF!*?O6M\SF(F(BYGK]_CS?_AEX,"YB0;M[OX(;2\%?;A\Y<
M_\_M8C)[>VL.+Z;]Q?3"&-GCB]EX\?9B;"P7;]^:L_ZPO_PO4(:/P;V"YZAV
M>,PL>QPN;#L?&%<[%QY&&R;&)N`_YL?F.OD0PV=W_`78L*DM-:*WRQ[3>_,_
M````__\#`%!+`P04``8`"````"$`;PIBR927``!%.0(`%````'AL+W-H87)E
M9%-T<FEN9W,N>&UL[)W;;AQ)DJ;O%]AW"`CJ*0I(4CR(E-A=I0%%237JUH$C
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M)8#\^[OSA]_?U5`W?#][,1G/+RJ&#HI!^Z_'Q70CV]GL9=N;6SOM/UZS4O;?
M#TZK^2SOS_]'^\OOVK_P<+XNSDM]`O0O\U'1'O7=07]>CLO%*#NZR$%9OUC,
MRWX^K'KLL+_1'NXG/009LWS(D$'Q(?M3<=D>]]WF)KM[\&!G>[/]IP,P.3!L
M/AWFY^V_?G?&VATH(UI.+J>=/WYWO+[5GB9^<%3,RHD.;9`]SN>=;_U^GI;#
M8I8=,N!\,NMNYGB4#S7@=3&=S$#7>78X&4WS<6?DX61<38;E@(D&V:-\F(_[
M178LPJNRM3?'C[/;=SJ0%GW(8<O(8?NJ/W;V>+B8S3B'[*"JF/_W[6\/\^K"
M"+:O?Q1_793O\B'CJ_;`U_^4CZ9_>)S-BG)TNIA5A1W.K.@7?'$Z[.#LNT\?
M/WUL3W(T*Z9Y.<B*#_!?552V\F1^`=;Z'L[<X&Q_^+@X*]C'(#LKQZ!+R.U/
MJCGT-R[FV>0LR_LPWV)H*,U'PO]/^7P)UYU,YE!D$RGMQ8YFB(<9W"M&%DJF
MVNO2I08%4J-?7K&4PWM[B0#`\S(_+8?EO"RZ1W/0-\E39=/\4A@V<-CG;`$>
M`@;;$]_HHVR=8W2XFN9LM#W)R\F\"*NV_P;Q(HKGI0`:,RZ"%_&S&/L#`,Q!
M6=DFVK,\AN'>@;5W13:L4=`>U3RL!%?+!UXQ`$X<E7,=HZ.Y/J(7(D*-@/GV
M;,?S2?_MQ60X0.5\ESV!`.:7'<:!E#U)5AJ>P3:+#A-HV<D8Y;1RQ,%@P.E/
MQA"E<48YSOKYM(1(VU#!`F6_1+LDE#Y8S,0*,%`V*-X5PXE1JI3A>0<6A\QE
M>VNOY$8FV#3*N\F75TJVHUR"Z*(PS7%GE:1KX;4'6F;+D=L96:&;)%,6\XO)
MK/RIJU17?5%6%3S51D,]VK;>R_S\D\7<K`TPW_XD/>\K(&\.NQ;LI<.7P^R'
M?@;`B2HZGB,^'8\@45\A`TVNK51*.U=:,%O;5_]Y=^OJO^]M7OGWU$#J:,1D
M)Z\:.UEM&;V&?\9=#O98@,F"Q.U(@M=%5>2SOE.C"1M&@=A0F1UI\V,Q!M%#
M)]T'(\PL&6(2C6WJ>IPH&S<\470!OO9'SR=5E2&#D,33266R1OHRJK7V>,?\
M4H#`D&R[/<[F/9M-1ID?BU'3'O/*-'N)K3XJLC6/P#L=!#X;SPL8=[YJ"S]B
MAFL+Q0=!M"BK"[,]V$70'1T-=GB1(]TSOCO+2R\_T'I(]!NK'6>6M(%O;_$E
MYL<0%*_Z?08B,56<&I!\`HK3O"K[=H"#<KC`"&Q__.>B/+^0<9BC:A'EV7@Q
M.F4>=IQ.Q;G6HN@F\S;$<^013>OP50EAR^3\*F%MQ-*&/I5![;\EZNX(0W"=
M]0ZO5G<8--&P>URKN\>)NF,G777W"(]F/!8%!PL[GV=_7(PWLJT=F=&;'9?C
M&5K`3''P<89_![%XD=_>Q>J1/>QX*:'V%YB4_:(85)EQC&1W6&G=60>?_<&J
ME9+=/JZ=ANYN_;@P309V;C*^/:[C;UPS[ZKQ[7D[(OV:>5>-;\^[TT;T-?.N
M&M^>]]YGSML9_VHJ,W"5"/10ME?=_<Q55XUOS[OWF?-VQGL94)GAZTP5>`I^
M*F;ORGZ7/ZX;'\AT!5QM^.^O&!>FN>GX]K@'GSGOJO'M>?<_<]Y5XUOS;G5D
MW-74WAW_YWQF02&ON]M@/JV5*T(ST:[OW7<=.?@(8T=N#/8.+AC:33&][*S(
MYPM4XRIO<3GU;ZV2)2M.N3L>?1A``/QQZLTZ^\H[VV4P4.:3Y=+Z9T\40&TC
MUFF1S',.LEDNW@R=1^`E&Q6S\V+V,SY9M=H)9UR=H>Y,.T6C*NL/B<:4G)?Y
M`1F[E]E(8*3YAS8D*XYKE8@.4+6)MS,^6BP8/I@L"E@]'4[>K_1/DA%/9:C6
MMKS"F>]61%T&?UE4/E+`AHGN3`@2*-CA+3VA0?^V@-ET-GE7$K[-3B^SM47%
M/\KQG6`18WL0@UVUD-E9Z]B"?(15IX"80_,*7FM8_RO&'*0.@7'DZ7PE5W4'
M0P)+8FSMXUUJ6R>\'^AG261EC6@Q4?:JN(.P</\"81V'H!UKM.C7ZE!CF#1;
M"Y/>63;KE:&Q*X"^Z7?71M4@&B/)-SKR9^.E]-A!=DWE1L//D%B5.697T/!1
M?FD>TB@?%*9VISCVQ(!G<BLZ,OEH@?/*F8BIH.<EH<\V4')Z&CM9!E7[HS8W
M/HV1W"MV\F@RFTW>8\6;#^M4AHL]#HK3.B0[.8-T9>M;4+B]LD>'33&^(K1Y
M3.3;1`OL&,-VT8N_9HV&@2]I77PH9OW2H36H0SL,"8XVB!&C.`I.H#RZS)9A
M:-F'G)YW=I=-;7A'@YQ&ATCG#+HF';\S#"7U8L2P=-#Q8CH=6I@()2Z-C?N+
M\G:($[6>(9/AOYCXZK"W+6/13IF$0;FV=]8<-<\_=*W&%:`(]O%DO-X7-&5D
M&$7SZ_3!%9*Y:=7$L_/*^'TYOT!ZG<[;`-_@,[.'/^\[M(VH:3HDZ69,C:\[
M[JS]N*CZL]*Y$.S^T:(JQP6!'^WY>#$:Y;-+8>6X/!^;/E="R*47Q#5'9*.6
M!<+365^MF)7?7S/K%>G(E^+&K>SO?_M?.)__^!W,E)9]Z6S+%"NLYPZ!`?KO
MB/]7_:0HL]*\M^X^_+X_&4*:('Y$/GE+OYD])67@AIR4(\C]9?$^>ST9Y6/]
M]2P?E<-+/X-^<=<FM?3S[ZLI9_?#K2E,@OM3W'H([A'A*].IDA+8>,SW=CQY
M/\[R"FG;GR^J[-\X>O&:2[MF:Z*,O__M?^,]3<DS_OUO_Z>G'\/LX6?W,3_=
MZ67OF4PQK1DY2DN6N3B')AKFF%*@2?\V4TL_O"S>Y8-<T;=7_?E$0:B]7K:U
MOW]_(SMAG%_9ILV)EA3#(;EY2WW/+Q`Z;CF;$AI\B]X0R^?>A,V,EW)V.)7B
MF9%'0PO%T*.L(K;ET\N<49(]?S56N**PL-CV`Y<7[=DZ`23`(*HH@PP6RC,E
MMRLQ/5L)>#,K.WORP0E0AZ`IN4V",UC<D^S]14E85_@(D^9]#&#-NK6Y^;N`
MK&"E2VHF`3EO*U<%J4VS-34^G,WR1'JVIN,[>N9`(3A6>-@,;0)$:X70D6'M
M0TD%0P&M[.]?!Q#X3-1:S*MDMS<W-K<L4%DI>-4+^_*;=B?=Q!4>P$16#,CL
M',.&,K\'R!Z,YVHQM/2LT92%/P.VW6$Y2G=A-I]Q,RP=/4-?]:E$,.RC]^>S
MR7`H664@)D.3T]G(#IRC).`8V\N*G/,#G^E7,NG)60/\YL;.SH[[$SZ$)@+[
M`;[LM:QQ'43CV%(<VJ$TEX@'-N@"0W5`P&P+I.KO?_MWZ%ZTZ41VU#D0(00)
M?6)'Z*/&\F*N0"#$BMW>F_`;B&,D59@=[@N3]R18H"%DOPQL#B1=+$BH=$4[
MV1/PU"(&`9([=0):C</=\3M_=9Z_+2;\\RZ8=\%>GYS/"NRVO@+=N$\2'XJ/
MAQTAJZ@+*&`";;RL%#"H\+7$?3HKSXHXK9(HM3)+U#P&"@4'OA@#/)(`*2I'
MSAX0G]3#[B4J!4)@87(Y"AN3UP[QWRP?J=P'2:*%.0E!$@LXO$G!6E6=/Q-,
M`M+969I>OW"JO.G&9^_9D3A%'[,SN9QG0[!BWW<P!@S:ZVQ@0L#DI]8)2,N4
MM<%-9[;3(8D29G10!XG+P&(*2_+1[+VLTS$J>-"IX`'EO::>@-.)GJ.M=UST
MG#_KC$]+ON]?C-&7Y\0%G,0V,BWG?C\^)2;F/<7Y>SN_F$T6YR979Y`#JE38
M&I9G8G8&X*IH+*:E/,4JDRUSGI7*W`^G%[D2PJ20\<C+T6@!^.PDG^)^`_/)
M'1E*<^8;V5FZ'$ZH==#I5B6*FHQR!)KU855M=SXY+S29TTI:[SUR!LF*#@:/
MU>(4\BNQI'K9BV(0!'E0Q2\.GJ%>UQS)YF?H'AVD<Z@Y5`P*'2IRAPEAEUK.
M9S`WJ$9#&`%H8'XJY:SB"!@$\@42&9W`;3FM"OU*_96$!3/'LW8$-YN@9?@/
M&G4G36W,56@34@1!A5G/4FR4&CII)VCCV=UGQ.D0NZKU0H,J;*?QR8C.G^<@
MARB$AAX/)_EX_4\%A&#.V:%H=I:I+(S_67MQ_*?#PSL4U,'33)O9SZQ\27:L
MY&?O5)Y;5(3I9'`]GBW.LP,GLX2!#?G1E,AM]TQ*#//%N"^BQ\)`\Y3K?;=6
MM'<RDJ#PKLD0@]'XB1Q<-KJD?(+2I&&Q>%N,RAQZ>O$<<F)UYG`T@IC&0CK]
MBSM(:3!'R3+LEF>`X1&.".-FL.B+RQ5F@'+[#A-G\L=%W&Z`49PL#@YW2/U"
MAK:>H,M4'()%4IY2\@@_<!YOV:*SG9I'"^!"-D"2+#1:3BTKZH@XD4$`27ZF
MRBHOLRD\+(M']&5,:RQEG'&"<''$V:8$LQ5A'$.*&%\ILPI:@FQ/BV+L``SX
MT^^UT[R_%-FB*FI;0-<I."+.*1F/1@OSB[=KUGY?HDIMH?=2"%&)J9+JTJ3)
MH%1$P#9%+:"!ZG%N2@5JI\1&)[$<Q8P%$&9B2UW9Z'3;=:;-H9>%[`DK'HJ4
MT2(4!"%9&[J!CDP,Y9&EUI'B,#PB=HIFK*LNXPR)9(6QYDJ3^UW.)4>ME*,#
M/I;S"R/6;5]=*D%O]-4O=5H(>L0'Q!.-7LR/,<E4)X,I[D).3ZXS9-V!5ME@
M,H*;0;2%EKTWP>>/J3_#$)'54:]DI)3*V2!DEUO+O<P@@U8DK#N`'7HG1V)"
M)BD;/T`1#[,M5T>YTUB[,5<3:D%X+/4LQ-1;:/PZ[,?D8P<LV_QR'^Y:5#I/
MM:X;9AO4OE"H(V=L>]=<'[9B@JQI&.2(6E2EQ>\-]E<HLEEU44Z1T3,[T8C@
M!%E,!5#:7?SK48/^JJ#SSCA8,S#"[IL8M3S%(%K66K.8F45M*W!HQ3#QB%(0
MUO)L?V?C/AY-2_>B8T5:$;+TH[[L!3.AB@\4T:#6NYSJ@$!;!/LVG<"E*]V2
M6*0)92)M))J0:L9@Z')T#'"8]>_L5FACZ:18*'X7K2F;YKMLH(9#PGQ!A"`Q
MHN/FO"LX4'6LC-GI[=_?[&WMW`^.S"HXTDG,+P\VH[/8MWH[V]N]S=W=9)ZE
MZ[?I4:S5_!V>^OSA(XI<3.X>23N.81])EO7LS3A?4/((_I[)#"A'(<S)=I)J
M>0RD+QRC.8$!9&I;#$+2C[I6#SGD:Y!?[P>(1H+Y"2&@B6K].%4QM(M0=&SZ
MQ)]!9)&`(N1:943^5"HF"[(OX\XQG\CT#?8C/YF4<HH9YL-JLX#"FXWCC>S'
M@X,CXST16MA`[;LD\5K'84ODB1::+02(V]:YZJTY55NP"\5Q'?C0^"<AE`%5
MC0ACB!R"TWW\Y-!@,YL&>IF:_S/)GLJ0W]I<_U?']-[N?R"ZY\:"7SX[7O]O
M\+IY19S3$/L<8"Y1/7)NV&M_N,#22=SO9+,V\=ED,G>G,U/01F<"KT:TF44A
M0AAB'840,N2*>O;UDLZG_#D$<K;`VS0_+;A]@C-/DI!KYO=B\T."['NL*ROR
M:XDJF56=C+WC(U:F5SE`G<EDBOD&JOF46"7VA*P")36HPJ@4%A8]Y*Y,+FY(
MH^VT+8#C'#3]'.C&N;6XR(ZW<2`C-_,;+&](!*]6Z`\+*3Q:C@>62\9"7+'`
MV8+=7V),&T9Q07X.3JN+R6+($<K@SDT_@<*_X!F8"(H^\_7<ZX$,8E"8$A8$
M'U'.`602@U_A;H;1DZ,EALX*-"GKR#2KF=7/9]9./AXO[#CE?"F<%DC^3W8P
MURT'KW(ZIH;COF"F8.'M.^O`VX!I!-5D=*>(+FJ<KT+Z!KRC1XP',/5!8D[R
MI57J'@UBR1EIZ@N.?2S,CQ"#5FVBH`OEO;)<!W#M*HP<U<*6PS^,<1YQT%>!
MD^N)-L@[D4Z#TER(S`EO*N1AKB9]&STN#WFX(`FL624))!,&H'A*C-X4V"+<
MKDAB[:G"P[.CO%E1CE7H?^.`>H*T4U3;ZE&?NCPQ3&+:S7)@1ZE-\56<"Y(0
M99ZZ3VSE)H>E00@6'/=+[]*[<Y*X_V6JW^NR*I'[(O\1T5@%C3R&Q3)4^2Q&
M/OQL;G=N<5FO`GQ8R`5!3=>[.UHFZI*ZB1"!%G\%TKH>`UI?I.H"M>)O"[;:
M.IYI'<GZDA=<RH7IO?HC0Q7FSD1!=_)D)D^=%N+R$9K`10.<"^HH/^Y_%26^
M+IHU3E^>^^7+H49$%.@A'U@.R*JM2@P#7[4%+IWV$7G9/[$8%!*)0>G:,%^%
M!E<1P!'9/YY@'/GK@5\>'R>U?#-&4R0(2E%DB+`:UL:0B[H$]+PI[6.H1"9Q
M?*$0Y`MTI(MWCE9GA06#="$7]&+D6I@,&\*J"&06^IUOD%`G1G?J[FTZ0V=!
M4DYF.<>C`+MN7)QE3Q\_.^0W*HX@K(CHLRCB//'>P_U>XZ2.*8%N9S-+9+1!
M).^1VX>ZTL'T+*R@[&D^?KOJ**DLX>#]K4:=I+LK]L6EYPMR=%A'6*(2!4*T
M`TP&),1,JD-"@7H[[GO:D'CGDM^CELD;H6\425TG,BH<F.-)8#-*N0$YA`+3
MDE.@>DHH/5-P778<@=VG,L&M_E0`G)4?+,5N!NROMGXE<R0`\.<+_AUDJNUZ
M;CX(=$B::>""*G'[P9V$KN/%B(@2V2D.<2,R;NQ&=8^2E($+G',GC1WF.9=0
M$<GKHA"FEO=#/%%!,L['V\A>Z^ZN6`PLZ68\,6-+0IE@QJ6'SATW$/XBTF/2
MQ\<XL:-6D>4S[(>2<@?D$N?R?#(^7W_.X1#BL8O`7U[.O(A>$ZAY5Q8421"2
M/X?8!*4_-KD&9;T3@LQC3A@*Y)AQAOBKBPF:1=,O9QP=SA;I$/W"G"(EOWP*
MMT_Q]*64FL\[CO)+<Z6<0T-FP"+7S,EX$AWX=R-NYCM/`B$TJ/4C`>P9B:._
M+DB9`8V7)<Z_>D9B"'&E>ZO.;+&SA_T05X[D@I*$C!;&'T3#_7U>=FY22+5>
M''I5370)FM]&+\008[1H)J)D(-K(2%$'Z[(&8:,"PMGF>-C80K!Q:>`E.`7X
M2H+730RPP;.\=-ZWRR5KCZ+NY,/WP1MD?6]$&!PA1]!7OF+^7L$]@7?6J&E/
MEA3=*]`<C\>@7D77CS%(W`UG)?N^<"SK`$6">HP`M65KNF>'!:_>"`;2E@`9
M&9'B@@%)40O"5Q(:(2+LP?!CI(.5^@AA[55=O3-2ZJ\+)9[#4(P:>&$C0Q0B
M`/WW[I=&0XHDR)E7%"%_EY/"M8J%&FXG>0:!?"3QQ4%^)K>JYK-?3@;%4(R'
M<L&XA?H9&6:?G%84:;G<D-L&]FQN0L\9U!K\E\7@W$26MAC89*6(,^3]FY$X
MU%G[,\_&:*Z%YOD*2*0^82F!`;<T%+'`R-"IVDGP+P1.Y"9THRNC@:T(Y!.T
M\DJ,^B'L4[5Y$,.'JP4YRM?U.B`^![$P6JI=56Z)NQ@Y,9"`Y?K)2[D4;,J<
M%R6JB=*8RSHVSTEP<"Z<)HF<R+;QE,HLMX-S,P*T+1F*?.-,:CE@`.SITM.>
M`"5LA+'@`'+4CZE).E8Y<2_^62OL3@:EJ$+S(QS;TU.P4!-8:5`Y\563,F"%
MG7$2BN]0$H"8]76T:11G_O`Y&H:,5O;,;1!)HPB[A0\YOG_$9J):<AZ:R%^[
M!UN*M&B;_EB%/<P,*SN=VQ]&)&2P"HQ3DJA+G<MRT&^GT/N-N.PU:T=)$4_$
MPKDF<,+F#43)M`2W.G\#3MI&%!D."/(KJ*9`'0Y0=?TY!,A?I87=3R'R.)))
M*2%AT>,F)C5YJ"193@(=PNFU#L,LADA'-YDO4&#<K82BHTYQE!'X2K3%CVZ$
MHFS-ZSWFG2.1X1'$I.I.WTV&R$O7L80.!XIZN+L&Q.RYWTI*%DU/)G]65F_Y
MJ9CW-RB@$WYK!M1)F5Z`0CE593?,>S)CE;&(Y=G$2F`80"#>RP*3P_RH/ZM[
MB46U0YT#I!9MS#9][:3T]:;+@!9I#:I#]"VZJ?G1'(;EIVQ8C8%[K"EC#+-M
MR")*.L2X"C4]"\<5Z6]M@B6RSHM9W!8P9^(WP+44$&^$U!M74J[[?R?:EPD3
MFTU*CL(?5Y2+F>BGEO0*S")IYKD893!/L.)<+U@FI"'X2D7W]6^<(\:!#4U&
MR3)D+TW<)K(.88)VK%/;JYQC2^NF>9J#X\/L@8H9ZFS6BIV(\)+HB(.&]@`Z
M-D+UE_(=(3FL$T'II;>#'M",A/D+:$`NIY%0Z;D&R02<2?(Y\=Z(Q"*2JLJD
M(M/JRWHRC%%^%XK<R'!YU@G&<TV6Z1I8+V:X5]$R<7Z>/(<DEE?K0]9(9EJ%
M+J?&0%!]^^"Z4S1L!4LHTJ.ZL'7+X#]]S+YO-47S$GWYKSL7`MWHG?;HQ]'2
M3>FX<PU%_'&P+!S3GF^]_8O;[5_XJ3HAG.8XR[D\<]TP3G2?Y<L[!B<0GR=-
MQ4B\/C>5F8H!9#"ED71(,[5F'9TD04R'N?W8_9P-;`\$.R0-@[@O>C(E?15D
M_F&5B'$:`4TCUP^9']BP=M%4?>%\M)K+:X-$L,J<5VD2JT0/+81'Q5+:E#/-
M4N&F+[5Z%'+.;Q!3$MZPVF3-:-K/[#J[)6%"P*K03DU`>]]3;K_Q<PJW9I?;
MZ>92>2^!@:IHB`7]TB(+RY`E+.>)+8NNG+RWR(O#TV**P&)I8$98F'"B`%.-
MM=ZJV!18QQ8^,*"UL>XBN.T8\.Q%^5>%AG+5'RJ<OFQ=K`WRT"&!S$]*!/MK
M:[G"29@+W36P!A)XZURT2X/6(E%&I<E3Y(X#Q%3]*C_[-4'L6'N9)C0/U1_N
MRW-8`[XT<VE7%8WV?%#"O"VH6%%Z4+_RPV8[(2/*<[PL$3>GCOYU(5,4KPX[
M<#=HU84,ZE"=X73&#PGF.I"MPO>QBO37'QF'QHN57SS`<9+L%&O5Y[:T_T3-
M(05<O99UI7`W(C)5(9IIH\&&1TL0R^ZL1<$C;M^]73_N4\*)C/1?RB&1%!PI
MG&#'8`$AZ6\DD15L"5=(KB#.M`3)&<6RZX*NA,,&%L/7N97`-%5KON2O(A/5
M"#2*,UT<+9W.6R]I%LX5J-GFG-A)D!+L7L0N\E0T(4H2I!9QEO#1#QY-DK,*
M$?<G7"1$0F2ZUV$#PK5DGUSR04AW@PH!5%`],[DDQV*?NRBC^-P+CM`81`HF
MU*69>HEKF]EG&[GBSGP+N(AX@YZ;!)2$^]M2J406Z,W*1>,3KPT]=QHT@;2(
MB$YF9[B1%O..RZ#VYB28%!BH_^YTQT9V)!D_650F7R/^H(1IO/GO1(*,-D1Q
M=.+!4G`Q#!LNP]E:("++V;+AO)S'0:U*()OF,6VH*LM27>BX4^O-H9Z:%GO%
M3P[RQ)^U1`A.C>]8:*?G>SCYVS2K9,:3<*5F[3E)ACO9$32#7!*+F#CY\E+Z
M!!('HJE"QYXDC6^;?;J:=X,"$XO)H5L.!-J24\J_G*#QO."Y2D(=N<F4*"QW
MQ6A-21<N&8"/YFRJ>!GA,<L8(J)/#PDK'=?YJ_>$MW7\YS$@JB,)\TC&A6MR
M7A6\_SEMQ9)L0FUON8UM9(]=_[)Z0S]W)[_J%J;#!1%-@:I`7AVZ)I,+(I5X
MJ0]?,:W)&!X-BA@W4+:)&2\M:M!)6-:LLVM1A&:M*):/E^;<+0LNQC#[$FBR
M-7]'3Y=TK>N.LU8IH4#&NJ8',JU\Q)A:/X7*$9:*3R69/IN:7RR'#-G4#W63
MIUS'P^@7I'*"7<V'B^_6]02Z>!*@)0_@U0'D&]/EKA*NZ[@3'K)[)6['=G%5
M-RY,AEOTW0'NBZY#^4ER!W&[M_V`TN8']\(W,M8C;J0\PM7(_=Z]>UN]_7O;
M8>0U2O*S-L+=HE^X$4#;>]![L+WOP?M#O0L?$?&9/L#>[3W8V^IMW@N;_@,<
M71/`V&J(B;E9@J+S\59O:W>[M[<?\/`',TO2"9!%WAUS>.].L=-[0#'C_;TP
M1]`<ATX\=@V.FE:ZQ)B0VRKE\!I'@N3O05WV1*7"F)LWKM_!5V#"GR3R83#!
M+.`4O$L'[Q`.<NET;4."@Z`?[.<3[C(042CI?NK;2Y0NI/5TJ)\^]IUS(;'$
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M-XLU(HJ0^'*KXK7#Q?D"KY_[5?:<AV\ZL!2:G0<_`Q#Y"KJ;`FTD4+B;8B[L
M(UT2-NA<KB?^.HZC6]@&L=/$4KI5F8K_F&8<0?PE!Z)ED>M$%510T+P%%T1.
M`+?9EL/+J=3GJ;VO>$ZV5#P<136=6QS;A&AU=BOD-3_R1X0Z\D$?9Y(OM4'C
MEPUHFI?\L!6T2',S!O'/Z=&Q9/?1V6@>LMWW\Q8)5&)"TA&&Q:()FO_"#AWA
M5)''TKS2E9X:O[7I*.JBN"@@S))0Y5"L5PEJS"[)BEAOTJ;#::5FEFG^,-55
M*+)`F"H2"!5/'`YVYG_BAAZ>()%NOW57CT1O6H4,"N);:P^U^O@%K3V">/DU
M^WN0#(Y']^\$@;ZU^;"&+U:5T<",K(U?I=='BOZOJ>%'6Y[>S*0Z=/$2I21N
MW/_#8X#(^Z_:!,0*$5J[2E.G7+2C[TC8P-<4&!`V$P/C5[T+VD+0T;>KH92.
M=;IA_5970UNG\8:X-2;[DRKD>K&?GGZ[*4IP\F<TB8C58TG(C2C#MYNB$%E(
M^8::-F1G;$.Z3(X2SB;%GW3-_^+B\XM<'&VQZZ%:,2M]8_]X0O2*6@F+WGYQ
M])S@D`=5%U0+&IZ0P%=^C[13;6@(IAD>[:V2B(;?F\O;Z!@^^^9HZRQ)SY#P
MI#1%YZFCG%HIZQ<_R&\72?_\__-%TM"%2@F37S5G0GS%15Q253!_*#GRE1?7
MKY88WXKJK=`NU@&;1(MF4;CNAUQ%Y'TM1?46YR.4W3[5UK-(2XP4@H+/OI6A
MNUA^HQB<@IJD'C+6]:7EW-_*T/UU<4R,;V7HNN&RA,&RUVEM=1I:^5:5;AFP
M8'#_HZK26R:J9;^^%:F3XOE6I*Y4U[<B]?H2PK<B=;MSF!KORR3XMYIUW03Y
M5K.^NOK^NIKU3Q]_2=W]%RY:I_Q-#FU:^!RJP),*^J^X9CV6V->UWE?U;?W%
M-=[;O1UNK&_MA+IM<Q67%@KQ6,5]6G;O[N_Y<O!0>]2(U"57NFZT`X)^Z6%9
M<5ZWW#Y<7G.^3P#OT\>TF'[[/B7@NZ%6_3K@;)_-LG2BJ/'&`A/O4)S_H+=]
M_Z;;I6J"*C!KMDX93.MVPPT*RENVX+?Z<CT`0)VW6F+]9O7EK4/X3U1N;EU*
M_IC3MGEVF?F7)/!I7`WZ"[N*O.5?95A2?#]_^.-$5:>'>IYG-FZ7;C7^>-W#
MB=NZ-Y<U/FG/=]#JYZ?J0]4!VDTWP:&,QY5/637KFG4]JEK8VRJZ+QJ:?[@[
M4J[;8'U;@=L-*@]6SS3]PV[X-*^]:[K<;K39;242NK?O]1[L[_3V=[><8.&*
ME=UMX)Z2JJF3NQ`23(S>OW>?VS7[W(SXC*M)[EZ,J@?T&#D7.-)>BHO87C:]
M%$VI'C416G-OL[>W<[]W;^N>.J)T[SW9FT3AEF07?<A*L!X*=H4<;E[9(T_(
MRE@1"%JL.-`N=/L6*Q7=_%RYM7H(T,W:G04[P%)S=__DZ&A*?PAVP+H&'Y%3
M?&#D^V*HCE;T);^H[$#(<YXA&R9T=Z25)C_I,@3]"2E<HW'<9,$KTK/BG(O2
M(AG14*JJDO9/4!.W&VCE9^=Z;I3.[T3IGA=B2Q"+EX=/06LRJ]N*GRG9#:2J
M^@^:7>K*&5OV5V7H5:1J:S7XY-%='ABRSD!IOWM+?M'$9,P]/G<E&8*TODY:
MUMT%]@V%N!</!K3/`6^\JG41ET+4[<I%`^.[<=;HL%+'B7#4H.IL01LI/G6=
MC)B;N]&TQZ,`T!YQ\JTK&.".$F@<'(96NE_H9I'N&B[8/,VVU>Z0^@;=T(/2
M-'G2:0'C,F$UW3@48];$H.&T$9J]U>0>;$[1+@XHO.U./IRD1;7'_GJ!E<"G
M^_(H4/0;@!=<L?"7@-ES&D`UI(3&HKJ_KOY!D'6U@)I\A6M*.O9.2R$AD0_I
M+Z)7X7S;]M(_P2["#5BM[0)[V%K0,)ID^X+V!\SA7VVR/QK&#('P&JUW;<>Q
MS44TW9=3Y6<)R,1<F7*Q@(.PVMH\:Y"_R*?D9!WUB4]T(UX]M8SRDT87DC%)
MLQ(1J!Z&K\2@GK!3E'NL^F<A:,U";Q%-<:KN!;J#H'=:^57=-H6C\,]6=)[(
M4"/WY.D)UV8+\N$(!0<"7Z$4""^"Z(5NJ^:!OZ<PVF&X?FJGNL`L;I7V]`\U
M:&I/%;KXSI,/,EQ9\^;BQ'OP3OWQ@_[3K:E3GN+]=5[V??@25LU6JF#6CF4B
MW8KL_W!:^4%OAUNIVYN[-]+*N[UM.3E;ZLGE"62%[_7IHQ[O\^I8O1;3GL9.
M-T-+MW=W>_?OX4?L[4CEMA->V]\T[HTT;LLF1R[$UHT@.>7"E/>^*>!O"MB;
M-;^%`EY&I-_TL3-?_N/HX_G#UVK1B2ET9%V,3M0&V!DPE5/2M2.P>N1U#O".
M.<"KOV^O9"_,+NT#F%(=M1&ZIHGR^M&]M\9]05P'&OYF/^+E3[/G>LN!K=&N
MR;:8%-MY0]EN'-K-"4G/Y6_JT%_GP-?[9__BG@:MLN=SKB>NH33M$KB]:3GH
M@N%>QG4TX8&Y(WNI^?)N=LW+N[IE$-NOVA.%L4.\M\8ZUG&*)HI(N`?]M#B=
MN4B(A4(VN>*:*A+\C/0>]'.Z?(\K'OU,4^*RXUG0O]04G@8_T&5G;='=GFN_
M):S>V7H%V6S=0YG_LSKIOG;\)QYC_O21;D5,(.?-.(<C$Y)T%RG>D\SK9>2S
MLN"`81C5!_[.[N;FG@T^PK!>*(S&%-IA_+"Y81Y3UPZYI4")I%P>-="UIY_U
M+`WW@EWII#F(0)DZ@'T]1Z+>45.H2HT-O#<57\-+$.NJ.=7E;QY?WW;52?FP
MDK\UG5I(@8<*S`E77Z_8)2^^Z)S&-[```I(&>F099VI0JHF8N\5\Z+<3.BH.
M</+1"G)PU>PQ8L-UI8G=_W2V@&T]D=1W>QP_4K'<[!2@='9TC772PAK?N#?J
MY.A7X.24\Z!Y[CO72`>2<[<6B?BX4M<$*[B#].2Y*.SU%@/)3IQV*1FXSM;R
M.YB2F[W-S4V=L/M\[91?;F^FO]TV(W>MKS\TAN]$Z-,MZPS!G3LF;TB%9?SS
M;NES&6<%U"&\Q#/Q+91QU5P_HF9P$;Y*MZB0F357O[WE@5YZ#%J`D8#3L9:;
M\S71!,<DKOWM+;]]6?$17!@`+PW?3+T$';.`RIT;"`L7'=V^;T=WI:1H@!'I
MU;]`7K.L7D5WSX9[$7!H`J?#.1Y814)R_[;YUMUM_Z(Y.")&<*J7R>1?@VQ[
M3YY?4^"$D,=Y[E_R-C;!*IH>";%G,Z?*3/K;``8_A],7/RU&^>GZ07][>S>*
MF.#:6M\7T>)M^NML/=@UW\@:$L+P+H2G,(\.&'B2"_W-_=N\;Z9`V@AVB48B
M%S:/6`7?/O`3^<'"B[/Y.NH,@A2=W+Z_W]O;W@DA"GUD=,9"?UQP[T<*D7/>
M7G'._AP<.='A8&'W)\V+]Z)#AV"1,,(@T%!XY%R`!TWJ0ERBMB`^X]Z%]RD!
MB/`:/:*4AH8CQTHZCG?,#6<%2>+%M$>^R4N3:ZG,TYQQPFJ^&%CS-YLV%<R"
MT/.H$!5!LP:CFL.W"%0HAP-T';2L$_M[Q5)KJYF>YGJ@J-&8T^(SD(*JZ42?
MDBQ@;T0_$Q=G6;DU1_@-B2G,V:M&Z#WIL0[O&_E*\'6LH']%/_%4-!^]_J=\
M-/W#8XA0D6.+]RFFU02[;5J]+LK1J6)/P5+UCT.8HC-(VU^T;(EG)I"=Z'62
M66@/O,/!A\<F].YQ`+'1"C6<D4F]V]N$Z!_L$*+G?&YO[^\3O("`O9A&$^F9
MV!JX%40=8-1+TIS\:G0V&4Z-05Q:P\%M\2RQV*8'Q\'V&>`\YD'4UT@BHXH7
M^4\Y>JYSA`%:][^RSIJ:Y$J)"ZIYJHP&F=#@,2^@Z#V6[*`I:I=!(2O2/9T`
M[;%'UY3B.I-),_EMB.)A5OB9)H>8AE@8@!`>,@`<Q`6B(\!6!=A0NB;S")TZ
M2ULB4]07`_GZLTQL1/+?_^?_73_P\KX.N<MPSTUOVPQ.`OC[^E(%"PO#G_'H
M%6^$>!G-LO"XB>U:=.`.V([3;7F2=<(\MO@4%03%K;:!%A<3C:JJW'^2JF!I
M@OBQWS)</A*J?;]`P9-6+3OQ<CI17UM&)6QD,*ZP,5+0+2TG.S*R75A*!Q6;
M[NWW]K&D:E\'6*WKK6NOVUS91Z'#/"83T5\\SHJ$5)$BT>5\;&_2&U?>WMRX
M_T!T<7MK8]>XQC[1*S)GIJZV-OWS:4VY0MQ5X5;W2T6!DT!P^>L%@Y,5D[#O
M'_$G>%3M,)^6DEKF/?:RY\\/;\"Z+Z"'I3:N63AF=H&=9FNIY/IF-`6<+;02
MDM3;?,L]=:@;ML<7(UV1+X'\CO@]84>8@Z?'R#L1[Y<Q:#[+"[C[&*(NN&UV
MC$&N;Q[;\RI.1B0D^>GC&@W%7M1OK#UE0O6<@E9%,TB)\&@U]WM9*Y(D7;Z4
MP,0R"08,,>=="-(G^)`JUD_>A&]3><$3R7./^1D#C4U<"TSU()+C$YC'>5#3
M!2\+]1MO%8EMV2,M_&32PVH.RZGIP&$YLV0IB@PU:1^Z4)!C`C'P68.M"#!`
M29S\UN;O`H#6M'T]]/T,J3[?5[/!AMXE$/X_;Z_>2K'N\&$AS_BR.<P'3$IS
M9#6XPAV)V*L[:D%OY*,EB)E&QK8<C9G>U@N.#0V3D.W6/?K89,LK*R7(CHC*
MK"(3F5&28+PY?%[Z=!)>2S08F%TFM#"!J1K>H^<,G8N.14HF(BH3[9&NZK@(
M&&4Z]CJ'18^P]<G9^I1VN]0J1$MP3):?4U(?'W9R>]><3@E\(]J.N<%67+M+
M5"ZKWD`^^/C$C7RI8GQ.\8*V4[L(CE,5GIK&M1G$$'>@Y+8P]BTP`YX\WE7X
M@48FM`*F')\9KWL>3^V`A,>EX?]%+['S$?]+II<'&@K";&I&;5`]XMU2YC7]
M].GC-:&6-KS68LMV:"ZO$;?JQBHQ\DVWM&']_C!")=MBJT?#A7`4K`YGYW4@
MT.L)07DKRH"(U$U;":9E#'L^TUN;4)J(PY=<6-!)L%^!]DS!"@Q+GMGQS;Q,
MN(4.Y9&X#:=QX>TH*'[VNB)YQ4.:*W"<T981T0PI$5$)A@P6!&+;<VAAS0[[
MA`VW?F^O18'R6K(ZS=^P1Y8*RMH228C//#_<"%DFCHIEP?&?/3.]]'CJ>1JB
M-X@Q^<5U'_X%[9V@#P*X"@-=?8`F.C2D7J$)&:4,=J(FFZ)Y!)[UT:.T:[`7
MKRQI10X&Q4J,6N3!Q&$@4@,"Z\1(5*<;:*CJ7_!&!.EW':CZVAHAIZ!$U$O5
ML_Z>+R2*VLB>5_:]]<(O5Q.UX23/=G\G'*H8RYGO8IT`0EPQ@&%\KM<L0EO#
MTT)N"PIHB+#59SBLU%=8/*>I^@U'%CT1"E04,;3FD?K>X_D*6/T(P_9R42#3
MV96N>HG47-X4N_-T8ARAKLS(!^_*:H**">)&PP4G5#+581A&POO=`(/E/\3]
MF=>'X$:T+:-MTS^1/FKCT(C"NU[2OTRX5M[1`P#ILF;O$9&8P]4"`_/PO)AA
MU:D-*0]0XRO1']T7G"!!ZV":]"8S82%@W?L$$$7C[E=ZF$;+'%L'_2>^(26-
MS176TSKB,W5BG\\FQ!HY6M!!M9Y':4MN+#\/%XP)9)^O%,GY.:[NN:R^I@((
M#);`7[%QR</2$$6\S/$!R124(V\D<2XH3CL"T.6,2V>)AOH=;;I[U@B\--SM
M]A-./MY%9@L0+6_FB6#IV$DN2H^$Q>D20`VY+2P!+;K*)*J@X#5T'CD$K430
MG`46B<T$9X<V;>MEK;E/T=P<;T!3`[84%+S&F#XAOH6I)`Z/TJ9^A(Z9!%C3
MO"&<U;5@C)R?2DP%S!/T,K009'-^=6W9?YB6KGNSCD=&Z1"#3='/R`O48:;)
M*N"`$K#S[-",)+NT*DI`1$+(U(9ZR"O>10FB))Q>=,:#A<3S6)3$*8YNG7-E
M[2ZGZLBS[7,TSDU-GY:@00ZU/Y%LD+)J&G-VHH=)R?Y+ZS%?GR3[0B1:/2[[
M57@RU7]!4)OLJ(])[WXEGI%0UP;'=J`.J[5>@Q!C>(%RHUT:X6_M)MI2TWB<
M=O1ZQZ;^<6'&7YE9/%/OB;M'JLFR+O'`GX6D;[)&DR)D-#3C85>ND,FQ_='6
M/O`.[:>/_F>+\K:<YB?CG_(LS.B8GP-#U&:'/`B;OAO\2F6>_!Y*OEFT+=V2
M]`5BO*+8%_1DU13'0Z3[LD#-ONUE+__HPJ(>TDA_,[D&&/*W=W"Q:T=&L<85
M$:5TU3IK=5^!6)UR%`?-!*(M^.GCBVHC(D.*7DYV-.\;)+`*.6-"!SP/[(,H
MW?344<C%2I@_"6ULFM&D^</EHVY6F+#\VRM7P&CW[71,#54*J7#,0F6=(D!)
M=ZO.C8T[`>HECN1SW*).#88C*2MUMFX^;2`_?=QUX;;V'YXN>,K&&MT+C6?E
M!_V[/>C3Q_O+OSZ9*"Z&_0%!H>G-$`T8:$_RG%#:[]%3:87@%,5.W`G[HSUZ
M;6OW'O>.[K5_?Z?]B[5[O:WMSLN2C:.+A]+3587F!!9O?*R'LSP@T9*6M-6Y
MW>2I%-NYV9T6#7)Y@D\?;]_CR9`T9>%E7!+7C,6M6[>(;O8G0[?JJ/CAEOUF
M]I0@F7J;_'#KD`3/Z:S4N+,<J\'>%OOAUK9^(46,-V#C>(-Q,M,O[UH);2.<
MF@0W7ZK^]9Y5X#2PM9*5?%JB,3BBUIE=*^F]0]@!8]U$5I.FN!6GVIVK20MB
MX<K;7N<AT>6@-@F@4]Q[)3'<+#GGBBAN[SYPEV!N[^WL-'-%'5UGAW'DGX41
M&W44>AOJZ[^X3LBYLT_G::_QZG/?28"-1N5BY$U<16]"$9`L`R+B.1&'>ZY6
M(X[U5DTPK>RH)UY%ABIT>1'AFL!4?N8E#[(U=%"R6-/RMB0X.2[%QI,L\.WM
M!Z&0)&398.`=K?[I(WHR)-P_??2@WR8\O;>S)UT;W#,]YX0M:N$:B8M$5%A#
M)B1_5]`[Z-*G"4YS2%P)%%]$PX(2/!%!YB\D^[,.<"18VL=E1[EK')V>JB'T
ML^BI/7$W,1GY&2Q:Q*N)\X8EKBJU:\BB0Q1@3I;N4IKX#2G!BCE^T?E'1%$S
MXA'URX_>LQ"F5ONDKCWFJX[2Q:);]4K]6,JB<Z3MHR567!Q9I@WO71P7XQ+J
MYXZHB['+Z'E#")&+1OPK!0F!K%"]0B2BT,IL['2`_5;6=O#&ZH>U;I.L-(Z5
M>/0!`07R2>V&0"S@W+[O2IY<PJ.?N$5C6S#-UF"'/=C9V-F)\=6ZFM(OZR)4
M\DGA>OP''H<DQ8G)XVY8Z84A.FG/A8=0:\6AG)B74]^A=ELE_`(^N//FG5M+
MDXK/0ZY*<TH.Z#:$JB[Q+[&69KHF"*0:B0=LKBDXEP5O/K)/@J1$U=Z&`CV:
M9X#?/BK774T;YH,0"7'CQ#H9.2>)#8S46W9$2XMLM,/V*L'.[1RGK1,@4#FE
MVQJXR!?S"4NJ:!)P_&$!)D!!=HKXXN;TWX;M4VPX+,UO^GVVMD7%+%!TTV!Y
M5I?"'+FD']:QRWMD:]L*P/M?>S<D.ZEC6_;<M;UAC:.L2)JBE%R9(JWE@F9I
MS":-CX2V8H(IS"O\*MDZF^*KN3"$)<CJ%PPSY5%<9A($,)^*?B`US?(&NYR?
MC@FH0@'PEXNZ_84#J@:E"VN,%G/2B3I**5IB$/Z-[3841S%%=*`4D3TY9O$O
M#?SK`BL^#6UY^,U#3V"5AHO>O?96T0)6=SCS[,W&\48RCP]_AF5`H]91CAE.
M\M%!!4[0XQ8N)W*G-PTE%DXG%'&YS)1%NAP'!IP$S)YRD0TSEVK`6"%,D3:'
ME(`KU'J,&HP^`4Q&KQ'N,=`C=ML(M4!^BG*WIQVWHR1^J@,RH32-\<T`+,*!
M:XY6TTJ09:Q+SU2PFBCC3ZV<#H>ON[O8U?+7,8.,<%V!#`J1;==LP9*ROT,G
MWMK!%+:#-*G9TD+0[E"-J]:.B>!)-F7[T+ED`9]UN/<Z4?!L>9RMNWQ+'A)W
M#:]D2L&&9#D%$>93@IGM!_=[FWM;2?BHL?M4DC.#BVER`]I)_A;%Q_VURQ$:
M2$BG7`K=%I?8=G?BRXI"VM;V7O(RI+"=0MDR^ZTB(LYL2L2DG3#?@1CZ]0D3
M8Q)T@"NJD>BW!)1MBL0/E1EBPV#&>DMC7RG1$R9>L5X;$^*7[GJ;6Z9J;K3>
M]]:8J;X8LD1I!)Z@*&1XJ?>GE])</*T_!Q*1[!G`"I@?EA7F1A%Z5Q(`K9'D
M>UW)P=.#XT?9P?%A=N^^J]A+RJLLSJE5`\'4^`D\@,?ID_DN^QP0Z%(%B+OD
MF?'D)6Z._O;N'C<=<?IKLMJCXD8U'ZXV4_M`%0;@YQ2_N0RZQ67K:'VRUW2J
MB)@.FX:Z?;0K@E&()2>@E*LONW*/0Q/C(%UF1E&E`KDSEI=1TC!D=NYOTS]F
M$W$6:O:BJ9)\BOK'9=&>K=*K)LI8OG-:J/Y:J&XA:6N#:'3]`7!H4#"#EE)$
M2PI9U"98OTDTY52AD)]<&&1K4S&0*R,J)]S-KQ0YI39SE(\U/HVL6`#FZB!*
MD\1]R9.38`36J[24R!*QW@'%HO/RMHD:[3U0F[,Q5XD'FYF^$IPT*H-SZ60Z
MZ@2`BTEM[]O+LB8>T90"SQ$-MBX7_1N/P5N1WEHP5>_4.J0EQ#/E#%U'"1XV
MSI6,6D?)RUBB%LCBO>K.,<5"_V`OMRM'F1IMT1QT'P21%8QIM.H*@]O1S!(V
M$".)[E?M"HH5",XF-\,@0$YIHJJ[=<^_16[M&-&GCZ_&V:O^?'***%;)O4)_
MS@,.4H5LU`=N`<F>TW)CJ=E@73M2ERC8W^3?EUYE-?_LX=2'E;FA+BL=)YVT
MY3U@U)>YG%>^(ZND<6ECQU+0@FC[G@%UW58;;V5NN8+&6(?<IH9`U&UC/Q#:
M#<U]>_!1,`9M4;\.B?D4;"(1I6($J;H5+SCYH\];II6KY?('DAAA*B:DD\%P
M$',E7;+2SMJ[<MSC1*(L=6B9LCZR7I0Q(CY-99KAEFS%S*\4XFLH+7N,N>\Y
M[,K88S/^@B6**PY,G@N<>1]J1%IQIGC9JY88[NI`.,[_Q]ZY[K9U9'O^58B&
M,Z,`DB)2E"A-3P>09;O;W8ZML91D#@;S@1)IFS$E"B*91/UA/LU+'.`,8,RC
M^%'F2>;W7ZNJ=NW:F[KXDKC/::`OB;AW[:I5ZWX=J9%*343HC+W^GG&Q!X/!
MCC74D<"X5+Q5R?D&RSMNOO`X?.[-XW\DL.![[_;Z=$:`=&I[OT61.<CK.W2Y
M'^<#@6.!R@U'D6W0`[=(:!YR_7[>"`D=@2%GD\OA-.1$E;OWP$N-DYJ[,=YH
M^3S>=+-.RK_[.O$M((;))FJ:%?(]TUVB+"N76ML>#!AUOE7^??4G!.8;=9AR
M*3YA:DSY]X/1B"B4B[QD]<9#E0_[?AJ>CHKF.;RY*,H7UX*SJOS[(0KMM0@:
MHVW)K;8TPTCW7D?*<J5'21MN!`.SGVZ+`;BW.'NA_,Q)QH85!"XU:>+85B8;
M;]JD7>3;>B$8.8#,GD,3($<*W3-D*_'O"WA&)TQJ]=CU*]P:X'RT(6]EHH*C
MZ:/*W9+2:3EU<4OPW(R\HXUC#BS5R`0NATJ4[0T-G;P&UX`E5,YG])#'6Y&[
M2?+U8V:;;Z-JUCODHIEU;@G,2LXBL'!!9C%B;')QN5R(>(39=2UPB`O_WPC%
MCD<;*`D;]D_X1$.]B%B!^IY)R2_,G9/9)2GNSV>;G3W2+M1<KK_EYG#<JYLN
M)JQ:E<8(\DKCJ[P&QYZ['5P2$4U[DM+R2=1_CO*H5!'6+C4+?K:<X[0*J*$+
M2!15>2)666%ZUE!))?V>-2]3)KL\,_'LWT>`5A87-ZEB5SW'90KBQ87!@&LX
MDQ[3B'I>X.H"4N;"FTPX3''YN;U(()S"\M5-&^#GW*367O+W\7(G`M%2YM8"
M)75"E:BZ;\_N!`P"-&!.P+#*?%HS='DV0\OO(`K.QN8^MRVS^E0%+/S+74X=
M_:QJ6>9H`Y_$S!8R*$_*(%3UE]+F,W8`8&797HU,N*2$J^Q>6$:@#[B8!0>%
M`=X5;EZE]5\LSZ5>ZV:47VA,(`=>1!\!;J16`VA@>-#'(X.3/I3!)%*Y:^5&
M=Y6>F#]W!Y#5SB#DP,\HB)6LTP>2AK)677U3,()F6!]6J``L*U4O"R22PR1%
MKAE'#,;;:KU`#N2&;'@RG%QU?I#P*;?[T*.0ZNV`]T.@CR&K\LF7Y8@TN)@B
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M-].J?*H?<H"_69$ZY;;[-_W-7J]]@<=44EB'A9]G8`S1#U*DUK8;6^_V2)[?
MZ'1W&\!)"XRHCJ=CYJAS/1FCEZSU&XL<7<U.LVZ<II3".T.<5KQ9^=CHC$IP
M)J#5"8?JK.TTUO+]]!LD*5JA@'DUVL`\O<LF^(/$072.K]#+4*T213006(OR
MR-N-EGM6>FPF8<B0Q4N'3]:0LG(]G:B$>$GPZ*%RHWDG")K*IFM@<V,;#\=G
M0WK4&C<_#-GZHQG8<8&ZYC[4$<$6!6`55)(*[X,8"-O-JDV:1R*;T!"?K3#`
M%:/JW^$^9T2^D(JXC.8J=A9O6774;.FTA+HF.`&3UVNJ)K1\.;S0W[EX\9VY
M2D4F-/Q`VEP;9R'DAC;4`$,6%,@`KR4*%.30I^,.).<7;G$R>6/D8S@+X437
M0=0`B&L1')4!%->I>MHB&JD8'-O.7<FZ:5MM1HCVAYZ1$P`YZJ:N5B0P[T2\
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MXUHY*8%N-$@>K.FC>,+TXJOI#-59OA6ID`M+"-'?"YU"KQ-@-OIO^3E\MZ&/
MZ345-KJNB_G:VZ6"?RQ]M1.K73LO9>A3OOD3NK7L$C4^.:%BUAXSX8U5\4O,
M8S'&@ZBRE!7T?'1R]CJ*?N"@+F9)6G*-U=-'=`#23B]URC,?RE'Z@?'^;M!?
MA\Q`[TDF`(5.,QB$[F.O,NN+WN^<5EEEV*KU'QK*<'Z_(?.AQ9.2CAZ\O<$B
M:3]IDX^]B"9L<--7H`SKL5U!)%_OLLS?X39`D+/9ZPM+<S!D2KE$88-<1>6*
M,T^]9^,:TB@W*CA$1O*25N?4OYDEP>@`I5%@%[J5[0[4J/_7D+?-XY0CR9T=
M2Q]X);^U<\O@<QJ*'.9OQI"4/$JNV6(A7\R%E>9DPG&01&Z5;1#OWAX1,NO&
M+TC;L40LLW)C\IL>32N(#=(@"7*\T6]!?G2[(\ON/EF0%F'"SH33X-C`8QW=
M`]#Z5#$L[2H.:7)7=YV5;38D:=PUK+54`=(A`,/*WVC%6?X&E^J[LZW7X.+\
MMKWZMW[7?]MKU%'Q7F_5>RLJ`ROG6:MO;;?=8_;2"K'AQ]`0?7CCR!X;,R+2
M2I$`$(8;6-MM0#3Q"[\MD(LBV;5!XSG\A<$GN=-P._);`%-3$&YMDA%IOLS6
M]P*8=AOB$.^I^&5Y6W@RV_XLC+WZ.*<8,]BL0!A@[A@>^T4E&;B]855,)+]_
MO/,,IV;;*7!3MOYYI_7/F>NIS5LBXKJCCT<<XD.\.Z!3VWZSC44'70A>:T^.
M8364-7?<*IQ%_MG>"O>4^<A.E>/`="?:+&_C$PYZ243ZY8)J,^N0T.#[('C;
MSE^JKE7<RM6LN'L\P%&JYE3"SD*,,_Y,:**F=]6\DHU-/,U&TI=XGO]V6T["
MP/QK^1OE:CHK&L>C,6S`,R#/-,AI,?P5NRKGQJH.XJ^A2L0=P_25H1P#-VC;
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M(3'1+/.6?(L'_>T.=>-3I4&`4\L+PT;12'E[5I?W_,4S'+24XJ5I6X:Y1A[Z
M)Q1G,UP"TW"/N7F]/5$+-9ER/].*ZN_P;4LET`<\.'!*-$+]L"EED)C/(N%:
M-83`"V3ND=H2HS;U6BFA['3X"\D/&O1@&U"`/B[K@7\^[I0>CX*)2'@"%FR%
M29#I\#7]_RG""^=C50M1^!7481W>K"9?+89OT?)IMZC&/B2JX,81R!4AT8>-
M;S2O-'("]!S+/Q(W"E3?H6X+#%#XJ;8/9LLNKT0COJ$:Y+U#=\I9,G#7;D)>
M4^4Y<>BLW[=!S=Y23@(?G`$9@B2*;%-$33'<F\EE:)H3!*$O,Z.W@[42RO<-
M%G('F+S81BIE9#4?49CUJ0])`]SG4/P1]#3\R#92![=06QU%(J^TDPFF?K5H
M--,XAD*\4]P"Z+T2]`E1+B%S2UIK2+`@5TX`>\5QDDC6J3+Z2XDM!9,'W^"\
ML6^5=3@+[;B,DI^$:T>6,_Y")6]VJ^QSN_]5R.E091QP`%3([PWM/WQW3<SU
M:T,?[>:.WLY;6/T3`%>L5G+!N.GJ^))M"VVY?'2-K,L^_VVZ2M?HFC\@/WJ[
MH1RO$@J@#2W,RR\<MF2&B+@JL[;QRD&9[YEG-#>>KCYP!P%!X-T3&NU6*@`U
M=DV67!QC**T`5X>\!<@T%(E[/7R;_N3Q2?C&W;_G_5DMK*Y]*?>LL:<7I/CA
M;O+4(/)NY`[?KM&E:28/8]_J1Z%AL$DAAIC(9%:3ZK\19W\S>=OYZV;GD09%
M&X,@SHXY[XV2'OL,4'["F+-&26N'CU^@X)IM'U95^_'`D_@_Q@B(T"&)["0'
MJ?G$+00P+,%_8%%(U;=:OU@Y#OD/$X.GB5@?;'N2-#5A;R9T*8KZ._0Z=JSA
MN!859U?OW\TGOWHVB=8AOGPU#^,!M&=8`?THS;FA(S::=$;'I&+KZLS9X%NG
MY0%.6!68R5Y&!,'>T2,G"S57%$_A:S1JO)0P0>HJ42-!_'2&4B`[2T,4XMFJ
M5=@I791QX5B&@O;NUXW@2NV@JKPZ_\W?'IJV8,N[$-#+;)&^@\;S(ZC((:0A
MU,^>XL&=_D)J)74T;-02!W0%@E$LJD:JVIP*2^3Q_$2W=?)O)^>;%25\CUIM
MJ#)<*(W4D)X/V<NX'1`C))F<Y0L')%\%S]`LUD'G``UYDP`;V*?/%T#S0FC$
M$\T84<%>B8'@=0VN#Y)\MKY*E5<"4L#'QNV?E;=_@'KGO3-UV[&R%FW;2H=3
M,J7=0$AU<;S#`4IA.9<;(C9Z0DW0L'$7T@13@8S]Q7$>R4[!E.W?ZN73M\TW
M9_@6=[!+H8AF]]RTDS]Z7T9RHNQ1D`<+5L#A_^+NM%FJURDKCYWX6Q_S0Y`(
M@J:PP9W[!0FGC&)?35YET#;Z53]CB36=.Q:_W4*PAK=&P%)<-:[7@,059/H-
M)OW%XII$;GA:O%YS`M2^.E;YG&Q_<\P$VS&\R5C8].?4%+'B&_Y-@U,J2PLS
MS!UY`SY(<;H@$<=JR>R""DIN(-<S&#`\QXCN);X$:\F6.&M#2)R(J@-.Z6.<
MVSQUE@U-N7]:2WZ)--"J-M,E<FV9!O01I;L<9H;Q+!#!$]XK%A._A5HW@S.I
M`:CQN'/IWZG8$J+4E8JTA4K+2PP33.ST.QN-+<RQCT`"7;Z1Q.R:=M=J9'HM
M/C'?5-U@M`+4H5IU#+8Z&Z`Z8/Q:"ATHV["5AW9%30?@P>GI;+$@<\VZ.PPO
MQRCM9XP<H&F$N4%R@-:`21<+ZZHJ(Y^"J]FE,3)M^HA]<+IX<^FR')XW?#"?
M)?"$$FC?%O/)#'+C*TS(-&*`CR]HVLO'15Z=9\-3]%+^G>:`VR)ZRXJW$%5H
MY&V=2DW]AR+)$9/N#HP7D]#Q`;R'E?RT]"MTWCB]?#/LT++$`WM*NYO17W>!
MM<I-&!\/D@OJYEYUQ]8(0Z"H:288,"-^PR!T#%33RW"G>O$!,4_OR-#`_QS^
MMG:%7A6J1/3@X/2#$B-X,""2ZCT>P#K?65VP.4+&"%VUM&X00)@.!BZGCS23
M%+Z+J-J@PJ.`KJ5@4-,4*ZY,9$.*N.8^P&S"6*VGG4,.8&/L3MSB(_<_P@TZ
M=)QK+$Q;E=L6_L"5:;5QZ\H?N'3_:]'==/;:CIOHQ?N26+%(WK+$K;='!XVS
MDW_%9`LDA^0:<0O9R6J-TGAP%U=*8MX,WN`5^J]'U!/UR!>C5QLW^CUQXH!&
MD3_6$=RU+!!1Q'<#C<NX5D^:)1AVO7%ZO1'^T?UI_'056!YDT?7.\VE3(A7I
MDX&*$C:(+6O>O5!:Z2E*I_0./83?8IYQ>?("6-Y7):*15I)^*L^U>86:U14Y
M82JV+^/>89I(QOD121NB*1/4>`:@0NA3'ZB>T[]%DK!62#<`<!,856_F3"02
M/!"V@6N4EEIA>-*:FJ]%WG"$K&2@0DE[2D!0W-I+>?7/*X1FL`P:W.O4OETB
MXOW&C`9O?%5<#HM/%>#N:N2>*BF?N$7%BUWR^+PS\XYDW;`7:?ZERH=4K23F
M+*8<^*==7.+SQ&IELI@M5DQES%_2C4>++0)-P^ET]]G:@C\PGFIB%?\O/$@"
M1*XB2))':,E5@A!&&GB#:,*Z[V+<,G;S(.,>:B#\_)$U#U8A?M;ER/RRF(E:
MW<-!)4V5'U3C*H.$]@A.C"<T&N+;K8M&MVMD67?_S/WXC-_H/3C*QS.4,#6J
M<BT[S7]*;B)BPO\A1LH=X_\$XERC`;$-W"")'L$=LKO!_PRL&HP-DG/?P)NS
M5H)\,7S;>3D9X2-^;GY7$`.%2DW#I$ZNO7CY_-G71H8'1T^%EIE^D%MXS,RC
MS`H#2W@A90DWCDR.Y+WE8>S198Q!K6(GJ<\-$1>Z2N/U=6LR6$;QZW++)]X6
MV:=VI[8D%PNTQ0OT8>D7D>/*8U016`,XOEJ)^0=\_.?CV13%6-HV&HAJ8>P?
M?E+6!=9Z+`F9Q]ERD:_Z1#C`H0NR\9$'9QN]WL[&7Y;?=?=W.FL'0,@F?D)=
M`DNXRWB:-"'.)I?.UY.29'JV,^VG"0;>]X4-VKZ`1!5P!?+R998!F>[F?HK(
M:,F,+TIT?M7H6JIS^&>JM>,']8&TEUJ[TTHM[1'*D@DNR6*2C@/#SP?PL%$E
MK%ZD\<GNYH/=)[.2?^8:7:9JQEG=$UAQ3WT!"O`.*')DV[49$666<;RQM.\&
M#)EIEL$1%"QB6KU-9C5X4(M%"F0YY0=GZ_%&39>,7[4@*+B*;L7="P2";WS4
M):^_'O-N@Z`5;UA%/7;131_=^W<^8K!$;V#M`Y'=7K^C9&6K<_Q8<U(1K4P]
MV-)1-W2!^T0__F6YD,HSATN78[8/36YWUI[\Y?#EX=?UA#7W9RXG1(=,[%R&
MLFV#4IQ*W2`/,]L>'NYUUI(\BR:>.X_L4];.IN(29_@+IF,9[E$-RJE+S$RW
M4O]6X[+D7[X8&=-VMP@;QFG@P2\3\YW+R<_66LYH67-73!O@)I'?3^#O42@G
M7(R(($=&S6-"XF7#JM4>=?)X7MMA1)MS9KR@%I]I3MHI$S?P"9K-SIE/KSL&
ME/15XQ/L*CQBA_<MVYUXOHE%5A\PM#DAOU`2`8"^':A!K2SQ%[O*XR+*EX%Y
MRF3G4+''<9Q=`11L&]\G:X-=5[[UFS"N;HW83J5OV>[]TJ?#4T?+U-P)5YB%
ML(PI"'XNRQ>_S$)D2WB01GCS`.J[["?;8[1QW;1?S,R_'%4\+>;?<_?W&91@
MW33#<]'(">H[SJ-?N`H@Z%L-4L`'GBO(9E\\6*'W=R/$.9Y_+D1-?3$CGQR_
M(D;[:265'.CR2T,+N0D9']5#M`,IO%'ZM=2HVK;0$+2O[(,MG*C6*^IF5E32
M8YWUF&;(5TZXB$A&MC59J!\Y/_M^GA_$<$)S+EC?5VT@,9#F[&P#B[8<_/>Z
M1V`<)FM70I.+NGFDMM]H"X#]M:*-5JL1=3-\ZRRC%<+;N[N5WH\Q?8\)Y9\#
MPJ2Q#OK[!N&L+51YRI%/&)=EI/YTL&342+&!B-?T5YOAQ.,/;_`8ZG?O(=MV
M=>+;%]';G5X\7:)#A'[(,%^QB@@_GN>ZJR@G'0ND[&PW".B-?:[E?L/8HSMU
M12_/7J<@H2%I+0H5*A>??9V,?V6#WVT^HK>\&'0FTEV2)QB4&J*)%%9`<[<V
M*,$!4FP`2BET*Z:QFG<*8"O&27!;0T%Y#+!>;$!7XK?!'4[I,OD,J.A^=T8W
MW;X&NJ9M52JK;8CO>>P/<K)&F#(32%X.N"K%ZVJV?/W&KT"Y&=^+1297@#ZA
MVTLZ9UT&%81O$0&ZI[AKU+:'M;3?WVU<[F35Y5:(0<]7TX+K7RS<(`5XTS9=
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M_2XX(P\-G+IB2K*1R/M&MH:98IC:(KTGA,EA+O3!6HZ9&RSJ_A>BW`P:^Q<G
MLFH)&0M,1Y`E!]'+.1#2CK<W5?_G9JY+U!L9Y]WVUM^];6\2:$FHILTAX[,B
MHVJ')EQ$+!9P<,,Q2!B]ZSNNUJO/+F#+8Q).65G]@!AKOK&8A0(+9)PVP@UG
MWAW9./:<%!3!7%\*X(-CUMF73V=@<5QY6CL7O-AX,Q2$AA![<?'^76H'&]21
M[1NACG2+]K(V>TPYY=33<`X2$$W06*0E3+9[_.)^<W@$7S#-IN(]?D'X*^1Y
M&+YHVEML7&L4H2@R*DM-:&=O5/+8,1XT$R>+4L3:`!OLBJ^B!61Y/BDMY,%N
M%;"ESPH?O_I95V.V=E#LR`9W]Q>F1)&/C,.NY._/U2YDSSRW;.KNZ7C.E<O5
M#DP[;7RU?JFK0F&"IUFBOT\(K..FX&\?`?,0A5HA/L7+,SZ]6BKQ[A\GA`7C
M\+S#+SB*52*J1(FE-R4G(`J2#(_RP4\3U"I7O>VK.8_X@%@/!N%.@]+O%<%Q
MY36E>,@K$5/D/B9LD^REQ"+DJ,=8_.*"1H$;1$8-KZV\P;?$C&0&EA=>./U!
MMD\?(?I___O_;AQ\3)`HG+D1WZB,8O#`[.('7<8O[%-UM%UJ#1\8$PJ?_N"0
M$.^CO@4)6+-\*W7HGN&>5=!H1'L`QOX^R53;(/*7'-[Y#Q[<,4PEIG$1>M;&
MX`6I1C&=+,8P2E<%U^J.<F.+*79<6?=NF3ZU3X1_?AI]/\7JTG*D["7.\@FC
M0@%EX]+:[></"H6/_LXQ(7;Q??(3R4PQ352`_F)"0FSQ*&0]_C81(3[X&0-"
M@O@E1A%4\!O$@^#NGR[R,Z;62BF0Q],93K*_8492.HAG+$2?@ZN:`^9Z6.;Q
MHTIL;^=+BEP,J/XEL!IV_+&A(8/U=9AJCMV:W+:%4\_ZHBB!!RS(4EPRB2NG
M[U]Q0I(R=SB\G,B=\V<<YI?KG6?/#O-<[I2T?0`NX8T8MCS/E"JEA3)D=VKI
M.@0GS\E659*;.73,\O^.\JUC>"SC4N0?>*-W8IF7.+)/LW__[@?)`?(CUC&Z
ME/&$N_?GR=7"HVDRK<UGH9/!1!G-&VJZM$0"!YQ>OE?+A\>29Y6.?9[/*@5J
M",:2]R/$.B*61U5J$@G%(>:JLV=E'Q!X[G[5V$^8A:[&R2?-MKV1N\I<S4OM
M'K$K'D.RX,Z>SJX5EY*W!NYWE!H-'5#(I^0;Z@/PTB10J+]E4&WYHQ6S\;+J
MV4DN(;E+DWWP_)$=HP&JEBT`5.:JK^7?(_@%*(._PS<\C;JH/6@VCJ`0MG2L
M@IG4G4H[.LIJL_1"PB!W'&2X97<N16Y\\9J4*@N(!V4Z1XV4/<,.TG7%3(>X
M*UW".8EGVCM;8V8:)8#T1O*!G#ERRUJ,RVB_8@OEIBSA\6=V%+QK!`6CHYW!
M2\288H2*H)%[T31QH1YED'E$9FDLKDF)V,T)HH+2RNT*$3R#(B""DV`^Z2NA
M4;Q`-E[1C]&-]0$+':Q"`RK+74F&H!@_H/,:)C4>GBH]03VNPT6KN/S:QQ^P
M?*B@#L^'1Z*JPHV&O]SOK.Y.LP^!L23@\:%0::5+HS('PRWT0]<]A_@@MT0:
M1#B<P)7/I@WOLZ58<<.@,'*?E4UUI1NN`E)>RLF5'?O@"8\E07,70I,VSI>W
M9%)M'YS'ZKXM);\J70_`2'!G,UPY8T=),'G_KNHK5KMF(84S#TL+=C'`*2PR
M.II9H-D;M5UWQK!F&%+8HH$J]8"K)IWP=X.83>(+*2>M^[6*HT@::=<P:S^C
MV$>L02;B1/FH9_OX2!5HB9,-%4?0$7SBF(*H%"H`]PMW/P?7M$6S(!LR7T2M
MNSLVGBPPG/`HT+-:25M3F3%&L?%>?QY.2+QQXDL?,8"#+#^&ONMB4>:=Y=8Q
M"ZSD4(BBK?(5):G.F<<E'FAE4;]HI\8S0L.79:HW(#DGS`3N4&4W5;:K7.1D
MD<<DZ,@@1\BQ2`<,`#Z;Y7-__ZAO":E3H2XL/[&(2W!.`N$E;2H\*@.V'R]8
MT`#&R48:B:!TNT1A`.8$>)<B5:)+X^G&%*O9G!"HFN.FFM_@I=55T9)!P[(#
M!^6.E2\UFITM]5'GK-JQS]S&J2D(,@40?<!JBY>+C=FKC4OF)U,=$?(6/1^"
M3_HL-'+L+?RDA0UL3;]6S'3Y5"DK-^E]7V;&"CO^+`DK37U2)J6COQ4\AT27
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MK93J$;-1\'9D76HM%Q,;S<;*#=4-(22OG%3)*W+/!+>!N1"DRZ)`CP#KJ+/K
M4Y,J'T9</*5P!!F8-O*9$VW\<Y%;AU2;*CTGRW%=E6KSV+IEE^S)_WI;KR;O
M==F^PL&EH(CA'^Q592('6UA&</E!61O>]<:R>&5+"_+A9-:;J5@!$\5/GV4\
MC3(K26:/+C,I"GK>#('>]OMW,C?T`5?JJLD39L!/;<AI,`K#_O.=G.7NC7I_
MP=0W)KG;J&1)_C)]-=A45-HDQT:\O\I[$#??2XT8?#<-Y;@$<[@X/)?RXV!0
M?@RP6Q=SO\H'`7TUV+\$6/=#R?8*2+\P#TZCMX$0U]N0RN<@`QG3%]\A)NWL
MU?MWL?@45[B/!&GT5OG1.^>,2HH@:5$MD,L_OQRK<)QOE3\<O(;IJ/](^</S
M91A%6?YPB&`(@SK+GY[R"YG=D[/R!]*BW?5RI&&=Y:_BHS0W"B/I&FVK?VB;
MW/BBZ@Q\A^F-%H>93LV!4'Y]K;^_OM\<RUS[0.(&G5@>4:YR@*K@MZ9^BQK)
M:;Z)W`TH#]`ICBK*[KTU'\_86#HX"@,J\0NI!EO49\GE\AS;[+JYT\[R0L69
MH9T_O(0ZM[E[1(*CHT/V:G.C[]_)NTU*P1:5"?U!O\$+@H/J?BB*=^U*';*H
M*EF)HGC)-*FROS[8W2O!%3^:G'(-1*:GXC;&[WZSIV+V+KU3Q\TW.6N/J1Y[
M_?*K=$]M3DK,'!TU;_F8F$]M!FF0UG:ORC*J)R%ZY:RNU'VV8MH12,D3A51X
ML+^SOD]+2%OF`?.ZU<\KNWS&R'>R+=TX%?43[:BWQT!X4L"UY0?=W3VO?ZGP
MD2V5D'RN+,]]R_)L%^02FR#`$WDD\?B&F1UXX4K/#8?/1+;W264;M-,<=-&Z
M][L*:8BB1#@[ZX.MP7IO9S_ZY%O$K(</=)9`A[N[Z_VM7GACW<8RBCII1+.]
MOZ>FG=YS.(9X&F<-1PF7PLT#]K8M@^P`<G]WH!W/*7O5C@?K>_M$=YDSL%I8
M53L."%,/BU!%M@^>#(@0W[9&K!Y"AR'TYC%H=>0(T83PI]36[L":[P1S5KA)
MWV<BO]L<04PC1:`X3WY@.+6@X&PI:B&F13YC(BY=B#O_:7A^^<>HAG76OO_;
MUYUGBQ'Q6?92/K.I[3A$T5\8PXL*0L"._^6/5KQ\-B3V:K5QVN,`U.CNDY+E
M;C$I1CBH17B,4*@O@-9$!G)R)S_8[>ZM]_>]\#\RS>2%MN_J`UV8Q^[^?OUX
MYL`."-4X023T^KUQ"<,H7;6Y_;W=]>W][1LN4=O%RV[XP/D4[&:1%%+PQO7:
M(A-?]R0=?"TC7&;=2(SR:YA.8?LGAE#").&8Q>/0M4U6+73#2"'71$TCS@:^
M&%CV\.4,5,WXE(.%HL4Z);3B`/?[K^BLR&M:6'`C2UKK3=<[WYW1[^U\<O8V
M(,L+'GMX1<%FYXA0_GI'F>G[6WT+4"C[/I)G[%E3',L^,D63F<9/&%2.J?JF
MYS"2]Z%*T!]XX-0C>4AC_6T\/[NBWP+X=3OEESQ_2)`&9C50ZB(!V8SN]V&C
M_#E>=B8-ZDC2,VS>BL\!Z(S2[%`Y4F21PD!W]DB=O,W$:9#V+O#L[O;O0-AD
M'9Y41A0.D,F(UBQUPMYL)4UQ.O7&N#]ETB5S?]MK@FX@S!TX[&Y]=Y^`+KL4
MG&W1&&4U<\VOX%:Z?/_NMR9,L&^KW]\D\>2WH$O4@][6AY/E*B)C\TVER@.F
M@<JX_9WN.O86).)%LKF8@W)H!`2#W]_;RZY2K"._/N,*2*&#&)A5NW^E&:0L
MA+95;J+)]<B@+02L9BUR])Q9W/5!=Y-X<H4/8CQ6B6,CJ=5M+KB&4N1VA+LQ
M,`$-V8";U7-=HEAW_9&#/%QYD.[Z#IBQLW5WS`Z2INT@S"K/)4YYD-CQ+CM'
M%7F^\2"N%.CJI2](_-6YF;0#:6`-AH8ULTM]_6#W)I;6K-1:_:4R2RAPV/LP
M0"D8W4$*V=U'-]FAS*K;]T+;&UC@%FT[>S?H)L+40C3>33OI[Z*J\OU/Q`4S
MI)?LJ[23@"GWU4X>]/>Y[-"T*=E:**DCM-R?L8,QF[,I-28#;^:'@E1#K)DX
M;>@J+^D$P."/.<CIFNT1#A-TF&?/CEQ143VK2*)-46G_QNVJRK;E>'TB525H
M$I2MTP==J2H7FL>Z#JHL\3V%SA`Q01`11T8-;-,>1\&!/1**WD%Y@OG>#4$\
MRQ$;DMS*R-!6D]XJH7`@QUA]D>-:LI_2TLZN)J=L<J+8&$RGL,Z"SM[WM@YQ
M]YQ(]T_6+NF4<%D[E"</-?RKPE\J,M#>=V@O$HX?%N!Z5-=9OIYR^^IV<PC&
MF&5\E$P5RZ.4*>T/\Y#^<\3_I"#-EL(J-P9I3ACVPIP5@APO9V02EL$:B^F$
MN$SGU_/I?YE?8FK]Z0^7`%<Y:'_X5MH#-TXRC>4OFO$A$,&121.S\24&8RZQ
M'<(-/+\;WT%E[&'@TF(@0!;IEPOL6_6MBM,8T?\HJVG%Q@OU_>/,N1WLH?U^
M3@\?NNUT[]_,)UPZ_\T1Q7)^W2I^H@3E+P%1FDB`N0[/$(9`&</W[[)LUI1\
MZQ9M6Q*CI6]WUIR:IM=DB$-5!\K:)B2QN<Z9_\U?DS9@G#:LPL="V$W(&Q.Y
MDZV89>C&-EFBYDB>N&.Y,_/(ABQ=DFQQ;LOQIT#(XMJMW>9Q<6FI:@?;#T_$
MH-\7]\F.+&?%9ET?3]\,6!<.D*QQG2161):>`[@/2L5@T/\P&@G-1(R^W'I*
M7WUCTTCRV:Z0'U9REY'(_7ZOLS8G%]79*NU?!3M.KH8X$NGRRUA0-/-0A*3,
M*'_%\NL^@CL<'[<?5N3V2MJZV3-R[],"W1VU+N]_^&F;%+SX-JBQ50:O/Q1)
M?/'MH\E<RKV<$P!=VF;RZ+\,(\\/-0MHO7,LF1<&R*6*G_]Q<*J\S+/%_RP7
M]OO:,N_LK;MP[V;\WYKEKT2LX0A_MMVV=;GWY9!=%\$5$7+3U)*4%%H+"2PO
MI3`,@.G.8"<%17+\SAFE(V2YN-R/UFN&3T-:_+RG14$^:OF5&(MDJL*O07)8
MFV4&;Y5;V1^@E>]@(+\(KGG0G[:)BL?@9M2,.<@^3H98X74;QW1T$RW#*R68
M)C-/?]/]#2^N3=&:6_(VIJ!^R*/+]I%-.B#]0MW@U3J9MYJZDKVN4.`%V<!>
M,Y"XD9.0.>2($>K;YK>+BI5_C^:/DN:*$&M%CXN#6;%:!4OW7^%X=&2-N8!Q
M$`UZK=Z87(@!>TPIQ:=I4NZ_MISCA)=LR,T\`Z0-%+&XUA!.O52R+DT.4<]M
MK)V'M.1]1[$+<?=Z!RZZ^\E@;L_-C7CJ_R\.6_'FFW#H5MS!=;>]WNMB`^V%
MYEWF>@Z8%;2D,,:28(1-RZD"[T80,3<O(JGIS00%=G;6>RQ:4FGS*.CAI(O8
MTDG]DE,W::3BINU6<IW'YD3+&ZN+"LPA;ZL^/GYQ9,)5/#X=MUM-9'57?.#>
M>B@/;08P0;3@FU"IU>1?O7T3%R?W@7C:M%G_^[B%B`WA"_"=W`;L%,O9PEL9
MP[8YA^KQPQ9Y.^%@G"KG66X?18[!>W.1,V9$2M\P!&]UW7<WMS./4#2#XQZ"
M/(ZN?`;:^[P[`3PGK/Z&V]$B%7Q)3$0<XKQ/3$'A7GQEO;VN@2<6K,!,?<ZZ
M\0<,D+<;QV=8/:KN,M:X(98F?>A\-AI/-SL_#"EKQ%QDVD'6*?KAK6]&+:&C
MZ1LCY)QF+R1Z[V_V]K_JJ!&&'!V6Q3J=O#(I&+P#ZQW&*U>__CR;PI6FH2=@
M=V?W*W=_,6RY\_?QE5+[PSHC\B5&1&[;>A'G!!=#K/`,NI]%Z.<8T&706P_W
MW#\L!FP/UG=W>E_B_6]O]G<_YO[[VY_R_NF^U';_^!;W:U';&QD`^E"D_=6D
MO[5))5)R!G\NTN_W$3G[_Q[O?7O_4]Z[)?6M[Y)?F%V_*EG31;H73/)XJC&"
M2#?Q381C]&EE^9]![OF['L*&97?I0K:%S^S&+Z!TO:)ZKOI"V@`55M)V*;Y<
M6CFY/F^MF6_1)8)XBX]+*",OR7/(]I&,33J"*G9Y1S[W!2$ZLV;V]]W[_X4)
MN-YF]Z,8W*#[\8B.:IRU_BJM<,Q)LUX8@#!@HC?\8LE8+%/?$O:Y59&A3#YE
M/E9X)W;F/H0VZR2WC'(FZI9?YCL@:&8[4"EMH*?XF9JR:=95W)<1*9Z8I1HD
M(\`)N?6R2)5_)&P!VHV#A:QR]\K<:NAM;*LROJT^BN\_V.ZO[PWVVSS9`7S2
ME'@P;.7.2J<N(VX_5SGHM+JSN][#:+Z)&(,*WJYUPG."'\PRA65F-;10C'3K
M(6"Q.D\E<;CE>JF4I9,WF)-IIW=637-#S\%?9I*L[Z@S]L"SC'XWVO5Q70WM
MM+NYMT(Y"8DU-RNGNUN;_?Y7G?_%D!!BIA\NL<P3LS)%.!:]!X=&2L(TWVCD
M^VIJ($]=F7+G@TR0"-U&6O&+F])J&S.L_RQ_3S,!\\9%NFVRJ_.%I,^NAI2;
M?-:9BQPR3#A99`_4[%N-1M$)0NYND;[IUMMMUU"WWA.3<AYAQHW&D8HE]4AF
M[`[\`A\H,7![I_AZ"=X?/5%W?EM51K=K_L+X>+E,<+B4FD7[R0@0)0]SSN!N
M\V,W[&IA<AG_:.5I@LW69L/U"]321@K^%8C9[M$LZPE=AT9J_*(K+,SIRB$N
MQ^3OQK%:S.D:,V>T$MXS(+Z]V1V@0LC$#N<G..X6=G0IK.9BM25W^YN#@:TY
M(.FP=P>]Q!A7'@M1T`J<'N,#I'=$1,?*H4K*WQI-/KZ6::3ZDRC[5_B:;FS[
M@:\2KV.M38CW(@Y.S-2JH.:631$J]T.!=&F;<A+3E,"F6P'87T+918>XB>HL
M<-9>>$,2M2RP4)0/R.794T+HH5,(3#AL(.S&O62T!%JH8S(!UGK'D7#&R=_=
M&0MVBQ*B%F,];;.\(-S.WBF"8`#;()V9F/:%^7'PO:9N$NLTPQ5RB'-Y%$?Z
MBQ:F-00-1-/ZUG4BKE55M;V!\GS<.*&QUD.CMJ"Z7>"_'O^JT42`X%J]C/6-
MZ#[69I/.%PZ6H!T2C4OL057E(&Q="V4'OWGO]&V*[O6<#Y3$OH+Y:FW%`+G_
M0GVIF`&\P)3D$)JI:9$QAZ<PW0(>Y!L*>%Y/LEZA3$:_E79G_O25#%A/1(3)
MDR3U]TJMB)!O*`(_1CH-NS.'=,@(J1)(.FO',3ZXTZC;*9?@_AA(0NQ!/:!L
MO6/3Y%^D3/6TV'YCL2I=PE+#*P+-0KS:JGG/&<7:+K_>OSOTI!8[PG/EP*QZ
M<.7>=HV`]&ZGN<U[B4G,@`A_(7>RR%'9:XGCM\=#E:Z3N:-UQU^"V*PBJU^:
MV(3QH.=+G+7)R+LH^NCYN_T[B$-AQ.?A0Q5TOU@^5,3^/P$?N@<3V6TPD=LY
M$APSI:"NX@RKPUCE&[=_S\2'*=XQ"2]&,,JUNGOD[W=WFIV@A6"W&(N!RY#H
M%XOU[F0G>D68CMM@IU32[0_*+3X.O0(Q.-%`T'E@MA2$TLQ'RI%BI/=_XU:S
MI6?0N_^G`Z>V"+*:[.3R$AE%U&LR?\,9<H?G:/QJ;%D_",+J8)<<S/T<^B=4
M76KC,0AQ_IHO9GS&^0E_6T#;_%LA/<GD",W]J,L]9X01+$E-_=X0,J\]A7N8
M%&32-L\FEZ8.^K<$SIC[1.<O'@J..T+G0QM_:;ZIG:VOHCZ=''NUW4L;E`_D
M:JQ;4@%R_O-\,T6/9?=8BJ"?G)FZIDT*;N?#7^T(:'_,)%1ZZ3*USJ4F>'RE
M%,N7:I6\'%.BZB,F#@DQ\B^>;MC?ZJZ]_=I/%NK1TC:XA+IN="?DK9P<"%D*
M8)6L%^QFBO[V=FXQFX^7IW,N4N;(8[5X;N@)C0=NP-3L60&AN=AS:1,^-"-[
MMOW#F6!7@LY805^L5MH45EOVKQB"Z1E`&9*V+HB5V@ZBYF%W[UE(#973=D5\
M1),D;MU614^5VSD,-BF(JY8I"`:`W"'G!%2\ZPB6=3IT4#MV`LJ-L=>/;F[X
M&17AU)A(;57]77323J_CUBBUZW24G2I\X[&>2@W+BB1[H>)?E&/%')8UHT2>
M3SA6Q3AZG,[BZPJ-W6[CLMFU*$\I(TOMEC8U7K:A385\[BP?/IJ?`1"6I70Z
MA(6P:]@<"448=PWO5P,C'EFVM3L=X5</E4V@7KP"Q7'J7X#=19DZG5]5('[@
M.Y2I>33#RIS`&=?B/S4D-+/`0SY<7+LN,BPQMOF04-0?5.KT[Y$]?0`?LTET
M10]?;P<LCD5&*_E<J2]QZ&O[`[C&B4GR>TJF:V=-ETJV:[JG_V/)KW%U,G3L
MW_UEY>O(A#"TF%U=:G@ZJ%'Q7DIQ391H46O=*%'P'(XQ&@HAXGQK<F"Z#!QP
M[IM(A65I2L'H.M):+!<6A!LNO)U`P+X0[9'P08Z-KUZ3MQ7SYRRI"\/=<KSP
M[$#BH,"99\D%Q.*F4LKSXEOG(/%_U2`H(>2=9DMF;HL$Q^-:M8`###M+=B+9
M>?ASK)6IX!///3PS\4WL=JL2G2M<49+TS*ED8A/Q68:-&K#C76FZ7-[-.=ZP
MBL^.GOI6@"-=*=\0D)%1;AV8K&H]6+'%;,I]LF:X0.UVQ88`K]17TRHI[AC&
ME*#"-TKXJ>91\INOP\K\+&`3RS6NP=QD!\*/+!@N'*M!V]F^8[Y'M+(""PUH
M(?N:'$\[CPG[F9?,S[5*]FAV.PQVX=KX4G`"47LW9("6%LO>BM[&46=K4Q-%
M[">XCEX$^H\CQ%]*[.@B!(YT;3D,7:^J?2)=&$E7Y6;D_0J0+;9DN9<QYB=N
MV6KXZZ7:YT7;$4'@ZW[V^OYMBPQB2W$ZT"@N3I84EW09Y\5R(9F7H?7`R0%:
MOTIC,D'6@!-&\'[]N$'Q92V&;\=*^?P&/Z^W98^N2W>X\@XJG-B)_*GQ1/"N
MT+I7!R?S%2Q0D;CRZG57@12]26WXNIB(X!=<G.B5I+W.T([Y.X2-1U69]R="
M$=\(2;;V40MW>]H8_7/5"@>A";_R7X-X=[[&@;03I)6<EOFW4`^\_ZUKW-HD
M:ZB8L^:B9&Z\@26R1+EGH!2]S,EF_/.K*8JO';(!,?:@LY:)H!%HRJ*;H,6Q
M6C11(C=V!LR#=-NHW+Y6ZC5JB/+(9X/>Q@U8.^]*C$#X/KUP6_W9U*3$VA2=
M3M!5S]Y<T#'NM6P%'^0LK)TP]<".%P:AZ$I.2==^&\MU`=<5EP*;%`)90$(=
M5X"*KD.:J+)=E&NH?U4ZPG!Z^085RZP?K`I"-,L+\V</+Z\[:^SYA*C!=+@0
MDS&TL!^!+W]C+T*4^80!;##"M&F^#^7JN(O9:QJ31YFE[]$O7[G@W@I?^O2$
MB-#5-=T*QJ-(+Y&/?W?P%.F[YACL?9.Y5[</N6.JM73'6'XL"!E6;+\CE1QE
M8>%3!O3@\%2R6U8B]`(V!_\H^T8P2"L-<X:M=T"Z>L,?_/.P'/XC)=\NGL[S
M-X%-0-$.YLM+$0Y@4M(3P@JT?_K-4U4<LSDB%\04---"SV=/-'Y>`)Q\_,7&
MBO$7G36;2\<\*;,-L25]3MW1FVLZ1DWX]Y53=6E7AN8HO,?0?AH+Q<4TIL/E
M!2T(N>K.N:8X;"B`Q(U"/ZX.9=-:_#A&7K1U[YQ?CZ<S6AM,Q\NWXW-*C=8.
MOGL&.O$9UG`<,3UY9M$?+D<"S0O/(6:8"))'P`GH+JO!:$1,UF:_B>BE@X.Y
MJ,)G;.O5Y/4;9U4^'$X8IRG3>`BFD[^;CV"&:).YC((R.9V-1"W<QUN.Z)I5
M_6K9N&:-H'B$0(^K#$'OPBA@(,G(L";$<<@BQL2_A(:E``F_C&@C93KK=.0L
M,<&U&ZDN]/,0X6-YL+;%56TJD&TPPD]_%QD/<7^T`%N`HU0#EG(*C."7<`X%
MF+A46U^T79&VV6WVH5\D'Y),\YQ@<9/11%$$.]3UI2MB`>8F8\!VAH7H)M"/
M6D`LU\:I=#".="NKO)OB<QA8(T?4A*^A-<$71"+/5&]SD(V_1+0RKE2-C]J`
MQT/_<-Q+1%@U&"2MD#%:L$N=\2.BV6QQLV-O.PUJ]G>&RCTX/+X^N+U(!.R+
M_J:HTL0#G4E?C1SZPC2X;"@&C"3;ZCQP2[]NJK4IMSN;<`V6?!1,$0CF$1P;
MK<5(+.GBA@@Y%XXLN%VU7N_8SL`DL?+&Q@X#2Q`3D=#CX`?0R;2C>E8_N.1Y
M[91AK?JN]=2Q9+D`4QVA]N=X'F,0C6W9X=L-0&!Q\RGO;`_?O$YG[4DP27]?
MN[D5"E\G73W<!DKZ[VSWBE-!%[KD3VOU/AQJ5#*8="2A$H<<;#"^?+@<65:P
M>5`GYTQ^MJ@^LN%I5:C5@@X?N>+O[TLY`<A2@4VU%*-9)EA8BP)@<;M^+HX3
M]4!T1D1"):@NL1E@-N9%*W7MS,Z`.Y!%<:GREZI.D-_1LOQ=80-CYO5OQA!<
M0J+UHZQ8:=7WF\>;G3\?'!R9E2DY%0]0V2]9U9V;)Z:A-`V`JZ4VXL=ZO43!
MA9'9!YN[P*L>'1)Z/AF,4%-LAQ:-X>/'A[8WD]U@H-+89**(.^`"V?AO]L4#
MA1_@VGM"5":"A,]WCC?^.[JT62O<DPJWV<PU7-Z20(*S$G4TF<7986WA5[/9
MPF\G#8['4$Q@,T-!B#!%3<EL/@1CL,-<8?D0!'FUQ`JT$$\TQ[3/X>BGY7SA
M'N`ULT=1OD%!SDUWZW.(#X.-TF_]+7N6/"M3Y$R$!3XQNT2/PHKBU2JA9;T:
M5_+^G1""="65;J43Z7'=*'>!0EO9F1%QW-[$=G5V,<8-$1E$?(5-&/SC8)0)
M%LCD8F0:-";&B@\H`\FK"V0^8PQ\"%#GA*\88H,JA5UG]`4,?T)'%[:Z!JO#
MW4Z^89.!_QL>Z,4;<EX\N./(Q*/$LV2$V;R@BEK#>J99I"G3,H/DYXHX_[<[
M?0YBY7;098)FKNU!35&;VG>E(JA?=4_G(_3=Z>Q26";&@8X7]M7"S5<^>S.?
M_JQMW4\X:KP9A)>1B;MM&&R7G0VDYFQG01$6*Y+AJ?%OQ*'X,YS2QE3)7Z+0
M(#<V@K!;8794,6-PXS#Y9\"K%JC=\/3-<+N]T\KAA[?#%]QN1_W(-H50`<J.
MKQY)<1G@$\3J5&)/M;LPW.D!@<^ST(RQE'0[M=7)`9T/C6ASN8FE1K1:KI76
M*_H>IL&.'L,Q"4$CK&"$E=("HH?944?.NDR"U>]N\>U+#96B8Z>B1^(9]=\A
MH^8CO^.%'@:K"TT!5AY<@>Y+S.&&R`B'@EDX6X+UG]L_JHT(;""Y$2LEL!7&
MA^J%*DJR?WA,`(+X+PL4\6D#U,IG/Q9B']]L*.<@D7W(W3?MO,%%@KR:3C@:
M;IV(E::?I'9-H%=4<(P$LB&'W`-ZDKD\D$)J4:+@;H02.:%+_"TA],D7$95+
MHD'R^H&M\IWR+FL^>?3TD+_,EU(3A?;F$5JX2S0V`;>+2-&1.(H*P<`Y6DC3
M-B.7?IBJX&))OK53&I&V7/<_;Q%B^1RWV+@SNTF<`+@"/M7E+;Y]B@%#\KO(
M&VQX-KMXO?$,-R+]A^;S<4FQBV^MYN`']>,U!,RL/?J\+$TEK7/#Q;?/)&P[
MVVB`EQ3NB*RQ1V9DKES];,ZNB?]=>N8(#9I^N^9IEV2IDIH-W^&Y;$ENQ#QK
MP%QR23V&/BP0_)]Y[A=\1*3;GELN`'1T2H6>Z:WY7^WU8"Z[$Y\4)F4K_&):
MXA)Y`='!/,^D3FM7K=L(E%%USA'WJ'*8S:^G!L$+Z6WJF>QG$9?,#W-.=,'(
M&3=C=7HI?HIC)J6>MY347_W%4_8Q2Z8&;7&BH.%GJ[R9X,S#(VR^?F[;0B>K
M^`0VD[IKPY;$75CYX/BPLR<'7&46KCB$&%8F3'PCV`^Z&53>:UB)"H8YE,!)
M.A;1@K!Q=F7XP"]``+TMUP4@M#I6$,\W<`GOW,BJZ2*`>#Z/J*TWJ\7.#']C
MV`93458O^"EQM_H;$1[SSD_+T6NM#"ER%VKFPTS9&"[S;*=@5F7P7P4N5N";
M`(@P4>@M?ML%VC6W-Y`X*`1`28\OD=XI+I!K[M;(J7SZ6(')#=PU7%ALZU0^
M\SC&*M>>S>;SKSM'>+^Y"$M2U>OUYTU@D`YZVUM?E@(00A.$`O"%G=FMQ]&[
M0+,*U:*J6G:#S@U*284R'=',-4L$J&M1LHV!+DNF9=9(=0.*/&?V!V0R]]4\
MHD&HPNAQI#8BD2==P%C0R352.[R>FB.Y,E?E7,2L!4A:F-ZL%HI#56I?AYU6
M99=YK7\6VK8H,Y,APDCB=*`//<EM1[`!YA]\!FLK:G>HF&:5'Y.5Y$33QDS"
MV87I7^+!7(#N2!E137305>C7Y@4*);3=.?&(.-C+HUS$,%F\93.=M9"0D95A
MB..@CQ(D\S:IBKT&V8N+!Z>"5$3O?U>U.@YWTKZQ6`(FEG5*=H2$GG,D3XT(
MLK!R3BKT$G=+(2(2V<XU^35F$(^MJ+<F8,CUL8B>G]7J8!3K,MR6&1:V[-GF
M,0T%=IQ*3GIJ4:7Y%?$=`2*FD0C+TY-TE/[_[)WK;EPWDL=?I3'(KF3`\EB2
M[<0[BP$DRTHR:UU@R9,/^:1+R]%&40O=DAT-]F'F6>;)]O>O(GEXR,/NENW)
M#A;Y%$=]>"L6BW7Y5Y&<TQ<OTY=#BFXXJ$KO67()9`HLL01.2E0XLOG]X^_Y
M!%]0QIA*M10!",M?,$&3-]?F(8X@RIP#Z/H;2C/WL_*U(_EU&"63Y3-U6UGS
M2L8-+7W_=]FM,,COLELR:_@6^EUV`^;[EY7=Z:KI)-\\K_52<@\84Z_H22[O
M>"<+.V-],PGDINBF[LC77S]]_)RB.<N)QJ56@,G\A21W+$6SW.06R^U-2MA^
M@^1>=KE9A/"ADMN\DH@M"X;=<8-CSQY.@9H0^K`B,T/^N;<DQ<]K\KE:^F=Z
MJL,%1S0/5RX7)*J/1P=E/BJ-&Q.9^4MSPQ.`WM8+G>9K)_`CSY[7&NX,1=1J
M/"3$&X.U&N-77-@!&X.7/[>)07>"FIM<@U]&?Y=K[P(+%Z6@CV9VFPA;*('+
MS2ZJ4ECFT_>WBJ"8U[X+$$+5#Y?CCR(G-),?W5!XBI`H&JCWU(KG8]$/'97F
M.!Z4%8.S#.@7U!S^0@D<QW(OS:KTC2P'Y)_KCNF;O3I]!,2AV2%0T?O1<1Z^
M6%T\5T4Z_)U-J.\=(6'C/^6YNB\'Y'!C>C&6I*W<\![-6V(PK-VNI7Q`UK+L
M?Q^%5$X!<^-IC%>95:(?N0(7+PQ-2H$),%3@B3UR0UC7[#&(E:NYS$K0@,GT
M7D>]3HO?@0W]F8TY`PN)"4I!YY%P8'R6(Y@1F"')ED)4&,4KLF8,U#EW[(#7
M'?)G3*H(G^D<0U:[M*3G]V[`'Y_\.H=RDGBXXW70;`D1S7OR:\.G6(Y"-=6.
M`@&1B#OL='S[<4R9$YD-P9-P2Y_0_,.ERH48$^E'`S[LCEDK0`-!`NXHEJ#7
M%^KW69DK00GS"EMS^$.WSAC$RIP5;IV>3FYO1]N`N`WR.09Y>C:#N:8WHQ_!
M\9Z.IU4Y\3UBW*@?`@F?W/N`W9_V0%`#?__Q#8E@H^\)\,VJ]MF>`L4.76%J
MJ:N2@`X);LV$8K($W'6WLCT@-O7<Q<[T[CU`OIL($#;<S?[.EN=UZ%E50ZN(
MC):2!)\X\,(<1K2BZ#IG@;V@A%PU'U4'L'(KVAW==Y>"UE\,]>JRN=O%G:WD
ME_K'WQ>-<^25,#RSSE)[ESG=F4X83Q2;7])4T@E!U>PP&YHJ40TF^"&\]]KZ
M_<A\F9Q&:*ECE$K9;^F=V/?^?@5NL?R[P$ZC+23$`A;*SE7>0SX29?+SE?"&
M1)`QHQ]-4(Z.*4HSVK[")U&Q:%C='-'6)3<F<69*3TGLG;M>I4[\\N=0I(PW
MH3.+431]*5*?4!<A.U1Q0MTM5DWJ"]WZ.V,PQE?X3U??'>V,OIIW_7^Y2(R.
M70!<F;"O%Y=NFACMJ:X5CY.M-[G;?]]8\/MF\_<OI58%`ANK$I1N$OKI:`]Q
M_]-L]%KL55)D?>ZO)%P_&6T$);%L"J/RH^=M;Y0_E@ITDQRYKG*8DF+\>+8$
M2-YFW_2;J/VT6AP$5^`6VE$ZP*V/]TCBXXK2+<#G2>UJ+F%7Z$#+1=;W%Y>_
M6I9N\W/)&DO_;8W_I3A$0DR<4>[-H==.$]Z*ZTD)3-/93Y<WJ!NW>*V)`:+0
MGJ:4.@MRG+GT*7M"*%ETR81I<B43:$1=M.R\+.;B-TL:PQ+VW$1K](H>0=9^
M,/"#V4C7F-N>!,O<M3=<5UW0@#7(WR];D^65':]P]T\GU)]`1\(4?5B.K#+*
M8M$_HHR0RN1R46+,;IR$HL7=\5EYM0*`:`"N!32_=#/$0U<%N\-^&.7RL2&)
M$[*DR.N9XZ]4['\,JI,@.%6WRJ]6=A6:L?J4U4]'LC:'?S-:])^&'DS!92/3
MF8#1+&YG>\_%4"3MIMVO!-DA<@"MU@(XB1.=><HY9_Q_<.%:!M(QL-4Y``G_
M6_J3O#-4S&+[RYYBX0$T*CC1N;E^:R9R;#7G;R?23SDK9.10V'#1E?EBKJPV
M<>RXHJ=5]=7LQ_5Y/SY]62XQ:_GTFWD_5B5^\I8OYK5\/N_'9_-^W)SW8W4G
MY1.J2LOZ7G"S^%ZT9.<^447S)G%>#+/<>9_*N8!UOR/1$%FCO#]`BI>WY2?S
M7!&+N&&)M@MU`Z/(!J]:J'!3.3E<1T]&$:A6_DCA%BY_!RY7+=^XI?08B=6!
ME]TQ$7&\,>=[ZSUX/%EWS>MRGX-=CDXR%E/S)+2*G?LIIJ-6BFGK]L4SQLH:
M-'D5\UV/S=.V>/:$7I]0,<,H7/'<T7]]WURV;XVGFU4$WF&*;[D6P$O=`R+_
MVXF"W:T%P=/QL;LCKZ<T&RV>^-;=^R<C/7@RQ!IOPA/?84_-,&D-__KZ/5>Q
M;?'B48<>_./IU%?-Q67NNRQSHGN>M]GPVSMFQ8417FG=PI\%OER^LGG#S3MT
M39&1@!R'J$.,J5K;4Z5\5Q?"UB^JT(/2`)R5[%)N[9-T/M!L!#JLCL+")A7W
M+!ZEDJM[)U+<E%,&FHX'"TTS%C3;$$S!05/I#7,&JI9Q3@(;[BU\62>^HG.P
MC04-RD9PMK<R[PD:F2'.Y21#I4!Y.&5Z-F7T'PHOE,U7CK&KZ\](__>.7.N*
ME6^"N.%$DB7L_CG4+6/]&?LZN[CD>S)T'(OI]WJ8'?JT3/C8;YB@_C0P.HX/
MO:`JS<"UW8`R_HK7G)]2MYJZ;_Q=53R"]IM&K-3!XXPB2I8HR9*8JZ3,'@:*
MZLP-C<(?<3I&_D1Y:6Q!O;1RE-W)]#V*)2Y-WW$V;4*=BO=F-%3,U,/+Y9DC
MT_'E+Z=WE!8Q&1-YT3UP0M!:',2<A>4$=)F;H\X1L.T/<T9F,QT_YH<YF`)B
M!1+/3)^+=X05$2C')+5A>KM&/3R.D;%MOX1"^?D.IR!N'4[>U+3\;ELE&694
MZ9+5JI#;-9;?H#/836&46R74T(CT%P[U6SG>RDY7*.-M;RFN/ZET-/&6F8]N
M65=-7PS;!"NA7FKU?:PU7OX0+7??)[83^B>`46XME`T+*[K;9W/8=Q!/NP9L
M)P2%UKLB94\K.%D#'M0_MA!EF-!H]>01Q]XCC&PIAQ+",TG*E(L^.N7OIX9#
MFT[..#H81!QO%L(IUH^Z7^7=ZPSI6.28BB&GZEL0XQ`OM1!/+!?=9_PT,&7=
M/W=<W>NK9X\X'/G1HM>OJ'0E,63T\G?)PVP,.N:8/"28%E:0N)).Q08%UV2T
M%RUH*+QSZJ;:EN-Z$`5[E=%_/E;H6!>51Y*O9HK165WY!E;-3<5(N2#90:_W
M=H8M(Y00Q%4B>+;372\Y:Z:@-V!$CG`<Q)_1H7;0$KQ@%ZZHVHW0GQD>9F,.
MBT"41=.W.WQ>`OBQ%JO0;K.H-@<;6:6*V/*\K[A'U5;\X$#W%Q%W&!A05Y-*
M@Q"+]T!,8O@>>2+##\TBN'(T$U59PHBRZT'BLYR%^3GQZT3)F@'DSPF>*:S3
M.N(%+YYTVD@G-WK,B&*&)E?.P#2*=*NZK]XB=_`C9P+!O'KY:'39@R"8KTPA
M@UM3J^X!TZLX'HCVSJ<`OC663X1PIXK.FA(1"[GTRMEY72-&<_ER9*#EZ-X`
MF:I'SQ5)L%@U4NC6"]"89*7,RO#I]2!$.HN^_(!'C9(0Y:<A`+O:F.@+F6,P
M\F`V_YE#^5<OC5`H6\Y95CPS<"3R$F$IEW9PPV5J3F"\DW+#)1'.J"^,W"7_
MQ.OS=$&55(<WU]\4#`\%H5)WV42'9%P&7A&G3U7"1W<!X1:BPM:"4WL#]9$L
M%7O:&?>R]Z;*G)+IA0D0B93T/`FY?")<AZE((7734&JT#[,8!^O0%?2D:6':
MW>'E#;8=QD@RT!+K5B<Q.,U'U'@TAW#)"<O>ROD930(9ELM`+1?D094'*W/9
ML<.##V`$V%N2RKF$*;O;BT6(.\7SSL3R#2YGZ!?OM++=`88$1P]9=J7R8\Z&
M2)Q.@56"9MFJT![3=GD?B>9E,[R.#%?#1A8YAE;?8#$\PJ6:NY]N(#;F+5*C
M'`;A*P40N@5<2LN0?^<>8J6EU2K2\V%U;\$:%CJH6NV;MC;.HD50F$7TRYUB
ME;G->U]'#I0APM4!9=XEH`PV:<H(8/81*+-O8:H6:?7KDM->2++<;;=9;K:M
M+;BC*K\`EBZ>K\UAE\\R4VSM2DZ3FXXFUUJU'YURGN'(<-93'J]%@`#,SJR*
M<=G@D/?Y+K%874C2;?*;D#*HRBSH(<-#162!^QHX)\/]E`-&0>:=<IDZ_.J!
MO0`!"%?Y14CK)@,IF;"8T(!-EIS0RLMP*Y8S;9,F3R5J$*?8K12^&X(9R9QF
M>]W(8>N*K:[FE>)T4N["-H$("Q3ELO(Z*:@,Z41=BV4\%EAVES.9?89&!<`"
M^2F_2_GUR@$8)$6TRA^^[=MJ=OFF\NZ3\/R,F9#Y!:,K61(4Q)`<?&6G7/IH
M+.&&"J%,;LSTQ$WYO5<W-"4@J-S^9(N[`CJT6]G.:6`P,>AY5FG(%8VZKBQ-
MRHR+LM/7]CX3BE,B:&<<E'M3K7R%9XS/3^ZKOQ<*M[\!E8\AIT<YDY6@/%F)
MV=EX_+-NXHC4DI[EW9B2<RU.23,V%XJ.4YA.+TO5*]8J"8HN)J=6&R_V&F"T
MPM=:CS%K3Q:R=*G^"/"Q_J@O97FJ8"'NK;0XNH]XW!!70=BF$OCKH02^>,GA
MN2$*L6G6MCK>>.9]5^I9N;'NH%43'`=3`:[3R0U;YG_RTBIB35D)]2XI=SN(
MH^",M3H'[E25.5;!9Z*T,0U=>.^N3KXM@Q3-H#=5H^T;V8(D_<\_WOZY`V7?
M_ODPB?$X'XCMA&ZU2%Z;+=EJS4A`[W`&\SIXF,RBCI#IEO&;/&EVY"3+PI?E
M$H(.K3+--Y=![@^Q^18E4F]C@`P5,)@]6FS99?;`PZ[>SFLI&#OTDB"YBQ2@
M[3$E&RWY/]2^>&R5RZK]2NL)$LTLRYP3]VU#\W>_&CV]345/O)*+#J(%01"_
MJ3;S.[TZ7!+@,&UR<,W%M\@B(IN>-#WC6+;FDZ8WN-"`(!QZD*RQRH?.]>$C
M#$ZT[6`<K8VVLF?97CYJ3/SAW6XOT^TR])@S^8ZOFA,_)OPS`YGM,8`$^4M5
M$3INT^6-JA#+)?@/#7)L^V,8K5_KT[.KJFU_5;6.DGV78OQV\\&-6<3B[>Z6
MV9"''*;V2(,3G\OO[;X>.NM/'&9PRG/8LSY;[24\O._R@+7[7H8\<Y;1/V7M
M83[[J+6[3N>M_<G0_38B!:`!/OYQO8)U_[A1_VFS_M.S^D_/JS]%]U+K-EYY
MYMX2'A,R-8GWOUX.:LDQ#CNG(^^@E"LKPUKWL6FL4[FXE`-C`>&>&4.E%\?E
MHQ+B/T9M&D]1:W!UZ?M!_Y'ZY(N?URY462NIF3(03;$^#\6$4#C[?CXOW2\=
M]9@"D)3;N2?7!#T;M3GHT6BDX:GLO,*,&4'E@K>[<@D)*I^2$3T&="[7()/"
M=7HNP^&GRYEES*`AI#E:\,A_H*@<<;SP[8<)."ZK(.Z.\.[_*0]T1C>V5+"S
MABUMKS3K.G6A'!P6S#[@D3>-T_YYK;\'CZTJ5?#O<]RV4$FV!ZDJ`[Z\3!U,
M2W([Q?+#QS2\OY0'ES6#\"5"Z;MM02/%S>3X/`L1%B_]<^L^[6MR.M&S/<^<
M?K"+6+0VC_^"`QG;Q"_N!'TN]R:;E6RBWLP(B:@37`6G)Z=>HAU:X,4V`&BT
MMU'A@*'_&_K*,^:LD2T$SW[R*`%!D&!V86CA`&I!50=E1'19M21%UXBD&/H?
MPE,7MJP.`PI'=1CBN@=/T<K;SSM"\8UI2/'<&,3C[/9/$7ASS03%IQRURMA\
M;4S">>XS5;GM!5F*+>YO<-EVY?^(9ZJUKAPNQYE+\F35O^$NQ,#8>5FH<_PK
MPDE"*MBC=A!JO!AX/DF)UX`XXG,B1W9P6A=&/[5Q9T&.CAQZ`=^JD(>5VBEW
MZBA+YI+<BLE<Y7<'<&'W]`(H"Y-M9#8.)NH,SG/.A1[S(''UJO82&9,,@&S9
MU+.[N*L:"0&MR2.,9[>S>2U?>0X"\OE"RGVZ3<\[0WM>\YZ)S^Z?CT]ODV][
MR8'3C:SL;][2!)LW;T@8.620BE<[0LUK,[P-40ZV9.;W/!/!1<[]Q$KNKDGC
MY(+3]G^4(J$KG9*M-3/W!XN#E'PTQ).CU3_L'[R9_:'*=$%2Y8X6NV?[#(U[
M83J]AR(?R2NLO`M?+L=VT5%;)MEV]#_QZ9U1@4.&@TY(W8#+!2Q"TBH_M>D,
M2AFY@J-XEFY)Y8=-Y_O/F\\#!_MM1B/MF5>K3`D,</9>YG#(+3:7EW,).;PM
MJ;OD`O'@$99_1:Q`T#RTSR.B"9_;Z99E*GG7.COJLYVZ^T#L/!PYF%?=(L3#
MN\=!$O.HPUL"@O%8'A?R;[1+?"IDPL^AOT@Z)_\]G,TLLNI/1%O\!6\*1L`9
MNG%<%'Z?P8Q6;X3:YU=PP%G&5I!*T\"NFG]#+YAK2RQ&F"1Y2BJ(90[4.VJ,
M&BQTT+>_<+H`;D&PGJFW^5,.*XU#H^(+?&<5%R;7=Y507?"YLD8$U3%<:2F7
M5E9?/=)KFX9!G-FZI#QA@<2ISDS_P8!@"FM0.[VSZ\'$B\L+W'Q!V7+3!C@#
MZ!RW0U2YP"HP`:#%D)C.A*=E`*G0!K_U")S92_;_TM$^3J8_4Z85B[F#C5'$
MX?KV?LVLD3B:V2R&'8U#C@404HC(K7C7UD-+WO9.?T[9AMT<2LJ\HJHL]=1_
M)0&:<AGCD<,ZIDR+E'+*O9[)2(W,6#9&0^(*_,6<Y`?Q";.Y^_".XA=&E9-;
MQ<OLJ$`G0Q2RWM1;>A`-54!$?/7Z0#HM9C[V)R2ZO-6C")BC`4+KVX5:U>$L
MW5:-UA-?GSJ^='NB4@`.9PO/DVFK&#K;X54,1GNS4X/+V`T@Z4H17W#N"ADQ
M1Q6UQ)E6VI1GU32R>MY"#V3:5H(N-+<K7/!E>A7Y)70Q2O?5PHX>=CD<FC3Y
MS.O7$\<LU/FT0J#$F7?HC18)#DY^'KV]/">%F1>>T32AVQM_&5'W0ZN5DY\W
MC.7P+`_!%A+GP^AH<L4!0G6=WPGUT=3)9MG)KHJ2?G=WJPSR&4?DE<[4=(0L
M]5295VP0_]^:8-#A3!#,.&*`5NE/#A8O%;QP1SW?S#/VJQ7^Y>XJ):-5/QIM
M8F9QN2QB;Y*&"I%PQ+B$$/)[3W8D];!XLH4N6)\7%&ALP%\F/T'V[R8WQ/5G
M"CG&(5O4VI]\`+#4.$U9>Z9\.+Z^GMU??3BYYO7&5G^6^A<C\R4)=A&0[)P$
M6*L]JUOX/GVK;78N:JZ*YT*XSJ"RE].3;D?^A]O5J79.TO#+SY,-$/L;]*IF
M-[%=LY/[DRL)U^&"/"L_!-R5JQ]X"Q'=\W1?S@=B7REOT_NUT_NU\$]W"?#3
M-(S'_I$P0V?KGMMPG=;*+[I+PK%)I@_OPG*UX+Y%Z"L!5R["_QBM$A!8WW@2
MH(H1/,PG($Y1`<XZQ5N$M,)QJNF3TKUN3+R&\'U\>::K-)_0*7Z_R5OZY=;_
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M<\V<C"(%KVS>)^=Z802[;3`>L@O%K8,E%2J>Q1ZMVHL'9KYIIIT`N/TX";Q3
M>0@_;1RZ)F1I5EG58SP#X9*T16@J&9O#%J*'R%!9Q_M5MGA)ZJ.8!JJC:.QA
M4*DA)-D^XG<-YA/_6H!.:+SP/CCLV3X?-YC6/")LN53E^%L8>^=F\,$+.F>R
M@0>Z"J`&8HIR9\UL_.L)-03183@>\,+Y'$/_&)+ADY4[PUZ-<U2FV"]XL>VM
M9@Q%T=91F9R[>]KH!.J/#O6,PQLJ4V.'7!];`)8D&<B:_XOG%H"G?Q7!#--D
MC\R@M3ZGE;0KM*.P*#5RQT2HO>U1388:R*0K:6L)9/WFN`"+MKPI,XM5K$9Z
MS,!JPF4^$)TQT8)ER,RV#$-6U?G@.72&BT(Z=8H2)@:O:WLT]>/X2G+,LZS2
M=1H3^<1J8F!1^?#N]&R25U']D_"K.G^S[AF"D*?%YS=7>%88%F=>.ONXE^C0
M-H2%G0L+**O'WSQ@-RO"XY/+DLA2/@W74C(<!PF+C7_CF6_45]BCAL8QRB-O
MD'ZU3HTS9;5R7!QY&Z&XHJ12JLY(<X]JKU:>MT#K9_94PQRY);+9!Q?;YM@)
M9<0PH&6S02/WN"07U5<ONN1:[7'(5G3T&O;9'5=!*-F[H4N8;`X?.+H;*DH1
M9V*#-?-P_`G\X$.ZNA*UI25CO;6)%F31P04UD;I6)6FYWXNEQ.&*[ITK/,FZ
M["3X/M+^<4PI/H",6B0CNA8G%$#EYI7+'MRQM>>6E(EA?+QV.PDQ<(LXVD64
MY?WICK#OLL//+1XK2E24/70;R.XU,Q\RPN8+!5`#K-`9KUST0?:42[PN8"[E
ML%SE&[5L?]F<$$;%IMB1C/5?VG/21G0<T:M9,7S#Y`)=8V1$$W'2_I2+7WGA
M&*4@<F'GB(T/QZAJH"LA=9?&05+L(>NBV5YMU&M'=BZLKA4]Z"T#O;N8#8C\
M>%3!I,L)5RU>FQ;).T,(P3HYXP?W!O/D&WX/5+&B1,,2`R[LX8$3>$N!(7\%
M#HEK41#5-CA6Y8=5;EY3Q\$,9VQ<DF#EFZ!X=4@WW;/-SZ@"$2X=WF09RAM9
MB=9[M`)&SP:_VWJ/JXQ*(A0:9N:<3?*J_BK(VQ)DG-/V@01,J0&'RL9YG#2`
MJA3-PIVSE($Z9I[(L1Z$U\8@-58BX/!Y(N_F\(>A;,<H)I,UR%L<*GC"H5$M
M2,#ZQM>C/=<F(&&]CJVDS[2.WZZ[WU(H`\>CP/RJ;&4J8JN=G+0A?@42]KKI
MNXOAL%F*EE`EZR%C!)*`8D""2@>=.QRJ"(R^(+"V':G2=D;'2ES_?O++S9\@
M2'-]+:A0>13CSL8=+7\OH<K([9`LXR8.B_(07,3NE1V\]>HG\6?=$3*-8KOR
M\T`H[S,DFB![^F,\;N0O*=A=#J!7U97K?8$-,F#2%_DDL:Y+9:>QN[V:,%H#
MTQL`999?"F,)3@,-)2NN4BY[63*W5I[:F^`P$]MNS'(<W"K#4.'40:!Y:Y]Y
M<R,!H,K.RY4'?=8<,Q5!MZEV@-_C;#KY.&1-#O&!:3%*#K6,1QCI>B!%BCQX
M2X!#U^92-2L#8[4:?JA_UBPE"A793+)@9=Z9TFQ_0:"?.1`LZ264%A\,MR_=
M?]3*'SK`NVN"O)/WUY=_0R/RQ@[NA3,3*H\)&_.5.P7,@F1V&DXL[-[Z+)@3
MAZI/AT#VZ-:5H-$<WX-42W7[7E@'F5KE.$X;C$:')J#KF!/%HF1=-T$5*QL?
MQMQB,T@#@R8MJ=K1UWWP5]E;;T.Z9[*DPAJ2H?S^R(`%`;Q@LCU3*?,?.V'=
M0HI4BN&WCMHHAURH%2S;;DE%KM%=4N(R[6Q]4'V8HSDU^LX)YS=FI.I"G6+C
MZ=.E;G9+;HG7>[AQ\VUL:0X#4VM=BC'AX[WO8SQ%+9E9[G.CN7M-@/X'=QO7
M'FNNBO#:F0I`_FA%GGP4-D(P$SFWW#-5CAJ5PO+O[?Y,-<>VSOIM>/;Q"81?
MW`:,RGBX3.16R8L/(*),`7"_F=SN4U7N<TG;NJI]?]+'.KB>?]`E?'H'KX\.
M#LM%HJ916$&V+E2]3CY7DYM1`M^@+Y;MCB>":(3/>F-K:0:@\4&'&ON,@XB-
MO`*3C*D=.+E7M;)E.:;5TZ`JUMD=LK5KP_.!G<G`+\EBF5D"))NZ-?/DC4$$
MUTXHX#%8FQ"13?2#G;^ZO*A"$>G'E#E372_IDW,]A\BYJ2Z%WEK/M%^JPQH?
MTAT^*+TVL-G%V*K]XZJ\DPK9.%Y)XN34@*659L-CO=J(R@S,+.FHX<;[V'SH
M2I21#]LE@_>B&:#ZY*.4NY.?Z)XV8-&#!9U5)$R:893450@D?='ICJG4A0.V
MG*0'=?+T"_/+[:/'C5Y6_9;Z)$).`E?T1'E@&SD^Z1A"$^Q#E$-_G5==5DMY
M:(>_S;3MP@KJ27_$<F,#H6W18?FL&%:8SIS._),W%-92%8AX+AH=\:A-!+HI
M>3)V'V_(ECY3/S!#\H5"H93TK8F^LAE\0@M\#(F+TISB]=OR,L3Y-C.UX@>9
M[,T2C0A'_[*T!$ZS^X2^%@GDH;X;DGVQ,/[8'9*@XPN@*[Y86]X^2#-"0F87
M^ZW=AHU+/5R2G,-0PL%'+5DOR<D=:N0K-&2^QLM30^'U5<)F/N\R?43F*<<O
MHGCQ+B;P@(=`<:@S^3[C?(:N=0O:Z0?D$,YFM`)@1FJF=TG,%62*DX7L8TC'
M`TN*@*O.,C1Z3OCI)S"_O:^DTP`IP\5.`2L9695WNZ]HA<D#'#XQ!*(]+I$F
M7ZZ\1VBFH'">K@>%R-"*/H$2Y:L_G3QAZ\H?DZL*D_D!P#DJY@0D7@/QO%A:
MI7I.K_529IH'$/V'3(3/EYQ)2?B2$GI+K)%;VIF*67S)<N=2<:PL%$K,$`M`
MH;YR2/8Z^RY\M"C^!W/!@7F0\C(^#P]_`+)1<#$-:3=W+#<4:VT,R']Z#15M
MPF$HY[JR3*BS:_3'V>SVS_\K`````/__`P!02P,$%``&``@````A`(B;9USS
M`@``L@D``!@```!X;"]W;W)K<VAE971S+W-H965T,RYX;6R4EEUOVC`4AN\G
M[3]$OF\^22`(J`I9MTF;-$W[N#:)0ZPF<62;TO[['<<4XI!FP`4DG,<O[WOL
MV"SN7ZK2>B9<4%8OD6>[R")URC):[Y;H]Z_'NQFRA,1UADM6DR5Z)0+=KSY^
M6!P8?Q(%(=("A5HL42%E,W<<D1:DPL)F#:FADC->80FW?.>(AA.<M8.JTO%=
M-W(J3&ND%>;\&@V6YS0E"4OW%:FE%N&DQ!+\BX(VXDVM2J^1JS!_VC=W*:L:
MD-C2DLK75A1953K_NJL9Q]L2<K]X$YR^:;<W%_(533D3+)<VR#G:Z&7FV(D=
M4%HM,@H)5-LM3O(E>O#F28R<U:+MSQ]*#J)S;8F"'3YSFGVC-8%FPS2I"=@R
M]J30KYGZ"@8[%Z,?VPGXP:V,Y'A?RI_L\(7072%AMD,(I'+-L]>$B!0:"C*V
M'RJEE)5@`-ZMBJJ5`0W!+^WG@6:R6*(@LL.I&WB`6ULBY"-5DLA*]T*RZJ^&
MO*.4%O&/(A-P?ZS[MC\+O3#ZOXJC';4!$RSQ:L'9P8)%`[\I&JR6H#<'994L
M@/X,)X-(:LR#&M0.!5K`;#RO)I.%\PP=3(_(^A+Q36)S27A3$TD&D-D)<2#!
M*08TIQMCW+Z"EPC>S_;#DVR;<*V1N,WF?;H+S/)FO)QTRZ[M>J?1AN?@%L\*
M[GF.3K+:LT9FVK.K7R:R&4)<DTG&&2,!+)CKNZ[@7H+>?*\U,FD3]&QM1FK)
M<,VP"L_9]585W+-Z7G>ZV1H9MCI22X9KAM7H%JL*[EF-S0E=:^3=M3Q>3KKE
M]]?R]!;/"C8]A[W97FO$7,L]9G,%DXPS1MO56=W9"<>W$`7W(IR?<KU"-*(C
M^$$41N&LOP4:B!?$7A3U-J*DBWA!%$UF[EG%\!_?XE_!/?]G6>U?(Z/^#638
M?Q=YQ[\^=O6IU.`=^8[YCM;"*DD.&[1K3^&9X?K0U3>2->WILV42#LOVLH#_
M1@2.)M<&.&=,OMVH8_WT;VOU#P``__\#`%!+`P04``8`"````"$`SY6JF'P%
M```H%@``&````'AL+W=O<FMS:&5E=',O<VAE970R+GAM;)R876^K1A"&[ROU
M/R#N8UAV^;)L'QV\2GND5JJJ?EP3C&T48RP@<?+O.\L0L[..,>E-$L+#,._,
M[`R[BV]OY<%ZS>NFJ(Y+F\U<V\J/6;4ICKNE_?=?CP^1;35M>MRDA^J8+^WW
MO+&_K7[^:7&NZN=FG^>M!1:.S=+>M^UI[CA-ML_+M)E5I_P(=[957:8M7-8[
MISG5>;KI'BH/CN>Z@5.FQ=%&"_-ZBHUJNRVR7%;92YD?6S12YX>T!?^;?7%J
M/JR5V11S95H_OYP>LJH\@8FGXE"T[YU1VRJS^8_=L:K3IP/H?F,BS3YL=Q=7
MYLLBJZNFVK8S,.>@H]>:8R=VP-)JL2E`@0J[5>?;I?V=S:7GV\YJT07HGR(_
M-]K?5K.OSK_4Q>:WXIA#M"%/*@-/5?6LT!\;]2]XV+EZ^K'+P!^UM<FWZ<NA
M_;,Z_YH7NWT+Z?9!D1(VW[S+O,D@HF!FAFYDU0$<@)]66:C2@(BD;]WO<[%I
M]TN;!S,_=#D#W'K*F_:Q4"9M*WMIVJK\%R&FG+H8\7HC`KSO[WLS+_*9']RW
MXJ!'G4"9MNEJ45=G"ZH&WMF<4E6#;`Z6/U<$7BCVNX*[1\#9!M+PNF+!PGF%
MR&4]DEPC'B76UP0+*2(_0:(+XH#G%_<A*-/=5S"$WK8&]^.+V4YA@@@$XH((
M2JSO$G*,(,Z#)].=5_#2!ML7SSR7NI8@$G:)X7$,/8)38JT3?L"B(#`"(`D!
M%1K&-R(/,9KNO((-YQEU+4%$C[QG5LY]1"(2=2'P>!CQ(7TD]+#L=._5@N;0
M%L;+7SUDJ#`"G"""[_>YZQHI6NOW61`R81B0.N#SZ(;[P?]Q7SUDN#^8Q_)'
M9#0)]Q&)2)\$W_/$C1(*J8KQX"O8\-XW2@@1?*]P!;^N?YWPP\B/F%%C4B<"
M%L=>,,2(5)":[5KCG%9!ZB%#A-E`$4$10<R&T'496NNWN<N,^I+Z;>;QH;J(
M[S'U?3SP"C9\-OIU@L@E\'$<&:M[K1,0^"@R%[?4B0"^;T0\O(4XSV"=ZI$?
M][ZC:=/WC)@F/:.7_9!T#/M]1(XB5(&:;U^N'893D4P`HWLG/8.9@*\+US43
M08@H#EUA2)6$"(3PV6"#RE"#[NLR<#SJ,KA1Q0E#II<1^D%DK)(U)1B+C%X@
M>T#/J59R5(>:>9J..P6%$Y+X/P0(VRA#YL;+^XI"!C4R`:/"B((<MT(EP*MT
M"=.Z$5-/T:7-C7Z8],RX%+0SQLC>3B_7$US[-J%2U`2<G@V<ER0;0]/KLZ'/
M5"_TPSBX*B<=X7XH8M]H$E)][T.P4(`0/`[8\"*J0,V_Z0IP6A(%QI),F#Y1
M.2S)P!_>W9>3CHA`<!8-_;-#)+'B>VXD-(0J4%-PN@*<F42!L1P3IL_5&PIT
MY(8"1/1"&T)%%:A!.%T!CDVBP"B1A"&COUMK*'T2[C-RW`X5H6;B=!$X0:&M
M7'8(W"B!A"&CBQ@"V&NXB\A1*T2!]Z59W=%&/S*68=(SNH*K-$Q@Y#A#11CC
M>GP^>-=CFIMCNF>PEW@\\(T\K2G`>&RT94D`QH/@UC>V!T4]O88ZFF9`&&,I
MZ1ET/F`>BUQS^JX)H\9W&+K&@I*$$1'LUN"S[_)%3S.@9J6V$*:--P\GK+ZJ
MA3FI>P;%/`2P8P@%,Y<$A7P8#UQHXPN[*X5$R.$35QLB5`^4KZ[G3D4IVDB*
M40^)ATR?%-C[F!^Y:T(P!C.$&TU:$@2V/OKV@OJO9N'7\X$3E.3#&&.).LD"
MK7B&`7NX3[82!/E\+T&0SS<3>-:'1V&G=)?_GM:[XMA8AWP+[=.=A>!(C2=]
M>-%6I^[HZZEJX82N^W,/)[(YG(NY,X"W5=5^7*BSQ,L9[^H_````__\#`%!+
M`P04``8`"````"$`#]HK1M$"``#%!P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970U-RYX;6R<5=MNFT`0?:_4?UCM>[C8@&/+.$H:I8W42E75R_-Z66`58-'N
M.D[^OC.LC7%P$K=^P%S.G'/FPK"\>JHK\BBTD:I):>@%E(B&JTPV14I__;R[
MN*3$6-9DK%*-2.FS,/1J]?'#<JOT@RF%L`08&I/2TMIVX?N&EZ)FQE.M:.!)
MKG3-+%SJPC>M%BSK@NK*GP1!XM=,-M0Q+/0Y'"K/)1>WBF]JT5A'HD7%+/@W
MI6S-GJWFY]#53#]LV@NNZA8HUK*2]KDCI:3FB_NB49JM*\C[*8P8WW-W%R/Z
M6G*MC,JM!W2^,SK.>>[/?6!:+3,)&6#9B19Y2J_#Q<V<^JME5Y_?4FS-X)R8
M4FT_:YE]E8V`8D.;L`%KI1X0>I_A+0CV1]%W70.^:Y*)G&TJ^T-MOPA9E!:Z
M'4-"F-<B>[X5AD-!@<:;Q,C$504&X$AJB9,!!6%/W?]69K9,Z33QXEDP#0%.
MUL+8.XF4E/"-L:K^XT#ACLJ13'8D\+\GB;TP"I+W.7SGITOOEEFV6FJU)3`R
MH&A:A@,8+H`7\XK`D7/19_I:HI`ADEPC2TH32B#<0',>5V$0SY?^(Y24[T`W
M#@3''I1$08_QP5#O"IP,79VN\EX<P2B.54<W-^[&4&@>Q*>%IO\BA.`C(7=C
M*)1<)J>%HF,AK',"4_AV9AB44DBGKU@8)(>2N6P="(X]*#IM`=IZ?E$1#$,Z
M8`7IL"=VT@YTAC1,QE`:LY^^FST&C;*?O+#@0%$W<X=G1\,T^Q]Q#!J)3U^(
M.]#,B<<!_'K`D0/\")QXR=YN/@:-'!Q:ZSK@0,Y!\KJ!^;&!MX41/!(^O#].
MV(&&K8?Y>#G[;IVZ?5,+78A/HJH,X6J#JS*$NO5W^RU^/>T6<?\`MFC+"O&-
MZ4(VAE0BA]#`F\'L:;>'W855;;?-ULK"_NQ.2_A<"E@(@0?@7"F[O\!-WW^`
M5W\!``#__P,`4$L#!!0`!@`(````(0"\F,O>Q0(``#H'```9````>&PO=V]R
M:W-H965T<R]S:&5E=#4V+GAM;)1576^;,!1]G[3_8/F]?"4D-`JIFE3=*FW2
M-.WCV3$F6,48V4[3_OM=XT`(-&WWDF!S[O&YYUY?EC?/HD1/3&DNJQ2'7H`1
MJZC,>+5+\>]?]U<)1MJ0*B.EK%B*7YC&-ZO/GY8'J1YUP9A!P%#I%!?&U`O?
MU[1@@FA/UJR"-[E4@AA8JIVO:\5(U@2)TH^"8.8+PBOL&!;J(QPRSSEE=Y+N
M!:N,(U&L)`;TZX+7NF43]"-T@JC'?7U%I:B!8LM+;EX:4HP$73SL*JG(MH2\
MG\,IH2UWLQC1"TZ5U#(W'M#Y3N@XYVO_V@>FU3+CD(&U'2F6I_@V7&QFV%\M
M&W_^<';0O6>D"WGXHGCVC5<,S(8RV0)LI7RTT(?,;D&P/XJ^;PKP0Z&,Y61?
MFI_R\)7Q76&@VC$D9/-:9"]W3%,P%&B\*+9,5)8@`'Z1X+8SP!#RG.((#N:9
M*5(\F7GQ/)B$`$=;ILT]MY08T;TV4OQUH/!(Y4@F1Q+X/Y*$D1<E<1C/WF?Q
MG:(FP3MBR&JIY`%!T\"9NB:V!<,%,+>9.1U=KI=2A1PMR:UE2?$,(\A"0WF>
M5F$03Y;^$YA*CZ#U&!3'YY!-"['%`(&=2C"NK_)UWULQ%FS%V#I8=6NW`=PG
M=?/!P:]`D@YR)@5,ZDNQADV@H=Z69(,`UU<0Q-/N`"?3@:8]T`"Q>0MQ)A)(
MAB*G%_NU]<T&-3UZLBD85FCM0'V14.G9>2:;,>B4R9E.T#34^;Z9-FBD<U#0
MM0,EDZ89`V_8:.YU/XT+"J&G_U^A#1HI//63*[<#S1N!R?4T&GAX]CI)3@DX
M`]VL<E=9,+5C&U:6&E&YMW,H`M9NMQN1MY&]$X/]-8S.9M#XW0L87379L>]$
M[7BE4<ERH`R\.9BFW/!S"R/K9H!LI8&AU3P6\(UB<.?`<8QR*4V[L#>Z^^JM
M_@$``/__`P!02P,$%``&``@````A`!*%F_I.!0``*!@``!D```!X;"]W;W)K
M<VAE971S+W-H965T-34N>&ULE)A=C[(X%,?O-]GO0+@?H`CR$O7)("`DN\EF
MLR_7#%8E(V"`>7F^_9Y24%K<5KT8Q\.O?^C_'$HYJQ_?Y5GYQ$U;U-5:19JA
M*KC*ZWU1'=?JWW_%+ZZJM%U6[;-S7>&U^A.WZH_-K[^LONKFO3UAW"F@4+5K
M]=1U%U_7V_R$RZS5Z@NNX,BA;LJL@Y_-46\O#<[V_:#RK)N&L=3+K*A4JN`W
MCVC4AT.1X[#./TI<=52DP>>L@^MO3\6E'=7*_!&Y,FO>/RXO>5U>0.*M.!?=
MSUY45<K<3X]5W61O9YCW-[*R?-3N?\SDRR)OZK8^=!K(Z?1"YW/V=$\'I<UJ
M7\`,B.U*@P]K]17Y*;)4?;/J#?JGP%_MY'^E/=5?NZ;8_U94&-R&/)$,O-7U
M.T'3/0G!8'TV.NXS\$>C[/$A^SAW?]9?"2Z.IP[2;<.,R,3\_<\0MSDX"C*:
M:1.EO#[#!<!?I2Q(:8`CV7?__57LN]-:72PUVS$6"'#E#;==7!!)5<D_VJXN
M_Z40&J2HB#F(P(A!!)F:Z=K(7CZALAQ4G)N*JR'+>$8#RKJ?#GR/5^(]/1UO
M$('OFXAKV];2=:2FZ-3@/E]AUF6;55-_*7`3@(7M)2.W%/)!>4P4M?6:NO_+
M'*2,B+P2E;4*5D%26BBWSPTRK.5*_X0:R0<HF$.VQ2+;$2$5083#,3`19H=$
M(S$.B<?`;8AMLV-V(S*.2?A`.@GHX-35+JBIJ5WWZWETA<#$E?$TP1BX79K)
M7MEV3M@NBX1SA!.)Y@0O$E,$9GE+F,.>9W<'X2XED2.I$&&L73QC+8$9:_G`
ME@^$?"#B`S$-3$U9FEP1[QY@DCGCF@O6W?0>@ZX,8XSUC#$$9HSA`UL^$/*!
MB`_$-$!75W);[OA`,@9N]32S+A4SS)1A/7O\-B,P/""FM6Q87#4'%()+N!8\
MO_9(B5!*1%(BEA([*9%(B51$,$;#DCTUFBS_"WC:B]<U,FBMPIU]]1)6>VYM
M""@D,EQ*A%(BDA(Q)5SZ4'+0<F$9U]NL?\;L&,)S+,?A2B.1GB45$8SAL(W@
M#;<@6V+#R:"9X1X[C8!"(L.E1"@E(BD14\+K#3<TX[:H4;?%AQ.I?BHB&*O)
MRP2WM9'7-AG$6VUS%1-02&2UE`BE1"0EXCGAF/Q>YP$FF3/<'9"*",9TV$,^
M;SH9-#.=*YR`0DY?5Y[M.=SQ[?2X8R*#2UHX/8Y<U^*!:`J8EC$#XBF`/-MQ
M^/WK;DJ8R%Y8%K<W2R@A*)U41#!6(UBHIUZ+UY">YDTV^45DH`37MY4CH1R)
MY$A\!YF7]UV(V[0E=R"^P(4(:SMY-YBL*Q+;Z9L$^[`T^8<EHI30=BD2RE4B
M.1(/B+N@CTS-A=[)Y(.B%ZZF=W+1A!?UD#?]N#/1E!VQT-!R.L#SIB/8_)!7
MCL?S0U]0V/PLN+4C0)02YD>*A'*52([$`S+DQ]"6QA*6JMN'?P#()9.9).R!
M;H*&P4FF/.\8#E,D-Y[-#'GI>3PS]!6)RPRWZ@>(4L+,2)%0KA+)D7A`QLRP
M^[.=\&@BET^%"&LTV#$U^K%M/30$[SR&N9L]&"BAX51(@(1RE4B.Q')D-R!C
M3C2N?A*Y!&F4$E_N3X?Z3ANAM+%6XN:(M_A\;I6\_B!-3O+R<8U>&["O??^5
MBP?(AR88-(RX>(A\Z'3-XS%IY-Z)!Z8?W-/?FCXT`.8ZH>E#'V`>CTP?V@$0
MUZ\7!'W:2W;$OV?-L:A:Y8P/,$5#(SW(AG9ZZ8^NOO3MQ;>Z@PYM_^\).O(8
M^@>&!O"AKKOQ!SD!Z3#W_<G-?P```/__`P!02P,$%``&``@````A`)K_8+5J
M!```9A$``!D```!X;"]W;W)K<VAE971S+W-H965T-3$N>&ULG)C;CJ,X$(;O
M1]IW0-P/8`@D1$E&S:%G1MJ55JL]7!-P$M2`(TPZW6\_9<S)AH1D;SH=_/%3
M?U79V-E\^\@SY1V7-"7%5D6:H2JXB$F2%L>M^L_?KU]7JD*KJ$BBC!1XJWYB
MJG[;_?9E<R7E&SUA7"F@4-"M>JJJ\UK7:7S">40U<L8%C!Q(F4<5?"V/.CV7
M.$KJF_),-PW#T?,H+52NL"X?T2"'0QKC@,27'!<5%REQ%E40/SVE9]JJY?$C
M<GE4OEW.7V.2GT%BGV9I]5F+JDH>KW\>"U)&^PQ\?Z!%%+?:]9>1?)[&):'D
M4&D@I_-`QYY=W=5!:;=)4G#`TJZ4^+!57]`Z1+:J[S9U@OY-\94._E?HB5R_
MEVGR>UI@R#;4B55@3\@;0W\F[!+<K(_N?JTK\&>I)/@07;+J+W+]@=/CJ8)R
MV^"(&5LGGP&F,6049#2S#B,F&00`?Y4\9:T!&8D^ZL]KFE2GK6HYFKTT+`2X
MLL>T>DV9I*K$%UJ1_#\.(194)V(V(O#9B)CH:1&K$8'/5F2A+4Q[N7HFE$6C
M`L&W*N;#*CI/3IWK(*JBW:8D5P4:&.S3<\2F`UJ#<IMDGI(N[;>R#IEB(B],
M9:LZJ@()I=`J[SMD&/9&?X?ZQ@WD<0C^]I!(^&,96Q()6H05B3TZ'%S0P5-G
M#"HV-#;=-6W\#&;QMZH>OS",U91B'1-H*2+!!+(2D7",.$XO(QB"[GG<$(.W
M*JAWN79,*94>9Z"M.F8A1N?/$L$L$=XC!'\0R./^&`P3>A"[8UIB]!YG[OF;
M)8)9(KQ'"/Y@=CWNC\%B_5Q;JH['F54]W4S+,I`E$;Y`+*V5[8HI"N:`D`/3
M.13<P=Q_W!V#17>P7#AB;!Z'IA]=3WV?$TT"#-LQEU*+!V,-4YK'X1CILR@X
M7#[CD,&B0U=>RCS.-.&;*P.M^B=S@P(Q5>%`("8J'-X!!'=LUR2]!RQX9=]?
M-ME-LDNYC)QQZRXU-%<:]H?#2#/E!KT_'/+AZ1X1[+G_QQZ[2;0';=JOSG6-
M/`Y-A\"KR(E;&0C&`J,>'2-]IP@V$93L^3+6=XE&75OVV4"W;/@SXX$P/JYT
M>'M<=,C>]U*C+F"5NM^HB.\2AN]#UY;>Q5X##4OIRBNF/P4YAKAT!9,0$J%P
M!A)=LWV"Y'I^>B*^NQBZA@8>V>;4T';?7;R#&Z$A`D+R7)V@)*'P+B(Z9ON&
MYQWSW<;0L>M(*[Z'.+2LER1G9:\,J7Y^0PS]RG,R>(`))Y@^(Z)=>-;0[DP[
M,UJ<L,A`D@L/<6KHHG]Z4]@Q,C8ZSX1W'R4:93N*Y^O*]R%B7>7]'CL<0E9X
M79%CN(8E[0=\`9DJ?=`0PZ3)&6&G7O:@&PRWRX^U_*B5X_*(?9QE5(G)A1U9
M3>B][FIWG'XQV0%$NNZS8W9]4.X&X)1[CH[XCZ@\I@55,GP`24-;0E@E/R?S
M+Q4YUP>\/:G@?%O_>X+?,S`<FPP-X`,A5?L%'JQWOY#L?@$``/__`P!02P,$
M%``&``@````A`/EBI8/A#0``KG,``!D```!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&ULG-U9<]K(%L#Q]UMUOP/%^V`D=E><*4`2$ON^O1$;Q]38Q@5D,O/M
M;PL)FS[2U5]V4C43-S\=6LLYM*3&^O;G/R_/F;^WA^-N_WJ7-7+Y;&;[>K]_
MV+W^O,O.ILX?U6SF>-J\/FR>]Z_;N^R_VV/VS^___<^WW_O#7\>G[?:441%>
MCW?9I]/I[?;FYGC_M'W9''/[M^VK>N5Q?WC9G-2/AY\WQ[?#=O-P7NCE^<;,
MY\LW+YO=:S:(<'M($V/_^+B[WUK[^U\OV]=3$.2P?=Z<5/^/3[NWXR7:RWV:
M<"^;PU^_WOZXW[^\J1`_=L^[T[_GH-G,R_VM]_-U?]C\>%;K_8]1W-Q?8I]_
MB(1_V=T?]L?]XRFGPMT$'8VN<^VF=J,B??_VL%-KX&_VS&'[>)>M&[?UAEG-
MWGS_=MY"\]WV]_'JWYGCT_YWZ[![Z.Y>MVISJQWE[X(?^_U?/O4>_":U\$UD
M:>>\"X:'S,/V<?/K^33>_W:WNY]/)[6_2VJ5_#6[??C7VA[OU29587)FR8]T
MOW]6'5#_S;SL_&-#;9+-/^?__]X]G)[NLH5RKE3)%PS%,S^VQY.S\T-F,_>_
MCJ?]RR)`1A@J"&*&0=0281##S)G5DE$J?R)*.8QB%M_#F(6<4<Q_)HC_?N<5
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MX'\X%=2()+D6^$MIM4`V-&6#)1MLV>`$#=>=5H,`_6ANI3!N"N.E,.T4II/"
M=%.87@K33V$&45,U"_HV'*8PHQ1FG,),4IAIG!&Y,TMAYBG,(H59IC"KJ%&#
M,?&!LDZ#ZO54JA&K/O:LEM-J+/V)SW5?:[DL&YJRP9(-MFQP@H;@C,$?9+9D
M@RL;/-G0E@T=V="5#3W9T)<-@TO#U5!!%IEA"C-*8<8IS"2%F:8PLQ1FGL(L
M4IAE"K.ZF,MH<7UI^-CPD<I4K\<A40KJC0N2PUEU%OB)P][7ZJ/N:LRH,E@,
M&AL!4F_X/K`4HHG"0F&C<%"T4+@H/!1M%!T4710]%'T4`Q1#%",48Q03%%,4
M,Q1S%`L42Q0K%&L4]3J3Q*S3/NC4Q1`MX],-7OVE[K)J&/V>U"KSQ4"S$:"D
MS$=AH;!1."A:*%P4'HHVB@Z*+HH>BCZ*`8HABA&*,8H)BBF*&8HYB@6*)8I5
M(*KGJXZ5DO]7/Z=88XAZG4EBTFF)KZ[S?B'Q_:4BB5_6UZ01H*3$1V&AL%$X
M*%HH7!0>BC:*#HHNBAZ*/HH!BB&*$8HQB@F**8H9BCF*!8HEBE4@@L2OJ;LI
M\F["&D/4ZTP2DTY+?/\>IKR7PI>K_*4BB2\NRC8"E)3X*"P4-@H'10N%&Q5J
MB".N,'M1)$YNVB@Z*+HH>BCZ*`8HAE$1W22C-&B<!DW2H&D4B3TPBXI*4>S'
M>0JS2&&6*<PJ:D2/UU$1W<[U>E1%UJN>F)%:5:A]J2KX2T6J@KCXWPA04E5`
M8:&P43@H6BA<%!Z*-HH.BBZ*'HH^B@&*(8H1BC&*"8HIBAF*.8H%BB6*52"J
MA?.)0#Z7EU>\,4*]SB0QY[2\-]2-JLAPH*BN,"3?O3HO)C/?%#=.&Z%*2GTF
M%A.;B<.DQ<1EXC%I,^DPZ3+I,>DS&3`9,ADQ&3.9,)DRF3&9,UDP63)9,5DS
M47-6_$2^RR;DFIK%$ICWXG-UR4XO"OZ4F,^?(QC^8I&B(&X^-$*5T-$F$XN)
MS<1ATF+B,O&8M)ETF'29])CTF0R8#)F,F(R93)A,F<R8S)DLF"R9K)BLF:BB
M$&1D0JZIHA"8\`)%L52J5#XNZ.EEP9\W\X6R$$RWT>\6F&+<TS`"E=#5)A.+
MB<W$8=)BXC+QF+29=)ATF?28])D,F`R9C)B,F4R83)G,F,R9+)@LF:Q"$N1J
MP30JU:H8<Z\YBBH+F&NJ+"09O2SX$VN^4!:"^3BB+'S,QSG/K&X8@4HL"T@L
MCF(S<9BTF+A,/"9M)ATF728])GTF`R9#)B,F8R83)E,F,R9S)@LF2R:KD`1E
MH6R42F:T+&"2J++`)CD?];*@<O8K9<%?+'(2(2Z1-HQ`)98%)!9'L9DX3%I,
MW)`$^]#,JZ\`R3O$'D=I:U$*A4)>?#QT.$97BU&NU>374GH:,(R"*2_\]#5A
MYLOJKWZ/>,#]&#(9,1DSF3"9,IDQF3-9,%DR63%9,U$%`5-(C1.2C%X0_'E+
M7Q@G!-.=Q#A!S)YH^%_>2[[\T61B,;&9.$Q:3%PF'I-V2&KAY69Q;Z;#$;K)
M$7K:RT:N('9,'UX?:*_G<Q5Q:VX8OIY0Z4=,QDPF3*8A"3:FD1.K.N,(<R8+
M)DLF*R9K)JH"8%JI"I!D]`K@3V#Z0@4(YCV)"O!QD2(\4\#944T#B<7$9N(P
M:3%Q8TC%%*OMQ2`Q6&K'D$B<3@P2<;HQ)!*GEP;UTZ!!#!(]&C(9,1DSF3"9
M,IDQF3-9,%DR63%9,U$%`E-*%8@DHQ<(?Z+3=8&`NY#!O"A1&.2L)`-G3S69
M6$QL)@Z3%A,W))7@*^PEHU:IB)7V.$I;BV(6:S516CH<HZO%*!:-DAA@]#1@
M%"KEDKCPV]=%OF2857'+:,`=&3(9,1DSF3"9,IDQF3-9,%DR63%9,U&5`--,
M58(DHU<"?WK3)RI!,!M*5`(QEFP8T3E3XA.ER<1B8C-QF+28N"$)[^@:N4I-
M_V/_(=+-XZ!M/:B9,\KYZS]&)&B'@W;UH(5<L00][7UZB;Z^1#%GUJ[[G8]V
M?,`='S(9,1DSF3"9,IDQF3-9,%DR63%9,U&5!=-6598DHU<6?_K4)RI+,-M*
M5!;Q,=<P<$Y6DXG%Q&;B,&DQ<6-(17[-UXM!HJ"V8TADGFHG!HDXW1@2B=-+
M@_IIT"`&B1X-F8R8C)E,F$R9S)C,F2R8+)FLF*R9J,*`6:<*0Y+1"H,IIT(F
MGWR<N;Q141#7N1NA2KA\U61B,;&9.$Q:3%PF'I-V2#X&+F+,W^$871FC(*IR
M3X*BN+O<EZ`D3H$&$I3S15D&0I*PAT=,QDPF3*8A>=^J9:,HMLF,H\R9+)@L
MF:R8K)FH7^>38NICHM'+@)S\"&4@;M)C01S-#1,G8C696$QL)@Z3%A,W))>Y
MI/KM/8\#M!,#=#A`-S%`+_'5?N*K`W[S(9,1DS&3"9,IDQF3.9,%DR63%9,U
M$Y7UF%+J5X@F&3WKU0#_$V<%IL\C'_[B7+L1JH2/AB83BXG-Q&'28N(R\9BT
MF71"<ID.43;$1W>78_28])D,F`R9C)B,F4R83)G,F,R9+)@LF:R8K)FH8A#D
M8T*FJ6*09/1BX$^$2G^)P`SF3:GP5[\.I2`.V$:H$KK89&(QL9DX3%HA"1+P
M#W5WH"1.;5P.XC%I,^EH75&W!_*R*UT.TF/29S)@,F0R8C)F,F$R93)C,F>R
M8+)DLF*R9J**08IYC(E&+P8J8S]3#'P>&1F(D\:&_\NZ8;H2$XN)S<0)2?A1
M6RE4Y4V\%@=QF7A,VDPZ3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP63)9,5DS6
M3%0UP%130X,DHU<#?[+3]=`@W2],\W^_?K0JB`EDC5"ISKP/)$3A:#*QF-A,
MG)!<YKJ9XEYJBT.X3#PF;28=)ETF/29])@,F0R8C)F,F$R93)C,F<R8+)DLF
M*R9K)JHF)$U9#)X5D9R,>DWPYS=]H28$TZ+$:8.X`MTPDR9/G;O:9&(QL9DX
M(0E&"H5BM2(N+K<XALO$8])FTF'29=)CTF<R8#)D,F(R9C)A,F4R8S)GLF"R
M9+)BLF:BB@)FFAHH)!F]*/A3G;Y0%((94M=%H583G[T-_R$]=/:`Q`JC!-FL
M?L-4L5@1HPV;W\AATF+BZGU1:UR47R3P=%)4WW'3[SFT^6TZ3+I,>DSZ3`9,
MADQ&3,9,)DRF3&9,YDP63)9,5DS63%1-P#12-2')Z#7!GZ1T71/@UF(PITFO
M!>(CUW]*FE\+@KG`M5*M(FX]-C50,0WYE4!+`T:U6I3"UH19S$>$$XJ$,Y<6
M$U=_GW+9J(@[*IXFC%I-5HDVOTN'29=)CTF?R8#)D,F(R9C)A,F4R8S)G,F"
MR9+)BLF:B2H"27,++V<+228H`L'#"(/GVKUL#S^WS>WS\S%SO__E/VC0_QA^
M;_UX"F+1?UB8:&\8M^H1=-%VR[A5SYF+MKO^TQ3C7FB8MXVX-VB:M^J))=%`
MEGFK'EP2;;?-6_7\$M5^\]Y3];#$M\W/;6]S^+E[/6:>MX]J'=77^]2)UR%X
MW&+PPVG_=GZ\WX_]23TF\?S/)_5<S*UZX$D^I_#C?G^Z_."_P?N3-K__#P``
M__\#`%!+`P04``8`"````"$`:]$1A7`#``!J"@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6R<EEMOFS`8AN\G[3\@[ALP9Z(D59.JVZ1-FJ8=KATP
MB57`R'::]M_O,R:`2=/331O@]<OS'?#GQ?5C55H/A`O*ZJ6-9JYMD3IC.:UW
M2_O/[[NKQ+:$Q'6.2U:3I?U$A'V]^OQI<63\7NP)D18XU&)I[Z5LYHXCLCVI
ML)BQAM3PI&"\PA(N^<X1#2<X;Q=5I>.Y;N14F-:V=ICSMWBPHJ`9N679H2*U
MU":<E%@"O]C31IS<JNPM=A7F]X?F*F-5`Q9;6E+YU)K:5I7-O^UJQO&VA+@?
M48"SDW=[<69?T8PSP0HY`SM'@Y['G#JI`TZK14XA`I5VBY-B:=^@^08AVUDM
MV@3]I>0H1K\ML6?'+YSFWVE-(-M0)U6!+6/W2OHM5[=@L7.V^JZMP$]NY:3`
MAU+^8L>OA.[V$LH=0D0JL'G^=$M$!AD%FYD7*J>,E0``?ZV*JM:`C.#']O^1
MYG*_M/UH%L:NCT!N;8F0=U19VE9V$))5_[2HC:@W\3H3'^B[Y][,2T(41J^[
M.)JH#?`62[Q:<':TH&O@G:+!J@?1')Q/D6F./M9+H4*,RN1&N2SMR+8@"@'U
M>5@AUX\7S@,D->M$ZW-1&)J2S4FBB@&`/27$/J9\/N\G&"56,*H.BFZM;X#W
M0#=AVSPC27HV`P62]'84)89BC]X<^6[OJ^FT)AAI`E.Q>4EAL(')F$T5TX=F
M?SE=:M'2A@3TV0D#WR18:\V8T?-,R49+DK;X7A*[$>H%!B,T_/L9U2*3$?IK
M*)!.I!9U!(&'DK0G:`6;L0"EL1='4:\P&*&1W\^H%IF,83CD0"-JC48,HC@)
MTHEBHQ47,FU`QA^!5(M,2$CD)$]K+;K`H%.I)3H0%/BA/[2#`:DFX&1[":`,
M+W>D6C2%#*:?C19U!!YRT^E7,Q:D2>0G0U,;B.E'$-6B,\1)+==:-*KV=+O3
M@@N)-B`1?,;31+[^:;>KSC"'4NFF[%1=*A,7H2EGIQB##MDV.=4./BKXRX6&
MF3U-8SS9F=>=1M.%49+&_O!NW8R&Q/=!$@PQ:CP]VO7DJPC?D0TI2V%E[*#&
MM@>[5G^W/U+<>&J$3.ZOU5&C/2ST#V#2-WA'?F"^H[6P2E*`I3N+H<^Y/BOH
M"\F:=MYNF809W_[<PYF.P(AR9R`N&).G"S4`^U/BZC\```#__P,`4$L#!!0`
M!@`(````(0`2:KZ6%00``+$.```9````>&PO=V]R:W-H965T<R]S:&5E=#4T
M+GAM;)Q7VXZC.!!]7VG_`?$^@+DV4<BH`^K=D7:DU6HOSP2<!#5@A$FG^^^W
M3`'!#I-.YB4$?'Q\3E7YMO[Z7I7:&VUYP>I()X:E:[3.6%[4ATC_Y^^7+T^Z
MQKNTSM.2U332/RC7OVY^_65]9NTK/U+::<!0\T@_=EVS,DV>'6F5<H,UM(:6
M/6NKM(/7]F#RIJ5IWG>J2M.V+-^LTJ+6D6'5WL/!]OLBHPG+3A6M.R1I:9EV
MH)\?BX:/;%5V#UV5MJ^GYDO&J@8H=D59=!\]J:Y5V>K;H69MNBO!]SMQTVSD
M[E^NZ*LB:QEG^\X`.A.%7GL.S=`$ILTZ+\"!"+O6TGVD/Y-50ES=W*S[`/U;
MT#.?_=?XD9U_:XO\CZ*F$&W(D\C`CK%7`?V6BT_0V;SJ_=)GX,]6R^D^/97=
M7^S\.RT.QP[2[8$C86R5?R249Q!1H#%L3S!EK`0!\*M5A2@-B$CZWC_/1=X=
M(]WQ#2^P'`)P;4=Y]U((2EW+3KQCU7\((@,5DM@#"3P'$IL\3.(,)/`<21S#
MM;W@Z1$I[L`"SY'%OIO%Q.#TL4[2+MVL6W;6H(#!/F]2,1W("IC'(&-(IK#_
M*.H0;D'R+%@BW=<U""B'4GG;$,MUUN8;Y#<;0%L$P>\%)"/B:QK/DR')"!&5
M`Q8F'Y"@N8_E(AGE"K"0*XI&Z-_BA[DT6QXWOD:00(8D"Y"G"2*)A4*X7ZP`
M1SJ03V'S;7_B1?V(@?Q-&%=&Q)\BDEL(23T,<[]Z`8:9-U,&E:&(VR+HEOQ/
M$<DMA"0?)O_]\@58#G[HJ>H1\X1E;P>!Y3M*?N(YQ'-\U_/4XD'$<@@D^3#)
M[I<OP+)\`IN87!I;!"T/W9=7C`AT&+B6;P6AS)',$:I!27[PB'P!EN6'ZH*P
M10QJ"UV7A*XZ=><(LIB?9`ZY*5\<+I3ETH&=[?9R(SJI-M0D(";LB\@R0J4\
M8KG9(TKXL7DYA5+XPY_1+SK)^J&*%(5;!"U+P"I"!%HDAJ.D*9DW6\;,HF2`
M0+0?ST#?2[80JE-P.X#&'`2*PUAI5W.4*.T_=""VL(=KB.#&-]\&(`F7_07W
M@0%U*PL+$%B1K[99'&Y.%/J7T>24B(U/,>3">G9[4A#<+N>&0N\RPN`'0;(,
M9>K$`Y,,4I*7+((NP\F&Q%:H&/I\EA/<0"5#OE+DVP$4]//<)\0-9E'%:2)!
M'-LGCG]EYNZ]&@[H/V-%]%*FBW]UG$,06@G]D#B6XC;N1X_T&V[%#4(,A1#5
M+68%;PAX:JUH>Z`Q+4NN9>PD3O\VA'+Z.MU,GFUQN%.^Q^+&(KZ;4P-<&)KT
M0+^G[:&HN5;2/5!:1@#EV^*5`U\ZUO1GY1WKX*K0_SW"U9#"X1'6*EW;,]:-
M+V*`Z;*Y^1\``/__`P!02P,$%``&``@````A`)80$&C,`@``P@<``!@```!X
M;"]W;W)K<VAE971S+W-H965T,2YX;6R4E5UOFS`4AN\G[3]8OF^`?#912-6N
MZE9IDZ9]7COF`%8Q9K;3M/]^QSAQ(.TV=@,87K^/S_'Q87WU)"OR"-H(5:<T
M&<640,U5)NHBI=^_W5U<4F(LJS-6J1I2^@R&7FW>OEGOE7XP)8`EZ%";E);6
M-JLH,KP$R<Q(-5#CEUQIR2P.=1&91@/+VDFRBL9Q/(\D$S7U#BL]Q$/EN>!P
MJ_A.0FV]B8:*65R_*45CCFZ2#[&33#_LF@NN9(,66U$)^]R:4B+YZKZHE6;;
M"N-^2J:,'[W;P0M[*;A61N5VA':17^C+F)?1,D*GS3H3&(%+.]&0I_0Z6=TL
M:;19M_GY(6!O.L_$E&K_7HOLHZ@!DXW;9-GV*U3`+62X<92X#=DJ]>"FWN.K
M&!FF%3B&^76D7(\=)0J8[O,1>=?NVF=-,LC9KK)?U/X#B**T2)IA%EPR5MGS
M+1B.NX"LT7CF7+FJT`*O1`I73IA%]N17)S);IG0R'\T6\21!.=F"L7?"65+"
M=\8J^=.+DH.5-QD?3/"^]]_'RW]-COQ"VAAOF66;M59[@@6&*-,P5Z[)"@U?
M#P0C<-IK)T[I'%.=4H/9?-S$Z^@1\\4/BANOP&M0)$$1(3)PD36<Z\2.ZQ+J
M%G+C7W0QX]<QDS[&[=<$2^7O8;I)J.L$,0GNGN\5TXYB&A2],%$R/$PG3BG&
M%I(W"ZZ>ZQ5=[CPH>ERLIN%<)^YS%\'5<[VBR[T,BAX7:V,XUXG[W&5P]5RO
MZ'*34\7UP(O_`3MQ'YR<RM23O:1'_D.)N?_!X!/DQ&?D\]KRDEE[O*;);'K:
MBU[`>.2'8YWX#'LJ6!^PE_0"/E6?)_L6Z=N'!%W`.Z@J0[C:N9:7X(K#V]#"
M#\TU?,!NV+`"/C%=B-J0"G*<&H\66&':]U,_L*IIF]-66>R#[6.)_TK`TQ^/
M4)PK98\#U[W#WW?S&P``__\#`%!+`P04``8`"````"$`TH)RHZH"``"-!@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R4E5UOVR`4AN\G[3\@[FO\
M$3MI%*=J4G6KM$G3M(]K@K&-:HP%I&G__0XFL1RGZ[J;Q."7E^<<#L>KFV?9
MH">NC5!MCJ,@Q(BW3!6BK7+\\\?]U0(C8VE;T$:U/,<OW.";]<</JX/2CZ;F
MW")P:$V.:VN[)2&&U5Q2$ZB.M_"F5%I2"T-=$=-I3HM^D6Q('(89D52TV#LL
M]7L\5%D*QN\4VTO>6F^B>4,M\)M:=.;D)ME[["35C_ONBBG9@<5.-,*^]*88
M2;9\J%JEZ:Z!N)^C&64G[WYP82\%T\JHT@9@1SSH9<S7Y)J`TWI5"(C`I1UI
M7N;X-EIN4TS6JSX_OP0_F-$S,K4Z?-*B^"):#LF&8W('L%/JT4D?"C<%B\G%
MZOO^`+YI5/"2[AO[71T^<U'5%DX[A8!<7,OBY8X;!@D%FR#N,9AJ``!^D12N
M,B`A]+G_/XC"UCE.LB"=ATD$<K3CQMX+9XD1VQNKY&\OBAS48!(?31*@/[Z/
M@WB11FGV;Q?BB?H`[ZBEZY56!P1%`WN:CKH2C);@?(K,<PRQ_BU4P',FM\XE
MQQE&$(6!XWE:9XMP19X@I^RHV5QJTO1<LCU)W%D`WP`)H8\A7T_[B<6)'8O+
MG8/;^`GP'N"B^63C5R2+07*&`CD:H[A\)5!/;R.Y1:`;$63A;/#WE%XS&VDF
MBNU;BC-&,/E_1K<HQY"((4MQ,B'8>,V8,8[/P]AZR=S70)K.%]D@.&.$NA\S
MOIT_)YZR36IGXS5^XSB9+Z;PT!^<B1=<9UDRBR9D_OK[VR&YKOB6-XU!3.W=
MU8XAI&%VZ#JWL:NSR?P&NE%_=\GP`KI!1RO^E>I*M`8UO`3+,)@#E/;]Q`^L
MZOH[N5,6^D#_6$/;YU#'80#B4BE[&KA;,GQ(UG\```#__P,`4$L#!!0`!@`(
M````(0"*@!3!\@<``-PQ```9````>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;)S;VW*B2A0&X/M=M=_!\GZ4@R!:27:-\7P^>VV4)-:HI(1,9MY^K[9![`7#
MKS,7CK8?BZ;I16/3>?COUV&?^^F>_)UW?,SK!2V?<X\;;[L[OCWF%_/F-R>?
M\X/U<;O>>T?W,?_;]?/_/?W[S\.7=_KAO[MND*,(1_\Q_QX$']5BT=^\NX>U
M7_`^W"-]\^J=#NN`/I[>BO['R5UOSQL=]D5#T^SB8;T[YF6$ZNF6&-[KZV[C
MUKW-Y\$]!C+(R=VO`ZJ__[[[\*-HA\TMX0[KTX_/CV\;[_!!(5YV^UWP^QPT
MGSMLJIVWHW=:O^SIN'_II?4FBGW^D`A_V&U.GN^]!@4*5Y0531YSI5@I4J2G
MA^V.CD`T>^[DOC[FO^O5E6[FBT\/YP9:[MPO_^I]SG_WOEJGW;:_.[K4VG2>
MQ!EX\;P?@G:VHH@V+B:V;I[/P/B4V[JOZ\]],/6^VN[N[3V@TVW1$8D#JVY_
MUUU_0RU*80J&)2)MO#U5@%YSAYWH&M0BZU_G_[]VV^#],6_:!:NLF3KQW(OK
M!\V=")G/;3[]P#NL)-+#4#*($08QJ?;A]U:A9%AEYYXHI3"*'4<Q"H9CZ99]
M1UW*813Z/ZR+42[H)>V>&)0<LE'$Z9`'9)CW!M$O37O5+,[=4:)6T>E-6!>3
M6NC&,R.Z@CR4N%7-VT^L'K6F>!/M72LXEE6RG?(=<2XM6HGCE.Z/8]`).1^.
M08T;U^?N_AIU6(/>A&%TYR^J0V=65B<^Q;>G3U&FXCFSZ^M@_?1P\KYR=+FD
M8_,_UN+BJU<-BASEM,S`2Y;_*<DINT64[R+,8Y[..^6O3U>FGT^V67DH_J2K
MR28T-6GH-38E337/:49733TRX@(C=M[@!4U>T)(%U]5C0=N1B()VHH*XMI:E
M5J0;D6B;7E00;\-VTX]$M,E`%M#KI5'X;H;1-C%A44>1B**.<=1)M,T?HTXC
M$46=X:CS)&%U720%/^!EDMB\HZS23+RK(O7N2Q>GO%.Z>/IP%?5DH45/CHZZ
M%A7$#667#+4G/*<94S7UI&%1&DFAE]4@S13BJ*0E";7/I4>Q_;23PF)!.DG"
MJ])-(2Q*+TE85?I)P:LR2!)>E6&2\"@C3,9)HK,#FB0).Z`I%+.DX,<S3Q*V
MFT52\"#+)$GTVU6:B?NMDD4T-MR114(K6<0+GGE!G1<T>$&3%[1DP757MTLE
M-1W:*<9@%_+.#:9[@^FE&5NM3_\&,[C!#%-,B1W7*,VP^HQO,),TPZY,TS3#
MTF=V@YFG&78GL;C!+%.,Q>XV5ME&Z?YT1ZQT?W&?5**;TNS!1&Q%OW*NKL6V
M%8]2Y[N7FC3T>KE>LR[\#$4=B@8432A:4+2AZ$#1A:('11^*`11#*$90C*&8
M0#&%8@;%'(H%%$LH5EE"22;*FT0RF?1S*SN9Q%:/>1JR+HEB6VQ<K$E#%;D8
MGDQ0U*%H0-&$H@5%&XH.%%TH>E#TH1A`,81B!,48B@D44RAF4,RA6$"QE,(Q
MSS^5M4+%+&O7_]@@O5)X/(`H246_;A-)A4<HL15/JO@.4(Y0TF0E%11U*!I0
M-*%H0=&&H@-%%XH>%'TH!E`,H1A!,89B`L44BAD4<R@64"RA6$D1IUU\8ZFD
M$DU`)E))UR@)LP<HL1G/)3;\U*3)RB4HZE`TH&A"T8*B#44'BBX4/2CZ4`R@
M&$(Q@F(,Q02**10S*.90+*!80K%*"OMJ)D_))_$`\'J2.3N-A.9IQ`;$FC19
M:01%78K*>0C6&]_8J-?(_KIY_;56T.)!^3QFMN#NVU!TH.A"T8.B#\4`BB$4
M(RC&4$R@F$(Q@V(.Q0**)10K*63G4[J/DCCT!.N.Q!&:)PZ;IJE)DY4X4-2A
M:$#1A*(%11N*#A1=*'I0]*$80#&$8@3%&(H)%-.DL/E<^NP&,T\S\=W6^1JY
MN,$LDX;=4:VRA)),.LTP*-ETVQS>>3.65C:;2:R%*"NO+D0\'=4*IFE>_^+3
MV$Q&_<+_.)71P*2)20N3-B8=3+J8]##I8S+`9(C)"),Q)A-,IIC,,)ECLL!D
M>2$W==+5A:=U4C7YQ`/;V^\!Q8(6/I;9[!ZK%J+,I)-Q,D@=1VE@TL2DA4D[
M)(Z\)ZW8CF.PBV9'(09=1'2371&[*BF;CL6"]!11*97T"G^DW5>(Y=BZQA^M
M#12B&^6R9E78C?I0-:9CZF6;7>I&JM$MPZXP,E:(62HY1IGM::(0PW`TW6$-
M,PU)1F^883+'9(')$I-5)E&S2SS(O<XN,;3A&75=/O]5IM3YV:F%**/1GC&I
M8]+`I(E)*R27.1Z3/81LXQ@=3+J8]##I8S+`9(C)"),Q)A-,IIC,,)ECLL!D
MB<DJDZ@I)AX6_T6*R6?,:HJQJ88:+=H5HUUXV3<-0[N:23G?*S^')",+ZY@T
M,&EBTL*DC4D'DRXF/4SZF`PP&6(RPF2,R023*28S3.:8+#!9AD3V7;-2IOL1
M-N<@UJ2+[IW>=V62R37G<F7JP3V]N<_N?N_G-MZG6$].`^'3PZ58+G9O&E5:
M$$2K]%@Y+8+_GE;>TJNTR#/I.WJ5%G(FRWMZE59K)LN'>I766R;+)WJ55DPF
MRVM&M996GV>C2FN@DKYN5&DI5+*\851I1125%R\'3&OK/]9O[F!]>ML=_=S>
M?:6VT@IBK?1)KLZ7'P+OX[S0]\4+:%7]^>T[_16%2VMGM0+A5\\+H@]B!Y>_
MRWCZ'P``__\#`%!+`P04``8`"````"$`+R9IGHD?``"+O@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6RLG5MSVSC2AN^_JN\_N'R_L25*\J&2;$DB
M)5+4@:+.NO,X2N*:.$K9GIG=?[\-$2T"_4(4/#4W$\^#E\TFT&B``$E]_/=_
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MX^^+U^_[O_HO3U^&3S]W5-W44*H)?MOO?U?2Y(M"=/`5'-T[-$'V<O%E]_7A
MCQ]O^?ZO>/?T[?L;M7>3+DE=V?V7_X:[UT>J4C+SH=Y4EA[W/\@!^N_%\Y.*
M#:J2A_\<_OWKZ<O;]T^7]>L/C7KSYK9&^HO?=J]OO2=E\_+B\8_7M_WSJE#5
MM*W"2EU;"<C]HCQH?6C>7`?O,=+01NA?;83^JC@IN7=PG?YEUVOE22L.;.D#
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M&L)K]\H<#PQ%1!Z'BE,C!0T1RDI;F?ET255/8\`KC6]_?J[?W7Z\^I.&I$>M
MZ:"F9BNZK%#CCS(;2A!)T).@+T$L02+!0(*407DUS:;MZI`E[.I(@K$$$PDR
M":82Y!+,))A+L)!@*<%*@K4$&PFV$K2/#<[7WSXV[Y%`<[:A/=MF@UY12![C
MDM+./Q&7RHR*2W:JPZ!LVKK=LEU6\"&A!)$$/0GZ$L02)!(,)$@9E)[6;FQ7
MARQA5T<2C"682)!),)4@EV`FP5R"A01+"582K"782+"5H-T&<FQ>KI$V-&<;
MVK-M-J@5A#2`_1-!J,Q\NJ3_&LGQSF[*CM;0L'<4-6Q)]RCABPN!1$!Z0/I`
M8B`)D`&0]$A.NCP\2MCE$9`QD`F0#,@42`YD!F0.9`%D"60%9`UD`V0+I-U&
M5+8[UU`;V[F-#=VV6MH*6II"_1-!J\Q0T%8/Z5I4%;5'"5]@""0"T@/2!Q(#
M28`,@*1'<CIJCQ)V>01D#&0")`,R!9(#F0&9`UD`60)9`5D#V0#9`FFW$740
M=1%A0[>MEK:BED+(BEKWP@1/-Y7Z$)S<0AU-:`9_S)_!];7(H$<1'Q8"B8#T
M@/2!Q$`2(`,@J29T#U$Z'<B9YE'$3H^`C(%,@&1`ID!R(#,@<R`+($L@*R!K
M(!L@6R#M-B)N^]OC+*_=114WM:'BMCX@*QHIZ[TC&I7:CL:"-`YK<H<[F2Z0
M$$@$I`>D#R0&D@`9`$D+$MP=ZVP(9`1D#&0")`,R!9(#F0&9`UD`60)9`5D#
MV0#9`FFW$740Z68UJK&MV]5$NF$+9,49I2LKS@YWW]<TK7WG[;>R8T>@)K0J
M4::6:WF_?11Q:@F!1$!Z0/I`8B`)D`&0]$@,IX.6G<2'1Q$[/0(R!C(!D@&9
M`LF!S(#,@2R`+(&L@*R!;(!L@;3;B#J(NHBPJ=M66UMQ2B.4%:?5H[-2V]%8
M$#,?`@F!1$!Z0/I`8B`)D`&0M"!!.3H,@8R`C(%,@&1`ID!R(#,@<R`+($L@
M*R!K(!L@6R#M-J(.HBXBW:Y&S;9UPQ;(BC-*5^^(,Z6VXTP32J!&UI,+/$<1
M)Y`02`2D!Z0/)`:2`!D`28_$<#J02SU'$3L]`C(&,@&2`9D"R8',@,R!+(`L
M@:R`K(%L@&R!M-N(.HBZB+"IVU9;6]&H=M?>$8X'N1V/&IF)#U&(*$+40]1'
M%"-*$`T0I1H%]7)&B&B$:(QH@BA#-$64(YHAFB-:(%HB6B%:(]H@VB*B%7`5
M'=3<9871&CBRKH-QBYO'<I,7S(Y#M?R.FS0?U.;PV_>GQ]\[>TIW)'(,RP%M
MQN@MFF(1GU9T.(5TU!XP78+:@#WFR]JMG"5ZJ4*M4GM(1UO!=6!/WJ)2Q4[T
MO,SWO51Q:=YT0BRD)J6*G1AXF4^]5$,OU:ATPG15U->X5+&K$R_SF9=J6IHW
MG1#UE9<J=F)VSKP=OVJ=OBI^Y_M?I^*7-H*/`5PL]UL!7*!S`>RC"FO:_.$I
MG$.7B1#U-*H^8]]+%:/Y!-'`RU;JI1IZJ4;HQ!C1Q,M6YJ6:HOD<T>R<+3OH
MU&*[&72.Y&@&EUZ;-[-C@6HTIS4RFEB>ZZH'8%0.I;G&404Y-&25:0M4D5;5
M5=+^\W.SUF@%@=A%[WE9ZK.JTJN85;97XHR)[570O&G<-85FX+8D1I+4I8(K
M'+I44%<C+]68578]B,GUA%5V/0CO,U;9MH1JRBK35A"([;Z<5;8MX=>,5:8M
MLR;L@%<K\&;`J\6D>DL]S^>:&)BQK]?NS=@OD#KV=%1W51:DV*_3PMAI5<BJ
M2EL1JRIM]5A5::O/JDI;,:LJ;26LJK0U8%6EK=2E"AIBEV+H4IFM?AB;1EZJ
ML5;1,T:'9W)N;ZY;(F`G7H8R5E56PY15E=60VTX%-S>UIJB#V3E#=N33Z?YF
MY*LCQ2U;@436%XN07?7@H4?6=]B"EHQ<MH)KD0MZK#)S0;TI\DJ?579>$4T>
ML\JT!7XEK#)M!=>0^1W7"'ZE;,L\8]`0?@U=*O!KY*4::Y4>2VN-H!F(A:")
MEZ&,568U@%-35ID7"*I<.'5[V[P1+3@[9\B.?.J.?S/RU9$B\@MT+N?[J$+U
M<*T:&2@X3H\,$:M(?%K58U6EK;Z7*O92):RJ]&O`JDJ_4I<J:(A0'+I4$#XC
M+]58JW3.K]W=U&]NQ:QUXF4I8U5E/4Q955D/N>T598C:G=R?GYVS9,>^VM/X
M>_,=O1MBSG<*)+*^Z)M=]>"W1]9WV(*VC-RV(.O[V.J[;8GL&K.J,D4EK#+3
M75`3X_.`5:8M1]9W>!\TQ!K'T&4+ZFODI1IKE<[Z=[>MX$Z<;N)E*&.560W@
MU)159C6`*K>=JM7OFG<XX7%4E6G)#GTZ'X1^K?G>!4%E10P!!:I.VUW52U1R
MKTP+H58U:4GT='*/6$5W$J=5/3YC98KILZK2KYC/6.E7PJI*OP9\QDJ_4I<J
MN!;)9>A2F1&@I_U%W5?7ZMCMO4@N$Z\S9JRJK-4IG[&R5G-6F;4:-,1ZXXS/
M:-:JF5SLOD`]%/L"O59&`:76QGEM\1T+Y<JBZ!<%4HX=HS2HB03;56M`'L-#
MH6K2<N/1%K1SI&TUBZ6@^G6M>7LM)@T]/I_I%5CJLXI.>_I\,9_/]DI,]A-6
M::]N:/K:$K=&`SY?I5>IEVKHI1IYJ<:LJJR'":LJO<^\5%,O5<ZJ2K]FK#KE
ME]4GU'M?_VR?.%BT^X1&YMXFHA!1A*B'J(\H1I0@&B!*-;*&M:`AYL1#5E4F
MNI%6G4G`K*H=UEUHC?..5CGLO;`)G\],<]!],U95>C7E\U6G7U857C4:P5VK
M)J9',S[?*:_L0%,;B'(.;DY$./M6+[[7<6N2D=DKZ#5ANPJ[I8IWID)$$:(>
MHCZB&%&":(`HU<@:+Z!IAUZJD9=JS"JSON",$U:=RB*'.4;FI9IZJ7)65?HU
M8]4IO^R@4QMU,NB\%KK5RZQB9-?(RF*%RD`AJB)$/41]1#&B!-$`4:J1R&*B
M2PQ=*@B$D9=JK%6\>MRHTSV[W0,G7H8R5IU)8D7%6Q<(KN>V4T'M]OI63&QG
M?#J_'"8W"KWW3>@N$\))[P::$URXA*X^4"URGYZ2A5K5-"LMD/DZ*E6<`GM>
MYOM>JK@T7[H:U,2,/2E5[,3`RWS**K/C!PTQI1RZ5%"K(R_56*OH'[4C4JO7
MKN_$1&#B92AC565FF[+*O$!P/=<J^N?@5//N&FZ*SAFR4R1%%J9(6F+POPM2
MK^++7%F@ZK#MZ@.K52&;+Z8B='\C\EA4"CBD>EZ6^UZJN#1_V!B[EOTJ*05\
M_H&7Y52KK"P6-$2*&KI4$!<C+]58JW2:IOO2V[M;<><V\;*4L<I,.>#5E%6G
MTNMA%I';7M4:U,^:(F_,SEFR@YK.=SJH/6>:RH:XCRE0=;QV57.J>_LS*5N;
M-YXAT@<&)>IYV>I[J6(TGR`:>-E*667FJJ`A(FGH4D&,C+Q48ZTZYCVU,`K9
M6->\Z16<+^/SG<G&/K9RX56KU6S=B?X[X_.=\LJ.7.I/&+D^CV:H-589KP6R
M[BV"FJBUKC[04D&MA6Z5:/&(57?%Z/1!?H>@QX)3E7%("'TO5>Q6"9<25K%+
M+7']`Q94NI1JE6K,XT0L:,B569<*ZG+DI1IKE<[5C=;-K5R'F'@9REAU)E47
MP6)=(+B>"Z?N[F[DXP<S/IU94Z8A.][59L;?NT,KMD',9SS55WFH"UB7$-3$
M%+'K4IG^'4(P=*M$<$6L,JLVP*!W^`5G[+.M4_5V\"MVJX1?":MLOX1JP*K*
M,Z9:9>>'NKB[&SI5\@'QD9=JS"HS0P=R'VS"*K/?FFO_A_K*6&7:@KJ?LLJT
M!:J<5::MH"D6ZV:L,FV9?MGQ3RJ(?W-9S.N!_;JR(N8J!;):+:B)?-75!UHJ
MN.[02Q6QRJH=&2<]5IFU$]1%'?9=*O`K]E(EK"H&@.L/@5C''+"@TJ54J^SD
M`EMS+A4X/M*J<RO#11,V[8FDF%Y,O,Z8L<I,".#7U,NOG%6F7T%3W)7-^(QF
M<CG=#2AH*KN!YYQ=F1']H$!VL]6%LUWU338Y<D#UA%K5I'1>S@'J(IRB4L6W
M@STO\WTO55R:-YT0MTM)J6(G!E[F4ZVJS@A#+]7(2S5F%37!L5:A[B>L,CLI
MJ#(OU=1+E;.JTJ\9JT[Y965[FLM5A[E7MC]8L:-<(ZO5@KJ8Z79=*JC#T$L5
ML<JLG:`NYEH]5IFU@]G>I0*_8B]5PBH]W9>/TP^XO-*C5*OLK"'O-X<N%?@]
MTJJ&>490C5E5^.U\H6/B=;Z,5=6IGL]G>H4O'["J\,KY0L>,SV<F>O/Z[![P
MSVP#JG<'1:+7R&ZRNA@MNRZ5Z6PQ^?=21:RR*UJ<L<>J4]5S.&/?2Q5[J1)6
M5?HU8%6E7ZE6&:^?#A&-$(T131!EB*:(<D0S1'-$"T1+1"M$:T0;1%M$].$V
M'9GFN[X.QH%H5"Q]NPV/Y2!SO.M+"`<3K\W-PY%B`"DVU,0`(FX8N_I`2^7H
M/0Y;H(K85I%:Y%C5XV(K/\%]@DL%IXJ]5`FK[!%-W#$-6%7I5ZI5]!V?<DY#
MKQ78.Z+#4L63M!&B,:()H@S1%%&.:(9HCFB!:(EHA6B-:(-HBXAZ4A%&Q;>0
M#EFRW7$P#DI3%SIT''"%SAZ4Y+YN]3,HM$`/@T^!C`<!NEIEH!!1A*B'J(\H
M1I0@&B!*-3*J:XAHA&B,:((H0S1%E".:(9HC6B!:(EHA6B/:(-HBHCC4S5U^
M`(WB$!DWN%&QE-%1QTWNBD.U:_JW%D,#=:3(Z`5JWAZ6XO\E5EBZ^HBFE:$"
ML:J7LEU+)??FAJ6JS&/:H;+2QJB:(,H031'EB&:(YH@6B):(5HC6B#:(MH@H
M?J`J*'Z0<8O8\8.ZR#K6SF,TE[/BYTP>4W(1-`6BH"G'+1A/NX&/*M4JXWJ&
MB$:(QH@FB#)$4T0YHAFB.:(%HB6B%:(UH@VB+2(*%-T>99^A0$'&U6]4+"4:
MU$46LP.%;@VL0%$/,I&],V]_TUX+!$R!.,O(=35]A,@R(A>E;-?.,F+U8EBJ
MRBRC'2IK;(RJ":(,T111CFB&:(YH@6B):(5HC6B#:(N(@@>J@H('6=?!0@>+
M+&8'C]K-,D>I,UFFV/PB>]QLG:!`Y[*,CRK5MHS.,$0T0C1&-$&4(9HBRA'-
M$,T1+1`M$:T0K1%M$&T14:#H]BC[#`4*LJZ#A0X66<P.%!I%K$!16>;F\+[-
MF9!1!XJ!J4"<9\2=5)<^$*B.:)D/M0?R+>Y4JZJ?S!EZJ49:5?W(Y;A4<?!/
MO,QG7JII:;X<KH.F6(3-2Q4[,?,R/_=2+4KSIA-B&6Q9JMB)E9?YM9=J4YHW
MG1#K%]M2Q4Y0?RA"ISHHJ(MXR3@0J\."AFL=SF52I,_TGSF#W;=HK(2^]>Y]
M8S7DRXY6H'.YV4>5:O/553OT4HW8U>-3H&(2,2X%W+83+\N9EVI:FM=/@8JI
M3EX*^/PS+\MS+]6B-.\^_[(4\/E77I;77JI-:=Y]_FTIX/-3WRK"I#H`J&]Y
MR;KE&=PN4+<J#-$ZZM&'Z)QQJUO1:@UVJV:M?%W:;Q_Z8,8>P#3B`4SLUW:Y
MF"[@N`D:R"<54JVJKL^AEVJD5;1"P74U1C3QLI5YJ:9H/D<T\[(U]U(MT/P2
MT<K+UMI+M4'S6T3T0QDJSLX](]SN^,DX>(RF;(>.LT;GS-E=P;53Y[6]T,#-
M.8W.C"I>JE2KK$T(>*IUZ%+!2L;(K1+3AC&KBJT*>H)(3&XF+*`1_-A[X629
MEVKJ5@F7<E:=<FG&@DJ7YEZJA5LE7%JRZNB2V#I9L:#2I;67:N-6"9>VK#KE
M$G7$(E:M8(*6HX[H)>NZ9<(KZIO:VDFW(E:<JBJ[I[HV`H-;C\_Y-?062SD-
M[6C$XY18A.ERL3U.B=$LU2I[+UX^B#MTJ:#N1VZ5J-,QJVC%X]@#`_G-LPFK
M:+'LJ((S9EZJJ5LE_,I99?G5$LOL,U95^C7W4BW<*N'7DE6V7V).O6)5I5]K
M+]7&K1)^;5EE^R7FVM1MB\"U`@P:DKJMEXR#6E@3KE&WU=9LWT2=T0]7G3FI
MW7?5!I'_8EI#[R>9'5:CXK>XU6^A=EE5HA!1A*B'J(\H1I0@&B!*-;*2+3R3
M/'2IH&U'7JHQJXI,6_L@?S)KP@(ST<(#:IE+!2Y-O50YJ]BENDB>,Q94NC1W
MJ<"EA9=JR2HKJ<LGMU>LJO1K[5*!7QLOU995/$[>B:JB/%`$OQU1\BD1R@,.
M&3C5YGYC64,9]R7UG97C*!+(ZJ(\X#BI&5IV'E`;?>_(`WI?T,P#&I6=OML`
M%"**$/40]1'%B!)$`T2I1E:^#>0SV4.7"EICI%7V,]DML3X\+E5\LSOQ,I]Y
MJ::E>2,BI!-YJ6(G9E[FYUZJA5:U:')9AF5+=)EEJ6(G5E[FUUZJC5:)YA"S
MR&VI8B>H*Q?!:@4%-#=U92\9AWYU9="07E@CV=$1[@\G';'[K=IW?4>_57*Q
M,*21V6\!A0U`$:(>HCZB&%&":(`HU<C*C_"4^="E@H8<>:G&K-*#I=S:F'!Y
MY9B4N53@T=1+E;.*/1)+`3,NK_1H[E*!1PLOU9)5]G`D-H%6K*KT:^U2@5\;
M+]665;JFY-?$J<<7,2W"2<ZG.RX9^$2#M\,:RK@CB<%;U!8-W@YKIP=ONB-X
M3Q)0<I$$-#*3`*"P`2A"U$/41Q0C2A`-$*4:6>DQD,_9#UTJ:(V1EVK,*KKZ
MX\!6DU_RF;"*&LY0B6C*O%13+U7.JDJ_9JRJ]&ONI5IXJ9:LJO1KQ:I*O]9>
MJHV7:LNJ2K\H+5`Y=0\KP"!T:"+@)>OZR;AKJ7?7C>@1R9W2PIF3VG,#]52%
M.3?P_EQ40S^/84[O-3(S!*"0#RQ5$:(>HCZB&%&":(`HU4CD=;&<,G2IH)E'
M7JHQJXJA1KY+,.'BRK$O<ZG`H:F7*F>5VZ$9%U<Z-'>IP*&%EVK)*K=#*RZN
M=&CM4H%#&R_5EE5NAR@+%,$M@DBD<\H"#AFX1),#+QEW'YH<'':8Q6T+=7^'
MF=.S`JK,O]G]U9%B@J!1V;&[ZH5"I2I1B"A"U$/41Q0C2A`-$*4:6?D[D-_^
M';I4T'`C+]685:U#L^$:7U%1MD-RD2AC(Y7CX=1+E;/*[=",B\U3F6%T>-EE
M[E)!#2V\5$M6N1U:<7&E0VN7"AS:>*FVK'([1-W?I\VH^SMDX!)U?R\9=Q^:
M!*CN+^.(NK_#C-EN]NA/]V-6]Z]^YK&AY*+/:U1V\"ZK2A0BBA#U$/41Q8@2
M1`-$J49VMFZ)Z=/0I8+6&KE58OHP9I5UU]L2J@FKJ.&,:9T813(OU=2M$F?,
M667[);;"9ZRJ]&ONI5JX5<*O):LLOV[$1N2*595^K;U4&[=*^+5EE>V7:"'*
M!U1.W<,*,`@=R@=>,NY&PIIPC58'M37;-U%GE!;.G-1*"^J;+^]("P>YG188
ME3F@BRA$%"'J(>HCBA$EB`:(4D;EL^9#1"-$8T031!FB*:(<T0S1'-$"T1+1
M"M$:T0;1%E&[[6`=!SLV>%FQ[6.+&^S8Y`=FQZ%Z!@5N3IOJQS"J!ZIF\?"*
M^3X'(S,BM:I$(:HB1#U$?40QH@31`%&J48OVZ(\#0G`CGB\8:I7UN%I@O!QI
MUZ3:[S=K\DS]%8\'6/6G45E97?6;'V)RCRA"U$/41Q0C2A`-$*6,RB`;(AHA
M&B.:(,H031'EB&:(YH@6B):(5HC6B#:(MHBH1^N&+"NLW7&P8X,;NM"A.S:Y
MHT>K_68S#M5RDXKD,_%8;%-;\:B1&8^`0OK!&1&B$:(>HCZB&%&":(`HU4CT
M9['].]0JNS_?E%NC=G]6>X*R'M5O+3[^\?JV?XYW3]]4S9ZOV&)OT:I8C<R*
M!12J#[[9?3]"U$/41Q0C2A`-$*4E*A-E#>[B2Q7OGXX0C1%-$&6(IHAR1#-$
M<T0+1$M$*T1K1!M$6T34]Z$AJ>\CZSJ8(PC:=A38,4OA"3'K\ZI=4QTHYI<:
MF4$**.0#2U6$J(>HCRA&E"`:($HU$KU?+-L-M4J\A%R.^79-JA5^L_>?R9[%
MAH#5R34J:Z:K7@>S>W2(*$+40]1'%"-*$`T0I8B&B$:(QH@FB#)$4T0YHAFB
M.:(%HB6B%:(UH@VB+2+JT="0U*.1.1J<YN>HLYO<CD.UU&S&H>=H7JQ06_&H
MD1F/@$+UQ(X=HA&B'J(^HAA1@FB`*-5(]&>Q.3_4*M&?RS'?KD>U9F?6XYG^
MK.0B'VIDUA^@4,TM9/T!ZJ&JCRA&E"`:($H1#1&-$(T131!EB*:(<D0S1'-$
M"T1+1"M$:T0;1%M$U)^AB:@_(^LZF*/%:80VC[7C4"T2F7&H^K/72QHJSF5(
M:F2&)*"0#RQ5$:(>HCZB&%&":(`HU4AT:;DRK%6J^HS;\G)!SJI*]9:_5975
M7?H@M[LTH[)FNHA"1!&B'J(^HAA1@FB`*$4T1#1"-$8T090AFB+*$<T0S1$M
M$"T1K1"M$6T0;1&UVP[6<3!'@[<=+=ZVF]R.0[7&);OT^1MN]4RJZ,^,S'C4
MJA*%J(H0]1#U$<6($D0#1*E&HC^+_8VA5JEN7?;GVW+EW*Y'M41BUN.9_JQ7
M5(R'8Y0W]N#;110BBA#U$/41Q8@21`-$*:(AHA&B,:()H@S1%%&.:(9HCFB!
M:(EHA6B-:(-HBXCZ,[1MN^-@C@:G_HS'VDUNQZ%:T#+CT'N(;NFE,#,D876L
MRRJS2X,J0E4/41]1C"A!-$"4:J0JR^BL8@MNJ%6B2\N[Z*O7[[O=6_CP]O#Y
MX_/NY=NNN_OQX_7B<?_'3[)]=T,[ZT=\\;+[^NF2>L0]9=G#]W)E4?.:BFC_
M@Q:7H$@=10NDKJ*&*FHXBUJJZ-!,8/!6%=VZCFHI-V@,<9RKIHIJSJ*@1D7%
MIRCDN0+E/'VCU&$P"%31X:,,<)2Z+OKZG^NHIBHZ!)8XBL:^>S6OP(,ZK1J5
M'-Y\@&/J5.)RK],*J,3IG7+.Z9MRS>59JMK"V10W5'#C\#A53>1LH3LJ.*R(
MRRMI-N[5ZJ;CZIM-*G'Y13?T5.)RK-.\H1*79W330"4NUSK-.RIQ^M:@8^B1
M$H=O#3J&=I4=)=0CU$:KJX1:DR8?KA)J36=/Z32I-6EMW'$,A:'Z>*RCI$$E
M]&J;JX3JFEZH<9507=,3]:X2JFMZJ-950G5-S]MA29LBS1F"'75^QP$=U=(N
M3N=VGIK.[#IQA]K+V5S46L[&HN0P<.:&3IU*Z.>S\>(Z=6I&^HUC+&E3.G%V
M23K`I4]5^G$5="@<7(92E91<!1T5"PZ/TD.J<A30MV7NU<=D\"+H&S#WZJ,O
M6$+?:KE7'V?!$OJFRKWZB`J6T(-=E'[5ITZPC%X,)!]<X4!OZY$/KA)ZA8Y\
M<)70>VWD@ZN$?*!X5"^2H0_T:;1[]>$S+*'OE=VKKY%A29L^(4;VG&7T$:Q[
M]9TK/(H^3W6OOD"%)?3A*/+!54*?="(?7"7D`R54]34EM#>JU>['-5=<3:DD
M=Y:,:G4ZQA5:4RK)G27T@3VZ5E<-T5?OZ%I=)?0A40KA8NU3#`3TG4A5Y.K6
M]`.S]^HW9/%:Z:=?[]6ONV))6&_2,:ZD0C^S2<>X2NCG@^@85YW2;_K0,:Z2
MD.HT<M9I3"6)LR2D.HV<=1I32>(LH5^0)M]<G9Q^UIE\<Y5TZBJ1'%KUZEC;
MKY\__GKXMAL]O'Q[^OEZ\6/WE:9]UX?O9[T4^Z;%_[SM?QVV4'_;O]&>ZN'/
M[[N'+SOZ?,&U>@;EZW[_QO]#U7_UU_[E]\/4\O/_!````/__`P!02P,$%``&
M``@````A`-DHQ4$1#0``/4<``!D```!X;"]W;W)K<VAE971S+W-H965T,3,N
M>&ULK)S;<N)($H;O-V+?@>!^,)(XA^V)-D(GSHK9W6L:8YMH8QQ`'^;M-TNJ
M%%7U0[D\T7W1MC_]RDHRLXX";O_\M7NM_=@<CMO]VUW=:S3KM<W;>O^X?7N^
MJ__GK^B/7KUV/*W>'E>O^[?-7?WOS;'^Y_V__W7[<W_X=GS9;$XULO!VO*N_
MG$[O@YN;X_IELUL=&_OWS1M=>=H?=JL3_7EXOCF^'S:KQ^*FW>N-WVQV;G:K
M[5N]M#`XN-C8/SUMUYMPO_Z^V[R=2B.'S>OJ1/X?7[;O1[:V6[N8VZT.W[Z_
M_['>[][)Q-?MZ_;T=V&T7MNM!^GSV_ZP^OI*K_N7UUJMV7;Q!YC?;=>'_7'_
M=&J0N9O247S-_9O^#5FZOWW<TBL08:\=-D]W]2_>(`^"^LW];1&@_VXW/X_*
M[[7CR_YG?-@^3K9O&XHVY4EDX.M^_TU(TT>!Z.8;N#LJ,K`XU!XW3ZOOKZ=\
M_S/9;)]?3I3N-KTB\<(&CW^'F^.:(DIF&GY;6%KO7\D!^K^VVXK2H(BL?A4_
M?VX?3R]W==]OM+O-P"-Y[>OF>(JVPF2]MOY^/.UW_RM%GC15&O&E$?HIC02=
MLQ'+C8&\L57=Z'D-K]7LB,8M]]'5PFOZ^;D&._)&*G]YHUN#?7D?_?Q<@QYE
MM`RP2*T,7KO1\MO=7A%BRZOTJN2<`^OFKL>!%;]\TF'*1>DPQ8H==DJ*U^4[
MZ1=NU'=)IT?I*-M4\F(/TDU9QT6W"%>GU?WM8?^S1F,-Q>SXOA(CES<0=KE#
ME'&NNLBU'D)=0UCY(LS<U2D$5/Q'ZM8_[H-><'OS@[KB6FH>4--NZY(A2T3'
M$W9#$XQ,$)D@-D%B@M0$F0G&)IB88&J"F0GF)EB88&F"7`$WE)\J253/OR-)
MPHQ($D?W@<$Y:U[7R`A+^)[0!",31":(39"8(#5!9H*Q"28FF)I@9H*Y"18F
M6)H@5X"6$1HG?D=&A)F[.OVO=)N6GH$'J:&QNQ(9DF$EJ;($9`0D`A(#28"D
M0#(@8R`3(%,@,R!S(`L@2R"Y2K2DT5#].Y(FS%#2[(.=%-FR5DFJK`$9`8F`
MQ$`2("F0#,@8R`3(%,@,R!S(`L@22*X2+6L40BUKEY=J/!$)=9$<#NJ#)#3)
M5OTGZ)D33R7BVT(@(R`1D!A(`B0%D@$9`YD`F0*9`9D#60!9`LE5HN6":OX3
MN1!J/1>2E"MK,<$/@81`1D`B(#&0!$@*)`,R!C(!,@4R`S('L@"R!)*K1`L\
M5>\G`B_4>N`EH?6XT@DZ^DPSK$15)P`R`A(!B8$D0%(@&9`QD`F0*9`9D#F0
M!9`ED%PE6BYHE?R)7`BUG@M)_&H=-@02`AD!B8#$0!(@*9`,R!C(!,@4R`S(
M',@"R!)(KA(M\%2]6N#+O4JC2\/5Z66[_O:PI^*F-?2%&2*@/4FY4Q%&]'R4
MQ*,)J.H;7L\S^H:+*)2VO6(#Y#<]7S<RJJYS!XM<S,8NHJ2R+39?U+;Q`M+J
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M,R.V?6IF_M'L(`X`C>E!(KTW]0U?AZRREFTH56T:3:^G=<0J.8\$0;-EG*5%
MW)Q>_^>B+>:ZF%56IQ)NSNI4RJK2J5:W991LQHU=<TG/EMCNV;+E.)_(7:,Z
M^)5(ZU]0?4,QVU.>[:K0235BE;571*RR]HK8294XJ5)66?W*6'7-+SUME%PM
M;1_,34)N3/<E,GJ34;A#\4A&S&#6P@U916);;Y).R+FI'03]3F#L_R,G4S&K
MK&XEK+*ZE4I5-67V@G;+/#+//C*E)X?<TI+SST9`8<7(68FTSA+TC<7MT),J
M:[F%4M4BL2UGI:T6[<$J5="'0?""7W[;&)=B)[\2)[]25NE^P8KB`[_TK(E]
MYF\8">5V51T)2Z1UM0LCH8LJ%`^K1(>TUO2(5=;D1JRRVHJ=5(F3*F65U:^,
M5=?\TM-&XZ4U;4Z;4=&ES,Y6(J.S&>/54-YH7XF%4M6FQ5W5C2XLWLL6.[3T
M453&#BSB%DFLJ(R!.V:5=1!(G/Q*I<KN5\8M7O-+SQKY9<V:X[)#F#'&2(F4
M4QV1'*$ZHQ#1"%&$*$:4($H198C&B":(IHAFB.:(%HB6B'(-:3GR+QTU!#WQ
M?@SY'@?GI]*%*3U/C"@W51G3@D#?>0S/*MY4AXA&B")$,:($48HH0S1&-$$T
M131#-$>T0+1$E&M(3]WGCBY\/+I@=#[!&2(*$8T018AB1`FB%%&&:(QH@FB*
M:(9HCFB!:(DHUY">"[&C5]<5]J6Z7QX`J"<5C/2N8LP+P[/JW%6DK7YU)#5"
M580H1I0@2A%EB,:()HBFB&:(YH@6B):(<@WIZ3&/*SY(#YY+T'E.,;V<HSQ$
M%"(:(8H0Q8@21"FB#-$8T031%-$,T1S1`M$24:XA/1<?'48XK>5\/(N02&RQ
MJ\D&5^!.JI#-TYA9V0KZQHGGZ*SBWA@ABA$EB%)$&:(QH@FB*:(9HCFB!:(E
MHERBJX'6TTT+"6UD+/;)]`Y,BJQXC,1K0/=G2F)I8JP');KJ47%`-W12A5+5
MZ18'N"W/[QH[SM%9<4Y[Z1/=Q"A&58(H191)9'\Q8R?5Y&Q>G$:WZ$&!4</3
MLX(]GR&:(UH@6B+*);KZ8O1:$5MY=18USU2X6#X8OLL3`6UV+=%5-V2!N*A"
M<4XFZJ]XXW1QXPA1))&]Q=A)E:#Y%%'F9&OLI)J@^2FBF9.MN9-J@>:7B/*/
M;.GE)(Y1U'+ZH&S*4Q>M;$HD=KW*-&"<>0U]J5*7;C#QA*Q2;>'Q`*M46ZVF
M\?PC8I5J"\_B6*7:`K\25JFV0)6RJE^,BG\$QIB8\7752N`;!Q9C5ED]FK!*
MM061FK)*M=5J&BW.6*7:@DC-6:7:@A@L6*7:`M6255<BE?-UU8H:*;V$2?69
M$A9R8PM>(C$.5R7<:IK'R;Y4T=!6J>"EA:Q2;8%J)%7RK+W;[M`3:GW''SD9
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M.XC`B)THG\8&K7ZK9RXEG`S%K+(ZE;#*ZE3*JG)0:34\HU(R%JAFU+24Q<LJ
MJTL35JFV($Y3J:(?HI.W.\W`*)69DYTYJZP^+5AE]6G)JC),7J-CN)2S0#6C
MADFO7O.PV-Q:.9VZ!'B&+)$Q(IM/T%AE[=:A5'WPN%JJ.C(P[6;+:QOS=\3M
MJ3T;TAZSRNI5XN15RJKRV,#K-OH]=8$!-5Y&4@N;FCQ9XU)E=7#"35NK;BI5
M,FQ!-^BTC8J:28GF%$1MSBJK4PLGIY:LDE%K-LS/BN3<FII)-5!ZE9O'\&:5
MNQT@T$-$<^$AD39V0VB&3JK0235BE36K$:O400#\BIU4B9,J9975KXQ55K_&
M3JJ)DVK**JM?,U99_9H[J19.JB6KK'[EK+KFEU[FYN,,L\S=!G-\RD%G6J+P
MM0&`/O"N[]Z&K+(.`*%4??!V"*FRO^T@XA;50>!"E4OOK7XEE_TR)I#4R:_,
MR:\QJZQ^32[[9<P;4R>_9MRB-5YS5EG]6ESVRXC7TLDO\6434%]J'LLJ+[]/
MHOS@_&YS>-X,-Z^OQ]IZ_UU\5P0=`=[?5KC\(HN']B`O'F*;O#/(B_=HF;P[
MR(NC>I/W!GE/'.&;W.L/Q)LH+ESQFP/QC!ZOT#GQ0!P,XQ4ZSQV(`UR\0N>N
M`W'0BE?H?'0@#D3Q"GV)QY?B32_@,[E\0?_@D\.7>$!?!G*!?VD-OE#>L.&'
MUB!O7>!A?T"?O4%]TA_0YV*0TP=)!N*3(WB%/O`Q$)_PP"OT@(["<;%UOTW!
MO50,]#"$[KETY<&G+T*AA_O8SH,OHG4Q7#[%BW:[=,]-%7GZ\I+WU?-FNCH\
M;]^.M=?-$Q5LL_C,U*'\^I/RCY/\_,[7_8F^MJ3X*,\+?4W-ACZCV11/QI[V
M^Q/_(1JHOOCF_O\```#__P,`4$L#!!0`!@`(````(0"7]Y:(XA$``.1?```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*R<VV[<.!*&[Q?8=S!\O[&E
M5K</2#)(ZT`==H'%8@_7CMV)&V.[#7=G,O/V6Y2*(JM^6BT;LQ?KS,=BB:PJ
MDE626A]_^?WQX>2WS<M^NWOZ=)I\.#\]V3S=[NZV3]\_G?[GW]7?+D]/]H>;
MI[N;A]W3YM/I'YO]Z2^?__J7CS]W+[_N[S>;PPEI>-I_.KT_')ZOS\[VM_>;
MQYO]A]WSYHE:ONU>'F\.])\OW\_VSR^;F[N^T^/#67I^OCI[O-D^G0X:KE_F
MZ-A]^[:]W12[VQ^/FZ?#H.1E\W!SH/'O[[?/>Z?M\7:.NL>;EU]_//_M=O?X
M3"J^;A^VAS]ZI:<GC[?7S?>GW<O-UP>:]^])=G/K=/?_`>H?M[<ON_WNV^$#
MJ3L;!HISOCJ[.B--GS_>;6D&UNPG+YMOGTZ_)-?=ZNKT[//'WD#_W6Y^[H-_
MG^SO=S_-R_;N[]NG#5F;_&0]\'6W^]6*-G<64><SZ%WU'OCGR\G=YMO-CX?#
MOW8_Z\WV^_V!W+VD&=F)7=_]46SVMV114O,A75I-M[L'&@#]_\GCUH8&6>3F
M]T^G"[KP]NYP3_]:?5A>G"\2$C_YNMD?JJU5>7IR^V-_V#W^;Q!*6-6@)&,E
M])>5I%['1#^Z0G]Q^LO]DO1#EBXO+ONK3_1<<4_Z^Z8K7G`_"G_N]X[I7K$2
M^ONFBR?DW7Z^]A_CA"<MFSC_V'_,N=C9X-\^7(J;P\WGCR^[GR>T!JG__OG&
MKNCDVBIS@3(8>0R=UR*'0L9J^6+5?#HELU-0["G<?_N<G5]\//N-0O269=8H
MDTB)W$G8>+1J"PU*#2H-C`-^),NEO$SM1-QE&@U:#;H`G)'E1O.E?X[YK!IK
M/C>BM0-^%JF<1.XD7)="@U*#2@/C@+]*HIQ6.Q%WF4:#5H,N`,)6M)=`J"TH
MY.-[DHLLVZO?AX+(NI2V6+,,[1=>2(KDHXB;2`&D!%(!,2-Y]5+U*.(NU0!I
M@70A$6:CW1/,9K?R-ZY0J\;NXJ&-8(FRT)0A1Q$WNP)(":0"8D;RNB%'$7>I
M!D@+I`N),"3-2AAR.NZL=&\O=_$U$SHK?)2=7ZDX&X5<MP)(":0"8IC0@>0O
MMM2+<Q1R%VN`M$"ZD`@#46R\P4!66AJ(R9!/V/T[!U(`*8%40`R0&D@#I`72
MA41,G9PJIFZ/P<6ES8W>NLZL)FD6)L*5R;F*FU'(N;(`4@*I@!@FE(/XN$E4
MD-:CD+M8`Z0%TH5$&,\6#6$.,;VPK+0T$),@;H`40$H@%1`#I`;2`&F!="$1
M4R<[BZGWZ5-Z\8'B9MH*MJ.T`A/I.9TAC4+.<P60$D@%Q`QD14>U#Y.E.E;K
M06A)?[Q0ZD<D#&%S5V&)Z>GWXG+^C+*^L.G3OQQ1@:A$5"$RC!8^RFI$#:(6
M42>0-(--%,.U8`-BF7RX.!H0-OE6$<%H1='G'9#H1)"EEE)J(?<7PU(97<7K
M2I6NVDNY^&H0M8@Z@:1%;#H86N1(8`S9(^4I;@3K9$!B@LFECT..E3E2AG6)
M*.`K^L!H4*I%U`DDYVR3N7#.0U6UZ,/@<+^]_76](R^0+R+&6%#YQ$45YX2A
M+0:D0B*3SLZ304JNW$2508:EZ#9$&!(J<&J62BBM&@,'K-^PU$*&EQI7ZZ6<
M<[MCZJ5=;6Z'=O5F_??N^36STE$^VI53Q-"N`SH68W.DC#45K>1IB]6SI!J6
M6BS&Y=`BZH[IDD:T^1\8<;6<LT?9KFK7'I`*R)4.R$%*!:1*9XVM:JSAQ$Z6
MJK"MG508MI&`C.A*+M4)U[*NU*ZYWSY?+,_I?W+HG;M<.*CP<M*V-L'4MDU7
M?1X96>IA3')J&L;D@,2!"*A(`)6(*D2&D4UQQX6=I<ISM9.BJXQ2X?3[G:IQ
M4J$ND&I9BFK^UZT]S$8,*E0DK6TSTO=9FW/9T-J,Z,\XT2Q1`9,GHY3;P0I$
M):(*D6&DPETMBMI)'0GW85Q"5VBWWDTMZ^)P3_IPAW@_HDEZ@%;%.SU@>ZJM
MA)$_B',['ROE48&H1%0A,HQ$:&6I<G#MI([$^S`NH2MB;A[]$.])?'LYHDF:
MFX(`S/V^,C6QJI3]&861ENG:,7<=^X<7?5@5B$I$%2+#R-K<K[E45ZM.*AP7
M&+MQ4J$ND&I9:GH%#'80HPHU"9>D;ZM[>G%I=H=\C.>("D0EH@J1821"-5NH
M55\[J>FP=U+3V[P;!(=]=)<YIDG:V)9&>I]/YE39J>VIS#T@6?JFRAXY=Y0)
M2U#[]H%OG'KONAI1@ZA%U`DDIV\+%#W]]ZWZE&N=X-QSR,\A1U0@*A%5B`PC
M67<N5/%6>REWK#:(6D2=0-)JL1HL7=H[,V^\<TZ;!001HW!+RG0UG;N.P5:)
MJ$14(3*,R([.0C6B!E&+J!-(&LV6+G]2J`U54%C(IXS"4`-4H%2)J$)D&,E0
M6^K3Q$LY0S:(6D2=0-)J%%-@M60HJ.97^W:'UGO5@&QY%YR/JD+/N:.0"L^K
MX9!VZB<K]-)+.>M4L]0;U]'[MD;4(&H1=0))2]OR0,?G%1W!O9GG5?_I4&*(
MP!S0M`5S[C@M53CUOF(O$56S=!F6DF?50OF_9BEY5JW\B28M:--[;<%9%6K*
MI4]X=D1J!7I/0U;0.7>TJ=<8Q9'XC.B"@KUD7;2#O59"5NYRDXF@<;-)@_V4
M)^A1@U(MHDX@:6V;W8.UZ3IOV!:L"I7"#,@ND]&@4+GG*4M-IG2%DPIU@7-*
MEIJHW*M9B@Q+';GGR%+3*ZUQ@YK<T5HOY7:T[IAZZ4);#;SJPIE;SE!1B"UG
M0*+(R%)5_.<I2]&?T=/@G<))D<-?ERI9BI=.M/BO9FDR3BH\EF!4]2RIAJ7"
M&YR(NF.ZA,?L.R7HL3DWX?J><JTQ4FM-W37(G=3T6G-2TVO-#6+BKD$U2Y-A
M*1EC*YU[QZ3`FPU+K;)QOVP1=<=T23_92BQ<6=-W2.VS!;41,I(3U/</<B<U
MO8B<U/0B8JG)131+DW&:PF#(5OJ!G).:#*S&286ZX.QL68I\]-K9V<45^8B1
M_HO5I;-2B066H8SD.M.W*7(G-6F.PDE)<_A9]`EQZ08Q<9NBFJ7)L)0,PY5.
MTV)2D74VF$;H`JG6Z9H,Z<Y)O1;2TINZ7CZR&K$HICV\7Z"^!,@1%8A*1!4B
MPTA&R$H]8JR=U&2$-$YJ,D):-XB)G;@[IDG:V%:[X8[W_M>,%EPX!]FX0V%0
M9/I62^ZE7#Y4("H158B,0][C-:(&48NH$TA:C;P$5GO7G1QZC@!'""-_CR9W
M4AX5B$I$%2+#2-Z36*@TK_92SB<-HA91)Y`T&BT`,-K[;AI2V@I68R1#31U>
MN>L8&G+LZ&9:HE2%R#@4AAKK\JA!J191)Y"TFBT!PP5Z9!/DBC%<A(S\H/(%
MH`)1B:A"9!C)>%JIBKOV4L[*#:(642>0M(RM)D/+]*^TG--I=<1$MI]*J0<T
M?5<C7["4O;DS_J9@H;9[PU*T#MQ,:T0-HA91)Y"</,4Y3C[)9KPRL;!=U?P'
M%#[79ZD`%8A*1!4BPTB95]\&92EUT\@__1?SIW%%YO_6&YR]%FD*1J+0SU*5
M.>4Q*<B)"J=^\G9`Z:5<P%2SU!O7T=\=JA$UB%I$G4#2TKHFZI?9%2VS-]SA
MM+N#BCE&PM!@PGR65.'4!W<X$56S=!F6DL&:J52]9BD5K/X4E2:T&72X4TUO
M4-F0<-.9X`)BS>B8L8:.TU*%4^_#ID14S;JBP8XUH@91BZ@32-I/%P)]DKJD
M0^R((;$BR`8DBIELH4ZKW$F%R03$9N&DZ%@8SP.H<4N6FKH_'%>D0LZPE`S,
ME;KO4[.4"DR_UTK#QK+_6?5RALD^(UD-+?S^W=>XN9.B3"DPFIIKX:0FJZ'2
M#6*B&JIF:3).DU\3-:(&48NH$TB:.U8V),<SE@R+!$:T;;L](D=4("H158@,
M(QEKF5HF-4O)6+MXY3%/9G/C<!.TB_A=-5.O29W:G'C;4\FG9GX[YM@;I9S1
M"J?+.[Y$5"$RB&I$#:(642>0C!B;J&NC9>=7QW_-D7&*'QXBD/7G3LHGJP6B
M$E&%R#!2,:-\4+.4BAF__N7T;<8=3O_(?C\DZ.+@9"0#0VV:>39*^<``5*)4
MA<@@JA$UB%I$G4#2,M'\/^M_.W_L5,3\/\/\'U&!J$14(3*,5&3X,ZE?G35+
MJ<CP%;R8_S*6_U_0!P&.Y01]1[EY,)+#6ZCAY2PEAY?YS:Z?A''J_7Y2(VH0
MM8@Z@>3LHSGYK!?FEYB),SKR2X-94H:EI"V7?GD/KG:ZPOPJN_!%EIRLS6K#
M3:`_.)+5C%)W.23$X8;`2`Y0I_<Y2REG^UAD9[/ZT-F`&C<(+]4BZ@22\X]E
MO^DY)6#3N^$2LU]&QSP]=)R6,JQ+&G+I?<B>9EW2T_Z>B9QI+!U=9-F,'RLL
M,1]E)`>8J0'F+*4\[0?(GF;U%V.Z5;LK>M0@:A%U`LGY1_/#><L:4\3E@*;=
MF,^2,BPE;7FA\T&G2SK;5P!RLK%\<$8RO.0D+DAL&,G1Z6PU9RGE:3\Z]C2K
MIUS)9Y(7.HMQ@PB=/W9T.42+4IU`TAZQ5,]NE&]\-]26Q>I6"R.RCQM:SHB,
MX9!Q':7W5*I4>RG7L4'4(NH$DC.WJ9;>X)-9N8P-;CW9`:E@4`[,N:,*!C59
MX]3[]+A&U"!J$74"R?F3Q<7\C^SK5EQE,`.REQB#%NY7Y':RU'%:RK!4>/\:
M48.H1=0)).:\BN5O\WS>=Y7S9Z1\KC,XEK*#&JV4+74&Y]0'/D?4(&H1=0+)
M^>L,;MKG*\S:&$U[,Y\E99SZ<,Y\18\:E&H1=0+).<<2N>3B\GC2;AVK0IZ1
M=+E.-'.64B[7>9Q3[^=:(VH0M8@Z@>3T=1YWQ.68OJWF)&;Y+"G#4N$R1]0@
M:A%U`LDYQS*Z9%9&0^]U@<\'9$T<+&"=T7%'Y7.=T3GUH<_YBAXU*-4BZ@22
M\]<9W1&?8Q:W&E!XHP]1@:A$5"$RC$08\"!",P!JL6,GD#1#+-=;#1\?>&-Z
ML\+TSR&YKZOD-/=2+G$I$)6(*D3&(6^B&E&#J$74"22MIC/"(\&#B=^*D1]G
MCJA`5"*J$!E$-:(&48NH$TB:(98>OB,QMA\$T(<((QDYJB3(74>?*Q>(2D05
M(N.0]TB-J$'4(NH$DB:SF5Z841^)'"NN,BI&?IRY?4/>2GE4("H158@,HAI1
M@ZA%9#]:ZL<UF&'X".GP5<G'S<OW3;YY>-B?W.Y^V`^,TJ]S/G\<\?#U4]H(
MZ?.G_=2@944M?;4)+1?4TI>`T'))+9>VMH*6*VKI(TFW+*F%#JU8GW/JTS_I
MT7U6]J.M_0_PH"6EEK[@@Y8%M?1/RJ$EHY;^=6K=LJ01T.W(R-B6=!VZ=Q5K
M(6UTKR/60A:E0CC60A:E0C'60A:E7#?2LJ`6>E$FTI+1J(>#4\\GHU'3\^98
M'QHU/<&+M="HZ4E-K(5&0+?J(RTI114]$(VUT$SI5SJ1E@6-@%X]C+60MF'Y
MZ?DL:&S#74YHH>O0.U01;0G%#GTD*=9"UJ%/"45:4NI#/PN.M5`?^NEKK(7B
MC9Y^QUIHIO0;1FQ9KU;7]MR-M5Q02VP^Z]4EM<2\L%Y=44MT95EG1ZYBR-!1
MK]FM("9/1HZ-R5!@Q$9$G_XB"\?6TSI;7ML'LI&99V23:/RM,[()/5>+]2&;
M1"-SG9%-Z(E+I`_MA#93C+0L%M?V->A82T8M,4NN%Z0M&K-KBEG[6F5,&\TG
M&K/K!8V:WA.+]$EHIO161ZR%^M`O_2(MZ?FU_3Y!K"6EEE@TKU.R032:URG9
M(!K-7[+K+]'P6U./J-'(9E$'V%41&R[9*^I^LDG4)&21J$$H+.V'ZB(&2>C2
M]+&<6`M=G+[B@BWT0?$O41,FU"$B;^Q^%.%KZXL(-W;'B?"UC=((-[0/Q7A!
MF[3]E3'.@'XY2RVQ6=.K?=?VQ;U(GRRAEM@\Z,4K:HF-F+Y5=FV_1(;:Z&M;
MU!*+$?JMX;7])6&D3WI%+3'_TD^FKNUOI*C/V7A.T#?6GV^^;_YQ\_)]^[0_
M>=A\HQ3IO'^X]C)\I7WXCP-_R.SK[D!?5^^_:79/7]/?T$=5S^T=G&^[W<']
MA[W`^'W^S_\7````__\#`%!+`P04``8`"````"$`D%J2;I`2``#@8P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RLG=ERV\B2AN\G8MY!H?LC$5PD
MDF'[A$7L^W)FYEHMT[:B)=$ARNWNMY\L5"4253^LQ6%?F-)767\M65D`$@#U
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M]?`C>KS]E-\^[&FVR4_*`W\<#G\JT^230E3Y'&J'O0?JQY-/^\_7W^^>VL./
M>'_[Y>L3N7M%(U(#VW[ZQ]\?;VA&2>9LOE)*-X<[Z@#]?W)_JY8&S<CUW_WG
MC]M/3U]5[;/U:K6\6%^2S!_[XU-XJS1/3VZ^'Y\.]_]GK(R65ID;%?HT*HN+
ML]7E;.%1H\]57)B*RZ&BMWY519+M^TV?IL7Y[%45+TQ%^N2NGLW7*V]U\4)7
M+TU%^C057]E5"K6^J_0YM"@S_,RL;DQ%^N06:7T\4\&C8NU-<<0K.^FQ)]0/
MKVR-G*9;$R>\MC7V@C=VPZLFQ6,_J!],1\GUKW*AQZY0/_`@7[?>/':&^L%4
M':_QYP/E7$=='\3^]=/UAW>/AQ\GM#-26!V_7:M]UMLJ90Y?[>0AH'\6SQ3(
M2N6CDGE_2G-)D7JD3>BO#\O+S;OSOVCCN#$V5VCCV18[ME"[A)+U71"X('1!
MY(+8!8D+4A=D+LA=4+B@=$'E@MH%C0M:%W0:T/_#K*Y6PY2=DP<'-U*X_0XW
M*AGE1G;`%0/IP7SH0.^B'5MP%=\%@0M"%T0NB%V0N"!U0>:"W`6%"TH75"ZH
M7="XH'5!I\'89][E,&66SVB?^QT^4S+O3^G_89$LU[.AQ=Y)5\:&MDDQLDUV
M@\G@2"`!D!!(!"0&D@!)@61`<B`%D!)(!:0&T@!I@72:T!%G8@8MMY+)[W"K
MDB&W/K^E&J/G_#J8#'X%$@`)@41`8B`)D!1(!B0'4@`I@51`:B`-D!9(IPG]
M_Y)?:9)_AU^53.]7]L>5)DLZ=9(NK-U#XV#$U7P@`9`02`0D!I(`28%D0'(@
M!9`22`6D!M(`:8%TFGBT^PZ3N/+D6&5%*,64Y<GI2Q4^M5'6ML,TN93#Y`Z(
M#R0`$@*)@,1`$B`ID`Q(#J0`4@*I@-1`&B`MD$X3.K.GU6NY@DZA+5>HT\^+
MY1EY\WFGJ'JV4PRAFL,"6*YE`>B3E<%HB"(@`9`02`0D!I(`28%D0'(@!9`2
M2`6D!M(`:8%TFJ@KL&$25]YB.%.P7$=7,);KGG>8LK8=9HC.":BS_1T0'T@`
M)`02`8F!)$!2(!F0'$@!I`12`:F!-$!:()TFWA*BB*[;+%>H*%K,+LY4`N5Y
MMZB:MEL,L>-(EH".H\%HB",@`9`02`0D!I(`28%D0'(@!9`22`6D!M(`:8%T
MFCAQM)R.(Y4SL;SWO,=Z<]MEC$:AA,A'%"`*$46(8D0)HA11ABA'5"`J$56(
M:D0-HA919]#$$<I3%^%NAF2^6KTBN/JJCJOT)?W"#B]9&3J\N*(XU$<4(`H1
M18AB1`FB%%&&*$=4("H158AJ1`VB%E%GD!-O/TF5J'-$RZ$OQ)N^H*<+,=[K
MKGH%\JNX9X?(1Q0@"A%%B&)$":(4488H1U0@*A%5B&I$#:(646<0'LJ4#RWO
M],>R#9U`ON`F<\4^=I-!=JS)JC"Q-EBQ?_V^#Y9_`T0AH@A1C"A!E"+*$.6(
M"D0EH@I1C:A!U"+J#%(?HW/$BY\<V]35]7CS?,&)YO)\[$2#QK$&R*=SHOX\
M1JP"1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J$'4(NH,FH@UB@S+.Z^]^E+W]YS3
M1D9VL,FR,,%F*HJ??*G(\1<@"A%%B&)$":(4488H1U0@*A%5B&I$#:(646>0
M$VP_R2>K6UF6.U\(-GU1;AW8-*)4%/MBUXN^/QTA'U&`*$04(8H1)8A21!FB
M'%&!J$14(:H1-8A:1!TCN$93=PLM[[PZV,QE^GA3U,A)&<JR,,$V6+$W_;X3
MEC<#1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J$'4(NH,<H)M_9,CF[H8?\.1S5S-
MCYVHT2BR=NJN,.VK(^0C"A"%B")$,:($48HH0Y0C*A"5B"I$-:(&48NH8X3!
MIB[`Q]Y1P>;-U^H1E)=.),W5_-A3YG)^O"UJ9'D*4*!NJ-O^#`VZ%*T(K6)$
M":(4M3)&X[.SY5K6<+\SY&+%.T.!J&0D7:T,&@V[1M0@:E&K,TA="8Q.).6A
M`2O9.'>3)+U#R9EO?$ZAU[$OR0VB#`!/QLZ@T3!]1`&BT*"Q=]$J1I0@2E$K
M8V1[5Z9,>U>L>$`%HI*1#+LR:#3L&E&#J$6MSB#:3*D3MBM_/:$R-]F346P:
M9'E/6XV&X1NK$0H0A099WM-:E_:,._$4<\5^L+T3$D0I(YGQC)$EOW'NWN=B
M)0X=^L6H9"N1KQC9\LZMQ5JL6*M!U#(2^<X@.X+GTGO;[6[:Y5<C&/,Q<XVL
M-:"1[;>-<SO(-Q7)BD<>(`H9R<@C1M;$KIU`C,6*Y1-$*2.1SQA9\ALG"9^+
M%<L7B$I&(E\QLN6=)&0M5BS?(&H9B7QG$%YOSJE!/"KK3.K3U]N;/Z\.ZC`]
M>81>T$-E?61][%6<+5P)4TWIQ,Y875)B8#BZ+&;.%/IBQ6,,$(6,1#YB-)9?
M;IS<4BQ6+)\@2AF)?,;(EG>NIG.Q8OD"4<E(Y"M&MKQS_5"+%<LWB%I&(M\9
M-+$`J,%G%\!_#M]^M@#HS&U8`4K&60$:62M`([H'QMWWYX`"1"$C&5'$2+1B
M1`FBE)%H98Q$*T=4("H9B5;%2+1J1`VBEI%H=09->$TE;<8GT\_G%=0IMNL=
MC=0%UA",RXUS%-V9BG3F(`X;*C(*V&K>/V4Z7RQFWL+9ND)C<^D-2A%7$_'8
M(*M7GGNNG$A%]53K[&SC1&&*C652A[N=2V.,"K%2RNNSC7-@+E&YDCHL4XNR
M3"X,H^&*>MHNUJOU3`[4_<;:8G.=01-KXFVYICGFF@RB5<<CV3&Z')#/2*P"
M1F(5&G0Y'RI&:!4S$JV$D6BEJ)6A5<Y(M`I&HE6B5H56-2/1:AB)5HM:G4%]
M/?M<2V5^WA"Q.E$TS@3.-;)B8[EQ3G!VQLJ*V*$BNS40*UF@*W?UA<:*8E:L
MYBNGQ4BT6#XVB+K**$&K5.39*D.K'+4*M"I1JT*K&K4:M&I1JS-HPJUORSG-
M,>=DD!5TVHH:Y8GQT2I@)%:A05;0@5;,%65Q)XQ$*T6M#*UR1J)5,!*M$K4J
MM*H9B5;#2+1:U.H,FO".2O:\(>AT;L@*.HVLH%O-G*/";JZMK*`;*K(/`[8R
MA\GY>N:MX3"IJUF'21"/C9+5*SB^)-S>K#\LTV'2.1=.C<&HL4SJ<+=S:8Q1
M(5;Z,#EZG+X_;I6H7$D=EJE%6?87&$;#%?6T>1>SS6SAC*3%]CJ#<%$LW+S5
M\^=.O;E]9FO0*'6Q0^0C"A"%B")$,:($48HH0Y0C*A"5B"I$-:(&48NH8Z1V
M..LXN5!9E''(_F).HM=QW*83--:#/JN9DX#8<44Y?_<1!8A"1!&B&%&"*$64
M(<H1%8A*1!6B&E&#J$74&3019VYVZ84XPR32PB!QQ0Z1CRA`%"**$,6($D0I
MH@Q1CJA`5"*J$-6(&D0MHLZ@">],)W[>G+U?Z#S/^)AI$&V/LJVOW#S/3JSX
M>.`C"A"%B")$,:($48HH0Y0C*A"5B"I$-:(&48NH8X0[ILJ@C'?,%^),)UPL
MAQDTCC-`_@)0@"A$%"&*$26(4D09HAQ1@:A$5"&J$36(6D2=01-QYF9J?O5X
MABD<=2!361WZ&%(XJYES1KD3*XFSH2*C`*U"1!&B&%&"*$64(<H1%8A*1!6B
M&E&#J$74&33AR;?E5RC`W)P;HW&<&2M!/EH%B$)$$:(848(H190ARA$5B$I$
M%:(:48.H1=09-.$=-[_RJW&&B9>%1GV;_>7-#HAO""T>"2FC)"@T5N.[F2`5
MHU2"*$6I#*1R-J)C]+!#P*,'A5AQWTM&DIJM0+TV9#3F!E&+4MU8RC[Y=[,I
MO^I$3+,L-!H[T26^L1D-*$`4&F0YT96*L5Z"*$6IS"#I9\Y&MA.=+%PA5N)$
MW:M11RM0KPT9C;E!U+*ZK(=N+&4[4>4KQN<CO^I$G?>@B.<172TTDLG9`?$-
M&0TH0!0:-)J;"*1B-K)GWKE'DH@5]S-E)-.5@7K.1I:Z^Z!!(5:L7C(2]0K4
M:S:RU9W$52-6K-XR$O5NK&ZY6IWB_PY7]SKVQ;I!(U<#\0UY_HF"0*QXC"$C
M&6,$ZC$;63/H/E"0B!6KIXQ$/0/UG(TL=?=Y@D*L6+UD).H5J-=L9*L[IX:-
M6+%ZRTC4N[&Z[?WI5$W_%M;KGQU8FJS,*,P-&OM>&PGQC<WS#Q,$8L4C#!G)
M""-H+V8CNN21`Z>;/TW$BM531J*>@7K.1K:Z<Q.S$"M6+QF)>@7J-1O9ZLZ3
M!(U8L7K+2-2[L;KM>S>YHS=Y\?WK'AM88M+'H/%C`XA\@T9/$@2(0D8RH@BU
M8K:2$[4$4<I(M#+4RME*M`I$)2/1JE"K9BO1:A"UC$2K,ZB/%MMKM!]8^_7S
MJ8*E,G>V98VL.P_XV("I.+K_YR,*#*)GD]1=!&]^>3F[6#A1$!JCT3V*"*5B
M01*O<"<AX0:'&R).4*386";*'"<YHL)67I[1U_V,_SD;;XGM5"A:"WIF4(TT
M+5:KF7N#!%OL#)I8)2K1,SZ!>V&5*'-GE6BD'E\9ML_5S''M;CE8\=3ZB`)&
M=#4UTG(\%QHKNO,I5GBKFK7D.!(+DHH3*\=T]5(OU;,+9WY3:9_'DHDRHQQ1
MP4CN<):H5;&5=+Q&U#`2K1:U.H,F_*[20F_PN\DBC0_<&EF[PVKFG##OEH,5
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M>^<7$RWT5<1P`#>(=K=14$!`#U8<`3YKB;\#1"&B"%&,*$&4(LH0Y8@*1"6B
M"E&-J$'4(E+?^:PF>N1)_17.^MM?[_>/7_:[_=W=\>3F\%U]/?.EVC0&K+\[
M^FJYWBIMFG&W9#'?JEO`4R4+*NG?J(`Z2RKI.P0E*RKIW0@E%U32Q[A;LKRD
MOO5G'VZ)1VKTYO1$WSQ2HS=TITI(35]"@!K-`;UH.%%G,:.^]9=";IV%1R7]
MT\=NR6;;;J:T/-+2EZ%N#8^TZ`M.)MKWR`?T\LU4"?E`OWH%:N0#^D(`K$/?
M$_YQ6HLJ3-A?4>.3]LK]$_8?E]N/TTN)>C35H2ORXJ03R8>3+B0/3BX'\M^4
M^RBKLU4Y&YP*RLAL5;X%2RB;LE6Y$BRA3,A6Y3FPA-('U,[45%$R@-J9*J%+
M>VIGJH0NU*F=J1)*1F]5]AE[0+GEK<H<8PGEA;<JZXLEE-/=JHPMEE`FE,8S
MM>PIBTGCF2JA#"2-9ZJ$LH<TGJD2NLU%XYGR*-VUHO%,E=!-*!K/5`G=0*+Q
M3)70G1AJ9VJ%T(T5:F>JA.Z34#M3)72/@]J9*J%7DK;J[2*<47J;:)M,EM"+
M0%OU3@_6H7=XMNIU'"S9S9?4SE1$T6LLU,Y4";V40NU,E=`K)M3.5,EN3O%#
MKP!B#R(J229+Z(5':F>J#KVK2.U,E>SF%#^4MYEJA^)GLH3>H*-VINK0RV_4
MSE3)SJ/XH9>2)]JA$O7^-9;0^]9;]>HTEM"KTEOU(C26T-O%-)ZI%1]1B7H3
M&.O0F[\TGJD2>FF7QM.7G`][/?U]A6_77_;%]>.7VX?CR=W^,QW@9WV^]%'_
MA0;]RY-YW>J/PQ/]887^S:NO])<T]O1EC/2W#$Y//A\.3_P+=>I\^-L<'_Y?
M`````/__`P!02P,$%``&``@````A`#$^3[6J#P``<5\``!D```!X;"]W;W)K
M<VAE971S+W-H965T,38N>&ULK)S;<MLX$H;OMVK?P>7[M:R33Y5D*A;/9[)F
M=Z\568Y58ULN29G,O/TV2#0)X*<H*+4WX\F'GXTF&@T2!_'3;W^]O5[\N=[M
M-]OWSY?CJ^O+B_7[:ONT>?_^^?+?OWO_NKN\V!^6[T_+U^W[^O/EW^O]Y6]?
M_OF/3S^WNS_V+^OUX8(LO.\_7[X<#A\/H]%^];)^6^ZOMA_K=RIYWN[>E@?Z
MY^[[:/^Q6R^?ZHO>7D>3Z^N;T=MR\W[96'C8V=C8/C]O5FMGN_KQMGX_-$9V
MZ]?E@?S?OVP^]FSM;65C[FVY^^/'Q[]6V[</,O%M\[HY_%T;O;QX6SV$W]^W
MN^6W5[KOO\:SY8IMU_\`\V^;U6Z[WSX?KLC<J'$4[_E^=#\B2U\^/6WH#D2S
M7^S6SY\OOXX?JMGL<O3E4]U`_]FL?^Z5_[_8OVQ_^KO-4[)Y7U-K4YQ$!+YM
MMW\(:?@D$%T\@JN].@+%[N)I_;S\\7JHMC^#]>;[RX'"/:<[$C?V\/2WL]ZO
MJ$7)S-5D+BRMMJ_D`/WWXFTCN@:UR/*O^N_/S=/AY?/E].9J?GL]'9/\XMMZ
M?_`VPN3EQ>K'_K!]^V\C&DM3C9&)-$)_>XP,7#B5%\[:"\?3J_'L^D94/G`=
ME=9>T]_S*KR1%]ZV%]I52.E25TA_987CFZO)W7P\/^7JO;R2_K*KXZZ!!^YQ
M3'VA"4W7K';.CKE9Q?^<62E%HJFT:UK+2KEIQ_0_9[;1F,+1U-K%1>V&0ZW$
MD1DKH1GJ0Z,F`>I\<I:'Y9=/N^W/"QJDJ(OO/Y9BR!L_"&.<24WE;6X=2RW*
M*6'EJS#S^9+:@+)F3^/!GU_FD_&GT9^4PRNI>>S1S'7)@B4B8X5=QP2N"3P3
M^"8(3!":(#)!;(+$!*D),A/D)BA,4)J@4L"(XM,&B5+A_Q$D848$B5OWD4$7
MM?&M$1&6\#6."5P3>";P31"8(#1!9(+8!(D)4A-D)LA-4)B@-$&E`"TB-,1`
M1&8T>/0_@#A+Q%7TJ-&R9*(W^*/4D*TVE6:Z9-%*VJ``<8%X0'P@`9`02`0D
M!I(`28%D0'(@!9`22*42+48TJ$.,Q$O"F4.;,"/>#Y2`X-@F14-1:R5MU("X
M0#P@/I``2`@D`A(#28"D0#(@.9`"2`FD4HD6-6I"+6K#&274=7"X41\EH4=9
MFS_SR=3(H%;$ESE`7"`>$!](`"0$$@&)@21`4B`9D!Q(`:0$4JE$BP7U^3-B
M(=1Z+"1IWL#%\WP!Q`'B`O&`^$`"("&0"$@,)`&2`LF`Y$`*("602B5:P],+
MH=;PXJUL,K^B0)TY>`E#>DPDH1=S)3_,)TPK:O,#B`O$`^(#"8"$0"(@,9`$
M2`HD`Y(#*8"40"J5:&&B048+T_!8)=1Z+"11\@.(`\0%X@'Q@01`0B`1D!A(
M`B0%D@')@11`2B"52K2&I]Y[1L,+M=[PDNA)8$Y&6E&;!$!<(!X0'T@`)`02
M`8F!)$!2(!F0'$@!I`12J42+A9BQGQ&,6JY'@]%].S-9('(0N8@\1#ZB`%&(
M*$(4(TH0I8@R1#FB`E&)J-*0'@LQ@U2G\\,CTKB9<-*[+7?Q1T84;N7Y<&.\
M/W4JOM!!Y"+R$/F(`D0AH@A1C"A!E"+*$.6("D0EHDI#>GC$=/*,\#2S3RT\
M$JFI`L@9`W(1>8A\1`&B$%&$*$:4($H198AR1`6B$E&E(3T68MZHQN*7W['$
M>J/Q?&&D9Y&YMM*INBR2MKKXNJCR$/F(`D0AH@A1C"A!E"+*$.6("D0EHDI#
M>N3$W%&-W(E!3DXUU4%.G7W6"XV+,2`'D8O(0^0C"A"%B")$,:($48HH0Y0C
M*A"5B"H-Z;$0<T<U%K^>17(6JH9)(CV+[LQG4:OJL@B0*Q9^1))VB>4A\A$%
MB$)$$:(848(H190ARA$5B$I$E8;TR(G)IQJY$UDDYZIJ>-3IJ\PB0([8&!$-
MWTUR7$0>(A]1@"A$%"&*$26(4D09HAQ1@:A$5&E(CX688:JQ^/4LDG-5-4SM
M]%5]H[LWLZA5=5D$R!5;5F86`?)1%2`*$46(8D0)HA11ABA'5"`J$54:TB,G
MIJAJY$YDD9S1JN%1)[DRBP`Y8FO.S")`'JI\1`&B$%&$*$:4($H198AR1`6B
M$E&E(3T68HIZ1BR$W)B(2J0]<*;79JJTJBY5`+EC0!XB'U&`*$04(8H1)8A2
M1!FB'%&!J$14:4@+S^2\=8):KH>'4?<H62!R$+F(/$0^H@!1B"A"%"-*$*6(
M,D0YH@)1B:C2D!X+<YW@EQ\X$UQ"8*1GD7$:8-&IVBQ"Y"+R$/F(`D0AH@A1
MC"A!E"+*$.6("D0EHDI#>N3$U-Y^D)O(E0#E@<.H>Q->('(0N8@\1#ZB`%&(
M*$(4(TH0I8@R1#FB`E&)J-*0'@MS"6'XX3_!=0)&>JH81P(6G:I+%5PG0)6'
MR$<4(`H118AB1`FB%%&&*$=4("H151K2PW/>.L$$UPD8J:DB51UR4.4B\A#Y
MB`)$(:((48PH090BRA#EB`I$):)*0WHLQ/1;';9^_8$C)_+JB-;.[949SM3<
M\Q>'*_6YBX/(1>0A\A$%B$)$$:(848(H190ARA$5B$I$E8;TR(GYNQJY$X.<
MG.ZKX9'HMMUE6$P`.8A<1!XB'U&`*$04(8H1)8A21!FB'%&!J$14:4B/A9AK
MGQ$+.3578]&@V42)!2!G`LA%Y"'R$06(0D01HAA1@BA%E"'*$16(2D25AO18
MB.GW&;&0LW4U%A+I#W_S*,:D574/?T`NJCQ$/J(`48@H0A0C2A"EB#)$.:("
M48FHTI`>'C']/B,\0F[,-B7JGO2+"2`'D8O(0^0C"A"%B")$,:($48HH0Y0C
M*A"5B"H-:;&8GC?SK^5Z+"02^Q#MKO3XSIQ26JD<-M\-@2XBS\J6;Z4*T'R(
M*+*R%5NI$JF:TV.V;:_9G;%SDG8J'EHR*_.YE:J0JFG7T"6BZI0MO2>9ZQ;#
M+R-37)R0Z%1/:BX<5CELOKM!%Y%G5:-OI0K0?(@HLK(56ZD2J3)ZDK%[D':J
MKB?9-&%NY40A55I/DJ'MVKXZ94OO2>>MHU#5YO-!HN$^LK!2.6R^NQL7D6=E
MR[=2!5)EQ-48(<).Q7&-K,S'5JJD,Z\,4_?&>GO:J=B)S,I\;J4J.O.J$\:S
MI>Q4[$1URKS>W\Y;*YKB6I%$I_I;<^&PRI&V].C?&^M.;J?B>_:LG/"M5$%G
M7FGX.V-H"3L5.Q%9F8^M5$EG7G'BWE@[2#L5.Y%9F<^M5$5G7G7"F`F4G8J=
MJ$Z9U[N@N1XFUF#&\ZM;6A@YO&Q6?SQN!>C]$=.4?M-7;TY^G>(RF43#?6YA
MI7+8/+G1OKE,KXUXN)V*F\*S,N];J8+.?.?$[-XX'QQV*G8BLC(?6ZF2SKSJ
MA'$2,^U4[$1F93ZW4A6=>=4)XR!;V:G8B>J4>;UGBJ4Y=;)F]LS?MQ_'>B:M
M7+5=4Z[P*7-L.G8BGMNGNJ:-RI&V*.?X+EU$GE6-OI4J0/,AHLC*5FRE2M!\
MBBBSLI5;J0HT7R*J3MG2NY-8752[TXE9@ER,5+M-@\19@W84FD^-`6`A?A,H
M.A>M"K0JF)4ZK%)M@<J5*MK-$#^>GMQ.[^;&D]"S,N2S:M"I@%6J4].I46/(
MJOO:J?'5Q!!$+%#-P+W%K!IT*6'5H*V458U+]),HXT4M8\&@F9Q5@RX5K%)M
M02N5K-)M&6-DQ2K5EMI4>@\6"[!J#S8'1+M'=;.,2S7S@/4X;9!8[F^[['QJ
M/%06K*+^W:I47^LW`4>JYK2Z<USELDI?NC%:Q^,:5;^@1I]5@WX%K!JT%;)*
MMV7X%;%JT%;,*MV6T3,35@W:2EFEVS+\RE@U:"NW4A56JI)5NE_&/5:L.N:7
MWLLI%P9[N>5C7Y@QU@L;I(W?T)T64QN58Z5R6:4/`D;S>*RBBH^GC&^E"JQ4
M(:L&_8I8->A7;*5*K%0IJP;]RE@UZ%=NI2JL5"6K!OVJ6'7,+[V;DRVMFY]X
M'1%RHSLWR!BUC3%A06?;Q85B^_!XYW)8=2Q#Z['=E2I:G#W^.M+C%.28S]4-
M.A6P:M"ID%4W1U]';%R*.S,#[92P:M"EE%6-2WVO(S8NY9V9`9<*5@VZ5+)*
M;W&CLU2L.F9+Z\$S<P/GEUY':BMZQY9(&Z?Q=815U)0#'5NJ9OI]&R.P*U4W
M3<`FU_0EJUOCO=[C^HYE=YTB/JL&O0I8-6@K9%7S5GM]=6^\D44L&#03LVK0
MI815@[925C4NW5V9"W,9"P;-Y%:JPDI5LFKP]BI6'?-+[]EB&V'H1=ON%60F
M=R.4-VV)M#$;AL>%E<JQ4KFL&DP`CU7'$E]V[N:&AKT/K&R%K!KT*V+5H%^Q
ME2JQ4J6L&O0K8]6@7[F5JK!2E:P:]*MBU3&_]&YN[G;]V@".FV!TD*A>`E&3
M;79O;",M6#68N(Y4S<GD\6'>995<*)E.K\=38Z7<X_I4KR#W?%8->A6P2K4%
M:P`AJXX/X#T-!2[%G9F!)DA8I;H$ME)6\0!^;SP*,Q8,FLE9-=A*!:M46]!*
MI53)1:Z;N_G=M;'95_494N]-[];FIIK9K2U';]QLFTG4;<@N$#F(7$0>(A]1
M@"A$%"&*$26(4D09HAQ1@:A$5&E(CY&YZS0\^Z&OQIJS'T9J#YQ/88R1%W;'
MM9SN0E[_<A%YB'Q$`:(0480H1I0@2A%EB')$!:(2D?@6;]VJ=>,TX6F^K=M\
M"_1MO?N^7JQ?7_<7J^T/\=W<^2W-L5K<?-3W<7+[(`Y$4F-"R1V5W/66W%-)
M7:UYS6Q*WPBN]U*@9,9?#S9+)O1=8?IM3)\'$RJILQ6NH7IHQ.F[ANJA(^M]
M)7,JJ7]F!M9NJ*1^S3-+QG0-_=RZQ]J8KJ$?__:54(O2CTO[2JA%:5K45T(M
M2EL./263:_*M_G"RZ1M=TGO%F*Z@K\GTV!I32].'3/I*J*7ILQI])=32]-F&
MOA)J:=J#PQ+Z4/37?EMT08_^482YCU/5?35_G3U\I<Z/%3^*/M;'*8J]0:08
M]H:0(M@;0(I?7_AH@_M!;%^C1[3K_"#VE+&$MH(?Q$8OEM#^[(/8?<42VJVD
M>OKNA'85J9Z^$MK]HWKZ2FB7CNKI*Z&C2U1/7TCHB!'5TU="YWZHGKX2.HQ#
M]?25T)$5JJ<OQ'2.A.KI*Z'#'51/7PF=N*!Z^DKH>"C5TY<2=(R3ZNDKH>.6
M5$]?"9V!I'KZ2NCP(-73U\7ID!_5TU="A_&HGKX2.B%']=0EHS;WZ8/G'\OO
MZW2Y^[YYWU^\KI]I8+^NCWOLFD^F-_\XR,WU;]L#?>J\WF=_H4_;K^E[C=?B
MDX//V^V!_T$=;=1^+/_+_P```/__`P!02P,$%``&``@````A`-P02#I-"P``
M9CL``!D```!X;"]W;W)K<VAE971S+W-H965T,3$N>&ULK)M;;^,X$H7?%]C_
M8/A]XDC.Q0Z2##K17;O`8C&[^^QVE,3HV`IL]^W?3U&\J(J'L>6>G8?IY--A
MB3HLBB5&NOW]Q_IM]*W9[E;MYFX<G9V/1\UFV3ZM-B]WX__\D?TV&X]V^\7F
M:?'6;IJ[\<]F-_[]_N]_N_W>;K_L7IMF/Z((F]W=^'6_?[^93';+UV:]V)VU
M[\V&CCRWV_5B3[]N7R:[]VVS>.H:K=\F\?GYU62]6&W&.L+-=DB,]OEYM6R2
M=OEUW6SV.LBV>5OLJ?^[U]7[SD9;+X>$6R^V7[Z^_[9LU^\4XO/J;;7_V04=
MC];+F_)ETVX7G]_HNG]$%XNEC=W]`N'7J^6VW;7/^S,*-]$=Q6N>3^83BG1_
M^[2B*U"VC[;-\]WX4W137T3CR?UM9]!_5\WW'?MYM'MMO^?;U=,_5IN&W*9Q
M4B/PN6V_*&GYI!`UGD#KK!N!?VU'3\WSXNO;_M_M]Z)9O;SN:;@OZ8K4A=T\
M_4R:W9(<I3!G\:6*M&S?J`/T_]%ZI5*#'%G\N!M/Z<2KI_TK_71U=GE]/HU(
M/OK<[/;92H4<CY9?=_MV_3\MZJ[(!;DP0:B%"1+1A1QH<&4:T+^!LQYH>&T:
MSEW#(V=2A[L+5#^<=J[(>J-^.'A=$VUJ-T;)8K^XO]VVWT>4^-1P][Y0TRBZ
M45'LZ.@K=./UT7#1.*DHGU28NS&912.QHQS[=A]?S6\GWR@OED;SH#7T?Z>)
MI.(1HUQ>2DEB)2I/U)E3'V0^R'U0^*#T0>6#FH$).>?LB_\_]JDPRCY[50\:
MT%F=5[$TXM$VZ171M90D5F*CIC[(?)#[H/!!Z8/*!S4#PBN:P)!J4\KY\(W`
M9I9JU4W^WHGK<WFA#UI#<]QI+J3BT42AZ?^1)'$29Q>0#$@.I`!2`JF`U)P(
MU^BJP#5U^SQQ@JHPZL[)#,`9JD6'?#1A#OGH),Y'(!F0'$@!I`12`:DY$3Y2
MEX6/A[-.J3N[[$4\:*)ND2Z#XFO_!F::4>G"1%.9BXD3V=@ID`Q(#J0`4@*I
M@-2<"(,H-4XP2*FE09K0(F8OZ]%H9HXD0%(@&9`<2`&D!%(!J3D1ETYKMKCT
M;A&,9ZH>.7)W4BVE#9I$-)]9"O@W;].,:@0F\NY9B1-90U,@&9`<2`&D!%(!
MJ3D19JFZG%<,AR>24DN#-+EP2?%H)+KV4VMZ`B0%D@')@11`2B`5D)H3<>4T
M7.+*59K$EV>4)"?>C%4@:8HFS!0CH7]8AOC%D!.Y#`&2`<F!%$!*(!60FA/A
MDRIDA5&'4Z232SL,8GY8$<L21"FB#%&.J$!4(JH0U0))%U3-.'RBJ)7%2PJ#
MN`M&1-:SM+CR%A@;:N[F6(HH0Y0C*A"5B"I$M4#2&%4@GF",KB>I=+%9_A!I
MQ(TQHOZ2$R.:]BA%E"'*$16(2D05HEH@Z8*J^+@+ZFXRU6O.B;<3M=CXJ:,1
M=\B(9.KXCPPV%#?--;3^9ZC*$16(2D05HEH@:9HJ[[AI1^XLIAKDJ:,1-X:7
MC-TS91(!2A%EB')$!:(2486H%DBZH&HX[H)*G:OIV?7I*Y%ZDO!31R/ND!')
MU)GY=QVGLGF2VNA]-F6(<D0%HA)1A:@62)JFJC]NVI'4,<4B3QV-N#%&Q!<E
M0&D$*$.4(RH0E8@J1+5`T@55UG$7_L)=QU2(W"&-N$.NC.0+EK<SE$1.U:<.
MH`Q5.:("48FH0E0+)$U3%2$W[4CJF`*2&Z,1-\:(^)R*KF`E=ZK>&$!9!"A'
M5"`J$56(:H&D,=1[8<Q?R"85RBL"->*F&1']TY<_,V\W*(F<JC<-4(:J'%&!
MJ$14(:H%$J;%?G6L3%/WK1-7_2Z.=,P@YI@547CFF+=MD?0JYQBB#%&.J$!4
M(JH0U0))Q_Q*^M?3+,8JVR!N6JC*GGG/\(D-U2]N*:(,48ZH0%0BJA#5`DG3
M3JNR8ZRR#>+&&!%;[VR['J6(,D0YH@)1B:A"5`LD75#%Z_!;=VQJ77;K-HB[
MX`IB/J?\73X;BJ>':VBG68:J'%&!J$14(:H%DL:H$O<$8TQ%S(W1B!L#97,2
M`TH198AR1`6B$E&%J!9(NJ!J5NZ"NK/\TI:.VBKTUB^#N$%&)-<O?]_/AN*9
MXQKVF0,HQX8%HA)1A:@62'JFREGNV>%J*#;5+\\<C;@Q1L2-P6K(AN+&N(:]
M,8!R;%@@*A%5B&J!I#&J9.7&_'HRF>*7>Z81]\Q5R/PVY&\1QDYE#4H198AR
M1`6B$E&%J!9(>J9*5^[9D60RE2XW1B-N#)3#20PH190ARA$5B$I$%:):(.F"
M*D]/<,%4L]P%C;@+1D3_L,K/?\"(G:I/#T`9JG)$!:(2486H%D@8H_X\?((Q
MG5R6Q`8Q8ZRHKU@21"FB#%&.J$!4(JH0U0))%T+U;W39[??L7U?++P^M>H0(
M_JUJ2B]CZ%<TIECZ&L3-T2*U]^2R)IKYSPNFW6%5:D\8Z?=!SB.O@LYZ@4V^
M?%#D8I"J[,-W[Z.<1]YE5+W`GK\^%EF.BU]BZR>Y?ES^:-\_&A=:7]W`8.D]
MU8@/C":'+4],N\.JU*BF4[>CGB'*!\4J!JE*#%\AJH_%DN:?5MG3Q?KUF4'<
M9"U2&QXN^^.9OT=NVJDG?*>".9):%8\5S;Q-T\RHJ$Y7.3H_5__)?=4\',C+
MY<*J#G:JM*J#G:J.=ZH.!^H[)8=*/00,7]ZFYIF!+6\&\:'2(E6FND&(?7L3
MTT[5;$X5&*I`+%!EH5CQS-O*S*U*].O24Q56=;!?I57Q6-"ORJIX+.A7;54\
M5LSZ)0>,5&+`NDKV:L#[$%/5TEN!->)CIXF<9G,O[Q,3ZM@T"\0"C[)0K'C>
MIVNW0N96Q6<']ZA3%59U9*8-Z5<5B@7]JJWJHW[)L5.//WRR#1\[U=(;.XWX
MV&DBY]W<6]D3]9X9A3HV[P*Q`F,7B!7/O>V6W)Z1;'<S/3!V@5APQC(4"U25
M55'(_HQ^OVJK^JA?<NS4PQH?N\-/0U/S;,=OE!KQ`=/$FVS^GH,)=6RR!6*!
M,9F)=7!-&Q*H&-2ITJKX[(!.5;)347PQO?)2J#X62`X5G4X,E5_[#:O)511O
MRFG$1U`3;\KY#_I3H^+I"#:D1G5)SU4N:4&5616MBTX5S[UGQ]R>\:/4-K?+
M(?TJ[1D/]JNR*MZOR*_/ZE"_^#7*<51/NWS*^>,XL(978;R!U(@/I"9B*O*.
M=88E],**"G58E0Y2959%(=U`PAESJZ*1^EA5#%*5@U2551WL5VU5'_5+#.2%
MOU70K7MTGQG^A-R%D(-H$!M$0[S9Z#\C6-7AV6BCRPOTGQ&,ZI+/,\CZW)Y1
MJKP2I["J@_TJ!_6KLJIY]^P2O*7:TWW4*3F"Q[8YADU%^I;)GXH&\5$THM@]
M`B>V78]21!FB'%&!J$14(5(?8G6=[SJAW=$?5NF/=M;-]J5Y;-[>=J-E^U5]
M-$6+UOVMP_J+KL=X?J,VU6A7PS\R/;]1&TV!(Q?N,S"_33RE:-U>`1RYH".=
MJW#DDHYT.VQPY(J.=!4+'+FF(]>AOL4S.M*]1NZWB:@-O;@1N)Z(VM`]-'2$
MW*%")W`D)G?HS]"A(^0._:TU="2F(]UP0=^H#;T%&6@341MZ,S!TA+RFU]]"
M1\AKVM<)'2&OZ?V!T!'RFMX%"ARA)L$6U""H)YN#+I/)08_)XJ##$3E,K\QB
MCVBW\$9M".(1VL>[45MU>(0VLJA-R$?:<*(VH2/TM>.G$']4@Q4XQZ,:WA"G
M@0J-TZ>+FT\TB;&SCS1^W?!-7)[05X[OBY?FGXOMRVJS&[TUSS2AS[OMPZW^
M3E+_LC?;B)_;/7W?V.THOM+WK`V]*G^NWCY_;MN]_85./'%?R-[_"0``__\#
M`%!+`P04``8`"````"$`[BO.6VP+```@/0``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6RLF]MRXKH2AN]WU7X'BOL5L,$$7$E633@:S!GVOF:(DU`3
M<`J8R<S;KY:M-I9^HU&FULV$^?R[U5*K=;#EN[]_[M]*/Z+C:1<?[LO.3;5<
MB@[;^&EW>+DOKU>]OYKETNF\.3QMWN)#=%_^%9W*?S_\]S]W'_'QV^DUBLXE
MLG`XW9=?S^=WOU(Y;5^C_>9T$[]'![KR'!_WFS/]]_A2.;T?H\U3<M/^K>)6
MJXW*?K,[E%,+_M'&1OS\O-M&G7C[?1\=SJF18_2V.9/_I]?=^XFM[;<VYO:;
MX[?O[W]MX_T[F?BZ>]N=?R5&RZ7]U@]>#O%Q\_6-ZOW3J6^V;#OY#YC?[[;'
M^!0_GV_(7"5U%.O<JK0J9.GA[FE'-1#-7CI&S_?E+XZ_=IURY>$N::#_[:*/
M4^YWZ?0:?_2/NZ=P=XBHM2E.(@)?X_B;D`9/`M'-%;B[ET1@=BP]1<^;[V_G
M1?PQB'8OKV<*MT<U$A7SGWYUHM.66I3,W+B>L+2-W\@!^K>TWXFN02VR^9G\
M_=@]G5_ORS7WINYZMTV']*6OT>G<VPF;Y=+V^^D<[_^?JI(J959<:87^LI7&
MC7=;K25&##?6Y(WT5][8NFEZ7KW1O*72#3?6Y8VDDC>Z5@4VY'WT5][G4,LT
M/<=KB/H:2KR5=[:R.^U*="BF:1.+X,K6LRS3R<)#/SY53X=#(G[(.VMV,7$X
M*.*'O+65ZQ.&-G(X+*(+?LY?#HQSB8QE5W`X,LYG0^-R:,2/K*96_8]R.HVJ
M^&%3TTJ:>$D>=S;GS</=,?XHT>!(]Y_>-V*H=7QAC#,X;>8LIZ^E-.6RL/)%
MF+DO4^-1LIYH'/KQX-9O[RH_:.S82LTC:AQ5T6:%&"B$V8X.NCKHZ:"O@X$.
M`AT,=3#20<C@4CW/4WT?LX1]G^A@JH.9#N8Z6.A@J8.5#M8Y4*$89X&F1/PW
M`BW,B$!S-1\97)K&55NFS0J^I:.#K@YZ.NCK8*"#0`=#'8QT$#*XN.YH?7;,
M$O9]HH.I#F8ZF.M@H8.E#E8Z6.>`$E4:(_^-J`HS-/<JZ=M4P_@H-32T9CE>
M5R7M3,+-U0'2!=(#T@<R`!(`&0(9`0DS<K42XTS"E9@`F0*9`9D#60!9`ED!
M6>>)$GN:[?Z-V`LS%'OSV"U%IN!G$FZW#I`ND!Z0/I`!D`#($,@(2)B1Z\'/
M)%R)"9`ID!F0.9`%D"60%9!UGBC!IT@HP2]><?/T+-1)C+E:CY+01BS+9K?>
MTO(Y$_%M'2!=(#T@?2`#(`&0(9`1D#`CN6HT:FHUQIF(JS$!,@4R`S('L@"R
M!+("LLX3):B4@Y\(JE"K094DW6F)!50;2`=(%T@/2!_(`$@`9`AD!"0$,@8R
M`3(%,@,R![(`L@2R`K+.$R5<M/+_1+B$6@V7)+1ON.2@5U4[;SL3<>?M`.D"
MZ0'I`QD`"8`,@8R`A!G)5:.A+0W&F8BK,0$R!3(#,@>R`+($L@*RSA,EJ.+1
M5'Y#9!Y8A5H-:DKJR7.39!/3!M(!T@72`](',@`2`!D"&0$)4U)SLU7]&,@$
MR!3(#,@<R`+($L@*R#I/E'!1\BCA2O>O-^+YS?EUM_WV&%-NT9ZH((PUVJ>F
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M*`4S6S"T=UF5+]%I:H]$>E+EBIGDQX/3<&M-;=W3+S:DC1`#5AF="EAE=&JH
M.>4UR"]U33DJ-J0Y%1:I7$^S-98J<ZM/V):Q@E-6&2LXDRIN]8(*SHL-:15<
ML,KHU))51J=6NE.U9E7K"NMB0Q>GU*013_SR2?-'"QOQ^D7/I12)UTU9_W<]
MS=>VO+&NJK1GWAVI<FF'E-DJR*6"$D'58U>K22[5G*JV$>IS87F7P,R`54:7
M`E89;0U5EQRWI?7]D969L$@%+3Z6*G.+3]B6L7I3J?)HY7`]+C-6I6LFK-Z<
M"S.VTH)51I>67)C1I16KKKFTYL*NN:3FD'AT:LHARY63?`*;>^DAWDU27BD3
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M/EJVQ8DQBSE*JNA/%@^(;=?*5H]5>5MN`[9+!7[EVS#)T4&1+?`K8!6%Y;KW
M0U;E_7*:6BZ,6&6T%5JIQE:JB95J:J6:L4JMH[8,G[/*6,>%E6III5JQRNC7
MFE77_%+S2KPBRR_R_FR^DB_:\FN_%"GS%?2YMCA7*6:B_-@$J@ZKC&-35ZK,
M8V:/553P]5[>YQ*-?@U89?0KX!*-41NRRNC7B$LT^A46J=R&EJ/C(A6T_815
MQCI.I<JCAT"Y5M56`3-6I4]2:U5'&\[F7)BQ>@M6&5U:<F%&EU:LD@]WW9KV
M)'G-A5US2<TF4F$VT9%H:A;QGI(G*?N7EB(S]`DK1<J$Y3:TT:DM;U14$-T.
MJXQ]LRM5=;4-M.CV6-5*GNTU6HXFZ'-AUP8F.5G)ZAE="K@PHTM#5J4N88<;
M6;D42E7^U3FB":(IHAFB.:(%HB6B%:*U@M2^2>D"?=/U1-^$8^!*9_W-ME^8
MU594*<J?CA!;#5+E4`=1%U$/41_1`%&`:(AHA"B4B()]&<K<AM:7QQ<5O^Z=
M()HBFB&:(UH@6B):(5HK2(F_^/X`XW^;'**`#F".>6)*C3DCM=6T1^GMBXI;
MK8.HBZB'J(]H@"A`-$0T0A0RNARS&R.:()HBFB&:(UH@6B):(5HK2(WYYU[*
MBD]#M%QF=&F&-J(.HBZB'J(^H@&B`-$0T0A1B&B,:()HBFB&:(YH@6B):(5(
M?,"7M'W2T&D0TP_RT@]Y]M'Q)6I';V^GTC;^+CZVH^,"#W<93K\$I,'+%T,`
M99=^Q:W21X+)>36XDGT^J%^I^W0TN<"6Y]/IU@+>\.D890&_]>DD7@%O^G3D
MJX`[=($F,KSRI>Y_H8;""X]UGXZ"%W#/I_/$!;SATRG5`G[KT]G'`M[TZ41=
M`:<&%Y-(P15J<#&N%%UQZ$I1+>A#SB_)\3PM$(]T0Y$^I,@5\4>7"B@H.72I
M#Q3PQYI/7U&@IV'-IP\3D'=;/AU60QZT?#I(AIQ.!/GB"!!>H9,[OCBJ@U>F
M+9^.<R%?MGPZ:H6<3M'XXM@,7J'3+KXXWD)7*EG#TO>I[YN7:+PYONP.I]);
M]$PI54TFPV/ZA6OZG[,\=O4U/M.'J<D)K%?Z$CFB8]=5L71ZCN,S_T<4D'W;
M_/`/````__\#`%!+`P04``8`"````"$`U%D0#<L)``".,P``&````'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;*R;;6_B.A;'WZ^TWP'Q_A:2`*6H[55+XH=H
M5UI=W;O[FM*T10.D`F8Z\^WW.+$3'_]SH1G-FU)^/C[Q>;!S[(3;W[_OMH-O
MQ>&X*?=WP^AJ/!P4^W7YO-F_W@W_^E/\-A\.CJ?5_GFU+??%W?!'<1S^?O_/
M?]Q^E(<OQ[>B.`U(P_YX-WP[G=X7H]%Q_5;L5L>K\KW84\M+>=BM3O3U\#HZ
MOA^*U7/5:;<=Q>/Q;+1;;?;#6L/B\!D=Y<O+9EVDY?KKKMB?:B6'8KLZT?B/
M;YOWH].V6W]&W6YU^/+U_;=UN7LG%4^;[>;THU(Z'.S6"_VZ+P^KIRW9_3V:
MK-9.=_4%U.\VZT-Y+%].5Z1N5`\4;;X9W8Q(T_WM\X8L,&X?'(J7N^%#M,@G
MX^'H_K9RT'\WQ<?1^W]P?"L_Y&'S_*_-OB!O4YQ,!)[*\HL1U<\&4><1]!95
M!/YS&#P7+ZNOV],?Y8<J-J]O)PKWE"PRABV>?Z3%<4T>)357\=1H6I=;&@#]
M'>PV)C7((ZOOU>?'YOGT=C=,)E?Q?!I-9R0_>"J.)[$Q.H>#]=?CJ=S]KY:*
MK*Y:2VRUT*?3,KN:7H^3J(>2Q"J9-$JB\U>E\55CI\^.JYX9[LQVI$E@.UZX
MTHWM0)_]KA110&O_FLA:UW5:-:H#4\4Y79U6][>'\F-`DX>DC^\K,Q6CA5'G
M(ES;U\3\[T).L39:'HR:NR%93L$\4IY^NX_CV>WH&^76VLH\HLQTRD663L1D
MDM&;AB`+@0B!#($*@0Y![H$1^:5Q#B7<KW".46.<XZQZ=*#U5G0=>,*)N#YI
M"+(0B!#($*@0Z!#D'F">H-GS*SQAU-`:P-(DL/S1RM"T:W)I$CBG$6F\`R0#
M(H!((`J(!I+[A#F)EI9?X22CAIQT?C)9H7->:D0:+P')@`@@$H@"HH'D/F%>
MHB$S+W7?2]S"8J0K9S@C'BVAU;7)CSB>!QG2"+EN*9`,B``B@2@@&DCN$V8[
MQ;2'[4::VV[)3;.4+(&D0#(@`H@$HH!H(+E/F*'7O0PUTMS0FDQHJGE!O@F"
MW`@U00:2`1%`)!`%1`/)?<)L-\6O?TL]G^!&FMMN2=P&&4@*)`,B@$@@"H@&
MDON$&4KU"C/4U`[Q](JROV?U8!1Q'UA"MZ,V_LDXB'\CU,0?2`9$`)%`%!`-
M)/<)<XLIHYA?SB=`)<ZM=\A+`40IH@R10"01*40:4<X0M]F44'[2FUR8)5?7
M_9/!%,M!-CC$TR$*TJ&5:O(!489(()*(%"*-*&>(N\C45KZ++J1%78I1&>"L
M>8PL\M,"4(I2&2*!2")2B#2BG"%NLZF5?)M-6B1SLUGLNT9$MNSR_6$1^<!;
M)>(P+1HIY\C4Z6H=F2$2B"0BA4@CRAGB+C*%DN^B"VEAZRK?#36JSP&J;=,R
M`I0BRA`)1!*10J01Y0QQFTV!Y-O\TW<.<Q@1+A86T?KL94429D4CU68%H,RI
M;PLN@4@B4H@THIPA[B%36?D>NI`5MA#SL\*OS6Q6`$HC0!DB@4@B4H@THIPA
M;K.IJ'R;359$T^H><GK;K+\\E@9T'D4D=.9@3R+JNHRMFS4R^=AD1#2'V\=G
MI-+(JH_J0XYQ%"PW62O@$DM8=/[Z\E-2JE5?';*,H\`,W0JXZ^>7-/,HF'+O
M7!3^+-__+@JTK#=AL%6CGY$U.N^&9?09J=1*)4ES=\P0B4_IDI^24JA>(\HO
MZ>*N-B5DZ.IX5MT=+\QW6WSZWJV1&4"3Y'$2GIQ$5HH^&BF8"JF3\G5%\V"/
MG3DIKBLXSA%.BNL*LE8Z*:XKD%).BNL*QJ6M5&S6A&_WL^GT>AX<1>;=BMK+
ML3#%_>KY2IS7\Q:9JJ?Q>IR$AY].BI;D1@ICXZ1\72"5N4&,ZV4JN9Z'J2`^
MI4@ZJ;.#4D[J[*`T']3-;)9,6I=7JW=^21$/3+CI.#]I8MQ8.%0_NS`GSDM$
M*:(,D4`D$2E$&E'.$+?9%/S^FG'!9KL_\!:*N-DRM&D6)\$,6;92[C:2(LH0
M"402D4*D$>4,<3>$&XL+;L#-`RT/5>78EG9+1"FB#)%`)!$I1!I1SA"WV13U
M/4)?[P'\0BBVB&^8@A5[V4JUH6\Z.I2AE$`D$2E$&E'.$'>#*=-[N,&(!\NQ
M1>WV;VF69B/5HA11AD@@DH@4(HTH9XC;;,KT'C;;JMZ?]37B)ZI)<.M<QHV4
MBW.**$,D$$E$"I%&E#/$W6"*[QYNL+6Z[P:+VC@O8T`IH@R10"01*40:4<X0
MMYF*'6:SV15-Z5;6\XPU-GJ">6"17W3%27C*[CJV"V6**$,D$$E$"I%&E#/$
M_4.C9_ZY<"<PXH$;+&)NF(2'S7$CU4X-0!E*"402D4*D$>4,,3<D_8K42IR[
MP2*^0H0%VK*5:MR`*$,D$$E$"I%&E#/$W="O)$RP)'3(*PD1I8@R1`*11*00
M:40Y0]SFL"0T*\3/G;W3_2^<'0[QV1&<>BQ;J38MK*YVW<A02B"2B!0BC2AG
MB+NH7[E(QPK@!HO\M`"4NHZM5(9(()*(%"*-*&>(V]RO7$RP7+0H6!'"D]16
MJ@U]K8LZ.I2AE$`D$2E$&E'.$'=#OW(QP7+1H3:H2T0IH@R10"01*40:4<X0
MMSDL%ZN3U%E]E-JS;J#]`\P%B_B2$!XUN8[M_$\198@$(HE((=*(<H:XC_K5
MD@G6D@ZU!BX1I8@R1`*11*00:40Y0]SFL)8\7RLE6#):%"P)X4E6*^7F?XHH
M0R00240*D4:4,\3=8.JVSV\C$EOF>=L(A_PEP4JU*$6I#)%`)!$I1!I1SA"S
MF9X.<IO-DO!S3V(K5;QV=(BO".&94BO5I`6B#)%`)!$I1!J1>5VZ6L^J65N[
MJ'[]N7XM=E<<7HMEL=T>!^ORJWFU>1+3&6J#Z_>N'Y.;A7$VV1&V3,;NE>RP
M)4FH3W5+A)8)M4RZM"53:JE2"OK,J*5*26BYII;K3FUS:IEWM<34A_:@'?;$
MU(=V7UTMY`/:D'2T).0#JM&[6NB%=:IDNUIB:JFVY:$],?6A`]&./C'UH3/"
MKA;R-9VD=;60K^EPJ:N%?$U',%TMY&LZE>AHB6AL],I'5PN-C5Z,Z&JAL='[
M`%TM-#9Z/-;50F.CI\5=+30V>J;:T4)=.GM0ATYY2H'.#*`$Z(P_A;\S^A%%
MG]X4PA'1P].%>3Z*+?18<V&>7&(+/>FC/EW7IR=RU*>KA7X5\=#M>1I8QS4>
M31IU<3-A._C#9/%`RP@.]I'B5X5OU.0P_1KB??5:_'MU>-WLCX-M\4)+RKAZ
MIGVH?T]1?SG9IZI/Y8E^!E$]8'VCW[T4]$AB;-ZH>RG+D_M"%QXUOZ2Y_S\`
M``#__P,`4$L#!!0`!@`(````(0#0-JDU2`X``&]0```8````>&PO=V]R:W-H
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MF[SOQO;X"!V`OQ>'O1\:D)'-C_[G]_W=Y>%V650WVF2%`GSQ:7>^?-S[D,O%
M]NOY<CS\#R'E._4:)*<@\)."J&QVD(*"P,^7(.5-7FNEJQE=*2D*_*0H.?QS
MH@Y0W"<#?M*;IR=CC8GMZ]1M+IL/[T_'[PL8_)"Z\_/&3R7U#@+[`A50YN$"
M05+]>W[W;^K?"O091M6W#Z9ZO_X&`V%+2#N`&([8`:3F2#>`-!QQ,5)GK\@:
M5+Y*A?J'4M,2/7R[A+]?)=;J-6R?A181J-\K4G+"CA+=*.%2!),'(W.Z/`\+
M>3GO?(N(Z<M;9/`??]V&KS=-(U[NPI=AU57B=8>O#V>/Z0)DNBX/"UT%[W>+
MR'##?6$M$G6OW"N3TKO1$"Y%,'4PYZ:K\[!0)X9<BPCV71D]4#=&E%K,RHZ]
M;,I:ER*!#HGA!#)M%=<V;6WQ;Q(:M:@@(L,=P`HB05DH=55+E:,A7(I@*@U7
MF5Y6/,S5&9'>%A'L^ZHR>5Z+M=4BD=#?C1(NU0J3YZU8L$&DY7F8RY.=;Q&A
MTJC,&"6&L.5$6<K:L==-56LM4NA"0J:0B6OFB/.P$">ZUB*2J(Q%XD5^6<9#
M<S2&2Q%,GH*=?'KQ>EH(%+5IB<'^Y_G0^L(05<OQW;'7\[RL52[2Z`@)\YA?
MMR<NT>__P?B<ML@H=`VPM[[NW;5<98@).R&R80FA:H)4)49B-Q[$)1&NU7N!
M0&MZ+BIT#J%&68N6&!2PTEF35;FP.9:81!ZZ<<2E6^(RO368+A.-1"BS%C:R
M5<B03&6*O,G$F+.,4461"\/2,:#,5%4%1K/?=AQ#5MI4K!TN$O(Y0Z2GQ=04
M1KA5R"3J9`FA\>HU1M9F/(I+(ERDMPK3*XG&@E52S+C67SQ"(E!!,;S^A(BJ
M,Q&B$R%@_6G$!NL("5/YYOKC?4(@<>+Z@^Z"28W6GY0#09NC$*%ZUEEA1)".
MB%")R(=+(KR<WC0$6D?6'[08H<9X_6$VI%!-7M2B?U8ADY#0C2..$%H"9$M<
MIK</TV6BV0AERFNA5C%#HBJC\R9:9D-&:96+/'0LB,FKLI87W8XAJ[K1K!TN
MTIN(Z2+1<C"10D"K4K:$QBLB-%Y!X\"`'8WBD@TQD?DL_]/38I$516B)0065
M`>^BQ3YA&9+#ELJO7CKV>F5,HRJ!.$+"(?_6^I/_DO_IWR6DBJ6C)2;LA,B&
M)02SD6=UTUQ=6E_Q;CR(2R*\G##^IH_9W--<8[3^$/.R*FC8$<M(),9)Y*&C
M,`G$I5OB,F?YGSSV/[(*+3$O\\X4C1+5MAPQN;PJZSA00IZR0NZ;C%G!$@:6
MN+BVQ%5"MF84T].\F(WPVJT_2@4F405+""4"5!:5\('=>!271+C(60;('R0+
MD7(W;(E!!67ESW?$ZF$98BHMC&+'7B\U[+FE6,L=(6$JWUR`?LD`Y1,,$#%A
M)Z*Y&1H@+U4FHQL/XI((+^<L`Y1/,$#$T`*D35'"?L`W#$M,F(>@&+3.QB9)
M,B[=%A<ZRP+E`Q9(5*HEAL8M+$#2WUA&]$L'ST/'`%571548,7L=8U:JSO-<
MY==EBHOT5F.R!<K1F#`+=%W:^BJTQ(25$GFPA&`>O,H\7H'&+5"R(2;2W\R9
M+K*G^3(;K4#$H(+"GX[+26<94I6-2$+'7B_JIM#9M49]*ATA82J#`<TE_I(%
M*B8<`1$3=D)(L81@-D`J2!'#=CR(2R)<ZRP+5,062%[KML10.94NY.F))2+,
M0E`*7']&H[AT%"YRE@$J8@,4^3QB4.2JU'4&EQZ\3I:8M$QL*\6X=%M<*`2:
M,3D]S2=G(T2T!3(HU)2Y/!"P#(#SRFCU80#<?"AU;L2.Y!BS`@C265WM&-<X
MRP(5L05JY&D>,6$1HEF)85X&=5%52F2J&X_BD@@7*4Q0^F2D&#`_0D%+#!52
MZTQ+DV894L-*S`=TQUXWNLSA5($CCI`PE<'4YA*%]YEVT%7$'B@Z:"<F[(3(
MAB4$L^&EEO)"<SR(2R)<ZRS[4PS8'[&=M<2@@%SG129&M24BS$)0"EIEL:6W
MH[AT%"YREOTI8OL3K[+(8/=65::+HA)ULA0G+3,V0#(5CN*\T1836LZR0#TM
M5EEQ!=42@XV#R2S@I)_/+,N0HC'1?78.9!4PA9C!CC&KO(9;G2:_FDZN4KB@
M]!)4QNY'21O7$A362DY,0C`37F9\N3D>Q241KG*6_REC_Q/966)0035X0<T0
MN'DD)G?'7H<$@*47>7*$A*D,AC27*-S/M(6VC%U0M-`2$W9"]-,2@MGP4N6@
MZ,:#N"3"M4)?IAN@TM-\:JI,;&DM02\CLJ[EDT>6B+)_OJ>J1`HZ&4"5HM[N
M-<#U[O&;Q13N9V(Q8Q>D,K'"M"5"R6J&-@B4RAC=>`R71'@Q9YF@,C9!T;4)
M,5C+'$Q0):IMB0B3$)0"=\W1*"X=A8L4-FADF8WM3[1KELB@R)4&IZKEHX:6
MF+1,C)-B7+HM+G26!RIC#Z2RZQ5!7XB6()J:_O!2BT%M&5(:$SW\PX#"P)98
M*3$H'&-6!3Q!5!3!`0.7.<L%E;$+4O(&<TM06`BQQEA",!->)ER@<`/1C4=Q
M282IU+,L4$_S=3;:-HE!!;AK"O=B&3+PA"A[7?OG+.52[0@)4QE,;RY1^)]I
M*ZV.?5"T;1(3=D+6DQ#,QN`CH^-!7!+A6F>Y(!V[H&BE)08%Y%53*7E]0D28
MA:`4N-*.1G'I*%RD\$'IE5;'_B=::8E!D2OPTG!S]NJF>PF6F+1,;"O%N'1;
M7"@$FFZ"M*?YY%1214L0*BV5AD<%(J$8!Q%MC#P/ZWB,4L%!4"$NA!QC5F4&
M=P7S8#GF,H45&JGGD`421JS5XQ:(D*O,>*4=C^*2"%<YRP3I"2:(&%2@X)F)
M6FZ:1*3&8S<:Q:6C<)&S3)">8(*(09&P9>>ZD4\.6V+2,B>8H'1;7.@L$Z2'
M3)`X=VP)0J5PNJKDSF\9,3@SL1T,`3/./V@H[(-C058EW%?,5'!:S%7.\D!Z
MR`.)W:(E**Q5M&=B'%3A90[,3$0245RR(::RFN6!>IHOL]&F20PJ@'6O$NN3
M)2#L?[1GC@5QZ2!<HO!`Z26VBKU/M&42@Q)7)7P<(1:)8=(BQQF7;(K+G&5_
MJMC^J$QL9"U!J+,`+QK-2D8,S4H&P*PT-?SAIMXQ!F9E4X#UOUXF<96S_$\5
M^Q\E[71+4%@J.2L)2<W*\2@NB7"5T)GIYJ?R-)^5T94),:2@,$UTC\LRQ-1-
M8%G0R#)`PZ??X#-$LI38E3"7P=SF&H7SF79I4L4.*+HT(2;L1%10#(/IZ+7*
M&TG=>!271+C860:HFF"`B$$%JH%;[+P4EH`P"T$IJ*+8T)M!7#H(ESC+_E2Q
M_5%RP+4$8??@1AT<6DB71TA:);:5"./28;C.6>ZG&G`_2HAH"<(.KN!9`U/+
M!R8L,6FAH04:CN/2<;C260ZH&G!`\I,_+4&HM##P47%Y/D)$6F=HDH:BN'04
MIM+,<D`]S=?:R!X0\U+.$H[:&CD[B4G*G,"X=%M<Z"P?9&(?I.3CKRU!J!2>
M<X[.JBPCX,$*>$"?KU,=(TJ\;2@&A6/,"DXNX1$V?0W$9<[R06;`!\G'@%N"
MPF+)#840S`3JC.XKC(=Q283+G&6$3&R$(HM`#$J`CR$T32GJ8!E29K5\TK!C
M@(9GW^$6+J^W(R1,9K`O<8T`A39HFD4P_EU\BD86@9BP$U%%,0RFH]<:';N/
M1W%)A(O])3]D8C\$EUP\Y2U!-$UK97+A]"TCX.,;P?UT=`H,:"J8ZB)?CH@P
MI6_65;BAB76-79&2#S"U!J&P%Z*CEA":JEZKW(2Z\2@NB?#"SC)&9L@879>Z
MOAHM0:'*(-<]8XE!F7`^)B]1.P:L!@B7;H:+%*YH8DF'W)$8FZU!*!0;E30T
M/EZ)CM6.1G')AKC:6<[(Q,XH.C4AAJKEG\P3)M$2$:9!UKP;C>+249C(>I8Q
MZFF^ZL:&GB":>@T<&&A92D*2,L?#N'08KG.6+ZJ'?)&H54L0ZH0[`-I_#(PO
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MOLUMN;@_'B\OO_BOI'O]JL`/_P<``/__`P!02P,$%``&``@````A`!<-_W5;
M"@``$#4``!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6R<F]MNXS@2AN\7
MV'<P?)]8/.D0)!FTCCO`+K!8S.Q>.XZ2&&U;@>UTNM]^BR)MLTH**4]?I!/[
M4XGZ657\=;K_[>=V,_O1[@_K;O<P9[?1?-;N5MWS>O?Z,/_SC_HFG<\.Q^7N
M>;GI=NW#_%=[F/_V^/>_W7]V^^^'M[8]SB#"[O`P?SL>W^\6B\/JK=TN#[?=
M>[N#;UZZ_79YA#_WKXO#^[Y=/O<;;3<+'D7Q8KM<[^8FPMU^2HSNY66]:LMN
M];%M=T<39-]NED<8_^%M_7XX1=NNIH3;+O??/]YO5MWV'4(\K3?KXZ\^Z'RV
M7=W]_KKK]LNG#1SW3R:7JU/L_H]!^.UZM>\.W<OQ%L(MS$"'QYPML@5$>KQ_
M7L,1:-EG^_;E8?Z-W362SQ>/][U`_UVWGP?G]]GAK?ML]NOG?ZYW+:@-\Z1G
MX*GKOFOT]V?]$6R\&&Q=]S/P[_WLN7U9?FR._^D^_]&N7]^.,-T*CD@?V-WS
MK[(]K$!1"'/+E8ZTZC8P`/@YVZYU:H`BRY_]_Y_KY^/;PUS$MRJ)!`-\]M0>
MCO5:AYS/5A^'8[?]GX&8#66"<!L$MK!!&+_EJ6(JOB)*;*,DERC)U*$LS&'U
M*I7+X_+Q?M]]SB#U8."']Z5.9'8'@4_RF(,Y"_:57B"4#O)-1WF8PP!!B@-,
M\H]'QL7]X@=,S,HR^0B#B>)$Z%G08<O3!Y>P2N%MJA-RVJ8V'\#/\U!4C+=I
M1I#DC"Q`F+,Z,'&N.N-)<Q)!PUJ$TU!R\X$[%'[>37^`Q9!0*4;*(<(N@^VC
M5",(B5*/("1*,T0NHT6BB&M$T3#4C#,=C$M\B+EAI,,0H@@299"H@D0=)!H?
M@32"@YF>.!I^F(/^YY1-:/$8).E+ZT:FF<@4PRH6"%$R!83(6"(D%3'C$:TG
MA`@I99(1I$:(4HD4,B;C;1`31[%()+N,!DD%3=&52G<@^66#/M6:WHBF%1EG
M;A@8R5G6RPA,^06),DA40:(.$HV/0%I!AW6U\O<C#>.T8IRTPMPP:9]7/)4B
MH5GE`GK-BR*<=J4+<,Y%1O=1(8(E0B2D]=0N$4>*1X*,LT&$$+&,+C&00K"&
M35=(PU2A2]P^1W+#N%G$+WW1I-$)T>N>Y!D1R/U6I43?ROTV%J2,:O.MF1[!
M8RYCLN_&1R!AM*%U%GI_ZF@8"Q/3ZC*(&9ID`TW,US[9RC!2A9':'8=2$4MI
MZF!`BNBR-B*!LFL$TC`6B/%+7),YAO%)4!C$B!@G*6-D\*4+)(F"/HJSJW(!
M6%D%[<2U"V21_H<C-!X`Z</`>[L9I!NU@,_\F=1O194B)9);R"N596RK8EG"
M24:6F%"<2S(C%2)D!*L;UJ)&`(=6EM%Z\Q%8+NTR)Q<<,YX4>0`R4;EE_"J9
M.#ZFG!"GFL#4EC$S<L/CD=SR(E@N;3\=N29FES&MKFQ,#'0ST&F<+&:,S&K!
M7(2G21R1S"@1<1.G2G*RGPHC3&0QJ>8:$W&6B4&WPDC&E,PN68P5TV;442Q0
MA\:ZPL^S&V*"+$8Y\_E;L]:%D3*,5&&D#B.-%\%:04%<H96F2<\2)&5R9B!?
MI143F-(RMJ\)&:67^>XEKQ`AX9H!60-J!-R`U29YU_C'@9727M3)JHEU:!RL
M6X?#\W_#F`-E#,X'B-LI]'49T-T2<E`<)0)N6!HQ$J)"A$R&%>CNXH8+D1$Q
M&Q0A3=SU$@NE+:DC5*#\C('%Y4<&GS,#N2E%VE`11LHP4H61.HPT7@1KI5VJ
MH]7$I#+>UDTJ)H@@.7,-\(U*531,*Q>!\X_8.1/M*ZQ$0820G+JH"A%*Q1$C
M'J9&!%S]2A-Z$M\@)%8B<98JK)?VK-?K99PNUHN8I)RY=AC.[\$Q8P]4(((S
MZA=+]+U@+"6[J"S@IC$]/:A#01H,@/-U5DJLE?:OCE:!.C1N%VM$VF7.7$M\
M(S.X!A*3Z2XP(^`JB4R)(2@QHSCC"2-,11B6*&HY:XR`:8UX3"\3-@3*A(IB
M?NEM2#).G+Q?LIXFUUKH:4AN(7?.2:468:0,(U48J<-(XT6P5E?9>#ZT\4R0
M]3RWD*L5K8]B`E-.8*H)3&T9ZX^%MO&TZ!L_@Q6#XII>D%S3U&N18LLM9$>8
M1D[?-*X4`RRE!K_$`!>*[**R@&]2:APD!2=&PS0$X2).+WO",FFO/;EO<>/,
M4=^2I)?D%O+(9*)88$PF!(S)9`"_3"B(&->),#ZA8&=7"*5ITJTD6>)R;B#W
M*`;=*HB4X2A5&*G#2.-%<%)I>^LDU32CI>]!TAJ4]'S'0JYFPZYE`OF8<D*<
MRC(F3V.I4GI.5`>)QD=@S:XR\MQX=%R(U,A;Z%1G<MA0"XOXI1J>#U#)JPEQ
MZ@E,XQTRUNLOF7D^8N;IY;?<0CY1"LO8W``C3KUZB0C%>);13EEA!-R;&)Q4
M$X1E+'*NQ/3+3N-GL&I_R=+S$4LOB=_.+604@7MQB<A(0A86\0E;3F"J"4P]
M@6DL,SYDK!NQ]Q,[VHC-IU=%<N[:?"'XF&XN$H\FFTM\D6PN$D=<<?H40XV&
MH@3<FLV<\QV;;&X8E;`8[M9]X2WT97EW&?`;_)XF%DQ>3AWZO><6.K6TF*=P
M5Y><.6)&,+B;.+@;AAEX!(82%2+@C@Y<Q"'I7&,DAGL^]/RL08C(X,Z'$P5E
MF+C*X?<T%8LZ?`L9L=38^`J,P/-$">TN91BI$,*RF`G2'&I+N)5/K$[C1;!4
M5UE[,6+MY25C;5X9R'8",D\]4M@X!N$JAG\D2HF04<$KC(P)7F-D;-H:A/C3
M2CO<JZV8,+X8?EXNTROJ\RWDF=,BC)1AI`HC=1AIO`C.+S@D5[-`W](T*47Z
M5$PN#"3[)QP@,VC+.GU]T9M:K/(<XFNFFL#49T8_)Q"GQ&`W]FN3YOI6[GFH
M6"-B\0,:C5A[1?:<B[!M+R8PY02FFL#4$YC&SV#%B,&?9B&$,=^X$B]S8KO7
MT*&3[EK8.)!GYXHF2!E&JC!2AY'&BV#-B,D/9-F(N:>W9G)A(%<(6FK%!*:<
MP%26L:M*`H_:DAY:!XG&1V"MB+4/:#5BZ>F#>KDPD%^K,%-.B%-9YJ15PH9:
MF3U]332^&%@K;6*=53&@E;&\Z&2;>N=<&,BOE>N=!=PX3(F_+6T4>XQP!B7H
M==L*(5QE#$SEN4?W_:!&B,I2!?>!,-)X$:25)"Y^6M_JMZ*K(G'JN86\FEG&
M*,)4!H_+X$,I$0&W)!)%^F.%""93J:C=KQ'"61+QP<KH1;!DQ,M/E&SDJCU]
M$BN7!O)+%F9*&\?(FJ4LH8I4$_94!Z,T/@)K1DS]1,U&S#U](B:'%SNT0W,U
M(SE4C"!T52@M8YY^EAQ.+.DCY-5(&+*G.AQ%OXBBQVMWE`K.G>>`C&CF11/S
M"L6VW;^V1;O9'&:K[D._1"+`9IX_/;_@\JU_OX5\GK.[HG]+A'Q>LCMXJ0'>
M(5B<OX#W4=Z7K^V_EOO7]>XPV[0OL*OH-@';MC=OM)@_CMU[_T+'4W>$-U'Z
M7]_@S:,67J6(;@%^Z;KCZ0^]@_.[3(__!P``__\#`%!+`P04``8`"````"$`
M0JMS-E$B``#WU0``&````'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*S=67/;
M2)+`\?>-V._@\/NV3>KP$;8GP/L^P)MO:EMN*]JV')*Z>^;;;Q:)K,JJ?UF'
M=U^F/3\D0+`R*TFB2.C=O_[][>NSOR]O;J^NO[]_7OOMY?-GE]\_7G^Z^O['
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MI`_O/EW),W##_NSF\O/[YT7M;=$_/WG^XL.[PPBMKR[_N37_?G;[Y?J?[LW5
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MG9Z_?O7`OI*!XXF&$7WDT-1T4-T_'G>BK_3!Y!]//5%)W?%$GYS#FB;1_:-Z
M6%OL]]1-7?-8#WFLG3VFXNJ:1O>/ZD%K)X_:4]/I:EKW?-QC:D;J(2./?$S-
M3#T,T>.>YXF.D/O'TP;W1'O02:C;1SZH5NU):""/S.B)#.JACMP_'C.Z+XZ-
M\]"'6Q=W%Q_>W5S_\TQ>W>3L;W]<N-?*VEMW,.W`QW+R/?EG+5EZL3M*X0[S
M_KDD3+KMK;R0_/VA=O;JW8N_I?=_K&(:F9@XHJD1KM&[P[92:*?02:&;0B^%
M?@J#%(8IC%(8IS!)89K"+(5Y"F4*"X4PJF=G\9`M-42';)7".H5-"ML4=BGL
M4RA\PO5Q"Y]>+TAG@7P62&B!C!9(:8&<%C:I+Z2T?7U+W_K_J&]W&%??^N0:
M"B$U]3@S38W075HIM%/HI-!-H9="/X5!"L,41BF,4YBD,$UAEL(\A3*%A4(8
ML5K2(98:HD.V2F&=PB:%;0J[%/8I%`7$IU?/I$`Z"^2S0$(+9+1`2@ODM+!)
MC8I97F%0S*?2M/-OE[4WN[WDC7'4FU_'Q=JH8N18OH&?QB%-'Z)CTH*T(1U(
M%]*#]"$#R!`R@HPA$\@4,H/,(25DX>6G0[CT(3J$*\@:LH%L(3O('E(4I)!W
M/:.">2Z8Z(*9+ICJ@KDNF.PBRG94[_*^"/7N/AX^\<V).XS[9&B*F^].JJ#[
M9H`/T<%J0=J0#J0+Z4'ZD`%D"!E!QI`)9`J90>:0$K+P\O,9X$-T"%>0-60#
MV4)VD#VD*$@-4I/$1!?,=,%4%\QUP6074;:C&2#E&,V`^SN]BSX4NHYNHQ+Y
M8.3[>NWL3=+9?9#NUH*T(1U(%]*#]"$#R!`R@HPA$\@4,H/,(25D48E\9/_Y
M("Y]D`[B"K*&;"!;R`ZRAQ0%27/_VK]I+9J,TE2;*,VU(4VV(<VV(4VW(<WW
M@:+*EF[\A,IVT7%E5W*\*N@^+#8A+4@;TH%T(3U('S*`#"$CR!@R@4PA,\@<
M4D(6E;SQ];"$K"!KR`:RA>P@>TA1D!HD36LX[4+S:D@3:T@S:TA3:TAS:TB3
M>Z"H9J6-/J%F771<LY5$C>3\9=*-?9`VDA:D#>E`NI`>I`\90(:0$60,F4"F
MD!ED#BDA"R^F&[\YCP=QZ8-T$%>0-60#V4)VD#VD*$@-4I/$5!?,=<%D%\QV
MP7074;ZCRI:2?$)EN^BXLBLQW1C2@K0A'4@7TH/T(0/($#*"C"$3R!0R@\PA
M)611B5RI#F\JSM,R]D&^C"%KR`:RA>P@>TA1D!JD)DE3;9JJYMJ0)MN09MN0
MIMN0YOM`41G+:$9E[*YFGY_\%I:/'GU!VQTI+O%*XH35XK[3]$&:L!:D#>E`
MNI`>I`\90(:0$60,F4"FD!ED#BDA"R^FZM^DEP%]D`[B"K*&;"!;R`ZRAQ0%
MJ4%BI@NFNF"N"R:[8+8+IKN(\AU5O5NGC<K^_D^)A_"XMI5,_R:U2&U2A]0E
M]4A]TH`T)(U(8]*$-"7-2'-225HH2:F$AOXFN<ZZ#%&^MDEKTH:T)>U(>Y(L
MWKB"D0HP/;61L6;&?!&8?7T5&/-E8,S7@3%?",9\)1PL+G6W$I6N5YX)/O&2
M8.VXHB77!#4/#:4H@>?IJDZ(TAU;I#:I0^J2>J0^:4`:DD:D,6E"FI)FI#FI
M)"T"V6F17(%:AB@=U15I3=J0MJ0=:4^2:5$5A2E%4Q5Z9D4S$Y<I`EG;Y/$R
M92#KFXS+%(*L<=JX>%JX%2P[+1YX!3@N>$757Y%]!0"UW+=Y7.,(46U2A]0E
M]4A]TH`T)(U(8]*$-"7-2'-225HHA?)9DE:D-6E#VI)VI#U)ZKK*6C@Q6:VG
M-3/F,V[V]2DWYG-NS"?=F,^Z,9_V@\5U[9:LGE#7U0J7[>H5Q5W])'G;[KYS
M%K\@MDAM4H?4)?5(?=*`-"2-2&/2A#0ES4AS4DE:!`I=7;X[&X_J,D1I[UR1
MUJ0-:4O:D?8DJ7[D5JJ?ULQ8I@BDJW/?3!E(5V=<IA"DJ]NXN/K=0M03JK]:
MM[+5CZ6L9@W4(K5)'5*7U"/U20/2D#0BC4D3TI0T(\U))6E!6I)6I#5I0]J2
M=J0]2>H:B92ZIF42+M_#8EPFY?)=+,9EDB[?QV)<G/:XKMTRU!/JNEJULG5=
M4=S5TV^LN*\*I%T=U&94A]0E]4A]TH`T)(U(8]*$-"7-2'-225HHR04]_Q&V
M_C*YQ+4,4:&K5Z,:%O[6C-J0MJ0=:4^2ZL=#2O73FAEK9<Q707@*4OT\GJ\#
M$^<+P9BOA(/%U>_6N)Y0_=62F*W^BL*[\*;[]GK\QKQ%:I,ZI"ZI1^J3!J0A
M:40:DR:D*6E&FI-*TH*T)*U(:]*&M"7M2'N2U#42*75-RR1<NCKC,BF7NF9<
M)NG2U1D7ISVN:[><9>O:77QWO\)X^L69:F',EGQ%<<-/O@S=K/DH;4TM4IO4
M(75)/5*?-"`-22/2F#0A34DSTIQ4DA9*<<-/+GDM0Y2.ZHJT)FU(6]*.M"?)
MQ*AR:YIL(V.^!DR<+P)CO@J,^3(PYNO`F"\$8[X2#A9/#+=`EDX,]]KRU&N6
MU4*;G185R<'\*W8M745LUGR4)K!%:I,ZI"ZI1^J3!J0A:40:DR:D*6E&FI-*
MTD(I;C;IVFR(TE%=D=:D#6E+VI'V))D656[-]91&QGP-F#A?!,9\%1CS96#,
MUX$Q7PC&?"4<+)X6,KR8%B>OW0\]GSPSW*&2%:V*9'C,S$A6&IONMW1NQS"1
M6Z0VJ4/JDGJD/FE`&I)&I#%I0IJ29J0YJ20M`H51K;],KJ8M0U28&1CH-:,V
MI"UI1]J39&;@(>6=%"U3`_).BG&9*I!W4HS+U(&\DV)<7`G1S'"_UXQFQOU7
M\P_A<?4KF4\(I!:I3>J0NJ0>J4\:D(:D$6E,FI"FI!EI3BI)"Z70S):D%6E-
MVI"VI!UI3Y(?*V46;S/6S)C/>'A2\J,E'L_GW,3YI!OS63?FTWZPN*[=^I5]
M(_1`75?+7>;]3KVBN*LGB^S-$*7]IT5JDSJD+JE'ZI,&I"%I1!J3)J0I:4::
MDTK2(I#MZLG5M&6(TE%=D=:D#6E+VI'V)*E^7P%Z%D4C8YD:D!_L<=],%<B/
M]AB7J0/YX1[CXDJ(J]^MN#VA^JL%.EO]%=FN#FJYG^K'EX+:I`ZI2^J1^J0!
M:4@:D<:D"6E*FI'FI)*T4`H-:TE:D=:D#6E+VI'V)*GK*FOAQ*2N:<V,^8R;
M?7W*C?F<&_-)-^:S;LRG_6!Q7;OUJR?4=;7<9>NZHKBK)]\1:=9]E,[\%JE-
MZI"ZI!ZI3QJ0AJ01:4R:D*:D&6E.*DF+0+:K)Y?,EB%*1W5%6I,VI"UI1]J3
MI/J16ZE^6J8&I*LS+E,%TM49EZD#Z>J,BRLAKGZW\O6$ZJ\6RFSU8^VL60>U
M2&U2A]0E]4A]TH`T)(U(8]*$-"7-2'-225HHA8:U)*U(:]*&M"7M2'N2U'65
MR'!B4M<TGW`3YS-NS*?<F,^Y,9]T8S[KQGS:#Q;7M5R%B>KZEZ_FN^LYR<49
MI:CAOTJ^/M(,4=J:6J0VJ4/JDGJD/FE`&I)&I#%I0IJ29J0YJ20M`MF&GUZV
M#%$ZJBO2FK0A;4D[TIXD$Z,JBG#A328&+5,#TO`9EZD":?B,R]2!-'S&Q940
M3PRW*&8;_B_>,:E>+:[95P*LMS4U*KSE;Y':I`ZI2^J1^J0!:4@:D<:D"6E*
MFI'FI)*T"&3G0'+9=QFBPAS`V*\9M2%M23O2GB1S``\I<X"6J0&9`XS+5(',
M`<9EZD#F`./B2HCG@%N+2^?`+RWUUJM5/3L+_$)?2&'M5?(ME*;N&!I(B]0F
M=4A=4H_4)PU(0]*(-"9-2%/2C#0GE:1%(#NJN,;CQSY,#-`Z'$NC-J0M:4?:
MDV1BX"%E8M`R-2`3@W&9*I")P;A,'<C$8%Q<"?'$D'<TT<1XX`JG"T^NW%<4
M&GZS#FJ1VJ0.J4OJD?JD`6E(&I'&I`EI2IJ1YJ22M"`M22O2FK0A;4D[TIXD
M=8U$2EW3,@F7NF9<)N52UXS+)%WJFG%QVN.Z=NM7MN$_4-?5<I?MZGX%S/:?
MY*LF37?CSF0]EM0F=4A=4H_4)PU(0]*(-"9-2%/2C#0GE:1%(#NJN,:#45V%
M';6%KTD;TI:T(^U)4OTX"ZE^6J8&I/H9EZD"J7[&9>I`JI]Q<25$U>]N"ON$
MZC^$QUU=R71U4HO4)G5(75*/U"<-2$/2B#0F34A3THPT)Y6DA5*X?+$DK4AK
MTH:T)>U(>Y+<58_KIXV,-3/F,QZ>E-Q9C\?S.3=Q/NG&?-:-^;0?+*YKMWYE
MN_HO7^-Q-T%.WL@HR>M,^`+.J^2K(LT0I7VH16J3.J0NJ4?JDP:D(6E$&I,F
MI"EI1IJ32M(BD!W5]!I/B-)179'6I`UI2]J1]B29&%P>;60L4P-RQTGNFZD"
MN><DXS)U('>=9%Q<"?'$<`MO=F+<_W;GI%JG,V]WE&S#KZ("M1C5)G5(75*/
MU"<-2$/2B#0F34A3THPT)Y6D!6E)6I'6I`UI2]J1]B2I:R2R:&2LF;%,QJ7A
M\WB9G,O-5!F7R;K<3M7&Q77MEK9L7?]ZPZ\6R6S)^W4SVYJ2*PQ-=Y?\Y!T^
MJ4WJD+JD'JE/&I"&I!%I3)J0IJ09:4XJ28N*3J5_F9?1]()FB`H-_SC0LJ/2
MFE$;TI:T(^U),C'PD#(Q:%H#YM2DX3-.J\#&:1E8TSJPIH5@32OA:/'$<&MR
M=F(\T/"K)3Q;_16%[MYT?];!E7J@%JE-ZI"ZI!ZI3QJ0AJ01:4R:D*:D&6E.
M*DD+TI*T(JU)&]*6M"/M25+72*34-2V3<*EKQF52+F]D&)=)NKR185R<]KBN
MW=*6K>M?;_C5(IDM>;]N9EM3<O&A*>6/A@]J,ZI#ZI)ZI#YI0!J21J0Q:4*:
MDF:D.:DD+2J2)F5'-?F*ZS)$:7=?D=:D#6E+VI'V))D8QT3:)MO(F-:`C6ME
MXK0*;)R6@36M`VM:"-:T$HX63PRWWF4GQ@,-OUH>L]5_I-/#'S@[_+6:IMQ/
MQY6ZH1:I3>J0NJ0>J4\:D(:D$6E,FI"FI!EI3BI)BXJD$K2(EZ05:4W:D+:D
M'6E/DKJNTAU.K&AD3!-NGH`T?.ZK*;=QFG-KFG1KFG5KFO:CQ77MEJN>4-?5
MZI:M:[_@9?M/<H6A>>*C-'4M4IO4(75)/5*?-"`-22/2F#0A34DSTIQ4DA85
M22>RHYI\Q749HG145Z0U:4/:DG:D/4FJ_YA;VTD;&=,:L'%:!-:T"JQI&5C3
M.K"FA6!-*^%H<?6[1:TG5'^U!F:K'\MB3?EQ(-[&@]J,ZI"ZI!ZI3QJ0AJ01
M:4R:D*:D&6E.*DD+TI*T(JU)&]*6M"/M25+7R)IT=5HFX=+5&9=)N;R-9UPF
MZ?(VGG%QVN.Z=LM5MJY__6U\M?!E2[XB^<_/KS`TY5ZAAUD05A9:I#:I0^J2
M>J0^:4`:DD:D,6E"FI)FI#FI)"T"A5&MO\3;>(SJ*NRHKP%KTH:T)>U(>Y),
M#)R%3`Q:I@9D8C`N4P4R,1B7J0.9&(R+*R&:&/)6.YX8][^-/X3'*[-*X:U>
MD]0BM4D=4I?4(_5)`]*0-"*-21/2E#0CS4DE::%4#V_C22O2FK0A;4D[TIXD
M?^VI6DD-)U8T,N83;N)\QHWYE!OS.3?FDV[,9]V83_O!XKIVRU6/;/AW7ZX^
M_MFXEMXM.V7J_T3^'.OQC[3*.Z9##S?-7TEFG6G^29MJABCM22U2F]0A=4D]
M4I\T(`U)(]*8-"%-23/2G%22%A6YN^*%47V=?(5U^:BHE1X^^N3P.OGBU#I$
M:88VCSK\]E%1NW!X^X22Q?Q]B-*3D#EXK+G[AT*FY:/"?"'&@Y&L,16^.,/:
MA_RYMD<]@E;L`^?KJ]B>R*MD54;^TMOQ,67QV0^(5O9/'R#N`VXI+^T#\M>E
MW1^T.,S[Y?6/G\U[^5F#G_C5BJ"=^':1\'CYZA34(K5)'5*7U"/U20/2D#0B
MC4D3TI0T(\U))6E1T4\S>1C5Y:.B5GKX$U\I:]+F4<?:/BIJQ\/O23)_CT5Q
M_Y.4^?NHL&;F$7R-A:<ND_51A]/">^#D?#&:1_#5:$S+\:>'BZ>F6["T4S/S
MTFNGX'%]4ZX.:BMHG%84O_8FUX2:(4IW;)':I`ZI2^J1^J0!:4@:D<:D"6E*
MFI'FI)*TJ"A)8K(JM<Q'):_0*SU\>-.V)FT>=:SMHZ)V//R>)+/R6#K)DTQ.
M7V;EH\)\B86G*2^A57$:TR)[X%&U\!X(\\5H'L%7HS$MQY\>+IZ5;GGT";.R
M6DVUL_)(\CE!YUOS%-0BM4D=4I?4(_5)`]*0-"*-21/2E#0CS4DE:5&1NPV=
M>?N;-+:E1D7M+WV3O-*H^%A)I:\U*CY6\GYLHU'W'FNK4?&QDD?<:=2]Q]IK
M5'RLY+QD.A\++!FPY"%E.E=A\='2,"W7Y&C)9SJ9X<>CR>T./KS[^\/)V:O3
M-V=ID!9U<JST(;70W6W.3,;3,"W^Y&CI@^J$N/?,=(HDQPH/&;<%MU!MV\(O
M7T`]K;Z[8#M&1?&33W_-KCN:"ZBD-JE#ZI)ZI#YI0!J21J0Q:4*:DF:D.:DD
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M8'&INZ\`I*^7]KK3XZXW5U\2L:^51_KIF_GJ2E2UH[VZ5DNO>;9.?93.DS:I
M4Y'<RUZCNB'*OF@D;:L7HG3'/FG`PP]#E#U\<I%R%*+T\&/2A(>?AJAP^/32
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M$Y-2I_F$FSB?<6,^Y<8TY_*E%%/J?`R?=1/GTWZPJ-3/GO:ME4-X7.H5)1<_
MTB_I:E0XJY92F)-M)7E:OKW57B<?+SM5E-SR6$>B&W94ZBF%P_>5[CW\@(<?
MAAWU\",EVXEKKY/K1V,]UO'"5OW5V:LWZ6>LB<:$IS/5@X?1FBG=^WAS/=8]
MCU=J3'B\147NFX!^W.NUY(/X,D3I**Q(:]*&M"7M2'M2462LD;%FQK3D[,N%
MUIPUK3!K6F+6M,:L:9$=+9YK;@G>?I*Y_V7%_2GQY&6EHN0:07(AJJE1X6-&
M2RE\Y&HKR8=`G_/,7#N>A-RB1W/>#3LJ]93"X?M*]QY^H%'A\$.E</8CI7#X
M<475Q9[L%>.)[A8./E4*!Y\IA8//'W'P4G<+!U_H;F'6+DDKTIJT(6U).]*>
M)%.FJJ1P8D4C8UHX]B5&*\>:EHZU3N9X6BDV3DO%FM;*T>(IXQ;?[91Q%\M_
M[0_SG!W7\>VJ=T5V?8W4(K5)'5*7U"/U20/2D#0BC4D3TI0T(\U))6E1D72[
MT$7JM>0K8<L0I2UC15J3-J0M:4?:DV0:5!40IJQ,`UHS8UH$MM-K%5C3,K"F
M=6!-"\&:5L+1XFG@5L#3:?"3C^T/O*A4:^FA`3;.*K(IK+U)/E,V0Y2FL$5J
MDSJD+JE'ZI,&I"%I1!J3)J0I:4::DTK20BGTW"5I15J3-J0M:4?:DV065.D.
M)R:S@.83;N)\QHWYE!OS.3?FDV[,9]V83_O!XEG@5HG36>!>=Y[XQPO/CJO-
MT2M!1>%-0%.C`K5(;5*'U"7U2'W2@#0DC4ACTH0T)<U(<U))6BC9-E)/%^"6
M(4K;R(JT)FU(6]*.M"?)'*C2';T2T'P-F#A?!,9\%1CS96#,UX$Q7PC&?"4<
M+)X#;L71SH$'VGVU)FK;?44V3[4WR6>]YIF/TCRU2&U2A]0E]4A]TH`T)(U(
M8]*$-"7-2'-225HHA4ZV)*U(:]*&M"7M2'N2E'J5R'!BTNYI/N$FSF?<F$^Y
M,9]S8S[IQGS6C?FT'RPN=;<\^812KU8S;:E7%%IX\PS4(K5)'5*7U"/U20/2
MD#0BC4D3TI0T(\U))6FA9+M%O98L("Y#E':+%6E-VI"VI!UI3Y)2KW)K.FDC
M8[X&3)PO`F.^"HSY,C#FZ\"8+P1COA(.%I>Z6SRTI?Y_^)A;K43;:5"1S6'M
M3?(9K7GFHS2'+5*;U"%U23U2GS0@#4DCTI@T(4U),]*<5)(62J&9+4DKTIJT
M(6U).]*>)-.@2F0X,>GX-)]P$^<S;LRGW)C/N3&?=&,^Z\9\V@\63P.IT&@:
M//#FQH4GBQ$5V8X/:IV!VJ0.J4OJD?JD`6E(&I'&I`EI2IJ1YJ22M%"2,?+7
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M=4W+)+S(9%Q:./?-Y+S()+W(9+V(TQ[7M5L0>T(+K];/;`NO*&[AR<>HYKF/
M"BT<U&94A]0E]4A]TH`T)(U(8]*$-"7-2'-225HHA6ZQ)*U(:]*&M"7M2'N2
ME'J5M7!B4NHTGW`3U\K$^92;.)]S8S[IQGS6C?FT'^Q8ZB]NOUQ>WK4N[BX^
MO/MV>?/'9?/RZ]?;9Q^O__HN'_QK\NL!X\]N+C^_?R[C_U:FS>';^GZ7:M/9
M*]DDUYFDD+'IM=MT^!",36_<IL.EH'33^4OW6(??OF-3S6TZ?($1F^INT^$;
MU>FF,[>7?,;.G:';2[[WD=ODGK(LD.<VG;I-I]E-9V[38;1Q&N=NTZ%5I)M.
MW5,^?IK!)K>7_#HK<QJG;N3EMR:Y36[DY0OQN4UNY.5+RIE-9^XTY/N3F4TG
M[BG+C=]SF]Q3/KX=3D_^Q)W\<;T=F]S)RRU=<P=T)W_\-@SV<B=__+Y8NJGN
M]CI^7Q&;W%[R]]9RC^6>LGR;,+?)E<WQODGI`4]<V<C?.,GMY<I&_I)$9E/=
M[57/[E5W>\F/S7-[N9&7/]B>V^1&7KX4FMOD1EY^QIK;Y$9>_J9H9E/-[77\
M=4'ZE&MNKUI^+S?R\CWPW`'=R,M/\C.;ZF[DZ]F1K[N1/W[-&Z?A]JIE]ZJY
MO6K9:5YS(U_+CGS-C7PM._(U-_+R4X[,R=?<R->R(^]VRNYSZ`RY@[E!SV;*
M#7EVQ-V`9\?;#7=NM.7JZ%MWT9=/1:X9R9;L/M*(W96#S#[G-=F2&VEYFR=;
M<@,MKXJR)3?.\ET\.8/L/F>R3[8%-\Y.94MNF&616[;D,B-K@K(E-]"R3");
M<B,M]VI\Z^XWF1F#4QD#N;E:;HL\G^-O\)+JE9OAR);L&)S*\Y&[8>2.)L]'
M?F^>V2(]V?T-D]P6V2?;D>46\K(E.P8G,@;9?BPW*)8MV=HYD=K)=F/YF[)O
MW=_%S9Q;7?;)]F+YBX5RM.Q8G\A89SNQ_-$KV9*MG1,9ZVP?;D@?+K-MN"%M
MN,QVX49=QCK;A!MU&>ML#Y8_I"Y;LF-=E['.=N"&=.`RVX`;TH#+;/]MU&2L
ML^VW49.QSG;?AG3?,MM\&])\RVSO;=1DGVSK;4CK+;.=MR&=M\PVWH8TWC+;
M=QO2=\MLVVU(VRVS7;?AID^NVF2'[-R18<YF1@8YVP=DB+/5+`.<ZYUR\PIY
M77%WL.(,D%\JRC9WGZG,-GD-RU:S&^!,_.+PFI?9T'`UGO'%X3U(9D/#39>,
M+]SK8VY#(2]TV7XNSUW.RMT`,_/\Y*Z5[KGGMLD-"-^Z.PYR+[E1X%MW9T!N
MD<>2)^3NWY?9)C?=<X^5VR:_R'OK?FW'O;JR)?_V6'X>^=;]^)'[R(\=W[J?
M,G*+W#I5GE/NV<K]3.4YY;;(+=]DG]R0RZW99)_<%KFG@TR`7$7+C]'EF>9J
M6GY6+L\TMT5N'R#/-+=%?ODOSS2W17[.*X^3FR/RPUQYG-P6^;FU/$YNB_QX
M6A[GL.6%?Q&]_?#NQ\4?E^.+FS^NOM\^^WKY63ZOOCS<B/3FZ@_WU9GC_[FK
M;DCZ^_7=W?6WP[U)OUQ>?+J\<0'R%;C/U]=W^G\D92_^N;[Y\_"9^,/_"@``
M`/__`P!02P,$%``&``@````A`+(HXFD4`P``@0D``!@```!X;"]W;W)K<VAE
M971S+W-H965T."YX;6R,5EUOVR`4?9^T_V#QWM@F'VVB.%6:JENE39JF?3P3
M&\>HMK&`-.V_W[V04I-4F5^<<'TXG'LN<+V\?6GJZ)DK+62;D724D(BWN2Q$
MN\O([U\/5S<DTH:U!:MERS/RRC6Y77W^M#Q(]:0KSDT$#*W.2&5,MXACG5>\
M87HD.]["FU*JAAD8JEVL.\5982<U=4R39!8W3+3$,2S4$`Y9EB+G]S+?-[PU
MCD3QFAG0KRO1Z3>V)A]"US#UM.^N<MET0+$5M3"OEI1$3;YXW+52L6T->;^D
M$Y:_<=O!&7TC<B6U+,T(Z&(G]#SG>3R/@6FU+`1D@+9'BI<96:>+39J2>+6T
M!OT1_*![_R-=R<,7)8IOHN7@-M0)*["5\@FACP6&8')\-OO!5N"'B@I>LGUM
M?LK#5RYVE8%R3R$C3&Q1O-YSG8.C0#.B4V3*90T"X!DU`K<&.,)>[.]!%*;*
M"!V/IM?).`5XM.7:/`BD)%&^UT8V?QW(9N1)Z)%D#.K=^_%L*$GL!-G\[IEA
MJZ62AP@V#2RI.X9;,%T`\<<)02:(72,X(S,2@58-57A>T72VC)_!N?R(N7,8
M>'I,&B(VYXCIU$-BT.7%0<;#Q2$8Q:'[J/;.!?I*J%_&(C;GB/3:0P(E8,UP
M)0C."#R]!;3'Z\0YS*2'F?B5G;A+B$`;D`S7AF#0=KF&#G1)W"5$(`ZV]W!Q
M"+;B?`U=)(5"];R\.7'J".KKI?2]UH$>2'RX'@2'>EQDXC?9IA<(UKD.U\$+
M@R:3T35HO7S&<&*XIHNDX7Z:GWCP$8B./2C0AEUI\)E'<*C'17H>N``(Q"NT
M?W[GX4+#3<")X:(N$II`$Y^?.S(?@M[/5:`MA28PW`6+#A4=0ST?^I%P+;SR
M>H[;]D%OL%?\9S=`4SMUXA@ZL>+LDCW>LL&NH:?WK&MXKB$T7.WXAM>UCG*Y
MQV9&X8KW4=]HUQ3K?!J?+-:N`<?^#33`CNWX=Z9VHM51S4O@3.P14*Z%NH&1
MG>U#6VF@]=F_%7SJ<+C#DQ$X5$IIW@:XP_S'T^H?````__\#`%!+`P04``8`
M"````"$`C^V\$`<%```C%0``&0```'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6R<F,MRZC@0AO=3->_@\C[X?J,"IT*X!Q)"F)FU8P2X#K8HVPG)VY^6A2%J
M.U$R&X.;S[^D[E^2T?6OMV2OO)(LCVG:48V6KBHDC>@Z3K<=]9_5\,I7E;P(
MTW6XIRGIJ.\D5W]U__[K^DBSW_F.D$(!A33OJ+NB.+0U+8]V)`GS%CV0%'[9
MT"P)"[C-MEI^R$BX+A]*]IJIZZZ6A'&J<H5V]AT-NMG$$>G3Z"4A:<%%,K(/
M"^A_OHL/>:661-^12\+L]\OA*J+)`22>XWU<O)>BJI)$[<DVI5GXO(=QOQEV
M&%7:Y4U-/HFCC.9T4[1`3N,=K8\YT`(-E+K7ZQA&P-*N9&3346^,]LI5M>YU
MF9]_8W+,/WQ7\AT]CK)X/8M3`LF&,K$"/%/ZFZ&3-0O!PUKMZ6%9@$6FK,DF
M?-D72WH<DWB[*Z#:#@R(C:N]?N^3/(*$@DS+=)A21/?0`;@J2<R<`0D)W\K/
M8[PN=AW5#%JF[QB."[SR3/)B&#--58E>\H(F_W'*.&EQ%?.D8D'W3[^;/U>Q
M3RKP6:DX+=MT/-_X05^@UWQ$X/!*YG]TQ@A..B:KR6E07LOQ=.L;O=%XFLNJ
M]<,B[%YG]*C`3(`\YH>0S2NCS92K>O'DGBOX60&A<DSEALET5%=5H#0YF.ZU
MZ[KVM?8*3HE.3*_..`BYK1#F"Z;;YP&X?M!U1-U!]="%,41B6!&5[*@*7!YQ
MD.JX0JIG)C@PQ8$[')CAP!P'[G'@`0<6./"(`TL<>.(!N)Z3YKAB1E8-B'=&
M-/#&V2`PE02#-$_DR@>,9CZHLM;C@8]],<_ME"6^K1..+R+].N*Z:$2#.H,:
M&M8)W-"HCAB7M)3='3<@J+N3.N*Z2&;:Q""=NR8F$%,S:V`\763F30R:(O=-
M#$K@0Q-CB6TMFA@TRQ^;&#3]EDT,*OE3G<'56M61RZ`$F\-.\0.;,[JCPO4\
MPUP/5;C'&=@[S@S*PZV4Z$N)@9082HF1E!A+B8F4F$J).RDQDQ)S*7$O)1ZD
MQ$)*/$J)I91XDA*KKPC!WF##']B;T?#B]<&Z'IKG/8YXY59_9=BF'A@(N140
M2S=,&^_W?0%Q/=/TT1P?"(3M!U;@H*5K*"".[0."9MI(0'S+-4P=+3AC`;%L
MV_8"A$P$Q(;NXDUH*A`6O"H&>$!W`N+`ZUN`NS(3$=?P'!^->2X@KNY8EGM9
MV,J-ZEY`;,?730LM40\"XG@6C!DUM!`0R[%,W4;)?101(S`M'R%+`7%@R*Z)
M&GH2$<>S+=M%CEH)C*N[EF<;EZ8$P\-;]P\,SVC1\*Z'=N,>9Z`+GZ[G4J(O
M)0:<\/F\L@.HB(NV_*&`6&!3VT<[_DA`'-,P/0,A8Q$!CP7(0!-.?#'@J92X
MDQ(S*3&7$O=2XD%*+*3$HY182HDG3E3EM6W==/%+Z$ID`LN!V7*9N8++X0_7
M#US.:.QR9*X>9_BZ7IMA_(6=(U_XHB\E!O)FAE*1T4<16$D;5HSQ1\3V+-\T
M<;HGTG:F4N).2LRDQ%Q*W$N)!RFQD!*/4F(I)9XXP5W47!DX@V)F_,1HW.3\
MD(D?5R0DVY);LM_G2D1?V`&2#6OD.7H^V[HQV7]/%.\9;3A:J,<'1AO.!NKQ
MD=&&?]40U\Y"<$9U"+=D'F;;.,V5/=E`%_26!Y,UXZ=<_*:@A_)0Y9D6<#A5
M?MW!822!PPR]!?"&TJ*Z80V<CS>[?P```/__`P!02P,$%``&``@````A`$0#
M67^=#P``OUD``!D```!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULK)Q=<Z.X
M$H;O3]7Y#ZG<;Q+;X*_*S-;$@,&`P=2><ZX]B3-Q31*G;,_.[K\_+4MMD%XL
MRU.[%YO,PTM+=+>$6A#N?__K[?7JS]5VM]Z\?[KNW-Q=7ZW>'S=/Z_=OGZ[_
M\T?TV_#Z:K=?OC\M7S?OJT_7?Z]VU[]__O>_[G]NMM]W+ZO5_HHLO.\^7;_L
M]Q_CV]O=X\OJ;;F[V7RLWNG(\V;[MMS3/[??;G<?V]7RZ7#2V^MM]^ZN?_NV
M7+]?2POCK8N-S?/S^G$5;!Y_O*W>]]+(=O6ZW%/_=R_KCQU;>WMT,?>VW'[_
M\?';X^;M@TQ\7;^N]W\?C%Y?O3V.DV_OF^WRZRM=]U\=;_G(M@__`/-OZ\?M
M9K=YWM^0N5O94;SFT>WHEBQ]OG]:TQ4(MU]M5\^?KK]TQI77O[[]?']PT'_7
MJY^[QN]7NY?-S^EV_92MWU?D;8J3B,#7S>:[D"9/`M')MW!V=(A`N;UZ6CTO
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M)IB:(#9!8H*9"5(39";(33`W06&"T@0+$U0-<$OQ.0:)4O>?")(P(X+$WGU@
M4$>M,S`BPA(^)S!!:(+(!%,3Q"9(3#`S06J"S`2Y">8F*$Q0FF!A@JH!M(C0
MS/!/1$28^71-_Z^'36^D1^!!:6B:.XH\73(Y2HY1`A("B8!,@<1`$B`S("F0
M#$@.9`ZD`%("60"IFD0+&LW-_T30A!D*FGVR4R);U(Z28]2`A$`B(%,@,9`$
MR`Q("B0#D@.9`RF`E$`60*HFT:)&+M2BUKZPXAN14!^"PTY]D&1`-]?C^/&]
M.V,$'45\6@`D!!(!F0*)@21`9D!2(!F0',@<2`&D!+(`4C6)%@O*^0MB(=1Z
M+"09#(^WH`F0`$@()`(R!1(#28#,@*1`,B`YD#F0`D@)9`&D:A+-\92]FN/%
M,LVGY<*%RS1A1H^()`-:6#=&1\<8'4?1<70`"8%$0*9`8B`)D!F0%$@&)`<R
M!U(`*8$L@%1-H@6)EL]:D.PSE5#KL9"$8L%NG@`)@(1`(B!3(#&0!,@,2`HD
M`Y(#F0,I@)1`%D"J)M$<3]E[@>.%6G>\),8@Z!J#X"CBZ`1`0B`1D"F0&$@"
M9`8D!9(!R8',@11`2B`+(%63:+$0!?<%P3C(]6@HU!P'B`)$(:((T111C"A!
M-$.4(LH0Y8CFB`I$):(%HDI#>BQ$06E6]]V^V(@ZL3_%RZB.+$5ID<O9_J"0
MV"1HW"J,(G_"*LJ/HZHS-&XH`:N:MD`5*E6W=]A0Z`X'=WW#4'3.D.X.4<W]
MFCMD':BY0R+ARN.%^IY9F8FM)IILNG1C/ZK@0@-6-6V!*E2JWMW!'9W1H#OH
M]_5)*CIG2?>'J)1^S1^JQFJFAT1&>L`&3XL*KC00&V_D-<T6J$)665,M8M6I
M5-,](JJ0ID?LM_".*EJ:;I#(2`LC3!-UXKFT:+'5X@;5"9467L_O&;>NB)L[
ME5^Z#TBE^4!N"=Z(C=;]R_KQ^\.&4IGFAQ;?B)&J-@2%%6->ETB+JN^9&TYB
M[US$WAK50*EH8]\RKD*EZO</(V8T[/>&QGP5<7-NZ2'6Y\WT,%WSQ^;CE&LH
M(XZ^D<M\;3:12$L;"/6DXZ(*G%0AJ\CDZ9DI8I6(/>_L-ONE9XY8&=O<XY8Y
M<GVM>4<B+7,&D#A*="9QI,JG>;GU@@[9&XH]>4I"7]YY>KWA:.#!H&KIU&G7
M4'Y97>.8.<*,,:H4TB[(O"],A.O$B=WC_3Q`%"**$$T1Q8@21#-$*:(,48YH
MCJA`5"):(*HTI&<T)1.$K>O?T'"XL/(6\YD9.86:">M[0_V./N$3ZZHP0!0B
MBA!-$<6($D0S1"FB#%&.:(ZH0%0B6B"J-*1%KGM9&7*0ZP.+43,\'1A8M8H7
MR@&B$%&$:(HH1I0@FB%*$66(<D1S1`6B$M$"4:4A/3QF9=*RF&C<,;M8CC!J
MAL?WC(<GDUI5AT?9J@=4B*H(T111C"A!-$.4(LH0Y8CFB`I$):(%HDI#>GA$
MV=*\DY\)CZQRFK?LKD3#P\L3AYOJ!%&`*$04(9HBBA$EB&:(4D09HAS1'%&!
MJ$2T0%1I2(^%*(::L1"+3J<BG@IG\YZCD+CC'9<_OF\^#6%5<VPUES;RV3RK
MFK9`%2H5_1!O!72];F=H#-+HG"'=':+<^35WJ$*I4:UU6RHLWS<V&2:LLBZ5
M`U:=6BK+E:52J2+>ZP^&WLAH+SIG2?>'J)=^S1_B3..>)Y&>'IY9Q(LJA4[4
M5!#XP$D5LLJ::A&K3J6:[A%1)34]<F;RDD65-GE))%JM1PE4JJ)Z)S><*>)9
MU;0%S@J5BO=VNIV[D;&5%)TSI/M`%"<7^$#6,IH/6LH;WS>*H$E7J:SA"UAU
M*GQJ:$A;:J8X#`TC\Z)SAG0?4'.:#PX3)S7BOHO1%2:,(2*1GAN^L:TP42=J
M*HAZH%0^K56/>0:JD%4T5QU5].J;7B=$YUK474/Q`M=TZ)5!Y1RN1B_PE+!H
M>$HB;9J`JKVK1/3C>''@@D"ISE3MK)*W&K]/57L/W-32J69[FIMH.+:XR:^W
MPMA/]AGF8$;W#2-[U5ZKCJM71"&B"-$448PH031#E"+*$.6(YH@*1"6B!:)*
M0WK8+BLN>EA<,&IFI>\;L]&D5M7AP>("51&B*:(848)HABA%E"'*$<T1%8A*
M1`M$E8;T\%Q67-">E3FS,*IWLR:(`D0AH@C1%%&,*$$T0Y0BRA#EB.:("D0E
MH@6B2D-Z+,SBXLQ,AA5%3R+QB.'T!#YQ4@5*1=WE`14BBIQL39U4,9I/$,V<
M;*5.JDRI?%H\'OWE#8U=O[Q6L2?F3N8+)U6I5`U'+Q!5YVSIF21**?<59T]6
M7LT5IT+G,DF>:%<%;+Z92:K%&D5.+4Z=5#&VF"":.=E*G5294AF99!37>:VJ
M,\G%A853)TJETC()'%V=LZ5GDB@O+\@D(3=65Q+9<V32<U$%2M6XP!!1Y&1K
MZJ2*E<J(JS%#)+6*XSIS,I\ZJ;+:?&.:&AD;17FMXD[,G<P73JJR-M_LA+%=
MLJA5W(GJG'D]WT0=?T&^R;)?F[DD.I=O+JJ`[(ITUJ,_,NKNL%;Q-4<*V3LQ
M=5+%M?F&X\U]NZ16<2=F3N93)U56FV]T8F14VGFMXD[,G<P73JJR-M_LA%%5
M+FH5=Z(Z9UY/0;'UT4Q!\\4"IR?G/;F!0BUS+QX4LB?%Q$D5L'DJ<8XKEY[Y
M5UYAK>).1$[FITZJN#9?=\(;&9594JNX$S,G\ZF3*JO--SMAO.23URKNQ-S)
M?.&D*FOSS4X8;T4L:A5WHCIG7L_,MDVTSN5;(+B1UI/H7&JZJ`)EBQ:L?)4A
MHLBIQ:F3*D;S":*9DZW4296A^1S1W,E6X:0JT?P"477.EIY.8ONM.=&=J3?E
M;ITVH[5LX/D]8P*8])2*?ASGJN8VGWR"Q2K*L=.JD%6Z+6.@1:RRVIJR2K=E
MK&AB5NFV8`78>HU&OV;MMHP64U99^Y6Q2N^782MGE6[+Z-><559;!:MT6T:+
M):MT6X:_%JS2;1G]JEBEVZI;U-+9.[=!['3?/EC1*QB%M.<'?L^XPTQ814O&
MT_D;*-69IPRLZAR>TU);GN\;OHFX/2J<3K<W996U5S&KK+825LDW..]NS&>S
M,Q98S:2LLG8I8Y755LXJV:7^S<"(RIP%5C,%JZQ=*EEEM;5@E=56Q:I3MO3,
M-O?0S16IVZ,/#_?6%=(>"\'4/'%2!4ZJD%7ZP*^'].%F$+'JU,`_J*9.JMA)
ME;#*VJ\9JZS]2IU4F9,J9Y6U7W-66?M5.*E*)]6"5=9^5:PZU2\]S2][%N'A
MLPB%C)G:F#DGK+*.T(!5IT:H?$[.G9`O_)^8J65'M5[!()MR>]9>Q:RR]BIA
MU>F9VJ5+:6W&<HO)6&7M4LZJTS.U2Y>*VHRE2R6KK%U:*!4]NQ1O0_6Z_4ZO
M;^1*=<Z2GL#F`QQSGG9;@>!S'4\]UVD.HY85B%)9AV2@;)WY:PVE4G^M,?#N
M^G<#8S<[:NM52UZ[]"IVLI6P:G2(6.?&_..:&0N:CH(NI:RR.BICE=56SBK9
MI5[+"J0E=M"E@LU8&RN=5`M662^O8M6I%O7,%H\1FJ6BF=F.*Q#U-**Q*>9)
M9)\<)TZJP$D5LLHZT4:LLDXA4R=5[*1*6&7MUXQ5UGZE3JK,296SRMJO.:NL
M_2J<5*63:L$J:[\J5IWJEY[FI+*FN=L$+JP8):1$VCK;&QE%\<13*NO`#93J
MS/M7K)+O7W6Z`_J#7;-FC;C!4W.`6F:[="MNMV5<8L*JYB7ZOE&US5AE[5?*
MJJ8MF%DS5EEMY:R2T[AWXPWOFO\9SQCF++<:+5AE[6#)*MV6X;B%4JD7,ON=
MCC?H&YJJW5)=6^FY3N/&FNN.4[HP8R2[0O7#_8E8;0A5C0)$(:((T111C"A!
M-$.4(LH0Y8CFB`I$):(%(O%%S-HY,D;R"Y?RXX!OJ^VWU63U^KJ[>MS\$%^O
MI#A_OC]B^6G-AVYW+/YP@?;<S2.]N[%X0:_M"'V/D]X-:SM"UF2T3&M>G[_A
M:1X9C>E+%"VV.M0^?1>A[<B0CAP^0&3:ZI`Q^H.REG.Z9(W^EJGM"%T-_1D-
M'J'/CGYI]0R=T*9_$*YLL?/0(Z>T\"_>^`L%$1M^\,A7;=P?5X?OCYJ73;YM
MM3,8TY=N6NR3_]K<1X\'Q^+A'YY!S^S&XHD<'J$':6/QF`R/T-.ML7AVA4?H
M60^UT]8#>B9#[;0=H6<GU$[;$7K&0>VT':$7/ZB=-H_1"QK43ML1>FN"VFD[
M0J\R4#MM1^B!/[73%@%Z"D_MM!VA1^/43ML1>EY-[;0=H9?KJ)VV5**7X*B=
MMB/TLAJUTW:$WB"C=MJ.T*M7U$Y;!M(K4M1.VQ%ZE8G::3M"[Q=1.X<CM\?$
MI<_G?BR_K?+E]MOZ?7?UNGJF">KN\%;V5GZ`5_YCK_X:_^MF3Q_./?QA_@M]
M*'E%'Q:EG>3KJ^?-9L__H$2[/7YZ^?/_`0``__\#`%!+`P04``8`"````"$`
M"!Z;!LL"``#4!P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R,55UO
MFS`4?9^T_V#YO3B00%H44B6INE7:I&G:Q[,#!JQBC&RG:?_]KNV40;)%O)!P
M.3[WW`\.J_M7T:`7IC27;8;#8(81:W-9\+;*\,\?CS>W&&E#VX(VLF49?F,:
MWZ\_?E@=I7K6-6,&`4.K,UP;TZ6$Z+QF@NI`=JR%)Z54@AJX5171G6*T<(=$
M0Z+9+"&"\A9[AE1-X9!ER7/V(/.#8*WQ)(HUU(!^7?-.O[.)?`J=H.KYT-WD
M4G1`L><--V^.%".1IT]5*Q7=-U#W:[B@^3NWN[F@%SQ74LO2!$!'O-#+FN_(
M'0&F]:K@4(%M.U*LS/`F3'>WF*Q7KC^_.#OJP7^D:WG\I'CQA;<,F@UCL@/8
M2_ELH4^%#<%A<G'ZT0W@FT(%*^FA,=_E\3/C56U@VC$49.M*B[<'IG-H*-`$
M46R9<MF``+@BP>UF0$/HJ_L]\L+4&8Z60;R<S4.`HSW3YI%;2HSR@S92_/:@
M\$3E2:(3R1S4^^?S9"H)\8)<?0_4T/5*R2."G8&4NJ-V`\,4B/]=$%1BL1L+
MSG""$6C5,(27=9R$*_("G<M/F*W'P+7'G"%VEX@X[DD(Z.K%0<73Q5FP%6>[
M;]5N?6"H).K3.,3N$A$N>\A(";1FNA(+SC!<^Q;$R5GJK<<L!IA%G]F+NX88
M:0.2Z=HL&+2-9S@?I]YZT#5QUQ`C<;#>T\59L!/7S]!'PN$0X^2\4R<03'/0
M\*2O::0'"I^NQX+'>GPD=&[AQ^0C"V<?P]U=CA,YQUA`'=??,'MJG/$4&0XC
M3OZ^+UZ$!X7CE?O/*MM/TN0WWH+'>GS$U>MS#P*^T]Y%O<L(IBJV8TVC42X/
MUB$C\(T^VIOW)K(-/(\OTHTS==(_`%/M:,6^4E7Q5J.&E4`Y"Y:P`LK;LK\Q
MLG/>MI<&[-3]K>'KR<`79@&`2RG-^PTD)OWW>/T'``#__P,`4$L#!!0`!@`(
M````(0!7L]9"YP@``,8H```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;*Q:6V_BR!)^7VG_`^)]0VS`)%:25<!W[Y&.5KOG/#O@!&L`(^Q,9O[]5KN[
MW)=J,(EV'B;)YZ^^KJ[JZIO]\/N/_6[TO3PU57UX'#LWM^-1>5C7F^KP]CC^
M^Z_HM[OQJ&F+PZ;8U8?R<?RS;,:_/_WZR\-'??K6;,NR'8'"H7D<;]OVZ$\F
MS7I;[HOFICZ6!WCR6I_V10M_GMXFS?%4%IO.:+^;N+>WWF1?5(<Q5_!/UVC4
MKZ_5N@SJ]?N^/+1<Y%3NBA;\;[;5L4&U_?H:N7UQ^O9^_&U=[X\@\5+MJO9G
M)SH>[==^^G:H3\7+#OK]PYD5:]3N_B#R^VI]JIOZM;T!N0EWE/;Y?G(_`:6G
MATT%/6!A'YW*U\?QL^/G[FP\>7KH`O2_JOQHE-]'S;;^B$_5YH_J4$*T(4\L
M`R]U_8U1TPV#P'A"K*,N`_\]C3;E:_&^:_^L/Y*R>MNVD.XY](AUS-_\#,IF
M#1$%F1MWSI36]0X<@/]'^XH-#8A(\>-Q[$+#U:;=/HZGWLU\<3MU@#YZ*9LV
MJICD>+1^;]IZ_W].<H04%YD)$?@I1$#N2MN%L(6?7W<`1G/7B_M>Q+FYF\]G
MWMWB^EXX$/Q.A?TB?%E\009#ZL`O0N9Z;R8\/UVZ@Z(MGAY.]<<(:@C$FF/!
M*M+QF3(FFJ>E3_VYS$/*F<HSDWD<>^,1)+6!X?K]R7/F#Y/O,,36@K.D'$=G
MK)#!QA.3#4P@-('(!&($I"=SPY$$*=A,:@*9">0*,('(]>&#`?EOA(_)L/"A
M1TL$9"]<(U;(0)/`!$(3B$P@1D"VXBST9A*D8#.I"60FD"N`%JOIOQ,K)M--
M+,I0\W2OEYPSA2+M23.=LNHIV+.`("%!(H+$/7*VJ:2G8%,I03*"Y"JBQ1&F
M0S+FIC"WV.=FK%!F!;.P$A'/3/92<"Z%K:=@7P*"A`2)"!+WR/FP]11L*B5(
M1I!<1;2P0:](V-B2]LF9CLFPU4P+Y)T^N):"!#_.CK^>@KT+"!(2)")(W"-G
MFTIZ"C:5$B0C2*XB6B"AZY9`WK`EL=U6ZV_+&CH-$Z9E/$YA:>`+!A/IPH@^
M+3G"%DD9,W>J!W;5D]`LX,@"TJZ8&<4>]B0TBXA0S!$/UGI%R&@_$69J:\Z=
ML8REG#2%$"A*ADM93T*7\@%M+0>PK;F8@[_JX[D<P`8,D\!4]"1P!)*`7JT(
M$G`$THV<D"`1L8H%<C%RR36DE).FT[[]C"#Y@)`62W9F,;=`P_,IL])CQQ$'
MFE;2;NP]5ISDR@`'%C/GSIA00F'F=ENKQ?P6_NF5$?4RF)58(/#CO#^)(*FC
MG@YHBQ)Q,>,DEY7X]R>;B[E51A:/EA1PZ`M)859Z4C@"1R4U",9V825(BWY$
M!;T91C,4R/W9[D7$)A8(FQAQ6SQSC<8308+J[TDT`Q8E0LHX"8;NV0P,R&@9
M8#/Q%U+0F>DY$)!1&<9.<R58:FE(PSX-R.*5X'258)8"-8L1@B'81WGF&BXD
MR((P]2P2YA19JA9A98(EZL'J:#ZDI.>#G4$^/T^Q0YU1$P(RBL*8<E;(4JH"
MH>[BH5O'0X1X73BVNH^0(\UBA/32,%Q(D'6Y-I"E:EGR(>+`J\/J:#ZDI.>#
MG7/4?%CV.\I:Z_!C$6P<<2PO!634Q;T^L:\$2ZL+K@6&J!4BZV)=$+,875#'
M\LPU7$B0-5`70E[5LN2!LR[7Q8"2G@=V4%+SP*XPAM=O1YROU'QP2*^+J3&[
MK(2A*X,?("0'>(B0J`O[/-6WAVF,T4P=RS/3A019`W4AY%4M2SY$'$1=V!S-
ML;US2GH^8*W5\C%0%XQNK!<"DCO,E4.@@$(AA2(*Q11**)12**-0KD%Z&"!8
M6AB^>K/&=,S[#J-`E^P<RX*H)L@X<*PD!T=;0*&00A&%8@G)A=)H+Y$<;"^E
M4$:A7(/TF+(CTA=*G9E!=)15G=Y].()T,80]![L42#.$0@I%%(HE="&$I+U4
MFF%[&85R#=)#R$Y&9@A9Q#]Y#<(6+5ZVTGW/,1;P);(N!E4HR6H/I!EV,J10
M1*%80M(K,BY)>ZDTP_8R"N4:I`<5ECQ+4#]Y)>(P%6,FY!#;)_8;TAFY%!&&
MP$+W`P$-7(M(%AI&5"L6T,#-"!K"1-V[2E:;5+`&[D8D"_W*A^3U?+!S#AWD
M,A_778\X_+BD;=DXI(1Z)5@*%`A(O2*A4$0-8X0N!C&YBI4*EGI/0J%\2$N+
M*^Q!:5Q=C[T"M-WV*;O?SE(?VP)2XK:B4""@F1S;(84B:A@CI.Y&9YZ\;>B.
M+XF-14>M8'ER?Y=1*!_2TD-I.\W-AN-(3W,NA]CLU!>>YYJ[5L$"'[&D`ILA
MN=8)T?#"U9,40NT8K;2)WS/>827(@F6N=]T2?=Y!-L@4EK'49$+KTNT'-J<+
MR2&A)XB=0<PYY(H$\:.+.F>XXL2C%K7GRF:[D;A"EG*L0$@.NQ"A2\=MY$BS
M6$!L$NU#.//,RVT;RY*.@<-9UYT,M2X>&7-DJ7ZI+>H982<5-2.7#Q9PPC27
M4X3D5F-%H8!"(84B"L4"T@;JS#/W'\@:&/3<>TU+C8R(LNCCI4L-;.^Z4<_.
M69^(,:,;T[J`U!@3*&!G;&8H62&%(@K%%$HHE%(HHQ#[@$8ZP8<:_R"&?R&Q
M+T]OY:K<[9K1NGYG'[M,9W"UVL/X)<["?P8EF/J,)[#[]=DFU?+$G?IL`-F>
MS.")30WVMC[;@E(;B`E^#&1X$$]]>(U,+9;0B+4-$++ASW/_&4ZZ%J&Y#Z\D
M+;@#+5@MXKD/;Q:I!9S*H7NV-F`+X+,UG]K`;M+/8$ZS/;F')_>V)Z#&%F]J
M`Y]4/;L6?.E`5RQX#)]@V?"E"QFT\5W(D@5?PEBP)2GP?'AO2?T,%CZ\<*-X
MZOGP4M&"+WQX049Q."/XH35ZL'^%)[;HP44#!,.>/TBL]<G2\<#&YAF<@<&F
M>S+I1RY\178LWLK_%*>WZM",=N4K%-YMMW4_\>_0^!^M>,/Y4K?P_5CWLG,+
MWPN6\-G0[0W,=:]UW>(?T/E)_P7BTS\```#__P,`4$L#!!0`!@`(````(0"=
MZ-H#M0D``%$S```9````>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;*R;W7+J
MN!*%[Z=JWH'B?@!CS(\KR52",388L*DYYUP3<!)J`TYALK/WVT_+<@M+#4))
MG9L0%I\7;75+EB5S]_>O_:[V,SWFV^QP7[<:K7HM/:RSS?;P>E__SS_^7_UZ
M+3^M#IO5+CND]_7?:5[_^^'//^X^L^./_"U-3S5P..3W];?3Z=UM-O/U6[I?
MY8WL/3W`)R_9<;\ZP=OC:S-_/Z:K37'0?M=LMUK=YGZU/=2Y@WLT\<A>7K;K
MU,O6'_OT<.(FQW2W.D'\^=OV/4>W_=K$;K\Z_OAX_VN=[=_!XGF[VYY^%Z;U
MVG[MAJ^'[+AZWL%Y_[(ZJS5Z%V^(_7Z[/F9Y]G)J@%V3!TK/>=`<-,'IX6ZS
MA3-@S5X[IB_W]4?+75K]>O/AKFB@_V[3S[SR?RU_RS['Q^TFVAY2:&W($\O`
M<Y;]8&BX81(<W"1'^T4&XF-MD[ZL/G:G9?89I-O7MQ.DVX$S8B?F;GY[:;Z&
M%@6;1MMA3NML!P'`W]I^RTH#6F3UJWC]W&Y.;_=UN]MP>BW;`KSVG.8G?\LL
MZ[7U1W[*]O_CD%5:<9-V:0*OI4F[:WRP71[<$0=;C;[C=+K]GGD$0!:G`:]E
M!+VOFT#,A4E/F'PC$NA8A0F\8H,V>E9K8+.ST;3AH#P.7L49M/N.Y719(C0'
M6E`S/(60I/+0;\1M81+9/R)R40FZ`#"#%OQ3'MD_UY#N2,@Y#_V<M^^$CHFS
MX)\R@';#K/$@USR"<](K]:^+'1,-O1N_U#SV)N^&1:_V5J?5P]TQ^ZS!4`DY
MS-]7;."U7.:,_9E'(GKXM0X./9NY/#*;^SHT!_3='$:EGP_==ONN^1-&DG7)
M/%'&<61DB`@;-YBOIPHC5?!58:P*@2J$JC!1A:DJ1*HP4X6Y*BQ4(5:%1!66
M%:$)^1%)@A[R_T@2LV%)PM9]0N&<-:NG9`01/,93A9$J^*HP5H5`%4)5F*C"
M5!4B59BIPEP5%JH0JT*B"LN*(&4$1AZ2D0X,*I<O@]A+V%%PP:OT$H?TDI(!
M+]&5.DI.!"*20I0147RBC(D2$"4DRH0H4Z)$1)D194Z4!5%BHB1$6585*4<P
MV),<L:G*%X<V9L-F*96$=-NVG)*G$M)E32`B:T09$<4GRI@H`5%"HDR(,B5*
M1)094>9$61`E)DI"E&55D;(&32AE3=^C&%TD!QOUB2M61XQR0Z&<>Y35M^0$
M>J516QPV(HIO8C0V@0+B'1)E8F(T-8$B#CG5"N[T^W(#S`2$+3DW\5Z80#&'
M['/C)D19WC"2:@3.Y`LUPFBY1K@"-:*IB*$)Y)7>YS,;$<4W,1J;0`'Q#HDR
M,3&:FD`1AY2R&2AE(R!1-B;>"Q,HYE"U;(BRO&$DE0U,N;]0-HR6RX8K-\K&
M!/)*[TK9$,4W,1J;0`&'E$0J_3\4$"9R8N(]-8$BX7WN;YU!2ZDD`6$`<Q/O
MA0D4"^]J`,HE(!$0!K"\X2T5%]P[?:&X&"T7%U=N%)<)Y'%(3O=`N1D;"0A/
MUC?Q'IM`@?"NM'9?&3A"`6$`$Q/OJ0D4">]*``-ERC83$`8P-_%>F$"Q\*X&
MH$SC$P%A`,L;WE*]P;J-5&_\QKW!5GU.;]OUCZ>,+Z-=F#_9<(/.;]N9B5R&
M7+E1AB:05WK#/:VXD;%;2A)&`L(V\$V\QR90(+S/`70&RHI#*"`,8&+B/36!
M(N%=#:"K#'L"P@#F)MX+$R@6WM4`E#O\1$`8P/*&MU2&;#506X?_9._%*M.%
M.H2%1BS$PD:NQ%*Z48I&E(?V]GEZ3R7?R&ML1`74/J32Q,AK:D1%U'Y&I;F1
MU\*(BJE]0J7E+2^YG-@26'4]\D;9\!4SN#G'XGVRN,36,L6XX]A*MQ\B!:4N
M*'I3B%35BU"CDFJS8?7G0[MG]QWE8N<;&8V1T@85(%4-RK:5;PR1&A1!68VV
M`DP0J-J0<YLBI0TI0DKK-4.*A^0T'&4"-D=`:[-`2AM2C%35B[12@I3LI8R0
M2Z2J7M6FDBN8+1E6*_A;%V:V*:)<F4N)[<Z(DG5LY7(R1`KNBP15C;5<5N?V
M#@S>UZE1Z>7(]\E*Z_CXC=6XR#>.D=+&%2"E]0J1DKV4N"9(:;VF2,E>2F5&
M2&F]9DC)7DI<<Z2T7@LC*C:B$J3DN)1S7")U+2ZYRMFJJZ[*#2_[Y>)M=?SF
MDC1^DW(:LJT_Z!]ZRC.B1DC)@X#2/#Y2UP:!HF.-C:C`B`J1TL8U04H;U]2(
MBHRH&5+:N.9(:>-:&%&Q$94@I8UKB=2UN.0R9\O4U3*_,1TI5[6KY<PE9=16
MQH0AF^1".;.G&*Z/QQY2UWIH48*CDK);FNG(A:!('QOCUVF#"I#2!A4BU;TZ
M'3$):7JVT;13A)0VI!E2/*1+TQ&3D!9G&TU(,5+:D!*DY!97BF6)U#4ON8*!
MDBKX>],1YJ+<GG%)&H$O3$=*2MLG/;8K!_8=^;R5$7A44EV>L'8+GE3I*?-Z
MOV2DJ"Y4MDE4@9%7B!2?U;8:`V5&-D'@VH!3]-HI4MJ&BI#2>LV0XB'U&^K:
MVQP!K<W"B(J-J`0I[>DMD;H6EUS94"W:RC:<@C`;I;2Y)(W9I(B&[.$?-F9#
M+>G&;!-JA%X`7_?RD=)^X]B("HRH$"EM7!.DM'%-C:C(B)HAI8UKCI0VKH41
M%1M1"5+:N)9(78M++G.V"5&=@GQO`.=;&=)"2;F[4>ULG8&R+32T2DK;<;V2
M<N"V\GK]CI`J%TILNV79RJ*XC]]7C8KTO3%2VJ@"I*I>9`T@1.KZ`'ZAH4A(
MT[.-I@DBI*HA$:\94CB`#Y1+X1P!K<T"*6TKQ4A5O4@K)255+G)U^TZ_I6S@
M+2\95<]-+FOX.FU9&X[>S$89O4OIO+DZ9-,!1ITECTHC*OE4&E,IH%)(I0F5
MIE2*J#2CTIQ*"RK%5$JHQ)X6/S<.SQ%_^IL_)[I/CZ_I,-WM\MHZ^V!/=ML6
M3.*%+!X[?RQ:5]&?V./H;'%6U=LN/%MW0;==>*"+ZH\=]Q$"I1\\=5QXENB"
M;O7Q07CEJ[V!"]M.](A@X,)N$-6C@3N[I,<#%_9.*`^;#>X(%KWI)[`IX+)=
M`/H)+-Z[;+6>?@*+["Y;5:>?>#UWU+N@!ST7-O,I'_7<V24][KG))=WKN[!+
M3'V"O@N;MU2/^B[LJ5(][KO))=US7'C&BO*!X\+34%2/'!<>4J)Z[+C))=WK
MNO`P#N6#K@N/S5`]ZKJS2WK<=9-";XI"@A\TO*]>T]GJ^+H]Y+5=^@+=HE7L
MO1[Y3R+XFU.Y]_6<G>"G#,4VV!O\="6%)YM;#;CZOV39"=]`0$WQ8YB'?P$`
M`/__`P!02P,$%``&``@````A`/](I7N^%@``W84``!D```!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&ULK%U=4QLYT[U_J][_0''_@+^Q74F>:K"-#0;\"88[
M`DY"!7`*D\WNOW]:'K5&HR.+#MF]6)RC,ZT>]>F69CPC?_COWT^/.W\M7]8/
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MQ!BV[''\UYU!I5DOUQLF$(D#RZR9+(0<)'OH._PN2Q#-!^>Y4T+*`8E@F3_8
M(YNYAE)'<LPSU_.XO<=U"5R9/U@'*GNZP>-89Q[D0??TG_)=`EW.(_T>WR7N
M7"2<[XV]6J5^T/RM%!055/Y(!151@?E@A_(=F50129@/ULP[!J<B^C`IX`*;
MCTTB/*8`;0)K/MA#&WOE6NFM=*J((LR'/W!=Y%'QXJI*BJI$TGRP#K`KB7.M
M2A&O_M%H5V6TS0?I^/>K:)5CM1EY\^']`UB5`)H/UDSE'8E1E7A6_RA/JY*G
MYH-UIYD7=N5$69/8UOXH2VN2I>:#=::J$7=-\M)\L`?ZZ9T064W44?NCL-8D
MK.:#<UTSS=0DD.:#BX#J2,G%>IY1[ZA&=4DS\\$YX.9VI03J$COSP5K1.[.?
M+=\VJ\'.[>OMIP\OJU\[O,9FE]8_;LV*O=PVEF4=F$74K0RW+0QY16BLD#'S
M<9=#PVN^-2]G__K4J-0^[/_%*]`[RSE$3KU>I!P)Q:PWC=U."'1#H!<"QR'0
M#X%!")R$P&D(#$/@+`3.0^`B!$8A,`Z!20A,!<B'M5P<L9DP9,3F(7`9`E<A
ML`B!ZQ"X"0%R`9=^R877(1!-@G`2Q),@H`01)0@I04P)@DH058*P$L25(+`$
MD24(+4%L"8)++KINQ"":!.$DB"=!0`DB2A!2OKJT*<N][W,Q<!6!B\"_41&,
M&5,1Y.0.!?"T?%`4\Y%0Y)A."'1#H!<"QR'0#X%!")R$P&D(#$/@+`3.0^`B
M!$8A,`Z!20A,!<B'K%(<L9DP9,3F(7`9`E<AL`B!ZQ"X"0$B0%QXQ1.":!*$
MDR">!`$EB"A!2`EB2BZH6\>.(,P$<28(-$&D"4)-$&N"8!-$FURXW1!">`GB
M2Q!@@@@3A)@@QN0'N5`/>,7W;]0#8Z90#T+@*`0Z(=`-@5X('(=`/P0&(7`2
M`J<A,`R!LQ`X#X&+$!B%P#@$)B$P%2!7,%^#!ODO')',/`0N0^`J!!8A<!T"
M-R%`!,@A(!!/@H`21)0@I`0Q)0@J053)A=4?O49Q]`A"31!K@F`31)L@W`3Q
M)@@X0<3)A5S"23,85H@P08@)8DP09((HDQ_F0@7@*SBH`.9J+GZO6"X)S%%\
M5[AP21!,^(>6P[;<=4-PU7#D*#(F'4"Z@/0`.0:D#\@`D!-`3@$9`G(&R#D@
M%X",`!D#,@%DZI"M0SAS%!G".2"7@%P!L@#D&I`;0(@0RN,N'A'&F3#0A)$F
M##5AK`F#31AMRL.]=3`)!4"H`$()$&J`4`2$*B"4`:$.*!>"&U,,/&'D"4-/
M&'O"X!-&GPKA+]003G&H(>;[IM^\SV#,F*^:O(+1J#2+9?W0DOC/UJKB*#)8
M'4"Z@/0`.0:D#\@`D!-`3@$9`G(&R#D@%X",`!D#,@%DZI"M0SAS%!G".2"7
M@%P!L@#D&I`;0(@0RN,N'M$1LC#0A)$F##5AK`F#31AMRL.]=3`)!4"H`$()
M$&J`4`2$*B"4`:$.*!>"&U,,/&'D"4-/&'O"X!-&GPKA+U05K@.%JI)>D1CV
MIGC(N1QF2+GF[E(<.22/5;D9W'3K6$,5=U@7D)[&T+&&U`?;`T!.-(9.-:1A
M1JKSG[QX-H,*>^9(,I+G&ML7&M(H(U7SP1T#,M$8FCJ2.#D#0W-`+@&Y<G;R
M$0%)+."P:T!N`"'2V"8KTW1,R$J767*^9(7J0UU5CU:]7A#(:M6'4)EDI<D9
ME1@L4LF55'HE*UC?+RM/'U+IDU0")50HH41)I5'*19H:+RO<-P0PST+K1]NJ
M^8UPJ!1.*'%"C9,5^=8>"^6;OY#[C?)MV,7RG2%;^]I\A72D(76L[;SH=`'I
M:0P=:TA]L#T`Y$1CZ%1#&F:D0#RMXIKYS)&D>)QK;%]H2*.,Y*7C&)")QM!4
M0YJ![3D@EX!<:4POX+!K0&X`(=+8IL.,E0X3637[.6ZUZT-6O.G$("MH+RYD
MY>M#*%:R:GW#O$K!I)(P60W[?EG%^I!*LJ32+*%H"55+*MF22K=DA?N&`*R8
M_6A;-;\1#I7""25.J'&R(M_:8Z'(\T,4OU'D#;M8Y#-D:U]9D=>0.M:V5^0!
MZ6D,'6M(_8P4A#-82`\<2<KNB<;VJ88T=+;SI46M50KJOB.)`^<:VQ<:TLC9
M]AT(KJ7&CB0.3#2VIQK2+"-Y)6(.R"4@5QK3BXR4CNZU(\FYW0!"I.F.#MV!
M_E@&P:0CQY(.R8K>KQ==58\V$XIGV`JB1S85?/.Y\)T35N;I'":5]$FE?;+B
M]T)/9]EI^Y!*ZZ02.T75'EXX$\J=5'HGE>#)*CX(6B@3FP5^T&P:O!$A56I0
M-#=`.9@<9+-CJQ.%:84?I_R-:<6PB]-*AFSM*YM6-*1.1@K&/'A0H^M(DA0]
MC>UC#:GO;'NUH1DL\`>.)`Z<:&R?:DA#9]MSH%4-9AI'$@?.-;8O-*21L^T[
M$'R3.'8D<6"BL3W5D&;.MN]`H(&Y(XD#EX!<:7I;N,.\WL*`7SN2]'8#")&F
M.SIT!WK]A?&E(\>2#BE/#0?91$CG'=GD"'(J""C9[/#K6)X+KD>K_#=Z5&4#
MJ=*!XOD0J('.<+Q4&4&JE*!H3H0B(4P*4F4%J=*"XGD15`;"Q"";&6\$394M
M%$V75B@FS!>R";/5B<)\9%ZG*DQ(V9/4>P?\%=3KMX>[[X<KOJ'.#UU&OJ.H
M\A/3FPF'-E:*$Y6%MGJ1S50J5D?,LQON[GZU%,2CF[,DB7HJ\\<J5C\WGSM1
M:P5/-@URECAQHC)_JF(-<_.^$\$#0F<Y2YPX5YF_4+%&N7G?B>`AF7'.$B<F
M*O-3%6N6F\^=`$W,<Y8X<8G0E:K'17Y@WB,(X#IG28\W"/&#Z";O.+'2WS@<
MYH?Z?0;QIJ.<)IWR0^M9#]7LW=7-ZPZ2(F_T*FG#A_J]!@'F!]RQ!R]+G">2
M$V_TJLL3?AQ>-7+13`%]\(/S>`ZZ7.'GZ56.;,F6H&[PD_?HB"Y?^(%\E2/1
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MKK55+]X#"O35DQY]OT`WQ\)*^M475M+60%A%6X%?)\)*VCH55M%6'MO-;>"A
ML)*VSH15M!7X=2ZLI*T+%6ND8HV%5?0K.,>)L))^356LF;"2/<Z%E>SQ4EA)
M6U?"2MI:""MIZUI825LWPDK:XJO;2-I">O`R0).WO`Q06>L(+>V;)'BAI*!O
M+L/3UER*)X>-UP*J,W5)GK86S?)Z*9R:79JGK>GRG)<#D5.HEX)$YRU.(L&J
MA%=-O!Z(T#`*6W(]G-.\9#<KP/)>(YS.=(G.E^4JMURJIT?6Y7I:0R[9T]9T
MV<[+`-4IN'Q/^^82?IMOQ66`>3TWM0Q0WMLU9H)[NQF47L`?F1L1X0T"$%5'
MQ>H*RU\F@:V>L)(+PV,5JZ]B#825].M$6$F_3E6LH8IU)JRD7^?"2OIUH6*-
M5*RQL))^3825]&L:8]5:P>V7F;"2/<Z%E>SQ4EB^K7IX&7DE+-\6U-R%L'Q;
MH.AK8?FV@'4CK*0M7@=H$I+7`9:6MJ9+;[X=H++F$CQYHKR%F,J:+L5Y':"R
MYI(\[5LTR^NE<';4I3EO8&9]2W<:3?1Z*4@"7@=$K($F>1T0H8'<>%.T*"T\
M4R_9MZX#HH:"RP)>!ZAH+M730^9R/:UOE^QI:]%LQR%SZ9ZVYO(][9M+^&W6
MBNL`7BT4U@%_1W<"=P\J&7HPWV=089%>KP:+S2.SZ8/BNC]B"\:K:VWQAK?;
M;_5K#!VKG.H+BTUNOQDQ$%9CZZU^C4NGN9E$9T-A)5TZ$U;F4NQ6O\:EB]Q,
MPJ61L)(NC8557,H&8ID(*VEKJF+-A%7L,:@B<V$E>[P45M+6E;"2MA;"2MJZ
M%E;2UHVPDK9XBF<K)@>3QGB*M[2T-9?1:6L=G37)Z3=\Z^FLN<1.^^8R.WVF
M+K73UD[$-Y]6+P5*XSO_W/YV%'0ISI?ZF35;"UNU6KE5"Q\Y/M=UZ1+=/P&H
MOCS!1T\`)WA+\P>W7@Z_5M'E.L_RT4[#P779GCX%E^Y2&6%-Y%(];4B7ZWRA
M'_4^'#+)=@EFH\P;T`=/Z?+=_JBM?"2*TSN/?F%Z?]_=?F,EF/4SJ'"5'[G;
M;UG)%4O'_`X#FZ_QG^T3;->R&EG,*B7^I8N#X-Y1SW(*7H&"CX65]*HOK&W+
MJ,V=]X&PW-=;P:V]$R$DS9P**^G24%A)6V?"REQJ[H5/_Y\+(6GF0L4:J5AC
M825/;R*LI%_3&`O*[$Q8R1[GPDKV>&E9\@U_I5DJ-X,O"*]4EA;"2GIU+:RB
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M88;0'*%+A*X06B!TC=`-0CQ5V(SQ2MIA!),$\4Z`;^+BL2)^GR=2]S$1MH^)
MC'U,1.MC(E$?$T'ZF,C/QT1L/B;2\C$1DH^);'Q,1.)C(@D?BPB`(@K@!X=Q
M3",:X*>$D1=1`3\2C+RB#HIEF%<>R3*L>ZG16`FN&C*HL#Z'A^..3#,?R$N(
M1.7L6%:='W[:7E^[PK*/!<>>SNQ)?]SM=DO'PDIZU1>6;PN>>!T(RZW=X*HA
M,E"P=#O-S20<'PK+=PELG0E+UFWADYGG0DB:N1!6<I1&PO)MP2B-+2OQ5.8D
M9@C.;6I97B;.$)HC=(G0%4(+A*X1ND&(RVX69L\Q7HXC)AGA\T3_/B9J]S%1
MMX^)EGU,E.MCHE,?.XGX)T+T>2(['Q.1^9CHRL=$13XFFO$Q48B/B21\+"(`
M+KLXSA$)\).?R(N(@._Q("\B`[Y_X_.*99>3)EEVE<]D&#-!W;50O@?6D:FN
MAI5#'82Z"/40.D:HC]``H1.$3A$:(G2&T#E"%PB-$!HC-$%H*E"^0IHA-$?H
M$J$KA!8(72-D?AIX$[3<":XAB!U&,!=P[U@7<0]S(?<P%W,/<T'W,!=U#W-A
M]S`7=P]S@?<P%WD/<Z'W,!=[#W/!]S`7?0]SX?<P%W\/BPB`:PB.?40"7$.0
M%Q$!UQ#D163`-<3G934D^\GG[$?^GI8O7Y='R\?']<[=ZJ?Y.>>6>1W7P?;'
MID_J_&O3FU.$EG+#_!#UYOH9VPY,VX&Y^8%M3=/6C+>U3-OFQZV#XPYK;?YI
M`[0WK;7-[S5@`_]D`]N*MO`YQ?NHMR>Q<^5<:9MX8R=3-L7[ND<:RCP"YI(D
MUL0#8*;-6!.?O\D&;#(_^[UY;30<ES*[%N%/-S\3'FDXK+0G,4/3"G>]J?1!
M#],J-\2.X%_2XA&.'<*_L<,MT6-XTX`V?R6U^0GRH"/^VHC;S%OZD=/G5^O;
M?,T3;>.WW=M\_1)MX_=+37^Q(>+^N,V\]AGMC]O,RYF1-GZCTO07;1MR<'D_
MN<A1(VX91UMFW,([KT6.67`+;X<6:1FR4GB?H$C+B%O&T989M_"..I%C%MS"
MV]Q$6H:<Y;QK=J1EQ"WC:,N,6^;1E@6W\-;0$6M#SA?>N#72,N*6<;1EQBV\
MZVGDF`6W\.ZDV&)D9+9:P!8C(K/W`;;P>IOU93;[B+3Q1AYMOG4<:^/7?;FO
MF$J,@,SKMA%[AT9;Y@7P2!N_W&WZBK6QA'BC/CR&!<1[YR'.VT9R-]&6'K?P
M3HUX#,N'-U]"G,7#^R$ASKN#<1_1EAZW\(9<>`Q+AW<F1YR%P_N'(\X[X',?
MT98>M_`^]'@,RX8WQD6<1</;UR+.&S!S']&6'K?P-LAX#*NE;;:"P1;62MML
MUX(MIC3&*Z,IC/&ZR$KA?F**8)UP/[$64Q+C%=$4Q'@][#3;O#DH^MQOMGD+
M3\2Y#$:K(!?!:`WLM-J\_QO:Z;?:O$L;XES^HM6/BU^T]G4:[6Y,"_U&FW^8
M(&*_T8Y6/2YZT9K7.6CSUMIHIW_0YCVQ$>=R%ZUV7.RR6K?O)L?UIP\_;K\N
MSVY?OCX\KW<>EU]XL5;:[+#R\O#5?%F?_>/5[K3R>?7ZNGK:;+KR;7E[O^0?
M2R[M\3WG+ZO5J_R#'=K_M7KYOOG5YT__$P```/__`P!02P,$%``&``@````A
M`/7QA19[#@``H%```!D```!X;"]W;W)K<VAE971S+W-H965T,S`N>&ULK%Q;
M<^(Z$G[?JOT/%.\G8(RY59)3$VQC`P;C.KO[S!"24!-""IC;O]^6I;:M;B.4
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M]SC?O6W!VQ`G$8&OA\,W08T?!02%6ZQTF$<@/38>MT_K[Z_G[/`SVNZ>7\X0
M;@]:)!HV>OSM;T\;\"C(W'0\H;0YO((!\']COQ.I`1Y9_\I__MP]GE_NFIW^
MS<#SNKU!'V2^;D_G<"<TFXW-]]/YL/^?9#E*2ZITE`K\5"IN[\;KMUT'*K45
M<95(MQ!Q/FX)5)>W!WXJ2P8W?:<]=#_0FI[2Z!<:GS`$.EAN"/Q$E]PXW79/
M.,3@R:$J!C]5L6HX#`4=2!T920B5*OH)LQT,I?BE,+P(I<D`C)\#OZB2@S()
M3"4AXM)T\/S?,!WB)67*P%6=9YG+#D9._/)A:UJR?^7=U5^?U_>WQ\//!HR!
M$)73^UJ,J,Y(*&-'E7XINNZEG@M=5JA\$3)W3?`3],D3##<_[GN=X6WK!PP1
M&\5YX!S/TRECI(@!0>CZ%`@H$%)@0H&(`C$%IA2846!.@80""PHL*9!28$6!
MK`*T(#Y%D"#G_XD@"1D1)/3N`P)EU)P^B0A2L(Q/@8`"(04F%(@H$%-@2H$9
M!>842"BPH,"2`BD%5A3(*H`6$1A+_HF(")F[)OQ?=!O/I=U&<6!\+DA=$J2"
M4D2)(0%#0H9,&!(Q)&;(E"$SALP9DC!DP9`E0U*&K!B251$M:#">_Q-!$S(0
M-&VP<]MZ2!X4R12U@E)$C2$!0T*&3!@2,21FR)0A,X;,&9(P9,&0)4-2AJP8
MDE41+6K@0BUJ]5-(?!$)=AX<=.J#1/HP<RGZ3\]U]'"-"Q(6\QD2,"1DR(0A
M$4-BADP9,F/(G"$)0Q8,63(D9<B*(5D5T6(!.?^!6`BV'@N)0"S0S6.&^`P)
M&!(R9,*0B"$Q0Z8,F3%DSI"$(0N&+!F2,F3%D*R*:(Z'J:/F>#%-Z_3$VNG"
MD@K[@RBHQT`B8JY7]`>OZY+^H$C53N,,2*?Q:Y08*9"DCIM/"CN#?KM'9,(K
M,IH?P.K/^4$4U/T@$>'!BA_HFU61("X%B371KU%BI$`9T,[]X`S[G7ZOISL]
MO**C.0(B\SE'B(*Z(R1"$H+.S&M(K(V^#2E0)/AQV:7A%27-%6*)J?G"_(;(
MZ;H'%$1R@81GC"QS,B"KFE?,4P$:H=*AZWINAV3#-2'=!V+IP-=Q-V)[X?RR
MVWQ[.("W@53C&]$UU2I.+D!@:H/C\X,C(9(==)6`+&-0?<7J&AT8*%:OE_>4
MX:#G#LCH%&)UT&%J<TAWC9C#FUSSU^']DFL@(PK?R*6`YAL):6G#0CT6.Q;0
MX\PLWXH5(,OHP1!9EU)0=X^8+IO<8Y<Y:M)=S1P):9G39XFC2%<21[(\\&1M
MO//L#<0&#SC:DZ\:UQT,^UW6J6J,JH9,=XV8DYI<8YDY:FI;]8V".D5'&SL,
M\CD4<"CDT(1#$8=B#DTY-./0G$,)AQ8<6G(HY="*0YD&Z3&")-=B5#/`57NQ
MH)/!7T'5%/2Z9!4^%IO7HF`Y=?4Y%'`HY-"$0Q&'8@Y-.33CT)Q#"8<6'%IR
M*.70BD.9!NGA@9'J(^$1=!(>"0WR\X:\HX\=!OD<"C@4<FC"H8A#,8>F')IQ
M:,ZAA$,+#BTYE')HQ:%,@_18B(DV'<ZL%A&.G*)K[[Z:6;OGD5V0L2KH5/M6
M=;A5F[PU6HP5*"U<270[SH!TTA"KLYL7B.GVY]PA)^J:.R2DO>0]CZQTQN)=
M".G=@?R]_![SD04CSF56H%BNG$%V>_U!=TCJ"Z\IZ>D!0?JD/T1)TFLE)`PH
MVN!UZ:)"Y`44U%@L\+X5*T`62!8U,JT0656[JBS-(YV/+2QRNNX&!>EIT:63
M(&29TP)9YK1`(]3"H@-GC&1-&UX3TGU`%Q;F]VN'KR`4I`79\\C$;(PL8_A\
M9%T*GYP(*I8:*?*N03(OO":D^T#,X-E(`8.6_<JJ(Q<!U2%#07IN>&2I,ZYC
M51-6CJ"*Y4'"7D[^`%DPTRQ8<*1.UIW7:M1=(^;3U#4.'+(KY^`,^0.>DC-T
MS5,UDW:VDH!HYV/)E022K"LK":6E5A)>#U82+G-3C5'5P.AN$I-[YB:O7)ZC
MGZ[T+K5&J*PD.L6RH8RI0W>6QB4+%_8^AP(.A1R:<"CB4,RA*8=F')IS*.'0
M@D-+#J4<6G$HTR`];&+2S\.&-R6L3\=%'Y<OR#)(/;KA\X"LZ@!/LFY<<LI`
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M\DLK5EK*5XT@VYFKDH5&9-?D]<RLVVYS/KQ9`O,#^I)6D#GIQE8L'^7=X@@W
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M+&-FVQV2N$*&+)8DI`W@+(G&JJ"9Y5NQ`F3I';_LTOD698BL2QT_9TVL6)$5
M*T:6T:XILHQVS:Q8<RM6@BRC70MD&>U:6K%2*]8*64:[,F1=LDM/<^@R6IJ;
MSR)@(L+264)DI"8CYU@5%!OQQ7C.DMY'UJ4>FJ=@@$;(6P471NH:JUA]$ZS/
M:%6$+*-5,;(NC]0V)LU*&8.CYL@RFI0@Z_)(;6/2LI0QF)0BRVC22K%@<T!\
M+-?M]!RW1W(ENZ:D)[`X,OG[,Q!U\%*=@:@3FVHWJIF!*):Q2_JN9%VY:ZY8
MZJYY'SX'W^Z3W>Q0<<ROA0FRC%9%R*JVD/61&%G#/&+.#3TIGB+!*#-#EM&D
M.;*,6@FRI$ENS0RD)G:L94N4,5:66K%6R#(V+T/6I1KUS`:6,;,M9R!"ALQ`
M)*0-V<P]8]>&Y5NQ`F09!]H06<8A9&+%BJQ8,;*,=DV19;1K9L6:6[$29!GM
M6B#+:-?2BI5:L5;(,MJ5(>N277J:0Y<QIKG=UJ]0(5DN(6VH[`[)HG@,=^A%
M07$5TS0QD:PK-[64EKJIY73Z\/E"NF8-L4+H79<KG"#+:%:$+%V+-#%&5E7+
M\\BJ;8HL78LL$F;(JFJQH6..+*-6@BPYC'=ONH-V]1\Y8U@@W2BZ1);1P!19
MNA9QW$JQU-7-GN-T^SW"R>J52K=IN0ZW<\RY;C>DYS)ZLB-4GM*..>1S*.!0
MR*$)AR(.Q1R:<FC&H3F'$@XM.+3D4,JA%8?$UTWEXT7N+QDC^?51\OMH]MOC
M\W:\?7T]-3:'[^*KH:#`_6T!R^^M>G!Z(_$1!SA9H$\ZW9&XRL>??.EXHR\@
MQI_`E3LHDU^<8VI0#RR=:LITV_C56:0,?*?6E[QQ!'^`[]K*OY>*XAVHHJX&
M=Y3EIPJ$_Z4+^G4-?("6U^+0NMK&0=MJF^:`$!R.U#3:`2GXE`]_`D=T(W$`
MQY_`N=E(G(KQ)W"8-1)'5?P)G#"-Q/D1?P+G+5!/G;O@7`3JJ7L"YQ=03]T3
M.&>`>NJ>P.6+D;AMP2V`2Q(C<06"/X&;"R-Q+X$_@>L$(W%9@#^!0W=H3UU2
MPDDXM*?N"1Q/0WOJGL"9,;2G[@E<<(/V]&LL@(MHT)ZZ)W!A#-I3]P1N<4%[
MZI[`]2>H9U!;SP#JJ7L"UXF@GKHG<,<'ZLF?M(I>`-\/][Y^WB;KX_/N[=1X
MW3[!(-'.#ZR/\AOFY!]G]7G>KX<S?#%<_M'>%_@FP"W<C(7=W&;CZ7`XXQ\0
MF%;QW8+W_P<``/__`P!02P,$%``&``@````A`$=#'PPW`P``4`P``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&ULE)==CZ(P%(;O-]G_0+@?$!10HT[&
M(;,[R6ZRV>S'=84BS0`E;1UG_OV>4G5H=8O>J,C3U_.><^BIB_NWNG)>,>.$
M-DLW\$:N@YN,YJ39+MW?OY[NIJ[#!6IR5-$&+]UWS-W[U>=/BSUE+[S$6#B@
MT/"E6PK1SGV?9R6N$?=HBQNX4U!6(P&7;.OSEF&4=XOJR@]'H]BO$6E<I3!G
MUVC0HB`93FFVJW$CE`C#%1(0/R])RX]J=7:-7(W8RZZ]RVC=@L2&5$2\=Z*N
M4V?SYVU#&=I4X/LMF*#LJ-U=G,G7)&.4TT)X(.>K0,\]S_R9#TJK14[`@4R[
MPW"Q=!^">1J$KK]:=`GZ0_">]SX[O*3[+XSDWTB#(=M0)UF!#:4O$GW.Y5>P
MV#];_=15X`=S<ER@725^TOU73+:E@')'X$@:F^?O*>899!1DO#"22AFM(`!X
M=6HB6P,R@MZZ]SW)1;ETQ[$7):-Q`+BSP5P\$2GI.MF."UK_55!PD%(BX4%D
M`M$?[H=>.(V"*!Y6\55$G<$4";1:,+IWH&O@-WF+9`\&<U"6SB;_=0:6Y)H'
MN:A;"C2'<KRNXO%XX;]""K,#LSYG0IUX/">"1$?2"\CTA/A@X>0#LG.[#[D(
M:N$Z/1^3DW[G=:T82,V),8C'02*U$9H+"*7OXG)_':L@X:4+VJ?(XG%D1*^8
MI*M1F$3)+(YUXK%/C*-D,HL^,MQE(.T3D\EX%@<?M=:BAR1='[V$S>B-V-:*
ML>5^D$AMA!8]='T_^NN>!+EHJ(,48W,Q2*0V0G,1ZR[L'21ALP9F!RFF'WUH
M/LC#2&I%-`/)+08D;!HP]I"U8OH&S`=XD$AMA!:]G/@W;Z=RT5`3*<;F8I!(
M;83F8J:[L#>1A,T:F$VDF'[T9TTTC*161#,0P(COU\'NH*--"\8NN#Y`?0]F
M'PTCJ171+<C9=W,K!6IBPI;=&PI&G.L#9+6B="Q(:E71K<CYU[,R4`TU+>US
M#4Y[LNML@TU#+D\V#;D\VM294!V96K3%WQ';DH8[%2X@PR,O@9V9J1.ANA"T
M[8Y&&RK@)-=]+.'DCN'<-/(`+B@5QPMYYCS]%UC]`P``__\#`%!+`P04``8`
M"````"$`>@:98HD"``!8!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6R,5<MNVS`0O!?H/Q"\QY3\3`3+@=,@;8`6*(H^SC1%241$42#I./G[[I*U
M*L5!XHL@KH8S.[M<:GW]I!OR**U3ILUI.DDHD:TPA6JKG/[Z>7=Q28GSO"UX
M8UJ9TV?IZ/7FXX?UP=@'5TOI"3"T+J>U]UW&F!.UU-Q-3"=;^%(:J[F'I:V8
MZZSD1=BD&S9-DB737+4T,F3V'`Y3EDK(6R/V6K8^DEC9<`_YNUIU[LBFQ3ET
MFMN'?7<AC.Z`8J<:Y9\#*25:9/=5:RS?->#[*9US<>0.BQ-ZK80USI1^`G0L
M)GKJ^8I=,6#:K`L%#K#LQ,HRI]LTNUE1MEF'^OQ6\N`&[\35YO#9JN*K:B44
M&]J$#=@9\X#0^P)#L)F=[+X+#?AN22%+OF_\#W/X(E55>^CV`@RAKZQXOI5.
M0$&!9C)=(),P#20`3Z(5G@PH"'_*Z12$5>'KG,Z6D\4JF:4`)SOI_)U"2DK$
MWGFC_T10&I**7"&U6^[Y9FW-@4"[`>TZCH<GS8#X]5P@"<1N$9S3)24@XZ!^
MCYO%8K5FCV!:_,/<1`P\!Y@>PD"UEP:Y\Z41C-)8%LSE)@:&.NG_5$8ZL[$.
MEGT&S7O;*FX"W,C&9>\CIA`Q\P%FWB-&&0#D?*<(QM8.:$^K'$%G2,/)&$JC
M^>D2S]<[_G%?R*(O>(RD4/=!9Z]>-PS)#U7?+C6"QU(Q,@\'=WAB5F/:,$!+
MF('WS."^L4*,I*/^+I,79N(DQW'1TE;RDVP:1X39XY1.80#Z:'^!;*>8]<OX
M/-N&BX7U'V"P.U[);]Q6JG6DD250)I,5>+'Q:H@+;[HPI#OC8:3#:PTWN(01
M2-!X:8P_+D"8]?^$S5\```#__P,`4$L#!!0`!@`(````(0"`CD=$GPL``/8]
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*Q;V7+B2A)]GXCY!X+W
M!K2QA>T;-HL6=N+.S#.-99MH8SF`;G?__<V2*D55IBC*/=T/;?MP='24F;6C
MF[]^[E]K/]+#<9>]W=:=1JM>2]^VV>/N[?FV_I^_QU^Z]=KQM'E[W+QF;^EM
M_5=ZK/]U]^]_W7QDAV_'ES0]U4#A[7A;?SF=WOO-YG'[DNXWQT;VGK[!)T_9
M8;\YP9^'Y^;Q_9!N'O.+]J]-M]5J-_>;W5N]4.@?;#2RIZ?=-AUFV^_[].U4
MB!S2U\T)_!]?=N]'5-MO;>3VF\.W[^]?MMG^'22^[EYWIU^Y:+VVW_;CY[?L
ML/GZ"L_]T_$W6]3._V#R^]WVD!VSIU,#Y)J%4?[,O6:O"4IW-X\[>`(1]MHA
M?;JMWSO]M=NI-^]N\@#]=Y=^')7?:\>7[",\[!ZGN[<4H@UY$AGXFF7?!#5^
M%!!<W&17C_,,+`^UQ_1I\_WUM,X^HG3W_'*"=`?P1.+!^H^_ANEQ"Q$%F88;
M"*5M]@H&X/_:?B=*`R*R^9G__-@]GEYNZUZ[$71:G@/TVM?T>!KOA&2]MOU^
M/&7[_Q4D1TH5(JX4@9]2Q.U\6L23(GXIXC2Z0>"WNQU[)\#,'P=^2B>]AML-
MG*#]B<=I2Q%H(U+D-YSTI`C\_'TG#M1#D1Y1&$7HW4]'UBF3?$[0;SR1@QD2
MOT@SW8;O!IWN9XK%@007SP1Q_OWX.AV4@5^D3/#Y7#N0Y,+-.=O6$6X6C2EO
MF\/-:7-W<\@^:M#A0<"/[QO1?3I]<0=LE44;*MOII68*[5.HW`N9VSJ$"5K@
M$?J6'W=MQ[UI_H#^8"LY#YP3!#IE@!31^H7ND`(C"HPI$%(@HD!,@80"$PI,
M*3"CP)P""PHL*;"BP%H!FI"?,DG0&/Y$DH2,2!)&]P&!<]:<#LD(4O":(05&
M%!A3(*1`1(&8`@D%)A284F!&@3D%%A184F!%@;4":!F!?N5/9$3(P#BF-!NO
MZ^L9>)`<&"?*MD4H@Y)29HDA(X:,&1(R)&)(S)"$(1.&3!DR8\B<(0N&+!FR
M8LA:1;2D07?^)Y(F9,3D0TE(V_%(UB3)E+624F:-(2.&C!D2,B1B2,R0A"$3
MADP9,F/(G"$+ABP9LF+(6D6TK$$(*[+6$%.MT\MN^^TA*V9]%?-(#T:B8GP2
M(GG.,-8/!2*&^+)9.5U'S^+`AC24VDX^[+DM.NZ-RL_QWF,;V="&%)7:8LB%
M>Y,'B,O/\=[)%5DM]%#BQM#_G;WG,XB*T,,D%F,O5/38%XB8;I2Q][ITY*D@
ML00-"U*[6"^(&<.((6,;H="&%#'MF"')%2$MOC`?U.)KCJ-@ZW$L$+%>4.+8
M)34L2>"K)/$X5B@Y7:(TD@9:>:$[7KO5:WEM_6[C2B%2E:&-I:A2B5B*B:56
MM^<Y9'1,*H7.EK2,0$E^(B."K6>D0$AE]_08#20)UEN&C%0HL;2-"I(K^KD?
M=X[?ZP0!38B-3FCC*+)1BC5''=_QW9;^],D5&2T=$"(M'<7JY)-]OQ#1LU0@
M>KOI$9\#23*WFX(4P)KW<BI'DB0'",]K^62V,*XPQ)(=VAB*;`S%FB&_XY,"
M3:[8T5(D%O[&'-D-$KF,GB4):8V)165@Q1I:L4;(@N>_G,XQLJ"0+[-"*U9D
MQ8J19?25(.N2+SUM8JVI+OS-8X_8F"&-2$*D%9W[U7SB-4"6N1DA2QW)6*I'
M:$(.0('G]=H>V4(86TF%R#+:BI!EM!436U[7"_PN:>')-2D].6+9J2;GM_H]
MIUB\PD(%)W\/$M*:E-<C&S4#9!G+;2A9OC&$(V3!(%PV%J]'HC/&.ZJEZP:D
M6PJ19?05X1V-OF)DZ;[HU`'O>,F7GC6Q\#1ES;(GE.M7-6T%I#4UUCP&8K,3
MVJB9-;1BC9!E#.(86<;V$5JQ(BM6C"RCKP19EWSI:1,K3U/:K!:88B%).\@"
M(HV-]%<#>:%C+.JA9`70I,MFQ"?HDM6&0E!89&$UQCNJ1<VJ*426T5=DY2NV
M\I7@'2_YTK,&N35FS;*Q"1DR[9"06W:;`W%,)5AG:,BA$8?&'`HY%'$HYE#"
MH0F'IAR:<6C.H06'EAQ:<6BM07J.H)56Y`@/Z.P/%X1.GJ1S6;?I,N_!D2S(
M55G\I#\?G#DX)`XY-.+0F$,AAR(.Q1Q*.#3AT)1#,P[-.;3@T))#*PZM-4A/
MI%A"__]=9+$0U^8C!00M'_,Q$*=ED&S1&91I9+W34+(\F):6+*]'=@=&9Q;*
MCSD4<BCB4,RAA$,3#DTY-./0G$,+#BTYM.+06D(70ZCG%KI;GELX68?(BNU5
M[$?M]UK%@$?[U`*ZZ$BN%6Q80RG?[N2;'K[C=D@K'YT9Y[07TG`10B%G11R*
M.91(R/PP$RO6]"PO=G!\V%$C-3P[,]#YG$,+#BTYM.+06D(7'T:O%9@,\%H)
MSOLQ6"Q7%I-"A@RZ!731ABP0&]903*6$O%?F>L2AL83,=PRM6!&7CSF46&E-
MK%A3+C_CT-Q*:V'%6G+Y%8?6U[2T<G+IUI&Y;'*Z7C82$D6L#`-DW3A`%M1%
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MV'Z'R%+;'8O`2+)DI^+Y/;_+IA(5IIA0B+<SFHJ09305(ZOH5/R&0RHE08(J
MHZ9%%J\T;K0TK=)BCS>3+!FGH-WR2)<RM])9(,OH:8DL]?F8IQ6RBC`YC3:Q
MM$:"*J.&2:_>/[(+[?)=:`F1'IGN0B/+V*R'DG7ER$>RVC(P0<MW`C)^C_%^
M:LMF(0Z197056;F*D55L&SB=1J^K3C!8C5=MWO/YLF09#4[QUL:JFTF6#)O7
M\=H!J:BYI&BY9%%;(,MH:FEE:H4L&;46O.>@?YUCC7=3,WFYRJ$M:'TT/=BT
MVT`0/3390)"0UG>ST`RL6$,KU@A9QJR.D:5V`LQ7:,6*K%@QLHR^$F09?4VL
M6%,KU@Q91E]S9!E]+:Q82RO6"EE&7VMD7?*E=^:@92QSJR-%5ZB0_8X"TCH`
MOT76(0-YH=B+,>UW%%I7CA2EUI4C1;RCV@E45+ET;_0522WBBPP@L96OQ,K7
M!%E&7]-J7V3<F%GYFN,=C?%:(,OH:UGMB\1K9>5KC7>\Y$NO\FNG0I:=.3\6
M@M<0\\H_G[<..#3DT(A#8PZ%'(HX%',HX="$0U,.S3@TY]""0TL.K3@D7ML\
MQZO(4?$:9O&JUSX]/*>#]/7U6-MFW\4KEK`K<'=3POC^9[M_#TIPS$`^@:/5
MOC@=K/C$[>!+H^0:V(7OBVUW?@WLEO?%]CC_!':U^V(;FW\"N\]]L=W,/X&W
M5N_S,B'W?X"W6?-7/RGN@N$*G0>OO\X/#`C_WN_?PPDWO_&#WU_GQY;D@F'0
MAV_\<WX4].';^!P?MOOPG76.1^T^?+N<XW#T":&H2A.<C$%@NQ77P#$37%/U
MR8,30)QR7\WR0>"MV_?-<SK;')YW;\?::_H$)=/*3WD.Q7N[Q1\G^?7_K]D)
MWK?-WP1X@?>K4_@:?DN<'SYEV0G_@`=IEF]LW_T#``#__P,`4$L#!!0`!@`(
M````(0#-#UO,5@8``-X;```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;*Q978^B2!1]WV3_`^%]1%!1B3IIY3N[R68SN_M,([:D10S0W3/_?FY15715
M71KIR<[#V!X/AUOGWOK>?/U>7+37K*KS\KK5S<E4U[)K6A[SZ]-6_^>;_V6E
M:W637(_)I;QF6_U'5NM?=[__MGDKJ^?ZG&6-!@K7>JN?F^;F&$:=GK,BJ2?E
M+;O"+Z>R*I(&OE9/1GVKLN38/E1<#&LZM8TBR:\Z57"J,1KEZ92GF5NF+T5V
M;:A(E5V2!N*OS_FMYFI%.D:N2*KGE]N7M"QN(/&87_+F1RNJ:T7J1$_7LDH>
M+]#N[^8\2;EV^P7)%WE:E75Y:B8@9]!`<9O7QMH`I=WFF$,+B.U:E9VV^H/I
MQ*:M&[M-:]"_>?96"W]K];E\"ZK\^$=^S<!MR!/)P&-9/A-J="00/&R@I_TV
M`W]5VC$[)2^7YN_R+<SRIW,#Z5Y`BTC#G.,/-ZM3<!1D)M:"**7E!0*`_[4B
M)Z4!CB3?M[H%+\Z/S7FKS^S)8CF=F4#7'K.Z\7,BJ6OI2]V4Q7^49#(I*C)C
M(O-.Q)RL%HNYO5J.%P%F&PE\LDB6$W,^M3\1A\TDH+B9Q"_$L68B\/FK<9B0
MQK8MY(]/1V+0%+49=Y,FV6VJ\DV#;@1)J&\)Z92F0Y1YKFEFNNQ_E'S(.E%Y
M(#);';R"O-90L:\[>[K<&*]092GC[#%GL9`I!TXA-45T717P5,!7@4`%0A6(
M5"`6``-\Z<R!`OX_S"$RQ!S>JCT'WMTR%;,.G,*?<57`4P%?!0(5"%4@4H%8
M`"0GH#<B)V90+OU#`J\*\A1T?J$JK.543OF><:"'=J4SERF'CM*9@1`/(3Y"
M`H2$"(D0$HN(Y`F,3,@3,DQ^LNL0&3)""@;8TY5LP9Z1AESJ*)U+"/$0XB,D
M0$B(D`@AL8A(+D'(DDO#%4/8K1F\$7N&T'F&C`D'A+@(\1#B(R1`2(B0""&Q
MB$@-A01*#:4CZ83,5LTY3Y_W)9WS>@R8P8A)QU$B(K>?(B;XV_4/<V7*Y7$8
M0W*9MMD.S];4M&01K_N=>^^/D0W&D,).FTP-\&ZE`5'W.W]W?$=6LGYYQ_IO
MY:V=Z7JLAY4`]YZHR-Y3Y([W8T@NTYYU<X"'$'^,4#"&%"+M""'Q'2')7[*P
M%Q<)PSX2MNPC14SXZ&K86JDS'B/!$JDCH4)W>Y3,E3)8>I1DD5[UNEM/R3^Y
MU/U>&:4F@S$!A;U*2D#1W8#B7IGW@*1L@$.?R`9AR]F@"%D"=T9;JH<'1H)>
MV)%P-GJ4$,GK4;)6:R4A/4K60B$%/4KH=6&/$B)%/4HHIKA'28Q)R@E9.DM)
M(:._99/]T9TU4ONDG"`&R?UEK=3P@;,@S($4<184V,<LC[-$+6O]7G_MY.1S
MEJ@E.M*R`LX2M5`&0LX2M1`KXBQ1"\45<Y:H)<8E9XHL]L7!;'RFZ#8!5FI\
MDMJ;%)+[TEJ96`^<-=R9.$OLE\@1C[-$+6L]4[H39XE:HB,L4RQZ40N],>S3
M0JR(LT0M%%?,61_%)6>*;$;$3`U/.R;=NTCIH9#2D=3M!7O0%(L,-=#E++'(
M$,MCK*&Y9Y10P%F#086<-1A4)`=E6O.9K11,?$](3@S9$HF)^:6EKLDV5F)W
MHI#2G=`A`6.)I88RX3+Y!0S,0P,?U5J(RVMK;:O=J2\N-#VQ-UJ#<86CXHHX
M2XS+5)=,,7^CV)U$)^2LD2W:4-;&K9+):EA94#!(ZF9B&.UH<QC%<D>Q/,X:
M[!T^9PWVCF`4*QS%BCAK,*Z8LSZ*2TX;)!>ES8+5^_A-)3F44%-&(:6GJ4MR
M]N!P1;N,-9>;HZR!/<9:R+6JO-'G;Y19RD(DX*P[/8VV<3BNB$>_;G<+_8-C
MCUEB?<OY@J!0OLS%^SG`R&Y&9)1E(8.L;OUQ@%N`EO4.N1CR,.1C*,!0B*$(
M0^0JXCT(Z@6]6J`'S456/66'['*IM;1\(=<&,-GL-AU,[S3V"P>.5F!AI>*F
MS2\[E%]<VX$C"_Q$:#MPG(!Q=^G`IAOCX=*![3'&X9;EH?55>>^>W+[T\/>6
M`\>G6&<_<^`,$>,/<^<!K,,_[.<.'*<!;G1OAMN56_*4_9E43_FUUB[9"6R<
MMC55T?L9^J5A!QV/90/W*NV9QQGNT3(X-IM.H(I/9=GP+^0%W<W<[B<```#_
M_P,`4$L#!!0`!@`(````(0##AF#&DR0``$[D```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;*S=6W/3R+;`\?=3=;X#Q?L![,2!I(!=LN6+?+?D^UL&
MPI`:(%-)9L_>W_ZLMK34EW]CG-2\[&'_M-22>ZUN298BO__7?[Y_>_'OF_N'
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M9`?D?U]\OS6U(5UR_9_#?_^^_?SX]</+LXM7K;=OSAH2_N*WFX?'WJUI\N6+
M3W\]/-Y]WY1!#;-3=2/-JA'Y;Z21(RN>52N>URLV6J^:[UJ-UH79_)$U9>EA
MO^6_U28;TMB1%2ZJ%:3R=843-W59K2G_U36/;ZHA62P[U7;(J9_+?(IR7?G'
MTSJS(;U8KBJ?5??TQ,_8>*OKRC^>N%GIT7*S3^_:AO:M^<?3-MO43FY*;=I/
M6Y?ND5)HUO7JY.?L5>/\S:^JKJG9,=7YQ(UJ`3:=[)RV4<U-TW:2E-,IG_1,
M.\G\XVG]>Z8SPYDMQ%.WJH5X9L>U.ZL<2<V9CFOSCY,Z^'4YH1WFQ_3Z\?KC
M^_N[OU_(44?V_^'/:W,,:UR9UG1F++=>SY4_FRIE>C.M)*:9#R\E9S(+/L@$
M_^^/K8MW[U__6^;D3U5,FS$-/Z*C$6;6-,VF(71#Z(70#V$00A;",(11".,0
M)B%,0YB%,`]A$4(>0J'@]&K+[[*EAFB7K4)8A[`)81O"+H1]"$F=<-UN4J>W
M%J0S03X3)#1!1A.D-$%.$S>IKZ6TZ_J6N>N?J&_3C*EO_7!M!9N:II^9CD;H
M*FD(W1!Z(?1#&(20A3`,813".(1)"-,09B',0UB$D(=0*-@>:[SUNVRI(=IE
MJQ#6(6Q"V(:P"V$?0I)`ZO3JGB1(9X)\)DAH@HPF2&F"G"9N4KUBEF,,BOE<
M)NWX::S.S68M.6%UYN9&*YR;JQAIJY[`S_WD=.H0[9,4TH7T('W(`))!AI`1
M9`R90*:0&60.64!R2%'+3[MP68=H%ZX@:\@&LH7L('M(DI#:).8Y8:(39CIA
MJA/F.F&R$R_;7KW+B1'JW5RV/?'DQ#1CKMB<XFY=7/KEW:Z"CHV`.D33ET*Z
MD!ZD#QE`,L@0,H*,(1/(%#*#S"$+2`XI:OGY"*A#M`M7D#5D`]E"=I`])$E(
M-N^Z1TF'44QTPDPG3'7"7"=,=N)EVQL!4H[>"#@^TYOH0Z'K9VF7\E:NC>IY
M7:Z(_-+OU$&Z6@KI0GJ0/F0`R2!#R`@RADP@4\@,,H<L(#FDJ,7MQ/!$O`[2
M3EQ!UI`-9`O90?:0)"'9W.L>)<QTPE0GS'7"9"?,=L)T)UZ^O<J6V?@)E6VB
M_<HNY>UE?4K>@:20+J0'Z4,&D`PRA(P@8\@$,H7,('/(`I)#BEIL&3<N+ORY
M8%D':=&L(&O(!K*%["![2)*0VB1F.F&J$^8Z8;(39CMANN7+Z4/]E=7FE;',
MK%X9F^]/6G*Y_,13%-.,7]^ER!9MMEIOPR],ZB#-5@KI0GJ0/F0`R2!#R`@R
MADP@4\@,,H<L(#FDJ,5V8N,RO.JL@[035Y`U9`/90G:0/21)2&U2A\14)\QU
MPF0GS';"="=>OKV2-W?%W*\,CY^3F&B_LDMQ9VY("NE">I`^9`#)($/("#*&
M3"!3R`PRARP@.:2HQ2WCX!)^60?590Q90S:0+60'V4.2A-0F=4A,=<)<)TQV
MPFPG3'?BY=LK8YE9O3)^YLQMFO'KNY1@Y@Z_':R#-%LII`OI0?J0`22##"$C
MR!@R@4PA,\@<LH#DD*(6M^2#:_9E':2=N(*L(1O(%K*#["%)0FJ3.B2F.F&N
M$R8[8;83ICOQ\NV5O+GEZM7\\:G[$.[7=D52W-KE'5)*ZI)ZI#YI0,I(0]*(
M-"9-2%/2C#0G+4@YJ2`M22O2FK0A;4D[TIXDMW1,=7QXZ>16;NK0(@F7&SN,
MBZ1<;NXP+I)TN<'#.#_M?EV;^U.GGY(TRMM9\H6@%G&[(OGL=KYIO3WS+XXZ
M-DI73$E=4H_4)PU(&6E(&I'&I`EI2IJ1YJ0%*2<5EFRORJ-/?J\N;93VZHJT
M)FU(6]*.M"=)]9=%X5<_+5(#4OV,BU2!5#_C(G4@U<\XOQ+\ZC>WKYY0_>7=
M+J_Z2W(^>Z<!2DE=4H_4)PU(&6E(&I'&I`EI2IJ1YJ0%*2<5%<DC%%K$2]**
MM"9M2%O2CK0G25U7Z;8[)K,Z31/N?`"I:\9IRMTXS;EKFG37-.NN:=I+\^O:
MW)QRZ]J<H3?ED9XG?[MB'A<+3M(K"B;\\)ZGC=*LIJ0NJ4?JDP:DC#0DC4AC
MTH0T)<U(<]*"E).*BIP$+TDKTIJT(6U).]*>)*.`-SK;$>M$3#/N?"AY;(7M
M:<[=.$VZ:YIUUS3MI?FCP-R-<D?!+\[9JYM7[KE-2=[L#DK-<Y'^V5^7U"/U
M20-21AJ21J0Q:4*:DF:D.6E!RDE%14[*EJ05:4W:D+:D'6E/DKJNTNW-[K1.
M)$XS[GPHJ6NNJSEWXS3IKFG67=.TE^;7M;ECY=;U<Y\\+.]\R>F,/<=LO0UN
M:[3-4P/F""#_J6^$8K*O8^QD#^K:EC2J1^J3!J2,-"2-2&/2A#0ES4ASTH*4
MDPI+/^W3I8W1WEJ1UJ0-:4O:D?8D&25(HYP#T3H12R,6J0$YMV=[D2J0<WO&
M^77@CQ)SXRD<)<^XO]0H;V!Y)_T5R5>R]9!HO0UNCG1TQ7?U>6U*ZI)ZI#YI
M0,I(0]*(-"9-2%/2C#0G+4@YJ5"R$_*2M"*M21O2EK0C[4DR!JITVQV3,4"K
M$^[$U1EWK$ZY8W7.':N3[EB==<?JM!_,'P/FWE<X!LPP>N(]5O/7&^55@%OP
MP6V4MD9)^_6PP)&B:LGN?VI7TXFN2^J1^J0!*2,-22/2F#0A34DSTIRT(.6D
MPM)/^W1I8[0#5Z0U:4/:DG:D/4E&"3(KHX36B5BD!.1\BNM&BD`><6=<I`SD
M,7<WSA\EYM::.TI^<9U0WHGS#@@5R2;JRF^$?\71:=11FJ>4U"7U2'W2@)21
MAJ01:4R:D*:D&6E.6I!R4J%DYXHE:45:DS:D+6E'VI.DU*M$VAV34J?5"7?B
MZHP[5J?<L3KGCM5)=ZS.NF-UV@_FE[JYI>:6^G,O'<I;<]X8P-VZCOFC.__"
M."5U23U2GS0@9:0A:40:DR:D*6E&FI,6I)Q45/1.OL.NIY'6V_#6K8W2:61%
M6I,VI"UI1]J39`R4N95]U;V0,4#3&G#CM`A<TRIP3<O`-:T#U[007--**,T;
M`^8/._^),7!HYW"/U\G6N^`635NCCIT4V1CMRY34)?5(?=*`E)&&I!%I3)J0
MIJ09:4Y:D')28<GV?'"BN;0QVJ<KTIJT(6U).]*>)'\>5=Z,=;_8<2I"]TS^
M1(IQD1*0/Y-B7*0(Y$^E&!<I`_ES*3?.'R7F1II[I#A^4M0L[[NY!P0E.3#6
MLUDC_..1CHW2WDA)75*/U"<-2!EI2!J1QJ0):4J:D>:D!2DG%17)O&9[M?4N
M>+IU::.T5U>D-6E#VI)VI#U)JK\L"G=>;D=,:\"-TR)P3:O`-2T#U[0.7--"
M<$TKH32_^LWM.[?ZGWF>9-X$@`OG=\$3;6V-.GJ,P`W%U*ZF2>Z2>J0^:4#*
M2$/2B#0F34A3THPT)RU(.:FP9,<)CA'HTY5=3?MT3=J0MJ0=:4^248*]2)R*
MT-V08P3C(B4@QPC&18I`CA&,BY2!'"/<.'^4_&.WF<U[+\IQHI^WK>0=/O`'
M6#9*5TQ)75*/U"<-2!EI2!J1QJ0):4J:D>:D!2DG%9;LL&B$O;JT4=JK*]*:
MM"%M23O2GB0#HRH*^P6Z#`Q:)V*1(I"!P74C92`#@W&10I"!X<;Y`\/<"_PG
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MS4ASTH*4DPI+/^W3I8W1/EV1UJ0-:4O:D?8D&25U]G4OY!A!BU2`'",8%ZD!
M.48P+E(%<HQ@G%\'_B@Q=^W<4?*+8T1UD\]YAJ]9D7N,:+T+GG+JV"CMH934
M)?5(?=*`E)&&I!%I3)J0IJ09:4Y:D')28<G6?NM=\`C,TD9IKZY(:]*&M"7M
M2'N25']=`;H74OVT2`U(]3,N4@52_8R+U(%4/^/\2O"K7XK6J_[G?@UEV@EN
M533/@VRUFU74T6-$':-]F=K5E+JD'JE/&I`RTI`T(HU)$]*4-"/-20M23BHL
MV7$2''>7-D8[<$5:DS:D+6E'VI-DE""S,DIHG8A%2D"NMKENI`CD:IMQD3*0
MJVTWSA\EYK:C>XPPH^19?^U@7H`:7F)4)%NO3YP:^/,V7=%^59&2NJ0>J4\:
MD#+2D#0BC4D3TI0T(\U)"U).*BKRWJZ$7EW:*#LPRG3(BDIK1FU(6]*.M"?)
MP,`F96#0.A'3(G!V5P8&U]4R<..T#ES30G!-*Z$T;V"8E_)Z`^/XR=,AW+_`
M5K)/EW1(*:E+ZI'ZI`$I(PU)(]*8-"%-23/2G+0@Y:2"M"2M2&O2AK0E[4A[
MDKS3T+WW6[Z+N!VQ2,+EM89<-Y)R>;$AXR))EU<;,LY/NU_7YKYB..$_X[%6
M\PKJ\+2H]2Y\K%6CCIT6V1B=EE)2E]0C]4D#4D8:DD:D,6E"FI)FI#EI0<I)
MA25[5`U/BVR,]NF*M"9M2%O2CK0GR2BI:L3.@$D[8IV(14I`WO[)]B)%(.__
M9%RD#.0-H&Z</TK,?;MPE#SKM.BLN@/H7%4K^:=%00H[-DI3F)*ZI!ZI3QJ0
M,M*0-"*-21/2E#0CS4D+4DXJ*I)#N1T6C;=!KRYME/;JBK0F;4A;THZT)\G`
M*(O"/15I1TQKP(W3(G!-J\`U+0/7M`Y<TT)P32NA-']@F/MVX<!XSN&CNO\G
M7VC5EP;-2QP^JJBCAX\Z1C.:FE]%,,<F.^]T23U2GS0@9:0A:40:DR:D*6E&
MFI,6I)Q46+(]CU&"#ES9U;2;UZ0-:4O:D?8D&278"SE\T#H1BY2`'#ZX;J0(
MY/#!N$@9R.'#C?-'B;F7YXZ27UP\5+?^W&-$1?XQ(K@ST3&_X6$*W;ET)G5)
M/5*?-"!EI"%I1!J3)J0I:4::DQ:DG%14)/.:K?W&VZ!7ES9*2WU%6I,VI"UI
M1]J3I/K+W+KS<CMB6@-N7!J)TRIPX[0,7-,Z<$T+P36MA-+\ZI?IVJO^9W[S
M:OYLFI<8P2/];8TZ>HRH6K('A-2NIDGNDGJD/FE`RDA#TH@T)DU(4]*,-"<M
M2#FIL&3'"8X1Z-.574W[=$W:D+:D'6E/DE&"O4B<BM#=2#J1N$@)R#&"[46*
M0(X1C(N4@1PCW#A_E)A[>>XQXMG?O,J#X]4XT<_;KD@&ITU@(WP]0<=&Z8HI
MJ4OJD?JD`2DC#4DCTI@T(4U),]*<M"#EI,+2D5Y=VBCMU15I3=J0MJ0=:4^2
M@5$6A3ME.U6A>R8#@W&1(I"!P;A(&<C`8%RD$&1@N''^P#"W^=R!\8N3)Q,>
M?/-:DOOJF3-02NJ2>J0^:4#*2$/2B#0F34A3THPT)RU(.:E0LF>62]**M"9M
M2%O2CK0G25U7B;0[EK0CUHE8G7%GW3KECM4Y=ZQ.NF-UUAVKTWXPOZ[-3;@G
MU+4)#^JZ)._M80V\.\,\T2<K.M6?DKJD'JE/&I`RTI`T(HU)$]*4-"/-20M2
M3BHLN;-Z<(-_::-T[ER1UJ0-:4O:D?8DJ7[D5JJ?UHE8I`AD5N>ZD3*069UQ
MD4*06=V-\ZO?W+E[0O67-_KD**'=W3ZK[OTY+P$FI:0NJ4?JDP:DC#0DC4AC
MTH0T)<U(<]*"E).*BN2D5'MU25J1UJ0-:4O:D?8DJ>LJW7;'I*YIG8AIQIT/
M)77-=37G;IPFW37-NFN:]M*\NCXW=]_<NG[V:?RA)7_"KRB8\(-O23LV2K.:
MDKJD'JE/&I`RTI`T(HU)$]*4-"/-20M23BHJ>B=?PM??/3?>!KVZM%':JRO2
MFK0A;4D[TIXD/QU6WMR5?=6]2-H1TQIPX[0(7-,J<$W+P#6M`]>T$%S32BC-
M'QCFYIH[,(Z?QI]7]^*<";^BM_;TJD-*25U2C]0G#4@9:4@:D<:D"6E*FI'F
MI`4I)Q45.7/9DK0BK4D;TI:T(^U)4M?NK=?J`8J(:<*=#Y!HQEW3E+NF.7=-
MD^Z:9MTU37MI?EV'MX9_4=>\_WM>W?V38U0]_[0N@Y=?=&R4COR4U"7U2'W2
M@)21AJ01:4R:D*:D&6E.6I!R4E&1S$1'>G5IH[175Z0U:4/:DG:D/4FJOZP`
M=R9M1TQKP(W3(G!-J\`U+0/7M`Y<TT)P32NA-+_ZS3VO)\SJU2TR=U8OR9O5
M0>DYJ$OJD?JD`2DC#4DCTI@T(4U),]*<M"#EI*(B9\):DE:D-6E#VI)VI#U)
MZKI*MWL:'[%.Q#3CSH>2'SME>YIS-TZ3[IIFW35->VE^79N[;6Y=/_\TOKHG
MZY9\1?Z$'_ZIY7D=I5-32NJ2>J0^:4#*2$/2B#0F34A3THPT)RU(.:FP9"?\
MYAN<QJ-75W9%[>@U:4/:DG:D/4D&!O9"3N-IG8A%BD`&!M>-E('\#C#C(H4@
MOP3LQOD#P]S`<@?&+TYWJOM=;O57Y'QO8WX]WGRW:2DE=4D]4I\T(&6D(6E$
M&I,FI"EI1IJ3%J2<5"C9J\`E:45:DS:D+6E'VI.DKJM$VAV3NJ9U(E9GW%FW
M3KEC=<X=JY/N6)UUQ^JT'\RO:W/_R:WK\B&%5V]E[Q^_WG[ZHWTG)^=RE1*I
M][.7']^7URSGY5TL]VO*BLPK[>NS^T;XDJG.25&I-B^[X;05O`*I:Z-T/NN=
MU'S_I*B!;=[=B>!%&IF-TIT8GM3\Z*2HL6W>W8G@F82)C=*=F)[4_.RDJ+EM
MWNY$>/ME88-T'_*36B].BEJ>%+6R.V'WM!&^.VMMHW17-R<UOSTI:F>;=W<B
M*)R]C=*=D&FE'%;'QY#,-">%Z5@S3WL[HRBH'?E:H1K+SELY=6C]8D=.&VYR
M-*ZW8'<DK)_$&6]UA^CH^NE^^%.;N45Z;&I;WOWYLZE-WO]0SVWEG59O;BOI
MI[MQF!0[YZ=$I564/$2I'[-+ZIW45O^DJ`&;STC#D]H:G10U9O,3TO2DMF8G
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M+^7U^N'9ZS3>4C!`9B=%S>-1P5XM3MBK/-Y2L%=%%14<KX*_-UAJE!2B4S5!
M6RN-DM'\\ZBU1OEM!8^>;33J:%M;C?+;"O9KIU%'V]IKE-]6L%\R&\IR^1HO
MZ+!@DTE;P_S6PC`=VD%K0;IE@BPW*B\0-55XUGI[?MD*@W1H!VV%F]2Q;7Y[
MX>=9DO.KZ.<,-UJ/[F-[IH/[IWOFS:JM\.&BX^=@AW#_":**@LT%-=V)1P7=
ME9X4U=4HOT^#VNEIU-$Z[)\4-3@I*M.HH_LUU*BC^S4Z*6I\4M2DBCI6S].3
M6IJ=%#4_*6IQPE[E)[54:$ON<:KY)JC`I4;YQ[R@`E<:Y;:%8_%:H_RV@@K<
M:-31MK8:Y;<5[-=.HXZVM=<HOZU@OY)$PXXVEK0US&\MV+-$A[9W6H4N2W1L
M5\?V\_.SRXM&\$U=HD/[%VWIV#8O*SPVJ^H'./XY=70?W3,=W#_=,W]6-<\>
MG7ZN:G[W,G@07\E>GW1(*:E+ZI'ZI`$I(PU)(]*8-"%-23/2G+0@Y:1"R3XJ
ML"2M2&O2AK0E[4A[D@R_*MUVQV2LT>J$.W%UQAVK4^Y8G7/'ZJ0[5F?=L3KM
M!_/KVCQ5Y-9U>4OKR;]8V2J?3I*O<NSX/<.;TS7*';[!=^H=&Z/7\2FI2^J1
M^J0!*2,-22/2F#0A34DSTIRT(.6DPI+M^:!/ES9&^W1%6I,VI"UI1]J39)14
M->)49CMBD0J08PW7C=1`$BF")%(%2:0,$K\._%%BGBD*1\FS7NW3JIY.<K[$
M4/).'_%HIXW2%*:D+JE'ZI,&I(PT)(U(8]*$-"7-2'/2@I23"DMV6#3"7EW:
M*.W5%6E-VI"VI!UI3Y*!416%?6A=#A^T3L0B12#G7%PW4@8R,!@7*009&&Z<
M/S#D>T,,C&>\VJ=EVCE<A=ILM2Z#D\FV1AT]?%0MV4DFM:MIDKND'JE/&I`R
MTI`T(HU)$]*4-"/-20M23BHLV9['X0-]NK*K:9^N21O2EK0C[4DR2K`7,DIH
MG8A%2D!&"=>-%(&,$L9%RD!&B1OGCQ(I6&^4_.(K&1,>?"53DO]NALO@PJW3
MJJ,T*2FI2^J1^J0!*2,-22/2F#0A34DSTIRT(.6DHB+S!ZCVHC/LU:6-TEY=
MD=:D#6E+VI'V)*G^JBB\8P1-:T`^D^ZMG#PQ3JO`C=,R<$WKP#4M!->T$DKS
MJU^N"9Y2_28\J/Z2G+].[[1`*:E+ZI'ZI`$I(PU)(]*8-"%-23/2G+0@Y:2B
M(N?)]B5I15J3-J0M:4?:DZ2NJW3;X[7,ZC1-N/,!I*X9IREWXS3GKFG27=.L
MNZ9I+\VO:_-D1'A1\)QSG^I)#/DP]2S4N@R.P>U6%25#N8X*8CHV1L=^2NJ2
M>J0^:4#*2$/2B#0F34A3THPT)RU(.:FP]-,^7=H8[=,5:4W:D+:D'6E/DE%2
M9U_W0D8)+5(!,DH8%ZD!N71F7*0*Y-*9<7X=^*-$#JX8)6?O7IFO73_]]?!X
M]WUP<_O[X5NGZ'/3$J</%[9,4\&1H2+_"!X^`*`KVF-B2NJ2>J0^:4#*2$/2
MB#0F34A3THPT)RU(.:FP9,=%(WRL8FFCM"97I#5I0]J2=J0]249&70&Z%S(R
M:)V(18I`K@JX;J0,Y*J`<9%"D*L"-\X?&>8.\3]Q_"CO-'M?O;8N@X>HVJTJ
MZNCQHX[1ODSM:DI=4H_4)PU(&6E(&I'&I`EI2IJ1YJ0%*2<5ENPX"8[)2QNC
M';@BK4D;TI:T(^U),DJ061DEM$[$(B4@HX3K1HI`1@GC(F4@H\2-\T;)1?@X
M@SE4F'LK3SQX'-KQ#QY*,D+K4ZK69?A+939*$YB2NJ0>J4\:D#+2D#0BC4D3
MTI0T(\U)"U).*BRYO1K<L5[:*.W5%6E-VI"VI!UI3TJ2B+4CUHE8I`B22!4D
MD3)((G601`HA\2O!'Q;F[N(_</"XJ.Y2^A<?P6-*;8TZ=O"P,9K1E-0E]4A]
MTH"4D8:D$6E,FI"FI!EI3EJ0<E)AR8Z3\.!A8[1/5Z0U:4/:DG:D/4E&">]D
M.Q6A>Y9T(G&1$I!1PO8B12"CA'&1,I!1XL;YHR2\NWW\B]>+^B:V?JBVDGN,
M:(07YQT;I2NFI"ZI1^J3!J2,-"2-2&/2A#0ES4ASTH*4DXJ*Y%=Z;>VW+L/G
MNVR4]NJ*M"9M2%O2CK0G2?671>'^RK!6A6M:`ZYI$;BF5>":EH%K6@>N:2&X
MII50FE_]YK;=/W&,J&[_><>(B^#F0_NBBCIZC*AC-*.I74VI2^J1^J0!*2,-
M22/2F#0A34DSTIRT(.6DPI(=)SA&H$]7=C7MTS5I0]J2=J0]248)]B)Q*D)W
M0XX1C(N4@!PC&!<I`CE&,"Y2!G*,<./\46)NV[FCY!?'B.HNG_,`A_PUV>%[
M*?\8$5R`=VR4]D9*ZI)ZI#YI0,I(0]*(-"9-2%/2C#0G+4@YJ5"R-P:6I!5I
M3=J0MJ0=:4^24G?O\U:OH8M8G7#[`9(ZXX[5*7>LSKEC==(=J[/N6)WV@_FE
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MNA!N29:81[)B_2`=+D]MQ)9<R))8:_(DE]F[6'/RH(M9%&M/'@PPBZ(-GIO<
MRNOTN!?R'C6S*+JM<[,M>7=39*V6*67Y[I:+Y-E@Z:38IN0)8?G`L1J71R1E
M26P=>2;:;"BVDCP7:A;%UI*74%V9%VEQ[^19?ME2;+_E5X^DN?+A@""[\LLO
M9E&T9\],,<NO37!3\LL"9E&LF.5-[&91M/S.3?G).YXC#9Z;3I?7Y,86F6Z2
M=XARD;Q(_<J\##ZR1#9E7I`=6R*]%-V0O*=4ED2W(S5FWE89:TT&1[3"Y#?^
MKLPOG476D27FYPMC2Z2UZ#KRVX:F5V,KR4^_F46Q+<EO2$F]QCI5?DE*MA2M
M(BD(\PM!L;V3"3%:#O)##;(D6@U-4PWRV^9L3GX"V^QW+$?R\[K2=]%,R!+S
MR\%L3GYE5);$UI&?%38;BJTD/ZUJ%L762IHR,)JQXF_+DES^!"RR#TWIH>@Z
MA6DMBZY4R$JR*+:EI"G#+-I#;5F2-V,]+C]"+TMB'2X_XRT]%.OOPFPGBS:7
M-*6'Y"\X8Q]6.KP9Z[IV4PH\NDYA6LNB*Q6RDBR*;2EI2H7+$Q:Q?9`!TXR5
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M^S\.7X%\_'\!````__\#`%!+`P04``8`"````"$`V(N#LF<)``#`+0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RLFEMSXC@3AN^W:O\#Q?T&;(YQ
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MZ8=@=,@\N<^K]^UI['VTW<W+ZXGB7:);DG?F//UJN,<U#2G)7-@EJ;3VMN0`
M_<WL-C(W:$A6/_W/C\W3Z?4Z6RA?E"KY@D7FF6_N\=3<2,EL9OU^/'F[16!D
M*:E`Q%8B]*E$K,O4C:D;WP/ZU(V_[`#UYFO0YV]K6/HNY!>C4BV5BN5J)?U8
M6`4]HO1%R50NOBY3UC+TY0^\J6@9^O('WN@!EG'5WE2_'":;TMN/D_RB9;X^
M-K9.6OE%R10N[&K)*I5EUI[+5!UD.PRR'?'@7%,=6+MH>K4B3=/.%9WOTM,O
M.J]SP@YS(JWS.@_L2`"_[GQ!!U!^4<[_1G(7=``+X1SYC:$L4"#\=))?_L`;
M'9%"&)'TWN2"@NK7Y\;JM+JY.G@?&?K5HWL\OJWD;ZCE2&5=F8,4,[7ZLU)-
M-5JJ""ESG:6`4Q4^T@_,CYMRWKK*_:#?A+6RJ:$-LZAK"_D#(&4;'-QRT.2@
MQ4&;@PX'70YZ'/0Y&'!PQ\&0@Q$']QR,.9AH$(YJJ10?U*DVT4,VXV#.P8*#
M!PZ6'#QR($S`=;_"A-<0"*>`>`H(J("("@BI@)C2ZD4E(/6>H]0V^4T%]/^1
MWU)&YK>^N9H&86CL>&3JVD(W:7!PRT&3@Q8';0XZ''0YZ''0YV#`P1T'0PY&
M'-QS,.9@HD$X8E8E/F13;:*';,;!G(,%!P\<+#EXY$`((":\VA,!X1003P$!
M%1!1`2$5$%,1#6HLF>EW")*Y2$4[>1FM:[-L10OF2&VV2M7XR->4#6F9`EZ,
MF]2-B1Z3!I!;($T@+2!M(!T@72`]('T@`R!W0(9`1D#N@8R!3`SY=`BGQD0/
MX0S(',@"R`.0)9!'($(@"N.N/1(89X&!%AAI@:$6&&N!P1:Q:,?RG19,D.]R
MV_C%Q8F4D3O&2'*7\ZQ<UY31N1E@3/1@-8#<`FD":0%I`^D`Z0+I`>D#&0"Y
M`S($,@)R#V0,9&+(YS/`F.@AG`&9`UD`>0"R!/((1`A$8=RU1Z*.5AAH@9$6
M&&J!L188;!&+=FP&4#K&9L#Y2B^M_437]U)3)#A3D4OJ.I`&D%L@32`M(&T@
M'2!=(#T@?2`#('=`AD!&0.Z!C(%,`E+TS[/\3<@4R`S(',@"R`.0)9!'($(@
M4E&-^"A46*-(Q36*5&"C2$4VBE1HHTC%-HI4<`,4RUFJL[&<#;:4%_)TZO2Z
M67^O><%174(N%VCK&&PHI4@\E0-B%<T:O*YL:.EO%BU6E=7UAC'2<^(62%-)
MA\O[EK&)2A?B*Z*V,=+2'2!=D.X9FZ@T6VSUC9&6'@"Y`^FAL0FE*VR-/3(V
M6OD>R!B4)XI098P,-=N^3],8S4QO4246M+DQTDXNTF@_I#%:&NVH`RRTC\9(
M.R!$&G%12V65G+DL!P2FKE"Y2Y,@ZCR+@]#Y?-XJ*<=YM@C,<:&2_%,?8K6`
M#O3.UH*I]^:?0274`CIYU,5`JL2+04`^]<&O(775K&`J1@/(+9"FDHX4`[!I
M`^D`Z8).#VSZ0`9`[D!G"#8C(/=`QJ`S4>1LFDS3&,V@MSF011JAAS1&2]!^
M!")$&B512V6%B20PDX1*I?,Y*71ZG1UTT<(;PIP3*ND^[3$V$^6SU.A![_D9
M)ZWC,RX@K"]V&EE7S>QPQ@&Y!=)4TI$9!S9M(!T@7=#I@4T?R`#('>@,P68$
MY![(&'0FBL2#SP9QFFC$:OP,>IL#6:01>DACM`3M1R!"I%$2M516F$BB@3VJ
M5&(YR49*Z/2*#SJW:J$\YIQ02?=IC[$91\^POC#CI'5\Q@7$(L<B:ZYR?`U:
M5T:7X8PSS?32Y=;81(78NK`9&-G!(W.Y4VR99EJH#=(=8W-&N@O2/=-,2_>-
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M)EVH%1QZCIC0H$`-DBX(&A!*&VPAZF6Z;[_BL+L0+;I"ISC89E9Q:)>.?%EQ
M:#^-7-0KU$?BE19=H?TIMJ%PT"(=.06#EM+(>U6']F/(AU6']E?(9V6'S@J1
M+\L.'>$AGU4=VB<A7U8=VM$@IV&E(S?D-*AT#(:\5W;HH!;YL.S0,2MR&E(Z
M-D!.`TJ;>^2]BD,G1,B'%8=.?(CG3/CI]=FWU8L[6!U>-OMC9NL^TZS,^Z?P
MA^`%W."?DSJ!^^:=Z,59_S#NE=Z4=FD'D+^@"O#L>2?]C^S`O'M]\Q\```#_
M_P,`4$L#!!0`!@`(````(0![?=`O9AL``*RF```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;*R=VW+;N+*&[W?5?@>7[Y=MBI)LJ9+LDD4=J?-9NO,X
M2N*:V$K9GC5KO?UNB&B2Z!^B.JZYB9T//YM-H-$`01+^]'__>?YY\>_]Z]O3
MX>7S97!U<WFQ?WD\?'UZ^?[Y<KEH_^ON\N+M_>'EZ\//P\O^\^5_]V^7__?E
M?__GT]^'US_??NSW[Q=DX>7M\^6/]_=?]>OKM\<?^^>'MZO#K_T+E7P[O#X_
MO--_7[]?O_UZW3]\/1[T_/.Z='-3O7Y^>'JY3"S47S4V#M^^/3WNH\/C7\_[
ME_?$R.O^Y\,[^?_VX^G7&UM[?M28>WYX_?.O7_]Z/#S_(A-_//U\>O_OT>CE
MQ?-CO??]Y?#Z\,=/NN[_!.6'1[9]_`^8?WYZ?#V\';Z]7Y&YZ\11O.;:=>V:
M+'WY]/6)KL!4^\7K_MOGRT90;[0JY<OK+Y^.-;1ZVO_]EOO]XNW'X>_.Z]/7
MP=/+GJJ;&LHTP1^'PY]&VOMJ$!U\#4>WCTTP>;WXNO_V\-?/]]GA[^[^Z?N/
M=VKO"EV2N;+ZU_]&^[='JE(R<U6J&$N/AY_D`/U[\?QD8H.JY.$_GR]#.O'3
MU_<?]%OUJG)[$P8DO_AC__;>?C(F+R\>_WI[/SRO$U%@325&RM8(_;1&2E=!
M^:9J3!0<1J7'<]-/>U@07-T&-[7PMOC`JCV0?J;G^UV?;ZT-^LDGO[JK5,K5
M.W-RY853-SI>`?U,'5%<>,T>1C_YW$'NY`55%E"`',]H?DE/^;O7'G"K!Z74
MR@>:/:"@29S)HB=_'<I*##A\S"_VFFI7I;M*4#E&D-8,AY,)_X]7#<=6D`77
M1ZZ)PRO(XJOT@6OB``NR"/M(U7#`!5G$E7Z[EY<X]LPO'+>YL%6V4XF#S_S"
M[528)TH4I<<X,[_PB8.K<JER>W=,4P4=IL0Q:G[AL_W^I7.(FHS&'GS@TCFX
M2EEP?:`Y2QQ<YI>/7Q/'5BF+K0]$>HECR_S"SA0V9\AQ9'[ARE0V9\C!8W[A
MLVF;\SH9^XY#:?3P_O#ET^OA[PN:H)"MMU\/9KH3U(UA'D23N$J'U5.C*@VG
MQDK#F/E\24U+`^8;S07^_:5Z4_MT_6\:OA^MYAXU@:MHLL*,U<9L)$%+@K8$
M'0FZ$O0DZ$L0,\BNIE)Q71VPA%T=2C"28"S!1(*I!#,)YA(L)%A*L))@+<%&
M@JT$.PD::8/S]3?2YDT)-&<#VK.1;]!K"LDT+BG=_1-Q:<R8N&2G[AED35MR
M6[;)"CXDDJ`E05N"C@1="7H2]"6(&62>!K>NJP.6L*M#"482C"682#"58";!
M7(*%!$L)5A*L)=A(L)5@)T&C`21M7JZ1!C1G`]JSD6]0)PAIW/PG@M"8.=YF
MI,FQ5)/)T6IHC$U%9;>UFZF$+RX"T@+2!M(!T@72`]('$J?DI,N#5,(N#X&,
M@(R!3(!,@<R`S($L@"R!K("L@6R`;('L@#0:B.X183LWL*$;3DL[04OSM7\B
M:(T9<T><"\AJ<..&Y+T5%45M*N$0B("T@+2!=(!T@?2`]('$*3D=M:F$71X"
M&0$9`YD`F0*9`9D#60!9`ED!60/9`-D"V0%I-!!E[<XUU&BB"ANZX;2T$[44
M0D[4^A=Q>+IIU,?@Y//?)Z1\7#$ZSAV;0"(@+2!M(!T@72`]('T@,9`!D"&0
M$9`QD`F0*9`9D#F0!9`ED!60-9`-D"V0'9!&`Q&V:@.;M8'M2NN.QP!)PL&)
M,\IG3IPE]SM79N'K_<?3XY_WAV3)SQ-_(=W7)'<[QH@;?@DQJSCI\!W<R=L;
MC2BRMFG&G5H*;T(W[[92$<=_6V.[HQ%U4]MY!\1<I)>*V(&^QG:L$0TTHF'J
M0-Y+44VC5,1>CC6V)QK1-+6==T!4TRP5L0/S,[:=6*4ECL)871Q^'6_@/;%*
MBS4<K,:*&ZP).1.L&E%D;8?I_54+2%MCJ*,1=<%V#TA?8RC6B`8:T1`<&`$9
M:PQ--*(IV)X!F9\QY`08K7XY`58<2$;M!E)"S`)M+E>)E9*F%=$262J"U!AY
M+(&HE8AH-=.L+U6"<C4,[]S$V-;8Z6@\ZGHMB=/U'(_"RFVY5A&2OM>.&!EB
MCPBN;>`101T--:*1%;E-(A87QAI+$Z\E<753CZ4P%#?`,Z\EX=/<8RE?!4YP
MT]4YP6U&^E+5/`H\\820$Z8YT(WSA)@C3X=PTXHHP9\611I++8VEML921V.I
MJ['4TUCJ:RS%'E%8%C>6`X\HW]#':=A0(QHE(EIO-TFC='=[4Q7A.=:8F5A1
M8>M.-99FCD/A[6U0$1<_/V/&B7+S,/1C87X\THUSBT1"K[HYMLDJ<K,@TEE%
M7?:TJL6JO*WP1G3[-JORMDH5D4$ZK,K;@J#ILBIO"U0]5N5MA3<RM[,J;PO\
MBGVJL"RB<.!3@5]#E6ID57:D#,IA)12KW&.5H0FK\M4`3DU9E:\&4,V$4W=W
ME5O1@O-SAMS(-P\EY*,K58(W[P"(#&_1F12O4D4J58M5A1FES:K"H:>C4G55
MJAZK"OWJLZK0K]BG"LLB%`<^%83/4*4:695-]T'MMG1[)R:D8Y6E":L*ZV'*
MJL)ZF+E>488(:C<RZ9^SY,:^>?+QL=A/GIG0NB[?DMZ;-V&H.XBL+_IFDU6%
MJ2!B56$J:+'*M059W^,7Q$7';TMDURZK"OWJL2KO5R@7O?NLRMOR9'V/]V%9
MK%`,?+;@&H<JU<BJ;-:OW57#FCC=6&5HPJI\-8!34U;EJP%4,]>IH%2KU&"^
M<\Z2&_KFB8D,_:#RFRMXYOTM.00DZ-P08%6%:2&RYBLT.2N:_"2VZ!W)`E7;
MVBKVJ\.J0K^Z*K]ZK"KTJ\]G+$Q]L4\5RE=#!CX5Q-*0_2JLU1&K7.]%<AFK
MSCAA56&M3OF,A7[-6)7W*RR+%<,YGS%?J_GDXO8%LH5]@5YBI8`RB]F\0*A?
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M7K:6T651\M&">1&RR:H,18A:B-J(.HBZB'J(^HABBYS!`0;N@4HU5*E&K"I,
M&6-6G4H9QP7$B4HU5:EFK"KT:\ZJ4WZY$6:>Y<BIKFZ%PSX7RM_E691%4-.\
MH&]"+T,1HA:B-J(.HBZB'J(^HM@BD;+$#&#@4T'H#56J$3MA5XG+);I!EQDK
MJ2S'*3C=A$]W)F-I;,U<I\+@[N9.S&+G?#I=PJ*@^V`XF2/%"&A1%CM-DP1D
M.`%JH:J-J(.HBZB'J(\HMLC\2,>:L"RF;@.?"MIWJ%*-K(K77TOT79<8<,<J
M0Q-6%2:5*:OR%PBNSX13E=H-WGPDS664:4WE#;G9B9SZ8#B9(T4X690/)T"1
MN;MP(ZR%J(VH@ZB+J(>HCRBVR$D$85GTS(%/E:_*Y`F62C5B)Y+L%`;!7>U.
MW)V,598FK#J3GI)J=JX0?)^Y7M&G?S7ZA-!-FG,^GRH_F6^K/A90QR/=@&*4
M"RA$$:(6HC:B#J(NHAZB/J+8(J?7A671P`.?"AIEJ%*-K(KS4\6LR<D$I;(T
M815%C#=C',-\RJI3>>6HF@FOJM5*M2:ZU?R<)2=#E3[\A.AXI`@H^]`H'U"`
M(CXP4[40M1%U$'41]1#U$<46.?TW+(L%_8%/Y0FHY!H=6Z`:L1-)ABI7;^_D
M'>98=;H)JXH3%*M.I14;3[9YK%.UVJU\L#P_9\@-)[.B_Z'IN/EX4PQXC+)`
M:2**$+40M1%U$'41]1#U$<46.?DI*(GY\<"KDJ_`#E6J$:OR6264CPW&K,IG
ME?Q2Z3$*)JS*VX(`GK(J;PM4,U;E;845L;8Q9U7>5MXO-ZC,,P`95+_].(,R
M.0281?D``Q3Q@9FJA:B-J(.HBZB'J(\HMLC),?B,P*>")AI:U9DE*E;EU^(#
M>7<U5IUQPJHS*2NI^V*_9CZ_PHJX\YWS&?/I[W2`>9\1_/8R50D?###*8J>)
M*$+40M1&U$'41=1#U$<46^2F,)F<!BK54*4:L2J?*B!:QZS*IPI0352JJ4HU
M8U6A7W-6G?++36$4A_]`"C-6Q)3+HGR``8I,VA`WA8C:B#J(NHAZB/J(8HO,
MCW0>',HY]<"G@N8>6E7Y5.4?Q[41JVJGWX8>J\XW8=69!)94L^,5OL7K>N5]
M(WK.Y\O75;X6W.`BKPJ#2[?*;G:=D-%E43ZZ`$5\8*9J(6HCZB#J(NHAZB.*
M&972EW8&B(:(1HC&B":(IHAFB.:(%HB6B%:(UH@VB+:(=HCHPW#;D%F%->X]
MK.EA:8OGCDV;_,C<^#1+N3A_XUU`U!MHF/U,D@#-$DA5/F6_9U6^ZX@UEV:F
MX3>\(D0M1&U$'41=1#U$?41QAK(K%+X/,@W[/D0T0C1&-$$T131#-$>T0+1$
MM$*T1K1!M$6T0T11;6,DRT44U<@\$4";'J#.C0$WJFGL<:*Z^!FFV49'9E>+
M,E^;K,I0A*B%J(VH@ZB+J(>HCRA&-$`T1#1"-$8T031%-$,T1[1`M$2T0K1&
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M[JA4W<S\\?NX&YG.>IF`S]]768Y5JH%*-<R<L%Z*-==1)F`OQRK+$Y5JFIFW
MYQ>M-,L$?/ZYRO)"I5IFYOWG7V4"/O]:97FC4FTS\_[S[S(!GY]V.S+][]R@
MVKC7R9K9&?PNT"9)R?EH%\/4!^X])[NJFS#,`R.\E\L^+="M-9`#<A9BT4DW
M;,9(#BQ616P^M^D"HK;JC!V5JHOF>XCZ*ENQ2C50J8;HQ`C16&5KHE)-T?P,
MT5QE:Z%2+='\"M%:96NC4FW1_`X1]6Y-L%+O5LF:GC-X`IUV/3MCSNW/'WY@
M&^(#6XN<1PAA(-Z::/I4<+L1^55B)M9B5;+"&US)[1_;+*!;JO1^!$[64:FZ
M?I5PJ<<J=JDJKK_/@D*78I\*ZG+@4\'E#?TJX?B(58GC-U>AF'N/65#H^$2E
MFOI5PJ49JTZY-&=!H4L+E6KI5PF75JQ*71+OC*Q94.C21J7:^E7"I1VK3KE$
MB2CIJT['A#"A1*22G>C`PBN::UAK)]U*>^^IJG(SE7DZG)]Y%*^WA?9!?G9K
M=&^1>;:2YH(P$+>Y39\*ZBKRJT0=M%CEKH:(?M5F5=XO.&-'I>KZ5<*O'JM<
MOX2JSZI"OV*?"FIUX%/!-0[]*N'7B%6.]W*KBS&K"KV?J%13OTKX-6.5XU=5
MO`0T9U6A7PN5:NE7";]6K'+]$K>':U85^K51J;9^E?!KQRK7+W';2,DKZ<E.
MMX70H>2EDIWHWL(U2E[6FNN;J#.::YTYJ9O!Y&LF9S(8ODX2)LC)XV$@1J"F
M3P45%JE4+5;10E.6,^6+;6U6Y1-Y6!*UU?&IP*^N2M5C53JXB"73/@L*78J]
M*EFA`Y\*'!^J5"-6)8X'5Z&8'HY94.CXQ*<"EZ8JU8Q5[%))K)3/65#HTL*G
M`I>6*M6*585AMV95H5\;GPK\VJI4.U9QV-5$55&V\G51V14H6WEDX%1#UY4I
M6UEKA=5%V<ISTGPW=;,5#02_,]\R<K$&G"`G<8<ED=^;]&F=.=!104U$5E6A
M1[2Y/"0Z?2M3\?)66V6^HU)U,_-Y)T0(]#(5.]%7F8]]*JBO@4\%]37,G,BY
M6A7U-<I4[.I897ZB4DTS\P5.S#(5.S%7F5^H5$NKJM*J2!8Y5=%HJTS%3JQ5
MYC<JU=:JW/"5*P.[3,5.4#[1=`_*)RH9=[;BRJ!\DE@C6>H(]ZV3_=1-'C1O
M^IWD8>0B>23(G>J4Q&#9-'OOF_7S_`@`G2%2J5JL<I.HN#ULLRI_QGP./2Y3
M=WPJ\*NK4O5898=GN2MHG\L+/8K]*E&?`Y\*_!ZJ5"-66;_E\^0QEQ?Z/?&I
MP*.I2C5C%7LD;L3G7%[HT<*G`H^6*M6*584QMV95H5\;GPK\VJI4.U;9FI+[
M@5):\G0\Z`:4ECPR\(FF.2I9VH\+:XNF.1YK>=_<3&5>^OJ-927[CEA^62E!
M3F(,2R*VFJ%'!341J50M5M%UID,:?)K19A7E\IP*;LHT?G55MGJL*O2KSZI"
MOV*?"FIUX%-!K0Y5JA&K"KT?LZK0^XE*-56I9JPJ]&O.JD*_%BK54J5:L:K0
MKS6K"OW:J%1;E6K'JD*_*(-I`I\RF$JFZ]XTL;+6BGU+._BI2G,S&`T+3@93
M[^(=FB/%M"M!SH0J+(GEL:8]T%%!MXM4JA:KDJ%&SO#:7%PX]G5\*G"HJU+U
M6.6.,F*1K<^J0K]BOTI4Y\"G`N^'*M6(5?[J''-QH=L3GPH<FJI4,U;Y'9IS
M<:%#"Y\*'%JJ5"M6^1U:<W&A0QN?"AS:JE0[5OD=HDQ%KLB;G/Q\YGC+09G*
M(P.7:*ZEDJ6=]X13:;<]54UNBJ*^],$498X4*2I!M(M<;EXCMQELAJF*;V$C
M1"U$;40=1%U$/41]1+%%[FQ1>C_PJ:`MARK5B%759*\Y<<LWYN+\6`/1-?&I
MP*&I2C5CE=^A.1<7.K3PJ<"AI4JU8I7?H347%SJT\:G`H:U*M6.5WR'*"$EP
MNT'D663VR,`ER@@J&7<?^A[,O%THGUO0;9?'3#Z0G(Q@>B]FA(K9EK7XJ=CQ
M0#<A6%2Y.SKV+W&'T^1B<B^]#PI#\5@VMBIG2A-6Q5W<P*>"&AWZ56+4'['*
M\:LJ5&-6Y?,LG'&B4DW]*G'&&:M<O\3\9\ZJ0K\6*M72KQ)^K5CE^'4KVG'-
MJD*_-BK5UJ\2?NU8Y?HEHI#^1*1]U;?0L<:]3L9![81K('>\:D1LS?5-U!G]
MR<DSOKE=U[Q?J%\Q*2>O(]*B#`_$]Q91A\UZ),1T4Z6*V7PM-3]`-$0T0C1&
M-$$T131#-$>T0+1$M$*T1K1!M$6T0T1Q:-LCJS`*.F1<_935N=THG%#7<I@;
M*.8%L'R@F!O3\$[QYZ7*R:MC3LPDB).\?(IHCZ@X@1Z*3AA;595L94/!K;`U
M8%OY\,P/&.Y%FC=`\A=Y9OA*7AAQKBQ!YWJ#1A67K?FLT0:(AHA&B,:()HBF
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M;]-L8D1'B`F5Z#"Q58FN(-Z9&/AM9=W*O4+J?,X5GND*1BZNS*(L?)ME0!&B
M%J(VH@ZB+J(>HCZB&-$`T1#1"-$8T031%-$,T1S1`M$2T0K1&M$&T1;1#A'U
M-&A(ZFG(/`U.=R^H<YO<B4.S#:$3A^J[E^.1;D@RRH4DH@A1"U$;40=1%U$/
M41]1;)'HTG(AS*J<X2:\S99&W*HTMXWZT<VD,]&E&>7KSZHR%*&JA:B-J(.H
MBZB'J(\H1C1`-$0T0C1&-$$T131#-$>T0+1$M$*T1K1!M$6T0]1H>-B]AS4]
MS-/B#;?)W3@T:PCY.-0-GN9/<<EXM"@+OB:K,A0A:B%J(^H@ZB+J(>HCBBT2
M_5DLYPZLRAWN[[*%0K<>S0UROAZ+A^B*O9_.K0`RRBJKB2A"U$+41M1!U$74
M0]1'%",:(!HB&B$:(YH@FB*:(9HC6B!:(EHA6B/:(-HBVB&B_FR;.VO;QKV'
M>1J\X6EQZL]Y>VX<^I945`N,YN])RBYM4>9VDU49BA"U$+41=1!U$?40]1'%
M%KE=&K;JM2K1I>4-Z/7;C_W^/7IX?_CRZ7G_^GW?W/_\^7;Q>/CKA>XL[LS&
M\"F^>-U_^WQ)D]8Z/3(X+C'*HDI`192H:<4$BD)3=-R10Q:5;JF(=M_S'%6Z
M,T5WOJ*R.1>M/GN.*IMST5*<KZABBHXM*MTH&S?HU@N/HFT%ZPVJ3RRAS07K
M9B='7\D=E?@\OP]K=?-J@.<8JEISF^`IJ=S4S6S-5Q)0B:\:[BLE*CGNQRDN
ME?HCE?CJY[Y2IA+_E9(UVK?=XT&)K-&&V[X2LD8;)?M**E3B:P;:A)1*CF.%
M\#HNF_;Q&(M-F_ILT:ZP5.(UUB!CWH)[<MEWDGMRV'>.^X`*:(W3<XT!70G]
M-3-?"44-_6$J7PE%#3W5\Y50;-`?B_&4E"@VZ*]^^$HH-N@/.&!)@SJ/MRWI
M`)\^-IW-5W!OHL)S@KAD:MY3<$_!XHN5V/197P&]H$`G-UN=X&70=TYU\Q43
MEM#'1W7S:1&6T!=!=?.]#Y;09SIU\Q$.EI`/%&/FNQA?68D2HMF+#<MH5R[R
MS]<TM%\6^><KH9VLR#]?">TQ1?[Y2LB_&^.?KXR\KINO=]`[^J"M;CY7PQ+:
ME[!N=AW$$MHLL&ZV`L02VL&O;O;GPQ+:5J]N-LW#$MJ?B.K'U[*TCQ#5CZ^$
M]ONA^O&5T+X\5#^^$FJ=NMD9#SV@S2+K9BM(+*':I'KSU2CM"$?UYBNA**5C
M?![0#E%TC*\DJM9;OB31K=9[/A[=UEN^U-&]K?=\?%BMCWQVIM7ZS,>'M_61
MS\[TMCX[\NLT+[]]^?3KX?M^^/#Z_>GE[>+G_AO-&6Z.FX&]/GTW=U?)?]X/
MO^@CK<N+/P[O]!CH^.N/_</7/?W9SAOSRL^WP^&=_T,-<?WWX?7/X[SDR_\+
M````__\#`%!+`P04``8`"````"$`*]3YZDD$``#&#P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6RL5UUOHS@4?5]I_P/B?<)7(!0E&24E!*)=:36:
MV7TFQ$E0`4?8:=I_O]<8W&`S+3/J2U,.A^/K<R\7W_G7E[+0GE%-<EPM=&MB
MZAJJ,GS(J]-"__$]^N+K&J%I=4@+7*&%_HJ(_G7YYQ_S&ZZ?R!DAJH%"11;Z
MF=)+8!@D.Z,R)1-\017<.>*Z3"E<UB>#7&J4'IJ'RL*P3=,SRC2O=*X0U&,T
M\/&89RC$V;5$%>4B-2I2"O&3<WXAG5J9C9$KT_KI>OF2X?("$ON\R.EK(ZIK
M918DIPK7Z;Z`?;]8TS3KM)L+1;[,LQH3?*03D#-XH.J>'XP'`Y26\T,..V"V
M:S4Z+O25%>Q\W5C.&W_^S=&-W/VOD3.^;>O\\%=>(3`;TL02L,?XB5&3`X/@
M84-Y.FH2\$^M'=`QO1;T&[[%*#^=*63;A0VQ?06'UQ"1#`P%F8GM,J4,%Q``
M_-7*G%4&&)*^+'0;%LX/]+S0'6_BSDS'`KJV1X1&.9/4M>Q**"[_XR2KE>(B
M3BLR%2+6Q'?=J>?/QHL`LXD$?MM(?CT0K]6`XFXU?B.0AU8$?G\[$`L2V>R&
M_?/+H1@\24W.PY2FRWF-;QJ\1Y`&<DG96VD%3+G+-L^-R/_/T@]Y9RHK)K/0
MP2S(+(&2?5YZIC,WGJ'.LI:S5CFNVZ<\=A1654PWE(&-#$0RL)6!6`82&=C=
M`0;X(LR!$OX,<Y@,,Z?;U;H#WMRR9I(3':5[)I2!C0Q$,K"5@5@&$AG8W0$]
M)^!]_`PGF`ST@[LRL6UIY^N6`R^MJ*6I9(Z@"'<49*,@D8)L%216D$1!=O=(
MSR1H5I]A$I-A3?/.`,^4+%BWI/=<$A3ADH)L%"12D*V"Q`J2*,CN'NFY!"$/
MN#1A?9V>\^QIC?G78>![XT!GX?V&B30>=7M;<\2"94796+XE%<X84MAJ6TT;
MLTW+[HMLQ/UN[6B,['8,*1;:K(7"VM(&$G&_6WOW@6S/>BBI=ZW_CB_-%V'`
M>OAV=]XSE;[W'/G`^S&DL-5V1*_<*$@T1F@[AA0KVHF"[#X0ZOD[&_#7]M@Q
MZ2>GI\Y2]F#?4HY8<.P0Y6P[4A-X;$EPK!`DI>;#`27+]Z6:'E22.G,TJ"15
MZ'9022+%@TI23`DGV>REA^.$Z\Y\KQ_U;E#F;:U>;MAT<G_0>;_&&;N?$(ZP
M5`JO;4<^O[0DJ!E!4A,RH*20-FT`)F]"SLR7DQ^-D=F."2@>HY3T`GKP/&?Z
M9G33DV$F89[U'+K?%\\&'SOX$;1$]0D]HJ(@6H:O;*2`$^AR+F`^[H1N`"T7
M^IV$QVX`[5#%0R^`IJ'BL1?`ZZWB,$ZM[`%\#6-6,Y1(ZZ[M`(Y)JL[:">!H
MH.*K:;!JQC599QK`1Q+XAK@!8]0E/:&_T_J45T0KT!$\,9M/8\T',7Y!VSZ]
MQQ0&J*9EGV%>1G!B-B=0H4>,:7?!%A`3^/)_````__\#`%!+`P04``8`"```
M`"$`X)LG^_P(```]+P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RL
M6EM3XS@3?=^J_0^IO"^)G=B`"]B:W._W?-]S"`92D\14;(:9?[\M2VVL;D<(
M9EYP.#X^:G6K6[*EFW]_'O:E'^$IWD7'V[)S42V7PN,V>M@=GV[+ZU7GGZMR
M*4XVQX?-/CJ&M^5?85S^]^[OOV[>HM/W^#D,DQ(H'./;\G.2O`252KQ]#@^;
M^")Z"8]PYS$Z'38)_'MZJL0OIW#SD#YTV%?<:M6O'#:[8UDJ!"<;C>CQ<;<-
M6]'V]1`>$RER"O>;!.R/GW<O,:H=MC9RA\WI^^O+/]OH\`(2][O]+OF5BI9+
MAVW0?SI&I\W]'OK]TZEOMJB=_L/D#[OM*8JCQ^0"Y"K24-[GZ\IU!93N;AYV
MT`/A]M(I?+PM?W."M5,O5^YN4@?];Q>^Q;G?I?@Y>NN>=@^CW3$$;T.<1`3N
MH^B[H/8?!`0/5]C3G30"LU/I(7S<O.Z31?36"W=/SPF$VX,>B8X%#[]:8;P%
MCX+,A>L)I6VT!P/@;^FP$T,#/++YF5[?=@_)\VVY5K_P+JLU!^BE^S!..CLA
M62YM7^,D.OQ?DAPE)45<)0)7)>)>7CCUJO\)C9K2@*O2\"^N/*_N7UW:&U)7
M(O"$$G$^+^(K$;@JD4]WYE))7&<27[##@<$@8R-&A?3[IRUQL@##CZ_[Q,$0
MBQ]*QH7>60X0!Z,K?JC'OQ!>2"3ED=\*L(,1%C^^[%B,L?-;078QR.+'5VUQ
M,<CBAQ*Q'W`561+2"M/:))N[FU/T5H*R#6+QRT9,`DX@E+&VR$J059MSQ0:J
MC%#Y)F1NR^!JJ",Q5,@?=W[5NZG\@*JV59P&YS@ZHXD,4<*$;(L";0IT*-"E
M0(\"?0H,*#"DP`B!]^YYI'=CI*#M$PI,*3"CP)P""PHL*;"BP#H'5"#&6:`A
MI_]$H(6,"#1VLX'`NVM<$E5DX",M"K0IT*%`EP(]"O0I,*#`D`(C!-Y-=RYU
MV\=(0=LG%)A28$:!.046%%A28$6!=0[0H@JE]D]$5<C`JB"7OF[]2G=%0W&@
M*F<Y7M<IS8R"[FHQI,V0#D.Z#.DQI,^0`4.&#!EER-E.C#,*=F+"D"E#9@R9
M,V3!D"5#5@Q9YQ$M]C!1_HG8"QF(O5Z[?3VR#44R!3^CH-]:#&DSI,.0+D-Z
M#.DS9,"0(4-&&7(^^!D%.S%AR)0A,X;,&;)@R)(A*X:L\X@6?(A$0?`OQ#HZ
M>=YMOS<BN:(O>$>HP?PL9VTADH8>>]N0B%B#94GN7-%I6I%$4SC;NQXAM6R4
MVI)4<](5@UMU:OJPZV3WT<"NC6S/AM3/M,5J!=HFT]8@NX]M#VUD1S:DL2+!
MY;P')S9*4TEZ]R#IQ2R[C[V8V\@N;$C+3%MYD`R!578?VUY_(*N-<"A(QA&^
MBE[2Y6O!"(=74ASB0D4?XA+Y8(C;D%HVI+8RH):MF#H,Z=H(]6Q(?:8]8,C0
M1FAD0QK;D"8VI*DDU=Z]-&/(W$9H84-:,NT50]8?"&E#%5X3M:%J'I*"K0])
MB3CPO2Y7#D@F-R6IGB_-KD<*9DLIP>MJIL3J=[N@.>>*+/<ZDN2*R>+'G>.[
MM2NRVNL6RI`:T+,QJ%^H1`P:Z`9Y/MBDSQ;#0AEBT*B`Y'I$:2Q)9E]/E)+1
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MLHPF+;$QHTDK9*DOM&Z-?`M>8V/G3-*S2>PTLFSR+T0JBOU$G*3L-Q?%#@O-
M+`EI<Y'KD^K45`]J+!;=%K*,8[.M6'7=!V2-UT'6=?K9SK]V"*&+C9TK3&E9
M[2'+:%(?&S.:-$"6-(D/N"$V9C1II%@U>2Q4G*D:<VC"H2F'9AR:<VC!H26'
M5AP2)VC3\9*:*L>F/!$KSZL=PM-3V`SW^[BTC5[%:5<XE'=WD\'J*&X]^`9"
ML.%(;C3J`9P(X/BH'L`F>P'NP(U")3CM^\TM>*+A!'!PK$@)A`KPAAO`D:0"
MOAO`<1^.-VH!'&CA^*@6P!D1CK>]`/;/.=[W`MC;YGC;#V!KDN-]/X!-1(Y/
MO0!VESF^]`+8^>7XU`]@4X_C2S^`[3?`*UG(X/#RR^8I'&].3[MC7-J'CQ#N
M:KIA<)+'G^4_B=H"OH\2.+:<[@8_PS'U$(9Y552NQRA*\!_10';P_>X_````
M__\#`%!+`P04``8`"````"$`(!E![F$#```%#0``$``(`61O8U!R;W!S+V%P
M<"YX;6P@H@0!**```0``````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````````"<
M5^]OVC`0_3YI_P/*]S;TUSI5(=,*=*VTM6BP[:-EG*-8#79J.ZSLK]\Y*6E2
M#F_JMR1^=WZ^]WP<R:>G5=Y;@[%2JT%T=-B/>J"$SJ2Z'T0_9E<''Z.>=5QE
M/-<*!M$&;/0I??\NF1A=@'$2;`]3*#N(ELX5%W%LQ1)6W![BLL*5A38K[O#5
MW,=ZL9`"1EJ4*U`N/N[W/\3PY$!ED!T43<*HSGBQ=F]-FFGA^=F?LTV!A-/D
M<U'D4G"'ITR_26&TU0O7&S\)R).XO9@@NRF(TDBW2?M)W'Y-IH+G,,3$Z8+G
M%I+XY4-R#=P7;<*EL6FR=A=K$$Z;GI5_L&S'46_.+7@Z@VC-C>3*(2T/JU^J
MY[RPSJ2_M'FP2P!GDQ@!]<?JL8UM/\O3].R\0N!3%^DSU$QPH<MQ)ET.]FXQ
MX<81E,_.VYPK%C7CFM!618;>8&/EL%[L1M5J2]UFWIQAJ)75N<RX@XQ=\IPK
M`6RZ<]+_P;,)__<64X<[>:=9IA?LKD#!FMR^]/5!.JR:$!\Q7')%AC2H*O&0
MVR6[RO7OCEY-_A%8863AK>>37I96*K"VJMNT)/-_T>@DAL0$&)K!=\BK*GKM
M-FQFN+)<^"UH#L^7=5.+]5C*PI>%W/M6.\#J;O@\APJ.-+`_..G?;\F0$1BY
MQKNU!GKW&VPH*V`S_K0',-2KE72U4MY.N*7#"F`CPO9";CG&,[@-N31U6CR@
MVE7!)V@R$O6+&RQ:]XHUDHU71:XW`&P$"Q2K)F3DO*QRDOFFY=S"8XE59>.U
MMQR)"GOAZ`TQQV3,?GN@"G,RA+:(AV.3("/"3MEWF,8JH=1MQX1P0>,PDO6.
M/4+Y:YN%$%L?A3!AU4](FN&84S*F;ANB;AOH7<=E3DL7\`>&D<G#(;3:>SP5
M8A8.H;<)&Y&^(>&8?9J\F#=TAE8_W*K`:.84<H834<EQ+&G:T<MO5>=>A"A0
MP#T<2&B(1/C2T0<-Q]`2A6-HB9XO;*@T70@+G72W5X02[T57>Y!Z-MTCE/<U
M:(^..[#0R<*_<+2&.S]Q6W.WC]:9-U]-F%^E>K`_BID>X>RR':&['Y/IDAO(
M<+C<KK]\2*YQ>C:Y3^(GLWO(MIC=!3_P_ZS_U:1'IX?]DS[.\JUO2?S<:'#`
M2/\"``#__P,`4$L#!!0`!@`(````(0!_FE=$,0$``$`"```1``@!9&]C4')O
M<',O8V]R92YX;6P@H@0!**```0``````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````"<D4%+PS`8AN^"_Z'DWJ9I122T&:CLY$!PHNP6DV];L$E#$FW[[\VZ
MKD[TY#&\;YX\WY=JT>LF^03G56MJ1+(<)6!$*Y79U>AYO4QO4.(#-Y(WK8$:
M#>#1@EU>5,)2T3IX=*T%%Q3X))*,I\+6:!^"I1A[L0?-?18;)H;;UFD>XM'M
ML.7BG>\`%WE^C34$+GG@^`!,[4Q$$U**&6D_7#,"I,#0@`83/"89P=_=`$[[
M/R^,R5E3JS#8.-.D>\Z6XAC.[=ZKN=AU7=:5HT;T)_AU]?`TCIHJ<]B5`,0.
M^VFX#ZNXRJT">3NP_LTUB??["O_.*BE&.RH<\``RB>_1H]TI>2GO[M=+Q(J<
M7*4Y24NR+@I:%I20385/K>D^FX%Z$O@W\01@H_?//V=?````__\#`%!+`0(M
M`!0`!@`(````(0"0-LX-*`(``(`B```3``````````````````````!;0V]N
M=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`
M````````````````800``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`#IH
M-4AI`@``]2$``!H`````````````````AP<``'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L!`BT`%``&``@````A`(:WAMY2!```H1````\`````````
M````````,`L``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0#/F#1)
M(@<``/H>```8`````````````````*\/``!X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"+0`4``8`"````"$`]U#"O-`"```/"```&0``````````````
M```'%P``>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+`0(M`!0`!@`(````
M(0`N"ON&"P0``#(-```9``````````````````X:``!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L!`BT`%``&``@````A`+EE2J"Y`@``$P<``!D`````
M````````````4!X``'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"+0`4
M``8`"````"$`ML:B<V,$```(%```&0````````````````!`(0``>&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;%!+`0(M`!0`!@`(````(0`LI!+A-P,``"`*
M```9`````````````````-HE``!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
M4$L!`BT`%``&``@````A`)D"M%,`!0``LQ0``!D`````````````````2"D`
M`'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"+0`4``8`"````"$`\246
M:60)``"5+P``&0````````````````!_+@``>&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+`0(M`!0`!@`(````(0#AK<\EV08``'TB```9````````````
M`````!HX``!X;"]W;W)K<VAE971S+W-H965T-#`N>&UL4$L!`BT`%``&``@`
M```A`-RLSA4N#0``W7$``!D`````````````````*C\``'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"+0`4``8`"````"$`I=;7Y0$$```5#P``&0``
M``````````````"/3```>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(M
M`!0`!@`(````(0!^U5#)M`(``.D&```9`````````````````,=0``!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L!`BT`%``&``@````A`+2Q/7?X`P``
MO1```!D`````````````````LE,``'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"+0`4``8`"````"$`@T/J`GT+``!]6```&0````````````````#A
M5P``>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+`0(M`!0`!@`(````(0#?
MC>:FLAD``"CW```9`````````````````)5C``!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L!`BT`%``&``@````A`!Y-C&%B!@``%!\``!D`````````
M````````?GT``'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"+0`4``8`
M"````"$`Y6-0YE<5``!WL@``&0`````````````````7A```>&PO=V]R:W-H
M965T<R]S:&5E=#4P+GAM;%!+`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3
M`````````````````*69``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&
M``@````A`/[[*WB7#```['<```T`````````````````:J```'AL+W-T>6QE
M<RYX;6Q02P$"+0`4``8`"````"$`;PIBR927``!%.0(`%```````````````
M```LK0``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"+0`4``8`"````"$`B)MG
M7/,"``"R"0``&`````````````````#R1`$`>&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L!`BT`%``&``@````A`,^5JIA\!0``*!8``!@`````````````
M````&T@!`'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(M`!0`!@`(````
M(0`/VBM&T0(``,4'```9`````````````````,U-`0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L!`BT`%``&``@````A`+R8R][%`@``.@<``!D`````
M````````````U5`!`'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"+0`4
M``8`"````"$`$H6;^DX%```H&```&0````````````````#14P$`>&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;%!+`0(M`!0`!@`(````(0":_V"U:@0``&81
M```9`````````````````%99`0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L!`BT`%``&``@````A`/EBI8/A#0``KG,``!D`````````````````]UT!
M`'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"+0`4``8`"````"$`:]$1
MA7`#``!J"@``&0`````````````````/;`$`>&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+`0(M`!0`!@`(````(0`2:KZ6%00``+$.```9````````````
M`````+9O`0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L!`BT`%``&``@`
M```A`)80$&C,`@``P@<``!@``````````````````G0!`'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0#2@G*CJ@(``(T&```9````
M``````````````1W`0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!`BT`
M%``&``@````A`(J`%,'R!P``W#$``!D`````````````````Y7D!`'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`+R9IGHD?``"+
MO@``&0`````````````````.@@$`>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+`0(M`!0`!@`(````(0#9*,5!$0T``#U'```9`````````````````,ZA
M`0!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!`BT`%``&``@````A`)?W
MEHCB$0``Y%\``!D`````````````````%J\!`'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"+0`4``8`"````"$`D%J2;I`2``#@8P``&0``````````
M```````OP0$`>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+`0(M`!0`!@`(
M````(0`Q/D^UJ@\``'%?```9`````````````````/;3`0!X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L!`BT`%``&``@````A`-P02#I-"P``9CL``!D`
M````````````````U^,!`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M+0`4``8`"````"$`[BO.6VP+```@/0``&0````````````````!;[P$`>&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````(0#461`-RPD`
M`(XS```8`````````````````/[Z`0!X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"+0`4``8`"````"$`T#:I-4@.``!O4```&`````````````````#_
M!`(`>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`!<-
M_W5;"@``$#4``!@`````````````````?1,"`'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+`0(M`!0`!@`(````(0!"JW,V42(``/?5```8````````````
M``````X>`@!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`"```
M`"$`LBCB:10#``"!"0``&`````````````````"50`(`>&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L!`BT`%``&``@````A`(_MO!`'!0``(Q4``!D`````
M````````````WT,"`'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"+0`4
M``8`"````"$`1`-9?YT/``"_60``&0`````````````````=20(`>&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0`('IL&RP(``-0'
M```9`````````````````/%8`@!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L!`BT`%``&``@````A`%>SUD+G"```QB@``!D`````````````````\UL"
M`'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"+0`4``8`"````"$`G>C:
M`[4)``!1,P``&0`````````````````190(`>&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+`0(M`!0`!@`(````(0#_2*5[OA8``-V%```9````````````
M`````/UN`@!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!`BT`%``&``@`
M```A`/7QA19[#@``H%```!D`````````````````\H4"`'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`1T,?##<#``!0#```&0``
M``````````````"DE`(`>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M
M`!0`!@`(````(0!Z!IEBB0(``%@&```9`````````````````!*8`@!X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L!`BT`%``&``@````A`(".1T2?"P``
M]CT``!D`````````````````TIH"`'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"+0`4``8`"````"$`S0];S%8&``#>&P``&0````````````````"H
MI@(`>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0##
MAF#&DR0``$[D```9`````````````````#6M`@!X;"]W;W)K<VAE971S+W-H
M965T,C`N>&UL4$L!`BT`%``&``@````A`-B+@[)G"0``P"T``!D`````````
M````````_]$"`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`
M"````"$`>WW0+V8;``"LI@``&0````````````````"=VP(`>&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+`0(M`!0`!@`(````(0`KU/GJ200``,8/```9
M`````````````````#KW`@!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!
M`BT`%``&``@````A`.";)_O\"```/2\``!D`````````````````NOL"`'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"+0`4``8`"````"$`(!E![F$#
M```%#0``$`````````````````#M!`,`9&]C4')O<',O87!P+GAM;%!+`0(M
M`!0`!@`(````(0!_FE=$,0$``$`"```1`````````````````(0)`P!D;V-0
C<F]P<R]C;W)E+GAM;%!+!08`````0@!"```2``#L"P,`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EINAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Minimum [Member]

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Maximum [Member]

</div>
          <div>Warrant [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantTextualAbstract', window );"><strong>Warrant (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockOptionGrantedToPurchaseCommonStock', window );">Warrant granted to Management Firm to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,716,340<span></span></td>
        <td class="nump">1,974,774<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice', window );">Warrants granted to Management Firm to purchase common stock, exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife', window );">Warrants granted to purchase common stock, term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Fair value of warrants recorded as stock-based compensation expense</a></td>
        <td class="nump">$ 95,971<span></span></td>
        <td class="nump">$ 72,100<span></span></td>
        <td class="nump">$ 188,400<span></span></td>
        <td class="nump">$ 240,400<span></span></td>
        <td class="nump">$ 1,957,754<span></span></td>
        <td class="nump">$ 2,153,442<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.82%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.92%<span></span></td>
        <td class="nump">3.17%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">60.64%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">64.77%<span></span></td>
        <td class="nump">70.72%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Warrants percentage of total issued and outstanding shares of capital stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockOptionGrantedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock option granted to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockOptionGrantedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock option granted to purchase common stock exercise price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockOptionGrantedToPurchaseCommonStockExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock option granted to purchase common stock weighted average contractual life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(v)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGVAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 750,000<span></span></td>
        <td class="nump">$ 750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | Phase II Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">750,000<span></span></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | Phase III Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | Biological License Application filing with U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,750,000<span></span></td>
        <td class="nump">1,750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | First Commercial Sale [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Memorial Sloan Kettering Cancer Center [Member] | New Drug Application [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">750,000<span></span></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Memorial Sloan Kettering Cancer Center [Member] | Receipt of Regulatory Approval From U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 1,750,000<span></span></td>
        <td class="nump">$ 1,750,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MilestonePaymentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MilestonePaymentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3PAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Going concern (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="12">12 Months Ended</th>
        <th class="th" colspan="1">151 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2000</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2008</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2006</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2005</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2004</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2003</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2002</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2001</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,420,913)<span></span></td>
        <td class="num">$ (3,012,454)<span></span></td>
        <td class="num">$ (672,286)<span></span></td>
        <td class="num">$ (4,893,951)<span></span></td>
        <td class="num">$ (5,483,954)<span></span></td>
        <td class="num">$ (8,361,205)<span></span></td>
        <td class="num">$ (3,444,795)<span></span></td>
        <td class="num">$ (467,266)<span></span></td>
        <td class="num">$ (3,425,986)<span></span></td>
        <td class="num">$ (5,570,905)<span></span></td>
        <td class="num">$ (5,617,581)<span></span></td>
        <td class="num">$ (6,053,362)<span></span></td>
        <td class="num">$ (4,580,237)<span></span></td>
        <td class="num">$ (5,734,791)<span></span></td>
        <td class="num">$ (3,532,044)<span></span></td>
        <td class="num">$ (3,192,384)<span></span></td>
        <td class="num">$ (5,090,621)<span></span></td>
        <td class="num">$ (55,743,463)<span></span></td>
        <td class="num">$ (60,637,414)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,947,969)<span></span></td>
        <td class="num">(3,795,480)<span></span></td>
        <td class="num">(5,212,710)<span></span></td>
        <td class="num">(517,592)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(44,402,658)<span></span></td>
        <td class="num">(49,350,627)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Accumulated deficit</a></td>
        <td class="nump">$ 60,637,414<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60,637,414<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 55,743,463<span></span></td>
        <td class="nump">$ 47,382,258<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 55,743,463<span></span></td>
        <td class="nump">$ 60,637,414<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GoingConcernTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GoingConcernTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 210<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details) (Subsequent Event [Member], Separation and Settlement Agreement [Member], Former Chief Executive Officer [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 28, 2013

</div>
          <div>Note</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Subsequent Event [Member] | Separation and Settlement Agreement [Member] | Former Chief Executive Officer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfInstallmentsInWhichConsiderationIsPayable', window );">Number of installments in which consideration is payable</a></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConsiderationPayableUnderAgreement', window );">Consideration payable under agreement</a></td>
        <td class="nump">$ 250,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountOfPerformanceBonus', window );">Performance bonus included in accounts payable and accrued liabilities</a></td>
        <td class="nump">$ 60,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PeriodOfService', window );">Period of service</a></td>
        <td class="text">August 15, 2012 to December 31, 2012<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountOfPerformanceBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of performance bonus.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountOfPerformanceBonus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConsiderationPayableUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Consideration payable under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ConsiderationPayableUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfInstallmentsInWhichConsiderationIsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of installments in which consideration is payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfInstallmentsInWhichConsiderationIsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PeriodOfService">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of service.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PeriodOfService</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SubsequentEventsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SubsequentEventsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETAAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative warrant instruments activity</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Fair Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,146,338</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Reclassification to paid-in capital</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,130,536</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td
 align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(600,880</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(216,112</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, September 30, 2013</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,015,802</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right"
 style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><span></span></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Fair Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2010</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with Convertible Notes (See Note 5)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">287,061</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">377,150</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Placement agent warrants related to issuance of Convertible Notes (See Note 5)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">143,532</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">188,579</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with Stock Offering (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,972,785</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,591,900</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Placement agent warrants related to issuance of stock (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">986,393</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,295,950</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(13,966</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td
 align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2011</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,389,771</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,439,613</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with Stock Offering (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">242,190</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">318,087</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Placement agent warrants related to Stock Offering (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">121,095</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">159,044</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with 2012 Common Stock Offering-A (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,118,988</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,409,554</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with 2012 Common Stock Offering-B (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,559,505</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,665,697</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Placement agent warrants related to 2012 Common Stock Offering (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">467,845</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">499,707</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Transfer from liability classification to equity classification</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,753,056</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4,231,324</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt;
 display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(685,420</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,146,338</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock', window );">Summary of fair values of derivative warrants on basis of valuation model</a></td>
        <td class="text"><div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Market value of common stock on measurement date (1)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.17</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.65</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Adjusted exercise price</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.48 - $0.81</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.50 - $2.475</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Risk free interest rate (2)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.10% - 0.77</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.33</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrant lives in years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4 months/5 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0 days/4.22 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected volatility (3)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">125% - 161</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">139</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected dividend yield (4)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%"
 valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Probability of stock offering in any period over 5 years (5)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25% - 40</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
</table>
</div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1)</font></div>
</td>
<td width="87%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The market value of common stock is based on an enterprise valuation.</font></div>
</td>
</tr>
<tr>
<td align="left" width="3%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="87%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2)</font></div>
</td>
<td width="87%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></div>
</td>
</tr>
<tr>
<td align="left" width="3%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="87%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3)</font></div>
</td>
<td width="87%" valign="top" style="text-align: justify;">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div>
</td>
</tr>
<tr>
<td align="left" width="3%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="87%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4)</font></div>
</td>
<td width="87%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div>
</td>
</tr>
<tr>
<td align="left" width="3%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="87%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5)</font></div>
</td>
<td width="87%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</font></div>
</td>
</tr>
</table>
</div><span></span></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="28%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">January 31,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 19,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 27,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="28%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="3%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="28%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td
 align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Market value of common stock on measurement date (1)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.37</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.37</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.39</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.39</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.39</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Adjusted exercise price</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.24 - $0.26</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.23 - $0.26</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.41 - $0.83</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.22 - $0.26</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.41 - $0.83</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Risk free interest rate (2)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.24</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.10% - 0.77</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.94</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new
 roman; font-size: 10pt;">0.10% - 0.77</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrant lives in years</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" nowrap="nowrap" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4 months/5years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" nowrap="nowrap" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4 months/5years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected volatility (3)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">156</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">157</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">125% - 161</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">161</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%"
 valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">125% - 161</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected dividend yield (4)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Probability of stock offering in any period over 5 years (5)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Range of percentage of existing shares offered (6)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Offering price range (7)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.18 - $0.55</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent:
 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.13 - $0.56</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.01 - $0.55</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.12 - $0.60</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.01 - $0.55</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1)&#160;&#160;</font></div>
</td>
<td align="left" width="80%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The market value of common stock is based on an enterprise valuation.</font></font></div>
</div>
</td>
</tr>
</table>
</div>
</div>
</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2)&#160;&#160;</font></div>
</td>
<td align="left" width="80%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The risk-free interest rate was determined by management using the average of 5 and 7 year and the 3-month Treasury Bill as of the respective measurement date.</font></div>
</td>
</tr>
</table>
</div>
</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3)&#160;&#160;</font></div>
</td>
<td width="80%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4)&#160;&#160;</font></div>
</td>
<td width="80%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times
 new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5)&#160;&#160;</font></div>
</td>
<td align="left" width="80%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management has determined that the probability of a stock offering is 25% for each quarter of the next five years.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(6)&#160;&#160;</font></div>
</td>
<td width="80%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management estimates that the range of percentages of existing shares offered in each stock offering will be between 35% of the shares outstanding.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(7)&#160;&#160;</font></div>
</td>
<td width="80%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Represents the estimated offering price range in future offerings as determined by management.</font></div>
</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants on basis of valuation model.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41678-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5580258-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41641-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5NEM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">127 Months Ended</th>
        <th class="th" colspan="1">151 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
        <th class="th" colspan="5">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="4">9 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1">127 Months Ended</th>
        <th class="th" colspan="1">151 Months Ended</th>
        <th class="th" colspan="8">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>A Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>May 31, 2013

</div>
          <div>Stock Options [Member]

</div>
          <div>Former Director And Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>2013 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>2013 Stock Plan [Member]

</div>
          <div>Employees Directors And Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>2013 Equity Incentive Plan [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>2013 Equity Incentive Plan [Member]

</div>
          <div>Employees Directors And Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Management Firm [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]

</div>
          <div>A Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]

</div>
          <div>B Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]

</div>
          <div>Management Firm [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Common Stock [Member]

</div>
          <div>Management Firm [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]

</div>
          <div>Laidlaw &amp; Co [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Common Stock [Member]

</div>
          <div>Laidlaw &amp; Co [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]

</div>
          <div>Laidlaw &amp; Co [Member]

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Common Stock [Member]

</div>
          <div>Laidlaw &amp; Co [Member]

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 19, 2012

</div>
          <div>Series E Preferred Stock</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">66,402<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">66,402<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 398,810<span></span></td>
        <td class="nump">$ 398,810<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 398,810<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsIssuedToPurchaseCommonStockOffering', window );">Warrants issued to purchase common stock offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">242,190<span></span></td>
        <td class="nump">19,972,785<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncreaseOfferingOfCommonStock', window );">Raised offering of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,151,450<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">759,300<span></span></td>
        <td class="nump">6,184,967<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42,711,791<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockSharesIssuedInStockOffering', window );">Common stock issued in stock offering, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,118,988<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">968,759<span></span></td>
        <td class="nump">7,891,141<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,707,259<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet', window );">Sale of common stock, net offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,469,776<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">660,164<span></span></td>
        <td class="nump">5,379,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlacementAgentCashFees', window );">Placement agent cash fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">618,174<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">91,116<span></span></td>
        <td class="nump">742,196<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlacementAgentCommission', window );">Placement agent commission</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">515,145<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,930<span></span></td>
        <td class="nump">618,497<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlacementAgentExpenseReimbursement', window );">Placement agent expense reimbursement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">103,029<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,186<span></span></td>
        <td class="nump">123,699<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsIssuedToPurchaseCommonStock', window );">Warrants issued to purchase common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">467,845<span></span></td>
        <td class="nump">3,118,988<span></span></td>
        <td class="nump">1,559,505<span></span></td>
        <td class="nump">1,716,340<span></span></td>
        <td class="nump">1,974,774<span></span></td>
        <td class="nump">121,095<span></span></td>
        <td class="nump">986,393<span></span></td>
        <td class="nump">588,940<span></span></td>
        <td class="nump">1,129,925<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Exercise price of warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="nump">$ 1.65<span></span></td>
        <td class="nump">$ 2.48<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="nump">$ 0.26<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsExpirationTerm', window );">Warrants expiration term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">120 days<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued to purchase common stock, fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">499,707<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,957,754<span></span></td>
        <td class="nump">2,153,442<span></span></td>
        <td class="nump">159,044<span></span></td>
        <td class="nump">188,579<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlacementAgentServicesFees', window );">Placement agent services fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">60,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,020<span></span></td>
        <td class="nump">60,904<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankEscrowFee', window );">Bank escrow fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,500<span></span></td>
        <td class="nump">2,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Common stock issued by conversion of note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,252,550<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccruedManagementFees', window );">Accrued management fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">96,744<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement', window );">Common stock issued to former shareholder under share exchange agreement, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement', window );">Common stock issued to former shareholders under share exchange agreement, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,986,566<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UnrecognizedShareBasedCompensationExpense', window );">Unrecognized share based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,014,474<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recorded option expense</a></td>
        <td class="nump">95,971<span></span></td>
        <td class="nump">72,100<span></span></td>
        <td class="nump">188,400<span></span></td>
        <td class="nump">240,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidForCancellationOfSharesByCompany', window );">Amount Paid For Cancellation Of Shares By Company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesPurchasedAfterCancelationOfOptions', window );">Shares Purchased After Cancelation Of Options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">49,950<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,463,641<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Sep.
				09,
				 2023<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Sep.
				09,
				 2023<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">450,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 284,371<span></span></td>
        <td class="nump">$ 312,500<span></span></td>
        <td class="nump">$ 2,223,926<span></span></td>
        <td class="nump">$ 2,173,377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6,052,036<span></span></td>
        <td class="nump">$ 6,336,407<span></span></td>
        <td class="nump">$ 284,371<span></span></td>
        <td class="nump">$ 168,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 284,371<span></span></td>
        <td class="nump">$ 168,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccruedManagementFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued management fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AccruedManagementFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidForCancellationOfSharesByCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid for cancellation of shares by company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidForCancellationOfSharesByCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankEscrowFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Bank escrow fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BankEscrowFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockSharesIssuedInStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares issued in stock offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockSharesIssuedInStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares issued to former shareholder under share exchange agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockSharesIssuedToFormerShareholderUnderShareExchangeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares issued to original shareholder under share exchange agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockSharesIssuedToOriginalShareholderUnderShareExchangeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EquityTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_EquityTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncreaseOfferingOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase offering of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IncreaseOfferingOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlacementAgentCashFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent cash fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlacementAgentCashFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlacementAgentCommission">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent commission.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlacementAgentCommission</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlacementAgentExpenseReimbursement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent expense reimbursement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlacementAgentExpenseReimbursement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlacementAgentServicesFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent services fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlacementAgentServicesFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of stock under stock offering, net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ProceedsFromIssuanceOfStockUnderStockOfferingNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesPurchasedAfterCancelationOfOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares purchased after cancelation of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SharesPurchasedAfterCancelationOfOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UnrecognizedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized share based compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_UnrecognizedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsExpirationTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Expiration Term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsExpirationTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsIssuedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued To Purchase Aggregate Shares Of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsIssuedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsIssuedToPurchaseCommonStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issued To Purchase Common Stock Offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsIssuedToPurchaseCommonStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 13<br><br> -Sentence Column A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentWarrantsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Warrant<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeBenefitsAndShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the equity-based award expires, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 19, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 27, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeTextualAbstract', window );"><strong>Derivative (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfRiskFreeInterestRateDetermination', window );">Description of risk free interest rate determination</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">Risk-free interest rate was determined by management using the average of 5 and 7 year and the 3-month Treasury Bill as of the respective measurement date.<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfProbabilityOfStockOffering', window );">Description of probability of stock offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">Probability of a stock offering is 25% for each quarter of the next five years.<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RangeOfPercentageOfExistingSharesOffered', window );">Range of percentage of existing shares offered</a></td>
        <td class="nump">35.00%<span></span></td>
        <td class="nump">35.00%<span></span></td>
        <td class="nump">35.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">35.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">35.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series E Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeTextualAbstract', window );"><strong>Derivative (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Exercise price of warrant</a></td>
        <td class="nump">$ 0.26<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr>
        <td colspan="9"></td>
      </tr>
      <tr>
        <td colspan="9">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfProbabilityOfStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of probability of stock offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfProbabilityOfStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfRiskFreeInterestRateDetermination">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of risk free interest rate determination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfRiskFreeInterestRateDetermination</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RangeOfPercentageOfExistingSharesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of percentage of existing shares offered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RangeOfPercentageOfExistingSharesOffered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 13<br><br> -Sentence Column A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentWarrantsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 429<span></span></td>
        <td class="nump">$ 581<span></span></td>
        <td class="nump">$ 633<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PropertyAndEquipmentTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDVFK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Option Plan (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="21">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2008

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2006

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Minimum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010

</div>
          <div>Minimum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2008

</div>
          <div>Minimum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Minimum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2006

</div>
          <div>Minimum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Maximum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010

</div>
          <div>Maximum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2008

</div>
          <div>Maximum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Maximum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2006

</div>
          <div>Maximum [Member]

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2003 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2003 Stock Plan [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2003 Stock Plan [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2012 Employee Stock Option Plan [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockOptionPlanTextualAbstract', window );"><strong>Stock Option Plan (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum granted option to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">757,575<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment', window );">Maximum granted option after amendment in 2008</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">978,154<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based payment award vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting', window );">Share based payment award monthly vesting percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering', window );">Percentage of aggregate issued and outstanding common shares reserved under offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock reserved for future issuance under ESOP</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,455,776<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Increment in number of shares under plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,217,880<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance', window );">Total shares reserved for issuance under plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,155,280<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockOptionGrantedToPurchaseCommonStock', window );">Stock option granted to employees to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,056,275<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">69,941<span></span></td>
        <td class="nump">113,220<span></span></td>
        <td class="nump">206,060<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice', window );">Stock option granted to purchase common stock, exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.90<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.90<span></span></td>
        <td class="nump">$ 1.35<span></span></td>
        <td class="nump">$ 1.35<span></span></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife', window );">Stock option granted to purchase common stock, term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,519,777<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 24,996<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 44,159<span></span></td>
        <td class="nump">$ 137,652<span></span></td>
        <td class="nump">$ 1,051,281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.80%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.16%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.46%<span></span></td>
        <td class="nump">3.46%<span></span></td>
        <td class="nump">4.29%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">171.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">139.00%<span></span></td>
        <td class="nump">143.00%<span></span></td>
        <td class="nump">156.00%<span></span></td>
        <td class="nump">160.44%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">161.49%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Stock option cancelled during period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,613<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock option forfeitures during period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(49,950)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">128,050<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EmployeeStockOptionUnitsReprised', window );">Employee stock option units repriced</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption', window );">Outstanding stock option exercise price after repricing of stock option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.28<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions', window );">Share based compensation cost after repricing of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34,879<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UnrecognizedShareBasedCompensationExpense', window );">Unrecognized share based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,014,474<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,998,435<span></span></td>
        <td class="nump">14,528<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recorded option expense</a></td>
        <td class="nump">$ 95,971<span></span></td>
        <td class="nump">$ 72,100<span></span></td>
        <td class="nump">$ 188,400<span></span></td>
        <td class="nump">$ 240,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 266,172<span></span></td>
        <td class="nump">$ 19,935<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EmployeeStockOptionUnitsReprised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employee stock option units reprised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_EmployeeStockOptionUnitsReprised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum granted option to purchase common stock after amendment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MaximumGrantedOptionToPurchaseCommonStockAfterAmendment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Outstanding stock option exercise price after repricing of stock option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OutstandingStockOptionExercisePriceAfterRepricingOfStockOption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of aggregate issued and outstanding common shares reserved under offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfAggregateIssuedAndOutstandingCommonSharesReservedUnderOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share base payment award periodic percentage of award vesting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ShareBasedCompensationArrangementByShareBasePaymentAwardPeriodicPercentageOfAwardVesting</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ShareBasedCompensationCostAfterRepricingOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation cost after repricing of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ShareBasedCompensationCostAfterRepricingOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation share based arrangement award shares reserved for issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ShareBasedCompensationShareBasedArrangementAwardSharesReservedForIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockOptionGrantedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock option granted to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockOptionGrantedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockOptionGrantedToPurchaseCommonStockExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock option granted to purchase common stock exercise price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockOptionGrantedToPurchaseCommonStockExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock option granted to purchase common stock weighted average contractual life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockOptionGrantedToPurchaseCommonStockWeightedAverageContractualLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockOptionPlanTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockOptionPlanTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UnrecognizedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized share based compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_UnrecognizedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(v)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) (Employment Contracts [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Employee Stock Option [Member] | Common Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options granted to purchase shares</a></td>
        <td class="nump">675,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Employee Stock Option [Member] | Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options granted to purchase shares</a></td>
        <td class="nump">125,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionGrantedToPurchaseSharesAsSignOnBonus', window );">Option granted as sign on bonus</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription', window );">Option granted as sign on bonus, Description</a></td>
        <td class="text">(C) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work. An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Chief Executive Officer And Director [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary at annual rate</a></td>
        <td class="nump">$ 350,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PerformanceObjectiveDescription', window );">Performance Objective Description</a></td>
        <td class="text">Upon the attainment of such performance objectives, the CEO shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary.<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommitmentsAndContingenciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionGrantedToPurchaseSharesAsSignOnBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Option granted to purchase shares as sign on bonus.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionGrantedToPurchaseSharesAsSignOnBonus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Option granted to purchase shares as sign on bonus description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PerformanceObjectiveDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description regarding remuneration of CEO and director upon the attainment of performance objective.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PerformanceObjectiveDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OfficersCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; font-weight: bold; display: inline;">Note 3 &#8211; Related Party Transactions</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;">MSKCC:</font></div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In 2010, General Atlantic Group Limited donated all of the equity shares of its wholly owned subsidiary, Actinium Holdings Ltd. (formerly named General Atlantic Investments Limited) to Memorial Sloan Kettering Cancer Center (MSKCC), a principal owner of the Company.</font></div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (SKI),&#160;an entity related to MSKCC.&#160;&#160;The agreement was amended in August 2006.&#160;&#160;Pursuant to the agreement, the Company licenses certain intellectual property from SKI, including critical patents with respect to the Company&#8217;s core technology, and also supports ongoing research and clinical development of related drug candidates.&#160;&#160;Certain amounts due under this agreement were deferred and then forgiven under the forbearance-related arrangements described above.&#160;&#160;On June 19, 2011, the Company nonetheless agreed to pay SKI (a) $50,000 in 2011, (b) $200,000 in 2012 and (c) $250,000 in 2013 under this agreement, in respect of the $50,000 annual maintenance fees and research payments. Since January 1, 2011, the Company has paid $100,000 under this agreement and as of December 31, 2012, the Company agreed to pay an additional $150,000 for research to be conducted in 2013.</font></div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On March 27, 2012, the Company entered into an additional clinical trial agreement with MSKCC Cancer Center with respect to conducting a Phase 1/2 trial of combination therapy of low dose cytarabine and fractionated dose of Lintuzumab-Ac225.&#160;&#160;The Company will pay $31,185 for each patient that has completed the clinical trial.&#160;&#160;Upon execution of the agreement, the Company was required to pay a start-up fee of $79,623, which was paid on July 10, 2012.</font></div>
</div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160; MSKCC agreed, subject to certain conditions, to utilize the donated funds for certain clinical and preclinical programs and activities related to the Company&#8217;s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by the Company. The following is a summary of activities related to the MSKCC arrangements for years ended December 31, 2012 and 2011:</font></div>
<div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%"
 valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Qualified R&amp;D costs incurred by the Company</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">655,786</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Reimbursements received from MSKCC</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">237,834</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">966,341</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In 2012 and 2011, the Company received total R&amp;D reimbursement payments of $237,834 and $299,200, respectively, from MSKCC.</font></div>
<div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; As of December 31, 2012 and 2011, the Company had a net receivable of $0 and $237,834, respectively, from MSKCC.</font></div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;">Dr. Rosemary Mazanet:</font></div>
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On January 1, 2012, the Company entered into a Consulting Services Agreement with Dr. Rosemary Mazanet, a director of Cactus.&#160;&#160;Pursuant to the agreement, Dr. Mazanet is to provide, among other things, consulting services in the areas of implementation of the Actimab&#8482;-A trial including all aspects of study initiation until first patient in at each clinical site.&#160;&#160;Dr. Mazanet receives compensation of $100,000 per year and may receive additional compensation in the form of options at determined by the board of the Company.&#160;&#160;Since January 1, 2011, Dr. Mazanet has also received options to purchase 99,900 shares of common stock of the Company. These options have exercise price ranging from $0.78 to $1.5 and have a life of 10 years.</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;<font style="font-style: italic; font-weight: bold; display: inline;">&#160;</font></font></div>
<div
 align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;">Jamess Capital Group, LLC:</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On May 9, 2011, the Company entered into a transaction management agreement with Jamess Capital Group, LLC. (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Sandesh Seth, a Director of the Company&#160;(&#8220;Management Firm&#8221;).&#160; The Management Firm received a monthly fee of $12,500 which is terminable by the Company three months after the effective date of the going public transaction and designees of Jamess, including entities affiliated with Mr. Seth, were issued warrants to purchase common stock equal to 10% of the fully-diluted capital stock of the Company as of the effective date of the going public transaction. The fully diluted shares for this calculation included all issued and outstanding shares as well as those reserved under the Employee Stock Option Plan.&#160; The Management Firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;">Placement Agent:</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On August 7, 2012, the Company entered into an engagement agreement with its placement agent for the 2012 Common Stock Offering,&#160;of which Mr. Seth, a director of the Company is Head of Healthcare Investment Banking.&#160;&#160;&#160;Pursuant to the agreement, the placement agent was engaged as the exclusive agent for the 2012 Common Stock Offering. &#160;&#160;In consideration for its services, the placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.&#160;&#160;The placement agent or its designees have also received warrants to purchase shares of the Company&#8217;s Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.&#160;&#160;The placement agent will also receive the same fee and expense schedule for any cash exercise of warrants within 6 months of the final closing of the 2012 Common Stock Offering and a 5% solicitation fee for any warrants exercised as a result of being called for redemption by the Company.&#160;&#160;Upon the final closing of the 2012 Common Stock Offering of the units, the placement agent has been engaged by the Company to provide certain financial advisory services to the Company for a period of at least 6 months for a monthly fee of $25,000.&#160;&#160;The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.&#160;&#160;For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent.&#160;&#160;The placement agent also was engaged by the Company as placement agent for its Stock Offering and Convertible Notes financing in 2011 and, as a part of the fee for that engagement, designees of the placement agent also hold warrants to purchase 1,251,015 shares of the Company&#8217;s Common Stock.</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; font-style: italic; font-weight: bold; display: inline;">Guagenti &amp; Associates LLC:</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">In 2010, the Company entered into an agreement with Guagenti &amp; Associates LLC (&#8220;G&amp;A&#8221;).&#160;&#160;G&amp;A is affiliated with Enza Guagenti, the former Chief Financial Officer of Cactus.&#160;&#160;Pursuant to the agreement, the Company leases storage space in Newark, NJ from G&amp;A.&#160;&#160;The rent is $300 per month.&#160;&#160;Since January 1, 2011, the Company has paid $7,200 pursuant to this agreement.&#160;&#160;&#160;Ms. Guagenti resigned as the Company&#8217;s Chief Financial Officer on March 9, 2013.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>37
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X
M9C8R,V0U8C<B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N=%]O9E]#:&%N/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT
M<U]O9E]#87-H7T9L;W=S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&5S8W)I<'1I;VY?;V9?0G5S:6YE<W-?86YD7U-U/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1V]I;F=?0V]N8V5R
M;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T
M961?4&%R='E?5')A;G-A8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N=#PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?4&%Y86)L95]A
M;F1?0V]N=F5R=&EB;&5?3CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D1E<FEV871I=F5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E
M;F-I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%
M<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=&]C:U]/<'1I;VY?4&QA;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E=A<G)A;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^16UP;&]Y965?1&5F:6YE9%]#;VYT<FEB=71I;VY?/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N
M=%]%=F5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y$97-C<FEP=&EO;E]O9E]"=7-I;F5S<U]A;F1?4W4Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&5S8W)I<'1I;VY?;V9?0G5S
M:6YE<W-?86YD7U-U,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS7U1A8CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%
M<75I<&UE;G1?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^3F]T95]087EA8FQE7V%N9%]#;VYV97)T:6)L95].,3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S
M7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/DEN8V]M95]487AE<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C8N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]/
M<'1I;VY?4&QA;E]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y%<75I='E?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(Y+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^5V%R<F%N='-?5&%B;&5S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&5S8W)I<'1I;VY?;V9?0G5S
M:6YE<W-?86YD7U-U,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D1E<V-R:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=30\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y';VEN9U]C;VYC97)N
M7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,S,N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y296QA=&5D7U!A<G1Y7U1R86YS86-T:6]N<U]$970\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,S0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y7U1R86YS
M86-T:6]N<U]$970Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,U+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N=%]$971A:6QS/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#,V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q
M=6EP;65N=%]$971A:6QS,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-RYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DYO=&5?4&%Y86)L95]A;F1?0V]N=F5R=&EB;&5?3C(\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7U!A>6%B
M;&5?86YD7T-O;G9E<G1I8FQE7TXS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,Y+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^1&5R:79A=&EV97-?1&5T86EL<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970T,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S7T1E=&%I
M;'-?,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970T,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E
M<FEV871I=F5S7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]$971A:6QS/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#0S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S
M7T1E=&%I;'-?,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DEN8V]M95]487AE<U]$971A:6QS7U1E>'1U86P\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M-#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N
M=&EN9V5N8VEE<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#0V+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?,CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970T-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N
M9%]#;VYT:6YG96YC:65S7S,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#@N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y%<75I='E?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T.2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D5Q=6ET>5]$971A:6QS7U1E>'1U86P\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]/<'1I
M;VY?4&QA;E]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4Q+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VM?3W!T:6]N7U!L86Y?1&5T86EL<U]497AT/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#4R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5V%R<F%N='-?1&5T
M86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970U,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E=A
M<G)A;G1S7T1E=&%I;'-?,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U-"YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E=A<G)A;G1S7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970U-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5M<&QO>65E7T1E9FEN961?
M0V]N=')I8G5T:6]N7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-38N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=6)S97%U96YT7T5V96YT<U]$971A:6QS/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#4W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X
M8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS
M:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C
M=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R
M;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X
M.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^
M/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P
M86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@
M;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?
M-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T,#$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$531$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M
M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT
M:71Y($EN9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA
M;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=!8W1I;FEU;2!0
M:&%R;6%C975T:6-A;',L($EN8RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`P,#$S.#@S,C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=3+3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4V5P(#,P+`T*"0DR,#$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B=3;6%L;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E
M8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O
M<FMS:&5E=',O4VAE970P,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q,04<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!!<W-E=',Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD
M(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,RPY.3`L,#8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U+#8Q."PV-CD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L-S`S+#<Y.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4B9A;7`[
M1"!R96EM8G5R<V5M96YT(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,W+#@S
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V-RPQ-#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#,X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@9FEN86YC:6YG(&-O<W1S+"!N970@;V8@86-C=6UU
M;&%T960@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,BPR-#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!#=7)R96YT($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-"PP-#,L,#8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PW.#4L.#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ.3DL,C8T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@
M97%U:7!M96YT+"!N970@;V8@86-C=6UU;&%T960@9&5P<F5C:6%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DQ.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,S,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,#0Y+#DX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L-S@X+#@R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L,C`P+#0Y-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT
M($QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3(L,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#DW+#`T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8T-"PU,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@
M97AP96YS97,@+2!R96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-S4L-C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S$L,3@U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T92!P
M87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,30P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO=&5S
M('!A>6%B;&4L(&YE="!O9B!U;F%M;W)T:7IE9"!D:7-C;W5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,C0L,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<U-RPY-C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4W-"PY-3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0S
M.2PV,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!#=7)R96YT($QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#0T-2PV-3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8T,RPQ.#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#(P."PT
M.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPT-#4L-C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PV-#,L,3@W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD
M(&-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!V
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L-C4W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L
M,SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,V+#8T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED(&EN(&-A<&ET86P\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q+#(Q."PP.#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-BPX-C<L-S`V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#@L,C,W+#8R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5F:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE(&1E
M=F5L;W!M96YT('-T86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V,"PV,S<L-#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4U+#<T,RPT-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#<L,S@R+#(U."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!3
M=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C`T+#,R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,30U+#8S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDY,BPP,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!,:6%B:6QI
M=&EE<R!A;F0@4W1O8VMH;VQD97)S)R!%<75I='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-"PP-#DL.3@Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#<X."PX,C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L,C`P
M+#0Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B
M7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5&0T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"
M86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E9F5R<F5D('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C:RP@<VAA<F5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(S+#8U-BPU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PS.3$L-C8U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-C8T+#@P,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N(%-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(S+#8U-BPU.#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PS.3$L-C8U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-C8T
M+#@P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B
M7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5--D)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3
M=&%T96UE;G1S(&]F($]P97)A=&EO;G,@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,34Q($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$V
M,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-T871E;65N=',@3V8@3W!E<F%T:6]N<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&5X<&5N<V5S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="P@;F5T(&]F(')E:6UB=7)S96UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-S@L,C,R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV
M-S<L,S`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPS-S,L,C`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPW,C,L-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT-#`L-#@U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(S+#<X.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#0R
M,"PU,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR."PW.3,L-S$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,P+#<S,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R,BPP,S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#<S,"PR,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#4R,"PR,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#4P-BPR,S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DU.2PR-#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PU,#0L.3<U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C<L,C,U+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(V,BPT-C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(V,BPT
M-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO<W,@;VX@9&ES<&]S:71I;VX@;V8@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-34P+#$X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4U-"PS,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R871I;F<@97AP96YS97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C`X+#DV,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,SDY
M+#0U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L,3`W+#4U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L,C0T+#$P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.30W+#(Y.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C@S+#8V-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#<S
M."PQ-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU.2PX-#4L-CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-C`X+#DV,BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#,Y.2PT-3`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-2PQ,#<L-34U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0L,C0T+#$P.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@W+#DT-RPR.3@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPR.#,L-C8W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4T+#<S
M."PQ-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-3DL.#0U+#8Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@:6YC;VUE("AE>'!E
M;G-E*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q+#(Y.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S,3@L-C(S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-3`X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DU,BPR-#$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP
M.3DL,S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3<U+#`Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L.38T+#<P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.38W+#(Q-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@97AT
M:6YG=6ES:&UE;G0@;V8@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@+2!D97)I=F%T
M:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.#DL,S0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,CDT+#,X,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,38L,3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@W+#8P-"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V.#4L-#(P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$S+#DV
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V.3DL,S@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDQ-2PT.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!I;F-O;64@*&5X<&5N
M<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#@L,#0Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C$S
M+#`P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,3,L-C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PR,SDL.#0U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q,RPY,#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C$L,3(X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#4L,S(Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-SDQ+#<Q-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q+#0R,"PY,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@S+#`Q,BPT-30I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T+#@Y,RPY-3$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U
M+#0X,RPY-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@X+#,V,2PR,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#0T-"PW.34I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U-2PW-#,L-#8S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H-C`L-C,W+#0Q-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@+2!B
M87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,RXW-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V+C@T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-RXU."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0N,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@879E<F%G92!N=6UB97(@;V8@8V]M;6]N('-H87)E<R!O
M=71S=&%N9&EN9R`M(&)A<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,RPV,#$L.#DU/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`Q+#<Y.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#0P,2PW,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,#$L-SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PQ,#,L-3(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#`Q+#<Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q
M,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E
M-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O
M4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14XR14L^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N="!O9B!#:&%N9V5S(&EN(%-T
M;V-K:&]L9&5R<R<@17%U:71Y("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T86P\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E9FEC:70@06-C
M=6UU;&%T960@1'5R:6YG('1H92!$979E;&]P;65N="!3=&%G93QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N
M8V4@870@2G5N+B`Q,RP@,C`P,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^27-S=6%N8V4@;V8@9F]U;F1E<B!S:&%R97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+#DY,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L
M,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@9F]U;F1E<B!S:&%R97,L(%-H87)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY.2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E
M9',@9G)O;2!I<W-U86YC92!O9B`M('-T;V-K/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0U-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S0X+#4T,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@:7-S=6%N8V4@;V8@+2!S=&]C:RP@4VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30U+#8X-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C<R+#(X-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8W,BPR
M.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,#`\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,3`W+#<Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#0T-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S8X+#4U,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8W,BPR
M.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"86QA;F-E+"!3:&%R97,@870@1&5C+B`S,2P@,C`P,#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,30T+#8X-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D
M<R!F<F]M(&ES<W5A;F-E(&]F("T@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#<S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-#@L,3(W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B`M('-T;V-K+"!3:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#<L,S$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#`Y
M,"PV,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U+#`Y,"PV,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,#$\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S,R+#DP-RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPS
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#`Q-BPV.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U+#<V,BPY,#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E+"!3:&%R97,@870@1&5C
M+B`S,2P@,C`P,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S,R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F("T@<W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#`T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPR-#@L,3DV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC
M92!O9B`M('-T;V-K+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.#`L,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S+#$Y,BPS.#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#$Y,BPS.#0I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M(&%T($1E8RX@,S$L(#(P,#(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L-C<U+#(Y,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-2PQ,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW+#(V-"PX-S8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#DU-2PR.3$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA
M;F-E+"!3:&%R97,@870@1&5C+B`S,2P@,C`P,CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-3$R+#,W-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES
M<W5A;F-E(&]F("T@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L-S@Q+#(U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L,#DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BPW-SDL,38P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!I<W-U86YC92!O9B`M('-T;V-K+"!3:&%R97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#@L.3DR/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#4S,BPP-#0I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M+#4S,BPP-#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,#,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3<S+#DQ-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#(Q-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#`T-"PP
M,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,BPT.#<L,S,U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%L86YC92P@4VAA<F5S(&%T($1E8RX@,S$L(#(P
M,#,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<R,2PS-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B`M('-T;V-K/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#8U.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3DR+#,T
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@+2!S
M=&]C:RP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S8U+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-2PW,S0L-SDQ*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PW
M,S0L-SDQ*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#`T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,SDL,3(T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L.#<S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L-C,V+#,W-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X
M+#(R,BPQ,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E+"!3:&%R97,@870@1&5C+B`S,2P@,C`P-#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#@W+#(V-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F("T@<W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-#DT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX.3,L-3`V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B`M('-T;V-K
M+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#DL
M,S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,34L,S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q-2PS.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-"PU.#`L,C,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PU.#`L,C,W
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#`U/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW-"PR-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,2PS-C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPX-#4L,C<Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(L.#`R+#,V
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)A;&%N8V4L(%-H87)E<R!A="!$96,N(#,Q+"`R,#`U/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,S8L-C$W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S
M(&9R;VT@:7-S=6%N8V4@;V8@+2!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPU-3`L-30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^."PS.3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4T,BPQ-3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F("T@<W1O8VLL(%-H87)E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S.2PP-#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U,BPS,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C4R+#,P.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#`U,RPS
M-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#`U,RPS-C(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA
M;F-E(&%T($1E8RX@,S$L(#(P,#8\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L.#(S+#<V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,Y+#<U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#8S.2PW,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R."PX-34L-S(U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%L86YC92P@4VAA<F5S(&%T($1E8RX@,S$L(#(P,#8\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#DW-2PV-3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!I<W-U86YC92!O9B`M('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#,R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-3DR+#8W-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@+2!S=&]C:RP@4VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,R+#8P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VL@:7-S=65D(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,SDX+#@Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8V-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y."PQ-#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&9O<B!S97)V:6-E<RP@4VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L-#`R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-34L
M,#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(U-2PP-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PV,3<L-3@Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PV,3<L-3@Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A
M="!$96,N(#,Q+"`R,#`W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#0V,"PP-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-RPW-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-RPX.#4L-C$Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S0L-#<S+#,P-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N
M8V4L(%-H87)E<R!A="!$96,N(#,Q+"`R,#`W/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PW-S0L-C8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S
M=6%N8V4@;V8@+2!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PY.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#DY,"PP,3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M(&ES<W5A;F-E(&]F("T@<W1O8VLL(%-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY.2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N(&5X
M<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V.2PV,3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C8Y+#8Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#4W,"PY,#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U+#4W,"PY,#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E
M8RX@,S$L(#(P,#@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M,34X+#<V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4W+#<S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0T+#$T-2PR,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,"PP-#0L,C$Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@
M4VAA<F5S(&%T($1E8RX@,S$L(#(P,#@\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#<W,RPV-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N(&5X<&5N<V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,BPS.#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$R+#,X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S+#0R-2PY.#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@S+#0R-2PY.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,#D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@T-2PQ-C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPW,S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-"PR-3<L-C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-#,L-#<P+#$Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4L(%-H87)E<R!A="!$96,N
M(#,Q+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW
M-S,L-C8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,2PQ-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,38V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#0V-RPR-C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-C<L,C8V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%L86YC92!A="!$96,N(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.3DL,#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3<L-S,W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L,C<X+#<X-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S+#DS-RPT-C,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E+"!3:&%R97,@870@1&5C+B`S,2P@,C`Q,#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-S<S+#8V,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M(&ES<W5A;F-E(&]F("T@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L,S<Y+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<X+#DQ,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,S`P+#0U-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@+2!S=&]C:RP@4VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX.3$L,30Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.2PY,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL.3,U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#$U,RPT-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ-3,L-#0R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1F%I<B!V86QU92!O9B!D97)I=F%T:79E('=A<G)A;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S+#@X-RPX-3`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L
M.#@W+#@U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96YE9FEC:6%L(&-O;G9E<G-I;VX@
M9F5A='5R92!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S<R+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S(L.#4P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-#0T
M+#<Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-#0T+#<Y-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M;&%N8V4@870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3DR+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S-BPV-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT."PR,S<L-C(P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#<L,S@R+#(U."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A;&%N8V4L(%-H87)E<R!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-C8T+#@P,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M(&ES<W5A;F-E(&]F("T@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L,3(Y+#DT,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0P+#@W-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#@Y+#`V,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@+2!S=&]C:RP@4VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP.#<L-S0W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;G9E<G-I;VX@;V8@;F]T97,@<&%Y86)L92!A;F0@86-C<G5E9"!I;G1E
M<F5S="!T;R!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3@Q+#<R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R+#4R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDV.2PR,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N
M(&]F(&YO=&5S('!A>6%B;&4@86YD(&%C8W)U960@:6YT97)E<W0@=&\@<W1O
M8VLL(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,C4R+#4U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&%T('1H92!R979E<G-E(&UE<F=E
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(S+#@V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(S+#@V-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&%T
M('1H92!R979E<G-E(&UE<F=E<BP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPS.#8L-38V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;B!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C8L,3<R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(V-BPQ-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.34W+#<U-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#DU-RPW-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&1E
M<FEV871I=F4@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#0L,#4R+#`X.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PP-3(L,#@Y*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1R86YS9F5R(&9R;VT@;&EA8FEL:71Y(&-L87-S:69I8V%T:6]N
M('1O(&5Q=6ET>2!C;&%S<VEF:6-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PR,S$L,S(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C,Q+#,R-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@X+#,V,2PR,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X
M+#,V,2PR,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,3(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PQ-#4L-C,U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,3,L.3$V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M-BPV-S4L,3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@U-2PW-#,L-#8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@4VAA<F5S(&%T($1E
M8RX@,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,2PS.3$L-C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E,5]F-61D7S1E
M8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%5E9"23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&%T96UE
M;G1S(&]F($-A<V@@1FQO=W,@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$U,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ-C`@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@1FQO=W,@1G)O
M;2!/<&5R871I;F<@06-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-"PX.3,L.34Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-2PT.#,L.34T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H."PS-C$L,C`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,RPT-#0L-SDU*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-34L-S0S+#0V,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8P+#8S
M-RPT,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@
M;&]S<R!T;R!N970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@;W!E<F%T
M:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#0L,S<Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S$R+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L,C(S+#DR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,3<S+#,W-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#4R+#`S-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,S,V+#0P-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5P<F5C:6%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(V,BPT-C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(V,BPT
M-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO<W,@;VX@9&ES<&]S:71I;VX@;V8@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$R,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,"PQ.#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-30L,S`X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ
M871I;VX@;V8@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8W."PQ,38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-S4L-C,W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(T+#,V,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F97)R960@9FEN86YC
M:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$Y+#<R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(U,BPR-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PT-#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3(L-CDR/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDR+#8Y,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1V%I;B!O;B!E>'1I;F=U:7-H;65N="!O9B!L:6%B:6QI='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-C`L,#`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V,"PP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!D97)I=F%T:79E(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,38L,3$R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X-RPV
M,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V.#4L-#(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$S+#DV-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V.3DL,S@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DQ-2PT.3@I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/BA)
M;F-R96%S92D@9&5C<F5A<V4@:6XZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E(F86UP.T0@<F5I;6)U<G-A8FQE
M(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,T+#`X.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#4V-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-S0V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E
M;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,30L
M,30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30L,S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3@L,#$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L-S8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C,L,SDW*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@W+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M;F-R96%S92`H9&5C<F5A<V4I(&EN.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N
M9"!A8V-R=65D(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U.#4L,#0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W,RPV,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S0L,C8S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34V+#`Q.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C,X+#<W
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8U,RPW,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@;&EA8FEL
M:71I97,@+2!R96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-#0L-3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,2PQ.#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L,3@U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S<U+#8X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!#87-H(%5S960@26X@3W!E<F%T:6YG($%C=&EV:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L.30W+#DV.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M+#<Y-2PT.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-2PR,3(L-S$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4Q-RPU.3(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#0L-#`R+#8U."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T.2PS-3`L
M-C(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@26YV97-T:6YG($%C=&EV
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!A>6UE;G0@;6%D92!F;W(@<&%T96YT(')I9VAT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,#`P+#`P,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M+#`P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#`S,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#@Q,BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M+#,U.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.#$U+#8U.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,C,L-C@Y*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!#87-H
M(%5S960@26X@26YV97-T:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#@L,#,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#$R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,S4Y*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#@Q-2PV-3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,RPX,C,L-C@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R
M;VT@1FEN86YC:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)O<G)O=VEN9W,@;VX@8V]N
M=F5R=&EB;&4@9&5B="P@;F5T(&]F(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV-#4L.#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0U+#@X.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T-2PX.#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE
M;G1S(&]N(&YO=&4@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,30P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,30P+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&5S(&]F(&-O;6UO
M;B!S=&]C:RP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8P+#$V,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3(Y+#DT
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,S<Y+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4S+#$Y,2PP.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,RPQ.3$L,#DX/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M('1H92!E>&5R8VES92!O9B!W87)R86YT<R!F;W(@8V%S:#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT-C<L,SDS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#8W+#,Y
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!#87-H(%!R;W9I9&5D($)Y($9I;F%N8VEN9R!!8W1I=FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,R-RPS.3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-C`L
M,38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PQ,CDL.30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPP,C4L,C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3,L.#,V+#DX-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W+#$V-"PS-SD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@8VAA;F=E(&EN(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L-C(X+#8P-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S+#$S-RPQ,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#4L,3(Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-3`W+#8V,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-C$X
M+#8V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L.3DP+#`V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V%S:"!A="!B96=I;FYI;F<@;V8@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#8Q."PV-CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#<P,RPW
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#<P,RPW.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.38L,3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@870@96YD(&]F('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY.3`L,#8S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU-C8L
M-C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PV,3@L-C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PW,#,L-SDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV,3@L-C8Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY.3`L,#8S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!C87-H(&9L;W<@:6YF
M;W)M871I;VXZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@:6YT97)E<W0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4V,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C0S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R('1A
M>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L
M(&1I<V-L;W-U<F4@;V8@;F]N+6-A<V@@:6YV97-T:6YG(&%N9"!F:6YA;F-I
M;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U
M<F4@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W,BPX-3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-S(L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S<R+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!W87)R86YT<R!I<W-U960@
M=VET:"!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S<L,34P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<W
M+#$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,W-RPQ-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=',@:7-S=65D('=I
M=&@@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,3@L,#@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPS.3,L,S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU.3$L.3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PY.#4L,C,X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PY
M.#4L,C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G1S(&ES<W5E9"!T;R!T:&4@
M<&QA8V5M96YT(&%G96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34Y+#`T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8U."PW-3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0X-"PU,CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$W,"PR
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#$W,"PR.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@;F]T97,@<&%Y86)L92!A;F0@
M86-C<G5E9"!I;G1E<F5S="!T;R!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.#$L-S(Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDX,2PW,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY.#$L-S(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%N<V9E<B!F<F]M(&QI
M86)I;&ET>2!C;&%S<VEF:6-A=&EO;B!T;R!E<75I='D@8VQA<W-I9FEC871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T+#(S,2PS,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`T+#(S,2PS,C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L.#,R+#(P-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D
M9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B
M-R]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$531SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY$97-C<FEP=&EO;B!/9B!"=7-I;F5S<R!A;F0@4W5M
M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O9B!3
M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M3F]T92`Q("8C.#(Q,3L@1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T
M:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/DYA='5R92!O9B!"=7-I;F5S<R`F(S@R
M,3$[/"]F;VYT/B!!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RX@9F]R
M;65R;'D@:VYO=VX@87,@0V%C='5S(%9E;G1U<F5S+"!);F,N("AT:&4@)B,X
M,C(P.T-O;7!A;GDF(S@R,C$[+"`F(S@R,C`[06-T:6YI=6TF(S@R,C$[+"`F
M(S@R,C`[0V%C='5S)B,X,C(Q.RDL('=A<R!I;F-O<G!O<F%T960@=6YD97(@
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!$96-E
M;6)E<B`R."P@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@=')A
M;G-A8W1I;VX@*'1H92`F(S@R,C`[4VAA<F4@17AC:&%N9V4F(S@R,C$[*2P@
M<'5R<W5A;G0@=&\@=VAI8V@@=&AE($-O;7!A;GD@86-Q=6ER960@,3`P)2!O
M9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!E<75I='D@<V5C=7)I=&EE
M<R!O9B!!8W1I;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RX@*"8C.#(R,#M!
M4$DF(S@R,C$[*2P@:6X@97AC:&%N9V4@9F]R('1H92!I<W-U86YC92!O9B!A
M<'!R;WAI;6%T96QY(#DY)2!O9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN
M9R!C;VUM;VX@<W1O8VLL('!A<B!V86QU92`D,"XP,2!P97(@<VAA<F4L(&]F
M('1H92!#;VUP86YY+B!4:&4@4VAA<F4@17AC:&%N9V4@8VQO<V5D(&]N($1E
M8V5M8F5R(#(X+"`R,#$R+B8C,38P.R8C,38P.T%S(&$@<F5S=6QT(&]F('1H
M92!3:&%R92!%>&-H86YG92P@=&AE(&9O<FUE<B!S:&%R96AO;&1E<G,@;V8@
M05!)(&)E8V%M92!T:&4@8V]N=')O;&QI;F<@<VAA<F5H;VQD97)S(&]F('1H
M92!#;VUP86YY+B!!="!T:&4@8VQO<VEN9RP@96%C:"!!4$D@<VAA<F5H;VQD
M97(@<F5C96EV960@,"XS,S,@<VAA<F5S("AT:&4@)B,X,C(P.T5X8VAA;F=E
M(%)A=&EO)B,X,C(Q.RD@;V8@06-T:6YI=6T@8V]M;6]N('-T;V-K(&9O<B!E
M86-H($%022!S:&%R92!E>&-H86YG960N($%T('1H92!C;&]S:6YG+"!A;&P@
M;V8@=&AE($%022!S:&%R96AO;&1E<G,F(S@R,3<[(&]P=&EO;G,@86YD('=A
M<G)A;G1S('1O('!U<F-H87-E($%022!C;VUM;VX@<W1O8VL@=V%S(&5X8VAA
M;F=E9"!A="!T:&4@17AC:&%N9V4@4F%T:6\@9F]R(&YE=R!O<'1I;VYS(&]R
M('=A<G)A;G1S+"!A<R!A<'!L:6-A8FQE+"!T;R!P=7)C:&%S92!!8W1I;FEU
M;2!C;VUM;VX@<W1O8VLN)B,Q-C`[)B,Q-C`[5&AE(%-H87)E($5X8VAA;F=E
M('=A<R!A8V-O=6YT960@9F]R(&%S(&$@<F5V97)S92!T86ME;W9E<B]R96-A
M<&ET86QI>F%T:6]N(&5F9F5C=&5D(&)Y(&$@<VAA<F4@97AC:&%N9V4L('=H
M97)E:6X@05!)(&ES(&-O;G-I9&5R960@=&AE(&%C<75I<F5R(&9O<B!A8V-O
M=6YT:6YG(&%N9"!F:6YA;F-I86P@<F5P;W)T:6YG('!U<G!O<V5S+B!4:&4@
M8V%P:71A;"P@<VAA<F4@<')I8V4L(&%N9"!E87)N:6YG<R!P97(@<VAA<F4@
M86UO=6YT(&EN('1H97-E(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<R!F;W(@=&AE('!E<FEO9"!P<FEO<B!T;R!T:&4@<F5V97)S92!M97)G
M97(@=V5R92!R97-T871E9"!T;R!R969L96-T('1H92!R96-A<&ET86QI>F%T
M:6]N(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@97AC:&%N9V4@<F%T:6\@97-T
M86)L:7-H960@:6X@=&AE(&UE<F=E<B!E>&-E<'0@;W1H97)W:7-E(&YO=&5D
M+CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX-"CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/D%022P@:6YC;W)P;W)A=&5D(&]N($IU;F4@,3,L(#(P,#`L
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M;"!A="!-96UO<FEA;"!3;&]A;BU+971T97)I;F<@0V%N8V5R($-E;G1E<B`H
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T
M97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^3VX@36%R8V@@,C`L(#(P,3,L(&EN(&%N
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M)B,Q-C`[)B,Q-C`[3VX@07!R:6P@,3$L(#(P,3,L('1H92!#;VUP86YY(&-H
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M="US:7IE.B`Q,'!T.R<^3VX@4V5P=&5M8F5R(#(U+"`R,#$S+"!I;B!A8V-O
M<F1A;F-E('=I=&@@82!#97)T:69I8V%T92!O9B!/=VYE<G-H:7`@365R9VEN
M9R!!8W1I;FEU;2!#;W)P;W)A=&EO;B!I;G1O('1H92!!8W1I;FEU;2!0:&%R
M;6%C975T:6-A;',L($EN8RX@*&9I;&5D(&EN($1E;&%W87)E+"!T:&4@0V]M
M<&%N>2!M97)G960@*'1H92`F(S@R,C`[365R9V5R)B,X,C(Q.RD@:6YT;R!I
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M.R8C,38P.T$@=&]T86P@;V8@,RPY-S`L,3,W('-H87)E<R!O9B!!8W1I;FEU
M;2!#;W)P;W)A=&EO;B!C;VUM;VX@<W1O8VL@=V%S(&5X8VAA;F=E9"!F;W(@
M,2PS,C(L,#4U('-H87)E<R!O9B!#;VUP86YY(&-O;6UO;B!S=&]C:RX\+V9O
M;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#LF(S$V,#L\+V1I=CX-"CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.PT*(&9O;G0M=V5I9VAT.B!B;VQD.R<^0F%S:7,@
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M("@F(S@R,C`[52Y3+B!'04%0)B,X,C(Q.RD@9F]R(&EN=&5R:6T@9FEN86YC
M:6%L(&EN9F]R;6%T:6]N+"!A;F0@:6X@86-C;W)D86YC92!W:71H('1H92!R
M=6QE<R!A;F0@<F5G=6QA=&EO;G,@;V8@=&AE(%5N:71E9"!3=&%T97,@4V5C
M=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE("8C.#(R,#M3
M14,F(S@R,C$[*2!W:71H(')E<W!E8W0@=&\@1F]R;2`Q,"U1(&%N9"!!<G1I
M8VQE(#@@;V8@4F5G=6QA=&EO;B!3+5@N($%C8V]R9&EN9VQY+"!T:&5Y(&1O
M(&YO="!I;F-L=61E(&%L;"!O9B!T:&4@:6YF;W)M871I;VX@86YD(&9O;W1N
M;W1E<R!R97%U:7)E9"!B>2!5+E,N($=!05`@9F]R(&-O;7!L971E(&9I;F%N
M8VEA;"!S=&%T96UE;G1S+B!4:&4@=6YA=61I=&5D(&EN=&5R:6T@8V]N<V]L
M:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&9U<FYI<VAE9"!R969L96-T
M(&%L;"!A9&IU<W1M96YT<R`H8V]N<VES=&EN9R!O9B!N;W)M86P@<F5C=7)R
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M;7!A;GD@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&%N
M9"!N;W1E<R!T:&5R971O(&-O;G1A:6YE9"!I;B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&%N;G5A;"!R97!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BP@87,@9FEL960@=VET:"!T:&4@4T5#
M($UA<F-H(#(Y+"`R,#$S+CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q
M-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT
M+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^
M#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@
M-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS
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M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S
M='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ
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M;G-U<F5D(&QI;6ET<RX@070@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!$96-E
M;6)E<B`S,2P@,C`Q,BP@86QL(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V%S
M:"!W87,@9&5P;W-I=&5D(&EN(&]N92!B86YK+CPO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J
M=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S<V5T<R`F(S@R
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M;F-E(&)E='=E96X@=&AE(&9A:7(@=F%L=64@;V8@<W5C:`T*(&%S<V5T(&%N
M9"!I=',@8V%R<GEI;F<@=F%L=64N/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<R`F(S@R,3$[/"]F;VYT/B!&86ER
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D
M:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^
M#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/DQE=F5L(#(@26YP=71S("8C.#(Q,3L@26YP=71S(&]T
M:&5R('1H86X@<75O=&5D('!R:6-E<R!I;F-L=61E9"!I;B!,979E;"`Q('1H
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`S($EN<'5T<R`F(S@R,3$[
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M9B!397!T96UB97(@,S`L(#(P,3,@86YD($1E8V5M8F5R(#,Q+B!!<R!R97%U
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C
M,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE
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M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^3&5V96P@,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3$E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C
M;VQS<&%N/3-$,SX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`S/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#)P>"!S;VQI9#LG(&-O;'-P86X],T0S/@T*/&1I=B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q,24@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0S/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3$E
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[070@4V5P=&5M8F5R
M(#,P+"`R,#$S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
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M)SXM/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C9F9F9F9F
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#0R)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P.T%T($1E8V5M8F5R(#,Q+"`R,#$R
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[#0H@9F]N="US:7IE.B`Q,'!T.R<^
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Y)2!V86QI
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S
M='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ
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M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M;W(@96%C:"!P97)I;V0@<')E<V5N=&5D+B!"87-I8R!E87)N:6YG<R`H;&]S
M<RD@<&5R(&-O;6UO;B!S:&%R92!I<R!C;VUP=71E9"!B>2!D:79I9&EN9R!T
M:&4@;F5T(&EN8V]M92`H;&]S<RD@879A:6QA8FQE('1O(&-O;6UO;B!S=&]C
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M97!T96UB97(@,S`L(#(P,3,L('!O=&5N=&EA;&QY(&ES<W5A8FQE('-H87)E
M<R!I;F-L=61E9"!S=&]C:R!O<'1I;VYS('1O('!U<F-H87-E(#(L,C@P+#$X
M-"!S:&%R97,@86YD('=A<G)A;G1S('1O#0H@<'5R8VAA<V4@.2PT-#$L.30R
M('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@
M1F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(L
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M(&%M;W5N="!O9B`Q,RPX,S$L-S8R('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:R!H879E(&)E96X@97AC;'5D960@9G)O;2!T
M:&4@8V%L8W5L871I;VXN/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS
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M<R`F(S@R,3$[/"]F;VYT/B!4:&4@0V]M<&%N>2!D;V5S(&YO="!E>'!E8W0@
M=&AA="!A;GD@<F5C96YT;'D@:7-S=65D(&%C8V]U;G1I;F<@<')O;F]U;F-E
M;65N=',@=VEL;"!H879E(&$@<VEG;FEF:6-A;G0@:6UP86-T(&]N('1H92!R
M97-U;'1S(&]F(&]P97)A=&EO;G,L(&9I;F%N8VEA;"!P;W-I=&EO;BP@;W(@
M8V%S:"!F;&]W<R!O9B!T:&4@0V]M<&%N>2X\+V9O;G0^/"]F;VYT/CPO9&EV
M/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#0U<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU
M<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#0U<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
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M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M8RXI("AT:&4@)B,X,C(P.T-O;7!A;GDF(S@R,C$[+"`F(S@R,C`[0V%C='5S
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`F(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
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M=&EC86QS+"!);F,N("@F(S@R,C`[06-T:6YI=6TF(S@R,C$[*2P@:6X@97AC
M:&%N9V4@9F]R('1H92!I<W-U86YC92!O9B!A<'!R;WAI;6%T96QY(#DY)2!O
M9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!C;VUM;VX@<W1O8VLL('!A
M<B!V86QU92`D,"XP,2!P97(@<VAA<F4L(&]F('1H92!#;VUP86YY+B!4:&4@
M4VAA<F4@17AC:&%N9V4@=V%S(&-L;W-E9"!O;B!$96-E;6)E<B`R."P@,C`Q
M,B!W:&5N('-H87)E:&]L9&5R<R!R97!R97-E;G1I;F<@;W9E<B`R,"4@;V8@
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P.R8C,38P.SPO9F]N
M=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[($%C=&EN:75M+"!I;F-O<G!O<F%T960@;VX@2G5N92`Q,RP@
M,C`P,"P@:7,@82!B:6]T96-H;F]L;V=Y(&-O;7!A;GD@8V]M;6ET=&5D('1O
M(&1E=F5L;W!I;F<@8G)E86MT:')O=6=H('1H97)A<&EE<R!F;W(@;&EF92!T
M:')E871E;FEN9R!D:7-E87-E<R!U<VEN9R!I=',@86QP:&$@<&%R=&EC;&4@
M:6UM=6YO=&AE<F%P>2`H05!)5"D@<&QA=&9O<FT@86YD(&]T:&5R(')E;&%T
M960@86YD('-I;6EL87(@=&5C:&YO;&]G:65S+B!!8W1I;FEU;2P@=&]G971H
M97(@=VET:"!I=',@=VAO;&QY(&]W;F5D('-U8G-I9&EA<GDL($UE9$%C=&EN
M:75M+"!);F,N("A-04DI+"`H:&5R96EN869T97(@<F5F97)R960@=&\@8V]L
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M0V%N8V5R($-E;G1E<B`H35-+0T,I('5N9&5R(&%N($U32T-#(%!H>7-I8VEA
M;B!);G9E<W1I9V%T:6]N86P@3F5W($1R=6<@07!P;&EC871I;VXN($EN(#(P
M,3(L($%C=&EN:75M(&QA=6YC:&5D(&$@;75L=&DM8V5N=&5R(&-O<G!O<F%T
M92!S<&]N<V]R960@=')I86P@:6X@86-U=&4@;7EE;&]I9"!L975K96UI82`H
M04U,*2!P871I96YT<RX@)B,Q-C`[06-T:6YI=6TF(S@R,3<[<R!O8FIE8W1I
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M:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%!R
M:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO;B`F(S@R,3$[/"]F;VYT/B!4:&4@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU9&4@=&AE
M($-O;7!A;GDF(S@R,3<[<R!A8V-O=6YT<R!A;F0@=&AO<V4@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!W:&]L;'D@;W=N960@<W5B<VED:6%R:65S+B!!;&P@
M<VEG;FEF:6-A;G0@:6YT97)C;VUP86YY(&%C8V]U;G1S(&%N9"!T<F%N<V%C
M=&EO;G,@:&%V92!B965N(&5L:6UI;F%T960N/"]F;VYT/CPO9&EV/@T*/&1I
M=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV#0H@86QI9VX],T1J=7-T
M:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-
M"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX]
M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^)B,Q-C`[/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^26UP86ER;65N
M="!O9B!,;VYG+4QI=F5D($%S<V5T<R`F(S@R,3$[/"]F;VYT/B!-86YA9V5M
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M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SY$
M97)I=F%T:79E<R`F(S@R,3$[/"]F;VYT/B!!;&P@9&5R:79A=&EV97,@87)E
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M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#0U<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`T-7!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5V96P@
M,2!);G!U=',@)B,X,C$Q.R!5;F%D:G5S=&5D('%U;W1E9"!P<FEC97,@:6X@
M86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A<W-E=',@;W(@;&EA8FEL
M:71I97,@=&AA="!T:&4@<F5P;W)T:6YG(&5N=&ET>2!H87,@=&AE(&%B:6QI
M='D@=&\@86-C97-S(&%T('1H92!M96%S=7)E;65N="!D871E+CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@-#5P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DQE=F5L(#(@26YP=71S("8C
M.#(Q,3L@26YP=71S(&]T:&5R('1H86X@<75O=&5D('!R:6-E<R!I;F-L=61E
M9"!I;B!,979E;"`Q('1H870@87)E(&]B<V5R=F%B;&4@9F]R('1H92!A<W-E
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M9',L(&-R961I=`T*(')I<VMS+"!E=&,N*2!O<B!I;G!U=',@=&AA="!A<F4@
M9&5R:79E9"!P<FEN8VEP86QL>2!F<F]M(&]R(&-O<G)O8F]R871E9"!B>2!M
M87)K970@9&%T82!B>2!C;W)R96QA=&EO;B!O<B!O=&AE<B!M96%N<RX\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#0U<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`S($EN<'5T
M<R`F(S@R,3$[(%5N;V)S97)V86)L92!I;G!U=',@9F]R(&1E=&5R;6EN:6YG
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE(&9O
M;&QO=VEN9R!T86)L97,@<V5T(&9O<G1H(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!A;F0@
M;F]N+7)E8W5R<FEN9R!B87-I<R!B>2!L979E;"!W:71H:6X@=&AE(&9A:7(@
M=F%L=64@:&EE<F%R8VAY(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R
M,#$Q+B!!<R!R97%U:7)E9"!B>2!!4T,@.#(P+"!F:6YA;F-I86P@87-S971S
M(&%N9"!L:6%B:6QI=&EE<R!A<F4@8VQA<W-I9FEE9"!I;B!T:&5I<B!E;G1I
M<F5T>2!B87-E9"!O;B!T:&4@;&]W97-T(&QE=F5L(&]F(&EN<'5T('1H870@
M:7,@<VEG;FEF:6-A;G0@=&\@=&AE(&9A:7(@=F%L=64@;65A<W5R96UE;G0N
M(%1H92!#;VUP86YY)B,X,C$W.W,@87-S97-S;65N="!O9B!T:&4@<VEG;FEF
M:6-A;F-E(&]F(&$@<&%R=&EC=6QA<B!I;G!U="!T;R!T:&4@9F%I<B!V86QU
M92!M96%S=7)E;65N="!R97%U:7)E<R!J=61G;65N="P@86YD(&UA>2!A9F9E
M8W0@=&AE('9A;'5A=&EO;B!O9B!F86ER('9A;'5E(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,@86YD('1H96ER('!L86-E;65N="!W:71H:6X@=&AE(&9A:7(@
M=F%L=64@:&EE<F%R8VAY(&QE=F5L<RX\+V9O;G0^/"]D:78^#0H\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE('-T>6QE
M/3-$)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#(E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS
M1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^3&5V96P@,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`R/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
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M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O
M;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^5&]T86P\+V9O;G0^/"]D:78^#0H\+W1D
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M,T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D#0H@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#LF(S$V,#M!="!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,RPU-S0L.34X/"]F;VYT/CPO9&EV
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-#(E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M)B,Q-C`[070@1&5C96UB97(@,S$L(#(P,3$\+V9O;G0^/"]D:78^#0H\+W1D
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
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M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-"PT,SDL-C$S/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\
M+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%)E<V5A<F-H(&%N9"!$979E;&]P;65N
M="!#;W-T<R`F(S@R,3$[/"]F;VYT/B!297-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@8V]S=',@87)E(&5X<&5N<V5D(&%S(&EN8W5R<F5D+B!297-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@<F5I;6)U<G-E;65N=',@86YD(&=R86YT<R!A<F4@
M<F5C;W)D960@8GD@=&AE($-O;7!A;GD@87,@82!R961U8W1I;VX@;V8@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S+CPO9F]N=#X\+V1I=CX-"CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%-H87)E+4)A<V5D(%!A>6UE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R!%87)N:6YG<R`H3&]S<RD@4&5R
M($-O;6UO;B!3:&%R92`F(S@R,3$[/"]F;VYT/B!4:&4@0V]M<&%N>2!P<F]V
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M:&4@<V%M92X@)B,Q-C`[5&AE('!O=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R
M:71I97,@*&]P=&EO;G,L('=A<G)A;G1S(&%N9"!C;VYV97)T:6)L92!I;G-T
M<G5M96YT<RD@=V5R92!E>&-L=61E9"!F<F]M('1H92!D:6QU=&5D(&QO<W,@
M<&5R(&-O;6UO;B!S:&%R92!C86QC=6QA=&EO;B!B96-A=7-E('1H96ER(&5F
M9F5C="!W;W5L9"!H879E(&)E96X@86YT:2!D:6QU=&EV92X@1F]R('1H92!Y
M96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"!P;W1E;G1I86QL>2!I<W-U
M86)L92!S:&%R97,@:6YC;'5D960@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S
M92`R+#,S,"PQ,S0@<VAA<F5S(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92`Q
M,BPW-S`L-3DV('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO
M;B!S=&]C:RX@1F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q
M+"!P;W1E;G1I86QL>2!I<W-U86)L92!S:&%R97,@:6YC;'5D97,@;W!T:6]N
M<R!A;F0@=V%R<F%N=',F(S$V,#MT;R!P=7)C:&%S92`R-S,L.#4Y('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A;F0@;F]T
M97,@<&%Y86)L92!C;VYV97)T:6)L92!T;R`S+#0T."PR-S8@<VAA<F5S(&]F
M('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&AA=F4@8F5E;B!E
M>&-L=61E9"!F<F]M('1H92!C86QC=6QA=&EO;BX\+V9O;G0^/"]D:78^#0H\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R!296-E;G0@06-C;W5N=&EN
M9R!0<F]N;W5N8V5M96YT<R`F(S@R,3$[/"]F;VYT/B!4:&4@0V]M<&%N>2!D
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX]
M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S#0H@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%-U
M8G-E<75E;G0@179E;G1S("8C.#(Q,3L\+V9O;G0^(%1H92!#;VUP86YY)B,X
M,C$W.W,@;6%N86=E;65N="!R979I97=E9"!A;&P@;6%T97)I86P@979E;G1S
M(&9R;VT@2F%N=6%R>2`Q+"`R,#$S('1H<F]U9V@@36%R8V@@,34L(#(P,3,N
M/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?
M-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T,#@N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$531SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY';VEN9R!#
M;VYC97)N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY';VEN9R!#;VYC97)N(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y';VEN9R!#;VYC97)N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^3F]T92`R("8C.#(Q,3L@1V]I;F<@
M0V]N8V5R;CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
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M,RPY-3$@86YD(&YE="!C87-H('5S960@:6X@;W!E<F%T:6]N<R!O9B`D-"PY
M-#<L.38Y+"!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S
M,"P@,C`Q,SL@86YD(&$@9&5F:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE
M(&1E=F5L;W!M96YT('-T86=E(&]F("0V,"PV,S<L-#$T(&%T(%-E<'1E;6)E
M<B`S,"P@,C`Q,RX@26X@861D:71I;VXL('1H92!#;VUP86YY(&AA<R!N;W0@
M8V]M<&QE=&5D(&ET<R!E9F9O<G1S('1O(&5S=&%B;&ES:"!A('-T86)L92!R
M96-U<G)I;F<@<V]U<F-E(&]F(')E=F5N=65S('-U9F9I8VEE;G0@=&\@8V]V
M97(@:71S(&]P97)A=&EN9R!C;W-T<R!F;W(@=&AE(&YE>'0@='=E;'9E(&UO
M;G1H<RX@5&AE<V4@9F%C=&]R<R!R86ES92!S=6)S=&%N=&EA;"!D;W5B="!R
M96=A<F1I;F<@=&AE($-O;7!A;GDF(S@R,3<[<R!A8FEL:71Y('1O(&-O;G1I
M;G5E(&%S(&$@9V]I;F<@8V]N8V5R;BX\+V9O;G0^/"]D:78^#0H\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M92X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^3F]T92`R
M("8C.#(Q,3L@1V]I;F<@0V]N8V5R;CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+V9O;G0^
M)B,Q-C`[/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
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M(&]F("0U+#(Q,BPW,3`L(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S
M,2PF(S$V,#LR,#$R.R!A;F0@86X@86-C=6UU;&%T960@9&5F:6-I="!O9B`D
M-34L-S0S+#0V,R!A="!$96-E;6)E<B`S,2P@,C`Q,BX@26X@861D:71I;VXL
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%1H92!A8FEL
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M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B
M7S$S93AF-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P
M964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T
M<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!0
M87)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5L871E9"!087)T>2!4<F%N
M<V%C=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
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M:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE
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M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M($EN(#(P,3`L($=E;F5R86P@071L86YT:6,@1W)O=7`@3&EM:71E9"!D;VYA
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M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX-"CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[($]N
M($9E8G)U87)Y(#$Q+"`R,#`R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M82!,:6-E;G-E+"!$979E;&]P;65N="!A;F0@0V]M;65R8VEA;&EZ871I;VX@
M06=R965M96YT('=I=&@@4VQO86XM2V5T=&5R:6YG($EN<W1I='5T92!O9B!#
M86YC97(@4F5S96%R8V@@*%-+22DL)B,Q-C`[86X@96YT:71Y(')E;&%T960@
M=&\@35-+0T,N)B,Q-C`[)B,Q-C`[5&AE(&%G<F5E;65N="!W87,@86UE;F1E
M9"!I;B!!=6=U<W0@,C`P-BXF(S$V,#LF(S$V,#M0=7)S=6%N="!T;R!T:&4@
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M+"`R,#$Q+"!T:&4@0V]M<&%N>2!N;VYE=&AE;&5S<R!A9W)E960@=&\@<&%Y
M(%-+22`H82D@)#4P+#`P,"!I;B`R,#$Q+"`H8BD@)#(P,"PP,#`@:6X@,C`Q
M,B!A;F0@*&,I("0R-3`L,#`P(&EN(#(P,3,@=6YD97(@=&AI<R!A9W)E96UE
M;G0L(&EN(')E<W!E8W0@;V8@=&AE("0U,"PP,#`@86YN=6%L(&UA:6YT96YA
M;F-E(&9E97,@86YD(')E<V5A<F-H('!A>6UE;G1S+B!3:6YC92!*86YU87)Y
M(#$L(#(P,3$L('1H92!#;VUP86YY(&AA<R!P86ED("0Q,#`L,#`P('5N9&5R
M('1H:7,@86=R965M96YT(&%N9"!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BP@
M=&AE($-O;7!A;GD@86=R965D('1O('!A>2!A;B!A9&1I=&EO;F%L("0Q-3`L
M,#`P(&9O<B!R97-E87)C:"!T;R!B92!C;VYD=6-T960@:6X@,C`Q,RX\+V9O
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M=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[($]N($UA<F-H(#(W+"`R
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M-2XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A>2`D,S$L,3@U(&9O
M<B!E86-H('!A=&EE;G0@=&AA="!H87,@8V]M<&QE=&5D('1H92!C;&EN:6-A
M;"!T<FEA;"XF(S$V,#LF(S$V,#M5<&]N(&5X96-U=&EO;B!O9B!T:&4@86=R
M965M96YT+"!T:&4@0V]M<&%N>2!W87,@<F5Q=6ER960@=&\@<&%Y(&$@<W1A
M<G0M=7`@9F5E(&]F("0W.2PV,C,L('=H:6-H('=A<R!P86ED(&]N($IU;'D@
M,3`L(#(P,3(N/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V
M,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`S-G!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z
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M35-+0T,@87)R86YG96UE;G1S(&9O<B!Y96%R<R!E;F1E9"!$96-E;6)E<B`S
M,2P@,C`Q,B!A;F0@,C`Q,3H\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS
M1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8V)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/@T*/&1I=B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C(P,3$\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#8V)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)0T*('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS
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M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
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M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXD/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
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M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY296EM8G5R<V5M
M96YT<R!R96-E:79E9"!F<F]M($U32T-#/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
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M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXY-C8L
M,S0Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@26X@,C`Q,B!A;F0@,C`Q
M,2P@=&AE($-O;7!A;GD@<F5C96EV960@=&]T86P@4B9A;7`[1"!R96EM8G5R
M<V5M96YT('!A>6UE;G1S(&]F("0R,S<L.#,T(&%N9"`D,CDY+#(P,"P@<F5S
M<&5C=&EV96QY+"!F<F]M($U32T-#+CPO9F]N=#X\+V1I=CX-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q
M+"!T:&4@0V]M<&%N>2!H860@82!N970@<F5C96EV86)L92!O9B`D,"!A;F0@
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
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M('-I=&4N)B,Q-C`[)B,Q-C`[1'(N($UA>F%N970@<F5C96EV97,@8V]M<&5N
M<V%T:6]N(&]F("0Q,#`L,#`P('!E<B!Y96%R(&%N9"!M87D@<F5C96EV92!A
M9&1I=&EO;F%L(&-O;7!E;G-A=&EO;B!I;B!T:&4@9F]R;2!O9B!O<'1I;VYS
M(&%T(&1E=&5R;6EN960@8GD@=&AE(&)O87)D(&]F('1H92!#;VUP86YY+B8C
M,38P.R8C,38P.U-I;F-E($IA;G5A<GD@,2P@,C`Q,2P@1'(N($UA>F%N970@
M:&%S(&%L<V\@<F5C96EV960@;W!T:6]N<R!T;R!P=7)C:&%S92`Y.2PY,#`@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B!T:&4@0V]M<&%N>2X@5&AE<V4@
M;W!T:6]N<R!H879E(&5X97)C:7-E('!R:6-E(')A;F=I;F<@9G)O;2`D,"XW
M."!T;R`D,2XU(&%N9"!H879E(&$@;&EF92!O9B`Q,"!Y96%R<RX\+V9O;G0^
M/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.SQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET
M86QI8SL@9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV#0H@86QI9VX],T1J=7-T
M:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="US='EL93H@:71A;&EC.R!F;VYT+7=E:6=H=#H@
M8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^2F%M97-S($-A<&ET86P@1W)O=7`L
M($Q,0SH\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L
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M.2P@,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@=')A;G-A8W1I
M;VX@;6%N86=E;65N="!A9W)E96UE;G0@=VET:"!*86UE<W,@0V%P:71A;"!'
M<F]U<"P@3$Q#+B`H9F]R;65R;'D@:VYO=VX@87,@06UE<F%S:6$@0V%P:71A
M;"!'<F]U<"P@3$Q#*2P@82!C;VYS=6QT:6YG(&9I<FT@869F:6QI871E9"!W
M:71H($UR+B!386YD97-H(%-E=&@L(&$@1&ER96-T;W(@;V8@=&AE($-O;7!A
M;GDF(S$V,#LH)B,X,C(P.TUA;F%G96UE;G0@1FER;28C.#(R,3LI+B8C,38P
M.R!4:&4@36%N86=E;65N="!&:7)M(')E8V5I=F5D(&$@;6]N=&AL>2!F964@
M;V8@)#$R+#4P,"!W:&EC:"!I<R!T97)M:6YA8FQE(&)Y('1H92!#;VUP86YY
M('1H<F5E(&UO;G1H<R!A9G1E<B!T:&4@969F96-T:79E(&1A=&4@;V8@=&AE
M(&=O:6YG('!U8FQI8R!T<F%N<V%C=&EO;B!A;F0@9&5S:6=N965S(&]F($IA
M;65S<RP@:6YC;'5D:6YG(&5N=&ET:65S(&%F9FEL:6%T960@=VET:"!-<BX@
M4V5T:"P@=V5R92!I<W-U960@=V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N
M('-T;V-K(&5Q=6%L('1O(#$P)2!O9B!T:&4@9G5L;'DM9&EL=71E9"!C87!I
M=&%L('-T;V-K(&]F('1H92!#;VUP86YY(&%S(&]F('1H92!E9F9E8W1I=F4@
M9&%T92!O9B!T:&4@9V]I;F<@<'5B;&EC('1R86YS86-T:6]N+B!4:&4@9G5L
M;'D@9&EL=71E9"!S:&%R97,@9F]R('1H:7,@8V%L8W5L871I;VX@:6YC;'5D
M960@86QL(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@<VAA<F5S(&%S('=E;&P@
M87,@=&AO<V4@<F5S97)V960@=6YD97(@=&AE($5M<&QO>65E(%-T;V-K($]P
M=&EO;B!0;&%N+B8C,38P.R!4:&4@36%N86=E;65N="!&:7)M(&ES(&%L<V\@
M96QI9VEB;&4@=&\@8F4@<F5I;6)U<G-E9"!U<&]N('1H92!S=6)M:7-S:6]N
M(&]F('!R;W!E<B!D;V-U;65N=&%T:6]N(&9O<B!O<F1I;F%R>2!A;F0@;F5C
M97-S87)Y(&]U="UO9BUP;V-K970@97AP96YS97,@;F]T('1O(&5X8V5E9"`D
M-2PP,#`@<&5R(&UO;G1H+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I
M=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[($]N($%U9W5S="`W+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN
M=&\@86X@96YG86=E;65N="!A9W)E96UE;G0@=VET:"!I=',@<&QA8V5M96YT
M(&%G96YT(&9O<B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<L)B,Q
M-C`[;V8@=VAI8V@@37(N(%-E=&@L(&$@9&ER96-T;W(@;V8@=&AE($-O;7!A
M;GD@:7,@2&5A9"!O9B!(96%L=&AC87)E($EN=F5S=&UE;G0@0F%N:VEN9RXF
M(S$V,#LF(S$V,#LF(S$V,#M0=7)S=6%N="!T;R!T:&4@86=R965M96YT+"!T
M:&4@<&QA8V5M96YT(&%G96YT('=A<R!E;F=A9V5D(&%S('1H92!E>&-L=7-I
M=F4@86=E;G0@9F]R('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RX@
M)B,Q-C`[)B,Q-C`[26X@8V]N<VED97)A=&EO;B!F;W(@:71S('-E<G9I8V5S
M+"!T:&4@<&QA8V5M96YT(&%G96YT('=I;&P@<F5C96EV92`H82D@82!C87-H
M(&9E92!E<75A;"!T;R`Q,"4@;V8@=&AE(&=R;W-S('!R;V-E961S(')A:7-E
M9"!I;B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<L("AB*2!A(&YO
M;BUA8V-O=6YT86)L92!E>'!E;G-E(')E:6UB=7)S96UE;G0@97%U86P@=&\@
M,B4@;V8@=&AE(&=R;W-S('!R;V-E961S(')A:7-E9"!I;B!T:&4@,C`Q,B!#
M;VUM;VX@4W1O8VL@3V9F97)I;F<L(&%N9"`H8RD@<F5I;6)U<G-E;65N="!O
M9B`D,3`P+#`P,"!F;W(@;&5G86P@97AP96YS97,@:6YC=7)R960@8GD@=&AE
M('!L86-E;65N="!A9V5N="XF(S$V,#LF(S$V,#M4:&4@<&QA8V5M96YT(&%G
M96YT(&]R(&ET<R!D97-I9VYE97,@:&%V92!A;'-O(')E8V5I=F5D('=A<G)A
M;G1S('1O('!U<F-H87-E('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M($-O;6UO;B!3=&]C:R!I;B!A;B!A;6]U;G0@97%U86P@=&\@,3`E(&]F('1H
M92!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&ES<W5E9"!A<R!P87)T(&]F('1H
M92!U;FET<R!S;VQD(&EN('1H92`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN
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M<B!A(&UO;G1H;'D@9F5E(&]F("0R-2PP,#`N)B,Q-C`[)B,Q-C`[5&AE(&%G
M<F5E;65N="!A;'-O('!R;W9I9&5S('1H870@*&DI(&EF('1H92!#;VUP86YY
M(&-O;G-U;6UA=&5S(&%N>2!M97)G97(L(&%C<75I<VET:6]N+"!B=7-I;F5S
M<R!C;VUB:6YA=&EO;B!O<B!O=&AE<B!T<F%N<V%C=&EO;B`H;W1H97(@=&AA
M;B!T:&4@4VAA<F4@17AC:&%N9V4I('=I=&@@86YY('!A<G1Y(&EN=')O9'5C
M960@=&\@:70@8GD@=&AE('!L86-E;65N="!A9V5N="P@=&AE('!L86-E;65N
M="!A9V5N="!W;W5L9"!R96-E:79E(&$@9F5E(&5Q=6%L('1O(#$P)2!O9B!T
M:&4@86=G<F5G871E(&-O;G-I9&5R871I;VX@:6X@<W5C:"!T<F%N<V%C=&EO
M;G,L(&%N9"`H:6DI(&EF+"!W:71H:6X@82!P97)I;V0@;V8@,3(@;6]N=&AS
M(&%F=&5R('1E<FUI;F%T:6]N(&]F('1H92!A9'9I<V]R>2!S97)V:6-E<R!D
M97-C<FEB960@86)O=F4L('1H92!#;VUP86YY(')E<75I<F5S(&$@9FEN86YC
M:6YG(&]R('-I;6EL87(@861V:7-O<GD@=')A;G-A8W1I;VX@=&AE('!L86-E
M;65N="!A9V5N="!W:6QL(&AA=F4@=&AE(')I9VAT('1O(&%C="!A<R!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA;"!A9'9I<V]R(&%N9"!I;G9E<W1M
M96YT(&)A;FME<B!I;B!S=6-H(&9I;F%N8VEN9R!O<B!T<F%N<V%C=&EO;B!P
M=7)S=6%N="!T;R!A('-E="!F964@<V-H961U;&4@<V5T(&9O<G1H(&EN('1H
M92!!=6=U<W0@-RP@,C`Q,B!E;F=A9V5M96YT(&%G<F5E;65N="XF(S$V,#LF
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M;F%N8VEN9R!I;B`R,#$Q(&%N9"P@87,@82!P87)T(&]F('1H92!F964@9F]R
M('1H870@96YG86=E;65N="P@9&5S:6=N965S(&]F('1H92!P;&%C96UE;G0@
M86=E;G0@86QS;R!H;VQD('=A<G)A;G1S('1O('!U<F-H87-E(#$L,C4Q+#`Q
M-2!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!#;VUM;VX@4W1O8VLN
M/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D
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M;7`[($%S<V]C:6%T97,@3$Q#.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\
M+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`S-G!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/DEN(#(P,3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A
M;B!A9W)E96UE;G0@=VET:"!'=6%G96YT:2`F86UP.R!!<W-O8VEA=&5S($Q,
M0R`H)B,X,C(P.T<F86UP.T$F(S@R,C$[*2XF(S$V,#LF(S$V,#M')F%M<#M!
M(&ES(&%F9FEL:6%T960@=VET:"!%;GIA($=U86=E;G1I+"!T:&4@9F]R;65R
M($-H:65F($9I;F%N8VEA;"!/9F9I8V5R(&]F($-A8W1U<RXF(S$V,#LF(S$V
M,#M0=7)S=6%N="!T;R!T:&4@86=R965M96YT+"!T:&4@0V]M<&%N>2!L96%S
M97,@<W1O<F%G92!S<&%C92!I;B!.97=A<FLL($Y*(&9R;VT@1R9A;7`[02XF
M(S$V,#LF(S$V,#M4:&4@<F5N="!I<R`D,S`P('!E<B!M;VYT:"XF(S$V,#LF
M(S$V,#M3:6YC92!*86YU87)Y(#$L(#(P,3$L('1H92!#;VUP86YY(&AA<R!P
M86ED("0W+#(P,"!P=7)S=6%N="!T;R!T:&ES(&%G<F5E;65N="XF(S$V,#LF
M(S$V,#LF(S$V,#M-<RX@1W5A9V5N=&D@<F5S:6=N960@87,@=&AE($-O;7!A
M;GDF(S@R,3<[<R!#:&EE9B!&:6YA;F-I86P@3V9F:6-E<B!O;B!-87)C:"`Y
M+"`R,#$S+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF
M-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E
M,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E
M=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%4T<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4')O<&5R='D@86YD($5Q=6EP;65N=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R
M='D@86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/DYO=&4@,R`F(S@R,3$[(%!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY0<F]P
M97)T>2!A;F0@97%U:7!M96YT(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG
M(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@1&5C96UB97(@,S$L(#(P,3(Z
M/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L
M:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.3`E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#4W)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$
M,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C(P,3(\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#4W)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U-R4@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$U-BPQ-C(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$-3<E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^1G5R;FET=7)E(&%N
M9"!F:7AT=7)E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS1#DE
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LW('EE87)S/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,RPQ,#`\+V9O;G0^
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0U-R4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-3<E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&]T86P@<')O<&5R='D@
M86YD(&5Q=6EP;65N=#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M-3<E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5S<SH@86-C=6UU;&%T960@9&5P<F5C
M:6%T:6]N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$-3<E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&]S
M<R!O;B!D:7-P;W-I=&EO;B!O9B!E<75I<&UE;G0\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#0L,3(R
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV
M+#DQ.#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#0U<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^1&5P<F5C:6%T:6]N(&5X<&5N<V4@9F]R
M('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@86YD
M(#(P,3(@=V5R92`D,"!A;F0F(S$V,#LD-#(Y(')E<W!E8W1I=F5L>2X\+V9O
M;G0^)B,Q-C`[/"]D:78^#0H\9&EV("!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C
M,38P.SPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY.;W1E(#0@)B,X,C$Q
M.R!0<F]P97)T>2!A;F0@17%U:7!M96YT/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C
M,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[(%!R;W!E<G1Y(&%N
M9"!E<75I<&UE;G0@8V]N<VES=&5D(&]F('1H92!F;VQL;W=I;F<@870@1&5C
M96UB97(@,S$L(#(P,3(@86YD(#(P,3$Z/"]F;VYT/CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL
M93TS1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#4V)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD
M:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#M,:79E<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C`Q,CPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD
M:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0U-B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$P
M)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#4V)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]F9FEC92!E
M<75I<&UE;G0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3`E
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LU('EE87)S/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C$U-BPQ-C(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R
M:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-38E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^#0H\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D9U
M<FYI='5R92!A;F0@9FEX='5R93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LW('EE87)S/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@
M<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L-
M"B!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,2PR.3(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#(Y,CPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-38E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-38E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C$U-RPT-30\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^,34U+#`Y-CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U-B4@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5S<SH@86-C=6UU
M;&%T960@9&5P<F5C:6%T:6]N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI
M9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[#0H@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B
M9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U
M-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^4')O<&5R='D@86YD(&5Q=6EP;65N=#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O
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M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`T<'@@9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#`Q,#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C$L,C,S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@1&5P<F5C:6%T
M:6]N(&5X<&5N<V4@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,B!A;F0@,C`Q,2!W97)E("0U.#$@86YD("0V,S,L(')E<W!E8W1I=F5L
M>2X\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U
M8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D
M9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15-'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@
M4&%Y86)L92!A;F0@0V]N=F5R=&EB;&4@3F]T97,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DYO=&4@4&%Y86)L92!A;F0@0V]N=F5R=&EB;&4@3F]T97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYO=&4@4&%Y86)L92!A;F0@0V]N=F5R=&EB;&4@3F]T97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY.;W1E
M(#0@)B,X,C$Q.R!.;W1E(%!A>6%B;&4\+V9O;G0^/"]D:78^#0H\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/D]N($1E8V5M8F5R(#(X+"`R,#$R+"!T:&4@
M0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!P<F5M:75M(&9I;F%N8V4@86=R965M
M96YT('1O('!A>2!A("0Q-#`L,#`P('!R96UI=6T@9F]R(&ET<R!D:7)E8W1O
M<B!A;F0@;V9F:6-E<B!L:6%B:6QI='D@:6YS=7)A;F-E('!O;&EC>2X@4'5R
M<W5A;G0@=&\@=&AE(&%G<F5E;65N="P@=&AE($-O;7!A;GD@<&%I9"!A(&1O
M=VX@<&%Y;65N="!O9B`D,C@L,#`P(&EN($IA;G5A<GD@,C`Q,R!A;F0F(S$V
M,#MI<R!R97%U:7)E9"8C,38P.W1O('!A>2`D,3(L-C,V(&EN(&UO;G1H;'D@
M:6YS=&%L;&UE;G0@9F]R(&YI;F4@;6]N=&AS+B!!<R!O9B!397!T96UB97(@
M,S`L(#(P,3,L('1H92!O=71S=&%N9&EN9R!B86QA;F-E(')E;&%T960@=&\@
M=&AE('!R96UI=6T@9FEN86YC92!A9W)E96UE;G0@=V%S("0P+CPO9F]N=#X\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^3F]T92`U("8C.#(Q,3L@3F]T
M92!087EA8FQE(&%N9"!#;VYV97)T:6)L92!.;W1E<SPO9F]N=#X\+V1I=CX-
M"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M3F]T92!087EA8FQE/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*
M/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@
M3VX@1&5C96UB97(@,C@L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT
M;R!A('!R96UI=6T@9FEN86YC92!A9W)E96UE;G0@=&\@<&%Y("0Q-#`L,#`P
M('!R96UI=6T@;V8@:71S(&1I<F5C=&]R(&%N9"!O9F9I8V5R(&EN<W5R86YC
M92!P;VQI8WDN(%!U<G-U86YT('1O('1H92!A9W)E96UE;G0L('1H92!#;VUP
M86YY('!A:60@82!D;W=N('!A>6UE;G0@;V8@)#(X+#`P,"!I;B!*86YU87)Y
M(#(P,3,@86YD(&AA<R!T;R!P87D@)#$R+#8S-B!I;B!M;VYT:&QY(&EN<W1A
M;&QM96YT(&9O<B!N:6YE(&UO;G1H<RX@07,@;V8@1&5C96UB97(@,S$L(#(P
M,3(L(&]U='-T86YD:6YG(&)A;&%N8V4@<F5L871E9"!T;R!T:&4@<')E;6EU
M;2!F:6YA;F-E(&%G<F5E;65N="!W87,@)#$T,"PP,#`N)B,Q-C`[/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I
M9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY#;VYV97)T:6)L92!.;W1E
M<SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M960@0V]N=F5R=&EB;&4@4')O;6ES<V]R>2!.;W1E<R`H)B,X,C(P.T-O;G9E
M<G1I8FQE($YO=&5S)B,X,C(Q.RD@:6X@=&AE(&%M;W5N="!O9B`D.3`P+#`P
M,"!A;F0@<F5C96EV960@;F5T('!R;V-E961S(&]F("0W-3`L,#`P+B!4:&4@
M8V]N=F5R=&EB;&4@;F]T97,@=V5R92!I<W-U960@870@.#,N,S,E(&]F('1H
M92!P<FEN8VEP86P@86UO=6YT(')E<W5L=&EN9R!I;B!A;B!O<FEG:6YA;"!I
M<W-U92!D:7-C;W5N="!O9B`D,34P+#`P,"XF(S$V,#M4:&4@0V]N=F5R=&EB
M;&4@3F]T97,@;6%T=7)E(&]N92!Y96%R(&9R;VT@=&AE(&1A=&4@;V8@:7-S
M=6%N8V4N($EN=&5R97-T(&%C8W)U97,@870@=&AE(')A=&4@;V8@."4@<&5R
M('EE87(@;VX@=&AE(&]U='-T86YD:6YG('!R:6YC:7!A;"!A;6]U;G0L(&%C
M8W)U960@<V5M:2UA;FYU86QL>2!A;F0@=&\@8F4@<&%I9"!A="!M871U<FET
M>2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M97(@;75T=6%L;'D@86=R965D('5P;VX@:G5R:7-D:6-T:6]N+"!O<B`H,RD@
M=&AE(&%C<75I<VET:6]N(&]R(')E8V5I<'0@8GD@=&AE($-O;7!A;GD@;V8@
M;F\@;&5S<R!T:&%N("0T+#`P,"PP,#`@;V8@9W)O<W,@<')O8V5E9',@:6X@
M<W5B<V5Q=65N="!O9F9E<FEN9W,@;V8@:71S(&-O;6UO;B!S=&]C:R!O<B!E
M<75I=F%L96YT<R!F;VQL;W=I;F<@=&AE(&ES<W5A;F-E(&]F('1H92!#;VUP
M86YY)B,X,C$W.W,@<W1O8VL@*%-E92!.;W1E(#DI(&%N9"!T:&4@0V]N=F5R
M=&EB;&4@3F]T97,N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*
M/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M,C@W+#`V,2!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=E<F4@:7-S=65D('1O
M(&EN=F5S=&]R<RX@5&AE(%!L86-E;65N="!!9V5N="!A;F0@=&AE($UA;F%G
M96UE;G0@1FER;2`H4V5E($YO=&4@.2D@=V5R92!I<W-U960@=V%R<F%N=',@
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M96UE;G0@1FER;2!A<F4@97AE<F-I<V%B;&4@870@)#`N,#$@<&5R('-H87)E
M(&%N9"!E>'!I<F4@;VX@2F%N=6%R>2`S,2P@,C`Q.2X\+V9O;G0^/"]D:78^
M#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J
M=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%1H92!#;VUP86YY(&%N
M86QY>F5D('1H92!#;VYV97)T:6)L92!.;W1E<R!A;F0@=&AE(%=A<G)A;G1S
M(&9O<B!D97)I=F%T:79E(&%C8V]U;G1I;F<@8V]N<VED97)A=&EO;B!U;F1E
M<B!&05-"($%30R`T-S`@86YD(&1E=&5R;6EN960@=&AA="!T:&4@:6YV97-T
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M<B!V86QU92!O9B`D,2XQ,2!P97(@<VAA<F4@;VX@=&AE(&1A=&4@;V8@=&AE
M($-O;G9E<G1I8FQE($YO=&5S+CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX]
M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/B8C,38P.SQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%1H
M92!T;W1A;"!F965S+"!I;F-L=61I;F<@8V%S:"!P87EM96YT<R!A;F0@=&AE
M(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&ES<W5E9"!T;R!T:&4@4&QA
M8V5M96YT($%G96YT+"!I;F-U<G)E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE
M(&9I;F%N8VEN9R!W97)E("0R.3(L-CDR+B!4:&5S92!F965S('=E<F4@86UO
M<G1I>F5D(&]V97(@=&AE(&QI9F4@*&]N92!Y96%R*2!O9B!T:&4@0V]N=F5R
M=&EB;&4@3F]T97,@=7-I;F<@=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D(&%S
M(&ET(&%P<')O>&EM871E<R!T:&4@969F96-T:79E(&EN=&5R97-T(&UE=&AO
M9"X@)B,Q-C`[5&AE("0Q-3`L,#`P(&]R:6=I;F%L(&ES<W5E(&1I<V-O=6YT
M(&]N('1H92!#;VYV97)T:6)L92!.;W1E<R!W87,@86QS;R!A;6]R=&EZ960@
M;W9E<B!T:&4@;&EF92!O9B!T:&4@3F]T97,@;VX@82!S=')A:6=H="!L:6YE
M(&)A<VES+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M3VX@3V-T;V)E<B`R,RP@,C`Q,BP@=&AE#0H@:6YV97-T;W)S(&5X=&5N9&5D
M('1H92!N;W1E(&UA='5R:71Y(&1A=&4@9F]R(#DP(&1A>7,N(%1H92!M871U
M<FET>2!D871E(&]F('1H92!N;W1E<R!H87,@8F5E;B!E>'1E;F1E9"!T;R!*
M86YU87)Y(#,Q+"`R,#$S+"!&96)R=6%R>2`Q."P@,C`Q,R!O<B!-87)C:"`R
M-RP@,C`Q,R!F;W(@=&AE(#(T(&YO=&5S+CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF
M(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[($]N($1E8V5M8F5R(#$Y+"`R,#$R+"!T:&4@0V]N=F5R
M=&EB;&4@3F]T97,@86YD('1H92!A8V-R=65D(&EN=&5R97-T<R!W97)E(&%U
M=&]M871I8V%L;'D@8V]N=F5R=&5D('1O(&-O;6UO;B!S=&]C:R!W:&5N('1H
M92!#;VUP86YY(&-L;W-E9"!O;B!A;B!O9F9E<FEN9R!O9B!I=',@8V]M;6]N
M('-T;V-K(&EN('=H:6-H('1H92!G<F]S<R!P<F]C965D<R!E>&-E961E9"!T
M:&4@)#0L,#`P+#`P,"!T:')E<VAO;&0N)B,Q-C`[)B,Q-C`[5&AE($-O;G9E
M<G1I8FQE($YO=&5S(&%N9"!A8V-R=65D(&EN=&5R97-T('=E<F4@8V]N=F5R
M=&5D(&EN=&\@,2PR-3(L-34P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&-O;6UO;B!S=&]C:RX\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P
M.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[($1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB
M97(@,S$L(#(P,3(L('1H92!#;VUP86YY(')E8V]R9&5D(&%M;W)T:7IA=&EO
M;B!E>'!E;G-E(')E;&%T960@=&\@=&AE(&1E9F5R<F5D(&9I;F%N8VEN9R!C
M;W-T<R!A;F0@=&AE(&1E8G0@9&ES8V]U;G0@;V8@)#(U,BPR-#@@86YD("0W
M-S4L-C,W+"!R97-P96-T:79E;'DN)B,Q-C`[)B,Q-C`[1'5R:6YG('1H92!Y
M96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE($-O;7!A;GD@<F5C
M;W)D960@86UO<G1I>F%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!T:&4@9&5F
M97)R960@9FEN86YC:6YG(&-O<W1S(&%N9"!T:&4@9&5B="!D:7-C;W5N="!O
M9B`D-#`L-#0T(&%N9"`D,3(T+#,V,RP@<F5S<&5C=&EV96QY+CPO9F]N=#X\
M+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU
M<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@02!S=6UM87)Y(&]F('1H
M92`X)2!396YI;W(@4W5B;W)D:6YA=&5D(%5N<V5C=7)E9"!#;VYV97)T:6)L
M92!0<F]M:7-S;W)Y($YO=&5S(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R(&%N
M9"`R,#$Q(&%R92!A<R!F;VQL;W=S.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V
M,#L\+V1I=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE('-T>6QE/3-$
M)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^
M#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R
M:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CDP,"PP,#`\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/CDP,"PP,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5S
M<SH@;W)I9VEN86P@:7-S=6%N8V4-"B!D:7-C;W5N=#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@Q-3`L,#`P/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXH,34P+#`P,#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^3&5S<SH@9&ES8V]U;G0@<F5L871E9"!T;R!F86ER('9A
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,S<W+#$U,#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^*#,W-RPQ-3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C9F9F
M9F9F/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8V)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^*#,W,BPX-3`\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B@S-S(L.#4P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CDP,"PP,#`\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,3(T+#,V,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[#0H@/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#8V)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY,97-S.B!P<FEN8VEP86P@86UO=6YT(&-O;G9E
M<G1E9"!T;R!S=&]C:SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH.3`P+#`P
M,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@-'!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/D-A<G)Y:6YG('9A;'5E(&%T($1E8V5M8F5R(#,Q
M+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'D\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^
M#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#1P>"!D;W5B;&4[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F
M-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D
M-6(W+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D1E<FEV871I=F5S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$97)I=F%T:79E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY.;W1E
M(#4@)B,X,C$Q.R!$97)I=F%T:79E<SPO9F]N=#X\+V1I=CX-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
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M9F]N="US:7IE.B`Q,'!T.R<^5&AE($-O;7!A;GD@:&%S(&1E=&5R;6EN960@
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M=&AA="!I<R!N;W0@86X@:6YP=70@=&\@=&AE(&9A:7(@=F%L=64@;V8@82`F
M(S@R,C`[9FEX960M9F]R+69I>&5D)B,X,C(Q.R!O<'1I;VX@87,@9&5F:6YE
M9"!U;F1E<B!&05-"($%30R!4;W!I8R!.;RX@.#$U("8C.#(Q,3L@-#`N(%1H
M92!W87)R86YT<R!G<F%N=&5D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S
M=6%N8V4@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!3=&]C:R!/9F9E<FEN9R!A
M;F0@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<L('1H92!#;VYV97)T:6)L
M92!.;W1E<R`H<')E=FEO=7-L>2!I<W-U960@86YD(&-O;G9E<G1E9"D@86YD
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M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#M!8W1I=FET:65S(&9O<B!D97)I
M=F%T:79E('=A<G)A;G0@:6YS=')U;65N=',@9'5R:6YG('1H92!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@=V5R92!A<R!F;VQL;W=S
M.CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$
M,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY5;FET<SPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$
M,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY"86QA;F-E
M+"!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/C4L,30V+#,S.#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M9F]N=`T*('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4F5C;&%S<VEF:6-A=&EO;B!T
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXH,RPQ,S`L-3,V/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXH-C`P+#@X,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C$V+#$Q,CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.@T*(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY"86QA;F-E+"!397!T96UB97(@,S`L(#(P,3,\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@
M9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXR+#`Q-2PX,#(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
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M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@
M9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4
M:&4@9F%I<B!V86QU97,@;V8@=&AE(&1E<FEV871I=F4@=V%R<F%N=',@=V5R
M92!C86QC=6QA=&5D('5S:6YG(&$@;6]D:69I960@8FEN;VUI86P@=F%L=6%T
M:6]N(&UO9&5L('=I=&@@=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N<R!A="!3
M97!T96UB97(@,S`L(#(P,3,@86YD($1E8V5M8F5R(#,Q+"`R,#$R+CPO9F]N
M=#X\+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`T-7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX]
M,T1L969T/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/D1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4V5P=&5M8F5R(#,P+#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^36%R:V5T('9A;'5E(&]F
M(&-O;6UO;B!S=&]C:R!O;B!M96%S=7)E;65N="!D871E("@Q*3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C$N,3<\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2XV-3PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F
M9F9F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N
M-#@@+2`D,"XX,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M,"XQ,"4@+2`P+C<W/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N,S,\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#8V)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS
M1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-"!M;VYT:',O
M-2!Y96%R<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^,"!D87ES+S0N,C(@>65A<G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.@T*
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^,3(U)2`M(#$V,3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXQ,SD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#8V)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D5X
M<&5C=&5D(&1I=FED96YD('EI96QD("@T*3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS
M1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^4')O8F%B:6QI='D@;V8@<W1O8VL@;V9F97)I;F<@:6X@86YY
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXE/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXR-24@+2`T,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@
M<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0S
M)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B@Q*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M=VED=&@],T0X-R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&IU<W1I
M9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@;6%R:V5T('9A;'5E
M(&]F(&-O;6UO;B!S=&]C:R!I<R!B87-E9"!O;B!A;B!E;G1E<G!R:7-E('9A
M;'5A=&EO;BX\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$.#<E('9A;&EG;CTS1'1O
M<#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,BD\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('=I9'1H/3-$.#<E('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX]
M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE(')I<VLM
M9G)E92!I;G1E<F5S="!R871E('=A<PT*(&1E=&5R;6EN960@8GD@;6%N86=E
M;65N="!U<VEN9R!T:&4@5')E87-U<GD@0FEL;"!A<R!O9B!T:&4@<F5S<&5C
M=&EV92!M96%S=7)E;65N="!D871E+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#,E('9A;&EG
M;CTS1'1O<#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X
M-R4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@W)2!V
M86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#,E('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#0I/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS1#@W)2!V86QI9VX],T1T;W`^#0H\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X-R4@=F%L:6=N/3-$=&]P/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0S
M)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B@U*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M=VED=&@],T0X-R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&IU<W1I
M9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY-86YA9V5M96YT(&AA<R!D
M971E<FUI;F5D('1H870@=&AE('!R;V)A8FEL:71Y(&]F(&$@<W1O8VL@;V9F
M97)I;F<@:7,@,C4E("T@-#`E(&9O<B!E86-H('%U87)T97(@;V8@=&AE(&YE
M>'0@9FEV92!Y96%R<RX\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^3F]T92`V("8C
M.#(Q,3L@1&5R:79A=&EV97,\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P.R8C,38P.R!4:&4@0V]M<&%N>2!H
M87,@9&5T97)M:6YE9"!T:&%T(&-E<G1A:6X@=V%R<F%N=',@=&AE($-O;7!A
M;GD@:&%S(&ES<W5E9"!C;VYT86EN('!R;W9I<VEO;G,@=&AA="!P<F]T96-T
M(&AO;&1E<G,@9G)O;2!F=71U<F4@:7-S=6%N8V5S(&]F('1H92!#;VUP86YY
M)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%T('!R:6-E<R!B96QO=R!S=6-H('=A
M<G)A;G1S)B,X,C$W.R!R97-P96-T:79E(&5X97)C:7-E('!R:6-E<R!A;F0@
M=&AE<V4@<')O=FES:6]N<R!C;W5L9"!R97-U;'0@:6X@;6]D:69I8V%T:6]N
M(&]F('1H92!W87)R86YT<R8C.#(Q-SL@97AE<F-I<V4@<')I8V4@8F%S960@
M;VX@82!V87)I86)L92!T:&%T(&ES(&YO="!A;B!I;G!U="!T;R!T:&4@9F%I
M<B!V86QU92!O9B!A("8C.#(R,#MF:7AE9"UF;W(M9FEX960F(S@R,C$[(&]P
M=&EO;B!A<R!D969I;F5D('5N9&5R($9!4T(@05-#(%1O<&EC($YO+B`X,34@
M)B,X,C$Q.R`T,"X@5&AE('=A<G)A;G1S(&=R86YT960@:6X@8V]N;F5C=&EO
M;B!W:71H('1H92!I<W-U86YC92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(%-T
M;V-K($]F9F5R:6YG(&%N9"`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9R8C
M,38P.RA3964@3F]T92`Y*2P@=&AE($-O;G9E<G1I8FQE($YO=&5S("A3964@
M3F]T92`U*2!A;F0@=&AE('!L86-E;65N="!A9V5N="!W87)R86YT<R!C;VYT
M86EN(&%N=&DM9&EL=71I;VX@<')O=FES:6]N<R!T:&%T('!R;W9I9&4@9F]R
M(&$@<F5D=6-T:6]N(&EN('1H92!E>&5R8VES92!P<FEC92!O9B!S=6-H('=A
M<G)A;G1S(&EN('1H92!E=F5N="!T:&%T(&9U='5R92!C;VUM;VX@<W1O8VL@
M*&]R('-E8W5R:71I97,@8V]N=F5R=&EB;&4@:6YT;R!O<B!E>&5R8VES86)L
M92!F;W(@8V]M;6]N('-T;V-K*2!I<R!I<W-U960@*&]R(&)E8V]M97,@8V]N
M=')A8W1U86QL>2!I<W-U86)L92D@870@82!P<FEC92!P97(@<VAA<F4@*&$@
M)B,X,C(P.TQO=V5R(%!R:6-E)B,X,C(Q.RD@=&AA="!I<R!L97-S('1H86X@
M=&AE(&5X97)C:7-E('!R:6-E(&]F('-U8V@@=V%R<F%N="!A="!T:&4@=&EM
M92X@5&AE(&%M;W5N="!O9B!A;GD@<W5C:"!A9&IU<W1M96YT(&ES(&1E=&5R
M;6EN960@:6X@86-C;W)D86YC92!W:71H('1H92!P<F]V:7-I;VYS(&]F('1H
M92!W87)R86YT(&%G<F5E;65N="!A;F0@9&5P96YD<R!U<&]N('1H92!N=6UB
M97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U960@*&]R(&1E96UE
M9"!I<W-U960I(&%T('1H92!,;W=E<B!0<FEC92!A;F0@=&AE(&5X=&5N="!T
M;R!W:&EC:"!T:&4@3&]W97(@4')I8V4@:7,@;&5S<R!T:&%N('1H92!E>&5R
M8VES92!P<FEC92!O9B!T:&4@=V%R<F%N="!A="!T:&4@=&EM92X\+V9O;G0^
M/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[($%C=&EV:71I97,@9F]R(&1E<FEV
M871I=F4@=V%R<F%N="!I;G-T<G5M96YT<R!D=7)I;F<@=&AE('EE87)S(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q('=E<F4@87,@9F]L;&]W
M<SH\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI
M9VX],T1L969T/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI
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M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^56YI=',\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^
M#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^1F%I<B!686QU93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0F%L86YC92P@
M1&5C96UB97(@,S$L(#(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.@T*(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0V-B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY787)R86YT<R!I<W-U960@=VET:"!#
M;VYV97)T:6)L92!.;W1E<R`H4V5E($YO=&4@-2D\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M,S<W+#$U,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY0;&%C96UE;G0@86=E;G0@=V%R
M<F%N=',@<F5L871E9"!T;R!I<W-U86YC92!O9B!#;VYV97)T:6)L92!.;W1E
M<R`H4V5E($YO=&4@-2D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C$T,RPU,S(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,3@X+#4W.3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SY787)R86YT<R!I<W-U960@=VET:"!3=&]C:R!/9F9E<FEN
M9R`H4V5E($YO=&4@.2D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C$L.3<R+#<X-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#4Y,2PY,#`\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^4&QA8V5M96YT(&%G96YT('=A<G)A;G1S(')E;&%T
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$L,CDU+#DU,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.PT*(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY#:&%N9V4@:6X@9F%I<B!V86QU93PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY"
M86QA;F-E+"!$96-E;6)E<B`S,2P@,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED
M.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY787)R86YT
M<R!I<W-U960@=VET:"!3=&]C:R!/9F9E<FEN9R`H4V5E($YO=&4@.2D\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.PT*
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C0R
M+#$Y,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E!L86-E
M;65N="!A9V5N="!W87)R86YT<R!R96QA=&5D('1O(%-T;V-K($]F9F5R:6YG
M("A3964@3F]T92`Y*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,3(Q+#`Y-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M,2PT,#DL-34T/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#8V)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,2PV-C4L-CDW/"]F;VYT/CPO9&EV/@T*/"]T
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/E!L86-E;65N="!A9V5N="!W87)R86YT<R!R96QA=&5D('1O(#(P,3(@0V]M
M;6]N(%-T;V-K($]F9F5R:6YG("A3964@3F]T92`Y*3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C0Y.2PW,#<\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5')A;G-F97(@9G)O;2!L
M:6%B:6QI='D@8VQA<W-I9FEC871I;VX@=&\@97%U:71Y(&-L87-S:69I8V%T
M:6]N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BD\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^0VAA;F=E(&EN(&9A:7(@=F%L=64\+V9O;G0^
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#8X-2PT
M,C`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F
M9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R<^#0H\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D)A;&%N
M8V4L($1E8V5M8F5R(#,Q+"`R,#$R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.PT*
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C4L,30V+#,S.#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/C,L-3<T+#DU.#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[($]N($1E8V5M
M8F5R(#$Y+"`R,#$R+"!A<R!T:&4@<F5S=6QT(&]F('1H92!3:&%R92!%>&-H
M86YG92P@:70@=V%S(&1E=&5R;6EN960@=&AA="!T:&4@9FQO;W(@9F]R(')E
M<V5T=&EN9R!T:&4@97AE<F-I<V4@<')I8V4@=V%S(&UE="!A;F0@=&AE(&5X
M97)C:7-E('!R:6-E(&]F('1H92!C97)T86EN('=A<G)A;G1S('=A<R!S970@
M=&\@8F4@)#`N,C8@*&)E9F]R92!%>&-H86YG92!2871I;R!A9&IU<W1M96YT
M*2XF(S$V,#M4:&5R969O<F4L('1H97-E('=A<G)A;G1S('=E<F4@8V]N<VED
M97)E9"!I;F1E>&5D('1O('1H92!#;VUP86YY)B,X,C$W.W,@<W1O8VL@86YD
M('%U86QI9FEE9"!F;W(@=&AE('-C;W!E(&5X8V5P=&EO;B!U;F1E<B!&05-"
M($%30R`X,34M,3`@86QL;W=I;F<@9F]R(&$@=')A;G-F97(@9G)O;2!L:6%B
M:6QI='D@8VQA<W-I9FEC871I;VX@=&\@97%U:71Y(&-L87-S:69I8V%T:6]N
M+CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[(%1H92!F86ER('9A;'5E<R!O9B!T:&4@9&5R:79A=&EV92!W87)R
M86YT<R!W97)E(&-A;&-U;&%T960@=7-I;F<@82!M;V1I9FEE9"!B:6YO;6EA
M;"!V86QU871I;VX@;6]D96P@=VET:"!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I
M;VYS(&%T(&5A8V@@8F%L86YC92!S:&5E="!D871E+"!T:&4@=')A;G-F97(@
M9&%T92!O;B!$96-E;6)E<B`Q.2P@,C`Q,BP@86YD('1H92!D871E(&9O<B!T
M:&4@;F5W(&=R86YT<R!I;B!*86YU87)Y(&%N9"!$96-E;6)E<B`R,#$R+B`H
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I
M=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DP)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0R."4@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#,E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^1&5C96UB97(@,S$L/"]F;VYT/CPO9&EV
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W
M:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^1&5C
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY$96-E;6)E<B`R-RP\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/D1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0R."4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.@T*(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C`Q
M,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C
M;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^
M#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,C@E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0S)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,C@E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^36%R:V5T('9A;'5E(&]F(&-O;6UO;B!S
M=&]C:R!O;B!M96%S=7)E;65N="!D871E("@Q*3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,R4@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N,S<\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C`N,SD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XS.3PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XR-"`M("0P+C(V/"]F;VYT/CPO
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C`N,C,@+2`D,"XR-CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXP+C0Q("T@)#`N.#,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XR,B`M("0P
M+C(V/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N-#$@+2`D,"XX,SPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0R."4-"B!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/E)I<VL@9G)E92!I;G1E<F5S="!R871E("@R*3PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,R4@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2XS-3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C`N,3`E("T@,"XW-SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C`N,3`E("T@,"XW-SPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^5V%R<F%N="!L:79E<R!I;B!Y96%R<SPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,R4@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H
M/3-$,3`E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^-"!M;VYT:',O-7EE87)S/"]F;VYT/CPO9&EV/@T*/"]T9#X-
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M-"!M;VYT:',O-7EE87)S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0-"B!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,C@E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^17AP96-T960@
M=F]L871I;&ET>2`H,RD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#,E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C$U-CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-3<\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,3(U)2`M(#$V,3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXQ-C$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,3(U)2`M(#$V,3PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,C@E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^17AP96-T960@9&EV:61E;F0@
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[#0H@;6%R9VEN+7)I9VAT.B`P
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E!R;V)A8FEL:71Y(&]F('-T;V-K
M(&]F9F5R:6YG(&EN(&%N>2!P97)I;V0@;W9E<B`U('EE87)S("@U*3PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,R4@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C4\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,C4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C4\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^,C4\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M,C4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#(X)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXS-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C,U
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C,U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/9F9E<FEN9R!P
M<FEC92!R86YG92`H-RD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#,E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C$X("T@)#`N-34\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^,"XQ,R`M("0P+C4V/"]F;VYT/CPO9&EV/@T*/"]T
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C`N,#$@+2`D,"XU-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C$R("T@
M)#`N-C`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XP,2`M("0P+C4U/"]F;VYT
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX-"CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<@8V5L;'-P86-I;F<],T0P#0H@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXH,2DF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#@P)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@
M;6%R:V5T('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!I<R!B87-E9"!O;B!A;B!E
M;G1E<G!R:7-E('9A;'5A=&EO;BX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]D
M:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CPO9&EV/@T*
M/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J
M=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/@T*
M/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#(I)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0X,"4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@<FES:RUF<F5E(&EN=&5R97-T
M(')A=&4@=V%S(&1E=&5R;6EN960@8GD@;6%N86=E;65N="!U<VEN9R!T:&4@
M879E<F%G92!O9B`U(&%N9"`W('EE87(@86YD('1H92`S+6UO;G1H(%1R96%S
M=7)Y($)I;&P@87,@;V8@=&AE(')E<W!E8W1I=F4@;65A<W5R96UE;G0@9&%T
M92X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I
M=CX-"CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[)B,Q-C`[/"]D:78^#0H\
M9&EV/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,RDF(S$V,#LF(S$V
M,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('=I9'1H/3-$.#`E('9A;&EG
M;CTS1'1O<#X-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^0F5C875S92!T:&4@0V]M<&%N>2!D;V5S(&YO="!H879E
M(&%D97%U871E('1R861I;F<@:&ES=&]R>2!T;R!D971E<FUI;F4@:71S(&AI
M<W1O<FEC86P@=')A9&EN9R!V;VQA=&EL:71Y+"!T:&4@=F]L871I;&ET>2!F
M86-T;W(@=V%S(&5S=&EM871E9"!B>2!M86YA9V5M96YT('5S:6YG('1H92!H
M:7-T;W)I8V%L('9O;&%T:6QI=&EE<R!O9B!C;VUP87)A8FQE(&-O;7!A;FEE
M<R!I;B!T:&4@<V%M92!I;F1U<W1R>2!A;F0@<F5G:6]N+CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P
M.SPO9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#0I
M)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS
M1#@P)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#4I)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0X,"4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#,E('9A;&EG;CTS
M1'1O<#X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B@V*28C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=VED=&@],T0X,"4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&IU
M<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY-86YA9V5M96YT(&5S
M=&EM871E<R!T:&%T('1H92!R86YG92!O9B!P97)C96YT86=E<R!O9B!E>&ES
M=&EN9R!S:&%R97,@;V9F97)E9"!I;B!E86-H('-T;V-K(&]F9F5R:6YG('=I
M;&P@8F4@8F5T=V5E;B`S-24@;V8@=&AE('-H87)E<R!O=71S=&%N9&EN9RX\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#,E('9A;&EG;CTS
M1'1O<#X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B@W*28C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=VED=&@],T0X,"4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&IU
M<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D
M7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W
M+U=O<FMS:&5E=',O4VAE970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X97,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YC;VUE(%1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^3F]T92`W("8C.#(Q,3L@26YC
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[($1E9F5R<F5D(&EN8V]M92!T87AE<R!R969L
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M8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q(&%R92!A<R!F;VQL;W=S.CPO9F]N
M=#X\+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE
M9G0^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@
M<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/D1E9F5R<F5D('1A>"!A<W-E=',Z/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[3F5T(&]P97)A=&EN9R!L;W-S97,\+V9O;G0^/"]D:78^#0H\+W1D
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,3,L-C`Y
M+#`S-CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,3,L,#@Y+#,Q-#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.@T*(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C,S+#`T,SPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^5&]T86P@9&5F97)R960@=&%X(&%S<V5T<SPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$U
M+#,S.2PV,S4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,3,L.#,U+#0X,SPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5S<SH@=F%L=6%T
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,34L,S,Y
M+#8S-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[#0H@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^#0H\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M;W!E<F%T:6YG(&QO<W-E<R`H)B,X,C(P.TY/3',F(S@R,C$[*2!A=F%I;&%B
M;&4@9F]R(&-A<G)Y(&9O<G=A<F0@=&\@9G5T=7)E('EE87)S+B!4:&4@8F5N
M969I="!F<F]M('1H92!C87)R>2!F;W)W87)D(&]F('-U8V@@3D],<R!W:6QL
M(&)E9VEN(&5X<&ER:6YG(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`R,"X@0F5C875S92!5;FET960@4W1A=&5S('1A>"!L87=S(&QI
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M;BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF
M(S$V,#LF(S$V,#L@5&AE(&1I9F9E<F5N8V4@8F5T=V5E;B!T:&4@:6YC;VUE
M('1A>"!P<F]V:7-I;VX@86YD('1H92!A;6]U;G0@=&AA="!W;W5L9"!R97-U
M;'0@:68@=&AE(%4N4RX@1F5D97)A;"!S=&%T=71O<GD@<F%T92!O9B`S-"4@
M=V5R92!A<'!L:65D('1O('!R92UT87@@:6YC;VUE("AL;W-S*2!F;W(@=&AE
M('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q(&%R92!A
M<R!F;VQL;W=S.CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I
M=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H
M.B`Y,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!W:61T:#TS1#0V)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#$T/@T*/&1I
M=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!W:61T:#TS1#(R)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#8^#0H\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^1&5C
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M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#(R)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED.R<@8V]L<W!A;CTS1#8^#0H\9&EV(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^1&5C96UB97(@,S$L(#(P,3$\
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM
M,S0N,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM,S0N,#`\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#0R)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N=`T*('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4VAA<F4M8F%S960@8V]M<&5N<V%T
M:6]N(&-O<W1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^-S4V+#$S-CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXY+C`T/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C(S,RPP-#,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,BXW.3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^-"PW-#@\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XQ,SPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^06UO<G1I>F%T:6]N(&]F(&1E8G0@9&ES8V]U;G1S/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C0N,3@\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C4V
M+#`S,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B4\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F
M9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0VAA;F=E(&EN
M('9A;'5A=&EO;B!A;&QO=V%N8V4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/@T*
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M,2PU,#0L,34Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,3<N.3D\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^#0H\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B4\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,S<S+#8U,SPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$P+C@U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N=`T*('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^#0H\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X
M(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[)SX-"CQD:78@86QI9VX]
M,T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P
M>"!D;W5B;&4[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M93X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B
M.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T,30N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$531SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N
M=',@86YD($-O;G1I;F=E;F-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N
M9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^3F]T92`V("8C.#(Q,3L@0V]M;6ET;65N
M=',@86YD($-O;G1I;F=E;F-I97,\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[
M/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY%;7!L;WEM96YT($-O;G1R
M86-T<SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3VX@4V5P
M=&5M8F5R(#$V+"`R,#$S+"!T:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F
M($1I<F5C=&]R<R!A<'!O:6YT960@1'(N($MA=7-H:6L@2BX@1&%V92!A<R!I
M=',@;F5W($-H:65F($5X96-U=&EV92!/9F9I8V5R("A#14\I)B,Q-C`[86YD
M($1I<F5C=&]R+B!-871E<FEA;"!T97)M<R!O9B!T:&4@16UP;&]Y;65N="!!
M9W)E96UE;G0@87)E(&%S(&9O;&QO=W,Z/"]F;VYT/CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S
M='EL93TS1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8E
M('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/F$\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@T)2!V86QI
M9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/D$@8F%S92!S86QA<GD@870@86X@86YN=6%L(')A=&4@;V8@
M)#,U,"PP,#`L('=H:6-H('=I;&P@8F4@<F4M979A;'5A=&5D('5P;VX@=&AE
M)B,Q-C`[<VEX(&UO;G1H(&%N;FEV97)S87)Y(&]F('1H92!S=&%R="!D871E
M(&%N9"!R96EM8G5R<V5M96YT(&]F(&-E<G1A:6X@97AP96YS97,N/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#@T)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8E('9A;&EG
M;CTS1'1O<#X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/F(\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('=I9'1H/3-$.#0E('9A;&EG;CTS1'1O<#X-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE($-%
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M)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$.#0E('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-B4@=F%L:6=N/3-$=&]P/@T*
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY!;B!O<'1I;VX@=&\@<'5R
M8VAA<V4@8V]M;6]N('-H87)E<R!O9B!T:&4@0V]M<&%N>2!A;F0@<F5S=')I
M8W1E9"!S=&]C:R`H=&AE("8C.#(R,#M'<F%N="8C.#(R,3LI+B8C,38P.R8C
M,38P.U1H92!'<F%N="!W:6QL(&-O;G-I<W0@;V8@*&DI(&%N(&]P=&EO;B!G
M<F%N="!T;R!P=7)C:&%S92`V-S4L,#`P(&-O;6UO;B!S:&%R97,@;V8@=&AE
M($-O;7!A;GD[("AI:2D@,3(U+#`P,"!S:&%R97,@;V8@<F5S=')I8W1E9"!A
M;F0@*&EI:2D@,3`P+#`P,"!S:&%R97,@;V8@<F5S=')I8W1E9"!S=&]C:R!A
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M('-T87)T(&1A=&4N)B,Q-C`[)B,Q-C`[07,@;V8@3V-T;V)E<B`R-2P@,C`Q
M,RP@=&AE(&]P=&EO;B!H87,@;F]T(&)E96X@9W)A;G1E9"!B>2!T:&4@0F]A
M<F0N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D
M:78^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/DQI8V5N<V4@86YD(%)E<V5A<F-H($%G<F5E;65N=',\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D
M:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=W:61T
M:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*
M/'1R/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0V)2!V86QI9VX],T1T
M;W`^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY!8F)O='0@0FEO
M=&AE<F%P975T:6-S($-O<G`@)B,X,C$Q.R!4:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@82!0<F]D=6-T($1E=F5L;W!M96YT(&%N9"!0871E;G0@3&EC96YS
M92!!9W)E96UE;G0@=VET:"!!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`N
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M;&EC96YS92!F964@<&%Y;65N="!O9B`D,RPP,#`L,#`P+CPO9F]N=#X\+V1I
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M:7IE.B`Q,'!T.R<^5&AE($-O;7!A;GD@86=R965D('1O(&UA:V4@;6EL97-T
M;VYE('!A>6UE;G1S('1O=&%L:6YG("0W+#<U,"PP,#`@9F]R('1H92!A8VAI
M979E;65N="!O9B!T:&4@9F]L;&]W:6YG(&%G<F5E9"!T;R!A;F0@8V]N=')A
M8W1E9"!M:6QE<W1O;F5S.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H-"B!B;&]C:SLG/B8C,38P.SPO
M9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#DP)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W."4@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^36EL97-T
M;VYE<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O
M;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^4&%Y;65N=',\+V9O;G0^/"]D:78^#0H\
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^-S4P+#`P,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0W."4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C<U,"PP,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$-S@E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#,I
M('=H96X@0V]M<&%N>2!I;FET:6%T97,@82!0:&%S92!)24D@0VQI;FEC86P@
M5')I86P@;V8@82!L:6-E;G-E9"!P<F]D=6-T/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2PU,#`L,#`P/"]F;VYT/CPO
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#<U,"PP,#`\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-S@E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^*#4I($9I<G-T(&-O;6UE<F-I86P@<V%L93PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$L-3`P+#`P,#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W."4@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.PT*(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B@V*2!A9G1E<B!T:&4@9FER<W0@)#$P+#`P,"PP,#`@
M:6X@;F5T('-A;&5S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,2PU,#`L,#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY5;F1E<B!T:&4@86=R965M96YT+"!T:&4@0V]M<&%N>2!S:&%L
M;"!P87D@=&\@06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(&]N(&$@8V]U
M;G1R>2UB>2UC;W5N=')Y(&)A<VES(&$@<F]Y86QT>2!O9B`Q,B4@;V8@;F5T
M('-A;&5S(&]F(&%L;"!L:6-E;G-E9"!P<F]D=6-T<R!U;G1I;"!T:&4@;&%T
M97(@;V8Z("@Q*2`Q,BXU('EE87)S(&%F=&5R('1H92!F:7)S="!C;VUM97)C
M:6%L('-A;&4L(&]R("@R*2!W:&5N('1H92!P871E;G1S(&5X<&ER92X\+V9O
M;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX]
M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE($-O;7!A
M;GD@;65T(&ET<R!F:7)S="!M:6QE<W1O;F4@:6X@,C`Q,B!A;F0@=7!O;B!R
M96%C:&EN9R!T:&4@;6EL97-T;VYE('1H92!#;VUP86YY('!A:60@06)B;W1T
M($)I;W1H97)A<&5U=&EC<R!#;W)P+B!A(&UI;&5S=&]N92!P87EM96YT(&]F
M("0W-3`L,#`P(&]N($IU;'D@,C0L(#(P,3(N)B,Q-C`[)B,Q-C`[5&AE(&UI
M;&5S=&]N92!P87EM96YT(&9O<B!T:&4@4&AA<V4@22!#;&EN:6-A;"!4<FEA
M;"!W87,@<F5C;W)D960@87,@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X
M<&5N<V4N/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^
M#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@
M.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0V)2!V86QI9VX],T1T;W`^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY-96UO<FEA;"!3;&]A;B!+971T97)I;F<@0V%N
M8V5R($-E;G1E<B`H35-+0T,I("8C.#(Q,3L@26X@1F5B<G5A<GD@,C`P,BP@
M=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;&EC96YS92!A9W)E96UE;G0@
M=VET:"!-4TM#0R!T:&%T(')E<75I<F5S(&$@=&5C:&YO;&]G>2!A8V-E<W,@
M9F5E(&]F("0U,"PP,#`@=7!O;B!E>&5C=71I;VXL(&%N(&%N;G5A;"!M86EN
M=&5N86YC92!F964@;V8@)#4P+#`P,"!A;F0@86YN=6%L(')E<V5A<F-H(&9U
M;F1I;F<@;V8@)#4P+#`P,"!F;W(@87,@;&]N9R!A<R!T:&4@86=R965M96YT
M(&ES(&EN(&9O<F-E+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L
M:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.3`E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#<X)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N
M/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY087EM96YT<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-S@E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$-S@E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-S@E
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,2D@9FEL:6YG(&]F(&%N($YE=R!$<G5G($%P
M<&QI8V%T:6]N("@F(S@R,C`[3D1!)B,X,C(Q.RD@;W(@<F5G=6QA=&]R>2!A
M<'!R;W9A;"!F;W(@96%C:"!L:6-E;G-E9"!P<F]D=6-T/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C<U,"PP,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-S@E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#(I('5P;VX@=&AE(')E8V5I
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#<U,"PP,#`\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^
M#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^56YD97(@=&AE(&%G<F5E;65N="P@
M=&AE($-O;7!A;GD@<VAA;&P@<&%Y('1O($U32T-#(&]N(&$@8V]U;G1R>2UB
M>2UC;W5N=')Y(&)A<VES(&$@<F]Y86QT>2!O9B`R)2!O9B!N970@<V%L97,@
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M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/@T*/"]D:78^#0H\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E1H92!#
M;VUP86YY(&5X<&5C=',@=&\@9FEL92!T:&4@3D1!(&9O<B!R96=U;&%T;W)Y
M(&%P<')O=F%L(&EN('1H92`R,#$V+3(P,3<@=&EM92!F<F%M92X\+V9O;G0^
M/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1L
M969T/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#8E('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX],T1R
M:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/F,N)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS1#@T)2!V86QI9VX]
M,T1T;W`^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/D]A:R!2:61G92!.871I;VYA;"!,86)O<F%T;W)Y("A/4DY,
M*2`F(S@R,3$[($%022!I<R!C;VYT<F%C=&5D('1O('!U<F-H87-E("0R,S,L
M,3`P(&]F(')A9&EO86-T:79E(&UA=&5R:6%L('1O(&)E('5S960@9F]R(')E
M<V5A<F-H(&%N9"!D979E;&]P;65N="P@=VET:"!A(')E;F5W86P@;W!T:6]N
M(&%T('1H92!C;VYT<F%C="!E;F0N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@
M:7,@8W5R<F5N=&QY(&YE9V]T:6%T:6YG('1H92`R,#$S(&%G<F5E;65N="X\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0V)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$.#0E('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#8E
M('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/F0N)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!W:61T:#TS1#@T)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M,#M4:&4@9&]W;B!P87EM96YT('1O=&%L:6YG("0R,SDL,#`P('=A<R!P86ED
M(&EN(#(P,#<@86YD(#(P,3(N)B,Q-C`[)B,Q-C`[3VX@075G=7-T(#8L(#(P
M,3(L($]C=&]B97(@,C(L(#(P,3(@86YD($UA>2`Q-BP@,C`Q,RP@=&AE(&%G
M<F5E;65N="!W87,@86UE;F1E9"!T;R!P<F]V:61E(&9O<B!A9&1I=&EO;F%L
M('-E<G9I8V5S+B8C,38P.R8C,38P.U1H92!T;W1A;"!P<F]J96-T(&ES(&YO
M=R!E<W1I;6%T960@870@87!P<F]X:6UA=&5L>2`D,BXR(&UI;&QI;VXN)B,Q
M-C`[07!T:793;VQU=&EO;G,@8FEL;',@=&AE($-O;7!A;GD@=VAE;B!S97)V
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@T)2!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0V)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#ME+B8C,38P.R8C,38P.SPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@],T0X-"4@=F%L:6=N/3-$
M=&]P/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY/;B!*=6YE(#$U+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D
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M;"!W:6QL(')A;F=E(&9R;VT@)#$S+C(@;6EL;&EO;B!T;R`D,C,N-2!M:6QL
M:6]N+"!D97!E;F1I;F<@;VX@=&AE('1R:6%L(&1E<VEG;B!A<R!R97%U:7)E
M9"!B>2!T:&4@1D1!+B8C,38P.R8C,38P.U5N9&5R('1H92!T97)M<R!O9B!T
M:&4@<W!O;G-O<F5D(')E<V5A<F-H(&%G<F5E;65N="P@=&AE($-O;7!A;GD@
M=VEL;"!F=6YD('1H92!&2$-20R!L86(@=VET:"`D,34P+#`P,"!P97(@>65A
M<B!F;W(@=&AE(&9I<G-T('1W;R!Y96%R<R!A;F0@)#(U,"PP,#`@=&AE<F5A
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M9')U9RP@<F]Y86QT>2!P87EM96YT<R!O9B`R)2!O9B!N970@<V%L97,@=VEL
M;"!B92!D=64@=&\@1DA#4D,N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-B4@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@T)2!V
M86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0V)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SYF+B8C,38P.R8C
M,38P.SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@],T0X-"4@=F%L
M:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY/;B!-87)C:"`R-RP@,C`Q,BP@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&$@8VQI;FEC86P@=')I86P@86=R965M96YT('=I=&@@
M35-+0T,N)B,Q-C`[5&AE($-O;7!A;GD@=VEL;"!P87D@)#,Q+#$X-2!F;W(@
M96%C:"!P871I96YT('1H870@:&%S#0H@8V]M<&QE=&5D('1H92!C;&EN:6-A
M;"!T<FEA;"X@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@=&AE
M($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@<&%Y(&$@<W1A<G0M=7`@9F5E(&]F
M("0W.2PV,C,N)B,Q-C`[)B,Q-C`[5&AE(&%M;W5N="!D=64@;V8@)#<Y+#8R
M,R!W87,@<&%I9"!O;B!*=6QY(#$P+"`R,#$R+CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE
M9G0^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED
M=&@],T0X-"4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0V)2!V86QI9VX],T1T;W`^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!*=6QY(#$Y+"`R,#$R+"!T:&4@
M0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;&EN:6-A;"!T<FEA;"!A9W)E96UE
M;G0@=VET:"!&2$-20RXF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A
M>2`D,S$L,S8V(&9O<B!E86-H('!A=&EE;G0@=&AA="!H87,@8V]M<&QE=&5D
M('1H92!C;&EN:6-A;"!T<FEA;"X@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G
M<F5E;65N="P@=&AE($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@<&%Y(&$@<W1A
M<G0M=7`@9F5E(&]F("0Q.2PW-#DN)B,Q-C`[)B,Q-C`[1'5R:6YG('1H92!C
M;&EN:6-A;"!T<FEA;"!A9&1I=&EO;F%L(&9E97,@87!P;'D@86YD('=I;&P@
M8F4@:6YV;VEC960@=VAE;B!A<'!L:6-A8FQE+B8C,38P.R8C,38P.U1H92!A
M;6]U;G0@9'5E(&AA<R!N;W0@8F5E;B!I;G9O:6-E9"!B=70@86-C<G5E9"!B
M>2!T:&4@0V]M<&%N>2!A<R!O9B!397!T96UB97(@,S`L(#(P,3,N/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#@T)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0V)2!V86QI
M9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M86P@=')I86P@:7,@87!P<F]X:6UA=&5L>2`D-3`P+#`P,"P@=VAI8V@@:6YC
M;'5D97,@82!N;VXM(')E9G5N9&%B;&4@:6YS=&ET=71I;VYA;"!F964@;V8@
M)#$T+#4P,"XF(S$V,#LF(S$V,#M4:&4@97-T:6UA=&5D(&-O<W0@:7,@8F%S
M960@;VX@=')E871I;F<@,C0@<&%T:65N=',@=&AR;W5G:"`R,#$S+B8C,38P
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@T)2!V86QI9VX],T1T;W`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0V)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SYI+B8C,38P.R8C,38P.SPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@=VED=&@],T0X-"4@=F%L:6=N/3-$=&]P/@T*/&1I
M=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M($1R=6<@17AE;7!T:6]N("A)3D0@,3`X,#<I(&AE;&0@8GD@=&AE($-O;7!A
M;GDN)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@=VEL;"!P87D@)#,X+#4P,2!P
M97(@<&%T:65N="P@=VAO(&AA<R!C;VUP;&5T960@=&AE(&-L:6YI8V%L('1R
M:6%L+B!4:&4@0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!P87D@82!S=&%R="UU
M<"!F964@;V8@)#(R+#@T-RP@86X@86YN=6%L('!H87)M86-Y(&9E92!O9B`D
M,BPP,C4@86YD(&%N(&%M96YD;65N="!P<F]C97-S:6YG(&9E92!O9B`D-3`P
M+"!W:&5N(&%P<&QI8V%B;&4N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-B4@=F%L:6=N/3-$
M=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@T)2!V
M86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0V)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SYJ+B8C,38P.R8C
M,38P.SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@],T0X-"4@=F%L
M:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY/;B!.;W9E;6)E<B`R,2P@,C`Q,BP@=&AE($-O;7!A
M;GD@96YT97)E9"!I;G1O(&$@8VQI;FEC86P@=')I86P@86=R965M96YT('=I
M=&@@=&AE(%5N:79E<G-I='D@;V8@4&5N;G-Y;'9A;FEA+B8C,38P.R8C,38P
M.U1H92!0:&%S92`Q+S(@8VQI;FEC86P@=')I86P@=VEL;"!B92!C;VYD=6-T
M960@=VET:"!!8W1I;FEU;2`R,C4N)B,Q-C`[)B,Q-C`[5&AE(&-L:6YI8V%L
M('1R:6%L('=I;&P@8F4@8V]N9'5C=&5D('5N9&5R('1H92!P<F]T;V-O;',@
M97-T86)L:7-H960@8GD@=&AE($-O;7!A;GD@86YD('!U<G-U86YT('1O(&%N
M($EN=F5S=&EG871I;VYA;"!.97<@1')U9R!%>&5M<'1I;VX@*$E.1"`Q,#@P
M-RD@:&5L9"!B>2!T:&4@0V]M<&%N>2XF(S$V,#LF(S$V,#M4:&4@0V]M<&%N
M>2!W:6QL('!A>2`D,S$L-S<Q('!E<B!P871I96YT+"!W:&\@:&%S(&-O;7!L
M971E9"!T:&4@8VQI;FEC86P@=')I86PN(%1H92!#;VUP86YY('=I;&P@8F4@
M<F5Q=6ER960@=&\@<&%Y(&$@<W1A<G0M=7`@9F5E(&]F("0Q-BPP,#`@86YD
M(&%D9&ET:6]N86P@861M:6YI<W1R871I=F4@9F5E<RP@=VAE;B!A<'!L:6-A
M8FQE+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO
M9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@-#5P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!!=6=U<W0@,2P@
M,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<F5N=&%L(&%G<F5E
M;65N="!F;W(@;V9F:6-E('-P86-E(&%T(#4P,2!&:69T:"!!=F5N=64L)B,Q
M-C`[3F5W(%EO<FLL($Y9+B!4:&4@86=R965M96YT('1E<FUI;F%T960@;VX@
M36%Y(#,Q+"`R,#$S+B!/;B!*=6YE(#$L(#(P,3,L('1H92!#;VUP86YY(&5N
M=&5R960@:6YT;R!A(')E;G1A;"!A9W)E96UE;G0@9F]R(&]F9FEC92!S<&%C
M92!A="`U-#8@1FEF=&@@079E;G5E+"8C,38P.TYE=R!9;W)K+"!.62X@5&AI
M<R!A9W)E96UE;G0@=&5R;6EN871E<R!O;B!$96-E;6)E<B`S,2P@,C`Q,RX@
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\
M+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`T-7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/D]N)B,Q-C`[1F5B<G5A<GD@,C@L(#(P,3,L('1H92!#;VUP
M86YY(&5N=&5R960@:6YT;R!A(%-E<&%R871I;VX@86YD(%-E='1L96UE;G0@
M06=R965M96YT('=I=&@@:71S(&9O<FUE<B!#14\N(%!U<G-U86YT('1O('1H
M92!A9W)E96UE;G0L('1H92!#;VUP86YY('!A:60@=&AE(&9O<FUE<B!#14\@
M)#$R-2PP,#`@;VX@36%R8V@@."P@,C`Q,R!A;F0@82!S96-O;F0@<&%Y;65N
M="!O9B`D,3(U+#`P,"!O;B!397!T96UB97(@,2P@,C`Q,RX@5&AE($-O;7!A
M;GD@86QS;R!P86ED('1H92!F;W)M97(@0T5/(&$-"B!P97)F;W)M86YC92!B
M;VYU<R!O9B`D-C`L,#`P(&9O<B!H:7,@<V5R=FEC92!F<F]M($%U9W5S="`Q
M-2P@,C`Q,B!T;R!$96-E;6)E<B`S,2P@,C`Q,BX\+V9O;G0^/"]D:78^#0H\
M9&EV("!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T
M-7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D('=I9'1H/3-$-"4@=F%L:6=N/3-$
M=&]P('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^#0H\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/F$N)B,Q
M-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS1#<Y
M)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/D%B8F]T="!":6]T:&5R87!E=71I8W,@0V]R
M<"`F(S@R,3$[(%1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(%!R;V1U8W0@
M1&5V96QO<&UE;G0@86YD(%!A=&5N="!,:6-E;G-E($%G<F5E;65N="!W:71H
M($%B8F]T="!":6]T:&5R87!E=71I8W,@0V]R<"X@*&9O<FUE<FQY($9A8V5T
M($)I;W1E8V@@9F]R;65R;'D@:VYO=VX@87,@4')O=&5I;B!$97-I9VX@3&%B
M<RD@:6X@,C`P,R!T;R!S96-U<F4@97AC;'5S:79E(')I9VAT<R!T;R!A('-P
M96-I9FEC(&%N=&EB;V1Y('=H96X@8V]N:G5G871E9"!W:71H(&%L<&AA(&5M
M:71T:6YG(')A9&EO:7-O=&]P97,N(%5P;VX@97AE8W5T:6]N(&]F('1H92!A
M9W)E96UE;G0L('1H92!#;VUP86YY(&UA9&4@82!L:6-E;G-E(&9E92!P87EM
M96YT(&]F("0S+#`P,"PP,#`N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L
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M86QI;F<@)#<L-S4P+#`P,"!F;W(@=&AE(&%C:&EE=F5M96YT(&]F('1H92!F
M;VQL;W=I;F<@86=R965D('1O(&%N9"!C;VYT<F%C=&5D(&UI;&5S=&]N97,Z
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS
M1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0W."4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C
M;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY087EM96YT<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-S@E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N
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M.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-S@E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXW
M-3`L,#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@R*2!W:&5N($-O;7!A;GD@:6YI
M=&EA=&5S(&$@4&AA<V4@24D@0VQI;FEC86P@5')I86P@;V8@82!L:6-E;G-E
M9"!P<F]D=6-T/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^-S4P+#`P,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0W."4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#4P,"PP,#`\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D#0H@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F
M9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W."4@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^,2PW-3`L,#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#<X)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@U
M*2!&:7)S="!C;VUM97)C:6%L('-A;&4\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#4P,"PP,#`\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F
M9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-S@E('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^*#8I(&%F=&5R('1H92!F:7)S="`D,3`L,#`P+#`P,"!I;B!N970@
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXQ+#4P,"PP,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#0U<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY5;F1E<B!T:&4@86=R965M96YT+"!T:&4@0V]M<&%N>2!S:&%L;"!P87D@
M=&\@06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(&]N(&$@8V]U;G1R>2UB
M>2UC;W5N=')Y(&)A<VES(&$@<F]Y86QT>2!O9B`Q,B4@;V8@;F5T('-A;&5S
M(&]F(&%L;"!L:6-E;G-E9"!P<F]D=6-T<R!U;G1I;"!T:&4@;&%T97(@;V8Z
M("@Q*2`Q,BXU('EE87)S(&%F=&5R('1H92!F:7)S="!C;VUM97)C:6%L('-A
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M<B`S,2P@,C`Q,BP@=&AE($-O;7!A;GD@;65T(&ET<R!F:7)S="!M:6QE<W1O
M;F4@86YD('5P;VX@<F5A8VAI;F<@=&AE(&UI;&5S=&]N92!T:&4@0V]M<&%N
M>2!P86ED($%B8F]T="!":6]T:&5R87!E=71I8W,@0V]R<"X@82!M:6QE<W1O
M;F4@<&%Y;65N="!O9B`D-S4P+#`P,"!O;B!*=6QY(#(T+"`R,#$R+B`F(S$V
M,#M4:&4@;6EL97-T;VYE('!A>6UE;G0@9F]R('1H92!0:&%S92!)($-L:6YI
M8V%L(%1R:6%L('=A<R!R96-O<F1E9"!A<R!R97-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@97AP96YS92X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^
M#0H\9&EV/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D('=I9'1H
M/3-$-"4@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/F(N)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!W:61T:#TS1#<Y)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DU32T-#("8C.#(Q
M,3L@26X@1F5B<G5A<GD@,C`P,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O
M(&$@;&EC96YS92!A9W)E96UE;G0@=VET:"!-4TM#0R!T:&%T(')E<75I<F5S
M(&$@=&5C:&YO;&]G>2!A8V-E<W,@9F5E(&]F("0U,"PP,#`@=7!O;B!E>&5C
M=71I;VXL(&%N(&%N;G5A;"!M86EN=&5N86YC92!F964@;V8@)#4P+#`P,"!A
M;F0@86X@86YN=6%L(')E<V5A<F-H(&9U;F1I;F<@;V8@)#4P+#`P,"!F;W(@
M87,@;&]N9R!A<R!T:&4@86=R965M96YT(&ES(&EN(&9O<F-E+CPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL
M93TS1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#<X)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0W."4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$I(&9I;&EN9R!O9B!A
M;B!.97<@1')U9R!!<'!L:6-A=&EO;B`H)B,X,C(P.TY$028C.#(R,3LI(&]R
M(')E9W5L871O<GD@87!P<F]V86P\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0W."4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/C<U,"PP,#`\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$-S@E('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M*#(I('5P;VX@=&AE(')E8V5I<'0@;V8@<F5G=6QA=&]R>2!A<'!R;W9A;"!F
M<F]M('1H92!5+E,N($9$02!F;W(@96%C:#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-S@E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^;&EC96YS960@<')O9'5C
M=#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C$L-S4P+#`P,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@-#5P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E5N
M9&5R('1H92!A9W)E96UE;G0L('1H92!#;VUP86YY('-H86QL('!A>2!T;R!-
M4TM#0R!O;B!A(&-O=6YT<GDM8GDM8V]U;G1R>2!B87-I<R!A(')O>6%L='D@
M;V8@,B4@;V8@;F5T('-A;&5S(&]F(&%L;"!L:6-E;G-E9"!P<F]D=6-T<R!U
M;G1I;"!T:&4@;&%T97(@;V8Z("@Q*2`Q,"!Y96%R<R!F<F]M('1H92!F:7)S
M="!C;VUM97)C:6%L('-A;&4L(&]R("@R*2!W:&5N('1H92!P871E;G1S(&5X
M<&ER92X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L
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M>2!A<'!R;W9A;"!I;B`R,#$U+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\
M+V1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@
M=VED=&@],T0T)2!V86QI9VX],T1T;W`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SX-"CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^8RXF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('=I9'1H/3-$-SDE('9A;&EG;CTS1'1O<#X-"CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3V%K(%)I
M9&=E($YA=&EO;F%L($QA8F]R871O<GD@*$]23DPI("8C.#(Q,3L@05!)(&AA
M<R!C;VYT<F%C=&5D('1O('!U<F-H87-E(')A9&EO86-T:79E(&UA=&5R:6%L
M('1O(&)E('5S960@9F]R(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!T:')O
M=6=H($1E8V5M8F5R(#(P,3(N($%022!I<R!C;VYT<F%C=&5D('1O('!U<F-H
M87-E("0R,S,L,3`P(&]F(')A9&EO86-T:79E(&UA=&5R:6%L('1O(&)E('5S
M960@9F]R(')E<V5A<F-H(&%N9"!D979E;&]P;65N="P@=VET:"!A(')E;F5W
M86P@;W!T:6]N(&%T('1H92!C;VYT<F%C="!E;F0N("8C,38P.U1H92!#;VUP
M86YY(&ES(&-U<G)E;G1L>2!N96=O=&EA=&EN9R!T:&4@,C`Q,R!A9W)E96UE
M;G0N)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I
M=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^9"XF(S$V,#LF(S$V,#L\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('=I9'1H/3-$-SDE('9A;&EG;CTS
M1'1O<#X-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^07!T:793;VQU=&EO;G,@<')O=FED97,@<')O:F5C="!M86YA
M9V5M96YT('-E<G9I8V5S(&9O<B!T:&4@<W1U9'D@;V8@=&AE(&1R=6<@06,M
M,C(U+4AU33$Y-2`H06-T:6UA8B8C.#0X,CLM02D@=7-E9"!I;B!T:&4@0V]M
M<&%N>2!C;&EN:6-A;"!T<FEA;',L(%!H87-E($D@86YD(%!H87-E($E)+B`F
M(S$V,#M4:&4@=&]T86P@<')O:F5C="!I<R!E<W1I;6%T960@=&\@8V]S="`D
M,2PX-3DL,S,S(&%N9"!R97%U:7)E<R!A(#$R+C4E(&1O=VX@<&%Y;65N="!O
M9B!T:&4@=&]T86P@97-T:6UA=&5D('!R;VIE8W0@8V]S="X@)B,Q-C`[5&AE
M(&1O=VX@<&%Y;65N="!T;W1A;&EN9R`D,C,Y+#`P,"!W87,@<&%I9"!I;B`R
M,#`W(&%N9"`R,#$R+B`F(S$V,#M/;B!!=6=U<W0@-BP@,C`Q,BP@=&AE(&%G
M<F5E;65N="!W87,-"B!A;65N9&5D('1O('!R;W9I9&4@9F]R(&%D9&ET:6]N
M86P@<V5R=FEC97,N("8C,38P.U1H92!T;W1A;"!P<F]J96-T(&ES(&YO=R!E
M<W1I;6%T960@870@)#$L.3DW+#<S,BX@)B,Q-C`[07!T:793;VQU=&EO;G,@
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+V1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#0E('9A;&EG;CTS1'1O<#X-"CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/F4N
M)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS
M1#<Y)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]N($IU;F4@,34L(#(P,3(L('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A(&QI8V5N<V4@86YD('-P;VYS;W)E9"!R
M97-E87)C:"!A9W)E96UE;G0@=VET:"!&<F5D($AU=&-H:6YS;VX@0V%N8V5R
M(%)E<V5A<F-H($-E;G1E<B`H1DA#4D,I+B!4:&4@0V]M<&%N>2!W:6QL(&)U
M:6QD('5P;VX@<')E=FEO=7,@86YD(&]N9V]I;F<@8VQI;FEC86P@=')I86QS
M+"!W:71H($)#."`H;&EC96YS960@86YT:6)O9'DI(&%N9"!E=F5N='5A;&QY
M(&1E=F5L;W`@82!C;&EN:6-A;"!T<FEA;"!W:71H($%C=&EN:75M(#(R-2X@
M)B,Q-C`[1DA#4D,@:&%S(&-U<G)E;G1L>2!C;VUP;&5T960@4&AA<V4@22!A
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M;FL@9&5V96QO<&5D(&)Y($9(0U)#+B`F(S$V,#M4:&4@8V]S="!T;R!D979E
M;&]P('1H92!T<FEA;"!W:6QL(')A;F=E(&9R;VT@)#$S+C(@;6EL;&EO;B!T
M;R`D,C,N-2!M:6QL:6]N+"!D97!E;F1I;F<@;VX@=&AE('1R:6%L(&1E<VEG
M;B!A<R!R97%U:7)E9"!B>2!T:&4@1D1!+B`F(S$V,#M5;F1E<B!T:&4@=&5R
M;7,@;V8@=&AE('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0L('1H92!#
M;VUP86YY('=I;&P@9G5N9"!T:&4@1DA#4D,@;&%B('=I=&@@)#$U,"PP,#`@
M<&5R('EE87(@9F]R('1H92!F:7)S="!T=V\@>65A<G,@86YD("0R-3`L,#`P
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M9RX@)B,Q-C`[57!O;B!C;VUM97)C:6%L('-A;&4@;V8@=&AE(&1R=6<L(')O
M>6%L='D@<&%Y;65N=',@;V8@,B4@;V8@;F5T('-A;&5S('=I;&P@8F4@9'5E
M('1O($9(0U)#+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0T)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SYF+B8C,38P.R8C,38P.SPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@=VED=&@],T0W.24@=F%L:6=N/3-$=&]P/@T*/&1I
M=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/
M;B!-87)C:"`R-RP@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@
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M82!S=&%R="UU<"!F964@;V8@)#<Y+#8R,RX@)B,Q-C`[5&AE(&%M;W5N="!D
M=64@;V8@)#<Y+#8R,R!W87,@<&%I9"!O;B!*=6QY(#$P+"`R,#$R+CPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+V9O;G0^/"]D:78^#0H\9&EV/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H
M.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*
M/'1R/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0T)2!V86QI9VX],T1T
M;W`^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!-87D@.2P@,C`Q,2P@
M06-T:6YI=6T@96YT97)E9"!I;G1O(&$@=')A;G-A8W1I;VX@;6%N86=E;65N
M="!A9W)E96UE;G0@=VET:"!*86UE<W,@0V%P:71A;"!'<F]U<"P@3$Q#+B`H
M9F]R;65R;'D@:VYO=VX@87,@06UE<F%S:6$@0V%P:71A;"!'<F]U<"P@3$Q#
M*2P@82!C;VYS=6QT:6YG(&9I<FT@869F:6QI871E9"!W:71H($UR+B!386YD
M97-H(%-E=&@L(&$@1&ER96-T;W(@;V8@0V%C='5S)B,Q-C`[5F5N='5R97,L
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M(&]F("0Q,BPU,#`@=VAI8V@@:7,@=&5R;6EN86)L92!B>2!T:&4@0V]M<&%N
M>2!T:')E92!M;VYT:',@869T97(@=&AE(&5F9F5C=&EV92!D871E(&]F('1H
M92!G;VEN9R!P=6)L:6,@=')A;G-A8W1I;VX@86YD(&1E<VEG;F5E<R!O9B!*
M86UE<W,L(&EN8VQU9&EN9R!E;G1I=&EE<R!A9F9I;&EA=&5D('=I=&@@37(N
M(%-E=&@L('=E<F4@:7-S=65D('=A<G)A;G1S('1O('!U<F-H87-E(&-O;6UO
M;B!S=&]C:R!E<75A;"!T;R`Q,"4@;V8@=&AE(&9U;&QY+61I;'5T960@8V%P
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M<'1I;VX@4&QA;BXF(S$V,#L@2F%M97-S($-A<&ET86P@1W)O=7`@9&]E<R!N
M;W0@<F5T86EN)B,Q-C`[8F5N969I8VEA;"!O=VYE<G-H:7`@;V8@=&AE('=A
M<G)A;G1S(&%S('1H97D@=V5R928C,38P.VES<W5E9"!T;R!D97-I9VYE97,@
M;V8@=&AE(&UE;6)E<G,@:6X@86UO=6YT<R!W:&EC:"!D;R!N;W0@<75A;&EF
M>2!E:71H97(@2F%M97-S(&]R('1H92!W87)R86YT(&AO;&1E<G,@9F]R(&EN
M8VQU<VEO;B!I;B!T:&4@8F5N969I8VEA;"!O=VYE<G-H:7`@=&%B;&4N)B,Q
M-C`[(%1H92!W87)R86YT<R!C;VYT86EN)B,Q-C`[82!P<F]V:7-I;VX@=VAE
M<F5I;B!T:&4@:&]L9&5R(&UA>2!W86EV92!T:&4@.3`@9&%Y(&5X97)C:7-E
M(&YO=&EC92!R97%U:7)E;65N="!B>2!G:79I;F<@-C4@9&%Y<R!P<FEO<B!N
M;W1I8V4@;V8@<W5C:"!W86EV97(N)B,Q-C`[(%1H92!S:&%R97,@879A:6QA
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M:6]N(%-T871E;65N="!I<R!D96-L87)E9"!E9F9E8W1I=F4N)B,Q-C`[5&AE
M(&-O;G-U;'1I;F<@9FER;2!I<R!A;'-O(&5L:6=I8FQE('1O(&)E(')E:6UB
M=7)S960@=7!O;B!T:&4@<W5B;6ES<VEO;B!O9B!P<F]P97(@9&]C=6UE;G1A
M=&EO;B!F;W(@;W)D:6YA<GD@86YD(&YE8V5S<V%R>2!O=70M;V8M<&]C:V5T
M(&5X<&5N<V5S(&YO="!T;R!E>&-E960@)#4L,#`P('!E<B!M;VYT:"X\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T
M:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<CX-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$-"4@=F%L:6=N/3-$
M=&]P/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.PT*(&UA
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M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!*=6QY(#$Y+"`R
M,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;&EN:6-A;"!T<FEA
M;"!A9W)E96UE;G0@=VET:"!&2$-20RX@)B,Q-C`[5&AE($-O;7!A;GD@=VEL
M;"!P87D@)#,Q+#,V-B!F;W(@96%C:"!P871I96YT('1H870@:&%S(&-O;7!L
M971E9"!T:&4@8VQI;FEC86P@=')I86PN(%5P;VX@97AE8W5T:6]N(&]F('1H
M92!A9W)E96UE;G0L('1H92!#;VUP86YY(&ES(')E<75I<F5D('1O('!A>2!A
M('-T87)T+75P(&9E92!O9B`D,3DL-S0Y+B`F(S$V,#M$=7)I;F<@=&AE(&-L
M:6YI8V%L('1R:6%L(&%D9&ET:6]N86P@9F5E<R!A<'!L>2!A;F0@=VEL;"!B
M92!I;G9O:6-E9"!W:&5N(&%P<&QI8V%B;&4N("8C,38P.U1H92!A;6]U;G0@
M9'5E(&AA<R!N;W0@8F5E;B!I;G9O:6-E9"!B=70@86-C<G5E9"!B>2!T:&4@
M0V]M<&%N>2!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BX\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^:2XF
M(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('=I9'1H/3-$
M-SDE('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^3VX@075G=7-T(#(X+"`R,#$R+"!T:&4@
M0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;&EN:6-A;"!T<FEA;"!A9W)E96UE
M;G0@=VET:"!4:&4@56YI=F5R<VET>2!O9B!497AA<R!-+D0N($%N9&5R<V]N
M($-A;F-E<B!#96YT97(N("8C,38P.U1H92!T;W1A;"!E<W1I;6%T960@8V]S
M="!O9B!C;VYD=6-T:6YG('1H92!C;&EN:6-A;"!T<FEA;"!I<R`D-#@Q+#(P
M-"P@=VAI8V@@:6YC;'5D97,@82!N;VXM(')E9G5N9&%B;&4@:6YS=&ET=71I
M;VYA;"!F964@;V8@)#$T+#4P,"X@)B,Q-C`[5&AE(&5S=&EM871E9"!C;W-T
M(&ES(&)A<V5D(&]N('1R96%T:6YG(#(T('!A=&EE;G1S('1H<F]U9V@@,C`Q
M,RX@)B,Q-C`[57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@=&AE
M($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@;6%K92!A('!A>6UE;G0@;V8@)#,S
M+#DT-BX@)B,Q-C`[)B,Q-C`[5&AE(&%M;W5N="!D=64@:&%S(&YO="!B965N
M(&EN=F]I8V5D(&)U="!A8V-R=65D(&)Y('1H92!#;VUP86YY(&%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$R+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*
M/"]T86)L93X-"CPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV/@T*
M/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0T)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SYJ+B8C,38P.R8C,38P.SPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@],T0W.24@=F%L:6=N/3-$=&]P
M/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY/;B!397!T96UB97(@,C8L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R
M960@:6YT;R!A(&-L:6YI8V%L('1R:6%L(&%G<F5E;65N="!W:71H($IO:&YS
M($AO<&MI;G,@56YI=F5R<VET>2X@)B,Q-C`[5&AE(%!H87-E(#$O,B!C;&EN
M:6-A;"!T<FEA;"!W:6QL(&)E(&-O;F1U8W1E9"!W:71H($%C=&EN:75M(#(R
M-2X@)B,Q-C`[5&AE(&-L:6YI8V%L('1R:6%L('=I;&P@8F4@8V]N9'5C=&5D
M('5N9&5R('1H92!P<F]T;V-O;',@97-T86)L:7-H960@8GD@=&AE($-O;7!A
M;GD@86YD('!U<G-U86YT('1O(&%N($EN=F5S=&EG871I;VYA;"!.97<@1')U
M9R!%>&5M<'1I;VX@*$E.1"`Q,#@P-RD@:&5L9"!B>2!T:&4@0V]M<&%N>2X@
M)B,Q-C`[5&AE($-O;7!A;GD@=VEL;"!P87D@)#,X+#4P,2!P97(@<&%T:65N
M="P@=VAO(&AA<R!C;VUP;&5T960@=&AE(&-L:6YI8V%L('1R:6%L+B!4:&4@
M0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!P87D@82!S=&%R="UU<"!F964@;V8@
M)#(R+#@T-RP@86X@86YN=6%L('!H87)M86-Y(&9E92!O9B`D,BPP,C4@86YD
M(&%N(&%M96YD;65N="!P<F]C97-S:6YG(&9E92!O9B`D-3`P+"!W:&5N(&%P
M<&QI8V%B;&4N("8C,38P.U1H92!A;6]U;G0@9'5E(&AA<R!N;W0@8F5E;B!I
M;G9O:6-E9"!B=70@86-C<G5E9"!B>2!T:&4@0V]M<&%N>2!A<R!O9B!$96-E
M;6)E<B`S,2P@,C`Q,BX\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^#0H\9&EV('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
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M1#`^#0H\='(^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#0E('9A;&EG
M;CTS1'1O<#X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/FLN)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!W:61T:#TS1#<Y)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]N($YO=F5M8F5R
M(#(Q+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;&EN:6-A
M;"!T<FEA;"!A9W)E96UE;G0@=VET:"!T:&4@56YI=F5R<VET>2!O9B!096YN
M<WEL=F%N:6$N("8C,38P.U1H92!0:&%S92`Q+S(@8VQI;FEC86P@=')I86P@
M=VEL;"!B92!C;VYD=6-T960@=VET:"!!8W1I;FEU;2`R,C4N("8C,38P.U1H
M92!C;&EN:6-A;"!T<FEA;"!W:6QL(&)E(&-O;F1U8W1E9"!U;F1E<B!T:&4@
M<')O=&]C;VQS(&5S=&%B;&ES:&5D(&)Y('1H92!#;VUP86YY(&%N9"!P=7)S
M=6%N="!T;R!A;B!);G9E<W1I9V%T:6]N86P@3F5W($1R=6<@17AE;7!T:6]N
M("A)3D0@,3`X,#<I(&AE;&0@8GD@=&AE($-O;7!A;GDN("8C,38P.U1H92!#
M;VUP86YY('=I;&P@<&%Y("0S,2PW-S$@<&5R('!A=&EE;G0L('=H;R!H87,@
M8V]M<&QE=&5D('1H92!C;&EN:6-A;"!T<FEA;"X@5&AE($-O;7!A;GD@=VEL
M;"!B92!R97%U:7)E9"!T;R!P87D@82!S=&%R="UU<"!F964@;V8@)#$V+#`P
M,"!A;F0@861D:71I;VYA;"!A9&UI;FES=')A=&EV92!F965S+"!W:&5N(&%P
M<&QI8V%B;&4N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/B8C,38P.SPO
M9&EV/@T*/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF(S$V,#LF(S$V,#L@3VX@075G=7-T
M(#$L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(')E;G1A;"!A
M9W)E96UE;G0@9F]R(&]F9FEC92!S<&%C92!A="`U,#$@1FEF=&@@079E;G5E
M+"`S<F0@1FQO;W(L($YE=R!9;W)K+"!.62`Q,#`Q-RX@)B,Q-C`[5&AE(&%G
M<F5E;65N="!T97)M:6YA=&5S($IA;G5A<GD@,S$L(#(P,3,@=6YL97-S(&$@
M3F]T:6-E(&]F(%1E<FUI;F%T:6]N(&ES('!R;W9I9&5D('1O('1H92!L86YD
M;&]R9"`V,"!D87ES('!R:6]R('1O($IA;G5A<GD@,2P@,C`Q,RX@)B,Q-C`[
M5&AE(&%G<F5E;65N="!A=71O;6%T:6-A;&QY(')E;F5W<R!O;B!A(&UO;G1H
M+71O+6UO;G1H(&)A<VES(&%N9"!R97%U:7)E<R!A('1W;R!M;VYT:"!N;W1I
M8V4@;V8@=&5R;6EN871I;VXN("8C,38P.U1H92!#;VUP86YY('!A:60@82!T
M=V\@;6]N=&@@<F5F=6YD86)L92!D97!O<VET+CPO9F]N=#X\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S!E930U-64Q
M7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R
M,V0U8C<O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4T<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^17%U:71Y/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%
M<75I='D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3-P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@
M=&5X="UI;F1E;G0Z(#!P=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
M<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V9F9F9F9CL@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SY.;W1E(#<@
M)B,X,C$Q.R!%<75I='D\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,W!X.R!F;VYT+7-T>6QE.B!N
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M:61T:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SXF(S$V,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX-"CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
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M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/@T*
M/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#LG/E1H92!";V%R9"!A<'!R;W9E9"!T:&4@0V]M<&%N>28C.#(Q-SMS(#(P
M,3,@4W1O8VL@4&QA;BXF(S$V,#LF(S$V,#M4:&4@97AP:7)A=&EO;B!D871E
M(&]F('1H92!P;&%N(&ES(%-E<'1E;6)E<B8C,38P.R8C,38P.SDL(#(P,C,F
M(S$V,#MA;F0@=&AE('1O=&%L(&YU;6)E<B!O9B!U;F1E<FQY:6YG('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A=F%I;&%B
M;&4@9F]R(&=R86YT('1O(&5M<&QO>65E<RP@9&ER96-T;W)S(&%N9"!C;VYS
M=6QT86YT<R!O9B!T:&4@0V]M<&%N>2!U;F1E<B!T:&4@<&QA;B!I<R`R+#<U
M,"PP,#`@<VAA<F5S+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-
M"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
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M=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C
M,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M:7,@-#4P+#`P,"!S:&%R97,N/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3-P>#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N
M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CL@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,W!X
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M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^3W!T:6]N<SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
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M875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C
M;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^5&AE(&9O;&QO=VEN9R!I<R!A
M('-U;6UA<GD@;V8F(S$V,#MO<'1I;VX@86-T:79I=&EE<SH\+V9O;G0^/"]D
M:78^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=C;VQO<CH@(S`P,#`P
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M(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('1E>'0M
M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI
M9VX],T1R:6=H="!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'@[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[
M)SX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0S/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0S/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S/@T*/&1I=B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^079E<F%G93PO
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0S/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG/E=E:6=H=&5D/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0S/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^4F5M86EN:6YG/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S/@T*/&1I=B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^06=G<F5G871E
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#,^#0H\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY!=F5R
M86=E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S/@T*
M/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M56YI=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[)R!C;VQS<&%N/3-$,SX-"CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/D5X97)C:7-E(%!R:6-E/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R<@8V]L<W!A;CTS1#,^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY497)M("AI;B!Y96%R<RD\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS
M<&%N/3-$,SX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#LG/E9A;'5E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S/@T*/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/D]U='-T86YD:6YG+"!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
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M;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^-C@U+#@P,#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI
M=&4^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-3(E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0-"B!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/D-A;F-E;&QA=&EO;CPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^*3PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED
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M;G0M<VEZ93H-"B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!V
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M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY/=71S=&%N9&EN9RP@4V5P=&5M8F5R
M(#,P+"`R,#$S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I
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M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/@T*/'1D('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/C`N.34\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
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M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[
M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C
M,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,W!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A
M=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@=VED;W=S.B!A=71O.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R!T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/D%L;"!O<'1I;VYS(&ES<W5E9"!A
M;F0@;W5T<W1A;F1I;F<@87)E(&)E:6YG(&%M;W)T:7IE9"!O=F5R('1H96ER
M(')E<W!E8W1I=F4@=F5S=&EN9R!P97)I;V1S+B!4:&4@=6YR96-O9VYI>F5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,R8C
M,38P.W=A<R`D,2PP,30L-#<T+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,W!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
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M+7-T<F]K92UW:61T:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F
M.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,W!X.R!F;VYT+7-T>6QE
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M92UW:61T:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/E=A<G)A;G1S/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F
M9F9F9F8[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('1E>'0M:6YD96YT.B`S
M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^5&AE(&9O;&QO=VEN9R!I<R!A('-U;6UA<GD@;V8@=V%R<F%N="!A
M8W1I=FET:65S.CPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
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M=6YD+6-O;&]R.B`C9F9F9F9F.R!T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^)B,Q-C`[/"]D:78^#0H\9&EV('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^#0H\9&EV
M(&%L:6=N/3-$<FEG:'0^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/E=E:6=H=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY!=F5R86=E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/@T*/&1I=B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^5V5I9VAT960\+V9O;G0^
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^06=G<F5G871E/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/@T*/&1I=B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^079E<F%G93PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/@T*/&1I=B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^0V]N=')A8W1U86P\+V9O
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/E5N
M:71S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY%
M>&5R8VES92!0<FEC93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X]
M,T0R/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^5&5R;2`H:6X@>65A<G,I/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T0C8V-E969F/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#4R)0T*('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
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M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@]
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M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,BPW-S`L-C,V/"]F;VYT/CPO=&0^
M#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N
M=#X\+W1D/@T*/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`V+#$Q-"PW-C@\+V9O;G0^/"]T9#X-
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^5V%R<F%N=',@97AE<F-I
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^*#(L,S`T+#DQ,#PO9F]N=#X\+W1D
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M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C$N-C4\+V9O;G0^
M/"]T9#X-"CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/E=A<G)A;G1S(&5X<&ER960\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!V
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^*3PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,2XV-3PO9F]N=#X\+W1D/@T*
M/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0-"B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!V86QI
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^3W5T<W1A;F1I;F<L(%-E<'1E;6)E<B`S,"P@
M,C`Q,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
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M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,"X@-S<\
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M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^-2XP.3PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,24@;F]W
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M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@]
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M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^.2PV,3$L-#`S/"]F;VYT/CPO=&0^#0H\=&0@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3-P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N
M<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N
M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CL@=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D1U<FEN9R!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,2P@,C`Q,R!A;F0@
M,C`Q,BP@=&AE($-O;7!A;GD@<F5C;W)D960@;W!T:6]N(&%N9"!W87)R86YT
M(&5X<&5N<V5S(&]F("0Y-2PY-S$L(&%N9"`D-S(L,3`P+"!R97-P96-T:79E
M;'DN($1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,Q
M+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!O<'1I;VX@
M86YD('=A<G)A;G0@97AP96YS97,@;V8@)#(X-"PS-S$@86YD("0Q-C@L,#`P
M+"!R97-P96-T:79E;'DN/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI9VX],T1J=7-T:69Y('-T
M>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG/DYO
M=&4@.2`F(S@R,3$[($5Q=6ET>3PO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N
M=#X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[
M('1E>'0M:6YD96YT.B`R-W!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#LF(S$V,#LF(S$V,#L@1G)O;2!I;F-E<'1I;VX@
M=&\@1&5C96UB97(@,S$L(#(P,3`L('1H92!#;VUP86YY(')A:7-E9"`D-#(L
M-S$Q+#<Y,2!B>2!I<W-U:6YG(#4L-S`W+#(U.2!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!S=&]C:R!A;F0@:7-S=65D(#8V+#0P,B!S:&%R97,L
M('9A;'5E9"!A="`D,SDX+#@Q,"P@9F]R('-E<G9I8V5S+CPO9F]N=#X\+V1I
M=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD
M96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`R-W!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#LF(S$V,#LF(S$V,#L@1'5R
M:6YG(#(P,3$L('1H92!#;VUP86YY(')A:7-E9"`D-BPQ.#0L.38W(&)Y('-E
M;&QI;F<@-RPX.3$L,30Q('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M('-T;V-K(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92`Q.2PY-S(L-S@U('-H
M87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('-T;V-K('1H<F]U9V@@86X@
M;V9F97)I;F<@*"8C.#(R,#M3=&]C:R!/9F9E<FEN9R8C.#(R,3LI+B8C,38P
M.R8C,38P.T$@;F5T(&%M;W5N="!O9B`D-2PS-SDL,S8W('=A<R!R96-E:79E
M9"!B>2!T:&4@0V]M<&%N>2!I;B`R,#$Q+B!4:&4@0V]M<&%N>2!P86ED($QA
M:61L87<@)F%M<#L@0V]M<&%N>2`H54LI($QT9"X@*"8C.#(R,#M,86ED;&%W
M("9A;7`[($-O+B8C.#(R,3LI+"!T:&4@<&QA8V5M96YT(&%G96YT+"!T;W1A
M;"!C87-H(&9E97,@;V8@)#<T,BPQ.38L('=H:6-H(&-O;G-I<W1E9"!O9B!P
M;&%C96UE;G0@86=E;G0@8V]M;6ES<VEO;B!O9B`D-C$X+#0Y-R!A;F0@97AP
M96YS92!R96EM8G5R<V5M96YT(&]F("0Q,C,L-CDY+B!4:&4@0V]M<&%N>2!A
M;'-O(&ES<W5E9"!,86ED;&%W("9A;7`[($-O+B!W87)R86YT<R!T;R!P=7)C
M:&%S92!A;B!A9V=R96=A=&4@;V8@.3@V+#,Y,R!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLL('=I=&@@86X@97AE<F-I<V4@
M<')I8V4@;V8@)#`N-S@@<&5R('-H87)E(&%N9"!A('1E<FT@;V8@-R!Y96%R
M<RX@5&AE<V4@<&QA8V5M96YT(&%G96YT('=A<G)A;G1S('=E<F4@=F%L=65D
M(&%T('1H96ER(&=R86YT(&1A=&4@9F%I<B!V86QU92!O9B`D,3@X+#4W.2XF
M(S$V,#M);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@<&%I9"!,86ED;&%W("9A
M;7`[($-O+B8C.#(Q-SMS(&]U='-I9&4@8V]U;G-E;"P@36-#;W)M:6-K("9A
M;7`[($\F(S@R,3<[0G)I96X@4$Q,0RP@)#8P+#DP-"!F;W(@:71S('-E<G9I
M8V5S(&%S('1H92!P;&%C96UE;G0@86=E;G0F(S@R,3<[<R!L96=A;"!C;W5N
M<V5L(&%N9"!3:6=N871U<F4@0F%N:R`D,BPU,#`@9F]R('1H92!B86YK(&5S
M8W)O=R!F964N/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T
M>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#(W<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD
M96YT.B`R-W!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#LF(S$V,#LF(S$V,#L@1'5R:6YG(#(P,3(L('1H92!#;VUP86YY
M(')A:7-E9"`D-S4Y+#,P,"!B>2!S96QL:6YG(#DV."PW-3D@<VAA<F5S(&%N
M9"!W87)R86YT<R!T;R!P=7)C:&%S92`R-#(L,3DP('-H87)E<R!O9B!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!U;F1E<B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(%-T;V-K($]F9F5R:6YG+B8C,38P.R8C,38P.T$@;F5T(&%M
M;W5N="!O9B`D-C8P+#$V-"!W87,@<F5C96EV960@8GD@=&AE($-O;7!A;GD@
M:6X@,C`Q,BX@5&AE($-O;7!A;GD@<&%I9"!,86ED;&%W("9A;7`[($-O+B!T
M;W1A;"!C87-H(&9E97,@;V8@)#DQ+#$Q-BP@=VAI8V@@8V]N<VES=&5D(&]F
M('!L86-E;65N="!A9V5N="!C;VUM:7-S:6]N(&]F("0W-2PY,S`@86YD(&5X
M<&5N<V4@<F5I;6)U<G-E;65N="!O9B`D,34L,3@V+B!4:&4@0V]M<&%N>2!A
M;'-O(&ES<W5E9"!,86ED;&%W("9A;7`[($-O+B!W87)R86YT<R!T;R!P=7)C
M:&%S92!A;B!A9V=R96=A=&4@;V8@,3(Q+#`Y-2!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLL('=I=&@@86X@97AE<F-I<V4@
M<')I8V4@;V8@)#`N-S@F(S$V,#MP97(@<VAA<F4@86YD(&$@=&5R;2!O9B`W
M('EE87)S+B!4:&5S92!P;&%C96UE;G0@86=E;G0@=V%R<F%N=',@=V5R92!V
M86QU960@870@=&AE:7(@9W)A;G0@9&%T92!F86ER('9A;'5E(&]F("0Q-3DL
M,#0T+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@<&%I9"!,86ED;&%W("9A
M;7`[($-O+B8C.#(Q-SMS(&]U='-I9&4@8V]U;G-E;"P@36-#;W)M:6-K("9A
M;7`[($\F(S@R,3<[0G)I96X@4$Q,0RP@)#@L,#(P(&9O<B!I=',@<V5R=FEC
M97,@87,@=&AE('!L86-E;65N="!A9V5N="8C.#(Q-SMS(&QE9V%L(&-O=6YS
M96PN/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#(W<'0[)SXF(S$V,#L\+V1I=CX\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`R-W!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#LF(S$V,#LF(S$V,#L@26X@,C`Q,BP@=&AE($-O;7!A;GD@86QS;R!R
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M9"!O9B`Q,C`@9&%Y<R!F<F]M('1H92!D87D@;V8@=&AE(&9I;F%L(&-L;W-I
M;F<@;V8@=&AE(&]F9F5R:6YG+"!A;F0@)B,X,C(P.T(@5V%R<F%N=',F(S@R
M,C$[('1O('!U<F-H87-E(#$L-34Y+#4P-2!S:&%R97,@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLL(&5X97)C:7-A8FQE(&%T(&$@<')I
M8V4@;V8@)#(N-#@@<&5R('-H87)E(&9O<B!A('!E<FEO9"!O9B`U('EE87)S
M(&9R;VT@=&AE(&1A=&4@;V8@=&AE(&9I;F%L(&-L;W-I;F<@;V8@=&AE(&]F
M9F5R:6YG+B`H)B,X,C(P.S(P,3(@0V]M;6]N(%-T;V-K($]F9F5R:6YG)B,X
M,C(Q.RDF(S$V,#LF(S$V,#M!(&YE="!A;6]U;G0@;V8@)#0L-#8Y+#<W-B!W
M87,@<F5C96EV960@8GD@=&AE($-O;7!A;GDN(%!U<G-U86YT('1O('1H92`R
M,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9R!A9W)E96UE;G0L('1H92!#;VUP
M86YY('!A:60@3&%I9&QA=R`F86UP.R!#;RX@=&]T86P@8V%S:"!F965S(&]F
M("0V,3@L,3<T+"!W:&EC:"!C;VYS:7-T960@;V8@<&QA8V5M96YT(&%G96YT
M(&-O;6UI<W-I;VX@;V8@)#4Q-2PQ-#4@86YD(&5X<&5N<V4@<F5I;6)U<G-E
M;65N="!O9B`D,3`S+#`R.2X@5&AE($-O;7!A;GD@86QS;R!I<W-U960@=&AE
M('!L86-E;65N="!A9V5N="!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R
M96=A=&4@;V8@-#8W+#@T-2!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<R!C;VUM;VX@<W1O8VLL('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N
M-S@@<&5R('-H87)E(&%N9"!A('1E<FT@;V8@-2!Y96%R<RX@5&AE<V4@<&QA
M8V5M96YT(&%G96YT('=A<G)A;G1S('=E<F4@=F%L=65D(&%T("0T.3DL-S`W
M(&%N9"!R96-O<F1E9"!A<R!D97)I=F%T:79E(&QI86)I;&ET:65S+B8C,38P
M.R8C,38P.TEN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!P86ED('1H92!,86ED
M;&%W("9A;7`[($-O+B8C.#(Q-SMS(&]U='-I9&4@8V]U;G-E;"P@4FEC:&%R
M9'-O;B`F86UP.R!0871E;"P@3$Q0+"`D-C`L,#`P(&9O<B!I=',@<V5R=FEC
M97,@87,@=&AE($QA:61L87<@)F%M<#L@0V\N)B,X,C$W.W,@;&5G86P@8V]U
M;G-E;"!A;F0@4VEG;F%T=7)E($)A;FL@)#,L-3`P(&9O<B!T:&4@8F%N:R!E
M<V-R;W<@9F5E+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&)L;V-K.R!T97AT+6EN9&5N=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,C=P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[)B,Q-C`[)B,Q-C`[($1U<FEN9R`R,#$R+"!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&-O;G9E<G1I8FQE(&YO=&5S+"!P;'5S(&%C8W)U960@:6YT97)E<W0L
M('=E<F4@8V]N=F5R=&5D('1O(#$L,C4R+#4U,"!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@87,@82!R97-U;'0@;V8@=&AE
M(#(P,3(@0V]M;6]N(%-T;V-K($]F9F5R:6YG+CPO9F]N=#X\+V1I=CX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&)L;V-K.R!T97AT+6EN9&5N=#H@,'!T.R<^
M)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!T97AT+6EN9&5N=#H@,C=P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[($%S(&$@<F5S=6QT
M(&]F('1H92!3:&%R92!%>&-H86YG92!D97-C<FEB960@:6X@3F]T92`Q+"!T
M:&4@0V]M<&%N>2!I<W-U960@-#`P+#`P,"!S:&%R97,@=&\@=&AE(&]R:6=I
M;F%L('-H87)E:&]L9&5R<R!O9B!T:&4@0V]M<&%N>2!A;F0@,2PY.#8L-38V
M('-H87)E<R!T;R!T:&4@9F]R;65R('-H87)E:&]L9&5R<R!O9B!!8W1I;FEU
M;2X\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@
M=&5X="UI;F1E;G0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@86QI9VX],T1J
M=7-T:69Y('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
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M('1H92!#;VUP86YY(&ES<W5E9"!,86ED;&%W("9A;7`[($-O+B!W87)R86YT
M<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@,2PQ,CDL.3(U('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VLL('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@
M)#`N-S@@<&5R('-H87)E+B8C,38P.R8C,38P.U=I=&@@=&AE(&UO;F5Y(')A
M:7-E9"!I;B`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@3&%I9&QA=R`F86UP
M.R!#;RX@=V%R<F%N=',@=&\@<'5R8VAA<V4@86X@86=G<F5G871E(&]F(#4X
M."PY-#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@=VET:"!A;B!E>&5R8VES
M92!P<FEC92!O9B`D,"XW."!P97(@<VAA<F4N/"]F;VYT/CPO9&EV/CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ#0H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N
M=#H@,C=P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE
M/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
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M92!#;VUP86YY(&5N=&5R960@:6YT;R!A)B,Q-C`[;6%N86=E;65N="!A9W)E
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M8VLL('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,#$@<&5R('-H87)E
M+B!4:&4@=V%R<F%N=',@:&%V92!A(&9A:7(@=F%L=64@;V8@)#(L,34S+#0T
M,B`H<V5E($YO=&4@,3$I(&%N9"!I;F-L=61E9"!A(&-A<VAL97-S(&5X97)C
M:7-E('!R;W9I<VEO;BXF(S$V,#LF(S$V,#M);B`R,#$R+"!T:&4@0V]M<&%N
M>2!I<W-U960@2F%M97-S('=A<G)A;G1S('1O('!U<F-H87-E(#$L-S$V+#,T
M,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=I=&@@86X@97AE<F-I<V4@<')I
M8V4@;V8@)#`N,#$@<&5R('-H87)E+B!4:&4@=V%R<F%N=',@:&%V92!A(&9A
M:7(@=F%L=64@;V8@)#$L.34W+#<U-"`H<V5E($YO=&4@,3$I(&%N9"!I;F-L
M=61E9"!A(&-A<VAL97-S(&5X97)C:7-E('!R;W9I<VEO;BX\+V9O;G0^/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P
M964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?
M,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K($]P=&EO;B!0;&%N
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D1I<V-L;W-U<F4@;V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',L
M(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;B!0
M;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^3F]T92`Q,"`F(S@R,3$[(%-T;V-K($]P=&EO;B!0;&%N
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@5&AE($-O;7!A;GD@
M:&%S(&%D;W!T960@82`R,#`S(%-T;V-K(%!L86X@=6YD97(@=VAI8V@@:70@
M;6%Y(&=R86YT('5P('1O(#<U-RPU-S4@;W!T:6]N<R!T;R!P=7)C:&%S92!C
M;VUM;VX@<W1O8VLN(%1H92`R,#`S(%-T;V-K(%!L86X@=V%S(&%M96YD960@
M:6X@,C`P."!T;R!I;F-R96%S92!T:&4@;G5M8F5R(&]F('-H87)E<R!T:&%T
M(&ET(&UA>2!G<F%N="!U<"!T;R`Y-S@L,34T+B!/<'1I;VX@87=A<F1S(&%R
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M:6UA=&5L>2`R)2!P97(@;6]N=&@N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P
M.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#L@26X@,C`Q,2P@=&AE(#(P,#,@4W1O8VL@4&QA;B!W87,@86UE
M;F1E9"!T;R!I;F-R96%S92!T:&4@;G5M8F5R(&]F('-H87)E<R!B>2`S+#(Q
M-RPX.#`N)B,Q-C`[)B,Q-C`[5&]T86P@<VAA<F5S(')E<V5R=F5D(&9O<B!I
M<W-U86YC92!U;F1E<B!T:&4@4&QA;B!W:6QL(&)E(&EN8W)E87-E9"!T;R`V
M+#$U-2PR.#`N/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^
M#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R!);B!A8V-O<F1A;F-E('=I=&@@=&AE('1E<FUS(&]F('1H92`R,#$R($-O
M;6UO;B!3=&]C:R!/9F9E<FEN9RP@=&AE($-O;7!A;GD@861O<'1E9"!A(#(P
M,3(@16UP;&]Y964@4W1O8VL@3W!T:6]N(%!L86X@*"8C.#(R,#LR,#$R($53
M3U`F(S@R,C$[*2!A;F0@<F5S97)V960@,34E(&]F('1H92!T;W1A;"!I<W-U
M960@86YD(&]U='-T86YD:6YG('-H87)E<R!A<R!O9B!T:&4@9FEN86P@8VQO
M<VEN9R!O9B!T:&4@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<N)B,Q-C`[
M)B,Q-C`[5&]T86P@<VAA<F5S(')E<V5R=F5D(&9O<B!I<W-U86YC92!U;F1E
M<B!T:&4@,C`Q,B!%4T]0('=A<R`Y+#0U-2PW-S8@<VAA<F5S+CPO9F]N=#X\
M+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&IU
M<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@1'5R:6YG(#(P,#8L(&]P
M=&EO;G,@=&\@<'5R8VAA<V4@,C`V+#`V,"!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K('=E<F4@9W)A;G1E9"!T;R!S979E<F%L(&5M<&QO>65E<R!A="!A;B!E
M>&5R8VES92!P<FEC92!O9B`D,2XS-2!P97(@<VAA<F4N(%1H97-E(&]P=&EO
M;G,@:&%V92!A('1E<FT@;V8@,3`@>65A<G,@86YD('9E<W0@;W9E<B!A(#0M
M-2!Y96%R('!E<FEO9"X@1F%I<B!V86QU92!O9B`D,2PP-3$L,C@Q('=A<R!C
M86QC=6QA=&5D('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC
M:6YG(&UO9&5L+B!687)I86)L97,@=7-E9"!I;B!T:&4@0FQA8VLM4V-H;VQE
M<R!O<'1I;VXM<')I8VEN9R!M;V1E;"!I;F-L=61E("@Q*2!D:7-C;W5N="!R
M871E(&]F(#0N,CDE("@R*2!E>'!E8W1E9"!L:69E(&]F(#4@>65A<G,L("@S
M*2!E>'!E8W1E9"!V;VQA=&EL:71Y(&]F(#$U-B4L(&%N9"`H-"D@>F5R;R!E
M>'!E8W1E9"!D:79I9&5N9',N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO
M9&EV/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M<F%L(&5M<&QO>65E<R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D,2XS-2!P
M97(@<VAA<F4N(%1H97-E(&]P=&EO;G,@:&%V92!A('1E<FT@;V8@,3`@>65A
M<G,@86YD('9E<W0@;W9E<B!A(#0M-2!Y96%R('!E<FEO9"X@1F%I<B!V86QU
M92!O9B`D,3,W+#8U,B!W87,@8V%L8W5L871E9"!U<VEN9R!T:&4@0FQA8VLM
M4V-H;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"X@5F%R:6%B;&5S('5S960@
M:6X@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96P@:6YC
M;'5D92`H,2D@9&ES8V]U;G0@<F%T92!O9B`S+C0V)2`H,BD@97AP96-T960@
M;&EF92!O9B`U('EE87)S+"`H,RD@97AP96-T960@=F]L871I;&ET>2!O9B`Q
M-#,E+"!A;F0@*#0I('IE<F\@97AP96-T960@9&EV:61E;F1S+CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[($1U<FEN9R`R,#`X+"!O<'1I;VYS
M('1O('!U<F-H87-E(#8Y+#DT,2!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=E
M<F4@9W)A;G1E9"!T;R!A;B!E;7!L;WEE92!A="!A;B!E>&5R8VES92!P<FEC
M92!O9B`D,"XY,"!P97(@<VAA<F4N(%1H97-E(&]P=&EO;G,@:&%V92!A('1E
M<FT@;V8@,3`@>65A<G,@86YD('9E<W0@;W9E<B!A(#0M-2!Y96%R('!E<FEO
M9"X@1F%I<B!V86QU92!O9B`D-#0L,34Y('=A<R!C86QC=6QA=&5D('5S:6YG
M('1H92!";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC:6YG(&UO9&5L+B!687)I
M86)L97,@=7-E9"!I;B!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN
M9R!M;V1E;"!I;F-L=61E("@Q*2!D:7-C;W5N="!R871E(&]F(#,N-#8E("@R
M*2!E>'!E8W1E9"!L:69E(&]F(#4@>65A<G,L("@S*2!E>'!E8W1E9"!V;VQA
M=&EL:71Y(&]F(#$S.24L(&%N9"`H-"D@>F5R;R!E>'!E8W1E9"!D:79I9&5N
M9',N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M;WEM96YT(&%N9"`Q,C@L,#4P(&]P=&EO;G,@=&\@;VYE(&5M<&QO>65E('=E
M<F4@9F]R9F5I=&5D(&%S('1H92!E;7!L;WEE92!D96-E87-E9"!D=7)I;F<@
M=&AE('EE87(N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/@T*/&1I
M=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@1'5R
M:6YG('1H92!Y96%R(&]F(#(P,3`L(&]P=&EO;G,@=&\@<'5R8VAA<V4@,S,L
M,S`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=V5R92!G<F%N=&5D('1O(&%N
M(&5M<&QO>65E(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+CDP('!E<B!S
M:&%R92X@5&AE<V4@;W!T:6]N<R!H879E(&$@=&5R;2!O9B`Q,"!Y96%R<R!A
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[($EN($9E8G)U87)Y(#(P,3(L('1H
M92!#;VUP86YY(')E+7!R:6-E9"`R-S,L.#4Y('5N:71S(&]F(&5M<&QO>65E
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R!$=7)I;F<@,C`Q
M,BP@;W!T:6]N<R!T;R!P=7)C:&%S92`R+#`U-BPR-S4@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!W97)E(&ES<W5E9"!T;R!S979E<F%L(&5M<&QO>65E<R!A
M;F0@8V]N<W5L=&%N=',@870@86X@97AE<F-I<V4@<')I8V4@<F%N9VEN9R!F
M<F]M("0P+C<X('1O("0Q+C4@<&5R('-H87)E+B8C,38P.R8C,38P.U1H97-E
M(&]P=&EO;G,@:&%V92!A('1E<FT@;V8@,3`@>65A<G,@86YD('9E<W0@;W9E
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M96%R<RP@*#,I(&5X<&5C=&5D('9O;&%T:6QI='D@;V8@,38P+C0T)2`F(S$R
M-CL@,38R+C0Y)2P@86YD("@T*2!Z97)O(&5X<&5C=&5D(&1I=FED96YD<RX\
M+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+V9O;G0^
M/"]D:78^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO9F]N=#X\+V1I
M=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R8C,38P.R8C,38P.R!4:&4@9F]L;&]W:6YG(&ES(&$@
M<W5M;6%R>2!O9B!S=&]C:R!O<'1I;VX@86-T:79I=&EE<R!F;W(@=&AE('EE
M87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q.CPO9F]N=#X\
M+V1I=CX-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1L
M969T/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y-24[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/E=E:6=H=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D%G9W)E9V%T93PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0T-R4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^3G5M8F5R(&]F/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY#;VYT<F%C='5A;#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P
M)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^26YT<FEN<VEC/"]F
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E1E<FT@*&EN('EE
M87)S*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY686QU93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#<E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z#0H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0T-R4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/=71S
M=&%N9&EN9RP@1&5C96UB97(@,S$L(#(P,3`\+V9O;G0^/"]D:78^#0H\+W1D
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P
M>"!S;VQI9#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T-R4@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#0W)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]U='-T86YD:6YG+"!$96-E
M;6)E<B`S,2P@,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C(W,RPX-3D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2XR.3PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI
M9#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT#0H@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXR+#`U-BPR-S4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XY-CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@-'!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]U='-T86YD:6YG+"!$96-E;6)E<B`S
M,2P@,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[)SX-"CQD:78@86QI9VX]
M,T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C(L,S,P+#$S-#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XY-CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N=`T*
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[
M)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LD/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX-"CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C8X-2PX
M,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M,S$L(#(P,3(@86YD(#(P,3$@=V5R92`D,2PY.3@L-#,U(&%N9"`D,30L-3(X
M+"!R97-P96-T:79E;'DN($1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB
M97(@,S$L(#(P,3(@86YD(#(P,3$L('1H92!#;VUP86YY(')E8V]R9&5D(&]P
M=&EO;B!E>'!E;G-E(&]F("0R-C8L,3<R(&%N9"`D,3DL.3,U+"!R97-P96-T
M:79E;'DN/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V
M,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q
M7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T
M,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY7
M87)R86YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY787)R86YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL
M:6YE.R<^3F]T92`Q,2`F(S@R,3$[(%=A<G)A;G1S/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@9&ES<&QA>3H@8FQO
M8VL[('1E>'0M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I
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M86=E;65N="!&:7)M(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C`Q('!E
M<B!S:&%R92X@5&AE<V4@=V%R<F%N=',@:&%V92!A('1E<FT@;V8@-R!Y96%R
M<R!A;F0@=F5S="!I;6UE9&EA=&5L>2X@1F%I<B!V86QU92!O9B`D,BPQ-3,L
M-#0R('=A<R!C86QC=6QA=&5D('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P
M=&EO;BUP<FEC:6YG(&UO9&5L+B!687)I86)L97,@=7-E9"!I;B!T:&4@0FQA
M8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"!I;F-L=61E("@Q*2!D
M:7-C;W5N="!R871E(')A;F=I;F<@9G)O;2`Q+CDR)2!T;R`S+C$W)2P@*#(I
M('=A<G)A;G0@;&EF92!O9B`Q,"!Y96%R<RP@*#,I(&5X<&5C=&5D('9O;&%T
M:6QI='D@<F%N9VEN9R!F<F]M(#8T+C<W)2!T;R`W,"XW,B4L(&%N9"`H-"D@
M>F5R;R!E>'!E8W1E9"!D:79I9&5N9',N(%1H92!M86YA9V5M96YT(&9I<FT@
M<F5C96EV97,@=V%R<F%N=',@97%U86P@=&\@=&5N("@Q,"4I('!E<F-E;G0@
M;V8@=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@8V%P:71A;"!S=&]C:R!O
M9B!T:&4@0V]M<&%N>2!O;B!A(&9U;&QY+61I;'5T960@8F%S:7,@;VX@=&AE
M(&5F9F5C=&EV92!D871E(&]F('1H92!A9W)E96UE;G0N)B,Q-C`[)B,Q-C`[
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M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`R-W!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO
M9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;BUL969T.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I
M9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&QE
M9G0^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E=A
M<G)A;G1S(&ES<W5E9"!W:71H(&-O;G9E<G1I8FQE(&YO=&5S("A3964@3F]T
M92`U*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^,C@W+#`V
M,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS
M1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X
M="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^5V%R<F%N=',@:7-S=65D('1O(&EN=F5S=&]R<R!W:71H(%-T;V-K
M($]F9F5R:6YG("A3964@3F]T92`Y*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P
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M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E!L86-E;65N="!A9V5N="!W
M87)R86YT<R!R96QA=&5D('1O(&ES<W5A;F-E(&]F.CPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R
M(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('=I9'1H/3-$.#@E
M('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT
M.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R8C,38P.R8C,38P.R8C,38P.T-O;G9E
M<G1I8FQE($YO=&5S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN
M9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXQ-#,L-3,R/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<B!B
M9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$.#@E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN
M9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M3=&]C:R!/9F9E<FEN9R`H4V5E
M($YO=&4@-B!A;F0@3F]T92`Y*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M#0H@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^.3@V+#,X,SPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O
M;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$.#@E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R<^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SY4
M;W1A;#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#1P>"!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`T<'@@9&]U8FQE.R<^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
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M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T
M<CX\+W1A8FQE/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L
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M9B`Q+#<Q-BPS-#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W97)E(&=R86YT
M960@=&\@=&AE($UA;F%G96UE;G0@1FER;2!A="!A;B!E>&5R8VES92!P<FEC
M92!O9B`D,"XP,2!P97(@<VAA<F4N(%1H97-E('=A<G)A;G1S(&AA=F4@82!T
M97)M(&]F(#<@>65A<G,@86YD('9E<W0@:6UM961I871E;'DN($9A:7(@=F%L
M=64@;V8@)#$L.34W+#<U-"!W87,@8V%L8W5L871E9"!U<VEN9R!T:&4@0FQA
M8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"X@5F%R:6%B;&5S('5S
M960@:6X@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96P@
M:6YC;'5D92`H,2D@9&ES8V]U;G0@<F%T92!O9B`Q+C@R)2P@*#(I('=A<G)A
M;G0@;&EF92!O9B`W('EE87)S+"`H,RD@97AP96-T960@=F]L871I;&ET>2!O
M9B`V,"XV-"4L(&%N9"`H-"D@>F5R;R!E>'!E8W1E9"!D:79I9&5N9',N)B,Q
M-C`[)B,Q-C`[4VEN8V4@=&AE<V4@=V%R<F%N=',@=F5S="!I;6UE9&EA=&5L
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M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)VUA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z
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M/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)VUA<F=I;BUL969T.B`R
M-W!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M
M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F=#X\=&%B
M;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^5V%R<F%N=',@
M:7-S=65D('1O(&EN=F5S=&]R<R!W:71H(%-T;V-K($]F9F5R:6YG("A3964@
M3F]T92`V*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO
M<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N
M/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
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M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[
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M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<B!B
M9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$.#@E
M('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT
M.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
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M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS
M1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X
M="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4W1O8VL@3V9F97)I;F<@
M*%-E92!.;W1E(#8@86YD($YO=&4@.2D\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G
M:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P
M<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L
M87DZ(&EN;&EN93LG/C$R,2PP.30\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0X."4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I;F<\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL
M93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/C0V-RPX-#4\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
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M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SY787)R86YT<R!I<W-U960@=&\@:6YV97-T
M;W)S('=I=&@@<W1O8VL@)B,X,C$Q.R!A8V-R=65D(&1I=FED96YD/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@
M<V]L:60[)SX\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T
M97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXQ.#`L,3$U)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[
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M;3H@-'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`T<'@@9&]U8FQE.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS
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M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO
M='(^/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT
M.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`R-W!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#LF(S$V,#L@5&AE(&9O;&QO=VEN9R!I<R!A('-U;6UA<GD@;V8@=V%R
M<F%N="!A8W1I=FET:65S(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@
M,S$L(#(P,3$@86YD(#(P,3(Z/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CQD:78@86QI9VX],T1L969T/CQT86)L92!S='EL93TS1"=W:61T:#H@
M,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@
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M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E=E:6=H=&5D/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.@T*(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T
M97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SY!=F5R86=E/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
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M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E=E:6=H=&5D/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^4F5M86EN:6YG/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^06=G
M<F5G871E/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/D%V97)A9V4\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SY#;VYT
M<F%C='5A;#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/DEN=')I;G-I8SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^56YI=',\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T#0H@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C
M;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^17AE<F-I<V4@4')I8V4\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E1E<FT@
M*&EN('EE87)S*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
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M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-3(E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/D]U='-T86YD:6YG+"!$96-E;6)E
M<B`S,2P@,C`Q,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E
M;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M+3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\
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M97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXM/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/BT\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXD/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^+3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T
M<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0U,B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[#0H@
M=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^1W)A;G1E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQD:78@86QI9VX],T1R
M:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N
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M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXP+C4Q
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD
M96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/C8N-S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#4R)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T
M<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0U,B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^3W5T<W1A;F1I;F<L($1E8V5M8F5R(#,Q
M+"`R,#$Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXU+#,V
M-"PU-3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P
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M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/C8N-S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
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M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY'<F%N=&5D/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C$N
M,S(\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI
M;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^,RXW-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-3(E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.@T*(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO
M='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0U,B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`T<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[
M('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/D]U='-T86YD:6YG+"!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B
M;&4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T
M<'@@9&]U8FQE.R<^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P
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M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXP+B`Y-SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXT+C0X/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN
M9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P>#LG/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
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M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\+V1I
M=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD
M96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF
M-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E
M,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E
M=#$X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M16UP;&]Y964@1&5F:6YE9"!#;VYT<FEB=71I;VX@4&QA;CQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE
M92!$969I;F5D($-O;G1R:6)U=&EO;B!0;&%N(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E
M($1E9FEN960@0V]N=')I8G5T:6]N(%!L86X\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^3F]T92`Q,B`F
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M96YT.B`S-G!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R8C,38P.R8C,38P.R!);B`R,#`T+"!T:&4@0V]M
M<&%N>2!E<W1A8FQI<VAE9"!A;B!E;7!L;WEE92!D969E<G)E9"!C;VYT<FEB
M=71I;VX@<&QA;BX@5&AE('!L86X@<F5Q=6ER97,@,3(@8V]N<V5C=71I=F4@
M;6]N=&AS(&]F('-E<G9I8V4@86YD(&$@;6EN:6UU;2!O9B`U,#`@:&]U<G,@
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M92!#;V1E(%-E8W1I;VX@-#`Q*&LI+B!4:&4@86UO=6YT(&-O;G1R:6)U=&5D
M(&)Y('1H92!#;VUP86YY(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@
M,S$L(#(P,3(@86YD(#(P,3$@=V%S("0X+#DT,B!A;F0@)#@L.#@U+"!R97-P
M96-T:79E;'DN/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?
M.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS
M:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=6)S97%U96YT($5V96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!E=F5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)SY.;W1E(#@@)B,X,C$Q.R!3=6)S97%U96YT($5V96YT<SPO9F]N=#X\
M+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`T-7!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^36%N86=E;65N="!H87,@
M979A;'5A=&5D('-U8G-E<75E;G0@979E;G1S(&%N9"!H87,@8V]N8VQU9&5D
M(&YO(&5V96YT<R!W87)R86YT(&1I<V-L;W-U<F4N/"]F;VYT/CPO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD
M96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M=V5I9VAT.B!B;VQD
M.R!D:7-P;&%Y.B!I;FQI;F4[)SY.;W1E(#$S("8C.#(Q,3L@4W5B<V5Q=65N
M="!%=F5N=',\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!B
M;&]C:SL@=&5X="UI;F1E;G0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#(W
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R8C,38P.R8C,38P.R!);B!&96)R=6%R>2`R."P@,C`Q,RP@=&AE($-O;7!A
M;GD@96YT97)E9"!I;G1O(&$@4V5P87)A=&EO;B!A;F0@4V5T=&QE;65N="!!
M9W)E96UE;G0@=VET:"!I=',@9F]R;65R($-%3RP@2F%C:R!486QL97DN(%!U
M<G-U86YT('1O('1H92!A9W)E96UE;G0L('1H92!#;VUP86YY('=I;&P@<&%Y
M($UR+B!486QL97D@:6X@,B!E<75A;"!I;G-T86QL;65N=',@=&AE(&%G9W)E
M9V%T92!A;6]U;G0@;V8@)#(U,"PP,#`@86YD(&$@<&5R9F]R;6%N8V4@8F]N
M=7,@;V8@)#8P+#`P,"!F;W(@:&ES('-E<G9I8V4@9G)O;2!!=6=U<W0@,34L
M(#(P,3(@=&\@1&5C96UB97(@,S$L(#(P,3(N(%1H92`D-C`L,#`P(&)O;G5S
M('=A<R!I;F-L=61E9"!I;B!T:&4@86-C;W5N=',@<&%Y86)L92!A;F0@86-C
M<G5E9"!L:6%B:6QI=&EE<R!O;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&)A;&%N
M8V4@<VAE970@870@1&5C96UB97(@,S$L(#(P,3(N/"]F;VYT/CPO9&EV/CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E
M;G0Z(#(W<'0[)SXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S
M93AF-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T
M-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3
M:&5E=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%54]!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O9B!3
M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE<RD\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D1E<V-R:7!T:6]N($]F($)U<VEN97-S(&%N9"!3=6UM
M87)Y($]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYA='5R92!O9B!"=7-I;F5S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^3F%T=7)E(&]F($)U<VEN97-S("8C
M.#(Q,3L\+V9O;G0^($%C=&EN:75M(%!H87)M86-E=71I8V%L<RP@26YC+B!F
M;W)M97)L>2!K;F]W;B!A<R!#86-T=7,@5F5N='5R97,L($EN8RX@*'1H92`F
M(S@R,C`[0V]M<&%N>28C.#(R,3LL("8C.#(R,#M!8W1I;FEU;28C.#(R,3LL
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M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M
M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M=6T@4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[05!))B,X,C(Q.RDL
M(&EN(&5X8VAA;F=E(&9O<B!T:&4@:7-S=6%N8V4@;V8@87!P<F]X:6UA=&5L
M>2`Y.24@;V8@=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@8V]M;6]N('-T
M;V-K+"!P87(@=F%L=64@)#`N,#$@<&5R('-H87)E+"!O9B!T:&4@0V]M<&%N
M>2X@5&AE(%-H87)E($5X8VAA;F=E(&-L;W-E9"!O;B!$96-E;6)E<B`R."P@
M,C`Q,BXF(S$V,#LF(S$V,#M!<R!A(')E<W5L="!O9B!T:&4@4VAA<F4@17AC
M:&%N9V4L('1H92!F;W)M97(@<VAA<F5H;VQD97)S(&]F($%022!B96-A;64@
M=&AE(&-O;G1R;VQL:6YG('-H87)E:&]L9&5R<R!O9B!T:&4@0V]M<&%N>2X@
M070@=&AE(&-L;W-I;F<L(&5A8V@@05!)('-H87)E:&]L9&5R(')E8V5I=F5D
M(#`N,S,S('-H87)E<R`H=&AE("8C.#(R,#M%>&-H86YG92!2871I;R8C.#(R
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M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[
M('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
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M<F%T960@;VX@2G5N92`Q,RP@,C`P,"P@:7,@82!B:6]T96-H;F]L;V=Y(&-O
M;7!A;GD@8V]M;6ET=&5D('1O(&1E=F5L;W!I;F<@8G)E86MT:')O=6=H('1H
M97)A<&EE<R!F;W(@;&EF92!T:')E871E;FEN9R!D:7-E87-E<R!U<VEN9R!I
M=',@86QP:&$@<&%R=&EC;&4@:6UM=6YO=&AE<F%P>2`H05!)5"D@<&QA=&9O
M<FT@86YD(&]T:&5R(')E;&%T960@86YD('-I;6EL87(@=&5C:&YO;&]G:65S
M+B!!4$DL('1O9V5T:&5R('=I=&@@:71S('=H;VQL>2!O=VYE9"!S=6)S:61I
M87)Y+"!-961!8W1I;FEU;2P@26YC+B`H34%)*2P@*&AE<F5I;F%F=&5R(')E
M9F5R<F5D('1O(&-O;&QE8W1I=F5L>2!A<R`F(S@R,C`[05!))B,X,C(Q.RD@
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M;BX@26X@,C`Q,BP@05!)(&QA=6YC:&5D(&$@;75L=&DM8V5N=&5R(&-O<G!O
M<F%T92!S<&]N<V]R960@=')I86P@:6X@86-U=&4@;7EE;&]I9"!L975K96UI
M82`H04U,*2!P871I96YT<RX@05!))B,X,C$W.W,@;V)J96-T:79E+"!T:')O
M=6=H(')E<V5A<F-H(&%N9"!D979E;&]P;65N="P@:7,@=&\@<')O9'5C92!R
M96QI86)L92!C86YC97(@9FEG:'1I;F<@<')O9'5C=',@=VAI8V@@=71I;&EZ
M92!M;VYO8VQO;F%L(&%N=&EB;V1I97,@;&EN:V5D('=I=&@@86QP:&$@<&%R
M=&EC;&4@96UI='1E<G,@;W(@;W1H97(@87!P<F]P<FEA=&4@<&%Y;&]A9',@
M=&\@<')O=FED92!V97)Y('!O=&5N="!T87)G971E9"!T:&5R87!I97,N(%1H
M92!I;FET:6%L(&-L:6YI8V%L('1R:6%L<R!O9B!!4$DF(S@R,3<[<R!C;VUP
M;W5N9',@:&%V92!B965N('=I=&@@<&%T:65N=',@:&%V:6YG(&%C=71E(&UY
M96QO:60@;&5U:V5M:6$@86YD(&ET(&ES(&)E;&EE=F5D('1H870@05!))B,X
M,C$W.W,@05!)5"!P;&%T9F]R;2!W:6QL(&AA=F4@=VED97(@87!P;&EC86)I
M;&ET>2!F;W(@9&EF9F5R96YT('1Y<&5S(&]F(&-A;F-E<B!W:&5R92!S=6ET
M86)L92!M;VYO8VQO;F%L(&%N=&EB;V1I97,@8V%N(&)E(&9O=6YD+CPO9F]N
M=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@.7!T.R<^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R!!<R!A(')E
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M97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/CQF;VYT('-T>6QE
M/3-$)VQE='1E<BUS<&%C:6YG.B`Y<'0[)SXF(S$V,#LF(S$V,#LF(S$V,#L\
M+V9O;G0^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[($]N($UA<F-H(#(P+"`R
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M<G!O<F%T:6]N+B8C,38P.R8C,38P.T]N($%P<FEL(#$Q+"`R,#$S+"!T:&4@
M0V]M<&%N>2!C:&%N9V5D(&ET<R!D;VUI8VEL92!F<F]M('1H92!3=&%T92!O
M9B!.979A9&$@=&\@=&AE(%-T871E(&]F($1E;&%W87)E(&%N9"!C:&%N9V5D
M(&ET<R!N86UE(&9R;VT@0V%C='5S(%9E;G1U<F5S+"!);F,N('1O($%C=&EN
M:75M(%!H87)M86-E=71I8V%L<RP@26YC+CPO9F]N=#X\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E
M;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG/DYA='5R92!O9B!"
M=7-I;F5S<R`F(S@R,3$[($%C=&EN:75M(%!H87)M86-E=71I8V%L<RP@26YC
M("A&;W)M97)L>3PO9F]N=#X@0V%C='5S(%9E;G1U<F5S+"!);F,N*2`H=&AE
M("8C.#(R,#M#;VUP86YY)B,X,C(Q.RP@)B,X,C(P.T-A8W1U<R8C.#(R,3LI
M+"!W87,@:6YC;W)P;W)A=&5D('5N9&5R('1H92!L87=S(&]F('1H92!3=&%T
M92!O9B!.979A9&$@;VX@3V-T;V)E<B`V+"`Q.3DW+B!4:&4@0V]M<&%N>2!W
M87,@82!S:&5L;"!E;G1I='D@=&AA="!I<R!I;B!T:&4@;6%R:V5T(&9O<B!A
M(&UE<F=E<B!W:71H(&%N(&%P<')O<')I871E(&]P97)A=&EN9R!C;VUP86YY
M+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN+6QE
M9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T
M97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[($]N($1E8V5M8F5R(#(X+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@82!T<F%N<V%C=&EO;B`H=&AE("8C.#(R,#M3:&%R92!%>&-H86YG
M928C.#(R,3LI+"!P=7)S=6%N="!T;R!W:&EC:"!T:&4@0V]M<&%N>2!A9W)E
M960@=&\@86-Q=6ER92`Q,#`E(&]F('1H92!I<W-U960@86YD(&]U='-T86YD
M:6YG(&5Q=6ET>2!S96-U<FET:65S(&]F($%C=&EN:75M(%!H87)M86-E=71I
M8V%L<RP@26YC+B`H)B,X,C(P.T%C=&EN:75M)B,X,C(Q.RDL(&EN(&5X8VAA
M;F=E(&9O<B!T:&4@:7-S=6%N8V4@;V8@87!P<F]X:6UA=&5L>2`Y.24@;V8@
M=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@8V]M;6]N('-T;V-K+"!P87(@
M=F%L=64@)#`N,#$@<&5R('-H87)E+"!O9B!T:&4@0V]M<&%N>2X@5&AE(%-H
M87)E($5X8VAA;F=E('=A<R!C;&]S960@;VX@1&5C96UB97(@,C@L(#(P,3(@
M=VAE;B!S:&%R96AO;&1E<G,@<F5P<F5S96YT:6YG(&]V97(@,C`E(&]F('1H
M92!I<W-U960@86YD(&]U='-T86YD:6YG('-H87)E<R!O9B!!8W1I;FEU;2!H
M860@9FEN:7-H960@=&AE(&5X8VAA;F=E('!R;V-E<W,N)B,Q-C`[)B,Q-C`[
M3VX@075G=7-T(#(R+"`R,#$S+"!S:&%R96AO;&1E<G,@<F5P<F5S96YT:6YG
M(#,X)2!O9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!S:&%R97,@;V8@
M06-T:6YI=6T@8V]M<&QE=&5D('1H92!E>&-H86YG92XF(S$V,#LF(S$V,#M!
M<R!A(')E<W5L="!O9B!T:&4@4VAA<F4@17AC:&%N9V4L('1H92!F;W)M97(@
M<VAA<F5H;VQD97)S(&]F($%C=&EN:75M(&)E8V%M92!T:&4@8V]N=')O;&QI
M;F<@<VAA<F5H;VQD97)S(&]F('1H92!#;VUP86YY+B!!="!T:&4@8VQO<VEN
M9RP@96%C:"!!8W1I;FEU;2!S:&%R96AO;&1E<B!S:&%L;"!R96-E:79E(#`N
M,S,S('-H87)E<R`H=&AE("8C.#(R,#M%>&-H86YG92!2871I;R8C.#(R,3LI
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M;VUM;VX@<W1O8VLN)B,Q-C`[)B,Q-C`[5&AE(%-H87)E($5X8VAA;F=E('=A
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M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#LF(S$V,#LF(S$V,#L\+V9O
M;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT
M.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG
M.B`Y<'0[)SXF(S$V,#LF(S$V,#LF(S$V,#L\+V9O;G0^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[($%C=&EN:75M+"!I;F-O<G!O<F%T960@;VX@2G5N92`Q
M,RP@,C`P,"P@:7,@82!B:6]T96-H;F]L;V=Y(&-O;7!A;GD@8V]M;6ET=&5D
M('1O(&1E=F5L;W!I;F<@8G)E86MT:')O=6=H('1H97)A<&EE<R!F;W(@;&EF
M92!T:')E871E;FEN9R!D:7-E87-E<R!U<VEN9R!I=',@86QP:&$@<&%R=&EC
M;&4@:6UM=6YO=&AE<F%P>2`H05!)5"D@<&QA=&9O<FT@86YD(&]T:&5R(')E
M;&%T960@86YD('-I;6EL87(@=&5C:&YO;&]G:65S+B!!8W1I;FEU;2P@=&]G
M971H97(@=VET:"!I=',@=VAO;&QY(&]W;F5D('-U8G-I9&EA<GDL($UE9$%C
M=&EN:75M+"!);F,N("A-04DI+"`H:&5R96EN869T97(@<F5F97)R960@=&\@
M8V]L;&5C=&EV96QY(&%S("8C.#(R,#M!8W1I;FEU;28C.#(R,3LI(&AA<R!I
M;FET:6%T960@8V]L;&%B;W)A=&EV92!E9F9O<G1S('=I=&@@;&%R9V4@:6YS
M=&ET=71I;VYS('1O(&5S=&%B;&ES:"!T:&4@<')O;V8@;V8@8V]N8V5P="!O
M9B!A;'!H82!P87)T:6-L92!I;6UU;F]T:&5R87!Y(&%N9"!H87,@<W5P<&]R
M=&5D(&]N92!0:&%S92!)+TEL(&-L:6YI8V%L('1R:6%L(&%N9"!O;F4@4&AA
M<V4@22!C;&EN:6-A;"!T<FEA;"!A="!-96UO<FEA;"!3;&]A;BU+971T97)I
M;F<@0V%N8V5R($-E;G1E<B`H35-+0T,I('5N9&5R(&%N($U32T-#(%!H>7-I
M8VEA;B!);G9E<W1I9V%T:6]N86P@3F5W($1R=6<@07!P;&EC871I;VXN($EN
M(#(P,3(L($%C=&EN:75M(&QA=6YC:&5D(&$@;75L=&DM8V5N=&5R(&-O<G!O
M<F%T92!S<&]N<V]R960@=')I86P@:6X@86-U=&4@;7EE;&]I9"!L975K96UI
M82`H04U,*2!P871I96YT<RX@)B,Q-C`[06-T:6YI=6TF(S@R,3<[<R!O8FIE
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M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN
M9SH@.7!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/B8C,38P.R8C,38P
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M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT
M871I;VX@+2!5;F%U9&ET960@26YT97)I;2!&:6YA;F-I86P@26YF;W)M871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQF;VYT
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M*"8C.#(R,#M5+E,N($=!05`F(S@R,C$[*2!F;W(@:6YT97)I;2!F:6YA;F-I
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M;6%N86=E;65N="P@;F5C97-S87)Y)B,Q-C`[9F]R(&$@9F%I<B!S=&%T96UE
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M92!#;VUP86YY(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,B!A;F0@;F]T97,@=&AE<F5T;R!C;VYT86EN960@:6X@=&AE($-O;7!A;GDF
M(S@R,3<[<R!A;FYU86P@<F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE
M87(@96YD960@1&5C96UB97(@,S$L(#(P,3(L(&%S(&9I;&5D('=I=&@@=&AE
M(%-%0R!-87)C:"`R.2P@,C`Q,RX\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5V96QO<&UE
M;G0@4W1A9V4@0V]M<&%N>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P
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M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<#X\<W1R;VYG/CQF;VYT('-I>F4],T0R/D1E=F5L;W!M96YT
M(%-T86=E($-O;7!A;GD@)B,X,C$Q.SPO9F]N=#X\+W-T<F]N9SXF(S$V,#M4
M:&4@0V]M<&%N>2!I<R!C;VYS:61E<F5D(&$@9&5V96QO<&UE;G0@<W1A9V4@
M8V]M<&%N>2!A;F0@:&%S(&AA9"!N;R!C;VUM97)C:6%L(')E=F5N=64@=&\@
M9&%T92X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<FEN8VEP;&5S(&]F($-O;G-O;&ED871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQF;VYT('-T>6QE/3-$
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M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&IU<W1I
M9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[('=O<F0M<W!A8VEN9SH@
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M/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^57-E(&]F($5S=&EM871E<R!I;B!&:6YA;F-I86P@
M4W1A=&5M96YT(%!R97-E;G1A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA
M>3H@:6YL:6YE.R<^57-E(&]F($5S=&EM871E<R!I;B!&:6YA;F-I86P@4W1A
M=&5M96YT(%!R97-E;G1A=&EO;B`F(S@R,3$[/"]F;VYT/B!4:&4@<')E<&%R
M871I;VX@;V8@=&AE<V4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(&EN(&-O;F9O<FUI='D@=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,@
M9V5N97)A;&QY(&%C8V5P=&5D(&EN('1H92!5;FET960@4W1A=&5S(&]F($%M
M97)I8V$@<F5Q=6ER97,@;6%N86=E;65N="!T;R!M86ME(&5S=&EM871E<R!A
M;F0@87-S=6UP=&EO;G,@=&AA="!A9F9E8W0@=&AE(')E<&]R=&5D(&%M;W5N
M=',@;V8@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A="!T:&4@9&%T92!O9B!T
M:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!T:&4@
M<F5P;W)T960@86UO=6YT<R!O9B!R979E;G5E<R!A;F0@97AP96YS97,@9'5R
M:6YG('1H92!R97!O<G1I;F<@<&5R:6]D+B!!8W1U86P@<F5S=6QT<R!C;W5L
M9"!D:69F97(@9G)O;2!T:&]S92!E<W1I;6%T97,N/"]F;VYT/CPO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
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M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8VQA<W-I9FEC
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQF
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M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M("8C.#(Q,3L\+V9O;G0^)B,Q-C`[0V5R=&%I;B!P<FEO<B!P97)I;V0@86UO
M=6YT<R!H879E(&)E96X@<F5C;&%S<VEF:65D('1O(&-O;F9O<FT@=&\@8W5R
M<F5N="!P97)I;V0@<')E<V5N=&%T:6]N+CPO9F]N=#X\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@
M86YD($-A<V@@17%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ
M(&EN;&EN93LG/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',@)B,X,C$Q.SPO
M9F]N=#X@5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!H:6=H;'D@;&EQ=6ED
M(&%C8V]U;G1S('=I=&@@;W)I9VEN86P@;6%T=7)I=&EE<R!O9B!T:')E92!M
M;VYT:',@;W(@;&5S<R!T;R!B92!C87-H(&5Q=6EV86QE;G1S+B!3=6-H(&)A
M;&%N8V5S(&%R92!U<W5A;&QY(&EN(&5X8V5S<R!O9B!&1$E#(&EN<W5R960@
M;&EM:71S+B!!="!*=6YE(#,P+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@,C`Q
M,BP@86QL(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V%S:"!W87,@9&5P;W-I
M=&5D(&EN(&]N92!B86YK+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX\9F]N="!S='EL
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M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
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M;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
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M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
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M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$97)I=F%T:79E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN+6QE9G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT
M+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L
M87DZ(&EN;&EN93LG/D1E<FEV871I=F5S("8C.#(Q,3L\+V9O;G0^($%L;"!D
M97)I=F%T:79E<R!A<F4@<F5C;W)D960@870@9F%I<B!V86QU92!O;B!T:&4@
M8F%L86YC92!S:&5E="X@1F%I<B!V86QU97,@9F]R('-E8W5R:71I97,@=')A
M9&5D(&EN('1H92!O<&5N(&UA<FME="!A;F0@9&5R:79A=&EV97,@87)E(&)A
M<V5D(&]N('%U;W1E9"!M87)K970@<')I8V5S+B!7:&5R92!M87)K970@<')I
M8V5S(&%R92!N;W0@<F5A9&EL>2!A=F%I;&%B;&4L(&9A:7(@=F%L=65S(&%R
M92!D971E<FUI;F5D('5S:6YG(&UA<FME="!B87-E9"!P<FEC:6YG(&UO9&5L
M<R!I;F-O<G!O<F%T:6YG(')E861I;'D@;V)S97)V86)L92!M87)K970@9&%T
M82!A;F0@<F5Q=6ER:6YG(&IU9&=M96YT(&%N9"!E<W1I;6%T97,N/"]F;VYT
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!686QU92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG
M/B!&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<R`F(S@R,3$[
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M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SY,979E;"`Q($EN<'5T<R`F(S@R,3$[
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M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/DQE=F5L(#(@26YP=71S("8C.#(Q,3L@
M26YP=71S(&]T:&5R('1H86X@<75O=&5D('!R:6-E<R!I;F-L=61E9"!I;B!,
M979E;"`Q('1H870@87)E(&]B<V5R=F%B;&4@9F]R('1H92!A<W-E="!O<B!L
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M97AT+6EN9&5N=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[
M)SX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M
M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
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M;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P
M<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS
M1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I
M9VAT.B`P<'0[('1E>'0M:6YD96YT.B`T-7!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SY4:&4@9F]L;&]W:6YG('1A8FQE<R!S970@
M9F]R=&@@87-S971S(&%N9"!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER
M('9A;'5E(&]N(&$@<F5C=7)R:6YG(&%N9"!N;VXM<F5C=7)R:6YG(&)A<VES
M(&)Y(&QE=F5L('=I=&AI;B!T:&4@9F%I<B!V86QU92!H:65R87)C:'D@87,@
M;V8@2G5N92`S,"P@,C`Q,R!A;F0@1&5C96UB97(@,S$N($%S(')E<75I<F5D
M(&)Y($%30R`X,C`L(&9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S
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M+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV
M(&%L:6=N/3-$;&5F=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^3&5V96P@,3PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS
M<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^3&5V96P@,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^3&5V96P@,SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N
M/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X
M="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^5&]T86P\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
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M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(]
M,T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I
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M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
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M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@
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M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-3(E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R8C,38P.T%T($IU;F4@
M,S`L(#(P,3,\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^+3PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/BT\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
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M9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXR+#DU-RPY-S<\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
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M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXR+#DU-RPY-S<\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0U,B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[
M070@1&5C96UB97(@,S$L(#(P,3(\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0-"B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXM/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^+3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/C,L-3<T+#DU.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G
M:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P
M<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L
M87DZ(&EN;&EN93LG/C,L-3<T+#DU.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P
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M<R`F(S@R,3$[/"]F;VYT/B!&86ER('9A;'5E(&ES(&1E9FEN960@87,@=&AE
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M;V-K.R!T97AT+6EN9&5N=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM;&5F=#H@,S9P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SY,
M979E;"`Q($EN<'5T<R`F(S@R,3$[(%5N861J=7-T960@<75O=&5D('!R:6-E
M<R!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L
M:6%B:6QI=&EE<R!T:&%T('1H92!R97!O<G1I;F<@96YT:71Y(&AA<R!T:&4@
M86)I;&ET>2!T;R!A8V-E<W,@870@=&AE(&UE87-U<F5M96YT(&1A=&4N/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@8FQO8VL[('1E>'0M
M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=M87)G:6XM;&5F=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SY,979E;"`R($EN<'5T<R`F
M(S@R,3$[($EN<'5T<R!O=&AE<B!T:&%N('%U;W1E9"!P<FEC97,@:6YC;'5D
M960@:6X@3&5V96P@,2!T:&%T(&%R92!O8G-E<G9A8FQE(&9O<B!T:&4@87-S
M970@;W(@;&EA8FEL:71Y+"!E:71H97(@9&ER96-T;'D@;W(@:6YD:7)E8W1L
M>2X@5&AE<V4@;6EG:'0@:6YC;'5D92!Q=6]T960@<')I8V5S(&9O<B!S:6UI
M;&%R(&%S<V5T<R!O<B!L:6%B:6QI=&EE<R!I;B!A8W1I=F4@;6%R:V5T<RP@
M<75O=&5D('!R:6-E<R!F;W(@:61E;G1I8V%L(&]R('-I;6EL87(@87-S971S
M(&]R(&QI86)I;&ET:65S(&EN(&UA<FME=',@=&AA="!A<F4@;F]T(&%C=&EV
M92P@:6YP=71S(&]T:&5R('1H86X@<75O=&5D('!R:6-E<R!T:&%T(&%R92!O
M8G-E<G9A8FQE(&9O<B!T:&4@87-S970@;W(@;&EA8FEL:71Y("AS=6-H(&%S
M(&EN=&5R97-T(')A=&5S+"!V;VQA=&EL:71I97,L('!R97!A>6UE;G0@<W!E
M961S+"!C<F5D:70@<FES:W,L(&5T8RXI(&]R(&EN<'5T<R!T:&%T(&%R92!D
M97)I=F5D('!R:6YC:7!A;&QY(&9R;VT@;W(@8V]R<F]B;W)A=&5D(&)Y(&UA
M<FME="!D871A(&)Y(&-O<G)E;&%T:6]N(&]R(&]T:&5R(&UE86YS+CPO9F]N
M=#X\+V1I=CX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&)L;V-K.R!T97AT+6EN
M9&5N=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@
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M=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y
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M(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q+B!!<R!R97%U:7)E
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M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!A
M;&EG;CTS1&QE9G0^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/DQE=F5L(#$\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A
M;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/DQE=F5L(#(\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/DQE=F5L(#,\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS
M1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M
M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/E1O=&%L/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.PT*(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/D1E<FEV871I=F4@;&EA8FEL:71I97,Z
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
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M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$
M(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$-3(E('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R8C,38P.T%T($1E8V5M8F5R(#,Q+"`R,#$R/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXM/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/BT\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
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M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
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M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/C,L-3<T+#DU.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T
M<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0U,B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[)B,Q-C`[070@1&5C96UB97(@
M,S$L(#(P,3$\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/BT\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24-"B!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXM
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C0L
M-#,Y+#8Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT
M+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXT+#0S.2PV,3,\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^
M/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&)L;V-K.R!T
M97AT+6EN9&5N=#H@,'!T.R<^)B,Q-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/CQF;VYT('-T
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG
M/DEN8V]M92!487AE<R`F(S@R,3$[/"]F;VYT/B!4:&4@0V]M<&%N>2!U<V5S
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M;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@0V]S=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L87DZ(&EN;&EN93LG/E)E
M<V5A<F-H(&%N9"!$979E;&]P;65N="!#;W-T<R`F(S@R,3$[/"]F;VYT/B!2
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M<W1I9GD[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
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M="!C;W-T<RX\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92U"87-E9"!087EM96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
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M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
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M+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5A<FYI;F=S("A,;W-S*2!097(@0V]M;6]N(%-H
M87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX\9F]N
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M97)I;V0@<')E<V5N=&5D+B!"87-I8R!E87)N:6YG<R`H;&]S<RD@<&5R(&-O
M;6UO;B!S:&%R92!I<R!C;VUP=71E9"!B>2!D:79I9&EN9R!T:&4@;F5T(&EN
M8V]M92`H;&]S<RD@879A:6QA8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@
M8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R
M97,@;W5T<W1A;F1I;F<@9'5R:6YG('1H92!R97!O<G1I;F<@<&5R:6]D+B!$
M:6QU=&5D(&5A<FYI;F=S('!E<B!C;VUM;VX@<VAA<F4@:7,@8V]M<'5T960@
M8GD@9&EV:61I;F<@=&AE(&YE="!I;F-O;64@879A:6QA8FQE('1O(&-O;6UO
M;B!S=&]C:VAO;&1E<G,F(S$V,#MB>2!T:&4@=V5I9VAT960@879E<F%G92!N
M=6UB97(@;V8@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9R!P;'5S(&1I;'5T
M:79E('-E8W5R:71I97,N(%-I;F-E('1H92!#;VUP86YY(&AA<R!O;FQY(&EN
M8W5R<F5D(&QO<W-E<RP@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R
M(&-O;6UO;B!S:&%R92!A<F4@=&AE('-A;64N("8C,38P.U1H92!P;W1E;G1I
M86QL>2!D:6QU=&EV92!S96-U<FET:65S("AO<'1I;VYS+"!W87)R86YT<R!A
M;F0@8V]N=F5R=&EB;&4@:6YS=')U;65N=',I('=E<F4@97AC;'5D960@9G)O
M;2!T:&4@9&EL=71E9"!L;W-S('!E<B!C;VUM;VX@<VAA<F4@8V%L8W5L871I
M;VX@8F5C875S92!T:&5I<B!E9F9E8W0@=V]U;&0@:&%V92!B965N(&%N=&ED
M:6QU=&EV92X@1F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P
M,3,L('!O=&5N=&EA;&QY(&ES<W5A8FQE('-H87)E<R!I;F-L=61E9"!S=&]C
M:R!O<'1I;VYS('1O('!U<F-H87-E(#(L,C@P+#$X-"!S:&%R97,@86YD('=A
M<G)A;G1S('1O('!U<F-H87-E(#DL-3,U+#8Y-"!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN($9O<B!T:&4@<VEX(&UO;G1H
M<R!E;F1E9"!*=6YE(#,P+"`R,#$R+"!P;W1E;G1I86QL>2!I<W-U86)L92!S
M:&%R97,@:6YC;'5D97,@;W!T:6]N<R!A;F0@=V%R<F%N=',F(S$V,#MT;R!P
M=7)C:&%S92`V+#@T,BPU,C@@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]M;6]N('-T;V-K(&%N9"!N;W1E<R!P87EA8FQE(&-O;G9E<G1I8FQE
M('1O(#@Q-2PR-S4@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M
M;6]N('-T;V-K(&AA=F4@8F5E;B!E>&-L=61E9"!F<F]M('1H92!C86QC=6QA
M=&EO;BX\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
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M;VUE(&%V86EL86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S)B,Q-C`[8GD@
M=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@
M;W5T<W1A;F1I;F<@<&QU<R!D:6QU=&EV92!S96-U<FET:65S+B!3:6YC92!T
M:&4@0V]M<&%N>2!H87,@;VYL>2!I;F-U<G)E9"!L;W-S97,L(&)A<VEC(&%N
M9"!D:6QU=&5D(&YE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@87)E('1H92!S
M86UE+B`F(S$V,#M4:&4@<&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE
M<R`H;W!T:6]N<RP@=V%R<F%N=',@86YD(&-O;G9E<G1I8FQE(&EN<W1R=6UE
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5N
M="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=CX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/CQF;VYT('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!D
M:7-P;&%Y.B!I;FQI;F4[)SY296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M
M96YT<R`F(S@R,3$[/"]F;VYT/B!4:&4@0V]M<&%N>2!D;V5S(&YO="!E>'!E
M8W0@=&AA="!A;GD@<F5C96YT;'D@:7-S=65D(&%C8V]U;G1I;F<@<')O;F]U
M;F-E;65N=',@=VEL;"!H879E(&$@<VEG;FEF:6-A;G0@:6UP86-T(&]N('1H
M92!R97-U;'1S(&]F(&]P97)A=&EO;G,L(&9I;F%N8VEA;"!P;W-I=&EO;BP@
M;W(@8V%S:"!F;&]W<R!O9B!T:&4@0V]M<&%N>2X\+V9O;G0^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'0[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@9&ES<&QA>3H@8FQO8VL[('=H:71E+7-P
M86-E.B!N;W)M86P[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
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M+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
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M;BX\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQP/CQS=')O;F<^/&9O;G0@<VEZ93TS1#(^4W5B
M<V5Q=65N="!%=F5N=',@)B,X,C$Q.SPO9F]N=#X\+W-T<F]N9SXF(S$V,#M4
M:&4@0V]M<&%N>28C.#(Q-SMS(&UA;F%G96UE;G0@<F5V:65W960@86QL(&UA
M=&5R:6%L(&5V96YT<R!F<F]M($IA;G5A<GD@,2P@,C`Q,R!T:')O=6=H($UA
M<F-H(#$U+"`R,#$S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S
M9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E,5]F
M-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E=#(Q
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%4T<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5S
M8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A
M;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1&5S8W)I<'1I;VX@3V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@3V8@4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R
M>2!O9B!S970@9F]R=&@@87-S971S(&%N9"!L:6%B:6QI=&EE<R!M96%S=7)E
M9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&%N9"!N;VXM<F5C=7)R
M:6YG(&)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#0R)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI
M9#LG(&-O;'-P86X],T0S/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^3&5V96P@,CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3$E('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)R!C;VQS<&%N/3-$,SX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`S/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG
M(&-O;'-P86X],T0S/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^1&5R:79A=&EV92!L:6%B
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#0R)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R8C,38P.T%T(%-E<'1E;6)E<B`S,"P@,C`Q,SPO9F]N=#X\+V1I=CX-"CPO
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M/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L
M;W(],T0C9F9F9F9F/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#0R)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P.T%T($1E8V5M8F5R(#,Q+"`R
M,#$R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
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M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,RPU-S0L.34X/"]F;VYT/CPO
M=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,RPU-S0L
M.34X/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL
M93TS1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#0R)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5V96P@,CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-
M"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY,979E;"`S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0T,B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[)B,Q-C`[070@1&5C96UB97(@,S$L(#(P,3(\+V9O;G0^/"]D
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C,L-3<T+#DU.#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
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M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,RPU-S0L.34X/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R8C,38P.T%T($1E8V5M8F5R(#,Q+"`R,#$Q/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C0L-#,Y+#8Q,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E
M,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V
M,C-D-6(W+U=O<FMS:&5E=',O4VAE970R,BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I
M;VYS("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-U;6UA<GD@;V8@86-T:79I=&EE<R!R96QA=&5D('1O(')E;&%T
M960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\=&%B
M;&4@<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C
M;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@=VED=&@],T0Q
M,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#)P>"!S;VQI9#LG(&-O;'-P86X],T0R/@T*/&1I=B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C8U-2PW.#8\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4F5I;6)U<G-E;65N
M=',@<F5C96EV960@9G)O;2!-4TM#0SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^.38V+#,T
M,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B
M;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P
M964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?
M,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970R,RYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M15-'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%
M<75I<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@<')O<&5R='D@86YD(&5Q
M=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQT86)L
M92!S='EL93TS1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#4W)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG
M/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$
M,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0U-R4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LU('EE87)S/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C$V,BPS.#0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-3<E('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^1G5R;FET=7)E(&%N9"!F:7AT=7)E/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#LW('EE87)S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^,RPQ,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2PR.3(\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^#0H\=&0@86QI9VX],T1L969T#0H@=VED=&@],T0U-R4@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-3<E('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^5&]T86P@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-3<E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@Q
M-30L-#0T/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,34T+#0T-#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&]S<R!O;B!D:7-P;W-I=&EO;B!O
M9B!E<75I<&UE;G0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^*#0L,3(R/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXM/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0-"B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
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M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV+#DQ.#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQT86)L92!S='EL93TS1"=W:61T:#H@.3`E.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#4V)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I
M9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#M,:79E<SPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A
M;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U-B4@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/D]F9FEC92!E<75I<&UE;G0\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C$U,RPX,#0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-38E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D9U<FYI='5R92!A;F0@9FEX='5R
M93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@],T0Q,"4@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD
M:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#LW('EE87)S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI
M9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@
M<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.PT*(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#(Y,CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-38E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-38E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&]T86P@<')O<&5R='DL
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,34U+#`Y-CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0U-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^3&5S<SH@86-C=6UU;&%T960@9&5P<F5C:6%T:6]N
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q,"4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B@Q-3,L.#8S/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<-"B!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U-B4@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4')O<&5R='D@86YD
M(&5Q=6EP;65N=#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXS+#`Q,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$L
M,C,S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D
M7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W
M+U=O<FMS:&5E=',O4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DYO=&4@4&%Y86)L92!A;F0@0V]N=F5R=&EB;&4@
M3F]T97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3F]T92!087EA8FQE(&%N9"!#;VYV97)T:6)L
M92!.;W1E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F('-E;FEO<B!S=6)O<F1I;F%T
M960@=6YS96-U<F5D(&-O;G9E<G1I8FQE('!R;VUI<W-O<GD@;F]T97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^
M#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@
M.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8V)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L
M<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4')I;F-I
M<&%L(&%M;W5N=#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXY,#`L,#`P/"]F;VYT/CPO9&EV/@T*
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXY,#`L,#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^*#$U,"PP,#`\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B@Q-3`L,#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^*#,W-RPQ-3`\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B@S-S<L,34P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^061D.B!A
M;6]R=&EZ871I;VX@;V8@9&ES8V]U;G0\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXY,#`L,#`P/"]F;VYT/CPO9&EV/@T*
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M-C8E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/DQE<W,Z('!R:6YC:7!A;"!A;6]U;G0@8V]N=F5R=&5D('1O('-T
M;V-K/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@Y,#`L,#`P/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/@T*
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L-"B`\+V9O;G0^/"]T9#X-"CQT
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY#87)R>6EN9R!V86QU92!A="!$96-E;6)E<B`S,2P@,C`Q,B!A
M;F0@,C`Q,2P@<F5S<&5C=&EV96QY/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
M8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B
M;&4^#0H\+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y
M7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K
M<VAE971S+U-H965T,C4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5404%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D1E<FEV871I=F5S("A486)L97,I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$97)I=F%T:79E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@9&5R:79A
M=&EV92!W87)R86YT(&EN<W1R=6UE;G1S(&%C=&EV:71Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\
M9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.3`E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8V)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
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M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E5N:71S/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D)A
M;&%N8V4L($1E8V5M8F5R(#,Q+"`R,#$R/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-2PQ-#8L,S,X/"]F;VYT/CPO9&EV
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4F5C;&%S<VEF:6-A=&EO
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,RPQ,S`L-3,V/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B@V,#`L.#@P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0VAA;F=E
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/BD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B
M9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V
M-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY"86QA;F-E+"!397!T96UB97(@,S`L(#(P,3,\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T
M<'@@9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXR+#`Q-2PX,#(\+V9O;G0^/"]D:78^#0H\+W1D/@T*
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M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T
M<'@@9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0-"B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C(L-S4W+#DV-CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^)B,Q-C`[/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#8V)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D)A;&%N8V4L($1E8V5M8F5R(#,Q+"`R
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/E=A<G)A;G1S(&ES<W5E9"!W:71H($-O;G9E<G1I8FQE($YO=&5S
M("A3964@3F]T92`U*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,C@W+#`V,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/E!L86-E;65N="!A9V5N="!W87)R86YT<R!R96QA=&5D('1O
M(&ES<W5A;F-E(&]F($-O;G9E<G1I8FQE($YO=&5S("A3964@3F]T92`U*3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.@T*(#$P<'0[)SXQ
M-#,L-3,R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C$X."PU-SD\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5V%R
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,BPU.3$L.3`P/"]F;VYT/CPO9&EV/@T*/"]T
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/E!L86-E;65N="!A9V5N="!W87)R86YT<R!R96QA=&5D('1O(&ES<W5A;F-E
M(&]F('-T;V-K("A3964@3F]T92`Y*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^.3@V+#,Y,SPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#(Y-2PY
M-3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M-C8E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI
M9#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BD\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C
M965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0F%L86YC92P@1&5C96UB
M97(@,S$L(#(P,3$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,RPS.#DL-S<Q
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^-"PT,SDL-C$S/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5V%R<F%N=',@:7-S=65D('=I=&@@
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C,Q
M."PP.#<\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4&QA8V5M96YT(&%G96YT('=A<G)A
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[#0H@9F]N
M="US:7IE.B`Q,'!T.R<^,34Y+#`T-#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY787)R
M86YT<R!I<W-U960@=VET:"`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9RU!
M("A3964@3F]T92`Y*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,RPQ,3@L.3@X/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$L-#`Y+#4U-#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY787)R86YT<R!I<W-U960@=VET:"`R,#$R($-O;6UO
M;B!3=&]C:R!/9F9E<FEN9RU"("A3964@3F]T92`Y*3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2PU-3DL-3`U/"]F;VYT
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C$L-C8U+#8Y-SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY0;&%C96UE;G0@86=E
M;G0@=V%R<F%N=',@<F5L871E9"!T;R`R,#$R($-O;6UO;B!3=&]C:R!/9F9E
M<FEN9R`H4V5E($YO=&4@.2D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C0V-RPX-#4\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-#DY+#<P-SPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@S+#<U,RPP-38\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B@T+#(S,2PS,C0\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[#0H@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG
M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY"86QA;F-E+"!$96-E;6)E<B`S
M,2P@,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@-'!X(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-2PQ-#8L,S,X/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@
M9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,RPU-S0L
M.34X/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-
M"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!F86ER('9A;'5E<R!O
M9B!D97)I=F%T:79E('=A<G)A;G1S(&]N(&)A<VES(&]F('9A;'5A=&EO;B!M
M;V1E;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`T-7!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SXF(S$V,#L\+V1I=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M-C8E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D1E
M8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^4V5P=&5M8F5R(#,P+#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C
M;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/DUA<FME="!V86QU92!O9B!C;VUM;VX@<W1O8VL@;VX@
M;65A<W5R96UE;G0@9&%T92`H,2D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+C$W/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C$N-C4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^061J=7-T960@
M97AE<F-I<V4@<')I8V4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C0X("T@)#`N.#$\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L-"B`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/E)I<VL@9G)E92!I;G1E<F5S="!R871E("@R*3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XQ,"4@+2`P+C<W/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/C`N,S,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
M9F9F9F9F/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8V)2!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^-"!M;VYT:',O-2!Y96%R<SPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS
M1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"!D87ES+S0N
M,C(@>65A<G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^17AP96-T960@=F]L871I;&ET
M>2`H,RD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C$R-24@+2`Q-C$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,3,Y/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY%>'!E8W1E9"!D:79I9&5N9"!Y
M:65L9"`H-"D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)0T*
M('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4')O8F%B
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-24@+2`T,#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.R8C,38P
M.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G
M=VED=&@Z(#DP)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0S)2!V86QI9VX]
M,T1T;W`^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B@Q*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@],T0X
M-R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@;6%R:V5T('9A;'5E(&]F(&-O;6UO
M;B!S=&]C:R!I<R!B87-E9"!O;B!A;B!E;G1E<G!R:7-E('9A;'5A=&EO;BX\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$.#<E('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,R4@
M=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXH,BD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('=I
M9'1H/3-$.#<E('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX],T1J=7-T:69Y
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE(')I<VLM9G)E92!I;G1E
M<F5S="!R871E('=A<R!D971E<FUI;F5D(&)Y(&UA;F%G96UE;G0@=7-I;F<@
M=&AE(%1R96%S=7)Y($)I;&P@87,@;V8@=&AE(')E<W!E8W1I=F4@;65A<W5R
M96UE;G0@9&%T92X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<CX-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^/&9O
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M.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,RD\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('=I9'1H/3-$.#<E('9A;&EG;CTS1'1O<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R<^#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0F5C875S92!T:&4@0V]M
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X-R4@=F%L:6=N/3-$=&]P
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0S)2!V86QI9VX],T1T;W`^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@T*3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@=VED=&@],T0X-R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY-86YA9V5M96YT
M(&1E=&5R;6EN960@=&AE(&1I=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D
M('5P;VX@:71S(&5X<&5C=&%T:6]N('1H870@:70@=VEL;"!N;W0@<&%Y(&1I
M=FED96YD<R!F;W(@=&AE(&9O<F5S965A8FQE(&9U='5R92X\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0S)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$.#<E('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,R4@=F%L:6=N/3-$
M=&]P/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXH-2D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('=I9'1H/3-$.#<E
M('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^36%N86=E;65N="!H87,@9&5T97)M:6YE9"!T
M:&%T('1H92!P<F]B86)I;&ET>2!O9B!A('-T;V-K(&]F9F5R:6YG(&ES(#(U
M)2`M(#0P)2!F;W(@96%C:"!Q=6%R=&5R(&]F('1H92!N97AT(&9I=F4@>65A
M<G,N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE
M9G0^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0R."4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#,E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^1&5C96UB97(@,S$L/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY*86YU87)Y(#,Q+#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^1&5C96UB97(@,3DL/"]F
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I
M9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY$96-E
M;6)E<B`R-RP\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/D1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0R
M."4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0S)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS
M<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,C@E('9A;&EG;CTS
M1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^36%R:V5T('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!O;B!M96%S
M=7)E;65N="!D871E("@Q*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,R4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N,S<\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^,"XS-SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C`N,SD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XS
M.3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B
M9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0R
M."4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/C`N,C0@+2`D,"XR-CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[#0H@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C`N,C,@+2`D,"XR-CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C0Q("T@)#`N
M.#,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XR,B`M("0P+C(V/"]F;VYT/CPO
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C`N-#$@+2`D,"XX,SPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0R."4@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY2
M:7-K(&9R964@:6YT97)E<W0@<F%T92`H,BD\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#,E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$N,S4\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^,2XR-#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C$P)2`M(#`N-S<\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XY-#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W#0H@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C`N,3`E("T@,"XW-SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,C@E('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^5V%R<F%N="!L:79E<R!I;B!Y96%R<SPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,R4@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-"!M
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-"!M;VYT:',O-7EE
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ
M-38\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,34W/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O
M;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C$R-24@+2`Q-C$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,38Q/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,3(U)2`M(#$V,3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^17AP96-T960@9&EV:61E;F0@>6EE;&0@*#0I/"]F
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0R."4@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SY0<F]B86)I;&ET>2!O9B!S=&]C:R!O9F9E<FEN9R!I;B!A
M;GD@<&5R:6]D(&]V97(@-2!Y96%R<R`H-2D\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#,E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C(U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.PT*(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^,C4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C4\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#(X)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS-3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXS-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS-3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS-3PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^3V9F97)I;F<@<')I8V4@<F%N9V4@*#<I
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M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,"XQ."`M("0P+C4U/"]F;VYT/CPO9&EV/@T*/"]T9#X-
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H-"B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,"XQ,R`M("0P+C4V/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N,#$@+2`D
M,"XU-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C$R("T@)#`N-C`\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^,"XP,2`M("0P+C4U/"]F;VYT/CPO9&EV/@T*/"]T
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX-"CQD:78@86QI9VX],T1J
M=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/@T*
M/&1I=CX-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#$I)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0X,"4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^#0H\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE(&UA<FME="!V86QU92!O
M9B!C;VUM;VX@<W1O8VL@:7,@8F%S960@;VX@86X@96YT97)P<FES92!V86QU
M871I;VXN/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO9&EV/@T*/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX-"CPO9&EV/@T*/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX-"CQD:78^#0H\=&%B;&4@
M<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#,E('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B@R*28C,38P.R8C,38P.SPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$.#`E('9A;&EG
M;CTS1'1O<#X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^5&AE(')I<VLM9G)E92!I;G1E<F5S="!R871E('=A<R!D971E
M<FUI;F5D(&)Y(&UA;F%G96UE;G0@=7-I;F<@=&AE(&%V97)A9V4@;V8@-2!A
M;F0@-R!Y96%R(&%N9"!T:&4@,RUM;VYT:"!4<F5A<W5R>2!":6QL(&%S(&]F
M('1H92!R97-P96-T:79E(&UE87-U<F5M96YT(&1A=&4N/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I=CX-"CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/B8C,38P.R8C,38P.SPO9&EV/@T*/&1I=CX-"CQT86)L92!S
M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^*#,I)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!W:61T:#TS1#@P)2!V86QI9VX],T1T;W`^#0H\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D)E
M8V%U<V4@=&AE($-O;7!A;GD@9&]E<R!N;W0@:&%V92!A9&5Q=6%T92!T<F%D
M:6YG(&AI<W1O<GD@=&\@9&5T97)M:6YE(&ET<R!H:7-T;W)I8V%L('1R861I
M;F<@=F]L871I;&ET>2P@=&AE('9O;&%T:6QI='D@9F%C=&]R('=A<R!E<W1I
M;6%T960@8GD@;6%N86=E;65N="!U<VEN9R!T:&4@:&ES=&]R:6-A;"!V;VQA
M=&EL:71I97,@;V8@8V]M<&%R86)L92!C;VUP86YI97,@:6X@=&AE('-A;64@
M:6YD=7-T<GD@86YD(')E9VEO;BX\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX-"CQD:78^
M#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#,E('9A;&EG;CTS1'1O<#X-"CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@T*28C,38P.R8C,38P.SPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=VED=&@],T0X,"4@=F%L:6=N/3-$
M=&]P/@T*/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY-86YA9V5M96YT(&1E=&5R;6EN960@=&AE(&1I=FED96YD('EI
M96QD('1O(&)E(#`E(&)A<V5D('5P;VX@:71S(&5X<&5C=&%T:6]N('1H870@
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X-"CQT<CX-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,R4@=F%L:6=N/3-$=&]P/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^*#4I)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X,"4@=F%L:6=N
M/3-$=&]P/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#,E('9A;&EG;CTS1'1O<#X-"CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY-86YA9V5M96YT(&5S=&EM871E<R!T:&%T
M('1H92!R86YG92!O9B!P97)C96YT86=E<R!O9B!E>&ES=&EN9R!S:&%R97,@
M;V9F97)E9"!I;B!E86-H('-T;V-K(&]F9F5R:6YG('=I;&P@8F4@8F5T=V5E
M;B`S-24@;V8@=&AE('-H87)E<R!O=71S=&%N9&EN9RX\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\
M+V1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#,E('9A;&EG;CTS1'1O<#X-"CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q
M,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E
M-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O
M4VAE970R-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DEN8V]M92!487AE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X97,@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<&]N96YT<R!O9B!D969E<G)E9"!T87@@87-S971S(&%N9"!L
M:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78@86QI9VX],T1L969T/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y,"4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T
M:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C`Q,CPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N
M/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O
M;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-B4@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY$969E<G)E9"!T87@@87-S971S.CPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$S+#8P.2PP,S8\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$S+#`X
M.2PS,30\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$-C8E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2PT.3<L-34V/"]F;VYT/CPO
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C<T,2PT,C`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0-"B!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#<T.3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-C8E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^
M#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI
M9#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^*#$U+#,S.2PV,S4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI
M9#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^*#$S+#@S-2PT.#,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0-"B!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0V-B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`T<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^1&5F97)R960@=&%X(&%S<V5T<RP@;F5T/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O
M=6)L93LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`T<'@@9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H
M961U;&4@;V8@9&EF9F5R96YC92!B971W965N('1H92!I;F-O;64@=&%X('!R
M;W9I<VEO;B!A;F0@=&AE(%4N4RX@1F5D97)A;"!S=&%T=71O<GD@<F%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI9VX],T1L
M969T/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1L
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M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#0V)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED
M.R<@8V]L<W!A;CTS1#$T/@T*/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/D1E8V5M8F5R(#,Q+"`R,#$R/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/D1E8V5M8F5R(#,Q+"`R,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY&961E<F%L(&EN
M8V]M92!T87AE<R!A="`S-"4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#(L.#0R+#@Q,#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^+3,T+C`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^*#$L,3<Q+#(S,#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[#0H@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXM,S0N,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#0R)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M.2XP-#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-S,V+#<Y-CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR
M,2XS.3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-#(E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0VAA;F=E(&EN
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C(N
M-SD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[#0H@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XQ
M,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$-#(E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^06UO<G1I>F%T:6]N
M(&]F(&1E8G0@9&ES8V]U;G1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,S0Y+#0X,#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXU-BPP,S,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2XV,SPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/D-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X
M('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/C$L-3`T+#$U,3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX-"CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^4')O=FES:6]N(&9O<B!I;F-O;64@=&%X/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M-'!X(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#1P>"!D;W5B;&4[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
M8FQE.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`T<'@@9&]U8FQE.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^#0H\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B
M7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T,C<N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$512D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N
M9"!#;VYT:6YG96YC:65S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06)B;W1T($)I;W1H
M97)A<&5U=&EC<R!#;W)P(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY-:6QE<W1O;F4@4&%Y;65N=',@36EL
M97-T;VYE($UE=&AO9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(&UI;&5S=&]N
M92!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
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M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F
M9F9F9CLG/CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY087EM96YT<SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-3`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H
M:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXW-3`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V86QI9VX],T1B;W1T;VT^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXQ+#4P,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0-"B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#<U,"PP,#`\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^*#4I($9I<G-T(&-O;6UE<F-I86P@
M<V%L93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#4P,"PP,#`\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/B@V*2!A9G1E<B!T:&4@9FER<W0@)#$P+#`P,"PP
M,#`@:6X@;F5T('-A;&5S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C$L-3`P
M+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D
M/CPO='(^/"]T86)L93X\+V1I=CX\9&EV/B8C,38P.SPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L
M:6=N/3-$;&5F=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^36EL97-T;VYE<SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG
M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SY087EM96YT<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A
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M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L
M;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L
M:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P
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M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^-S4P+#`P
M,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS
M1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X
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M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S
M='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C<U,"PP,#`\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$8F]T=&]M/CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L
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M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXQ+#4P,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
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M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C$L-S4P+#`P,#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXH
M-2D@1FER<W0@8V]M;65R8VEA;"!S86QE/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXQ+#4P,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B@V*2!A9G1E<B!T:&4@9FER
M<W0@)#$P+#`P,"PP,#`@:6X@;F5T('-A;&5S/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.PT*(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I
M9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/C$L-3`P+#`P,#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G9&ES
M<&QA>3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DU32T-#(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY-:6QE<W1O;F4@4&%Y;65N=',@36EL97-T;VYE($UE
M=&AO9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
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M<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CLG/CQT
M86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY087EM96YT<SPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T
M<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C$I(&9I;&EN
M9R!O9B!A;B!.97<@1')U9R!!<'!L:6-A=&EO;B`H)B,X,C(P.TY$028C.#(R
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M-S4P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#<U,"PP,#`\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^
M/"]D:78^/&1I=CXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&QE9G0^/'1A
M8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M
M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/DUI;&5S=&]N97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C$I(&9I;&EN9R!O9B!A
M;B!.97<@1')U9R!!<'!L:6-A=&EO;B`H)B,X,C(P.TY$028C.#(R,3LI(&]R
M(')E9W5L871O<GD@87!P<F]V86P\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
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M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^
M/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I
M9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F
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M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C<U
M,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L
M;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L
M:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P
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M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO
M='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS
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M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C$L-S4P+#`P,#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SXF(S$V
M,#L\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-PT*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E,5]F-61D7S1E8CE?
M.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VL@3W!T:6]N
M(%!L86X@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!O9B!#;VUP96YS871I;VX@
M4F5L871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5M;6%R>2!O9B!S=&]C:R!O<'1I;VX@86-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI9VX],T1L969T/@T*/'1A
M8FQE('-T>6QE/3-$)W=I9'1H.B`Y-24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P
M)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5V5I9VAT960\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/D%V97)A9V4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#<E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I
M9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/D%G9W)E9V%T93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T-R4@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS
M1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3G5M8F5R(&]F
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L-"B`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/D%V97)A9V4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY);G1R:6YS:6,\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED
M.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^56YI=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T
M:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^17AE<F-I<V4@
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M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED
M.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^5&5R;2`H:6X@>65A<G,I/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/E9A;'5E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0T-R4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0T-R4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/=71S=&%N9&EN9RP@1&5C96UB97(@
M,S$L(#(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X-
M"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C$N,CD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^-2XU,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0T-R4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^1W)A;G1E9#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0T-R4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<PT*(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#<E('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^3W5T<W1A;F1I;F<L($1E8V5M8F5R(#,Q+"`R,#$Q/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C<S
M+#@U.3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O
M;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T-R4@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#`U-BPR-S4\
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,"XY-CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
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M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B
M9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T
M-R4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[)SX-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^3W5T<W1A;F1I;F<L($1E8V5M8F5R(#,Q+"`R,#$R/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O
M=6)L93LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@-'!X(&1O=6)L93LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,BPS,S`L,3,T/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!X.R<^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX-"CQD:78@86QI9VX],T1R
M:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C8X-2PX,#`\+V9O;G0^/"]D:78^#0H\
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P964T
M-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E
M.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970R.2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13-"
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^17%U:71Y("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M5V%R<F%N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V-H961U;&4@;V8@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3
M=&]C:R!/<'1I;VYS+"!!8W1I=FET>2!;5&%B;&4@5&5X="!";&]C:UT\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$;&5F
M=#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.34E.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F
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M=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$P
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I
M9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^
M#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M-#<E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DYU
M;6)E<B!O9CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[#0H@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^26YT<FEN<VEC/"]F;VYT/CPO9&EV
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D5X
M97)C:7-E(%!R:6-E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E1E<FT@*&EN('EE87)S*3PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N
M/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY686QU93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A
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M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3W5T<W1A;F1I;F<L($1E
M8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R0\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C4N-3$\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F9F8^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG
M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^+3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX],T1R
M:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,-"B!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/D]U='-T86YD:6YG+"!$96-E;6)E<B`S,2P@
M,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C(W,RPX-3D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^,2XR.3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/BT\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$-#<E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/D=R86YT960\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/@T*/&1I
M=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,BPP
M-38L,C<U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/C`N.38\+V9O;G0^/"]D:78^#0H\+W1D/@T*
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^."XX.3PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D#0H@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-C8V5E9F8^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-#<E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!X.R<^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/D]U='-T86YD:6YG+"!$96-E;6)E<B`S,2P@,C`Q,CPO
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#1P>"!D;W5B;&4[)SX-"CQD:78@86QI9VX],T1R:6=H="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C(L,S,P+#$S-#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#1P>#LG/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^,"XY-CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R<^#0H\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV.#4L.#`P/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DP)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P
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M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q,24@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3$E('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,SX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SY796EG:'1E9#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$Q)2!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#,^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#0R)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
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M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,24@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0S/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I
M9'1H/3-$,3$E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX-"CQD:78@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY!=F5R
M86=E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
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M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-#(E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,24@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0S/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$
M,3$E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX-"CQD:78@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY796EG:'1E9#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3$E
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX-"CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY296UA:6YI;F<\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$Q)2!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#,^#0H\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#0R)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
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M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D('=I9'1H/3-$,3$E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,SX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SY!=F5R86=E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!W:61T:#TS1#$Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS
M<&%N/3-$,SX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY5;FET<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
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M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3$E('9A
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M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#)P>#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)R!C;VQS<&%N/3-$,SX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY686QU93PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#(E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q,24@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$Q)2!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#,^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q,24@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F
M9CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T
M=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SY/=71S=&%N9&EN9RP@1&5C96UB97(@,S$L(#(P,3(\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXR+#,S,"PQ,S0\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
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M<'0[(&1I<W!L87DZ(&EN;&EN93LG/C`N.38\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
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M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXD/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V9F9F9F9CX-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
M:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T#0H@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C8V-E969F/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#0R)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D-A;F-E;&QA=&EO;CPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M.2PY-3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T0C9F9F9F9F/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#0R)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
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M<&QA>3H@:6YL:6YE.R<^3W5T<W1A;F1I;F<L(%-E<'1E;6)E<B`S,"P@,C`Q
M,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/@T*/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
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M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXX+C$W/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
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M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ+#8P.2PP,S4\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.3`E.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#0R)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$P
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T
M,B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS
M1#$P)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^079E<F%G93PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q,"4@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^5V5I9VAT960\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E)E;6%I;FEN9SPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^06=G<F5G871E/"]F;VYT
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^079E<F%G93PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P
M)2!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0V]N=')A8W1U86P\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DEN
M=')I;G-I8SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<CX-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD
M:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY5
M;FET<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/@T*/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)R!C;VQS<&%N/3-$,CX-"CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY%>&5R8VES92!0<FEC93PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX-"CQD
M:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!W:61T:#TS1#$P)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^#0H\9&EV(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5F%L=64\+V9O;G0^/"]D:78^
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/D]U='-T86YD:6YG+"!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ#0H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,BPW-S`L-C,V
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N.3<\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
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M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X-"CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;3X-"CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`V+#$Q-"PW-C@\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-F9F9F
M9F8^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$-#(E('9A;&EG;CTS1&)O
M='1O;3X-"CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/BD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O
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M.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(V-C965F9CX-"CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0T,B4@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^#0H\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[#0H@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/C$N-C4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
M"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]U='-T86YD:6YG+"!397!T96UB
M97(@,S`L(#(P,3,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/CDL-#0Q+#DT,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^#0H\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^#0H\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+B`W
M-SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-"CQT
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/C4N,#D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X-
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M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/@T*/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^.2PV,3$L-#`S
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M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D
M9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B
M-R]7;W)K<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY787)R86YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY787)R86YT
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6UM87)Y(&]F('=A<G)A;G0@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XM;&5F=#H@,C=P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
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M+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0^/'1A
M8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E=A<G)A;G1S
M(&ES<W5E9"!W:71H(&-O;G9E<G1I8FQE(&YO=&5S("A3964@3F]T92`U*3PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^,C@W+#`V,3PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E
M;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M5V%R<F%N=',@:7-S=65D('1O(&EN=F5S=&]R<R!W:71H(%-T;V-K($]F9F5R
M:6YG("A3964@3F]T92`Y*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X
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M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R
M/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/E!L86-E;65N="!A9V5N="!W87)R86YT
M<R!R96QA=&5D('1O(&ES<W5A;F-E(&]F.CPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L
M;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('=I9'1H/3-$.#@E('9A;&EG
M;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[
M('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R8C,38P.R8C,38P.R8C,38P.T-O;G9E<G1I8FQE
M($YO=&5S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ-#,L
M-3,R/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R
M/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$.#@E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#M3=&]C:R!/9F9E<FEN9R`H4V5E($YO=&4@
M-B!A;F0@3F]T92`Y*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQD:78@86QI9VX],T1R:6=H
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/CDX-BPS.#,\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#@X)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
M8FQE.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D#0H@86QI9VX],T1R:6=H="!W:61T:#TS1#DE
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`T<'@@9&]U8FQE.R<^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z
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M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\+W1A
M8FQE/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1J=7-T
M:69Y('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M)VUA<F=I;BUL969T.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I
M9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\9&EV(&%L
M:6=N/3-$;&5F=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R(&)G8V]L;W(],T0C
M8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X
M="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^5V%R<F%N=',@:7-S=65D('1O(&EN=F5S=&]R<R!W:71H(%-T;V-K
M($]F9F5R:6YG("A3964@3F]T92`V*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^,C0R+#$X.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0X."4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z
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M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E!L86-E;65N="!A9V5N
M="!W87)R86YT<R!R96QA=&5D('1O(&ES<W5A;F-E(&]F.CPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^
M/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I
M9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R8C,38P.R8C,38P.R8C,38P.U-T
M;V-K($]F9F5R:6YG("A3964@3F]T92`V(&%N9"!.;W1E(#DI/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ,C$L,#DT/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$.#@E('9A;&EG;CTS1&)O='1O;3X\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R8C,38P.R8C,38P.R8C,38P.S(P,3(@0V]M;6]N(%-T;V-K($]F9F5R:6YG
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXT-C<L.#0U/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI
M=&4^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
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M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,G!X('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,G!X('-O;&ED.R<^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M<FEG:'0Z(#!P=#L-"B!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ.#`L,3$U)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#@X)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#1P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z
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M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93LG/CQD:78@86QI
M9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C4L-C@Y+#<S
M-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R8C,38P.SPO
M9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@=V%R<F%N="!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^)B,Q-C`[
M/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0^/'1A8FQE('-T>6QE/3-$)W=I9'1H
M.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@
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M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^5V5I9VAT960\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T
M97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SY!=F5R86=E/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L
M87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
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M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E=E:6=H=&5D/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^4F5M86EN:6YG/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^06=G
M<F5G871E/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/D%V97)A9V4\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T#0H@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I
M=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/D-O
M;G1R86-T=6%L/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^26YT<FEN<VEC/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SY5;FET<SPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C
M;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^17AE<F-I<V4@4')I8V4\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/E1E<FT@
M*&EN('EE87)S*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
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M;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$-3(E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/D]U='-T86YD:6YG+"!$96-E;6)E
M<B`S,2P@,C`Q,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E
M;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^
M+3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\
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M97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXM/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0-"B!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^+3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
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M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXM/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#4R)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@
M:6YL:6YE.R<^1W)A;G1E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#LG/CQD:78@86QI9VX],T1R
M:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N
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M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXP+C4Q
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD
M96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/C8N-S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#4R)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0-"B!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#4R)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SY/=71S=&%N9&EN9RP@1&5C96UB97(@
M,S$L(#(P,3$\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C4L
M,S8T+#4U-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT
M+6EN9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXP+C4Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/C8N-S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL
M969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P=#L@
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M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
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M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY'<F%N=&5D/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
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M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD
M:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD96YT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/C$N
M,S(\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R<^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I;BUL969T.B`P
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M)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
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M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$-3(E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#$E#0H@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO
M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO
M='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0U,B4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`T<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[
M('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/D]U='-T86YD:6YG+"!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B
M;&4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T
M<'@@9&]U8FQE.R<^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES<&QA
M>3H@:6YL:6YE.R<^,3(L-S<P+#8S-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)VUA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9&EV(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXP+B`Y-SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N
M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9&EV(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXT+C0X/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6EN
M9&5N=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P>#LG/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
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M:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\+V1I
M=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M:6YD
M96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF
M-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E
M,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E
M=#,Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%0E-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O9B!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@9F]R=&@@87-S971S(&%N9"!L
M:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R
M:6YG(&%N9"!N;VX@<F5C=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-S4W+#DV
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,RPU-S0L.34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T+#0S.2PV,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#$@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM
M87)Y(&]F(&9O<G1H(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;65A<W5R960@
M870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!A;F0@;F]N(')E8W5R<FEN
M9R!B87-I<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,979E;"`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!F;W)T:"!A
M<W-E=',@86YD(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@
M;VX@82!R96-U<G)I;F<@86YD(&YO;B!R96-U<G)I;F<@8F%S:7,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A
M=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V
M96P@,R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@9F]R=&@@87-S971S(&%N9"!L:6%B
M:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG
M(&%N9"!N;VX@<F5C=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-S4W+#DV-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,RPU-S0L.34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T+#0S.2PV,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF
M-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E
M,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E
M=#,R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%15!"23X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@4W5M;6%R>2!O9B!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS(%1E>'1U86PI
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,C4L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`R."P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-U8G-E<75E;G0@179E;G0@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,CQB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^4W1O
M8VL@3W!T:6]N<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/E-T;V-K($]P=&EO;G,@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CY787)R86YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^5V%R<F%N="!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/E=A<G)A;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY#;VYV97)T:6)L92!0<F5F
M97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY#;VYV97)T:6)L92!.;W1E<R!0
M87EA8FQE(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L
M92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/D]P=&EO;G,@06YD(%=A<G)A;G1S(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^36%C:&EN97)Y(&%N9"!E<75I<&UE;G0@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY-
M86-H:6YE<GD@86YD(&5Q=6EP;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D9U<FYI='5R
M92!A;F0@9FEX='5R97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY&=7)N:71U<F4@86YD(&9I
M>'1U<F5S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,C4L(#(P,3,\8G(^06-T:6YI=6T@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`R."P@,C`Q,CQB<CY!
M8W1I;FEU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A4
M97AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!O=VYE
M<G-H:7`@:6YT97)E<W0@=&\@8F4@86-Q=6ER960@8GD@8V]M<&%N>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY,RXW,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VL@:7-S=6%B;&4@:6X@8V]N
M<VED97)A=&EO;B!F;W(@97%U:71Y(&EN=&5R97-T(&%C<75I<VET:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY.2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!S:&%R97,@:7-S=65D(&EN(&5X
M8VAA;F=E(&]F(&5Q=6ET>2!S96-U<FET:65S(&EN('!E<F-E;G1A9V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B=!<'!R;WAI;6%T96QY(#DY)2!O9B!T:&4@:7-S=65D(&%N9"!O=71S
M=&%N9&EN9R!C;VUM;VX@<W1O8VL@:6UM961I871E;'D@869T97(@=&AE(&-L
M;W-I;F<@;V8@=&AE(%-H87)E($5X8VAA;F=E+"!P87(@=F%L=64@)#`N,#$@
M<&5R('-H87)E+"!O9B!T:&4@0V]M<&%N>2X@5&AE(%-H87)E($5X8VAA;F=E
M('=A<R!C;&]S960@;VX@1&5C96UB97(@,C@L(#(P,3(N/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VLL('!A<B!V86QU92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%<W1I;6%T960@=7-E9G5L(&QI=F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T9I=F4@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG1FEV92!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=3979E;B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=3979E;B!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M97,@<F5C96EV960@8GD@96%C:"!!4$D@<VAA<F5H;VQD97(@;V8@06-T:6YI
M=6T@8V]M;6]N('-T;V-K(&9O<B!E86-H($%022!S:&%R92!E>&-H86YG960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C,S,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`N,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&]T96YT:6%L;'D@:7-S=6%B;&4@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DV."PX
M,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#,S,"PQ,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-S,L.#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.2PT-#$L.30R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX-C$L,#0T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-S<P+#4Y
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S+#@S,2PW-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#$U,BPV.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#0T."PR-S8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(X,"PQ.#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!E<F-E;G1A9V4@3V8@4VAA<F5S($5X8VAA;F=E9"!);B!3:&%R92!%>&-H
M86YG92!0<F]G<F%M;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0G5S:6YE<W,@86-Q=6ES
M:71I;VX@;G5M8F5R(&]F('-H87)E<R!E>&-H86YG960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,S(R+#`U-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#DW,"PQ,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T
M96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970S,RYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P13-004<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1V]I;F<@
M8V]N8V5R;B`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3(^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,34Q($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$V,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,#`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,#D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`P.#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#`W/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,#8\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`P-3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Q/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY';VEN9R!#;VYC
M97)N("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PT,C`L.3$S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RPP,3(L
M-#4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H-C<R+#(X-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#0L.#DS+#DU,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4L-#@S+#DU-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#@L,S8Q
M+#(P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#,L-#0T+#<Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#0V-RPR-C8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#0R-2PY.#8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#4W
M,"PY,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@U+#8Q-RPU.#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@V+#`U,RPS-C(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T+#4X,"PR,S<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U
M+#<S-"PW.3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@S+#4S,BPP-#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#$Y,BPS.#0I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#`Y,"PV,C$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@U-2PW-#,L-#8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H-C`L-C,W+#0Q-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@
M;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-"PY-#<L.38Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,L-SDU+#0X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U+#(Q,BPW,3`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3$W+#4Y,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-#0L-#`R+#8U."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T.2PS-3`L-C(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V,"PV,S<L-#$T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8P+#8S-RPT,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U-2PW-#,L-#8S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-RPS.#(L,C4X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-34L-S0S+#0V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-C`L-C,W+#0Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P
M,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE
M971S+U-H965T,S0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)0D%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS("A$971A:6QS
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!A8W1I=FET:65S(')E;&%T960@
M=&\@<F5L871E9"!P87)T>3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E%U86QI9FEE9"!2)F%M<#M$(&-O<W1S(&EN8W5R
M<F5D(&)Y('1H92!#;VUP86YY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V-34L-S@V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296EM8G5R<V5M96YT<R!R
M96-E:79E9"!F<F]M($U32T-#/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(S-RPX,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#DV-BPS-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S
M93AF-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T
M-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3
M:&5E=#,U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%0C1%2SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R`H1&5T86EL<R!497AT
M=6%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^
M,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#(W+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(Y
M+"`R,#$R/&)R/DQI8V5N<V4L($1E=F5L;W!M96YT(&%N9"!#;VUM97)C:6%L
M:7IA=&EO;B!!9W)E96UE;G0@6TUE;6)E<ET\8G(^3F]T93QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/DQI8V5N
M<V4L($1E=F5L;W!M96YT(&%N9"!#;VUM97)C:6%L:7IA=&EO;B!!9W)E96UE
M;G0@6TUE;6)E<ET\8G(^3F]T93QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y!<'(N(#,P+"`R,#$P/&)R/DUE;6]R:6%L(%-L;V%N($ME='1E
M<FEN9R!#86YC97(@0V5N=&5R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^365M;W)I86P@4VQO
M86X@2V5T=&5R:6YG($-A;F-E<B!#96YT97(@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CY-96UO
M<FEA;"!3;&]A;B!+971T97)I;F<@0V%N8V5R($-E;G1E<B!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#(W+"`R,#$R
M/&)R/DUE;6]R:6%L(%-L;V%N($ME='1E<FEN9R!#86YC97(@0V5N=&5R(%M-
M96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#$Y+"`R,#$Q
M/&)R/E-+22!;365M8F5R73QB<CY,:6-E;G-E+"!$979E;&]P;65N="!A;F0@
M0V]M;65R8VEA;&EZ871I;VX@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3`\8G(^4TM)
M(%M-96UB97)=/&)R/DQI8V5N<V4L($1E=F5L;W!M96YT(&%N9"!#;VUM97)C
M:6%L:7IA=&EO;B!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY32TD@6TUE;6)E
M<ET\8G(^3&EC96YS92P@1&5V96QO<&UE;G0@86YD($-O;6UE<F-I86QI>F%T
M:6]N($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#(Q+"`R,#$R/&)R/E-+22!;365M8F5R73QB<CY,
M:6-E;G-E+"!$979E;&]P;65N="!A;F0@0V]M;65R8VEA;&EZ871I;VX@06=R
M965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIA;BX@,S$L(#(P,3(\8G(^1'(N(%)O<V5M87)Y($UA>F%N970@6TUE
M;6)E<ET\8G(^0V]N<W5L=&EN9R!397)V:6-E<R!!9W)E96UE;G0@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CY$<BX@4F]S96UA<GD@36%Z86YE="!;365M8F5R73QB<CY#;VYS
M=6QT:6YG(%-E<G9I8V5S($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#`W+"`R,#$R/&)R/DQA:61L
M87<@86YD($-O;7!A;GD@6TUE;6)E<ET\8G(^16YG86=E;65N="!!9W)E96UE
M;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CY,86ED;&%W(&%N9"!#;VUP86YY(%M-96UB97)=
M/&)R/D5N9V%G96UE;G0@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`P.2P@,C`Q,3QB<CY*86UE<W,@
M0V%P:71A;"!'<F]U<"!,3$,@6TUE;6)E<ET\8G(^5')A;G-A8W1I;VX@;6%N
M86=E;65N="!A9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY'=6%G96YT:2`F86UP
M.R!!<W-O8VEA=&5S($Q,0R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS
M86-T:6]N<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!0
M871I96YT<R!E;G)O;&QE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT('!A:60@=6YD97(@86=R
M965M96YT(&EN(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@<&%I9"!U;F1E
M<B!A9W)E96UE;G0@:6X@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT('!A:60@
M=6YD97(@86=R965M96YT(&EN(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA:6YT96YA
M;F-E(&9E97,@86YD(')E<V5A<F-H('!A>6UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M
M;W5N="!P86ED('5N9&5R(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I
M;VYA;"!A;6]U;G0@9'5E('5N9&5R(&%G<F5E;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]N9&ET:6]N(&9O<B!T97)M:6YA=&EO;B!O9B!F;W)B96%R86YC92!P97)I
M;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M5&AE(&9O<F)E87)A;F-E('!E<FEO9"!T97)M:6YA=&5D(&]N($]C=&]B97(@
M,S`L(#(P,3$L('=H96X@=&AE($-O;7!A;GD@<V%T:7-F:65D(&$@9FEN86YC
M:6YG(&-O;F1I=&EO;B!T;R!T:&4@=&5R;6EN871I;VX@;V8@=&AE(&9O<F)E
M87)A;F-E('!E<FEO9"!B>2!R86ES:6YG(&EN(&5X8V5S<R!O9B`D,RPP,#`N
M,#`P(&EN(&YE=R!E<75I='D@9FEN86YC:6YG+CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y497)M:6YA
M=&EO;B!D871E(&]F(&9O<F)E87)A;F-E(&%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/8W0@,S`L#0H)"3(P,3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M3V-T(#,P+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@;F5W(&5Q=6ET>2!F
M:6YA;F-I;F<@;F5E9&5D('5N9&5R(&-O;F1I=&EO;B!F;W(@=&5R;6EN871I
M;VX@9F]R8F5A<F%N8V4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R9VEV96X@86UO
M=6YT(&]F(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@
M9&5V96QO<&UE;G0@<F5I;6)U<G-E;65N="!P87EM96YT<R!R96-E:79E9"!F
M<F]M($U32T-#/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,S<L.#,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CDY+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<F5C96EV86)L92!F
M<F]M($U32T-#/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C,W+#@S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@<&%I9"!T;R!E86-H('!A
M=&EE;G0@869T97(@0V]M<&QE=&EN9R!C;&EN:6-A;"!T<FEA;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PQ.#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&%R="UU<"!F964@9F]R(&-L:6YI8V%L('1R:6%L/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y+#8R,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1U92!D871E(&]F('-T87)T+75P(&9E93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*=6P@,3`L#0H)"3(P,3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"87-E('-A;&%R>2!A="!A;FYU86P@<F%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!T:6]N($5X97)C:7-E(%!R:6-E(%)A;F=E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`N-S@@=&\@,2XU/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1E<FT@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S8@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/<'1I;VYS(')E8V5I=F5D('1O('!U<F-H87-E(&-O;6UO;B!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY.2PY,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!R96-E:79A8FQE<R!O
M9B!P;&%C96UE;G0@86=E;G0@9F]R('-E<G9I8V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U!L86-E;65N="!A
M9V5N="!W:6QL(')E8V5I=F4@*&$I(&$@8V%S:"!F964@97%U86P@=&\@,3`E
M(&]F('1H92!G<F]S<R!P<F]C965D<R!R86ES960@:6X@=&AE(#(P,3(@0V]M
M;6]N(%-T;V-K($]F9F5R:6YG+"`H8BD@82!N;VXM86-C;W5N=&%B;&4@97AP
M96YS92!R96EM8G5R<V5M96YT(&5Q=6%L('1O(#(E(&]F('1H92!G<F]S<R!P
M<F]C965D<R!R86ES960@:6X@=&AE(#(P,3(@0V]M;6]N(%-T;V-K($]F9F5R
M:6YG+"!A;F0@*&,I(')E:6UB=7)S96UE;G0@;V8@)#$P,"PP,#`@9F]R(&QE
M9V%L(&5X<&5N<V5S(&EN8W5R<F5D(&)Y('1H92!P;&%C96UE;G0@86=E;G0N
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E<V-R:7!T:6]N(&]F('=A<G)A;G1S(')E8V5I=F%B;&5S(&)Y('!L
M86-E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=4:&4@<&QA8V5M96YT(&%G96YT(&]R(&ET<R!D97-I9VYE
M97,@:&%V92!A;'-O(')E8V5I=F5D('=A<G)A;G1S('1O('!U<F-H87-E('-H
M87)E<R!O9B!T:&4@0V]M<&%N>2=S($-O;6UO;B!3=&]C:R!I;B!A;B!A;6]U
M;G0@97%U86P@=&\@,3`E(&]F('1H92!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(&ES<W5E9"!A<R!P87)T(&]F('1H92!U;FET<R!S;VQD(&EN('1H92`R,#$R
M($-O;6UO;B!3=&]C:R!/9F9E<FEN9R!A;F0@=&AE('-H87)E<R!O9B!#;VUM
M;VX@4W1O8VL@:7-S=6%B;&4@=7!O;B!E>&5R8VES92!O9B!T:&4@0B!W87)R
M86YT<R!I;F-L=61E9"!I;B!S=6-H('5N:71S+CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)I;V0@;V8@97AE
M<F-I<V4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG5VET:&EN(#8@;6]N=&AS(&]F('1H92!F
M:6YA;"!C;&]S:6YG(&]F('1H92`R,#$R(&-O;6UO;B!S=&]C:R!/9F9E<FEN
M9RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&5R8V5N=&%G92!O9B!S;VQI8VET871I;VX@9F5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^36]N=&AL>2!F964@9F]R(&9I;F%N8VEA;"!A9'9I<V]R>2!S97)V:6-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!A9&1I=&EO;F%L(')E8V5I
M=F%B;&4@8GD@<&QA8V5M96YT(&%G96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U1H92!A9W)E96UE;G0@86QS
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M;&0@<F5C96EV92!A(&9E92!E<75A;"!T;R`Q,"4@;V8@=&AE(&%G9W)E9V%T
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M96YG86=E;65N="!A9W)E96UE;G0N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@:&5L9"!B>2!P;&%C
M96UE;G0@86=E;G0@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(U,2PP
M,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DUO;G1H;'D@9F5E(')E8V5I=F5D(&)Y(&UA;F%G96UE;G0@9FER
M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&9U;&QY(&1I;'5T960@8V%P
M:71A;"!S=&]C:R!E<75A;"!T;R!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36%X:6UU;2!A;6]U;G0@;V8@;W5T(&]F('!O8VME="!E>'!E;G-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P97)A=&EN9R!L96%S92!M;VYT:&QY(&%M;W5N="!O9B!R96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%M;W5N="!P86ED('1O('!U<G-U86YT(&QE87-E(&%G<F5E
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`W+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D
M-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U
M9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T,S8N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R54%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R
M;W!E<G1Y(&%N9"!%<75I<&UE;G0@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5M;6%R>2!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L('!R;W!E<G1Y+"!P;&%N="!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V-2PT.#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U-RPT-30\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U-2PP
M.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/BA,97-S*2!!8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$U-"PT-#0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34T+#0T-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-3,L.#8S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&]S<R!O;B!D:7-P;W-I=&EO;B!O9B!E<75I<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0L,3(R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD
M(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY
M,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/9F9I8V4@97%U:7!M96YT(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R
M>2!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5S969U;"!,:79E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L('!R;W!E<G1Y+"!P;&%N="!A;F0@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C(L,S@T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34V+#$V,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,RPX,#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9U<FYI='5R92!A;F0@9FEX='5R97,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F('!R
M;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^57-E9G5L($QI=F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M<')O<&5R='DL('!L86YT(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,RPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,CDR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#(Y,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D
M9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B
M-R]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)14%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@*$1E
M=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R
M;W!E<G1Y(&%N9"!%<75I<&UE;G0@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@
M97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T
M96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970S."YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P148U044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^3F]T92!0
M87EA8FQE(&%N9"!#;VYV97)T:6)L92!.;W1E<R`H1&5T86EL<RD@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#(W+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@<V5N:6]R('-U8F]R9&EN
M871E9"!U;G-E8W5R960@8V]N=F5R=&EB;&4@<')O;6ES<V]R>2!N;W1E<SPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')I;F-I<&%L(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Y,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,97-S.B!O<FEG:6YA;"!I<W-U86YC92!D:7-C
M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&5S<SH@9&ES8V]U;G0@<F5L871E9"!T;R!T:&4@8F5N969I8VEA;"!C
M;VYV97)S:6]N(&9E871U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S-S(L.#4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%R<GEI;F<@=F%L=64@870@1&5C96UB97(@
M,S$L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,C0L,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^."4@4V5N:6]R(%-U8F]R9&EN871E9"!5;G-E8W5R960@0V]N
M=F5R=&EB;&4@4')O;6ES<V]R>2!.;W1E<R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F
M('-E;FEO<B!S=6)O<F1I;F%T960@=6YS96-U<F5D(&-O;G9E<G1I8FQE('!R
M;VUI<W-O<GD@;F]T97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,Z(&]R
M:6=I;F%L(&ES<W5A;F-E(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,34P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-3`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,Z(&1I<V-O=6YT
M(')E;&%T960@=&\@9F%I<B!V86QU92!O9B!D97)I=F%T:79E('=A<G)A;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S<W+#$U,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-S<L
M,34P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQE<W,Z(&1I<V-O=6YT(')E;&%T960@=&\@=&AE(&)E;F5F:6-I
M86P@8V]N=F5R<VEO;B!F96%T=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,S<R+#@U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S-S(L.#4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9#H@86UO<G1I>F%T:6]N
M(&]F(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R-"PS-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,97-S.B!P<FEN8VEP86P@86UO=6YT(&-O;G9E
M<G1E9"!T;R!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#DP,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87)R>6EN9R!V86QU92!A="!$
M96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(T
M+#,V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-PT*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E,5]F-61D7S1E8CE?.#`S
M8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E=#,Y+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%159#2SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(%!A>6%B;&4@
M86YD($-O;G9E<G1I8FQE($YO=&5S("A$971A:6QS(%1E>'1U86PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#0^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$U,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ-C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`Q.2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#(S
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`R."P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#(W+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@4&%Y86)L92!A;F0@0V]N
M=F5R=&EB;&4@3F]T97,@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M('!R;VUI<W-O<GD@;F]T92!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@;V8@;W)I
M9VEN86P@:7-S=64@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,34P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R96UI=6T@9FEN86YC92!A
M9W)E96UE;G0@<')I;F-I<&%L(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT('5N9&5R
M('!R96UI=6T@9FEN86YC92!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;VYT:&QY(&%M;W5N
M="!P87EA8FQE('5N9&5R('!R96UI=6T@9FEN86YC92!A9W)E96UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#8S-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$=7)A=&EO;B!O9B!P97)I;V1I8R!P87EM96YT<R!F;W(@<')E;6EU;2!F
M:6YA;F-E(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SD@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R96UI=6T@9FEN86YC92!A9W)E
M96UE;G0@;W5T<W1A;F1I;F<@86UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;VUI<W-O<GD@;F]T
M92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@;V8@<')O;6ES<V]R
M>2!N;W1E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@<')I;F-I<&QE(&%M;W5N="!I
M;B!W:&EC:"!C;VYV97)T:6)L92!N;W1E(&ES<W5E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,RXS,R4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I
M8FQE(&YO=&4@;6%T=7)I='D@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)T]N92!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S('!R;V-E961S
M(&EN('-U8G-E<75E;G0@;V9F97)I;F=S(&]F(&-O;6UO;B!S=&]C:R!O<B!E
M<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@=&\@:6YV
M97-T;W)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@W+#`V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G0@=V%R<F%N="!G<F%N="!D871E(&9A
M:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4V-2PW,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U<F4@
M9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,W,BPX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S<R+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P<FEC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C<X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XW.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N=F5R=&EB;&4@;F]T92!F86ER('9A;'5E('!E<B!S:&%R93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C$Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X=&5N9&5D(&UA='5R:71Y(%!E<FEO9"!O9B!C;VYV97)T:6)L92!N;W1E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG.3`@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@97AT96YD960@;6%T=7)I='D@9&%T
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG0V]M<&%N>2!W
M87,@<V5E:VEN9R!A<'!R;W9A;"!T;R!E>'1E;F0@=&AE(&YO=&4@;6%T=7)I
M='D@9&%T92!F;W(@.3`@9&%Y<RX@5&AE($-O;7!A;GD@=V%S(&%B;&4@=&\@
M;V)T86EN(&%P<')O=F%L<R!F<F]M(&%L;"!N;W1E(&AO;&1E<G,@86YD('1H
M92!M871U<FET>2!D871E(&]F('1H92!N;W1E<R!H87,@8F5E;B!E>'1E;F1E
M9"!T;R!*86YU87)Y(#,Q+"`R,#$S+"!&96)R=6%R>2`Q."P@,C`Q,R!O<B!-
M87)C:"`R-RP@,C`Q,R!F;W(@=&AE(#(T(&YO=&5S+CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M=F5R=&EB;&4@;F]T97,@86YD('1H92!A8V-R=65D(&EN=&5R97-T(&-O;G9E
M<G1E9"!I;G1O(&-O;6UO;B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@
M;V8@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-S@L,3$V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<U+#8S-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-"PS-C,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F97)R960@9FEN86YC
M:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Q.2PW,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-3(L,C0X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`L-#0T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDR+#8Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y,BPV
M.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]W;B!P87EM96YT('5N9&5R(&EN<W5R86YC92!P;VQI8WD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5M:75M(&UO;G1H;'D@:6YS=&%L;&UE;G0@9F]R(&YI;F4@;6]N=&AS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPV,S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@
M<&%Y;65N="!O9B!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`S+#`U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#,L,#4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!L86-E;65N
M="!!9V5N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@4&%Y86)L92!A;F0@0V]N
M=F5R=&EB;&4@3F]T97,@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!S:&%R97,@<'5R8VAA<V%B;&4@=&AR;W5G:"!W87)R86YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30S+#4S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES92!P<FEC92!O9B!W87)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@97AP:7)A
M=&EO;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y*86X@,S$L#0H)"3(P,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')O;6ES<V]R
M>2!N;W1E(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CDR+#8Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.3(L-CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@;V8@;W)I9VEN86P@
M:7-S=64@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,34P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!P
M97)I;V0@;V8@;F]T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)T]N92!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA;F%G96UE;G0@1FER;2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/DYO=&4@4&%Y86)L92!A;F0@0V]N=F5R=&EB;&4@3F]T97,@
M*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!S:&%R97,@<'5R8VAA
M<V%B;&4@=&AR;W5G:"!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(V+#@R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!O
M9B!W87)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@97AP:7)A=&EO;B!D871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*86X@,S$L#0H)"3(P
M,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X
M,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T-#`N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4U5D)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E<FEV871I=F5S
M("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,34Q($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$V,"!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@9&5R:79A=&EV
M92!W87)R86YT(&EN<W1R=6UE;G1S(&%C=&EV:71Y/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!B
M86QA;F-E+"!5;FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PQ-#8L,S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPS.#DL-S<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPS.#DL-S<Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!I<W-U960@=VET:"!#;VYV97)T:6)L92!.;W1E<R`H4V5E($YO
M=&4@-2DL(%5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.#<L,#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E8VQA<W-I9FEC871I;VX@=&\@<&%I9"!I;B!C87!I
M=&%L+"!5;FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPQ
M,S`L-3,V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0;&%C96UE;G0@86=E;G0@=V%R<F%N=',@<F5L871E
M9"!T;R!I<W-U86YC92!O9B!#;VYV97)T:6)L92!.;W1E<R`H4V5E($YO=&4@
M-2DL(%5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-#,L-3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!W:71H(%-T;V-K($]F9F5R:6YG
M("A3964@3F]T92`Y*2P@56YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C0R+#$Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.3<R+#<X-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;&%C96UE;G0@86=E;G0@
M=V%R<F%N=',@<F5L871E9"!T;R!I<W-U86YC92!O9B!3=&]C:R!/9F9E<FEN
M9R`H4V5E($YO=&4@.2DL(%5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R,2PP.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY.#8L,SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!W
M:71H(#(P,3(@0V]M;6]N(%-T;V-K($]F9F5R:6YG("T@02`H4V5E($YO=&4@
M.2DL(%5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,3$X+#DX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D('=I=&@@,C`Q,B!#;VUM;VX@
M4W1O8VL@3V9F97)I;F<@+2!"("A3964@3F]T92`Y*2P@56YI=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-3DL-3`U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;&%C
M96UE;G0@86=E;G0@=V%R<F%N=',@<F5L871E9"!T;R`R,#$R($-O;6UO;B!3
M=&]C:R!/9F9E<FEN9R`H4V5E($YO=&4@.2DL(%5N:71S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0V-RPX-#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R(&9R
M;VT@;&EA8FEL:71Y(&-L87-S:69I8V%T:6]N('1O(&5Q=6ET>2!C;&%S<VEF
M:6-A=&EO;BP@56YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,RPW-3,L,#4V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@56YI=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,#$U+#@P,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$T-BPS,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,X.2PW
M-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#$T-BPS,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#`Q-2PX,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!B86QA;F-E+"!&86ER
M(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-3<T
M+#DU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-"PT,SDL-C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`T+#0S.2PV,3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M8VQA<W-I9FEC871I;VX@=&\@<&%I9"!I;B!C87!I=&%L+"!&86ER(%9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,#`L.#@P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT<R!I<W-U960@=VET:"!#;VYV97)T:6)L92!.;W1E<R`H4V5E
M($YO=&4@-2DL($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,W-RPQ-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&QA8V5M96YT(&%G96YT('=A<G)A;G1S
M(')E;&%T960@=&\@:7-S=6%N8V4@;V8@0V]N=F5R=&EB;&4@3F]T97,@*%-E
M92!.;W1E(#4I+"!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.#@L-3<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!W:71H(%-T
M;V-K($]F9F5R:6YG("A3964@3F]T92`Y*2P@1F%I<B!686QU93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3@L,#@W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU.3$L.3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!L86-E;65N="!A9V5N="!W87)R86YT<R!R96QA=&5D('1O(&ES<W5A;F-E
M(&]F(%-T;V-K($]F9F5R:6YG("A3964@3F]T92`Y*2P@1F%I<B!686QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3DL,#0T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.34L
M.34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!W:71H(#(P,3(@0V]M;6]N(%-T;V-K
M($]F9F5R:6YG("T@02`H4V5E($YO=&4@.2DL($9A:7(@5F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#DL-34T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!I<W-U960@=VET:"`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9R`M
M($(@*%-E92!.;W1E(#DI+"!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C8U+#8Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&QA8V5M96YT(&%G96YT
M('=A<G)A;G1S(')E;&%T960@=&\@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F97)I
M;F<@*%-E92!.;W1E(#DI+"!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0Y.2PW,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R(&9R;VT@;&EA
M8FEL:71Y(&-L87-S:69I8V%T:6]N('1O(&5Q=6ET>2!C;&%S<VEF:6-A=&EO
M;BP@1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#(S,2PS,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR,S$L,S(T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX,S(L,C`T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M:&%N9V4@:6X@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C$V+#$Q,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-C@U+#0R,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPY-C8I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4L($9A
M:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPW
M-3<L.38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPU-S0L.34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T+#0S.2PV,3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-3<T+#DU.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPW
M-3<L.38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D9%\T96(Y7S@P
M,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970T,2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14%(04D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5R:79A=&EV97,@
M*$1E=&%I;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,3DL(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`R-RP@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@
M9F%I<B!V86QU97,@;V8@9&5R:79A=&EV92!W87)R86YT<R!O;B!B87-I<R!O
M9B!V86QU871I;VX@;6]D96P\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%R:V5T('9A
M;'5E(&]F(&-O;6UO;B!S=&]C:R!O;B!M96%S=7)E;65N="!D871E("@Q*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C,Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$N,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E(&EN=&5R97-T(')A=&4@
M*#(I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XY-"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C(T
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`N,S,E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CQS=7`^6S)=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XS-24\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G0@;&EV97,@:6X@>65A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<W('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@=F]L871I;&ET>2`H,RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-C$N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34W+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S.2XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,UT\
M+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-38N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I
M9&5N9"!Y:65L9"`H-"D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/'-U<#Y;-%T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;-%T\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V)A8FEL:71Y
M(&]F('-T;V-K(&]F9F5R:6YG(&EN(&%N>2!P97)I;V0@;W9E<B`U('EE87)S
M("@U*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M<W5P/ELU73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y286YG92!O9B!P97)C96YT86=E(&]F(&5X:7-T:6YG('-H87)E
M<R!O9F9E<F5D("@V*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@
M;V8@9F%I<B!V86QU97,@;V8@9&5R:79A=&EV92!W87)R86YT<R!O;B!B87-I
M<R!O9B!V86QU871I;VX@;6]D96P\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061J=7-T
M960@97AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XX,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXT-S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S="!R871E("@R*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XW-R4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C<W)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELR73PO<W5P/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!L:79E<R!I;B!Y
M96%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<T('EE87)S(#(@;6]N=&AS(#$Y(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D@*#,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-C$N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38Q+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\<W5P/ELS73PO<W5P/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8F%B:6QI='D@;V8@<W1O8VL@;V9F
M97)I;F<@:6X@86YY('!E<FEO9"!O=F5R(#4@>65A<G,@*#4I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;-5T\+W-U<#X\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!P<FEC92!R86YG92`H-RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XU-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XV/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XU-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XU-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@9F%I<B!V86QU97,@
M;V8@9&5R:79A=&EV92!W87)R86YT<R!O;B!B87-I<R!O9B!V86QU871I;VX@
M;6]D96P\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061J=7-T960@97AE<F-I<V4@<')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XT,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XR
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XR,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C(T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K
M(&9R964@:6YT97)E<W0@<F%T92`H,BD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`N,3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,"XQ,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/'-U<#Y;,ET\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G0@;&EV97,@:6X@>65A<G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<T(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<T(&UO;G1H<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D@*#,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELS73PO<W5P/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8F%B:6QI='D@
M;V8@<W1O8VL@;V9F97)I;F<@:6X@86YY('!E<FEO9"!O=F5R(#4@>65A<G,@
M*#4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U
M<#Y;-5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!P<FEC
M92!R86YG92`H-RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XQ,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT9"!C;VQS<&%N/3-$.3X\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V
M86QI9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0X
M('9A;&EG;CTS1'1O<#Y4:&4@;6%R:V5T('9A;'5E(&]F(&-O;6UO;B!S=&]C
M:R!I<R!B87-E9"!O;B!A;B!E;G1E<G!R:7-E('9A;'5A=&EO;CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-
M"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,ET\+W1D/@T*("`@("`@("`\
M=&0@8V]L<W!A;CTS1#@@=F%L:6=N/3-$=&]P/E1H92!R:7-K+69R964@:6YT
M97)E<W0@<F%T92!W87,@9&5T97)M:6YE9"!B>2!M86YA9V5M96YT('5S:6YG
M('1H92!4<F5A<W5R>2!":6QL(&%S(&]F('1H92!R97-P96-T:79E(&UE87-U
M<F5M96YT(&1A=&4\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^
M6S-=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0X('9A;&EG;CTS1'1O
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M86UE(&EN9'5S=')Y(&%N9"!R96=I;VX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V
M86QI9VX],T1T;W`^6S1=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0X
M('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT(&1E=&5R;6EN960@=&AE(&1I=FED
M96YD('EI96QD('1O(&)E(#`E(&)A<V5D('5P;VX@:71S(&5X<&5C=&%T:6]N
M('1H870@:70@=VEL;"!N;W0@<&%Y(&1I=FED96YD<R!F;W(@=&AE(&9O<F5S
M965A8FQE(&9U='5R93PO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O
M<#Y;-5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#@@=F%L:6=N/3-$
M=&]P/DUA;F%G96UE;G0@:&%S(&1E=&5R;6EN960@=&AA="!T:&4@<')O8F%B
M:6QI='D@;V8@82!S=&]C:R!O9F9E<FEN9R!I<R`R-24@+2`T,"4@9F]R(&5A
M8V@@<75A<G1E<B!O9B!T:&4@;F5X="!F:79E('EE87)S/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF
M-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E
M,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E
M=#0R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2UI!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY$97)I=F%T:79E<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0S/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`Q.2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#(W+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIA;BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1&5R:79A=&EV92`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5S8W)I<'1I;VX@;V8@<FES:R!F<F5E(&EN=&5R97-T(')A=&4@9&5T
M97)M:6YA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=2:7-K+69R964@:6YT
M97)E<W0@<F%T92!W87,@9&5T97)M:6YE9"!B>2!M86YA9V5M96YT('5S:6YG
M('1H92!A=F5R86=E(&]F(#4@86YD(#<@>65A<B!A;F0@=&AE(#,M;6]N=&@@
M5')E87-U<GD@0FEL;"!A<R!O9B!T:&4@<F5S<&5C=&EV92!M96%S=7)E;65N
M="!D871E+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C
M=&5D(&1I=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-C<FEP
M=&EO;B!O9B!P<F]B86)I;&ET>2!O9B!S=&]C:R!O9F9E<FEN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)TUA;F%G96UE;G0@:&%S(&1E
M=&5R;6EN960@=&AA="!T:&4@<')O8F%B:6QI='D@;V8@82!S=&]C:R!O9F9E
M<FEN9R!I<R`R-24@+2`T,"4@9F]R(&5A8V@@<75A<G1E<B!O9B!T:&4@;F5X
M="!F:79E('EE87)S+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=0
M<F]B86)I;&ET>2!O9B!A('-T;V-K(&]F9F5R:6YG(&ES(#(U)2!F;W(@96%C
M:"!Q=6%R=&5R(&]F('1H92!N97AT(&9I=F4@>65A<G,N/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@<&5R8V5N=&%G92!O9B!E
M>&ES=&EN9R!S:&%R97,@;V9F97)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V5R:65S($4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&5R:79A=&EV92`H5&5X='5A;"D\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@;V8@=V%R<F%N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#`N,C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0Y/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@
M/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A
M;CTS1#@@=F%L:6=N/3-$=&]P/DUA;F%G96UE;G0@9&5T97)M:6YE9"!T:&4@
M9&EV:61E;F0@>6EE;&0@=&\@8F4@,"4@8F%S960@=7!O;B!I=',@97AP96-T
M871I;VX@=&AA="!I="!W:6QL(&YO="!P87D@9&EV:61E;F1S(&9O<B!T:&4@
M9F]R97-E96%B;&4@9G5T=7)E/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-PT*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E,5]F-61D7S1E8CE?.#`S
M8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E=#0S+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%04I!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY);F-O;64@5&%X97,@
M*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D('1A>"!A
M<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3,L-C`Y+#`S-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,L,#@Y+#,Q-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#0Y-RPU-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW-#$L-#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!D:69F97)E;F-E<R!I;B!T
M87@@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S,RPP
M-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#<T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(&1E9F5R<F5D('1A>"!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#,S.2PV,S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPX,S4L-#@S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M97-S.B!V86QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q-2PS,SDL-C,U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$S+#@S-2PT.#,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@
M=&%X(&%S<V5T<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P
M,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE
M971S+U-H965T-#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T1D%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/DEN8V]M92!487AE<R`H1&5T86EL<R`Q*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4V-H961U;&4@;V8@9&EF9F5R96YC92!B971W965N('1H92!I;F-O;64@
M=&%X('!R;W9I<VEO;B!A;F0@=&AE(%4N4RX@1F5D97)A;"!S=&%T=71O<GD@
M<F%T93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9E9&5R86P@:6YC;VUE('1A>&5S(&%T(#,T)3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@R+#@T,BPX,3`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#$W,2PR,S`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M961E<F%L(&EN8V]M92!T87AE<R!A="`S-"4L(%!E<F-E;G1A9V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,T+C`P)2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-"XP,"4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92UB87-E9"!C;VUP96YS871I;VX@8V]S=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<U-BPQ,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,S8L-SDV/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP
M96YS871I;VX@8V]S=',L(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDN,#0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C$N,SDE/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU
M92!O9B!D97)I=F%T:79E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C,S+#`T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L-S0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D97)I
M=F%T:79E<RP@4&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BXW.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C$S)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E8G0@9&ES8V]U
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#DL-#@P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L
M,#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5B="!D:7-C;W5N=',L(%!E<F-E;G1A
M9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0N,3@E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XV,R4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4P-"PQ-3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S,L-C4S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@
M=F%L=6%T:6]N(&%L;&]W86YC92P@4&5R8V5N=&%G93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<N.3DE/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N.#4E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O=FES:6]N(&9O
M<B!I;F-O;64@=&%X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO;B!F;W(@:6YC
M;VUE('1A>"P@4&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S!E930U-64Q7V8U9&1?-&5B
M.5\X,#-B7S$S93AF-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R
M:W-H965T<R]3:&5E=#0U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4T1!0SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,@*$1E=&%I;',@5&5X='5A;"D@
M*%531"`D*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DEN8V]M92!487AE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO
M<W-E<R`H(DY/3',B*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&ER871I;VX@9&%T97,@;V8@;W!E<F%T:6YG(&QO<W,@8V%R
M<GEF;W)W87)D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C
M(#,Q+`T*"0DR,#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^52Y3+B!&961E<F%L('-T871U=&]R>2!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S!E930U-64Q
M7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-PT*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R
M,V0U8C<O5V]R:W-H965T<R]3:&5E=#0V+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1U9!1SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%B8F]T="!":6]T
M:&5R87!E=71I8W,@0V]R<"!;365M8F5R72!\(%!H87-E($D@0VQI;FEC86P@
M5')I86P@;V8@82!L:6-E;G-E9"!P<F]D=6-T(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F
M(&UI;&5S=&]N92!P87EM96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE<R!P87EM96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-3`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@6TUE;6)E<ET@?"!0:&%S92!)
M22!#;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U8W0@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-U;6UA<GD@;V8@;6EL97-T;VYE('!A>6UE;G0\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=('P@
M4&AA<V4@24E)($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC96YS960@<')O9'5C
M="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5M;6%R>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N
M97,@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P
M(%M-96UB97)=('P@0FEO;&]G:6-A;"!,:6-E;G-E($%P<&QI8V%T:6]N(&9I
M;&EN9R!W:71H(%4N4RX@1D1!(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N
M92!P87EM96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36EL97-T;VYE<R!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PW-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8F)O='0@0FEO
M=&AE<F%P975T:6-S($-O<G`@6TUE;6)E<ET@?"!&:7)S="!#;VUM97)C:6%L
M(%-A;&4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@;6EL97-T;VYE('!A>6UE;G0\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE
M<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%B8F]T="!":6]T:&5R87!E=71I8W,@
M0V]R<"!;365M8F5R72!\($%F=&5R($9I<G-T($YE="!386QE<R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5M;6%R>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N97,@<&%Y;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^365M;W)I86P@4VQO86X@2V5T=&5R:6YG($-A;F-E<B!#96YT
M97(@6TUE;6)E<ET@?"!.97<@1')U9R!!<'!L:6-A=&EO;B!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M
M;6%R>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N97,@<&%Y;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-96UO<FEA;"!3;&]A;B!+971T97)I;F<@0V%N8V5R($-E;G1E<B!;365M
M8F5R72!\(%)E8V5I<'0@;V8@4F5G=6QA=&]R>2!!<'!R;W9A;"!&<F]M(%4N
M4RX@1D1!(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL
M97-T;VYE<R!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$L-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?
M,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E
M930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S
M+U-H965T-#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5$1T%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A$971A:6QS
M(%1E>'1U86PI("A%;7!L;WEM96YT($-O;G1R86-T<R!;365M8F5R72P@55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M
M<&QO>65E(%-T;V-K($]P=&EO;B!;365M8F5R72!\($-O;6UO;B!3=&]C:R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H5&5X='5A;"D\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M=&EO;G,@9W)A;G1E9"!T;R!P=7)C:&%S92!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8W-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K($]P
M=&EO;B!;365M8F5R72!\(%)E<W1R:6-T960@4W1O8VL@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET
M;65N=',@86YD($-O;G1I;F=E;F-I97,@*%1E>'1U86PI/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&=R86YT
M960@=&\@<'5R8VAA<V4@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VX@9W)A;G1E9"!A<R!S:6=N(&]N(&)O
M;G5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<'1I;VX@9W)A;G1E9"!A<R!S:6=N(&]N(&)O;G5S+"!$97-C<FEP=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RA#*2`Q,#`L,#`P('-H
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M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H:65F($5X96-U=&EV92!/
M9F9I8V5R($%N9"!$:7)E8W1O<B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N
M=&EN9V5N8VEE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A<V4@<V%L87)Y(&%T(&%N;G5A;"!R871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,S4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R
M9F]R;6%N8V4@3V)J96-T:79E($1E<V-R:7!T:6]N/"]T9#X-"B`@("`@("`@
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M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y
M7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K
M<VAE971S+U-H965T-#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$595DU-/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A$
M971A:6QS(%1E>'1U86P@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#,^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,#$L(#(P,3(\8G(^
M4F5N=&%L($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E)E;G1A;"!!9W)E96UE
M;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CY!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@
M6TUE;6)E<ET\8G(^4')O9'5C="!$979E;&]P;65N="!A;F0@4&%T96YT($QI
M8V5N<V4@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^06)B;W1T($)I;W1H97)A
M<&5U=&EC<R!#;W)P(%M-96UB97)=/&)R/E!R;V1U8W0@1&5V96QO<&UE;G0@
M86YD(%!A=&5N="!,:6-E;G-E($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D%B
M8F]T="!":6]T:&5R87!E=71I8W,@0V]R<"!;365M8F5R73QB<CY!9G1E<B!&
M:7)S="!.970@4V%L97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY!8F)O='0@0FEO=&AE<F%P
M975T:6-S($-O<G`@6TUE;6)E<ET\8G(^069T97(@1FER<W0@3F5T(%-A;&5S
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-
M96UB97)=/&)R/D%F=&5R($9I<G-T($YE="!386QE<R!;365M8F5R73QB<CY0
M<F]D=6-T($1E=F5L;W!M96YT(&%N9"!0871E;G0@3&EC96YS92!!9W)E96UE
M;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CY!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@
M6TUE;6)E<ET\8G(^069T97(@1FER<W0@3F5T(%-A;&5S(%M-96UB97)=/&)R
M/E!R;V1U8W0@1&5V96QO<&UE;G0@86YD(%!A=&5N="!,:6-E;G-E($%G<F5E
M;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/D%B8F]T="!":6]T:&5R87!E=71I8W,@0V]R
M<"!;365M8F5R73QB<CY0:&%S92!)($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC
M96YS960@<')O9'5C="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D%B8F]T="!":6]T:&5R87!E
M=71I8W,@0V]R<"!;365M8F5R73QB<CY0:&%S92!)($-L:6YI8V%L(%1R:6%L
M(&]F(&$@;&EC96YS960@<')O9'5C="!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D%B8F]T="!"
M:6]T:&5R87!E=71I8W,@0V]R<"!;365M8F5R73QB<CY0:&%S92!)($-L:6YI
M8V%L(%1R:6%L(&]F(&$@;&EC96YS960@<')O9'5C="!;365M8F5R73QB<CY0
M<F]D=6-T($1E=F5L;W!M96YT(&%N9"!0871E;G0@3&EC96YS92!!9W)E96UE
M;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1F5B+B`R."P@,C`P,CQB<CY-96UO<FEA;"!3;&]A;B!+971T97)I;F<@0V%N
M8V5R($-E;G1E<B!;365M8F5R73QB<CY,:6-E;G-E(&%G<F5E;65N="!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/DUE;6]R:6%L(%-L;V%N($ME='1E<FEN9R!#86YC97(@0V5N
M=&5R(%M-96UB97)=/&)R/DQI8V5N<V4@86=R965M96YT(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^365M;W)I86P@4VQO86X@2V5T=&5R:6YG($-A;F-E<B!#96YT97(@6TUE
M;6)E<ET\8G(^3&EC96YS92!A9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`R-RP@,C`Q,CQB<CY-96UO
M<FEA;"!3;&]A;B!+971T97)I;F<@0V%N8V5R($-E;G1E<B!;365M8F5R73QB
M<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY/86L@
M4FED9V4@3F%T:6]N86P@3&%B;W)A=&]R>2!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D]A:R!2
M:61G92!.871I;VYA;"!,86)O<F%T;W)Y(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,#8L(#(P,3(\8G(^07!T:78@
M4V]L=71I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^07!T:78@4V]L=71I;VYS(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^07!T:78@4V]L=71I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#<\8G(^07!T:78@
M4V]L=71I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D%U9RX@,3(L(#(P,3,\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E
M<B!297-E87)C:"!#96YT97(@6TUE;6)E<ET\8G(^;&EC96YS92!A;F0@<W!O
M;G-O<F5D(')E<V5A<F-H(&%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#$U+"`R,#$R/&)R/D9R960@
M2'5T8VAI;G-O;B!#86YC97(@4F5S96%R8V@@0V5N=&5R(%M-96UB97)=/&)R
M/FQI8V5N<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q
M-2P@,C`Q,CQB<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E
M;G1E<B!;365M8F5R73QB<CYL:6-E;G-E(&%N9"!S<&]N<V]R960@<F5S96%R
M8V@@86=R965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^1G)E9"!(=71C:&EN<V]N($-A
M;F-E<B!297-E87)C:"!#96YT97(@6TUE;6)E<ET\8G(^;&EC96YS92!A;F0@
M<W!O;G-O<F5D(')E<V5A<F-H(&%G<F5E;65N="!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#$U+"`R,#$R/&)R/D9R
M960@2'5T8VAI;G-O;B!#86YC97(@4F5S96%R8V@@0V5N=&5R(%M-96UB97)=
M/&)R/FQI8V5N<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@
M6TUE;6)E<ET\8G(^36%X:6UU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#$U+"`R,#$R/&)R/D9R960@2'5T8VAI
M;G-O;B!#86YC97(@4F5S96%R8V@@0V5N=&5R(%M-96UB97)=/&)R/FQI8V5N
M<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@6TUE;6)E<ET\
M8G(^36EN:6UU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6PN(#$Y+"`R,#$R/&)R/D9R960@2'5T8VAI;G-O;B!#86YC
M97(@4F5S96%R8V@@0V5N=&5R(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L
M($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y!=6<N(#(X+"`R,#$R/&)R/E5N:79E<G-I='D@;V8@5&5X87,@
M32Y$+B!!;F1E<G-O;B!#86YC97(@0V5N=&5R(%M-96UB97)=/&)R/D-L:6YI
M8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB<CY.;W1E/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,C8L(#(P,3(\8G(^2F]H
M;G,@2&]P:VEN<R!5;FEV97)S:71Y(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R
M:6%L($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y.;W8N(#(Q+"`R,#$R/&)R/E5N:79E<G-I='D@;V8@4&5N
M;G-Y;'9A;FEA(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N
M="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87D@,#DL(#(P,3$\8G(^2F%M97-S($-A<&ET86P@1W)O=7`@3$Q#(%M-96UB
M97)=/&)R/E1R86YS86-T:6]N(&UA;F%G96UE;G0@86=R965M96YT(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3,\8G(^1F]R;65R($-%3R!;365M8F5R73QB<CY397!A<F%T:6]N(&%N
M9"!3971T;&5M96YT($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(X+"`R,#$S/&)R/D9O<FUE<B!#
M14\@6TUE;6)E<ET\8G(^4V5P87)A=&EO;B!A;F0@4V5T=&QE;65N="!!9W)E
M96UE;G0@6TUE;6)E<ET\8G(^3F]T93QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D9O<FUE<B!#14\@6TUE;6)E
M<ET\8G(^4V5P87)A=&EO;B!A;F0@4V5T=&QE;65N="!!9W)E96UE;G0@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*%1E>'1U86PI
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@9F5E
M('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#<U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T('-A;&5S(&EN(&UI;&5S=&]N97,@<&%Y;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36EL97-T;VYE('!A>6UE;G0@9&%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/DIA;B`S,2P-"@D),C`Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^2G5L(#(T
M+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S
M8W)I<'1I;VX@;V8@<F]Y86QT>2!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG5V4@86=R965D('1O('!A>2!T;R!!8F)O='0@
M0FEO=&AE<F%P975T:6-S($-O<G`@;VX@82!C;W5N=')Y+6)Y+6-O=6YT<GD@
M8F%S:7,@82!R;WEA;'1Y(&]F('5P('1O(#$R)2!O9B!N970@<V%L97,@;V8@
M86QL(&QI8V5N<V5D('!R;V1U8W1S('5N=&EL('1H92!L871E<B!O9CH@*#$I
M(#$R+C4@>65A<G,@869T97(@=&AE(&9I<G-T(&-O;6UE<F-I86P@<V%L92P@
M;W(@*#(I('=H96X@=&AE('!A=&5N=',@97AP:7)E+CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=#;VUP86YY('-H86QL
M('!A>2!T;R!!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@;VX@82!C;W5N
M=')Y+6)Y+6-O=6YT<GD@8F%S:7,@82!R;WEA;'1Y(&]F(#$R)2!O9B!N970@
M<V%L97,@;V8@86QL(&QI8V5N<V5D('!R;V1U8W1S('5N=&EL('1H92!L871E
M<B!O9CH@*#$I(#$R+C4@>65A<G,@869T97(@=&AE(&9I<G-T(&-O;6UE<F-I
M86P@<V%L92P@;W(@*#(I('=H96X@=&AE('!A=&5N=',@97AP:7)E+CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)U=E(&%G<F5E<R!T;R!P87D@=&\@35-+0T,@;VX@82!C;W5N=')Y+6)Y
M+6-O=6YT<GD@8F%S:7,@82!R;WEA;'1Y(&]F(#(E(&]F(&YE="!S86QE<R!O
M9B!A;&P@;&EC96YS960@<')O9'5C=',@=6YT:6P@=&AE(&QA=&5R(&]F.B`H
M,2D@,3`@>65A<G,@9G)O;2!T:&4@9FER<W0@8V]M;65R8VEA;"!S86QE+"!O
M<B`H,BD@=VAE;B!T:&4@<&%T96YT<R!E>'!I<F4N/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T-O;7!A;GD@<VAA;&P@
M<&%Y('1O($U32T-#(&]N(&$@8V]U;G1R>2UB>2UC;W5N=')Y(&)A<VES(&$@
M<F]Y86QT>2!O9B`R)2!O9B!N970@<V%L97,@;V8@86QL(&QI8V5N<V5D('!R
M;V1U8W1S('5N=&EL('1H92!L871E<B!O9CH@*#$I(#$P('EE87)S(&9R;VT@
M=&AE(&9I<G-T(&-O;6UE<F-I86P@<V%L92P@;W(@*#(I('=H96X@=&AE('!A
M=&5N=',@97AP:7)E+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B=2;WEA;'1Y('!A>6UE;G1S(&]F(#(E
M(&]F(&YE="!S86QE<R!W:6QL(&)E(&1U92!T;R!&2$-20RX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG4F]Y86QT>2!P
M87EM96YT<R!O9B`R)2!O9B!N970@<V%L97,@=VEL;"!B92!D=64@=&\@1DA#
M4D,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F]Y86QT>2!O9B!.970@4V%L97,@4&5R8V5N=&%G
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I<G-T(&-O;6UE<F-I
M86P@<V%L92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<Q,B!Y96%R<R`V(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y496-H;F]L;V=Y(&%C8V5S<R!F964\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;FYU86P@;6%I;G1E;F%N8V4@9F5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YN=6%L(')E<V5A<F-H(&9U;F1I
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!R
M861I;V%C=&EV92!M871E<FEA;"!U<V5D(&9O<B!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,S,L,3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,S+#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O:F5C="!E<W1I;6%T960@8V]S="!F;W(@8VQI;FEC86P@=')I86QS(&]F
M(&1R=6<@06,M,C(U+4AU33$Y-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX
M-3DL,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;W=N('!A>6UE;G0@;V8@<')O:F5C
M="!E<W1I;6%T960@8V]S="!P97)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(N-3`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(N-3`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;W=N('!A>6UE;G0@9F]R('!R;VIE8W0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C,Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(S.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC86P@=')I
M86P@8V]S="!F;W(@87!P<F]V86P@;V8@9F]O9"!A;F0@9')U9R!A9&UI;FES
M=')A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,RPU,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L,C`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&=6YD(&9O<B!&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H
M($-E;G1E<B!L86(@*"!097(@>65A<B!F;W(@=&AE(&9I<G-T('1W;R!Y96%R
M<R`I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U;F0@
M9F]R($9R960@2'5T8VAI;G-O;B!#86YC97(@4F5S96%R8V@@0V5N=&5R(&QA
M8B`H('1H97)E869T97(@*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2;WEA;'1Y('!A>6UE;G0@9F]R('1H92!C;VUM97)C:6%L('5S
M92!O9B!D<G5G<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,W+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!0871I96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT
M('!A:60@=&\@96%C:"!P871I96YT(&%F=&5R($-O;7!L971I;F<@8VQI;FEC
M86P@=')I86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,Q+#$X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#,V-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X,2PR,#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PU
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS,2PW-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&%R="UU<"!F964@9F]R(&-L:6YI8V%L('1R:6%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW.2PV,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PW-#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPY-#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPX-#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&%R="UU<"!D=64@8V]S="!P86ED(&1A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;"`Q,"P-"@D)
M,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-"@D),C`Q
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F]N("T@<F5F=6YD86)L92!I;G-T:71U=&EO;F%L(&9E93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-"PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N;G5A;"!P:&%R;6%C>2!F
M964\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!P<F]C
M97-S:6YG(&9E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;G1H;'D@
M9F5E(')E8V5I=F5D(&)Y(&UA;F%G96UE;G0@9FER;3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@9G5L;'D@9&EL=71E9"!C
M87!I=&%L('-T;V-K(&5Q=6%L('1O(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@97AE<F-I<V%B;&4@;F]T:6-E
M('!E<FEO9"!D97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5&AE('=A
M<G)A;G1S(&-O;G1A:6X@82!P<F]V:7-I;VX@=VAE<F5I;B!T:&4@:&]L9&5R
M(&UA>2!W86EV92!T:&4@.3`@9&%Y(&5X97)C:7-E(&YO=&EC92!R97%U:7)E
M;65N="!B>2!G:79I;F<@-C4@9&%Y<R!P<FEO<B!N;W1I8V4@;V8@<W5C:"!W
M86EV97(N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!P97)I;V0@;V8@<VAA<F5S(&%V
M86EL86)I;&ET>2!B>2!E>&5R8VES92!O9B!W87)R86YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B=4:&4@<VAA<F5S(&%V86EL86)L92!B>2!E>&5R8VES92!O9B!T
M:&ES(%=A<G)A;G0@87)E(&%L<V\@<F5S=')I8W1E9"!A;F0@;6%Y(&YO="!B
M92!S;VQD(&]R(&]T:&5R=VES92!T<F%N<V9E<F5D('5N=&EL('1H92!E87)L
M:65R(&]F('1W96QV92!M;VYT:',@9G)O;2!T:&4@8VQO<VEN9R!D871E(&]F
M('1H92!0=6)C;R!4<F%N<V%C=&EO;CL@;W(@9F]R('-I>"!M;VYT:',@869T
M97(@=&AE('!L86YN960@4F5G:7-T<F%T:6]N(%-T871E;65N="!I<R!D96-L
M87)E9"!E9F9E8W1I=F4N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(&%M;W5N="!O9B!O=70@;V8@
M<&]C:V5T(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYS:61E<F%T:6]N('!U<G-U86YT('1O(&%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG5&AE($-O;7!A;GD@<&%I9"!-<BX@5&%L;&5Y("0Q,C4L
M,#`P(&]N($UA<F-H(#@L(#(P,3,@86YD(&$@<V5C;VYD('!A>6UE;G0@;V8@
M)#$R-2PP,#`@;VX@4V5P=&5M8F5R(#$L(#(P,3,N(%1H92!#;VUP86YY(&%L
M<V\@<&%I9"!-<BY486QL97D@82!P97)F;W)M86YC92!B;VYU<R!O9B`D-C`L
M,#`P(&9O<B!H:7,@<V5R=FEC92!F<F]M($%U9W5S="`Q-2P@,C`Q,B!T;R!$
M96-E;6)E<B`S,2P@,C`Q,BX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!P87EA8FQE(&EN(&EN<W1A;&QM
M96YT<R!U;F1E<B!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R($]F($EN<W1A;&QM96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y097)F;W)M86YC92!B;VYU<R!P87EA8FQE('5N9&5R(&%G<F5E
M;65N="!F;W(@<V5R=FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E;G1A;"!A9W)E96UE;G0@<F5N97=A;"!D97-C<FEP=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG5&AE(&%G<F5E;65N="!A=71O
M;6%T:6-A;&QY(')E;F5W<R!O;B!A(&UO;G1H+71O+6UO;G1H(&)A<VES(&%N
M9"!R97%U:7)E<R!A('1W;R!M;VYT:"!N;W1I8V4@;V8@=&5R;6EN871I;VXN
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT(&]F
M(&9I<G-T(&EN<W1A;&QM96YT(&9O<B!S97)V:6-E<R!B>2!C;VUP86YY/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG('!A>6UE
M;G0@;V8@9FEN86P@:6YS=&%L;&UE;G0@9F]R('-E<G9I8V5S(&)Y(&-O;7!A
M;GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N="!O9B!P
M97)F;W)M86YC92!B;VYU<R!F;W(@<V5R=FEC97,@8GD@8V]M<&%N>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5N="!A9W)E96UE;G0@=&5R
M;6EN871I;VX@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M2F%N(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^2F%N(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]T:6-E('!E<FEO9"!F;W(@=&5R;6EN
M871I;VX@;V8@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG-C`@9&%Y<R!P<FEO<B!T;R!*86YU87)Y(#$L(#(P,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U1H92!A
M9W)E96UE;G0@=&5R;6EN871E9"!-87D@,S$L(#(P,3,N/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X
M9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U
M93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE
M970T.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P138R0D<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^17%U:71Y("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#0^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`P.3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T
M:6]N<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!S=&]C:R!O<'1I;VX@86-T:79I
M=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!5;FET<RP@0F5G:6YN:6YG(&)A;&%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S,P+#$S-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W,RPX-3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-S,L.#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A;F-E;&QA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-#DL.34P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$R."PP-3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&5X<&ER960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PV,3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!5;FET<RP@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,C@P+#$X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S,P+#$S-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W,RPX-3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S,L
M.#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@0F5G:6YN
M:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XY-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2XR.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XR.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E
M(%!R:6-E+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C(Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@
M079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@>65A<G,I
M+"!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S@@>65A<G,@,B!M;VYT:',@,2!D87D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG."!Y96%R<R`Q,"!M;VYT:',@,C@@
M9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<U('EE87)S(#8@;6]N=&AS(#0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#8@;6]N=&AS
M(#0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L($)E9VEN;FEN
M9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8X
M-2PX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@
M26YT<FEN<VEC(%9A;'5E+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PV,#DL,#,U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C@U+#@P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O
M9B!S=&]C:R!O<'1I;VX@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!5;FET<RP@
M0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R+#<W,"PV,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#,V-"PU-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&5X97)C:7-E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPS,#0L.3$P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=A<G)A;G1S(&5X<&ER960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L,#(S+#<X-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI=',L($5N9&EN
M9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#0T
M,2PY-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPW-S`L-C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PS-C0L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M17AE<F-I<V4@4')I8V4L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D
M($%V97)A9V4@17AE<F-I<V4@4')I8V4L(&5X97)C:7-E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C8U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E
M<F%G92!%>&5R8VES92!0<FEC92P@97AP:7)E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%
M>&5R8VES92!0<FEC92P@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XW-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XY-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XU,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M("AI;B!Y96%R
M<RDL($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-2!Y96%R<R`Q(&UO;G1H(#(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<T('EE87)S(#4@;6]N=&AS(#(S
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG-B!Y96%R<R`Y(&UO;G1H<R`T(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN
M=')I;G-I8R!686QU92P@0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L,3$T+#<V.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C8Q+#,V-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G
M<F5G871E($EN=')I;G-I8R!686QU92P@16YD:6YG($)A;&%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2PV.3$L,S`R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#$Q-"PW
M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,L,C8Q+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R,V0U
M8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?9C5D
M9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970U,"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P135.14T^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^17%U
M:71Y("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R-R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ-3$@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,38P($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0U/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-#XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0T/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R-R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ-3$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#@^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`P-SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E=A<G)A;G0@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,CQB<CY787)R86YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^02!787)R86YT(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^4W1O8VL@3W!T:6]N<R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/E-T;V-K($]P
M=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%Y(#,Q+"`R,#$S/&)R/E-T;V-K($]P=&EO;G,@6TUE;6)E<ET\8G(^
M1F]R;65R($1I<F5C=&]R($%N9"!#;VYS=6QT86YT<R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/C(P,3,@4W1O8VL@4&QA;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/C(P,3,@4W1O8VL@4&QA
M;B!;365M8F5R73QB<CY%;7!L;WEE97,@1&ER96-T;W)S($%N9"!#;VYS=6QT
M86YT<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/C(P,3,@17%U:71Y($EN8V5N=&EV92!0;&%N
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^,C`Q,R!%<75I='D@26YC96YT:79E(%!L86X@6TUE
M;6)E<ET\8G(^16UP;&]Y965S($1I<F5C=&]R<R!!;F0@0V]N<W5L=&%N=',@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CY-86YA9V5M96YT($9I<FT@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY#
M;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CY#;VUM;VX@4W1O8VL@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`P-SQB<CY#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CY#;VUM;VX@4W1O
M8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CY#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY#
M;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^02!787)R86YT(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/D(@5V%R<F%N=',@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CY#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^36%N86=E;65N="!&
M:7)M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/DUA
M;F%G96UE;G0@1FER;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D-O;6UO;B!3=&]C:R!;365M
M8F5R73QB<CY,86ED;&%W("9A;7`[($-O(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^0V]M;6]N
M(%-T;V-K(%M-96UB97)=/&)R/DQA:61L87<@)F%M<#L@0V\@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CY#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^3&%I9&QA=R`F86UP.R!#
M;R!;365M8F5R73QB<CY0;&%C96UE;G0@06=E;G0@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CY#
M;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^3&%I9&QA=R`F86UP.R!#;R!;365M
M8F5R73QB<CY0;&%C96UE;G0@06=E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`Q.2P@,C`Q,CQB<CY397)I97,@
M12!0<F5F97)R960@4W1O8VL\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y("A497AT=6%L*3PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@9F]R
M('-E<G9I8V5S+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV-BPT,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-BPT,#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!F;W(@<V5R=FEC97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SDX+#@Q,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SDX
M+#@Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,SDX+#@Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!I<W-U960@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K(&]F9F5R:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-#(L,3DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3DL.3<R+#<X-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%I<V5D
M(&]F9F5R:6YG(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,34Q+#0U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3DL
M,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPQ.#0L.38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0R+#<Q,2PW.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@:7-S=65D(&EN('-T;V-K(&]F9F5R:6YG+"!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$Q."PY.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.38X+#<U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<L.#DQ+#$T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#<P-RPR-3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M86QE(&]F(&-O;6UO;B!S=&]C:RP@;F5T(&]F9F5R:6YG/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT-CDL-S<V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8V,"PQ-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#,W.2PS-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!L86-E;65N="!A
M9V5N="!C87-H(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3@L,3<T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ+#$Q-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<T
M,BPQ.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!L86-E;65N="!A9V5N="!C;VUM:7-S:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3$U+#$T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW-2PY,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV,3@L-#DW/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;&%C96UE;G0@86=E
M;G0@97AP96YS92!R96EM8G5R<V5M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S+#`R.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-2PQ.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,C,L-CDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I<W-U960@=&\@<'5R8VAA
M<V4@8V]M;6]N('-T;V-K+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C<L.#0U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ
M,3@L.3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PU-3DL-3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PW,38L,S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY-S0L-S<T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Q+#`Y-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDX-BPS
M.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU.#@L.30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PQ,CDL.3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@;V8@=V%R<F%N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXT.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XR-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@97AP:7)A
M=&EO;B!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3(P(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S<@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D('1O('!U
M<F-H87-E(&-O;6UO;B!S=&]C:RP@9F%I<B!V86QU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y
M.2PW,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L.34W+#<U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,34S+#0T,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U.2PP-#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#@L-3<Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M;&%C96UE;G0@86=E;G0@<V5R=FEC97,@9F5E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX+#`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8P+#DP-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%N:R!E<V-R;W<@9F5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&)Y
M(&-O;G9E<G-I;VX@;V8@;F]T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-3(L-34P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C<G5E9"!M86YA9V5M96YT(&9E97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38L-S0T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@=&\@9F]R;65R('-H
M87)E:&]L9&5R('5N9&5R('-H87)E(&5X8VAA;F=E(&%G<F5E;65N="P@4VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M(&ES<W5E9"!T;R!F;W)M97(@<VAA<F5H;VQD97)S('5N9&5R('-H87)E(&5X
M8VAA;F=E(&%G<F5E;65N="P@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PY.#8L-38V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@<VAA<F4@8F%S960@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP,30L-#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M8V]R9&5D(&]P=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY-2PY-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,BPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.#@L-#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0P+#0P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!086ED($9O<B!#86YC96QL
M871I;VX@3V8@4VAA<F5S($)Y($-O;7!A;GD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!0=7)C:&%S960@069T97(@0V%N8V5L871I;VX@
M3V8@3W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#DL.34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XV-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M(%=A<G)A;G0@17AE<F-I<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L-#8S+#8T,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!I<F%T:6]N(&1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397`@.2P-"@D),C`R
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y397`@.2P-"@D),C`R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!A=F%I;&%B;&4@9F]R(&=R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-3`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(X-"PS-S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,Q,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(L,C(S+#DR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,BPQ-S,L,S<W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L,#4R+#`S-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-BPS,S8L-#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R.#0L,S<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q-C@L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C@T+#,W,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38X+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X
M9C8R,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U
M93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE
M970U,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15%'04<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4W1O8VL@3W!T:6]N(%!L86X@*$1E=&%I;',I("A3=&]C:R!/<'1I;VYS
M(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@3W!T:6]N<R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=6UM87)Y(&]F('-T;V-K(&]P=&EO;B!A8W1I=FET:65S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@56YI=',L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#,S,"PQ,S0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S,L.#4Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<S+#@U.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!5;FET<RP@1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L,#4V+#(W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@56YI=',L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#(X,"PQ.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#,S,"PQ,S0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S,L.#4Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<S+#@U.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@0F5G:6YN:6YG(&)A
M;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XY-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2XR.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2XR.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L
M($=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0
M<FEC92P@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XY-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XY-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XR.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XR.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E
M<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2`H:6X@>65A<G,I+"!/
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S@@
M>65A<G,@,B!M;VYT:',@,2!D87D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG."!Y96%R<R`Q,"!M;VYT:',@,C@@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<U('EE87)S(#8@;6]N=&AS(#0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#8@;6]N=&AS(#0@
M9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@
M5&5R;2`H:6X@>65A<G,I+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S@@>65A<G,@,3`@;6]N=&AS(#(Q(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G
M<F5G871E($EN=')I;G-I8R!686QU92P@0F5G:6YN:6YG(&)A;&%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C@U+#@P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU
M92P@1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I
M8R!686QU92P@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PV,#DL,#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.#4L.#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P964T-35E,5]F-61D7S1E
M8CE?.#`S8E\Q,V4X9C8R,V0U8C<O5V]R:W-H965T<R]3:&5E=#4R+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%1%9&2SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!/
M<'1I;VX@4&QA;B`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,CDL(#(P
M,3(\8G(^4W1O8VL@3W!T:6]N<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-T;V-K($]P=&EO
M;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^
M4W1O8VL@3W!T:6]N<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/E-T;V-K($]P=&EO;G,@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`P.3QB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#@\8G(^4W1O8VL@
M3W!T:6]N<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#`W/&)R/E-T;V-K($]P=&EO;G,@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P
M-CQB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^36EN:6UU;2!;365M
M8F5R73QB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^36EN:6UU;2!;
M365M8F5R73QB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#@\8G(^36EN:6UU
M;2!;365M8F5R73QB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#<\8G(^36EN
M:6UU;2!;365M8F5R73QB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#8\8G(^
M36EN:6UU;2!;365M8F5R73QB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^36%X:6UU;2!;365M8F5R73QB<CY3=&]C:R!/<'1I;VYS(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3`\8G(^36%X:6UU;2!;365M8F5R73QB<CY3=&]C:R!/<'1I;VYS(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,#@\8G(^36%X:6UU;2!;365M8F5R73QB<CY3=&]C:R!/<'1I;VYS(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,#<\8G(^36%X:6UU;2!;365M8F5R73QB<CY3=&]C:R!/<'1I;VYS
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,#8\8G(^36%X:6UU;2!;365M8F5R73QB<CY3=&]C:R!/<'1I
M;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^,C`P,R!3=&]C:R!0;&%N(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^,C`P,R!3=&]C:R!0;&%N(%M-96UB97)=/&)R/DUI;FEM=6T@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CXR,#`S(%-T;V-K(%!L86X@6TUE;6)E<ET\8G(^36%X:6UU;2!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/C(P,3(@16UP;&]Y964@4W1O8VL@3W!T:6]N(%!L86X@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W1O8VL@3W!T:6]N(%!L86X@*%1E>'1U86PI/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@9W)A;G1E9"!O<'1I;VX@=&\@<'5R
M8VAA<V4@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U-RPU-S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM
M=6T@9W)A;G1E9"!O<'1I;VX@869T97(@86UE;F1M96YT(&EN(#(P,#@\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3<X+#$U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4@8F%S960@<&%Y;65N="!A=V%R9"!V
M97-T:6YG('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<T('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E(&)A<V5D('!A>6UE;G0@87=A<F0@;6]N
M=&AL>2!V97-T:6YG('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E
M<F-E;G1A9V4@;V8@86=G<F5G871E(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@
M8V]M;6]N('-H87)E<R!R97-E<G9E9"!U;F1E<B!O9F9E<FEN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K(')E<V5R=F5D(&9O<B!F=71U<F4@:7-S=6%N
M8V4@=6YD97(@15-/4#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#0U-2PW-S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E;65N
M="!I;B!N=6UB97(@;V8@<VAA<F5S('5N9&5R('!L86X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR
M,3<L.#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!S:&%R97,@<F5S97)V960@9F]R(&ES<W5A;F-E
M('5N9&5R('!L86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ-34L,C@P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I
M;VX@9W)A;G1E9"!T;R!E;7!L;WEE97,@=&\@<'5R8VAA<V4@8V]M;6]N('-T
M;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`U
M-BPR-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S,L,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8Y+#DT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Q,RPR,C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#8L,#8P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K(&]P=&EO;B!G<F%N=&5D('1O('!U<F-H87-E(&-O;6UO;B!S
M=&]C:RP@97AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+CD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,S4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N(&=R86YT960@=&\@<'5R
M8VAA<V4@8V]M;6]N('-T;V-K+"!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E
M(&]F('-T;V-K(&]P=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+#4Q.2PW-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-"PY.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-"PQ-3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S-RPV
M-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L,#4Q+#(X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C;W5N="!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C@P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C$V
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+C0V)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,N-#8E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"XR.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@;&EF
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<Q+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SDN,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30S+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U
M-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-C`N-#0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V,2XT.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@9&EV
M:61E;F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VL@;W!T:6]N(&-A;F-E;&QE9"!D=7)I;F<@<&5R:6]D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PV,3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VL@;W!T:6]N(&9O<F9E:71U<F5S(&1U<FEN9R!P97)I
M;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#DL.34P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R."PP-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@<W1O8VL@
M;W!T:6]N('5N:71S(')E<')I8V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C<S+#@U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U
M='-T86YD:6YG('-T;V-K(&]P=&EO;B!E>&5R8VES92!P<FEC92!A9G1E<B!R
M97!R:6-I;F<@;V8@<W1O8VL@;W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4@8F%S960@8V]M<&5N<V%T:6]N(&-O<W0@869T97(@<F5P<FEC:6YG
M(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-"PX-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G
M;FEZ960@<VAA<F4@8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,30L-#<T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY.3@L
M-#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30L-3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;W)D960@;W!T:6]N
M(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.34L
M.3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`W,BPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$X."PT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T,"PT,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8V+#$W,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL
M.3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E
M.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U
M-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H
M965T-3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5)3D%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E=A<G)A;G1S("A$971A:6QS*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@=V%R<F%N
M="!I<W-U960\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT<R!I<W-U960@=VET:"!C;VYV97)T:6)L92!N;W1E
M<R`H4V5E($YO=&4@-2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.#<L,#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I<W-U960@=&\@:6YV
M97-T;W)S('=I=&@@4W1O8VL@3V9F97)I;F<@*%-E92!.;W1E(#8@86YD($YO
M=&4@.2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T,BPQ.#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#DW,BPW-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!T;R!I;G9E<W1O<G,@=VET:"!#
M;VUM;VX@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M-C<X+#0Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!L86-E;65N="!A9V5N="!W87)R86YT
M<R!R96QA=&5D('1O(&ES<W5A;F-E(&]F($-O;G9E<G1I8FQE($YO=&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30S
M+#4S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&QA8V5M96YT(&%G96YT('=A<G)A;G1S(')E;&%T960@=&\@:7-S
M=6%N8V4@;V8@4W1O8VL@3V9F97)I;F<@*%-E92!.;W1E(#8@86YD($YO=&4@
M.2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,2PP.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.#8L
M,S@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0;&%C96UE;G0@86=E;G0@=V%R<F%N=',@<F5L871E9"!T;R!I<W-U
M86YC92!O9B`R,#$R($-O;6UO;B!3=&]C:R!/9F9E<FEN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#8W+#@T-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G0@:7-S=65D('1O(&EN=F5S=&]R<R!W:71H('-T;V-K("T@86-C<G5E
M9"!D:79I9&5N9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P
M+#$Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PV.#DL-S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPS.#DL-S0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R
M,V0U8C<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5E-#4U93%?
M9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W+U=O<FMS:&5E=',O4VAE970U
M-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P1559044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M5V%R<F%N=',@*$1E=&%I;',@,2D@*%=A<G)A;G0@6TUE;6)E<ETL(%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@=V%R<F%N
M=',@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI=',L($)E9VEN;FEN9R!B86QA
M;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPW-S`L-C,V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PS-C0L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F(%5N:71S+"!'<F%N=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT,#8L,#<Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS-C0L-34W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@56YI=',L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#0T,2PY-#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPW-S`L-C,V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS-C0L-34W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!"96=I;FYI;F<@
M8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+CDW
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@1W)A
M;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XU,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@16YD:6YG
M($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XW
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XY-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XU,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N
M=')A8W1U86P@5&5R;2`H:6X@>65A<G,I+"!'<F%N=&5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,@.2!M;VYT:',@-"!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S8@>65A<G,@.2!M;VYT:',@-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E
M;6%I;FEN9R!#;VYT<F%C='5A;"!497)M("AI;B!Y96%R<RDL($]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`Q
M(&UO;G1H(#(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<T('EE87)S(#4@;6]N=&AS(#(S(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-B!Y96%R
M<R`Y(&UO;G1H<R`T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L
M($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#8L,3$T+#<V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,RPR-C$L,S8W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I
M;G-I8R!686QU92P@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@.2PV.3$L,S`R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#$Q-"PW-C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,C8Q+#,V
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E
M-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S
M93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T-34N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)
M3D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E=A<G)A;G1S("A$971A:6QS
M(%1E>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0T/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^5V%R<F%N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/E=A<G)A;G0@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CY-:6YI;75M(%M-96UB97)=/&)R/E=A<G)A;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CY-87AI;75M(%M-96UB97)=/&)R/E=A<G)A;G0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V%R
M<F%N="`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&=R86YT960@=&\@36%N86=E
M;65N="!&:7)M('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S$V+#,T,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3<T+#<W-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT<R!G<F%N=&5D('1O($UA;F%G96UE;G0@1FER;2!T;R!P=7)C
M:&%S92!C;VUM;VX@<W1O8VLL(&5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G1S(&=R86YT960@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K+"!T97)M/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G1S(')E8V]R9&5D(&%S('-T
M;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#DU+#DW,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S(L,3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.#@L-#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M-#`L-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#DU-RPW-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(L,34S+#0T,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&ES8V]U;G0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$N.#(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$N.3(E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXQ-R4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O
M;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M,"XV-"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C0N-S<E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S`N-S(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S('!E<F-E;G1A9V4@;V8@=&]T86P@:7-S=65D(&%N9"!O=71S=&%N
M9&EN9R!S:&%R97,@;V8@8V%P:71A;"!S=&]C:SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P
M,V)?,3-E.&8V,C-D-6(W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE
M971S+U-H965T-38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$531$%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D5M<&QO>65E($1E9FEN960@0V]N=')I8G5T:6]N(%!L86X@
M*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!$969I;F5D($-O;G1R
M:6)U=&EO;B!0;&%N("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<V-R:7!T:6]N(&]F(&5M<&QO>65E
M(&1E9F5R<F5D(&-O;G1R:6)U=&EO;B!P;&%N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG5&AE('!L86X@<F5Q=6ER97,@,3(@8V]N<V5C=71I
M=F4@;6]N=&AS(&]F('-E<G9I8V4@86YD(&$@;6EN:6UU;2!O9B`U,#`@:&]U
M<G,@;V8@<V5R=FEC92!F;W(@<&%R=&EC:7!A=&EO;BX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E
M(&]F(&5M<&QO>65R(&UA=&-H:6YG(&-O;G1R:6)U=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')I8G5T:6]N(&]F
M('1H92!C;VUP86YY(&EN(&5M<&QO>65E(&1E9F5R<F5D(&-O;G1R:6)U=&EO
M;B!P;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L.30R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`X+#@X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,&5E-#4U93%?9C5D9%\T96(Y7S@P,V)?,3-E.&8V,C-D-6(W#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S!E930U-64Q7V8U9&1?-&5B.5\X
M,#-B7S$S93AF-C(S9#5B-R]7;W)K<VAE971S+U-H965T-3<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5$2D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U8G-E<75E;G0@
M179E;G1S("A$971A:6QS*2`H4W5B<V5Q=65N="!%=F5N="!;365M8F5R72P@
M4V5P87)A=&EO;B!A;F0@4V5T=&QE;65N="!!9W)E96UE;G0@6TUE;6)E<ETL
M($9O<FUE<B!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<B!;365M8F5R72P@55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L
M(#(P,3,\8G(^3F]T93QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W5B<V5Q=65N="!%=F5N="!;365M8F5R72!\(%-E<&%R871I;VX@
M86YD(%-E='1L96UE;G0@06=R965M96YT(%M-96UB97)=('P@1F]R;65R($-H
M:65F($5X96-U=&EV92!/9F9I8V5R(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S
M("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F(&EN<W1A;&QM96YT<R!I;B!W:&EC:"!C;VYS
M:61E<F%T:6]N(&ES('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G-I9&5R871I;VX@<&%Y86)L92!U;F1E<B!A9W)E96UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4&5R9F]R;6%N8V4@8F]N=7,@:6YC;'5D960@:6X@86-C;W5N=',@<&%Y86)L
M92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<FEO9"!O9B!S97)V:6-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG075G=7-T(#$U+"`R,#$R('1O
M($1E8V5M8F5R(#,Q+"`R,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\P964T-35E,5]F-61D7S1E8CE?.#`S8E\Q,V4X9C8R
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M+BXO5V]R:V)O;VLN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S`N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,T+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,S8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#,W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S."YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,SDN:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#0P+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970T,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970T-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T-#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T-#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#0Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970U,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970U-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-3<N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'10
L87)T7S!E930U-64Q7V8U9&1?-&5B.5\X,#-B7S$S93AF-C(S9#5B-RTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
        <td class="nump">$ 13,609,036<span></span></td>
        <td class="nump">$ 13,089,314<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
        <td class="nump">1,497,556<span></span></td>
        <td class="nump">741,420<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other differences in tax basis</a></td>
        <td class="nump">233,043<span></span></td>
        <td class="nump">4,749<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Total deferred tax assets</a></td>
        <td class="nump">15,339,635<span></span></td>
        <td class="nump">13,835,483<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
        <td class="num">(15,339,635)<span></span></td>
        <td class="num">(13,835,483)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComponentsOfDeferredTaxAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from other provisions, reserves, allowances, and accruals not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3BAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrant [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
        <td class="text"><div align="left">
<table style="width: 95%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Remaining</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Aggregate</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Number of</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Contractual</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Intrinsic</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercise Price</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Term (in years)</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2010</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display:
 inline; font-family: times new roman; font-size: 10pt;">273,859</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.29</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.51</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times
 new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2011</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">273,859</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.29</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.51</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,056,275</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.96</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.89</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td
 align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,330,134</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.96</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.91</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">685,800</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div><span></span></td>
        <td class="text"><table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="42%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;"></font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Remaining</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Aggregate</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Number of</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Contractual</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Intrinsic</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;
 </font></td>
<td width="11%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Exercise Price</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Term (in years)</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td width="11%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">2,330,134</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">0.96</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">8.91</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">685,800</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left"
 width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Cancellation</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">(49,950</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size:
 10pt; display: inline;">Outstanding, September 30, 2013</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">2,280,184</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">0.95</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">8.17</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">1,609,035</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td>
</tr>
</table><span></span></td>
        <td class="text"><div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Remaining</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Aggregate</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Number of</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Contractual</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Intrinsic</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercise Price</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Term (in years)</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2012</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display:
 inline; font-family: times new roman; font-size: 10pt;">12,770,636</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.97</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4.48</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; 6,114,768</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants exercised</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2,304,910</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.65</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants expired</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,023,784</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.65</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, September 30, 2013</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9,441,942</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0. 77</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.09</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9,611,403</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activities</a></td>
        <td class="text"><div align="left">
<table style="width: 95%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Remaining</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Aggregate</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Number of</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Contractual</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Intrinsic</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercise Price</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Term (in years)</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2010</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display:
 inline; font-family: times new roman; font-size: 10pt;">273,859</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.29</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.51</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times
 new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2011</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">273,859</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.29</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.51</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,056,275</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.96</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.89</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td
 align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,330,134</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.96</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.91</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">685,800</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Defined Contribution Plan (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EmployeeDefinedContributionPlanTextualAbstract', window );"><strong>Employee Defined Contribution Plan (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Description of employee deferred contribution plan</a></td>
        <td class="text">The plan requires 12 consecutive months of service and a minimum of 500 hours of service for participation.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employer matching contribution</a></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution of the company in employee deferred contribution plan</a></td>
        <td class="nump">$ 8,942<span></span></td>
        <td class="nump">$ 8,885<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EmployeeDefinedContributionPlanTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_EmployeeDefinedContributionPlanTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the terms and benefits provided by the employer's defined contribution plans. A defined contribution plan provides benefits in return for services rendered, provides an individual account for each participant, and has terms that specify how contributions to the individual's account are to be determined rather than the amount of benefits the individual is to receive. Under a defined contribution pension plan, the benefits a participant will receive depend solely on the amount contributed to the participant's account, the returns earned on investments of those contributions, and forfeitures of other participants' benefits that may be allocated to such participant's account. A description of the plan(s) including employee groups covered, the basis for determining contributions, and the nature and effects of significant matters affecting comparability of information for all periods presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Defined Contribution Postretirement Plan<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510416<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4FAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Schedule of difference between the income tax provision and the U.S. Federal statutory rate</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at 34%</a></td>
        <td class="num">$ (2,842,810)<span></span></td>
        <td class="num">$ (1,171,230)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at 34%, Percentage</a></td>
        <td class="num">(34.00%)<span></span></td>
        <td class="num">(34.00%)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation costs</a></td>
        <td class="nump">756,136<span></span></td>
        <td class="nump">736,796<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation costs, Percentage</a></td>
        <td class="nump">9.04%<span></span></td>
        <td class="nump">21.39%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in fair value of derivatives</a></td>
        <td class="nump">233,043<span></span></td>
        <td class="nump">4,748<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in fair value of derivatives, Percentage</a></td>
        <td class="nump">2.79%<span></span></td>
        <td class="nump">0.13%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization', window );">Amortization of debt discounts</a></td>
        <td class="nump">349,480<span></span></td>
        <td class="nump">56,033<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization', window );">Amortization of debt discounts, Percentage</a></td>
        <td class="nump">4.18%<span></span></td>
        <td class="nump">1.63%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Change in valuation allowance</a></td>
        <td class="nump">1,504,151<span></span></td>
        <td class="nump">373,653<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Change in valuation allowance, Percentage</a></td>
        <td class="nump">17.99%<span></span></td>
        <td class="nump">10.85%<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income tax, Percentage</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to amortization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible amortization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationOtherAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfWarrantsIssuedTableTextBlock', window );">Summary of warrant issued</a></td>
        <td class="text"><div style="text-align: justify; margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">During the year ended December 31, 2011, the Company also issued the following warrants:</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued with convertible notes (See Note 5)</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">287,061</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued to investors with Stock Offering (See Note 9)</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1,972,766</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Placement agent warrants related to issuance of:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;&#160;Convertible Notes</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">143,532</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;&#160;Stock Offering (See Note 6 and Note 9)</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">986,383</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Total</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td
 align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3,389,742</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; During the year ended December 31, 2012, the Company also issued the following warrants:</font></div><div align="justify" style="margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued to investors with Stock Offering (See Note 6)</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">242,189</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued to investors with Common Stock</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">4,678,491</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Placement agent warrants related to issuance of:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;&#160;Stock Offering (See Note 6 and Note 9)</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">121,094</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;&#160;2012 Common Stock Offering</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">467,845</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued to investors with stock &#8211; accrued dividend</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt;
 text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">180,115&#160;</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Total</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">5,689,734</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfWarrantActivitiesTableTextBlock', window );">Summary of warrant activities</a></td>
        <td class="text"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">&#160;</div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Weighted</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Average</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Weighted</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Remaining</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Aggregate</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="text-align: center;" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Number of</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Average</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left"
 valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Contractual</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Intrinsic</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Units</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Exercise Price</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Term (in years)</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Value</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Outstanding, December 31, 2010</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td
 align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Granted</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">5,364,557</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">0.51</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">6.76</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left"
 width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Outstanding, December 31, 2011</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">5,364,557</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">0.51</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">6.76</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3,261,367</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Granted</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">7,406,079</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1.32</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3.76</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%"
 valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Outstanding, December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">12,770,636</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">0. 97</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">4.48</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">6,114,768</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfWarrantsIssuedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrant issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ScheduleOfWarrantsIssuedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SummaryOfWarrantActivitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Summary of warrant activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SummaryOfWarrantActivitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract', window );"><strong>Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 2,757,966<span></span></td>
        <td class="nump">$ 3,574,958<span></span></td>
        <td class="nump">$ 4,439,613<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract', window );"><strong>Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract', window );"><strong>Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract', window );"><strong>Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 2,757,966<span></span></td>
        <td class="nump">$ 3,574,958<span></span></td>
        <td class="nump">$ 4,439,613<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28370219&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Going Concern<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GoingConcernTextBlock', window );">Going Concern</a></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 2 &#8211; Going Concern</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $4,893,951 and net cash used in operations of $4,947,969, for the nine months ended September 30, 2013; and a deficit accumulated during the development stage of $60,637,414 at September 30, 2013. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The ability of the Company to continue its operations is dependent on the successful execution of management&#8217;s plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div><span></span></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;<font style="display: inline; font-weight: bold;">Note 2 &#8211; Going Concern</font></font></div>
<div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font>&#160;</div>
<div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $8,361,205 and net cash used in operations of $5,212,710, for the year ended December 31,&#160;2012; and an accumulated deficit of $55,743,463 at December 31, 2012. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The ability of the Company to continue its operations is dependent on the successful execution of management&#8217;s plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.</font></div>
<div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font>&#160;</div>
<div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GoingConcernAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GoingConcernAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GoingConcernTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Going Concern assumption.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GoingConcernTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEPBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 25, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Subsequent Event [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Stock Options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Convertible Notes Payable [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Convertible Notes Payable [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Options And Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Machinery and equipment [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Machinery and equipment [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Furniture and fixtures [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Furniture and fixtures [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 25, 2013

</div>
          <div>Actinium [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2012

</div>
          <div>Actinium [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfOwnershipInterestToBeAcquired', window );">Percentage of ownership interest to be acquired by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93.70%<span></span></td>
        <td class="nump">100.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition', window );">Common Stock issuable in consideration for equity interest acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage', window );">Common stock shares issued in exchange of equity securities in percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Approximately 99% of the issued and outstanding common stock immediately after the closing of the Share Exchange, par value $0.01 per share, of the Company. The Share Exchange was closed on December 28, 2012.<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Five years<span></span></td>
        <td class="text">Five years<span></span></td>
        <td class="text">Seven years<span></span></td>
        <td class="text">Seven years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares received by each API shareholder of Actinium common stock for each API share exchanged</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially issuable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,968,829<span></span></td>
        <td class="nump">2,330,134<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="nump">9,441,942<span></span></td>
        <td class="nump">5,861,044<span></span></td>
        <td class="nump">12,770,596<span></span></td>
        <td class="nump">13,831,762<span></span></td>
        <td class="nump">1,152,692<span></span></td>
        <td class="nump">3,448,276<span></span></td>
        <td class="nump">2,280,184<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfSharesExchangedInShareExchangeProgramme', window );">Percentage Of Shares Exchanged In Share Exchange Programme</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">38.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BusinessAcquisitionNumberOfSharesExchanged', window );">Business acquisition number of shares exchanged</a></td>
        <td class="nump">1,322,055<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,970,137<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BusinessAcquisitionNumberOfSharesExchanged">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business acquisition number of shares exchanged.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BusinessAcquisitionNumberOfSharesExchanged</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock issuable in consideration for equity interest acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares issued in exchange of equity securities in percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockSharesIssuedInExchangeOfEquitySecuritiesInPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfOwnershipInterestToBeAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of ownership interest to be acquired by company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfOwnershipInterestToBeAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfSharesExchangedInShareExchangeProgramme">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of shares exchanged in share exchange programme.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfSharesExchangedInShareExchangeProgramme</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5VBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">151 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract', window );"><strong>Schedule of derivative warrant instruments activity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsUnits', window );">Beginning balance, Units</a></td>
        <td class="nump">5,146,338<span></span></td>
        <td class="nump">3,389,771<span></span></td>
        <td class="nump">3,389,771<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsIssuedWithConvertibleNotes', window );">Warrants issued with Convertible Notes (See Note 5), Units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">287,061<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital', window );">Reclassification to paid in capital, Units</a></td>
        <td class="num">(3,130,536)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes', window );">Placement agent warrants related to issuance of Convertible Notes (See Note 5), Units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">143,532<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsIssuedWithStockOffering', window );">Warrants issued with Stock Offering (See Note 9), Units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">242,190<span></span></td>
        <td class="nump">1,972,785<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock', window );">Placement agent warrants related to issuance of Stock Offering (See Note 9), Units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">121,095<span></span></td>
        <td class="nump">986,393<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsIssuedWithCommonStockOffering', window );">Warrants issued with 2012 Common Stock Offering - A (See Note 9), Units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,118,988<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne', window );">Warrants issued with 2012 Common Stock Offering - B (See Note 9), Units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,559,505<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativePlacementAgentWarrantsRelatedToStock', window );">Placement agent warrants related to 2012 Common Stock Offering (See Note 9), Units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">467,845<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TransferFromLiabilityClassificationToEquityClassification', window );">Transfer from liability classification to equity classification, Units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,753,056)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsUnits', window );">Balance, Units</a></td>
        <td class="nump">2,015,802<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,146,338<span></span></td>
        <td class="nump">3,389,771<span></span></td>
        <td class="nump">5,146,338<span></span></td>
        <td class="nump">2,015,802<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Beginning balance, Fair Value</a></td>
        <td class="nump">$ 3,574,958<span></span></td>
        <td class="nump">$ 4,439,613<span></span></td>
        <td class="nump">$ 4,439,613<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue', window );">Reclassification to paid in capital, Fair Value</a></td>
        <td class="num">(600,880)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes', window );">Warrants issued with Convertible Notes (See Note 5), Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">377,150<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes', window );">Placement agent warrants related to issuance of Convertible Notes (See Note 5), Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">188,579<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering', window );">Warrants issued with Stock Offering (See Note 9), Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">318,087<span></span></td>
        <td class="nump">2,591,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock', window );">Placement agent warrants related to issuance of Stock Offering (See Note 9), Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">159,044<span></span></td>
        <td class="nump">1,295,950<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering', window );">Warrants issued with 2012 Common Stock Offering - A (See Note 9), Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,409,554<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne', window );">Warrants issued with 2012 Common Stock Offering - B (See Note 9), Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,665,697<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock', window );">Placement agent warrants related to 2012 Common Stock Offering (See Note 9), Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">499,707<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer from liability classification to equity classification, Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,231,324<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,231,324<span></span></td>
        <td class="nump">4,832,204<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ChangeInFairValueOfDerivativeWarrants', window );">Change in fair value</a></td>
        <td class="num">(216,112)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(685,420)<span></span></td>
        <td class="num">(13,966)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Balance, Fair Value</a></td>
        <td class="nump">$ 2,757,966<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,574,958<span></span></td>
        <td class="nump">$ 4,439,613<span></span></td>
        <td class="nump">$ 3,574,958<span></span></td>
        <td class="nump">$ 2,757,966<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ChangeInFairValueOfDerivativeWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of derivative warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ChangeInFairValueOfDerivativeWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative placement Agent warrants related to issuance of convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative Placement Agent warrants related to issuance of stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativePlacementAgentWarrantsRelatedToIssuanceOfStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativePlacementAgentWarrantsRelatedToStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative placement agent warrants related to stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativePlacementAgentWarrantsRelatedToStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantsIssuedWithCommonStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants issued with Common Stock Offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantsIssuedWithCommonStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants issued with Common Stock Offering one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantsIssuedWithCommonStockOfferingOne</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantsIssuedWithConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants Issued With Convertible Notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantsIssuedWithConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantsIssuedWithStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants issued with Stock offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantsIssuedWithStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantsUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantsUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification to paid in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantUnitsReclassificationToPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification to paid in capital, fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative placement agent warrants related to issuance of convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative placement agent warrants related to issuance of Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToIssuanceOfStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative placement agent warrants related to stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativePlacementAgentWarrantsRelatedToStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants issued with Common Stock Offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants issued with Common Stock Offering one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativeWarrantsIssuedWithCommonStockOfferingOne</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants issued with convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativeWarrantsIssuedWithConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants issued with stock offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativeWarrantsIssuedWithStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EINAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsIssuedAbstract', window );"><strong>Summary of warrant issued</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsIssuedWithConvertibleNotes', window );">Warrants issued with convertible notes (See Note 5)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">287,061<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsIssuedToInvestorsWithStockOffering', window );">Warrants issued to investors with Stock Offering (See Note 6 and Note 9)</a></td>
        <td class="nump">242,189<span></span></td>
        <td class="nump">1,972,766<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsIssuedToInvestorsWithCommonStock', window );">Warrants issued to investors with Common Stock</a></td>
        <td class="nump">4,678,491<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes', window );">Placement agent warrants related to issuance of Convertible Notes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">143,532<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering', window );">Placement agent warrants related to issuance of Stock Offering (See Note 6 and Note 9)</a></td>
        <td class="nump">121,094<span></span></td>
        <td class="nump">986,383<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock', window );">Placement agent warrants related to issuance of 2012 Common Stock Offering</a></td>
        <td class="nump">467,845<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantIssuedToInvestorsWithStockAccruedDividend', window );">Warrant issued to investors with stock - accrued dividend</a></td>
        <td class="nump">180,115<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsIssued', window );">Total</a></td>
        <td class="nump">5,689,734<span></span></td>
        <td class="nump">3,389,742<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent warrants related to issuance of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlacementAgentWarrantsRelatedToIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent warrants related to issuance of convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlacementAgentWarrantsRelatedToIssuanceOfConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent warrants related to issuance of stock offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlacementAgentWarrantsRelatedToIssuanceOfStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantIssuedToInvestorsWithStockAccruedDividend">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrant issued to investors with stock accrued dividend.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantIssuedToInvestorsWithStockAccruedDividend</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsIssuedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsIssuedAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsIssuedToInvestorsWithCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued to investors with common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsIssuedToInvestorsWithCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsIssuedToInvestorsWithStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued to investors with Stock offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsIssuedToInvestorsWithStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsIssuedWithConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued with convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsIssuedWithConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELLAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 3,990,063<span></span></td>
        <td class="nump">$ 5,618,669<span></span></td>
        <td class="nump">$ 5,703,798<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">R&amp;D reimbursement receivable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">237,834<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">53,000<span></span></td>
        <td class="nump">167,143<span></span></td>
        <td class="nump">5,384<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs, net of accumulated amortization</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">252,248<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">4,043,063<span></span></td>
        <td class="nump">5,785,812<span></span></td>
        <td class="nump">6,199,264<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
        <td class="nump">6,918<span></span></td>
        <td class="nump">3,010<span></span></td>
        <td class="nump">1,233<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">4,049,981<span></span></td>
        <td class="nump">5,788,822<span></span></td>
        <td class="nump">6,200,497<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">312,001<span></span></td>
        <td class="nump">897,044<span></span></td>
        <td class="nump">644,511<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable and accrued expenses - related party</a></td>
        <td class="nump">375,686<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">140,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, net of unamortized discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">124,363<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">2,757,966<span></span></td>
        <td class="nump">3,574,958<span></span></td>
        <td class="nump">4,439,613<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">3,445,653<span></span></td>
        <td class="nump">4,643,187<span></span></td>
        <td class="nump">5,208,487<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">3,445,653<span></span></td>
        <td class="nump">4,643,187<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
        <td class="nump">23,657<span></span></td>
        <td class="nump">21,392<span></span></td>
        <td class="nump">136,648<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
        <td class="nump">61,218,085<span></span></td>
        <td class="nump">56,867,706<span></span></td>
        <td class="nump">48,237,620<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(60,637,414)<span></span></td>
        <td class="num">(55,743,463)<span></span></td>
        <td class="num">(47,382,258)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">604,328<span></span></td>
        <td class="nump">1,145,635<span></span></td>
        <td class="nump">992,010<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 4,049,981<span></span></td>
        <td class="nump">$ 5,788,822<span></span></td>
        <td class="nump">$ 6,200,497<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsAndOtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.15(1),(5))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.15)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph 1, 5<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of current deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsCurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details Textual) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses ("NOLs")</a></td>
        <td class="nump">$ 43<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Expiration dates of operating loss carryforwards</a></td>
        <td class="text">Dec. 31,
				 2020<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory rate</a></td>
        <td class="nump">34.00%<span></span></td>
        <td class="nump">34.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IncomeTaxesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwardsExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVVBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">151 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (4,893,951)<span></span></td>
        <td class="num">$ (5,483,954)<span></span></td>
        <td class="num">$ (8,361,205)<span></span></td>
        <td class="num">$ (3,444,795)<span></span></td>
        <td class="num">$ (55,743,463)<span></span></td>
        <td class="num">$ (60,637,414)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">284,371<span></span></td>
        <td class="nump">312,500<span></span></td>
        <td class="nump">2,223,926<span></span></td>
        <td class="nump">2,173,377<span></span></td>
        <td class="nump">6,052,036<span></span></td>
        <td class="nump">6,336,407<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">429<span></span></td>
        <td class="nump">581<span></span></td>
        <td class="nump">633<span></span></td>
        <td class="nump">3,262,462<span></span></td>
        <td class="nump">3,262,462<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="nump">4,122<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">550,186<span></span></td>
        <td class="nump">554,308<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">678,116<span></span></td>
        <td class="nump">775,637<span></span></td>
        <td class="nump">124,363<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">900,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">219,725<span></span></td>
        <td class="nump">252,248<span></span></td>
        <td class="nump">40,444<span></span></td>
        <td class="nump">292,692<span></span></td>
        <td class="nump">292,692<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(260,000)<span></span></td>
        <td class="num">(260,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GainOnChangeInFairValueOfDerivatives', window );">Change in fair value derivative liabilities</a></td>
        <td class="num">(216,112)<span></span></td>
        <td class="nump">287,604<span></span></td>
        <td class="num">(685,420)<span></span></td>
        <td class="num">(13,966)<span></span></td>
        <td class="num">(699,386)<span></span></td>
        <td class="num">(915,498)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">R&amp;D reimbursable receivable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">234,088<span></span></td>
        <td class="nump">41,567<span></span></td>
        <td class="num">(3,746)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">114,143<span></span></td>
        <td class="nump">14,386<span></span></td>
        <td class="num">(18,013)<span></span></td>
        <td class="nump">4,766<span></span></td>
        <td class="num">(23,397)<span></span></td>
        <td class="nump">87,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num">(585,043)<span></span></td>
        <td class="nump">173,614<span></span></td>
        <td class="nump">334,263<span></span></td>
        <td class="nump">556,019<span></span></td>
        <td class="nump">1,238,773<span></span></td>
        <td class="nump">653,730<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued liabilities - related party</a></td>
        <td class="nump">344,501<span></span></td>
        <td class="nump">2,100<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="nump">375,686<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(4,947,969)<span></span></td>
        <td class="num">(3,795,480)<span></span></td>
        <td class="num">(5,212,710)<span></span></td>
        <td class="num">(517,592)<span></span></td>
        <td class="num">(44,402,658)<span></span></td>
        <td class="num">(49,350,627)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment made for patent rights</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(3,000,000)<span></span></td>
        <td class="num">(3,000,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(8,030)<span></span></td>
        <td class="num">(1,812)<span></span></td>
        <td class="num">(2,359)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(815,659)<span></span></td>
        <td class="num">(823,689)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
        <td class="num">(8,030)<span></span></td>
        <td class="num">(1,812)<span></span></td>
        <td class="num">(2,359)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(3,815,659)<span></span></td>
        <td class="num">(3,823,689)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Borrowings on convertible debt, net of offering costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">645,888<span></span></td>
        <td class="nump">645,888<span></span></td>
        <td class="nump">645,888<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
        <td class="num">(140,000)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(140,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Sales of common stock, net of offering costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">660,163<span></span></td>
        <td class="nump">5,129,940<span></span></td>
        <td class="nump">5,379,367<span></span></td>
        <td class="nump">53,191,098<span></span></td>
        <td class="nump">53,191,098<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the exercise of warrants for cash</a></td>
        <td class="nump">3,467,393<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,467,393<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">3,327,393<span></span></td>
        <td class="nump">660,163<span></span></td>
        <td class="nump">5,129,940<span></span></td>
        <td class="nump">6,025,255<span></span></td>
        <td class="nump">53,836,986<span></span></td>
        <td class="nump">57,164,379<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash</a></td>
        <td class="num">(1,628,606)<span></span></td>
        <td class="num">(3,137,129)<span></span></td>
        <td class="num">(85,129)<span></span></td>
        <td class="nump">5,507,663<span></span></td>
        <td class="nump">5,618,669<span></span></td>
        <td class="nump">3,990,063<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
        <td class="nump">5,618,669<span></span></td>
        <td class="nump">5,703,798<span></span></td>
        <td class="nump">5,703,798<span></span></td>
        <td class="nump">196,135<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
        <td class="nump">3,990,063<span></span></td>
        <td class="nump">2,566,669<span></span></td>
        <td class="nump">5,618,669<span></span></td>
        <td class="nump">5,703,798<span></span></td>
        <td class="nump">5,618,669<span></span></td>
        <td class="nump">3,990,063<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashPaidForAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">561<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">682<span></span></td>
        <td class="nump">1,243<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">372,850<span></span></td>
        <td class="nump">372,850<span></span></td>
        <td class="nump">372,850<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfWarrantsIssuedWithDebt', window );">Fair value of warrants issued with debt</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">377,150<span></span></td>
        <td class="nump">377,150<span></span></td>
        <td class="nump">377,150<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfWarrantsIssuedWithStock', window );">Fair value of warrants issued with stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">318,087<span></span></td>
        <td class="nump">3,393,338<span></span></td>
        <td class="nump">2,591,900<span></span></td>
        <td class="nump">5,985,238<span></span></td>
        <td class="nump">5,985,238<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfWarrantsIssuedToPlacementAgent', window );">Fair value of warrants issued to the placement agent</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">159,044<span></span></td>
        <td class="nump">658,753<span></span></td>
        <td class="nump">1,484,529<span></span></td>
        <td class="nump">2,170,282<span></span></td>
        <td class="nump">2,170,282<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock', window );">Conversion of notes payable and accrued interest to stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">981,729<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">981,729<span></span></td>
        <td class="nump">981,729<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer from liability classification to equity classification</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 4,231,324<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,231,324<span></span></td>
        <td class="nump">$ 4,832,204<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashPaidForAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CashPaidForAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion of notes payable and accrued interest to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfWarrantsIssuedToPlacementAgent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued to the placement agent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfWarrantsIssuedToPlacementAgent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfWarrantsIssuedWithDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued with debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfWarrantsIssuedWithDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfWarrantsIssuedWithStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued with stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfWarrantsIssuedWithStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GainOnChangeInFairValueOfDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain on change in fair value of the derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GainOnChangeInFairValueOfDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeBenefitsAndShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromDebtNetOfIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EB4EK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 27, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>License, Development and Commercialization Agreement [Member]

</div>
          <div>Note</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>License, Development and Commercialization Agreement [Member]

</div>
          <div>Note</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2010

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2012

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2011

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2010

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 21, 2012

</div>
          <div>SKI [Member]

</div>
          <div>License, Development and Commercialization Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Dr. Rosemary Mazanet [Member]

</div>
          <div>Consulting Services Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Dr. Rosemary Mazanet [Member]

</div>
          <div>Consulting Services Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 07, 2012

</div>
          <div>Laidlaw and Company [Member]

</div>
          <div>Engagement Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Laidlaw and Company [Member]

</div>
          <div>Engagement Agreement [Member]</div>
        </th>
        <th class="th">
          <div>May 09, 2011

</div>
          <div>Jamess Capital Group LLC [Member]

</div>
          <div>Transaction management agreement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Guagenti &amp; Associates LLC [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfPatients', window );">Number of Patients enrolled</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidUnderAgreementInYearTwoThousandEleven', window );">Amount paid under agreement in 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve', window );">Amount paid under agreement in 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen', window );">Amount paid under agreement in 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MaintenanceFeesAndResearchPayments', window );">Maintenance fees and research payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidUnderAgreement', window );">Amount paid under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdditionalAmountDueUnderAgreement', window );">Additional amount due under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfConditionForTerminationOfForbearancePeriod', window );">Condition for termination of forbearance period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The forbearance period terminated on October 30, 2011, when the Company satisfied a financing condition to the termination of the forbearance period by raising in excess of $3,000.000 in new equity financing.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TerminationDateOfForbearanceAgreement', window );">Termination date of forbearance agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 30,
				 2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 30,
				 2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod', window );">Minimum new equity financing needed under condition for termination forbearance period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000.000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForgivenAmountOfObligations', window );">Forgiven amount of obligations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">360,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty', window );">Research and development reimbursement payments received from MSKCC</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">237,834<span></span></td>
        <td class="nump">299,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Net receivable from MSKCC</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">237,834<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StartUpDueCostPaidDate', window );">Due date of start-up fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 10,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary at annual rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionExercisePriceRange', window );">Option Exercise Price Range</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">0.78 to 1.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term of options</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsReceivedToPurchaseCommonStock', window );">Options received to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfReceivablesOfPlacementAgentForServices', window );">Description of receivables of placement agent for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfWarrantsReceivablesByPlacement', window );">Description of warrants receivables by placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The placement agent or its designees have also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PeriodOfExerciseOfWarrants', window );">Period of exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Within 6 months of the final closing of the 2012 common stock Offering.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfSolicitationFee', window );">Percentage of solicitation fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PeriodicFeeForFinancialAdvisoryServices', window );">Monthly fee for financial advisory services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfAdditionalReceivableByPlacementAgent', window );">Description of additional receivable by placement agent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockPurchaseByHoldingOfWarrant', window );">Warrant held by placement agent to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,251,015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PeriodicFeeReceivedByManagementFirm', window );">Monthly fee received by management firm</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock', window );">Percentage of fully diluted capital stock equal to common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MaximumAmountOfOutOfPocketExpenses', window );">Maximum amount of out of pocket expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PeriodicAmountOfRent', window );">Operating lease monthly amount of rent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidToPursuantLeaseAgreement', window );">Amount paid to pursuant lease agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7,200<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdditionalAmountDueUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional amount due under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdditionalAmountDueUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidToPursuantLeaseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid to pursuant lease agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidToPursuantLeaseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidUnderAgreementInYearTwoThousandEleven">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand eleven.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidUnderAgreementInYearTwoThousandEleven</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidUnderAgreementInYearTwoThousandThirteen">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand thirteen.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidUnderAgreementInYearTwoThousandThirteen</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidUnderAgreementInYearTwoThousandTwelve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount paid under agreement in year two thousand twelve.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidUnderAgreementInYearTwoThousandTwelve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockPurchaseByHoldingOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock purchase by holding of warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockPurchaseByHoldingOfWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfAdditionalReceivableByPlacementAgent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of additional receivable by placement agent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfAdditionalReceivableByPlacementAgent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfConditionForTerminationOfForbearancePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of condition for termination of forbearance period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfConditionForTerminationOfForbearancePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfReceivablesOfPlacementAgentForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of receivables of placement agent for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfReceivablesOfPlacementAgentForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfWarrantsReceivablesByPlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of warrants receivables by placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfWarrantsReceivablesByPlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForgivenAmountOfObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Forgiven amount of obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ForgivenAmountOfObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MaintenanceFeesAndResearchPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maintenance fees and research payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MaintenanceFeesAndResearchPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MaximumAmountOfOutOfPocketExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum amount of out of pocket expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MaximumAmountOfOutOfPocketExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum new Equity Financing needed under condition for termination Forbearance period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MinimumNewEquityFinancingNeededUnderConditionForTerminationForbearancePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfPatients">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfPatients</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionExercisePriceRange">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Option exercise price range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionExercisePriceRange</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsReceivedToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options received to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsReceivedToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of fully diluted capital stock equal to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfSolicitationFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of solicitation fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfSolicitationFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PeriodicAmountOfRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Periodic amount of rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PeriodicAmountOfRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PeriodicFeeForFinancialAdvisoryServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Periodic fee for financial advisory services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PeriodicFeeForFinancialAdvisoryServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PeriodicFeeReceivedByManagementFirm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Periodic fee received by management firm.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PeriodicFeeReceivedByManagementFirm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PeriodOfExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PeriodOfExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RelatedPartyTransactionsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RelatedPartyTransactionsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development prepayments amount received by related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ResearchAndDevelopmentPrepaymentsAmountReceivedByRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StartUpDueCostPaidDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up due cost paid date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StartUpDueCostPaidDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TerminationDateOfForbearanceAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Termination date of forbearance agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TerminationDateOfForbearanceAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OfficersCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of activities related to related party</a></td>
        <td class="text"><table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Qualified R&amp;D costs incurred by the Company</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">655,786</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Reimbursements received from MSKCC</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">237,834</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">966,341</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2UAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
        <td class="nump">$ 165,484<span></span></td>
        <td class="nump">$ 157,454<span></span></td>
        <td class="nump">$ 155,096<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">(Less) Accumulated depreciation</a></td>
        <td class="num">(154,444)<span></span></td>
        <td class="num">(154,444)<span></span></td>
        <td class="num">(153,863)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LossOnDispositionOfPropertyAndEquipment', window );">Loss on disposition of equipment</a></td>
        <td class="num">(4,122)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
        <td class="nump">6,918<span></span></td>
        <td class="nump">3,010<span></span></td>
        <td class="nump">1,233<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Office equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
        <td class="nump">162,384<span></span></td>
        <td class="nump">156,162<span></span></td>
        <td class="nump">153,804<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture and fixtures [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
        <td class="nump">$ 3,100<span></span></td>
        <td class="nump">$ 1,292<span></span></td>
        <td class="nump">$ 1,292<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LossOnDispositionOfPropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loss on disposition of property and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_LossOnDispositionOfPropertyAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable and Convertible Notes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable and Convertible Notes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of senior subordinated unsecured convertible promissory notes</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Principal amount</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">900,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">900,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: original issuance discount</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(150,000</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(150,000</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: discount related to fair value of derivative warrants</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%"
 valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(377,150</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(377,150</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: discount related to the beneficial conversion feature</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(372,850</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(372,850</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Add: amortization of discount</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">900,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">124,363</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: principal amount converted to stock</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(900,000</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Carrying value at December 31, 2012 and 2011, respectively</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">124,363</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDebtTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001213900-14-000604-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-14-000604-xbrl.zip
M4$L#!!0````(`,"+/T2L8'6D!V8!`/=_&0`0`!P`9FEL+3(P,3,P.3,P+GAM
M;%54"0`#Z"/L4N@C[%)U>`L``00E#@``!#D!``#L76USH[B6_CY5\Q]\\WGI
M&.R\WNF^E3=/)Y/$J3@].U.[6RD%9$>W,7@$N./9JOWM*P&VP08''`,2G*JI
M*7=`@,YYSJN.='[YU]O8;$TQ=8AM?=Y3/[7W6MC2;8-8H\][WYYZRO%>ZU]?
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MHTVC@CNB@W3;LUPZBQ/`P?JGD3W=#R_ZE%;:JM)18T,]2AEJTL:&5_E@;7VP
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MS=IN?T+M":8N83-<ZM?@`7S>G_<<,IZ8B[^]^H!AREV9J^]/;XZQU]J?FX@+
MVW+QF]L:8-WEUB6T'H%]T,.+A*F`\,;G,^>Y/WQ^[JC*)=;94]OMO>4`9C*(
M.UO^FQC\+T.":<N?;GQV<VA=7/^V]X4]2.T<'W>T]B_[JX/Y`_>3W\"(06PC
M\D9?4[OL#_S3%*8+.^IR]/+J_"_+\?NQ.><EPO/`9:IRS#[OZB^/?>&%/9[8
M%ONG<_9&G&?VS[%M#5Q;_WZ'QR^8ED.TX&\.'O$/F__!8*]DFIKHQ`V^I640
M=CUP3D*Y.]TXG;TO\]O6YO7+?N(K(@2.?(W</#TS#,)E!ID/B!C7U@6:$!>9
MM>+OQCDVB=>Z[HT]DWM#EWC(YWKI4>:=7^(I-NT)'\<>,,+U8GZN2<N+A@O/
M<>WQL]I5;CPK0(.HYHU-F+J7C"-SDK0/%;4;(7'D^N*CC>B`%1HNKQ9)0[".
MQ<E(/2$!QA6@`K999-LL+)AZ?UY%73M59`/N9U/::G:JJ651#4QV::(C+0C`
M2`,XP"P+;9;%@<]:SD4LPQQ+-:P1H;#$$]C9LA+'XO`4S&:#>`U6L/+$<6%H
M"-,6[`4]_,+1H#UKQ\O?C]@GP0,SN+,GBBP'^6NLSODL>L6'"9NR30DR!Z:-
MK-^PZV).KPM><T(OV&0Q#8CR?#:BV.>`/^R6Z(Q%>/%'.5"4G2Y[7X;$/,U*
MG`U`>O?;^'MBM`U>G4S@$OPV3>'_Y?#;_`':<>%NOR:4U[9.M7S>KE92L*2!
MFU>FZ,@)`O`+`1S@2(KE2`H+G[5(1"S#''/`UXA06#@&=K:L=(HX/`6SV2!>
M@Q6L/)U2&!I6/**.4`9MQ1'HY'4$.B7YD1VP@*5Y@]*"`$PF@`-LK%@V5ECX
MK#EI8AGFF&^R1H3"/%6PLV5%FN+P%,QF@W@-5K#R2+,P-*QX1%VA#-J*(]#-
MZPAT2_(CNV`!2_,&I04!F$P`!]A8L6RLL/!9<]+$,LPQWV2-"(5YJF!GRXHT
MQ>$IF,T&\1JL8.619F%H6/&(#H0R:"N.P$%>1^"@)#_R`"Q@:=Z@M"``DPG@
M`!LKEHT5%CYK3II8ACGFFZP1H3!/%>QL69&F.#P%L]D@7H,5K#S2+`P-*Q[1
MH5`&;<41.,SK"!R6Y$<>@@4LS1N4%@1@,@$<8&/%LK'RP.?L!Z+&TVR"?;A<
MC2>F/</85[W]"1<Y.9`1F\82":GS:3;3'Y$U"AA^1RPR]L;SXUSJ`8;%])9`
MB,US`_,!<$4##KTU`W#1>0+@"@;<6NY!K'@S%G*O$:&P!`R$CV4E4,7A*42#
M#>(U!'>5)U`+0\.*#W4DE$%;<02.\CH"1R5YGD=@`4OS!J4%`9A,``?86+%L
MK#SPJ4D*0\#T@L!,AP1J&O,!<$4##A*H`+@2O:(+$SE.?^B31_*8:74J$"^E
M:9OLK2+.F,1,![;I^3?(`8B\'1^2YM@H@*QE)L7*1L42<FM$*"P]"\FELI97
MQ.$IY(H:Q&M(_52^O%(8&E9\GF.A#-J*(W"<UQ$X+LE3/`8+6)HW*"T(P&0"
M.,#&BF5CY8%/31*<`B8?!68Z+*^D,1\`5S3@8'D%`%=\`E6L>#,6<J\1H;`$
M#(2/9250Q>$I1(,-XC4$=Y4G4`M#PXH/=2*405MQ!$[R.@(G)7F>)V`!2_,&
MI04!F$P`!]A8L6RL//"I20I#P/2".$Q?\\S%\L9B#ND:$0H+3\"Y*BN](`Y/
MP5=J$*_!]:D\O5`X&MK*V80R-*CM/%7I`]-&UF_8=3&GS37[)N)Z+NX/+Y"E
M8_J('8RH_CI?Y1E1[)/>'WM+=,8;'"'HF65PG8JI3I!)_D;\K8LQ<J`K;\E[
M+@)^9/G(KZ^/TC]X_U9,*!KM:EMI=Y5.>_=HO_`<UQX_,W]R@79`/B"_4N3'
MHYT`^SFBG75AV56TLSMA852R*2-JG.<!HR\8?3"M)\:SSKM1L(IG3M2V4"'T
M.M5RI1[8@%+R34S\(.8N473D!`$$Z0`.B.K%BNKE@0\L:#20Z5`1OG6<"8#[
M(."@(AP`5_B2K6#QYDK:LZ0E'P@?RUJR%8BG$`TVB-<0W%6]9%LJ&FKB+8G@
MR93#PW!M1>TJ-Y[%BS#:PKHH*]5XS+4[5-2N`*[=9AK"R8I%>_D"0F&Q/*D^
MMT^4.S0+?N=8JKQ!8^PXH=_P*[6]2>(2?N0I=\AB1L6_4N\5^S32%+`XGX6\
M)82Q*E\#5=O9`<X&'"CMD\(`KK67H%9/0KV7#^!0N`*%*T4)RP%#8RYA8>:C
M`&$)'63M:.X,J$(Y5#$/4^4F43O:O8>YDFD5BP3KT,F7+E1+RD^KD"<K4W_(
M"0)(K`$X(!,G5B9.'OA`ZJZ!3(?<5(.9#X7S,A7."PRD,S83@_!V*5,\P#HS
ML2[!SM6;;GH&-GK4'G,#[;E^0J`_O$+48E1T'C`=O"**SV?)#Y#<$!5'%#!K
MN7R9_T24B;HD6<`4_R4VAV8S-UNEGE1,K[`Z#X"5!*P--<?2`ZND.F,`UC91
MUC,G9']XQFDWBBQX(6*8Z(>_P"('\G8<CF5^;R+]P@6K-2(V');>B\,\3$1G
M`V3B*"R7:]V2@"UM)E%[&I]2LUE?9,3&7CK%U"4O)KZW7>P\H!EBO^5`4BE1
MVT8*-1N819C*#8KNP41Z6-,CC[*3W++N0JOSER;Q#H0GJ_#4R/A7)`_@=&R&
MY]KV`+%*?]:KGTK9(P&5/&7M>!.'IU"8TR!>0YU-Y3O>RD0#E,W(ST,HA!"Z
M$$(0V99JX:>J19G*>-5#A/Z.3`^?SQ8_OS(R\BTPLUMNAWPF+JY=6Q//=?P+
MJAPLS3;#):\W3!4X'Y!#:P[G->!\E!R=YG"^4T/./U";/<N=/9C(WW;(PQ,_
MS#B?+>QU?\@B$;RX(@?#,TQLR>W$&3:.SSV/6L3U*&;7>^2-_W)JR.ST:=:*
MXW?HWS;ELW?ZPTO\,B>+.UM991Y@B]ATX+W8U"`6CUB^60Z_!1N1Y55&X3%Q
M')O._(56.6"1D03A+O#MZ5`KW*14A8K.ZP]4?DK-HV@1HHP\REA$*3B/EITU
M%CP2=;EN;9F3D42P9<X;Y)^"H@E%MQB0.,D*%O8Y$4`AR\4C4,@B\&BID!<\
M$E6QK"AD+6_=R1H-=]\N*HF&=3Y)2K*#FJ2!3([UP4?;P6-$9W?H;V1A=[Z#
M*(8Y]E;',UUBC0:83AES'$GPM>WB82)1-@!L6Z"_2]B&@KJ'7P(@:R?+WU"X
M4"`$\L4F_@"MN-,:4R$`IE`<4R@(9)9G%MXAFMO\92T36;6()G/?=60^\;&2
M(*S"2IJM[>,&,I<1,W4*.6`R1*QZ,#^&-A=B>Q0;7SU7?V6?8UOQHU,W(#94
M)$Q[#";LP39[RGS4"F&E383DQ'560A:`Z^S,^,C+1<H0'2KJ0:,E2:IT%4B2
MN'F\1DH22(Q8$B,XFB/IL3F:`=F`[)(#Y,.\`7)<&(KJ]@/"`,)0A3#DZ7=4
MF##,_1S>`L8L2P":E"VJ$/)59XN.8CU9=NS+:,=+Q#*_YLP;):7$']D/:2"6
MPL;$.92CI(X4[3B7DCJ.F?A=KX(<+-G,U.'B=PZ%=39QR71@\].=V`UBPV%;
MC9,TQW+@PKA_D!<NA\7!):HACK:"2_18I/$$6;-$<W9EC9K1MR^%'`68KE22
MEJ7WVKGUWM'N@3Q?RCO>"KS?+#+%U&%3[P^?\!MR[BX9Y]A?YFX(>&@^UG+1
MJ89NVG',R.\^Y;3`+N`8<%RT_Y$OP12'_NZ+=A9P[RQ_"UX#O`4-"]R4H1TJ
M`SS)K3)N[%?+^6I/OC-MMA2+QFN(362I@4)8-6PGBA:)+G9OV!;(!)0"2C^@
M<D_RJMPXL'>E<CMW_#3:]@+*@ANJH_Q4Z[1W3[43N:B6N[2]'*I!![)&=B!K
M*"`OH,&"X`T6&@I,N4Y(+`.(93?!:BCP8B?=X"&F%!L2':%>MDY,HE&SP=DC
M%K+X#K!K%N93;[DV)ZOOES(A\-NV!$*HR/N6)&Y6*O]YSF)U,HUB^3(!U]?=
M,`'76?P6._Y6VSEIR`9HG=W3<)Y>5Y5[>_JA%;D';%G.S)PBBZ#&IRXW$Z8&
MR<N5%+NJ*EIQ!QVI)_.3S,22ZE4B:(74.:X30=J-J-7OMZR$1U)M<:Q^)U]!
M/%H[(E$35K&LNPMYSY18H>'N7:XD&H)>:A2+0:W5D\7IS4<'['78N9(Q,Y>A
MM^B&V34*'LN8<"GUV6/"^&DX/&E!7,_%_6%\R].F#9'U.+AJV]@Q%P$+""6%
M.5EKW2TL,,;4CL1T!1.(4-S)2Q$B@"\G%X_`&1.!1PF>E:B*92?NAU;H9B<A
MZ98`I`)VS:P3X?D6CY!YY7]=L(65N1$6$5WF#4Q.5[X\W)T:^_R21+[0_4U+
MD1<4NKL1^4(WRB31$)!?26A9!*-[?UY%&PD)+AZY%[H+:DRS2K5W&M?S6,VV
M9,S-;.Y-OS:O4D1'4A"<&0;A<3HR'Q`QKJT+-"$N,FL%B(US!'!L`(>N>V//
M3SY=XB$GSJ7'DTV1G`][P$B2"JFL:,DUZ6;#I_B#XN?'L-4[EYN5.,6E<:7H
MFU(6K*%32@.9GI(DK0L8/I!,!<`5#;CHRD.=`9=QA04`5ZRSOU:P(6\J(+U,
M`](`V[KJ<.@E``1J=XI$']3NU%D\LD;S=4/U#K(8#0`2G%P#)]>(!<A8O"G7
MD1[)\9\$AW`(&/,]<T+VAV><=J.(PQ8YQ%L.5.PX.,S\WD3ZK9^$#K`L!I;/
M`^_%848`T=D`F3CZT`<3Z>'I\-+$%+*C./M$T]@6O#2)=R`\684G72;ND!6V
M3`!YV!*>R[QVG)3-AN<#M=F3W!D37#^OP,LM_!S#^6SA9?:'0Z+CQ14Y$)AA
M8DM,),X0@/$>,'H>B^Q<C_+&>SWRQG])DH'.A8[T:38;(K";K-Y,A>UGM6%J
M]GSXH^W@,?.?[M#?R,)NXK(0>X_CF2ZQ1@-,I\QR.C5?`DHD2@%+/>\2%F`,
MS?V@N9^$T(6#O>%@;]%UYMG+B^VZY\1V7S%%$\Q(K#L7-IW(@:S<546;IPNP
MR0@;&?/U>;$">>V/E-@L,JX]0F6))_.6TR3,$0"R&\/S?&M;HR=,QP\>U5^1
M@_G2`7&#=-T%>]3(IK/^\-K%BSN,0#/QG\Q'L)G;&SU+N3\,:^J,!VH;GEY3
MI;6]@<O\25MR)E2J^=@#XB2".#V]$@K2)*HT9>8."%/%PL2>:-HCSJ;YIMX)
M9P22IPRT;@+T/D=`:"H6&N9;.^YRZP.O\0!9J4)64AD!(E*QB)P-74Q]]MQC
ME_-%DHJ,NDE(&A]`0$2(8@+]!5&,<&*3CSO-%B9>O':/QD&USM,/^^G5]AQD
M&4^O--PWQ>^0`\?1N01(>&="P/JLK)>UI&N7D,BN3Z&.K`#8R50>*@SLH"8U
M3RWZ'=)?B87I+'I=$L3E*4;?,,]F@Z2(XRVWC3'N\8]+ZHUJG]+-2LC*PXHT
MAH#(B"(RCUC'9.+VAX]XQ`_T9;<Q;E%[BDQ>%/AMT#,0"%&E0I2=12!6.TIR
MQ<O5P]Q'_"2H!_9$RVW&T<L%9J]2RMESDQR@+^@"",B27)G@+1900,B;(N3Y
ME@E`].42_9TM`H%"$$TA]-'W1V*,\#T*FOS<HA>;^J%$/47MO?D"<#("YU</
M\:TWA`GBF>/8.F&7:UK:LF&JS89+ZO+3#VQ.<<*)H759_WY_?LT&1IY#UGK$
M0A8O6N0G>5-OX15*M8NZJO/54H@'.Z^+!:5S#K#<"I9<D:[0L%&@#%N.B]J=
M=[V;=Y0(.^Z[#LUV2^FR(RA/H7=N@W@-K7#?FW2MT%"3)GPB-,BKC(?0LD?H
MECV"R+9407I5#4\JXU4/$?H[,CU\/EO\_,K(R-NCS6ZY'0IV\<ZO75L3SW7\
M"ZH<+,TVP\C1T>E3!<X'Y-":PWD-.!\E1Z<YG._4D//0.J+4UA%"\QDZ0=2)
MXW?HWS;ELW?ZPTO\,B>+.ULY>'B`+6+3@?=B4X-8/&+Y9CG\%FRPIT\96<F+
MB1F%Q\1Q;#J[MZ59L\](@K!#\/9TJ!5N)-WQ6<7F2Q%X)--F\"KV9<N0"X/#
MEVO`;SC(H_:<A`HU>?E\X3FN/7Y6N\J-9S$^M]O"%E3$"U':;:5]J*C="(FK
M*D393,,\M5*BR\F.:Z"VE@UAH;!4FS>(0T'M""5",9W2X95<!>J4]I((PA)D
MI;BMD[>X;8V&.P:2=JST\$M`0][_%__E\6*)*?O?(C^U\O>PZC)FK0=X@JB_
M2X/%^@/LNF92%ZOG)^+RQL+7ED&FQ/!0F-ZVZ1C3BU>"AU=O+/+GS8F"S*`D
M:]$IA%OJK$0*;M!;'_`KLG%B%^].9&9XPNU['"W<GV%RHRG:<6%^:U1N<D2<
M&TBRLL\R&Q]%EXP\T>K"P&\%FW<_*66WXH?E17"\AK92.UKB%70^Z/R:Z/QU
M]XI)T5$N]RHN=CL.V9CSEBAV8#+`9.P([CFCB:+A?H?H(B);_`:X`]QW`O=.
M7KAWBDS(^7"?1>`>_M[D\EP2BG77IGXW:;]A.=]>=[=Y)Z.T5?GO^@N;R+$+
MA^7=/;>E;A!8!_1!7D`?%)IA;BMGWB@`L:HM?^?0WSV*C:^>R\_9=6PKJ*]_
MQ`[F!7^QLR[CRGQ^,@S3,!/V8)L]93ZJQ@K=EX.,!"M`LV<G>CG"<*RH[5S"
MP`9HQ:5&#Q1F^@(!N,4C9%[Y$PHWR;G$(J+7?QB8G*Y\>7B&5>SSRTANG"C:
M07')C?:24Q&N";X0P$B2#^UQ&NY8]:?0$)#_<;4F"*,[=_R,C;8LXG&4US,Z
M43KMW5/M1"ZJY5Y=+(=JA9R6GNQ!UMM;S$J<`KW%*CQ#46$-F^<;R/0\1_@R
MHDT'MNGY-\@!AMP'XB;,$0`"QS$(>QR#/$""\QMJS%S8`ESJ%N!Z`0/V##<:
M(K!9M-Y,A=VEM6$J+)T6%D3`TJGP\(]#]9']0*8DJ$SA?.(<&LYD-A.#F'XU
MVO*(CZLWW?0,;/#VEOS<5<_UB\CZPRO$G#IKY#Q@.GA%%)_/DA\@8=!;'"$@
MA$X`7NWJY40O5Y,-"*&L]"U)CJO.THMA,9EFLWQWC11%!T5Y'0H!-J7UWV36
MW;:,+"T:`9ZYJ[X_WD`S.WM`G$00IZ=70D&:1)6FS-P!8:I8F-@337O$V33/
M<$TX(Y`\(53=!.A]CH#05"PT0;=M=C.F/'8;(%.2<+-NLI+*"!"1BD7D;.AB
MZK/G'KN<+Y)4*]1-0M+X``(B0A03Z"^(8H03FWS<:;8P92E?NT-\T1[36?2Z
M'-#.5;^V89[-!DD1^\&V5;WW^,<E]4:UCW3+V#NV$VV;QA`0&5%$YA'KF$S<
M_O`1CWC;7'8;XQ:UI\CD50[?!CT#@1!5*D39601BM2/?/U[L%KJ$D1;2S`EX
M8$^TW&;L52[0J4^IS<M-<H"^H'DAD"6Y`N0M\DH@Y*()>1]]?R3&"-_[/C<R
M;]&+37W/H9Y"]=Y\`3AP:"L<VEI;@!>Y;2$HS788\<.J74G6NPK=P>#KW!3"
M-!N*[]2ORX&==S<OP,Z5!<-S]=T0G?$[[X71``"DMRTEU,78JE?GTL0Y`0`V
M`2#HF'YMZ7S*4UPS**3.#D"10RND=!J8;Q)TYJ?K.TG'Z]<"1]E52N;W;NA9
MD(VP`.&M]!J`>1NE"+`N!];)X$Q,ZC#BS0F9F`,+R,W_R=]&D2X+B#=`*!LA
M=ISHBF^*3R!HLR&;$759#S%>]AD/]!1/!-D6^V>0\9*FU_B.@919>G9XR'+V
MR'P3RRKMJ0Z",Q><1^RXE.@N-D!X9!2>1/XU2H#"ADFB=LE8[T44)<*.&X-#
M=X"2^DE5PD.IUF.J.H*[,E[U$*&_(]/#Y[/%SZ^,C/Q4QMDMKQ<*MNO.KUU;
M$\]U_`NJ'"S--L/(^<GI4P7.!^30FL-Y#3@?)4>G.9SOU)#ST#^AU/X)0O,9
MVB'4B>/0W4`J'D&S`A%X-&_AWE5N/(OQJ-T6-B$33V2UVTK[4%&[(B:R-*'H
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MQT;I#_&JN`S:O(VS[-$,5FRZCR+9KRMH?JX7%DOT:F9UN_B2]8"SI5XD!ES^
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M0ZWI2ZS5.J3$SZS#D5AW>U!*HD9BN]CB,GZT`869</.)\4_+7Y/X*ED5;[=W
M]F/^]G&=+@"=%*4,H>?QF"N6X?AIEJU4(J)'XLO)\=-U%X*,98253ZE:QM./
M>^I6APC:GVJ+@T5(LMH).TH6%&97P0K&)>^/TY[8[;\<3&:]B;2$\C2J1,E'
MR/B@Z!7^F4$>S)J7&!IP4WL0CU!2.4]HI`B.[=__&_]GG=FSPOSB^EQ?[1?V
MS>-!U93/.DW6V>?[JW6VM*?@>OE/LW<Q7]'+$A`3(]PF>;[.'@M(NXO'Z?+O
MLO4`H3?&?(?AJ9<]G>LL>8CM.[3G*Q.$-5%*[`%M>2=;3Q`66,OZPP153`X(
MK..*@P43BG-W8&$$R'`DJ2R%_&%`-`N+<DI0,!!=0P$3@W-&>H`(/05]R`(P
M7?5;^P*8N_?0]L9(IXO.W+O$.][$W%:9?L3Z'B1OC].*AR(^5T\AB+A,FRN1
MGM'@M[>88-=TB'!>/GH]I.%/O^66"!&%`Y#ONOP0SD0W\F?+9;(M!GH9)\L/
MZ=OX+MG$*Y"P06(B."YM/FJ(@>%INQ"57(B(!\?3]2`0822CR@:Z'4^I"O#G
M37RCWQG2V5V6Y/I<7]O\/;.YO;^]+W:TY_>V5/_A+T!$*XC$N!IY^>(:@\L6
MA3'A):&<G"B77=4PXD101$-Q6?B=K^O54F?Y=E/623912\H(BH0H@WY.!@2$
M<Q&(9M"4BK$AUSB9+O`%EZP<1X[$0$G[MOIX7`D[<#3G`N/RT6`8CIJ=Z1P)
M@E447#$0K"X34E[:QX'<7Y=IA#B7XS,`J,O,!%L#J%'SFCE'7#"L4'`4L,K,
M$`Z^EK1![J_,`IO=C@CNQEH9`%1FJ=@0:M0<&B$FB$(L.`A8718X?%S4!MDC
MR*`1I1$)KLRM'``JLW$N4A`27)%H\Y)G=#F\EZ.@REQ,W-B0/919<F)V5\'7
MY%8.()79[/PQPL$-E#4O>12+X/;$0'69(,*#:T(;Y/ZZ;#9*E&$1?$ENY0!0
MEPU/$:[<E(?AB;=XB>*@-#@(6&U6@@77YC;(_;79)LXJ08)O`%LY@-1F*1D3
M.+A;%"VWC=P8<7!M%J#:3(4(?S+7!ME#FX41/4?!?7,K!X#:3"@U,7,4/,Z0
MS8J!F-E9!S<I":K-3`@27)O;('N<S5%D(@VB1N<`4)NI"=(I#F^AJCEEFS+$
MPV,X/65N@^RCS-@>S(X^Z:#*3*B(D`HME997X_;5<'!E1K`W@$,H<RMD+V46
M4LCQ.0!59D4$#;X';,FH4`I77JL%P@!\!5C-LAH'LX<V/TM0&HD#2&U^EID3
MAJ>65R<F@./!S[L1["6@3=I#H;<;K9C[JS/C7#`D0^^\VSF`O--^EH(%RE/G
M%"E*<&>3*F57VU[409:+9X]XVXC"`W1\^#L8P+Z/A5T`5A.C+^/L(BML8EGD
MU^Z;0_<2=*F<6PDP?O53]+K\.+4;@E"8<1?,I,`\.N@Z?1@*=/'G_.Q^\W6=
M)7_JI;M6[$K=E5!^^/C>+++1[G]U6`\I0V/$T\5X5.@M&*$@?LCS>Q@Q&S?5
M@FI+"Q)1LU`'1-11A%"(+NXWMISHTA;)&T1T)8+@V'R%&``;F#AKL)5B_3'6
MXP[D`=%B^12,_ZIOXM6[HI+C+OS>UO@\%EY/DAGOL&)@N+X!17^X0X82#61!
MT?4+(@*CZQ,^`*"#BQRVR(KSN>CX0\2ZM=$+5`=A;D]9RC>J@4"YR-`^F.1,
M>LX4<`C158;M"V*0***K-*'A`<NU!M[G>*7S3_I!I_>ZKO#;^W^]Z_M\N\OP
MI%K.V>7A=I?A5=CA#R8'>OACW1^"$2.'A;6#2@)Z^)9&&=V)?=*YMDVX;)OS
MI[/<7<'57A92O<^U!8M+IZR-Y/QPM9E6]3*#"T'*`5Q`8&U&6;VP$)A0I@8!
MUF;.!RF`-*+EA^T!@;DY@NK\<8HCAH:9P#8?4LUN%Q(3/(;&M166$`27(]V!
M!=L5IA2*B%Z"_46G.HM7MMCC\M;LHVT/#%NV"<S+8<44IJ5KQA:*ON"<7)W`
M."KGIP3&YN3M$,,1+N=1!0;GY/$HBWC%8@.#\_%Z!BM5Y<<SPVI@L^E*$E6R
M\H?5P+:J;B2J%+H>0<B=H6)BJ[[UPGJN[S(S6&S3$.SW;VWOF#^+_^OO_SBI
MU%.II>0#R"V\*Q=O#P3(R=%1K((#<G)NK'Q-'@B0AT,CF)L%-;P0/7:!GOH2
MDI2'D^D[\1=WMI=<DM[L?,_Q&GR.>T=)>/EUY3,:[@"<O`@F2IF%%12`H]>@
M%$4*%("3EQ"*"EQNC04`P,,K,)L)B2@.J1(MU2-X)!6'!>`4KS`4"<98<(ET
MA:,D95PY&^F'=+&^U;^N<P`_,:]W%$]D^J!P<A;S>F_AA\+)8\SK788?"B>W
M,:_W&WXH/'S'O,%Y@*I)L\',ZST(J)JTH*AW(_`"ZHRIWI<<!_7!T,QT#G=:
M/4>"1:I43N6`@BMQ)P="D.28@-%V<AO*MC5#8+3=G(5Q5XI@`4;=QTD@Q:F(
MX+"X!1=8J5#R;SE:8.5CA0#SWW4&%!>X7)RK`<HO<9+FUB7H_")]]X=U$_=)
M_M6>`6\;1D#?[_8CZ''CVX^@QQTPR)2&)^AU/53-ZFD%`*X`+OM^$`4(3]#G
M3--''D\-..S/[*\NTJ?/^F9X'"P(I*;G1PU)?WR.NPY%2?4H+SA`MPT)EH)'
M=%"`;N$'EXR6WXL.`-`G0N$F6)*C:F3+$BX5H4?;]PRED"T>!_&#VX%1Q-T1
MK4*,JKZS^7&=KJL[*+"=4C&))5RUI/KC<?.#')&H[&8"`'+S>P@3NY\-BLCM
M.MLL9>6=30`\'GX-11$CY4R`\!K5YL=D1-60"M7FMP@/K.`^AS="(8&<M4MO
M/`[\6KI)/.L#4*$&"6/$W@8>/%6=1UL_`Q:IJ%+Q")#RD+4'PK'1LAX0I#"1
M-`CE(2OXA6.CQ<,0LSY4>E,#4AYR`L.QT5PJ?,X$H4(%T7WO`N%-392AP3A5
M8QD4&&CCD&#";B[B/:?,UE\602A/2<U`JW(/"@RR-%4X83?7UYYSLU\@Y7M4
M0,I34C/0<MF#`H,,>\,)N[GP]9QQ)"JYDH"4IZ1FH'6L!P4&N6B&$W9S16I;
M$\WL3%@0RE-2,]`"TX,"@RV`%TK8S:6BYX1BIL*<'W@7B(:4)FCIYT&!@1;;
M#R7LEB+.<\H%YF$(3TC+8&LR#PH,<@<03-9M6;^4FAUN""_J7U(94IB@M9('
M!0;;.`1,V&X7B\1\@S*8\SJW&T1&)5%`E-U2(B3A"`<)4/S+.T-J,&C=YD&!
M079E!12V5W[^L[+0<#;>EI-/<:00#&6W/'PJE;%QF!VGS_4MCS@1%'5Q-N_B
M+#6JEN_KVOT<Y\G"UF!(5O>;FOI=S2M[;07#.7U=?C?>0MD79/.Z4`^2O"ZW
M:0X,LGD)J0?)7Y<O[0*#;%YMZD&*U^4F!\.*NU/A1PLR>AV-)FX'D.4Z[0X@
M?]/)S5?SV=F#SLP"\O'>+B`7U\7/2F75/(V^IK2;C)`H/X'H!R80.PWNX139
M:7`DI\A.@\NIJ\*((L+*J2"3XJ?!.]7718R0+.^1)L50@R>K8PA3HW$(5$+]
MJF:VIG@U[5IJU8]27NFZU5BZLA]NGX.,VN*EMEI8%!:WSRZQ#C=#F%3:BP?`
MW99(U`>WP`<]Q@/@]LG?J;->*@4.C=LG(:0&M^WHSE%@W#X9!G6XE6"\7#@R
M!&Z?*^L:W+9+,Z^T?`R`V^<.M`:W[?H8'+?/I=J(N+VN:<;$'62]/"SV'0(X
M[((9'2L"W@S;CKPMI[X]B31;S62];8#P4?]>_`4\PY]4WXYVPC`$:-`.ADJI
M$^2Q?\=#&[4&8'BKO2-)M<8U6-%V4.`#Z&5F+[/U0NME_CY;W]J_QNE"7UR7
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M]^OCALNPZ7'3WQ*8O0M"TV9NRI;0\EJ0$:$J652#3Z__H\+JFB`5&C."@'V6
M>"`KLV=E8ZYX@9\VAC:%EB9*MLT`'=/3^#\"K!ZQ1%*,:MGA;A18)%7$Q[PX
M#/P4$=P4?'H#D`@)Z7R3>9VLVK^XS>$8.^MDF^%09)T[H(9@$O!N_3A;4A#[
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M"PJ%LON?71IO+K#:1A7],`S``6RV-&:8G3;#_5=OQ16VR>(GS3WT.MZ+G1&W
M`H4&[\\/>@+?\UUV2V>&IAW+S%QVH[/^'J9FCD%HP>:+$VDKK78!-R03_>U[
M/E6.0MAL`_`1K=-*@'60P?,M^MGR/R80L4CR+^L:'=A7&]-+BU.G>6R_5,"[
MN+/_S#]IPT:>;/0NQ-B&'Y_T8GV3%B,"Y`@C1F2IKMQ`P*<Z5P$+L)X0FQY'
M"B_J-(64Z@G-07-BM@E_2/2B+U`YXB>B$N&>6[^HTQ3RV"<T!\U7&W;O52Z;
M]/?6EY`]MTZ(31_W\Z).$[C$F=`<-#]!P%QQ]+)<0;V&.!&5".=^7M1I"B\V
M)C0'S1WO$,)$XA=]"=^C[X38]*B;]J).@S4S/`E=:TD%P0B5>^/]K=4E:._&
M$V+3(_AYT::A>ER>AJHUOWE%2A'VHB[A6WJ>$)L>H<^+-DW@??"$YJ#E,:5M
MHO$2*4/E`9V(2@0\]WE1IY'SE[KP_UN<9;$!]8?EO5,J5DL9<,0(W3_2<P<0
M&'H`HQX/K<^VY(2%=$*FTKS@(L6$8'2:4@BQ_HV'UB>(/F$AC68J[^-DF]M[
M<7UNELL'LZ@^Z!U_W9[M-F<A$RF%W&>H>P,:EK,1#2LX>(_$\K^P2$_7#)L7
ML#F-F"T,<HHR&W-]"P[>PPS_PB(-8H8EU%\,TOQ:9[9HPJ])?)6L+`;[D#4Q
MU(I]Y9?U#EGETZ/,-73['@6/DV>@F"""=U$3!*3!V0OD'J:"WZ,]PE]=M*?E
M)CRJYYV>)(\Q>[0__1%F)<'?7B9#,>MRT+A]1[M)KE;Z7%]M?DLV7Y^>UK[7
M\>8^`SA^(P++<L,E*&2C<3OR,?Q0?'@\;ON;23S81=V[V[O5^E'KGW5JQC74
MTN7QRP&(0W)!2+D";F?:<(#;XLN#%Y2VI^&D\/[[?9+&Z2*)5Q_2W$C3"KY0
MD#V9TAU.EW,^+J-3X7"W*;I(:Y1\:HRY74-C3%2Y>\8(@#V"*F[WSV1<^`>*
MU!P884F)0)/""VS:I\2ADVE/@#&/B)P3PFGDNPB>Z[O,C%I\;OZ]TO8?MC;-
M[=H$(W\"+=@&ZQ/.+B1!(#HMT12K$2"Z]3&0:`2('LZ<8(XIQ^.+_IDE-<2Q
MH!/5T9:])ZK\N3W_O=J<)_EB?9]N+C-]F]S?`B378DK*C1E:2?KC<S)@VRP9
M\4'Q.5FO$(P3,2@^#],][#(ZO+1=;!9N>CH:+.#T[$*9].;M.H>XW*<1I;0.
M6968%R@GX\1("<P&0.6V5V(84SD`*I\>+68SI_#P\NQO?CWGH^M^RW$^['GU
M+W&27J1OO\;IC?Z0'KTH!3`\1-2^K%P7@M[@G`QPCJ7@^_/[0>`Y62*7C.)H
M0'0^1Q1*$3FBH%OL`W&$\,@SV74518PJZ89U;_<?TD6FS<[6B*SX[X?T;%$L
MN/DGO=#F%U<K_4D7Y]R7L?$0$!8^IXB56RJZ8PC`08]$A[!SV.:("(W*U00G
M,8D^FUQ1;K<P"6X\EO*`\PF$QP34=W%B+Z]TENGE+MW7[(TO-E]U=I;G&B1%
ME@K>*-8N,`(QXK;P(UJL5I/DQ"W?7T:(3)01KR:,1#6N*=/1M.;5?&[[.M%3
MDE!7QJ2H;/9#\+7WLL^JP^^3:D`"&,9XA%27U:H)1R!.G-P:$H0C.E%.G-P:
M(13S1JL9D1,/OV8+!PDQ5<;</!N3+&KV;!.34=<[1$8$:?1LX'P![,EZA:_=
MR3L>;#:O#(WD`T]<6TX2DFPRT'TV8)-BQ,FQ$$I9A":#W><&4S#>O,WHS,E'
MO7D;YU\OL_5#LM3+GQ__F=LF.1=W.HLW27ISMM@D#T`!T9PAP<K'R=V)`T)V
MV]`1H1B5T<B8W0Y]&$98H+$Q>SB9.:4TPIS)::E*2]Q"%16*JPE.>W<."(LX
M%KXL&*^SS[]>_-]]DAF'M(G3&YMN[7%DU!")]"/H<9@+PF%X@CX+?71PZ]Z*
M`%P@+D>7<//3=0V&G1]C8<:F-H^7JSC=F,#?/B<HW@<$-Q4WRF[G!A+AA@FJ
MI1QNIMI.!YD:&:^'Q4K$^.CXG99,&9$F`QIKOKNBQX1+[_FN66$_I`\Z!PC`
M&SR!)V7'BY&**^A..MQ4M=Z<LO90+BQ@GPB:''J#43AP"Z"K[F`R4]X5/CET
M"/TX,%]?:+W,[2-?F]MH1KFXMDTSXW2A@=(6.66RG!;03A,`H4^X#3(G`U#T
MR72:@$R<(FZX&>IZ@.XU0Y_TW6Z!KO:&AEY6G>AXV(0//\'HN.E_H%ELUB)$
MJ_NV.DJ@<Q`06]D*]LI_<7V9[:['B^>')OC<?J#-'XM/G*47-;>B0((=;(=[
MP0K$V$%GD98'[_B$6&EN#BL8(8*BTV"EN=$DYX?G+1-FI;EI'7]V=#1=5MIR
M7(A0I)RE.RE6W)ZT\0B54T,FQ8G;TU6$E:)3U2^/$)D1I%"D:D+`T3D#"J8#
MS&_'\&.X^?4JK^L\CXW4@+:E_7@+3`TL'/>?U[;<#"Z(:O6^Y5*=P-,2'FC-
M<="W5W20J18\P@PSUGH6=80X(&2O]7<4Q'[K["B0O=932;@J9Q)-04U:#)#@
MJ@%.9M*[+K("<6K"9E\.[$_,TFO_8R^6'N*5/2?8-GPY3`B#2&:/!"^;IPMY
M4-B.^5N("%2N-C,:;K?K)\FF@=K'NW`D.9\"$XXO:SB6/.(3P.T3IR@511#V
M^L%`R72^L?4SX1/(6\;V>F[KAAMT;)]KH'(#Z#(AGXEK69$X`B#I<^R-J^\]
MZA`LUK?Z2_R'/08/H8SMP_L]_W9%#ST\V&ZPQU0Y/D/NQ4O/"F17FZ>ZAF^?
M"@-O*_O9LH=OPY>^[H,B"!<>&AYJ)D?!X%6CX#1D.XJ5>+UZ@9G7@Z+Z^Z,:
M>WBCE[84N!T8PL0%VK>(:B7GA\N__4K_20A+S,L,QYK_+H8%.R6=+0AZ2H"N
M$3%32$5=D'V[7_"`YEA-7D92#(3,\2V[(H3(@:#Y'`0HR?!@0$,88YC;-N!I
M^;*^7,6+HAG%V4W?ER,'Z4B2,JQ:$![2A0'J]M"$J8@^[Y<S!$ZWRGM,"D9&
MP>E3-`>)"$L\!37PMN;><]6Y(J#/7#W%J]5\OZ=*$/O#D2_K4C<AJ*,0:`@]
MX]*`L]!2AUDBL7=W/4&$X,&GLO0T.>IIU:$GM6LE39A)W>]C+[*;.-T5U37#
MY>M5LHQW)>@OS2^-?Z@6W(U7W[I.Y;;R]6J=FZVM[4"1W*1%SS?C5K8%()+T
MYM*,MTAT_L5P_?.JLYW\]-UJ\V:9/,SBE1GUQU>VJ59R_?AJEF\>5]I(QOQJ
MGJ1+`^*'672W>3-;)OG=*G[\879EJ;R9W<;939+.5_IZ_XW=)UER\W7WT:OO
M;C9O+*5K@V,_]+>!DG25I/K-S/YQ?AW?)BOSX2:YU?DLU;_/LO5MG.[^FB=_
MZA]FJ"!3?/"[WE*Y6J^66S)6/#,T^RZ^O7OS/Q(C]&9VKO-%EA2]66;KZ]G/
M][FAE^>S.%W./M_?&KR/]O/2O,Z>)G:VGUF+_WM+=,_,]V;>[+__^[].=A*W
M8Q93A?Z?O7=M;MM(%H:_N\K_8<K'>8Y4!3&\7^PD5;)L[WHWCGTL9_?=3ZDA
M,"01@P"#BV3NKW^[>P8W$KQ)H@2`L[5)1!*8Z>GI^_1T]YNOZ[O$O<9<)Z8,
M:N[Q%_M-1LJRM)>E3SSY=[&B_N<9]^=@,40A4*$3&.R#:[*S]YX_%[ZSS.T.
MN^)F&`7L7X!Q&%L^VSAG9^%,)(.WFZ^Q20UWE\DWK==&[F<:)?/KN<%N>0!X
M,3U_X?E83P:$I"5\A@,[_#;`9>#?))WPPV_BAEN<`7-],D-O#(_V#=8:C08-
M]A6>4Q#0L)P%,^$X#("VPR4,PT-FXVPT(A#$-Q'"7OCP("QY"D/=@F,$C,KX
M8N%["]^F.>.Z%"#C:.Q&?0FWB+#JOUCV,(QW+Z;]Y(+B,*GE%6L/#8;ZTB`Z
MC2E:D,ZW8,FA!Q0;8M]6X"=4,ZML2%VCV+OO)A7CSO/;(O(QH3!D,,KMS#9G
MN4GXU!<P!\X@[YL#PIH_Q$QHDZ-!FLR+PB"$/Y`O!+6I9($P(U^F-\'S6\5,
M@YUEP(T?S0,*;"K4"HA)8P`P&1(G(![]#A94*)PE&XUV06F2I004!*0':.`^
MNT$WBKUL-IHM!DP.T@+09L3#*)1(L9+'*$D7-)%@&J]@XP"QPI7#S4"Z@RW'
M?.P'A&87@N+=X,,[\4H#Y)$YXQ:;P)\@V"QZ-4'1`G-&@Z!11%U`7)?1%-B3
MM=L$8<?8`EUG>`?`4#8Z(ER!JA":2Y3,\'[DA(ETSZ%7TOV$%%$>SNR,8V'R
MN:!'T?CT/<=)8,L\G]O*RU`^#UL'SQI,<*#_9,3,J_@W:`Z?2F8+UFQT.IUX
MV:O<EE#%%S2ILT2,\RO-F:4^(N>"J1.T6>N0(C1J-47P)DJU-7@-&@NE@K0X
M;^.<96!I8'T8/Q"Y74NA0J).(&!<`I!?'$&.@C6>`C[&,P",`3(EV*_HK!BY
M&0NP4$@;&WB-2P,9P")U+0D(?238?_Y-(#_]"'LE&_'&+;[$9"),?&>\)%,@
MBV$#6=07(&,27-B4E1G8%DE97+L2@;Z<-+71$:^3V&U"WL$&)O`]K'8!,B&0
M(D-!HS@-^-,V85I\5W#?A>>#5.@P/L?!E6DB,[>4SR:R<P6)CY:(Q`5E6^'P
M^(5'W\6XB:T:6!$R7$BCP3.^F#B`&O7L"MH`!ERK;Y&@)8LH)VA\(@0<;>Q(
M.10;5'(V>%`L@+.Q</*M#5"XX"-9)V8TG9+Y="^[)V8_(^\$`!W^(W+!^NB@
MOFHV#61/SL8VT)(Y<SW'FRYC>YRDBATJVK9D&VSDQ[$O^+=PYGO1E&C8!T(7
MDG,<>X*J`QX(!?(BXA:S%`.&+M.4V<!AW%G,.!H*8+@XH`OG\\CUY#!+=G;Y
M^</7<P9H#%%1216)/P)#45U,^B:P`:5@:21`VR@=TC6'WE302\1F..DMR',P
M9[Q;%X8(HC'((YO[2X-]%%;ZGC2A/EY^`#OI3`HR/@EI<GF)"C%APD@"T[S1
M/N(!VV%Q@6V!OA$8<`0^OLW'N!VH`$&6@I`+))RP(I`#M@OT&D92#X09B2#%
MDN^!NH+_@R23\F"R':&(+H0@B!8H3XD&!!J/($$^_/C!`54(P($%"98OBD)"
M>/K$VL\A8&SNT=_7CL?=BW\*(!%LE`[*"$#RV159U(#&ZW]>79TKOQ.</_H,
MXRX#S/=PF:JM,N6RZ3MXH+?LK1]-V:54=OAU`YY2-GNB4!P>N2;*1W`OP=:Q
M+TPY84+F+%B@F*?M(D!)]$;PPWP)-&Q;S!'1-S&W.9#;QU^!VF`N%/Z-C,>R
MNI5@`(!:'O\I=QY-*4G_:-]QT,:$."OM%4^<A:K:]ZS(1'W@V+(,@<32!&4)
M:3=Z@$@4O0;8>%`9`*KG>F"EN+0EH3WV+.0QV(QOL"SI3^>W71"O^F0[2([)
M>ML+OH3=LF*0\/("`V6V9`O@?/1:D/:4F2GY66I;2;BK5)*S&',80MD!*A<F
MFG&@[[$`@YV@C7&,WY.R+]X0Q*)-X80Q(`S0:<GX0N%D*"M247%K@RU'L][:
MEEP^V4Q8C'M)TLFR)W3U$9:[7$A#6^T&62W`(W9(>U2,?'@6H(*18'TGH7=/
M8(GWTK'[.5QQ#`!HVO5NX15T+3)QKTPD+!8JJ4;B">==@!X`]0"J>I'S_)-A
M,AH:2#KD(/44=8>HC\F\W8=L]]W#(FJI"X$\;:3Y;:I&,$`[36DH$W#.!Y*_
MY@DMXW'QK%9BDHABDHF-`PQ_N!X9?,)7WM>-<"-!EA_H#TTW5:";SV"&F?;"
MD:HM=SZYG7)VN\4PL!-9(BO0<JI8N?$R.!+.P%U?"1+EGBZVQJ41#TH\R)SA
MV6C;)?2:FR6-U&:M#3`;YK""T_.-=R[V^;.J+O=IV>IW2<SO`&<8%:>3KN1X
MGR7G^RR;`+"=WQ;8%LOG\5GVOK$IU.B>B\8N6K32"4C#9XN4^Z?"!9,"60Q^
M!R\Q#2;]#O8\?"*@I14/$A\X#00^!>4"V%<75`0M"(3_G'\3Z(*JE2/?\2"(
MYBI.2;8YIX"@BGHI)U,&WF@&+FMZXZM.IF./"H1:ZOPQW$L,2>E2/(]26?(A
M(3N-!<R*?&E9B6Q$D8)[%#&(2-FA#8=:,W(LY26P"5"DDF3)^D]"HM1VB4\K
M1;X(TP%6(+VV74)<*>M=QIY5(#HF]%31^<F`<5R*1`/]&?GDYB9![%0P:1*N
M\A*?EH3Q0CI)5_HC<S5]/[\D=DH".G6;`9"@H!P;AK%2RXZTF@?(M#'Z,L><
MF^3L&P/+%)P)9Q3F<C`'!\A]C%$U@$BD$#78=63.V)@[Z`+#C."61T%$.E&>
M@..[,.;[MQ^N,.8:H:^$IB.^>QFFA\^=ECI\QH5C<F[NT+#(NB58\'C-`H43
MV$K[8E!US-UOF@&KO,2G=O!DEP*BQ;19PD;N^\C-&8#ERQ=$\@*G@TL\C)0G
MTJ87A"J`#;K"M..S(@[K]#DNY@*7!_0;V(%,LXAM(@O82DPB!WCG1G+I!`\V
MEH+[P$CO(Q\,3DR;DX>[WRG-[;CS!V@'Q@#\&S-&8@N49@UMY'20'F!J6H:R
M.]7TR1F3:4;S2/Z=@(0Z6PXQ]S`NK0Q$D<@N>0J-DBX>9XIJ'`65!\+&#N(#
M8B409-@/A&*#8?%@VY>FZYRCS^O2,3&9L9:=8LV<8:">]'WF_7+P6X[]2R]<
MNKW:2)</<Z0>XFR@_U\]=WKQJXTDJMHI;9$/B:\'WI,M;@,@57C;H;<5V^#)
MB9W.@#E8@CCPAE0__"JCW=(_M7U@'<QH,ND+"ZU=(?U$8C7N^TLZ_Y&9&7.^
MQ$0&5.&^H&0)/'_!O)`0S_=LUYY'>`KL2M6=\>8F7N2#J?!7Q'T\_5/Z&-F^
MP3Y,\,!18"*:2KX(8@=7L7PJ/B81R:<(0`WB;!C2X!/'`WP`$CPED)*<#4*,
M9$=4_^I<./EEQ1A0"Y99<722#O#.49S9!*:=V[T`S18Y`1X8"+13N*_2Y63J
M#3G5&.?-;`IYKF,:7[F^TKM6)UXF^@SA+;H-A#MX3P&4GU(>OZU"7<KH;XWX
M]RVX:3>4$+"%5S$P:F4>7-6AV3V5NZR,7\S6%B'HXN0!R=.9O%)0LE8:(P+%
MXL9IW%(IYV<%+2S5\U\1IB#%CU(FEE2YOLA_2:\AFP./6S:&I6ZX[<ATMDD&
M+'PL80]+Y8RHD>2L.!Y]Z5G"R6:XXY?QZ-XX$/Z-/,F5+UL\Y$K#HQ3`A_^,
MK*DTAM`TTA&>4V9`8HU_Q?(PC>VF)4NV,&;*5RBQ+3$AVN6!RM<!^I?J+Y'1
M*ON5E$:`%RFX,E$-5'P++*.$Z@2/-S`0R9.PZ9*RMSF:E!;>)<DEJ\?R/68\
MR@NQ%YR<X<NL>)C98#CZYFQ)9W_RT"23=HBR(:,YW444JD#OE$0`+@N==WA'
MAJCH$H@72P/%\91S0SE.$B!E1R#IT*FU,BXH9RP3%%;Q75"]J\-';H:M)512
M*1:N#-/:<$H'E?BK,NJOW1)",M@CLL^O>%#,6D#VM.<9BF>_N]S"Y<`&/\0^
M)_9@&I-7MXEFBG'BO!VZ,D'!&O7&7'`,UI#HKO#1]!-M;KMH<]57,FL,ML9=
MVV,Z_"4#(:81>?*#]^%2KHQSIZ4MF=ER$%S"IM$M,,'-$'6T3]Z!_$2,C(G5
MB(?DK#D/!)DL*N^SF*C62-$H&"*ES'W&BVDZ62T:,5RE`-H[T'88BMB9LL/E
MD3>*/TQFA$7<>`X/%5"&/#M<RF2.!58S-Y@)'H@=/G_&?#OX!I]%B)<("<.I
M\):VE4^*1QT5DDM%80R/TB=];ZSRA,?+G.4T7M+/&-6@(\LXPQ!X<;_H@V;`
MF`$[Q=)U3;?)A$5E"R<^;\963D]6BV1K?!4!W6`2K/D\UELW=XS+QUX4QG29
M/]PM,">4)1,%"&MBD2=4O0I0*>FCA,8KV3)DL!`ZD18"%LBKM.%LTS&Z4H<%
M+B">Z>-!8'RUQO5@'<DW,I0*C.T066)LPUX+#J3V%">"VWPHTL!LR#C$@L->
M7E^Q8;MI9,[Q-R4"8!PE/<F44``(2+>^`,&8^)L9RU!"#2`1MR1WD+.90RHD
MDUE.QG3(W6K.9S(!E$$0AV-PA'10=4-2<4.$JD/-OVVN-+<B]CD-%>A=9G,G
M4IL;@^CI2)O0)DUE>&P1UZ?9N8N$M4-\7.2$.CNXM+[T%YG]K6"ZM:UP]HJ-
MFC\<#`XSP:T+%AP%(Y8AH<\+;EGJ<V9&/_.WE4<[`?#SBV[[AQ>XD_3+V`M#
M;YYLB1KS0G[]BK47WQ_G9O<:AD-KYT):%5Q'#'IS,^QC\L83T,?`C=]P`8QR
MF9`8/*0%>+']HI`(Y?V5JK"9<@!V\%A=Z:$NZ]!TO<$_UG1=Z75HNM[@=FJZ
MKO0Z-%VON<M>R)U3I.H?<S[#W?R')U_$_IM16E"+6'&%Q1[;S:T9ABL$JB8&
M30R:&#0Q:&(HO^%3Z2AWFBN8/0W8E>%2U2VO+%.E=ZTKB^,*@5IZ<J@\ABL$
MJB8&30R:&(YM?;'Q%/#H^3^_^!_3%&(R>;%S5;6TQXKN:19='[Z;@48K*#59
M5(B"-Z%UM"=9JK>J09<7M?<(-&]HWM"\<1J\46D3X>5#Z/Y:,F+'Z`VZQJ@W
MU`Q9(E@U0VJ&K"E#;G9B)_0_[<1N<V+OF/1;-]E7$E!/0!QI0[U,L%86K9HW
M:K")Y8:ULFBM)6]TC6YG9/1;1\IZ+^UF`JS/GY48VLHB5G-)!3<SY^S]2'=[
M,Y\?I09!9:Y4R"^V%J[=3B05+HRVUYC'JNF;H>8/KNG-!?O*OV^K`YBMJ!T%
MJAY76KTQK2<S%^',LYCJ.ZJ:1%`)'#E/B/,TV.^J+[P=J#<,K&&FNAWR[]NJ
M-F1*]24U&M**DT%2DJRHJ2M5FDP`6:T+NK5Q!!;9]45:^4*6":2JGBZGZKHX
MHI\TK*!^][($&[:(&U/9$E5*DSI*YRMERK5A%4TSZ>M*?5]S-2.2@JE%R*+&
MMIF"#ARK>E#Y"(FG:`%?PM141$>VNYM[/F9T?L.FDE1+""L-)66RUB=)UC*)
ML(J/+)Y*'8Z+YC6PUFA23)1Z$ZHN@(!+K%(<A$4+,;+PIHU!$MI<J9?!`U4(
MP_;C:JZZY4#5E_BDTI%]R;;7S/9%N_*";449OVQHRTFUOE,.=P-9JA$D$;;,
ML!J;7_2%/1]'(`;23C13V0(\5XEUO,PU_5,]M;'#IZKLLJEAJ(1,\TJ5E_BT
MO$+-)R_>D,3^+$O$[6E'I`V>UJM#"PZT*CO9R^[TC-]R/VED3SP@NSB-EQE5
M_`:O'U]<FS./VM')-W/5>XD!DFGB%O:XAF"EY!,/PER+^XR&LZBM!O*<#3!A
M7:9EYE=D<3_<VJLC.ZR:+]N22K:1IT6N51O-F#^^4#UV@K2A0%+J3Z(+[9V`
MY,3414TMVQA0X2=$?]*5*JYQ+ML!8_VV^<+QED)DBYAGV_ABX3@L,BO;FLAF
M\KFYJ387+>1"XA6KEH/H2W&$Y<+SP"4;0",$#!LM(X6`J9&UC!#T?)=3DG6*
MD.*A$9I,P77/GPC5TB"9!LS/T/.I+F/ZN[3A&MA8[<;VHH#LG`3$W"JD6,>*
M6F`2):5*R7:3A?!DHP9J][4R08(L67`L3]X"VV%/"K:I@5U>J?\,6$MCX8J)
MC?82E70'`RO6"0I65`.`2\NR"5K</6Y;%]2B=6&'W-%RO\I+?%JY_X[[6"$R
M8&>_>D%PSCYC$W8IUV0_XKUT@!(GQ).V*:T3VXF0C40\P8+:K*>"&A:(+<<D
M"Q*7H[+(=QU#H^H-#9D,<^80G.NCR?[AD:I`"@1A6[$^<448^XOJ]:2&O&Q^
MELIQ[*^,7::4*2;QCDP(`A>[W[H1'6JO*1TO"K%Q!4VYM6W@V]UXV6\ENY:0
M;O)]UK)PHD#N)=X:3,O^-]BU[9JYGJY4?MESJ4F6M(BI=XV0GN`*6>!"J+/-
MVO+Q']*>?`Y><[H*ZGU)#>=MV<YC'2AV)FT%F!'DL#*P793V+BPYM&6%U*0L
M^SF@A&QY5:$X:<H3`UD,(.@9+-^H"J>;/)+],K#JI(H+4(G3M-D>MH%/P&VP
M]TIE8+L1U!'"6L_X-W)+M8,@DM4%Y08E-96SIA7YSXL(O`/0BZQM=#I-H]7I
MQN\@'A*D9)^$R0:#IM$;]9/]W\_DV6LEK;U6$B1KR(*9[GUN98..,>R-#@16
M53%%,W7!EP1"EBI@@H[1[0Z-]N!0-&3;!Z]14H96M):N\A*?.I*!AP'L,HW%
M?O8]%_XVQ0&>FN7A2KU06>&JM#?9W3B\8D]AY1L#Y^:AP"$1/,]WVH89L+F0
MJ[2>[(D+')0V&LM6\Z76AO`E-:W(-$S*LYSFF/(N\?FSLO/,=30.P.-%OGEW
MLS>3Y,3\?+7%&?*&0YU%P9H#.E9MS$C<_X.[$?>73.J]#C8<]:+IC'VD@%VK
M)[_>3-,__1@%%U/.%Z\^^5/NJOCW5=+6&CY<NE:V3_BG2=)M)FDD'KRU`Q/L
M%G!0X>GKE$53V?$9QC/!6OH*!/0&*>67Y\]^>JJY40LC)7\1DY]?7,F__QA]
M?/?''YWFQ;587"#27ORRP@O'SX\%6L8[OD<^(?T-#!+6RI7S?RL"T[<7<<3W
M#4;%J(,)V"_7T7R.)`;?9[";4PL*OWN(E6,<63].V?R'W9M"674T$^'^),,I
M^)0EC8UR[=($HK"C.?L,%NV<FR*B[B6@BC^X9@.=[CFU@OKFRJ8.[`JC7`'[
M%^P7AMC4<V>HD^-)VLW7*Z*RW7IM9'^.9]WTNYPD\^NY01V/TWYL>&JH3I:%
M/(%5A@&)&OSPF[CA%D=[XY,9>NAO]`W6&HT&^7/66SI""6;8*$OU"))GN32=
M;`DD>U3(4U=`QQ3&HF:-&'-;@/FS\&V:5!HRP&/F1NOD_GK\OCQ2<S;]Y*8.
M9GL8N\K9&`3ES%`G"&S^E&MRMDK&,K[U3H6]\_0(WB8XJK(1A`RFYP[F3!5)
M;S6;/\2T&=O.&/3-!%`PZ`YDEPE2P/,[&/,LRTV?/^1!*PK5DUL==YA`HOT>
M!]Q'HUT`9GU9`T]!U`G%RV:CV:+H!_G#QJIQ3HR6QR%#[2]C\FO;U"B\)R)/
M.-%;2%@\-Z*AVK6BH))PQ`$ZQ.+G#Q2`F0MU<.*&ON<XN*C51W.`7ZIVL@`L
M/&O(P",.EGDK;;37;'0ZG3@FL$I#R<J_H%64W:C<-N?B!4FL,YDRV5!K';A,
MO_@5$(.,K5H8/\F%>?#E'!@H`Y-YXR.+_'H(5.3)>'3X&`]NT+G$8@'VANS%
MF9NL:.&%%%!`1"2TS;B=+@EF22:42,-"_DW@\=>/L$/R_$.9JRK\)J.F?`6S
M!J;,^`*8!Q%!(58WL"V2%?)XAUC:E_.E!I5L/;Z>@@1+!2=6J#:""A!#34H]
MO&2?EER85P4X9?=BJ7\"HEME9HOL7$%B5B=LG@3';?S"4[ZV1$NLN@0='M'+
M:V=8:QA3^5V^1<(CZ5&<R!=RW7,-'F.M*6>#!\4BE`V];NV`6IP!$6ME^!C*
M$`C9R!M-L*/_B%SP*#HH<YM-RM7B;&S#KI@SUW.\Z3(V7X@U[5!1B<HEH>9.
MON#?8N<5-Q9(1D@:=.P)BEIX(!345PR6(3CF$<JS>^S^S)W%+&YRA.'V^3QR
M/3G,DIT!S%_/L>E0B#)=ZB)*9(N[WN,W<6>]!&@Z;Z#EAMY4)KX1K>)\MR`,
ML27@+1ZE!^#SVY9-:6H?A16+H5BM?KS\``KT3`H"/@EIWCAQ#0]1'&05D/H.
M)=]LUL)TU`%#A[*Y-[[(J?T=GD>`&`(A$4@081U3>>A@AU$2ID\X2O5Y]3!2
MAL<PKN2GR78T(I(0@B!:H#RBG1=H2P`'?OCQ@P/:`X##\_"0PA2$YO2)M9]#
M0-;<H[^O'8^[%_\4(48X8$NO4#+X[(KL*L#@]3^OKLZ5=0X6,GV&<9<!N)WP
M^8-+)]U3$B\PW&]`PV_]:,HNI::@0#@\I2PWE,4.CUP310N8WY@I<"'SGEE"
MURQ8H(2D32(826I%\,-\"41K6\P1T3<QMSG0U\=?@;Q@&B%;UZ;;)GO7C?\4
MJ@%C3.&;4JJ(=V2F!"8E((':\MA`8F2"K*XBI)BA%2@[,<)NB_\%V#S7`R7N
M$OI#>^Q9R$6`^&]Q-_B5+1;$C7Z0=DC,NA\+OH2=L8)L\@8(_J4Z70&M"'06
M2F4F.59J)DFDJQ01FT^KAQH+T$PP1WJB08#&^,3O22<6(U_V?T>TC0%7@IH4
MH[.U.@_*@%0$I!'E6]N2BR:30N8A4R-#E5T+BUPNI/VL]H!4.G"!+7MO%:,<
MGJ545UR:UDR/HYGV,^MC=\K&4XE;>`7MVHR'G?&Y8VXE)<`3:KX`.0KB%13<
M(N=()2-D]!H03,@I:89H)T0M1N95O7M,'L<+ET%M;-&(\5G56EPV^8PCE]D=
MIEV/+027'#9OEQ,LQ4G`+&\.XV+[6XRRJ\`/O/X6+(9;<DPWG=)FK8'MDQDL
M]H,*`;Q2JHA.<0N<&$#()<AIA[5:,4+65B^*5E,4TU)V??)UO$Z9R;`*)@U3
M'+;;B6)-]P?3_3689RJNT<O2_HH3Q<%@`K6.\7FYB9_`//6#F;T`2\LG3B@B
M+AFU(E=_1X!H`B1$SE@A%TCWS%J+5GPDKRUGR-*,0$W"F12#=,;9J-,8_+!F
M89]+![?P)5-0;B9:NM_M(*0DTE6-(($QB@=0B2TTY4I6/!J^9)N0('<<Y33(
M5&/2,MZ&I>#1=^&0^5`(VARYH`^,=Y5QFK;&,RYAT2&GD$W'&`TP!6>0&:<8
M6YO#,@A+R^BTVT:SU]L)3RG.DHM.96LI#LIW9O3\V:93HS?4L1D()WN&RR[8
M[RZ/+!O]A@_H=-ESEASKPC=I?N;6HW.4?D2.*->B9$1;C;@[OH7\&P<`9(Y6
MZH%0RWH9T5\7L]D\%>I*C_<%I@)D+66;P>\HKY.HU>\N`4:J5;(C"$J0J[F`
M^^^-ZP;[V^7EYYR<E'<?Y8+2-6126`UU*[$PH.9'CHB7.57Y8$E<.@_5=7I0
M@,\G45%,RK6#H/`@X]U5#E::%O99)OEXF*8W!P*Y^#\IL)6_.<3YOR3@L.N+
M_Z]!1\D^VN#.DC0*)@V1W%2)>MEP=#9_E\*DGA?*W<OV\D[022A$0G$$YLT7
MT('T6.]"0)/(=V5\,NE=#W#*5'[YQ!G%>V42/L#O(N1.MLEY^NQY?'T"M:JB
M''0AE%V;)H48Z:U(=7Y(%SP2N&)$Q>E0R6F-6I<,YP;99.>8"^-74)TA^N.)
M;,JNM2B2<B,V38#7.BDIDS`:W`VGP8S26,<X/"?*AG?^C%QYF):0]NZ!5GR!
MR1[IKYEL38QG"`K.N>B^I<Q<V'_==:,D3(_AT)CT_[G7M'2F(4VK9'W`7+&W
M,]J8PJ.-Z`IKS4TZ,WMC])KB##$)[Y5MF3]CXKGKFC)L$0<IXG#NC"/1DTTG
M?'7>="/<B)Q19#!->:=!>9]38X9L_4P:WG;:VRV,8SV^48)*DTH:'^',"\2*
M_,X]77SX(H]K0`7E,H11\204GYLES='(&G["L>>P@N+S1$WV-23[WR6QO4LN
M%(.F3]V1),TT[\-LY0?I/&1#DGN=MTM;!ZU;/(-X6%=#V<:YY&(0[W/^362N
M4E.=DB"(YO'5'DK5E]>+TGMEJ%=VESP)URXF[^>1;9I'*27YD+JF&VR_]'8I
M+\_&=JI)EJ4\UXD#H2AIDO4?);?NP>(:6DP\J9CX(DP':%U&5[>*@"MUY",3
M9E3V3$S)J:;QDP'C/`#B??H3[S'"BO+74C?=Y](TJFE43G.%=YI0/M(?[T#D
MWW!G_YM:L>,04!QC!J.#BG%L&,9*;2?22QYL@(TGWG/,"T\23#%)AP[$PQDE
M%#A4;<!#;YZN6XD4H@:[CL"['7.')P6LHB"2US4IUQ3?A3'?O_UPA9DL5#<+
MC3/*L`@S9R(==1ZH"NZL>]=I\*CP5B5"AO%O2]`%,:E-J4@'=XO"VYK?-+_%
M'A/F"H32ET9VDW[V1F;[R,T93._+%T3R0JX<$Y=UE51F$,A^TX[3[#BLQ^<(
MQ04N@RZX![(J2UJL)`K$)'*`56XD4TXP9(?Q)^";]QBQI)L<,L/TNZQI<M3Y
M`S3<8@#^C<7K8I.19@TI9`O"`FQ#RTAKT62C\R!\HGDD_TY`H@`P#3'W;K*W
MGV-1)6/C\J:I?!?+QI%<PAOV5#V&PK:*XY,[HUA2:\%M7]J:<XY.I$NA=;([
M+3O%FCGC=.8)0B[SOKZCH87&1J'Q88ZT%4?J?_7<Z<6OE/)_*=EBB_18N1<:
M`"'#VPZ]G:GC:*<S8+%(0?PI[XSB80B=[$AWT_:!L?!.ADE?6#)S(*GAN%+B
MDHH5X;F`C,YC/C<FP.$91(AYE+9KSZ.Y"H=CK8S4.9MXD0]VPU\1]T-9_"..
MBC?8APG5C$IK8&6J1DF!D*G$%)'TB@#4(,[5S]SD!B1X2EPEH715:-17D4^5
M=9O\LF(+J`7+RRB4HJPJ9LDZ25G<HFQ#&T9.@.ED\;F,/%)2=3D\JJ^4VY3X
MB(,R%63!J3!7T#.I0QJN%3?#*;%5=U(^%9-R\G#KR-5I2)*WX![>T)'<MMN8
M8/U:F0=7=7V6NB2]*9L<+S"*$&R&Y`$I73)WRL`8L-+@$RA`-[[8*(V'_*Q)
MY;2_(KRO$3]*UU:D:>"+_)?)022>!>(A9%)]R,C`O5;95UX+4"/)67-E_+*7
M/O'+>'1OC(7I9%*O?-GB(5>6",HC?/C/R)I*HPU-N#N'CK)<01SSBB'=OV;:
M4:@AIQ(/_2L6X=EDEZ0LU&8.3AD0E8PE)D3D/%"W.&Q3:>S;].1<72($_1+@
M)62N;&XJ?()E_$@#X@$(AD)Y6H%;I=0RE`YX13M[D35623&'T@T">\'EE8>L
M')G98`G[YBR3-9>]S(5")*/LW444JE#SE&0%+@N##_".C*'1!6HO%AM*-%#.
M"Z4C2("4Z8-42[G8RAZB^T/Y2MQTO=N[71T^<C/\+Z%:JY^9K@RO..&46*XZ
M>%5ZA5O.`A4T^*]X0LU:P`M$"-FJ%+^[25W,A]C\Q*Y-CPK4]?R9XJ;X`@C>
MXC8I`J7>4)7;2?!O.!/7F[QSD]M%FZR^DI>/J([\ZEZK\F:PZ3&MR(,I3+I-
M638I($N6<6;K0:H)FT:WP*4PL>(4I=7%G^)TI3DB)#FJS@-!AH^Z(%A,7&LD
M:10,D5+H/N/%M)VL%DTAKFZ2V3O0=AB*V)ER9>2).<I&JF1KL!L/,_4D4(8\
MVES*;)*%$!9\98)'9</C=O`-/HG0;)Q+_*9R7=IG/NDD=8Y)#B*%;"@_S_>]
ML;I..E[FK*_QDGX6*E\PN:8&'%D8:=%LN),-.\6R=DW]R7MPRJY.//F,W9T>
M_Q9)VB0ITE5B-G\IDFJ_I&?-?.Q%84R=^1/H`HM#&3M8!--.BW0GM+T*T`%)
MZD<K\E1ORGJ8\FG[_D5F&=E>M.U(LP$+9$&=<+8I)R%IO[+F]O)L3BXE@0+Z
MDF]DF!L$D4/L@Y$E>RTTDYJ&G!AC]_D4W4_))BU?7E^Q(=YN2Y,CMK2RR9P>
M2VBP%"S5`P=QGJ]&+XU="3V`1MPM60O6E4V74H&QS+(RAD]C8\6Z3$.5N`A]
M,J@J#Z.X-T*%I^;?-E>:L!+[VX8*QB^S"2FI&X$''>E(6_KP2$0!O<OBDCMW
MD[!6NB87C\7!AXG-]!=Y-5I!1PW77K%1\X>#`6-XURI8<!3O/[]HRL\+K$HO
M/V=FS+;)WK\1=@RC&O-"?OV*M1??'Q7GN[O\Q6WK"OK6Q2"-R6]/UC#&AA:X
M$D9Y5XA-#Y$)+W:*FP$^1O.WX[F0.ZAU$T(!GZYWZ_/%SR_D?S?B=SU:]]1D
MHZGFWCZIIAI--8>[4)IJ--4<@,6O>#W[\6GF^;.24TVNX>T=3;A266F%G8:+
M&&*%T$NQ&P]#=*5:C]X/O1]Z/_1^5&(_'DH;/EY0^YA82].;LD&\@K/VK5:4
M)O`2$;C>#[T?>C_T?E1E/U84,AM/`>N>__.+_S%-(2:3%SNWKMXJNNC,J/!N
MWMV4-JWE19:DGL[U/X3PJT?H*?RC_>"GK7F$!5R<EL#1M*]I7].^IOW[PO^R
MHB3?-@:]@3'J]S7I:]+7I'\"I+_9Q9K0_[2+5>ABK=4YT1Y6N>F\!'(G+M2M
M[4Q-_:='_9KV->UKVL\NH&/T!EUCU!MJ'M`\H'G@E'@@YW7]2+=U,I^K>#=2
M%RHY9$SY14%Q,M?TYH)]Y=^WU13*%@V-`E6R(ZU(E=XJGXMPYB7]:50E:]G4
MAN8)<9X&^YT:NX8S.U!O&%CF1'7(Y=^WW8+,E/U)[CRF=;2"I&I)43=MV3HG
M!F2UVMG6ZM986-`7Z8U267*(:I6YG"H*XHA^4E7;X;?J,C-U'AW3M655(`QK
MM*W4_Y)KP]I@9M)0FQINY^Y@)F7@BI`E6\.D%R0YWI:EZY@23]$"^ZG,9%]C
MV4!U[OF8:O4-&Q%310&L-Y`4S5B?)%D+=GY9JI)PU$V^:%X#*Z@E)=*HT:UJ
M*0NXQ,J,05BT$",+;UJ]?-/]4QZHBZ6V']>HTV63M=#;4=H[TXPYVW_ER@NV
M%6;ZLJ&),Q4P35G8#62Y)A`U6-?;:FQ^T1?V?!P!GZ?U\*<^U3O(E6U;:23(
M99M#[`>MKD)O:B\M(=/U234W;.8&ZIE\\8:$[F=9ZV5/4R!M)+%>ME(VRI3]
M-1=2,=QRWXKK*Q&5RVX1XV5&F[[!"V(7U^;,H[8T\LU<,3\B\62:N#.E;%F9
MKX+`@S#?]#)54A:5^T:NL@$F+%6PS/R*3.R'6VN(9X=5\V5;7\@.H;3(M9IB
M&0O&%ZK4?Y#604YJ]DATH<D2D"28NJAL9?5EJH4@@DSWB[CXJFHJ!XN8+QQO
M*42VNFJVK3O6?L%2<K+XNNS^EYN;RE700BXD7K&<*@BW%$=8QS0/7+(!-$+`
M(D=2"%@+6>,&0<^WDB5II@@I'AJAR52"]?R)4)68DVG`@@P]GPHLI;]+,ZR!
M#5QN;"\*R%1)0,RM0@IN+#(!5DU2>XS,+UG+1M:7IK8B*Q,DR)(U./+D+6#;
M%"GDMZF!K1:I2CX8/&/ABHF-)@_5F@4;*9;Z"E84](!+R[()6MP];EL7U%Y\
M88?<T9)=2_;-DOT=][&,4\#.?O6"X)Q]!LEQ)247"?W]I+P2&,1UMBDM#-N)
MD%%$/`$0=TX4LVS73N)C5`?Y]B9H&+VA(9-ASAR"<WTTDKB+2)4+`RJRK5AC
MN"*,G3KU>E(T5G99224U*!7J=J',*8DP9#,0J=@ISXWHA'5-K7A1B#6S:<JM
M#8C>[L;+?BLYZA(63A3(+<2K-FEYWP:[METSU[2-"B5Z+O7HD,8LU=(7TDM;
MH0:$GRKMKZT:_R&UR.>BL)\U=='R0A2ELI+X.G3L3%H#,#5(6F4D8Z]ZS[W!
M+NBRC%E27O4<<$/VN"HFF'0+B*$MAA0TB1FWJAT+DT>R5#>66E+..]4A2[OZ
M`!QV#&T#&X'*K<0"XJHOBNP"NIXB;>16;`=!)&OHR`U+JB!F;2CR=1<1&/J@
M`%G;:`^;1FO8C=]!="2X"3V\#!X_.S*ZW98QZK8SW;WW,6X.6E+[WDL"$/M#
M8]@>J7=>I^M1-9M497H`OV<,^RVCV>TFSV9)0;9U7?"EJF^W\G++:/7:1G_4
M3EY>I2604BHV(<%='Z)C##LM8]`_%*?9[H-KY)DA0%UC6FOWK5$,K(U!O;15
MH/6S[[GPMRD.\.$L#V?W0F6?J_J=9)'C\(J-A95O39B;AZ*"1-,\WXL39C##
MV#V*N_(!DZ2=4[*E[Z@9$[4XQPJA:8^'/%=IBU?SQ)981C0.P-=%OGAWLS<3
MY"3U?+7K"M*^0YW/P,H#.E6=5<*9[T736>KZ[]?RDJP2Q5)49#B%F`9&$C#!
M-HE\D?1G.T0;_/1C%%Q,.5^\^N1/N:O"X;GFOI>NE>UM^FF2U*=/FI\&;Q,H
MX.GKE*E3:?,9QC/!+OL*5/P&J?67Y\]^FMC.J[]Y\"M,:`K?37ZDQNKPX8N8
M_/SB2O[]Q_O_O/OCCT[KXJTP+]!\>/'+8YT_/BPU%@B!W:.O$^]O8+*P=JY(
M+^&2*63>QQS870CY&"C)P;A#2#X]M`]2J5;6>,VT&8L[E)&DP=W<*2.,-0\L
MB.B@T,I4K95NF*JHG>A3$/_HP=FR!;<@"SM_A#BCPX/$50/E^G)H=,"0;C=[
MLA0N_$3:-PI6^Z31TSVC#8;^H(5E:Y5K@&V=E$^035-.D8+,_5IU9UMI[@9B
MQ0[EP#UCT.T8W7X'HVAK^<X-]B$-A:VC"$T81+(C".^``'#8P#TG_R+I1D$=
M[<@C2#$9>.!]B%S+8<0W"C=9(=>DD"L.J5!!FQBH,U?IN7^')V^%<Q.[2'&-
M^0E80![XZSZWX1,*^Y"3?P2&5S1&%3/E?A(!**RUF[8H0!EJNU3N%A8R]10U
MH6PH6[W:Q\EPJ=\2[R-YOF8:6N2-YASQ9`@9>9I:S&"70ZKF+.55$%$S#&SK
M*+X#H\3'C!N.XP$!%):AHX>XGT(<R3?#I&`S,@'%T,28NA'@J412NUI%M`W9
MR"V@*)CB=@R^1S)V)>6=[('@\_1G*483;L:0.L%!G"7\N8P'&`QM%T>V<<.]
MD>X.#IY)3A@OL_C!J%!>'N#C[-;SOQ'_2;#C(Y:Y['6;E;C41$_(8P4R_++K
M4BA0F2F1G_TMFX!"2(G;6E)I;4&2+0!*YTK+%$D/\=T.0NHPQYUP1@:K*R.*
M=B@-4I1A,7;3P,2<6T)51J?Z_#YEDH`%B`<E]"-ACA"9'2W.$$D"F`_?L4$;
M*@\H+@XR3#+T07U!_+A+;$X5R?+YL3@@NQ_4<G),G$G264FXDA'BT`XF/$EL
M6.F00LH6#Q8<&!CS)O"9,1X?@[A*=&X1Z)9')D(LG2B-@L[[Y,^RWP@*"T]!
M25I_F6]Y02Y>OBO\"HRR?P4UEAF+-/N)!3.*&V=E\AC;6J8Q_CNH]I]^W.AO
M'>Z,C3ZB,]:\N!8+=,8Z:\Y8=93JPSE83]]<YL'B0@\G?ZKGX72-X:ACC'JM
MO3R<KC'JXL7<4>KA['.>HQR<Q*?)^3GIJ6$V.PLP,B41]K+?-/J=@=%M=='Y
M61]<>S^/X?W4*0[\</RN_0KM5YR`7U%CYM56?GVM_/BXYXMDXL^8R_HU;>.;
M.<FYYV',;OM_G:P+:'\?+_G>YCY;99W4_N_D['^%-49H8UF\/62T\:D04XB%
MXP14GW3OZ558)2A,V]R?'CY>__/J:E=]Z?V/(RN_RQ5=W\.$P\"_`K$'[M;?
MA`M&FL,N0P>=%9/]S?>B!?O5!F,$73FPH4*5$Z"L865LI5E@:`K?SCQ,@O-N
M,=$?71_;LND>W"7(%]>.YNSO0)F4)?IK:#78&2;,4A-VE\_AE34P/KB82BX5
MF0+F')7*1S'W*#'AVO'`COJG"#%1`:,::%OY[(HZZ+`SHO9S`ULSQBUY"3I_
M=X9-S0CFR==7(?EZ1.9CGUSV7HS]"$VG%AWS-MOYV`:1+@5IL$,[D+V)-T.,
MW*4]-"HQJUWX:`W&1N?EU!=IPT_)&Q<I;WQP`>%A)&_L*$9);NF=7?_SPWGF
M^#II:)QX2LAVR$X;DYEY.CW:>G,9-`+;]C*:PE[C4ON%+W\&>S?*M&9-!LHC
MQI&8"!@`3HX:MO%V,":'5U7`Y<0;3*KA-JPFZ[::F$^--V86/%2^%?F`@<S_
M\[;DL&(:MS!GKN=XTZ5LT,J=`+W%Q8*B39XKC=K<?403"(<FS(:^*."D@F-^
MA/XNN(H67=PI0LN56F9\5=N*T*Y.;I%GT"W\S-5EY7#0'82I?0-_Q"_1_9TQ
M`(E[?Q&#0LG&T]B9$`'@:HQ?C\%-*(0+2/@?D2M8:T1QNE9^EUS/Q?O6#E[X
M(1#E#2QPW&%/V!D_9R][3:/9;")ER-?/QO`E4$?FVS8MX\S$'W*/=PI1@'N=
M;*<2[?$TW'61/N8<R<4EWWLB5.9XLF>JX7MR'^`?W)4L6K1$C#[BI23VLJ6`
M+MP6(A72C6N)'?GQ\FC*W'X"L%^VU#(PMI"`"X^.*5<.[\-*)J.(Z=.+^;*H
ML9/5+A^)0-J#(D++JY8<G24"*R2[BN=5"0G^%>-J580J:J3B$NRSO-KP8UN-
M)R_GC&U7:BH,.O(%Q2`<[Q;L2WC87(8@F<9XZH"<,_&E4RK%I2<#(K\"Y-%_
MHSD?7UR:[79OHRZ*5TPQ-.2JE\!ZK6$O<S$+(*$@),8UD*/3LP09#,GBHW">
MWQ=T)S03T]VBO%`EYJZD(J=C&,</+\#2!HE$9R*#D=%O=^(0TVTL:#P4N6`F
MM]2EDUV,_OAL_P"1Q$Z_8FRIV$**;P,=GC]C7E"J&WG"5EG_\#40"E8/D6=B
MBK1EP!S),GDI)CUD@X4ODL]@XDQ]/E>E68`[;F1H+F.A;;)CR-ZP5BS(9.`@
MC*QE,GPNWH^7U*1N)!Y.UA6HT*:ZN!P7?J%8()TIW.+Q5QI6'7M^?/T\];KD
M-7$/JZ?@9*@]`8OS.5?AR8U+5(C/6BZ(04S*#`JR,E.+`I7Y`=&/"M/K899`
M^DLIN]KW^_?J:G\,!-^Q36H%UQ&#WMRSY?$%%;=6C8]?L_QOBJ)P<2N_J(#F
M6I/D=G'X8&>3Y%(QYMVK5U>>?.JR#LT&#\(&K5-D@T.;GA;INR=?Q/Z;45I0
MBWAWA<,>VRS;#\//GU4&QYH<CD\.I</P_9M(;A)YE8Y<_E\$0$]L<$>_$"KQ
MG[?*>TZJR^2=XKNIQP.K?)>(!VNXZP7=F0[?PX(:XH6(46]5`S,%G2@>PO@K
M$7%K1BP1N6E&W(29/MX\'Q:T8:L%.]Z_WUHMK9$O^<K+6.W(OHD+<5%(71L?
M)0+U!,10NS,PAIUN3<60YA#-(??%RJC?-SK=(P5-GWPK#VS1<XS+3552X`^:
M]IT>B*^6)5=F0>CA9;QLX"+7NB')F:/$%27):<R7[='(P'R^.#T(AG.61L;.
M>*C+JW4Z@C\M&KPL3HS<0),S;JG[[9(Z*4<!R:ZI"$Y2WX,07$4WXV$8JK+W
MFM[Z#?;%`\F$N4,?^7\Y$(N^YE2!33]R.FP^D7O[50NL&(K=.]PINY:=0H+5
M.Q5%9(;7BRP;!%/H^?)JA1E&Q2G]6VXZX,AJ0$R$2[N6&'@!`$!2-_5G>'W*
MH"O-"M8@AC6N2^(+F79N8T+K/*YY&B>HXEVL.1^K],#NL/WZXE)EZ:9Y?WC3
MBY,HI9%D@J#MVJ$MQY)W_R>V'X1))BU>50AE<FV:66B'Q9<(LLM5%D>0[U."
MXCW.K\>:]51Q$:4]%@%0K^0RF+,O*U3@_3)9?5D5(`ASS?3DP<O8PRXFJQ?"
M"F#><#4@NQ0JQ(+70Q(KJJCD.YA'(UA5>GDNWUMGLI8DB=G/:AQ*J13?\>9/
M(*A-$/9F<:=)18>7S<9@B-.];#5D>4M5I]JQ)Z0T6TV9*/F@]1/+*CZ*1K^C
MBMDF=[=B\?FS\N/Q/HCY!Y_C;9\K5;Z#[HX:[-=?][IG_.@%*TI-KO>^_+%D
MA;>R5C1=F%[ZSQ;_7KGUL7%?LS=WO[G>K8OWG"[A,P]L7O`\W<#-:"S0&W/&
M)Q/;L2FK6]XQ`3%Z#>)*!#-0O^$,WWF;4:MKJ>VXZ+,XR[W=?/TQ7<A[F"#Y
MI?7Z/"/.*>=\Y=%46G-9S0G6%=_(`)NA![):%>0)F-0>Y("LM"@,9X"]N&(6
MGX3JSIULHH+**MLM3=X97$1CX+3<=LANAMA30$C=('<AFY1/%S.I16L1"@EU
MV9+KF?8HJ0K*:1SQ%]Z0@Y];S1]B`*G?Z47<.28NS5.DH=0EM\/7JO+_HZ3[
M#=X:ESI1UMG"SD&9YC1),Q6T3N(6#=AU+-/H)VX+@U7GR8:!8?#R$%Z=\W&'
MT\N0[^)N<=>TJ$^R\=YGA[N[R,562EZ`N+%5G9.Q2,,CJI.K+/\TG@.HRJ"1
MEU29Y9E1:I?A6CTL"896A2S6%A=7@95=>).+!<`GPO2N!?6L];"3"MX;?-E+
M;"0BOE*6":JL<@-ZD$T_P!7`E6CD/JY*4Y?'][K/*-SI!E6&U2D6R4YRW,FD
MEA_%G>(><5(48&%&D":9^_#`O%(%I#(V[_5EX0+Y\'?!R:>`_SKAS,3*9VDQ
M"_:&NUCQK-#+V,M;I'M9*^O!VX(2`Y:4>ZH56$".TIY+;K`B2#ZX^<8<-!#B
M-/8]-T"$MR]C5PVO?G/5Y$:(0ITS]:E!F>^A7%,E%)-RFUNVB6Z0<[QZ?J%:
M]I!^CIMJYL/6R<3M^\\;7U+/SY#U7!%1CIAB>;I8>J\F_JU@;7.SN!7LJBU(
MC07IY^6\ST+=O[MU5VZYZ-?'50@*MVV#'QMKZ("*[,4/1R[1#0C<W0A.BZ<E
M,^0AB[NM1>HJKG2*U4QOLHW4E.4`4U*=/8)B;TP3'6<1FW3V(U+.W(-D@3D3
M5N3(5JDH"XC@LZ`E0*%@`GCZL<D8&UZVO(_M47U']>4.'''6^X&NC)AV;%2(
M%(1DQA@,*VZGC08Y%9H3LOZBXZ@6/4">8BX-HI4[FT4X^SVV=@Z%/4L3Q2($
M`RJR;9R2;*M&=]K=-[Z<FE;)X]:-'7A8I"X.D>6OR$H,Q3TZ\<9I",R*/923
M39%/K#H%;3*Y]JB$0D23=!.E.[)G]CGVOLV"0:[17+:5IC*7PI\*'\2+^5=D
MQQW"XF*`N8OTJ'OB"IZ)"W$6APJYW!79^/2=ZGA\+C4BM3FE"G"@/7T/6Q'+
MLIKA!KFT0<33C=\D'+=1M//I%"O?ABL=GA*&S,`?*+EJ$Z*,F$^R^P0$E?>S
MI%.6NX>_MO<KM4U63SWI;CZR15H`%7M5V6`'8>`Q'BZ+Z(TZCR0Q55ND@HEH
MG9AAK)2+!.X:S:HRIHG%,`:+`6L2*W3E8,R"M,C8#!S6'M*.)%*)OO!\M(@D
M^'GSJM""*B3S]UG.$=+WP@;C,DJ;.K_?%[:?EL0$U*#=B14/DN&#O!DG;\V[
M0BZ'2'6=A@TI6F4';[42M$E7#;$DM!M;:@&;XW*QJNH"V?+^6I@X/&MZK0@H
M7FQXHA(L$.17F6Z<OU$[SW2G5;T<?,Z0`CRK5V.!3S(FW48C'TPHHEA:`3;9
M+;866D:[US*:K=Z!=L.IA)>KOL3[.,=_BXB$;)8DB;#+(/!,FU1962/`)<P:
M22HQ;BW7D_=I=R*?9:.C?TN>NMP0&4W_RCQ+L:Z5,.,[][\\F=U(#MJP--#,
M%A.6]%9$V6:;XAZGHKGZ;V"98:E^$./80@!K2Y#P_TV`W/IFL-_^(0_`,M!O
ME.(^'5@&[&4G'SG;_]2ON"#8`/.><DHX7Q1LA\?_,6BDV^I+P6UMLQLV(CPN
M!#4R=E0&2YMG'E!-.5N$^;,JO(>!T_#2M=Z!(44U9AZQ"G-9RH]O[<+2S55A
MCM%&:C_!67G%95E0O$]=IAQN18Q;Z7D$*,9BFRDI/534??$N!8.JV[VU/L6"
M>@]1+.AA$?SPU45471%<0%PKI'##=M8'*2E)_HH)0<?)>C\%6KA_W9A2T46)
MRB<]-C'491V:J`N(NBS%D!Z5&`XMAE2DSY]\$0>4E"DMK!4"]0Z5>HYM(M<,
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MN;8EL-NXK/!Y)&NCW)$7'2/5,=)*2?6S5J]K=+M',GSJ+?_.[X8T+1FT9*@`
M=9]1IDR_HR7#D27#\0):)6&J$D20GC^KH]=9(5!U"%R#6AE0-;%6-K+2K87]
M4%Q^Y)$C*MV2N1MW]IO*MI![^4VP&&9YT=@1-:#S8UU3N!\&*^6F=8QFJ_FX
M/EK9^$D+!BT8M&`HR'[M/'+PIAS\=&!+X`IRQ[8Z`C5;WWUZ?[S-G$8FY?7C
M!A9T50GK3@MK2^$^V0;I96_8DFUB^YU.OD7L/F4Q#ZEO^:!U,4<?L2YF\^):
M++`N9J>N=3$[%:V+V>V5"<5;/,\=A2^!OD+%0$U9+99>7V.K,I3!W&_;*E&E
M<E#!H\,CG:Q5]<JL+E*IZ_GEZOD]U7'K4Q-#7=:AB5I77BT\][B3.G_R16R`
M51^)'0547990$X,FAC*>0&^0S96.LCU,C<I][[I4RVA):4N7J*P+O>N:>!N/
MBOIMHS/4EQ_+!*MFQ]-EQUI7C'V`=/<Z6F,/6(6R[B;9<>M,/CF#5(B73THL
M=XQ6\TB9=L??R`,NP&@.T1Q2NH*+3[Z1QPLBE80^*Q3@UQ)*7WNJ*EK+#6ME
MT:JI53OEQRZJ^."W\<I-M%IN:3_@KN<)/:.KSQ-*!6MET5I/#JEUN5&=<%&(
MOZ/72]3VA):6=926QRU26'FY<JPZA"4B<LV/92(XS8^EJOY72UO)"P+FN024
M%]ATA=N;Z.A+*6'5TKE,K'/6-5KM(Q[#'BA7GC\K%WJTM50F4$^`'R]TE*=.
M%0SV-"6JL@Y=C?Y$JM&79$W5OM2M^:8*-*;YIFSD=IPHQZ8UU[D(M`'O'2GZ
ML1.=)6$%7>]5UWM]"$%?KWJO?6/4&A['U:P*/VG!H`6#%@RZ0GR1T?GTA:`/
MJ#Q:.'T)J\5NK;#LPJAL#J_-XCK+&^K$4L5E66BYB5^DF'K9;8^VE5O>@=+-
MNWC/7;M_;>>W8KQW&>?W_\$RSJV+M\+$,L[MNI9Q[N7*.--7G_F22N\BF0`Z
M;@#5-G[&'W==`*\5@E;HL&:K3FE`;?@>B]QW48<(WXIA++.J^]3)_^2FI;K;
M0UFJVR`1?N7-%]Q=,BH4`0+<=D./<09"?VY'<S:Q7>Z:P)U37PBJ$PX_+_B2
MO6QUFT:SV4R>]";,#@/`'JB+$/0#\K-']<=\&!1$((VS\!S;7#;8Y\@/(BZ'
M0S"2\?-0+;@-E@I8:K<NSDH`P$0O80TXM^VR?W`WXOXR534S'J0PMHU^IX^/
MD9)RE@A)R!V'!D(MEM%@#789X.!K-<T-YD4AO.:B`<3&W*&5^$(F^*H%;$;8
M+0`48ZMQ$)-K^G]]$AKA5,3_,839@'BTE1<;)OS7$<B=*,GL&V!4E$7"1P8&
M%A_^`(:J:P/_7T?H'@+/XL._@VUK1B@%LV0']M_<#@(/A`Q1(#N+;9AVLX`^
MX]]:K\]1\)!PFWN1$ERCII2:**E`4`HP>2T,]^(-1%,(BR30RT%/2@OV%=XV
M,U.X!``9T@!2A`L,V;#3Z'1^B-LVP'I=TUYP)YX6C.O("7'E``YWF0=;#0MV
MY`A((68"7JNW*J:^$EI7%@E$0W6,/%=V66$3P!'-;DE4T]@H!QOL`RF6(,1;
M$7X$[P+$^*2OGH2]`/-:#N-)?&7%[>IR##6.Q0(0N!?<!?'O.#*"#J)X+)3.
M""6,=KBE?XN6M`_/G%^+2%"1YCH=X:[%^VDGA((5LJ(08`UMDS97L8#4ML#<
MH+!AZ>A,*6("XG%LH")O\HJ=M<[E=\#PY%,F1,G9_P&QV!,;!OH<C<$289^4
M5##86?L<'E!?QX+D*U@M`3?1^368)4"Y(\N!"+#Q85\`5.`.SX4_Q<E]%MB`
M<B#D,'T/2#*\%<+-"2A:-ZS$7WB^=*UO9QZ,1/+'#FU$#6!A0=```F`\BU!$
MH_SNVHB+ZY`C#F%:#[[UV9_P:F#9<M9Y%"K&0$/$V@@%>+6FM%,NIV1^P7!G
MMBU1^%?DA3Q.S,V\F3AQ@]=!%F:TJ!:1;X(-)AVZ@#LH)6"MOS>N&YGQ`N'?
M@&D83Z?FF]@.\ORM'<Y04O'%`I9/WJ$OIGBA"H7PV+.6@"[;G,&#CJ/D6XR;
M>&UC`71"S6M<M&U!#A2C6&&68)3H9N([+,"=B@3="'J"Y57$1@MX-XMZN::.
M7!$W_XKL.+G9ER)_$;+Q,@<L8-?UF",",%UA:O:RBU*8%`7\-/4Q4SI1$`!5
M$(T#\5<DK6%)P$%L@.?8`Z;$8\4;V`8WQ/V)6_K@[+&,WKJY-,S9M9`<RT;G
M4M(6<;,6M(\I:#^X*!9=(=F=6*9X4U=VR0"'Q`?Q%$HW*>%6^(25$."U]G!@
M-/LM%LR`08BN<C25M3Y@!!O&AQ_\0%HK*_(DH9:/W.53^<-[VY_G22H[9"%T
MK6['Z'7:,4@X:*O=-X;MT08H5UJX$6C)R"GP81'$`(OX+GS3#F1@*F0OFXW!
MD,P4FDT>UW]?V&0")2ZH\A='#98WGS;,NXJ1XGF;K?WG/2W'X:06>S=#+%7T
MW%G^5VR0VPF/_CLF5-3CEB#'">TGL-#0C$.]05WBX">IQ2-`HL_>7UZ_89?7
M5ZP[D(Z-!:Z7/R=;"=29M-!B,9%R0SSK(N$_/I7Q$OF`H>P`T'\8*"(C;L)M
M'T^H(I)O+WO]GC$`&9`*D_ZY`59&;.3A.C+`A[[@H9P)IE>A&AN$7F:MV:$V
MJSHIL;+K](#:`H_-..(+K`\7C$4:6]JN`:)K(J3;E'.Y.H.V,>PU,VY:XDQE
M7@636LKT55$D#2$[@"E!M4LK*H^D5J.5E2'*QXIMXCMK\D=@KAROZPA\>83+
MBIB1EL-$H'$!GI\3D>=N\F`6!VU3;L\39[BW6J:1(U^&J`LM'\7.Z#_006-[
MU#;ZHS;I?CRS%#';@E,*Q([BT`.RIW=!7@#KQ^&,\\T.:Q3$UG,`G@-NV(5#
M(601SCQR#>T0_1;?^V[/R3W+NZ*)DRM?6#45X@#,YB"-NTD@H4A#";1I=6I)
M\FER=^(5,%K!F`>V-N&?AHL^N>R3&7H4T.QD3F>>/TO-:S#\0GG&3B?OJ*'B
M")?2C:#L1DWX>ZE,\?S/:O]E!!$/2<88#D@']5;M20#DO1C[]%5KJ`[S88Z/
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M@7H"8NA,)0L=3PY5FF%U%>@R@:KY4?/C`7C148\M1DB2&9')J\CGU682VN/T
M6BT-2P3J*4C#SF!@@$34TE!;)Z4'5?.CYL<'L4YTB*30.L%DO*UWXK0T+!&H
MIR$-Z=JEEH;:.BD]J)H?-3_JV,E]<7AI6:_RUU,P4*+/;LH'Z@G(NWH?(6L.
MT1QR7ZRH6WY5Y9#GSYXDS6)GJGZE5;@,,*R5E\S=5:?[V4=2Y^6^"*$;_NV[
MIFI+QK.C&@_UEB#'"FQHR:`EP]-3]Y'ZD)>;N(\7[B@)@3^],5M'4/=RH4H"
M:X70JD'5Q%IRM#ZNYUV/3M57W/>76*A)IACR<$M=G'QAID<VN,O1EU+W>=5]
M7JMOWY>-E[10T$)!"X5'/2@I-T>5K/WS45&Q<7_33L4;.@[?M2GQZ",V)6Y>
M7(L%-B7NK#4EK@@BY1<;.A)W-W8DWL%0CX&'!ZA\7<*6X@_?C):OMZ/%LN0;
M^]$Z-A_;#I9&?\3.M.ENV@%X2']%`%GFRWOUK%UONVZL=5*\6^/:YN;"N@<*
MGOA&V@=8CA]15XA+U_J[L(#NII?H+5)7MGVETZFT3._G!%2*1MT)=^\E=OIE
M7N.NYDW8JV&UHQ((L9!C-?VD6=K*"ZJ7"C(./K?PO1L;[UL$\GWX'()89%A7
M7_B!;#DTB:@[45S98N]B^(P&M/$-V80HB+`W8WSO-'TM$Q>*.YV)^$U5^IN^
M2&`UO<BQ,@T>YYYE@P3/M:0LFB<_.+8VB5L\WG#?I@+)A`80Q*Z'/>I@\$64
MB/S\75J>,&"[^7IB?Q?6!4CA"_HK^058TUL06+1;LE'H2GNLK]["-L'$:+!A
MJY?CZFYSI4,=M;S:W.IFG\Z-U[0U<7_3.#C7QF=QY_(_IZ27[<NWJ9%$^DSO
M?&<;KX0&X8-]8=E.%,J&5FL4>6-;LHL)=E:U(KEFU8-S94=AW3DB2QZ[(:L`
M!U34G"/4,VS1FO;_S'96)E,#VV5F.O`A+-GWSY%@%&?A4-1C5(X3^MQ4?4%I
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M5A:MM>20HQ?5U5Y\^3;]\Z94ETQJ939%1^OTJH!Z`A*KU>T8O<Z1VI^7=BO+
M#6MET5I/#AD.C=Y@5%,.T<[X_L[X2@YM-C>VIM1125!/0289HT';&`Q[M:<[
MK;<UC]PQ6F7T1L`GM:VJK+WQ!_'&U540K<M+">H)R*G1L&]T1I6M;*TU>9G0
M6DL.:1GM4<\8G6!<O5JUWY\_>]0:=#/N3O&F9N:"[G$(I-RIX[J:\[YKJK84
M/,EJSKKFNN;22G'I6:MCC/K])^+52GON)>EJ5Q*>*KW56DE0=>5L#6IE0-7$
MJIWL<MY/NV,.L+;AM0U?`;+O&)WAR!@,CI3I7A4BU]RJN;4"W-HUNIV1T6\]
M<LGS<A"Y=H,UJ-JST*#6&51-K*5W@ROOZ>I\[T<']?DSG0-S0#9KMVVT1G7-
M@-%98F70H=7FD$YK:#2'@YIRB,[V+L3?/MG>6HU7`M03$%&M=LMHCO2EK3+!
M6EFTUI-#>B.CV>W6E$.T\[V_\[VY.]'%I=;A)07U!"14QVB!HS$:#FM/=UJ+
M:QZYZX6M;G-D]'JGI\=/VAD_5(^_T7J\I*">A(SJ@:_1:VIOO$RP5A:M->61
M?K]G]$>G%U0_:7]\GZ#Z9K6NE7I)0:V5P-J4/=#M#XQA5ROU,L%:6;16G$<V
M<,AH9`R:IZ?23]HU_PH*/`#]S";P%'-L/K8=.UPRT^%!8$]LDX<V=FKWF/@K
M6O^AIL1225!/0$2==8Q!KV,T>T>JHU!Y=KZC7:V-!LV1=^3(KM'NM(Q.^X@A
M_=/A2'T7_7`$ZW)O^EKK*5UKU>7>].5SS:5EY]*S_K!G=-M'NI=3;XVNZ[U5
MU-^I$*CZ[K`&M3*@:F(M_=G^)HW<K85&WECO[4C](7=BLR+$OM7>A<4PRXO&
MCBC5FNYGQ*\NJCQ6?)P8<!@">T:KVS<ZG2-E]5>%T._L=9=M(0_*L966Z2GR
M7MZ-MNLJ*.YV^:<WZ!JCWDF*B9Q%]6/(84\SGW/KKSRO[-C?S/K^C(+0GBPK
MN,1[_,4^N:F-V!I)&]%@/&#A3#!?!)$38G,]_'0]X[Y@[[Z;=(!C,!L32@-F
MB5#X<UB&!4_QD!Z=.)[G`]P^#B'"$+-)\7OQ7?BF'0BV\&U3T.MS$3+N6D4_
MJWE-X8?<=M/L57P-1L4DE[%@+YN-=I^=C05,EX+'OF"^"^,6;BNFP)XWTE5_
MG0F?'C=P@D!DAH8?F.FY@0T2$%:$^_]=)LHB*%?>?,'=I1QIV&X-7@,DE#2+
M2_@K`E*:V/`XKAR?#TQO@<LRQ8+2<B(8SF?O+Z_?L,OK*S9L]2Y:32!`Q[M%
M%.%KG(7W2_%IG`+)G\`2[\/57Y$'D]/5(.:DVY5[7<!4NZGZRG-O@`-MT!*4
M#!ZD">(QWZZ.NX5;%JLIZ<APOC"]J0NHL!@)%-^^`5*^208&0(/0C_"U@(&(
M2=I^(@`HE.:"!Q'R*_R8KAL_"6[.8/R%YY,06L#8GM4@!"GP\@*L"&]9`1$%
MM'`V]RS)ZF/;]>8V=^@5R9GPFW`T&]9CB4=@PW4"CQ4/=\Q(WLS8F\[DY4PB
M7"_6(Z`.HCEIG"#A@;$,";%@)D!U6C`)*;]4V^!7S"LV!Q2?TR.Q;D,<3A7;
MN^P?W(VXOZ1'DQ'P[08[0S3`YGV#>25?`AY,>>.$Q(RAU#2L<L4"P-&\6-K(
MKQ9H4;CXK.7A3GHAL/?$$::T/&S@:7.#R=+8=5"U+\%V^F6FV+W72!9]QKU!
M1R"&B7R;5VS4_.%@<,!@<YP`M@$V[><73?E9>4+X.1O-W>E<M8<E#$EO@+53
M3E!C-[59X*>:'NX4?-$N=NI-9#6_*F([&^T^CF-?AOVL$*BG0WJQ_M.45PY0
M3X?RLO::)KT2@'J"I-<>:-(K`Z@G2'KU5;@KB2]W<I7NG%S]_%G)/*G2IXEO
MX[T]TZAKQJ-W[R]9E\L/E5^')NH"HG[D)+K2$$-=UJ&)6A-U[=:AB5H3=>W6
MH8E:$_7#.<-/OHAJG1L6TLT>D:7CPEVG<%W50=7$H(E!$X,F!DT,FA@T,52B
M*.HFN[C2UWT^;DDNQ916E1Y.:>>4PWK6>HB"YE6RVVNXZ\>Z!EF(F$K=;FPV
M.G4M"UU;4"O"BIO*]6MFU,Q8'U`KPHR:%0]FQ9%FQ6J!JEE1LV*=Z;M"H&I6
MU*Q8+?J^?^W`6L;++HNO6^N06-4W5@NYS4*NW647LEA0385=;4'5+%E7ENQH
MEJPFJ)HE:\J2W99DR6%'LV2U0-4L65.6;+>UEJPFJ)HE:\J2M=>2#Y-H]OQ9
M[;CBBQU\8Q-?8`/+4/@B")E/&65MG5%6(E!/0`JU&IW>\:1/I9GTAYI*Y4J"
M>A*LJ-MI:U8L/Z@GP(K-1JOY`QCGS<;@B%F7FB5+3><5`O4D6'*DM:-FQ=*#
M>A*LJ+7C0[*DSB\KQ.&_5=L>Q[X1U!UD*;@?U#<^=CIE=P</MI7EU@55`%53
MG::ZIZ4ZU[OU^>+G%_*_=:?"+IO#U[/@QYZFQK*`>CHRL*]E8&E`U3+P_C+P
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M!3/NPS`4/1,6.^OK"%F)0#T!Z:?K!VLSI/R@:D;4C'A/O!3W(2@)?6M6+!/%
M:5;4.K'\H&I&U(RH&;$$H&I&U(QXSQC92>>3?8I3QZ@!/?,I9'8VT)&PRN^L
M;A^XI0C[4+8/[!U1M%:(SBL$JF;)NK*D:D5_S-)R%:+S"H&J6;*F+-EL:2U9
M35`U2]:4)5NJ%7V_J5FR6J!JEJPI2]9>2^8B9S^&?.R(S.?<$C.[^&<4A/9D
M695]3+&Q8Q<?9XE/,E>&.G&3XZF(-!%7S1\.1BTSA8/M%TS;G?[\HHF)`/C-
M@EN6^B8;E-TM0[(QQ=!;U$"`G+7.,[2W+Q7N(TN&S7V0=2PU5'F!<(0QO\X$
M+N&;"'%?(LI&-;WYW'/516X[8&,>"(MY>)&;46>2A6\'@I[GH>VYC77*V$(F
M>YZ';)?JVSY5>(-+*O$?00IK&;PB@]OUE,''DF$@D;Y=3'PA8""04"((F<]#
MP6YYP"P!W\QA=(N-EP"8RZ=B#FMA48#'C"&\SF^$KW+Q>R#F+";;"]*?^'OG
M@GH<L:^^X$'D+]D;VW$8QTQ]^ATFQ%J?]@U(4WI"3F`!"`72\0@B\)&$WB:2
M7(5%2XS'EQB=AY`8!PF)BJG7-\+D$1@NR+!7WGR!=6DL#U_T0C8#$<"X)?Z*
M4&R$/D>Z8C,;K"!@]]!+I0BSPT#]8)O<29Y-^U\9-$6F']:$F_`T"2.03/:<
MAUMD46;H9`B;+@6A9;;@/G$4_>GB][9+KP5\CL+/@CT!@%%P^6):;)T]B/Q!
M.MAWWXNL&RTRGIPAL!"U%AG;,/0Q9=",%8'LME+3&P3$6+#F#\I9BA;@+J&<
M$%0#G-PD>(V'\"4@#&P'E#D+ODS&"0``GT:&_XI`"&*"212"+:%96+/P)A;N
M:3_A#LP\R[L%Q)G(>XM\+3O.5JO9!0P[1R"K"F[.&%@+/HP2NP$N((!-T`N@
M"G>:;S7?;N+;OE:]>W-K;#,'*:/ZZQ?I@VTWZ<%()H9=X6=2Q:"XQR*\%<)E
M'6!NQ<OQ`%$8A&!-P].:G34[;V+G@6;G'94OQ`+-6C<,B+M2-]@K2O<'=I6F
M;_)SP+9$\AZ>,W_Z,0HNIIPO7KV%Z6\XAO8^N.!:1SA?<.E:?Q<6X&YZB5$_
M<M#?VH'I>!C[^PI;\09Q_LOS9S\]Q#C@[;NXOU_$Y.<75_+O/T8?W_WQ1Z=Y
M<2T6%^UFJ_/BEVK:9O*+6R%G&7N.):?YS0L%ZS')3<-VJ_6:I3C<U6;^,="P
M70KOQ:?=7IEV(HFFQ]&Q(C/9%'[(@3]ON0^\JM@Y^X(=!!$\C"2+SX%)?6,'
MX/\J[0V?0W")V0PV6OC@]@(P,;/CJ]PU11)75^,F-#!X'>2/)VE`&]\8"\>[
M94$$2CX&+?-:-D(OOH/-@">8ZDT5Y*<O$EA-+W(PA!9$3HCB:.Y9]L0VI2>O
MH"N:)S]XYNP4)+IODSZ6<0`9=N0N#+Z(0@P@D///;3\]B>4)];>;KR?V=V%=
M@.MQ07\EOP!?>`L"BW9K0EL5`8'Y[/WE]1MV>7W%OGH+VV2_>0TV;.59JMML
ML*^9M;`I_D=:3+"%+N(,AKZUPQD!&&_1MAVZIJU)[G$A?D%`M?%9W+G\SX8:
MQKT!PK(1/\CX`3L#?7%C>U'@+&.2PH%,^:"PSI/#&2!Y4QJ*H`[@W\E28A*$
M#_:%93L1+:6`(#$$0TX=AQVW(KED%5==V5"L<)ZEL>2Q&YR:!E3$G*/3,Q@\
M$&;DRUBNF5FN[<+>HT,I)Y)Q'_B<??\<Z45A`8<:"_A5CA/ZW`PC[B@TX>OG
MR!9<`0P&LK1EV5F.G'[U;N&7S_A,AI3.$^IT1$`(V@<+3%GE*&$D.?&Y%\'W
M2,,@%NA9;J$HI'VR<V(%=\@T/=\BNDHH+;-/>7Z#;?:%VG`@`4LL*'Y&,3?R
MPJ/Y6/KDB1.PFM.0(-+"@2SUS7F\C@QN$BH#L4T[[+';F6W.UI[;`V6Y-60P
M]A"Z[+Z:9#]E5A&38F5)J6U%C&4E5D2R&W9JDC$K\N.C&!>/>^CD-V!`8T`H
M8&R%@LBKTS10JG48D(!`T3OQ'-!`P:O*6"8T_79G<?0$OF(N"MGOKZ>?QC"J
M,2_DUZ]8>_'],:CIP7*P2[^.&/3F9MC'(+:%GX`^!E7\#1?``L^Q+20&#VD!
M7FP7N[$F99151:;\[MKA+M>CKM10EW5HJE[%WGMT.OZ%3L<IDO9*&8X[J:0G
M7T2%+F]L`K6('U?X[+APUQ[#%0)5$T-YNM9M$GB5]@[?<`?##09[*TSET+7(
MH6O?30?F3[C*2`@5HMF3NJ_9,UK=OM'I#(]C?)5V,\L-J[Y`?;(,V3%Z@ZXQ
MZM65(>_?FZ/D+M!!<N;YLPI(FE(B=@/SEP36RJ*UW+!6%JV:6K4;>8RT-M/A
M09"FAH0>6W#;NL#T";ZP0^YH?[)$H)Z`^7K6,5J=IM'K'+%L9:5Y]HZ5I#5'
M:HZ\ZV6/9M,8#H]8(.]T^+'VSFN%6+="H&I?0(-:&5`UL6K']=A*]VJ67+1*
MKAQHN[A$H)Z`77QQ/(.XE)M8;E@KB]9:\L99N]4W6G?-1M$^X_%]QG)GM1X@
M@ZJRD'W3C'=E;Y=H23L%60775.UL\,?@F^?/2KHE%:(RS3EEXYSC.-J;UMR-
MUUQI,R;)0EZ_5WHD9WPG/BO&"X7L#8MAEA>-'5&J-=U/9JTNJMK^3=MHMGK&
ML'DD!Z<J9*[Y=2_2KI),/U9B]4D)AT%O8(SZ1\I@*3=/W:VYE:YR=7"5J_3@
M(ZDPLUX:))#U/4SNF)%#!>MDI7:N*D)A*3K;]>8VEFN/.^+@;\))2]G(TB#T
M6A!$<ZK6%&`)F()R(EAO9NU.6M5*Q&2XLBI519Z<[ZL5B3_@HNX:B52K.D*6
M&8\7C7_J_:P0J*=#>CGU4%/:>XCR&^4.C-4EP*=KYQ2Y*G>N&%!Y8JC+.C11
M%Q#U'>//U28&70JJ'*#JZC^:&*I/#,^?E0['.AFZ$'\?MW7`QG#>2D]7ABW2
MZ^F.G5`.H:Z`LPDSK49KH.F[6J!J5JPI*_9[-67%XUWEK30O7%*?#&&M-)"H
M*1%H(:>%W.MFHSMD%^QELS%L:3JO%JB:)6O)DJU&KXDLV6YT!Z=G@)QT-.2+
M'7QC$U]0:S+ABR!D/@4]VCKH42)03T`(-1NMY@\@A9J-P1'C$95FUA\T2Y8'
MU)-@R<Z1CH9/BQ5U\*,0A_]6#1D=[/&,U6F6@OM'ZKA6!L%Q.KF,7=5(\\=>
MW?>T0J">#ODUF<67P8_=1KM=*OI[_DQ[M8]"`.^^8_]W8;$;S^&A[=CADIUU
MM$=;(E!/P'QNM7OHT+;Z1XQS5YI-M3];(E!/@2$[(\V)VIT]MM$!\-L`I,66
MMG`L=M;5AD>)0#T!.5?_6JL:5,T:FC5T(&`7_C[[WIB/90#`F\1)_I.)\+%`
MA^TR[B[9`CYY%O-NA,]4P)*=];32+A&H)R"9VD?,O*DT#^LH08E`/0E&Q*A=
M5W?P>NA0P>[Z9ED,$&I>,5SD:_;X1<ZJ4-JJDR&OT%M4G[8.OVJI,#$<[(.*
MK87KRH<-K%LWWW9;U0[8F`?"PFNKW&5T1KOP\19)4IUN5S&Y>Y5$***_DNBI
M')R%U%$F=^T$.?W@_.*Z<SKP[;>+@DSL6QX\?\8L`=_-87R+C9<`FLNG\HJZ
MK%")A2>_^G1S?<G>V([#>%+G$H;"P#36N5R]VZZE@Y8.9>2'PW,U-NUED4FI
MA,/K%3QM>?)![<\CX.N-,'D$:A_9_<J;+S"J97GXHA>R&0?.YY;X*T)Q$OH<
M;4TVL\&&`&$1>JEL8788J!]LDSO)LVD6C4%39+)J)MR$IU%(,9!8]IRJYFZ2
M4)FADR%L69#71*A],K+I3]>6*:'X6L#G*!0MV`P`&&OF^F*J;1LMO4K*C8<?
M^-;9MOF82H*,$4,%N//GY"")QH(U?U`^3;0`KP8%DJ!S=5EK.YSQ$+X$A(&)
M@\)MP9?).`$`X*L:W&#T"$'B9!*%8/)H6:%E11FYX_!SIA.1%3.P*'+R`A@?
M67N1/]'C:V=Z`8L#N#^0/!#<G#&P?7P8*W:)7$`#FZ!'1*=]=Q<.FT*:/_T8
M!1=3SA>OWB9=!CZX8+]$N+C@TK7^+BS`ZO02'3.R@M[:@>EXZ)Y]!>C>X&[\
M\OS93_$X'URPB\17_KW@.3"97-S9+V+R\XLK^?<?[__S[H\_.JV+M\*\P,*U
M+WZI)IO(+VZ%G&7L.:J/VV\>6+,#)D7-L-UJO6821PR0)':E_*\:_-N6?DC8
M>"O#=?IE0NSJL@K^8F\%L)4/_&=+U(:(6C"_)PZH9,5*(7[+!#"@&<J@@Y@O
M/)_[J)F1+85KPDMC$=X*(2UZD_O^DEIDS+W(E6_Q(!#P%YKWCBTY''T`9.&)
M[7+7Q*X;OH"10WQS$?D++Q#R!1PS'BI"XP'?2D%.'FZP:]@E>P(N"*`1'0W/
M%6K^C.^4T-3@-0HAA0(<:`.0()O6VGC00_!'BW%?8#A&-@8)7NU!F=7BT"+^
MV']])3]CT27HGW`=NEJW+D%?NW5HHBX@ZB-=D2HW,>BDS4+\O5VWN'893=5/
MK,J#6MDZZ)7!<(5`U<2@J]`^81`@_>LW\/6]A?`Y>>".!Z+YCJ45=K9"?G)2
M.:&,3ET8<_.%8:/?'!G-SI&:$Y>(RC5'EHCN-$=NX<CF<&1T6MV:<J3V">]E
MHES/N"\N9`8!QO>%&U#F@#932@3J*<@IHSL:&+V>-AS*!&MET7I_'GG^K(1<
M,N@"G[2/>-.NI*K\/M&&G2'MD]#SG\*9\'/Y!9@LS+]C\J!]K*!$N4\3#C\5
MV77,5*(E[12'AZRIVJ9%NP,^4/<D>S9K7M6\6BE>[1J#[I%J#I:;P(\7QB@)
MD9?>^JPDJ'MY/26!M4)HU:!J8BTY6O71?"'^OGHA=XIRT'5`NT2@GD)`NV=T
M.B.CWZEK@TC-))I)'N!T>MCI&=WA$=NFE51+W\>MJW=(^U<1!*_2BERP!,>[
MY>Y=N[SKR)>.?%6`ZL^.;3#46VC<L?JT%@Y:..Q%W<^?/;5X.+*II,7#(X16
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M>M`VE7JU(C^N+(^C,@$[;:WBJ]ULL+@\_N^NC>7IKT-8>$#8<OAMP!Q[;LMB
MEKAM\;"W,UM.G@<K``)98J%J0*)CPVA\RFTW"./UP:B$`[DE>=RK-R.7G@"<
MA/P;%JC&=AW6#7=#/J4F/UCU&B>FVI?K6YR4O@QF7N18N2FF@%-J&Y*'H\'>
M1SY>F9$`Y3`?81W^_\JS29B<T+VR9)/F`="#:/PG5?[T)-;HK0!01LM!@O*Q
M3*=W"U`$,WO!S!EWIXALK-\KA_%,,_+CVOXQW$"5=DAU;&TWPN<]YG/L9(3B
M%R>!44V^@!D=V,^XZ1'11P:0=5(/[+3>)ZT,<2JWUA<\NVZZ/"3Q$F`5X<@U
MA1_"WNZJ#JQ+R>XES;Y2Q??XOE:N'&R6MGWOQ@[HF#Q7UU42T"T1D"^"R`F9
M+6NVDB!\K[@D`$*(J*\%,0%L:Z?[`[L5?LJO0%D+7US@9&K>,Y1NYRPN'B\;
MP!8*DP>IZEKA?=U[C56H[-IMU_]XM+3KB/=@2YQP_R*8K6ZQ'U.M*ICOU^7/
MX[HVY2".0UM"/"T;/W^F&1E!;V_9A?T9N5\'/EZS&4Z1BVNT#DWANRA<%V^^
MHYYZ\D54Z%!:5\?5Q*")X<DQ7"%0-3%H8M#$4,+LL$VF4*4/+-^O'=3(QF"=
M[@]W,X_K=@VUTKNK*S)OO,G1-H9=^*=UQ#*.E2:=8UWEJAC[EP34$^#(BTZW
MT=3<6(P<K8RKOX=:&6^^5FFT!BVCW='LKY5Q^4$]`8[4ROBAE/']KS&7)N[P
M_-E#8G%3SQ/X$.A"<:4"]00$WJ#7-UJZ85JI8*TL6FO)(:-&\XC=RT['(-"\
MJ'GQWMJJTS<&(ZVMR@1K9=%:2PYIMQJ=([6P."UUI<_-"W%X13<$\3[@A-L^
MU4FEBUN6\.T;\&-O=(_Q4H%Z"B+OF!VV2KN5Y8:ULFBM)X<T!MHFT"YL^4$]
M`5[$'G-#K:M*!&MET5I+_F@V6D<TY4Y'5]7H_/4A<7@YQWI+:1T92XQ#A-#$
MLB7:=2T3J-47=L^?[<1+ISLRNL,C9IR4<C/+#6MET5I%'MEM,#=:1[27*ZW,
MM/-:)E!/@!=[?:/9T9'6,L%:6;36DD%:C;[V7DM[^KJS1$VE$9P>S>KNE8=R
MU[ZEH4JTI%(UJ'MBJ6OTFEVCU3O)RE::6S6W5HM;!XW1D8ZCZZW@C^7N:[&@
MQ<+34W=GT#'ZO:?J+UM*>JCP0C2OUIE76\W&4#>*?[H@R'V/\$O"416*758(
M5-U<]\E!?=B*`?7&JR97#6IE0-7$JD&M#*B:6$M?1WF3M].MA;?S.6D/B-WZ
MTE++CQS'+$<3X`>*C>B&VKJA=JYBW>.&8<K&2UHH%)%T2=:D^53SJ>93K;RU
M4-!"00L%K;PUGU:)O',1CQ^I*7SFLUK_3S]&P<64\\6K#^3>?^7?W]J!Z7A!
MY(NOL*MO</M^>?[LI_BY*V\^M\,Y['1PZ5I7,#LL7;BF+8*"-YD)#\"'+V+R
M\XLK^?<?[__S[H\_.JV+M\*\P):]+WY9(:X_HR"T)\L*D)?\XE;(6<:>H_(#
M?O-"P89,;M:PW6J]9AG$,>Y:+(>Z'02*N-D7%RM44CS8/HCN]LJ$:1KSZTP@
M'A?<7;(9Q[[MH?"%!4.&'G-L4[B!(.3Z(A#<-V?TP1(WPO$6B'K&I[X0<A-N
M[7#&PIGM6VS!_1!V@46P=)_=SFQS1MWAX[GL@'EC0!D/83*8:LZ_"7AI*0>R
M77IXXOESO),>+28^KCOY'0"]%8Z#_X7%BB#T7`6EM^1.N$R>;#"@&V14#+8Y
M$8;>U.@`@`F33SU_R;@O7CTRO62D(X&GQB;1B/O3_.'@[60FH"18<!-XX.<7
M3?E925+\G(W6YH1S'([-R./06^1)F+Y_Q8@D5Q78QN=8><4,C<D;F5W:TNEP
MJVI3V!N,5M!WN'@H'X(NQZB!V1O;`W;T^4)$H6T&P,3^(B>)LU(D)T$X^^Q[
M5F2&[&U69`"G?@;F@S]_52+F,I8B4HALF;C!SE`N"-]9LO?<%/(I`?(E^?J;
MZ]VZ*!Q@\E``N[\5`:"?_<K'P3FR?[O9[*#4"80)NI6)[R0;;H2DVX`1Y,%"
MF/;$-@'<T!Y[UA+$F,"N!.Z?D91;!"IW%C/.!&@B5#[,YY;MV8$')"!`_/R^
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MU19;2(?D(<YJRD@W)U1`0_=1W=S$C-R0XU@"3T[B][\&5$_1V-XM&K5LK`B-
M:W%U`N+JM"VYSA[B2LNKBA#Y2<DK+*]T!XGU_%EEME.;6,4RJWN.ITV.-R61
ME!Q>+18@DF2!N8E-9P%T-/1[X[K!WK^]U/*I1*">A'S2%M4I2J?>.7MO^T'(
M3&\^%[Z)!E/`G6/5NGQR.J@0R9Z8_+F3?529S=364;'\Z9\S/@F%3'V8D"1Z
MV6K&62N8>..*D"22;BQ3)E"U2*J72-)97OO@]G=*3=Z2CA?,N.-@GA>F:&U+
MA<2ZXHP:9OG+B_'R0OW)QCRP,9H59R5[$]9J_X#_2>0@!;1@EM60%F9.A[9#
M\#@<9:HW><7P]+/5;O384G`_6!.V*V:?P3R?):<"^-B"DBX#)KXO;%_L2B.L
M\-[NG<U;X35>$O&\%::8CX$,.BV#X=V/E912(#0;=EP22#Y9/L+<5%]@CJ([
MI;?2W[-C++AM;<_(Y>MYD92Q&J=#PCS_B)PE:W<EC`V6;M#764%699)`N>%(
M_Y8'`+F)"5X6H[\WW$X`2D>^VH?4=7I_S=+[QSJ]?T<2Z?4_KZYRB?P?7/9>
MC/V(@_9J-YLKPF0EM3^Y'I3/W9>CAC,>`EO^%8&B01V(&?HN1DZ7C)NF"`)*
M;T<AH61$E,N4-X"3X?]N!,P^YS"A<+%KQ^I+R.[I@XD4F$0NLD7V210H("@<
M#Q.O@[S:Q]M(-M7D,7=*BOM8717TZ>ZB2'7R>,DW52>/Z^1QG3R^*9QWY^#=
M4U-U56(594@>?_Y,IX^?8(BZ=1X?T&/<Q66_P?-O_6B:.\(_BRWB=O/U;V\O
MDT^MU^<84?'%-')X2!?'%PO?`QS5-*A8!D8]538]Z9,D=-8P+J4S_>JWM_K6
MADZ#UA9)[M8&A;XP(N4+4]@+BIT76!EL`@/1<W%B(8L%94UIII*@ZBKSVD`Z
MMM30=E&)03T!4^6D,HQU.LW#I]/(0\(#$F?NGS?35%DSB15UM*0930[Y&EJ8
MA&'*LFH3VY'));\IZ[7(SJ4*;:V>3MHXP:0-4R=M;$?0)_Z-?;&M*;`0A:OQ
M'AH?>[[DH;-/7W[[]3R7TW'Y^0.5=LT4F`-&7$2^2;E55+`0OL;RAW.4F"@)
MX8&Q8!$*5LFD&]*KPIGO1=-9FH4FL[MP2GOCC"_;G8[1PK2PR;UF-U0!1G@`
MD(:7@Q<4O^<A29AX=B9<:S7A+%.&UHQ\>#]TEH#YJ8<WD.-L.%A+)U5F]Z;+
M>]@4BH.1X$K/P(=DC)1)XA8:[ZORM_J6NZ7EZXZT6A`B-]>>0VEH`=J5-[8E
MZ(\_P8H!4%P^E6EC@?!OP/X,DFS5((RL95SHTZ)S1?.BW>Y=_#WZV!KUV-DE
M2+HY'ROQW!VV7U]<GDM)IVI>QY+)C!->0Q2)@9%DPE+Q7%4>856L42G2!%(0
M;B+`^90`-CVZD&,,>R.CT^FHLMY)AAXFEO_`+"R=F\GA#9-AT['B"7#`51!R
M[Z>E4=N=$:7A8>(NY1/+*KP#`F(U)?B3RRZC*9`-ZV=SFC-YACS`R_3PMZ5T
MB]PEF>4'O*X48[Q!._'D>K>9]7%"TV@T,`:='&`KM#&V0=3D=HV<AH0LN(\A
M7?2+<%!8:/91F;X<J+BO0Q.K;&5<T4:5BT@/=):BUCG5T3E"ZYP=-CW>CW`%
M:_6*[G!L2KL&P1`L0`YY^&,J+_+9V._QQ[]'(5[R",`XOL(T:I]]B1^_HM'9
MV?N_7WVY.F_D2KG?@GQCX\AVU%V1A2]N;"^2W38\=^JA:%]35#3MFZLA.TN"
M,W$%]7-Z$X29&T;<`9-;"3:,`N6&457@05NZ=C1GH$*S8IA@E3Y-8KR;`+,C
M4(@6*<I8DZW,LBJ3*<_<HD!%$'(_Q!4ON*\J>Z!N80O[AI2'',`1G!+-J88W
MG<C%08Q-'@="/1:@):8^8(5D_GKQ>80),9A4GI>J6BJ).0]PQU#&L#%WO\5(
MA)_&2T:X69V<-#^,&Z.;E+K",XP"D(`[27&QEZU.HXWW<1Q<,KP"FKO1B[\P
M8`304#*WWLT,8\D"^W03APP*@@5_!YQDH4FCA+"&>1#ORS8ZSC,#`8SY_7)T
MH@2'CR7!O&RI;/\%3(+1OL0RD[&^\-:+K\[!`"_;ZFF\T23H,ET6U#@E5I;E
M#[U;[EO)S0(97QPK%@$,`^RVM+/HN=5&),R[E9:*A%@9>U/8=I<@RED9&VY3
MM9)]B6>U(I&.22R:)<&DXCRM'<W1W$[@XRO!SZSI:A2L83T,6P2)-DZT<5(=
MXV2BC9.=QLE'DLCMP1[6R:J&7;D;)N8>?7_M>*`P_RE"#/F!/%5FB;1&-NE.
M$C9X@/2RTS):PUZ2_H)G-+:,1X+O)H.=L3FPKO8/[,IB9Y0:NIHP/Y?FP46T
M2"ZD#49&'U3E"N1\CB=:)!W3AU(G.+X7VVJJ>[%:<FK)69GMF6K)N8?D7+(1
M,7?+2/V9%9D9@@$>X"$(R(-,>'%%=OZ#S_':[!5?V.B`_,WWHH7!?OWU*ML1
M*VE]=0F?>6#S@N?/#3IU=X/(H;,.L`_GC$_P8D3:UNHC2.%KL))%,&/7(ISA
M.V]!!IJAAV?J,*P91D&Z[?]"GPZ,=X-]<+-G>.`&W-A^*`4@=MU;>($MCVDP
MZ&AEADS0`UZ;/^<FE1@`ES(SF@0+P&&4'_`1D85+^`S2V*7#_OCH)[>XP)O3
M_+<S#]S!N3RJLFD3@E#&Z6;"(9\%EF%3YT+`H_1B/,`,Z";I,PA0*]Y2B,1S
M^>P`H+1)E]/\*1'[#0WX%50-VZW!Z]AM38<&!,28"$!_6>AH^C:=?3GD?08S
M>X%/Q=LDO0#`@QQ</:U<1^P9JNZXX,?K&2[PW7=SAGY>%L+/D1]$G`*U11HP
M0XN$QEMJ$#F%[W)!UPRVD]`G5DR)MS-V7&/H\/'YG,>JES,92%A$8\<V<\R`
M^CT>)@OWUP+@*'?V!H,-;`[,.`-FB'4SF"P]C#U3%TH@''0];9?4A/)28UT?
MS@`!\OUL>14QF0AY1FG!2F*\;@1;AFS1(U:$(EG7D$THR7],R*R0[XC?;H$Z
M`=H@PI^XC^&"('>.BLX;S`:.HOF-@84B3TY;S1\2QR]RG.6%93L1#F\J02"?
M5X\D;<X2@CYLK3)@1!.Q>*(`Z2T^%*$^FXX923)6&,!=`E-.+8ZB25$()I7T
MK=7[F2:?(?$MA@9\W.$H"2*\4^S(KFE1G^0!,/"DFR67(LG)+`\EN(=%"D)N
MNQF))5P!;$G5ID$&^)+U)!J2?9`E!):T2>FK:D$4:<EL/_$2"1VJ,R"-PD#1
MH^41%+A]H-J8L#$:$8.LHA=J6C;S'`L'0=0F#4WC8$(AW&0,K;).L@H\(L^M
MG4NFIF%O,2JBQI83`\_!BCG2!GXY:@*)8'8/1A!@?V`9P/NQL4R<">PUM6]P
M4_L]?#@65.I1P$T0`0YH3'\5S)@.;KCMQ,R:3$9H!>+ZMT(-BCC0%71P`E8^
M)1T@82'(B-^QP)O;%F*4*MC<XB!$R!/A^T14<=Z8X+YC*V4"%'B3"(0D<RP6
ML%D.^1R-38]]35GC-<Z%.Q78W]=%"A@7+BJ8+V)J`\"2.ZY#&#"N2&$)T^$(
M6<*1C?^W$M7+:SE4B8@!`<:2C?B2>12PB?,Q"'IAI1<-@F@\!V)5$ACV'`-F
MEF=&.'D:[O1\8$BL!8*8=`66[<!/P*P7WN1B`2PGDA([DIE@2O'=Q+:&+WM)
M)(X6KWT;[=O<S[=Y_NPQ-VBFO9L]#JTP>#&Z=UBH\-"B,.K3Z??+%/6!M0^Z
MHRSD;R,_/A]877.:ES!!PX`O%HZ4K'$0W79O/%"+EDPCX/)*.NKOS5$E7+54
M;\)-WQ]'(599\J/T'"9OZ*U5C=/264OGZD2>;"V;=\IFE4'5'MY;.J/(^=U%
M"SVPY66,K^([R)&/C;<-=HF^6":QH#B"OYI!1@?2,!"8L'AK8X/$!!G\LCML
M&>UFUXB]=^D_8O#']=P+D-%X(DM\9[LP?!BE(E9*Z"[Z_JOPK$`"$XTY&LAH
M'OM"I@"WN[&""9(\9TP)7CM$O:-*H7[B/-_AO6.,NOWL!%KP:\&O!7\RYI]:
M\.\4_-=B$:K+&/U[R_Y_>#,W8'_W%M]`O&:TP*I`E8E6K1_;ZXE<*D%&2OHX
MS+DIM>OKNA98'R&-_RU\+_2P]!!*=&!".Y@52#XPL1>92#=WV0?W!E7`-+Y!
MD]2!>O==S&40\>S#;V\!L</FX#PY',B,NH>W,@3-TZ(`B-(CJ,2\/1R5KP?[
M(>VV,>P.LD53%_(,)0V"MXUFNY<43,74:=IEP""&=2B(E-16;1HU<T$>XS+-
M72\E/JP4D%_<"@G<V'.L=)JQSW[$OPLN/VO=]N2B^YO6;3MUVV_>C5)MA=7N
M#U)MX9I;\UFX;K!T;KAK<ZW@]@G'#0;W5G#QZO>)MO73HM]I,(U;<QA=GJ'<
M4(7P8%U]/9)N*8VTWR`_MER`OUOE@4Z_=&*B4(JF)XMI:&0?$8)I&CG10<=B
ME+;!4)<)O"R&9MY[>X)<?R/<2!BLXUOLO>-YOD&<]Q_/_P9__0<59VNP9DLE
M@ZO$!.R!_`_N4A5^91UU0"8X>"+,00;&9Z=?U>-T")Q<54P2+1Q@%,<#2/K-
M[-DK_!H/KL;>#!"/0@\S-4RZK4'WK`-9M8/.]"Y"[X+^B"MVY&\48KJ]_#D]
M[PU3F#=)&$J-S+Z="?)8@O*'-O/S3S]&P<64\\4K&&YNAY2Y?NE:5_`L&!K"
M-6T1O+4#/,*-?/$5B/D-$NTOSY_]=+<WZ10=/GP1DY]?7,F__QA]?/?''YWF
M!3AC%XCB%[]4,RBR2<``$0K6S]49R&"-""&'M]T69QFKII0`T3+#A9@1$8H%
M#30R#P^%M&0HI),3]IF4O("]\?#>#CJF22(>V`^>39>TWOH-]D\>!3/[&_M'
M@[WE8&B`E8.=E1",JYDM)FA:81P8?OHD\_K8V=6[3^>9[!K@BGCT!ON8E+O(
MWH3*[/=E*H9]FF[B.8YW&[S:8_^/+67VHY@J=`+I[^,I55Q:\P.]R"(\#??R
MN"N"*%GI@0Y]\"(;I3B%V4Y"*K'K94=>$8R/GU)GY4(`+B(Z0HJSJE*F2#*^
M<#SR,"EM2MUUI)NEE#HF[265GA6?`H'@P*2\)*_J[K[+':G_N$;YW2H^%E+?
MDP+Z$)BN*OMLDC/CNT6K]A,M%3,_R*-Y]TF5/02902G?3AS@\,$ALK&T(&4$
M)X?(8#R,/9<2^KVIS^>QX$E'60\#2<LE&P"2[Z2_R;<YW4RFX45RS1Q`--3A
M=Y(=BATAQ4TBD&Y].PPIM@^[85N1NCAO>O["DX)R_*=,4`UD.J_JKY:=VQ+2
M\2LN!?%[,G.(HB^>F`9;"!]OMU#WMW0B(P:^&+^<F3R8*51*!*L3"YD3FX"S
M@D154`PD]%00"#`UWH`6/K9S8F?=Y@_GL1S/*`\MHK6(+ID,VB2B32VB4P/0
MC4L&%EVKD;</5N_)D,66W#"0=VG.\(G8F6PW7_\-;R0DGUNOSPN%'BH(>E):
ME9C-;\NLJ#,;"Z7$L%&AD!R$_8',K=\&Z6L8Q<9NT?+1])F5^Q'P%#XFFZ,7
M/R87R1G>:+F`^:14I>MTJ&8F]B0C(FDM>/80EV'$2W!4BF.[*4S*AS[C4?2M
MYQ<?A\&694+_X2U,N;R8H-J,`:#,X!P4Q`-X.!U?PL#B(>I-+_+7[V:D8!7#
M0(O_!%X\G43ULI$%M6>Y,_&XTDM6TU0Y[>H`W[_\@F"3G/PU4V4I*9:41&1T
M".[@(M`SNCR:.5S)UK':6.TN.8H(XD-;&VU=%!,B4.>DJ;6;29KQP$B>QM=.
M*=4R*6.C[K2A58F,'"TF/JX[^3US\3#?,'VU($X#SV)4[JFZC*=&IUN/H9A2
M66M?[!.Q.P:YE#3^EL_DV,OJJE0F!R_.Y+AG3D<]3;`QMGQ@;VRZE,D7=.<_
M`$;V%[G#I:^;CV@_R\K_[&U6;&#M-ZK;SV)!?IG/_M@R<;:>PGMN"OF40%-G
MK<P"3![B)=FWL@#:KWP<G*O:IATJ(P=>O2\*B[R!0;40ICVQS;3.&Z4M@"7X
M9S1-KX1S9S'C3,S!"T?;B$IFVX$')("530]*0:=29FD)04RLR.6?4ZP3_BE/
MOL0#Z$79^Z!49)\E9]JJ5$VMU7X+,F5T!W'?E:2PW4JL1BHV/";"Y].A9<`F
M*<>>3++78=+.'7O^K#[*:>\V\1N;65?5%*8Q=6]XW1M>]X:_<PA1]X8_#JBZ
MY;3NPWI4(8<MPLCZ3FM!V]@,AA(9XY+25W$>\U=*W*'B5;H58^UH0;>HUBVJ
M=;/95#2V=XM&+1LK0N-:7)V`N#IM2ZZSA[C2\JHB1'Y2\JJ%M6I.4F*=MH'5
M/<<C)L>;DD!*3JSD]559C=.F`P`Z#_J]<=W`1B]:.I4(U).03MJ>.D7IU#MG
M[ZF%U$JW*"U_2@3J2<@?;1U57/X\?W8G"=0_SV3GRG9V+UO-.%D%\VV2CG1:
M*)4(5"V4ZB642IC<53Z*2%N<;DC"DS?6L,81=LG9D@!)A59,O+;F+R_&RPOU
M9UQL)<E']B:LM=J8$^-9,,MJ1"O(]+G`KCQ8S.85P\-/;/\>-T==D;4K=I^!
MC2V20P&J4D6IE@%>6;;]G<66JKNU>Z?P5G>)V<S$.5`3EKB05)`F)E)^:ZM-
M285T;\?'2S=Q$>?TN2S14U&?K4FW?$/;VSCC,6Z6V.[&]2(W7*I:'R9.EMQP
MCG]+?8M-S.JR9`_C#;<1U)7\DA!XI=,LZWX'8/R`U1S7,O]S.*#O7S%%::]?
M;%;(*T\^9/'38Z!POV:Q[.SC]3^OKLYSUP4^N.R]&/M4Y*S=;&ZO\99<1%KI
M58O#RMXBV9IFPIRY&*I=8GE;K,B6ELTE,17E\O&S)7GGG/K+TTWVE9=D65Y9
M>B06/G&K\<QCU((^8(Z'N=U!WL;`2T\VM6TRCUKNL$2W"\LGU73RN$X>U\GC
M.GE<)X^7"52=/*XINIKXUA2M#WV?)JQ]'J><8"#13>O'9Y-2SC(U;WY[>YFM
M>,.H=_D4VSY3#80%%J?&MEQQ[T:=:E<[FM'7)G0><DW/K>]Z;2(IJ>@+4]B+
M4%;6*A"+<6?Q.+?O207E\V<5$)4ED>HG(+U.*N^O4@'0BA#082?B,NY^P-GW
M_8^^F^K@.Q'#1SOW/B@_HBRGB;4@PEP%J>\+8<HJ3.#ER(/JWY32+5+/JF)<
MN]GJ8S>7`4T)U,+GAYP%ET%B9`1T28Y,ZGX0;![S(/C1I<01$/2)?V-?;&L*
M+!AWJ_N5C[&R./+@V:<OO_V:/]R]_/P!#SLSY:RRQ7%?MCL=HX7Y(A-9*HU3
MQ7`V3]JM4`7P"#6#Y/?B9`\C+@9.7:_PAJ`L[:K*VL:S,^%:&S-1,O4HS<C'
M7F+.$O`Q]?`^8IPO0]V]$L6H2XE7M91XW059,9EK09:,>0D"XN;:<RCQ(VG'
M1W]@VP(`Q>53F:L1"/\&S-,@R4P+PLA*RF);%&@U+]KMWL7?HX^M48^=83_1
M.1]?7)Y+T:5,DEC"Y#ML!D:2ZD:5,-6EYXURB@H,)G#:U&S4GL?5<TT/ZVBC
M+?2=O@09]K+5&&&>G4,2,=_U#Q-)?V`6%LC,I/&%R33IV/&$.,%&V'(#I940
MVYT1I<1@[A[E%LJBFP."9F-Z8-K\,6F-GM3Q;AMI5N-'<$7R+<,RR4$P(_7/
M5HI';K/,S4E+D\<[O#_.7>\V@QN^AO)VHQVC/#/H"M&-X8$@1QGDK"3TAIW$
M?(3=5_7?LX_*',A`!:P<@D.E/.)*-Z9%XO[I-D5:<954+J>X*J[GKU58:HMC
MCK4K6*NW1V_<;`'W8`'2Q\,?4RF13Z=\CS_^/0HQ43P`K:&2.)/:^G$VY_N_
M7WVY.B_J$1W9CLHW7_CBQO8BV<K!<Z<>JH0U%4C3OKD:LK,D%!076B[NR$%3
MR_;5B;6>-K(NTJBQ9EOM-+XB6"GOTZ)X@^PM`0M8<%]=[4?%P1;V#2D$.8`C
M..5^RF;>>!X0QR)V^AH(?J[M1%'M:>I#`9A)"D]+'2Y%_IP'N!/HQ[,Q=[_%
MLEZVL"`D;82";`680+TBU7[:Y1Q`F@H99GO9ZJ0*#5\!E=[HQ5\8V.E7J`18
M-S.,)0MM4Y:^:ABN^FH`EHJ;2R71QURCS6T4FR=[@ARS<>4T1"0.'TOZ>ME2
MN;G8!IWZG,0FG8PA8A=C=:L&!GC95D_C_0=!]VP*88ZSYF3![M"CSEUQ0K`,
M8([3OO&P"%O::O3<:IL"YMU*4T6"KBS'*5"$2Z`5-SG9<!NCE6Q9/+T5B71P
M8L\LO29%J0D;:-EN[@"V$F_-FL-&P:K6([]%(&F[1-LEY52V$VV-[+1&/I)@
M;@_V,$=6=7#!;8Y&L<HDL8&G3R\[+:,U[*6'[PM0T>1WXBT0T*S/GV4,@G7%
M?V`W!CNCQ*@IY!*;0J"!<!$MDBLB@Y'1!]6X2>.JOH8H\M*G4[<XOC77:L:W
MYNXJ#@\[&:WB0<-Q!>).P?UTLEJ+ZAVH*C9:M*C..XXH9D;WEM3;'8Q"F=WI
M]S?+[,>7V("$07=4N(2WD1^;\*M82&.',$Z`!K0C_;+8JK7=&P\<64N&]+A,
MQ`79NH]JR#4D3`8:1R'>8O2CU(M*NM*0@7TM%J&88WBT(_5'1YO3VIPNIPB:
M:1F]4T:KPX_V\-Y2&N7+[[*AJRW3L+Z*[R`T/C;>-M@EAEPR03X9V]MQ%)*>
M?5`0"48T/1<3MS8(3#M8/2%1E7CBGNG4E-&B,RG7<R]`<F,$1?5KA,G"*)6W
M4FYWL9C/1C!7`(3Y9=]TC$_Y0A[HM[NQ_L%C%-^+IC,E-C<%/>ZH>JA7&,]W
M;^L8HVY?"V@MH,LI?VPMH'<*Z-3@:O?O+:/_X<W<@/W=6WP#>9>1UALEG#S6
M:/W87ATX"35+B1QWIL2D!->.YJS=[FT^$M@U5)0$Z$&:AQ[>8T19"X+:#F8%
MEBF8Q(O(#R+5%IV[[(.+O;ZQWZ\4Z,EMM7??Q5RF;9U]^.TMH'K8')RSF7!6
M1SW$WQB"EFA1O%^)>E0XWAZNQM>#/8EVVQAV!]DB(HL9]^?<7*:/&,UV3Q40
MD7D)1`"`2JQ.@CHIK35"JG'%=]#:0FN+,@K#/[6VV*DM?O-NE+)HW5M9A&L&
M_6?ANL'2N>&N7=S16JN,_4-4@\&]54:,AGTB4/VTK%0:5^+6'$8/0DP\N*$:
M5,$#*H2JW)RJ6J_HU&W?A\DQ;27'W!@7]283V\24!P[_YB%#^^6]/4%VO!%N
M)(P4=<@'__'\;P;[[3^2_-*A,'_"=LD#]ES*D>RT5%20)9E#V:3)>\'8[>\+
M(T8"UH$,$,BWPE3QRP32W^,[N71KBV==;WQW-=V31R%L3HA,Z2SE98!`WDZ;
MPV[-+D+O@OZ(;Z;EDV$Q_4/^['HAK@]G4A!B(F>.P>G`CC-,N9#O9"(6EEAX
M()@?JO3D?>F\KJR6209+Z@<.]R#IZS2?"RG@6H2A(^GG,J]FJ9ZJY\\Q*O;N
M4X-]SJBE+=$?(@W9W#U^%Z1\NQ=71I7GY`I2*?=9(%!AYK-WTC=23S/AC%Q7
M>B?P"F?ESY^A(L-OJ)+AV',C.BMXV4^+%")+JIQCF>T52S"55XBK767-G4?3
M2%B;U<8]:?>G'Z/@8LKYXA5@8&Z'E&-TZ5I7``XX4<(U;1&\M0/3\8+(%U]A
M_C=(L;\\?_93_.8U6"+?9IZ#P<]W(`+"Y6]>*`I>HMM#\.&+F/S\XDK^_<?[
M_[S[XX].ZP+P@I<,VR]^V<%-ZRO>P$P9#*S7_"QDIE7NV(>9;H6<9@P(R("B
MV)&F072P4>XRE\33QIVO#`H*U[N'WW+T!;8'C[3"@K_8>^1]&\2$M*@+N+Z9
MEW,^MS&D_K+;-@8ML)I'+;2Z[2"(,)+1,P;-@='NC?#&N"^27$[U=D)7@]<@
M?I`921+BVS!FOV]TFVWUIH'N8"3O6;SLC(;&$"%!T95>W-ASRW+FK";(<A.D
M.G\'PFL5$U[?:`V[QJ@_0+H+A$.WC0;&<-0R6MW6071WRWU,P0YRUU-;(V,T
M`.(>]O8>*SY'XFBG3F0)Y&SI+5([[)/Z*?FA];HXR_V2$F95;@#%!8W.8&1T
M8,FJ$+H`[W#-AY9%WUL%%NNO\"^'WTJQCO\D/Y_]_L]S]FMH-7+P%CW?R((M
M=P;VUE0F^%3:0W1,:/)@)C,D*-T-!$5KU(^/_$"O@A%.#LID=0!*+P99H.S]
ME_W6T.B.Y(6Q^):3+^SY&"PRD;&8.D9_-"HPCI18*5Q-\=YC@'8*]MT4O!,<
M?#3L&YU19P]"0-`!;**'^&(R'1WZ)I`M6_C*M7C9;`R&%&>@,94AB`X'_CJ0
MF>BTEF`-P2G,MV#99N0C`&7[\CH!LQ#T"8?/]+M$T7!H]`;9?)</;A)V*#!C
MM^X_+=>+P@#OU&'1#^!!@WTTK\#>M(',TY<^95YYX]O"99]__?7*(#MTU.R2
M,$=K.[W[%A3156YB!_;&B:>5ECQ(01Z"\<;>X%6(EVT\(DYR_.EZA`A,W[M%
MFMQ;9U18JM9_A=OU1KM8;PQZ($*!,C):8]0?&H/45MFH$MHDPYH'BH%,#+3H
MT;Q2V$\1](%S6OWN'FJ@O:<::!0*;=2EK3O)[$'/&'6:NT1V#W1X_R@2N]5N
M&<W1/JK[((F=[LECBVZ@VF:WVV!/*[&'1K/=O+_`+H?X+0POU%LZ?G`+)".Q
M7"P>@25[+:/;:Q9:LT"*'1`)0V,T'&9X"XDA)_*0)S*&Y"7[MZ+[C/68X]^B
M4??C6,6I%'O%N_@9CFTU^KV,C:7N;\)*/$O*B";PVC)330P^I=?@\"`&XT%J
MW?AEC`=C=8%O=BZP9?2`A7O-PT72E@6V&]WAE@7V5JNE64HZ[EQ@W@^@0."5
M!&JS#[.7YNH:W?[(&`SZVW37>K!U,P1;X[#[:SKT,5J#[EU470_56+>W2]<U
M.R`[M[@G!0)T/U77[8/7VWUP5;?1.>G=3<.][(Y&&!52!R]I$R\PCNP;>=#I
MV'QL.Z#<-I3CV*[\\(L[*,`OL.'<MS`+-GWK,V:J&NS77S\;N7AYD=K;/>=N
M;Z5S/V]E]6A%Z:(-\:H35'R;W((5_G!OA!_:*&E=+\3@X\+!X@7JYH5-1TD!
MY@0@;:O'Y?E^RVCWP.7L'>P=<"J2*8+(2<KO;)9VFA+N30F7Z_B^)BGW[CO(
M`:QZ8"'GV6-9NXE.0EJK&=XDL;NJJ[':<*6J/%@VJ5;Z6ATRK5`#B8"6@6&E
M7K^_,H`ZPEM]/<['T22P!PD4C;G'L=<.TOF<J+I+4G69X['<IJ"9#<+!%68H
MZR^HK"W@9Y$$(E28MI"R[N/X&JWVR!BUL_;`'?5^H0K^]Y;%M!]Z,;TA^`3=
MYD,LY<$=SN?/2D+K]8_X'8>;/Z95_M[;8-INX^9U3LVGE:3#9FH'KB;Y\SEV
MH;SB"QO]C[^!=[U`"_.*G4F1[RP-=@G_O0QL#I.:#2/K8LK7LPX7F8MJU$Q]
M._1=0+FAN9-8JG'%(*RCK(K3H`I*<CS'8(_/Z5M@QK%CFPXX9#Y'"QW@S]]$
M*$2'[5(E)HN]'/6-0;>+$B&#"O2S5F)7R=Q*3*B%["GD1N"K#0;=NTD&=2E`
M2@9RR))99_P&;VNM1-_:1JO7,;K=-CL+A%`V0>M<'EK+RVOH(:%+Z>`B,K/"
MG@3Y0H"KF"R6FMO0T3(&K;[1V2@8'WCU@.W>P!CTNO=8_2;1E&;S[)V3\W")
M/*./F,C3O+@6"TSDZ:PE\N0R!JA7RBOV/TWZWXHD^]\54?:_^<2USN)[_`4.
M]@K<"W_.'?7=#?=MCG(T]VTLX>(O'6JK>Z$*:V2^!X%W,5MYV/,78,P&KR@K
MLJB!,'T#+.X&*'SP14S%NYW9H:`I,C#>VI9WFPQU"XY["D03%P:@CK_9,!R.
M&82^]TU<J/HA]/N8F]^F(.Y<ZR)&HFPX\VA9A3NV)]5,.;62ID(-#DF%VG&=
M0]-1J>AH1X)L73:-2/$50X34<1O+>T?H'J+G<J4T'Z4,RX`0N*+N`V68/_U=
MCI)M!XV*=M$;#ZLTR@*)PMH8SEO9ELUE"=)K#-F#&`#6Q5NF29YWT?M4K:?=
M2;^(*Y?*PPPWHE1-&)&2#9PE6?\'!B)ON.W0*1/Z%?(H&JQ.,5\XWI)N(%FV
M+\S04R4RE9_!58G'K`V;N?6E%M>.6U,IJ!Z\!4\-Z7!?L2#-$?08T5<#"UX+
MAY()A\(=DK[7@PJ%W>*A3#*A>Y!$T*99J4RSQQ5Y>P0Y-5V<(%U\HNLJP?[*
M3D=T2NO"[6DLU&L'GWZ_<H34Z9?4VIIXCN/=HE=#346#:#['*[_>)*6:N.T;
M=I&C%*)7IRH6:D94^\F%V@99OY=E5W>4"F\UUVJ%[\/A]ZT6+EFW.CWI]Y5Z
M>YN\6PMGK>"%80$><,=^?M$Y:1RYWJW/%S^_D/]=1U,6`5DS_(G64KL=?OY,
M[_'V/3YT6TU*2'GRC=T;%?\F'2BLD]K4ZC.N9MO[%8/4UHIFB5-B";W#)[##
M=;=5+F^$SZ?BI/94<VVM=UB;*MI4T2QQ:HKL))WNNF_J%S'GMHO%&/2NUF=7
M+^/[3J>SJ]HF.5S?UIT-?HLS%T^'#4Y@5T_1H:[[GN*E2I^;8<0=O:\UVM</
ML*VV&]CFZ>SJ70V1&%J5O7(AOW[%VHOOK[65LHZG,=8`\Q6:XFRCL<-QJ?G?
M5(H1(A+K;N1^4TE:@>?8UNOZ\=_OKAWN2G!^*-YC&RFW=&+V/B1T6@3T+B['
M\!F+0&A*TI1TYT1LK`!Y9KNR`.2Y)B5-2G=%\K^PNLR)$Y".=^DS.'T&IW=8
M[[#>8;W#>H<KL\,KA@L;3\G&_?G%_YBF$)/)B\W$H/J\]]H_U-&L^12%0<BI
MOJ:QWC;U;J:.NM>H$-<JQMN3<_QF\,I,R"G@H_T`I\TX)N1MH]-I&JU.]Q",
M5UB4:#J_#^`OJT;>S<:HKRE;4W:-)?BP,6II$M<D7C_AW1_VC&&S>2+$O=')
MH;(;=W=QGIP+JL2RSY^5C&FKJY?N)B<KS,`5(W5-Z)K0-:&7&LN:T)]\(9K0
M-:'7G]#U`<L&!%YQ%\L#4KWT=13JXY2R`%X6R7'6'1FC7M5#%@69EIJX-7&?
MG%K4A*X)71.Z)G1-Z'4A]&,=LE3<S;EO>KR6&EIJU%AJ:$+7A*X)71-Z$>#/
MGVE2UZ1^$J2N";V*A*[/=C8@,'=Y)NE[RSI-NCW3T9Y0V2BY?,*D;;2'3:,U
MU+=G-)W7,`&[V1CU-&5KRJZQ!!\V6@--XIK$ZR>\6T:_.3*:G5.1X#D_YT=J
M&)OY?!J-F$^Q/_N?41#:DV5]-O'IM^Q!NVD?12A<.@Z3_=<#9@=!)$"WN1;S
M4I>><5^PL:"_YIX?P@#P^PTX^"%L@L]\$2P$MFX7[$8`!<%S"^';GA4T&#:`
MCUQ?F-[4I?=,;[X0;D!IH$Q\Q[\%XV%1U"`AVEL>L)<MH]GJ&MU!M[$CG(`$
M71<"SBJ&RLBE0T2.5AKE51H/+6[R2!][CB4G^C?W`4L[*R5KOJX07VM3X@1-
M"53V$\]QO%NT`>R`<19$<P!AR;P)NY5LSCB:"G9HB^#5'AS_Y/3T_)FFJ`=P
M,>HB!RHIN???QC7&DP&N3)`#HP'Q;BIH6LWF#W<0&0SO@ZDE__RB*3^K@L_X
M.7O6FHNRE#'$5@&8TO*=[7+`5^$0F=YQO>-EA&EUQ]?D>=6Z#>B^M]4@M">'
MK\([OJV;1`5(H8PP:?+4.ZYW_+1VO/*VCNZM6TJ8M&31IDZ)8=+D>>H[7GG%
MIYU\36B/0FA?Q)S;KNU.-:65"Z;:4=KE=.J+*0]/R)K7MMV#P_3\6>T8X[>(
MLCR]2148HXXT53N*TF&34L)4.SJ[@B]];H81=S2ME0NFVM':!R`UVPUL\W0H
M[0#S,090)8M=R*]?L?;B>QE64B.`QYYO"5_!&Z<9CAV.+)+_3>4"MBDS,?>+
MRM8,/,>V7M>/57]W[9UW%QZ*35GE"*AR`&N*WXGD=]^%;]J!8)]]VWPLNUN3
MOB;]IR?]K\*?LS/;94O!_:"@NX.F?4W[-:7]?W$G.G5IO\U)R5UI+J/37&D`
M=[)3M4HF;L-*73U\38*:!,N]PZ4'4"=[:5K0XJ@V)/@P%:6?/ZM[3>FWPE3%
MH5I4'*I]((D484X7:ZQW/=)6VQ@,FD:_TS\$Y146)IK.3ZDH:;,Q.KURNYJP
M3TB`=QO=H:9P3>&U$]TIIEG?:+6ZQJ!_*H2NNX86HB\N@<F$.EH_]"J4EAZG
MIQ_/VD:GV35&K6;%A4?!,;HF[U-5CJU&_U3Z+&C"/DFY?3>4:SK7=*[IO-1;
MH/N#[G9O%K:OG9O246[YA,=9RVBV.\:@\@U!M7.CG9NG=6Z>/]-F7^5(N[J2
M^^3,/DWGFLY/@<[UV4TA^G*):@5M#+6O4RXR+I\D&1G=;LL8=0NR&FLI2#29
MGY+/TVRP@<Y4TY1=8P'>:S1'FL(UA==.=H^,?JME=)L%5FPMJ3OGXOQ(O0XS
MG_.&>_E:E<IO=:/2>S4JU;M8A5U\&_G88SB<"?C'%X+-`6FS@`D8WLIZX?*^
M6(>!@TX7QPQZY\J;+[B[9+XPL8*'Q;Q%:'LN/17W*1;?%\(-8%N]"7LYZAFC
M`8R%#[P<M(U6$]Q[7P0+@=V,A;-LL`Q(+FS*L2%J#[M&9]"2$+7Z0Z.Y!E*6
MP'_Z,0HNIIPO7EV'@.J9YUC"#][]%=GA\C<O%&_MP'2\(/+%5]BF-[@=OSQ_
M]E/\4OKSIPF""G!PA.^+<'@HK"LO"(/K&??%&QX(ZS-?SF&7@V0H9@(RX,,7
M,?GYQ97\^X_W_WGWQQ^=UL5;85X@(E[\LH,'GRP4M,+>ZTHFS[-I:WO$+#S!
MI-`9MENMUXSPSS[)[?WL<'='A"C3/7DG`NXCX<J+W=55W>,O]C7#:S,>,&X!
MHP&[<>#%9D=M#NX*`Q$&[`I2TIPQ.X2E+MF4V#!:L-!C@][`Z`UZBD\#_&H1
M^2:,*8#:Y\#]L'H8K$%3K@Y^BU//I6RP7?QYB"/8KND+'(&D2%PIFP7(63#%
MC(=%H(P&0Z/5ZS9BHN(@,"P8WQ=L*ESA<\=1+P@TU,(9"(TDTYPML(@;$W]%
MW,'!<&;8UF\B5+_`_!D!E5#RX'4@%\@`*'S``D$0/TR3-=C?O5MQ(WR#!;`P
MD9-S-NRX!U-$8\<V`3Q03X`+*0LGW/9C&&ZPZ%`\K)S/%PO`!LH7^O*-!ZO%
M)][:(#Q#SP\R,+*Q"$!P`J7/`3P#U%.`LM6E-VT7]2&7.+OAMH/VGA'_6K`>
MW$F%W!2Q-SB#!\L$&IIX$6R8SR8@@*E$&%L(W_8LQ!%GOAJ1+Q:^]YT@@O?;
M/^!#4ETTM"QX1%GP`1D/_!O:XFT<NI,SQTO6,8#>C.&PV2B:ZZL7`GNIIY%Z
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M(W+O6!3$KNT;+(EY<6V"`XDK)``N$$Y\8.Y9PFFP?V%$8XR_1X&T;_=[$W6=
M$UF"G;7.D8!,+P(ZB*VF;J,]^H&=M<_)#S81+,>>T$]R58'!SCJ97V\\`-YV
MP,$EI/3Z/TC__:Q[SOXK?"]]$BC;!MJU]N)R;7\]/#\-BOFIU0*KJEUA?NH,
MC'ZO749NZC2Z_?MP4[>CN:FLW#0LYJ;^R!AU6_LR$_)-;`5N9*-F8]0\/AMU
MN^#VC.K(19V1YJ*R<M$(X_1&O]7),I/GBI0MB&5,=",<!UT:&8\"YHJ<D#P6
M('SP8LAW4@Z,?!>#X[3MK?803*[F]AG`7YD(.TQG2'ZVA"E#`U9Z]H!4ITGF
M"4@F1CYN-?B2S6(AW.D8G>;>%DV)A'"[:XQ&_3(*X7:C=2\A/&@]C!"N/!.<
MP!+O&6][+\9^Q/UEX<$MT2P037O0,89@KT38&`HI+&%AR>09L>"+B0.41@.9
MD>^C7D@X>?,Y2-%9S/J94UY4$"3<<>(QXNER0;@<?"2,?&%%IA1&X#2UARN"
M9OW<&F04A:Q1QV$`+W-8#!\"4HPO.UUC.!BA/N-9?4G:,V%];_+\60R,YK]Z
M+/%!3#-DO<+P&]A2?:,]Z&U5KRH`71PO`"U@PK!`D'1?O5#G@GJ>(B`36#-J
MW\%0<4<VHE`8CKZ;8LZKY:_Q`6DV;-=KC8S!8/"TVOE5L7IN-88;M/-@'^W<
M;S:ZW1]4!D6KW7\-7[4;W0=RG$IUX^C.:29WD2%EZ3[TJ(O>*CCOFUCXZ))3
MR@+/<;Q;9$8;M6D0S>=HH.#9=$:;,XY)879HPZ1X_A4[*W%^VEJ!]3@]K?7J
M)+![F*3(9#ZCP(QA4GF0H]X/!X/#,(:@,BU_?M&4GU4/+/R<F7%+TRF5A-T=
M/$0V_J$X9$]W<>"10&T69.7?JQ_+_<FT9ABN$*B:&$Z3&`[8_^K:7#3FO\GD
M*D^UKI,F.RV#CHKAO?MZ:A-+4W2E,5PA4#4QG"8QG(Z)=8D!Z.FA3;4KM)55
M!U6+(&UA51/?FJ(U,=12J3Y_IB,750*U-H2W$RM?Q)S;KNU.-=V5`-33H;O+
MZ=074Q[6U8_0IJ-FGJ-AY;?X+G]-F:=:H)X.W>G03WE`/1VJP]I;/C?#B#N:
M\DH`ZNE0W@<@/-L-;+.F=/<01FH,N$K\NY!?OV+MQ??C;<P1.*OTZ]C&=@JD
M,5YG\1/0QY@&CPM@@>?8UNNZL>?O>%GI.*Q9>FJHRSHT5:]B[UU\<^<SWMS1
MY%WI=6CR7L7>5[P[=F:[\BI'0:=)3=\56H>F[U7L_0NO.)XB5>N(=SE`U<D2
M%2>&Y\\T.6ART+*ADABN$*B:&(YD^J1=9O_'-(683%[L7-4F8ZBJ51]HS%R7
MV=7;^LV[V<@$=ZF)H4)TNPFM!:W<"HE1O54-:E0EKH[CFI5V*\L-ZSYHK;0(
M3'%2T$?Q<'E72\9L-=J:*\L$:V716DOVZ#5Z+<T>)8)5*RVMM%Y?U)0E-[NR
MLB7JW5S9G2<7E>:7O\GBUT=R:,M]ZG/XZ=6N\\`2+6FG'#MD35K>59BX3X9+
M2P3JWMRWOU;1+%<=2M4L]]0XURQ7#99[_DPGI)TRSY5D(=6FG>.=X59D>S2H
M1PM`EP36"J%5@ZJ)M3)HU:!J8JT,6C6HFEA+CM;CG$$51B>J=,RT-9WRCBD"
M=3MW+PFH)W``KM,IRP=K9=%:2P[1>8TE@[6R:*TE>^B\QI+!6EFTUI(]3B_!
M\#[G+#K!4.=1Z`3#QY9WSY\]J$=I-'M]HSWH'4?R587,3X9?2P3JJ><]-1NC
MON:Z6BQ$<UUEN&[8&!XI0%078JW+.DH$JDXW+,4ZCG?&69'MT:#J/`,-:JU!
MU<2J0:T,J)I8-:B5`543:V5/I+JU.)':FHO8OEM0X\XAN&XI/+H'.JB"Q3#+
MB\:.*-6:[G=2M;JH:L?MVD:GTS1:G>[C!N_*1N8GPZ^5E]8I3HY5T.MP;5<I
MCG_\\[&R\<C#,?O#)@W4T2#5?)>>D(V.E"-Z>GQ7`:[32O:4F;T_[!G#YAW[
M`E2;WW,AB!]##HY2YG-N_97GCAW[FUG?GU$0VI-E\1([_3*O,=WX2\=AWB*T
M/3=@=A!$`DC6M9B7!E`8]P4;"_IK[ODAC`J_WPB?A3-A^\P7P4*8H7TCV(T`
MC,!S"^';GA4TV->98)'K"].;NO2>Z<T7P@TX3LC$=_Q;,!ZNQV@("KPXRFX%
MS/^R98Q&0Z/;Z=$/+UM=H]<>&IG)G66#O8U\G![@DNT;F8#=L+8,;M"S5P`4
M=Y<,X?3Q!8F0!#YOPEZV^WVC-6BKV4?&J--;F7TCX?ST8Q1<3#E?O'IK!Z;C
M!9$O/DVN,ICX(AP>"NO*"\+@>@;X?L,#87WFRSG04O`5Z.H-TL\OSY_]-+&=
M5__F/F9<IS\`6EVDOB]B\O.+*_GW'^__\^Z//SJM"UC]!2[ZQ2\Q_6;IE6CY
M%5.T7$2A&V@X0[%LC;D+:7B5*/>AX5LAIQE[CI4!17$!3?.;%PH&="*)>MAN
MM5ZS&$,;]V0?5*PN?,,J\Y+C@/'OC^KVX(%P78C8(GF1D1PKS+:!U^#?MVHS
M6.BQ1>2;,R!N!OP\Z!J#09<%2/`!,AD(ASFP71`B21/;3^7-`GP3Y_G(73X5
MR!3LO>W/47!P9%/5D7B!'8F)6YN-9@NED!R<Y!#\G@`RXR"L..`2QH#'!TI:
M(&^C"&/V?"XL&U@2A<I[#D+N!MMF2D%@M'H=H]MMPW`!,[EC1L2\+`IB=+S!
MH.+%M3GS'%P8"9,+!`X?F'N6<!KL7]RW48\&\!Z\;+M[O@E/FDYD"7;6.L=M
M,[T(L.$#!/`O=XK/36!36:LQ:O^`>.LT6H,?#';6/H_7SQQ[0FMI->7"X=?.
M.4D[$Q=RX\&";,<.E_DA^]W&8$!C#IJ-01L&182==<_9?X7OI>\#W=M`G['\
MGZ>;-L%-`RDK0&(&Z7:(OR+NT!X+%];5_.$<]P[[JB*4B)<-FLGD"SN$5R7%
MJ&=C:0Z4Q-DD<ISEA64[$4(VYH$=X`_XG)A,E-JR$'OJ;3[U!0';*")Z7$\"
M-NK%(!K_":,@\%)4(92@&V'%S(6]HYE1ERQ\[\8.2,W"LV.1I1P%D().PK$`
M77`!W""6<@TL7H-:L_U?J4-7%ATMX#O4,8@>^`V_"P'<@)OXN`%;X'*7R,GS
MF0>O^K?`.@:\B'`A@B6!Q;3\.1H[MIF,GQN+UH1,'\Z`$X/(G,$`H5VX:&!$
ML#1<+P0Z@6V&O1!+S[5HCAC_.$'"S&IA";;'2_J\2DW`'+`0)1\R"]\.>X-=
MPS(%/I65"ZO,O\$\(.J!A<+^3S8)!Y`-1)478U3EQ7:/M2)!)1UD`5)TK]:N
M`-EL:1RL=4B!/)F&WZ5U3F29]U*N60+E3N#%)(/?3SS'\6YQG)B@7CT<3I_4
M-KPOY60]U/A[<FMC>,A31UB:/QSL:S%3.-BF$J7LSR^:\K-R[/%S,N&&L_PM
MD8/A<',\>)/G7?)=^_>*K+NUPQGZ,Z!$0QMW!'0&#'-V+00C4[]WOG5[5>#B
MP##E\6ER8XCE_M'_)P%T[QR?C?&^DA-F>S@PFOW-\?VJ;J$*YJU*H-N9'0HM
M?]"4M%TT!#WP"$D879-W\0G<!=+)J20::4E4!D!K+XDP5M(V!OW-9_Q5W<0-
MLNATK:'/#C>E=PM>+OP[\01]&2(F\02"BKL4Z=INSU>1(BH(Z)VRG35*M65R
MKQ!!^M=5QEE"NV3[J8>V2DHF%2IKE70[1J^S.9F^JEOX\#;)7E>]:RZD-CI1
M?3IT.)X_E>9S[GW3OI2";>L%AAWEP\HI``]=454%Y6C8-SK#SL,+RC(3]K%L
MN2<GZY)KKPH"JOVGREDNW1I8+E^]D#M',#@.3N4M)2G?ZQ)H.<7(P4NJJL'1
M`7-C9`RZ1_#-RDS<&?&7YJBOKKJBPFI+;L,C3K4!D:N)\">1V-K>D-C*7<:G
M4U],55);RQBTP/[O-JN6Z-HR1KV!,>AU2Y?HBEAM#-L;LEH'NY):X9E^L]'O
M[I'`6AC).$KF8(KM)\T<K!-'G]):[R"]'CIS<!]TECL1<\\5ZJS!I]^U>V3M
M]'763AD`K?WY6+O;-EI;*FA7=0OU*?V!DNA*6OLDD+3H*0&@M1<]7:,_&!K=
M+<5)JKJ).F'PR1,&GS\K&4U4AGCUD9<V1DX\&T?3M3965O,(VRVC.=I<K+2J
M6ZA-E3L*)ZK0DW6:$D&E!5()`*V]0.KV!\:PN[G-9U6W\*%MI3JG->^.ZLC#
MV_^7*3K%3=./,L>'#T]`94[XU)G,]<]D;@V;1JO5V_/(K'8DKO,K=7ZESJ_4
M^94]HX_YE5L:;#RX^"L#<9](?N5))A!1I<8TZ\<.&&=!-`=`*5\NSK'#ZGDW
M=FC#+!//WUEHMQ47VFWOG3Y44:(Y9'6)5'C\U*%-`JE<CFJEH6-@%<)>P!?M
M)R&\FJ"QW-#I3:[))N^QKQGQC26)A5\5]?1O59#XKE;J09OU_)DF)BTQ'CC&
M4@V0*PV=IDN]R7J3JP)=G<V52]DVX5&L%4U)6EQH6Z5JT&FZK,DFUUF-/:K7
MK4FISJ3T1<RY[=XI[[&DNU5NZ.I,2Y=Q39)ZT)(VO8Y/_@J(;"LH2?.O'\42
M^RVBHV1O4FFDEANZ6DL\'4_0E/0@6,".RCXWP^@N^8PEW:]R0U=G:OH`Q&2[
M@6W6@Y;N8HF5.<F[VJ#?\6)"K1CL=]?>T?E]\W:O%S<H^89K6JTTK;Z+2WI^
MQI*>#Z012K[O%09=DVSX^BL6DSVS79GY?8<B$57<^`J#KFDV?/TOK+-[`I2J
MPZ+Z1+J":"PW='J3]2;K3:X#='J3'Z/00:]=N])5GZ(P"+F+]IZQ=LNU>;AA
MJ<M2Z;)4AV+DXJ[^2^4VK\R0[HO2B@JZE_>599KQ-.-I1:3YH1:;5V9(M2+2
MC%=YQKM/2=(B-W.OV/Q#<L3S9X^X_W^332*/X&Z6^4Q#%Q:M?V'1GM'I=XU>
M;_#P$JX:I'TB'%H:0/?FO'TU2:78K=GH':$U5#5(5'.:YK3'X[1^8]#7G%;I
M99P8ISWY,JI,_,<[."W]MFA`=1-`#6CM`-5$J@$M/:":2#6@I0=4$VE)#XT*
M8@Q5.BG=FIMXAS!?_8[`GQS0VI],'_'\IJ2;6&9(*XK2>O#%\V>/<-12TATL
M,Z0516D]F.(1SD1*NG]EAK2B**TA2W2,=K\%-E3][*>'/Q%Y]!P_G>%7&HFD
M,_RJ*N$&1K?9-YJ#T<-+N&J0]HEP:&D`/>V\HU:CT]:<5NEE:$ZK!*=U3CC#
M[S1641I`=8+?DZ_B6&>/I=\4#:@^[]>`U@Y03:0:T-(#JHE4`UIZ0.])I,^?
M::3N,+*/<&;4K<&9T=;\OSL$`>\</NN6P#][H*,D6`JSO&CLB!*MZ'YG245+
MJFK,K=4V!H.FT>\\8N2M7-1](DQ:<=%\C")6AZJR2C%VL\%&CU@#IES,<&(\
M_>2`GC:K=1O=H>:T2B]#:T_-TKG$:J/5ZAJ#_HGQ=29<\&/(P<$I6G5%>2!%
MP<8]_>G'B>V\^C?W,7<T^`J@O4'`?WG^[*<HN)AROGCU6;B![;F7KO4IG`G_
MLQ>$O@AM7\QA!6^$*R9V&+RU`]/Q@L@7R1C,A/G@PQ<Q^?G%E?S[C_?_>??'
M'YW6Q5MA7F"$X<4O*_C],PI">[+,-Y#/8FL3BC.;L([T0A2OXFP'BHMWY%;(
M6<:>LR%U](C3Y+<T_O#\V<$X+2#3G;2]F6SOL[9B2O[-"P5KM9FDZ&&[U7K-
MWLT7CK<4@KT%"G2%Q:C3MCV.0J!6]MGA[D:JEQ@Z+5K8EY^*),<)HVT?%NKT
MGY*'=HG^@K_8!Y>UF\VNP4"B`]_,%]Q=,A&@`K2#&?`2=YF(^<L2$^'[\*69
M93"8TVVPK_`^_L5\\5<$.B%`+H7G`F'"8S>"S>&=6<"\"0N$?V.;`H:&X=G<
M=NUY-,<?>LTFFWF1GWMJXOELP?W0-NT%QPGE7,C6;.%[-[8%<^%#"DP?D!V:
M,S`OY)`_X']P=<DR<M`C$(`X$S69YW)_F?LY:"32)6`FS)C\*%BT8*%'(\_Y
M=UH"=QSO%DT'%@%!^/3;!VQPZ7*'?1$WPHT$NU;KNO(L_&`2%-UFZ^S;N5P9
MGWL1T$`ZD\7&R]S^X&KQ,[5.90+FLM9#]K0RO+O/;GG`7@Z-45=^!W\.AST#
M-BI8X/0WPEDV=DC(U$JXKS&0-2BNHW$`U`(OO`/<9*R.A[$8RF.4':;=.CGM
MEB*)22QM-<LS`GYUL1M65BC@CX[9]N"1[-T-0N^]&/L1<GM[2.S269&`R+7`
M5;8++,Z!34$"\41>7(LP=(C0V>74%_*O6SN<,:!YY,XY\.'5NT\&^P>>F7P%
MN2"6#?89)%L$UG4L-GC\;G[N6]MQ0.(MV4>_H=X%.%B;`16`'+%=D,Z.@^\%
M:A@89\K#1'*`O'O9[C6-)HA3*6,7PD>HN`MR9^RY$0G8EWWY"$J3F1VD`A<P
MRRZC*>PY:_64,`&0UR2,%%?Q,')<E#6V:SJ11=B3`)HFPA7@HD@Z$E"FZ4?P
MC&/SL>W8H0W;ZKE91"1,,'@=L#%W"'K022)D/"R`9B=?/`8Q%W)3*C4W2KR[
MB\711Q2+S0N@412+G36QF'-4J^=%D4P<WE$DKIEO1T/&%COY@:;O]AYO,VC,
MC]SE4RG<9L#6XH8[$4=S)$CQ+PC_Q-'X#!"HXGW7BW^[E3$%LK*D,;"950_D
ME#=1`(L+`I`88]LE`1U\]AS;7!YH061WA+;J%5-B8@_;_8EC.T5C[F-K\!"V
M`A5!C,4<CUV"9>C:8-1^GG'0'*8`>]CD3F"`]C39V7M2<LXRMY/LBILA*(%_
MP:IA;/ELXYR=H52/!V\W7Z\(^';KM9'[F4;)_'INQ'K%\Q>>3S286M@.OPUB
M&_\Z1#T('WX#:K4X:I1/9NBAGN@;K#4:#:322G0M#,M1J8#*!:#M$`UMT"YV
M$"LOV-MOH'%028*O(OPI#$6J'IP!O@`'9.';-"?H6"!`\#I,.?9N?51EHBLR
ML$YBO6R[;?D8?[%/;FK^*/NUO=5^#4$`!URZFJO,>`W\+=B[[^:,NU.1Y[I%
MQF*]G=GF+#<)V:\6_L9-\OD!OZF[;0=!1/$#BWEI;AD:L<AE&!;PE=4WV2YL
M&NPL`V[\:!Y08%:A5I!XQP@`V8PP`7$J..G`J<Z2C4:[H`0>G@.N@A!(S\#P
M`YYD@//^LMEHMM"<!ID!:#/B811*I'#)8Y1D#"H^F,8KV#A`K'#E<#.0U@(\
M>E\L0'JB/,(@Q@T^O!.O-$`>F3-NL0G\27$<BH#$(`$R3!#XC2+J`N)2QG^[
M';M&FZ'K#.\`&$I(1X0K4!5"<XGR&=Z/G#"1\3GT2KI7/E<.SNR,8V'RN:!'
M*:[B.4X"6^;YW%9>AO)YV#I*BA0<Z#\9,?,J_@WZPX>=Q4!7L]'I=.)EKW);
M0A5?T%K)$C'.K_1GEOID:&M]Z@1MUCJD"(U:31&\B6H%SPKT%EE-M&W*4@N0
MI8'U8?Q`Y'8MA0J).H$`_3&<++\X@AP%:SP%?(QG`!@#9$HPU=`C-'(S%F"A
MD#8V\)IR-P$L4MJ2@(")8.20?Q/(3S_"7O&%#7ZT_5_IUHO)1)@JU,97,&P@
MB_H"9$R""YM,W<"V2,I*)Y=$H"\GE2`@B2%>@0E!$-D<:03L%_H>5KL`F1!(
MD:&@49P&_`F.N$'O"NZ[\'R0"IW8S9<&2D`43>4]R"Y*YPK0%I)A@E@DPABV
M9^'P^(6,0L2XB6T;6!$R7$BCP3.^F#B`&O7L"MH`!ERK;Y&@);LH)V@H:)*+
M)\=FE9P-'A0+X&P,(=[:`(4+WIYU>J;3:1A1*V.""@`KY2)8<!,H_!4;%3C3
M.U&TK\T4LZZ1=R.`AO\1N1AT15W7;!K(VIR-;:!#<^9ZCC==QA8]220[5'QA
M`=\XW@)Y>>P+_BV<^5XT)?KW@4G4H81C3U#MP`.A0#Y&S`@0<@%#IVM*`4/N
M+&9<G7$XH$?G\\CUY#!+=G;Y^</7<SQ:"5')2?6*/P(S.K0$_":P82/`2DF`
MME&RI&L.O:F@EY(HY2WH`C"%O%M7.?2V97-_:;"/PDK?D^;7Q\L/8&.=22'(
M)R%-KHZ"`!,FC!0?)*"\W6&M4:``O@UM`A_?YF/<#E2>((=!0`823E@1R!`,
M>-JA/([!Z1)I(D6:[X&J@_]CZ(%DR60[0N-011`M4!83#0@T/$'Z?/CQ@P-J
M%(`#ZQ.L9A2CA/#TB;6?0\#8W*._KQV/NQ?_)++&S;U"J>BS*[+&`8W7_[RZ
M.E>>*[B/]!G&708V"&P7D'T#:[.G)%IAN-^`G][ZT91=2D4I#[_HQ`[M_409
M.3QR33JK8W.PD^P+4TZ8D#D+%J@B:+L(4!+;>(8U7P(-VQ9S1/1-S&T.Y/;Q
M5Z`VF`L51R/C[:QN)85EO?&?<N?1#)/TC[8A!TTN3]8DD\@@MRT-"]^S(A-U
M"89^'=1]A*4)RB32C/0`D2AZ'+#QH&[H_-`#"\>E+0GML6<AC\%F?(-E28\\
MO^V">-4GNT-R3-9?7_`E[)85@X3'B`P4X9(M@//1XT':4R:JY&>IJ27AKE))
MSMK,80AE!ZAKF&C&@;['`HQ]@C;&,7Y/AD+QAB`6;0I(C`%A@$Y+1B@*)T-9
MD8H*.DB@66]M2RZ?["T,M\M#1,L&L\>GY2X7TDA7NT$6#_"(3:E0&Y"/!Z)C
M-+YA?:>BL^N\RB?5S_LY>G'L`?C!]6[A%71I,E&W3!PN%DBI-N,)UUZ`#@'5
M`FI^D8LX),-DM#NP0\A!8BK."%&7DUF]3QA[<X3Z'G'LS4<^-:*^AXECY^/3
M.^),$Q749M^`MEPT90H#VH?&LPN,H)+%NU,^E//JR+=6!4^G"LH2WI81'>M1
MHMJ?/U0GH+TEF'V,&.[G#P\8OH7!LI%;%;.U[A.T+0Z0IF';>,I]([9Y$`\,
MUL++CQ:G+5QX62*U@`@=I-5!6JWERZKE@4-/*A:+RWVR,&S>O-`1V`>*P(*2
M.6;P-;-M.MJZ%FU=0<[1`JTK\^@8JU:Y556YQXNQHG9[M/!J'>A`4_LCA)$^
MDFIL-^,\-E2];GJ3<"5FP(@)8DO0I8B#MRN*(]5&P"QO#N,ZZOJ,"L?2K1F'
MWU)D9=/5EJS5MWTR@\6.?"&`5\KD0"-E4V8?Z&.'M5I%=YZR8^=74Q1I5HYI
M\G6\3D+(&I@T3'$P?2>*:\T@N\7`P6=)/+"#3Y/+)+HA'Y'_ON-5HK*=^3!:
M))+=9YF**MGY@OWN\LBRT9"D>[?VG+U/0BT?7+H#1T]N/"'ZJNZK$4N@*(B2
M$6TUXNY(#K)`[!%BK"1KDBY\O$LH8RRK49E,1`KX%(9=./#N5+B@;M%+A-_!
MOTKC,[^[!!CQH+2)YP"AR7.AY=\;UPWVM\O+SSD/$"W3>$'I&NP413*PM2%T
MY$<(F%SF-'*XBAM."J"Z3D/B^'P2_[M"_ST("D/V[ZYRL-*TZK8RB@N\>P(T
M=_%_-.*E<D"&./^7!!QV??'_8084`@\(=98D[,#R\'!+XCN*V<!K9O$R(.AY
MH=P]=:6=0HX).@F%<29S(1U(%^8N!#2)?)6V'0?V$$YNH5B33YQ19#,(U35W
M%R&G%.3()\<W\^RY<NU("2G*0=-+*<!Y<LO+`'[%M'#01*E<DL=_$V[[*8`Q
MQJ0IF48NXP7*"&;`5)XX!KQC=HQ?04V!^Q#/"$(#7K?(Q[X1FR:81(`&O/5.
MJ`WNAMQ@YD6.A4X5F)I$XO#.G^#%T\XG-+Y[H!7K(7LK?^NE?$E4Z.D*"MNX
M:/^F7%UD(W#7C9+(-`;*8A[XYU[34AA_`OK<2M<'7!;;1R-I#NR5S["7=D%]
MA.6$WJ8!B6OT"-32]M%%Q7?U%C%D0>A[[C2O0T`7_?RB30HB,S&CF9-=VB3Y
MZ4-FU-S91<8CRIPH\&S`A4F7)W9PXA@7WL%P/8I6"E^=+L@Z$!BV!%*22%](
M+.^/LP?`\&$7A\MN2-W5DCB<4MBC4,0I&[R'L4$LFJX2@0UR_.XB9DNE`(06
MUMY9?/]1*=S_75GU_[YF5&;^%?N?)OU/X98R%-"\>`5[C]>QU^]^K_K&<H8]
MJPG=@I63OMI<?%_?=FHN1<^(=/`Q-[]-?8PM7L1P3^A_KQEPS_B;#:`CI"@8
MOXD+JNPGQ]]=L*@`-VL4]*"\_#FUF?$N598<-HO]G)S?K?-CNW&CHHYK72"[
MAS,O$"MF0N[IXM,?>5X$EDX`5&A/P":B@V2@CD26Y&9)LU^RCH9P[#EZB=M.
M:E.]OHUY[L5DU?$I[T(^3%/-/E3S>R`^3=Z!,)V33WB0,"X;G?PN-R==#9CM
M:9#A.O&1<I&)K?0C0P+9B.1>^2+2<4&E@D=-#QM`2(JXI=XAFB=S_DW@Z:]:
M.=7Q"8)HKA*'Z+R,4WZ.<M_4^:Y,AJ$9X'FA2#!;^D=E)EDJFKB?`R:YI7@>
M953)A\3WA7#QH-^*?'EL(;)9/N2NTG4IZ61)I],D-U$>W\5Q4.3,9/W[<$B>
M\@_DB<K(3LT3FB<>@B<^8\[;9YKZBS`=P`LI,L3D91+0>BL"T[<)O=JL/P&S
M?I42]K#EK]29LLRA5`F5,2.DQHZ?C!QG4)'HH#\CGW(VDF3,5'#M0^*'$O*#
M,T%E5,?>N\LJO:E7/)A=NA;^YQVHD1ONH+2^5Y2B;#N):R/-0G]D5KE?)"T.
MHP5TUC&#Z4`Y.S8,8Z6>"VET#X2FC6E2<[SZE5RWP,S.M,RP#Y(WH'RS,2:]
M`40BA:C!KB-S%A>5E*<141"1/2!O7N"[,.;[MQ^N,/TQ\JE4)5@5`27O;ZZV
MF\OE+_+>"!;,?K=`V0;J[(+R&\?<_;:7U[4/+3T,\55&C)P2\5&2=$<EM="B
MBPY\2D>%GWW,&PN76+D[A#?Q+8KOWB]66^5@^)T#G1*3\D0]1N-F2O_(L1XZ
MIMN2X9^\P.D6"9Z0R[M!IA>$*I$8=*-IQUGY'`#T.8)U@4``B5#V!18FBPU_
M"TA83"('Z/1&<L0$SW&I0GF#O<?S;+JF*V_:?*<$H./.'Z"S$P/P;ZRQ%KM9
M-&M(!_K`J>!/689RKM3T23:_:4;S2/Z=@$3I`33$W,,DX21#*I83,G,"I4H\
MSA3-%A0*'C"V'<2'^HKG9#(EU9K_`DZO[4O_;,XQ>.=2X@7Y:I:=8LV<8<(T
MV3>9]W<>')6@`O*^4N#!)$=E5)CF:LW5!W'U_9CJPQRAPH<^^6^!'KV`.Y\F
MOWKN]%>\$7M):"VS:J9F*Z73S2E:D5P1G1>$3R81NHV=DZBB+VYL<1L`9<';
M#KVMJ)S2]M(9L'2H((:1I;8Q(XW2ZV0DU/:!TO$*N$E?4':5D!%)X@SN^Y3C
MJ.ZJSOF2<K)D9A1>'\5K*9C_%6;ZM,A4)+!5,W'#B1?Y8!O_%7$?[SXINU,F
M:GV84`\963R<KJ.F"7620U-NGT0D3B(7:X6KJ\%DJ4X<#_`!2/"4_$C2F`@Q
MDGO0S%5WX9)?5HQ>M6!Y]YTN#@*\<Y0^-H%IYW8O0#M=3H!W(>+D.)G7)^\A
M4_@6\T`RFQ*GE^%-.1EDE7%<=1$(>S"(\!9C%80[3*V3`.6GC#/+\U#O(P[N
MPMI'$0V5T;U,LZUFVZJS[5OA@QN.^;-:;Q\L`3+(VU(_RG&`]M('5TW=+%%(
M,LGUK0&3.7E`"H5,P1BPA3,]<\"><^,*3-)VSL\*QK*THO^*L!A#_"C5I)"6
ML2_R7R8IUYCUC.G6_(;;CJSJ,<F`A8\E_&6IJ_%J)#DKCD=?>I9PLF6J\,MX
M=&^,_83DQ5;YLL5#K@QQ%"/X\)^1-94^"WHPAYPA;J;U>W!$9=25)M8:$BNB
M^U^XK$^3)'?B@PL^<C1/(ZM:DN]D#B+;?\6:.7O_*\'E9J9):1YM!TLUE.6!
MJG2!_='($+M-[Y"H"E)@-@185H^KD(3!J'&E+0T;2A3`^@!)AL=274=ER)!8
M=#!;Q2RV-&*FB/M?RK(06=:=V<+'6QQ+2BZ7.7R92C[(MQD;SEU$H<I)F1)[
MXK+PN`/>D0>K5!+0BSE5<2-=`Y-=/`D@9=$B%="U;F7F4HV53/Z*2D4!(W!U
M^,C-L)R$2IIGA2O#,C`X);;7#%[=*SW^(9HB[LU4LAULJ8X<?L6T>M8"9B!*
MR/`!WIVD4VS8]H?8_<1?29.*5,7)F6*GN$H&-9"A0R_UQEQP//0B87O0C8C'
M:GE9VHUM%VVL^DI698%M<=?V-^W7&-.'3%O#NJHIG\8WS:2?D]EN$&7"IM$M
M<`_-$#6J3YZK_!3?UILC9I)DZ#P09&"HRDG%!+5&AD;!$"E5[C->3,_):M'D
MX*K$CKT#;8>AB)TI'U'F9*-`Q.I`L(@;#V^L2J`,F?BXE/>'%D)8\)4)WK$-
MC]O!-_@D0FRI1OA-A;FT@WQ21"K+D9Q]"F/3/57?]\:JSM9XF;-RQDOZ6:A[
MLTG]'N#"?<Z4-.M)GND4R]0U/2>+`BF;-8G$9&S:-"&T2*(F%X)=)4[_-V"R
M6'&:<\K'7A3&=)C/1"TP*)0M$P4(86(O)U2\"D;I***$IBM9,F2N$"IQ][&_
M+A53#F>;\GV5VBMPSGCV9C?=((:E)=_(@S-@8X<($6-L]EJ0*K6F>"#K=6S*
M8&I@G:#LE??+ZRLVQ"(J:<+QIHQEC.>EV7<2"MLG2O4%",'$$\S8A1)J`(GX
M@\7]%[/76%1H,+.<C(F0JW"=OU8#4`9!]L9Z.J@JHZLX(4(UH>;?-E>:!!Y[
M@X8ZUEMFD[Q3BQN/3-.1-J%-&LKP&)"2F;:3WK:+A+7]C_PK=9=W_]I(V=7%
MW\MJ:@H>E=J,)9QWP;(*^@MF@C^GLJ]_?M&4GQ?<LM3G9$(_^<O*X_M&?1I[
M8>C-$_RK,2[DUZ]8>VOB]0.VKEQ#9VC5`_0-T([)MTZ`'3O8CAU`9G2)`G?8
MPPUVX[(!*V0E2SE6A6V4Z;Z59VJSX14&7=-JXJUJ6BTYZ)I6$_=.TVK)0=>T
M"HZG%W+G!"CUQXS-O:_U_?046EWHBICD,=V^FJ"QW-`]["8_?Z:WN930:5[6
MFZPW^0$,B8J&5]-LI&P0>GM:167V4[.%EGUZD_4FZTVN`W1ZD^]@Q;#QE(H^
M_?SB?TQ3B,GDQ:9%T.'HSR]Z[1_J9N-D-C5M0UM0MN5PHX?6DZ"NM1ES)>&H
M"@":1^EH+V)4[U2#&B_N:EM7;O/*#&E%4:KYH<*;5V9(]T5I14V`E_?5[35D
MO([1&W2-46^H&;`$D&H&U`Q8&P;<X()2>6+M@&YR0.^0K5D_^?;D@-9>[)R4
MP?W\66EAK2A2-4=4>//*#&E%45I#?N@:W<[(Z+?NG.9<N4TL,Z051:GFBPIM
M8L9A^Y&N3!8M[(&N<Z>ED/8J<O0P59$V][<];E6DX_J516/N4^!25T7259$J
M2_3[7PBO\"KK79JIBCMR2G2G*T?IRE%/4SGJZ#SS,,7\[L^X1RUH]`@B0E>X
M*BT5'XVLNKUCTE4%ZF1M;;:F2V75L%16Q63S`49J-C"5Q*MTM2Q=*>,$*V7H
M:EG5`%W3JJZ65170-:WJ:EE5`5W3JJZ65>(;K66'[ODS?7'Y!+99;[+>9+W)
M>I/U)J\;$OO7F:C7U1Y=/TLSBI:&>I.K#9W>9+W)>I.WVS7Z\G+N\G(N%>*N
MYDYI[T-4$-#:W[ZI\RU-#:AF!\T.]06THKI?5^U9QTG;&/4&QF@PT/Q7'4`U
M_VG^*SU9Z\+-^[F>#U"XN>24<#=`GS_3%K>VN+7&+P>@FATJO'D:4,T.NIJK
M!E2SA6:+>]?,JK;GM6G;[E'&ZX-K>G/QE7^7/WV%9;W!11=6[GK_'ZS<U;H`
MKP\K=[63REU'6WO1F'M4U9*K8K`LL:5Z5N;.-=8@"#)U/K+7FY=L+L*99\ER
M):87N529AVJ3R'E"G*?!?@=RP&(A=J#>,+`DE_#Q#CH\LNW&>5R5`6^KQ_?+
M+7L"+PL7*Y/$%;;2Z^MIB2`<+P6$F=SWE_3]'$'-5G4HNK2-LR<7]Z,@+L`@
M7&Z&"FZJ:B)?YK>JFL.M[3A84`QP(N2E\=N9D'>]LW#CZ.+[0LBQ/(#Z1OB!
MR-UWQR]M<1L4(@NQS#.7T3D6):"K[Q)/T0*^A*FIOHE-M^[GGH\9@-\$5BG#
M(B]8`B8IK;0^2;*6280%5GP!0N*_PL+*907S&LR>`-UB[27N8U6T@"U\[\;&
M:CM\RFU@MJ*%&%EX@>#YE.[()[2Y<M<?RSUYZD*]!(C`V'Q7/A4!FSCZSER_
ML5Y?V;B>:;;7;*_9?C/;?Q&!P-(;EZ[U%J^#>@N<]1ULE!N(+14[*Z/W6;Q"
M51`F62,07;"MD&;N/2OSGDGOQ?3L!K*\)O!=A#O=V/RB+^SY.`*BER4\\>>I
M3T6/<#!?F'BADVK3A!F>@+&Q5HX5F7'I%7\K9/M0QAZ[_A!$HLNZ9M[3=%BC
M0HP'>6`'<ALB''XA,?\%"_8)BTBD5N[8]0QH[>(-:<+/LA3BGO:9``J9DQVR
M4D4**%)PH,8@1.QX"ZFM;[EOQ151B<JI%BH2=VKBO,&K\Q?7YLS#HF;JS;CV
MW-RSA$,DGDP#:G4.3P2XAF"E^A</PN1W`B2U'"S/%9*K;(`)2W0M,[\B$_M)
M2:^BPE^Y8=5\M)BX#!C"(Q>Y5HLX8U:"O8B<ZX82@\BL:4E+B2ZT(P.2!%,7
M+2#FW0CYP`VB'[`"L-I@"%L1E6N[G=DD!IB8+QQO*81\715;`_M%&48,RP]B
M"6HT%K^;8))-17YN*M-&"[F0>#4SW!`+NA7@D@V@$0(6.9)"P(3+6IP(NI$3
M:23-%"'%0R,T,8E1]>F)L,,HM\]@UH>>3_5'T]^E;=Q@G]&&]:*`[,<$Q-PJ
MI.#&XFI@:B;5@LDFEN44"1MF&*U/D"!+UI[+D[>`;5.DD-^F!GOWG2H#HQ4Z
M%JZ8V&B'@OD*6#`2J:]@14$/N+0LFZ#%W>.V!7(5'(J%'7)G'PMC3R'V4'*O
M.@ZI%GQ:\&G!IP5?1O"]XS[6W@T^"Y^D0ZT,/1:OCIW]Z@7!.8-5(ATB0]-J
M]Q-^BH^(&&U3>ARV$R']B'@"V/.<A`(X@&KFDO:(O%%**@96H@`=I3<T9#+,
MF4-PKH]&@F@1J>K:@&O;B@6I*\(X\J9>YS?<=JA@)]!15H"!K+6$'\3NE40A
M4A](&@Y2P8TH>VY-VGI1&(2P;IQ229]\7X"8Y-_NQLM^*]FUA-0)NL]:%DX4
MR+W$:_H!E@"6I9W9M>U2MY*4"K#G@>>"A(F]7(;(%C*FMD(6N!#\=7WY^`^I
M#3X7#9:N`NEMX84H8:BN>@%0[$PJ29@1!)!RFET4<RXL.;1E9>WD<.T<4$+^
MN:J]3Y7:9614`ED,(`A8K-VK&JF8'*MAJY+#*L)*1;)G@&;9,`7@L!-P&^R]
MDI5+(`$4CL):S\HT<DNU@R"2U67E!B7=`K(V!44B%Q%XLJ`06-OH=)I&J].-
MWT$\)$C)/@F3#09-HS?J)_N_GZ[?:R6MO582)&O(@IGN?6YE@XXQ[(T.!%95
ML4;[;,&7!$*6*F""CM'M#HWVX%`T9#9ZG9(RM+*/>MJA:^ZKEBICAV>R"+2"
MT@I**ZCC*ZAU_138W\'+=,-9H&1[[MKZ`VBH]A`TU'"WAAH9O4[/Z(^Z=U90
M6Y>RG[(]1$7UC6&W;?3:PP=74L-6#U14KQHJZC=Q>YF<PW_V/1?^E)T&E+]U
M+U=J4Y<!!!]45F?Q_4<7Q;?#_G=%6?WO:T;7@UZQ_VG2_]39A.RB!^^\PGX7
MHN#$@CDB#(5_H:KSXW,X0^%QQ_H9R:WG6^FKS<7W]6,3*I1!SXAT\#$WOTU]
M0)YU$<,]H?^]9J!,Q]]L`!TA!;GA?1,7JO=`<VN]U%B/%^!F3?$_\$$;EK9E
M*6&P/&5LU.=Y01N+=,M#Z+U0A514*R8*HN`\BI]1IZ03+O(34EH!<0C/-0"Q
M8088446T@-TB1V9I>"!QN1+C::+'P@LH,D&-&4T>S-@$^PFN\.@^+'8HWSPX
MSU7&3KPS,3%-0YMIZ#H:!^*O"$]!;QY"6"]B,%%`N=/\A@/AQ$65TGF9G'BS
M+,`/F=&*1$-.&Z:9/"J+"7<3M@S#J3YB7L@)22O^@[L1]Y>LI7H5A3,0OM,9
M^TC'Z:"!Z6NY"XL\VO="W</@NC),NO^V;FRJM._VQ3N5'$'(DP27:J[+R'G"
M:^!!A#'W"O)JB,>I"6(*,0V,ZS+!UL9P-XX&GJ2_M\%T,$DD*>&_IBF`'U7F
MWR?W2]R%Z]*U?O/<I"D7>J'!5[09[VE/Y5+MURV@#8D>&3-GW18J2LI0>'K^
MK&CZ])>BKDJC(S554C/ZF;^+[U-T"ZZ+'URV?I57#EW1GK<MMBZDX&)(Z=<1
M@][<#/NAO1?6B'"E^\)#<L$1L+>K`Y-<7EWIH2[KT'1=3->;*U1HNJ[".C1=
M%]/UYL*?FJZKL`Y-UZO8V]X%JL94_6/.9[B;__#DB[C?W?%2@%K$BCL*=S\L
MW+7'<(5`U<2@B4$3@R8&30SE-WR*H\`5,7L/;6-U+T/XR;=<,Y66L)H8GAS#
M%0)5$X,F!DT,Q[:]BFN>/ZHU]OQ9*>RQS%[?K?+Y5@,M7W2RC(11(1H^L);G
M&F'FJWF6W$_87/.Y+AZ!Y@W-&YHW3H,W*AVRV=P;Z`#=7TM&W%UR6C.D9DC-
MD)HAC^[&RCMNC^_&EF+;]W1B[YCT6S?95Q)03T`<:4.]3+!6%JV:-VJPB>6&
MM;)HK25O=(UN9V3T6T?*>B_M9I8;ULJB5?-(!3<SY^JE;;_4Y\VML>Y[#_KQ
M+E=O;JF@MF*U6(V^7[VO1__$-T!VBJF8[[9<7MG_.E"G6)I5ZSK0W:XE9^27
MZ]WZ?/'S"_G?C6C-=JC`E;YFFD:J12.'IF)H&CD]&CG4*-(T<DHT<I>KI[6E
MD%I?1RVB^15:+@EWWH.NRK`,C7V-?8U]C?V**J]*G_X?\4JAIF(M0S3V-?8U
M]NN)_?)="RN%1MV03W<M%J%*J%-]+>ZF8TMPZ'L(=5>&FE.P"TY\B\"FC3@>
MW`4I/C64(9JN-5UKNKXGJ,^?U8JR"VYHE)F@V\:@-S!&_;XF;"VP-5E7DZSU
MW:!#?)GZ%+BHE`31)E_)L:[I6M.UINLR$(BFZ^-<!-?T70Y"T?2MZ?LNKLT3
MW86Y-F?"BASQ:?)%.-@=\3/WP^57[(+,3>I->N=^@J6\5M+OE^Y:B6Z7<[KM
M<N[NHE>>&.JR#DW4!41]DHTH#TU;+-)%3[Z("MTEUO6E-3%H8BA!E;9]L\HV
M";Q*G\3\7P1`3VQAL2^$2OSG+9!8$`8P+'IA\--X26WHX[[V=U*.)0B"Z&*5
M6\Z,=;'*3;'W6E0NT8Q82G+3C+@),_U>SQ@,"[)$:L&.]\\+J:4U\D78\W'D
M!V(.``;,%Z:P;\``F<!+[./U/Z^NM/%1(E!/0`RU.P-CV.G65`QI#M$<<E^L
MC/I]H],]4LCTR;=RPREG>JYYZ!%D]OCRL^\M!#S]V>%N>.E:[_Z*[`6JOMH<
M6/:J>&#Y`&<BA6Q=K7.0%&._@@T6'(>_3X$6ZG<^I@]]J[T.3=3ZT/=NA[Y%
M^OS)%W'`X5EI8:T0J/I,4A.#)H82'E!O$LZ5#@E_FDQL4S`1N\8':ND=NJ#B
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MH"5#!:C[C#)E^G=LS*<EP]Y(.UY`JR1,5:4(4ND=E4J"J@/@&M2C@?K\F2;7
M$M/`XT96NK6P'^(2&X]R?K,3E26A]#O[365;R+W\)E@,L[QH[(@:T/FQKBG<
M#X.5<M,Z1K/5?%P?K6S\I`6#%@Q:,!1DOW8>.7A3#G[:6?QL=P&S!RAW-OJ(
MY<Z:%]=B@>7..F4N=S:H8`SZ2"':JMZ]TM7.=&&H7&&HIXK;/S4QU&4=FJAU
M";_"`-J=U/F3+V(#K#JV^EAG;+J^E28&30Q/?I2Q0397.ECS,,7.]DV:KI;1
MDM*6KG56%WK7Q94VQAS[;:,SU+=HR@2K9L?39<=:EQY\@+S).EIC#UC.K.XF
MV7$+ECTY@U2(ET]*+'>,5O-(*1NEW<ARPUI9M-:2/XY8M^O)-_+N(:3GSW2`
M7\NH2H"J\^<UM585K9I:M5-^[.I<#WZMH]Q$J^66]@3N>I[0,[KZ/*%4L%86
MK?7DD%K7K=,)%X7X.WKA+6U/:&E91VEYW&I7E9<KQRIH52(BU_Q8)H+3_%BJ
M,E*UM)6\(&">2T!Y@8T&$O,F.OI22EBU="X3ZYQUC5;[B`>QE98KVE8J$Z@G
MP(T7QX_Q/']6HRA/N2]U[F]*5&4=NJSQB90U+LF:JGVI6_--%6A,\TW9R.TX
M48Y-:ZYS-5$#WCM2]&,G.DO""KIPH"X<^!""OEZ%`_O&J#4\CK-9%7[2@D$+
M!BT8=*GA(J/S_A5%K\V9L")'?)J\%>/P*PZWO9;H^_]@+='6Q5MA8BW1MJPE
MBF2T+^&LK'=]WU:Y.K.)92Q9VK]+L\6*R>32KD.7)M2E"6NW#DW4!43=.D6B
M/K3>9I$N>O)%5/(45]<MU,2@B:'TI^V;!%ZEXP.??=LU[05W&)][T5WS`NN6
MWE/I+=6%X39A9M1L&DU=@ZA4L&IVU.Q82W:\_Y%]+0T.>8G3@ZEL%ZP..P@B
M[IH"@32U`5(R4$]`")VU>D>60I5F5YWO7R90-3]J?CP`+SKFL<4$B0T.Y@M9
M3"+TV(3;/BXW$GA9TA*^?<-#^T:P6^[[W`UUS>0R@;HF#9\_JZ$\[`P&!LA$
M+0^U?5)Z4$_!/M'\6*+:#2=FGX0SP<;"%1/;M+F#27,WP@^PML-$\#LTO-#2
M4$O#^TK#MC'4TE!;)Q4`5?.CYD<=/;DO#B\MZQ4FB_BA_5\>UY72IS<E!/4$
MY%V]CY`UAV@.N2]66NVNT>EW:LHAQXD@[$S4K[0"E^&%Q4KBIPHFJ$!#$`*<
M1U+FY;X&H0N[[+NF:LO%LZ.:#O66(,<*:VC)H"7#TU/WD2I.EINXCQ?L..ZR
MGC^KHU]2(5!U&T$-:F5`U<1:6=^['C4)K[CO+V%9*LF0A^RM,,5\+'S6:1D,
M"VI0N4(L0F`P7P0+86("HK-\9).['!6(=$4O7=&K^A9^V7A)"P4M%+10>-2#
MDG)SU(9"?^KSUH)Y%=G<;05-U/K2LH;;"A5N*F@8WQ3YX`:A'V$-Q."NQ0V/
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M:WUX),LAPZ'1&XQJRB':'=_?';_&V^KLTV0B?,RM3_7V2.OM$H%Z"C+)&`W:
MQF#8JSW=:;VM>>2.\2JC-P(^J6W5)NV//X@_3B5HM"XO*:@G(*=&P[[1&=6U
M<I;6Y)I#[F_MMD<]8W2"D75=76[C#?<9=Z<"1L@TTSD.>90[<5Q7B]IW3=66
M@2=9+4K7=--<6BDN/6MUC%&__T2\6FF%7I*:^27AJ=+;K)4$5=?E>E!0GS^K
M$+`5!%63JW:RRWD_[8Y9P-J*UU9\!<B^8W2&(V,P.%*N>U6(7'.KYM8*<&O7
MZ'9&1K_UR"75RD'DVA'6H&K/0H-:9U`UL9;>#:Z\IZOSO:L+Z@EDP+2[;:,U
MJFO^B\X1TQQR[YA-:V@TAX.:<HC.]2[$WSZYWEJ)5P+4$Q!1K7;+:([TE:TR
MP5I9M%:<0YX_V\`CO9'1['9KRB/:^=[?^:8>95?>?.ZY*SK\XE)K\9*"6BL9
MM>EPN`6NQF@XK#W=:3VN>>2N%[:ZS9'1ZYV>'C]I=_Q0/?Y&Z_&2@GH2,JH'
MOD:OJ?WQ,L%:6;36E$?Z_9[1'YU>6/VD_?%]PNJ;U;I6ZB4%]00$5K<_,(9=
MK=++!&MET5I/#AF-C$'S]!3Z23OF7T%]!Z"=V02>8H[-Q[9CATMF.CP([(EM
M\M`&/0YJ7?P5K?]04V*I)*@G(*+..L:@US&:O2/54:@\.]_1JM9&@^;(.W)D
MUVAW6D:G?<2`_H$<^?Q9N5#T0.5+]%UT7?#MH62DOM9:99FK"[[IR^>:2\O.
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M`HFA(9I_Q4;-'P[>&&8*QPD6W`2.^/E%4WY6'(*?LS;^@UKT58TCEW8=,>C-
MN\>+@3&0%N#%=K$Z,8'>A5\5@?.[:X?!$T6.GYH:ZK(.3=6KV'N/Q_/_.M7C
M^96PDSZ5>")0B_AQA<\>VX:L&88K!*HF!IU@7ZG`N4[5U:FZI0QEEW8SRPUK
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MFR=>I4;S:^W*=Y2Y:,?S9Q5!8ML8]`;&J'^D')9R<U7)RG84UI*X6U6-B>V\
MPKO&=-4X^T+<AO23^X8'=O!I@D]01MU'SQ+.5\3!]EH;[_^#M39:%V^%B;4V
MVFNU-OZ,@M">+'6YC:W,TAZ6.NZ;@[533E`/N,&Z1B+5*AN0O3EYO##U4^]G
MA4`]'=+[!W<C[B\UY94$U-.AO$3HM4::],H`Z@F27GN@2:\,H)X@Z=57X1Y:
M!JK(52KW$<W^?E3IUZ%KN*V%S)JMUN-&RTI##'59AR;J`J)^Y!.BTA!#7=:A
MB5H3=>W6H8E:$W7MUJ&)6A/UP[G"3[Z(:IT:%M*-+H)[XK4Q-#D\M=8N+:B:
M&#0Q:&+0Q*")H<QW6C99QI5.<?[(_6\BE"4CF#<!XIK//1=FP.1,^&,N>!#Y
M`O,_F<5#P<Y:=RRZ5EG+O8:[KNN%;\),L]$9'"=,4#'ZKA"HFA4U*]:9OBL$
MJF;%NK+B2+-BM4#5K*A9L<[T72%0-2MJ5JP6?=^_REHMHV67%EX]%A83WX5O
MVH%@"]\V'Z+3L@Z(:2%72LPT&^TNNV`OX;]'[$)R7#I__DQ;'IHIZ\64G:HS
MI69)S9*U8LEN2[+D\(X%_VI&YQ4"5;-D35FRW=9:LIJ@:I:L*4O67DOJ1+-"
M_'VQ@V]LX@ML4Q0*7P0A\RF?K*WSR4H$Z@G(H%:CTSN>[*DTD_Y04YE<25!/
M@A7;7<V*FA7+#NH)L&*ST6K^`*9YLS$X8M:E9LE2TWF%0#T)EAQI[:A9L?2@
MUH,5GS_3^O$1F5)GF!7B4'7/8(Y]`T_;+EL*[@?UC9"=3MG=P8-M9;FU015`
MU52GJ>YIJ<[U;GV^^/F%_&_=J;#+YO#U+/BQIZFQ+*">C@SL:QE8&E"U#*RW
M#-39#X7X>_?_L_>MS6WCR-K?7>7_P,J[4YM420YONB4SJ?)UUGOBV&_LS-1\
M2L$4)'&'(K6\V-;Y]0?@1:(DDJ(H4@+(/G4FZXM,/MUXNM%H-!IO,ZS1@T,O
MEH%<W=#=N?!>@<H'AJ#6(XN5O=W:J;`.DFO[A'PR0U`;88F01`9+9!YJ$RQ1
M[M!M':E;T8U+8)#,LYPCJ$TP2+!$L$3VH6Y8XNE)#6T1)D<H>3A8;HS@UPG(
MH3#7L3$4WJN0'V,(:@-"CS9,L``53`-,`Z"":8!I`%0P#3"-VO"-(ZA@&MP.
M(A0`)>KOP;:>T7-0^&.-A/!^K=$(V[HYIN<\D#D79N0[:RA8+]@6.D'1HO"^
M`UD0AJ`VP#/)T!T%]E^8APJ&"(8(AL@`5#!$,$0PQ.)03T_`%,$4P109,$4P
M1#!$*`EB0(??D3GVKZ.?89N>\D3!=_A-=UR:+W,FR":/\?-G>"B\[T*.C"&H
M#?!^T$$8PA#VH8(A@B&"(3(`%0P1#!$,D0&H8(A@B&"(#$`%0P1#W#-#UNAZ
MLONH=,R_@%ZP_839^Q[DP;@?6;@\,*,%>S^X/+!3H6OEB.<<0063W-\D3T\8
MU`TQRO`J^BJ;RW'$=(Z@@E'6=)X4)9@G^80*)EE3DY3"J^B[(I@D7U#!)&MJ
MDK6?)5=R9Q]=]&S@V/<K(L9&\3^>X^JC.2_CN-3&EE$\C(A'>5>,G720HU?Y
MU*2Z$G_96;6"A@UZ_8*FF^/?WHG!]S,T'(;?QY.RVSU(/*?H6K,:N(_WTH<8
M\_)R,(\GZ8MYE%75),2].ZC@F4\33$7X&[MT7#R_%E6SIE/+#`]RZX[PC!P\
M%"QZD%OP[R69V;J#_<\C5[?,LTUF9-`DYWY(MD_/^H[C`6;4WX,//KP/ENOI
M@ZOR8<0C_=T>V1B3!Q$/A1U7L)&+A5?D"$-,?C(E3Q\*SW,"S$1C/"6R")Y#
MMQE=\N?H!=MA)7Z'N+FA$%PNZ'])?Z^T_1N.A"<;(\>SY\*%;A@"HG7Z_N_)
M"VFG3_V%>%/_$\$+A@1"@G>LP`4>R.FE47(="WB,PWL,I0R/L9.3X&QZO<`:
M\DC@0@WVTIK.:%^:H47_T'*%"7$!`AKB_WK4;;@VHKP2)CJ)@HBYN];2BPBZ
MZX2_T#5D+#Z[O/^JY;\B=A_6"&GDT[XS(IY)GR(WPQ?%'KUXA.X?":*1V0S9
MOD7Y7YKTY[KI_YF#IM3Y#<F8$,#4<=EXG!R=E>)_*`_RCGM2=`,NX^@&0=M0
M@\O(TM#=TD!C400UM[6.WL1!/&-!_"5<+'DSLERB?@+['<#]91+Y,^22'Q*%
MD=B!^IP9FB^>XQ``MO]D\K_8P=@W@I'GDEBBWB9\>@)&O(\1=V"E4,"<)ZL+
M`]\VJ?7-5KO9(6&]GYTCT)LCJ+%BI$T$$B_8Y"G10L`D"A!&=!W@][BKM^6"
MW>YCMUV8?'-;:Q0U.TM#M3</TCM9)^E)F.P;[)H]^Y,QF;J?L?N*L2DHQ+A#
M6XX>X+F.2^)I\FDP9S#G-'/N@3EOZ7R!9S2P-5W'MZ[E0MA**O@GYAH$OXM?
M.T)&+J]\R_SUXT@W/MT@W?Z#;HS<CZX(BA=$<WQ_(IN`=)U[\P(YNG,_^B/:
M"KFSAMAXH@]\(H-Q0;7^Y?3DUW*>1-;\)AWC[WCTV[O+X.N?@[OKGS\5L?V(
M9VU9E)1W7W9AB=HI*Q^8E9'T0\1LGS0X@DM:"7:[70:K'#@JR%@Z+TG<A$>H
M2T>*_$!.]F6:O['(BRN[PAJ>/I.H7Y%:)2RT&!U/CJ`VAWK$S[LA]\2Z<F_M
M8&0AWQT!#^>#=O#C3X(\>SO$!GYIUL6\'%FF%T)ZMNPAMA?0GPU$@ADB@.!8
MAC[\7#<3)6&87(UE,D^&NL@!I$X@M=)$4I<Q%QU="([F_C2H.2*[:G'77L,<
M004RL'.G59K#XWRC,*,DFGRQ7N0GT)KY>B[&X$39MB%LP(DRZ4SJ`;_Y@@JF
M6%-3[#;B4&>A*P-J&8R<#^D>'AX*^`W;&CUZY6^4UI0$X.3`R7T6S]2P'UI?
M`IY7#O7T!(P2C')[Y-$1J5'*9VJO>2%(H_,AWW7G;R'A>"4]IEI/(G`)M0%.
M2#R3Q%^(%Q+/>A5F)+@V5N@&SQ#41IBD4M'6<+-,$=(?B3H,:Z0%0W\)3CO[
M)ZOJZ^.:4\NH"GY7#>=CI^YCRA'4YM!/%(9H[GQ4SV2YUOR#-6VB_J[]H_EX
M&&_409NHU),$7$)M0/`LT=/D;4'J5ICGYMI,837+$-0F&*0R`$N$Q6S50<=:
M_R#:B@G\'#-0&^#GVL`W@%J&:9R>@''P,HR0"DC4W\-JTZ_UEE^T\_F<]AG2
MK:%@O6!;"!.6`FV^5D^F<`FU`=.V#%<O0YZ`>:B-,$2:MU,KO/.L.>:X1ZL\
M7S6?!"KD9^$8K>YY:G*5J^T>3RS;_=AEU&&O5\,.>Q5=YI,[R5>(?XS,6"LX
M$]G!TL*M@9:^<Z5QW2U]SRMO#GJ5#?@&\`T5^H:=JS;2QC(IM`Q=P^<U/65\
MLM0XM`)]P44XX+V8`0K>:^>MWSI'-KS?N`.^`GQ%A;YBY_VFAOB*/:_SH8G<
M(U[J4^9=`Y[3'B,T^_2H3?#0,_R'$6%M/'Q";^>.@UWGW!Q^U0.MD+@IQR4#
M-W_12P:D]A76Z"4#\L8E`SPD/Z%+]!'E@(:ZT"6Z=G(`J1-(7=$Y!K;)`'55
MB?J+(@_!16\"\F./3]70X^@,@%;%[$P<S$(%,D"KR$H=;F+52L)7W[`K6#-L
M(_^F3,,BKKG@Z>?52B\6J=*@HBOH79=^JJ_5%0<M4>G6/OX`BV2(=V"1&18I
M]@<M15)K:I&P)MPK1'FDMV^W@\T]NL>/3<=/>T.8PA#4)OBIECKHM3H="!Q8
MPLJM6FMI(SV56(E<X5$81B?R?7(-6Q/:C9CE[]T)M@ETNA^/32VLXD-OM*I'
MKRHEP?9>PNY[(MLVF1@2*1B;TY,,=[B+5'R[35DA:R"UD=>J@K7R8ZU@J^29
M:JNG5M08C&V"5Y?&8(3DS,>?7$+-M>IA!"M':@6H0%;&U0I;\XGZ>[)<9`C#
MS8HH2&@S!+4!R3JITU*40:NKU/4.-S`2,)(2=J?[2J>E]BN\V8C167J?95V]
MD]I?L>-\6K;*(2(8UBLRBU[%#)DOR'QQP/KW50<,]78:!1O$@G,`Y\`!N]]7
M'2B!<SA`8H41NV(^:.82*G?)S65U`-N*Y8@#'$'ECJXLJ_6PJWRU%G-RPJ'E
M%ODC]\!QO%JG.)X((PPM[]G`-2!(56=Z]M,@5\N&BN[7X<66P"F`4P"G`$YA
M/4+;?O4%AY81*_M/&]]?/^[9M2ZY\1WM;6R9F';/&]V:FC7%Y&'T!D[3P1?8
MQ"/=;4KS.U5F)(/<N.Y@:L8"*G]W,$E-=O!\M0>["1ON!I?G88)S>*2L,3L^
MGR?CK3!"9%:.$+J<,0;YS;A;!RLF$R&>/F-;4*26`&TLN9<#&+Z-X=#3LN`L
M=70A.,K50]-`(`.0X>@:Y@@JD`'(`&1@<-,\+13B.H][@\D2`!GD$3232G?'
MR1\A5U#4@E>OU^UT#M>C"XTJ4TM<Y59?)?])<-7[82O<.3-_1J`VP"+;BGHF
M@C4F*P<F8_['$";C]/,F+:DGM62%7?,_/8'IF`$'P`C4!M@D3,=E3<?[G_"J
M9>8AK14\^<:!_CE,06V`N^MUNBT)[I%A"BNW:JVEA0S.Q`HO=>%Z*H/5.4M0
M&V"+/:7;Z@U@MF()*[=JK:6%R-*94E%G[V9-5[!OGJC#RPDRQYC>:S)"NNVW
MC\."-1*&V-9?R#KV!:Y>90IJ$UQ>E1>/,#N4;&/E5JWUM)"S'L0$L(1E'VH#
M;)%>O=.'N8HAK-RJE7G[.#TIHA?Q3*HPF&O.;`7[KXDZ/)]:MJO_;[#GZJ]<
MGUV*4+,\$_9?F8+*F;LKHA5%';34?ETO&P8+`0O9.V`^DRJ,E[F>RF#QRA+4
M!MABI]L2%<BTLH256[76TD"DLRZL79G=?=W:HH9K!2^W9N%2KUVM*V]K*(9$
M@GM[EEZWU1'5EM1I9&<KL%:P5KZLM7<VJ&@[NMX3?%7+?7`+X!:.SVZEI[2Z
MG6-=O,<D'S@6!&RU=K9Z>A*?Q,6S/MR@>[PTR+Y;^(S8%$?92XZ@PJV#`)4;
MJ$!6@,H-5"`K0.4&*I"5^3[*:6N=>EP^_&!;+[I#]R%'EAUKM7S@/"8;=R.6
ME!N!>T;AGM&5?G6'3<*P9DO@%)(HS8A,8*=@IV"G,'F#4P"G`$X!)F^P4Y[H
MO9+Q^.A?!!_[?D5^3F>PI2I2Q_?7CY[3'B,T^_2H3?#0,_#]Z-*:SBR3R.3<
MCV[]I,83>KM^HYV<\04V\4AWGZBVGHCT%U3,+Z<GOXYTX].=;F#')7_Z@.93
M^O>+']QA=V(-5_]*T`@>\LUW//KMW67P]<^;OZY__E2D]A76VO2VXI_?L8%<
M/'Q`MCM_LI'I((U6?CL7\_AOSM]TY^<=GEJVCHQ'PT+F_V#7Q39AW24M#[<O
M_2MM[_R+8M]]21K32#,^$:)1\+E-52K^LO,("!HVZ(UN&@'QVSLQ^#XT!?K]
MXH7VXJLUR]JSIB2-M9N<3&%MC*/"!M436;NNA"TZ6R>Y_\P%:=(/J\=L>0>]
MY:XI*D.*'&XHA%YPE)/N"TR_PYGQ,8\<1@-&_&/,WO-:_O%)RB^Z;?=JEHN4
M7S6N\#)Y^V<'(3B=>Z0/`@EDB,N@G5.0*7PCG[^RO;%P/IL9NA8<.GL?:+0O
MR^+G;U?GB^^DSQ\$RQ9L//9(9&+9<P'-9K9%-%226P-#J[&AO4YT%Z>:6;C(
MZO?3MXXY-3FZ=8J1-A&(?=$5QE`@-C/T-'=WHRETKOV(!K0=**=CFIXZS3EV
M&<4<J3D6QG72ZX@M,>/FK;VYPI8[VQ8WU->AO9<_"-Z,Q`GN!)-@0,/ZS*7A
M1$)<((S(@_S/_3A[/!-NKLZ%R!W6CB<<`BU48`8JA9!GB]8@TF$0:.T#$*G5
M@!!DN8^S+A@=MO6]E7!84L9@=:VYV##9?:>#D?V1\V<Z7!>Z10(.&\VPY^J:
M<VG9,]@6X<!\85L$MD5J/.*P+0+96A;5".F-]?2&]$%XG6!3H&4BR)R37^JN
M3B(-1T#"PP0Y6+@5+LGG=0T9PA,MR/`W4R"_6Q\.0'ZW\?G=IN9N:'9WF_L#
M_\<XI\$MU=4M-3@N4W(X)O!,C-.Z09Z)=C5NE&]J;,BD?A`N=**#L>]XO@;>
M9J6D+BRZ>]7=R6(K'+P0`T`;X(4@0FJ*'^I\$&YTVW$%S9I.L:W1`,A!1OKE
M$>!IP--`O`/QSHY^IOM!0",7VWYEW\CW./^0_*&G_]$;;$SL^IZGP,Y>*:YG
MZ\W%X'S`^?`QB`TJ_AG<T>(?L?V(9[3X1SG(X>A5FONN_9/P_T3__];&]9]K
M`_O/U?(?9?86_8`^[)-@6O84&>'/7A"!1\=@Y:>O.#"7Z(>&C[P=U@_%?DYH
MTYZL?=BR9Q.BE$\"\EQK8Z3?PI^X5'$C\B?T#^E)>W_>\E\1PTCX;[TN'O5J
MV<,E"/]9!.KSWSIY''VFX]K6W[@=UDGYOW]&VM]CV_+,83M28M#D?&GT.6NL
MMJBYVBJKS-H1YOHDY%$5?>IQBJNX55>.QA*;ZLI3T!69AE_616QFY7>A1<B^
M-:W\)O0GA4K`F%?V,8K`&L3,?0K/&J0FT,BN=I;MA1JNG09J!!P-$`<<#?#E
ML([F(!L_)2N1W[&JY*E5-:5))E;!?AREI:W9ZZ%Y.-]5O&"<>>4<I62<>:U4
M7GO`+5]*F_8JVX6$2:_*IY;4126913"UP=3&AG(:,,<=H,*N0=3)N]V=\'3^
M-[%W[6`!>]>P=UW[+2_8NX:]:U:5#7O7L*5T?#6!1F!+"?C2Z"VE"A)4'/3!
MX3=I``DGV$N!O136_#TO>RG5;$<PW_:'7]L%=P_["^#WCT\<B/,W/3\7?97X
M-5]P_>#ZBV\M5WZJN4'4@:!_W?4SU[CJD*9Z>G)L0H*U@J.'&B*(\@_AZH_0
M&XQ?<P17#JX<8G86J`,Q^[HC9Z/Y&K_V";X=?#OX=A:H<[Q2?\]ICQ&:?7K4
M)GCH&?A^]#A!-KY`#A[2-#@V'3_]\>B2/[B?^>7ZYYJKO^CNO,`EENDW3YZ>
M^"Q)J"T?=*JY>C)\HQW[.IFC:B]?*\1L]FP'O1CT%<8$+,D$F+-58RGXMK=J
MS(8J;F+==D%=N;AKKV&.H`(9FDF&'<8_^!L&#T;DT\J?_F$O/$R-!`+Y.!Y+
MWJ&"#RI+PQ]78BG&XBI@-#`:R`!D:`H9FA-BG;]@&XW3M^\@P@(75!,-0X3%
M!E1@=#/)T)Q)%?(6#$%M#NV^XRG23=T<`^\8@-H<WIV/QS8>([>NJP@(',%X
M*M/*-X^VY!.L$:_&<WH"S..2>9#Z80=J<UA'BYMLI+D>,H!Y#$!M#O-N"?%T
MT]&UFO*NC#`U`I[9.9(#RV)>CBRS"R&M]#\-^Z52`=)ZH')NGC],/:,!ZEZF
MR3P;ZB('L'I=>]=O])"D@X4'6]<JBK69IT5=Y`!ZKVOO"=M3X;UN"G.,;.<#
M\)MK.8#?Z]K[`QE>([TVY+S9@`K%$D`&(`.0`<@`9``R'#[P26[[5"@4V@B%
MV3B8GT]_]Y[KN,BDD6I+N,*:?Y&<H$@M01:E]#X&F1%R[BXAS)D;TU!S-=#8
M(./!6VB<GNRC%[FGM/J=035+,V8'DVVL>=3*M1-<ZB3]:I$=/!ZSIKF/CJ0S
M&:R2):S<JK66YM$YZTA@'@QAA4D+)JW/[9J:9/IB-KB7NMAB=NO.!=?V\KN-
MS,)GM[9Z/K9W?7;?O=JV'\B02%O]V"XR@;_CF-R-L5*&H.:VOORS"I@</TP%
MDSNVSL'D&F9R39&#(:C[6QPC@O#-G>KV<#D9'H!:6?J9$:P<J16@`EDK4>OI
M"4=@&PX5Z`I0N8$*9&5^#RHQ.\'3-E-F067!$H&Z[;LS`K4!&^!03LD>5F[5
M6DL+@;I&QK!RJ]9:F@?4-3*&E5NUUM(\FE=@N,]."Q080AT%%!CR[._DEMCI
MMN1>IQJ_QPO)&V.M#$%M>M63>#;H@M750A"P.FZLKG_6KR@]5!>RLB['Z4DC
MS8X10?AF3W5[G)P,#T"%.@.`6FNH0%:`R@U4("M`Y08JD)7;'2FU%CM2F;6(
M<K&T1N$DG,K$BJZDC2HBC#"TO&<#,R73?CM5ZT+QG;F36XHBMB1%/6SZCC6:
M-\9>N??62YU4U=!K]]F.*XL__`X9:S;2*&-G!&K3K:Y_-JBH0I07LC;*ZF"*
M;;*Q=_N=5E\L>"\`W_:^DH#XZ"*R3(I]OR(_]]:1.KZ_?O2<]ABAV:=';8*'
MGH'O1X\39.,+Y.#AI36=8=-!KFZ9CRX1Z'Y&OW3.-5=_T=WY$U7:$U'"!97V
MR^G)K^4]3=`(7/+-=SSZ[=UE\/7/P=WUSY^*V'[$L[8L2LK/\U=D#Y_F,WS^
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M&$[^A_.6C*9N.KI6T\$L8^+?^;`P2W1-JKQN^V<8POKKS\+J[\(=9RK<VF_\
M1WV*N@K5S!!^F+KK5&,$1^;/Z0DPZ!`,NG[#MJ8[6'BP=:VB6`=<40.(](3M
MJ?!>-X4Y1K;S`9@$3"JH[S^0X372$]4EWP.;+Z!AT#!H&#3,SF12I`=`RO2R
M:]T^4\'%48[Y'YT,'/&VZI;X3+&QXG/WS`XFVUBK.-K'%.VJ.M#'OT%6=RR>
M(7[7S189@=H`\ZCN_#JSX\@V5IBJ&FN+E1XO/SK%2^@FS79VM&Y>AA&HA?I(
M@EIKQ];3$S[``E^!K[RJ%=@*;&49*K`5]I,JKRQ')NU0Y#=>*F.IRN+0<\32
M1F4`WJN#UJ!380:`:\LL6(((Y@AS,:]J91LKMVH%M@);688*;(6-!S!"IM0*
M1@AL91DJL!78RJM:@:W`5I:A`EMAVZ&,Y.;I2>Z#+(]XYH8G643_)(L"R4^&
MH#9@+T)NR7VQ)?7A)`M+6&N_R0/EP1DG63I@BPQAY5:MM32/_IG4`_-@""M,
M58VU1:G5%0<M4:GK?)5R&V*][@?\$]DV,MWXG8#KAAH;/)YO"UPGPZZ@#Q@_
M,`%5S.KI(A\`=^TUS!%4($,SR;##^&\$,UO;%ZX%*L>]&?CPU\4`[<`''4?#
M576L9((F'$$%1@,9@`P-)T-S0JR#W\P#K`,7!!$6,!H8W30R-&=2A;P%0U";
M0[LCW,@+O`/>'>/R8`@<P7CJ83Q'N.>XW,',<[T@,V"!>9#Z81%J<UAWE/NC
M@7G`O&-<=<U=F!H!SWVK(Z.6Q;P<66870EJYIS2\UY0*L'E7:2W,DZ4+N('5
MP.IRM,?DI>!`;Z!W.=IC\ZIRX#?PNQSM_<'0!>K<+2:.+@1'BS<HE@`R`!F.
MKF&.H`(9@`Q`AJH#GR-V26,J$%[ID7:%M;!%FN2W2)-KFE'G$FHU72Y*)^/I
MR3YZD>16KR>VNLH!KQ@'ZAVC\0Q37I"IQC-,:48\&QRP"13#_`:H-9VP]M&*
M>J;VP3KX@@H352U-,<:6;DN2U%:O6U?3K.[^':YM(VROY@@XW)N'<UH,06V`
M"WHOMQ11;0TDANX;94I!%=41,,3RV@\A!""IJ:NS[@&[LS+,;X!ZD.MP0*T`
M%<C*N5IA5W+;4FZFV["08PEJ`T*Y]U)+E)56K\JKFKBV3UC(<3^$?"WD3D]@
M*=?<*8<CJ!`=`U1NH`)985?NH`6F95W"RSP9N(3:@)7=H*6J4FN@0F4S9U"Y
M]H%\K;4.6UXJ]*"^%*#"=)6HE<Z9.`#KX`LJS%2U-,5!JRM)+56LZXHEY0;>
M\/L5$6-#^!_/<?71/'D0U<Y^H[AZ"#6$4/:5P"/=B#TIVGB\=1P/#W-<^7OS
M%[WR5VI?88U>^2LOK_6-:\37UB<AU-::#N1>AIKBUT]O6$@B:]9IL(4UZR3S
MGWGEV62]+K@3[#<`$C!YZ7#C>"CYEWZ"ZAR9<T()QQ)T7W'^ST>685BO]#FO
MH58_I=K.SDK+<A#'T5G6F>DU*>,^(?IYTGW/DEC1A<\;*:I8M4&&W^KWTQU7
MVH3'^*@M*@U"XK[J[H0:^@NV79V.B&FYY#'O'S$6OI$OA4[ZWF?,IV9-C[O<
MOUX:)U.]__[3U%&`YDY=I\8;C!-3[O=:8E?:G6R,#V$89ZQ[H->)[F+P/X)+
MIE#B?!S7LIW`&?EAC'`_&F%_3EYZH@%X(A:`UMX32:U!3V[UNNDM&7@=Q!1?
MU-QHZ,%`),0G[Q'0F/X;!>Z"C0WDANZ)."ID:EBP1MGQ/(^,X!!HH4U\4"E$
M)OG7LYE?7<862S0N2>_U#E$)@UZ!VZA$55H=)7T?G]<A+#\FB83(;$A<<R>5
MNHCJ"L@<5KB>RJ7\HWN+;381@=O6)9P9@;:ZOUTEXM5-#OK=EM)/W[3:FQ(L
M$KNJ2.[HM&9\[N(0**R>N(M;U!K$+4^6FW%/8OGAALJ`5RXIW""B"$/+(\M-
M!B0Z/2DGXD@2BM>00R$!QZ#5RZBQ+CWH8('>,0>X+)]9EYI3=[5[;<-Z8=#^
M`OIE,D=:2`KY"F+D\@MB\JB3P0(B*(;AT<SWV(SNPF8T"T!KG_:55;DE]=.+
MXGD=0MA\VM$3D4EV:IF!0P+7PP#0VKL>M=7M]5OJH#$U><T-A*`.AC^@D,F%
M4.3PF0$&MIB!UQ"JK!?'R%)+'*1W+^1U""%0*>B<:')R9<FT<%3@D!@`6GN'
MI'9[K;Z:WE21UR$L.U:J<ZW>]IR.XWNF0/5]69(^"TC3;/I9(K).(*8W@BY,
M();KF*!`[T@%>J<GAPS6^F)+DCHYM\QJ1W(H'(+"H>85#D'9T+KJ.JTN+1M2
M*EBULDSNAI0-;9_<?OV8OQ7/HG&/-R4"SA<?#MO\Z-C9JW5/U:I.;&R4]/(%
MU0]?#Y-F96RMO[A&1UA)QX+\0#Y*(59-U,@V.ACDF@QRCG&-N6^-N'QL\S)1
M_XGI:S/NV>)ML/A%!_ZB0-J`#\A<HP->PB##(/."KL[!ROD+MM$80ZQR='3@
M+B!681$=\+(F@USG:0S6W$"EDK3P'4^1;A8JYF-TM-A&5V<NG8_'-AXCMR;Q
M-81>U=,_!!&_M"/@_.>#1&+?/+\'@S7B6JELHZNUQZMQ/N'TA#U\=>82K2VQ
MD>9Z18KT..`3>^CJS*9;0B;=='2M'EPJ$HNQ7+G,-_2"]?:U,K`?INX6Z%?/
MXW!S#!V8ZGZ^?L.VICM8>+!UK:Q8E?%QYQ@Z4-;]_(3MJ?!>-_V.B4Z!S@<\
M#CS'T(&S[N<_D.$UP;M"6A1VI#E4(]OH8)!AD&&0ZX`.!OD09_<[<NWZ,=U[
MKN,BD\9[K8WV\.+N@27T6H)>2[MJI%UT_<+=X+&,-*]*.75T_]C7EX'A<6%X
M:1<<L8B5&Z6"1=1N\%A&"E,1&![WAK=/I\VDA6:N[#RG%O$[[854Y&0)7&<-
MW3*99G:GI7355J?3*]^_\4'MAE@H,T!S6U[>>80K<Q//.A7<=L0'1<'2P-(.
M9VG=LUX7+(UK,1IF:4<7@V?R5[=QRORP`%"XV0Z`U@XHD!2`,@\42`I`F0?*
M&4E/3]A5:MF;1@E9!I[VA3*K$PLD^NJW!7YTH+7?F:YP!X?10609*:<JK:%=
M5+/5PNCXL8R44Y76T"2JV1-A=/Q81LJI2FMH$DI+[DHD@JI?]%3^C@A4^#5W
MKQ4J_'CU<+V6*G9;8F]0OH?C@]H-L5!F@#:[[D@Z4V2P-*[%`$OCPM*4!E?X
M-4,*9H!"@=_1I:AJYY'Y00&@-=_OCZF4Q=L%>!M];H#R2U,`VAB@0%(`RCQ0
M("EW>T9J#?:,,JO_"B0!"Z?/5`;69R5M)1%1A*'E/1N8(8GVVTM*$HG7G)LD
MMWH]L=55#IAY8XO=#3%2SEUS%2VL=IW*N#)L\4P8'+`'#%O&T#";/CK09IN:
M>J;VP=*X%@-F3S#IE<+JEB2IK5ZW878=2Q=\=!%9X"1)S:D-+%60.J:_?ASI
MQJ=';TJ`SN]'?R*;%I&>:Z[^HKLZ=IZH2IX(X@LJSY?3DU\]ISU&:/;I"MOZ
M"R*?PU]U]*P;_L<%C;R#?/H['OWV[C+X^N>Y\_-^]/.G(K6OL-:FIPK?"9ZI
M!Q_Z\7CU3AAB39\BP_GMG?CNBZHJ@ZZD_/HQ\TUE0?EY@W3[#WK#U\5\\>6_
M=&PC6YO,O^(7;)R_Z<[R8[?FS',=_Q?2G9\N69?FS=$_F;KQVSO7]O"[CRP@
ME;E!JB0C/1Y#Y$PH2J>G#CK]`T'AAJQ[(3TH6?="FH>LAV"(V'[$,RJ-D@E%
M[G5Z@V[W0%!8)VLY2`]!UG*0YB%K?H;0L.$!V_0F3S3&]Z/[5Q/;SD2?W=*K
M/;'C/ED7^%S[KZ?;>)@EG=Q?FN)7/$;&M>GJ[MP7@\8AINY--Y#//!O'H<OO
MODAGHAA$,[EAE2M'9SE*A>50WGT1SP9*KZ`@E]9T:IF/+@G5;AW'H[';K4EP
M.OJ04,35+?/&LJ_)W[CSZ#'^(QR=_BY1NDO/(;'Z3S'F,,L:,2+I(!!T/]P)
MTC].$/D0?18>WIK7;]H$F52+P3,>L>;9/I-OS:6.*Q#_R_EL9EMO1&07&W-A
M,/A%L$:".\&"[D,3D#D4K.46'(%`12!K`"*#H$^G>*@'?XI&1&S_+S7#<NA'
MPP?YD@J1A"UAAFRZ_/*P\`_Q3)2$&?DSAWZF%?T%4=,,F?,SX6GCSX57Y/@O
M(-`(C,5^H-P/]@//-H:KB*+CSO#!M@A"=_Y@T&6'.:1_-YN2SUT[KJ^VX0\'
MCSSC*_%`R4[RYJ_KU?D\]9$7\Z?Y#`?^T;,),0DER>]O]#?ZE1.-V2-QEN']
MU$L_N!-.!@2\0]J$K`/M>?SWD80WY%T,"3BXNUZ=Y.HV@H4$/-P(7GC$H6#'
MB;G455\;VO>]'3GG;QZ%<3^*6W\!]QF;'GP7Y6Q,A8H26^65@_.PDLNQ42\4
M(1Q',><$V5`W/!KX+9TX<>^&-\3#&]N:TEG$<_VYF7A[1(S1'#O$Q_M//)]:
MGNGF\6;2SSU?=3%/?H"OU>OIS+#F&/M3U?V,/B&'@OTX6.EW!DL-EZ*/&BJ8
MO/2%^!R=4LIRL?.`YI1>^92LJ&I?[G6YU/*:2Y?9I+$TZ/;[,I\\/JB&]^*Q
M)'7D[D`&+6_3<KB[D$^KG7Y7$E45M+H#=Q]L/,*VC8>^I\C)7J6O2+TNG_3=
M6!LQZ89E12$Q'Y]4/JB&=W(0DMSKB9U!+>('A1VU#E15&JA\NH.#:C7P``Y9
M:8?Z=7)Z`[DO2OTJO,%ZSCA8W45)N>&MZ?\@^O[!ML8VFDZ3$Y\;JGSTGAW\
M7X_F$U[(/XL\Q=K/\R5^E?YFACLGVDC0A$7OZJIV\:0"Z_/MDZ8LBYU.($1^
M)`?!OD]N@:[*!CWRD%Y1T?Z_APQ]I./A=^Q@NBM%[..*;C]9?B[JTJ+9").0
MG$0I%_/OV*")J0=DN_-<J]G,W:MNI]/K=P/DQ7$<1I*-LH*$'4.*XCO6I\^>
M[6#Z3N<[UC#Q$KY3*%=W@VY74:5`=_G>63["[%(+6>GU:1"U.\*(L@_$@]+/
M;TE5_AN90:BCQ+X^']O8?YMO4E]UXK8<'*,#(0?=%B'^3">T^5_?5R_^9L/R
MZ"(S+M[MMQLB8"#;.MJ"4MS@YS#A.EA^S9T4Y]YXD39>?!T?XR<R\SI(\Z?B
M52OT1?QA$F+8Q'/-[T=/^`TY=U=$1O(3R[Q$IH;M2TQSI(%H:^JY-(C;U)#Q
M9!-E[*H%-5L-P:3]@/3A#PIG\?1;\R_B:YY>K:>)Y3G('%X;_F9&]C1PA^9!
MKD\:M/_MF<'7.VCIT;"0^3_8)9H@D<6MZ9"YPW/)G!SH*'*`B5K:ET2;AMX1
MQ6@K?T<U[:S=IU=LO&3N_-9.N[)80+V!GG97[T2W7=PP^LI%^!MI*E+Q'=*)
MEDR*_P9CNLB(I'A`\^DVQUD[G<94NETSVVB:+\_!K:ZD'`:^4-%PZ`?U9'[S
M/WGEX1RZBBJ>:J&MN+5NTT:DMBOL:+8^"];C1"O!G]U8]A.VI[H9+M3)]\]$
M%"H56>?JUK8M\O.9394ITF7WXFNF%?N%EA"-EF+2:B,JIQNJ(2@CNM=<R^\J
M(`9W"K6$UPF9$V*U2()#'N_0M9:`A)%.C3NHA@HU*[B6_W%WJ=ZHFBGA[<]S
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M'8L>E3>A3G84IS(-')X58B'A5Q<H3]8UHFLX/T^6N>SHD<6M79F@Q9*`"?Y4
MDOJ=]578BI![Z,!?U!L[Z^#&QL-_>2XM+%XD0",KKD8'2K=;E0[8S0@GG%CM
M2[*H5J:)[K+2:`=-_-N:F,Z_K-G?A`U+K93,@'Y'E"J36VI_LU[V8L`#-DUG
M;KP@4T=E<[_7RR?YHTN@_9C=8$SBKI7WU<`-]@9=60F[#*3*N9\F.'&&TJ"G
M#JK5!$\N45$&:K=B=;#K%V6YK_8JEIYE[RAU%XO-W/)?>9@675`_2K,LG#A'
MFBR2VV*O+:W*NR9-<5D9<G]45J4M#A:)L;)E9<W![2!PM$"Z'XUT\D:'IKZQ
MZ:#4D]?[K/6_6PZF'7WNT/\B$[O)@I$_]0R7$/P1VR\$DU-DERE+K$)B;Q0>
M/NFN@>]'M^90?]&''@HZ'%Q.=#RZ?L.:7S89/IUF(G0;:ZZ5/)9!!7=0O66Z
M-M'?9LUF4@>/?*+2\0^*0@DN6],=_&"3#W[W3U87*#DZ^'A_$<]Z?;K7(IV%
M*]<T<>(CN^@U<>XXWC0HBKU^FY%1P$.:@,U7F_;EH??74L7;GKGW^[-5SQ::
M(Q#A01*/(__"V9%9;>GX*.7"0]%O=`-@`;/#)LI@FV*!4KT[+DH2#2TJ++\\
M=`^IL\U)C(VQS,)US-';F/W2]:7^)=])@RM&P*TI3=P1UW*R653S/ED/'HE%
MD8-C_4:8CY22S]0,!M%J)X^0B64FRX2Z0Q9F!M("?&/R#UDW1<!*U\]7$L(:
MZ#787:2U&LF!E3E&XQ#0^E020140Q2J\ZH8AV('XPGOT04""AIR),,*8UF.0
M-2T-0,1%IYRQ;3F.,+,M#>.AXU=VX"$MX*"_I-((@>:$@!\D./,7;2WA_3-]
MMFF9;13L25#="?B-QFR8((A5D"]?+.__7MK3Y[WV8>T-M/Z$Q,RT`H76K`@&
M/:01H7'(<X.#!+1XA;Y@MJJUI,*4?(1(Y%)T8"GVB(OY<J"8X]#3ID8$HD/=
M=8B=.?K8Q$2%$T0(12S.BM@U%%Y#.>G(SD(["[HA.6O=D/[IK`XG&6=$_C\X
M:I9$R^535GLVA7V='-J(R8T^3+V#0R]CST$@GS^K;UA%%K;P$+R91:N;@M`\
M>M/%4F9"*?\`&7VEXVF3`$42D[+I$#M9IEO#^U&T&EC^'7N$^5-W)T3LKD#T
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M@OP%G>Q69])19`_1XWW!=?,%.Z[_R&=D_DW$BY2T@BP.A/@D,MF9P9N(Q*X_
M#HXVP4./S(#^#RR;C'HXJQ*/03R)T`NZ%0IX0><E=9/FOSP6F=!D,HK<+^;_
M(C,[@;^8&+AQ<BF-%3J2*'4V>CVFRYLP!RRKONZ0&>*XT;-S%M*BCE+Z*0Z6
M1UAVV;M#4^)++M&,3%#&[[;ES1)U$WO*$MY.Z6\Z&6S,!6E")\4)-YYAS*_H
ML7\\#/'Z6KZF7N;)VK;F95UEB>&$)&Z&$_GUL#P;Y2="%L6I'OGG@?P>N]?1
M<HI'C26?>HH./6T3>=T$HX]^KR*:^-WS)P6=>*!SQ[$TVJ0VUT[*NLW$4285
M`CV$$\!73/Q.=0>XBLK3DS</6J6!SM52-.K0.4I>-Q1J!1ML5VVT$%W)M^8`
M=#3\69U>5[9I#B1$H6ZN#`U"Z>UV*QF$W_WT6[Z*[RT'_#IBO$E4]AM+Q[8'
M.[*E4OJBRK94&9S)#JWBO10/*UAV!Q*ITU,[1U/Z/MX^6ZJNU#V>QFM&I9Q7
ML4C=CMH_-)5*F;.RI9(5UJ4J2"5%BI<`Y1?L7-.\J>?'FU=X9F,:6])CHGAF
M8/^('@DYIY;MAB?V4A]<SE2H]+O*REF=4K`=3]YM_EI55;4&\N9U*A7*2Q<Y
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MOL7,XAH&::_T>D0CX>[J3A)6J9?C&T()>EDAUL8S+K")R4)=1T:`T_'K<A!=
MV/+#';F_T%%A:0^EKRTW0O,E2ZW'/KZZ)=+Q%DC(JM)5DC23+%?Y.C@^.Z+@
M?3\=/-BZJ>FSJ*]CB(A2:EN9!1NT2.D-7YF0QQ_W=OK`YY(SHUSKRL-/EG\1
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M8=RA/*(`O*#UMM\)/^4O\W4@4F(=B+)QROVE*K>_??V<2E'`.Q6W2')7Z:Z>
M/-D!ZI5GAUG&M3]V;JS],']Y&-R%*:X"[]A"R7O/=5QDTH-Z.]SOO*_9;+PU
M?5_WEB"PB1?[3CR)/V\-E^?"=J]'2#Z_WD_;G\UZ^5*Q0?./X`K>13;3SV&6
M43#1Z\35F?ZNI..#H?T;8;''K?GG1-<F:W]Y&W2CV%N7*M5E7U&4S>-[.^!(
M9\(=W</1W3F=N6(G<_.E*J35/G++*6>G=T4Z]@MXH\&X-9>W&T=-(1QZ)=`B
ME+JW:5K\A2SZ\F95LPO_Q%C:>Q\HRRV"]5WE8"QH@XQ<E,XHE4R^W;K?$[M2
ME+?/__((\$9@\SO]AP[68J^\A&+';J<799YSO#"=N#$IEEN2?B@L%=I+WA*%
M[PPB>:=H(5ATA7@!C6:L`"4I:=MFXZ41MNLW%Y-9>!@99A09YJ+GTAO<:V[8
M[4Y9?$TG6-J);)?7)/;L6/_CU.!_&YZH+\,K<@0'X[_]AC\SVDDC:"V!_1?Y
MS0Q,&J9/PQ<*0_I&VCAJ()*OY\Z9\!1K\T`?YS<%(H^PGEU$^TJ$3W6$$9E2
M!&08P1,GED$[WR[:#*V^(>PR8?H*GY"G/M/K.W$H/GT\B0D]9,\%1?*[+"@M
MX08_V_Z/I'[P(]K&X8[V$1;D7O@3BMQOMJ,&STYJPY"DY'736Q)\L>^WLB5,
MIJ!DR\O.<.=SRKL"V0E\<)]ZX""31=@GX9&CYX/<Z>PBXPK>I?=VO.".+=HD
M:'YEO9IA'+O%'>ZZTDA_40H4"IS8@+]T*@]1;&&Q]7WIL\BY24S*6*SH\N#+
M>R)$5,3U4=WVWO30X8??QBS7O"8F$"ZUBF&/]VR-1Q2E/UA<Q)'RJE*0R-N0
M="2U2]!4AB21$LDQFBAU^J)<#(G_V^]8HRY''^F:OVQ]LFCK@ULS[(FQZ]F0
M1)1M12+DC<RK$(Y-(5;35,O&=V&%V;+<H)+@.%[>40*F/$%^L#2(>@N6(L2@
M)_>BJZURO[H2K%MM3E9E:2#N#37W".7N4;M5RX-^5QDHA:FRUD>V.D&V#H$D
M2^)@@RW["I*TH%RNA,ND$+W';=!/==N9``KBIBF,4E3?Z0PZ8@Y+3<:P,WW*
M(XW:[?7574FS0A5_NX*(0O-I7W7TK!MD17&Y-ED$)8VK/RT%?UOI=<CD%<Y=
MA;&LAHR1&A(/#7S#.6MZQ?6`,2$L*_N=V6E0554&76GED.VVUU8!<DM9?Z>G
M#CK](X',&>[+O4YOT.WN"K)P?)6=DMOI,'"[*XK]?MI4O1.82*3,PS7EI4&S
MC_P4!)$IP\&"V(0%9;]/*)8AVM[!;$Z%[177)O7V'4B+'OU%(%0-?XMWDOIB
MOU<1^FJCW\2N/31N*8-D*R'!@83;UI-D(*KJ862K)$A.W!4>=#I9,NT4+!=_
M0H&X.:F'4;?3'>QF2]GQ<Y%A+HEMZF#P?^Q=:W/;-M;^*YS.=J:=J?/R?MEW
MUC..';?9K6./X[233QE:I"PV%.GR8D?[ZQ<'("E*X@6@P(L433N-JE#$>1X<
M``?`N1AB$Q86D_H2Y]E^'["'Y3(-_S-)L?*JT51-<I>OF=,SW=1461Q40#93
M2I9T29(["'AC1U_=)'NLK-3!C6O':80UI:U&8VT_-UQN*D:>YY92`-X2%Y7?
M#D/BVJNK)HFM,24NUR`[#(F9K[X%S_G7#^\3=_E%PM?@X^ITW631+KV2NW$S
M2]]<\:O-M;DBUO:^IOH92V@1M5!](]@HD4:-0!T)P;KZY*'V016";GV@C(&`
MI@(F+0)S2@@Z]8$JC8&@M&H=Z#BH0=!M',CCSJ8<QL$H6D139Y1Z')BC(*"H
M2$J!0,&A4H8V(0@=.D%Z4W:IV1O!O1=_O8Y<M^R1SKJ+KG381DA;F*YJFINX
M+26V6X5OLWP&$K[*79!B#%2#$@WC($#5C(H:4%++<!@:5/5>LT9X:TPUHRZ/
MW01CO7.;@I)15]:F@Z1/0,4:3M^:1#>(Z$J+[=U%]+Q\]A^A;R?8G8#'JD'6
MME8SM:IIC@)W7C>(^"VZ/Z#XG%8.$E7?:KA.!A;E(,>PY%93<'A8=*O'-'J%
MP_I1/ODS)P^*6KE*A['B)#2-81'9D!Z?)2M6G])?>5#'-W"ZKR$-/F1[-<RX
M%O0O1DOPT.!B-$U6?8G1<%M:U7!)EV6.4K2.IUHIU!HIW@?/:0(!MX^9BR9<
ME<[MU*>*G&^-1:^<@>K;Y"'B/J;4R`)3#;1)"DQM/XPB<.O@K5F&M)'DW:E6
MN9^%(^%-F5JUFQP/1Q>CQNS8'W"GBYO&F4:*-`[OD"")%SR1J$[LQ-2<.()A
MXE.RJV3:9CF+23O=C2DFPR0WII@,4]O(G=ZWF!6F2^[Y-ZB#@Z9M.??5R-.C
MW)VNL21S4+FY.3/D(3TCRMV-;V4XN7DZ+@RIWSS=%41I.+EY.BGHVV[WP\O=
M3;_E,>;!P])OGFX(K/J]D>BEZL;CRD6?EU!"@CH&\QS><S9'+Q*\[$U"!,<%
MD`W'R=Z'+(7'E;`L\FH*:0Q!#Y"+QGYQ(T@U%\X%#:?#,7#BL"(SCG*V1$TO
MA(<(>SJNA+>>[POHW5F2'-0@G%5X+ZZP7/M"XCPZ5>EM6E%7<K5AQW<(W#@O
MO0`$MX48AQ:$^5N\6)"U'W&"'M>>+82_4SM"0A69@-!;A3E@!&XJ\_;4B\@#
MT<XYS_DZ22K.4%3JZ61A)UCJ9SK09X(J]@A]'85)DN,_V-_0,'&3^!8-+!ML
M2RAN>VE'T0K)\&I'3H>L)Q41+(IH6HI4NM=F$*!7N5LB;Q1=M$1%YR\W^I!_
M!^>+0>Q"XBST)QYW%X%#*DLE,9[LWMHQ5*]9/W`9QEP"G0U5PH$C?<HY#1[:
M`L8L0].:^GEX(F[1B(^X1+,;JL6$#+?<G[3-72$KBJ@JO<O+9UHS%4TUV83M
M1<ZV"$]%L?2RZ]V^<H*!113?]\-7B/X<B,_=AGN1<V\^&>7LGK>B,5=&UU9V
MX#>T\CZ8A4L7M7'OHG?/D.6!<1=?9^J438\7R;7KH!73ATR!:1)&J_7O.]SU
M5L5J2H8D*Z4UC:N`HR)OB0*5354VI2&0OT,F)=YF;#RQV0KGGJ[PE3P3WRAJ
M.0LF![%&0-GB$=HWRAHE^1!"XM-TAM-A9(K":(,QC5M#T0U+;]5=-K%&P=D\
M2@U-EY0^<=*H1[^=6^G6+$MECR'^0HY/0;MGMR6J0U%0HU9Y['U70XEI2*-]
MA]FJZ`P2#8^/;:?"%R&-?O38G76!%0J;!A\.^/;A*QN,,QA?W:Z:#,KUB_8?
ML)J^$1K048Z!H+2DGU(MU6PWA5FP=)VP]^FCFD`TG7$43A%F^WA3);,_F#4*
M@8^2+IR_4E*`@TOJ/477VD?5=L,]R=IVL(%(UZ2]A*7IJ'U9KM07230U-GT9
M`T:KVDN&Q;C,4*G.YEZ_DUK3'`*Q-\-RUE3-!KS8"U)(<48N8\*@HT8-UC23
M:WR/=UQG.C+3E>UJ(G1W6O5/=2A)"24`9/%,DG%)2=8F\EO=W\/@Z<&-EG=I
M-%O8^(IFZ>%!<>/Y;IR$@1LWU;+8I]SDQ>-CF"1OO1!&H_WLIHDWBR_#Z#FK
M[UHOV]O5)7K54QBM;N?@2IL_X9`REO#Q(PQXY]+W`F]F^P^19_NW\]^]&8PU
MYRX*8=&K\I=H*._&P-71T_NP\*+]V94T\43O%KWHC7[X!+1F?%X\/_M9MF0:
M2D\:NT/IM1?%"3P,&3UL'\J[GY2S$Y,7\\2-,)T?W`1XC$]$=I]$B5Y^QTL4
M0A<"[(]^:`?_<9,$NUU=PO%.=.F"C]V>-']P7Z^B](EM"CT16D\HVD>YWG-R
M.[]WGU+4.'KL(BM2")4Q/GV\=NSO?)4JRBB3@4[&\97[XOKA,ZG8AEZ6H`_Y
M^IX_3Z.:1\S;,%-IO]TS;N_LQB=.I'>.8S,V67J/8S,V17H/?#,V14H/<S,V
M128/<C,V12*/9S.V#[NGS=BA$7HDF[$^IX0I;\;NW&@>1DM<">KQ+W)75HI,
MH^/JP4M\%RE'X$"RI=3V2>WXA>?.WWUS9RF\]'8^1^@BA/7*BU`[853)SKOE
MLQ]B":&U")&>+RCGGYZ1/#C>,DEL+\!=&<Z%.)TMA.<U#"',<<2_X,<OW]T*
M\<+V?>'1%="/0%A'2$+!%F9VO!`>PR"-!2\0;/3O,DS1:]%?HF<W0S_A56]#
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MR-(3P$X9LTDV!?;.?[K\64`,_8(H$@B!8!9%Q<-9-@5;B!'2,P2-F&+HF=>%
MAZRZN3<OV56OD#7C!9)S9,D9D`!YHHT`K6A1C(RLW.Z*D75&4F@(*=B-^/\A
M8\-K&'U](UP@4\]Q/`!H^T+RBMZ_.L,I&O+6<"*'C29=[VD!"ZF`LWG$)+U'
M]LLPC8JOX41D2P96!=FR!['92$9H<1YP[=(F/3Z,C4SASE8#EI6'0]W0T?"0
M3_'WJ,D@Q7ZE3P%6YF*?=^,FB]#9?."_-=GN2ME=TRQ-F*2M/S,0=QVYSF]I
M,EMX01P&Y)0!S0UHC,X6&Z<-FPSF-`7.1S16XQ"])?\5-77@$REMNT2R$]0?
MO9)ZHK</>J=X'5QW*M[KS)%US]3Z9XJ'[0?=/[B::OY<MD+4>FQGDX]LH@G'
M)^,#S?,7Z1/YO(GW'GU`N_\M3.?0:V?H5TJ6JZVJ<6;!IFRG`&+Y3#3.9+4=
M\69NMG!E^\DJ>^PA+(M^\&OO>89.>";PL*4N_PC_#=P$3CF1@8]-9C@\35TX
M1KW^[?+^LC*+70-3?*@=Q(>MFLQMXF"[9`>K[!@:T0?4W'S\S^4EVL3`.32<
M.D>KL\?56?81#HX]M)D0HHSS"JHA(1UZG9]=$$*R.E#T&$U"B>?C+0C`@CQT
M_Q1^DF`O1C+0"?,H7.*_G\,<B)K/;\+QFW\1PDCX2?X9[<)<<N+^C$=+++@0
MOU&=E'#2W=G[A%'9P:158:M9`=IEZ79I_WZ7WVA9SZ]WIP?4]8-<@-*-Y#]=
MP8;O8NC@TT`>NC=/B]P!'7,4@\4I#19.DV+Z#"\[AJDQ>^9VGF]%UK4##J['
M6XHDY,FU&R`7^:EW/?18;FPFQ,GYG21_UF^R--=UL,H;[P=WM@C`YW/UT8U>
MT%MCR!-4?6VRWC]<NX\(NRC#7J_X/-I"V9BP9',77`.WS,B-#8FY`Y#EJ*G8
MQEG,$?EB%3AES5O?Y1T;(52@BRN![&P'S;>VXX4V=JFY@6D>YF[>>XE;^^N]
MYSRY'VQR>_2[_1A&V.^-`IZL*%)QN-\D=G=L^\R%`V.+0O!_>A<GZ"4)W%/7
MI&S+%5E;'UR)^OHSRV2/%N:7CZ&?X@=:#[TUA$HNW\=42,R,9J^-+)/\<.AH
M:I:B*!S%WVNM9:9?LBCIOPI?@^*ZK.K!%K.JQU[9MH448@ME%3L8!.>%M<<N
M[!/K=1AEOZ'H0='H=5S)BE6H9:6(^\K?\[Q`+?]&-`)T$7JD</`.H^LP=&"!
M!I]Z9XD>C9.H/IE87B!IHB?<=%5X=E8(I1S.TI6O[YWO^NI!.TN"(G/D^SH-
MG,V-^:?`<:-"4G@';-H>7L//X&MT@#13Q&)ENU,V+F@IQ+>M\`/TNZ/C3V;@
MKTS$QDT[.0]IJAV1.Y&(N=FK?)'D]>>#H4L!Y^+2#?@&\ERA/H0!^CDBTW[T
M77!$]9*4;$CJO+W66]UB5X"VNEUV")^(*R$NQ/3@?K/CFZL+Z,2"JP:.-N8B
MID&H:KD.-6(OC/6%'2WMV:J=CLS$0W3HZ\\,=/P[7`3Q;^'S5Z0M:VKXHI?%
MW#XLX<JA7J"7./`B9)?,W!B*KAT'ZJ+'JQ'F^/^TX<`C>?<-3@QC4(H/88+&
M(CDV;/,++DT;SQ&IN"I:9S?V*JN^RD")O70AF]^SE]C^KU&85I^/EMZR+J^V
M<R3ZL(#B>A@8.<NS(?P*3NM?O!BPO"[<R/7(,?LB]-'X$Y;V"OT&7'3A2TL4
M'/2%2VAQA0"3(D3NWZF7U<][7`E/W@OX_.H:/!RC]WMAE#^:AX[A=T;9Z3TU
MVY6W-YDG[XOM^5DQM[>K[%7N[3Q[]Z'U4^:X;1-4O@N\%K1C;VLO%G)LZ%$!
M*7A8=O(&/VGH/,0[W)G%J#OA*@6?M[_"2Q*0A11C7E_3H)7%][(:>J^N#[41
MB7]U<>4Y\T-<@A$[>6=NWW?IXRP42N#^'YJ"PGRQ]VW70_O9MP,([[MWG]:&
M=.'J#M7]T)#U;9#,S3.)5MWS4'5\,:/E+$,PE>>X#?;[/AOURO#+2EU`;[>C
MO"#:1S=)_'IMR!T=GFW/$6ZB-\*#[?ON2O@'VN-C/W^$Y`:,`L'\10"1<??;
M0HRSK^27JM!=Y5\@"1+<B""17Z'WEAK#&I6WF#5H;\1\%H$#_]!)N`%T.2AF
M3*X4B-8@>P"-,T'2<",RW""BS39I6"$MRUGW5G?2>E&"FTFT9R:+-"S32"I\
M7;QI\366K<W/XD?N5UKKEAIT8<:E\'X(+%P_2751@0B9'CEH(7!WXG^R"\TJ
MI!41UCBV(R-P9V>577X=NL;HI>-:-N0[\^.]&[BOMK]G[%.-4RO,+W8Q3.T4
M*2`"C@PY?X46+]1P3-P1\)IQEH19#=_,%0%-99FI`7X)"=K7DK]>VQ:E>KS;
M4\HNKIW@%KS-+FG3FB74P?FTV#R4T"Q,Z%!*GZ>J-7GP(C,)%<RAK=*)N782
M=IC;'J['SEQYIF+AH'QR\[MKQ^YF5G-I$#_\)@'V$;`LE++^S-8X.<=8[YL0
MBP_KZ?!VWFP>M4FBB^7='++A_FT'*81^9K9C?HY"T?[^PO)8?/*E`NTRT(XO
MMT25-XQ`]@[\SL*[;],$31R!@_96Q*ZAJU<@TL82MT=5RX9B:A:'4/8Z1!.@
M2SK1M0]=V9Z:EB)-T55-,XZ;(YFC2BD*FH'4[XLO1IV29,,0]7)5T",BJ;RB
M<5,JV10E\SB5JI8O1J6R5%6R5/E`.$+VR-SUDA0A:<RHL^6:8W'1*;SY,46-
M1\Z;>CQCT+5K5/(:@F>J90U)&$CX/HY3U[E*P668/$*.RTOBQ_EA>2<^Z(<8
MKK>NB*I5KK?.+B1/G5AOG\890K*HEZO#]@!G#+:X:HPDRHK!<]WJF:32E/\G
M25KD7+RXD?WDYAI\%[6<-.^WK?OT\>K+,R2-`BFWHH"D-W(_6Y4FJ)-EM\LN
M\,1N5W;KAGT3H^*;<F75[YW1+EO,9G:M?O9/1\%N-WVU^CGF."1&]S*=3_K:
ME=UN^FI,7%_C5FN.O+FPY9B)[6BM-AL"NL9`*U>,G-G=L96/DE\FE#L,/[8/
MF4?F(7/O+FTO@$#?D"2-36T?KI]DFO`E^GW#^9WV6;]1K[;H'!;2`3!*OU<X
M,=J-T<V)X/Q._VR=6*0(5*372_.S)-[(YHE31DZW-5/]K-W(RHE&;B?GH)KR
MC71B="_;"18>Z4:>&(M\]A/O42M>$'NS/VP_[??P]`?A6^S],_#\?_V01*G[
MP_]-"%+'$\M#@M2P']B.9I1U2='[V;]N(ID071W/`+>]+TW-Y%*NY("9HU<T
M79)40S>_"[KV/;S;]A'014M46#;K1T@=O:99NB4I8C\.*+MTE6(N8W(%OZZ+
M4BI==3N?XXQC=)NZ(H#OTK?C^':.7T'\RYFJ88'R6)8A&Z:V$1U*(VE/X&2>
MX&15EBRQ,[3WP2P"!_#\^]MYZ6&J2ABBN&$K=8.VJ\*J;$B28679ZAO%[(Z%
MD]953?6F:H%-,9SP<G.@NJ1!?H)!!>+&IJ%9BL@B>^DKX@%$1L1[BK':BWI7
MCES-$`T97+[I)>:`K\^)UC`M9.)(XR*2VZ14),FT3'-D*7GR;NFFT4V1<+8*
MUXFARC,\B`O:$E%PA.?&CSZX5#G/^,VBFF)82CZ+LHK:)\3FN595=<LP]`F*
MS6]]TT5)5_=$Z-NS+-X/!++CQ36DY.>M85_`?KZ=EVQ=D@K)]AS??L7E<&F6
M(#"S\BZM%'Q_6$S=PP<6FJ\EWJ@:5U".*BB9DJ%VD!W*2\4X0<TT50W;CD8E
ML$)T'M!&4#=LR/6`;""5(T9T%_FSW&CWKK=\3*.X/A1U?/639$6WK"J052#X
MPAU!)5&7FI4S8`]H!U)3251$F;D'*0X/)J&QU1:PJ2N60GT*<A"8OWQ,'V//
M\>QH!24FRB_=[%7*4S!)MBR9_A!L5([JH:\3G=$>_AFJD=L)P\/N?4:K!BU+
MHC5:5_>#F?-PT$S34NG/34>EB.-H,"1=.138D``G@`H[D`0G2@O=8`K\VCCM
M.7#$\5O*7M8T2Q.'&_^]V#65R%3=,-7NP-8>NN!D,J(Y<WYG?-Y$L2G:_H+W
MM/!,37"Z.0+*=XE7!R1W,=+!&8NSW!Q'*XUT^17TA?,7:AA>'#^$%XZ#2V7;
M_AW2L?=!ENHV>PL9T9/8;505XS$UHQ2?R8QK8J1T,BXJDHQ*FJ*6<UY,CY=1
M3A<L456/AQ1.RB)9FF%HT^)EH,,9U;(,T=@3^>[)3I[@<,)7*.#"57E>7Y:=
M#[H11KHIRI4GVQS`#76A4DJEV0KAK1U\?1?/HO"UKI##^`HG%]49-J3M#&$$
MK5*:(5S,9A&:$M9S+\/PYS.36[JA9H.Z4I@6SXF'\#;RGB#1+?Z65(D@M\;P
M_^^^H1T=5)=J3-_)Z@"BEBM/\9&K%>9U&"VS'P\#4K),7=/U%I0L8N48/P61
M.PN?`N^_KE/M5]I4`ZES/&1+Z1TY.^*AEJX7.'S<ZB7+,E5%&P70=JA0RTV3
MI*KYX3J3H(7YX_OA#++F3D63+*OL9DXGWC"`Z-V_=_=B0\)0-C6HV5?*D*5R
M`,F@@EHL@LJJJ(XF:2^SC*SKDC&6DC"%RK)M)4?4]>;9TM(L0YJ&KK=,ZZ;9
M4=?+)68\R'2.R^WY?I;JG!@?](4(5J5"!-GG!R\!<_5]X'@OGI/:/M878L=<
M>6@%2L((6]=!G/H)'$FVG+AV'#S:3DF==KPY0^3K_+["P14ER0^SWV51-P?#
M3[693;*4L@#FFG3F5W([U#7?#!_SHIQ[9I_@V7'!#I!SCQ_`"?,Z<N:][Y+C
M;HFA%);@R>/D=8H+37.G,27%/LY.V\GTP>I$,V"^M&X,E\--,A!%8KO]35]%
MU15=+2U<3<UQB17?++U$UZEWOAU\L)=D@GMX#1\681K;@?.P\*+$=<E)'SRT
MKCHE*V>BA?[E$!.^*?%D27CW=^HEJ_?(R@R@$-DAT5$Y0'Z-PICR<+][6OD>
M$[QP0L/D_<>]9%`%B`EPQ+-HD*CILL$QT\9A,,:D588JZJ+!,4=[#4?%UKG[
MJ_&;W>W%M2[M%L]\BX,+/UG&V',K2B?^&/(H*F-J7%]3`/H_,"<H\@9-ZZ!J
M*)@<CE+Z@)D7$2<GGA<OMN=#N6RT+<98:5.,U=NV40:Q9,ZVK58:_,-AL6K!
MEL\?-_8W;YDNLZ%$NJ+2.Q\?`U^@USO47@]<B;$,4]*RR^N.0G/1&?R?/]PX
M*<I655?WW:H>I7^YQ_X9V&<'34](_.R$A7ZY43]ST(L*^2?#"^E69EZT(^3%
M..E+.R\G?2EX,4_ZTL[+25]*R=%.^M+*RTE?.FV+CU$OV(S9NL%U(F>+G/((
MZWGDL!XXE%])7N/-T)]P06$_0;!`J9E>MT//:84K`>0+[A,1%W4JO[R4E)@$
M7I"NYWFI4$F4Q"/C.060(ERH3.C34^0^P8D)]N"_")S2C[-M*M[KWKNQ&[VX
M#G;H9\M,6:M4KZ[_XE9,T_0Z)N79L[A!*FM5:9N>1<YM_O`ZC*Y3J'.=IRG<
M^SB&B9'J0PBXGS)*7CS,(/@<SR6++.XC3["+P.,_AS^7463),$TN905J435/
MW^MOR_%;\,:=ON"F2AV(TB5-DTVQ:=KN@*2@9JW.V;%8URPHHLZQT#GZ)P-,
M)U\/<`Q><"1)D>71X9B\X.B6E6=_'@U-IW(]U=.04B0='P_-7MX/&[G/QL/`
MQSM!+/DF3`L/6Y^4,W#U@X'59;;3]-SB/LO623O.?GVB[3)['R[:+I-[B\LY
MF_(.B;9KK;8#1<LG3$-D6[('12CO?:9,7<#</!`6.IT@4[`@80_Z*9-P8,J^
MY414\AWZW9MS7I?/[R3Q,Q.R9ND&ATJ_*!\\5/H5^="A,M6//W"H;6ZQQD&C
M8[FK._".;/,VY=Z1O*HLPS4+%'HB]S#7MA=A9TI*GZE.EL1..AA-DLWMJ-\>
M($V%MHY;R6W:%$/7MN--CYBUCEO2G2I;DK8=@G&\I'6O0KZ5Q<;:B1@_8M(X
MI>/2),LPMH/(AJ"MRYU7\;J+.$Z7I,$K+YY!DI+K,+H+X^2%7,C?HS_0O@8_
MT=<BL7T+K.)-F"KS")[JAG3B)'=94JI)5E26W!#?%<E=5J`3R6PD=UJQJDG^
M7WO7UMPF#H7_BC8[?:MCK@9WMIU)V^U.=MI-IVFWCQT9BY@I!J\$2?WO]QP!
MCHG!@"WB),Z++T*7\WV2CJZ<8^C/)-<N.]MM#;:]X)2W:EW%*]-/G_`M.]+=
M"-?'7>S-'!7AN\SA[I)L9B2[SQSOM[=>TWC=!]1X=YF65Q6-1@T]W-1A?*YX
M"Z7B4G(O4C\<;KKL[A\;-UV.`XZ,FT[G!\?&3=.!@]R&/R9"NIQ1.$?.3=6A
MQ@'X4#5/*$KY-T:#LF&0++_4F1'K84\KLSW8UQ*U&ML#I%+%SI6DTC*/G4H5
M^U/9S<2^]ED?"Y5*=J$DE4X7:\9/DLI>]IH<S>EK]?@XB56UIS2R-HZLCHY8
ME=='*TC63T<E[X[/).][.[6:9-TZ^F%LKQVZD39Z8JWT/=H<9]'TGJ?YVJFF
MXK74ML@>'(V*IOC'3J.BZ?V1TZAJ:G_L-.YE"^.XJ5-Q-OE,X\Z3F\-0AY>_
M*RKZ&T@IOK`%#\1V#^.:/OC`)AEN8WS[6]5+TH[IXL78-F(6<.X:H,FBEEY^
MDG9/93H/8N7^@K-X]P-V^RNXA?O7_9!LMPKR+A;)EL1-[MK4\;#AL\1UQMN,
M@#0)7L#.^UWN'?A[D,P`Q37C23`)V3]QTM*W=&,+=1UME+^'UURD6N&J_"97
MV('>+/!K?![A_8.8"RP[HZ^#6:5&5O2Q8SB%P^;V9?<C;:-[:<,R='?<B[!=
M+60HJM&N1B`:W1^.'-<:5S;S^I)7)K]"ZF6F>J[@HTC]!?TERN2YJ9X+OY<.
MJENF;>;6X':6Y%Z@=.C.K>50W[7'[LATS8Y\5G:<_D`T.Y0W=&ULW2N(_C1!
M7R*TTPIVYZZUH2#RV/4J]\SS`/%J\JJF";A`LEW2:*T%J-;!2KJ7:;ICQS*J
M-.WNI3:288^@5-.J*[58DKQGPN.!G&==^.^9'T0X-T-W%Y,4`S_#)`W7*%%F
MK`ZO.7*6!%PV##0%UU(/OODZ8V0!\0EG_Z607A#=P*2">2GZ/R/0A)*9(+%/
MT.0;6EV`>3*A9)X=C.`#6]/(+$YY*98?<[*@H)B]8"&GDZ>W"Z[]T96YVLP`
MXN2S8OZ))MZL\,*R*D`:DNQ:HY4KR77WD;N+T@$07F]%.N*(\N5ZI,RE=-?.
ML;DR<%W7;HVI09K[Q65LQS6V#)6XL`L7WDW03R8-0VR@XCSZ/@L\7&@(4&*9
MD[]S\9DNT>_)MN6>X11+//.'X=[^ODPG`KHGY/WG-7RL%GYWPO/SLY*MR$L&
MG3#;SXBFERQ)PGSLX$S^R--L<\OZ;A8P'];"F4*`81FZ-]]88.+D:],M7*;G
M.I-4L%MZFC^3=EQ7\F\SH/G8**SQ%Y^;DFKFHF`M:Z$7/J@6T,)SG`V\C:-T
MZT[#8VYZF[R-;FFK(V/-3'(03V'.F8];3XJC-V?I%<A.=/LE0?5(DIB`JI0/
MB:EG@2O;RNL\K.OMOV@0?8R%N(A`*2YB$60#]YD0+!'M;AW?K:TM3K1V*,TL
M.WG=&`74EC:^U]*:1CBUI>4M7;<&?Z<1'CIJK4?7@6UKNKMVGW5[\6JK?,,]
M<Z]5OMT9],#2#>.>:*BJK[9BVK9E:FX'04'4WP8#\B&.DPA&>W+)Y-M49#!`
M%&$0_7SEY\\^PA_R2P8EH`Y?GX"PL)QCTY,\E,<AA,Z29/%J.+RYN3G]->'A
M:<ROA@#"'.+C(48\664=QEXI1_A/8>E89#CC"//W\X0!'45@2"<,V@!\_<@?
M##=$/>/E?"GWBN3PLT'./,;0IUXR*'(LDOL\GI<*+\J)7Y\4)/Z`3A5S&,5?
MG^BGVIIX'>":=7#-0\(U^X)KU<&U#@G7JH1K[P]W5`=W=$BXH[[@.G5PG4/"
M=?J"Z];!=0\)UZV$.]X?KJ[5JF;MH+I9ZPUQ_6!TV-&H>CA2@=BH16P<%+%1
MB1BG27M#KAV3](,.2GKUJ*0$LET+V3XH9+L:\D@!Y-JQ23_HX*17CTY*(->.
M3_I!!RB]>H2JA5QD5Y*.,Q&GW&-W(*[/5=LO5M8$GH>0570%BYYH\.TR.V.9
M4_Z3)>1:.BJ/?5C,X>$<$?*(,!!$OA9+((1&A,':CLNK5C*^W![Z8UC"L1\P
M6R$P$//GP.>,D0#%9B(A'"_PW5`!ZTT(F>,N.YDL@8*(9O?I2"KP?#F!Y%_1
MKU+*E^1M$(:$RB,D#(>,\!Z=/(&2,;*$4\A:*15C152\91Y-H<)0=KQ$1:,E
MF<9,$(A/9A1@T"G[+T5F$D[QHAF9!7CTN<0]N151)$A$_B#P:+B*>[UZ4>*E
M+.+V/\'N$G/)-QHZF>,Q<"W=:UFOL@B8R%LD[D5F1Q0(`,.#2"83=([U.TU%
M`@+C`2!G5ZI;I6XJJHM/M\C76B#BF!;GVLN`A5-D?L*(]B+O?>D"^A]6`)-W
M.&6_@V0T@4!R@^T3*W-!EZM\A#SFQ)SAFPG&)'V^=+2FEIN1>FYFY1XJ@2*4
M!8\G=)(U+F@7-%=2<7$M!+258;\@`V(!<XB?46]&H&USR*OHOQ'[E1`?N^^2
M42XJR"B'?(0_,A3A!*_P$_[^#U!+`P04````"`#`BS]$"I:?R6P+```(MP``
M%``<`&9I;"TR,#$S,#DS,%]C86PN>&UL550)``/H(^Q2Z"/L4G5X"P`!!"4.
M```$.0$``.U=67/C-A)^WZK]#R[E698UWB.>BI/2R/:4JQQ+97LV>4O!9$O"
MA@(4@+2M_?4+\+!U@`!XF`3E>4EF-.A&-[X&T`TTFC_]\K(,CIZ`<4S)>6]X
M?-([`N)1'Y/Y>>_;PU7_Q][1+S___6\_!9C\^8@X'`D"PL][BS!<?1X,GI^?
MCU\>67!,V7SPZ>3D=)`U["4M/[]PO-7Z^31K.QS\_NO-O;>`)>ICPD-$O#<J
MR49%-SP[.QO$_RJ:<OR9Q_0WU$-AK()1KJ/<%O)O_:Q97_[4'W[JGPZ/7[C?
MDV/`:`!W,#N*N_\<KE=PWN-XN0JDV/%O"P:S\]X,!X)\>'IR=GHBB7\84\)I
M@'T4@O\%!5+1^P5`R'M'DN>WN^M7P3WDA1%_`A)&##@FWK%'EP/9:I#/92"E
M\U#@14$\##="EBTIX24$XH.?R2GY5>LRM@GJ;?422!0HVQZ,M)-XJ&>(/\;C
M'?'^'*'50([2`(*09[_$X]8_&:;#_D/Z\Q\CSD6OXX@Q(6;608`>(8B[_2.G
MW:!A,<>(+T;$E_^[_"O"3R@08O!1.$:,K<6<^@\*(M"(;TF_B_>(;6N(F)=U
M(OZX!?:^V:<M!CQ:+F-N?1S",J.?,;K4#G':+RVE"&4^,+'NB&4GXD)(NI("
MH*!W]`QXO@C%/_6:QG#D>322PA)_$BZ`W8$'0H''`/@MA!8F:$?O/H:6BJ08
M?G()PRF#%<+^Y<L*"(=,`=M%Q(K:??RLU$C1.W4)O0N8@1#/O\)$[CACRE\%
M%H:G`<Y$Z#YF)@U2N/YAA&NPXPY\$`_!Z!HT[Q-4<5W:M=7<C4&YA#BUB4\9
M70$+UU-AD:%8^J03LEH:%Q`]F<.0Z`6WWJ(_W*IQ@]$C#G"(P6*&JAJWY9U.
MT5IZ8@)J\0N+P-\73OS;+26>M<-:G&6K$R(?NCQ'MKB"+BYM.]K<02!GT10Q
M.R.V(^\FLCG*N!BAW-(0,K'-H"E;=P0CI>PNAAUB4WH2>R@6<A9#QT38$:!,
M:EC''HV&B@P_B6%X@D([N9ZL(WCIE4C1^N=WGT_C\]DY>\U[>?6XI0Z8<)[M
M:BS6[&Q].(N]#ZGWYX(&8GRXC.S"M<8<5(U;.']-SK%B84RW'LK6K5IP_H`K
M#EGW97<Q;!C3Y9(2*SSVFW8$C'W!773]1[Z/$RFF"/O79(Q6.)0BY<=L>10=
MP257?A?#@`MX@H#&AV?W(9K#)0F!K1CF<`$S[.%0!)W1,HHCS8N(83+?I=`Z
MGM69=P3T.E0UAQS]C^H3;'A0(^(7\A#,I-_]W9+^KA:*6IW@AET''"XAR040
M,R`4DQ6(IP^@M%2=Q$NKD8N>1CUQ0]=@4K6T=C14^T@M>7]B1Q/:2MN9S"8K
M8'$/Y1,`<]@UD@F8TW?#QIWV3.9I@HMN+5*T;7PNH@#XG?!P2`3Z2^B]EJW.
MPMQAWIMVNV*;M[)^\TOB'7`00R"3$S?<S50W#2@&NFY`9%#"Q2WL*Q"A7"#O
M;/TE)IB'+#[R-B-FI.P&9D8UW(RA5PP\G`RKD'Q)68C_%_]5&QQKJ+J!EE8%
M%R_0OB),;BCG$W*!^8KR^)QF,DNRC8:ZZ64@[`9>)BW,MVAM'D`XYHA=$R$E
MR.&T<<4V6W]WQ@K:]?Y0U^".-;_ZU.'#=P`+A>AF7^O[PG)+"=T>9+/7IZ%I
MVKBOY8$W<(O@8J]EJX9M'/9=\]X3W\G(3V[U7,Y2$+O]Y8O4+L)\(:U\,KN`
M1]TN8$';+<@L%'(Q&GQ+>=IPW%Y_,ST.,M)V"T,+A2H=>WZ0309"*[]UIUUK
MGE)%)[LUZU8-<ZZ?M-G41;_U/3P3IY'1"%_I<5'IJY7-Q4.^,K\*Z'.QVQ0U
MAW>[0%%WU_QB)_N>,OJ$A0Y?UM\X^-?D==Z-/+%UF#)CBS!I?&)66,U;G(`%
M0=F;G=O:N+AB7HHY3=<`7X#`#,<7Z/<+Q.`+$LJ.Z5(N)J;SX0(\.@YH`4W=
M=-/?3L'%GP,H?P^03]YQB.V4=/%RYS"O#*HC:GF78)',V&0R\H:Y)9&_$#Y^
M5#EEL,314H.G!6W'(;70T/J=56N@)K5$A+YQ-1%K/'?)#@K*7>52%/_E$HH'
M?6!9RVIK=X+Y[YH6W+T85/P0BS$AXP4B<[@F5PBS^.6)%"$[B5--.7O2CL)D
MKV"*TH].;8LBG&*`Y%.%Y/_7)"LU\%8%;;O:@/9ZISBSCL)>1>74$,X<-X2T
MK%I6J4M97JV0,=@Q/#B#L%/[]2S#<:NPJ3%3:HG0,SPXJ[!3.[,*IXZXC,K4
ML&'D<#IT,\C9*H;N5#1S^7C_F@A'J^KQOI))XW4%T#H>XP<Z\OZ*,!.6$@KO
M4I:L,6Z\%K0N3B,->'NU",P:.IF9LR=W;C7#(O!JF!P:SAI5W<LS='FE?#T6
MJK)2*IFT4`#5`_#YE;`_>1HB9)W,KCF/7LL*Z^:2!;&+<T@#GZ)@JE%%%^]1
M[T30M$YGSV:5-@V:^20=QS!?,?M5KZ4IF5G:9+9=0$@LWLD/(`M+R%\LIVD1
MAAV'O:S:+MZEJG7Y#3$F=G+;)5I%>)`8OZGG7!U\)[P:]5=7IL`P]7=C;(UM
M%6/30HI7"SEL;4VE,I`JTL.LE771YVGG6.,`$5<JZV("63OAV0$BKE2VG6(X
MV2$%VCB?N(`0X:!8WK:.S[ME;^LZ;=YE?*=/F[B@Q%>F3]PV$;8ZD6V@L?YR
M2ZJ0BQOR9N5&BS36,L>Y]771.8NH3_6:CT&4"5"*C-=,(@/4A:@[@V(AK<P[
ML>YTOO16+`_+WB[8=[_[4&93MN/X;MNS7?>-E\U\S^^)-/J<XS&\)CQDD;3:
M*^2!6'\BPP<V\DC:];2M(-E_JI&GC(N;\[:TWPA*]@JQF:2IZ]:P*6D[CY]2
MJR9VRJRW-)GE@2HS8C5GOV68=`BN,NK9;Z`5<-LRGST)DS=ZPDD+$G6Y$.`*
MD-RD\C"LP+!K>%90M>;W4A;8[CSWR5\O[4D[C5>>4O6^>;(`9LJ$NX=7*$@V
MWE0O:4$;G_RPPLF24Z=AL]31^LU3K;%'\E#]`;V4"S04Y.\652CZ:MR72^ZT
MA0Q)!I_XPT["O-:;LZ!NWCW=$>KU&DI&S6.QLZ]GE#TCYNN.`0MQ:74R%X`P
M[V/P5DJZ&8H8==\L9B!"]ZS@@;K:@<S+JF;O);H[&.NI931<O"VTT#1^4U3-
M=%(6!VP.J8;.%8US<!\VE1I4-7=P6M3B/#@S&31W*E;:=&(+E8<AR5@'`7V6
M>7%%0%11=Q=$E3;5'CS4&-8,*\8UPR8#FV'3*^JK".GL2WT/C2WG4K3PSC,1
MY`X\*@+M(+F?S9%O%%Z!+[_@(3-$(R'2^HT>A?JJT+7VT^HT-\"M>!!:I^HN
M+NPY*MY2.:$C+S[]2=4L%0S5Q/\`K*:HRBZ&.#FJ9;55JGD)=3`_`#LII*^+
MCTD*V+]E)<;2'`_`',Q*NO@]IQQEDIHJ_G\CGGR_M#CF^QP.`.-]I:ROMMH[
M_&C<5[^<S4"FC\.66Y5\_S;"9+[Y.=-<LRK"I/'BQ$K9MDVEO!]?"_=6)UMQ
M`]@K:%S'&+CHQMLH5IM/_QZ=?0##.H0`P$;/>J*!VGOZ`!;6^="A[#2RC"/J
M8?\!#*F;08>-9@4BD'+L/H!UU!RNE+[LR/)ORR1P[=*^VR7';D?5\A$S;K(8
MQ9LL.ZF&NXTJYD!NL_L-AXO=S$`K.=2$K4R7_)'<S&:T$;_>6,!B^!]H\GJ>
M,BXEBG,H)V+.,C&[K6#0,^@,''HUZG6=B\-B3@>V)^\J)*HDWYJ<324@TP!Y
M<>F;T5S\)Q/M-<?_K7R/Y>I5@9_#D%70JEZ7KQJ&-NM>66:'@)YZ/7S/EQ(%
M#,NT-I9C=0BPE7L847D3R]]2TZKG%UB6<R$&A[,`&X?!*JZ,^0,OFNAG(`5X
M1!S$7_X/4$L#!!0````(`,"+/T1]A@BLX4,``(VG!``4`!P`9FEL+3(P,3,P
M.3,P7V1E9BYX;6Q55`D``^@C[%+H(^Q2=7@+``$$)0X```0Y`0``[7U;<^,V
MMN[[J3K_(=7[N=.19'<F4SMGEWS+>+:[Y;+=D[.?4#0)29A0I,*+;>77;X`7
MB9)P)0$"=.LE<=L`N+[UX;JPL-9__M?;*OSA!28IBJ-?/XQ^_.G##S#RXP!%
MBU\_?'NZ^?BW#S_\U__[O__G/T,4_?'LI?`'7"%*?_VPS++UWS]]>GU]_?'M
M.0E_C)/%I_%//TT^U04_E"7__I:BO=*OD[KLZ-/__W+WZ"_ARON(HC3S(G]7
MBS1#JS?ZY9=?/A5_Q453]/>TJ'\7^UY60!#*]0.S!/G7Q[K81_*KCZ/QQ\GH
MQ[<TV,J%RP39]C/-!LX_E7_\\`/1EY?X21S"!SC_H?KQV\/M<3T499\"M/I4
ME?GDA2'^%!'B[]EF#7_]D*+5.H3U[Y8)G#,QU@(0T<^)T/]!6OO401K\,XQ(
MU_@8P+F7AYE&V8[;UB1IO/)09$;0LNE.<A9-?%S!U3-,=`JYUVX7"9=8F,3/
MG^''+7"-<M):[R)M%&=3K4.F:K"0J19(U/@<A;B!T>2G7R8_%8U<QE$:ARCP
M,AA<>"&9V!Z7$&;IAQ\.D?F>G^7I"XRR/($IBOP?_7CUJ<#&;L60=&LOP7(L
M889\+]0CZGZ3^N3&JT4&<0?*XKF_]*(%D2?-8O^/91P&>#F#?^8HV^"9!?DH
M:PU%[2O=T#W6WTIG\TLO7=Z$\:M:?Z&WT%7GJQ7*BD:]*,"ZR?#.`.\0$$R?
MO.<0JO9H46O=I+TN^&@AV%[%;C)<P=1/T)KL1N+Y18Z_`U."]C%?K;QD$\\?
MT2)"N,=X43;U_3@OE'"/NQQ1PQ7,/!2J":_GBPZ@'O4/>]01]P,,R42!I[EL
MDR5>E&)YL4!!V7H&W[)<<2J5:[&;U/=)C)?A;(.U17K^FHS(-CV/UTXW";_&
M&;SW-F1`3HN9`I]1,H3_1?[0:I3(M=B#U$\M.H52PUU'<H)>\&'JI?6P/*ZO
M6Z(V*F2W8FR%;---)9K3)N^4_H$VVI5OM2?IU3JM0K,Z=BA!BXZQ7U.C%&T6
M*6H#7?>_>%\]*Y;S>WR`:#-V&$V8D*O-&.&WU$W*W[T$[Q6R=E/V466MLK11
M%:.)CDSFS^3$AK\'R4=;3<^L-@K)R$$P0H3?.RS&GH`8`,1[N*`6D336S090
M&&5C?^\K(3&#Q@G5]%&8/>9>^ES8/O+TX\+SUI^(@C[!,$OKWQ0J^_C3J+)[
M_D?U:[`]7&)H\!;_F-9?";UG&!;?!NS"X*<//WRR)7)QKI,1MR@(1I6H.SJG
MR;[07N+7S56&*"7+[CR)5S(*JSX9BZ2-DP`FOW[`-?(42Q(74PP9<3^4UJV_
M^WA!PSWP.BSJX>$"%^2'#]N_AW$*@U\_9$D.+?)T&7II.IL7\^3T#4GUL,,Z
M8&R$/8Y5E,/FEB$!DS00;%+[YJ<IW=6>=9U"S'%A,#'"",OBSZ&#IF8Z,W04
M[X@2<%5?Z)BE9O_:R!@W.SA,CGJ?U?!Y$Z;3>]PD3!(8%/)^V;OWH<UK[%K@
MS`Q9M!NI8Z+H(X(QK_%!N#.,2D$O6G%$K07.A\41$T3%T<@9DBY;D42M!3X/
MBR0FB(JD<2>2CHY)^!?UAY]>8TFUBRN!GUW7NAR&2ND3<TK'16`+M;.J@;\-
M2?$\%)7JSXRI_B;.$W7-LVJ!7P:D>!Z(2N_GSBP&5ZT6`VHM,/K)=99D450T
M?7:&INM6-%%K@9$9JXPQFM@H*II^=H"F:9K"+)T^IUGB^1F'F?V"8&3&R"))
MAHJQC"*X0UO;4KK+/"%.4M(T')0'(T,&%CDV*!KF44$3WIT#(7&;(A>`^'_D
MBNO%"XLKP>S22Y(-BA;_\L*<9TF6J@]&5D_R;!X8]A9I3.[P6/G[D,O<6;:$
MR0/T(9:<N'=]A5F%G3?09.J#D=73OBJ/\I@<FB'Q*KKV4'#]MH91"FO1]Z!S
M:)2H#496K0&J),HBTF(:T$/A5;4/ND$1N;Z\C-.MJ+C?<=CC5P0CJP8%5>(D
MP&BQ+!C8F,AN2,#(JJ5!>3X\DEV+?4'7O%=Z5A)'D6S:<*_D#QE>-3"R:H^0
MWB<*,3BT/)6@A`,$C*T:&12WZ(6T#BT@=\A[1B%6&B1[E\?&^XO2#4WBX"3;
M!!A;-3.HG&R5(+G)IOS!EUT)C*W:(I18$!))P^;>H6KGB(Y_D^0PH""(@J]Q
MY$N?LU2;!&.K-@\!9?SS5RNLSO:"ZKG*O9<TY)=GG%H=C*T:2'2PR\;ET.ZE
M>#Q2"2QFCE(:C*U:0%H1Q8+AT!)Y^+Y'FB)^13"V:NIHQ98$(H>.S;LW1L=@
MN88.=C4PMFKF:$6:$(]#!VTEHFAPK-H\6M'#0.'0+7]#0CDVP-BJ;:,K#87X
M#EW?<Y[#<5<?9BTPL6H`T7!*$X%S:%O7RD+"4<K$JDU$`W<";`[M_/:=1D2W
MS9328&+9-8.K:>:=%A6&.V=>,OCC2(J3PZ)@8M52T8H0*@:')KAI$*#RX_<>
M"FZC2V^-,B_DL,*H`296#0VMR.%!<6@FNX(O,(R+>YO'S%O`ZRB#R3I!*;PJ
MPR5-?3]?Y865Y"I/\&)Z6(-[8.K:.)A8M5RT8EX3:H?.R\=J4-JA@(E5@T8K
M$ADHW#P14S=<':[9P,058X:&RQHV0M$(^[0?**#OT`'[,?E.<01.<01.<01.
M<00&\&C]%$?`.4I.<01.<01.<01.<01.<03<)^D41^`41^`41^`41^`41^`4
M1^`41V`@-`TBCL"^C/=>,DN*`UE07!_>P^1QZ27R-]FL!@84=T`!D$-;Y'VI
M"Q'3:9XMXP3]M3-`"_D[K&@Y0D%[WJA`'+IDI4E[FZ:Y,E=E)<N!";KRU`#A
MT!TG3=)9GI%T=R3+GB)1C9J6PP]T9>L0B4,WH`W_EQ9KF41MRT$'5*B31>/0
MWKXALL(2QJEE.=1`2[JH*!S:VQ^)*ERY&#4LQQWH1$\#@4/[^2,QY18L7C7+
MT0<ZD70(HV+J;^[X=Z@E*CRY?)Q</MZ9RT?I?85'[CJ.BC<:DFX?M'J#=/U@
M`7'GDO1`0J&[`;6\.TX@+(73>6*">7?\..<1HH4H!QU#'DCJJ0@&UUX2X9U)
M*C2+TRO8=0=AC@LZ.VP([HPC_0X[5NT\B@P)<#AD[-;OM&/5J-.*)R8.AXS<
M^OUVK%IS6O'$Q&'>BT2GZXY5.XVDXN5@&'<AT>Z]8]7\TD+W/"!:C,T].O#8
M]0U15SX7B$,F9`->/%;=0UJM#6P@#EF4#3CR6/4%:<44&XC(HFS']B_DYZBL
M94\/15;HXE=<_.(`%XRW_D)>N/4L>WDH<B2&LCU2ND!8XP5^>=E"?X@O9E"I
M(<NN(*J4JF.K.7;";M`Q:,%P?#\8PKMDPU&XG:;<Y0[&K8,NNTM&&M)52F>&
M<C#?XQU/7/H)?86OQ5_X%W(2]0?DZ"&/QR%718;09>?KP.)!`P-R!5$`Y)#_
MXGT2^Q`&Z0W&3B0DH3]F\\9NET.AL*[E7!9J;J<R6,P9DX3?+_L1PZ@D67L`
M*2M4T;AD8>+,X^6O;^($G^Y?D-]Z?3MJQW)."UWK'!V72T8IWNRN@5U&0Y:3
M5VA;_^C`M)BRJ--I&0N>>'_,YLU@\+M,&K<D(AY,LZ=X%[R2,;NV:\QR9@K9
MR;8#."W6+SWT<5?'EJU9SEAAC,`&.CWV,/KM6&/<3[,'2&2$7V"R@`EOK(FJ
M64Y,(4N*%`P]EBI5[7.'BK">Y1P3&O3?P%$3X()59!K\.T_+H/%/,<.278A^
MX:4P(`94&*4>*50,ZEDA>?I`O/=3E,%JG2W7X`?HQXN2*^Y-0"\26$Z#H901
MOD>-U'W1@'N.#(S?O23QHJQ*%LR8'=0;LIQL0W:Z:`FLYLR`:X^,1#<>*E>3
MV7R71J<2DS7!=V[7<GH.G8R*<=8$&S#X-#[^A#^8SF%"[!UUT.!-$?X#S9%?
MS"=/<75QMO=;!L<ZFK:<R4.69FU0:Z:[&9*H3#_`#"5[?6PK'H-`3@WK23OD
M>!$AJ-7M@FE'9JIHY):[@L_9[RA;[LY=-]`C3RX[;JUD/F$]0XC>O9,TY+J[
MN.#T]!5FMY$?K^!=G/(,?7OEK&</D2?N6.Y:^TQ#3S^/F+<@TMG\TDN7-V'\
MFIX>*)\>*+^3!\IXX)%N?9_$+P@/CXO-MY38[F9KF'@D@]S4Q^MHF4Y"G*--
MO3%#3YG-S%`ML#GDBM1R";')3SN=2ZTP+CW(W-NU$!--Y*,0[@G\%.L;I28^
M9_>1KLY^8DH[#LT$UZMU&&\@O(`19JO(%THW*'(ZD70;=A\'FV*3WG>4E.+.
M_',%UPGT42$9_CF$!4E1,%W%^)STEZ@KR%2W^_2XWUX@JP^'9H3?L!:)%F;1
M%4K7<5H0-)M/TQ1FZ8C#/;^BW8?,_;(NUH1#WM#-KDCL9<\9%MJ/\RB[3^`*
MY2O>]D%4U^XKZGY9EU*&0Q[4^_+>H,C#ZHD6EW%*O;R1J6;WX;9-NH_UX)"/
M-9F/4@(?XBGI^HT@S5&Z))HJ.ZI@5N?6M?Q@O/^97:P-<U[:Y/NSZ+((FW@;
M4>\/61>O,E4M/RGOATLE93CDWHV5D$"/)%`N_]^$7>PL),[[TFU8?K+>[ZA6
MTXI#3N''@D_]8L>18IU!W)&?0_@`B]>K]UY"E*'4-T2-67Y!KT:;+/52H-TY
ML!\#P+O-M8?(<^4B?$/E+X0/G;-L"9-2,TK=0*9!RP_US70%:>`.'=\YFFCF
M`^^T5%`:LORJWYGU@J4:AX*FL*>\(\?]!II6"P>O0<NQ!5IPJ+J""-&[O(H<
M@-"PBZ"V9#FN07^]@`+;H55#_M9,RY6_Y>`(FN^254`[9/AE2'X;X;.O+G</
M3F,#BJS0$IQ#7.-)J/:$]/_,48+GI\R+%L3Q47@@$-:U'&6A)3MTJN7`NK-P
M'\F+U8"GGFQS'WI1AK<>Q.%\73F923/,;,1R``>S5/-1N[]:4]2@9<:V'.)!
M*^F*J!V:PAF2;R^>="S7G,8&%`BB)3B'KF:;`6C(K1)&-)O7D6A$%[3BRI8C
M0[3DAS&+RZ%U9\5^@.MJX=D/E\!AE%7%<H`(K3QR,3JT]M)C0^T'2\9[A_(7
M$/^Q71`S48.6PU`8&\**&G!H?::CX+R&EJMH.=Y%#T3O(75H$9:'KF6C93DL
MA5:B%5$[Y"I%Q,9S#?D?.?Z]>"%9DLJ(&8<V7@[M*LT,($1%:UC.,SO%'35)
M-KA/LH)"*=4?0'`*=3SFW-F*2<)#)"X?Y]#**#F0"!$LR9WR+"OCLQ$QN5=[
MNV*6PD#P%,JZF#L0VIV38.F;\.2]D<..0/-[)2U%86BC_&.Y'3K+U8_XO\:1
MCW_<&0&C@+)5(=[\89SF"90PL'5M>D#Q&K1`=<BIDEB1;B,L6TX4T`@14C[E
M\U$=-T0N]$J;YL#$JF%'"Z/TSM):&SJF;5$<K/HD6H9M)-%@&(\CI.J!B543
MC0$2Y6%KF>35Z6+9VN0J@HE54XL-PG:XM5C2U!A[BN]#SR^6F>F"?D.M5!],
MK%I0^N:/"M]<CEV5,,_\]!T=6@,3J[820Q1W48:YY+ZN!X@\LVIJ,3_:NVE&
M9+3I)V0:Z:VH],OWH@#W<Z(BB)4#TR)JED+X-&H?_8)P&UD<P=J99_N++S!;
MQL$=)TB:4GVUN&FM9&5%1Y.NVV?`-&7E'7=U:4P##ZO6\/S>%&,:#Q<,(+W8
M-/\R?4.\>R3Y1@R%45OBFHF?/\./^+<P2AN3NUJOV-+*\@-0`>J.,:\I79E4
M5)+-7092$XM9S=7'8$^FX_5,3>]B[G:PWA%'X`K.O3S,3'-5?Z5OLG;XF*1U
M#2O__!QGV06*R0M*;PWS#/GI99RLF5F&)6K9C3A'[_7'ZYT$"&-&+OR).$%>
M^!C&7O3?,,.G"1*KA#A@))>0'"ZX^I>M;C?`FRP1*FC,&;*DULDGO*VY"-G'
M:+5&[$1>ZVNKN`=3Q%L_QY_R=*9ZTM&8;OHHVN"46)`6Q3[Y8K,K4NEU^NHE
MW#.3OL:M!*+VES#(0WRV%LJ?L@`(8UCK^H:5\-=::*7O-[0J9N!'PA(,_HK@
MU+=7SN;!S@B)]'YRA-F=\T-[S#M044">EWWU5E!X`C'Q.>OGS"-Z&;.%(>RG
MSJ15H:X<B*WV*JVG9KUAO1MI`)D'/&$=N\=K4S,!O8=PE>#.Y%'=!`LYW2MG
M]W3>+X]'P!UR.Q1MHIJY.ZLKQ(W0&J"O<;OQV6T>0>1TXX9IX0JF?H**3\?S
MBQS_$:;DCO4Q7ZV\9!//']$B*JZ$L7[*4$0H6MS'(2*7KU<P\U#8NTUB>[M=
M!>6+FB&QOD"/7)`'L^@!^GF2E)?I7^,HJ?^)"4.IC'E"ZW=L6"IT`!!9*K1]
MPX:E0CO#]!E#JXX&;K38ZN)BL_WQ'P@FF*_EY@Z^P%!@S9!KP`4SAU;:!3U+
MJ`QW=IU;02L5%+NV8^F%9U&E=JQ;+.29$C`MB_:[)]P5JT+/S#MH1]@*>QNM
M\RPM,(^$ITY.+;NV!.6A*."5CL_!\=L0=-R*OK$+)@2#](V=M!30))VTXJ^J
M9?=L;Y"_!CYS+UFJLW6=R8N^+9QF.Q_NPQWBP]X.4?#DW=#7["9B,WQN,ZPW
MAZ:&7:(:N2#MU/)VTK,9)HD^:3#Q"U;K`5GS1AT?4S2$F&V%F&Z%F/&%X-GE
M-+:NX2%&-TEXSS0TM-SW(PZ-M!Q/Q9KTX83A+(7^CXOX!<\'J)RE\0^'DS/^
M%;B#"R^\QD"8;SHHI6P_VM!$U'X/8.#4?3R2)::4@FFK."QBS>[$4-NQ;@^E
M'8QB;=MW6FJXA]<1/AY6*%_Q'T/L%;)C4*%UO^/I_UA2=TPCS&#O%QL)QTR)
MVH9,)7:G=$7\#IV7F!(3>84&;(G:IDPKTO<4DIPH$KH/<`#C5Q^?MI>I_HAU
M\.;AB^<O\925;)HR"TV?G%IV[5Z2XXO.H0"5.X/R)D^P9DF4"Q(%XZVP<XC-
MU<Q*=LQ36BCC@W)H79SB93]`84XL8X_$IE88QJ[?_#`/8$!BCQ`/N3RK\MQ?
M>QA7M"`Q?TL?N@V]`='#%G-?!68B!+FQ[S*L-X?"Z=,%E7KJ(*H*1H8B!\D_
M@C%+HTK?.5"+.VN)V0[@RM[.U9[@X(Y0[YN6D=7@X5)CD4X>'Y([X[?=$Y61
MU51S'6@YAN'0)J\19W<_K8Z0'4%-,+*:%:X#7S+`'-H.-<1M1HA4X>^X'AA9
M]<;3PQX#EKE`J/4#H2BHX[%RS?6LXD4R\4$I7XC&I6PONS"I$F/DH"P86763
MZS0N:%"T)'#1]/8Q?T[AGSF,LNN7RI0B,!4P:H"1&7N>&^=\'FB'4J11Q!0'
M(F#5`2-#YC[I8SE/Z](\-<"XLQG7390KQV>]C#EXZ#T05[B64<L7^;`M/NGF
M#A(IFAHXC,5([#BAP[<L]T*!3[?6;X"QE0CHKGL-4I1D+HKC/=XLX/[I+>!L
M/GN-8)(NT7H7K?\"3OT_<Y1`6G8OI?I@;,5@98:/8\[5]&!L#FCLGXL$M7B3
M=AOAPV:*\`<+&^Q-G)11'6OA"L'2@@\&Q]T:!6,K)K&^B->@''.CNR%<86ZO
M,J_<1M=O_I($))G-2]%VQ[3;:->5Q?VA3:M%WMWOHD.TUHY3AKLMG'LOF25%
M9KV@>--27^+(F298M<'8BA&OC^Z@J@6'3L9,YY'K-$,K(OZW%,[S\`Z]<)]M
M*;4#QE9,BGUV!75].&24W.IEMX#MKVS57#=+ZJ7P:TY47L6KJO[*Z2UZ/@#&
MUN*$]]6--"K*(>-J1V>"Z8KHTYS75MD^&%MQQ.RS=^G3DY8DX<*#:]FGZ_T5
MWFH5OZC_C:?<1>*M5JSM;(N6P-C:P^.^#[,J&M&2!)G*-F6^VY_0M@(R2)9O
M`(RM&!O[XE91$16E?[/[O+S*C+(FF5&R7;Z@H'PWGI7`^PX&R4ABM#4.<A8B
M456[R27DLC/))Y)0:,]&*$89,AA&_K80G7@0?LH(V"IQA"+5])YSRA)XRA+H
M+$>N7(X/-TM@7^GJ!I$W4`6-L8NQ_8_?1FF&LCS#TWDIQP-,(8:_Y-*BU,8P
M4@DJ0S*83U#8371PJ/DK=N,1ZAN!RJ#-!2E\P#M;<MK]XOWE19#M,<0L:_>A
MM"PG3-'-.7[?>2@(O==I5"2-\*(-5[>,TG;?-,MJER.\EOL4JG[_Z:U@FEYZ
M:Y1YX6])G/.3`K.*&WH`K%G#/.FU7"E05?Q;[BWPA(4PL=,TC7V$9>4_7^#4
M,/:.5J^F10C,V=BGBP06!@C&4?ZHC*E7B3:.ZG1PYO8_VV\QSVR44L;>&PI/
MU'3U<%38$-C8+K^M#FV?>-LKT_Q9]A(70+X7/I$=Y%8`[IS+JV+IQ26K*Q[K
M6"B\L=Y[AWS<4>`5B0<>%TXAY?YEA><^+`OZJTPE)D5!J[8LO:>4YZ8]*I,^
MEE&*!R`^-CW"Y`4+F$H.$E$]2P\L%4:*%`)S)\7K:.&5.?7D-,XL;^F]I+RF
M^9*;.S$V-DU?O$A)V3)53;V!U*9W:1#F#I6L/:S<>QW)VL:>+JJ?A.1N8%6Q
MF9O^:^>)>[STD'0@#"(.BUEZTJ:JMV.M4X&8V]`7KF3W'@J^1?@3VZ%W&_T/
M])*GU_AI&><DT<!UB/<$S`V_6BL6WZ5UXZ8-3H,'6EEIGEYA^,+RSE-LQ>(S
MLYZX:^`TM[62EV:)D@QV'WEU.Q9?B_7%7Q.IN:W;%PPW@Q&YOKF!D'@1UI<X
M5=)IUDHEKFCQ`5<WCB2AF=O,L3J)XNBQ^&3*S"!IOGXR<&LP#0)4ME4*<)5#
M.?V+ZEE\L-21""EDYFX6]CR=+^.HE.8F3IY@LD)1];``__L9#T\R7N]A@F*6
M<W?+UBR^$^K&7A>\YGST&Q^_\HCO0$,`T4B3JFOQY4TWON31B=SM.^P'L,)6
M^>HK?"T?BMT@L@ZB:/$5P@"6\S&C*\D.0YV?L/C"IN,>0[<2JB[QBP'3Q;Z,
M\,%#*0PN-I7+!,N2P:]E\?E,1\.&!*[M85D_&9C\!<*'\G(]GLUGSR%:%-V"
MM5'GU`"3@5HP1)AJ`@R8*^JC`#X5-.Z7[A.XKLX&I4P/T(=8PF#?AX!I?NW0
M)I@,U)31'75-LPL!,*J'=FDI+O$5:8B+8'J9)PE]8Z/8`I@,T/31!F/-K@&K
MQ^Z`^11?>^1<7UBIA>?KO=)@,E#[!@]/K70#5HW'#(O[;7T#(9Z^]]PG&'IG
M5P"3@5HV!)!J[1LP;E1?QB?XRS@MR"=G#+[F#PJ#R4#-&!PXM<9-&R_*1].%
MZ'-8[.9EC!3'M<#D/1@C&+AJ,KI9'?2LY[/Y'/DP2<F^'F*L&:(&ON,5!Y,!
M&B*$@&J2#!@?RJCKUV_$32N%]PDBQZN(&6".51Q,!FH4X`*J]=[MA*\I`9Z'
MDB(NV31-\U49*__Z;0U]C)TQM\E6!9,!&@:4P&VO8XWE;*B/3$_Q?8X/6%X*
M&Z'EN(.)7Q6<#=1>(`VNYL:`X6!O`=R=?]+9_#[T_,IE#/\';PQK/TF9+8)<
M2^!LH$:"MEAK(@TX/>R)5*<':8AVL=F*)D,@OP5P-L#3?AN,-6$&3ONEE7PV
MKQ?6G3P,?M@5P-E`S_P"2+7V#1S[]Z*$%3&HRH!P^`S,5C^K!C@;Z,%?A*DF
MP,#)OZ0>^:71H;IHP@('+RB-DXU@L9&L#<X&:AM0P5>39-I8L'.[V$V8C?FR
M6/!DEA:9=L#9>S`H2".M*33@V-`,WUQM+R\V_XC#`$6+[73+H$VJ+C@;H#U!
M#5U-CP'C0F.@[ZZ4=L\U;A#3)"=1$YP-U.0@BZTFQH!_07-IO,G#<'-%8LK"
MH`H:4'2;ZS\QE*=8?(QMUQ@X&Z#1H2/<K4^Q":?B-^+<LKV=S_%_[O%W84:,
M(5'*W&R(*X+S@9H@)*'5K)C)X5,,]5J$!_8N@E84G`_4A,`$4^O:Z,.(PM:4
MYGB!NX-XW9/WY695!.<#M0A(0JM981H"^HDE7&=@\!K)%Z[*0,)]1Q!F)H.X
MDX@A+*YL-XHP4S[YP,'\)FS$"I93.OT.0077P`,$,P%>;)XVPHRY$K7="@DL
MYI/>(R2!NA-:E@UT(Y&05:*V]0#!DI0H\KD/\+OBTW9HI?Z(=3#[;NGKL956
MF'V76MYNE&'),47GC8G'G2%XDR=8IWB7BK'=H+=BORKDB5W);MCA3F3Q06F)
M4V!XUOP*Z]F$'95%O1&[,8:[['C5,`Z!X3HYWYQW@)&H;3=&L1HOBMSN@W1G
MHF4*_%L2IZV.(T5%N_&0C3*YQ>?0R)SZ?K[*"VO5%5PGD$3#Q;+@GT-8Z#X*
MIJLXR:I0@$QL'+YU?<)N'&<=/4.G)LS%JKG#O7067:%T'9?YS'8'<@'C"K4M
MQXKNPJ8JRB%D(<:P6^ZM3(6H=F'"KN&)`MCT8VC_&F?PWML0$U@1I35ZP4(C
MDHH6_R&U9'+?&>V>$B\H0I?6^4VQD+-L"9/J#],TA5DJ8XEOW:9=`[V<L/+6
M>H7V;)CN.[$DLN@K8A^X>?^+]^\X(7-5.IM?P>=Z#LHV#?Q\$[]D"VZ9^15)
MIO<9!>3NG)TDA!9:BZ7;L'X'H$!1:XY=O`WHF657;@;ZI-M\NH9'&*$X><R?
M\0=(7"$2<B@E<L#F%@QO(5<H)7[0Q6:,G_:N?8MVKPZ4AN'QF:DC;G.I#.ML
MX&PI!%'!%5JP>Y^@<<_6`K=#9B_2?4E6OB0OG'<]'Y9.5YR9F%7%SG5""_73
M)UL>+'>6TGTIOT5>:2:#P15*?27B*'7M7!X88I"!SUQ8\OHKE<_C4[Q]VTU6
MB02]>!EZ@8*'A&J-V+DCZ$Q8.Z#F#+W['>=(L@L88?62-UXEV+1XA><1PQ2+
MQ=8-VK'MZV&T$VAS`<OWY6K>*^">QIXU9:M:,N`;H(R#SUSD\GT1[A,4^6A=
M1X^N<)'N(W[(TZ(E2S9[`]S)P]42#5W/9N;0=%\9]<6!#_D5C>6N[&D?(X%.
M%$#=H8N8ZJG'Z3[&<06<[F-.]S&'?4@NS['@2D:^D7=X*Z,&WAT[PW$.<4F&
M';EJ4=.[F#L7KU4Z<^3*18DILLQ?BNS'"^'>=M"*VKW&H/?OXY,&2W)C%Q'[
MT22X6J45M7NU(*M5EN0&,XIRM^MR>5^5VK#[P$#S'8\R<I.9P8^BXUSE\"F^
M3<D3>5\<KDZ^`7M7`LKZ/J9,#:;NA3V%_H^+^`5C?X%I5B[KY<^'"WKY6W!;
M_(_,"+58>X%]*5S*5;1W2]"10WEXVF]4M9"W1LDV-Y<:>\V:]JX$S-%WB$_+
MW8Y[-^+VK@8Z4B>%S"%_?K/7XO9N"8S0R()H-#WM[C%/%5>6(&!L3UC%+1KV
M->Q&N*A$MS+]&/1W%^^U]7[4M]U^)X*,19Y2VH:M?2>&R(I^4-*&?9RA,];,
M<23OT&W:)#^&R&1=EW'!(DVA@&$":TKMD)F2B"6,/-$H9=]XW%0D1]<[<0>M
M;6?,P(IJ=S`N3A6S4ZC_O7*6K<#[/9FN]R-YW>GP55YDL<J;Y2R;B*54?BBO
M.7OBUFN%ZX,YBRZ\%*6S.2E1[&*_Q`$4&8RUM&W7D"RU8=**U1S57[SD#YA5
MLC7LH[/H"_12?"`H?#?9>1ZEZSO@2]Z5!=J=C0)Z=Z9(>I(QOFE9NJX#/NAZ
MB59"[M!3'IJ\#RC]XR:!\!:?R/!A/WN@CVS5)ASP4N^/<Y8"'+)9F\RNZ(![
M>Y_C^P"Y0S9NGKS_BD,,/439IL4(IS?B@F]\_\13=*#%+&Z^"URA%Q3`*.C0
M`9I-N.!$WS_]1QIPZ+7$5N[;:)UGZ7T2/WO/15<EZMFSK?!X9]<&(VNI"ONB
M7`!>]*RB_;FK./+/YLWL.]=O*,V(6U*1VGPVG^/=14!A4*4Z&%G+=FCPV*6$
MON+00+HVRL11?!B+P3I%R50#(VN)$`UR)H6ZXHJ9N\W6K:>E-TL[07:7]>EO
MF$0295'M.I37@-T;4HID%YM_P&"!>T;A.TO6XR5:7VQN(TP1?,SP6ES$A2;2
MX3]>;&B-D5.:_.6K:2'LWNN*R!==]?:AG8'?(F\A7X9>BJ?&P@PHN%5FUG'K
MEKD/]ND]D*L@=\RI3>F$[VZ."UN_WN:JF<X,'<4[HL25.W!-W#AX-?Z(YP28
M7M_C)F&"-^N%O,);6TXMN]?F]!'!F-?X((R]HVIX#DD][F&6MWM=WG9C(X3D
MYJL!+4\^K,5BXRI\GQ]Y*((1TL\QD=SWHD+.U"M<@(G]`48^LA9S_"Z.%N2F
MHG[<M)-0YK`H4=O&29$MENAX)ZAIXTPFJ6/ZLB&!9^"GJ.\POH0$J?3><(HD
M<8HDX2Q'KAR?AAM)8OK\'&?9!8K)NW1O#?,,^>EEG*RYX0\$M8817T("A+E0
M$W`5)\@+'\/8B_X;9EEQ0W%)7H<GEY!X_/##3TA6'TA("@4T#CF^L9?4B\TE
M!KZ(R147V6S5)0+!EJ)EBX9.7?WL+SI@'D1?8&`0+G<M6S3E_RR];^G`IVH'
M$2K"G9V.0_W#E3V3.QVEAWA=Y'LW*$FS2UP4^5[X1!:\V?P.^5A?>(U,XB#W
M!9&\E!JQF\>UPZ`]WA^H`S>V;RM$>81^'`5=F91OQ6[B5?U4JB$W]RBI$.9I
MB9+.7$HW8CGMJGXNU9";RZ6`CW%AO"!"5%^?KM<A*AT#N/R)*UK.L*J5,TFT
MYK(BE-,XAD"N6O"1SPO9K\:YY2TYBAMAA0_28'R<.3Y;%Q__"C/R57[B-%9Q
M2P[<1JC@8M3BE4^/D0E?KY)\(3MIL8I;\L,VP@07HT&/>>A#M,YF\P>X(*GB
ML=!8A"1^\<(;#/C;XTW@<;F1;\"2![81MA11F_.6_X+PF,WBB(3-*H('\WU/
M6,7!R.K;_U87N$(\YK;2;'FW`J651`PB%%H`(VN/_+GJ/69#%91K#B=3NL.)
M\CL%9CAAQG?N.'XDLE75G$A4)60YA<A4Z],C1$5;Q_U7!LG`?4&>4$9B==]&
M`7F#21S'^'<TU/(V/3QD>:(;39EPW+&='XGX.\J6S1<!3_$U!BSA0J#8DG4?
M$"8YDER*X9U8=LB+Q#3=YN\Y+I<(SJ_?H)\33]S9?(Y\F.`9Z0HET,=-<`].
M<I7M^I:T&&*4554:J+%[C.DB@65N%?IJ=U3&D">)P16."L'<"6C[*>;\1"EE
MRE]>N,)0E</1WTY<\UU238&V)^^VFG3PJ=3U:AW&Q6&4C"]RK&7;@X5U[`7B
MHW1:^@+*E=V=G='TU4N")_P5P<EDKYRAZ_\>3B1',!P*>%:$_;@@ME",;XWQ
M>Z5B$Q(II`![L=F5J6U$!-`.513<AU[TU5M!X4[6Q.=,.1-('VJ.^*5W`U/8
MW1G7[Z(SV5Y^G>A5SJ[E$)9Q8M?<&T5A'<M>*Z:F`MZN@*4%AZ:/^LG^]9\Y
M/G`2U<11L=Y*A@.AU3/EZ]+#OD&,RZ&@F@<R"B=O:GEC+C#J(3V8.F>,,28<
M=\:7+HI<62%U<^7@HM<(C2Y<[([*6O9B8@\).BUT^=T9/@\PS1)$@IO*\4$M
M;]F?2943-@:S27E9"Z94]!7Y!BQ&C#1SA4V!Y]";LNIB(&UN>CD#B%;<DA=3
M"[W3!Q03D[D''C"9Q\FJ2-/\_&_HDQN:*YCZ"5HS]"]1RZ+#4B<:9*$Y-&B$
M9T764;&<ZQN1GLI,[4LO*L^`Z6]%C*#;*H=F%T.+)A'`R%H*%"V#NU<]F7MY
M4GZS^"0,GN+:U:^,$#U-']$BFD47<92S[EGE&P`C:PE0.L\CBBC-O4"1%T0\
M[[=J"XRMI3;ID<5#P*)7+([YMBHD(#XYMYZ<6QUU;OV.`IUU,QZ?HIR=HIPY
MRY$K%N13E+-3E#,EM9^BG-F,<D8__7A_/*!@`;]Z98MWWG.<%,\UN52(JMG-
ME"Q+@0P*<X:"*6[IY3$.\V+2Y,\\E*)V'"J5IQN&Y`8C2B0P^$>>^4L4I7%4
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M[9',`8L2]0&IV..-7<MR)"(9@F11U#RYX(S@3H1P0WY`/5CFNR!VR"_%G0#0
MIGR1C$<(/PZQI$,5[MP3N-1%7+ER<*FO]'!-H2L>YR!C?X\4`W(:C_/=<\!V
M.\Y=9EAK`;V'T!S2P4X,>6CU&NVDX71EXC*C5;2.L2'348MX)V.J3Q!-8,<B
MGHQ'MA?G]LKL(=-&.:]<P1<8QNM"P`@?+#-((J>6$<]KJ?ASMVH[8&S%<L?J
MM)0IN14B8YU?B0V6@%8L>/(JYXAM,!1O]=$H>%S'41HG,*AO`-64+6X`C*W8
M]=0)D(1B;KG<VP7)T<"K`L;67N+)*5XHO#E_@/O0\\N5:5'\1VJVY]4!8VN/
MZ"1G=J'TYJ[Z&WZ`7[S(6U1RR"A=IBH8.Q-&C*Y[:1#F[N`?\(=D)Q5J63"V
M]I!,3LELJ<W=FC_"M9>4+]+PZ@&S+%3HVG*5P=C:<RXYO2O`T'*;;C->WF1P
M1WXV#H<"W;R'(&<36U8+-L/TGF`,O3N7).^C/]FVX#C2L1P,(:0W;M[$JC>7
ML>F`WDGX:G!H"C$2.&]BQA9E/7#>9*+I^.A25+:)(;N5IL!Y$Z;W$QN..^-+
M%T6N+)*ZN7)PU>L6.&]BU7F0/23HM-#E=V?XZ`F<-['Z($^5$S8&AUSX'LBV
M210KH2X#)F8,EWW$0MC#H,5NJ9$`\7C8E0(30X9-^?@&>[KDZ+LAL$-340N%
MN[)JJVO>P77YB_>&5OE*2,%>.3"Q^[KQH#O357\LL3O=_@M6FI36F^7`F=V'
MB7):/Y+X?02F/;/R)-%<^"D*/'-$58:?K6_F#63%_J*4!&?6W)X4%7C,``N.
M.9^G7K-DGUGSCNK,C"I,ETX)\`5&.7R`?KPHE;X5^0O,EG&P7^`OR`LEJ]X8
M.+/FDM6)]8Z(S7EN'69\O_(RUO1(*PK.7(R9+C<*F7C,.6\UHH;.Y@_QQ@NS
M3?7UI[CY3)1!@71]<#:$R.AT7M1`FO/]JCX]F]<O<^YAXA-7G05KA'!J@+,A
MQ$BG$R*"9<[WJWQB@^7''R2QQ?#'F?')N>7!V1""B=/5SP>EQ45,4XYSZ"^C
M.(P7FT>8O.!-9WH9IQG/GLBH`<Z&$`B<O<KS8#GD2?8%*R.#$0G8(R+JL"@X
M'T*0;S9#5#SFXKMLO?*CH/E`9>>JP%I01/7`N8NF`<EE10J<N>@O]>D+;S*\
M`,5>D?OCBT<"5WHA@Q!N'7`^8&.!$)B>"#&L5VTD]<IU2J*^9<2?)V6-"%I1
M<#Y<4P`3CYY`+_132/P:;8U#-`&$&UV%%L#Y,$_L;6#6G!DXIS=$N8F32A8Q
M.[NRX'RX)W4VH%KC!L[J>V^\"-DD+N5ZG<0O18C*FS@.R,J5Y(MIL,)%"8(,
M,7.IM&T.G`_W)-\)<TVM@9/]31X%^Z:$;R1ZY?;A!Y&-'+J>7N/_P5L4UF%3
MK15P/EP+0!NH-7\FS`("<8J@*D00+$]+\II-@/,!&P]4<=:TN6!0J`Q/UV_$
MNYNV%Z$7!.?#-A]0T-2L&`CG^C4G</#^!D^]1&[&@#DL!CX/TP+`Q%*KV,#Q
M?[J*\RB[]Q`>BM>>OZR^R]`THS3X/-RC/@]2K7<#)_S'#$]XW]8W$.(%:F\S
MPE`]NP+X/-RSO0#5]G+1&`%7>6%E(_QS[A?IA<'GX1[N.8AJI1LXWG^-HP<X
MQ^L^\8,E:411EI=MLUU?N'7`Y^$>X<7`:B8,'-KOEUZR\OP-Q^5H5P)\'NX!
M_1!&K5,#Q_(I%C,@HMXGL0_3%$O*5B^],/@\W",U!U&M=!,93XK[1N3C3SU`
M'Z(7&%QL=@%!\-EOQ>K@XIK@\W`/QK+P:FX,'(9W-LC9_"8/P\T5"G-BGRP#
MO1<O3J[_Q%">XL;;(#9=+1H#GX=[0.Z`N";50'B6WSUR#99=OY$[_Y2L75_C
M#/G5Q;\X<[-T??!YF&=E=9`U6P:.T'L>2U6RZ!</84Y0B++-Q:82$7>Q2F89
M_RZIAL#/PSV&MT1;$VG@H%X]VRB/J[/Y+"?W/GBXPZPRQK"L(^**X.?A'M\E
MT=7$&#C);^V56/H4X<_PKEKHA<'/PSW!<Q!MG57-F:TVY=F)G)Z\,"Q@[!N1
M!88L87WP\W#/^&H@:[9,'/LKHV93`H$MMUD4_#S@0SX+3ZUN$V=[F,QC?.B-
M?'@11WE:]8"C>['*`Y"]WU9I!?P\8!M!"Z@U?R;L"/4G'V`$7[U0O*?FU``_
M#]BB((!5<V#"K%#[UA27QXW1N^L&Z4419\&+6$\BE-H`/P_8U*`,M&;.A-%A
M)PQNKS-SXC;`SP,V,2@#K9DS8%G8^;,=S,=MF)-I`_P\7`N#.M":.1?\^^^@
MET)\0D/E<8'</8THC/**@[\-T[P@Q%3S9,"(T#1"X7Y"'OKB<5]:.41')JFZ
MX&_#-27(`ZP98EH3/NW0W^'/[.N#_&9/(5@ZB+>:VY=C>RKQL<!Y^H(_G2<P
M19'_HQ^O/A5**6,]!3#S4)A^<"T<+"O"Y5T=G($SWKLW#NK)H4^5^$L8Y"&L
M+(:MXG\6$:)XFM'U#6!FH.+MP_'PU$LK?3K5JAAV'`H"/,C^[N/I!0_;ZS(L
M^Z\?4KBHIL[J[V&,V_[U0Y;DL/^.V"X.NQD;I%38-",DTOO)$69WHA^]BPC;
M3@5L'S-G"T/83YU)JT)="6EGM5<Y&!U/;ZQV*]9]TS,!O8=PE>#.Y%'=:0LY
MW2L'K`8C[I?'(^`.Q<%JO<LN^V,ZR[,T\Z(`'Y\?XI"\AB-_-'%:XWX06(VC
M;/2H8DQ?[[,7EG>H_73`\EO`REV,^?YAO#_NU.?.8M85'M;?'*+"_'8;,6,\
M&?P:L'*_--3>R%"@2U,CV?S=IFD.@ZL\P7HII2S=#!L[P[1V,N3V-^7&@-4@
MU;UWIU;ZT1+5THWI:W?%U,?T1?D:&%F-SSVT^8NEP2&EEI17Z>\0+989#*8O
M,/$6L!Z$]PG=,:UG"<#(RG7F4+NNBE8=RFS6WG1PL'1L!ZRI7JU5$#"RXG7N
M;.?6KUR',OAH0'^T+-GKY4JB@)$5%_X!]W-U]3H4ZK?`]BS6][/R(O8`">'X
M]\2YB#@2D:>7,%F-19V]7VG`R.T+%1/]W8*&'8J6K%'EMQ@IBE+D_\L+\YYV
MX/O?!".W[Y'<W7-3]"B*&VW!43$KG3'[]E>\#+TTG<T+BX^,"R*UO&6O0B++
MQ::03,%/\+"6#<\_IC:%SGPTZ0?NGK=-:]S4BFP*],,ZCKGMT>AB&68YB-RY
M/6I*)_2".BYLW2&.JV8Z,W04[X@25]S*-''CH(-8M[3F5L\O]-[/8(,FNCL#
MY1$?WF$ZO<=-PB2136O.J677Q4N%&0$(EVZ#"TDO6I%$K677<4J=)"8(ERYA
M"TDO6Y%$K677PTB=)"8(<QD)JP\_O<:2:A=7LNM)(Z-U.0SF,@O6W\9%8`NU
MLZK9]3E153P/A;F,@M77;^(\4=<\JY9EYPM%S7-1N'3'4(A[U6HYH-:R[&B@
MOAZP4;AD%R]$O6Y%$[66Y2MS=9K8*+1D%-1Z3)$]F-0@K-[JMCB+-.36DCE0
MZ_%#]L!1@QC,$?U8;CW9`C7EI<4?F,T;MST",S"UO*D;,_,V8#8<AP[H3=>)
M:11\Q6+L?O.$?TI)2LHX2H5C2+$E,#)TDI<V'K/YH?/9!J`[YC*;1+MBDC;/
MN%9K-?4@=>>A(/1>BRA`W+/3<4$PLFJ7:3-^C@]3#%@Z!AH]-+7OQ\D*^7_,
M+O!:&]V'H<]5.[,\&%FUS^C1/A^=0^O:8_Z<H@!YR>;1VZ[;HFMH5ATP,F/A
MZ>$>F@O))1OT3CSR1'TV;W1)<7P.864P-F0IDK^JYC+!8$\.ESN;#/,LNK*5
M,$:G^1W$?>CYY>YG`3EA,%A%P=CNLR&Y,7&\=#&QN#-\=@F,A)OPPZ)@;/>]
M2QM6N%@<VDO4<5,$VX=F,3`V8\`SOV,X0N'0TTSI@%T'D6[&A@QZTHO_D5+Y
MNF^([<[DU%[YKJS9;5DPOR0_O<9/RSA/O2AX6J(D@[#TNR*B<!=H<44PMNK6
M1.G2QTNS)`IC9WS*]TNO_MN(Y*A#+[`-$<PFP-BJ$U-;2OAX'%JO2;C_R$=E
MR/\DE[AY8-0`8S,&,_.K.`^00X_3BUWB'";$(E7&]4?1HLS7<"!]2FRW*?U/
MPA5)YV?`V)`93WHSP>.6<1.E&[\[NY)A]B!7=D36NU+/U@Y_L\UU(&_W.*H$
MQE8=_K2/9H&MA([?V&;LGWAKDJ95&N#?DCA?WPFN7#@UP,2JAV`/5(G`:]F7
M\7(ESR+(9>>P&)A8M1_V0`D5L4-W+>T"($^L&A@-T\:&;.X)0/4MCGL:I128
M6/4,[&_T[`%VZ,BB-SK\Q*JK84^#B@_?H3A23R@CY^S;*$`O*"!)M00.B[3R
M8#)8AT4F')<Y^AUERP<8EC&=EFC]%%]'&<HVXC.=6DM@8MUAD<F/))\2`!TZ
MV5LDVI7SN7G&S1_`;^)D!9,KE$`?5RBS%Z;XBV2-Y^Y\Q!7!Q*I#8YOQ=;S?
MD81I[+Q=K\YI+4*JP)%<93"QZOJHAR<%J.;.W.4=S$'*3Q8WM+)@XLQCU3MV
MJ"2^^`Y=-7$#L)>_;Z0LYCF_*34$SJRE!V;30E^26@!S9P_"$+X(0:>!77H[
M10;?09/+P67<'%GUJ:?X/D_\I9?"1AB;V1P?=K&4`E.+1`O@S(HU3(6C-HBT
M&"FI[-Q&?D)R@M>?F\T;,C#XX-8!9U8,8:H,B#&8,S`VOM2<;F^E!H-<97!F
MQ8"ERH("&'/11^Z3V(<P2&\P#/)]+_)K^\RW"']T3Y:OD+6M4VT&G%EQ`%.E
MJ!4L<_%*]KW%+[UT>0.I2SR[,#BSXN:EK'BV\%J"DLBH%P]/E#8MFGP%;XN#
M,RL&@(XJWA=?2T@1"25?OY$`S/`!HM5SGJ2PBADK5C>M(CBS<J+OIG@F$"WA
M0MIN2MMO1L&9E;.\@4UH@41[W)`4^C\NXA>,[P6F67GJ*W\^/.^5O\6;-?(_
MTBUJF45I/^0J@G/GC^L*0/2$&.$.EUV6#I*20#!"]@N#<^=/SP+A:_VZ8-^:
M!O_.R_Z0/L73($"E)/<>PIOGRNFH@E(.;XX11+DM<.[\(;L;MIII`^?M_96O
M-L%([V&;%<#Y($[:`@"UK@V<LR^\Z(_K%(-ZQ5]CJ'>O##@?Q*GY6.9:B2XX
MXES!9[R5QNM50K;2Y4\9.=/7CBG-D_Z(,R^I-03.G3].=P!6$VS@1#WU_01_
M9_?8ES,94<N"\T&<I]FRU\HU<)YF&+B>XEF"%@A_HOCM,@ZQ!*4YA?S[^@UO
MQ*,%W/IWJ]D"55L'YX,XK>M$6U-NX'3/%+-T*#!#N$K;X'P0-@)]6&NR#=@1
MOD4)].-%A/Z"`3VI5F7<8!`J71^<#\*FH(:G)L:%D*33L&A<G4:U!L!GYTT.
M+0!M[R<-;$]6<1YEY,"&Q_TEN7T(2P>AV;R<%BXV1"HOVK#V+-(-@,^#,%$H
M`JJY,7"U7WZNMAL&TWD&*X$J>:IT@0QF9*N#S\[;&Y3AU*RX\.ZH<_+>WTH[
MLN4,S?)2@,_.6TYL::7NETZ$%6I</5=&NFTZ=$Y'XE4#GYVW\$C#J*ERP>C3
M.J'LSLY^A;<:7:8'N2^`SX,Q$^E$7/<5%UX*M<=5!;K9OG";94N8/.$3'W6N
M,]*9U$0`GYTWC5E12=T=74BK4[\?N(`1YJ@(PDS7!:<_2;<!/CMO:FN'J6:4
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M/4/KN`I*=2@F[/?GFV$U#I)SG5JO8AW*&56@>A9K^EEY.#]`0C7^_64<%9=<
MN1>21WQC40?O5QHPLAH"W4I/MZ!A<W%#.FJP&+GP<,BRP/!<*/N2`8SL9ICL
MJ<?:T:M#H7PU*OH6`T51BOPB]%@_6^;];X*1U?CXSFTH.NE12^`9-SKIX3D6
M_XMXR_768:6^#T96LPH,K?/*ZU04W,>FMU+EHG5R6CHY+9V<EDY.2\5;@#:9
MKK\+EZ5#R.[<B[3-RVS;2^A0HWR]N^C>TUKSKKC4M*.@YW382>6IH9:"^;B6
M71<7D7.*)(!>4F"_PO`%4KQDE!@0-V+7,T25$#D\#EU//A0!*O@+^;:,(4\)
MUU;Q/;RN<27TWFN4,N5+(+UZ[VF2H^R=N.ZLVRVT[<J*K:IV!_U6OV#-K?*5
M4/][Y>RZ(!ST9+K>C^1UI\-_\=[D5-XL9_>"7$[EA_(Z-*6W>_]CZ*[6M77X
M&/2[<(5QY]6&J1O4EF^`1NV=J-NB=V?V?1_]R94=D.6.Y>"&2N]#(,>OL=M.
M!_1.PE>#.U.(GL34ABYY7=M<L,$[Y)9H+[OQR)`=M&,:ZQ'SO5X;@`X/W1Z)
M=F7--L^X^3N);?K?-MF1J9F"1U;MWVU&U;&%7(S0V(V%+`D4L:P^"]2C>#HJ
M<]E5#VX\Y#)0\RN!T3`?Q-WQ\U9+@';(3-5:"^43T3H4\/3%0R'9EMW$2>$/
M9\)'2_!),+(6;UZ"\Y:GU"ZZ,#;U5G;7RON\Q$W-ZU;$)IYBH8/*R8DV2[1L
M#8RL1:I7IKLKS/<P813_^1=,LVV:<%Y2'IV?`6-KL?#[GQA8^,VE]E81M2EI
M*1WR\?]]_#MO@7=%3>E9FPI#GP-C:U'Y6\TG1O7@D*6D]4AH`FR\$"B474W&
M)B8@B<^"L;5$`_U/2++Z,)AXO=G3%XL$+LACC2++#SZV-F2J%N%B2_4`4YB\
MP*!(^E/G'6=,2?H^`,;6,@:TFH0T(W?H<6)C0U;E[]P7'N^T;W+RU*9.5L^9
M2Y3;`F-KZ0-:3Q#M0+Z+EWXD$'GQI]O(3R#^\Q4L_V]B?6%_#8RMY1SH?UD1
MJ$'T\$[W=G?WVX;LA:!'HX`S86AM'XRM)070N*%M"[SJ``9R\37`58=YZC%>
M;!/EU09C:P'\VY&G`*NBIELVOB[4B,(1M6T*C(=C@>R$<6N/LD;A0<B+1J2+
M.S3OR"F_;3`>EMU1'^B:=6?,D!W"_!!C!TF%75I#;CR4%(_VA29)`Y\$DX&:
M)TWIHNYG@W`&9NU/MYBF>%>R*E%?H=0G.37Q7N4^3K.7TN"&=S`9GEF+$B8.
M#.TD`9/AF$-MJJCNK,Z82MN,2AI^DG?7)ZL%3%9&ID7A1\%DH&92<]JH>]N@
M<S'RH/XK)HXP(<HV#X;R-,I_'4R&8XSM6RUU1W3!5&L$\Q7QSH)18*,;-K\-
M)L,S!?>CE+H+#MMVO`59I5(UFE:4_34P^9YLQWPUU!VKF_'8C8Z%=Z]SB(J0
M<#UT+,K7P&0X5FC3:J@[E@&C-.4ETS>L[/0!KA.40AKI,M7`9%AF:"D\-0T&
M#-"'#@ZE"'L&U,*]KY#'QZ5F\T8Y!DG=&@6381FE-:#=^KKU=?MW&:<91RB:
M6:=]8T4NY0$1V@%E3:2!!PW?H@3Z\2)"?T%&OFFR\8RH=_A*]<'9<,R[ZL!J
MAERPU4[#HG%U/M4:`&?#LXPJ(*L991HT^XE9_+N7%%&6JV#%HU.8XE.88I5O
MG,(4O]\PQ>UB*WT?@8J/,+OS%/X]!,*Q'37YB-Z6%HQ3;G47.I,K`1JL]BH'
M0RI5FT]A&*6]<M]3#O4CX`.:&$YYTT]YTX?4"T]YTW7U#^/]\90WW<#73GG3
M-2CP?4Z-I[SI[Z?CGO*FG_*F#Z]3.Y@W_91$NDQV_%VD/;>C5RVQ.MQX"-8B
MW[O!-V*MLL]_%]G2;6O8H=`D&E5^RIONVH;BE#>=?HX]Y4T??N<=6M[T`Q^D
M4\+TDR?2R1/IY(G4.LGJ]^&!M(?7G7N0!^6LG[9]??84R='U3MQ!:]L59QA5
MM3OHO](NQZI5_Y6#GDS7^Y&\[G3X=CE6K3IYR*G\4%Z';A+;^0%_'ZG.CS`[
MQ-M[\-VTG8#]B%_=%UA\[.Y,O.^B,[FR][':JQS<2+5S!';;[Z/EB*?WA"/@
MQI(.55^2RSQ&+SQ0WP6.38:/M9=T<`9C(-NYPN?KE'+]KH#&V.BP'?G8SB6T
M(:J.H5D?21;C'=NYH#5$K016A[P+^XIH8.<:4X7B%H!<RV'5P6G%I6C5IO*'
MZ^\K1E7P'ES@'`W[:R<Q=J\]3$X)[\'G;/!QT.UD"V_=&WO6S'OP.!M,/&H[
M"=.M=T6.-K2D^7*X^SD3A=I>;G4GNMZ1+K2D%SLER&4EA+67V[VW[B:K!E&V
MM'Y<81_SYQ3^F>,_0?+WVB6V=U_8K1C71(P[&0]71A4K?JO[L@A=4"G%K7B3
M<E3(&!4,R0?N[GD(2^QZPJCAA"LH@R,Y1MV,,'<LI/A"GU7'NO\G1^72'#D9
MNDTO2Z[X3NBDRT%7B`-IA2X1U/*68Z3QQH<41RYZGM:N&H*5J%G,D-^IP>7G
M4'J'O!FE7<<.?&H,V16EEY=#E?(5OQ/:O9ZOK'E7EHQV%&A='.A."7#ME9F1
MIE'P"+.LW(Y/%PDL?F!._O*5[4;U.N[5%(\":1SNC(@GE!&O\MLH(`8K8L#@
M+PK4\H;\%PVN#DP8#OER',GX.\J6#S`L$Y`MT?HIOHXRE&V$LYEB2Z:\'J47
M&B8[DF2*X3D\`/MCV95%S33=YI>_FSA9P>1RB>#\^@WZ>89>L(1SY,.$N_()
MZUD.2M5B9!TOBW(@S3FZ[B\,J9P_N*"6[1A*TO9562SF_%7+$+>D$Z69%X;%
M@X+;Z/<E\I>7N!,A_-VB.]VF]]Z&8=]NU8Y%/U09C1_SU`ZAL8&S]\WJB]\B
M_(OMAI;!E+BB1?_1=M1(0C(WBJ8KXELSF]_#9([G4R_RX44<Y:Q$@:SB%ITQ
MVRF>"T3+9IVJ[M*#<S9_A,D+^^'#02F+?HCME$N37^0$3;D]_D0:)AZ+^!__
M"U!+`P04````"`#`BS]$3#(0Z7&8``"C?`D`%``<`&9I;"TR,#$S,#DS,%]L
M86(N>&UL550)``/H(^Q2Z"/L4G5X"P`!!"4.```$.0$``.V]>7/D.)(G^O\S
M>]\!UOMV.LM,66??LS-KH:M*W<H,K:3J?F-E:VT4`R%Q*H*,)AG*C/[TBX-7
M!`GB)-U5.V8S74H)<.#GA!]P.!S_XW]^WF[(*\V+)$O_[5???/GUKPA-XVR5
MI,__]JL?'Z_?_^%7Y'_^^__[__R/39+^_!05E+`.:?%OOWHIR]V?OOKJTZ=/
M7WY^RC=?9OGS5]]^_?5W7]4-?R5;_NESD1RU_O1=W?:;K_[_#[</\0O=1N^3
MM"BC-&Y[<3)#_;[YXQ__^)7X*VM:)'\J1/_;+(Y*`4$[+Z)LP?_UOF[VGO_J
M_3??OO_NFR\_%ZM?<1[DV8;>TS41P_^I/.SHO_VJ2+:[#9^V^-U+3M?#<]CD
M^5>\_U<I?8Y*NN+T_\CI?_,[3O^_5;^^C9[HYE>$M_SQ_D8)YX]'M&2GK_Z=
MS#'#.YHGV>HJ=9OJ2>]9Y_Q01GGI,>M._YGF_9B5T<9IQIV>,\WU(W7C;=-O
M+IXR94?=>-KV##C7LC]/:T:V'.2:FO]\R\8_FAG]7-)T15?UW'C/$6TI"`LM
M*Y1_%A\1VW!UF^7'.-?)AD'YYKNO__C=UP((^\7?+[-XOZ5IN4B9T)=)>;A)
MUUF^%<IZ\524>127-1DQ<4'\[W_Y[>]^_Y=O__#;W_SV+[_]NSF=K_Z]QG\T
MW9P6V3Z/J15V^0F.9Q8]_?W#[__PQP^_^?KWO_O]A]];S(Q9-4:%&U6:OO_Q
MX5?_7G<C4;HBLB/I]"0_U7W_]_^0<PD'C9G[IZR1@5\BPE4UM!@(#N*7I\`6
M^;$<17E<SX[]J$%6M?@JSIB?M"O?'ZW0=9YMO42GFE;FPZ"OC'5%!5(`+&C\
MY7/V^M6*)E]Q_<%_$(KD_=??5-[7?V._^KL<]YX^)WRXM/P8;>F`ZOC=MW_^
M\Y]_^YO?_/G[/_SFCW_^S?5O?OO]]=_5_6=0&7_XS>WM[>]_][O;FZ]_]\WM
M[W[XW>]O?AB946^550NK;4=XP[G5PCPHYI`0RQ5R+!EV;)A#(BZ86.;1YH99
M]\]_H0>=-1WI.+?Y',.@6#Y50R):$M84U#I.`6!V&Z%=28-&0=UKVC6_8%9H
MQ2W1]29ZME'_)QTA]?XIAM.ETOR=\`9H%+W?M$$U^^"JT:KTXU[3KNO:P7ID
M9$U4^'%[",U],F.E;\S_#JZE?28+HI&'UH-2$1\UGF>=-H&\RZBT<L,5!"#U
ML0J3<I7(AFS'MR*\*1H-'1H(J,X>76E:W3W<>PY__#K9T/R"C?:<Y1;>^$DW
M.%_\=/X*1U8T(W4[<`4?<.Z`'OC@VM'XW\=]W%;X.BJ>!(9]\?XYBG9RF=--
M6=2_.5WOU:___E"RD;F@+=?721JE<1)M[K(BT01X!Z7>CB:4Q;!$?KH$SZ,-
M/^@D#R^4E@5@G'<*<$TWDJU)TY'4/4?0@ID:EX4\:GVL"(*)ZV/TM-%N-%2]
MYC9.RMFKU]]/H@GLX4FX:<]NDL;7RZ!%4G0!6^$7FZ@HENN',HM_7GQ."F<K
MU">$QO0,8#Q=6Z()6:Z):,0T,&N&U-88H\G&T>"Q):HU:&=`>E3FEJGN!"ZS
M;93T#E55^F.H)Y3U&$2A$Q?9$(<=L0"0Z0"`613U6AJU*@/=9K<L-$]HL;AC
M)&F>TY68RP>Z?:*YM6T9(P5N749Q]GP7T9HTK>MU)SL@LS0NR!:GV/"9&_W"
M-#,X(W1@A.W<4-B&?=<Q$F!;F%%<BB5XCD:\)L2$QD(9++WQ#=!(?Q@QN@AG
MLQ2D<-@L%4[%$KQ`(U838'O_#08!<U]1UG9KF(ZYP`WF+U>D'S]E+I;(A`)$
MSK(6E5)@6!<T0A,.UOMO=;+BC<4Z)=D:S')?\CM4_.H62;.4M:=TRT-PI*B_
M7LF^WJX!6HBOE^4DZ_0<:_LE$;NP9)VPWWQ*RI<DE7]XR38KFA>_)O0?>WZ^
MEJQ/9L`&Z<Z',61S(%%)RA?VMYTX&F`[5OZOI"CV-!\:J:3;799'^:$S"B>Z
ME?V30N!(5E3087JI9(P_(0ON8YCK%&4JMJ9[((7'FE`?K\&,%I3;8(A4K09Y
M)S2*<`J([[\#5XDA89DH1_%-C=7C4.O_4I#!?$0;733J)!H1"J,TKYD(>+J)
M:A*`?N((+J6&Y'W0*,B`P-[_!EPO!D!CH`[7_`.::L.AQO^E#$-ZBSK=HG,7
ME?UA(E*7X2)2"E(X(E(JG`KU<HE&9<Z`#8VO8;$T+>)1PW1@Q.W*_QQ%00+V
M'$6%2[$$K]"(UX28P*V6Q=(S.$<9[@^657:;I/2&_>B>3M:A`&ZCAE"-)"?R
M9D2T0V:/PN&`-T+*E6:7--9VGUM6%D5!R\*TNHNJ%Y1AZ<V^=\U5-,!2H,5R
MVFB,P_`B&;4')UU@EO7%GIFBM'2]VJ(@`FT(5-B&%]$9J5IBO;UB"J>&(=O_
M"9TM&%UR1N9@F,+L^<-1\;)(5_P_5__8)Z_1ALVF6)0749X?DO3YK]%F;WP9
MQ9`86):Q(=;>6F0=1!TI\4.GZQD/?=6]B>B.PN)X`XWY#[3M&AS5KE?V<0YD
M)7FBSTF:\J^5K8F<Q$38VC*<\R"C[+,I,<&EE-NHE_$L<R-*LWL><9SM^3S2
MU;)\H?D]C2F;V].&%A]I62EW:T_$C"BX9V*(O>>I5/V$IA$]2:?K&6&=&S<&
ME^_B"/C^7Z+M[E\O24Z3[=,^+^16-V]ZXW-N;%:UF;-C1'%NZ;W+Z2Y*5E>?
M=S0M:#VW(\?,U/4Q(@7E^)CA/%VV52]2=>N(Z\E>`X7/XX>1RFY2)V4"9%SM
M0")<NW.+-3MJ3TWHS"V/EU4X65[*IQ=9T<R%:0E;,ZJC!FT_M6A[M8'JPX2J
M!Q%=&C$4EA.5P71'N)9E&9B?'DN,*16%*Z(XWF_W&U[SFT3;+"^3?XI<#'0F
MU&PI&]E.#2G08)M="!G<$.K,`4;#IINS>$]`8ZV\)UYVGCL(.>WC,!\:(VMO
M3F$-YUV>L8U_>;AC+!:%P-D.>;=U,YOCM*"-I@9IW[^3S<^(Z""KP===\!E,
M1W0"%FUA#1C+%=VQ#6<R:"RGU0[3`T9G_$W$T<CTCQ*",?QV%A_:U!N?M@*:
M=J5Q1&;+E?-$:;PMK/;LDG2;1$_))BEY28=4)D]5F==7(B/:]0C;G"ZT&;?@
MP.F:ZW1MS#FS"!.>=Y>==ZGF@WFS.+^YO7F\N7H@BX^7Y.&'Q?W5#\O;RZO[
MAU^3J__UX\WC?Z#R70)^TH>CNPBR.SHC;RO$1@;?F"B@RM+GV0RJY3$*4$["
M**J153I+FLVHVO&'4R/8M)U0.$5.(#J=0'*%K%>\@7,RTAWJF/LN.O`S.Z::
MV&_R/5T-S#%=?62\\COYMA\'VJ'QX)#R?+RB)4QB1:V[T%%9_RGP[SKXHPI_
M?5"'SAWP%1&K8W3K08`5QCT54:B[*._,T#B28$0++,Y@AE0GY&>DZDFJKL@.
M(3Q1CHDR>4_R"ON.$81_],%E$8^'&4P(S2VB'[.2UC-R3%0;)`%MB8=QG:Y,
MT:H5OJEDS3UT8`.CDBY4#H'Y_%73!S?I(Q)B9*V'^L^>WY^E["N6"9N"F<`/
MI_%JJ(!E].O0]?:+;0<RDPIP2N#WP95V=4)S&+A/JWP9?AB8%,(@(3A:L$=:
M7[=XY0G?///]DL;BYC'Y[ILSPL3@6^%EL!_8/QF('8W+Y)5N\/@59C(YG@T_
M3F+^Q+T\>8TXF_L;$5NG8IP6M'>A0=I/:*N;DZ'P(2J+[0YM)(0(;L1-EJ9A
M&MX((?APO'L8'E/XW3#LCL)(&\W^.#MOREB[O>VU`#`09T=C3O5R;8H>4(H]
MCOKAC>(QCA$!1I1Y-CYGN>J!5[OY`G`[80;8C&ZW2;FE\B(8\V%+YLC3-!Y>
M_PK?>80$W#9T#%=_K]:TEK?*N^U16#8_//$8'L!-EW;M:79<ZO[SE[P*E3&&
M.4?,*H7HX27*:9,R=$G729Q@"N=Z@%E-!,:OK)<-G(%T+GP570)E<"'*V3HN
MSV=5R66P*^#UY0$<`U=YN[46S\@W7W]]]K7\?R(DJB!??OT-/U\EBWWYDN4\
M%GI&OB:=DLL(DKALT19]M(5$^_]QN#L&-SJ"FTT(U_'FMCU@&?Y%XUV,B)KN
M%G:O'X17GJ6C.F)4<?;[0WL.`XB&G-8LK56%:'5&;GAQ\?`%@=R]!G,@2BUP
M-JP&OOGF[)O?_I:U^P.D/@@)'DXC6$J'A3/1ZSQ['M=JE?`K@]'F+DI6-^E%
MM$O*J/<IE1DTJNY@V5I*/+W4I:8EX4W)34JJQBB,IA,04>HD24D\$1"'FV7&
M,.[&YPZ7)#8N(>-Y88J^\Q_?OM)-)BZ6/I31,[U*F<G:Y4E!JXWTHKU)?+G/
MF:$X[6%_R.L_(K27$81K_5/5I@D1;4A+]JR.:Y`.92))DUY'1&[,))Q:'-UN
MQQ<B>7N@_RA!I_29T\<#NE[U1_4,Y*KG3P*M.BN_&%KYX#Y@./UJF*G@/1Q\
M1-O4Q1SJ"?;RR1`*DV@H691EGCSM2Y$D_YCQ(-7LZ<A!(/VZJ(P43>->QAV(
MIVR$0)[W%D=Q=SIX[QC`2;9`8')SVAN!:_%F(QSG387F\VC#ZYTAJ<]L-OGA
M*<.]\Z-4J^//^_2[82N1X9$OHZ`'O9TP0&Q6"@.5%^R`2FJRS0DV>-T\#<Y?
M9.T+UXRD86*PYZ;,%5OFXNVFE8C!WM%<G":Z':6JJ>$X71U!JSUPY2>KRYS(
MWO),A;#^\O`5A2\8`&MUT,+/4S`?0>I6K<6II)(4K%S*(_WV)-_6(]!1@_8'
MM&BU\E@E/;2=4'D&'O@J&:S2'"(E/G`[:;9B#4M!CI+"((OR^-S-+AY3P&$+
M3U"9RMM$603^]LX8S[%\)8-XD-BYH95G8=N.NF.0H4XN6@B#=D0.HT4[QFLJ
M8F`9>X'Q?<R^Y'>S95/TUMGR6U7J8R2]"*5]'I!`9P/=I068UN>[A34B!7GY
M1H]S//]OWIVK_2F,%T;=CA7$,PF*B+]Z*-4-&B_%0OJTUXYT=``UB^\F?)04
MM+\RCG-<H^#>>SLA>S.[;H/U:9M]"[[?[LW%;K.M[([`:FNVI4-R!9.J'P:(
MR>8:VB1;(#D&PC-TZ>?XA;6F?&<CS^E(0>-]+L^XV"_C;+N+4DSUF$9ER]0^
M@\82>O/P""2,TT)GE<>WI</J8\H`0E##;`/N#6RX39:IFVV&W&K?I$RE4>&:
M;QU>1E!VAS+.:CS]S+^J34&6:[)D^S#QPE@QY;L(+K;-')%L29JF(TC`#)9F
MO8T:+%7?V3-^HPTM[NDK3??4X97"7G=HL]3'TY,5W@*5M='/N?HC.CNB6#UF
M%1I.^LZ]\BLMF3Y7;V\7MO9BA`"4Q1C#=+JFKA1/.(`8!IN)-VV;TO5XWIK1
M+JI1HZ#N/;=PW-.",CZ\+-)5YU)*-2U;(Z$A!FTR=%C[REBV%WFBW?M^51=4
MML4+7.=*5U/`.J?)]FF?%]+=1&>1C!:ND7T:IS2W0'Y/4Z8;-ORIF=4V21.N
M%W@17+5(#NHG+1DHRZ7'=[I2JQ[R6::C/E"".`&PZ*@/&C-GN!I'C9V.QORW
M[]NGN?FD9)E^\4];@S=*"MK<C>/L7_IM6_.+[[L-Y3]*J>MT/2,?LW279ZM]
M/,G;YGY7P%T12QGLM*]=3G1VSV#U&EY:5M.9W>9%27J;%<4RO4R*75:((AW+
MM7PM^AMCDZ>A`F;Q=.AZ=H%U(.]XER\(6XF=7MPO"_V>NED5@C#(>&,.:74,
MB9]:":<+C]TS6I'C9F^<!'@4Q-;6#1"`MG!#F-1!!*@XB#<$>7%1]1*G_QF\
M\R5,\\EGO5`..L.J%!`C<]KO#2;@\L2!JQ[K`&>W*WAH\PB'6JQY`Q0;0+.)
M?Z0EV7`SR)=E+1=9BN%]$C,`MP:3AP_+]H7`+"#;Z3?_`Z%I=CR-2I>X%ILW
M(`AMP4TP]T2_?*$YJ<Z-WU7MOT!EU=UA)16LRDQ^@:]NN_$R-7RS4T=M_N22
MDK+U,G(&HL@1..D&ETQR.O]^RH5L@2I\:C%M16@&9`OL/VW`K);!A:[)9CGN
M`Q$I*KAUIFQ???69:XU]4KSPV,%R?4F?K&VD`4%H&VF">2B$5,@8$BV^(,N4
M''?DV6.\*Z+;G*XPB0C6'H'+UDTY(US5F=!C#%"2=":,X'Z0L2HR\H/TU.#>
M&.Y$,IO?#:<0#MH9`T)0OI()1O4[O&>D&ZEG.K;[)]89P6T9%X!UD+ZZ5<(0
MKJ.DOOG)1%+6`*YIX(B]N."\&,+WO@-MFN=C/9Q-%Y2\Y5<;OT\*YJ(:ZZ!1
MIU5/!4VH)UB(!]YM'</8K\O1MGVCD1U%J'<XJH/H#,<&4'668P0)W#_3RIA?
M?&I^G4%+^Y.=DTY0?M;IW(<DI19[X4TA<)U,YKS!<O9D,ME:8C?3,-CZN,F5
MP6#>R*`$CGH>QSWFUAA74<X+NQ=UX9+SJ$ABGN6<;/:E?>T0+3EHCT./=W"K
MPPL/U1=[(2KG!L;4'##S(CUQ53F`=V5[FR?>6V;\R_[HK+;AFC6RW3I:<\OC
MWVCR_,(&7K`%$3W3C_OM$\V7:S&WSG5JO9@.:B=7ZE`^@3,W3A=\38A4E(@D
MQ4/<_?*%9^2\D8'+81D`,>#AN1%5W$@E-V0=D$89')4MP*(9@JYK`_/L2'K^
MQYJJR^-L:MI'TTVMN2%1:)MNBEU9*(&K`1GI*_B;HH.O0<$53Y@8.Z]U:@<8
MW`&P6NQF]\^-*(()M9P'<T!W6<IO6BX^)\;;>PT1N'?9QK'U;JC+5=FV8PN4
MM<11RF0J,("/5!FL/,U[56,49M_F'D_B,MM&B?5-/@41:/.GPJ9;=.0GV127
M00N.!MQ:C:X]LTWJ((7YRT"4;%BZJK?,'RAWA4W-D*HWE/U1HND709`-2=V2
M_"3;AI<;^P"T/8K+X1>*P2S-^*H:-3&*KH!E'I4B85J`;T:I,"WEIUQ2W4*'
M0#(1%`,J,QCL`X";/Z5XV-:4!!+OQ6HEKN5&F[LH6=VD%]$N*:.-G?73$($R
M@CILO:?NF_:$=WA_DY*J"R:CZ(LJ:5"AL9)&BW#46(Y3F%VH.J_=2X=D^-%[
M-X-J2QW:VEISH[>"6P*U@T<DB:.:9(+(=)+J8^^\65##/F*%9`'/7.RQ`9V=
M=!,)(R-J27KV,*=!<?3A*!5()?3A<)=!97`$A<Z=YWX>L7_&E+Q+ZL/!\.E!
M.YHGV8JMQ+P,/W_ZG*1\ET@J)&=3O?`F45RE=FG;%M]`-7.X8+&N:KPAXOF/
M5]BN0KX-(?7AG?ATXB&GC_23^(MU"1Q#HM`NARGV_KDAWVS*CK5]E5W/Y!MM
M_%;+)]D`5Q4=5\3\#T+U96NRSO;IJG[7#%]Y&JL%;7@N:D(1B>!*C3(FN8JS
M+C-J<">EAFAM9+7V1>"$-2Q6M93B,Y=6JU=SR&I$:OY'E+.8TE5QS1A1?YCE
MNA/*LS6J!@2A#:H)YO[SO+(/X9U(LX1Y-M*4<6F?UY3M08JG';JIA?)AI*J"
M>+9>4Z&8XJP(6;$RR'/+'E]4%+]*.DKIO02.SF<PEE7#!Y=UU,QUT3K9"`7S
M]1^_^UJH%_8+_0!2]^ELOQ6IN0V_'4XWI0+TOOD4.%6B-MD.?Y7%>QXS&RP'
M/A?(KC8%W(^X2]6(>V-#!\G>0^R(Y*^OL_R!YJ])'#9X,$`<VN>QY85#,*'Z
M(Z-#:D*HG`1?%AP]VUJ]U[IF8`L%6'!_P6G]>\<:^I21R'WW@=EQP;??"\)(
MO/U&TU?4C]^/!I7U:<#KA/QMA2BT4AZ"B9[;A(LL95^Z$-7T/V8E+>ZB0_2T
MH?P5BSC.V6!UE<+'3,Q,:!E3<^TS`I3-]N)*?T'7A/B^0I`B%2WY&(RD1IJZ
MEH]9M>T0%%%8\*D8PGSS5#!DUV%(5#$DJ1E29L/Q@,DW)XAY43E]7Z+Q>?PU
MR:CCXT%^;O5H'E5Q)@T197'G0SB-B"00,PDK;.4?2\`&!3-D4`=$&X:3:DV4
MQY6NI_[K>IV+DK\[G1?T`\V?:6[M".II0;I\!DB'T]3JW=BB)%4O(KLA<^'<
M`58;L:@4":)Y!7(KNN)QRZ;!)\MZXO*T3(52ZU-I"4VG/<S])`,B$!Z1"39;
MA8'$P_&`-B9*>+R6B0"J'!%W@,?EC3]2LW1?5XCWQVC*/$J+*);OU"*)NUEI
M%:4SI:<P_]VY_]P7I7@<_C%3W$"JRZ[1%;_@3MFWX8V$L[?<B9?#[OG;GT52
MTBHZ*".']S3.GM/$Y4GFV:8%?4`W'__[=^J:D?E6]^2*'6DO#E8R^%[,@'2G
M<%9MD*M9G)%F'O7Q0'6"0#I30>&7PK-?=D7[0/7,>L'LDM1,<_)T/DVF^;<H
M9T;.]'4R5ZH0[JD3>F?=1"I2*!Y!"P:_!A7\B317OS7X1RTS$K4?=<<_:I*2
MN/JHGX[QXPBPN8NUTAUT(#F#;KJ.$KD+YT\6U>]K5-,PSI<*-!AD8"X$K]P5
M&Z<L`WGRE;?F.9N:.@H_:BH^71\];--YS.?35.B=PW]3+Y-Q5;G6,0I7!#&8
M_M&&&/U'\E2U'>*//*"QICG/E+VMG\*[V$1%D:R36*RXQZPJ(7?T6Q/',,PX
M$*YB(`X-ZHY&<]:49;)]0YL<D^'*N*Y7>/0'P&(Y$[*H88I(6F]>9R3Q,5.8
MZJ&2*?&T3+'ULG&RY:QCM.%]]BFEJS$XGAS#X=F'U-1*7S_(()XFZ9Z627YD
M[)KA;?SZ43*0'OLXOH&"FZSUB7=]B^K%86=0Q[[@=,\H.WO-(5'A<G$-A$SK
MO([1P'A")).$RN1I0_DKQW]+RI<V;^B:1N4^UP8YPX\'5[,Q&,<\#FTZ(XA'
MX@D?@W2RW:I14%S@F)!EYS05%=48C^(6_%JV)ZNDB+-]BJ?:<FAQTY2<##08
MX&,Z%U'Q<KW)/A4!WM`9H`5]0*Q!.OYB#NM`1(\W\#B.';K,$!WX0:K)2K5]
M`*=/".`96SZ)NSQ[359T=7[XL>")P,OZD=U%S)P6\>3ZB%2JGN>TI@SX(*X]
M%X9>>A1+N29#S@_D':?$S/D7I"%&6FI32K/3$[O^7.@(LPC4#<'^$PI7)0S<
MQ<,/Y/IV^;<'<GV__$"6=U?WB\>;C]^3Q<7CS5]O'F^N'GIP(9_,=91VW;NZ
MMF1!-S\\1R2-DPT]>A#X,?/7A.:I.,'F`.W73,19S8:I&8CT'BOG?WXK>A@;
M9\N,Y`UGT_KI8O9;_G/,F;JKF?K$F+HOQ'VJ+TC6,#6"T_)OCYD5_\S8!^X!
M3ZE#[?,&0TU@]O?QMKM-=J!4AC/*8I&NAG,=31UM"X)0_K4-YM[K<U5?4G<6
MESEE)O-3+Y,9A6?I`U=DN%;`XDY3R`1CWV5GX$*:4YM;7B_ICFGQ1`S.?MY0
M_@._-+O-\C+YITI41S6I&4UHS\X0>?]YD+;;&6DZRKOYG:ZHW(,`6-%>`;!9
MP49VV(C@[#N\SN#\P.VIO*R.!.YRNDWV6^-S*STAL`,I`XP]C[331YZ1/Y6D
M[D;>51W#/S'B\)B8"[K5ZD\DZD+D9\N*LR"8$S'?;R8.R]DWPW?"92IQXT=7
M6BJPFN0Z22.VSTB?+WC9;.N8SR@M:`NO0:I3)4T'<H&NI+@/-"%Q:YKGO'A@
M@W&P;#JX<3=9K&:;ZS%"GOEJWT=)NDPO7AC'Z4TZF*UM5,G!C`Y$"K0APM-E
MQ[N194ID1Y[VH;HN`E_4P0<B$ZI80F3_.+[JP*L@K":$:9UO.P_.R6H\3/T]
M+X;P#63S)4B*/=CH'F72KQ&1N?V4FS3.:5302RK_VXUS%@4MG0^J+`A#>S`V
M/.@]9%3U)>_JWE_P9=TY(!(4L*;<^$!_5W?^@HENQ84DQ7?D8+W$C5P=<ZKP
M(KV(Q5ZHN*<Q99KF:4/OJ7A>]B[*N8XUC6JX4(8*<SAQP42ZF7]54R(M*5[N
M1+YB7%%#$3<(PH3[?XFVNW^])#E-MD_[O)`Y=WE#`-0)F12I*/NI!@H6-'&7
M\-$HB@-9>-UVEU-^#?JRVFM7I1$6Z6K)G.5<JF)_W\5L%'R.C"%W#/5>1:VN
MKR).8P2ARLM![MHX,J-&71W-R+/C3,".]XP04X918/AFBA`Y?(2.GXVR</0"
MC8:`5YN-LWK;;K5ML[-MJ>)Q!37HK3=Y'3*`.[VIP:\ZX/'D([NM;4M':)0D
MO#37?EJO''MGNOY.D-DH^)P@0^[8;OZ&WHNX50<ND3E#CDQIT`^]B@`<MIUD
M.7LY`T9#H%,?H8-#"K)XW`$=?D?-\-9B0J;P374`>4_RB@$[1JQ7<`*1RV`D
M`8[!DV&:>"]IVCH*-I2AG0,K+AA=SARZ"H3H_H\WX*$[)EF*R[N9!.3119KP
M7S0KHPT,6+&$JZML1LL7W'>SUUU&_IH%623:^B9]I<4D5^I'*2.[4C_.A;ZS
M5K6>4D$'O#MNA^[TJOP06CRQ&O=E[7)W?(SLW`+-G,"ZLD[\CWV2,_^P9-^1
M%])Q.Z,R(`CM;)E@[ITV5'U$02O9B[3=,)XS>:`DVVA%Q=/B.[8UX(?JR?,+
MLG.DZ>&!NQ?&LFGD5>BI@>L>IBB9CU,>[MA7*Q?IBI<7W?$FIDZ$#44HY\$*
MM8D:JON?$4'A3(0]&B(H7`H_S&R&+Q$_X<W6O$1#!7;'NPJL-#Q6CXR?(%B[
M4,<Q@OE,]M([ZBM9D,.[Z0D4HAJD#.TU67'!LG[8+'NAX,$J<^A'<9RD`3MA
M'&>"L)4AW*M'(@J'_?AP=4EN/K+_^^O5PTG5,/QA*\ME78>M3!8RN%]IK\]\
MPE9#9)%H\.8B8/"PU2AE9&&K<2Y8:O+VVBR""F33<>$TO#4$&W4E2$NX)Y4@
MKV\^+CY>O+%*D`;2[A+-&R,[^XXZSV)*5P5?D[S:`)OR<LU?<F8SI$YW_$TH
M0GNF1JC[Z<.RDY1?WNU,E%M<KDG=%>'-?R>HYUF>9Y_8"BW$'=Y.R?V5@,U+
M]K']9K9>TQQO,0#SM6T6#M.3FUMZ[^FNV@0OUQ^SDM89&J:^B+H_E,<Q@JC_
M>DK=E*]%T;C.5T)A1RV@-$$Z)FTI:UKG(Z$(3TV``\S0ZP1FU)PK.T,:[5H!
M+==W>7530Q1-7*0K^0O*_BA^XV/(;4;!9-RMN#-N\!L;S^Q]0XR(OB+>VM*3
MOT04C0K&D8=H(X/J<;;=,ADO>#M#=P"-%Q1F38B7`9-Z38C@>[TFBJ'/C\H;
MLE<:UAZ2Q1`XU.?(4^##IQD:*F"GA3ITXTOZIK.DH=[DG@(7+SA$/],\3N19
M6?V0M#C5Y]%V-#Z*V?(</QH;)X$WF!KH.&R0,K1?8L6%`$%45`;8&WSON86V
M%.%;2F[V^-HFWQC<R[`7=9^3HB&R<RLW/B_FU/#_\(2#5^8B\ZLRS!/.5J=7
M:4Q]"SN:4)Z&)?+!$Q&^<Q(_="B<$4F##-Q.0W`<Y`F;RW8R>!-]T`T!\;4\
M(=Y\O+B_6CQ<\<-\<1"T^'@I?[CZ7S_>_'5Q>_7Q<>83_:F^9%O?$I4/Z:*4
M1CU**X*>]7&%IH^2U766V]9L5':'?+]]&,^@.A3/';-VN)[@,@?QL-_M-J*L
M6K01)=HW6;'/JY@1![C>9)^8M+!-UU9<O\/Q+);E5Q)5A!@$/!4B-6*C?9E]
MJ._\M_G9RJ1%R>=AZB@=]X&[AW\T\_Z]+?EG(=TH[+MFPD>+G$FK;(S&N`TM
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M?VS)&5OSWE!SW)](;)\XMM44V*Q?6)H07.]9)9`WAXRE3OG@D)["E(K!*GO2
ME!ID0-H(K8.NF";OT36@ZXYR7+`&T_LF5QLP,$$4B)=<&0:\#4A-I5(>L[M-
M%(M]YN+9H%2))3%4OL<`5CN]\IB1A@(1)/`Z(Z9@E7)79B)-<=<`CB8!',Y#
MF0@Q<K=%)<#V[DN/DN_)>;-A.KZATI;KKH]"'K,+D<)O[=LX#P%Z`N_,EUX8
MM=W"+T\NG1V5SV_._)@"DQ21>4>3L$1$2CE+ANIIU^>(7.B1^5"PS.A>IL'E
M<'GJ$WW:@2/]N6/&R_PY2JO7P-F<BVR3K,0_Y&V6HEYSS4OAT>:!_48H=NL"
M(8$&@SJ["L6K?EBYB/-D5U:J]WQ?)"DMY"->#_OM-LH/_/</R7.:K).8EWJK
MZM;S\YD[-HT8X:-&4W&K2U=$X%O*]6W%AC;75`UUTI(?X178F59021P]V`HS
MTIO25)W3N735$:16CFHQ>J2?R_.-PZ7B^><'?:H&\$6\E,%2H0PZJ0!"Y>KT
M+)\0$3/"]5`X@N_1-669PI1E6E.&QE.$UCU&QXVS3\YS*_]]QJA>\*^1IZ8>
MI+H?1%!0@>!4&$0S4K7#XIY-,'^0&-;8*E*&JP8[!5S.UL[#"`'(J)(*DV:%
M8#.,SE#PQ&_<OD14%/NML,*XHBZCLJ*-J0SWGK\R6?-&W.$QC]*")T@RLVL;
M#-'3@:M4ID78KUC6/J)X(-U.6.S>W.``"X&9K4]-03`-$2Q2U_JOSAMW*]+0
M>VX[/EBLY&X^/#8[/C5X-#;28[4;;15MZ`+4KAI^X\+6L!H0`JQ@I<4X4.RI
M??JDZ8#-K/H@JQ[K,08(6;_*;(GJ2EAIJ*`1O0#6U8XVM'FUY(3=BGX+)C80
M`\;?W0*WKRX+WK1.I#EAB/MA[G=.5;VA;*D23:^8#2_7W,UDZMS(J?*<D!E3
M8VCB0IK1358PFSF^Z$8-I:(KK-@X&T(E&6B;I\:G76Y8K9@Y)+UR0&>\-.O1
M^(HB#I.4)Z]1F;S2]L)DP>SF#W3U'*A6@M<0<,;-AR]]N:VI(31UTP#M7-.6
MV0<50>L2$("&TULT--;5G?X;4!,>=MIG+'AC[L6I<`*%US68B$$8'05_J3'T
M)CP&`JM:YNY2C)*`*]4WAFNTDADRG\`5"7*#;K#P-+7^U/T1")&SP1VG!6U0
M-4@-5R-6:^B,#J&Y,UF3=E4$,9@K?CDL*6N+>I&)G%R:QG[U`^V(@A4+M,3>
MO[+8]*]C.RT%7"\Q^T*]SO(MS<G%U9+\](%NGVB.PY9/^PEQ&WPGT1TO26A%
M$:6J<G83;*E#.P[6W'!?^EB]BVE9@,X!<5O_1BZ))>FY)9\?<Y<'6R_DM!>4
MF]&;_>DRE`VP;9/]IPUF&8?7RZCI.^DR]PH7U1E>LLV*>79R*OQP,(!9LR`,
M;=%L>-"K0-WI^VM2K4QQ^/H6#)D/<MD>G;&R7M!&=LJ<ZNQ'2,T<EFMF37<T
M+<1EK"HE^H(_[/SP$N7T*2IXAO3!J<*)[RA@Y\V^W.F=BQP5F>^2)'4>OB!Z
M1@39]X(NJ0EC,[5OASUPQ]5!Y&O\Q-IO"+0:Y[P[7?=S:]_AH-T+?WZ-2-G2
M1,K.3Z0,JSL2GE/";I.E+-S!DY?1^2N!I,GL/-MS+,^*`G4E39OB&/T^$(4Q
M!F9^NM*:,KA(3'RX:8.4P5"M%64)C%Z'0(O5J?3%0&?(LA=#6-0+`9MUL$6`
M1L6/+B-M58A^3X!SC\9$+-+5/2V3G!Y?^G$XH#4G"7@\:X&[%Q?9[C;9@5)R
M2==)2F5P/T^>]HT/@L5$A,%[Y'[RPXRV/_YS3-OUK3O%-*8W^U58-C$YK67Y
M0O,[YNKES?SD^TUEB--,]W&@MVD>'.K=%I6DA#0(8N28&JG)O8D@<4#&Z'4C
M&N,=2G#,KM>Z#C+[<='^J:#_V+-97;VZQ)'5_:&,_0BB_FNC=5,BVV(SY!-A
M`3/0NM4V:HV5G:%EQOU(54T(VGB.8318>EA-GR,L*AJC,V7:A6AV%*JD,K=@
MU568F=_]E*3"[2Y$5=^#J3D:HP!ED$91]9ZJK0M1=UO+>M,'\E/U7T#I\D?X
M4;ZZVRFZC<8\Z=??J($:Z3Z[)$5%4BS7)\6Q#_)_G>V5*55HXV6,OB=]O"-?
MFFW7,T3"-S'HHS<(WI,?TVB_2LKZ):UDVWF4X"9=9_E6M$1G%>W6OI&)-"3I
M>4)QR=R,32:J,#V4T3/EX:<H-1#:WF&+*26(HS=CE/T;S$U'(GJ2JBL&T9P!
M)OPCE.$QX7AFTD[PE">6AF3F/_7I/+7AZ0&,TX*V^QJD`P\%MLW?C)VW!'F7
M)\QD[S:TD`E\G<[H++?)2C6\A3)":&[Y^[&@R_5542;,7Z*%Z4[VM!?4[K4W
M^],%QAKPI+6F"29!<D>4=1"1)!UZC^O(7P:W8^.K;73?>M)E_J*^29;?L0U&
MMKJG\28J"O&TDSAT7?WGOA"WR3KO=5F?8%K3A[9C#ASIUY`_[H=)*N?&CL[.
MN:YXP\J^EL1G]T>CXH7?#67_X3=O7J,-CSI;[G(MB8%E'AEB[;FFK(.\2,Q_
MZ'3%),?S($9C6:W6[7A>D1$E-,7U/?>,YG3A[:XQ!ZP*ZF,2VJD9\%8+ZOML
M-XV)SE[];+N+DIS/9)E?)L4N*Z+-<GV;I<^WR2M=+8J".EM>-]I@10?=.-&K
M*]:0(<N<U(3X_I>3>B]H$4D,D]#/Q))L@`UHS+>/+(R7.W0A#%>8V$#>#8NU
M@DBW87U7@X7;:8Q)5B<!B,X.Z]>C94%?<`F[9DK@K]%F3SO/EW>J#-OE,1D2
M@[*FIEA[Q?]8/R(Z<I/932=H^F(2Q:FP9PKL:&REU5H>-8YFE,"J`GO:0C4=
M:$LX@E!=*Q>3[(5'A]`*ZM:A715@:`MX3PO*N,)#6YU4B*O/_`X=M;-_1J3@
MGATWP=D_E9"]1("DFQ!3=<0D?'/`%L4IT%@\B[6K>8]<3P?RVG>W,HAW+I`A
M66A;:(Y_]"KT224>/-(Z$?BA4D/H+*CEVC:M86M$<_;BM5&>)NES<4=S\6T<
M`[=:,F#E;;7X>M>/JQZ$=9&EL3#)96B0[VZSHOA"8.5EEIE*$A30V%##]3E>
M/5=#8VZ9^T@_=;+^\RQE/\:TLW?U-*+V]*&MJ0-'>E?`Z*?.#1MR3`23!$_-
MB'L:<U=8R0MTYM95'(SLKC5QZ(O?IAK`Z"X\G+@;W;8W7=*]R^"8Y'E:I&@,
ML=4ZM:JY@$,.FZ#R;1(])1OQ8N,'&O%**JLE<]GC?9[SYQS3U<<LS>M_BDM\
MC_S];&=K'7!@:#,>DH?JHXXSTB%/:OIDR7?3%4D1&.J.0>2%U)_$,&BM_Y3\
M>]AOMU%^X.=$!2W).LO+%Q*)/`+!K4V'I]N:IQ%KR/G^*H^84A*1_(C':9:^
M;W_SQ&>"SK\(+ME&CD>X46?W2.(7NMIOZ')=!2KNHKP\/.916D2Q*$"@57C#
M%L2:+IB?8L^!GKA5)/B9=!WD$U1(EPP"A309`UI]$[6/9.<5*\JL^7''2>-Q
M<QP7_[C'8TL439IV^`1M1.Z*$6JKI&P$\AP><4>2=]V$;/KV$K(#IV)CL-&7
M]*GTM<=#-.!M[R"R,3O+.R"0P""PNMYZFF0Y*?9/6;[B):"8S=RG!?<8V4],
M3-ATRH1C9M*Y38HB8_W2K(1)37%8:58&=(``I.S5F:*=]#/WRHW&=*$-IP4'
MQN6U[MQ-6$0@P9.#9V*]:L%_DD7\2=)A0N4S(WPZSW+UFY6+-"7J60VKDSG:
M#E2_H;!,JY)<O(4XJ/^0K>C&SKB&&@6BBE80[HRG9W=$OGE+9)E6T3GV]X8X
M$=01Z()YN-2Q]VW`K1C6$P4/Q#W5!?9>&XYM^4CP!;VF6T6O=:*[)4]P%`0+
MIWN4Q<("#`'I3*UISES:Q^BSO-[&=EJ=V*G?(8OS,)A<+3O^C'M>DA9/8:_N
M5(HM??=@!5[USL08GIJ7I<+K$KJE8DW)6#-\/H+:)W,0(FL7S68,.(72?M?E
MNKG/4&5-5\]E^`9.'(:`CZNX\&5,F73DA_VKO1M37T(@[RJJ7R#0*7/RAFN3
M9,V$A3+1)D^T_$1I2LH7RG9Z@DE<Q>SR[#5I'@+B?_SQRX<OR35E3DZT(05S
MO/8E#^GD48DG+3.`E!D&?.SI>^X1/R0;6I1LR#H_O?G%!UJ^9"LQFJG_84$0
M\NU'4\RG2[UIUKX;W/Y*=JUD'H?S\%:QZC9A$X+=U6"WS:^VHBO(KLI7R`P<
M'G-J\]^%'#X\/C]T_[+XG!@7A+6A"'<ST@)U/QFZFWKQ$V^%P^68'!7@K4?;
M5:JY_&A,#E(>+[-ME%B7D1VB`!UQ&$2E68&R'0X;/P$.\`V^>J49[=T'NGLZ
MR8NGIZPLSY.,OT09[>B^3.+B(LMW'^CVB>8Z^V-$`N((1(_K=`7)'N2D"^%]
MR$^R%_R9Q1N!97W6X(SKZ017S/K@."8PE"SE&8"NO^_NF&ZS/(DV#YLL2O]"
M2_Z(4_I\$3&0^07E;SHI-8#:=S>F";I'-D?>VTU578GH2YK.1/8FLOMT<L6(
MNVR4WRY@Y]B`!^2'OUQ<P*G&2;]B(;[BS\U7C.57C$5W9'$`2_VD#P68$IPX
M['B;I/2FI%OMWMZ2&(2798/5*0S'"1!!`=[W>M-@K3VR,&AQ!1U]Q$OCK9E3
MFN-4PSJ]PH4R^G..L;,]\T,`=(D30?!W\M2VI]**R.<)]YEQ::)@0ACR'`1#
MKH>HZR/*BG4+;3V4;%9+\2)1L:@2JGU3/MQ'@L_\\.#26)*#+.KV)(JZ=0F?
M$4&:5+3/2$T=@8J<D5.=JSR"'9D@T+D5"^[3A)<GP^0.YV&P:9H%S[%]EG6%
MS@]MFTIO+CY%N5WBR`0#0Q\LA>2ABSHBW0'(T^&H834($:.@REGYY;`/_!@M
MN!1;9L[ZCCJWUI-#LU%L<DI..D%Y/:=S[QT$B97*&V!*"_&>-9CO,+A61MV`
MXQZS6W1G66SGG:YX28"/T9:ZI7],,P=P.S\-9WLE;/^QYUN)RN)@S$"9B1%=
MG8`U@65*:3,SPE-,8/9BW=O=)CM0VMD@F>7;&!``*]`]@JDG\E7;H[@"T+&Y
M-YAJ@XLC2<@%P%%P1PD#KG*X3EC&:X8K>\\M]-7]7;NT&D5G:-?@%,OIDJK^
MCBD3QG3J"S+YY'U\$5_.@WL0@V)@9/J/>Z+;9ZC\#N.$CY`C@9U1A.#2\&,S
MXY$L32`+2R+)&^83W&E&,,D;/\WP'\8SMZ,-,-:U/FZ*8D\]<CI,*4+F<ABC
M'KN[WA0ADGT1'$Q.@+<]@&PJC8F>>!(VG+&Q!OM-E)-54L2;C!?7[L/$E:EA
M)ZS:#`U#<KX:1BZA9I!%<W9M7QW-G!9$:JH%4I6<M6J%M+T1:)8IL':$39W/
M,+E>F0T9CO136VE49I\:$P)[C&6HP)#-*PJV\9*``T/'6D+R<*2H8T6I>F9M
MY`46C#D5;X1'X,&7X/)H]X2*]ZA@^NO\T/SX0T)S_HKSX9:_X6R346%*#2IX
M8XQV[$VGI@.F=(Q9D($%2.Q6Z6@0Q)`4F!QV-7!_@F[9&Y;$T?@#AKP86]+'
M!JUCZ3IK'6-&!A(>X+'G-G)A9[.-*(/I@YMTMR\+H9B^L4NA&"4!;H$'<8VM
M8MGAC(@NY!M<V0AVL'00X.VL>M69&=>!_A@DZ%NWW(114FBLY2!.<XGZ%F<Z
M@!T\'10\]DR]*NVLUP`=#)+VG;^M^@ZCK?K.0;*^PV^KU+!T$%#9JN\\;=5W
MT!+D$3_JY0+,&4F^G34Q9_)8W%@.2E?.%0]2V+WT/9*1@L/R(F!DYLE(/'8_
MI(3/%IN^#98`5)_CC4UF4;;/`YW.Z_YH7HNGHLRCN+0ZS0\]-.CA?W`^CN0*
MZ(1T47:#2T.ZK_.;2F;KD1'E&,S&4OZ$6I:7+XK'>\BV9FQ4=MY:X[HP(OD1
M:U/VN_8WXG4Q<#]M!G'7IPL$'G=NO[!]&ZTS?UO_3D$$VD]383N5ELY#C'7#
MWENCH'Z2`Y"-"@BXGS*ZXHS\C6$*GG[#)2WB/!&7FY;K\WW!_)&"BW4CZ`_)
M<YJLDUCD!L79/BV9\-YEFR2N<X1,?(0@PT#X`V'XTU^Q#55N_VNZPN1T_((.
M;=(2)S5UJ'R:_V*24T;B]%QB?L]3ETM%I^Y4ATM1RZ5=11V%4Q-0%RD=F!!C
MN#DK!8V_?,Y>OUK11/HI[(=3]X3]ZN^W]#G:7+%AE>_X#-J9P:Y0KL@PCGX$
ME+4@L@E0RL^TLP=S.D;6T:BK,=1OVM4N!U)FWQSIB'[[N3V"@1GW"A14"P(H
M]R7P=&>W`ZHU,:C0>XU]G[2)F;)/]EO[]RM.>T+>BNNAZ-U3KQK@.I=&,G7G
M"VS&<T=C)=1+7GOG[*3;W.&;NSS;T;P\\&(\)?/>>"&HG;QH:UNKSH@4U$&Y
M&<[3A5;W.B.BG]@*-#W/T!6\FQLDV,&ZQ:H=/6`WH8-&(OF,W)*KC4A"!UO-
M<#LM7HS9T_/#!0_<6JQLHS"N";VYI?=#%+\D*<T/W?G8)9J-DH"RG^.X>D\^
MU*V/%RBN)#,?2%0+"<PV&JS`49LXUG_VI+-]GB;E/N?E(J^3S_RGPC$_>H02
MM.4;1=E+2:H;BW58-\>U`0T`;*T#!F[-]&O3+/=)36;V"N5IF:R2S9X?C#[P
M[`)Q+GKU.=[L5W1US=C"BS+MY89^N;Z*V,S3Y^*.YK(FTV&8@%6]\RFG`%8]
M?5*^]H(CG<:D;8UIGXJ9(7`UWZ>7OO$*\A..CT.3N=>6U].#]B$,$!O*Q1GA
MO7!NFF=#">Y=F*Y@(Q]#2VQN^;S(4K8,RN1I0^\869KG="6*0]OME+5DH"R^
M'M_I,NWT($V7JC0[JEWS/-#`K+#ARARUI#H:@-+V,2MI<1<=>/:-VT9:0PS:
M#NJPCBU.T8%4/?!N/(T^IY%=&*?DF0)0OSF8KNIBFF;*?;PO1.;J"!+5.Q2L
M;5L.%\&;&JAA6.=_.B#A,:6J!"62PI,Z^5`F7BH[SEZ-?_]4T'_LV9>[>JU.
M76SR++5DH&V)&E__NE3=DHBFD)D!`)#`3:)F)9H]:J6@@4"JS)(Z#0B`O4@Q
M@LEPX6'(`IT>#MS[#KI5-_YL@[(WL/2X[7$41)#9(_5;8J=+#N7A8'`TV*R0
MPX9LF`+HQ<1;TY>3@@[U]BXHWHZ4$0EU_^X6R0-*_\6MF:\LFK++_=HBCCUQ
M8%4UT=W%=AS8*^/T<[F/-B,%9I1W%0(/#'E')S0/)])&U4"`U610<#!3<##3
M<_!=-=(7:/R^R418>VDH[*B>6NR.LH7*3.$S7:Z7GU*:%R_)[B8M*5O$Y6-V
M3A?Q/_9)3E<F'J0%,0@?T09K+W>_Z<L51M.;U-W)8T;.*:DI@'MX@;`RT<X:
MK$F-M<S($V6.B*3`'\2,L^TN2L/7S;%VU6!PXW#`K&59Z6*94_)4/Q?9=INE
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MNOJQH.O]YC9YM:_%:DD<^E#4EA>6-^H;*D22(8(."K<U%`=:B'L)<3,$$?QT
MU6G1^]41&*0\M[`WX;W6@SMV[2IMM<QK7_#CGA\;+]==76::/!1J-*A,HV#<
M.I62)FS=H7S6V]I6WAG;L]3DSX@<0(2XQ1`H4I@FXU/EIN8TIDQ<1(2+1O$+
M6=S=2$_D)=NL)#N:$F1QUUT1&[ZC'HW#THN)@J5+A17*T=RJ0$/AN()I?)UT
ML>6'%K:^2Z!!H7V:4+PSO0E=4R:<-.G0%EO+BCK?3DH-=D;D"*B\H*EX=I>5
MS!-(HLWFT$:IBD%%#NXB!94YCYNEMB,&/("4.J_>M[$MG/A%_6_FZ3WGT79K
M%(1R(@M]*&F.?_QXLC+C#2$>3Q*_:\-.#3'PZ-(OC@%>9Y9!.,`SQB0'&N>+
M1X:._3&RJXGAB!-Y*`*C<TQ3FI[Z;,#C.W;IFAG8G%[:4(4\J;1";[)+JS=@
M`T(][XW,B2%W3L5(VNPY3Z48SXGBG*AQ'1/:"[CV2-""I*=V^CYC'MP%1YZG
M^A34GHX>[0[A/8WC.5UWHC6IFB/(Z@P*!S3%TFZE:*SV6-^Y(R'W=,-CR'=1
M7AX>\R@MV"28>%[N*=\?/6;=OU_L\YSI4MN<[B!#04<]_/ATNK*KUD0T)QUZ
M9X11E)&.=X_9%^2HX1FI*&-+U)Z&29WT:T[G58:#\HHC9=;\N./TT-C0@))E
M%.7P&<?3VOXOIKF2=4)7][2@C&<OBW1UR=^!S\0)U47&X[\I?PF4KLX/W8F8
M&&,?ZA"VVHL;IXN_(49J:N+PMT./"(*DIDC.#\?:`MS83\6/?XFVNW^])+&`
MG]3PGPZD?*$B/HPB47LB]'EW-:PZJZ'/CB/UB",&XJ\PE$Z5!VE/+7A/D^W3
MGFVM^3C%?76VR)6O1N,IMV"F%"$C(<:H^[Y/MR.I>TJG!U2#38ZU.7?F(D(^
M//SEX@)/Q&,:D/!*R%O*#(,<AN1FKSD2O]#5?D.7:X6C6!QK0Z.WGCV)@U7Z
M<>1%;V=2T>%16^56KCCKN60H7G*>C!G9.#.>#)D!5V7(1U+&*Q`Y4?9T2QXV
M693^A98ES9/T^28MRJ3<EVP.%Q&//-5NDOTCF):$(9T46Q[TUC;O3QH"I*'`
M)5_2:/=GJ`H9!4'_EQN$#W"&^:8_-]\T:;XI4V"Q_*;U+@N7P^(DT5J_Q8ZJ
MIU)B5+(\B3;'@\J1+BC/&?156[T]9_`A(6)+X?G6>T*L&H&<ZKQ*S<E1>G]%
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MBBQ.HG+DU>A^VN%8=Y`$U5$\O8S.JK6P!FU[//;9$8Y(2>D"`A7QD!\I:MKC
ML-H&\J/.NQWIZRG6B^><BH-?FS>&!CI"VNE3#+T+NO7?,;T=A&+BSC;7>.:X
MK.O@:M>:U.->H03.[/FAP2X0]K(_[Y'5BN%9(323MK9Z%K/&8=L4:UIIST[;
M^Y9.9`V2.-H\\B!T0]M^%SI.![3.[#C"7J&ZJCD1[4EGC6/;D:('YE[9U1%9
M*9!%..VGB:3IZZR.$?&-&B<Q30O:R9^6X:XMS9G7O$G^*;ZC7D?T@VYNA$$B
MSHX\Z`5`)9VCJQM54/>8%`(%,S43SG!PP3[<'7@MK$ZX$/>X`*NY0LFM+I3N
M1-6[0G1:[#?\R9$'FK^R&10^OHZ>&&QA?3W6@4?GJSZD[H1`,_T2('J4M_?"
M6-08L;I#IA)I4'M>1\E3>5RES]&S#&+8.S\CG2$<G#$LO3*\35L,@A(*"C(C
MJUU<2D.J[NFYWCMW%#Y$J?'25XJZ&3U(DVF(^'15=;J1MA]FPQD`Z+8%&L%K
MA;F1XC*B-I*JM:-&Q)"4JKDU?0/:G`[4_40#A,:59/`\R#P[.K`;A*8K=/2R
MH):(=[F"X2N('B_V&I.$+5A@BMMX%:)^.7<2O#C?N;5<T@97^<WH>4IB70/Q
MCGDTS*QJ#=AP'XBMX\#,3Q=16]>T;C1O/5./.6?MG`E-V5`;!`_>.DT??F=N
M->U=U0C'=EPEGLI=>*^#;XZ+*$!_%R6K'],5S1O_^R;]#QKECY^RQY=L7T3I
MZFI#7ZG5:['6I$$3TZSYT$OT$!0()T$$C<[&_"8EG`QA=$A-B$A*:&QY,`[L
M.`?V@@/MCCU)"5M[W^#9L$\.]\`_>,D^>%E_<"HHX=K2.\J_/A'/DNY<:NSQ
M$]V\&KU^84T2)-7/&K>WVI*4P'V58,A'U-6W\+[-Y##[:JH4E'#X1XYRK4YG
MM*0WFUIZ2?*23N1?M<3?A(?5X86_LJIHO3TO2\^%$<7UW1OTL]P!#ZBPBM8;
M];5.M4$X;ZNA[%MC*4K2DJ:\),@UI<4B;4KBWD6'K6F@R80*2"4D$W2]&C5M
M)\)[B:2[IDQ1W1'<;_+&MJZQ-66B=U-ALZ]$-!TX'/Z0N=RI2P#I24SD]81P
M;G#Z,':N"GIGQ,X$X_<U[/"\#:?!VS?PEO+52KRR%6WD")=[JA7W_OY.3P0D
MK&*`K;>BFC[5Z\#BF1U@T0^-+)+(5@P9M!:8#QH.TV\L;^K@AY:"ITJXI$6<
M)SOYU/%%ELKAKK/\D>;;)*W>0&;_?F+^!G=`[FB>9%:/>#H/`>DVN/.E5VJO
MI22*H=:T".M,.M3X'SOTB"2(QO$(QY"6`VO&@;+#@6S-?]5P8#<-!YQ]E6G6
M!*]S:L<17-Z.IP;1.D.N]'U3W%OJEQ$OIMH9P<I?,B0$X3.98NRE0'=6*.]X
MJKKP^$XA$*XB68VX*XB(?*C)(>+PI:SD4>E/F5'QC;0F:;+=;S_23U?_V"?E
MX3KAH9LD??Y(Z8K*/9U"D7DY6F''A?2^`G.P%SZ4Y`FC3^0`I!F!R"&J7:#:
M6T/LJLW$O91QCTKNK1ONI9)[<CNF]FLPNWDSLJ^W^`S9=XW<)YQ"`VH=Q:"#
M^N9P'T^"WD=)P1^8K&H#F_B-6A(@&=Y:7+TTWM-E3HGLQ)]!F^I95NLL:B=8
M1\J/DES">CK4!:WA?<-I<.%P"`U%3)V6K>GOJ0&82GE.7FDJXW;+]?)IDSR+
M#V=5"'24#*2+-H[O=%G5K>LX.]LP=CJ@\9P<055Q:+:!RB8$Y>S0A$2%R\\P
M$#*MVS!&P_M.Y=";TW<YK3,4Y)CUH[##3UN/^0B>`T!X$+X\Z=]*[+Q\WBTC
MUB%9:YWF4>G3%UC!'9!)N=(M*Y9WGR-N,F50/$$-QY1=9ZE46J]A"'-[X!^K
M#BWX&M?(C_K<!2`6<<QG4[VMS=_([4PGH<7%/L\M4IFLR4)Y8?;X>T?I54_2
M=CT[4HRL]QFI^J-PTOPQ?Z2U</->(_H.S+%Q7->CCHXMS6#IA(_95<33%,75
M5Z/T(E57V+M:ISC&<@<?,\(;U]>MP9T+:Q0BQ:[,"(U$-JUH3:)U*0+BV]V&
MBOJ!\:9;5!G>7;"&R1`^40F6!UAIYYN1\B4JR4M4B)@'`TSY#05Z@AF'+Z`1
M-H.+5<?]?!^8+YDJ^7%W32G;61U5H[:)>XQ1`7TZ?@Q=[TUQWIC\N..7"\0!
MTG&%=106U0W4^_V.)]X+N0'6`[.@PA7VT(N8_GEW-8DP\G^YIQ=9(=0+/VDW
M,?VJGA"67XE"*>,\=9BWE3X`;PU<V<88`I]YG0%2=.0`W'&Q^PA\UCP5..8?
M05CUU10?P=HO"8$"AZ<Q+MI*1T/1+63F\L-+Q+ZE*,JUIN)DU\;9T))"DXD\
MB%.3<2S[D+J3R&)!XWKXH>,*2Z(K:W0\3:+]U].!+'ZX/2>L[1-]B39KWH7]
M!H^7,@D#<+DKAI)JEPD\0&?NP.-RO4YB9I+YGIBFQ>"G5]4$'>X+56%6@>1T
MY=7-?DVZ#5%4D35$<!X5E!31)LH/).*/K*2\3&<^X">`58L=6U6C%6('.WH:
MV:60MJO/_.65@M[E"<^32)^'W'FE^*MI0)K5$62]92]U;=V6B,9$M$9C1Y'"
M<3:+]GAHC6<G\.2\-2X[J!,FK0%4$IC;\EU'2?[7:+.GBZ+8;\6LBJO/.QJ7
M=*5PO@=UG9X.E$4T0-A+G&%=B.A#.IW.2-UM&L?;/";@`8W_6B0"[4#RM4+!
M^%N4,[50DDWRRCSFJ@Q1#PV8Y3>5JE$O0$LDB$=0U&?_C]D=^]@OS*WB#[1E
MZ4.9Q3_;>P<Z>O">@A;QL%DJVJ2CQXS4/8GL2D1?9#Z$,]`F9:;,R*X&&DN@
MQ21`/;V+Z9!B]#O,1-;0!]$0"QG::U,5BN7Z;A/%U:LS['^NL[Q^T,WD?,&)
M+,3A@QM^31BP0T>4WZ\I$4%*'$_6Q,`#_^$9P)R7O,,`7E6^84`D&,`/_8JI
M&&!]:`#-`1P'#AZ*0'D:X4(SI#ZKG-!."E9Q?FB&=CZVT)%%<X2AQ:_18W7_
M(X5V?F@5&AI_*AQL)JR?:MA=(7XZM$*,Q[N:%S<N7\M!U.W./30T/365O/VZ
M7-<QIG8\$P=KK#>$'S6*YG3=R<9<PS21T8ZV`7>)7+`P\6FBHAU1@O=N`H+!
MX:CHY4;ICXQT]1?FF'^59T;S(=LD<2*_T#6U.K\9)0/I5HSC&UA&56N1%-%I
MS],ST3@-SJ!X*D`7U!0)7,XN04A4N`R^@9!I#?P8C2`&/8EEHF=5$B/:+%:O
M29'E!YOPB3$I.%-O@G/8O"1QDZ3=="9U;SR!$7>8'[*T?-D<FOSF=8,RJE'B
MB7X$^)H&.#&Y#L82JO$C]'1"QC+:\K3M=J2S&Q%Q%.>(AAEQ-'$-0UYHHAN=
MZL8MF:/PAHS7HO%70O.`&?RHY4'GIF9WSR\#EGC<&T`FX/*&G+6#71#$B+*G
MHNN<9]5'7.>''[+-*DF?FSV:B=]D2`C":S+%V"_AW!Y?MX?:3$M5?3N1$W"7
MR15CG2SR0C>K`;G#<\H=^JL*%"TV!OVE^JIMV`6'ZV0EHDK'R8Q*N'U86S;C
M0Y2RM<2_[75B=V/%B!QP;,8`[^A>K%NMI^U)>%<TWH\;S.Y>K%MH9MNB7$^!
MTB=\X_,U-3AQN3`6DFH2V-'2"ACDO=YO-H?+9+,OZ>HBVB5EM!%J[>H?^VCS
MF(UGZ`UM3)TH`X5_W+@P'B46I$A%BU3$*K='D.-)?9"Y?+,P@A>&%XQ858R(
M*T9(3X$*1C!W")<7A(43.%PE/S4Q%G1R(>O]E.EG7NFYJ=BX9_]SQ^C2DF<Z
MI\5@/%M=K-J`&F@Q?!.T_1<R1:=NO=6]^(_L2>JN:#PI+Y2=4J5[\9^=1$FG
M0NE>7'Y*F+@<*7,IU9=VUY,*M#^KA[@W+%<VW`_R!.P$@=(I;S7#/88B98;3
M7^YH'HGR8QO*HQ/;:BO5BL8DM0J=3[!,O\;Q_-'X#$J9T!Y#'74*6$[P;I\7
M^R@M;_GG]WRG6$T-QXO%(V@U]0?K?D1T1/V.L3W(NCSAK@8I50'JUXW#H\1E
M[,U%U.+U8R6IN>\[/\0O=+7?L$W.79XQ"U3RLZ:T7*0K_H2$J([\R,^@=!Z#
M/3VH^\\6B'MEK*JN8K=1=3XCHKNHO-T0(#\)$O\;Q77B$(`S1\!@-XYMU_7H
MS6-C8C!U>II)?*#;)YJ;>@P:(M#%OU78ADOW=)>B;#J[\(5$0[5HP(MXCZX]
MHY+=PQ3FEB&E2-\F*;TIZ5:;0FI#"<KJ&:'L[>'&53[O2D1?'(9N9HQ@MLU\
MQ8Y:-0,R:&3Q(RW/#X]L^,534>91;/WFA0UE:,MGQ06K]7Q&&(DSGG;`J9"?
M:CJX;*47_H?]=LMKX/$8<D5'\*"QJ.@,J?VB-[*N%F31B/F/!5WO-[?)VGB_
M:40*G=$]PFDIP;(OX9UQ6]U1D`V*U_X9%C[#VE^7;I:U0P>-S'V?9X7QJ;(I
M-;0FM$9K*72BV[P5[L+B>\QX,L>N0;EK4"H-(TX?0`6P]=DY*/Z@'8A>\9*:
M$-9=D@)XJ6Z_W8OWMB[I+J=Q(DX4V,_\2:4L93-<;+.\3/XI?J^<O:G9#S<>
ME&\0D&,#C]_5I$F7]AEIJ`LAZ=(_.XWOGAVK0!2NQH0\>W=+B^(+TF7=JC-$
M./A_E/!3^LP'>:/PP3RTT'IFU(T+-IAGDL`MT^C+]#(I=EF1R&MB]5@:W:D\
MU#0F"9DN8([[=#GSGF29DD[?[ID=64RJVIP/U3T!,Y"K#F!E!*1WOCZU-IL/
M,+XHCX,`:_,(3.GY9@X.T'RDG\M]M!D)P_:3K4S(@.05&N%3[11/3@JJCH`Q
MU6GQO:MZ?@'N"U@N374^GP&-N?=173_#-B9SW!<Z`G."I%\38`KG.D#@P6+>
M=78Z&ELSMHJ,H@I''>%2T1[SB%]1?J#Q/D_XX]U,1)?E"\VK/RR*@I:%8UZ:
M%7'X)#4[7HQEK%4=2$M*J'A!K/FC)(<T?RT0+[(@O$"0VN8@)X9Y;C:4Y]83
M'Z+_S')^?EDLUY?TJ=YJEX?.;#\GUD<:QF2A+:LY_OYM*]93'/V+0OF\<^/E
ME8>N,/S$*>#*"@@#.W.`#6[/+5>\D:DWI8E0NB^S;908OT=I01#*VMM@]I!I
M20.'40\%62//"LA@MMMZ=8_::W-JGI&@!YHF6?ZP?\IR9OUYJ.]'MN]A8]#5
M19:R[U\FS!-@&^IM4O"2C!^SDA9VV>C>PT!&JOWXTW-4!372)4<:>J1#D+04
MB2")*_<]/&?^\-\)1N8X!_PG63=%ES7[AC5QAS6[EC4I)XGKQET`;:,-H?N,
M@3TP<FM[<<%C@+<2(+D=N0+@'"2Y178!8A*FV$9+1ICR9D(F/0D*&C:Y=;A?
M,>R6R5SWY5JMLFSO2UB3!76[K/"K;@HPJ1]W&W#=D@@'G+]`X>PRX/(8[`5!
M[R%8T)S_F/"IO$G9X,+MO(YB*DL+F!I\=7\H>SZ"J'\$Q_;[;=LSPEM717\0
M/$)N@>1"+5]5V1P4;H4%HKL\2>-DQ]^D&)P_F`>@DYA1`Z_L#"OW/Z:13#^D
MJ\NDB!4*0'-2K"4(?=QA@EFK(CK=2-T/T74.%XR+MF1>GCPG_#D%IC_VE*?$
M38//+ZT"_5?TR&7T0<DSK_]T_`TCIM^4GQ'\-,I8"1FFG.BH^3[K4]&YIR*3
M^S&[CI+\K]%F3WG0/$]>HS)YI3:/@=I2!'EHW19U3_@J`J2BP&NO<1I$$)%'
M3349/&^)_D)@VS^J'@QW7N$N,[+FN%\%;F9E5BUNY0NE4RO?\+BE]EVYH`?W
M;=VUF_H)>3MRWB^N=75_;^QSFM)UPI]ZDQNE0CP<&97[W.J55Y]18-]@\^".
MQI<B0WJNI4A:DJ2BB<!;#LZ4#N"X!;R6[7'YT?\7+`B/-^I"\R5I^3)D&LH7
M2I[&U@Z>&U9!>:,VEEJ.H-G%A+$[!H_Z.0\1U*AV+Z@R$ZX.$_4]"R,Z('L;
M,X0ZC=?M*!Q[('T?"M]BM?H3B;J@N-\Z%2C[+8K'5^OH8Q5`'(7E;81/[82;
M$`FJ)9JPO0PJ5N<27%&-OZQEJ&$-R>-QMDWYH5,Q[7%(%:UM*$$_KS4Q(Z2G
ML#LY#:H/E*7/`/.:UAPKH*.NQED`_II66`%V\HW,:/M>93]Z0%F9F=R_9SS8
M#^2R^C""W@'L\6/J8`G!Z.=O_^Z-+0"X1\P-E['&#1GLY/V^7?>%4/L;`L/]
M8=^P&T34O[-R],POPEQT>R#X7K@=6UX&3[$-=/9<[SQ-["XZ\'NRB[2;62[R
MQQR*J5@2A+!4MIA/5QAO1BH"(L^XFR8E4S(1%EN9`36N$BQ.2UMI;.RH>4IE
MQ[&\8^OB)2KHY9X^9C=5[L5R/9(.H%0^-E0A+985^G[*8KMG)75WPOKS#6U-
M@4?3H%(")H4M'T,N7B(V<?Y\&:<B!+9\R;/]\XOR;!C.K$\%FY(5^^AL#]LD
M+&5K=6(`J%=@+^Y:7\&"I%N.:$'C+Y^SUZ\2I@B+4F:(RI]/<T/E;_]^(_[#
MET@]\M5GFL=)0=D&.QXZ,#_2Z*94YG8HC-&=+MVV1Z.*SDC=B8A>H#Z#,[`&
MPXXWZ$@=N%=@MQ('70%#$H`RM4MR604V*HVS4(S)0;D%YG@-Q(RTG0COA<(#
M<$?8P*(MK-4`+#`39[E81VV;*2W_9X_;LLGB6>7EFCOZ)CM@=5^(S>X(DH&$
M_?;D4K;ECC)O#;Y[=86QDS"8$4JG@&$=I`V#`T?05B<DRKVTLJ-W/6"Z3?;;
MZR3E+F[S9O')`8[-EMF4(N1VV1AU_RZ<Z$BJGNU3Y;UC8106,@C6=86U><N[
M=P"*9V<\`UA<^V`[^=7N@0W)^2J=Z"`O!JUHKAC1Z"#7A`S(N:X1OMX2E+V(
MZ$:4F@;<K_!#MQ?H=BIQ@W<W)H6'PPNQD#_U2;(!#5\U(?R<)'93%VJ5:4,6
MU$NQPM];D55O@E2O3`3[0Y:6+YM#G9JUJT[?L*F=J3^Z'7QD/HV]W.L=&PN:
MOFFX^[Q*[#T9M+C.?-P=-[H@R?QN'.CE759DQ#-/)]JL((P4'F4V.0OXPT\U
M"W8U"]89)I6&D`<XW"T?A:"^4.!"=)I@T7)?%F64BF)XH<)%`S01!HR&D)N'
MC#J]WTC0R`9O/Y*2=?"^D<!1:,#('"U+>78-'_4)PA;9NDE+RE97>1^5]*'D
MMS>9#HWYLGDV?GS(AB*.`GP:U-I*375_P@F<$4F"M#00UK6SA'QW4J\OJ1'G
M0&?#WBMOQ(EP(.?_]F1,Z:JX9OA.LT'M7(8Q.K!NPBC"@?4FFA/>OI\<C,@;
ML(+UD?)3DPJ:?+&V*U:8C+[;Y^("ZE%F%YL3H)=*`\,_0L0_#%PI(/XDKCB(
MVE3%.F_2O[TD\<O)B#QADZZ,3I!<28.<*CGS82!*6%&2+VA7M.H+S3<I$>1Z
M&HE(BN#!E4DX(115S8DJ?)JDY)/@1%><I6LP#2?L3ZNPL`)'J,535ZA/NQSI
MPNYS/O#B,TEYX.E]E[2(\V3G]@BQ$5%<1875V+4;G;JKR'0](YW>*#PR7[P7
MIP*\K?$RUW^+QC=Q6M(.Y6E5%#V]EN_SK"AJM^@F?=@_%?0?>QX,6:\ITR#/
M!7^%H+EQLLSY*V^OT88:%JSUHP_AOWARY'09"W*D\<F9T])2)`U)^1)(YW[;
M,B<=NN"NS"1,:39?S&@7+5.RABG,P'?+E!"VCZ$3,L7:J\'(%1P.3@BUHO1R
MO(A[%Z\ZK40K7:B_)>6I;V45++*C"UNNRHH#?3>F5\.ZVJ\13F&&\))K]5<O
MV$?76>561-Q@%;==LAQ/$,T39_--*XR?!K\I>?=`J[WZ;[_@CRLDF.XMAUOA
MGXQ6.*Y`FXN&,ZB[94'44T7W;I!]S_^'^\U-17$3S]6(#(2#:H9/?UN2B'YB
M]]AY9P#<U?2&5PD=>1;_R^]+=@KJPSN-T^+#X?Y9B*#2RS.A`1NWZBBNMI2R
MN"7^C5_L:I0PKOC5.`^T,:Q.][-NH7>0(@F3P>X`VPT!0Q:\,EC7#@&L,:I!
M*PHWZN&.Y@^\<(R)M=>2@*\V/H1+5P6X\WX0ZT5$-W`+;P^K%PONO)"S8[B*
M27!YUADW_EZ=FKU#N'"8=$,9,ZPLWN_OJ0*N/I<T7=%5'2:O+Y_[Q&3,:4+&
M8RR0]^OYR*[M45);&P)OFD\(P-L3P"*F>JQC$`4DYD*,*Q!A*]+:((0Q06]W
MI#F>6ZY/!U44;QK0MUHB,"Z)'EO?R#5]N&;I:QV(4DW!D3&!HCUA&ZK6!.&7
M3`0-BVMB*&\CSHF.`D2DH=TF-2\3'+W-LD]+IT"#&5T,<09##@QZU6W?L\[;
M)]W@`Z++3`%`G^Z1"E'*F;^.%L5QSD\?FGL"[4,@[%?M4R"BR"H:%\!5$HQ#
M$T9$T<F]V"U5IR=#TJ^\BV%#%?(FD!5Z1\F79##D"0=#/G3`_'3H/H>HJ)0'
M>D'(?JEK+PE9D/0^:"SV.;]!>)=MDOAPF7U*J\O--E&&,2J0<851=/WCJ:HQ
MD:T);UX704!A8:TA"02[HWI)28-R)PC@B1!8(:ON3_`7#+L8V;]/`>(*".CE
M31L"&"$15AEPE1-M-IRR6B<,G)MJB<!D'.BQ:35"IQ>48@@"K+Y'OZTJ."4=
M7+S*1YJD5/X108:J"\!6/0Q!Q*8M7&1(FWF@HP";=[!(TWVT:8I=6OH<=C0Q
M1`$,D&L3#63/3OE;3+Z))]@65$<X90B@*JR&QHR[+&B'7`,%04\3_Q"_T-5^
M0Y?K7CIC.W2QB-GOD_)@\[2:*V4(9\"9"Z?+MB8D'D#O985WI+<@-35,KZZ%
MYP-WR'NYPYWL@()$%35XQP(2/0X_PT\;*)T/1[+!K[6(G'R;.(:2!*[+*C4N
MDWLIT]Q+"'<S`QY+F3'7>$(DCYQ^>XUBHG(&LESC0QGEY818SNESDJ:\R-I3
MM.';BZDNOD@X5^EJ2C#30@AX=\=`2)KUM>=M<06]-)K9X>:-[!_:8`BJ]S3>
M1$61K)-8?+G'["Y*5C?I1;1+F"";Y;TX$8;)A7'C@5Y=2ZDBIZ3X0Z><&+]%
M7I$#=X-#,:&'M<S8[C7A1]0DEKV@E`TD9AR^KI>TCV3=N%`-IKCN-E$LZGXN
MGMM+1FSX#:^1UGU/-<R];H_A<'C0/OP:47D-62+HMAYK1?GT=6>\B<G3L*KE
M3_3<N?Y7D+SBS\E#R&_VLO5$ZVMWLKYT_$.>%1U0?UGXCNYC35AO0U;WJ&I^
M./F6:F(H_,D1K+9E-:JJ0A4!?%ZC!=3!$A/'^#HJ[X]@*F^J[_M)C;\N$H34
M:]3)KKFGJ*0TOW<HQI_8):S&>&-^8,V9@,Z?(/F6'3X53VR]/(3Z#GCIZ#@F
M,F/?O"]WI&VF<.#D`)-626LKLP7RW09)8O/@AG';ET?K%HE\"^Z<&>Y!IXZM
MJV^'$9/W9(%"Z4V[!`9=O4&&X/?X1N3>R>\;HC>OVEJF0S=Y'0NK#5/'X?%9
M<".(/B.,%D(GSX,-]NKM'(5ZFVUQF&LZDJ4P]XZ#"K;SZ:V6]%P[8-6^=\0H
MF%&$==P,47ON:4'VL>%1F^Q:1[0<!@TWZ5+8&?`';E_J+:G&WIL1.4_%]<AH
M%FQA\;>=;I/H*=DDY>'BY"B95P(__:V-#^<Q"*0KY\.;7DI>14N^!M=0(Q>]
M5!5)\.0/:/RZ27@BGES;-#SIIW=0R9/C/Z#S[A#Q!I>KYZUDM!Z?^PCS7TJK
MU7M3S:^;M/Z1:J^^V%""*TEA@%+M`IQU2G">$=8:2;4)Y*`,,K+#`1M(S)ZP
M'KHV.SL@,#T<P.H?IMI#4_%#2P8BTWGLI0'S.(+E2*B"A;9<"ID4#?B<P7P,
M,DJ8GI`1X4*'LW`"^(F$R83>-9!H-XRG#AW4S4X/:/5B%LZD(<*,[GPX7?.=
MPNZ#UZ?G?E3+-O08CA-.+TX!ZL6I%X6L'C]XF_J81S@2G<,)M"8:Z4IW"M4W
MR]63T"-#NI?!N6BL3W\YUU,FYV'HFRH8G==Y%N*0#C<Y2WI#]UBFT8M:/SCP
ML//XQ=;)DFYT$7O$NIPY.W<86?9D(![8WXMY@UZPT4(P=H$+A+=F?'2"K_,;
M-)O23]5:7ZL),MS;]7%5V2C!'%M<5V^F85;06SB_//=U=(V%\%D?\-W1":C%
M)G9.@V11&4=)G"[Q^%!'[)V:W>NP#=EBO.@3E"'^=W[>H`-KL5:,W5C$-X+\
M]8E_0#?X/2'WD2VO#'D.A,Z;];@K$D![HKI6%)H__C>,WHR_ZKN*_/0JOOM'
M0=21FW,ZUZTD%\_8^(*2!W$T3JGC716OZ`".2TPAV1'T/A-ZY]1GS;CN]A'=
M=O+6*7:>Z1QWH"Y>V(>B-^FHKK9Q0`T)0CJ:IIA[#R:*?CQK5.M:HG$:/;$F
M:2<-$H^3%Q*5PJW#Y;!9B:G6,3.C!G<[Z)&_0*3SPY3=X._]U/,?R5#_2;2!
M?9,FY,01W`HY6C6&5T!DG[E7^CT7O\7GQ-BP#G2$?F:MBZ&77B^T[$_\K[.O
M\$DF#?[Z66_%&#UQUO8"6>$?Z/:)YJ9Z_*@+E`X_GK=BB5QFVRA)<>ANGPF#
MZ>R!U3&JK[OMYU[)'Z+/R7:_5:[E4;$]Z0RMLT^QG"Z7ZN_D)]D"E^[VG3RX
M#A]<249Z_+CG[!*0I*,2,"CB)YV@]/GIW'N+1OX=;,5/,FDPO3ZX4D8U^W$/
MN!WG;9+2FY)NK3WR01+0>GX8U]BFCK<CHB$NI1\4";@%&%EOAD\6]_O[OE"\
MWVZC_+!<C\:"ENEY5"3%<LU;B&C=AVS%&&KS8'&8@4#>+P[$H]Y#MI(N#R'K
M<Q66*1'T^=^;$8@8`M4;QQ/S*EMW0K>%ZDB><>9),(O]_;5AUI:/`6XL@TN=
M^F'@(*-X*I@/4?XS+:O1NT?]Z0<:%?M<''!=1J55EI,%4<B#)AOL_>T,[]OJ
MA./S8R;Y+07"2:`PVX%`-^<RL01=7;IA$MP!O6(DR+MOOL!S*C4G<ES'4]9"
MKCVB,J<X]Z:A4::+HMAO=WR1%%>?:1XG!;W+D]CXX,J`$-2VV03C2&)0I]<9
MJ?L1T1'%!ML%WF+UG_N"IZ30&L]N"`_8WMMX68[NQ_54,(C;?5+\?)U3>I.6
ME*V9\M["?;"G"[V;M^"`J4SR[H3W)S4!<H_%AP@`6\!;<WA)#2\7WL*W/6\!
M/"9@N[Z-`@7&1#%(\]7G'8V99OUKMF$N%R]>JY!G"[TW3!&7.56@-K>KD@!I
M*8`(<7C$#;+7%MF[[T!$UWO).=O<07*8Q/4R>4U6-%V%,K[#=#$:7P4'K`6W
M[C^-V#(M']#R&F)NL*UJ;(>$;E;H'0L_>.3=;]Z&8S$FN\Z.Q2!1,$UUD^[V
M97&79T]5)7P>\UQ'^XUQ;7DC4N"NQ"C.$54D^YV13D]YY"#ZXG(>K#!V`=6/
MMS:%>GC*=Y0>B"RE3C(V+?);<J!17I!WOT7H6NB7L9E/,4+',[`ODK*6ZSO*
M5D1:1OSGJ\])43)N/[Q$;*V(2TYT91/7-Z<)&=:W0#Z<D,?DK>W,_U5W)[(_
MJ0@@\`F"X&7BN&OQLG_1&F\A\683X74]PY@-,7GW.T0'&+/!QG5Z8:O)M(<7
MQ@1#W7%NO;'Z9JG12809#=`;RVID1MNM]J8M_.F#(ZX&@3AO(+D0M'>_GU]M
M!/M(\I`S:C]2=@01V5U?C6SIK_2J",!E.]ZD19F+;UU\'R7I;584YX<?Z.J9
MS4U<+^;;NI=D=WZX2>-L2Q_8FA`'KK>9?/7A_#!$C$>855?W#//BII\9=$!I
MUJ\PDBC9&?V,\/').SZ#+\CY@523(-U9G/$_R(F09B:DGHKXZR!U>=8$=-WQ
M;7^))]67>!K]$D\N7P(\7#6_=K),N9U\6JCLP>U(0KSF'NXX-?C;V1JT+I(*
MF3^/"RV">^`FJ]GP>O@HJ6"O!#[2S^4^&LNF-W@+K$<$Q]M^?6PC*ZYJ#)C/
M'AK1NZHUGN,AHZ5G\3C<*05OJ2CB/*EV2T,I*Y>4_;Q-TL%=ZO`3]784(<(=
MUJC[2ZXAP./)BOPN<D0&/!@2%'6V)KDB[6LU*6KKL`D(;!Q!%3?I5H98+,F%
M5$U')VJZJN8CBMB0)*PQ-\6MT4HG1\ZPA<HGALM/0L8.I/$<^LR#%]>)CZ4H
M&[A#9O3FWN)?9-M=EO+MBSCVIWE.5X_1YT51T+)8I*O;1$XTH87I75XOTE";
M?S<^]*H'-E2JC!E!AS!"1%(B4;HB'5I8+N9.Q@9Q_;9B0\G8$+5LV+2TP%V/
M`.(P&C!PH8M+%5B&'BR)0I^YF&*W%WADD0I?P)=]8?X3&L/MM)*-@OQF%.>/
MSY_,9+FC;&/'_`@>A[R(\ORPSO)/4;ZR"-);D(2+U-O@5B[A5DK/2$.!<!+D
MB,89><S*J%<7`BAL[P/](RU)UB#=L!Z(;*_#:M8$Z<WI@4LN^Z'^'<^63PO*
M50[[K]BM,0_AG*9TG92%2`\[CPJZZC:XR`IKTSS-'*`M^42<-5(B_.?F#]5@
M9Z1+33B^]8!G,IGWO1CSN!D?%96_,!-;)4.>!$/B3G-T+L:4`FR8=C#!!!"J
MP67Y8EY3TIP>&M=%C=A#Y0@2./T5<[SB]V25B$QH)JD%OZ+#MQVB<!=>MT6S
MANU\%A4QA)(Z@?_Q)MP)/U$%V5I,`%G@&(KUA;^BQ$?"B.PM."6A?0QX1=04
M)5QL-MDG_FRUL[<P1`J-HS"(TTCQM,5`FZXX?0,CB+>T*/[4J=D9A<?T1XDI
MI<_\'35,F/!X.6JQLW-P!NB`JY2/U#^8(FB@\UXD,B.MP6.%1Y6$FP_T)IP6
M#=+6BI^1E(:/M01T4OR0X'-*.M+EYH5P`G/K"'EC@TVA\GNJ8,I%EI9)NN</
M$LO@<I863=-[ROF6;!*IWRS3)T*.".7$!.7:J014%YRXSJK(DW?5`%_PJ&L]
M!FD'.2.=3L<#8<O$F)1U#_$+7>TW\F7+)L!"GFCYB=*4E"\\4U0PBFN779Z]
M)D4=O>9__/'+AR_)-5VQ&6Q(44;EGHG=0225HO%8PDOLJ&,3<#@PW78\'P6B
M15E]^(?ZN[?]'0J]!1X<VN,*S<L1I7<\PI%J&]"'B[(1V&:P(VV(K;KKU)RL
MN=$J.EJ0J"3?_>:_H_.A)I%0(^<K[,AS:[8K9MIB>4VO,XT3M6NMSP;-39"A
MH/RT,'SJU4*LJ9[JF9[J`E%.HZ6N9F23A3,%XHE.@WI$_9YU:I^A".J!?W<P
M)SJ@`AWUGD.,@\1M_IBE*[:Y8FB>-K0RC^&2M@(-BM1-MN:=A7M\1+L]?WT[
M*5A3\4R5<\7^42`\Y`PJ=CX^L.6(&'U?;UWE;#00*BQGP^0M@>:.\EM08G!\
M'-=D8VXE:@?+3[7-]3F0N%\7+[S\Y4WJEB?B8GFL1D3J>-EQS<+KDH297AN\
M'(<@,V5^;E4L2=+..[7'S]2^&:?+0=A\/"Z;X3"Z6WZZR=E^8%-0SA;)3^[,
MO2ST2@N(@P::Z\TZ61ZJ;):O@<2]&G(*%]LL+Y-_#M:5";B;/QX&J2-EP!__
MF%67X%OPEQR8TOVS5#%/)5DE19SMT[<=E!J2EM!AJ*,Q,'I"#FHDZ/9Y=ET2
M=!>ND1WO<!*D?IF34>-*YLVZ,K9:9SJ6(W%:Q)5)^3R[J-0<R$GIDT7JE`S@
MMW!"Y#W<3O>WX'(80&YW,T@NWH19@_X>18\F1@_"0*:=%2B(8#MK88.E;NX1
M@`O[E&P8E?@W:^YU*B`<1Y%<NG$VWZ=DT)CK'CZ;NRXXS;$7),7U'42W],QQ
MWC6W9]99WDEWQ.MA#$N;G4=Q0@.'!S%T&<?/;QBFB,M;4*`V]A'F$L9PCH$A
M8E/)G%;-S(?K#7DX8Y+JX-<,DO-\[*$9@!8>SS.-48%\TF$4G=J4TP+S$TWN
MH'"^TJ1?@MIW"49(S&VS_8L78ZQ5;%6?=ZP*,0I[ZUUMF+S[U<?E;?$K$$&R
M7C0&!@=146'U5)@WGDBS=^EP1=N<+O2&VH(#-J)W1MKNY!+;16D/T!U8*]9"
M/-=Q++$D'M-!X'M6VR5OM(DU)CJW@-]FZ?,CS;=W;'F]1*+`[S81L3G5H^J#
M&D]+!LI6ZO'U"J>Q'N]Y%U+W(6TGJ#?%0V(K+;&!F5'#M3EJ2W4T\,C;^>&"
M*8#G+#\LU_RMW[K%:O$YL3Y>=AX&VMRZ\Z=W,E.UYA7G>/MFR:_8/I)UP;&'
MG!!W9H@;W.)ZRH21`78=`X]^4,SR,MM&B7%RFS-Y?/9;QP\KNWY&QM2%I(G=
MZ#LQ1.4,=!@RH$<4#$'H*1A)C:,',4[;,Q9\QVE=)WE17K"F21QM'O,DVBS7
MMTG,C\%6=WG&\^0^T.W3X&L6RA"?+67(F+$U%WH'%V)="PJD)D$$#2[H-152
MD2$_24(X?(.`#+@Y!<^$.B*;&OYN:OC.#P4'PK\6"R"N>5"J>8#KS6`W+:`-
MT5N2#:'*'G@>T,I1E_7>=+<F.;?_XH9[>/%*$IC5UV30;[`KKLF0%_*C]U46
M"H7E+Y`CGI<+O1`JZO$ER5TUU+@&MZ`,[FW9<&%XZ0H*F-75U`RX0:^VYN``
M4M453%)M?"USLIZ*[#S)-MDS'Z4BO]CM&-O%.C!WKTRH0'A41NA.5V3;J=9`
MI-,-C\\T!3A&EQ^[?DK*EZK"_N4"D;/D"[E2*"1JN^%PA\S%4.D!&9#PU!5R
M`YAMMS2/F49ZB#;4WK\9(0+IRHQAZ]4-EM&AIC'AK?$Y)X@A.;L;]ICB%E/!
M6N-R(;02I?46U!0\A7VQ+FDNJ'^D)2=;F+L#ZKX03L`(DMYM?-ZTBO[RU$'1
M&H_%QXO$VI);0Y$1V91!X6)<X##;.B%1&FME1T^I_4@_7>;[9Q,G7JF4U#0@
M#?0(LG[2[R?"VZ)PV]\>(&?C;(EHQ1%!>^(.4F!HF94$/$7\GL8TV97+]3U]
MWF]XIP,;(\]>H\TU@_7CP_4J,C?5-M0@C+<5VM-55G7FL<2V.ZG[$TZ`_$@>
M"*.!Q\@'09R-(<:WKP^%.6\Q1S7F=1<S#K?!7H25CH0%*3RI:;=)2GD*3,`T
MU0Y)O"FI7=R6:>2\JTBK>C-YJ%JPZKSR$;"(DT][J]HST;2EY^DQ?$C8_J+,
M4GH7'3AATV>`Q_M">`,C2$Z76-.45&VQO*YKB>-AO]U&,JMRVT#:R6XHC)EN
M=2E-E[*CYW)72U0S8E$-:;,MMB(+N5.VPS^DFHG2#K44:K%"88W\87>`5<(5
M_K:S\\8ZP!<5QG97?]&X_:+;'G!<^W`':=9NS6UH>BJCEG2Q2%>R",@S3>.$
M%D87)LUH0-AB`V2]JT9M%_&.^U$G%%<EWQ0PZVUV`&1QMQ..W;2IB"D=$2V!
MN7?.CTFYH<OU3;I*7I,5+XCB<*53001Z=ZS"=KKP1#MQEZAIB?$>9G@XX#O<
MT=5GM*<=I@`N17]+RI=[NI&UMUZ2W6-VQ42]/-A=B;0F"W45TAY_/[+:-B9E
M1F1S7/<;_5$.B:9(@+.$#W:;T7&AC]YBM*7IZR:_)'1]]9G&>UXX;[E>)S'-
MF3&^3'(:,Q+VI]BF%"%WZL:H^U6D64?2]"155\+ZDKHSP@-B9[P_),\O;%]&
M\BC]F>>GT@9Y)HF<D4\O&6%[.;+?E,F6EQ7?1FGT3$4J.0.Y8ZLV>4HV7(!Y
M2<KRA1(JY9F[M;QW3G=9SMQ<)NG\KT]9E*_$DQS5[&#<7>\%;K@G-B0W>Q7=
M[6Z3B9TX]\MY>-`P#\V``%B-W!%,O?)835O2-%9*-EP%5=U7&B^8JNP]]VJ[
M9THF3^*2KA[*+/[9SNIHB$!OO%38^DY?W8Z(AM/9D9+FCKNNX%C`-UVC*\]H
MTS5,8;KPY=@AODV,9MZ3>YO@S]@)MB;B!WA<_PM`&#*P:0/Q;04W>P+H$N"\
M#95D,!9$=:]-;D,5="=G@]Y.TIJZWQC+F<^!&XVM=EOF^IV7.4G?J@4T9WO?
M+7]J:OGTG_*1@DM:Q'FR,WGQU(@$2.$4+:[>K?.V!VFZD$X?>)MF#ZKS5YX)
M&^4K'BO)Z7:?5B].\'#&Q=522%L=UB#['?L#CWA$91DEJ=AKLG:[#HNR>@(X
MC*+A.E87"]'TGWO;^?`2Y?2<UX)CNH`_6B0?7L]S_E:<K#G9-JFSI7@UZ*M_
M[)/R<),R]2`65R'>2WM\B=*E0%)\STB4Q4W*$"?9RG8G.]^\H#?',WZ!7H(?
MI_O^211*[`Y..J.3IP/IMJM3&L44SHB<!.G,HGI$L63S(-5$SHB<"G][4$X&
MT88>D/_<_#)N%R(^$+U&R8:?^8L@\3/OB\+70L"GJIUD"EN#9=;FDQ5\3'RE
M^>?6JT9QFMDFY>DL2J+?RZ_]F-6Y<F)NQ:)X2)[397J>I7NC`)`--0@7T@KM
ML&B0JC=YS-K<64F`+`K"29!E2@01\*!0"+RU)H@*4G!P[%=/DX"S]IU#HNOK
MN1Y@'%ZQO<`J'60+4K-IF?&-JG+#[C@`9##)E2?^:FG2';!KC"DP.U1:ZPQT
M^S\W>@.M1E8M05RI#UY*0QN/<Z/NJP>CG^^3U3/]*!:(>*HUR\5U7O.[_'H:
M()Z5'EEOK48_$]&'U)U(VPO/3?VW@\S>@7*#E@MH:0UMT_1"XB$9"IG:+](1
M\"VZQ73)ZT.VV8O]G'W2XW!_2%]&@:A7XXDW(TT[?-5ZL.%P]B>L@!1U.USV
M?TQ,M.9]L+-O9<R<KG[8E_%+DA99>L$/%O)[6E`&].6"?26J3F#N*2ES6A#6
MW`)IKQXCZTK:OD1V)G5O(KOC,>]O&*JUO??%^M)BC276O,8:B^XX'`!;.54Z
M`L:$0KPS<+-(5S?)437PZRQ?Q#S1_>DFO=JL:+XY+.)]23\<Z"9+5K=T_S/=
M)NHZ8.-%S?T'!'^5(`#/5"\C\</SF^2T8#^C3BKRY"8EU0!$C$"J(4@]!C[_
M9F*F?=5_X0`)P_Q>/IAZF?5>1>#'DE'%M20EM.):)+BVK;BVJ<;`Y;4%U65F
MSRAXC^:IOG],$R:015(>ENM'^CDJ/ERR&;'?U#;#UCFT)`CA(=IB/EW_;7]>
MMU%0(!_():F)U,X4-G<Q(.ZLP?WEY9>S`[=V'L,B+UOD48V\\BDQN9).HJWT
M)^VH>6JE/V<O:?%#MON9.:_MP/:^XC@=2!=0@_!T`8KFI&I/.LL1G9N&'IBS
M.^6$[*5"MF\ZX')Y3"1-Z\F,$O&ME1<EJTWT2>2=FWLA0[T@7(W!V??*G\E&
MU0T#//Z"U>3_)=KN_G72Z5M;?6OFQ]EV%Z5(CH+4"U]IHP>Z!-P>W-$T+0Z;
MURAU"=OH*$$:8RW*\1U`MPL^@^P#+IL+G+-1]D2WZW3!99C-)$]KFC5DYKY'
M,EC#PZY<QB@)J((9X[A,B^/`U#$(`.@ZR[=\WW^UQ%?YPV#)C=;^&.OO>W8B
MWTF]I*]TD^U$&GVZNHM*RDNKRQ<2GW,J4NX=SDGLB8.>B3CPHA>8KAXA[A`1
M?ITDTSXG6A-":,]"LF%UPH:=9$/SQ&A-")?A<Q8*?<#=FK+OWM54B/O./YR$
M]G<5INMN1OFRWLK:8HC@=41`$$AVM$;B:PH[D&RFJP=>>2_+Z:I.C_`PNC94
M05]@L$&O7%[,IC3=V]0A>/&?!O:F`[MH8#=91`@TQO2?>PPW+C?"7K[UCS*8
MD_3=&&RB6)!;/(O_L?8?-`1`2J!H,/6\V+H]$1T0J)6W",F^J(LSINA9_B\J
MG\-(DM1E6$9[>S^3RC[+QL/94!"`]"M4F/IE+WD[#`(0"@I2,SBZR+06;[BW
MY[I_H+M(%GOBEI26Y:82,6LK9TH)PMP9H^Q5VVDZ2@>[Z8K1`KY-E-9&<4J8
M..RDG5`J#:8A&5_W6-:<6:XKC_R:#KU2IHXP#G4'C7T/XNEY6E5)K>6ZB62S
MAFCVUF8@ZIFOJ?*-4,#@NRL$7#9_1#ST,?*!OO/7N'^EZ9[>TSA[3A/^$9M'
M#S_0\B5;'3?X)QTJ&SAX%NA"&>I(V8D+?>=4M"$=*F?M$ZE$$CHC)\T8+10O
M)P5AP4=:DB)BW?AME/Y;HN#6UW_5CQY?.Y`-_)CW951:F>?A_I#V68%(_Z`W
M;XC&0%NCJ"2$K*9`X6RDO6#@,M1CDJ*UU(.=/46W4RYHN;[/#M&F/%3D'S/Q
MMAHO^)B7!Y/=N04QB`VZ#=:Q.M;,':]Z-V+_F)&*`!$4P+?IH;!F:Y)76*&<
M]QFQ\1)D>?4==YP"CJVZM9`J=^OFE'Q#W9+V<LV<L0?NB]W1G%^5BYZM/(-1
M,J!A[U%\/:>\6F9,<W#G5'0@;0\T#H,;JFPF5.Z!?5=8:;.3V#4]<#D4!G*F
MC_F/T/`M0I3D1<FKF3.*2;3AU)5E__N54=2=0<H,C6#II4?SMJ1M+(1CJA+W
MUD6$K('$+1`N#EP:I@!B7R(H$!(<9EXK+.K2/\J>LS]P3N.7--MDSX<'FK\F
M,2TNLJ(<*L<^_MZ[B@STHQQJ?+TGO)N6I&Y*1%L4UMX+3Q2S=@4/AZ.QA8;K
MS^@U!!6-N67I0Y2D)4UYK065$`W&%?O]H"+:`PAZ49NV"8QXN$Y\D:9[9D6V
MG?D#"83A(C`('?<Z>2<\5<F2Z:I[!Z-]5\0N^4E+##812H]UX"W@*J4V71W=
M8>IT0V$N7`%60M*D#J_W*7\`#M'6T/>K'5VY:KLAVR6:RJ%!?IB.DF^F1U7:
M?KF^CU9)%HF'\#Y$)>6%TDQVC1H"((G0&DR]O(_Z%00>:6Y[D+H+^`[2&1`/
MN78`;:LN9,]?D.-U!'.%;,'O-4-CQK'G-!(W=;;T:&__N]+\'<RK@E=&+/G3
M9(65OS#<'_C&\Q"B@=N\O!EIV@G'&(T?8(F"-BABUE`(^7']T()+R"K?/Y-%
M_/[;;W_[_H?]AV_^^%L\/H(78%R.P)A,F=RF[G?V/7_./J5-!MK0`*/G1OV3
M,AMR(&?05GA[IY>L-^EDA0YK"L"3I2GPUF>SO'C/L$[9P9TY!0;<_E&4'<WX
M/9,6;`U?@,[I/_9)7KE-JPZC<#@6#H*M/K6VH!5.'UUG>366C=>A(`#I=J@P
MC6H77@J]:HK&\[`"4JL-+AZ[B8`XNQ2^2'!Y%:-"HW4KAGM[RO%1?76N(GB-
M]1WCWJLHMWZ=92L>PF!>YV*U94V+,A_\B$.JS9TVA,?AP8E>%;/-T6L)PM<0
M3R94Y,0_.$$9SQ0N_1%-<'=D"F;(1Q":S4U4,X,9\'7-"[&]B:;EA;6K@H@9
M.'P67Z6A=&"<"?NFW^S3U7%>WX^\@GMS.8^/S5,''C]E_T$CJZOHUJ0A/2![
M/O2R1QB%7I8O$50Z]U>%_A-Y)HP2X:30^$Z!6,"%VO`E,38=\H[O1<F!_5[T
M+%\H60O^E(P__-<%^0*/5Q:(1Z=)Q&0OEDE;+HBSHF4#)X7+GW-4&UI/SY;N
MQ-IOL6;+E`_$QC/Q^^SH@:0HVB%V4W*"B%BU7,N!NW0A,%MK-:;(<AH)1LRO
MOR9A@59I2;1"E3.MA<-A<Y%P=1*E#;'9;TC+'.VKSSM^1]O445/UALZB[*%1
MY>!7+>8MCQUFZMVH#?=[.IG'>WDJS/=!O70W\`S*X95FE#AYTM73?'_,TGO*
M$X:BIPV]28LR*??RB?/AZA\][:`A`&&@=9AZ5]F9(6H[D*,>$+5`@@!ZSRQ-
M`RDY@C2003F_.77!-(8(AZTT$B>E<1SO[?^B<+Z-XH-M59]N-^#7?3OS'W@\
M5?P55^V>T2E7:9N[>N808NG+;2C!,UNNIBD7G3Z>0K9@S%YQAM_E&;^^D:3/
MAG94U1/"@"I1])9PW9"T+5%83`<$NQ8!"@/I#0&'11R7"*4I5'3S%,^_B>3Q
M\NHSWR,4W,I^S,HDKN[Q=>[MVUA("Z*0]M,&^^D2J_J23F<B>U?7;4FG/QKS
M&P(Q[2!.)6)YFY6L)D3L;+9G@XS+ZEO+M=8G,*<8LC;0`_-$:+%XC1(VN623
ME(?S0S4%NEQ7<S+Q)ERH@E<+,D6O*1LDR9`N'7)^J'67N.]1T0)W4X+#%V\O
M"EEE/Q62$5&7$4^'6KY%=.S31(SP*S<4B!/F^'&X2NZJP*P4D1E)WQU0'<F_
MR-(B65%EQI=2F:LH0#I/2E0]9[PYRCEJB2"V;@7CZ.]DM\^+?20K=S5G57B<
M'D=4)V=OJ!R:<2G2>B^*[M[!C6S/-F31088G>8`RVFSX,,7Q(9Y9O,.8&$P(
MQ!QK?T/.^Y*J,[E)2;?[Z5$_X*NT@8#N*J!)*L+R#5"-@$&$5.;"BL.AL!;8
MD7",*27?\\@]?\E@N>Z.8.,\#/>'=!T4B'KG6Z(9WYQT&^(QLG8PF&O=%0]<
MT8*Q-:8UK8.=?8_F:+[.\BW/A3K/TGU1R5DO;Z^JE&1B7JU)@I1LL,8]<)6O
MID`$B<;J#F4-5W2`+6Y8U$\"=6V6AI)@BXE0VQ=W@`&.PQ8[RKBZ*H0EO5#;
M^GN:TD_1QO&L9)0,B@W^(#[U+K]J/NGYA^=>WPC1Z7-[)*^`H3SFL,/6#0OF
M]#G*>76L!B!S59`^,F@@<^:1@`$:H9X+$]<).OY0JW6*\\-%MMU%J='+!I8$
M03P62\PCCXW)*TP=$ET7I>`G%A49:'<E$&1^.5%`[FP,NF:ZX+'Y>"+(]KX*
M`&HDCHJ+6*O=%"MJX312&FWL-9+^Z3<SPB@>/33DP:B&XKFUZ#34'-#[^\JY
MH'N_$^D(?KDO61=1.+1;#&@MU@!&E8V6$[B<2">=:/Z>I1'54&K]=,_K[6B:
M$01U-`TQH]1ECHZF)V29`W,2)\*BM:9$W8^.K;L?^DGYH6']3!NIUON91M3F
MOEAZ2Z."7GW>)?(@GK\I^(VI_SE.`_J2J0)9[W%GWHRT[?`\X6D)A,?).E$R
MIN&VS`(*2$/O>8)?-!U;>4;730<)>%\Z;5-IF7P^MDQ<KJV22`P)P5Q"-</8
MO^?83:OGEKK3E9OSZ1)'[*^E>D&L$E7%U>T.Q&X\%MX\A_F,8QAQ1'VL1'+D
M`JL)E;FMK\A[/6=J;,7M/TT+,:/.<PKGA[9)Y4@L/D7Y:BGBY$5G0WB?;7@M
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M88?;3)EQ5-0SW6Q`ZO`C@/_0W2FM.RMBM<_%<?K@JGCS&Z<1+3;+KFEH_-DM
M`?_T-T6QIZM+\;'E/.2=<_'':K+UC?,A13]LFQTH@VUZ7+@PI5JNQYE2*3OM
M:D(PZF]UL*HNZ0"B6H(M6A./T9[L6W,)V[-&,)=P<`IOW24<YNNTNJ<9\1?I
M$IIQM*.D=OPIP5^46VBXJ+IN82Q=9+9N?ME.X8@>F\4I'!K_K=F"3H#C;S1Y
M?BGI:L&6>_1,:_MVEQM<B)Y].K^`F+N&W[-%D.MYD&HB;1TW,14<SNQ_L?T7
M$-&W9+V&0_]7Q/U#L^R7?SI@8L;F.C,8G0LZ5Z'0^CM5I*/V=BP]!C]G,/#L
MT&\V0W\-%\-6>`3!T#D6N#^'5G.#1N!0B6[(+5[8J;U!E=[;PLZR#0P^+[3[
MP?!?8&)%/A!11*?*L7X*`R4^&*'$ZW=/I$#\'/#0DP)1VT_Z'<:3]0[CGFZC
MA.^(+[*TS*.XW$<;?D?D6R=W?.XIHO#)9_\N<!&G9E:D,RUQ&PZ?;P[^62RX
M1]XQTRF>A?_BZ!/@]-QA%)&Y^S[S_-#Y\.;AIAL&)4F+)/YKM-E#G-F<3@"M
M5^[!T]G4=3,R$4._#1_[OQB+XJ1%R]S%\S,OU%G24V[\7W&JXL.>7_X)RK`9
MF>O,Y&3TV<UQ_$)7^PU=KD5.S?GA8A,5Q2.O_&R]AQHC!;[7&<79T\55:_'Z
MF\@UXD6M>`_RD^@3_E:WUX[!#5Q6@WO2@(-WW/6KU,S!'J$SN^0QJT"+Q0=J
M=9WWN!.8PWDR]]X2$W\G/\D&(.O)A'TFFOZH!\P:.5>ND7&A.>X,KH%/L"C6
MS#GHJK%AJ(W>.>HY]RIZ9`,LUQWO9/$Y&7H#:5!D%)VA-(\*R^EJXNU$<:O.
MYHDY7.1CEK[O_NZ1_5CP$AS\!.@G3FQVT^Z/,QO&&=GA!-/*H^MS5#L/]YQ;
MOKI'-8MTQ5C?X7R7\6YZW)H\M*:WYT=O/]H]RM6+[67&HYNX?/*)F*"6:043
MP*VFHW08V55;VIYE)C_$<99OD_CGY3FSY^G=9A.;N>^:SA#E),>PG*[$IBU9
M$M&:\.9*1VU6@VF/Y:+"\B_1=O>O9/GK"M'M[<5TB*S+1+I!:CX/`X.C#*16
M9)2E']4]9]^%[9^*9)5$^>$A:F('"A]Z?`.A)@1ML\<P]BO9U6W/"&_=1LE@
M'.CI@&7CP,!MJW9EFNU.E51FE[1V_(_1EOW8L>'2OS$.E!E0`HN>F:#LK<VN
MH)T1WI'_L],5S`\.##([!IF9@82+*1JOV?%`HY[,W-+X(4HCZ4J[;5S[_:&M
MW`"BGC/5-`'S;P-"N$[R+=Z`JFJ!&5FM7N>YQ>..,9V+JDTT];@/E`$ZF7GO
M!1CV+ZE[$05$/><,9AZ&5LFH(3CJ`+6FE<[6J#R?]H96]STT(ZL&8PPQP/S!
M=?SPBC+2\"==/8-WCY^RQY=L7T3IZO$ER4M*4^%M\5',HW@F5"#">4;H>H='
MGS)2]R)UMVK'*Y86F@B?$SR^!&9!8QW=<_Y:9?VUROIKR;<$=JPECH"?N9@I
M(W\&),+K@JM_[)/R<,/`IF7R2D>U@O)M3#NZD*_Z6G+`3'-("J0A`:M$IL(N
MU,K,4)W?K@WPG?LZATKP20,>3/T$DD0#I\2:Z-RN.W\X-XT3^7ANOK?-\U%V
MA]JDJO&<+M*F)6F;8MJZ3H($;$.K66>C>UM5W]DSXGAL=4USGC0@'W--TF?Y
M]O3)]`J>8E0,_\EMDQQV;.@M=F!.#J6W%?R<8T@RD&;^S,*2S)8EX(&`*63.
M*(P0=&#?E^<W42P3%9]I&A^:)RS-`Q`Z"B!OR^M0#<2M9`<B>[1OT.().;P)
M4/:OP[NCBB0J9._,FDF4^IGW\>Z>XO[G:$N+XB+:)66T^3[/]KO;D91!Y69F
ME`QD%&$<W^E2DJU)U9R(]N06,)%P0EQG!#2?,"RRN$+V++\84&ZAFW@8;NW'
M:'@J@:I>_S*EYE:^WP?"K@_,7/D8`6LTW7(??9+!8]J(#+/%I+.4XK"]JI6M
MM+:]#F%$R_:&Y&!72#O:QZ&4,_7]2#!KJ9_].6GFC\\D&C.?G..R>XK5K[5U
MI_T\A?`ZR[<TOTQR&K,.;)-]D:7%?E/R(<PMG@D5"!MHA*X7QQ6=2-V+L&ZD
MTP^1V?&!MZKA\<.AN.V'PSB9+TNEN3(@X2D[5]O=)CM06M2#%(;RHU0*IA0A
MS9TQZM.%UW1L1*O`(UNXX():)KMEK358AN3F/D42Q6.JG/W;)*4W)=T:G[<J
M.D.=MJJP]-XC%G6"V@M?O"T1C7&<M=KAR$QP@)VTCJZOT7/6X9Z^MDJD.CS2
MS[QXZ.*I$'5$K4S3,`%02Z3`U-/$,N/E7=7R"_)3W1C/-LP5"R[+,;;(](9B
ML'>@((-\)?<QNV,?]"4JZ$6VW68R,W&Y7E/^]*1%:,^,'&#4SQ"O,E`ANY/'
MC-0$B*10J=R:!OA!7R"\B<1;9F17XXTE7IFBFTV%US74.-<'QK$==)!B71C3
MB):G\KE)XYPRTC6]Y;HSB(WQU1""-,(ZC*<KL&[?K##NCW:7'AJ3;(OL/N(O
M7C6J@ONG71V"9TOK_,E4T'!%5HVD3NN-C%/Q5`P=4J+4<*6,;NP=$E-*$+Z(
M,<K>_JYKB637VF#=H/-`?%%*!Z-R0))3A^.,%((HO.,1!J=$HX2+P]VP$T^E
MIV%(QC<K,<]B2E?%-</#!^"5WJOHP8_IBN9'@WVD5IM^>]J0KH@#)WH)<Q4)
MPFF0FD@;,A-T3C008:30."T!>%#7<>E:^#.2TA)N%S3+)^<*02@F\<D9`Z1J
MVHM/?JJ5&3MP>3VN:D#K"%D3#IEE75Y$Q<LUI=K(_%A/\*SJ+HKQQ..2\*:$
MMP5W;!P@1`)"S"&LIX#@ES'MA`&'1S(N%&8)TFVWL!+*S`33F@,?9%1=*6F`
M>A!J9%JY;1KC\05<T%3+?SHT[K8^!!QD1ELC27KCK"(05,2O/O-GDN@]3;9/
M^[P0?[`WR,-4X(VS`IU.X*MNY*@?,J-M#4V*"ZV@Y9-"\S3F(;%A-/)C0F=H
M\`=)3'^@:N,'&)'#D-T]CM?UG`V-K^`)4W-^"A;%G/&SML\P5A'KDW,M7)Z'
MA1@;IZ2/T0JD=9A&2W+QL?D#R#89&Z<](9,S>BB4ZZQM"?+4>0`$M$503H'`
M.8'"^2/@<!;&)4*;_7#2;?97EU;_N2]*6;8A6ZQ6"9])M+F+DM5-6EWDK*8J
MM8JI3^$Q`'0U%A>>])X=:FEPX]12(9P,/SVM")W5E[HJ4X;"$0G)"7/79!TE
M.7D=>ET;O.R*LYB8/<!D33UH5$&6<Z&%6WC_N#=\%.$$C2YZ4#?'&.HWAB)W
MU$4-!6/(WP<+#D.O%QK#:,!15T])/H_2GZ\*!N@3HV:SWS_I"+FS/\70N_?,
M_DYD`RZE*"RD\;RIG/=Z@GD[[[DM)XYKPSRXXK5;X^->GD*WB..<6>'V[0Q3
MRZGH"&$T51AZCJQL1[K/H6"PE+;SW[;SQV$>/0'@L(FCDJ`TA\.]IDGE?<R6
M>?*<,'=:_/8EVZQH+O-E^+^O/K.=2/I,FY)E-C8TV)"0UC<<WRRRA]F6N"9/
M.O3KM#[^&U(/T58`1&/Y)^?942XRVS&O9:V(HL.J*AU.L(K6K&K*"IY5#,?C
M=,S$L^.\9L:ZK%YGYLS#Y?`$5FQ:5RG4>%/I<UE/Q%F;FR:9VPZ$Z&*'-8_L
M-'=5N`:OWIZ;3WIM76!5US"LZBEI:_N&P_T-JJ-LKZ]8CN*ICG],<QIGSVGR
M3[H2(YQ'!5VQJ?',%K&ZJB07&P?:@BBDBVR#_73==_M6"E+T)MWN=0X;&@<W
M&&(IOT\"<=Q%3"="[.R?S@89EW=I+==:_]&<XNR'W1M!W%Z!#186,J4&58S*
M&&WO_CS[?/F*WZ#?32JJYO6(O2%=-T?+_#[9I_I(.J^11H7T3-[/J*E<"G--
M_4W!JG39B>9HV2Y#4KYG`-MLGY;\B)YY81?\+MYF(^@OU])).S_P4:/T8.,0
MV5"%](BLT/<BVJ*S3(1AW4FWO[CA*W<'YP=2T<#C)(3`O>.XV8:'Q%W<_)JK
MQ/UT$/J'T<#E*=BO>*VK8$'24UPEN3HA=K58,^,C!ZS&6PJ]:'2*9TX+(B9D
M@;1WX5PNP*8O$9U)IS<7SZH_?*C"'^FN01H)I'$'*1-(:2N1'+79KF!E.,&8
MT-SN^;"]7G!?31X3,G70MKF+#B*CACESJVK&W\OL]_2.YDFV^AM-GE^8&[!@
MCE;T3*\^TSQ."GJ7)[%QD`)D:M#YK_-^AT'1K/SPHQA)=P+<2'8;5I,@8A9G
MM8HZ(]]7J:<ID7,Y(_5L2#4=4L^'B`G-N\E!_!DF9HM/5C(L8S0+J%IS_41N
M\!QF`/5JE/T\Y[SF-FG=FBU5!G<](>,:Y^,TH*)+&F3CQ7WJ*P]-#W`/R^:#
MC48?1@F@\ZA4DM7>2KJ,RO#>DNFPZ#TA8_ZY>#D:)Z=S&XX/\K9,M#/C.JA7
M`ZCQ6UD[D0MC00W'?#/J:=#P?Y]GA;%1G61H*%L\#1^'5=;`X75799W7*NO<
M9%]VT^[+Q*@HSECFX>;'/7]MAT>9?DR3L@#=-LPG(08.U!3CA@@>NT^I^K(G
M&Y-[NHV2-$F?+[)4O+"QCS:*6@K*D/S,$X,\<9K[&PQJOZ'4G2'M1P:T7Z7\
M:CGO!Z*:R9#.;$"J3:#]"!8\(^^2E!QHE!=?*'4KW#DB&D9&%2/SAI%QAY&\
M4(@XJJRR!B(^A8(\R^'/>%SUUW?I?Z0?TLO']`?VGX=?BU3.J#P3W>CG:+O;
MT#/6ZIO_^.V';[Z[_#4;:<=8+8*XY0L?>)?E?"9K-J8X=$FI^&Z,0O)*R99-
MYX691_XZ9OF2L*:4>_X'F%,9+)K8\'QUWEF]]>T#^Q??!MTP5$E:)/%?>;X0
MU(9",9E?RA9#Q>NY-QT\"LDG0IJ9D+\.52#Y1>Q$3)G>5E`[X<HO?Y<RJ@-F
MW;<,S\1S)_/X*7M\R?8%LZ:/K!D5EPKNV,>W?R)92PIRMZ#'>;KF60]2=R&B
M3W7]B?>:[CED5T_<'B`?<Q9(SDZQVT<KZX]6BH\F+QCM6#-<#J*AY&E=.AV=
M@`KB$]V\TOK5:/FZA%!5H_JBE[=D2Q$B9\X:];CV$"1(3:-^I49NH4#527C@
M;`%]"X+4.ELPR#=NE8W\QK1&7CU+(Y&#:1]OX=.D#EJ2\WTJNWZP?NS9>Q-7
M14,(].EL#<;>\6?=7@1$.CWPN2AO`)JSJ^*'+6Y[X')2C"1._W[X*!7OLA!Z
M13!P3QM"Z`<N<NM7"@:1QCMQAW(&5C/'8;6UHF<`T_?(\]B@/]+//,R[>"I$
MQ-?JC%)#"?1048>R%X[L.;A5'_)3W0N/`0Z`[EW5Z0M49LIL<>I/1\;)O)GC
M#)E*4E^96[Q&"8.]H==9+J*(DY]@:,=_<X<6>HY.<$Y1902U%V";<<4M63'R
MVSZ6L&?KA^ASLMUOZQ/G>H.MJB$/;KWGDN5I3B)T@WOZ%-7'K(Z0I.(=?*1&
M7$E<L&FM;"MR.@\!Z86X\T4E+G6.467*58]>5?=[&XIH/)?P'#E1(/*Z;U1W
MY(DL;-9_P!-@F)P#*A5ZRAI<`0I/%:)U"5WIOQE?4?S/7VE1)NFS/&G^9G+_
M<'#,-^<3#G-N`C]09HM6(U6I*F_;[[-@754W;5>Q1"0<DM>*%[M!7KP])V]$
M"*=Q[(8&G#$GOCL5.7P2L__&W#`^T^6Z.[VITM_MYO!6,MTM.>N?U'Z2TUZ/
M2=I!^0;V2(6A\2IG9^R0+A/YS)M#5Z=51/$XGT",.JJZ%QW?@RV:=B?\W-4K
ML&4DSR(_,ARX?-BI-6?0K'"K";P9+[B+8+DOBS)*5PR`\.RK+<#D7K'1'-Z<
MEVS&V0F\YF,#U!FZ"G54@R,H8CHS;YOW-X\59)F5T::NP,Z3$K(.RPH9@&;-
M8OGZY'!X]6WM0MS8=^?"M0>F*=E/5^2.:3N:Y[^$A'D+G3G-)L9D`K[OHG8M
M6WT)0E;;7Z2KSJ!5)$A\\'O*'ZND*U%\?[EFW]MR&Q-R5,B-2U#NC<@AWV"T
M-U1:6>PJ_3K,+46R'J1ZIZ0>!LW.9"[.<<>XX9Q"B]7!8,FYO.:<?(XCFXIS
MSGN5-\<Z7)N1\!I/N_T(..3<&X[.`4#U+/?Q[*ZS_'I?[G,!AY=4-=U%.!"&
MVAJX\&#L?:DS4I'I*6N>]2!)D9H6"@\T!`?DIJ11$?RR_%I"3:I.E=JX>EC>
MH7$>G=?_J$=H3_7-!!J6Y4OU(---&N>4_?F2RO^:.HB33N'-UM<;Y>L4=\CY
M>%48O!Z1O*O'[&5'@CB2\S)5-*ES)]*FF%7E^TC=Q>]!H?%V9I#E:8OUC8P_
MR5E>^]O.Y,1,>NK9U-T)/!C8\PJ!>&5\'-?]0U=IR7.V(;\)A<,T-;\>133N
M=+O%?:D3)VI($4V^9058.@/G:$7G#]TS-7E`-L8[''=A@NNF\7<Q@HP4[NY-
ME8@VF(+F>`EGG"22VS@:W*,75^KD5U76*X(G'OS0UM73ZXS.,B,?HC2J!/LZ
MR;?&"?)PN1B>W[K*8NVP@#97;&<#[YY@$1S](&!<H49+M69S?6N4WCS:6/>\
M4-^P.=$%<7G=.."EI$&?Y9F*`\U1O(/F/B.TYL@.XD6>:5>%H4*;G`GV/CT`
M%TZ8@,1/]U"3:I?<A>@\^OZD*&JG%NIMLC:.[@8<\`UX[EJ>^9F,7G7H;DUH
M/L+;\ORMN35D7A1JM$1557S2U6-L6B;AR=1;A&F90CZ=U@GO5@??L!'>Y!;#
M3'>'VH!H1@,YRWS2GS\\]<X?9)U:GNQ-5W6=VNLHR45E6KMKA).,#YHL/0U'
M)W@VK"F'+8?MOHW*AYZH_+5CFO0\7!6X7_E?^1'FI\J,HL@U`>-"MZ`E^`9C
M+MVE3UR>8O`WD\W2S'E1%/NM1'69%'&V3\OK++_+BK*Z<77/_L,V8Z+%;)DN
MKM-[LUDPSM]C@@R9UG:0SFS.2#T?<2K=F1'I3@G%5@3/YVAXEO^B7KCT4Q_3
M)M<XSNW-..]#^*X^[VC,=RULXSN]^VXP@S?GP)MP=49=6P\-\F@</&<;^)N!
M6-_;\UF-178:KU4__)OV6VLH?\TVC,PF*0_W<[YT;C.E7Y1_JN0[A)YL)T'N
M?S%/J'MQO6'-:]/RE^V`CNN!^9U.Q7Q^$;KV,GE-5C1=*31MV/OJYA-Y<T4V
M+'@,H57K*8#H5#2<;MBQJMKUHAQOKP:$K7!/4PC">!:!WA_JG//]F"9E<4]W
M><+F9)/DH:>%X16B$:2J%VV.W_P2O4C=#84_Y8OOZ&6OO<#'G[!.8DSOB4\!
MD'7#=;IO*H_&#Q0I"7DJCM/J-'*(HRPU43]8C!>S5LMUIYU)\K#O"!!IQ-Y<
M.5W!_2)?E18ZSAVNJIPW9,4+"YWFX)FTDS+F2+J/$T>K4M]YPQC-L>_\V;58
M.8,CY3:,FE$FWWJ2G^1.\D56E".#&I\U^XR`KS:P`5>,KQIS6CJ-B>.\=@)^
M#-R?C3D_-.H@/#\"E^Z=G2&X'$<_7>)83U=+WE-!UMG>5>4L]<M\/;NAZ@GA
M%"I1*)/;JX)_<._MN6-XV&^W47[H)!E6E>10N!/C"TKI)BBZ!5W=?TO*EXLL
M91^F3)XV]&-64BM3;T(-TJP;H=5)!.]&.OV(Z(C&5/MAK"HN?N(8XP[&E'<D
M[QZHA$M^&[X6D[,MGA`Q+OMJ+JQ:6VI`*JAF><QN4I[8E>4%'TP::'4-7XW2
M'*<&;U\U:'4:YC$C37^I;JI=`5`]W8G05I)79B1IT'[JH^UHG=^)4K#BQS_.
MKX!@V`!:S]9+#JT<FE%24ZHBQTH_YC3Q.#RCR.V5TJ3%?L*X/VZ(E1(Y*>)`
M_D]@R'$',F9O2"_5EC[1"$'?UP\V42S+FSVS_ZE'O:>;2%QMK<N;+=<&6[&>
M@O8@#N$W^?"B5T6^ID4$,=(L[HJ<4&%UP<+E&GX/-Q,W(L&-^KHER2MN<%FO
MN9'-P0UK_PJ2'3BV@B'%6^..N5.>2QWJ-HWJQQ<<1P!]Y,65*[Y:$7:K.2<_
MS!0!TLTH/D85\-O5X!K`T'-T)#^?'SFVQ?6Q,?-N<WULUM@NR-YQA*IR.ST'
MS&2=K<5OCXN"H8E-!N((Z%8?RV<&+W(;2#>%<WV#!0&J4=3!ST4<Y_LVT=XA
M-FE!&T&,TH83JDK=FO.3BE!S<0:-<QN0!<I`GG3/WI.H8L)J*B;XQC%GX,(I
M#W`YJZZJP33`:4XXZ+F+_3$OAJ-<_<D(N,>CG;!\OZ4Q]L.Y4/Z.*Q\E\*3A
M/2_SU2#9BL--&I8\PZ/80&+_2#_SXILC&9,Z#=BC@,!-Z:-2V:"J)6`&93@L
M[ZJFO3@7!D.I6&BFYO"T>Z#;K)=TG:0\53DM\^1IS_4-VV>D>JGH";,M10BC
M:8U:>4VRHD"Z)`BG@4"@0&"#RI[W8M18'DMR<Y?GN*1%G"?B(L%R/31'FA;\
M,GTJ7XWDY>MR6B;RQ4X.P+HJ9X@1H0L9!>%:KUAC2Y3'8(?E11(6!S/R*=EC
MVD*@<*1JS\:K;-T\V456=$WS7-PTZG`-Y?.QX23/J+90@.'FUTV#*K/2J/F'
MJ(Q?DO3Y&`5;V:G6Z0@Q`E2Q'R^N].5(893/2$V0U!2/&IV1BBB*LCQ!>5+]
MA3]2T:J6G&QK-G15"[C'$DY61DOL>)!'IC5X+5ZNV+(TR@_=1HLM+]%K[\WX
MC0;OR7ARRT6C'%$];BGI(G-@`K/H"#!3,<S>BIO147K@CVB\36<FA-`9.C)>
M0\U>_W#_5-!_[)DFO'IE__,8/6W,2Q8.]@6K,CB,I'\WN6Y&1#ORDV@)&\J8
M"`-<X;V1535>*V^HHV=`\#K+MS2_>$GH^NHSC9FTO=+E>IW$S#&@VR>:FQI5
M0V*007(3K+WW<$0?(CJ1IA>INI&?9$<\P?.WA-'Y+-X%Y%J"C`5(VH#,9#=<
M9^S&0JD]1=!3`K:IM\P?N"GI5GM]2-\?B6WM(M+;)MZ:B.8HC6PP,%BL;6^]
MV5C<MK-O7;-CNH7':;26%&BE,BU.W:(J$!RL30I/>8`&9UZ]8%$)JY1]<-E5
M0['3U_K2T/'4#A_WW#(OUS=I44:;#?^&Q4WZMY<DYG50BF1%<_%-;XJ[Z&"R
M)W4D"G%4[X+]=#5*&OP<KDN%_8,(.N2($+DI2$4*_,`^(/AL39(N^"0EGP3X
M^`A\4I#=1."MD]D@T>-(C',6?&4&@SU%3]UU1+6B^6/*?K%XSJDXC[1Q;DRH
M0?HW1F@'0LB=-5CU(J(;:?JA\7$"0*QDC.P%Q&@RB,X.SW08<?D_YL*I=8$,
M2'EJ$AGS7Z[O:,YC-_R.TWF6[HWJC*C[0O@T(TA.%Y5LREV73F,B6H-[)Q8P
MNI-_XFV8!8XW^Y5\:3Z*Q8NJC?$5&5'UK9=-$CWQ%Z\2##4^[+\<\SQVI^!Q
M.!<Z>5+Z$,J.OC?$Q1/HR_4#S5^3>&@3H[XQ?]H5M!A&#\>`.+`6HGZ%;(/&
MNAO/G9=0F&CN[L4D[">/RQXK)$!?T>&DGUC]$M@M(_#O[&?V'UZVG?WA_P!0
M2P,$%`````@`P(L_1&-[8-\F7```+K4&`!0`'`!F:6PM,C`Q,S`Y,S!?<')E
M+GAM;%54"0`#Z"/L4N@C[%)U>`L``00E#@``!#D!``#M?5EWXSBRYON<,_^A
M3MWGJBQ)SJRN/K?O/5ZK?=N9\MC.KIDG')J"9'11I(J+T^I?/P`7B1*QDJ`"
M9/DE%QL`\<47V`*!B/_\[[=U\-TKCA,2A7_[?O+C3]]_AT,_6I!P];?OOS[=
M_/"7[[_[[__ZW__K/P,2_O[L)?@[6B%,_O;]2YIN_OKAP[=OWWY\>XZ#'Z-X
M]6'ZTT^S#U7![XN2?WU+R$'I;[.J[.3#__U\]^B_X+7W`PF3U`O]?2W6#*_>
MY)=??OF0_Y863<A?D[S^7>1[:0Y!V:_OA"78_WZHBOW`?O3#9/K#;/+C6[+X
MGLD@C@+\@)??Y9__:[K=X+]]GY#U)F#=SG_V$N/EW[Y?DH!6G\Q^^F7V$ZO\
M'U>1GZUQF)Z'B^LP)>GV-EQ&\3KO\N3[[UB[7Q]N=YWW/3_-DE=:(8MQ0D+_
M1S]:?V"E/LA;^M"IEY=1F$0!67@I7EQX`:/C\07C-#'JH;B5GGJW\6+:CQ><
M$M\+['3UL$E[_7Y,Z9^,OF2^G&]PG-/67KR"YNSU-ZD^$"W]%R]<L;XD:>3_
M_A(%"SIIX#\RJH(+O"0^25O#,/M*-W1UD5UZR<M-$'TS(X#?0K=>7>'$C\F&
MT3=?7F3T@SA)Z!!_S-9K+][.EX]D%1**WZ,CW_>CC`[]<'5/!>@3;-;]CI_J
MAO-+E.)D8C;C576Z??D!!TS5[KTXW3[%7IC0#U(1&/5$U$:WGMW'$1VZZ9;-
MZ%31-TRUC+K%;:`[3_?>UGL.,&V5CE6Z0T@)_5].AC%]DJ:ZCIN8O-)9[]5X
M$.SK=>O!+=TLK?&3]V;8@WJ]KO/U>DW2?$(J!,S&*]W#F4X,LG:Z]?`ZG[^-
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M#9\:S?5F<>TP.O1;/5'OS936H%D;IZPV&[G#FA9[T6:;QFW`ZJFXS=@1--%'
MO]J,$7E+=D[.;<1V7-=J3\S&8:.RU;ZT(4W01*^W&FU(U&RRXUC(GID_`_T^
M9IUHI6VB-HQZQO.""N*X^$*(5^P,R7R@?F$^4)-/>>?+']]YSYBC`L<.5;\<
MM%54^O!?WYVBA_=TIQDMKL-V73VJ?=(^/Z;TW-ZAU[7Z)^KW4Y1Z0:L>UVJ>
MJ*]?<#O9[NJ=2J;,ZZF=3/<U+?8U;?;36)!["=)9:D/G-#IUY0YK=[0;!QVD
M"P0.%WA1=9$UT-TW,G=BC?R#+P7,;32*%7,V_0&2M7W^G*0Q[5;53,"`YHTC
MW:KHI^^_^Z#=PU(4N9@3[/^XBEX_+##YP'K-_I%W_X>?)J7OZG_0'Z'BTP]X
M1=@7P_2+M\:<#HN*HDG9P3ISY_%A9[W8KYJD_SR@K>EM6Y;X4/A:_N"_D&#'
M^#*.UN8"++L2J9%$\0+'?_N>ULD2VL<HWU&R;<TI.+BD4&(ON*4J_O8/O)62
M<%0638?+`@=*2</DU#R<4QP+AN4F\%8"^1^40;,ARKT!H93W]-3RKB`\T68%
MXJX706=#E/8Q@E+8,RAA[W:Q5W1?H)#Z05GT<<CB;T`I>3B#F>QO2(#C2]J5
M513+I_J#DNC3$#D0`"D9^"A@X,/Q9O`8M[4-HOAI2BM-6'K)<R[@+/EAY7F;
M0AUPD";53X[UHOPQVKTAF"]O2$C[0;S@/DJ(8C=I4KW]CM("K-R%1`=`7A!J
M;VDJSD.%%V,1[BXIOB6.X](8(NE_WOF@.&"!D7@9>$DR7^8VU_,WDNCP>5P'
M:L,J)D=!(@_`L/FL([J*UAX))40V"T-M?;68X9/)!S%L%A_IM@8GY_=57W-P
MG_'Z&<>R<2FN!;7)EI,D&)UR&):8?<7Q<[0SN\$0?-&*8&XMJ&U\>X*%,,1V
M@N$Q?-F*86XMJ$-">X:%,,26B=,PS+7YEGU^^A9I<J:NA'YVGS(]%&+SA@.,
MT2*X!6>B:N@OPV)-AD-L#H'G[2;*8G/:1+70+X-B309#;$$9W@)XU6H!Y-9"
MDY_<IU@71\GQIS%P?-V*8VXM-`&V#IES+,91<OSSP#FNCN1W),2W])]:IJ%=
M8309FE'HL.NV3B-`EH3S),%IHF%E/BR()JX8@@[9X%/'Z?LHK`0%KLLL9A+3
MYO"H/)H`VWXX[,AHY'5_%&RR\%',69[^Q=S!7[T@=Y]/+[TXWI)P]4\OR&37
M*%KUT038$"0F46"^U48U"B4H'^6R5Q/S]`7'#]C'%#1[@_T%IZ789$-<ISZ:
M`-N*3)5`']4XC(-TR[CQR.+Z;8/#!%>H#Z0FT0&-VF@";'HRU0!=3-"F0SO\
M7Y5=+2Z@\664[%!2?9=0+Z^()L"F*U/6->!`6QY[V,GI[N#0!-BF93R--WIO
MR_Z8UIX=G'ZR+H(!L&=!:3WLHGRHRJJA*;`I2WM/KD0QC@6YD(=R8*(IL'G*
M\"R5]]?6D@DY!N^(]TP"DC+'@+`PM)7A@HN7M1J'8]TFT-05@Y6.Z<,(U3C&
M:@VROFE$7`E-@4U=1A0JM8"';E0GYWV8&/J3.*-];X(/%U^BT-<^3)LVB:;`
M)C4%W_)#=BNT8U2A6JBO/71]=>%61U-@^YL-U1`C&\<*D@>5*K&J:>>41E-@
M`ULKED5`QF%3.0X:ILVOO"*:`EO26E&M@6D<AI5]E+&FG*1V-'$U-`6VHK5B
M7(D(VA6LK\V_T:8?38%-:JVX%>"PY2?FR,%>CT@T`S:==64P!V#+_0N2.FDJ
M$LEJ*ZR%9L#6-0LG<16\<6R@6QG@)/*<`9O<+!"O0#>./?:AJZ/*8853&LW`
M_<JD-`DOI[E`1F$483-6%&H1>EP4S8#M8*W8Y*(8Q[Q\OEB0HM_W'EG<AI?>
MAJ0,A-BFQ:^!9L!FK%;,RL",8P*^PJ\XB/(+V,?46^'K,,7Q)B9)'L?2)RSI
M0[;.<O/=51;3O<=Q#>FAN&OC:`9L%VNE-I9P=S:H\$)H.K"U,]K2H1FPN:R5
M!@APC,%[1;6U[7!CCF;N&,HLW)R*,=HRE3;TP(%@2(?)K]\C([U'1GJ/C'2(
MYSTRTGMDI/?(2(ZP^!X9Z3TRTGMDI!$P_!X9Z3TRDMN4O4=&>H^,]!X9Z3TR
M4D\+X'MDI/?(2.^1D0;-\7MDI`%'1CI4SGLOGL<YT$7N%'"/X\<7*D5M]Q91
M`\.*I&2`:136AD.\.;CD/$M?HIC\>W_)HB3_N")XS*4.I'.QC,/RP`-ZFR29
M,=-%)?!82YU9KN&`MCSTQ_`\2Y/4"Q<DY&7_TJP)'E*I,]?'8*`-%]:]%ULL
MX1JUP2,I&1&O"\B:9TLM=2D@]08+MZ06>/BDME1S@8S#5M)`J5RO!37`@REU
M([<&PMK;(9?&KMXB+:L&'E.I&\''2'HTD<!XG>W$D\R7\PV.\R^=/!??;4@[
MAW=]T7`R$]0`\2OS`IP\8"KJ#,N#CQV5A/8LD\A08')J]G\4]H92\<-5&>A2
M)S*WL`ZT4YDQJU(DXS`Q/%`FJ!192./:(X$2KX1D:3UHWS,I;WRJE7A&,9Q_
MQ2&53,!"*2W6),SSSK,0#&J^%36AO=):,*Z!:!Q#_`K3WOJDH(2B74=Q2OZ=
M_U="N*06M(=:"[(5:,9A3/S5(^%=E"3S\(HDF](1?KXL0FM.9(-;6A':7:W-
MV%8"&L?CMX9H3+9ET#YM+7CE8AC#J[<=L&*/RG17A\I]:6A7M_9[ZT,,8PC^
M^R4*HT-T59H`]>%)61?:.\Z8:"U$X[C<N64/L7&B<7PZ*@GN$*=%$I]?'I2N
MAR4G%E>VB4C8O(3I/N+ZC8DF(\E+\>#P"C_+AK&R+KA[7`?&]<"-Y?!4A2FL
M[2EW/U,E/U'4!?>HZZ`$>N#&<;`2BJG-0@[N8->!=#FHWL(.G))JG&IMP0_*
M@;O/F6_*&MT?PRGJVHM#JIE)Y3IRX27$9Q9=$F2I]!)>41/<<\Z88!U`X_"X
M^`V3U0N%=$Z[X:WPEXQY[<^7.>K:);6^+K1K$-SASEA%.N#L\<T+S&5_4HDM
M6OHO7KAB19-:<!V<!]=9%.&U`*/.M`QDJE'_/>Y,F[@S<GD*?`7&&GBF$,!E
MM-Y$(?.;T0T^PZL'[2M@_-9(!&+8W!ZA4L:AX9:'=@=0<B380HFP#)O2!YQ2
M''A1[1"5CSSY%:!O_(7LB/P[1"`LL0GIG6H_R!#P<<>07`62<5@B[0<:`CZP
MM")9B&0<ED;[L8:`+_E;D2Q$`GU->+)P0\"W^9JLZ0%Q.7*-]8A#P+?S+8B3
M08&V$)XPZ!#T#;PY<U(H8XI*8S7R$+#MJ-5Z*(8RDL`T]H,/`9N/6M$LAE+2
M_)=ATUQ[0Z@DMU$6_-K<D%(^@)+(7X9L;1!DK5%2*JT'?H5N2*\:S,[J,&BN
M:YEDBLLO?D(9-?E&#8'?MYMJ@SFZ2CV&;I7J&E/.E3`U+6+*?;)G6@2[NNN6
M/,G%6#.?Q!1R^V_)_K^A6[B(!0V(4ZBA:!"8@A-BR<%8,F(JN=VW-1@=H)*I
M:A%"I5A([O,NY7&1ON!O^6_D$ZU&?2<CS,A'KQ:DD=P$\/$6FM]!!XX:<#(*
MC:D2\#!!7Q78B@\8^1@ODALJ-P:.Y4&;+VMG2XD"*.NBJ2N.5#K<Z\%Q\K)!
MV?5"@066:\W:>=)`Y]DT!01]`]'_>E[\^":*'W'\2OS6ZWJC'31UQ>^JZ_K.
MAS:2*P[9DF9!-P0-H:F#$9_;K?M\;-`W(]R%X#(*:7M)'HSB2Y3BY-[;,KL#
M"TGB^S&%4;VF?8KV"=\%ZT*[QM#4P2#0W&6B`S[H^Q([Y$MW!2U;0U-7#&[6
MZ:\!M'7-8M=OH39;G:<L6&"<X,\X7N%8-LQ5U=!T"$8X;236KDU.Q9UTE"KK
MH>D0[&[Z4$9RK7&^^%>6I'GTUZ=(<-=7O:O$"W9/A,,DIRZ?BN8YZ.2!/1M+
M2(K+G4FQ:WG`?K0*B2+^VHEZ@*9#,@*>4BB5)KN5VU)'`K]Y<>S)@GBV:PC-
MAF`J[("M8MPM]V(=,#<>*990%G^EBL%1(A0M39W;1;,AF`_M0:W4PRW;8JW?
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M;(%N!$%JVIT;@$^+[=C2.56,(_+0P0&9W:"$/@GP`=*GR-[4T,?GH&,=V52Q
MON1CZV4%I*I>KS=!M,7X`H=X2=+D/%SPKPHE^J?=!G1LI;X4@:]V1F(912*]
M>CXQ^N\`Y_RV2JXFJ@X=N>FT*J0KD7'$<NLK4QNP+]%I548MB\XOP9S(0U,?
M`D5^%8K7C[(PO8_QFF1KV89)51<Z8-5I549+'.-X.78(]8:$'I5LN+J,$JY'
MB$XU\!A9D,K"$07T6S-[:]%XTUR=?DG2SHS5WC^DX[+$]1!A79^'EWGR@]N0
MZPTE\B33J0H>D>LTBF`DCLX/V)S8GE#YQ9@>]*YP\7==8OE63,.NH]T&>!2P
MT\XG9G*!?O+6ESZ=^_D6+:'BQG0`/0?X`>>QENZ]F,G12+%4C8$'(C/C7%=O
MM&"/(FUG$SO=VV\\PB)SY1BJ;'?A8IZ^X+@0JI$.Z30('L*L'SW2AM[94..H
M,NV$6'F2ZMU<F#4$'A;-F65.)!SH%[Y]KW6-QZXU0;1:[V0-@L=Q:Z$`I@N?
M$O\H[B64^"WLG+@M@<>/.YT*<8"/XU9"_R;:BO<.>/PYR\X=)K!MQ:@#3I7,
M@WP;ON+$EM.7I#$7(]>9>GVIX(UC7J'S9O6$QO\C(S&=4E,O7+$7,\K#E[(N
M>!"[EM3R]40/[BC.Z0VH5()TMDRW]X$7IG2?QEYMY*&S3=1#V`AX>+Q^]42.
M>QR'<7T)6EEHP./G6=480]PCWJ#L;G)M;%`DC;D88L]T@Z*"9TU-`!U#Z^%(
MV1TM%<5\6<4E5?E+J"N#!]QK2:U@X='#.PICR@/>E,OL800ZB3J(JH"'W;.J
M!%*4X]AK\&,4'R;HHMNLX@>8_K)=-&Y5@^#!_7J;/`QE,+:%9@]?$J9)KR)X
M",$3Z,@!UG$X:.I+S<JN%#S0GU4M,<1MRU,3\C3#\-+)D?W%#O>O7L`6X")V
MX?&=A41C3)IQ,>*?\`1C#,S6-.*>4IS3P1''6SH.1(&%C>J[&.C/4`UXB&Q-
M"O#IHDZD!:X$6+"G!183C+2/!\0/%L]6-X^PM`82XY2@I(L!^AI4R?IN*[4'
MY&Z_BD[/\$G]+/;%P(+CR;@0>4D<=7L4%I_"N^W)>V,F#05M!R7!XMNU8:[9
M\W'<,U>QD[Y$H4__N;_:"!><@P%[^1=$219C#>M_UZ9=C)TG73P[@QW'8P1F
MXKX-*:R,R:X6ZK,(=>"3*OZG7A35-LV!Q^JSH@Y\36LM#^#51A6)NS)7%=DR
M6$A8P4-*K7IH!FS@ZT$#](%#KTWF7(NN`O0JHAFPH0Z"[3URZ.R]9G0_1?>!
MY^<+Z_F*[ZID5!^=`5O<3DT^5P#0!O[.Z=OD"7H[M(;.@$UQ/>E'%W%`AV$8
M9%J.,V!C7O_S3#?9V#(+-BQ0IPLL?843/R:;(GS)149_B9,\-%NV7GOQ=KY\
M)*LP1TWGWN*)"\NL&@5TWXU/'H%Z'J^\L(RV0F>#A'9CX95!P.YKXME%8O&"
M?>1LC1.\E?8A8EIWZGAMX%#B97P_436[".0^+*?N"G1<;FLZPS_]0HBSOX/S
MZ2:V?(,PF>C/4/R`-U$>S"GT<1PJKEAX1<VF`F4/9,-/6!9J?,ADTER3A5T?
M@R[6'H-N\QT'+<JV;B=W5>5V0V=A5%6%6/-$?=I/>CK+E4$KT"N-#@G\1<00
MY!C&7/76Z>"-V.E].?GOK31&G+(NQ)`3=LILS)DT`SWHM'C@CSI3F&,8=FS;
MM3?+U"YK\OW8J0=@%;Q5^PJ77P%BJ!WV1&=4"6I`#R"Q2,77?2,>(/5(F2=7
MJ>K3^^M49NOY.UZLVGL]=&@59EP9=U=O\+5O%GZ$=F)0-(R["60,8[WF177J
ML;[[M-%8EM2"&*N<[NB,15DUZ+&FD#!_+*D`C6&LL`L[DE:S!-TX,NLD#B%N
M&21=,?,'-&D'8GQI=5!GQ)DU!#T&C7GACTIST&,8IV5.Z%/GY<J_JC'F#@O"
MI)<]SBG-CKYFXTF[#>BAU!0W?ZP8`1K#,,D!S_.>,_//R8]Z.\G.E_7<:J4A
M.(_!D6=?>V;9UZI`43JGO4X-@QSX='M\4>^QUIFO6\O08[<[E8*37W>QC&$&
MV(5LZ';_6S6CN'T^+F;AYKEJ4G7KW"@'>>/,DT/SMIG;Y3$H795D\PHO28CS
M36E,GC.H9:@^_.D>^0&G),:'-R!ZYRC=5D`NQ6C?BI[EZ0WNZ?P6[[I893LU
MO"!KV23TDF+(E.#:K`/X,8SAPG-I=NJQ^I@])_B/C/;H^E5S,RBJ`G+L.NJ+
MUC%+5`=Z',D$*SA@R:",8534')6CG:.RMW-4CN2.RN\.RXXY+%<,TA7CF?8L
M]T;*2=I*T(HK00_8GIV`Y<!'$56!'@9),E\>#=UM\:?.9*[7``)^TM*WHF@+
MP<D7LU?X%0=1[B-%4:\PVT]ZH882Z%=&P%%O>E(`,P%`OY^U=;JLB4]_HI!5
M0\#1N'N>'E30H=_4VM&+KPF>+Z^3E*R]5!H8\[`@`@[!W3/W3;#0;V)M^223
M*"XB.#Y@_^"1YCY!8>WT(/5+-FL*`<?KZ5ECVHC#UI-8^"!1G#"A^DN,3GT$
M'+*G[[5&5P:VXOA!3T,"9W]]K=%M`@%'^NE]VM$7PS@"B-W2?3J)&<1Y?$62
M391XP7QY%[&LE*]X423UTM>C-LTAX'A"/>M46Y&,(X-P[<V!OA:)*Z$)</RA
MGI5%@;S4B5^&K1.U("@[(=4\]96V6*WZ:#)NNZR^$';FMF%KS<X3W6`U$E1!
MDW&;8J6X*W48>##=!RHE*G2VSZ\9'Z_?F!,`5DXA&K719)SF6E,15/HR>(LM
MWQW0Q'BKU0*:C-V0JR^&2G<&;M6]]N*0A"N6K"7W'M77&45--!FWX5<'?J4C
M`[<%?\'?:E>?<132?Q9Q0Q/3ZV33IM!DW,;@5O*HU&K@YN!CYRI37=*JCR;C
MM@?K"Z'2FCXLPD-Q6'MB$53>W=5<<5?;'?2K(+&4HL_88_['BSG=@?E9'!>!
M:;]$85S]-_?&R9G4F26L?6/DSG!6Y30&UUA!=+<49`H969#!1_\%+[(`SY>B
MWFF/;].FH(=Q^W"#;9".82!6-Y=>[=(29B'_\T0>['2Q[LQ8ZR/*X.B&ESRV
M(,Q`&W"$P?TLS?K48AEK5H,>1J:Q!E58QC!J:K?94$/D/>S@@:9Q.FXZ\&1-
MP`_"'L()FH!W/._?'D`5AF`>EN]V6(F<KL_1`@?**=E.P]!/HJSJBSV1]/A`
M"B0")<SD/XHXE/7)IV">=JWP&:1Z6C-#M=I$&;0(/;6WBE[9`>LH7K;N\;-;
M^RADT]M\N1-EZ>Q1!K9HH4'&K4)/^!VUJ!7>4<SFM8B3WE'$29C9?0"14KF[
ML<^$"BNE2E1%']O]X#-.7Z)%+DW!ADNK+O1$W3'$J1%.2Y-T`.7"R+=07VSK
MOSE_([*'I/J-0,V]1HSR9V`SD./1BJMH[1'9L]%F8>@@`V94J>G>HX*BE3N-
MGS\_1VEZ02(6)\S;X"PE?G(9Q9O/>/V,8\$$KJ@%'0*`+_?F_*P!PT5#".U=
M%+,;_R#RPG_@-,7L=O[28YG_+C'+WRPE3[<Z]&-^719-\#@9LD6UJ-#-+[Y-
M\9JW?!K5AWILWV'E-,8W2(:US)1FC4`]C3<FK.6VF??^?=`GTZ-PYT`73>]!
MSYO6DGVD[7K/:WPEI8%]V\+TU+9QZ.-Q7Z'/[4AF#!-"D>0!9AX84K(0A<*<
MLTNK5>$9>[%M1,T__^;%0F.5]6]`CUKM9",V`0_;CE%@H5]1&+`.RD'?#UCE
MCZ\B#;S#IKF]G/:""!=LY_;%6V.EP:N/ST&;S!H:(9A;>H(^;/VKTD[4]C="
M*XZR#K0!KB^*^0HE%<,H[K]+SQNE0AR4@[;?G58)&M"A#4$G6I9$,I09#>TU
M#AV^\P3['#M"LJ6-4+LCQXTAP.^^[>A(;P81>Q;2`,02LLLU9F@+<2P;W)[)
MJO';),FPGO5?K[+[>>/T<;AX]5I&'MAU?N]9K4>B9G5(%Q=-&@V0C,)QL%LL
MBBN<>B1X#T;A7#`*GA.U220$B7"L?0/::'RJ8!0VY#1L(]!.%!?;W3__3G#,
MXAMN[UAT0X416J\!:.NT5<852J44Q$@TIA1;/N::B)7V:*-VH`W-^N0JE$,7
M[$ATY#;<9&F2"VBBM"5*:D&;EXWY4Z@!'^$H+,<\C--6W$_=L"KWR/UT;,9C
M'LA9*_++6M#FWA[)KR$<1VH_&YLLG4L$J]^!-N2><F=J2U[0<Y7<4"9#>9[N
MXPP<`WXX`*PPUO;T->@L4=9516+'LR^Y4>R?]M$O:G*1^3GSRD-EANJ98/[\
M)I3`&'QRK5B!)^]FX,YF8$'NZQT[\QT[YSMVYAKQH@4+C(661VK%M2@=%ZPL
M"?9_7$6O'Q:8%..+_N-X6-$?H3N\\H)KBD/XL)U3"O):SQ)'A^0+,`J)[)>3
MHA-"4^=Q$2@KID!H3<D>=]:"6/EOP'U*-<G6\B??!X6@+(`\L33GHV9?1[$7
M%8:IO=AJO$_0J`UEV^MM?C+$/G`G/7$88_IEY0V01FUH\Y\FC88Z<(C/A4U(
M>Q7X[%$1ACC>U@$J+;Z26M`&.4W6^)0K<(UB4;C)XI"P@RK%>$/>\B.KVL0O
MK`1M\NK$MQP6M)W4TG-$NNXM2)`Q`\LC,\WD]I7K-S_(%GAQ0P7*G(.SZBQW
MG+GN8LMO0/6XL;^O0AK'>MUT]"PS6[=44,]JN>"TWDZJJH(G5^^9>1-U.Y+*
ML'<W=M](0B=6UR*,S[4<U"CV->V>/$(G1._`:1/(.#8LM20S]U6W<[U54JNH
M"9[8O`/9.M#&X89RG&.HS#YD0GZS'GAN<CO4"X"5Q'=.-FXG0FCUM#!<5"^#
MI'9B47'P%.$M*%/B*9GJG/([Q3'@`%VORU>D&H/RJ"QXRNY.`Y$'IJ2T<[IM
MJ(?:ARFB->X%!#7`<FGW?BZ7`0:;>GMC7QV)2%0'38!M@3*BM*FM81GVX?<(
MFW*NYI9'$R!KFQY#6JS6D#@52KW;I'6G"/)LJ74T!;*-]3:MVQ:.K3V=57?J
MCI+#;VGF!0HG:JO?0%/`2!0VU<&VLO'DY&*DBWL<^XRV%9XOY]]">D!Y(9M;
M%DT?)^E3=('/_3\R$N]=:(^T2;L^F@[7*X[#95-?S"3AHB[43DHL6`N;AV]S
M'U)"^YK3=1/%16C9"E>.*2'L=P(%Z=8HF@(9_TZE-1;$`VT_5NE2?ME5AO^Y
M#:_?_!<6+FN^+%#M3_.WX7X(J96I3:MH"F1/!-"FUO(9BSUZ)XE[+Y['N8_[
M(G_Z4MV_ZAG`1+71=+A>E$I=,I6#+7N*HXZWUTE*U@SYUP0OL^".98AOXV+)
M:P=-`;/UG$J/S"4"?3RSHU$[D>Z7[,.UO)R@YW&U^'_)F-6C#`)9_E:B:G8^
M@*;#-0)KZZ!%4=FZ/!BTB^'YFE'1GS-AT3Z:`EFG3ZF:]B15:N8GI\X"]9-Q
M,9:J[2C=F>8_J/Y/UXE5[*W7HOU_BY;0=+B.I\9V!Q.9E*KRLU.JPIFD#V?A
M'3:!AN@W@&;#-9%K*8:A*$I]^(MU)X?3/=O_-:)"\B.6$30T#L7*U<>\Q<NB
M185=G5?4PF/W>K-Z!GY)#<BXT2+Y-!57`6`4?J]?<'H;4L7%=U$B.TL>E(-\
M6*X@A;^Q:?3>$G>0CE04TZ67O-#%])70.>IB2X^N=*6=;W)[;;C:A\B6TZK9
M"-3S]2Z<&T"S9;R&U(@K%E@NRNT9CVP?=LT.E)N8)/@*TR6<L!4\6V=YPLRK
MC,78.:XAT93NC4,]XF^M078@]VC'/MV.IIX<_2GVPH06I>TO8.+,"WJC$SM(
M514B.KR@3U<99D?NIZC^^\LL9KK>'JE.J]"Q@W1(X@_9CJ!=O`W_/W2NHB<P
MO'B@7%`YOM#C66V>R3,?T\T-`T,7N3I`P;Z\?8/0@=P[LMO<X7<3A8O:\H#)
M^CFC>Y`\CM8#]C%Y+4QW&IJA5QDZ'+MU+="'/8K4,B6H#0.5-M;RM-@=O2_I
MW;RG=VFG1+T[G$[T,X(;M#?<9;PUW&'[W.N!53RPT6\$>CEOS;+1WD\`?#R:
MHGQRTRSLZ!(NH$I--WSJ%.YF[#->1S$+;!I$7O@/G*:8&0DN/6:&N,3,FB!]
MVZI;'3H_"I^)YC[+!`^H@98?8OZ@U[=ADI(T2^GD50"H3A!21HW:@$Y]HDNK
M,2@G'875RFE#`2Q_!3I"HKV1;PP;VCV8?_JF+;%[\\_>O[T0BQ]-"LM"QS_4
M)538>6@/7"XM=QY9!-ZW\S#/9.V%6RDQ@M+0H0IUJ9%T']J9E4O._WAKG"27
MWH:D7O!K'&4;*3NBXE!Q_4SID?4?VI^3[_B1>2N*GU"%.D^2R"<4ICPFBZ0&
M>*P\79I4&)QT<#Q?Q3@W8@I,!(TRX$'I+)D`^,#`XFO+R1&>USFEP"+,\24J
MD7JMOTZ=P2]I`>)[P1/;?^YZ*YV_9%7`HL")A-VD1-E]%^^M[HB/0^98L;M\
M*S8P:QRSU#!E(AD]_EJU!1;C39_8]KB</'&SU\59P%RQ'G'\2K$EFL-350\L
M]IO!&-7"X.09]SI<T:U1KGU:=`G+@P5STZ=)WG>W`B?6-DV?O="((IVJH`':
M]-C2A@%]#N[UMO!.(XFNJBI\++:37`T>XG5RMA7!UWN"H5D;/$R;%C\<*Z0!
M/!<WO=4SJ'LJ;^9Z)&#QN!AH4#43F3<9XT)Q[ZZO>,EZ[Y'%UY#V;;>&W(;_
M#WOQT[?HZ27*6"+6ZX!NQH5G>;-60&.8=:.U#5(GSR3:0)Z^X>!5]#S8L!70
MD&0G(KZ&U,EU5A_("XE3W'W,5^V`1A8[%?EUK$[>$'ZFIXH4LSS$^`9C]@*Z
MNG&^][9KR=JLK@@:[*L;P9K@H(]31@/:<-R"AM?J9WC6(V6Y==5XOEB0HAM%
MWZ\RK$>>JAYH<*N.+&IA<_(Z\B"XQ&44%D!NHO@)QVL25NG?H_B9SBELDKG'
M,8E$$35:M@8:4ZH;]5T0.QE5I=;O*X\Y=]7ZKAKC6G5!HS1U(UL?GZT`*78W
M4"0DZVS]!7\K@IG=$+9M(.'J"\8+7*Q``A76G0!L?@(T&E/'39EM,93Z](M3
M^G0$#S]X)&%O,$N?-I&E3%X+--121\.9!K*=1<4I)JG2K<@K#HOMRWPY?P[(
M*A>\Z$PEJ8%F@[61J5!5[+EE$.,_C+Z/\:8\`19PJD>S6@_0.[6)9H,UEG7'
M7>G(P(-BEY'DRJ?6[.JNAI3@I'RU+;G`U&P!S09I7&N#LE(-M^QJ>QO$4W3M
M,;M1?N^C-,(<E$:SP5K09(@JQMRRFSVF%.G7S0W&=,$Z<"44D":N@&:#M9TI
M0%74N64^*SM]E6$6N(0I'3M)RFD[*HQF@S6420!5='4VCUF\8CXP[A1Q4'/,
MM#?LQ*9C!&O60K-Q&+L$R"H>P:Q:=K8_\^62^%23V-D-4S$Q#)*]#J\XF@W2
MT*6$5#'LEG&K2,I\_<;\K!-\'Q-V_@Z%V8%$Q=%LL$8G*:2*-#`+DIUA>>.1
M.$\I<YXDV;K(PWW]ML$^%9M@2M:MBLX&:7@R@K=SZW!HD2VSJ5<GZJ?H/J/G
M;R_!M81"TD$LKXK.!FN-TH97T>J66>I@M[`_'B?SY7W@^:7C-_V#[MZK!Q8Z
M.RJ]EM#98$U0;=%66N"6T]8!FM^\F(JC;BQ)+K8[5#KLRUM`9X.T);5!6;'M
MEBVIN+*:+ZM=R!Z*@%QQ!70V6(N2`E1%G5M&I8/<,'GRD$+B-U@KP\YA#70V
M6+.2"E7%GEMVI4+EB%]8P\K[9HIU\4J2*-XJ%EC-VNALL)8G$X05PPY[:NT]
MSO9+1&V%R/<'.LNI3COH;!P&*VVL%?]N.6;5\ZN6YX"+[=^C8$'"U6Z!$7"N
M51>=#=)>98:OXM8MXU5M=MK?+._?Q]X0H;%9HR8Z&ZQ)2Q==Q:I;_E'UG<1-
M%@3;*Y:W$2_*P%*YNE[_0:7P%*EM'>T:0Q\':=3J"'CW?,4I=?CLO3&GP)UO
M44;_N*==QBFSTX6)<'>FKH@^#M;(I0FNHM0M$U<U/U6]?Q!ONWA%T<?!&JF$
M<"JBW+)"U7T\Z`XAR>A^X`[3;8+^FR-11?1QL#8G37`5I7V8FDZ74J/**^_5
M4LH;)_ZT<XLE3'&OD4E#61<VE8:P>_K9,^1-0"?,T)(__XK.!.*P4Q\(\5UL
MG^BW%=DQ-&J[DQ9#325?&31!CE0/&$1E3@R-VM!),C19-%2!0WS#5H'"C6@'
M31CC3%H>.GN&)E-\FH6(1I&<^B:+0\)V6U0L-^0MWW<I2197@DZHT8EI.2SH
M8#H]3^EW&C'MU)6ALV7TN+`?8!RY,GS!U0K8X433:`0Z\X8>M89JP44YBJ5!
M"/EK@I=9<$>6L@.A1FWH=!]FG!KJQ2',<2O$KW&4M%HW\HK0:45Z58,=0ELK
M1CO776N/2K-UEILLKS#M-DO904'0?P<X)RU<G*^C."W#I`N%(E$56Y\`SX)B
M0ZNL"J-S3,!?"@4,\8IUR(YA_XZ.CGEX19)-E)#"SZ-"H5`8@]K@*5BZZ((I
MSLZQ_SK2W/_.M.5>%"S/RTG6F0J@K4"!:91Z`?A-#Z[@[3*G)R"ITQVZ\>%?
M9'-F`[WPY1HU!WAE8X!L%#OS^NY`HHKU8E!7,`;4\*?`8Q#]$7BZ*>]+E.)[
M;\LL4WF^H9#V)B7T?^P7"=`U]Q5^3NF>PP^BA-E$U3,=OP+LA?93["WR%$!^
M%A,6T(7*=YZ^X+C\Q7F2X#31O]TV:`]ZWA33H;K?-@0Y[!NNS]Z_HICMOI+Y
MDHFLG)32;0V^_,);LP5W+KT-^>6KBP'JT2N(\BY<NPWH&W$#5ENK!?S=.#^V
M#PY)%#]FS[17+)HG"_29L$[C^HI,]RYKDK!'1_G:+$WZU:%%Z"MS(QJ;F^^.
MR$>Q*3>=;W5N8%NW"7TQ;WGQZ20'Z,M;_NR3K==>O,VCD`O&A^(H;]"".]?T
M+>CCS#9FR$<QN[!)^3:DH++\*97GX\(=7'$^XU6!NI=O09W()"`&-D*ROX9>
M<>N#%^Q\9\0ZIR[4-7Q/]`L0=I[T^[C^JCI8O@-YBG9AH-BN*R:OE(M7K(C!
M8=8(U&U[9[;;077RUO-081N@+G"(EX3%-RCDE.3A*SQF-A2I0.L&P>[)[>A#
M-]S0=Z4:RE&_WZ<Z+I[N=:N"78;W0+@$H9,)TPY[?Q^3T">;*NM4*1*FM^KG
MY"U:`KO_[H%X?<#02=CL[/^.;X3*NR)U$']Y130!?/MJ9>NG@<]6WC9`CPBM
MZ\'R`O7]EO#]EO#]EM"ZKHA>ZA]FD%%<%.HW,K*[0C/@X]$4Y;U@LS#T!:`9
M56JZ';WL.XP;)[W%XQ6%OI[C2[BY;1;UW2DN#B."2;G@%86^VM+E0M1W6]=1
M0/.=6]><`[O8ZNV:TX$WJMRQ+C_*Z/DL&[4!_>BT$X7-2<08._#]EVXLU*L,
M/T6W"8MAY:O#CNLW`'FY9<Q5DVXSH`[==2;8_W$5O7X@%'22%JM)\>_C=:3X
M*;K-_V*K8X7H(!4.1Q'T*D+>=W54`'V`T%.]=>8W)-[E:3>COEX3]'*K/_(;
M$#M?<CIAY+;IT0)YR=61>"ULG6\N'7A-WJ]3"^1M5R\:(`)I[<6GO9Q@!X_2
MRV0J#+I@-R<J#GH]96'S)L4%?3$I>$>*UR1;%_DU]F%DCZY;178RK<IH`FPZ
MT[WP,(0$O07C\UEDO?\:TKX)L(C(5-=$$V##FQ&3FGB@MU+2..4=Z-1O`4V`
M;6A&M!KBLK5OLNL6E,6E"],1G.0F,N2Y35-H`FPB,R&\-4`G'<($'9YG:9)Z
M86X4;+'B-JJC"7"D-0MK+A\4]"ZJCY/0;4BWXO30_T"/]X]I?K6TRZ6B?222
M-9*G$QB".K2$9LOCR_)0CWR,%\D-E<;Q:4(XO,55T!0XOIG9D%8`*1ES*V-;
M/8-1N>,/2AO,;?C;"_%?CK`PH_S>N:^Y`VO3&IH.Q#^L*\92!<`2N_4QDW]F
M3PU(NF6&VEHN0^U)7%`?38&]P[K-WS)4I1:XE0@NC^%9S6&WX6/VG.`_,K8G
M6=(NT0U)PIR8=Q=U\YB]E'_U`BR^P.S2))H"NXB93`F=@>[L*DZI1/.Q63&5
M_4;2XSE.^&S/H`DT'9#1S!A813%0;%PNP8U[MU_9'VS*VCTY%/"J41--!V0Y
MT\53L>B6Z<REIY;3`1G6.L*LE&%$%Y2UJ6N/.??`F&AOZ"1MH.E`K'#MD%4*
MX9;][?B.O9S/Z#GF\<73G`(:M=!T0-8V'2P5=V[=55Z7C^FJXT1UPZJY_=*M
MCJ8#,989@ZIH=<M.5CL1SI?'>`3N8%KUT&Q`%C,]-!6#8'8S>^OL?M'8/>8^
M>.=/-Q^J95:G"30;B#FM%;!*'T9@1)-BSI>F\E3922L.&D*S`9K5#.%5&@)F
M8+.C(4>!/TJYY=FPB]M#B5(HZZ+90.QK9HAVGBUCHKZX)2;AZC)*N,96G6IH
M-A#KFC:8BFNWO-'HQ)3%[%+_/@J(O[V*OH6E\X;0E":J@&:#LJ!)851DN64X
M.^HT6U2\(,B]'TTX:]9#LP&9P?305`R"N979F5K-0@OQXNW,!F;#$F&H"`5R
MJN_#?'D>AID7[#R7Q8/8I#J:#<3490RJTH`^;%ZG"QRUOXJ#2R)3]6`O=O;P
M^>]XL6*N?#[]51%-WBR&5.M6+63;VC_I;EQUUKM3=&*KBMK=JC'XJ%&="&@N
MM.W%X.(#]^85^->0B`/X\DM#9NAJ3X>./\`.GB7N-KF9^S'UXG28[AV081A[
M95J.V<DW4PT0N;8^8#_PDH0LB9^S\Q3=>V1Q&UYZ&Y*R'NLI@4Y;4+&E>M<&
M7?!.OL':HSF,J55I^LXU8A^:PWBF:-TR5`BL_E2FDRC<?.4EF1P+W\?2([+%
M@G)0'RH&UBE7DP9@)Y]WM5!G>=#O=LV!YG>!G1UV^*$?BK789NZ=HMM/#)Q6
M0-.]G&RSR87MY,,P0QSS4.P!8]H0:"X8.%4HD3OYZ$Q[CK.R4)1Y$B!3P$"L
M#WO8T*_.N#J0AUVF'V?/)>^(]TP""OWRZ-149.,\_*E`'5JW!YLKQJ)F=).`
MDX_2[)@807/"G,#&6`N0U?T%66%FO`[-$SW9ODOAICW[@O6N3$258;/!6%(&
M0[C6GI[U;X+6L9ZIWJ9U:Q0L=)<3ELE#,;CYVDV:#M'X"J-E:V!QP6RK21?\
MUA[`]:\?MNW9=C\"%H[L)-K432QN/JK3'#8ZIJTV38&%,P.:?IK@W7ROUTW_
M9>8."RV#14AS:Y;9R\+-QX':*[*N[;Q]@V!!U,!V.7P1@+]!M*PH8OMZIS;!
MXK6YHRZ5%,!?*5I;GFPO2L7T"Q7QS86E:"\!\)>**BVQ;:6WT3189+@>=:>;
M,,!?/7+5Z/+%"U?X-I1.I@(]T:H+%B/.MB+HHP5_\S@,(S]4)#D@(W\MOESW
M!Y;<"R#(USR3]^<\`'GC]]U5980_*CFJ5SL2C`-/X,U6'%4F]ZH,=*)VCO3Y
M-!WT>`0$"=-$<TJ!YU2ORUY"S[ZWPR;HL_=&UIDXDS>W''A*]4,&^#0U>NQ0
MRM4.?)%0CZ]Z.?"TZUI\'?<8^LF9[1W(G48V=4YIZ#SIVLN6H._0-/+?A6?K
MM1=OYTOI874>7G@)2>9+5B*7^^=H@54YSZVT#9T+74!F\]1O#:V+C\,_>_'O
M."U1U>WDX6?LL3UW'G%9'.E2NS[H2P];##:5PPC_*-;GG0S/DR1;YQ"4V=&U
MZX(^`NE'2XRP0R\E_:G(`TE^OXDQKB?,,M047A.P[T5.KS%"&4"_4^]S<ME@
MGUW(X5@62E-5%?;]",3<<H0=^B%Z_QKRSRB@4F-7<BUF%WXCL(]2X+2&(P7H
M5^W]Z\\5>24+'"XZ:$^]"=@W+'"ZTY`!]'MWRYIS&VZRE.41>RX=`)ADEUX6
MR*Z5-&K#/FDYD;XHX#OY*CZW[N5)GG<9):_?2)*2<%5$-<^]RH39-G6KP[Y5
MZ>^,;(3?R8?PG-FN<B04'7EUJL$^)^F/<"W</;YVA_2">*)-913%NR\$Y$U$
MK;N_>B2\BY+D8EOV.O?O9/N5%[*YV-Z&E,PB=3<K?A<5_GH76UYC[/2M[V;1
M=R=&[L%Q"O$-^VI[ASCW-2U?S"B<181UW'$>.07Q?.63"F?8NE)'=!6MJ5PE
M2M(L#.VU(F6&3R8?Q+!9?*1ZC9/K^ZJO.3BEJX2D%K2C"Y\DP>B4PQ@VL]+I
MS\RQ0M8`M*.,"[.\OJ2@K^,4P5C*LX;"6T-8WAV_&Q4/S2.F%)1#]^P)]G]<
M1:\?2)ZXO)@.BG\?3P3%3YL9SI67ZWH5(>.N2LDZY%8?C(O>-`>94GE7M5>8
M_GM-0MG;.[-&H/QJ>DN^80X?>I8>WL44>!;I'@P')N!M.4NTRZBEGCH.KD?T
MPBYKU0;SECG-;*$`#NT``7NW-"9CH3%R6[X+C0%_NJN&XA3TY+V!I4_;]<#H
M#D%2"^*.X#):;Z*0*5]^\9Q33SM'%PV<ZV/UJI]JH@:X%JU!6^T5?`AL:>UP
M.G00ZTMCNNI()2U@ZWM+@MMH2PWQ*/2C@7"^P;''UB%FQ[BDY]?M,HJ_>?%"
M;K[3;@7:%J]-K\C\9H1TG#K"YM_R9^R0$B:8297^79`9+BYPB)<D3?*]S(67
MX$6]`,NN;J),%CX'?E-@6>LLB60<Q@<-Z<S3%^DEDVX3T#<0_>O1#N8XWF1H
M(.ZF%M#W$/UK1.U2HK/U(8U2+W!%%79>@>=!$'UC<5M-5*%9&_I1L&U5X"/L
M;(WXI5"%$*]8I$)7E$$5#JQ9'/KRPC;=)21;[QT:0QW2VG3R\%ZC,#?MNE.N
M!.6F\C(*Z8$G8X%HB\-/%":[H@_8CT*?GK:+X6"`N?-'!FF<L@M_%.=-`4Z!
MI,[3&TQ!>P'SL<EHE[;[^O(;1ZO?@;:!V=4CA:[:$M@HU/5ZN<1^<3=4@W<D
MV]9*:J%U:)/;*533DIC&81`12/%+Q#93F9_GOBFY:&6AL](^M$D.<,(T%]0X
MC#$Z@]2:DMK_&+3QSY5YU%QJT,XKO4ZK56#U;O:E[HU#6R(!)U1#*8TC&(C.
M4+6CFY:_!&TG=64>-139.`*1&&R)SM=1G))_B]S-.[8(;;YU;/]Y+!KH6":P
M.TY-U;/1/+0_NRNSH8Z<H..K]#H%YC?OYXM_9<7;(9F_E68+X![S@',<5Q8]
MAFUQ;%(S4*8VS8%[Y+LR:W$%4ZH96,*]7F__S*_RP,)0@DQ#'.P[J_*0W6?X
MHX$G0^.YAM<(6/Q)^!E&*(Y*CSI?3X#[9J3,-V,!&G0,V$.#^YZNYKBB%QY!
M7&%0SA!J**.X*6[UMD+RP``PNK.<+?YL)T<R<H;I*D**N5R0D,2T":A;??OL
M-W&-XQK>?<<0P)#-;53($N3.E^EB#^;3[:,NH_6:%&=.+UP46\85IG(`>V%=
MZ]'Y<8],MEA&[4"XQ=Y%X8HEIKC/8O_%RY]>E1U6A5=5U(3>LQE+GC],-5`.
M.]Q='N$-+^Z].-T^Q5Z84'&P0]K%MOX;5>);[4:@74LU^.0K@AG$\>B$,D1I
MLS"TCZ8956JZX6.6<@_8Y\_/49I>D(B9;;T-SE+B)Y=1O!&&(=6H!>W)R)=[
M\X2M`</%N'2T=U%,Z(8NB+SP'SA-\Z!(E\PM(K[$++::E#S=ZM#>?;HLFN"Q
M=8YJ%RJL[]W6Q?:22FQ%M_CS)8NV6958*%;>EBU"^]>U7H8[X+6E0$"+LABY
M`+=RY6[9(K3+6P<5,-4II1R<VA#<L\[=D#A)+VE1XGO!$YM<Y\L[XK-;G\5]
M'#&G%.D28]8(M.-9!^J:JY$Y=!>W&#F*1V9'6G15`_U6H!V_[.N!&79H(Z]8
M$YY>2-Q9$;0;`??2LJ\(9MBA'S=Q%8$>DX)HQ?I?=OQ\LPE($;Q?2KZZ(KCS
ME%7"-?%"/P'BI\;+%RZ*GH5GIT<J+\!2;H7EP5V<K%(JAPG]>H9OV%G2,VK>
M[R\X91U.Y!8=07%PKR.K/$I10C\GX=+X!7^[BK.5[EPK*@Z6C+87&J4HH=]I
M\.."8Q^333I?/N!5%K!*6]K[.'KU@ALJJZ^/-PM/2JQ^`V!Y9WNAVA#W.-Y#
MB"5XIY$Z2J,V6*K:'DUWA^"<W$)_)G3%2:,0WWM;UF6%+Z.H.)HX:SP[)(%C
MJY=!<M$0(H:Z@Y*46`0L&K2`)D"6,"4U329-8?5'+HB+4<,=!-1U>P">1MS1
M)?F>R'-(I]K`W89T(0[;/^2)I`&F.\%PP=(Y,7='^24EMSRDQ[<.1?Q-C!#*
MR!C]C:0O]>2?3]$U%9*&.Y!A2]"^0D(^->E7HW/JBO#RA>#E]1OV,^9Z/%\N
MB8]C.@2N2(Q]VH3T(*M7&=J#J`5%G#E<&ZI3])ZO8IRGYA5,R(TR4(Y"[29A
M;O?!W#KD#`@G2DXI*&\<KCPE(M_W=MBKW?5Z$T3Y^89I'=O)B2WLRCJ0^7PY
MS/#7+6GOATWF.7MW]42_HMB$'I2#\EOIMOEL0+!E*@.BCA]H\9SEF5[E:IU<
M;/=E*N,&$\)>$N'B/O#"+]X:*[>F?7P.VO&EH1)\S>D+^K"GCF)6Q+C(4+N1
M7M$IZX"[OO3%L6Q%$<EAV'K!GEOF$KO^(Z,'A<M=<A+%$B.M!^8ITVW-46.R
MY0T#-0D<XE*N(MSRX#XS:IH$PUB(9MA#F"E\%.:3DW)*;Y0%]YP1L\)GD8]@
MV`P^X"2-B9_BA1Z+W/+@SC.F3(I1N&7GD"PH=Q)'!]VJ8)XP[0U3VK!L^1SV
M3J1>V";]!L!<5XSH,;O0XR`<1_"?PN2=U(\2DLF75QS,UZ4%9_S)6(C*17>7
M>QPOHWC-WL[.G_]5Q):YPHD?DXV`/(U:H&XMG3C4!3?P5Z'*0[_HS%]L3&Y#
M*L`L%W$>_?7IQ0N+PWSR*VTB36Y#*D02+21C_U1=0!,@6YNU^>2DDG+2C;+H
M;MY;O'B**@^T''5RGCR253@/+Z(P$VT>]1M`4R![G)6IRQ"GDR^2]#&HUZE6
M;:&IHR8WRRIP#+G'5TT.>FR>/!_RN\OFN\OFT/:)?Y(P;]WN.MYCO&D0[X;?
MYGN,M_<8;^\QWH;`XG!BO/$/,=[O#V2QPE^\HBNTU2C.'[-*6515@P[`ILN>
M#@XG+0WGM!.OCU&0Y<N"?+KD%(4.<J8]1PKZ[J1!X(9^]>]92J&'21064\`#
M%2\5S8O&S*A;'3HHF2YW)GB<#%22QT>ZI9OL6W(0(.DFBL_I=FSM/=^&UP'M
M>+`]][,4?][B("*+.YS]CM=$'C7!2MO0WIFZFF`-K).!4+Z&A+:7D'0[7S[A
M-R_Y?$6ATI]42J\Q]HW:`'?%U.7=')63(5+^)WH)D[]'F]_I1+:').535@4\
MII@N?4H0T#%-^'$1/+((O&^Y;43*4;,@N)NC+C."KD/G3%5.C_<X#)-M\.J%
MBN517@G<@;'-!"B``9V`E#_C>6O,,C]M2.H%O\91)C?(B(J#NR=JSW0R`-92
M@L*Z/''?_*J=A\6UP,-YZ;"KB\->OL[W^/L$+HI7MPN2+F@'[FCE3OA]=T.(
MJ97`5*W4DG#KNL96Y-:!AM7GQQN3PG3Q!@<BD0*4<V,_E+<`[V0(??.`*JYZ
M'>I&5*EY$YX^K(#%D"J0KG]-B4JD7NNO4VM9.4*O\"L.HDV.)J1'B12S4*%%
M</P*@GP>-&T'30&=AWBT<*:W5IB<HM>(0Q$HP+3=>D1).N[D>E/U-UP\;J(P
MB6@GJAM!,Z;4#:`I8,9L,_8TP3CIAW"P_]'C4%8%30$?QNJQINR^D[X)]X'G
M%VOV*O]#:VF3U4%3%Z*ZR9<Q9?^==#NH^7M^]D)O54+084RG*IHZ%-&-3YPV
M#"?]`1Z83#7G0FY9-`5\E:K'D+C?MF[P[6P#'S%%7(B/KK(X30.#T:17&4T!
MWVWJL64`Q-:5/I`9NUVTQ-F@C!IB#`,/536&>(DS8-^>IE+PE:<W\,-^-F0W
M9.(,.FI:7R3S=4HNB%'$C>DG=.(,T-#45^C$V<S>\0IJ,K`2.G$&[`.EIDDP
MFH5HACW%=PN=.`/V>1*SPF>1CV`4<[&="(HSX)=JIH2*4<"^+K3$*=N9J)[I
M5V70S-$(;(IG^`?]MV7"@GIGS\"HA]Z^%)I!/U\[$+^$HEI_A[WB??;>R#I;
M*UDZ*(=FT(_+CCC@,]7L\RC6ML\DU*.L7@Z=0;\+TZ.LT6<G[ZK[#@%\YFCP
MKHXA@,\FCK[B.V4DX#,WXP,=LF1$,`^AD[ZMA1%KYXEY@T5QOS@ET9FCAAB.
M\#G7W0)`+M)TVN359X"N0)UI-04*O9C:.MR_XC###]B/5B')3<D5VL\X?8D6
MAP7^O0_`R#WYFS:&SAP-T*]4F8Z8G70R.TX`?^6EHEF=5Q2=.?H:36O\"Q$Y
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M+J7KA`4F3)GK7"(:B[RBZ..0C4U"1-;BX]@];4;?PIW9D]=WY9G$H`7T<:@V
MH39`*\+=L@354-Q$<0E#3>V^+/HX9%N0&%)%EUO6H(.WDDS)6,37S2:.7O/@
MKS=1M&`+?9RMSA=K6I2!9]T6W<"U;`Y]'+*MJ!/J2B_<LAW=9.'BT,[UE<6%
MW3U(8K#8N?SI6_3_Z'909)$P:P5]'+*-J0W8BGS'#$\*)'D\)8:!0FG)?+T)
M]''0YBE3I!7G`S=9E2;5ZS?V;(6W>>,71)^&;J#BX*DH[6R8LI@WY$O&O+?H
M3I(*F`$6#-3C8NC34"U,0C05.VZ9E\[741:F]QZAL\>UY[^471;0)"B-/@W9
ME"0#59'FE@7I,:43_-?-#<9T-3_8]@EX$U=`GX9L.U+@VCDIN,C>59:;GIG>
M2?P4^(71IR$;CR28*L;<,A]]B<('O*0[+.;SRM)/DS0KNB5V&Y3609^&;")2
M0ZMH=,LH=/_BQ6O/WTI\/?<ET*<A&X".@52$N&7V.:<(%PSE?1SY.$DH2#$W
M_,+HTY!--A),%6-N&60*EP?BTUX^8!^35[RXV.YC+]V0>"T:6NJ:Z-.0#2^Z
M`"MBW3*V[*WZ\^5-%@3;*Q)DS.)?Y+K(WY!>_T&E\!35G@J+N6[1&/HT9`-,
M!\R51KCU#N8WCUVFI]=OS.$I84O]ER@E?NGU5'-,%"B!=GWT\U!M,>8P*ZK=
M2H5UX&6:!WI)SE\]0@DE`4FW%]L2'57M$JZ.5ZY60^CG(1MZ6N*MM,`M4U#Y
M1+8PA\R7\XQ=`-,Y"J>ED5%DO%-71#\/V4"DB:]BU2U;T>X&@`)/".VA[.*4
M7QC]/&0;D033[F6$0P;SRAJY+0[7['CM!4&.__!&1V&B5=9'/P_9AF0&LR+:
MI8SJU25!O>N*VY%Z4?3SH$U((D054XXDW:"[N&44KYF?\$449DFI<(TK]=))
M7'P>,FD%_3QHTU,+L!7KG<U3-B?BJJ\/.,3?O$!]XI'40#\/VDRE`%;1U]E6
M99&^G0]C[NU2FV?VJI=<Y/&TO%#TR-"H#?3SH*U7QE`KTCO;L?HAG7:D,^GJ
M-M#/@[99&4.M2'?+5+7W5SY:>]K0KM,&^LN035;F4"O:@3R+[+B*W6$OP?3$
M3HH3(+MSGG"4058<_66HUBHEJHIBMVQ2=5LJU4X6WX1.586]3742UJJ+_C)D
MRY0^Q(K>/HQ3'^JBNZ-]/!8G^]F!/"DX3,\#.[$<2-2G>+/DE5;.:!LD]'_T
MHW7Q\2((Z@*G'@F2[T'"/$N"?_$+HI]./]4]^B]XD06X-$JW"NV>!WB3H+3V
M#02<"J%)%W_JM`IXV)%"VZ5/@<YR8),_OHHT\`Z;YE$D6G$ISXIP6]87]&'K
MG]TL*]#Y%7JBF*]04C%8T@K(PUQYG:Y4AX-R"#@IPVE5H`%]'!$?E4(4R?!.
M$HW97N,(.$_$"78Y=H1D2QM=W1N)A%!,QLD\2Y/4"Q?TQ/\0!>R!-OME'ZHI
M_2`"NI>RJTN6]50IL5'D#K`HGN(Z_S3*6WP+`6<'Z4^W>M?EO0`MJ?$FMS_F
MK[H&JLI4_$M,<GOC;2B,;MGCUQ!P$I6AJ;-`A&-(;96?V&Z3),.+JRRF`BW@
M%=[%M>-<4OD62U75N#$T`4X.<W)5;"<BZ`#H;DR<^YO$4TR<G*^A"?#MP=!F
M3I$,;46)!YTZ![VCG4#?CPQ,D_D2M!4#O]C47H>+X>OR;YBL7E*\.*=KC;?"
MU3IV'_,]ED_<`S0!OJ(9L-XKY6HKH\``CGA":^;1]FVW[/4U+*QV!$U<O[8Z
M]>BP+]YQ)&^P(+C&SA!NB!AU!4U<O]AS;Y"8"W@<:2_^1/LJZ)M(UP:%1;G:
M2A7BQ"GC62VS9V.9/6#FG4!_SMR:F6,E"WV"X_54-3).VQLT&>H%:)=1`B!C
MZ%0LSJT>MU1()$R(_T\OR$ZT7AQ^$TW>+U$M2M):FIH!'+:'I>;OEZL6)6DM
MPP]W[P/TEB@MGEN]/RG2>5+$[D0OMI>!ER0&CX2.:PWPV0\/PK`][.DBDQ;!
MD1BH$J+B48^PCD,/?'A,B:[_)6B&36X=D?+Q3;,P]-,9*3-\,OD@!L[B/EJH
M\K5#HRSTHQ<^(0+R>)T?AZ<MW>G@Y/R^ZK(>F9):T`]93&A5P!C)HY0<Y$4K
MAKFUH)^1F#,LA#$23[D<Y&4KAKFUH%]>F#,LA&'+=\QNFI6BST_?(DW.U)6@
M'QWH4*:'PI:75"^,T2*X!6>B:M"^]::LR7#8\N?I@[>;*(O-:1/5`O=#-Z1-
MBF,D'B8YTJM62R"W%KCSMOD:*,8Q$O>('.5U*XZYM<#=FLTY%N.P=>WO`L?G
MN@?0"C^P.:C%F;/6<UO7SU!VVN*(I7NBK(`/R/K3[+FU^U0@SEBXCOFR=NVF
ML*MSR\.[-K8QJHNA##SJ0]W%\CQ<?*%=W__DB?XK\?S\#E4Y4@U;`O?F$U/*
M5X$V^*`,]=Q3S9U'%H'W+0_,*3W(-`N".Y6U$7[S9",`!FR2Y^<N\OTH7A/_
M]_D%74;"^R#PI9P)RX/[1-FA3HYO)#;W[#DA"^+%VT=OMSZI[JY%=>"=A%I=
M7DOAV#*\0^UY]Y!8N+/YLJ;]ZEB2RLIH"AWH0$J>@'`]6$XMI/>!YQ<[AA66
M1.P3%453Z!?^>C)O3L)"-*.XU-ZGME7N=8^+HBFTIU`;2J5HQK&D5J$E%:MH
MO1B:0KL)M5DX&PAL76$"K97:,9:/@H=.@2U$#1[D=-5Z[=02]_0M>GJ)LL0+
M%T\O)$XQ+OR86+^E"YZZ(IH"&X`XLF\N=9HX7#PZ<KI>N`;?ABRA-WG%;5@4
M-H&FP(:<MGS*$8UC_6-YL$*?%+FPXDS#:"NH@:;0SPK;K(HR,+8\1J",\6R#
M1[O);"I%CBL2KHK$9T>($V;I3/B_4BZO-C^#IL"F*)DZ".S^MN$[M<H?G.?\
M[2[!DOZ1ME$)38'-3M894QR#^1)P<5_P/W2-3))+;T-2+_@UCK+-G<*H+*F!
M9L#&IA/PK((/O47@LEPF29B'6$KM<3$T`S9*G8!/+F9;-N7AY0Z9`=NL>F9<
M#!HV,JALU$H<8CBET`S84G6Z,7L`&=K7V])3::NYH&;`=J\3#6:Y`*"=R2V=
M[$C*CKFWX8*\D@7+F:IPL^*51[-!NED)H=BB%NJT?@SL-Y*^/."@B%CW0C9/
MT768DG2K/I";M81FT&Y60DHU54`#GU.'ZILH7N/XBL38IQ6*-,A)%J1L%9.N
M[NJ*:`9LA&M#3G--UP3J%*O5PI-4W4X,F-6KC&;`YC$[[!J`';CO;-T;_$XC
M%Q^W/)H-T4]+#`7Z91A_].97/4<IZ$6#E5<6G3GT>.]0X)P1*$0P"C\=:7Z;
MXN=TA2D.(5@>]\>D(70&9"&34\H?GRV@C5DW\F!O%E2#WPXZ`[*D6=0,"3*7
MS=RE+C]%]UGLOW@)KL7<F2]IYRA`A3%-HP5T!F1H,R&X#2;H2"9<:F]#/\:T
MTU5/Y\M:]P5D2NN@,R#CF"E]:A1.!B:I=;*^P-QJ#4.]RN@,R)QE2J$!'&@S
M-M\E((Y\C!?)#94`Z[H7^M7)X&M(^WL`XPL6;:)-FT%G0&8J4WY;`8.V2VN\
M8KCTDI<;S-T3B0NC,R![E#%KXNX[>5X]ZB^=4TB2T&[IL;,KCLZ`+$H=^3D$
M`!V'1(.AZS<6E1H_8+)^SN(D_X465[R*Z`S((M2--2$4Z!@C;<\/[<\-Z".0
MM:B'\T*.Q:5<%PGV?UQ%KQ](^(J3M#`-%/\^-@H4/Z6[:O874\<*KBJQD5Y%
M]'$`!B$#*-;"D_0R4/<)OE@*%L78/"R,/@[`/J/HOK4D!;#VN?/%O[)"#Y.G
MZ'RQ(`6(>X_0(U+I:5E*H9B3)#8ZX[;0QP&8<;JAJ]3$+8O.X4:A,BYJ'S?J
M%=#'@=AR%!`JHMRRY%QXX>_7"17'-]I1`3<'9=#'@=AEFKVN&!BX&^$5?J8'
M)KJ\Q^S`5/PK90:GRJFN;H::2*93LX;0QP$8;#I`J[3#+9O-N>_'M(O[!_N2
M.91;%GT<B,5&W/N*&;<L-@*[[U,TC\F*T-[E/WV)`MKYPE#(_G_]1H];X0KO
MGA"9&<E-6T<?!V(/LHFWTA>W[$="A(5S7#_:8M(V^C@0*Y0]M)6FN&6I^AK&
MV(]6(?DW7O`3X966-X$V:-='GP9BM3)#5+'JA/&JP\DYR!LWUP&S!M"G`1BU
M6D#:>3JXX4Y\OHZR,&6'>3I+7;)+Q*!PLYTOBTGL8LN0>.%6M+O3;@!]&HCU
MRQ!2Q>CIO8>YC!9=K`SHB_-EBDL0)88R%ZF`3]WJZ-,`;%C&@"HN!QO9496@
M-E%DJ/VUN(8)"V>\HSSDJNL*@%Z@3P,PPT')I=)FH`?&E@*PU1Q=2CMSA50:
M24]2#7T:@+%0&TC%\E`#"+5.JKV_G;JB>Z\N\Y'>%]"G`9D:;6*N-&S@[YG;
MBZ0,T+9['CY/7W#\1$_NW'FY%TTTZP+Z-`#S*HA0*EWN;+6%7!.KIXT7.,1+
MDH>SYPM1HHK:;:!/`S#6MD-5*4,?)MD/=6G=T;X>2Y#][$"$%"0.%WM7@P,A
M^A1WEKS2RAEM@X3^CWZT+CY>BT'!8D=>X=0C0?+]J>__2.('44)[E[\6V`DZ
M?[?+9)^D24[%<VT8)Y(WD'8:1C\!+#3[EZRM=_SYNU?92F+K&P@XWE9W>@6K
MBDT!#3O1?8&%?D41P.6@'(*.)&^3/X'9]ACOL&EN+Z>](,*%=L#S/CZ'@`.)
M-33"MB%'#GW8^F<WD!AP'+&^*)9O6[EB&,>#^+:'O#N-@";=&T?N1"GK:[6S
M(R3H1_C`VE@:%N99FJ1>N"#AZB$*@ILH9K_L0T.E'T3`,=7LJ)1E=55*[,\]
MGS;%\R53Y3ZV_2T$G<.A-]WJ79?W`K2DQILB($_JQ>E`5?G0ROMK'"6][!7$
M7T/`\?*&ILX"$;YO+>`G9N@8@`/39*X`;04S*F;FZW`Q?$WNRY'(3@_0!#IA
M[7#57BE76Y&B!K!/&9USW00Z0;!KX\*R;*$C;[VO$X;S&?2=F&OCP:)<;<4F
M<V+7]*R6V;.QS!XPNT2@/[^,POSR._,"%I=CJAH9I^T-FD#GK888)0`R=C)B
M7$?AYPLH/EXY17*0O6$Y51_0Q/6;2DOJ#B-9Z*![SFV1;JF,2)@0/X^4?9I-
MT>$WT03ZLG2XVR".)&V%)1S``=G0+DS_Q]X@G$SCM;Z/)D.]='7$VB^6JDO1
M'=_G^I*7]ZM:BY*T%MJ2>\J%?G)0/M-X?WGP_O+@_>7!^\L#]GBY]']5/#RH
M%_L3O#LXACL.CI4/!MQR]3\F04X5O(\^U]KV]"UZ>HFRA&XXGFBQPG^<]5F:
M!E11"]KU7N4TKPD!V,U3R=<W'+QBCN._$7WJ1J`]VTW9U$,T#E^QASSVGWQM
MW)4!=_;N?V$\P#KPI+PY%N7[IUHI:*?H`^%+^-GW=MC[EL\D).MLK:3HH!RT
MJ^\1`WR:&CT>Q8N'S]Z;'E_U<M`.K7I\'?=X'*M;NV?GX+Z8IWYW7G.2_/.%
M'73GY3FTKV-3*6S[*"K`#WLUM_OXW'E'O[8D\W5*+HA1[!Z>2,KF]-MP05[)
M@@63DB]*W/+PKFW]+TYBX+8\^8%FB`:PWTCZ\E"&`4Y>R.8IN@Y3DFZ5ZX]A
M2^`>8F)*-55``Y]39M%J/F/AWRYIE[,@93X(4JN:M`ZXRU,;2IIV-C5&%XVF
MN@QR$`&;S.RPQL<UCC-B]P@2?7C%[!J'=W\91%R8FFL+V%LFOC?ZX?W!41Q1
MD?NXM!*:#/6U_R%?S7E&`_<HC@*M!5@\\:ZR@)R_>B1@0^LFBG.OQCYF(L4G
MT00P.9:&OEB><72DX>(.IC3PEL\?"I%QDYSGV4G.*=X%PRR8GUJVAJ:`:;6,
M=:4KT#_Y]BC_XY\X24FX*ARO92E7;7X&30$3=YU^2A))P)9%'^QQ7AUD`8SX
M]&^?,;JB^]$Z<`OO\$P^AZ:`F<1:S62]2L*676Z@4UU=-C7O^YRG<@7I8^K3
M^"R:`N9(._U4J"L1)T^*!R-LM8KQBKU1RC.XGH>+&IQRVY'O0!\HJ_$K7N0)
M7>=+VG?Q9&CO`V@*F/.LU?1G&;NM4!&P$UYM_WKI;4A:)I/>X::GFIN,/;UA
M@F()"R6SF'%;:`J8`JWUU-0.)G2<!.AGA2PI4OZKV]"/,?WU%2[^[F-9%'\-
M30'3IYU^-50(`CJN@<'Y8/_3&NP<8V/T2:8JJ^VC*6!^,XLG@+;0;<4,Z,O8
M7IILN,8:M=5=5AM-`;.1M6/>`!CT"_@NO*J"M;5M"DV'9./NA-+:\W`(_H^B
M^M2"^=R194>%D+>-9D.S;-N#7:G,&`S='6*H,7L87E1!1FX\$N=!%Y1&[QX^
MB6:#-8#W)8U*2<&LX<!'L)TXSNDF;ET(C$4?B+(PI5N[^RA)7PN#+MWPI70Y
MR$OT<3QKUQ,T&Y+!'5)(E::/P1C?9C;@B>[Z;8-]ML3A>-W+A*S\*)H-UA#?
MGSPJ5?VS1I^62>F?$?/1#$BZ??#27NQD^E]'LR&9^T\MF$J+!WX9T(NXKIC7
M,0X7$#I<_S::#?&RX31BJ?3W3WL[L9,/B0NW^.H,T<OMA/!K:/;GNIV0"Z+2
MRC]YV&6ZV5]BDH<_/(%6<KZ&9D.ZY^A;$)56NG7MP7D\^S4D:?*`-S%),$]C
M=*JAV=`N.K0051RZ=<5Q[*Y4]/[`0)_[&.=0?%IJOJR5$S#<K5$T&]JUAP6\
M.Z]9I[2#/Y^Q^*`2/#SS7?O&T-G@KCC:XZRT`.Q.@ZL%7\,8^]$J)/_&"SXX
MMLD/N6XU1O71V9`N$,RA5?0._#;@/,@;-U<&LP;0V1!M[P;8*G7HPV1^NHCH
MOWEQGN>@#(6N'P.=.]=4K2E>JAX7,PLY+OURZ9VK]_W#PE!QO442:<Y7XGZ[
M^'KPL+<LA,!E%-(OI.0YP%^B%(NV&NJ*4,&VY22H"!,A<9^\I^@V9%>'49PP
M$,7T*G\WH-\`5$3M;F2J$$$_Y#1G5>WKJ%L=*A*W54:/\#CY,))N;OS"]W9%
M_ZC@E(D@*)[2]Y;EB=":>5NW!Q6MVY3Q3@"A'RQV4P&=2;M=8U`1OGLCOX'.
MS:=_^KJLFMC;-`45][O'(7^`S=9KO13'EI=O\0;DW/?C;'];*U_&M9N!"A[>
M<CDWP@7]R$YCFZ:U&8,*&-YMRU4+&M[YRC:-4B]PPH@R&8(5Q=)-]7OB-EL&
MGE[@#CLX=KM(_-`QL$\=B'_PF=CZB!K>Q=^E39!RX`#;#8T0S"T]01^V_I5S
MLS+N_D$YZ&QS?5')5YP&]&$S[GKX7N"HW<.(WCN:='I=_0[YN<)[]/@4)R=W
M>D;44BG+ZJJ4F*6)M)V5R3G]+2+EGD9UBV]!IR_L3[-ZU^2]`"TI\2;WF7Y,
MO3@=J"K_6ABW2N_O7^,HZ66G(/X:=*+'H:FS0(3O&POXB1DX!>;0-)DK0%M>
M"\7,?!TNAJ_)1\%I5.&?3MP#^#RBPU5[I5QM.7`,8)\B/)=SU[V^QH2]7H#G
M.75N7%B6+;2+R_LZ83B?05]SN38>+,K5ENM/^UU3YS08'!&4$?N.T#]@9OG/
M8YCOHO2Q8#M&SP![Z@-\WMH3*3F,9*%]G]P(P2B>&$3"FZJF_]/V!CQ/+\A2
M`"!CZ-CGSFV1;JF02)@0/P\;=)I-T>$WP1,<#W@;Q)&DK?CL`S@@&]J%Z?^N
M6/*74VF\UO?!$T4/3?OUI0H=T=Z-4>#87/]^56M1DM:"]G-/N6#.]V6LAW<7
M_'<7_'<7_.[:]<"`*MSO=V7^!*[W!UA'0*W2Z;E6"MK)_4#V$GKVO1TV09])
MR)*/*BDZ*`?MEW[$`)^F1H^!0Z!8XJM(%JOFJUX.VM=;CZ_C'H_#/ZK=^S+H
M,_>IWY=]LD>WJ\\]!O#`#/CLVU`)VUX+<NC#7LC;/3!SW9.W)95\Q6E`'\6.
MP/5W9M`NMH-X9V;1C;:/*"%'P4WEEJI&)-2A>IL>T--TII#`=3':XFE2$$.Y
M4"H(X;C"&``"?3_G9-YA*,_`OF@6^N=U/HZ<GG3`9,-0OG1]J84&7%O+-N3C
MVE.%:X=R(C-2CQ:8;+WY`']@W<'AS:4LTU`.6ZWTK%<IV'IQ,4C-=#3A+I1#
MU6FU4T\.MEY!#-0$,_CDYU#N4NUU^<3"&='[!UN2<S*1]`0^_C"0(DL$\B=_
MC#"(_-$3^*#,P(K;$(>M%P8#55MZ$/"9(JSP?'F<=[)TLNA#8S4^BZ:`F1I/
MIZRZDK#E_]\XG)W.,;K*:WN%ER1D@F(^X,\9^P:[E37.^&9GZ!SP12<&G)(X
M9XQMVH(HH3`D5UDM6K&07$XA2;T;.+-&H!RE6PJX:<4UASN*&_\KG/@QR;L^
M7_*P4Z$6(IVG+S@_GL0[V3+!R$Z0W1N'3)QGKA'\N=^.%$:B;5Q1EI*./WLI
MY:-\S;R33KX`2K6L;:.0F?SL:5<7]./PBU7(@"T!;$118/&V7NA\S:PN[55+
MT3!D6L$3J9>&!'KT13K=WO0Q>T[P'QG]%6:_-T\_;.D<M^O&==X-C9VGJ`K(
MT[_#OBA?\7&*0^\S9>(4'/T$*(;M(GR,2OTH05`#_`V>@!X],L>3TZ8)3/UN
M0%0'^N&=A"5M6L>2+.8(FM*GGUL>^I&>E!\M2D?V=*]ZIJ"8<^O%H!_NF4VT
MQST?^(LN[;=81^]/@-_N';,@YVK?9Z@ID^_JBBG8RC#XB-,T*-/KQCC_AW!*
MU*\,_=JMR4#3P*F/9!0SY!-)V4.=VW#!KO3865<^57++@[]I,YHSA1!L'<&!
M)L\&+I8@.4^(S:YN7\CF*;H.4Y)NE;.K84O0[\V$A&KRKT;GU$1]$\5K'%^^
M$+R\?L-^EI)7"F=)?!Q+YVAE/?!G8RV8:4[@>C!',7D?S7MW.J]+!57@`_%W
M,3`<PK#U-L#N6\`CBYC>[;*B%GRX>!D/G,V5!AP7'W(6F7?8S)2D7A#D+Y=O
MP]]>B/]R26<F0GN<2_XVN?>V`G-MJW9`GW?IL-7DN!U&%UD_Z&[9V:\A_<'N
M,""@65T1]%U6.UXU04%?E7*9+*[9YLM['"_I]L`+?7P1A1EOH905!WWEU(XU
M*10GXQ\4CZKFRT<<OXJ?4!^5`GWATXX9'H(>=R[<2^`/K%?L'1']S_\'4$L#
M!!0````(`,"+/T0);(`&R1P``#E<`0`0`!P`9FEL+3(P,3,P.3,P+GAS9%54
M"0`#Z"/L4N@C[%)U>`L``00E#@``!#D!``#M/5UW&RFR[W/._`<=O]R]#X[C
MR63N)F<R>_PYXUT[TK65G;U/>U`WDMBT0`/=MC6__O+1K88&6K2D)'24ET1N
MJH"J@J*J*.#GOSTOLL$CI`P1_.[H],7+HP'$"4D1GKT[^C"^/O[KT>!OOWS_
MW<\LF<,%&.2`SF#^'BP@6X($OCN:Y_GR[<E)`I*\8(\0YP6%#.'D14(6)S^\
M/'WU\LTK46D&%[SPFM#%)9R"(LO?'?U1@`Q-$4R/!M]_Q_N!V=LIRH*K_/Z[
M@41:(SP]/;UX>O6"T!F'>GEZ\J^[VP?9ZZ/!&OAMAO!'`^-Y0K,*Y]6)*)X`
M!G44`9'F:R0=X?6)*C3`LY;Z_W7+&VA6CEH0$&8YP(G9(8N(DNS3-V_>G,C2
MFCUO,9R!'*;>-MZ<4)+!DQ),;R<A!<[IRJ2<P>3%C#R>E(52(,<O3X]?G1JH
M!:5\(/EPRU*!_(.-G$+DQN,%GO92N*0PV4`GH(DD=<I'UC%\7F8`@YS0U37_
M6Z\,/B=S=P=$B:<'"#]"EKO15)D'$0.4,#>>+!)HIPXT@G&Q<%.;YO0D7RVY
M4`D^YE"0HL3`W8QH(U$X]?+VIQ->J@,SE+A)X@4>@EB^I!X<7N)!*MCQ#(#E
M&F\*V$1VJBSP\+PL/09Y[D?EA11-BARR!JK@$'/BR9)FFT)]`HQ)#G*N97_Y
M&2R7"$^)^"RFZELQ)L<<<2!^?+B_V:`!Y1"^)$DA%.H93J]PCO+5#:^1+F0+
MO%7$IT$[R+KU%$X11K)G7&D.C@<5GOX3X'2@*AEHM?Q\TJRAJK1@,!WB7^1O
M/C$9KT-B".U78I4@+HRZPC#X!&1)D?D;.#'8O!/?+PAF)$.IT#3G(!.:^6$.
M8<X4S_W%;G[_P)G\P%D#2X;K^(.R@H&JX1NS:VXN`5\^\CG,$>_-!LZ;L&XQ
MO`H7P^`O([W"_SYPL:RYQH;3X1)2V0''9/#`N<7Q8YLXZIH&9#JHZSIP0;"*
M+62:S`&>"5"6D^3CG&0IM^_A'P77WH*8!.6V?+JAN\7V.DAL0FH7JHD!POQ[
MW<A_#:YD,P<H2GU^7``VO\[(4SF-W$5N$?S4$($Y603V0*(?((<O(4LH6HJF
MAM/S@A="QKAM]%`L%H"NAM,'-,/<'4T`-YD2Z=UP)WC$!W""8"F*'>MPR^Q_
MA*&%6)(1QCLM_JA;$5*KVI%&6-F2^*ZU-:@;&U2M':"(WQ-NJY^6YF_UAYOI
M?VTR_5<BF,=55@+I(1JV]S`3>IH;-_EJ3`%F')0WJWCI*W3S]DV3MR7Z0.(/
MM`H.<9".*.$V2[X2;AE?[99".RLN.TN<+#Y]V61QA:L\M0K[`-DKIOT(K,`D
M@YR/?#X_<K8@_I?4![5J:(%QL_RTR7(!/"BKD6S7*I*%ASBZ+R%%C[REQWK)
MK#^X&?N#O?ZM40Z0@S>8_X1C\%QQ4/_@YN"K)@<5RD#B'"`++\AB@7)I]JKY
M+0PCB&L[K@W`S>(?FRS6JJ@F?UW)`?)<>6Z*O>5O-R=?-SEYP#X?=WV'TLX?
M90!7WI[YT<W$GYI,E&@#A3<0B`?(S]\!Y:9E%8I=_^7FH.5U5?`'R+BKQ3(C
M*P@O11>AU(=RX\,8F)N`W&RV_*RJFD%9ST"OZ%!'KO)57^F.ZRL/0RWGZJ&8
MB.B<B/=<B<H/<0!K$1.RCLN`=5R&M,=EO#&>7>IR2N\'RV_;3ZQG\)?JUR'N
M1^PFL;'PW_8B^[(FM^0M]W%?DE>M'J+</5&I7!-H.XA;4I8_Z@]?'3+WJX@3
MT*)5^EQJ*7?SW?)BW3&M0^9Y>^!*YWX0I%L.EJN[.=!UR#+1HE7F4M+\[.:V
MY0YKB(?,5BWJI;/5_NQFJ^4@ZR&Q0^:K%K<"C="7SN?-8&Z^6VYU:YSLD`71
M"/3HS'<7N1EN.=A6).B0F:QBBSIOC2]NEEHNML(Y9#Y6P3&=DXUO3EZ^LAS>
M"NN0N;F;FWD)<X"RO7BL555NV7TRE[5L]IOHMY37Z1YE[TF0>>78E=VK\`=C
M^)P7AYE`*W.-$I5J9,QF5X%;/):SK/*72MR#GF*>F$^J,WH#C)OGEF/<%ACZ
M)H"EX$IN,3=7\]Z0PP90MS@LSSE`'(>L=5P!.4/[M`&X16!YV;Z0W0'/!HVK
ML&+(>GPS;2Z$`+K%8#G=&\1PR+.@/3!JS(<P4+=(++<\)(AZP+,DB-=C?>GH
MA.$6DN7H=Q#2(<\A+43=<$:M[T[&_^C8!M>"W@<\#6P.GOI8ZW'<?G1X[39O
M!Z??N&MI%'^QF]-MB<O?](2YAV/H"<=W-X=;$YL/6E'8+#SU\=:G*"QWULG<
MP]04BA6YX$3JT!3^8C>K+5?5S>H#5A4M^XV&Z@B`<XO`<E4W;$P>L&YI.1WA
M6C;#P=V2Z;IE_&VVA$OHM*.(?&N%Y<YVD]%A+B)7Y9T)FOHR/[EY[=U^/F"5
M9/#-B"`[2YR,?6UYG0W&'K)&::2<&&NNI\S-9,O]=.2C'/!`=O/26$_;0=Q<
MMUQ1/]</>917R2?&\&Y^='/8<D7K1)8#'LX-WITZ.>HQ*EY;#JC%TL.T&QKL
M,Y2#I\S-8,OMM!E\P,I@PX%&0T<$PKK%8+F>F\]`'K12J4\T0GF@T31&/(5N
MUEN^I75:\JOAM/A'W%Q\#Z<#>07P6W$9Z;LCAOAH@T?EM[F\Q76*LN/J(N5_
M<XI>/"^R"D)4W'(?L910DPEENU45Y3V[[3<4\TKD)C7W%T^JOA^=[$X.9W=7
M<DP)Q41,!B9=B>$H,(N-#CZFN]+1F`;[I>:DNH.7_ZIOYN4%G!!"\P&V+CAO
MO5A878Y^2Q)9CWF)L1/Q!&8YJ[X<UU6]>&:IZF%01^SKAK?OB:RK6U?:;BOW
M=,1&$7\=5WC'XM/QZ0_;MK^6<L?V*[S=VM]TPWA(GS)*C5JNZDI$Y]Z(SIW^
MM%7G9)WK:]Y#.Z-C[:D''5A18>S0LOLR])`.Z)CO%>)>^K%='[;I@/NM@L"Y
M42&()E^'-M;V/$";<G+A57]TTTJ;7QH(ZH>.N/[KN*ZF:T^:;Q>$=*+"$3]V
M8(+U:D%(VVLD^6N'UAV/'X2TKZ&5OW?H@_V00D@7:BSU\[BNH&L'FL\>A#1?
MX8@?NS3=?#TAJ.T*2?YRMEX^Z2*;;W]MX&S"<BI70.'!<</PWV'0RKB4+Z2\
MY=\0GMWD<"&\GJ,!**'>'>6T$*:GA.+6'B+I6.*EA;H9_&B`49:)E+X*EG$G
MD#<JW>U?*2F652.(5W\T./EE8)'WP"N&[&+\1$;<NH5<&Z0RQ'H'%Q-(:\(V
MP2F2U-L=;U.R``A_<9JXO0[#J/)#1DC7-2EH$%E^P)BH&E&20)BR:TH6-XP5
MPEP>3L4^+,&RTP]S0*NSF8*Z8`1CFLEO+B*G(&.?GDJ5<"M>HQI.9<)MG>)[
MEB2\UO0&YY!W,1\32<0_02::JHC>%E_G`></S`%=;<D%5391KT:\.TKXH!(W
M[G\)YC2'Q-85Q#1$5)_$B(;I67X/!47P#M(9I(W!L!FR%V)O(:,IX`#0F$1Y
MEOZG8"J+9$S.TE3&X$`V`H@/Q`NP1#G(RCT+[@=#S#3A;H/;"W&'$'8-D!K"
MPVF==&S>?QG*HPU5]8)E&@WRV!]?RL6J=XO`!&7<NKS(`&/R5+*H=$Q4XH?Y
MM>;:?FK[=(Q+X61/?+N'.:*&X-=$UNQH!>K%\/B5VVU#K!Z=N<'.`:]-FC#H
M7A`N'GP1D_V:4-L'<Q9&Y')IG*_4D5K8?D?Y_!).<N>,]8'V0EZM=$B#+)#F
M$K;?1(_)*`.)!#V;01PB;QNE%RSH8I=K#MQVAKU102_8(^^V*)_FL?68NS0B
M1:9W4.3;G&>&[#S%1NPAK[Y_.5N]FFBV`.R2B)B_OJ7*9KRC*#:F7W(/+B/R
M]/Y##F:0S]TEP"MYF\[*05(H?&QTMCHA0WP.&&+#J8"0;=Z1%&;R_C`'#_91
M5VS\N4,9U]U</W.]+MVY]8<[F,]YDZ+^F@6!X)]YFJ;YVSG'I$DQ@3=^]W<R
M(7E^CD@^AQ0L(:\E81>$+IO1VXV`,45O>9\(12![R`C`_X`Y7XR%UA=+);T0
MR6RT25XX1E1T;AAYMPA+V;/PP:JA1+2N!$TQAW;JBA>;)GI(YC`M,MOR]M`;
M"A\=G=63GF6WSQ*^C*"\NO_616DP1K2TGC$&Y1'!*L+#.W\'@<B=3<_R>F'%
M]U!D1/#YQV'?D_I/N;C:%N(G:R`BA;#;V["-!7POE<6YO/-9@5&QL%;SQO>8
M%C5UC$KPO])AS=[[(6*B8[=1Y5BZ]U;AUS./U7D:1\;+?JN-B&$C/N7%88`9
M7^.'3QA2-D?+.MQT#L^2/PI$1<[I.C4A'*6</WSR+!52IV52Y17O*TBWCIO)
M=`I>VPT6;]RC%"IV7A.J]H(J4B09#)G;2[O6LQM']IRMT4@F4;;=#;YZ3N3^
MR7"J"'D0Z[=<[6]P+7PG3[:K*&P^?!ZNZ*-;45-1P0F2'ZJ_1Y3,*%@LH'MJ
M!"-'-"36JJT>LN\+L11:Y-0T=\&)*7VA&;EU*OY6H(C4^/_RCO'U!Z;WD$%`
MDSE?G+1PX@5AW'7#,A$Z/5_I%RC7M.Y21S_VR]%B4E`FOS'NE$#T"%.1'.#F
M1RA\+W9AS$#4#5;X(J50QJ0JD5M)EMW08K*7-X?@MN3)WBN.B6OWA(]W/H#O
MP)^`#^4F[9[BF"BX!2C-P).\*DGNGS1I\`+$1,7?Q;$`5F9Y29PF&7Z(F.CX
MM0!B*Q^)O6S&2(*XXK0<\%:@F*@YFU&H\A.>D9ZI9W[^_*&;%/'610)!2^BF
MZN.E9*&C\U5!3`R_R!#F7G4V%@IWW=/F^&F'BHF>6Y2(9%;-K%)J:,$M?]YW
M]*<Z1.,C=$OTF#@@?.4B$^&1!T@?.3W,+];-H#%1=H5G7(VI["4/12T@,5&B
MO;YQ!_`FHL*@8Z+/\X",/_X7C!"12U@YX2->)302R^T2O=N(6[`S2+_@N8*%
MB)^*Y-8/.(5T/9)N\/]QLWG\1,9S4H@+9*\R<8N,MI)U1>R%YQ9,U?@)9H]P
M"W94B%\9.^:(YG"K\5&C]H(E=T#,62SJO890[$M4'F:5IJ`YKP&PO2#:)\S-
MXNX+@>L3/XJ0RP)Z*=T,NC/)Z\V83Q:?,S;9N.VG:+HF=`SI`F&@"OC?$SY>
M1>,CV3W/+EV7"F+:?]#Z>@E$S$CKKT/T@>`ZA2F'^Y+)D!@MBL5[^*3VA*Z1
M4$:<Y>\A3*&:JA[9M8A^O[5^LLFR1_70(!7>`\1$7+Z,:6G6WB;`/E#+A31#
MW&93^FTX'4XR-)/BT]:V5J!>Z'SWSLN(PF6Y."O2JKT(WT[.CM7T@E7UZCXF
M5T"8+]*9<2W_#8`>+(4/O$_YAR6WT/B8-J);VM9,"TQ_2.2FBMA8%&(2ZY=%
MGE6^TTJVSXP2P]I0.]W5@6.QNGC,$A=@3.:'RH6[>A8!109'%(D%`^O9'GZ(
M^.A8[]J.R:C@"A$PZ#R!%P8=4_:",:A4OT6-;#@USU!RW5`%3STC,A0Y)ND:
M!%1)FQHAYZLU(1ZJ-R'%1*TR2X?3:L[5O3<RC[PPD=%29TC)_$AU?2M?QCQI
M5$V@B-*E%--1HM;@TN?@3GCZB!BA*WOB!2/TP@0S)E0=@ZBGE#:C&F?`MT"-
M:11KRT*U4IRO?B-9RGNUGGG.!,DV\)C6%VVDUFY"O;USC70+)PBX%T-:USS7
M19:M+E%6<,^H3+.0(N3>-#>TW4?YM\6/2*G=@6<12ED[T07_9\0[":N;F(QH
M\F;83R?W_3DCU0"N"+DWE)6[M`]TZ3XPUSSB&L'\%G+UTQHN]\/V@>9;PM@0
M7R*V)"H;F0])=9/\2EQ8^D>!EB;AP0A]")2Y>N[=U@X"CFA+^P%BQ%V28D)H
M*J*W(K#+Q)D"J#\ASZE:(";L*7F9BGUOZ`Z5Q)3%L#Y\Y.]VRV'.$*2(1"_>
M@5$Q2QFI')/`2_2ZXO4@<B:NQ!(YQ51>PFP1>`XQG"+A5M3W"EU#(%[JT>WO
M[>OH'8OXRL8'^I_E_E]%K(\9/N@^:'^3DA&?L0E:5KO"Y8P7\G7:KELA]X$K
MIB?97`_<I3$I>M.3LHXC.$MCZK]85>HKS;2%1RXW7NND(UI$BY7#W[\LX)C4
M%WG;"U47G)@"!;JZK(*00D"&8^&!B"FD,Z)P@8I%N4F^]GD::E"WG</@>[!:
MEIE?,DG"0Y9&=PAP7V(]TJWO1GX7I%ZPX;)L@WN])FWLFFSFQW;8QB9N64-T
M4W]8Y&+FB2!MX.1W8/0A8J*_-=%<9MTO4MA0O;`#M>!LJ:>Y:2$%=8-_GZ-D
MWJ!+W6/@CNYVJF"W\.X^LQ8X&&.5*&]P_:+J<#J5IU69\<K(4-YE\0@R,XMX
MMUKZH1:MX$!]0;-_DG3#BLF.NY&O=(D/9<]_%?^(G)MUQ*0F,PBX)V+6G=YU
M[T?EDQL^[]@!:,QQ^>W+"?/J.8?<,DGO1,@&Y:O*[/8/W'",N-9N8R.Y2829
M418`&I-#P@=;H;*2Y?V_E^0)EZ:5/@_],#UP/!K=%],+9)ETHS90Z@+M`<'U
M?9K60E'K%E;>/;ER1.^WQ(\H-F*OD!\PREN7T!)@Q]5RO[F?C3[*+M[#I/&X
MC/%63PN)8>@QF0LU"6;\M,ZK*[<2],?K-EM-.U06)W<\KWM4=G*8Y=A`B9/2
M8-%9VP[;UA`G'UR&?^T)=9*[$[''5`\QW)IPB1LG[1O&[;;C/<)17IU;V.%]
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M\<`FG2&P,=&F)M_ZWNH'D,$F22T@,5%R-N7KF>SK>YB+3EKG#?T0,='Q'CY=
MTF+6,L;\$#'1(>\?6,I#VK."N\"$KGB/*7D$F=AQ^/!PG0+K48L..#'1VGR-
MUE[(_1`1+>.W!,_$15CZG4M()A>NN\^L?*!.2+T(?JP)8.JTD_#?('8\+[H9
M\C,+-^SMT(LY@N)ZHJ00S@\WCOE*1<4-A8C"A,\YZ_;_0/B89F2+:!P/<(9!
M1S13VT:>SY?H@A,1J2-(IX0NY)[%Y#]09-1!S=\SS@2T`\;D_*E[[F2RMG[+
MG0H3G3'QBND0GQ-<:*.T"TY,._3A_7;*=4OTJ*0-/MZC=`;?RRJY;P`FA$KS
MQGH!>2-D3%KVC//Z\8%D$L>VMYVE,?7_FL+TMR)/Y@@S@LTWX=0#<I8S%(P1
M$YW2^[[A6O\&&>[W-:$B17D!)C?X*DLAS59G?)6'=RN8$93>PN(C7"#+3-]3
M=3%QZ`-&\G8-$3/DJR%@=Y=GXD3I6LCNX=`1+2:*_T[FF/U&EA_Y2*[)L-ZV
M:X6*B1[],<&VAP9C[+L^C$808[;*'@&V)]XFN)AH*@-ZY@MI(Y#S'U5HS/>.
MU1:H,5&^B;P^T8#3AR5?O`G5'B/>1%<(3DRTFGD;_E'9#A831>)>Q)97&CW%
M,5'P`)=`52>&$\SSK&2]AZ10^)AH+*-BZST0\^9E5V$?PF?-2&<C%<19JM/U
M91_%,;?-R0ID^:KLZIBXW_CH@!*33UKV=#BM-D/JM!5-4[0![9;$\JFWL=2Y
MZ=9MK`K$&'Y?_""U^\V8,Y$I-FO<^1(`V@>5485T^/0!*2)`AN[N@'BT73^L
MN0&L%Y12(B*35TQXR>(V:L+,6V`=I7V@2SOO+A-P+#)<RJ434D3*1NNWO%I)
M=MQ)EE[<!S$:T1PA`1'1J39@";TF)!6J1FP^IPL.*OIL!FNWKV%G_GSZ2P.N
M"YR:2[KYN*-\28*O,N,G(MXQU=:>KHA?`3-DMD7YG&LX)TRL'K#A/<'W<,JI
M$O6(JQ]*=#[<=7-^`U@?E,-H#N@")"O33=$_]H&*,_X[%7_+2[,8XS:X09"O
MO`^TE<<)RI>'@#HQB*K7-)V;:QU08G)>'"^YG3T"E)5YO^<KZ_6EUE?@-N+&
M1/M:5UX0S!!7GHTEV%<>%0WE$Q<KI0ZU2X38ID>D`U`^V;*QSU=C"Q&0&DYU
M.K3EPEFJTR4>#Y]!^N5$J*5;R,WW4C*685,^I>7,TPA#[(,XUQV_AQ@^@<RI
M;%N!8IJ>:Z],6J7:(-3>(70\<-P1K0]+JD82M]6VX40(6J\XT9R_@9P(0^L#
M)W0+J?FFO6/A"@2/:?[?)0D7%4H^#L\I@GB498GUV($?)*8]%NY&CN>D8("[
MG7-$<PC+F_WYJ&B2%`(;.6WJNIX;+`)DZD1Z")4M6#'1:VS`)JNPC5H'7$PT
M_9W_RUAYFY#$N;7G6BM03-24_M(06X>([)((^\W./=VN"V+J-5],%I!66?@J
MIYL5F3!UK5S,$-B8:+M:+#.R@I!576;M](7"1T6C5+O>?'U/<9B=\%FGC;H6
MQOE6NWU6NQ.20>P7OY>=^XMR^[&\[T:_RL(XLMT&]ND,W#UZLUJ/58!,">O&
M)]-0^)C$J;^BT;@42X8BC*Z_A^8V;4?,/G@U9GK;!6#S:VB\.N(I[R%MXB`4
M8T9HQ@_1/_K*%Y_O(5I,"LH:[F@(;!]H#EA'.BTZ<6FGJL-</DA5*^(&-D'-
M\KA2F<RQ5H5[VO2*"=.'<7@.\,<KEE#R9.PC-C[W@9*S).&HJ?:,I2$H3W$?
M*//8)V,RI&@F(K3RZYR(,TMJ"1=_7STG\F([1TQO;Q7&I'.\1"GG<6\\ZE9=
M3!SZ@+ES2688_0E3V=]SOH:D(GC-%U'93+F>ZD=V@E'Z,).J75@D0MGRB!NO
M4M]*=VP!=,'I`P]4IRL3(I4I2XJLDBIU8EE3G>$8,8UV]W#5LHO/5S5(=:_)
M$Z"I<6+[=XAF<_[_V2.D?.&XAR+FPATC<0&!H*8`F6G:?.9FX[*8C.@\UX%A
MFQ4NP)@B77IGGV#V"*MPG7*5I=PV$1F"%Q/-ZXAD8.`R_GAE"Q61][PQ7+PA
MUTUP$<5>[\`S6A2+4MNI/CO]6KG8K+,:]4MYMZR@KTN4OE2HW7B4Z%?URH)_
M0GE=[W:K4;<6R@D2PXD&HY,S;GO/0/5D+E=+VF/*Y;"04A>'C^@C3*7U;L>$
M]UEG1*QRCX?ZJS8RI+A-NK@!7$6,-PVQK:K<<6[N\P9F39=:=_<X8W3!"%$I
MH+!.5RG%C2NUM\,V9L,7?M\VD(*&-:X9X;=HVITAFZJ+RZ9W&*WEVU)+RJ6:
MVL:@'S*FL:_I<*W#QF"5MH/L?2*W0C4X[<ZK'>N):CXX=;DX"-="0C-2L`5^
M'^(FYB:,;7W[RB.RNKN\E=:W=^>;>V3J:7E"6<M#75UP>D-KT`ZB'R,F.O?P
M>MU7\A!PMV?1'.[,EOB]Y(%S!FR''1/]U0/M7F55;G%>HD>40IQ:L[\#9H1T
ME[K+I].B[+,W5.<KC\A8J*SY2SA%&,H;ERF:%!NCD%WQ(B)9;>TZ+PQW9R2W
M@D850N8H\(]"I$P]\G_\UVQO!(Q(7*YCIC?X]SE*YL;AX9OJD&;["=4-J#KA
M7_SXJM%)YQ%4<W=C$^S.#MCG.*0J-^+MHWC-K7H71!\<3!5SYR:8X\BQ61`V
M!S_52#QAR1PNP"_??_?_4$L!`AX#%`````@`P(L_1*Q@=:0'9@$`]W\9`!``
M&````````0```*2!`````&9I;"TR,#$S,#DS,"YX;6Q55`4``^@C[%)U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`#`BS]$"I:?R6P+```(MP``%``8````
M```!````I(%19@$`9FEL+3(P,3,P.3,P7V-A;"YX;6Q55`4``^@C[%)U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`#`BS]$?88(K.%#``"-IP0`%``8````
M```!````I($+<@$`9FEL+3(P,3,P.3,P7V1E9BYX;6Q55`4``^@C[%)U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`#`BS]$3#(0Z7&8``"C?`D`%``8````
M```!````I($ZM@$`9FEL+3(P,3,P.3,P7VQA8BYX;6Q55`4``^@C[%)U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`#`BS]$8WM@WR9<```NM08`%``8````
M```!````I('Y3@(`9FEL+3(P,3,P.3,P7W!R92YX;6Q55`4``^@C[%)U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`#`BS]$"6R`!LD<```Y7`$`$``8````
M```!````I(%MJP(`9FEL+3(P,3,P.3,P+GAS9%54!0`#Z"/L4G5X"P`!!"4.
=```$.0$``%!+!08`````!@`&`!0"``"`R`(`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description Of Business and Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Nature of Business &#8211;</font> Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that was in the market for a merger with an appropriate operating company.</font></font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;
 font-weight: bold;">Basis of Presentation - Unaudited Interim Financial Information &#8211;</font> The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.</font></font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date.</font></font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Principles of Consolidation &#8211;</font> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Reclassification &#8211;</font> Certain prior period amounts have been reclassified to conform to current period presentation.</font></font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2013 and December 31, 2012, all of the Company&#8217;s cash was deposited in one bank.</font></font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Impairment of Long-Lived Assets &#8211;</font> Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such
 asset and its carrying value.</font></font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></font></div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity&#8217;s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1</font></div>
</td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2</font></div>
</td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3</font></div>
</td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">Total</font></div>
</td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;
 padding-bottom: 2px;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">Derivative liabilities:</font></div>
</td>
<td align="left" width="11%" valign="bottom" colspan="3"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At September 30, 2013</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: times new roman;
 font-size: 10pt;">-</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same.&#160;&#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the nine months ended September 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to
 purchase 9,441,942 shares of the Company&#8217;s common stock. For the nine months ended September 30, 2012, potentially issuable shares included stock options to purchase 1,968,829 shares; warrants in the amount of 5,861,044 shares; convertible notes payable in the amount of 1,152,692 shares; and convertible preferred stock in the amount of 13,831,762 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></font></div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.</font></font></div><span></span></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Nature of Business &#8211; Actinium Pharmaceuticals, Inc (Formerly</font> Cactus Ventures, Inc.) (the &#8220;Company&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that is in the market for a merger with an appropriate operating company.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company agreed to acquire 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange was closed on December 28, 2012 when shareholders representing over 20% of the issued and outstanding shares of Actinium had finished the exchange process.&#160;&#160;On August 22, 2013, shareholders representing 38% of the issued and outstanding shares of Actinium completed the exchange.&#160;&#160;As a result of the Share Exchange, the former shareholders of Actinium became the controlling shareholders of the Company. At the closing, each Actinium shareholder shall receive 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Cactus common stock for each Actinium share exchanged. At the closing, all of the Actinium shareholders&#8217; options and warrants to purchase Actinium common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Cactus common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein Actinium is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Actinium, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &#160;Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; As a result of the Share Exchange, the Company is now a holding company operating through Actinium, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Principles of Consolidation &#8211;</font> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;</font></div>
<div
 align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Reclassification &#8211;</font> Certain prior period amounts have been reclassified to conform to current period presentation.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At December 31, 2012 and 2011, all of the Company&#8217;s cash was deposited in one bank.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;<font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Impairment of Long-Lived Assets &#8211;</font> Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit
 risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity&#8217;s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of December 31, 2012 and 2011. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Derivative liabilities:</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td
 align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2011</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,439,613</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%"
 valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,439,613</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been anti dilutive. For the year ended December 31, 2012, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,596 shares of the Company&#8217;s common stock. For the year ended December 31, 2011, potentially issuable shares includes options and warrants&#160;to purchase 273,859 shares of the Company&#8217;s common stock and notes payable convertible to 3,448,276 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times
 new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events from January 1, 2013 through March 15, 2013.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EFCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">23,656,582<span></span></td>
        <td class="nump">21,391,665<span></span></td>
        <td class="nump">13,664,802<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
        <td class="nump">23,656,582<span></span></td>
        <td class="nump">21,391,665<span></span></td>
        <td class="nump">13,664,802<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsTextBlock', window );">Warrants</a></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; font-weight: bold; display: inline;">Note 11 &#8211; Warrants</font></div><div style="text-align: justify; display: block; text-indent: 0pt;">&#160;</div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; During the year ended December 31, 2011, warrants to purchase 1,974,774 shares of common stock were granted to the Management Firm at an exercise price of $0.01 per share. These warrants have a term of 7 years and vest immediately. Fair value of $2,153,442 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate ranging from 1.92% to 3.17%, (2) warrant life of 10 years, (3) expected volatility ranging from 64.77% to 70.72%, and (4) zero expected dividends. The management firm receives warrants equal to ten (10%) percent of the issued and outstanding capital stock of the Company on a fully-diluted basis on the effective date of the agreement.&#160;&#160;The warrants are subject to weighted average non-dilution provisions to be calculated on the basis of the post-money fully diluted capitalization of the Company upon closing of any transaction, financing or otherwise, up to and including the Public Company transaction, provided that such anti-dilution provisions shall not extend beyond the date of any exercise of the warrants by the management firm prior to the closing of the Public Company transaction. Since these warrants vest immediately, the Company recorded the entire fair value of $2,153,442 as stock-based compensation expense during the year on these warrants issued by the Company.</font></div><div style="text-align: justify; margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div style="text-align: justify; margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; During the year ended December 31, 2011, the Company also issued the following warrants:</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued with convertible notes (See Note 5)</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">287,061</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued to investors with Stock Offering (See Note 9)</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1,972,766</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Placement agent warrants related to issuance of:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;&#160;Convertible Notes</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">143,532</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;&#160;Stock Offering (See Note 6 and Note 9)</font></div></td><td align="right" width="1%" valign="bottom"
 style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">986,383</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Total</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3,389,742</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; During the year ended December 31, 2012, warrants to purchase an aggregate of 1,716,340 shares of common stock were granted to the Management Firm at an exercise price of $0.01 per share. These warrants have a term of 7 years and vest immediately. Fair value of $1,957,754 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 1.82%, (2) warrant life of 7 years, (3) expected volatility of 60.64%, and (4) zero expected dividends.&#160;&#160;Since these warrants vest immediately, the Company recorded the entire fair value of $1,957,754 as stock-based compensation expense during the year on these warrants issued by the Company.</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; During the year ended December 31, 2012, the Company also issued the following warrants:</font></div><div align="justify" style="margin-left: 27pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued to investors with Stock Offering (See Note 6)</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">242,189</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued to investors with Common Stock</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">4,678,491</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Placement agent warrants related to issuance of:</font></div></td><td align="left" width="1%"
 valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;&#160;Stock Offering (See Note 6 and Note 9)</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">121,094</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;&#160;2012 Common Stock Offering</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">467,845</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Warrants issued to investors with stock &#8211; accrued dividend</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">180,115&#160;</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Total</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">5,689,734</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160; The following is a summary of warrant activities for the years ended December 31, 2011 and 2012:</font></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Weighted</font></div></td><td align="left" valign="bottom"><font style="font-size:
 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Average</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Weighted</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Remaining</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Aggregate</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="text-align: center;" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Number of</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Average</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Contractual</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Intrinsic</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Units</font></div></td><td align="left"
 valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Exercise Price</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Term (in years)</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Value</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Outstanding, December 31, 2010</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt;
 text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Granted</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">5,364,557</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">0.51</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">6.76</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Outstanding, December 31, 2011</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">5,364,557</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display:
 inline;">0.51</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">6.76</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3,261,367</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Granted</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">7,406,079</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1.32</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3.76</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size:
 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Outstanding, December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">12,770,636</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">0. 97</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">4.48</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">6,114,768</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Actinium Pharmaceuticals, Inc.<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001388320<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">S-1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Defined Contribution Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Defined Contribution Plan [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Defined Contribution Plan</a></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"></font></font>
<div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; font-weight: bold; display: inline;">Note 12 &#8211; Employee Defined Contribution Plan</font></div>
<font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"></font></font>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"></font></font>
<div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;&#160;&#160; In 2004, the Company established an employee deferred contribution plan. The plan requires 12 consecutive months of service and a minimum of 500 hours of service for participation. The Plan provides for employer matching of 50% of the employee contribution and discretionary contributions. Employees can contribute up to the maximum allowable under the Internal Revenue Service Code Section 401(k). The amount contributed by the Company for the years ended December 31, 2012 and 2011 was $8,942 and $8,885, respectively.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EM6BG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">151 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements Of Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
        <td class="nump">778,232<span></span></td>
        <td class="nump">1,677,301<span></span></td>
        <td class="nump">2,373,200<span></span></td>
        <td class="nump">2,723,459<span></span></td>
        <td class="nump">3,440,485<span></span></td>
        <td class="nump">323,788<span></span></td>
        <td class="nump">26,420,519<span></span></td>
        <td class="nump">28,793,719<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">830,730<span></span></td>
        <td class="nump">722,037<span></span></td>
        <td class="nump">2,730,233<span></span></td>
        <td class="nump">1,520,221<span></span></td>
        <td class="nump">4,506,232<span></span></td>
        <td class="nump">2,959,246<span></span></td>
        <td class="nump">24,504,975<span></span></td>
        <td class="nump">27,235,208<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">112<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">429<span></span></td>
        <td class="nump">581<span></span></td>
        <td class="nump">633<span></span></td>
        <td class="nump">3,262,462<span></span></td>
        <td class="nump">3,262,462<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,122<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">550,186<span></span></td>
        <td class="nump">554,308<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">1,608,962<span></span></td>
        <td class="nump">2,399,450<span></span></td>
        <td class="nump">5,107,555<span></span></td>
        <td class="nump">4,244,109<span></span></td>
        <td class="nump">7,947,298<span></span></td>
        <td class="nump">3,283,667<span></span></td>
        <td class="nump">54,738,142<span></span></td>
        <td class="nump">59,845,697<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(1,608,962)<span></span></td>
        <td class="num">(2,399,450)<span></span></td>
        <td class="num">(5,107,555)<span></span></td>
        <td class="num">(4,244,109)<span></span></td>
        <td class="num">(7,947,298)<span></span></td>
        <td class="num">(3,283,667)<span></span></td>
        <td class="num">(54,738,142)<span></span></td>
        <td class="num">(59,845,697)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(1,299)<span></span></td>
        <td class="num">(318,623)<span></span></td>
        <td class="num">(2,508)<span></span></td>
        <td class="num">(952,241)<span></span></td>
        <td class="nump">1,099,327<span></span></td>
        <td class="nump">175,094<span></span></td>
        <td class="nump">1,964,707<span></span></td>
        <td class="num">(1,967,215)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">260,000<span></span></td>
        <td class="nump">260,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value - derivative liabilities</a></td>
        <td class="nump">189,348<span></span></td>
        <td class="num">(294,381)<span></span></td>
        <td class="nump">216,112<span></span></td>
        <td class="num">(287,604)<span></span></td>
        <td class="num">(685,420)<span></span></td>
        <td class="num">(13,966)<span></span></td>
        <td class="num">(699,386)<span></span></td>
        <td class="nump">915,498<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="nump">188,049<span></span></td>
        <td class="num">(613,004)<span></span></td>
        <td class="nump">213,604<span></span></td>
        <td class="num">(1,239,845)<span></span></td>
        <td class="nump">413,907<span></span></td>
        <td class="nump">161,128<span></span></td>
        <td class="nump">1,005,321<span></span></td>
        <td class="num">(791,717)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,420,913)<span></span></td>
        <td class="num">$ (3,012,454)<span></span></td>
        <td class="num">$ (4,893,951)<span></span></td>
        <td class="num">$ (5,483,954)<span></span></td>
        <td class="num">$ (8,361,205)<span></span></td>
        <td class="num">$ (3,444,795)<span></span></td>
        <td class="num">$ (55,743,463)<span></span></td>
        <td class="num">$ (60,637,414)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (3.76)<span></span></td>
        <td class="num">$ (0.22)<span></span></td>
        <td class="num">$ (6.84)<span></span></td>
        <td class="num">$ (7.58)<span></span></td>
        <td class="num">$ (4.30)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
        <td class="nump">23,601,895<span></span></td>
        <td class="nump">801,799<span></span></td>
        <td class="nump">22,401,711<span></span></td>
        <td class="nump">801,799<span></span></td>
        <td class="nump">1,103,521<span></span></td>
        <td class="nump">801,799<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (a),(c),(d),(e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeGainLossOnDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 5 &#8211; Derivatives</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></div>
<div align="left" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Activities for derivative warrant instruments during the nine months ended September 30, 2013 were as follows:</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Fair Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,146,338</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Reclassification to paid-in capital</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,130,536</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(600,880</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(216,112</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display:
 inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, September 30, 2013</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,015,802</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at September 30, 2013 and December 31, 2012.</font></div>
<div align="left" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%"
 valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Market value of common stock on measurement date (1)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.17</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.65</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Adjusted exercise price</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.48 - $0.81</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.50 - $2.475</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Risk free interest rate (2)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.10% - 0.77</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.33</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrant lives in years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4 months/5 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0 days/4.22 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family:
 times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected volatility (3)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">125% - 161</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">139</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected dividend yield (4)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Probability of stock offering in any period over 5 years (5)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25% - 40</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
</table>
</div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1)</font></div>
</td>
<td width="87%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The market value of common stock is based on an enterprise valuation.</font></div>
</td>
</tr>
<tr>
<td align="left" width="3%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="87%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2)</font></div>
</td>
<td width="87%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The risk-free interest rate was
 determined by management using the Treasury Bill as of the respective measurement date.</font></div>
</td>
</tr>
<tr>
<td align="left" width="3%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="87%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3)</font></div>
</td>
<td width="87%" valign="top" style="text-align: justify;">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div>
</td>
</tr>
<tr>
<td align="left" width="3%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="87%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4)</font></div>
</td>
<td width="87%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div>
</td>
</tr>
<tr>
<td align="left" width="3%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="87%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="3%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5)</font></div>
</td>
<td width="87%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</font></div>
</td>
</tr>
</table>
</div><span></span></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 6 &#8211; Derivatives</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160; The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering&#160;(See Note 9), the Convertible Notes (See Note 5) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div>
<div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160; Activities for derivative warrant instruments during the years ended December 31, 2012 and 2011 were as follows:</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Fair Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2010</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display:
 inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with Convertible Notes (See Note 5)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">287,061</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">377,150</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Placement agent warrants related to issuance of Convertible Notes (See Note 5)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">143,532</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">188,579</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with Stock Offering (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,972,785</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,591,900</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Placement agent warrants related to issuance of stock (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">986,393</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,295,950</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(13,966</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2011</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,389,771</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,439,613</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with Stock Offering (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">242,190</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">318,087</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Placement agent warrants related to Stock Offering (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">121,095</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">159,044</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with 2012 Common Stock Offering-A (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,118,988</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,409,554</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants issued with 2012 Common Stock Offering-B (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,559,505</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,665,697</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Placement agent warrants related to 2012 Common Stock Offering (See Note 9)</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">467,845</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">499,707</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Transfer from liability classification to equity classification</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,753,056</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4,231,324</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(685,420</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline;
 font-family: times new roman; font-size: 10pt;">5,146,338</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 19, 2012, as the result of the Share Exchange, it was determined that the floor for resetting the exercise price was met and the exercise price of the certain warrants was set to be $0.26 (before Exchange Ratio adjustment).&#160;Therefore, these warrants were considered indexed to the Company&#8217;s stock and qualified for the scope exception under FASB ASC 815-10 allowing for a transfer from liability classification to equity classification.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The fair values of the warrants issued in the Company&#8217;s stock and Convertible Notes Offering and the warrants issued to the Company&#8217;s placement agent were recognized as derivative warrant instruments at issuance and are measured at fair value at each reporting period. The Company determined the fair values of these warrants using a modified binomial valuation model.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date, the transfer date on December 19, 2012, and the date for the new grants in January and December 2012. (The market value of common stock, adjusted exercise price and offering price presented does not reflect the impact of the Share Exchange.)</font></div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="28%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">January 31,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 19,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 27,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31,</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="28%" valign="bottom" style="padding-bottom: 2px;"><font style="display:
 inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="3%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="28%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Market value of common stock on measurement date (1)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.37</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.37</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.39</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.39</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.39</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Adjusted exercise price</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.24 - $0.26</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.23 - $0.26</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.41 - $0.83</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.22 - $0.26</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.41 - $0.83</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%"
 valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Risk free interest rate (2)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.24</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.10% - 0.77</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.94</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.10% - 0.77</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrant lives in years</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" nowrap="nowrap" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4 months/5years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6 years</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" nowrap="nowrap" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4 months/5years</font></div>
</td>
<td align="left"
 width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected volatility (3)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">156</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">157</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">125% - 161</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">161</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">125% - 161</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected dividend yield (4)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Probability of stock offering in any period over 5 years (5)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Range of percentage of existing shares offered (6)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%"
 valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="28%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Offering price range (7)</font></div>
</td>
<td align="left" width="3%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.18 - $0.55</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.13 - $0.56</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.01 - $0.55</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.12 - $0.60</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.01 - $0.55</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0"
 cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1)&#160;&#160;</font></div>
</td>
<td align="left" width="80%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The market value of common stock is based on an enterprise valuation.</font></font></div>
</div>
</td>
</tr>
</table>
</div>
</div>
</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2)&#160;&#160;</font></div>
</td>
<td align="left" width="80%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The risk-free interest rate was determined by management using the average of 5 and 7 year and the 3-month Treasury Bill as of the respective measurement date.</font></div>
</td>
</tr>
</table>
</div>
</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3)&#160;&#160;</font></div>
</td>
<td width="80%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4)&#160;&#160;</font></div>
</td>
<td width="80%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5)&#160;&#160;</font></div>
</td>
<td align="left" width="80%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management has determined that the probability of a stock offering is 25% for each quarter of the next five years.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(6)&#160;&#160;</font></div>
</td>
<td width="80%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management estimates that the range of percentages of existing shares offered in each stock offering will be between 35% of the shares outstanding.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="3%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(7)&#160;&#160;</font></div>
</td>
<td width="80%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Represents the estimated offering price range in future offerings as determined by management.</font></div>
</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5708775-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5708773-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41635-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4H<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624258-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668309&amp;loc=d3e80748-113994<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4E<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624181-113959<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668309&amp;loc=d3e80784-113994<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4D<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624177-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5580258-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41641-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable and Convertible Notes<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable and Convertible Notes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note Payable and Convertible Notes</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 4 &#8211; Note Payable</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On December 28, 2012, the Company entered into a premium finance agreement to pay a $140,000 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and&#160;is required&#160;to pay $12,636 in monthly installment for nine months. As of September 30, 2013, the outstanding balance related to the premium finance agreement was $0.</font></div><span></span></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 5 &#8211; Note Payable and Convertible Notes</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note Payable</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 28, 2012, the Company entered into a premium finance agreement to pay $140,000 premium of its director and officer insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and has to pay $12,636 in monthly installment for nine months. As of December 31, 2012, outstanding balance related to the premium finance agreement was $140,000.&#160;</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Convertible Notes</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 27, 2011, the Company completed a private offering of 8% Senior Subordinated Unsecured Convertible Promissory Notes (&#8220;Convertible Notes&#8221;) in the amount of $900,000 and received net proceeds of $750,000. The convertible notes were issued at 83.33% of the principal amount resulting in an original issue discount of $150,000.&#160;The Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount, accrued semi-annually and to be paid at maturity.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The principal amount of the Convertible Notes and accrued interest are automatically converted to common stock at the earlier of: (1) the effective date of a Qualified Public Offering, (2) a Public Company Transaction, defined as (i) a reverse merger or similar transaction between the Company and a corporation whose securities are publicly traded in the United States or other jurisdiction mutually agreed between the Company and Placement Agent, or (ii) the quotation of the Company&#8217;s securities for purchase and sale on a U.S. quotation service, or (iii) the filing with an applicable regulatory body which will result in the Company becoming an entity whose securities are traded on a public exchange in the U.S. or other mutually agreed upon jurisdiction, or (3) the acquisition or receipt by the Company of no less than $4,000,000 of gross proceeds in subsequent offerings of its common stock or equivalents following the issuance of the Company&#8217;s stock (See Note 9) and the Convertible Notes.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In connection with the issuance of the Convertible Notes, warrants to purchase a total of 287,061 shares of common stock were issued to investors. The Placement Agent and the Management Firm (See Note 9) were issued warrants to purchase 143,532 shares and 126,829 shares of common stock, respectively. The warrants issued to the Placement Agent are exercisable at $0.78 per share and expire on January 31, 2019. &#160;The warrants issued to the Management Firm are exercisable at $0.01 per share and expire on January 31, 2019.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company analyzed the Convertible Notes and the Warrants for derivative accounting consideration under FASB ASC 470 and determined that the investor warrants and the placement agent warrants, with a grant date fair value of $565,729 (See Note 6), qualified for accounting treatment as a financial derivative (See Note 6) and the Convertible Notes were determined to also have a beneficial conversion feature discount of $372,850 resulting from the conversion price of $0.78 per share which is below the fair value of $1.11 per share on the date of the Convertible Notes.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;<font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The total fees, including cash payments and the fair value of the warrants issued to the Placement Agent, incurred in connection with the financing were $292,692. These fees were amortized over the life (one year) of the Convertible Notes using the straight-line method as it approximates the effective interest method. &#160;The $150,000 original issue discount on the Convertible Notes was also amortized over the life of the Notes on a straight line basis.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On October 23, 2012, the
 investors extended the note maturity date for 90 days. The maturity date of the notes has been extended to January 31, 2013, February 18, 2013 or March 27, 2013 for the 24 notes.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 19, 2012, the Convertible Notes and the accrued interests were automatically converted to common stock when the Company closed on an offering of its common stock in which the gross proceeds exceeded the $4,000,000 threshold.&#160;&#160;The Convertible Notes and accrued interest were converted into 1,252,550 shares of the Company&#8217;s common stock.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the years ended December 31, 2012, the Company recorded amortization expense related to the deferred financing costs and the debt discount of $252,248 and $775,637, respectively.&#160;&#160;During the years ended December 31, 2011, the Company recorded amortization expense related to the deferred financing costs and the debt discount of $40,444 and $124,363, respectively.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; A summary of the 8% Senior Subordinated Unsecured Convertible Promissory Notes as of December 31, 2012 and 2011 are as follows:</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Principal amount</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">900,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">900,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: original issuance
 discount</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(150,000</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(150,000</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: discount related to fair value of derivative warrants</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(377,150</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(377,150</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: discount related to the beneficial conversion feature</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(372,850</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(372,850</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Add: amortization of discount</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">900,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">124,363</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: principal amount converted to stock</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(900,000</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Carrying value at December 31, 2012 and 2011, respectively</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">124,363</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
        <td class="text"><table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="57%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Lives</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="57%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Office equipment</font></div>
</td>
<td width="9%" valign="bottom">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;5 years</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">162,384</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">156,162</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Furniture and fixture</font></div>
</td>
<td width="9%" valign="bottom">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;7 years</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,100</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,292</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left"
 width="57%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total property and equipment</font></div>
</td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">165,484</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">157,454</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: accumulated depreciation</font></div>
</td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Loss on disposition of equipment</font></div>
</td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4,122</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="57%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="57%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment, net</font></div>
</td>
<td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,918</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,010</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table><span></span></td>
        <td class="text"><table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Lives</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="56%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="56%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Office equipment</font></div>
</td>
<td width="10%" valign="bottom">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;5 years</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">156,162</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">153,804</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Furniture and fixture</font></div>
</td>
<td width="10%" valign="bottom" style="padding-bottom: 2px;">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;7 years</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,292</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,292</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="56%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="56%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total property, plant and equipment</font></div>
</td>
<td align="left" width="10%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">157,454</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">155,096</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: accumulated depreciation</font></div>
</td>
<td align="left" width="10%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(153,863</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="56%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new
 roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="56%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment</font></div>
</td>
<td align="left" width="10%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,010</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,233</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 8 &#8211; Subsequent Events</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management has evaluated subsequent events and has concluded no events warrant disclosure.</font></div><span></span></td>
        <td class="text"><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; font-weight: bold; display: inline;">Note 13 &#8211; Subsequent Events</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; In February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO, Jack Talley. Pursuant to the agreement, the Company will pay Mr. Talley in 2 equal installments the aggregate amount of $250,000 and a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012. The $60,000 bonus was included in the accounts payable and accrued liabilities on the Company&#8217;s balance sheet at December 31, 2012.</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;">&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
        <td class="text"><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Note 7 &#8211; Equity</font></div>
<div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Approval of the 2013 Stock Plan</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The Board approved the Company&#8217;s 2013 Stock Plan.&#160;&#160;The expiration date of the plan is September&#160;&#160;9, 2023&#160;and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 2,750,000 shares.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Approval of the Equity Incentive Plan</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The Board approved the Company&#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September&#160;&#160;9, 2023&#160;&#160;and the total number of shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 450,000 shares.</font></div>
</div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Options</font></div>
<div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The following is a summary of&#160;option activities:</font></div>
<div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;">
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family:
 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Remaining</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Aggregate</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Number of</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Contractual</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Intrinsic</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px;
 border-bottom-style: solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Units</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Exercise Price</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Term (in years)</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Value</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="3">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="52%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,330,134</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.96</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8.91</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">685,800</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="52%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td
 width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="52%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Cancellation</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(49,950</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="52%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size:
 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="52%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, September 30, 2013</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,280,184</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.95</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8.17</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,609,035</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
</table>
</div>
<div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30, 2013&#160;was $1,014,474.</font></div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;">&#160;</div>
<div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Warrants</font></div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;">&#160;</div>
<div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The following is a summary of warrant activities:</font></div>
<div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal;
 font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;">
<div align="right">
<table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Remaining</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Aggregate</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"
 colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Number of</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Contractual</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Intrinsic</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Units</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Exercise Price</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Term (in years)</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Value</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="2">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="2">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="2"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" valign="bottom" colspan="2">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div>
</td>
<td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="52%"
 valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, December 31, 2012</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">12,770,636</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.97</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">4.48</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160; 6,114,768</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="52%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Warrants exercised</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(2,304,910</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.65</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="52%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Warrants expired</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(1,023,784</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.65</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font
 style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" width="52%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, September 30, 2013</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9,441,942</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0. 77</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">5.09</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9,611,403</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td>
</tr>
</table>
</div>
</div>
<div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">During the three months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $95,971, and $72,100, respectively. During the nine months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $284,371 and $168,000, respectively.</div><span></span></td>
        <td class="text"><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; font-weight: bold; display: inline;">Note 9 &#8211; Equity</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; From inception to December 31, 2010, the Company raised $42,711,791 by issuing 5,707,259 shares of the Company&#8217;s stock and issued 66,402 shares, valued at $398,810, for services.</font></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; During 2011, the Company raised $6,184,967 by selling 7,891,141 shares of the Company&#8217;s stock and warrants to purchase 19,972,785 shares of the Company&#8217;s stock through an offering (&#8220;Stock Offering&#8221;).&#160;&#160;A net amount of $5,379,367 was received by the Company in 2011. The Company paid Laidlaw &amp; Company (UK) Ltd. (&#8220;Laidlaw &amp; Co.&#8221;), the placement agent, total cash fees of $742,196, which consisted of placement agent commission of $618,497 and expense reimbursement of $123,699. The Company also issued Laidlaw &amp; Co. warrants to purchase an aggregate of 986,393 shares of the Company&#8217;s common stock, with an exercise price of $0.78 per share and a term of 7 years. These placement agent warrants were valued at their grant date fair value of $188,579.&#160;In addition, the Company paid Laidlaw &amp; Co.&#8217;s outside counsel, McCormick &amp; O&#8217;Brien PLLC, $60,904 for its services as the placement agent&#8217;s legal counsel and Signature Bank $2,500 for the bank escrow fee.</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; During 2012, the Company raised $759,300 by selling 968,759 shares and warrants to purchase 242,190 shares of the Company&#8217;s common stock under the Company&#8217;s Stock Offering.&#160;&#160;A net amount of $660,164 was received by the Company in 2012. The Company paid Laidlaw &amp; Co. total cash fees of $91,116, which consisted of placement agent commission of $75,930 and expense reimbursement of $15,186. The Company also issued Laidlaw &amp; Co. warrants to purchase an aggregate of 121,095 shares of the Company&#8217;s common stock, with an exercise price of $0.78&#160;per share and a term of 7 years. These placement agent warrants were valued at their grant date fair value of $159,044. In addition, the Company paid Laidlaw &amp; Co.&#8217;s outside counsel, McCormick &amp; O&#8217;Brien PLLC, $8,020 for its services as the placement agent&#8217;s legal counsel.</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;">&#160;</div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; In 2012, the Company also raised $5,151,450 through an offering of 3,118,988 shares of its common stock and &#8220;A Warrants&#8221; to purchase 3,118,988 shares of the Company&#8217;s common stock, exercisable at a price of $1.65 per share for a period of 120 days from the day of the final closing of the offering, and &#8220;B Warrants&#8221; to purchase 1,559,505 shares of the Company&#8217;s common stock, exercisable at a price of $2.48 per share for a period of 5 years from the date of the final closing of the offering. (&#8220;2012 Common Stock Offering&#8221;)&#160;&#160;A net amount of $4,469,776 was received by the Company. Pursuant to the 2012 Common Stock Offering agreement, the Company paid Laidlaw &amp; Co. total cash fees of $618,174, which consisted of placement agent commission of $515,145 and expense reimbursement of $103,029. The Company also issued the placement agent warrants to purchase an aggregate of 467,845 shares of the Company&#8217;s common stock, with an exercise price of $0.78 per share and a term of 5 years. These placement agent warrants were valued at $499,707 and recorded as derivative liabilities.&#160;&#160;In addition, the Company paid the Laidlaw &amp; Co.&#8217;s outside counsel, Richardson &amp; Patel, LLP, $60,000 for its services as the Laidlaw &amp; Co.&#8217;s legal counsel and Signature Bank $3,500 for the bank escrow fee.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; During 2012, the Company&#8217;s convertible notes, plus accrued interest, were converted to 1,252,550 shares of the Company&#8217;s common stock as a result of the 2012 Common Stock Offering.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160; As a result of the Share Exchange described in Note 1, the Company issued 400,000 shares to the original shareholders of the Company and 1,986,566 shares to the former shareholders of Actinium.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">&#160;&#160;&#160; Placement Agent &#8211;</font> In connection with the money raised in 2011, the Company issued Laidlaw &amp; Co. warrants to purchase an aggregate of 1,129,925 shares of common stock, with an exercise price of $0.78 per share.&#160;&#160;With the money raised in 2012, the Company issued Laidlaw &amp; Co. warrants to purchase an aggregate of 588,940 shares of common stock, with an exercise price of $0.78 per share.</font></div><div align="justify" style="margin-left: 0pt; display:
 block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">&#160;&#160;&#160; Management Firm &#8211;</font> In 2011, the Company entered into a&#160;management agreement with Jamess Capital Group, LLC (formerly, AmerAsia Inc., &#8220;Jamess&#8221;) for Jamess to provide consulting services related to funding and Actinium becoming a publicly traded entity.&#160;In 2011, the Company incurred $96,744 in management fees. In addition, Actinium issued Jamess warrants to purchase an aggregate of 1,974,774 shares of common stock, with an exercise price of $0.01 per share. The warrants have a fair value of $2,153,442 (see Note 11) and included a cashless exercise provision.&#160;&#160;In 2012, the Company issued Jamess warrants to purchase 1,716,340 shares of common stock with an exercise price of $0.01 per share. The warrants have a fair value of $1,957,754 (see Note 11) and included a cashless exercise provision.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 7 &#8211; Income Taxes</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160; Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at December 31, 2012 and 2011 are as follows:</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred tax assets:</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;Net operating losses</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">13,609,036</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">13,089,314</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;Share-based compensation</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,497,556</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent:
 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">741,420</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;Other differences in tax basis</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">233,043</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,749</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total deferred tax assets</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">15,339,635</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">13,835,483</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: valuation allowance</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(15,339,635</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block;
 margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(13,835,483</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred tax assets, net</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160; As of December 31, 2012, for U.S. federal income tax reporting purposes, the Company has approximately $43 million of unused net operating losses (&#8220;NOLs&#8221;) available for carry forward to future years. The benefit from the carry forward of such NOLs will begin expiring during the year ended December 31, 2020. Because United States tax laws limit the time during which NOL carry forwards may be applied against future taxable income, the Company may be unable to take full advantage of its NOL for federal income tax purposes should the Company generate taxable income. Further, the benefit from utilization of NOLs carry forwards could be subject to limitations due to material ownership changes that could occur in the Company as it continues to raise additional capital. Based on such limitations, the Company has significant NOLs for which realization of tax benefits is uncertain.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160; The difference between the income tax provision and the amount that would result if the U.S. Federal statutory rate of 34% were applied to pre-tax income (loss) for the years ended December 31, 2012 and 2011 are as follows:</font></div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="46%" valign="bottom" style="border-bottom: black 2px solid;" colspan="14">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the years ended</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="22%" valign="bottom" style="border-bottom: black 2px solid;" colspan="6">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31, 2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="22%" valign="bottom" style="border-bottom: black 2px solid;" colspan="6">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31, 2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Federal income taxes at 34%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2,842,810</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-34.00</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,171,230</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-34.00</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">Share-based compensation costs</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">756,136</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9.04</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">736,796</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">21.39</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value of derivatives</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">233,043</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2.79</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,748</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.13</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Amortization of debt discounts</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times
 new roman; font-size: 10pt;">349,480</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4.18</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">56,033</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.63</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in valuation allowance</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,504,151</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">17.99</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">373,653</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">10.85</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Provision for income tax</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 6 &#8211; Commitments and Contingencies</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Employment Contracts</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On September 16, 2013, the Company&#8217;s Board of Directors appointed Dr. Kaushik J. Dave as its new Chief Executive Officer (CEO)&#160;and Director. Material terms of the Employment Agreement are as follows:</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="6%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">a</font></div>
</td>
<td align="left" width="84%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">A base salary at an annual rate of $350,000, which will be re-evaluated upon the&#160;six month anniversary of the start date and reimbursement of certain expenses.</font></div>
</td>
</tr>
<tr>
<td align="left" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="6%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">b</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The CEO shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to which the Board shall award bonuses to the CEO, based upon the achievement of written individual and corporate objectives such as the Board shall determine.&#160;&#160;Upon the attainment of such performance objectives, the CEO shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary.</font></div>
</td>
</tr>
<tr>
<td align="left" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="6%" valign="top">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">c</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">An option to purchase common shares of the Company and restricted stock (the &#8220;Grant&#8221;).&#160;&#160;The Grant will consist of (i) an option grant to purchase 675,000 common shares of the Company; (ii) 125,000 shares of restricted and (iii) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work.&#160;&#160;An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date.&#160;&#160;As of October 25, 2013, the option has not been granted by the Board.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">License and Research Agreements</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">a.&#160;&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></div>
<div style="text-indent: 0pt; display:
 block;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="78%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Milestones</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Payments</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="78%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4) Biological License Application filing with U.S. FDA</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5) First commercial sale</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline;
 font-family: times new roman; font-size: 10pt;">(6) after the first $10,000,000 in net sales</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&#160;&#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">b.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top" style="text-align: justify;">
<div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Memorial Sloan Kettering Cancer Center (MSKCC) &#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and annual research funding of $50,000 for as long as the agreement is in force.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="78%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Milestones</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Payments</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="78%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="78%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval for each licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></div>
<div style="text-indent: 0pt; display: block;">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company expects to file the NDA for regulatory approval in the 2016-2017 time frame.</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">c.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Oak Ridge National Laboratory (ORNL) &#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&#160;&#160;The Company is currently negotiating the 2013 agreement.</font></div>
</td>
</tr>
<tr>
<td align="left" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">d.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase I and Phase II.&#160;&#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&#160;&#160;The down payment totaling $239,000 was paid in 2007 and 2012.&#160;&#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&#160;&#160;The total project is now estimated at approximately $2.2 million.&#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></div>
</td>
</tr>
<tr>
<td align="left" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;e.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&#160;&#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&#160;&#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&#160;&#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&#160;&#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&#160;&#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&#160;&#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&#160;&#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div>
</td>
</tr>
<tr>
<td align="left" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">f.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On March 27, 2012, the Company entered into a clinical trial agreement with MSKCC.&#160;The Company will pay $31,185 for each patient that has
 completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623.&#160;&#160;The amount due of $79,623 was paid on July 10, 2012.</font></div>
</td>
</tr>
</table>
</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">g.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&#160;&#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $19,749.&#160;&#160;During the clinical trial additional fees apply and will be invoiced when applicable.&#160;&#160;The amount due has not been invoiced but accrued by the Company as of September 30, 2013.</font></div>
</td>
</tr>
<tr>
<td align="left" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">h.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&#160;&#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&#160;&#160;The estimated cost is based on treating 24 patients through 2013.&#160;&#160;Upon execution of the agreement, the Company is required to make a payment of $33,946.</font></div>
</td>
</tr>
<tr>
<td align="left" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">i.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable.</font></div>
</td>
</tr>
<tr>
<td align="left" width="6%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="84%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="right" width="6%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">j.&#160;&#160;</font></div>
</td>
<td width="84%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&#160;&#160;The Phase 1/2 clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&#160;New York, NY. The agreement terminated on May 31, 2013. On June 1, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&#160;New York, NY. This agreement terminates on December 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination. The Company paid a one month refundable deposit.</font></div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On&#160;February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO. Pursuant to the agreement, the Company paid the former CEO $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid the former CEO a
 performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.</font></div>
<div  style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;">&#160;</div><span></span></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 8 &#8211; Commitments and Contingencies</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td width="4%" valign="top" style="text-align: right;">
<div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">a.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="78%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Milestones</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Payments</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="78%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div>
</td>
<td
 align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4) Biological License Application filing with U.S. FDA</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5) First commercial sale</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(6) after the first $10,000,000 in net sales</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of December 31, 2012, the Company met its first milestone and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012. &#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td width="4%" valign="top" style="text-align: right;">
<div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">b.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">MSKCC &#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and an annual research funding of $50,000 for as long as the agreement is in force.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="78%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Milestones</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Payments</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="78%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">for each licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2) upon the receipt of regulatory approval from the U.S. FDA for each</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="78%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">licensed product</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,750,000</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 45pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company expects to file the NDA for regulatory approval in 2015.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td width="4%" valign="top" style="text-align: right;">
<div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">c.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Oak Ridge National Laboratory (ORNL) &#8211; API has contracted to purchase radioactive material to be used for research and development through December 2012. API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end. &#160;The Company is currently negotiating the 2013 agreement.&#160;&#160;</font></div>
</td>
</tr>
</table>
</div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="4%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">d.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab&#8482;-A) used in the Company clinical trials, Phase I and Phase II. &#160;The total project is estimated to cost $1,859,333 and requires a 12.5% down payment of the total estimated project cost. &#160;The down payment totaling $239,000 was paid in 2007 and 2012. &#160;On August 6, 2012, the agreement was
 amended to provide for additional services. &#160;The total project is now estimated at $1,997,732. &#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="4%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">e.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody) and eventually develop a clinical trial with Actinium 225. &#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval. &#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. &#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA. &#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter. &#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year. &#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug. &#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="4%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">f.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On March 27, 2012, the Company entered into a clinical trial agreement with Memorial Sloan Kettering Cancer Center. &#160;The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623. &#160;The amount due of $79,623 was paid on July 10, 2012.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="4%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">g.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On May 9, 2011, Actinium entered into a transaction management agreement with Jamess Capital Group, LLC. (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Sandesh Seth, a Director of Cactus&#160;Ventures, Inc.&#160;by virtue of his position as a director of Actinium Pharmaceuticals.&#160; Mr. Seth is a Managing Partner of the consulting firm some of whose member interests are held by entities owned by officers and employees of the Placement Agent.&#160; None of Cactus&#8217; current officers or directors had a prior relationship or affiliation with Cactus prior to the closing of the Share Exchange.&#160; Pursuant to the agreement, the management firm was engaged to provide consulting services to Actinium related to the consummation of a going public transaction for Actinium.&#160; The management firm received a monthly fee of $12,500 which is terminable by the Company three months after the effective date of the going public transaction and designees of Jamess, including entities affiliated with Mr. Seth, were issued warrants to purchase common stock equal to 10% of the fully-diluted capital stock of the Company as of the effective date of the going public transaction. The fully diluted shares for this calculation included all issued and outstanding shares as well as those reserved under the Employee Stock Option Plan.&#160; Jamess Capital Group does not retain&#160;beneficial ownership of the warrants as they were&#160;issued to designees of the members in amounts which do not qualify either Jamess or the warrant holders for inclusion in the beneficial ownership table.&#160; The warrants contain&#160;a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver.&#160; The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transferred until the earlier of twelve months from the closing date of the Pubco Transaction; or for six months after the planned Registration Statement is declared effective.&#160;The consulting firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="4%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">h.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC. &#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $19,749. &#160;During the clinical trial additional fees apply and will be invoiced when applicable. &#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="4%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">i.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center. &#160;The total estimated cost of conducting the clinical trial is $481,204, which includes a non- refundable institutional fee of $14,500. &#160;The estimated cost is based on treating 24 patients through 2013. &#160;Upon execution of the agreement, the Company is required to make a payment of $33,946. &#160;&#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.</font></div>
</td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="4%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">j.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University. &#160;The Phase 1/2 clinical trial will be conducted with Actinium 225. &#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company. &#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable. &#160;The amount due has not been invoiced but accrued by the Company as of December 31, 2012.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
<div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><br /> </font></div>
<div>
<table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="right" width="4%" valign="top">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">k.&#160;&#160;</font></div>
</td>
<td width="79%" valign="top">
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania. &#160;The Phase 1/2 clinical trial will be conducted with Actinium 225. &#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company. &#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.</font></div>
</td>
</tr>
</table>
</div>
<div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font>&#160;</div>
</div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160; On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue, 3rd Floor, New York, NY 10017. &#160;The agreement terminates January 31, 2013 unless a Notice of Termination is provided to the landlord 60 days prior to January 1, 2013. &#160;The agreement automatically renews on a month-to-month basis and requires a two month notice of termination. &#160;The Company paid a two month refundable deposit.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Option Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 10 &#8211; Stock Option Plan</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has adopted a 2003 Stock Plan under which it may grant up to 757,575 options to purchase common stock. The 2003 Stock Plan was amended in 2008 to increase the number of shares that it may grant up to 978,154. Option awards are generally granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of the grant. However, since the Company is not publicly traded, the fair market value of the stock represents the Board of Directors&#8217; best estimate, based on the information available, on the date of the grant. The awards generally vest over a four or five year period at a rate of approximately 2% per month.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In 2011, the 2003 Stock Plan was amended to increase the number of shares by 3,217,880.&#160;&#160;Total shares reserved for issuance under the Plan will be increased to 6,155,280.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In accordance with the terms of the 2012 Common Stock Offering, the Company adopted a 2012 Employee Stock Option Plan (&#8220;2012 ESOP&#8221;) and reserved 15% of the total issued and outstanding shares as of the final closing of the 2012 Common Stock Offering.&#160;&#160;Total shares reserved for issuance under the 2012 ESOP was 9,455,776 shares.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2006, options to purchase 206,060 shares of common stock were granted to several employees at an exercise price of $1.35 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $1,051,281 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 4.29% (2) expected life of 5 years, (3) expected volatility of 156%, and (4) zero expected dividends.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2007, options to purchase 113,220 shares of common stock were granted to several employees at an exercise price of $1.35 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $137,652 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 3.46% (2) expected life of 5 years, (3) expected volatility of 143%, and (4) zero expected dividends.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2008, options to purchase 69,941 shares of common stock were granted to an employee at an exercise price of $0.90 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $44,159 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 3.46% (2) expected life of 5 years, (3) expected volatility of 139%, and (4) zero expected dividends.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2009, 20,613 options to one employee were cancelled as the result of termination of the employment and 128,050 options to one employee were forfeited as the employee deceased during the year.</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the year of 2010, options to purchase 33,300 shares of common stock were granted to an employee at an exercise price of $0.90 per share. These options have a term of 10 years and vest over a 4-5 year period. Fair value of $24,996 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 2.16% (2) expected life of 5 years, (3) expected volatility of 171%, and (4) zero expected dividends.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In February 2012, the Company re-priced 273,859 units of employee stock options to reflect the current per share fair market value of the Company&#8217;s common stock. The exercise prices of all of the current outstanding stock options were reduced to $1.28 per share. The Company recorded an incremental compensation cost of $34,879 as a result of the re-pricing of
 options.</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; During 2012, options to purchase 2,056,275 shares of common stock were issued to several employees and consultants at an exercise price ranging from $0.78 to $1.5 per share.&#160;&#160;These options have a term of 10 years and vest over a 4 year period. The fair value of $1,519,777 was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.8% (2) expected life of 7 years, (3) expected volatility of 160.44% &#126; 162.49%, and (4) zero expected dividends.</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div>
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160; The following is a summary of stock option activities for the years ended December 31, 2012 and 2011:</font></div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left">
<table style="width: 95%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times
 new roman; font-size: 10pt;">Weighted</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Remaining</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Aggregate</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Number of</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Contractual</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Intrinsic</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercise Price</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Term (in years)</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Value</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2010</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">273,859</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.29</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.51</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2011</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">273,859</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.29</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.51</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">2,056,275</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.96</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.89</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="47%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="47%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,330,134</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.96</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.91</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="padding-bottom: 4px;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">685,800</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160; All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31, 2012 and 2011 were $1,998,435 and $14,528, respectively. During the years ended December 31, 2012 and 2011, the Company recorded option expense of $266,172 and $19,935, respectively.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract', window );"><strong>Summary of activities related to related party</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty', window );">Qualified R&amp;D costs incurred by the Company</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 655,786<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ReimbursementsReceivedFromRelatedParty', window );">Reimbursements received from MSKCC</a></td>
        <td class="nump">$ 237,834<span></span></td>
        <td class="nump">$ 966,341<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Qualified research and development costs incurred by related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_QualifiedResearchAndDevelopmentCostsIncurredByRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ReimbursementsReceivedFromRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reimbursements received from related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ReimbursementsReceivedFromRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Option Plan (Details) (Stock Options [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">2,330,134<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Units, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,056,275<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">2,280,184<span></span></td>
        <td class="nump">2,330,134<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="nump">273,859<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
        <td class="text">8 years 2 months 1 day<span></span></td>
        <td class="text">8 years 10 months 28 days<span></span></td>
        <td class="text">5 years 6 months 4 days<span></span></td>
        <td class="text">5 years 6 months 4 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">8 years 10 months 21 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">$ 685,800<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">$ 1,609,035<span></span></td>
        <td class="nump">$ 685,800<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageRemainingContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description Of Business and Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of set forth assets and liabilities measured at fair value on a recurring and non-recurring basis</a></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1</font></div>
</td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2</font></div>
</td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3</font></div>
</td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="11%" valign="bottom" style="border-bottom: black 2px solid;" colspan="3">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total</font></div>
</td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Derivative liabilities:</font></div>
</td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="11%" valign="bottom" colspan="3"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At September 30, 2013</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td>
<td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
</tr>
</table>
</div><span></span></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Derivative liabilities:</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display:
 block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2012</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2011</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,439,613</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,439,613</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets and liabilities</a></td>
        <td class="text"><div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred tax assets:</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;Net operating losses</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">13,609,036</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">13,089,314</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;Share-based compensation</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,497,556</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">741,420</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;Other differences in tax basis</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right"
 width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">233,043</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,749</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total deferred tax assets</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">15,339,635</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">13,835,483</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: valuation allowance</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(15,339,635</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(13,835,483</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="66%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left"
 width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="66%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred tax assets, net</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of difference between the income tax provision and the U.S. Federal statutory rate</a></td>
        <td class="text"><div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="46%" valign="bottom" style="border-bottom: black 2px solid;" colspan="14">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the years ended</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="22%" valign="bottom" style="border-bottom: black 2px solid;" colspan="6">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31, 2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="22%" valign="bottom" style="border-bottom: black 2px solid;" colspan="6">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31, 2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Federal income taxes at 34%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2,842,810</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-34.00</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,171,230</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block;
 margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-34.00</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Share-based compensation costs</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">756,136</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9.04</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">736,796</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">21.39</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value of derivatives</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">233,043</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2.79</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,748</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline;
 font-family: times new roman; font-size: 10pt;">0.13</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Amortization of debt discounts</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">349,480</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4.18</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">56,033</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.63</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in valuation allowance</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,504,151</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">17.99</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">373,653</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">10.85</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="42%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="42%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Provision for income tax</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E62BG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">2,330,134<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancellation</a></td>
        <td class="num">(49,950)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">128,050<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Warrants expired</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,613<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">2,280,184<span></span></td>
        <td class="nump">2,330,134<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="nump">273,859<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
        <td class="text">8 years 2 months 1 day<span></span></td>
        <td class="text">8 years 10 months 28 days<span></span></td>
        <td class="text">5 years 6 months 4 days<span></span></td>
        <td class="text">5 years 6 months 4 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">$ 685,800<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">1,609,035<span></span></td>
        <td class="nump">685,800<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">12,770,636<span></span></td>
        <td class="nump">5,364,557<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Warrants exercised</a></td>
        <td class="num">(2,304,910)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Warrants expired</a></td>
        <td class="num">(1,023,784)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">9,441,942<span></span></td>
        <td class="nump">12,770,636<span></span></td>
        <td class="nump">5,364,557<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 0.97<span></span></td>
        <td class="nump">$ 0.51<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised</a></td>
        <td class="nump">$ 1.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, expired</a></td>
        <td class="nump">$ 1.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 0.77<span></span></td>
        <td class="nump">$ 0.97<span></span></td>
        <td class="nump">$ 0.51<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
        <td class="text">5 years 1 month 2 days<span></span></td>
        <td class="text">4 years 5 months 23 days<span></span></td>
        <td class="text">6 years 9 months 4 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">6,114,768<span></span></td>
        <td class="nump">3,261,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">$ 9,691,302<span></span></td>
        <td class="nump">$ 6,114,768<span></span></td>
        <td class="nump">$ 3,261,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAHAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 19, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 27, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MarketValueOfCommonStockOnMeasurementDate', window );">Market value of common stock on measurement date (1)</a></td>
        <td class="nump">$ 0.39<span></span></td>
        <td class="nump">$ 0.39<span></span></td>
        <td class="nump">$ 0.37<span></span></td>
        <td class="nump">$ 1.65<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 1.17<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 0.37<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.94%<span></span></td>
        <td class="nump">1.24%<span></span></td>
        <td class="nump">0.33%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1.35%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant lives in years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">7 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">161.00%<span></span></td>
        <td class="nump">157.00%<span></span></td>
        <td class="nump">139.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">156.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="nump">25.00%<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
        <td class="nump">25.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RangeOfPercentageOfExistingSharesOffered', window );">Range of percentage of existing shares offered (6)</a></td>
        <td class="nump">35.00%<span></span></td>
        <td class="nump">35.00%<span></span></td>
        <td class="nump">35.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">35.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">35.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Adjusted exercise price</a></td>
        <td class="nump">$ 0.83<span></span></td>
        <td class="nump">$ 0.26<span></span></td>
        <td class="nump">$ 0.26<span></span></td>
        <td class="nump">$ 2.475<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.81<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.26<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="nump">0.77%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0.77%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant lives in years</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years 2 months 19 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">5 years<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">161.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">161.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueAssumptionOfferingPrice', window );">Offering price range (7)</a></td>
        <td class="nump">$ 0.55<span></span></td>
        <td class="nump">$ 0.60<span></span></td>
        <td class="nump">$ 0.56<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.55<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.55<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Adjusted exercise price</a></td>
        <td class="nump">$ 0.41<span></span></td>
        <td class="nump">$ 0.22<span></span></td>
        <td class="nump">$ 0.23<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.48<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.24<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="nump">0.10%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0.10%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant lives in years</a></td>
        <td class="text">4 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">0 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">4 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">125.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">125.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueAssumptionOfferingPrice', window );">Offering price range (7)</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.12<span></span></td>
        <td class="nump">$ 0.13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.18<span></span></td>
      </tr>
      <tr>
        <td colspan="9"></td>
      </tr>
      <tr>
        <td colspan="9">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The market value of common stock is based on an enterprise valuation</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[4]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[5]</td>
              <td style="vertical-align: top;" valign="top">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueAssumptionOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value assumption offering price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueAssumptionOfferingPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MarketValueOfCommonStockOnMeasurementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Market value of common stock on measurement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MarketValueOfCommonStockOnMeasurementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RangeOfPercentageOfExistingSharesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Range of percentage of existing shares offered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RangeOfPercentageOfExistingSharesOffered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsProbabilityOfDefault">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bbb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueInputsProbabilityOfDefault</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EN2EK">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital</div>
        </th>
        <th class="th">
          <div>Deficit Accumulated During the Development Stage</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 13, 2000</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of founder shares</a></td>
        <td class="nump">$ 30,000<span></span></td>
        <td class="nump">$ 9,990<span></span></td>
        <td class="nump">$ 20,010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of founder shares, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">999,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">1,750,000<span></span></td>
        <td class="nump">1,457<span></span></td>
        <td class="nump">1,748,543<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">145,687<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(672,286)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(672,286)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2000</a></td>
        <td class="nump">1,107,714<span></span></td>
        <td class="nump">11,447<span></span></td>
        <td class="nump">1,768,553<span></span></td>
        <td class="num">(672,286)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2000</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,144,687<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">2,250,000<span></span></td>
        <td class="nump">1,873<span></span></td>
        <td class="nump">2,248,127<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">187,313<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(5,090,621)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(5,090,621)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2001</a></td>
        <td class="num">(1,732,907)<span></span></td>
        <td class="nump">13,320<span></span></td>
        <td class="nump">4,016,680<span></span></td>
        <td class="num">(5,762,907)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2001</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,332,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">3,250,000<span></span></td>
        <td class="nump">1,804<span></span></td>
        <td class="nump">3,248,196<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">180,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(3,192,384)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,192,384)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2002</a></td>
        <td class="num">(1,675,291)<span></span></td>
        <td class="nump">15,124<span></span></td>
        <td class="nump">7,264,876<span></span></td>
        <td class="num">(8,955,291)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2002</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,512,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">6,781,250<span></span></td>
        <td class="nump">2,090<span></span></td>
        <td class="nump">6,779,160<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">208,992<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(3,532,044)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,532,044)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2003</a></td>
        <td class="nump">1,573,915<span></span></td>
        <td class="nump">17,214<span></span></td>
        <td class="nump">14,044,036<span></span></td>
        <td class="num">(12,487,335)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2003</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,721,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">4,600,000<span></span></td>
        <td class="nump">7,659<span></span></td>
        <td class="nump">4,592,341<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">765,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(5,734,791)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(5,734,791)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2004</a></td>
        <td class="nump">439,124<span></span></td>
        <td class="nump">24,873<span></span></td>
        <td class="nump">18,636,377<span></span></td>
        <td class="num">(18,222,126)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2004</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,487,267<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">3,900,000<span></span></td>
        <td class="nump">6,494<span></span></td>
        <td class="nump">3,893,506<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">649,350<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Option expense</a></td>
        <td class="nump">315,388<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">315,388<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(4,580,237)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(4,580,237)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2005</a></td>
        <td class="nump">74,275<span></span></td>
        <td class="nump">31,367<span></span></td>
        <td class="nump">22,845,271<span></span></td>
        <td class="num">(22,802,363)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2005</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,136,617<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">7,550,541<span></span></td>
        <td class="nump">8,390<span></span></td>
        <td class="nump">7,542,151<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">839,042<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Option expense</a></td>
        <td class="nump">252,308<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">252,308<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(6,053,362)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(6,053,362)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2006</a></td>
        <td class="nump">1,823,762<span></span></td>
        <td class="nump">39,757<span></span></td>
        <td class="nump">30,639,730<span></span></td>
        <td class="num">(28,855,725)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2006</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,975,659<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">6,600,000<span></span></td>
        <td class="nump">7,326<span></span></td>
        <td class="nump">6,592,674<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">732,600<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
        <td class="nump">398,810<span></span></td>
        <td class="nump">664<span></span></td>
        <td class="nump">398,146<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">66,402<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Option expense</a></td>
        <td class="nump">255,061<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">255,061<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(5,617,581)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(5,617,581)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2007</a></td>
        <td class="nump">3,460,052<span></span></td>
        <td class="nump">47,747<span></span></td>
        <td class="nump">37,885,611<span></span></td>
        <td class="num">(34,473,306)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2007</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,774,661<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">6,000,000<span></span></td>
        <td class="nump">9,990<span></span></td>
        <td class="nump">5,990,010<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">999,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Option expense</a></td>
        <td class="nump">269,618<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">269,618<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(5,570,905)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(5,570,905)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2008</a></td>
        <td class="nump">4,158,765<span></span></td>
        <td class="nump">57,737<span></span></td>
        <td class="nump">44,145,239<span></span></td>
        <td class="num">(40,044,211)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2008</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,773,661<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Option expense</a></td>
        <td class="nump">112,382<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">112,382<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(3,425,986)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(3,425,986)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2009</a></td>
        <td class="nump">845,161<span></span></td>
        <td class="nump">57,737<span></span></td>
        <td class="nump">44,257,621<span></span></td>
        <td class="num">(43,470,197)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2009</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,773,661<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Option expense</a></td>
        <td class="nump">21,166<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">21,166<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(467,266)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(467,266)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2010</a></td>
        <td class="nump">399,061<span></span></td>
        <td class="nump">57,737<span></span></td>
        <td class="nump">44,278,787<span></span></td>
        <td class="num">(43,937,463)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,773,661<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">5,379,367<span></span></td>
        <td class="nump">78,911<span></span></td>
        <td class="nump">5,300,456<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,891,141<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Option expense</a></td>
        <td class="nump">19,935<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">19,935<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense', window );">Warrant expense</a></td>
        <td class="nump">2,153,442<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,153,442<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants', window );">Fair value of derivative warrants</a></td>
        <td class="num">(3,887,850)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(3,887,850)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature discount</a></td>
        <td class="nump">372,850<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">372,850<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(3,444,795)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(3,444,795)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2011</a></td>
        <td class="nump">992,010<span></span></td>
        <td class="nump">136,648<span></span></td>
        <td class="nump">48,237,620<span></span></td>
        <td class="num">(47,382,258)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,664,802<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of - stock</a></td>
        <td class="nump">5,129,940<span></span></td>
        <td class="nump">40,877<span></span></td>
        <td class="nump">5,089,063<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProceedsFromIssuanceOfCommonStockShares', window );">Proceeds from issuance of - stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,087,747<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue', window );">Conversion of notes payable and accrued interest to stock</a></td>
        <td class="nump">981,729<span></span></td>
        <td class="nump">12,525<span></span></td>
        <td class="nump">969,204<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares', window );">Conversion of notes payable and accrued interest to stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,252,550<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesIssuedAtReverseMergerValue', window );">Shares issued at the reverse merger</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">23,866<span></span></td>
        <td class="num">(23,866)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesIssuedAtReverseMergerShares', window );">Shares issued at the reverse merger, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,386,566<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Option expense</a></td>
        <td class="nump">266,172<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">266,172<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense', window );">Warrant expense</a></td>
        <td class="nump">1,957,754<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,957,754<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants', window );">Fair value of derivative warrants</a></td>
        <td class="num">(4,052,089)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(4,052,089)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer from liability classification to equity classification</a></td>
        <td class="nump">4,231,324<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,231,324<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(8,361,205)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(8,361,205)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
        <td class="nump">$ 1,145,635<span></span></td>
        <td class="nump">$ 213,916<span></span></td>
        <td class="nump">$ 56,675,182<span></span></td>
        <td class="num">$ (55,743,463)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,391,665<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustments to additional paid in capital fair value of derivative warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdjustmentsToAdditionalPaidInCapitalFairValueOfDerivativeWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustments to additional paid in capital warrant expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdjustmentsToAdditionalPaidInCapitalWarrantExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConversionOfNotesPayableAndAccruedInterestToStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion of notes payable and accrued interest to stock, shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ConversionOfNotesPayableAndAccruedInterestToStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConversionOfNotesPayableAndAccruedInterestToStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion of notes payable and accrued interest to stock, Value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ConversionOfNotesPayableAndAccruedInterestToStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProceedsFromIssuanceOfCommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of common stock shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ProceedsFromIssuanceOfCommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesIssuedAtReverseMergerShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued at the reverse merger shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SharesIssuedAtReverseMergerShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesIssuedAtReverseMergerValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued at the reverse merger value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SharesIssuedAtReverseMergerValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 51<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32707879&amp;loc=d3e34017-109320<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 3 &#8211; Property and Equipment</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment consisted of the following at September 30, 2013 and December 31, 2012:</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="57%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Lives</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="57%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Office equipment</font></div>
</td>
<td width="9%" valign="bottom">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;5 years</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">162,384</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">156,162</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Furniture and fixture</font></div>
</td>
<td width="9%" valign="bottom">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;7 years</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,100</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,292</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="57%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total property and equipment</font></div>
</td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">165,484</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">157,454</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: accumulated depreciation</font></div>
</td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="57%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Loss on disposition of equipment</font></div>
</td>
<td align="left" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4,122</font></div>
</td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt;
 display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="57%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="57%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment, net</font></div>
</td>
<td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,918</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,010</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div>
<div align="left" style="text-indent: 45pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Depreciation expense for the nine months ended September 30, 2013 and 2012 were $0 and&#160;$429 respectively.</font>&#160;</div>
<div  style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;">&#160;</div><span></span></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 4 &#8211; Property and Equipment</font></div>
<div style="text-indent: 0pt; display: block;">&#160;</div>
<div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160; Property and equipment consisted of the following at December 31, 2012 and 2011:</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left">
<table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0">
<tr>
<td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Lives</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr>
<td align="left" width="56%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="56%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Office equipment</font></div>
</td>
<td width="10%" valign="bottom">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;5 years</font></div>
</td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">156,162</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">153,804</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Furniture and fixture</font></div>
</td>
<td width="10%" valign="bottom" style="padding-bottom: 2px;">
<div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;7 years</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt;
 margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,292</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,292</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="56%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="56%" valign="bottom">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total property, plant and equipment</font></div>
</td>
<td align="left" width="10%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">157,454</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">155,096</font></div>
</td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="56%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: accumulated depreciation</font></div>
</td>
<td align="left" width="10%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 2px solid;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(153,863</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div>
</td>
</tr>
<tr bgcolor="#ffffff">
<td align="left" width="56%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="10%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="9%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
<tr bgcolor="#cceeff">
<td align="left" width="56%" valign="bottom" style="padding-bottom: 4px;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment</font></div>
</td>
<td align="left" width="10%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,010</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
<td align="left" width="1%" valign="bottom" style="border-bottom: black 4px double;">
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div>
</td>
<td align="right" width="9%" valign="bottom" style="border-bottom: black 4px double;">
<div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,233</font></div>
</td>
<td align="left" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td>
</tr>
</table>
</div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div>
<div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Depreciation expense for the years ended December 31, 2012 and 2011 were $581 and $633, respectively.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentsMilestoneMethodLineItems', window );"><strong>Milestone Payments Milestone Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentsMilestoneMethodTableTextBlock', window );">Summary of milestone payment</a></td>
        <td class="text"><div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(4) Biological License Application filing with U.S. FDA</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font
 style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(5) First commercial sale</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(6) after the first $10,000,000 in net sales</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr></table></div><div>&#160;</div><span></span></td>
        <td class="text"><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="border-bottom: black 2px solid;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">(4) Biological License Application filing with U.S. FDA</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">(5) First commercial sale</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">(6) after the first $10,000,000 in net sales</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt;
 font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div style="display: block; text-indent: 0pt;">&#160;</div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">MSKCC [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentsMilestoneMethodLineItems', window );"><strong>Milestone Payments Milestone Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentsMilestoneMethodTableTextBlock', window );">Summary of milestone payment</a></td>
        <td class="text"><div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval&#160;</font>for each licensed product</font></div></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(2) upon the receipt of regulatory approval from the U.S. FDA for each&#160;</font>licensed product</font></div></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td></tr></table></div><div>&#160;</div><span></span></td>
        <td class="text"><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="border-bottom: black 2px solid;"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">for each licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">(2) upon the receipt of regulatory approval from the U.S. FDA for each</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">licensed product</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div style="display: block; text-indent: 0pt;">&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MilestonePaymentsMilestoneMethodLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MilestonePaymentsMilestoneMethodLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MilestonePaymentsMilestoneMethodTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payments milestone method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MilestonePaymentsMilestoneMethodTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>325</ContextCount>
  <ElementCount>367</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DocumentAndEntityInformation1</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/ConsolidatedBalanceSheetsparenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Consolidatedstatementofchangesinstockholdersequitydeficit</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Notes11</Role>
      <ShortName>Going Concern</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/RelatedPartyTransaction</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note Payable and Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cactusventuresinc.com/role/NotePayableAndConvertibleNotes</Role>
      <ShortName>Note Payable and Convertible Notes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Derivatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Derivatives</Role>
      <ShortName>Derivatives</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Employee Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/EmployeeDefinedContributionPlan</Role>
      <ShortName>Employee Defined Contribution Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Notes13</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/RelatedPartyTransactiontables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note Payable and Convertible Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesTables</Role>
      <ShortName>Note Payable and Convertible Notes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Derivatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DerivativesTables</Role>
      <ShortName>Derivatives (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Going concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/GoingconcernDetails</Role>
      <ShortName>Going concern (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/RelatedPartyTransactiondetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Relatedpartytransactiondetailstextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Propertyandequipmentdetailstesxtual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note Payable and Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetails</Role>
      <ShortName>Note Payable and Convertible Notes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note Payable and Convertible Notes (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cactusventuresinc.com/role/NotePayableAndConvertibleNotesDetailsTextual</Role>
      <ShortName>Note Payable and Convertible Notes (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DerivativesDetails</Role>
      <ShortName>Derivatives (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Derivatives (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DerivativesDetails1</Role>
      <ShortName>Derivatives (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Derivatives (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DerivativesDetailsTextual</Role>
      <ShortName>Derivatives (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/IncometaxesdetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - Commitments and Contingencies (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1</Role>
      <ShortName>Commitments and Contingencies (Details Textual 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Equitydetails</Role>
      <ShortName>Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>050 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Equitydetailstextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>051 - Disclosure - Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/StockOptionPlanDetails</Role>
      <ShortName>Stock Option Plan (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>052 - Disclosure - Stock Option Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/StockOptionPlanDetailsTextual</Role>
      <ShortName>Stock Option Plan (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>053 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>054 - Disclosure - Warrants (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/WarrantsDetails1</Role>
      <ShortName>Warrants (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>055 - Disclosure - Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/WarrantsDetailsTextual</Role>
      <ShortName>Warrants (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>056 - Disclosure - Employee Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/EmployeeDefinedContributionPlanDetails</Role>
      <ShortName>Employee Defined Contribution Plan (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>057 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/SubsequenteventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element fil_PercentageOfOwnershipInterestToBeAcquired had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_CommonStockParOrStatedValuePerShare had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_FairValueAssumptionsExercisePrice had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_PreferredStockParOrStatedValuePerShare had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2004'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2003'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2002'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2001'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2000'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">	Process Flow-Through: Removing column '6 Months Ended
Dec. 31, 2000'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2004'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2003'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2002'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2001'</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>fil-20130930.xml</File>
    <File>fil-20130930.xsd</File>
    <File>fil-20130930_cal.xml</File>
    <File>fil-20130930_def.xml</File>
    <File>fil-20130930_lab.xml</File>
    <File>fil-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EF5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Note Payable and Convertible Notes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 27, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfConvertiblePromissoryNotesAbstract', window );"><strong>Summary of senior subordinated unsecured convertible promissory notes</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 900,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: original issuance discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature', window );">Less: discount related to the beneficial conversion feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(372,850)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Carrying value at December 31, 2012 and 2011, respectively</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">124,363<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">8% Senior Subordinated Unsecured Convertible Promissory Notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfConvertiblePromissoryNotesAbstract', window );"><strong>Summary of senior subordinated unsecured convertible promissory notes</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: original issuance discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(150,000)<span></span></td>
        <td class="num">(150,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DiscountRelatedToFairValueOfDerivativeWarrants', window );">Less: discount related to fair value of derivative warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(377,150)<span></span></td>
        <td class="num">(377,150)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature', window );">Less: discount related to the beneficial conversion feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(372,850)<span></span></td>
        <td class="num">(372,850)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtInstrumentAmortizationOfDiscount', window );">Add: amortization of discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">124,363<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock', window );">Less: principal amount converted to stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(900,000)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Carrying value at December 31, 2012 and 2011, respectively</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 124,363<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DebtInstrumentAmortizationOfDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt instrument amortization of discount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DebtInstrumentAmortizationOfDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt instrument discount related to the beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DebtInstrumentDiscountRelatedToBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DebtInstrumentPrincipalAmountConvertedToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt instrument principal amount converted to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DebtInstrumentPrincipalAmountConvertedToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DiscountRelatedToFairValueOfDerivativeWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Discount related to fair value of derivative warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DiscountRelatedToFairValueOfDerivativeWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SummaryOfConvertiblePromissoryNotesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SummaryOfConvertiblePromissoryNotesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description Of Business and Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Nature of Business</a></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Nature of Business &#8211;</font> Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that&#160;was in the market for a merger with an appropriate operating company.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="letter-spacing: 9pt;">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="letter-spacing: 9pt;">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="letter-spacing: 9pt;">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="letter-spacing: 9pt;">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><span></span></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Nature of Business &#8211; Actinium Pharmaceuticals, Inc (Formerly</font> Cactus Ventures, Inc.) (the &#8220;Company&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that is in the market for a merger with an appropriate operating company.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company agreed to acquire 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange was closed on December 28, 2012 when shareholders representing over 20% of the issued and outstanding shares of Actinium had finished the exchange process.&#160;&#160;On August 22, 2013, shareholders representing 38% of the issued and outstanding shares of Actinium completed the exchange.&#160;&#160;As a result of the Share Exchange, the former shareholders of Actinium became the controlling shareholders of the Company. At the closing, each Actinium shareholder shall receive 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Cactus common stock for each Actinium share exchanged. At the closing, all of the Actinium shareholders&#8217; options and warrants to purchase Actinium common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Cactus common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein Actinium is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="letter-spacing: 9pt;">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; Actinium, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Actinium, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;Actinium&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, Actinium launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. &#160;Actinium&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of Actinium&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that Actinium&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="letter-spacing: 9pt;">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; As a result of the Share Exchange, the Company is now a holding company operating through Actinium, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Basis of Presentation - Unaudited Interim Financial Information &#8211;</font> The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary&#160;for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DevelopmentStageCompanyPolicyTextBlock', window );">Development Stage Company</a></td>
        <td class="text"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><span></span></td>
        <td class="text"><p><strong><font size="2">Development Stage Company &#8211;</font></strong>&#160;The Company is considered a development stage company and has had no commercial revenue to date.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Principles of Consolidation &#8211;</font> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div><span></span></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Principles of Consolidation &#8211;</font>&#160;The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><span></span></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Reclassification &#8211;</font> Certain prior period amounts have been reclassified to conform to current period presentation.</font></div><span></span></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Reclassification &#8211;</font>&#160;Certain prior period amounts have been reclassified to conform to current period presentation.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At June 30, 2013 and December 31, 2012, all of the Company&#8217;s cash was deposited in one bank.</font></div><span></span></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At December 31, 2012 and 2011, all of the Company&#8217;s cash was deposited in one bank.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div><span></span></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 27pt;">&#160;</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Impairment of Long-Lived Assets &#8211;</font> Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div><span></span></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Impairment of Long-Lived Assets &#8211;</font> Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div><span></span></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">&#160;</div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">&#160;</div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 45pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of June 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 1</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 2</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 3</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Total</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td
 align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Derivative liabilities:</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;At June 30, 2013</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">2,957,977</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">2,957,977</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;At December 31, 2012</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font
 style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3,574,958</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3,574,958</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><span></span></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div><div style="text-align: justify; display: block; text-indent: 0pt;">&#160;</div><div style="text-align: justify; margin-left: 36pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="margin-left: 36pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="margin-left: 36pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of December 31, 2012 and 2011. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font></div><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 1</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 2</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Level 3</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Total</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman;
 display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">Derivative liabilities:</font></div></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" valign="bottom" colspan="2"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;At December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3,574,958</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">3,574,958</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;&#160;At December 31, 2011</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%"
 valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">4,439,613</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td><td align="right" width="9%" valign="bottom"><div align="right" style="margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">4,439,613</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160; </font></td></tr></table></div><div style="display: block; text-indent: 0pt;">&#160;</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div><span></span></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><font style="font-size: 10pt; font-family: times new roman; display: inline;">&#160;</font></div><span></span></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div><span></span></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">&#160; Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the six months ended June 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,535,694 shares of the Company&#8217;s common stock. For the six months ended June 30, 2012, potentially issuable shares includes options and warrants&#160;to purchase 6,842,528 shares of the Company&#8217;s common stock and notes payable convertible to 815,275 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></div><span></span></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;"> Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders&#160;by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same. &#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been anti dilutive. For the year ended December 31, 2012, potentially issuable shares included stock options to purchase 2,330,134 shares and warrants to purchase 12,770,596 shares of the Company&#8217;s common stock. For the year ended December 31, 2011, potentially issuable shares includes options and warrants&#160;to purchase 273,859 shares of the Company&#8217;s common stock and notes payable convertible to 3,448,276 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div><span></span></td>
        <td class="text"><div align="justify" style="font: 13px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Recent Accounting Pronouncements &#8211;</font>&#160;The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div><font style="font-size: 10pt; font-family: times new roman; display: inline;"><font style="font-weight: bold; display: inline;">Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.</font></div><span></span></td>
        <td class="text"><p><strong><font size="2">Subsequent Events &#8211;</font></strong>&#160;The Company&#8217;s management reviewed all material events from January 1, 2013 through March 15, 2013.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DevelopmentStageCompanyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Development Stage Company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DevelopmentStageCompanyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2303973<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -Subparagraph (a)-(d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PriorPeriodReclassificationAdjustmentDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
